"review_id","dataset","analysis_key","analysis_name","analysis_group","analysis_number","subgroup","effect_class","outcome_type","k","yi","se","tau2","mean_year","mean_ctrl_risk","mean_total_n"
"CD000028","CD000028_pub4_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","reported","reported",13,0.901515775418985,0.0403145269952051,0.0049372462066312,1987,0.183356112839507,1994.76923076923
"CD000028","CD000028_pub4_data","1|2|Cause of cardiovascular mortality|Fatal CHD","Cause of cardiovascular mortality",1,2,"Fatal CHD","reported","reported",10,0.754642608057417,0.0607089970512606,0,1988.22222222222,0.039572652985439,2447.8
"CD000028","CD000028_pub4_data","1|2|Cause of cardiovascular mortality|Fatal stroke","Cause of cardiovascular mortality",1,2,"Fatal stroke","reported","reported",11,0.575551870031422,0.0813950602486427,0.0107187558260704,1989.3,0.0228279710391807,2342.09090909091
"CD000028","CD000028_pub4_data","1|3|Cardiovascular mortality and morbidity|","Cardiovascular mortality and morbidity",1,3,"","reported","reported",15,0.730033359822391,0.0426713944928334,0.0140109704284919,1985.64285714286,0.232819731983583,1783.13333333333
"CD000028","CD000028_pub4_data","1|4|Cerebrovascular mortality and morbidity|","Cerebrovascular mortality and morbidity",1,4,"","reported","reported",13,0.64103379177343,0.0398527475651115,0,1986.41666666667,0.0841784049785072,2003.23076923077
"CD000028","CD000028_pub4_data","1|5|Coronary heart disease mortality and morbidity|","Coronary heart disease mortality and morbidity",1,5,"","reported","reported",11,0.763971045728561,0.0484319324477763,0,1986.4,0.0643816146185654,2232.63636363636
"CD000028","CD000028_pub4_data","1|6|Withdrawal due to adverse effects|","Withdrawal due to adverse effects",1,6,"","reported","reported",4,2.50039622129715,1.18304915690672,5.23280567919386,1990,0.0458134140556612,2827.5
"CD000028","CD000028_pub4_data","2|1|All-cause mortality|60 to 79 years old","All-cause mortality",2,1,"60 to 79 years old","reported","reported",9,0.804666901713259,0.0728862883907606,0.0263110352979882,1987,0.137488996212279,2113
"CD000028","CD000028_pub4_data","2|1|All-cause mortality|80 years or older","All-cause mortality",2,1,"80 years or older","reported","reported",7,1.03566460548668,0.0944410746125355,0.0233151491453199,1991.5,0.199036960216479,956.285714285714
"CD000028","CD000028_pub4_data","2|2|Cardiovascular mortality and morbidity|60 to 79 years old","Cardiovascular mortality and morbidity",2,2,"60 to 79 years old","reported","reported",8,0.694146040178173,0.0454141016767067,0.00720024752582898,1987.25,0.167315311033409,2310.5
"CD000028","CD000028_pub4_data","2|2|Cardiovascular mortality and morbidity|80 years or older","Cardiovascular mortality and morbidity",2,2,"80 years or older","reported","reported",7,0.733002584839975,0.0572887737494813,0,1991,0.163972164679996,935.142857142857
"CD000028","CD000028_pub4_data","2|3|Cerebrovascular mortality and morbidity|60 to 79 years old","Cerebrovascular mortality and morbidity",2,3,"60 to 79 years old","reported","reported",8,0.628815229601354,0.0583144868945578,0.00645666491935925,1987.25,0.0732277621198817,2310.5
"CD000028","CD000028_pub4_data","2|3|Cerebrovascular mortality and morbidity|80 years or older","Cerebrovascular mortality and morbidity",2,3,"80 years or older","reported","reported",7,0.584542143144652,0.0775914019641016,0.000752806578409737,1991,0.116214028529132,935.142857142857
"CD000028","CD000028_pub4_data","2|4|Coronary heart disease mortality and morbidity|60 to 79 years old","Coronary heart disease mortality and morbidity",2,4,"60 to 79 years old","reported","reported",7,0.780760381699057,0.0543392606026424,0,1989.14285714286,0.0535127505384513,2612
"CD000028","CD000028_pub4_data","2|4|Coronary heart disease mortality and morbidity|80 years or older","Coronary heart disease mortality and morbidity",2,4,"80 years or older","reported","reported",5,0.776354169395207,0.169519300154989,0,1990.25,0.0326594154021526,1051.2
"CD000028","CD000028_pub4_data","3|1|All-cause mortality|60 to 79 years old","All-cause mortality",3,1,"60 to 79 years old","reported","reported",3,0.73342856946689,0.116717491016452,0.0204289356312587,1990,0.0682330884099371,2935.33333333333
"CD000028","CD000028_pub4_data","3|1|All-cause mortality|80 years or older","All-cause mortality",3,1,"80 years or older","reported","reported",3,1.0639558789763,0.150736914882558,0.014855894774895,1990,0.14577797681246,392
"CD000028","CD000028_pub4_data","3|2|Cardiovascular morbidity and mortality|60 to 79 years old","Cardiovascular morbidity and mortality",3,2,"60 to 79 years old","reported","reported",3,0.63688125420462,0.042783525660361,0,1990,0.112594567008584,2935.33333333333
"CD000028","CD000028_pub4_data","3|2|Cardiovascular morbidity and mortality|80 years or older","Cardiovascular morbidity and mortality",3,2,"80 years or older","reported","reported",3,0.753548561165725,0.117307946997682,0.00700550704211434,1990,0.198079315320695,392
"CD000028","CD000028_pub4_data","3|3|Cerebrovascular morbidity and mortality|60 to 79 years old","Cerebrovascular morbidity and mortality",3,3,"60 to 79 years old","reported","reported",3,0.609537784008502,0.0837471298216939,0.00313991349983993,1990,0.0395122857053357,2935.33333333333
"CD000028","CD000028_pub4_data","3|3|Cerebrovascular morbidity and mortality|80 years or older","Cerebrovascular morbidity and mortality",3,3,"80 years or older","reported","reported",3,0.503770734864126,0.112322933356879,0.000621919328014219,1990,0.138120117430462,392
"CD000028","CD000028_pub4_data","3|4|Coronary heart disease morbidity and mortality|60 to 79 years old","Coronary heart disease morbidity and mortality",3,4,"60 to 79 years old","reported","reported",3,0.723077046431773,0.0832853491405425,0,1990,0.0422815751213662,2935.33333333333
"CD000028","CD000028_pub4_data","3|4|Coronary heart disease morbidity and mortality|80 years or older","Coronary heart disease morbidity and mortality",3,4,"80 years or older","reported","reported",3,0.790440773895894,0.191926376946278,0,1990,0.049390456287008,392
"CD000028","CD000028_pub4_data","3|5|Withdrawal due to adverse effects 60 years or older|","Withdrawal due to adverse effects 60 years or older",3,5,"","reported","reported",2,1.82486493501389,0.168701965212266,0,1988.5,0.0442655857037974,2643.5
"CD000143","CD000143_pub2_data","1|1|Extubation failure|CPAP level < 7 cm H2O","Extubation failure",1,1,"CPAP level < 7 cm H2O","reported","reported",8,0,0.118099834696305,0,1994.375,0.456399835796388,79.25
"CD000143","CD000143_pub2_data","1|2|Endotracheal reintubation|CPAP level < 7 cm H2O","Endotracheal reintubation",1,2,"CPAP level < 7 cm H2O","reported","reported",8,0,0.118099834696305,0,1994.375,0.374177613574165,79.25
"CD000143","CD000143_pub2_data","1|4|Oxygen dependency at 28 days|","Oxygen dependency at 28 days",1,4,"","or","binary",5,-0.163337185690353,0.392316758813164,0.52432685751128,1995.6,0.442793650793651,86.6
"CD000143","CD000143_pub2_data","2|1|Extubation failure|≤ 1500 g","Extubation failure",2,1,"≤ 1500 g","or","binary",5,-0.807238821743403,0.598072119619822,1.44342261922397,1994.6,0.476906403940887,68.2
"CD000143","CD000143_pub2_data","2|1|Extubation failure|1001 to 1500 g","Extubation failure",2,1,"1001 to 1500 g","or","binary",2,-0.232615885843022,0.526804971242391,0,1994.5,0.204805491990847,43.5
"CD000143","CD000143_pub2_data","2|1|Extubation failure|Birthweight ≤ 1000g","Extubation failure",2,1,"Birthweight ≤ 1000g","or","binary",4,0.138844886858723,1.07598441179896,3.62177825856952,1994.5,0.529854809437387,33.25
"CD000143","CD000143_pub2_data","2|2|Endotracheal reintubation|≤ 1500 g","Endotracheal reintubation",2,2,"≤ 1500 g","or","binary",2,-0.314780275196055,0.506748722880446,0.260859528793695,1996.5,0.355555555555556,75.5
"CD000143","CD000143_pub2_data","3|2|Endotracheal reintubation|Extubation within 14 days after birth ","Endotracheal reintubation",3,2,"Extubation within 14 days after birth ","or","binary",3,0.0533142420412604,0.353750671316049,0.151193405219815,1997,0.288148148148148,100.666666666667
"CD000143","CD000143_pub2_data","4|1|Extubation failure|Methylxanthines given","Extubation failure",4,1,"Methylxanthines given","reported","reported",8,0,0.105981793454686,0,1996.375,0.448066502463054,88.5
"CD000143","CD000143_pub2_data","5|1|Extubation failure|No Rescue CPAP used","Extubation failure",5,1,"No Rescue CPAP used","reported","reported",5,0,0.141188322307369,0,1996.4,0.371619047619048,81.6
"CD000143","CD000143_pub2_data","5|1|Extubation failure|Rescue CPAP used","Extubation failure",5,1,"Rescue CPAP used","reported","reported",3,0,0.160405944011117,0,1996.33333333333,0.575478927203065,100
"CD000143","CD000143_pub2_data","5|2|Endotracheal reintubation|No Rescue CPAP used","Endotracheal reintubation",5,2,"No Rescue CPAP used","or","binary",4,-0.343617264818794,0.246598616180362,0,1993.75,0.374773242630385,73.5
"CD000143","CD000143_pub2_data","5|2|Endotracheal reintubation|Rescue CPAP used","Endotracheal reintubation",5,2,"Rescue CPAP used","reported","reported",3,0,0.20522207400018,0,1996.33333333333,0.270140485312899,100
"CD000219","CD000219_pub5_data","1|1|Pain|Pain at 2 to 3 days","Pain",1,1,"Pain at 2 to 3 days","or","binary",7,-0.41676164690069,0.125893032768757,0,1990.28571428571,0.213854085142622,331.428571428571
"CD000219","CD000219_pub5_data","1|1|Pain|Pain at 4 to 7 days","Pain",1,1,"Pain at 4 to 7 days","or","binary",7,-0.44950524692391,0.212771792184257,0.0679601080959826,1994.71428571429,0.228462794968922,180.571428571429
"CD000219","CD000219_pub5_data","1|2|Vomiting, diarrhoea or rash|","Vomiting, diarrhoea or rash",1,2,"","or","binary",8,0.521215015125913,0.163319631946894,0.0730377562087402,1999.75,0.17154218810941,263.375
"CD000219","CD000219_pub5_data","1|3|Abnormal tympanometry|2 to 4 weeks","Abnormal tympanometry",1,3,"2 to 4 weeks","or","binary",7,-0.332849455774826,0.143993489938346,0.0701085453241841,1994,0.462280861007244,305.428571428571
"CD000219","CD000219_pub5_data","1|3|Abnormal tympanometry|3 months","Abnormal tympanometry",1,3,"3 months","or","binary",3,-0.0757003349647501,0.232618940623511,0.0723234252477108,1992.33333333333,0.245618345618346,269.666666666667
"CD000219","CD000219_pub5_data","1|3|Abnormal tympanometry|6 to 8 weeks","Abnormal tympanometry",1,3,"6 to 8 weeks","or","binary",3,-0.243617034618439,0.134926057517551,3.25283719474977e-06,2001.66666666667,0.473335269066976,317.666666666667
"CD000219","CD000219_pub5_data","1|4|Tympanic membrane perforation|","Tympanic membrane perforation",1,4,"","or","binary",5,-0.883344066638029,0.373956297833314,0,2001.6,0.0504115851251659,215
"CD000219","CD000219_pub5_data","1|5|Contralateral otitis (in unilateral cases)|","Contralateral otitis (in unilateral cases)",1,5,"","or","binary",4,-0.771960839497422,0.320925966225891,0.203621397705462,1992,0.183270260392375,226.5
"CD000219","CD000219_pub5_data","1|6|Late AOM recurrences|","Late AOM recurrences",1,6,"","or","binary",6,-0.106401851568843,0.116983051716596,0.00408908821615109,1992.33333333333,0.179519613315768,366.666666666667
"CD000219","CD000219_pub5_data","2|1|Pain|Pain at 3 to 7 days","Pain",2,1,"Pain at 3 to 7 days","or","binary",4,-0.388050533049638,0.234877368956904,0.0999176876088378,2004.75,0.336491047600323,239.75
"CD000219","CD000219_pub5_data","2|2|Vomiting, diarrhoea or rash|","Vomiting, diarrhoea or rash",2,2,"","or","binary",3,0.782995851738636,0.184647536779443,0,2009.33333333333,0.126443278943279,315.333333333333
"CD000219","CD000219_pub5_data","2|4|Tympanic membrane perforation|","Tympanic membrane perforation",2,4,"","or","binary",2,0.475378413844603,0.921647634128117,0,2014,0.00240384615384615,287.5
"CD000219","CD000219_pub5_data","2|5|AOM recurrences|","AOM recurrences",2,5,"","or","binary",2,0.0605069592309015,0.19651364324975,0.0051374667974161,2013,0.242664974619289,292
"CD000478","CD000478_pub5_data","1|1|Failure to maintain remission|Azathioprine versus placebo","Failure to maintain remission",1,1,"Azathioprine versus placebo","or","binary",4,-0.715061153552537,0.268022209147583,0,1992,0.611732711732712,58
"CD000478","CD000478_pub5_data","7|1|Any adverse event|AZA versus placebo","Any adverse event",7,1,"AZA versus placebo","or","binary",3,1.46878467109697,0.965383119036398,0,1998,0,54
"CD000478","CD000478_pub5_data","7|2|Withdrawal due to adverse event|AZA versus placebo","Withdrawal due to adverse event",7,2,"AZA versus placebo","or","binary",3,0.980070769085628,1.04706277093475,0,1998,0,54
"CD000478","CD000478_pub5_data","7|3|Pancreatitis|","Pancreatitis",7,3,"","or","binary",2,1.47630916597649,1.15804024504185,0,2000,0,33
"CD000478","CD000478_pub5_data","7|4|Bone marrow suppression|","Bone marrow suppression",7,4,"","or","binary",2,0.680450745989273,0.939512351027133,0,2007,0.0106382978723404,83
"CD000478","CD000478_pub5_data","8|1|Failure to maintain remission - all trials|Azathioprine versus placebo","Failure to maintain remission - all trials",8,1,"Azathioprine versus placebo","or","binary",4,-0.632744654055663,0.265712584997255,0,1992,0.596581196581197,58
"CD000547","CD000547_pub3_data","1|1|Uterine volume (mL) (preoperative)|GnRHa vs no pretreatment","Uterine volume (mL) (preoperative)",1,1,"GnRHa vs no pretreatment","or","binary",11,0.0911717671311511,0.609617880363658,0,1995.81818181818,0,73.6363636363636
"CD000547","CD000547_pub3_data","1|1|Uterine volume (mL) (preoperative)|GnRHa vs placebo","Uterine volume (mL) (preoperative)",1,1,"GnRHa vs placebo","or","binary",2,0,1.44384575136887,0,1991.5,0,24
"CD000547","CD000547_pub3_data","1|3|Fibroid volume (mL) (preoperative)|GnRHa vs no pretreatment","Fibroid volume (mL) (preoperative)",1,3,"GnRHa vs no pretreatment","or","binary",5,0.0294946229721454,0.904656474149391,0,1995,0,85.4
"CD000547","CD000547_pub3_data","1|5|Haemoglobin (preoperative)|GnRHa vs no pretreatment","Haemoglobin (preoperative)",1,5,"GnRHa vs no pretreatment","or","binary",6,0.0331633490941834,0.824855017707274,0,1995.66666666667,0,51.3333333333333
"CD000547","CD000547_pub3_data","1|5|Haemoglobin (preoperative)|GnRHa vs placebo","Haemoglobin (preoperative)",1,5,"GnRHa vs placebo","or","binary",5,-0.371560269679964,0.902379505210349,0,1993.8,0,105.2
"CD000547","CD000547_pub3_data","1|7|Total frequency of adverse events|GnRHa vs placebo","Total frequency of adverse events",1,7,"GnRHa vs placebo","or","binary",5,1.03117697185506,0.193955460528525,0.0121999618529266,1999.2,0.594488524381715,151
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Abdominal/pelvic pain","Individual adverse events",1,8,"Abdominal/pelvic pain","or","binary",3,0.792430788591853,0.43901708602171,0,1999.33333333333,0.0204081632653061,205
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Arthralgia","Individual adverse events",1,8,"Arthralgia","or","binary",2,0.21181757745805,0.414011942729095,0,1995.5,0.0408163265306122,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Asthenia","Individual adverse events",1,8,"Asthenia","or","binary",3,-0.11182615827112,0.347826428374448,0.0694713224526872,1999.33333333333,0.0782312925170068,205
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Breast pain/tenderness","Individual adverse events",1,8,"Breast pain/tenderness","or","binary",2,-0.319978791697643,0.362702609526924,0,1995.5,0.0714285714285714,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Change in breast size","Individual adverse events",1,8,"Change in breast size","or","binary",2,2.19404654718099,0.789073476122002,0,1995,0.0147058823529412,130.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Change in libido","Individual adverse events",1,8,"Change in libido","or","binary",3,0.632830498830158,0.462794078333536,0.0503779821816269,1994.66666666667,0.10239651416122,110.666666666667
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Depression","Individual adverse events",1,8,"Depression","or","binary",2,0.697668547940075,0.440589494838638,0,1995.5,0.0306122448979592,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Dizziness","Individual adverse events",1,8,"Dizziness","or","binary",2,0.813800542980429,0.371461358563213,0,1995.5,0.0459183673469388,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Headache","Individual adverse events",1,8,"Headache","or","binary",6,0.457896084207018,0.212701248244108,0.0604942630500979,1998.16666666667,0.175132275132275,146.166666666667
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Hot flushes","Individual adverse events",1,8,"Hot flushes","or","binary",6,1.95763097937207,0.214214866986778,0.0683353748348936,1998.16666666667,0.156385331910542,146.166666666667
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Nausea","Individual adverse events",1,8,"Nausea","or","binary",2,0.843026924521858,1.37705828687422,2.90688543093298,1995.5,0.076530612244898,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Pain","Individual adverse events",1,8,"Pain","or","binary",2,-0.46151029030154,0.288538424254936,0,1995.5,0.127551020408163,252.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Skin changes","Individual adverse events",1,8,"Skin changes","or","binary",2,0.203727791458932,0.453232772197581,0,1995,0.0555222088835534,130.5
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Sweating","Individual adverse events",1,8,"Sweating","or","binary",4,2.4673213562127,0.39464875280727,0,2000,0.028141256502601,124.25
"CD000547","CD000547_pub3_data","1|8|Individual adverse events|Vaginitis","Individual adverse events",1,8,"Vaginitis","or","binary",5,1.19930515600858,0.362244858653539,2.04149785017554e-07,1997.2,0.0359410430839002,150.2
"CD000547","CD000547_pub3_data","2|1|Duration of surgery (minutes)|GnRHa vs no pretreatment","Duration of surgery (minutes)",2,1,"GnRHa vs no pretreatment","or","binary",4,0.199243683025891,1.00857725802504,0,1998.5,0,80.25
"CD000547","CD000547_pub3_data","2|1|Duration of surgery (minutes)|GnRHa vs placebo","Duration of surgery (minutes)",2,1,"GnRHa vs placebo","or","binary",2,0.0456876374411893,1.4192131987706,0,1996,0,148
"CD000547","CD000547_pub3_data","2|10|Proportion with vertical incision|GnRHa vs no pretreatment","Proportion with vertical incision",2,10,"GnRHa vs no pretreatment","or","binary",2,-1.10102040082433,0.300970389448435,0,1995.5,0.541265675123943,150.5
"CD000547","CD000547_pub3_data","2|10|Proportion with vertical incision|GnRHa vs placebo","Proportion with vertical incision",2,10,"GnRHa vs placebo","or","binary",2,-0.977819174177471,0.362130812959664,0,1995,0.359658678286129,114
"CD000547","CD000547_pub3_data","2|11|Duration of hospital stay (days)|GnRHa vs no pretreatment","Duration of hospital stay (days)",2,11,"GnRHa vs no pretreatment","or","binary",3,0.0161892196442233,1.16139773268955,0,1998.33333333333,0,91.6666666666667
"CD000547","CD000547_pub3_data","2|13|Postoperative haemoglobin|GnRHa vs no pretreatment","Postoperative haemoglobin",2,13,"GnRHa vs no pretreatment","or","binary",2,0.0243359719707703,1.42394221139051,0,1996,0,86.5
"CD000547","CD000547_pub3_data","2|3|Intraoperative blood loss (mL)|GnRHa vs no pretreatment","Intraoperative blood loss (mL)",2,3,"GnRHa vs no pretreatment","or","binary",4,0.14347207695168,1.0135755634801,0,1995,0,64.5
"CD000547","CD000547_pub3_data","2|5|Frequency of blood transfusions|GnRHa vs no pretreatment","Frequency of blood transfusions",2,5,"GnRHa vs no pretreatment","or","binary",5,-0.623599740325943,0.375452173112557,0,1997,0.0859035112760491,97.4
"CD000547","CD000547_pub3_data","2|6|Postoperative morbidity (complications)|GnRHa vs no treatment","Postoperative morbidity (complications)",2,6,"GnRHa vs no treatment","or","binary",5,-0.502267137340173,0.328316775859944,0.172831000250226,1998.4,0.223275822406257,101.4
"CD000547","CD000547_pub3_data","2|6|Postoperative morbidity (complications)|GnRHa vs placebo","Postoperative morbidity (complications)",2,6,"GnRHa vs placebo","or","binary",2,-0.732293323876017,0.418998380336936,0.080370890117332,1995,0.238295318127251,132.5
"CD000547","CD000547_pub3_data","2|8|Proportion with difficult surgery|GnRH vs no pretreatment","Proportion with difficult surgery",2,8,"GnRH vs no pretreatment","or","binary",2,-0.118705277063985,0.24542624335586,0,1997,0.247468527640941,173.5
"CD000547","CD000547_pub3_data","2|8|Proportion with difficult surgery|GnRH vs placebo","Proportion with difficult surgery",2,8,"GnRH vs placebo","or","binary",3,-0.508433944405534,0.231530077339785,0,1995.33333333333,0.484358518646958,121.666666666667
"CD000547","CD000547_pub3_data","2|9|Proportion undergoing vaginal rather than abdominal procedure|GnRHa vs no treatment","Proportion undergoing vaginal rather than abdominal procedure",2,9,"GnRHa vs no treatment","or","binary",2,2.40761550463885,0.693816587692335,0.721463969157418,1996,0.146031746031746,106.5
"CD000547","CD000547_pub3_data","3|1|Duration of surgery (minutes)|GnRHa vs no pretreatment","Duration of surgery (minutes)",3,1,"GnRHa vs no pretreatment","or","binary",6,-0.00156377775591525,0.823990616641131,0,2002.83333333333,0,70.8333333333333
"CD000547","CD000547_pub3_data","3|3|Intraoperative blood loss (mL)|GnRHa vs no pretreatment","Intraoperative blood loss (mL)",3,3,"GnRHa vs no pretreatment","or","binary",10,-0.0283219291057138,0.641417143492852,0,1998.9,0,53.1
"CD000547","CD000547_pub3_data","3|4|Frequency of blood transfusions|GnRHa vs no pretreatment","Frequency of blood transfusions",3,4,"GnRHa vs no pretreatment","or","binary",3,-0.216964668624516,0.688370337252858,0,1992.66666666667,0.240740740740741,34.3333333333333
"CD000547","CD000547_pub3_data","3|5|Postoperative morbidity (complications)|GnRHa vs no pretreatment","Postoperative morbidity (complications)",3,5,"GnRHa vs no pretreatment","or","binary",4,0.209992112512261,0.496939499905426,0,1994.5,0.173611111111111,43
"CD000547","CD000547_pub3_data","3|7|Duration of hospital stay (days)|GnRHa vs no pretreatment","Duration of hospital stay (days)",3,7,"GnRHa vs no pretreatment","or","binary",3,-0.145750720954311,1.1616469338115,0,2007.66666666667,0,90.6666666666667
"CD000547","CD000547_pub3_data","4|1|Duration of surgery (minutes)|","Duration of surgery (minutes)",4,1,"","or","binary",2,-0.0248425308580532,1.42712793136386,0,2013.5,0,61.5
"CD000547","CD000547_pub3_data","5|10|Adverse events|Abdominal or pelvic pain","Adverse events",5,10,"Abdominal or pelvic pain","or","binary",3,0.447476442012109,0.309901040476773,5.06208387060241e-06,2008.66666666667,0.176666666666667,127.666666666667
"CD000547","CD000547_pub3_data","5|10|Adverse events|Cutaneous disorder","Adverse events",5,10,"Cutaneous disorder","or","binary",2,0.377985530610396,0.514593278883982,0,2006,0.0559782608695652,178.5
"CD000547","CD000547_pub3_data","5|10|Adverse events|Headache","Adverse events",5,10,"Headache","or","binary",5,0.911452321142022,0.668170752708209,1.56245997767176,2009.2,0.138356821589205,98.6
"CD000547","CD000547_pub3_data","5|10|Adverse events|Hot flushes","Adverse events",5,10,"Hot flushes","or","binary",6,2.05723712773225,0.470407138964599,0.696490463585942,2006.66666666667,0.181284357821089,84.5
"CD000547","CD000547_pub3_data","5|10|Adverse events|Mood disorder or anxiety","Adverse events",5,10,"Mood disorder or anxiety","or","binary",2,1.43602318379431,2.4641051839695,10.4976365731341,2003.5,0.0434782608695652,53
"CD000547","CD000547_pub3_data","5|10|Adverse events|Nausea","Adverse events",5,10,"Nausea","or","binary",3,-0.88832070875773,0.699394914410874,0.740740411135964,2006.33333333333,0.172971014492754,135.666666666667
"CD000547","CD000547_pub3_data","5|10|Adverse events|Procedural pain","Adverse events",5,10,"Procedural pain","or","binary",2,0.138516292984244,0.838877377157654,0.734570416817497,2009.5,0.06,166.5
"CD000547","CD000547_pub3_data","5|10|Adverse events|Vaginal dryness","Adverse events",5,10,"Vaginal dryness","or","binary",3,3.46365728388434,1.36392354561865,3.07991889658399,2000.33333333333,0,40
"CD000547","CD000547_pub3_data","5|2|Fibroid volume|GnRHa vs cabergoline","Fibroid volume",5,2,"GnRHa vs cabergoline","reported","reported",2,0,9.50609006502429,0,2008,0,55
"CD000547","CD000547_pub3_data","5|4|Haemoglobin at end of preoperative treatment|","Haemoglobin at end of preoperative treatment",5,4,"","or","binary",2,0.083038651338569,1.42249314520218,0,2016,0,121
"CD000547","CD000547_pub3_data","6|3|Haemoglobin (g/dL)|Comparator was mifepristone","Haemoglobin (g/dL)",6,3,"Comparator was mifepristone","reported","reported",2,0,0.50271089996986,0,2015,0,77
"CD000547","CD000547_pub3_data","6|6|Serious adverse events|Hyperplasia","Serious adverse events",6,6,"Hyperplasia","or","binary",2,-0.959946396749537,1.56935305077011,2.15149024439573,2010,0.0104166666666667,131.5
"CD000547","CD000547_pub3_data","6|6|Serious adverse events|Menometrorrhagia","Serious adverse events",6,6,"Menometrorrhagia","or","binary",2,-0.725060767019265,1.49220594320003,2.69542852275028,2016.5,0.0184811827956989,182.5
"CD000547","CD000547_pub3_data","6|6|Serious adverse events|Uterine haemorrhage","Serious adverse events",6,6,"Uterine haemorrhage","or","binary",2,-1.43911913880586,2.03007949376709,5.87769112351364,2010,0.2,137
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Abdominal pain","Other adverse events",6,7,"Abdominal pain","or","binary",4,0.533598858882924,0.536824076715623,0.265903692279924,2012.5,0.0434811827956989,107
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Breast pain or tenderness","Other adverse events",6,7,"Breast pain or tenderness","or","binary",3,0.659357161771627,0.767346937572263,0,2013.66666666667,0.0333333333333333,132.666666666667
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Constipation","Other adverse events",6,7,"Constipation","or","binary",2,-0.598145628105881,0.685219457849763,0,2010,0.110416666666667,137
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Diarrhoea","Other adverse events",6,7,"Diarrhoea","or","binary",3,0.505936079663712,0.936973555689784,0,2012.66666666667,0.0053763440860215,62.3333333333333
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Dizziness","Other adverse events",6,7,"Dizziness","or","binary",2,0.62810764998625,0.859277316177242,0,2016.5,0.00806451612903226,182.5
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Fatigue","Other adverse events",6,7,"Fatigue","or","binary",2,0.277241015198105,0.611194044476634,0,2015,0.109879032258065,77
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Headache","Other adverse events",6,7,"Headache","or","binary",4,-0.456256859018037,0.665695282781055,0.869654498344446,2012.5,0.249731182795699,107
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Lower back pain","Other adverse events",6,7,"Lower back pain","or","binary",2,0.201845938012849,0.698122105382831,0,2008.5,0.13125,31.5
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Micturition problem","Other adverse events",6,7,"Micturition problem","or","binary",2,0.423905372292625,0.890594020058906,0,2008.5,0.05,31.5
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Nasopharyngitis","Other adverse events",6,7,"Nasopharyngitis","or","binary",2,-0.79560779993543,0.757159082841707,0.148016425798541,2010,0.25,137
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Nausea","Other adverse events",6,7,"Nausea","or","binary",3,0.538338414167082,0.564288553711198,0,2012.66666666667,0.0928763440860215,62.3333333333333
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Vaginal infections","Other adverse events",6,7,"Vaginal infections","or","binary",2,1.00042214570655,1.14411128551675,0,2014.5,0,78.5
"CD000547","CD000547_pub3_data","6|7|Other adverse events|Vomiting","Other adverse events",6,7,"Vomiting","or","binary",2,0.725216326202962,1.27757218571641,0,2015,0,77
"CD001155","CD001155_pub3_data","1|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",1,1,"Clinical vertebral fractures, Primary","or","binary",6,-0.744400383247868,0.305756349837553,0,2003.8,0.0106237816764133,352.666666666667
"CD001155","CD001155_pub3_data","1|1|Clinical vertebral fractures|Clinical vertebral fractures, Secondary","Clinical vertebral fractures",1,1,"Clinical vertebral fractures, Secondary","or","binary",2,-0.80117595435522,0.24799090656344,0,1998,0.0348756218905473,1084.5
"CD001155","CD001155_pub3_data","1|2|Non-vertebral fractures|Non-vertebral fracture, Primary","Non-vertebral fractures",1,2,"Non-vertebral fracture, Primary","or","binary",7,-0.364780412591778,0.197392804492855,0.0632315535871642,2003,0.0445091288620107,1051
"CD001155","CD001155_pub3_data","1|2|Non-vertebral fractures|Non-vertebral fracture, Secondary","Non-vertebral fractures",1,2,"Non-vertebral fracture, Secondary","or","binary",3,-0.259519838836202,0.127818443499348,0,2000.66666666667,0.0959565807327001,745
"CD001155","CD001155_pub3_data","1|3|Hip fractures|Hip fractures, Primary","Hip fractures",1,3,"Hip fractures, Primary","or","binary",7,-0.254906956210549,0.271510660171299,0,2003,0.00437410710531937,1042.71428571429
"CD001155","CD001155_pub3_data","1|3|Hip fractures|Hip fractures, Secondary","Hip fractures",1,3,"Hip fractures, Secondary","or","binary",5,-0.677222539271454,0.319325486076824,0,2003.4,0.00925615823322412,532.6
"CD001155","CD001155_pub3_data","1|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",1,4,"Wrist fractures, Primary","or","binary",8,0.0620234802992147,0.365846252241,0.25365929419917,2002.28571428571,0.00590219799665293,934.625
"CD001155","CD001155_pub3_data","1|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",1,4,"Wrist fractures, Secondary","or","binary",3,-0.61221004763668,0.260121095349015,0,2004.66666666667,0.0135986733001658,730.333333333333
"CD001155","CD001155_pub3_data","1|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",1,5,"Radiographic vertebral fractures, Primary","or","binary",3,-0.560492661504384,0.177431654721109,0,1996.5,0.145851388220189,1422.66666666667
"CD001155","CD001155_pub3_data","1|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",1,5,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.721072551975353,0.141134884819859,0,1998,0.0805475543497703,857.666666666667
"CD001155","CD001155_pub3_data","1|6|Withdrawals due to adverse events|Withdrawals due to adverse events, Primary","Withdrawals due to adverse events",1,6,"Withdrawals due to adverse events, Primary","or","binary",14,0.0259205991928548,0.0796074097597087,0,2003.25,0.0619113962262465,596.5
"CD001155","CD001155_pub3_data","1|7|Serious adverse events|Serious adverse events, Primary","Serious adverse events",1,7,"Serious adverse events, Primary","or","binary",6,0.0803962470382805,0.15234556533691,0,2003.83333333333,0.0773187454673034,436.5
"CD001155","CD001155_pub3_data","1|7|Serious adverse events|Serious adverse events, Secondary","Serious adverse events",1,7,"Serious adverse events, Secondary","or","binary",9,-0.331306389642977,0.140081078290846,0,2007.125,0.104971616241085,256.888888888889
"CD001155","CD001155_pub3_data","1|8|Gastrointestinal adverse events|Gastrointestinal adverse events, Primary","Gastrointestinal adverse events",1,8,"Gastrointestinal adverse events, Primary","or","binary",7,0.0207344787835052,0.0555622082217475,0,2000.33333333333,0.252294881051726,813
"CD001155","CD001155_pub3_data","1|8|Gastrointestinal adverse events|Gastrointestinal adverse events, Secondary","Gastrointestinal adverse events",1,8,"Gastrointestinal adverse events, Secondary","or","binary",12,0.0174177002074062,0.0645557524680059,4.48257353955233e-06,2002.27272727273,0.280998344070034,391.5
"CD001155","CD001155_pub3_data","1|9|Atypical femoral fracture|Atypical femoral fracture, Primary","Atypical femoral fracture",1,9,"Atypical femoral fracture, Primary","or","binary",4,-0.108410608946539,1.00535953124065,0,2007.66666666667,0,209.75
"CD001155","CD001155_pub3_data","1|9|Atypical femoral fracture|Atypical femoral fracture, Secondary","Atypical femoral fracture",1,9,"Atypical femoral fracture, Secondary","or","binary",2,-0.309951396203091,1.41708179007425,0,1998,0,1084.5
"CD001155","CD001155_pub3_data","10|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",10,5,"Radiographic vertebral fractures, Primary","or","binary",2,-0.565119695007521,0.178122824199099,0,1998,0.218777082330284,2103.5
"CD001155","CD001155_pub3_data","10|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",10,5,"Radiographic vertebral fractures, Secondary","or","binary",2,-0.712983919479809,0.141656231074103,0,1996,0.106115449171714,1235.5
"CD001155","CD001155_pub3_data","12|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",12,1,"Clinical vertebral fractures, Primary","or","binary",6,-0.744400383247868,0.305756349837553,0,2003.8,0.0106237816764133,352.666666666667
"CD001155","CD001155_pub3_data","12|1|Clinical vertebral fractures|Clinical vertebral fractures, Secondary","Clinical vertebral fractures",12,1,"Clinical vertebral fractures, Secondary","or","binary",2,-0.80117595435522,0.24799090656344,0,1998,0.0348756218905473,1084.5
"CD001155","CD001155_pub3_data","12|2|Non-vertebral fractures|Non-vertebral fracture, Primary","Non-vertebral fractures",12,2,"Non-vertebral fracture, Primary","or","binary",6,-0.153215773339758,0.0889635224993143,0,2003.8,0.0454902954329582,908.166666666667
"CD001155","CD001155_pub3_data","12|2|Non-vertebral fractures|Non-vertebral fracture, Secondary","Non-vertebral fractures",12,2,"Non-vertebral fracture, Secondary","or","binary",3,-0.259519838836202,0.127818443499348,0,2000.66666666667,0.0959565807327001,745
"CD001155","CD001155_pub3_data","12|3|Hip fractures|Hip fractures, Primary","Hip fractures",12,3,"Hip fractures, Primary","or","binary",5,-0.21857669229126,0.291842372465635,0,2005.25,0.00216411181244364,1054.2
"CD001155","CD001155_pub3_data","12|3|Hip fractures|Hip fractures, Secondary","Hip fractures",12,3,"Hip fractures, Secondary","or","binary",4,-0.693154021744188,0.348551834257732,0,2003.75,0.0054726368159204,584
"CD001155","CD001155_pub3_data","12|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",12,4,"Wrist fractures, Primary","or","binary",6,0.195776496963313,0.161302429574537,0,2003.8,0.0052599939885783,908.166666666667
"CD001155","CD001155_pub3_data","12|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",12,4,"Wrist fractures, Secondary","or","binary",3,-0.61221004763668,0.260121095349015,0,2004.66666666667,0.0135986733001658,730.333333333333
"CD001155","CD001155_pub3_data","12|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",12,5,"Radiographic vertebral fractures, Primary","or","binary",2,-0.592169705276781,0.19077486383858,0,1996.5,0.0187770823302841,2097.5
"CD001155","CD001155_pub3_data","12|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",12,5,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.721072551975353,0.141134884819859,0,1998,0.0805475543497703,857.666666666667
"CD001155","CD001155_pub3_data","13|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",13,1,"Clinical vertebral fractures, Primary","or","binary",5,-0.375847776832032,0.857104576190524,0,2005.25,0.00222222222222222,203.4
"CD001155","CD001155_pub3_data","13|2|Non-vertebral fractures|Non-vertebral fracture, Primary","Non-vertebral fractures",13,2,"Non-vertebral fracture, Primary","or","binary",6,-0.648607835484338,0.238102657959431,0,2004,0.0298353422536503,487.5
"CD001155","CD001155_pub3_data","13|2|Non-vertebral fractures|Non-vertebral fracture, Secondary","Non-vertebral fractures",13,2,"Non-vertebral fracture, Secondary","or","binary",2,-0.613404241650964,0.579193296057808,0,2005.5,0.0703030303030303,104
"CD001155","CD001155_pub3_data","13|3|Hip fractures|Hip fractures, Primary","Hip fractures",13,3,"Hip fractures, Primary","or","binary",5,-0.239745620164864,0.639759063709782,0,2005.5,0.000626304801670146,549.4
"CD001155","CD001155_pub3_data","13|3|Hip fractures|Hip fractures, Secondary","Hip fractures",13,3,"Hip fractures, Secondary","or","binary",4,-0.6058073361014,0.65780493382964,0,2005.25,0.00609756097560976,159
"CD001155","CD001155_pub3_data","13|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",13,4,"Wrist fractures, Secondary","or","binary",2,0.237907186490516,1.28012224735812,0,2009,0,82
"CD001155","CD001155_pub3_data","13|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",13,5,"Radiographic vertebral fractures, Primary","or","binary",2,-0.336361169089295,0.469635942314949,0,1995,0.2,67
"CD001155","CD001155_pub3_data","13|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",13,5,"Radiographic vertebral fractures, Secondary","or","binary",2,-0.796406027732041,0.465308394842613,0,2000,0.0456917978458989,313.5
"CD001155","CD001155_pub3_data","14|2|Non-vertebral fractures|Non-vertebral Fractures, Primary","Non-vertebral fractures",14,2,"Non-vertebral Fractures, Primary","or","binary",2,0.20988074092138,0.410305565852016,0.115492799779182,1998,0.0417220008853475,589
"CD001155","CD001155_pub3_data","14|2|Non-vertebral fractures|Non-vertebral Fractures, Secondary","Non-vertebral fractures",14,2,"Non-vertebral Fractures, Secondary","or","binary",2,-0.577595455250569,0.315894766270329,0,2005.5,0.108745421245421,453
"CD001155","CD001155_pub3_data","14|4|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",14,4,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.521756291455955,0.247241826644757,0,2005.5,0.0711075211955494,476
"CD001155","CD001155_pub3_data","14|5|Withdrawals due to adverse events|Withdrawal due to adverse events, Primary","Withdrawals due to adverse events",14,5,"Withdrawal due to adverse events, Primary","or","binary",3,0.37546505683292,0.231208114023824,0,1999.66666666667,0.0401505090748119,420
"CD001155","CD001155_pub3_data","14|5|Withdrawals due to adverse events|Withdrawal due to adverse events, Secondary","Withdrawals due to adverse events",14,5,"Withdrawal due to adverse events, Secondary","or","binary",3,0.151596961751061,0.272005837847592,0,2005.5,0.0545041678542938,502
"CD001155","CD001155_pub3_data","14|6|Serious adverse events|Serious adverse events, Primary","Serious adverse events",14,6,"Serious adverse events, Primary","or","binary",2,0.18688502548173,0.223902337507709,0,1998,0.0798804780876494,589
"CD001155","CD001155_pub3_data","14|6|Serious adverse events|Serious adverse events, Secondary","Serious adverse events",14,6,"Serious adverse events, Secondary","or","binary",3,-0.229566542142007,0.15134520996257,0,2005.5,0.19663364751526,502
"CD001155","CD001155_pub3_data","14|7|Gastrointestinal adverse events|Gastrointestinal adverse events, Primary","Gastrointestinal adverse events",14,7,"Gastrointestinal adverse events, Primary","or","binary",2,-0.0102458031607629,0.127780108844967,0,1998,0.291854803010182,589
"CD001155","CD001155_pub3_data","14|7|Gastrointestinal adverse events|Gastrointestinal adverse events, Secondary","Gastrointestinal adverse events",14,7,"Gastrointestinal adverse events, Secondary","or","binary",2,-0.109138323146495,0.163351041485343,0,1997,0.335884518504166,391.5
"CD001155","CD001155_pub3_data","16|2|Non-vertebral fractures|Non-vertebral Fractures, Secondary","Non-vertebral fractures",16,2,"Non-vertebral Fractures, Secondary","or","binary",2,-0.577595455250569,0.315894766270329,0,2005.5,0.108745421245421,453
"CD001155","CD001155_pub3_data","16|4|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",16,4,"Radiographic vertebral fractures, Secondary","or","binary",2,-0.523920242065101,0.294381860918387,0,2005.5,0.0756753663003663,453
"CD001155","CD001155_pub3_data","18|2|Non-vertebral fractures|Non-vertebral Fractures, Primary","Non-vertebral fractures",18,2,"Non-vertebral Fractures, Primary","or","binary",2,0.20988074092138,0.410305565852016,0.115492799779182,1998,0.0417220008853475,589
"CD001155","CD001155_pub3_data","19|2|Non-vertebral fractures|Non-vertebral Fractures, Primary","Non-vertebral fractures",19,2,"Non-vertebral Fractures, Primary","or","binary",2,0.20988074092138,0.410305565852016,0.115492799779182,1998,0.0417220008853475,589
"CD001155","CD001155_pub3_data","19|2|Non-vertebral fractures|Non-vertebral Fractures, Secondary","Non-vertebral fractures",19,2,"Non-vertebral Fractures, Secondary","or","binary",2,-0.56425022132386,0.315789344728666,0,2005.5,0.107481559536354,473
"CD001155","CD001155_pub3_data","19|4|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",19,4,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.528246941262077,0.246795310609638,0,2005.5,0.0671948389073402,515
"CD001155","CD001155_pub3_data","2|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",2,1,"Clinical vertebral fractures, Primary","or","binary",4,-0.108410608946539,1.00535953124065,0,2007.66666666667,0,209.75
"CD001155","CD001155_pub3_data","2|2|Non-vertebral fractures|Non-vertebral fractures, Primary","Non-vertebral fractures",2,2,"Non-vertebral fractures, Primary","or","binary",5,-0.674278726262902,0.253169209089839,0,2005.5,0.0246912995932693,549.4
"CD001155","CD001155_pub3_data","2|3|Hip fractures|Hip fractures, Primary","Hip fractures",2,3,"Hip fractures, Primary","or","binary",5,-0.239745620164864,0.639759063709782,0,2005.5,0.000626304801670146,549.4
"CD001155","CD001155_pub3_data","2|3|Hip fractures|Hip fractures, Secondary","Hip fractures",2,3,"Hip fractures, Secondary","or","binary",3,-0.63111243287251,1.16614916814168,0,2005.33333333333,0,103
"CD001155","CD001155_pub3_data","2|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",2,4,"Wrist fractures, Primary","or","binary",5,-0.469785435257824,0.519538174779194,0.163448832078562,2005.5,0.00313152400835073,549.4
"CD001155","CD001155_pub3_data","2|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",2,5,"Radiographic vertebral fractures, Primary","or","binary",2,-0.336361169089295,0.469635942314949,0,1995,0.2,67
"CD001155","CD001155_pub3_data","20|1|Non-vertebral fractures|Non-vertebral Fractures, Secondary","Non-vertebral fractures",20,1,"Non-vertebral Fractures, Secondary","or","binary",2,-0.577595455250569,0.315894766270329,0,2005.5,0.108745421245421,453
"CD001155","CD001155_pub3_data","20|3|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",20,3,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.521756291455955,0.247241826644757,0,2005.5,0.0711075211955494,476
"CD001155","CD001155_pub3_data","22|1|Non-vertebral fractures|Non-vertebral Fractures, Secondary","Non-vertebral fractures",22,1,"Non-vertebral Fractures, Secondary","or","binary",2,-0.577595455250569,0.315894766270329,0,2005.5,0.108745421245421,453
"CD001155","CD001155_pub3_data","22|3|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",22,3,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.521756291455955,0.247241826644757,0,2005.5,0.0711075211955494,476
"CD001155","CD001155_pub3_data","23|6|Serious adverse events|Serious adverse events, Primary","Serious adverse events",23,6,"Serious adverse events, Primary","or","binary",2,0.27664234160518,0.431530200971199,0,2005.5,0.0568181818181818,407.5
"CD001155","CD001155_pub3_data","23|9|Osteonecrosis of the jaw|Osteonecrosis of the jaw, Primary","Osteonecrosis of the jaw",23,9,"Osteonecrosis of the jaw, Primary","or","binary",2,-0.0075958778455641,1.41529885638317,0,2005.5,0,650.5
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",24,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",4,0.410969321352098,0.660695018509337,0,2001.25,0.0034965034965035,214
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 10 mg/day vs (Alendronate 10 mg/day + HRT)","or","binary",2,-0.621328451866374,0.846315668526896,0,2002,0.0273809523809524,146
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs HRT","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 10 mg/day vs HRT","or","binary",2,-0.0590980018253396,0.925325863655635,0,2002,0.00699300699300699,147.5
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate  150 mg/month","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 70 mg/week vs  Ibandronate  150 mg/month","or","binary",3,-0.0913512405875674,0.556578943381106,0,2011,0.001906941266209,671
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",3,-0.512236041497707,1.1599003723637,0,2010,0,130.666666666667
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 70 mg/week vs Denosumab 60 mg/6 months, SC","or","binary",3,0.185372817186691,1.07149953393336,0,2011.33333333333,0,595.333333333333
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 70 mg/week vs Raloxifene 60 mg/day","or","binary",3,0.909736385923063,1.03367885566454,0,2005,0,787
"CD001155","CD001155_pub3_data","24|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Strontium ranelate 2 g/day","Alendronate vs Other active agent, Secondary",24,2,"Alendronate 70 mg/week vs Strontium ranelate 2 g/day","or","binary",2,-0.600903455802322,1.27734577981439,0,2009.5,0.0108695652173913,64.5
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",25,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",5,0.053253373481084,0.39165060660178,0.117230550728544,2002,0.0262666928087489,259
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",3,0.317720226027413,0.579195226770349,0,2003,0.0119047619047619,244
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 10 mg/day vs  HRT","or","binary",3,-0.156411900150925,0.516248881084917,0,2003,0.0297591297591298,244.666666666667
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",5,-0.104708766894793,0.263094982359152,0,2005.2,0.0212800977672301,571.2
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,-0.668670187038088,0.566102223026462,0,2012.5,0.0158102766798419,303.5
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate 150 mg/month","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 70 mg/week vs  Ibandronate 150 mg/month","or","binary",2,-0.1783281173996,0.38189246319592,0,2008,0.0080091533180778,949.5
"CD001155","CD001155_pub3_data","25|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",25,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",3,-0.519853551421484,1.16198987505047,0,2006,0,109
"CD001155","CD001155_pub3_data","26|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","Alendronate vs Other active agent, Primary",26,1,"Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","or","binary",2,-0.0278731493313582,1.41967452125907,0,2009.5,0,165
"CD001155","CD001155_pub3_data","26|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, IV","Alendronate vs Other active agent, Primary",26,1,"Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, IV","or","binary",2,0.85692373604824,1.27314114047621,0,2013.5,0,101
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",26,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",5,0.00795841781192973,0.897639952195194,0,2002,0,259
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",3,0.599602121318142,1.07572285052842,0,2003,0,244
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 10 mg/day vs  HRT","or","binary",3,0.604374079649848,1.07571791376938,0,2003,0,244.666666666667
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",4,-0.502642795841159,0.743758146980996,0,2005,0.00175265198060062,697.25
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,-0.513784691318288,1.41922911431766,0,2012.5,0,303.5
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate 150 mg/month","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 70 mg/week vs  Ibandronate 150 mg/month","or","binary",2,-0.691058891996631,1.42057410758513,0,2014,0,140
"CD001155","CD001155_pub3_data","26|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",26,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",4,-0.385176342583266,1.00580878384811,0,2008.66666666667,0,110.5
"CD001155","CD001155_pub3_data","27|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","Alendronate vs Other active agent, Primary",27,1,"Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","or","binary",2,-0.0278731493313582,1.41967452125907,0,2009.5,0,165
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",27,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",5,-0.411092741938406,0.710633070436997,0,2002,0.0089998475045204,259
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",3,0.655567623116742,1.07342030407705,0,2003,0,244
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 10 mg/day vs  HRT","or","binary",3,-0.0645004480223636,0.858971045005031,0,2003,0.0134421134421134,244.666666666667
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",3,-0.341992511642709,0.484039816037683,0,2005.33333333333,0.00526424913437416,767.333333333333
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,0.253407360659622,1.26847613300999,0,2012,0,642
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",3,-0.519853551421484,1.16198987505047,0,2006,0,109
"CD001155","CD001155_pub3_data","27|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Zolendronic acid 5 mg/year, IV","Alendronate vs Other active agent, Secondary",27,2,"Alendronate 70 mg/week vs  Zolendronic acid 5 mg/year, IV","or","binary",2,1.10287292641827,1.26837041267347,0,2014,0,353.5
"CD001155","CD001155_pub3_data","28|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",28,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",2,-0.304291564101768,0.563484742882106,0,2002.5,0.0183282597666159,328.5
"CD001155","CD001155_pub3_data","28|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",28,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",2,0.00878307173418905,0.652851132589842,0,2002.5,0.0159090909090909,309
"CD001155","CD001155_pub3_data","28|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",28,2,"Alendronate 10 mg/day vs  HRT","or","binary",2,-0.415039158567936,0.580594227273836,0,2002.5,0.0183282597666159,307.5
"CD001155","CD001155_pub3_data","28|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",28,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",2,0.274241805485127,0.42808586519775,0,2006,0.0187849297438339,476.5
"CD001155","CD001155_pub3_data","28|2|Alendronate vs Other active agent, Secondary|Alendronate 5 mg/day vs  Alfacalcidol 1 μg/day","Alendronate vs Other active agent, Secondary",28,2,"Alendronate 5 mg/day vs  Alfacalcidol 1 μg/day","or","binary",2,-0.752146559995351,0.420950098636819,0,2000.5,0.109375,147.5
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Primary",29,1,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",2,-0.418045553387529,0.528737966986014,0,2004.5,0.0593637992831541,169
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|Alendronate 10 mg/day vs (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Primary",29,1,"Alendronate 10 mg/day vs (Alendronate 10 mg/day + HRT)","or","binary",2,0.253383499973317,1.04716903011726,0.602471307213127,2001.5,0.025,133.5
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|Alendronate 10 mg/day vs Calcitonin 100 IU/day, IN","Alendronate vs Other active agent, Primary",29,1,"Alendronate 10 mg/day vs Calcitonin 100 IU/day, IN","or","binary",2,0.487054573210087,0.928193227043988,0,1995,0.00666666666666667,122
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|Alendronate 10 mg/day vs HRT","Alendronate vs Other active agent, Primary",29,1,"Alendronate 10 mg/day vs HRT","or","binary",2,0,0.718084705406644,0,2001.5,0.023252688172043,133
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","Alendronate vs Other active agent, Primary",29,1,"Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","or","binary",3,1.17353338865541,0.63473975711806,0,2009.66666666667,0.0111082628385884,169.333333333333
"CD001155","CD001155_pub3_data","29|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, IV","Alendronate vs Other active agent, Primary",29,1,"Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, IV","or","binary",2,-0.388214210414278,1.05451671007539,0.735725083676661,2010.5,0.0176991150442478,163
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",29,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",5,-0.102578689281787,0.20127978572009,0,2004.6,0.0746380103627232,315.8
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",2,-0.712089132610572,0.349541434795829,0.0111442841001432,2002.5,0.0850649350649351,336
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs  HRT","or","binary",3,-0.683079701489103,0.336277555925352,0,2007,0.0569871528775638,290.666666666667
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",6,0.0158952737874669,0.15166514408796,0,2006.16666666667,0.0619354529362922,492.666666666667
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs (Alendronate 10 mg/day + Raloxifene 60 mg/day)","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs (Alendronate 10 mg/day + Raloxifene 60 mg/day)","or","binary",2,-0.242785017470948,0.418125183246127,0,2008,0.0824324324324324,265.5
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs Calcitriol 0.5 μg/day","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs Calcitriol 0.5 μg/day","or","binary",2,1.43129097515304,0.816633471371669,0,1999,0.0147058823529412,65.5
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs cyclic Etidronate 400 mg/day","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 10 mg/day vs cyclic Etidronate 400 mg/day","or","binary",2,2.36467804380036,1.07049316392397,0,2002.5,0,59.5
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",3,-0.0202074559909655,0.393560361747679,0,2011.33333333333,0.00976700060210581,595.333333333333
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",4,-0.149802766165141,0.188791494389625,0,2005.25,0.064977064977065,362
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Zolendronic acid 5 mg/year, IV","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 70 mg/week vs  Zolendronic acid 5 mg/year, IV","or","binary",2,1.80127680290596,0.485665677129918,0,2014,0.00612745098039216,353.5
"CD001155","CD001155_pub3_data","29|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Strontium Ranelate 2 g/day","Alendronate vs Other active agent, Secondary",29,2,"Alendronate 70 mg/week vs Strontium Ranelate 2 g/day","or","binary",2,-0.790733290457165,0.406723736291275,0,2011,0.119055706521739,237.5
"CD001155","CD001155_pub3_data","3|2|Non-vertebral fractures|Non-vertebral fractures, Secondary","Non-vertebral fractures",3,2,"Non-vertebral fractures, Secondary","or","binary",2,-0.613404241650964,0.579193296057808,0,2003,0.0703030303030303,104
"CD001155","CD001155_pub3_data","3|3|Hip fractures|Hip fractures, Secondary","Hip fractures",3,3,"Hip fractures, Secondary","or","binary",3,-0.546636740261663,0.696176748913702,0,2006.66666666667,0.00813008130081301,163.666666666667
"CD001155","CD001155_pub3_data","3|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",3,4,"Wrist fractures, Secondary","or","binary",2,0.237907186490516,1.28012224735812,0,2009,0,82
"CD001155","CD001155_pub3_data","3|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",3,5,"Radiographic vertebral fractures, Secondary","or","binary",2,-1.01632068030365,0.185771791781989,0,1998,0.0717739451801663,998.5
"CD001155","CD001155_pub3_data","30|1|Alendronate vs Other active agent, Primary|Alendronate 70mg/week vs Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Primary",30,1,"Alendronate 70mg/week vs Denosumab 60 mg/6 months, SC","or","binary",2,0.671859455188853,0.51910635118954,0,2011,0.0240481927710843,203.5
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",30,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",4,-0.0235517974090734,0.252143881110942,0,2001.5,0.0495800928043919,308.75
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",2,-0.00363003530007493,0.372282656574931,0,2002.5,0.0701298701298701,336
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 10 mg/day vs  HRT","or","binary",2,0.197335097605495,0.382321518754145,0,2002.5,0.0594405594405594,337
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",5,0.0327559422377888,0.281812136696214,0.129662691081689,2005.6,0.0331692073874793,576.6
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",3,0.0844843548183251,0.201590334404333,0,2011.33333333333,0.0388747064456427,595.333333333333
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate 150 mg/month","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 70 mg/week vs  Ibandronate 150 mg/month","or","binary",2,-0.24034429932802,0.767450104380458,0.925421081342455,2011,0.0837147215865751,923.5
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",5,-0.0938002246189684,0.18482335084522,0,2007.4,0.0633782014227235,295
"CD001155","CD001155_pub3_data","30|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Strontium Ranelate 2 g/day","Alendronate vs Other active agent, Secondary",30,2,"Alendronate 70 mg/week vs Strontium Ranelate 2 g/day","or","binary",2,-0.197834239849813,0.632112420470969,0.473244285556225,2011,0.0896419437340154,237.5
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",32,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",4,0.130993654648537,0.154746967515421,1.91035212140451e-06,2007.25,0.196180442091657,250.75
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",32,2,"Alendronate 10 mg/day vs  Raloxifene 60 mg/day","or","binary",4,0.0561024736330983,0.225864156059724,0.109790094061514,2005.25,0.121337410666919,606.75
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|Alendronate 5 mg/day vs Alfacalcidol 1 μg/day","Alendronate vs Other active agent, Secondary",32,2,"Alendronate 5 mg/day vs Alfacalcidol 1 μg/day","or","binary",2,-0.56578108085183,0.445545970625906,0.309987793541353,2000.5,0.293571428571429,283.5
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",32,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,0.0540513555661427,0.110105105795903,0,2009.5,0.252904438475228,840.5
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",32,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",2,0.16520806502068,0.135145917829809,0,2004.5,0.229792450678527,619.5
"CD001155","CD001155_pub3_data","32|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs Strontium ranelate 2 g/day","Alendronate vs Other active agent, Secondary",32,2,"Alendronate 70 mg/week vs Strontium ranelate 2 g/day","or","binary",2,-0.136513839798273,0.223334487306269,0,2011,0.29156010230179,237.5
"CD001155","CD001155_pub3_data","33|1|Alendronate vs Other active agent, Primary|Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","Alendronate vs Other active agent, Primary",33,1,"Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC","or","binary",2,0.0393936948316682,1.41940833577669,0,2009.5,0,168
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|(Alendronate 10 mg/day + HRT) vs HRT","Alendronate vs Other active agent, Secondary",33,2,"(Alendronate 10 mg/day + HRT) vs HRT","or","binary",5,0.00795841781192973,0.897639952195194,0,2002,0,259
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)","or","binary",3,0.139776027991195,1.15912399293349,0,2003,0,244
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs  HRT","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 10 mg/day vs  HRT","or","binary",3,0.145321505401603,1.15911781661115,0,2003,0,244.666666666667
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 10 mg/day vs Raloxifene 60 mg/day","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 10 mg/day vs Raloxifene 60 mg/day","or","binary",2,0.0176420635636817,1.41579871596128,0,2004.5,0,445
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,-0.513784691318288,1.41922911431766,0,2012.5,0,303.5
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate 150 mg/month","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 70 mg/week vs  Ibandronate 150 mg/month","or","binary",2,-0.691058891996631,1.42057410758513,0,2014,0,140
"CD001155","CD001155_pub3_data","33|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Risedronate 35 mg/week","Alendronate vs Other active agent, Secondary",33,2,"Alendronate 70 mg/week vs  Risedronate 35 mg/week","or","binary",4,-0.377641620088706,1.00578012360901,0,2008.66666666667,0,110.75
"CD001155","CD001155_pub3_data","34|1|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Ibandronate 150 mg/month","Alendronate vs Other active agent, Secondary",34,1,"Alendronate 70 mg/week vs  Ibandronate 150 mg/month","or","binary",2,-0.863528538676493,0.227599896128707,0,2011,0.0951563691838291,923.5
"CD001155","CD001155_pub3_data","36|2|Alendronate vs Other active agent, Secondary|Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","Alendronate vs Other active agent, Secondary",36,2,"Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC","or","binary",2,0.0141047891854192,1.15592940169959,0,2009.5,0.000843170320404722,840.5
"CD001155","CD001155_pub3_data","4|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",4,4,"Wrist fractures, Primary","or","binary",2,1.59643212127901,1.11596592116465,0,1998,0,149
"CD001155","CD001155_pub3_data","4|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",4,5,"Radiographic vertebral fractures, Secondary","or","binary",2,-0.712983919479809,0.141656231074103,0,1996,0.106115449171714,1235.5
"CD001155","CD001155_pub3_data","7|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",7,1,"Clinical vertebral fractures, Primary","or","binary",2,-0.565653547158751,1.27387026105555,0,2002.5,0.00555555555555556,110.5
"CD001155","CD001155_pub3_data","7|1|Clinical vertebral fractures|Clinical vertebral fractures, Secondary","Clinical vertebral fractures",7,1,"Clinical vertebral fractures, Secondary","or","binary",2,-0.80117595435522,0.24799090656344,0,1998,0.0348756218905473,1084.5
"CD001155","CD001155_pub3_data","7|2|Non-vertebral fractures|Non-vertebral fracture, Primary","Non-vertebral fractures",7,2,"Non-vertebral fracture, Primary","or","binary",3,-0.141326189765251,0.0899501023359337,0,2001,0.0765913569114651,1551
"CD001155","CD001155_pub3_data","7|2|Non-vertebral fractures|Non-vertebral fracture, Secondary","Non-vertebral fractures",7,2,"Non-vertebral fracture, Secondary","or","binary",2,-0.255371628902415,0.128753269729359,0,2000.5,0.11363184079602,1084.5
"CD001155","CD001155_pub3_data","7|3|Hip fractures|Hip fractures, Primary","Hip fractures",7,3,"Hip fractures, Primary","or","binary",2,-0.218558500084125,0.301566745883914,0,2002.5,0.00541027953110911,2237.5
"CD001155","CD001155_pub3_data","7|3|Hip fractures|Hip fractures, Secondary","Hip fractures",7,3,"Hip fractures, Secondary","or","binary",5,-0.677222539271454,0.319325486076824,0,2003.4,0.00925615823322412,532.6
"CD001155","CD001155_pub3_data","7|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",7,4,"Wrist fractures, Primary","or","binary",3,0.186976273355628,0.163248469388175,0,2001,0.0105199879771566,1551
"CD001155","CD001155_pub3_data","7|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",7,4,"Wrist fractures, Secondary","or","binary",3,-0.61221004763668,0.260121095349015,0,2004.66666666667,0.0135986733001658,730.333333333333
"CD001155","CD001155_pub3_data","7|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",7,5,"Radiographic vertebral fractures, Primary","or","binary",2,-0.565119695007521,0.178122824199099,0,1998,0.218777082330284,2103.5
"CD001155","CD001155_pub3_data","7|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",7,5,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.721072551975353,0.141134884819859,0,1998,0.0805475543497703,857.666666666667
"CD001155","CD001155_pub3_data","9|1|Clinical vertebral fractures|Clinical vertebral fractures, Primary","Clinical vertebral fractures",9,1,"Clinical vertebral fractures, Primary","or","binary",6,-0.747204612225522,0.305748737279786,0,2003.8,0.0106237816764133,353.5
"CD001155","CD001155_pub3_data","9|1|Clinical vertebral fractures|Clinical vertebral fractures, Secondary","Clinical vertebral fractures",9,1,"Clinical vertebral fractures, Secondary","or","binary",2,-0.80117595435522,0.24799090656344,0,1998,0.0348756218905473,1084.5
"CD001155","CD001155_pub3_data","9|2|Non-vertebral fractures|Non-vertebral fracture, Primary","Non-vertebral fractures",9,2,"Non-vertebral fracture, Primary","or","binary",7,-0.367547858475937,0.198026976976835,0.0638963619660991,2003,0.0442710336239155,1051.71428571429
"CD001155","CD001155_pub3_data","9|2|Non-vertebral fractures|Non-vertebral fracture, Secondary","Non-vertebral fractures",9,2,"Non-vertebral fracture, Secondary","or","binary",3,-0.259519838836202,0.127818443499348,0,2002.33333333333,0.0959565807327001,745
"CD001155","CD001155_pub3_data","9|3|Hip fractures|Hip fractures, Primary","Hip fractures",9,3,"Hip fractures, Primary","or","binary",7,-0.257137441516024,0.271505329667797,0,2003,0.00437410710531937,1043.42857142857
"CD001155","CD001155_pub3_data","9|3|Hip fractures|Hip fractures, Secondary","Hip fractures",9,3,"Hip fractures, Secondary","or","binary",5,-0.676507518855985,0.319300797162115,0,2003.4,0.00925615823322412,533.4
"CD001155","CD001155_pub3_data","9|4|Wrist fractures|Wrist fractures, Primary","Wrist fractures",9,4,"Wrist fractures, Primary","or","binary",8,0.0576390873383083,0.364949892241019,0.251623322730482,2002.28571428571,0.00590219799665293,935.25
"CD001155","CD001155_pub3_data","9|4|Wrist fractures|Wrist fractures, Secondary","Wrist fractures",9,4,"Wrist fractures, Secondary","or","binary",3,-0.611742230779178,0.260107749539526,0,2004.66666666667,0.0135986733001658,731.666666666667
"CD001155","CD001155_pub3_data","9|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Primary","Radiographic vertebral fractures",9,5,"Radiographic vertebral fractures, Primary","or","binary",3,-0.542302987191657,0.175450020236137,0,1996.5,0.105055605650736,1531.33333333333
"CD001155","CD001155_pub3_data","9|5|Radiographic vertebral fractures|Radiographic vertebral fractures, Secondary","Radiographic vertebral fractures",9,5,"Radiographic vertebral fractures, Secondary","or","binary",3,-0.71979969073254,0.140796758121115,0,1998,0.0732314080312125,920.666666666667
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|Adults with neuromuscular dysfunction of the bladder with incomplete bladder emptying","Symptomatic UTI: culture-verified UTI",1,1,"Adults with neuromuscular dysfunction of the bladder with incomplete bladder emptying","or","binary",3,-0.0576129329089886,0.186665870613039,0,2008.33333333333,0.410247208931419,154.666666666667
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|Children","Symptomatic UTI: culture-verified UTI",1,1,"Children","or","binary",5,-1.12229321443157,0.350658806595974,0.32511351659211,2012.2,0.44836886617243,100.8
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|Elderly men and women in institutions","Symptomatic UTI: culture-verified UTI",1,1,"Elderly men and women in institutions","or","binary",3,-0.074121708634848,0.176229674482929,0.00563876130719174,2011.66666666667,0.100921053746494,496.333333333333
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|People with a susceptibility to UTIs due to an intervention","Symptomatic UTI: culture-verified UTI",1,1,"People with a susceptibility to UTIs due to an intervention","or","binary",6,-0.895291504348193,0.148834418971673,1.78143471888227e-07,2017,0.227318632350491,239
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|Pregnant women","Symptomatic UTI: culture-verified UTI",1,1,"Pregnant women","or","binary",3,0.148965170782696,0.183585380671262,0,2011,0.226107226107226,255
"CD001321","CD001321_pub7_data","1|1|Symptomatic UTI: culture-verified UTI|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI",1,1,"Women with recurrent UTIs","or","binary",8,-0.407827377716001,0.198680886243886,0.167215380044989,2010.125,0.283614223087415,194.375
"CD001321","CD001321_pub7_data","1|2|Clinical UTI: symptoms, no culture|Elderly men and women in institutions","Clinical UTI: symptoms, no culture",1,2,"Elderly men and women in institutions","or","binary",2,-0.140047477817926,0.133939536253246,0,2015,0.214115762983299,556.5
"CD001321","CD001321_pub7_data","1|3|Microbiological UTI: positive culture without known symptoms|Elderly men and women in institutions","Microbiological UTI: positive culture without known symptoms",1,3,"Elderly men and women in institutions","or","binary",2,-0.391048605840364,0.334992051958493,0,2002,0.482570806100218,104.5
"CD001321","CD001321_pub7_data","1|4|Death|","Death",1,4,"","or","binary",4,0.0933186372332569,0.13012463417634,0,2013.5,0.122783914908143,393.5
"CD001321","CD001321_pub7_data","1|5|Gastrointestinal adverse events|","Gastrointestinal adverse events",1,5,"","or","binary",10,0.28967898193149,0.253912362242692,0,2014,0.107231461454244,216.6
"CD001321","CD001321_pub7_data","10|1|Symptomatic UTI: culture-verified UTI (commercial involvement)|Adults with neuropathy or neuropathic bladders","Symptomatic UTI: culture-verified UTI (commercial involvement)",10,1,"Adults with neuropathy or neuropathic bladders","or","binary",2,-0.0905737780021962,0.213588832377575,0,2005.5,0.415370813397129,176.5
"CD001321","CD001321_pub7_data","10|1|Symptomatic UTI: culture-verified UTI (commercial involvement)|Children","Symptomatic UTI: culture-verified UTI (commercial involvement)",10,1,"Children","or","binary",2,-0.560940470981064,0.298587791875082,0,2013,0.271799358413532,167
"CD001321","CD001321_pub7_data","10|1|Symptomatic UTI: culture-verified UTI (commercial involvement)|Elderly men and women","Symptomatic UTI: culture-verified UTI (commercial involvement)",10,1,"Elderly men and women","or","binary",4,-0.0749664387608484,0.161943612497214,0,2011.25,0.252161378545165,381.5
"CD001321","CD001321_pub7_data","10|1|Symptomatic UTI: culture-verified UTI (commercial involvement)|People with a susceptibility to UTIs due to an intervention","Symptomatic UTI: culture-verified UTI (commercial involvement)",10,1,"People with a susceptibility to UTIs due to an intervention","or","binary",2,-0.660520300573201,0.293796994706889,0,2017.5,0.210416666666667,185
"CD001321","CD001321_pub7_data","10|1|Symptomatic UTI: culture-verified UTI (commercial involvement)|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI (commercial involvement)",10,1,"Women with recurrent UTIs","or","binary",2,-0.193936822339673,0.199151830166369,0,2014.5,0.269670814933762,293
"CD001321","CD001321_pub7_data","10|2|Symptomatic UTI: culture-verified UTI (no commercial involvement)|People with a susceptibility to UTI due to an intervention","Symptomatic UTI: culture-verified UTI (no commercial involvement)",10,2,"People with a susceptibility to UTI due to an intervention","or","binary",3,-1.24673503668499,0.422110963757229,0.197823024557679,2017,0.25880393136765,336.333333333333
"CD001321","CD001321_pub7_data","10|2|Symptomatic UTI: culture-verified UTI (no commercial involvement)|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI (no commercial involvement)",10,2,"Women with recurrent UTIs","or","binary",5,-0.537862086842,0.352679654630766,0.418582937984366,2010,0.281914430966359,163.8
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|Adults with bladder emptying issues or multiple sclerosis","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"Adults with bladder emptying issues or multiple sclerosis","or","binary",3,-0.0576129329089886,0.186665870613039,0,2008.33333333333,0.410247208931419,154.666666666667
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|Children","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"Children","or","binary",4,-0.883535810780118,0.335326927713684,0.167828415927563,2011.75,0.402566345873432,107
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|Elderly men and women","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"Elderly men and women","or","binary",2,0.0273752059695201,0.17869601378368,0,2015,0.114344543582704,556.5
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|People with a susceptibility to UTIs due to an intervention","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"People with a susceptibility to UTIs due to an intervention","or","binary",2,-1.21221093036214,0.471776135276377,0.242212830931756,2017.5,0.322988505747126,482
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|Pregnant women","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"Pregnant women","or","binary",2,1.10659168382902,1.20569463423984,0,2011.5,0,110.5
"CD001321","CD001321_pub7_data","11|1|Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)",11,1,"Women with recurrent UTIs","or","binary",5,-0.451387738327407,0.298619311735072,0.29616999380488,2008.2,0.284375969427897,182.4
"CD001321","CD001321_pub7_data","11|2|Symptomatic UTI: culture-verified UTI (< 108 CFU/L)|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI (< 108 CFU/L)",11,2,"Women with recurrent UTIs","or","binary",2,-0.60060485450988,0.632457465291592,0.547092884375711,2013.5,0.244271685761047,215
"CD001321","CD001321_pub7_data","2|1|Symptomatic UTI: culture-verified UTI|Children","Symptomatic UTI: culture-verified UTI",2,1,"Children","or","binary",4,-0.82500456259079,0.380419684161813,0.286597337531209,2011.75,0.402566345873432,100.25
"CD001321","CD001321_pub7_data","2|1|Symptomatic UTI: culture-verified UTI|Pregnant women","Symptomatic UTI: culture-verified UTI",2,1,"Pregnant women","or","binary",2,0.147750315178419,0.184340882310988,0,2009,0.339160839160839,366
"CD001321","CD001321_pub7_data","2|1|Symptomatic UTI: culture-verified UTI|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI",2,1,"Women with recurrent UTIs","or","binary",6,-0.239689108340088,0.188621379622153,0.0980023959819555,2009.16666666667,0.283859493479663,220.333333333333
"CD001321","CD001321_pub7_data","3|1|Symptomatic UTI: culture-verified UTI|Adults with bladder emptying issues or multiple sclerosis","Symptomatic UTI: culture-verified UTI",3,1,"Adults with bladder emptying issues or multiple sclerosis","or","binary",3,-0.0576129329089886,0.186665870613039,0,2008.33333333333,0.410247208931419,154.666666666667
"CD001321","CD001321_pub7_data","3|1|Symptomatic UTI: culture-verified UTI|Elderly men and women","Symptomatic UTI: culture-verified UTI",3,1,"Elderly men and women","or","binary",2,0.0273752059695201,0.17869601378368,0,2015,0.114344543582704,556.5
"CD001321","CD001321_pub7_data","3|1|Symptomatic UTI: culture-verified UTI|People with a susceptibility to UTIs due to an intervention","Symptomatic UTI: culture-verified UTI",3,1,"People with a susceptibility to UTIs due to an intervention","or","binary",6,-0.883468664895484,0.148669578350728,0,2017,0.206485299017158,242.333333333333
"CD001321","CD001321_pub7_data","3|1|Symptomatic UTI: culture-verified UTI|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI",3,1,"Women with recurrent UTIs","or","binary",3,-0.973321305567002,0.28796908867715,0,2009.33333333333,0.295252274607113,111
"CD001321","CD001321_pub7_data","3|2|Clinical UTI: symptoms, no culture|Elderly","Clinical UTI: symptoms, no culture",3,2,"Elderly","or","binary",2,-0.140047477817926,0.133939536253246,0,2015,0.214115762983299,556.5
"CD001321","CD001321_pub7_data","7|2|Clinical UTI: symptoms, no culture|Women with recurrent UTIs","Clinical UTI: symptoms, no culture",7,2,"Women with recurrent UTIs","or","binary",2,0.512097101310043,0.248725132432668,0,2010,0.460835913312693,168
"CD001321","CD001321_pub7_data","9|1|Symptomatic UTI: culture-verified UTI (low dose PAC < 40 mg/day)|Women with recurrent UTIs","Symptomatic UTI: culture-verified UTI (low dose PAC < 40 mg/day)",9,1,"Women with recurrent UTIs","or","binary",3,-0.683573903807337,0.339235082344409,0.141385734982383,2013,0.308082463286359,141.666666666667
"CD001321","CD001321_pub7_data","9|2|Symptomatic UTI: culture-verified UTI (moderate dose PAC 40 to 80 mg/day)|People with a susceptibility to UTIs due to an intervention","Symptomatic UTI: culture-verified UTI (moderate dose PAC 40 to 80 mg/day)",9,2,"People with a susceptibility to UTIs due to an intervention","or","binary",2,-0.594760163001986,0.42505448090784,0,2018,0.131884057971014,127.5
"CD001396","CD001396_pub4_data","1|1|Self-rated overall premenstrual symptoms|Continuous administration","Self-rated overall premenstrual symptoms",1,1,"Continuous administration","or","binary",9,-0.355845836267019,0.672896319973264,0,2000.88888888889,0,117.222222222222
"CD001396","CD001396_pub4_data","1|1|Self-rated overall premenstrual symptoms|Luteal administration","Self-rated overall premenstrual symptoms",1,1,"Luteal administration","or","binary",7,-0.308766883913798,0.760730759842487,0,2008,0,98.1428571428571
"CD001396","CD001396_pub4_data","1|10|Dry mouth|Continuous administration","Dry mouth",1,10,"Continuous administration","or","binary",9,0.762018532353349,0.29930406672224,0,2001,0.0399420480133268,102.888888888889
"CD001396","CD001396_pub4_data","1|10|Dry mouth|Luteal administration","Dry mouth",1,10,"Luteal administration","or","binary",7,0.923976084620558,0.278363660595327,0,2008,0.0567208964418321,118.142857142857
"CD001396","CD001396_pub4_data","1|11|Asthenia/decreased energy|Continuous administration","Asthenia/decreased energy",1,11,"Continuous administration","or","binary",9,1.0873907707748,0.238975193496733,0,2000.33333333333,0.0461479096495195,119.777777777778
"CD001396","CD001396_pub4_data","1|11|Asthenia/decreased energy|Luteal administration","Asthenia/decreased energy",1,11,"Luteal administration","or","binary",4,1.07020282008399,0.358608561453366,0,2003.5,0.0393939393939394,156.5
"CD001396","CD001396_pub4_data","1|12|Diarrhoea|Continuous administration","Diarrhoea",1,12,"Continuous administration","or","binary",9,0.673014411716436,0.326803206983712,0,2003,0.0198888833661934,135.333333333333
"CD001396","CD001396_pub4_data","1|12|Diarrhoea|Luteal administration","Diarrhoea",1,12,"Luteal administration","or","binary",10,0.580710385009522,0.239544432146788,0,2005.1,0.0340650658975115,146.3
"CD001396","CD001396_pub4_data","1|13|Constipation|Continuous administration","Constipation",1,13,"Continuous administration","or","binary",8,0.889901501413856,0.399207381184616,0,2001.875,0.0175145384959491,115.375
"CD001396","CD001396_pub4_data","1|13|Constipation|Luteal administration","Constipation",1,13,"Luteal administration","or","binary",2,-0.408272542094474,0.970383574264118,0.307629927028364,2008,0.0606617647058824,49.5
"CD001396","CD001396_pub4_data","1|14|Withdrawal due to adverse effects|Continuous administration","Withdrawal due to adverse effects",1,14,"Continuous administration","or","binary",13,0.143818865715162,0.171737510813685,0.0658328465931335,2000.23076923077,0.111676956959657,133
"CD001396","CD001396_pub4_data","1|14|Withdrawal due to adverse effects|Luteal administration","Withdrawal due to adverse effects",1,14,"Luteal administration","or","binary",13,0.284647391307452,0.215458852009524,0,2005,0.0652677351483779,132.769230769231
"CD001396","CD001396_pub4_data","1|15|Psychological symptoms|Continuous administration","Psychological symptoms",1,15,"Continuous administration","or","binary",5,-0.256782955416374,0.898231204954513,0,2000.6,0,137.8
"CD001396","CD001396_pub4_data","1|15|Psychological symptoms|Luteal administration","Psychological symptoms",1,15,"Luteal administration","or","binary",3,-0.461422499504579,1.15923417348574,0,2008.33333333333,0,137.333333333333
"CD001396","CD001396_pub4_data","1|16|Physical symptoms|Continuous administration","Physical symptoms",1,16,"Continuous administration","or","binary",5,-0.245413446155725,0.900807795302842,0,1996.6,0,129.4
"CD001396","CD001396_pub4_data","1|16|Physical symptoms|Luteal administration","Physical symptoms",1,16,"Luteal administration","or","binary",2,-0.0863604263693916,1.41903673649984,0,2008.5,0,164
"CD001396","CD001396_pub4_data","1|17|Functional symptoms|Luteal administration","Functional symptoms",1,17,"Luteal administration","or","binary",3,-0.448234716936244,1.16116637587981,0,2004.33333333333,0,128
"CD001396","CD001396_pub4_data","1|18|Irritability|Continuous administration","Irritability",1,18,"Continuous administration","or","binary",3,0.0224771705520156,1.16536210245409,0,1997.66666666667,0,124.333333333333
"CD001396","CD001396_pub4_data","1|18|Irritability|Luteal administration","Irritability",1,18,"Luteal administration","or","binary",4,-0.330692371778971,1.00819434060296,0,2008.25,0,103.75
"CD001396","CD001396_pub4_data","1|19|Response rates|Continuous administration","Response rates",1,19,"Continuous administration","or","binary",19,0.938050718561465,0.116102239961263,0.0527714380013852,2000.36842105263,0.331156784962845,106.210526315789
"CD001396","CD001396_pub4_data","1|19|Response rates|Luteal administration","Response rates",1,19,"Luteal administration","or","binary",11,0.747509565214702,0.113874969253808,0,2005.81818181818,0.454189407765519,134.909090909091
"CD001396","CD001396_pub4_data","1|2|Nausea|Continuous administration","Nausea",1,2,"Continuous administration","or","binary",14,1.0036247509922,0.173807838236338,0,2000.78571428571,0.0726829027989967,118.5
"CD001396","CD001396_pub4_data","1|2|Nausea|Luteal administration","Nausea",1,2,"Luteal administration","or","binary",14,1.19978539320719,0.1612682577931,3.80771174639915e-06,2006,0.0970945520436025,143.214285714286
"CD001396","CD001396_pub4_data","1|20|Withdrawal for any reason|Continuous administration","Withdrawal for any reason",1,20,"Continuous administration","or","binary",8,-0.0372509533602427,0.190591121832121,0,1999.125,0.24195646678199,78.875
"CD001396","CD001396_pub4_data","1|20|Withdrawal for any reason|Luteal administration","Withdrawal for any reason",1,20,"Luteal administration","or","binary",10,-0.0571245592281776,0.146276644529829,0,2006.3,0.186684056628683,113.5
"CD001396","CD001396_pub4_data","1|3|Insomnia or sleep disturbance|Continuous administration","Insomnia or sleep disturbance",1,3,"Continuous administration","or","binary",13,0.694865805394353,0.213503731852492,0.00312795118968418,1999.92307692308,0.0589770135682465,125.923076923077
"CD001396","CD001396_pub4_data","1|3|Insomnia or sleep disturbance|Luteal administration","Insomnia or sleep disturbance",1,3,"Luteal administration","or","binary",16,0.548569894528019,0.171471402729584,0,2006.625,0.0565366985462018,130.3125
"CD001396","CD001396_pub4_data","1|4|Sexual dysfunction or decreased libido|Continuous administration","Sexual dysfunction or decreased libido",1,4,"Continuous administration","or","binary",11,0.923703667468188,0.259796128650971,0,2000.81818181818,0.0304279687375269,120.272727272727
"CD001396","CD001396_pub4_data","1|4|Sexual dysfunction or decreased libido|Luteal administration","Sexual dysfunction or decreased libido",1,4,"Luteal administration","or","binary",12,0.487182494081783,0.265389091122762,9.73598186825604e-07,2004.91666666667,0.043122400570246,121.5
"CD001396","CD001396_pub4_data","1|5|Fatigue or sedation|Continuous administration","Fatigue or sedation",1,5,"Continuous administration","or","binary",8,0.509989376176211,0.320422557518131,0.183514582432762,1999,0.0835233813031471,79
"CD001396","CD001396_pub4_data","1|5|Fatigue or sedation|Luteal administration","Fatigue or sedation",1,5,"Luteal administration","or","binary",6,0.300337178327224,0.2509927579423,0,2009,0.100423985463356,99.6666666666667
"CD001396","CD001396_pub4_data","1|6|Dizziness or vertigo|Continuous administration","Dizziness or vertigo",1,6,"Continuous administration","or","binary",13,0.694367351114313,0.234750210405323,0,2001.53846153846,0.0268359509539615,128.384615384615
"CD001396","CD001396_pub4_data","1|6|Dizziness or vertigo|Luteal administration","Dizziness or vertigo",1,6,"Luteal administration","or","binary",8,0.402463120190103,0.257166442226219,0,2008,0.0641558888849301,120.5
"CD001396","CD001396_pub4_data","1|7|Tremor|Continuous administration","Tremor",1,7,"Continuous administration","or","binary",6,1.41725475143353,0.447043649445926,0,2000,0.00911416693316278,164.333333333333
"CD001396","CD001396_pub4_data","1|7|Tremor|Luteal administration","Tremor",1,7,"Luteal administration","or","binary",2,1.79371519569347,1.04927435819647,0,2005,0,183
"CD001396","CD001396_pub4_data","1|8|Somnolence/decreased concentration|Continuous administration","Somnolence/decreased concentration",1,8,"Continuous administration","or","binary",10,1.46808009432743,0.291928408292412,0,2001.6,0.0173771773746589,155.1
"CD001396","CD001396_pub4_data","1|8|Somnolence/decreased concentration|Luteal administration","Somnolence/decreased concentration",1,8,"Luteal administration","or","binary",4,0.547386235990153,0.398959891544527,0.124483171222467,2009.5,0.0552806379971734,124.75
"CD001396","CD001396_pub4_data","1|9|Sweating|Continuous administration","Sweating",1,9,"Continuous administration","or","binary",10,0.822174724003242,0.278214011888389,0,1999.4,0.0281723010760516,143.9
"CD001396","CD001396_pub4_data","1|9|Sweating|Luteal administration","Sweating",1,9,"Luteal administration","or","binary",6,0.624524576383895,0.467570084199753,0.419961047724483,2008,0.0242344706911636,144.166666666667
"CD001396","CD001396_pub4_data","2|1|Self-rated overall premenstrual symptoms|PMDD","Self-rated overall premenstrual symptoms",2,1,"PMDD","or","binary",11,-0.37902930251741,0.605981010401134,0,2004.27272727273,0,130.909090909091
"CD001396","CD001396_pub4_data","2|1|Self-rated overall premenstrual symptoms|PMS","Self-rated overall premenstrual symptoms",2,1,"PMS","or","binary",3,0.0126050270836709,1.177918839732,0,2003,0,52.6666666666667
"CD001396","CD001396_pub4_data","2|2|Response rates|PMDD","Response rates",2,2,"PMDD","or","binary",23,0.866357853179901,0.0932164158016795,0.0331369890120077,2001.82608695652,0.400376003849381,124.565217391304
"CD001396","CD001396_pub4_data","2|2|Response rates|PMS","Response rates",2,2,"PMS","or","binary",5,0.906273801411553,0.205815128611095,0,2004.2,0.284930481283422,94
"CD001396","CD001396_pub4_data","3|1|Self-rated overall premenstrual symptoms, SSRI type|Escitalopram","Self-rated overall premenstrual symptoms, SSRI type",3,1,"Escitalopram","or","binary",2,-0.693099584203165,1.42457456897336,0,2008,0,75.5
"CD001396","CD001396_pub4_data","3|1|Self-rated overall premenstrual symptoms, SSRI type|Fluoxetine","Self-rated overall premenstrual symptoms, SSRI type",3,1,"Fluoxetine","or","binary",5,-0.236644403332169,0.90704522693268,0,2004,0,77.8
"CD001396","CD001396_pub4_data","3|1|Self-rated overall premenstrual symptoms, SSRI type|Paroxetine","Self-rated overall premenstrual symptoms, SSRI type",3,1,"Paroxetine","or","binary",2,-0.647646722038539,1.41919694367784,0,2004,0,156.5
"CD001396","CD001396_pub4_data","3|1|Self-rated overall premenstrual symptoms, SSRI type|Sertraline","Self-rated overall premenstrual symptoms, SSRI type",3,1,"Sertraline","or","binary",7,-0.212915212075173,0.759891331729987,0,2002.85714285714,0,127
"CD001396","CD001396_pub4_data","4|1|Response rate|","Response rate",4,1,"","reported","reported",3,0,0.263009533651547,0,2003,0.651086048454469,89.6666666666667
"CD001431","CD001431_pub6_data","1|1|Informed values-choice congruence - all studies|","Informed values-choice congruence - all studies",1,1,"","or","binary",22,0.969714443114495,0.162433147396311,0.461381727900955,2014.95454545455,0.294544673295699,426.227272727273
"CD001431","CD001431_pub6_data","1|2|Informed values-choice congruence - without studies of high risk of bias|","Informed values-choice congruence - without studies of high risk of bias",1,2,"","or","binary",18,1.24926864212067,0.218845940685177,0.692992869118636,2014.16666666667,0.296743358220729,399
"CD001431","CD001431_pub6_data","1|3|Informed values-choice congruence - old vs new studies|Newer studies (2015-2022)","Informed values-choice congruence - old vs new studies",1,3,"Newer studies (2015-2022)","or","binary",12,0.784654857937901,0.215552971604941,0.429120174096485,2018.83333333333,0.271073215638542,395.916666666667
"CD001431","CD001431_pub6_data","1|3|Informed values-choice congruence - old vs new studies|Older studies (2014 and earlier)","Informed values-choice congruence - old vs new studies",1,3,"Older studies (2014 and earlier)","or","binary",10,1.16884062358291,0.226835722422781,0.411014248499443,2010.3,0.322710422484287,462.6
"CD001431","CD001431_pub6_data","1|4|Informed values-chose congruence - using MMIC|","Informed values-chose congruence - using MMIC",1,4,"","reported","reported",13,0,0.0279051832592777,0,2013.15384615385,0.342481254794228,463.846153846154
"CD001431","CD001431_pub6_data","1|5|Informed values-chose congruence - using non-MMIC measures|","Informed values-chose congruence - using non-MMIC measures",1,5,"","reported","reported",9,0,0.0582799815612205,0,2017.55555555556,0.22530294446449,369.666666666667
"CD001431","CD001431_pub6_data","10|1|Preparation for decision-making - all studies|","Preparation for decision-making - all studies",10,1,"","or","binary",8,-0.101840194446184,0.711687146458939,0,2017.875,0,156.125
"CD001431","CD001431_pub6_data","10|2|Preparation for decision-making studies without high risk of bias|","Preparation for decision-making studies without high risk of bias",10,2,"","or","binary",7,0.00498889320596879,0.761339057263635,0,2017.85714285714,0,130.428571428571
"CD001431","CD001431_pub6_data","10|3|Preparation for decision-making - old vs new studies|Newer studies (2015-2022)","Preparation for decision-making - old vs new studies",10,3,"Newer studies (2015-2022)","or","binary",7,-0.133779511223611,0.761166234553518,0,2019.14285714286,0,157.142857142857
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Benign prostatic hyperplasia","Choice: surgery over conservative option (subgroup by condition)",11,1,"Benign prostatic hyperplasia","or","binary",2,0.255399282041125,1.01617310511209,1.58677058715571,1999,0.079382183908046,160.5
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Breast cancer - mastectomy vs lumpectomy","Choice: surgery over conservative option (subgroup by condition)",11,1,"Breast cancer - mastectomy vs lumpectomy","or","binary",8,-0.341302070228945,0.202435868906277,0.123883145654186,2014.5,0.310999451881231,134.75
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Breast cancer - prophylactic mastectomy","Choice: surgery over conservative option (subgroup by condition)",11,1,"Breast cancer - prophylactic mastectomy","or","binary",2,0.66543807453982,0.332029265273208,0.0342093545650326,2014.5,0.427491601343785,132.5
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Coronary revascularization","Choice: surgery over conservative option (subgroup by condition)",11,1,"Coronary revascularization","or","binary",2,-0.619808786108883,0.239419109585783,0,1999,0.623245614035088,145
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Joint replacement","Choice: surgery over conservative option (subgroup by condition)",11,1,"Joint replacement","or","binary",8,-0.11148468925099,0.148581590394093,0.0732880270569006,2017.5,0.539229992842928,260
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Left ventricular assist device (LVAD)","Choice: surgery over conservative option (subgroup by condition)",11,1,"Left ventricular assist device (LVAD)","or","binary",3,-1.11993669758467,0.303654006636103,0.120046143096216,2018,0.818691502177741,156.333333333333
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Menorrhagia","Choice: surgery over conservative option (subgroup by condition)",11,1,"Menorrhagia","or","binary",3,0.00591042325782815,0.277916933478448,0.138228940380702,2004,0.319708655510927,324
"CD001431","CD001431_pub6_data","11|1|Choice: surgery over conservative option (subgroup by condition)|Prostate cancer","Choice: surgery over conservative option (subgroup by condition)",11,1,"Prostate cancer","or","binary",4,-0.597046820522377,0.464568035401141,0.765434324020183,2012,0.609291176113606,251.25
"CD001431","CD001431_pub6_data","11|2|Choice for screening|Breast cancer genetic testing","Choice for screening",11,2,"Breast cancer genetic testing","or","binary",4,0.0851391122034797,0.23677464433216,0.107336069088617,2005.25,0.312682567877436,231.25
"CD001431","CD001431_pub6_data","11|2|Choice for screening|Breast cancer screening (mammography)","Choice for screening",11,2,"Breast cancer screening (mammography)","or","binary",7,-0.0820609870478861,0.0277420515768978,0,2017.57142857143,0.465392280936909,3214
"CD001431","CD001431_pub6_data","11|2|Choice for screening|Colorectal cancer screening","Choice for screening",11,2,"Colorectal cancer screening","or","binary",17,0.305227772706791,0.14835811047597,0.29980088848879,2011.88235294118,0.359756062497342,1030
"CD001431","CD001431_pub6_data","11|2|Choice for screening|Prenatal diagnostic testing","Choice for screening",11,2,"Prenatal diagnostic testing","or","binary",4,0.0584080110578529,0.108453674257586,0,2015.25,0.632577025003972,380
"CD001431","CD001431_pub6_data","11|2|Choice for screening|PSA screening","Choice for screening",11,2,"PSA screening","or","binary",11,-0.240500955462664,0.116614618227216,0.0741263049067945,2006.27272727273,0.449550870978884,380.454545454545
"CD001431","CD001431_pub6_data","11|3|Choice: diabetes medication (uptake of new medication)|","Choice: diabetes medication (uptake of new medication)",11,3,"","or","binary",6,1.23284065032221,0.534126515036723,1.46908357334481,2012.16666666667,0.209556690751653,326.666666666667
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Benign prostatic hyperplasia","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Benign prostatic hyperplasia","or","binary",2,0.255399282041125,1.01617310511209,1.58677058715571,1999,0.079382183908046,160.5
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Breast cancer - mastectomy vs lumpectomy","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Breast cancer - mastectomy vs lumpectomy","or","binary",6,-0.395679111441274,0.299702067266743,0.277869509307345,2012.16666666667,0.308068713619419,113.833333333333
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Breast cancer - prophylactic mastectomy","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Breast cancer - prophylactic mastectomy","or","binary",2,0.66543807453982,0.332029265273208,0.0342093545650326,2014.5,0.427491601343785,132.5
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Coronary revascularization","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Coronary revascularization","or","binary",2,-0.619808786108883,0.239419109585783,0,1999,0.623245614035088,145
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Joint replacement","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Joint replacement","or","binary",8,-0.11148468925099,0.148581590394093,0.0732880270569006,2017.5,0.539229992842928,260
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Left ventricular assist device (LVAD)","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Left ventricular assist device (LVAD)","or","binary",2,-0.801317697669039,0.461498870051654,0.212798579835038,2018,0.811370586599944,117
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Menorrhagia","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Menorrhagia","or","binary",3,0.00591042325782815,0.277916933478448,0.138228940380702,2004,0.319708655510927,324
"CD001431","CD001431_pub6_data","11|4|Choice: surgery over conservative option - studies without high risk of bias|Prostate cancer","Choice: surgery over conservative option - studies without high risk of bias",11,4,"Prostate cancer","or","binary",2,-0.463620840683048,0.206602968842303,0,2013,0.618582352227212,233.5
"CD001431","CD001431_pub6_data","11|5|Choice for screening - studies without high risk of bias|Breast cancer genetic testing","Choice for screening - studies without high risk of bias",11,5,"Breast cancer genetic testing","or","binary",4,0.0851391122034797,0.23677464433216,0.107336069088617,2005.25,0.312682567877436,231.25
"CD001431","CD001431_pub6_data","11|5|Choice for screening - studies without high risk of bias|Breast cancer screening (mammography)","Choice for screening - studies without high risk of bias",11,5,"Breast cancer screening (mammography)","or","binary",5,-0.113530505889602,0.0570164142009997,0,2017.4,0.401224512857278,1141.2
"CD001431","CD001431_pub6_data","11|5|Choice for screening - studies without high risk of bias|Colorectal cancer screening","Choice for screening - studies without high risk of bias",11,5,"Colorectal cancer screening","or","binary",15,0.231443762297001,0.135465889583102,0.203604921937144,2011.66666666667,0.368892751763547,1120.8
"CD001431","CD001431_pub6_data","11|5|Choice for screening - studies without high risk of bias|Prenatal diagnostic testing","Choice for screening - studies without high risk of bias",11,5,"Prenatal diagnostic testing","or","binary",4,0.0584080110578529,0.108453674257586,0,2015.25,0.632577025003972,380
"CD001431","CD001431_pub6_data","11|5|Choice for screening - studies without high risk of bias|PSA screening","Choice for screening - studies without high risk of bias",11,5,"PSA screening","or","binary",10,-0.252789947516422,0.129181696823728,0.0935715081587456,2006.2,0.409172624743439,391.4
"CD001431","CD001431_pub6_data","11|6|Choice: diabetes medication (uptake of new medication) - studies without high risk of bias|","Choice: diabetes medication (uptake of new medication) - studies without high risk of bias",11,6,"","or","binary",4,0.598568854064837,0.268789631455224,0,2009.5,0.146246072561862,111.75
"CD001431","CD001431_pub6_data","12|1|Confidence - all studies|Decision Self-efficacy Scale","Confidence - all studies",12,1,"Decision Self-efficacy Scale","or","binary",6,0.0820180982748281,0.818952639695849,0,2018.16666666667,0,425
"CD001431","CD001431_pub6_data","12|1|Confidence - all studies|Study-specific questionnaire","Confidence - all studies",12,1,"Study-specific questionnaire","or","binary",6,0.029571241653982,0.818445819701954,0,2016.16666666667,0,355.166666666667
"CD001431","CD001431_pub6_data","12|2|Confidence - studies without high risk of bias|Decision Self-efficacy Scale","Confidence - studies without high risk of bias",12,2,"Decision Self-efficacy Scale","or","binary",5,0.0779212191749309,0.897303395650503,0,2017.4,0,459.4
"CD001431","CD001431_pub6_data","12|2|Confidence - studies without high risk of bias|Study-specific questionnaire","Confidence - studies without high risk of bias",12,2,"Study-specific questionnaire","or","binary",5,-0.0269849982303958,0.896869638472928,0,2015.2,0,274.8
"CD001431","CD001431_pub6_data","12|3|Confidence - old vs new studies|Decision Self-efficacy Scale - newer studies (2015-2022)","Confidence - old vs new studies",12,3,"Decision Self-efficacy Scale - newer studies (2015-2022)","or","binary",5,0.0708434260605393,0.897513832368276,0,2019.8,0,385
"CD001431","CD001431_pub6_data","12|3|Confidence - old vs new studies|Study-specific questionnaire - newer studies (2015-2022)","Confidence - old vs new studies",12,3,"Study-specific questionnaire - newer studies (2015-2022)","or","binary",5,0.027592102118008,0.89682996598349,0,2019,0,314.8
"CD001431","CD001431_pub6_data","13|1|Consultation length - subgroup by timing of intervention (in consultation versus in preparation for consultation)|In consultation","Consultation length - subgroup by timing of intervention (in consultation versus in preparation for consultation)",13,1,"In consultation","or","binary",8,-0.0506523989365921,0.709948116286736,0,2015.125,0,337.75
"CD001431","CD001431_pub6_data","13|1|Consultation length - subgroup by timing of intervention (in consultation versus in preparation for consultation)|In preparation for consultation","Consultation length - subgroup by timing of intervention (in consultation versus in preparation for consultation)",13,1,"In preparation for consultation","or","binary",5,-0.0420893321712272,0.901564802504233,0,2018.2,0,84
"CD001431","CD001431_pub6_data","13|2|Consultation length - subgroup by timing of intervention - studies without high risk of bias|In consultation","Consultation length - subgroup by timing of intervention - studies without high risk of bias",13,2,"In consultation","or","binary",5,-0.0580444465675491,0.899061023831639,0,2014,0,290.2
"CD001431","CD001431_pub6_data","13|2|Consultation length - subgroup by timing of intervention - studies without high risk of bias|In preparation for consultation","Consultation length - subgroup by timing of intervention - studies without high risk of bias",13,2,"In preparation for consultation","or","binary",5,-0.0420893321712272,0.901564802504233,0,2018.2,0,84
"CD001431","CD001431_pub6_data","13|3|Consultation length - old vs new studies (in consultation)|Newer studies","Consultation length - old vs new studies (in consultation)",13,3,"Newer studies","or","binary",6,0.047009250710292,0.818461582781117,0,2017.83333333333,0,397.5
"CD001431","CD001431_pub6_data","13|3|Consultation length - old vs new studies (in consultation)|Older studies","Consultation length - old vs new studies (in consultation)",13,3,"Older studies","or","binary",2,-0.347445537140953,1.42680032369856,0,2007,0,158.5
"CD001431","CD001431_pub6_data","13|4|Consultation length - old vs new studies (in preparation for consultation)|Newer studies","Consultation length - old vs new studies (in preparation for consultation)",13,4,"Newer studies","or","binary",4,-0.0567879340019777,1.00897633666719,0,2019.5,0,74.25
"CD001431","CD001431_pub6_data","2|1|Knowledge - all studies|","Knowledge - all studies",2,1,"","or","binary",108,-0.0218185426241152,0.193297006824582,0,2013.34259259259,0,236.037037037037
"CD001431","CD001431_pub6_data","2|2|Knowledge - studies without high risk of bias|","Knowledge - studies without high risk of bias",2,2,"","or","binary",96,-0.0202542970472761,0.205029670249533,0,2013.28125,0,240.447916666667
"CD001431","CD001431_pub6_data","2|3|Knowledge - old vs new studies|Newer studies (2015-2022)","Knowledge - old vs new studies",2,3,"Newer studies (2015-2022)","or","binary",57,-0.00232920931662567,0.266385442660402,0,2018.47368421053,0,215.754385964912
"CD001431","CD001431_pub6_data","2|3|Knowledge - old vs new studies|Older studies (2014 and earlier)","Knowledge - old vs new studies",2,3,"Older studies (2014 and earlier)","or","binary",51,-0.043492621558057,0.280919781410898,0,2007.60784313725,0,258.705882352941
"CD001431","CD001431_pub6_data","3|1|Accurate risk perceptions - all studies|","Accurate risk perceptions - all studies",3,1,"","or","binary",25,1.15208870032141,0.146030418690961,0.392250194934026,2010.28,0.280991833654537,311.84
"CD001431","CD001431_pub6_data","3|2|Accurate risk perceptions - studies without high risk of bias|","Accurate risk perceptions - studies without high risk of bias",3,2,"","or","binary",20,1.18935365967057,0.169058974833967,0.418700866289675,2009.25,0.288876891736521,307.6
"CD001431","CD001431_pub6_data","3|3|Accurate risk perceptions - old vs new studies|Newer studies (2015-2022)","Accurate risk perceptions - old vs new studies",3,3,"Newer studies (2015-2022)","or","binary",9,0.929642258265069,0.208428053224503,0.239057546699826,2017.88888888889,0.278450589828105,308.555555555556
"CD001431","CD001431_pub6_data","3|3|Accurate risk perceptions - old vs new studies|Older Studies (2014 and earlier)","Accurate risk perceptions - old vs new studies",3,3,"Older Studies (2014 and earlier)","or","binary",16,1.26371489587387,0.19580014548193,0.485395309798308,2006,0.282421283306904,313.6875
"CD001431","CD001431_pub6_data","4|1|Decisional conflict - uninformed - all studies|","Decisional conflict - uninformed - all studies",4,1,"","or","binary",59,-0.0630753928779044,0.261650191567225,0,2013.61016949153,0,205.152542372881
"CD001431","CD001431_pub6_data","4|2|Decisional conflict - uninformed - without studies having high risk of bias|","Decisional conflict - uninformed - without studies having high risk of bias",4,2,"","or","binary",52,-0.0516857785865172,0.278774086988548,0,2013.46153846154,0,191.961538461538
"CD001431","CD001431_pub6_data","4|3|Decisional conflict - uninformed - old vs new studies|Newer studies (2015-2022)","Decisional conflict - uninformed - old vs new studies",4,3,"Newer studies (2015-2022)","or","binary",33,-0.0687646063780806,0.350246734141561,0,2018.54545454545,0,197.545454545455
"CD001431","CD001431_pub6_data","4|3|Decisional conflict - uninformed - old vs new studies|Older studies (2014 and earlier)","Decisional conflict - uninformed - old vs new studies",4,3,"Older studies (2014 and earlier)","or","binary",26,-0.0558908473593586,0.393593238193258,0,2007.34615384615,0,214.807692307692
"CD001431","CD001431_pub6_data","4|4|Decisional conflict - unclear values - all studies|","Decisional conflict - unclear values - all studies",4,4,"","or","binary",56,-0.0616547231136287,0.268569437239524,0,2014.14285714286,0,212.142857142857
"CD001431","CD001431_pub6_data","4|5|Decisional conflict - unclear values - without studies having high risk of bias|","Decisional conflict - unclear values - without studies having high risk of bias",4,5,"","or","binary",49,-0.0493633894338671,0.287188228639991,0,2014.0612244898,0,199.142857142857
"CD001431","CD001431_pub6_data","4|6|Unclear values - old vs new studies|Newer studies (2015-2022)","Unclear values - old vs new studies",4,6,"Newer studies (2015-2022)","or","binary",34,-0.065273107008559,0.345009046082646,0,2018.52941176471,0,203.941176470588
"CD001431","CD001431_pub6_data","4|6|Unclear values - old vs new studies|Older studies (2014 and earlier)","Unclear values - old vs new studies",4,6,"Older studies (2014 and earlier)","or","binary",22,-0.0560900553194689,0.42785122788692,0,2007.36363636364,0,224.818181818182
"CD001431","CD001431_pub6_data","5|1|Participation in decision-making - all studies|Clinician-controlled decision-making","Participation in decision-making - all studies",5,1,"Clinician-controlled decision-making","or","binary",21,-0.442826214100197,0.136642507503953,0.190515309102899,2008.95238095238,0.256800933137163,207.047619047619
"CD001431","CD001431_pub6_data","5|1|Participation in decision-making - all studies|Patient-controlled decision-making","Participation in decision-making - all studies",5,1,"Patient-controlled decision-making","or","binary",20,0.421356583257766,0.171188780302054,0.373741698467954,2009.15,0.367862742258934,185.75
"CD001431","CD001431_pub6_data","5|1|Participation in decision-making - all studies|Shared decision-making","Participation in decision-making - all studies",5,1,"Shared decision-making","or","binary",20,-0.023203146159643,0.107580014203373,0.0940876205179107,2008.9,0.414206772736286,189.95
"CD001431","CD001431_pub6_data","5|2|Participation in decision-making - studies without high risk of bias|Clinician-controlled decision-making","Participation in decision-making - studies without high risk of bias",5,2,"Clinician-controlled decision-making","or","binary",17,-0.289381449092359,0.126133197602081,0.0684370031962672,2009.17647058824,0.241570479578653,191.117647058824
"CD001431","CD001431_pub6_data","5|2|Participation in decision-making - studies without high risk of bias|Patient-controlled decision-making","Participation in decision-making - studies without high risk of bias",5,2,"Patient-controlled decision-making","or","binary",15,0.386207741907434,0.202893979080973,0.35629036341679,2008.86666666667,0.341290988489146,162.2
"CD001431","CD001431_pub6_data","5|2|Participation in decision-making - studies without high risk of bias|Shared decision-making","Participation in decision-making - studies without high risk of bias",5,2,"Shared decision-making","or","binary",16,-0.0684865188557956,0.149958223073028,0.189159977734296,2009.125,0.433113348892325,168.75
"CD001431","CD001431_pub6_data","5|3|Participation in decision-making - clinician-controlled - old vs new studies|Newer studies (2015-2022)","Participation in decision-making - clinician-controlled - old vs new studies",5,3,"Newer studies (2015-2022)","or","binary",5,-0.199825408971902,0.291662076665188,0.259533640722745,2020.2,0.319285351690625,233.6
"CD001431","CD001431_pub6_data","5|3|Participation in decision-making - clinician-controlled - old vs new studies|Older studies (2014 and earlier)","Participation in decision-making - clinician-controlled - old vs new studies",5,3,"Older studies (2014 and earlier)","or","binary",16,-0.532846172053325,0.154157040392796,0.165531825987871,2005.4375,0.237274552339207,198.75
"CD001431","CD001431_pub6_data","5|4|Participation in decision-making - patient-controlled - old vs new studies|Newer studies (2015-2022)","Participation in decision-making - patient-controlled - old vs new studies",5,4,"Newer studies (2015-2022)","or","binary",5,0.127012163091203,0.361277993683646,0.272751500837822,2019.8,0.361043814793081,141.2
"CD001431","CD001431_pub6_data","5|4|Participation in decision-making - patient-controlled - old vs new studies|Older studies (2014 and earlier)","Participation in decision-making - patient-controlled - old vs new studies",5,4,"Older studies (2014 and earlier)","or","binary",15,0.490692289457945,0.194813875982091,0.401428094721523,2005.6,0.370135718080885,200.6
"CD001431","CD001431_pub6_data","5|5|Participation in decision-making - shared decision-making - old vs new studies|Newer studies (2015-2022)","Participation in decision-making - shared decision-making - old vs new studies",5,5,"Newer studies (2015-2022)","or","binary",4,-0.0226088817536608,0.165514030992497,0,2020.25,0.411722483024562,150.75
"CD001431","CD001431_pub6_data","5|5|Participation in decision-making - shared decision-making - old vs new studies|Older studies (2014 and earlier)","Participation in decision-making - shared decision-making - old vs new studies",5,5,"Older studies (2014 and earlier)","or","binary",16,-0.0156045754154393,0.133156641377245,0.146711332979915,2006.0625,0.414827845164217,199.75
"CD001431","CD001431_pub6_data","6|1|Decision regret - all studies|","Decision regret - all studies",6,1,"","or","binary",22,-0.0145636019538043,0.429537595407329,0,2017.90909090909,0,168.5
"CD001431","CD001431_pub6_data","6|2|Decision regret - studies without high risk of bias|","Decision regret - studies without high risk of bias",6,2,"","or","binary",17,-0.0629500766000228,0.489158640806385,0,2017.70588235294,0,155.294117647059
"CD001431","CD001431_pub6_data","6|3|Decision regret - old vs new studies|Newer studies (2015-2022)","Decision regret - old vs new studies",6,3,"Newer studies (2015-2022)","or","binary",17,0.0331411345959167,0.489209360301569,0,2019.29411764706,0,131.647058823529
"CD001431","CD001431_pub6_data","6|3|Decision regret - old vs new studies|Older studies (2014 and earlier)","Decision regret - old vs new studies",6,3,"Older studies (2014 and earlier)","or","binary",5,-0.175109446426477,0.897456777329811,0,2013.2,0,293.8
"CD001431","CD001431_pub6_data","7|1|Proportion undecided - all studies|","Proportion undecided - all studies",7,1,"","reported","reported",42,0,0.0408595396938104,0,2013.71428571429,0.247941985613871,203.52380952381
"CD001431","CD001431_pub6_data","7|2|Proportion undecided - studies without high risk of bias|","Proportion undecided - studies without high risk of bias",7,2,"","or","binary",37,-0.571495415956492,0.133596228745904,0.387416216889206,2013.54054054054,0.258406702866505,201.918918918919
"CD001431","CD001431_pub6_data","7|3|Proportion undecided - old vs new studies|Newer studies (2015-2022)","Proportion undecided - old vs new studies",7,3,"Newer studies (2015-2022)","or","binary",20,-0.405037204771149,0.226549099403592,0.615928158844156,2018.95,0.21782189073279,160.35
"CD001431","CD001431_pub6_data","7|3|Proportion undecided - old vs new studies|Older studies (2014 and earlier)","Proportion undecided - old vs new studies",7,3,"Older studies (2014 and earlier)","or","binary",22,-0.669155979961898,0.133053727374062,0.201107749015436,2008.95454545455,0.275323890051217,242.772727272727
"CD001431","CD001431_pub6_data","8|1|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)|Collaborate","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)",8,1,"Collaborate","or","binary",2,0.134863522350894,1.42676203833542,0,2018,0,56
"CD001431","CD001431_pub6_data","8|1|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)|OPTION-12","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)",8,1,"OPTION-12","or","binary",8,-0.190702577496977,0.710272443801696,0,2015.5,0,298.875
"CD001431","CD001431_pub6_data","8|1|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)|OPTION-5","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)",8,1,"OPTION-5","or","binary",2,0.559055912647397,1.41692778634284,0,2021.5,0,332.5
"CD001431","CD001431_pub6_data","8|1|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)|SDM-Q-9","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)",8,1,"SDM-Q-9","or","binary",3,0.0583195529296994,1.15944887760262,0,2019.66666666667,0,508.333333333333
"CD001431","CD001431_pub6_data","8|2|Discussed topic with provider|","Discussed topic with provider",8,2,"","or","binary",11,0.950667024610822,0.178134893508604,0.241779504131053,2014.72727272727,0.475941029480573,355.727272727273
"CD001431","CD001431_pub6_data","8|3|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias|Collaborate","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias",8,3,"Collaborate","or","binary",2,0.134863522350894,1.42676203833542,0,2018,0,56
"CD001431","CD001431_pub6_data","8|3|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias|OPTION-12","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias",8,3,"OPTION-12","or","binary",3,-0.0687742948648611,1.15825744339713,0,2012.33333333333,0,275
"CD001431","CD001431_pub6_data","8|3|Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias|SDM-Q-9","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias",8,3,"SDM-Q-9","or","binary",3,0.0583195529296994,1.15944887760262,0,2019.66666666667,0,508.333333333333
"CD001431","CD001431_pub6_data","8|4|Discussed topic with provider - studies without high risk of bias|","Discussed topic with provider - studies without high risk of bias",8,4,"","or","binary",10,0.910826193638688,0.19731368382607,0.271864693948039,2014.1,0.454498435180924,315.7
"CD001431","CD001431_pub6_data","9|1|Satisfaction with the decision-making process - all studies|","Satisfaction with the decision-making process - all studies",9,1,"","or","binary",12,-0.0403832835245151,0.579598603047095,0,2009.25,0,172.166666666667
"CD001431","CD001431_pub6_data","9|2|Satisfaction with the decision-making process - studies without high risk of bias|","Satisfaction with the decision-making process - studies without high risk of bias",9,2,"","or","binary",8,0.00686917994313693,0.709943855711101,0,2008.625,0,174.25
"CD001431","CD001431_pub6_data","9|3|Satisfaction with the decision-making process - old vs new studies|Newer studies (2015-2022)","Satisfaction with the decision-making process - old vs new studies",9,3,"Newer studies (2015-2022)","or","binary",3,0.0233065632864452,1.16025738345635,0,2018.33333333333,0,134.333333333333
"CD001431","CD001431_pub6_data","9|3|Satisfaction with the decision-making process - old vs new studies|Older studies (2014 and earlier)","Satisfaction with the decision-making process - old vs new studies",9,3,"Older studies (2014 and earlier)","or","binary",9,-0.0615615576321604,0.669059160315567,0,2006.22222222222,0,184.777777777778
"CD001533","CD001533_pub7_data","1|1|Number with frequent relapses by 12 to 24 months|","Number with frequent relapses by 12 to 24 months",1,1,"","or","binary",8,-0.319934242130109,0.176815362321513,0.0688600510364954,2001,0.411133607826519,122
"CD001533","CD001533_pub7_data","1|2|Number relapsing by 12 to 24 months|","Number relapsing by 12 to 24 months",1,2,"","reported","reported",12,0,0.0416440021589103,0,2002.91666666667,0.65354267791068,106.583333333333
"CD001533","CD001533_pub7_data","1|3|Number with frequent relapses by 12 to 24 months: stratified by risk of selection bias|Low risk of selection bias","Number with frequent relapses by 12 to 24 months: stratified by risk of selection bias",1,3,"Low risk of selection bias","or","binary",5,-0.0920906153846559,0.151073876741641,0,2004.8,0.450450152745017,151.2
"CD001533","CD001533_pub7_data","1|3|Number with frequent relapses by 12 to 24 months: stratified by risk of selection bias|Unclear or high risk of selection bias","Number with frequent relapses by 12 to 24 months: stratified by risk of selection bias",1,3,"Unclear or high risk of selection bias","or","binary",3,-1.01646966050144,0.33931118318467,0,1994.66666666667,0.345606032962355,73.3333333333333
"CD001533","CD001533_pub7_data","1|4|Number relapsing by 12 to 24 months: stratified by risk of selection bias|Unclear or high risk of selection bias","Number relapsing by 12 to 24 months: stratified by risk of selection bias",1,4,"Unclear or high risk of selection bias","or","binary",6,-0.835625992590843,0.390702109675941,0.670783052569762,1998.66666666667,0.645278239417491,78.5
"CD001533","CD001533_pub7_data","1|5|Adverse events|Cataracts/eye disorders","Adverse events",1,5,"Cataracts/eye disorders","or","binary",6,-0.57735382848358,0.530605900528601,0,1999,0.0495253241219708,103.833333333333
"CD001533","CD001533_pub7_data","1|5|Adverse events|Cushingoid facies","Adverse events",1,5,"Cushingoid facies","or","binary",5,0.168376107639144,0.220430658535665,1.86024755795771e-06,2003.6,0.27678019971598,109.4
"CD001533","CD001533_pub7_data","1|5|Adverse events|Hypertension","Adverse events",1,5,"Hypertension","or","binary",7,0.524268283272944,0.525424626371757,0.566291445836224,1997.57142857143,0.0336082836082836,78.2857142857143
"CD001533","CD001533_pub7_data","1|5|Adverse events|Infections","Adverse events",1,5,"Infections","or","binary",2,-0.362811233454527,0.318702367317155,0,1995.5,0.401094276094276,86
"CD001533","CD001533_pub7_data","1|5|Adverse events|Osteoporosis","Adverse events",1,5,"Osteoporosis","or","binary",3,-0.60402714896238,0.845705403164604,0,1992,0.0549860205032619,77.6666666666667
"CD001533","CD001533_pub7_data","1|5|Adverse events|Psychological disorders","Adverse events",1,5,"Psychological disorders","or","binary",4,-0.268095914039604,0.613915882809212,0.53050548719253,1998.75,0.245164889660303,114
"CD001533","CD001533_pub7_data","1|5|Adverse events|Retarded growth","Adverse events",1,5,"Retarded growth","or","binary",4,-0.605115387955049,0.411676389984336,0,1996.75,0.074477886977887,88.5
"CD001533","CD001533_pub7_data","11|3|Number of days to remission|","Number of days to remission",11,3,"","or","binary",3,0.0503724461037975,1.16287032461247,0,2004.66666666667,0,80.6666666666667
"CD001533","CD001533_pub7_data","11|5|Serious adverse events|","Serious adverse events",11,5,"","or","binary",2,-1.05844614024931,0.520566424817721,0.0944838074004636,1995.5,0.334468085106383,69
"CD001533","CD001533_pub7_data","12|1|Time to remission|","Time to remission",12,1,"","or","binary",2,0.0135988436804067,1.43776843775182,0,2019.5,0,37.5
"CD001533","CD001533_pub7_data","12|2|Number with relapse|","Number with relapse",12,2,"","or","binary",4,0.0378912193727258,0.345442465747534,2.47555484366071e-06,2020,0.601094276094276,44.25
"CD001533","CD001533_pub7_data","15|1|Relapse at 6 months|","Relapse at 6 months",15,1,"","or","binary",2,0.0574923188641568,0.339358997171593,0,2018,0.383333333333333,73
"CD001533","CD001533_pub7_data","15|2|Adverse events|Cushingoid features","Adverse events",15,2,"Cushingoid features","or","binary",2,0.154285139766849,0.44434016940813,0,2018,0.149612403100775,72
"CD001533","CD001533_pub7_data","15|2|Adverse events|Hypertension","Adverse events",15,2,"Hypertension","or","binary",2,-1.11235877263744,0.870137013206031,0,2018,0.0798449612403101,72
"CD001533","CD001533_pub7_data","15|2|Adverse events|Serious infections","Adverse events",15,2,"Serious infections","or","binary",2,-0.53580947460158,0.549459639292642,0,2018,0.12984496124031,72
"CD001533","CD001533_pub7_data","2|1|Number with frequent relapses by 12 to 24 months|","Number with frequent relapses by 12 to 24 months",2,1,"","or","binary",6,-0.45908377525523,0.298580007086377,0.31332572977189,2010.5,0.368131318866613,117.666666666667
"CD001533","CD001533_pub7_data","2|2|Number relapsing by 12 to 24 months|","Number relapsing by 12 to 24 months",2,2,"","or","binary",8,-1.17600255042382,0.2895868051119,0.455140520794439,2008.125,0.731282836071735,114
"CD001533","CD001533_pub7_data","2|3|Number with frequent relapses: stratified by risk of selection bias|High or unclear risk of selection bias","Number with frequent relapses: stratified by risk of selection bias",2,3,"High or unclear risk of selection bias","or","binary",3,-1.05910280951824,0.283922110526664,0,2010.66666666667,0.28996138996139,110
"CD001533","CD001533_pub7_data","2|3|Number with frequent relapses: stratified by risk of selection bias|Low risk of selection bias","Number with frequent relapses: stratified by risk of selection bias",2,3,"Low risk of selection bias","or","binary",3,-0.0242366248395313,0.246609818429474,0.0457105742968908,2010.33333333333,0.446301247771836,125.333333333333
"CD001533","CD001533_pub7_data","2|4|Number relapsing by 12 to 24 months: stratified by risk of selection bias|High or unclear risk of selection bias","Number relapsing by 12 to 24 months: stratified by risk of selection bias",2,4,"High or unclear risk of selection bias","or","binary",5,-1.666841326476,0.206756674239242,0,2006.8,0.764411688999924,107.2
"CD001533","CD001533_pub7_data","2|4|Number relapsing by 12 to 24 months: stratified by risk of selection bias|Low risk of selection bias","Number relapsing by 12 to 24 months: stratified by risk of selection bias",2,4,"Low risk of selection bias","or","binary",3,-0.376952166795063,0.219786376199929,2.16589154230379e-06,2010.33333333333,0.676068081191421,125.333333333333
"CD001533","CD001533_pub7_data","2|5|Adverse events|Cushingoid appearance","Adverse events",2,5,"Cushingoid appearance","or","binary",6,-0.221105362434391,0.295842755640349,0.364678978368041,2007.66666666667,0.391987221894053,127
"CD001533","CD001533_pub7_data","2|5|Adverse events|Eye complications","Adverse events",2,5,"Eye complications","or","binary",5,-0.775993512434211,0.523785291355359,0,2005.6,0.0778476589797344,122.8
"CD001533","CD001533_pub7_data","2|5|Adverse events|Growth","Adverse events",2,5,"Growth","or","binary",3,-0.356989463889211,0.400180671728467,0.196880249093945,2009.33333333333,0.151983834286066,145.333333333333
"CD001533","CD001533_pub7_data","2|5|Adverse events|Hypertension","Adverse events",2,5,"Hypertension","or","binary",6,0.102447641763076,0.256989715465342,0.108510621585099,2007.66666666667,0.131838670682484,125.333333333333
"CD001533","CD001533_pub7_data","2|5|Adverse events|Infections","Adverse events",2,5,"Infections","or","binary",5,-0.0273765880958894,0.20740520572551,0.0133149497835506,2008.6,0.186498090994918,140.4
"CD001533","CD001533_pub7_data","2|5|Adverse events|Psychological disorders","Adverse events",2,5,"Psychological disorders","or","binary",4,-0.989889094706268,0.763169488331604,0.729115846060607,2007.75,0.0664838035527691,126.25
"CD001533","CD001533_pub7_data","6|1|Time to remission [days]|","Time to remission [days]",6,1,"","or","binary",2,0.151343021989374,1.451250312386,0,2003,0,19
"CD001533","CD001533_pub7_data","7|1|Number with relapse with infection|All children","Number with relapse with infection",7,1,"All children","or","binary",2,-0.303918045485499,0.431492086046323,0.198346576598585,2011,0.440508021390374,155
"CD001533","CD001533_pub7_data","7|1|Number with relapse with infection|Subgroup analysis: children receiving alternate-day prednisone","Number with relapse with infection",7,1,"Subgroup analysis: children receiving alternate-day prednisone","or","binary",2,-0.522651285623986,0.391494511752602,0,2011,0.469208211143695,55
"CD001533","CD001533_pub7_data","8|1|Number with remission|","Number with remission",8,1,"","or","binary",2,0.845800851301179,0.895623357431361,0,2012.5,0.877622377622378,33.5
"CD001533","CD001533_pub7_data","8|2|Number with relapse by 9 to 12 months|","Number with relapse by 9 to 12 months",8,2,"","or","binary",2,-1.53457714476963,0.917228382348535,0.916474445087431,2006,0.586363636363636,31.5
"CD001552","CD001552_pub3_data","1|1|Clinical improvement at short-term follow-up: 3 months or less|","Clinical improvement at short-term follow-up: 3 months or less",1,1,"","or","binary",2,0.213713720340053,1.07040785863024,1.98325674154228,2004,0.615267947421638,99
"CD001552","CD001552_pub3_data","1|2|Clinical improvement at long-term follow-up: over 3 months|","Clinical improvement at long-term follow-up: over 3 months",1,2,"","or","binary",3,2.18188794607692,0.707700069225413,0.694687519750107,1990.66666666667,0.423572551073861,70
"CD001552","CD001552_pub3_data","1|3|Symptoms at short-term follow-up: 3 months or less|","Symptoms at short-term follow-up: 3 months or less",1,3,"","or","binary",2,0.401865032777853,1.42762492565487,0,2004,0,99
"CD001552","CD001552_pub3_data","1|4|Symptoms at long-term follow-up: over 3 months|","Symptoms at long-term follow-up: over 3 months",1,4,"","or","binary",2,0.396527818450875,1.42766426931611,0,2004,0,97.5
"CD001552","CD001552_pub3_data","1|5|Function at short-term follow-up: 3 months or less|","Function at short-term follow-up: 3 months or less",1,5,"","or","binary",2,0.401865032777853,1.42762492565487,0,2004,0,99
"CD001552","CD001552_pub3_data","1|6|Function at long-term follow-up: over 3 months|","Function at long-term follow-up: over 3 months",1,6,"","or","binary",2,0.396527818450875,1.42766426931611,0,2004,0,97.5
"CD001552","CD001552_pub3_data","1|8|Adverse effects|","Adverse effects",1,8,"","or","binary",2,0.920243824988116,0.694360878480439,0.478035334512206,2004,0.258426966292135,105
"CD001552","CD001552_pub3_data","2|1|Clinical improvement at short-term follow-up: 3 months or less|","Clinical improvement at short-term follow-up: 3 months or less",2,1,"","or","binary",2,-0.926678283377683,0.510490159550996,0.285856029882678,2010,0.784221525600836,92.5
"CD001552","CD001552_pub3_data","2|2|Clinical improvement at long-term follow-up: over 3 months|","Clinical improvement at long-term follow-up: over 3 months",2,2,"","or","binary",3,0.780802479287512,1.01840064187518,2.67668069164957,2009.33333333333,0.601212121212121,62.3333333333333
"CD001552","CD001552_pub3_data","2|4|Symptoms at long-term follow-up: over 3 months|","Symptoms at long-term follow-up: over 3 months",2,4,"","or","binary",2,-0.0290663640629417,1.42621877065286,0,2011.5,0,59
"CD001552","CD001552_pub3_data","2|6|Function at long-term follow-up: over 3 months|","Function at long-term follow-up: over 3 months",2,6,"","or","binary",2,0.0440365646533387,1.42217858515945,0,2011.5,0,95.5
"CD001552","CD001552_pub3_data","2|9|Adverse effects|","Adverse effects",2,9,"","or","binary",2,0.306787040065481,0.79911406802952,0,2009,0.045,45
"CD001552","CD001552_pub3_data","5|2|Symptoms at short-term follow-up: 3 months or less|","Symptoms at short-term follow-up: 3 months or less",5,2,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001552","CD001552_pub3_data","5|3|Symptoms at long-term follow-up: over 3 months|","Symptoms at long-term follow-up: over 3 months",5,3,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001552","CD001552_pub3_data","5|4|Function at short-term follow-up: 3 months or less|","Function at short-term follow-up: 3 months or less",5,4,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001552","CD001552_pub3_data","5|5|Function at long-term follow-up: over 3 months|","Function at long-term follow-up: over 3 months",5,5,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001552","CD001552_pub3_data","5|6|Pain at short-term follow-up: 3 months or less|","Pain at short-term follow-up: 3 months or less",5,6,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001552","CD001552_pub3_data","5|7|Pain at long-term follow-up: over 3 months|","Pain at long-term follow-up: over 3 months",5,7,"","or","binary",2,0,1.42062103526994,0,2016,0,110
"CD001703","CD001703_pub4_data","1|1|Non-specific low back pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)|SNRI","Non-specific low back pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)",1,1,"SNRI","reported","reported",6,0,0.883370099612562,0,2010.5,0,237.333333333333
"CD001703","CD001703_pub4_data","1|1|Non-specific low back pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)|TCA","Non-specific low back pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)",1,1,"TCA","or","binary",2,0.892437396606352,1.4440198821042,0,1998,0,39
"CD001703","CD001703_pub4_data","1|10|Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): TCA|TCA","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): TCA",1,10,"TCA","reported","reported",2,0,0.693722201831105,0,2008,0,97
"CD001703","CD001703_pub4_data","1|13|Non-specific low back pain: HRQoL (EQ-5D, 0 to 1) at short-term follow-up (> 4 to 16 weeks): SNRI|SNRI","Non-specific low back pain: HRQoL (EQ-5D, 0 to 1) at short-term follow-up (> 4 to 16 weeks): SNRI",1,13,"SNRI","reported","reported",6,0,0.00998132889465703,0,2010.5,0,233.5
"CD001703","CD001703_pub4_data","1|14|Non-specific low back pain: HRQoL (SMD) at short-term follow-up (> 4 to 16 weeks): TCA|TCA","Non-specific low back pain: HRQoL (SMD) at short-term follow-up (> 4 to 16 weeks): TCA",1,14,"TCA","reported","reported",2,0,0.147611369852374,0,2008,0,97
"CD001703","CD001703_pub4_data","1|16|Spine-related leg pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)|TCA","Spine-related leg pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)",1,16,"TCA","reported","reported",3,0,2.76421899275141,0,2012.66666666667,0,51.6666666666667
"CD001703","CD001703_pub4_data","1|2|Non-specific low back pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)|SNRI","Non-specific low back pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)",1,2,"SNRI","reported","reported",6,0,0.977909272631998,0,2010.5,0,235.833333333333
"CD001703","CD001703_pub4_data","1|2|Non-specific low back pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)|TCA","Non-specific low back pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)",1,2,"TCA","reported","reported",2,0,3.39344476660179,0,2019,0,108.5
"CD001703","CD001703_pub4_data","1|25|Non-specific low back pain and spine-related leg pain: total adverse events|SSRI","Non-specific low back pain and spine-related leg pain: total adverse events",1,25,"SSRI","or","binary",2,0.545798698759536,1.35444059101682,2.89606787447506,2003,0.552556818181818,53.5
"CD001703","CD001703_pub4_data","1|25|Non-specific low back pain and spine-related leg pain: total adverse events|TCA","Non-specific low back pain and spine-related leg pain: total adverse events",1,25,"TCA","reported","reported",2,0,0.117660556527499,0,2020,0.25,62.5
"CD001703","CD001703_pub4_data","1|26|Non-specific low back pain and spine-related leg pain: serious adverse events|TCA","Non-specific low back pain and spine-related leg pain: serious adverse events",1,26,"TCA","or","binary",2,1.01403877102514,1.16685833656663,0,2020,0,71
"CD001703","CD001703_pub4_data","1|27|Non-specific low back pain and spine-related leg pain: withdrawals due to adverse events|SNRI","Non-specific low back pain and spine-related leg pain: withdrawals due to adverse events",1,27,"SNRI","reported","reported",2,0,0.328208563704445,0,2012.5,0.0689811663262991,304.5
"CD001703","CD001703_pub4_data","1|27|Non-specific low back pain and spine-related leg pain: withdrawals due to adverse events|TCA","Non-specific low back pain and spine-related leg pain: withdrawals due to adverse events",1,27,"TCA","reported","reported",3,0,0.661529890289623,0,1996.33333333333,0.0364942528735632,59
"CD001703","CD001703_pub4_data","1|4|Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): SNRI|SNRI","Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): SNRI",1,4,"SNRI","reported","reported",6,0,0.204966015709001,0,2010.5,0,224.666666666667
"CD001703","CD001703_pub4_data","1|6|Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): TCA|","Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): TCA",1,6,"","reported","reported",2,0,0.554761124242624,0,2012.5,0,94.5
"CD001703","CD001703_pub4_data","1|8|Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): SNRI|","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): SNRI",1,8,"","reported","reported",3,0,0.426225593679928,0,2009,0,129.333333333333
"CD001797","CD001797_pub4_data","1|1|Significant improvement in disability within 6 weeks|Cross-over design","Significant improvement in disability within 6 weeks",1,1,"Cross-over design","or","binary",2,1.93479394333148,0.566885884626748,0,1996,0.0925925925925926,35.5
"CD001797","CD001797_pub4_data","1|1|Significant improvement in disability within 6 weeks|Parallel design","Significant improvement in disability within 6 weeks",1,1,"Parallel design","or","binary",3,1.33146083300426,0.322865906838421,7.46202950483436e-08,2000.66666666667,0.220851112905086,66
"CD001797","CD001797_pub4_data","1|10|Frequency of any side effects|Parallel design","Frequency of any side effects",1,10,"Parallel design","or","binary",2,1.45762544797673,0.417083705855704,0.160440051877917,2004.5,0.298496240601504,129
"CD001797","CD001797_pub4_data","1|2|Significant improvement in disability within 6 weeks; generic inverse variance approach|","Significant improvement in disability within 6 weeks; generic inverse variance approach",1,2,"","reported","reported",2,1.25925040704467,0.410281774804887,0,1996,0,35.5
"CD001797","CD001797_pub4_data","1|3|Improvement ≥ 1 point on Rankin scale|Parallel design","Improvement ≥ 1 point on Rankin scale",1,3,"Parallel design","or","binary",2,0.90401141589667,0.708339504866977,0.364656962499919,1997,0.163003663003663,39
"CD001797","CD001797_pub4_data","1|4|Change in mean disability score within 6 weeks|Cross-over design","Change in mean disability score within 6 weeks",1,4,"Cross-over design","or","binary",2,-0.0656607604016279,1.44862001008732,0,1996,0,22
"CD001797","CD001797_pub4_data","1|4|Change in mean disability score within 6 weeks|Parallel design","Change in mean disability score within 6 weeks",1,4,"Parallel design","or","binary",3,-0.182864314055057,1.16693186448964,0,2000.66666666667,0,61
"CD001797","CD001797_pub4_data","1|6|Change in mean disability score on Rankin scale within 6 weeks|Parallel design","Change in mean disability score on Rankin scale within 6 weeks",1,6,"Parallel design","reported","reported",2,0,0.121783103122807,0,1997,0,39
"CD001797","CD001797_pub4_data","1|9|Frequency of serious side effects|Parallel design","Frequency of serious side effects",1,9,"Parallel design","or","binary",2,-0.336116519201365,0.460638789620469,0,2004.5,0.0897243107769423,129
"CD001837","CD001837_pub4_data","1|1|Quit at longest follow-up (6 + months)|Intensity 1 vs 0","Quit at longest follow-up (6 + months)",1,1,"Intensity 1 vs 0","or","binary",2,0.723885283663439,0.658824297060007,0.731727890092774,2012,0.195348732495835,708.5
"CD001837","CD001837_pub4_data","1|1|Quit at longest follow-up (6 + months)|Intensity 2 vs 0","Quit at longest follow-up (6 + months)",1,1,"Intensity 2 vs 0","or","binary",12,0.332101525521783,0.148742997380229,0.122971122623272,2005.91666666667,0.207869990450494,369.333333333333
"CD001837","CD001837_pub4_data","1|1|Quit at longest follow-up (6 + months)|Intensity 3 vs 0","Quit at longest follow-up (6 + months)",1,1,"Intensity 3 vs 0","or","binary",7,0.0680441048556092,0.101515726581896,0.0105539242381994,2000.14285714286,0.254660986711412,661
"CD001837","CD001837_pub4_data","1|1|Quit at longest follow-up (6 + months)|Intensity 4 vs 0","Quit at longest follow-up (6 + months)",1,1,"Intensity 4 vs 0","or","binary",28,0.481505676120083,0.0752920792903094,0.0527687765220071,2004.85714285714,0.258362166569366,294.071428571429
"CD001837","CD001837_pub4_data","2|1|Quit at longest follow-up (6 + months)|Bupropion vs placebo or no bupropion","Quit at longest follow-up (6 + months)",2,1,"Bupropion vs placebo or no bupropion","or","binary",4,0.144563403408511,0.161668474996161,7.60663521937604e-07,2009.75,0.231596717202843,218
"CD001837","CD001837_pub4_data","2|1|Quit at longest follow-up (6 + months)|NRT vs placebo or no NRT","Quit at longest follow-up (6 + months)",2,1,"NRT vs placebo or no NRT","or","binary",8,0.382251835438026,0.140953255576423,0.0462863982104191,2003.875,0.154881708410021,479.75
"CD001837","CD001837_pub4_data","2|1|Quit at longest follow-up (6 + months)|Varenicline vs placebo or no varenicline","Quit at longest follow-up (6 + months)",2,1,"Varenicline vs placebo or no varenicline","or","binary",4,0.376822163336324,0.173483438883758,0.0126343781223465,2017.25,0.236508560543977,207.25
"CD001837","CD001837_pub4_data","3|1|Behavioural support|Asynchronous","Behavioural support",3,1,"Asynchronous","or","binary",2,-0.0416325826626356,0.113107643883939,0,2018.5,0.297049089906233,799
"CD001837","CD001837_pub4_data","3|1|Behavioural support|Synchronous","Behavioural support",3,1,"Synchronous","or","binary",8,0.295400335452557,0.164814906253212,0.0789410495422844,2013.75,0.228254649102021,287.375
"CD001837","CD001837_pub4_data","3|2|Combined (pharmacotherapy + behavioural) support versus no support post-discharge|","Combined (pharmacotherapy + behavioural) support versus no support post-discharge",3,2,"","or","binary",7,0.246939633207381,0.0739274644334495,0,2015.42857142857,0.149863500803484,801.428571428571
"CD001837","CD001837_pub4_data","4|1|Quitline referral vs control|","Quitline referral vs control",4,1,"","or","binary",2,0.174139488850013,0.286818374992907,0.119426943055613,2016,0.140345911949686,935
"CD001837","CD001837_pub4_data","4|2|Health system telephone counselling vs quitline|","Health system telephone counselling vs quitline",4,2,"","or","binary",3,0.263029893158073,0.0988686723214568,9.78404152013817e-07,2019.33333333333,0.120366514434311,1086.66666666667
"CD001837","CD001837_pub4_data","5|2|Bupropion vs placebo or no bupropion|Not selected for interest in quitting","Bupropion vs placebo or no bupropion",5,2,"Not selected for interest in quitting","or","binary",3,0.0302215033131786,0.260788446673987,0.0498981397270695,2008.66666666667,0.235462289603791,160
"CD001837","CD001837_pub4_data","5|3|Varenicline vs placebo or no varenicline|Interested in quitting","Varenicline vs placebo or no varenicline",5,3,"Interested in quitting","or","binary",2,0.367650301444998,0.285188585293066,0.0419491712383464,2019,0.23416539310579,190
"CD001837","CD001837_pub4_data","5|3|Varenicline vs placebo or no varenicline|Not selected for interest in quitting","Varenicline vs placebo or no varenicline",5,3,"Not selected for interest in quitting","or","binary",2,0.171770914774607,0.488616715282566,0.33478013854091,2015.5,0.238851727982163,224.5
"CD001837","CD001837_pub4_data","5|4|Combined (pharmacotherapy + behavioural) support vs neither|Interested in quitting","Combined (pharmacotherapy + behavioural) support vs neither",5,4,"Interested in quitting","or","binary",3,0.291024659884659,0.155960726394368,0.035932342897047,2017.33333333333,0.126826594181179,1057.33333333333
"CD001837","CD001837_pub4_data","5|4|Combined (pharmacotherapy + behavioural) support vs neither|Not selected for interest in quitting","Combined (pharmacotherapy + behavioural) support vs neither",5,4,"Not selected for interest in quitting","or","binary",4,0.247742039894827,0.103128329688148,0,2014,0.167141180770213,609.5
"CD001837","CD001837_pub4_data","6|1|Patients with cardiovascular disease|Bupropion vs no placebo or no bupropion","Patients with cardiovascular disease",6,1,"Bupropion vs no placebo or no bupropion","or","binary",3,0.210620420445485,0.168996493214566,0,2010,0.229430543572045,263
"CD001837","CD001837_pub4_data","6|1|Patients with cardiovascular disease|Intensity 2 vs intensity 0","Patients with cardiovascular disease",6,1,"Intensity 2 vs intensity 0","or","binary",4,0.224816353694273,0.203569115380373,0.0866220782895577,2001.75,0.220443918244403,463.25
"CD001837","CD001837_pub4_data","6|1|Patients with cardiovascular disease|Intensity 3 vs intensity 0","Patients with cardiovascular disease",6,1,"Intensity 3 vs intensity 0","or","binary",3,0.0736673132222159,0.186313297548251,0,1997,0.480139693042919,205
"CD001837","CD001837_pub4_data","6|1|Patients with cardiovascular disease|Intensity 4 vs intensity 0","Patients with cardiovascular disease",6,1,"Intensity 4 vs intensity 0","or","binary",16,0.579164597179128,0.0900881005322124,0.0341390382078352,2004.125,0.323225320001075,218.4375
"CD001837","CD001837_pub4_data","6|1|Patients with cardiovascular disease|Post-discharge intervention","Patients with cardiovascular disease",6,1,"Post-discharge intervention","or","binary",2,1.85198906372373,1.86348706760367,6.00234028567948,2017,0.133928571428571,252
"CD001837","CD001837_pub4_data","6|2|Patients with respiratory disease|Counselling","Patients with respiratory disease",6,2,"Counselling","or","binary",3,0.323252090231873,0.385106070000511,0.326628243771707,1998.66666666667,0.242728842676786,238.333333333333
"CD001837","CD001837_pub4_data","6|2|Patients with respiratory disease|Nicotine replacement therapy","Patients with respiratory disease",6,2,"Nicotine replacement therapy","or","binary",2,0.35741589963339,0.741661928563268,0.709578502442145,1993.5,0.119602272727273,86.5
"CD001837","CD001837_pub4_data","6|3|Patients with stroke|Post-discharge behavioural intervention","Patients with stroke",6,3,"Post-discharge behavioural intervention","or","binary",2,0.282945986927495,0.331879745365903,0.0862318576604314,2018,0.273351648351648,154.5
"CD001909","CD001909_pub4_data","1|1|≥ 50% reduction in seizure frequency (intention-to-treat analysis)|Any dose of lamotrigine, adults or children","≥ 50% reduction in seizure frequency (intention-to-treat analysis)",1,1,"Any dose of lamotrigine, adults or children","or","binary",12,0.760909151309207,0.179859401570336,0.0806729658216064,1995.5,0.111909340872724,110.166666666667
"CD001909","CD001909_pub4_data","1|1|≥ 50% reduction in seizure frequency (intention-to-treat analysis)|Cross-over studies","≥ 50% reduction in seizure frequency (intention-to-treat analysis)",1,1,"Cross-over studies","or","binary",8,0.923691761123856,0.314684793344959,0,1992.125,0.074629884004884,47.75
"CD001909","CD001909_pub4_data","1|2|≥ 50% reduction in seizure frequency (worst-case analysis)|","≥ 50% reduction in seizure frequency (worst-case analysis)",1,2,"","or","binary",12,0.100419847323258,0.213913894661998,0.22097268788841,1995.5,0.190247575807477,110.166666666667
"CD001909","CD001909_pub4_data","1|3|≥ 50% reduction in seizure frequency (best-case analysis)|","≥ 50% reduction in seizure frequency (best-case analysis)",1,3,"","or","binary",12,1.50930836417233,0.136319802040046,0,1995.5,0.111909340872724,110.166666666667
"CD001909","CD001909_pub4_data","2|1|Treatment withdrawal|Cross-over studies","Treatment withdrawal",2,1,"Cross-over studies","or","binary",8,0.546965857077728,0.376839896761322,0,1992.125,0.0375343406593407,47.75
"CD001909","CD001909_pub4_data","2|1|Treatment withdrawal|Parallel-group studies (adults)","Treatment withdrawal",2,1,"Parallel-group studies (adults)","or","binary",4,0.174128506665808,0.160674779447651,0,2001.25,0.160034425182891,296.75
"CD001909","CD001909_pub4_data","3|1|Ataxia|Cross-over studies","Ataxia",3,1,"Cross-over studies","or","binary",8,1.16120211361502,0.327503785954933,0,1992.125,0.0405410561660562,47.75
"CD001909","CD001909_pub4_data","3|1|Ataxia|Parallel-group studies (adults)","Ataxia",3,1,"Parallel-group studies (adults)","or","binary",3,1.26540881988465,0.361618895590626,0.117899499207829,1999.33333333333,0.052184679370631,314.666666666667
"CD001909","CD001909_pub4_data","3|2|Dizziness|Cross-over studies","Dizziness",3,2,"Cross-over studies","or","binary",8,0.421100904903321,0.261282650852005,0,1992.125,0.138701923076923,47.75
"CD001909","CD001909_pub4_data","3|3|Fatigue|Cross-over studies","Fatigue",3,3,"Cross-over studies","or","binary",8,-0.483462507155688,0.296823132037215,0,1992.125,0.19739010989011,47.75
"CD001909","CD001909_pub4_data","3|3|Fatigue|Parallel-group studies (adults)","Fatigue",3,3,"Parallel-group studies (adults)","or","binary",3,-0.199143031776469,0.28983697134525,0.0658329178868219,2004,0.0946962147258624,323.666666666667
"CD001909","CD001909_pub4_data","3|4|Nausea|Cross-over studies","Nausea",3,4,"Cross-over studies","or","binary",8,0.52583609621877,0.299223597550208,0,1992.125,0.0865613553113553,47.75
"CD001909","CD001909_pub4_data","3|4|Nausea|Parallel-group studies (adults)","Nausea",3,4,"Parallel-group studies (adults)","or","binary",3,0.587659604737765,0.224175660596071,0,1998.33333333333,0.0953216397720103,301.666666666667
"CD001909","CD001909_pub4_data","3|5|Somnolence|Cross-over studies","Somnolence",3,5,"Cross-over studies","or","binary",8,0.0108698592760669,0.439063569164201,0.436168375390102,1992.125,0.0966651404151404,47.75
"CD001909","CD001909_pub4_data","3|5|Somnolence|Parallel-group studies (adults)","Somnolence",3,5,"Parallel-group studies (adults)","or","binary",4,0.45200081410197,0.220079905834844,0,2001.25,0.0718220768485711,296.75
"CD001909","CD001909_pub4_data","3|6|Diplopia|","Diplopia",3,6,"","or","binary",3,1.56768623631939,0.244000461117836,0,1999.33333333333,0.0678396783759652,314.666666666667
"CD001909","CD001909_pub4_data","3|7|Headache|","Headache",3,7,"","or","binary",5,0.159560649069085,0.133024235692379,0,2000.8,0.222410845024198,277.2
"CD001920","CD001920_pub4_data","1|1|Independence in ADL scales|Barthel Index","Independence in ADL scales",1,1,"Barthel Index","reported","reported",51,0,0.030557352416636,0,2009.25490196078,0,101.470588235294
"CD001920","CD001920_pub4_data","1|1|Independence in ADL scales|Other ADL measure","Independence in ADL scales",1,1,"Other ADL measure","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD001920","CD001920_pub4_data","1|2|Motor function scales|Fugl Meyer","Motor function scales",1,2,"Fugl Meyer","reported","reported",47,0,0.0303975066079737,0,2009.28260869565,0,109.617021276596
"CD001920","CD001920_pub4_data","1|2|Motor function scales|Other motor function measure","Motor function scales",1,2,"Other motor function measure","reported","reported",3,0,0.118119946091075,0,2004,0,96.6666666666667
"CD001920","CD001920_pub4_data","1|3|Balance (Berg Balance Scale)|","Balance (Berg Balance Scale)",1,3,"","reported","reported",8,0,0.108752548757895,0,2016.5,0,45.25
"CD001920","CD001920_pub4_data","1|4|Gait velocity|Gait speed (distance/time)","Gait velocity",1,4,"Gait speed (distance/time)","reported","reported",11,0,0.0723898255588859,0,2011.72727272727,0,67.0909090909091
"CD001920","CD001920_pub4_data","1|4|Gait velocity|Timed up and go test","Gait velocity",1,4,"Timed up and go test","reported","reported",4,0,0.237933071543015,0,2017.25,0,52.75
"CD001920","CD001920_pub4_data","1|4|Gait velocity|Timed walk (time to walk set distance)","Gait velocity",1,4,"Timed walk (time to walk set distance)","reported","reported",2,0,0.23862456076036,0,2004,0,68.5
"CD001920","CD001920_pub4_data","1|6|Adverse events|","Adverse events",1,6,"","reported","reported",5,0,0.355608792760631,0,2019.4,0.0159313725490196,56.6
"CD001920","CD001920_pub4_data","10|1|Length of time post stroke|Early (2 weeks or less post-stroke)","Length of time post stroke",10,1,"Early (2 weeks or less post-stroke)","reported","reported",21,0,0.0450691645228497,0,2009.85,0,105.428571428571
"CD001920","CD001920_pub4_data","10|1|Length of time post stroke|Later (more than 2 weeks post-stroke)","Length of time post stroke",10,1,"Later (more than 2 weeks post-stroke)","reported","reported",9,0,0.0868840109248303,0,2012,0,74.8888888888889
"CD001920","CD001920_pub4_data","10|2|Geographical location - continent of study conduct|All other continents","Geographical location - continent of study conduct",10,2,"All other continents","reported","reported",3,0,0.118119946091075,0,2004,0,96.6666666666667
"CD001920","CD001920_pub4_data","10|2|Geographical location - continent of study conduct|Asia","Geographical location - continent of study conduct",10,2,"Asia","reported","reported",50,0,0.0297377214392252,0,2009.59183673469,0,107.58
"CD001920","CD001920_pub4_data","10|3|Amount of treatment (less or more than 2.5 hours/week)|Less than 2.5 hours/week","Amount of treatment (less or more than 2.5 hours/week)",10,3,"Less than 2.5 hours/week","reported","reported",7,0,0.0800689516532074,0,2009.5,0,101
"CD001920","CD001920_pub4_data","10|3|Amount of treatment (less or more than 2.5 hours/week)|More than 2.5 hours/week","Amount of treatment (less or more than 2.5 hours/week)",10,3,"More than 2.5 hours/week","reported","reported",38,0,0.0402556805977544,0,2008.92105263158,0,82.6052631578947
"CD001920","CD001920_pub4_data","10|4|Duration of intervention|Longer (> 2 months)","Duration of intervention",10,4,"Longer (> 2 months)","reported","reported",23,0,0.038672710210969,0,2009.72727272727,0,130.130434782609
"CD001920","CD001920_pub4_data","10|4|Duration of intervention|Short (≤ 2 months)","Duration of intervention",10,4,"Short (≤ 2 months)","reported","reported",24,0,0.0458609577792285,0,2007.875,0,97.1666666666667
"CD001920","CD001920_pub4_data","10|5|Focus of treatment components|Functional task training","Focus of treatment components",10,5,"Functional task training","reported","reported",19,0,0.0525247503944817,0,2012.31578947368,0,99.5263157894737
"CD001920","CD001920_pub4_data","10|5|Focus of treatment components|Mixed treatment components","Focus of treatment components",10,5,"Mixed treatment components","reported","reported",27,0,0.039996888136537,0,2007.77777777778,0,103.814814814815
"CD001920","CD001920_pub4_data","10|6|Named approaches|Named as ""Bobath"" approach","Named approaches",10,6,"Named as ""Bobath"" approach","reported","reported",10,0,0.072387645740211,0,2007.4,0,87.9
"CD001920","CD001920_pub4_data","10|6|Named approaches|Named as ""three-stage approach""","Named approaches",10,6,"Named as ""three-stage approach""","reported","reported",14,0,0.0442353540313662,0,2009.07692307692,0,162.428571428571
"CD001920","CD001920_pub4_data","10|6|Named approaches|Other","Named approaches",10,6,"Other","reported","reported",29,0,0.044745285322654,0,2010,0,86.7586206896552
"CD001920","CD001920_pub4_data","10|7|Provider of intervention|Medical/therapeutic staff","Provider of intervention",10,7,"Medical/therapeutic staff","reported","reported",17,0,0.0625281269936525,0,2009.76470588235,0,72.9411764705882
"CD001920","CD001920_pub4_data","10|7|Provider of intervention|Medical/therapeutic staff + family/carers","Provider of intervention",10,7,"Medical/therapeutic staff + family/carers","reported","reported",16,0,0.0453926093621655,0,2009.53333333333,0,149.4375
"CD001920","CD001920_pub4_data","10|7|Provider of intervention|Others/not stated","Provider of intervention",10,7,"Others/not stated","reported","reported",20,0,0.0465555522571912,0,2008.65,0,101.9
"CD001920","CD001920_pub4_data","11|1|Length of time post stroke|Early (2 weeks or less post-stroke)","Length of time post stroke",11,1,"Early (2 weeks or less post-stroke)","reported","reported",2,0,0.177701394293324,0,2017.5,0,68
"CD001920","CD001920_pub4_data","11|1|Length of time post stroke|Later (more than 2 weeks post-stroke)","Length of time post stroke",11,1,"Later (more than 2 weeks post-stroke)","reported","reported",8,0,0.0708323722289869,0,2010.875,0,107.25
"CD001920","CD001920_pub4_data","11|2|Geographical location - continent of study conduct|All other continents","Geographical location - continent of study conduct",11,2,"All other continents","reported","reported",3,0,0.0980042948811119,0,2008.66666666667,0,139.333333333333
"CD001920","CD001920_pub4_data","11|2|Geographical location - continent of study conduct|Asia","Geographical location - continent of study conduct",11,2,"Asia","reported","reported",18,0,0.0569926123533794,0,2013.94444444444,0,86.3333333333333
"CD001920","CD001920_pub4_data","11|3|Amount of additional treatment (less or more than 2.5 hours/week)|Between 2.5 and 5 hours/week","Amount of additional treatment (less or more than 2.5 hours/week)",11,3,"Between 2.5 and 5 hours/week","reported","reported",4,0,0.124275333065033,0,2010.5,0,66
"CD001920","CD001920_pub4_data","11|3|Amount of additional treatment (less or more than 2.5 hours/week)|Less than 2.5 hours/week","Amount of additional treatment (less or more than 2.5 hours/week)",11,3,"Less than 2.5 hours/week","reported","reported",2,0,0.100083838115547,0,2012.5,0,200.5
"CD001920","CD001920_pub4_data","11|3|Amount of additional treatment (less or more than 2.5 hours/week)|More than 5 hours/week","Amount of additional treatment (less or more than 2.5 hours/week)",11,3,"More than 5 hours/week","reported","reported",10,0,0.0759990274399736,0,2014.6,0,93.5
"CD001920","CD001920_pub4_data","11|4|Duration of intervention|Longer (> 2 months)","Duration of intervention",11,4,"Longer (> 2 months)","reported","reported",4,0,0.0767540919308574,0,2012.5,0,172
"CD001920","CD001920_pub4_data","11|4|Duration of intervention|Short (≤ 2 months)","Duration of intervention",11,4,"Short (≤ 2 months)","reported","reported",11,0,0.0805171424079485,0,2013.27272727273,0,77.4545454545455
"CD001920","CD001920_pub4_data","11|5|Focus of treatment components|Functional task training added to less functional approach","Focus of treatment components",11,5,"Functional task training added to less functional approach","reported","reported",11,0,0.0905741390777923,0,2012,0,64.8181818181818
"CD001920","CD001920_pub4_data","11|5|Focus of treatment components|Neurophysiological approach added to a mixed or other approach","Focus of treatment components",11,5,"Neurophysiological approach added to a mixed or other approach","reported","reported",3,0,0.0966105485400027,0,2015.33333333333,0,149
"CD001920","CD001920_pub4_data","11|6|Provider of intervention|Medical/therapeutic staff","Provider of intervention",11,6,"Medical/therapeutic staff","reported","reported",7,0,0.0722088603304874,0,2009.57142857143,0,111.571428571429
"CD001920","CD001920_pub4_data","11|6|Provider of intervention|Medical/therapeutic staff + family/carers","Provider of intervention",11,6,"Medical/therapeutic staff + family/carers","reported","reported",6,0,0.0916415392548051,0,2016,0,102.333333333333
"CD001920","CD001920_pub4_data","11|6|Provider of intervention|Others/not stated","Provider of intervention",11,6,"Others/not stated","reported","reported",7,0,0.101891462532661,0,2014.85714285714,0,75.2857142857143
"CD001920","CD001920_pub4_data","12|1|Length of time post stroke|Later (more than 2 weeks post-stroke)","Length of time post stroke",12,1,"Later (more than 2 weeks post-stroke)","reported","reported",13,0,0.0595258495548898,0,2011.91666666667,0,91.7692307692308
"CD001920","CD001920_pub4_data","12|2|Geographical location - continent of study conduct|All other continents","Geographical location - continent of study conduct",12,2,"All other continents","reported","reported",7,0,0.0801166068384593,0,2011,0,90.2857142857143
"CD001920","CD001920_pub4_data","12|2|Geographical location - continent of study conduct|Asia","Geographical location - continent of study conduct",12,2,"Asia","reported","reported",15,0,0.0576258000718159,0,2013.71428571429,0,88.8666666666667
"CD001920","CD001920_pub4_data","12|3|Amount of additional treatment (less or more than 2.5 hours/week)|Between 2.5 and 5 hours/week","Amount of additional treatment (less or more than 2.5 hours/week)",12,3,"Between 2.5 and 5 hours/week","reported","reported",5,0,0.153253305005731,0,2008.75,0,35.6
"CD001920","CD001920_pub4_data","12|3|Amount of additional treatment (less or more than 2.5 hours/week)|Less than 2.5 hours/week","Amount of additional treatment (less or more than 2.5 hours/week)",12,3,"Less than 2.5 hours/week","reported","reported",2,0,0.0987701735836454,0,2019.5,0,206
"CD001920","CD001920_pub4_data","12|3|Amount of additional treatment (less or more than 2.5 hours/week)|More than 5 hours / week","Amount of additional treatment (less or more than 2.5 hours/week)",12,3,"More than 5 hours / week","reported","reported",8,0,0.0759374138680999,0,2013.125,0,95.625
"CD001920","CD001920_pub4_data","12|4|Duration of intervention|Longer (> 2 months)","Duration of intervention",12,4,"Longer (> 2 months)","reported","reported",4,0,0.084298202892357,0,2008.25,0,145.5
"CD001920","CD001920_pub4_data","12|4|Duration of intervention|Short (≤ 2 months)","Duration of intervention",12,4,"Short (≤ 2 months)","reported","reported",12,0,0.0706562989124399,0,2013.54545454545,0,72.0833333333333
"CD001920","CD001920_pub4_data","12|5|Focus of treatment components|Functional task training added to less functional approach","Focus of treatment components",12,5,"Functional task training added to less functional approach","reported","reported",9,0,0.087654701320724,0,2010.66666666667,0,63.7777777777778
"CD001920","CD001920_pub4_data","12|5|Focus of treatment components|Neurophysiological approach added to a mixed or other approach","Focus of treatment components",12,5,"Neurophysiological approach added to a mixed or other approach","reported","reported",3,0,0.117722108568396,0,2013,0,99.6666666666667
"CD001920","CD001920_pub4_data","12|6|Provider of intervention|Medical/therapeutic staff","Provider of intervention",12,6,"Medical/therapeutic staff","reported","reported",12,0,0.0611433513436179,0,2010.90909090909,0,91.1666666666667
"CD001920","CD001920_pub4_data","12|6|Provider of intervention|Medical/therapeutic staff + family/carers","Provider of intervention",12,6,"Medical/therapeutic staff + family/carers","reported","reported",3,0,0.127543628714265,0,2015.66666666667,0,93.3333333333333
"CD001920","CD001920_pub4_data","12|6|Provider of intervention|Others/not stated","Provider of intervention",12,6,"Others/not stated","reported","reported",7,0,0.0883970374031515,0,2014.57142857143,0,84.4285714285714
"CD001920","CD001920_pub4_data","2|1|Independence in ADL scales|Barthel Index","Independence in ADL scales",2,1,"Barthel Index","reported","reported",13,0,0.0764632866408579,0,2005.69230769231,0,56.8461538461538
"CD001920","CD001920_pub4_data","2|2|Motor function scales|Fugl Meyer","Motor function scales",2,2,"Fugl Meyer","reported","reported",10,0,0.051838608475246,0,2007.1,0,163.2
"CD001920","CD001920_pub4_data","2|2|Motor function scales|Other motor function measure","Motor function scales",2,2,"Other motor function measure","reported","reported",2,0,0.131083308016251,0,1997,0,117
"CD001920","CD001920_pub4_data","2|3|Balance (Berg Balance Scale)|","Balance (Berg Balance Scale)",2,3,"","reported","reported",3,0,0.144961793845877,0,2014,0,51.3333333333333
"CD001920","CD001920_pub4_data","2|4|Gait velocity|Gait speed (distance/time)","Gait velocity",2,4,"Gait speed (distance/time)","reported","reported",4,0,0.108061595521544,0,2011.75,0,76.25
"CD001920","CD001920_pub4_data","2|4|Gait velocity|Timed up and go test","Gait velocity",2,4,"Timed up and go test","reported","reported",2,0,0.247817667588795,0,2018,0,54
"CD001920","CD001920_pub4_data","3|1|Independence in ADL scales|Other ADL measure","Independence in ADL scales",3,1,"Other ADL measure","or","binary",2,-0.0328769565651881,1.42747191295409,0,2014.5,0,53
"CD001920","CD001920_pub4_data","3|2|Motor function scales|Other motor function measure","Motor function scales",3,2,"Other motor function measure","reported","reported",2,0,0.226546165282847,0,2006.5,0,39.5
"CD001920","CD001920_pub4_data","3|3|Balance (Berg Balance Scale)|","Balance (Berg Balance Scale)",3,3,"","reported","reported",2,0,0.177378991149246,0,2010,0,65.5
"CD001920","CD001920_pub4_data","3|4|Gait velocity|Gait speed (distance/time)","Gait velocity",3,4,"Gait speed (distance/time)","reported","reported",5,0,0.114059417640388,0,2007.8,0,63.8
"CD001920","CD001920_pub4_data","3|4|Gait velocity|Timed up and go test","Gait velocity",3,4,"Timed up and go test","reported","reported",2,0,0.341373410176663,0,2009,0,34.5
"CD001920","CD001920_pub4_data","3|6|Adverse events|","Adverse events",3,6,"","reported","reported",3,0,0.49921332304315,0,2010,0.0511567285760834,96.6666666666667
"CD001920","CD001920_pub4_data","4|2|Motor function scales|Other motor function measure","Motor function scales",4,2,"Other motor function measure","reported","reported",2,0,0.223264930969075,0,2006.5,0,40.5
"CD001920","CD001920_pub4_data","4|4|Gait velocity|Gait speed (distance/time)","Gait velocity",4,4,"Gait speed (distance/time)","reported","reported",2,0,0.250880680952566,0,2004.5,0,33
"CD001920","CD001920_pub4_data","4|4|Gait velocity|Timed up and go test","Gait velocity",4,4,"Timed up and go test","reported","reported",2,0,0.285048780679735,0,2009,0,33.5
"CD001920","CD001920_pub4_data","5|1|Independence in ADL scales|Barthel Index","Independence in ADL scales",5,1,"Barthel Index","reported","reported",19,0,0.057419923408031,0,2012.73684210526,0,80.7368421052632
"CD001920","CD001920_pub4_data","5|2|Motor function scales|Fugl Meyer","Motor function scales",5,2,"Fugl Meyer","reported","reported",14,0,0.0613179081842066,0,2011.61538461538,0,83.5
"CD001920","CD001920_pub4_data","5|2|Motor function scales|Other motor function measure","Motor function scales",5,2,"Other motor function measure","reported","reported",6,0,0.114518220923611,0,2014.66666666667,0,54
"CD001920","CD001920_pub4_data","5|3|Balance (Berg Balance Scale)|","Balance (Berg Balance Scale)",5,3,"","reported","reported",13,0,0.0847258861066955,0,2011.46153846154,0,54.5384615384615
"CD001920","CD001920_pub4_data","5|4|Gait velocity|Gait speed (distance/time)","Gait velocity",5,4,"Gait speed (distance/time)","reported","reported",8,0,0.117238306132662,0,2011.5,0,40.25
"CD001920","CD001920_pub4_data","5|4|Gait velocity|Timed up and go test","Gait velocity",5,4,"Timed up and go test","reported","reported",2,0,0.46206221677512,0,2017.5,0,39
"CD001920","CD001920_pub4_data","5|4|Gait velocity|Timed walk (time to walk set distance)","Gait velocity",5,4,"Timed walk (time to walk set distance)","reported","reported",6,0,0.221791151146724,0,2016,0,23.1666666666667
"CD001920","CD001920_pub4_data","5|5|Adverse events|","Adverse events",5,5,"","reported","reported",4,0,0.108949368335641,0,2013.5,0.356057739511348,175.5
"CD001920","CD001920_pub4_data","7|1|Functional task training compared to other: Independence in ADL scales|Functional task training compared to 'less' functional task training","Functional task training compared to other: Independence in ADL scales",7,1,"Functional task training compared to 'less' functional task training","reported","reported",11,0,0.0732720005381226,0,2015.7,0,79.7272727272727
"CD001920","CD001920_pub4_data","7|1|Functional task training compared to other: Independence in ADL scales|Functional task training compared to Neurophysiological","Functional task training compared to other: Independence in ADL scales",7,1,"Functional task training compared to Neurophysiological","reported","reported",9,0,0.0957471349070565,0,2009,0,52
"CD001920","CD001920_pub4_data","7|10|Neurophysiological approaches compared to other approaches: Gait velocity|Neurophysiological (Bobath) compared to neurophysiological (other)","Neurophysiological approaches compared to other approaches: Gait velocity",7,10,"Neurophysiological (Bobath) compared to neurophysiological (other)","reported","reported",3,0,0.265937490519779,0,2017.33333333333,0,22.6666666666667
"CD001920","CD001920_pub4_data","7|10|Neurophysiological approaches compared to other approaches: Gait velocity|Neurophysiological compared to functional task training","Neurophysiological approaches compared to other approaches: Gait velocity",7,10,"Neurophysiological compared to functional task training","reported","reported",5,0,0.149818189790448,0,2006.8,0,36.8
"CD001920","CD001920_pub4_data","7|10|Neurophysiological approaches compared to other approaches: Gait velocity|Neurophysiological compared to no (or minimal) neurophysiological","Neurophysiological approaches compared to other approaches: Gait velocity",7,10,"Neurophysiological compared to no (or minimal) neurophysiological","reported","reported",7,0,0.128958617589779,0,2009.42857142857,0,42.5714285714286
"CD001920","CD001920_pub4_data","7|2|Functional task training compared to other: Motor function scales|Functional task training compared to 'less' functional task training","Functional task training compared to other: Motor function scales",7,2,"Functional task training compared to 'less' functional task training","reported","reported",9,0,0.0764236116405241,0,2016.625,0,102.555555555556
"CD001920","CD001920_pub4_data","7|2|Functional task training compared to other: Motor function scales|Functional task training compared to neurophysiological","Functional task training compared to other: Motor function scales",7,2,"Functional task training compared to neurophysiological","reported","reported",9,0,0.0975915449335763,0,2008.22222222222,0,49.1111111111111
"CD001920","CD001920_pub4_data","7|3|Functional task training compared to other: Balance (Berg Balance Scale)|Functional task training compared to 'less' functional task training","Functional task training compared to other: Balance (Berg Balance Scale)",7,3,"Functional task training compared to 'less' functional task training","reported","reported",17,0,0.0740447045938404,0,2015.47058823529,0,50.6470588235294
"CD001920","CD001920_pub4_data","7|3|Functional task training compared to other: Balance (Berg Balance Scale)|Functional Task Training compared to Neurophysiological","Functional task training compared to other: Balance (Berg Balance Scale)",7,3,"Functional Task Training compared to Neurophysiological","reported","reported",4,0,0.247277840359282,0,2007.25,0,26.5
"CD001920","CD001920_pub4_data","7|4|Functional task training compared to other: Gait velocity|Functional task training compared to 'less' functional task training","Functional task training compared to other: Gait velocity",7,4,"Functional task training compared to 'less' functional task training","reported","reported",18,0,0.0664578139850761,0,2015.83333333333,0,56.8333333333333
"CD001920","CD001920_pub4_data","7|4|Functional task training compared to other: Gait velocity|Functional Task Training compared to Neurophysiological","Functional task training compared to other: Gait velocity",7,4,"Functional Task Training compared to Neurophysiological","reported","reported",5,0,0.149827551498982,0,2006.8,0,36.8
"CD001920","CD001920_pub4_data","7|6|Functional task training compared to other approaches: Adverse events|","Functional task training compared to other approaches: Adverse events",7,6,"","reported","reported",6,0,0.160304189533442,0,2016.66666666667,0.123333333333333,78.8333333333333
"CD001920","CD001920_pub4_data","7|7|Neurophysiological approaches compared to other: Independence in ADL scales|Neurophysiological (Bobath) compared to Neurophysiological (other)","Neurophysiological approaches compared to other: Independence in ADL scales",7,7,"Neurophysiological (Bobath) compared to Neurophysiological (other)","reported","reported",2,0,0.356917592643773,0,2014,0,25
"CD001920","CD001920_pub4_data","7|7|Neurophysiological approaches compared to other: Independence in ADL scales|Neurophysiological compared to Functional Task Training","Neurophysiological approaches compared to other: Independence in ADL scales",7,7,"Neurophysiological compared to Functional Task Training","reported","reported",9,0,0.0991773186909358,0,2009,0,52
"CD001920","CD001920_pub4_data","7|7|Neurophysiological approaches compared to other: Independence in ADL scales|Neurophysiological compared to no (or minimal) neurophysiological","Neurophysiological approaches compared to other: Independence in ADL scales",7,7,"Neurophysiological compared to no (or minimal) neurophysiological","reported","reported",3,0,0.159330006214869,0,2007,0,60
"CD001920","CD001920_pub4_data","7|8|Neurophysiological approaches compared to other: Motor function scales|Neurophysiological (Bobath) compared to neurophysiological (other)","Neurophysiological approaches compared to other: Motor function scales",7,8,"Neurophysiological (Bobath) compared to neurophysiological (other)","reported","reported",2,0,0.242940255446047,0,2014,0,25
"CD001920","CD001920_pub4_data","7|8|Neurophysiological approaches compared to other: Motor function scales|Neurophysiological compared to functional task training","Neurophysiological approaches compared to other: Motor function scales",7,8,"Neurophysiological compared to functional task training","reported","reported",9,0,0.100979977607301,0,2008.22222222222,0,49.1111111111111
"CD001920","CD001920_pub4_data","7|8|Neurophysiological approaches compared to other: Motor function scales|Neurophysiological compared to no (or minimal) neurophysiological","Neurophysiological approaches compared to other: Motor function scales",7,8,"Neurophysiological compared to no (or minimal) neurophysiological","reported","reported",3,0,0.221970413889009,0,2011.33333333333,0,57
"CD001920","CD001920_pub4_data","7|9|Neurophysiological approaches compared to other: Balance (Berg Balance Scale)|Neurophysiological compared to functional task training","Neurophysiological approaches compared to other: Balance (Berg Balance Scale)",7,9,"Neurophysiological compared to functional task training","reported","reported",3,0,0.193638108503436,0,2014.33333333333,0,50
"CD001920","CD001920_pub4_data","8|1|Functional task training compared to other approaches: Independence in ADL scales|Functional task training compared to 'less' functional task training","Functional task training compared to other approaches: Independence in ADL scales",8,1,"Functional task training compared to 'less' functional task training","reported","reported",4,0,0.126297389362765,0,2014.33333333333,0,100
"CD001920","CD001920_pub4_data","8|1|Functional task training compared to other approaches: Independence in ADL scales|Functional Task Training compared to Neurophysiological","Functional task training compared to other approaches: Independence in ADL scales",8,1,"Functional Task Training compared to Neurophysiological","or","binary",2,-0.123758259714742,1.43279866745928,0,2005.5,0,39
"CD001920","CD001920_pub4_data","8|2|Functional task training compared to other approaches: Motor function scales|Functional task training compared to 'less' functional task training","Functional task training compared to other approaches: Motor function scales",8,2,"Functional task training compared to 'less' functional task training","reported","reported",5,0,0.0779372110261706,0,2012.5,0,137.6
"CD001920","CD001920_pub4_data","8|2|Functional task training compared to other approaches: Motor function scales|Functional task training compared to neurophysiological","Functional task training compared to other approaches: Motor function scales",8,2,"Functional task training compared to neurophysiological","or","binary",2,-0.122559687610872,1.42584361361123,0,2006,0,64
"CD001920","CD001920_pub4_data","8|3|Functional task training compared to other approaches: Balance (Berg Balance Scale)|Functional task training compared to 'less' functional task training","Functional task training compared to other approaches: Balance (Berg Balance Scale)",8,3,"Functional task training compared to 'less' functional task training","reported","reported",4,0,0.116436042315299,0,2012.75,0,90
"CD001920","CD001920_pub4_data","8|4|Functional task training compared to other approaches: Gait velocity|Functional task training compared to 'less' functional task training","Functional task training compared to other approaches: Gait velocity",8,4,"Functional task training compared to 'less' functional task training","reported","reported",7,0,0.0788516365134152,0,2013.57142857143,0,97.4285714285714
"CD001920","CD001920_pub4_data","8|7|Neurophysiological approaches compared to other approaches: Motor function scales|Neurophysiological compared to functional task training","Neurophysiological approaches compared to other approaches: Motor function scales",8,7,"Neurophysiological compared to functional task training","or","binary",2,0.122559687610872,1.42584361361123,0,2006,0,64
"CD001920","CD001920_pub4_data","9|1|Length of time post stroke|Early (2 weeks or less post-stroke)","Length of time post stroke",9,1,"Early (2 weeks or less post-stroke)","reported","reported",17,0,0.0606446675784697,0,2009.82352941176,0,83.1176470588235
"CD001920","CD001920_pub4_data","9|1|Length of time post stroke|Later (more than 2 weeks post-stroke)","Length of time post stroke",9,1,"Later (more than 2 weeks post-stroke)","reported","reported",12,0,0.073699301002384,0,2011.33333333333,0,77.5833333333333
"CD001920","CD001920_pub4_data","9|2|Geographical location - continent of study conduct|All other continents","Geographical location - continent of study conduct",9,2,"All other continents","reported","reported",6,0,0.100255775713926,0,2008.83333333333,0,73
"CD001920","CD001920_pub4_data","9|2|Geographical location - continent of study conduct|Asia","Geographical location - continent of study conduct",9,2,"Asia","reported","reported",48,0,0.0312776646090289,0,2009.8125,0,103.4375
"CD001920","CD001920_pub4_data","9|3|Amount of treatment (less or more than 2.5 hours/week)|Less than 2.5 hours/week","Amount of treatment (less or more than 2.5 hours/week)",9,3,"Less than 2.5 hours/week","reported","reported",7,0,0.0859124828285155,0,2010.57142857143,0,86.1428571428571
"CD001920","CD001920_pub4_data","9|3|Amount of treatment (less or more than 2.5 hours/week)|More than 2.5 hours/week","Amount of treatment (less or more than 2.5 hours/week)",9,3,"More than 2.5 hours/week","reported","reported",39,0,0.0395122223351779,0,2008.97435897436,0,84.0769230769231
"CD001920","CD001920_pub4_data","9|4|Duration of intervention|Longer (> 2 months)","Duration of intervention",9,4,"Longer (> 2 months)","reported","reported",18,0,0.0457091404428946,0,2011.55555555556,0,120.666666666667
"CD001920","CD001920_pub4_data","9|4|Duration of intervention|Short (≤ 2 months)","Duration of intervention",9,4,"Short (≤ 2 months)","reported","reported",30,0,0.0430488588758152,0,2007.96666666667,0,89.5
"CD001920","CD001920_pub4_data","9|5|Focus of treatment components|Functional task training","Focus of treatment components",9,5,"Functional task training","reported","reported",19,0,0.05759755898159,0,2011.89473684211,0,83.7894736842105
"CD001920","CD001920_pub4_data","9|5|Focus of treatment components|Mixed treatment components","Focus of treatment components",9,5,"Mixed treatment components","reported","reported",29,0,0.0381555166439711,0,2009.03448275862,0,110.896551724138
"CD001920","CD001920_pub4_data","9|6|Named approaches|Named as ""Bobath"" approach","Named approaches",9,6,"Named as ""Bobath"" approach","reported","reported",12,0,0.0687519387876711,0,2009,0,93.3333333333333
"CD001920","CD001920_pub4_data","9|6|Named approaches|Named as ""three-stage approach""","Named approaches",9,6,"Named as ""three-stage approach""","reported","reported",11,0,0.0535215838271624,0,2008.81818181818,0,144.727272727273
"CD001920","CD001920_pub4_data","9|6|Named approaches|Other","Named approaches",9,6,"Other","reported","reported",31,0,0.0422189906020524,0,2010.29032258065,0,86.8064516129032
"CD001920","CD001920_pub4_data","9|7|Provider of intervention|Medical/therapeutic staff","Provider of intervention",9,7,"Medical/therapeutic staff","reported","reported",19,0,0.0602657018018215,0,2009.73684210526,0,72.6842105263158
"CD001920","CD001920_pub4_data","9|7|Provider of intervention|Medical/therapeutic staff + family/carers","Provider of intervention",9,7,"Medical/therapeutic staff + family/carers","reported","reported",16,0,0.0476417319258486,0,2010.625,0,129.8125
"CD001920","CD001920_pub4_data","9|7|Provider of intervention|Others/not stated","Provider of intervention",9,7,"Others/not stated","reported","reported",19,0,0.0496434860095015,0,2008.89473684211,0,102.368421052632
"CD002042","CD002042_pub6_data","1|1|Participants exposed to blood transfusion (all trials)|","Participants exposed to blood transfusion (all trials)",1,1,"","reported","reported",52,0.611187044041179,0.031294791946988,0.0445917106786908,2009.80952380952,0.868194725188905,498.096153846154
"CD002042","CD002042_pub6_data","1|10|30-day mortality: subgroup by prospective trial registration vs no prospective registration|Prospectively registered trials","30-day mortality: subgroup by prospective trial registration vs no prospective registration",1,10,"Prospectively registered trials","reported","reported",23,0.979794285076061,0.0611223528417295,0.00890224724192397,2015.78947368421,0.0962942595961959,740.478260869565
"CD002042","CD002042_pub6_data","1|10|30-day mortality: subgroup by prospective trial registration vs no prospective registration|Trials without prospective registration","30-day mortality: subgroup by prospective trial registration vs no prospective registration",1,10,"Trials without prospective registration","reported","reported",14,0.835783760472675,0.110088102552649,0.0249989730622765,2003.72727272727,0.0942044753893734,329.785714285714
"CD002042","CD002042_pub6_data","1|11|30-day mortality: sensitivity analysis by allocation concealment|Low risk of bias","30-day mortality: sensitivity analysis by allocation concealment",1,11,"Low risk of bias","reported","reported",28,0.945585375264607,0.0628215855494258,0.0210547212473941,2012.61538461538,0.0970561049156529,695.821428571429
"CD002042","CD002042_pub6_data","1|12|30-day mortality sensitivity analysis excluding trials at high risk of non-anaemic participants|","30-day mortality sensitivity analysis excluding trials at high risk of non-anaemic participants",1,12,"","reported","reported",25,0.981386458056354,0.0594800152679573,0.0112496692485492,2011.09523809524,0.116878534940237,557
"CD002042","CD002042_pub6_data","1|13|In-hospital mortality (as defined by triallists)|","In-hospital mortality (as defined by triallists)",1,13,"","reported","reported",15,0.867962128244625,0.0499108113270748,0,2010.07692307692,0.131840637035196,521.4
"CD002042","CD002042_pub6_data","1|14|90-day mortality|","90-day mortality",1,14,"","reported","reported",8,1.09832906905683,0.0963690659159805,0.0160545881401941,2016.14285714286,0.188528105072378,521.5
"CD002042","CD002042_pub6_data","1|15|6-month, 12-month mortality|12-month mortality","6-month, 12-month mortality",1,15,"12-month mortality","reported","reported",3,1.03226361021249,0.0915110235812677,0,2017,0.248560575227242,530.333333333333
"CD002042","CD002042_pub6_data","1|15|6-month, 12-month mortality|6-month and 12-month mortality together","6-month, 12-month mortality",1,15,"6-month and 12-month mortality together","reported","reported",12,1.00286906827895,0.0406431292416168,0,2016.625,0.215362413795849,999.916666666667
"CD002042","CD002042_pub6_data","1|15|6-month, 12-month mortality|6-month mortality","6-month, 12-month mortality",1,15,"6-month mortality","reported","reported",9,0.981324099127778,0.0542672132146133,0.0039974771168935,2016.5,0.204296359985385,1156.44444444444
"CD002042","CD002042_pub6_data","1|16|Neurocritically ill patients: unfavourable neurological outcome (dichotomised GOS-E or Rankin) at 6 to 12 months|","Neurocritically ill patients: unfavourable neurological outcome (dichotomised GOS-E or Rankin) at 6 to 12 months",1,16,"","reported","reported",4,1.13060414977148,0.0436031870335658,0,2019,0.459516469535553,574.25
"CD002042","CD002042_pub6_data","1|17|Morbidity: myocardial infarction|","Morbidity: myocardial infarction",1,17,"","reported","reported",26,0.881955000686579,0.153783759208707,0.102073921566989,2011,0.0234488545859914,747.5
"CD002042","CD002042_pub6_data","1|18|Morbidity: congestive heart failure|","Morbidity: congestive heart failure",1,18,"","reported","reported",16,0.708283772490164,0.125492318781759,0.052498907001898,2011.84615384615,0.063577830948801,652.9375
"CD002042","CD002042_pub6_data","1|19|Morbidity: cerebrovascular accident (CVA) – stroke|","Morbidity: cerebrovascular accident (CVA) – stroke",1,19,"","reported","reported",24,0.915621336216934,0.11481241257458,0.0457301378030356,2012.55,0.0450519637518327,809.125
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Acute myocardial infarction","Participants exposed to blood transfusion by clinical specialties",1,2,"Acute myocardial infarction","reported","reported",4,0.355448497918265,0.0108259592268237,2.62357975704527e-06,2017,0.986407882241216,1081
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Cardiac surgery","Participants exposed to blood transfusion by clinical specialties",1,2,"Cardiac surgery","reported","reported",8,0.686752249785749,0.0182679757906081,0.000785728528028828,2010,0.80539596733596,1084.75
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Critical care","Participants exposed to blood transfusion by clinical specialties",1,2,"Critical care","reported","reported",8,0.711465001905917,0.0406426652866028,0.00872201845649753,2010,0.874156611610136,359.75
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Gastrointestinal bleeding","Participants exposed to blood transfusion by clinical specialties",1,2,"Gastrointestinal bleeding","reported","reported",5,0.492851800337255,0.0927372880310424,0.0332345529658905,2004.66666666667,0.80600793723293,390.8
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Haematological malignancies","Participants exposed to blood transfusion by clinical specialties",1,2,"Haematological malignancies","reported","reported",5,0.900597589360665,0.0742413244618834,0.0236925832255451,2016,0.959096774193548,102.8
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Neurocritical care","Participants exposed to blood transfusion by clinical specialties",1,2,"Neurocritical care","reported","reported",6,0.553166002816013,0.0763853198076818,0.0302997675143553,2009,0.952018058608924,407.166666666667
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Orthopaedic surgery","Participants exposed to blood transfusion by clinical specialties",1,2,"Orthopaedic surgery","reported","reported",12,0.516493410545741,0.0652176332233207,0.0424399742906138,2010.09090909091,0.784754003672227,339
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Trauma","Participants exposed to blood transfusion by clinical specialties",1,2,"Trauma","reported","reported",2,0.832013997158533,0.0434363327794235,0.0011190856650528,1956,0.97948717948718,216.5
"CD002042","CD002042_pub6_data","1|2|Participants exposed to blood transfusion by clinical specialties|Vascular surgery","Participants exposed to blood transfusion by clinical specialties",1,2,"Vascular surgery","reported","reported",2,0.789704718480197,0.125259845634594,0.0239678398698073,2008,0.938775510204082,78.5
"CD002042","CD002042_pub6_data","1|20|Morbidity: infection (composite)|","Morbidity: infection (composite)",1,20,"","reported","reported",36,0.927120364282035,0.0558902878672589,0.046586488101838,2013.30769230769,0.225686410112289,641.916666666667
"CD002042","CD002042_pub6_data","1|21|Morbidity: pneumonia|","Morbidity: pneumonia",1,21,"","reported","reported",20,0.939337769072039,0.0498759166313137,0,2012.375,0.12802095054603,554.85
"CD002042","CD002042_pub6_data","1|22|Morbidity: sepsis/bacteraemia|","Morbidity: sepsis/bacteraemia",1,22,"","reported","reported",17,1.00065516118791,0.0765337743383671,0.0236717642060714,2014.18181818182,0.136069187097182,667.176470588235
"CD002042","CD002042_pub6_data","1|23|Morbidity: sepsis|","Morbidity: sepsis",1,23,"","reported","reported",13,1.03279706204284,0.135644131638851,0.0776960199717051,2011.71428571429,0.110121854054452,478.769230769231
"CD002042","CD002042_pub6_data","1|24|Morbidity: bacteraemia|","Morbidity: bacteraemia",1,24,"","reported","reported",11,0.938544826717331,0.0898779697033281,0,2015.28571428571,0.0823092365230671,706.909090909091
"CD002042","CD002042_pub6_data","1|25|Morbidity: meningitis, ventriculitis or brain abscess|","Morbidity: meningitis, ventriculitis or brain abscess",1,25,"","reported","reported",3,0.874253600788867,0.232776142887119,0,2019,0.04685964442062,501.666666666667
"CD002042","CD002042_pub6_data","1|26|Morbidity: wound infection|","Morbidity: wound infection",1,26,"","reported","reported",15,0.742649735143321,0.13452177128027,0.0691768780380918,2014,0.116046767059161,420.866666666667
"CD002042","CD002042_pub6_data","1|27|Morbidity: thromboembolism|","Morbidity: thromboembolism",1,27,"","reported","reported",19,0.700626491975688,0.119840863873093,0,2013.85714285714,0.0332617762198725,546.473684210526
"CD002042","CD002042_pub6_data","1|28|Morbidity: rebleeding|","Morbidity: rebleeding",1,28,"","reported","reported",11,0.790032901948204,0.128592843265827,0.089420618041721,2013,0.135059935243474,693.363636363636
"CD002042","CD002042_pub6_data","1|29|Morbidity: clinically significant bleeding through thrombocytopaenia at longest follow-up|","Morbidity: clinically significant bleeding through thrombocytopaenia at longest follow-up",1,29,"","reported","reported",4,0.893785506514371,0.139148785233177,0.0169569273353834,2014.66666666667,0.30805765271105,134.75
"CD002042","CD002042_pub6_data","1|3|Participants exposed to blood transfusion by threshold difference|Difference between liberal and restrictive haemoglobin thresholds &lt; 2.0 g/dL","Participants exposed to blood transfusion by threshold difference",1,3,"Difference between liberal and restrictive haemoglobin thresholds &lt; 2.0 g/dL","reported","reported",7,0.817156677740285,0.0543360594675756,0.0149294530432693,2009.33333333333,0.820773497355995,430
"CD002042","CD002042_pub6_data","1|3|Participants exposed to blood transfusion by threshold difference|Difference between liberal and restrictive haemoglobin thresholds ≥ 2.0 g/dL","Participants exposed to blood transfusion by threshold difference",1,3,"Difference between liberal and restrictive haemoglobin thresholds ≥ 2.0 g/dL","reported","reported",35,0.580511308958718,0.0379434266011643,0.0445211959046738,2011.51851851852,0.88155500610692,584.6
"CD002042","CD002042_pub6_data","1|30|Morbidity: acute kidney injury (AKI)|","Morbidity: acute kidney injury (AKI)",1,30,"","reported","reported",14,0.981034883184158,0.0323952812427647,0,2014.91666666667,0.171796682749293,999.928571428571
"CD002042","CD002042_pub6_data","1|31|Morbidity: renal failure requiring dialysis/replacement therapy|","Morbidity: renal failure requiring dialysis/replacement therapy",1,31,"","reported","reported",6,1.02127676982248,0.141005977170455,0.0270645376027686,2014.16666666667,0.0723367185165158,1129.66666666667
"CD002042","CD002042_pub6_data","1|32|Morbidity: delirium|","Morbidity: delirium",1,32,"","reported","reported",10,1.1326544316017,0.0797647420908549,0,2012.1,0.117301870024239,694.4
"CD002042","CD002042_pub6_data","1|33|Adverse events (composite of all)|","Adverse events (composite of all)",1,33,"","reported","reported",18,0.285168978688885,0.0515440475477779,0,2015.54545454545,0.0562180214858631,639.166666666667
"CD002042","CD002042_pub6_data","1|34|Adverse events (serious only)|","Adverse events (serious only)",1,34,"","reported","reported",10,0.306302935765276,0.0717118241975992,0,2017.57142857143,0.0267470154657351,841
"CD002042","CD002042_pub6_data","1|4|Participants exposed to blood transfusion by restrictive threshold|Restrictive &nbsp;8.0 g/dL to 9.0 g/dL","Participants exposed to blood transfusion by restrictive threshold",1,4,"Restrictive &nbsp;8.0 g/dL to 9.0 g/dL","reported","reported",21,0.614113346635579,0.0545212152413898,0.0558043052753371,2004.15789473684,0.86548377435811,323.52380952381
"CD002042","CD002042_pub6_data","1|4|Participants exposed to blood transfusion by restrictive threshold|Restrictive 7.0 g/dL to 7.5 g/dL","Participants exposed to blood transfusion by restrictive threshold",1,4,"Restrictive 7.0 g/dL to 7.5 g/dL","reported","reported",20,0.577546605421927,0.0503367629318319,0.0444156439988482,2013.0625,0.895239383645051,644.7
"CD002042","CD002042_pub6_data","1|5|Units of blood transfused|","Units of blood transfused",1,5,"","reported","reported",21,-1.37907012396675,0.233810914417493,0.809130933342657,2006.88235294118,NA,444.904761904762
"CD002042","CD002042_pub6_data","1|6|30-day mortality|","30-day mortality",1,6,"","reported","reported",37,0.932602007934196,0.0562862255198955,0.0161755015264054,2011.46666666667,0.0955035304368577,585.081081081081
"CD002042","CD002042_pub6_data","1|7|30-day mortality: subgroup by restrictive haemoglobin level|Restrictive 7.0 g/dL to 7.5 g/dL","30-day mortality: subgroup by restrictive haemoglobin level",1,7,"Restrictive 7.0 g/dL to 7.5 g/dL","reported","reported",17,0.925024046172285,0.0718258916781625,0.0201282996817611,2013.07142857143,0.140774717926312,699.058823529412
"CD002042","CD002042_pub6_data","1|7|30-day mortality: subgroup by restrictive haemoglobin level|Restrictive 8.0 g/dL to 9.0 g/dL","30-day mortality: subgroup by restrictive haemoglobin level",1,7,"Restrictive 8.0 g/dL to 9.0 g/dL","reported","reported",16,0.839795095213199,0.112186640760273,0,2009,0.0516687336034838,359.1875
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Acute myocardial infarction","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Acute myocardial infarction","reported","reported",4,0.997981079454262,0.225541958453795,0.0719569858342572,2017,0.0581989937062401,1077.75
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Cardiac surgery","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Cardiac surgery","reported","reported",4,0.903592005531498,0.123162174797236,0,2014.75,0.0276664463817795,2019.5
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Critical care","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Critical care","reported","reported",8,0.968069368918679,0.0889981962296942,0.0171281658996751,2010,0.238071368158698,366
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Gastrointestinal (GI) bleeding","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Gastrointestinal (GI) bleeding","reported","reported",4,0.609916163740533,0.139417198516681,0,2004.66666666667,0.076096801441918,393.5
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Haematological malignancies","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Haematological malignancies","reported","reported",4,0.399084153247746,0.574696627735725,0,2012,0.054797633160708,70.75
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Neurocritical care","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Neurocritical care","reported","reported",3,1.09485673074622,0.145639306364979,0,2009,0.128582371125126,308.666666666667
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Orthopaedic surgery","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Orthopaedic surgery","reported","reported",7,1.01205823448016,0.301103209634565,0.0923580150731508,2010.14285714286,0.0341140271714197,426.285714285714
"CD002042","CD002042_pub6_data","1|8|30-day mortality: subgroup by clinical specialties (random-effects model)|Vascular surgery","30-day mortality: subgroup by clinical specialties (random-effects model)",1,8,"Vascular surgery","reported","reported",3,0.836410853935073,0.715971629674489,0,2008,0.0653718038939714,69
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Acute myocardial infarction","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Acute myocardial infarction","reported","reported",4,0.997981079454262,0.225541958453795,0.0719569858342572,2017,0.0581989937062401,1077.75
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Cardiac surgery","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Cardiac surgery","reported","reported",4,0.903592005531498,0.123162174797236,0,2014.75,0.0276664463817795,2019.5
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Critical care","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Critical care","reported","reported",8,0.968069368918679,0.0889981962296942,0.0171281658996751,2010,0.238071368158698,366
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Gastrointestinal (GI) bleeding","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Gastrointestinal (GI) bleeding","reported","reported",4,0.609916163740533,0.139417198516681,0,2004.66666666667,0.076096801441918,393.5
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Haematological malignancies","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Haematological malignancies","reported","reported",4,0.399084153247746,0.574696627735725,0,2012,0.054797633160708,70.75
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Neurocritical care","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Neurocritical care","reported","reported",3,1.09485673074622,0.145639306364979,0,2009,0.128582371125126,308.666666666667
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Orthopaedic surgery","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Orthopaedic surgery","reported","reported",7,1.01205823448016,0.301103209634565,0.0923580150731508,2010.14285714286,0.0341140271714197,426.285714285714
"CD002042","CD002042_pub6_data","1|9|30-day mortality: subgroup by clinical specialties (fixed-effect model)|Vascular surgery","30-day mortality: subgroup by clinical specialties (fixed-effect model)",1,9,"Vascular surgery","reported","reported",3,0.836410853935073,0.715971629674489,0,2008,0.0653718038939714,69
"CD002042","CD002042_pub6_data","2|1|Participants exposed to blood transfusion (all trials)|","Participants exposed to blood transfusion (all trials)",2,1,"","reported","reported",5,0.617417011410732,0.0883873965139726,0.0322826524591835,2013,0.882250262881178,491.2
"CD002042","CD002042_pub6_data","2|11|6-month mortality|","6-month mortality",2,11,"","reported","reported",2,1.29071038265893,0.291946550987585,0,2016,0.189160239931448,785.5
"CD002042","CD002042_pub6_data","2|12|Morbidity: cardiac events (aggregate)|","Morbidity: cardiac events (aggregate)",2,12,"","reported","reported",2,0.97439433005476,0.659776088572166,0,2010,0.0433461853020213,372
"CD002042","CD002042_pub6_data","2|15|Morbidity: cerebrovascular accident (CVA)|","Morbidity: cerebrovascular accident (CVA)",2,15,"","reported","reported",2,0.136504900742964,1.72262544302903,0,2007,0.00157728706624606,399.5
"CD002042","CD002042_pub6_data","2|16|Morbidity: infection (composite)|","Morbidity: infection (composite)",2,16,"","reported","reported",3,0.866551221355721,0.090250141188774,0,2013,0.156560169379276,788
"CD002042","CD002042_pub6_data","2|17|Morbidity: pneumonia|","Morbidity: pneumonia",2,17,"","reported","reported",3,1.160748679991,0.372793346360896,0,2013,0.0448070367557094,769
"CD002042","CD002042_pub6_data","2|18|Morbidity: sepsis/bacteraemia|","Morbidity: sepsis/bacteraemia",2,18,"","reported","reported",2,1.17017782118893,0.320182481402483,0,2013,0.0236025398781961,1100
"CD002042","CD002042_pub6_data","2|19|Morbidity: thrombosis|","Morbidity: thrombosis",2,19,"","reported","reported",3,1.02823739626379,0.707564534729634,0,2007,0.0417060988433228,277.333333333333
"CD002042","CD002042_pub6_data","2|2|Participants exposed to blood transfusion by clinical specialties|Cardiac surgery","Participants exposed to blood transfusion by clinical specialties",2,2,"Cardiac surgery","reported","reported",3,0.443142218615877,0.181331981695226,0.0870039622648938,2007,0.811111111111111,115.666666666667
"CD002042","CD002042_pub6_data","2|3|Units of blood transfused|","Units of blood transfused",2,3,"","reported","reported",2,-0.489886495715141,0.278375963149992,0.137271771061537,2010,NA,372
"CD002042","CD002042_pub6_data","2|4|30-day mortality|","30-day mortality",2,4,"","reported","reported",3,1.09809958764037,0.351637644557582,0,2013,0.0302204890536007,788
"CD002042","CD002042_pub6_data","2|5|30-day mortality: subgroup by clinical specialties|Cardiac surgery","30-day mortality: subgroup by clinical specialties",2,5,"Cardiac surgery","reported","reported",2,0.978288884624403,0.947962263452539,0,2007,0.0348790322580645,143.5
"CD002042","CD002042_pub6_data","2|5|30-day mortality: subgroup by clinical specialties|Haematological malignancies/bone marrow disorders","30-day mortality: subgroup by clinical specialties",2,5,"Haematological malignancies/bone marrow disorders","or","binary",2,0,1.47153441476392,0,2013,0,20
"CD002042","CD002042_pub6_data","2|6|30-day mortality: subgroup by prospective trial registration vs no prospective registration|Prospectively registered trials","30-day mortality: subgroup by prospective trial registration vs no prospective registration",2,6,"Prospectively registered trials","reported","reported",2,1.47227112489755,0.744400238805907,0,2019,0.0232487146529563,863.5
"CD002042","CD002042_pub6_data","2|7|30-day mortality: sensitivity analysis by allocation concealment|Low risk of bias","30-day mortality: sensitivity analysis by allocation concealment",2,7,"Low risk of bias","reported","reported",3,1.09809958764037,0.351637644557582,0,2013,0.0302204890536007,788
"CD002042","CD002042_pub6_data","2|8|30-day mortality (sensitivity analysis excluding Maitland study)|","30-day mortality (sensitivity analysis excluding Maitland study)",2,8,"","reported","reported",2,0.988999402002754,0.376740184087172,0,2007,0.0408320189274448,399.5
"CD002042","CD002042_pub6_data","2|9|In-hospital mortality (as defined by triallists)|","In-hospital mortality (as defined by triallists)",2,9,"","reported","reported",3,0.642213207068435,0.287738652165094,0,2018,0.0806335830212235,127.333333333333
"CD002052","CD002052_pub4_data","1|3|All‐cause mortality until hospital discharge|NA","All‐cause mortality until hospital discharge",1,3,NA,"or","binary",3,-0.294876675490587,0.457775805385533,0,1998,0.238185425685426,40.6666666666667
"CD002052","CD002052_pub4_data","1|4|Days on mechanical ventilation|NA","Days on mechanical ventilation",1,4,NA,"or","binary",2,-0.0653239165183134,1.42970389208348,0,1996.5,0,44.5
"CD002052","CD002052_pub4_data","1|5|Days of supplemental oxygen use|NA","Days of supplemental oxygen use",1,5,NA,"or","binary",2,-0.0653239165183134,1.42970389208348,0,1996.5,0,44.5
"CD002052","CD002052_pub4_data","1|6|Intraventricular haemorrhage (any grade)|NA","Intraventricular haemorrhage (any grade)",1,6,NA,"or","binary",3,0.656000207206168,0.447705879094244,0,1998,0.154401154401154,40.6666666666667
"CD002052","CD002052_pub4_data","1|7|Pneumothorax|NA","Pneumothorax",1,7,NA,"or","binary",3,0.0634633372298491,0.560714342116415,0,1998,0.0916305916305916,40.6666666666667
"CD002052","CD002052_pub4_data","1|8|Length of NICU stay (days)|NA","Length of NICU stay (days)",1,8,NA,"or","binary",2,-0.0653239165183134,1.42970389208348,0,1996.5,0,44.5
"CD002052","CD002052_pub4_data","2|4|Days on mechanical ventilation|NA","Days on mechanical ventilation",2,4,NA,"or","binary",2,0.0424760618289537,1.4274791584078,0,2008,0,53
"CD002052","CD002052_pub4_data","2|7|Pneumothorax|NA","Pneumothorax",2,7,NA,"or","binary",2,1.46552081010281,1.14085406096816,0,2008,0,53
"CD002112","CD002112_pub2_data","1|1|Mean number of wet nights at the end of treatment|100 mcg vs placebo","Mean number of wet nights at the end of treatment",1,1,"100 mcg vs placebo","or","binary",2,-0.299340239930075,1.44466491584605,0,1983,0,25.5
"CD002112","CD002112_pub2_data","1|1|Mean number of wet nights at the end of treatment|200 mcg vs placebo","Mean number of wet nights at the end of treatment",1,1,"200 mcg vs placebo","reported","reported",5,0,0.170180251167653,0,1995.75,0,54.6
"CD002112","CD002112_pub2_data","1|1|Mean number of wet nights at the end of treatment|400 mcg vs placebo","Mean number of wet nights at the end of treatment",1,1,"400 mcg vs placebo","reported","reported",3,0,0.262169568264721,0,1990,0,60.6666666666667
"CD002112","CD002112_pub2_data","1|1|Mean number of wet nights at the end of treatment|600 mcg vs placebo","Mean number of wet nights at the end of treatment",1,1,"600 mcg vs placebo","reported","reported",2,0,0.241152591057399,0,1999,0,54.5
"CD002112","CD002112_pub2_data","1|2|Number of children achieving 14 consecutive dry nights by the end of treatment|200 mcg vs placebo","Number of children achieving 14 consecutive dry nights by the end of treatment",1,2,"200 mcg vs placebo","reported","reported",2,0,1.10814826139262,0,1999,0,53.5
"CD002112","CD002112_pub2_data","1|2|Number of children achieving 14 consecutive dry nights by the end of treatment|400 mcg vs placebo","Number of children achieving 14 consecutive dry nights by the end of treatment",1,2,"400 mcg vs placebo","reported","reported",3,0,0.759193508214931,0,1999,0.0196078431372549,53.3333333333333
"CD002112","CD002112_pub2_data","1|2|Number of children achieving 14 consecutive dry nights by the end of treatment|600 mcg vs placebo","Number of children achieving 14 consecutive dry nights by the end of treatment",1,2,"600 mcg vs placebo","reported","reported",2,0,1.0632639857679,0,1999,0,55.5
"CD002112","CD002112_pub2_data","1|3|Mean number of wet nights at follow-up|100 mcg vs placebo","Mean number of wet nights at follow-up",1,3,"100 mcg vs placebo","or","binary",2,-0.174532194905106,1.4464442159545,0,1983,0,24
"CD002112","CD002112_pub2_data","1|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|20 mcg vs placebo","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",1,4,"20 mcg vs placebo","or","binary",2,2.12500945110016,1.83614986789751,3.77282579035931,1997,0,67.5
"CD002112","CD002112_pub2_data","1|6|Adverse events|","Adverse events",1,6,"","reported","reported",3,0,0.352902386198191,0,1992,0.217185436710055,89.6666666666667
"CD002112","CD002112_pub2_data","2|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Oral vs nasal","Number of children achieving 14 consecutive dry nights by the end of treatment",2,2,"Oral vs nasal","or","binary",2,-0.471928331656102,0.729175756398493,0.431742885911566,1998.5,0.485,70
"CD002112","CD002112_pub2_data","3|1|Mean number of wet nights at the end of treatment|","Mean number of wet nights at the end of treatment",3,1,"","or","binary",4,-0.171770980537976,1.00745166205907,0,2002.75,0,71.25
"CD002112","CD002112_pub2_data","3|2|Number of children achieving 14 consecutive dry nights by the end of treatment|","Number of children achieving 14 consecutive dry nights by the end of treatment",3,2,"","or","binary",15,-0.0253827131993247,0.155116189163977,0.136947261657249,2010.46666666667,0.511499059821256,102
"CD002112","CD002112_pub2_data","3|3|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",3,3,"","or","binary",6,-0.57668464611607,0.274253874789033,0.218860062329134,2006.66666666667,0.461816958935603,114.166666666667
"CD002112","CD002112_pub2_data","3|4|Adverse events|","Adverse events",3,4,"","or","binary",4,0.348242178995824,0.976671357303124,2.72250196381409,2005.25,0.215716486902928,115.25
"CD002112","CD002112_pub2_data","4|1|Mean number of wet nights at the end of treatment|Desmopressin vs tricyclics","Mean number of wet nights at the end of treatment",4,1,"Desmopressin vs tricyclics","or","binary",4,-0.0196410169014002,1.01045329877792,0,1995.25,0,82.75
"CD002112","CD002112_pub2_data","4|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Desmopressin vs anticholinergics","Number of children achieving 14 consecutive dry nights by the end of treatment",4,2,"Desmopressin vs anticholinergics","or","binary",2,1.85647640435785,2.37939849864038,10.1724617232629,2015.5,0.59557945041816,63.5
"CD002112","CD002112_pub2_data","4|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Desmopressin vs tricyclics","Number of children achieving 14 consecutive dry nights by the end of treatment",4,2,"Desmopressin vs tricyclics","or","binary",7,-0.0709060267772018,0.524750695345738,1.34443770496966,2002.42857142857,0.450368561326425,53
"CD002112","CD002112_pub2_data","4|3|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin vs tricyclics","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",4,3,"Desmopressin vs tricyclics","or","binary",2,-0.241017275959835,0.56016878907166,0.149503084470418,2005,0.413594470046083,46
"CD002112","CD002112_pub2_data","5|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin vs laser acupuncture","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",5,4,"Desmopressin vs laser acupuncture","or","binary",2,-0.62270449494685,0.87933825701664,1.20879888819338,2015.5,0.566129032258065,77
"CD002112","CD002112_pub2_data","6|1|Mean number of wet nights at the end of treatment|Desmopressin + alarm vs alarm","Mean number of wet nights at the end of treatment",6,1,"Desmopressin + alarm vs alarm","or","binary",6,-0.041722943946862,0.822190928146762,0,2002.66666666667,0,88
"CD002112","CD002112_pub2_data","6|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Desmopressin + tricyclics vs tricyclics","Number of children achieving 14 consecutive dry nights by the end of treatment",6,2,"Desmopressin + tricyclics vs tricyclics","or","binary",2,-0.0443538534569333,0.456427800703732,0,1998,0.585548172757475,58.5
"CD002112","CD002112_pub2_data","6|3|Mean number of wet nights at follow-up|Desmopressin + alarm vs alarm","Mean number of wet nights at follow-up",6,3,"Desmopressin + alarm vs alarm","or","binary",3,-0.0225883777545888,1.16396278219122,0,2008.66666666667,0,65.3333333333333
"CD002112","CD002112_pub2_data","6|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin + alarm vs alarm","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",6,4,"Desmopressin + alarm vs alarm","or","binary",6,0.196937977890904,0.226809694007032,0.0993653100014564,2004.16666666667,0.365689141229201,98.1666666666667
"CD002112","CD002112_pub2_data","6|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin + laser acupuncture vs laser acupuncture","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",6,4,"Desmopressin + laser acupuncture vs laser acupuncture","or","binary",2,-0.767675833507056,1.764499203219,5.77862672582628,2015.5,0.632795698924731,77
"CD002112","CD002112_pub2_data","7|1|Mean number of wet nights at the end of treatment|Desmopressin + alarm vs desmopressin","Mean number of wet nights at the end of treatment",7,1,"Desmopressin + alarm vs desmopressin","or","binary",2,0.117120908115996,1.42344123668967,0,2009,0,78
"CD002112","CD002112_pub2_data","7|1|Mean number of wet nights at the end of treatment|Desmopressin + anticholinergics vs desmopressin","Mean number of wet nights at the end of treatment",7,1,"Desmopressin + anticholinergics vs desmopressin","or","binary",3,-0.0308720660832495,1.16511941526914,0,2010.33333333333,0,62.6666666666667
"CD002112","CD002112_pub2_data","7|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Desmopressin + alarm vs desmopressin","Number of children achieving 14 consecutive dry nights by the end of treatment",7,2,"Desmopressin + alarm vs desmopressin","or","binary",5,0.589811173253972,0.223526571969984,0,2009.8,0.40713542750156,74
"CD002112","CD002112_pub2_data","7|2|Number of children achieving 14 consecutive dry nights by the end of treatment|Desmopressin + tricyclics vs desmopressin","Number of children achieving 14 consecutive dry nights by the end of treatment",7,2,"Desmopressin + tricyclics vs desmopressin","or","binary",3,1.49952653802022,0.383934846176635,0,2005,0.302941176470588,52.3333333333333
"CD002112","CD002112_pub2_data","7|3|Mean number of wet nights at follow-up|Desmopressin + alarm vs desmopressin","Mean number of wet nights at follow-up",7,3,"Desmopressin + alarm vs desmopressin","or","binary",2,0.1814931915689,1.42418396446342,0,2009,0,74.5
"CD002112","CD002112_pub2_data","7|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin + alarm vs desmopressin","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",7,4,"Desmopressin + alarm vs desmopressin","or","binary",2,1.06267221423243,0.394114079102362,0,2009,0.148741418764302,80.5
"CD002112","CD002112_pub2_data","7|4|Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)|Desmopressin + laser acupuncture vs desmopressin","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)",7,4,"Desmopressin + laser acupuncture vs desmopressin","or","binary",2,0.473874010506446,0.521813260065119,0.219814942397464,2015.5,0.382258064516129,77
"CD002112","CD002112_pub2_data","7|5|Adverse effects |","Adverse effects ",7,5,"","or","binary",2,0.469707386317447,0.435069372996262,0,2021,0.110909090909091,93.5
"CD002115","CD002115_pub6_data","1|11|Condition-specific quality of life measures (continuous)|Probiotics","Condition-specific quality of life measures (continuous)",1,11,"Probiotics","or","binary",3,-0.0772746885113205,1.16378167652881,0,2020.33333333333,0,66.6666666666667
"CD002115","CD002115_pub6_data","1|13|Number of participants with adverse events (dichotomous)|Probiotics","Number of participants with adverse events (dichotomous)",1,13,"Probiotics","or","binary",3,0.733602421845782,0.980430707848404,0.868489266624099,2019,0.00833333333333333,81.6666666666667
"CD002115","CD002115_pub6_data","1|2|Number of participants with self-reported improvement in constipation (dichotomous)|Probiotics","Number of participants with self-reported improvement in constipation (dichotomous)",1,2,"Probiotics","or","binary",4,1.65309603332144,0.282156591227042,0.00160724934747975,2019.75,0.216324150677698,72.75
"CD002115","CD002115_pub6_data","1|6|Mean number of bowel movements per week (continuous)|Probiotics","Mean number of bowel movements per week (continuous)",1,6,"Probiotics","or","binary",6,-0.0904310334518906,0.82964248732479,0,2015.66666666667,0,62.5
"CD002115","CD002115_pub6_data","2|1|Self-reported improvement in faecal incontinence (continuous)|Transanal irrigation","Self-reported improvement in faecal incontinence (continuous)",2,1,"Transanal irrigation","reported","reported",2,-3.66006553624774,1.53831885494495,3.356874162368,2014.5,0,69
"CD002115","CD002115_pub6_data","2|11|Number of participants with adverse effects (dichotomous)|Abdominal massage","Number of participants with adverse effects (dichotomous)",2,11,"Abdominal massage","or","binary",2,0.0688798359558068,0.82775588214898,0,2014.5,0.01,110
"CD002115","CD002115_pub6_data","2|2|Number of participants with self-reported improvement in constipation (continuous)|Abdominal massage","Number of participants with self-reported improvement in constipation (continuous)",2,2,"Abdominal massage","reported","reported",5,-0.637378576269773,0.551786754616393,1.40536713926737,2014.2,0,58.2
"CD002115","CD002115_pub6_data","2|2|Number of participants with self-reported improvement in constipation (continuous)|Transanal irrigation","Number of participants with self-reported improvement in constipation (continuous)",2,2,"Transanal irrigation","reported","reported",2,-0.883224668530187,0.238470139624051,0.0286782435135,2014.5,0,55
"CD002115","CD002115_pub6_data","2|3|Neurogenic Bowel Dysfunction score (continuous; GIV)|Multiple sclerosis","Neurogenic Bowel Dysfunction score (continuous; GIV)",2,3,"Multiple sclerosis","reported","reported",2,-2.16408373204107,1.32960255876013,1.8824586602395,2014.5,0,91
"CD002115","CD002115_pub6_data","2|3|Neurogenic Bowel Dysfunction score (continuous; GIV)|Spinal cord injury","Neurogenic Bowel Dysfunction score (continuous; GIV)",2,3,"Spinal cord injury","reported","reported",3,-2.80933980410994,1.04677648256752,0,2013.66666666667,0,38.6666666666667
"CD002115","CD002115_pub6_data","2|5|Mean number of bowel movements per week (continuous)|Abdominal massage","Mean number of bowel movements per week (continuous)",2,5,"Abdominal massage","or","binary",2,0.0171482097870712,1.42696302206463,0,2011.5,0,110
"CD002115","CD002115_pub6_data","2|7|Mean time spent per week on bowel care (continuous)|Massage therapy","Mean time spent per week on bowel care (continuous)",2,7,"Massage therapy","or","binary",3,0.0101570969431281,1.16817131149582,0,2015,0,82.6666666666667
"CD002122","CD002122_pub3_data","1|6|Quality of life|SF-36 (6 months)","Quality of life",1,6,"SF-36 (6 months)","reported","reported",2,4.11158320719747,0.869471430635386,0,2014,NA,180.5
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Any side effects","Adverse effects",1,7,"Any side effects","reported","reported",3,1.05762831185519,0.113501931877219,0,2015,0.434750271997824,163.666666666667
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Breast Pain/tension","Adverse effects",1,7,"Breast Pain/tension","reported","reported",2,1.11540343462388,0.385408444251954,0,2013.5,0.242050438596491,118
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Headache/migraine","Adverse effects",1,7,"Headache/migraine","reported","reported",3,1.1039197246624,0.39602959376544,0,2014.33333333333,0.157711988304094,123
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Irregular bleeding including spotting/breakthrough bleeding/genital bleeding","Adverse effects",1,7,"Irregular bleeding including spotting/breakthrough bleeding/genital bleeding","reported","reported",4,2.68658350909506,1.24833989963215,0,2011,0.0934887693312247,96.25
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Mood changes/depression/irritability","Adverse effects",1,7,"Mood changes/depression/irritability","reported","reported",2,1.05942250062177,1.58866015123811,0,2013.5,0.0367324561403509,118
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Nausea/vomiting/bloating","Adverse effects",1,7,"Nausea/vomiting/bloating","reported","reported",2,0.87320618158855,0.635759629841597,0,2013.5,0.099780701754386,118
"CD002122","CD002122_pub3_data","1|7|Adverse effects|Study withdrawal due to side effects","Adverse effects",1,7,"Study withdrawal due to side effects","reported","reported",4,1.14445062094094,1.68431582991263,0,2007.75,0.00648013565891473,156.5
"CD002122","CD002122_pub3_data","10|1|Pain (dichotomous)|Dysmenorrhoea (6 months)","Pain (dichotomous)",10,1,"Dysmenorrhoea (6 months)","reported","reported",2,0.933364721669238,0.020045862856192,0,2006,0.974424552429668,274
"CD002122","CD002122_pub3_data","10|1|Pain (dichotomous)|Dyspareunia (6 months)","Pain (dichotomous)",10,1,"Dyspareunia (6 months)","reported","reported",2,0.93335404907935,0.0340377031257396,0,2006,0.872442455242967,274
"CD002122","CD002122_pub3_data","10|2|Adverse effects|Headache/migraine","Adverse effects",10,2,"Headache/migraine","reported","reported",2,0.631643196650966,0.232565029274184,0,2006,0.0821931691496909,284.5
"CD002122","CD002122_pub3_data","10|2|Adverse effects|Hot flushes","Adverse effects",10,2,"Hot flushes","reported","reported",2,0.285648289637227,0.106738180313868,0,2006,0.13826391000304,284.5
"CD002122","CD002122_pub3_data","10|2|Adverse effects|Irregular bleeding","Adverse effects",10,2,"Irregular bleeding","reported","reported",2,8.80658969088207,13.1251453072311,0,2006,0.0071196919023006,284.5
"CD002122","CD002122_pub3_data","4|1|Pain (visual analogue scale)|Pelvic pain (6 months)","Pain (visual analogue scale)",4,1,"Pelvic pain (6 months)","reported","reported",2,0.126310539602314,0.997799034043254,1.58662600357755,2021.5,NA,55.5
"CD002122","CD002122_pub3_data","4|4|Quality of life|WHOQOL-BREF (6 months)","Quality of life",4,4,"WHOQOL-BREF (6 months)","reported","reported",2,-5.56246403540669,4.93121470312276,0,2021.5,NA,55.5
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Any side effects","Adverse effects",4,6,"Any side effects","reported","reported",3,1.07351145876899,0.202352802564862,0,2011.33333333333,0.346747967479675,61
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Bloating (listed separate from nausea)","Adverse effects",4,6,"Bloating (listed separate from nausea)","reported","reported",3,0.633250981430007,0.228055469583556,0.0388968830404697,2009.33333333333,0.255081300813008,76.6666666666667
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Breast pain","Adverse effects",4,6,"Breast pain","reported","reported",2,0.412110995777213,0.188407071263784,0,2013,0.24657012195122,73
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Decreased libido","Adverse effects",4,6,"Decreased libido","reported","reported",3,0.606874075698417,0.736825549414113,0,2009.33333333333,0.063770325203252,76.6666666666667
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Headache","Adverse effects",4,6,"Headache","reported","reported",3,0.481008043220233,0.147007036945883,0,2009.33333333333,0.279217479674797,76.6666666666667
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Irregular bleeding","Adverse effects",4,6,"Irregular bleeding","reported","reported",3,0.660632743830596,0.117812247685243,0.0122341646976016,2016,0.530738304093567,67
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Mood changes","Adverse effects",4,6,"Mood changes","reported","reported",2,0.606041456766466,0.13807057738703,0,2013,0.399390243902439,73
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Nausea (listed separate from bloating)","Adverse effects",4,6,"Nausea (listed separate from bloating)","reported","reported",3,0.279477749286571,0.141416074021983,0,2009.33333333333,0.233993902439024,76.6666666666667
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Study withdrawal due to side effects","Adverse effects",4,6,"Study withdrawal due to side effects","reported","reported",2,0.756645359591583,0.53596539218903,0,2003.5,0.0888888888888889,90
"CD002122","CD002122_pub3_data","4|6|Adverse effects|Weight gain","Adverse effects",4,6,"Weight gain","reported","reported",3,0.41154187272229,0.141836113563687,3.07256196530156e-06,2009.33333333333,0.310382791327913,71
"CD002122","CD002122_pub3_data","5|1|Pain (visual analogue scale)|Overall pain (6 months)","Pain (visual analogue scale)",5,1,"Overall pain (6 months)","reported","reported",2,-0.0123129227461366,0.147979566775532,0,2017.5,NA,133.5
"CD002122","CD002122_pub3_data","5|1|Pain (visual analogue scale)|Pelvic pain (6 months)","Pain (visual analogue scale)",5,1,"Pelvic pain (6 months)","reported","reported",2,0.2,0.110634053728141,0,2012.5,NA,161
"CD002122","CD002122_pub3_data","5|2|Pain (dichotomous)|Dysmenorrhoea (6 months – change from baseline)","Pain (dichotomous)",5,2,"Dysmenorrhoea (6 months – change from baseline)","reported","reported",2,0.794836415093519,0.182773304744378,0.0554164642069671,2006.5,0.834535256410256,117
"CD002122","CD002122_pub3_data","5|2|Pain (dichotomous)|Dyspareunia (6 months – change from baseline)","Pain (dichotomous)",5,2,"Dyspareunia (6 months – change from baseline)","reported","reported",2,0.852698278003514,0.400173375348879,0.267906052501442,2006.5,0.427083333333333,117
"CD002122","CD002122_pub3_data","5|2|Pain (dichotomous)|Pelvic pain (6 months – change from baseline)","Pain (dichotomous)",5,2,"Pelvic pain (6 months – change from baseline)","reported","reported",2,0.887256968999104,0.108393437478472,0,2006.5,0.61698717948718,117
"CD002122","CD002122_pub3_data","5|3|Assessment of implant (continuous)|American Fertility Society score","Assessment of implant (continuous)",5,3,"American Fertility Society score","reported","reported",3,0.213328843879234,2.94643294437673,0,2006.33333333333,NA,91
"CD002122","CD002122_pub3_data","5|3|Assessment of implant (continuous)|Change in American Fertility Society score","Assessment of implant (continuous)",5,3,"Change in American Fertility Society score","reported","reported",2,5.20574132736915,7.38748228345218,87.6622781603332,2001.5,NA,84
"CD002122","CD002122_pub3_data","5|3|Assessment of implant (continuous)|Change in endometrioma size","Assessment of implant (continuous)",5,3,"Change in endometrioma size","reported","reported",2,-3.12331247211065,1.23980126503898,1.25547943262534,2010,NA,81
"CD002122","CD002122_pub3_data","5|5|Quality of life|SF-36 improvement in mental health (6 months)","Quality of life",5,5,"SF-36 improvement in mental health (6 months)","reported","reported",2,0.837181812146205,0.812565477334164,0,2010.5,NA,217.5
"CD002122","CD002122_pub3_data","5|5|Quality of life|SF-36 improvement in physical health (6 months)","Quality of life",5,5,"SF-36 improvement in physical health (6 months)","reported","reported",2,3.53785231411359,4.09768187387619,31.9514360756804,2010.5,NA,217.5
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Acne/greasy skin/seborrhoea","Adverse effects",5,7,"Acne/greasy skin/seborrhoea","reported","reported",2,0.890506870193423,0.652523698528402,0,2006.5,0.0234375,148
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Any side effects (cumulative)","Adverse effects",5,7,"Any side effects (cumulative)","reported","reported",3,1.37022989453025,0.513589578658823,0.447907865781233,2001.5,0.399838763308301,100.666666666667
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Breast pain/tension","Adverse effects",5,7,"Breast pain/tension","reported","reported",2,3.15539763185476,3.79834332770433,0,2021,0.0123456790123457,140
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Decreased libido","Adverse effects",5,7,"Decreased libido","reported","reported",2,0.766229647372003,0.321923644286512,0,2016.5,0.0929783950617284,197
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Hair loss","Adverse effects",5,7,"Hair loss","reported","reported",3,0.693227496511875,0.243892338232042,0,2016.33333333333,0.0947239621157105,166.333333333333
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Headache/migraine","Adverse effects",5,7,"Headache/migraine","reported","reported",7,0.709705860466196,0.100466241620259,0,2012.83333333333,0.142195852398807,170.571428571429
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Hot flushes","Adverse effects",5,7,"Hot flushes","reported","reported",8,0.304652979705514,0.098630712822514,0.0637224422375107,2011.28571428571,0.568906695779482,164.25
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Irregular bleeding","Adverse effects",5,7,"Irregular bleeding","reported","reported",6,2.1603414072354,0.753439625573504,1.03419362346162,2011.16666666667,0.156127840385645,155.333333333333
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Joint pain/muscle cramps","Adverse effects",5,7,"Joint pain/muscle cramps","reported","reported",2,0.0841379714112333,0.335212246440522,0,2016,0.0545800409716125,119.5
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Mood changes/depression/irritability","Adverse effects",5,7,"Mood changes/depression/irritability","reported","reported",4,0.501204899105027,0.224318930688552,0.0974687979219314,2011.33333333333,0.188205966472835,144
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Sleep disorder/insomnia","Adverse effects",5,7,"Sleep disorder/insomnia","reported","reported",2,0.143335179273717,0.170950640686121,0,2012,0.0987639925373134,191
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Study withdrawal due to side effects","Adverse effects",5,7,"Study withdrawal due to side effects","reported","reported",2,0.683439082263988,0.580730476307953,0,2014,0.0489430147058824,176.5
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Vaginal dryness","Adverse effects",5,7,"Vaginal dryness","reported","reported",4,0.24766022170954,0.10770800686492,7.95266052920455e-06,2017,0.123077183122306,192.5
"CD002122","CD002122_pub3_data","5|7|Adverse effects|Weight gain","Adverse effects",5,7,"Weight gain","reported","reported",3,1.99760789810866,0.935189423259647,0,2010.33333333333,0.0496811427209154,179.333333333333
"CD002122","CD002122_pub3_data","6|2|Adverse effects|Irregular bleeding","Adverse effects",6,2,"Irregular bleeding","reported","reported",2,0.433329144095083,0.652851734244046,0,2019.5,0.3125,44.5
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 1 month","FEV1 % predicted (mean change from baseline)",1,1,"at 1 month","or","binary",2,0.0761100311010479,1.42374124638353,0,2002.5,0,114.5
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 12 months","FEV1 % predicted (mean change from baseline)",1,1,"at 12 months","or","binary",2,-0.060493609647164,1.42346013862474,0,2012,0,76
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 2 months","FEV1 % predicted (mean change from baseline)",1,1,"at 2 months","or","binary",5,-0.103472394616776,0.902904338069821,0,2007.4,0,62
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 3 months","FEV1 % predicted (mean change from baseline)",1,1,"at 3 months","or","binary",2,0.0215783717696692,1.42410217712764,0,2002.5,0,112.5
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 4 months","FEV1 % predicted (mean change from baseline)",1,1,"at 4 months","or","binary",2,0.0479167344811447,1.42681820867953,0,2004,0,61.5
"CD002203","CD002203_pub5_data","1|1|FEV1 % predicted (mean change from baseline)|at 6 months","FEV1 % predicted (mean change from baseline)",1,1,"at 6 months","or","binary",4,0.0472342677446697,1.00564306589052,0,2005.25,0,137.25
"CD002203","CD002203_pub5_data","1|10|Acquisition of Staphylococcal aureus|after 6 months","Acquisition of Staphylococcal aureus",1,10,"after 6 months","or","binary",2,-1.05292787792374,0.424291232076579,0.0130999085246186,2006.5,0.307152875175316,120
"CD002203","CD002203_pub5_data","1|13|Acquisition of meticillin-resistant Staphylococcus aureus (MRSA)|after 6 months","Acquisition of meticillin-resistant Staphylococcus aureus (MRSA)",1,13,"after 6 months","or","binary",2,0.315197929484121,0.458140622144323,0,2006.5,0.0415411106328024,197.5
"CD002203","CD002203_pub5_data","1|17|Need for additional oral antibiotics|After 6 months","Need for additional oral antibiotics",1,17,"After 6 months","or","binary",3,-1.24138128954194,0.205430392780613,2.12498438469821e-06,2005,0.784849958134133,175.666666666667
"CD002203","CD002203_pub5_data","1|2|FVC % predicted (percentage change from baseline)|at 1 month","FVC % predicted (percentage change from baseline)",1,2,"at 1 month","or","binary",2,0.125498105200101,1.42449430685159,0,2002.5,0,112.5
"CD002203","CD002203_pub5_data","1|2|FVC % predicted (percentage change from baseline)|at 2 months","FVC % predicted (percentage change from baseline)",1,2,"at 2 months","or","binary",2,-0.115619556548273,1.43252829308474,0,2002,0,38
"CD002203","CD002203_pub5_data","1|2|FVC % predicted (percentage change from baseline)|at 3 months","FVC % predicted (percentage change from baseline)",1,2,"at 3 months","or","binary",2,0.0441780398180038,1.42510201359233,0,2002.5,0,110
"CD002203","CD002203_pub5_data","1|2|FVC % predicted (percentage change from baseline)|at 6 months","FVC % predicted (percentage change from baseline)",1,2,"at 6 months","or","binary",2,0.0746591110286141,1.42453232922858,0,2002.5,0,109
"CD002203","CD002203_pub5_data","1|20|Need for intravenous antibiotics|After 6 months","Need for intravenous antibiotics",1,20,"After 6 months","or","binary",3,-0.243366449808791,0.231542604202122,1.11590462817941e-07,2005,0.219517339928976,175.666666666667
"CD002203","CD002203_pub5_data","1|26|Change in weight (kg) from baseline|After 6 months","Change in weight (kg) from baseline",1,26,"After 6 months","reported","reported",2,0.616923076923077,0.183051064754326,0,2006.5,NA,0
"CD002203","CD002203_pub5_data","1|3|Number free of pulmonary exacerbation|at 3 months","Number free of pulmonary exacerbation",1,3,"at 3 months","or","binary",2,0.763799649730922,0.611151391163705,0.377122153650043,2004,0.692602040816326,101.5
"CD002203","CD002203_pub5_data","1|3|Number free of pulmonary exacerbation|at 6 months","Number free of pulmonary exacerbation",1,3,"at 6 months","or","binary",4,0.66198305200674,0.264589170069652,0.146592152343206,2005.25,0.440453521170238,152.25
"CD002203","CD002203_pub5_data","1|4|Time to first pulmonary exacerbation|","Time to first pulmonary exacerbation",1,4,"","reported","reported",4,-0.486182415974393,0.102624137647793,0,2013,NA,0
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Abdominal pain","Adverse effects of antibiotic treatment",1,5,"Abdominal pain","or","binary",4,-0.0771921383111666,0.210492750283361,0,2009.25,0.183317513051732,187
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Any adverse events occuring during the study","Adverse effects of antibiotic treatment",1,5,"Any adverse events occuring during the study","or","binary",2,-0.121192774631419,0.338698851667045,0,2013.5,0.645969498910675,76.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Cough","Adverse effects of antibiotic treatment",1,5,"Cough","or","binary",2,-0.760737805552581,0.232821553391241,0.0196220945108679,2006.5,0.760876443600696,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Decreased lung function","Adverse effects of antibiotic treatment",1,5,"Decreased lung function","or","binary",2,0.0109225789539515,0.770438022197736,0.973971472229933,2006.5,0.0977297895902547,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Diarrhoea","Adverse effects of antibiotic treatment",1,5,"Diarrhoea","or","binary",4,0.248891262527375,0.535761405672289,0.630287657172468,2009.25,0.0655355165321943,187
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Fatigue","Adverse effects of antibiotic treatment",1,5,"Fatigue","or","binary",2,-0.410158470340186,0.257311069339397,0,2006.5,0.23406106628698,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Fever","Adverse effects of antibiotic treatment",1,5,"Fever","or","binary",3,-0.424866133134985,0.203382060126151,0,2006.33333333333,0.252201655856141,175.666666666667
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Headache","Adverse effects of antibiotic treatment",1,5,"Headache","or","binary",3,-0.174914079086779,0.221394963519312,0.012528550516624,2006.33333333333,0.208801349997363,175.666666666667
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Hemoptysis","Adverse effects of antibiotic treatment",1,5,"Hemoptysis","or","binary",2,-0.396293787985804,0.343743225143256,0,2004.5,0.151360544217687,133.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Nasal congestion","Adverse effects of antibiotic treatment",1,5,"Nasal congestion","or","binary",2,0.0675072291236048,0.197964788968714,0,2006.5,0.346464167062174,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Nausea","Adverse effects of antibiotic treatment",1,5,"Nausea","or","binary",2,0.437157149412989,0.515879780732019,0.380209289402375,2006.5,0.128144280968201,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Respiratory, thoracic and mediastinal disorders","Adverse effects of antibiotic treatment",1,5,"Respiratory, thoracic and mediastinal disorders","or","binary",2,-0.594304983014504,0.284004534024543,0,2019,0.340840840840841,168
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Rhinorrhoea","Adverse effects of antibiotic treatment",1,5,"Rhinorrhoea","or","binary",2,-0.0673422504702264,0.431279866344729,0.276945783697953,2006.5,0.267085904129093,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Sore throat","Adverse effects of antibiotic treatment",1,5,"Sore throat","or","binary",2,-0.142505187174526,0.422260826186063,0.272810558142056,2006.5,0.350340136054422,222.5
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Vomiting","Adverse effects of antibiotic treatment",1,5,"Vomiting","or","binary",4,-0.110801540102923,0.284870097271129,0.052008685181287,2009.25,0.098342825502294,187
"CD002203","CD002203_pub5_data","1|5|Adverse effects of antibiotic treatment|Wheezing","Adverse effects of antibiotic treatment",1,5,"Wheezing","or","binary",2,0.763433638134006,0.704188546308097,0.729917338811072,2006.5,0.0552918841955387,222.5
"CD002203","CD002203_pub5_data","1|7|Admission to hospital|After 6 months","Admission to hospital",1,7,"After 6 months","or","binary",2,-0.46454882064799,0.330525183288474,0.0693827385047576,2006.5,0.198346780572694,222.5
"CD002203","CD002203_pub5_data","1|9|Acquisition of Pseudomonas aeruginosa|after 6 months","Acquisition of Pseudomonas aeruginosa",1,9,"after 6 months","or","binary",2,-0.383141253989015,0.537638264611625,0,2006.5,0.0396739130434783,210.5
"CD002243","CD002243_pub5_data","1|1|28-day all-cause mortality|","28-day all-cause mortality",1,1,"","reported","reported",68,0,0.0221394737402706,0,2010.66176470588,0.337114028747898,327.073529411765
"CD002243","CD002243_pub5_data","1|10|Long-term mortality|","Long-term mortality",1,10,"","or","binary",12,-0.0382453115975292,0.0579509172727971,0.00523048472070601,2014,0.389764080342279,705.666666666667
"CD002243","CD002243_pub5_data","1|13|Intensive care unit mortality|","Intensive care unit mortality",1,13,"","or","binary",24,-0.154788955742177,0.05593654289519,0.00346543030230894,2012.20833333333,0.319557431070855,369.416666666667
"CD002243","CD002243_pub5_data","1|14|Length of intensive care unit stay for all participants|","Length of intensive care unit stay for all participants",1,14,"","or","binary",25,-0.0864029744364771,0.40234734184152,0,2011.76,0,322.76
"CD002243","CD002243_pub5_data","1|15|Length of intensive care unit stay for survivors|","Length of intensive care unit stay for survivors",1,15,"","or","binary",10,-0.254332380628714,0.639675069563638,0,2005,0,77.8
"CD002243","CD002243_pub5_data","1|16|Length of hospital stay for all participants|","Length of hospital stay for all participants",1,16,"","or","binary",31,-0.0194331501739498,0.36092832762941,0,2013.67741935484,0,546.903225806452
"CD002243","CD002243_pub5_data","1|17|Length of hospital stay for survivors|","Length of hospital stay for survivors",1,17,"","or","binary",9,-0.359372376141365,0.675143489167388,0,2005.22222222222,0,78.8888888888889
"CD002243","CD002243_pub5_data","1|18|Number of participants with shock reversal at day 7|","Number of participants with shock reversal at day 7",1,18,"","or","binary",18,0.710829204053764,0.135634863104962,0.129342321512683,2007.44444444444,0.497681373542365,385.444444444444
"CD002243","CD002243_pub5_data","1|19|Number of participants with shock reversal at 28 days|","Number of participants with shock reversal at 28 days",1,19,"","or","binary",16,0.282982669235109,0.0606419498722564,6.85452437216842e-06,2011.75,0.585222310862834,463.4375
"CD002243","CD002243_pub5_data","1|2|28-day all-cause mortality - sensitivity analysis based on methodological quality|Blinded trials","28-day all-cause mortality - sensitivity analysis based on methodological quality",1,2,"Blinded trials","or","binary",46,-0.156226023144118,0.0645925119832969,0.043031078514686,2011.19565217391,0.337075999364926,295.152173913043
"CD002243","CD002243_pub5_data","1|2|28-day all-cause mortality - sensitivity analysis based on methodological quality|Studies judged at low risk of bias","28-day all-cause mortality - sensitivity analysis based on methodological quality",1,2,"Studies judged at low risk of bias","or","binary",25,-0.161423340162643,0.0636194568535641,0.0144066562701335,2014.56,0.255503438068215,445
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Cardiac event","Number of participants with adverse events",1,21,"Cardiac event","or","binary",14,-0.0220384217225902,0.125238980627536,0,2017,0.0286560123940054,892
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Gastroduodenal bleeding","Number of participants with adverse events",1,21,"Gastroduodenal bleeding","or","binary",32,-0.0171058818387415,0.114257060902171,0,2008.5,0.0586088388112906,218.0625
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Hyperglycaemia","Number of participants with adverse events",1,21,"Hyperglycaemia","or","binary",29,0.580182187354634,0.0705801889628591,2.30109993288601e-06,2010.20689655172,0.2507243654369,377
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Hypernatraemia","Number of participants with adverse events",1,21,"Hypernatraemia","or","binary",12,0.474555789355162,0.176418061475308,0.146283415419856,2015.5,0.126928203572925,548.916666666667
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Muscle weakness","Number of participants with adverse events",1,21,"Muscle weakness","or","binary",7,0.186800075543623,0.113189442310439,6.71028020478657e-07,2012.71428571429,0.0842546480718501,961.285714285714
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Neuropsychiatric event","Number of participants with adverse events",1,21,"Neuropsychiatric event","or","binary",10,0.0615550239101369,0.274441185051467,0.186515050706056,2011.2,0.0266530479950062,792.6
"CD002243","CD002243_pub5_data","1|21|Number of participants with adverse events|Superinfection","Number of participants with adverse events",1,21,"Superinfection","or","binary",36,-0.0439896819814023,0.0710137672508041,0.0157049945449901,2009.47222222222,0.179396235899461,221.138888888889
"CD002243","CD002243_pub5_data","1|3|28-day all-cause mortality by subgroups based on study drug|Hydrocortisone","28-day all-cause mortality by subgroups based on study drug",1,3,"Hydrocortisone","or","binary",29,-0.206012223772803,0.0906637535774931,0.0553410195273161,2011.58620689655,0.348428547947619,274.51724137931
"CD002243","CD002243_pub5_data","1|3|28-day all-cause mortality by subgroups based on study drug|Hydrocortisone plus fludrocortisone","28-day all-cause mortality by subgroups based on study drug",1,3,"Hydrocortisone plus fludrocortisone","or","binary",4,-0.242789983367453,0.0996994378021545,0,2012.25,0.534588624609818,428.5
"CD002243","CD002243_pub5_data","1|3|28-day all-cause mortality by subgroups based on study drug|Methylprednisolone","28-day all-cause mortality by subgroups based on study drug",1,3,"Methylprednisolone","or","binary",14,-0.306793742692301,0.195904824912465,0.242274706414727,2004.92857142857,0.309478586842642,145.5
"CD002243","CD002243_pub5_data","1|3|28-day all-cause mortality by subgroups based on study drug|Prednisone/prednisolone","28-day all-cause mortality by subgroups based on study drug",1,3,"Prednisone/prednisolone","or","binary",6,-0.0682407592430505,0.214587828056906,0,2005,0.230409462435012,262
"CD002243","CD002243_pub5_data","1|4|28-day all-cause mortality by subgroups based on treatment dose/duration|Long course of low-dose corticosteroids","28-day all-cause mortality by subgroups based on treatment dose/duration",1,4,"Long course of low-dose corticosteroids","reported","reported",2,0,0.0917150660528263,0,2020,0.482432432432432,189.5
"CD002243","CD002243_pub5_data","1|4|28-day all-cause mortality by subgroups based on treatment dose/duration|Short course of high-dose corticosteroids","28-day all-cause mortality by subgroups based on treatment dose/duration",1,4,"Short course of high-dose corticosteroids","or","binary",5,-0.147810850141458,0.385023056134172,0.572125436466999,1984.4,0.416121853187337,182
"CD002243","CD002243_pub5_data","1|5|28-day all-cause mortality based on mode of drug administration|Continuous infusion","28-day all-cause mortality based on mode of drug administration",1,5,"Continuous infusion","or","binary",23,-0.243624904784834,0.10747588442272,0.0618972937312477,2011.95652173913,0.235531757919739,317.173913043478
"CD002243","CD002243_pub5_data","1|6|28-day all-cause mortality based on mode of drug termination|With taper off","28-day all-cause mortality based on mode of drug termination",1,6,"With taper off","or","binary",25,-0.252449165551739,0.107060008051216,0.0692424043855791,2013.28,0.296030322514424,150.72
"CD002243","CD002243_pub5_data","1|6|28-day all-cause mortality based on mode of drug termination|Without taper off","28-day all-cause mortality based on mode of drug termination",1,6,"Without taper off","reported","reported",2,0,0.179906004195533,0,2020,0.308663366336634,229.5
"CD002243","CD002243_pub5_data","1|7|28-day all-cause mortality by subgroups based on age|Adults","28-day all-cause mortality by subgroups based on age",1,7,"Adults","reported","reported",2,0,0.186886974495604,0,2021.5,0.234493670886076,437.5
"CD002243","CD002243_pub5_data","1|7|28-day all-cause mortality by subgroups based on age|Children","28-day all-cause mortality by subgroups based on age",1,7,"Children","or","binary",5,0.0491197140191801,0.404397741346893,0,2010.4,0.115123706702654,55.6
"CD002243","CD002243_pub5_data","1|8|28-day all-cause mortality by subgroups based on targeted population|COVID-19","28-day all-cause mortality by subgroups based on targeted population",1,8,"COVID-19","or","binary",7,-0.180088738375054,0.0572042063701909,0,2020.85714285714,0.276614960650241,1109.14285714286
"CD002243","CD002243_pub5_data","1|8|28-day all-cause mortality by subgroups based on targeted population|Sepsis and ARDS","28-day all-cause mortality by subgroups based on targeted population",1,8,"Sepsis and ARDS","or","binary",5,-0.767053673782196,0.262741862544915,0.0766138580652579,2013.6,0.413448329710896,99.2
"CD002243","CD002243_pub5_data","1|8|28-day all-cause mortality by subgroups based on targeted population|Sepsis and community-acquired pneumonia","28-day all-cause mortality by subgroups based on targeted population",1,8,"Sepsis and community-acquired pneumonia","or","binary",16,-0.399668178032335,0.137544152593982,0.0200860860274885,2011.25,0.120046740966972,238.625
"CD002243","CD002243_pub5_data","1|8|28-day all-cause mortality by subgroups based on targeted population|Septic shock only","28-day all-cause mortality by subgroups based on targeted population",1,8,"Septic shock only","reported","reported",2,0,0.125486325366638,0,2015,0.449981942939689,224.5
"CD002243","CD002243_pub5_data","1|9|28-day mortality in participants with versus without critical illness-related corticosteroid insufficiency|Patients with critical illness associated with corticosteroid insufficiency","28-day mortality in participants with versus without critical illness-related corticosteroid insufficiency",1,9,"Patients with critical illness associated with corticosteroid insufficiency","reported","reported",12,0,0.0574021421730362,0,2008.16666666667,0.59425777629439,91.75
"CD002243","CD002243_pub5_data","1|9|28-day mortality in participants with versus without critical illness-related corticosteroid insufficiency|Patients without critical illness associated with corticosteroid insufficiency","28-day mortality in participants with versus without critical illness-related corticosteroid insufficiency",1,9,"Patients without critical illness associated with corticosteroid insufficiency","reported","reported",3,0,0.408309133961777,0,2003.66666666667,0.585185185185185,20
"CD002243","CD002243_pub5_data","2|1|28-day all-cause mortality|","28-day all-cause mortality",2,1,"","or","binary",3,0.0510449877040738,0.229567307108669,2.44499691524144e-06,2016.33333333333,0.448780912574016,103.333333333333
"CD002243","CD002243_pub5_data","2|10|SOFA score at day 7|","SOFA score at day 7",2,10,"","or","binary",3,-0.106347001097259,1.16165029169624,0,2016.33333333333,0,86.6666666666667
"CD002243","CD002243_pub5_data","2|11|Number of participants with adverse events|Gastrointestinal bleeding","Number of participants with adverse events",2,11,"Gastrointestinal bleeding","or","binary",2,-0.182664116906641,0.971757043024483,1.26847515488752,2017.5,0.0939393939393939,96.5
"CD002243","CD002243_pub5_data","2|11|Number of participants with adverse events|Hyperglycaemia","Number of participants with adverse events",2,11,"Hyperglycaemia","or","binary",3,-0.210300929324147,0.539989455370387,0.692024577892683,2016.33333333333,0.427830024381748,103.333333333333
"CD002243","CD002243_pub5_data","2|11|Number of participants with adverse events|Hypernatraemia","Number of participants with adverse events",2,11,"Hypernatraemia","or","binary",2,-0.375917445978154,0.482380775250665,0.212381977416281,2016.5,0.252612330198537,93.5
"CD002243","CD002243_pub5_data","2|11|Number of participants with adverse events|Superinfection","Number of participants with adverse events",2,11,"Superinfection","or","binary",2,0.133762455855836,0.692776082032074,0.710331112176256,2017.5,0.226515151515152,96.5
"CD002243","CD002243_pub5_data","2|3|Hospital mortality|","Hospital mortality",2,3,"","or","binary",3,-0.146559427058275,0.227078220687614,0,2017.33333333333,0.378288633461047,117.333333333333
"CD002243","CD002243_pub5_data","2|5|Intensive care unit mortality|","Intensive care unit mortality",2,5,"","or","binary",4,0.024532652529175,0.214673124560263,0,2014,0.393123040752351,89.5
"CD002243","CD002243_pub5_data","2|8|Number of participants with shock reversal at day 7|","Number of participants with shock reversal at day 7",2,8,"","or","binary",4,-0.534979725878094,0.378844524170979,0.34871425460459,2014,0.696695402298851,89.5
"CD002290","CD002290_pub6_data","1|1|Relapse|12 months","Relapse",1,1,"12 months","or","binary",3,-3.10016614648026,0.789671553276579,0.550292465068299,2015.33333333333,0.963888888888889,36
"CD002290","CD002290_pub6_data","1|1|Relapse|3 months","Relapse",1,1,"3 months","or","binary",3,-1.58013034939722,0.428600859725779,2.5729272962475e-06,2012.33333333333,0.557716049382716,44
"CD002290","CD002290_pub6_data","1|1|Relapse|6 months","Relapse",1,1,"6 months","or","binary",5,-3.38217938435022,0.666564737578694,1.0488786970691,2016.4,0.8675,36.4
"CD002290","CD002290_pub6_data","1|2|Adverse events|Arthropathy","Adverse events",1,2,"Arthropathy","or","binary",3,1.3530235047907,0.945674052274031,0,2015.33333333333,0,38
"CD002290","CD002290_pub6_data","1|2|Adverse events|Moderate to severe infusion reactions","Adverse events",1,2,"Moderate to severe infusion reactions","or","binary",4,1.43961758381298,0.690873801618563,0,2014.25,0.0104166666666667,40.5
"CD002290","CD002290_pub6_data","1|2|Adverse events|Severe infection","Adverse events",1,2,"Severe infection","or","binary",3,0.775422288875819,0.69866595264208,0,2014,0.0277777777777778,44
"CD002290","CD002290_pub6_data","13|1|Relapse|Relapse at 6 to 9 months after therapy","Relapse",13,1,"Relapse at 6 to 9 months after therapy","or","binary",2,0.488905261782228,0.42425163081339,0,2003,0.560185185185185,48.5
"CD002290","CD002290_pub6_data","13|1|Relapse|Relapse at end of therapy","Relapse",13,1,"Relapse at end of therapy","or","binary",2,0.737806867716461,1.0382068762159,1.55796245684938,2003,0.293518518518519,48.5
"CD002290","CD002290_pub6_data","13|2|Adverse events|Leucopenia","Adverse events",13,2,"Leucopenia","or","binary",2,-1.280121014487,0.845957798493319,0,2003,0.0990740740740741,48.5
"CD002290","CD002290_pub6_data","17|1|Relapse|Relapse after completing CSA (12 to 24 months)","Relapse",17,1,"Relapse after completing CSA (12 to 24 months)","reported","reported",2,0,0.205149533110002,0,1990,0.875,47.5
"CD002290","CD002290_pub6_data","17|1|Relapse|Relapse at end of CSA therapy (6 to 9 months) ","Relapse",17,1,"Relapse at end of CSA therapy (6 to 9 months) ","reported","reported",2,0,0.261823958640634,0,1990,0.425,47.5
"CD002290","CD002290_pub6_data","17|3|Adverse events|Gum hypertrophy","Adverse events",17,3,"Gum hypertrophy","reported","reported",2,0,1.01728078041745,0,1990,0.236111111111111,53
"CD002290","CD002290_pub6_data","17|3|Adverse events|Hypertrichosis","Adverse events",17,3,"Hypertrichosis","reported","reported",2,0,1.00559054242372,0,1990,0.352777777777778,53
"CD002290","CD002290_pub6_data","17|3|Adverse events|Serum creatinine","Adverse events",17,3,"Serum creatinine","reported","reported",2,0,1.05565405466969,0,1990,0.105555555555556,53
"CD002290","CD002290_pub6_data","18|1|Relapse at 6 to 12 months|Chlorambucil versus prednisone or placebo (at 6 months)","Relapse at 6 to 12 months",18,1,"Chlorambucil versus prednisone or placebo (at 6 months)","or","binary",2,-3.17295583631797,0.902947003866444,0,1977,0.853535353535354,20.5
"CD002290","CD002290_pub6_data","18|1|Relapse at 6 to 12 months|Cyclophosphamide versus prednisone (6 or 12 months)","Relapse at 6 to 12 months",18,1,"Cyclophosphamide versus prednisone (6 or 12 months)","or","binary",4,-1.63317741803615,0.351126166622183,0,1979.5,0.689506327006327,40.25
"CD002290","CD002290_pub6_data","18|2|Relapse at 12 to 24 months|Chlorambucil versus prednisone or placebo (at 12 months)","Relapse at 12 to 24 months",18,2,"Chlorambucil versus prednisone or placebo (at 12 months)","or","binary",2,-4.72335131820806,1.32714194604961,0,1977,1,16
"CD002290","CD002290_pub6_data","18|2|Relapse at 12 to 24 months|Cyclophosphamide versus prednisone (12 to 24 months)","Relapse at 12 to 24 months",18,2,"Cyclophosphamide versus prednisone (12 to 24 months)","or","binary",2,-3.28972693103666,1.00306916735917,0,1971.5,0.954545454545455,13.5
"CD002290","CD002290_pub6_data","18|3|Leucopenia|Cyclophosphamide","Leucopenia",18,3,"Cyclophosphamide","or","binary",2,2.75528648235648,1.08312028055116,0,1987,0,39
"CD002290","CD002290_pub6_data","21|1|Relapse|Relapse at 12 to 24 months (end of study)","Relapse",21,1,"Relapse at 12 to 24 months (end of study)","reported","reported",2,0,0.134561819808821,0,2005,0.619047619047619,41.5
"CD002290","CD002290_pub6_data","21|1|Relapse|Relapse at 6 months","Relapse",21,1,"Relapse at 6 months","reported","reported",2,0,0.244976694522904,0,2005,0.523809523809524,41.5
"CD002290","CD002290_pub6_data","21|3|Adverse events|All infections","Adverse events",21,3,"All infections","or","binary",2,-2.06293177556497,0.811901767595833,0,2005,0.238095238095238,41.5
"CD002290","CD002290_pub6_data","21|3|Adverse events|Hair loss","Adverse events",21,3,"Hair loss","or","binary",2,-2.02045936316441,1.1219619791212,1.27560704173936,2005,0.380952380952381,41.5
"CD002290","CD002290_pub6_data","21|3|Adverse events|Leucopenia","Adverse events",21,3,"Leucopenia","or","binary",2,-1.0256556904972,0.748265918704845,0,2005,0.142857142857143,41.5
"CD002290","CD002290_pub6_data","26|1|Relapse at 6 months|","Relapse at 6 months",26,1,"","or","binary",2,-0.868205370894791,0.323416252103482,0,2016.5,0.321428571428571,123.5
"CD002290","CD002290_pub6_data","27|1|Relapse at 6 months|","Relapse at 6 months",27,1,"","or","binary",2,-0.429281021966977,0.541367280984025,0,1973.5,0.597222222222222,30
"CD002290","CD002290_pub6_data","3|1|Relapse by 12 months|","Relapse by 12 months",3,1,"","reported","reported",4,0,0.171558918915571,0,2021,0.536385918003565,59.5
"CD002290","CD002290_pub6_data","7|1|Relapse at 12 months|","Relapse at 12 months",7,1,"","or","binary",3,0.944524097522091,0.415260041855431,0,2013,0.312962962962963,38
"CD002290","CD002290_pub6_data","7|2|Relapse rate/year|","Relapse rate/year",7,2,"","or","binary",3,0.0227713308255051,1.1686669958009,0,2012.33333333333,0,47.3333333333333
"CD002290","CD002290_pub6_data","7|3|Adverse events|Gum hypertrophy","Adverse events",7,3,"Gum hypertrophy","or","binary",3,-2.70364982372731,0.877509089717389,0,2012.33333333333,0.266666666666667,48
"CD002290","CD002290_pub6_data","7|3|Adverse events|Hypertension","Adverse events",7,3,"Hypertension","or","binary",3,-1.30971936645721,0.63774668830548,0.482385948531765,2012.33333333333,0.3,48
"CD002290","CD002290_pub6_data","7|3|Adverse events|Hypertrichosis","Adverse events",7,3,"Hypertrichosis","or","binary",3,-2.16668010922442,0.522398256783967,0,2012.33333333333,0.413888888888889,46.6666666666667
"CD002290","CD002290_pub6_data","7|3|Adverse events|Lymphopenia","Adverse events",7,3,"Lymphopenia","or","binary",2,-0.402331344827132,0.985658180358809,0,2010.5,0.0583333333333333,42
"CD002290","CD002290_pub6_data","9|1|Relapse|Relapse at 6 to 12 months","Relapse",9,1,"Relapse at 6 to 12 months","reported","reported",8,0,0.0501142590342195,0,2000.375,0.859973155929038,57.75
"CD002290","CD002290_pub6_data","9|1|Relapse|Relapse during treatment (4 to 12 months)","Relapse",9,1,"Relapse during treatment (4 to 12 months)","reported","reported",8,0,0.0656303687203473,0,2000.375,0.741490249946132,59.25
"CD002290","CD002290_pub6_data","9|2|Mean relapse rate/patient/month|","Mean relapse rate/patient/month",9,2,"","or","binary",2,-0.0851227220617152,1.4305609932261,0,1999.5,0,45
"CD002290","CD002290_pub6_data","9|3|Adverse events|Leucopenia","Adverse events",9,3,"Leucopenia","or","binary",3,1.08020188507849,0.759429352501558,0,2007.66666666667,0.00666666666666667,71.3333333333333
"CD002290","CD002290_pub6_data","9|4|Relapse during treatment according to risk of bias|Studies at unclear or high risk of bias","Relapse during treatment according to risk of bias",9,4,"Studies at unclear or high risk of bias","or","binary",5,-1.96112534228573,0.299346820060312,0.0426466408165724,2000.6,0.680084033613445,53.2
"CD002303","CD002303_pub4_data","3|1|Reulceration|NA","Reulceration",3,1,NA,"or","binary",5,0.958983702545924,0.376388395288718,0.577799713129934,2011.2,0.324703510606902,262.8
"CD002303","CD002303_pub4_data","3|2|Noncompliance |NA","Noncompliance ",3,2,NA,"or","binary",5,-0.501060899875673,0.240719851113908,0.146787273954079,2011.2,0.278340682655208,274.4
"CD002971","CD002971_pub6_data","1|1|Necrotising enterocolitis|Sole diet","Necrotising enterocolitis",1,1,"Sole diet","reported","reported",4,0,0.589735290621189,0,1990.75,0.0997692000981475,90
"CD002971","CD002971_pub6_data","1|1|Necrotising enterocolitis|Supplement to maternal milk","Necrotising enterocolitis",1,1,"Supplement to maternal milk","reported","reported",6,0,0.201575328317674,0,2011.5,0.0646849637185386,305.166666666667
"CD002971","CD002971_pub6_data","1|10|Bayley-III|Cognitive","Bayley-III",1,10,"Cognitive","reported","reported",2,0,1.29981851757725,0,2020,0,361
"CD002971","CD002971_pub6_data","1|10|Bayley-III|Language","Bayley-III",1,10,"Language","reported","reported",2,0,1.4848032545625,0,2020,0,357
"CD002971","CD002971_pub6_data","1|10|Bayley-III|Motor","Bayley-III",1,10,"Motor","reported","reported",2,0,1.4704237566691,0,2020,0,357
"CD002971","CD002971_pub6_data","1|11|Cerebral palsy|","Cerebral palsy",1,11,"","reported","reported",3,0,0.263894498077064,0,1994.66666666667,0.0813975740446329,245.666666666667
"CD002971","CD002971_pub6_data","1|14|Bayley-III score < 70|Cognitive","Bayley-III score < 70",1,14,"Cognitive","reported","reported",2,0,0.158980553731804,0,2020,0.145048737261852,391
"CD002971","CD002971_pub6_data","1|14|Bayley-III score < 70|Language","Bayley-III score < 70",1,14,"Language","reported","reported",2,0,0.126970404240933,0,2020,0.223403052572075,389
"CD002971","CD002971_pub6_data","1|14|Bayley-III score < 70|Motor","Bayley-III score < 70",1,14,"Motor","reported","reported",2,0,0.153637329847581,0,2020,0.163070146091223,389.5
"CD002971","CD002971_pub6_data","1|2|Late-onset invasive infection|Supplement to maternal milk","Late-onset invasive infection",1,2,"Supplement to maternal milk","reported","reported",6,0,0.0867786147427385,0,2017.16666666667,0.211752856382481,259.666666666667
"CD002971","CD002971_pub6_data","1|3|All-cause mortality|Sole diet","All-cause mortality",1,3,"Sole diet","reported","reported",2,0,0.464580116127545,0,1998.5,0.100877192982456,106
"CD002971","CD002971_pub6_data","1|3|All-cause mortality|Supplement to maternal milk","All-cause mortality",1,3,"Supplement to maternal milk","reported","reported",5,0,0.166417534128967,0,2019.6,0.0668249995956437,278.4
"CD002971","CD002971_pub6_data","1|4|In-hospital rate of weight gain (g/kg/day) until term equivalent|Sole diet","In-hospital rate of weight gain (g/kg/day) until term equivalent",1,4,"Sole diet","reported","reported",3,0,0.65133396908215,0,1993,0,63
"CD002971","CD002971_pub6_data","1|4|In-hospital rate of weight gain (g/kg/day) until term equivalent|Supplement to maternal milk","In-hospital rate of weight gain (g/kg/day) until term equivalent",1,4,"Supplement to maternal milk","or","binary",4,0.0223688396079796,1.0024664905203,0,2007.25,0,271.25
"CD002971","CD002971_pub6_data","1|5|In-hospital rate of head circumference growth (mm/week) until term equivalent|Sole diet","In-hospital rate of head circumference growth (mm/week) until term equivalent",1,5,"Sole diet","reported","reported",5,0,0.26384112512548,0,1988,0,56.6
"CD002971","CD002971_pub6_data","1|5|In-hospital rate of head circumference growth (mm/week) until term equivalent|Supplement","In-hospital rate of head circumference growth (mm/week) until term equivalent",1,5,"Supplement","reported","reported",3,0,0.351093894540036,0,2001.66666666667,0,179
"CD003129","CD003129_pub2_data","1|1|Treatment response|NA","Treatment response",1,1,NA,"or","binary",3,0.821545675679218,0.248986008986178,0,1998.33333333333,0.299981522542498,109.333333333333
"CD003129","CD003129_pub2_data","1|6|Serious adverse events|NA","Serious adverse events",1,6,NA,"or","binary",3,-0.365547645401198,1.01419117685532,0,1998.33333333333,0.00813008130081301,109.333333333333
"CD003216","CD003216_pub3_data","1|1|Incidence of pressure ulcers|NA","Incidence of pressure ulcers",1,1,NA,"or","binary",3,-0.117528410638332,0.193945268477972,0.0560813264217151,1999.66666666667,0.23209147619733,544.666666666667
"CD003216","CD003216_pub3_data","13|2|PUSH score|NA","PUSH score",13,2,NA,"or","binary",2,-0.551315708764597,1.42282364275945,0,2012,0,91.5
"CD003216","CD003216_pub3_data","13|4|At least one adverse gastrointestinal effect|NA","At least one adverse gastrointestinal effect",13,4,NA,"or","binary",2,0.57846447748234,0.853901579215452,0,2017.5,0.0119047619047619,77
"CD003216","CD003216_pub3_data","16|1|Pressure ulcers healed|NA","Pressure ulcers healed",16,1,NA,"or","binary",2,0.17497003979625,0.722344790490811,0.638490065739954,1984.5,0.394444444444444,54
"CD003216","CD003216_pub3_data","5|1|Incidence of pressure ulcers|NA","Incidence of pressure ulcers",5,1,NA,"or","binary",4,-0.456701599585456,0.243825842133818,0,2006.25,0.170938574826383,1066
"CD003216","CD003216_pub3_data","5|2|At least one adverse gastrointestinal effect|NA","At least one adverse gastrointestinal effect",5,2,NA,"or","binary",2,-0.377621141690426,1.31763622969263,2.43698387468045,2011,0.154761904761905,70
"CD003216","CD003216_pub3_data","7|1|Pressure ulcers healed|NA","Pressure ulcers healed",7,1,NA,"or","binary",3,0.58145892061438,0.184523358276219,0,2005.66666666667,0.163815856394113,192.333333333333
"CD003216","CD003216_pub3_data","8|1|Pressure ulcers healed|NA","Pressure ulcers healed",8,1,NA,"or","binary",2,0.343012856269568,0.656796541961793,0,2009.5,0.15625,30.5
"CD003216","CD003216_pub3_data","8|2|Change in pressure ulcer area (cm²)|NA","Change in pressure ulcer area (cm²)",8,2,NA,"or","binary",2,0.0458125900896654,1.43433526069821,0,2009.5,0,35.5
"CD003216","CD003216_pub3_data","8|3|PUSH score|NA","PUSH score",8,3,NA,"or","binary",3,0.0951199198672378,1.18417099312794,0,2008,0,26.6666666666667
"CD003216","CD003216_pub3_data","9|3|Change in pressure ulcer area (percentage)|NA","Change in pressure ulcer area (percentage)",9,3,NA,"or","binary",2,0.0827199132288876,1.42693957063956,0,2015.5,0,115.5
"CD003216","CD003216_pub3_data","9|6|At least one adverse gastrointestinal effects|NA","At least one adverse gastrointestinal effects",9,6,NA,"or","binary",3,0.520396576915555,0.824417199265539,0.511397214557504,2016,0.0101010101010101,94
"CD003218","CD003218_pub3_data","1|1|Mean improvement in the Maintenance of Wakefulness Test|","Mean improvement in the Maintenance of Wakefulness Test",1,1,"","reported","reported",3,3.56844397429204,1.79016895872633,6.34313931659194,2008,0,38
"CD003218","CD003218_pub3_data","1|2|Mean improvement in the Epworth Sleepiness Scale|","Mean improvement in the Epworth Sleepiness Scale",1,2,"","reported","reported",5,-2.60941904927295,0.850710517603367,2.61432406684903,2006.6,0,43.8
"CD003218","CD003218_pub3_data","1|3|Mean improvement in the Multiple Sleep Latency Test|","Mean improvement in the Multiple Sleep Latency Test",1,3,"","reported","reported",2,-1.82202349869452,1.91415080926155,7.09045,2003,0,24
"CD003218","CD003218_pub3_data","1|4|Quality of life|Mean improvement in total score of Short Form 36","Quality of life",1,4,"Mean improvement in total score of Short Form 36","reported","reported",2,1.26685244221098,2.49914083246222,0,2006,0,33
"CD003218","CD003218_pub3_data","1|5|Proportion of participants with at least 1 adverse event|","Proportion of participants with at least 1 adverse event",1,5,"","reported","reported",5,0.530313038885419,0.416863156161459,0,2005.4,0,40.8
"CD003331","CD003331_pub6_data","1|1|All-cause mortality up to 12 months' follow-up|High ROB","All-cause mortality up to 12 months' follow-up",1,1,"High ROB","or","binary",28,-0.359192600715875,0.186704592923768,0,2009.07142857143,0.0594615488628658,89.2142857142857
"CD003331","CD003331_pub6_data","1|1|All-cause mortality up to 12 months' follow-up|Low ROB","All-cause mortality up to 12 months' follow-up",1,1,"Low ROB","or","binary",8,0.234271396282114,0.205223707275033,0,2011.5,0.0541946822361529,180.375
"CD003331","CD003331_pub6_data","1|2|All-cause mortality more than 12 months' follow-up|High ROB","All-cause mortality more than 12 months' follow-up",1,2,"High ROB","or","binary",5,-0.741703178603701,0.27783036509669,0,2006.8,0.238903902137352,80
"CD003331","CD003331_pub6_data","1|2|All-cause mortality more than 12 months' follow-up|Low ROB","All-cause mortality more than 12 months' follow-up",1,2,"Low ROB","or","binary",3,-0.05177876408588,0.0930251552183009,0,2011.33333333333,0.223813064081311,1126.66666666667
"CD003331","CD003331_pub6_data","1|3|Hospital admissions (all-cause) up to 12 months' follow-up|High ROB","Hospital admissions (all-cause) up to 12 months' follow-up",1,3,"High ROB","or","binary",18,-0.634664423963681,0.206400322222195,0.180315328750585,2007.83333333333,0.219888182342628,78.2777777777778
"CD003331","CD003331_pub6_data","1|3|Hospital admissions (all-cause) up to 12 months' follow-up|Low ROB","Hospital admissions (all-cause) up to 12 months' follow-up",1,3,"Low ROB","or","binary",6,-0.296439107845999,0.18488311146489,0,2013.16666666667,0.190760987162318,145.666666666667
"CD003331","CD003331_pub6_data","1|4|Hospital admissions (all-cause) more than 12 months' follow-up|High ROB","Hospital admissions (all-cause) more than 12 months' follow-up",1,4,"High ROB","or","binary",6,-0.715827841156552,0.348956964861445,0.323004323860685,2008.66666666667,0.442063492063492,60.1666666666667
"CD003331","CD003331_pub6_data","1|4|Hospital admissions (all-cause) more than 12 months' follow-up|Low ROB","Hospital admissions (all-cause) more than 12 months' follow-up",1,4,"Low ROB","or","binary",2,-0.123227678749113,0.0737802394569364,0,2014.5,0.635022414127895,1574
"CD003331","CD003331_pub6_data","1|5|Hospital admissions (heart failure only) up to 12 months' follow-up|High ROB","Hospital admissions (heart failure only) up to 12 months' follow-up",1,5,"High ROB","or","binary",6,-0.328712004193346,0.424394287341565,0.204734863608295,2005.33333333333,0.135048899289655,61.5
"CD003331","CD003331_pub6_data","1|5|Hospital admissions (heart failure only) up to 12 months' follow-up|Low ROB","Hospital admissions (heart failure only) up to 12 months' follow-up",1,5,"Low ROB","or","binary",4,-0.291985609088088,0.462518761649314,0.0286851003845555,2014.25,0.0642734504607144,135.5
"CD003331","CD003331_pub6_data","1|6|Hospital admissions (heart failure only) more than 12 months' follow-up|High ROB","Hospital admissions (heart failure only) more than 12 months' follow-up",1,6,"High ROB","or","binary",5,-0.716048261106079,0.302268299930116,0.00341226184022658,2008.8,0.379923344947735,56
"CD003331","CD003331_pub6_data","1|7|Health-related quality of life (MLWHF) up to 12 months' follow-up|High ROB","Health-related quality of life (MLWHF) up to 12 months' follow-up",1,7,"High ROB","or","binary",15,-0.0189365976004683,0.520150723762229,0,2011.2,0,116.8
"CD003331","CD003331_pub6_data","1|7|Health-related quality of life (MLWHF) up to 12 months' follow-up|Low ROB","Health-related quality of life (MLWHF) up to 12 months' follow-up",1,7,"Low ROB","or","binary",7,0.0397611623947805,0.758950884977129,0,2011.57142857143,0,135.285714285714
"CD003331","CD003331_pub6_data","1|8|Health-related quality of life (all scales) up to 12 months' follow-up|High ROB","Health-related quality of life (all scales) up to 12 months' follow-up",1,8,"High ROB","or","binary",29,-0.157597143391451,0.375783656559532,0,2011.81481481481,0,78.4137931034483
"CD003331","CD003331_pub6_data","1|8|Health-related quality of life (all scales) up to 12 months' follow-up|Low ROB","Health-related quality of life (all scales) up to 12 months' follow-up",1,8,"Low ROB","or","binary",9,-0.0286451628898514,0.670431029603332,0,2011.88888888889,0,277.222222222222
"CD003331","CD003331_pub6_data","1|9|Health-related quality of life (MLWHF) more than 12 months' follow-up|High ROB","Health-related quality of life (MLWHF) more than 12 months' follow-up",1,9,"High ROB","or","binary",2,-0.0452578455135674,1.42077345849684,0,2005.5,0,108.5
"CD003333","CD003333_pub4_data","1|1|All-cause mortality|NA","All-cause mortality",1,1,NA,"or","binary",4,0.0057931366613246,0.0799993915263984,0,2007.75,0.214463623965756,915.75
"CD003333","CD003333_pub4_data","1|2|Non-fatal cardiovascular events (non-fatal stroke, myocardial infarction, pulmonary embolism, peripheral arterial embolism)|NA","Non-fatal cardiovascular events (non-fatal stroke, myocardial infarction, pulmonary embolism, peripheral arterial embolism)",1,2,NA,"or","binary",4,-0.242547210394096,0.126642026377602,4.99296857381575e-06,2007.75,0.0736072478600392,915.75
"CD003333","CD003333_pub4_data","1|3|Major bleeding events|NA","Major bleeding events",1,3,NA,"or","binary",4,0.6846123980039,0.186851606320161,0.00979556809625503,2007.75,0.0184932712363912,915.75
"CD003357","CD003357_pub5_data","1|2|Clinical pregnancy rate per woman|","Clinical pregnancy rate per woman",1,2,"","or","binary",2,0.590291189313343,1.47082100659704,3.51448658521413,1998.5,0.126984126984127,43
"CD003357","CD003357_pub5_data","2|1|Live birth rate per woman|","Live birth rate per woman",2,1,"","or","binary",2,1.19745418850062,0.723963773946155,0.65433595489751,2006.5,0.15993265993266,78
"CD003357","CD003357_pub5_data","3|1|Live birth rate per woman|Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle) ","Live birth rate per woman",3,1,"Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle) ","or","binary",2,0.530314817280505,0.444569722901044,0.209917950943557,2007,0.253748370273794,110.5
"CD003357","CD003357_pub5_data","3|1|Live birth rate per woman|Treatment-naive women IVF vs IUI + gonadotropins (1 IVF to 2-3 IUI cycles)","Live birth rate per woman",3,1,"Treatment-naive women IVF vs IUI + gonadotropins (1 IVF to 2-3 IUI cycles)","or","binary",3,0.168516964318519,0.156238591650216,0,2013,0.339976326468229,243.666666666667
"CD003357","CD003357_pub5_data","3|2|Clinical pregnancy rate per woman|Treatment-naive women IVF vs IUI + gonadotropins","Clinical pregnancy rate per woman",3,2,"Treatment-naive women IVF vs IUI + gonadotropins","or","binary",3,0.153103276660988,0.158262444718023,0,2013,0.387136464770915,243.666666666667
"CD003357","CD003357_pub5_data","3|3|Multiple pregnancy rate per woman|Treatment-naive women IUI + gonadotropins","Multiple pregnancy rate per woman",3,3,"Treatment-naive women IUI + gonadotropins","or","binary",3,-0.17917614994234,0.375027294433404,0,2013,0.0427024433276024,243.666666666667
"CD003357","CD003357_pub5_data","3|3|Multiple pregnancy rate per woman|Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle)","Multiple pregnancy rate per woman",3,3,"Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle)","or","binary",2,-0.26365100162105,0.369517691833601,0,2007,0.172913950456323,110.5
"CD003357","CD003357_pub5_data","3|4|Incidence of OHSS per woman|Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle)","Incidence of OHSS per woman",3,4,"Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle)","or","binary",2,0.173629249149358,0.575372437814962,0,2007,0.0457953063885267,110.5
"CD003376","CD003376_pub4_data","1|1|Clinical vertebral fractures|Clinical vertebral fractures, primary","Clinical vertebral fractures",1,1,"Clinical vertebral fractures, primary","or","binary",2,1.13548244071566,1.1666067927162,0,NA,0,81.5
"CD003376","CD003376_pub4_data","1|2|Non-vertebral fractures|Non-vertebral fractures, primary","Non-vertebral fractures",1,2,"Non-vertebral fractures, primary","or","binary",2,-0.55003904082864,0.542900142996939,0,NA,0.11010101010101,81.5
"CD003376","CD003376_pub4_data","1|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",1,2,"Non-vertebral fractures, secondary","or","binary",5,0.0672719571429937,0.232670808847407,0,1990,0.129245313357463,119.6
"CD003376","CD003376_pub4_data","1|3|Hip fractures|Hip fractures, primary","Hip fractures",1,3,"Hip fractures, primary","or","binary",2,0.00910579407968451,1.42177076257322,0,NA,0,94.5
"CD003376","CD003376_pub4_data","1|3|Hip fractures|Hip fractures, secondary","Hip fractures",1,3,"Hip fractures, secondary","or","binary",2,-0.134554967606181,0.88974057133325,0,1990,0.0285714285714286,141.5
"CD003376","CD003376_pub4_data","1|4|Wrist fractures|Wrist fractures, secondary","Wrist fractures",1,4,"Wrist fractures, secondary","or","binary",2,-0.093143947561732,0.841006868450039,0,NA,0.0285714285714286,70
"CD003376","CD003376_pub4_data","1|5|Radiographic vertebral fractures|Radiographic vertebral fractures, primary","Radiographic vertebral fractures",1,5,"Radiographic vertebral fractures, primary","or","binary",2,-1.27031207266244,1.21602489994388,0,NA,0.0375,116
"CD003376","CD003376_pub4_data","1|5|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",1,5,"Radiographic vertebral fractures, secondary","or","binary",4,-0.824925280935834,0.319784195260981,0,1990,0.180224425333121,121.75
"CD003376","CD003376_pub4_data","1|6|Withdrawals due to adverse events|Withdrawals due to adverse events, secondary","Withdrawals due to adverse events",1,6,"Withdrawals due to adverse events, secondary","or","binary",5,0.0847431148616585,0.384999121575382,0,1990,0.0814728884822343,124.8
"CD003376","CD003376_pub4_data","1|7|Serious adverse events|Serious adverse events, primary","Serious adverse events",1,7,"Serious adverse events, primary","or","binary",5,-0.103760012055237,0.303270863050728,0,NA,0.108128382338909,99.4
"CD003376","CD003376_pub4_data","1|9|Atypical femoral fractures|Atypical femoral fractures, primary","Atypical femoral fractures",1,9,"Atypical femoral fractures, primary","or","binary",2,0.00910579407968451,1.42177076257322,0,NA,0,94.5
"CD003376","CD003376_pub4_data","10|1|Clinical vertebral fractures|Clinical vertebral fractures, primary","Clinical vertebral fractures",10,1,"Clinical vertebral fractures, primary","or","binary",2,1.13548244071566,1.1666067927162,0,NA,0,81.5
"CD003376","CD003376_pub4_data","10|2|Non-vertebral fractures|Non-vertebral fractures, primary","Non-vertebral fractures",10,2,"Non-vertebral fractures, primary","or","binary",2,-0.55003904082864,0.542900142996939,0,NA,0.11010101010101,81.5
"CD003376","CD003376_pub4_data","10|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",10,2,"Non-vertebral fractures, secondary","or","binary",3,0.134837069846996,0.305718229176558,0,1990,0.13040663040663,103.333333333333
"CD003376","CD003376_pub4_data","10|3|Hip fractures|Hip fractures, primary","Hip fractures",10,3,"Hip fractures, primary","or","binary",2,0.00910579407968451,1.42177076257322,0,NA,0,94.5
"CD003376","CD003376_pub4_data","10|5|Radiographic vertebral fractures|Radiographic vertebral fractures, primary","Radiographic vertebral fractures",10,5,"Radiographic vertebral fractures, primary","or","binary",2,-1.27031207266244,1.21602489994388,0,NA,0.0375,116
"CD003376","CD003376_pub4_data","10|5|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",10,5,"Radiographic vertebral fractures, secondary","or","binary",2,-0.698142636127927,0.448520521006995,0,1990,0.193833943833944,112
"CD003376","CD003376_pub4_data","11|1|Hip fractures|Hip fractures, secondary","Hip fractures",11,1,"Hip fractures, secondary","or","binary",2,-0.686451827374962,1.2742396227141,0,NA,0.00757575757575758,90.5
"CD003376","CD003376_pub4_data","11|2|Wrist fractures|Wrist fractures, secondary","Wrist fractures",11,2,"Wrist fractures, secondary","or","binary",2,-0.019879454416792,1.42388548306883,0,NA,0,90.5
"CD003376","CD003376_pub4_data","11|3|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",11,3,"Radiographic vertebral fractures, secondary","or","binary",3,-1.35944488925802,0.490765264308189,0.247703607369386,NA,0.352525252525253,73.6666666666667
"CD003376","CD003376_pub4_data","11|7|Atypical femoral fractures|Atypical femoral fractures, secondary","Atypical femoral fractures",11,7,"Atypical femoral fractures, secondary","or","binary",2,-0.019879454416792,1.42388548306883,0,NA,0,90.5
"CD003376","CD003376_pub4_data","13|1|Hip fractures|Hip fractures, secondary","Hip fractures",13,1,"Hip fractures, secondary","or","binary",2,-0.686451827374962,1.2742396227141,0,NA,0.00757575757575758,90.5
"CD003376","CD003376_pub4_data","13|2|Wrist fractures|Wrist fractures, secondary","Wrist fractures",13,2,"Wrist fractures, secondary","or","binary",2,-0.019879454416792,1.42388548306883,0,NA,0,90.5
"CD003376","CD003376_pub4_data","13|3|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",13,3,"Radiographic vertebral fractures, secondary","or","binary",3,-1.35944488925802,0.490765264308189,0.247703607369386,NA,0.352525252525253,73.6666666666667
"CD003376","CD003376_pub4_data","15|1|Hip fractures|Hip fractures, secondary","Hip fractures",15,1,"Hip fractures, secondary","or","binary",2,-0.686451827374962,1.2742396227141,0,NA,0.00757575757575758,90.5
"CD003376","CD003376_pub4_data","15|2|Wrist fractures|Wrist fractures, secondary","Wrist fractures",15,2,"Wrist fractures, secondary","or","binary",2,-0.019879454416792,1.42388548306883,0,NA,0,90.5
"CD003376","CD003376_pub4_data","15|3|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",15,3,"Radiographic vertebral fractures, secondary","or","binary",3,-1.35944488925802,0.490765264308189,0.247703607369386,NA,0.352525252525253,73.6666666666667
"CD003376","CD003376_pub4_data","16|1|Hip fractures|Hip fractures, secondary","Hip fractures",16,1,"Hip fractures, secondary","or","binary",2,-0.686451827374962,1.2742396227141,0,NA,0.00757575757575758,90.5
"CD003376","CD003376_pub4_data","16|2|Wrist fractures|Wrist fractures, secondary","Wrist fractures",16,2,"Wrist fractures, secondary","or","binary",2,-0.019879454416792,1.42388548306883,0,NA,0,90.5
"CD003376","CD003376_pub4_data","16|3|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",16,3,"Radiographic vertebral fractures, secondary","or","binary",2,-0.964319701809952,0.399921347794675,0,NA,0.253787878787879,90.5
"CD003376","CD003376_pub4_data","19|1|Treatment versus reference, secondary|Etidronate 200 mg/day versus menatetrenone 45 mg/day","Treatment versus reference, secondary",19,1,"Etidronate 200 mg/day versus menatetrenone 45 mg/day","or","binary",2,-0.0405787640301564,1.42403604602865,0,NA,0,90
"CD003376","CD003376_pub4_data","20|1|Treatment versus reference, secondary|Etidronate 200 mg/day versus menatetrenone 45 mg/day","Treatment versus reference, secondary",20,1,"Etidronate 200 mg/day versus menatetrenone 45 mg/day","or","binary",2,-0.0405787640301564,1.42403604602865,0,NA,0,90
"CD003376","CD003376_pub4_data","21|1|Treatment versus reference, secondary|Etidronate 200 mg/day versus menatetrenone 45 mg/day","Treatment versus reference, secondary",21,1,"Etidronate 200 mg/day versus menatetrenone 45 mg/day","or","binary",2,-0.119594687982684,0.446773801784472,0,NA,0.111660079051383,90
"CD003376","CD003376_pub4_data","22|2|Treatment versus reference, secondary|Etidronate 400 mg/day versus alendronate 10 mg/day","Treatment versus reference, secondary",22,2,"Etidronate 400 mg/day versus alendronate 10 mg/day","or","binary",2,-2.36467804380036,1.07049316392397,0,2002.5,0.143581081081081,59.5
"CD003376","CD003376_pub4_data","22|2|Treatment versus reference, secondary|Etidronate 400 mg/day versus intermittent/cyclic alendronate 10 mg/day","Treatment versus reference, secondary",22,2,"Etidronate 400 mg/day versus intermittent/cyclic alendronate 10 mg/day","or","binary",2,-0.694595699113596,1.27850755460715,0,2002.5,0.0151515151515152,57.5
"CD003376","CD003376_pub4_data","25|1|Treatment versus reference, secondary|Etidronate 200 mg/day versus menatetrenone 45 mg/day","Treatment versus reference, secondary",25,1,"Etidronate 200 mg/day versus menatetrenone 45 mg/day","or","binary",2,-0.0405787640301564,1.42403604602865,0,NA,0,90
"CD003376","CD003376_pub4_data","3|1|Clinical vertebral fractures|Clinical vertebral fractures, primary","Clinical vertebral fractures",3,1,"Clinical vertebral fractures, primary","or","binary",2,1.13548244071566,1.1666067927162,0,NA,0,81.5
"CD003376","CD003376_pub4_data","3|2|Non-vertebral fractures|Non-vertebral fractures, primary","Non-vertebral fractures",3,2,"Non-vertebral fractures, primary","or","binary",2,-0.55003904082864,0.542900142996939,0,NA,0.11010101010101,81.5
"CD003376","CD003376_pub4_data","3|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",3,2,"Non-vertebral fractures, secondary","or","binary",2,0.215681917079135,0.272856674034412,0,1990,0.132997843278217,211.5
"CD003376","CD003376_pub4_data","3|4|Radiographic vertebral fractures|Radiographic vertebral fractures, primary","Radiographic vertebral fractures",3,4,"Radiographic vertebral fractures, primary","or","binary",2,-1.27031207266244,1.21602489994388,0,NA,0.0375,116
"CD003376","CD003376_pub4_data","3|4|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",3,4,"Radiographic vertebral fractures, secondary","or","binary",3,-1.06873808652645,0.366248193411461,0,1990,0.14532568880395,156.333333333333
"CD003376","CD003376_pub4_data","5|1|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",5,1,"Non-vertebral fractures, secondary","or","binary",2,-0.350852185224267,0.614554618560548,0,NA,0.0777777777777778,67.5
"CD003376","CD003376_pub4_data","5|4|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",5,4,"Radiographic vertebral fractures, secondary","or","binary",2,-0.837352111543435,0.489126905084132,0,NA,0.267460317460317,54.5
"CD003376","CD003376_pub4_data","6|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",6,2,"Non-vertebral fractures, secondary","or","binary",4,0.147157652595918,0.24560951640159,0,1990,0.125842355982543,131
"CD003376","CD003376_pub4_data","6|5|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",6,5,"Radiographic vertebral fractures, secondary","or","binary",3,-0.749517660232401,0.371729105843977,0,1990,0.154584948063209,137.666666666667
"CD003376","CD003376_pub4_data","7|1|Clinical vertebral fractures|Clinical vertebral fractures, primary","Clinical vertebral fractures",7,1,"Clinical vertebral fractures, primary","or","binary",2,1.13548244071566,1.1666067927162,0,NA,0,81.5
"CD003376","CD003376_pub4_data","7|2|Non-vertebral fractures|Non-vertebral fractures, primary","Non-vertebral fractures",7,2,"Non-vertebral fractures, primary","or","binary",2,-0.55003904082864,0.542900142996939,0,NA,0.11010101010101,81.5
"CD003376","CD003376_pub4_data","7|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",7,2,"Non-vertebral fractures, secondary","or","binary",5,0.0793024006780579,0.232270885102378,0,1990,0.120673884786034,124.8
"CD003376","CD003376_pub4_data","7|3|Hip fractures|Hip fractures, primary","Hip fractures",7,3,"Hip fractures, primary","or","binary",2,0.00910579407968451,1.42177076257322,0,NA,0,94.5
"CD003376","CD003376_pub4_data","7|3|Hip fractures|Hip fractures, secondary","Hip fractures",7,3,"Hip fractures, secondary","or","binary",2,-0.0553854952921054,0.885520182123364,0,1990,0.02,154.5
"CD003376","CD003376_pub4_data","7|4|Wrist fractures|Wrist fractures, secondary","Wrist fractures",7,4,"Wrist fractures, secondary","or","binary",2,0,0.834769613384165,0,NA,0.02,83
"CD003376","CD003376_pub4_data","7|5|Radiographic vertebral fractures|Radiographic vertebral fractures, primary","Radiographic vertebral fractures",7,5,"Radiographic vertebral fractures, primary","or","binary",2,-1.27031207266244,1.21602489994388,0,NA,0.0375,116
"CD003376","CD003376_pub4_data","7|5|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",7,5,"Radiographic vertebral fractures, secondary","or","binary",4,-0.740214757750556,0.316883699986985,0,1990,0.154838046169822,139.5
"CD003376","CD003376_pub4_data","8|1|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",8,1,"Non-vertebral fractures, secondary","or","binary",5,0.0793024006780579,0.232270885102378,0,1990,0.120673884786034,124.8
"CD003376","CD003376_pub4_data","8|2|Hip fractures|Hip fractures, secondary","Hip fractures",8,2,"Hip fractures, secondary","or","binary",2,-0.0553854952921054,0.885520182123364,0,1990,0.02,154.5
"CD003376","CD003376_pub4_data","8|3|Wrist fractures|Wrist fractures, secondary","Wrist fractures",8,3,"Wrist fractures, secondary","or","binary",2,0,0.834769613384165,0,NA,0.02,83
"CD003376","CD003376_pub4_data","8|4|Radiographic vertebral fractures|Radiographic vertebral fractures, primary","Radiographic vertebral fractures",8,4,"Radiographic vertebral fractures, primary","or","binary",2,-1.27031207266244,1.21602489994388,0,NA,0.0375,116
"CD003376","CD003376_pub4_data","8|4|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",8,4,"Radiographic vertebral fractures, secondary","or","binary",4,-0.824925280935834,0.319784195260981,0,1990,0.180224425333121,121.75
"CD003376","CD003376_pub4_data","9|2|Non-vertebral fractures|Non-vertebral fractures, secondary","Non-vertebral fractures",9,2,"Non-vertebral fractures, secondary","or","binary",5,0.0793024006780579,0.232270885102378,0,1990,0.120673884786034,124.8
"CD003376","CD003376_pub4_data","9|3|Hip fractures|Hip fractures, secondary","Hip fractures",9,3,"Hip fractures, secondary","or","binary",2,-0.0553854952921054,0.885520182123364,0,1990,0.02,154.5
"CD003376","CD003376_pub4_data","9|4|Wrist fractures|Wrist fractures, secondary","Wrist fractures",9,4,"Wrist fractures, secondary","or","binary",2,0,0.834769613384165,0,NA,0.02,83
"CD003376","CD003376_pub4_data","9|5|Radiographic vertebral fractures|Radiographic vertebral fractures, secondary","Radiographic vertebral fractures",9,5,"Radiographic vertebral fractures, secondary","or","binary",4,-0.824925280935834,0.319784195260981,0,1990,0.180224425333121,121.75
"CD003414","CD003414_pub4_data","1|1|Live birth rate per woman|Natural cycle FET versus HT + GnRHa FET","Live birth rate per woman",1,1,"Natural cycle FET versus HT + GnRHa FET","or","binary",2,-0.116333292436967,0.216530655454023,0,2017,0.315252641489696,200
"CD003414","CD003414_pub4_data","1|1|Live birth rate per woman|Natural cycle FET versus modified natural cycle FET (HCG trigger)","Live birth rate per woman",1,1,"Natural cycle FET versus modified natural cycle FET (HCG trigger)","or","binary",3,-0.0272301762482408,0.202187933792554,0,2017.33333333333,0.350641025641026,147.333333333333
"CD003414","CD003414_pub4_data","1|2|Miscarriage rate per woman|Natural cycle FET versus modified natural cycle FET (HCG trigger)","Miscarriage rate per woman",1,2,"Natural cycle FET versus modified natural cycle FET (HCG trigger)","or","binary",4,-0.0797299349304781,0.345182170244235,0,2017.75,0.0558077593138569,199.5
"CD003414","CD003414_pub4_data","1|3|Ongoing pregnancy rate per woman|Natural cycle FET versus modified natural cycle FET (HCG trigger)","Ongoing pregnancy rate per woman",1,3,"Natural cycle FET versus modified natural cycle FET (HCG trigger)","or","binary",3,0.246275293271467,0.182117353719804,4.18450980162043e-06,2016.33333333333,0.216730198437516,217.666666666667
"CD003414","CD003414_pub4_data","1|4|Clinical pregnancy rate per woman|Natural cycle FET versus HT + GnRHa FET","Clinical pregnancy rate per woman",1,4,"Natural cycle FET versus HT + GnRHa FET","or","binary",2,-0.109822487613443,0.210448458757941,0,2017,0.346375143843498,200
"CD003414","CD003414_pub4_data","1|4|Clinical pregnancy rate per woman|Natural cycle FET versus HT FET","Clinical pregnancy rate per woman",1,4,"Natural cycle FET versus HT FET","or","binary",2,0.119985954962497,0.24162446912748,0,2006.5,0.257139983909895,166.5
"CD003414","CD003414_pub4_data","1|4|Clinical pregnancy rate per woman|Natural cycle FET versus modified natural cycle FET (HCG trigger)","Clinical pregnancy rate per woman",1,4,"Natural cycle FET versus modified natural cycle FET (HCG trigger)","or","binary",4,0.138746173075454,0.160448097332942,0,2018,0.356450646237232,172.5
"CD003414","CD003414_pub4_data","1|6|Multiple pregnancy rate per woman|Natural cycle FET versus HT + GnRHa FET","Multiple pregnancy rate per woman",1,6,"Natural cycle FET versus HT + GnRHa FET","or","binary",2,0.145233783897332,0.436714296442597,0.102244849474985,2017,0.0729678836698399,200
"CD003414","CD003414_pub4_data","1|6|Multiple pregnancy rate per woman|Natural cycle FET versus HT FET","Multiple pregnancy rate per woman",1,6,"Natural cycle FET versus HT FET","or","binary",2,0.216479806831377,0.393060218619897,0,2006.5,0.0530973451327434,166.5
"CD003414","CD003414_pub4_data","2|1|Live birth rate per woman|Modified natural cycle FET versus HT + GnRHa FET","Live birth rate per woman",2,1,"Modified natural cycle FET versus HT + GnRHa FET","or","binary",3,0.0574971448474091,0.164904721982659,0,2017.66666666667,0.343333910115384,214.666666666667
"CD003414","CD003414_pub4_data","2|1|Live birth rate per woman|Modified natural cycle FET versus HT FET","Live birth rate per woman",2,1,"Modified natural cycle FET versus HT FET","or","binary",2,0.230478835525965,0.172617616605254,0,2017.5,0.181349176075679,594.5
"CD003414","CD003414_pub4_data","2|2|Miscarriage rate per woman|Modified natural cycle FET versus HT + GnRHa FET","Miscarriage rate per woman",2,2,"Modified natural cycle FET versus HT + GnRHa FET","or","binary",3,-0.301439618129491,0.399857434599792,0,2017.66666666667,0.0402945433671437,214.666666666667
"CD003414","CD003414_pub4_data","2|2|Miscarriage rate per woman|Modified natural cycle FET versus HT FET","Miscarriage rate per woman",2,2,"Modified natural cycle FET versus HT FET","or","binary",2,-0.52774646591338,0.653531724821474,0,2018.5,0.0515974201289935,158.5
"CD003414","CD003414_pub4_data","2|3|Ongoing pregnancy rate per woman|Modified natural cycle FET versus HT + GnRHa FET","Ongoing pregnancy rate per woman",2,3,"Modified natural cycle FET versus HT + GnRHa FET","or","binary",2,0.0271360262294523,0.209996831478187,0,2018.5,0.327613028682547,204
"CD003414","CD003414_pub4_data","2|3|Ongoing pregnancy rate per woman|Modified natural cycle FET versus HT FET","Ongoing pregnancy rate per woman",2,3,"Modified natural cycle FET versus HT FET","or","binary",3,0.196931886165594,0.163137735058313,0,2017.66666666667,0.168970754048504,425.333333333333
"CD003414","CD003414_pub4_data","2|4|Clinical pregnancy rate per woman|Modified natural cycle FET versus HT + GnRHa FET","Clinical pregnancy rate per woman",2,4,"Modified natural cycle FET versus HT + GnRHa FET","or","binary",3,0.00505967365977494,0.161325855703047,0,2017.66666666667,0.399876129188193,214.666666666667
"CD003414","CD003414_pub4_data","2|4|Clinical pregnancy rate per woman|Modified natural cycle FET versus HT FET","Clinical pregnancy rate per woman",2,4,"Modified natural cycle FET versus HT FET","or","binary",3,0.177122726989256,0.141002685674115,0,2017.66666666667,0.207971605730058,425.333333333333
"CD003414","CD003414_pub4_data","2|7|Endometrial thickness|Modified natural cycle FET versus HT + GnRHa FET","Endometrial thickness",2,7,"Modified natural cycle FET versus HT + GnRHa FET","or","binary",3,0.0111649214984228,1.1574398643018,0,2017.66666666667,0,214.666666666667
"CD003414","CD003414_pub4_data","2|7|Endometrial thickness|Modified natural cycle FET versus HT FET","Endometrial thickness",2,7,"Modified natural cycle FET versus HT FET","or","binary",3,0.21048094973565,1.15821152523681,0,2017.66666666667,0,425.333333333333
"CD003414","CD003414_pub4_data","3|1|Live birth rate per woman|HT FET versus HT + GnRHa","Live birth rate per woman",3,1,"HT FET versus HT + GnRHa","or","binary",5,-0.114876695542593,0.166236760510463,0.0437164544864927,2017.2,0.339358734046724,226.4
"CD003414","CD003414_pub4_data","3|2|Miscarriage rate per woman|HT FET versus HT + GnRHa","Miscarriage rate per woman",3,2,"HT FET versus HT + GnRHa","or","binary",11,-0.0975641086677837,0.185215859009089,2.18764894642075e-06,2012.09090909091,0.0680719806037447,185.090909090909
"CD003414","CD003414_pub4_data","3|3|Ongoing pregnancy rate per woman|HT FET versus HT + GnRHa","Ongoing pregnancy rate per woman",3,3,"HT FET versus HT + GnRHa","or","binary",4,-0.0567490074225163,0.1957775796769,0,2013.25,0.189864597952076,160
"CD003414","CD003414_pub4_data","3|4|Clinical pregnancy rate per woman|HT FET versus HT + GnRHa","Clinical pregnancy rate per woman",3,4,"HT FET versus HT + GnRHa","or","binary",12,-0.0498935399492381,0.100217871339762,0,2013.66666666667,0.292295961254861,177.666666666667
"CD003414","CD003414_pub4_data","3|5|Multiple pregnancy rate per woman|HT FET versus HT + GnRHa","Multiple pregnancy rate per woman",3,5,"HT FET versus HT + GnRHa","or","binary",2,-0.254936177375006,0.609971786729156,0.451802827317659,2020,0.0843330667377588,211
"CD003414","CD003414_pub4_data","3|6|Cycle cancellation rate per woman|HT FET versus HT + GnRHa","Cycle cancellation rate per woman",3,6,"HT FET versus HT + GnRHa","or","binary",4,0.25586389845092,0.45991669839425,0.175170374210228,2006.25,0.0186428050198359,244.75
"CD003414","CD003414_pub4_data","3|7|Endometrial thickness|HT FET versus HT + GnRHa","Endometrial thickness",3,7,"HT FET versus HT + GnRHa","or","binary",5,0.0935677732217843,0.8972582859189,0,2008.2,0,191.8
"CD003429","CD003429_pub5_data","1|1|Annualized joint bleeding rates|","Annualized joint bleeding rates",1,1,"","reported","reported",3,0,0.533373530465918,0,2011.33333333333,0,42
"CD003429","CD003429_pub5_data","1|10|Adverse events|Development of inhibitors","Adverse events",1,10,"Development of inhibitors","or","binary",2,0.628646847388002,0.775937023701486,0,2009,0.0526315789473684,52.5
"CD003429","CD003429_pub5_data","1|10|Adverse events|Infections","Adverse events",1,10,"Infections","reported","reported",2,0,0.588582568736725,0,2009,0.0909090909090909,52.5
"CD003429","CD003429_pub5_data","1|2|Joint function protection (number of participants with no joint damage)|","Joint function protection (number of participants with no joint damage)",1,2,"","or","binary",2,1.72488410646784,0.558352631282543,0,2009,0.538986354775828,47.5
"CD003429","CD003429_pub5_data","1|3|Sensitivity analysis (fixed-effect model): joint function protection (number of participants with no joint damage)|","Sensitivity analysis (fixed-effect model): joint function protection (number of participants with no joint damage)",1,3,"","or","binary",2,1.72488410646784,0.558352631282543,0,2009,0.538986354775828,47.5
"CD003429","CD003429_pub5_data","1|6|Radiologic joint score (Pettersson score)|","Radiologic joint score (Pettersson score)",1,6,"","or","binary",2,-0.0943391018919422,1.43867369186459,0,2013.5,0,30.5
"CD003429","CD003429_pub5_data","1|7|Clotting factor concentrate usage |Factor concentrate usage (× 1000 IU/month) ","Clotting factor concentrate usage ",1,7,"Factor concentrate usage (× 1000 IU/month) ","reported","reported",3,0,0.235892206526263,0,2011.33333333333,0,42
"CD003429","CD003429_pub5_data","1|7|Clotting factor concentrate usage |Factor concentrate usage [× 1000 IU/month] – standard prophylaxis dose","Clotting factor concentrate usage ",1,7,"Factor concentrate usage [× 1000 IU/month] – standard prophylaxis dose","reported","reported",2,0,0.533578185861912,0,2009,0,52.5
"CD003429","CD003429_pub5_data","1|8|Sensitivity analysis (fixed-effect model): clotting factor concentrate usage |Factor concentrate usage [× 1000 IU/month] ","Sensitivity analysis (fixed-effect model): clotting factor concentrate usage ",1,8,"Factor concentrate usage [× 1000 IU/month] ","reported","reported",3,0,0.235892206526263,0,2011.33333333333,0,42
"CD003429","CD003429_pub5_data","1|8|Sensitivity analysis (fixed-effect model): clotting factor concentrate usage |Factor concentrate usage [× 1000 IU/month] – standard prophylaxis dose","Sensitivity analysis (fixed-effect model): clotting factor concentrate usage ",1,8,"Factor concentrate usage [× 1000 IU/month] – standard prophylaxis dose","reported","reported",2,0,0.533578185861912,0,2009,0,52.5
"CD003429","CD003429_pub5_data","1|9|Number of clotting factor infusions (per participant per month)|","Number of clotting factor infusions (per participant per month)",1,9,"","reported","reported",2,0,5.17826767163616,0,2011.5,0,43
"CD003451","CD003451_pub3_data","1|1|Overjet|Facemask","Overjet",1,1,"Facemask","or","binary",2,-0.252299303174501,1.43505377893291,0,2016.5,0,46
"CD003451","CD003451_pub3_data","1|2|ANB|Chin cup","ANB",1,2,"Chin cup","reported","reported",2,0,0.193775695876437,0,2010,0,25
"CD003451","CD003451_pub3_data","1|2|ANB|Facemask","ANB",1,2,"Facemask","or","binary",5,-0.192383785290531,0.909118100424518,0,2011.6,0,36.8
"CD003451","CD003451_pub3_data","1|3|Wits|Chin cup","Wits",1,3,"Chin cup","or","binary",2,-1.31567679390594,1.45440686701195,0,2010,0,25
"CD003451","CD003451_pub3_data","1|3|Wits|Facemask","Wits",1,3,"Facemask","reported","reported",2,0,0.374149411864327,0,2012,0,32.5
"CD003451","CD003451_pub3_data","7|2|ANB|","ANB",7,2,"","or","binary",2,-0.00202011393603668,1.43688859818454,0,2007,0,30
"CD003451","CD003451_pub3_data","7|3|Wits|","Wits",7,3,"","or","binary",2,-0.00202011393603668,1.43688859818454,0,2007,0,30
"CD003451","CD003451_pub3_data","8|1|ANB|","ANB",8,1,"","or","binary",4,-0.0172237025004276,1.01578241909603,0,2013.75,0,32.75
"CD003451","CD003451_pub3_data","8|2|Wits|","Wits",8,2,"","or","binary",3,-0.0229890937992282,1.17354125174935,0,2013.33333333333,0,32.3333333333333
"CD003477","CD003477_pub5_data","1|1|Emotional well-being including quality of life|","Emotional well-being including quality of life",1,1,"","reported","reported",4,0,0.171706312333891,0,2016.25,0,38.5
"CD003477","CD003477_pub5_data","1|2|Mood disturbance or negative affect: depression|","Mood disturbance or negative affect: depression",1,2,"","reported","reported",9,0,0.0982531894198977,0,2013.88888888889,0,49
"CD003477","CD003477_pub5_data","1|3|Mood disturbance or negative affect: anxiety|","Mood disturbance or negative affect: anxiety",1,3,"","reported","reported",7,0,0.121519649344808,0,2012,0,40.2857142857143
"CD003477","CD003477_pub5_data","1|4|Behaviour problems: agitation or aggression|","Behaviour problems: agitation or aggression",1,4,"","reported","reported",11,0,0.0906456637047069,0,2010.72727272727,0,45.7272727272727
"CD003477","CD003477_pub5_data","1|5|Behaviour problems: overall|","Behaviour problems: overall",1,5,"","reported","reported",10,0,0.107180682375895,0,2014.4,0,38.5
"CD003477","CD003477_pub5_data","1|7|Cognition|","Cognition",1,7,"","reported","reported",7,0,0.10792708207257,0,2014.85714285714,0,50.4285714285714
"CD003477","CD003477_pub5_data","2|1|Emotional well-being including quality of life|","Emotional well-being including quality of life",2,1,"","reported","reported",3,0,0.235390905153973,0,2017.33333333333,0,28.6666666666667
"CD003477","CD003477_pub5_data","2|2|Mood disturbance or negative affect: depression|","Mood disturbance or negative affect: depression",2,2,"","reported","reported",5,0,0.12449495848427,0,2012.8,0,55.2
"CD003477","CD003477_pub5_data","2|3|Mood disturbance or negative affect: anxiety|","Mood disturbance or negative affect: anxiety",2,3,"","reported","reported",3,0,0.173007171122363,0,2010.33333333333,0,47
"CD003477","CD003477_pub5_data","2|4|Behavioural problems: agitation or aggression|","Behavioural problems: agitation or aggression",2,4,"","reported","reported",4,0,0.130834984228489,0,2010.5,0,60.25
"CD003477","CD003477_pub5_data","2|5|Behavioural problems: overall|","Behavioural problems: overall",2,5,"","reported","reported",6,0,0.135555835955947,0,2013.66666666667,0,40.8333333333333
"CD003477","CD003477_pub5_data","2|6|Cognition|","Cognition",2,6,"","reported","reported",2,0,0.168151466107078,0,2012.5,0,73
"CD003477","CD003477_pub5_data","3|1|Emotional well-being including quality of life|","Emotional well-being including quality of life",3,1,"","reported","reported",10,0,0.120938740492518,0,2015.1,0,29.8
"CD003477","CD003477_pub5_data","3|2|Mood disturbance or negative affect: depression|","Mood disturbance or negative affect: depression",3,2,"","reported","reported",10,0,0.108703033149493,0,2015.8,0,35.9
"CD003477","CD003477_pub5_data","3|3|Mood disturbance or negative affect: anxiety|","Mood disturbance or negative affect: anxiety",3,3,"","reported","reported",10,0,0.128783493935053,0,2013.5,0,29.1
"CD003477","CD003477_pub5_data","3|4|Behaviour problems: agitation or aggression|","Behaviour problems: agitation or aggression",3,4,"","reported","reported",6,0,0.159516440784277,0,2013.5,0,28
"CD003477","CD003477_pub5_data","3|5|Behaviour problems: overall|","Behaviour problems: overall",3,5,"","reported","reported",8,0,0.125113440773129,0,2016,0,36.5
"CD003477","CD003477_pub5_data","3|6|Social behaviour|","Social behaviour",3,6,"","reported","reported",4,0,0.215402701821669,0,2014.25,0,21
"CD003477","CD003477_pub5_data","3|7|Cognition|","Cognition",3,7,"","reported","reported",5,0,0.166347428680157,0,2014.6,0,29.4
"CD003477","CD003477_pub5_data","4|1|Emotional well-being including quality of life|","Emotional well-being including quality of life",4,1,"","reported","reported",4,0,0.18683649799909,0,2015.75,0,32.5
"CD003477","CD003477_pub5_data","4|2|Mood disturbance or negative affect: depression|","Mood disturbance or negative affect: depression",4,2,"","reported","reported",4,0,0.163926125850649,0,2015,0,43.5
"CD003477","CD003477_pub5_data","4|3|Mood disturbance or negative affect: anxiety|","Mood disturbance or negative affect: anxiety",4,3,"","reported","reported",4,0,0.191202830048991,0,2012.5,0,31
"CD003477","CD003477_pub5_data","4|4|Behavioural problems: agitation or aggression|","Behavioural problems: agitation or aggression",4,4,"","reported","reported",2,0,0.220385049239229,0,2014.5,0,44.5
"CD003477","CD003477_pub5_data","4|5|Behavioural problems: overall|","Behavioural problems: overall",4,5,"","reported","reported",4,0,0.15506775699036,0,2016.25,0,49.25
"CD003477","CD003477_pub5_data","4|6|Social behaviour|","Social behaviour",4,6,"","reported","reported",2,0,0.297410751099022,0,2013,0,24
"CD003477","CD003477_pub5_data","5|1|Music-based therapeutic interventions versus usual care for behaviour problems: agitation or aggression at end of treatment; subgroup analysis: individual therapy versus group therapy|Group therapy","Music-based therapeutic interventions versus usual care for behaviour problems: agitation or aggression at end of treatment; subgroup analysis: individual therapy versus group therapy",5,1,"Group therapy","or","binary",6,-0.0379550567950683,0.826087356957459,0,2011.5,0,51.3333333333333
"CD003477","CD003477_pub5_data","5|1|Music-based therapeutic interventions versus usual care for behaviour problems: agitation or aggression at end of treatment; subgroup analysis: individual therapy versus group therapy|Individual therapy","Music-based therapeutic interventions versus usual care for behaviour problems: agitation or aggression at end of treatment; subgroup analysis: individual therapy versus group therapy",5,1,"Individual therapy","reported","reported",5,0,0.147876192965925,0,2009.8,0,39
"CD003511","CD003511_pub6_data","1|1|Miscarriage (all trials)|New Subgroup","Miscarriage (all trials)",1,1,"New Subgroup","reported","reported",8,0,0.0867837306523421,0,1975.25,0.283301266082805,159.5
"CD003511","CD003511_pub6_data","1|2|Miscarriage (placebo-controlled trials only)|Trials with placebo control group","Miscarriage (placebo-controlled trials only)",1,2,"Trials with placebo control group","or","binary",6,-0.0582500255631668,0.134593242302122,0,1974,0.288243407187975,172.166666666667
"CD003511","CD003511_pub6_data","1|2|Miscarriage (placebo-controlled trials only)|Trials without placebo controls","Miscarriage (placebo-controlled trials only)",1,2,"Trials without placebo controls","or","binary",2,-0.665982491352071,0.318078385765208,0,1979,0.268474842767296,121.5
"CD003511","CD003511_pub6_data","1|3|Miscarriage (women with previous recurrent miscarriage only)|Women with a history of 2 or more prior miscarriages","Miscarriage (women with previous recurrent miscarriage only)",1,3,"Women with a history of 2 or more prior miscarriages","or","binary",5,-0.0392523848071674,0.28043932162915,0,1963.4,0.221459595825946,58
"CD003511","CD003511_pub6_data","1|3|Miscarriage (women with previous recurrent miscarriage only)|Women with a history of 3 or more prior miscarriages","Miscarriage (women with previous recurrent miscarriage only)",1,3,"Women with a history of 3 or more prior miscarriages","or","binary",3,-0.510563398205343,0.371758732992328,0.245249492417213,1995,0.386370716510903,328.666666666667
"CD003511","CD003511_pub6_data","1|4|Miscarriage (by route of administration versus placebo)|Intramuscular versus placebo/control","Miscarriage (by route of administration versus placebo)",1,4,"Intramuscular versus placebo/control","or","binary",2,-0.587988852658664,0.503213370744707,0,1963.5,0.37536231884058,40
"CD003511","CD003511_pub6_data","1|4|Miscarriage (by route of administration versus placebo)|Oral versus placebo/control","Miscarriage (by route of administration versus placebo)",1,4,"Oral versus placebo/control","or","binary",4,-0.173499353873812,0.403834649331534,0.243395987596367,1976.5,0.234072580645161,64.25
"CD003511","CD003511_pub6_data","1|5|Live birth rate|","Live birth rate",1,5,"","or","binary",5,0.131155644161336,0.131652019690574,0,1973.8,0.708654179062311,212.6
"CD003511","CD003511_pub6_data","1|6|Preterm birth|","Preterm birth",1,6,"","or","binary",4,0.101210672470427,0.459916238275782,0,1971.5,0.145067065287654,64
"CD003511","CD003511_pub6_data","1|7|Neonatal death|","Neonatal death",1,7,"","or","binary",3,0.343945905292805,0.780193006002946,0,1991.33333333333,0.00980392156862745,241.333333333333
"CD003511","CD003511_pub6_data","1|8|Fetal genital abnormalities/virilization|","Fetal genital abnormalities/virilization",1,8,"","or","binary",3,-0.206441000427462,0.901612483105625,0,1995,0.00120772946859903,221.666666666667
"CD003511","CD003511_pub6_data","1|9|Stillbirth|","Stillbirth",1,9,"","or","binary",2,-0.405737417187269,0.921196739577542,0,1984.5,0.00350877192982456,322
"CD003519","CD003519_pub5_data","1|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|","Exclusive breastfeeding at hospital discharge to 1 month post birth",1,1,"","reported","reported",12,1.26100055022097,0.0464522210959235,7.73472941154153e-06,2012.58333333333,0.5206389249296,129.666666666667
"CD003519","CD003519_pub5_data","1|10|Placental separation time/duration of the third stage of labor - Gunduz 2023 sensitivity analysis|","Placental separation time/duration of the third stage of labor - Gunduz 2023 sensitivity analysis",1,10,"","reported","reported",3,-0.90469478052822,0.453274593802778,0,2015.33333333333,NA,122
"CD003519","CD003519_pub5_data","1|11|Maternal postpartum blood loss (mL) - vaginal delivery&nbsp;|","Maternal postpartum blood loss (mL) - vaginal delivery&nbsp;",1,11,"","reported","reported",2,-145.924439543508,138.285455325958,37251.3905854622,2021,NA,71.5
"CD003519","CD003519_pub5_data","1|12|Breastfeeding 1 month to 4 months post birth|","Breastfeeding 1 month to 4 months post birth",1,12,"","reported","reported",14,1.15641704575399,0.085764272277851,0.0258290011700204,1992.57142857143,0.487828839090815,63.3571428571429
"CD003519","CD003519_pub5_data","1|13|Breastfeeding 1 month to 4 months post birth - Sosa 1976a sensitivity analysis|","Breastfeeding 1 month to 4 months post birth - Sosa 1976a sensitivity analysis",1,13,"","reported","reported",13,1.22157315840509,0.0632629155523319,0,1993.84615384615,0.456123365174723,63.6153846153846
"CD003519","CD003519_pub5_data","1|14|Duration of breastfeeding in days|","Duration of breastfeeding in days",1,14,"","reported","reported",7,42.4860160379729,24.1668911494817,2710.75309565145,1986,NA,46.2857142857143
"CD003519","CD003519_pub5_data","1|15|Duration of breastfeeding in days - Sosa 1976a sensitivity analysis|","Duration of breastfeeding in days - Sosa 1976a sensitivity analysis",1,15,"","reported","reported",6,63.7282979766411,13.1491048481221,0,1987.66666666667,NA,44
"CD003519","CD003519_pub5_data","1|16|Breastfeeding status one month post birth|","Breastfeeding status one month post birth",1,16,"","reported","reported",3,0.847549694112328,0.71888134443607,1.29070465187532,2001,NA,81.6666666666667
"CD003519","CD003519_pub5_data","1|17|Success of the first breastfeeding (IBFAT or LATCH score)|","Success of the first breastfeeding (IBFAT or LATCH score)",1,17,"","reported","reported",6,0.794098414315858,0.294530863847224,0.443813851565594,2014.5,NA,96.6666666666667
"CD003519","CD003519_pub5_data","1|18|Successful first breastfeeding (IBFAT score 10-12 or BAT score 8-12 or not specified)|","Successful first breastfeeding (IBFAT score 10-12 or BAT score 8-12 or not specified)",1,18,"","reported","reported",8,1.44739230223057,0.158427940740955,0.107736450673134,2012.375,0.516879370629371,103.125
"CD003519","CD003519_pub5_data","1|19|Time postbirth of first breastfeeding initiation|","Time postbirth of first breastfeeding initiation",1,19,"","reported","reported",2,-48.0639999524251,3.75523421030093,14.971041631249,2017.5,NA,102
"CD003519","CD003519_pub5_data","1|2|Exclusive breastfeeding at hospital discharge to 1 month post birth - Marin 2010 sensitivity analysis|","Exclusive breastfeeding at hospital discharge to 1 month post birth - Marin 2010 sensitivity analysis",1,2,"","reported","reported",11,1.28122985235307,0.0549858143057123,2.73342634654257e-07,2012.81818181818,0.504333372650472,119.818181818182
"CD003519","CD003519_pub5_data","1|20|Infant transferred to the neonatal intensive care unit|","Infant transferred to the neonatal intensive care unit",1,20,"","reported","reported",4,0.33134929711372,0.18168535683921,0,2014,0.0569433485606131,208.25
"CD003519","CD003519_pub5_data","1|21|Infant transferred to the neonatal intensive care unit - Marin 2010 sensitivity analysis|","Infant transferred to the neonatal intensive care unit - Marin 2010 sensitivity analysis",1,21,"","reported","reported",3,0.243555399003689,0.258799501650944,0,2015.33333333333,0.0467273844555133,186.333333333333
"CD003519","CD003519_pub5_data","1|22|Infant body weight change (grams) day 14 post birth|","Infant body weight change (grams) day 14 post birth",1,22,"","reported","reported",2,-7.99627619592919,85.5116739579567,0,2002,NA,21.5
"CD003519","CD003519_pub5_data","1|23|Maternal pain during to 2-hours post-episiotomy or perineal laceration repair|","Maternal pain during to 2-hours post-episiotomy or perineal laceration repair",1,23,"","reported","reported",5,-0.58220237488405,0.244671179004743,0.217600278948782,2018,NA,152.2
"CD003519","CD003519_pub5_data","1|24|Maternal state anxiety 2 hours to 3 days post birth|","Maternal state anxiety 2 hours to 3 days post birth",1,24,"","reported","reported",4,-0.495734016183519,0.178212249355477,0.0812329133948321,2006.66666666667,NA,122.5
"CD003519","CD003519_pub5_data","1|25|Mother's most certain preference for same postdelivery care in the future|","Mother's most certain preference for same postdelivery care in the future",1,25,"","reported","reported",3,5.21887448501439,2.68206369586002,10.8319848883216,2009,0.151307189542484,146.333333333333
"CD003519","CD003519_pub5_data","1|3|Exclusive breastfeeding at hospital discharge to 1 month post birth - Perez-Jimenez 2023 sensitivity analysis|","Exclusive breastfeeding at hospital discharge to 1 month post birth - Perez-Jimenez 2023 sensitivity analysis",1,3,"","reported","reported",11,1.2598995958501,0.0464468254172891,3.11308800513031e-06,2011.63636363636,0.5566060999232,134.181818181818
"CD003519","CD003519_pub5_data","1|4|Exclusive breastfeeding 6 weeks to 6 months post birth|","Exclusive breastfeeding 6 weeks to 6 months post birth",1,4,"","reported","reported",11,1.22214176378698,0.0850826116655968,0.0259847670010312,2010.44444444444,0.466058324388716,103.181818181818
"CD003519","CD003519_pub5_data","1|5|Exclusive breastfeeding 6 weeks to 6 months post birth &nbsp;- Mulupuru 2019 sensitivity analysis|","Exclusive breastfeeding 6 weeks to 6 months post birth &nbsp;- Mulupuru 2019 sensitivity analysis",1,5,"","reported","reported",10,1.27383737495355,0.0688250097093535,0.00320233481932403,2010.44444444444,0.416874683143377,94.3
"CD003519","CD003519_pub5_data","1|6|Infant axillary temperature 30 minutes to 2.5 hours post birth|","Infant axillary temperature 30 minutes to 2.5 hours post birth",1,6,"","reported","reported",11,0.278645851287078,0.0734049957360859,0.050305331433889,2006.4,NA,122.636363636364
"CD003519","CD003519_pub5_data","1|7|Blood glucose mg/dL at 75-180 minutes post birth|","Blood glucose mg/dL at 75-180 minutes post birth",1,7,"","reported","reported",3,10.4898122161232,1.06947861288709,0,2002.33333333333,NA,48
"CD003519","CD003519_pub5_data","1|8|SCRIP score first 6 hours post birth|","SCRIP score first 6 hours post birth",1,8,"","reported","reported",2,1.24116268150115,0.24643849692545,0,2010,NA,40.5
"CD003519","CD003519_pub5_data","1|9|Placental separation time/duration of the third stage of labor&nbsp;|","Placental separation time/duration of the third stage of labor&nbsp;",1,9,"","reported","reported",4,-2.26276455175618,1.47583965343415,7.37445881569694,2017.25,NA,112.5
"CD003519","CD003519_pub5_data","2|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|","Exclusive breastfeeding at hospital discharge to 1 month post birth",2,1,"","reported","reported",5,1.22949268197917,0.0846576648650415,2.52001059504714e-06,2018.8,0.422748950330278,144.4
"CD003519","CD003519_pub5_data","2|2|Exclusive breastfeeding 6 weeks to 6 months post birth|","Exclusive breastfeeding 6 weeks to 6 months post birth",2,2,"","reported","reported",2,1.1195440883275,0.108906289863359,0,2011,0.522058823529412,72
"CD003519","CD003519_pub5_data","2|3|Breastfeeding 1 month to 4 months post birth|","Breastfeeding 1 month to 4 months post birth",2,3,"","reported","reported",2,1.20235224851915,0.0990302179167772,0,2012,0.610752688172043,110
"CD003519","CD003519_pub5_data","2|4|Success of the first breastfeeding (IBFAT score)|","Success of the first breastfeeding (IBFAT score)",2,4,"","reported","reported",2,1.36714750639515,0.637674395412952,0,2012,NA,62
"CD003519","CD003519_pub5_data","2|5|Infant transferred to the neonatal intensive care unit|","Infant transferred to the neonatal intensive care unit",2,5,"","reported","reported",2,0.237347448784176,0.259467566714366,0,2021,0.0316295382217315,264
"CD003519","CD003519_pub5_data","2|6|Maternal pain post cesarean birth - at arrival to recovery to 4 hours post-op|","Maternal pain post cesarean birth - at arrival to recovery to 4 hours post-op",2,6,"","reported","reported",2,-3.10817413572705,1.68444679168094,5.30929945014252,2016,NA,57.5
"CD003519","CD003519_pub5_data","2|7|Maternal plasma hemoglobin 2 to 3-days postbirth|","Maternal plasma hemoglobin 2 to 3-days postbirth",2,7,"","reported","reported",2,0.155191965248647,0.375896551799874,0.236609136566925,2021,NA,135.5
"CD003519","CD003519_pub5_data","3|1|Exclusive breastfeeding at hospital discharge to 1 month postbirth|Early contact (10 minutes to 24 hours post birth)","Exclusive breastfeeding at hospital discharge to 1 month postbirth",3,1,"Early contact (10 minutes to 24 hours post birth)","reported","reported",4,1.26343709770655,0.0854102164188461,1.77068325077008e-06,2016.5,0.468475822532403,108.5
"CD003519","CD003519_pub5_data","3|1|Exclusive breastfeeding at hospital discharge to 1 month postbirth|Immediate contact (less than 10 minutes post birth)","Exclusive breastfeeding at hospital discharge to 1 month postbirth",3,1,"Immediate contact (less than 10 minutes post birth)","reported","reported",8,1.25996171502535,0.0553303228827863,1.62935134132331e-07,2010.625,0.546720476128198,140.25
"CD003519","CD003519_pub5_data","3|2|Exclusive breastfeeding 6 weeks to 6 months post birth|Early contact (10 minutes to 24 hours post birth)","Exclusive breastfeeding 6 weeks to 6 months post birth",3,2,"Early contact (10 minutes to 24 hours post birth)","reported","reported",6,1.29372226625588,0.0968973937202335,0.0128163166572965,2012.5,0.481768050549207,109
"CD003519","CD003519_pub5_data","3|2|Exclusive breastfeeding 6 weeks to 6 months post birth|Immediate contact (less than 10 minutes post birth)","Exclusive breastfeeding 6 weeks to 6 months post birth",3,2,"Immediate contact (less than 10 minutes post birth)","reported","reported",5,1.11175638183282,0.126638791210973,0.026040088871919,2006.66666666667,0.447206652996127,96.2
"CD003519","CD003519_pub5_data","3|3|Breastfeeding 1 month to 4 months post birth|Early contact (10 minutes to 24 hours post birth)","Breastfeeding 1 month to 4 months post birth",3,3,"Early contact (10 minutes to 24 hours post birth)","reported","reported",9,1.25972812510749,0.158391153465968,0.0761256368583196,1987.88888888889,0.465979184071289,47.2222222222222
"CD003519","CD003519_pub5_data","3|3|Breastfeeding 1 month to 4 months post birth|Immediate contact (less than 10 minutes post birth)","Breastfeeding 1 month to 4 months post birth",3,3,"Immediate contact (less than 10 minutes post birth)","reported","reported",6,1.18814005154704,0.0698921081725884,0,2002.66666666667,0.548751251423375,99.5
"CD003519","CD003519_pub5_data","3|4|Duration of breastfeeding in days|Early contact (10 minutes to 24 hours post birth)","Duration of breastfeeding in days",3,4,"Early contact (10 minutes to 24 hours post birth)","reported","reported",5,65.9957955799286,15.4462734381537,0,1984.4,NA,41.2
"CD003519","CD003519_pub5_data","3|5|Infant axillary temperature 30 minutes to 2.5 hours post birth|Early contact (10 minutes to 24 hours post birth)","Infant axillary temperature 30 minutes to 2.5 hours post birth",3,5,"Early contact (10 minutes to 24 hours post birth)","reported","reported",3,0.102298025518626,0.186582417469491,0.0894205278768037,2010.33333333333,NA,142.666666666667
"CD003519","CD003519_pub5_data","3|5|Infant axillary temperature 30 minutes to 2.5 hours post birth|Immediate contact (less than 10 minutes post birth)","Infant axillary temperature 30 minutes to 2.5 hours post birth",3,5,"Immediate contact (less than 10 minutes post birth)","reported","reported",8,0.277372556992859,0.0997461259805345,0.071346687316684,2004.71428571429,NA,109.625
"CD003519","CD003519_pub5_data","4|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|High dose (more than 60 minutes)","Exclusive breastfeeding at hospital discharge to 1 month post birth",4,1,"High dose (more than 60 minutes)","reported","reported",9,1.24799926890747,0.0505187561943044,6.31599893480428e-06,2011.33333333333,0.530944321692333,127.777777777778
"CD003519","CD003519_pub5_data","4|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|Low dose (60 minutes or less)","Exclusive breastfeeding at hospital discharge to 1 month post birth",4,1,"Low dose (60 minutes or less)","reported","reported",3,1.33207716926282,0.118116970890668,0,2016.33333333333,0.4897227346414,135.333333333333
"CD003519","CD003519_pub5_data","4|2|Exclusive breastfeeding 6 weeks to 6 months postbirth|High dose (more than 60 minutes)","Exclusive breastfeeding 6 weeks to 6 months postbirth",4,2,"High dose (more than 60 minutes)","reported","reported",7,1.25317229673009,0.0947704500811549,0.00886529188092209,2009.85714285714,0.397441688539823,82
"CD003519","CD003519_pub5_data","4|2|Exclusive breastfeeding 6 weeks to 6 months postbirth|Low dose (60 minutes or less)","Exclusive breastfeeding 6 weeks to 6 months postbirth",4,2,"Low dose (60 minutes or less)","reported","reported",3,1.28482249521759,0.240129124189939,0.131954958905853,2005,0.636217437533227,161
"CD003519","CD003519_pub5_data","4|3|Breastfeeding 1 month to 4 months post birth|High dose (more than 60 minutes)","Breastfeeding 1 month to 4 months post birth",4,3,"High dose (more than 60 minutes)","reported","reported",5,1.21371235654032,0.0966944038668557,0,2003,0.440015360983103,59.6
"CD003519","CD003519_pub5_data","4|3|Breastfeeding 1 month to 4 months post birth|Low dose (60 minutes or less)","Breastfeeding 1 month to 4 months post birth",4,3,"Low dose (60 minutes or less)","reported","reported",10,1.15773266873878,0.0964011112313725,0.0323993628697812,1989.2,0.528624336026634,72.4
"CD003519","CD003519_pub5_data","4|4|Duration of breastfeeding in days|High dose (more than 60 minutes)","Duration of breastfeeding in days",4,4,"High dose (more than 60 minutes)","reported","reported",3,62.2530071121989,17.2121363531632,0,1999,NA,38.6666666666667
"CD003519","CD003519_pub5_data","4|4|Duration of breastfeeding in days|Low dose (60 minutes or less)","Duration of breastfeeding in days",4,4,"Low dose (60 minutes or less)","reported","reported",3,65.7960588721651,20.3772751777142,0,1976.33333333333,NA,49.3333333333333
"CD003519","CD003519_pub5_data","4|5|Infant axillary temperature 30 minutes to 2.5 hours post birth|High dose (more than 60 minutes)","Infant axillary temperature 30 minutes to 2.5 hours post birth",4,5,"High dose (more than 60 minutes)","reported","reported",8,0.357027284339577,0.0891809105446785,0.0523347942178767,2005.125,NA,93.75
"CD003519","CD003519_pub5_data","4|5|Infant axillary temperature 30 minutes to 2.5 hours post birth|Low dose (equal to or less than 60 minutes)","Infant axillary temperature 30 minutes to 2.5 hours post birth",4,5,"Low dose (equal to or less than 60 minutes)","reported","reported",3,0.0875044006698586,0.064831836200891,0.009475344333988,2011.5,NA,199.666666666667
"CD003519","CD003519_pub5_data","5|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|","Exclusive breastfeeding at hospital discharge to 1 month post birth",5,1,"","reported","reported",3,1.0110803693021,0.024861963019224,7.77774196710002e-07,2018.66666666667,0.833706485982226,232.333333333333
"CD003519","CD003519_pub5_data","5|2|Exclusive breastfeeding 6 weeks to 6 months post birth|","Exclusive breastfeeding 6 weeks to 6 months post birth",5,2,"","reported","reported",2,1.12632329610076,0.107020072030405,0,2018.5,0.359630405791579,322
"CD003519","CD003519_pub5_data","5|3|Number of infants transferred to the NICU|","Number of infants transferred to the NICU",5,3,"","reported","reported",2,0.845916817438435,0.79613248081459,0,2018.5,0.0683874948580831,208
"CD003519","CD003519_pub5_data","6|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|","Exclusive breastfeeding at hospital discharge to 1 month post birth",6,1,"","reported","reported",2,1.21055294405438,0.20522273227205,0.0697018261929693,2023.5,0.606376262626263,269
"CD003519","CD003519_pub5_data","7|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|World Bank country income classification (low or low middle)","Exclusive breastfeeding at hospital discharge to 1 month post birth",7,1,"World Bank country income classification (low or low middle)","reported","reported",3,1.33182080184353,0.0826921601278719,5.90407449902389e-07,2012.33333333333,0.544177819538305,138.666666666667
"CD003519","CD003519_pub5_data","7|1|Exclusive breastfeeding at hospital discharge to 1 month post birth|World Bank country income classification (upper middle or high)","Exclusive breastfeeding at hospital discharge to 1 month post birth",7,1,"World Bank country income classification (upper middle or high)","reported","reported",9,1.22836493948135,0.0561244783422159,1.33806791616754e-06,2012.66666666667,0.512792626726698,126.666666666667
"CD003519","CD003519_pub5_data","7|2|Exclusive breastfeeding 6 weeks to 6 months post birth|World Bank country income classification (low or low middle)","Exclusive breastfeeding 6 weeks to 6 months post birth",7,2,"World Bank country income classification (low or low middle)","reported","reported",6,1.27544698670627,0.123773332909004,0.047285525176093,2011.25,0.538326636442158,144
"CD003519","CD003519_pub5_data","7|2|Exclusive breastfeeding 6 weeks to 6 months post birth|World Bank country income classification (upper middle or high)","Exclusive breastfeeding 6 weeks to 6 months post birth",7,2,"World Bank country income classification (upper middle or high)","reported","reported",5,1.14870681554267,0.102222482505535,0,2009.8,0.379336349924585,53.8
"CD003519","CD003519_pub5_data","7|3|Infant axillary temperature 30 minutes to 2.5 hours post birth|World Bank country income classification (low or low middle)","Infant axillary temperature 30 minutes to 2.5 hours post birth",7,3,"World Bank country income classification (low or low middle)","reported","reported",6,0.208004040385446,0.0830309947259,0.0368977783795741,2015.2,NA,142
"CD003519","CD003519_pub5_data","7|3|Infant axillary temperature 30 minutes to 2.5 hours post birth|World Bank country income classification (upper middle or high)","Infant axillary temperature 30 minutes to 2.5 hours post birth",7,3,"World Bank country income classification (upper middle or high)","reported","reported",5,0.249622227329031,0.113709521056991,0.0493685960045461,1997.6,NA,99.4
"CD003594","CD003594_pub7_data","1|1|Complete remission|All renal pathologies","Complete remission",1,1,"All renal pathologies","or","binary",4,1.41957114887267,0.660087141759014,0,1994.75,0.0416666666666667,18.5
"CD003594","CD003594_pub7_data","1|1|Complete remission|FSGS","Complete remission",1,1,"FSGS","or","binary",3,1.41670122274489,0.708767698537065,0,1997,0.0555555555555556,19.3333333333333
"CD003594","CD003594_pub7_data","1|2|Complete or partial remission|All renal pathologies","Complete or partial remission",1,2,"All renal pathologies","or","binary",4,2.30156417315318,0.831445013426667,0.751400231503178,1994.75,0.166666666666667,18.5
"CD003594","CD003594_pub7_data","1|2|Complete or partial remission|FSGS","Complete or partial remission",1,2,"FSGS","or","binary",2,2.80537854930696,1.53783348286841,3.20694840022897,1999,0.333333333333333,24.5
"CD003594","CD003594_pub7_data","2|1|Treatment response at 3 to 6 months|Complete or partial remission","Treatment response at 3 to 6 months",2,1,"Complete or partial remission","or","binary",2,1.70641503118205,0.365657215324186,0,2010,0.317743490838959,78
"CD003594","CD003594_pub7_data","2|1|Treatment response at 3 to 6 months|Complete remission","Treatment response at 3 to 6 months",2,1,"Complete remission","or","binary",2,1.65631198654713,0.402211211027737,0,2010,0.103182256509161,78
"CD003594","CD003594_pub7_data","2|1|Treatment response at 3 to 6 months|Partial remission","Treatment response at 3 to 6 months",2,1,"Partial remission","or","binary",2,0.664290631566742,0.857439933559103,1.09112944888403,2010,0.214561234329798,78
"CD003594","CD003594_pub7_data","3|2|Treatment response at 12 months|Complete and partial remission","Treatment response at 12 months",3,2,"Complete and partial remission","or","binary",2,0.511396661023503,0.71746419319949,0,2009.5,0.875,29
"CD003594","CD003594_pub7_data","3|2|Treatment response at 12 months|Complete remission","Treatment response at 12 months",3,2,"Complete remission","or","binary",2,-0.476643232647055,0.534022836363389,0,2009.5,0.475,29
"CD003594","CD003594_pub7_data","3|2|Treatment response at 12 months|Partial remission","Treatment response at 12 months",3,2,"Partial remission","or","binary",2,0.911045964255161,0.582916852271165,0,2009.5,0.4,29
"CD003594","CD003594_pub7_data","3|5|Adverse events|Worsening hypertension","Adverse events",3,5,"Worsening hypertension","or","binary",2,-1.28932524500235,1.31617920525209,2.35637275592972,2009.5,0.45,29
"CD003594","CD003594_pub7_data","8|1|Complete remission|All renal pathologies","Complete remission",8,1,"All renal pathologies","or","binary",2,0.0441947567875453,0.463565041423899,0,1985,0.373626373626374,42
"CD003594","CD003594_pub7_data","8|1|Complete remission|FSGS","Complete remission",8,1,"FSGS","or","binary",2,0.111161475611502,0.690063115318894,0.189800318227442,1985,0.142857142857143,31.5
"CD003594","CD003594_pub7_data","9|1|Complete remission|","Complete remission",9,1,"","or","binary",2,1.50457266109329,1.56599417101308,3.57230320080252,2005.5,0.345,30.5
"CD003594","CD003594_pub7_data","9|5|Adverse events|Bacterial infection","Adverse events",9,5,"Bacterial infection","or","binary",2,-0.034846726309512,1.32387672778778,2.0008666173813,2005.5,0.165,30.5
"CD003594","CD003594_pub7_data","9|5|Adverse events|Vomiting","Adverse events",9,5,"Vomiting","or","binary",2,0.955702667494315,1.19444868892574,0.925109272737606,2005.5,0.02,30.5
"CD003598","CD003598_pub3_data","1|1|All-cause death|","All-cause death",1,1,"","or","binary",23,-0.264594132294805,0.103334992287685,0,1998.91304347826,0.06374101791508,144.652173913043
"CD003598","CD003598_pub3_data","1|10|Any rejection|","Any rejection",1,10,"","or","binary",14,-0.02791621474898,0.182098185073591,0,1998.71428571429,0.287689793260225,65.4285714285714
"CD003598","CD003598_pub3_data","1|11|Acute rejection|","Acute rejection",1,11,"","or","binary",13,0.0858558382730414,0.173066535899144,0,1999.46153846154,0.19362420822042,69.6923076923077
"CD003598","CD003598_pub3_data","1|13|Rejection rate|Proven or suspected","Rejection rate",1,13,"Proven or suspected","reported","reported",4,-0.135518155231754,0.166690043827418,0.0334751959280804,1990.5,0,2
"CD003598","CD003598_pub3_data","1|15|Nonfatal myocardial infarction|","Nonfatal myocardial infarction",1,15,"","or","binary",3,-0.641605993905568,0.811672370996564,0,1995,0.0258882377784817,175.333333333333
"CD003598","CD003598_pub3_data","1|16|Fatal myocardial infarction|","Fatal myocardial infarction",1,16,"","or","binary",2,1.35816965186405,1.16279769291347,0,1998.5,0,110
"CD003598","CD003598_pub3_data","1|17|Thrombosis of the graft arteria|","Thrombosis of the graft arteria",1,17,"","or","binary",2,0.342412529419307,0.806216350597796,0,1994,0.0544117647058824,36.5
"CD003598","CD003598_pub3_data","1|18|Any adverse event|","Any adverse event",1,18,"","reported","reported",2,0,0.0994246235159021,0,2011,0.301190988664084,820
"CD003598","CD003598_pub3_data","1|2|Graft loss|","Graft loss",1,2,"","or","binary",24,-0.256164555232341,0.0908079704569633,0,1997.25,0.146071206675993,149.041666666667
"CD003598","CD003598_pub3_data","1|20|New onset hypertension|","New onset hypertension",1,20,"","or","binary",4,-0.136239488756757,0.249735649164248,0,1993.75,0.464367114367114,68.75
"CD003598","CD003598_pub3_data","1|21|New onset diabetes|","New onset diabetes",1,21,"","or","binary",2,-0.503606517585392,0.748928872606947,0,2013,0.0704545454545455,76.5
"CD003598","CD003598_pub3_data","1|24|Withdrawal due to adverse events|","Withdrawal due to adverse events",1,24,"","or","binary",11,0.275378829913193,0.27172841201986,0,2000.90909090909,0.0417361790088891,99.7272727272727
"CD003598","CD003598_pub3_data","1|28|Withdrawal due to hypotension|","Withdrawal due to hypotension",1,28,"","or","binary",4,0.988990073079225,1.01339840831857,2.30761537673406,2000.75,0.0446428571428571,101
"CD003598","CD003598_pub3_data","1|3|Creatinine clearance [mL/min]|","Creatinine clearance [mL/min]",1,3,"","or","binary",11,-0.0728503886622108,0.607163435991313,0,1998.09090909091,0,229.545454545455
"CD003598","CD003598_pub3_data","1|4|eGFR [mL/min/1.73 m²]|","eGFR [mL/min/1.73 m²]",1,4,"","or","binary",11,-0.110888194526964,0.607820299845997,0,1999.18181818182,0,204.545454545455
"CD003598","CD003598_pub3_data","1|5|Serum creatinine [µmol/L]|","Serum creatinine [µmol/L]",1,5,"","or","binary",19,-0.0844683664959964,0.463355690823223,0,2000.78947368421,0,151.842105263158
"CD003598","CD003598_pub3_data","1|6|Cardiovascular death|","Cardiovascular death",1,6,"","or","binary",16,0.0648647326841098,0.442552005263792,0,1998.25,0.00594919786096257,77.125
"CD003598","CD003598_pub3_data","1|7|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",1,7,"","or","binary",3,-0.082429905846385,1.16641260831066,0,1995.33333333333,0,109.666666666667
"CD003598","CD003598_pub3_data","1|8|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",1,8,"","or","binary",3,-0.082429905846385,1.16641260831066,0,1995.33333333333,0,109.666666666667
"CD003598","CD003598_pub3_data","1|9|Mean arterial pressure [mm Hg]|","Mean arterial pressure [mm Hg]",1,9,"","or","binary",2,-0.0279001002940323,1.42555705869814,0,1996.5,0,143.5
"CD003598","CD003598_pub3_data","10|11|Haemoglobin [g/dL]|","Haemoglobin [g/dL]",10,11,"","or","binary",2,-0.251804701229021,1.43068549867406,0,2004.5,0,67.5
"CD003598","CD003598_pub3_data","10|12|Serum potassium (mmol/L)|","Serum potassium (mmol/L)",10,12,"","or","binary",2,-0.311002382685898,1.43088939615987,0,2004.5,0,64.5
"CD003598","CD003598_pub3_data","10|14|Withdrawal due to adverse events|","Withdrawal due to adverse events",10,14,"","or","binary",3,-1.13263329736479,0.527131170464652,0,2006.66666666667,0.185185185185185,104.666666666667
"CD003598","CD003598_pub3_data","10|2|Serum creatinine [µmol/L]|","Serum creatinine [µmol/L]",10,2,"","or","binary",3,-0.250745737745676,1.16995511301422,0,2003.66666666667,0,53
"CD003598","CD003598_pub3_data","10|6|Mean arterial pressure [mm Hg]|","Mean arterial pressure [mm Hg]",10,6,"","or","binary",2,0.00936042481393223,1.44211192045762,0,2002,0,57.5
"CD003598","CD003598_pub3_data","11|1|Serum creatinine [μmol/L]|","Serum creatinine [μmol/L]",11,1,"","or","binary",2,-0.106138230854481,1.43001682238588,0,2002,0,67.5
"CD003598","CD003598_pub3_data","11|11|Serum potassium [mmol/L]|","Serum potassium [mmol/L]",11,11,"","or","binary",2,-0.106138230854481,1.43001682238588,0,2002,0,67.5
"CD003598","CD003598_pub3_data","11|13|Withdrawal due to adverse events|","Withdrawal due to adverse events",11,13,"","or","binary",2,-0.108379473106882,0.80149516052347,0,2002,0.0833333333333333,72.5
"CD003598","CD003598_pub3_data","11|9|Haemoglobin [g/dL]|","Haemoglobin [g/dL]",11,9,"","or","binary",2,-0.106138230854481,1.43001682238588,0,2002,0,67.5
"CD003598","CD003598_pub3_data","19|1|Creatinine clearance [mL/min]|Dihydropyridine CCB","Creatinine clearance [mL/min]",19,1,"Dihydropyridine CCB","or","binary",6,0.116397830891643,0.822272309263897,0,1996.83333333333,0,114.166666666667
"CD003598","CD003598_pub3_data","19|1|Creatinine clearance [mL/min]|Non-dihydropyridine CCB","Creatinine clearance [mL/min]",19,1,"Non-dihydropyridine CCB","or","binary",5,-0.299742846038979,0.900346733950916,0,1999.6,0,368
"CD003598","CD003598_pub3_data","19|2|eGFR [mL/min/1.73 m²]|Dihydropyridine CCB","eGFR [mL/min/1.73 m²]",19,2,"Dihydropyridine CCB","or","binary",6,0.119712935710904,0.82288978818442,0,1997.66666666667,0,80.8333333333333
"CD003598","CD003598_pub3_data","19|2|eGFR [mL/min/1.73 m²]|Non-dihydropyridine CCB","eGFR [mL/min/1.73 m²]",19,2,"Non-dihydropyridine CCB","or","binary",5,-0.387761694810296,0.90167837210634,0,2001,0,353
"CD003598","CD003598_pub3_data","19|3|Serum creatinine [µmol/L]|Dihydropyridine CCB","Serum creatinine [µmol/L]",19,3,"Dihydropyridine CCB","or","binary",7,-0.000477924470946647,0.762268003049695,0,1996.14285714286,0,104.285714285714
"CD003598","CD003598_pub3_data","19|3|Serum creatinine [µmol/L]|Non-dihydropyridine CCB","Serum creatinine [µmol/L]",19,3,"Non-dihydropyridine CCB","or","binary",13,-0.103275544328204,0.560590792249807,0,2002.53846153846,0,169.846153846154
"CD003598","CD003598_pub3_data","3|1|All-cause death|","All-cause death",3,1,"","or","binary",7,0.0887421668492405,0.347011378657507,0,2000.42857142857,0.034044627025122,100.285714285714
"CD003598","CD003598_pub3_data","3|10|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",3,10,"","or","binary",4,-0.0901690663515942,1.01332229881891,0,1996.5,0,42.5
"CD003598","CD003598_pub3_data","3|11|Mean arterial pressure [mm Hg]|","Mean arterial pressure [mm Hg]",3,11,"","or","binary",5,-0.0292049220928523,0.904203036256745,0,2005,0,51
"CD003598","CD003598_pub3_data","3|13|Any rejection|","Any rejection",3,13,"","or","binary",4,0.407428397549646,0.493342651751771,0.17795219879802,2000.25,0.188492063492063,88.25
"CD003598","CD003598_pub3_data","3|14|Acute rejection|","Acute rejection",3,14,"","or","binary",4,0.511307644788856,0.452207252414752,0.0538618461399705,2006,0.0341141833077317,97
"CD003598","CD003598_pub3_data","3|16|Proteinuria [g/24 hours]|","Proteinuria [g/24 hours]",3,16,"","or","binary",5,-0.0345181593377327,0.902159500659003,0,2008.2,0,88.2
"CD003598","CD003598_pub3_data","3|2|Graft loss|","Graft loss",3,2,"","or","binary",6,-0.383332142046371,0.311520521453505,0.0944595186465169,2004.16666666667,0.196924827061767,119.666666666667
"CD003598","CD003598_pub3_data","3|21|Cardiovascular events|","Cardiovascular events",3,21,"","or","binary",2,-1.54813683423707,0.633571224915814,0,2003.5,0.1875,59.5
"CD003598","CD003598_pub3_data","3|22|Heart failure|","Heart failure",3,22,"","or","binary",3,-0.96029755581103,0.646125599774707,0,2005,0.039854000197297,109.333333333333
"CD003598","CD003598_pub3_data","3|25|Haemoglobin [g/dL]|","Haemoglobin [g/dL]",3,25,"","or","binary",6,-0.0751860686045752,0.823465359625305,0,2005.66666666667,0,110.666666666667
"CD003598","CD003598_pub3_data","3|26|Haematocrit [%]|","Haematocrit [%]",3,26,"","or","binary",2,0.0890671247923001,1.44126968334947,0,1995,0,26.5
"CD003598","CD003598_pub3_data","3|27|Serum potassium [mmol/L]|","Serum potassium [mmol/L]",3,27,"","or","binary",2,0.0471745936558879,1.43208971214388,0,1999,0,142
"CD003598","CD003598_pub3_data","3|28|Hyperkalaemia|","Hyperkalaemia",3,28,"","or","binary",4,0.760023784503263,0.64076454411073,0,1999.5,0.0250208507089241,72.75
"CD003598","CD003598_pub3_data","3|3|Creatinine clearance [mL/min]|","Creatinine clearance [mL/min]",3,3,"","or","binary",3,-0.0837934897258104,1.17934700648371,0,2000.66666666667,0,29
"CD003598","CD003598_pub3_data","3|30|Cough|","Cough",3,30,"","or","binary",3,0.498920693714069,0.325556752564627,4.20481275782671e-06,2011,0.0939393939393939,177
"CD003598","CD003598_pub3_data","3|33|Withdrawal due to adverse events|","Withdrawal due to adverse events",3,33,"","or","binary",7,1.60475007401184,0.457374573635835,0,1999.85714285714,0.00911473847253664,65.8571428571429
"CD003598","CD003598_pub3_data","3|35|Withdrawal due to hyperkalaemia|","Withdrawal due to hyperkalaemia",3,35,"","or","binary",2,1.32825968704373,1.13944203927889,0,2008.5,0,58.5
"CD003598","CD003598_pub3_data","3|4|eGFR [mL/min/1.73 m²]|","eGFR [mL/min/1.73 m²]",3,4,"","or","binary",4,-0.124773250083404,1.01008391653265,0,2006.75,0,127.25
"CD003598","CD003598_pub3_data","3|5|Serum creatinine [µmol/L]|","Serum creatinine [µmol/L]",3,5,"","or","binary",5,-0.0217644027421354,0.905794513274706,0,2000.2,0,44.6
"CD003598","CD003598_pub3_data","3|6|Doubling of serum creatinine|","Doubling of serum creatinine",3,6,"","or","binary",2,0.229351791126924,0.429888427809823,0,2007.5,0.0574134359277893,138
"CD003598","CD003598_pub3_data","3|7|Acute kidney injury|","Acute kidney injury",3,7,"","or","binary",2,1.40346066640966,1.4332107135105,1.10892033396373,1997.5,0,41
"CD003598","CD003598_pub3_data","3|8|Cardiovascular death|","Cardiovascular death",3,8,"","or","binary",7,-0.204996157099876,0.480713577294729,0,2000.42857142857,0.0206686344262476,100.285714285714
"CD003598","CD003598_pub3_data","3|9|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",3,9,"","or","binary",4,-0.0901690663515942,1.01332229881891,0,1996.5,0,42.5
"CD003598","CD003598_pub3_data","4|1|All-cause death|","All-cause death",4,1,"","or","binary",6,-0.352793222535105,0.338706413774611,0,2011.5,0.0385290148448043,173.5
"CD003598","CD003598_pub3_data","4|10|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",4,10,"","or","binary",10,0.0342754492718658,0.63760466533052,0,2009.8,0,123.9
"CD003598","CD003598_pub3_data","4|11|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",4,11,"","or","binary",9,0.0395840512188164,0.672460244159619,0,2009.77777777778,0,120.666666666667
"CD003598","CD003598_pub3_data","4|14|Acute rejection|","Acute rejection",4,14,"","or","binary",4,0.0105581636813367,0.431066904548124,0,2011.5,0.0419407894736842,80.75
"CD003598","CD003598_pub3_data","4|15|Nonfatal myocardial infarction|","Nonfatal myocardial infarction",4,15,"","or","binary",2,-1.18010700060271,1.16512186913908,0,2007.5,0.0248842592592593,88.5
"CD003598","CD003598_pub3_data","4|17|Cardiovascular events|","Cardiovascular events",4,17,"","or","binary",4,0.239453777659621,0.346352621909933,0,2006.5,0.0389763367304202,225.25
"CD003598","CD003598_pub3_data","4|19|Haemoglobin [g/dL]|","Haemoglobin [g/dL]",4,19,"","or","binary",7,0.0590327137854984,0.760390149953384,0,2010.57142857143,0,147.714285714286
"CD003598","CD003598_pub3_data","4|21|Serum potassium [mmol/L]|","Serum potassium [mmol/L]",4,21,"","or","binary",7,0.0598293211011678,0.761068590217004,0,2010.57142857143,0,143.285714285714
"CD003598","CD003598_pub3_data","4|22|Hyperkalaemia|","Hyperkalaemia",4,22,"","or","binary",3,1.29092828332374,0.474869550124547,0,2009.33333333333,0.0219298245614035,79.3333333333333
"CD003598","CD003598_pub3_data","4|24|Hypotension|","Hypotension",4,24,"","or","binary",2,1.41496543819094,1.14613378564292,0,2009,0,42.5
"CD003598","CD003598_pub3_data","4|25|Withdrawal due to adverse events|","Withdrawal due to adverse events",4,25,"","or","binary",6,-0.187065753697483,0.252892103269878,0,2011.33333333333,0.0324119316859789,148.5
"CD003598","CD003598_pub3_data","4|27|Withdrawal due to acute rejection|","Withdrawal due to acute rejection",4,27,"","or","binary",2,0.388667219802784,0.80014130104772,0,2013.5,0.03125,60
"CD003598","CD003598_pub3_data","4|3|Graft loss|","Graft loss",4,3,"","or","binary",6,-0.940984811871833,0.418730039997172,0,2007.16666666667,0.0332995951417004,148.666666666667
"CD003598","CD003598_pub3_data","4|5|eGFR [mL/min/1.73 m²]|","eGFR [mL/min/1.73 m²]",4,5,"","or","binary",5,0.0745501329034297,0.905023863502662,0,2012.6,0,60
"CD003598","CD003598_pub3_data","4|6|Serum creatinine [µmol/L]|","Serum creatinine [µmol/L]",4,6,"","or","binary",6,0.0145437468398647,0.822355467352813,0,2010.16666666667,0,87
"CD003598","CD003598_pub3_data","4|7|Doubling of serum creatinine|","Doubling of serum creatinine",4,7,"","or","binary",3,-0.231926901185504,0.735646265338123,0.65150762570996,2006.33333333333,0.0310391363022942,222.666666666667
"CD003598","CD003598_pub3_data","4|9|Cardiovascular death|","Cardiovascular death",4,9,"","or","binary",4,-0.716015561002475,0.922141784747274,0,2013.25,0.00303643724696356,189.25
"CD003598","CD003598_pub3_data","9|1|All-cause death|","All-cause death",9,1,"","or","binary",4,1.11904148936379,0.850734126444896,0,1999.75,0,72.5
"CD003598","CD003598_pub3_data","9|10|Any rejection|","Any rejection",9,10,"","or","binary",2,0.932926629281759,0.327388716646387,0,2003,0.217948717948718,110.5
"CD003598","CD003598_pub3_data","9|13|Proteinuria [g/24 hours]|","Proteinuria [g/24 hours]",9,13,"","or","binary",2,-0.058624855866967,1.4248136430827,0,1998,0,75
"CD003598","CD003598_pub3_data","9|17|Haemoglobin [g/dL]|","Haemoglobin [g/dL]",9,17,"","or","binary",4,0.0615765068869255,1.0096151508647,0,2001,0,78.25
"CD003598","CD003598_pub3_data","9|18|Haematocrit [%]|","Haematocrit [%]",9,18,"","or","binary",4,-0.0275739148746777,1.01476809988755,0,1997,0,40.25
"CD003598","CD003598_pub3_data","9|19|Serum potassium [mmol/L]|","Serum potassium [mmol/L]",9,19,"","or","binary",5,-0.0456678259027778,0.905842628728477,0,1998.2,0,52.6
"CD003598","CD003598_pub3_data","9|2|Graft loss|","Graft loss",9,2,"","or","binary",2,0.540098448029126,0.89984584660639,0.744922642359061,1998.5,0.166666666666667,100
"CD003598","CD003598_pub3_data","9|20|Hyperkalaemia|","Hyperkalaemia",9,20,"","or","binary",3,1.66675926228407,0.422885116057297,0,2000.33333333333,0.0386473429951691,70.3333333333333
"CD003598","CD003598_pub3_data","9|21|Cough|","Cough",9,21,"","or","binary",2,2.25345873755611,1.08071860758761,0,2003,0,95
"CD003598","CD003598_pub3_data","9|22|Peripheral oedema|","Peripheral oedema",9,22,"","or","binary",2,-1.68615575617071,0.684911361099693,0.192296935714428,2003,0.219096334185848,95
"CD003598","CD003598_pub3_data","9|23|Withdrawn due to adverse events|","Withdrawn due to adverse events",9,23,"","or","binary",7,-0.0365650635022388,0.354510845335887,0.123796862049908,1998.28571428571,0.125953458306399,68.1428571428571
"CD003598","CD003598_pub3_data","9|26|Withdrawn due to hypotension|","Withdrawn due to hypotension",9,26,"","or","binary",2,-0.00762503754337152,1.67814347175423,3.17677482689729,1996,0.0416666666666667,101
"CD003598","CD003598_pub3_data","9|3|Clearance creatinine [mL/min]|","Clearance creatinine [mL/min]",9,3,"","or","binary",2,0.0597321077348273,1.43519897083239,0,2001,0,44
"CD003598","CD003598_pub3_data","9|4|eGFR [mL/min/1.73 m²]|","eGFR [mL/min/1.73 m²]",9,4,"","or","binary",3,0.00615040242311032,1.16754329367868,0,1995,0,65.3333333333333
"CD003598","CD003598_pub3_data","9|5|Serum creatinine [μmol/L]|","Serum creatinine [μmol/L]",9,5,"","or","binary",6,0.00315888028378561,0.825723566398078,0,1998.33333333333,0,64.3333333333333
"CD003598","CD003598_pub3_data","9|6|Cardiovascular death|","Cardiovascular death",9,6,"","or","binary",4,0.0361735534308511,1.01072917488448,0,1999.75,0,72.5
"CD003598","CD003598_pub3_data","9|7|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",9,7,"","or","binary",3,0.00984127150980339,1.16533335059238,0,1999.33333333333,0,54.3333333333333
"CD003598","CD003598_pub3_data","9|8|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",9,8,"","or","binary",3,0.00984127150980339,1.16533335059238,0,1999.33333333333,0,54.3333333333333
"CD003598","CD003598_pub3_data","9|9|Mean arterial pressure [mm Hg]|","Mean arterial pressure [mm Hg]",9,9,"","or","binary",5,-0.0456678259027778,0.905842628728477,0,1999.2,0,52.6
"CD003774","CD003774_pub5_data","1|1|CMV disease|All symptomatic CMV disease","CMV disease",1,1,"All symptomatic CMV disease","or","binary",19,-1.24632955550344,0.126868726782263,0,1995.47368421053,0.418239091477047,104.263157894737
"CD003774","CD003774_pub5_data","1|1|CMV disease|CMV organ involvement","CMV disease",1,1,"CMV organ involvement","or","binary",12,-1.21167744726746,0.249284832347679,0.173042780885068,1995.41666666667,0.184940449522914,135.666666666667
"CD003774","CD003774_pub5_data","1|1|CMV disease|CMV syndrome","CMV disease",1,1,"CMV syndrome","or","binary",11,-0.976409625058457,0.184572724951632,0,1995.45454545455,0.192620537303587,142.727272727273
"CD003774","CD003774_pub5_data","1|10|All-cause death for different organ transplants|Heart transplant recipients","All-cause death for different organ transplants",1,10,"Heart transplant recipients","or","binary",3,0.524475070263468,0.678504109669696,0.0479766996165248,1996.33333333333,0.0558482613277134,77.3333333333333
"CD003774","CD003774_pub5_data","1|10|All-cause death for different organ transplants|Kidney transplant recipients","All-cause death for different organ transplants",1,10,"Kidney transplant recipients","or","binary",10,-0.610961039728327,0.333168480265117,0,1995.1,0.0245811247275059,110.9
"CD003774","CD003774_pub5_data","1|10|All-cause death for different organ transplants|Liver transplant patients","All-cause death for different organ transplants",1,10,"Liver transplant patients","or","binary",4,-0.562685035865548,0.277469664941077,0,1996.5,0.220997174122174,124.25
"CD003774","CD003774_pub5_data","1|11|All-cause death and ganciclovir duration|More than 6 weeks","All-cause death and ganciclovir duration",1,11,"More than 6 weeks","or","binary",4,-0.456817854002235,0.385532314680845,0,1996.75,0.0373376623376623,109.75
"CD003774","CD003774_pub5_data","1|11|All-cause death and ganciclovir duration|Six weeks or less","All-cause death and ganciclovir duration",1,11,"Six weeks or less","or","binary",6,-0.164685853396099,0.613666707886661,0.599037344049263,1993.83333333333,0.0403358261112664,75.8333333333333
"CD003774","CD003774_pub5_data","1|12|All-cause death with or without ATG therapy and antiviral efficacy|With ATG therapy","All-cause death with or without ATG therapy and antiviral efficacy",1,12,"With ATG therapy","or","binary",10,-0.1602835717477,0.408363823373478,0,1994.9,0.0368194740935618,64.3
"CD003774","CD003774_pub5_data","1|12|All-cause death with or without ATG therapy and antiviral efficacy|Without ATG therapy","All-cause death with or without ATG therapy and antiviral efficacy",1,12,"Without ATG therapy","or","binary",5,-0.566326752644162,0.274924928528202,0,1996.4,0.176797739297739,105.8
"CD003774","CD003774_pub5_data","1|13|CMV infection|Total CMV infection","CMV infection",1,13,"Total CMV infection","or","binary",17,-1.08564925191465,0.10971268308081,4.43759730923401e-06,1995.88235294118,0.594618115938257,105.058823529412
"CD003774","CD003774_pub5_data","1|14|Death due to CMV disease or other causes|CMV disease","Death due to CMV disease or other causes",1,14,"CMV disease","or","binary",7,-1.30836991438798,0.556908282384036,0,1995.57142857143,0.0370118315677991,185.714285714286
"CD003774","CD003774_pub5_data","1|14|Death due to CMV disease or other causes|Other causes","Death due to CMV disease or other causes",1,14,"Other causes","or","binary",7,-0.341574350757045,0.259532322404089,0,1995.57142857143,0.0847056207159119,185.714285714286
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Acute rejection","Additional outcomes: all medications",1,15,"Acute rejection","or","binary",13,-0.200676345313701,0.165454569603305,0.0821861716360472,1995.84615384615,0.494497444780528,109.230769230769
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Bacterial infection","Additional outcomes: all medications",1,15,"Bacterial infection","or","binary",3,-0.737271187870602,0.319868024850467,2.54273192200396e-06,1997,0.481675731675732,58
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|EBV-associated PTLD","Additional outcomes: all medications",1,15,"EBV-associated PTLD","or","binary",2,-0.00209873420713835,1.16389056717528,0,1998,0.00324675324675325,179.5
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Graft loss","Additional outcomes: all medications",1,15,"Graft loss","or","binary",10,-0.303819244669175,0.242071145585267,0,1994.8,0.108982140836132,82.5
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Herpes simplex and H. zoster infection","Additional outcomes: all medications",1,15,"Herpes simplex and H. zoster infection","or","binary",9,-1.60866078322377,0.166966175023688,0,1996.33333333333,0.282523231238054,164.777777777778
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Invasive fungal infection","Additional outcomes: all medications",1,15,"Invasive fungal infection","or","binary",3,-0.594779595406863,0.632628665948743,0.328555373424247,1995.33333333333,0.104256854256854,63
"CD003774","CD003774_pub5_data","1|15|Additional outcomes: all medications|Protozoal infections","Additional outcomes: all medications",1,15,"Protozoal infections","or","binary",2,-1.26231918364845,0.63620402506223,0,1993.5,0.161616161616162,57
"CD003774","CD003774_pub5_data","1|16|Acute rejection according to method of diagnosis|Biopsy-proven acute rejection","Acute rejection according to method of diagnosis",1,16,"Biopsy-proven acute rejection","or","binary",5,0.108570511421709,0.378043824262182,0.34561457861355,1996.6,0.415726425212441,164.2
"CD003774","CD003774_pub5_data","1|16|Acute rejection according to method of diagnosis|Clinical diagnosis of acute rejection or method not stated","Acute rejection according to method of diagnosis",1,16,"Clinical diagnosis of acute rejection or method not stated","or","binary",8,-0.288859630588061,0.169872455528175,0,1995.375,0.543729332010582,74.875
"CD003774","CD003774_pub5_data","1|17|Valaciclovir: additional outcomes|Total with acute rejection","Valaciclovir: additional outcomes",1,17,"Total with acute rejection","or","binary",2,-0.558552638899401,0.169820841527709,0,2000.5,0.706451612903226,321.5
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Kidney dysfunction for all medications","Adverse effects",1,18,"Kidney dysfunction for all medications","or","binary",5,0.6467142860831,0.365235513602372,0.172771271160178,1994.4,0.0721441420071557,133.6
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Kidney dysfunction with aciclovir","Adverse effects",1,18,"Kidney dysfunction with aciclovir","or","binary",2,0.136870640408495,0.760612095707632,0.308150179321379,1994,0.111111111111111,79.5
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Kidney dysfunction with ganciclovir","Adverse effects",1,18,"Kidney dysfunction with ganciclovir","or","binary",3,0.852995994136448,0.420280867307217,0.15855791729442,1994.66666666667,0.0461661626045188,169.666666666667
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Leucopenia for all medications","Adverse effects",1,18,"Leucopenia for all medications","or","binary",4,0.0337458167583025,0.233234092186184,0,1995.75,0.0556754337134364,281.25
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Leucopenia with ganciclovir","Adverse effects",1,18,"Leucopenia with ganciclovir","or","binary",3,-0.0104166421097113,0.457265571076613,0.11934293954717,1994.66666666667,0.0473521911878076,169.666666666667
"CD003774","CD003774_pub5_data","1|18|Adverse effects|Neurological dysfunction with ganciclovir","Adverse effects",1,18,"Neurological dysfunction with ganciclovir","or","binary",3,0.531719133373594,0.292858339778108,0,1994.66666666667,0.0476190476190476,169.666666666667
"CD003774","CD003774_pub5_data","1|2|All symptomatic CMV disease stratified by antibody status|CMV -ve donor / CMV -ve recipient","All symptomatic CMV disease stratified by antibody status",1,2,"CMV -ve donor / CMV -ve recipient","or","binary",4,0,0.920280655357067,0,1994.75,0.0625,9.5
"CD003774","CD003774_pub5_data","1|2|All symptomatic CMV disease stratified by antibody status|CMV -ve donor / CMV +ve recipient","All symptomatic CMV disease stratified by antibody status",1,2,"CMV -ve donor / CMV +ve recipient","or","binary",5,-1.19308237641672,0.582893839694744,0,1995,0.268067226890756,32
"CD003774","CD003774_pub5_data","1|2|All symptomatic CMV disease stratified by antibody status|CMV +ve donor / CMV -ve recipient","All symptomatic CMV disease stratified by antibody status",1,2,"CMV +ve donor / CMV -ve recipient","or","binary",10,-1.12660132816754,0.301438068854861,0.222402153645019,1994.6,0.563152066486972,42.3
"CD003774","CD003774_pub5_data","1|2|All symptomatic CMV disease stratified by antibody status|CMV +ve donor / CMV +ve recipient","All symptomatic CMV disease stratified by antibody status",1,2,"CMV +ve donor / CMV +ve recipient","or","binary",5,-1.84349993092119,0.422253824693773,9.995291655444e-07,1995,0.461363636363636,55.2
"CD003774","CD003774_pub5_data","1|2|All symptomatic CMV disease stratified by antibody status|CMV antibody +ve recipients","All symptomatic CMV disease stratified by antibody status",1,2,"CMV antibody +ve recipients","or","binary",13,-1.30032958650987,0.212039200608069,0.12645744454621,1995.23076923077,0.309696936287515,103.692307692308
"CD003774","CD003774_pub5_data","1|3|CMV disease in all patients by antiviral medication|Aciclovir","CMV disease in all patients by antiviral medication",1,3,"Aciclovir","or","binary",6,-1.10556445956071,0.263472316445093,0,1994.66666666667,0.310439360929557,70.1666666666667
"CD003774","CD003774_pub5_data","1|3|CMV disease in all patients by antiviral medication|Ganciclovir","CMV disease in all patients by antiviral medication",1,3,"Ganciclovir","or","binary",11,-1.26771805245116,0.17250391360713,6.2276806676451e-06,1995,0.493529065804665,83.3636363636364
"CD003774","CD003774_pub5_data","1|3|CMV disease in all patients by antiviral medication|Valaciclovir","CMV disease in all patients by antiviral medication",1,3,"Valaciclovir","or","binary",2,-1.33905640209884,0.266149345041994,0,2000.5,0.327543424317618,321.5
"CD003774","CD003774_pub5_data","1|4|CMV disease for different organ transplants|Heart transplant recipients","CMV disease for different organ transplants",1,4,"Heart transplant recipients","or","binary",3,-1.24187567287843,0.30697544410081,0,1996.33333333333,0.414446284309298,77.3333333333333
"CD003774","CD003774_pub5_data","1|4|CMV disease for different organ transplants|Kidney transplant recipients","CMV disease for different organ transplants",1,4,"Kidney transplant recipients","or","binary",11,-1.31405408651,0.172982012683092,2.63367843662197e-06,1995.09090909091,0.463704343311808,102.909090909091
"CD003774","CD003774_pub5_data","1|4|CMV disease for different organ transplants|Liver transplant recipients","CMV disease for different organ transplants",1,4,"Liver transplant recipients","or","binary",5,-0.921174561428367,0.304527498777581,0.196094581751182,1995.8,0.320491221741222,123.2
"CD003774","CD003774_pub5_data","1|5|CMV disease and ganciclovir duration|More than 6 weeks","CMV disease and ganciclovir duration",1,5,"More than 6 weeks","or","binary",4,-1.47455218314408,0.29441912001906,0,1996.75,0.402049037918603,109.75
"CD003774","CD003774_pub5_data","1|5|CMV disease and ganciclovir duration|Six weeks or less","CMV disease and ganciclovir duration",1,5,"Six weeks or less","or","binary",7,-1.14952174850583,0.24064468412461,0.067686225416676,1994,0.543948079884269,68.2857142857143
"CD003774","CD003774_pub5_data","1|6|CMV disease and ATG therapy and antiviral efficacy|CMV disease in all treated patients","CMV disease and ATG therapy and antiviral efficacy",1,6,"CMV disease in all treated patients","or","binary",11,-1.35576484321995,0.193108393144949,0,1994.90909090909,0.473825154890861,60.5454545454545
"CD003774","CD003774_pub5_data","1|7|CMV disease and immunosuppression without ATG induction and antiviral efficacy|CMV disease in all treated patients","CMV disease and immunosuppression without ATG induction and antiviral efficacy",1,7,"CMV disease in all treated patients","or","binary",6,-1.03108398549601,0.250729469353174,0.0660887958920306,1995.83333333333,0.333742684784351,108.166666666667
"CD003774","CD003774_pub5_data","1|8|All-cause death according to antiviral medication|Aciclovir","All-cause death according to antiviral medication",1,8,"Aciclovir","or","binary",5,-0.483803753099553,0.354269509306516,0,1995,0.141394335511983,60.2
"CD003774","CD003774_pub5_data","1|8|All-cause death according to antiviral medication|Ganciclovir","All-cause death according to antiviral medication",1,8,"Ganciclovir","or","binary",10,-0.377283901436122,0.305852875672493,0,1995,0.0391365606018248,89.4
"CD003774","CD003774_pub5_data","1|8|All-cause death according to antiviral medication|Valaciclovir","All-cause death according to antiviral medication",1,8,"Valaciclovir","or","binary",2,-0.669582755931483,0.422615493400473,0,2000.5,0.0995037220843673,321.5
"CD003774","CD003774_pub5_data","1|9|All-cause death according to CMV status|CMV -ve recipients of CMV +ve organs","All-cause death according to CMV status",1,9,"CMV -ve recipients of CMV +ve organs","or","binary",4,0.223302664954952,0.560320961471187,0,1995.75,0.00943396226415094,72
"CD003774","CD003774_pub5_data","1|9|All-cause death according to CMV status|CMV +ve recipients","All-cause death according to CMV status",1,9,"CMV +ve recipients","or","binary",7,-0.581051062056222,0.357149725579865,0,1996.71428571429,0.0744942665710973,105.428571428571
"CD003774","CD003774_pub5_data","10|2|CMV infection|","CMV infection",10,2,"","or","binary",2,-0.966757518407302,0.606401008404105,0,2018,0.0574829931972789,128
"CD003774","CD003774_pub5_data","2|1|Allocation concealment|Adequate","Allocation concealment",2,1,"Adequate","or","binary",4,-0.98416221854685,0.305572388835977,0,1996,0.394270833333333,65.5
"CD003774","CD003774_pub5_data","2|1|Allocation concealment|Inadequate/unclear","Allocation concealment",2,1,"Inadequate/unclear","or","binary",15,-1.29186409498631,0.139540089070116,0,1995.33333333333,0.423764826116236,114.6
"CD003774","CD003774_pub5_data","2|2|Blinding of participants/investigators|Blinding","Blinding of participants/investigators",2,2,"Blinding","or","binary",5,-1.293890847646,0.191501127236672,0,1995.8,0.310327819625732,227
"CD003774","CD003774_pub5_data","2|2|Blinding of participants/investigators|No blinding","Blinding of participants/investigators",2,2,"No blinding","or","binary",14,-1.19557803954023,0.169519312466502,0,1995.35714285714,0.455851187639158,60.4285714285714
"CD003774","CD003774_pub5_data","2|3|Intention-to-treat analysis (ITT)|ITT not undertaken","Intention-to-treat analysis (ITT)",2,3,"ITT not undertaken","or","binary",9,-1.26312745271489,0.250017913879173,0.0387598871631972,1995.66666666667,0.517733368060165,45.7777777777778
"CD003774","CD003774_pub5_data","2|3|Intention-to-treat analysis (ITT)|ITT undertaken","Intention-to-treat analysis (ITT)",2,3,"ITT undertaken","or","binary",10,-1.23204558337609,0.149604509219793,0,1995.3,0.327395541253539,156.9
"CD003774","CD003774_pub5_data","2|4|CMV disease by time of outcome assessment|Outcome at 3-6 months","CMV disease by time of outcome assessment",2,4,"Outcome at 3-6 months","or","binary",11,-1.21085485062816,0.181797993761029,0,1995.54545454545,0.473938450191322,64
"CD003774","CD003774_pub5_data","2|4|CMV disease by time of outcome assessment|Outcome at 9-12 months","CMV disease by time of outcome assessment",2,4,"Outcome at 9-12 months","or","binary",8,-1.27174244184293,0.223838698952224,0.0999270852076898,1995.375,0.341652473244919,159.625
"CD003774","CD003774_pub5_data","2|5|CMV disease by trial publication date|Trials published before 1997","CMV disease by trial publication date",2,5,"Trials published before 1997","or","binary",12,-1.12424910782315,0.172839302192835,1.61804631264187e-07,1993.83333333333,0.448721682429558,68.4166666666667
"CD003774","CD003774_pub5_data","2|5|CMV disease by trial publication date|Trials published in 1997 and later","CMV disease by trial publication date",2,5,"Trials published in 1997 and later","or","binary",7,-1.38894859457507,0.186813423029255,0,1998.28571428571,0.365983221272742,165.714285714286
"CD003774","CD003774_pub5_data","3|1|Allocation concealment|Adequate","Allocation concealment",3,1,"Adequate","or","binary",3,-1.10155735148745,0.676579015891135,0,1997,0.113782051282051,47.3333333333333
"CD003774","CD003774_pub5_data","3|1|Allocation concealment|Inadequate/unclear","Allocation concealment",3,1,"Inadequate/unclear","or","binary",14,-0.419142335390457,0.212854626530837,0,1995.35714285714,0.0685190391254965,121.071428571429
"CD003774","CD003774_pub5_data","3|2|Blinding of participants and investigators|Blinding","Blinding of participants and investigators",3,2,"Blinding","or","binary",5,-0.502901905478355,0.25554036139594,1.03498445636328e-06,1995.8,0.115650258800164,227
"CD003774","CD003774_pub5_data","3|2|Blinding of participants and investigators|No blinding","Blinding of participants and investigators",3,2,"No blinding","or","binary",12,-0.442412699171065,0.334406000206108,0,1995.58333333333,0.0601967839668571,58.5
"CD003774","CD003774_pub5_data","3|3|Intention-to-treat analysis (ITT)|ITT not undertaken","Intention-to-treat analysis (ITT)",3,3,"ITT not undertaken","or","binary",8,-0.452095288018042,0.39048349041383,0,1995.75,0.0785618248853543,48.625
"CD003774","CD003774_pub5_data","3|3|Intention-to-treat analysis (ITT)|ITT undertaken","Intention-to-treat analysis (ITT)",3,3,"ITT undertaken","or","binary",9,-0.491165735797124,0.237706092513282,0,1995.55555555556,0.0746797891689189,160.888888888889
"CD003774","CD003774_pub5_data","3|4|All-cause death and time of outcome assessment or trial publication date|Outcome at 4-6 months","All-cause death and time of outcome assessment or trial publication date",3,4,"Outcome at 4-6 months","or","binary",7,-0.390627938619889,0.397616607249119,0,1996.28571428571,0.082675925840589,66.8571428571429
"CD003774","CD003774_pub5_data","3|4|All-cause death and time of outcome assessment or trial publication date|Outcome at 9-12 months","All-cause death and time of outcome assessment or trial publication date",3,4,"Outcome at 9-12 months","or","binary",10,-0.511176604433935,0.236152351850448,0,1995.2,0.0718613246862772,137
"CD003774","CD003774_pub5_data","3|5|All-cause death and trial publication date|Outcome in trials published before 1997","All-cause death and trial publication date",3,5,"Outcome in trials published before 1997","or","binary",10,-0.340354432411657,0.402030416217648,0,1993.8,0.0356394041634919,67.8
"CD003774","CD003774_pub5_data","3|5|All-cause death and trial publication date|Outcome in trials published in 1997 or later","All-cause death and trial publication date",3,5,"Outcome in trials published in 1997 or later","or","binary",7,-0.527468806355001,0.235248053621322,0,1998.28571428571,0.134421526587425,165.714285714286
"CD003774","CD003774_pub5_data","4|1|CMV disease in all treated patients|CMV disease in all patients","CMV disease in all treated patients",4,1,"CMV disease in all patients","or","binary",7,-1.08805373607672,0.235223265663512,0.0676303475275072,1997.14285714286,0.192318911057951,159
"CD003774","CD003774_pub5_data","4|1|CMV disease in all treated patients|CMV disease in patients treated with ganciclovir for 2-4 weeks then aciclovir","CMV disease in all treated patients",4,1,"CMV disease in patients treated with ganciclovir for 2-4 weeks then aciclovir","or","binary",3,-1.10907473076724,0.296364143811169,0,1994.66666666667,0.2205755902939,136.666666666667
"CD003774","CD003774_pub5_data","4|1|CMV disease in all treated patients|CMV disease in patients treated with ganciclovir for 3 months","CMV disease in all treated patients",4,1,"CMV disease in patients treated with ganciclovir for 3 months","or","binary",4,-1.22180182189615,0.441688754053067,0.349552214457705,1999,0.171126401630989,175.75
"CD003774","CD003774_pub5_data","4|1|CMV disease in all treated patients|CMV organ involvement","CMV disease in all treated patients",4,1,"CMV organ involvement","or","binary",7,-1.3136818927579,0.293250203779647,0,1997.14285714286,0.126974074623273,147.714285714286
"CD003774","CD003774_pub5_data","4|1|CMV disease in all treated patients|CMV syndrome","CMV disease in all treated patients",4,1,"CMV syndrome","or","binary",6,-0.993568381939448,0.499159392097414,0.762025768847698,1997.83333333333,0.123803815075297,168.166666666667
"CD003774","CD003774_pub5_data","4|10|CMV infection and effect of prophylaxis for different transplanted organs|CMV infection in heart or lung transplant patients","CMV infection and effect of prophylaxis for different transplanted organs",4,10,"CMV infection in heart or lung transplant patients","or","binary",2,-0.34371537166413,0.788842046525471,0.739066979669807,1996.5,0.676666666666667,37.5
"CD003774","CD003774_pub5_data","4|10|CMV infection and effect of prophylaxis for different transplanted organs|CMV infection in kidney transplant patients","CMV infection and effect of prophylaxis for different transplanted organs",4,10,"CMV infection in kidney transplant patients","or","binary",2,-1.86737161844227,0.570938808671488,0.229617293019993,1999,0.412820512820513,84
"CD003774","CD003774_pub5_data","4|10|CMV infection and effect of prophylaxis for different transplanted organs|CMV infection in liver transplant patients","CMV infection and effect of prophylaxis for different transplanted organs",4,10,"CMV infection in liver transplant patients","or","binary",4,-1.37228448720865,0.311946304838835,0.198632171506055,1996.5,0.553690196735971,143
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Acute rejection","Additional outcomes",4,11,"Acute rejection","or","binary",6,-0.0480151130561268,0.130046133297015,1.96601027558881e-06,1997.83333333333,0.464813528969105,168.166666666667
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Graft loss","Additional outcomes",4,11,"Graft loss","or","binary",3,-0.667121258239936,0.398914590840738,0,1993.33333333333,0.155501384374624,89.3333333333333
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Invasive fungal infections","Additional outcomes",4,11,"Invasive fungal infections","or","binary",3,-0.531670753514342,0.326845532120082,0,1998.33333333333,0.128815628815629,133.666666666667
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Kidney dysfunction","Additional outcomes",4,11,"Kidney dysfunction","or","binary",4,-0.0908499351369481,0.185880443911283,0,1997,0.332131935342945,165.25
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Leucopenia","Additional outcomes",4,11,"Leucopenia","or","binary",6,1.10898845148682,0.382608192092312,0,1997,0.0110935615522771,159.166666666667
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Neurological dysfunction","Additional outcomes",4,11,"Neurological dysfunction","or","binary",2,0.0196919117624703,0.656468762556894,0,1995.5,0.0248993963782696,153
"CD003774","CD003774_pub5_data","4|11|Additional outcomes|Other viral infections","Additional outcomes",4,11,"Other viral infections","or","binary",4,-0.231965958471699,0.415631691241971,3.86478357680872e-06,1997,0.0458638583638584,185
"CD003774","CD003774_pub5_data","4|2|CMV disease by antibody +ve recipients|All symptomatic CMV disease","CMV disease by antibody +ve recipients",4,2,"All symptomatic CMV disease","or","binary",5,-1.36075524476476,0.357736839181072,0.0298792116756087,1997.4,0.143638081125863,144.4
"CD003774","CD003774_pub5_data","4|3|CMV disease by +ve donors / CMV -ve recipients|All symptomatic CMV disease","CMV disease by +ve donors / CMV -ve recipients",4,3,"All symptomatic CMV disease","or","binary",5,-0.619109918172664,0.306699576217364,3.06712058536639e-06,1996.8,0.383916083916084,49.2
"CD003774","CD003774_pub5_data","4|4|CMV -ve donor / CMV -ve recipient|CMV disease","CMV -ve donor / CMV -ve recipient",4,4,"CMV disease","or","binary",3,-0.666008870844486,0.910737988535304,0,1995.33333333333,0.138888888888889,13.6666666666667
"CD003774","CD003774_pub5_data","4|5|CMV disease and effect of prophylaxis for different transplanted organs|CMV disease in heart or lung transplant patients","CMV disease and effect of prophylaxis for different transplanted organs",4,5,"CMV disease in heart or lung transplant patients","or","binary",2,-0.734356853615979,0.939126639809983,0.859723726099463,1996.5,0.305,37.5
"CD003774","CD003774_pub5_data","4|5|CMV disease and effect of prophylaxis for different transplanted organs|CMV disease in kidney transplant patients","CMV disease and effect of prophylaxis for different transplanted organs",4,5,"CMV disease in kidney transplant patients","or","binary",2,-1.24403877892609,0.649716163445095,0.332320526279263,1999,0.226495726495726,84
"CD003774","CD003774_pub5_data","4|5|CMV disease and effect of prophylaxis for different transplanted organs|CMV disease in liver transplant patients","CMV disease and effect of prophylaxis for different transplanted organs",4,5,"CMV disease in liver transplant patients","or","binary",5,-1.14288710239941,0.263187848345642,0,1997.8,0.1884772447119,158.2
"CD003774","CD003774_pub5_data","4|6|Death|All-cause death","Death",4,6,"All-cause death","or","binary",8,0.140862844893991,0.187960591703252,0,1996.625,0.111514993868173,142.25
"CD003774","CD003774_pub5_data","4|6|Death|Death associated with CMV disease","Death",4,6,"Death associated with CMV disease","or","binary",6,-0.859687915222619,0.713755345056122,0,1997,0.0210141964729121,138.666666666667
"CD003774","CD003774_pub5_data","4|7|CMV infection|CMV infection","CMV infection",4,7,"CMV infection","or","binary",6,-1.37429776418637,0.278043193018109,0.245656463893619,1996.16666666667,0.547011413208596,135.833333333333
"CD003774","CD003774_pub5_data","4|8|CMV infection by antibody +ve recipients|CMV infection","CMV infection by antibody +ve recipients",4,8,"CMV infection","or","binary",5,-1.78205006164771,0.325333732187442,0.198981202328884,1995.4,0.519609659983492,104.4
"CD003774","CD003774_pub5_data","4|9|CMV infection by +ve donors / CMV -ve recipients|CMV infection","CMV infection by +ve donors / CMV -ve recipients",4,9,"CMV infection","or","binary",4,-0.86857883227143,0.289661479708669,6.1435740259677e-08,1997.5,0.607517482517482,57
"CD003774","CD003774_pub5_data","7|1|CMV disease in all treated patients|CMV disease","CMV disease in all treated patients",7,1,"CMV disease","or","binary",4,-0.517673736586617,0.540845678867504,0,2010,0.049702380952381,82.75
"CD003774","CD003774_pub5_data","7|2|Death|All-cause death","Death",7,2,"All-cause death","or","binary",3,0.480255174134249,0.736716142056085,0,2006.66666666667,0.0185185185185185,91
"CD003774","CD003774_pub5_data","7|3|CMV infection|CMV infection","CMV infection",7,3,"CMV infection","or","binary",4,0.35408171605139,0.254638865984222,0,2010,0.202083333333333,82.75
"CD003774","CD003774_pub5_data","7|3|CMV infection|CMV infection in donor +ve or -ve/recipient +ve","CMV infection",7,3,"CMV infection in donor +ve or -ve/recipient +ve","or","binary",2,0.0826334873709001,0.601573088498432,0.381278506110892,2007.5,0.208176100628931,85.5
"CD003774","CD003774_pub5_data","7|3|CMV infection|CMV infection in donor +ve/recipient -ve","CMV infection",7,3,"CMV infection in donor +ve/recipient -ve","or","binary",2,1.10183071296983,1.11552957539107,0.659847676156715,2007.5,0.464285714285714,11.5
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Acute rejection","Additional outcomes",7,4,"Acute rejection","or","binary",3,-0.144615399507594,0.610096836579203,0.796127931701985,2006.66666666667,0.211507936507937,90.3333333333333
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Anaemia","Additional outcomes",7,4,"Anaemia","or","binary",2,-0.181126859840446,0.605319853114328,0.43872538423297,2007.5,0.213725490196078,93.5
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Dose reduction or cessation for adverse effects","Additional outcomes",7,4,"Dose reduction or cessation for adverse effects","or","binary",2,-0.732530003813796,0.38268741514713,0,2007.5,0.251190476190476,94
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Graft loss","Additional outcomes",7,4,"Graft loss","or","binary",2,-0.475697368399709,0.60091640493851,0,2007.5,0.0805555555555555,95
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Leucopenia","Additional outcomes",7,4,"Leucopenia","or","binary",2,-0.358690331458062,0.335712047056541,0,2007.5,0.266666666666667,94
"CD003774","CD003774_pub5_data","7|4|Additional outcomes|Thrombocytopenia","Additional outcomes",7,4,"Thrombocytopenia","or","binary",2,-0.163855396742539,0.438020533348499,0.131772054545785,2007.5,0.260714285714286,94
"CD003774","CD003774_pub5_data","7|5|Kidney function at end of study|Calculated GFR","Kidney function at end of study",7,5,"Calculated GFR","or","binary",2,0.0226026860158456,1.42218318488636,0,2007.5,0,94
"CD003774","CD003774_pub5_data","8|2|Oral versus IV ganciclovir|Acute rejection","Oral versus IV ganciclovir",8,2,"Acute rejection","or","binary",2,-0.247991019352158,0.441040526781561,0.00707812544537725,2004.5,0.330357142857143,47
"CD003774","CD003774_pub5_data","8|2|Oral versus IV ganciclovir|CMV disease","Oral versus IV ganciclovir",8,2,"CMV disease","or","binary",2,-0.582127699564011,0.68568112201738,0,2004.5,0.133928571428571,47
"CD003774","CD003774_pub5_data","8|2|Oral versus IV ganciclovir|CMV syndrome","Oral versus IV ganciclovir",8,2,"CMV syndrome","or","binary",2,-0.71647870126208,0.761897724759114,0,2004.5,0.118303571428571,47
"CD003774","CD003774_pub5_data","9|1|CMV disease|CMV disease at end of treatment","CMV disease",9,1,"CMV disease at end of treatment","or","binary",2,-1.86401891710849,0.302970301339823,0,2010,0.31553262688232,227
"CD003774","CD003774_pub5_data","9|2|CMV syndrome|","CMV syndrome",9,2,"","or","binary",2,-1.1693960551436,0.250965746302425,0,2010,0.276398958914296,227
"CD003774","CD003774_pub5_data","9|3|CMV invasive disease|Number at 12 months","CMV invasive disease",9,3,"Number at 12 months","or","binary",2,-1.58234219477535,1.03867388159611,1.24458359487537,2010,0.112195575385759,227
"CD003774","CD003774_pub5_data","9|5|CMV infection|CMV infection at end of treatment","CMV infection",9,5,"CMV infection at end of treatment","or","binary",2,-1.91631792794771,0.717776316603524,0.89567703025682,2010,0.542108198549916,227
"CD003774","CD003774_pub5_data","9|7|Acute rejection|Biopsy-proven acute rejection at 12 months","Acute rejection",9,7,"Biopsy-proven acute rejection at 12 months","or","binary",2,-0.544603622408209,0.249596532434564,0,2010,0.252556237218814,227
"CD003774","CD003774_pub5_data","9|8|Other outcomes|Opportunistic infections","Other outcomes",9,8,"Opportunistic infections","or","binary",2,-0.440613768627956,0.474547081463918,0.349113901434594,2010,0.39929785661493,228
"CD003774","CD003774_pub5_data","9|9|Adverse effects|CMV mutations known to confer ganciclovir resistance","Adverse effects",9,9,"CMV mutations known to confer ganciclovir resistance","or","binary",2,0.58568753552458,0.661244979152303,0,2010,0.0375757575757576,104
"CD003774","CD003774_pub5_data","9|9|Adverse effects|Total treatment-related adverse effects","Adverse effects",9,9,"Total treatment-related adverse effects","or","binary",2,0.338687999167346,0.197554719758667,0,2010,0.35310421286031,228
"CD003774","CD003774_pub5_data","9|9|Adverse effects|Treatment-related serious adverse effects","Adverse effects",9,9,"Treatment-related serious adverse effects","or","binary",2,0.208232908617754,0.370840332040263,0,2010,0.047209903917221,228
"CD003833","CD003833_pub5_data","1|1|Walking distance|Maximum walking distance","Walking distance",1,1,"Maximum walking distance","or","binary",3,-0.0286369197382591,1.16668738751926,0,2002,0,54.6666666666667
"CD003833","CD003833_pub5_data","1|1|Walking distance|Pain-free walking distance","Walking distance",1,1,"Pain-free walking distance","or","binary",3,-0.00809580625670286,1.17312588360675,0,2002,0,49
"CD003833","CD003833_pub5_data","1|2|Ankle brachial index|Post-intervention","Ankle brachial index",1,2,"Post-intervention","or","binary",3,-0.0309428458651942,1.16642963197596,0,2002,0,56
"CD003833","CD003833_pub5_data","1|3|Cholesterol|High-density lipoprotein cholesterol","Cholesterol",1,3,"High-density lipoprotein cholesterol","or","binary",5,-0.0110945537269799,0.90738522091402,0,1997,0,41.2
"CD003833","CD003833_pub5_data","1|3|Cholesterol|Low-density lipoprotein cholesterol","Cholesterol",1,3,"Low-density lipoprotein cholesterol","or","binary",4,-0.013807452453979,1.01226346119567,0,2000.25,0,46.5
"CD003833","CD003833_pub5_data","1|3|Cholesterol|Total cholesterol","Cholesterol",1,3,"Total cholesterol","or","binary",5,-0.0110945537269799,0.90738522091402,0,1997,0,41.2
"CD003833","CD003833_pub5_data","1|4|Triglycerides|Post-intervention","Triglycerides",1,4,"Post-intervention","or","binary",4,-0.0384576623452861,1.01537956020934,0,1994.25,0,41.25
"CD003833","CD003833_pub5_data","1|5|Blood pressure|Diastolic blood pressure","Blood pressure",1,5,"Diastolic blood pressure","or","binary",2,-0.0464327288448093,1.42886277104661,0,2000.5,0,59
"CD003833","CD003833_pub5_data","1|5|Blood pressure|Systolic blood pressure ","Blood pressure",1,5,"Systolic blood pressure ","or","binary",2,-0.0464327288448093,1.42886277104661,0,2000.5,0,59
"CD003833","CD003833_pub5_data","1|6|Vascular events|Non-fatal coronary events","Vascular events",1,6,"Non-fatal coronary events","or","binary",2,-0.414264663226162,0.674467473726584,0,2015,0.0649095200629426,70.5
"CD003833","CD003833_pub5_data","1|6|Vascular events|Non-fatal stroke","Vascular events",1,6,"Non-fatal stroke","or","binary",2,-0.0714539608950545,0.894458858597511,0,2015,0.024390243902439,55
"CD003962","CD003962_pub3_data","1|1|Kidney failure or doubling of serum creatinine|ACEi versus CCB or BB","Kidney failure or doubling of serum creatinine",1,1,"ACEi versus CCB or BB","or","binary",2,0.713523489878263,0.835526801205412,0,1996.5,0.0625,30
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi + ARB versus ARB or ACEi","Creatinine clearance",1,12,"ACEi + ARB versus ARB or ACEi","or","binary",2,0.795205313635022,1.45058035938919,0,2004,0,21.5
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","Creatinine clearance",1,12,"ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","or","binary",2,-0.104144704666803,1.42624014447955,0,2002.5,0,63.5
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi or ARB versus anticoagulant/antiplatelet","Creatinine clearance",1,12,"ACEi or ARB versus anticoagulant/antiplatelet","or","binary",2,0,1.43373543419514,0,2003,0,35
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi or ARB versus CCB","Creatinine clearance",1,12,"ACEi or ARB versus CCB","or","binary",4,-0.395417676540542,1.02637310944294,0,2002,0,27.25
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi or ARB versus placebo","Creatinine clearance",1,12,"ACEi or ARB versus placebo","reported","reported",2,0,7.16575805698093,0,2000,0,12
"CD003962","CD003962_pub3_data","1|12|Creatinine clearance|ACEi versus ARB","Creatinine clearance",1,12,"ACEi versus ARB","or","binary",3,-0.0199278802120302,1.18113560063453,0,2000.66666666667,0,22
"CD003962","CD003962_pub3_data","1|13|Adverse events|ACEi or ARB versus CCB","Adverse events",1,13,"ACEi or ARB versus CCB","or","binary",2,0.362737292882973,0.706954310758342,0,1999,0.269230769230769,28
"CD003962","CD003962_pub3_data","1|13|Adverse events|RASi versus placebo","Adverse events",1,13,"RASi versus placebo","or","binary",3,0.177543004778574,0.855194761916137,0.979729068082805,2006.66666666667,0.0787878787878788,67.3333333333333
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi + ARB versus ARB or ACEi","Proteinuria",1,4,"ACEi + ARB versus ARB or ACEi","or","binary",4,0.71682170088643,1.033574686391,0,2005.5,0,16.75
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi or ARB + herbal medicine versus herbal medicine","Proteinuria",1,4,"ACEi or ARB + herbal medicine versus herbal medicine","or","binary",2,-0.0392332653677925,1.42247357460398,0,2006,0,96.5
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","Proteinuria",1,4,"ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","or","binary",3,-0.0853887124500438,1.16580049955767,0,2001.66666666667,0,56
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi or ARB versus CCB","Proteinuria",1,4,"ACEi or ARB versus CCB","reported","reported",2,0,0.262094818135906,0,2000,0,12
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi or ARB versus placebo","Proteinuria",1,4,"ACEi or ARB versus placebo","reported","reported",2,0,0.317193723109407,0,2000,0,12
"CD003962","CD003962_pub3_data","1|4|Proteinuria|ACEi versus ARB","Proteinuria",1,4,"ACEi versus ARB","or","binary",4,-0.0149901964740094,1.02440778529972,0,2002.25,0,20.5
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi + ARB versus ARB or ACEi","Serum creatinine",1,8,"ACEi + ARB versus ARB or ACEi","or","binary",2,0.795205313635022,1.45058035938919,0,2004,0,21.5
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi or ARB + herbal medicine versus herbal medicine","Serum creatinine",1,8,"ACEi or ARB + herbal medicine versus herbal medicine","or","binary",2,-0.0392332653677925,1.42247357460398,0,2006,0,96.5
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","Serum creatinine",1,8,"ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required","or","binary",3,-0.0853887124500438,1.16580049955767,0,2001.66666666667,0,56
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi or ARB versus CCB","Serum creatinine",1,8,"ACEi or ARB versus CCB","reported","reported",2,0,9.74674549348941,0,2000,0,12
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi or ARB versus placebo","Serum creatinine",1,8,"ACEi or ARB versus placebo","reported","reported",2,0,12.112639357687,0,2000,0,12
"CD003962","CD003962_pub3_data","1|8|Serum creatinine|ACEi versus ARB","Serum creatinine",1,8,"ACEi versus ARB","or","binary",2,0.065422411571177,1.44598837140242,0,2002,0,23
"CD003962","CD003962_pub3_data","2|19|Hyperkalaemia|Anticoagulant + ACEi or ARB versus ACEi or ARB","Hyperkalaemia",2,19,"Anticoagulant + ACEi or ARB versus ACEi or ARB","or","binary",2,0.692913015408225,0.880965277397299,0,2015.5,0.005,142
"CD003962","CD003962_pub3_data","2|2|Kidney failure|Anticoagulant + ACEi or ARB versus ACEi or ARB","Kidney failure",2,2,"Anticoagulant + ACEi or ARB versus ACEi or ARB","or","binary",2,-1.13163175169753,0.727892812088381,0,2006.5,0.130952380952381,57.5
"CD003962","CD003962_pub3_data","3|10|Change in serum creatinine|Fish oil versus placebo/no treatment","Change in serum creatinine",3,10,"Fish oil versus placebo/no treatment","reported","reported",2,0,42.0450835766146,0,1989,0,18.5
"CD003962","CD003962_pub3_data","3|13|Creatinine clearance|Fish oil versus placebo/no treatment","Creatinine clearance",3,13,"Fish oil versus placebo/no treatment","or","binary",2,0.139827682368785,1.43418550368869,0,1991.5,0,34.5
"CD003962","CD003962_pub3_data","3|13|Creatinine clearance|Fish oil versus symptomatic treatment of BP","Creatinine clearance",3,13,"Fish oil versus symptomatic treatment of BP","or","binary",2,0,1.43761553567623,0,2005,0,29
"CD003962","CD003962_pub3_data","3|2|Kidney failure|Fish oil versus placebo/no treatment","Kidney failure",3,2,"Fish oil versus placebo/no treatment","or","binary",2,0.00821380493025081,0.563358606999408,0,1991.5,0.0892156862745098,71.5
"CD003962","CD003962_pub3_data","3|3|Proteinuria|Fish oil versus symptomatic treatment of BP","Proteinuria",3,3,"Fish oil versus symptomatic treatment of BP","or","binary",2,0,1.43761553567623,0,2005,0,29
"CD003962","CD003962_pub3_data","3|4|Change in proteinuria|Fish oil versus placebo/no treatment","Change in proteinuria",3,4,"Fish oil versus placebo/no treatment","or","binary",2,0.151246811571204,1.45044180577968,0,1989,0,18.5
"CD003962","CD003962_pub3_data","3|6|Change in haematuria (cells/mL x 105)|Fish oil versus placebo/no treatment","Change in haematuria (cells/mL x 105)",3,6,"Fish oil versus placebo/no treatment","or","binary",2,0.151246811571204,1.45044180577968,0,1989,0,18.5
"CD003962","CD003962_pub3_data","3|8|Serum creatinine|Fish oil versus placebo/no treatment","Serum creatinine",3,8,"Fish oil versus placebo/no treatment","or","binary",2,-0.0186989337565106,1.43418550368869,0,1998.5,0,34.5
"CD003962","CD003962_pub3_data","5|1|Remission of proteinuria|","Remission of proteinuria",5,1,"","or","binary",2,1.98276745771496,0.892856263296845,1.14557622248442,2004.5,0.386680988184748,71.5
"CD003962","CD003962_pub3_data","5|4|Remission of haematuria|Microscopic haematuria","Remission of haematuria",5,4,"Microscopic haematuria","or","binary",2,1.98443266474584,0.489631971049,0.117162527938849,2004.5,0.445220193340494,71.5
"CD003962","CD003962_pub3_data","6|5|Proteinuria|Herbal medicine versus other treatment","Proteinuria",6,5,"Herbal medicine versus other treatment","or","binary",2,0.0151446812384638,1.42451357894064,0,2005,0,67.5
"CD003962","CD003962_pub3_data","6|5|Proteinuria|Herbal medicine versus placebo/no treatment or standard care","Proteinuria",6,5,"Herbal medicine versus placebo/no treatment or standard care","or","binary",2,0.0212796913164955,1.42918086986442,0,1992,0,62
"CD003962","CD003962_pub3_data","6|8|Serum creatinine|Herbal medicine versus placebo/no treatment or standard care","Serum creatinine",6,8,"Herbal medicine versus placebo/no treatment or standard care","or","binary",2,0.0218537946260256,1.43316213646968,0,2000,0,37.5
"CD003962","CD003962_pub3_data","8|13|Adverse events|Vitamin D versus no treatment/standard care","Adverse events",8,13,"Vitamin D versus no treatment/standard care","or","binary",2,-0.0326076308124154,0.342481110705841,0,2016,0.223684210526316,176.5
"CD003962","CD003962_pub3_data","8|15|Diarrhoea|Vitamin D versus no treatment/standard care","Diarrhoea",8,15,"Vitamin D versus no treatment/standard care","or","binary",2,-1.15794181792052,1.16468819209481,0,2016,0.0241228070175439,176.5
"CD003962","CD003962_pub3_data","8|18|Infection|Vitamin D versus no treatment/standard of care","Infection",8,18,"Vitamin D versus no treatment/standard of care","or","binary",2,0.0751285352446342,0.528949915342608,0,2016,0.110745614035088,176.5
"CD003962","CD003962_pub3_data","8|2|Proteinuria|Phenytoin versus placebo/no treatment","Proteinuria",8,2,"Phenytoin versus placebo/no treatment","or","binary",2,-0.0330412233232449,1.43105885554419,0,1982,0,41.5
"CD003962","CD003962_pub3_data","8|8|Serum creatinine|Phenytoin versus placebo/no treatment","Serum creatinine",8,8,"Phenytoin versus placebo/no treatment","or","binary",2,-0.0330412233232449,1.43105885554419,0,1982,0,41.5
"CD004184","CD004184_pub3_data","1|10|Surge of DBP (mmHg)|Angiotensin II receptor blockers","Surge of DBP (mmHg)",1,10,"Angiotensin II receptor blockers","or","binary",3,-0.00543905156046964,1.15732223080431,0,2010.33333333333,0,329
"CD004184","CD004184_pub3_data","1|10|Surge of DBP (mmHg)|Calcium channel blockers","Surge of DBP (mmHg)",1,10,"Calcium channel blockers","or","binary",2,-0.0304622630335667,1.41764278194713,0,2008.5,0,209
"CD004184","CD004184_pub3_data","1|3|Overall adverse events|Calcium channel blockers","Overall adverse events",1,3,"Calcium channel blockers","or","binary",3,-0.576612880510876,0.570452747714854,0.626813062385845,2010.66666666667,0.234163615809057,167
"CD004184","CD004184_pub3_data","1|3|Overall adverse events|Diuretics","Overall adverse events",1,3,"Diuretics","or","binary",2,0.478659889795335,0.551224311932027,0,2007,0.0548931942374565,92.5
"CD004184","CD004184_pub3_data","1|4|Withdrawals from treatment due to adverse events|Angiotensin II receptor blockers","Withdrawals from treatment due to adverse events",1,4,"Angiotensin II receptor blockers","or","binary",3,-0.250080718501923,0.386543964435015,0.0870956274780046,2010.33333333333,0.0397065136791164,370
"CD004184","CD004184_pub3_data","1|4|Withdrawals from treatment due to adverse events|Calcium channel blockers","Withdrawals from treatment due to adverse events",1,4,"Calcium channel blockers","or","binary",3,-0.506077694017806,0.405911968623024,0,2008,0.0593782466235116,182.333333333333
"CD004184","CD004184_pub3_data","1|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Angiotensin-converting enzyme inhibitors","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",1,5,"Angiotensin-converting enzyme inhibitors","reported","reported",6,-0.615374199475113,0.882579231352164,3.89151381453578,2000,0,52.1666666666667
"CD004184","CD004184_pub3_data","1|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Angiotensin II receptor blockers","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",1,5,"Angiotensin II receptor blockers","reported","reported",7,-0.380709460455653,0.558590866194583,0.267901828164704,2006,0,192.142857142857
"CD004184","CD004184_pub3_data","1|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Calcium channel blockers","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",1,5,"Calcium channel blockers","reported","reported",9,-1.27035748320271,0.806355800090597,3.81653499937459,2004.44444444444,0,124.777777777778
"CD004184","CD004184_pub3_data","1|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Diuretics","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",1,5,"Diuretics","reported","reported",2,-6.21666666666667,1.59208109787857,3.1501,2007,0,85.5
"CD004184","CD004184_pub3_data","1|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Angiotensin-converting enzyme inhibitors","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",1,6,"Angiotensin-converting enzyme inhibitors","reported","reported",6,-1.18025317188446,0.738405100705304,2.96331610411352,2000,0,52.1666666666667
"CD004184","CD004184_pub3_data","1|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Angiotensin II receptor blockers","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",1,6,"Angiotensin II receptor blockers","reported","reported",7,-0.413366624970387,0.526717479239477,0.909276276194955,2006,0,192.142857142857
"CD004184","CD004184_pub3_data","1|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Calcium channel blockers","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",1,6,"Calcium channel blockers","reported","reported",9,-0.19781257639696,0.483662190509087,1.26028498376607,2004.44444444444,0,124.777777777778
"CD004184","CD004184_pub3_data","1|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Diuretics","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",1,6,"Diuretics","reported","reported",2,-5.601490192103,0.623665283731658,0,2007,0,85.5
"CD004184","CD004184_pub3_data","1|7|Mean SBP change by ABPM (mmHg)|Calcium channel blockers","Mean SBP change by ABPM (mmHg)",1,7,"Calcium channel blockers","reported","reported",4,-3.94999082716797,1.29771620090267,3.27249468530242,2002.25,0,150.25
"CD004184","CD004184_pub3_data","1|8|Mean DBP change by ABPM (mmHg)|Calcium channel blockers","Mean DBP change by ABPM (mmHg)",1,8,"Calcium channel blockers","reported","reported",4,-2.72926371092426,1.0800572454854,2.58810740681143,2002.25,0,150.25
"CD004184","CD004184_pub3_data","1|9|Surge of SBP (mmHg)|Angiotensin II receptor blockers","Surge of SBP (mmHg)",1,9,"Angiotensin II receptor blockers","reported","reported",3,0,0.107554456273423,0,2010.33333333333,0,329
"CD004184","CD004184_pub3_data","1|9|Surge of SBP (mmHg)|Calcium channel blockers","Surge of SBP (mmHg)",1,9,"Calcium channel blockers","reported","reported",2,0,0.219650583885124,0,2008.5,0,209
"CD004184","CD004184_pub3_data","2|10|Surge of DBP (mmHg)|Angiotensin II receptor blockers","Surge of DBP (mmHg)",2,10,"Angiotensin II receptor blockers","or","binary",3,-0.00543905156046964,1.15732223080431,0,2010.33333333333,0,329
"CD004184","CD004184_pub3_data","2|10|Surge of DBP (mmHg)|Calcium channel blockers","Surge of DBP (mmHg)",2,10,"Calcium channel blockers","or","binary",2,-0.0304622630335667,1.41764278194713,0,2008.5,0,209
"CD004184","CD004184_pub3_data","2|3|Overall adverse events|Calcium channel blocker","Overall adverse events",2,3,"Calcium channel blocker","or","binary",3,-0.576612880510876,0.570452747714854,0.626813062385845,2010.66666666667,0.234163615809057,167
"CD004184","CD004184_pub3_data","2|3|Overall adverse events|Diuretics","Overall adverse events",2,3,"Diuretics","or","binary",2,0.478659889795335,0.551224311932027,0,2007,0.0548931942374565,92.5
"CD004184","CD004184_pub3_data","2|4|Withdrawals from treatment due to adverse events|Angiotensin II receptor blockers","Withdrawals from treatment due to adverse events",2,4,"Angiotensin II receptor blockers","or","binary",3,-0.250080718501923,0.386543964435015,0.0870956274780046,2010.33333333333,0.0397065136791164,370
"CD004184","CD004184_pub3_data","2|4|Withdrawals from treatment due to adverse events|Calcium channel blockers","Withdrawals from treatment due to adverse events",2,4,"Calcium channel blockers","or","binary",3,-0.506077694017806,0.405911968623024,0,2008,0.0593782466235116,182.333333333333
"CD004184","CD004184_pub3_data","2|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Angiotensin-converting enzyme inhibitors","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",2,5,"Angiotensin-converting enzyme inhibitors","reported","reported",6,-0.615374199475113,0.882579231352164,3.89151381453578,2000,0,52.1666666666667
"CD004184","CD004184_pub3_data","2|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Angiotensin II receptor blockers","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",2,5,"Angiotensin II receptor blockers","reported","reported",7,-0.380709460455653,0.558590866194583,0.267901828164704,2006,0,192.142857142857
"CD004184","CD004184_pub3_data","2|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Calcium channel blockers","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",2,5,"Calcium channel blockers","reported","reported",9,-1.27035748320271,0.806355800090597,3.81653499937459,2004.44444444444,0,124.777777777778
"CD004184","CD004184_pub3_data","2|5|24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)|Diuretics","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)",2,5,"Diuretics","reported","reported",2,-6.21666666666667,1.59208109787857,3.1501,2007,0,85.5
"CD004184","CD004184_pub3_data","2|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Angiotensin-converting enzyme inhibitors","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",2,6,"Angiotensin-converting enzyme inhibitors","reported","reported",6,-1.18025317188446,0.738405100705304,2.96331610411352,2000,0,52.1666666666667
"CD004184","CD004184_pub3_data","2|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Angiotensin II receptor blockers","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",2,6,"Angiotensin II receptor blockers","reported","reported",7,-0.413366624970387,0.526717479239477,0.909276276194955,2006,0,192.142857142857
"CD004184","CD004184_pub3_data","2|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Calcium channel blockers","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",2,6,"Calcium channel blockers","reported","reported",9,-0.19781257639696,0.483662190509087,1.26028498376607,2004.44444444444,0,124.777777777778
"CD004184","CD004184_pub3_data","2|6|24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)|Diuretics","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)",2,6,"Diuretics","reported","reported",2,-5.601490192103,0.623665283731658,0,2007,0,85.5
"CD004184","CD004184_pub3_data","2|7|Mean SBP change by ABPM (mmHg)|Calcium channel blockers","Mean SBP change by ABPM (mmHg)",2,7,"Calcium channel blockers","reported","reported",4,-3.94999082716797,1.29771620090267,3.27249468530242,2002.25,0,150.25
"CD004184","CD004184_pub3_data","2|8|Mean DBP change by ABPM (mmHg)|Calcium channel blockers","Mean DBP change by ABPM (mmHg)",2,8,"Calcium channel blockers","reported","reported",4,-2.72926371092426,1.0800572454854,2.58810740681143,2002.25,0,150.25
"CD004184","CD004184_pub3_data","2|9|Surge of SBP (mmHg)|Angiotensin II receptor blockers","Surge of SBP (mmHg)",2,9,"Angiotensin II receptor blockers","reported","reported",3,0,0.107554456273423,0,2010.33333333333,0,329
"CD004184","CD004184_pub3_data","2|9|Surge of SBP (mmHg)|Calcium channel blockers","Surge of SBP (mmHg)",2,9,"Calcium channel blockers","reported","reported",2,0,0.219650583885124,0,2008.5,0,209
"CD004307","CD004307_pub7_data","1|1|Smoking cessation (subgrouped by when incentives were provided)|Incentives not provided at longest follow-up","Smoking cessation (subgrouped by when incentives were provided)",1,1,"Incentives not provided at longest follow-up","reported","reported",5,0,0.395741855272376,0,2021,0.0903934807973798,107.4
"CD004307","CD004307_pub7_data","1|1|Smoking cessation (subgrouped by when incentives were provided)|Incentives provided at longest follow-up","Smoking cessation (subgrouped by when incentives were provided)",1,1,"Incentives provided at longest follow-up","or","binary",7,0.621638731457511,0.0970361148327684,0,2015.57142857143,0.0784539752932657,460.142857142857
"CD004307","CD004307_pub7_data","1|2|Smoking cessation (grouped by substance misuse)|Non-substance misusers","Smoking cessation (grouped by substance misuse)",1,2,"Non-substance misusers","reported","reported",3,0,0.552036859259819,0,2021,0.0848809964237267,141
"CD004307","CD004307_pub7_data","1|2|Smoking cessation (grouped by substance misuse)|Substance misusers","Smoking cessation (grouped by substance misuse)",1,2,"Substance misusers","reported","reported",3,0,0.471200600496119,0,2020,0.0537784679089027,158
"CD004307","CD004307_pub7_data","1|3|Smoking cessation in mixed populations (generic inverse-variance analysis - including new cluster trials)|","Smoking cessation in mixed populations (generic inverse-variance analysis - including new cluster trials)",1,3,"","reported","reported",46,0.448497516958142,0.0718814547985468,0.0598780070462153,2014.81395348837,0,520.869565217391
"CD004307","CD004307_pub7_data","2|3|Contingent rewards versus guaranteed payments|","Contingent rewards versus guaranteed payments",2,3,"","or","binary",3,1.1277840956114,0.536609731184824,1.3410410991499e-06,2011.33333333333,0.033974358974359,75
"CD004372","CD004372_pub3_data","1|1|Mean difference in HADS-D scores at 3-month follow-up|NA","Mean difference in HADS-D scores at 3-month follow-up",1,1,NA,"or","binary",2,0.0175176671471194,1.42542969046308,0,2016,0,78
"CD004372","CD004372_pub3_data","1|2|Mean difference in HADS-D scores at 12-month follow-up|NA","Mean difference in HADS-D scores at 12-month follow-up",1,2,NA,"or","binary",2,0.282334298864902,1.41945558473322,0,2014,0,143.5
"CD004376","CD004376_pub4_data","1|1|Knee pain severity immediately post-intervention|A) Exercise vs attention control/placebo","Knee pain severity immediately post-intervention",1,1,"A) Exercise vs attention control/placebo","reported","reported",28,-0.620298641452941,0.1426897148829,0.489350209704584,2012.55555555556,NA,102.607142857143
"CD004376","CD004376_pub4_data","1|1|Knee pain severity immediately post-intervention|B) Exercise vs no treatment/usual care/limited education","Knee pain severity immediately post-intervention",1,1,"B) Exercise vs no treatment/usual care/limited education","reported","reported",56,-0.754817379576443,0.104073019074603,0.506051160077338,2013.375,NA,74.7142857142857
"CD004376","CD004376_pub4_data","1|1|Knee pain severity immediately post-intervention|C) Exercise when added to another co-intervention","Knee pain severity immediately post-intervention",1,1,"C) Exercise when added to another co-intervention","reported","reported",47,-0.771298640312216,0.113972511700897,0.523803062520656,2016.10869565217,NA,94.4893617021277
"CD004376","CD004376_pub4_data","1|2|Self-reported physical function immediately post-intervention|A) Exercise vs attention control/placebo","Self-reported physical function immediately post-intervention",1,2,"A) Exercise vs attention control/placebo","reported","reported",24,-0.614410927568834,0.115013839405756,0.241939505109968,2011.69565217391,NA,105.666666666667
"CD004376","CD004376_pub4_data","1|2|Self-reported physical function immediately post-intervention|B) Exercise vs no treatment/usual care/limited education","Self-reported physical function immediately post-intervention",1,2,"B) Exercise vs no treatment/usual care/limited education","reported","reported",54,-0.753677325292831,0.110663042791282,0.56573327597044,2013.22222222222,NA,78.6111111111111
"CD004376","CD004376_pub4_data","1|2|Self-reported physical function immediately post-intervention|C) Exercise when added to another co-intervention","Self-reported physical function immediately post-intervention",1,2,"C) Exercise when added to another co-intervention","reported","reported",44,-0.734353952022796,0.106717369966872,0.42096047869398,2016.11627906977,NA,99.5681818181818
"CD004376","CD004376_pub4_data","1|3|Quality of life immediately post-intervention|A) Exercise vs attention control/placebo","Quality of life immediately post-intervention",1,3,"A) Exercise vs attention control/placebo","reported","reported",6,0.555968012583674,0.327745398502334,0.522600935380939,2015.4,NA,75.6666666666667
"CD004376","CD004376_pub4_data","1|3|Quality of life immediately post-intervention|B) Exercise vs no treatment/usual care/limited education","Quality of life immediately post-intervention",1,3,"B) Exercise vs no treatment/usual care/limited education","reported","reported",28,0.371974513035551,0.0767313641721361,0.0925604257272933,2013.14285714286,NA,83.1428571428571
"CD004376","CD004376_pub4_data","1|3|Quality of life immediately post-intervention|C) Exercise when added to another co-intervention","Quality of life immediately post-intervention",1,3,"C) Exercise when added to another co-intervention","reported","reported",12,0.323315259967551,0.129821564543591,0.15684753778996,2018.83333333333,NA,138.333333333333
"CD004376","CD004376_pub4_data","1|4|Participant-reported treatment success immediately post-intervention|A) Exercise vs attention control/placebo","Participant-reported treatment success immediately post-intervention",1,4,"A) Exercise vs attention control/placebo","reported","reported",2,1.45260559868293,0.207805737425231,0,2015.5,0.305161943319838,182
"CD004376","CD004376_pub4_data","1|4|Participant-reported treatment success immediately post-intervention|B) Exercise vs no treatment/usual care/limited education","Participant-reported treatment success immediately post-intervention",1,4,"B) Exercise vs no treatment/usual care/limited education","reported","reported",3,1.24416241179466,0.369027191069625,0.262053744784556,2012,0.342723267622461,135
"CD004376","CD004376_pub4_data","1|4|Participant-reported treatment success immediately post-intervention|C) Exercise when added to another co-intervention","Participant-reported treatment success immediately post-intervention",1,4,"C) Exercise when added to another co-intervention","reported","reported",6,1.6311645401376,0.292640244723704,0.381498559497147,2019,0.402932646849053,189.833333333333
"CD004376","CD004376_pub4_data","1|5|Study withdrawals at final follow-up|A) Exercise vs attention control/placebo","Study withdrawals at final follow-up",1,5,"A) Exercise vs attention control/placebo","reported","reported",28,0.895592863220597,0.083512382466829,0.00091361075264552,2012.62962962963,0.166415322014146,102.035714285714
"CD004376","CD004376_pub4_data","1|5|Study withdrawals at final follow-up|B) Exercise vs no treatment/usual care/limited education","Study withdrawals at final follow-up",1,5,"B) Exercise vs no treatment/usual care/limited education","reported","reported",46,0.848626942711174,0.0818431734853152,0,2013.5,0.135587816330541,86.3695652173913
"CD004376","CD004376_pub4_data","1|5|Study withdrawals at final follow-up|C) Exercise when added to another co-intervention","Study withdrawals at final follow-up",1,5,"C) Exercise when added to another co-intervention","reported","reported",30,0.691677822006696,0.0672445578917409,0,2015.5,0.167136837281919,101.833333333333
"CD004376","CD004376_pub4_data","1|6|Adverse events at final follow-up|A) Exercise vs attention control/placebo","Adverse events at final follow-up",1,6,"A) Exercise vs attention control/placebo","reported","reported",5,1.07352771066368,0.695620384219965,0.497151838429881,2009.8,0.0872962584537537,241.6
"CD004376","CD004376_pub4_data","1|6|Adverse events at final follow-up|B) Exercise vs no treatment/usual care/limited education","Adverse events at final follow-up",1,6,"B) Exercise vs no treatment/usual care/limited education","reported","reported",8,0.844221324535237,0.0948184415252531,0,2018.375,0.12328125,95.375
"CD004376","CD004376_pub4_data","1|6|Adverse events at final follow-up|C) Exercise when added to another co-intervention","Adverse events at final follow-up",1,6,"C) Exercise when added to another co-intervention","reported","reported",8,1.1849015747203,0.202234840922006,0,2020.125,0.0836445370775378,156.5
"CD004376","CD004376_pub4_data","2|1|Knee pain severity|A) Exercise vs attention control/placebo","Knee pain severity",2,1,"A) Exercise vs attention control/placebo","reported","reported",2,-0.119168042565903,0.101639444226428,0,2021,NA,194
"CD004376","CD004376_pub4_data","2|1|Knee pain severity|B) Exercise vs no treatment/usual care/limited education","Knee pain severity",2,1,"B) Exercise vs no treatment/usual care/limited education","reported","reported",12,-0.322296462212081,0.161956413863232,0.257263205982145,2011.25,NA,124.5
"CD004376","CD004376_pub4_data","2|1|Knee pain severity|C) Exercise when added to another co-intervention","Knee pain severity",2,1,"C) Exercise when added to another co-intervention","reported","reported",13,-0.787760602721984,0.216792436021722,0.551099881988298,2015,NA,116.692307692308
"CD004376","CD004376_pub4_data","2|2|Self-reported physical function|A) Exercise vs attention control/placebo","Self-reported physical function",2,2,"A) Exercise vs attention control/placebo","reported","reported",2,0.0125163834408735,0.10155022300627,0,2021,NA,194
"CD004376","CD004376_pub4_data","2|2|Self-reported physical function|B) Exercise vs no treatment/usual care/limited education","Self-reported physical function",2,2,"B) Exercise vs no treatment/usual care/limited education","reported","reported",12,-0.32068637008002,0.0991969163728883,0.0693192117758337,2011.25,NA,124.5
"CD004376","CD004376_pub4_data","2|2|Self-reported physical function|C) Exercise when added to another co-intervention","Self-reported physical function",2,2,"C) Exercise when added to another co-intervention","reported","reported",12,-0.616445768656674,0.18883032374773,0.38263273154655,2015.83333333333,NA,127.083333333333
"CD004376","CD004376_pub4_data","2|3|Quality of life|B) Exercise vs no treatment/usual care/limited education","Quality of life",2,3,"B) Exercise vs no treatment/usual care/limited education","reported","reported",6,0.0537266600376522,0.0743352232870086,0,2011.5,NA,133.166666666667
"CD004376","CD004376_pub4_data","2|3|Quality of life|C) Exercise when added to another co-intervention","Quality of life",2,3,"C) Exercise when added to another co-intervention","reported","reported",6,0.412395496310949,0.176914903327716,0.148428621146993,2018,NA,149.5
"CD004376","CD004376_pub4_data","3|1|Selection bias: knee pain severity|A) Exercise vs attention control/placebo","Selection bias: knee pain severity",3,1,"A) Exercise vs attention control/placebo","reported","reported",13,-0.586252034820703,0.175769821031851,0.318675957430877,2012.5,NA,103.538461538462
"CD004376","CD004376_pub4_data","3|1|Selection bias: knee pain severity|B) Exercise vs no treatment/usual care/limited education","Selection bias: knee pain severity",3,1,"B) Exercise vs no treatment/usual care/limited education","reported","reported",23,-0.536854154567059,0.0778548465358772,0.0741109128378232,2013.91304347826,NA,78.8695652173913
"CD004376","CD004376_pub4_data","3|1|Selection bias: knee pain severity|C) Exercise when added to another co-intervention","Selection bias: knee pain severity",3,1,"C) Exercise when added to another co-intervention","reported","reported",17,-0.391482263263538,0.0842575636500467,0.0697666129799315,2017.23529411765,NA,144.352941176471
"CD004376","CD004376_pub4_data","3|2|Selection bias: self-reported physical function|A) Exercise vs attention control/placebo","Selection bias: self-reported physical function",3,2,"A) Exercise vs attention control/placebo","reported","reported",9,-0.634491670253405,0.149430766014683,0.124433071479364,2009.75,NA,112.333333333333
"CD004376","CD004376_pub4_data","3|2|Selection bias: self-reported physical function|B) Exercise vs no treatment/usual care/limited education","Selection bias: self-reported physical function",3,2,"B) Exercise vs no treatment/usual care/limited education","reported","reported",25,-0.610601528709439,0.0959366930442293,0.162768863083942,2013.88,NA,88.2
"CD004376","CD004376_pub4_data","3|2|Selection bias: self-reported physical function|C) Exercise when added to another co-intervention","Selection bias: self-reported physical function",3,2,"C) Exercise when added to another co-intervention","reported","reported",16,-0.368739365121431,0.094448668887272,0.0937984167905369,2017.0625,NA,151.875
"CD004376","CD004376_pub4_data","3|3|Attrition bias: knee pain severity|A) Exercise vs attention control/placebo","Attrition bias: knee pain severity",3,3,"A) Exercise vs attention control/placebo","reported","reported",14,-0.365019901955629,0.073373274758013,0.0248147134051538,2012.71428571429,NA,119.928571428571
"CD004376","CD004376_pub4_data","3|3|Attrition bias: knee pain severity|B) Exercise vs no treatment/usual care/limited education","Attrition bias: knee pain severity",3,3,"B) Exercise vs no treatment/usual care/limited education","reported","reported",28,-0.620507952720035,0.117467089515815,0.300123168218611,2012.10714285714,NA,88.7857142857143
"CD004376","CD004376_pub4_data","3|3|Attrition bias: knee pain severity|C) Exercise when added to another co-intervention","Attrition bias: knee pain severity",3,3,"C) Exercise when added to another co-intervention","reported","reported",23,-0.729106515279744,0.162078343670296,0.527239600984542,2016.47826086957,NA,131.434782608696
"CD004376","CD004376_pub4_data","3|4|Attrition bias: self-reported physical function|A) Exercise vs attention control/placebo","Attrition bias: self-reported physical function",3,4,"A) Exercise vs attention control/placebo","reported","reported",12,-0.453577355948897,0.111241459294808,0.0841092987753402,2012.33333333333,NA,122.25
"CD004376","CD004376_pub4_data","3|4|Attrition bias: self-reported physical function|B) Exercise vs no treatment/usual care/limited education","Attrition bias: self-reported physical function",3,4,"B) Exercise vs no treatment/usual care/limited education","reported","reported",27,-0.669677653425982,0.134560269339288,0.405536363606864,2011.81481481481,NA,86.2962962962963
"CD004376","CD004376_pub4_data","3|4|Attrition bias: self-reported physical function|C) Exercise when added to another co-intervention","Attrition bias: self-reported physical function",3,4,"C) Exercise when added to another co-intervention","reported","reported",22,-0.580247113375616,0.128629862252179,0.298513843639595,2016.31818181818,NA,136.318181818182
"CD004376","CD004376_pub4_data","3|5|Detection bias: knee pain severity|A) Exercise vs attention control/placebo","Detection bias: knee pain severity",3,5,"A) Exercise vs attention control/placebo","reported","reported",2,-0.722923180535181,0.242301197981956,0,2009.5,NA,38.5
"CD004376","CD004376_pub4_data","3|5|Detection bias: knee pain severity|C) Exercise when added to another co-intervention","Detection bias: knee pain severity",3,5,"C) Exercise when added to another co-intervention","reported","reported",7,-0.639113977996412,0.195744340727019,0.231581778789547,2016.28571428571,NA,146
"CD004376","CD004376_pub4_data","3|6|Detection bias: self-reported physical function|A) Exercise vs attention control/placebo","Detection bias: self-reported physical function",3,6,"A) Exercise vs attention control/placebo","reported","reported",2,-0.668036913725549,0.24132697540881,0,2009.5,NA,38.5
"CD004376","CD004376_pub4_data","3|6|Detection bias: self-reported physical function|C) Exercise when added to another co-intervention","Detection bias: self-reported physical function",3,6,"C) Exercise when added to another co-intervention","reported","reported",7,-0.640509227014459,0.208467216161689,0.267494659900533,2016.28571428571,NA,146
"CD004376","CD004376_pub4_data","4|1|Exercise vs attention control/placebo (pain severity)|Mind-body","Exercise vs attention control/placebo (pain severity)",4,1,"Mind-body","reported","reported",6,-0.522402780674066,0.139531518035698,0.0293388613212031,2013.66666666667,NA,49
"CD004376","CD004376_pub4_data","4|1|Exercise vs attention control/placebo (pain severity)|Mixed","Exercise vs attention control/placebo (pain severity)",4,1,"Mixed","reported","reported",5,-0.331291751592058,0.104750256379703,0.0172230969686144,2005.4,NA,113.2
"CD004376","CD004376_pub4_data","4|1|Exercise vs attention control/placebo (pain severity)|Strengthening","Exercise vs attention control/placebo (pain severity)",4,1,"Strengthening","reported","reported",9,-0.240408160696543,0.132607475563934,0.105878695073713,2013.125,NA,128.777777777778
"CD004376","CD004376_pub4_data","4|1|Exercise vs attention control/placebo (pain severity)|Stretching","Exercise vs attention control/placebo (pain severity)",4,1,"Stretching","reported","reported",2,-2.50436962026316,0.341037450764747,0.0218811867079801,2021,NA,36
"CD004376","CD004376_pub4_data","4|2|Exercise vs attention control/placebo (physical function)|Mind-body","Exercise vs attention control/placebo (physical function)",4,2,"Mind-body","reported","reported",6,-0.669879813359435,0.143280424131907,0.0335926912620512,2013.66666666667,NA,49
"CD004376","CD004376_pub4_data","4|2|Exercise vs attention control/placebo (physical function)|Mixed","Exercise vs attention control/placebo (physical function)",4,2,"Mixed","reported","reported",6,-0.854630750352613,0.322336993139997,0.55475237992313,2008.16666666667,NA,100
"CD004376","CD004376_pub4_data","4|2|Exercise vs attention control/placebo (physical function)|Strengthening","Exercise vs attention control/placebo (physical function)",4,2,"Strengthening","reported","reported",6,-0.16978259398201,0.0977229285639124,0.0189507444570726,2011,NA,143.333333333333
"CD004376","CD004376_pub4_data","4|3|Exercise vs no treatment/usual care/limited education (pain severity)|Aerobic","Exercise vs no treatment/usual care/limited education (pain severity)",4,3,"Aerobic","reported","reported",6,-1.10851625560522,0.542432908303506,1.65703734104284,2017.66666666667,NA,53.3333333333333
"CD004376","CD004376_pub4_data","4|3|Exercise vs no treatment/usual care/limited education (pain severity)|Mind-body","Exercise vs no treatment/usual care/limited education (pain severity)",4,3,"Mind-body","reported","reported",7,-1.39792372338869,0.817685552033284,4.5143854670665,2013.85714285714,NA,88.7142857142857
"CD004376","CD004376_pub4_data","4|3|Exercise vs no treatment/usual care/limited education (pain severity)|Mixed","Exercise vs no treatment/usual care/limited education (pain severity)",4,3,"Mixed","reported","reported",18,-0.512817072877363,0.0698020772511008,0.0309133255303213,2012.44444444444,NA,90.0555555555556
"CD004376","CD004376_pub4_data","4|3|Exercise vs no treatment/usual care/limited education (pain severity)|Strengthening","Exercise vs no treatment/usual care/limited education (pain severity)",4,3,"Strengthening","reported","reported",19,-0.803099856885991,0.19877751697229,0.643255665442095,2012.15789473684,NA,68.5789473684211
"CD004376","CD004376_pub4_data","4|4|Exercise vs no treatment/usual care/limited education (physical function)|Aerobic","Exercise vs no treatment/usual care/limited education (physical function)",4,4,"Aerobic","reported","reported",6,-1.03364176857985,0.536383901725756,1.62026031263971,2017.66666666667,NA,53.3333333333333
"CD004376","CD004376_pub4_data","4|4|Exercise vs no treatment/usual care/limited education (physical function)|Mind-body","Exercise vs no treatment/usual care/limited education (physical function)",4,4,"Mind-body","reported","reported",6,-1.20248167894945,0.529530567021174,1.55610348143654,2012.66666666667,NA,56.1666666666667
"CD004376","CD004376_pub4_data","4|4|Exercise vs no treatment/usual care/limited education (physical function)|Mixed","Exercise vs no treatment/usual care/limited education (physical function)",4,4,"Mixed","reported","reported",19,-0.433375441569686,0.0593953735090674,0.0188452562379541,2013,NA,103.526315789474
"CD004376","CD004376_pub4_data","4|4|Exercise vs no treatment/usual care/limited education (physical function)|Strengthening","Exercise vs no treatment/usual care/limited education (physical function)",4,4,"Strengthening","reported","reported",18,-0.948490427682773,0.251316832895993,1.02184814347106,2011.05555555556,NA,73.5555555555556
"CD004376","CD004376_pub4_data","4|5|Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)|Aerobic","Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)",4,5,"Aerobic","reported","reported",9,-0.900045730889769,0.25553733032284,0.463306301996802,2017,NA,40.2222222222222
"CD004376","CD004376_pub4_data","4|5|Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)|Mixed","Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)",4,5,"Mixed","reported","reported",12,-0.424199284595927,0.0930991941085026,0.0470895093872578,2017.08333333333,NA,108.333333333333
"CD004376","CD004376_pub4_data","4|5|Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)|Strengthening","Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)",4,5,"Strengthening","reported","reported",23,-0.897725438016465,0.200688285186355,0.844756535191076,2014.91304347826,NA,107.608695652174
"CD004376","CD004376_pub4_data","4|6|Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)|Aerobic","Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)",4,6,"Aerobic","reported","reported",7,-1.02355210785389,0.208703319321342,0.186260011490662,2018.42857142857,NA,42.5714285714286
"CD004376","CD004376_pub4_data","4|6|Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)|Mixed","Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)",4,6,"Mixed","reported","reported",13,-0.63727422965435,0.25981271963496,0.788456366505361,2017.23076923077,NA,105.538461538462
"CD004376","CD004376_pub4_data","4|6|Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)|Strengthening","Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)",4,6,"Strengthening","reported","reported",21,-0.723187650120568,0.153676121660138,0.429127676846223,2014.28571428571,NA,114.619047619048
"CD004406","CD004406_pub6_data","1|1|Resolution of symptoms post-treatment (ITT analysis)|Adults","Resolution of symptoms post-treatment (ITT analysis)",1,1,"Adults","or","binary",2,-0.251931805979912,0.135226153319432,0,1997,0.276709677419355,581.5
"CD004406","CD004406_pub6_data","1|1|Resolution of symptoms post-treatment (ITT analysis)|Children","Resolution of symptoms post-treatment (ITT analysis)",1,1,"Children","or","binary",3,-0.181478035167163,0.378956877535489,0.297208020124797,1988.33333333333,0.231955652490004,285
"CD004406","CD004406_pub6_data","1|2|Resolution of symptoms post-treatment (evaluable participants)|Adults","Resolution of symptoms post-treatment (evaluable participants)",1,2,"Adults","or","binary",2,-0.573378626322199,0.43626815771928,0.252295517172333,1997,0.115128598999567,440
"CD004406","CD004406_pub6_data","1|2|Resolution of symptoms post-treatment (evaluable participants)|Children","Resolution of symptoms post-treatment (evaluable participants)",1,2,"Children","or","binary",3,-0.737731310203144,0.59276228958465,0.775631619957053,1988.33333333333,0.134452846233923,260
"CD004406","CD004406_pub6_data","1|4|Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)|Sponsor not reported","Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)",1,4,"Sponsor not reported","or","binary",2,-0.736990301772668,0.27654529412498,0,1993.5,0.128076335877863,384.5
"CD004406","CD004406_pub6_data","1|4|Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)|Sponsored studies","Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)",1,4,"Sponsored studies","or","binary",3,-0.097188460374855,0.136009715869908,0.0061233699951532,1990.66666666667,0.331044546850998,416.333333333333
"CD004406","CD004406_pub6_data","1|7|Incidence of relapse (evaluable participants)|Adults","Incidence of relapse (evaluable participants)",1,7,"Adults","or","binary",2,-0.834140406767327,0.359229715660994,0,1997,0.0635673127291776,385
"CD004406","CD004406_pub6_data","1|7|Incidence of relapse (evaluable participants)|Children","Incidence of relapse (evaluable participants)",1,7,"Children","or","binary",2,-0.100625562402344,0.485767617817995,0,1991.5,0.0709425821440425,308
"CD004406","CD004406_pub6_data","1|9|Adverse events (ITT analysis)|","Adverse events (ITT analysis)",1,9,"","or","binary",3,-0.0529065470673808,0.557217124478262,0.821822294415283,1995,0.219660522273426,426.333333333333
"CD004406","CD004406_pub6_data","2|1|Resolution of symptoms post-treatment (ITT analysis)|Adults","Resolution of symptoms post-treatment (ITT analysis)",2,1,"Adults","or","binary",5,0.0698013726045918,0.114503000708855,0,1994.4,0.4270331297972,247.8
"CD004406","CD004406_pub6_data","2|2|Resolution of symptoms post-treatment (evaluable participants only)|Adults","Resolution of symptoms post-treatment (evaluable participants only)",2,2,"Adults","or","binary",5,-0.126187184839706,0.203144711876363,0,1994.4,0.144409447564793,160.2
"CD004406","CD004406_pub6_data","2|3|Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)|Sponsor not reported","Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)",2,3,"Sponsor not reported","or","binary",3,0.104471173605938,0.144677293773084,0,1992.66666666667,0.392545454802057,286.666666666667
"CD004406","CD004406_pub6_data","2|3|Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)|Sponsored studies","Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)",2,3,"Sponsored studies","or","binary",3,0.109332417965763,0.136098871524599,0,1996.66666666667,0.437785835146241,289.333333333333
"CD004406","CD004406_pub6_data","2|4|Sore throat post-treatment (ITT analysis)|","Sore throat post-treatment (ITT analysis)",2,4,"","or","binary",2,-0.0340418582158232,0.208863944559084,0,1991,0.455693581780538,185.5
"CD004406","CD004406_pub6_data","2|5|Fever post-treatment (ITT analysis)|","Fever post-treatment (ITT analysis)",2,5,"","or","binary",2,0.0617535693008028,0.240592025739317,0.0219377461401529,1991,0.379158040027605,185.5
"CD004406","CD004406_pub6_data","2|6|Incidence of relapse (evaluable participants)|Adults","Incidence of relapse (evaluable participants)",2,6,"Adults","or","binary",5,-0.13368349342358,0.404420047549662,8.47240821284474e-06,1994.4,0.0638716241213467,99
"CD004406","CD004406_pub6_data","2|7|Adverse events (ITT analysis)|Adults","Adverse events (ITT analysis)",2,7,"Adults","or","binary",5,0.0456275330680361,0.152065782374885,0.0254426382889609,1994.4,0.368688356502021,247.6
"CD004406","CD004406_pub6_data","4|1|Resolution of symptoms post-treatment (ITT analysis)|Adults","Resolution of symptoms post-treatment (ITT analysis)",4,1,"Adults","or","binary",2,-0.281008980766012,0.243845530176913,0.0505610307083865,1992,0.364581724581725,281
"CD004406","CD004406_pub6_data","4|2|Resolution of symptoms post-treatment (evaluable participants)|Adults","Resolution of symptoms post-treatment (evaluable participants)",4,2,"Adults","or","binary",2,-0.499485727159014,0.321858991609607,0,1992,0.12322974036192,205
"CD004406","CD004406_pub6_data","4|3|Incidence of relapse (evaluable participants)|","Incidence of relapse (evaluable participants)",4,3,"","or","binary",3,0.213373808658999,0.335460103939508,0,1992,0.0611438605292863,174.333333333333
"CD004406","CD004406_pub6_data","4|4|Adverse events (ITT analysis)|","Adverse events (ITT analysis)",4,4,"","or","binary",3,0.0731808422629367,0.184331520873399,0,1992,0.190964719460295,265
"CD004417","CD004417_pub6_data","1|1|Number of participants with pain on days 3 to 6: delayed versus immediate antibiotics|Delayed (prescription at time of visit) versus immediate antibiotics","Number of participants with pain on days 3 to 6: delayed versus immediate antibiotics",1,1,"Delayed (prescription at time of visit) versus immediate antibiotics","or","binary",3,0.962783244572634,0.853651375868837,2.05002359500077,1999.66666666667,0.400907908167436,204.333333333333
"CD004417","CD004417_pub6_data","1|2|Pain severity on day 3: delayed versus immediate antibiotics|","Pain severity on day 3: delayed versus immediate antibiotics",1,2,"","or","binary",2,-0.0074379378984512,1.4189359800738,0,1994,0,163.5
"CD004417","CD004417_pub6_data","1|3|Duration of pain: delayed versus immediate antibiotics (days)|Pharyngitis: delayed (prescription at time of visit) versus immediate antibiotics","Duration of pain: delayed versus immediate antibiotics (days)",1,3,"Pharyngitis: delayed (prescription at time of visit) versus immediate antibiotics","or","binary",2,0.0217742948384936,1.41717670708934,0,2016.5,0,246.5
"CD004417","CD004417_pub6_data","1|4|Duration of pain: delayed versus no antibiotics (days) |Pharyngitis pain: delayed (prescription at time of visit) versus no antibiotics","Duration of pain: delayed versus no antibiotics (days) ",1,4,"Pharyngitis pain: delayed (prescription at time of visit) versus no antibiotics","or","binary",2,-0.00880611985510804,1.41721919482064,0,2016.5,0,242.5
"CD004417","CD004417_pub6_data","2|1|Number of participants with malaise on days 3 to 6: delayed versus immediate antibiotics|Delayed (all strategies) versus immediate antibiotics","Number of participants with malaise on days 3 to 6: delayed versus immediate antibiotics",2,1,"Delayed (all strategies) versus immediate antibiotics","or","binary",2,1.76985900698239,0.872231929473574,1.34742208701717,1996,0.0883883883883884,257
"CD004417","CD004417_pub6_data","2|2|Malaise severity on day 3: delayed versus immediate antibiotics|Delayed (both strategies) versus immediate antibiotics","Malaise severity on day 3: delayed versus immediate antibiotics",2,2,"Delayed (both strategies) versus immediate antibiotics","or","binary",2,-0.0216373303598146,1.41852482655871,0,1994,0,199
"CD004417","CD004417_pub6_data","2|3|Duration of malaise: delayed versus immediate antibiotics |Delayed (prescription at time of visit) versus immediate antibiotics","Duration of malaise: delayed versus immediate antibiotics ",2,3,"Delayed (prescription at time of visit) versus immediate antibiotics","or","binary",2,0.0217742948384936,1.41717670708934,0,2016.5,0,246.5
"CD004417","CD004417_pub6_data","2|4|Duration of malaise: delayed versus no antibiotics|Delayed (prescription at time of visit) versus no antibiotics","Duration of malaise: delayed versus no antibiotics",2,4,"Delayed (prescription at time of visit) versus no antibiotics","or","binary",2,-0.00880611985510804,1.41721919482064,0,2016.5,0,242.5
"CD004417","CD004417_pub6_data","3|1|Number of participants with fever on days 3 to 6: delayed (prescription at time of visit) versus immediate antibiotics|","Number of participants with fever on days 3 to 6: delayed (prescription at time of visit) versus immediate antibiotics",3,1,"","or","binary",2,-0.145962016413491,0.238913984690871,0,2004,0.221319427601261,197
"CD004417","CD004417_pub6_data","3|2|Fever severity on day 3: delayed (prescription at time of visit) versus immediate antibiotic|","Fever severity on day 3: delayed (prescription at time of visit) versus immediate antibiotic",3,2,"","or","binary",3,-0.0138408861274555,1.15880877363335,0,1993.33333333333,0,154
"CD004417","CD004417_pub6_data","4|1|Antibiotic use: delayed versus immediate antibiotics|Antibiotic use: delayed (both strategies) versus immediate antibiotics","Antibiotic use: delayed versus immediate antibiotics",4,1,"Antibiotic use: delayed (both strategies) versus immediate antibiotics","or","binary",8,-3.56836072942851,0.482879488862464,1.54334713478572,2005.625,0.923926074227469,282.125
"CD004417","CD004417_pub6_data","4|1|Antibiotic use: delayed versus immediate antibiotics|Antibiotic use: delayed (prescription at time of visit) versus immediate antibiotics","Antibiotic use: delayed versus immediate antibiotics",4,1,"Antibiotic use: delayed (prescription at time of visit) versus immediate antibiotics","or","binary",4,-2.76195306932407,0.532594990805181,0.982475632818902,2010.25,0.890856630521062,223
"CD004417","CD004417_pub6_data","4|1|Antibiotic use: delayed versus immediate antibiotics|Antibiotic use: delayed (prescription collection) versus immediate antibiotics","Antibiotic use: delayed versus immediate antibiotics",4,1,"Antibiotic use: delayed (prescription collection) versus immediate antibiotics","or","binary",5,-4.13560361474155,0.495048981891624,0.834353362895498,2003.2,0.947774632168882,293.2
"CD004417","CD004417_pub6_data","4|2|Antibiotic use: delayed versus no antibiotics|Antibiotic use: delayed (all strategies) versus no antibiotics","Antibiotic use: delayed versus no antibiotics",4,2,"Antibiotic use: delayed (all strategies) versus no antibiotics","or","binary",5,0.906111851411641,0.197789984402149,0.100003774359075,2008.6,0.13130158975833,305.8
"CD004417","CD004417_pub6_data","4|2|Antibiotic use: delayed versus no antibiotics|Antibiotic use: delayed (prescription at time of visit) versus no antibiotics","Antibiotic use: delayed versus no antibiotics",4,2,"Antibiotic use: delayed (prescription at time of visit) versus no antibiotics","or","binary",3,1.15474112544675,0.199197101346287,0,2013.66666666667,0.122455122894228,231.333333333333
"CD004417","CD004417_pub6_data","4|2|Antibiotic use: delayed versus no antibiotics|Antibiotic use: delayed (prescription collection) versus no antibiotics","Antibiotic use: delayed versus no antibiotics",4,2,"Antibiotic use: delayed (prescription collection) versus no antibiotics","or","binary",3,0.710366045016059,0.280359900234269,0.14232958154898,2004.66666666667,0.135596546310832,312.333333333333
"CD004417","CD004417_pub6_data","5|1|Patient satisfaction: delayed versus immediate antibiotics|Patient satisfaction: delayed (all strategies) versus immediate antibiotics","Patient satisfaction: delayed versus immediate antibiotics",5,1,"Patient satisfaction: delayed (all strategies) versus immediate antibiotics","or","binary",7,-0.257854444443746,0.264242340019201,0.266867852564679,2005.57142857143,0.908538801904545,275.285714285714
"CD004417","CD004417_pub6_data","5|1|Patient satisfaction: delayed versus immediate antibiotics|Patient satisfaction: delayed (prescription at time of visit) versus immediate antibiotics","Patient satisfaction: delayed versus immediate antibiotics",5,1,"Patient satisfaction: delayed (prescription at time of visit) versus immediate antibiotics","or","binary",2,0.476266414580147,0.347984937804187,0,2011.5,0.90693112467306,211.5
"CD004417","CD004417_pub6_data","5|1|Patient satisfaction: delayed versus immediate antibiotics|Patient satisfaction: delayed (prescription collection) versus immediate antibiotics","Patient satisfaction: delayed versus immediate antibiotics",5,1,"Patient satisfaction: delayed (prescription collection) versus immediate antibiotics","or","binary",4,-0.713237570519668,0.191839239549968,0.00159275123288149,2001,0.931031796441969,301.25
"CD004417","CD004417_pub6_data","5|2|Patient satisfaction: delayed versus no antibiotics|Patient satisfaction: delayed (all strategies) versus no antibiotics","Patient satisfaction: delayed versus no antibiotics",5,2,"Patient satisfaction: delayed (all strategies) versus no antibiotics","or","binary",5,0.368553943928551,0.151898188163369,0,2008.6,0.845347089869303,304.6
"CD004417","CD004417_pub6_data","5|2|Patient satisfaction: delayed versus no antibiotics|Patient satisfaction: delayed (prescription at time of visit) versus no antibiotics","Patient satisfaction: delayed versus no antibiotics",5,2,"Patient satisfaction: delayed (prescription at time of visit) versus no antibiotics","or","binary",2,0.367440581648776,0.334717062746134,0,2014.5,0.909225352112676,247
"CD004417","CD004417_pub6_data","5|2|Patient satisfaction: delayed versus no antibiotics|Patient satisfaction: delayed (prescription collection) versus no antibiotics","Patient satisfaction: delayed versus no antibiotics",5,2,"Patient satisfaction: delayed (prescription collection) versus no antibiotics","or","binary",2,0.317814006009411,0.202298475386756,0,2001,0.810202978621187,366
"CD004417","CD004417_pub6_data","6|1|Vomiting: delayed versus immediate antibiotics|Delayed (all strategies) versus immediate antibiotics","Vomiting: delayed versus immediate antibiotics",6,1,"Delayed (all strategies) versus immediate antibiotics","or","binary",3,1.01106185616617,1.01945640212645,2.93893077440731,1998,0.0762726636410847,302.333333333333
"CD004417","CD004417_pub6_data","6|1|Vomiting: delayed versus immediate antibiotics|Delayed (prescription at time of visit) versus immediate antibiotics","Vomiting: delayed versus immediate antibiotics",6,1,"Delayed (prescription at time of visit) versus immediate antibiotics","or","binary",2,1.53807868085673,1.54872380186237,4.59225226112982,1998.5,0.074408995461627,247
"CD004417","CD004417_pub6_data","6|3|Diarrhoea: delayed versus immediate antibiotics|Delayed (all strategies) versus immediate antibiotics","Diarrhoea: delayed versus immediate antibiotics",6,3,"Delayed (all strategies) versus immediate antibiotics","or","binary",4,-0.525102281883154,0.337551471286323,0.316327884939716,2001.5,0.181518220036896,267
"CD004417","CD004417_pub6_data","6|3|Diarrhoea: delayed versus immediate antibiotics|Delayed (prescription at time of visit) versus immediate antibiotics","Diarrhoea: delayed versus immediate antibiotics",6,3,"Delayed (prescription at time of visit) versus immediate antibiotics","or","binary",2,-0.763795174044411,0.53990384249601,0.409828718587633,2004,0.213315546931846,197
"CD004417","CD004417_pub6_data","6|3|Diarrhoea: delayed versus immediate antibiotics|Delayed (prescription collection) versus immediate antibiotics","Diarrhoea: delayed versus immediate antibiotics",6,3,"Delayed (prescription collection) versus immediate antibiotics","or","binary",2,-0.315752852476859,0.51713755887068,0.424496364896519,1999,0.149720893141946,337
"CD004417","CD004417_pub6_data","6|5|Rash: delayed (prescription collection) versus immediate antibiotics|","Rash: delayed (prescription collection) versus immediate antibiotics",6,5,"","or","binary",2,-0.0366601505518773,0.324841512751126,0,1999,0.0575563909774436,332.5
"CD004417","CD004417_pub6_data","7|1|Reconsultation rate: delayed versus immediate antibiotics|Reconsultation rate: delayed (all strategies) versus immediate antibiotics","Reconsultation rate: delayed versus immediate antibiotics",7,1,"Reconsultation rate: delayed (all strategies) versus immediate antibiotics","or","binary",4,0.0277418019433767,0.225312154346014,0,2006.5,0.0999775902112924,243
"CD004417","CD004417_pub6_data","7|1|Reconsultation rate: delayed versus immediate antibiotics|Reconsultation rate: delayed (prescription at time of visit) versus immediate antibiotics","Reconsultation rate: delayed versus immediate antibiotics",7,1,"Reconsultation rate: delayed (prescription at time of visit) versus immediate antibiotics","or","binary",4,0.0541431437778013,0.228136851908787,0,2006.5,0.0999775902112924,218
"CD004417","CD004417_pub6_data","7|2|Reconsultation rate: delayed versus no antibiotics|Reconsultation rate: delayed (all strategies) versus no antibiotics ","Reconsultation rate: delayed versus no antibiotics",7,2,"Reconsultation rate: delayed (all strategies) versus no antibiotics ","or","binary",2,-0.189973066985813,0.300723864095124,0,2016.5,0.0904713998275366,292
"CD004417","CD004417_pub6_data","7|2|Reconsultation rate: delayed versus no antibiotics|Reconsultation rate: delayed (prescription at time of visit) versus no antibiotics ","Reconsultation rate: delayed versus no antibiotics",7,2,"Reconsultation rate: delayed (prescription at time of visit) versus no antibiotics ","or","binary",2,-0.118627504923522,0.31123267334051,0,2016.5,0.0904713998275366,242
"CD004508","CD004508_pub5_data","1|1|Postoperative ileus|NA","Postoperative ileus",1,1,NA,"or","binary",4,-0.624129879887743,0.432162081452604,0,2005,0.0634920634920635,104.5
"CD004508","CD004508_pub5_data","1|10|Time to the first solid diet (random-effects model)|NA","Time to the first solid diet (random-effects model)",1,10,NA,"or","binary",3,0.0208888249383351,1.15907871697041,0,2004.66666666667,0,140
"CD004508","CD004508_pub5_data","1|11|Hospital stay (random-effects model)|NA","Hospital stay (random-effects model)",1,11,NA,"or","binary",5,0.0539836827697496,0.899255727660093,0,2006.4,0,120.6
"CD004508","CD004508_pub5_data","1|12|Febrile morbidity|NA","Febrile morbidity",1,12,NA,"or","binary",3,-0.0624292879747298,0.316080117828062,0.118352510576761,2004.33333333333,0.296056057731652,151
"CD004508","CD004508_pub5_data","1|13|Infectious complications|NA","Infectious complications",1,13,NA,"or","binary",2,-1.60468402634777,0.656430662172398,0,2009,0.137626262626263,91.5
"CD004508","CD004508_pub5_data","1|14|Wound complications|NA","Wound complications",1,14,NA,"or","binary",4,-0.259872647454737,0.39055190280821,0.0841283870215093,2004.5,0.104637493420434,118.5
"CD004508","CD004508_pub5_data","1|15|Pneumonia|NA","Pneumonia",1,15,NA,"or","binary",3,-0.814782462898974,0.802708447201241,0,2003,0.0225344722570797,144.666666666667
"CD004508","CD004508_pub5_data","1|2|Nausea or vomiting, or both (random-effects model)|NA","Nausea or vomiting, or both (random-effects model)",1,2,NA,"or","binary",6,-0.106936691412765,0.279018198203202,0.283899499190463,2005.33333333333,0.378716967669251,123.666666666667
"CD004508","CD004508_pub5_data","1|3|Nausea (random-effects model)|NA","Nausea (random-effects model)",1,3,NA,"or","binary",3,0.301443981725001,0.533042926438239,0.59847158205227,2004.33333333333,0.171104105444581,151
"CD004508","CD004508_pub5_data","1|4|Vomiting|NA","Vomiting",1,4,NA,"or","binary",4,-0.19930770560064,0.272016873926173,0,2003.5,0.134322433374813,139.75
"CD004508","CD004508_pub5_data","1|5|Abdominal distension|NA","Abdominal distension",1,5,NA,"or","binary",4,-0.0156474748896631,0.208344267398413,0,2003.5,0.215854043272069,139.75
"CD004508","CD004508_pub5_data","1|6|Postoperative placement of nasogastric tube|NA","Postoperative placement of nasogastric tube",1,6,NA,"or","binary",3,-0.677668231898253,0.588373436464054,0,2004.33333333333,0.0272833513124775,151
"CD004508","CD004508_pub5_data","1|7|Time to the presence of bowel sounds (random-effects model)|NA","Time to the presence of bowel sounds (random-effects model)",1,7,NA,"or","binary",3,0.0659314293178712,1.1583920713505,0,2002.33333333333,0,159
"CD004508","CD004508_pub5_data","1|8|Time to the first passage of flatus|NA","Time to the first passage of flatus",1,8,NA,"or","binary",5,0.0296045762335029,0.897720597115189,0,2004.6,0,140.4
"CD004508","CD004508_pub5_data","1|9|Time to the first passage of stool|NA","Time to the first passage of stool",1,9,NA,"or","binary",4,0.00885680338229087,1.00396431493261,0,2006.25,0,126.75
"CD004661","CD004661_pub4_data","1|12|Adverse effects severe enough to stop treatment|","Adverse effects severe enough to stop treatment",1,12,"","reported","reported",2,0,0.282195476748641,0,2005.5,0.0335523644589545,1651.5
"CD004661","CD004661_pub4_data","1|2|Cerebral palsy (up to 2 years' corrected age)|","Cerebral palsy (up to 2 years' corrected age)",1,2,"","reported","reported",5,0,0.11923595571425,0,2007.8,0.0608579093402175,952.2
"CD004661","CD004661_pub4_data","1|3|Death or cerebral palsy (up to 2 years' corrected age)|","Death or cerebral palsy (up to 2 years' corrected age)",1,3,"","reported","reported",3,0,0.110227696594514,0,2010.66666666667,0.155714106404027,1099.33333333333
"CD004661","CD004661_pub4_data","1|9|Major neurodevelopmental disability (school age)|","Major neurodevelopmental disability (school age)",1,9,"","reported","reported",2,0,0.165429694430746,0,2004.5,0.117130648953241,470
"CD004661","CD004661_pub4_data","10|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|No","Death (fetal, neonatal, or later (up to 2 years' corrected age))",10,1,"No","reported","reported",4,0,0.110531380518334,0,2008.5,0.0818246210342647,908.75
"CD004661","CD004661_pub4_data","10|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|Yes","Death (fetal, neonatal, or later (up to 2 years' corrected age))",10,1,"Yes","reported","reported",2,0,0.122720059353951,0,2014,0.0738248691148954,1562
"CD004661","CD004661_pub4_data","10|2|Cerebral palsy (up to 2 years' corrected age)|No","Cerebral palsy (up to 2 years' corrected age)",10,2,"No","reported","reported",4,0,0.15649406053003,0,2008.5,0.0501482237195103,763.75
"CD004661","CD004661_pub4_data","10|2|Cerebral palsy (up to 2 years' corrected age)|Yes","Cerebral palsy (up to 2 years' corrected age)",10,2,"Yes","reported","reported",2,0,0.168310018299516,0,2014,0.0600942029729924,1526
"CD004661","CD004661_pub4_data","10|3|Death or cerebral palsy (up to 2 years' corrected age)|No","Death or cerebral palsy (up to 2 years' corrected age)",10,3,"No","reported","reported",4,0,0.0862910697070614,0,2008.5,0.125406269458193,839.25
"CD004661","CD004661_pub4_data","10|3|Death or cerebral palsy (up to 2 years' corrected age)|Yes","Death or cerebral palsy (up to 2 years' corrected age)",10,3,"Yes","reported","reported",2,0,0.0950232868241889,0,2014,0.131473378820239,1562
"CD004661","CD004661_pub4_data","10|4|Death or major neurodevelopmental disability (up to 2 years' corrected age)|No","Death or major neurodevelopmental disability (up to 2 years' corrected age)",10,4,"No","reported","reported",2,0,0.0799716875723996,0,2013,0.189430244941427,1254
"CD004661","CD004661_pub4_data","10|5|Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)|No","Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)",10,5,"No","reported","reported",2,0,1.06873077335464,0,2004.5,0.00179856115107914,813
"CD004661","CD004661_pub4_data","10|6|Adverse effects severe enough to stop treatment|No","Adverse effects severe enough to stop treatment",10,6,"No","reported","reported",2,0,0.207202155435781,0,2013,0.0272756921683629,1247.5
"CD004661","CD004661_pub4_data","11|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|","Death (fetal, neonatal, or later (up to 2 years' corrected age))",11,1,"","reported","reported",6,-0.0490162106900818,0.106954989539432,0.0127950011841574,2010.33333333333,0,209.166666666667
"CD004661","CD004661_pub4_data","11|2|Cerebral palsy (up to 2 years' corrected age)|","Cerebral palsy (up to 2 years' corrected age)",11,2,"","reported","reported",6,-0.363253021754067,0.117610380449152,3.53259349195886e-06,2010.33333333333,NA,0
"CD004661","CD004661_pub4_data","11|3|Death or cerebral palsy (up to 2 years' corrected age)|","Death or cerebral palsy (up to 2 years' corrected age)",11,3,"","reported","reported",6,-0.160461796292991,0.0685792817576912,3.84474162668755e-06,2010.33333333333,NA,0
"CD004661","CD004661_pub4_data","11|4|Death or major neurodevelopmental disability (up to 2 years' corrected age)|","Death or major neurodevelopmental disability (up to 2 years' corrected age)",11,4,"","reported","reported",3,-0.0588026573237182,0.0569500619352223,0,2011.33333333333,NA,0
"CD004661","CD004661_pub4_data","11|5|Cerebral palsy (school age)|","Cerebral palsy (school age)",11,5,"","reported","reported",2,0.0807968826351878,0.186246075749538,0.0133672607595,2004.5,NA,0
"CD004661","CD004661_pub4_data","2|10|Severe intraventricular haemorrhage (grade 3 or 4)|","Severe intraventricular haemorrhage (grade 3 or 4)",2,10,"","reported","reported",5,0,0.127359447736559,0,2011.2,0.0624151270208573,1177
"CD004661","CD004661_pub4_data","2|11|Cystic periventricular leukomalacia|","Cystic periventricular leukomalacia",2,11,"","reported","reported",3,0,0.217910081469697,0,2008.33333333333,0.0218660274121025,639
"CD004661","CD004661_pub4_data","2|14|Neonatal convulsions|","Neonatal convulsions",2,14,"","reported","reported",2,0,0.406425260233755,0,2013,0.0194658944658945,680
"CD004661","CD004661_pub4_data","2|16|Necrotising enterocolitis|","Necrotising enterocolitis",2,16,"","reported","reported",3,0,0.199170219771421,0,2009.66666666667,0.0386811899007021,865
"CD004661","CD004661_pub4_data","2|17|Retinopathy of prematurity|","Retinopathy of prematurity",2,17,"","reported","reported",2,0,0.103135498908971,0,2014,0.162853123564538,1546
"CD004661","CD004661_pub4_data","2|18|Patent ductus arteriosus|","Patent ductus arteriosus",2,18,"","reported","reported",2,0,0.0862082935340006,0,2014,0.120129000153116,1546
"CD004661","CD004661_pub4_data","2|19|Respiratory distress syndrome|","Respiratory distress syndrome",2,19,"","reported","reported",2,0,0.0950132452499732,0,2014.5,0.388095159715135,1181
"CD004661","CD004661_pub4_data","2|2|Neonatal death|Defined, where possible, as up to hospital discharge","Neonatal death",2,2,"Defined, where possible, as up to hospital discharge","reported","reported",4,0,0.0933078353259219,0,2009.25,0.0905718391346969,1253.25
"CD004661","CD004661_pub4_data","2|2|Neonatal death|Variously defined","Neonatal death",2,2,"Variously defined","reported","reported",6,0,0.0974074180133335,0,2010.33333333333,0.0603491973363849,1125.16666666667
"CD004661","CD004661_pub4_data","2|20|Chronic lung disease/bronchopulmonary dysplasia|","Chronic lung disease/bronchopulmonary dysplasia",2,20,"","reported","reported",3,0,0.126477283489593,0,2009.66666666667,0.207666725959409,865
"CD004661","CD004661_pub4_data","2|21|Use of respiratory support (endotracheal intubation)|","Use of respiratory support (endotracheal intubation)",2,21,"","reported","reported",2,0,0.0605278764741457,0,2013,0.453238953238953,680
"CD004661","CD004661_pub4_data","2|22|Use of respiratory support (mechanical ventilation or continuous positive airway pressure) |","Use of respiratory support (mechanical ventilation or continuous positive airway pressure) ",2,22,"","reported","reported",2,0,0.0363386250699573,0,2004.5,0.782736394931517,959
"CD004661","CD004661_pub4_data","2|23|Use of inotropic support|","Use of inotropic support",2,23,"","reported","reported",2,0,0.0817056277181387,0,2014,0.197285063543102,1546
"CD004661","CD004661_pub4_data","2|3|Birthweight|Birthweight (grams)","Birthweight",2,3,"Birthweight (grams)","reported","reported",3,0,14.9539866762978,0,2010.33333333333,0,1443.33333333333
"CD004661","CD004661_pub4_data","2|7|Apgar score less than 7 at 5 minutes|","Apgar score less than 7 at 5 minutes",2,7,"","reported","reported",3,0,0.106755606873816,0,2009.66666666667,0.105155111557551,865
"CD004661","CD004661_pub4_data","2|8|Use of active resuscitation at birth|Any","Use of active resuscitation at birth",2,8,"Any","reported","reported",3,0,0.016412123986803,0,2011.33333333333,0.638592169339758,1258.66666666667
"CD004661","CD004661_pub4_data","2|8|Use of active resuscitation at birth|Chest compressions","Use of active resuscitation at birth",2,8,"Chest compressions","reported","reported",2,0,0.147666522047468,0,2014,0.0220295513703874,1546.5
"CD004661","CD004661_pub4_data","2|8|Use of active resuscitation at birth|Intubation","Use of active resuscitation at birth",2,8,"Intubation","reported","reported",2,0,0.0411282360647397,0,2014,0.2359181212678,1546.5
"CD004661","CD004661_pub4_data","2|8|Use of active resuscitation at birth|Supplementary oxygen","Use of active resuscitation at birth",2,8,"Supplementary oxygen","reported","reported",2,0,0.0377478180172385,0,2014,0.59441988210075,1546.5
"CD004661","CD004661_pub4_data","2|9|Intraventricular haemorrhage|","Intraventricular haemorrhage",2,9,"","reported","reported",3,0,0.0841540643425592,0,2008.33333333333,0.203165776529905,639
"CD004661","CD004661_pub4_data","3|1|Later death (up to 2 years' corrected age)|","Later death (up to 2 years' corrected age)",3,1,"","reported","reported",4,0,0.280663928828184,0,2009.25,0.00952681008338408,1253.25
"CD004661","CD004661_pub4_data","3|10|Death or substantial gross motor dysfunction (up to 2 years' corrected age)|","Death or substantial gross motor dysfunction (up to 2 years' corrected age)",3,10,"","reported","reported",2,0,0.0921925958709172,0,2007,0.143978390132199,1561
"CD004661","CD004661_pub4_data","3|2|Cerebral palsy severity (up to 2 years' corrected age)|Mild","Cerebral palsy severity (up to 2 years' corrected age)",3,2,"Mild","reported","reported",4,0,0.189059407231031,0,2008.25,0.0238584211745853,1039
"CD004661","CD004661_pub4_data","3|2|Cerebral palsy severity (up to 2 years' corrected age)|Moderate to severe","Cerebral palsy severity (up to 2 years' corrected age)",3,2,"Moderate to severe","reported","reported",5,0,0.184512420032998,0,2011.2,0.0225246135552267,1100.4
"CD004661","CD004661_pub4_data","3|7|Developmental delay/intellectual impairment (up to 2 years' corrected age)|Any","Developmental delay/intellectual impairment (up to 2 years' corrected age)",3,7,"Any","reported","reported",3,0,0.056099042737295,0,2005.66666666667,0.303500073184144,1332
"CD004661","CD004661_pub4_data","3|8|Gross motor dysfunction (up to 2 years' corrected age)|Any","Gross motor dysfunction (up to 2 years' corrected age)",3,8,"Any","reported","reported",2,0,0.0989746241131391,0,2004.5,0.213503516090188,824
"CD004661","CD004661_pub4_data","4|2|Cerebral palsy severity (school age)|Mild to moderate","Cerebral palsy severity (school age)",4,2,"Mild to moderate","or","binary",2,0.0784202845071885,0.222360113534522,0,2004.5,0.0847312754513488,532.5
"CD004661","CD004661_pub4_data","4|2|Cerebral palsy severity (school age)|Severe","Cerebral palsy severity (school age)",4,2,"Severe","or","binary",2,-0.199243061012032,0.435699901663356,0,2004.5,0.0245117275938057,519
"CD004661","CD004661_pub4_data","4|3|Any neurodevelopmental disability (school age)|Any","Any neurodevelopmental disability (school age)",4,3,"Any","or","binary",2,-0.152486124576066,0.163931880266967,0.00962407904278015,2004.5,0.573338433406725,470
"CD004661","CD004661_pub4_data","4|8|Gross motor dysfunction (school age)|Motor dysfunction/deficits","Gross motor dysfunction (school age)",4,8,"Motor dysfunction/deficits","reported","reported",2,0,0.0825101398076852,0,2004.5,0.391627172195893,513
"CD004661","CD004661_pub4_data","5|1|Death|","Death",5,1,"","or","binary",4,-0.377727072483536,0.943444803574462,0,2010,0.000899280575539568,1325
"CD004661","CD004661_pub4_data","5|2|Cardiac arrest|","Cardiac arrest",5,2,"","or","binary",4,-0.00862245012172747,1.00048161785914,0,2010,0,1325
"CD004661","CD004661_pub4_data","5|21|Postpartum haemorrhage|Severe postpartum haemorrhage","Postpartum haemorrhage",5,21,"Severe postpartum haemorrhage","reported","reported",2,0,0.266712769393844,0,2004.5,0.0255177262364681,813
"CD004661","CD004661_pub4_data","5|3|Respiratory arrest|","Respiratory arrest",5,3,"","or","binary",4,-0.00862245012172747,1.00048161785914,0,2010,0,1325
"CD004661","CD004661_pub4_data","5|5|Side effect: respiratory depression|As defined","Side effect: respiratory depression",5,5,"As defined","reported","reported",3,0,0.145081160859823,0,2004.66666666667,0.0508417368919677,1455
"CD004661","CD004661_pub4_data","7|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|< 32 weeks' gestation","Death (fetal, neonatal, or later (up to 2 years' corrected age))",7,1,"< 32 weeks' gestation","reported","reported",2,0,0.133265740334723,0,2014,0.0556078648573802,1456.5
"CD004661","CD004661_pub4_data","7|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|< 34 weeks' gestation","Death (fetal, neonatal, or later (up to 2 years' corrected age))",7,1,"< 34 weeks' gestation","reported","reported",3,0,0.199190536025745,0,2010.33333333333,0.052123988855058,793.333333333333
"CD004661","CD004661_pub4_data","7|2|Cerebral palsy (up to 2 years' corrected age)|< 32 weeks' gestation","Cerebral palsy (up to 2 years' corrected age)",7,2,"< 32 weeks' gestation","reported","reported",2,0,0.175156052562629,0,2014,0.0567697923003389,1438
"CD004661","CD004661_pub4_data","7|2|Cerebral palsy (up to 2 years' corrected age)|< 34 weeks' gestation","Cerebral palsy (up to 2 years' corrected age)",7,2,"< 34 weeks' gestation","reported","reported",3,0,0.224186091496199,0,2010.33333333333,0.0396269442070773,669.333333333333
"CD004661","CD004661_pub4_data","7|3|Death or cerebral palsy (up to 2 years' corrected age)|< 32 weeks' gestation","Death or cerebral palsy (up to 2 years' corrected age)",7,3,"< 32 weeks' gestation","reported","reported",2,0,0.101612818528706,0,2014,0.111153420105234,1456.5
"CD004661","CD004661_pub4_data","7|3|Death or cerebral palsy (up to 2 years' corrected age)|< 34 weeks' gestation","Death or cerebral palsy (up to 2 years' corrected age)",7,3,"< 34 weeks' gestation","reported","reported",3,0,0.143421252166799,0,2010.33333333333,0.0878686361678995,700.666666666667
"CD004661","CD004661_pub4_data","8|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|> 4 g","Death (fetal, neonatal, or later (up to 2 years' corrected age))",8,1,"> 4 g","reported","reported",2,0,0.122720059353951,0,2014,0.0738248691148954,1562
"CD004661","CD004661_pub4_data","8|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|4 g","Death (fetal, neonatal, or later (up to 2 years' corrected age))",8,1,"4 g","reported","reported",4,0,0.110531380518334,0,2008.5,0.0818246210342647,908.75
"CD004661","CD004661_pub4_data","8|2|Cerebral palsy (up to 2 years' corrected age)|> 4 g","Cerebral palsy (up to 2 years' corrected age)",8,2,"> 4 g","reported","reported",2,0,0.168310018299516,0,2014,0.0600942029729924,1526
"CD004661","CD004661_pub4_data","8|2|Cerebral palsy (up to 2 years' corrected age)|4 g","Cerebral palsy (up to 2 years' corrected age)",8,2,"4 g","reported","reported",4,0,0.15649406053003,0,2008.5,0.0501482237195103,763.75
"CD004661","CD004661_pub4_data","8|3|Death or cerebral palsy (up to 2 years' corrected age)|> 4 g","Death or cerebral palsy (up to 2 years' corrected age)",8,3,"> 4 g","reported","reported",2,0,0.0950232868241889,0,2014,0.131473378820239,1562
"CD004661","CD004661_pub4_data","8|3|Death or cerebral palsy (up to 2 years' corrected age)|4 g","Death or cerebral palsy (up to 2 years' corrected age)",8,3,"4 g","reported","reported",4,0,0.0862910697070614,0,2008.5,0.125406269458193,839.25
"CD004661","CD004661_pub4_data","8|4|Death or major neurodevelopmental disability (up to 2 years' corrected age)|4 g","Death or major neurodevelopmental disability (up to 2 years' corrected age)",8,4,"4 g","reported","reported",2,0,0.0799716875723996,0,2013,0.189430244941427,1254
"CD004661","CD004661_pub4_data","8|5|Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)|4 g","Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)",8,5,"4 g","reported","reported",2,0,1.06873077335464,0,2004.5,0.00179856115107914,813
"CD004661","CD004661_pub4_data","8|6|Adverse effects severe enough to stop treatment|4 g","Adverse effects severe enough to stop treatment",8,6,"4 g","reported","reported",2,0,0.207202155435781,0,2013,0.0272756921683629,1247.5
"CD004661","CD004661_pub4_data","9|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|1 g/hour","Death (fetal, neonatal, or later (up to 2 years' corrected age))",9,1,"1 g/hour","reported","reported",2,0,0.120422721117871,0,2011.5,0.121071567391284,967.5
"CD004661","CD004661_pub4_data","9|1|Death (fetal, neonatal, or later (up to 2 years' corrected age))|No","Death (fetal, neonatal, or later (up to 2 years' corrected age))",9,1,"No","reported","reported",3,0,0.199190536025745,0,2010.33333333333,0.052123988855058,793.333333333333
"CD004661","CD004661_pub4_data","9|2|Cerebral palsy (up to 2 years' corrected age)|1 g/hour","Cerebral palsy (up to 2 years' corrected age)",9,2,"1 g/hour","reported","reported",2,0,0.186831514965855,0,2011.5,0.0712074688280852,840.5
"CD004661","CD004661_pub4_data","9|2|Cerebral palsy (up to 2 years' corrected age)|No","Cerebral palsy (up to 2 years' corrected age)",9,2,"No","reported","reported",3,0,0.224186091496199,0,2010.33333333333,0.0396269442070773,669.333333333333
"CD004661","CD004661_pub4_data","9|3|Death or cerebral palsy (up to 2 years' corrected age)|1 g/hour","Death or cerebral palsy (up to 2 years' corrected age)",9,3,"1 g/hour","reported","reported",2,0,0.0965923038834277,0,2011.5,0.182807804249106,967.5
"CD004661","CD004661_pub4_data","9|3|Death or cerebral palsy (up to 2 years' corrected age)|No","Death or cerebral palsy (up to 2 years' corrected age)",9,3,"No","reported","reported",3,0,0.143603777925345,0,2010.33333333333,0.0878686361678995,700.666666666667
"CD004667","CD004667_pub6_data","1|1|Spontaneous vaginal birth (as defined by trial authors)|","Spontaneous vaginal birth (as defined by trial authors)",1,1,"","or","binary",15,0.17553679128838,0.0333188174928056,5.01337625083256e-06,2002.26666666667,0.656238907098833,1190.93333333333
"CD004667","CD004667_pub6_data","1|10|Induction of labour|","Induction of labour",1,10,"","or","binary",14,-0.10265426642702,0.0528676422036295,0.0152743949025362,2001.5,0.21848966180269,1261.85714285714
"CD004667","CD004667_pub6_data","1|11|Instrumental vaginal birth (forceps/vacuum)|","Instrumental vaginal birth (forceps/vacuum)",1,11,"","or","binary",14,-0.137345513631583,0.0450386600550821,0,2001.5,0.13457988396827,1269.21428571429
"CD004667","CD004667_pub6_data","1|12|Episiotomy|","Episiotomy",1,12,"","or","binary",15,-0.232317765855247,0.0512437244791459,0.0128747187205225,2001.6,0.23394271581191,1189.26666666667
"CD004667","CD004667_pub6_data","1|13|Third or fourth degree tear|","Third or fourth degree tear",1,13,"","or","binary",7,0.0906172461658514,0.159550041279864,0,2003.14285714286,0.0157455099836432,1348.14285714286
"CD004667","CD004667_pub6_data","1|14|Postpartum haemorrhage (as defined by trial authors)|","Postpartum haemorrhage (as defined by trial authors)",1,14,"","or","binary",11,-0.0896558965806375,0.0631847984436655,0,2002.36363636364,0.0935881072033506,1309.72727272727
"CD004667","CD004667_pub6_data","1|15|Breastfeeding initiation|","Breastfeeding initiation",1,15,"","or","binary",8,0.288339790290136,0.0924840165100421,0.0310510696148393,2004.375,0.626372904529546,1071.875
"CD004667","CD004667_pub6_data","1|2|Caesarean birth|","Caesarean birth",1,2,"","or","binary",16,-0.110581575214185,0.0495389298161632,0.00650650022368496,2002.3125,0.18557961741528,1127.3125
"CD004667","CD004667_pub6_data","1|20|Birth weight less than 2500 g|","Birth weight less than 2500 g",1,20,"","or","binary",8,-0.089237545760633,0.0854029047094991,0,2003.625,0.0589026874074035,1552.5
"CD004667","CD004667_pub6_data","1|22|Apgar score less than or equal to 7 at 5 minutes|","Apgar score less than or equal to 7 at 5 minutes",1,22,"","or","binary",13,-0.0561000096401455,0.130001301414621,0.0333309414300855,2003.15384615385,0.0255990294744426,985.076923076923
"CD004667","CD004667_pub6_data","1|23|Admission to special care nursery/neonatal intensive care unit|","Admission to special care nursery/neonatal intensive care unit",1,23,"","or","binary",13,-0.131250577261854,0.0759785965900946,0.0233038344395273,2001.61538461538,0.106244643977419,1250.76923076923
"CD004667","CD004667_pub6_data","1|24|Fetal loss before 24 weeks gestation|","Fetal loss before 24 weeks gestation",1,24,"","or","binary",12,-0.198008613559922,0.107686772733868,0,2002.25,0.0308986103464253,1326.08333333333
"CD004667","CD004667_pub6_data","1|3|Regional analgesia (epidural/spinal)|","Regional analgesia (epidural/spinal)",1,3,"","or","binary",15,-0.219655405302752,0.0491109485398273,0.0137067257243949,2001.6,0.290641424419926,1183.6
"CD004667","CD004667_pub6_data","1|4|Intact perineum|","Intact perineum",1,4,"","or","binary",12,0.0735509682334193,0.0521484092474401,0.0111497353245136,2000.66666666667,0.334180525543615,1189
"CD004667","CD004667_pub6_data","1|5|Fetal loss at or after 24 weeks gestation|","Fetal loss at or after 24 weeks gestation",1,5,"","or","binary",12,0.184274941795678,0.251695700937782,0,2002.08333333333,0.00360302494266455,1343.5
"CD004667","CD004667_pub6_data","1|6|Preterm birth (< 37 weeks)|","Preterm birth (< 37 weeks)",1,6,"","or","binary",10,-0.061635206347191,0.0989199178356731,0.0319972295442999,2003.5,0.0658423746497396,1385
"CD004667","CD004667_pub6_data","1|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|","Neonatal death (baby born alive at any gestation and dies within 28 days)",1,7,"","or","binary",10,-0.143988561479271,0.318727431478668,0,2003.1,0.00315592029191373,1471.8
"CD004667","CD004667_pub6_data","1|9|Maternal death|","Maternal death",1,9,"","or","binary",3,-0.238738237993463,1.15549414465384,0,2014.33333333333,0,1427.33333333333
"CD004667","CD004667_pub6_data","2|1|Spontaneous vaginal birth (as defined by trial authors)|Caseload/one-to-one","Spontaneous vaginal birth (as defined by trial authors)",2,1,"Caseload/one-to-one","or","binary",5,0.132863867517655,0.0637722945966358,0.00694889146598433,2008.2,0.613723221110203,1420.2
"CD004667","CD004667_pub6_data","2|1|Spontaneous vaginal birth (as defined by trial authors)|Team","Spontaneous vaginal birth (as defined by trial authors)",2,1,"Team","or","binary",10,0.197830067045111,0.0451088697516053,1.01350107842174e-06,1999.3,0.677496750093148,1076.3
"CD004667","CD004667_pub6_data","2|2|Caesarean birth|Caseload/one-to-one","Caesarean birth",2,2,"Caseload/one-to-one","or","binary",5,-0.103975029534821,0.0865675432322071,0.0168076041621729,2008.2,0.21543686537247,1420.2
"CD004667","CD004667_pub6_data","2|2|Caesarean birth|Team","Caesarean birth",2,2,"Team","or","binary",11,-0.096051197175751,0.0619479817842598,3.05156736869049e-07,1999.63636363636,0.172008141071103,994.181818181818
"CD004667","CD004667_pub6_data","2|3|Regional analgesia (epidural/spinal)|Caseload/one-to-one","Regional analgesia (epidural/spinal)",2,3,"Caseload/one-to-one","or","binary",5,-0.139598895900018,0.0760938424248919,0.0122713564405528,2008.2,0.321272391174741,1384.8
"CD004667","CD004667_pub6_data","2|3|Regional analgesia (epidural/spinal)|Team","Regional analgesia (epidural/spinal)",2,3,"Team","or","binary",10,-0.268401211093786,0.0586365244242195,0.00935879835509659,1998.3,0.275325941042519,1083
"CD004667","CD004667_pub6_data","2|4|Intact perineum|Caseload/one-to-one","Intact perineum",2,4,"Caseload/one-to-one","or","binary",4,0.121828646431155,0.100860931749642,0.0186638001844698,2007.25,0.336107778096923,1201.5
"CD004667","CD004667_pub6_data","2|4|Intact perineum|Team","Intact perineum",2,4,"Team","or","binary",8,0.0513979339178677,0.0643673212618847,0.0114943064597397,1997.375,0.333216899266961,1182.75
"CD004667","CD004667_pub6_data","2|5|Fetal loss at or after 24 weeks gestation|Caseload/one-to-one","Fetal loss at or after 24 weeks gestation",2,5,"Caseload/one-to-one","or","binary",4,-0.320338757196676,0.500225758489459,0,2010.25,0.00405459956875347,1401.75
"CD004667","CD004667_pub6_data","2|5|Fetal loss at or after 24 weeks gestation|Team","Fetal loss at or after 24 weeks gestation",2,5,"Team","or","binary",8,0.355339181618311,0.291250144257591,0,1998,0.00337723762962009,1314.375
"CD004667","CD004667_pub6_data","2|6|Preterm birth (< 37 weeks)|Caseload/one-to-one","Preterm birth (< 37 weeks)",2,6,"Caseload/one-to-one","or","binary",4,-0.0999220978329979,0.169674282355533,0.0553426393218177,2010.25,0.0711487012486358,1376.75
"CD004667","CD004667_pub6_data","2|6|Preterm birth (< 37 weeks)|Team","Preterm birth (< 37 weeks)",2,6,"Team","or","binary",6,-0.0187045012289865,0.144831112056494,0.0507137399403497,1999,0.0623048235838088,1390.5
"CD004667","CD004667_pub6_data","2|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|Caseload/one-to-one","Neonatal death (baby born alive at any gestation and dies within 28 days)",2,7,"Caseload/one-to-one","or","binary",4,-0.413775254281916,0.497679743822326,0,2010.25,0.00299556020961134,1401.75
"CD004667","CD004667_pub6_data","2|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|Team","Neonatal death (baby born alive at any gestation and dies within 28 days)",2,7,"Team","or","binary",6,0.043603839826608,0.414999375969886,4.00012448426262e-07,1998.33333333333,0.00326282701344865,1518.5
"CD004667","CD004667_pub6_data","3|1|Spontaneous vaginal birth (as defined by trial authors)|Low risk","Spontaneous vaginal birth (as defined by trial authors)",3,1,"Low risk","or","binary",8,0.198955051186196,0.0468946974052193,0.00147078812417596,2001.375,0.6689224488911,1372.875
"CD004667","CD004667_pub6_data","3|1|Spontaneous vaginal birth (as defined by trial authors)|Mixed risk","Spontaneous vaginal birth (as defined by trial authors)",3,1,"Mixed risk","or","binary",7,0.142259384943301,0.0511445784733599,0,2003.28571428571,0.641743430764813,983
"CD004667","CD004667_pub6_data","3|2|Caesarean birth|Low risk","Caesarean birth",3,2,"Low risk","or","binary",9,-0.141766124434991,0.0814136313105769,0.0179564006098157,2001.55555555556,0.180672060623294,1239.55555555556
"CD004667","CD004667_pub6_data","3|2|Caesarean birth|Mixed risk","Caesarean birth",3,2,"Mixed risk","or","binary",7,-0.0796479727678138,0.0624445727654443,0,2003.28571428571,0.19188933329069,983
"CD004667","CD004667_pub6_data","3|3|Regional analgesia (epidural/spinal)|Low risk","Regional analgesia (epidural/spinal)",3,3,"Low risk","or","binary",8,-0.285710076737581,0.0751675447475607,0.0220571384475336,2000.125,0.281256203726062,1359.125
"CD004667","CD004667_pub6_data","3|3|Regional analgesia (epidural/spinal)|Mixed risk","Regional analgesia (epidural/spinal)",3,3,"Mixed risk","or","binary",7,-0.146097754348947,0.0674829124228666,0.00845519391945521,2003.28571428571,0.3013673909272,983
"CD004667","CD004667_pub6_data","3|4|Intact perineum|Low risk","Intact perineum",3,4,"Low risk","or","binary",6,0.148498831126441,0.0793340791698665,0.0184184221220556,1997.66666666667,0.279799923881055,1430.33333333333
"CD004667","CD004667_pub6_data","3|4|Intact perineum|Mixed risk","Intact perineum",3,4,"Mixed risk","or","binary",6,-0.0213692027538638,0.0622274688055146,0,2003.66666666667,0.388561127206175,947.666666666667
"CD004667","CD004667_pub6_data","3|5|Fetal loss at or after 24 weeks gestation|Low risk","Fetal loss at or after 24 weeks gestation",3,5,"Low risk","or","binary",6,0.101327923666604,0.322190152486055,0,2000.33333333333,0.00353594510566555,1782
"CD004667","CD004667_pub6_data","3|5|Fetal loss at or after 24 weeks gestation|Mixed risk","Fetal loss at or after 24 weeks gestation",3,5,"Mixed risk","or","binary",6,0.314163805698455,0.403178934139111,0,2003.83333333333,0.00367010477966356,905
"CD004667","CD004667_pub6_data","3|6|Preterm birth (< 37 weeks)|Low risk","Preterm birth (< 37 weeks)",3,6,"Low risk","or","binary",5,-0.00534006800015498,0.170663540736629,0.0805587158721939,2002.6,0.0422578672623554,1925
"CD004667","CD004667_pub6_data","3|6|Preterm birth (< 37 weeks)|Mixed risk","Preterm birth (< 37 weeks)",3,6,"Mixed risk","or","binary",5,-0.0898429488128866,0.144856135611658,0.0325808280304593,2004.4,0.0894268820371237,845
"CD004667","CD004667_pub6_data","3|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|Low risk","Neonatal death (baby born alive at any gestation and dies within 28 days)",3,7,"Low risk","or","binary",6,-0.128582516305994,0.359961831229412,0,2000.33333333333,0.00390374535804536,1782
"CD004667","CD004667_pub6_data","3|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|Mixed risk","Neonatal death (baby born alive at any gestation and dies within 28 days)",3,7,"Mixed risk","or","binary",4,-0.308104982717577,0.779477319613047,0.43739095309303,2007.25,0.00203418269271629,1006.5
"CD004667","CD004667_pub6_data","5|1|Spontaneous vaginal birth (as defined by trial authors)|Very high HDI","Spontaneous vaginal birth (as defined by trial authors)",5,1,"Very high HDI","or","binary",14,0.170313240201599,0.033429716449572,1.36498650607402e-07,2001.5,0.672115810166539,1268.42857142857
"CD004667","CD004667_pub6_data","5|2|Caesarean birth|Very high HDI","Caesarean birth",5,2,"Very high HDI","or","binary",15,-0.0989134054301305,0.0493745399085653,0.00590910844282082,2001.6,0.160215742853028,1195.4
"CD004667","CD004667_pub6_data","5|3|Regional analgesia (epidural/spinal)|Very high HDI","Regional analgesia (epidural/spinal)",5,3,"Very high HDI","or","binary",15,-0.219655405302752,0.0491109485398273,0.0137067257243949,2001.6,0.290641424419926,1183.6
"CD004667","CD004667_pub6_data","5|4|Intact perineum|Very high HDI","Intact perineum",5,4,"Very high HDI","or","binary",12,0.0735509682334193,0.0521484092474401,0.0111497353245136,2000.66666666667,0.334180525543615,1189
"CD004667","CD004667_pub6_data","5|5|Fetal loss at or after 24 weeks gestation|Very high HDI","Fetal loss at or after 24 weeks gestation",5,5,"Very high HDI","or","binary",12,0.184274941795678,0.251695700937782,0,2002.08333333333,0.00360302494266455,1343.5
"CD004667","CD004667_pub6_data","5|6|Preterm birth (< 37 weeks)|Very high HDI","Preterm birth (< 37 weeks)",5,6,"Very high HDI","or","binary",10,-0.061635206347191,0.0989199178356731,0.0319972295442999,2003.5,0.0658423746497396,1385
"CD004667","CD004667_pub6_data","5|7|Neonatal death (baby born alive at any gestation and dies within 28 days)|Very high HDI","Neonatal death (baby born alive at any gestation and dies within 28 days)",5,7,"Very high HDI","or","binary",10,-0.143988561479271,0.318727431478668,0,2003.1,0.00315592029191373,1471.8
"CD004703","CD004703_pub3_data","1|1|Serious adverse events|NA","Serious adverse events",1,1,NA,"or","binary",19,-0.229536510129176,0.399458672866725,0,2012.63157894737,0.00429824561403509,91.3157894736842
"CD004703","CD004703_pub3_data","1|2|Chronic pain (persisting for > 6 months after surgery)|NA","Chronic pain (persisting for > 6 months after surgery)",1,2,NA,"or","binary",6,-0.365010263119596,0.48041026431896,0,2015.5,0.0193735827664399,143.333333333333
"CD004703","CD004703_pub3_data","1|3|Hernia recurrence|NA","Hernia recurrence",1,3,NA,"or","binary",17,0.0620735259971996,0.345253476145498,0,2012.47058823529,0.015388067950116,100.705882352941
"CD004703","CD004703_pub3_data","2|1|Bleeding|NA","Bleeding",2,1,NA,"or","binary",15,0.00823466674765602,0.411725848833086,0,2012.73333333333,0.0122222222222222,96.5333333333333
"CD004703","CD004703_pub3_data","2|2|Conversion to another hernia repair method|NA","Conversion to another hernia repair method",2,2,NA,"or","binary",13,-0.79467594986856,0.442474062962483,0,2012.61538461538,0.0316129703629704,90.6153846153846
"CD004703","CD004703_pub3_data","3|1|Return to work (days)|NA","Return to work (days)",3,1,NA,"or","binary",6,-0.0056665867676816,0.822866704527715,0,2009.16666666667,0,97.6666666666667
"CD004703","CD004703_pub3_data","3|2|Early postoperative pain (6 hours postoperative)|NA","Early postoperative pain (6 hours postoperative)",3,2,NA,"reported","reported",2,0,0.235537606333929,0,2014,0,59
"CD004703","CD004703_pub3_data","3|4|Early postoperative pain (30th postoperative day)|NA","Early postoperative pain (30th postoperative day)",3,4,NA,"or","binary",3,-0.0501178089299215,1.16221812820044,0,2008,0,94
"CD004736","CD004736_pub6_data","1|1|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)|","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)",1,1,"","or","binary",14,-1.69551978091422,0.303371424117809,0.827932378213218,1984.35714285714,0.346059038782478,967.357142857143
"CD004736","CD004736_pub6_data","1|10|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",1,10,"Malarial setting","or","binary",2,-1.79392859079645,0.690310815237873,0.599986056386537,2003.5,0.491025641025641,96
"CD004736","CD004736_pub6_data","1|10|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",1,10,"Non-malarial setting","or","binary",6,-1.10543165787614,0.321782779899825,0.521682956680153,1999.5,0.56901763139952,446.833333333333
"CD004736","CD004736_pub6_data","1|11|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more) (ALL)|","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more) (ALL)",1,11,"","or","binary",7,-0.904173892331657,0.12356053102345,7.65409661084949e-07,2001,0.162061840287564,386.285714285714
"CD004736","CD004736_pub6_data","1|12|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,12,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",5,-0.858010979731056,0.128697237791594,3.0795320259903e-06,2001.4,0.14812209763811,455.2
"CD004736","CD004736_pub6_data","1|12|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,12,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",2,-1.56774399819152,0.624455735372972,0.247903255435705,2000,0.196911196911197,214
"CD004736","CD004736_pub6_data","1|13|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,13,"Non-anaemic at the start of supplementation","or","binary",6,-0.886642028138213,0.124003876245954,1.62949608225801e-07,2002.66666666667,0.159832380920286,430.666666666667
"CD004736","CD004736_pub6_data","1|14|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,14,"Higher daily dose (60 mg elemental iron or more)","or","binary",3,-1.19387550342016,0.713506852655291,0.694683031919066,2005,0.130798734158755,628
"CD004736","CD004736_pub6_data","1|14|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,14,"Low daily dose (30 mg or less of elemental iron)","or","binary",3,-1.0352888090271,0.54622146093831,0.448015699635398,2001,0.178893178893179,193
"CD004736","CD004736_pub6_data","1|15|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",1,15,"Non-malarial setting","or","binary",6,-0.90802543450388,0.123797109031595,1.47137106458817e-06,1999.5,0.189072147002157,426
"CD004736","CD004736_pub6_data","1|16|Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)|","Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)",1,16,"","or","binary",3,-0.44022792775421,0.694625393744534,0,2006.33333333333,0.00138657296491508,4686.66666666667
"CD004736","CD004736_pub6_data","1|17|Adverse effects (any reported throughout the intervention period) (ALL)|","Adverse effects (any reported throughout the intervention period) (ALL)",1,17,"","or","binary",11,0.339268695177652,0.286032194699941,0.497110723771176,1986.22222222222,0.17838950553006,220.272727272727
"CD004736","CD004736_pub6_data","1|18|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,18,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",5,0.00637297798668018,0.253163219509105,0.0881324848860991,2001.33333333333,0.150512214342002,237.2
"CD004736","CD004736_pub6_data","1|18|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,18,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",5,0.533709427862404,0.317820890936546,0.236292809003488,1976.8,0.24194469782413,206.4
"CD004736","CD004736_pub6_data","1|19|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,19,"Non-anaemic at the start of supplementation","or","binary",7,0.0314834643571608,0.144807249508976,0.0101694403349746,2000.8,0.25445981265756,235.428571428571
"CD004736","CD004736_pub6_data","1|19|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,19,"Unspecified or mixed anaemia status","or","binary",4,1.75571534193747,0.953271801914282,2.50396046683642,1968,0.0452664680569348,193.75
"CD004736","CD004736_pub6_data","1|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,2,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",7,-1.47146454891656,0.53837549714633,1.21817035582798,1993.57142857143,0.243440268487092,1727.57142857143
"CD004736","CD004736_pub6_data","1|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,2,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",5,-1.59755281416322,0.297330331111214,0.26357327435567,1982.6,0.450635018052237,235.6
"CD004736","CD004736_pub6_data","1|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Unspecified or mixed gestational age","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,2,"Unspecified or mixed gestational age","or","binary",2,-2.86205743470459,0.770342739774268,0.738036634583232,1956.5,0.443784786641929,136
"CD004736","CD004736_pub6_data","1|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",1,20,"Higher daily dose (60 mg elemental iron or more)","or","binary",5,1.42122313653551,0.860111336485158,2.1520641058842,1968,0.0398472596585804,133
"CD004736","CD004736_pub6_data","1|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",1,20,"Low daily dose (30 mg or less of elemental iron)","or","binary",6,0.00720250139129336,0.151071009381485,0.0126563454001692,1996.2,0.28977758285226,255.5
"CD004736","CD004736_pub6_data","1|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Medium daily dose (more than 30 mg and less than 60 mg elemental iron)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",1,20,"Medium daily dose (more than 30 mg and less than 60 mg elemental iron)","or","binary",2,0.689623221868517,0.570514819050632,0,1974.5,0.0212765957446809,112.5
"CD004736","CD004736_pub6_data","1|21|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting",1,21,"Non-malarial setting","or","binary",10,0.274458575678339,0.20569721133608,0.172775879480989,1986,0.196228456083066,221.8
"CD004736","CD004736_pub6_data","1|22|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)|","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)",1,22,"","or","binary",8,-0.939423673873639,0.699553997135762,1.18646901637666,1989.42857142857,0.036231884057971,174.75
"CD004736","CD004736_pub6_data","1|23|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,23,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",4,-1.29872181531297,0.88674785690316,0.778126066656742,1998.33333333333,0.0289855072463768,172.5
"CD004736","CD004736_pub6_data","1|23|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,23,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",3,-0.614448616410483,1.52445323219734,4.18246644844571,1992,0.0579710144927536,186.333333333333
"CD004736","CD004736_pub6_data","1|24|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,24,"Non-anaemic at the start of supplementation","or","binary",4,0.553644639887653,0.935827780495394,0,2001,0,166.75
"CD004736","CD004736_pub6_data","1|24|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,24,"Unspecified or mixed anaemia status","or","binary",4,-2.15065216054296,0.658540958626517,0,1980.75,0.072463768115942,182.75
"CD004736","CD004736_pub6_data","1|25|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron",1,25,"Higher daily dose (60 mg elemental iron or more)","or","binary",5,-1.93993907367837,0.6275643468954,0,1980.75,0.0579710144927536,148.8
"CD004736","CD004736_pub6_data","1|25|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron",1,25,"Low daily dose (30 mg or less of elemental iron)","or","binary",3,0.659039145324655,1.04909561370828,0,2001,0,218
"CD004736","CD004736_pub6_data","1|26|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting",1,26,"Malarial setting","or","binary",2,-2.67782789053264,0.743532402562692,0,1988.5,0.144927536231884,187.5
"CD004736","CD004736_pub6_data","1|26|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting",1,26,"Non-malarial setting","or","binary",6,0.315350921547032,0.781136718635876,0,1989.8,0,170.5
"CD004736","CD004736_pub6_data","1|28|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",1,28,"","or","binary",12,-0.208245044344868,0.095339506898282,0.0196175005447532,2004.1,0.0901997338102513,1524.16666666667
"CD004736","CD004736_pub6_data","1|29|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,29,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",6,-0.460958978712734,0.232970357366031,0.162651418619102,2006.5,0.139605558794468,2304.33333333333
"CD004736","CD004736_pub6_data","1|29|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,29,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",3,0.0443761178871981,0.367316523467626,0,1998,0.032958085528179,221.666666666667
"CD004736","CD004736_pub6_data","1|29|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Unspecified or mixed gestational age at the start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,29,"Unspecified or mixed gestational age at the start of supplementation","or","binary",3,-0.128610855146994,0.140860933173309,0,2007,0.04862973212389,1266.33333333333
"CD004736","CD004736_pub6_data","1|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,3,"Non-anaemic at the start of supplementation","or","binary",8,-1.30089167762301,0.396463147911642,0.809798367544101,1991.625,0.260820877055955,1579.875
"CD004736","CD004736_pub6_data","1|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,3,"Unspecified or mixed anaemia status","or","binary",6,-2.13452302278223,0.373470340513337,0.425373763845742,1974.66666666667,0.459709921084507,150.666666666667
"CD004736","CD004736_pub6_data","1|30|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,30,"Non-anaemic at the start of supplementation","or","binary",8,-0.358234173560796,0.268101717251848,0.22147579073722,2004.66666666667,0.0602153430668292,1644.625
"CD004736","CD004736_pub6_data","1|30|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,30,"Unspecified or mixed anaemia status","or","binary",4,-0.248265127390443,0.0892462617893075,0,2003.25,0.150168515297095,1283.25
"CD004736","CD004736_pub6_data","1|31|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron|Higher daily dose of iron (60 mg elemental iron or more)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron",1,31,"Higher daily dose of iron (60 mg elemental iron or more)","or","binary",6,-0.251490807572289,0.0881511399278091,0,2004.33333333333,0.11827473669379,898.5
"CD004736","CD004736_pub6_data","1|31|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron|Low daily dose of iron (30 mg or less of elemental iron)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron",1,31,"Low daily dose of iron (30 mg or less of elemental iron)","or","binary",6,-0.388917982645054,0.327537919432784,0.310875088779771,2003.75,0.0621247309267125,2149.83333333333
"CD004736","CD004736_pub6_data","1|32|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting",1,32,"Malarial setting","or","binary",5,-0.256238615133242,0.0884630795230958,0,2004.6,0.138083530186394,1056.2
"CD004736","CD004736_pub6_data","1|32|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting",1,32,"Non-malarial setting","or","binary",7,-0.32553670461302,0.300621432141724,0.266586348436116,2003.6,0.0559970221130063,1858.42857142857
"CD004736","CD004736_pub6_data","1|33|Birthweight (g) (ALL)|","Birthweight (g) (ALL)",1,33,"","or","binary",16,-0.0810873693011572,0.503497398525954,0,1998.16666666667,0,1159.625
"CD004736","CD004736_pub6_data","1|34|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,34,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",11,-0.117201487042013,0.608443275195336,0,1994.71428571429,0,1289.45454545455
"CD004736","CD004736_pub6_data","1|34|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,34,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",3,-0.0305125306468342,1.15958504141558,0,1999,0,227
"CD004736","CD004736_pub6_data","1|34|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Unspecified or mixed gestational age at the start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,34,"Unspecified or mixed gestational age at the start of supplementation","or","binary",2,0.0388621460442566,1.41462476973535,0,2009,0,1844.5
"CD004736","CD004736_pub6_data","1|35|Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,35,"Non-anaemic at the start of supplementation","or","binary",10,-0.056300474513764,0.638869973942271,0,2000.83333333333,0,1311.3
"CD004736","CD004736_pub6_data","1|35|Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,35,"Unspecified or mixed anaemia status","or","binary",6,-0.12172048300064,0.817977706472844,0,1995.5,0,906.833333333333
"CD004736","CD004736_pub6_data","1|36|Birthweight (g): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Birthweight (g): SUBGROUP ANALYSIS by dose of iron",1,36,"Higher daily dose (60 mg elemental iron or more)","or","binary",10,-0.105075461132829,0.638123592003922,0,1995.375,0,556.6
"CD004736","CD004736_pub6_data","1|36|Birthweight (g): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Birthweight (g): SUBGROUP ANALYSIS by dose of iron",1,36,"Low daily dose (30 mg or less of elemental iron)","or","binary",7,-0.134141402255754,0.759390477682208,0,1996.2,0,1855.42857142857
"CD004736","CD004736_pub6_data","1|37|Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting",1,37,"Malarial setting","or","binary",5,0.0327552656377636,0.895651861842828,0,2005.2,0,1059.4
"CD004736","CD004736_pub6_data","1|37|Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting",1,37,"Non-malarial setting","or","binary",11,-0.133686454568911,0.608801703879278,0,1993.14285714286,0,1205.18181818182
"CD004736","CD004736_pub6_data","1|38|Preterm birth (less than 37 weeks of gestation) (ALL)|","Preterm birth (less than 37 weeks of gestation) (ALL)",1,38,"","or","binary",11,-0.0869977051251599,0.0548119022834159,0,2005.88888888889,0.0973891586643775,1711.54545454545
"CD004736","CD004736_pub6_data","1|39|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,39,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",7,-0.046393835963886,0.0634547122428433,0,2007,0.10044369558264,2096.28571428571
"CD004736","CD004736_pub6_data","1|39|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,39,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",2,-0.575513538771677,0.363519154937041,0,2000,0.0684681023973994,238.5
"CD004736","CD004736_pub6_data","1|39|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Unspecified or mixed gestational age at the start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,39,"Unspecified or mixed gestational age at the start of supplementation","or","binary",2,-0.170026861982627,0.114012932412494,0,2009,0.115619335717435,1838
"CD004736","CD004736_pub6_data","1|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,4,"Higher daily dose (60 mg elemental iron or more)","or","binary",9,-2.11110796914405,0.265469130915899,0.231528720881698,1975.22222222222,0.425537665668009,148.888888888889
"CD004736","CD004736_pub6_data","1|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,4,"Low daily dose (30 mg or less of elemental iron)","or","binary",4,-0.478203202239142,0.297199607647169,0.187417133985568,2003.75,0.173746887985652,3033.5
"CD004736","CD004736_pub6_data","1|40|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,40,"Non-anaemic at the start of supplementation","or","binary",7,-0.253833666769414,0.166351488748504,0.0495638855306414,2005,0.0787120577088563,1861.14285714286
"CD004736","CD004736_pub6_data","1|40|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified/mixed anaemia status","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,40,"Unspecified/mixed anaemia status","or","binary",4,-0.0744020137231923,0.0828443160928265,0,2007,0.13007408533654,1449.75
"CD004736","CD004736_pub6_data","1|41|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",1,41,"Higher daily dose (60 mg elemental iron or more)","or","binary",6,-0.0835560746906075,0.0821519955178343,0,2007.6,0.101673321848291,993.333333333333
"CD004736","CD004736_pub6_data","1|41|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",1,41,"Low daily dose (30 mg or less of elemental iron)","or","binary",5,-0.228531423430647,0.170729811511167,0.0485615415971315,2003.75,0.0922481628436809,2573.4
"CD004736","CD004736_pub6_data","1|42|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",1,42,"Malarial setting","or","binary",5,-0.0839134444175841,0.0822167344922857,0,2007.6,0.12200798621795,1189.4
"CD004736","CD004736_pub6_data","1|42|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",1,42,"Non-malarial setting","or","binary",6,-0.223353669630099,0.167952497040622,0.0464437545454432,2003.75,0.0768734690364007,2146.66666666667
"CD004736","CD004736_pub6_data","1|43|Neonatal death (within 28 days after delivery) (ALL)|","Neonatal death (within 28 days after delivery) (ALL)",1,43,"","or","binary",4,-0.0228220504214532,0.126566941111988,0,2007.75,0.0273456460561652,4310.75
"CD004736","CD004736_pub6_data","1|44|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,44,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",2,0.0528107224897878,0.185346761543141,0,2006.5,0.0204731483939069,6690.5
"CD004736","CD004736_pub6_data","1|44|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Unspecified or mixed gestational age at the start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,44,"Unspecified or mixed gestational age at the start of supplementation","or","binary",2,-0.0592108555131128,0.216781705761734,0.0293507013945437,2009,0.0342181437184234,1931
"CD004736","CD004736_pub6_data","1|45|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,45,"Unspecified or mixed anaemia status","or","binary",3,-0.0610104765817989,0.145799481833174,0,2006.33333333333,0.0348241078242943,1803.66666666667
"CD004736","CD004736_pub6_data","1|46|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron",1,46,"Higher daily dose (60 mg elemental iron or more)","or","binary",3,-0.0610104765817989,0.145799481833174,0,2006.33333333333,0.0348241078242943,1803.66666666667
"CD004736","CD004736_pub6_data","1|47|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting",1,47,"Malarial setting","or","binary",3,-0.0610104765817989,0.145799481833174,0,2006.33333333333,0.0348241078242943,1803.66666666667
"CD004736","CD004736_pub6_data","1|48|Congenital anomalies (ALL)|","Congenital anomalies (ALL)",1,48,"","or","binary",4,-0.12084039203128,0.21338240547189,0,2007.33333333333,0.0209861639390265,3594.25
"CD004736","CD004736_pub6_data","1|49|Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)",1,49,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",4,-0.12084039203128,0.21338240547189,0,2007.33333333333,0.0209861639390265,3594.25
"CD004736","CD004736_pub6_data","1|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",1,5,"Malarial setting","or","binary",2,-1.53408996791914,0.38030860011056,0.166593328064831,1986.5,0.767425431711146,165
"CD004736","CD004736_pub6_data","1|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",1,5,"Non-malarial setting","or","binary",12,-1.77359086566427,0.369881156508734,1.06676189566278,1984,0.2758313066277,1101.08333333333
"CD004736","CD004736_pub6_data","1|50|Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,50,"Non-anaemic at the start of supplementation","or","binary",2,0.00134013735903878,0.500659415438294,0,2012,0.000587051325058705,5987.5
"CD004736","CD004736_pub6_data","1|50|Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,50,"Unspecified or mixed anaemia status","or","binary",2,-0.14796070488042,0.235878704692399,0,2005,0.0413852765529944,1201
"CD004736","CD004736_pub6_data","1|51|Congenital anomalies: SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Congenital anomalies: SUBGROUP ANALYSIS by dose of iron",1,51,"Higher daily dose (60 mg elemental iron or more)","or","binary",2,-0.14796070488042,0.235878704692399,0,2005,0.0413852765529944,1201
"CD004736","CD004736_pub6_data","1|51|Congenital anomalies: SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Congenital anomalies: SUBGROUP ANALYSIS by dose of iron",1,51,"Low daily dose (30 mg or less of elemental iron)","or","binary",2,0.00134013735903878,0.500659415438294,0,2012,0.000587051325058705,5987.5
"CD004736","CD004736_pub6_data","1|52|Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting",1,52,"Malarial setting","or","binary",2,-0.141124560411105,0.197686150932423,0,2005,0.05234296080978,1199.5
"CD004736","CD004736_pub6_data","1|52|Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting",1,52,"Non-malarial setting","or","binary",2,0.00134013735903878,0.500659415438294,0,2012,0.000587051325058705,5987.5
"CD004736","CD004736_pub6_data","1|53|Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)|","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)",1,53,"","or","binary",14,-1.71706017186099,0.259365548199378,0.532365471110678,1984.21428571429,0.379360148123701,212.928571428571
"CD004736","CD004736_pub6_data","1|56|Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)|","Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)",1,56,"","or","binary",18,-0.13471658782528,0.475686225965073,0,1988.8,0,148.055555555556
"CD004736","CD004736_pub6_data","1|57|Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)|","Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)",1,57,"","or","binary",7,-0.113952676792604,0.762380601718126,0,1989.42857142857,0,116.857142857143
"CD004736","CD004736_pub6_data","1|58|Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)|","Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)",1,58,"","or","binary",8,0.864608249018835,0.307816498436755,0.490230377408931,1986.85714285714,0.145802698854825,182.625
"CD004736","CD004736_pub6_data","1|59|Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)|","Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)",1,59,"","or","binary",7,1.5634147136423,0.644110599438472,2.11638191892633,1981.85714285714,0.0803669142548558,204.142857142857
"CD004736","CD004736_pub6_data","1|6|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)|","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)",1,6,"","or","binary",8,-1.2330236559366,0.285937876300998,0.506937553476401,2000.5,0.54951963380605,359.125
"CD004736","CD004736_pub6_data","1|60|Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)|","Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)",1,60,"","or","binary",3,-0.733196114175999,0.544157518574534,0.197415238486303,2000.33333333333,0.0438095238095238,255.333333333333
"CD004736","CD004736_pub6_data","1|61|Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)|","Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)",1,61,"","or","binary",7,-0.471349263838356,0.74723091364391,0.555472038995267,1986.85714285714,0.0248447204968944,156
"CD004736","CD004736_pub6_data","1|62|Severe anaemia postpartum (Hb less than 80 g/L) (ALL)|","Severe anaemia postpartum (Hb less than 80 g/L) (ALL)",1,62,"","or","binary",7,-0.769821010944014,0.717738936905564,0,1986.14285714286,0.00489795918367347,162.714285714286
"CD004736","CD004736_pub6_data","1|63|Puerperal infection (ALL)|","Puerperal infection (ALL)",1,63,"","or","binary",3,-0.419387138326945,0.164888141059449,0,1992.33333333333,0.0585507902631911,1215.66666666667
"CD004736","CD004736_pub6_data","1|65|Postpartum haemorrhage (ALL)|","Postpartum haemorrhage (ALL)",1,65,"","or","binary",2,-0.228701452450348,0.283442031808737,0,1972,0.0836438923395445,258.5
"CD004736","CD004736_pub6_data","1|67|Diarrhoea (ALL)|","Diarrhoea (ALL)",1,67,"","or","binary",2,-0.724388133960914,0.359080274131108,0,1966,0.142105263157895,180.5
"CD004736","CD004736_pub6_data","1|68|Constipation (ALL)|","Constipation (ALL)",1,68,"","or","binary",3,-0.199323241138298,0.40336238979104,0.250183076058139,1984.5,0.198067006596952,256
"CD004736","CD004736_pub6_data","1|69|Nausea (ALL)|","Nausea (ALL)",1,69,"","or","binary",3,0.963783392227956,0.83136042611436,1.12215695340129,1976.33333333333,0.0735294117647059,216.666666666667
"CD004736","CD004736_pub6_data","1|7|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,7,"Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)","or","binary",5,-1.05644148311757,0.390802424289667,0.633393606314997,1997.4,0.523322323180589,454
"CD004736","CD004736_pub6_data","1|7|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (supplementation started at 20 weeks of gestation or later)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",1,7,"Late gestational age (supplementation started at 20 weeks of gestation or later)","or","binary",3,-1.54962757688356,0.429097320770598,0.379544911443212,1999,0.593181818181818,201
"CD004736","CD004736_pub6_data","1|70|Heartburn (ALL)|","Heartburn (ALL)",1,70,"","or","binary",2,0.238054205411936,0.292707151950857,0.103308028024191,2003,0.386764705882353,298
"CD004736","CD004736_pub6_data","1|71|Vomiting (ALL)|","Vomiting (ALL)",1,71,"","or","binary",3,-0.0966406191070973,0.241729968024358,0,1981.5,0.0996732026143791,221.666666666667
"CD004736","CD004736_pub6_data","1|74|Pre-eclampsia (ALL)|","Pre-eclampsia (ALL)",1,74,"","or","binary",2,-0.375071301044957,0.964355416315919,0,2003.5,0.028149386845039,97.5
"CD004736","CD004736_pub6_data","1|75|Very low birthweight (less than 1500 g) (ALL)|","Very low birthweight (less than 1500 g) (ALL)",1,75,"","or","binary",4,-0.368676289003075,0.429497373495601,0,2001,0.0125635268468361,490
"CD004736","CD004736_pub6_data","1|76|Very premature birth (less than 34 weeks' gestation) (ALL)|","Very premature birth (less than 34 weeks' gestation) (ALL)",1,76,"","or","binary",5,-0.462185684015336,0.209523250910976,0,2004.2,0.0345929086791057,873.2
"CD004736","CD004736_pub6_data","1|77|Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)|","Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)",1,77,"","or","binary",3,-0.0239525361752819,1.15625733894978,0,2004,0,4025.66666666667
"CD004736","CD004736_pub6_data","1|8|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at the start of supplementation","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,8,"Non-anaemic at the start of supplementation","or","binary",6,-0.900206080849355,0.19859477422228,0.156088938706095,2002.66666666667,0.525382903554265,451.5
"CD004736","CD004736_pub6_data","1|8|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified/mixed anaemia status","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",1,8,"Unspecified/mixed anaemia status","or","binary",2,-2.70575956901844,0.445300369848597,0,1994,0.621929824561404,82
"CD004736","CD004736_pub6_data","1|9|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron or more)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,9,"Higher daily dose (60 mg elemental iron or more)","or","binary",4,-1.73830763283958,0.476891663449165,0.678283121943228,2003,0.574121124314719,482.25
"CD004736","CD004736_pub6_data","1|9|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg or less of elemental iron)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",1,9,"Low daily dose (30 mg or less of elemental iron)","or","binary",3,-1.07797055255555,0.287215161582299,0.157572671753024,2001,0.512390857729841,234.333333333333
"CD004736","CD004736_pub6_data","2|1|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)|","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)",2,1,"","or","binary",4,-1.36556030171816,0.461907505938797,0.482251510934957,1987.5,0.317557821133441,490.5
"CD004736","CD004736_pub6_data","2|10|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)|","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)",2,10,"","or","binary",4,-1.55802549956734,0.669681222862778,0,1994,0.0467597765363128,126.5
"CD004736","CD004736_pub6_data","2|11|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation",2,11,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",3,-1.43824421207228,0.74375932570218,0,2000,0.0223463687150838,152
"CD004736","CD004736_pub6_data","2|12|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",2,12,"Unspecified or mixed anaemic status at start of supplementation","or","binary",3,-1.72952007459298,0.710250300994063,0,1994,0.0623463687150838,136.333333333333
"CD004736","CD004736_pub6_data","2|13|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron",2,13,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-1.72797104103987,0.709725879648325,0,1990.33333333333,0.0623463687150838,154
"CD004736","CD004736_pub6_data","2|14|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting",2,14,"Malarial setting","or","binary",3,-1.72952007459298,0.710250300994063,0,1994,0.0623463687150838,136.333333333333
"CD004736","CD004736_pub6_data","2|16|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",2,16,"","or","binary",2,0.0750527854129096,0.793526666477898,0.767343118915806,1991.5,0.20859872611465,655.5
"CD004736","CD004736_pub6_data","2|17|Birthweight (ALL)|","Birthweight (ALL)",2,17,"","or","binary",2,0.102892371125323,1.4221007356751,0,1991.5,0,682.5
"CD004736","CD004736_pub6_data","2|18|Preterm birth (less than 37 weeks of gestation) (ALL)|","Preterm birth (less than 37 weeks of gestation) (ALL)",2,18,"","or","binary",3,0.160480222018926,0.132744834167927,3.19047681091046e-06,1996,0.0681265206812652,499
"CD004736","CD004736_pub6_data","2|19|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation",2,19,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,0.502777117752184,0.740625702629466,0.652183368938152,1991.5,0.102189781021898,683
"CD004736","CD004736_pub6_data","2|20|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",2,20,"Unspecified or mixed anaemic status at start of supplementation","or","binary",3,0.160480222018926,0.132744834167927,3.19047681091046e-06,1996,0.0681265206812652,499
"CD004736","CD004736_pub6_data","2|21|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",2,21,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,0.502777117752184,0.740625702629466,0.652183368938152,1991.5,0.102189781021898,683
"CD004736","CD004736_pub6_data","2|22|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings|Malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings",2,22,"Malarial setting","or","binary",2,0.146147471686294,0.133228579538908,0,2003,0.102189781021898,724.5
"CD004736","CD004736_pub6_data","2|23|Neonatal death (within 28 days after delivery) (ALL)|","Neonatal death (within 28 days after delivery) (ALL)",2,23,"","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","2|24|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation",2,24,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","2|25|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",2,25,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.231351973414738,0.247751022532563,0,1991.5,0.0228310502283105,848
"CD004736","CD004736_pub6_data","2|26|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron",2,26,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","2|27|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation|Non-malarial setting","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation",2,27,"Non-malarial setting","or","binary",2,0.561037064231504,1.27593080877144,0,1988,0,72.5
"CD004736","CD004736_pub6_data","2|29|Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)|","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)",2,29,"","or","binary",3,-1.85812359524958,0.444751135558005,0.0866753296056693,1978.66666666667,0.339869281045752,115.333333333333
"CD004736","CD004736_pub6_data","2|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",2,3,"Non-anaemic at start of supplementation","or","binary",2,-1.40717438671773,0.532778463205343,0,1980,0.0833333333333333,140
"CD004736","CD004736_pub6_data","2|32|Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)|","Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)",2,32,"","or","binary",3,-0.164834405271212,1.16703932532547,0,1984,0,46.6666666666667
"CD004736","CD004736_pub6_data","2|33|Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)|","Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)",2,33,"","or","binary",2,0.206711253234625,1.4227101604566,0,1991.5,0,229.5
"CD004736","CD004736_pub6_data","2|34|Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)|","Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)",2,34,"","or","binary",2,0.618294466634396,0.615845887915966,0.53044903436893,2003,0.13072625698324,223
"CD004736","CD004736_pub6_data","2|35|Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)|","Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)",2,35,"","or","binary",2,1.53149370723744,1.0476717627125,0,1985.5,0,157
"CD004736","CD004736_pub6_data","2|36|Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)|","Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)",2,36,"","or","binary",3,-1.12044693215026,0.351524389631631,0,1994,0.116101694915254,163.666666666667
"CD004736","CD004736_pub6_data","2|37|Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more ) (ALL)|","Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more ) (ALL)",2,37,"","or","binary",3,-1.05386860515527,1.04597205848521,0,1991.66666666667,0.04,63.6666666666667
"CD004736","CD004736_pub6_data","2|38|Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)|","Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)",2,38,"","or","binary",3,-1.55772341468619,1.13018215089508,0.669085057047643,1994,0.019774011299435,163.666666666667
"CD004736","CD004736_pub6_data","2|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",2,4,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-1.85812359524958,0.444751135558005,0.0866753296056693,1978.66666666667,0.339869281045752,115.333333333333
"CD004736","CD004736_pub6_data","2|40|Antepartum haemorrhage (ALL)|","Antepartum haemorrhage (ALL)",2,40,"","or","binary",2,0.13914875556463,0.786486311552896,0,1988,0.0227272727272727,72.5
"CD004736","CD004736_pub6_data","2|44|Very premature birth (less than 34 weeks' gestation) (ALL)|","Very premature birth (less than 34 weeks' gestation) (ALL)",2,44,"","or","binary",2,0.986670789455488,1.24332038475482,0,1993.5,0,46
"CD004736","CD004736_pub6_data","2|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",2,5,"Non-malarial setting","or","binary",2,-1.40717438671773,0.532778463205343,0,1980,0.0833333333333333,140
"CD004736","CD004736_pub6_data","3|1|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)|","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)",3,1,"","or","binary",13,-1.81688513885985,0.276328324912906,0.512263917814517,1982.23076923077,0.372169541491789,148.923076923077
"CD004736","CD004736_pub6_data","3|10|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",3,10,"Malarial setting","or","binary",2,-1.79392859079645,0.690310815237873,0.599986056386537,2003.5,0.491025641025641,96
"CD004736","CD004736_pub6_data","3|10|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",3,10,"Non-malarial setting","or","binary",5,-1.1668484527618,0.41700054731629,0.746153822007867,1996.6,0.528706444462466,212.8
"CD004736","CD004736_pub6_data","3|11|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more) (ALL)|","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more) (ALL)",3,11,"","or","binary",6,-1.11638434344583,0.320258283733113,0.144572428919237,1998.83333333333,0.152912546004651,181.333333333333
"CD004736","CD004736_pub6_data","3|12|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,12,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",4,-0.953476349093573,0.475522666247966,0.330654777560913,1998.25,0.130913220551378,165
"CD004736","CD004736_pub6_data","3|12|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,12,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",2,-1.56774399819152,0.624455735372972,0.247903255435705,2000,0.196911196911197,214
"CD004736","CD004736_pub6_data","3|13|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,13,"Non-anaemic at start of supplementation","or","binary",5,-1.00734533977487,0.301209159808142,0.0881622261174787,2000.4,0.148407335907336,193.6
"CD004736","CD004736_pub6_data","3|14|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Daily low dose (60 mg elemental iron or less)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,14,"Daily low dose (60 mg elemental iron or less)","or","binary",3,-1.0352888090271,0.54622146093831,0.448015699635398,2001,0.178893178893179,193
"CD004736","CD004736_pub6_data","3|14|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|High dose (60 mg elemental iron and above)","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,14,"High dose (60 mg elemental iron and above)","or","binary",2,-1.88890710986292,1.69901019066497,2.84529748691922,2000.5,0.087719298245614,134
"CD004736","CD004736_pub6_data","3|15|Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",3,15,"Non-malarial setting","or","binary",5,-1.1644371076294,0.342922244555698,0.189107691039902,1996.6,0.183495055205582,188
"CD004736","CD004736_pub6_data","3|16|Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)|","Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)",3,16,"","or","binary",2,-0.29508760310039,0.767514919175812,0,2003.5,0.002,773.5
"CD004736","CD004736_pub6_data","3|17|Adverse effects (any reported throughout the intervention period) (ALL)|","Adverse effects (any reported throughout the intervention period) (ALL)",3,17,"","or","binary",9,0.577697597882027,0.235798286928666,0.177268955178522,1983,0.159717985088355,186.333333333333
"CD004736","CD004736_pub6_data","3|18|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,18,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",3,0.38248978455976,0.281087288522892,0,1996,0.075912792224849,146
"CD004736","CD004736_pub6_data","3|18|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,18,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",5,0.530765407366602,0.316701441127018,0.233811124780563,1976.8,0.24194469782413,206.8
"CD004736","CD004736_pub6_data","3|19|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,19,"Non-anaemic at start of supplementation","or","binary",5,0.162778577799676,0.156101199563926,0.000668991875956243,1998,0.251279198713492,180
"CD004736","CD004736_pub6_data","3|19|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,19,"Unspecified or mixed anaemic status at start of supplementation","or","binary",4,1.74109660702857,0.947069208445032,2.45995166771259,1968,0.0452664680569348,194.25
"CD004736","CD004736_pub6_data","3|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,2,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",6,-1.83804074802483,0.564455260565075,0.905365305861518,1990.5,0.279214571691142,91.5
"CD004736","CD004736_pub6_data","3|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,2,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",6,-1.68931908596243,0.270192515980181,0.250352537775541,1978.5,0.453760474227205,216.833333333333
"CD004736","CD004736_pub6_data","3|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",3,20,"Higher daily dose (60 mg elemental iron and above)","or","binary",5,1.63650167198809,0.721886567568736,1.09720696066081,1968,0.0327044025157233,133.4
"CD004736","CD004736_pub6_data","3|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",3,20,"Low daily dose (30 mg elemental iron or less)","or","binary",4,0.121660045020211,0.159341969733802,0,1992.25,0.312081390174696,196.25
"CD004736","CD004736_pub6_data","3|20|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron|Medium daily dose (31 mg to 59 mg elemental iron)","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron",3,20,"Medium daily dose (31 mg to 59 mg elemental iron)","or","binary",2,0.689623221868517,0.570514819050632,0,1974.5,0.0212765957446809,112.5
"CD004736","CD004736_pub6_data","3|21|Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting",3,21,"Non-malarial setting","or","binary",8,0.464641449412358,0.21340939407783,0.119066242549565,1982.28571428571,0.1796827332244,184
"CD004736","CD004736_pub6_data","3|22|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)|","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)",3,22,"","or","binary",7,-0.211161952096554,0.696382234353113,0,1987.5,0.0171428571428571,154
"CD004736","CD004736_pub6_data","3|23|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,23,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",3,-0.0147412496253733,1.16979107385261,0,1997,0,138.666666666667
"CD004736","CD004736_pub6_data","3|23|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,23,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",3,-0.253320378211585,1.24407341643905,1.8113303301994,1992,0.04,171
"CD004736","CD004736_pub6_data","3|24|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation|Non-anaemic at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation",3,24,"Non-anaemic at start of supplementation","or","binary",5,0.359742442102728,0.848166730612349,0,1989.5,0,163.2
"CD004736","CD004736_pub6_data","3|24|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation",3,24,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-1.39210691375498,1.21987229835692,0,1983.5,0.06,131
"CD004736","CD004736_pub6_data","3|25|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron",3,25,"Higher daily dose (60 mg elemental iron and above)","or","binary",4,-0.89661658717363,0.931096333900002,0,1974,0.03,106
"CD004736","CD004736_pub6_data","3|25|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron",3,25,"Low daily dose (30 mg elemental iron or less)","or","binary",3,0.659039145324655,1.04909561370828,0,2001,0,218
"CD004736","CD004736_pub6_data","3|26|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting",3,26,"Non-malarial setting","or","binary",6,0.315350921547032,0.781136718635876,0,1989.8,0,170.5
"CD004736","CD004736_pub6_data","3|28|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",3,28,"","or","binary",7,-0.337830197857611,0.272135373239401,0.17916370503651,2002.85714285714,0.0640459086247392,357
"CD004736","CD004736_pub6_data","3|29|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,29,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,-1.16321495088771,0.407414758262732,0,2006.5,0.128205128205128,180.5
"CD004736","CD004736_pub6_data","3|29|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,29,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",3,0.0443761178871981,0.367316523467626,0,1998,0.032958085528179,221.666666666667
"CD004736","CD004736_pub6_data","3|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,3,"Non-anaemic at start of supplementation","or","binary",8,-1.86138652803025,0.437395286693766,0.938691967693123,1984.5,0.309494298170834,155.5
"CD004736","CD004736_pub6_data","3|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,3,"Unspecified or mixed anaemic status at start of supplementation","or","binary",5,-1.77117766094139,0.316667130770072,0.160538323255742,1978.6,0.472449930805317,138.4
"CD004736","CD004736_pub6_data","3|30|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,30,"Non-anaemic at start of supplementation","or","binary",5,-0.428351226528118,0.444959625118722,0.430601537701241,2003.2,0.0635394200814762,191
"CD004736","CD004736_pub6_data","3|30|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,30,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.13909072251094,0.202092466852032,0,2002,0.065312129982897,772
"CD004736","CD004736_pub6_data","3|31|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron",3,31,"Higher daily dose (60 mg elemental iron and above)","or","binary",4,-0.166523418391656,0.190264547766785,0,2004.25,0.0598996547350382,450.5
"CD004736","CD004736_pub6_data","3|31|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron",3,31,"Low daily dose (30 mg elemental iron or less)","or","binary",3,-0.502218829838527,0.711954967697279,0.900475562885176,2001,0.0695742471443406,232.333333333333
"CD004736","CD004736_pub6_data","3|32|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting",3,32,"Malarial setting","or","binary",3,-0.186349644682422,0.193463490374907,0,2004.66666666667,0.0734559499031279,564
"CD004736","CD004736_pub6_data","3|32|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting",3,32,"Non-malarial setting","or","binary",4,-0.329874570236181,0.579320702780222,0.677791973007719,2001.5,0.0569883776659478,201.75
"CD004736","CD004736_pub6_data","3|33|Birthweight (g) (ALL)|","Birthweight (g) (ALL)",3,33,"","or","binary",10,-0.087657619803623,0.637233035995892,0,1995.22222222222,0,274.1
"CD004736","CD004736_pub6_data","3|34|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,34,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",5,-0.020275060807827,0.90507727323467,0,1996,0,104.8
"CD004736","CD004736_pub6_data","3|34|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,34,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",4,-0.199660600005545,1.00398270897842,0,1990.75,0,213.5
"CD004736","CD004736_pub6_data","3|35|Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,35,"Non-anaemic at start of supplementation","or","binary",6,-0.0165266945666979,0.825410630153416,0,1998.6,0,148.166666666667
"CD004736","CD004736_pub6_data","3|35|Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,35,"Unspecified or mixed anaemic status at start of supplementation","or","binary",4,-0.192599436158853,1.00257095142095,0,1991,0,463
"CD004736","CD004736_pub6_data","3|37|Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting",3,37,"Malarial setting","or","binary",3,0.0416921274757337,1.15710282627699,0,2005.66666666667,0,569.333333333333
"CD004736","CD004736_pub6_data","3|37|Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting",3,37,"Non-malarial setting","or","binary",7,-0.143964806845926,0.763433262273031,0,1990,0,147.571428571429
"CD004736","CD004736_pub6_data","3|38|Preterm birth (less than 37 weeks of gestation) (ALL)|","Preterm birth (less than 37 weeks of gestation) (ALL)",3,38,"","or","binary",7,-0.152676497801714,0.115905454256184,0,2005.33333333333,0.0834804840687825,437.571428571429
"CD004736","CD004736_pub6_data","3|39|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,39,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",4,-0.0956008824912675,0.213304363198455,0,2007.33333333333,0.0706159200092609,309
"CD004736","CD004736_pub6_data","3|39|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,39,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",2,-0.575513538771677,0.363519154937041,0,2000,0.0684681023973994,238.5
"CD004736","CD004736_pub6_data","3|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,4,"Higher daily dose (60 mg elemental iron and above)","or","binary",9,-2.11110796914405,0.265469130915899,0.231528720881698,1975.22222222222,0.425537665668009,148.888888888889
"CD004736","CD004736_pub6_data","3|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,4,"Low daily dose (30 mg elemental iron or less)","or","binary",3,-0.760065850040736,0.264453064253942,6.96524479665177e-06,2001,0.222064367559938,196.666666666667
"CD004736","CD004736_pub6_data","3|40|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,40,"Non-anaemic at start of supplementation","or","binary",5,-0.358952455305766,0.249581042647506,0,2003.25,0.0703359589076777,170.2
"CD004736","CD004736_pub6_data","3|40|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,40,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.0959569293633068,0.13087411192974,0,2009.5,0.116341796971544,1106
"CD004736","CD004736_pub6_data","3|41|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",3,41,"Higher daily dose (60 mg elemental iron and above)","or","binary",4,-0.117373708559004,0.128194623304988,0,2009.66666666667,0.0806067959216696,593.25
"CD004736","CD004736_pub6_data","3|41|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",3,41,"Low daily dose (30 mg elemental iron or less)","or","binary",3,-0.310774481412469,0.271286677074971,0,2001,0.087312068264933,230
"CD004736","CD004736_pub6_data","3|42|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",3,42,"Malarial setting","or","binary",3,-0.118376016604424,0.128441033425247,0,2009.66666666667,0.107475727895559,786.666666666667
"CD004736","CD004736_pub6_data","3|42|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",3,42,"Non-malarial setting","or","binary",4,-0.303114464450636,0.268987694266195,0,2001,0.0654840511986997,175.75
"CD004736","CD004736_pub6_data","3|44|Congenital anomalies (ALL)|","Congenital anomalies (ALL)",3,44,"","or","binary",2,-0.14796070488042,0.235878704692399,0,2005,0.0413852765529944,1201
"CD004736","CD004736_pub6_data","3|45|Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)|","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)",3,45,"","or","binary",14,-1.57501083346215,0.251952495200873,0.44924196982679,1984.21428571429,0.366617789120126,191.285714285714
"CD004736","CD004736_pub6_data","3|46|Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)|","Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)",3,46,"","or","binary",8,-1.22120432795025,0.292184069544128,0.528332303946336,2000,0.471125246493389,281
"CD004736","CD004736_pub6_data","3|47|Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicator at 34 weeks' gestation or more) (ALL)|","Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicator at 34 weeks' gestation or more) (ALL)",3,47,"","or","binary",7,-1.08397662876416,0.194240999850329,1.31314626555271e-06,2000.42857142857,0.143578807253332,291.857142857143
"CD004736","CD004736_pub6_data","3|48|Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)|","Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)",3,48,"","or","binary",16,-0.102186497213627,0.504046794580072,0,1989.71428571429,0,162.4375
"CD004736","CD004736_pub6_data","3|49|Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)|","Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)",3,49,"","or","binary",6,-0.194123816172475,0.824402065392833,0,1987.5,0,86.8333333333333
"CD004736","CD004736_pub6_data","3|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",3,5,"Malarial setting","or","binary",2,-1.32738098532678,0.264803308993565,0,1986.5,0.778511404561825,133.5
"CD004736","CD004736_pub6_data","3|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",3,5,"Non-malarial setting","or","binary",11,-1.96487500250762,0.344739265397699,0.704888614841376,1981.45454545455,0.298289202751782,151.727272727273
"CD004736","CD004736_pub6_data","3|50|Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)|","Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)",3,50,"","or","binary",7,0.815993264444944,0.359981946270476,0.601978619236987,1984.5,0.157852725267445,163.714285714286
"CD004736","CD004736_pub6_data","3|51|Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)|","Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)",3,51,"","or","binary",7,1.49922007300917,0.629007402986642,1.98209868953041,1981.85714285714,0.0803669142548558,169.857142857143
"CD004736","CD004736_pub6_data","3|52|Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)|","Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)",3,52,"","or","binary",3,-0.652902680623109,1.21165888849037,1.45793497251023,1992,0.0666666666666667,151
"CD004736","CD004736_pub6_data","3|53|Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)|","Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)",3,53,"","or","binary",7,-0.252643588827437,0.694580393016859,0,1986.85714285714,0.0171428571428571,149.428571428571
"CD004736","CD004736_pub6_data","3|54|Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)|","Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)",3,54,"","or","binary",6,-0.216530995588817,0.822972960111633,0,1983.66666666667,0,125.5
"CD004736","CD004736_pub6_data","3|55|Puerperal infection (ALL)|","Puerperal infection (ALL)",3,55,"","or","binary",2,-0.446997335619861,0.245295295571362,0,1988,0.0493076668762681,1146
"CD004736","CD004736_pub6_data","3|57|Postpartum haemorrhage (ALL)|","Postpartum haemorrhage (ALL)",3,57,"","or","binary",2,-0.228701452450348,0.283442031808737,0,1972,0.0836438923395445,258.5
"CD004736","CD004736_pub6_data","3|6|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)|","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)",3,6,"","or","binary",7,-1.31041991807219,0.345002107440018,0.656077677870852,1998.57142857143,0.517940500623373,179.428571428571
"CD004736","CD004736_pub6_data","3|60|Constipation (ALL)|","Constipation (ALL)",3,60,"","or","binary",2,-0.12723302065218,0.780575790754984,0.762483712983457,1984.5,0.0471005098954282,290
"CD004736","CD004736_pub6_data","3|61|Nausea (ALL)|","Nausea (ALL)",3,61,"","or","binary",3,0.963783392227956,0.83136042611436,1.12215695340129,1976.33333333333,0.0735294117647059,216.666666666667
"CD004736","CD004736_pub6_data","3|63|Vomiting (ALL)|","Vomiting (ALL)",3,63,"","or","binary",2,-0.115830730472634,0.497095438291821,0.179892640585166,1981.5,0.0661764705882353,238.5
"CD004736","CD004736_pub6_data","3|67|Very low birthweight (less than 1500 g) (ALL)|","Very low birthweight (less than 1500 g) (ALL)",3,67,"","or","binary",3,-0.38851668687759,0.909254463585936,0.500255698580979,2001,0.0119742990654206,232.333333333333
"CD004736","CD004736_pub6_data","3|68|Very premature birth (less than 34 weeks' gestation) (ALL)|","Very premature birth (less than 34 weeks' gestation) (ALL)",3,68,"","or","binary",4,-0.425278959725012,0.289184261550215,0.0256928802844306,2003.25,0.0384173103455265,510
"CD004736","CD004736_pub6_data","3|69|Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)|","Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)",3,69,"","or","binary",2,-0.0347583753154809,1.41704567750357,0,2000,0,266.5
"CD004736","CD004736_pub6_data","3|7|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,7,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",4,-1.12328015587066,0.53862273532992,0.990504587908072,1998.25,0.461509512454539,163.25
"CD004736","CD004736_pub6_data","3|7|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",3,7,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",3,-1.54962757688356,0.429097320770598,0.379544911443212,1999,0.593181818181818,201
"CD004736","CD004736_pub6_data","3|8|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,8,"Non-anaemic at start of supplementation","or","binary",5,-0.898231354474821,0.262965999658034,0.241654801840278,2000.4,0.476344771048161,218.4
"CD004736","CD004736_pub6_data","3|8|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",3,8,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-2.70575956901844,0.445300369848597,0,1994,0.621929824561404,82
"CD004736","CD004736_pub6_data","3|9|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,9,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-2.11832618058892,0.536318114804609,0.526770262699114,1999.33333333333,0.50863697705803,104
"CD004736","CD004736_pub6_data","3|9|Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Low daily dose (30 mg elemental iron or less)","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",3,9,"Low daily dose (30 mg elemental iron or less)","or","binary",3,-1.07797055255555,0.287215161582299,0.157572671753024,2001,0.512390857729841,234.333333333333
"CD004736","CD004736_pub6_data","4|1|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)|","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)",4,1,"","or","binary",3,-1.85812359524958,0.444751135558005,0.0866753296056693,1978.66666666667,0.339869281045752,115.333333333333
"CD004736","CD004736_pub6_data","4|10|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)|","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)",4,10,"","or","binary",4,-1.55802549956734,0.669681222862778,0,1994,0.0467597765363128,126.5
"CD004736","CD004736_pub6_data","4|12|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",4,12,"","or","binary",2,0.0750527854129096,0.793526666477898,0.767343118915806,1991.5,0.20859872611465,655.5
"CD004736","CD004736_pub6_data","4|13|Birthweight (ALL)|","Birthweight (ALL)",4,13,"","or","binary",2,0.102892371125323,1.4221007356751,0,1991.5,0,682.5
"CD004736","CD004736_pub6_data","4|14|Preterm birth (less than 37 weeks of gestation) (ALL)|","Preterm birth (less than 37 weeks of gestation) (ALL)",4,14,"","or","binary",3,0.160480222018926,0.132744834167927,3.19047681091046e-06,1996,0.0681265206812652,499
"CD004736","CD004736_pub6_data","4|15|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",4,15,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,0.502777117752184,0.740625702629466,0.652183368938152,1991.5,0.102189781021898,683
"CD004736","CD004736_pub6_data","4|16|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",4,16,"Unspecified or mixed anaemic status at start of supplementation","or","binary",3,0.160480222018926,0.132744834167927,3.19047681091046e-06,1996,0.0681265206812652,499
"CD004736","CD004736_pub6_data","4|17|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",4,17,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,0.502777117752184,0.740625702629466,0.652183368938152,1991.5,0.102189781021898,683
"CD004736","CD004736_pub6_data","4|18|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",4,18,"Malarial setting","or","binary",2,0.146147471686294,0.133228579538908,0,2003,0.102189781021898,724.5
"CD004736","CD004736_pub6_data","4|19|Neonatal death (within 28 days after delivery) (ALL)|","Neonatal death (within 28 days after delivery) (ALL)",4,19,"","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","4|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",4,2,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",2,-1.94408719453722,0.470356881363227,0.113536910770381,1971,0.509803921568627,124.5
"CD004736","CD004736_pub6_data","4|20|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation",4,20,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","4|21|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation",4,21,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.231351973414738,0.247751022532563,0,1991.5,0.0228310502283105,848
"CD004736","CD004736_pub6_data","4|22|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron",4,22,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-0.205540613939569,0.244990247332722,0,1992.33333333333,0.015220700152207,597.666666666667
"CD004736","CD004736_pub6_data","4|23|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting",4,23,"Non-malarial setting","or","binary",2,0.561037064231504,1.27593080877144,0,1988,0,72.5
"CD004736","CD004736_pub6_data","4|25|Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)|","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)",4,25,"","or","binary",3,-1.85812359524958,0.444751135558005,0.0866753296056693,1978.66666666667,0.339869281045752,115.333333333333
"CD004736","CD004736_pub6_data","4|28|Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)|","Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)",4,28,"","or","binary",3,-0.164834405271212,1.16703932532547,0,1984,0,46.6666666666667
"CD004736","CD004736_pub6_data","4|29|Maternal Hb concentration within 6 weeks postpartum (g/L) (ALL)|","Maternal Hb concentration within 6 weeks postpartum (g/L) (ALL)",4,29,"","or","binary",2,0.206711253234625,1.4227101604566,0,1991.5,0,229.5
"CD004736","CD004736_pub6_data","4|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",4,3,"Non-anaemic at start of supplementation","or","binary",2,-1.40717438671773,0.532778463205343,0,1980,0.0833333333333333,140
"CD004736","CD004736_pub6_data","4|30|Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)|","Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)",4,30,"","or","binary",2,0.618294466634396,0.615845887915966,0.53044903436893,2003,0.13072625698324,223
"CD004736","CD004736_pub6_data","4|31|Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)|","Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)",4,31,"","or","binary",2,1.53149370723744,1.0476717627125,0,1985.5,0,157
"CD004736","CD004736_pub6_data","4|32|Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)|","Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)",4,32,"","or","binary",2,-1.11234633738004,0.373332252009361,0,2003,0.0741525423728814,229
"CD004736","CD004736_pub6_data","4|33|Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)|","Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)",4,33,"","or","binary",3,-1.05386860515527,1.04597205848521,0,1991.66666666667,0.04,63.6666666666667
"CD004736","CD004736_pub6_data","4|34|Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)|","Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)",4,34,"","or","binary",3,-1.55772341468619,1.13018215089508,0.669085057047643,1994,0.019774011299435,163.666666666667
"CD004736","CD004736_pub6_data","4|36|Antepartum haemorrhage (ALL)|","Antepartum haemorrhage (ALL)",4,36,"","or","binary",2,0.13914875556463,0.786486311552896,0,1988,0.0227272727272727,72.5
"CD004736","CD004736_pub6_data","4|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron",4,4,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-1.85812359524958,0.444751135558005,0.0866753296056693,1978.66666666667,0.339869281045752,115.333333333333
"CD004736","CD004736_pub6_data","4|40|Very premature birth (less than 34 weeks' gestation) (ALL)|","Very premature birth (less than 34 weeks' gestation) (ALL)",4,40,"","or","binary",2,0.986670789455488,1.24332038475482,0,1993.5,0,46
"CD004736","CD004736_pub6_data","4|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",4,5,"Non-malarial setting","or","binary",2,-1.40717438671773,0.532778463205343,0,1980,0.0833333333333333,140
"CD004736","CD004736_pub6_data","5|1|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)|","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)",5,1,"","or","binary",4,-0.988853420536036,0.437780156439707,0.638348022911833,1992,0.314202418625675,3365.75
"CD004736","CD004736_pub6_data","5|10|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,10,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,-0.145994453915228,0.171400328172205,0.0440104562127336,2006.5,0.219182976749705,6545
"CD004736","CD004736_pub6_data","5|11|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemia status","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",5,11,"Unspecified or mixed anaemia status","or","binary",2,-0.274714521147465,0.0994712486446871,0,2004.5,0.235024900611294,1794.5
"CD004736","CD004736_pub6_data","5|12|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron",5,12,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,-0.274714521147465,0.0994712486446871,0,2004.5,0.235024900611294,1794.5
"CD004736","CD004736_pub6_data","5|13|Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting",5,13,"Malarial setting","or","binary",2,-0.274714521147465,0.0994712486446871,0,2004.5,0.235024900611294,1794.5
"CD004736","CD004736_pub6_data","5|14|Birthweight (g) (ALL)|","Birthweight (g) (ALL)",5,14,"","or","binary",3,0.0119708359738393,1.15495174776361,0,2007,0,5138.66666666667
"CD004736","CD004736_pub6_data","5|15|Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,15,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,-0.00697385158744149,1.41452305010601,0,2006.5,0,6545
"CD004736","CD004736_pub6_data","5|16|Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",5,16,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,0.0193974265013628,1.41464522171654,0,2004.5,0,1794.5
"CD004736","CD004736_pub6_data","5|17|Birthweight (g): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Birthweight (g): SUBGROUP ANALYSIS by dose of iron",5,17,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,0.0193974265013628,1.41464522171654,0,2004.5,0,1794.5
"CD004736","CD004736_pub6_data","5|18|Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting",5,18,"Malarial setting","or","binary",2,0.0193974265013628,1.41464522171654,0,2004.5,0,1794.5
"CD004736","CD004736_pub6_data","5|19|Preterm birth (less than 37 weeks of gestation) (ALL)|","Preterm birth (less than 37 weeks of gestation) (ALL)",5,19,"","or","binary",3,-0.0491769744035168,0.0631728474167694,5.38975471106535e-07,2007,0.115794157701915,5139.66666666667
"CD004736","CD004736_pub6_data","5|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,2,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,-0.411362272380358,0.354824124712103,0.23687669736132,2013,0.139708945329651,6580
"CD004736","CD004736_pub6_data","5|2|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Late gestational age (20 weeks or more of gestation) at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,2,"Late gestational age (20 weeks or more of gestation) at start of supplementation","or","binary",2,-1.77555358486029,0.377516045660311,0,1971,0.488695891921698,151.5
"CD004736","CD004736_pub6_data","5|20|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,20,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,-0.01899641246414,0.0676425535660316,0,2006.5,0.140553652660255,6546.5
"CD004736","CD004736_pub6_data","5|21|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",5,21,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.0797031977272776,0.152577226370847,0.0228159684146735,2004.5,0.143806373701535,1793.5
"CD004736","CD004736_pub6_data","5|22|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron",5,22,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,-0.0797031977272776,0.152577226370847,0.0228159684146735,2004.5,0.143806373701535,1793.5
"CD004736","CD004736_pub6_data","5|23|Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting",5,23,"Malarial setting","or","binary",2,-0.0797031977272776,0.152577226370847,0.0228159684146735,2004.5,0.143806373701535,1793.5
"CD004736","CD004736_pub6_data","5|24|Neonatal death (within 28 days after delivery) (ALL)|","Neonatal death (within 28 days after delivery) (ALL)",5,24,"","or","binary",3,-0.0679386837964344,0.136681982918388,0,2007,0.0287537323138079,5292
"CD004736","CD004736_pub6_data","5|25|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation|Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation",5,25,"Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation","or","binary",2,0.0528107224897878,0.185346761543141,0,2006.5,0.0204731483939069,6690.5
"CD004736","CD004736_pub6_data","5|26|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Unspecified or mixed anaemic status at start of supplementation","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",5,26,"Unspecified or mixed anaemic status at start of supplementation","or","binary",2,-0.13322939124536,0.161913482267229,0,2004.5,0.0406754680948229,2022
"CD004736","CD004736_pub6_data","5|27|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron",5,27,"Higher daily dose (60 mg elemental iron and above)","or","binary",2,-0.13322939124536,0.161913482267229,0,2004.5,0.0406754680948229,2022
"CD004736","CD004736_pub6_data","5|28|Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting|Malarial setting","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting",5,28,"Malarial setting","or","binary",2,-0.13322939124536,0.161913482267229,0,2004.5,0.0406754680948229,2022
"CD004736","CD004736_pub6_data","5|29|Congenital anomalies (ALL)|","Congenital anomalies (ALL)",5,29,"","or","binary",2,-0.236102616176111,0.290238837463865,0,2006.5,0.0125324438165263,6793
"CD004736","CD004736_pub6_data","5|3|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation|Non-anaemic at start of supplementation","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation",5,3,"Non-anaemic at start of supplementation","or","binary",2,-0.703683146610182,0.720939930306721,0.921797014612229,1989,0.0998673101014818,5892
"CD004736","CD004736_pub6_data","5|30|Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)|","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)",5,30,"","or","binary",2,-1.77555358486029,0.377516045660311,0,1971,0.488695891921698,151.5
"CD004736","CD004736_pub6_data","5|37|Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)|","Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)",5,37,"","or","binary",2,-1.77598068929704,1.19130189528425,0,1988.5,0.0171428571428571,193
"CD004736","CD004736_pub6_data","5|4|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more ): SUBGROUP ANALYSIS by dose of iron|Higher daily dose (60 mg elemental iron and above)","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more ): SUBGROUP ANALYSIS by dose of iron",5,4,"Higher daily dose (60 mg elemental iron and above)","or","binary",3,-1.32090023699545,0.413629766006795,0.350966887333729,1985.33333333333,0.409338408413302,639.666666666667
"CD004736","CD004736_pub6_data","5|5|Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting|Non-malarial setting","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting",5,5,"Non-malarial setting","or","binary",3,-0.673164555837122,0.383903450335514,0.371582560324452,1997.33333333333,0.150119353866491,4466.66666666667
"CD004736","CD004736_pub6_data","5|8|Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)|","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)",5,8,"","or","binary",2,-2.05262971597104,0.916303072054541,0.295823810503931,1988.5,0.0579710144927536,160
"CD004736","CD004736_pub6_data","5|9|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",5,9,"","or","binary",3,-0.153075531386953,0.115053354629328,0.0197978462864726,2007,0.163739434164233,5138.66666666667
"CD004736","CD004736_pub6_data","6|2|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",6,2,"","or","binary",2,-0.727540261566219,0.422800318846334,0,NA,0.0714285714285714,187.5
"CD004736","CD004736_pub6_data","6|3|Birthweight (g) (ALL)|","Birthweight (g) (ALL)",6,3,"","or","binary",3,-0.15425872261997,1.16857573625441,0,NA,0,132.333333333333
"CD004736","CD004736_pub6_data","6|6|Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)|","Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)",6,6,"","or","binary",2,-0.373791066560441,1.44316631019448,0,1971,0,24.5
"CD004762","CD004762_pub3_data","1|2|Relaxation time (seconds, 90% to 5%)|Mexiletine 150 mg 3 times daily ","Relaxation time (seconds, 90% to 5%)",1,2,"Mexiletine 150 mg 3 times daily ","reported","reported",2,-1.36567992493099,0.25438402145032,0,2015.5,0,37
"CD004762","CD004762_pub3_data","2|2|Relaxation time (seconds)|Eye closure","Relaxation time (seconds)",2,2,"Eye closure","reported","reported",2,-1.035374705064,0.881068743336015,1.291101655,2015,0,84
"CD004762","CD004762_pub3_data","2|2|Relaxation time (seconds)|Hand grip","Relaxation time (seconds)",2,2,"Hand grip","reported","reported",2,-0.615677043209876,0.387023296434287,0.222201595,2015,0,84
"CD004762","CD004762_pub3_data","2|4|Quality of life: 36-item Short Form|Physical Component Score (PCS)","Quality of life: 36-item Short Form",2,4,"Physical Component Score (PCS)","reported","reported",2,6.44921947180246,1.08757387425358,0.798077156519498,2015,0,84
"CD004762","CD004762_pub3_data","2|5|Quality of life: Individualized Neuromuscular Quality of Life|","Quality of life: Individualized Neuromuscular Quality of Life",2,5,"","reported","reported",2,-7.35178624455716,5.65845777662091,53.27277342534,2015,0,84
"CD004871","CD004871_pub5_data","1|1|Pain (short-term)|Low-dose (single session)","Pain (short-term)",1,1,"Low-dose (single session)","or","binary",5,0.0064978517785335,0.904799261843564,0,2011.8,0,44.2
"CD004871","CD004871_pub5_data","1|1|Pain (short-term)|Medium-dose","Pain (short-term)",1,1,"Medium-dose","or","binary",2,-0.130309526306298,1.44044525142702,0,2008.5,0,64
"CD004871","CD004871_pub5_data","1|8|Pain (short-term): subgroup analysis by disorder classification|Neck pain without radiculopathy","Pain (short-term): subgroup analysis by disorder classification",1,8,"Neck pain without radiculopathy","or","binary",7,-0.0321805333434634,0.765851064891107,0,2011.14285714286,0,51.8571428571429
"CD004871","CD004871_pub5_data","2|1|Pain (short-term)|Medium-dose","Pain (short-term)",2,1,"Medium-dose","or","binary",5,-0.049738710574476,0.906974103564421,0,2018.2,0,45
"CD004871","CD004871_pub5_data","2|3|Function-disability (short-term)|High-dose","Function-disability (short-term)",2,3,"High-dose","or","binary",2,0.0396381889100232,1.43556356029786,0,2008.5,0,47
"CD004871","CD004871_pub5_data","2|3|Function-disability (short-term)|Medium-dose","Function-disability (short-term)",2,3,"Medium-dose","or","binary",4,-0.0862241150544665,1.01139802600963,0,2018.5,0,51.5
"CD004871","CD004871_pub5_data","3|1|Pain (short-term)|Massage as an adjunct to a passive treatment method","Pain (short-term)",3,1,"Massage as an adjunct to a passive treatment method","or","binary",7,-0.0268012738898117,0.766030207373443,0,2015.42857142857,0,43.5714285714286
"CD004871","CD004871_pub5_data","3|1|Pain (short-term)|Massage as an adjunct to an active (including exercise) treatment method","Pain (short-term)",3,1,"Massage as an adjunct to an active (including exercise) treatment method","or","binary",5,-0.0134918354671916,0.902557443687989,0,2018.2,0,98
"CD004871","CD004871_pub5_data","3|10|Pain (short-term): subgroup analysis by disorder classification|Cervicogenic headache","Pain (short-term): subgroup analysis by disorder classification",3,10,"Cervicogenic headache","or","binary",2,-0.052483869647768,1.43006968532741,0,2016.5,0,53
"CD004871","CD004871_pub5_data","3|10|Pain (short-term): subgroup analysis by disorder classification|Neck pain without radiculopathy","Pain (short-term): subgroup analysis by disorder classification",3,10,"Neck pain without radiculopathy","or","binary",8,-0.010248412813388,0.715653260699446,0,2015.875,0,45.375
"CD004871","CD004871_pub5_data","3|11|Pain (short-term): subgroup analysis by symptom duration|Chronic","Pain (short-term): subgroup analysis by symptom duration",3,11,"Chronic","or","binary",6,-0.0424445561764266,0.825830667933068,0,2017.83333333333,0,86.5
"CD004871","CD004871_pub5_data","3|11|Pain (short-term): subgroup analysis by symptom duration|Subacute ","Pain (short-term): subgroup analysis by symptom duration",3,11,"Subacute ","or","binary",2,0,1.42616150964178,0,2013,0,58
"CD004871","CD004871_pub5_data","3|12|Function-disability (short-term): subgroup analysis by dose|Medium-dose ","Function-disability (short-term): subgroup analysis by dose",3,12,"Medium-dose ","or","binary",6,-0.0284892312114195,0.82593251316409,0,2017,0,83.6666666666667
"CD004871","CD004871_pub5_data","3|13|Function-disability (short-term): subgroup analysis by disorder classification|Neck pain without radiculopathy","Function-disability (short-term): subgroup analysis by disorder classification",3,13,"Neck pain without radiculopathy","or","binary",5,-0.0164304059378695,0.906146663572995,0,2016.2,0,41.8
"CD004871","CD004871_pub5_data","3|14|Function-disability (short-term): subgroup analysis by disorder duration|Chronic","Function-disability (short-term): subgroup analysis by disorder duration",3,14,"Chronic","or","binary",2,-0.0853794704175004,1.42981854629665,0,2019.5,0,160
"CD004871","CD004871_pub5_data","3|14|Function-disability (short-term): subgroup analysis by disorder duration|Subacute","Function-disability (short-term): subgroup analysis by disorder duration",3,14,"Subacute","or","binary",2,0,1.42616150964178,0,2013,0,58
"CD004871","CD004871_pub5_data","3|4|Function-disability (short-term)|Massage adjuvant to a passive method","Function-disability (short-term)",3,4,"Massage adjuvant to a passive method","or","binary",3,-0.0275234876389494,1.17280573589169,0,2016,0,36.3333333333333
"CD004871","CD004871_pub5_data","3|4|Function-disability (short-term)|Massage adjuvant to an active (including exercise) method","Function-disability (short-term)",3,4,"Massage adjuvant to an active (including exercise) method","or","binary",4,-0.0221721380376517,1.00959275439895,0,2018,0,105.75
"CD004871","CD004871_pub5_data","3|7|Health-related quality of life (short-term)|Medium-dose adjuvant to an active (including exercise) method","Health-related quality of life (short-term)",3,7,"Medium-dose adjuvant to an active (including exercise) method","reported","reported",2,0,0.606027559802877,0,2018,0,176
"CD004871","CD004871_pub5_data","3|9|Pain (short-term): subgroup analysis by dose|Medium-dose","Pain (short-term): subgroup analysis by dose",3,9,"Medium-dose","or","binary",11,-0.0231398799180434,0.609762284910215,0,2016.45454545455,0,69.5454545454545
"CD004904","CD004904_pub4_data","1|1|Postpartum endometritis|NA","Postpartum endometritis",1,1,NA,"reported","reported",4,0,0.35184903401421,0,1996.75,0.0506408653291228,243.5
"CD004925","CD004925_pub4_data","1|1|Urine leak and obstruction|Ureteric obstruction","Urine leak and obstruction",1,1,"Ureteric obstruction","reported","reported",2,0,0.955187835896232,0,2005.5,0.0182945736434109,200
"CD004925","CD004925_pub4_data","1|1|Urine leak and obstruction|Urine leak","Urine leak and obstruction",1,1,"Urine leak","or","binary",11,-1.21953021243876,0.360437259135813,1.47106480085368e-06,2005.27272727273,0.0455492543024459,166.727272727273
"CD004925","CD004925_pub4_data","1|2|Subgroup analysis for major urological complications: duration of stenting|Stent duration > 14 days","Subgroup analysis for major urological complications: duration of stenting",1,2,"Stent duration > 14 days","or","binary",8,-1.44813028100204,0.472193845418578,0.365863899753929,2002,0.0741037744169487,155.75
"CD004925","CD004925_pub4_data","1|2|Subgroup analysis for major urological complications: duration of stenting|Stent duration ≤ 14 days","Subgroup analysis for major urological complications: duration of stenting",1,2,"Stent duration ≤ 14 days","or","binary",2,-1.01249838688546,0.337206891878133,0,2010,0.152846715328467,240
"CD004925","CD004925_pub4_data","1|3|Subgroup analysis for major urological complications: surgeon's experience|Many surgeons","Subgroup analysis for major urological complications: surgeon's experience",1,3,"Many surgeons","or","binary",6,-1.43594095244261,0.487169632947895,0.43706289099384,2007,0.0815260974220765,209
"CD004925","CD004925_pub4_data","1|3|Subgroup analysis for major urological complications: surgeon's experience|Same surgeon","Subgroup analysis for major urological complications: surgeon's experience",1,3,"Same surgeon","or","binary",4,-0.898690503341213,0.698417110252887,0.164237581402389,1999,0.0516010196242754,95
"CD004925","CD004925_pub4_data","1|5|UTI: diagnostic criteria|Culture only","UTI: diagnostic criteria",1,5,"Culture only","or","binary",4,0.800252236324231,0.836926001020695,2.35545012175049,2004.75,0.338492745322642,150.5
"CD004925","CD004925_pub4_data","1|5|UTI: diagnostic criteria|Culture plus symptoms/signs","UTI: diagnostic criteria",1,5,"Culture plus symptoms/signs","or","binary",4,0.244496016112335,0.241103642618999,0,2002.25,0.156769554310719,188
"CD004925","CD004925_pub4_data","1|6|UTI: antibiotic regimen|Co-trimoxazole: 480 mg once/day (960 mg on alternate days)","UTI: antibiotic regimen",1,6,"Co-trimoxazole: 480 mg once/day (960 mg on alternate days)","or","binary",3,-0.039386384624985,0.216843091832529,0,1996.33333333333,0.235185273981726,198
"CD004925","CD004925_pub4_data","1|6|UTI: antibiotic regimen|Other regimen","UTI: antibiotic regimen",1,6,"Other regimen","or","binary",5,0.683111171776194,0.247340601840902,0.00383417707928068,2006.4,0.213098675317653,172
"CD004953","CD004953_pub5_data","1|10|Duration of mechanical ventilation|","Duration of mechanical ventilation",1,10,"","or","binary",7,0.00789899204787359,0.761509771894848,0,2015.16666666667,0,89.7142857142857
"CD004953","CD004953_pub5_data","1|11|Sensitivity analysis - Duration of mechanical ventilation|","Sensitivity analysis - Duration of mechanical ventilation",1,11,"","or","binary",6,-0.0114528248852103,0.823115278102874,0,2015.16666666667,0,77.6666666666667
"CD004953","CD004953_pub5_data","1|12|Retinopathy of prematurity (ROP) stage ≥ 3|","Retinopathy of prematurity (ROP) stage ≥ 3",1,12,"","or","binary",9,-0.21877926974747,0.246598467500625,0.0385334648051118,2016,0.107136218657692,98.2222222222222
"CD004953","CD004953_pub5_data","1|13|Patent ductus arteriosus (PDA)|PDA - pharmacological treatment","Patent ductus arteriosus (PDA)",1,13,"PDA - pharmacological treatment","or","binary",7,-0.0191493121636004,0.195264305251176,0.101650511486712,2014.66666666667,0.329414473943543,161
"CD004953","CD004953_pub5_data","1|13|Patent ductus arteriosus (PDA)|PDA - surgical closure","Patent ductus arteriosus (PDA)",1,13,"PDA - surgical closure","or","binary",4,-0.297251328665706,0.497310622294297,0,2016.5,0.013986013986014,114
"CD004953","CD004953_pub5_data","1|2|Death during hospitalisation|","Death during hospitalisation",1,2,"","reported","reported",9,0,0.102677147025544,0,2016.25,0.18863168745773,161.444444444444
"CD004953","CD004953_pub5_data","1|3|Death|Death during hospitalisation","Death",1,3,"Death during hospitalisation","or","binary",12,-0.0839641363426178,0.198577807840322,0.116723465248014,2016.36363636364,0.141473765593298,143.5
"CD004953","CD004953_pub5_data","1|5|Chronic lung disease|BPD any grade","Chronic lung disease",1,5,"BPD any grade","or","binary",4,-0.0230209950420704,0.15809851812067,0,2013.66666666667,0.336809233248906,183.75
"CD004953","CD004953_pub5_data","1|5|Chronic lung disease|Moderate to severe BPD","Chronic lung disease",1,5,"Moderate to severe BPD","or","binary",6,-0.147597316203051,0.293891250669333,0.154385670780994,2016.6,0.157226820507114,121.166666666667
"CD004953","CD004953_pub5_data","1|6|Pneumothorax during hospitalisation|","Pneumothorax during hospitalisation",1,6,"","reported","reported",11,0,0.194532657081056,0,2016.3,0.0768714142501754,149.181818181818
"CD004953","CD004953_pub5_data","1|7|Cranial ultrasound abnormalities|Cystic periventricular leukomalacia","Cranial ultrasound abnormalities",1,7,"Cystic periventricular leukomalacia","or","binary",6,-0.340329187496777,0.426417828605828,0,2014.2,0.0438874195300144,113.166666666667
"CD004953","CD004953_pub5_data","1|7|Cranial ultrasound abnormalities|Intraventricular haemorrhage grade 3-4","Cranial ultrasound abnormalities",1,7,"Intraventricular haemorrhage grade 3-4","or","binary",8,-0.0396080177635438,0.262943311658449,0.0456511807883327,2015.57142857143,0.0820444702176648,106.875
"CD004953","CD004953_pub5_data","1|7|Cranial ultrasound abnormalities|IVH any grade","Cranial ultrasound abnormalities",1,7,"IVH any grade","or","binary",4,-0.00950565409335786,0.187479557820869,0,2017.5,0.155987002728709,159.5
"CD004953","CD004953_pub5_data","1|8|Endotracheal intubation|intubation in the delivery room (DR)","Endotracheal intubation",1,8,"intubation in the delivery room (DR)","or","binary",8,-0.416255031377934,0.242395491718286,0.235152701408038,2016,0.316396104053055,160.875
"CD004953","CD004953_pub5_data","1|8|Endotracheal intubation|intubation in the first 72 hours of age","Endotracheal intubation",1,8,"intubation in the first 72 hours of age","or","binary",6,-0.129444023933578,0.292920398012054,0.242820323229585,2014.4,0.386735972150532,142.5
"CD004953","CD004953_pub5_data","1|9|Surfactant administration|Surfactant given at any time","Surfactant administration",1,9,"Surfactant given at any time","or","binary",12,0.027377460571818,0.114498144144137,0,2016.36363636364,0.431168906908877,143.5
"CD004953","CD004953_pub5_data","1|9|Surfactant administration|Surfactant given in the delivery room","Surfactant administration",1,9,"Surfactant given in the delivery room","or","binary",4,0.103454438842782,0.167533432665305,0,2013.66666666667,0.203864947279474,190.25
"CD004953","CD004953_pub5_data","2|4|Pneumothorax during hospitalisation|","Pneumothorax during hospitalisation",2,4,"","reported","reported",2,0,0.103118863021408,0,2019.5,0.0714285714285714,17
"CD004953","CD004953_pub5_data","2|5|Cranial ultrasound abnormalities|Intraventricular haemorrhage grade 3 to 4","Cranial ultrasound abnormalities",2,5,"Intraventricular haemorrhage grade 3 to 4","or","binary",2,-0.65942413042618,0.84596435524932,0,2019.5,0.321428571428571,17
"CD004953","CD004953_pub5_data","2|8|Retinopathy of prematurity (ROP) stage ≥ 3|","Retinopathy of prematurity (ROP) stage ≥ 3",2,8,"","or","binary",2,-1.27730472964184,1.12958376995662,0,2019.5,0.375,17
"CD004992","CD004992_pub4_data","1|1|Recurrence of pelvic pain|Recurrence of dysmenorrhoea","Recurrence of pelvic pain",1,1,"Recurrence of dysmenorrhoea","or","binary",2,-1.35390684547193,0.376304974480303,0,2002,0.504705882352941,70
"CD004992","CD004992_pub4_data","1|1|Recurrence of pelvic pain|Recurrence of dyspareunia","Recurrence of pelvic pain",1,1,"Recurrence of dyspareunia","or","binary",2,-2.33196082373216,0.452629636739639,0,2002,0.645,65.5
"CD004992","CD004992_pub4_data","1|2|Recurrence of endometrioma|Excision vs drainage and ablation","Recurrence of endometrioma",1,2,"Excision vs drainage and ablation","or","binary",3,-1.64680055838244,0.341254024016232,0,2005,0.354429824561404,81.3333333333333
"CD004992","CD004992_pub4_data","1|3|Requirement for further endometrioma surgery|","Requirement for further endometrioma surgery",1,3,"","or","binary",2,-1.48378243797173,0.754275086065289,0.691546094102427,2008.5,0.292631578947368,89
"CD004992","CD004992_pub4_data","1|4|Spontaneous pregnancy rate over the 12 months after surgery|","Spontaneous pregnancy rate over the 12 months after surgery",1,4,"","or","binary",3,0.208377267675453,0.559173296740584,0.192729157207781,2009,0.172385620915033,33.6666666666667
"CD004992","CD004992_pub4_data","1|5|Serum anti-Müllerian hormone levels (ng/mL) three months after surgery (short term)|","Serum anti-Müllerian hormone levels (ng/mL) three months after surgery (short term)",1,5,"","or","binary",3,0,1.16364316177854,0,2015.33333333333,0,69.3333333333333
"CD004992","CD004992_pub4_data","1|7|Antral follicle count (number of follicles) six months after surgery|Excision vs drainage and ablation","Antral follicle count (number of follicles) six months after surgery",1,7,"Excision vs drainage and ablation","or","binary",2,0,1.42347238478543,0,2015.5,0,80
"CD004992","CD004992_pub4_data","1|8|Ovarian volume (cm3) six months after surgery|Excision vs drainage and ablation","Ovarian volume (cm3) six months after surgery",1,8,"Excision vs drainage and ablation","or","binary",2,0,1.42347238478543,0,2015.5,0,80
"CD005133","CD005133_pub4_data","1|1|All symptomatic CMV disease|","All symptomatic CMV disease",1,1,"","or","binary",7,-1.3821997068478,0.485382504243116,0.498325620160648,2002.28571428571,0.316698521513869,45
"CD005133","CD005133_pub4_data","1|2|Death (any cause)|","Death (any cause)",1,2,"","or","binary",3,0.186967875742848,0.610409158176025,0,2000.33333333333,0.0421052631578947,58.6666666666667
"CD005133","CD005133_pub4_data","1|3|CMV organ involvement|","CMV organ involvement",1,3,"","or","binary",5,-0.770534813447494,0.838724350182991,1.25580978335963,2000,0.0832957393483709,43.4
"CD005133","CD005133_pub4_data","1|4|CMV-associated symptoms|","CMV-associated symptoms",1,4,"","or","binary",5,-1.52967462280389,0.777768101244717,1.25077208358095,2000,0.320144110275689,43.4
"CD005133","CD005133_pub4_data","1|5|Acute rejection|","Acute rejection",1,5,"","or","binary",3,0.233845407003647,0.394404953068579,0,2000.66666666667,0.169787213130866,61.6666666666667
"CD005133","CD005133_pub4_data","1|6|Other infections|","Other infections",1,6,"","or","binary",2,-0.235303831957726,0.649192700065346,0,2008,0.196078431372549,48
"CD005133","CD005133_pub4_data","1|8|Adverse events|Leucopenia","Adverse events",1,8,"Leucopenia","or","binary",2,0.462740740885789,1.21235305586426,0.332766283352255,2000,0.0238095238095238,57
"CD005133","CD005133_pub4_data","2|1|All symptomatic CMV disease|","All symptomatic CMV disease",2,1,"","or","binary",11,-0.034349641616033,0.368508831003043,0.809037179201569,2008.90909090909,0.0960784169976066,120.181818181818
"CD005133","CD005133_pub4_data","2|10|Low-risk recipients: D+ or D-/R+ serostatus|CMV infection","Low-risk recipients: D+ or D-/R+ serostatus",2,10,"CMV infection","or","binary",2,1.90355672360954,0.434939856462201,0,2007,0.372727272727273,64.5
"CD005133","CD005133_pub4_data","2|10|Low-risk recipients: D+ or D-/R+ serostatus|Symptomatic CMV","Low-risk recipients: D+ or D-/R+ serostatus",2,10,"Symptomatic CMV","or","binary",2,-1.66246680728283,1.12391638414893,0,2007,0.0651515151515152,64.5
"CD005133","CD005133_pub4_data","2|2|Death (any cause)|","Death (any cause)",2,2,"","or","binary",9,-0.0240869013833584,0.259840022355545,0,2007.77777777778,0.0507212778566525,122
"CD005133","CD005133_pub4_data","2|3|CMV infection|","CMV infection",2,3,"","or","binary",8,1.47182507634539,0.162366122367785,8.07594822496289e-07,2008.125,0.339530332681018,108.375
"CD005133","CD005133_pub4_data","2|4|Acute rejection|","Acute rejection",2,4,"","or","binary",8,0.316214282571493,0.233260783930758,0.150249240702388,2010.125,0.13879666164411,127.625
"CD005133","CD005133_pub4_data","2|5|Other infections|Bacterial","Other infections",2,5,"Bacterial","or","binary",4,0.0100611384218394,0.223134205363783,0,2014,0.31360044017607,124
"CD005133","CD005133_pub4_data","2|5|Other infections|Fungal","Other infections",2,5,"Fungal","or","binary",3,0.252457783313235,0.417887248564466,0,2016.66666666667,0.0513713818860878,132.666666666667
"CD005133","CD005133_pub4_data","2|7|Graft loss|","Graft loss",2,7,"","or","binary",8,0.167298206642664,0.453458260030866,0.529020377736227,2005.875,0.0524666487599606,117.625
"CD005133","CD005133_pub4_data","2|8|Adverse events|Anaemia","Adverse events",2,8,"Anaemia","or","binary",3,0.197523708994356,0.307736246658186,0,2012.33333333333,0.143038837156484,119.333333333333
"CD005133","CD005133_pub4_data","2|8|Adverse events|Cardiovascular events","Adverse events",2,8,"Cardiovascular events","or","binary",2,-0.0185484330729852,0.334757781677212,0,2015.5,0.210084033613445,105
"CD005133","CD005133_pub4_data","2|8|Adverse events|Hypercholesterolaemia/hyperlipidemia","Adverse events",2,8,"Hypercholesterolaemia/hyperlipidemia","or","binary",2,-0.594866256392659,0.328118724892007,0,2015.5,0.803781512605042,105
"CD005133","CD005133_pub4_data","2|8|Adverse events|Leucopenia","Adverse events",2,8,"Leucopenia","or","binary",7,-0.645365273836057,0.182943066771568,2.61014588883496e-07,2006.85714285714,0.229157535442378,124.142857142857
"CD005133","CD005133_pub4_data","2|8|Adverse events|Malignancy","Adverse events",2,8,"Malignancy","or","binary",3,0.0959571096228818,0.336458743898118,0,2016.66666666667,0.0770658263305322,132.666666666667
"CD005133","CD005133_pub4_data","2|8|Adverse events|Neurological dysfunction","Adverse events",2,8,"Neurological dysfunction","or","binary",3,-0.681063636783167,0.6893839267436,0.476694692253917,2001,0.198529411764706,62.3333333333333
"CD005133","CD005133_pub4_data","2|8|Adverse events|Neutropenia","Adverse events",2,8,"Neutropenia","or","binary",5,-0.531018033339136,0.264924586293526,0.084181998459729,2013.2,0.18260907621101,171.8
"CD005133","CD005133_pub4_data","2|8|Adverse events|Thrombocytopenia","Adverse events",2,8,"Thrombocytopenia","or","binary",3,-0.0793106639198043,0.331632721871022,0,2012.33333333333,0.134521916874858,119.333333333333
"CD005133","CD005133_pub4_data","2|9|High-risk recipients: D+/R- serostatus|CMV infection","High-risk recipients: D+/R- serostatus",2,9,"CMV infection","or","binary",2,0.395872201031817,0.63793478570516,0,2007,0.59375,19.5
"CD005133","CD005133_pub4_data","2|9|High-risk recipients: D+/R- serostatus|Symptomatic CMV disease","High-risk recipients: D+/R- serostatus",2,9,"Symptomatic CMV disease","or","binary",2,0.0543921568394904,1.13247132139649,0.856214151333889,2007,0.09375,19.5
"CD005187","CD005187_pub6_data","1|5|Death from any cause|Vaccinated and unvaccinated residents","Death from any cause",1,5,"Vaccinated and unvaccinated residents","or","binary",3,-0.374384721684882,0.123850083138444,0.0276875297590647,2005,0.145623706134327,2469.66666666667
"CD005187","CD005187_pub6_data","2|5|Death from any cause|Vaccinated and unvaccinated residents","Death from any cause",2,5,"Vaccinated and unvaccinated residents","or","binary",3,-0.360270535989352,0.114653462943763,5.9759219387788e-06,2005,0.146267601759053,1166.66666666667
"CD005343","CD005343_pub7_data","1|1|Overall survival|","Overall survival",1,1,"","reported","reported",4,-0.0389731828718417,0.0570535555705272,0,2014.25,0,423
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Cognitive functioning (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Cognitive functioning (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Emotional functioning (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Emotional functioning (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Global health (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Global health (QLQ-C30 score)","or","binary",3,0.00809382277092585,1.15905759557658,0,2013.66666666667,0,132.333333333333
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Physical functioning (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Physical functioning (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Role functioning (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Role functioning (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|11|EORTC QLQ-C30 QoL at 12 months; functional status|Social functioning (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; functional status",1,11,"Social functioning (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Apetite loss (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Apetite loss (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Constipation (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Constipation (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Diarrhoea (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Diarrhoea (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Dyspneoa (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Dyspneoa (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Fatigue (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Fatigue (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Insomnia (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Insomnia (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Nausea and vomiting (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Nausea and vomiting (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|12|EORTC QLQ-C30 QoL at 12 months; symptoms|Pain (QLQ-C30 score)","EORTC QLQ-C30 QoL at 12 months; symptoms",1,12,"Pain (QLQ-C30 score)","or","binary",2,0.0494769072462869,1.41958077169802,0,2013,0,132
"CD005343","CD005343_pub7_data","1|15|Chemotherapy-related G3+AEs|","Chemotherapy-related G3+AEs",1,15,"","or","binary",2,-0.130359054433343,0.222373197027232,0.054474623424102,2015.5,0.434658727109745,384
"CD005343","CD005343_pub7_data","1|2|Overall survival by age|Age < 50 years","Overall survival by age",1,2,"Age < 50 years","reported","reported",2,0.116701206460764,0.283967624713038,0.0504630006375001,2013,0,64.5
"CD005343","CD005343_pub7_data","1|2|Overall survival by age|Age > 70 years","Overall survival by age",1,2,"Age > 70 years","reported","reported",3,-0.0135878809314515,0.120984322581923,0,2013.66666666667,0,112.666666666667
"CD005343","CD005343_pub7_data","1|2|Overall survival by age|Age 60-70 years","Overall survival by age",1,2,"Age 60-70 years","reported","reported",2,-0.0741186166241147,0.140386079308946,0,2015.5,0,135.5
"CD005343","CD005343_pub7_data","1|3|Overall survival by stage|Stage 3","Overall survival by stage",1,3,"Stage 3","reported","reported",3,-0.0186799427458081,0.0788228050372551,0.00474164391080705,2013.66666666667,0,376
"CD005343","CD005343_pub7_data","1|3|Overall survival by stage|Stage 4","Overall survival by stage",1,3,"Stage 4","reported","reported",3,-0.123245282622959,0.127851657639686,0.0109068814559333,2013.66666666667,0,130.333333333333
"CD005343","CD005343_pub7_data","1|4|Overall survival by residual disease|0.5cm > Residual disease ≤ 1cm","Overall survival by residual disease",1,4,"0.5cm > Residual disease ≤ 1cm","reported","reported",2,-0.150983606557377,0.115233191939606,0,2012.5,0,199.5
"CD005343","CD005343_pub7_data","1|4|Overall survival by residual disease|Residual disease > 1 cm","Overall survival by residual disease",1,4,"Residual disease > 1 cm","reported","reported",2,-0.144839406276261,0.16367238761171,0,2015.5,0,97
"CD005343","CD005343_pub7_data","1|4|Overall survival by residual disease|Residual disease up to 0.5cm","Overall survival by residual disease",1,4,"Residual disease up to 0.5cm","reported","reported",2,0.11,0.33,0.1817,2012.5,0,167
"CD005343","CD005343_pub7_data","1|5|Progression-free survival|","Progression-free survival",1,5,"","reported","reported",4,-0.025151524431136,0.0514021069885305,0,2014.25,0,423
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Gastrointestinal fistula (G3+)","Surgically-related adverse effects (G3+)",1,7,"Gastrointestinal fistula (G3+)","or","binary",4,-0.971241972920539,0.532898286918619,0,2014.25,0.0247883024177413,385.25
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Haemorrhage (G3+)","Surgically-related adverse effects (G3+)",1,7,"Haemorrhage (G3+)","or","binary",3,-0.085313432352401,0.393390717624915,0.325689844980798,2013.66666666667,0.201855365802235,421.333333333333
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Infection (G3+)","Surgically-related adverse effects (G3+)",1,7,"Infection (G3+)","or","binary",4,-1.15809694063471,0.358646634361644,0.0755485248600173,2014.25,0.0557300632863116,372.5
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Nausea (G3+)","Surgically-related adverse effects (G3+)",1,7,"Nausea (G3+)","or","binary",2,-0.799227796426045,1.27935228874754,2.35204513736875,2015.5,0.0331447963800905,288.5
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Need for blood transfusion","Surgically-related adverse effects (G3+)",1,7,"Need for blood transfusion","or","binary",3,-0.476250662508441,0.224084442440905,0.0761579119181755,2014,0.507754969045292,334.333333333333
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Overall post-operative adverse events (G3+)","Surgically-related adverse effects (G3+)",1,7,"Overall post-operative adverse events (G3+)","or","binary",2,-1.81796411342941,0.576095863343573,0.458944848263858,2016,0.348639455782313,217.5
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Urinary/vaginal fistula (G3+)","Surgically-related adverse effects (G3+)",1,7,"Urinary/vaginal fistula (G3+)","or","binary",2,0.0571607780878919,0.818766189047052,0,2012.5,0.00357368753953194,553
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Venous thromboembolism (G3+)","Surgically-related adverse effects (G3+)",1,7,"Venous thromboembolism (G3+)","or","binary",4,-1.4332984404253,0.707095794148437,0.671926982774015,2014.25,0.0368946992286651,372.5
"CD005343","CD005343_pub7_data","1|7|Surgically-related adverse effects (G3+)|Vomiting (G3+)","Surgically-related adverse effects (G3+)",1,7,"Vomiting (G3+)","or","binary",2,-0.811410400014841,1.19439153793235,2.11247461637534,2015.5,0.0427601809954751,288.5
"CD005343","CD005343_pub7_data","1|8|Surgical resection|Splenectomy","Surgical resection",1,8,"Splenectomy","or","binary",3,-1.5439827413932,0.871188160131499,1.69527924708139,2014,0.238175700387682,355.666666666667
"CD005343","CD005343_pub7_data","1|8|Surgical resection|Stoma formation","Surgical resection",1,8,"Stoma formation","or","binary",2,-1.52434108549226,0.749619345273893,0.955015215913347,2015.5,0.310924369747899,316
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Cognitive functioning","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Cognitive functioning","or","binary",2,0.0201518190972461,1.41857694963647,0,2013,0,171
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Emotional functioning ","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Emotional functioning ","or","binary",2,0.0201518190972461,1.41857694963647,0,2013,0,171
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Global health","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Global health","reported","reported",2,0,2.42270868634797,0,2015.5,0,173.5
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Physical functioning","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Physical functioning","or","binary",2,0.0201518190972461,1.41857694963647,0,2013,0,171
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Role functioning","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Role functioning","or","binary",2,0.0201518190972461,1.41857694963647,0,2013,0,171
"CD005343","CD005343_pub7_data","1|9|EORTC QLQ-C30 QoL at 6 months: functional status|Social functioning ","EORTC QLQ-C30 QoL at 6 months: functional status",1,9,"Social functioning ","or","binary",2,0.0201518190972461,1.41857694963647,0,2013,0,171
"CD005495","CD005495_pub5_data","1|1|Cognitive outcome in infancy - Developmental Quotient|","Cognitive outcome in infancy - Developmental Quotient",1,1,"","or","binary",25,-0.0287087690382833,0.405248610549675,0,2008.92,0,125.28
"CD005495","CD005495_pub5_data","1|2|Cognitive outcome at preschool age - Intelligence Quotient |","Cognitive outcome at preschool age - Intelligence Quotient ",1,2,"","or","binary",9,-0.0131131967671072,0.671349480910645,0,2001.77777777778,0,169.333333333333
"CD005495","CD005495_pub5_data","1|4|Motor outcome in infancy - Developmental Quotient|","Motor outcome in infancy - Developmental Quotient",1,4,"","or","binary",23,-0.0273292151700305,0.422978757291805,0,2010.95652173913,0,119
"CD005495","CD005495_pub5_data","1|5|Motor outcome at preschool age |","Motor outcome at preschool age ",1,5,"","or","binary",3,-0.0138097947574052,1.16326005463571,0,2008,0,88
"CD005495","CD005495_pub5_data","1|8|Rate of cerebral palsy|","Rate of cerebral palsy",1,8,"","or","binary",9,-0.1934561464252,0.226779389704847,0,2005.88888888889,0.135678513194236,114.777777777778
"CD005495","CD005495_pub5_data","3|1|Cognitive outcome in infancy - Developmental Quotient|< 1000 grams birthweight","Cognitive outcome in infancy - Developmental Quotient",3,1,"< 1000 grams birthweight","or","binary",2,0.259275587034586,1.4274543774799,0,2005,0,68.5
"CD005495","CD005495_pub5_data","3|1|Cognitive outcome in infancy - Developmental Quotient|1500 to < 2500 grams birthweight","Cognitive outcome in infancy - Developmental Quotient",3,1,"1500 to < 2500 grams birthweight","or","binary",2,0.145266632811916,1.4212496301468,0,1999.5,0,190.5
"CD005495","CD005495_pub5_data","4|1|Cognitive outcome in infancy - Developmental Quotient|Presence of PVL/IVH","Cognitive outcome in infancy - Developmental Quotient",4,1,"Presence of PVL/IVH","or","binary",2,-0.0419076309077001,1.44717450906938,0,2002.5,0,20.5
"CD005495","CD005495_pub5_data","4|2|Motor outcome in infancy - Developmental Quotient|Presence of PVL/IVH","Motor outcome in infancy - Developmental Quotient",4,2,"Presence of PVL/IVH","or","binary",2,-0.0419076309077001,1.44717450906938,0,2002.5,0,20.5
"CD005495","CD005495_pub5_data","5|1|Cognitive outcome in infancy - Developmental Quotient|Inpatient","Cognitive outcome in infancy - Developmental Quotient",5,1,"Inpatient","or","binary",15,-0.343363621723723,0.525962945811481,0,2010.2,0,86.9333333333333
"CD005495","CD005495_pub5_data","5|1|Cognitive outcome in infancy - Developmental Quotient|Post hospital discharge","Cognitive outcome in infancy - Developmental Quotient",5,1,"Post hospital discharge","or","binary",10,-0.00792168442616288,0.637791872569025,0,2007,0,175
"CD005495","CD005495_pub5_data","5|2|Cognitive outcome at preschool age - Intelligence Quotient|Inpatient","Cognitive outcome at preschool age - Intelligence Quotient",5,2,"Inpatient","or","binary",4,0.0357161895458188,1.0067866102776,0,2006,0,83
"CD005495","CD005495_pub5_data","5|2|Cognitive outcome at preschool age - Intelligence Quotient|Post hospital discharge","Cognitive outcome at preschool age - Intelligence Quotient",5,2,"Post hospital discharge","or","binary",5,-0.0522099119516401,0.900879974623997,0,1998.4,0,238.4
"CD005495","CD005495_pub5_data","5|3|Cognitive outcome at school age - Intelligence Quotient |Inpatient","Cognitive outcome at school age - Intelligence Quotient ",5,3,"Inpatient","or","binary",3,0.0683460975140576,1.16102298005613,0,2000.66666666667,0,107.333333333333
"CD005495","CD005495_pub5_data","5|4|Motor outcome in infancy - Developmental Quotient|Inpatient","Motor outcome in infancy - Developmental Quotient",5,4,"Inpatient","or","binary",14,-0.0672727700785286,0.543819851916919,0,2011.78571428571,0,92.3571428571429
"CD005495","CD005495_pub5_data","5|5|Motor outcome at preschool age |Post hospital discharge","Motor outcome at preschool age ",5,5,"Post hospital discharge","or","binary",2,-0.0207906479743454,1.42730640773594,0,2007.5,0,66
"CD005495","CD005495_pub5_data","5|8|Rate of cerebral palsy|Inpatient","Rate of cerebral palsy",5,8,"Inpatient","or","binary",3,-0.268880284682377,0.742306390431853,1.05175115710359,2009.33333333333,0.0861111111111111,118
"CD005495","CD005495_pub5_data","5|8|Rate of cerebral palsy|Post hospital discharge","Rate of cerebral palsy",5,8,"Post hospital discharge","or","binary",6,-0.237858828278952,0.266771432681138,0,2004.16666666667,0.160462214235799,113.166666666667
"CD005495","CD005495_pub5_data","6|1|Cognitive outcome in infancy - Developmental Quotient|Infant development","Cognitive outcome in infancy - Developmental Quotient",6,1,"Infant development","or","binary",3,0.0389209782541658,1.16061377996405,0,1994,0,111.333333333333
"CD005495","CD005495_pub5_data","6|1|Cognitive outcome in infancy - Developmental Quotient|Parent-infant relationship","Cognitive outcome in infancy - Developmental Quotient",6,1,"Parent-infant relationship","or","binary",2,0.0462296387573195,1.42574071936922,0,2010,0,73
"CD005495","CD005495_pub5_data","6|1|Cognitive outcome in infancy - Developmental Quotient|Parent-infant relationship and Infant development","Cognitive outcome in infancy - Developmental Quotient",6,1,"Parent-infant relationship and Infant development","or","binary",20,-0.00812176966679465,0.453869887331067,0,2011.05,0,127.95
"CD005495","CD005495_pub5_data","6|2|Cognitive outcome at preschool age - Intelligence Quotient |Parent-infant relationship and Infant development","Cognitive outcome at preschool age - Intelligence Quotient ",6,2,"Parent-infant relationship and Infant development","or","binary",7,0.0733477721031697,0.760802572620703,0,2001.57142857143,0,198.714285714286
"CD005495","CD005495_pub5_data","6|4|Motor outcome in infancy |Infant development","Motor outcome in infancy ",6,4,"Infant development","or","binary",2,0.064173856514925,1.4231018772209,0,1992,0,78.5
"CD005495","CD005495_pub5_data","6|4|Motor outcome in infancy |Parent-infant relationship and infant development","Motor outcome in infancy ",6,4,"Parent-infant relationship and infant development","or","binary",20,-0.157020875606613,0.453533527127586,0,2012.45,0,125.7
"CD005495","CD005495_pub5_data","6|5|Motor outcome at preschool age|Parent-infant relationship and infant development","Motor outcome at preschool age",6,5,"Parent-infant relationship and infant development","or","binary",3,-0.0138097947574052,1.16326005463571,0,2008,0,88
"CD005495","CD005495_pub5_data","6|8|Rate of cerebral palsy|Infant development","Rate of cerebral palsy",6,8,"Infant development","or","binary",4,0.177372563192232,0.417768796617087,0.0736695826902572,2001,0.162797619047619,71.25
"CD005495","CD005495_pub5_data","6|8|Rate of cerebral palsy|Parent-infant relationship and infant development","Rate of cerebral palsy",6,8,"Parent-infant relationship and infant development","or","binary",5,-0.385054329021516,0.27754887225895,0,2009.8,0.11398322851153,149.6
"CD005495","CD005495_pub5_data","7|1|Cognitive outcome in infancy - Developmental Quotient|High risk of selection bias","Cognitive outcome in infancy - Developmental Quotient",7,1,"High risk of selection bias","or","binary",11,0.0593849710982558,0.614162049987626,0,2007.63636363636,0,67.8181818181818
"CD005495","CD005495_pub5_data","7|2|Cognitive outcome at preschool age - Intelligence Quotient |High risk of selection bias","Cognitive outcome at preschool age - Intelligence Quotient ",7,2,"High risk of selection bias","or","binary",5,-0.146674073493546,0.904224672240217,0,2007.8,0,63.8
"CD005495","CD005495_pub5_data","7|2|Cognitive outcome at preschool age - Intelligence Quotient |Low risk of selection bias","Cognitive outcome at preschool age - Intelligence Quotient ",7,2,"Low risk of selection bias","or","binary",8,0.0579202107921315,0.711040691613193,0,2008.25,0,188.375
"CD005495","CD005495_pub5_data","7|4|Motor outcome in infancy - Developmental Quotient|Low risk of selection bias","Motor outcome in infancy - Developmental Quotient",7,4,"Low risk of selection bias","reported","reported",2,0,0.156356890813418,0,2021.5,0,81.5
"CD005495","CD005495_pub5_data","7|5|Motor outcome at preschool age |Low risk of selection bias","Motor outcome at preschool age ",7,5,"Low risk of selection bias","or","binary",2,-0.0205929168013871,1.42050293516616,0,2009,0,114
"CD005495","CD005495_pub5_data","7|8|Rate of cerebral palsy|High risk of selection bias","Rate of cerebral palsy",7,8,"High risk of selection bias","or","binary",3,-0.253849957849623,0.493685078829283,0,1999.66666666667,0.175396825396825,75
"CD005495","CD005495_pub5_data","7|8|Rate of cerebral palsy|Low risk of selection bias","Rate of cerebral palsy",7,8,"Low risk of selection bias","or","binary",6,-0.152176133010904,0.260739303157944,1.87920819998375e-06,2009,0.109530048916841,134.666666666667
"CD005566","CD005566_pub4_data","1|1|Mortality, including 'no major complications'|","Mortality, including 'no major complications'",1,1,"","or","binary",25,-0.112721827278612,0.0926486029226967,0,2003.28,0.0324196562006953,597.6
"CD005566","CD005566_pub4_data","1|3|Pulmonary complications, including 'no major complications'|","Pulmonary complications, including 'no major complications'",1,3,"","or","binary",18,-0.165985485311126,0.088385261724771,0.00711389276374248,2004.05555555556,0.0954760993524791,752.722222222222
"CD005566","CD005566_pub4_data","2|10|ICU stay (hours)|","ICU stay (hours)",2,10,"","or","binary",30,0.0104605059201231,0.370218738081672,0,2004.46666666667,0,55.2
"CD005566","CD005566_pub4_data","2|11|Hospital stay (days)|","Hospital stay (days)",2,11,"","or","binary",25,0.0140439084102888,0.404566321996811,0,2006.4,0,73.64
"CD005566","CD005566_pub4_data","2|2|Gastrointestinal bleeding|","Gastrointestinal bleeding",2,2,"","or","binary",6,0.187889619048422,0.16756388508109,0,2008.83333333333,0.0142971658370885,2088.83333333333
"CD005566","CD005566_pub4_data","2|3|Atrial fibrillation|","Atrial fibrillation",2,3,"","or","binary",28,-0.474104388640711,0.116398674889431,0.128412470747118,2008.78571428571,0.314335862877509,516.714285714286
"CD005566","CD005566_pub4_data","2|4|Re-thoracotomy|","Re-thoracotomy",2,4,"","or","binary",12,0.349877570042168,0.111577066145466,0,2004.75,0.032393306807374,473.583333333333
"CD005566","CD005566_pub4_data","2|6|Renal failure|","Renal failure",2,6,"","or","binary",13,-0.176245790295168,0.101909097254657,0,2008.69230769231,0.0448697137644122,984.538461538462
"CD005566","CD005566_pub4_data","2|7|Inotropic support|","Inotropic support",2,7,"","or","binary",23,-0.125281731855103,0.169887069792066,0.220727048584087,2003.30434782609,0.328326333407555,81.6521739130435
"CD005566","CD005566_pub4_data","2|8|Postoperative bleeding (mL)|","Postoperative bleeding (mL)",2,8,"","or","binary",5,0.0300269370019734,0.901973293300728,0,2005.4,0,128.6
"CD005566","CD005566_pub4_data","2|9|Mechanical ventilation time (minutes)|","Mechanical ventilation time (minutes)",2,9,"","or","binary",32,0.00395169442436464,0.358245225885946,0,2005.1875,0,61.65625
"CD005566","CD005566_pub4_data","3|1|Mortality|High dose","Mortality",3,1,"High dose","or","binary",17,-0.137935336018688,0.0955685548934345,0,2003.70588235294,0.0320005644060018,815.941176470588
"CD005566","CD005566_pub4_data","3|1|Mortality|Low dose","Mortality",3,1,"Low dose","or","binary",8,0.281078540572239,0.377690824523346,0,2002.375,0.0333102262644188,133.625
"CD005566","CD005566_pub4_data","3|2|Cardiac complications|High dose","Cardiac complications",3,2,"High dose","or","binary",19,0.0761154581315926,0.123660076123875,0.0222114218906422,2002.78947368421,0.0513341653541383,723.473684210526
"CD005566","CD005566_pub4_data","3|2|Cardiac complications|Low dose","Cardiac complications",3,2,"Low dose","or","binary",6,-0.117342846917864,0.382262441727792,0,2006.83333333333,0.025865301804037,170
"CD005566","CD005566_pub4_data","3|3|Pulmonary complications|High dose","Pulmonary complications",3,3,"High dose","or","binary",12,-0.172215929968048,0.0963052803868408,0.00955777493960731,2001.41666666667,0.0974704167531997,1068.83333333333
"CD005566","CD005566_pub4_data","3|3|Pulmonary complications|Low dose","Pulmonary complications",3,3,"Low dose","or","binary",6,-0.115279399694488,0.396666068677413,0,2007.33333333333,0.0914874645510378,120.5
"CD005566","CD005566_pub4_data","3|4|Atrial fibrillation|High dose","Atrial fibrillation",3,4,"High dose","or","binary",20,-0.37987945847014,0.137187786794541,0.118244593217848,2008.65,0.280051044416248,666.4
"CD005566","CD005566_pub4_data","3|4|Atrial fibrillation|Low dose","Atrial fibrillation",3,4,"Low dose","or","binary",8,-0.642386682273317,0.201713232432566,0.102660572247289,2008.75,0.366714575697329,142.5
"CD005566","CD005566_pub4_data","3|5|Inotropic support|High dose","Inotropic support",3,5,"High dose","or","binary",18,-0.170801047844615,0.249467137245355,0.545681140524603,2001.5,0.344083803486529,62.1111111111111
"CD005566","CD005566_pub4_data","3|5|Inotropic support|Low dose","Inotropic support",3,5,"Low dose","or","binary",5,-0.068255358579745,0.190294634696466,0,2009.8,0.271599441123251,152
"CD005566","CD005566_pub4_data","3|6|Mechanical ventilation (minutes)|High dose","Mechanical ventilation (minutes)",3,6,"High dose","or","binary",26,0.00508406072834294,0.397673350384484,0,2004.84615384615,0,50.8846153846154
"CD005566","CD005566_pub4_data","3|6|Mechanical ventilation (minutes)|Low dose","Mechanical ventilation (minutes)",3,6,"Low dose","or","binary",6,-0.000924338431593899,0.825213513268841,0,2006.66666666667,0,108.333333333333
"CD005566","CD005566_pub4_data","3|7|Length of ICU stay (hours)|High dose","Length of ICU stay (hours)",3,7,"High dose","or","binary",26,0.0122964230375512,0.397871976477789,0,2003.88461538462,0,50.9230769230769
"CD005566","CD005566_pub4_data","3|7|Length of ICU stay (hours)|Low dose","Length of ICU stay (hours)",3,7,"Low dose","or","binary",4,-0.00138657488739034,1.01070052472655,0,2008.25,0,83
"CD005566","CD005566_pub4_data","3|8|Length of hospital stay (days)|High dose","Length of hospital stay (days)",3,8,"High dose","or","binary",21,0.0161281212136381,0.441512352426312,0,2005.71428571429,0,68.7619047619048
"CD005566","CD005566_pub4_data","3|8|Length of hospital stay (days)|Low dose","Length of hospital stay (days)",3,8,"Low dose","or","binary",4,0.00313093790090386,1.01028363844963,0,2010,0,99.25
"CD005566","CD005566_pub4_data","4|1|Mortality|CABG","Mortality",4,1,"CABG","or","binary",13,-0.10238780559378,0.311402854028035,0,1999.53846153846,0.0404118991092521,101.769230769231
"CD005566","CD005566_pub4_data","4|1|Mortality|Mixed","Mortality",4,1,"Mixed","or","binary",12,-0.113725411765685,0.0970431475238565,0,2007.33333333333,0.0237613930497587,1134.75
"CD005566","CD005566_pub4_data","4|2|Cardiac complications|CABG","Cardiac complications",4,2,"CABG","or","binary",15,-0.128854867015095,0.245654006342027,0,1999.8,0.0510099613694917,105
"CD005566","CD005566_pub4_data","4|2|Cardiac complications|Mixed","Cardiac complications",4,2,"Mixed","or","binary",10,0.115541813960298,0.130605916719256,0.0205837362842408,2009.7,0.0365391532010474,1319.1
"CD005566","CD005566_pub4_data","4|3|Pulmonary complications|CABG","Pulmonary complications",4,3,"CABG","or","binary",8,-0.240221240322777,0.351113219979759,0,1999.125,0.0637427206184357,123.125
"CD005566","CD005566_pub4_data","4|3|Pulmonary complications|Mixed","Pulmonary complications",4,3,"Mixed","or","binary",10,-0.162517464070076,0.0942562757140536,0.00832161956284738,2006.8,0.120862802339714,1256.4
"CD005566","CD005566_pub4_data","4|4|Atrial fibrillation|CABG","Atrial fibrillation",4,4,"CABG","or","binary",16,-0.780210894104844,0.149362886462033,0.0257152786889263,2007.125,0.307745597105749,87.5
"CD005566","CD005566_pub4_data","4|4|Atrial fibrillation|Mixed","Atrial fibrillation",4,4,"Mixed","or","binary",11,-0.248180427939535,0.130408112096622,0.0734766538735879,2011.72727272727,0.325224964261661,1186.18181818182
"CD005566","CD005566_pub4_data","4|5|Inotropic support|CABG","Inotropic support",4,5,"CABG","or","binary",16,-0.0305785710608456,0.24833748821678,0.413905887737157,2003.25,0.309749625646014,75.3125
"CD005566","CD005566_pub4_data","4|5|Inotropic support|Mixed","Inotropic support",4,5,"Mixed","or","binary",5,-0.0904018174677985,0.18951152353173,1.41281619448446e-06,2003.6,0.277363201172725,121.4
"CD005566","CD005566_pub4_data","4|5|Inotropic support|Valve","Inotropic support",4,5,"Valve","or","binary",2,-1.05651018836461,0.496073104899879,0,2003,0.604347826086957,33
"CD005566","CD005566_pub4_data","4|6|Mechanical ventilation (minutes)|CABG","Mechanical ventilation (minutes)",4,6,"CABG","or","binary",21,0.00689236318327604,0.442685687055422,0,2004.19047619048,0,53.0476190476191
"CD005566","CD005566_pub4_data","4|6|Mechanical ventilation (minutes)|Mixed","Mechanical ventilation (minutes)",4,6,"Mixed","or","binary",8,-0.00222238968308866,0.712358846400071,0,2009.375,0,98.625
"CD005566","CD005566_pub4_data","4|6|Mechanical ventilation (minutes)|Valve","Mechanical ventilation (minutes)",4,6,"Valve","or","binary",3,0,1.17540333012836,0,2001,0,30
"CD005566","CD005566_pub4_data","4|7|Length of ICU stay (hours)|CABG","Length of ICU stay (hours)",4,7,"CABG","or","binary",21,0.0120716075056801,0.443189923065241,0,2003.47619047619,0,40.9047619047619
"CD005566","CD005566_pub4_data","4|7|Length of ICU stay (hours)|Mixed","Length of ICU stay (hours)",4,7,"Mixed","or","binary",7,-0.00254449526369056,0.762236145298476,0,2007.85714285714,0,104.142857142857
"CD005566","CD005566_pub4_data","4|7|Length of ICU stay (hours)|Valve","Length of ICU stay (hours)",4,7,"Valve","or","binary",2,0,1.43824901705639,0,2003,0,33
"CD005566","CD005566_pub4_data","4|8|Length of hospital stay (days)|CABG","Length of hospital stay (days)",4,8,"CABG","or","binary",21,0.0143682901057724,0.441954677753014,0,2005.19047619048,0,51.8095238095238
"CD005566","CD005566_pub4_data","4|8|Length of hospital stay (days)|Mixed","Length of hospital stay (days)",4,8,"Mixed","or","binary",4,0.0123664116453342,1.00503320578654,0,2012.75,0,188.25
"CD005566","CD005566_pub4_data","5|1|Mortality|Dexamethasone","Mortality",5,1,"Dexamethasone","or","binary",6,-0.0683376407209989,0.220683074566444,0,2008.16666666667,0.0139809705912336,902.666666666667
"CD005566","CD005566_pub4_data","5|1|Mortality|Hydrocortisone","Mortality",5,1,"Hydrocortisone","or","binary",2,0.387045416239818,0.547969375096672,0,2005,0.0625,166
"CD005566","CD005566_pub4_data","5|1|Mortality|Methylprednisolone","Mortality",5,1,"Methylprednisolone","or","binary",14,-0.127112944307093,0.105411658934783,0,1998.78571428571,0.0308677548496657,622
"CD005566","CD005566_pub4_data","5|2|Cardiac complications|Dexamethasone","Cardiac complications",5,2,"Dexamethasone","or","binary",8,-0.0700145267854051,0.198352271928122,0,2008,0.0224104779143381,693.625
"CD005566","CD005566_pub4_data","5|2|Cardiac complications|Hydrocortisone","Cardiac complications",5,2,"Hydrocortisone","or","binary",2,-0.501799827067676,0.752528704661606,0,2013,0.0211776859504132,208.5
"CD005566","CD005566_pub4_data","5|2|Cardiac complications|Methylprednisolone","Cardiac complications",5,2,"Methylprednisolone","or","binary",13,0.0704512404467492,0.168713582893767,0.0365569638185875,1998.69230769231,0.0673370525108287,641.153846153846
"CD005566","CD005566_pub4_data","5|3|Pulmonary complications|Dexamethasone","Pulmonary complications",5,3,"Dexamethasone","or","binary",6,-0.335560411970362,0.15386255153226,0,2008,0.028878321205226,872.166666666667
"CD005566","CD005566_pub4_data","5|3|Pulmonary complications|Methylprednisolone","Pulmonary complications",5,3,"Methylprednisolone","or","binary",8,-0.108756640783844,0.0757705248861067,0,1998.875,0.120520092349709,1006.875
"CD005566","CD005566_pub4_data","5|4|Atrial fibrillation|Dexamethasone","Atrial fibrillation",5,4,"Dexamethasone","or","binary",9,-0.358168047820442,0.22192811957179,0.180626995293777,2007.55555555556,0.281278824591374,597.888888888889
"CD005566","CD005566_pub4_data","5|4|Atrial fibrillation|Hydrocortisone","Atrial fibrillation",5,4,"Hydrocortisone","or","binary",3,-0.713348988927812,0.193019021462919,0,2010.66666666667,0.525968238535083,151
"CD005566","CD005566_pub4_data","5|4|Atrial fibrillation|Methylprednisolone","Atrial fibrillation",5,4,"Methylprednisolone","or","binary",11,-0.334184081603837,0.195961232435463,0.107629673602384,2007.45454545455,0.282919249053817,727.636363636364
"CD005566","CD005566_pub4_data","5|4|Atrial fibrillation|Methylprednisolone and dexamethasone","Atrial fibrillation",5,4,"Methylprednisolone and dexamethasone","or","binary",2,-0.938770611829704,0.395083121494013,0.0879866203254285,2011.5,0.390429338103757,95
"CD005566","CD005566_pub4_data","5|5|Inotropic support|Dexamethasone","Inotropic support",5,5,"Dexamethasone","or","binary",10,-0.212363572312173,0.170776390006786,6.55534503657723e-06,2005.4,0.371078376688108,99.6
"CD005566","CD005566_pub4_data","5|5|Inotropic support|Methylprednisolone","Inotropic support",5,5,"Methylprednisolone","or","binary",12,-0.0754202589801226,0.325958046838255,0.664708600664872,2000.25,0.282181370578936,58.8333333333333
"CD005566","CD005566_pub4_data","5|6|Mechanical ventilation (minutes)|Dexamethasone","Mechanical ventilation (minutes)",5,6,"Dexamethasone","or","binary",9,0.0223917078988973,0.674958175941452,0,2005.55555555556,0,99.5555555555556
"CD005566","CD005566_pub4_data","5|6|Mechanical ventilation (minutes)|Hydrocortisone","Mechanical ventilation (minutes)",5,6,"Hydrocortisone","or","binary",2,-0.0416392724995152,1.42313482459861,0,2007.5,0,85.5
"CD005566","CD005566_pub4_data","5|6|Mechanical ventilation (minutes)|Methylprednisolone","Mechanical ventilation (minutes)",5,6,"Methylprednisolone","or","binary",18,-0.000397474673204902,0.478239085993297,0,2005,0,40.0555555555556
"CD005566","CD005566_pub4_data","5|6|Mechanical ventilation (minutes)|Prednisolone","Mechanical ventilation (minutes)",5,6,"Prednisolone","or","binary",2,0,1.43935710611501,0,2002,0,30
"CD005566","CD005566_pub4_data","5|7|Length of ICU stay (hours)|Dexamethasone","Length of ICU stay (hours)",5,7,"Dexamethasone","or","binary",10,0.0278031021823013,0.640949196209774,0,2004.7,0,72.7
"CD005566","CD005566_pub4_data","5|7|Length of ICU stay (hours)|Methylprednisolone","Length of ICU stay (hours)",5,7,"Methylprednisolone","or","binary",15,0.00694579936292581,0.524335044334888,0,2004.06666666667,0,38.2
"CD005566","CD005566_pub4_data","5|8|Length of hospital stay (days)|Dexamethasone","Length of hospital stay (days)",5,8,"Dexamethasone","or","binary",5,0.066889925793295,0.900261745653521,0,2008.8,0,119.6
"CD005566","CD005566_pub4_data","5|8|Length of hospital stay (days)|Methylprednisolone","Length of hospital stay (days)",5,8,"Methylprednisolone","or","binary",17,0.000791508597562903,0.491832865763183,0,2004.41176470588,0,40.4117647058824
"CD005566","CD005566_pub4_data","6|1|Mortality (sensitivity analysis)|","Mortality (sensitivity analysis)",6,1,"","or","binary",2,-0.135944871987494,0.102495235109152,0,2013.5,0.0311530631223057,5994.5
"CD005566","CD005566_pub4_data","6|2|Cardiac complications (sensitivity analysis)|","Cardiac complications (sensitivity analysis)",6,2,"","or","binary",2,0.135241075458075,0.14413439431261,0.0232070906389836,2013.5,0.061849879441245,5994.5
"CD005566","CD005566_pub4_data","6|3|Pulmonary complications (sensitivity analysis)|","Pulmonary complications (sensitivity analysis)",6,3,"","or","binary",2,-0.201877584658943,0.13361571462197,0.0221953233028013,2013.5,0.0715576822164212,5994.5
"CD005582","CD005582_pub5_data","1|1|The presence of PHN six months after the onset of acute herpetic rash|NA","The presence of PHN six months after the onset of acute herpetic rash",1,1,NA,"or","binary",2,-0.0525345014312535,0.460889907159547,0,1978.5,0.171621621621622,57
"CD005582","CD005582_pub5_data","1|3|Serious adverse events|NA","Serious adverse events",1,3,NA,"or","binary",6,0.442342599314077,0.561167430680605,0,1987.83333333333,0.00485529322162986,125.833333333333
"CD005582","CD005582_pub5_data","1|4|Non-serious adverse events|NA","Non-serious adverse events",1,4,NA,"or","binary",6,0.294601490141687,0.217054388602551,0,1987.83333333333,0.0826700939324702,125.833333333333
"CD005595","CD005595_pub4_data","1|10|Adverse events|Deep infection","Adverse events",1,10,"Deep infection","or","binary",3,0.0109328708975527,1.16469716080042,0,1998.66666666667,0,66.6666666666667
"CD005595","CD005595_pub4_data","1|10|Adverse events|DVT","Adverse events",1,10,"DVT","or","binary",3,0.192082986435246,0.694638893501034,0,2020,0.0246880022526007,229
"CD005595","CD005595_pub4_data","1|10|Adverse events|Dystrophy/atrophy","Adverse events",1,10,"Dystrophy/atrophy","or","binary",2,-0.733406794633832,1.27784255193594,0,2013.5,0.0135135135135135,61
"CD005595","CD005595_pub4_data","1|10|Adverse events|Loss of fixation","Adverse events",1,10,"Loss of fixation","or","binary",2,0.917936353871657,0.856366924457857,0,2016,0.00177935943060498,331.5
"CD005595","CD005595_pub4_data","1|10|Adverse events|Loss of reduction","Adverse events",1,10,"Loss of reduction","or","binary",2,0.0253472471279487,1.41973870079027,0,2018.5,0,134.5
"CD005595","CD005595_pub4_data","1|10|Adverse events|Low grade infection or superficial infection","Adverse events",1,10,"Low grade infection or superficial infection","or","binary",8,0.549951648792198,0.359679495138934,0,2001.85714285714,0.032258151008151,127.125
"CD005595","CD005595_pub4_data","1|10|Adverse events|Non-union","Adverse events",1,10,"Non-union","or","binary",2,-0.655275253191051,1.26742747113536,0,2021,0.00177935943060498,364
"CD005595","CD005595_pub4_data","1|10|Adverse events|Re-dislocation","Adverse events",1,10,"Re-dislocation","or","binary",3,-0.268588186412269,1.03062565918076,0.205185193260977,1987,0.0350877192982456,45.6666666666667
"CD005595","CD005595_pub4_data","1|10|Adverse events|Re-operation","Adverse events",1,10,"Re-operation","or","binary",7,-0.381469159274053,0.508882748438865,0.508244484616252,1998.5,0.0390081025566536,143.857142857143
"CD005595","CD005595_pub4_data","1|10|Adverse events|Swelling, skin irritation and/or blistering","Adverse events",1,10,"Swelling, skin irritation and/or blistering","or","binary",2,-0.0502798069716982,1.17672500575337,0,1991,0.0263157894736842,39
"CD005595","CD005595_pub4_data","1|10|Adverse events|Wound dehiscence","Adverse events",1,10,"Wound dehiscence","or","binary",3,0.241225951571054,0.495554048636683,0,2006,0.0142645314353499,249.666666666667
"CD005595","CD005595_pub4_data","1|4|HRQoL (using different measurement tools; at end of treatment)|","HRQoL (using different measurement tools; at end of treatment)",1,4,"","or","binary",4,-0.00107590818336545,1.00672935246351,0,2014.33333333333,0,166.25
"CD005595","CD005595_pub4_data","1|5|HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)|","HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)",1,5,"","or","binary",5,-0.0521456803815093,0.900626776214282,0,2015.75,0,147.8
"CD005595","CD005595_pub4_data","1|6|HRQoL (using different measurement tools; long-term follow-up, > 6 months)|","HRQoL (using different measurement tools; long-term follow-up, > 6 months)",1,6,"","or","binary",3,-0.0254635770116976,1.15941667316535,0,2018,0,213.666666666667
"CD005595","CD005595_pub4_data","1|8|Pain (VAS; end of treatment)|","Pain (VAS; end of treatment)",1,8,"","or","binary",2,0,1.4292056445532,0,2013.5,0,46
"CD005595","CD005595_pub4_data","2|1|Activity limitation after surgical fracture management (using different measurement tools; end of treatment)|","Activity limitation after surgical fracture management (using different measurement tools; end of treatment)",2,1,"","or","binary",7,-0.0316701005381609,0.76169587156095,0,2008.28571428571,0,97.4285714285714
"CD005595","CD005595_pub4_data","2|10|Pain after non-surgical fracture management (VAS; short-term and long-term follow-up)|Long-term follow-up > 6 months","Pain after non-surgical fracture management (VAS; short-term and long-term follow-up)",2,10,"Long-term follow-up > 6 months","or","binary",2,-0.0491969736871063,1.42774110724942,0,2018.5,0,84.5
"CD005595","CD005595_pub4_data","2|10|Pain after non-surgical fracture management (VAS; short-term and long-term follow-up)|Short-term follow-up ≤ 6 months","Pain after non-surgical fracture management (VAS; short-term and long-term follow-up)",2,10,"Short-term follow-up ≤ 6 months","or","binary",2,-0.128294443152326,1.43020097315889,0,2018.5,0,83.5
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Deep infection","Adverse events (after surgical fracture management)",2,11,"Deep infection","or","binary",4,1.22722492120878,0.863514597312494,0,2005,0,82.5
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|DVT","Adverse events (after surgical fracture management)",2,11,"DVT","or","binary",4,-0.427000937836087,0.666640079330736,0.115210125059523,2012.25,0.0299886320575976,151
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Fixation/implant failure","Adverse events (after surgical fracture management)",2,11,"Fixation/implant failure","or","binary",2,0.696952791514303,1.27894292513051,0,1996.5,0,56.5
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Loss of fixation","Adverse events (after surgical fracture management)",2,11,"Loss of fixation","or","binary",3,0.500390255813897,1.07666051300113,0,2006.33333333333,0,85.6666666666667
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Loss of reduction","Adverse events (after surgical fracture management)",2,11,"Loss of reduction","or","binary",4,-0.0295726606537696,1.01125938495637,0,2007,0,55.5
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Low grade/superficial infection","Adverse events (after surgical fracture management)",2,11,"Low grade/superficial infection","or","binary",9,0.417638501082777,0.353003726238253,0.23673261442802,2000.77777777778,0.0572678264417053,69.6666666666667
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Pulmonary embolism","Adverse events (after surgical fracture management)",2,11,"Pulmonary embolism","or","binary",2,-0.361658659518374,0.949630059202936,0,2009.5,0.0206043956043956,209.5
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Unplanned return to theatre","Adverse events (after surgical fracture management)",2,11,"Unplanned return to theatre","or","binary",6,0.133067174587069,0.5726017974513,0.918315785886922,2004.66666666667,0.068040293040293,104
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Wound dehiscence","Adverse events (after surgical fracture management)",2,11,"Wound dehiscence","or","binary",3,0.632221598044886,0.845030165553468,0,2005,0.00813008130081301,96
"CD005595","CD005595_pub4_data","2|11|Adverse events (after surgical fracture management)|Wound healing complications","Adverse events (after surgical fracture management)",2,11,"Wound healing complications","or","binary",3,0.61214857619217,0.69748649957273,0,2008,0.0364758698092031,62
"CD005595","CD005595_pub4_data","2|12|Adverse events (after non-surgical fracture management)|DVT","Adverse events (after non-surgical fracture management)",2,12,"DVT","or","binary",3,-1.42964459466838,0.728001036382136,0,2009,0.0634572542467279,168.666666666667
"CD005595","CD005595_pub4_data","2|12|Adverse events (after non-surgical fracture management)|Non-union","Adverse events (after non-surgical fracture management)",2,12,"Non-union","or","binary",2,0.186366718594801,0.615031927096042,0,2019,0.0131578947368421,234.5
"CD005595","CD005595_pub4_data","2|12|Adverse events (after non-surgical fracture management)|Skin irritation/ulceration","Adverse events (after non-surgical fracture management)",2,12,"Skin irritation/ulceration","or","binary",2,-0.30839845562917,1.340166739834,1.00095135035049,2004,0.0119047619047619,100.5
"CD005595","CD005595_pub4_data","2|2|Activity limitation (using different measurement tools; short-term follow-up, ≤ 6months)|After non-surgical fracture management","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6months)",2,2,"After non-surgical fracture management","or","binary",3,-0.109983856403627,1.16419115534226,0,2018.66666666667,0,133
"CD005595","CD005595_pub4_data","2|2|Activity limitation (using different measurement tools; short-term follow-up, ≤ 6months)|After surgical fracture management","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6months)",2,2,"After surgical fracture management","or","binary",6,-0.0754102671258619,0.821432949103717,0,2014.5,0,112.833333333333
"CD005595","CD005595_pub4_data","2|3|Activity limitation (using different measurement tools; long-term follow-up, > 6 months)|After non-surgical fracture management","Activity limitation (using different measurement tools; long-term follow-up, > 6 months)",2,3,"After non-surgical fracture management","or","binary",2,-0.0483403025546284,1.42845596773126,0,2018.5,0,84
"CD005595","CD005595_pub4_data","2|3|Activity limitation (using different measurement tools; long-term follow-up, > 6 months)|After surgical fracture management","Activity limitation (using different measurement tools; long-term follow-up, > 6 months)",2,3,"After surgical fracture management","or","binary",6,-0.0164321341793841,0.824551147293699,0,2003.83333333333,0,63.3333333333333
"CD005595","CD005595_pub4_data","2|4|Activity limitation after non-surgical fracture management (using OMAS; end of treatment)|","Activity limitation after non-surgical fracture management (using OMAS; end of treatment)",2,4,"","or","binary",3,-0.0183697444154286,1.16153094304569,0,2018.66666666667,0,141
"CD005595","CD005595_pub4_data","2|5|HRQoL (using different measurement tools; end of treatment)|After non-surgical fracture management","HRQoL (using different measurement tools; end of treatment)",2,5,"After non-surgical fracture management","or","binary",3,-0.0244562607592083,1.16163509481921,0,2018.66666666667,0,141.333333333333
"CD005595","CD005595_pub4_data","2|5|HRQoL (using different measurement tools; end of treatment)|After surgical fracture management","HRQoL (using different measurement tools; end of treatment)",2,5,"After surgical fracture management","or","binary",2,-0.0375781609941189,1.41889317207274,0,2017.5,0,185
"CD005595","CD005595_pub4_data","2|6|HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)|After non-surgical fracture management","HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)",2,6,"After non-surgical fracture management","or","binary",3,-0.100703332869185,1.16420966145587,0,2018.66666666667,0,132.333333333333
"CD005595","CD005595_pub4_data","2|6|HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)|After surgical fracture management","HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)",2,6,"After surgical fracture management","or","binary",3,-0.10835344108104,1.15931983870793,0,2019.66666666667,0,159
"CD005595","CD005595_pub4_data","2|7|HRQoL (using different measurement tools; long-term follow-up, > 6 months)|After surgical fracture management","HRQoL (using different measurement tools; long-term follow-up, > 6 months)",2,7,"After surgical fracture management","or","binary",2,-0.056157310146668,1.42219288119604,0,2018,0,89
"CD005595","CD005595_pub4_data","2|8|Pain after surgical fracture management (numbers with pain; all time points)|Long-term follow-up > 6 months","Pain after surgical fracture management (numbers with pain; all time points)",2,8,"Long-term follow-up > 6 months","or","binary",3,-0.80433288729951,0.662136745310735,0.810416502471899,1992.33333333333,0.520772946859903,38.6666666666667
"CD005595","CD005595_pub4_data","2|9|Pain after non-surgical fracture management (VAS; end of treatment)|","Pain after non-surgical fracture management (VAS; end of treatment)",2,9,"","or","binary",2,-0.0097843991999618,1.42538090240002,0,2018.5,0,92
"CD005595","CD005595_pub4_data","3|1|Activity limitation (using different measurement tools; at end of treatment)|After the initial fracture management period after either surgical or non-surgical treatment","Activity limitation (using different measurement tools; at end of treatment)",3,1,"After the initial fracture management period after either surgical or non-surgical treatment","or","binary",4,-0.162041760831369,1.01360001931009,0,2004.75,0,109.75
"CD005595","CD005595_pub4_data","3|1|Activity limitation (using different measurement tools; at end of treatment)|During initial fracture management period after surgical treatment","Activity limitation (using different measurement tools; at end of treatment)",3,1,"During initial fracture management period after surgical treatment","or","binary",3,-0.0452800930656339,1.16466131586382,0,2020,0,67.6666666666667
"CD005595","CD005595_pub4_data","3|10|Pain (using different measurement tools; long-term follow-up, > 6 months)|During initial fracture management period after surgical treatment","Pain (using different measurement tools; long-term follow-up, > 6 months)",3,10,"During initial fracture management period after surgical treatment","or","binary",2,-0.100678184229244,1.42605961007027,0,2021,0,71
"CD005595","CD005595_pub4_data","3|12|Adverse events (during initial fracture management period after surgical treatment)|Deep infection","Adverse events (during initial fracture management period after surgical treatment)",3,12,"Deep infection","or","binary",2,-0.652208944698923,0.897934736291977,0,2021,0.0472411186696901,76
"CD005595","CD005595_pub4_data","3|12|Adverse events (during initial fracture management period after surgical treatment)|Low grade infection/superficial infection","Adverse events (during initial fracture management period after surgical treatment)",3,12,"Low grade infection/superficial infection","or","binary",2,0.616413315037453,1.20824824776665,1.39295394248032,2021,0.0287226001511716,76
"CD005595","CD005595_pub4_data","3|13|Adverse events (after initial fracture management period after either surgical or non-surgical treatment)|Total adverse events (type not specified)","Adverse events (after initial fracture management period after either surgical or non-surgical treatment)",3,13,"Total adverse events (type not specified)","or","binary",2,-0.0505527999710297,0.424912575819278,0,2007,0.135869565217391,115
"CD005595","CD005595_pub4_data","3|2|Activity limitation (using different measurement tools; short-term follow-up, ≤ 6 months)|After the initial fracture management period after either surgical or non-surgical treatment","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6 months)",3,2,"After the initial fracture management period after either surgical or non-surgical treatment","or","binary",5,-0.124873412028062,0.899134374910863,0,2009.25,0,111.4
"CD005595","CD005595_pub4_data","3|2|Activity limitation (using different measurement tools; short-term follow-up, ≤ 6 months)|During initial fracture management period after surgical treatment","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6 months)",3,2,"During initial fracture management period after surgical treatment","or","binary",3,-0.0600203399744656,1.16530922572121,0,2020,0,63.6666666666667
"CD005595","CD005595_pub4_data","3|3|Activity limitation (using different measurement tools; long-term follow-up, > 6 months)|During initial fracture management period after surgical treatment","Activity limitation (using different measurement tools; long-term follow-up, > 6 months)",3,3,"During initial fracture management period after surgical treatment","or","binary",2,-0.100678184229244,1.42605961007027,0,2021,0,71
"CD005595","CD005595_pub4_data","3|4|HRQoL (using different measurement tools; at end of treatment)|After initial fracture management period after either surgical or non-surgical treatment","HRQoL (using different measurement tools; at end of treatment)",3,4,"After initial fracture management period after either surgical or non-surgical treatment","or","binary",2,0.00516842142400236,1.41974179956884,0,2011.5,0,143.5
"CD005595","CD005595_pub4_data","3|5|HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)|After initial fracture management period after either surgical or non-surgical treatment","HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)",3,5,"After initial fracture management period after either surgical or non-surgical treatment","or","binary",4,0.0325025557296792,1.00540275257654,0,2010.66666666667,0,106
"CD005595","CD005595_pub4_data","3|7|Participant satisfaction (100-mm VAS; end of treatment)|After initial fracture management period after either surgical or non-surgical treatment","Participant satisfaction (100-mm VAS; end of treatment)",3,7,"After initial fracture management period after either surgical or non-surgical treatment","or","binary",2,-0.344295068835773,1.42077527977373,0,2006.5,0,116
"CD005595","CD005595_pub4_data","3|8|Pain (using different measures; at end of treatment|After initial fracture management period after either surgical or non-surgical treatment","Pain (using different measures; at end of treatment",3,8,"After initial fracture management period after either surgical or non-surgical treatment","or","binary",3,-0.215281768660147,1.15923470028279,0,2009.33333333333,0,142.333333333333
"CD005595","CD005595_pub4_data","3|8|Pain (using different measures; at end of treatment|During initial fracture management period after surgical treatment","Pain (using different measures; at end of treatment",3,8,"During initial fracture management period after surgical treatment","or","binary",2,-0.0678177499123945,1.42533740843286,0,2021,0,77.5
"CD005595","CD005595_pub4_data","3|9|Pain (using different measurement tools; short-term follow-up, ≤ 6 months)|After initial fracture management period after either surgical or non-surgical treatment","Pain (using different measurement tools; short-term follow-up, ≤ 6 months)",3,9,"After initial fracture management period after either surgical or non-surgical treatment","or","binary",4,-0.182943561694306,1.00536020198364,0,2009.33333333333,0,113.25
"CD005595","CD005595_pub4_data","3|9|Pain (using different measurement tools; short-term follow-up, ≤ 6 months)|During initial fracture management period after surgical treatment","Pain (using different measurement tools; short-term follow-up, ≤ 6 months)",3,9,"During initial fracture management period after surgical treatment","or","binary",2,-0.089865103192788,1.42589484164023,0,2021,0,73.5
"CD005595","CD005595_pub4_data","4|2|Pain (10-cm VAS; end of treatment)|During initial fracture management period","Pain (10-cm VAS; end of treatment)",4,2,"During initial fracture management period","or","binary",2,0.0448427329615758,1.43580285950421,0,2008,0,40.5
"CD005951","CD005951_pub5_data","1|1|Death or dependence (mRS 4–6) at day 90|Acute spontaneous ICH","Death or dependence (mRS 4–6) at day 90",1,1,"Acute spontaneous ICH","or","binary",6,-0.315566510324821,0.225035941877486,0.128246763947092,2009.16666666667,0.530463551659387,238.833333333333
"CD005951","CD005951_pub5_data","1|2|Intracerebral haemorrhage expansion by 24 hours|Acute spontaneous ICH","Intracerebral haemorrhage expansion by 24 hours",1,2,"Acute spontaneous ICH","or","binary",4,-0.392529184723711,0.38273857663479,0.110813640250738,2010.5,0.435522880835381,55
"CD005951","CD005951_pub5_data","1|3|All serious adverse events|Acute spontaneous ICH","All serious adverse events",1,3,"Acute spontaneous ICH","or","binary",2,-0.39521010102922,0.614750835567437,0,2005.5,0.198863636363636,43.5
"CD005951","CD005951_pub5_data","1|4|Thromboembolic adverse events|Acute spontaneous ICH","Thromboembolic adverse events",1,4,"Acute spontaneous ICH","or","binary",6,0.140789583246184,0.222130959993384,0,2008.33333333333,0.0781904809233707,244.5
"CD005951","CD005951_pub5_data","1|5|Death from any cause by day 90|Acute spontaneous ICH","Death from any cause by day 90",1,5,"Acute spontaneous ICH","or","binary",7,-0.374170012785554,0.248898941780034,0.142446055226024,2008.85714285714,0.196289098567949,217.571428571429
"CD005951","CD005951_pub5_data","1|6|Death or dependence (Extended Glasgow Outcome Scale (GOS-E) 1–4) at day 90|Acute spontaneous ICH","Death or dependence (Extended Glasgow Outcome Scale (GOS-E) 1–4) at day 90",1,6,"Acute spontaneous ICH","or","binary",3,-0.374324826980125,0.253588306597088,0,2005.33333333333,0.732954545454545,162
"CD005951","CD005951_pub5_data","2|1|Death or dependence (mRS 4–6) at day 90|Acute spontaneous ICH","Death or dependence (mRS 4–6) at day 90",2,1,"Acute spontaneous ICH","or","binary",5,-0.000331876859454584,0.077820195390516,0,2019.2,0.521941183309405,536.6
"CD005951","CD005951_pub5_data","2|11|Barthel Index|Acute spontaneous ICH","Barthel Index",2,11,"Acute spontaneous ICH","or","binary",2,-0.323172171081233,1.42969953259021,0,2016,0,1174.5
"CD005951","CD005951_pub5_data","2|2|Intracerebral haemorrhage expansion by 24 hours|Acute spontaneous ICH","Intracerebral haemorrhage expansion by 24 hours",2,2,"Acute spontaneous ICH","or","binary",8,-0.197490439996227,0.0867632915310403,2.0627260937089e-06,2016.5,0.366032448786394,358.25
"CD005951","CD005951_pub5_data","2|3|All serious adverse events|Acute spontaneous ICH","All serious adverse events",2,3,"Acute spontaneous ICH","or","binary",4,0.0535114101173104,0.261938792963605,0.09836945265601,2018,0.235833333333333,649.75
"CD005951","CD005951_pub5_data","2|4|Thromboembolic adverse events|Acute spontaneous ICH","Thromboembolic adverse events",2,4,"Acute spontaneous ICH","or","binary",6,0.205251589706393,0.176513504629437,0,2019.33333333333,0.0271838339267995,472.166666666667
"CD005951","CD005951_pub5_data","2|5|Death by day 90|Acute spontaneous ICH","Death by day 90",2,5,"Acute spontaneous ICH","or","binary",8,0.0260804947807761,0.0945757180443329,0,2016.5,0.144227544134955,358.25
"CD005951","CD005951_pub5_data","2|7|Quality of life (EuroQoL health utility score)|Acute spontaneous ICH","Quality of life (EuroQoL health utility score)",2,7,"Acute spontaneous ICH","or","binary",2,-0.323172171081233,1.42969953259021,0,2016,0,1174.5
"CD005951","CD005951_pub5_data","2|8|Mood (Zung Depression Scale)|","Mood (Zung Depression Scale)",2,8,"","or","binary",2,-0.323172171081233,1.42969953259021,0,2016,0,1174.5
"CD005951","CD005951_pub5_data","4|4|Death by day 90|Acute anticoagulant-associated ICH","Death by day 90",4,4,"Acute anticoagulant-associated ICH","or","binary",2,-0.869868423432274,0.716297705831422,0,2005,0.472222222222222,21
"CD006023","CD006023_pub4_data","1|1|Death (all causes)|","Death (all causes)",1,1,"","or","binary",6,-0.593000850575648,0.469365806733268,0,2017.16666666667,0.018539345223721,130.166666666667
"CD006023","CD006023_pub4_data","1|11|Fracture|","Fracture",1,11,"","or","binary",2,0.000256259595779573,1.13208472694159,0,2016,0.0175438596491228,144.5
"CD006023","CD006023_pub4_data","1|13|Vomiting|","Vomiting",1,13,"","or","binary",3,0.0222367152098293,0.384785547486541,0,2016.33333333333,0.0514512989760515,122.333333333333
"CD006023","CD006023_pub4_data","1|14|Abdominal pain|","Abdominal pain",1,14,"","or","binary",3,-0.987986377371634,0.564489770224875,0,2013.33333333333,0.0499003920056552,123.333333333333
"CD006023","CD006023_pub4_data","1|15|Diarrhoea|","Diarrhoea",1,15,"","or","binary",3,-0.17691078660657,0.438072671892928,4.00135135089633e-06,2016.33333333333,0.061490359562272,122.333333333333
"CD006023","CD006023_pub4_data","1|16|Abdominal bloating|","Abdominal bloating",1,16,"","or","binary",2,0.141147052122909,0.53247728810762,0,2020,0.0375729880680376,140
"CD006023","CD006023_pub4_data","1|17|Kidney failure|","Kidney failure",1,17,"","or","binary",3,0.327285036246012,0.38450248171051,0,2018,0.0637527167350881,113.666666666667
"CD006023","CD006023_pub4_data","1|19|Serum calcium|","Serum calcium",1,19,"","or","binary",5,0.133119487188064,0.900908962832083,0,2011.6,0,73.2
"CD006023","CD006023_pub4_data","1|2|Cardiovascular death|","Cardiovascular death",1,2,"","or","binary",3,0.00620598370426287,1.16313018772619,0,2016,0,74
"CD006023","CD006023_pub4_data","1|20|Serum calcium-by-phosphate product|","Serum calcium-by-phosphate product",1,20,"","or","binary",3,-0.243495469222132,1.15989097874631,0,2014.66666666667,0,150.666666666667
"CD006023","CD006023_pub4_data","1|21|Serum iPTH|","Serum iPTH",1,21,"","or","binary",3,-0.0213263643610208,1.16199098544552,0,2016,0,102.666666666667
"CD006023","CD006023_pub4_data","1|23|Serum bicarbonate|","Serum bicarbonate",1,23,"","or","binary",6,0.00104658257065216,0.82179023729216,0,2012,0,95.1666666666667
"CD006023","CD006023_pub4_data","1|24|eGFR|","eGFR",1,24,"","or","binary",4,0.166323787724921,1.00701809166408,0,2010,0,76.5
"CD006023","CD006023_pub4_data","1|5|Constipation|","Constipation",1,5,"","or","binary",5,1.36117499736627,0.548492425142743,0.442472987681069,2016.2,0.016918533958659,126.4
"CD006023","CD006023_pub4_data","1|6|Serum phosphate [mg/dL]|","Serum phosphate [mg/dL]",1,6,"","or","binary",6,-0.113962869633789,0.821297635446425,0,2014.33333333333,0,111.833333333333
"CD006023","CD006023_pub4_data","1|7|Coronary artery calcium score|","Coronary artery calcium score",1,7,"","or","binary",2,0.0535828283173342,1.42628918973458,0,2010,0,57.5
"CD006023","CD006023_pub4_data","1|8|Myocardial infarction|","Myocardial infarction",1,8,"","or","binary",3,0.0514347699829511,1.0100942388152,0,2011,0.0111111111111111,68.3333333333333
"CD006023","CD006023_pub4_data","13|2|Serum phosphate|","Serum phosphate",13,2,"","or","binary",2,-0.00516877083828977,1.42706277441414,0,2009,0,54.5
"CD006023","CD006023_pub4_data","13|3|Serum calcium|","Serum calcium",13,3,"","or","binary",2,-0.00516877083828977,1.42706277441414,0,2009,0,54.5
"CD006023","CD006023_pub4_data","17|1|Death (all causes)|","Death (all causes)",17,1,"","or","binary",5,0.0916012871219734,0.468801865584604,0,2015.8,0.00402774858103847,384.2
"CD006023","CD006023_pub4_data","17|10|Serum calcium|","Serum calcium",17,10,"","or","binary",3,0.00294702724144048,1.15749927591565,0,2018,0,206.333333333333
"CD006023","CD006023_pub4_data","17|2|Cardiovascular death|","Cardiovascular death",17,2,"","or","binary",4,-0.127409982299001,0.945553675920705,0,2016.25,0.00186567164179104,215.25
"CD006023","CD006023_pub4_data","17|3|Nausea|","Nausea",17,3,"","or","binary",2,1.41264417383687,1.26777750846503,2.41517486525404,2012.5,0.0360678925035361,628.5
"CD006023","CD006023_pub4_data","17|8|Abdominal pain|","Abdominal pain",17,8,"","or","binary",2,-0.762288360488107,1.44167076071669,3.36317287319708,2012.5,0.0591868244981987,215.5
"CD006023","CD006023_pub4_data","17|9|Diarrhoea|","Diarrhoea",17,9,"","or","binary",5,-1.39445607616806,0.273725810271791,0.13658224389034,2015.8,0.172542350919159,387.4
"CD006023","CD006023_pub4_data","2|1|Death (all causes)|","Death (all causes)",2,1,"","or","binary",7,-0.912331644729273,0.516741374664761,0,2015.57142857143,0.018290393080309,99.1428571428571
"CD006023","CD006023_pub4_data","2|10|Hospitalisation|","Hospitalisation",2,10,"","or","binary",2,0.195583516953943,0.410223305754015,0,2016,0.152450980392157,70
"CD006023","CD006023_pub4_data","2|12|Pruritus|","Pruritus",2,12,"","or","binary",2,-0.86125579618391,1.28085491907117,0.719905273306155,2011.5,0.0181818181818182,130
"CD006023","CD006023_pub4_data","2|14|Vomiting|","Vomiting",2,14,"","or","binary",3,0.988140200390406,0.981075969179269,1.75414943975399,2012.33333333333,0.0457469431153642,87
"CD006023","CD006023_pub4_data","2|15|Abdominal pain|","Abdominal pain",2,15,"","or","binary",2,-1.53249400575905,1.12856693977899,0,2011.5,0.0679824561403509,60
"CD006023","CD006023_pub4_data","2|16|Diarrhoea|","Diarrhoea",2,16,"","or","binary",4,-0.282125172471415,0.583896353981926,0.739663459849896,2014,0.108735575569941,90.5
"CD006023","CD006023_pub4_data","2|17|Kidney failure|","Kidney failure",2,17,"","or","binary",2,0.230367604752243,0.953871315820112,0,2016.5,0.00980392156862745,122
"CD006023","CD006023_pub4_data","2|2|Cardiovascular death|","Cardiovascular death",2,2,"","or","binary",3,-0.207656960514574,1.16927302630098,0,2013,0,67
"CD006023","CD006023_pub4_data","2|20|Serum calcium|","Serum calcium",2,20,"","or","binary",5,-0.00755225316382443,0.904859225695902,0,2015.4,0,55.2
"CD006023","CD006023_pub4_data","2|21|Serum calcium-by-phosphate product|","Serum calcium-by-phosphate product",2,21,"","or","binary",2,-0.241518571671243,1.42332652653319,0,2014.5,0,97
"CD006023","CD006023_pub4_data","2|22|Serum iPTH|","Serum iPTH",2,22,"","or","binary",5,-0.135686031253917,0.90738884477562,0,2013.4,0,54.4
"CD006023","CD006023_pub4_data","2|23|eGFR|","eGFR",2,23,"","or","binary",3,-0.150412256736399,1.16393443494535,0,2013.66666666667,0,72.6666666666667
"CD006023","CD006023_pub4_data","2|25|Serum FGF23|","Serum FGF23",2,25,"","or","binary",3,-0.176534106774369,1.17942206602636,0,2013,0,23
"CD006023","CD006023_pub4_data","2|4|Nausea|","Nausea",2,4,"","or","binary",5,1.14837891856844,0.385461277448982,0,2012.8,0.0438840416549395,96.8
"CD006023","CD006023_pub4_data","2|5|Constipation|","Constipation",2,5,"","or","binary",4,1.10447890136096,0.462099592709762,0,2012.5,0.022408293460925,74.75
"CD006023","CD006023_pub4_data","2|6|Serum phosphate|","Serum phosphate",2,6,"","reported","reported",2,0,0.16275197489891,0,2015,0,47.5
"CD006023","CD006023_pub4_data","2|8|Myocardial infarction|","Myocardial infarction",2,8,"","or","binary",3,0.545223560956903,1.01278563213983,0,2010.66666666667,0,79.6666666666667
"CD006023","CD006023_pub4_data","20|1|Death (all causes)|","Death (all causes)",20,1,"","or","binary",2,-1.09762180719307,0.559783898334676,0,2010.5,0.0521132376395534,268
"CD006023","CD006023_pub4_data","3|10|Hospitalisation|","Hospitalisation",3,10,"","or","binary",2,-0.433851939216319,0.282159210227727,0,2002.5,0.261433286185761,121
"CD006023","CD006023_pub4_data","3|12|Vomiting|","Vomiting",3,12,"","or","binary",2,-0.0732003856383827,0.341834699804351,0,2008.5,0.137378640776699,131.5
"CD006023","CD006023_pub4_data","3|13|Abdominal pain|","Abdominal pain",3,13,"","or","binary",4,0.541144278332111,0.485214287910912,0,2009.75,0.028042071197411,90.75
"CD006023","CD006023_pub4_data","3|14|Diarrhoea|","Diarrhoea",3,14,"","or","binary",3,-0.0279399774850398,0.334250802544612,0,2009,0.0979337814289271,105
"CD006023","CD006023_pub4_data","3|15|Abdominal bloating|","Abdominal bloating",3,15,"","or","binary",2,1.4651069398218,0.829631687423162,0,2009.5,0.0192307692307692,56
"CD006023","CD006023_pub4_data","3|19|Serum calcium-by-phosphate product|","Serum calcium-by-phosphate product",3,19,"","or","binary",13,-0.0685837895273063,0.557703187073645,0,2005.69230769231,0,229.461538461538
"CD006023","CD006023_pub4_data","3|2|Cardiovascular death|","Cardiovascular death",3,2,"","or","binary",13,-0.549928606275803,0.417372590466882,0.604665492416691,2010.30769230769,0.0311572676407841,268.692307692308
"CD006023","CD006023_pub4_data","3|20|Serum iPTH|","Serum iPTH",3,20,"","or","binary",18,-0.000433817158240894,0.475532669145352,0,2009.27777777778,0,85.1666666666667
"CD006023","CD006023_pub4_data","3|21|Serum alkaline phosphatase|","Serum alkaline phosphatase",3,21,"","or","binary",8,-0.0124159556826388,0.712761059727423,0,2008.5,0,86.375
"CD006023","CD006023_pub4_data","3|22|Serum bicarbonate|","Serum bicarbonate",3,22,"","or","binary",8,-0.00451901888508645,0.711955426936099,0,2007.25,0,94.875
"CD006023","CD006023_pub4_data","3|23|eGFR|","eGFR",3,23,"","or","binary",3,-0.00750143636224984,1.16609451762707,0,2016.66666666667,0,56
"CD006023","CD006023_pub4_data","3|24|Serum FGF23|","Serum FGF23",3,24,"","or","binary",2,0.0783072254768567,1.42549923114166,0,2018,0,65
"CD006023","CD006023_pub4_data","3|3|Hypercalcaemia|","Hypercalcaemia",3,3,"","or","binary",20,-1.51535749166236,0.247500744368055,0.567442979596387,2006.6,0.253670651095049,206.2
"CD006023","CD006023_pub4_data","3|4|Nausea|","Nausea",3,4,"","or","binary",4,-0.0223239367385877,0.324074873973857,4.71586367403646e-06,2008.75,0.0908688075678367,91.25
"CD006023","CD006023_pub4_data","3|5|Constipation|","Constipation",3,5,"","or","binary",6,0.32969012030405,0.35044851075183,1.0445957441062e-06,2009.83333333333,0.079410652873436,442
"CD006023","CD006023_pub4_data","3|6|Serum phosphate|","Serum phosphate",3,6,"","reported","reported",2,0,0.32234914782272,0,2017.5,0,57
"CD006023","CD006023_pub4_data","3|7|Coronary artery calcium score|","Coronary artery calcium score",3,7,"","or","binary",4,-0.0665647191970285,1.00509303558266,0,2007.75,0,129.25
"CD006023","CD006023_pub4_data","3|8|Myocardial infarction|","Myocardial infarction",3,8,"","or","binary",3,0.0183236207928564,1.01007706035452,0,2014,0.0111111111111111,72.3333333333333
"CD006023","CD006023_pub4_data","3|9|Stroke|","Stroke",3,9,"","or","binary",3,0.853053751284445,1.01432154752391,0,2011,0,47.3333333333333
"CD006023","CD006023_pub4_data","31|1|Death (all causes)|","Death (all causes)",31,1,"","or","binary",2,0.0937915777990663,1.0304397522236,0,1993,0.0142857142857143,37
"CD006023","CD006023_pub4_data","31|3|Hypercalcaemia|","Hypercalcaemia",31,3,"","or","binary",2,-1.07575539187467,0.534310747824981,0,1994,0.604395604395604,46
"CD006023","CD006023_pub4_data","31|4|Serum phosphate|","Serum phosphate",31,4,"","or","binary",3,0.0413733786767662,1.18536741684322,0,1994.66666666667,0,32.6666666666667
"CD006023","CD006023_pub4_data","31|5|Serum calcium|","Serum calcium",31,5,"","or","binary",3,0.0413733786767662,1.18536741684322,0,1994.66666666667,0,32.6666666666667
"CD006023","CD006023_pub4_data","31|8|Serum alkaline phosphatase|","Serum alkaline phosphatase",31,8,"","or","binary",2,-0.0369835209187782,1.4643176978757,0,1995,0,17.5
"CD006023","CD006023_pub4_data","32|1|Death (all causes): age|Mean study age above 60 years","Death (all causes): age",32,1,"Mean study age above 60 years","or","binary",5,-0.688340357889747,0.72365533002871,1.62131285192899,2010.4,0.100150119567595,171.8
"CD006023","CD006023_pub4_data","32|2|Death (all causes): CKD GFR category|Stage 5D","Death (all causes): CKD GFR category",32,2,"Stage 5D","reported","reported",2,0,0.701695810320301,0,2004,0.12708719851577,70.5
"CD006023","CD006023_pub4_data","32|4|Cardiovascular death: age|Mean study age 60 years or below","Cardiovascular death: age",32,4,"Mean study age 60 years or below","reported","reported",2,0,0.108725602669757,0,2006,0.121020408163265,1102
"CD006023","CD006023_pub4_data","32|4|Cardiovascular death: age|Mean study age above 60 years","Cardiovascular death: age",32,4,"Mean study age above 60 years","reported","reported",2,0,0.663415710381203,0,2010.5,0.0576923076923077,291.5
"CD006023","CD006023_pub4_data","32|5|Cardiovascular death: CKD GFR category|Stage 5D","Cardiovascular death: CKD GFR category",32,5,"Stage 5D","reported","reported",4,0,0.107204667198749,0,2006,0.101261119832548,678
"CD006023","CD006023_pub4_data","32|6|Cardiovascular death: study duration|Equal to or longer than 12 months","Cardiovascular death: study duration",32,6,"Equal to or longer than 12 months","reported","reported",3,0,0.107529560799977,0,2007,0.119141810570382,890
"CD006023","CD006023_pub4_data","32|6|Cardiovascular death: study duration|Less than 12 months","Cardiovascular death: study duration",32,6,"Less than 12 months","reported","reported",2,0,1.05129845901799,0,2007.5,0.0238095238095238,79.5
"CD006023","CD006023_pub4_data","33|1|Death (all causes): random sequence generation and allocation concealment|Low risk","Death (all causes): random sequence generation and allocation concealment",33,1,"Low risk","reported","reported",2,0,0.566891911596793,0,2006.5,0.115613235585496,152
"CD006023","CD006023_pub4_data","33|1|Death (all causes): random sequence generation and allocation concealment|Unclear/high risk","Death (all causes): random sequence generation and allocation concealment",33,1,"Unclear/high risk","or","binary",12,-0.461329154586835,0.382289187507648,0.790520666348647,2007.66666666667,0.089353456102631,287.75
"CD006023","CD006023_pub4_data","33|2|Cardiovascular death: random sequence generation and allocation concealment|Low risk","Cardiovascular death: random sequence generation and allocation concealment",33,2,"Low risk","reported","reported",2,0,0.602571923934114,0,2007,0.108712715855573,283.5
"CD006023","CD006023_pub4_data","33|2|Cardiovascular death: random sequence generation and allocation concealment|Unclear/high risk","Cardiovascular death: random sequence generation and allocation concealment",33,2,"Unclear/high risk","reported","reported",4,0,0.108425899195088,0,2005.25,0.0469047619047619,585.5
"CD006023","CD006023_pub4_data","4|10|Hospitalisation|","Hospitalisation",4,10,"","or","binary",2,-0.232916769587433,0.540656353105471,0,2011.5,0.197628458498024,44
"CD006023","CD006023_pub4_data","4|11|Fracture|","Fracture",4,11,"","or","binary",2,0.179665543145832,0.321412439717239,0,2013,0.025006546216287,1110
"CD006023","CD006023_pub4_data","4|13|Vomiting|","Vomiting",4,13,"","or","binary",2,1.30634892389542,0.909942044879302,1.32666116141868,2006.5,0.0599676540687777,529
"CD006023","CD006023_pub4_data","4|14|Abdominal pain|","Abdominal pain",4,14,"","or","binary",2,-1.48711487067682,1.09700378105748,0,2011,0.0647773279352227,68.5
"CD006023","CD006023_pub4_data","4|15|Diarrhoea|","Diarrhoea",4,15,"","or","binary",3,0.783052228279118,0.689505309218401,0.623128442497198,2010.33333333333,0.0324594257178527,294.333333333333
"CD006023","CD006023_pub4_data","4|17|Serum calcium|","Serum calcium",4,17,"","or","binary",10,0.0680905603712835,0.640796624202246,0,2012.1,0,44.7
"CD006023","CD006023_pub4_data","4|18|Serum calcium-by-phosphate product|","Serum calcium-by-phosphate product",4,18,"","or","binary",5,-0.0226740584980103,0.901083266357,0,2009.2,0,201.4
"CD006023","CD006023_pub4_data","4|19|Serum iPTH|","Serum iPTH",4,19,"","or","binary",9,-0.0317051896422824,0.675811366372015,0,2011.44444444444,0,69.1111111111111
"CD006023","CD006023_pub4_data","4|20|Serum alkaline phosphatase|","Serum alkaline phosphatase",4,20,"","or","binary",3,-0.235222368582256,1.16826785067446,0,2007.33333333333,0,285.333333333333
"CD006023","CD006023_pub4_data","4|22|Serum FGF23|","Serum FGF23",4,22,"","or","binary",3,-0.0253627144321878,1.17003678826311,0,2014,0,47
"CD006023","CD006023_pub4_data","4|3|Hypercalcaemia|","Hypercalcaemia",4,3,"","or","binary",8,-1.99876240577115,0.562786749935187,1.43151378745773,2007.75,0.228208287223048,168.375
"CD006023","CD006023_pub4_data","4|4|Nausea|","Nausea",4,4,"","or","binary",5,0.58595421854245,0.32984700880647,0.151402162934818,2009,0.0546056939315366,238.2
"CD006023","CD006023_pub4_data","4|5|Constipation|","Constipation",4,5,"","or","binary",5,-0.249967805100832,0.246896108558805,0,2008.8,0.0738327964170661,242.6
"CD006023","CD006023_pub4_data","5|1|Death (all causes)|","Death (all causes)",5,1,"","or","binary",5,-0.299066556824851,0.430702420787152,0,2017.8,0.0246735586358228,176
"CD006023","CD006023_pub4_data","5|11|Serum calcium|","Serum calcium",5,11,"","or","binary",5,-0.60884197363598,0.900462312094159,0,2016.4,0,97.6
"CD006023","CD006023_pub4_data","5|15|Serum bicarbonate|","Serum bicarbonate",5,15,"","or","binary",2,-0.481935664640439,1.42070290694227,0,2017,0,127
"CD006023","CD006023_pub4_data","5|16|eGFR|","eGFR",5,16,"","or","binary",3,-0.549456368768874,1.16059740205825,0,2016,0,114.666666666667
"CD006023","CD006023_pub4_data","5|2|Nausea|","Nausea",5,2,"","or","binary",2,0.713980579289019,0.723397946163442,0.661467486744232,2016,0.0467148182665424,191
"CD006023","CD006023_pub4_data","5|3|Constipation|","Constipation",5,3,"","or","binary",4,0.651907527662545,0.277581556516308,0,2015.25,0.0625077663870767,163.75
"CD006023","CD006023_pub4_data","5|4|Serum phosphate|","Serum phosphate",5,4,"","or","binary",5,-0.60884197363598,0.900462312094159,0,2016.4,0,97.6
"CD006023","CD006023_pub4_data","5|6|Pruritus|","Pruritus",5,6,"","or","binary",2,-0.908936267951323,0.703156197717148,0,2017,0.0538812785388128,119.5
"CD006023","CD006023_pub4_data","5|8|Abdominal pain|","Abdominal pain",5,8,"","or","binary",3,0.48781881612787,0.469614038783947,0,2015.66666666667,0.0287701494598046,188.333333333333
"CD006023","CD006023_pub4_data","6|1|Death (all causes)|","Death (all causes)",6,1,"","or","binary",2,-0.881271545459166,0.839919309239943,0,2014.5,0.0490785256410256,95
"CD006023","CD006023_pub4_data","6|10|Pruritus|","Pruritus",6,10,"","or","binary",2,0.194264412014038,0.706126202056249,0,2010,0.0322094298245614,98.5
"CD006023","CD006023_pub4_data","6|12|Abdominal pain|","Abdominal pain",6,12,"","or","binary",2,-0.214380511995007,0.725349916455713,0,2010,0.0419407894736842,98.5
"CD006023","CD006023_pub4_data","6|13|Diarrhoea|","Diarrhoea",6,13,"","or","binary",2,-0.0223614402665208,0.475723382918554,0,2010,0.0995065789473684,98.5
"CD006023","CD006023_pub4_data","6|14|Serum calcium|","Serum calcium",6,14,"","or","binary",4,0.0201392630213366,1.01178765784252,0,2007.5,0,56.25
"CD006023","CD006023_pub4_data","6|16|Serum iPTH|","Serum iPTH",6,16,"","or","binary",2,0.0406198756436271,1.42475442784531,0,2009,0,66.5
"CD006023","CD006023_pub4_data","6|17|Serum alkaline phosphatase|","Serum alkaline phosphatase",6,17,"","or","binary",2,0,1.43818994756293,0,2000.5,0,39
"CD006023","CD006023_pub4_data","6|18|Serum bicarbonate|","Serum bicarbonate",6,18,"","or","binary",2,-0.0507687213135446,1.4244568961584,0,2009,0,69
"CD006023","CD006023_pub4_data","6|2|Hypercalcaemia|","Hypercalcaemia",6,2,"","or","binary",3,2.01517252210003,0.73181241408357,0,2004.66666666667,0.00584795321637427,71.6666666666667
"CD006023","CD006023_pub4_data","6|3|Nausea|","Nausea",6,3,"","or","binary",2,-0.368231539393792,0.694735456679535,0.134217385327373,2010,0.0634594298245614,98.5
"CD006023","CD006023_pub4_data","6|4|Constipation|","Constipation",6,4,"","or","binary",2,0.915005320885228,0.975308494874511,1.07508091136957,2010,0.0331688596491228,98.5
"CD006023","CD006023_pub4_data","6|7|Myocardial infarction|","Myocardial infarction",6,7,"","or","binary",2,0.3196854151074,1.44897540626419,1.47341950104753,2008,0.0166666666666667,73.5
"CD006023","CD006023_pub4_data","6|8|Stroke|","Stroke",6,8,"","or","binary",2,1.12187120451351,1.27338962147003,0,2010,0,98.5
"CD006023","CD006023_pub4_data","8|14|Serum iPTH|","Serum iPTH",8,14,"","or","binary",2,-0.482551720399623,1.42120462658581,0,2016.5,0,316
"CD006023","CD006023_pub4_data","8|15|Serum calcium-by-phosphate product|","Serum calcium-by-phosphate product",8,15,"","or","binary",2,0,1.44286063068485,0,2010.5,0,37
"CD006023","CD006023_pub4_data","8|4|Constipation|","Constipation",8,4,"","or","binary",2,0.110181566751535,0.569891636623682,0,2016.5,0.0439110070257611,375.5
"CD006023","CD006023_pub4_data","8|5|Serum phosphate|","Serum phosphate",8,5,"","reported","reported",2,0,0.139562549534856,0,2016.5,0,304.5
"CD006023","CD006023_pub4_data","8|8|Pruritus|","Pruritus",8,8,"","or","binary",2,0.802964474901521,0.313014051970371,0,2015,0.0327868852459016,370
"CD006023","CD006023_pub4_data","8|9|Diarrhoea|","Diarrhoea",8,9,"","reported","reported",2,0,0.123907337025728,0,2020,0.207971713275474,412.5
"CD006027","CD006027_pub3_data","1|1|Pain (change from baseline in pain score (VAS-10 cm) at 30 minutes)|NA","Pain (change from baseline in pain score (VAS-10 cm) at 30 minutes)",1,1,NA,"or","binary",3,0.0581033036402029,1.16742996440542,0,1994.66666666667,0,83.3333333333333
"CD006027","CD006027_pub3_data","1|2|Need for rescue medication|NA","Need for rescue medication",1,2,NA,"or","binary",4,-3.25194798690288,0.887513005432162,2.23622999434666,1992,0.857058823529412,70
"CD006027","CD006027_pub3_data","12|1|Need for rescue medication|NA","Need for rescue medication",12,1,NA,"or","binary",2,0.327918453921699,0.211187816021655,0,2005,0.288366336633663,205
"CD006027","CD006027_pub3_data","12|2|Serious adverse events|NA","Serious adverse events",12,2,NA,"or","binary",2,0.182063272023033,0.406632609443066,0,2005,0.0505871341048332,215
"CD006027","CD006027_pub3_data","12|3|Minor adverse events|NA","Minor adverse events",12,3,NA,"or","binary",2,-0.182063272023034,0.406632609443066,0,2005,0.949412865895167,215
"CD006027","CD006027_pub3_data","13|1|Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)|NA","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)",13,1,NA,"or","binary",3,0.455134136641305,1.16104330046824,0,2021.33333333333,0,108.333333333333
"CD006027","CD006027_pub3_data","13|2|Need for rescue medication|NA","Need for rescue medication",13,2,NA,"or","binary",2,0.00396308103121339,0.31816163001003,0,2021.5,0.177840909090909,162.5
"CD006027","CD006027_pub3_data","14|1|Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)|NA","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)",14,1,NA,"or","binary",2,0.0455977229502484,1.42519281645083,0,2007.5,0,67
"CD006027","CD006027_pub3_data","14|2|Need for rescue medication|NA","Need for rescue medication",14,2,NA,"or","binary",3,-0.608029490363374,0.50854849928966,0.331221897351993,2001.66666666667,0.25228878766329,75
"CD006027","CD006027_pub3_data","14|4|Minor adverse events|NA","Minor adverse events",14,4,NA,"or","binary",2,0.607822399264654,0.45432327897034,0,1993,0.0928905033731188,87
"CD006027","CD006027_pub3_data","15|2|Need for rescue medication|NA","Need for rescue medication",15,2,NA,"or","binary",3,-0.151644344044179,0.312952660736487,0,2006.66666666667,0.204401709401709,86.6666666666667
"CD006027","CD006027_pub3_data","15|4|Minor adverse events|NA","Minor adverse events",15,4,NA,"or","binary",2,0.652635867030487,1.27510523933147,0,2002.5,0,80
"CD006027","CD006027_pub3_data","2|1|Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)|NA","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)",2,1,NA,"or","binary",2,-0.061522202141143,1.42400282509231,0,1998.5,0,72
"CD006027","CD006027_pub3_data","2|2|Need for rescue medication|NA","Need for rescue medication",2,2,NA,"or","binary",3,-0.0690774316814209,0.320350895641813,0,2004,0.194444444444444,81.3333333333333
"CD006027","CD006027_pub3_data","2|4|Minor adverse events|NA","Minor adverse events",2,4,NA,"or","binary",2,-0.722679652802017,1.27588489229784,0,1998.5,0.0125,72
"CD006027","CD006027_pub3_data","4|1|Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)|NA","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)",4,1,NA,"or","binary",3,0.449484709358107,1.16636244469792,0,2012.33333333333,0,56.6666666666667
"CD006027","CD006027_pub3_data","4|2|Need for rescue medication|NA","Need for rescue medication",4,2,NA,"or","binary",3,-0.20925967922557,0.354761019433627,0,2012.33333333333,0.333333333333333,56.6666666666667
"CD006027","CD006027_pub3_data","4|3|Minor adverse events|NA","Minor adverse events",4,3,NA,"or","binary",3,-0.722908383526755,0.671678276909499,0,2012.33333333333,0.0638888888888889,56.6666666666667
"CD006027","CD006027_pub3_data","5|2|Need for rescue medication|NA","Need for rescue medication",5,2,NA,"or","binary",2,0.613457295420226,0.508106892854056,0,1997,0.116666666666667,57
"CD006027","CD006027_pub3_data","6|1|Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)|NA","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)",6,1,NA,"or","binary",2,0.0245455945099362,1.41857072367894,0,2020,0,180.5
"CD006027","CD006027_pub3_data","7|2|Need for rescue medication|NA","Need for rescue medication",7,2,NA,"or","binary",2,-0.430241263540128,0.523010390098391,0.3048180310537,1993,0.304359107420861,87
"CD006027","CD006027_pub3_data","7|3|Minor adverse events|NA","Minor adverse events",7,3,NA,"or","binary",2,0.607822399264654,0.45432327897034,0,1993,0.0928905033731188,87
"CD006027","CD006027_pub3_data","8|2|Need for rescue medication|NA","Need for rescue medication",8,2,NA,"or","binary",2,-0.0356739462655373,0.650221146599512,0.548852776007789,2005,0.281944444444444,83
"CD006027","CD006027_pub3_data","8|4|Minor adverse events|NA","Minor adverse events",8,4,NA,"or","binary",2,0.628822486786055,0.344259053303988,0,2005,0.265277777777778,83
"CD006027","CD006027_pub3_data","9|1|Need for rescue medication|NA","Need for rescue medication",9,1,NA,"or","binary",2,0.745723944724756,1.52617699326977,3.24281623342881,1990,0.07,60
"CD006124","CD006124_pub3_data","1|1|Analgesia requirements|","Analgesia requirements",1,1,"","or","binary",5,0.118471334494377,0.899405663879111,0,2005.4,0,111.2
"CD006124","CD006124_pub3_data","1|2|Duration of procedure|","Duration of procedure",1,2,"","or","binary",7,0.0860073543927945,0.760480144643971,0,2007.28571428571,0,116.428571428571
"CD006124","CD006124_pub3_data","1|3|Blood loss|","Blood loss",1,3,"","or","binary",6,0.10014130543426,0.820590924309943,0,2007.33333333333,0,129.166666666667
"CD006124","CD006124_pub3_data","1|4|Perioperative complications|2010 onwards","Perioperative complications",1,4,"2010 onwards","or","binary",2,1.20981829597383,0.275279810716229,0,2013.5,0.228896103896104,151.5
"CD006124","CD006124_pub3_data","1|4|Perioperative complications|Pre-2010","Perioperative complications",1,4,"Pre-2010","or","binary",4,-0.541974224585763,0.337946626649843,0.206521043354453,2004.25,0.263514492753623,116
"CD006124","CD006124_pub3_data","1|5|Reoperations|","Reoperations",1,5,"","or","binary",6,-0.326355117626237,0.635534877247651,0,2005.66666666667,0.0178703703703704,99.3333333333333
"CD006124","CD006124_pub3_data","1|6|Warm ischaemia time|","Warm ischaemia time",1,6,"","or","binary",7,0.0860073543927945,0.760480144643971,0,2007.28571428571,0,116.428571428571
"CD006124","CD006124_pub3_data","1|7|Hospital stay|","Hospital stay",1,7,"","or","binary",6,0.10014130543426,0.820590924309943,0,2007.33333333333,0,129.166666666667
"CD006124","CD006124_pub3_data","2|1|Early graft loss|","Early graft loss",2,1,"","or","binary",4,-0.831099920968653,0.716541946068416,0,2005.5,0.0420729813664596,89
"CD006124","CD006124_pub3_data","2|2|Delayed graft function|","Delayed graft function",2,2,"","or","binary",6,0.0189396143278404,0.374082230670061,0.018723033732269,2007.5,0.0437615283267457,119.166666666667
"CD006124","CD006124_pub3_data","2|3|Acute rejection|","Acute rejection",2,3,"","or","binary",6,0.42236818748411,0.254813462774751,1.51092789702415e-06,2007.66666666667,0.163549313005835,115.5
"CD006124","CD006124_pub3_data","2|4|Ureteric complications|","Ureteric complications",2,4,"","or","binary",6,0.46467038496164,0.416374880876307,0,2007.33333333333,0.0371382562686911,129.166666666667
"CD006124","CD006124_pub3_data","2|5|Kidney function at one year|","Kidney function at one year",2,5,"","or","binary",5,0.151049088836023,0.899974947088903,0,2009,0,107.6
"CD006124","CD006124_pub3_data","2|6|One year graft loss|","One year graft loss",2,6,"","or","binary",3,-0.135002114256981,0.595698815388302,0,2011,0.0312987012987013,134.333333333333
"CD006124","CD006124_pub3_data","3|1|Analgesia requirements|","Analgesia requirements",3,1,"","or","binary",3,0,1.16500344289798,0,2010,0,90
"CD006124","CD006124_pub3_data","3|2|Duration of procedure|","Duration of procedure",3,2,"","or","binary",3,0,1.16500344289798,0,2010,0,90
"CD006124","CD006124_pub3_data","3|3|Blood loss|","Blood loss",3,3,"","or","binary",3,0,1.16500344289798,0,2010,0,90
"CD006124","CD006124_pub3_data","3|4|Perioperative complications|","Perioperative complications",3,4,"","or","binary",3,0.334315564803283,0.312662405606659,0,2010,0.178947368421053,90
"CD006124","CD006124_pub3_data","3|5|Reoperations|","Reoperations",3,5,"","or","binary",3,0.308949103753795,0.862656895087755,0,2010,0.00350877192982456,90
"CD006124","CD006124_pub3_data","3|6|Warm ischaemia time|","Warm ischaemia time",3,6,"","or","binary",3,0,1.16500344289798,0,2010,0,90
"CD006124","CD006124_pub3_data","3|7|Hospital stay|","Hospital stay",3,7,"","or","binary",3,0,1.16500344289798,0,2010,0,90
"CD006124","CD006124_pub3_data","4|1|One-year graft loss|","One-year graft loss",4,1,"","or","binary",2,0.26915646909129,0.505753437794039,0,2012,0.0565789473684211,115
"CD006140","CD006140_pub3_data","1|10|Study treatment terminated due to adverse event|NA","Study treatment terminated due to adverse event",1,10,NA,"reported","reported",3,0.651239064264064,0.334169976511288,0,NA,0.068815331010453,252.333333333333
"CD006140","CD006140_pub3_data","1|13|Days of amphetamine or cocaine use|NA","Days of amphetamine or cocaine use",1,13,NA,"reported","reported",2,0.202429297805555,0.163494771130524,0,NA,NA,75.5
"CD006140","CD006140_pub3_data","1|14|Days of benzodiazepine use|NA","Days of benzodiazepine use",1,14,NA,"reported","reported",2,-0.00814498719783135,0.163209650402083,0,NA,NA,75.5
"CD006140","CD006140_pub3_data","1|16|Depression|NA","Depression",1,16,NA,"reported","reported",2,-0.0683665978056072,0.13191134040035,0.0180866792200018,NA,NA,337.5
"CD006140","CD006140_pub3_data","1|2|Days of illicit opioid use|NA","Days of illicit opioid use",1,2,NA,"reported","reported",2,-0.336927878472941,0.164262944567695,0,NA,NA,75.5
"CD006140","CD006140_pub3_data","1|3|Opioid negative urine drug screens (proportion or count)|NA","Opioid negative urine drug screens (proportion or count)",1,3,NA,"reported","reported",2,0.0721410548311673,0.176851349371275,0.046665948385177,NA,NA,356.5
"CD006140","CD006140_pub3_data","1|4|Retention|NA","Retention",1,4,NA,"reported","reported",3,0.995987985833213,0.144224280769404,0.0295800491120103,NA,0.419681755587899,257.666666666667
"CD006140","CD006140_pub3_data","1|5|Acceptability|NA","Acceptability",1,5,NA,"reported","reported",3,0.90280360736813,0.105769173097371,0.0225201722939228,NA,0.791989493131821,257.666666666667
"CD006140","CD006140_pub3_data","1|6|Any serious adverse event|NA","Any serious adverse event",1,6,NA,"reported","reported",2,1.3597597186148,0.304209788315937,0,NA,0.0748403019744483,356.5
"CD006140","CD006140_pub3_data","1|7|Any non-serious adverse event|NA","Any non-serious adverse event",1,7,NA,"reported","reported",2,1.36054387697034,0.542841873240901,0.512418987753169,NA,0.38796941540844,356.5
"CD006140","CD006140_pub3_data","1|9|Overdose|NA","Overdose",1,9,NA,"reported","reported",2,1.64657018392958,0.839059181302175,0,NA,0.0208817266744096,356.5
"CD006140","CD006140_pub3_data","2|3|Retention|NA","Retention",2,3,NA,"reported","reported",3,2.20703381952193,0.378166097413331,2.16816040426734e-07,2019,0.202704248366013,154.666666666667
"CD006140","CD006140_pub3_data","2|4|Acceptability|NA","Acceptability",2,4,NA,"reported","reported",3,1,0.00674455736153309,0,NA,1,158
"CD006140","CD006140_pub3_data","2|5|Any serious adverse event|NA","Any serious adverse event",2,5,NA,"reported","reported",2,0.949724376746673,0.717589548216762,0,2019,0.066875,130
"CD006140","CD006140_pub3_data","2|6|Any non-serious adverse event|NA","Any non-serious adverse event",2,6,NA,"reported","reported",2,0.920508042373801,0.198147809154744,0,NA,0.204117647058824,134.5
"CD006140","CD006140_pub3_data","2|7|Death|NA","Death",2,7,NA,"reported","reported",2,0.710352506741817,0.745673229914633,0,2019,0.035625,130
"CD006140","CD006140_pub3_data","3|1|Any illicit opioid use (urine drug screen)|NA","Any illicit opioid use (urine drug screen)",3,1,NA,"or","binary",3,-0.708876155001457,0.358811812464214,0.207602931469111,NA,0.804400637196336,147.666666666667
"CD006140","CD006140_pub3_data","3|10|Study treatment terminated due to adverse event|NA","Study treatment terminated due to adverse event",3,10,NA,"reported","reported",2,0.609685940513044,1.18025616240197,0,NA,0.03584229390681,145
"CD006140","CD006140_pub3_data","3|3|Retention|NA","Retention",3,3,NA,"reported","reported",4,1.59870490876284,0.239835242436993,0.0536737294979019,NA,0.299021716213367,148.5
"CD006140","CD006140_pub3_data","3|7|Any non-serious adverse event|NA","Any non-serious adverse event",3,7,NA,"reported","reported",4,1.48296628929852,0.193449373331321,0,NA,0.28768219832736,120.75
"CD006140","CD006140_pub3_data","3|8|Death|NA","Death",3,8,NA,"or","binary",2,-0.00799170650412687,1.41910814386483,0,NA,0,175
"CD006140","CD006140_pub3_data","4|1|Any illicit opioid use (urine drug screen)|NA","Any illicit opioid use (urine drug screen)",4,1,NA,"reported","reported",4,0.69772966537951,0.084396992060997,0.0105340055472136,NA,0.71029639575896,119.75
"CD006140","CD006140_pub3_data","4|10|Overdose|NA","Overdose",4,10,NA,"reported","reported",4,0.17900114320419,0.224292878730189,0,NA,0.0914821215224441,125.75
"CD006140","CD006140_pub3_data","4|16|Quality of life|NA","Quality of life",4,16,NA,"reported","reported",2,0.59493753152353,3.05427875263742,10.1448281967397,NA,NA,211
"CD006140","CD006140_pub3_data","4|17|Any arrest or reincarceration|NA","Any arrest or reincarceration",4,17,NA,"reported","reported",3,0.852143315459397,0.123754904074107,0,NA,0.370392731872808,158.666666666667
"CD006140","CD006140_pub3_data","4|2|Any illicit opioid use (self report)|NA","Any illicit opioid use (self report)",4,2,NA,"reported","reported",3,0.725422420864464,0.128218133284225,0.0313051876230836,NA,0.648542501649846,94
"CD006140","CD006140_pub3_data","4|3|Days of illicit opioid use|NA","Days of illicit opioid use",4,3,NA,"reported","reported",3,-0.242033837136871,0.434884738568341,0.483487828915081,NA,NA,100
"CD006140","CD006140_pub3_data","4|5|Retention|NA","Retention",4,5,NA,"reported","reported",3,1.09224909792944,0.228054962165701,0,NA,0.421112631098951,42
"CD006140","CD006140_pub3_data","4|6|Acceptability|NA","Acceptability",4,6,NA,"reported","reported",8,0.754289796878736,0.088291345829139,0.0481456498781317,NA,0.811557873076174,136.75
"CD006140","CD006140_pub3_data","4|7|Any serious adverse event|NA","Any serious adverse event",4,7,NA,"reported","reported",5,0.492016519243812,0.168219868258614,0.0287595596316548,NA,0.120880631275656,195.2
"CD006140","CD006140_pub3_data","4|8|Any non-serious adverse event|NA","Any non-serious adverse event",4,8,NA,"reported","reported",5,1.20277695905632,0.124950463048412,0.0255921328828134,NA,0.321066996144184,178.8
"CD006140","CD006140_pub3_data","4|9|Death|NA","Death",4,9,NA,"reported","reported",5,0.435687126470591,0.464015086121975,0,NA,0.0243917079619649,176.2
"CD006182","CD006182_pub3_data","1|4|Mortality before discharge from hospital|BW <1000g","Mortality before discharge from hospital",1,4,"BW <1000g","or","binary",2,0.164358302719077,0.22719415730547,0,2014.5,0.31019656019656,189
"CD006182","CD006182_pub3_data","1|6|Subsequent laparotomy during initial hospitalisation|BW <1000g","Subsequent laparotomy during initial hospitalisation",1,6,"BW <1000g","or","binary",3,1.25171668086216,0.344915829375628,0.181560072214236,2011.66666666667,0.213119702774875,155
"CD006182","CD006182_pub3_data","2|1|Mortality within 28 days of the primary procedure|BW <1000g","Mortality within 28 days of the primary procedure",2,1,"BW <1000g","or","binary",3,-0.0548524615631641,0.220936233744934,0,2011.66666666667,0.259486759486759,156
"CD006182","CD006182_pub3_data","2|2|Mortality within 90 days of the primary procedure|BW <1000g","Mortality within 90 days of the primary procedure",2,2,"BW <1000g","or","binary",3,-0.000668961482736166,0.207466824422622,0,2011.66666666667,0.303303303303303,156
"CD006182","CD006182_pub3_data","2|3|Mortality within 6 months of primary procedure|BW <1000g","Mortality within 6 months of primary procedure",2,3,"BW <1000g","or","binary",2,0.0673192617282089,0.2297845649959,0,2014.5,0.31019656019656,189
"CD006182","CD006182_pub3_data","2|4|Mortality before corrected age of one year|BW <1000g","Mortality before corrected age of one year",2,4,"BW <1000g","or","binary",2,0.152103291458587,0.223314755026022,0,2014.5,0.320331695331695,189
"CD006182","CD006182_pub3_data","3|1|Subsequent laparotomy within 7 days of the primary procedure|BW <1000g","Subsequent laparotomy within 7 days of the primary procedure",3,1,"BW <1000g","or","binary",2,1.22896156380055,2.11428817262914,7.2806437688666,2007,0.0262626262626263,79
"CD006182","CD006182_pub3_data","4|1|Laparotomy after 7 days of the primary procedure|BW <1000g","Laparotomy after 7 days of the primary procedure",4,1,"BW <1000g","or","binary",2,1.54486271674371,0.734657007256952,0.778046430878572,2007,0.172727272727273,79
"CD006182","CD006182_pub3_data","5|2|Abdominal abscess|BW <1000g","Abdominal abscess",5,2,"BW <1000g","or","binary",3,-0.333614354123067,0.501302575804588,0,2011.66666666667,0.0417185554171856,155.333333333333
"CD006182","CD006182_pub3_data","5|3|Intestinal fistula |BW <1000g","Intestinal fistula ",5,3,"BW <1000g","or","binary",3,0.806099831551013,0.588714571585778,0,2011.66666666667,0.0197606697606698,156
"CD006182","CD006182_pub3_data","6|3|Need for TPN for more than 3 months after the primary procedure among survivors|BW <1000g","Need for TPN for more than 3 months after the primary procedure among survivors",6,3,"BW <1000g","or","binary",2,0.403797740108159,0.454664711477301,0,2007,0.245454545454545,49.5
"CD006182","CD006182_pub3_data","8|1|Length of stay in the hospital among survivors to discharge (days)|BW <1000g","Length of stay in the hospital among survivors to discharge (days)",8,1,"BW <1000g","or","binary",2,0.115901316832456,1.43023524104544,0,2007,0,43.5
"CD006185","CD006185_pub6_data","1|1|Independent walking at end of intervention phase, all electromechanical devices used (critical outcome)|","Independent walking at end of intervention phase, all electromechanical devices used (critical outcome)",1,1,"","reported","reported",4,0,0.374268975414999,0,2021.75,0.203125,44.75
"CD006185","CD006185_pub6_data","1|2|Independent walking at follow-up after study end (critical outcome)|","Independent walking at follow-up after study end (critical outcome)",1,2,"","or","binary",8,0.466136215734464,0.331592104379996,0.408353641781474,2012.125,0.624194125219028,71.125
"CD006185","CD006185_pub6_data","1|3|Walking velocity (metres per second) at end of intervention phase|","Walking velocity (metres per second) at end of intervention phase",1,3,"","reported","reported",6,0,0.0237723620879771,0,2022.16666666667,0,36.8333333333333
"CD006185","CD006185_pub6_data","1|4|Walking velocity (metres per second) at follow-up|","Walking velocity (metres per second) at follow-up",1,4,"","or","binary",17,-0.0680533075670313,0.491464588672984,0,2014.70588235294,0,50.4117647058824
"CD006185","CD006185_pub6_data","1|5|Walking capacity (metres walked in 6 minutes) at end of intervention phase|","Walking capacity (metres walked in 6 minutes) at end of intervention phase",1,5,"","reported","reported",5,0,4.84536984010046,0,2021.4,0,35.8
"CD006185","CD006185_pub6_data","1|6|Walking capacity (metres walked in 6 minutes) at follow-up|","Walking capacity (metres walked in 6 minutes) at follow-up",1,6,"","or","binary",15,-0.0361054670889798,0.523727624202513,0,2015.53333333333,0,49.0666666666667
"CD006185","CD006185_pub6_data","1|7|Lost to study during intervention phase, dropouts|All studies using end-effector devices","Lost to study during intervention phase, dropouts",1,7,"All studies using end-effector devices","reported","reported",2,0,0.0392314040948936,0,2008.5,0,35
"CD006185","CD006185_pub6_data","1|7|Lost to study during intervention phase, dropouts|All studies using exoskeleton devices","Lost to study during intervention phase, dropouts",1,7,"All studies using exoskeleton devices","reported","reported",2,0,0.0412496649238306,0,2021,0.0454545454545455,49
"CD006185","CD006185_pub6_data","1|7|Lost to study during intervention phase, dropouts|All studies using mobile devices","Lost to study during intervention phase, dropouts",1,7,"All studies using mobile devices","reported","reported",4,0,0.0448245781411406,0,2021.5,0.0833333333333333,34.25
"CD006185","CD006185_pub6_data","1|8|Death from all causes until end of intervention phase|","Death from all causes until end of intervention phase",1,8,"","reported","reported",7,0,0.0103015279651671,0,2021.71428571429,0,49
"CD006185","CD006185_pub6_data","3|1|Independent walking at end of intervention phase, all electromechanical devices used|Chronic phase: more than 3 months after stroke","Independent walking at end of intervention phase, all electromechanical devices used",3,1,"Chronic phase: more than 3 months after stroke","or","binary",18,0.0206745596601273,0.279072403167643,0,2012.55555555556,0.831917211328976,29.3333333333333
"CD006185","CD006185_pub6_data","4|1|Recovery of independent walking: ambulatory status at start of study|Studies that included dependent and independent walkers","Recovery of independent walking: ambulatory status at start of study",4,1,"Studies that included dependent and independent walkers","or","binary",12,0.260793261260795,0.230741268204727,0.133278972052086,2011.25,0.387450621274151,44.75
"CD006185","CD006185_pub6_data","4|1|Recovery of independent walking: ambulatory status at start of study|Studies that included independent walkers","Recovery of independent walking: ambulatory status at start of study",4,1,"Studies that included independent walkers","or","binary",15,0.193404029442566,0.388547527175164,0,2011.6,0.945945945945946,33.3333333333333
"CD006185","CD006185_pub6_data","4|2|Walking velocity: ambulatory status at start of study|Studies that included dependent and independent walkers","Walking velocity: ambulatory status at start of study",4,2,"Studies that included dependent and independent walkers","or","binary",10,-0.102534671788247,0.642293008719437,0,2014,0,35.3
"CD006185","CD006185_pub6_data","4|2|Walking velocity: ambulatory status at start of study|Studies that included independent walkers","Walking velocity: ambulatory status at start of study",4,2,"Studies that included independent walkers","reported","reported",2,0,0.0601757601413596,0,2021,0,49
"CD006185","CD006185_pub6_data","4|3|Walking capacity: ambulatory status at start of study|Studies that included dependent and independent walkers","Walking capacity: ambulatory status at start of study",4,3,"Studies that included dependent and independent walkers","reported","reported",8,0,6.7027796811884,0,2016,0,58.625
"CD006185","CD006185_pub6_data","4|3|Walking capacity: ambulatory status at start of study|Studies that included dependent walkers","Walking capacity: ambulatory status at start of study",4,3,"Studies that included dependent walkers","reported","reported",8,0,10.3255312915335,0,2016.875,0,63
"CD006185","CD006185_pub6_data","4|3|Walking capacity: ambulatory status at start of study|Studies that included independent walkers","Walking capacity: ambulatory status at start of study",4,3,"Studies that included independent walkers","reported","reported",26,0,3.02070923107796,0,2018,0,38.1923076923077
"CD006185","CD006185_pub6_data","5|1|Different devices for regaining walking ability|All studies using ankle devices","Different devices for regaining walking ability",5,1,"All studies using ankle devices","or","binary",3,0.895624414475437,0.574621991089981,0,2016,0.431372549019608,36.6666666666667
"CD006185","CD006185_pub6_data","5|1|Different devices for regaining walking ability|All studies using end-effector devices","Different devices for regaining walking ability",5,1,"All studies using end-effector devices","or","binary",12,0.631441719041818,0.290228382027511,0.279756037149979,2010.41666666667,0.486433317884483,53.4166666666667
"CD006185","CD006185_pub6_data","5|1|Different devices for regaining walking ability|All studies using exoskeleton devices","Different devices for regaining walking ability",5,1,"All studies using exoskeleton devices","or","binary",20,0.573473305200422,0.196777539783997,0,2011.6,0.45266624737213,37.75
"CD006185","CD006185_pub6_data","5|1|Different devices for regaining walking ability|All studies using mobile devices","Different devices for regaining walking ability",5,1,"All studies using mobile devices","reported","reported",2,0,0.453598873963464,0,2022.5,0.175,53
"CD006185","CD006185_pub6_data","5|2|Different devices for regaining walking speed|All studies using ankle devices","Different devices for regaining walking speed",5,2,"All studies using ankle devices","or","binary",3,-0.204628858980073,1.17327696697754,0,2017.66666666667,0,35
"CD006185","CD006185_pub6_data","5|2|Different devices for regaining walking speed|All studies using end-effector devices","Different devices for regaining walking speed",5,2,"All studies using end-effector devices","or","binary",17,-0.162565208610823,0.492013227528466,0,2014.29411764706,0,49.4117647058824
"CD006185","CD006185_pub6_data","5|2|Different devices for regaining walking speed|All studies using exoskeleton devices","Different devices for regaining walking speed",5,2,"All studies using exoskeleton devices","reported","reported",3,0,0.0511634506949325,0,2021.66666666667,0,42.6666666666667
"CD006185","CD006185_pub6_data","5|2|Different devices for regaining walking speed|All studies using mobile devices","Different devices for regaining walking speed",5,2,"All studies using mobile devices","or","binary",17,-0.0450970384432984,0.492110814539846,0,2020.05882352941,0,36.8235294117647
"CD006185","CD006185_pub6_data","5|3|Different devices for regaining walking capacity|All studies using ankle devices","Different devices for regaining walking capacity",5,3,"All studies using ankle devices","or","binary",2,0.0497993092747921,1.44570960522869,0,2015.5,0,21.5
"CD006185","CD006185_pub6_data","5|3|Different devices for regaining walking capacity|All studies using end-effector devices","Different devices for regaining walking capacity",5,3,"All studies using end-effector devices","or","binary",8,-0.15486800647692,0.7176849581416,0,2015,0,55.75
"CD006185","CD006185_pub6_data","6|1|Independent walking at end of intervention phase, all electromechanical devices used (primary outcome)|Subgroup control group contents physiotherapy or gait training","Independent walking at end of intervention phase, all electromechanical devices used (primary outcome)",6,1,"Subgroup control group contents physiotherapy or gait training","reported","reported",28,0,0.122532261190232,0,2014.35714285714,0.306578046283433,52
"CD006257","CD006257_pub2_data","1|1|Death: any cause|","Death: any cause",1,1,"","or","binary",24,-0.10998765565762,0.13309955312287,0.0304046372562325,1994.91666666667,0.030945180426625,308.875
"CD006257","CD006257_pub2_data","1|10|GFR (at end of treatment) [mL/min/1.73 m²]|","GFR (at end of treatment) [mL/min/1.73 m²]",1,10,"","or","binary",7,0.0908963448706993,0.770170582124232,0,1993.14285714286,0,26.8571428571429
"CD006257","CD006257_pub2_data","1|11|Micro- to macroalbuminuria|","Micro- to macroalbuminuria",1,11,"","or","binary",19,-0.975615522174983,0.222519961038783,0.315858519782767,1997.63157894737,0.238473248237092,120.105263157895
"CD006257","CD006257_pub2_data","1|12|Micro- to normoalbuminuria|","Micro- to normoalbuminuria",1,12,"","or","binary",17,1.34759787929475,0.281203135514442,0.368084186450622,1998.11764705882,0.061473287424478,115.235294117647
"CD006257","CD006257_pub2_data","1|13|Hyperkalaemia|","Hyperkalaemia",1,13,"","or","binary",4,-0.263578571886783,0.390957570996647,0,1998.25,0.17581472017162,322.25
"CD006257","CD006257_pub2_data","1|14|Cough|","Cough",1,14,"","or","binary",10,1.17333303638356,0.176261808152751,0,1996.7,0.0258614193696009,661.5
"CD006257","CD006257_pub2_data","1|15|Headache|","Headache",1,15,"","or","binary",5,-0.154040289712746,0.437366228154712,3.63920203576109e-06,1998.8,0.0372719191325481,1248.8
"CD006257","CD006257_pub2_data","1|16|Impotence|","Impotence",1,16,"","or","binary",5,-0.0171216000780087,0.563672717890967,0,1996.4,0.0228758169934641,305.6
"CD006257","CD006257_pub2_data","1|2|Withdrawn|","Withdrawn",1,2,"","or","binary",7,0.0380814355667123,0.0804684394007765,2.91998012838942e-06,1997.57142857143,0.0903573456366611,758
"CD006257","CD006257_pub2_data","1|3|Cardiovascular death|","Cardiovascular death",1,3,"","or","binary",17,0.0474777870091413,0.120484310033024,0,1995.11764705882,0.0119922331022324,330.882352941176
"CD006257","CD006257_pub2_data","1|4|Kidney failure|","Kidney failure",1,4,"","or","binary",8,-0.504588350802323,0.230184558345909,0,1994.125,0.0430259528261076,830.375
"CD006257","CD006257_pub2_data","1|5|Fatal or nonfatal myocardial infarction|","Fatal or nonfatal myocardial infarction",1,5,"","or","binary",3,-0.243282629742954,0.169970541714321,0,1996.33333333333,0.025710844836504,1700
"CD006257","CD006257_pub2_data","1|6|Fatal or nonfatal stroke|","Fatal or nonfatal stroke",1,6,"","or","binary",2,0.022213265181918,0.133280428851631,0,1992.5,0.0529030567269435,2472
"CD006257","CD006257_pub2_data","1|7|Doubling of serum creatinine|","Doubling of serum creatinine",1,7,"","or","binary",8,-0.448536107570621,0.236779069085454,0.155845495430621,1994.75,0.156464376821864,837.75
"CD006257","CD006257_pub2_data","1|8|Reduction in GFR|","Reduction in GFR",1,8,"","or","binary",3,-0.207636229082276,0.585693512734224,0,1997.33333333333,0.255555555555556,38.6666666666667
"CD006257","CD006257_pub2_data","1|9|Change in GFR [mL/min/1.73 m²]|","Change in GFR [mL/min/1.73 m²]",1,9,"","or","binary",3,-0.101743715961438,1.17422085868166,0,1994,0,29.3333333333333
"CD006257","CD006257_pub2_data","10|1|Type of diabetes|Type I","Type of diabetes",10,1,"Type I","or","binary",7,-0.506311084678856,0.731397437527561,0,1995.71428571429,0.0214285714285714,42.2857142857143
"CD006257","CD006257_pub2_data","10|1|Type of diabetes|Type II","Type of diabetes",10,1,"Type II","or","binary",5,0.0653789674355876,0.123258382642203,0,1997.8,0.0107735925475901,1026.2
"CD006257","CD006257_pub2_data","10|2|Presence of hypertension|Patients without hypertension","Presence of hypertension",10,2,"Patients without hypertension","or","binary",11,0.0686155627980119,0.121935859611505,0,1994.18181818182,0.00489708752163187,482.818181818182
"CD006257","CD006257_pub2_data","10|3|Microalbuminuria versus macroalbuminuria|Microalbuminuria","Microalbuminuria versus macroalbuminuria",10,3,"Microalbuminuria","or","binary",14,-0.409089717348045,0.530394401826348,0,1995.64285714286,0.0107142857142857,46.9285714285714
"CD006257","CD006257_pub2_data","11|1|Type of diabetes|Type I","Type of diabetes",11,1,"Type I","or","binary",10,-0.961820238022742,0.229758725749523,0,1998.3,0.192701350563109,75.3
"CD006257","CD006257_pub2_data","11|1|Type of diabetes|Type II","Type of diabetes",11,1,"Type II","or","binary",6,-1.40455494147213,0.485756026789958,0.932066714088398,1999.33333333333,0.383996368478943,244.333333333333
"CD006257","CD006257_pub2_data","11|2|Presence of hypertension|Patients with hypertension","Presence of hypertension",11,2,"Patients with hypertension","or","binary",2,-1.98707518692439,0.594959958829566,0.158338541536319,2005,0.552777777777778,58.5
"CD006257","CD006257_pub2_data","11|2|Presence of hypertension|Patients without hypertension","Presence of hypertension",11,2,"Patients without hypertension","or","binary",15,-1.02785645155146,0.221661893227744,0.0620854311634895,1996.46666666667,0.197272121121769,64.1333333333333
"CD006257","CD006257_pub2_data","11|3|Microalbuminuria versus macroalbuminuria|Macroalbuminuria","Microalbuminuria versus macroalbuminuria",11,3,"Macroalbuminuria","or","binary",2,-1.17830838050212,0.367774066405443,0,1998,0.234649122807018,144.5
"CD006257","CD006257_pub2_data","11|3|Microalbuminuria versus macroalbuminuria|Microalbuminuria","Microalbuminuria versus macroalbuminuria",11,3,"Microalbuminuria","or","binary",16,-0.961848289242981,0.277750754585368,0.483034022784457,1997.625,0.242826430165963,119.875
"CD006257","CD006257_pub2_data","12|1|Type of diabetes|Type I","Type of diabetes",12,1,"Type I","or","binary",11,1.64735093694474,0.288241189488768,0,1998.54545454545,0.0467154925211191,54.5454545454545
"CD006257","CD006257_pub2_data","12|1|Type of diabetes|Type II","Type of diabetes",12,1,"Type II","or","binary",4,0.728245063632142,0.690185501299896,0.975573909943723,2001,0.082793867120954,328
"CD006257","CD006257_pub2_data","12|2|Presence of hypertension|Patients with hypertension","Presence of hypertension",12,2,"Patients with hypertension","or","binary",2,1.6814387021437,1.0785225080541,0,2005,0,58.5
"CD006257","CD006257_pub2_data","12|2|Presence of hypertension|Patients without hypertension","Presence of hypertension",12,2,"Patients without hypertension","or","binary",13,1.56285385841096,0.263684815625797,3.22611484752061e-06,1996.92307692308,0.070297724440947,49.1538461538462
"CD006257","CD006257_pub2_data","12|3|Microalbuminuria versus macroalbuminuria|Microalbuminuria","Microalbuminuria versus macroalbuminuria",12,3,"Microalbuminuria","or","binary",15,1.28094673170727,0.308727126279576,0.398000761105099,1997.93333333333,0.0618265884928398,121.333333333333
"CD006257","CD006257_pub2_data","13|1|Micro- to macroalbuminuria|","Micro- to macroalbuminuria",13,1,"","or","binary",3,-0.793737946194839,0.424691324016351,0,1999.33333333333,0.195055413469736,77.3333333333333
"CD006257","CD006257_pub2_data","13|2|Micro- to normoalbuminuria|","Micro- to normoalbuminuria",13,2,"","or","binary",3,1.68466486522119,0.436367695930477,0,1999.33333333333,0.0537084398976982,77.3333333333333
"CD006257","CD006257_pub2_data","14|1|Cardiovascular death|","Cardiovascular death",14,1,"","or","binary",2,0.188203578018111,1.45336059003076,0,1990,0,17.5
"CD006257","CD006257_pub2_data","14|2|Micro- to macroalbuminuria|","Micro- to macroalbuminuria",14,2,"","or","binary",3,-0.209406314281655,0.783697804244724,1.07769878372241,1991.33333333333,0.143469785575049,87
"CD006257","CD006257_pub2_data","14|3|Micro- to normoalbuminuria|","Micro- to normoalbuminuria",14,3,"","or","binary",2,2.12791878001085,1.1574555235632,0,1990,0,18
"CD006257","CD006257_pub2_data","2|1|Death: any cause|","Death: any cause",2,1,"","or","binary",11,-0.0159001007538744,0.0938186502212962,0,2005,0.0471979499747339,387.272727272727
"CD006257","CD006257_pub2_data","2|10|Micro- to macroalbuminuria|","Micro- to macroalbuminuria",2,10,"","or","binary",5,-1.13080507042674,0.46002385542452,0.677628412847922,2005,0.41691894127378,163
"CD006257","CD006257_pub2_data","2|11|Micro- to normoalbuminuria|","Micro- to normoalbuminuria",2,11,"","or","binary",4,2.13998668283609,0.686878004071093,1.05903310196572,2005,0.0987068965517241,167.75
"CD006257","CD006257_pub2_data","2|12|Hyperkalaemia|","Hyperkalaemia",2,12,"","or","binary",4,1.48661795101493,0.487668924384308,0,2006.25,0.0193972531406626,324.75
"CD006257","CD006257_pub2_data","2|13|Cough|","Cough",2,13,"","or","binary",3,1.6213902013521,0.194918848555932,9.09610524949127e-07,2000,0.0811459941670956,261.333333333333
"CD006257","CD006257_pub2_data","2|2|Withdrawn|","Withdrawn",2,2,"","or","binary",3,-0.208363707429429,0.222320507942986,4.93684050614204e-06,2007.33333333333,0.166560360590211,240.333333333333
"CD006257","CD006257_pub2_data","2|4|Kidney failure|","Kidney failure",2,4,"","or","binary",3,-0.25874302935939,0.0872261586546895,0,2002.66666666667,0.235581818950024,1075.66666666667
"CD006257","CD006257_pub2_data","2|5|Fatal and nonfatal myocardial infarction|","Fatal and nonfatal myocardial infarction",2,5,"","or","binary",2,-0.692950277544622,0.621176795050077,0,2007.5,0.0123239436619718,309.5
"CD006257","CD006257_pub2_data","2|6|Fatal or nonfatal stroke|","Fatal or nonfatal stroke",2,6,"","or","binary",2,-0.260942703237012,0.429211440775672,0,2007.5,0.0378847157016171,309.5
"CD006257","CD006257_pub2_data","2|7|Doubling of serum creatinine|","Doubling of serum creatinine",2,7,"","or","binary",4,-0.269506804802638,0.0813384630190148,9.99062670628819e-07,2004.25,0.322501612325481,820
"CD006257","CD006257_pub2_data","2|8|Reduction in GFR|","Reduction in GFR",2,8,"","or","binary",2,-1.08628852275196,0.87455213062801,0,2005.5,0.0512820512820513,85.5
"CD006257","CD006257_pub2_data","3|1|Death: any cause|","Death: any cause",3,1,"","or","binary",15,0.109610180043298,0.244777821652644,0,2006.73333333333,0.0193343722322226,115.933333333333
"CD006257","CD006257_pub2_data","3|10|Micro- to normoalbuminuria|","Micro- to normoalbuminuria",3,10,"","or","binary",4,-0.0922734569907889,0.543002232909132,0.302989249872155,2008.5,0.717320261437909,54
"CD006257","CD006257_pub2_data","3|11|Hyperkalaemia|","Hyperkalaemia",3,11,"","or","binary",5,0.129308125379261,0.298413335687203,0,2010,0.209954055276502,178.2
"CD006257","CD006257_pub2_data","3|12|Cough|","Cough",3,12,"","or","binary",4,-1.60312762520631,0.482530939520842,0,2002.5,0.0840864978275735,217
"CD006257","CD006257_pub2_data","3|15|Dizziness|","Dizziness",3,15,"","or","binary",2,-1.72660828922715,1.3638606975227,0.681292186675008,2000,0.0517241379310345,57.5
"CD006257","CD006257_pub2_data","3|2|Withdrawn: any cause|","Withdrawn: any cause",3,2,"","or","binary",6,-0.133602283603989,0.232600165408811,0,2010,0.109520218343748,102
"CD006257","CD006257_pub2_data","3|3|Cardiovascular death|","Cardiovascular death",3,3,"","or","binary",13,0.0817473721969167,0.370562583714201,0,2005.30769230769,0.00249090634795581,123.538461538462
"CD006257","CD006257_pub2_data","3|4|Kidney failure|","Kidney failure",3,4,"","or","binary",3,-0.648800284074495,0.398034703416014,0.0498446578658621,2013,0.179511351282723,279
"CD006257","CD006257_pub2_data","3|5|Fatal or nonfatal myocardial infarction|","Fatal or nonfatal myocardial infarction",3,5,"","or","binary",6,0.200449782888392,0.347063309218384,0,2007.83333333333,0.0262386671818433,201.5
"CD006257","CD006257_pub2_data","3|6|Fatal or nonfatal stroke|","Fatal or nonfatal stroke",3,6,"","or","binary",5,-0.0875505035300229,0.418670033700316,0,2006.8,0.0226951918270032,229.2
"CD006257","CD006257_pub2_data","3|7|Doubling of serum creatinine|","Doubling of serum creatinine",3,7,"","or","binary",2,-0.138647173543637,0.29143100324549,0,2010,0.142614326183731,383.5
"CD006257","CD006257_pub2_data","3|9|Micro- to macroalbuminuria|","Micro- to macroalbuminuria",3,9,"","or","binary",4,-0.0382126403336712,0.213529819983486,0,2004.75,0.0817751639094634,241.25
"CD006257","CD006257_pub2_data","5|1|Death: any cause|ACEi","Death: any cause",5,1,"ACEi","or","binary",6,0.0814289112109795,0.306070435187993,0,2008.83333333333,0.0263784728573461,194.333333333333
"CD006257","CD006257_pub2_data","5|1|Death: any cause|ARB","Death: any cause",5,1,"ARB","or","binary",7,0.0337598949889796,0.159148594455862,0,2008.85714285714,0.0350410588185303,372.428571428571
"CD006257","CD006257_pub2_data","5|10|Micro- to normoalbuminuria|ACEi","Micro- to normoalbuminuria",5,10,"ACEi","or","binary",3,-0.028171815869392,0.489894991886319,0.109299766345313,2004.66666666667,0.562037037037037,48.3333333333333
"CD006257","CD006257_pub2_data","5|10|Micro- to normoalbuminuria|ARB","Micro- to normoalbuminuria",5,10,"ARB","or","binary",3,0.142749587716635,0.369129095982528,0,2004.66666666667,0.562037037037037,50.3333333333333
"CD006257","CD006257_pub2_data","5|11|Hyperkalaemia|ACEi","Hyperkalaemia",5,11,"ACEi","or","binary",4,-0.0396566357909656,0.274217654652373,0,2010.75,0.251249923785135,225
"CD006257","CD006257_pub2_data","5|11|Hyperkalaemia|ARB","Hyperkalaemia",5,11,"ARB","or","binary",5,-0.286963883033217,0.294595681447772,0.197436399937578,2010.4,0.220889441790539,468.2
"CD006257","CD006257_pub2_data","5|12|Cough|ACEi","Cough",5,12,"ACEi","or","binary",2,0.711822424285147,0.440681078790302,0,2004,0.00985915492957747,365
"CD006257","CD006257_pub2_data","5|12|Cough|ARB","Cough",5,12,"ARB","or","binary",2,-1.38209477692788,0.821820211081466,0,2004,0.00985915492957747,364
"CD006257","CD006257_pub2_data","5|2|Withdrawn: any cause|ACEi","Withdrawn: any cause",5,2,"ACEi","or","binary",2,-0.2280238833422,0.473999279684852,0,2016,0.140909090909091,86
"CD006257","CD006257_pub2_data","5|2|Withdrawn: any cause|ARB","Withdrawn: any cause",5,2,"ARB","or","binary",3,-0.21232175980972,0.22732220017051,0,2013.66666666667,0.110053574418215,538.333333333333
"CD006257","CD006257_pub2_data","5|3|Cardiovascular death|ACEi","Cardiovascular death",5,3,"ACEi","or","binary",4,0.807674610115928,0.62963737169796,0,2005.25,0.00140845070422535,248.5
"CD006257","CD006257_pub2_data","5|3|Cardiovascular death|ARB","Cardiovascular death",5,3,"ARB","or","binary",4,0.811760574105725,0.629644011888964,0,2005.25,0.00140845070422535,248
"CD006257","CD006257_pub2_data","5|4|Kidney failure|ACEi","Kidney failure",5,4,"ACEi","or","binary",3,0.399709535538169,0.338305741539375,0,2013,0.140406072800439,293.333333333333
"CD006257","CD006257_pub2_data","5|4|Kidney failure|ARB","Kidney failure",5,4,"ARB","or","binary",4,0.147077084655669,0.308465827695884,0.128607324098226,2012,0.114627759020219,580.25
"CD006257","CD006257_pub2_data","5|5|Fatal or nonfatal myocardial infarction|ACEi","Fatal or nonfatal myocardial infarction",5,5,"ACEi","or","binary",3,-0.721623249954605,0.45686311875443,3.06588690595259e-06,2013,0.0637176594923074,293.333333333333
"CD006257","CD006257_pub2_data","5|5|Fatal or nonfatal myocardial infarction|ARB","Fatal or nonfatal myocardial infarction",5,5,"ARB","or","binary",4,-0.371387923971704,0.194859349143911,0,2012,0.0657440457242029,580.25
"CD006257","CD006257_pub2_data","5|6|Fatal or nonfatal stroke|ACEi","Fatal or nonfatal stroke",5,6,"ACEi","or","binary",2,-0.302925552757686,0.552790099243237,0,2013,0.0373452838241571,387.5
"CD006257","CD006257_pub2_data","5|6|Fatal or nonfatal stroke|ARB","Fatal or nonfatal stroke",5,6,"ARB","or","binary",3,-0.294022938195396,0.398554152427034,0.113495903969461,2011.66666666667,0.0331841487004509,741
"CD006257","CD006257_pub2_data","5|7|Doubling of serum creatinine|ACEi","Doubling of serum creatinine",5,7,"ACEi","or","binary",2,0.163976199491574,0.277743359571268,0,2010,0.13682092555332,406.5
"CD006257","CD006257_pub2_data","5|7|Doubling of serum creatinine|ARB","Doubling of serum creatinine",5,7,"ARB","or","binary",3,0.18831715085677,0.179156550871311,0,2009.66666666667,0.107788536004239,750.666666666667
"CD006257","CD006257_pub2_data","5|9|Micro- to macroalbuminuria|ACEi","Micro- to macroalbuminuria",5,9,"ACEi","or","binary",3,0.25380433095847,0.337948971879831,0.102530494199114,2006.66666666667,0.0653364632237872,319.333333333333
"CD006257","CD006257_pub2_data","5|9|Micro- to macroalbuminuria|ARB","Micro- to macroalbuminuria",5,9,"ARB","or","binary",4,0.0816656087351668,0.182152986413239,0,2007.25,0.0552178170311,602.5
"CD006257","CD006257_pub2_data","6|1|Death: any cause|","Death: any cause",6,1,"","or","binary",3,0.0654720582931296,1.17021839751627,0,1999.33333333333,0,89.6666666666667
"CD006257","CD006257_pub2_data","6|2|Withdrawn|","Withdrawn",6,2,"","or","binary",2,-0.116520183174579,0.579924640127213,0,2001.5,0.0784090909090909,97
"CD006257","CD006257_pub2_data","6|3|Cardiovascular death|","Cardiovascular death",6,3,"","or","binary",3,0.0654720582931296,1.17021839751627,0,1999.33333333333,0,89.6666666666667
"CD006257","CD006257_pub2_data","7|1|Death: any cause|","Death: any cause",7,1,"","or","binary",5,-0.307439116996788,0.693118652135594,1.02530136526498,2009.6,0.0113319429108903,408.2
"CD006257","CD006257_pub2_data","7|10|Hyperkalaemia|","Hyperkalaemia",7,10,"","or","binary",2,0.0871590502214282,0.704294564610967,0.38440494359001,2011,0.0141242937853107,532.5
"CD006257","CD006257_pub2_data","7|2|Cardiovascular death|","Cardiovascular death",7,2,"","or","binary",4,0.227502821079154,0.478743699181933,0,2010,0.0034965034965035,340
"CD006257","CD006257_pub2_data","8|1|Death: any cause|","Death: any cause",8,1,"","or","binary",2,0.0594945739635708,1.45067104868573,0,2014.5,0,78
"CD006257","CD006257_pub2_data","8|3|Cardiovascular death|","Cardiovascular death",8,3,"","or","binary",2,0.0594945739635708,1.45067104868573,0,2014.5,0,78
"CD006257","CD006257_pub2_data","8|5|Hyperkalaemia|","Hyperkalaemia",8,5,"","or","binary",3,0.13334337473312,0.766232282997558,0,2014.66666666667,0.00971058644325971,140.666666666667
"CD006273","CD006273_pub4_data","1|1|Adverse events|NA","Adverse events",1,1,NA,"or","binary",2,2.33753461372868,1.10333525183833,0,2009,0,121
"CD006404","CD006404_pub5_data","1|1|Total failure: day 28 (polymerase chain reaction-adjusted)|","Total failure: day 28 (polymerase chain reaction-adjusted)",1,1,"","reported","reported",8,0.224596867530182,0.0965360521848348,0,2015.875,0.0597881473419544,401.625
"CD006404","CD006404_pub5_data","1|10|First treatment, bilirubin increase greater than 2.5 times the upper limit of normal|","First treatment, bilirubin increase greater than 2.5 times the upper limit of normal",1,10,"","reported","reported",6,0.400164026888155,0.53258946057834,0,2014.33333333333,0.00797218583765451,521.666666666667
"CD006404","CD006404_pub5_data","1|11|Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal",1,11,"","reported","reported",3,2.19445397066418,5.19025778250859,0,2016,0.0019723865877712,234
"CD006404","CD006404_pub5_data","1|12|Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal",1,12,"","reported","reported",4,0.832067728051062,2.02036466688525,0,2016,0.0103386476373954,216.25
"CD006404","CD006404_pub5_data","1|13|Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal|","Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal",1,13,"","reported","reported",3,0.392772893374218,0.716685826291376,0,2016,0.0108413248996803,260.666666666667
"CD006404","CD006404_pub5_data","1|14|Paediatric trials — total failure: day 28 (polymerase chain reaction-adjusted)|","Paediatric trials — total failure: day 28 (polymerase chain reaction-adjusted)",1,14,"","reported","reported",3,0.219594142056494,0.101060602758573,0,2017.66666666667,0.135299762947453,276.333333333333
"CD006404","CD006404_pub5_data","1|15|Trials in children — total failure: day 42 (polymerase chain reaction-adjusted)|","Trials in children — total failure: day 42 (polymerase chain reaction-adjusted)",1,15,"","reported","reported",2,0.822682560317531,0.410224374631299,0.0167632484125791,2015,0.0663588532159347,279
"CD006404","CD006404_pub5_data","1|16|Trials in children — total failure: day 28 (unadjusted)|","Trials in children — total failure: day 28 (unadjusted)",1,16,"","reported","reported",3,0.53018766454209,0.200858792633364,0.073509017652229,2017.66666666667,0.180174871854037,286
"CD006404","CD006404_pub5_data","1|17|Trials in children — total failure: day 42 (unadjusted)|","Trials in children — total failure: day 42 (unadjusted)",1,17,"","reported","reported",2,0.967331851762506,0.150333025502704,0,2015,0.244797371303395,327
"CD006404","CD006404_pub5_data","1|2|Total failure: day 42 (polymerase chain reaction-adjusted)|","Total failure: day 42 (polymerase chain reaction-adjusted)",1,2,"","reported","reported",7,0.670152498835418,0.289824970466287,0,2014.85714285714,0.0298746697602765,367.857142857143
"CD006404","CD006404_pub5_data","1|3|Total failure: day 28 (unadjusted)|","Total failure: day 28 (unadjusted)",1,3,"","reported","reported",8,0.235696418312206,0.0701418420418068,0.0198765735842913,2015.875,0.1674880654798,414.25
"CD006404","CD006404_pub5_data","1|4|Total failure: day 42 (unadjusted)|","Total failure: day 42 (unadjusted)",1,4,"","reported","reported",7,0.577555253377895,0.105694453956133,0.0598950070371181,2014.85714285714,0.286260837381261,440
"CD006404","CD006404_pub5_data","1|6|Serious adverse events|","Serious adverse events",1,6,"","reported","reported",3,0.765847289368554,1.09512606960237,0,2013.33333333333,0.00157604412923562,668
"CD006404","CD006404_pub5_data","1|7|Adverse events leading to withdrawal|","Adverse events leading to withdrawal",1,7,"","reported","reported",3,1.35441815819688,0.636910950834668,0,2013.33333333333,0.0137559101654846,668
"CD006404","CD006404_pub5_data","1|8|First treatment, alanine aminotransferase increase greater than five times the upper limit of normal|","First treatment, alanine aminotransferase increase greater than five times the upper limit of normal",1,8,"","reported","reported",6,1.25858721153278,1.80284577296334,0,2014.33333333333,0.00244606308436096,536.333333333333
"CD006404","CD006404_pub5_data","1|9|First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal|","First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal",1,9,"","reported","reported",5,2.04758979588192,1.83006962991125,0,2014,0.00407710527428837,609
"CD006404","CD006404_pub5_data","2|1|Total failure: day 28 (polymerase chain reaction-adjusted)|","Total failure: day 28 (polymerase chain reaction-adjusted)",2,1,"","reported","reported",3,0.213424618683868,0.611082339362093,0,2016,0.00783918848362796,345
"CD006404","CD006404_pub5_data","2|10|Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal|","Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal",2,10,"","reported","reported",2,1.38514773804077,3.22962526120322,0,2016,0.0109109624292331,224
"CD006404","CD006404_pub5_data","2|2|Total failure: day 42 (polymerase chain reaction-adjusted)|","Total failure: day 42 (polymerase chain reaction-adjusted)",2,2,"","reported","reported",2,1.00301328954462,1.61533980250744,0,2016,0.00857052498418722,364.5
"CD006404","CD006404_pub5_data","2|3|Total failure: day 28 (unadjusted)|","Total failure: day 28 (unadjusted)",2,3,"","reported","reported",5,0.445702063683834,0.141002506556941,0,2016,0.1145949405984,244.8
"CD006404","CD006404_pub5_data","2|4|Total failure: day 42 (unadjusted)|","Total failure: day 42 (unadjusted)",2,4,"","reported","reported",5,0.921849075542016,0.125276288084921,0.00880137369806246,2016,0.196825744526046,240.4
"CD006404","CD006404_pub5_data","2|5|First treatment, alanine aminotransferase increase greater than five times the upper limit of normal|","First treatment, alanine aminotransferase increase greater than five times the upper limit of normal",2,5,"","reported","reported",3,1.03847671898838,2.80580338912775,0,2016,0.00298824756327464,363
"CD006404","CD006404_pub5_data","2|6|First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal|","First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal",2,6,"","reported","reported",3,0.423687163382619,1.00891335507826,0,2016,0.00782022327201307,363
"CD006404","CD006404_pub5_data","2|8|Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal",2,8,"","reported","reported",4,1.09109753204083,2.7655696989132,0,2016,0.00689590024560741,190
"CD006404","CD006404_pub5_data","2|9|Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal",2,9,"","reported","reported",4,0.646425634511908,1.97641387320543,0,2016,0.0048886948930598,190
"CD006404","CD006404_pub5_data","4|1|Serious adverse events|","Serious adverse events",4,1,"","reported","reported",5,0.951248264434821,0.672112116614086,0,2012,0.00736406619385343,742.8
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Blood and lymphatic: anaemias","Other adverse events",4,10,"Blood and lymphatic: anaemias","reported","reported",5,1.06366841510813,0.172491140667374,0,2013.4,0.0350023412392431,903.4
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Blood and lymphatic: eosinophilic disorders","Other adverse events",4,10,"Blood and lymphatic: eosinophilic disorders","reported","reported",2,1.19357640584821,0.262764859745541,0,2011,0.0366430260047281,1271.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Blood and lymphatic: leukocytosis","Other adverse events",4,10,"Blood and lymphatic: leukocytosis","reported","reported",2,0.634164527588997,0.291672974803867,0.0603991504316037,2014,0.0195801756666772,1307.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Blood and lymphatic: neutropenias","Other adverse events",4,10,"Blood and lymphatic: neutropenias","reported","reported",2,0.825648812855351,0.119978674039151,0,2013,0.0796049085201509,1308
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Cardiac: cardiac signs and symptoms","Other adverse events",4,10,"Cardiac: cardiac signs and symptoms","reported","reported",5,0.469474133206987,0.123869361647782,0,2007,0.031210648431893,421.6
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Gastrointestinal: diarrhoea (excl infective)","Other adverse events",4,10,"Gastrointestinal: diarrhoea (excl infective)","reported","reported",4,0.515478905371426,0.613928767502494,0,2005.75,0.037867192331478,102.75
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Gastrointestinal: gastrointestinal and abdominal pains","Other adverse events",4,10,"Gastrointestinal: gastrointestinal and abdominal pains","reported","reported",8,0.942412768284203,0.138055269492313,0,2010,0.0454966572906951,568
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Gastrointestinal: nausea and vomiting symptoms","Other adverse events",4,10,"Gastrointestinal: nausea and vomiting symptoms","reported","reported",10,0.730051562284148,0.120267134634613,0.00480882153124021,2010.5,0.0553617702866722,553.4
"CD006404","CD006404_pub5_data","4|10|Other adverse events|General: asthenic conditions","Other adverse events",4,10,"General: asthenic conditions","reported","reported",2,1.10015902297242,0.491440841677752,0,2014.5,0.0293311403508772,326.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|General: febrile disorders","Other adverse events",4,10,"General: febrile disorders","reported","reported",2,1.43825891093872,0.636998841923587,0,2013.5,0.0263888888888889,357.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Infections and infestations: lower respiratory tract infection and lung","Other adverse events",4,10,"Infections and infestations: lower respiratory tract infection and lung","reported","reported",3,0.964247356046022,0.147282977050437,0.0361757691175506,2014.66666666667,0.161905366283495,1072
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Infections and infestations: upper respiratory tract infection","Other adverse events",4,10,"Infections and infestations: upper respiratory tract infection","reported","reported",8,1.00085748936672,0.0827781061571365,0,2013.875,0.0730477875808805,668.75
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Investigations: electrocardiograph","Other adverse events",4,10,"Investigations: electrocardiograph","reported","reported",5,0.439783239718483,0.0832914039029845,0.00808107640555874,2013.8,0.0770168635980842,669.4
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Investigations: platelets","Other adverse events",4,10,"Investigations: platelets","reported","reported",2,0.881097896180444,0.252085722165367,0,2011.5,0.0527777777777778,282.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Investigations: skeletal/cardiac muscle analyses","Other adverse events",4,10,"Investigations: skeletal/cardiac muscle analyses","reported","reported",2,1.12637126844089,0.617857351517589,0,2013,0.0175438596491228,318
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Metabolism and nutrition: appetite disorders","Other adverse events",4,10,"Metabolism and nutrition: appetite disorders","reported","reported",3,1.12510658427617,0.615495893673113,0.359783945104171,2013.33333333333,0.035453216374269,227.666666666667
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Metabolism and nutrition: metabolic disorders","Other adverse events",4,10,"Metabolism and nutrition: metabolic disorders","reported","reported",2,0.892641959010168,0.179007512133212,0,2016,0.0394999866139554,1340.5
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Musculoskeletal and connective tissue: muscle pains","Other adverse events",4,10,"Musculoskeletal and connective tissue: muscle pains","reported","reported",3,1.40652263988156,0.274865157630787,0,2013.66666666667,0.0491463958359255,641.333333333333
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Nervous system: headaches","Other adverse events",4,10,"Nervous system: headaches","reported","reported",10,1.01139762909744,0.103986041253839,0,2010.3,0.0590804212310034,627.1
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Respiratory: coughing and associated symptoms","Other adverse events",4,10,"Respiratory: coughing and associated symptoms","reported","reported",7,0.94753241385232,0.0947255743005993,0,2013.57142857143,0.0806624710290267,916
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Respiratory: upper respiratory tract signs and symptoms","Other adverse events",4,10,"Respiratory: upper respiratory tract signs and symptoms","reported","reported",3,0.882715884994841,3.86843323658633,0,2014.66666666667,0.00277777777777778,135.666666666667
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Skin and subcutaneous tissue: dermatitis and eczema","Other adverse events",4,10,"Skin and subcutaneous tissue: dermatitis and eczema","reported","reported",2,0.428536250035664,2.0582707696834,0,2005.5,0.00833333333333333,138
"CD006404","CD006404_pub5_data","4|10|Other adverse events|Skin and subcutaneous tissue: pruritis","Other adverse events",4,10,"Skin and subcutaneous tissue: pruritis","reported","reported",2,0.220363050347096,0.145952118597111,0.0241889838266649,1997,0.399582560296846,92
"CD006404","CD006404_pub5_data","4|2|Adverse events leading to withdrawal|","Adverse events leading to withdrawal",4,2,"","reported","reported",5,0.835117719483195,0.385906706544808,0,2012.6,0.0118991850192858,746.2
"CD006404","CD006404_pub5_data","4|3|First treatment, alanine aminotransferase increase greater than five times the upper limit of normal|","First treatment, alanine aminotransferase increase greater than five times the upper limit of normal",4,3,"","reported","reported",11,1.27678464071224,1.50663472539961,0,2014.27272727273,0.00236410794453119,548.545454545455
"CD006404","CD006404_pub5_data","4|4|First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal|","First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal",4,4,"","reported","reported",10,0.815016439721291,0.862929892433819,0,2014.1,0.00482321610997618,586.1
"CD006404","CD006404_pub5_data","4|5|First treatment, bilirubin increase greater than 2.5 times the upper limit of normal|","First treatment, bilirubin increase greater than 2.5 times the upper limit of normal",4,5,"","reported","reported",9,0.421659922043786,0.510287607629774,0,2013.88888888889,0.00654166573618038,591.666666666667
"CD006404","CD006404_pub5_data","4|6|Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal",4,6,"","reported","reported",7,1.33508653509154,2.44070975941072,0,2016,0.00478582296367761,208.857142857143
"CD006404","CD006404_pub5_data","4|7|Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal|","Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal",4,7,"","reported","reported",8,0.737205504680371,1.41281830997323,0,2016,0.0076136712652276,203.125
"CD006404","CD006404_pub5_data","4|8|Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal|","Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal",4,8,"","reported","reported",5,0.439347866733407,0.699665673571534,0,2016,0.0108691799115015,246
"CD006404","CD006404_pub5_data","4|9|Sensitivity analysis: first treatment, alanine aminotransferase increase greater than five times the upper limit of normal|","Sensitivity analysis: first treatment, alanine aminotransferase increase greater than five times the upper limit of normal",4,9,"","reported","reported",9,2.71121149635202,2.67148275799095,0,2014.33333333333,0.0017529705153362,563.333333333333
"CD006475","CD006475_pub3_data","1|1|Asthma by 2 years of age|","Asthma by 2 years of age",1,1,"","reported","reported",4,0,0.203185014971463,0,2009.5,0.091909770143189,238.5
"CD006475","CD006475_pub3_data","1|10|Subgroup analysis: eczema by 2 years by probiotic type|Probiotic containing L. rhamnosus","Subgroup analysis: eczema by 2 years by probiotic type",1,10,"Probiotic containing L. rhamnosus","reported","reported",4,0,0.142741937696823,0,2007.25,0.261451574812937,166.5
"CD006475","CD006475_pub3_data","1|10|Subgroup analysis: eczema by 2 years by probiotic type|Probiotic not containing L. rhamnosus","Subgroup analysis: eczema by 2 years by probiotic type",1,10,"Probiotic not containing L. rhamnosus","reported","reported",11,0,0.0595245665574425,0,2009.36363636364,0.348375433604292,136.454545454545
"CD006475","CD006475_pub3_data","1|11|Subgroup analysis: eczema by 2 years by period of supplementation|Mothers did not receive prenatal probiotic","Subgroup analysis: eczema by 2 years by period of supplementation",1,11,"Mothers did not receive prenatal probiotic","reported","reported",12,0,0.0734535319946927,0,2009.75,0.242354542023677,172.333333333333
"CD006475","CD006475_pub3_data","1|11|Subgroup analysis: eczema by 2 years by period of supplementation|Mothers received prenatal probiotic","Subgroup analysis: eczema by 2 years by period of supplementation",1,11,"Mothers received prenatal probiotic","or","binary",7,-0.356031281760158,0.146334158055571,0.0457245361072634,2008.14285714286,0.461528501060794,213.428571428571
"CD006475","CD006475_pub3_data","1|2|Eczema by 2 years of age|","Eczema by 2 years of age",1,2,"","reported","reported",18,0,0.046850265207799,0,2009.05555555556,0.322005381602919,194.111111111111
"CD006475","CD006475_pub3_data","1|3|Allergic rhinitis by 2 years |","Allergic rhinitis by 2 years ",1,3,"","reported","reported",5,0,0.349072161761741,0,2009.6,0.0315110769798037,209
"CD006475","CD006475_pub3_data","1|4|Food allergy by 2 years|","Food allergy by 2 years",1,4,"","reported","reported",3,0,0.211434316888238,0,2013.33333333333,0.0894653577209358,285.666666666667
"CD006475","CD006475_pub3_data","1|5|Cow's milk protein allergy by 2 years|","Cow's milk protein allergy by 2 years",1,5,"","reported","reported",4,0,0.0972974656245785,0,2009,0.261281370656371,64.75
"CD006475","CD006475_pub3_data","1|6|Sensitivity analysis: eczema by 2 years by definition of allergic disease|Eczema","Sensitivity analysis: eczema by 2 years by definition of allergic disease",1,6,"Eczema","or","binary",18,-0.210511064313677,0.0794041850552002,0.00450214738803385,2009.05555555556,0.322005381602919,194.111111111111
"CD006475","CD006475_pub3_data","1|7|Sensitivity analysis: eczema by 2 years by risk of bias|","Sensitivity analysis: eczema by 2 years by risk of bias",1,7,"","reported","reported",4,0,0.114197853446379,0,2008,0.241196023912224,223
"CD006475","CD006475_pub3_data","1|8|Subgroup analysis: eczema by 2 years by risk of allergy|Infant at high risk of allergy or food hypersensitivity","Subgroup analysis: eczema by 2 years by risk of allergy",1,8,"Infant at high risk of allergy or food hypersensitivity","reported","reported",11,0,0.0613995862693899,0,2007.72727272727,0.377442203685083,215.636363636364
"CD006475","CD006475_pub3_data","1|8|Subgroup analysis: eczema by 2 years by risk of allergy|Infant not selected for risk of allergy or food hypersensitivity","Subgroup analysis: eczema by 2 years by risk of allergy",1,8,"Infant not selected for risk of allergy or food hypersensitivity","reported","reported",3,0,0.306428516957216,0,2008,0.155336617405583,96.3333333333333
"CD006475","CD006475_pub3_data","1|9|Subgroup analysis: eczema by 2 years by method of feeding|Infants fed predominately cow's milk formula","Subgroup analysis: eczema by 2 years by method of feeding",1,9,"Infants fed predominately cow's milk formula","reported","reported",4,0,0.0768301622513038,0,2010.75,0.260464058178628,210.75
"CD006475","CD006475_pub3_data","1|9|Subgroup analysis: eczema by 2 years by method of feeding|Infants fed predominately human milk","Subgroup analysis: eczema by 2 years by method of feeding",1,9,"Infants fed predominately human milk","reported","reported",9,0,0.0813974098864525,0,2007.88888888889,0.362767126423,112.555555555556
"CD006475","CD006475_pub3_data","2|1|Eczema by 2 years of age|","Eczema by 2 years of age",2,1,"","reported","reported",3,0,0.0923582782068968,0,2012,0.252487965419,411.666666666667
"CD006475","CD006475_pub3_data","2|3|Sensitivity analysis: eczema by 2 years of age by definition of allergic disease|Eczema","Sensitivity analysis: eczema by 2 years of age by definition of allergic disease",2,3,"Eczema","or","binary",3,-0.253806965148068,0.385981110307299,0.292821457255891,2012,0.252487965419,411.666666666667
"CD006475","CD006475_pub3_data","2|4|Subgroup analysis: eczema by 2 years of age by risk of allergy|Infant not selected for risk of allergy or food hypersensitivity","Subgroup analysis: eczema by 2 years of age by risk of allergy",2,4,"Infant not selected for risk of allergy or food hypersensitivity","or","binary",2,-0.543011690239489,1.02083829397484,1.68845306958756,2015,0.217094017094017,155
"CD006475","CD006475_pub3_data","2|5|Subgroup analysis: eczema by 2 years of age by synbiotic type|Synbiotic containing L. rhamnosus","Subgroup analysis: eczema by 2 years of age by synbiotic type",2,5,"Synbiotic containing L. rhamnosus","or","binary",2,-0.752657549832067,0.672072392074485,0.631316750850508,2009,0.250526819923372,504.5
"CD006475","CD006475_pub3_data","2|6|Subgroup analysis: eczema by 2 years of age by period of supplementation|Mothers did not receive prenatal synbiotic","Subgroup analysis: eczema by 2 years of age by period of supplementation",2,6,"Mothers did not receive prenatal synbiotic","or","binary",2,-0.543011690239489,1.02083829397484,1.68845306958756,2015,0.217094017094017,155
"CD006475","CD006475_pub3_data","3|10|Subgroup analysis: eczema by 10 years of age by period of supplementation|Mothers did not receive prenatal probiotic","Subgroup analysis: eczema by 10 years of age by period of supplementation",3,10,"Mothers did not receive prenatal probiotic","or","binary",3,-0.08484225444263,0.13660917263176,1.59936560132289e-06,2009,0.321042989466411,333.666666666667
"CD006475","CD006475_pub3_data","3|10|Subgroup analysis: eczema by 10 years of age by period of supplementation|Mothers received prenatal probiotic","Subgroup analysis: eczema by 10 years of age by period of supplementation",3,10,"Mothers received prenatal probiotic","or","binary",4,-0.454718495840077,0.277193384329234,0.196245504658467,2006.25,0.476396887426299,177.25
"CD006475","CD006475_pub3_data","3|2|Eczema by 10 years of age|","Eczema by 10 years of age",3,2,"","or","binary",8,-0.174315127884737,0.143656321978799,0.0741947846431413,2007.625,0.401558314763054,245.625
"CD006475","CD006475_pub3_data","3|3|Allergic rhinitis by 10 years of age|","Allergic rhinitis by 10 years of age",3,3,"","or","binary",6,0.127144833307943,0.231041245286319,0.0647547104277539,2007,0.114204400287208,152
"CD006475","CD006475_pub3_data","3|4|Sensitivity analysis: eczema by 10 years of age by definition of allergic disease|Eczema","Sensitivity analysis: eczema by 10 years of age by definition of allergic disease",3,4,"Eczema","reported","reported",2,0,0.209540702806887,0,2009,0.330965909090909,91.5
"CD006475","CD006475_pub3_data","3|6|Sensitivity analysis: eczema by 10 years of age by risk of bias|","Sensitivity analysis: eczema by 10 years of age by risk of bias",3,6,"","or","binary",2,-0.270237349984081,0.284180711939942,0.101268079833837,2007.5,0.462820512820513,324.5
"CD006475","CD006475_pub3_data","3|7|Subgroup analysis: eczema by 10 years of age by risk of allergy|Infant at high risk of allergy or food hypersensitivity","Subgroup analysis: eczema by 10 years of age by risk of allergy",3,7,"Infant at high risk of allergy or food hypersensitivity","or","binary",7,-0.22295413361314,0.144859898823424,0.0653935895740414,2007.42857142857,0.40981664544349,266.428571428571
"CD006475","CD006475_pub3_data","3|8|Subgroup analysis: eczema by 10 years of age by method of feeding|Infants fed predominately human milk","Subgroup analysis: eczema by 10 years of age by method of feeding",3,8,"Infants fed predominately human milk","or","binary",5,-0.218275111686224,0.236586907532782,0.174096814169035,2006.2,0.44690698362525,202.8
"CD006475","CD006475_pub3_data","3|9|Subgroup analysis: eczema by 10 years of age by probiotic type|Probiotic containing L. rhamnosus","Subgroup analysis: eczema by 10 years of age by probiotic type",3,9,"Probiotic containing L. rhamnosus","or","binary",4,-0.473606170403239,0.261172131260405,0.16821460395684,2006.75,0.458096201369931,196.75
"CD006475","CD006475_pub3_data","3|9|Subgroup analysis: eczema by 10 years of age by probiotic type|Probiotic not containing L. rhamnosus","Subgroup analysis: eczema by 10 years of age by probiotic type",3,9,"Probiotic not containing L. rhamnosus","or","binary",4,0.00636243693045181,0.132388435406002,0,2008.5,0.341815299951048,255.75
"CD006515","CD006515_pub2_data","1|10|Mechanical complications|Hernias","Mechanical complications",1,10,"Hernias","or","binary",2,0.227408367555811,0.71468486172692,0,1996.5,0.0365853658536585,53.5
"CD006515","CD006515_pub2_data","1|10|Mechanical complications|PD fluid leaks","Mechanical complications",1,10,"PD fluid leaks","or","binary",2,0.0444145574793859,1.1907462644459,0.0652877415326523,1996.5,0.0121951219512195,53.5
"CD006515","CD006515_pub2_data","1|2|Hospital admissions|","Hospital admissions",1,2,"","or","binary",2,-0.117436480952357,0.718725865502687,0.641106625374084,1996.5,0.444652908067542,53.5
"CD006515","CD006515_pub2_data","1|3|Peritonitis|","Peritonitis",1,3,"","or","binary",2,-0.569215174195843,0.411000857456475,0,1996.5,0.381801125703565,53.5
"CD006515","CD006515_pub2_data","1|4|Change of dialysis modality|Change to any other form of dialysis modality including other forms of PD","Change of dialysis modality",1,4,"Change to any other form of dialysis modality including other forms of PD","or","binary",2,-0.822509007071567,0.479361999421497,0,1996.5,0.229555236728838,58
"CD006515","CD006515_pub2_data","1|4|Change of dialysis modality|Change to haemodialysis","Change of dialysis modality",1,4,"Change to haemodialysis","or","binary",2,-0.882180899287354,0.585270545315838,0,1996.5,0.156384505021521,58
"CD006515","CD006515_pub2_data","1|5|Residual kidney function (end of study CrCl) [mL/min]|","Residual kidney function (end of study CrCl) [mL/min]",1,5,"","or","binary",2,-0.0415915388347424,1.44179565559524,0,1996.5,0,24.5
"CD006515","CD006515_pub2_data","1|9|Other infectious complications|Exit-site infections","Other infectious complications",1,9,"Exit-site infections","or","binary",2,0.112226053598612,0.449621219973224,0,1996.5,0.172607879924953,53.5
"CD006515","CD006515_pub2_data","1|9|Other infectious complications|Tunnel infections","Other infectious complications",1,9,"Tunnel infections","or","binary",2,-0.0277137873420549,0.894727594778848,0,1996.5,0.024390243902439,53.5
"CD006536","CD006536_pub5_data","1|1|All-cause mortality|Long-term follow-up (≥ 12 months)","All-cause mortality",1,1,"Long-term follow-up (≥ 12 months)","or","binary",23,-0.10812825720415,0.235185939532245,0.126558564436795,2012.30434782609,0.0715858120983086,83.0434782608696
"CD006536","CD006536_pub5_data","1|1|All-cause mortality|Short-term follow-up (< 12 months)","All-cause mortality",1,1,"Short-term follow-up (< 12 months)","or","binary",21,-0.278975127284274,0.287502142767614,0,2010.85714285714,0.0454241690983382,91.6190476190476
"CD006536","CD006536_pub5_data","1|10|NYHA classification|Long-term follow-up (≥ 12 months)","NYHA classification",1,10,"Long-term follow-up (≥ 12 months)","or","binary",6,-0.304599340917477,0.826348447575417,0,2012.66666666667,0,57
"CD006536","CD006536_pub5_data","1|10|NYHA classification|Short-term follow-up (< 12 months)","NYHA classification",1,10,"Short-term follow-up (< 12 months)","or","binary",5,-0.306600812773073,0.903418580502868,0,2010.2,0,79.6
"CD006536","CD006536_pub5_data","1|11|Exercise tolerance|Long-term follow-up (≥ 12 months)","Exercise tolerance",1,11,"Long-term follow-up (≥ 12 months)","or","binary",2,-0.166026243339667,1.43667911870404,0,2011,0,35.5
"CD006536","CD006536_pub5_data","1|11|Exercise tolerance|Short-term follow-up (< 12 months)","Exercise tolerance",1,11,"Short-term follow-up (< 12 months)","or","binary",5,-0.164224162358223,0.90419960126144,0,2006.8,0,53.4
"CD006536","CD006536_pub5_data","1|12|Maximum VO2 (mL/kg/min)|Short-term follow-up (< 12 months)","Maximum VO2 (mL/kg/min)",1,12,"Short-term follow-up (< 12 months)","or","binary",3,-0.297883549844454,1.16723319479916,0,2007,0,58.3333333333333
"CD006536","CD006536_pub5_data","1|13|VE/VCO2 slope|Short-term follow-up (< 12 months)","VE/VCO2 slope",1,13,"Short-term follow-up (< 12 months)","or","binary",3,-0.304775351713509,1.1672534815696,0,2007,0,58
"CD006536","CD006536_pub5_data","1|14|Peak heart rate (bpm)|Short-term follow-up (< 12 months)","Peak heart rate (bpm)",1,14,"Short-term follow-up (< 12 months)","or","binary",3,-0.250020930962794,1.16490290515841,0,2006.33333333333,0,66
"CD006536","CD006536_pub5_data","1|17|LVEF measured by echocardiography (< 12 months)|Combined","LVEF measured by echocardiography (< 12 months)",1,17,"Combined","or","binary",21,-0.133470331971145,0.443525238132739,0,2009.14285714286,0,42.2857142857143
"CD006536","CD006536_pub5_data","1|17|LVEF measured by echocardiography (< 12 months)|Mean change from baseline","LVEF measured by echocardiography (< 12 months)",1,17,"Mean change from baseline","or","binary",7,-0.132262868344965,0.763700786760836,0,2010.71428571429,0,56.8571428571429
"CD006536","CD006536_pub5_data","1|17|LVEF measured by echocardiography (< 12 months)|Mean value at endpoint","LVEF measured by echocardiography (< 12 months)",1,17,"Mean value at endpoint","or","binary",21,-0.133470331971145,0.443525238132739,0,2009.14285714286,0,42.2857142857143
"CD006536","CD006536_pub5_data","1|18|LVEF measured by echocardiography (≥ 12 months)|Combined","LVEF measured by echocardiography (≥ 12 months)",1,18,"Combined","or","binary",14,-0.137021608442912,0.543198763098391,0,2011.85714285714,0,42.7142857142857
"CD006536","CD006536_pub5_data","1|18|LVEF measured by echocardiography (≥ 12 months)|Mean change from baseline","LVEF measured by echocardiography (≥ 12 months)",1,18,"Mean change from baseline","or","binary",5,-0.102112166842315,0.90786695460692,0,2013.4,0,35.8
"CD006536","CD006536_pub5_data","1|18|LVEF measured by echocardiography (≥ 12 months)|Mean value at endpoint","LVEF measured by echocardiography (≥ 12 months)",1,18,"Mean value at endpoint","or","binary",13,-0.0905696083467603,0.563974565904503,0,2012.07692307692,0,41.6923076923077
"CD006536","CD006536_pub5_data","1|19|LVEF measured by SPECT (< 12 months)|Combined","LVEF measured by SPECT (< 12 months)",1,19,"Combined","or","binary",8,-0.230776464190217,0.715893503094939,0,2010.75,0,52.5
"CD006536","CD006536_pub5_data","1|19|LVEF measured by SPECT (< 12 months)|Mean change from baseline","LVEF measured by SPECT (< 12 months)",1,19,"Mean change from baseline","or","binary",6,-0.323007859698826,0.826341962652966,0,2010.83333333333,0,52
"CD006536","CD006536_pub5_data","1|19|LVEF measured by SPECT (< 12 months)|Mean value at endpoint","LVEF measured by SPECT (< 12 months)",1,19,"Mean value at endpoint","or","binary",7,-0.152281999014559,0.764772640344761,0,2010.85714285714,0,57.2857142857143
"CD006536","CD006536_pub5_data","1|2|Cardiovascular mortality|Long-term follow-up (≥ 12 months)","Cardiovascular mortality",1,2,"Long-term follow-up (≥ 12 months)","or","binary",14,-0.0740910330001908,0.289409731672731,0.0855014776099242,2011.71428571429,0.0774470438143552,88.7857142857143
"CD006536","CD006536_pub5_data","1|2|Cardiovascular mortality|Short-term follow-up (< 12 months)","Cardiovascular mortality",1,2,"Short-term follow-up (< 12 months)","or","binary",9,-0.329754992275148,0.450729978761975,0,2011,0.0711471617464008,75.2222222222222
"CD006536","CD006536_pub5_data","1|20|LVEF measured by SPECT (≥ 12 months)|Combined","LVEF measured by SPECT (≥ 12 months)",1,20,"Combined","or","binary",5,-0.267176973197069,0.904992543002641,0,2011.4,0,53.8
"CD006536","CD006536_pub5_data","1|20|LVEF measured by SPECT (≥ 12 months)|Mean change from baseline","LVEF measured by SPECT (≥ 12 months)",1,20,"Mean change from baseline","or","binary",2,-0.402763942389655,1.43133220226522,0,2009,0,46
"CD006536","CD006536_pub5_data","1|20|LVEF measured by SPECT (≥ 12 months)|Mean value at endpoint","LVEF measured by SPECT (≥ 12 months)",1,20,"Mean value at endpoint","or","binary",4,-0.139139126517701,1.01039045094104,0,2011.75,0,62.5
"CD006536","CD006536_pub5_data","1|21|LVEF measured by left ventricular angiography (< 12 months)|Combined","LVEF measured by left ventricular angiography (< 12 months)",1,21,"Combined","or","binary",10,-0.0973668066508153,0.638352962791198,0,2009.1,0,79.8
"CD006536","CD006536_pub5_data","1|21|LVEF measured by left ventricular angiography (< 12 months)|Mean change from baseline","LVEF measured by left ventricular angiography (< 12 months)",1,21,"Mean change from baseline","or","binary",4,-0.0598007861050854,1.00958787134404,0,2009.25,0,91.5
"CD006536","CD006536_pub5_data","1|21|LVEF measured by left ventricular angiography (< 12 months)|Mean value at endpoint","LVEF measured by left ventricular angiography (< 12 months)",1,21,"Mean value at endpoint","or","binary",10,-0.0973668066508153,0.638352962791198,0,2009.1,0,79.8
"CD006536","CD006536_pub5_data","1|22|LVEF measured by left ventricular angiography (≥ 12 months)|Combined analysis","LVEF measured by left ventricular angiography (≥ 12 months)",1,22,"Combined analysis","or","binary",2,-0.464873859846126,1.42416714383842,0,2013.5,0,80
"CD006536","CD006536_pub5_data","1|22|LVEF measured by left ventricular angiography (≥ 12 months)|Mean value at endpoint","LVEF measured by left ventricular angiography (≥ 12 months)",1,22,"Mean value at endpoint","or","binary",2,-0.464873859846126,1.42416714383842,0,2013.5,0,80
"CD006536","CD006536_pub5_data","1|23|LVEF measured by radionuclide ventriculography (RNV) (< 12 months)|Combined","LVEF measured by radionuclide ventriculography (RNV) (< 12 months)",1,23,"Combined","or","binary",4,-0.502924288776681,1.01154458196532,0,2009.75,0,95.75
"CD006536","CD006536_pub5_data","1|23|LVEF measured by radionuclide ventriculography (RNV) (< 12 months)|Mean change from baseline","LVEF measured by radionuclide ventriculography (RNV) (< 12 months)",1,23,"Mean change from baseline","or","binary",3,-0.408468902436965,1.16692252279567,0,2011.33333333333,0,114.666666666667
"CD006536","CD006536_pub5_data","1|23|LVEF measured by radionuclide ventriculography (RNV) (< 12 months)|Mean value at endpoint","LVEF measured by radionuclide ventriculography (RNV) (< 12 months)",1,23,"Mean value at endpoint","or","binary",3,-0.698873615918692,1.17169425641901,0,2008,0,52.3333333333333
"CD006536","CD006536_pub5_data","1|3|Composite measure of death, reinfarction, re-hospitalisation for heart failure|Long-term follow-up (≥ 12 months)","Composite measure of death, reinfarction, re-hospitalisation for heart failure",1,3,"Long-term follow-up (≥ 12 months)","or","binary",6,-0.54917674839128,0.321341977166568,0.0545917781199917,2008.66666666667,0.176065051560101,82.8333333333333
"CD006536","CD006536_pub5_data","1|3|Composite measure of death, reinfarction, re-hospitalisation for heart failure|Short-term follow-up (< 12 months)","Composite measure of death, reinfarction, re-hospitalisation for heart failure",1,3,"Short-term follow-up (< 12 months)","or","binary",3,-0.997819936453586,0.554917072094421,0,2008.66666666667,0.0650236494896689,126.333333333333
"CD006536","CD006536_pub5_data","1|4|Incidence of reinfarction|Long-term follow-up (≥ 12 months)","Incidence of reinfarction",1,4,"Long-term follow-up (≥ 12 months)","or","binary",22,-0.155590926188988,0.21371273033439,0,2011.81818181818,0.0680557359716959,90.5909090909091
"CD006536","CD006536_pub5_data","1|4|Incidence of reinfarction|Short-term follow-up (< 12 months)","Incidence of reinfarction",1,4,"Short-term follow-up (< 12 months)","or","binary",18,-0.558411745872652,0.327121405086318,0,2009.72222222222,0.0315261498484326,88.3333333333333
"CD006536","CD006536_pub5_data","1|5|Incidence of re-hospitalisation for heart failure|Long-term follow-up (≥ 12 months)","Incidence of re-hospitalisation for heart failure",1,5,"Long-term follow-up (≥ 12 months)","or","binary",16,-0.445800622935269,0.241834988765824,0.102792025410319,2012.875,0.0886919666981281,96.625
"CD006536","CD006536_pub5_data","1|5|Incidence of re-hospitalisation for heart failure|Short-term follow-up (< 12 months)","Incidence of re-hospitalisation for heart failure",1,5,"Short-term follow-up (< 12 months)","or","binary",14,-0.29146556275839,0.324622870506507,0,2009.21428571429,0.0443886965903305,92.2142857142857
"CD006536","CD006536_pub5_data","1|6|Incidence of arrhythmias|Short-term follow-up (< 12 months)","Incidence of arrhythmias",1,6,"Short-term follow-up (< 12 months)","or","binary",6,0.0513759075852411,0.352228148963518,0,2010.33333333333,0.0674895450317014,91.8333333333333
"CD006536","CD006536_pub5_data","1|7|Incidence of restenosis|Long-term follow-up (≥ 12 months)","Incidence of restenosis",1,7,"Long-term follow-up (≥ 12 months)","or","binary",6,-0.515675994622664,0.401105357381851,0,2008.83333333333,0.118909014961647,65.8333333333333
"CD006536","CD006536_pub5_data","1|7|Incidence of restenosis|Short-term follow-up (< 12 months)","Incidence of restenosis",1,7,"Short-term follow-up (< 12 months)","or","binary",8,-0.0940127766410568,0.25668603017661,0,2007.125,0.153994299311236,80.125
"CD006536","CD006536_pub5_data","1|8|Incidence of target vessel revascularisation|Long-term follow-up (≥ 12 months)","Incidence of target vessel revascularisation",1,8,"Long-term follow-up (≥ 12 months)","or","binary",9,0.0282132430395075,0.221497388142977,0.0685755902494221,2010.22222222222,0.132540876768519,93.6666666666667
"CD006536","CD006536_pub5_data","1|8|Incidence of target vessel revascularisation|Short-term follow-up (< 12 months)","Incidence of target vessel revascularisation",1,8,"Short-term follow-up (< 12 months)","or","binary",6,-0.429177076122643,0.235608393676761,0,2009.83333333333,0.143093958913833,131.5
"CD006536","CD006536_pub5_data","1|9|Quality of life measures|Long-term follow-up (≥ 12 months)","Quality of life measures",1,9,"Long-term follow-up (≥ 12 months)","or","binary",2,-0.163877485737144,1.43354870671679,0,2012,0,40.5
"CD006536","CD006536_pub5_data","1|9|Quality of life measures|Short-term follow-up (< 12 months)","Quality of life measures",1,9,"Short-term follow-up (< 12 months)","or","binary",4,-0.073960732618092,1.01144333109498,0,2008.75,0,52.25
"CD006536","CD006536_pub5_data","10|1|All-cause mortality (< 12 months)|Heparin","All-cause mortality (< 12 months)",10,1,"Heparin","or","binary",8,-0.390102811403665,0.466082047543823,0,2010.375,0.0317780738337967,74.625
"CD006536","CD006536_pub5_data","10|1|All-cause mortality (< 12 months)|No heparin","All-cause mortality (< 12 months)",10,1,"No heparin","or","binary",10,-0.441935023705491,0.396926380698355,0,2010.5,0.0699682960394729,99.9
"CD006536","CD006536_pub5_data","10|2|All-cause mortality (≥ 12 months)|No heparin","All-cause mortality (≥ 12 months)",10,2,"No heparin","or","binary",6,-0.44539683639984,0.359908629942549,0,2010.66666666667,0.115643274853801,82.1666666666667
"CD006536","CD006536_pub5_data","10|3|LVEF measured by MRI (< 12 months)|Heparin","LVEF measured by MRI (< 12 months)",10,3,"Heparin","or","binary",9,-0.218485591351946,0.672967517552074,0,2008.44444444444,0,75.7777777777778
"CD006536","CD006536_pub5_data","10|3|LVEF measured by MRI (< 12 months)|No heparin","LVEF measured by MRI (< 12 months)",10,3,"No heparin","or","binary",9,-0.646573087732107,0.672028628211923,0,2011.44444444444,0,88.2222222222222
"CD006536","CD006536_pub5_data","10|4|LVEF measured by MRI (≥ 12 months)|Heparin","LVEF measured by MRI (≥ 12 months)",10,4,"Heparin","or","binary",7,-0.167909867857693,0.761700213847606,0,2010.28571428571,0,75
"CD006536","CD006536_pub5_data","10|4|LVEF measured by MRI (≥ 12 months)|No heparin","LVEF measured by MRI (≥ 12 months)",10,4,"No heparin","or","binary",5,-0.426438138017169,0.901207160207758,0,2012.6,0,88.6
"CD006536","CD006536_pub5_data","10|5|LVEF measured by left ventricular angiography (< 12 months)|Heparin","LVEF measured by left ventricular angiography (< 12 months)",10,5,"Heparin","or","binary",5,0.0129487243570672,0.90483976222578,0,2007.8,0,51.2
"CD006536","CD006536_pub5_data","10|5|LVEF measured by left ventricular angiography (< 12 months)|No heparin","LVEF measured by left ventricular angiography (< 12 months)",10,5,"No heparin","or","binary",4,-0.0767147894663568,1.00653168547969,0,2010,0,120
"CD006536","CD006536_pub5_data","2|1|All-cause mortality|Long-term follow-up (≥ 12 months)","All-cause mortality",2,1,"Long-term follow-up (≥ 12 months)","or","binary",22,-0.119113314574732,0.238709366862672,0.133855563084939,2012.04545454545,0.0748397126482317,83.6818181818182
"CD006536","CD006536_pub5_data","2|1|All-cause mortality|Short-term follow-up (< 12 months)","All-cause mortality",2,1,"Short-term follow-up (< 12 months)","or","binary",19,-0.306936459110302,0.296401558998175,0,2010.57894736842,0.0502056605823738,96.0526315789474
"CD006536","CD006536_pub5_data","3|1|All-cause mortality (random sequence generation)|Long-term follow-up (≥ 12 months)","All-cause mortality (random sequence generation)",3,1,"Long-term follow-up (≥ 12 months)","or","binary",13,-0.259329543732338,0.261013431787938,0,2012.69230769231,0.0589664867296446,104.846153846154
"CD006536","CD006536_pub5_data","3|1|All-cause mortality (random sequence generation)|Short-term follow-up (< 12 months)","All-cause mortality (random sequence generation)",3,1,"Short-term follow-up (< 12 months)","or","binary",12,0.0920250510683828,0.420864943799871,0,2011,0.00978014773419862,108
"CD006536","CD006536_pub5_data","3|2|All-cause mortality (allocation concealment)|Long-term follow-up (≥ 12 months)","All-cause mortality (allocation concealment)",3,2,"Long-term follow-up (≥ 12 months)","or","binary",5,-0.441104116464405,0.314046121408647,0,2009.4,0.0591461988304094,164
"CD006536","CD006536_pub5_data","3|2|All-cause mortality (allocation concealment)|Short-term follow-up (< 12 months)","All-cause mortality (allocation concealment)",3,2,"Short-term follow-up (< 12 months)","or","binary",8,-0.169022874591279,0.489432031584759,0,2008.5,0.0146702216012979,104.75
"CD006536","CD006536_pub5_data","4|1|All-cause mortality|Long-term follow-up (≥ 12 months)","All-cause mortality",4,1,"Long-term follow-up (≥ 12 months)","or","binary",19,-0.271329934649671,0.241610207449318,0,2012.68421052632,0.0521750852335563,91.1052631578947
"CD006536","CD006536_pub5_data","4|1|All-cause mortality|Short-term follow-up (< 12 months)","All-cause mortality",4,1,"Short-term follow-up (< 12 months)","or","binary",16,-0.334319447261159,0.335035971512648,0,2010.6875,0.0518067219415689,77
"CD006536","CD006536_pub5_data","4|2|Cardiovascular mortality|Long-term follow-up (≥ 12 months)","Cardiovascular mortality",4,2,"Long-term follow-up (≥ 12 months)","or","binary",10,-0.362091438155453,0.329766966449558,0,2012.2,0.0671758613400972,106.8
"CD006536","CD006536_pub5_data","4|2|Cardiovascular mortality|Short-term follow-up (< 12 months)","Cardiovascular mortality",4,2,"Short-term follow-up (< 12 months)","or","binary",6,-0.530888109565966,0.572059748122275,0,2010.66666666667,0.0900540759529345,60
"CD006536","CD006536_pub5_data","5|1|All-cause mortality|Long-term follow-up (≥ 12 months)","All-cause mortality",5,1,"Long-term follow-up (≥ 12 months)","or","binary",10,-0.436383726179218,0.347922592972368,0,2013.5,0.0278366800535475,97.2
"CD006536","CD006536_pub5_data","5|1|All-cause mortality|Short-term follow-up (< 12 months)","All-cause mortality",5,1,"Short-term follow-up (< 12 months)","or","binary",10,-0.469688679921988,0.416606871717175,0,2011.3,0.0285047901942296,99.1
"CD006536","CD006536_pub5_data","5|2|Cardiovascular mortality|Long-term follow-up (≥ 12 months)","Cardiovascular mortality",5,2,"Long-term follow-up (≥ 12 months)","or","binary",4,-0.605925644485338,0.482926379614014,0,2013.25,0.0315361445783133,128.75
"CD006536","CD006536_pub5_data","5|2|Cardiovascular mortality|Short-term follow-up (< 12 months)","Cardiovascular mortality",5,2,"Short-term follow-up (< 12 months)","or","binary",3,-0.540222987944236,0.931294785248909,0,2013.33333333333,0.0163654618473896,155.666666666667
"CD006536","CD006536_pub5_data","6|1|All-cause mortality (< 12 months)|Baseline LVEF < 45%","All-cause mortality (< 12 months)",6,1,"Baseline LVEF < 45%","or","binary",4,-0.370839438965406,0.706078122023576,2.61666461376812e-06,2010.25,0.0895833333333333,119.5
"CD006536","CD006536_pub5_data","6|1|All-cause mortality (< 12 months)|Baseline LVEF ≥ 45%","All-cause mortality (< 12 months)",6,1,"Baseline LVEF ≥ 45%","or","binary",7,-0.23409359877192,0.494265784008319,0,2009.57142857143,0.0241835499619229,92.5714285714286
"CD006536","CD006536_pub5_data","6|2|All-cause mortality (≥ 12 months)|Baseline LVEF < 45%","All-cause mortality (≥ 12 months)",6,2,"Baseline LVEF < 45%","or","binary",2,-0.542269098310656,0.809302105260955,0,2009.5,0.183333333333333,68
"CD006536","CD006536_pub5_data","6|2|All-cause mortality (≥ 12 months)|Baseline LVEF ≥ 45%","All-cause mortality (≥ 12 months)",6,2,"Baseline LVEF ≥ 45%","or","binary",8,-0.14646719717094,0.407224603504156,0.154080010956109,2011.625,0.0336155913978495,89.375
"CD006536","CD006536_pub5_data","6|3|LVEF measured by MRI (< 12 months)|Baseline LVEF < 45%","LVEF measured by MRI (< 12 months)",6,3,"Baseline LVEF < 45%","or","binary",6,-0.533180371512997,0.822922903804276,0,2009.5,0,96.5
"CD006536","CD006536_pub5_data","6|3|LVEF measured by MRI (< 12 months)|Baseline LVEF ≥ 45%","LVEF measured by MRI (< 12 months)",6,3,"Baseline LVEF ≥ 45%","or","binary",11,-0.426230226679705,0.608887749040951,0,2009.54545454545,0,67.8181818181818
"CD006536","CD006536_pub5_data","6|4|LVEF measured by MRI (≥ 12 months)|Baseline LVEF < 45%","LVEF measured by MRI (≥ 12 months)",6,4,"Baseline LVEF < 45%","or","binary",5,-0.564942743638209,0.910280919793302,0,2012.2,0,80.4
"CD006536","CD006536_pub5_data","6|4|LVEF measured by MRI (≥ 12 months)|Baseline LVEF ≥ 45%","LVEF measured by MRI (≥ 12 months)",6,4,"Baseline LVEF ≥ 45%","or","binary",8,-0.215843244770413,0.713276926937522,0,2011.5,0,64.5
"CD006536","CD006536_pub5_data","7|1|All-cause mortality (< 12 months)|Haematopoietic progenitor cells","All-cause mortality (< 12 months)",7,1,"Haematopoietic progenitor cells","or","binary",4,-0.420523226246072,0.757229540281366,0,2013.75,0.0122740963855422,89.25
"CD006536","CD006536_pub5_data","7|1|All-cause mortality (< 12 months)|Mesenchymal stem cells","All-cause mortality (< 12 months)",7,1,"Mesenchymal stem cells","or","binary",2,0.0115579555773676,0.897673095858685,0,2013.5,0.0333333333333333,50.5
"CD006536","CD006536_pub5_data","7|1|All-cause mortality (< 12 months)|Mononuclear cells","All-cause mortality (< 12 months)",7,1,"Mononuclear cells","or","binary",17,-0.259400479250285,0.31777553564305,0,2010.17647058824,0.0507732058150746,89.7058823529412
"CD006536","CD006536_pub5_data","7|2|All-cause mortality (≥ 12 months)|Haematopoietic progenitor cells","All-cause mortality (≥ 12 months)",7,2,"Haematopoietic progenitor cells","or","binary",3,-0.690926675993265,0.932189862101672,0,2016,0.028714859437751,76.3333333333333
"CD006536","CD006536_pub5_data","7|2|All-cause mortality (≥ 12 months)|Mesenchymal stem cells","All-cause mortality (≥ 12 months)",7,2,"Mesenchymal stem cells","or","binary",2,1.1764612570049,1.17654358281714,0,2017,0,39.5
"CD006536","CD006536_pub5_data","7|2|All-cause mortality (≥ 12 months)|Mononuclear cells","All-cause mortality (≥ 12 months)",7,2,"Mononuclear cells","or","binary",17,-0.0513003415381804,0.260083186176267,0.142844219829822,2010.82352941176,0.0664812965367245,91.4117647058823
"CD006536","CD006536_pub5_data","8|1|All-cause mortality (< 12 months)|> 108 and ≤ 109 cells","All-cause mortality (< 12 months)",8,1,"> 108 and ≤ 109 cells","or","binary",15,-0.334258073579418,0.327293997508256,0,2010.73333333333,0.03976518881264,94.6666666666667
"CD006536","CD006536_pub5_data","8|1|All-cause mortality (< 12 months)|≤ 108 cells","All-cause mortality (< 12 months)",8,1,"≤ 108 cells","or","binary",6,-0.267846125181986,0.626877913544512,0,2011.5,0.0637382864792503,76.3333333333333
"CD006536","CD006536_pub5_data","8|2|All-cause mortality (≥ 12 months)|> 108 and ≤ 109 cells","All-cause mortality (≥ 12 months)",8,2,"> 108 and ≤ 109 cells","or","binary",10,-0.438236284496693,0.27679452753953,0,2012,0.0552923976608187,115.1
"CD006536","CD006536_pub5_data","8|2|All-cause mortality (≥ 12 months)|> 109 cells","All-cause mortality (≥ 12 months)",8,2,"> 109 cells","or","binary",2,0.425413865204544,0.801316396096747,0,2006.5,0.0333333333333333,43.5
"CD006536","CD006536_pub5_data","8|2|All-cause mortality (≥ 12 months)|≤ 108 cells","All-cause mortality (≥ 12 months)",8,2,"≤ 108 cells","or","binary",11,0.107009144003274,0.425719322997631,0.363499773000298,2013.63636363636,0.0940214523784287,59.0909090909091
"CD006536","CD006536_pub5_data","8|3|LVEF measured by MRI (< 12 months)|> 108 and ≤ 109 cells","LVEF measured by MRI (< 12 months)",8,3,"> 108 and ≤ 109 cells","or","binary",12,-0.505362333112616,0.582653436254662,0,2009.41666666667,0,74.0833333333333
"CD006536","CD006536_pub5_data","8|3|LVEF measured by MRI (< 12 months)|≤ 108 cells","LVEF measured by MRI (< 12 months)",8,3,"≤ 108 cells","or","binary",6,-0.214148579646029,0.823359662493902,0,2011.5,0,85.6666666666667
"CD006536","CD006536_pub5_data","8|4|LVEF measured by MRI (≥ 12 months)|> 108 and ≤ 109 cells","LVEF measured by MRI (≥ 12 months)",8,4,"> 108 and ≤ 109 cells","or","binary",8,-0.376339399074347,0.713402098765912,0,2010.875,0,76.5
"CD006536","CD006536_pub5_data","8|4|LVEF measured by MRI (≥ 12 months)|≤ 108 cells","LVEF measured by MRI (≥ 12 months)",8,4,"≤ 108 cells","or","binary",5,-0.305650631061443,0.909896864931346,0,2013.2,0,63.2
"CD006536","CD006536_pub5_data","8|5|LVEF measured by left ventricular angiography (< 12 months)|> 108 and ≤ 109 cells","LVEF measured by left ventricular angiography (< 12 months)",8,5,"> 108 and ≤ 109 cells","or","binary",6,-0.0110152687795362,0.824177144289629,0,2007.83333333333,0,91.3333333333333
"CD006536","CD006536_pub5_data","8|5|LVEF measured by left ventricular angiography (< 12 months)|> 109 cells","LVEF measured by left ventricular angiography (< 12 months)",8,5,"> 109 cells","or","binary",2,0.01439858764069,1.42984832299948,0,2008,0,50.5
"CD006536","CD006536_pub5_data","9|1|All-cause mortality (< 12 months)|> 10 days since AMI","All-cause mortality (< 12 months)",9,1,"> 10 days since AMI","or","binary",5,-0.518668895861693,0.659478588936351,0,2013.4,0.0868965517241379,90.2
"CD006536","CD006536_pub5_data","9|1|All-cause mortality (< 12 months)|≤ 10 days since AMI","All-cause mortality (< 12 months)",9,1,"≤ 10 days since AMI","or","binary",12,-0.185418610995098,0.378390130060878,0,2010.41666666667,0.0328687327037011,91.4166666666667
"CD006536","CD006536_pub5_data","9|2|All-cause mortality (≥ 12 months)|> 10 days since AMI","All-cause mortality (≥ 12 months)",9,2,"> 10 days since AMI","or","binary",4,0.202607540218721,0.682152494071424,0.815195701872798,2012.25,0.222120098039216,42
"CD006536","CD006536_pub5_data","9|2|All-cause mortality (≥ 12 months)|≤ 10 days since AMI","All-cause mortality (≥ 12 months)",9,2,"≤ 10 days since AMI","or","binary",15,-0.367707899382938,0.255001197459779,0,2012.4,0.0438662190736157,105.8
"CD006536","CD006536_pub5_data","9|3|LVEF measured by MRI (< 12 months)|> 10 days since AMI","LVEF measured by MRI (< 12 months)",9,3,"> 10 days since AMI","or","binary",2,-0.268179078933861,1.42236072217196,0,2012,0,95
"CD006536","CD006536_pub5_data","9|3|LVEF measured by MRI (< 12 months)|≤ 10 days since AMI","LVEF measured by MRI (< 12 months)",9,3,"≤ 10 days since AMI","or","binary",15,-0.318383070030876,0.520594189779461,0,2009.86666666667,0,80.5333333333333
"CD006536","CD006536_pub5_data","9|4|LVEF measured by MRI (≥ 12 months)|> 10 days since AMI","LVEF measured by MRI (≥ 12 months)",9,4,"> 10 days since AMI","or","binary",2,0.0486297096084822,1.42203994367146,0,2016.5,0,92.5
"CD006536","CD006536_pub5_data","9|4|LVEF measured by MRI (≥ 12 months)|≤ 10 days since AMI","LVEF measured by MRI (≥ 12 months)",9,4,"≤ 10 days since AMI","or","binary",12,-0.223196397525057,0.582248778831934,0,2010.83333333333,0,70.25
"CD006536","CD006536_pub5_data","9|5|LVEF measured by left ventricular angiography (< 12 months)|> 10 days since AMI","LVEF measured by left ventricular angiography (< 12 months)",9,5,"> 10 days since AMI","or","binary",3,0.0215253984312347,1.16663172788927,0,2010,0,52
"CD006536","CD006536_pub5_data","9|5|LVEF measured by left ventricular angiography (< 12 months)|≤ 10 days since AMI","LVEF measured by left ventricular angiography (< 12 months)",9,5,"≤ 10 days since AMI","or","binary",6,-0.172057060123866,0.821815441266099,0,2009,0,103.666666666667
"CD006606","CD006606_pub5_data","1|1|Live birth – low risk of bias (odds ratio, random-effect)|NA","Live birth – low risk of bias (odds ratio, random-effect)",1,1,NA,"or","binary",2,-0.739914688322612,0.516988694536416,0.485257880383863,2021,0.458570075757576,369.5
"CD006606","CD006606_pub5_data","1|10|Ovarian hyperstimulation syndrome – low risk of bias (risk ratio, random-effects)|NA","Ovarian hyperstimulation syndrome – low risk of bias (risk ratio, random-effects)",1,10,NA,"or","binary",2,-2.47099750788078,1.05918555328531,0,2021,0.0364583333333333,369.5
"CD006606","CD006606_pub5_data","1|11|Preterm birth – low risk of bias (odds ratio, random-effects)|NA","Preterm birth – low risk of bias (odds ratio, random-effects)",1,11,NA,"or","binary",2,-0.347563436598838,0.376354451669015,0.127207615110474,2021,0.0991950757575758,369.5
"CD006606","CD006606_pub5_data","1|12|Preterm birth – low risk of bias (risk ratio, random-effects)|NA","Preterm birth – low risk of bias (risk ratio, random-effects)",1,12,NA,"or","binary",2,-0.347563436598838,0.376354451669015,0.127207615110474,2021,0.0991950757575758,369.5
"CD006606","CD006606_pub5_data","1|2|Live birth – low risk of bias (risk ratio, random-effects)|NA","Live birth – low risk of bias (risk ratio, random-effects)",1,2,NA,"or","binary",2,-0.739914688322612,0.516988694536416,0.485257880383863,2021,0.458570075757576,369.5
"CD006606","CD006606_pub5_data","1|3|Miscarriage – low risk of bias (odds ratio, random-effects)|NA","Miscarriage – low risk of bias (odds ratio, random-effects)",1,3,NA,"or","binary",2,0.499604505668046,0.246944407292196,0,2021,0.199749373433584,189
"CD006606","CD006606_pub5_data","1|4|Miscarriage – low risk of bias (risk ratio, random-effects)|NA","Miscarriage – low risk of bias (risk ratio, random-effects)",1,4,NA,"or","binary",2,0.499604505668046,0.246944407292196,0,2021,0.199749373433584,189
"CD006606","CD006606_pub5_data","1|5|Clinical pregnancy – low risk of bias (odds ratio, random-effects)|NA","Clinical pregnancy – low risk of bias (odds ratio, random-effects)",1,5,NA,"or","binary",2,-0.716215502120444,0.63449988239334,0.759175835132221,2021,0.597301136363636,369.5
"CD006606","CD006606_pub5_data","1|6|Clinical pregnancy – low risk of bias (risk ratio, random-effects)|NA","Clinical pregnancy – low risk of bias (risk ratio, random-effects)",1,6,NA,"or","binary",2,-0.716215502120444,0.63449988239334,0.759175835132221,2021,0.597301136363636,369.5
"CD006606","CD006606_pub5_data","1|7|Clinical pregnancy – all studies (odds ratio, random-effects)|NA","Clinical pregnancy – all studies (odds ratio, random-effects)",1,7,NA,"or","binary",4,0.0283861607205723,0.609875473854969,1.19201407212492,2017.5,0.381377840909091,202.5
"CD006606","CD006606_pub5_data","1|8|Clinical pregnancy – all studies (risk ratio, random-effects)|NA","Clinical pregnancy – all studies (risk ratio, random-effects)",1,8,NA,"or","binary",4,0.0283861607205723,0.609875473854969,1.19201407212492,2017.5,0.381377840909091,202.5
"CD006606","CD006606_pub5_data","1|9|Ovarian hyperstimulation syndrome – low risk of bias (odds ratio, random-effects)|NA","Ovarian hyperstimulation syndrome – low risk of bias (odds ratio, random-effects)",1,9,NA,"or","binary",2,-2.47099750788078,1.05918555328531,0,2021,0.0364583333333333,369.5
"CD006632","CD006632_pub3_data","1|1|Inhospital mortality|RCT","Inhospital mortality",1,1,"RCT","reported","reported",7,-0.239190827308187,0.229672133462843,0.209881903490772,2005.4,0,657.571428571429
"CD006632","CD006632_pub3_data","1|10|Sensitivity analysis: Risk of bias inhospital complications (studies at high RoB excluded)|","Sensitivity analysis: Risk of bias inhospital complications (studies at high RoB excluded)",1,10,"","reported","reported",5,-0.582532971362719,0.253673031838303,0.101042345303933,2001,0,444.4
"CD006632","CD006632_pub3_data","1|11|Sensitivity analysis: Risk of bias hospital readmission (up to 6 months; studies at high RoB excluded)|","Sensitivity analysis: Risk of bias hospital readmission (up to 6 months; studies at high RoB excluded)",1,11,"","reported","reported",5,-0.239723685324037,0.453726078432266,0.474476114667029,2001.75,0,224.4
"CD006632","CD006632_pub3_data","1|12|Sensitivity analysis: Risk of bias length of hospital stay in days (studies at high RoB excluded)|","Sensitivity analysis: Risk of bias length of hospital stay in days (studies at high RoB excluded)",1,12,"","or","binary",12,0.0142184818984671,0.580152059631341,0,2002.18181818182,0,272.916666666667
"CD006632","CD006632_pub3_data","1|2|Mortality (up to 6 months)|","Mortality (up to 6 months)",1,2,"","reported","reported",3,0.324899945362114,0.308761810986319,0.0338421823686958,2008,0,268.333333333333
"CD006632","CD006632_pub3_data","1|3|Inhospital complications|RCT","Inhospital complications",1,3,"RCT","reported","reported",11,-0.570256648571039,0.182605493039732,0.182529450296692,2004.14285714286,0,333.454545454545
"CD006632","CD006632_pub3_data","1|4|Hospital readmission (up to 6 months)|RCTs","Hospital readmission (up to 6 months)",1,4,"RCTs","reported","reported",9,-0.427528074395669,0.191214962051519,0,2004.875,0,175.333333333333
"CD006632","CD006632_pub3_data","1|5|Length of hospital stay (days)|NRCT studies","Length of hospital stay (days)",1,5,"NRCT studies","or","binary",2,-0.340132342258869,1.42044194271609,0,2008.5,0,377.5
"CD006632","CD006632_pub3_data","1|5|Length of hospital stay (days)|RCT studies","Length of hospital stay (days)",1,5,"RCT studies","or","binary",21,0.011839796683635,0.438409482233687,0,2003.3125,0,247.666666666667
"CD006632","CD006632_pub3_data","1|6|Hospital cost and charges|RCT studies hospital cost and charges","Hospital cost and charges",1,6,"RCT studies hospital cost and charges","or","binary",10,-0.0304514147506415,0.635811504858979,0,2002.25,0,211.3
"CD006632","CD006632_pub3_data","1|7|Adherence to recommended practice|RCT","Adherence to recommended practice",1,7,"RCT","reported","reported",3,2.21267192623978,0.838830677429492,1.63319431319664,2009.5,0,191
"CD006632","CD006632_pub3_data","1|8|Sensitivity analysis: Risk of bias inhospital mortality (studies at high RoB excluded)|","Sensitivity analysis: Risk of bias inhospital mortality (studies at high RoB excluded)",1,8,"","reported","reported",5,-0.287601103331978,0.347719906034982,0.425794019891391,2003.25,0,759
"CD006632","CD006632_pub3_data","1|9|Sensitivity analysis: Risk of bias 6 months mortality (studies at high RoB excluded)|","Sensitivity analysis: Risk of bias 6 months mortality (studies at high RoB excluded)",1,9,"","reported","reported",2,0.587876731179801,0.328531858243823,0,2000,0,257
"CD006632","CD006632_pub3_data","2|1|Inhospital mortality|","Inhospital mortality",2,1,"","reported","reported",2,-0.161743452159,0.537740375556892,0.479876936206,2000,0,3152
"CD006632","CD006632_pub3_data","2|2|Mortality (up to 6 months)|","Mortality (up to 6 months)",2,2,"","reported","reported",3,0.0465918092641742,0.0913834986111111,0,2001,0,2177
"CD006632","CD006632_pub3_data","2|3|Hospital readmission (up to 6 months)|","Hospital readmission (up to 6 months)",2,3,"","reported","reported",2,-0.936631558521798,1.01130007211232,1.7529185531055,2003,0,784.5
"CD006632","CD006632_pub3_data","2|4|Length of hospital stay (days)|","Length of hospital stay (days)",2,4,"","or","binary",4,-0.0644157714695144,1.00339358551802,0,2006.75,0,484
"CD006632","CD006632_pub3_data","2|5|Hospital cost and charges|Hospital cost and charges","Hospital cost and charges",2,5,"Hospital cost and charges","or","binary",4,-0.0796698573933477,1.00325244483461,0,2007.75,0,503.75
"CD006632","CD006632_pub3_data","2|5|Hospital cost and charges|Hospital costs","Hospital cost and charges",2,5,"Hospital costs","or","binary",3,-0.0275020767534113,1.15958493873,0,2010.33333333333,0,170.333333333333
"CD006632","CD006632_pub3_data","2|6|Sensitivity analysis: Risk of bias 6-month mortality (studies at high risk of bias excluded)|","Sensitivity analysis: Risk of bias 6-month mortality (studies at high risk of bias excluded)",2,6,"","reported","reported",2,0.0649811171706548,0.118673879440306,0,2001,0,865.5
"CD006689","CD006689_pub3_data","1|1|Maternal peripheral parasitaemia at delivery (amplification techniques)|NA","Maternal peripheral parasitaemia at delivery (amplification techniques)",1,1,NA,"or","binary",5,-0.460767488447149,0.221429629428791,0,2018.6,0.0445463726323245,481.2
"CD006689","CD006689_pub3_data","1|10|Mean haemoglobin at delivery (in g/dL)|NA","Mean haemoglobin at delivery (in g/dL)",1,10,NA,"or","binary",4,0.0225499189688012,1.00128470951463,0,2019,0,536.25
"CD006689","CD006689_pub3_data","1|11|Maternal severe anaemia at delivery (< 7 g/dL)|NA","Maternal severe anaemia at delivery (< 7 g/dL)",1,11,NA,"or","binary",4,0.180199880047796,0.254046127119253,0,2019,0.0162134344790828,655.25
"CD006689","CD006689_pub3_data","1|12|Low birth weight (less than 2500 g)|NA","Low birth weight (less than 2500 g)",1,12,NA,"or","binary",5,0.169995841120759,0.11451179247697,0,2018.6,0.12587954845664,583
"CD006689","CD006689_pub3_data","1|13|Mean birth weight (g)|NA","Mean birth weight (g)",1,13,NA,"or","binary",4,0.0291923513274475,1.00097561010544,0,2019,0,679.5
"CD006689","CD006689_pub3_data","1|14|Cord blood parasitaemia (blood smear)|NA","Cord blood parasitaemia (blood smear)",1,14,NA,"or","binary",5,-0.718490403893152,0.672941549928702,0,2018.6,0.00236822001527884,539.2
"CD006689","CD006689_pub3_data","1|16|Prematurity|NA","Prematurity",1,16,NA,"or","binary",5,0.0762724657841242,0.174055752552438,3.84903095422097e-08,2018.6,0.0685131247337501,480.2
"CD006689","CD006689_pub3_data","1|18|Foetal loss|NA","Foetal loss",1,18,NA,"or","binary",5,0.047747365881467,0.199317029482295,0.0227133471080934,2018.6,0.0359221241932734,591.4
"CD006689","CD006689_pub3_data","1|2|Maternal peripheral parasitaemia at delivery (microscopy)|NA","Maternal peripheral parasitaemia at delivery (microscopy)",1,2,NA,"or","binary",3,-0.18158644568715,0.834686834695784,0.92049262843549,2021.66666666667,0.0138211382113821,538
"CD006689","CD006689_pub3_data","1|20|Maternal mortality|NA","Maternal mortality",1,20,NA,"or","binary",4,-0.227007887934908,0.560039251595067,0,2019,0.00530435678236688,696.75
"CD006689","CD006689_pub3_data","1|21|Neonatal mortality|NA","Neonatal mortality",1,21,NA,"or","binary",4,0.173479075829867,0.290598181930302,0,2019,0.0157471563360192,676.5
"CD006689","CD006689_pub3_data","1|4|Placental malaria (any test)|NA","Placental malaria (any test)",1,4,NA,"reported","reported",2,0,0.298434981735677,0,2014,0.061068381456731,559.5
"CD006689","CD006689_pub3_data","1|5|Placental malaria (blood smear)|NA","Placental malaria (blood smear)",1,5,NA,"or","binary",3,-0.645728502439017,0.291592882991821,0,2015,0.0274045877494153,445.666666666667
"CD006689","CD006689_pub3_data","1|6|Placental malaria (amplification techniques)|NA","Placental malaria (amplification techniques)",1,6,NA,"or","binary",3,-0.804390817090591,0.791222578502686,1.09030134425125,2015,0.0441503898784497,390.333333333333
"CD006689","CD006689_pub3_data","1|7|Placental malaria (histopathologic analysis)|NA","Placental malaria (histopathologic analysis)",1,7,NA,"or","binary",3,-0.45225899650477,0.172848551672367,8.22897436252999e-07,2021.66666666667,0.0942897236614853,523.333333333333
"CD006689","CD006689_pub3_data","1|9|Clinical malaria episodes during pregnancy|NA","Clinical malaria episodes during pregnancy",1,9,NA,"reported","reported",3,-0.393470803367307,0.341020863784223,0,2020.66666666667,NA,0
"CD006689","CD006689_pub3_data","2|1|Maternal peripheral parasitaemia at delivery (polymerase chain reaction)|NA","Maternal peripheral parasitaemia at delivery (polymerase chain reaction)",2,1,NA,"or","binary",2,-0.648822341803853,0.299361615741179,0,2014,0.067639802631579,494.5
"CD006689","CD006689_pub3_data","2|10|Cord blood parasitaemia|NA","Cord blood parasitaemia",2,10,NA,"or","binary",2,-0.705074785905434,0.879016052477419,0,2014,0.00324675324675325,583
"CD006689","CD006689_pub3_data","2|11|Prematurity|NA","Prematurity",2,11,NA,"or","binary",2,0.0770691224421226,0.323755655212362,0.0584982977514574,2014,0.0927125506072874,412
"CD006689","CD006689_pub3_data","2|12|Severe adverse events during pregnancy|NA","Severe adverse events during pregnancy",2,12,NA,"or","binary",2,-0.411462497075076,0.180359374952425,0,2014,0.103795447522917,673.5
"CD006689","CD006689_pub3_data","2|13|Foetal loss|NA","Foetal loss",2,13,NA,"or","binary",2,0.106719334008307,0.506513342768679,0.357261453109421,2014,0.0468637346791637,673.5
"CD006689","CD006689_pub3_data","2|14|Congenital malformations|NA","Congenital malformations",2,14,NA,"or","binary",2,-0.442542297185844,0.486726370026697,0,2014,0.0146163053597553,656
"CD006689","CD006689_pub3_data","2|15|Maternal mortality|NA","Maternal mortality",2,15,NA,"or","binary",2,-0.553641213053097,0.629579330504688,0,2014,0.0106087135647338,673.5
"CD006689","CD006689_pub3_data","2|16|Neonatal mortality|NA","Neonatal mortality",2,16,NA,"or","binary",2,0.266226199701509,0.360998798351544,0,2014,0.0217010631644778,619.5
"CD006689","CD006689_pub3_data","2|17|Adverse events: headache|NA","Adverse events: headache",2,17,NA,"or","binary",2,-0.186414028920709,0.374211968439075,0.107804672236491,2014,0.0512926150993923,673.5
"CD006689","CD006689_pub3_data","2|18|Adverse events: vomiting|NA","Adverse events: vomiting",2,18,NA,"or","binary",2,3.30262942073241,1.32466609162791,2.71055800806982,2014,0.0150375939849624,673.5
"CD006689","CD006689_pub3_data","2|19|Adverse events: dizziness|NA","Adverse events: dizziness",2,19,NA,"or","binary",2,3.074537390302,1.70410279422501,4.9392235512143,2014,0.037593984962406,673.5
"CD006689","CD006689_pub3_data","2|2|Maternal anaemia at delivery (< 9.5 g/dL)|NA","Maternal anaemia at delivery (< 9.5 g/dL)",2,2,NA,"or","binary",2,-0.0868381509070112,0.170464566153852,0.00790360139919406,2014,0.180946006247211,598.5
"CD006689","CD006689_pub3_data","2|20|Adverse events: fatigue/weakness|NA","Adverse events: fatigue/weakness",2,20,NA,"or","binary",2,1.11932768239834,1.22019209858623,2.72753138640046,2014,0.0215521680914615,673.5
"CD006689","CD006689_pub3_data","2|21|Mother-to-child transmission of HIV|NA","Mother-to-child transmission of HIV",2,21,NA,"or","binary",2,0.668658957171142,0.280755204763461,0,2014,0.0277914614121511,509.5
"CD006689","CD006689_pub3_data","2|22|Undetectable viral load|NA","Undetectable viral load",2,22,NA,"or","binary",2,-0.118590933475436,0.122885784781938,0,2014,0.504504504504504,610
"CD006689","CD006689_pub3_data","2|3|Placental malaria (blood smear)|NA","Placental malaria (blood smear)",2,3,NA,"or","binary",2,-0.70204366348626,0.296318161076293,0,2014,0.041106881624123,572
"CD006689","CD006689_pub3_data","2|4|Placental malaria (polymerase chain reaction)|NA","Placental malaria (polymerase chain reaction)",2,4,NA,"or","binary",2,-1.25015246100905,0.369806156288631,0,2014,0.0610172514843412,488.5
"CD006689","CD006689_pub3_data","2|6|Mean haemoglobin at delivery (in g/dL)|NA","Mean haemoglobin at delivery (in g/dL)",2,6,NA,"or","binary",2,0.0636876291932997,1.41630673774906,0,2014,0,583.5
"CD006689","CD006689_pub3_data","2|7|Maternal severe anaemia at delivery|NA","Maternal severe anaemia at delivery",2,7,NA,"or","binary",2,-0.0670325738077879,0.405232046283858,0,2014,0.012396694214876,583.5
"CD006689","CD006689_pub3_data","2|8|Low birth weight (< 2500 g)|NA","Low birth weight (< 2500 g)",2,8,NA,"or","binary",2,0.206890478575882,0.172245838658243,0,2014,0.150499706055262,610
"CD006689","CD006689_pub3_data","2|9|Mean birth weight (g)|NA","Mean birth weight (g)",2,9,NA,"or","binary",2,0.0253413153804753,1.41601141035059,0,2014,0,610
"CD006689","CD006689_pub3_data","3|1|Maternal peripheral parasitaemia at delivery (amplification techniques)|NA","Maternal peripheral parasitaemia at delivery (amplification techniques)",3,1,NA,"or","binary",3,-0.442385741689769,0.384923660210023,0.0967978286311388,2021.66666666667,0.0291507526328215,505.666666666667
"CD006689","CD006689_pub3_data","3|10|Low birth weight (< 2500 g)|NA","Low birth weight (< 2500 g)",3,10,NA,"or","binary",3,0.140773386465686,0.153294107621656,0,2021.66666666667,0.109466110057559,565
"CD006689","CD006689_pub3_data","3|11|Mean birth weight (g)|NA","Mean birth weight (g)",3,11,NA,"or","binary",2,0.0330388420172263,1.41517552666222,0,2024,0,749
"CD006689","CD006689_pub3_data","3|12|Cord blood parasitaemia (microscopy)|NA","Cord blood parasitaemia (microscopy)",3,12,NA,"or","binary",3,-0.73748636442208,1.04597690106166,0,2021.66666666667,0.0017825311942959,510
"CD006689","CD006689_pub3_data","3|14|Prematurity |NA","Prematurity ",3,14,NA,"or","binary",3,0.0537433020234826,0.2966208938444,0.0896460689374767,2021.66666666667,0.0523801741513919,525.666666666667
"CD006689","CD006689_pub3_data","3|18|Maternal mortality|NA","Maternal mortality",3,18,NA,"or","binary",2,1.01137375787524,1.22587861424219,0,2024,0,720
"CD006689","CD006689_pub3_data","3|19|Neonatal mortality|NA","Neonatal mortality",3,19,NA,"or","binary",2,0.0237042243172957,0.519841361218699,0.0492456856060406,2024,0.00979324950756061,733.5
"CD006689","CD006689_pub3_data","3|2|Maternal peripheral parasitaemia at delivery (microscopy)|NA","Maternal peripheral parasitaemia at delivery (microscopy)",3,2,NA,"or","binary",3,-0.18158644568715,0.834686834695784,0.92049262843549,2021.66666666667,0.0138211382113821,538
"CD006689","CD006689_pub3_data","3|20|Adverse events: headache |NA","Adverse events: headache ",3,20,NA,"or","binary",2,0.418476350713584,0.462985292126947,0,2024,0.00842490842490842,723.5
"CD006689","CD006689_pub3_data","3|21|Adverse events: gastrointestinal disorders after first IPTp dose|NA","Adverse events: gastrointestinal disorders after first IPTp dose",3,21,NA,"or","binary",2,0.363242086467254,0.534604432739223,0.408320293775758,2024,0.032967032967033,723.5
"CD006689","CD006689_pub3_data","3|23|Mother-to-child transmission of HIV|NA","Mother-to-child transmission of HIV",3,23,NA,"or","binary",2,0.314127044599586,0.772249133084672,0,2024,0.00374409558210614,531.5
"CD006689","CD006689_pub3_data","3|3|Maternal anaemia at delivery (< 11g/dL)|NA","Maternal anaemia at delivery (< 11g/dL)",3,3,NA,"or","binary",2,-0.103367975399599,0.147334041957854,0.0210824525981833,2024,0.524252386957305,727
"CD006689","CD006689_pub3_data","3|5|Placental malaria (histopathologic analysis)|NA","Placental malaria (histopathologic analysis)",3,5,NA,"or","binary",3,-0.45225899650477,0.172848551672367,8.22897436252999e-07,2021.66666666667,0.0942897236614853,523.333333333333
"CD006689","CD006689_pub3_data","3|7|Clinical malaria episodes during pregnancy|NA","Clinical malaria episodes during pregnancy",3,7,NA,"reported","reported",2,-0.585820592369254,0.559850728767496,0,2024,NA,0
"CD006689","CD006689_pub3_data","3|9|Maternal severe anaemia at delivery (< 7g/dL)|NA","Maternal severe anaemia at delivery (< 7g/dL)",3,9,NA,"or","binary",2,0.340284862966065,0.326081635009124,0,2024,0.0200301747432895,727
"CD006689","CD006689_pub3_data","4|1|Maternal peripheral parasitaemia at delivery (blood smear)|NA","Maternal peripheral parasitaemia at delivery (blood smear)",4,1,NA,"or","binary",2,-1.55427196201888,0.307592698841143,0,2006.5,0.204421128149942,311
"CD006689","CD006689_pub3_data","4|14|Neonatal mortality|NA","Neonatal mortality",4,14,NA,"or","binary",2,-0.115260829164543,1.07539641698843,1.90213768222734,2006.5,0.0457113507960966,320
"CD006689","CD006689_pub3_data","4|2|Maternal anaemia at delivery (haemoglobin < 11 g/dL)|NA","Maternal anaemia at delivery (haemoglobin < 11 g/dL)",4,2,NA,"or","binary",2,-0.145578139306315,0.17472436654457,0,2006.5,0.631582525151817,302
"CD006689","CD006689_pub3_data","4|3|Placental malaria (blood smear)|NA","Placental malaria (blood smear)",4,3,NA,"or","binary",2,-0.930431552384772,0.32030133369573,0,2006.5,0.127208799134511,306
"CD006689","CD006689_pub3_data","4|5|Maternal haemoglobin at delivery (in g/dL)|NA","Maternal haemoglobin at delivery (in g/dL)",4,5,NA,"or","binary",2,-0.00152248672300197,1.41661822963165,0,2006.5,0,302
"CD006689","CD006689_pub3_data","4|6|Low birth weight (< 2500 g)|NA","Low birth weight (< 2500 g)",4,6,NA,"or","binary",2,-0.160639121869863,0.216170257127778,0,2006.5,0.18308615819209,312
"CD006689","CD006689_pub3_data","4|7|Mean birth weight (in kg)|NA","Mean birth weight (in kg)",4,7,NA,"or","binary",2,-0.0320046603009597,1.41656111296867,0,2006.5,0,312
"CD006689","CD006689_pub3_data","5|11|Prematurity|NA","Prematurity",5,11,NA,"or","binary",3,-0.101753969935701,0.307228342835365,0,2016,0.0975121055267991,130.333333333333
"CD006689","CD006689_pub3_data","5|12|SAEs during pregnancy|NA","SAEs during pregnancy",5,12,NA,"or","binary",3,0.608929703315892,0.37184327556297,0.0598019731018989,2016,0.0565023331304524,137.333333333333
"CD006689","CD006689_pub3_data","5|13|Spontaneous abortion|NA","Spontaneous abortion",5,13,NA,"or","binary",3,-0.671040892528332,0.809960313055328,0,2016,0.0154276192012041,133.333333333333
"CD006689","CD006689_pub3_data","5|14|Stillbirth|NA","Stillbirth",5,14,NA,"or","binary",3,-0.0578292561860541,0.534245411872425,0,2016,0.0426140945008869,133.333333333333
"CD006689","CD006689_pub3_data","5|15|Congenital malformations|NA","Congenital malformations",5,15,NA,"or","binary",2,-0.0573646497166934,1.00749484301202,0,2013.5,0.00442477876106195,138.5
"CD006689","CD006689_pub3_data","5|16|Maternal mortality|NA","Maternal mortality",5,16,NA,"or","binary",2,0.612668871476208,1.26942375645921,0,2017,0,181
"CD006689","CD006689_pub3_data","5|17|Neonatal mortality|NA","Neonatal mortality",5,17,NA,"or","binary",3,0.994062754132649,0.98588093277615,0,2016,0,130.666666666667
"CD006689","CD006689_pub3_data","5|2|Maternal anaemia during delivery|NA","Maternal anaemia during delivery",5,2,NA,"or","binary",2,0.51157524625172,0.308004302816976,0.0248756877047153,2017,0.141357273280584,181
"CD006689","CD006689_pub3_data","5|20|Mother-to-child transmission of HIV|NA","Mother-to-child transmission of HIV",5,20,NA,"or","binary",2,0.0085799042256515,0.550185127283785,0,2017,0.0275229357798165,155
"CD006689","CD006689_pub3_data","5|5|Clinical malaria episodes during pregnancy|NA","Clinical malaria episodes during pregnancy",5,5,NA,"or","binary",2,0.433082707184849,0.279796484507853,0,2017,0.116935483870968,181
"CD006689","CD006689_pub3_data","5|7|Low birth weight (< 2500 g)|NA","Low birth weight (< 2500 g)",5,7,NA,"or","binary",3,0.107056105613407,0.289626054886742,0,2016,0.110532726775549,130.666666666667
"CD006689","CD006689_pub3_data","5|8|Mean birth weight (in grams)|NA","Mean birth weight (in grams)",5,8,NA,"or","binary",2,-0.0792297397943315,1.42303708917753,0,2013.5,0,140.5
"CD006712","CD006712_pub3_data","12|1|Pain with dilation|","Pain with dilation",12,1,"","or","binary",2,-0.0227823642441705,1.41818052171125,0,2009,0,178.5
"CD006712","CD006712_pub3_data","12|2|Pain with aspiration|","Pain with aspiration",12,2,"","or","binary",2,-0.0227823642441705,1.41818052171125,0,2009,0,178.5
"CD006712","CD006712_pub3_data","16|1|Pain with dilation|","Pain with dilation",16,1,"","or","binary",2,0.0533854932229597,1.42163199336358,0,1994.5,0,114.5
"CD006712","CD006712_pub3_data","16|2|Pain with aspiration|","Pain with aspiration",16,2,"","or","binary",2,0.0533854932229597,1.42163199336358,0,1994.5,0,114.5
"CD006712","CD006712_pub3_data","17|2|Pain with aspiration|Local anaesthetic","Pain with aspiration",17,2,"Local anaesthetic","or","binary",2,0.0693030046569042,1.42534872582755,0,2008.5,0,100.5
"CD006712","CD006712_pub3_data","8|3|Pain with aspiration (lidocaine)|","Pain with aspiration (lidocaine)",8,3,"","or","binary",2,0.050286326583334,1.41915714808564,0,1993.5,0,145.5
"CD006714","CD006714_pub3_data","1|3|Bleeding: hemorrhage requiring transfusion|","Bleeding: hemorrhage requiring transfusion",1,3,"","or","binary",3,-1.0705221006185,0.641188158768132,0,2009.66666666667,0.041965811965812,89.6666666666667
"CD006714","CD006714_pub3_data","1|6|Injury: cervix, vagina, uterus |","Injury: cervix, vagina, uterus ",1,6,"","or","binary",2,0.653976227278358,1.27185954293575,0,2012.5,0,125.5
"CD006742","CD006742_pub3_data","1|1|All-Cause Mortality|NA","All-Cause Mortality",1,1,NA,"reported","reported",4,0,0.149228480572555,0,1986.75,0.025032080893837,2279.25
"CD006742","CD006742_pub3_data","1|3|Stroke|NA","Stroke",1,3,NA,"or","binary",4,-0.723744747962923,0.357197318687498,0,1989.5,0.0141398819285011,1823
"CD006742","CD006742_pub3_data","1|4|Coronary Heart Disease|NA","Coronary Heart Disease",1,4,NA,"or","binary",3,0.114756296418395,0.172485508294015,0,1984.66666666667,0.00975708055898282,2360
"CD006839","CD006839_pub5_data","1|1|Proportion of participants with clinical improvement in function compared to baseline|Simple decompression versus submuscular transposition","Proportion of participants with clinical improvement in function compared to baseline",1,1,"Simple decompression versus submuscular transposition","or","binary",2,-0.206170829409681,0.427822148710624,0,2005.5,0.747619047619048,57
"CD006839","CD006839_pub5_data","1|3|Proportion of participants with deep/superficial wound infections|Simple decompression vs submuscular transposition","Proportion of participants with deep/superficial wound infections",1,3,"Simple decompression vs submuscular transposition","or","binary",2,-0.994997189686964,0.703583960575837,0.0937454492384502,2005.5,0.180952380952381,57
"CD006839","CD006839_pub5_data","2|1|Proportion of participants with clinical improvement in function compared to baseline|Excellent/good outcome as measured with Bishop score at long follow-up (around 12 months)","Proportion of participants with clinical improvement in function compared to baseline",2,1,"Excellent/good outcome as measured with Bishop score at long follow-up (around 12 months)","or","binary",2,-0.135034705161322,0.569255212263245,0,2016,0.885668276972625,49.5
"CD006839","CD006839_pub5_data","2|2|Proportion of participants with hematoma/pain from scarring|","Proportion of participants with hematoma/pain from scarring",2,2,"","reported","reported",2,0,0.842324951872565,0,2016,0.14573268921095,49.5
"CD006913","CD006913_pub3_data","1|1|Quality of life (short-term) -  psychotherapy vs care-as-usual, with Xiao|IBD unspecified","Quality of life (short-term) -  psychotherapy vs care-as-usual, with Xiao",1,1,"IBD unspecified","reported","reported",15,0,0.0602598279915701,0,2018.46666666667,0,74.5333333333333
"CD006913","CD006913_pub3_data","1|1|Quality of life (short-term) -  psychotherapy vs care-as-usual, with Xiao|Ulcerative colitis","Quality of life (short-term) -  psychotherapy vs care-as-usual, with Xiao",1,1,"Ulcerative colitis","or","binary",3,-0.0434768346639828,1.16638938516728,0,2008.66666666667,0,48.3333333333333
"CD006913","CD006913_pub3_data","1|10|Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual|CBT-based","Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual",1,10,"CBT-based","reported","reported",8,0,0.078644724612415,0,2018.875,0,82.375
"CD006913","CD006913_pub3_data","1|10|Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual|Multimodular","Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual",1,10,"Multimodular","reported","reported",3,0,0.132772442859454,0,2009,0,96.3333333333333
"CD006913","CD006913_pub3_data","1|10|Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual|Single component therapy","Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual",1,10,"Single component therapy","reported","reported",3,0,0.169128678627469,0,2020,0,47
"CD006913","CD006913_pub3_data","1|11|Quality of life (long-term), by type of therapy - psychotherapy vs care-as-usual|Multimodular","Quality of life (long-term), by type of therapy - psychotherapy vs care-as-usual",1,11,"Multimodular","reported","reported",4,0,0.119254730130051,0,2011.75,0,87
"CD006913","CD006913_pub3_data","1|12|Quality of life (short-term), by therapy intensity - psychotherapy vs care-as-usual|High intensity","Quality of life (short-term), by therapy intensity - psychotherapy vs care-as-usual",1,12,"High intensity","or","binary",2,0.129011926894704,1.42036747448413,0,2018.5,0,114.5
"CD006913","CD006913_pub3_data","1|12|Quality of life (short-term), by therapy intensity - psychotherapy vs care-as-usual|Low intensity","Quality of life (short-term), by therapy intensity - psychotherapy vs care-as-usual",1,12,"Low intensity","reported","reported",16,0,0.0610252109069255,0,2016.9375,0,70.5
"CD006913","CD006913_pub3_data","1|13|Quality of life (long-term), by therapy intensity - psychotherapy vs care-as-usual|Low intensity","Quality of life (long-term), by therapy intensity - psychotherapy vs care-as-usual",1,13,"Low intensity","reported","reported",4,0,0.113425869280554,0,2012,0,86.5
"CD006913","CD006913_pub3_data","1|14|Quality of life (short-term), by mode of application - psychotherapy vs care-as-usual|Phone or VC, live","Quality of life (short-term), by mode of application - psychotherapy vs care-as-usual",1,14,"Phone or VC, live","or","binary",4,0.0462027937066775,1.00948315889101,0,2018.5,0,87.5
"CD006913","CD006913_pub3_data","1|15|Quality of life (short-term), by training of provider - psychotherapy vs care-as-usual|Psychotherapist","Quality of life (short-term), by training of provider - psychotherapy vs care-as-usual",1,15,"Psychotherapist","or","binary",15,0.0407296771455354,0.520874883557132,0,2017,0,73.2666666666667
"CD006913","CD006913_pub3_data","1|2|Quality of life (short-term) -  psychotherapy vs care-as-usual, revised|IBD unspecified","Quality of life (short-term) -  psychotherapy vs care-as-usual, revised",1,2,"IBD unspecified","reported","reported",15,0,0.0602598279915701,0,2018.46666666667,0,74.5333333333333
"CD006913","CD006913_pub3_data","1|2|Quality of life (short-term) -  psychotherapy vs care-as-usual, revised|Ulcerative colitis","Quality of life (short-term) -  psychotherapy vs care-as-usual, revised",1,2,"Ulcerative colitis","or","binary",3,-0.0434768346639828,1.16638938516728,0,2008.66666666667,0,48.3333333333333
"CD006913","CD006913_pub3_data","1|3|IBDQ (short-term) -  psychotherapy vs care-as-usual|Crohn's disease","IBDQ (short-term) -  psychotherapy vs care-as-usual",1,3,"Crohn's disease","or","binary",2,-0.0326023987011454,1.43391660807236,0,2011.5,0,37.5
"CD006913","CD006913_pub3_data","1|3|IBDQ (short-term) -  psychotherapy vs care-as-usual|IBD unspecified","IBDQ (short-term) -  psychotherapy vs care-as-usual",1,3,"IBD unspecified","reported","reported",8,0,0.0771610831804649,0,2018,0,85.125
"CD006913","CD006913_pub3_data","1|3|IBDQ (short-term) -  psychotherapy vs care-as-usual|Ulcerative colitis","IBDQ (short-term) -  psychotherapy vs care-as-usual",1,3,"Ulcerative colitis","or","binary",2,-0.0652389359673205,1.42878879073979,0,2012,0,47.5
"CD006913","CD006913_pub3_data","1|4|Quality of life (long-term) - psychotherapy vs care-as usual|Crohn's disease","Quality of life (long-term) - psychotherapy vs care-as usual",1,4,"Crohn's disease","or","binary",3,-0.0963047262776453,1.16532307226888,0,2004.66666666667,0,58
"CD006913","CD006913_pub3_data","1|4|Quality of life (long-term) - psychotherapy vs care-as usual|IBD unspecified","Quality of life (long-term) - psychotherapy vs care-as usual",1,4,"IBD unspecified","reported","reported",3,0,0.138902538732042,0,2018.33333333333,0,71.6666666666667
"CD006913","CD006913_pub3_data","1|5|IBDQ (long-term) - psychotherapy vs care-as-usual |IBD unspecified","IBDQ (long-term) - psychotherapy vs care-as-usual ",1,5,"IBD unspecified","reported","reported",3,0,0.138902538732042,0,2018.33333333333,0,71.6666666666667
"CD006913","CD006913_pub3_data","1|6|Quality of life (short-term), by disease activity - psychotherapy vs care-as-usual|Acute flare/chronic active","Quality of life (short-term), by disease activity - psychotherapy vs care-as-usual",1,6,"Acute flare/chronic active","reported","reported",2,0,0.150897543170101,0,2016,0,104
"CD006913","CD006913_pub3_data","1|6|Quality of life (short-term), by disease activity - psychotherapy vs care-as-usual|In remission","Quality of life (short-term), by disease activity - psychotherapy vs care-as-usual",1,6,"In remission","reported","reported",7,0,0.0890207989937097,0,2017.42857142857,0,72.8571428571429
"CD006913","CD006913_pub3_data","1|7|Quality of life (long-term), by disease activity - psychotherapy vs care-as-usual|In remission","Quality of life (long-term), by disease activity - psychotherapy vs care-as-usual",1,7,"In remission","reported","reported",3,0,0.124994613572361,0,2016.66666666667,0,87
"CD006913","CD006913_pub3_data","1|8|Quality of life (short-term), by comorbidity - psychotherapy vs care-as-usual|No explicit comorbidity ","Quality of life (short-term), by comorbidity - psychotherapy vs care-as-usual",1,8,"No explicit comorbidity ","reported","reported",8,0,0.0790153874819615,0,2015.125,0,86.125
"CD006913","CD006913_pub3_data","1|8|Quality of life (short-term), by comorbidity - psychotherapy vs care-as-usual|Psychological / IBS comorbidity","Quality of life (short-term), by comorbidity - psychotherapy vs care-as-usual",1,8,"Psychological / IBS comorbidity","reported","reported",9,0,0.0809317083849831,0,2019.33333333333,0,68.6666666666667
"CD006913","CD006913_pub3_data","1|9|Quality of life (long-term), by comorbidity - psychotherapy vs care-as-usual|No explicit comorbidity ","Quality of life (long-term), by comorbidity - psychotherapy vs care-as-usual",1,9,"No explicit comorbidity ","reported","reported",4,0,0.114346033364253,0,2011.75,0,87
"CD006913","CD006913_pub3_data","2|1|Depressive symptoms (short-term) - psychotherapy vs care-as-usual|IBD unspecified","Depressive symptoms (short-term) - psychotherapy vs care-as-usual",2,1,"IBD unspecified","reported","reported",14,0,0.0619170317914419,0,2018.78571428571,0,76
"CD006913","CD006913_pub3_data","2|10|Disease activity (long-term) - psychotherapy vs care-as-usual|Crohn's disease","Disease activity (long-term) - psychotherapy vs care-as-usual",2,10,"Crohn's disease","or","binary",2,0.153166344077443,1.42893627838909,0,2006.5,0,47.5
"CD006913","CD006913_pub3_data","2|10|Disease activity (long-term) - psychotherapy vs care-as-usual|Ulcerative colitis","Disease activity (long-term) - psychotherapy vs care-as-usual",2,10,"Ulcerative colitis","or","binary",2,-0.12823282090752,1.42871793084273,0,2006.5,0,48
"CD006913","CD006913_pub3_data","2|11|Number of patients completing program - psychotherapy vs any control, all populations|Adults","Number of patients completing program - psychotherapy vs any control, all populations",2,11,"Adults","reported","reported",24,0,0.00977953245048156,0,2017,0.857066013715437,91.9166666666667
"CD006913","CD006913_pub3_data","2|11|Number of patients completing program - psychotherapy vs any control, all populations|Children and  adolescents","Number of patients completing program - psychotherapy vs any control, all populations",2,11,"Children and  adolescents","reported","reported",5,0,0.033499692181566,0,2014.2,0.829652766743954,107
"CD006913","CD006913_pub3_data","2|3|Anxiety (short-term) - psychotherapy vs care-as-usual|IBD unspecified","Anxiety (short-term) - psychotherapy vs care-as-usual",2,3,"IBD unspecified","reported","reported",13,0,0.0650094195314185,0,2019.15384615385,0,74.3846153846154
"CD006913","CD006913_pub3_data","2|4|Anxiety (long-term) - psychotherapy vs care-as-usual|IBD unspecified","Anxiety (long-term) - psychotherapy vs care-as-usual",2,4,"IBD unspecified","or","binary",2,0.255960983080542,1.42316567444086,0,2018,0,84.5
"CD006913","CD006913_pub3_data","2|5|Failure to induce or maintain remission (short-term) - psychotherapy vs care-as-usual (ITT)|IBD unspecified","Failure to induce or maintain remission (short-term) - psychotherapy vs care-as-usual (ITT)",2,5,"IBD unspecified","reported","reported",3,0,0.112690253791843,0,2005,0.389213564213564,107.333333333333
"CD006913","CD006913_pub3_data","2|7|Failure to induce or maintain remission (long-term) - psychotherapy vs care-asusual  (ITT)|IBD unspecified","Failure to induce or maintain remission (long-term) - psychotherapy vs care-asusual  (ITT)",2,7,"IBD unspecified","reported","reported",4,0,0.0665056890990774,0,2006.5,0.596612269309638,109
"CD006913","CD006913_pub3_data","2|8|Failure to induce or maintain remission (long-term) - psychotherapy vs care-as-usual (PP, sensitivity analysis)|IBD unspecified","Failure to induce or maintain remission (long-term) - psychotherapy vs care-as-usual (PP, sensitivity analysis)",2,8,"IBD unspecified","reported","reported",2,0,0.455852980568674,0,2012.5,0.744047619047619,69
"CD006913","CD006913_pub3_data","2|9|Disease activity (short-term) - psychotherapy vs care-as-usual|Crohn's disease","Disease activity (short-term) - psychotherapy vs care-as-usual",2,9,"Crohn's disease","reported","reported",8,0,0.0905744534630081,0,2015.875,0,64.25
"CD006913","CD006913_pub3_data","2|9|Disease activity (short-term) - psychotherapy vs care-as-usual|Ulcerative colitis","Disease activity (short-term) - psychotherapy vs care-as-usual",2,9,"Ulcerative colitis","reported","reported",7,0,0.107887746018354,0,2015.14285714286,0,50.7142857142857
"CD006913","CD006913_pub3_data","3|1|Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao|Crohn's disease","Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao",3,1,"Crohn's disease","or","binary",3,-0.0216750510550753,1.16917408989162,0,2008.33333333333,0,41.6666666666667
"CD006913","CD006913_pub3_data","3|1|Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao|IBD unspecified","Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao",3,1,"IBD unspecified","reported","reported",6,0,0.0853042304474348,0,2016.5,0,100.666666666667
"CD006913","CD006913_pub3_data","3|1|Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao|Ulcerative colitis","Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao",3,1,"Ulcerative colitis","or","binary",3,-0.078221121743829,1.16512673187567,0,2011,0,57
"CD006913","CD006913_pub3_data","3|10|Quality of life (long-term), by type of therapy - educational intervention vs care-as-usual|Education","Quality of life (long-term), by type of therapy - educational intervention vs care-as-usual",3,10,"Education","or","binary",2,0.257731371045546,1.41713518310375,0,2003.5,0,345.5
"CD006913","CD006913_pub3_data","3|10|Quality of life (long-term), by type of therapy - educational intervention vs care-as-usual|Multimodular","Quality of life (long-term), by type of therapy - educational intervention vs care-as-usual",3,10,"Multimodular","reported","reported",4,0,0.0667055425658585,0,2011,0,239.75
"CD006913","CD006913_pub3_data","3|11|Quality of life (short-time), by therapy intensity - educational intervention vs care-as-usual|Low intensity","Quality of life (short-time), by therapy intensity - educational intervention vs care-as-usual",3,11,"Low intensity","reported","reported",7,0,0.0800060652130102,0,2012.85714285714,0,98.5714285714286
"CD006913","CD006913_pub3_data","3|12|Quality of life (long-term), by therapy intensity - educational intervention vs care-as-usual|Low intensity","Quality of life (long-term), by therapy intensity - educational intervention vs care-as-usual",3,12,"Low intensity","reported","reported",3,0,0.132456635967486,0,2009,0,95.6666666666667
"CD006913","CD006913_pub3_data","3|13|Quality of life (short-term), by mode of application - educational intervention vs care-as-usual|Tape or digital, not live","Quality of life (short-term), by mode of application - educational intervention vs care-as-usual",3,13,"Tape or digital, not live","or","binary",2,-0.168042165575867,1.42483301598598,0,2022,0,75.5
"CD006913","CD006913_pub3_data","3|14|Quality of life (short-term), by training of provider - educational intervention vs care-as-usual|Not a person","Quality of life (short-term), by training of provider - educational intervention vs care-as-usual",3,14,"Not a person","or","binary",2,-0.168042165575867,1.42483301598598,0,2022,0,75.5
"CD006913","CD006913_pub3_data","3|14|Quality of life (short-term), by training of provider - educational intervention vs care-as-usual|Psychotherapist","Quality of life (short-term), by training of provider - educational intervention vs care-as-usual",3,14,"Psychotherapist","or","binary",6,-0.0200941447978211,0.822411429504556,0,2015.83333333333,0,95.1666666666667
"CD006913","CD006913_pub3_data","3|2|Quality of life (short-term) - educational intervention vs care-as-usual, revised|Crohn's disease","Quality of life (short-term) - educational intervention vs care-as-usual, revised",3,2,"Crohn's disease","or","binary",3,-0.0216750510550753,1.16917408989162,0,2008.33333333333,0,41.6666666666667
"CD006913","CD006913_pub3_data","3|2|Quality of life (short-term) - educational intervention vs care-as-usual, revised|IBD unspecified","Quality of life (short-term) - educational intervention vs care-as-usual, revised",3,2,"IBD unspecified","reported","reported",5,0,0.0899856083810398,0,2015.4,0,99.6
"CD006913","CD006913_pub3_data","3|2|Quality of life (short-term) - educational intervention vs care-as-usual, revised|Ulcerative colitis","Quality of life (short-term) - educational intervention vs care-as-usual, revised",3,2,"Ulcerative colitis","or","binary",3,-0.078221121743829,1.16512673187567,0,2011,0,57
"CD006913","CD006913_pub3_data","3|3|IBDQ (short-term) - educational intervention vs care-as-usual|Crohn's disease","IBDQ (short-term) - educational intervention vs care-as-usual",3,3,"Crohn's disease","or","binary",2,-0.0326023987011454,1.43391660807236,0,2011.5,0,37.5
"CD006913","CD006913_pub3_data","3|3|IBDQ (short-term) - educational intervention vs care-as-usual|IBD unspecified","IBDQ (short-term) - educational intervention vs care-as-usual",3,3,"IBD unspecified","reported","reported",3,0,0.123794948012036,0,2013.33333333333,0,88
"CD006913","CD006913_pub3_data","3|4|Quality of life (long-term) - educational intervention vs care-as usual|Crohn's disease","Quality of life (long-term) - educational intervention vs care-as usual",3,4,"Crohn's disease","or","binary",2,0.153166344077443,1.42893627838909,0,2006.5,0,47.5
"CD006913","CD006913_pub3_data","3|4|Quality of life (long-term) - educational intervention vs care-as usual|IBD unspecified","Quality of life (long-term) - educational intervention vs care-as usual",3,4,"IBD unspecified","reported","reported",3,0,0.0698419530076065,0,2017,0,276
"CD006913","CD006913_pub3_data","3|4|Quality of life (long-term) - educational intervention vs care-as usual|Ulcerative colitis","Quality of life (long-term) - educational intervention vs care-as usual",3,4,"Ulcerative colitis","or","binary",3,0.0123201516944453,1.16380280628699,0,2005.33333333333,0,85
"CD006913","CD006913_pub3_data","3|5|IBDQ (long-term) - educational intervention vs care-as-usual|IBD unspecified","IBDQ (long-term) - educational intervention vs care-as-usual",3,5,"IBD unspecified","reported","reported",2,0,0.163514964393642,0,2017,0,78.5
"CD006913","CD006913_pub3_data","3|5|IBDQ (long-term) - educational intervention vs care-as-usual|Ulcerative colitis","IBDQ (long-term) - educational intervention vs care-as-usual",3,5,"Ulcerative colitis","or","binary",2,0.0184460339469174,1.42404224884471,0,2007,0,102.5
"CD006913","CD006913_pub3_data","3|6|Quality of life (short-term), by disease activity - educational intervention vs care-as-usual|Acute flare/chronic active","Quality of life (short-term), by disease activity - educational intervention vs care-as-usual",3,6,"Acute flare/chronic active","reported","reported",2,0,0.146950849615688,0,2016,0,106
"CD006913","CD006913_pub3_data","3|8|Quality of life (short-term), by comorbidity - educational intervention vs care-as-usual|No explicit comorbidity ","Quality of life (short-term), by comorbidity - educational intervention vs care-as-usual",3,8,"No explicit comorbidity ","reported","reported",5,0,0.0941550923352617,0,2009.6,0,103
"CD006913","CD006913_pub3_data","3|8|Quality of life (short-term), by comorbidity - educational intervention vs care-as-usual|Psychiatric/psychological/IBS comorbidity","Quality of life (short-term), by comorbidity - educational intervention vs care-as-usual",3,8,"Psychiatric/psychological/IBS comorbidity","reported","reported",2,0,0.151475943232927,0,2021,0,87.5
"CD006913","CD006913_pub3_data","3|9|Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual|CBT-based","Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual",3,9,"CBT-based","reported","reported",2,0,0.151475943232927,0,2021,0,87.5
"CD006913","CD006913_pub3_data","3|9|Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual|Education","Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual",3,9,"Education","reported","reported",2,0,0.133541707318426,0,2010.5,0,113
"CD006913","CD006913_pub3_data","3|9|Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual|Multimodular","Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual",3,9,"Multimodular","reported","reported",3,0,0.132772442859454,0,2009,0,96.3333333333333
"CD006913","CD006913_pub3_data","4|1|Depressive symptoms (short-term) - educational intervention vs care-as-usual|IBD unspecified","Depressive symptoms (short-term) - educational intervention vs care-as-usual",4,1,"IBD unspecified","reported","reported",6,0,0.0781099064749009,0,2019.33333333333,0,110.833333333333
"CD006913","CD006913_pub3_data","4|10|Disease activity (long-term) - educational intervention vs care-as-usual|Crohn's disease","Disease activity (long-term) - educational intervention vs care-as-usual",4,10,"Crohn's disease","or","binary",2,0.153166344077443,1.42893627838909,0,2006.5,0,47.5
"CD006913","CD006913_pub3_data","4|10|Disease activity (long-term) - educational intervention vs care-as-usual|Ulcerative colitis","Disease activity (long-term) - educational intervention vs care-as-usual",4,10,"Ulcerative colitis","or","binary",2,-0.12823282090752,1.42871793084273,0,2006.5,0,48
"CD006913","CD006913_pub3_data","4|13|Number of patients completing program|Adults","Number of patients completing program",4,13,"Adults","reported","reported",23,0,0.00807996229704282,0,2014.86956521739,0.884915755481879,195.391304347826
"CD006913","CD006913_pub3_data","4|13|Number of patients completing program|Children and adolescents","Number of patients completing program",4,13,"Children and adolescents","reported","reported",3,0,0.0753663290595781,0,2014.33333333333,0.88568194680249,42.3333333333333
"CD006913","CD006913_pub3_data","4|2|Depressive symptoms (long-term) - educational intervention vs care-as-usual|Ulcerative colitis","Depressive symptoms (long-term) - educational intervention vs care-as-usual",4,2,"Ulcerative colitis","reported","reported",2,0,0.140028461555806,0,2002.5,0,103.5
"CD006913","CD006913_pub3_data","4|3|Anxiety (short-term) - educational intervention vs care-as-usual|IBD unspecified","Anxiety (short-term) - educational intervention vs care-as-usual",4,3,"IBD unspecified","reported","reported",3,0,0.110182341787861,0,2019.66666666667,0,111.666666666667
"CD006913","CD006913_pub3_data","4|7|Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs care-as-usual|IBD unspecified ","Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs care-as-usual",4,7,"IBD unspecified ","reported","reported",2,0,0.0580927750402259,0,2007.5,0.906773758216882,398
"CD006913","CD006913_pub3_data","4|7|Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs care-as-usual|Ulcerative colitis","Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs care-as-usual",4,7,"Ulcerative colitis","reported","reported",2,0,0.0920278550431573,0,2010,0.495330459770115,166.5
"CD006913","CD006913_pub3_data","4|8|Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - educational intervention vs care-as-usual|Ulcerative colitis","Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - educational intervention vs care-as-usual",4,8,"Ulcerative colitis","or","binary",2,0.225092166110638,0.353331207952685,0.109293892948195,2010,0.376153011394465,132.5
"CD006913","CD006913_pub3_data","4|9|Disease activity (short-term) - educational intervention vs care-as-usual|Crohn's disease","Disease activity (short-term) - educational intervention vs care-as-usual",4,9,"Crohn's disease","reported","reported",3,0,0.175841106551671,0,2016.33333333333,0,47.3333333333333
"CD006913","CD006913_pub3_data","4|9|Disease activity (short-term) - educational intervention vs care-as-usual|Ulcerative colitis","Disease activity (short-term) - educational intervention vs care-as-usual",4,9,"Ulcerative colitis","reported","reported",4,0,0.159962508962811,0,2017.5,0,40.5
"CD006913","CD006913_pub3_data","5|1|Quality of life (short-term) - relaxation techniques vs care-as-usual, with You|IBD unspecified","Quality of life (short-term) - relaxation techniques vs care-as-usual, with You",5,1,"IBD unspecified","reported","reported",4,0,0.169023727389739,0,2019.75,0,67.25
"CD006913","CD006913_pub3_data","5|10|Quality of life (short-term), by type of therapy - relaxation techniques vs care-as-usual|CBT-based","Quality of life (short-term), by type of therapy - relaxation techniques vs care-as-usual",5,10,"CBT-based","reported","reported",4,0,0.145524355367041,0,2019.5,0,78.75
"CD006913","CD006913_pub3_data","5|10|Quality of life (short-term), by type of therapy - relaxation techniques vs care-as-usual|Multimodular","Quality of life (short-term), by type of therapy - relaxation techniques vs care-as-usual",5,10,"Multimodular","reported","reported",2,0,0.180399749814763,0,2006.5,0,96
"CD006913","CD006913_pub3_data","5|11|Quality of life (long-term), by type of therapy - relaxation techniques vs care-as-usual|Multimodular","Quality of life (long-term), by type of therapy - relaxation techniques vs care-as-usual",5,11,"Multimodular","reported","reported",2,0,0.174304994956569,0,2006.5,0,95.5
"CD006913","CD006913_pub3_data","5|12|Quality of life (short-term), by therapy intensity - relaxation techniques vs care-as-usual|Low intensity","Quality of life (short-term), by therapy intensity - relaxation techniques vs care-as-usual",5,12,"Low intensity","reported","reported",7,0,0.113248629760816,0,2014.85714285714,0,79.5714285714286
"CD006913","CD006913_pub3_data","5|13|Quality of life (long-term), by therapy intensity - relaxation techniques vs care-as-usual|Low intensity","Quality of life (long-term), by therapy intensity - relaxation techniques vs care-as-usual",5,13,"Low intensity","reported","reported",3,0,0.181463746772681,0,2008.66666666667,0,80.3333333333333
"CD006913","CD006913_pub3_data","5|15|Quality of life (short-term), by training of provider - relaxation techniques vs care-as-usual|Psychotherapist","Quality of life (short-term), by training of provider - relaxation techniques vs care-as-usual",5,15,"Psychotherapist","or","binary",7,0.0053930431005351,0.762649520699362,0,2016.14285714286,0,66
"CD006913","CD006913_pub3_data","5|2|Quality of life (short-term) - relaxation techniques vs care-as-usual, revised|IBD unspecified","Quality of life (short-term) - relaxation techniques vs care-as-usual, revised",5,2,"IBD unspecified","reported","reported",3,0,0.224952535459784,0,2019,0,66.3333333333333
"CD006913","CD006913_pub3_data","5|3|IBDQ (short-term) - relaxation techniques vs care-as-usual|Crohn's Disease","IBDQ (short-term) - relaxation techniques vs care-as-usual",5,3,"Crohn's Disease","or","binary",2,-0.0326023987011454,1.43391660807236,0,2011.5,0,37.5
"CD006913","CD006913_pub3_data","5|6|Quality of life (short-term), by disease activity - relaxation techniques vs care-as-usual|Acute flare/chronic active","Quality of life (short-term), by disease activity - relaxation techniques vs care-as-usual",5,6,"Acute flare/chronic active","reported","reported",3,0,0.150832662848171,0,2017.66666666667,0,109.333333333333
"CD006913","CD006913_pub3_data","5|6|Quality of life (short-term), by disease activity - relaxation techniques vs care-as-usual|In remission","Quality of life (short-term), by disease activity - relaxation techniques vs care-as-usual",5,6,"In remission","reported","reported",2,0,0.407774808536097,0,2014,0,37
"CD006913","CD006913_pub3_data","5|8|Quality of life (short-term), by comorbidity - relaxation techniques vs care-as-usual|No explicit comorbidity ","Quality of life (short-term), by comorbidity - relaxation techniques vs care-as-usual",5,8,"No explicit comorbidity ","reported","reported",6,0,0.0955594189490749,0,2014,0,80.5
"CD006913","CD006913_pub3_data","5|8|Quality of life (short-term), by comorbidity - relaxation techniques vs care-as-usual|Psychiatric/psychological/IBS comorbidity","Quality of life (short-term), by comorbidity - relaxation techniques vs care-as-usual",5,8,"Psychiatric/psychological/IBS comorbidity","reported","reported",2,0,0.269476146551707,0,2021,0,87.5
"CD006913","CD006913_pub3_data","5|9|Quality of life (long-term), by comorbidity - relaxation techniques vs care-as-usual|No explicit comorbidity","Quality of life (long-term), by comorbidity - relaxation techniques vs care-as-usual",5,9,"No explicit comorbidity","reported","reported",3,0,0.181463746772681,0,2008.66666666667,0,80.3333333333333
"CD006913","CD006913_pub3_data","6|1|Depressive symptoms (short-term) - relaxation techniques vs care-as-usual|IBD unspecified","Depressive symptoms (short-term) - relaxation techniques vs care-as-usual",6,1,"IBD unspecified","reported","reported",3,0,0.151328042736095,0,2019.33333333333,0,60
"CD006913","CD006913_pub3_data","6|10|Disease activity (long-term) - relaxation techniques vs care-as-usual|Crohn's disease","Disease activity (long-term) - relaxation techniques vs care-as-usual",6,10,"Crohn's disease","or","binary",2,0.153166344077443,1.42893627838909,0,2006.5,0,47.5
"CD006913","CD006913_pub3_data","6|10|Disease activity (long-term) - relaxation techniques vs care-as-usual|Ulcerative colitis","Disease activity (long-term) - relaxation techniques vs care-as-usual",6,10,"Ulcerative colitis","or","binary",2,-0.12823282090752,1.42871793084273,0,2006.5,0,48
"CD006913","CD006913_pub3_data","6|12|Number of patients completing program  - relaxation techniques vs any type of control, all populations|Adults","Number of patients completing program  - relaxation techniques vs any type of control, all populations",6,12,"Adults","reported","reported",15,0,0.0214719948258215,0,2018.33333333333,0.881898803148083,77.7333333333333
"CD006913","CD006913_pub3_data","6|12|Number of patients completing program  - relaxation techniques vs any type of control, all populations|Children and adolescents","Number of patients completing program  - relaxation techniques vs any type of control, all populations",6,12,"Children and adolescents","reported","reported",3,0,0.0656926885159668,0,2014.33333333333,0.982456140350877,34.3333333333333
"CD006913","CD006913_pub3_data","6|3|Anxiety (short-term) - relaxation techniques vs care-as-usual|IBD unspecified","Anxiety (short-term) - relaxation techniques vs care-as-usual",6,3,"IBD unspecified","reported","reported",3,0,0.151316099469753,0,2019.33333333333,0,60
"CD006913","CD006913_pub3_data","6|3|Anxiety (short-term) - relaxation techniques vs care-as-usual|Ulcerative Colitis","Anxiety (short-term) - relaxation techniques vs care-as-usual",6,3,"Ulcerative Colitis","reported","reported",2,0,0.202283508458346,0,2008.5,0,50.5
"CD006913","CD006913_pub3_data","6|5|Failure to induce and maintain remission (short-term) (ITT) - relaxation techniques vs care-as-usual|IBD unspecified","Failure to induce and maintain remission (short-term) (ITT) - relaxation techniques vs care-as-usual",6,5,"IBD unspecified","reported","reported",2,0,0.213383654860779,0,2000,0.339772727272727,73
"CD006913","CD006913_pub3_data","6|7|Failure to induce or maintain remission (long-term) (ITT) - relaxation techniques vs care-as-usual|IBD unspecified","Failure to induce or maintain remission (long-term) (ITT) - relaxation techniques vs care-as-usual",6,7,"IBD unspecified","reported","reported",3,0,0.072613081913542,0,2003.66666666667,0.648657628920787,86.6666666666667
"CD006913","CD006913_pub3_data","6|8|Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - relaxation techniques vs care-as-usual|IBD unspecified","Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - relaxation techniques vs care-as-usual",6,8,"IBD unspecified","reported","reported",2,0,0.40162720529133,0,2012.5,0.744047619047619,69
"CD006913","CD006913_pub3_data","6|9|Disease activity (short-term) - relaxation techniques vs care-as-usual|Crohn's Disease","Disease activity (short-term) - relaxation techniques vs care-as-usual",6,9,"Crohn's Disease","reported","reported",3,0,0.189405054242849,0,2019.33333333333,0,60
"CD006913","CD006913_pub3_data","6|9|Disease activity (short-term) - relaxation techniques vs care-as-usual|Ulcerative Colitis","Disease activity (short-term) - relaxation techniques vs care-as-usual",6,9,"Ulcerative Colitis","reported","reported",3,0,0.257498559983762,0,2019.33333333333,0,33.3333333333333
"CD006913","CD006913_pub3_data","7|1|Quality of life (short-term) - psychotherapy vs active control|IBD unspecified (control - education)","Quality of life (short-term) - psychotherapy vs active control",7,1,"IBD unspecified (control - education)","reported","reported",2,0,0.0935097155409463,0,2017.5,0,229.5
"CD006913","CD006913_pub3_data","7|10|Depressive symptoms (long-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Depressive symptoms (long-term) - educational intervention vs active control",7,10,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.239025962552198,0,2018,0,36
"CD006913","CD006913_pub3_data","7|12|Anxiety (long-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Anxiety (long-term) - educational intervention vs active control",7,12,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.237425083404371,0,2018,0,36
"CD006913","CD006913_pub3_data","7|17|Disease activity (short-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Disease activity (short-term) - educational intervention vs active control",7,17,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.170434212184742,0,2021,0,70
"CD006913","CD006913_pub3_data","7|18|Disease activity (long-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Disease activity (long-term) - educational intervention vs active control",7,18,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.23795437025527,0,2018,0,36
"CD006913","CD006913_pub3_data","7|19|Quality of life (short-term) - relaxation technique vs active control|Ulcerative colitis (control - education)","Quality of life (short-term) - relaxation technique vs active control",7,19,"Ulcerative colitis (control - education)","reported","reported",3,0,0.169726051604469,0,2019.66666666667,0,72.3333333333333
"CD006913","CD006913_pub3_data","7|20|IBDQ (short-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","IBDQ (short-term) - relaxation techniques vs active control",7,20,"Ulcerative colitis (control - education)","reported","reported",3,0,4.25585729883777,0,2019.66666666667,0,72.3333333333333
"CD006913","CD006913_pub3_data","7|21|Quality of life (long-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","Quality of life (long-term) - relaxation techniques vs active control",7,21,"Ulcerative colitis (control - education)","reported","reported",2,0,0.240781879627772,0,2018,0,36
"CD006913","CD006913_pub3_data","7|22|IBDQ (long-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","IBDQ (long-term) - relaxation techniques vs active control",7,22,"Ulcerative colitis (control - education)","reported","reported",2,0,4.82378999840613,0,2018,0,36
"CD006913","CD006913_pub3_data","7|24|Depressive symptoms (long-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","Depressive symptoms (long-term) - relaxation techniques vs active control",7,24,"Ulcerative colitis (control - education)","reported","reported",2,0,0.239111101554358,0,2018,0,36
"CD006913","CD006913_pub3_data","7|26|Anxiety (long-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","Anxiety (long-term) - relaxation techniques vs active control",7,26,"Ulcerative colitis (control - education)","reported","reported",2,0,0.237422271342884,0,2018,0,36
"CD006913","CD006913_pub3_data","7|29|Disease activity (short-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","Disease activity (short-term) - relaxation techniques vs active control",7,29,"Ulcerative colitis (control - education)","reported","reported",3,0,0.162740082099848,0,2019.66666666667,0,72.3333333333333
"CD006913","CD006913_pub3_data","7|3|Depressive symptoms (short-term) - psychotherapy vs active control|IBD unspecified (control - education)","Depressive symptoms (short-term) - psychotherapy vs active control",7,3,"IBD unspecified (control - education)","reported","reported",2,0,0.0928095850005298,0,2017.5,0,233
"CD006913","CD006913_pub3_data","7|30|Disease activity (long-term) - relaxation techniques vs active control|Ulcerative colitis (control - education)","Disease activity (long-term) - relaxation techniques vs active control",7,30,"Ulcerative colitis (control - education)","reported","reported",2,0,0.237921427955791,0,2018,0,36
"CD006913","CD006913_pub3_data","7|4|Anxiety (short-term) - psychotherapy vs active control|IBD unspecified (control - education)","Anxiety (short-term) - psychotherapy vs active control",7,4,"IBD unspecified (control - education)","reported","reported",2,0,0.0927182700364864,0,2017.5,0,233
"CD006913","CD006913_pub3_data","7|5|Quality of life (short-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Quality of life (short-term) - educational intervention vs active control",7,5,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.169769806497057,0,2021,0,70
"CD006913","CD006913_pub3_data","7|6|Quality of life (long-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","Quality of life (long-term) - educational intervention vs active control",7,6,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.240777037017774,0,2018,0,36
"CD006913","CD006913_pub3_data","7|7|IBDQ (short-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","IBDQ (short-term) - educational intervention vs active control",7,7,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.169769806497057,0,2021,0,70
"CD006913","CD006913_pub3_data","7|8|IBDQ (long-term) - educational intervention vs active control|Ulcerative colitis (control - relaxation)","IBDQ (long-term) - educational intervention vs active control",7,8,"Ulcerative colitis (control - relaxation)","reported","reported",2,0,0.240777037017774,0,2018,0,36
"CD006913","CD006913_pub3_data","7|9|Depressive symptoms (shortterm) - educational intervention vs active control|IBD unspecified (control - psychotherapy)","Depressive symptoms (shortterm) - educational intervention vs active control",7,9,"IBD unspecified (control - psychotherapy)","reported","reported",2,0,0.0928099318612438,0,2017.5,0,233
"CD006913","CD006913_pub3_data","8|1|Quality of life (short-term) - psychotherapy vs care-as-usual|IBD unspecified","Quality of life (short-term) - psychotherapy vs care-as-usual",8,1,"IBD unspecified","or","binary",2,-0.0498048632245731,1.44577409288344,0,2013,0,27
"CD006919","CD006919_pub5_data","1|1|Live birth/ongoing pregnancies primary analysis|","Live birth/ongoing pregnancies primary analysis",1,1,"","reported","reported",2,0,0.609355179803343,0,2002.5,0.0597713097713098,64
"CD006919","CD006919_pub5_data","1|2|Live birth/ongoing pregnancies all studies|","Live birth/ongoing pregnancies all studies",1,2,"","reported","reported",2,0,0.726952749791336,0,1990,0.0747863247863248,36
"CD006919","CD006919_pub5_data","1|3|Clinical pregnancies primary analysis|Non-selected group","Clinical pregnancies primary analysis",1,3,"Non-selected group","or","binary",4,0.117664594512046,0.266027158249554,5.7569824206449e-06,1992.25,0.235925925925926,80
"CD006919","CD006919_pub5_data","1|3|Clinical pregnancies primary analysis|Poor responder group","Clinical pregnancies primary analysis",1,3,"Poor responder group","or","binary",4,0.9713118146391,0.394733348534449,0,2005,0.082212638247121,58
"CD006919","CD006919_pub5_data","1|4|Clinical pregnancies all studies|","Clinical pregnancies all studies",1,4,"","or","binary",19,0.385692549491535,0.149616122475673,0.0960198654375078,1995.36842105263,0.182968438752607,83.2631578947368
"CD006919","CD006919_pub5_data","1|5|Number of oocytes|Non-selected group","Number of oocytes",1,5,"Non-selected group","or","binary",6,-0.00364337622314958,0.824036281540593,0,1996.66666666667,0,85.3333333333333
"CD006919","CD006919_pub5_data","1|5|Number of oocytes|Poor responders","Number of oocytes",1,5,"Poor responders","or","binary",4,-0.0470384756938524,1.00907062512951,0,2005,0,56.75
"CD006919","CD006919_pub5_data","1|6|Amount of gonadotropins administered|Non-selected group","Amount of gonadotropins administered",1,6,"Non-selected group","or","binary",4,-0.032039207342188,1.00525372192718,0,1999.75,0,109.75
"CD006919","CD006919_pub5_data","1|6|Amount of gonadotropins administered|Poor responders","Amount of gonadotropins administered",1,6,"Poor responders","or","binary",4,-0.0470384756938524,1.00907062512951,0,2005,0,56.75
"CD006919","CD006919_pub5_data","1|7|Cycle cancellation|Non selected","Cycle cancellation",1,7,"Non selected","or","binary",11,-0.0860323429559022,0.326889824633778,0.417556708121493,1997.45454545455,0.0988081838327983,93.2727272727273
"CD006919","CD006919_pub5_data","1|7|Cycle cancellation|Poor responders","Cycle cancellation",1,7,"Poor responders","or","binary",4,-0.986991033220369,0.445564689416114,0.0320009925789025,2005,0.179895936701744,56.75
"CD006919","CD006919_pub5_data","10|4|Clinical pregnancy 100 µg vs 25 µg|","Clinical pregnancy 100 µg vs 25 µg",10,4,"","or","binary",2,0.869272610270318,1.40476200009115,3.56680235752359,NA,0.279176201372998,66.5
"CD006919","CD006919_pub5_data","10|8|Number of oocytes 100 µg vs 25 µg|","Number of oocytes 100 µg vs 25 µg",10,8,"","or","binary",2,-0.191516472708095,1.42508241040376,0,NA,0,66.5
"CD006919","CD006919_pub5_data","2|2|Clinical pregnancies|","Clinical pregnancies",2,2,"","or","binary",2,0.429264995149058,0.338961436602552,0,1992,0.160590823381521,115
"CD006919","CD006919_pub5_data","2|3|Number of oocytes|","Number of oocytes",2,3,"","or","binary",2,0.0607133925763334,1.42092254081627,0,1992,0,115
"CD006919","CD006919_pub5_data","4|2|Clinical pregnancies|","Clinical pregnancies",4,2,"","or","binary",5,-0.000360879042476975,0.247351048836704,0.139672102289925,1996.8,0.276204551384825,150
"CD006919","CD006919_pub5_data","4|3|Number of oocytes|","Number of oocytes",4,3,"","or","binary",4,-0.35537739147632,1.00580045619531,0,1997,0,131.75
"CD006919","CD006919_pub5_data","4|4|Amount of gonadotropins administered|","Amount of gonadotropins administered",4,4,"","or","binary",4,-0.35537739147632,1.00580045619531,0,1997,0,131.75
"CD006919","CD006919_pub5_data","4|5|Cycle cancellation|","Cycle cancellation",4,5,"","or","binary",2,0.226227589179603,0.644866377431165,0,2004.5,0.0338915470494418,133.5
"CD006919","CD006919_pub5_data","5|2|Ongoing pregnancy rate all studies|","Ongoing pregnancy rate all studies",5,2,"","or","binary",2,-0.38421410214775,0.399038514048885,0,2002,0.162931034482759,97
"CD006919","CD006919_pub5_data","5|3|Clinical pregnancies|","Clinical pregnancies",5,3,"","or","binary",3,-0.263222296008127,0.320722312385695,0,2001.33333333333,0.181524678837052,88
"CD006919","CD006919_pub5_data","5|4|Number of oocytes|","Number of oocytes",5,4,"","or","binary",3,-0.00187492005806982,1.161472747054,0,2001.33333333333,0,88
"CD006919","CD006919_pub5_data","5|5|Amount of gonadotropins administered|","Amount of gonadotropins administered",5,5,"","or","binary",3,-0.00187492005806982,1.161472747054,0,2001.33333333333,0,88
"CD006919","CD006919_pub5_data","5|6|Cycle cancellation|","Cycle cancellation",5,6,"","or","binary",3,0.176662602408779,0.918908508583382,1.68786584779342,2001.33333333333,0.0566768086544963,88
"CD006919","CD006919_pub5_data","6|3|Clinical pregnancies|","Clinical pregnancies",6,3,"","or","binary",4,0.0185345945428086,0.202612318033701,0,2003.25,0.373346438482886,101.75
"CD006919","CD006919_pub5_data","6|4|Number of oocytes|","Number of oocytes",6,4,"","or","binary",3,-0.0396657181237987,1.16251142444798,0,2004,0,91.6666666666667
"CD006919","CD006919_pub5_data","6|5|Amount of gonadotropins administered|","Amount of gonadotropins administered",6,5,"","or","binary",2,-0.0205929168013871,1.42050293516616,0,2007,0,114
"CD006919","CD006919_pub5_data","6|6|Cycle cancellation|","Cycle cancellation",6,6,"","or","binary",2,-0.00703435394376361,0.830224052748243,0,2007,0.0151515151515152,114
"CD006942","CD006942_pub4_data","1|2|Clinical pregnancy per couple|0-33 hours versus 34-40 hours","Clinical pregnancy per couple",1,2,"0-33 hours versus 34-40 hours","reported","reported",2,0,0.223605567739507,0,2016,0.223220153340635,297
"CD006942","CD006942_pub4_data","5|1|Live birth or ongoing pregnancy rate per couple|Sensitivity analyses","Live birth or ongoing pregnancy rate per couple",5,1,"Sensitivity analyses","reported","reported",4,0,0.45705924426989,0,2000.25,0.19375,53.5
"CD006982","CD006982_pub5_data","1|1|Growth (g) at 3 and 6 months|at 3 months","Growth (g) at 3 and 6 months",1,1,"at 3 months","reported","reported",2,0,146.490546988925,0,2012,0,93.5
"CD006982","CD006982_pub5_data","1|2|Growth (daily weight gain, grams/d) during neonatal care|","Growth (daily weight gain, grams/d) during neonatal care",1,2,"","or","binary",2,0.0456362285603202,1.42732005088512,0,2007,0,64
"CD006982","CD006982_pub5_data","1|3|Retinopathy of prematurity (any stage)|","Retinopathy of prematurity (any stage)",1,3,"","reported","reported",2,0,0.157111197239376,0,1998,0.543010752688172,94.5
"CD006982","CD006982_pub5_data","1|4|Retinopathy of prematurity (stage ≥ 3)|","Retinopathy of prematurity (stage ≥ 3)",1,4,"","reported","reported",3,0,0.356145142121508,0,2005.66666666667,0.137572964669739,112
"CD006982","CD006982_pub5_data","1|5|Duration of initial hospitalisation (days) |","Duration of initial hospitalisation (days) ",1,5,"","reported","reported",4,0,2.85897696091337,0,2008.5,0,113.5
"CD006982","CD006982_pub5_data","2|1|Duration of initial hospitalisation (days)|","Duration of initial hospitalisation (days)",2,1,"","reported","reported",4,0,0.122326474227563,0,2012.25,0,109.75
"CD007024","CD007024_pub3_data","1|1|Frequency of cocaine use|Versus no pharmacological treatment","Frequency of cocaine use",1,1,"Versus no pharmacological treatment","or","binary",2,-0.18113059875046,1.42973933513179,0,1998,0,45
"CD007024","CD007024_pub3_data","1|1|Frequency of cocaine use|Versus placebo","Frequency of cocaine use",1,1,"Versus placebo","or","binary",11,-0.0514632945258654,0.608966398127107,0,2008.90909090909,0,66.1818181818182
"CD007024","CD007024_pub3_data","1|2|Amount of cocaine use|Versus placebo","Amount of cocaine use",1,2,"Versus placebo","or","binary",7,-0.505408775044732,0.765585246926647,0,2007.71428571429,0,53.7142857142857
"CD007024","CD007024_pub3_data","1|3|Continuous abstinence|Versus no pharmacological treatment","Continuous abstinence",1,3,"Versus no pharmacological treatment","or","binary",2,1.02639547924581,0.436275383360425,0,1998,0.291062801932367,45
"CD007024","CD007024_pub3_data","1|3|Continuous abstinence|Versus placebo","Continuous abstinence",1,3,"Versus placebo","or","binary",4,-0.0874417376916682,0.282368611792278,6.41912433024981e-06,2011.25,0.284940189009956,74
"CD007024","CD007024_pub3_data","1|4|Point abstinence|Versus placebo","Point abstinence",1,4,"Versus placebo","or","binary",3,0.663359592661118,0.365342602166576,1.1433444456144e-06,2012.33333333333,0.331718898385565,47.3333333333333
"CD007024","CD007024_pub3_data","1|5|Dropout for any reason|Versus placebo","Dropout for any reason",1,5,"Versus placebo","or","binary",13,0.197346094848853,0.190674130355621,0.0908099142174216,2010.38461538462,0.236311765691707,64.0769230769231
"CD007024","CD007024_pub3_data","1|8|Individual adverse events|Anxiety","Individual adverse events",1,8,"Anxiety","or","binary",2,0.353321550400576,0.334214314084228,0.0556633139352307,2006,0.260777170613236,114
"CD007024","CD007024_pub3_data","1|8|Individual adverse events|Diarrhoea","Individual adverse events",1,8,"Diarrhoea","or","binary",2,0.0809396562243405,0.347003066300855,0,2006,0.162112932604736,114
"CD007024","CD007024_pub3_data","1|8|Individual adverse events|Drowsiness","Individual adverse events",1,8,"Drowsiness","or","binary",3,0.439324305918628,0.278286788962943,0,2008.33333333333,0.185488767455981,86
"CD007024","CD007024_pub3_data","1|8|Individual adverse events|Headache","Individual adverse events",1,8,"Headache","or","binary",3,0.281850297417223,0.268649506293877,0,2008.33333333333,0.310524185387573,86
"CD007024","CD007024_pub3_data","2|1|Frequency of cocaine use|","Frequency of cocaine use",2,1,"","or","binary",2,-0.00963187344965342,1.43567457386186,0,2000.5,0,61.5
"CD007024","CD007024_pub3_data","2|2|Amount of cocaine use|","Amount of cocaine use",2,2,"","or","binary",2,-0.00963187344965342,1.43567457386186,0,2000.5,0,61.5
"CD007024","CD007024_pub3_data","2|3|Dropout for any reason|","Dropout for any reason",2,3,"","or","binary",3,-0.470411669235234,0.387456881617377,6.85094041340779e-06,2000.5,0.618233618233618,43.6666666666667
"CD007024","CD007024_pub3_data","3|1|Frequency of cocaine use (according to the presence of alcohol dependence)|Mix of participants with and without alcohol dependence","Frequency of cocaine use (according to the presence of alcohol dependence)",3,1,"Mix of participants with and without alcohol dependence","or","binary",7,-0.0487444194065443,0.762593259689148,0,2009.14285714286,0,56.2857142857143
"CD007024","CD007024_pub3_data","3|1|Frequency of cocaine use (according to the presence of alcohol dependence)|With comorbid alcohol dependence","Frequency of cocaine use (according to the presence of alcohol dependence)",3,1,"With comorbid alcohol dependence","or","binary",3,-0.11401965239184,1.16491421924685,0,2001.33333333333,0,65.6666666666667
"CD007024","CD007024_pub3_data","3|1|Frequency of cocaine use (according to the presence of alcohol dependence)|Without comorbid alcohol dependence","Frequency of cocaine use (according to the presence of alcohol dependence)",3,1,"Without comorbid alcohol dependence","or","binary",2,-0.0948022294688002,1.44228743009592,0,2006.5,0,25
"CD007024","CD007024_pub3_data","3|2|Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)|With comorbid opioid dependence","Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)",3,2,"With comorbid opioid dependence","or","binary",5,-0.100283314676311,0.903699839758225,0,2007.4,0,74.2
"CD007024","CD007024_pub3_data","3|2|Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)|Without comorbid opioid dependence","Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)",3,2,"Without comorbid opioid dependence","or","binary",6,-0.0517198145916303,0.824479921286382,0,2004.16666666667,0,58
"CD007024","CD007024_pub3_data","3|3|Dropout for any reason (according to the presence of comorbid alcohol dependence)|With comorbid alcohol dependence","Dropout for any reason (according to the presence of comorbid alcohol dependence)",3,3,"With comorbid alcohol dependence","or","binary",2,0.719827487924485,1.89949557973728,5.83768689245899,2007.5,0.328703703703704,57.5
"CD007024","CD007024_pub3_data","3|3|Dropout for any reason (according to the presence of comorbid alcohol dependence)|With intermediate comorbid alcohol dependence","Dropout for any reason (according to the presence of comorbid alcohol dependence)",3,3,"With intermediate comorbid alcohol dependence","or","binary",8,0.428549434579308,0.242150264947764,0,2011.125,0.194232179111211,53.125
"CD007024","CD007024_pub3_data","3|3|Dropout for any reason (according to the presence of comorbid alcohol dependence)|Without comorbid alcohol dependence","Dropout for any reason (according to the presence of comorbid alcohol dependence)",3,3,"Without comorbid alcohol dependence","or","binary",3,-0.0660586687944555,0.690444341212081,0.7228501508825,2008.33333333333,0.226851851851852,41.3333333333333
"CD007024","CD007024_pub3_data","3|4|Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)|With comorbid opioid dependence","Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)",3,4,"With comorbid opioid dependence","or","binary",9,0.455428968457365,0.186875610928742,0,2009.11111111111,0.231062662389244,66.3333333333333
"CD007024","CD007024_pub3_data","3|4|Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)|Without comorbid opioid dependence","Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)",3,4,"Without comorbid opioid dependence","or","binary",3,-0.284886148616571,1.09136734569288,2.47852643611434,2009.33333333333,0.330246913580247,48.3333333333333
"CD007026","CD007026_pub7_data","1|1|All-cause death|Cerebrolysin dose: 30 mL for 10 days","All-cause death",1,1,"Cerebrolysin dose: 30 mL for 10 days","or","binary",3,-0.125781027982194,0.240630072349471,0,2012.66666666667,0.0713009515480989,411.666666666667
"CD007026","CD007026_pub7_data","1|2|Non-death attrition|Cerebrolysin dose: 30 mL for 10 days","Non-death attrition",1,2,"Cerebrolysin dose: 30 mL for 10 days","or","binary",3,-0.17280963592816,0.304771367230192,0.100943512151731,2012.66666666667,0.102499034013179,411.666666666667
"CD007026","CD007026_pub7_data","1|3|Total number of people with SAEs|Cerebrolysin dose: 30 mL for 10 days","Total number of people with SAEs",1,3,"Cerebrolysin dose: 30 mL for 10 days","or","binary",2,0.218549516756208,0.21430042197297,0,2012,0.0925937529371221,594.5
"CD007026","CD007026_pub7_data","1|4|Total number of people with fatal SAEs|Cerebrolysin dose: 30 mL for 10 days","Total number of people with fatal SAEs",1,4,"Cerebrolysin dose: 30 mL for 10 days","or","binary",2,-0.103113826575543,0.246883680258999,0,2012,0.0634731664525831,594.5
"CD007026","CD007026_pub7_data","1|5|Total number of people with non-fatal SAEs|Cerebrolysin dose: 30 mL for 10 days","Total number of people with non-fatal SAEs",1,5,"Cerebrolysin dose: 30 mL for 10 days","or","binary",2,1.01903230417013,0.424859969671696,0,2012,0.029120586484539,594.5
"CD007026","CD007026_pub7_data","1|6|Total number of people with adverse events|Cerebrolysin dose: 30 mL for 10 days","Total number of people with adverse events",1,6,"Cerebrolysin dose: 30 mL for 10 days","or","binary",2,-0.338455191369929,0.556333395172899,0.432747978877987,2012,0.707634950969642,594.5
"CD007026","CD007026_pub7_data","2|1|All-cause death. Sensitivity 1. Best-case|Cerebrolysin dose: 30 mL for 10 days","All-cause death. Sensitivity 1. Best-case",2,1,"Cerebrolysin dose: 30 mL for 10 days","or","binary",3,-0.125781027982194,0.240630072349471,0,2012.66666666667,0.0713009515480989,411.666666666667
"CD007026","CD007026_pub7_data","2|2|All-cause death. Sensitivity 2. Worst-case|Cerebrolysin dose: 30 mL for 10 days","All-cause death. Sensitivity 2. Worst-case",2,2,"Cerebrolysin dose: 30 mL for 10 days","or","binary",3,-0.220689728553695,0.192293908398573,0.0236135416687106,2012.66666666667,0.174416128506441,411.666666666667
"CD007026","CD007026_pub7_data","2|3|All-cause death. Sensitivity 3. Complete case (missing data excluded)|Cerebrolysin dose: 30 mL for 10 days","All-cause death. Sensitivity 3. Complete case (missing data excluded)",2,3,"Cerebrolysin dose: 30 mL for 10 days","or","binary",3,-0.167060645876973,0.241928334091496,0,2012.66666666667,0.0789920870595101,351.333333333333
"CD007026","CD007026_pub7_data","2|4|All-cause death. Sensitivity 4. Risk of bias|High risk of bias for incomplete outcome data","All-cause death. Sensitivity 4. Risk of bias",2,4,"High risk of bias for incomplete outcome data","or","binary",3,-0.110044613968902,0.22721660907233,0,2009.66666666667,0.0717272090076044,445
"CD007026","CD007026_pub7_data","2|4|All-cause death. Sensitivity 4. Risk of bias|Low and unclear risk of bias","All-cause death. Sensitivity 4. Risk of bias",2,4,"Low and unclear risk of bias","or","binary",4,0.184830556369668,0.537987265153835,0,2010.5,0.0842391304347826,88.5
"CD007079","CD007079_pub4_data","1|1|Preterm birth < 37 weeks' gestation|Main analysis","Preterm birth < 37 weeks' gestation",1,1,"Main analysis","or","binary",11,-0.324351916163122,0.149979811336348,0.101680307767541,1996.63636363636,0.161314102333121,1398.09090909091
"CD007079","CD007079_pub4_data","1|14|Maternal death|","Maternal death",1,14,"","or","binary",2,-0.905722133237089,0.714182163600194,0.0020024143065985,2009.5,0.00222700462991114,4487
"CD007079","CD007079_pub4_data","1|15|Mode of birth: vaginal birth|","Mode of birth: vaginal birth",1,15,"","or","binary",7,0.0647873738002464,0.0645628249159202,0,1995.28571428571,0.761981308007877,973.714285714286
"CD007079","CD007079_pub4_data","1|16|Mode of birth: instrumental vaginal birth|","Mode of birth: instrumental vaginal birth",1,16,"","or","binary",2,-0.152391206872773,0.195763875420491,0.00243854105268403,1999,0.227103347889374,337.5
"CD007079","CD007079_pub4_data","1|17|Mode of birth: caesarean section|","Mode of birth: caesarean section",1,17,"","or","binary",8,-0.0269689025527716,0.0644523762234249,0,1997,0.164936733660206,917.5
"CD007079","CD007079_pub4_data","1|2|Preterm birth < 37 weeks' gestation by dose of calcium|High dose","Preterm birth < 37 weeks' gestation by dose of calcium",1,2,"High dose","or","binary",11,-0.324351916163122,0.149979811336348,0.101680307767541,1996.63636363636,0.161314102333121,1398.09090909091
"CD007079","CD007079_pub4_data","1|3|Preterm birth < 37 weeks' gestation by started to take calcium|Started calcium at 20 weeks or more","Preterm birth < 37 weeks' gestation by started to take calcium",1,3,"Started calcium at 20 weeks or more","or","binary",7,-0.559049128915829,0.25213315469267,0.150247608448412,1993.85714285714,0.171996849101847,303.285714285714
"CD007079","CD007079_pub4_data","1|3|Preterm birth < 37 weeks' gestation by started to take calcium|Started calcium before 20 weeks","Preterm birth < 37 weeks' gestation by started to take calcium",1,3,"Started calcium before 20 weeks","or","binary",4,-0.131384412507613,0.146008568009253,0.0463873784769431,2001.5,0.142674414442274,3297.5
"CD007079","CD007079_pub4_data","1|4|Preterm birth < 37 weeks' gestation by type of calcium|Carbonate","Preterm birth < 37 weeks' gestation by type of calcium",1,4,"Carbonate","or","binary",10,-0.326947678801125,0.151243363801984,0.103497494837477,1997.4,0.177445512566433,1528.7
"CD007079","CD007079_pub4_data","1|5|Preterm birth < 34 weeks' gestation|","Preterm birth < 34 weeks' gestation",1,5,"","or","binary",3,-0.0846900356503117,0.253009119896571,0.0728342714726276,2001.66666666667,0.0343826214452738,1856.33333333333
"CD007079","CD007079_pub4_data","1|6|Maternal weight gain (g/week)|","Maternal weight gain (g/week)",1,6,"","or","binary",3,0.0076336579552905,1.16111387997504,0,1991,0,134.666666666667
"CD007079","CD007079_pub4_data","2|1|Low birthweight (< 2500 g)|","Low birthweight (< 2500 g)",2,1,"","or","binary",6,-0.259253981956304,0.171368494029692,0.0832778059027932,1998.33333333333,0.232879580989229,2360.33333333333
"CD007079","CD007079_pub4_data","2|10|Intrauterine growth restriction|","Intrauterine growth restriction",2,10,"","or","binary",5,-0.264545114690371,0.233630617450049,0,1996.8,0.0996800059401785,208.2
"CD007079","CD007079_pub4_data","2|11|Neonatal bone mineral density (g/cm2)|Total body","Neonatal bone mineral density (g/cm2)",2,11,"Total body","or","binary",2,0.0883100552465932,1.42341884227211,0,2001.5,0,150
"CD007079","CD007079_pub4_data","2|2|Low birthweight (< 2500 g) by starting time of taking calcium|Started calcium at 20 weeks or more","Low birthweight (< 2500 g) by starting time of taking calcium",2,2,"Started calcium at 20 weeks or more","or","binary",3,-0.935855533115591,0.310452257834638,0,1992.66666666667,0.0949207078832452,245.666666666667
"CD007079","CD007079_pub4_data","2|2|Low birthweight (< 2500 g) by starting time of taking calcium|Started calcium before 20 weeks","Low birthweight (< 2500 g) by starting time of taking calcium",2,2,"Started calcium before 20 weeks","or","binary",3,-0.0244222631854845,0.0622187058844724,0,2004,0.370838454095212,4475
"CD007079","CD007079_pub4_data","2|3|Low birthweight (< 2500 g) by type of calcium|Carbonate","Low birthweight (< 2500 g) by type of calcium",2,3,"Carbonate","or","binary",5,-0.263934955555366,0.174515090155613,0.0867922951021587,2000.2,0.279455497187075,2814
"CD007079","CD007079_pub4_data","2|4|Stillbirth or fetal death|","Stillbirth or fetal death",2,4,"","or","binary",5,-0.0848830816181185,0.118928610767178,0,2004.8,0.0185252260851271,2921.8
"CD007079","CD007079_pub4_data","2|5|Perinatal mortality|","Perinatal mortality",2,5,"","or","binary",7,-0.126270908869159,0.103293722843426,0,1999,0.0218307707703615,2160.71428571429
"CD007079","CD007079_pub4_data","2|6|Admission to neonatal intensive care unit|","Admission to neonatal intensive care unit",2,6,"","or","binary",4,0.0563071814812492,0.0655416401157232,1.44365597117022e-06,1997,0.100823118927413,3515.5
"CD007079","CD007079_pub4_data","2|7|Birthweight (g)|","Birthweight (g)",2,7,"","or","binary",19,-0.0946653487265444,0.462715918306413,0,1993.73684210526,0,439.157894736842
"CD007079","CD007079_pub4_data","2|8|Birth length (cm)|","Birth length (cm)",2,8,"","or","binary",6,0.132195341653928,0.820823286024931,0,1992,0,1053.5
"CD007079","CD007079_pub4_data","2|9|Head circumference (cm)|","Head circumference (cm)",2,9,"","or","binary",3,-0.124004322516968,1.17756117967035,0,1993,0,130.666666666667
"CD007079","CD007079_pub4_data","3|2|Urinary stones|","Urinary stones",3,2,"","or","binary",3,-0.070569209386912,0.452319555250447,3.41965098106053e-06,1998,0.00937589424797434,4473
"CD007079","CD007079_pub4_data","3|3|Urinary tract infection|","Urinary tract infection",3,3,"","or","binary",3,-0.0602790299230933,0.176157952334836,0,1993.33333333333,0.0621075255256202,581
"CD007110","CD007110_pub4_data","1|1|All trials|","All trials",1,1,"","reported","reported",2,-0.0864768897573377,1.0997096204256,1.775358231696,2005,0,622.5
"CD007110","CD007110_pub4_data","13|1|All trials|","All trials",13,1,"","reported","reported",2,0.507538713238781,0.284217852248225,0.00266726311449992,2014,0,349
"CD007110","CD007110_pub4_data","14|1|All trials|","All trials",14,1,"","reported","reported",2,-0.170228200867608,0.233281556169183,0.024623010804,2014,0,349
"CD007110","CD007110_pub4_data","15|2|Second-cancer-related mortality|","Second-cancer-related mortality",15,2,"","or","binary",2,0.716238256488923,0.509639140721892,0,2014,0.0162541692850583,435
"CD007110","CD007110_pub4_data","15|3|Cardiac disease-related mortality|","Cardiac disease-related mortality",15,3,"","or","binary",2,0.406296535616506,0.780151969214386,0,2014,0.0072992700729927,435
"CD007110","CD007110_pub4_data","2|1|All trials|","All trials",2,1,"","reported","reported",2,-1.01293735175836,0.316279182139497,0.136719991,2005,0,622.5
"CD007110","CD007110_pub4_data","3|1|Second-cancer-related mortality|","Second-cancer-related mortality",3,1,"","or","binary",2,-0.0739921285132081,2.21569544995801,7.3712876742596,2005,0.00384615384615385,622.5
"CD007110","CD007110_pub4_data","4|1|All trials|","All trials",4,1,"","reported","reported",2,-0.232195721517609,0.918404398985175,1.27302376,2004,0,286
"CD007110","CD007110_pub4_data","5|1|All trials|","All trials",5,1,"","reported","reported",2,-0.343486370157819,0.2545381504104,0,2004,0,286
"CD007110","CD007110_pub4_data","6|1|Infection-related mortality|","Infection-related mortality",6,1,"","or","binary",2,0.314865878366139,0.887106040435824,0.129264526186492,2004,0.00894861561486655,286
"CD007110","CD007110_pub4_data","6|2|Second-cancer-related mortality|","Second-cancer-related mortality",6,2,"","or","binary",2,-0.496243046528898,0.750603640695186,0,2004,0.0136879521077575,286
"CD007110","CD007110_pub4_data","7|1|All trials|","All trials",7,1,"","reported","reported",2,-0.364672570569814,0.641084665150907,0,NA,0,344
"CD007130","CD007130_pub5_data","1|1|Total mortality|NA","Total mortality",1,1,NA,"or","binary",14,0.164397868789669,0.292387359037027,0,2013.28571428571,0.0184029382407245,117.642857142857
"CD007130","CD007130_pub5_data","1|10|Diastolic blood pressure 3 to 12 months (mmHg)|NA","Diastolic blood pressure 3 to 12 months (mmHg)",1,10,NA,"or","binary",13,-0.0588288034181723,0.559658275865829,0,2015.15384615385,0,100.692307692308
"CD007130","CD007130_pub5_data","1|11|Smoking 3 to 12 months|NA","Smoking 3 to 12 months",1,11,NA,"or","binary",6,0.0236406791090677,0.175915916321713,0,2004.5,0.268050745093852,164.333333333333
"CD007130","CD007130_pub5_data","1|2|Exercise capacity ≤ 12 months|NA","Exercise capacity ≤ 12 months",1,2,NA,"or","binary",28,0.0170094006648676,0.38176068511367,0,2009.75,0,83.6785714285714
"CD007130","CD007130_pub5_data","1|3|Exercise capacity 12 to 24 months|NA","Exercise capacity 12 to 24 months",1,3,NA,"or","binary",3,-0.0110601715273257,1.15658799076971,0,2004,0,358
"CD007130","CD007130_pub5_data","1|4|Completers|NA","Completers",1,4,NA,"or","binary",26,0.307371730308214,0.169572997393669,0.272785490443161,2010.11538461538,0.806152411793726,101.461538461538
"CD007130","CD007130_pub5_data","1|5|Total cholesterol 3 to 12 months (mmol/L)|NA","Total cholesterol 3 to 12 months (mmol/L)",1,5,NA,"or","binary",11,-0.217713056579712,0.607456276715767,0,2014.72727272727,0,117.272727272727
"CD007130","CD007130_pub5_data","1|6|HDL cholesterol 3 to 12 months (mmol/L)|NA","HDL cholesterol 3 to 12 months (mmol/L)",1,6,NA,"or","binary",9,-0.227780056838925,0.672012661123381,0,2017.44444444444,0,118.222222222222
"CD007130","CD007130_pub5_data","1|7|LDL cholesterol 3 to 12 months (mmol/L)|NA","LDL cholesterol 3 to 12 months (mmol/L)",1,7,NA,"or","binary",6,-0.371005240650127,0.823270562644244,0,2004.83333333333,0,71.5
"CD007130","CD007130_pub5_data","1|8|Triglycerides 3 to 12 months (mmol/L)|NA","Triglycerides 3 to 12 months (mmol/L)",1,8,NA,"or","binary",7,-0.324779947520061,0.762778733273911,0,2019.85714285714,0,76.4285714285714
"CD007130","CD007130_pub5_data","1|9|Systolic blood pressure 3 to 12 months (mmHg)|NA","Systolic blood pressure 3 to 12 months (mmHg)",1,9,NA,"or","binary",14,-0.0143230422929137,0.539030172068386,0,2013.92857142857,0,103.928571428571
"CD007156","CD007156_pub3_data","1|1|Interincisal distance (mm)|Antioxidants vs placebo","Interincisal distance (mm)",1,1,"Antioxidants vs placebo","reported","reported",2,0,0.223767364955902,0,2017.5,0,260
"CD007156","CD007156_pub3_data","1|1|Interincisal distance (mm)|Vasodilators vs placebo","Interincisal distance (mm)",1,1,"Vasodilators vs placebo","reported","reported",2,0,1.78716173204138,0,2014.5,0,42.5
"CD007156","CD007156_pub3_data","1|2|Burning sensation (VAS)|Vasodilator vs placebo","Burning sensation (VAS)",1,2,"Vasodilator vs placebo","or","binary",2,-0.192502686979227,1.43389762739831,0,2014.5,0,42.5
"CD007156","CD007156_pub3_data","2|1|Interincisal distance (mm)|Antioxidant vs placebo","Interincisal distance (mm)",2,1,"Antioxidant vs placebo","or","binary",3,0,1.1586638069407,0,2017.66666666667,0,206.666666666667
"CD007156","CD007156_pub3_data","2|1|Interincisal distance (mm)|Pentoxifylline vs placebo","Interincisal distance (mm)",2,1,"Pentoxifylline vs placebo","or","binary",2,0,1.42875705485419,0,2014.5,0,68
"CD007156","CD007156_pub3_data","2|1|Interincisal distance (mm)|Vasodilator vs placebo","Interincisal distance (mm)",2,1,"Vasodilator vs placebo","or","binary",2,-0.192502686979227,1.43389762739831,0,2014.5,0,42.5
"CD007156","CD007156_pub3_data","2|2|Burning sensation (VAS)|Antioxidant vs placebo","Burning sensation (VAS)",2,2,"Antioxidant vs placebo","or","binary",2,0,1.41857939191505,0,2019,0,250
"CD007156","CD007156_pub3_data","2|2|Burning sensation (VAS)|Vasodilator vs placebo","Burning sensation (VAS)",2,2,"Vasodilator vs placebo","or","binary",2,-0.192502686979227,1.43389762739831,0,2014.5,0,42.5
"CD007156","CD007156_pub3_data","2|4|Difficulty in swallowing|Antioxidant vs placebo","Difficulty in swallowing",2,4,"Antioxidant vs placebo","or","binary",2,-1.37412140836006,0.452843878026853,0,2016.5,0.206666666666667,110
"CD007156","CD007156_pub3_data","4|1|Interincisal distance (mm)|Steroid vs alternative (medicinal treatment)","Interincisal distance (mm)",4,1,"Steroid vs alternative (medicinal treatment)","or","binary",4,-0.0322551748441044,1.0153159907259,0,2011.75,0,32
"CD007156","CD007156_pub3_data","4|1|Interincisal distance (mm)|Steroid vs alternative (steroid + adjunct)","Interincisal distance (mm)",4,1,"Steroid vs alternative (steroid + adjunct)","or","binary",2,0,1.42912935533692,0,2011.5,0,74
"CD007156","CD007156_pub3_data","4|2|Burning sensation (VAS)|Steroid vs alternative","Burning sensation (VAS)",4,2,"Steroid vs alternative","or","binary",2,0,1.43761553567623,0,2013,0,29
"CD007156","CD007156_pub3_data","5|1|Interincisal distance (mm)|Steroid vs alternative","Interincisal distance (mm)",5,1,"Steroid vs alternative","or","binary",3,0,1.17209714366946,0,2013.33333333333,0,32.6666666666667
"CD007156","CD007156_pub3_data","5|1|Interincisal distance (mm)|Steroid vs alternative (steroid + adjunct)","Interincisal distance (mm)",5,1,"Steroid vs alternative (steroid + adjunct)","or","binary",2,0,1.42912935533692,0,2011.5,0,74
"CD007156","CD007156_pub3_data","5|2|Burning sensation (VAS)|Steroid vs alternative","Burning sensation (VAS)",5,2,"Steroid vs alternative","or","binary",3,0,1.17209714366946,0,2013.33333333333,0,32.6666666666667
"CD007310","CD007310_pub3_data","1|10|Complications|Endometritis requiring antibiotics","Complications",1,10,"Endometritis requiring antibiotics","or","binary",2,-1.10504936733802,1.16265581059737,0,2009.5,0.0183150183150183,119.5
"CD007310","CD007310_pub3_data","1|10|Complications|Uterine perforation","Complications",1,10,"Uterine perforation","or","binary",2,1.12904981316116,1.16265879573215,0,2009.5,0,119.5
"CD007310","CD007310_pub3_data","1|12|Pain experienced by participants between initiation of cervical preparation method and abortion procedure|","Pain experienced by participants between initiation of cervical preparation method and abortion procedure",1,12,"","or","binary",2,1.02042420534758,1.21898281975734,2.53225345644441,2004,0.212307692307692,103
"CD007310","CD007310_pub3_data","1|15|Provider assessment of difficulty of procedure|","Provider assessment of difficulty of procedure",1,15,"","or","binary",2,1.91617879309493,0.663715653209754,0,1999.5,0.0238095238095238,66.5
"CD007310","CD007310_pub3_data","1|2|Dilation achieved (mm)|","Dilation achieved (mm)",1,2,"","or","binary",3,0.0236867324098569,1.16299344437135,0,2004.66666666667,0,72.3333333333333
"CD007310","CD007310_pub3_data","1|3|Need for additional dilation|","Need for additional dilation",1,3,"","or","binary",2,1.22981365669044,1.39002601188285,3.61493821284273,2010,0.269933554817276,83.5
"CD007310","CD007310_pub3_data","1|4|Ability to complete procedure (number completed on first attempt)|","Ability to complete procedure (number completed on first attempt)",1,4,"","or","binary",2,-0.705273248039557,1.27470701667477,0,2010,1,83.5
"CD007310","CD007310_pub3_data","1|6|Side effects: nausea|Any nausea","Side effects: nausea",1,6,"Any nausea","or","binary",3,0.406927222323307,0.688278216388118,0.815295758471524,2011.33333333333,0.0995670995670996,106.333333333333
"CD007310","CD007310_pub3_data","1|7|Side effects: vomiting|Vomiting","Side effects: vomiting",1,7,"Vomiting","or","binary",3,-0.0779519628325516,0.870950293278545,1.58223229910413,2011.33333333333,0.135642135642136,106.333333333333
"CD007310","CD007310_pub3_data","1|8|Side effects: diarrhea|","Side effects: diarrhea",1,8,"","or","binary",3,1.04979331393388,0.496389399808806,0.129826317170773,2011.33333333333,0.0411255411255411,106.333333333333
"CD007310","CD007310_pub3_data","1|9|Side effects: fever/chills|Chills","Side effects: fever/chills",1,9,"Chills","or","binary",3,1.37010805170602,0.366248341643043,0,2011.33333333333,0.0728715728715729,106.333333333333
"CD007310","CD007310_pub3_data","14|10|Side effects: diarrhea|","Side effects: diarrhea",14,10,"","or","binary",2,0.970287740987045,0.45761386118186,0,2011.5,0.0159722222222222,493.5
"CD007310","CD007310_pub3_data","14|11|Side effects: fever/chills|","Side effects: fever/chills",14,11,"","or","binary",2,-0.0974473751866855,0.129942854244535,0,2011.5,0.328472222222222,493.5
"CD007310","CD007310_pub3_data","14|7|Adverse events|Pre-procedure expulsion","Adverse events",14,7,"Pre-procedure expulsion","or","binary",2,1.52282751238594,0.556621338279757,0,2011.5,0.00344036697247706,488.5
"CD007310","CD007310_pub3_data","14|8|Side effects: nausea|","Side effects: nausea",14,8,"","or","binary",2,0.0307231664214203,0.705249647834408,0.81048340120713,2011.5,0.128611111111111,493.5
"CD007310","CD007310_pub3_data","14|9|Side effects: vomiting|","Side effects: vomiting",14,9,"","or","binary",2,0.426765270248558,0.35587228287312,0.0646827028395085,2011.5,0.0605555555555556,493.5
"CD007310","CD007310_pub3_data","3|1|Procedure time|","Procedure time",3,1,"","or","binary",5,0.0340972248840606,0.901069889975189,0,2011.4,0,109
"CD007310","CD007310_pub3_data","3|10|Side effects: chills|After pills","Side effects: chills",3,10,"After pills","or","binary",3,1.82617446536589,0.306370272810164,0.0617913809064776,2015,0.0812203669346526,141
"CD007310","CD007310_pub3_data","3|11|Complications|Hemorrhage requiring transfusion","Complications",3,11,"Hemorrhage requiring transfusion","or","binary",2,0.694930663811953,0.879829058514494,0,2014.5,0.00510204081632653,197
"CD007310","CD007310_pub3_data","3|11|Complications|Hospitalization","Complications",3,11,"Hospitalization","or","binary",2,0.193061946413843,0.616767465209395,0,2014.5,0.0203566274994846,197
"CD007310","CD007310_pub3_data","3|11|Complications|Reaspiration","Complications",3,11,"Reaspiration","or","binary",2,0.000102566678332887,0.822722347248954,0,2014.5,0.0101525458668316,197
"CD007310","CD007310_pub3_data","3|12|Patient acceptability/satisfaction|","Patient acceptability/satisfaction",3,12,"","or","binary",2,0.49625949218534,0.317348357918664,0,2015.5,0.720779220779221,114
"CD007310","CD007310_pub3_data","3|14|Pain experienced by participants between initiation of cervical preparation method and abortion procedure|Any time between initiation of preparation method and abortion procedure","Pain experienced by participants between initiation of cervical preparation method and abortion procedure",3,14,"Any time between initiation of preparation method and abortion procedure","or","binary",2,1.76733683183191,0.657987594353253,0.503034869293424,2015,0.117687074829932,112
"CD007310","CD007310_pub3_data","3|16|Provider assessment of the procedure as very difficult|","Provider assessment of the procedure as very difficult",3,16,"","or","binary",3,-0.474980947303759,0.221450119793615,0,2011.66666666667,0.253788833153913,182.333333333333
"CD007310","CD007310_pub3_data","3|3|Dilation achieved (mm)|","Dilation achieved (mm)",3,3,"","or","binary",4,0.0293012882313713,1.00730203678687,0,2012.75,0,121
"CD007310","CD007310_pub3_data","3|5|Need for additional dilation|","Need for additional dilation",3,5,"","or","binary",5,-0.71005332669533,0.258414853526675,0.0593287727531688,2011.4,0.478052721088435,109.2
"CD007310","CD007310_pub3_data","3|7|Adverse events: cervical tear requiring suturing|","Adverse events: cervical tear requiring suturing",3,7,"","or","binary",3,0.415801188352857,0.842103691833095,0.968715250317037,2015,0.0305091733663162,141
"CD007310","CD007310_pub3_data","3|8|Side effects: nausea/vomiting|After pills","Side effects: nausea/vomiting",3,8,"After pills","or","binary",2,-0.228374899378116,0.283333935568951,0,2015,0.275510204081633,112
"CD007310","CD007310_pub3_data","3|9|Side effects: diarrhea|After pills","Side effects: diarrhea",3,9,"After pills","or","binary",2,0.0375812259608937,0.885231984300449,0,2015,0.0408163265306122,112
"CD007310","CD007310_pub3_data","6|5|Adverse events|","Adverse events",6,5,"","or","binary",2,-0.830984707723817,0.901117662553261,0,2016,0.0654761904761905,48.5
"CD007374","CD007374_pub3_data","1|1|Death|Cardiovascular disease-related death","Death",1,1,"Cardiovascular disease-related death","or","binary",2,-0.138910952468923,0.570067179932236,0,2011.5,0.0400157697614824,144.5
"CD007374","CD007374_pub3_data","1|1|Death|Death (any cause)","Death",1,1,"Death (any cause)","reported","reported",4,0,0.495848985275877,0,2013,0.0384440522036799,106
"CD007374","CD007374_pub3_data","1|13|Patient-oriented measures: behavioural changes at the end of follow-up|Diet: general","Patient-oriented measures: behavioural changes at the end of follow-up",1,13,"Diet: general","or","binary",2,0.0926709287779986,1.42592755825644,0,2012,0,71
"CD007374","CD007374_pub3_data","1|13|Patient-oriented measures: behavioural changes at the end of follow-up|Diet: specific diet","Patient-oriented measures: behavioural changes at the end of follow-up",1,13,"Diet: specific diet","or","binary",2,0.0926709287779986,1.42592755825644,0,2012,0,71
"CD007374","CD007374_pub3_data","1|13|Patient-oriented measures: behavioural changes at the end of follow-up|Exercise","Patient-oriented measures: behavioural changes at the end of follow-up",1,13,"Exercise","or","binary",2,0.0926709287779986,1.42592755825644,0,2012,0,71
"CD007374","CD007374_pub3_data","1|13|Patient-oriented measures: behavioural changes at the end of follow-up|Foot care","Patient-oriented measures: behavioural changes at the end of follow-up",1,13,"Foot care","or","binary",2,0.0926709287779986,1.42592755825644,0,2012,0,71
"CD007374","CD007374_pub3_data","1|13|Patient-oriented measures: behavioural changes at the end of follow-up|Home blood glucose monitoring","Patient-oriented measures: behavioural changes at the end of follow-up",1,13,"Home blood glucose monitoring","or","binary",2,0.0926709287779986,1.42592755825644,0,2012,0,71
"CD007374","CD007374_pub3_data","1|18|Non-fatal cardiovascular events|Stroke","Non-fatal cardiovascular events",1,18,"Stroke","or","binary",2,1.4244048155244,1.13064281340503,0,2011.5,0,144.5
"CD007374","CD007374_pub3_data","1|2|HbA1c [%]|","HbA1c [%]",1,2,"","reported","reported",4,-0.418492313337449,0.0553573447084432,0,2011.75,0,101.75
"CD007374","CD007374_pub3_data","1|22|Serious adverse events: emergency hospitalisation or death (including serious hypoglycaemic and CVD events)|","Serious adverse events: emergency hospitalisation or death (including serious hypoglycaemic and CVD events)",1,22,"","or","binary",2,-0.335394771892465,0.482040473472349,0.284496607740706,2011.5,0.23063276167948,144.5
"CD007374","CD007374_pub3_data","2|5|Glycaemic events|Hypoglycaemia","Glycaemic events",2,5,"Hypoglycaemia","reported","reported",2,0,0.102739779666367,0,2019.5,0.458333333333333,105
"CD007388","CD007388_pub3_data","5|1|Eclampsia|","Eclampsia",5,1,"","or","binary",2,0.60903416260314,0.567578411984049,0,2017.5,0.0241293532338308,231
"CD007388","CD007388_pub3_data","5|12|Caesarean section|","Caesarean section",5,12,"","or","binary",2,-0.0230257316972988,0.214122713649391,0,2017.5,0.319402985074627,231
"CD007388","CD007388_pub3_data","5|13|Vaginal birth|","Vaginal birth",5,13,"","or","binary",2,-0.43190932188075,0.387795605029655,0,2017.5,0.319900497512438,231
"CD007388","CD007388_pub3_data","5|14|Placental abruption|","Placental abruption",5,14,"","or","binary",2,0.109835178581545,0.469277842182326,0,2017.5,0.0340796019900498,231
"CD007388","CD007388_pub3_data","5|15|Postpartum haemorrhage|","Postpartum haemorrhage",5,15,"","or","binary",2,0.296239280736758,0.550254475968583,0,2017.5,0.0266169154228856,231
"CD007388","CD007388_pub3_data","5|2|Perinatal death|","Perinatal death",5,2,"","or","binary",2,-0.72175323153576,0.546081577357297,0.246276639216119,2017.5,0.160696517412935,231
"CD007388","CD007388_pub3_data","5|4|Neonatal death|","Neonatal death",5,4,"","or","binary",2,-0.426851755267239,0.444733646591468,0,2017.5,0.0606965174129353,231
"CD007388","CD007388_pub3_data","5|5|Maternal death|","Maternal death",5,5,"","or","binary",2,0,1.42083741657379,0,2017.5,0,231
"CD007388","CD007388_pub3_data","5|9|Severe morbidity: renal failure|","Severe morbidity: renal failure",5,9,"","or","binary",2,0.678423600249161,0.740003878794518,0,2017.5,0.0191542288557214,231
"CD007388","CD007388_pub3_data","7|1|Eclampsia|Short maintenance regimen for 12 hours","Eclampsia",7,1,"Short maintenance regimen for 12 hours","or","binary",2,-0.0305144503757802,1.41892222618309,0,2009,0,158
"CD007388","CD007388_pub3_data","8|4|Side effects: flushing|2g per hour vs 1g per hour maintenance dose","Side effects: flushing",8,4,"2g per hour vs 1g per hour maintenance dose","or","binary",2,0.354862066228849,0.972016959560466,0,2018,0.0277777777777778,49.5
"CD007388","CD007388_pub3_data","8|5|Side effects: nausea|2g per hour vs 1g per hour maintenance dose","Side effects: nausea",8,5,"2g per hour vs 1g per hour maintenance dose","or","binary",2,0.706904164914667,0.555097758289141,0,2018,0.0922939068100358,49.5
"CD007491","CD007491_pub3_data","1|1|Mortality at 3 months using IPD|","Mortality at 3 months using IPD",1,1,"","reported","reported",3,-0.113960041293218,0.246549468605665,1.90623888077163e-06,2001.33333333333,0,140
"CD007491","CD007491_pub3_data","1|2|Mortality at 6 months' follow-up (using published data, and IPD from Wilson and Shepperd)|","Mortality at 6 months' follow-up (using published data, and IPD from Wilson and Shepperd)",1,2,"","reported","reported",5,-0.132408624186046,0.128693664732346,0,2007.2,0,300.4
"CD007491","CD007491_pub3_data","1|3|Readmission to hospital after discharge from hospital at home or inpatient care (3 to 12 months' follow-up)|Readmission for older patients with a medical condition using IPD and published data. N=1856","Readmission to hospital after discharge from hospital at home or inpatient care (3 to 12 months' follow-up)",1,3,"Readmission for older patients with a medical condition using IPD and published data. N=1856","reported","reported",8,0.0479995252524796,0.134940328403763,0.0529967268096475,2006.25,0,219.625
"CD007491","CD007491_pub3_data","1|5|Living in residential care at follow-up|With a medical condition (6 months' follow-up)","Living in residential care at follow-up",1,5,"With a medical condition (6 months' follow-up)","reported","reported",4,-1.60378483618371,0.648200568289725,0.939251393583944,2010.5,0,317.75
"CD007569","CD007569_pub4_data","1|1|Return to work|NA","Return to work",1,1,NA,"or","binary",6,0.310199207293915,0.220004068207857,0.0271166011845036,2009.2,0.603324915824916,85.3333333333333
"CD007569","CD007569_pub4_data","1|2|Quality of life|NA","Quality of life",1,2,NA,"or","binary",2,-0.728805497712908,1.4269412843736,0,2003,0,62
"CD007569","CD007569_pub4_data","3|1|Return to work|NA","Return to work",3,1,NA,"reported","reported",6,0.203344952058777,0.0644319960726564,7.94474902435796e-07,2015.33333333333,0,72.3333333333333
"CD007569","CD007569_pub4_data","3|2|Quality of life|NA","Quality of life",3,2,NA,"or","binary",2,-0.8334291487147,1.4237519394665,0,2019,0,86.5
"CD007569","CD007569_pub4_data","4|1|Return to work (odds ratios)|NA","Return to work (odds ratios)",4,1,NA,"reported","reported",6,0.692203478710378,0.22153716605754,0,2007.16666666667,0,82.8333333333333
"CD007572","CD007572_pub4_data","1|1|Failure to induce clinical remission (6 to 12 weeks)|6.0 mg/kg IV ","Failure to induce clinical remission (6 to 12 weeks)",1,1,"6.0 mg/kg IV ","reported","reported",2,0,0.0515232017117034,0,2012,0.843181818181818,244.5
"CD007572","CD007572_pub4_data","1|10|Serious adverse events (8 weeks, sensitivity analysis)|","Serious adverse events (8 weeks, sensitivity analysis)",1,10,"","reported","reported",2,0,0.0452257806148136,0,2011.5,0.059458398744113,422
"CD007572","CD007572_pub4_data","1|11|Withdrawals due to adverse events|","Withdrawals due to adverse events",1,11,"","reported","reported",2,0,0.0445196008319321,0,2015.5,0.0897435897435897,99.5
"CD007572","CD007572_pub4_data","1|2|Failure to induce clinical remission (subgroup analyses anti-TNF pre-treated vs anti-TNF naive participants)|Anti-TNF naive","Failure to induce clinical remission (subgroup analyses anti-TNF pre-treated vs anti-TNF naive participants)",1,2,"Anti-TNF naive","reported","reported",2,0,0.0647685605551041,0,2022,0.818032786885246,219
"CD007572","CD007572_pub4_data","1|2|Failure to induce clinical remission (subgroup analyses anti-TNF pre-treated vs anti-TNF naive participants)|Anti-TNF pre-treated","Failure to induce clinical remission (subgroup analyses anti-TNF pre-treated vs anti-TNF naive participants)",1,2,"Anti-TNF pre-treated","reported","reported",2,0,0.0651235287548213,0,2013.5,0.90659645232816,271.5
"CD007572","CD007572_pub4_data","1|3|Failure to induce clinical remission (8 weeks, sensitivity analysis)|130 mg IV ","Failure to induce clinical remission (8 weeks, sensitivity analysis)",1,3,"130 mg IV ","or","binary",2,-0.687751098910404,0.229498137904528,0,2015,0.867260787992495,340.5
"CD007572","CD007572_pub4_data","1|3|Failure to induce clinical remission (8 weeks, sensitivity analysis)|6.0 mg IV ","Failure to induce clinical remission (8 weeks, sensitivity analysis)",1,3,"6.0 mg IV ","or","binary",2,-1.04541067518935,0.223378726920377,0,2015,0.863709677419355,343.5
"CD007572","CD007572_pub4_data","1|5|Disease activity (change in CDAI)|6.0 mg/kg IV once","Disease activity (change in CDAI)",1,5,"6.0 mg/kg IV once","or","binary",2,-0.532134964466567,1.42053959869341,0,2017.5,0,135
"CD007572","CD007572_pub4_data","1|6|Failure to induce endoscopic remission|","Failure to induce endoscopic remission",1,6,"","reported","reported",2,0,0.99615317764673,0,2015,0.964285714285714,126
"CD007572","CD007572_pub4_data","1|7|Failure to induce endoscopic response|","Failure to induce endoscopic response",1,7,"","reported","reported",2,0,0.996461721453656,0,2015,0.883928571428571,126
"CD007572","CD007572_pub4_data","1|8|Quality of life (IBDQ score)|130 mg IV once","Quality of life (IBDQ score)",1,8,"130 mg IV once","or","binary",2,-0.696640974618278,1.4165605759722,0,2015,0,340.5
"CD007572","CD007572_pub4_data","1|8|Quality of life (IBDQ score)|6.0 mg/kg IV once","Quality of life (IBDQ score)",1,8,"6.0 mg/kg IV once","reported","reported",2,0,2.73464895036928,0,2015,0,340.5
"CD007572","CD007572_pub4_data","1|9|Serious adverse events|","Serious adverse events",1,9,"","reported","reported",4,0,0.045185148293718,0,2017,0.0596399136577708,270
"CD007639","CD007639_pub3_data","2|1|Treatment time (minutes)|2 to 4 weeks","Treatment time (minutes)",2,1,"2 to 4 weeks","or","binary",2,0,1.43020191368069,0,2008,0,43
"CD007639","CD007639_pub3_data","2|1|Treatment time (minutes)|Single dose","Treatment time (minutes)",2,1,"Single dose","or","binary",4,-0.109856842946627,1.01706623497817,0,2006.75,0,43.5
"CD007639","CD007639_pub3_data","2|1|Treatment time (minutes)|Up to 1 week","Treatment time (minutes)",2,1,"Up to 1 week","or","binary",2,0,1.42695166044055,0,2011.5,0,59
"CD007639","CD007639_pub3_data","2|10|Adherence|","Adherence",2,10,"","or","binary",2,0,1.4411929215192,0,2009,0,25
"CD007639","CD007639_pub3_data","2|11|Adverse events|2 to 3 weeks","Adverse events",2,11,"2 to 3 weeks","or","binary",2,-0.891496849785506,1.78812171114553,5.19376484708991,2008,0.787878787878788,40
"CD007639","CD007639_pub3_data","2|11|Adverse events|Single dose","Adverse events",2,11,"Single dose","or","binary",2,-0.449540769966406,0.713225322291115,0.36459473380764,2004.5,0.475757575757576,48.5
"CD007639","CD007639_pub3_data","2|12|FEV1: reduction over 10%|Single dose","FEV1: reduction over 10%",2,12,"Single dose","or","binary",2,0.341799804302914,0.559266007749319,0,2004.5,0.132034632034632,48.5
"CD007639","CD007639_pub3_data","2|14|Change in FEV1 |","Change in FEV1 ",2,14,"","or","binary",2,0.00242564707272092,1.42659517420693,0,2014,0,56
"CD007639","CD007639_pub3_data","2|15|Device malfunctions|Single dose","Device malfunctions",2,15,"Single dose","or","binary",2,-1.91950845307685,1.57592098138322,2.01989149284919,2007,0.0943396226415094,65
"CD007639","CD007639_pub3_data","2|2|Deposition (serum Cmax)|2 to 3 weeks","Deposition (serum Cmax)",2,2,"2 to 3 weeks","or","binary",2,0,1.42892502178493,0,2008,0,47
"CD007639","CD007639_pub3_data","2|2|Deposition (serum Cmax)|4 weeks","Deposition (serum Cmax)",2,2,"4 weeks","or","binary",2,0,1.42466288108671,0,2013.5,0,74
"CD007639","CD007639_pub3_data","2|2|Deposition (serum Cmax)|Single dose","Deposition (serum Cmax)",2,2,"Single dose","or","binary",5,-0.0884270449853997,0.912490256246617,0,2008,0,40.4
"CD007639","CD007639_pub3_data","2|3|Deposition (serum AUC)|Single dose","Deposition (serum AUC)",2,3,"Single dose","or","binary",5,-0.0884270449853997,0.912490256246617,0,2008,0,40.4
"CD007639","CD007639_pub3_data","2|3|Deposition (serum AUC)|Up to 4 weeks","Deposition (serum AUC)",2,3,"Up to 4 weeks","or","binary",3,0,1.16463648954742,0,2011.33333333333,0,64
"CD007639","CD007639_pub3_data","2|6|Deposition (sputum Cmax)|Single dose","Deposition (sputum Cmax)",2,6,"Single dose","or","binary",2,-0.215789695178405,1.4254468557001,0,2008,0,67
"CD007639","CD007639_pub3_data","2|7|Deposition (sputum AUC)|Single dose","Deposition (sputum AUC)",2,7,"Single dose","or","binary",2,-0.215789695178405,1.4254468557001,0,2008,0,67
"CD007639","CD007639_pub3_data","3|1|Treatment time |","Treatment time ",3,1,"","or","binary",2,0.458735579124459,1.44061118381109,0,2019,0,33
"CD007674","CD007674_pub3_data","1|1|Reduction in anxiety severity|3 to 6 months post-treatment","Reduction in anxiety severity",1,1,"3 to 6 months post-treatment","or","binary",8,-0.197896409750713,0.715197522778295,0,2007.875,0,50.75
"CD007674","CD007674_pub3_data","1|1|Reduction in anxiety severity|Post-treatment","Reduction in anxiety severity",1,1,"Post-treatment","or","binary",18,-0.120895818102531,0.477322485564339,0,2009.55555555556,0,60.8333333333333
"CD007674","CD007674_pub3_data","1|2|Clinical recovery or improvement|3 to 6 months post-treatment","Clinical recovery or improvement",1,2,"3 to 6 months post-treatment","or","binary",3,-0.582854969173808,0.420682200951145,0,2007,0.605616605616606,36.6666666666667
"CD007674","CD007674_pub3_data","1|2|Clinical recovery or improvement|Post-treatment","Clinical recovery or improvement",1,2,"Post-treatment","or","binary",15,0.907134142071363,0.262897430739202,0.603772655883126,2008.6,0.313444133399042,68.4666666666667
"CD007674","CD007674_pub3_data","1|3|Symptoms of worry|3 to 6 months post-treatment","Symptoms of worry",1,3,"3 to 6 months post-treatment","or","binary",4,-0.143723703339379,1.00974964497643,0,2008.5,0,59.25
"CD007674","CD007674_pub3_data","1|3|Symptoms of worry|Post-treatment","Symptoms of worry",1,3,"Post-treatment","or","binary",10,-0.206220455578781,0.639323204208469,0,2008.8,0,71.4
"CD007674","CD007674_pub3_data","1|4|Symptoms of depression|3 to 6 months post-treatment","Symptoms of depression",1,4,"3 to 6 months post-treatment","or","binary",6,-0.0465282239038523,0.825422248700546,0,2006.33333333333,0,51.8333333333333
"CD007674","CD007674_pub3_data","1|4|Symptoms of depression|Post-treatment","Symptoms of depression",1,4,"Post-treatment","or","binary",16,-0.0725421360250088,0.50714066332119,0,2008.0625,0,53.9375
"CD007674","CD007674_pub3_data","1|5|Dropout rates|3 to 6 months post-treatment","Dropout rates",1,5,"3 to 6 months post-treatment","or","binary",6,-0.161905993477377,0.232941834046392,0,2007.16666666667,0.230861726874658,70.8333333333333
"CD007674","CD007674_pub3_data","1|5|Dropout rates|Post-treatment","Dropout rates",1,5,"Post-treatment","or","binary",18,0.222238108542751,0.238473362879094,0.444181851809371,2008.77777777778,0.172799557262083,68.5555555555556
"CD007674","CD007674_pub3_data","1|7|Quality of life|Mental component - 6 months post-treatment","Quality of life",1,7,"Mental component - 6 months post-treatment","or","binary",3,-0.380484425127327,1.16423509822553,0,2012,0,69.3333333333333
"CD007674","CD007674_pub3_data","1|7|Quality of life|Mental component - post-treatment","Quality of life",1,7,"Mental component - post-treatment","or","binary",8,-0.259751279045837,0.716634076300313,0,2012.375,0,78.875
"CD007674","CD007674_pub3_data","1|7|Quality of life|Physical component - 6 months post-treatment","Quality of life",1,7,"Physical component - 6 months post-treatment","or","binary",3,-0.380484425127327,1.16423509822553,0,2012,0,69.3333333333333
"CD007674","CD007674_pub3_data","1|7|Quality of life|Physical component - post-treatment","Quality of life",1,7,"Physical component - post-treatment","or","binary",7,-0.319712137897875,0.766445932604828,0,2011.57142857143,0,80.8571428571429
"CD007674","CD007674_pub3_data","2|1|Reduction in anxiety severity|4 to 6 months post-treatment","Reduction in anxiety severity",2,1,"4 to 6 months post-treatment","or","binary",2,0.0556859968432456,1.43483520879548,0,2020.5,0,36
"CD007674","CD007674_pub3_data","2|1|Reduction in anxiety severity|Post-treatment","Reduction in anxiety severity",2,1,"Post-treatment","or","binary",2,0.0611743581706148,1.43246910010154,0,2020.5,0,46.5
"CD007674","CD007674_pub3_data","2|2|Symptoms of depression|4 to 6 months post-treatment","Symptoms of depression",2,2,"4 to 6 months post-treatment","or","binary",2,0.087829566421801,1.43543189502138,0,2020.5,0,34.5
"CD007674","CD007674_pub3_data","2|2|Symptoms of depression|Post-treatment","Symptoms of depression",2,2,"Post-treatment","or","binary",2,0.0742124865452706,1.43300650322155,0,2020.5,0,43.5
"CD007674","CD007674_pub3_data","2|3|Dropout rates|4 to 6 months post-treatment","Dropout rates",2,3,"4 to 6 months post-treatment","or","binary",2,0.335335180595346,0.37770876241971,0,2020.5,0.317391304347826,60
"CD007674","CD007674_pub3_data","2|3|Dropout rates|Post-treatment","Dropout rates",2,3,"Post-treatment","or","binary",2,0.309447457278657,0.408900883743777,0,2020.5,0.219565217391304,60
"CD007674","CD007674_pub3_data","3|1|Reduction in anxiety severity - individual or group intervention|Post-treatment - group intervention","Reduction in anxiety severity - individual or group intervention",3,1,"Post-treatment - group intervention","or","binary",5,-0.0754671383880338,0.904213720861413,0,2010.2,0,56
"CD007674","CD007674_pub3_data","3|1|Reduction in anxiety severity - individual or group intervention|Post-treatment - individual intervention","Reduction in anxiety severity - individual or group intervention",3,1,"Post-treatment - individual intervention","or","binary",13,-0.199643096712969,0.56225943870054,0,2009.30769230769,0,61.6153846153846
"CD007674","CD007674_pub3_data","3|2|Clinical recovery or improvement - individual or group intervention|Post-treatment group intervention","Clinical recovery or improvement - individual or group intervention",3,2,"Post-treatment group intervention","or","binary",4,1.43865441473789,0.570744910994554,0.767673408139447,2008.5,0.209963252726411,61
"CD007674","CD007674_pub3_data","3|2|Clinical recovery or improvement - individual or group intervention|Post-treatment individual intervention","Clinical recovery or improvement - individual or group intervention",3,2,"Post-treatment individual intervention","or","binary",11,0.747344904580002,0.300719957344778,0.588944448138649,2008.63636363636,0.349539990387593,71.0909090909091
"CD007674","CD007674_pub3_data","3|3|Reduction in anxiety severity - waiting list or other comparator|Post-treatment - other minimal management comparator","Reduction in anxiety severity - waiting list or other comparator",3,3,"Post-treatment - other minimal management comparator","or","binary",13,-0.172192701229366,0.561462928411622,0,2009,0,66.8461538461538
"CD007674","CD007674_pub3_data","3|3|Reduction in anxiety severity - waiting list or other comparator|Post-treatment - waiting-list comparator","Reduction in anxiety severity - waiting list or other comparator",3,3,"Post-treatment - waiting-list comparator","or","binary",7,-0.23100075320345,0.76718966063744,0,2009.71428571429,0,37.7142857142857
"CD007674","CD007674_pub3_data","3|4|Clinical recovery or improvement - waiting list or other comparator|Post-treatment other comparator (minimal management)","Clinical recovery or improvement - waiting list or other comparator",3,4,"Post-treatment other comparator (minimal management)","or","binary",15,0.781369619720424,0.290479549417221,0.780506553941991,2008.6,0.352592911998801,65.6
"CD007674","CD007674_pub3_data","3|4|Clinical recovery or improvement - waiting list or other comparator|Post-treatment waiting list","Clinical recovery or improvement - waiting list or other comparator",3,4,"Post-treatment waiting list","or","binary",6,1.74335987836954,0.462950220404545,0.353860534142518,2006.33333333333,0.191895141895142,27.6666666666667
"CD007674","CD007674_pub3_data","3|5|Reduction in anxiety severity - GAD versus mixed anxiety disorders|Post-treatment - GAD only","Reduction in anxiety severity - GAD versus mixed anxiety disorders",3,5,"Post-treatment - GAD only","or","binary",10,-0.0594931096834459,0.640924563646774,0,2007.9,0,70.3
"CD007674","CD007674_pub3_data","3|5|Reduction in anxiety severity - GAD versus mixed anxiety disorders|Post-treatment - mixed anxiety disorders","Reduction in anxiety severity - GAD versus mixed anxiety disorders",3,5,"Post-treatment - mixed anxiety disorders","or","binary",7,-0.187230234479616,0.764658573240793,0,2010.71428571429,0,49.7142857142857
"CD007674","CD007674_pub3_data","3|6|Clinical recovery or improvement - GAD versus mixed anxiety disorders|Post-treatment - GAD only","Clinical recovery or improvement - GAD versus mixed anxiety disorders",3,6,"Post-treatment - GAD only","or","binary",9,1.01114478286138,0.350921893540105,0.650976688556103,2005.44444444444,0.297674378710338,75.5555555555556
"CD007674","CD007674_pub3_data","3|6|Clinical recovery or improvement - GAD versus mixed anxiety disorders|Post-treatment - mix of anxiety diagnoses","Clinical recovery or improvement - GAD versus mixed anxiety disorders",3,6,"Post-treatment - mix of anxiety diagnoses","or","binary",5,0.30588557401524,0.244264270647677,1.40500388863633e-06,2012.4,0.367481481481481,57.8
"CD007674","CD007674_pub3_data","3|7|Reduction in anxiety severity - adapted for older people versus not adapted|Post-treatment - adapted for older people","Reduction in anxiety severity - adapted for older people versus not adapted",3,7,"Post-treatment - adapted for older people","or","binary",5,-0.276754637822237,0.91362796878046,0,2007.4,0,38.2
"CD007674","CD007674_pub3_data","3|7|Reduction in anxiety severity - adapted for older people versus not adapted|Post-treatment - not adapted for older people","Reduction in anxiety severity - adapted for older people versus not adapted",3,7,"Post-treatment - not adapted for older people","or","binary",13,-0.0623827543574551,0.559796416124073,0,2010.38461538462,0,69.5384615384615
"CD007674","CD007674_pub3_data","3|8|Clinical recovery or improvement - adapted for older people versus not adapted|Post-treatment - adapted for older people","Clinical recovery or improvement - adapted for older people versus not adapted",3,8,"Post-treatment - adapted for older people","or","binary",6,1.53971185768529,0.538775549738514,0.868901351729611,2006.66666666667,0.18454525954526,39.3333333333333
"CD007674","CD007674_pub3_data","3|8|Clinical recovery or improvement - adapted for older people versus not adapted|Post-treatment - not adapted for older people","Clinical recovery or improvement - adapted for older people versus not adapted",3,8,"Post-treatment - not adapted for older people","or","binary",9,0.675410363190754,0.30625640937582,0.571104808733904,2009.88888888889,0.39937671596823,87.8888888888889
"CD007674","CD007674_pub3_data","4|1|Reduction in anxiety severity - high quality studies|3 to 6 months post-treatment","Reduction in anxiety severity - high quality studies",4,1,"3 to 6 months post-treatment","or","binary",3,-0.511031935325012,1.16652874482985,0,2011.33333333333,0,64
"CD007674","CD007674_pub3_data","4|1|Reduction in anxiety severity - high quality studies|Post-treatment","Reduction in anxiety severity - high quality studies",4,1,"Post-treatment","or","binary",4,-0.206192811301024,1.00687532335303,0,2012.25,0,89
"CD007674","CD007674_pub3_data","4|2|Reduction in anxiety severity - available cases (no imputed data)|Post-treatment","Reduction in anxiety severity - available cases (no imputed data)",4,2,"Post-treatment","or","binary",17,-0.119587838478569,0.491179603921463,0,2009.17647058824,0,62
"CD007674","CD007674_pub3_data","4|3|Clinical recovery or improvement - high quality studies|Post-treatment","Clinical recovery or improvement - high quality studies",4,3,"Post-treatment","or","binary",4,0.48175605942017,0.279865406098948,0.134320917292212,2012.25,0.502403273809524,99.75
"CD007674","CD007674_pub3_data","4|4|Clinical recovery or improvement - best and worst case scenario|Post-treatment worst-case scenario","Clinical recovery or improvement - best and worst case scenario",4,4,"Post-treatment worst-case scenario","or","binary",14,-0.0200103083363624,0.292671384427163,0.808308643831142,2007.92857142857,0.49403797036722,74.6428571428571
"CD007693","CD007693_pub3_data","1|1|Fluorosis|At 12 months or younger versus older than 12 months","Fluorosis",1,1,"At 12 months or younger versus older than 12 months","reported","reported",2,-0.0235398618530727,0.0974327403941606,0,1999.5,NA,0
"CD007693","CD007693_pub3_data","10|1|Fluorosis|Less than 1000 ppm versus 1000 ppm or higher","Fluorosis",10,1,"Less than 1000 ppm versus 1000 ppm or higher","reported","reported",4,-0.234153552104268,0.136155045588668,0.00660373433814842,NA,NA,0
"CD007693","CD007693_pub3_data","12|1|Fluorosis|Fluoride varnish applied before 4 years of age versus no varnish","Fluorosis",12,1,"Fluoride varnish applied before 4 years of age versus no varnish","reported","reported",2,0.779447086671522,0.204276307566737,0.038693825,2011,NA,0
"CD007693","CD007693_pub3_data","2|1|Fluorosis|Younger than 24 months versus older than 24 months","Fluorosis",2,1,"Younger than 24 months versus older than 24 months","reported","reported",7,0.804671630944726,0.312525055223082,0.477751508835099,2002.83333333333,NA,0
"CD007693","CD007693_pub3_data","3|1|Fluorosis|Younger than 12 months versus older than 12 months","Fluorosis",3,1,"Younger than 12 months versus older than 12 months","reported","reported",8,0.197317772302259,0.111926589939489,0.0446181375407956,2008.75,NA,0
"CD007693","CD007693_pub3_data","3|1|Fluorosis|Younger than 24 months versus older than 24 months","Fluorosis",3,1,"Younger than 24 months versus older than 24 months","reported","reported",6,0.116100360817269,0.122624246288975,0.0318880462290786,2010.5,NA,0
"CD007693","CD007693_pub3_data","3|1|Fluorosis|Younger than 4 years versus older than 4 years","Fluorosis",3,1,"Younger than 4 years versus older than 4 years","reported","reported",2,0.472218859429715,0.376467736469941,0.20441275,2009,NA,0
"CD007693","CD007693_pub3_data","4|1|Fluorosis|Less than twice per day versus twice or more per day","Fluorosis",4,1,"Less than twice per day versus twice or more per day","reported","reported",2,0.487131958106397,0.357609282993673,0,2013,NA,0
"CD007693","CD007693_pub3_data","5|1|Fluorosis|Less than once per day versus once or more per day","Fluorosis",5,1,"Less than once per day versus once or more per day","reported","reported",2,-0.472335542618771,0.0852402534354752,0,2005.5,NA,0
"CD007693","CD007693_pub3_data","5|1|Fluorosis|Less than twice a day versus twice or more per day","Fluorosis",5,1,"Less than twice a day versus twice or more per day","reported","reported",4,-0.132914766109399,0.108425400169935,0,NA,NA,0
"CD007693","CD007693_pub3_data","6|1|Fluorosis|Less than half the brush versus half the brush or more","Fluorosis",6,1,"Less than half the brush versus half the brush or more","reported","reported",2,-0.259032118644068,0.324314593533134,0.0656186550000001,2013,NA,0
"CD007693","CD007693_pub3_data","7|1|Fluorosis|Pea-sized amount or less versus more than pea-sized amount","Fluorosis",7,1,"Pea-sized amount or less versus more than pea-sized amount","reported","reported",4,-0.080378587379579,0.169127832908989,0.0621001869406265,NA,NA,0
"CD007693","CD007693_pub3_data","9|1|Fluorosis|Less than 1000 ppm versus 1000 ppm or higher","Fluorosis",9,1,"Less than 1000 ppm versus 1000 ppm or higher","reported","reported",2,-0.114858170494855,0.273280161936621,0,2013,NA,0
"CD007784","CD007784_pub3_data","1|1|Major cardiovascular events|","Major cardiovascular events",1,1,"","or","binary",14,-0.420020073314543,0.0565555591794932,0.011987868797296,2001.35714285714,0.169430717162979,2582.57142857143
"CD007784","CD007784_pub3_data","1|11|End of treatment kidney function|CrCl [mL/min]","End of treatment kidney function",1,11,"CrCl [mL/min]","or","binary",7,-0.190539120279353,0.765269833535884,0,2002.14285714286,0,45.5714285714286
"CD007784","CD007784_pub3_data","1|12|End of treatment proteinuria|","End of treatment proteinuria",1,12,"","or","binary",7,-0.0431090670801897,0.764297586567652,0,2001.85714285714,0,50.8571428571429
"CD007784","CD007784_pub3_data","1|13|Elevated liver enzymes|","Elevated liver enzymes",1,13,"","or","binary",7,-0.225164235979941,0.317082925708406,0,1999.14285714286,0.00251659821006977,1141.57142857143
"CD007784","CD007784_pub3_data","1|15|Cancer|","Cancer",1,15,"","or","binary",2,0.0306473345543493,0.123282978957381,0,2000,0.0489463235475285,2790.5
"CD007784","CD007784_pub3_data","1|17|Elevated creatine kinase|","Elevated creatine kinase",1,17,"","or","binary",7,-0.115397098502727,0.594904835412565,0,1997.14285714286,0.00151478382193494,644.857142857143
"CD007784","CD007784_pub3_data","1|2|Death|","Death",1,2,"","or","binary",13,-0.21546663990683,0.0841495461246972,0.0284427642479478,2002.30769230769,0.0883016144616984,2690.61538461538
"CD007784","CD007784_pub3_data","1|21|HDL cholesterol|","HDL cholesterol",1,21,"","reported","reported",2,0,1.55152237012393,0,2009.5,0,54
"CD007784","CD007784_pub3_data","1|22|Subgroup analysis (cardiovascular disease): death|Cardiovascular disease","Subgroup analysis (cardiovascular disease): death",1,22,"Cardiovascular disease","or","binary",8,-0.237114693596174,0.0472849022564165,0,2000,0.095244901729948,2674.375
"CD007784","CD007784_pub3_data","1|22|Subgroup analysis (cardiovascular disease): death|No cardiovascular disease","Subgroup analysis (cardiovascular disease): death",1,22,"No cardiovascular disease","or","binary",4,-0.363561588771641,0.119678284965125,0.0213071901973527,2006,0.0601631013000581,3365.5
"CD007784","CD007784_pub3_data","1|23|Subgroup analysis (cardiovascular disease): major cardiovascular events|Cardiovascular disease","Subgroup analysis (cardiovascular disease): major cardiovascular events",1,23,"Cardiovascular disease","or","binary",9,-0.388127905864907,0.0613921305333076,0.00752886768401771,1999.77777777778,0.216002352642546,2487.77777777778
"CD007784","CD007784_pub3_data","1|23|Subgroup analysis (cardiovascular disease): major cardiovascular events|No cardiovascular disease","Subgroup analysis (cardiovascular disease): major cardiovascular events",1,23,"No cardiovascular disease","or","binary",5,-0.51957826556938,0.129051235956561,0.0394054615786598,2004.2,0.0856017732997592,2753.2
"CD007784","CD007784_pub3_data","1|24|Subgroup analysis (statin dose): major cardiovascular death|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): major cardiovascular death",1,24,"< 20 mg/day simvastatin equivalent","or","binary",4,-0.797815837192494,0.15730810517161,0,2002.5,0.118234735542312,907.5
"CD007784","CD007784_pub3_data","1|24|Subgroup analysis (statin dose): major cardiovascular death|≥ 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): major cardiovascular death",1,24,"≥ 20 mg/day simvastatin equivalent","or","binary",10,-0.356594614321932,0.0466425279648321,0.00447238535051608,2000.9,0.189909109811247,3252.6
"CD007784","CD007784_pub3_data","1|25|Subgroup analysis (statin dose): death|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): death",1,25,"< 20 mg/day simvastatin equivalent","or","binary",4,-0.336845006177059,0.15974774071166,0.028385561636837,2007,0.0416262014211596,2467.25
"CD007784","CD007784_pub3_data","1|25|Subgroup analysis (statin dose): death|≥ 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): death",1,25,"≥ 20 mg/day simvastatin equivalent","or","binary",8,-0.250864706232638,0.0456481285127051,0,1999.5,0.104513351669397,3123.5
"CD007784","CD007784_pub3_data","1|26|Subgroup analysis (statin dose): withdrawal due to adverse events|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): withdrawal due to adverse events",1,26,"< 20 mg/day simvastatin equivalent","or","binary",5,0.956119860066823,0.637428385301053,0.0586378442268158,1998.4,0.0244444444444444,50
"CD007784","CD007784_pub3_data","1|26|Subgroup analysis (statin dose): withdrawal due to adverse events|≥ 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): withdrawal due to adverse events",1,26,"≥ 20 mg/day simvastatin equivalent","or","binary",7,0.10069162020837,0.222131972913122,0.133902111593114,1999.57142857143,0.144312561709671,562.714285714286
"CD007784","CD007784_pub3_data","1|27|Subgroup analysis (statin dose): total cholesterol|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): total cholesterol",1,27,"< 20 mg/day simvastatin equivalent","or","binary",15,0.0185795038727226,0.525655916932032,0,1998.6,0,34
"CD007784","CD007784_pub3_data","1|28|Subgroup analysis (statin dose): LDL cholesterol|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): LDL cholesterol",1,28,"< 20 mg/day simvastatin equivalent","or","binary",12,0.029159731379922,0.587496167896142,0,1998.08333333333,0,36.0833333333333
"CD007784","CD007784_pub3_data","1|29|Subgroup analysis (statin dose): HDL cholesterol|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): HDL cholesterol",1,29,"< 20 mg/day simvastatin equivalent","or","binary",12,0.0207397473111264,0.587496167896142,0,1998.08333333333,0,36.0833333333333
"CD007784","CD007784_pub3_data","1|3|Rhabdomyolysis|","Rhabdomyolysis",1,3,"","or","binary",2,0.711605816880822,1.2659867784006,0,1995,0,1309
"CD007784","CD007784_pub3_data","1|30|Subgroup analysis (statin dose): triglycerides|< 20 mg/day simvastatin equivalent","Subgroup analysis (statin dose): triglycerides",1,30,"< 20 mg/day simvastatin equivalent","or","binary",10,0.00210244901643149,0.642175414877826,0,1999.6,0,39.8
"CD007784","CD007784_pub3_data","1|31|Subgroup analysis (age): total cholesterol|< 55 years","Subgroup analysis (age): total cholesterol",1,31,"< 55 years","or","binary",14,0.0338277667427936,0.542359969663233,0,2000.42857142857,0,112.285714285714
"CD007784","CD007784_pub3_data","1|32|Subgroup analysis (age): withdrawal due to adverse events|< 55 years","Subgroup analysis (age): withdrawal due to adverse events",1,32,"< 55 years","or","binary",6,0.211829688660912,0.465667684242497,0.432539093807656,1999.16666666667,0.12811398985993,185.166666666667
"CD007784","CD007784_pub3_data","1|32|Subgroup analysis (age): withdrawal due to adverse events|≥ 55 years","Subgroup analysis (age): withdrawal due to adverse events",1,32,"≥ 55 years","or","binary",6,0.296458343024614,0.259459134691598,0.11530624464241,1999,0.0606210358383904,513
"CD007784","CD007784_pub3_data","1|33|Subgroup analysis (age): LDL cholesterol|< 55 years","Subgroup analysis (age): LDL cholesterol",1,33,"< 55 years","or","binary",10,0.0321043670848072,0.642205854512159,0,1998.7,0,120.3
"CD007784","CD007784_pub3_data","1|34|Subgroup analysis (age): HDL cholesterol|< 55 years","Subgroup analysis (age): HDL cholesterol",1,34,"< 55 years","or","binary",9,0.0532277540762924,0.677104920899044,0,2000,0,73
"CD007784","CD007784_pub3_data","1|35|Subgroup analysis (age): triglycerides|< 55 years","Subgroup analysis (age): triglycerides",1,35,"< 55 years","or","binary",6,-0.00653958625545606,0.829328481122738,0,1999.33333333333,0,38
"CD007784","CD007784_pub3_data","1|36|Subgroup analysis (diabetes mellitus): withdrawal due to adverse events|< 20% with DM ","Subgroup analysis (diabetes mellitus): withdrawal due to adverse events",1,36,"< 20% with DM ","or","binary",8,0.0233597607435471,0.207927937405678,0.0798764566874809,1999.875,0.116698216562325,442.625
"CD007784","CD007784_pub3_data","1|36|Subgroup analysis (diabetes mellitus): withdrawal due to adverse events|≥ 20% with DM","Subgroup analysis (diabetes mellitus): withdrawal due to adverse events",1,36,"≥ 20% with DM","or","binary",5,0.492769964136613,0.193009430391779,2.93177320367671e-06,1996.6,0.0797648843382632,135.6
"CD007784","CD007784_pub3_data","1|37|Subgroup analysis (diabetes mellitus): death|< 20% with DM","Subgroup analysis (diabetes mellitus): death",1,37,"< 20% with DM","or","binary",7,-0.328673276689356,0.0835703283573654,0.0104533017653314,2000.42857142857,0.0537619839870208,3810.28571428571
"CD007784","CD007784_pub3_data","1|37|Subgroup analysis (diabetes mellitus): death|≥ 20% with DM","Subgroup analysis (diabetes mellitus): death",1,37,"≥ 20% with DM","or","binary",6,-0.204006429045253,0.0735494787296661,0.000654009333925824,2004.5,0.114636032111522,1384.66666666667
"CD007784","CD007784_pub3_data","1|38|Subgroup analysis (diabetes mellitus): major cardiovascular death|< 20% with DM","Subgroup analysis (diabetes mellitus): major cardiovascular death",1,38,"< 20% with DM","or","binary",9,-0.488422015875159,0.0925697762491557,0.0263817017996821,2000.88888888889,0.129560759186563,3001.55555555556
"CD007784","CD007784_pub3_data","1|38|Subgroup analysis (diabetes mellitus): major cardiovascular death|≥ 20% with DM","Subgroup analysis (diabetes mellitus): major cardiovascular death",1,38,"≥ 20% with DM","or","binary",5,-0.370644657082056,0.0805249563192163,0.00780868177441998,2002.2,0.241196641520529,1828.4
"CD007784","CD007784_pub3_data","1|39|Subgroup analysis (diabetes mellitus): total cholesterol|< 20% with DM or not reported","Subgroup analysis (diabetes mellitus): total cholesterol",1,39,"< 20% with DM or not reported","or","binary",15,-0.090565247778078,0.522223346752661,0,2002.86666666667,0,117.266666666667
"CD007784","CD007784_pub3_data","1|40|Subgroup analysis (diabetes mellitus): LDL cholesterol|< 20% with DM or not reported","Subgroup analysis (diabetes mellitus): LDL cholesterol",1,40,"< 20% with DM or not reported","or","binary",14,-0.0947966443798604,0.540145499102143,0,2002.92857142857,0,124.928571428571
"CD007784","CD007784_pub3_data","1|41|Subgroup analysis (diabetes mellitus): HDL cholesterol|< 20% with DM or not reported","Subgroup analysis (diabetes mellitus): HDL cholesterol",1,41,"< 20% with DM or not reported","or","binary",13,-0.113935417694449,0.561210992899312,0,2002.07692307692,0,74.8461538461538
"CD007784","CD007784_pub3_data","1|42|Subgroup analysis (diabetes mellitus): triglycerides|< 20% with DM or not reported","Subgroup analysis (diabetes mellitus): triglycerides",1,42,"< 20% with DM or not reported","or","binary",11,-0.115963442572918,0.60973568058575,0,2003.36363636364,0,69.9090909090909
"CD007784","CD007784_pub3_data","1|43|Subgroup analysis (baseline cholesterol): total cholesterol|≥ 230 mg/dL","Subgroup analysis (baseline cholesterol): total cholesterol",1,43,"≥ 230 mg/dL","or","binary",11,-0.0197224727822246,0.612827768086857,0,1997.72727272727,0,43.2727272727273
"CD007784","CD007784_pub3_data","1|44|Subgroup analysis (baseline cholesterol): LDL cholesterol|≥ 230 mg/dL","Subgroup analysis (baseline cholesterol): LDL cholesterol",1,44,"≥ 230 mg/dL","or","binary",10,-0.0244090545598009,0.642669411777776,0,1998.4,0,44.8
"CD007784","CD007784_pub3_data","1|45|Subgroup analysis (baseline cholesterol): withdrawal due to adverse events|< 230 mg/dL","Subgroup analysis (baseline cholesterol): withdrawal due to adverse events",1,45,"< 230 mg/dL","or","binary",7,0.308117395622739,0.365235145935533,0.338747621830456,2002.57142857143,0.083056749962826,256.857142857143
"CD007784","CD007784_pub3_data","1|45|Subgroup analysis (baseline cholesterol): withdrawal due to adverse events|≥ 230 mg/dL","Subgroup analysis (baseline cholesterol): withdrawal due to adverse events",1,45,"≥ 230 mg/dL","or","binary",6,0.0120650838629225,0.161496471723248,0,1994,0.125168817408356,403.5
"CD007784","CD007784_pub3_data","1|46|Subgroup analysis (baseline cholesterol): HDL cholesterol|≥ 230 mg/dL","Subgroup analysis (baseline cholesterol): HDL cholesterol",1,46,"≥ 230 mg/dL","or","binary",10,-0.034484782985278,0.642669411777776,0,1998.4,0,44.8
"CD007784","CD007784_pub3_data","1|47|Subgroup analysis (baseline cholesterol): triglycerides|≥ 230 mg/dL","Subgroup analysis (baseline cholesterol): triglycerides",1,47,"≥ 230 mg/dL","or","binary",9,-0.072239939846707,0.676526760501054,0,1998.11111111111,0,47.8888888888889
"CD007784","CD007784_pub3_data","1|48|Subgroup analysis (allocation concealment): death|High/Unclear RoB","Subgroup analysis (allocation concealment): death",1,48,"High/Unclear RoB","or","binary",5,-0.0364769956880256,0.137030796619256,0,2004.2,0.10669663232212,567.6
"CD007784","CD007784_pub3_data","1|48|Subgroup analysis (allocation concealment): death|Low RoB","Subgroup analysis (allocation concealment): death",1,48,"Low RoB","or","binary",8,-0.276289629091563,0.0411642005712558,0,2001.125,0.0663333648709595,4017.75
"CD007784","CD007784_pub3_data","1|49|Subgroup analysis (allocation concealment): total cholesterol|Low RoB","Subgroup analysis (allocation concealment): total cholesterol",1,49,"Low RoB","or","binary",5,0.0242906982606691,0.904431444123737,0,2004.4,0,216.6
"CD007784","CD007784_pub3_data","1|5|Myocardial infarction|","Myocardial infarction",1,5,"","or","binary",10,-0.59269620601343,0.141918697422104,0,2002.7,0.0581047497837868,947.5
"CD007784","CD007784_pub3_data","1|50|Subgroup analysis (allocation concealment): major cardiovascular events|High/Unclear RoB","Subgroup analysis (allocation concealment): major cardiovascular events",1,50,"High/Unclear RoB","or","binary",5,-0.572865604320766,0.116583648104295,0.000121896002562231,2002.4,0.124723258136753,973.8
"CD007784","CD007784_pub3_data","1|50|Subgroup analysis (allocation concealment): major cardiovascular events|Low RoB","Subgroup analysis (allocation concealment): major cardiovascular events",1,50,"Low RoB","or","binary",9,-0.373154507407743,0.0555611042008265,0.00783629933384203,2000.77777777778,0.194268194399772,3476.33333333333
"CD007784","CD007784_pub3_data","1|51|Subgroup analysis (allocation concealment): triglycerides|Low RoB","Subgroup analysis (allocation concealment): triglycerides",1,51,"Low RoB","or","binary",4,0.0263206609968223,1.01106098113876,0,2004.75,0,86.25
"CD007784","CD007784_pub3_data","1|52|Subgroup analysis (kidney function): end of treatment kidney function|≥ 55 mL/min","Subgroup analysis (kidney function): end of treatment kidney function",1,52,"≥ 55 mL/min","or","binary",12,-0.0272146654281918,0.584059617730077,0,2003.08333333333,0,80.25
"CD007784","CD007784_pub3_data","1|53|Sensitivity analysis (excluding SHARP): major cardiovascular events|","Sensitivity analysis (excluding SHARP): major cardiovascular events",1,53,"","or","binary",13,-0.456388703151698,0.0631260287324209,0.0128011561707753,2000.69230769231,0.173296977785249,2300.69230769231
"CD007784","CD007784_pub3_data","1|54|Sensitivity analysis (excluding SHARP): death|","Sensitivity analysis (excluding SHARP): death",1,54,"","or","binary",12,-0.257222644575017,0.0449180932498204,0,2001.66666666667,0.078748395958733,2394.41666666667
"CD007784","CD007784_pub3_data","1|55|Sensitivity analysis (funding): major cardiovascular events|Non-industry funding/not reported","Sensitivity analysis (funding): major cardiovascular events",1,55,"Non-industry funding/not reported","or","binary",5,-0.65799256856912,0.159351366594744,0,2003.4,0.0920204242329407,825.2
"CD007784","CD007784_pub3_data","1|56|Sensitivity analysis (funding): death|Non industry funding/not reported","Sensitivity analysis (funding): death",1,56,"Non industry funding/not reported","or","binary",5,-0.321389707386074,0.249427295214289,0.0717578193899371,2002.8,0.0426551019996147,849.8
"CD007784","CD007784_pub3_data","1|57|Sensitivity analysis (funding): withdrawal due to adverse events|Non industry funding/not reported","Sensitivity analysis (funding): withdrawal due to adverse events",1,57,"Non industry funding/not reported","or","binary",9,0.361130388383658,0.379597557993982,0.341137921131885,1999.44444444444,0.108866116696743,140.777777777778
"CD007784","CD007784_pub3_data","1|6|Stroke|","Stroke",1,6,"","or","binary",7,-0.437645796380638,0.267675166813014,0.187941923044054,2004.71428571429,0.0208007379589514,1302.14285714286
"CD007784","CD007784_pub3_data","1|7|Revascularisation procedure|","Revascularisation procedure",1,7,"","or","binary",3,-0.543555835540154,0.162479177842545,0,2002.66666666667,0.099732346945403,1385.33333333333
"CD007784","CD007784_pub3_data","1|9|Kidney failure|","Kidney failure",1,9,"","or","binary",3,-0.0340135587317081,0.0531364039419727,0,2009.66666666667,0.137962812172751,2234.66666666667
"CD007784","CD007784_pub3_data","2|1|Major cardiovascular events|","Major cardiovascular events",2,1,"","or","binary",2,0.0659698122174666,0.714554570611618,0.72631001351831,2007.5,0.0755842108226815,1613
"CD007784","CD007784_pub3_data","2|2|Death|","Death",2,2,"","or","binary",3,0.0473772953093169,0.57066238705148,0.571471286692466,2007,0.0421716558804893,1155
"CD007784","CD007784_pub3_data","2|5|Serious adverse events|","Serious adverse events",2,5,"","or","binary",2,0.131088303421235,0.269673323640795,0,2008.5,0.187755698421975,179
"CD007837","CD007837_pub3_data","1|6|Quality of life (SRS-22 Total score) (points)|Physiotherapeutic scoliosis-specific exercise (PSSE) vs  no treatment","Quality of life (SRS-22 Total score) (points)",1,6,"Physiotherapeutic scoliosis-specific exercise (PSSE) vs  no treatment","or","binary",2,-0.344048085213101,1.44311398932042,0,2015.5,0,30.5
"CD007837","CD007837_pub3_data","2|1|Cobb angle (°)|Physiotherapeutic scoliosis-specific exercise (PSSE) plus bracing versus bracing","Cobb angle (°)",2,1,"Physiotherapeutic scoliosis-specific exercise (PSSE) plus bracing versus bracing","or","binary",2,0,1.43113243404085,0,2017,0,42
"CD007837","CD007837_pub3_data","4|1|Cobb angle (°)|","Cobb angle (°)",4,1,"","or","binary",4,0,1.01429756837018,0,2018.25,0,48
"CD007837","CD007837_pub3_data","4|2|Angle of trunk rotation (°)|","Angle of trunk rotation (°)",4,2,"","or","binary",2,0,1.42939645203396,0,2017.5,0,69
"CD007837","CD007837_pub3_data","4|4|Subjective evaluation (SRS-22 Self-Image, WRVAS) (points)|","Subjective evaluation (SRS-22 Self-Image, WRVAS) (points)",4,4,"","or","binary",3,0,1.16911333672211,0,2019,0,56
"CD007837","CD007837_pub3_data","4|5|Quality of life (SRS-22 Total score) (points)|","Quality of life (SRS-22 Total score) (points)",4,5,"","or","binary",3,0,1.16911333672211,0,2019,0,56
"CD007837","CD007837_pub3_data","4|6|Back pain (SRS-22 Pain) (points)|","Back pain (SRS-22 Pain) (points)",4,6,"","or","binary",2,0,1.42863651006977,0,2018,0,70
"CD007837","CD007837_pub3_data","4|7|Mental health (SRS-22 Mental Health) (points)|","Mental health (SRS-22 Mental Health) (points)",4,7,"","or","binary",2,0,1.42863651006977,0,2018,0,70
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 1","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 1","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 2","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 2","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 3","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 3","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 4","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 4","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 5","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 5","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 6","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 6","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","1|4|Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)|Day 7","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)",1,4,"Day 7","or","binary",2,-0.0116948702228519,1.42647077298104,0,2002.5,0,63.5
"CD007859","CD007859_pub5_data","2|3|Pain (100-mm VAS)|Day 0 (within 1 hour)","Pain (100-mm VAS)",2,3,"Day 0 (within 1 hour)","or","binary",2,0.0159454586772875,1.43970391479648,0,2008.5,0,71
"CD007859","CD007859_pub5_data","2|3|Pain (100-mm VAS)|Day 1","Pain (100-mm VAS)",2,3,"Day 1","or","binary",2,0.0159454586772875,1.43970391479648,0,2008.5,0,71
"CD007859","CD007859_pub5_data","2|3|Pain (100-mm VAS)|Day 2","Pain (100-mm VAS)",2,3,"Day 2","or","binary",2,0.0159454586772875,1.43970391479648,0,2008.5,0,71
"CD007859","CD007859_pub5_data","2|3|Pain (100-mm VAS)|Day 3","Pain (100-mm VAS)",2,3,"Day 3","or","binary",2,0.0241068001952695,1.43972705090263,0,2008.5,0,70.5
"CD007859","CD007859_pub5_data","4|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 12 weeks","Alignment rate (LII reduction; mm)",4,1,"Lower 3-3 over 12 weeks","or","binary",2,0,1.44213857282166,0,2021,0,25
"CD007859","CD007859_pub5_data","4|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 4 weeks","Alignment rate (LII reduction; mm)",4,1,"Lower 3-3 over 4 weeks","or","binary",5,-0.010086286896433,0.90774787995488,0,2019.2,0,36.6
"CD007859","CD007859_pub5_data","4|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 8 weeks","Alignment rate (LII reduction; mm)",4,1,"Lower 3-3 over 8 weeks","or","binary",3,-0.0836403061810439,1.17796205848269,0,2015.66666666667,0,24.3333333333333
"CD007859","CD007859_pub5_data","4|1|Alignment rate (LII reduction; mm)|Upper 3-3 over 4 weeks","Alignment rate (LII reduction; mm)",4,1,"Upper 3-3 over 4 weeks","or","binary",3,0.0151757277515643,1.16858717559959,0,2017.66666666667,0,41.6666666666667
"CD007859","CD007859_pub5_data","4|1|Alignment rate (LII reduction; mm)|Upper 3-3 over 8 weeks","Alignment rate (LII reduction; mm)",4,1,"Upper 3-3 over 8 weeks","or","binary",3,-0.0828339447337067,1.17227004405575,0,2014,0,35
"CD007859","CD007859_pub5_data","4|2|Alignment rate (change in arch width; mm)|Lower 3-3 arch width increase over 4 weeks","Alignment rate (change in arch width; mm)",4,2,"Lower 3-3 arch width increase over 4 weeks","or","binary",2,0.0228364812145214,1.43351072161723,0,2018.5,0,36.5
"CD007859","CD007859_pub5_data","4|2|Alignment rate (change in arch width; mm)|Upper 3-3 arch width increase over 4 weeks","Alignment rate (change in arch width; mm)",4,2,"Upper 3-3 arch width increase over 4 weeks","or","binary",2,0.0226963372658924,1.42910533577465,0,2017.5,0,46.5
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 0","Pain (100-mm VAS)",4,6,"Day 0","or","binary",2,-0.100066357804087,1.42608009681158,0,2018.5,0,65.5
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 1","Pain (100-mm VAS)",4,6,"Day 1","or","binary",3,-0.060089566181257,1.1741596898618,0,2016.33333333333,0,31.3333333333333
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 2","Pain (100-mm VAS)",4,6,"Day 2","or","binary",2,-0.0895517599025445,1.43339107096862,0,2014,0,37
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 3","Pain (100-mm VAS)",4,6,"Day 3","or","binary",2,-0.0895517599025445,1.43339107096862,0,2014,0,37
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 4","Pain (100-mm VAS)",4,6,"Day 4","or","binary",2,-0.0895517599025445,1.43339107096862,0,2014,0,37
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 5","Pain (100-mm VAS)",4,6,"Day 5","or","binary",2,-0.0895517599025445,1.43339107096862,0,2014,0,37
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 6","Pain (100-mm VAS)",4,6,"Day 6","or","binary",2,-0.0895517599025445,1.43339107096862,0,2014,0,37
"CD007859","CD007859_pub5_data","4|6|Pain (100-mm VAS)|Day 7","Pain (100-mm VAS)",4,6,"Day 7","or","binary",3,-0.060089566181257,1.1741596898618,0,2016.33333333333,0,31.3333333333333
"CD007859","CD007859_pub5_data","4|7|Pain (analgesic consumption)|Until next appointment (more than 4 days)","Pain (analgesic consumption)",4,7,"Until next appointment (more than 4 days)","or","binary",2,0.504251826481789,0.267194514738806,0,2018,0.219775070290534,138.5
"CD007859","CD007859_pub5_data","5|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 12 weeks","Alignment rate (LII reduction; mm)",5,1,"Lower 3-3 over 12 weeks","or","binary",2,0,1.43675753407464,0,2015,0,32
"CD007859","CD007859_pub5_data","5|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 4 weeks","Alignment rate (LII reduction; mm)",5,1,"Lower 3-3 over 4 weeks","or","binary",2,0,1.43675753407464,0,2015,0,32
"CD007859","CD007859_pub5_data","5|1|Alignment rate (LII reduction; mm)|Lower 3-3 over 8 weeks","Alignment rate (LII reduction; mm)",5,1,"Lower 3-3 over 8 weeks","or","binary",2,0,1.43675753407464,0,2015,0,32
"CD007859","CD007859_pub5_data","6|1|Pain (100-mm VAS): 0.014-inch versus 0.016-inch|Day 0","Pain (100-mm VAS): 0.014-inch versus 0.016-inch",6,1,"Day 0","or","binary",2,-0.0274846438169281,1.42596385444823,0,2012.5,0,74.5
"CD007859","CD007859_pub5_data","6|1|Pain (100-mm VAS): 0.014-inch versus 0.016-inch|Day 1","Pain (100-mm VAS): 0.014-inch versus 0.016-inch",6,1,"Day 1","or","binary",2,-0.0274846438169281,1.42596385444823,0,2012.5,0,74.5
"CD007859","CD007859_pub5_data","6|1|Pain (100-mm VAS): 0.014-inch versus 0.016-inch|Day 2","Pain (100-mm VAS): 0.014-inch versus 0.016-inch",6,1,"Day 2","or","binary",2,-0.0274846438169281,1.42596385444823,0,2012.5,0,74.5
"CD007859","CD007859_pub5_data","6|1|Pain (100-mm VAS): 0.014-inch versus 0.016-inch|Day 7","Pain (100-mm VAS): 0.014-inch versus 0.016-inch",6,1,"Day 7","or","binary",2,-0.0274846438169281,1.42596385444823,0,2012.5,0,74.5
"CD007872","CD007872_pub4_data","1|14|Clinical diagnosis of postpartum haemorrhage|Women with no anaemia","Clinical diagnosis of postpartum haemorrhage",1,14,"Women with no anaemia","or","binary",2,-0.323322754773864,0.112285248291496,0,2020.5,0.052158273381295,1953
"CD007872","CD007872_pub4_data","1|15|Estimated mean blood loss|","Estimated mean blood loss",1,15,"","or","binary",2,-0.00584980436556733,1.41432785868675,0,2021,0,9478.5
"CD007872","CD007872_pub4_data","1|17|Myocardial infarction|","Myocardial infarction",1,17,"","or","binary",2,-0.0047533503866948,1.41433272661302,0,2021,0,9379.5
"CD007872","CD007872_pub4_data","1|18|Stroke|","Stroke",1,18,"","or","binary",2,-0.0047533503866948,1.41433272661302,0,2021,0,9379.5
"CD007872","CD007872_pub4_data","1|19|Seizures|","Seizures",1,19,"","or","binary",3,0.918048373158973,0.562006839145625,0,2021.66666666667,0.000133564845732603,6258
"CD007872","CD007872_pub4_data","1|20|Organ failure/dysfunction                     |","Organ failure/dysfunction                     ",1,20,"","or","binary",2,-0.0592918746655176,1.43566148288964,0,2020.5,0,1854
"CD007872","CD007872_pub4_data","1|3|Estimated blood loss ≥ 1000 mL|","Estimated blood loss ≥ 1000 mL",1,3,"","reported","reported",2,0,0.111053246479269,0,2021,0.0224764941653636,9448.5
"CD007872","CD007872_pub4_data","1|8|Receipt of additional surgical interventions to control postpartum haemorrhage|","Receipt of additional surgical interventions to control postpartum haemorrhage",1,8,"","or","binary",3,-0.429602651900792,0.327978223789491,0,2021.66666666667,0.00161332515014148,6324
"CD007872","CD007872_pub4_data","1|9|Thromboembolic events|","Thromboembolic events",1,9,"","or","binary",3,-0.786716490317978,0.788391385921842,0,2021.66666666667,0.000721110510185686,6258
"CD007895","CD007895_pub3_data","1|1|Systolic blood pressure, measured as change-from-baseline|NA","Systolic blood pressure, measured as change-from-baseline",1,1,NA,"or","binary",4,0.0505781933347446,1.01040386431227,0,1997.5,0,196
"CD007895","CD007895_pub3_data","1|2|Diastolic blood pressure, measured as change-from-baseline|NA","Diastolic blood pressure, measured as change-from-baseline",1,2,NA,"or","binary",5,0.0322251697528019,0.902767003744261,0,1995.8,0,176.4
"CD007895","CD007895_pub3_data","1|3|Heart rate, measured as change-from-baseline|NA","Heart rate, measured as change-from-baseline",1,3,NA,"or","binary",2,0.0677252537916416,1.43454377631511,0,1992.5,0,95
"CD007895","CD007895_pub3_data","1|4|Withdrawals due to adverse effects|NA","Withdrawals due to adverse effects",1,4,NA,"or","binary",4,0.156349192967114,0.540830873938125,0,1997.5,0.0187049062049062,201.5
"CD007896","CD007896_pub4_data","1|1|Systolic blood pressure|","Systolic blood pressure",1,1,"","reported","reported",56,0,0.196211896432083,0,2011.41071428571,0,188.982142857143
"CD007896","CD007896_pub4_data","1|2|Diastolic blood pressure|","Diastolic blood pressure",1,2,"","reported","reported",56,0,0.164222776027053,0,2011.41071428571,0,188.982142857143
"CD007896","CD007896_pub4_data","1|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",1,3,"","reported","reported",18,0,0.390131394675601,0,2009.33333333333,0,193.944444444444
"CD007896","CD007896_pub4_data","1|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",1,4,"","reported","reported",9,0,0.343887865822111,0,2013,0.0244092486360528,255.888888888889
"CD007896","CD007896_pub4_data","2|1|Systolic blood pressure|Age < 18 years","Systolic blood pressure",2,1,"Age < 18 years","reported","reported",13,0,0.368609815968759,0,2013.23076923077,0,250.384615384615
"CD007896","CD007896_pub4_data","2|1|Systolic blood pressure|Age ≥ 18 years","Systolic blood pressure",2,1,"Age ≥ 18 years","reported","reported",43,0,0.231777102674761,0,2010.86046511628,0,170.418604651163
"CD007896","CD007896_pub4_data","2|2|Diastolic blood pressure|Age < 18 years","Diastolic blood pressure",2,2,"Age < 18 years","reported","reported",13,0,0.317766517037796,0,2013.23076923077,0,250.384615384615
"CD007896","CD007896_pub4_data","2|2|Diastolic blood pressure|Age ≥ 18 years","Diastolic blood pressure",2,2,"Age ≥ 18 years","reported","reported",43,0,0.191825689831593,0,2010.86046511628,0,170.418604651163
"CD007896","CD007896_pub4_data","2|3|Heart rate (beats per minute)|Age < 18 years","Heart rate (beats per minute)",2,3,"Age < 18 years","reported","reported",11,0,0.451520204543415,0,2013.09090909091,0,285
"CD007896","CD007896_pub4_data","2|3|Heart rate (beats per minute)|Age ≥ 18 years","Heart rate (beats per minute)",2,3,"Age ≥ 18 years","reported","reported",36,0,0.256898240605266,0,2011.52777777778,0,192.777777777778
"CD007896","CD007896_pub4_data","2|4|Withdrawals due to adverse effects|Age < 18 years","Withdrawals due to adverse effects",2,4,"Age < 18 years","reported","reported",10,0,0.266771736159759,0,2013.6,0.0188453153643027,256.6
"CD007896","CD007896_pub4_data","2|4|Withdrawals due to adverse effects|Age ≥ 18 years","Withdrawals due to adverse effects",2,4,"Age ≥ 18 years","reported","reported",25,0,0.137511562562331,0,2012.84,0.0320183583826005,232.68
"CD007896","CD007896_pub4_data","3|1|Systolic blood pressure|Trial duration > 4 weeks to < 8 weeks","Systolic blood pressure",3,1,"Trial duration > 4 weeks to < 8 weeks","reported","reported",20,0,0.315801575079383,0,2011.15,0,217.8
"CD007896","CD007896_pub4_data","3|1|Systolic blood pressure|Trial duration ≤ 4 weeks","Systolic blood pressure",3,1,"Trial duration ≤ 4 weeks","reported","reported",17,0,0.401764247731583,0,2008.52941176471,0,105.529411764706
"CD007896","CD007896_pub4_data","3|1|Systolic blood pressure|Trial duration ≥ 8 weeks","Systolic blood pressure",3,1,"Trial duration ≥ 8 weeks","reported","reported",19,0,0.32021708880988,0,2014.26315789474,0,233.315789473684
"CD007896","CD007896_pub4_data","3|2|Diastolic blood pressure|Trial duration > 4 weeks to < 8 weeks","Diastolic blood pressure",3,2,"Trial duration > 4 weeks to < 8 weeks","reported","reported",20,0,0.264177978053914,0,2011.15,0,217.8
"CD007896","CD007896_pub4_data","3|2|Diastolic blood pressure|Trial duration ≤ 4 weeks","Diastolic blood pressure",3,2,"Trial duration ≤ 4 weeks","reported","reported",17,0,0.373650084880413,0,2008.52941176471,0,105.529411764706
"CD007896","CD007896_pub4_data","3|2|Diastolic blood pressure|Trial duration ≥ 8 weeks","Diastolic blood pressure",3,2,"Trial duration ≥ 8 weeks","reported","reported",19,0,0.253280981043777,0,2014.26315789474,0,233.315789473684
"CD007896","CD007896_pub4_data","3|3|Heart rate (beats per minute)|Trial duration > 4 weeks to < 8 weeks","Heart rate (beats per minute)",3,3,"Trial duration > 4 weeks to < 8 weeks","reported","reported",18,0,0.363577549425567,0,2011.5,0,234.888888888889
"CD007896","CD007896_pub4_data","3|3|Heart rate (beats per minute)|Trial duration ≤ 4 weeks","Heart rate (beats per minute)",3,3,"Trial duration ≤ 4 weeks","reported","reported",12,0,0.507426375676748,0,2009.08333333333,0,136.416666666667
"CD007896","CD007896_pub4_data","3|3|Heart rate (beats per minute)|Trial duration ≥ 8 weeks","Heart rate (beats per minute)",3,3,"Trial duration ≥ 8 weeks","reported","reported",17,0,0.340826296581436,0,2014.29411764706,0,247.647058823529
"CD007896","CD007896_pub4_data","3|4|Withdrawals due to adverse effects|Trial duration > 4 weeks to < 8 weeks","Withdrawals due to adverse effects",3,4,"Trial duration > 4 weeks to < 8 weeks","reported","reported",13,0,0.183310123239435,0,2012.30769230769,0.0297739208943643,245.153846153846
"CD007896","CD007896_pub4_data","3|4|Withdrawals due to adverse effects|Trial duration ≤ 4 weeks","Withdrawals due to adverse effects",3,4,"Trial duration ≤ 4 weeks","reported","reported",8,0,0.370109609615572,0,2012.625,0.0251893166041798,178.625
"CD007896","CD007896_pub4_data","3|4|Withdrawals due to adverse effects|Trial duration ≥ 8 weeks","Withdrawals due to adverse effects",3,4,"Trial duration ≥ 8 weeks","reported","reported",14,0,0.182955080935219,0,2014,0.0285954720534189,269.071428571429
"CD007896","CD007896_pub4_data","4|1|Systolic blood pressure|","Systolic blood pressure",4,1,"","reported","reported",51,0,0.19958379325571,0,2011.47058823529,0,191.686274509804
"CD007896","CD007896_pub4_data","4|2|Diastolic blood pressure|","Diastolic blood pressure",4,2,"","reported","reported",51,0,0.169094504909695,0,2011.47058823529,0,191.686274509804
"CD007896","CD007896_pub4_data","4|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",4,3,"","reported","reported",18,0,0.390131394675601,0,2009.33333333333,0,193.944444444444
"CD007896","CD007896_pub4_data","4|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",4,4,"","reported","reported",9,0,0.343887865822111,0,2013,0.0244092486360528,255.888888888889
"CD007896","CD007896_pub4_data","5|1|Systolic blood pressure|","Systolic blood pressure",5,1,"","reported","reported",37,0,0.24910078235927,0,2010.86486486486,0,174.972972972973
"CD007896","CD007896_pub4_data","5|2|Diastolic blood pressure|","Diastolic blood pressure",5,2,"","reported","reported",37,0,0.210472853739363,0,2010.86486486486,0,174.972972972973
"CD007896","CD007896_pub4_data","5|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",5,3,"","reported","reported",12,0,0.50319030579801,0,2008.58333333333,0,182.75
"CD007896","CD007896_pub4_data","5|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",5,4,"","reported","reported",5,0,0.454340290251654,0,2013.8,0.0250782550782551,309
"CD007896","CD007896_pub4_data","6|1|Systolic blood pressure|","Systolic blood pressure",6,1,"","reported","reported",19,0,0.42334142510141,0,2008.10526315789,0,88.2105263157895
"CD007896","CD007896_pub4_data","6|2|Diastolic blood pressure|","Diastolic blood pressure",6,2,"","reported","reported",19,0,0.364224592666002,0,2008.10526315789,0,88.2105263157895
"CD007896","CD007896_pub4_data","6|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",6,3,"","reported","reported",5,0,0.820944693206282,0,2002.2,0,143.8
"CD007896","CD007896_pub4_data","7|1|Systolic blood pressure|","Systolic blood pressure",7,1,"","reported","reported",47,0,0.20856520433152,0,2012.25531914894,0,217.851063829787
"CD007896","CD007896_pub4_data","7|2|Diastolic blood pressure|","Diastolic blood pressure",7,2,"","reported","reported",47,0,0.16980289492067,0,2012.25531914894,0,217.851063829787
"CD007896","CD007896_pub4_data","7|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",7,3,"","reported","reported",15,0,0.399671956924988,0,2010.66666666667,0,222.066666666667
"CD007896","CD007896_pub4_data","7|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",7,4,"","reported","reported",8,0,0.355105841390133,0,2014,0.0170437380488927,284.375
"CD007896","CD007896_pub4_data","8|1|Systolic blood pressure|","Systolic blood pressure",8,1,"","reported","reported",48,0,0.230373436720456,0,2010.58333333333,0,156.520833333333
"CD007896","CD007896_pub4_data","8|2|Diastolic blood pressure|","Diastolic blood pressure",8,2,"","reported","reported",48,0,0.190339730344507,0,2010.58333333333,0,156.520833333333
"CD007896","CD007896_pub4_data","8|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",8,3,"","reported","reported",17,0,0.396124693384242,0,2008.70588235294,0,200.117647058824
"CD007896","CD007896_pub4_data","8|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",8,4,"","reported","reported",5,0,0.596336505709464,0,2011.4,0.028008658008658,169
"CD007896","CD007896_pub4_data","9|1|Systolic blood pressure|","Systolic blood pressure",9,1,"","reported","reported",55,0,0.196536094569184,0,2011.23636363636,0,190.981818181818
"CD007896","CD007896_pub4_data","9|2|Diastolic blood pressure|","Diastolic blood pressure",9,2,"","reported","reported",55,0,0.164551888079335,0,2011.23636363636,0,190.981818181818
"CD007896","CD007896_pub4_data","9|3|Heart rate (beats per minute)|","Heart rate (beats per minute)",9,3,"","reported","reported",18,0,0.390131394675601,0,2009.33333333333,0,193.944444444444
"CD007896","CD007896_pub4_data","9|4|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",9,4,"","reported","reported",9,0,0.343887865822111,0,2013,0.0244092486360528,255.888888888889
"CD008063","CD008063_pub3_data","1|1|Extent of substance use|Long-term follow-up","Extent of substance use",1,1,"Long-term follow-up","reported","reported",9,0.107030493998049,0.0542466635351556,2.35067785085666e-06,2008.33333333333,0,169.444444444444
"CD008063","CD008063_pub3_data","1|1|Extent of substance use|Medium-term follow-up","Extent of substance use",1,1,"Medium-term follow-up","reported","reported",16,0.121393441034338,0.0387027385983295,0.000842779393955457,2007.375,0,196.0625
"CD008063","CD008063_pub3_data","1|1|Extent of substance use|Post-intervention","Extent of substance use",1,1,"Post-intervention","reported","reported",6,0.480852234913395,0.215594533580093,0.196085721373548,2005.66666666667,0,78.5
"CD008063","CD008063_pub3_data","1|1|Extent of substance use|Short-term follow-up","Extent of substance use",1,1,"Short-term follow-up","reported","reported",19,0.198165141227523,0.0366834059007481,0.00407278834047002,2008.05263157895,0,176.368421052632
"CD008063","CD008063_pub3_data","1|2|Readiness to change|","Readiness to change",1,2,"","reported","reported",5,0.0550037189542525,0.0821161991799358,0.0139854271191096,2007.4,0,299
"CD008063","CD008063_pub3_data","1|3|Retention in treatment|","Retention in treatment",1,3,"","reported","reported",2,0.256258116883117,0.132936825633234,0.0170875,2004,0,213.5
"CD008063","CD008063_pub3_data","2|1|Extent of substance use|Long-term follow-up","Extent of substance use",2,1,"Long-term follow-up","reported","reported",8,0.0598825675277132,0.0546389708941976,4.22235681576967e-06,2010.25,0,181.125
"CD008063","CD008063_pub3_data","2|1|Extent of substance use|Medium-term follow-up","Extent of substance use",2,1,"Medium-term follow-up","reported","reported",9,0.120555427312159,0.0547063277904607,0.00316820660434811,2011.33333333333,0,180.444444444444
"CD008063","CD008063_pub3_data","2|1|Extent of substance use|Post-intervention","Extent of substance use",2,1,"Post-intervention","reported","reported",5,-0.142960039041293,0.064647467314557,4.35015368350443e-07,2008.6,0,195.2
"CD008063","CD008063_pub3_data","2|1|Extent of substance use|Short-term follow-up","Extent of substance use",2,1,"Short-term follow-up","reported","reported",14,0.0674910371105033,0.0516566738516494,0.0156593263304844,2010.57142857143,0,219
"CD008063","CD008063_pub3_data","2|2|Readiness to change|","Readiness to change",2,2,"","reported","reported",2,0.0623721162705794,0.167230568932893,0,2010.5,0,75
"CD008063","CD008063_pub3_data","2|3|Retention in treatment|","Retention in treatment",2,3,"","reported","reported",5,-0.0801677884100367,0.120547006349319,0.0292568584852387,2009.8,0,259
"CD008063","CD008063_pub3_data","3|1|Extent of substance use|Long-term follow-up","Extent of substance use",3,1,"Long-term follow-up","reported","reported",3,0.241251497467534,0.0878293300870116,0.000874239748253162,2007.66666666667,0,149.333333333333
"CD008063","CD008063_pub3_data","3|1|Extent of substance use|Medium-term follow-up","Extent of substance use",3,1,"Medium-term follow-up","reported","reported",6,0.236981031058275,0.0818862268965213,0,2005.66666666667,0,114.666666666667
"CD008063","CD008063_pub3_data","3|1|Extent of substance use|Short-term follow-up","Extent of substance use",3,1,"Short-term follow-up","reported","reported",7,0.0916173681794753,0.0726708044999511,0,2007.71428571429,0,122
"CD008063","CD008063_pub3_data","4|1|Extent of substance use|Long-term follow-up","Extent of substance use",4,1,"Long-term follow-up","reported","reported",10,0.0228453223275042,0.046630537228604,0,2010.6,0,190.8
"CD008063","CD008063_pub3_data","4|1|Extent of substance use|Medium-term follow-up","Extent of substance use",4,1,"Medium-term follow-up","reported","reported",15,0.084277741832524,0.0468951622010571,0.00491052684249236,2009.46666666667,0,156.8
"CD008063","CD008063_pub3_data","4|1|Extent of substance use|Post-intervention","Extent of substance use",4,1,"Post-intervention","reported","reported",3,0.0662943210329445,0.116912778227266,0.00340634236087089,2010,0,112.666666666667
"CD008063","CD008063_pub3_data","4|1|Extent of substance use|Short-term follow-up","Extent of substance use",4,1,"Short-term follow-up","reported","reported",18,0.0499256155258757,0.0395998366380852,0,2010.11111111111,0,155.277777777778
"CD008063","CD008063_pub3_data","4|2|Readiness to change|","Readiness to change",4,2,"","reported","reported",5,0.144911529453685,0.083424611089574,0.010268395066771,2012,0,197.6
"CD008063","CD008063_pub3_data","4|3|Retention in treatment|","Retention in treatment",4,3,"","reported","reported",12,-0.0435892560005578,0.0966176183603531,0.0503632992985776,2012.16666666667,0,162.083333333333
"CD008145","CD008145_pub4_data","1|1|Reception of DTP3 by 1 year of age|Community-based health education","Reception of DTP3 by 1 year of age",1,1,"Community-based health education","reported","reported",3,0.430009521810717,0.0909748328820739,0.00943055583501148,2012.66666666667,0,673.333333333333
"CD008145","CD008145_pub4_data","1|1|Reception of DTP3 by 1 year of age|Facility-based health education","Reception of DTP3 by 1 year of age",1,1,"Facility-based health education","reported","reported",3,0.195545026635219,0.101513747732757,0.0275488680917822,2012.33333333333,0,785
"CD008145","CD008145_pub4_data","1|2|Uptake of BCG vaccine|","Uptake of BCG vaccine",1,2,"","reported","reported",2,-0.0134337116016666,0.0137379475445943,0,2017.5,0,778.5
"CD008145","CD008145_pub4_data","1|6|Uptake of measles vaccine|Community-based education","Uptake of measles vaccine",1,6,"Community-based education","reported","reported",3,0.316790504569492,0.102777477083573,0.0206265554799594,2015.66666666667,0,830.666666666667
"CD008145","CD008145_pub4_data","1|8|Reception of all recommended vaccines by 2 years of age|","Reception of all recommended vaccines by 2 years of age",1,8,"","reported","reported",3,0.242049899030006,0.119674310296768,0.0369293810460607,2018.33333333333,0,795.666666666667
"CD008145","CD008145_pub4_data","2|2|Uptake of measles/MMR vaccine|Household monetary incentive","Uptake of measles/MMR vaccine",2,2,"Household monetary incentive","reported","reported",2,0.0589274118825301,0.0658311948497422,0.007394280198,2004.5,0,1354.5
"CD008145","CD008145_pub4_data","2|3|Under 5 years of age fully immunised with all scheduled vaccine|","Under 5 years of age fully immunised with all scheduled vaccine",2,3,"","reported","reported",2,0.0475691928959339,0.0679202210854189,0,2008.5,0,500
"CD008145","CD008145_pub4_data","3|1|Uptake of DTP3 vaccine|HBR + health education","Uptake of DTP3 vaccine",3,1,"HBR + health education","reported","reported",2,0.400575344149459,0.10153875277643,0.016374175,2010,0,751
"CD008145","CD008145_pub4_data","3|1|Uptake of DTP3 vaccine|Home-based record only","Uptake of DTP3 vaccine",3,1,"Home-based record only","reported","reported",3,0.305488790026481,0.13053508756519,0.0391077786839171,2013,0,1339.66666666667
"CD008145","CD008145_pub4_data","4|1|Uptake of DTP3 vaccine|","Uptake of DTP3 vaccine",4,1,"","reported","reported",2,-0.0153079557846014,0.0536694684105192,0,2017,0,164
"CD008145","CD008145_pub4_data","5|1|Reception of DTP3/Penta 3 by 2 years of age|Rural","Reception of DTP3/Penta 3 by 2 years of age",5,1,"Rural","reported","reported",2,-0.0065827195696493,0.0198794517699371,0.000312302476000001,2016.5,0,534.5
"CD008145","CD008145_pub4_data","5|1|Reception of DTP3/Penta 3 by 2 years of age|Urban","Reception of DTP3/Penta 3 by 2 years of age",5,1,"Urban","reported","reported",3,0.144118095634513,0.073359706490791,0.0103539807133933,2017.33333333333,0,401.333333333333
"CD008145","CD008145_pub4_data","5|3|Reception of all recommended vaccines by 2 years of age|Phone call/SMS only","Reception of all recommended vaccines by 2 years of age",5,3,"Phone call/SMS only","reported","reported",5,0.0527485823280151,0.0299945617297972,0.00262374010652646,2017.6,0,2082.8
"CD008145","CD008145_pub4_data","5|4|Uptake of BCG vaccine|Phone call/SMS only","Uptake of BCG vaccine",5,4,"Phone call/SMS only","reported","reported",2,0.310046415204407,0.328396300849518,0.2082876841545,2019,0,1582
"CD008145","CD008145_pub4_data","5|5|Uptake of OPV3 vaccine|Phone call/SMS only","Uptake of OPV3 vaccine",5,5,"Phone call/SMS only","reported","reported",2,-0.00677547648084981,0.0261110877721068,0.000617977916499999,2016.5,0,534.5
"CD008145","CD008145_pub4_data","6|1|Reception of DTP3/Penta 3 vaccine by 2 years of age|","Reception of DTP3/Penta 3 vaccine by 2 years of age",6,1,"","reported","reported",2,0.0209751726620135,0.0242813086383101,0,2019,0,783.5
"CD008165","CD008165_pub5_data","1|1|Medication appropriateness (as measured by an implicit tool)|NA","Medication appropriateness (as measured by an implicit tool)",1,1,NA,"reported","reported",8,0,0.309185770380278,0,2011.625,0,118.375
"CD008165","CD008165_pub5_data","1|2|Medication appropriateness (as measured by an implicit tool) (excluding Crotty 2004a)|NA","Medication appropriateness (as measured by an implicit tool) (excluding Crotty 2004a)",1,2,NA,"reported","reported",7,0,0.321701573653361,0,2012.71428571429,0,125.142857142857
"CD008165","CD008165_pub5_data","1|3|Number of potentially inappropriate medications|NA","Number of potentially inappropriate medications",1,3,NA,"reported","reported",9,0,0.0409362740343654,0,2013.44444444444,0,267.111111111111
"CD008165","CD008165_pub5_data","1|4|Proportion of patients with one or more potentially inappropriate medication|NA","Proportion of patients with one or more potentially inappropriate medication",1,4,NA,"reported","reported",13,0,0.0342194681522724,0,2014.92307692308,0.475402093373518,348.769230769231
"CD008165","CD008165_pub5_data","1|5|Number of potential prescribing omissions|NA","Number of potential prescribing omissions",1,5,NA,"reported","reported",3,0,0.0798066966449142,0,2013.33333333333,0,230.333333333333
"CD008165","CD008165_pub5_data","1|6|Proportion of patients with one or more potential prescribing omission|NA","Proportion of patients with one or more potential prescribing omission",1,6,NA,"reported","reported",7,0,0.031763198010052,0,2014.57142857143,0.476594850934081,395
"CD008176","CD008176_pub3_data","1|1|Cardiovascular death|CKD stage 5D","Cardiovascular death",1,1,"CKD stage 5D","or","binary",4,-0.191556165962558,0.304898121674542,0.00159667723450816,2005.75,0.108361981156099,111
"CD008176","CD008176_pub3_data","1|1|Cardiovascular death|CKD stages 3-5","Cardiovascular death",1,1,"CKD stages 3-5","or","binary",3,-0.233159369758754,0.489676390839756,0.550423184566192,2007,0.118308933714585,1089.66666666667
"CD008176","CD008176_pub3_data","1|10|Change in eGFR|CKD stages 3-5","Change in eGFR",1,10,"CKD stages 3-5","or","binary",26,-0.191846046643289,0.396719874181531,0,2013.65384615385,0,156.038461538462
"CD008176","CD008176_pub3_data","1|10|Change in eGFR|Kidney transplant","Change in eGFR",1,10,"Kidney transplant","or","binary",2,-0.0836848570264848,1.45068857428265,0,2006.5,0,35.5
"CD008176","CD008176_pub3_data","1|11|Serum creatinine at end of study|CKD stages 3-5","Serum creatinine at end of study",1,11,"CKD stages 3-5","or","binary",9,-0.130366097378517,0.675761368120218,0,2012.22222222222,0,62.4444444444444
"CD008176","CD008176_pub3_data","1|11|Serum creatinine at end of study|Kidney transplant","Serum creatinine at end of study",1,11,"Kidney transplant","or","binary",13,0.00690431411154543,0.561032236282244,0,2003.38461538462,0,78.8461538461538
"CD008176","CD008176_pub3_data","1|12|Change in serum creatinine|CKD stages 3-5","Change in serum creatinine",1,12,"CKD stages 3-5","or","binary",11,-0.212806351310478,0.609952506282652,0,2012.18181818182,0,270
"CD008176","CD008176_pub3_data","1|12|Change in serum creatinine|Kidney transplant","Change in serum creatinine",1,12,"Kidney transplant","or","binary",5,-0.0352330439808202,0.910532034688951,0,2006.2,0,42
"CD008176","CD008176_pub3_data","1|13|Urinary albumin/creatinine ratio at end of study|CKD stages 3-5","Urinary albumin/creatinine ratio at end of study",1,13,"CKD stages 3-5","or","binary",5,0.00222006521189584,0.906650500785732,0,2011.8,0,234.8
"CD008176","CD008176_pub3_data","1|14|Change in urinary albumin/creatinine ratio|CKD stages 3-5","Change in urinary albumin/creatinine ratio",1,14,"CKD stages 3-5","or","binary",7,-0.353189913766658,0.765738021778547,0,2013.71428571429,0,183.714285714286
"CD008176","CD008176_pub3_data","1|15|Proteinuria at end of study|CKD stages 3-5","Proteinuria at end of study",1,15,"CKD stages 3-5","or","binary",9,-0.134968996144918,0.673763488560563,0,2011.66666666667,0,59.5555555555556
"CD008176","CD008176_pub3_data","1|16|Change in proteinuria|CKD stages 3-5","Change in proteinuria",1,16,"CKD stages 3-5","or","binary",8,-0.100852525203062,0.714129163291605,0,2013.25,0,58.5
"CD008176","CD008176_pub3_data","1|17|Albuminuria at end of study|CKD stages 3-5","Albuminuria at end of study",1,17,"CKD stages 3-5","or","binary",4,-0.0421202600424403,1.00631628505593,0,2009.25,0,98.75
"CD008176","CD008176_pub3_data","1|18|Change in albuminuria|CKD stages 3-5","Change in albuminuria",1,18,"CKD stages 3-5","or","binary",4,-0.0421202600424403,1.00631628505593,0,2009.25,0,98.75
"CD008176","CD008176_pub3_data","1|19|Vascular access thrombosis|CKD stage 5D","Vascular access thrombosis",1,19,"CKD stage 5D","or","binary",3,0.161934151482398,0.585339603522529,0.133259717728259,2012,0.148366013071895,69.6666666666667
"CD008176","CD008176_pub3_data","1|2|Death (any cause)|CKD stage 5D","Death (any cause)",1,2,"CKD stage 5D","or","binary",21,-0.154923497170597,0.173641174726655,0,2014.09523809524,0.0710377223756317,107.666666666667
"CD008176","CD008176_pub3_data","1|2|Death (any cause)|CKD stages 3-5","Death (any cause)",1,2,"CKD stages 3-5","or","binary",13,0.0190815530339784,0.149863327751378,0.02092739084768,2013.23076923077,0.0763809344679921,325.307692307692
"CD008176","CD008176_pub3_data","1|2|Death (any cause)|Kidney transplant","Death (any cause)",1,2,"Kidney transplant","or","binary",11,-0.198083299573352,0.246685509170427,0,2002.54545454545,0.0831320012668687,94.5454545454545
"CD008176","CD008176_pub3_data","1|22|Delayed graft function|Kidney transplant","Delayed graft function",1,22,"Kidney transplant","or","binary",11,-0.19660565361408,0.157500189785285,4.43422566778475e-06,2008.72727272727,0.316828241329182,78.0909090909091
"CD008176","CD008176_pub3_data","1|23|Malignancy|CKD stage 5D","Malignancy",1,23,"CKD stage 5D","or","binary",2,0.292285688315995,1.40930807312584,1.41029053733134,2006.5,0.0121951219512195,140
"CD008176","CD008176_pub3_data","1|24|Major bleeding|CKD stage 5D","Major bleeding",1,24,"CKD stage 5D","or","binary",4,0.483035297863545,0.644420228524029,0,2007.25,0.0340909090909091,88.25
"CD008176","CD008176_pub3_data","1|24|Major bleeding|CKD stages 3-5","Major bleeding",1,24,"CKD stages 3-5","or","binary",2,-0.430060894546911,1.05424391916223,0.602227151208199,2008.5,0.0833333333333333,48
"CD008176","CD008176_pub3_data","1|25|Infection|CKD stage 5D","Infection",1,25,"CKD stage 5D","or","binary",5,0.344781524943029,0.348822861663394,0,2008.8,0.0622474747474747,123.2
"CD008176","CD008176_pub3_data","1|25|Infection|CKD stages 3-5","Infection",1,25,"CKD stages 3-5","or","binary",6,0.516592741330757,0.0925966086822978,0,2013.83333333333,0.0810883496189032,467
"CD008176","CD008176_pub3_data","1|25|Infection|Kidney transplant","Infection",1,25,"Kidney transplant","or","binary",3,0.117453947706558,0.313090104142641,4.06819601966798e-06,1997.33333333333,0.295088702147526,93
"CD008176","CD008176_pub3_data","1|26|Sensitivity analysis: change in eGFR without imputed SD|CKD stages 3-5","Sensitivity analysis: change in eGFR without imputed SD",1,26,"CKD stages 3-5","or","binary",8,-0.154038701616232,0.710308555418957,0,2014.75,0,376.75
"CD008176","CD008176_pub3_data","1|27|Sensitivity analysis: change in serum creatinine without imputed SD|CKD stages 3-5","Sensitivity analysis: change in serum creatinine without imputed SD",1,27,"CKD stages 3-5","or","binary",2,-0.558056860694074,1.42204828184805,0,2010.5,0,143.5
"CD008176","CD008176_pub3_data","1|28|Sensitivity analysis: change in urinary albumin/creatinine ratio without imputed SD|CKD stages 3-5","Sensitivity analysis: change in urinary albumin/creatinine ratio without imputed SD",1,28,"CKD stages 3-5","or","binary",2,-0.639646320579952,1.42598178514295,0,2018.5,0,72.5
"CD008176","CD008176_pub3_data","1|3|Cardiovascular disease|CKD stage 5D","Cardiovascular disease",1,3,"CKD stage 5D","or","binary",6,-0.160703906275471,0.345513881999726,0.0774622133451873,2011.83333333333,0.130700362460679,92.8333333333333
"CD008176","CD008176_pub3_data","1|3|Cardiovascular disease|CKD stages 3-5","Cardiovascular disease",1,3,"CKD stages 3-5","or","binary",8,-0.338750127729582,0.174828023727676,0.0877799945039996,2005.875,0.172937584798915,506.25
"CD008176","CD008176_pub3_data","1|3|Cardiovascular disease|Kidney transplant","Cardiovascular disease",1,3,"Kidney transplant","or","binary",2,0.97028549671393,1.23487696407233,0,2001.5,0,80.5
"CD008176","CD008176_pub3_data","1|4|Coronary heart disease|CKD stage 5D","Coronary heart disease",1,4,"CKD stage 5D","or","binary",6,-0.575229567033247,0.336091440303414,0.11086929430508,2006.5,0.132229154287978,93.5
"CD008176","CD008176_pub3_data","1|4|Coronary heart disease|CKD stages 3-5","Coronary heart disease",1,4,"CKD stages 3-5","or","binary",7,-0.0354892851729832,0.143551675707261,0,2009.42857142857,0.0523303147107111,544.428571428571
"CD008176","CD008176_pub3_data","1|5|Heart failure|CKD stages 3-5","Heart failure",1,5,"CKD stages 3-5","or","binary",6,0.369630344310123,0.128969525193966,0,2010,0.0417185621797511,622.166666666667
"CD008176","CD008176_pub3_data","1|6|Cerebrovascular disease|CKD stage 5D","Cerebrovascular disease",1,6,"CKD stage 5D","or","binary",4,-0.258400269933736,0.434073548253123,0,2007.5,0.0401515151515152,130.25
"CD008176","CD008176_pub3_data","1|6|Cerebrovascular disease|CKD stages 3-5","Cerebrovascular disease",1,6,"CKD stages 3-5","or","binary",3,-0.0118178307384588,0.192711130835922,0,2006.66666666667,0.0470574429384498,382.333333333333
"CD008176","CD008176_pub3_data","1|7|Peripheral vascular disease|CKD stage 5D","Peripheral vascular disease",1,7,"CKD stage 5D","or","binary",2,-0.650514494952777,0.395629270823804,0,2001.5,0.126118326118326,165
"CD008176","CD008176_pub3_data","1|7|Peripheral vascular disease|CKD stages 3-5","Peripheral vascular disease",1,7,"CKD stages 3-5","or","binary",2,-0.00712597526128148,0.608894659371497,0.40115189283598,2003.5,0.100563078784494,581
"CD008176","CD008176_pub3_data","1|8|Kidney failure|CKD stages 3-5","Kidney failure",1,8,"CKD stages 3-5","or","binary",9,-0.45250580368288,0.349893998600828,0.524291007287787,2012.33333333333,0.129285142813702,336
"CD008176","CD008176_pub3_data","1|9|eGFR at end of study|CKD stages 3-5","eGFR at end of study",1,9,"CKD stages 3-5","or","binary",22,-0.219038845503179,0.43184130957954,0,2012.95454545455,0,72.5909090909091
"CD008176","CD008176_pub3_data","1|9|eGFR at end of study|Kidney transplant","eGFR at end of study",1,9,"Kidney transplant","or","binary",10,-0.10135795733298,0.637734281150563,0,2007.5,0,83.8
"CD008176","CD008176_pub3_data","4|1|Cardiovascular death|CKD stage 5D","Cardiovascular death",4,1,"CKD stage 5D","or","binary",2,-0.620722756094839,0.423324385613336,0,2003.5,0.13458110516934,115
"CD008176","CD008176_pub3_data","4|10|Change in eGFR|CKD stages 3-5","Change in eGFR",4,10,"CKD stages 3-5","or","binary",4,0.11503753589281,1.01021500692005,0,2014,0,60.25
"CD008176","CD008176_pub3_data","4|11|Serum creatinine at end of study|Kidney transplant","Serum creatinine at end of study",4,11,"Kidney transplant","or","binary",2,0,1.4505549245172,0,2004,0,36
"CD008176","CD008176_pub3_data","4|13|Urinary albumin/creatinine ratio at end of study|CKD stages 3-5","Urinary albumin/creatinine ratio at end of study",4,13,"CKD stages 3-5","or","binary",2,-0.0210774106432065,1.4202203517384,0,2007.5,0,527
"CD008176","CD008176_pub3_data","4|14|Change in urinary albumin/creatinine ratio|CKD stages 3-5","Change in urinary albumin/creatinine ratio",4,14,"CKD stages 3-5","or","binary",2,-0.0210774106432065,1.4202203517384,0,2007.5,0,527
"CD008176","CD008176_pub3_data","4|17|Vascular access thrombosis|CKD stage 5D","Vascular access thrombosis",4,17,"CKD stage 5D","or","binary",3,0.161934151482398,0.585339603522529,0.133259717728259,2012,0.148366013071895,69.6666666666667
"CD008176","CD008176_pub3_data","4|19|Delayed graft function|Kidney transplant","Delayed graft function",4,19,"Kidney transplant","or","binary",2,-0.19544888332156,0.392803371712279,0,2009,0.254536290322581,73
"CD008176","CD008176_pub3_data","4|2|Death (any cause)|CKD stage 5D","Death (any cause)",4,2,"CKD stage 5D","or","binary",10,-0.107952776534957,0.243788632987108,0,2012.5,0.0615347663262501,135.3
"CD008176","CD008176_pub3_data","4|2|Death (any cause)|CKD stages 3-5","Death (any cause)",4,2,"CKD stages 3-5","or","binary",2,-0.120716501026582,0.164657929669059,0,2007.5,0.0941295546558704,527
"CD008176","CD008176_pub3_data","4|21|Major bleeding|CKD stage 5D","Major bleeding",4,21,"CKD stage 5D","or","binary",2,0.262115598309937,0.870611003337687,0.264968089985645,2003,0.0681818181818182,119
"CD008176","CD008176_pub3_data","4|22|Infection|CKD stage 5D","Infection",4,22,"CKD stage 5D","or","binary",4,0.375105504256786,0.365165857133437,0,2007.5,0.070864898989899,136.25
"CD008176","CD008176_pub3_data","4|3|Cardiovascular disease|CKD stage 5D","Cardiovascular disease",4,3,"CKD stage 5D","or","binary",4,0.165157529812185,0.486742517400587,9.29908163611563e-07,2011.5,0.104979115119589,94
"CD008176","CD008176_pub3_data","4|3|Cardiovascular disease|CKD stages 3-5","Cardiovascular disease",4,3,"CKD stages 3-5","or","binary",3,-0.442239346977083,0.371594104723128,0.2672677040349,2000.33333333333,0.231505633107464,427.333333333333
"CD008176","CD008176_pub3_data","4|4|Coronary heart disease|CKD stage 5D","Coronary heart disease",4,4,"CKD stage 5D","or","binary",4,-0.773419098454582,0.622461612550378,0.578718348759232,2005.75,0.135843731431967,86.75
"CD008176","CD008176_pub3_data","4|4|Coronary heart disease|CKD stages 3-5","Coronary heart disease",4,4,"CKD stages 3-5","or","binary",3,-0.0777281944937046,0.166118598802565,0,2003.66666666667,0.0922372821686323,370
"CD008176","CD008176_pub3_data","4|6|Cerebrovascular disease|CKD stage 5D","Cerebrovascular disease",4,6,"CKD stage 5D","or","binary",2,0.041353093539636,0.561696462130366,0,2007,0.0303030303030303,153.5
"CD008176","CD008176_pub3_data","4|6|Cerebrovascular disease|CKD stages 3-5","Cerebrovascular disease",4,6,"CKD stages 3-5","or","binary",3,-0.0118178307384588,0.192711130835922,0,2006.66666666667,0.0470574429384498,382.333333333333
"CD008176","CD008176_pub3_data","4|9|eGFR at end of study|CKD stages 3-5","eGFR at end of study",4,9,"CKD stages 3-5","or","binary",4,0.11503753589281,1.01021500692005,0,2014,0,60.25
"CD008176","CD008176_pub3_data","4|9|eGFR at end of study|Kidney transplant","eGFR at end of study",4,9,"Kidney transplant","or","binary",2,-0.240190707186305,1.4241915130475,0,2009,0,73
"CD008176","CD008176_pub3_data","5|1|Cardiovascular death|CKD stage 5D","Cardiovascular death",5,1,"CKD stage 5D","or","binary",2,0.264285874061919,0.436581351222888,0,2008,0.0821428571428571,107
"CD008176","CD008176_pub3_data","5|1|Cardiovascular death|CKD stages 3-5","Cardiovascular death",5,1,"CKD stages 3-5","or","binary",2,-0.537768420287205,1.00402014055442,1.72391875193181,2012.5,0.119771092879571,1138
"CD008176","CD008176_pub3_data","5|10|Change in eGFR|CKD stages 3-5","Change in eGFR",5,10,"CKD stages 3-5","or","binary",22,-0.247803308110817,0.431375240144625,0,2013.59090909091,0,173.454545454545
"CD008176","CD008176_pub3_data","5|11|Serum creatinine at end of study|CKD stages 3-5","Serum creatinine at end of study",5,11,"CKD stages 3-5","or","binary",8,-0.142783389011312,0.717253492337396,0,2011.375,0,62.625
"CD008176","CD008176_pub3_data","5|11|Serum creatinine at end of study|Kidney transplant","Serum creatinine at end of study",5,11,"Kidney transplant","or","binary",11,0.00811882185670282,0.608378771364218,0,2003.27272727273,0,86.6363636363636
"CD008176","CD008176_pub3_data","5|12|Change in serum creatinine|CKD stages 3-5","Change in serum creatinine",5,12,"CKD stages 3-5","or","binary",10,-0.230997463562685,0.639943494318051,0,2011.5,0,290.9
"CD008176","CD008176_pub3_data","5|12|Change in serum creatinine|Kidney transplant","Change in serum creatinine",5,12,"Kidney transplant","or","binary",4,-0.0434973104484055,1.01169906600994,0,2006.5,0,50
"CD008176","CD008176_pub3_data","5|13|Urinary albumin/creatinine ratio at end of study|CKD stages 3-5","Urinary albumin/creatinine ratio at end of study",5,13,"CKD stages 3-5","or","binary",3,0.0182457605349544,1.17790356857148,0,2014.66666666667,0,40
"CD008176","CD008176_pub3_data","5|14|Change in urinary albumin/creatinine ratio|CKD stages 3-5","Change in urinary albumin/creatinine ratio",5,14,"CKD stages 3-5","or","binary",5,-0.489304866461011,0.909213838353984,0,2016.2,0,46.4
"CD008176","CD008176_pub3_data","5|15|Proteinuria at end of study|CKD stages 3-5","Proteinuria at end of study",5,15,"CKD stages 3-5","or","binary",9,-0.134968996144918,0.673763488560563,0,2011.66666666667,0,59.5555555555556
"CD008176","CD008176_pub3_data","5|16|Change in proteinuria|CKD stages 3-5","Change in proteinuria",5,16,"CKD stages 3-5","or","binary",8,-0.100852525203062,0.714129163291605,0,2013.25,0,58.5
"CD008176","CD008176_pub3_data","5|17|Albuminuria at end of study|CKD stages 3-5","Albuminuria at end of study",5,17,"CKD stages 3-5","or","binary",3,-0.0490865271657437,1.16238372255332,0,2010.66666666667,0,100.666666666667
"CD008176","CD008176_pub3_data","5|18|Change in albuminuria|CKD stages 3-5","Change in albuminuria",5,18,"CKD stages 3-5","or","binary",3,-0.0490865271657437,1.16238372255332,0,2010.66666666667,0,100.666666666667
"CD008176","CD008176_pub3_data","5|2|Death (any cause)|CKD stage 5D","Death (any cause)",5,2,"CKD stage 5D","or","binary",11,-0.203289172557748,0.247382212191232,0,2015.54545454545,0.079676773329615,82.5454545454545
"CD008176","CD008176_pub3_data","5|2|Death (any cause)|CKD stages 3-5","Death (any cause)",5,2,"CKD stages 3-5","or","binary",11,0.173444783082512,0.185118612904225,0,2014.27272727273,0.0731539126156506,288.636363636364
"CD008176","CD008176_pub3_data","5|2|Death (any cause)|Kidney transplant","Death (any cause)",5,2,"Kidney transplant","or","binary",10,-0.153774003907124,0.258295620017454,0,2002.5,0.078541975587104,97.8
"CD008176","CD008176_pub3_data","5|21|Delayed graft function|Kidney transplant","Delayed graft function",5,21,"Kidney transplant","or","binary",9,-0.196829505303857,0.171923276582192,3.6005294787697e-07,2008.66666666667,0.330670897108427,79.2222222222222
"CD008176","CD008176_pub3_data","5|23|Major bleeding|CKD stage 5D","Major bleeding",5,23,"CKD stage 5D","or","binary",2,1.14963277922919,1.16980855312008,0,2011.5,0,57.5
"CD008176","CD008176_pub3_data","5|23|Major bleeding|CKD stages 3-5","Major bleeding",5,23,"CKD stages 3-5","or","binary",2,-0.430060894546911,1.05424391916223,0.602227151208199,2008.5,0.0833333333333333,48
"CD008176","CD008176_pub3_data","5|24|Infection|CKD stages 3-5","Infection",5,24,"CKD stages 3-5","or","binary",5,0.519965687399776,0.0929146075263702,6.69886223611879e-06,2012.8,0.0906393528760171,548.2
"CD008176","CD008176_pub3_data","5|24|Infection|Kidney transplant","Infection",5,24,"Kidney transplant","or","binary",3,0.117453947706558,0.313090104142641,4.06819601966798e-06,1997.33333333333,0.295088702147526,93
"CD008176","CD008176_pub3_data","5|3|Cardiovascular disease|CKD stage 5D","Cardiovascular disease",5,3,"CKD stage 5D","or","binary",2,-0.414057324752487,0.48443433244703,0.0998127030472397,2012.5,0.182142857142857,90.5
"CD008176","CD008176_pub3_data","5|3|Cardiovascular disease|CKD stages 3-5","Cardiovascular disease",5,3,"CKD stages 3-5","or","binary",5,-0.34181649863126,0.162943983095706,0,2009.2,0.137796755813786,553.6
"CD008176","CD008176_pub3_data","5|3|Cardiovascular disease|Kidney transplant","Cardiovascular disease",5,3,"Kidney transplant","or","binary",2,0.97028549671393,1.23487696407233,0,2001.5,0,80.5
"CD008176","CD008176_pub3_data","5|4|Coronary heart disease|CKD stage 5D","Coronary heart disease",5,4,"CKD stage 5D","or","binary",2,-0.32492730290866,0.410411580034866,0,2008,0.125,107
"CD008176","CD008176_pub3_data","5|4|Coronary heart disease|CKD stages 3-5","Coronary heart disease",5,4,"CKD stages 3-5","or","binary",4,0.0890646233750077,0.285259812024447,0,2013.75,0.0224000891172703,675.25
"CD008176","CD008176_pub3_data","5|5|Heart failure|CKD stages 3-5","Heart failure",5,5,"CKD stages 3-5","or","binary",5,0.433222240423665,0.184751014458392,0,2012.8,0.0245562017412074,548
"CD008176","CD008176_pub3_data","5|6|Cerebrovascular disease|CKD stage 5D","Cerebrovascular disease",5,6,"CKD stage 5D","or","binary",2,-0.46715318533834,0.989572314511929,0.793117821560431,2008,0.05,107
"CD008176","CD008176_pub3_data","5|8|Kidney failure|CKD stages 3-5","Kidney failure",5,8,"CKD stages 3-5","or","binary",8,-0.576579884883818,0.372180714749825,0.52257538873578,2013.25,0.137293611752371,366.375
"CD008176","CD008176_pub3_data","5|9|eGFR at end of study|CKD stages 3-5","eGFR at end of study",5,9,"CKD stages 3-5","or","binary",18,-0.293735884355429,0.477686119916425,0,2012.72222222222,0,75.3333333333333
"CD008176","CD008176_pub3_data","5|9|eGFR at end of study|Kidney transplant","eGFR at end of study",5,9,"Kidney transplant","or","binary",8,-0.0665383948546041,0.713237362569915,0,2007.125,0,86.5
"CD008176","CD008176_pub3_data","6|1|Cardiovascular death|CKD stage 5D","Cardiovascular death",6,1,"CKD stage 5D","or","binary",2,-0.620722756094839,0.423324385613336,0,2003.5,0.13458110516934,115
"CD008176","CD008176_pub3_data","6|10|Change in eGFR|CKD stages 3-5","Change in eGFR",6,10,"CKD stages 3-5","or","binary",9,-0.257208127855833,0.674924342721779,0,2012.33333333333,0,81
"CD008176","CD008176_pub3_data","6|11|Serum creatinine at end of study|CKD stages 3-5","Serum creatinine at end of study",6,11,"CKD stages 3-5","or","binary",2,-0.179109522432584,1.42804756750294,0,2009.5,0,52
"CD008176","CD008176_pub3_data","6|11|Serum creatinine at end of study|Kidney transplant","Serum creatinine at end of study",6,11,"Kidney transplant","or","binary",2,0,1.42450102514177,0,2010.5,0,68
"CD008176","CD008176_pub3_data","6|12|Change in serum creatinine|CKD stages 3-5","Change in serum creatinine",6,12,"CKD stages 3-5","or","binary",3,-0.438352700879128,1.16365832906857,0,2010,0,109
"CD008176","CD008176_pub3_data","6|13|Urinary albumin/creatinine ratio at end of study|CKD stages 3-5","Urinary albumin/creatinine ratio at end of study",6,13,"CKD stages 3-5","or","binary",2,0.123255155418691,1.44870732604643,0,2017.5,0,39
"CD008176","CD008176_pub3_data","6|14|Change in urinary albumin/creatinine ratio|CKD stages 3-5","Change in urinary albumin/creatinine ratio",6,14,"CKD stages 3-5","or","binary",3,-0.321815628976734,1.17838893098811,0,2018.33333333333,0,38.3333333333333
"CD008176","CD008176_pub3_data","6|15|Proteinuria at end of study|CKD stages 3-5","Proteinuria at end of study",6,15,"CKD stages 3-5","or","binary",3,-0.145867993604151,1.16841229800687,0,2012.66666666667,0,44
"CD008176","CD008176_pub3_data","6|16|Change in proteinuria|CKD stages 3-5","Change in proteinuria",6,16,"CKD stages 3-5","or","binary",3,-0.145867993604151,1.16841229800687,0,2012.66666666667,0,44
"CD008176","CD008176_pub3_data","6|17|Albuminuria at end of study|CKD stages 3-5","Albuminuria at end of study",6,17,"CKD stages 3-5","or","binary",2,0.0188759518936493,1.42004075624188,0,2008,0,131
"CD008176","CD008176_pub3_data","6|18|Change in albuminuria|CKD stages 3-5","Change in albuminuria",6,18,"CKD stages 3-5","or","binary",2,0.0188759518936493,1.42004075624188,0,2008,0,131
"CD008176","CD008176_pub3_data","6|19|Vascular access thrombosis|CKD stage 5D","Vascular access thrombosis",6,19,"CKD stage 5D","or","binary",3,0.161934151482398,0.585339603522529,0.133259717728259,2012,0.148366013071895,69.6666666666667
"CD008176","CD008176_pub3_data","6|2|Death (any cause)|CKD stage 5D","Death (any cause)",6,2,"CKD stage 5D","or","binary",10,-0.0553602098176381,0.238677897728301,0,2013.6,0.069018243308599,97
"CD008176","CD008176_pub3_data","6|2|Death (any cause)|CKD stages 3-5","Death (any cause)",6,2,"CKD stages 3-5","or","binary",4,-0.317108064877685,0.764067139883677,0,2015.25,0.0209059233449477,124.5
"CD008176","CD008176_pub3_data","6|2|Death (any cause)|Kidney transplant","Death (any cause)",6,2,"Kidney transplant","or","binary",2,-0.753637448739842,0.743249834552198,0,2010,0.0806451612903226,62
"CD008176","CD008176_pub3_data","6|20|Graft loss|Kidney transplant","Graft loss",6,20,"Kidney transplant","or","binary",3,-0.366282890050495,0.61866151532621,0,2012.66666666667,0.0645161290322581,66
"CD008176","CD008176_pub3_data","6|21|Delayed graft function|Kidney transplant","Delayed graft function",6,21,"Kidney transplant","or","binary",3,0.179549213552001,0.33232270233507,0,2012.66666666667,0.335777126099707,57.3333333333333
"CD008176","CD008176_pub3_data","6|23|Major bleeding|CKD stage 5D","Major bleeding",6,23,"CKD stage 5D","or","binary",2,1.40983420187268,1.13401112897266,0,2008,0,124
"CD008176","CD008176_pub3_data","6|24|Infection|CKD stage 5D","Infection",6,24,"CKD stage 5D","or","binary",2,0.304317649148484,0.44054745320347,0,2005,0.0508207070707071,146
"CD008176","CD008176_pub3_data","6|24|Infection|CKD stages 3-5","Infection",6,24,"CKD stages 3-5","or","binary",3,0.175656502129744,0.476604296824498,0,2010.33333333333,0.058725597518701,145.333333333333
"CD008176","CD008176_pub3_data","6|3|Cardiovascular disease|CKD stage 5D","Cardiovascular disease",6,3,"CKD stage 5D","or","binary",2,-0.875430201034171,1.30251582089816,1.84363562161588,2013,0.134313725490196,61.5
"CD008176","CD008176_pub3_data","6|3|Cardiovascular disease|CKD stages 3-5","Cardiovascular disease",6,3,"CKD stages 3-5","or","binary",4,-0.549192738722579,0.286427488805411,0.0539363227826277,2006.75,0.150378957251837,171.25
"CD008176","CD008176_pub3_data","6|4|Coronary heart disease|CKD stage 5D","Coronary heart disease",6,4,"CKD stage 5D","or","binary",3,-1.31265026177322,0.471928381562396,0,2005.66666666667,0.135670429788077,101.666666666667
"CD008176","CD008176_pub3_data","6|4|Coronary heart disease|CKD stages 3-5","Coronary heart disease",6,4,"CKD stages 3-5","or","binary",4,-0.448695529545055,0.448997307333384,0,2009.25,0.045927694047713,128.25
"CD008176","CD008176_pub3_data","6|5|Heart failure|CKD stages 3-5","Heart failure",6,5,"CKD stages 3-5","or","binary",3,-0.00621377600051772,0.494844497652474,0,2010.33333333333,0.0281649245063879,145
"CD008176","CD008176_pub3_data","6|8|Kidney failure|CKD stages 3-5","Kidney failure",6,8,"CKD stages 3-5","or","binary",4,-0.0986533518810583,0.450428669549602,0,2009,0.0336969673058208,132.25
"CD008176","CD008176_pub3_data","6|9|eGFR at end of study|CKD stages 3-5","eGFR at end of study",6,9,"CKD stages 3-5","or","binary",8,-0.289746366831627,0.716344197869378,0,2011.375,0,82.375
"CD008176","CD008176_pub3_data","6|9|eGFR at end of study|Kidney transplant","eGFR at end of study",6,9,"Kidney transplant","or","binary",3,-0.0543764211015628,1.16471776728242,0,2012.66666666667,0,57.3333333333333
"CD008176","CD008176_pub3_data","7|1|Cardiovascular death|CKD stages 3-5","Cardiovascular death",7,1,"CKD stages 3-5","or","binary",3,-0.233159369758754,0.489676390839756,0.550423184566192,2007,0.118308933714585,1089.66666666667
"CD008176","CD008176_pub3_data","7|1|Cardiovascular death|CKD stages 5D","Cardiovascular death",7,1,"CKD stages 5D","or","binary",3,-0.27417826283521,0.358214555080272,0.0489392569158906,2003.33333333333,0.127815974874798,121.333333333333
"CD008176","CD008176_pub3_data","7|10|Change in eGFR|CKD stages 3-5","Change in eGFR",7,10,"CKD stages 3-5","or","binary",16,-0.219714455224078,0.505187952228586,0,2012.4375,0,214.0625
"CD008176","CD008176_pub3_data","7|10|Change in eGFR|Kidney transplant","Change in eGFR",7,10,"Kidney transplant","or","binary",2,-0.0836848570264848,1.45068857428265,0,2006.5,0,35.5
"CD008176","CD008176_pub3_data","7|11|Serum creatinine at end of study|CKD stages 3-5","Serum creatinine at end of study",7,11,"CKD stages 3-5","or","binary",4,-0.200044888692634,1.01051059637323,0,2011,0,81.5
"CD008176","CD008176_pub3_data","7|11|Serum creatinine at end of study|Kidney transplant","Serum creatinine at end of study",7,11,"Kidney transplant","or","binary",7,0.119453361436046,0.764235818219275,0,2005,0,100.142857142857
"CD008176","CD008176_pub3_data","7|12|Change in serum creatinine|CKD stages 3-5","Change in serum creatinine",7,12,"CKD stages 3-5","or","binary",6,-0.290890989564544,0.822737606060367,0,2011.33333333333,0,455.666666666667
"CD008176","CD008176_pub3_data","7|12|Change in serum creatinine|Kidney transplant","Change in serum creatinine",7,12,"Kidney transplant","or","binary",3,-0.08687860915656,1.17893792979601,0,2006.33333333333,0,37.6666666666667
"CD008176","CD008176_pub3_data","7|13|Urinary albumin/creatinine ratio at end of study|CKD stages 3-5","Urinary albumin/creatinine ratio at end of study",7,13,"CKD stages 3-5","or","binary",3,0.298102499703824,1.1615570682532,0,2011.33333333333,0,373
"CD008176","CD008176_pub3_data","7|14|Change in urinary albumin/creatinine ratio|CKD stages 3-5","Change in urinary albumin/creatinine ratio",7,14,"CKD stages 3-5","or","binary",3,-0.0941840939099896,1.16379808466157,0,2011.33333333333,0,362
"CD008176","CD008176_pub3_data","7|15|Proteinuria at end of study|CKD stages 3-5","Proteinuria at end of study",7,15,"CKD stages 3-5","or","binary",5,-0.1625257141322,0.906283249481489,0,2010,0,46.6
"CD008176","CD008176_pub3_data","7|16|Change in proteinuria|CKD stages 3-5","Change in proteinuria",7,16,"CKD stages 3-5","or","binary",4,-0.123152378771618,1.01151239380266,0,2012.75,0,52.25
"CD008176","CD008176_pub3_data","7|17|Albuminuria at end of study|CKD stages 3-5","Albuminuria at end of study",7,17,"CKD stages 3-5","or","binary",3,0.00536065630932878,1.15995825447419,0,2009.33333333333,0,117.666666666667
"CD008176","CD008176_pub3_data","7|18|Change in albuminuria|CKD stages 3-5","Change in albuminuria",7,18,"CKD stages 3-5","or","binary",3,0.00536065630932878,1.15995825447419,0,2009.33333333333,0,117.666666666667
"CD008176","CD008176_pub3_data","7|2|Death (any cause)|CKD stage 5D","Death (any cause)",7,2,"CKD stage 5D","or","binary",7,-0.0170221281700496,0.209643904692697,5.67257941913142e-06,2009.28571428571,0.124301366860629,164.428571428571
"CD008176","CD008176_pub3_data","7|2|Death (any cause)|CKD stages 3-5","Death (any cause)",7,2,"CKD stages 3-5","or","binary",8,0.01201441824314,0.155563659298282,0.024026345406732,2012.25,0.124119018510487,482.5
"CD008176","CD008176_pub3_data","7|2|Death (any cause)|Kidney transplant","Death (any cause)",7,2,"Kidney transplant","or","binary",8,-0.209327915140873,0.25617752231294,0,2002.75,0.089440910344095,106.875
"CD008176","CD008176_pub3_data","7|20|Graft loss|Kidney transplant","Graft loss",7,20,"Kidney transplant","or","binary",7,-0.0667623054794336,0.22937971852031,0.0742884836584034,2002,0.180734914465916,113.428571428571
"CD008176","CD008176_pub3_data","7|22|Delayed graft function|Kidney transplant","Delayed graft function",7,22,"Kidney transplant","or","binary",5,-0.240496601951476,0.18675997187193,0,2005.6,0.380173401696439,114.2
"CD008176","CD008176_pub3_data","7|24|Major bleeding|CKD stages 3-5","Major bleeding",7,24,"CKD stages 3-5","or","binary",2,-0.430060894546911,1.05424391916223,0.602227151208199,2008.5,0.0833333333333333,48
"CD008176","CD008176_pub3_data","7|24|Major bleeding|CKD stages 5D","Major bleeding",7,24,"CKD stages 5D","or","binary",3,0.366381664969112,0.69953223314487,0,2004.33333333333,0.0454545454545454,100.333333333333
"CD008176","CD008176_pub3_data","7|25|Infection|CKD stage 5D","Infection",7,25,"CKD stage 5D","or","binary",3,0.353653032762702,0.389315804443512,0,2006.66666666667,0.0875420875420875,149.666666666667
"CD008176","CD008176_pub3_data","7|25|Infection|CKD stages 3-5","Infection",7,25,"CKD stages 3-5","or","binary",5,0.524824013677716,0.0927601363747458,0,2012.6,0.0900332922699565,536.4
"CD008176","CD008176_pub3_data","7|3|Cardiovascular disease|CKD stage 5D","Cardiovascular disease",7,3,"CKD stage 5D","or","binary",4,-0.286040741632752,0.465106950731854,0.239260830628438,2009.75,0.175217210357684,97
"CD008176","CD008176_pub3_data","7|3|Cardiovascular disease|CKD stages 3-5","Cardiovascular disease",7,3,"CKD stages 3-5","or","binary",7,-0.349536188287074,0.17966581844818,0.0933830091406091,2005.57142857143,0.192351948764898,571
"CD008176","CD008176_pub3_data","7|4|Coronary heart disease|CKD stage 5D","Coronary heart disease",7,4,"CKD stage 5D","or","binary",4,-0.67522527946945,0.409582292218605,0.221721113934119,2004,0.185843731431967,101.5
"CD008176","CD008176_pub3_data","7|4|Coronary heart disease|CKD stages 3-5","Coronary heart disease",7,4,"CKD stages 3-5","or","binary",5,-0.043271258816495,0.144463616367746,0,2007.2,0.0732624405949956,733.4
"CD008176","CD008176_pub3_data","7|5|Heart failure|CKD stages 3-5","Heart failure",7,5,"CKD stages 3-5","or","binary",5,0.371847035408473,0.129236283642683,0,2008,0.0500622746157013,722.6
"CD008176","CD008176_pub3_data","7|6|Cerebrovascular disease|CKD stage 5D","Cerebrovascular disease",7,6,"CKD stage 5D","or","binary",3,-0.361395554889107,0.449959070546701,2.65004886110819e-06,2005.66666666667,0.0535353535353535,147
"CD008176","CD008176_pub3_data","7|6|Cerebrovascular disease|CKD stages 3-5","Cerebrovascular disease",7,6,"CKD stages 3-5","or","binary",3,-0.0118178307384588,0.192711130835922,0,2006.66666666667,0.0470574429384498,382.333333333333
"CD008176","CD008176_pub3_data","7|7|Peripheral vascular disease|CKD stage 5D","Peripheral vascular disease",7,7,"CKD stage 5D","or","binary",2,-0.650514494952777,0.395629270823804,0,2001.5,0.126118326118326,165
"CD008176","CD008176_pub3_data","7|7|Peripheral vascular disease|CKD stages 3-5","Peripheral vascular disease",7,7,"CKD stages 3-5","or","binary",2,-0.00712597526128148,0.608894659371497,0.40115189283598,2003.5,0.100563078784494,581
"CD008176","CD008176_pub3_data","7|8|Kidney failure|CKD stages 3-5","Kidney failure",7,8,"CKD stages 3-5","or","binary",8,-0.197789795846895,0.174412629539576,2.84193793551975e-07,2011.75,0.0769934047130338,367.5
"CD008176","CD008176_pub3_data","7|9|eGFR at end of study|CKD stages 3-5","eGFR at end of study",7,9,"CKD stages 3-5","or","binary",15,-0.233778241314866,0.522112959157246,0,2012.4,0,82.6
"CD008176","CD008176_pub3_data","7|9|eGFR at end of study|Kidney transplant","eGFR at end of study",7,9,"Kidney transplant","or","binary",5,-0.0365678207850189,0.900041236420642,0,2007.8,0,102.4
"CD008237","CD008237_pub4_data","1|2|Independent procedure completion: type of endoscopic procedure under study|Colonoscopy","Independent procedure completion: type of endoscopic procedure under study",1,2,"Colonoscopy","or","binary",5,0.954599476885784,0.312466641015792,0.186337184392709,2007.6,0.213954802259887,81.6
"CD008237","CD008237_pub4_data","1|3|Independent procedure completion: level of participant endoscopy experience|Limited prior training in endoscopy","Independent procedure completion: level of participant endoscopy experience",1,3,"Limited prior training in endoscopy","or","binary",3,0.839568754799355,0.412266886591946,0.320660967284414,2007.66666666667,0.212146892655367,109.666666666667
"CD008237","CD008237_pub4_data","1|3|Independent procedure completion: level of participant endoscopy experience|No prior training in endoscopy","Independent procedure completion: level of participant endoscopy experience",1,3,"No prior training in endoscopy","or","binary",3,1.15332465300637,0.235584466734807,0,2006.33333333333,0.377613574165298,162
"CD008237","CD008237_pub4_data","1|4|Performance time|","Performance time",1,4,"","or","binary",2,-0.024844639229955,1.46174434021005,0,2011,0,14.5
"CD008309","CD008309_pub3_data","1|1|Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)|","Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)",1,1,"","or","binary",2,0.313912153992159,0.799129160005682,0,2017,0.0333333333333333,55
"CD008309","CD008309_pub3_data","1|12|Pulmonary air leak, any (during first hospitalisation)|","Pulmonary air leak, any (during first hospitalisation)",1,12,"","or","binary",5,0.279475288846254,0.418904021917956,0,2017.8,0.0504761904761905,66.6
"CD008309","CD008309_pub3_data","1|13|Duration of any respiratory support (mechanical ventilation, continuous positive airway pressure, high flow) (days; in survivors)|","Duration of any respiratory support (mechanical ventilation, continuous positive airway pressure, high flow) (days; in survivors)",1,13,"","or","binary",2,0,1.42494748116715,0,2016.5,0,65
"CD008309","CD008309_pub3_data","1|15|BPD (clinical definition) among survivors to 36 weeks' PMA|","BPD (clinical definition) among survivors to 36 weeks' PMA",1,15,"","or","binary",4,0.206194955763334,0.506038664112896,0,2018.75,0.0449612403100775,66
"CD008309","CD008309_pub3_data","1|16|Any intraventricular haemorrhage|","Any intraventricular haemorrhage",1,16,"","or","binary",2,0,0.745850974476826,0,2018.5,0.05,55
"CD008309","CD008309_pub3_data","1|2|Failure to place LMA or ETT at first attempt|","Failure to place LMA or ETT at first attempt",1,2,"","or","binary",2,-0.958732072786833,0.571217066212115,0,2018,0.135714285714286,81.5
"CD008309","CD008309_pub3_data","1|24|Duration of hospitalisation (days)|","Duration of hospitalisation (days)",1,24,"","or","binary",4,-0.048193317494135,1.00717264155111,0,2017.75,0,70.75
"CD008309","CD008309_pub3_data","1|26|Death (all causes) during the first hospitalisation|","Death (all causes) during the first hospitalisation",1,26,"","or","binary",3,-0.563889321616403,1.07824049841805,0,2018.66666666667,0.00793650793650794,67.6666666666667
"CD008309","CD008309_pub3_data","1|28|Number of hospital readmissions with respiratory illness in the first two years|","Number of hospital readmissions with respiratory illness in the first two years",1,28,"","or","binary",2,0,1.42494748116715,0,2015,0,65
"CD008309","CD008309_pub3_data","1|3|Bradycardia (heart rate < 100 beats per minute) during the intervention|","Bradycardia (heart rate < 100 beats per minute) during the intervention",1,3,"","or","binary",3,-0.742394245662888,0.625095510127011,0,2018.66666666667,0.0746031746031746,67.6666666666667
"CD008309","CD008309_pub3_data","1|4|Hypoxaemia (oxygen saturation < 80%) during the intervention|","Hypoxaemia (oxygen saturation < 80%) during the intervention",1,4,"","or","binary",3,0.781582748607908,0.67209172835352,0,2018.66666666667,0.0158730158730159,67.6666666666667
"CD008309","CD008309_pub3_data","1|6|Surfactant reflux during the intervention|","Surfactant reflux during the intervention",1,6,"","or","binary",3,-0.300195514929846,0.508733399727266,0.255209784083618,2017.33333333333,0.215873015873016,74.3333333333333
"CD008309","CD008309_pub3_data","1|7|Postintervention intratracheal surfactant received|","Postintervention intratracheal surfactant received",1,7,"","or","binary",4,0.564164170938602,0.38622206249019,0,2016.75,0.113095238095238,60
"CD008309","CD008309_pub3_data","2|1|Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)|Sedation or analgesia for InSurE","Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)",2,1,"Sedation or analgesia for InSurE","or","binary",2,0.313912153992159,0.799129160005682,0,2017,0.0333333333333333,55
"CD008309","CD008309_pub3_data","2|2|Mechanical ventilation at any time|Sedation or analgesia for InSurE","Mechanical ventilation at any time",2,2,"Sedation or analgesia for InSurE","or","binary",4,-0.92127570294283,0.474334536819735,0.499660153191876,2018.75,0.376904761904762,65.75
"CD008309","CD008309_pub3_data","2|3|Pulmonary air leak, any (during first hospitalisation)|Sedation or analgesia for InSurE","Pulmonary air leak, any (during first hospitalisation)",2,3,"Sedation or analgesia for InSurE","or","binary",4,0.292112312059404,0.428270099455512,0,2018.75,0.0630952380952381,65.75
"CD008309","CD008309_pub3_data","2|4|BPD (clinical definition) among survivors to 36 weeks' PMA|Sedation or analgesia for InSurE","BPD (clinical definition) among survivors to 36 weeks' PMA",2,4,"Sedation or analgesia for InSurE","or","binary",4,0.206194955763334,0.506038664112896,0,2018.75,0.0449612403100775,66
"CD008309","CD008309_pub3_data","2|6|Death (all causes) during the first hospitalisation|Sedation or analgesia for InSurE","Death (all causes) during the first hospitalisation",2,6,"Sedation or analgesia for InSurE","or","binary",3,-0.563889321616403,1.07824049841805,0,2018.66666666667,0.00793650793650794,67.6666666666667
"CD008309","CD008309_pub3_data","3|2|Mechanical ventilation at any time|28 to 36 weeks","Mechanical ventilation at any time",3,2,"28 to 36 weeks","or","binary",3,-0.863209022757079,0.593008820602899,0.756742527740818,2019,0.449206349206349,71
"CD008309","CD008309_pub3_data","3|2|Mechanical ventilation at any time|32 to 36 weeks","Mechanical ventilation at any time",3,2,"32 to 36 weeks","or","binary",2,-0.990785504628039,0.887045625275093,0,2016,0.08,60
"CD008309","CD008309_pub3_data","3|3|Pulmonary air leak, any (during first hospitalisation)|28 to 36 weeks","Pulmonary air leak, any (during first hospitalisation)",3,3,"28 to 36 weeks","or","binary",3,0.305867803602914,0.438237669580953,0,2019,0.0841269841269841,71
"CD008309","CD008309_pub3_data","3|3|Pulmonary air leak, any (during first hospitalisation)|32 to 36 weeks","Pulmonary air leak, any (during first hospitalisation)",3,3,"32 to 36 weeks","or","binary",2,0,1.42607059757457,0,2016,0,60
"CD008309","CD008309_pub3_data","3|4|BPD (clinical definition) among survivors to 36 weeks' PMA|28 to 36 weeks","BPD (clinical definition) among survivors to 36 weeks' PMA",3,4,"28 to 36 weeks","or","binary",3,0.220008791172407,0.522714683073925,0,2019,0.0599483204134367,71.3333333333333
"CD008309","CD008309_pub3_data","3|6|Death (all causes) during the first hospitalisation|28 to 36 weeks","Death (all causes) during the first hospitalisation",3,6,"28 to 36 weeks","or","binary",2,-0.788723912676527,1.27520852850362,0,2019,0.0119047619047619,76.5
"CD008309","CD008309_pub3_data","4|2|Surfactant reflux during the intervention|","Surfactant reflux during the intervention",4,2,"","or","binary",2,-1.24314660654273,1.25060806056886,2.13915653347468,2019,0.238095238095238,76.5
"CD008309","CD008309_pub3_data","4|3|Postintervention intratracheal surfactant received|","Postintervention intratracheal surfactant received",4,3,"","or","binary",3,0.796705969554645,0.431773464149296,0,2017.66666666667,0.122222222222222,56.6666666666667
"CD008309","CD008309_pub3_data","4|4|Mechanical ventilation at any time|","Mechanical ventilation at any time",4,4,"","or","binary",4,-0.92127570294283,0.474334536819735,0.499660153191876,2018.75,0.376904761904762,65.75
"CD008309","CD008309_pub3_data","4|5|Pulmonary air leak, any (during first hospitalisation)|","Pulmonary air leak, any (during first hospitalisation)",4,5,"","or","binary",4,0.292112312059404,0.428270099455512,0,2018.75,0.0630952380952381,65.75
"CD008309","CD008309_pub3_data","4|7|Duration of hospitalisation (days)|","Duration of hospitalisation (days)",4,7,"","or","binary",3,-0.0642643520325716,1.16304247380151,0,2019,0,71
"CD008309","CD008309_pub3_data","6|1|Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)|","Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)",6,1,"","or","binary",2,0.749309519927666,0.594561946806622,0,2015.5,0.27866473149492,64.5
"CD008309","CD008309_pub3_data","6|10|Duration of any respiratory support (mechanical ventilation, continuous positive airway pressure, high flow) (days; in survivors)|","Duration of any respiratory support (mechanical ventilation, continuous positive airway pressure, high flow) (days; in survivors)",6,10,"","or","binary",2,0.0292406409297117,1.43048706456342,0,2015.5,0,64.5
"CD008309","CD008309_pub3_data","6|12|Bronchopulmonary dysplasia (clinical definition) among survivors to 36 weeks' PMA|","Bronchopulmonary dysplasia (clinical definition) among survivors to 36 weeks' PMA",6,12,"","or","binary",2,0.749309519927666,0.594561946806622,0,2015.5,0.27866473149492,64.5
"CD008309","CD008309_pub3_data","6|4|Postintervention intratracheal surfactant received|","Postintervention intratracheal surfactant received",6,4,"","or","binary",2,-1.12165898966799,0.391294595416833,0,2015.5,0.436139332365747,64.5
"CD008309","CD008309_pub3_data","6|7|Mechanical ventilation at any time|","Mechanical ventilation at any time",6,7,"","or","binary",2,-1.04651701402001,0.377676295003655,0,2015.5,0.436139332365747,64.5
"CD008309","CD008309_pub3_data","6|8|Pulmonary air leak, any (during first hospitalisation)|","Pulmonary air leak, any (during first hospitalisation)",6,8,"","or","binary",2,-0.403244019001117,0.565400450647707,0,2015.5,0.16255442670537,64.5
"CD008309","CD008309_pub3_data","6|9|Duration of mechanical ventilation via ETT (days; in survivors)|","Duration of mechanical ventilation via ETT (days; in survivors)",6,9,"","or","binary",2,0.0292406409297117,1.43048706456342,0,2015.5,0,64.5
"CD008349","CD008349_pub5_data","1|1|Upper limb function post intervention (composite measure)|","Upper limb function post intervention (composite measure)",1,1,"","reported","reported",63,0,0.0400823572779712,0,2016.90476190476,0,41.5396825396825
"CD008349","CD008349_pub5_data","1|10|Timed Up and Go Test post intervention |","Timed Up and Go Test post intervention ",1,10,"","or","binary",10,-0.00846685900275858,0.641578575199544,0,2017.5,0,40
"CD008349","CD008349_pub5_data","1|11|Balance post intervention |","Balance post intervention ",1,11,"","or","binary",24,0.00424226239168105,0.414778420128059,0,2019.08333333333,0,36.2916666666667
"CD008349","CD008349_pub5_data","1|12|Cognitive function post intervention|","Cognitive function post intervention",1,12,"","or","binary",9,0.00621968050429502,0.6784576022724,0,2017.66666666667,0,31
"CD008349","CD008349_pub5_data","1|14|Participation restriction and quality of life post intervention |","Participation restriction and quality of life post intervention ",1,14,"","reported","reported",15,0,0.0678780897525384,0,2018.06666666667,0,61.2666666666667
"CD008349","CD008349_pub5_data","1|2|Hand function post intervention (grip strength)|","Hand function post intervention (grip strength)",1,2,"","reported","reported",2,0,0.31310005087267,0,2020.5,0,33.5
"CD008349","CD008349_pub5_data","1|3|Upper limb function post intervention: amount of use (subjective)|","Upper limb function post intervention: amount of use (subjective)",1,3,"","reported","reported",10,0,0.0975613062333796,0,2015.3,0,42.8
"CD008349","CD008349_pub5_data","1|4|Upper limb function at short term follow-up (up to 3 months)|","Upper limb function at short term follow-up (up to 3 months)",1,4,"","reported","reported",13,0,0.081764353312283,0,2013.92307692308,0,46.5384615384615
"CD008349","CD008349_pub5_data","1|5|Upper limb function: subgroup analysis based on amount of therapy |Less than 15 hours of intervention","Upper limb function: subgroup analysis based on amount of therapy ",1,5,"Less than 15 hours of intervention","or","binary",32,-0.0367436284837921,0.359434425305513,0,2017.5625,0,38.8125
"CD008349","CD008349_pub5_data","1|5|Upper limb function: subgroup analysis based on amount of therapy |More than 15 hours of intervention","Upper limb function: subgroup analysis based on amount of therapy ",1,5,"More than 15 hours of intervention","or","binary",34,-0.0767984781691015,0.34973717991829,0,2017.17647058824,0,43.8823529411765
"CD008349","CD008349_pub5_data","1|6|Upper limb function: subgroup analysis based on time since onset of stroke|Less than 6 months","Upper limb function: subgroup analysis based on time since onset of stroke",1,6,"Less than 6 months","or","binary",28,-0.0486629582231846,0.383799813166468,0,2018.03571428571,0,51.1428571428571
"CD008349","CD008349_pub5_data","1|6|Upper limb function: subgroup analysis based on time since onset of stroke|More than 6 months","Upper limb function: subgroup analysis based on time since onset of stroke",1,6,"More than 6 months","or","binary",35,-0.0523616990592479,0.34526803098687,0,2016.6,0,32.2571428571429
"CD008349","CD008349_pub5_data","1|7|Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings |Gaming","Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings ",1,7,"Gaming","or","binary",21,-0.0379835251145051,0.44285718731725,0,2017.80952380952,0,49.1428571428571
"CD008349","CD008349_pub5_data","1|7|Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings |Specialised","Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings ",1,7,"Specialised","reported","reported",2,0,0.225309985875313,0,2020,0,77.5
"CD008349","CD008349_pub5_data","1|8|Upper limb function: subgroup analysis based on level of immersion of customised virtual reality application |Immersive virtual reality ","Upper limb function: subgroup analysis based on level of immersion of customised virtual reality application ",1,8,"Immersive virtual reality ","reported","reported",4,0,0.18520238786338,0,2017.5,0,31.5
"CD008349","CD008349_pub5_data","1|8|Upper limb function: subgroup analysis based on level of immersion of customised virtual reality application |Non-immersive virtual reality ","Upper limb function: subgroup analysis based on level of immersion of customised virtual reality application ",1,8,"Non-immersive virtual reality ","or","binary",39,-0.0420904600842218,0.325794876384479,0,2017.07692307692,0,41.4102564102564
"CD008349","CD008349_pub5_data","1|9|Gait speed post intervention |","Gait speed post intervention ",1,9,"","or","binary",10,-0.0115404258029629,0.644640783782845,0,2014.1,0,30.4
"CD008349","CD008349_pub5_data","2|1|Upper limb function post intervention (composite measure)|","Upper limb function post intervention (composite measure)",2,1,"","or","binary",22,-0.0556045936711017,0.436891687147719,0,2015.54545454545,0,31.3181818181818
"CD008349","CD008349_pub5_data","2|10|Activity limitation post intervention|","Activity limitation post intervention",2,10,"","or","binary",15,0.00143365414808364,0.527450489776994,0,2015.66666666667,0,34.2
"CD008349","CD008349_pub5_data","2|11|Participation restriction and quality of life post intervention|","Participation restriction and quality of life post intervention",2,11,"","or","binary",2,0.034495650722605,1.43839691803288,0,2019.5,0,38
"CD008349","CD008349_pub5_data","2|2|Upper limb function post intervention: amount of use (subjective)|","Upper limb function post intervention: amount of use (subjective)",2,2,"","or","binary",4,0.0173977223577142,1.02151034898901,0,2021.5,0,28
"CD008349","CD008349_pub5_data","2|3|Upper limb function: subgroup analysis based on amount of therapy|Less than 15 hours of intervention","Upper limb function: subgroup analysis based on amount of therapy",2,3,"Less than 15 hours of intervention","or","binary",17,-0.0619879431092244,0.496604379959396,0,2015.76470588235,0,35
"CD008349","CD008349_pub5_data","2|3|Upper limb function: subgroup analysis based on amount of therapy|More than 15 hours of intervention","Upper limb function: subgroup analysis based on amount of therapy",2,3,"More than 15 hours of intervention","or","binary",5,-0.0337462609291287,0.918956073437457,0,2014.8,0,18.8
"CD008349","CD008349_pub5_data","2|4|Upper limb function: subgroup analysis based on time since onset of stroke|Less than 6 months","Upper limb function: subgroup analysis based on time since onset of stroke",2,4,"Less than 6 months","or","binary",11,-0.053326084943433,0.61898151234627,0,2014.54545454545,0,37.5454545454545
"CD008349","CD008349_pub5_data","2|4|Upper limb function: subgroup analysis based on time since onset of stroke|More than 6 months","Upper limb function: subgroup analysis based on time since onset of stroke",2,4,"More than 6 months","or","binary",10,-0.0569722695187682,0.64723942211512,0,2017,0,24.7
"CD008349","CD008349_pub5_data","2|5|Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings |Customised ","Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings ",2,5,"Customised ","or","binary",13,-0.0287915777723127,0.570440272644392,0,2015.15384615385,0,32.4615384615385
"CD008349","CD008349_pub5_data","2|5|Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings |Non-customised","Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings ",2,5,"Non-customised","or","binary",9,-0.093648168800356,0.679482079667263,0,2016.11111111111,0,29.6666666666667
"CD008349","CD008349_pub5_data","2|6|Gait speed post intervention|","Gait speed post intervention",2,6,"","or","binary",3,0.0304713430407142,1.18357170895352,0,2014.33333333333,0,19
"CD008349","CD008349_pub5_data","2|8|Balance post intervention|","Balance post intervention",2,8,"","or","binary",12,-0.019481308041295,0.589018416262994,0,2015.83333333333,0,26.75
"CD008349","CD008349_pub5_data","2|9|Global motor function post intervention|","Global motor function post intervention",2,9,"","or","binary",3,-0.113387274175643,1.19372523687854,0,2010.66666666667,0,14.3333333333333
"CD008469","CD008469_pub3_data","1|1|Exacerbations leading to emergency department (ED) visits: subgrouped by time frame of follow-up|ED visits – long time frame (> 6 months)","Exacerbations leading to emergency department (ED) visits: subgrouped by time frame of follow-up",1,1,"ED visits – long time frame (> 6 months)","or","binary",5,0.0193984683479771,0.323126410177376,0.110245568348238,2009.4,0.168132942326491,125.4
"CD008469","CD008469_pub3_data","1|1|Exacerbations leading to emergency department (ED) visits: subgrouped by time frame of follow-up|ED visits – short time frame (≤ 6 months)","Exacerbations leading to emergency department (ED) visits: subgrouped by time frame of follow-up",1,1,"ED visits – short time frame (≤ 6 months)","reported","reported",2,0,1.47411515615316,0,2007.5,0.19047619047619,126
"CD008469","CD008469_pub3_data","1|2|Exacerbations requiring a course of oral corticosteroids: subgrouped by time frame of follow-up|Exacerbations requiring a course of oral corticosteroids: long time frame (> 6 months)","Exacerbations requiring a course of oral corticosteroids: subgrouped by time frame of follow-up",1,2,"Exacerbations requiring a course of oral corticosteroids: long time frame (> 6 months)","or","binary",3,-0.440548374498627,1.15898700742367,0,2013,0,157.666666666667
"CD008469","CD008469_pub3_data","1|2|Exacerbations requiring a course of oral corticosteroids: subgrouped by time frame of follow-up|Exacerbations requiring a course of oral corticosteroids: short time frame (≤ 6 months) ","Exacerbations requiring a course of oral corticosteroids: subgrouped by time frame of follow-up",1,2,"Exacerbations requiring a course of oral corticosteroids: short time frame (≤ 6 months) ","or","binary",2,-0.693199808842029,1.42051364851864,0,2009,0,125
"CD008469","CD008469_pub3_data","1|3|Quality of life|Caregiver quality of life","Quality of life",1,3,"Caregiver quality of life","reported","reported",2,0,0.0774347537361253,0,2012,0,341
"CD008469","CD008469_pub3_data","1|3|Quality of life|Children quality of life","Quality of life",1,3,"Children quality of life","or","binary",3,-0.511704178975577,1.1608013803045,0,2013.33333333333,0,101.666666666667
"CD008469","CD008469_pub3_data","1|4|Day symptoms (change in mean symptom-free days in 2 weeks)|","Day symptoms (change in mean symptom-free days in 2 weeks)",1,4,"","or","binary",2,0.0144003621465598,1.41629845138781,0,2012,0,341
"CD008469","CD008469_pub3_data","1|5|Days missed from school|Mean days off school in 6 months","Days missed from school",1,5,"Mean days off school in 6 months","or","binary",2,-0.0641653396184225,1.42003414334791,0,1986,0,129.5
"CD008469","CD008469_pub3_data","1|6|Exacerbations leading to hospitalisations: subgrouped by time frame of follow-up|Hospitalisations – short time frame (≤ 6 months)","Exacerbations leading to hospitalisations: subgrouped by time frame of follow-up",1,6,"Hospitalisations – short time frame (≤ 6 months)","or","binary",4,0.27973724672237,0.193697134746719,0,1997.5,0.204688766901146,154.5
"CD008469","CD008469_pub3_data","2|1|Exacerbations leading to emergency department visits|","Exacerbations leading to emergency department visits",2,1,"","reported","reported",2,0,0.929117682808958,0,2012,0,233.5
"CD008469","CD008469_pub3_data","2|2|Exacerbations requiring a course of oral corticosteroids|","Exacerbations requiring a course of oral corticosteroids",2,2,"","or","binary",3,-0.08869283945646,1.15758151087639,0,2010,0,201.666666666667
"CD008469","CD008469_pub3_data","2|4|Exacerbations leading to hospitalisation |","Exacerbations leading to hospitalisation ",2,4,"","or","binary",4,-1.22444043166369,0.467206573126692,0,2010.5,0.119476744186047,172.25
"CD008493","CD008493_pub5_data","1|3|Myocardial infarction|","Myocardial infarction",1,3,"","reported","reported",2,0,1.14512835386305,0,2009.5,0.0278571428571429,128.5
"CD008493","CD008493_pub5_data","1|4|Atrial fibrillation|","Atrial fibrillation",1,4,"","reported","reported",2,0,1.02288947549215,0,2009.5,0.371428571428571,128.5
"CD008493","CD008493_pub5_data","1|5|Stroke|","Stroke",1,5,"","reported","reported",2,0,1.01650618135594,0,2019.5,0.0159725550401954,1510.5
"CD008493","CD008493_pub5_data","1|6|Renal failure|","Renal failure",1,6,"","or","binary",4,0.0438720695113455,0.162868556006848,0.0514594624142335,2015.75,0.150969799168054,1182
"CD008493","CD008493_pub5_data","1|7|Length of stay in the intensive care unit (hours)|","Length of stay in the intensive care unit (hours)",1,7,"","reported","reported",3,0,0.992824295668277,0,2018.33333333333,0,1509.33333333333
"CD008493","CD008493_pub5_data","1|8|Length of stay in the hospital (days)|","Length of stay in the hospital (days)",1,8,"","reported","reported",3,0,0.0539983622062249,0,2018.33333333333,0,1509.33333333333
"CD008493","CD008493_pub5_data","2|1|Mortality|Statins discontinuation > 21 days before surgery or statin-naive participants","Mortality",2,1,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",2,0,1.06733525447937,0,2014,0,130
"CD008493","CD008493_pub5_data","2|1|Mortality|Statins discontinuation ≤ 21 days before surgery","Mortality",2,1,"Statins discontinuation ≤ 21 days before surgery","reported","reported",2,0,0.350580835857671,0,2019.5,0.00836980677557806,1398
"CD008493","CD008493_pub5_data","2|2|Myocardial infarction|Statins discontinuation > 21 days before surgery or statin-naive participants","Myocardial infarction",2,2,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",3,0,0.796020719261811,0,2010.33333333333,0.0296825396825397,105.666666666667
"CD008493","CD008493_pub5_data","2|3|Atrial fibrillation|Statins discontinuation > 21 days before surgery or statin-naive participants","Atrial fibrillation",2,3,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",7,0,0.125398174595666,0,2013,0.282009508348794,299.857142857143
"CD008493","CD008493_pub5_data","2|3|Atrial fibrillation|Statins discontinuation ≤ 21 days before surgery","Atrial fibrillation",2,3,"Statins discontinuation ≤ 21 days before surgery","reported","reported",3,0,0.0543596872522131,0,2018.33333333333,0.274160564084421,1149.66666666667
"CD008493","CD008493_pub5_data","2|4|Stroke|Statins discontinuation > 21 days before surgery or statin-naive participants","Stroke",2,4,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",2,0,0.483051385081877,0,2016,0.0427272727272727,190.5
"CD008493","CD008493_pub5_data","2|4|Stroke|Statins discontinuation ≤ 21 days before surgery","Stroke",2,4,"Statins discontinuation ≤ 21 days before surgery","reported","reported",2,0,0.358819048080699,0,2019.5,0.00967394439072387,1398
"CD008493","CD008493_pub5_data","2|5|Renal failure|Statins discontinuation > 21 days before surgery or statin-naive participants","Renal failure",2,5,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",3,0,0.243487576274162,0,2013.33333333333,0.138333333333333,193.666666666667
"CD008493","CD008493_pub5_data","2|5|Renal failure|Statins discontinuation ≤ 21 days before surgery","Renal failure",2,5,"Statins discontinuation ≤ 21 days before surgery","reported","reported",2,0,0.111139812689124,0,2019.5,0.162306817989041,1398
"CD008493","CD008493_pub5_data","2|7|Length of stay in the hospital (days)|Statins discontinuation > 21 days before surgery or statin-naive participants","Length of stay in the hospital (days)",2,7,"Statins discontinuation > 21 days before surgery or statin-naive participants","reported","reported",3,0,0.153857607491929,0,2012,0,153.333333333333
"CD008493","CD008493_pub5_data","3|1|Mortality|CABG","Mortality",3,1,"CABG","reported","reported",3,0,0.340328960177021,0,2017,0.00496496724168587,1027
"CD008493","CD008493_pub5_data","3|2|Myocardial infarction|CABG","Myocardial infarction",3,2,"CABG","reported","reported",4,0,0.107090147092297,0,2013.5,0.0555121125757036,680.75
"CD008493","CD008493_pub5_data","3|3|Atrial fibrillation|CABG","Atrial fibrillation",3,3,"CABG","reported","reported",5,0,0.0552769718267185,0,2014,0.285969805566235,867.4
"CD008493","CD008493_pub5_data","3|3|Atrial fibrillation|Non-CABG","Atrial fibrillation",3,3,"Non-CABG","reported","reported",2,0,0.152510800471579,0,2016,0.409574468085106,192.5
"CD008493","CD008493_pub5_data","3|5|Renal failure|CABG","Renal failure",3,5,"CABG","reported","reported",2,0,0.110958449851055,0,2015.5,0.0752660016625104,1303
"CD008493","CD008493_pub5_data","3|7|Length of stay in the hospital (days)|CABG","Length of stay in the hospital (days)",3,7,"CABG","reported","reported",3,0,0.0783788981732531,0,2014.33333333333,0,888.666666666667
"CD008493","CD008493_pub5_data","4|1|Mortality|","Mortality",4,1,"","or","binary",3,0.204613856535388,0.336749021606791,0,2018.33333333333,0.00422569125811021,1509.33333333333
"CD008493","CD008493_pub5_data","4|2|Myocardial infarction|","Myocardial infarction",4,2,"","or","binary",2,-0.135000199222933,0.108660819710104,0,2019.5,0.087810186937369,2164
"CD008493","CD008493_pub5_data","4|3|Atrial fibrillation|","Atrial fibrillation",4,3,"","or","binary",3,-0.0832059312561958,0.082214941662826,0.00413079052427403,2018.33333333333,0.321377775243112,1509.33333333333
"CD008493","CD008493_pub5_data","4|5|Renal failure|","Renal failure",4,5,"","or","binary",3,0.0697165390750863,0.161954460925848,0.0487888571176414,2018.33333333333,0.191293065557405,1509.33333333333
"CD008493","CD008493_pub5_data","4|6|Length of stay in the intensive care unit (hours)|","Length of stay in the intensive care unit (hours)",4,6,"","reported","reported",3,0,0.992824295668277,0,2018.33333333333,0,1509.33333333333
"CD008493","CD008493_pub5_data","4|7|Length of stay in the hospital (days)|","Length of stay in the hospital (days)",4,7,"","reported","reported",3,0,0.0539983622062249,0,2018.33333333333,0,1509.33333333333
"CD008552","CD008552_pub8_data","1|1|Vegetable intake|","Vegetable intake",1,1,"","reported","reported",15,0.480905696145038,0.12956889212226,0.181120767448859,2015.73333333333,0,131.733333333333
"CD008552","CD008552_pub8_data","1|2|Vegetable intake - sensitivity analysis - risk of bias|","Vegetable intake - sensitivity analysis - risk of bias",1,2,"","reported","reported",5,0.707896339823517,0.419314199201517,0.77853488005483,2014,0,101.4
"CD008552","CD008552_pub8_data","1|3|Vegetable intake - sensitivity analysis - primary outcome|","Vegetable intake - sensitivity analysis - primary outcome",1,3,"","reported","reported",13,0.538276005461003,0.161789957946998,0.259392611066341,2015.92307692308,0,130.461538461538
"CD008552","CD008552_pub8_data","1|4|Vegetable intake - sensitivity analysis - missing data|","Vegetable intake - sensitivity analysis - missing data",1,4,"","reported","reported",9,0.522153061888822,0.212921747762131,0.330690607623116,2014.77777777778,0,113.666666666667
"CD008552","CD008552_pub8_data","1|5|Vegetable intake - subgroup analysis - setting|Home","Vegetable intake - subgroup analysis - setting",1,5,"Home","reported","reported",4,0.307098363670155,0.0925302783705188,0,2018.25,0,140.75
"CD008552","CD008552_pub8_data","1|5|Vegetable intake - subgroup analysis - setting|Home + lab","Vegetable intake - subgroup analysis - setting",1,5,"Home + lab","reported","reported",3,0.875442561432221,0.244894255468282,0,2014,0,25
"CD008552","CD008552_pub8_data","1|5|Vegetable intake - subgroup analysis - setting|Preschool or childcare","Vegetable intake - subgroup analysis - setting",1,5,"Preschool or childcare","reported","reported",6,0.704185954199103,0.36412308223574,0.709448874372135,2015.33333333333,0,115.666666666667
"CD008552","CD008552_pub8_data","1|6|Vegetable intake - subgroup analysis - modality|Face-to-face + written materials","Vegetable intake - subgroup analysis - modality",1,6,"Face-to-face + written materials","reported","reported",2,0.317066746617594,0.138465038143639,0,2016.5,0,108
"CD008552","CD008552_pub8_data","1|6|Vegetable intake - subgroup analysis - modality|Face-to-face only","Vegetable intake - subgroup analysis - modality",1,6,"Face-to-face only","reported","reported",11,0.612326232555286,0.197741279329786,0.341488663801635,2015,0,129.181818181818
"CD008552","CD008552_pub8_data","1|7|Vegetable intake - subgroup analysis - age|< 12 months","Vegetable intake - subgroup analysis - age",1,7,"< 12 months","reported","reported",4,0.242758787876423,0.143136301180335,0.0511331791933967,2016.25,0,233.75
"CD008552","CD008552_pub8_data","1|7|Vegetable intake - subgroup analysis - age|≥ 12 months","Vegetable intake - subgroup analysis - age",1,7,"≥ 12 months","reported","reported",11,0.580358592457517,0.178823120486695,0.263105477403178,2015.54545454545,0,94.6363636363636
"CD008552","CD008552_pub8_data","2|1|Fruit and vegetable intake|","Fruit and vegetable intake",2,1,"","reported","reported",14,0.295369437416482,0.100475952539072,0.0977247380690539,2018.14285714286,0,308.428571428571
"CD008552","CD008552_pub8_data","2|2|Fruit and vegetable intake - sensitivity analysis - risk of bias|","Fruit and vegetable intake - sensitivity analysis - risk of bias",2,2,"","reported","reported",2,0.680413634254708,0.134282276055191,0,2017,0,200.5
"CD008552","CD008552_pub8_data","2|3|Fruit and vegetable intake - sensitivity analysis - primary outcome|","Fruit and vegetable intake - sensitivity analysis - primary outcome",2,3,"","reported","reported",11,0.364314288374041,0.140330655885974,0.155684881237758,2018.36363636364,0,250
"CD008552","CD008552_pub8_data","2|4|Fruit and vegetable intake - sensitivity analysis - missing data|","Fruit and vegetable intake - sensitivity analysis - missing data",2,4,"","reported","reported",7,0.380987039350066,0.109067701675774,0.0456213404669281,2018.14285714286,0,243.714285714286
"CD008552","CD008552_pub8_data","2|5|Fruit and vegetable intake - subgroup analysis - setting|Home","Fruit and vegetable intake - subgroup analysis - setting",2,5,"Home","reported","reported",2,0.678375837931576,0.245176204483908,0,2020.5,0,52.5
"CD008552","CD008552_pub8_data","2|5|Fruit and vegetable intake - subgroup analysis - setting|Preschool + home","Fruit and vegetable intake - subgroup analysis - setting",2,5,"Preschool + home","reported","reported",3,0.442048547191427,0.21301337162692,0.106295102693129,2017.66666666667,0,232.666666666667
"CD008552","CD008552_pub8_data","2|5|Fruit and vegetable intake - subgroup analysis - setting|School or preschool or childcare","Fruit and vegetable intake - subgroup analysis - setting",2,5,"School or preschool or childcare","reported","reported",8,0.181730796217808,0.144242346908268,0.122653769805792,2017.5,0,413.875
"CD008552","CD008552_pub8_data","2|6|Fruit and vegetable intake - subgroup analysis - modality|Face-to-face + written materials","Fruit and vegetable intake - subgroup analysis - modality",2,6,"Face-to-face + written materials","reported","reported",5,0.123702355257822,0.0965321865566635,0.0239431740512575,2016,0,468.8
"CD008552","CD008552_pub8_data","2|6|Fruit and vegetable intake - subgroup analysis - modality|Face-to-face + written materials + telephone","Fruit and vegetable intake - subgroup analysis - modality",2,6,"Face-to-face + written materials + telephone","reported","reported",2,0.366943692362737,0.37809927289019,0.23653612195,2021.5,0,366.5
"CD008552","CD008552_pub8_data","2|6|Fruit and vegetable intake - subgroup analysis - modality|Face-to-face only","Fruit and vegetable intake - subgroup analysis - modality",2,6,"Face-to-face only","reported","reported",4,0.423844329416144,0.402453894800832,0.51385676653155,2018.25,0,78.5
"CD008552","CD008552_pub8_data","3|1|Fruit and vegetable intake|","Fruit and vegetable intake",3,1,"","reported","reported",14,0.105298312584525,0.0670763551815649,0.0378034804107313,2014.57142857143,0,294.428571428571
"CD008552","CD008552_pub8_data","3|2|Fruit and vegetable intake - sensitivity analysis - primary outcome|","Fruit and vegetable intake - sensitivity analysis - primary outcome",3,2,"","reported","reported",11,0.05960408908933,0.0391316140533177,0.00231522034310712,2014.72727272727,0,346.181818181818
"CD008552","CD008552_pub8_data","3|3|Fruit and vegetable intake - sensitivity analysis - missing data|","Fruit and vegetable intake - sensitivity analysis - missing data",3,3,"","reported","reported",8,0.114023200821831,0.0460965594122609,0.0037364173719912,2013.375,0,377.625
"CD008552","CD008552_pub8_data","3|4|Fruit and vegetable intake - subgroup analysis - setting|Healthcare setting only","Fruit and vegetable intake - subgroup analysis - setting",3,4,"Healthcare setting only","reported","reported",3,-0.0548464116846652,0.0955410995656447,0,2016.33333333333,0,198
"CD008552","CD008552_pub8_data","3|4|Fruit and vegetable intake - subgroup analysis - setting|Home","Fruit and vegetable intake - subgroup analysis - setting",3,4,"Home","reported","reported",5,0.0711814209809137,0.121689667018974,0.0495412647226741,2010.8,0,403.8
"CD008552","CD008552_pub8_data","3|4|Fruit and vegetable intake - subgroup analysis - setting|School or preschool or childcare","Fruit and vegetable intake - subgroup analysis - setting",3,4,"School or preschool or childcare","reported","reported",3,0.0548696603841281,0.103154652480465,0,2016.66666666667,0,178
"CD008552","CD008552_pub8_data","3|5|Fruit and vegetable intake - subgroup analysis - modality|Face-to-face + written materials","Fruit and vegetable intake - subgroup analysis - modality",3,5,"Face-to-face + written materials","reported","reported",2,0.0704232783357245,0.0646784348262754,0.003014775,2010.5,0,847.5
"CD008552","CD008552_pub8_data","3|5|Fruit and vegetable intake - subgroup analysis - modality|Face-to-face only","Fruit and vegetable intake - subgroup analysis - modality",3,5,"Face-to-face only","reported","reported",6,0.0906176653073723,0.138419843246749,0.0853810486526494,2014.66666666667,0,179.333333333333
"CD008552","CD008552_pub8_data","3|5|Fruit and vegetable intake - subgroup analysis - modality|Telephone + written materials","Fruit and vegetable intake - subgroup analysis - modality",3,5,"Telephone + written materials","reported","reported",2,0.401892874718064,0.226451608485628,0.063059145,2012,0,193
"CD008552","CD008552_pub8_data","3|6|Fruit and vegetable intake - subgroup analysis - age|< 12 months","Fruit and vegetable intake - subgroup analysis - age",3,6,"< 12 months","reported","reported",3,-0.0664626863068666,0.0968370281562083,0,2014,0,292.666666666667
"CD008552","CD008552_pub8_data","3|6|Fruit and vegetable intake - subgroup analysis - age|≥ 12 months","Fruit and vegetable intake - subgroup analysis - age",3,6,"≥ 12 months","reported","reported",11,0.126833352984661,0.0919095576467098,0.0618516054731427,2014.72727272727,0,292.363636363636
"CD008552","CD008552_pub8_data","4|1|Vegetable intake|","Vegetable intake",4,1,"","reported","reported",2,1.33297797483925,1.47245844123291,4.2018147275615,2020,0,55
"CD008564","CD008564_pub3_data","1|1|Total mortality|","Total mortality",1,1,"","reported","reported",6,0,0.0859514054604264,0,2005.33333333333,0.0912243017122516,1224.66666666667
"CD008564","CD008564_pub3_data","1|10|Proportion of participants reaching target blood pressure levels at end of study|","Proportion of participants reaching target blood pressure levels at end of study",1,10,"","reported","reported",6,0,0.0242869996028204,0,2005.33333333333,0.604787823861172,832
"CD008564","CD008564_pub3_data","1|11|Number of antihypertensive drugs that each participant needed at end of study|","Number of antihypertensive drugs that each participant needed at end of study",1,11,"","or","binary",4,0.132010189270481,1.00075707561988,0,2009,0,1311.5
"CD008564","CD008564_pub3_data","1|2|Total serious adverse events|","Total serious adverse events",1,2,"","reported","reported",6,0,0.034173329192536,0,2005.33333333333,0.250776204735466,1224.66666666667
"CD008564","CD008564_pub3_data","1|3|Total cardiovascular events|","Total cardiovascular events",1,3,"","reported","reported",5,0,0.0717535735684057,0,2007.6,0.138297279536118,1301.6
"CD008564","CD008564_pub3_data","1|4|Cardiovascular mortality|","Cardiovascular mortality",1,4,"","reported","reported",6,0,0.129100671857363,0,2005.33333333333,0.044556162772154,1224.66666666667
"CD008564","CD008564_pub3_data","1|5|Progression to end-stage renal disease |","Progression to end-stage renal disease ",1,5,"","reported","reported",4,0,0.0829689530132895,0,2005.25,0.13844106453325,1197
"CD008564","CD008564_pub3_data","1|7|Doubling of serum creatinine level or 50% reduction in GFR at the end of study|","Doubling of serum creatinine level or 50% reduction in GFR at the end of study",1,7,"","reported","reported",5,0,0.120331130178927,0,2003.8,0.0686928408366298,1313.4
"CD008564","CD008564_pub3_data","1|8|Systolic blood pressure change from baseline at one year|","Systolic blood pressure change from baseline at one year",1,8,"","reported","reported",6,0,0.447187332006905,0,2005.33333333333,0,1183.5
"CD008564","CD008564_pub3_data","1|9|Diastolic blood pressure change from baseline at one year|","Diastolic blood pressure change from baseline at one year",1,9,"","reported","reported",6,0,0.234498996105998,0,2005.33333333333,0,1183.5
"CD008564","CD008564_pub3_data","2|1|Total mortality|Participants with diabetes","Total mortality",2,1,"Participants with diabetes","reported","reported",5,0,0.141268596508621,0,2003.4,0.169159348217659,262.8
"CD008564","CD008564_pub3_data","2|1|Total mortality|Participants without diabetes","Total mortality",2,1,"Participants without diabetes","or","binary",5,0.00873322375955029,0.172437268087754,0.0614850476681489,2004.4,0.0631166646464565,1206.8
"CD008564","CD008564_pub3_data","2|2|Total serious adverse events|Participants with diabetes","Total serious adverse events",2,2,"Participants with diabetes","reported","reported",5,0,0.0900389533088338,0,2003.4,0.289536452409632,262.8
"CD008564","CD008564_pub3_data","2|2|Total serious adverse events|Participants without diabetes","Total serious adverse events",2,2,"Participants without diabetes","or","binary",5,0.0791150993877696,0.0921234557094093,0.0126657619490981,2004.4,0.213686516396031,1206.8
"CD008564","CD008564_pub3_data","2|3|Total cardiovascular events|Participants with diabetes","Total cardiovascular events",2,3,"Participants with diabetes","reported","reported",4,0,0.118486878146422,0,2005.75,0.185724913375019,317.75
"CD008564","CD008564_pub3_data","2|3|Total cardiovascular events|Participants without diabetes","Total cardiovascular events",2,3,"Participants without diabetes","or","binary",4,0.0599281935723811,0.145784806594701,0.035965582786894,2007,0.10742915731709,1309.25
"CD008564","CD008564_pub3_data","2|4|Cardiovascular mortality|Participants with diabetes","Cardiovascular mortality",2,4,"Participants with diabetes","reported","reported",5,0,0.206512697645324,0,2003.4,0.106027791947992,262.8
"CD008564","CD008564_pub3_data","2|4|Cardiovascular mortality|Participants without diabetes","Cardiovascular mortality",2,4,"Participants without diabetes","or","binary",5,0.158805289671001,0.291805624814282,0.236227533882808,2004.4,0.029625298454455,1206.8
"CD008564","CD008564_pub3_data","2|5|Progression to end-stage renal disease|Participants with diabetes","Progression to end-stage renal disease",2,5,"Participants with diabetes","reported","reported",2,0,0.168398566404626,0,2006,0.126674715687802,464
"CD008564","CD008564_pub3_data","3|1|Total mortality|Females","Total mortality",3,1,"Females","or","binary",6,0.0406306595605384,0.147596184774445,0,2005.33333333333,0.0715876807010466,597.166666666667
"CD008564","CD008564_pub3_data","3|1|Total mortality|Males","Total mortality",3,1,"Males","reported","reported",6,0,0.109139868945952,0,2005.33333333333,0.108239420897526,627.5
"CD008564","CD008564_pub3_data","3|2|Total serious adverse events|Females","Total serious adverse events",3,2,"Females","or","binary",6,0.033939816015214,0.164093422187705,0.094294861605434,2005.33333333333,0.229977001675206,597.166666666667
"CD008564","CD008564_pub3_data","3|2|Total serious adverse events|Males","Total serious adverse events",3,2,"Males","reported","reported",6,0,0.0434628997259983,0,2005.33333333333,0.261801696971285,627.5
"CD008564","CD008564_pub3_data","3|3|Total cardiovascular events|Females","Total cardiovascular events",3,3,"Females","or","binary",5,0.0832781922177949,0.210541385232941,0.131474700685558,2007.6,0.116985136457432,650.2
"CD008564","CD008564_pub3_data","3|3|Total cardiovascular events|Males","Total cardiovascular events",3,3,"Males","reported","reported",5,0,0.0936000454281146,0,2007.6,0.154062899059702,651.4
"CD008564","CD008564_pub3_data","3|4|Cardiovascular mortality|Females","Cardiovascular mortality",3,4,"Females","or","binary",6,0.192937856071289,0.218731947524386,0,2005.33333333333,0.0271791683626376,597.166666666667
"CD008564","CD008564_pub3_data","3|4|Cardiovascular mortality|Males","Cardiovascular mortality",3,4,"Males","reported","reported",6,0,0.148706080435077,0,2005.33333333333,0.0776369024992934,627.5
"CD008564","CD008564_pub3_data","3|5|Progression to end-stage renal disease|Females","Progression to end-stage renal disease",3,5,"Females","or","binary",4,-0.0737988341933453,0.167566892688994,0,2005.25,0.135521749558685,502.75
"CD008564","CD008564_pub3_data","3|5|Progression to end-stage renal disease|Males","Progression to end-stage renal disease",3,5,"Males","reported","reported",4,0,0.108227652987879,0,2005.25,0.143408524261665,694.25
"CD008564","CD008564_pub3_data","4|1|Total mortality|75 years and older","Total mortality",4,1,"75 years and older","reported","reported",3,0,0.155543100594324,0,2012.66666666667,0.160461850522702,456.333333333333
"CD008564","CD008564_pub3_data","4|1|Total mortality|Younger than 75 years","Total mortality",4,1,"Younger than 75 years","or","binary",6,-0.015387489642162,0.125402155979046,0.0173148767160159,2005.33333333333,0.074611255303872,996.5
"CD008564","CD008564_pub3_data","4|2|Total serious adverse events|75 years and older","Total serious adverse events",4,2,"75 years and older","reported","reported",3,0,0.0517051887458074,0,2012.66666666667,0.431916055546887,456.333333333333
"CD008564","CD008564_pub3_data","4|2|Total serious adverse events|Younger than 75 years","Total serious adverse events",4,2,"Younger than 75 years","or","binary",6,0.0818755125435164,0.0655733236644095,5.22660014780658e-06,2005.33333333333,0.230419651062987,996.5
"CD008564","CD008564_pub3_data","4|3|Total cardiovascular events|75 years and older","Total cardiovascular events",4,3,"75 years and older","reported","reported",3,0,0.14768930142772,0,2012.66666666667,0.145865189577157,456.333333333333
"CD008564","CD008564_pub3_data","4|3|Total cardiovascular events|Younger than 75 years","Total cardiovascular events",4,3,"Younger than 75 years","or","binary",5,0.0974861723660025,0.0940259102451151,2.57055350315865e-06,2007.6,0.13061067284791,1027.8
"CD008564","CD008564_pub3_data","4|4|Cardiovascular mortality|75 years and older","Cardiovascular mortality",4,4,"75 years and older","or","binary",3,-0.588208228376167,0.295770019608957,0,2012.66666666667,0.085580173714048,456.333333333333
"CD008564","CD008564_pub3_data","4|5|Progression to end-stage renal disease|75 years and older","Progression to end-stage renal disease",4,5,"75 years and older","reported","reported",2,0,0.792495914818749,0,2012.5,0.021816976127321,609
"CD008564","CD008564_pub3_data","4|5|Progression to end-stage renal disease|Younger than 75 years","Progression to end-stage renal disease",4,5,"Younger than 75 years","or","binary",4,-0.0707571894409667,0.108698065823851,0,2005.25,0.139980951062889,892.5
"CD008564","CD008564_pub3_data","5|1|Total mortality|Primary prevention","Total mortality",5,1,"Primary prevention","reported","reported",5,0,0.116489041567026,0,2003.8,0.0684488935820878,1081
"CD008564","CD008564_pub3_data","5|1|Total mortality|Secondary prevention","Total mortality",5,1,"Secondary prevention","or","binary",6,0.17052787722409,0.223575752794253,0.14411303207022,2005.33333333333,0.109110640295309,304.5
"CD008564","CD008564_pub3_data","5|2|Total serious adverse events|Primary prevention","Total serious adverse events",5,2,"Primary prevention","reported","reported",5,0,0.0423798340734554,0,2003.8,0.22033820020242,1085
"CD008564","CD008564_pub3_data","5|2|Total serious adverse events|Secondary prevention","Total serious adverse events",5,2,"Secondary prevention","or","binary",6,0.0640904067228686,0.132778437884557,0.0300608601199459,2005.33333333333,0.308712528107174,304.5
"CD008564","CD008564_pub3_data","5|3|Total cardiovascular events|Primary prevention","Total cardiovascular events",5,3,"Primary prevention","reported","reported",4,0,0.0940337582105241,0,2006.25,0.117559477542293,1173.75
"CD008564","CD008564_pub3_data","5|3|Total cardiovascular events|Secondary prevention","Total cardiovascular events",5,3,"Secondary prevention","or","binary",5,0.0843409375660448,0.132876075511093,0,2007.6,0.177333707030796,343.4
"CD008564","CD008564_pub3_data","5|4|Cardiovascular mortality|Primary prevention","Cardiovascular mortality",5,4,"Primary prevention","reported","reported",5,0,0.179447765269694,0,2003.8,0.0328618857712133,1085
"CD008564","CD008564_pub3_data","5|4|Cardiovascular mortality|Secondary prevention","Cardiovascular mortality",5,4,"Secondary prevention","or","binary",6,0.102496986490542,0.201258794489224,0,2005.33333333333,0.0608770466119385,304.5
"CD008564","CD008564_pub3_data","5|5|Progression to end-stage renal disease|Primary prevention","Progression to end-stage renal disease",5,5,"Primary prevention","reported","reported",4,0,0.0881114520182899,0,2005.25,0.143488546344049,959.25
"CD008564","CD008564_pub3_data","5|5|Progression to end-stage renal disease|Secondary prevention","Progression to end-stage renal disease",5,5,"Secondary prevention","or","binary",4,-0.261589049460704,0.340796164392798,0.102991075441804,2005.25,0.1141810570382,237.75
"CD008564","CD008564_pub3_data","6|1|Total mortality|GFR < 30 mL/min","Total mortality",6,1,"GFR < 30 mL/min","or","binary",3,-0.201611009514736,0.485827710040231,0.495351069377352,2003.66666666667,0.137850989551939,238.666666666667
"CD008564","CD008564_pub3_data","6|1|Total mortality|GFR 30 to 60 mL/min","Total mortality",6,1,"GFR 30 to 60 mL/min","reported","reported",5,0,0.104695349746628,0,2006.8,0.0955410498388707,891.4
"CD008564","CD008564_pub3_data","6|2|Total serious adverse events|GFR < 30 mL/min","Total serious adverse events",6,2,"GFR < 30 mL/min","or","binary",4,0.098981672994279,0.189961913728157,0.0541003705213514,2006,0.327169723672442,275.25
"CD008564","CD008564_pub3_data","6|2|Total serious adverse events|GFR 30 to 60 mL/min","Total serious adverse events",6,2,"GFR 30 to 60 mL/min","reported","reported",5,0,0.0379519272672777,0,2006.8,0.2660281385751,891.4
"CD008564","CD008564_pub3_data","6|3|Total cardiovascular events|GFR < 30 mL/min","Total cardiovascular events",6,3,"GFR < 30 mL/min","or","binary",2,-0.503289685802588,0.321643798567033,0,2008.5,0.174321880650995,165.5
"CD008564","CD008564_pub3_data","6|3|Total cardiovascular events|GFR 30 to 60 mL/min","Total cardiovascular events",6,3,"GFR 30 to 60 mL/min","reported","reported",4,0,0.0859134275747515,0,2010,0.152188494190857,1000.5
"CD008564","CD008564_pub3_data","6|4|Cardiovascular mortality|GFR < 30 mL/min","Cardiovascular mortality",6,4,"GFR < 30 mL/min","or","binary",3,-0.386111844644064,0.802729399419112,1.40738189698377,2003.66666666667,0.0675350361663653,238.666666666667
"CD008564","CD008564_pub3_data","6|4|Cardiovascular mortality|GFR 30 to 60 mL/min","Cardiovascular mortality",6,4,"GFR 30 to 60 mL/min","reported","reported",5,0,0.164991393405999,0,2006.8,0.045325078866534,891.4
"CD008564","CD008564_pub3_data","6|5|Progression to end-stage renal disease|GFR < 30 mL/min","Progression to end-stage renal disease",6,5,"GFR < 30 mL/min","or","binary",3,-0.0363570722219672,0.163706807953744,0,2003.66666666667,0.396252134820173,238.666666666667
"CD008564","CD008564_pub3_data","6|5|Progression to end-stage renal disease|GFR 30 to 60 mL/min","Progression to end-stage renal disease",6,5,"GFR 30 to 60 mL/min","reported","reported",4,0,0.155942628740546,0,2005.25,0.0564618079940417,1018
"CD008628","CD008628_pub3_data","1|1|Function in the long term; measured using AOFAS|Open reduction and internal fixation","Function in the long term; measured using AOFAS",1,1,"Open reduction and internal fixation","or","binary",4,-0.0518589373109866,1.00935935568675,0,2011,0,69.25
"CD008628","CD008628_pub3_data","1|10|Ability to wear usual footwear|","Ability to wear usual footwear",1,10,"","or","binary",4,0.846589253487918,0.600233171172171,1.00319199674402,2003.25,0.596031148450503,54.75
"CD008628","CD008628_pub3_data","1|11|Radiological measurements: Böhler angle|","Radiological measurements: Böhler angle",1,11,"","or","binary",2,-0.0467479125086533,1.43371033092823,0,2014.5,0,36
"CD008628","CD008628_pub3_data","1|2|Function in the long term; using measurement tools other than AOFAS score |Open reduction and internal fixation","Function in the long term; using measurement tools other than AOFAS score ",1,2,"Open reduction and internal fixation","or","binary",3,0.0166807350046236,1.1616154934815,0,2016,0,93.3333333333333
"CD008628","CD008628_pub3_data","1|3|Function in the long term; number of people with scores of excellent, good, or satisfactory/fair|Excellent","Function in the long term; number of people with scores of excellent, good, or satisfactory/fair",1,3,"Excellent","or","binary",3,1.26587752884775,0.558442543215523,0,2011,0.0941919191919192,29.3333333333333
"CD008628","CD008628_pub3_data","1|3|Function in the long term; number of people with scores of excellent, good, or satisfactory/fair|Good","Function in the long term; number of people with scores of excellent, good, or satisfactory/fair",1,3,"Good","or","binary",3,0.248078514260394,0.428550638048779,0,2011,0.436742424242424,29.3333333333333
"CD008628","CD008628_pub3_data","1|3|Function in the long term; number of people with scores of excellent, good, or satisfactory/fair|Satisfactory/Fair","Function in the long term; number of people with scores of excellent, good, or satisfactory/fair",1,3,"Satisfactory/Fair","or","binary",3,-0.496311202392881,0.54592324654464,0,2011,0.201136363636364,29.3333333333333
"CD008628","CD008628_pub3_data","1|4|Chronic pain; number of people with pain|","Chronic pain; number of people with pain",1,4,"","or","binary",4,-1.34097237768782,0.538684158056893,0.665835626611178,2005.5,0.726634286412512,43.75
"CD008628","CD008628_pub3_data","1|6|HRQoL in the long term; measured using SF-36 (PCS)|","HRQoL in the long term; measured using SF-36 (PCS)",1,6,"","or","binary",2,0.0427090605090689,1.42182042548283,0,2013.5,0,96
"CD008628","CD008628_pub3_data","1|7|Return to normal activity (work) |","Return to normal activity (work) ",1,7,"","or","binary",5,0.774072819593127,0.393381389583193,0.300143173749726,2009.2,0.528058813945911,50
"CD008628","CD008628_pub3_data","1|8|Postoperative complications requiring unplanned return to theatre|Implant removal","Postoperative complications requiring unplanned return to theatre",1,8,"Implant removal","or","binary",3,1.99772945090765,0.89465959455063,0,2009.66666666667,0,219
"CD008628","CD008628_pub3_data","1|8|Postoperative complications requiring unplanned return to theatre|Subtalar arthrodesis","Postoperative complications requiring unplanned return to theatre",1,8,"Subtalar arthrodesis","or","binary",3,-1.04006262117189,0.720463062667319,0.937638619342695,2009.66666666667,0.102728769701247,219
"CD008628","CD008628_pub3_data","1|9|Postoperative complications not requiring return to theatre|Superficial infection","Postoperative complications not requiring return to theatre",1,9,"Superficial infection","or","binary",7,2.42782132499507,0.592887864111689,0,2010.71428571429,0,121
"CD008628","CD008628_pub3_data","1|9|Postoperative complications not requiring return to theatre|Wound breakdown/dehiscence","Postoperative complications not requiring return to theatre",1,9,"Wound breakdown/dehiscence","or","binary",2,1.69177924261849,1.13411479751026,0,2018,0,45.5
"CD008628","CD008628_pub3_data","2|3|HRQoL in the long term|","HRQoL in the long term",2,3,"","or","binary",3,0.0448731446812854,1.16041574700244,0,2013.66666666667,0,104.333333333333
"CD008688","CD008688_pub3_data","1|1|Pancreatic fistula (free definition)|NA","Pancreatic fistula (free definition)",1,1,NA,"or","binary",3,-0.0968295821062585,0.185412935044357,0,2010.33333333333,0.465339105339105,171.666666666667
"CD008688","CD008688_pub3_data","1|2|Postoperative pancreatic fistula (ISGPS)|NA","Postoperative pancreatic fistula (ISGPS)",1,2,NA,"or","binary",2,0.123454629353652,0.20922487775041,0,2016,0.307402597402597,243
"CD008688","CD008688_pub3_data","1|3|Postoperative mortality|NA","Postoperative mortality",1,3,NA,"or","binary",3,-0.339253484354439,0.839876827037147,0,2010.33333333333,0.00380952380952381,171.666666666667
"CD008688","CD008688_pub3_data","1|4|Overall postoperative morbidity|NA","Overall postoperative morbidity",1,4,NA,"or","binary",2,0.148894810881666,0.241049324465006,0.0420755524496805,2016,0.569004329004329,243
"CD008688","CD008688_pub3_data","1|5|Delayed gastric emptying|NA","Delayed gastric emptying",1,5,NA,"or","binary",2,0.458394005587393,1.2309159432077,1.44774826987743,2016,0.0151515151515152,243
"CD008688","CD008688_pub3_data","1|6|Postoperative haemorrhage|NA","Postoperative haemorrhage",1,6,NA,"or","binary",2,-0.316789271711865,0.453360045709205,0,2016,0.0314285714285714,243
"CD008688","CD008688_pub3_data","1|7|Intra-abdominal fluid collection|NA","Intra-abdominal fluid collection",1,7,NA,"or","binary",2,0.357795647904777,0.601335773100139,0.427856185885248,2016,0.104718614718615,243
"CD008688","CD008688_pub3_data","1|8|Operation time|NA","Operation time",1,8,NA,"or","binary",3,0.00805547814613239,1.16296215929514,0,2010.33333333333,0,171.666666666667
"CD008709","CD008709_pub4_data","2|1|Subjective cure or improvement of urinary incontinence: at 12 months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: at 12 months",2,1,"Trials including other SIS (not TVT-S)","or","binary",2,-0.095127516472567,0.355157714400003,0,2016,0.885690957338232,148.5
"CD008709","CD008709_pub4_data","2|1|Subjective cure or improvement of urinary incontinence: at 12 months|Trials including TVT-S","Subjective cure or improvement of urinary incontinence: at 12 months",2,1,"Trials including TVT-S","or","binary",2,-0.692845597851884,0.661921110962686,0.346935220526097,2012.5,0.934955050237969,94.5
"CD008709","CD008709_pub4_data","2|10|Bladder or urethral injuries: less than 30 days after surgery|Trials including other SIS (not TVT-S)","Bladder or urethral injuries: less than 30 days after surgery",2,10,"Trials including other SIS (not TVT-S)","or","binary",2,-0.0628936618729615,1.16396034781611,0,2013,0.0072463768115942,104.5
"CD008709","CD008709_pub4_data","2|10|Bladder or urethral injuries: less than 30 days after surgery|Trials including TVT-S","Bladder or urethral injuries: less than 30 days after surgery",2,10,"Trials including TVT-S","or","binary",5,-0.44787917222992,0.476095406161378,0,2011.5,0.0349145051721476,115.6
"CD008709","CD008709_pub4_data","2|11|Other injuries: less than 30 days after surgery|Trials including TVT-S","Other injuries: less than 30 days after surgery",2,11,"Trials including TVT-S","or","binary",3,-0.0875983604064032,0.703171918970408,0,2012.5,0.0105403491230263,149.666666666667
"CD008709","CD008709_pub4_data","2|12|Infections (e.g. UTI, mesh infection)|Trials including TVT-S","Infections (e.g. UTI, mesh infection)",2,12,"Trials including TVT-S","or","binary",3,-0.119694018124706,0.321819940201081,0.0931405375781421,2010.5,0.232812701690977,144.666666666667
"CD008709","CD008709_pub4_data","2|13|De novo urgency|Trials including TVT-S","De novo urgency",2,13,"Trials including TVT-S","or","binary",3,0.359790111342082,0.480836174879113,0.299889017546423,2010.66666666667,0.129716647823629,82
"CD008709","CD008709_pub4_data","2|14|Requiring repeat continence surgery or mesh revision|Trials including other SIS (not TVT-S)","Requiring repeat continence surgery or mesh revision",2,14,"Trials including other SIS (not TVT-S)","or","binary",2,1.54645738338116,1.34190277520938,2.51371477645232,2013,0.0344827586206897,91
"CD008709","CD008709_pub4_data","2|14|Requiring repeat continence surgery or mesh revision|Trials including TVT-S","Requiring repeat continence surgery or mesh revision",2,14,"Trials including TVT-S","or","binary",2,0.0640625657850707,0.940320836257377,1.17373780041481,2011,0.0394325709286339,194
"CD008709","CD008709_pub4_data","2|2|Subjective cure or improvement of urinary incontinence: 36 + months|","Subjective cure or improvement of urinary incontinence: 36 + months",2,2,"","or","binary",2,-0.792763340890863,0.774856724387546,0.856223626538309,2010,0.885579937304075,94
"CD008709","CD008709_pub4_data","2|3|Objective cure or improvement of urinary incontinence: at 12 months|Trials including other SIS (not TVT-S)","Objective cure or improvement of urinary incontinence: at 12 months",2,3,"Trials including other SIS (not TVT-S)","or","binary",2,-0.104700160090882,0.397969235615428,0,2016,0.914064094713207,148.5
"CD008709","CD008709_pub4_data","2|3|Objective cure or improvement of urinary incontinence: at 12 months|Trials including TVT-S","Objective cure or improvement of urinary incontinence: at 12 months",2,3,"Trials including TVT-S","or","binary",2,-1.34209995366049,0.752182038437288,0.688349382940247,2012.5,0.921004842615012,89.5
"CD008709","CD008709_pub4_data","2|6|Patient-reported pain: 12 to 24 months|Trials including TVT-S","Patient-reported pain: 12 to 24 months",2,6,"Trials including TVT-S","or","binary",3,-0.213257636070701,0.652911929657043,0,2012,0.0285714285714286,80.6666666666667
"CD008709","CD008709_pub4_data","2|7|Dyspareunia|Trials including TVT-S","Dyspareunia",2,7,"Trials including TVT-S","or","binary",2,0.640332411243301,0.650506925818535,0,2010.5,0.0333333333333333,87.5
"CD008709","CD008709_pub4_data","2|8|Number of women affected by mesh exposure, extrusion or erosion in any area|Trials including other SIS (not TVT-S)","Number of women affected by mesh exposure, extrusion or erosion in any area",2,8,"Trials including other SIS (not TVT-S)","or","binary",3,0.283464137168227,0.989887659806221,0,2014,0.0104166666666667,89
"CD008709","CD008709_pub4_data","2|8|Number of women affected by mesh exposure, extrusion or erosion in any area|Trials including TVT-S","Number of women affected by mesh exposure, extrusion or erosion in any area",2,8,"Trials including TVT-S","or","binary",3,0.250288895049833,0.685880661169236,0,2012.5,0.0137357830271216,150.666666666667
"CD008709","CD008709_pub4_data","2|9|Urinary retention|Trials including other SIS (not TVT-S)","Urinary retention",2,9,"Trials including other SIS (not TVT-S)","or","binary",2,-0.62160176855394,0.666432065646183,0,2013,0.0592885375494071,104.5
"CD008709","CD008709_pub4_data","2|9|Urinary retention|Trials including TVT-S","Urinary retention",2,9,"Trials including TVT-S","or","binary",4,-0.226413652955587,0.478316834432905,9.47243556613243e-07,2010.66666666667,0.0545208990578764,127.5
"CD008709","CD008709_pub4_data","3|1|Subjective cure or improvement of urinary incontinence: 12 months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: 12 months",3,1,"Trials including other SIS (not TVT-S)","or","binary",17,-0.0275430596349902,0.128652614452888,0,2015.41176470588,0.877405835243877,138.764705882353
"CD008709","CD008709_pub4_data","3|1|Subjective cure or improvement of urinary incontinence: 12 months|Trials including TVT-S","Subjective cure or improvement of urinary incontinence: 12 months",3,1,"Trials including TVT-S","or","binary",3,-0.861585700963415,0.299930082751443,2.2456232050586e-07,2011.33333333333,0.901684822076979,126.333333333333
"CD008709","CD008709_pub4_data","3|10|Patient-reported pain: 12 to 24 months|Trials including other SIS (not TVT-S)","Patient-reported pain: 12 to 24 months",3,10,"Trials including other SIS (not TVT-S)","or","binary",2,0.0345838364763394,1.66277005254865,4.19862048308242,2018.5,0.111111111111111,64.5
"CD008709","CD008709_pub4_data","3|10|Patient-reported pain: 12 to 24 months|Trials including TVT-S","Patient-reported pain: 12 to 24 months",3,10,"Trials including TVT-S","or","binary",6,-1.16276229546449,0.41252742593228,0,2010.5,0.0974206349206349,84.5
"CD008709","CD008709_pub4_data","3|11|Patient-reported pain: 24+ months|Trials including other SIS (not TVT-S)","Patient-reported pain: 24+ months",3,11,"Trials including other SIS (not TVT-S)","or","binary",2,-2.00436716550054,0.775081506864468,0,2015,0.0813046192259675,125
"CD008709","CD008709_pub4_data","3|12|Dyspareunia|Trials including other SIS (not TVT-S)","Dyspareunia",3,12,"Trials including other SIS (not TVT-S)","or","binary",8,-0.334702570516014,0.37957452321697,0,2016.625,0.0639825218476904,101.25
"CD008709","CD008709_pub4_data","3|12|Dyspareunia|Trials including TVT-S","Dyspareunia",3,12,"Trials including TVT-S","or","binary",2,-0.364579415129609,0.498938742974125,0,2013.5,0.122208436724566,83
"CD008709","CD008709_pub4_data","3|13|Number of women affected by mesh exposure, extrusion or erosion in any area|Trials including other SIS (not TVT-S)","Number of women affected by mesh exposure, extrusion or erosion in any area",3,13,"Trials including other SIS (not TVT-S)","or","binary",16,-0.461085694546546,0.236482005053376,0,2014.5625,0.0369582902347343,148.625
"CD008709","CD008709_pub4_data","3|13|Number of women affected by mesh exposure, extrusion or erosion in any area|Trials including TVT-S","Number of women affected by mesh exposure, extrusion or erosion in any area",3,13,"Trials including TVT-S","or","binary",7,0.706544198305221,0.471749810004739,0.572846736726406,2011.5,0.0386771755750624,125.714285714286
"CD008709","CD008709_pub4_data","3|14|Urinary retention|Trials including other SIS (not TVT-S)","Urinary retention",3,14,"Trials including other SIS (not TVT-S)","or","binary",23,-0.38961517956433,0.196630836624323,0,2014.47826086957,0.0394591749046853,125.695652173913
"CD008709","CD008709_pub4_data","3|14|Urinary retention|Trials including TVT-S","Urinary retention",3,14,"Trials including TVT-S","or","binary",9,-0.324158560901984,0.37652771489446,0,2010.625,0.0285734788718591,111.444444444444
"CD008709","CD008709_pub4_data","3|15|Bladder or urethral injuries: less than 30 days after surgery|Trials including other SIS (not TVT-S)","Bladder or urethral injuries: less than 30 days after surgery",3,15,"Trials including other SIS (not TVT-S)","or","binary",19,-0.533253281363298,0.377686587372219,0,2013.68421052632,0.00821631305335771,131.421052631579
"CD008709","CD008709_pub4_data","3|15|Bladder or urethral injuries: less than 30 days after surgery|Trials including TVT-S","Bladder or urethral injuries: less than 30 days after surgery",3,15,"Trials including TVT-S","or","binary",6,0.614806353527306,0.712119863944422,0,2010.66666666667,0,115
"CD008709","CD008709_pub4_data","3|16|Other injuries: less than 30 days after surgery|Trials including other SIS (not TVT-S)","Other injuries: less than 30 days after surgery",3,16,"Trials including other SIS (not TVT-S)","or","binary",11,-0.535235702577464,0.359574579452555,0,2013.81818181818,0.0205162580864828,111.636363636364
"CD008709","CD008709_pub4_data","3|16|Other injuries: less than 30 days after surgery|Trials including TVT-S","Other injuries: less than 30 days after surgery",3,16,"Trials including TVT-S","or","binary",6,-0.27394403619502,0.526274073426227,0,2010,0.0183982683982684,127.666666666667
"CD008709","CD008709_pub4_data","3|17|Infections (e.g. UTI, mesh infections)|Trials including other SIS (not TVT-S)","Infections (e.g. UTI, mesh infections)",3,17,"Trials including other SIS (not TVT-S)","or","binary",14,0.0398553062314347,0.202367531918348,0,2014.35714285714,0.0732709837269649,126.642857142857
"CD008709","CD008709_pub4_data","3|17|Infections (e.g. UTI, mesh infections)|Trials including TVT-S","Infections (e.g. UTI, mesh infections)",3,17,"Trials including TVT-S","or","binary",5,-0.0625404222898142,0.39224945416802,0.102874262618427,2011.4,0.042732212099426,129.2
"CD008709","CD008709_pub4_data","3|18|De novo urgency|Trials including other SIS (not TVT-S)","De novo urgency",3,18,"Trials including other SIS (not TVT-S)","or","binary",13,0.0457254985253845,0.182797205114378,0,2014,0.0814945185255534,112.615384615385
"CD008709","CD008709_pub4_data","3|18|De novo urgency|Trials including TVT-S","De novo urgency",3,18,"Trials including TVT-S","or","binary",7,0.164416613799583,0.37857097367816,0.4846079988395,2010.57142857143,0.10612972461712,104.142857142857
"CD008709","CD008709_pub4_data","3|19|Quality of life: at 12 months|Trials including other SIS (not TVT-S)","Quality of life: at 12 months",3,19,"Trials including other SIS (not TVT-S)","or","binary",8,-0.098828393521368,0.712333066945383,0,2015.875,0,86.125
"CD008709","CD008709_pub4_data","3|19|Quality of life: at 12 months|Trials including TVT-S","Quality of life: at 12 months",3,19,"Trials including TVT-S","or","binary",4,0.0924688921212651,1.00505387882912,0,2011.25,0,106.5
"CD008709","CD008709_pub4_data","3|2|Subjective cure or improvement of urinary incontinence: 12 to 24 months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: 12 to 24 months",3,2,"Trials including other SIS (not TVT-S)","or","binary",2,-0.395649617574996,0.39667073629828,0.0967287622073669,2012,0.853266888150609,127.5
"CD008709","CD008709_pub4_data","3|20|Requiring repeat continence surgery or mesh revision|Trials including other SIS (not TVT-S)","Requiring repeat continence surgery or mesh revision",3,20,"Trials including other SIS (not TVT-S)","or","binary",13,0.316763785314448,0.222004512660662,0,2012.91666666667,0.0436196265936373,119.923076923077
"CD008709","CD008709_pub4_data","3|20|Requiring repeat continence surgery or mesh revision|Trials including TVT-S","Requiring repeat continence surgery or mesh revision",3,20,"Trials including TVT-S","or","binary",8,0.679631424733845,0.427319916417052,0.416392178867607,2010.57142857143,0.038123536581533,114.5
"CD008709","CD008709_pub4_data","3|3|Subjective cure or improvement of urinary incontinence: 24 to 36 months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: 24 to 36 months",3,3,"Trials including other SIS (not TVT-S)","or","binary",3,-0.188332788247364,0.320613251046877,0,2015.66666666667,0.929586938740368,178
"CD008709","CD008709_pub4_data","3|3|Subjective cure or improvement of urinary incontinence: 24 to 36 months|Trials including TVT-S","Subjective cure or improvement of urinary incontinence: 24 to 36 months",3,3,"Trials including TVT-S","or","binary",2,-0.314982532064993,0.940786851827514,1.60245940416352,2010.5,0.785386029411765,161
"CD008709","CD008709_pub4_data","3|4|Subjective cure or improvement of urinary incontinence: 36+ months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: 36+ months",3,4,"Trials including other SIS (not TVT-S)","or","binary",4,-0.231016047116852,0.217827768635748,3.67815532192266e-07,2013.25,0.806716995741386,151
"CD008709","CD008709_pub4_data","3|4|Subjective cure or improvement of urinary incontinence: 36+ months|Trials including TVT-S","Subjective cure or improvement of urinary incontinence: 36+ months",3,4,"Trials including TVT-S","or","binary",2,-0.594755608859939,0.288275532788078,0,2012,0.737536656891496,109
"CD008709","CD008709_pub4_data","3|5|Objective cure or improvement of incontinence: at 12 months|Trials including other SIS (not TVT-S)","Objective cure or improvement of incontinence: at 12 months",3,5,"Trials including other SIS (not TVT-S)","or","binary",19,0.0992037721592099,0.125233032303696,0,2015.26315789474,0.864469094432216,136.157894736842
"CD008709","CD008709_pub4_data","3|5|Objective cure or improvement of incontinence: at 12 months|Trials including TVT-S","Objective cure or improvement of incontinence: at 12 months",3,5,"Trials including TVT-S","or","binary",7,-1.16138357553937,0.321893880110577,0.272552882886106,2012.16666666667,0.909858956041099,90.8571428571429
"CD008709","CD008709_pub4_data","3|6|Objective cure or improvement of incontinence: 12 to 24 months|Trials including other SIS (not TVT-S)","Objective cure or improvement of incontinence: 12 to 24 months",3,6,"Trials including other SIS (not TVT-S)","or","binary",2,-0.340104472164897,0.358052721734047,0,2012,0.852159468438538,127
"CD008709","CD008709_pub4_data","3|7|Objective cure or improvement of incontinence: 24 to 36 months|Trials including other SIS (not TVT-S)","Objective cure or improvement of incontinence: 24 to 36 months",3,7,"Trials including other SIS (not TVT-S)","or","binary",3,-0.177976035411258,0.443747082940926,0.235665322728569,2015.66666666667,0.913116416978777,161.333333333333
"CD008709","CD008709_pub4_data","3|7|Objective cure or improvement of incontinence: 24 to 36 months|Trials including TVT-S","Objective cure or improvement of incontinence: 24 to 36 months",3,7,"Trials including TVT-S","or","binary",3,-0.837950971109784,0.456408415064431,0.326652087658112,2011.66666666667,0.898770619358855,131
"CD008709","CD008709_pub4_data","3|8|Objective cure or improvement of incontinence: 36+ months|Trials including other SIS (not TVT-S)","Objective cure or improvement of incontinence: 36+ months",3,8,"Trials including other SIS (not TVT-S)","or","binary",4,-0.176004923980234,0.266924403718252,9.4432262702138e-08,2013.25,0.877063704269587,145.5
"CD008709","CD008709_pub4_data","3|8|Objective cure or improvement of incontinence: 36+ months|Trials including TVT-S","Objective cure or improvement of incontinence: 36+ months",3,8,"Trials including TVT-S","or","binary",2,-1.14585036987931,0.389140857106639,0,2012,0.845533498759305,77
"CD008709","CD008709_pub4_data","3|9|Patient-reported pain: 30 days to 12 months|Trials including other SIS (not TVT-S)","Patient-reported pain: 30 days to 12 months",3,9,"Trials including other SIS (not TVT-S)","or","binary",5,-1.29188224381261,0.409742426620775,0,2011,0.143872549019608,113.2
"CD008709","CD008709_pub4_data","3|9|Patient-reported pain: 30 days to 12 months|Trials including TVT-S","Patient-reported pain: 30 days to 12 months",3,9,"Trials including TVT-S","or","binary",2,-1.99227947194018,1.72634200088717,3.00234897265259,2010,0.138888888888889,75.5
"CD008709","CD008709_pub4_data","4|1|Subjective cure or improvement of urinary incontinence: 12 months|Trials including other SIS (not TVT-S)","Subjective cure or improvement of urinary incontinence: 12 months",4,1,"Trials including other SIS (not TVT-S)","or","binary",2,-0.19951405227784,0.157480429626218,0,2015.5,0.665306560721572,399
"CD008709","CD008709_pub4_data","4|10|Dyspareunia|Trials including other SIS (not TVT-S)","Dyspareunia",4,10,"Trials including other SIS (not TVT-S)","or","binary",2,0.4137420501848,0.441869248402627,0.248339358871492,2015.5,0.11406598858844,285
"CD008709","CD008709_pub4_data","4|11|Number of women affected by mesh exposure, extrusion or erosion in any area|Trials including other SIS (not TVT-S)","Number of women affected by mesh exposure, extrusion or erosion in any area",4,11,"Trials including other SIS (not TVT-S)","or","binary",2,-0.259811612927881,0.679876403415227,0,2015.5,0.0110256622288376,408.5
"CD008709","CD008709_pub4_data","4|12|Urinary retention|Trials including other SIS (not TVT-S)","Urinary retention",4,12,"Trials including other SIS (not TVT-S)","or","binary",2,-0.0818869147487286,0.657528265128142,0,2015.5,0.00766283524904215,410
"CD008709","CD008709_pub4_data","4|13|Bladder or urethral injuries: less than 30 days after surgery|Trials including other SIS (not TVT-S)","Bladder or urethral injuries: less than 30 days after surgery",4,13,"Trials including other SIS (not TVT-S)","or","binary",2,-2.59441446415174,1.04797660938476,0,2015.5,0.0291570881226054,421
"CD008709","CD008709_pub4_data","4|18|Requiring repeat continence surgery or mesh revision|Trials including other SIS (not TVT-S)","Requiring repeat continence surgery or mesh revision",4,18,"Trials including other SIS (not TVT-S)","or","binary",2,0.442334479016332,0.386342527087882,0.0183289474541436,2015.5,0.0263513327269219,408.5
"CD008709","CD008709_pub4_data","4|4|Objective cure or improvement of urinary incontinence: at 12 months|Trials including other SIS (not TVT-S)","Objective cure or improvement of urinary incontinence: at 12 months",4,4,"Trials including other SIS (not TVT-S)","or","binary",2,0.110102538454932,0.880461077223332,1.24842135387679,2015.5,0.903748733535968,254.5
"CD008709","CD008709_pub4_data","4|7|Patient-reported pain: 30 days to 12 months|Trials including other SIS (not TVT-S)","Patient-reported pain: 30 days to 12 months",4,7,"Trials including other SIS (not TVT-S)","or","binary",2,0.274062063714247,0.250828771373988,0,2015.5,0.0593869731800766,410
"CD008771","CD008771_pub3_data","1|11|Plasma ammonia level at days 3 to 4 after birth|NA","Plasma ammonia level at days 3 to 4 after birth",1,11,NA,"or","binary",3,0.157714402873071,1.18203732281896,0,2004,0,32
"CD008771","CD008771_pub3_data","1|12|BUN level in first 2 days after birth|NA","BUN level in first 2 days after birth",1,12,NA,"or","binary",4,0.0246687684488084,1.00989050438403,0,2003.75,0,71.25
"CD008771","CD008771_pub3_data","1|13|BUN level at days 3 to 4 after birth|NA","BUN level at days 3 to 4 after birth",1,13,NA,"or","binary",4,0.0232372191883935,1.01446660969181,0,2004.25,0,60.5
"CD008771","CD008771_pub3_data","1|14|BUN level at days 6 to 7 after birth|NA","BUN level at days 6 to 7 after birth",1,14,NA,"or","binary",3,0.005641598166982,1.16206398349404,0,2007.33333333333,0,87.3333333333333
"CD008771","CD008771_pub3_data","1|2|Head circumference|NA","Head circumference",1,2,NA,"or","binary",2,-0.0751133673395484,1.43528136837321,0,2009,0,43.5
"CD008771","CD008771_pub3_data","1|20|Time to regain birthweight in days|NA","Time to regain birthweight in days",1,20,NA,"or","binary",2,0.0240695276050622,1.43870176272697,0,2009.5,0,41.5
"CD008771","CD008771_pub3_data","1|4|Nitrogen balance|NA","Nitrogen balance",1,4,NA,"or","binary",4,0.0710463624059644,1.02139622077005,0,2003,0,23.25
"CD008771","CD008771_pub3_data","1|5|Metabolic acidosis, pH within first 24 hours of birth|NA","Metabolic acidosis, pH within first 24 hours of birth",1,5,NA,"or","binary",2,-0.00760254437887714,1.42206426633954,0,2007,0,100.5
"CD008771","CD008771_pub3_data","1|7|Metabolic acidosis, bicarbonate level within first 24 hours of birth|NA","Metabolic acidosis, bicarbonate level within first 24 hours of birth",1,7,NA,"or","binary",3,0.005641598166982,1.16206398349404,0,2007.33333333333,0,87.3333333333333
"CD008771","CD008771_pub3_data","1|8|Metabolic acidosis, bicarbonate level at 2 days after birth|NA","Metabolic acidosis, bicarbonate level at 2 days after birth",1,8,NA,"or","binary",2,0.0382185629664728,1.42248081950057,0,2006.5,0,98
"CD008771","CD008771_pub3_data","1|9|Metabolic acidosis, bicarbonate level at days 3 to 4|NA","Metabolic acidosis, bicarbonate level at days 3 to 4",1,9,NA,"or","binary",2,-0.0137562346048316,1.42515655673268,0,2008.5,0,63.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|1 or more adverse events","Participants with adverse events",1,2,"1 or more adverse events","or","binary",5,1.03190451646009,0.185468370295298,0.0756755614262267,2010.4,0.324990278525895,1423.8
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|1 or more serious adverse events regardless of type of storage of the vaccine","Participants with adverse events",1,2,"1 or more serious adverse events regardless of type of storage of the vaccine","or","binary",6,0.0743036853595592,0.0643837265693848,0.0010946965747543,2010.5,0.0105336700306991,8504.83333333333
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Death","Participants with adverse events",1,2,"Death","or","binary",5,0.037864935138144,0.100520885600506,0.00863650183330891,2010.2,0.00878442264640655,10164
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Erythema inoculation site","Participants with adverse events",1,2,"Erythema inoculation site","or","binary",4,1.9830642280569,0.0755004326852267,2.08791732026978e-06,2010.5,0.0870253603496496,1739.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Injection site adverse events","Participants with adverse events",1,2,"Injection site adverse events","or","binary",4,1.66629245213098,0.555619498703149,0.9798532497057,2010.75,0.10442286633054,1760
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Mass inoculation or induration site","Participants with adverse events",1,2,"Mass inoculation or induration site","or","binary",2,2.07518573697721,0.440995073072221,0,2007,0.0503057169061449,3347.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Pain inoculation site","Participants with adverse events",1,2,"Pain inoculation site","or","binary",4,2.14793232875395,0.474764613845883,0.529214935755787,2010.5,0.0477684889982353,1739.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Pruritus inoculation site","Participants with adverse events",1,2,"Pruritus inoculation site","or","binary",4,1.5487876816855,0.482012478521584,0.370274825348766,2010.5,0.0258025877561188,1739.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Rash unrelated to herpes zoster (day of vaccination to day 42)","Participants with adverse events",1,2,"Rash unrelated to herpes zoster (day of vaccination to day 42)","or","binary",2,-0.0389675599638474,0.0581942402308602,0,2007,0.0289026875455595,19312
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Swelling inoculation site","Participants with adverse events",1,2,"Swelling inoculation site","or","binary",3,2.0161476481862,0.0914512712340057,0,2011,0.0276785410995133,2293
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Systemic adverse events","Participants with adverse events",1,2,"Systemic adverse events","or","binary",5,0.284516283922233,0.238268276638822,0.103210523615862,2010.4,0.14849250831825,1423.8
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Systemic pruritus","Participants with adverse events",1,2,"Systemic pruritus","or","binary",2,0.488453313263226,1.24602566185464,1.48587688518761,2014,0.037037037037037,131.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Vaccine-related adverse events","Participants with adverse events",1,2,"Vaccine-related adverse events","or","binary",3,1.29942225473353,0.678944922154479,1.08772680987467,2012.33333333333,0.162477954144621,114
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Vaccine-related serious adverse events","Participants with adverse events",1,2,"Vaccine-related serious adverse events","or","binary",4,3.494838856688e-05,0.588164216433444,0,2008.75,8.05959976598938e-05,12691.5
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Vaccine-related systemic adverse events","Participants with adverse events",1,2,"Vaccine-related systemic adverse events","or","binary",3,0.276377886673656,0.106682941738237,0,2008,0.0329715683277285,2285.33333333333
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Varicella-like rash not at injection site (day of vaccination to day 42)","Participants with adverse events",1,2,"Varicella-like rash not at injection site (day of vaccination to day 42)","or","binary",3,0.069315493832438,0.347237581618553,0.0196191705224008,2008.66666666667,0.0236853206971489,12944.3333333333
"CD008858","CD008858_pub5_data","1|2|Participants with adverse events|Warmth inoculation site","Participants with adverse events",1,2,"Warmth inoculation site","or","binary",3,1.50999818408397,0.306120931295805,0,2011,0.0134666410015437,2293
"CD008858","CD008858_pub5_data","1|4|Dropouts|Clinical adverse event","Dropouts",1,4,"Clinical adverse event","or","binary",2,0.286665298656045,0.313990600561511,0,2011.5,0.00609590509540485,6094.5
"CD008858","CD008858_pub5_data","1|4|Dropouts|Discontinued due to vaccine-related adverse events","Dropouts",1,4,"Discontinued due to vaccine-related adverse events","or","binary",2,1.02786153850623,1.2292211976796,0,2011,0,185
"CD008858","CD008858_pub5_data","1|4|Dropouts|For any reason","Dropouts",1,4,"For any reason","or","binary",3,-0.0104988698117141,0.0477812129547621,1.11577647143191e-08,2009,0.0355274639785027,12972
"CD008858","CD008858_pub5_data","1|4|Dropouts|Lost to follow-up","Dropouts",1,4,"Lost to follow-up","or","binary",5,0.240851403619051,0.145106150549898,0,2010.6,0.00844479317792079,10173.6
"CD008858","CD008858_pub5_data","1|4|Dropouts|Protocol deviation","Dropouts",1,4,"Protocol deviation","or","binary",2,0.402891042270565,0.763670485742762,0.151899440966994,2011.5,0.00492865480359227,6094.5
"CD008858","CD008858_pub5_data","1|4|Dropouts|Withdrew consent","Dropouts",1,4,"Withdrew consent","or","binary",4,-0.0451815757214909,0.310914401722304,0.13966377014595,2009.25,0.0162705396661216,12703.5
"CD008858","CD008858_pub5_data","1|5|Participants with no follow-up|","Participants with no follow-up",1,5,"","or","binary",3,-0.147951615342413,0.345648180748366,0.147830149086365,2008.66666666667,0.0279549684689939,16875.6666666667
"CD008858","CD008858_pub5_data","2|1|Cumulative incidence of herpes zoster at least 3.2 years follow-up|","Cumulative incidence of herpes zoster at least 3.2 years follow-up",2,1,"","or","binary",2,-2.53772995185708,0.499801922006964,0.407858597269973,2015.5,0.0344694310906645,11011
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Any local symptom","Participants with adverse events",2,3,"Any local symptom","or","binary",2,3.42420489744539,0.100147061891419,0.00951164683571721,2015.5,0.109134833976886,4884.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Any symptom","Participants with adverse events",2,3,"Any symptom","or","binary",2,2.18667389036543,0.0486008972758627,0,2015.5,0.336620139846497,4968
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Any systemic symptom","Participants with adverse events",2,3,"Any systemic symptom","or","binary",2,1.39765324063465,0.164206133782476,0.0448586310358036,2015.5,0.273412743284379,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Death","Participants with adverse events",2,3,"Death","or","binary",2,-0.068178841318882,0.0586530424257788,0,2015.5,0.0443012404545442,14655.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Fatigue","Participants with adverse events",2,3,"Fatigue","or","binary",2,1.2480458336276,0.222034589762241,0.0863890473896136,2015.5,0.159380611427977,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Fever","Participants with adverse events",2,3,"Fever","or","binary",2,1.98523839983241,0.253010083647902,0.0891633824325479,2015.5,0.027946664013135,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Gastrointestinal symptom","Participants with adverse events",2,3,"Gastrointestinal symptom","or","binary",2,0.62930753507405,0.229017318914891,0.0833473341872508,2015.5,0.0838022244435499,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Grade 3 any local symptom","Participants with adverse events",2,3,"Grade 3 any local symptom","or","binary",2,2.60976502607612,0.734016991038605,0.988445830234789,2015.5,0.0117287259911735,4884.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Grade 3 any symptom","Participants with adverse events",2,3,"Grade 3 any symptom","or","binary",2,1.81232790748334,0.0899110942006251,0,2015.5,0.0261347563327761,4968
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Grade 3 any systemic adverse events","Participants with adverse events",2,3,"Grade 3 any systemic adverse events","or","binary",2,1.48834466571282,0.240014320477096,0.0688604738588402,2015.5,0.0220069745668034,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Headache","Participants with adverse events",2,3,"Headache","or","binary",2,1.15661638250972,0.1072771028082,0.0129462288339324,2015.5,0.134400625992247,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Local pain","Participants with adverse events",2,3,"Local pain","or","binary",2,3.33491535601484,0.108051289589396,0.0119408831073121,2015.5,0.0985486691232523,4884.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Local redness","Participants with adverse events",2,3,"Local redness","or","binary",2,3.81804581549523,0.128310959754585,0,2015.5,0.0116902711518582,4884.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Local swelling","Participants with adverse events",2,3,"Local swelling","or","binary",2,3.53469495174253,0.147340453882885,0,2015.5,0.00723493870977228,4884.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Myalgia","Participants with adverse events",2,3,"Myalgia","or","binary",2,1.805954266282,0.0699137451023514,0.0025450146231758,2015.5,0.101123981744908,4881
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Potential immune-mediated disease","Participants with adverse events",2,3,"Potential immune-mediated disease","or","binary",2,-0.131838067454477,0.105517659540433,0,2015.5,0.0132665023173993,14655.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Serious adverse events","Participants with adverse events",2,3,"Serious adverse events","or","binary",2,-0.0352150827798095,0.0352634064164499,0,2015.5,0.131808504188481,14655.5
"CD008858","CD008858_pub5_data","2|3|Participants with adverse events|Shivering","Participants with adverse events",2,3,"Shivering","or","binary",2,1.63567208787571,0.243119173604956,0.0910399072425642,2015.5,0.0513618949834682,4881
"CD008858","CD008858_pub5_data","2|4|Dropouts|Diagnosis of herpes zoster < 30 days after dose 2","Dropouts",2,4,"Diagnosis of herpes zoster < 30 days after dose 2","or","binary",2,-1.05780033374309,0.387419041347749,0,2015.5,0.00169892557366009,14655.5
"CD008858","CD008858_pub5_data","2|4|Dropouts|Did not receive second dose","Dropouts",2,4,"Did not receive second dose","or","binary",2,0.236414736405898,0.0568368717848128,0,2015.5,0.0398991425296169,14655.5
"CD008858","CD008858_pub5_data","2|4|Dropouts|Did not receive vaccine according to protocol","Dropouts",2,4,"Did not receive vaccine according to protocol","or","binary",2,0.126753402389331,0.528951932739058,0,2015.5,0.000417421022341986,14655.5
"CD008858","CD008858_pub5_data","2|4|Dropouts|Received wrong vaccine","Dropouts",2,4,"Received wrong vaccine","or","binary",2,0.452630796697718,0.342346482714003,0,2015.5,0.000899667663768635,14655.5
"CD008873","CD008873_pub5_data","1|10|Birth length (cm)|","Birth length (cm)",1,10,"","or","binary",2,-0.3103320142628,1.41911893625162,0,2013,0,151
"CD008873","CD008873_pub5_data","1|11|Head circumference at birth (cm)|","Head circumference at birth (cm)",1,11,"","or","binary",3,-0.216471476867232,1.1576188230554,0,2012.66666666667,0,420.666666666667
"CD008873","CD008873_pub5_data","1|12|Birthweight (g)|","Birthweight (g)",1,12,"","or","binary",6,-0.293440547625052,0.81935621491405,0,2011.66666666667,0,290.666666666667
"CD008873","CD008873_pub5_data","1|13|Stillbirth|","Stillbirth",1,13,"","or","binary",3,-0.899815493233335,0.822291789722229,0,2010.66666666667,0.0139856396431499,194.666666666667
"CD008873","CD008873_pub5_data","1|14|Neonatal death|","Neonatal death",1,14,"","or","binary",2,-1.11743554947195,0.847669405349031,0,2009.5,0.0287448465414567,163
"CD008873","CD008873_pub5_data","1|4|Preterm birth (less than 37 weeks' gestation) (ALL)|","Preterm birth (less than 37 weeks' gestation) (ALL)",1,4,"","or","binary",3,-0.38105126318647,0.673162998927951,0.875330158703639,2012,0.0815451116541059,456
"CD008873","CD008873_pub5_data","1|5|Low birthweight (less than 2500 g) (ALL)|","Low birthweight (less than 2500 g) (ALL)",1,5,"","or","binary",3,-0.459616825313981,0.275527556883867,0,2012.33333333333,0.233904204956837,123.666666666667
"CD008873","CD008873_pub5_data","1|6|Caesarean section|","Caesarean section",1,6,"","or","binary",3,-0.0967250546751968,0.213660247720406,0,2011.33333333333,0.390829777145567,156.666666666667
"CD008873","CD008873_pub5_data","1|7|Gestational hypertension|","Gestational hypertension",1,7,"","or","binary",2,-0.253276424424834,0.331212972516724,0,2013.5,0.0505198180636777,565
"CD008873","CD008873_pub5_data","1|9|Maternal vitamin D concentration at term (25-hydroxyvitamin D) (nmol/L) (ALL)|","Maternal vitamin D concentration at term (25-hydroxyvitamin D) (nmol/L) (ALL)",1,9,"","or","binary",6,-0.17887610184322,0.819649897805694,0,2011.83333333333,0,301.166666666667
"CD008879","CD008879_pub3_data","1|3|Length of hospital stay (days)|NA","Length of hospital stay (days)",1,3,NA,"or","binary",2,-0.00989449960820712,1.42765665194558,0,1990,0,67.5
"CD008879","CD008879_pub3_data","2|2|Length of hospital stay (days)|NA","Length of hospital stay (days)",2,2,NA,"reported","reported",2,0,2.13547436348411,0,2000.5,0,63
"CD008879","CD008879_pub3_data","3|1|Non-infectious complications|NA","Non-infectious complications",3,1,NA,"reported","reported",4,0,0.132785094166184,0,2008.25,0.303107088989442,158
"CD008879","CD008879_pub3_data","3|2|Infectious complications|NA","Infectious complications",3,2,NA,"reported","reported",6,0,0.13316120020444,0,2009.5,0.300868254663321,124.833333333333
"CD008879","CD008879_pub3_data","4|1|Non-infectious complications|NA","Non-infectious complications",4,1,NA,"reported","reported",3,0,0.190087501506849,0,2010.66666666667,0.238129117259552,108
"CD008879","CD008879_pub3_data","4|2|Infectious complications|NA","Infectious complications",4,2,NA,"reported","reported",3,0,0.140492677283971,0,2010.66666666667,0.453184014053579,108
"CD008879","CD008879_pub3_data","4|3|Length of hospital stay (days)|NA","Length of hospital stay (days)",4,3,NA,"reported","reported",3,0,0.862904354823332,0,2010.66666666667,0,99.6666666666667
"CD008940","CD008940_pub4_data","1|1|Participants abstinent at end of treatment|","Participants abstinent at end of treatment",1,1,"","reported","reported",3,0,0.218177719857263,0,2014.33333333333,0.323201621073961,71.6666666666667
"CD008940","CD008940_pub4_data","1|3|Participants experiencing severe adverse events|","Participants experiencing severe adverse events",1,3,"","reported","reported",4,0,0.700476201486202,0,2015,0.0211864381034042,117
"CD008940","CD008940_pub4_data","1|4|Participants withdrawn due to adverse effects|","Participants withdrawn due to adverse effects",1,4,"","reported","reported",3,0,0.757587827316178,0,2015.33333333333,0.0143596952489834,138.333333333333
"CD008940","CD008940_pub4_data","1|5|Completion of scheduled treatment|","Completion of scheduled treatment",1,5,"","reported","reported",2,0,0.175561348511312,0,2017,0.538461538461539,38
"CD008940","CD008940_pub4_data","1|6|Cannabis use at end of treatment|Amount of cannabis","Cannabis use at end of treatment",1,6,"Amount of cannabis","reported","reported",2,0,0.272581518449431,0,2016.5,0,27.5
"CD008940","CD008940_pub4_data","11|3|Completion of scheduled treatment|","Completion of scheduled treatment",11,3,"","or","binary",2,-0.215203783492776,0.289427613645174,0,2020.5,0.822916666666667,149
"CD008940","CD008940_pub4_data","16|3|Participants experiencing severe adverse events|","Participants experiencing severe adverse events",16,3,"","reported","reported",2,0,0.575688438722142,0,2020,0.0147058823529412,97.5
"CD008940","CD008940_pub4_data","2|2|Participants experiencing adverse events|","Participants experiencing adverse events",2,2,"","or","binary",2,0.442266838034389,0.715348488968659,0,2018.5,0.434782608695652,40
"CD008940","CD008940_pub4_data","2|3|Participants experiencing severe adverse events|","Participants experiencing severe adverse events",2,3,"","or","binary",2,-0.481267336106746,1.4501727867819,0,2018.5,0,46
"CD008940","CD008940_pub4_data","2|4|Participants withdrawn due to adverse effects|","Participants withdrawn due to adverse effects",2,4,"","or","binary",2,-0.481267336106746,1.4501727867819,0,2018.5,0,46
"CD008940","CD008940_pub4_data","2|6|Cannabis use at end of treatment|Amount of cannabis","Cannabis use at end of treatment",2,6,"Amount of cannabis","reported","reported",2,0,0.246092385896976,0,2018.5,0,38
"CD008940","CD008940_pub4_data","3|1|Participants abstinent at end of treatment|","Participants abstinent at end of treatment",3,1,"","reported","reported",2,0,0.568458794103383,0,2015,0.277573529411765,28.5
"CD008940","CD008940_pub4_data","3|6|Cannabis use at end of treatment|Frequency of use","Cannabis use at end of treatment",3,6,"Frequency of use","or","binary",2,0.0217646288097493,1.42506167171595,0,2013,0,64.5
"CD008940","CD008940_pub4_data","4|5|Completion of scheduled treatment|","Completion of scheduled treatment",4,5,"","or","binary",2,-0.190906264738281,0.311567495973635,0,2011,0.550641025641026,84.5
"CD008940","CD008940_pub4_data","5|3|Participants experiencing severe adverse events|","Participants experiencing severe adverse events",5,3,"","reported","reported",2,0,0.529232146205178,0,2020.5,0.0877477477477478,112.5
"CD008940","CD008940_pub4_data","5|4|Participants withdrawn due to adverse effects|","Participants withdrawn due to adverse effects",5,4,"","reported","reported",3,0,0.650202715403169,0,2011,0.0539316239316239,47
"CD008940","CD008940_pub4_data","5|5|Completion of scheduled treatment|","Completion of scheduled treatment",5,5,"","reported","reported",2,0,0.198662408378711,0,2014,0.64527027027027,50
"CD008940","CD008940_pub4_data","5|6|Cannabis use at end of treatment|Amount of cannabis","Cannabis use at end of treatment",5,6,"Amount of cannabis","reported","reported",2,0,0.215869210029731,0,2014.5,0,58
"CD008940","CD008940_pub4_data","5|6|Cannabis use at end of treatment|Frequency of use","Cannabis use at end of treatment",5,6,"Frequency of use","reported","reported",2,0,0.188938290576712,0,2014.5,0,58
"CD008940","CD008940_pub4_data","5|6|Cannabis use at end of treatment|Urine THC levels","Cannabis use at end of treatment",5,6,"Urine THC levels","or","binary",2,0,1.44141994364587,0,2013,0,33
"CD008940","CD008940_pub4_data","6|1|Participants abstinent at end of treatment|","Participants abstinent at end of treatment",6,1,"","or","binary",2,-1.06108378056116,0.703659093597706,0,2010.5,0.25,20.5
"CD008940","CD008940_pub4_data","6|4|Completion of scheduled treatment|","Completion of scheduled treatment",6,4,"","or","binary",2,0.10545978377773,0.415010291462691,0,2010.5,0.4,46
"CD008940","CD008940_pub4_data","7|2|Participants experiencing adverse events|","Participants experiencing adverse events",7,2,"","reported","reported",2,0,0.0723245583145753,0,2012,0.669172932330827,127.5
"CD008940","CD008940_pub4_data","7|4|Participants withdrawn due to adverse effects|","Participants withdrawn due to adverse effects",7,4,"","reported","reported",2,0,0.727997292407103,0,2012,0.0369674185463659,127.5
"CD008940","CD008940_pub4_data","7|5|Completion of scheduled treatment|","Completion of scheduled treatment",7,5,"","reported","reported",2,0,0.132613937358968,0,2012,0.450814536340852,127.5
"CD008940","CD008940_pub4_data","9|4|Participants withdrawn due to adverse effects|","Participants withdrawn due to adverse effects",9,4,"","or","binary",2,-0.503043889182526,1.55287332627247,2.3310942628625,2014.5,0.0100671140939597,209
"CD008973","CD008973_pub3_data","1|1|Complete resolution of phimosis|","Complete resolution of phimosis",1,1,"","or","binary",10,1.77911666816585,0.311399637873999,0.579395562402891,2006.7,0.216873171247155,83.4
"CD008973","CD008973_pub3_data","1|2|Partial resolution of phimosis|","Partial resolution of phimosis",1,2,"","or","binary",7,0.8736455765214,0.210085129237414,0.0661683382903165,2008.85714285714,0.241593703729145,106.428571428571
"CD008973","CD008973_pub3_data","1|3|Change in retractability score|","Change in retractability score",1,3,"","or","binary",2,0.0365534545298348,1.42530755964901,0,2003,0,88.5
"CD008973","CD008973_pub3_data","1|4|Long-term complete resolution of phimosis|","Long-term complete resolution of phimosis",1,4,"","or","binary",2,2.77334187871365,0.762915221509021,0.771304636431661,2002,0.183333333333333,140
"CD008973","CD008973_pub3_data","1|5|Adverse effects (any)|","Adverse effects (any)",1,5,"","or","binary",11,-0.431408339387691,0.544819678659744,0,2005.18181818182,0.0255681818181818,99.1818181818182
"CD008973","CD008973_pub3_data","1|6|Complete resolution of phimosis (subgroup analysis based on age)|< 3 years of age","Complete resolution of phimosis (subgroup analysis based on age)",1,6,"< 3 years of age","or","binary",2,2.38411262268212,0.502427623239181,0,2012,0.075,60
"CD008973","CD008973_pub3_data","1|6|Complete resolution of phimosis (subgroup analysis based on age)|≥ 3 years of age","Complete resolution of phimosis (subgroup analysis based on age)",1,6,"≥ 3 years of age","or","binary",8,1.66594274455711,0.363741206225584,0.69719133431853,2005.375,0.252341464058943,89.25
"CD008973","CD008973_pub3_data","1|7|Complete resolution of phimosis (subgroup analysis based on duration of treatment)|4 weeks' treatment","Complete resolution of phimosis (subgroup analysis based on duration of treatment)",1,7,"4 weeks' treatment","or","binary",4,2.33567539166285,0.593319090618323,1.02302589406076,2005,0.162800762910798,96.5
"CD008973","CD008973_pub3_data","1|7|Complete resolution of phimosis (subgroup analysis based on duration of treatment)|6–8 weeks' treatment","Complete resolution of phimosis (subgroup analysis based on duration of treatment)",1,7,"6–8 weeks' treatment","or","binary",6,1.2915699866809,0.224297142419757,2.83832551716682e-06,2007.83333333333,0.252921443471392,74.6666666666667
"CD008973","CD008973_pub3_data","1|8|Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)|High-potency corticosteroid","Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)",1,8,"High-potency corticosteroid","or","binary",5,1.87601653888868,0.591502776330001,1.3752727009238,2004.2,0.26698338638643,91.8
"CD008973","CD008973_pub3_data","1|8|Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)|Low-potency corticosteroid","Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)",1,8,"Low-potency corticosteroid","or","binary",2,2.1155296272577,0.66021224851599,0,2012,0.040625,55.5
"CD008973","CD008973_pub3_data","1|8|Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)|Medium-potency corticosteroid","Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)",1,8,"Medium-potency corticosteroid","or","binary",3,1.55164816517065,0.338413641241938,0.0907559800219131,2007.33333333333,0.250854926846466,88
"CD008995","CD008995_pub3_data","1|2|Clinical pregnancy|NA","Clinical pregnancy",1,2,NA,"or","binary",2,0.0139074215274133,0.213408583716617,0,2013.5,0.477325581395349,188.5
"CD009022","CD009022_pub4_data","1|10|Intra-abdominal collection (rate)|NA","Intra-abdominal collection (rate)",1,10,NA,"or","binary",5,0.429898845590842,0.442720951859434,0,2013.2,0.0189101165413467,135.2
"CD009022","CD009022_pub4_data","1|11|Postoperative ileus (rate)|NA","Postoperative ileus (rate)",1,11,NA,"or","binary",3,-0.3150067284515,0.575866317291564,0,2013,0.02546748679929,165.666666666667
"CD009022","CD009022_pub4_data","1|12|Length of hospital stay (days)|NA","Length of hospital stay (days)",1,12,NA,"or","binary",10,0.00260588617866673,0.635565876664769,0,2014.7,0,124.1
"CD009022","CD009022_pub4_data","1|13|Return to normal activities (days)|NA","Return to normal activities (days)",1,13,NA,"or","binary",4,-0.00619407775428075,1.00663513735496,0,2014.75,0,112.75
"CD009022","CD009022_pub4_data","1|3|Wound cosmesis: Body Image Questionnaire (BIQ score)|NA","Wound cosmesis: Body Image Questionnaire (BIQ score)",1,3,NA,"or","binary",3,0.0104037796883511,1.16244280552302,0,2015.66666666667,0,88.6666666666667
"CD009022","CD009022_pub4_data","1|4|Wound cosmesis: VAS scale|NA","Wound cosmesis: VAS scale",1,4,NA,"or","binary",3,0.0331441044486286,1.16095450727868,0,2016,0,141
"CD009022","CD009022_pub4_data","1|5|Operating time (minutes)|NA","Operating time (minutes)",1,5,NA,"or","binary",11,-1.57087127914478e-05,0.606117935112344,0,2015.45454545455,0,123.818181818182
"CD009022","CD009022_pub4_data","1|6|Visceral or vascular injury (rate)|NA","Visceral or vascular injury (rate)",1,6,NA,"or","binary",3,-1.22313568797913,0.977655268406908,0,2013.66666666667,0.0299000188643652,112.333333333333
"CD009022","CD009022_pub4_data","1|7|Conversion to laparoscopic (use of more than one additional port)/open surgery (rate)|NA","Conversion to laparoscopic (use of more than one additional port)/open surgery (rate)",1,7,NA,"or","binary",9,0.948523050675653,0.36830869170094,0,2013.77777777778,0.0130062384472287,127
"CD009022","CD009022_pub4_data","1|8|Use of additional port site (rate)|NA","Use of additional port site (rate)",1,8,NA,"or","binary",5,1.15380837140497,0.536564884368886,0.188488575852491,2015.4,0.0165984220513333,132.8
"CD009022","CD009022_pub4_data","1|9|Wound infection (rate)|NA","Wound infection (rate)",1,9,NA,"or","binary",5,0.0842895300918917,0.415747324856875,0,2013.2,0.038020320662177,99.8
"CD009102","CD009102_pub2_data","1|1|Death before discharge|","Death before discharge",1,1,"","or","binary",3,-0.329185540228235,0.242221970424956,0,2010.33333333333,0.0921458082286108,374.666666666667
"CD009102","CD009102_pub2_data","1|11|Need for supplemental oxygen at 36 weeks' corrected gestational age|","Need for supplemental oxygen at 36 weeks' corrected gestational age",1,11,"","or","binary",2,0.0771045343190681,0.197646122314526,0,2013,0.262837837837838,253.5
"CD009102","CD009102_pub2_data","1|12|Cranial ultrasound abnormalities (IVH grade ≥ 3 or periventricular leukomalacia)|","Cranial ultrasound abnormalities (IVH grade ≥ 3 or periventricular leukomalacia)",1,12,"","or","binary",3,-0.0632904374415462,0.309780037985207,0.0330175168801109,2015.66666666667,0.073344005162187,249.666666666667
"CD009102","CD009102_pub2_data","1|2|Intubation and mechanical ventilation in DR|","Intubation and mechanical ventilation in DR",1,2,"","or","binary",5,-0.473839693072067,0.159013376644621,5.15375313802001e-06,2013.6,0.194521701925377,281.2
"CD009102","CD009102_pub2_data","1|3|Chest compressions in DR|","Chest compressions in DR",1,3,"","or","binary",3,-1.06062155971548,0.531271824161717,0.366797440628776,2010.33333333333,0.0561544028104538,374.666666666667
"CD009102","CD009102_pub2_data","1|5|Apgar scores at 5 minutes|","Apgar scores at 5 minutes",1,5,"","or","binary",3,-0.00543238079935393,1.16069003209036,0,2016.66666666667,0,146
"CD009102","CD009102_pub2_data","1|6|Intubation and mechanical ventilation within 24 hours of birth|","Intubation and mechanical ventilation within 24 hours of birth",1,6,"","or","binary",3,-0.0668718071701679,0.147674909637434,1.28420453970426e-07,2015.66666666667,0.587594619412801,249.666666666667
"CD009102","CD009102_pub2_data","1|8|Air leak (pneumothorax, pneumomediastinum, pneumopericardium, pulmonary interstitial emphysema) reported either individually or as a composite outcome|","Air leak (pneumothorax, pneumomediastinum, pneumopericardium, pulmonary interstitial emphysema) reported either individually or as a composite outcome",1,8,"","or","binary",2,0.17015877280192,0.496397262309261,0.221843796411405,2013,0.0586711711711712,253.5
"CD009235","CD009235_pub4_data","1|1|Duration of mechanical ventilation|","Duration of mechanical ventilation",1,1,"","reported","reported",51,0,0.0120545620048672,0,2013.52,0,77.0392156862745
"CD009235","CD009235_pub4_data","1|10|Self-extubation|","Self-extubation",1,10,"","reported","reported",6,0,0.390525595749179,0,2008,0.0353703703703704,93.8333333333333
"CD009235","CD009235_pub4_data","1|11|Non invasive ventilation following extubation|","Non invasive ventilation following extubation",1,11,"","or","binary",23,-0.362561485028372,0.117507409728121,0,2013.86363636364,0.153004287826445,106.565217391304
"CD009235","CD009235_pub4_data","1|12|Prolonged mechanical ventilation|","Prolonged mechanical ventilation",1,12,"","or","binary",11,-0.659966372823588,0.249566429636218,0,2012.3,0.0977156109815362,108.272727272727
"CD009235","CD009235_pub4_data","1|13|Tracheostomy|","Tracheostomy",1,13,"","or","binary",17,-0.355360055882466,0.127836102944234,0,2013.47058823529,0.214044716550955,109.235294117647
"CD009235","CD009235_pub4_data","1|14|Duration of mechanical ventilation by study population|Medical ICU population","Duration of mechanical ventilation by study population",1,14,"Medical ICU population","reported","reported",4,0,0.0734662097152599,0,2015.25,0,71.25
"CD009235","CD009235_pub4_data","1|14|Duration of mechanical ventilation by study population|Mixed ICU patient population","Duration of mechanical ventilation by study population",1,14,"Mixed ICU patient population","reported","reported",5,0,0.108379085676908,0,2007.2,0,66.6
"CD009235","CD009235_pub4_data","1|14|Duration of mechanical ventilation by study population|Surgical ICU population","Duration of mechanical ventilation by study population",1,14,"Surgical ICU population","reported","reported",6,0,0.0386550984891861,0,2012.16666666667,0,108
"CD009235","CD009235_pub4_data","1|15|ICU length of stay by study population|Mixed ICU population","ICU length of stay by study population",1,15,"Mixed ICU population","reported","reported",3,0,0.122548738754339,0,2014,0,58
"CD009235","CD009235_pub4_data","1|15|ICU length of stay by study population|Surgical ICU population","ICU length of stay by study population",1,15,"Surgical ICU population","reported","reported",3,0,0.046902936628229,0,2004.33333333333,0,66
"CD009235","CD009235_pub4_data","1|16|Reintubation by study population|Medical ICU population","Reintubation by study population",1,16,"Medical ICU population","reported","reported",3,0,0.408984309719554,0,2014.5,0.125315904139434,99
"CD009235","CD009235_pub4_data","1|16|Reintubation by study population|Mixed ICU population","Reintubation by study population",1,16,"Mixed ICU population","reported","reported",13,0,0.1387352413702,0,2012.76923076923,0.18333881262087,91.3846153846154
"CD009235","CD009235_pub4_data","1|16|Reintubation by study population|Surgical ICU population","Reintubation by study population",1,16,"Surgical ICU population","reported","reported",6,0,0.183238397969117,0,2013.16666666667,0.0836379236379236,122.5
"CD009235","CD009235_pub4_data","1|17|Duration of mechanical ventilation by automated system|ASV","Duration of mechanical ventilation by automated system",1,17,"ASV","reported","reported",6,0,0.0343386739782526,0,2010.5,0,76.3333333333333
"CD009235","CD009235_pub4_data","1|17|Duration of mechanical ventilation by automated system|Automode","Duration of mechanical ventilation by automated system",1,17,"Automode","or","binary",3,0,1.17836075744498,0,2003,0,26
"CD009235","CD009235_pub4_data","1|17|Duration of mechanical ventilation by automated system|Intellivent-ASV","Duration of mechanical ventilation by automated system",1,17,"Intellivent-ASV","or","binary",7,0.0206428508796803,0.762025044496674,0,2019.57142857143,0,84.4285714285714
"CD009235","CD009235_pub4_data","1|17|Duration of mechanical ventilation by automated system|PAV+","Duration of mechanical ventilation by automated system",1,17,"PAV+","or","binary",5,-0.135321086902208,0.901679821618309,0,2016.2,0,76.6
"CD009235","CD009235_pub4_data","1|17|Duration of mechanical ventilation by automated system|SmartCare/PS","Duration of mechanical ventilation by automated system",1,17,"SmartCare/PS","reported","reported",3,0,0.13200069385217,0,2011,0,144
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|ASV","ICU length of stay by automated system",1,18,"ASV","or","binary",15,0.00969790585601727,0.520296315939651,0,2014,0,82.6
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|Intellivent-ASV","ICU length of stay by automated system",1,18,"Intellivent-ASV","or","binary",4,0.0299585259768039,1.00731617518016,0,2019.25,0,99.5
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|NAVA","ICU length of stay by automated system",1,18,"NAVA","or","binary",4,0.107333140608015,1.00751768709715,0,2018,0,84.25
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|Other","ICU length of stay by automated system",1,18,"Other","or","binary",3,0.0075791958967562,1.16148213701226,0,2021.66666666667,0,85.6666666666667
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|PAV+","ICU length of stay by automated system",1,18,"PAV+","or","binary",8,-0.10465626943207,0.714769730525113,0,2014.875,0,79.25
"CD009235","CD009235_pub4_data","1|18|ICU length of stay by automated system|SmartCare/PS","ICU length of stay by automated system",1,18,"SmartCare/PS","reported","reported",2,0,0.138047066255101,0,2013,0,65.5
"CD009235","CD009235_pub4_data","1|19|Reintubation by automated system|ASV","Reintubation by automated system",1,19,"ASV","reported","reported",4,0,0.549585635248811,0,2010.66666666667,0.0517647058823529,65
"CD009235","CD009235_pub4_data","1|19|Reintubation by automated system|NAVA","Reintubation by automated system",1,19,"NAVA","reported","reported",3,0,0.22015238250365,0,2018.33333333333,0.202966314731021,175.666666666667
"CD009235","CD009235_pub4_data","1|19|Reintubation by automated system|PAV+","Reintubation by automated system",1,19,"PAV+","reported","reported",4,0,0.319433555084967,0,2016.75,0.145326086956522,85.5
"CD009235","CD009235_pub4_data","1|19|Reintubation by automated system|SmartCare/PS","Reintubation by automated system",1,19,"SmartCare/PS","reported","reported",9,0,0.137243621053773,0,2011.88888888889,0.173353933226254,94.8888888888889
"CD009235","CD009235_pub4_data","1|2|Mortality|ICU mortality","Mortality",1,2,"ICU mortality","reported","reported",6,0,0.142768800882513,0,2017.83333333333,0.212882139472528,77.6666666666667
"CD009235","CD009235_pub4_data","1|20|Duration of mechanical ventilation by non-automated strategy (control arm)|protocolized weaning (non-automated)","Duration of mechanical ventilation by non-automated strategy (control arm)",1,20,"protocolized weaning (non-automated)","reported","reported",5,0,0.0603286813702304,0,2011,0,51.4
"CD009235","CD009235_pub4_data","1|21|ICU length of stay by non-automated strategy (control arm)|Protocolized weaning (non-automated)","ICU length of stay by non-automated strategy (control arm)",1,21,"Protocolized weaning (non-automated)","reported","reported",31,0,0.0142154037310127,0,2014.87096774194,0,96.3225806451613
"CD009235","CD009235_pub4_data","1|21|ICU length of stay by non-automated strategy (control arm)|Usual care","ICU length of stay by non-automated strategy (control arm)",1,21,"Usual care","reported","reported",7,0,0.0295765893697588,0,2015.16666666667,0,61
"CD009235","CD009235_pub4_data","1|22|Reintubation by non-automated strategy (control arm)|Protocolized weaning (non-automated)","Reintubation by non-automated strategy (control arm)",1,22,"Protocolized weaning (non-automated)","reported","reported",14,0,0.115850043764554,0,2014.21428571429,0.152047006548413,117.214285714286
"CD009235","CD009235_pub4_data","1|22|Reintubation by non-automated strategy (control arm)|Usual care","Reintubation by non-automated strategy (control arm)",1,22,"Usual care","reported","reported",8,0,0.269175756891562,0,2010.71428571429,0.141565215829922,72.375
"CD009235","CD009235_pub4_data","1|3|ICU length of stay|","ICU length of stay",1,3,"","reported","reported",37,0,0.0128611957020338,0,2014.66666666667,0,89.5405405405405
"CD009235","CD009235_pub4_data","1|4|Hospital length of stay|","Hospital length of stay",1,4,"","reported","reported",3,0,0.0901355886346833,0,2010.66666666667,0,94.6666666666667
"CD009235","CD009235_pub4_data","1|5|Time from randomization to first extubation|","Time from randomization to first extubation",1,5,"","reported","reported",6,0,0.034361086814652,0,2007.5,0,76.8333333333333
"CD009235","CD009235_pub4_data","1|6|Time from intubation (or ICU admission if admitted ventilated) to successful extubation|","Time from intubation (or ICU admission if admitted ventilated) to successful extubation",1,6,"","reported","reported",13,0,0.0402702870415645,0,2009.07692307692,0,93.3846153846154
"CD009235","CD009235_pub4_data","1|7|Time from intubation to randomization|","Time from intubation to randomization",1,7,"","reported","reported",5,0,0.0266969918936086,0,2006.2,0,48.2
"CD009235","CD009235_pub4_data","1|9|Reintubation|","Reintubation",1,9,"","reported","reported",9,0,0.137964598912081,0,2008,0.193700253572575,87.8888888888889
"CD009235","CD009235_pub4_data","2|1|Duration of mechanical ventilation (hours)|","Duration of mechanical ventilation (hours)",2,1,"","reported","reported",51,0,0.0305035414463749,0,2013.52,0,77.0392156862745
"CD009235","CD009235_pub4_data","2|2|ICU length of stay (days)|","ICU length of stay (days)",2,2,"","reported","reported",9,0,0.0192752658420024,0,2009.44444444444,0,77.3333333333333
"CD009235","CD009235_pub4_data","2|3|Hospital length of stay (days)|","Hospital length of stay (days)",2,3,"","reported","reported",6,0,0.535462731275383,0,2013.83333333333,0,67.6666666666667
"CD009235","CD009235_pub4_data","3|1|Duration of mechanical ventilation (hours)|","Duration of mechanical ventilation (hours)",3,1,"","reported","reported",6,0,0.0404271717863043,0,2009.66666666667,0,51.5
"CD009252","CD009252_pub2_data","2|1|Lower urinary tract symptom-specific quality of life|","Lower urinary tract symptom-specific quality of life",2,1,"","reported","reported",8,0,0.0626434218145259,0,2018,0,131.75
"CD009252","CD009252_pub2_data","2|2|Number or change in number of leakage episodes in 24 hours|","Number or change in number of leakage episodes in 24 hours",2,2,"","or","binary",12,-0.0791563168440602,0.583211477410875,0,2006.33333333333,0,77.6666666666667
"CD009252","CD009252_pub2_data","2|3|Subjective symptom of cure or improvement|","Subjective symptom of cure or improvement",2,3,"","reported","reported",9,0,0.126161459465463,0,2004.44444444444,0.409280097408827,119.333333333333
"CD009252","CD009252_pub2_data","2|4|Satisfaction with treatment outcome|","Satisfaction with treatment outcome",2,4,"","or","binary",6,0.86740011207078,0.256442651829759,0.0971600582858652,2009.83333333333,0.51977969017611,65
"CD009252","CD009252_pub2_data","3|1|Lower urinary tract symptom-specific quality of life (diagnosis subgroup analysis)|Other combinations of UI","Lower urinary tract symptom-specific quality of life (diagnosis subgroup analysis)",3,1,"Other combinations of UI","reported","reported",4,0,0.0849092236015178,0,2009.25,0,139.75
"CD009252","CD009252_pub2_data","3|1|Lower urinary tract symptom-specific quality of life (diagnosis subgroup analysis)|SUI or SP-MUI ","Lower urinary tract symptom-specific quality of life (diagnosis subgroup analysis)",3,1,"SUI or SP-MUI ","reported","reported",7,0,0.0840137419366428,0,2017.71428571429,0,87.1428571428571
"CD009252","CD009252_pub2_data","3|2|Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)|Authors don’t report on amount of supervision in groups","Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)",3,2,"Authors don’t report on amount of supervision in groups","reported","reported",2,0,0.179880060750544,0,2015,0,65
"CD009252","CD009252_pub2_data","3|2|Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)|Authors report different amounts of supervision in randomised groups","Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)",3,2,"Authors report different amounts of supervision in randomised groups","reported","reported",2,0,0.211004760991499,0,2016,0,55
"CD009252","CD009252_pub2_data","3|2|Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)|Authors report the same amount of supervision in both randomised groups","Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)",3,2,"Authors report the same amount of supervision in both randomised groups","reported","reported",7,0,0.0663700305684039,0,2014.14285714286,0,132.714285714286
"CD009252","CD009252_pub2_data","3|3|Lower urinary tract symptom-specific quality of life (selection bias)|Low risk of bias","Lower urinary tract symptom-specific quality of life (selection bias)",3,3,"Low risk of bias","reported","reported",4,0,0.0696557649290251,0,2013.25,0,210.5
"CD009252","CD009252_pub2_data","3|3|Lower urinary tract symptom-specific quality of life (selection bias)|Unclear risk","Lower urinary tract symptom-specific quality of life (selection bias)",3,3,"Unclear risk","reported","reported",7,0,0.116030155678119,0,2015.42857142857,0,46.7142857142857
"CD009252","CD009252_pub2_data","3|4|Lower urinary tract symptom-specific quality of life (attrition bias)|High risk","Lower urinary tract symptom-specific quality of life (attrition bias)",3,4,"High risk","reported","reported",2,0,0.204481144936145,0,2017,0,52.5
"CD009252","CD009252_pub2_data","3|4|Lower urinary tract symptom-specific quality of life (attrition bias)|Low risk of bias","Lower urinary tract symptom-specific quality of life (attrition bias)",3,4,"Low risk of bias","reported","reported",3,0,0.0721418404763769,0,2012.66666666667,0,261
"CD009252","CD009252_pub2_data","3|4|Lower urinary tract symptom-specific quality of life (attrition bias)|Unclear risk","Lower urinary tract symptom-specific quality of life (attrition bias)",3,4,"Unclear risk","reported","reported",6,0,0.124687026844073,0,2014.83333333333,0,46.8333333333333
"CD009252","CD009252_pub2_data","5|1|Lower urinary tract symptom-specific quality of life|","Lower urinary tract symptom-specific quality of life",5,1,"","or","binary",2,-0.251214333185812,1.4346673456158,0,2007.5,0,45.5
"CD009252","CD009252_pub2_data","5|2|Number or change in number of leakage episodes in 24 hours|","Number or change in number of leakage episodes in 24 hours",5,2,"","or","binary",2,0,1.43284220470215,0,2007.5,0,60
"CD009298","CD009298_pub3_data","1|1|Operative delivery|","Operative delivery",1,1,"","reported","reported",6,0.908498063845052,0.0586740272540453,0.00151490465134302,2019.5,0.517581083719778,167
"CD009298","CD009298_pub3_data","1|10|Perinatal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Perinatal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)",1,10,"Occiput posterior position","or","binary",5,-0.00609948685243483,0.899711491289591,0,2019,0,163.4
"CD009298","CD009298_pub3_data","1|10|Perinatal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput transverse postion","Perinatal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)",1,10,"Occiput transverse postion","or","binary",2,0.0692922278178524,1.44081094288875,0,2021.5,0,86.5
"CD009298","CD009298_pub3_data","1|11|Perinatal mortality (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Perinatal mortality (Subgroup analysis: nulliparous versus multiparous)",1,11,"Multiparous","or","binary",5,0.0404027051536624,0.918064402223278,0,2019.2,0,42.4
"CD009298","CD009298_pub3_data","1|11|Perinatal mortality (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Perinatal mortality (Subgroup analysis: nulliparous versus multiparous)",1,11,"Nulliparous","or","binary",6,0.000574403175576454,0.821570245987258,0,2019.5,0,131.666666666667
"CD009298","CD009298_pub3_data","1|12|Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,12,"Digital (fingers) rotation","or","binary",3,0.0316763139986648,1.16394517387239,0,2018,0,93
"CD009298","CD009298_pub3_data","1|12|Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,12,"Method unknown","or","binary",2,0.0817555074321807,1.45696431682833,0,2021.5,0,16
"CD009298","CD009298_pub3_data","1|12|Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,12,"Whole-hand rotation","or","binary",5,-0.0447631124518701,0.899540162401288,0,2021.2,0,138.2
"CD009298","CD009298_pub3_data","1|13|Caesarean section|","Caesarean section",1,13,"","reported","reported",6,0.962833448234231,0.206893705094494,0,2019.5,0.104651254548222,167
"CD009298","CD009298_pub3_data","1|14|Caesarean section (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Caesarean section (Subgroup analysis: occiput posterior versus occiput transverse position)",1,14,"Occiput posterior position","reported","reported",5,1.00618413944738,0.229200547074895,0,2019,0.10825409092086,163.4
"CD009298","CD009298_pub3_data","1|15|Caesarean section (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Caesarean section (Subgroup analysis: nulliparous versus multiparous)",1,15,"Multiparous","reported","reported",3,0.183970707031906,0.569041778186533,0,2021,0.0740713976008094,61
"CD009298","CD009298_pub3_data","1|15|Caesarean section (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Caesarean section (Subgroup analysis: nulliparous versus multiparous)",1,15,"Nulliparous","reported","reported",6,1.04857680398756,0.234735388735597,0,2019.5,0.117190640322459,131.666666666667
"CD009298","CD009298_pub3_data","1|16|Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,16,"Digital (fingers) rotation","reported","reported",3,1.0551736863962,0.328180537269673,0,2018,0.163215488215488,93
"CD009298","CD009298_pub3_data","1|16|Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,16,"Method unknown","reported","reported",2,0.729639802890258,1.38483620177679,0,2021.5,0.174242424242424,16
"CD009298","CD009298_pub3_data","1|16|Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,16,"Whole-hand rotation","reported","reported",4,0.920171961180327,0.30609182054655,0,2021,0.0815675224808869,162.25
"CD009298","CD009298_pub3_data","1|17|Instrumental delivery|","Instrumental delivery",1,17,"","reported","reported",6,0.859690176756519,0.0700803348090707,0,2019.5,0.412929829171556,167
"CD009298","CD009298_pub3_data","1|18|Instrumental delivery (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Instrumental delivery (Subgroup analysis: occiput posterior versus occiput transverse position)",1,18,"Occiput posterior position","reported","reported",5,0.850449770436725,0.0776892338911011,0,2019,0.406922200581705,163.4
"CD009298","CD009298_pub3_data","1|18|Instrumental delivery (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput transverse postion","Instrumental delivery (Subgroup analysis: occiput posterior versus occiput transverse position)",1,18,"Occiput transverse postion","reported","reported",2,1.0486689557532,0.1969520814513,0,2021.5,0.349107142857143,86.5
"CD009298","CD009298_pub3_data","1|19|Instrumental delivery (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Instrumental delivery (Subgroup analysis: nulliparous versus multiparous)",1,19,"Multiparous","reported","reported",5,0.79277570720766,0.250084597304122,0,2019.2,0.332431320666615,42.4
"CD009298","CD009298_pub3_data","1|19|Instrumental delivery (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Instrumental delivery (Subgroup analysis: nulliparous versus multiparous)",1,19,"Nulliparous","reported","reported",6,0.830610786831623,0.071929311796428,0.00169794081300553,2019.5,0.452365199200329,131.666666666667
"CD009298","CD009298_pub3_data","1|2|Operative delivery (Subgroup analysis: occiput posterior versus occiput transverse)|Occiput posterior","Operative delivery (Subgroup analysis: occiput posterior versus occiput transverse)",1,2,"Occiput posterior","reported","reported",5,0.907123846964277,0.0598593584084836,0,2019,0.515176291502565,163.4
"CD009298","CD009298_pub3_data","1|2|Operative delivery (Subgroup analysis: occiput posterior versus occiput transverse)|Occiput transverse","Operative delivery (Subgroup analysis: occiput posterior versus occiput transverse)",1,2,"Occiput transverse","reported","reported",2,1.0175982783435,0.161218362355026,0,2021.5,0.392857142857143,86.5
"CD009298","CD009298_pub3_data","1|20|Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,20,"Digital (fingers) rotation","reported","reported",3,0.883993624307313,0.111946991655288,0,2018,0.533501683501683,93
"CD009298","CD009298_pub3_data","1|20|Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,20,"Method unknown","reported","reported",2,0.700060066125703,0.291576367695489,0,2021.5,0.53030303030303,16
"CD009298","CD009298_pub3_data","1|20|Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,20,"Whole-hand rotation","reported","reported",5,0.843140991220452,0.0960976882240537,0,2021.2,0.338560759780007,138.2
"CD009298","CD009298_pub3_data","1|21|Third- or fourth-degree perineal trauma|","Third- or fourth-degree perineal trauma",1,21,"","reported","reported",6,0.502572162271733,0.218004042590831,0,2019.5,0.0701244493209117,167
"CD009298","CD009298_pub3_data","1|22|Third- or fourth-degree perineal trauma (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Third- or fourth-degree perineal trauma (Subgroup analysis: occiput posterior versus occiput transverse position)",1,22,"Occiput posterior position","reported","reported",5,0.472224981416235,0.218789644076513,0,2019,0.0749989906952168,163.4
"CD009298","CD009298_pub3_data","1|23|Third- or fourth-degree perineal trauma (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Third- or fourth-degree perineal trauma (Subgroup analysis: nulliparous versus multiparous)",1,23,"Multiparous","reported","reported",3,0.438764584712698,2.1308100480868,0,2021.33333333333,0.0151515151515152,46.6666666666667
"CD009298","CD009298_pub3_data","1|23|Third- or fourth-degree perineal trauma (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Third- or fourth-degree perineal trauma (Subgroup analysis: nulliparous versus multiparous)",1,23,"Nulliparous","reported","reported",6,0.513286545566448,0.224721497298952,0,2019.5,0.081951680261718,131.666666666667
"CD009298","CD009298_pub3_data","1|24|Third- or fourth-degree perineal trauma (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Third- or fourth-degree perineal trauma (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,24,"Digital (fingers) rotation","reported","reported",3,0.434364203179464,0.26326128874168,2.12126373883782e-07,2018,0.114983164983165,93
"CD009298","CD009298_pub3_data","1|24|Third- or fourth-degree perineal trauma (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Third- or fourth-degree perineal trauma (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,24,"Whole-hand rotation","reported","reported",5,0.448618445432319,0.365468028694081,0,2021.2,0.0406465952099091,138.2
"CD009298","CD009298_pub3_data","1|25|Postpartum haemorrhage ≥ 500 mL|","Postpartum haemorrhage ≥ 500 mL",1,25,"","reported","reported",6,0.913698759102298,0.140709838473421,0,2019.5,0.166965345899735,167
"CD009298","CD009298_pub3_data","1|26|Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: occiput posterior versus occiput transverse position)",1,26,"Occiput posterior position","reported","reported",5,0.936434241607367,0.174614800087284,0,2019,0.143367044352832,163.4
"CD009298","CD009298_pub3_data","1|26|Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput transverse postion","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: occiput posterior versus occiput transverse position)",1,26,"Occiput transverse postion","reported","reported",2,0.856682631264486,0.242212077793095,0,2021.5,0.210669077757685,85.5
"CD009298","CD009298_pub3_data","1|27|Postpartum haemorrhage ≥ 500 mL &nbsp;(Subgroup analysis: nulliparous versus multiparous)|Multiparous","Postpartum haemorrhage ≥ 500 mL &nbsp;(Subgroup analysis: nulliparous versus multiparous)",1,27,"Multiparous","reported","reported",4,0.242449359472707,0.241469572143225,0,2021.25,0.141033052797759,52
"CD009298","CD009298_pub3_data","1|27|Postpartum haemorrhage ≥ 500 mL &nbsp;(Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Postpartum haemorrhage ≥ 500 mL &nbsp;(Subgroup analysis: nulliparous versus multiparous)",1,27,"Nulliparous","reported","reported",6,0.900903061797571,0.155547117652165,0,2019.5,0.174854458204857,131.666666666667
"CD009298","CD009298_pub3_data","1|28|Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,28,"Digital (fingers) rotation","reported","reported",3,0.87251160615006,0.205110980110699,0,2018,0.24520202020202,93
"CD009298","CD009298_pub3_data","1|28|Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,28,"Method unknown","reported","reported",2,0.399425105322208,0.330481680406829,0,2021.5,0.401515151515151,16
"CD009298","CD009298_pub3_data","1|28|Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,28,"Whole-hand rotation","reported","reported",5,0.934386739242768,0.233624550215096,0,2021.2,0.123086252927702,138.2
"CD009298","CD009298_pub3_data","1|29|Forceps delivery|","Forceps delivery",1,29,"","reported","reported",4,0.921848530237397,0.134032500484559,0,2018.75,0.268905839895013,127.25
"CD009298","CD009298_pub3_data","1|3|Operative delivery (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Operative delivery (Subgroup analysis: nulliparous versus multiparous)",1,3,"Multiparous","reported","reported",5,0.649298432627463,0.225670993541032,0.0359832866235747,2019.2,0.3768741592271,42.4
"CD009298","CD009298_pub3_data","1|3|Operative delivery (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Operative delivery (Subgroup analysis: nulliparous versus multiparous)",1,3,"Nulliparous","reported","reported",6,0.924173149981943,0.0789570836272676,0.0136402571144746,2019.5,0.569555839522788,131.666666666667
"CD009298","CD009298_pub3_data","1|30|Vacuum-assisted delivery|","Vacuum-assisted delivery",1,30,"","reported","reported",4,0.842412411868951,0.191500708207014,0,2018.75,0.180577427821522,127.25
"CD009298","CD009298_pub3_data","1|31|Episiotomy|","Episiotomy",1,31,"","reported","reported",4,0.861331144981634,0.0959519984327145,0.00735279486958769,2021.25,0.347333514685552,226.75
"CD009298","CD009298_pub3_data","1|32|Duration from intervention to delivery (minutes)|","Duration from intervention to delivery (minutes)",1,32,"","reported","reported",3,1.61144322182255,8.92553243477372,97.6703488489701,2018,NA,148
"CD009298","CD009298_pub3_data","1|33|Duration of second stage of labour (minutes)|","Duration of second stage of labour (minutes)",1,33,"","reported","reported",6,-8.56819770954132,8.03317121139106,230.935261331354,2019.5,NA,167
"CD009298","CD009298_pub3_data","1|34|Maternal postnatal infection|","Maternal postnatal infection",1,34,"","reported","reported",2,1.34428417221934,3.23252939185063,0,2021.5,0.0101870078740157,207
"CD009298","CD009298_pub3_data","1|35|Duration of maternal hospital stay (days)|","Duration of maternal hospital stay (days)",1,35,"","reported","reported",2,0.122840900474773,0.269454198897481,0.0817061912436224,2021.5,NA,207
"CD009298","CD009298_pub3_data","1|36|Negative experience of childbirth at 6 weeks post delivery (as defined by trial authors)|","Negative experience of childbirth at 6 weeks post delivery (as defined by trial authors)",1,36,"","reported","reported",2,0.5120291938245,0.121247557650839,0,2021.5,0.319611848825332,142
"CD009298","CD009298_pub3_data","1|37|Postnatal depression at &lt; 6 months' follow up|","Postnatal depression at &lt; 6 months' follow up",1,37,"","reported","reported",2,0.554138105177181,1.45752914381143,0,2021.5,0.0185185185185185,142
"CD009298","CD009298_pub3_data","1|38|Postnatal depression at ≥ 6 months' follow up|","Postnatal depression at ≥ 6 months' follow up",1,38,"","reported","reported",2,0.620711032359847,1.38000980705642,0,2021.5,0.030952380952381,124
"CD009298","CD009298_pub3_data","1|39|Breastfeeding not successful &lt; 6 months' follow up|","Breastfeeding not successful &lt; 6 months' follow up",1,39,"","reported","reported",2,0.727810213991241,0.183129897645751,0,2021.5,0.238605045579818,140
"CD009298","CD009298_pub3_data","1|4|Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,4,"Digital (fingers) rotation","reported","reported",3,0.940134601689288,0.0799325631282044,0,2018,0.696717171717172,93
"CD009298","CD009298_pub3_data","1|4|Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,4,"Method unknown","reported","reported",2,0.704137177811478,0.199691912315453,0,2021.5,0.704545454545455,16
"CD009298","CD009298_pub3_data","1|4|Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,4,"Whole-hand rotation","reported","reported",5,0.901213643936128,0.100065746337435,0.0105219723607111,2021.2,0.403814777764716,138.2
"CD009298","CD009298_pub3_data","1|40|Breastfeeding not successful at ≥ 6 months' follow up|","Breastfeeding not successful at ≥ 6 months' follow up",1,40,"","reported","reported",2,1.04729518650417,0.158499352657956,0,2021.5,0.418382352941176,124.5
"CD009298","CD009298_pub3_data","1|43|Cord blood gas acidosis|","Cord blood gas acidosis",1,43,"","reported","reported",5,0.91660332845529,0.378558718976691,0,2019.2,0.0302438714862034,186.4
"CD009298","CD009298_pub3_data","1|44|Admission to neonatal intensive care unit|","Admission to neonatal intensive care unit",1,44,"","reported","reported",3,0.433771724368986,0.445905923633279,0,2018,0.0893447837150127,149
"CD009298","CD009298_pub3_data","1|47|Neonatal jaundice treated with phototherapy|","Neonatal jaundice treated with phototherapy",1,47,"","reported","reported",4,0.717052235774597,0.240051939004756,0,2018.75,0.0979500953924877,170
"CD009298","CD009298_pub3_data","1|48|Neonatal exchange transfusion|","Neonatal exchange transfusion",1,48,"","or","binary",4,0.00425015771334895,1.00574043681345,0,2018.75,0,170
"CD009298","CD009298_pub3_data","1|49|Polycythaemia treated with partial volume exchange transfusion|","Polycythaemia treated with partial volume exchange transfusion",1,49,"","or","binary",4,0.00425015771334895,1.00574043681345,0,2018.75,0,170
"CD009298","CD009298_pub3_data","1|5|Maternal mortality|","Maternal mortality",1,5,"","or","binary",6,0.00430768087933125,0.820908663051191,0,2019.5,0,167
"CD009298","CD009298_pub3_data","1|50|Neonatal stroke|","Neonatal stroke",1,50,"","or","binary",4,0.00425015771334895,1.00574043681345,0,2018.75,0,170
"CD009298","CD009298_pub3_data","1|53|Scalp haematoma (e.g. cephalohaematoma or subgaleal haemorrhage)|","Scalp haematoma (e.g. cephalohaematoma or subgaleal haemorrhage)",1,53,"","reported","reported",4,0.637664018946484,0.457757152617381,0,2018.75,0.0301550196850394,127.25
"CD009298","CD009298_pub3_data","1|54|Neonatal encephalopathy|","Neonatal encephalopathy",1,54,"","or","binary",4,0.00425015771334895,1.00574043681345,0,2018.75,0,170
"CD009298","CD009298_pub3_data","1|55|Neonatal neuropraxia|","Neonatal neuropraxia",1,55,"","reported","reported",2,0.333333,1.45571867715164,0,2021.5,0.0101870078740157,207
"CD009298","CD009298_pub3_data","1|6|Maternal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput posterior position","Maternal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)",1,6,"Occiput posterior position","or","binary",5,-0.00609948685243483,0.899711491289591,0,2019,0,163.4
"CD009298","CD009298_pub3_data","1|6|Maternal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)|Occiput transverse postion","Maternal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)",1,6,"Occiput transverse postion","or","binary",2,0.0692922278178524,1.44081094288875,0,2021.5,0,86.5
"CD009298","CD009298_pub3_data","1|7|Maternal mortality (Subgroup analysis: nulliparous versus multiparous)|Multiparous","Maternal mortality (Subgroup analysis: nulliparous versus multiparous)",1,7,"Multiparous","or","binary",5,0.0404027051536624,0.918064402223278,0,2019.2,0,42.4
"CD009298","CD009298_pub3_data","1|7|Maternal mortality (Subgroup analysis: nulliparous versus multiparous)|Nulliparous","Maternal mortality (Subgroup analysis: nulliparous versus multiparous)",1,7,"Nulliparous","or","binary",6,0.000574403175576454,0.821570245987258,0,2019.5,0,131.666666666667
"CD009298","CD009298_pub3_data","1|8|Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Digital (fingers) rotation","Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,8,"Digital (fingers) rotation","or","binary",3,0.0316763139986648,1.16394517387239,0,2018,0,93
"CD009298","CD009298_pub3_data","1|8|Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Method unknown","Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,8,"Method unknown","or","binary",2,0.0817555074321807,1.45696431682833,0,2021.5,0,16
"CD009298","CD009298_pub3_data","1|8|Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)|Whole-hand rotation","Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)",1,8,"Whole-hand rotation","or","binary",5,-0.0447631124518701,0.899540162401288,0,2021.2,0,138.2
"CD009298","CD009298_pub3_data","1|9|Perinatal mortality|","Perinatal mortality",1,9,"","or","binary",6,0.00430768087933125,0.820908663051191,0,2019.5,0,167
"CD009362","CD009362_pub4_data","1|1|Pressure ulcer|","Pressure ulcer",1,1,"","or","binary",18,-0.698093550183402,0.222123696749362,0.503177736328928,2017.5,0.137059923710214,327.944444444444
"CD009362","CD009362_pub4_data","1|2|Pressure ulcer stage|Deep tissue injury","Pressure ulcer stage",1,2,"Deep tissue injury","or","binary",3,-1.01626035990233,0.572579190534788,0,2017.33333333333,0.0289377289377289,280
"CD009362","CD009362_pub4_data","1|2|Pressure ulcer stage|Stage 1","Pressure ulcer stage",1,2,"Stage 1","or","binary",8,-1.06403455992959,0.454114393505652,0.742121485446623,2017.875,0.0615020469837972,227.875
"CD009362","CD009362_pub4_data","1|2|Pressure ulcer stage|Stage 2","Pressure ulcer stage",1,2,"Stage 2","or","binary",10,-0.768380368452338,0.218892777649026,0.00440071422136777,2017.2,0.0929304978199282,287.3
"CD009362","CD009362_pub4_data","1|2|Pressure ulcer stage|Stage 3","Pressure ulcer stage",1,2,"Stage 3","or","binary",3,-0.825498557571048,1.04616128156577,0.738690355588173,2019.66666666667,0.0528693528693529,239.333333333333
"CD009362","CD009362_pub4_data","1|2|Pressure ulcer stage|Stage 4","Pressure ulcer stage",1,2,"Stage 4","or","binary",2,-1.58082391373432,1.09845519988704,0,2016.5,0.0128778467908903,305
"CD009362","CD009362_pub4_data","1|3|Time to pressure ulcer development|","Time to pressure ulcer development",1,3,"","or","binary",2,-0.0047566010800702,1.42013518213062,0,2020,0,245
"CD009362","CD009362_pub4_data","1|4|Anatomical location of pressure ulcer development|Heel pressure ulcer","Anatomical location of pressure ulcer development",1,4,"Heel pressure ulcer","or","binary",4,-0.811747587141968,0.383237725506661,0.204828424721654,2018.5,0.0501825544344132,656
"CD009362","CD009362_pub4_data","1|4|Anatomical location of pressure ulcer development|Sacral pressure ulcer","Anatomical location of pressure ulcer development",1,4,"Sacral pressure ulcer","or","binary",5,-0.936328714763101,0.25568315516305,0.0849447489192738,2018.6,0.0704355284365941,573.6
"CD009362","CD009362_pub4_data","14|2|Anatomical location of pressure ulcer development|Heel pressure ulcer","Anatomical location of pressure ulcer development",14,2,"Heel pressure ulcer","or","binary",2,0.205199636459112,0.579572561320096,0,2019.5,0.0208333333333333,321.5
"CD009362","CD009362_pub4_data","14|2|Anatomical location of pressure ulcer development|Sacral pressure ulcer","Anatomical location of pressure ulcer development",14,2,"Sacral pressure ulcer","or","binary",2,0.453960884929462,0.491120773375985,0.0164814485868537,2019.5,0.0243055555555556,321.5
"CD009362","CD009362_pub4_data","14|3|Adverse event|","Adverse event",14,3,"","reported","reported",2,0,1.12025264459508,0,1996.5,0,369
"CD009362","CD009362_pub4_data","15|1|Pressure ulcer |","Pressure ulcer ",15,1,"","reported","reported",2,0,0.455694171926271,0,2015,0.179040404040404,90.5
"CD009362","CD009362_pub4_data","15|2|Pressure ulcer stage|Pressure ulcer stage 1","Pressure ulcer stage",15,2,"Pressure ulcer stage 1","or","binary",2,-0.000657346006459961,0.412055836998441,0,2018.5,0.133333333333333,90
"CD009362","CD009362_pub4_data","15|2|Pressure ulcer stage|Pressure ulcer stage 2","Pressure ulcer stage",15,2,"Pressure ulcer stage 2","or","binary",2,-1.67428052465085,0.523411027456819,0,2018.5,0.25,90
"CD009362","CD009362_pub4_data","15|4|Anatomical location of pressure ulcer|Buttock pressure ulcer","Anatomical location of pressure ulcer",15,4,"Buttock pressure ulcer","or","binary",2,-0.492936683085191,0.511651954544413,0,2018.5,0.108333333333333,90
"CD009362","CD009362_pub4_data","15|4|Anatomical location of pressure ulcer|Iliac pressure ulcer","Anatomical location of pressure ulcer",15,4,"Iliac pressure ulcer","or","binary",2,0.051333741183258,0.885797830686862,0,2018.5,0.025,90
"CD009362","CD009362_pub4_data","15|4|Anatomical location of pressure ulcer|Sacral pressure ulcer","Anatomical location of pressure ulcer",15,4,"Sacral pressure ulcer","or","binary",3,-1.20403209090711,0.42798520326073,0,2019,0.172222222222222,84
"CD009362","CD009362_pub4_data","15|4|Anatomical location of pressure ulcer|Shoulder pressure ulcer","Anatomical location of pressure ulcer",15,4,"Shoulder pressure ulcer","or","binary",2,0,0.729470435780824,0,2017.5,0.0444444444444444,66
"CD009362","CD009362_pub4_data","17|1|Pressure ulcer|","Pressure ulcer",17,1,"","or","binary",3,0.262015637793693,0.49174905845734,0.534071762659659,2001.66666666667,0.250175098599211,171
"CD009362","CD009362_pub4_data","2|1|Pressure ulcer|Foam dressing versus film dressing","Pressure ulcer",2,1,"Foam dressing versus film dressing","or","binary",3,-0.437390900147009,0.80951340285419,1.61220396064502,2019.66666666667,0.221281464530892,189.666666666667
"CD009362","CD009362_pub4_data","20|1|Pressure ulcer|","Pressure ulcer",20,1,"","or","binary",2,-2.16273257933698,0.359540643864517,0.0228655286030141,2018.5,0.543609022556391,108.5
"CD009362","CD009362_pub4_data","5|1|Pressure ulcer|","Pressure ulcer",5,1,"","or","binary",2,0.825489326126826,0.994831208487139,1.68699895647341,2017,0.145087585681645,150
"CD009417","CD009417_pub3_data","1|1|Mortality (any cause during hospitalisation or follow-up)|NA","Mortality (any cause during hospitalisation or follow-up)",1,1,NA,"or","binary",4,-0.232978659656828,0.850418280957533,0,2003.25,0.0225095785440613,77.25
"CD009417","CD009417_pub3_data","1|10|Duration of stay in the ICU|NA","Duration of stay in the ICU",1,10,NA,"or","binary",2,-0.128848904118317,1.42783333946572,0,1997,0,53.5
"CD009417","CD009417_pub3_data","1|2|Length of hospitalisation (days)|NA","Length of hospitalisation (days)",1,2,NA,"or","binary",6,0.0215071270489249,0.823160764111693,0,2004,0,122.833333333333
"CD009417","CD009417_pub3_data","1|3|Adverse events of any severity or seriousness|NA","Adverse events of any severity or seriousness",1,3,NA,"or","binary",5,0.230660132470272,0.297648176116016,0.0949023031158685,2004.4,0.41253659338852,68
"CD009417","CD009417_pub3_data","1|4|Serious adverse events|NA","Serious adverse events",1,4,NA,"or","binary",4,0.0673367265225163,0.327864790100085,0,2006.25,0.200885368126747,59.5
"CD009417","CD009417_pub3_data","1|5|Need for mechanical ventilation|NA","Need for mechanical ventilation",1,5,NA,"or","binary",4,0.295069314392041,0.444967613142894,0.313404403068019,2004.25,0.178601055806938,85.25
"CD009417","CD009417_pub3_data","1|6|Duration of mechanical ventilation|NA","Duration of mechanical ventilation",1,6,NA,"or","binary",3,-0.0906123205601347,1.1721230398616,0,1997.33333333333,0,33.3333333333333
"CD009417","CD009417_pub3_data","1|7|Need for supplemental oxygen|NA","Need for supplemental oxygen",1,7,NA,"or","binary",2,0.589067808295763,0.380530220053478,0,2011.5,0.657657657657658,71
"CD009417","CD009417_pub3_data","1|8|Duration of supplemental oxygen|NA","Duration of supplemental oxygen",1,8,NA,"or","binary",3,-0.0225649864248594,1.17181882315536,0,2003.66666666667,0,38.3333333333333
"CD009417","CD009417_pub3_data","1|9|Need for ICU admission|NA","Need for ICU admission",1,9,NA,"or","binary",5,0.16864886610354,0.390861961584282,0.372851431890419,2007.2,0.23686090571313,150.8
"CD009508","CD009508_pub2_data","1|1|Incontinence quality of life|Co-ordinated PFMT versus direct PFMT","Incontinence quality of life",1,1,"Co-ordinated PFMT versus direct PFMT","reported","reported",3,0,0.190735196155289,0,2016.33333333333,0,43
"CD009508","CD009508_pub2_data","1|1|Incontinence quality of life|Combined indirect training with direct PFMT versus direct PFMT","Incontinence quality of life",1,1,"Combined indirect training with direct PFMT versus direct PFMT","reported","reported",3,0,0.122418181317342,0,2015.66666666667,0,89.3333333333333
"CD009508","CD009508_pub2_data","1|1|Incontinence quality of life|Indirect training versus direct PFMT","Incontinence quality of life",1,1,"Indirect training versus direct PFMT","reported","reported",2,0,0.252851565859283,0,2018,0,33.5
"CD009508","CD009508_pub2_data","1|2|Incontinence episodes|Co-ordinated PFMT versus direct PFMT","Incontinence episodes",1,2,"Co-ordinated PFMT versus direct PFMT","reported","reported",4,0,0.0481050228821833,0,2015.5,0,31.75
"CD009508","CD009508_pub2_data","1|2|Incontinence episodes|Combined indirect training with direct PFMT versus direct PFMT","Incontinence episodes",1,2,"Combined indirect training with direct PFMT versus direct PFMT","or","binary",2,-0.0521296042479226,1.43253425259687,0,2018.5,0,38
"CD009508","CD009508_pub2_data","2|3|Subjective cure/improvement|PFMT more days per week (higher) versus PFMT fewer days per week (lower)","Subjective cure/improvement",2,3,"PFMT more days per week (higher) versus PFMT fewer days per week (lower)","or","binary",2,2.01721703867637,1.51749416173676,2.67760867245043,2015.5,0.75,54
"CD009508","CD009508_pub2_data","2|3|Subjective cure/improvement|PFMT with resistance device (higher) versus PFMT without resistance device (lower)","Subjective cure/improvement",2,3,"PFMT with resistance device (higher) versus PFMT without resistance device (lower)","or","binary",3,0.290388871906686,0.351861418549949,0,2009.33333333333,0.673538521099497,53.6666666666667
"CD009508","CD009508_pub2_data","3|1|Incontinence quality of life|In-person clinic supervision (more) versus no clinic supervision (less)","Incontinence quality of life",3,1,"In-person clinic supervision (more) versus no clinic supervision (less)","or","binary",3,0.045275392530612,1.16747085267954,0,2017.66666666667,0,45.6666666666667
"CD009508","CD009508_pub2_data","3|1|Incontinence quality of life|In-person individual supervision versus in-person group supervision","Incontinence quality of life",3,1,"In-person individual supervision versus in-person group supervision","reported","reported",5,0,0.085757306880438,0,2016.2,0,108.8
"CD009508","CD009508_pub2_data","3|2|Incontinence episode frequency|In-person individual supervision versus in-person group supervision","Incontinence episode frequency",3,2,"In-person individual supervision versus in-person group supervision","reported","reported",2,0,0.0145706309367252,0,2014.5,0,198
"CD009508","CD009508_pub2_data","3|3|Subjective cure/improvement|In-person clinic supervision (more) versus no clinic supervision (less)","Subjective cure/improvement",3,3,"In-person clinic supervision (more) versus no clinic supervision (less)","or","binary",4,1.14333436624887,0.483234800224892,0.291508676298425,1998.75,0.605459770114943,43.75
"CD009508","CD009508_pub2_data","3|3|Subjective cure/improvement|More clinician contact (more) versus less clinician contact (less)","Subjective cure/improvement",3,3,"More clinician contact (more) versus less clinician contact (less)","or","binary",2,3.66910349133533,1.10422430594654,0,2009.5,0.423529411764706,28
"CD009508","CD009508_pub2_data","3|3|Subjective cure/improvement|PFMT delivered via technology (more) versus PFMT delivered via written instruction only (less)","Subjective cure/improvement",3,3,"PFMT delivered via technology (more) versus PFMT delivered via written instruction only (less)","or","binary",2,0.151865046883086,0.904837465724047,0.977879815951061,2016.5,0.632743362831858,119.5
"CD009508","CD009508_pub2_data","3|4|Satisfaction|In-person individual supervision versus in-person group supervision of PFMT","Satisfaction",3,4,"In-person individual supervision versus in-person group supervision of PFMT","reported","reported",2,0,0.306245207583123,0,2014.5,0.751807228915663,198.5
"CD009508","CD009508_pub2_data","3|4|Satisfaction|PFMT with more clinician contact (more) versus PFMT with less clinician contact (less)","Satisfaction",3,4,"PFMT with more clinician contact (more) versus PFMT with less clinician contact (less)","or","binary",2,1.25307311278669,0.540824553498945,0.258079169275235,2013.5,0.376190476190476,56.5
"CD009531","CD009531_pub3_data","1|1|Quality of life: average change in mental health component - 12 months|","Quality of life: average change in mental health component - 12 months",1,1,"","or","binary",3,0.174555964341318,1.1624699106648,0,2012,0,75.6666666666667
"CD009531","CD009531_pub3_data","2|1|Quality of life|Quality of life: average endpoint in mental health - up to 6 months","Quality of life",2,1,"Quality of life: average endpoint in mental health - up to 6 months","or","binary",5,0.0625043491267779,0.900022001049118,0,2014.33333333333,0,81.2
"CD009531","CD009531_pub3_data","2|1|Quality of life|Quality of life: average endpoint in mental health component (more than 12 months)","Quality of life",2,1,"Quality of life: average endpoint in mental health component (more than 12 months)","or","binary",2,0.0983050722625744,1.42000941634086,0,2006,0,190.5
"CD009531","CD009531_pub3_data","2|1|Quality of life|Quality of life: average endpoint in physical health - 12 months","Quality of life",2,1,"Quality of life: average endpoint in physical health - 12 months","or","binary",3,0.0917268488484704,1.16217250423985,0,2012,0,79
"CD009531","CD009531_pub3_data","2|1|Quality of life|Quality of life: average endpoint in physical health - more than 12 months","Quality of life",2,1,"Quality of life: average endpoint in physical health - more than 12 months","or","binary",2,0.0983050722625744,1.42000941634086,0,2006,0,190.5
"CD009531","CD009531_pub3_data","2|1|Quality of life|Quality of life: average endpoint in physical health - up to 6 months","Quality of life",2,1,"Quality of life: average endpoint in physical health - up to 6 months","or","binary",5,0.0625043491267779,0.900022001049118,0,2014.33333333333,0,81.2
"CD009531","CD009531_pub3_data","2|11|Social functioning/disability|Social functioning/disability - 12 months","Social functioning/disability",2,11,"Social functioning/disability - 12 months","or","binary",4,-0.0357117553029231,1.00558781431096,0,2011.5,0,120
"CD009531","CD009531_pub3_data","2|11|Social functioning/disability|Social functioning/disability (up to 6 months)","Social functioning/disability",2,11,"Social functioning/disability (up to 6 months)","or","binary",3,0.162149324734488,1.16238302384767,0,2012,0,76.6666666666667
"CD009531","CD009531_pub3_data","2|19|Attrition/leaving the study early|Attrition/leaving the study early (lost to follow-up 12 months)","Attrition/leaving the study early",2,19,"Attrition/leaving the study early (lost to follow-up 12 months)","or","binary",3,0.129738009473823,0.245705745807455,0,2011,0.207923033389926,168
"CD009531","CD009531_pub3_data","2|19|Attrition/leaving the study early|Attrition/leaving the study early (lost to follow-up 6 months)","Attrition/leaving the study early",2,19,"Attrition/leaving the study early (lost to follow-up 6 months)","or","binary",3,0.36833256807128,0.353735576212684,0,2016,0.12757473255782,78.3333333333333
"CD009531","CD009531_pub3_data","2|2|Mental state|Mental state (depressive symptoms) 12 months","Mental state",2,2,"Mental state (depressive symptoms) 12 months","or","binary",3,0.174555964341318,1.1624699106648,0,2012,0,75.6666666666667
"CD009531","CD009531_pub3_data","2|2|Mental state|Mental state (depressive symptoms) up to 6 months","Mental state",2,2,"Mental state (depressive symptoms) up to 6 months","or","binary",4,0.138633273362362,1.00909988028513,0,2015,0,64.75
"CD009531","CD009531_pub3_data","2|2|Mental state|Mental state (manic symptoms) 12 months","Mental state",2,2,"Mental state (manic symptoms) 12 months","or","binary",3,0.174555964341318,1.1624699106648,0,2012,0,75.6666666666667
"CD009531","CD009531_pub3_data","2|2|Mental state|Mental state (manic symptoms) up to 6 months","Mental state",2,2,"Mental state (manic symptoms) up to 6 months","or","binary",3,0.162149324734488,1.16238302384767,0,2012,0,76.6666666666667
"CD009531","CD009531_pub3_data","2|6|Physical health status|Blood pressure, mmHg diastolic - 12 months","Physical health status",2,6,"Blood pressure, mmHg diastolic - 12 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","2|6|Physical health status|Blood pressure, mmHg diastolic - 6 months","Physical health status",2,6,"Blood pressure, mmHg diastolic - 6 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","2|6|Physical health status|Blood pressure, mmHg systolic - 12 months","Physical health status",2,6,"Blood pressure, mmHg systolic - 12 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","2|6|Physical health status|Blood pressure, mmHg systolic - up to 6 months","Physical health status",2,6,"Blood pressure, mmHg systolic - up to 6 months","or","binary",3,0.0414380409129726,1.16660678209169,0,2015,0,55
"CD009531","CD009531_pub3_data","2|6|Physical health status|BMI  - 12 months","Physical health status",2,6,"BMI  - 12 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","2|6|Physical health status|Body mass index (BMI) - 6 months","Physical health status",2,6,"Body mass index (BMI) - 6 months","or","binary",3,0.0414380409129726,1.16660678209169,0,2015,0,55
"CD009531","CD009531_pub3_data","2|6|Physical health status|Low-density lipoprotein (LDL) - 6 months","Physical health status",2,6,"Low-density lipoprotein (LDL) - 6 months","or","binary",2,0.0470503544880664,1.43076086300255,0,2018,0,50
"CD009531","CD009531_pub3_data","2|6|Physical health status|Waist circumference - 12 months","Physical health status",2,6,"Waist circumference - 12 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","2|6|Physical health status|Waist circumference - 6 months","Physical health status",2,6,"Waist circumference - 6 months","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","4|1|Quality of life, physical health at 6 months - subgroup analysis: quality of study|Physical health at 6 months (higher-quality studies)","Quality of life, physical health at 6 months - subgroup analysis: quality of study",4,1,"Physical health at 6 months (higher-quality studies)","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","4|1|Quality of life, physical health at 6 months - subgroup analysis: quality of study|Physical health at 6 months (lower-quality studies)","Quality of life, physical health at 6 months - subgroup analysis: quality of study",4,1,"Physical health at 6 months (lower-quality studies)","or","binary",3,0.0847405736216228,1.16117077260914,0,2015.5,0,90
"CD009531","CD009531_pub3_data","4|2|Quality of life, mental health at 6 months - subgroup analysis: quality of study|Mental health at 6 months (higher-quality studies)","Quality of life, mental health at 6 months - subgroup analysis: quality of study",4,2,"Mental health at 6 months (higher-quality studies)","or","binary",2,0.0290416704362773,1.42444577859331,0,2012,0,68
"CD009531","CD009531_pub3_data","4|2|Quality of life, mental health at 6 months - subgroup analysis: quality of study|Mental health at 6 months (lower-quality studies)","Quality of life, mental health at 6 months - subgroup analysis: quality of study",4,2,"Mental health at 6 months (lower-quality studies)","or","binary",3,0.0847405736216228,1.16117077260914,0,2015.5,0,90
"CD009531","CD009531_pub3_data","4|3|Quality of life, physical health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems |Physical health at 6 months (no pharmacy collaborative care)","Quality of life, physical health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems ",4,3,"Physical health at 6 months (no pharmacy collaborative care)","or","binary",3,0.162149324734488,1.16238302384767,0,2012,0,76.6666666666667
"CD009531","CD009531_pub3_data","4|3|Quality of life, physical health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems |Physical health at 6 months (pharmacy collaborative care)","Quality of life, physical health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems ",4,3,"Physical health at 6 months (pharmacy collaborative care)","or","binary",2,-0.0866680187588062,1.42221661451401,0,2015.5,0,88
"CD009531","CD009531_pub3_data","4|4|Quality of life, mental health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems |Mental health at 6 months (no pharmacy collaborative care)","Quality of life, mental health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems ",4,4,"Mental health at 6 months (no pharmacy collaborative care)","or","binary",3,0.162149324734488,1.16238302384767,0,2012,0,76.6666666666667
"CD009531","CD009531_pub3_data","4|4|Quality of life, mental health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems |Mental health at 6 months (pharmacy collaborative care)","Quality of life, mental health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems ",4,4,"Mental health at 6 months (pharmacy collaborative care)","or","binary",2,-0.0866680187588062,1.42221661451401,0,2015.5,0,88
"CD009535","CD009535_pub3_data","1|1|Cardiovascular death|","Cardiovascular death",1,1,"","or","binary",2,-0.0892388589360939,0.0855086275004365,0,2013,0.172454638390836,15450
"CD009535","CD009535_pub3_data","1|14|Physical Component Summary (SF-12; SF-36)|SF-12","Physical Component Summary (SF-12; SF-36)",1,14,"SF-12","or","binary",4,0.964351651307122,1.00455215894987,0,2013,0,210.5
"CD009535","CD009535_pub3_data","1|15|Mental Component Summary (SF-12; SF-36)|SF-12","Mental Component Summary (SF-12; SF-36)",1,15,"SF-12","or","binary",4,0.964351651307122,1.00455215894987,0,2013,0,210.5
"CD009535","CD009535_pub3_data","1|16|Symptoms and problems (KDQOL-SF)|","Symptoms and problems (KDQOL-SF)",1,16,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|17|Effects of kidney disease (KDQOL-SF)|","Effects of kidney disease (KDQOL-SF)",1,17,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|18|Burden of kidney disease (KDQOL-SF)|","Burden of kidney disease (KDQOL-SF)",1,18,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|19|Work status (KDQOL-SF)|","Work status (KDQOL-SF)",1,19,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|2|All-cause death|","All-cause death",1,2,"","or","binary",9,-0.345526891150866,0.138805035514883,0.113118676484585,2015.22222222222,0.347475498133609,6553.77777777778
"CD009535","CD009535_pub3_data","1|20|Cognitive function (KDQOL-SF)|","Cognitive function (KDQOL-SF)",1,20,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|21|Quality of social interaction (KDQOL-SF)|","Quality of social interaction (KDQOL-SF)",1,21,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|22|Sexual function (KDQOL-SF)|","Sexual function (KDQOL-SF)",1,22,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|23|Sleep (KDQOL-SF)|","Sleep (KDQOL-SF)",1,23,"","or","binary",2,-0.0147844314164054,1.42554710586174,0,2014.5,0,65.5
"CD009535","CD009535_pub3_data","1|24|Recovery time|","Recovery time",1,24,"","or","binary",2,0.387059992180618,1.42137801393215,0,2018,0,174
"CD009535","CD009535_pub3_data","1|25|Annual direct healthcare costs in first year of dialysis (currency as reported)|Dialysis vintage not specified","Annual direct healthcare costs in first year of dialysis (currency as reported)",1,25,"Dialysis vintage not specified","or","binary",2,2.75823936261067,1.42462515976436,0,2010,0,1866
"CD009535","CD009535_pub3_data","1|25|Annual direct healthcare costs in first year of dialysis (currency as reported)|Year 1 of dialysis","Annual direct healthcare costs in first year of dialysis (currency as reported)",1,25,"Year 1 of dialysis","or","binary",2,2.91735739186492,1.54817235821684,0.774773358172771,2019,0,5038.5
"CD009535","CD009535_pub3_data","1|26|Annual direct healthcare costs in second year of dialysis (currency as reported)|Dialysis vintage not specified","Annual direct healthcare costs in second year of dialysis (currency as reported)",1,26,"Dialysis vintage not specified","or","binary",2,2.75823936261067,1.42462515976436,0,2010,0,1866
"CD009535","CD009535_pub3_data","1|26|Annual direct healthcare costs in second year of dialysis (currency as reported)|Year 2 of dialysis","Annual direct healthcare costs in second year of dialysis (currency as reported)",1,26,"Year 2 of dialysis","or","binary",2,2.91735739186492,1.54817235821684,0.774773358172771,2019,0,5038.5
"CD009535","CD009535_pub3_data","1|27|Systolic blood pressure (NRSIs)|NRSIs, clinic or other measurements","Systolic blood pressure (NRSIs)",1,27,"NRSIs, clinic or other measurements","or","binary",2,0.982836836882707,1.43173756763105,0,2010.5,0,159
"CD009535","CD009535_pub3_data","1|27|Systolic blood pressure (NRSIs)|NRSIs, pre-dialysis measurement","Systolic blood pressure (NRSIs)",1,27,"NRSIs, pre-dialysis measurement","or","binary",2,-0.0151079076567163,1.42278306035983,0,2010,0,86.5
"CD009535","CD009535_pub3_data","1|28|Diastolic blood pressure (NSRIs)|NRSIs, clinic or other measurement","Diastolic blood pressure (NSRIs)",1,28,"NRSIs, clinic or other measurement","or","binary",2,0.982836836882707,1.43173756763105,0,2010.5,0,159
"CD009535","CD009535_pub3_data","1|29|Mean arterial pressure|","Mean arterial pressure",1,29,"","or","binary",2,0.0871628581980716,1.44474486747869,0,2007,0,22
"CD009535","CD009535_pub3_data","1|3|All-cause annual hospital admission rate (number of admissions/patient-year)|","All-cause annual hospital admission rate (number of admissions/patient-year)",1,3,"","or","binary",2,0.829237319792348,1.41970382802553,0,2010.5,0,417
"CD009535","CD009535_pub3_data","1|30|Left ventricular mass index [g/m2]|","Left ventricular mass index [g/m2]",1,30,"","or","binary",2,0.0857059643827216,1.43261980878448,0,2007,0,65
"CD009535","CD009535_pub3_data","1|4|All-cause hospitalisation days/patient-year|","All-cause hospitalisation days/patient-year",1,4,"","or","binary",2,0.829237319792348,1.41970382802553,0,2010.5,0,417
"CD009535","CD009535_pub3_data","1|5|Kidney transplantation during study period|","Kidney transplantation during study period",1,5,"","or","binary",6,0.394697048700219,0.204957523815959,0.151840096473928,2013.5,0.298291929074317,1818.33333333333
"CD009609","CD009609_pub3_data","1|1|Length of hospital stay|NA","Length of hospital stay",1,1,NA,"reported","reported",7,-0.662708267066503,0.427397452357759,1.07298049820999,2017.57142857143,NA,278.714285714286
"CD009609","CD009609_pub3_data","1|10|Duration of oxygen therapy|NA","Duration of oxygen therapy",1,10,NA,"reported","reported",7,-0.632386555708904,0.290155872400463,0.44826943090115,2017.28571428571,NA,304.571428571429
"CD009609","CD009609_pub3_data","1|2|Adverse events|NA","Adverse events",1,2,NA,"reported","reported",4,0.606754940415351,0.593508143286961,0,2019.25,0.049984623324595,447.25
"CD009609","CD009609_pub3_data","1|3|Change in respiratory rate at 1 hour|NA","Change in respiratory rate at 1 hour",1,3,NA,"reported","reported",4,-4.25305095897365,1.10052413530147,3.34520246435844,2020,NA,122.5
"CD009609","CD009609_pub3_data","1|4|Change in respiratory rate at 4 to 6 hours|NA","Change in respiratory rate at 4 to 6 hours",1,4,NA,"reported","reported",5,-6.48478284600346,2.99532532495763,39.6254455729906,2019.4,NA,138.4
"CD009609","CD009609_pub3_data","1|5|Change in respiratory rate at 24 hours|NA","Change in respiratory rate at 24 hours",1,5,NA,"reported","reported",4,-5.07451600348027,2.09988276308738,12.8588065306419,2019.25,NA,106
"CD009609","CD009609_pub3_data","1|6|Change in heart rate at 1 hour|NA","Change in heart rate at 1 hour",1,6,NA,"reported","reported",4,-5.71410829214052,2.56186407261409,23.8270743082919,2020,NA,121.75
"CD009609","CD009609_pub3_data","1|7|Change in heart rate at 4 to 6 hours|NA","Change in heart rate at 4 to 6 hours",1,7,NA,"reported","reported",5,-9.6905378286212,3.52079037124087,58.209930848242,2019.4,NA,138.4
"CD009609","CD009609_pub3_data","1|8|Change in heart rate at 24 hours|NA","Change in heart rate at 24 hours",1,8,NA,"reported","reported",4,-8.45111578385068,1.33411444148216,2.5588131673633,2019.25,NA,105.25
"CD009609","CD009609_pub3_data","1|9|Need for treatment escalation|NA","Need for treatment escalation",1,9,NA,"reported","reported",8,0.481950234514943,0.0508639482449924,1.09205306931817e-06,2018.75,0.254885914373449,276.875
"CD009679","CD009679_pub3_data","3|2|Complications|Deep venous thrombosis","Complications",3,2,"Deep venous thrombosis","or","binary",3,-0.545067549496112,0.813530718584878,0,2014,0.0230796335447498,76.3333333333333
"CD009679","CD009679_pub3_data","3|2|Complications|Fracture nonunion","Complications",3,2,"Fracture nonunion","or","binary",2,-0.615278479722422,1.27459074854424,0,2011.5,0.0116279069767442,84.5
"CD009679","CD009679_pub3_data","3|2|Complications|Hardware irritation","Complications",3,2,"Hardware irritation","or","binary",2,2.14776787248217,1.0826196918257,0,2013.5,0,72
"CD009679","CD009679_pub3_data","3|2|Complications|Loss of alignment","Complications",3,2,"Loss of alignment","or","binary",3,1.21688950195939,0.573624070660551,0,2014,0.0299741602067183,76.3333333333333
"CD009679","CD009679_pub3_data","3|2|Complications|Loss of fracture reduction","Complications",3,2,"Loss of fracture reduction","or","binary",2,-0.371562648457883,0.665755884261487,0,2011.5,0.0576109936575053,84.5
"CD009679","CD009679_pub3_data","3|2|Complications|Total complications","Complications",3,2,"Total complications","or","binary",2,-1.66309515279731,2.31250278462009,10.1938675367896,2013.5,0.727519379844961,77
"CD009679","CD009679_pub3_data","3|3|Reoperations (up to 24 months)|Metalwork removal","Reoperations (up to 24 months)",3,3,"Metalwork removal","or","binary",2,0.410467729974062,0.602948078177182,0.00924299899931802,2013.5,0.0631782945736434,72
"CD009679","CD009679_pub3_data","3|5|Operative duration (minutes)|","Operative duration (minutes)",3,5,"","or","binary",3,0.0390148763541847,1.16233334309864,0,2014,0,76.3333333333333
"CD009679","CD009679_pub3_data","3|6|Perioperative blood loss (mL)|","Perioperative blood loss (mL)",3,6,"","or","binary",3,0.0390148763541847,1.16233334309864,0,2014,0,76.3333333333333
"CD009679","CD009679_pub3_data","3|8|Time to radiological union (weeks)|","Time to radiological union (weeks)",3,8,"","or","binary",3,0.0390148763541847,1.16233334309864,0,2014,0,76.3333333333333
"CD009679","CD009679_pub3_data","3|9|Hospital length of stay (days)|","Hospital length of stay (days)",3,9,"","or","binary",2,0.0349796412221152,1.42408721110257,0,2017,0,72.5
"CD009679","CD009679_pub3_data","4|2|Complications|Development of traumatic knee osteoarthritis","Complications",4,2,"Development of traumatic knee osteoarthritis","or","binary",2,-1.46939128763617,0.756589102122555,0,2018,0.246491228070175,53
"CD009679","CD009679_pub3_data","4|2|Complications|Knee stiffness","Complications",4,2,"Knee stiffness","or","binary",3,-1.06806079056858,0.613414110921412,0,2015,0.08734335839599,69.6666666666667
"CD009679","CD009679_pub3_data","4|2|Complications|Overall complications","Complications",4,2,"Overall complications","or","binary",3,-0.912456346933229,0.461773474734932,0,2015,0.151002506265664,69.6666666666667
"CD009679","CD009679_pub3_data","4|4|Knee range of motion (degrees)|Short-term results","Knee range of motion (degrees)",4,4,"Short-term results","or","binary",2,0,1.43005716618818,0,2018,0,53
"CD009679","CD009679_pub3_data","4|5|Operative duration (minutes)|","Operative duration (minutes)",4,5,"","or","binary",3,-0.210605483299493,1.16690330426876,0,2015.66666666667,0,54.6666666666667
"CD009679","CD009679_pub3_data","4|8|Hospital length of stay (days)|","Hospital length of stay (days)",4,8,"","or","binary",3,-0.044191522496983,1.1658514588302,0,2017.66666666667,0,60.3333333333333
"CD009679","CD009679_pub3_data","4|9|Time to radiological union (months)|","Time to radiological union (months)",4,9,"","or","binary",2,-0.314232346393468,1.42536298557245,0,2014,0,67
"CD009679","CD009679_pub3_data","5|4|Adverse events|Infection","Adverse events",5,4,"Infection","or","binary",5,-0.0904280582740636,0.517559354037162,0,2009.8,0.0488263762855414,63
"CD009679","CD009679_pub3_data","5|4|Adverse events|Joint line depression","Adverse events",5,4,"Joint line depression","or","binary",4,-0.125351878233615,0.65529271535203,0.945132249929419,2016,0.147504456327986,68.75
"CD009679","CD009679_pub3_data","5|4|Adverse events|Loss of reduction-fracture displacement","Adverse events",5,4,"Loss of reduction-fracture displacement","or","binary",2,-0.970203293880302,0.872830194443984,0,2004,0.0836206896551724,75
"CD009679","CD009679_pub3_data","5|4|Adverse events|Nonunion","Adverse events",5,4,"Nonunion","or","binary",2,-0.90919904900438,1.27248054570855,0,2013.5,0.00862068965517241,115
"CD009679","CD009679_pub3_data","5|4|Adverse events|Prominent metalwork","Adverse events",5,4,"Prominent metalwork","or","binary",2,-0.270063713813078,0.743990937856783,0,2002,0.130555555555556,30
"CD009679","CD009679_pub3_data","5|4|Adverse events|Reoperation (for complication)","Adverse events",5,4,"Reoperation (for complication)","or","binary",2,-0.349213417225006,0.730637923804216,0,2002,0.161111111111111,30
"CD009679","CD009679_pub3_data","5|6|Knee range of motion at 12 months|Flexion ≥ 120 degrees","Knee range of motion at 12 months",5,6,"Flexion ≥ 120 degrees","or","binary",2,0.833908993030031,0.492110480670783,0.0477720391680472,2015,0.55448717948718,57
"CD009679","CD009679_pub3_data","5|6|Knee range of motion at 12 months|Full extension","Knee range of motion at 12 months",5,6,"Full extension","or","binary",2,0.432974952031163,0.519873621606402,0.0659117480319769,2015,0.592948717948718,57
"CD009679","CD009679_pub3_data","5|7|Intraoperative results|Operative duration (minutes)","Intraoperative results",5,7,"Operative duration (minutes)","or","binary",2,-0.0936666023811196,1.43362289051459,0,2017,0,72
"CD009730","CD009730_pub3_data","17|2|FVC|","FVC",17,2,"","or","binary",2,0,1.43675753407464,0,1988,0,32
"CD009730","CD009730_pub3_data","4|1|FEV1 % predicted (absolute change)|Azlocillin plus placebo versus azlocillin plus tobramycin","FEV1 % predicted (absolute change)",4,1,"Azlocillin plus placebo versus azlocillin plus tobramycin","or","binary",2,0.197165902375966,1.43211674354346,0,1991,0,46.5
"CD009730","CD009730_pub3_data","4|3|FVC % predicted (absolute change)|Azlocillin plus placebo versus azlocillin plus tobramycin","FVC % predicted (absolute change)",4,3,"Azlocillin plus placebo versus azlocillin plus tobramycin","or","binary",2,0.0157344556664985,1.43211674354346,0,1991,0,46.5
"CD009730","CD009730_pub3_data","4|8|Adverse effects|All adverse effects","Adverse effects",4,8,"All adverse effects","or","binary",2,0.0650008194083012,0.398511584362142,0,1991,0.149122807017544,72.5
"CD009730","CD009730_pub3_data","4|8|Adverse effects|Nephrotoxicity","Adverse effects",4,8,"Nephrotoxicity","or","binary",2,-0.323555448800656,0.939158449099862,0,1990,0.0222222222222222,52
"CD009730","CD009730_pub3_data","4|8|Adverse effects|Ototoxicity","Adverse effects",4,8,"Ototoxicity","or","binary",2,-0.56367338125522,1.43496472004717,0,1990,0,44
"CD009730","CD009730_pub3_data","5|13|Adverse effects|Liver transaminase enzyme elevation","Adverse effects",5,13,"Liver transaminase enzyme elevation","or","binary",4,0.271128254099481,0.534553968830734,0.39579595118741,1987,0.176482371794872,41
"CD009730","CD009730_pub3_data","5|13|Adverse effects|Rash","Adverse effects",5,13,"Rash","or","binary",3,0.0679485357874396,0.791721062707078,0,1987,0.0474537037037037,43
"CD009730","CD009730_pub3_data","5|15|Antibiotic resistance – number of participants isolating resistant strains|All antibiotics","Antibiotic resistance – number of participants isolating resistant strains",5,15,"All antibiotics","or","binary",3,-0.665857389422632,1.1268000687559,2.3753466592536,1987,0.17287784679089,35.6666666666667
"CD009730","CD009730_pub3_data","6|1|FEV1 (all measures)|Single antibiotic (no placebo) versus combination regimen","FEV1 (all measures)",6,1,"Single antibiotic (no placebo) versus combination regimen","or","binary",4,-0.0942531745196736,1.01538252700392,0,1989.75,0,38
"CD009730","CD009730_pub3_data","6|1|FEV1 (all measures)|Single antibiotic plus placebo versus combination regimen","FEV1 (all measures)",6,1,"Single antibiotic plus placebo versus combination regimen","or","binary",5,0.218865384364711,0.912224114756806,0,1989.8,0,44.6
"CD009730","CD009730_pub3_data","6|2|FEV1 % predicted (absolute change)|Azlocillin plus placebo versus azlocillin plus tobramycin","FEV1 % predicted (absolute change)",6,2,"Azlocillin plus placebo versus azlocillin plus tobramycin","or","binary",2,0.197165902375966,1.43211674354346,0,1991,0,46.5
"CD009730","CD009730_pub3_data","6|6|FVC % predicted (absolute change)|Azlocillin plus placebo versus azlocillin plus tobramycin","FVC % predicted (absolute change)",6,6,"Azlocillin plus placebo versus azlocillin plus tobramycin","or","binary",2,0.0157344556664985,1.43211674354346,0,1991,0,46.5
"CD009730","CD009730_pub3_data","6|7|FVC (all measures)|Single antibiotic (no placebo) versus combination regimen","FVC (all measures)",6,7,"Single antibiotic (no placebo) versus combination regimen","or","binary",2,-0.0140144584806078,1.43037924101724,0,1992.5,0,50.5
"CD009730","CD009730_pub3_data","6|7|FVC (all measures)|Single antibiotic with placebo versus combination regimen","FVC (all measures)",6,7,"Single antibiotic with placebo versus combination regimen","or","binary",3,0.149865539137405,1.17270921688141,0,1987.66666666667,0,38.6666666666667
"CD009749","CD009749_pub3_data","1|1|Live birth/ongoing pregnancy rate - DHEA|DHEA 12 weeks","Live birth/ongoing pregnancy rate - DHEA",1,1,"DHEA 12 weeks","or","binary",6,0.153861419005153,0.224341650068925,0.0730124326375221,2015.66666666667,0.162072357218343,209.833333333333
"CD009749","CD009749_pub3_data","1|1|Live birth/ongoing pregnancy rate - DHEA|DHEA 8 weeks","Live birth/ongoing pregnancy rate - DHEA",1,1,"DHEA 8 weeks","or","binary",2,0.844660629820259,0.38654056528869,0,2010,0.147321428571429,71
"CD009749","CD009749_pub3_data","1|10|Sensitivity analyses |Clinical pregnancy rate for DHEA","Sensitivity analyses ",1,10,"Clinical pregnancy rate for DHEA","or","binary",6,-0.00665356454674117,0.16054527959473,0,2016.5,0.232171050090758,187.833333333333
"CD009749","CD009749_pub3_data","1|10|Sensitivity analyses |Clinical pregnancy rate for Testosterone ","Sensitivity analyses ",1,10,"Clinical pregnancy rate for Testosterone ","or","binary",3,0.405436422243986,0.359962662125375,3.38653735982708e-06,2021,0.153116531165312,65
"CD009749","CD009749_pub3_data","1|10|Sensitivity analyses |Live birth rate for DHEA ","Sensitivity analyses ",1,10,"Live birth rate for DHEA ","or","binary",6,0.0743985605486519,0.221100681887354,0.0497293627969691,2016.5,0.182490827636813,187.833333333333
"CD009749","CD009749_pub3_data","1|10|Sensitivity analyses |Miscarriage rate for DHEA","Sensitivity analyses ",1,10,"Miscarriage rate for DHEA","or","binary",7,-0.114716407868633,0.268703529364359,1.37552749583527e-06,2016.8,0.0745603768097437,174.714285714286
"CD009749","CD009749_pub3_data","1|10|Sensitivity analyses |Miscarriage rate for Testosterone","Sensitivity analyses ",1,10,"Miscarriage rate for Testosterone","or","binary",2,0.140373600349803,0.632423325731341,0,2023,0.0577235772357724,73.5
"CD009749","CD009749_pub3_data","1|3|Miscarriage rate - DHEA|DHEA 12 weeks","Miscarriage rate - DHEA",1,3,"DHEA 12 weeks","or","binary",8,0.042820414299444,0.247478549636679,0,2015.75,0.0486369645202549,182.5
"CD009749","CD009749_pub3_data","1|5|Clinical pregnancy rate - DHEA|12 weeks","Clinical pregnancy rate - DHEA",1,5,"12 weeks","or","binary",10,0.149092252197119,0.142432311628509,0.0177385646426219,2015.4,0.186276525818201,171.2
"CD009749","CD009749_pub3_data","1|5|Clinical pregnancy rate - DHEA|8 weeks","Clinical pregnancy rate - DHEA",1,5,"8 weeks","or","binary",2,0.44097289979178,0.360187209968614,0,2010,0.223214285714286,71
"CD009749","CD009749_pub3_data","1|7|Multiple pregnancy|DHEA","Multiple pregnancy",1,7,"DHEA","or","binary",6,0.468885496415533,0.764206878518298,0,2013.75,0,56.5
"CD009749","CD009749_pub3_data","1|7|Multiple pregnancy|Testosterone","Multiple pregnancy",1,7,"Testosterone","or","binary",5,0.381072857123815,0.627828759012894,0,2014.6,0.0113296616837136,89.8
"CD009749","CD009749_pub3_data","1|8|Adverse effects to the woman|Gastrointestinal upset","Adverse effects to the woman",1,8,"Gastrointestinal upset","or","binary",2,1.08821729769733,1.16666608086744,0,2019,0,84
"CD009749","CD009749_pub3_data","1|8|Adverse effects to the woman|Increased acne - DHEA","Adverse effects to the woman",1,8,"Increased acne - DHEA","or","binary",5,1.53224426007116,0.71182195146592,0,2017,0,89
"CD009749","CD009749_pub3_data","1|9|Pregnancy complications|Pre-term Birth","Pregnancy complications",1,9,"Pre-term Birth","or","binary",2,1.58675840312652,1.12520834097721,0,2019,0,61
"CD009752","CD009752_pub3_data","1|11|Number of participants receiving any red cell transfusion|","Number of participants receiving any red cell transfusion",1,11,"","or","binary",2,-4.70095370841529,1.401803286463,2.55179207234684,2010.5,0.983333333333333,92.5
"CD009752","CD009752_pub3_data","1|12|Number of participants receiving any fresh frozen plasma |","Number of participants receiving any fresh frozen plasma ",1,12,"","reported","reported",2,0,1.09248902213107,0,2010.5,0.0161290322580645,92.5
"CD009752","CD009752_pub3_data","1|16|Duration of mechanical ventilation (hours)|","Duration of mechanical ventilation (hours)",1,16,"","reported","reported",2,0,0.938402031934599,0,2012,0,84
"CD009752","CD009752_pub3_data","1|17|Duration of ICU stay (days)|","Duration of ICU stay (days)",1,17,"","or","binary",3,-0.0505387802805531,1.16372082537834,0,2011.66666666667,0,76
"CD009752","CD009752_pub3_data","1|3|Severe adverse events: cardiac events|","Severe adverse events: cardiac events",1,3,"","or","binary",2,0.0256471717062505,0.337448270786797,0,2011.5,0.283452807646356,116
"CD009752","CD009752_pub3_data","1|4|Severe adverse events: acute lung injury|","Severe adverse events: acute lung injury",1,4,"","or","binary",2,0.105805433192858,0.289398424245178,0,2011.5,0.397849462365591,116
"CD009752","CD009752_pub3_data","1|7|Severe adverse events: renal failure (needing renal replacement therapy) |","Severe adverse events: renal failure (needing renal replacement therapy) ",1,7,"","or","binary",2,-0.686641067842259,1.27099835322644,0,2011,0.00806451612903226,143.5
"CD009752","CD009752_pub3_data","1|8|Severe adverse events: infection|","Severe adverse events: infection",1,8,"","or","binary",2,-0.239238157709566,0.342562892506539,0,2011.5,0.191457586618877,116
"CD009752","CD009752_pub3_data","1|9|Severe adverse events: haemorrhage (return to theatre for bleeding)|","Severe adverse events: haemorrhage (return to theatre for bleeding)",1,9,"","or","binary",4,0.507221844703037,0.751612573775443,0,2011.5,0.00462962962962963,113.5
"CD009752","CD009752_pub3_data","2|10|'Peak' lactate levels (mmol/L) |","'Peak' lactate levels (mmol/L) ",2,10,"","or","binary",2,0,1.43199439687391,0,2009.5,0,75
"CD009752","CD009752_pub3_data","2|22|Blood glucose (mg/dL) in prime prior to CPB |","Blood glucose (mg/dL) in prime prior to CPB ",2,22,"","or","binary",2,0,1.45133834054069,0,1998.5,0,18
"CD009788","CD009788_pub3_data","1|1|Service use: hospitalization|Short-term follow-up (3–6 months)","Service use: hospitalization",1,1,"Short-term follow-up (3–6 months)","or","binary",3,0.0866404577368709,1.01376075998559,2.08793893133659,2016.33333333333,0.175586498689653,46.3333333333333
"CD009788","CD009788_pub3_data","1|10|Quality of life|Long-term follow-up","Quality of life",1,10,"Long-term follow-up","or","binary",2,0.0183215405861064,1.41668769060479,0,2013.5,0,345.5
"CD009788","CD009788_pub3_data","1|10|Quality of life|Short-term follow-up","Quality of life",1,10,"Short-term follow-up","or","binary",2,-0.0958970198368223,1.42995451000983,0,2017.5,0,46.5
"CD009788","CD009788_pub3_data","1|11|Leaving the study early|Long-term follow-up","Leaving the study early",1,11,"Long-term follow-up","or","binary",3,-0.748389343559709,0.44884058189927,0.311454268088834,2010.66666666667,0.184656084656085,247.666666666667
"CD009788","CD009788_pub3_data","1|11|Leaving the study early|Short-term follow-up","Leaving the study early",1,11,"Short-term follow-up","or","binary",2,-0.591453662511235,0.415579168414116,0,2017.5,0.268181818181818,62.5
"CD009788","CD009788_pub3_data","1|2|Functioning – general|Activities of Daily Living (ADL)","Functioning – general",1,2,"Activities of Daily Living (ADL)","or","binary",2,-0.0251046873598749,1.42291951392887,0,2014.5,0,89.5
"CD009788","CD009788_pub3_data","1|8|Functioning – specific: social skills|","Functioning – specific: social skills",1,8,"","or","binary",2,-0.0678796006626457,1.42598059663922,0,2018.5,0,59
"CD009788","CD009788_pub3_data","1|9|Mental state|Brief Psychiatric Rating Scale (BPRS)","Mental state",1,9,"Brief Psychiatric Rating Scale (BPRS)","or","binary",3,0.0123124545136658,1.16135620709696,0,2013.33333333333,0,203.666666666667
"CD009945","CD009945_pub3_data","1|1|50% responder|NA","50% responder",1,1,NA,"or","binary",3,0.962904694908973,0.414848916875382,0,2009,0.142156862745098,57.3333333333333
"CD009945","CD009945_pub3_data","1|2|Treatment withdrawal|NA","Treatment withdrawal",1,2,NA,"or","binary",3,-0.0306690050975256,0.688214722891409,0,2009,0.0294117647058824,57.3333333333333
"CD010001","CD010001_pub4_data","1|1|Live birth or ongoing pregnancy|Glyceryl trinitrate","Live birth or ongoing pregnancy",1,1,"Glyceryl trinitrate","or","binary",2,0.109815948769689,0.301150416769396,0,2003.5,0.222352941176471,119
"CD010001","CD010001_pub4_data","1|1|Live birth or ongoing pregnancy|Nifedipine","Live birth or ongoing pregnancy",1,1,"Nifedipine","or","binary",3,0.281611402957622,0.26079782178241,0,2021,0.207011144883485,130
"CD010001","CD010001_pub4_data","1|2|Vasodilator side effects|Glyceryl trinitrate","Vasodilator side effects",1,2,"Glyceryl trinitrate","or","binary",2,0.516888269159768,0.944152148386316,0.9479908531522,1997.5,0.0656862745098039,129
"CD010001","CD010001_pub4_data","1|3|Specific vasodilator side effects|Blurred vision","Specific vasodilator side effects",1,3,"Blurred vision","or","binary",3,0.672818185293386,0.558107512350348,0,2020.66666666667,0.03,73.3333333333333
"CD010001","CD010001_pub4_data","1|3|Specific vasodilator side effects|Gastrointestinal disturbances","Specific vasodilator side effects",1,3,"Gastrointestinal disturbances","or","binary",3,-0.0301606165105847,1.14945154696401,2.72633957256953,2020.66666666667,0.0816666666666667,73.3333333333333
"CD010001","CD010001_pub4_data","1|3|Specific vasodilator side effects|Headache","Specific vasodilator side effects",1,3,"Headache","or","binary",5,1.10246383105672,0.364463897875426,0.145259880117336,2018.6,0.117333333333333,76
"CD010001","CD010001_pub4_data","1|3|Specific vasodilator side effects|Hot flushes","Specific vasodilator side effects",1,3,"Hot flushes","or","binary",5,0.56880354286431,0.434391849546654,0.109493032407544,2018.6,0.0541904761904762,76
"CD010001","CD010001_pub4_data","1|4|Clinical pregnancy|Glyceryl trinitrate","Clinical pregnancy",1,4,"Glyceryl trinitrate","or","binary",4,0.0974692185130984,0.210569246882024,0,2000.75,0.294019607843137,104.5
"CD010001","CD010001_pub4_data","1|4|Clinical pregnancy|Nifedipine","Clinical pregnancy",1,4,"Nifedipine","or","binary",4,0.165629439119492,0.219823623949098,0.0057216697308658,2021.25,0.226685401160764,132.75
"CD010001","CD010001_pub4_data","1|4|Clinical pregnancy|Pentoxifylline (PTX) + vitamin E","Clinical pregnancy",1,4,"Pentoxifylline (PTX) + vitamin E","or","binary",2,0.530834193792858,0.203449245505669,0,2015,0.396428571428571,196
"CD010001","CD010001_pub4_data","1|4|Clinical pregnancy|Tadalafil","Clinical pregnancy",1,4,"Tadalafil","or","binary",2,0.91824956145017,0.355547131781182,0,2022,0.127631578947368,98
"CD010001","CD010001_pub4_data","1|5|Endometrial thickness|Amlodipine","Endometrial thickness",1,5,"Amlodipine","or","binary",2,0,1.42279957904663,0,2019.5,0,92
"CD010001","CD010001_pub4_data","1|5|Endometrial thickness|Isosorbide mononitrate","Endometrial thickness",1,5,"Isosorbide mononitrate","or","binary",3,-0.229473977150473,1.16476597097055,0,2014,0,80
"CD010001","CD010001_pub4_data","1|6|Other adverse effects|Ectopic pregnancy","Other adverse effects",1,6,"Ectopic pregnancy","or","binary",4,0.15260819725533,0.56744125159394,0,2013,0.0159599052386912,135.75
"CD010001","CD010001_pub4_data","1|6|Other adverse effects|Miscarriage","Other adverse effects",1,6,"Miscarriage","or","binary",8,0.0115872893316538,0.287497326781646,0,2014.5,0.0654341115878976,103.625
"CD010001","CD010001_pub4_data","1|6|Other adverse effects|Multiple gestation or birth","Other adverse effects",1,6,"Multiple gestation or birth","or","binary",7,0.202323588390229,0.338419093454567,0,2014.85714285714,0.0359672857255978,109
"CD010001","CD010001_pub4_data","3|1|Clinical pregnancy: vasodilators versus placebo or no treatment|Thin endometrium among inclusion criteria","Clinical pregnancy: vasodilators versus placebo or no treatment",3,1,"Thin endometrium among inclusion criteria","or","binary",4,0.24375616014816,0.330410865110768,0.0269311314937525,2017,0.20512617012617,59.5
"CD010001","CD010001_pub4_data","3|2|Endometrial thickness: vasodilators versus placebo or not treatment|Thin endometrium among inclusion criteria","Endometrial thickness: vasodilators versus placebo or not treatment",3,2,"Thin endometrium among inclusion criteria","or","binary",4,-0.232670040592583,1.0084907003033,0,1767,0,62.75
"CD010001","CD010001_pub4_data","3|3|Clinical pregnancy: vasodilators versus oestrogens|Thin endometrium among inclusion criteria","Clinical pregnancy: vasodilators versus oestrogens",3,3,"Thin endometrium among inclusion criteria","reported","reported",3,0,0.300664885764392,0,2021.66666666667,0.157575757575758,81.3333333333333
"CD010001","CD010001_pub4_data","4|1|Live birth or ongoing pregnancy: vasodilators versus placebo or no treatment|Oral administration","Live birth or ongoing pregnancy: vasodilators versus placebo or no treatment",4,1,"Oral administration","or","binary",5,0.344386521535105,0.200338846449439,0,2015.4,0.210206686930091,120.4
"CD010001","CD010001_pub4_data","4|3|Clinical pregnancy: vasodilator versus placebo or no treatment|Skin patches","Clinical pregnancy: vasodilator versus placebo or no treatment",4,3,"Skin patches","or","binary",2,0.159819955431902,0.306597605428396,0,2002.5,0.289705882352941,99
"CD010001","CD010001_pub4_data","4|3|Clinical pregnancy: vasodilator versus placebo or no treatment|Vaginal route of administration","Clinical pregnancy: vasodilator versus placebo or no treatment",4,3,"Vaginal route of administration","or","binary",5,0.616842505726934,0.450366782807837,0.635712139070394,2018.75,0.184471306471306,76.4
"CD010001","CD010001_pub4_data","4|4|Endometrial thickness: vasodilator versus placebo or no treatment|Vaginal administration","Endometrial thickness: vasodilator versus placebo or no treatment",4,4,"Vaginal administration","or","binary",12,-0.134914089259864,0.582283978312904,0,2017.75,0,63.4166666666667
"CD010001","CD010001_pub4_data","4|5|Clinical pregnancy: vasodilator versus oestrogen|Vaginal administration","Clinical pregnancy: vasodilator versus oestrogen",4,5,"Vaginal administration","reported","reported",3,0,0.306813658777557,0,2021.66666666667,0.157575757575758,68
"CD010001","CD010001_pub4_data","4|6|Endometrial thickness: vasodilators versus oestrogens|Oral administration","Endometrial thickness: vasodilators versus oestrogens",4,6,"Oral administration","or","binary",2,-0.0202136052372818,1.42165177124062,0,2020.5,0,94
"CD010136","CD010136_pub4_data","2|1|Pain at 24 hours|NA","Pain at 24 hours",2,1,NA,"or","binary",2,0.0723685747045256,1.43919415456394,0,1998.5,0,30.5
"CD010136","CD010136_pub4_data","2|2|Pain at 48 hours|NA","Pain at 48 hours",2,2,NA,"or","binary",2,0.0723685747045256,1.43919415456394,0,1998.5,0,30.5
"CD010136","CD010136_pub4_data","2|3|Pain at 72 hours|NA","Pain at 72 hours",2,3,NA,"or","binary",2,0.0723685747045256,1.43919415456394,0,1998.5,0,30.5
"CD010136","CD010136_pub4_data","2|5|Swelling at 24 hours|NA","Swelling at 24 hours",2,5,NA,"or","binary",2,0.117308571451499,1.43849034568293,0,1998.5,0,31
"CD010136","CD010136_pub4_data","2|6|Swelling at 48 hours|NA","Swelling at 48 hours",2,6,NA,"or","binary",2,0.0723685747045256,1.43919415456394,0,1998.5,0,30.5
"CD010136","CD010136_pub4_data","2|7|Swelling at 72 hours|NA","Swelling at 72 hours",2,7,NA,"or","binary",2,0.0723685747045256,1.43919415456394,0,1998.5,0,30.5
"CD010145","CD010145_pub2_data","1|10|Two-year survival rate|Melatonin plus chemotherapy versus placebo plus chemotherapy","Two-year survival rate",1,10,"Melatonin plus chemotherapy versus placebo plus chemotherapy","or","binary",2,0.476520345925751,0.545928064562306,0,2017.5,0.0625937031484258,117
"CD010145","CD010145_pub2_data","1|11|Three-year survival rate|Melatonin plus chemotherapy versus placebo plus chemotherapy","Three-year survival rate",1,11,"Melatonin plus chemotherapy versus placebo plus chemotherapy","or","binary",2,0.986990363215176,0.829015273325984,0,2017.5,0.0172413793103448,117
"CD010145","CD010145_pub2_data","1|7|Adverse event (fatigue)|Melatonin plus chemotherapy versus placebo plus chemotherapy","Adverse event (fatigue)",1,7,"Melatonin plus chemotherapy versus placebo plus chemotherapy","reported","reported",2,0,0.0679910944580407,0,2017.5,0.558333333333333,85
"CD010145","CD010145_pub2_data","1|9|One-year survival rate|Melatonin plus chemotherapy versus placebo plus chemotherapy","One-year survival rate",1,9,"Melatonin plus chemotherapy versus placebo plus chemotherapy","or","binary",2,0.214734327142338,0.337840884570671,0,2017.5,0.254872563718141,117
"CD010145","CD010145_pub2_data","2|18|(Additional table) CR until progression of the disease|","(Additional table) CR until progression of the disease",2,18,"","reported","reported",10,0,0.36605180710394,0,1999.9,0.00273224043715847,133.7
"CD010145","CD010145_pub2_data","2|19|(Additional table) PR until progression of the disease|","(Additional table) PR until progression of the disease",2,19,"","reported","reported",11,0,0.220948466450718,0,1999.81818181818,0.117913234629641,127.545454545455
"CD010145","CD010145_pub2_data","2|2|Adverse event (fatigue)|Melatonin plus immunotherapy versus immunotherapy","Adverse event (fatigue)",2,2,"Melatonin plus immunotherapy versus immunotherapy","or","binary",2,-1.1323298934415,0.493678299181532,0,1996,0.205128205128205,79.5
"CD010145","CD010145_pub2_data","2|20|(Additional table) SD until progression of the disease|","(Additional table) SD until progression of the disease",2,20,"","reported","reported",11,0,0.104960399638241,0,2001.09090909091,0.301933734516241,291.090909090909
"CD010145","CD010145_pub2_data","2|21|(Additional table) PD until progression of the disease|","(Additional table) PD until progression of the disease",2,21,"","reported","reported",12,0,0.0722949063944862,0,2000.5,0.595806234712041,273.5
"CD010145","CD010145_pub2_data","2|22|One-year survival rate without Novik 2021|Melatonin plus chemotherapy versus chemotherapy","One-year survival rate without Novik 2021",2,22,"Melatonin plus chemotherapy versus chemotherapy","or","binary",2,1.20890038739094,0.244976311634506,0,1998,0.212301587301587,160
"CD010145","CD010145_pub2_data","2|4|One-year survival rate|Melatonin plus chemotherapy versus chemotherapy","One-year survival rate",2,4,"Melatonin plus chemotherapy versus chemotherapy","or","binary",3,1.09550397693384,0.23571364604506,1.41742000854339e-06,2005.66666666667,0.385978835978836,114.666666666667
"CD010145","CD010145_pub2_data","2|6|Three-year survival rate|Melatonin plus immunotherapy versus immunotherapy","Three-year survival rate",2,6,"Melatonin plus immunotherapy versus immunotherapy","or","binary",2,2.29105183229106,1.08430711461631,0,1999,0,54.5
"CD010145","CD010145_pub2_data","3|11|Incidence of dermatitis at least grade 3|","Incidence of dermatitis at least grade 3",3,11,"","or","binary",2,-0.979606613545446,0.728343081622092,0,2018.5,0.0769230769230769,63
"CD010189","CD010189_pub3_data","1|1|Overall survival|Related donor","Overall survival",1,1,"Related donor","reported","reported",5,0.157483899176642,0.164310404946309,0.0574610900352627,2005.2,0,160.8
"CD010189","CD010189_pub3_data","1|10|Incidence of acute GvHD grade II-IV|Related donor","Incidence of acute GvHD grade II-IV",1,10,"Related donor","reported","reported",5,0.0165713829223096,0.158581760065542,0.0526396844131141,2005.2,0,160.8
"CD010189","CD010189_pub3_data","1|2|Disease free survival|Related donor","Disease free survival",1,2,"Related donor","reported","reported",5,0.0796880126345191,0.136220426777934,0.0260494086494815,2005.4,0,139.8
"CD010189","CD010189_pub3_data","1|3|Incidence of non-relapse or transplant-related mortality|Related donor","Incidence of non-relapse or transplant-related mortality",1,3,"Related donor","reported","reported",2,0.0389600932129333,0.23962394073647,0,2007,0,116
"CD010189","CD010189_pub3_data","1|4|Incidence of extensive chronic GvHD|","Incidence of extensive chronic GvHD",1,4,"","reported","reported",4,-0.373724399384426,0.161687118987076,0.0324075196436011,2006,0,191.25
"CD010189","CD010189_pub3_data","1|5|Incidence of acute GvHD grade III-IV|Related donor","Incidence of acute GvHD grade III-IV",1,5,"Related donor","reported","reported",2,-0.344802303262956,0.23864010117471,0,2006.5,0,199.5
"CD010189","CD010189_pub3_data","1|6|Incidence of overall chronic GvHD|Related donor","Incidence of overall chronic GvHD",1,6,"Related donor","reported","reported",3,-0.308168006810262,0.172328128059731,0.0415528173967981,2004.66666666667,0,198.333333333333
"CD010189","CD010189_pub3_data","1|7|Incidence of relapse|Related donor","Incidence of relapse",1,7,"Related donor","reported","reported",2,1.17022321428571,0.52686314314436,0.29215,2006.5,0,105.5
"CD010189","CD010189_pub3_data","1|8|Time to platelet engraftment|","Time to platelet engraftment",1,8,"","reported","reported",4,0.80451529924985,0.227431809172581,0.113976897166671,2001,0,83.25
"CD010189","CD010189_pub3_data","1|9|Time to neutrophil engraftment|","Time to neutrophil engraftment",1,9,"","reported","reported",5,0.673921408276752,0.0921906463678067,0,2002.8,0,132.4
"CD010216","CD010216_pub9_data","1|1|Smoking cessation|Not selected on pregnancy","Smoking cessation",1,1,"Not selected on pregnancy","or","binary",7,0.540052896459263,0.125663648740516,1.94206224313375e-06,2817.42857142857,0.145223420304701,317.857142857143
"CD010216","CD010216_pub9_data","1|15|FEV1|Change from baseline","FEV1",1,15,"Change from baseline","or","binary",2,-0.40219946163515,1.4354383714661,0,2017.5,0,40.5
"CD010216","CD010216_pub9_data","1|16|FEV1/FVC (%)|Change from baseline","FEV1/FVC (%)",1,16,"Change from baseline","or","binary",2,-0.40219946163515,1.4354383714661,0,2017.5,0,40.5
"CD010216","CD010216_pub9_data","1|18|Product use at 6+ months|","Product use at 6+ months",1,18,"","or","binary",6,1.07352162252944,0.503354521642224,1.31880941027946,2950,0.238577795923616,272.5
"CD010216","CD010216_pub9_data","1|2|Adverse events|6 months","Adverse events",1,2,"6 months","or","binary",2,0.0091060976046284,0.183478204176578,0,2017.5,0.244532409698169,281.5
"CD010216","CD010216_pub9_data","1|3|Serious adverse events|6 months","Serious adverse events",1,3,"6 months","or","binary",2,0.428304767792307,0.340464522305718,0,2017.5,0.0325581395348837,281.5
"CD010216","CD010216_pub9_data","11|3|Serious adverse events at 24 weeks|","Serious adverse events at 24 weeks",11,3,"","or","binary",2,0.14396282629477,0.617195844732362,0,2020,0.0165289256198347,194
"CD010216","CD010216_pub9_data","13|1|Smoking cessation|","Smoking cessation",13,1,"","or","binary",2,-0.0140496336889156,0.310055529738643,0.06838849887503,2020.5,0.292439024390244,157
"CD010216","CD010216_pub9_data","14|1|Smoking cessation|","Smoking cessation",14,1,"","or","binary",2,0.0298394339939896,0.0958477001916962,0,2022,0.200387457917488,1326
"CD010216","CD010216_pub9_data","15|1|Smoking cessation|","Smoking cessation",15,1,"","or","binary",2,0.590991280864428,0.270419616621708,0,2016.5,0.0700400801603207,519.5
"CD010216","CD010216_pub9_data","15|4|Carbon monoxide (ppm)|change from baseline","Carbon monoxide (ppm)",15,4,"change from baseline","or","binary",2,-0.192752347225998,1.43549456092117,0,2020.5,0,35
"CD010216","CD010216_pub9_data","16|1|Smoking cessation|","Smoking cessation",16,1,"","or","binary",2,1.32202691154391,0.316959998664673,0,2018.5,0.0378620689655172,490
"CD010216","CD010216_pub9_data","16|2|Adverse events|12 weeks","Adverse events",16,2,"12 weeks","or","binary",2,0.0260237597770221,0.65986156111852,0.682775935441765,2016.5,0.487037037037037,210.5
"CD010216","CD010216_pub9_data","4|11|Product use at 6+ months|","Product use at 6+ months",4,11,"","or","binary",4,0.207789318289781,0.18997097621494,0.0460540661750413,2016.25,0.329535040642752,218.5
"CD010216","CD010216_pub9_data","4|2|Adverse events|6 months","Adverse events",4,2,"6 months","or","binary",2,-0.0507379562804116,0.290530785098826,0,2017.5,0.228070175438596,256.5
"CD010216","CD010216_pub9_data","4|3|Serious adverse events|1 year","Serious adverse events",4,3,"1 year","or","binary",2,-0.232723297545752,1.41987086780074,0,2016.5,0,128.5
"CD010216","CD010216_pub9_data","4|3|Serious adverse events|6 months","Serious adverse events",4,3,"6 months","or","binary",5,-0.118861635132447,0.31169472594133,0,2017.4,0.0597469413051676,201.8
"CD010216","CD010216_pub9_data","4|4|Carbon monoxide (ppm)|Absolute values at follow-up","Carbon monoxide (ppm)",4,4,"Absolute values at follow-up","or","binary",3,-0.140707297706392,1.16499447398055,0,2018,0,115
"CD010216","CD010216_pub9_data","5|1|Smoking cessation|","Smoking cessation",5,1,"","reported","reported",3,0,0.104294512140744,0,2021.66666666667,0.108317407230451,570.333333333333
"CD010216","CD010216_pub9_data","5|16|FEV1 (SMD)|Change from baseline","FEV1 (SMD)",5,16,"Change from baseline","or","binary",2,-0.823676165204581,1.41657213980611,0,2017.5,0,357
"CD010216","CD010216_pub9_data","5|17|FEF 25-75 (litres/second))|Change from baseline","FEF 25-75 (litres/second))",5,17,"Change from baseline","or","binary",2,-0.890279241411697,1.41778007708462,0,2016.5,0,277.5
"CD010216","CD010216_pub9_data","5|2|Adverse events|12 weeks","Adverse events",5,2,"12 weeks","or","binary",2,1.17733117334137,0.458245832733682,0.295696364539191,2016.5,0.755793226381462,328.5
"CD010216","CD010216_pub9_data","5|2|Adverse events|6 months","Adverse events",5,2,"6 months","or","binary",3,0.289569141756164,0.102218394346853,2.11999826845875e-06,2022,0.313159288520104,548
"CD010216","CD010216_pub9_data","5|3|Serious adverse events|12 weeks","Serious adverse events",5,3,"12 weeks","or","binary",2,0.607809047654747,1.19099807117664,0,2017.5,0,429
"CD010216","CD010216_pub9_data","5|3|Serious adverse events|4 to 6 weeks","Serious adverse events",5,3,"4 to 6 weeks","or","binary",2,-0.338302400154737,1.42111674858693,0,2019.5,0,123
"CD010216","CD010216_pub9_data","5|4|Carbon monoxide (ppm)|Absolute values at follow-up","Carbon monoxide (ppm)",5,4,"Absolute values at follow-up","or","binary",9,-0.316780473847935,0.672477447296687,0,1869.11111111111,0,97.3333333333333
"CD010216","CD010216_pub9_data","5|6|Systolic blood pressure|Absolute values at follow-up","Systolic blood pressure",5,6,"Absolute values at follow-up","or","binary",2,-0.295686465678004,1.42698291881998,0,2019.5,0,65
"CD010216","CD010216_pub9_data","5|9|NNAL (SMD)|Absolute values at follow-up","NNAL (SMD)",5,9,"Absolute values at follow-up","or","binary",2,-0.678290319350926,1.4251693774485,0,2016.5,0,74
"CD010216","CD010216_pub9_data","5|9|NNAL (SMD)|Change from baseline","NNAL (SMD)",5,9,"Change from baseline","or","binary",3,-0.792003406889914,1.15722831909244,0,2018.33333333333,0,304
"CD010216","CD010216_pub9_data","6|4|Carbon monoxide (ppm)|Change from baseline","Carbon monoxide (ppm)",6,4,"Change from baseline","or","binary",2,-0.0194944877092134,1.41875787981167,0,2014.5,0,154.5
"CD010290","CD010290_pub4_data","1|1|Live birth rate per woman by urinary gonadotropins|rFSH versus HP-FSH","Live birth rate per woman by urinary gonadotropins",1,1,"rFSH versus HP-FSH","or","binary",3,0.0804822277381646,0.295570469988836,3.86272722074804e-08,2004.66666666667,0.176882098114975,100.333333333333
"CD010290","CD010290_pub4_data","1|10|Total gonadotrophin dose per woman (IU) by urinary gonadotropins|rFSH versus HP-FSH","Total gonadotrophin dose per woman (IU) by urinary gonadotropins",1,10,"rFSH versus HP-FSH","or","binary",3,-0.0142566133312067,1.1574358114671,0,2007.66666666667,0,224
"CD010290","CD010290_pub4_data","1|10|Total gonadotrophin dose per woman (IU) by urinary gonadotropins|rFSH versus uFSH","Total gonadotrophin dose per woman (IU) by urinary gonadotropins",1,10,"rFSH versus uFSH","or","binary",2,-0.0358160420389842,1.43269843611224,0,2004,0,95
"CD010290","CD010290_pub4_data","1|11|Total duration of stimulation per woman (days) by urinary gonadotropins|rFSH versus HP-FSH","Total duration of stimulation per woman (days) by urinary gonadotropins",1,11,"rFSH versus HP-FSH","or","binary",3,-0.0142566133312067,1.1574358114671,0,2007.66666666667,0,224
"CD010290","CD010290_pub4_data","1|11|Total duration of stimulation per woman (days) by urinary gonadotropins|rFSH versus uFSH","Total duration of stimulation per woman (days) by urinary gonadotropins",1,11,"rFSH versus uFSH","or","binary",2,0.306540509427145,1.42035462458394,0,2001.5,0,133
"CD010290","CD010290_pub4_data","1|13|Sensitivity analysis: live birth rate per woman - random effects model|rFSH versus HP-FSH","Sensitivity analysis: live birth rate per woman - random effects model",1,13,"rFSH versus HP-FSH","or","binary",3,0.0804822277381646,0.295570469988836,3.86272722074804e-08,2004.66666666667,0.176882098114975,100.333333333333
"CD010290","CD010290_pub4_data","1|14|Sensitivity analysis: live birth rate per woman - odds ratio|rFSH versus HP-FSH","Sensitivity analysis: live birth rate per woman - odds ratio",1,14,"rFSH versus HP-FSH","or","binary",3,0.0804822277381646,0.295570469988836,3.86272722074804e-08,2004.66666666667,0.176882098114975,100.333333333333
"CD010290","CD010290_pub4_data","1|15|Sensitivity analysis: multiple pregnancy per woman - low risk studies|rFSH versus HP-FSH","Sensitivity analysis: multiple pregnancy per woman - low risk studies",1,15,"rFSH versus HP-FSH","or","binary",2,-0.0214544622011233,0.526423277025518,0,2008.5,0.0326380240763802,206
"CD010290","CD010290_pub4_data","1|16|Sensitivity analysis: multiple pregnancy per woman - random effects model|rFSH versus HP-FSH","Sensitivity analysis: multiple pregnancy per woman - random effects model",1,16,"rFSH versus HP-FSH","or","binary",4,-0.195185638971814,0.403517637296405,0,2006,0.0579856787048568,186.5
"CD010290","CD010290_pub4_data","1|16|Sensitivity analysis: multiple pregnancy per woman - random effects model|rFSH versus uFSH","Sensitivity analysis: multiple pregnancy per woman - random effects model",1,16,"rFSH versus uFSH","or","binary",3,-0.357182617076297,0.592996558250255,0,2000.33333333333,0.032795246329329,146
"CD010290","CD010290_pub4_data","1|17|Sensitivity analysis: multiple pregnancy per woman - odds ratio|rFSH versus HP-FSH","Sensitivity analysis: multiple pregnancy per woman - odds ratio",1,17,"rFSH versus HP-FSH","or","binary",4,-0.195185638971814,0.403517637296405,0,2006,0.0579856787048568,186.5
"CD010290","CD010290_pub4_data","1|17|Sensitivity analysis: multiple pregnancy per woman - odds ratio|rFSH versus uFSH","Sensitivity analysis: multiple pregnancy per woman - odds ratio",1,17,"rFSH versus uFSH","or","binary",3,-0.357182617076297,0.592996558250255,0,2000.33333333333,0.032795246329329,146
"CD010290","CD010290_pub4_data","1|2|Live birth rate per woman by sponsor|Ferring","Live birth rate per woman by sponsor",1,2,"Ferring","or","binary",3,0.0433144001067193,0.255795609148386,0,2004.66666666667,0.190313111545988,136.333333333333
"CD010290","CD010290_pub4_data","1|2|Live birth rate per woman by sponsor|unknown","Live birth rate per woman by sponsor",1,2,"unknown","or","binary",2,1.1596288361567,0.868348233981931,0.584523416906982,2005,0.0512820512820513,48
"CD010290","CD010290_pub4_data","1|3|Multiple pregnancy per woman by urinary gonadotropins|rFSH versus HP-FSH","Multiple pregnancy per woman by urinary gonadotropins",1,3,"rFSH versus HP-FSH","or","binary",4,-0.195185638971814,0.403517637296405,0,2006,0.0579856787048568,186.5
"CD010290","CD010290_pub4_data","1|3|Multiple pregnancy per woman by urinary gonadotropins|rFSH versus uFSH","Multiple pregnancy per woman by urinary gonadotropins",1,3,"rFSH versus uFSH","or","binary",3,-0.357182617076297,0.592996558250255,0,2000.33333333333,0.032795246329329,146
"CD010290","CD010290_pub4_data","1|4|Multiple pregnancy per woman by sponsor|Ferring","Multiple pregnancy per woman by sponsor",1,4,"Ferring","or","binary",3,0.113984989658027,0.512469620475176,0.0621222223620145,2004.66666666667,0.0646879756468798,136.333333333333
"CD010290","CD010290_pub4_data","1|4|Multiple pregnancy per woman by sponsor|Merck - Serono","Multiple pregnancy per woman by sponsor",1,4,"Merck - Serono","or","binary",2,-0.592389442856573,0.632725077165615,0,2004.5,0.0423768939393939,178.5
"CD010290","CD010290_pub4_data","1|4|Multiple pregnancy per woman by sponsor|Unknown","Multiple pregnancy per woman by sponsor",1,4,"Unknown","or","binary",2,-0.0633595056389486,0.720238611495103,0,2005,0.0182926829268293,215
"CD010290","CD010290_pub4_data","1|5|Clinical pregnancy rate per woman by urinary gonadotropins|rFSH versus HP-FSH","Clinical pregnancy rate per woman by urinary gonadotropins",1,5,"rFSH versus HP-FSH","or","binary",3,0.211064235650759,0.231521288778211,0,2006,0.190673861906739,162
"CD010290","CD010290_pub4_data","1|5|Clinical pregnancy rate per woman by urinary gonadotropins|rFSH versus uFSH","Clinical pregnancy rate per woman by urinary gonadotropins",1,5,"rFSH versus uFSH","or","binary",4,-0.0308330636987022,0.173733965792696,0,1999.25,0.286897597703989,165
"CD010290","CD010290_pub4_data","1|6|Multiple pregnancy per clinical pregnancy by urinary gonadotropins|rFSH versus HP-FSH","Multiple pregnancy per clinical pregnancy by urinary gonadotropins",1,6,"rFSH versus HP-FSH","or","binary",4,-0.476399018120024,0.472323055924154,0,2006,0.270917678812416,41.75
"CD010290","CD010290_pub4_data","1|6|Multiple pregnancy per clinical pregnancy by urinary gonadotropins|rFSH versus uFSH","Multiple pregnancy per clinical pregnancy by urinary gonadotropins",1,6,"rFSH versus uFSH","or","binary",3,-0.440898313569254,0.620878221777815,0,2000.33333333333,0.139921482026745,39
"CD010290","CD010290_pub4_data","1|7|Miscarriage rate per woman by urinary gonadotropins|rFSH versus uFSH","Miscarriage rate per woman by urinary gonadotropins",1,7,"rFSH versus uFSH","or","binary",5,0.211371258788228,0.308601602918616,0,2000.2,0.0491560923604972,127
"CD010290","CD010290_pub4_data","1|9|Incidence of OHSS per woman by urinary gonadotropins|rFSH versus HP-FSH","Incidence of OHSS per woman by urinary gonadotropins",1,9,"rFSH versus HP-FSH","or","binary",4,0.288676799228875,0.402969156722338,0,2006,0.0406721322817213,186.5
"CD010290","CD010290_pub4_data","1|9|Incidence of OHSS per woman by urinary gonadotropins|rFSH versus uFSH","Incidence of OHSS per woman by urinary gonadotropins",1,9,"rFSH versus uFSH","or","binary",5,0.284409226193735,0.46987614889729,0,2000.2,0.0507409381663113,127
"CD010290","CD010290_pub4_data","2|1|Live birth rate per woman|","Live birth rate per woman",2,1,"","or","binary",2,0.430242664354016,0.569833248121963,0,1990.5,0.154901960784314,39.5
"CD010290","CD010290_pub4_data","2|10|Sensitivity analysis: multiple pregnancy per woman - random effects model|","Sensitivity analysis: multiple pregnancy per woman - random effects model",2,10,"","or","binary",3,0.771133648589177,1.08866282936983,0,1988.66666666667,0,34
"CD010290","CD010290_pub4_data","2|2|Multiple pregnancy per woman|","Multiple pregnancy per woman",2,2,"","or","binary",3,0.771133648589177,1.08866282936983,0,1988.66666666667,0,34
"CD010290","CD010290_pub4_data","2|3|Clinical pregnancy rate per woman|","Clinical pregnancy rate per woman",2,3,"","or","binary",3,0.347916198378804,0.465788952991528,0,1988.66666666667,0.203267973856209,34
"CD010290","CD010290_pub4_data","2|4|Multiple pregnancy per clinical pregnancy|","Multiple pregnancy per clinical pregnancy",2,4,"","or","binary",3,0.748673004845066,1.16357709462489,0,1988.66666666667,0,7.33333333333333
"CD010290","CD010290_pub4_data","2|5|Miscarriage rate per woman|","Miscarriage rate per woman",2,5,"","or","binary",2,-1.03379547804807,0.885655089415177,0,1990.5,0.114705882352941,49
"CD010290","CD010290_pub4_data","2|6|Incidence of OHSS per woman|","Incidence of OHSS per woman",2,6,"","or","binary",2,1.447804126538,1.23565494903016,0,1988,0,26.5
"CD010290","CD010290_pub4_data","2|7|Sensitivity analysis: live birth rate per woman - odds ratio|","Sensitivity analysis: live birth rate per woman - odds ratio",2,7,"","or","binary",2,0.430242664354016,0.569833248121963,0,1990.5,0.154901960784314,39.5
"CD010290","CD010290_pub4_data","2|8|Sensitivity analysis: live birth rate per woman - random effects model|","Sensitivity analysis: live birth rate per woman - random effects model",2,8,"","or","binary",2,0.430242664354016,0.569833248121963,0,1990.5,0.154901960784314,39.5
"CD010290","CD010290_pub4_data","2|9|Sensitivity analysis: multiple pregnancy per woman - odds ratio|","Sensitivity analysis: multiple pregnancy per woman - odds ratio",2,9,"","or","binary",3,0.771133648589177,1.08866282936983,0,1988.66666666667,0,34
"CD010441","CD010441_pub3_data","1|1|Incidence of perineal trauma (tears or episiotomy or both)|NA","Incidence of perineal trauma (tears or episiotomy or both)",1,1,NA,"reported","reported",3,0,0.127087754368326,0,1999,0.797811447811448,142
"CD010441","CD010441_pub3_data","1|2|Incidence of episiotomy|NA","Incidence of episiotomy",1,2,NA,"or","binary",3,-0.24739271166642,0.228538655351205,3.66687652322214e-06,1999,0.415580462155805,142.333333333333
"CD010441","CD010441_pub3_data","1|3|Incidence of first and second degree perineal lacerations|NA","Incidence of first and second degree perineal lacerations",1,3,NA,"reported","reported",2,0,0.176141721021929,0,1993,0.573232323232323,92.5
"CD010441","CD010441_pub3_data","1|4|Incidence of third and fourth degree perineal trauma|NA","Incidence of third and fourth degree perineal trauma",1,4,NA,"or","binary",3,-0.571599438027091,0.527438617461392,0,1999,0.0490740740740741,142
"CD010441","CD010441_pub3_data","2|1|Incidence of perineal trauma (tears or episiotomy or both)|NA","Incidence of perineal trauma (tears or episiotomy or both)",2,1,NA,"reported","reported",3,0,0.113432267833094,0,1979.66666666667,0.78130888719124,124.333333333333
"CD010441","CD010441_pub3_data","2|2|Incidence of episiotomy|NA","Incidence of episiotomy",2,2,NA,"or","binary",3,-0.326279141029788,0.60529216885226,0.78581803364967,1979.66666666667,0.426373822256175,124.333333333333
"CD010441","CD010441_pub3_data","2|4|Incidence of third and fourth degree perineal trauma|NA","Incidence of third and fourth degree perineal trauma",2,4,NA,"or","binary",3,0.0852571267823729,1.15942828902444,0,1979.66666666667,0,124.333333333333
"CD010533","CD010533_pub3_data","1|1|Overall survival (OS)|","Overall survival (OS)",1,1,"","reported","reported",2,-0.178844056073251,0.944021921117089,0.995299794047501,2015,0,512
"CD010533","CD010533_pub3_data","1|2|Progression-free survival (PFS)|","Progression-free survival (PFS)",1,2,"","reported","reported",2,1.50881787044113,0.9376987325546,1.483485561245,2015,0,517
"CD010533","CD010533_pub3_data","1|4|Incidence of second primary malignancy|","Incidence of second primary malignancy",1,4,"","reported","reported",2,0,0.301395056542169,0,2015,0.0461458480191738,491.5
"CD010533","CD010533_pub3_data","11|1|Overall survival|BEACOPP as initial treatment","Overall survival",11,1,"BEACOPP as initial treatment","reported","reported",2,-0.651146790664125,0.352588479928403,0.0788852528305,2009.5,0,850
"CD010533","CD010533_pub3_data","11|2|Progression-free survival|BEACOPP as initial treatment","Progression-free survival",11,2,"BEACOPP as initial treatment","reported","reported",2,-0.235733932448819,0.209058431692915,0,2009.5,0,850
"CD010533","CD010533_pub3_data","11|3|Treatment-related mortality|BEACOPP as initial treatment","Treatment-related mortality",11,3,"BEACOPP as initial treatment","reported","reported",2,0,0.711359261544756,0,2009.5,0.0132163034705408,914
"CD010533","CD010533_pub3_data","11|5|Incidence of second primary malignancy|BEACOPP as initial treatment","Incidence of second primary malignancy",11,5,"BEACOPP as initial treatment","reported","reported",2,0,0.253663246842638,0,2009.5,0.0366100323624595,912
"CD010533","CD010533_pub3_data","2|2|Progression-free survival (PFS)|","Progression-free survival (PFS)",2,2,"","reported","reported",2,0.69091072920723,0.350442686067343,0.076532109868,2007,0,290
"CD010533","CD010533_pub3_data","3|1|Overall survival (OS)|","Overall survival (OS)",3,1,"","reported","reported",2,-0.0947864402178794,0.392656912886608,0,2012,0,536.5
"CD010533","CD010533_pub3_data","3|2|Progression-free survival (PFS)|","Progression-free survival (PFS)",3,2,"","reported","reported",2,0.462364410697768,0.264762991933353,0,2012,0,536.5
"CD010533","CD010533_pub3_data","4|1|Overall survival|","Overall survival",4,1,"","reported","reported",3,-0.429326986002395,0.259065233791373,0.0808996974324023,2009,0,877.666666666667
"CD010533","CD010533_pub3_data","4|2|Progression-free survival|","Progression-free survival",4,2,"","reported","reported",3,-0.0374110391065028,0.155875169819053,0.018737241626751,2009,0,877.666666666667
"CD010533","CD010533_pub3_data","4|4|Adverse events, grade 3-4|","Adverse events, grade 3-4",4,4,"","or","binary",2,-0.505936213432648,0.388308741895352,0.255972107415182,2008,0.825167887667888,965
"CD010533","CD010533_pub3_data","5|2|Progression-free survival|","Progression-free survival",5,2,"","reported","reported",2,-0.246983673792312,0.308544637736921,0,2008,0,206
"CD010533","CD010533_pub3_data","7|1|Overall survival|","Overall survival",7,1,"","reported","reported",2,0.330584472400428,0.325462882421465,0.00117245675950009,2008,0,397.5
"CD010533","CD010533_pub3_data","7|2|Progression-free survival|","Progression-free survival",7,2,"","reported","reported",2,0.025403440084284,0.207554979561486,0.0065313158440001,2008,0,291
"CD010533","CD010533_pub3_data","7|5|Adverse events, grade 3-4|","Adverse events, grade 3-4",7,5,"","reported","reported",2,0,0.0159787896261226,0,2008,0.679321583775954,293
"CD010583","CD010583_pub6_data","1|5|Morbidity|","Morbidity",1,5,"","or","binary",2,0.0865685767145771,0.181961698371719,0,2015,0.674739055342795,266
"CD010583","CD010583_pub6_data","1|6|Length of hospital stay (days)|","Length of hospital stay (days)",1,6,"","or","binary",2,-0.0155550896800583,1.41766083000637,0,2015,0,266
"CD010583","CD010583_pub6_data","1|7|Additional open procedures for postoperative complications|","Additional open procedures for postoperative complications",1,7,"","or","binary",2,-0.146978279601306,0.642808555581346,0.559074956993745,2015,0.100473079522415,266
"CD010583","CD010583_pub6_data","2|4|Morbidity|","Morbidity",2,4,"","or","binary",2,0.35757225499797,0.348162653499851,0.18931041789031,2017,0.440196078431373,313
"CD010583","CD010583_pub6_data","2|5|Length of hospital stay (days)|","Length of hospital stay (days)",2,5,"","or","binary",2,-0.0327962662414746,1.41648646186144,0,2017,0,313
"CD010583","CD010583_pub6_data","2|6|Additional open procedures for postoperative complications|","Additional open procedures for postoperative complications",2,6,"","or","binary",2,0.107156183974142,0.484165049251701,0.128311257894442,2017,0.0364450127877238,313
"CD010583","CD010583_pub6_data","2|7|Additional radiological interventions for postoperative complications|","Additional radiological interventions for postoperative complications",2,7,"","or","binary",2,0.294766984795188,0.260475858141175,0.0105957620022383,2017,0.100724637681159,313
"CD010583","CD010583_pub6_data","3|1|Mortality (30 days)|Open pancreaticoduodenectomy","Mortality (30 days)",3,1,"Open pancreaticoduodenectomy","reported","reported",2,0,0.718593009674606,0,2017,0.0185185185185185,160.5
"CD010583","CD010583_pub6_data","3|2|Intra-abdominal infection|Open pancreaticoduodenectomy","Intra-abdominal infection",3,2,"Open pancreaticoduodenectomy","reported","reported",2,0,0.317913693562332,0,2017,0.0992402659069326,160.5
"CD010583","CD010583_pub6_data","3|3|Wound infection|Open pancreaticoduodenectomy","Wound infection",3,3,"Open pancreaticoduodenectomy","reported","reported",2,0,0.371102751462473,0,2017,0.0880816714150048,160.5
"CD010583","CD010583_pub6_data","4|2|Intra-abdominal infection|Open or laparoscopic pancreaticoduodenectomy","Intra-abdominal infection",4,2,"Open or laparoscopic pancreaticoduodenectomy","reported","reported",2,0,0.357076483105583,0,2019.5,0.191483516483516,122.5
"CD010583","CD010583_pub6_data","4|3|Wound infection|Open or laparoscopic pancreaticoduodenectomy","Wound infection",4,3,"Open or laparoscopic pancreaticoduodenectomy","reported","reported",2,0,0.547473233093607,0,2019.5,0.0357142857142857,122.5
"CD010583","CD010583_pub6_data","4|4|Morbidity|","Morbidity",4,4,"","reported","reported",2,0,0.216968756005917,0,2020,0.483974358974359,208
"CD010583","CD010583_pub6_data","4|5|Length of hospital stay (days)|","Length of hospital stay (days)",4,5,"","reported","reported",3,0,0.441270126446181,0,2019.5,0,185.666666666667
"CD010583","CD010583_pub6_data","4|6|Hospital costs|","Hospital costs",4,6,"","reported","reported",2,0,0.113537996928141,0,2020,0,208
"CD010583","CD010583_pub6_data","4|8|Additional radiological interventions for postoperative complications|","Additional radiological interventions for postoperative complications",4,8,"","reported","reported",2,0,0.694386478518972,0,2020,0.0480769230769231,208
"CD010779","CD010779_pub2_data","1|2|Passive range of motion with standardised force |Wrist extension","Passive range of motion with standardised force ",1,2,"Wrist extension","reported","reported",4,0,0.177960971984688,0,2010.75,0,36.25
"CD010779","CD010779_pub2_data","1|5|Function|","Function",1,5,"","reported","reported",2,0,0.21925530712105,0,2013,0,46
"CD010779","CD010779_pub2_data","2|2|Passive range of motion with standardised force|Wrist extension","Passive range of motion with standardised force",2,2,"Wrist extension","reported","reported",3,0,0.190619729929448,0,2012.66666666667,0,39
"CD010856","CD010856_pub3_data","1|1|Change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted after 1975","Change in the number of decayed, missing or filled primary teeth (dmft)",1,1,"Studies conducted after 1975","or","binary",2,-0.0348412832488961,1.41471383699887,0,2018.5,0,1454
"CD010856","CD010856_pub3_data","1|1|Change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted in 1975 or earlier","Change in the number of decayed, missing or filled primary teeth (dmft)",1,1,"Studies conducted in 1975 or earlier","or","binary",5,-0.29858674172037,0.895072047128127,0,1966.4,0,1141.8
"CD010856","CD010856_pub3_data","1|11|Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted after 1975","Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled primary teeth (dmft)",1,11,"Studies conducted after 1975","or","binary",2,-0.0348412832488961,1.41471383699887,0,2018.5,0,1454
"CD010856","CD010856_pub3_data","1|11|Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted in 1975 or earlier","Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled primary teeth (dmft)",1,11,"Studies conducted in 1975 or earlier","or","binary",2,-0.248929039870404,1.41559430163943,0,1965.5,0,574
"CD010856","CD010856_pub3_data","1|12|Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled permanent teeth (DMFT)|Studies conducted after 1975","Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled permanent teeth (DMFT)",1,12,"Studies conducted after 1975","or","binary",2,0.204756745610822,1.41556376134058,0,2000,0,767.5
"CD010856","CD010856_pub3_data","1|2|Change in the number of decayed, missing or filled permanent teeth (DMFT)|Studies conducted after 1975","Change in the number of decayed, missing or filled permanent teeth (DMFT)",1,2,"Studies conducted after 1975","or","binary",4,0.0252249322668076,1.0013463609391,0,2000.25,0,714
"CD010856","CD010856_pub3_data","1|4|Change in the proportion of caries-free participants (primary teeth)|Studies conducted after 1975","Change in the proportion of caries-free participants (primary teeth)",1,4,"Studies conducted after 1975","or","binary",2,-0.0348412832488961,1.41471383699887,0,2018.5,0,1454
"CD010856","CD010856_pub3_data","1|4|Change in the proportion of caries-free participants (primary teeth)|Studies conducted in 1975 or earlier","Change in the proportion of caries-free participants (primary teeth)",1,4,"Studies conducted in 1975 or earlier","or","binary",5,-0.310709094001255,0.894943450568322,0,1966.4,0,1255.6
"CD010856","CD010856_pub3_data","1|5|Change in the proportion of caries-free participants (permanent teeth)|Studies conducted in 1975 or earlier","Change in the proportion of caries-free participants (permanent teeth)",1,5,"Studies conducted in 1975 or earlier","or","binary",4,-0.261906029742918,1.00052355763323,0,1965.75,0,1554.75
"CD010856","CD010856_pub3_data","1|6|Sensitivity analysis - all included studies: change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted after 1975","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled primary teeth (dmft)",1,6,"Studies conducted after 1975","or","binary",3,-0.0811701100397807,1.15502502719341,0,2007,0,2207.33333333333
"CD010856","CD010856_pub3_data","1|6|Sensitivity analysis - all included studies: change in the number of decayed, missing or filled primary teeth (dmft)|Studies conducted in 1975 or earlier","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled primary teeth (dmft)",1,6,"Studies conducted in 1975 or earlier","or","binary",8,-0.446111039207065,0.707556497967356,0,1965.5,0,2190
"CD010856","CD010856_pub3_data","1|7|Sensitivity analysis - all included studies: change in the number of decayed, missing or filled permanent teeth (DMFT)|Studies conducted after 1975","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled permanent teeth (DMFT)",1,7,"Studies conducted after 1975","or","binary",6,0.305376996383073,0.817280039342977,0,2000.66666666667,0,2151
"CD010856","CD010856_pub3_data","1|7|Sensitivity analysis - all included studies: change in the number of decayed, missing or filled permanent teeth (DMFT)|Studies conducted in 1975 or earlier","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled permanent teeth (DMFT)",1,7,"Studies conducted in 1975 or earlier","or","binary",6,-0.490954413261985,0.816701030174517,0,1964.66666666667,0,5055.66666666667
"CD010856","CD010856_pub3_data","1|8|Sensitivity analysis - all included studies: change in the proportion of caries-free participants (primary teeth)|Studies conducted after 1975","Sensitivity analysis - all included studies: change in the proportion of caries-free participants (primary teeth)",1,8,"Studies conducted after 1975","or","binary",4,-0.498651354786112,1.00029336762857,0,2004.5,0,2402
"CD010856","CD010856_pub3_data","1|8|Sensitivity analysis - all included studies: change in the proportion of caries-free participants (primary teeth)|Studies conducted in 1975 or earlier","Sensitivity analysis - all included studies: change in the proportion of caries-free participants (primary teeth)",1,8,"Studies conducted in 1975 or earlier","or","binary",8,-0.342850093969714,0.707541184267325,0,1965.5,0,1547.875
"CD010856","CD010856_pub3_data","1|9|Sensitivity analysis - all included studies: change in the proportion of caries-free participants (permanent teeth)|Studies conducted in 1975 or earlier","Sensitivity analysis - all included studies: change in the proportion of caries-free participants (permanent teeth)",1,9,"Studies conducted in 1975 or earlier","or","binary",6,-0.354234734484996,0.816823066569492,0,1965.5,0,2909.83333333333
"CD010861","CD010861_pub3_data","1|10|Flushing/Fishbane reaction|","Flushing/Fishbane reaction",1,10,"","reported","reported",4,2.31789318808532,7.95585218908887,0,2014.5,0,145.75
"CD010861","CD010861_pub3_data","1|11|Injection site discomfort / reaction|","Injection site discomfort / reaction",1,11,"","reported","reported",5,4.12863779389604,10.4507220059289,0,2014.2,0,214.4
"CD010861","CD010861_pub3_data","1|12|Constipation|","Constipation",1,12,"","reported","reported",9,0.0866673711720987,0.0562354555036855,0,2012,0.113854016566091,195.777777777778
"CD010861","CD010861_pub3_data","1|13|Nausea|","Nausea",1,13,"","reported","reported",7,0.119210251861278,0.0911632168996071,0,2011.83333333333,0.0952730901710517,181
"CD010861","CD010861_pub3_data","1|14|Gastrointestinal pain|","Gastrointestinal pain",1,14,"","reported","reported",4,0.178631549391738,0.339672044976059,0,2013,0.0343037890832009,188.25
"CD010861","CD010861_pub3_data","1|15|Number of RBC transfused women|","Number of RBC transfused women",1,15,"","reported","reported",5,0.551569249749376,1.00784330344701,0,2013.6,0.0192454463775218,187.6
"CD010861","CD010861_pub3_data","1|16|Hb (g/dL) 0-7 days|","Hb (g/dL) 0-7 days",1,16,"","reported","reported",7,0.481053411919419,0.229245919106344,0.311346457797344,2014.14285714286,NA,108
"CD010861","CD010861_pub3_data","1|17|Hb (g/dL) 8-28 days|","Hb (g/dL) 8-28 days",1,17,"","reported","reported",6,0.941529738937174,0.321163360744536,0.566440899584678,2013.83333333333,NA,111
"CD010861","CD010861_pub3_data","1|18|Hg (g/dL) > 28 days|","Hg (g/dL) > 28 days",1,18,"","reported","reported",9,0.682562795065668,0.231871457918301,0.441214336180403,2015.875,NA,148.111111111111
"CD010861","CD010861_pub3_data","1|3|Fatigue 8-28 days|","Fatigue 8-28 days",1,3,"","reported","reported",2,-0.260713114135718,0.124924352279801,0.0149950133919328,2012,NA,257.5
"CD010861","CD010861_pub3_data","1|4|Fatigue > 28 days|","Fatigue > 28 days",1,4,"","reported","reported",3,-0.100776821743532,0.0731851309677594,0,2016,NA,261
"CD010861","CD010861_pub3_data","1|6|Infection|","Infection",1,6,"","reported","reported",2,1.22679951762073,0.553993651773753,0.234191784285994,2007.5,0.0785465310604975,352.5
"CD010861","CD010861_pub3_data","1|7|Compliance to treatment|","Compliance to treatment",1,7,"","reported","reported",7,1.13099247186174,0.0442711659149951,0.00711495755501785,2012,0.830816889328537,144.428571428571
"CD010861","CD010861_pub3_data","1|8|Serious adverse events|","Serious adverse events",1,8,"","reported","reported",2,1.11583740192265,0.516274663377155,0,2012.5,0.0535135135135135,244.5
"CD010861","CD010861_pub3_data","1|9|Anaphylaxis or evidence of hypersensitivity|","Anaphylaxis or evidence of hypersensitivity",1,9,"","reported","reported",2,2.73286149187612,10.9527196369515,0,2009.5,0,247
"CD010861","CD010861_pub3_data","2|10|Hb (g/dL) > 28 days|","Hb (g/dL) > 28 days",2,10,"","reported","reported",2,-1.03953435010882,0.334545210594702,0,2023,NA,14.5
"CD010861","CD010861_pub3_data","2|2|Fatigue 0-7 days|","Fatigue 0-7 days",2,2,"","reported","reported",2,-0.0448105612012557,0.372100164378316,0,2023,NA,14.5
"CD010861","CD010861_pub3_data","2|4|Fatigue > 28 days|","Fatigue > 28 days",2,4,"","reported","reported",2,-0.586143778745128,0.577359939495718,0.352762308822124,2023,NA,14.5
"CD010861","CD010861_pub3_data","2|8|Hb (g/dL) 0-7 days|","Hb (g/dL) 0-7 days",2,8,"","reported","reported",2,0.542376061853313,0.508971306282457,0.225835849343763,2023,NA,13.5
"CD010861","CD010861_pub3_data","3|4|Anaphylaxis or evidence of hypersensitivity|","Anaphylaxis or evidence of hypersensitivity",3,4,"","or","binary",2,0.09405368878812,1.42550858659472,0,2004,0,84
"CD010861","CD010861_pub3_data","3|6|Number of RBC transfused women|","Number of RBC transfused women",3,6,"","reported","reported",2,0.455784347530085,0.290927332710689,0,2011,0.106349206349206,100
"CD010861","CD010861_pub3_data","3|9|Hb (g/dL) > 28 days|","Hb (g/dL) > 28 days",3,9,"","reported","reported",2,0.247282557215743,0.295331798535628,0.0877598675007809,2011,NA,76.5
"CD010861","CD010861_pub3_data","5|2|Hb (g/dL) > 28 days|","Hb (g/dL) > 28 days",5,2,"","reported","reported",3,1.30458814121696,0.572090027846841,0.924934823550811,1994,NA,79
"CD010861","CD010861_pub3_data","6|3|Breastfeeding at hospital discharge|","Breastfeeding at hospital discharge",6,3,"","reported","reported",2,1.33843455865196,0.435950859956505,0.302261390632386,2004.5,0.75,40
"CD010861","CD010861_pub3_data","6|4|Serious adverse events|","Serious adverse events",6,4,"","or","binary",2,0,1.43135617084109,0,2005.5,0,40
"CD010861","CD010861_pub3_data","6|5|Anaphylaxis or evidence of hypersensitivity|","Anaphylaxis or evidence of hypersensitivity",6,5,"","or","binary",3,0.0191037634383751,1.16719675332907,0,1997,0,51.6666666666667
"CD010861","CD010861_pub3_data","6|8|Hb (g/dL) 0-7 days|","Hb (g/dL) 0-7 days",6,8,"","reported","reported",3,0.287186434302321,0.207724794103564,0,2004.33333333333,NA,36.6666666666667
"CD010861","CD010861_pub3_data","6|9|Hb (g/dL) 8-28 days|","Hb (g/dL) 8-28 days",6,9,"","reported","reported",3,0.181080549314347,0.188118196226823,0,2004.33333333333,NA,36.6666666666667
"CD010861","CD010861_pub3_data","7|1|IV vs. oral iron - Hb (g/dL) 0-7 days (iron dosage and type)|High dose iron (≥ 1000 mg ferrous carboxymaltose or isomaltoside)","IV vs. oral iron - Hb (g/dL) 0-7 days (iron dosage and type)",7,1,"High dose iron (≥ 1000 mg ferrous carboxymaltose or isomaltoside)","reported","reported",2,0,0.131827846819193,0,2016.5,0,141.5
"CD010861","CD010861_pub3_data","7|1|IV vs. oral iron - Hb (g/dL) 0-7 days (iron dosage and type)|Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","IV vs. oral iron - Hb (g/dL) 0-7 days (iron dosage and type)",7,1,"Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","reported","reported",5,0,0.0476790632853312,0,2013.2,0,94.6
"CD010861","CD010861_pub3_data","7|2|IV vs. oral iron - Hb (g/dL) 8-28 days (iron dosage and type)|Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","IV vs. oral iron - Hb (g/dL) 8-28 days (iron dosage and type)",7,2,"Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","reported","reported",5,0,0.0665020256015803,0,2013.2,0,94.6
"CD010861","CD010861_pub3_data","7|3|IV vs. oral iron - Hb (g/dL) > 28 days (iron dosage and type)|High dose iron (≥ 1000 mg ferrous carboxymaltose, isomaltoside or dextran)","IV vs. oral iron - Hb (g/dL) > 28 days (iron dosage and type)",7,3,"High dose iron (≥ 1000 mg ferrous carboxymaltose, isomaltoside or dextran)","reported","reported",5,0,0.0532226983654207,0,2018.5,0,162.2
"CD010861","CD010861_pub3_data","7|3|IV vs. oral iron - Hb (g/dL) > 28 days (iron dosage and type)|Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","IV vs. oral iron - Hb (g/dL) > 28 days (iron dosage and type)",7,3,"Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)","reported","reported",4,0,0.0548785105880714,0,2013.25,0,108
"CD010861","CD010861_pub3_data","8|1|IV vs. oral iron - Hb (g/dL) 0-7 days (bias in allocation excluded)|","IV vs. oral iron - Hb (g/dL) 0-7 days (bias in allocation excluded)",8,1,"","or","binary",4,0.0125547541153169,1.01241416046017,0,2013,0,141.25
"CD010861","CD010861_pub3_data","8|2|IV vs. oral iron - Hb (g/dL) 8-28 days (bias in allocation excluded)|","IV vs. oral iron - Hb (g/dL) 8-28 days (bias in allocation excluded)",8,2,"","or","binary",4,0.0125547541153169,1.01241416046017,0,2013,0,141.25
"CD010861","CD010861_pub3_data","8|3|IV vs. oral iron - Hb (g/dL) > 28 days (bias in allocation excluded)|","IV vs. oral iron - Hb (g/dL) > 28 days (bias in allocation excluded)",8,3,"","or","binary",6,0.00320641772653189,0.823910378575203,0,2015.5,0,162
"CD010966","CD010966_pub4_data","10|1|Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)|At 6 months","Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)",10,1,"At 6 months","or","binary",2,0.025081184553155,1.41618509230211,0,2014,0,357.5
"CD010966","CD010966_pub4_data","10|10|BMI (absolute change from baseline)|At 6 months","BMI (absolute change from baseline)",10,10,"At 6 months","or","binary",2,0.0247723423728476,1.41615783481667,0,2014,0,362.5
"CD010966","CD010966_pub4_data","10|10|BMI (absolute change from baseline)|At up to 1 month","BMI (absolute change from baseline)",10,10,"At up to 1 month","or","binary",2,0.00807942763562795,1.41612091748513,0,2014,0,369.5
"CD010966","CD010966_pub4_data","10|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At 6 months","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",10,2,"At 6 months","or","binary",2,0.0358261816507622,1.41615825169527,0,2014,0,362.5
"CD010966","CD010966_pub4_data","10|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At up to 1 month","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",10,2,"At up to 1 month","or","binary",2,0.00807942763562795,1.41612091748513,0,2014,0,369.5
"CD010966","CD010966_pub4_data","10|3|Quality of life - EQ-5D-3L VAS score (absolute change from baseline)|At 6 months","Quality of life - EQ-5D-3L VAS score (absolute change from baseline)",10,3,"At 6 months","or","binary",2,0.0336662313852099,1.416193587165,0,2014,0,356
"CD010966","CD010966_pub4_data","10|4|FEV1 % predicted (relative change from baseline)|At 6 months","FEV1 % predicted (relative change from baseline)",10,4,"At 6 months","or","binary",2,0.0166842815559162,1.41617134504927,0,2014,0,360
"CD010966","CD010966_pub4_data","10|5|FEV1 % predicted (absolute change from baseline)|At 6 months","FEV1 % predicted (absolute change from baseline)",10,5,"At 6 months","or","binary",2,0.0166842815559162,1.41617134504927,0,2014,0,360
"CD010966","CD010966_pub4_data","10|5|FEV1 % predicted (absolute change from baseline)|At up to 1 month","FEV1 % predicted (absolute change from baseline)",10,5,"At up to 1 month","or","binary",2,0.00807942763562795,1.41612091748513,0,2014,0,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Abdominal pain","Adverse events by end of study (at 6 months)",10,6,"Abdominal pain","or","binary",2,-0.220912805276103,0.271241858107924,0,2014,0.0865503261061167,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Abnormal respiration","Adverse events by end of study (at 6 months)",10,6,"Abnormal respiration","or","binary",2,0.599421384966333,0.522391835769292,0.390966950321727,2014,0.059536400493566,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Any adverse event","Adverse events by end of study (at 6 months)",10,6,"Any adverse event","or","binary",2,0.00358842960398383,0.373338773398001,0,2014,0.96196897585052,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|At least 1 serious adverse event","Adverse events by end of study (at 6 months)",10,6,"At least 1 serious adverse event","or","binary",2,-0.315269207769482,0.176139380437277,0.004642368934216,2014,0.287105587872378,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Cough","Adverse events by end of study (at 6 months)",10,6,"Cough","or","binary",2,-0.320640401728719,0.153628773331841,0,2014,0.400757976379341,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Diarrhoea","Adverse events by end of study (at 6 months)",10,6,"Diarrhoea","or","binary",2,0.157593557157927,0.253676807801634,0,2014,0.0839062224572537,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Discontinuation due to an adverse event","Adverse events by end of study (at 6 months)",10,6,"Discontinuation due to an adverse event","or","binary",2,0.777270352061888,0.465309554209953,0,2014,0.0163053058346554,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Dyspnoea","Adverse events by end of study (at 6 months)",10,6,"Dyspnoea","or","binary",2,0.697719198972167,0.240136195180982,0,2014,0.0785739467653799,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Fatigue","Adverse events by end of study (at 6 months)",10,6,"Fatigue","or","binary",2,0.0315952992381117,0.268866738352183,0,2014,0.0787942887361185,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Haemoptysis","Adverse events by end of study (at 6 months)",10,6,"Haemoptysis","or","binary",2,0.0418543727316587,0.211930369500002,0,2014,0.135466243610083,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Headache","Adverse events by end of study (at 6 months)",10,6,"Headache","or","binary",2,-0.00298335408623879,0.201082312160799,0,2014,0.157015688348317,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Increased sputum","Adverse events by end of study (at 6 months)",10,6,"Increased sputum","or","binary",2,-0.295967641505839,0.199486193746087,0,2014,0.18918561607615,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Infective pulmonary exacerbation","Adverse events by end of study (at 6 months)",10,6,"Infective pulmonary exacerbation","or","binary",2,-0.410761513872102,0.148814915838806,0,2014,0.493081262118808,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Nasal congestion","Adverse events by end of study (at 6 months)",10,6,"Nasal congestion","or","binary",2,-0.395965561631972,0.673638607257656,0.777975548950511,2014,0.119381279746166,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Nasopharyngitis","Adverse events by end of study (at 6 months)",10,6,"Nasopharyngitis","or","binary",2,-0.582654780498675,0.269696231832949,0,2014,0.108408249603384,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Nausea","Adverse events by end of study (at 6 months)",10,6,"Nausea","or","binary",2,0.0352268796356234,0.273223076444,0,2014,0.075753569539926,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Oropharyngeal pain","Adverse events by end of study (at 6 months)",10,6,"Oropharyngeal pain","or","binary",2,0.441797189022814,0.462123184235708,0.299169606014842,2014,0.0810858452317997,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Pyrexia","Adverse events by end of study (at 6 months)",10,6,"Pyrexia","or","binary",2,0.0292926979198881,0.250722459007616,0,2014,0.0919266701921382,369.5
"CD010966","CD010966_pub4_data","10|6|Adverse events by end of study (at 6 months)|Upper respiratory tract infection","Adverse events by end of study (at 6 months)",10,6,"Upper respiratory tract infection","or","binary",2,0.169542646063373,0.349596183514309,0.0518220486902767,2014,0.0542041248016922,369.5
"CD010966","CD010966_pub4_data","10|7|Time to first pulmonary exacerbation|","Time to first pulmonary exacerbation",10,7,"","reported","reported",2,-0.350026465696466,0.109430580621013,0,2014,0,369.5
"CD010966","CD010966_pub4_data","10|8|Rate of exacerbations|","Rate of exacerbations",10,8,"","reported","reported",2,-0.352540125789328,0.110415182931068,0,2014,0,369.5
"CD010966","CD010966_pub4_data","10|9|Weight (kg) (absolute change from baseline)|At 6 months","Weight (kg) (absolute change from baseline)",10,9,"At 6 months","or","binary",2,0.0247723423728476,1.41615783481667,0,2014,0,362.5
"CD010966","CD010966_pub4_data","11|1|Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)|At 6 months","Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)",11,1,"At 6 months","or","binary",2,0.0451666003050769,1.41620544361603,0,2014,0,354
"CD010966","CD010966_pub4_data","11|10|BMI (absolute change from baseline)|At 6 months","BMI (absolute change from baseline)",11,10,"At 6 months","or","binary",3,0.0513638921217364,1.15874809797105,0,2016.33333333333,0,262
"CD010966","CD010966_pub4_data","11|10|BMI (absolute change from baseline)|At up to 1 month","BMI (absolute change from baseline)",11,10,"At up to 1 month","or","binary",2,0.00544948704380482,1.41611847722599,0,2014,0,370
"CD010966","CD010966_pub4_data","11|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At 6 months","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",11,2,"At 6 months","or","binary",3,0.0645259618697871,1.15875310154954,0,2016.33333333333,0,261
"CD010966","CD010966_pub4_data","11|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At up to 1 month","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",11,2,"At up to 1 month","or","binary",2,0.00544948704380482,1.41611847722599,0,2014,0,370
"CD010966","CD010966_pub4_data","11|3|Quality of life - EQ-5D-3L VAS score (absolute change from baseline)|At 6 months","Quality of life - EQ-5D-3L VAS score (absolute change from baseline)",11,3,"At 6 months","or","binary",2,0.0394631621541829,1.41619951954001,0,2014,0,355
"CD010966","CD010966_pub4_data","11|4|FEV1 % predicted (relative change from baseline)|At 6 months","FEV1 % predicted (relative change from baseline)",11,4,"At 6 months","or","binary",3,0.0416827058254089,1.15880354198095,0,2016.33333333333,0,259
"CD010966","CD010966_pub4_data","11|5|FEV1 % predicted (absolute change from baseline)|At 6 months","FEV1 % predicted (absolute change from baseline)",11,5,"At 6 months","or","binary",3,0.0416827058254089,1.15880354198095,0,2016.33333333333,0,259
"CD010966","CD010966_pub4_data","11|5|FEV1 % predicted (absolute change from baseline)|At up to 1 month","FEV1 % predicted (absolute change from baseline)",11,5,"At up to 1 month","or","binary",2,0.00544948704380482,1.41611847722599,0,2014,0,370
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Abdominal pain","Adverse events by end of study (at 6 months)",11,6,"Abdominal pain","or","binary",2,-0.00729754355216045,0.718380840281688,0.887092877046131,2014,0.0865503261061167,369
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Abnormal respiration","Adverse events by end of study (at 6 months)",11,6,"Abnormal respiration","or","binary",3,0.205968642923446,0.255395969440216,3.37379420614969e-06,2016.33333333333,0.123024266995711,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Any adverse event","Adverse events by end of study (at 6 months)",11,6,"Any adverse event","or","binary",3,-0.378407714361761,0.363914412660572,0.0465362593163983,2016.33333333333,0.965386724641087,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|At least 1 serious adverse event","Adverse events by end of study (at 6 months)",11,6,"At least 1 serious adverse event","or","binary",3,-0.244806041546717,0.44872818127963,0.48803452222405,2016.33333333333,0.274737058581585,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Cough","Adverse events by end of study (at 6 months)",11,6,"Cough","or","binary",3,-0.529283042927149,0.151842390337828,0,2016.33333333333,0.341246058326968,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Diarrhoea","Adverse events by end of study (at 6 months)",11,6,"Diarrhoea","or","binary",3,0.325192304701433,0.251155851395831,0.0150210095421968,2016.33333333333,0.0837152594159469,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Discontinuation due to an adverse event","Adverse events by end of study (at 6 months)",11,6,"Discontinuation due to an adverse event","or","binary",3,1.00176425809538,0.5101387882482,0.140974505489411,2016.33333333333,0.0108702038897703,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Dyspnoea","Adverse events by end of study (at 6 months)",11,6,"Dyspnoea","or","binary",3,0.40501136283939,0.312493542168924,0.0920031011779117,2016.33333333333,0.0801604089546977,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Fatigue","Adverse events by end of study (at 6 months)",11,6,"Fatigue","or","binary",3,0.216825749974557,0.314893573872736,0.0656575909492644,2016.33333333333,0.052529525824079,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Haemoptysis","Adverse events by end of study (at 6 months)",11,6,"Haemoptysis","or","binary",3,0.0288535057049191,0.247127792359629,0.0401369639774299,2016.33333333333,0.108829347591907,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Headache","Adverse events by end of study (at 6 months)",11,6,"Headache","or","binary",3,-0.0265090007888866,0.199595167835603,3.60845026389414e-06,2016.33333333333,0.123195644084063,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Increased sputum","Adverse events by end of study (at 6 months)",11,6,"Increased sputum","or","binary",3,-0.337262265177578,0.295206837621705,0.116308034179396,2016.33333333333,0.172420040347063,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Infective pulmonary exacerbation","Adverse events by end of study (at 6 months)",11,6,"Infective pulmonary exacerbation","or","binary",3,-0.500786353446087,0.143627340117848,1.63458556388791e-07,2016.33333333333,0.43983195252365,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Nasal congestion","Adverse events by end of study (at 6 months)",11,6,"Nasal congestion","or","binary",2,-0.640849826624031,0.262375432845613,0,2014,0.119381279746166,369
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Nasopharyngitis","Adverse events by end of study (at 6 months)",11,6,"Nasopharyngitis","or","binary",3,0.192334773364516,0.217301262955643,0,2016.33333333333,0.100049944180034,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Nausea","Adverse events by end of study (at 6 months)",11,6,"Nausea","or","binary",3,0.412254895750868,0.25639441397855,0.0225077183279713,2016.33333333333,0.0967986759895803,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Oropharyngeal pain","Adverse events by end of study (at 6 months)",11,6,"Oropharyngeal pain","or","binary",3,-0.301399847123231,0.270732166061972,0,2016.33333333333,0.0910942671915702,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Pyrexia","Adverse events by end of study (at 6 months)",11,6,"Pyrexia","or","binary",3,0.075486763338751,0.359914987932742,0.140619680415946,2016.33333333333,0.0612844467947588,269.333333333333
"CD010966","CD010966_pub4_data","11|6|Adverse events by end of study (at 6 months)|Upper respiratory tract infection","Adverse events by end of study (at 6 months)",11,6,"Upper respiratory tract infection","or","binary",3,0.563280173902752,0.262761439064608,0,2016.33333333333,0.0731731202381652,269.333333333333
"CD010966","CD010966_pub4_data","11|7|Time to first pulmonary exacerbation|","Time to first pulmonary exacerbation",11,7,"","reported","reported",2,-0.499425,0.129805,0.00809867604999999,2014,0,370
"CD010966","CD010966_pub4_data","11|8|Rate of exacerbations|","Rate of exacerbations",11,8,"","reported","reported",2,-0.498017273920569,0.114163992733328,0,2014,0,370
"CD010966","CD010966_pub4_data","11|9|Weight (kg) (absolute change from baseline)|At 6 months","Weight (kg) (absolute change from baseline)",11,9,"At 6 months","or","binary",2,0.0304060717728837,1.41616343803571,0,2014,0,361.5
"CD010966","CD010966_pub4_data","12|1|Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)|At 6 months","Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)",12,1,"At 6 months","or","binary",2,-0.656655601571016,1.41569204345956,0,2014,0,530.5
"CD010966","CD010966_pub4_data","12|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At 6 months","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",12,2,"At 6 months","or","binary",3,-0.403496568029755,1.1584765706337,0,2016.33333333333,0,379.666666666667
"CD010966","CD010966_pub4_data","12|2|Quality of life - CFQ-R respiratory domain (absolute change from baseline)|At up to 1 month","Quality of life - CFQ-R respiratory domain (absolute change from baseline)",12,2,"At up to 1 month","or","binary",2,-0.685037528540592,1.41564242722378,0,2014,0,554
"CD010966","CD010966_pub4_data","12|3|Quality of life - EQ-5D-3L VAS score (absolute change from baseline)|At 6 months","Quality of life - EQ-5D-3L VAS score (absolute change from baseline)",12,3,"At 6 months","or","binary",2,-0.655160899298923,1.41569269686381,0,2014,0,530
"CD010966","CD010966_pub4_data","12|4|FEV1 % predicted (relative change from baseline)|At 6 months","FEV1 % predicted (relative change from baseline)",12,4,"At 6 months","or","binary",3,-0.42636725218446,1.15852773420942,0,2016.33333333333,0,378
"CD010966","CD010966_pub4_data","12|5|FEV1 % predicted (absolute change from baseline)|At 6 months","FEV1 % predicted (absolute change from baseline)",12,5,"At 6 months","or","binary",3,-0.42636725218446,1.15852773420942,0,2016.33333333333,0,378
"CD010966","CD010966_pub4_data","12|5|FEV1 % predicted (absolute change from baseline)|At up to 1 month","FEV1 % predicted (absolute change from baseline)",12,5,"At up to 1 month","or","binary",2,-0.685037528540592,1.41564242722378,0,2014,0,554
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Abdominal pain","Adverse events by end of study (at 6 months)",12,6,"Abdominal pain","or","binary",2,-0.0956000713895739,0.436617055111568,0.274208767536207,2014,0.0865503261061167,554
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Abnormal respiration","Adverse events by end of study (at 6 months)",12,6,"Abnormal respiration","or","binary",3,0.244419628559743,0.362724273031335,0.215854232066398,2016.33333333333,0.123024266995711,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Any adverse event","Adverse events by end of study (at 6 months)",12,6,"Any adverse event","or","binary",3,-0.205296170455678,0.303896800578682,1.10994311564411e-06,2016.33333333333,0.965386724641087,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|At least 1 serious adverse event","Adverse events by end of study (at 6 months)",12,6,"At least 1 serious adverse event","or","binary",3,-0.173603214309496,0.356244648322137,0.287558108078337,2016.33333333333,0.274737058581585,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Cough","Adverse events by end of study (at 6 months)",12,6,"Cough","or","binary",3,-0.429332500774705,0.129916379672574,0,2016.33333333333,0.341246058326968,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Diarrhoea","Adverse events by end of study (at 6 months)",12,6,"Diarrhoea","or","binary",3,0.220792694131166,0.214395320370645,8.8531146360056e-07,2016.33333333333,0.0837152594159469,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Discontinuation due to an adverse event","Adverse events by end of study (at 6 months)",12,6,"Discontinuation due to an adverse event","or","binary",3,0.868904508226519,0.411921267546801,0,2016.33333333333,0.0108702038897703,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Dyspnoea","Adverse events by end of study (at 6 months)",12,6,"Dyspnoea","or","binary",3,0.505881293673255,0.264707972595648,0.0541725268526772,2016.33333333333,0.0801604089546977,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Fatigue","Adverse events by end of study (at 6 months)",12,6,"Fatigue","or","binary",3,0.115631686796621,0.258710382387364,0.028174600942347,2016.33333333333,0.052529525824079,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Haemoptysis","Adverse events by end of study (at 6 months)",12,6,"Haemoptysis","or","binary",3,0.0304086132747882,0.180411161047042,0,2016.33333333333,0.108829347591907,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Headache","Adverse events by end of study (at 6 months)",12,6,"Headache","or","binary",3,-0.0304869218587386,0.173371947666217,2.05617307451639e-06,2016.33333333333,0.123195644084063,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Increased sputum","Adverse events by end of study (at 6 months)",12,6,"Increased sputum","or","binary",3,-0.333862001962069,0.165732620166826,0,2016.33333333333,0.172420040347063,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Infective pulmonary exacerbation","Adverse events by end of study (at 6 months)",12,6,"Infective pulmonary exacerbation","or","binary",3,-0.447730329802605,0.124548886794777,3.73805025387634e-07,2016.33333333333,0.43983195252365,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Nasal congestion","Adverse events by end of study (at 6 months)",12,6,"Nasal congestion","or","binary",2,-0.51665157585561,0.478316435668554,0.36559020876575,2014,0.119381279746166,554
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Nasopharyngitis","Adverse events by end of study (at 6 months)",12,6,"Nasopharyngitis","or","binary",3,-0.130622851041343,0.20023666174091,0,2016.33333333333,0.100049944180034,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Nausea","Adverse events by end of study (at 6 months)",12,6,"Nausea","or","binary",3,0.226179744856819,0.218974633917637,0,2016.33333333333,0.0967986759895803,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Oropharyngeal pain","Adverse events by end of study (at 6 months)",12,6,"Oropharyngeal pain","or","binary",3,-0.00974866017515419,0.37734471956744,0.216054816995925,2016.33333333333,0.0910942671915702,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Pyrexia","Adverse events by end of study (at 6 months)",12,6,"Pyrexia","or","binary",3,0.0150061021787718,0.216973424724555,5.77541918825664e-06,2016.33333333333,0.0612844467947588,392.666666666667
"CD010966","CD010966_pub4_data","12|6|Adverse events by end of study (at 6 months)|Upper respiratory tract infection","Adverse events by end of study (at 6 months)",12,6,"Upper respiratory tract infection","or","binary",3,0.376452425868523,0.245147752898413,0,2016.33333333333,0.0731731202381652,392.666666666667
"CD010966","CD010966_pub4_data","12|7|Weight (kg) (absolute change from baseline)|At 6 months","Weight (kg) (absolute change from baseline)",12,7,"At 6 months","or","binary",2,-0.664168109990908,1.4156680794786,0,2014,0,540.5
"CD010966","CD010966_pub4_data","12|8|BMI (absolute change from baseline)|At 6 months","BMI (absolute change from baseline)",12,8,"At 6 months","or","binary",3,-0.413771645408109,1.15847669040628,0,2016.33333333333,0,381.333333333333
"CD010966","CD010966_pub4_data","12|8|BMI (absolute change from baseline)|At up to 1 month","BMI (absolute change from baseline)",12,8,"At up to 1 month","or","binary",2,-0.685037528540592,1.41564242722378,0,2014,0,554
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Back pain","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Back pain","or","binary",2,-0.484290688337492,1.50116099429498,1.72876313510286,2014,0.0769230769230769,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Cough","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Cough","or","binary",2,-0.22912058226257,0.640387682861039,0,2014,0.392307692307692,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Diarrhoea","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Diarrhoea","or","binary",2,0.914780049288581,0.902046445095794,0,2014,0.0384615384615385,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Dyspnoea","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Dyspnoea","or","binary",2,-0.185015884634529,0.824511131988756,0,2014,0.238461538461538,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Forced expiratory volume decreased","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Forced expiratory volume decreased","or","binary",2,-1.70652354407216,1.1780351085637,0,2014,0.176923076923077,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Headache","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Headache","or","binary",2,0.624755255786961,0.93283957224903,0,2014,0.0384615384615385,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Infective pulmonary exacerbation of cystic fibrosis","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Infective pulmonary exacerbation of cystic fibrosis","or","binary",2,-1.53710606807557,1.78876118801287,4.83527541849467,2014,0.807692307692308,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Nasal congestion","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Nasal congestion","or","binary",2,-0.457497972525128,1.05301595099734,0.500018707742689,2014,0.115384615384615,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Number of participants with serious adverse events","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Number of participants with serious adverse events","or","binary",2,-0.633567999924808,0.660126770556073,0,2014,0.392307692307692,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Number of participants with treatment-emergent adverse events","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Number of participants with treatment-emergent adverse events","or","binary",2,0.152266124150939,1.4551349985102,0,2014,1,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Pulmonary function test decreased","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Pulmonary function test decreased","or","binary",2,0.172007554737583,0.846741522193655,0,2014,0.138461538461538,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Respiration abnormal","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Respiration abnormal","or","binary",2,0.533157118549843,1.01638232621048,0,2014,0.1,19.5
"CD010966","CD010966_pub4_data","17|4|Most common adverse events (occurring in at least 10% of participants in either group)|Sputum increased","Most common adverse events (occurring in at least 10% of participants in either group)",17,4,"Sputum increased","or","binary",2,-1.18982482223671,0.924459342596478,0,2014,0.276923076923077,19.5
"CD010966","CD010966_pub4_data","18|1|CFQ-R respiratory domain (absolute change from baseline) |Up to and including 6 months","CFQ-R respiratory domain (absolute change from baseline) ",18,1,"Up to and including 6 months","reported","reported",5,3.19344969527474,0.75824046717369,1.09222592594566,2017.5,0,189.2
"CD010966","CD010966_pub4_data","18|13|FEV1 % predicted (relative change from baseline) |Up to and including 6 months","FEV1 % predicted (relative change from baseline) ",18,13,"Up to and including 6 months","reported","reported",5,3.67967100949502,1.45068758205807,7.80358104383479,2017.5,0,188.8
"CD010966","CD010966_pub4_data","18|14|FEV1 % predicted (absolute change from baseline) |At 1 month","FEV1 % predicted (absolute change from baseline) ",18,14,"At 1 month","reported","reported",3,3.53847657872031,0.586327287292827,0,2016.66666666667,0,185.333333333333
"CD010966","CD010966_pub4_data","18|14|FEV1 % predicted (absolute change from baseline) |Up to and including 6 months","FEV1 % predicted (absolute change from baseline) ",18,14,"Up to and including 6 months","reported","reported",5,1.91501437039012,0.779053123975692,2.36237955857514,2017.5,0,188.8
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Cough","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Cough","or","binary",7,-0.275287610159498,0.145464874766699,0,2017.83333333333,0.231393917289825,145.428571428571
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Fatigue","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Fatigue","or","binary",3,0.0302507614603181,0.654620638421825,0.761261465167492,2017.5,0.0557379540963672,231.666666666667
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Haemoptysis","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Haemoptysis","or","binary",5,-0.0247517813747736,0.26677379134213,0.0433275442556042,2017,0.0721737997524591,154
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Headache","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Headache","or","binary",4,0.0609720048970101,0.25004424436957,0.0255373676678925,2017.75,0.120705803350534,166.25
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Increased sputum","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Increased sputum","or","binary",4,-0.245017056471687,0.207460654533681,0,2017.66666666667,0.114492298651276,203.75
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Nasal congestion or nasopharyngitis","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Nasal congestion or nasopharyngitis","or","binary",5,0.0656345695116509,0.204035919309221,2.37710067495083e-06,2017.75,0.120344602957462,166.6
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Nausea","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Nausea","or","binary",4,0.212532516073476,0.305466536147139,1.24335594884799e-06,2017,0.0650609080841639,150.5
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Number of participants with serious adverse events","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Number of participants with serious adverse events","or","binary",6,-0.491608115727687,0.18271447697983,0,2017.8,0.20845778984528,166.666666666667
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Number of participants with treatment-emergent adverse events","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Number of participants with treatment-emergent adverse events","or","binary",6,-0.245710004151244,0.183736656122393,1.57268365399181e-06,2017.8,0.76289366414552,166.666666666667
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Oropharyngeal pain","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Oropharyngeal pain","or","binary",2,-0.242494397583815,0.281816027111186,0,2017.5,0.103820598006645,275
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Pulmonary exacerbation","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Pulmonary exacerbation","or","binary",7,-0.367873210303328,0.143345689367605,3.25474833766397e-06,2017.83333333333,0.302064475468564,145.428571428571
"CD010966","CD010966_pub4_data","18|16|Most common adverse events (occurring in at least 10% of participants in either group)|Pyrexia","Most common adverse events (occurring in at least 10% of participants in either group)",18,16,"Pyrexia","or","binary",3,-0.0680284623400278,0.258411516060147,0,2017.66666666667,0.0730897009966777,189.333333333333
"CD010966","CD010966_pub4_data","18|20|Sweat chloride (change from baseline) |At 1 month","Sweat chloride (change from baseline) ",18,20,"At 1 month","reported","reported",3,-9.13766217914475,0.915133143458453,5.39655007161555e-06,2016.66666666667,0,184
"CD010966","CD010966_pub4_data","18|20|Sweat chloride (change from baseline) |Up to and including 6 months","Sweat chloride (change from baseline) ",18,20,"Up to and including 6 months","reported","reported",4,-6.42271658663754,1.51102473340227,7.50451279763722,2017.33333333333,0,209.25
"CD010966","CD010966_pub4_data","18|23|Absolute change from baseline in body weight|At 3 months","Absolute change from baseline in body weight",18,23,"At 3 months","or","binary",2,-0.0499937302932122,1.42835512711084,0,2014,0,97.5
"CD010966","CD010966_pub4_data","18|24|BMI (change from baseline) |Over 1 month and up to and including 6 months","BMI (change from baseline) ",18,24,"Over 1 month and up to and including 6 months","reported","reported",3,0.0190925385594977,0.0562735098053045,0,2015.5,0,233
"CD010966","CD010966_pub4_data","21|1|Quality of life: change in CFQ-R respiratory domain|At 1 month","Quality of life: change in CFQ-R respiratory domain",21,1,"At 1 month","or","binary",2,-0.334352638595846,1.42760942766568,0,2017.5,0,206
"CD010966","CD010966_pub4_data","21|8|Sweat chloride (change from baseline) (mmol/L)|At 1 month","Sweat chloride (change from baseline) (mmol/L)",21,8,"At 1 month","or","binary",2,-0.334352638595846,1.42760942766568,0,2017.5,0,206
"CD010966","CD010966_pub4_data","28|1|Quality of life: CFQ-R respiratory domain (change from baseline)|At up to 1 month","Quality of life: CFQ-R respiratory domain (change from baseline)",28,1,"At up to 1 month","or","binary",2,-0.259743576389018,1.42607344851395,0,2019,0,218
"CD010966","CD010966_pub4_data","28|9|Sweat chloride (absolute change from baseline)|At up to 1 month","Sweat chloride (absolute change from baseline)",28,9,"At up to 1 month","or","binary",2,-0.259743576389018,1.42607344851395,0,2019,0,218
"CD010966","CD010966_pub4_data","29|1|Quality of life: CFQ-R respiratory domain (change from baseline)|At up to 1 month","Quality of life: CFQ-R respiratory domain (change from baseline)",29,1,"At up to 1 month","or","binary",2,-0.545692768538349,1.43304131352288,0,2019,0,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Cough","Adverse events (at up to 1 month)",29,5,"Cough","or","binary",2,0.854874819083757,0.525715140989721,0,2019,0.10989010989011,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Haemoptysis","Adverse events (at up to 1 month)",29,5,"Haemoptysis","or","binary",2,-0.406827135196129,0.851926554385353,0.354798958833845,2019,0.0480769230769231,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Headache","Adverse events (at up to 1 month)",29,5,"Headache","or","binary",2,-0.722319223471166,0.784890165294817,0.221922199761331,2019,0.10989010989011,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Nasopharyngitis","Adverse events (at up to 1 month)",29,5,"Nasopharyngitis","or","binary",2,-0.035528106832839,0.819745219172793,0.37500184328641,2019,0.0906593406593407,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Number experiencing  severe adverse events","Adverse events (at up to 1 month)",29,5,"Number experiencing  severe adverse events","or","binary",2,-1.71774041276095,1.17965695244381,0,2019,0.081043956043956,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Number experiencing moderate adverse events","Adverse events (at up to 1 month)",29,5,"Number experiencing moderate adverse events","or","binary",2,-0.108614671876649,0.43343068824417,0,2019,0.177197802197802,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Number of participants experiencing at least one adverse event","Adverse events (at up to 1 month)",29,5,"Number of participants experiencing at least one adverse event","or","binary",2,0.228060104143721,0.679473598964633,0.505210908447035,2019,0.674450549450549,67.5
"CD010966","CD010966_pub4_data","29|5|Adverse events (at up to 1 month)|Oropharyngeal pain","Adverse events (at up to 1 month)",29,5,"Oropharyngeal pain","or","binary",2,0.426233048337538,1.67908988059835,3.76355350932726,2019,0.0714285714285714,67.5
"CD010966","CD010966_pub4_data","29|7|Sweat chloride (absolute change from baseline)|At up to 1 month","Sweat chloride (absolute change from baseline)",29,7,"At up to 1 month","or","binary",2,-0.545692768538349,1.43304131352288,0,2019,0,67.5
"CD010966","CD010966_pub4_data","30|4|Adverse events (at 1 month)|Infective pulmonary exacerbation","Adverse events (at 1 month)",30,4,"Infective pulmonary exacerbation","or","binary",2,-1.64597093349152,0.640517995441133,0,2019,0.307692307692308,68
"CD011039","CD011039_pub2_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","or","binary",2,-0.333653470464095,0.586389359983576,0.430353088758144,2001,0.628110599078341,65
"CD011039","CD011039_pub2_data","1|2|Morbidity due to any cause|","Morbidity due to any cause",1,2,"","or","binary",2,-0.0722407960488682,0.383680306739601,0,2001,0.656221198156682,65
"CD011039","CD011039_pub2_data","1|3|Morbidity (by type)|Encephalopathy","Morbidity (by type)",1,3,"Encephalopathy","or","binary",2,0.594494480643681,0.369352030309192,0,2001,0.505990783410138,65
"CD011039","CD011039_pub2_data","1|3|Morbidity (by type)|Refractory ascites","Morbidity (by type)",1,3,"Refractory ascites","or","binary",2,-1.72560556107538,0.423545109349089,0,2001,0.656221198156682,65
"CD011039","CD011039_pub2_data","1|4|Serious adverse events|","Serious adverse events",1,4,"","or","binary",2,0.447863555075356,1.31239756870153,2.68792097068224,2001,0.0949308755760369,65
"CD011039","CD011039_pub2_data","1|5|Serious adverse events (by type)|Gastrointestinal bleeding","Serious adverse events (by type)",1,5,"Gastrointestinal bleeding","or","binary",2,-0.279630411508403,0.488876366236295,0.00917187813043111,2001,0.178801843317972,65
"CD011039","CD011039_pub2_data","1|5|Serious adverse events (by type)|Heart failure","Serious adverse events (by type)",1,5,"Heart failure","or","binary",2,0.996442440707835,1.10728592514693,0.687208997507054,2001,0.0161290322580645,65
"CD011039","CD011039_pub2_data","1|6|Participants who did not receive a liver transplant|","Participants who did not receive a liver transplant",1,6,"","reported","reported",2,0,0.348203265314311,0,2001,0.867741935483871,65
"CD011039","CD011039_pub2_data","1|9|Improvement in liver function (parameters)|Albumin (g/dL)","Improvement in liver function (parameters)",1,9,"Albumin (g/dL)","or","binary",2,0.0327610599892942,1.42495365728762,0,2001,0,65
"CD011039","CD011039_pub2_data","1|9|Improvement in liver function (parameters)|Bilirubin (mg/dL)","Improvement in liver function (parameters)",1,9,"Bilirubin (mg/dL)","or","binary",2,0.0327610599892942,1.42495365728762,0,2001,0,65
"CD011039","CD011039_pub2_data","1|9|Improvement in liver function (parameters)|Prothrombin time","Improvement in liver function (parameters)",1,9,"Prothrombin time","or","binary",2,0.0327610599892942,1.42495365728762,0,2001,0,65
"CD011044","CD011044_pub3_data","1|1|Overall survival|","Overall survival",1,1,"","reported","reported",4,0.0804986296783578,0.104073017468498,0,1997,0,74.5
"CD011044","CD011044_pub3_data","2|1|Overall survival|Fixed dose rate gemcitabine","Overall survival",2,1,"Fixed dose rate gemcitabine","reported","reported",2,-0.236468211325503,0.0900528974965047,0,2003,0,322
"CD011044","CD011044_pub3_data","2|1|Overall survival|FOLFIRINOX","Overall survival",2,1,"FOLFIRINOX","reported","reported",2,-0.671552617801047,0.0826742369574579,0.00427054499999999,2012.5,0,326
"CD011044","CD011044_pub3_data","2|2|Progression-free survival|FOLFIRINOX","Progression-free survival",2,2,"FOLFIRINOX","reported","reported",2,-0.771358436700432,0.105892797327877,0,2012.5,0,326
"CD011044","CD011044_pub3_data","2|3|Degradation of QoL at 6 months|","Degradation of QoL at 6 months",2,3,"","reported","reported",2,-0.77597233666423,0.146230225170467,0,2012.5,NA,0
"CD011044","CD011044_pub3_data","2|4|Response rates|Fixed dose rate gemcitabine","Response rates",2,4,"Fixed dose rate gemcitabine","or","binary",2,0.483059598691244,0.301406422268878,0,2003,0.051317254174397,322
"CD011044","CD011044_pub3_data","2|5|Grade 3/4 anaemia|Fixed dose rate gemcitabine","Grade 3/4 anaemia",2,5,"Fixed dose rate gemcitabine","or","binary",2,0.684002170714377,0.227908164408491,0,2003,0.139109461966605,322
"CD011044","CD011044_pub3_data","2|6|Grade 3/4 neutropenia|Fixed dose rate gemcitabine","Grade 3/4 neutropenia",2,6,"Fixed dose rate gemcitabine","or","binary",2,1.08637282072948,0.16462819901862,0,2003,0.290834879406308,322
"CD011044","CD011044_pub3_data","2|7|Grade 3/4 thrombocytopaenia|Fixed dose rate gemcitabine","Grade 3/4 thrombocytopaenia",2,7,"Fixed dose rate gemcitabine","or","binary",2,1.28258974428056,0.206042098214123,0,2003,0.112838589981447,322
"CD011044","CD011044_pub3_data","2|8|Grade 3/4 nausea|Fixed dose rate gemcitabine","Grade 3/4 nausea",2,8,"Fixed dose rate gemcitabine","or","binary",2,0.459004142211331,0.269769690044237,0,2003,0.104155844155844,322
"CD011044","CD011044_pub3_data","2|9|Grade 3/4 diarrhoea|Fixed dose rate gemcitabine","Grade 3/4 diarrhoea",2,9,"Fixed dose rate gemcitabine","or","binary",2,-0.754261638749349,0.504371929865225,0,2003,0.0553617810760668,322
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus fluoropyrimidine","Overall survival",3,1,"Gemcitabine plus fluoropyrimidine","reported","reported",10,-0.130485734776425,0.0409146401903008,6.52944607923152e-06,2017,0,271.8
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus other agent(s)","Overall survival",3,1,"Gemcitabine plus other agent(s)","reported","reported",5,-0.152707560422566,0.145222870829778,0.06142392810007,2018,0,181.8
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus other combinations of chemotherapy","Overall survival",3,1,"Gemcitabine plus other combinations of chemotherapy","reported","reported",2,-0.595373728583084,0.182836669900382,0.01607712,2015,0,83
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus platinum agent","Overall survival",3,1,"Gemcitabine plus platinum agent","reported","reported",6,-0.0650277164244294,0.0755826076514996,0.00662991353370057,NA,0,190
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus taxane","Overall survival",3,1,"Gemcitabine plus taxane","reported","reported",2,-0.345482986231117,0.0702493160293003,0,2020,0,493
"CD011044","CD011044_pub3_data","3|1|Overall survival|Gemcitabine plus topoisomerase inhibitor","Overall survival",3,1,"Gemcitabine plus topoisomerase inhibitor","reported","reported",3,0.00777889331909052,0.0738860385340194,0,NA,0,279.666666666667
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus fluoropyrimidine","Progression-free survival",3,2,"Gemcitabine plus fluoropyrimidine","reported","reported",8,-0.230793092259496,0.0469573120339394,0.00539993697512772,2017,0,326
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus other agent(s)","Progression-free survival",3,2,"Gemcitabine plus other agent(s)","reported","reported",2,0.0823611003264903,0.129539762865481,0,2018,0,109
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus other combinations of chemotherapy","Progression-free survival",3,2,"Gemcitabine plus other combinations of chemotherapy","reported","reported",2,-0.836870119521912,0.186625201941183,0.01225574,2015,0,83
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus platinum agent","Progression-free survival",3,2,"Gemcitabine plus platinum agent","reported","reported",4,-0.222069994952532,0.0876946674493029,0.0142564606736419,NA,0,253.75
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus taxane","Progression-free survival",3,2,"Gemcitabine plus taxane","reported","reported",2,-0.398808659401178,0.0810070707191398,0,2020,0,493
"CD011044","CD011044_pub3_data","3|2|Progression-free survival|Gemcitabine plus topoisomerase inhibitor","Progression-free survival",3,2,"Gemcitabine plus topoisomerase inhibitor","reported","reported",2,-0.0921571090251416,0.0817628755624452,0,NA,0,354.5
"CD011044","CD011044_pub3_data","3|3|Response rates|Gemcitabine plus fluoropyrimidine","Response rates",3,3,"Gemcitabine plus fluoropyrimidine","or","binary",9,0.709363616224963,0.202928237144766,0.177225015342274,2017,0.118651206966711,241.777777777778
"CD011044","CD011044_pub3_data","3|3|Response rates|Gemcitabine plus other agent(s)","Response rates",3,3,"Gemcitabine plus other agent(s)","or","binary",4,0.983280815490517,0.667044183300606,1.31144226521179,2018,0.0660191869300912,208.25
"CD011044","CD011044_pub3_data","3|3|Response rates|Gemcitabine plus platinum agent","Response rates",3,3,"Gemcitabine plus platinum agent","or","binary",7,0.44873597991769,0.169371548498498,0,2004,0.0968194315988353,169.428571428571
"CD011044","CD011044_pub3_data","3|3|Response rates|Gemcitabine plus taxane","Response rates",3,3,"Gemcitabine plus taxane","or","binary",2,1.12086186633312,0.319550690190157,0.115098165161766,2020,0.145994832041344,493
"CD011044","CD011044_pub3_data","3|3|Response rates|Gemcitabine plus topoisomerase inhibitor","Response rates",3,3,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,0.422111567762717,0.271737786850538,0,NA,0.081992337164751,243
"CD011044","CD011044_pub3_data","3|4|Grade 3/4 anaemia|Gemcitabine plus fluoropyrimidine","Grade 3/4 anaemia",3,4,"Gemcitabine plus fluoropyrimidine","or","binary",8,0.105485446995424,0.153642424798907,0,2017,0.0645726999383642,269.75
"CD011044","CD011044_pub3_data","3|4|Grade 3/4 anaemia|Gemcitabine plus other agent(s)","Grade 3/4 anaemia",3,4,"Gemcitabine plus other agent(s)","or","binary",4,1.04762779522193,0.33809679700427,0.125373510190683,2018,0.0646374748037152,205.75
"CD011044","CD011044_pub3_data","3|4|Grade 3/4 anaemia|Gemcitabine plus platinum agent","Grade 3/4 anaemia",3,4,"Gemcitabine plus platinum agent","or","binary",7,0.417906741881755,0.289207626469103,0.210971929842608,2004,0.101075798075634,165.142857142857
"CD011044","CD011044_pub3_data","3|4|Grade 3/4 anaemia|Gemcitabine plus topoisomerase inhibitor","Grade 3/4 anaemia",3,4,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,0.0886889739273456,0.237722917182377,0,NA,0.0831559262230502,265.666666666667
"CD011044","CD011044_pub3_data","3|5|Grade 3/4 neutropenia|Gemcitabine plus fluoropyrimidine","Grade 3/4 neutropenia",3,5,"Gemcitabine plus fluoropyrimidine","or","binary",9,0.629259513484647,0.136323577055711,0.0360123799403815,2017,0.15710213397576,241.888888888889
"CD011044","CD011044_pub3_data","3|5|Grade 3/4 neutropenia|Gemcitabine plus other agent(s)","Grade 3/4 neutropenia",3,5,"Gemcitabine plus other agent(s)","or","binary",4,0.31694839230155,0.636446272446677,1.37659599099633,2018,0.189163157353694,205.75
"CD011044","CD011044_pub3_data","3|5|Grade 3/4 neutropenia|Gemcitabine plus platinum agent","Grade 3/4 neutropenia",3,5,"Gemcitabine plus platinum agent","or","binary",6,0.393353828956869,0.259725304091323,0.189850871587175,2004,0.206824763837423,160.166666666667
"CD011044","CD011044_pub3_data","3|5|Grade 3/4 neutropenia|Gemcitabine plus topoisomerase inhibitor","Grade 3/4 neutropenia",3,5,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,0.572630118707393,0.23548875521777,0.0769595989841059,NA,0.207722099882805,265.666666666667
"CD011044","CD011044_pub3_data","3|6|Grade 3/4 thrombocytopaenia|Gemcitabine plus fluoropyrimidine","Grade 3/4 thrombocytopaenia",3,6,"Gemcitabine plus fluoropyrimidine","or","binary",9,0.404741460609339,0.219724161411305,0.121782528996702,2017,0.0521023448303343,241.888888888889
"CD011044","CD011044_pub3_data","3|6|Grade 3/4 thrombocytopaenia|Gemcitabine plus other agent(s)","Grade 3/4 thrombocytopaenia",3,6,"Gemcitabine plus other agent(s)","or","binary",4,0.354076785522778,0.431279824333554,0.412026471329699,2018,0.0974221583236929,205.75
"CD011044","CD011044_pub3_data","3|6|Grade 3/4 thrombocytopaenia|Gemcitabine plus platinum agent","Grade 3/4 thrombocytopaenia",3,6,"Gemcitabine plus platinum agent","or","binary",6,0.732776509096192,0.391528227615147,0.545280197596698,NA,0.0898999297160767,185
"CD011044","CD011044_pub3_data","3|6|Grade 3/4 thrombocytopaenia|Gemcitabine plus topoisomerase inhibitor","Grade 3/4 thrombocytopaenia",3,6,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,0.895657437706573,0.439809975554546,0.289588126571218,NA,0.0621992738602244,265.666666666667
"CD011044","CD011044_pub3_data","3|7|Grade 3/4 nausea|Gemcitabine plus fluoropyrimidine","Grade 3/4 nausea",3,7,"Gemcitabine plus fluoropyrimidine","or","binary",7,0.250656971328371,0.197161905444708,0,2017,0.0388333576786139,296.428571428571
"CD011044","CD011044_pub3_data","3|7|Grade 3/4 nausea|Gemcitabine plus other agent(s)","Grade 3/4 nausea",3,7,"Gemcitabine plus other agent(s)","or","binary",5,0.646122156975534,0.553573136073358,0.577726568896643,2018,0.0288019823313941,176.6
"CD011044","CD011044_pub3_data","3|7|Grade 3/4 nausea|Gemcitabine plus platinum agent","Grade 3/4 nausea",3,7,"Gemcitabine plus platinum agent","or","binary",6,0.833594554196076,0.256254868590969,0,NA,0.0505069264342213,185
"CD011044","CD011044_pub3_data","3|7|Grade 3/4 nausea|Gemcitabine plus topoisomerase inhibitor","Grade 3/4 nausea",3,7,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,0.457760672495029,0.276810165395131,0,NA,0.0515469505180431,265.666666666667
"CD011044","CD011044_pub3_data","3|8|Grade 3/4 diarrhoea|Gemcitabine plus fluoropyrimidine","Grade 3/4 diarrhoea",3,8,"Gemcitabine plus fluoropyrimidine","or","binary",8,0.830261447832038,0.28272032109771,0.0918145177831863,2017,0.0140911095899437,260.875
"CD011044","CD011044_pub3_data","3|8|Grade 3/4 diarrhoea|Gemcitabine plus platinum agent","Grade 3/4 diarrhoea",3,8,"Gemcitabine plus platinum agent","or","binary",6,0.37066302886167,0.42262147455949,0.296211281595123,NA,0.0390472610242868,185
"CD011044","CD011044_pub3_data","3|8|Grade 3/4 diarrhoea|Gemcitabine plus topoisomerase inhibitor","Grade 3/4 diarrhoea",3,8,"Gemcitabine plus topoisomerase inhibitor","or","binary",3,1.16745516009313,0.777015644940067,1.12071495676224,NA,0.0175641115376539,265.666666666667
"CD011044","CD011044_pub3_data","4|1|Overall survival|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Overall survival",4,1,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","reported","reported",2,0.0913333333333333,0.149571239065388,0.016,2019,0,183.5
"CD011044","CD011044_pub3_data","4|1|Overall survival|Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","Overall survival",4,1,"Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","reported","reported",6,-0.262354457702241,0.0753321539713021,0.00556498824908062,2020.16666666667,0,214.166666666667
"CD011044","CD011044_pub3_data","4|10|Grade 3/4 fatigue|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 fatigue",4,10,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,0.0439929739171334,0.273070014041175,0,2019,0.178624078624079,181.5
"CD011044","CD011044_pub3_data","4|2|Progression-free survival|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Progression-free survival",4,2,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","reported","reported",2,-0.113928571428571,0.279934166823384,0.1278,2019,0,183.5
"CD011044","CD011044_pub3_data","4|2|Progression-free survival|Fluoropyrimidine-based combinations vs gemcitabine plus nab-paclitaxel","Progression-free survival",4,2,"Fluoropyrimidine-based combinations vs gemcitabine plus nab-paclitaxel","reported","reported",6,-0.413047740531845,0.0642155024508446,0,2020.16666666667,0,214.166666666667
"CD011044","CD011044_pub3_data","4|3|Response rate|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Response rate",4,3,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,0.345689152233072,0.482277441130225,0.341135836512039,2019,0.269374068554396,169
"CD011044","CD011044_pub3_data","4|3|Response rate|Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","Response rate",4,3,"Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","reported","reported",3,0,0.257042612236548,0,2020.66666666667,0.307754370162377,346.666666666667
"CD011044","CD011044_pub3_data","4|4|Grade 3/4 anaemia|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 anaemia",4,4,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,0.606580564537589,0.367020237431812,0,2019,0.0633906633906634,181.5
"CD011044","CD011044_pub3_data","4|4|Grade 3/4 anaemia|Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","Grade 3/4 anaemia",4,4,"Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","reported","reported",2,0,0.545851369897065,0,2022.5,0.137196218885945,462.5
"CD011044","CD011044_pub3_data","4|5|Grade 3/4 neutropenia|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 neutropenia",4,5,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,0.574089453275967,0.481009335680312,0.361581619710214,2019,0.312162162162162,181.5
"CD011044","CD011044_pub3_data","4|5|Grade 3/4 neutropenia|Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","Grade 3/4 neutropenia",4,5,"Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel","reported","reported",2,0,0.232846801066087,0,2022.5,0.242992182644817,462.5
"CD011044","CD011044_pub3_data","4|6|Grade 3/4 thrombocytopaenia|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 thrombocytopaenia",4,6,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,-0.581116516732206,0.380570975381287,0,2019,0.108599508599509,181.5
"CD011044","CD011044_pub3_data","4|8|Grade 3/4 diarrhoea|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 diarrhoea",4,8,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,-0.289008001751444,0.820368034877785,0.870758036351844,2019,0.0588452088452088,181.5
"CD011044","CD011044_pub3_data","4|8|Grade 3/4 diarrhoea|Fluoropyrimidine-based combinations vs gemcitabine plus nab-paclitaxel","Grade 3/4 diarrhoea",4,8,"Fluoropyrimidine-based combinations vs gemcitabine plus nab-paclitaxel","reported","reported",2,0,1.01402166267673,0,2022.5,0.0536093939096589,462.5
"CD011044","CD011044_pub3_data","4|9|Grade 3/4 neuropathy|Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","Grade 3/4 neuropathy",4,9,"Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing","or","binary",2,-0.335644585772762,0.359225947601482,0.0128080549540209,2019,0.104422604422604,181.5
"CD011044","CD011044_pub3_data","5|1|Overall survival|","Overall survival",5,1,"","reported","reported",4,-0.204064595130301,0.199742960460976,0.114616404791646,1989.75,0,122.75
"CD011044","CD011044_pub3_data","5|2|Progression-free survival|","Progression-free survival",5,2,"","reported","reported",2,-0.656200770760816,0.500727600043133,0.447963635,2003,0,127.5
"CD011044","CD011044_pub3_data","5|3|Response rates|","Response rates",5,3,"","or","binary",4,0.19056467945186,0.470024890976868,0.42233825060454,1989.75,0.131535283759989,102.5
"CD011044","CD011044_pub3_data","5|4|Grade 3/4 anaemia|","Grade 3/4 anaemia",5,4,"","or","binary",2,-0.78939247912317,1.09538098984042,1.4740730661238,2003,0.108722741433022,127.5
"CD011044","CD011044_pub3_data","5|5|Grade 3/4 neutropenia|","Grade 3/4 neutropenia",5,5,"","or","binary",2,1.82433910012285,1.07565079958552,0,2003,0,127.5
"CD011044","CD011044_pub3_data","5|6|Grade 3/4 thrombocytopaenia|","Grade 3/4 thrombocytopaenia",5,6,"","or","binary",2,0.223781877549184,0.665955040614815,0,2003,0.0426791277258567,127.5
"CD011044","CD011044_pub3_data","5|8|Grade 3/4 nausea|","Grade 3/4 nausea",5,8,"","or","binary",2,0.0205610388187795,0.587117350527537,0,2003,0.0520249221183801,127.5
"CD011044","CD011044_pub3_data","5|9|Grade 3/4 diarrhoea|","Grade 3/4 diarrhoea",5,9,"","or","binary",2,-0.117391306895764,0.550200804423969,0,2003,0.0566978193146417,127.5
"CD011120","CD011120_pub3_data","1|1|Tobacco use cessation|Behavioural support + NRT vs brief advice + NRT","Tobacco use cessation",1,1,"Behavioural support + NRT vs brief advice + NRT","or","binary",5,0.178048896511326,0.161092851211622,0.00977437159586441,2015.4,0.130474684247151,320.2
"CD011120","CD011120_pub3_data","1|1|Tobacco use cessation|Behavioural support + varenicline vs varenicline","Tobacco use cessation",1,1,"Behavioural support + varenicline vs varenicline","or","binary",2,-0.405155532128902,0.788620461585715,0,2015,0.0377492877492877,79
"CD011120","CD011120_pub3_data","1|1|Tobacco use cessation|Behavioural support vs brief advice","Tobacco use cessation",1,1,"Behavioural support vs brief advice","or","binary",2,-0.196170977166443,0.346508089388715,0,2016,0.0935143288084465,277.5
"CD011120","CD011120_pub3_data","3|1|Tobacco use cessation|","Tobacco use cessation",3,1,"","or","binary",2,1.223138722023,1.37785153692517,3.29546953268688,2016.5,0.0523023023023023,177.5
"CD011120","CD011120_pub3_data","5|1|Tobacco use cessation|","Tobacco use cessation",5,1,"","or","binary",2,0.702000337234073,0.337085521231789,0,2018.5,0.0653333333333333,213.5
"CD011120","CD011120_pub3_data","5|2|Adverse events|","Adverse events",5,2,"","or","binary",2,-0.16973547970812,0.285243537134509,0.0738419425996543,2018.5,0.463555555555556,213.5
"CD011120","CD011120_pub3_data","5|3|Serious adverse events|","Serious adverse events",5,3,"","or","binary",2,0.142514033951478,0.361256573610161,0,2018.5,0.0646666666666667,213.5
"CD011197","CD011197_pub3_data","1|1|Mortality|NA","Mortality",1,1,NA,"or","binary",9,0.0629162465183284,0.219085900203059,0,2014.625,0.0298237698754495,130.333333333333
"CD011197","CD011197_pub3_data","1|11|Quality of life, SF-36 physical role functioning|NA","Quality of life, SF-36 physical role functioning",1,11,NA,"or","binary",6,0.0219490740572218,0.821744879621758,0,2018.2,0,107
"CD011197","CD011197_pub3_data","1|12|Quality of life, SF-36 bodily pain|NA","Quality of life, SF-36 bodily pain",1,12,NA,"or","binary",8,0.00276340329622844,0.711981901331825,0,2018.42857142857,0,95.5
"CD011197","CD011197_pub3_data","1|13|Quality of life, SF-36 general health|NA","Quality of life, SF-36 general health",1,13,NA,"or","binary",8,0.00276340329622844,0.711981901331825,0,2018.42857142857,0,95.5
"CD011197","CD011197_pub3_data","1|14|Quality of life, SF-36 vitality|NA","Quality of life, SF-36 vitality",1,14,NA,"or","binary",8,0.00276340329622844,0.711981901331825,0,2018.42857142857,0,95.5
"CD011197","CD011197_pub3_data","1|16|Quality of life, SF-36 role emotional|NA","Quality of life, SF-36 role emotional",1,16,NA,"reported","reported",2,0,2.76642384330231,0,2013.5,0,50
"CD011197","CD011197_pub3_data","1|2|Serious adverse events|NA","Serious adverse events",1,2,NA,"reported","reported",2,0,0.0604580181030248,0,2023,0.0514285714285714,180
"CD011197","CD011197_pub3_data","1|3|AF recurrence|NA","AF recurrence",1,3,NA,"or","binary",4,-0.836419886719371,0.243906638197005,0,2019.25,0.435675549322113,94.5
"CD011197","CD011197_pub3_data","1|5|AFSS symptom burden|NA","AFSS symptom burden",1,5,NA,"reported","reported",3,0,0.617175410534952,0,2019.33333333333,0,105.666666666667
"CD011197","CD011197_pub3_data","1|6|AFSS episode frequency|NA","AFSS episode frequency",1,6,NA,"reported","reported",3,0,0.4637660133967,0,2019.33333333333,0,105.666666666667
"CD011197","CD011197_pub3_data","1|7|AFSS episode duration|NA","AFSS episode duration",1,7,NA,"reported","reported",3,0,0.276543642665829,0,2019.33333333333,0,105.666666666667
"CD011197","CD011197_pub3_data","1|9|Quality of life, SF-36 physical component score|NA","Quality of life, SF-36 physical component score",1,9,NA,"or","binary",6,0.0216797081863505,0.822004243467299,0,2019.4,0,84
"CD011204","CD011204_pub3_data","1|1|Cognitive function, assessed with ADAS-cog: change from baseline at 3 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Cognitive function, assessed with ADAS-cog: change from baseline at 3 months",1,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.0233702783479508,1.41756284946063,0,2005.5,0,359.5
"CD011204","CD011204_pub3_data","1|2|Cognitive function, assessed with ADAS-cog, change from baseline at 6 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Cognitive function, assessed with ADAS-cog, change from baseline at 6 months",1,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.395263362235473,0,2004,0,667.5
"CD011204","CD011204_pub3_data","1|2|Cognitive function, assessed with ADAS-cog, change from baseline at 6 months|Galantamine 32 mg/day (16 mg twice daily)","Cognitive function, assessed with ADAS-cog, change from baseline at 6 months",1,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.0200750511009223,1.41590259100236,0,2000,0,418
"CD011204","CD011204_pub3_data","10|2|Global rating, no change or improvement, galantamine 16 to 24 mg/day|","Global rating, no change or improvement, galantamine 16 to 24 mg/day",10,2,"","or","binary",3,0.547595696187178,0.249959598784189,0.121820512958925,2002,0.584790673025967,360.666666666667
"CD011204","CD011204_pub3_data","10|3|Global rating, no change or improvement, galantamine 24 to 32 mg/day|","Global rating, no change or improvement, galantamine 24 to 32 mg/day",10,3,"","or","binary",6,0.735438514158264,0.103297697173788,0,2000.66666666667,0.567720590964879,286.166666666667
"CD011204","CD011204_pub3_data","10|5|Global rating, no change or improvement, galantamine 32 to 36 mg/day|","Global rating, no change or improvement, galantamine 32 to 36 mg/day",10,5,"","or","binary",4,0.565410460427893,0.158966343630216,0.0283343111233191,2000,0.586726733170136,282.5
"CD011204","CD011204_pub3_data","14|2|DAD, change from baseline at 6 months (OC)|Galantamine 24 mg/day (12 mg twice daily)","DAD, change from baseline at 6 months (OC)",14,2,"Galantamine 24 mg/day (12 mg twice daily)","or","binary",2,-0.23305321878563,1.41686043799854,0,2001,0,287.5
"CD011204","CD011204_pub3_data","16|2|NPI, change from baseline at 6 months (OC)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","NPI, change from baseline at 6 months (OC)",16,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",3,-0.137406424653996,1.15641471902406,0,2002.33333333333,0,392.333333333333
"CD011204","CD011204_pub3_data","17|2|Proportion of all-cause discontinuations at 6 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of all-cause discontinuations at 6 months",17,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.141997767107065,0,2004,0.168048446398962,709
"CD011204","CD011204_pub3_data","17|2|Proportion of all-cause discontinuations at 6 months|Galantamine 16 to 24 mg/day prolonged/extended release","Proportion of all-cause discontinuations at 6 months",17,2,"Galantamine 16 to 24 mg/day prolonged/extended release","or","binary",2,0.0646674429338604,0.0888282792948678,0,2009.5,0.223426016436769,1347.5
"CD011204","CD011204_pub3_data","17|2|Proportion of all-cause discontinuations at 6 months|Galantamine 32 mg/day (16 mg twice daily)","Proportion of all-cause discontinuations at 6 months",17,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.957618228039694,0.172407838358487,0.00396880352282974,2000,0.163685991920515,428.5
"CD011204","CD011204_pub3_data","18|2|Proportion of discontinuations due to adverse events at 6 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of discontinuations due to adverse events at 6 months",18,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.198078508356516,0,2004,0.073624828779468,709
"CD011204","CD011204_pub3_data","18|2|Proportion of discontinuations due to adverse events at 6 months|Galantamine 32 mg/day (16 mg twice daily)","Proportion of discontinuations due to adverse events at 6 months",18,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,1.38374659564264,0.334057562711327,0.138082420061418,2000,0.0817447319576373,428.5
"CD011204","CD011204_pub3_data","2|2|Cognitive function, assessed with ADAS-cog: change from baseline at 6 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Cognitive function, assessed with ADAS-cog: change from baseline at 6 months",2,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",5,-0.0332840525088063,0.895810467960572,0,2001.4,0,353
"CD011204","CD011204_pub3_data","2|2|Cognitive function, assessed with ADAS-cog: change from baseline at 6 months|Galantamine 32 mg/day (16 mg twice daily)","Cognitive function, assessed with ADAS-cog: change from baseline at 6 months",2,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.205175869139617,1.41661986472199,0,2000,0,298.5
"CD011204","CD011204_pub3_data","21|1|Proportion of participants experiencing nausea|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants experiencing nausea",21,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.172434723790731,0,2004,0.0510777881911903,709
"CD011204","CD011204_pub3_data","21|1|Proportion of participants experiencing nausea|Galantamine 32 mg/day (16 mg twice daily)","Proportion of participants experiencing nausea",21,1,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,1.58902060685828,0.174396617287754,0,2000,0.126192815809586,428.5
"CD011204","CD011204_pub3_data","21|2|Proportion of participants experiencing vomiting|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants experiencing vomiting",21,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.203236718173302,0,2004,0.0482301203950688,709
"CD011204","CD011204_pub3_data","21|2|Proportion of participants experiencing vomiting|Galantamine 32 mg/day (16 mg twice daily) ","Proportion of participants experiencing vomiting",21,2,"Galantamine 32 mg/day (16 mg twice daily) ","or","binary",2,1.45259287597919,0.235087552007283,0,2000,0.0584889180041489,428.5
"CD011204","CD011204_pub3_data","21|3|Proportion of participants experiencing dizziness|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants experiencing dizziness",21,3,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",3,0.489924999879743,0.19313192331203,0.00132799800829259,2001.66666666667,0.067645894748335,502
"CD011204","CD011204_pub3_data","21|3|Proportion of participants experiencing dizziness|Galantamine 32 mg/day (16 mg twice daily)","Proportion of participants experiencing dizziness",21,3,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.718677253446705,0.223923286604901,0,2000,0.0795938421225025,428.5
"CD011204","CD011204_pub3_data","21|4|Proportion of participants experiencing diarrhoea|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants experiencing diarrhoea",21,4,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.192684258343657,0,2004,0.0761120322975993,709
"CD011204","CD011204_pub3_data","21|4|Proportion of participants experiencing diarrhoea|Galantamine 32 mg/day (16 mg twice daily)","Proportion of participants experiencing diarrhoea",21,4,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.714815955892505,0.214239146479858,0,2000,0.0865050769734687,428.5
"CD011204","CD011204_pub3_data","21|5|Proportion of participants experiencing anorexia|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants experiencing anorexia",21,5,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.217265137849056,0,2004,0.0389301420229255,709
"CD011204","CD011204_pub3_data","21|5|Proportion of participants experiencing anorexia|Galantamine 32 mg/day (16 mg twice daily)","Proportion of participants experiencing anorexia",21,5,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,2.30236288230529,1.2008192874364,2.0962928140947,2000,0.028169014084507,428.5
"CD011204","CD011204_pub3_data","21|6|Proportion of participants experiencing weight loss|Galantamine 32 mg/day (16 mg twice daily)","Proportion of participants experiencing weight loss",21,6,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,1.21721978980853,0.534531840867047,0.249956798824797,2000,0.0257997597991047,428.5
"CD011204","CD011204_pub3_data","23|2|Proportion of participants deceased at 6 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants deceased at 6 months",23,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","reported","reported",2,0,0.604975005488705,0,2004,0.00699300699300699,709
"CD011204","CD011204_pub3_data","24|1| ADAS-cog, change from baseline at 12 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," ADAS-cog, change from baseline at 12 months (ITT)",24,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.0268521880586262,1.4149596841983,0,2004,0,950.5
"CD011204","CD011204_pub3_data","24|2| ADAS-cog, change from baseline at 24 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," ADAS-cog, change from baseline at 24 months (ITT)",24,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.0268521880586262,1.4149596841983,0,2004,0,950.5
"CD011204","CD011204_pub3_data","25|1| ADAS-ADL-MCI, change from baseline at 12 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," ADAS-ADL-MCI, change from baseline at 12 months (ITT)",25,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.0268521880586262,1.4149596841983,0,2004,0,950.5
"CD011204","CD011204_pub3_data","25|2| ADAS-ADL-MCI, change from baseline at 24 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," ADAS-ADL-MCI, change from baseline at 24 months (ITT)",25,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.0268521880586262,1.4149596841983,0,2004,0,950.5
"CD011204","CD011204_pub3_data","26|1| CDR-SB, change from 0.5 to ≥ 1.0 at 24 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," CDR-SB, change from 0.5 to ≥ 1.0 at 24 months (ITT)",26,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,-0.296805599481729,0.121135114666271,0,2004,0.196510832481859,951.5
"CD011204","CD011204_pub3_data","27|1| Proportion of all-cause discontinuations at 24 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," Proportion of all-cause discontinuations at 24 months",27,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.538601009116495,0.0937148794790294,0,2004,0.286633325755854,1028.5
"CD011204","CD011204_pub3_data","28|1| Proportion of discontinuations due to adverse events at 24 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"," Proportion of discontinuations due to adverse events at 24 months",28,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,0.933777019012793,0.126763461031065,0,2004,0.102148215503524,1028.5
"CD011204","CD011204_pub3_data","30|1|Proportion of participants deceased at 24 months|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Proportion of participants deceased at 24 months",30,1,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",2,1.34268518283427,0.801490636453568,0,2004,0.00100401606425703,1028.5
"CD011204","CD011204_pub3_data","4|2|ADAS-cog, ≥ 4-point improvement at 6 months (OC)|Galantamine 24 mg/day (12 mg twice daily)","ADAS-cog, ≥ 4-point improvement at 6 months (OC)",4,2,"Galantamine 24 mg/day (12 mg twice daily)","or","binary",3,0.895129387443138,0.146184417100759,0,2000,0.171069144907563,350.333333333333
"CD011204","CD011204_pub3_data","4|2|ADAS-cog, ≥ 4-point improvement at 6 months (OC)|Galantamine 32 mg/day (16 mg twice daily) ","ADAS-cog, ≥ 4-point improvement at 6 months (OC)",4,2,"Galantamine 32 mg/day (16 mg twice daily) ","or","binary",2,1.00417665224175,0.197549051421547,0,2000,0.158825939583566,298.5
"CD011204","CD011204_pub3_data","7|2|Global rating, no change or improvement at 6 months (ITT)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Global rating, no change or improvement at 6 months (ITT)",7,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",6,0.478964176482061,0.121085532213101,0.0498358703089823,2002.5,0.538787241313645,500.333333333333
"CD011204","CD011204_pub3_data","7|2|Global rating, no change or improvement at 6 months (ITT)|Galantamine 32 mg/day (16 mg twice daily)","Global rating, no change or improvement at 6 months (ITT)",7,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.596150880744252,0.149392989228847,0,2000,0.531931738212526,384
"CD011204","CD011204_pub3_data","8|2|Global rating, no change or improvement at 6 months (OC)|Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","Global rating, no change or improvement at 6 months (OC)",8,2,"Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)","or","binary",5,0.629122224328216,0.140385578697128,0.051506484074352,2001.4,0.525408853301999,405.4
"CD011204","CD011204_pub3_data","8|2|Global rating, no change or improvement at 6 months (OC)|Galantamine 32 mg/day (16 mg twice daily)","Global rating, no change or improvement at 6 months (OC)",8,2,"Galantamine 32 mg/day (16 mg twice daily)","or","binary",2,0.669462037679178,0.169593428237929,0,2000,0.523855996530037,303
"CD011204","CD011204_pub3_data","9|2|Global rating, no change or improvement, galantamine 16 to 24 mg/day|","Global rating, no change or improvement, galantamine 16 to 24 mg/day",9,2,"","or","binary",4,0.424797571033839,0.174076191956659,0.0713905863085889,2003.5,0.578032174634765,416
"CD011204","CD011204_pub3_data","9|3|Global rating, no change or improvement, galantamine 24 to 32 mg/day|","Global rating, no change or improvement, galantamine 24 to 32 mg/day",9,3,"","or","binary",7,0.597102377373998,0.119282588925767,0.0435457765858192,2001.71428571429,0.567247980775928,350.142857142857
"CD011204","CD011204_pub3_data","9|4|Global rating, no change or improvement, galantamine 32 to 36 mg/day|","Global rating, no change or improvement, galantamine 32 to 36 mg/day",9,4,"","or","binary",4,0.50479857015775,0.133041129438876,0.0162538120381685,2000,0.595301869825558,353.25
"CD011305","CD011305_pub3_data","1|11|Adverse transfusion reactions (0 to 3 months)|NA","Adverse transfusion reactions (0 to 3 months)",1,11,NA,"or","binary",3,-0.0353600632017069,0.429504085580776,2.83723930483164e-06,2021,0.166203703703704,120.666666666667
"CD011305","CD011305_pub3_data","1|14|Number of participants with VOD (0 to 3 months)|NA","Number of participants with VOD (0 to 3 months)",1,14,NA,"or","binary",2,-1.41496125627641,1.87659916757259,5.08502657742148,2016.5,0.513333333333333,152.5
"CD011305","CD011305_pub3_data","1|15|Mean number of RBC transfusions (units) per participant (0 to 3 months)|NA","Mean number of RBC transfusions (units) per participant (0 to 3 months)",1,15,NA,"or","binary",5,-0.0742706357888822,0.91294110138079,0,2018.33333333333,0,91.4
"CD011305","CD011305_pub3_data","1|16|Interval between RBC transfusions (days) (0 to 3 months)|NA","Interval between RBC transfusions (days) (0 to 3 months)",1,16,NA,"or","binary",2,0.15309430306795,1.43597886691742,0,2022,0,31.5
"CD011305","CD011305_pub3_data","1|19|Number of PLT transfusions (doses) per participant (0 to 3 months)|NA","Number of PLT transfusions (doses) per participant (0 to 3 months)",1,19,NA,"or","binary",3,0.103395442685442,1.16711687863262,0,2021,0,120.666666666667
"CD011305","CD011305_pub3_data","1|2|All-cause mortality at 8 to 30 days|NA","All-cause mortality at 8 to 30 days",1,2,NA,"reported","reported",2,0,1.04747978999243,0,2020,0.0345833333333333,165
"CD011305","CD011305_pub3_data","1|3|All-cause mortality at 31 to 100 days|NA","All-cause mortality at 31 to 100 days",1,3,NA,"reported","reported",3,0,0.582660731855715,0,2020,0.0266666666666667,139.666666666667
"CD011305","CD011305_pub3_data","1|4|Death due to infection (0 to 3 months)|NA","Death due to infection (0 to 3 months)",1,4,NA,"or","binary",3,-0.171348615660432,0.891137559562994,0,2017.5,0.0393518518518519,23
"CD011305","CD011305_pub3_data","1|5|Death due to bleeding  (0 to 3 months)|NA","Death due to bleeding  (0 to 3 months)",1,5,NA,"or","binary",4,0.0796591693379172,1.02442823062183,0,2018.33333333333,0,92
"CD011305","CD011305_pub3_data","1|6|Chemotherapy-related mortality (0 to 30 days)|NA","Chemotherapy-related mortality (0 to 30 days)",1,6,NA,"reported","reported",2,0,1.04514633516517,0,NA,0.0440705128205128,64.5
"CD011305","CD011305_pub3_data","1|9|Clinically significant bleeding - WHO/CTCAE grade ≥ 2 or equivalent (0 to 3 months)|NA","Clinically significant bleeding - WHO/CTCAE grade ≥ 2 or equivalent (0 to 3 months)",1,9,NA,"reported","reported",2,0,1.03536286675601,0,2021,0.185555555555556,165.5
"CD011330","CD011330_pub2_data","1|1|Global symptoms score|Intramuscularly","Global symptoms score",1,1,"Intramuscularly","or","binary",4,-0.092909607439164,1.02115049965045,0,1995.5,0,27.25
"CD011330","CD011330_pub2_data","1|1|Global symptoms score|Nasally","Global symptoms score",1,1,"Nasally","or","binary",3,0,1.1712430733321,0,1993,0,40
"CD011330","CD011330_pub2_data","1|3|Withdrawal due to adverse events|Intramuscularly","Withdrawal due to adverse events",1,3,"Intramuscularly","or","binary",2,0,1.02410427774451,0,1996,0.0161290322580645,41
"CD011330","CD011330_pub2_data","1|3|Withdrawal due to adverse events|Nasally","Withdrawal due to adverse events",1,3,"Nasally","or","binary",2,2.27059262677502,1.08729359849275,0,1990,0,42
"CD011330","CD011330_pub2_data","1|4|Psychological symptoms|Intramuscularly","Psychological symptoms",1,4,"Intramuscularly","or","binary",3,-0.123988695641916,1.17964270751127,0,1996.33333333333,0,28.3333333333333
"CD011330","CD011330_pub2_data","1|4|Psychological symptoms|Nasally","Psychological symptoms",1,4,"Nasally","or","binary",3,0,1.1712430733321,0,1993,0,40
"CD011330","CD011330_pub2_data","1|5|Physical symptoms|Intramuscularly","Physical symptoms",1,5,"Intramuscularly","or","binary",3,-0.123988695641916,1.17964270751127,0,1996.33333333333,0,28.3333333333333
"CD011330","CD011330_pub2_data","1|5|Physical symptoms|Nasally","Physical symptoms",1,5,"Nasally","or","binary",3,0,1.1712430733321,0,1993,0,40
"CD011381","CD011381_pub3_data","1|1|Comparisons for relapse (12 months) |Glatiramer acetate versus placebo/no treatment","Comparisons for relapse (12 months) ",1,1,"Glatiramer acetate versus placebo/no treatment","or","binary",2,-0.93184432078922,0.503573608129461,0.371877238394733,2000,0.512451193058568,727
"CD011381","CD011381_pub3_data","1|1|Comparisons for relapse (12 months) |Immunoglobulins versus placebo/no treatment","Comparisons for relapse (12 months) ",1,1,"Immunoglobulins versus placebo/no treatment","or","binary",2,-1.96413455537831,0.59536183118254,0,2000,0.919444444444444,45.5
"CD011381","CD011381_pub3_data","1|1|Comparisons for relapse (12 months) |Interferon beta-1a and 1b versus azathioprine","Comparisons for relapse (12 months) ",1,1,"Interferon beta-1a and 1b versus azathioprine","or","binary",2,0.622621978907612,0.281770807490809,0,2010.5,0.233904393478862,122
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Dimethyl fumarate versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Dimethyl fumarate versus placebo/no treatment","or","binary",2,-0.763631807177742,0.0966753100720386,0.00148061355465636,2012,0.434502452462541,1153.5
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Fingolimod versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Fingolimod versus placebo/no treatment","or","binary",2,-1.00679809742445,0.146715804663037,0.0262851176520828,2012,0.509346991037132,1177.5
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Glatiramer acetate versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Glatiramer acetate versus placebo/no treatment","or","binary",3,-0.401730292994279,0.132184056859449,0,1998,0.60687568323932,338
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Immunoglobulins versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Immunoglobulins versus placebo/no treatment","or","binary",2,-1.30028100998713,1.02931816010967,1.38304616917745,1997.5,0.813333333333333,95
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","Comparisons for relapse (24 months)",1,2,"Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","or","binary",2,0.644061687110266,0.181025902911311,0.0335714671856908,2012,0.274795598231687,624
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Interferon beta-1a (Avonex, Rebif) versus interferon beta-1b (Betaferon)","Comparisons for relapse (24 months)",1,2,"Interferon beta-1a (Avonex, Rebif) versus interferon beta-1b (Betaferon)","or","binary",2,0.491329764813139,0.2472031156193,0,2004,0.528125,139
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","or","binary",3,-0.49820151002558,0.153428440054487,0.0255559120003191,2002.66666666667,0.653957014362694,543
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Interferon beta-1b (Betaferon) versus glatiramer acetate","Comparisons for relapse (24 months)",1,2,"Interferon beta-1b (Betaferon) versus glatiramer acetate","or","binary",2,0.262014656598775,0.376714029340843,0.200166561212089,2009,0.346382783882784,1159.5
"CD011381","CD011381_pub3_data","1|2|Comparisons for relapse (24 months)|Laquinimod versus placebo/no treatment","Comparisons for relapse (24 months)",1,2,"Laquinimod versus placebo/no treatment","or","binary",3,-0.328500691904696,0.0696554616375062,6.34949403961777e-10,2015.66666666667,0.437910860500789,1152.33333333333
"CD011381","CD011381_pub3_data","1|3|Comparisons for relapse (36 months)|Interferon beta-1b (Betaferon) versus placebo/no treatment","Comparisons for relapse (36 months)",1,3,"Interferon beta-1b (Betaferon) versus placebo/no treatment","or","binary",2,-0.492499091475582,0.289123829526902,0,1993,0.859465737514518,201.5
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Dimethyl fumerate versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Dimethyl fumerate versus placebo/no treatment","or","binary",2,-0.476783028023789,0.129611759479905,0.00809067020377039,2012,0.219781700579437,1153
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Fingolimod versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Fingolimod versus placebo/no treatment","or","binary",2,-0.448991922455315,0.119666455705171,0,2012,0.1832300020217,1177.5
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Glatiramer acetate versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Glatiramer acetate versus placebo/no treatment","or","binary",3,-0.286065758049046,0.196805370453082,0.0278842853823719,1998,0.298837727928637,338
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Immunoglobulins versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Immunoglobulins versus placebo/no treatment","or","binary",2,-0.335353138083909,0.369076350219633,0,1997.5,0.188333333333333,95
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","Comparisons for disability worsening (24 months)",1,4,"Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","or","binary",2,0.36478427435405,0.180310639950708,0,2012,0.10078670913153,624
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Interferon beta-1a (Avonex, Rebif) versus interferon beta-1b (Betaferon)","Comparisons for disability worsening (24 months)",1,4,"Interferon beta-1a (Avonex, Rebif) versus interferon beta-1b (Betaferon)","or","binary",2,0.582375464449507,0.380244266815992,0.186890197853549,2004,0.172138713080169,244.5
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","or","binary",2,-0.389683321721073,0.193645068937698,0,2005,0.217777777777778,534.5
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Laquinimod versus placebo/no treatment","Comparisons for disability worsening (24 months)",1,4,"Laquinimod versus placebo/no treatment","or","binary",3,-0.282645852367558,0.1527047010799,0.0263929123577295,2015.66666666667,0.108304419527441,1152.33333333333
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Ocrelizumab versus interferon beta-1a (Avonex, Rebif)","Comparisons for disability worsening (24 months)",1,4,"Ocrelizumab versus interferon beta-1a (Avonex, Rebif)","or","binary",2,-0.454212494801542,0.176954428115153,0,2017,0.104861523417036,828
"CD011381","CD011381_pub3_data","1|4|Comparisons for disability worsening (24 months)|Teriflunomide versus ofatumumab","Comparisons for disability worsening (24 months)",1,4,"Teriflunomide versus ofatumumab","or","binary",2,0.381352324285804,0.153741414807027,0,2020,0.0845192587128071,941
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Dimethyl fumarate versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Dimethyl fumarate versus placebo/no treatment","or","binary",2,0.184065827112137,0.132235405003942,0,2012,0.119743558580457,1150
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Fingolimod versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Fingolimod versus placebo/no treatment","or","binary",2,0.544568784131684,0.154940835952681,0.00619963115734282,2012,0.0903901880180605,1177.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Glatiramer acetate versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Glatiramer acetate versus placebo/no treatment","or","binary",4,0.472751324146742,0.375868017458589,0.229453897520857,2001.75,0.0314087219776433,604.25
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Immunoglobulins versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Immunoglobulins versus placebo/no treatment","or","binary",2,0.765318738045159,0.850061798089094,0,1999.5,0.00684931506849315,99.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","Number of patients who discontinued treatment due to adverse effects",2,1,"Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","or","binary",3,1.38325757215023,0.379863785283908,0.189955685590634,2010.66666666667,0.0200168703315242,504.666666666667
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Interferon beta-1a (Avonex, Rebif) versus glatiramer acetate","Number of patients who discontinued treatment due to adverse effects",2,1,"Interferon beta-1a (Avonex, Rebif) versus glatiramer acetate","or","binary",2,0.299880774109477,0.245301689620845,0,2010.5,0.0465688545688546,632.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment","or","binary",2,0.3585876790443,0.290632335168665,0,2006,0.023784907902555,728.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Interferon beta-1a and 1b versus azathioprine","Number of patients who discontinued treatment due to adverse effects",2,1,"Interferon beta-1a and 1b versus azathioprine","or","binary",2,-0.674921692713772,0.45611442019325,0.0471872639505574,2010.5,0.13336416897934,117.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Laquinimod versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Laquinimod versus placebo/no treatment","or","binary",3,0.395093758580518,0.163209054863943,0,2015.66666666667,0.0394192033760379,1152.33333333333
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Ocrelizumab versus interferon beta-1a (Avonex, Rebif)","Number of patients who discontinued treatment due to adverse effects",2,1,"Ocrelizumab versus interferon beta-1a (Avonex, Rebif)","or","binary",2,-0.574890832548115,0.235131654724242,0,2017,0.0617608602604469,825.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Ozanimod versus interferon beta-1a (Avonex, Rebif)","Number of patients who discontinued treatment due to adverse effects",2,1,"Ozanimod versus interferon beta-1a (Avonex, Rebif)","or","binary",2,-0.388997593496352,0.226432112582906,0,2015.5,0.0383856913551938,1329.5
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Teriflunomide versus ofatumumab","Number of patients who discontinued treatment due to adverse effects",2,1,"Teriflunomide versus ofatumumab","or","binary",2,-0.0897050233992169,0.201076201382024,0,2020,0.0570987861310442,941
"CD011381","CD011381_pub3_data","2|1|Number of patients who discontinued treatment due to adverse effects|Teriflunomide versus placebo/no treatment","Number of patients who discontinued treatment due to adverse effects",2,1,"Teriflunomide versus placebo/no treatment","or","binary",2,0.591387143434853,0.318594579558673,0.150162388294002,2006,0.0708727386328136,1126.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Dimethyl fumarate versus placebo/no treatment","Number of patients with any serious adverse effect",2,2,"Dimethyl fumarate versus placebo/no treatment","or","binary",2,0.0462837490004482,0.224110070946323,0.041827717257567,2012,0.0704302382109869,1150
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Fingolimod versus placebo/no treatment","Number of patients with any serious adverse effect",2,2,"Fingolimod versus placebo/no treatment","or","binary",2,-0.0261208673106374,0.177395460353152,0.0280331738664665,2012,0.126777410876744,1177.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Glatiramer acetate versus placebo/no treatment","Number of patients with any serious adverse effect",2,2,"Glatiramer acetate versus placebo/no treatment","or","binary",3,-0.0443407503140845,0.195151636561748,3.96946608102502e-06,2006.66666666667,0.0408960438540403,789.666666666667
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Interferon beta-1b (Avonex, Rebif) versus alemtuzumab","Number of patients with any serious adverse effect",2,2,"Interferon beta-1b (Avonex, Rebif) versus alemtuzumab","or","binary",3,-0.216557400904148,0.174763180072235,0.0141130327407094,2010.66666666667,0.169299881241745,504.666666666667
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Interferon beta-1b (Avonex, Rebif) versus glatiramer acetate","Number of patients with any serious adverse effect",2,2,"Interferon beta-1b (Avonex, Rebif) versus glatiramer acetate","or","binary",2,0.191453204979467,0.189295457317124,0,2010.5,0.0939150579150579,632.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Interferon beta-1b (Betaferon) versus glatiramer acetate","Number of patients with any serious adverse effect",2,2,"Interferon beta-1b (Betaferon) versus glatiramer acetate","or","binary",2,0.0504394972129662,0.151922486288306,0,2009,0.153788533563814,1147.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Laquinimod versus placebo/no treatment","Number of patients with any serious adverse effect",2,2,"Laquinimod versus placebo/no treatment","or","binary",3,0.17257085708888,0.160527492365366,0.0269849832494613,2015.66666666667,0.0731759817371328,1152.33333333333
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Ocrelizumab versus interferon beta-1b (Avonex, Rebif)","Number of patients with any serious adverse effect",2,2,"Ocrelizumab versus interferon beta-1b (Avonex, Rebif)","or","binary",2,-0.188922679658615,0.187118578158069,0,2017,0.0810158718990578,825.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Ozanimod versus interferon beta-1b (Avonex, Rebif)","Number of patients with any serious adverse effect",2,2,"Ozanimod versus interferon beta-1b (Avonex, Rebif)","or","binary",2,0.182610591056575,0.201921504131516,0,2015.5,0.040724604448521,1329.5
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Teriflunomide versus ofatumumab","Number of patients with any serious adverse effect",2,2,"Teriflunomide versus ofatumumab","or","binary",2,-0.268365266727128,0.164414653493488,0,2020,0.0974224845192587,941
"CD011381","CD011381_pub3_data","2|2|Number of patients with any serious adverse effect|Teriflunomide versus placebo/no treatment","Number of patients with any serious adverse effect",2,2,"Teriflunomide versus placebo/no treatment","or","binary",2,0.139367938200555,0.13605731928652,0,2012.5,0.117218340859391,1126.5
"CD011381","CD011381_pub3_data","3|10|Comparisons for quality of life - mental (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)|Interferon beta 1a Avonex Rebif versus Ozanimod","Comparisons for quality of life - mental (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)",3,10,"Interferon beta 1a Avonex Rebif versus Ozanimod","or","binary",2,-0.688598629372874,1.41480891048003,0,2015.5,0,1333
"CD011381","CD011381_pub3_data","3|11|Mortality|Dimethyl fumarate versus placebo/ no treatment","Mortality",3,11,"Dimethyl fumarate versus placebo/ no treatment","or","binary",2,-0.103100860734689,0.927001926625971,0,2012,0.00137741046831956,1153.5
"CD011381","CD011381_pub3_data","3|11|Mortality|Fingolimod versus placebo/ no treatment","Mortality",3,11,"Fingolimod versus placebo/ no treatment","or","binary",2,-1.39724323146893,0.874110611871272,0,2012,0.00380079520183301,1177.5
"CD011381","CD011381_pub3_data","3|11|Mortality|Glatiramer acetate versus placebo/ no treatment","Mortality",3,11,"Glatiramer acetate versus placebo/ no treatment","or","binary",2,-0.582184815158666,0.94432191088908,0,2012.5,0.00246200916680112,1058.5
"CD011381","CD011381_pub3_data","3|11|Mortality|Interferon beta 1a (Avonex, Rebif) versus alemtuzumab","Mortality",3,11,"Interferon beta 1a (Avonex, Rebif) versus alemtuzumab","or","binary",3,-0.786270579447146,0.911437207818648,0,2010.66666666667,0.00538214646796771,527.333333333333
"CD011381","CD011381_pub3_data","3|11|Mortality|Interferon beta 1a (Avonex, Rebif) versus glatiramer acetate","Mortality",3,11,"Interferon beta 1a (Avonex, Rebif) versus glatiramer acetate","or","binary",2,0.384632968557449,0.944969983795086,0,2010.5,0.00193050193050193,636.5
"CD011381","CD011381_pub3_data","3|11|Mortality|Interferon beta 1a (Avonex, Rebif) versus placebo/ no treatment","Mortality",3,11,"Interferon beta 1a (Avonex, Rebif) versus placebo/ no treatment","or","binary",3,-0.338693331977387,0.818783427355304,0,2002.66666666667,0.00561394881881697,543
"CD011381","CD011381_pub3_data","3|11|Mortality|Laquinimod versus placebo/ no treatment","Mortality",3,11,"Laquinimod versus placebo/ no treatment","or","binary",4,-0.589728392718667,0.57815879801477,0,2015.25,0.00302459653898503,1242.25
"CD011381","CD011381_pub3_data","3|11|Mortality|Ocrelizumab versus interferon beta 1a (Avonex, Rebif)","Mortality",3,11,"Ocrelizumab versus interferon beta 1a (Avonex, Rebif)","or","binary",2,-0.365037415593769,0.944225210325494,0,2017,0.00241271726096928,828
"CD011381","CD011381_pub3_data","3|2|Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (24 months) |Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (24 months) ",3,2,"Interferon beta-1a (Avonex, Rebif) versus alemtuzumab","or","binary",2,1.09652676903415,0.181629709227593,0,2012,0.0818605890976943,572
"CD011381","CD011381_pub3_data","3|2|Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (24 months) |Ocrelizumab versus interferon beta-1a (Avonex, Rebif) ","Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (24 months) ",3,2,"Ocrelizumab versus interferon beta-1a (Avonex, Rebif) ","or","binary",2,-1.59802500847135,0.141231734690406,0,2017,0.331473591077894,828
"CD011381","CD011381_pub3_data","3|4|Comparisons for new or enlarging T2-weighted MRI lesions (24 months)|Interferon beta 1a (Avonex, Rebif) versus alemtuzumab","Comparisons for new or enlarging T2-weighted MRI lesions (24 months)",3,4,"Interferon beta 1a (Avonex, Rebif) versus alemtuzumab","or","binary",2,0.591476854208334,0.307190475798529,0.154752824100812,2012,0.473193473193473,565.5
"CD011381","CD011381_pub3_data","3|4|Comparisons for new or enlarging T2-weighted MRI lesions (24 months)|Ocrelizumab versus interferon beta 1a (Avonex, Rebif)","Comparisons for new or enlarging T2-weighted MRI lesions (24 months)",3,4,"Ocrelizumab versus interferon beta 1a (Avonex, Rebif)","or","binary",2,-0.932226503769515,0.100858196667346,0,2017,0.616377955505885,828
"CD011381","CD011381_pub3_data","3|8|Comparisons for quality of life - physical (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)|Interferon beta 1a Avonex Rebif  versus Ozanimod","Comparisons for quality of life - physical (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)",3,8,"Interferon beta 1a Avonex Rebif  versus Ozanimod","or","binary",2,-0.688598629372874,1.41480891048003,0,2015.5,0,1333
"CD011468","CD011468_pub2_data","1|1|Secondary patency|","Secondary patency",1,1,"","or","binary",2,-0.842924423431537,0.88212749527374,0.860826951313058,2015,0.235042735042735,67
"CD011468","CD011468_pub2_data","2|1|Post-thrombotic syndrome|VCSS","Post-thrombotic syndrome",2,1,"VCSS","or","binary",2,-0.012529480205309,1.42502061724934,0,2015,0,66.5
"CD011468","CD011468_pub2_data","2|2|Secondary patency|","Secondary patency",2,2,"","or","binary",2,-1.88990847332979,0.803367701662969,0.914869745545544,2015,0.531339031339031,66.5
"CD011468","CD011468_pub2_data","2|3|Quality of life|CIVIQ","Quality of life",2,3,"CIVIQ","or","binary",2,-0.012529480205309,1.42502061724934,0,2015,0,66.5
"CD011535","CD011535_pub7_data","1|1|Non-targeted treatments versus placebo|Fumaric acid esters","Non-targeted treatments versus placebo",1,1,"Fumaric acid esters","reported","reported",3,3.63487693370959,1.18927467315004,0,2008.33333333333,0.0331843424082351,388
"CD011535","CD011535_pub7_data","1|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",1,1,"Methotrexate","reported","reported",3,1.20871770634678,0.619993185683343,0,2012,0.0377358490566038,106.333333333333
"CD011535","CD011535_pub7_data","1|10|Anti-TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti-TNF alpha versus other biologics",1,10,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,0.68285889259741,0.0323027711870335,3.40547448171581e-06,2016,0.632821908130762,552.666666666667
"CD011535","CD011535_pub7_data","1|10|Anti-TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti-TNF alpha versus other biologics",1,10,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.335183779021263,0.0488513414678977,0.00361759573035454,2015,0.659264565425024,1104.5
"CD011535","CD011535_pub7_data","1|11|Anti-IL12/23 versus other biologics|Brodalumab","Anti-IL12/23 versus other biologics",1,11,"Brodalumab","reported","reported",2,0.787386173520244,0.0360515693406654,0,2015,0.60077581398751,1544
"CD011535","CD011535_pub7_data","1|11|Anti-IL12/23 versus other biologics|Risankizumab","Anti-IL12/23 versus other biologics",1,11,"Risankizumab","reported","reported",3,0.600663830271065,0.0464198489796821,0,2015.33333333333,0.70687880415324,321
"CD011535","CD011535_pub7_data","1|11|Anti-IL12/23 versus other biologics|Secukinumab","Anti-IL12/23 versus other biologics",1,11,"Secukinumab","reported","reported",2,0.715157178417618,0.0252301814990964,0,2015.5,0.774418667386026,889
"CD011535","CD011535_pub7_data","1|13|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",1,13,"Apremilast","reported","reported",7,5.17561939520978,1.4325958367693,0,2015.14285714286,0.0209487417125149,410.428571428571
"CD011535","CD011535_pub7_data","1|14|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",1,14,"Deucravacitinib","reported","reported",4,12.9633760374746,3.9713544447236,0,2018.25,0.0263388477066719,437.75
"CD011535","CD011535_pub7_data","1|15|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",1,15,"Deucravacitinib","reported","reported",2,0.511040705024177,0.0773747982119569,0,2018,0.31274019758093,632.5
"CD011535","CD011535_pub7_data","1|2|Ciclosporin versus methotrexate|","Ciclosporin versus methotrexate",1,2,"","reported","reported",4,0.803861729881804,0.173467828936723,0.0674863604640744,2009.25,0.587647819660015,65.5
"CD011535","CD011535_pub7_data","1|3|Fumaric acid esters versus methotrexate|","Fumaric acid esters versus methotrexate",1,3,"","reported","reported",2,0.240405889128113,0.124045275462279,0,2013,0.227777777777778,84
"CD011535","CD011535_pub7_data","1|4|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",1,4,"Adalimumab","reported","reported",9,10.690095144516,3.17433460498207,27.8066833237331,2012,0.0346507655902753,380.111111111111
"CD011535","CD011535_pub7_data","1|4|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",1,4,"Certolizumab","reported","reported",5,14.7941775266622,11.0940436120522,0,2015.2,0.015474664442048,230.6
"CD011535","CD011535_pub7_data","1|4|Anti-TNF alpha versus placebo|Etanercept","Anti-TNF alpha versus placebo",1,4,"Etanercept","reported","reported",15,7.54846429226635,1.97749746808623,0,2010.07692307692,0.0152141321485864,384.066666666667
"CD011535","CD011535_pub7_data","1|4|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",1,4,"Infliximab","reported","reported",5,32.8361973688081,34.4748068372666,0,2007.6,0.00748050968639204,329
"CD011535","CD011535_pub7_data","1|5|Anti-IL12/23 versus placebo|","Anti-IL12/23 versus placebo",1,5,"","reported","reported",11,12.6910586277264,2.65625346777187,0,2012.63636363636,0.0233020545988523,410.909090909091
"CD011535","CD011535_pub7_data","1|6|Anti-IL17 versus placebo|Bimekizumab","Anti-IL17 versus placebo",1,6,"Bimekizumab","reported","reported",4,18.1149157495718,9.91159470001262,0,2018.5,0.0149551695152704,284
"CD011535","CD011535_pub7_data","1|6|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",1,6,"Brodalumab","reported","reported",6,20.7815446697126,5.7349371184601,0,2015.5,0.0139403623307558,695.166666666667
"CD011535","CD011535_pub7_data","1|6|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",1,6,"Ixekizumab","reported","reported",5,23.253671354705,9.11502355600504,0,2014.66666666667,0.0128816215621813,741.2
"CD011535","CD011535_pub7_data","1|6|Anti-IL17 versus placebo|Netakimab","Anti-IL17 versus placebo",1,6,"Netakimab","reported","reported",2,3.65540432820049,1.67556613238251,0,2019.5,0.0892857142857143,166.5
"CD011535","CD011535_pub7_data","1|6|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",1,6,"Secukinumab","reported","reported",17,12.1049468307665,3.56979493304212,0,2016.13333333333,0.0143881207845288,279.647058823529
"CD011535","CD011535_pub7_data","1|7|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",1,7,"Guselkumab","reported","reported",5,26.7010506159207,8.73888450977504,0,2016.5,0.0153477408761057,353.4
"CD011535","CD011535_pub7_data","1|7|Anti-IL23 versus placebo|JNJ-77242113","Anti-IL23 versus placebo",1,7,"JNJ-77242113","reported","reported",2,18.320203260451,29.3360670941827,0,2022,0.0116279069767442,172
"CD011535","CD011535_pub7_data","1|7|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",1,7,"Risankizumab","reported","reported",6,9.76431001066459,5.59334114762953,52.004027645782,2017.5,0.0612254851837581,280.5
"CD011535","CD011535_pub7_data","1|7|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",1,7,"Tildrakizumab","reported","reported",5,14.3004658424091,5.06897559505773,0,2019.25,0.022790922322922,471
"CD011535","CD011535_pub7_data","1|8|Biologics versus non-targeted treatements|Experimental: Etanercept; Control: Acitretin","Biologics versus non-targeted treatements",1,8,"Experimental: Etanercept; Control: Acitretin","reported","reported",2,2.85556855519386,6.03277902450706,0,2008.5,0.025,51
"CD011535","CD011535_pub7_data","2|1|Non-targeted treatments versus placebo|Fumaric acid esters","Non-targeted treatments versus placebo",2,1,"Fumaric acid esters","reported","reported",2,0.853759022419874,0.448752016901212,0,2017.5,0.0274617364215089,565
"CD011535","CD011535_pub7_data","2|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",2,1,"Methotrexate","reported","reported",2,0.0828848293544242,0.17161297147485,0,2012,0.0783994795055303,141.5
"CD011535","CD011535_pub7_data","2|10|Anti-TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti-TNF alpha versus other biologics",2,10,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,0.8961655101686,0.420050095112476,0,2016,0.0182894062012113,552.666666666667
"CD011535","CD011535_pub7_data","2|10|Anti-TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti-TNF alpha versus other biologics",2,10,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.836874866392434,0.336806609185563,0,2015,0.0190399473760494,1104.5
"CD011535","CD011535_pub7_data","2|11|Anti-IL12/23 versus other biologics|Brodalumab","Anti-IL12/23 versus other biologics",2,11,"Brodalumab","reported","reported",2,0.583807932621906,0.343746308433393,0,2015,0.0153559444240533,1544
"CD011535","CD011535_pub7_data","2|11|Anti-IL12/23 versus other biologics|Risankizumab","Anti-IL12/23 versus other biologics",2,11,"Risankizumab","reported","reported",3,1.18458889306507,0.587040181314001,0,2015.33333333333,0.0435786887854557,321
"CD011535","CD011535_pub7_data","2|11|Anti-IL12/23 versus other biologics|Secukinumab","Anti-IL12/23 versus other biologics",2,11,"Secukinumab","reported","reported",2,0.737081448916174,0.258371830040107,0,2015.5,0.0275640679794982,889
"CD011535","CD011535_pub7_data","2|14|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",2,14,"Apremilast","reported","reported",9,0.484234700504798,0.18502582191385,0,2015.44444444444,0.0216219671003788,381.777777777778
"CD011535","CD011535_pub7_data","2|14|Phosphodiesterase-4 inhibitors versus placebo|Orismilast","Phosphodiesterase-4 inhibitors versus placebo",2,14,"Orismilast","reported","reported",2,1.92892854317759,4.4199465964346,0,2023,0.0277777777777778,119
"CD011535","CD011535_pub7_data","2|15|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",2,15,"Deucravacitinib","reported","reported",4,0.416391736371828,0.220443736073259,0,2018.25,0.025429327271992,437.75
"CD011535","CD011535_pub7_data","2|16|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",2,16,"Deucravacitinib","reported","reported",2,0.451981417226965,0.440257390019334,0,2018,0.0183699573244053,632.5
"CD011535","CD011535_pub7_data","2|2|Ciclosporin versus methotrexate|","Ciclosporin versus methotrexate",2,2,"","or","binary",3,0.00608496007189832,1.16225877747734,0,2011.33333333333,0,77.3333333333333
"CD011535","CD011535_pub7_data","2|4|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",2,4,"Adalimumab","reported","reported",10,0.714642180763849,0.266818606644719,0.0058147186458482,2012,0.0213860857326763,348.5
"CD011535","CD011535_pub7_data","2|4|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",2,4,"Certolizumab","reported","reported",5,0.178353418112972,0.132662427656815,0,2015.2,0.0325475664773561,230.6
"CD011535","CD011535_pub7_data","2|4|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",2,4,"Infliximab","reported","reported",5,0.849074795332998,0.47200586034399,0,2007.6,0.0205288132919712,329
"CD011535","CD011535_pub7_data","2|5|Anti-IL12/23 versus placebo|","Anti-IL12/23 versus placebo",2,5,"","reported","reported",11,0.639113705366239,0.22995240394623,0,2012.54545454545,0.0221920467507649,436.272727272727
"CD011535","CD011535_pub7_data","2|6|Anti-IL17 versus placebo|Bimekizumab","Anti-IL17 versus placebo",2,6,"Bimekizumab","reported","reported",3,0.517232390216262,0.477090990235358,0,2017.66666666667,0.0237205744350603,363
"CD011535","CD011535_pub7_data","2|6|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",2,6,"Brodalumab","reported","reported",5,0.680039659105228,0.260101974387296,0,2014,0.0203363439490164,821.8
"CD011535","CD011535_pub7_data","2|6|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",2,6,"Ixekizumab","reported","reported",5,0.521708507112307,0.252496524627621,0.0181487194449445,2014.66666666667,0.0241080743716499,741.2
"CD011535","CD011535_pub7_data","2|6|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",2,6,"Secukinumab","reported","reported",18,0.575030072856437,0.252788411779012,0,2016.375,0.0190680800325826,267.666666666667
"CD011535","CD011535_pub7_data","2|7|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",2,7,"Guselkumab","reported","reported",5,0.892391930761528,0.558425219379067,0,2016.5,0.0168795354626834,353.4
"CD011535","CD011535_pub7_data","2|7|Anti-IL23 versus placebo|JNJ-77242113","Anti-IL23 versus placebo",2,7,"JNJ-77242113","reported","reported",2,1.59943056051104,5.67256239920387,0,2022,0,172
"CD011535","CD011535_pub7_data","2|7|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",2,7,"Risankizumab","reported","reported",7,0.270062957774686,0.135972750990614,0,2018,0.0195510322355543,265.285714285714
"CD011535","CD011535_pub7_data","2|7|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",2,7,"Tildrakizumab","reported","reported",5,0.632779026237929,0.42820449005709,0,2019.25,0.0100548913452139,471
"CD011535","CD011535_pub7_data","3|1|Non-targeted treatments versus placebo|Fumaric acid esters","Non-targeted treatments versus placebo",3,1,"Fumaric acid esters","reported","reported",2,2.37142389160815,0.368588528828133,0,2017.5,0.165921712041176,565
"CD011535","CD011535_pub7_data","3|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",3,1,"Methotrexate","reported","reported",2,1.98496904244721,0.608371743851609,0,2012,0.146063760572544,141.5
"CD011535","CD011535_pub7_data","3|10|Anti-TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti-TNF alpha versus other biologics",3,10,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,0.806208342698355,0.0227767870033694,5.83195374366286e-07,2016,0.831970391767921,552.666666666667
"CD011535","CD011535_pub7_data","3|10|Anti-TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti-TNF alpha versus other biologics",3,10,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.560457789702626,0.0627273580457895,0.00686089510408261,2015,0.847002181515466,1104.5
"CD011535","CD011535_pub7_data","3|11|Anti-IL12/23 versus other biologics|Brodalumab","Anti-IL12/23 versus other biologics",3,11,"Brodalumab","reported","reported",2,0.907329907679712,0.0262122997797337,0,2015,0.767635253133886,1544
"CD011535","CD011535_pub7_data","3|11|Anti-IL12/23 versus other biologics|Risankizumab","Anti-IL12/23 versus other biologics",3,11,"Risankizumab","reported","reported",3,0.821199882514606,0.0371966540681628,0.000551185316472801,2015.33333333333,0.875039781994669,321
"CD011535","CD011535_pub7_data","3|11|Anti-IL12/23 versus other biologics|Secukinumab","Anti-IL12/23 versus other biologics",3,11,"Secukinumab","reported","reported",2,0.876076823015349,0.016882144624966,0,2015.5,0.919606150526032,889
"CD011535","CD011535_pub7_data","3|13|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",3,13,"Apremilast","reported","reported",8,3.41447233348348,0.540629738948943,0.910908762643012,2014.875,0.0853161028957633,391.625
"CD011535","CD011535_pub7_data","3|13|Phosphodiesterase-4 inhibitors versus placebo|Orismilast","Phosphodiesterase-4 inhibitors versus placebo",3,13,"Orismilast","reported","reported",2,2.89741066216625,1.0361784521398,0,2023,0.106209150326797,119
"CD011535","CD011535_pub7_data","3|14|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",3,14,"Deucravacitinib","reported","reported",4,10.6857420699918,1.80697191789613,0,2018.25,0.0920928547257392,437.75
"CD011535","CD011535_pub7_data","3|15|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",3,15,"Deucravacitinib","reported","reported",2,0.478399819988875,0.0995832758043467,0.0126349029608285,2018,0.557335015207602,632.5
"CD011535","CD011535_pub7_data","3|15|Apremilast versus other systemic treatements|Methotrexate","Apremilast versus other systemic treatements",3,15,"Methotrexate","reported","reported",3,1.75565143345452,0.812909122687516,0,2023.66666666667,0.623992673992674,68
"CD011535","CD011535_pub7_data","3|2|Ciclosporin versus methotrexate|","Ciclosporin versus methotrexate",3,2,"","reported","reported",3,1.00623587007641,0.0321171840982391,1.5457317721841e-06,2011.33333333333,0.603473762010347,77.3333333333333
"CD011535","CD011535_pub7_data","3|3|Fumaric acid esters versus methotrexate|","Fumaric acid esters versus methotrexate",3,3,"","reported","reported",2,0.329058854586965,0.0879545991741506,0,2013,0.451851851851852,84
"CD011535","CD011535_pub7_data","3|4|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",3,4,"Adalimumab","reported","reported",10,7.26039320891953,1.18377547348649,4.81584777024756,2012,0.0821510179195399,348.5
"CD011535","CD011535_pub7_data","3|4|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",3,4,"Certolizumab","reported","reported",5,8.36166215064407,2.2967060962419,0,2015.2,0.0757247550087077,230.6
"CD011535","CD011535_pub7_data","3|4|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",3,4,"Infliximab","reported","reported",6,10.3879223933573,5.90039964364717,43.9702429759021,2006.5,0.051344788109494,279.666666666667
"CD011535","CD011535_pub7_data","3|5|Anti-IL12/23 versus placebo|","Anti-IL12/23 versus placebo",3,5,"","reported","reported",12,9.40430549159815,0.950695331571045,0,2012.66666666667,0.0637837225789432,403.5
"CD011535","CD011535_pub7_data","3|6|Anti-IL17 versus placebo|Bimekizumab","Anti-IL17 versus placebo",3,6,"Bimekizumab","reported","reported",2,13.188655368994,5.2040607938281,0,2017.5,0.0599541021227768,327
"CD011535","CD011535_pub7_data","3|6|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",3,6,"Brodalumab","reported","reported",6,10.513511828939,1.50174464715808,0,2015.5,0.041240617479759,695.166666666667
"CD011535","CD011535_pub7_data","3|6|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",3,6,"Ixekizumab","reported","reported",5,13.5259453146931,2.2353283584537,3.1344566352782e-06,2014.66666666667,0.0578822135970231,741.2
"CD011535","CD011535_pub7_data","3|6|Anti-IL17 versus placebo|Netakimab","Anti-IL17 versus placebo",3,6,"Netakimab","reported","reported",2,3.80621587713456,1.51130999447987,0,2019.5,0.107142857142857,166.5
"CD011535","CD011535_pub7_data","3|6|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",3,6,"Secukinumab","reported","reported",17,11.552787275197,2.00772178322791,5.05802450176319,2016.13333333333,0.0384005981654234,279.647058823529
"CD011535","CD011535_pub7_data","3|7|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",3,7,"Guselkumab","reported","reported",5,11.8357050470533,2.0548919644211,0,2016.5,0.0496470946554373,353.4
"CD011535","CD011535_pub7_data","3|7|Anti-IL23 versus placebo|JNJ-77242113","Anti-IL23 versus placebo",3,7,"JNJ-77242113","reported","reported",2,6.39341755145313,3.41814051701773,0,2022,0.0673449612403101,172
"CD011535","CD011535_pub7_data","3|7|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",3,7,"Risankizumab","reported","reported",5,8.64867604406512,2.20477618531571,8.16410607906961,2017.2,0.107577780537502,305.2
"CD011535","CD011535_pub7_data","3|7|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",3,7,"Tildrakizumab","reported","reported",5,7.77782009075594,1.66208491971268,3.94999642486052,2019.25,0.073091036076937,471
"CD011535","CD011535_pub7_data","3|8|Biologics versus non-targeted treatements|Experimental: Etanercept; Control: Acitretin","Biologics versus non-targeted treatements",3,8,"Experimental: Etanercept; Control: Acitretin","reported","reported",3,1.8687896668782,0.489053138384263,0,2011,0.25906432748538,47.3333333333333
"CD011535","CD011535_pub7_data","4|1|Non-targeted treatments versus placebo|Fumaric acid esters","Non-targeted treatments versus placebo",4,1,"Fumaric acid esters","reported","reported",3,2.13276465970701,0.390325482196842,0.0659827885620499,2008.33333333333,0.109598627477538,388
"CD011535","CD011535_pub7_data","4|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",4,1,"Methotrexate","reported","reported",3,2.80926574858106,1.14754142599455,0,2012,0.0803321979409851,106.333333333333
"CD011535","CD011535_pub7_data","4|10|Anti TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti TNF alpha versus other biologics",4,10,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,0.791104203337694,0.0254951642584855,0,2016,0.793096545412949,552.666666666667
"CD011535","CD011535_pub7_data","4|10|Anti TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti TNF alpha versus other biologics",4,10,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.497676083927507,0.0362359598887228,0.00147264934045247,2015,0.780154712928174,1104.5
"CD011535","CD011535_pub7_data","4|11|Anti IL12/23 versus other biologics|Brodalumab","Anti IL12/23 versus other biologics",4,11,"Brodalumab","reported","reported",2,0.855197195211104,0.0364048759319618,0.000726160826237557,2015,0.690415996697941,1544
"CD011535","CD011535_pub7_data","4|11|Anti IL12/23 versus other biologics|Risankizumab","Anti IL12/23 versus other biologics",4,11,"Risankizumab","reported","reported",3,0.735638120516105,0.0389996011827977,0,2015.33333333333,0.833579484425349,321
"CD011535","CD011535_pub7_data","4|11|Anti IL12/23 versus other biologics|Secukinumab","Anti IL12/23 versus other biologics",4,11,"Secukinumab","reported","reported",2,0.778070797380152,0.0293905872224612,0.000556005639701114,2015.5,0.80370650121392,889
"CD011535","CD011535_pub7_data","4|14|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",4,14,"Apremilast","reported","reported",8,3.3581489247061,0.538590687857334,0.739381895796673,2015.75,0.076305847325277,397
"CD011535","CD011535_pub7_data","4|14|Phosphodiesterase-4 inhibitors versus placebo|Orismilast","Phosphodiesterase-4 inhibitors versus placebo",4,14,"Orismilast","reported","reported",2,3.11469983763146,1.76525585425448,0,2023,0.0669934640522876,119
"CD011535","CD011535_pub7_data","4|15|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",4,15,"Deucravacitinib","reported","reported",4,11.7586257654567,2.20564042890877,0,2018.25,0.0731994751661655,437.75
"CD011535","CD011535_pub7_data","4|16|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",4,16,"Deucravacitinib","reported","reported",2,0.465147321649729,0.0593870734677071,0,2018,0.515626105203593,632.5
"CD011535","CD011535_pub7_data","4|2|Ciclosporin versus methotrexate|","Ciclosporin versus methotrexate",4,2,"","reported","reported",2,0.591378685754346,0.173616116762652,0.0200066696769015,2003,0.626515151515151,59
"CD011535","CD011535_pub7_data","4|4|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",4,4,"Adalimumab","reported","reported",9,7.00146376409249,0.806575485023683,0.14595078887691,2012.75,0.0881112969191798,370.777777777778
"CD011535","CD011535_pub7_data","4|4|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",4,4,"Certolizumab","reported","reported",5,15.7193451181725,11.4543744465269,0,2015.2,0.0188233723462623,230.6
"CD011535","CD011535_pub7_data","4|4|Anti-TNF alpha versus placebo|Etanercept","Anti-TNF alpha versus placebo",4,4,"Etanercept","reported","reported",13,6.94271225364691,1.09378736336363,2.25828553233299,2011.09090909091,0.0469176191719219,386.846153846154
"CD011535","CD011535_pub7_data","4|4|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",4,4,"Infliximab","reported","reported",3,10.1161833074177,4.73959894505644,0,2009,0.0702969545074808,187
"CD011535","CD011535_pub7_data","4|5|Anti IL12/23 versus placebo|","Anti IL12/23 versus placebo",4,5,"","reported","reported",12,9.92770189306504,1.49745314164801,8.73722068592117,2012.66666666667,0.0638512579434782,403.5
"CD011535","CD011535_pub7_data","4|6|Anti-IL17 versus placebo|Bimekizumab","Anti-IL17 versus placebo",4,6,"Bimekizumab","reported","reported",4,17.0340189778684,8.07144607898183,0,2018.5,0.0268599314200323,284
"CD011535","CD011535_pub7_data","4|6|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",4,6,"Brodalumab","reported","reported",6,17.1724510099798,3.36530052010315,0,2015.5,0.0287814207972614,695.166666666667
"CD011535","CD011535_pub7_data","4|6|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",4,6,"Ixekizumab","reported","reported",5,15.3194557445062,3.91869964338279,21.6512672114479,2014.66666666667,0.0463629237071527,741.2
"CD011535","CD011535_pub7_data","4|6|Anti-IL17 versus placebo|Netakimab","Anti-IL17 versus placebo",4,6,"Netakimab","reported","reported",2,2.93690897871076,0.938246638065224,0,2019.5,0.154220779220779,166.5
"CD011535","CD011535_pub7_data","4|6|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",4,6,"Secukinumab","reported","reported",13,12.2224103183889,3.79900430313023,43.8404109335636,2016.08333333333,0.0288125997522981,332.538461538462
"CD011535","CD011535_pub7_data","4|7|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",4,7,"Guselkumab","reported","reported",5,10.589521206945,1.69079205693734,0,2016.5,0.0606393016049579,353.4
"CD011535","CD011535_pub7_data","4|7|Anti-IL23 versus placebo|JNJ-77242113","Anti-IL23 versus placebo",4,7,"JNJ-77242113","reported","reported",2,4.82683549569081,2.24839114383343,0,2022,0.0789728682170543,172
"CD011535","CD011535_pub7_data","4|7|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",4,7,"Risankizumab","reported","reported",7,6.81875481930056,1.77673488276262,9.79316719796446,2018,0.105174093383722,265.285714285714
"CD011535","CD011535_pub7_data","4|7|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",4,7,"Tildrakizumab","reported","reported",5,7.49579816594375,1.44976135068929,0,2019.25,0.0527788913431491,471
"CD011535","CD011535_pub7_data","4|8|Biologics versus non-targeted treatements|Experimental: Etanercept; Control: Acitretin","Biologics versus non-targeted treatements",4,8,"Experimental: Etanercept; Control: Acitretin","reported","reported",2,3.52632265697743,5.6136685300981,0,2012,0.0513157894736842,41
"CD011535","CD011535_pub7_data","5|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",5,1,"Methotrexate","reported","reported",2,-0.666435803608078,0.372612203801476,0.238858136943636,2012,NA,141.5
"CD011535","CD011535_pub7_data","5|10|Anti IL12/23 versus other biologics|Risankizumab","Anti IL12/23 versus other biologics",5,10,"Risankizumab","reported","reported",2,0.297815917983032,0.0821916137704233,0,2016,NA,398.5
"CD011535","CD011535_pub7_data","5|11|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",5,11,"Apremilast","reported","reported",8,-0.607683187029914,0.0456446210874211,0.0044015637598639,2015.75,NA,397
"CD011535","CD011535_pub7_data","5|12|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",5,12,"Deucravacitinib","reported","reported",3,-0.920099207901536,0.0813386125015322,0.00818430346232217,2018,NA,510.333333333333
"CD011535","CD011535_pub7_data","5|13|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",5,13,"Deucravacitinib","reported","reported",2,0.327565018373081,0.0599944346121607,0,2018,NA,632.5
"CD011535","CD011535_pub7_data","5|3|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",5,3,"Adalimumab","reported","reported",9,-0.981143268260246,0.0701479722068708,0.0223301850365601,2011.5,NA,340
"CD011535","CD011535_pub7_data","5|3|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",5,3,"Certolizumab","reported","reported",3,-0.918235181144372,0.104127722306586,0,2016.33333333333,NA,196
"CD011535","CD011535_pub7_data","5|3|Anti-TNF alpha versus placebo|Etanercept","Anti-TNF alpha versus placebo",5,3,"Etanercept","reported","reported",9,-1.05475126474925,0.120297477339383,0.112456174437118,2010.85714285714,NA,379.444444444444
"CD011535","CD011535_pub7_data","5|3|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",5,3,"Infliximab","reported","reported",5,-1.25804207415085,0.114076251649395,0.0367900332347442,2007.6,NA,329
"CD011535","CD011535_pub7_data","5|4|Anti IL12/23 versus placebo|","Anti IL12/23 versus placebo",5,4,"","reported","reported",8,-1.41742427761251,0.103674308704694,0.0582824797292477,2012.25,NA,379.875
"CD011535","CD011535_pub7_data","5|5|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",5,5,"Brodalumab","reported","reported",2,-0.575127555428693,0.131917508589768,0,2012,NA,174.5
"CD011535","CD011535_pub7_data","5|5|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",5,5,"Ixekizumab","reported","reported",4,-1.84269239415852,0.158805766147048,0.0908069920119308,2016,NA,891
"CD011535","CD011535_pub7_data","5|5|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",5,5,"Secukinumab","reported","reported",3,-1.39742046750989,0.154851204804939,0,2018,NA,74.3333333333333
"CD011535","CD011535_pub7_data","5|6|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",5,6,"Guselkumab","reported","reported",4,-1.32752707540075,0.0809701335895193,0.0105869750874531,2016.66666666667,NA,422.25
"CD011535","CD011535_pub7_data","5|6|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",5,6,"Risankizumab","reported","reported",2,-1.81968684573445,0.111072113460056,0.007119712076877,2016,NA,399
"CD011535","CD011535_pub7_data","5|6|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",5,6,"Tildrakizumab","reported","reported",5,-1.28935690480089,0.0809004917034112,0.0167335914083813,2019.25,NA,471
"CD011535","CD011535_pub7_data","5|9|Anti TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti TNF alpha versus other biologics",5,9,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,0.217790593934283,0.0524094784270657,5.87122634582732e-06,2016,NA,552.666666666667
"CD011535","CD011535_pub7_data","5|9|Anti TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti TNF alpha versus other biologics",5,9,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.43833534867838,0.0466841553914506,0.000206086285262967,2015,NA,1104.5
"CD011535","CD011535_pub7_data","6|1|Non-targeted treatments versus placebo|Fumaric acid esters","Non-targeted treatments versus placebo",6,1,"Fumaric acid esters","reported","reported",2,1.30670625687464,0.111890836358706,0.011364241507765,2017.5,0.535419206284708,565
"CD011535","CD011535_pub7_data","6|1|Non-targeted treatments versus placebo|Methotrexate","Non-targeted treatments versus placebo",6,1,"Methotrexate","reported","reported",2,0.939884019858426,0.0665839336577105,0.00355823343755077,2012,0.86174365647365,141.5
"CD011535","CD011535_pub7_data","6|10|Anti TNF alpha versus other biologics|Experimental: Adalimumab; Control: Guselkumab","Anti TNF alpha versus other biologics",6,10,"Experimental: Adalimumab; Control: Guselkumab","reported","reported",3,1.01286137001753,0.0529496161956082,0,2016,0.495233318500305,552.666666666667
"CD011535","CD011535_pub7_data","6|10|Anti TNF alpha versus other biologics|Experimental: Etanercept; Control: Ixekizumab","Anti TNF alpha versus other biologics",6,10,"Experimental: Etanercept; Control: Ixekizumab","reported","reported",2,0.940971003807226,0.0403892403681636,0.000328919702811123,2015,0.573233139709899,1104.5
"CD011535","CD011535_pub7_data","6|11|Anti IL12/23 versus other biologics|Brodalumab","Anti IL12/23 versus other biologics",6,11,"Brodalumab","reported","reported",2,0.995010505539748,0.0394704527586039,0,2015,0.566336700266333,1544
"CD011535","CD011535_pub7_data","6|11|Anti IL12/23 versus other biologics|Risankizumab","Anti IL12/23 versus other biologics",6,11,"Risankizumab","reported","reported",3,1.02130238622622,0.0671116099438604,3.67311484552247e-07,2015.33333333333,0.574111369694077,321
"CD011535","CD011535_pub7_data","6|11|Anti IL12/23 versus other biologics|Secukinumab","Anti IL12/23 versus other biologics",6,11,"Secukinumab","reported","reported",2,0.9378821038206,0.0419065896378837,0,2015.5,0.556263825195576,889
"CD011535","CD011535_pub7_data","6|14|Phosphodiesterase-4 inhibitors versus placebo|Apremilast","Phosphodiesterase-4 inhibitors versus placebo",6,14,"Apremilast","reported","reported",9,1.19944814798671,0.0472184369807394,0.00307074665402892,2015.44444444444,0.479794488566817,381.777777777778
"CD011535","CD011535_pub7_data","6|14|Phosphodiesterase-4 inhibitors versus placebo|Orismilast","Phosphodiesterase-4 inhibitors versus placebo",6,14,"Orismilast","reported","reported",2,1.42976402311574,0.413058876124411,0.293820512755505,2023,0.669934640522876,119
"CD011535","CD011535_pub7_data","6|15|TYK-2 inhibitors versus placebo|Deucravacitinib","TYK-2 inhibitors versus placebo",6,15,"Deucravacitinib","reported","reported",4,1.33648685279402,0.171573939151206,0.0198183185479241,2018.25,0.43943952811777,437.75
"CD011535","CD011535_pub7_data","6|16|Apremilast versus other systemic treatements|Deucravacitinib","Apremilast versus other systemic treatements",6,16,"Deucravacitinib","reported","reported",2,1.08315771567799,0.133011208919055,0,2018,0.551753000259354,632.5
"CD011535","CD011535_pub7_data","6|2|Ciclosporin versus methotrexate|","Ciclosporin versus methotrexate",6,2,"","reported","reported",3,1.11515850582422,0.116174439941875,0.00515616279841731,2011.33333333333,0.562996209140977,77.3333333333333
"CD011535","CD011535_pub7_data","6|3|Fumaric acid esters versus methotrexate|","Fumaric acid esters versus methotrexate",6,3,"","reported","reported",2,0.980593998591197,0.0904301386074746,0.00692954139053054,2013,0.848148148148148,84
"CD011535","CD011535_pub7_data","6|4|Anti-TNF alpha versus placebo|Adalimumab","Anti-TNF alpha versus placebo",6,4,"Adalimumab","reported","reported",10,1.02854754639229,0.0341098316982839,0.00181524591829518,2012,0.585172666441386,348.5
"CD011535","CD011535_pub7_data","6|4|Anti-TNF alpha versus placebo|Certolizumab","Anti-TNF alpha versus placebo",6,4,"Certolizumab","reported","reported",5,0.924619049468804,0.050372596692519,0,2015.2,0.657300013259953,230.6
"CD011535","CD011535_pub7_data","6|4|Anti-TNF alpha versus placebo|Etanercept","Anti-TNF alpha versus placebo",6,4,"Etanercept","reported","reported",11,1.06248806030839,0.0403293261593234,0.00404476618437742,2012.44444444444,0.500156246344006,384
"CD011535","CD011535_pub7_data","6|4|Anti-TNF alpha versus placebo|Infliximab","Anti-TNF alpha versus placebo",6,4,"Infliximab","reported","reported",4,1.20799389166574,0.0665853347590838,2.28639926010701e-07,2008.25,0.535467108570824,316.75
"CD011535","CD011535_pub7_data","6|5|Anti IL12/23 versus placebo|","Anti IL12/23 versus placebo",6,5,"","reported","reported",12,1.05952207249005,0.0304114163616723,0,2012.66666666667,0.492220782065299,403.5
"CD011535","CD011535_pub7_data","6|6|Anti-IL17 versus placebo|Bimekizumab","Anti-IL17 versus placebo",6,6,"Bimekizumab","reported","reported",3,1.36704907395284,0.140628984340392,0.0140377232793137,2017.66666666667,0.411333039800398,363
"CD011535","CD011535_pub7_data","6|6|Anti-IL17 versus placebo|Brodalumab","Anti-IL17 versus placebo",6,6,"Brodalumab","reported","reported",6,1.12872343435442,0.0401631618885724,0,2015.5,0.513040458850372,695.166666666667
"CD011535","CD011535_pub7_data","6|6|Anti-IL17 versus placebo|Ixekizumab","Anti-IL17 versus placebo",6,6,"Ixekizumab","reported","reported",5,1.25829286006206,0.0949135554280941,0.0248508664436569,2014.66666666667,0.458683144623782,741.2
"CD011535","CD011535_pub7_data","6|6|Anti-IL17 versus placebo|Netakimab","Anti-IL17 versus placebo",6,6,"Netakimab","reported","reported",2,0.900174414057938,0.203163757056193,0,2019.5,0.298701298701299,166.5
"CD011535","CD011535_pub7_data","6|6|Anti-IL17 versus placebo|Secukinumab","Anti-IL17 versus placebo",6,6,"Secukinumab","reported","reported",17,1.10884514795883,0.0608590229669381,0.0303628514478411,2016.4,0.534646379296769,271.764705882353
"CD011535","CD011535_pub7_data","6|7|Anti-IL23 versus placebo|Guselkumab","Anti-IL23 versus placebo",6,7,"Guselkumab","reported","reported",5,0.985810834602738,0.0523349357584904,0,2016.5,0.543128608506807,353.4
"CD011535","CD011535_pub7_data","6|7|Anti-IL23 versus placebo|JNJ-77242113","Anti-IL23 versus placebo",6,7,"JNJ-77242113","reported","reported",2,0.955303317571428,0.126226986677192,0,2022,0.547480620155039,172
"CD011535","CD011535_pub7_data","6|7|Anti-IL23 versus placebo|Risankizumab","Anti-IL23 versus placebo",6,7,"Risankizumab","reported","reported",7,0.954162018190718,0.0568629541133283,0,2018,0.416260153676224,265.285714285714
"CD011535","CD011535_pub7_data","6|7|Anti-IL23 versus placebo|Tildrakizumab","Anti-IL23 versus placebo",6,7,"Tildrakizumab","reported","reported",5,0.941177879826701,0.0826662116904222,0.0198265980862066,2019.25,0.502628153077699,471
"CD011535","CD011535_pub7_data","6|8|Biologics versus non-targeted treatements|Experimental: Etanercept; Control: Acitretin","Biologics versus non-targeted treatements",6,8,"Experimental: Etanercept; Control: Acitretin","reported","reported",2,1.15959271024565,0.323624299200136,0,2012,0.338157894736842,41
"CD011535","CD011535_pub7_data","7|1|Biologic 1 versus biologic 2|Risankizumab versus ustekinumab","Biologic 1 versus biologic 2",7,1,"Risankizumab versus ustekinumab","or","binary",2,1.58751606931395,0.189115724381232,0.00993061892876917,2016,0.468211527035056,399.5
"CD011535","CD011535_pub7_data","7|1|Biologic 1 versus biologic 2|Secukinumab 150 versus secukinumab 300","Biologic 1 versus biologic 2",7,1,"Secukinumab 150 versus secukinumab 300","or","binary",3,-0.711033045715855,0.148775099355892,0,2015.5,0.759900626917434,339
"CD011535","CD011535_pub7_data","7|1|Biologic 1 versus biologic 2|Secukinumab versus ustekinumab","Biologic 1 versus biologic 2",7,1,"Secukinumab versus ustekinumab","or","binary",2,0.620675837959456,0.102118076044775,0,2015.5,0.598323072976786,889
"CD011535","CD011535_pub7_data","8|1|Biologic 1 versus biologic 2|Risankizumab versus ustekinumab","Biologic 1 versus biologic 2",8,1,"Risankizumab versus ustekinumab","or","binary",2,1.45463313871363,0.220772012143464,0.003042322105466,2016,0.726975638740345,399.5
"CD011535","CD011535_pub7_data","8|1|Biologic 1 versus biologic 2|Secukinumab versus ustekinumab","Biologic 1 versus biologic 2",8,1,"Secukinumab versus ustekinumab","or","binary",2,0.793800256274765,0.238662786856422,0.073598163966542,2015.5,0.796756765422598,889
"CD011575","CD011575_pub3_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","or","binary",4,0.143361153136202,0.204933077119635,0.122986532903467,2013,0.0490582147581711,4183
"CD011575","CD011575_pub3_data","1|10|Total minor adverse events|","Total minor adverse events",1,10,"","or","binary",2,-0.00705041376566617,0.0558581143414374,0,2009,0.215260391977855,3748.5
"CD011575","CD011575_pub3_data","1|11|Withdrawals due to adverse effects|","Withdrawals due to adverse effects",1,11,"","or","binary",3,-0.0234409207175375,0.218783312314349,0.073133644197643,2013,0.0135671553731897,5336
"CD011575","CD011575_pub3_data","1|12|Mean systolic BP achieved|","Mean systolic BP achieved",1,12,"","or","binary",4,0.00187706218948715,1.00025867690194,0,2013,0,3835.75
"CD011575","CD011575_pub3_data","1|13|Mean diastolic BP achieved|","Mean diastolic BP achieved",1,13,"","or","binary",4,0.00187706218948715,1.00025867690194,0,2013,0,3835.75
"CD011575","CD011575_pub3_data","1|15|Stroke (excluding Wei)|","Stroke (excluding Wei)",1,15,"","or","binary",3,0.226457078512123,0.156030870724159,0.0200906386491971,2013,0.0138534127905398,5336
"CD011575","CD011575_pub3_data","1|16|Serious cardiovascular adverse events (excluding Wei)|","Serious cardiovascular adverse events (excluding Wei)",1,16,"","reported","reported",2,0,1.00278682270098,0,2015.5,0.0325330050561099,5795
"CD011575","CD011575_pub3_data","1|17|Cardiovascular mortality (excluding Wei)|","Cardiovascular mortality (excluding Wei)",1,17,"","reported","reported",3,0,0.83364846872796,0,2013,0.00514357953300756,5336
"CD011575","CD011575_pub3_data","1|18|All-cause mortality (excluding JATOS)|New Subgroup","All-cause mortality (excluding JATOS)",1,18,"New Subgroup","reported","reported",3,0,0.107889275035569,0,2014.66666666667,0.0572735208228297,4104.66666666667
"CD011575","CD011575_pub3_data","1|19|Serious cardioavascular adverse events (excluding JATOS)|","Serious cardioavascular adverse events (excluding JATOS)",1,19,"","reported","reported",2,0,1.00173834476738,0,2017,0.0724190678018373,4617.5
"CD011575","CD011575_pub3_data","1|2|Stroke|","Stroke",1,2,"","or","binary",4,0.295641619517086,0.139630542059742,0.0197918796090321,2013,0.0248528695102602,4183
"CD011575","CD011575_pub3_data","1|20|Stroke (excluding JATOS)|","Stroke (excluding JATOS)",1,20,"","reported","reported",2,0,1.0044135540682,0,2017,0.0345819950409328,4617.5
"CD011575","CD011575_pub3_data","1|21|Cardiovascular mortality (excluding JATOS)|","Cardiovascular mortality (excluding JATOS)",1,21,"","or","binary",3,0.445565539156439,0.218554947127022,0.0442883309124197,2014.66666666667,0.026744181973656,4104.66666666667
"CD011575","CD011575_pub3_data","1|3|Serious cardiovascular adverse events|","Serious cardiovascular adverse events",1,3,"","or","binary",4,0.236901871989195,0.11388633108097,0.0244829036378545,2013,0.0535344225635239,4183
"CD011575","CD011575_pub3_data","1|4|Cardiovascular mortality|","Cardiovascular mortality",1,4,"","or","binary",4,0.327842410764151,0.221893897959868,0.0743413033483862,2013,0.0210753155037502,4183
"CD011575","CD011575_pub3_data","1|5|Non-cardiovascular mortality|","Non-cardiovascular mortality",1,5,"","or","binary",4,0.0167384290349106,0.177842965945686,0.0593957057347472,2013,0.0279828992544209,4183
"CD011575","CD011575_pub3_data","1|7|Heart failure (decompensation/hospitalisation/death)|","Heart failure (decompensation/hospitalisation/death)",1,7,"","or","binary",3,0.647039183865807,0.405134917454284,0.218762348274951,2014,0.00695086968288046,4551
"CD011575","CD011575_pub3_data","1|8|Renal failure|","Renal failure",1,8,"","or","binary",3,-0.0292937135355181,0.281122975257105,0,2013,0.00322702336194417,5336
"CD011600","CD011600_pub3_data","1|1|Moderate-to-severe exacerbations (Rate)|","Moderate-to-severe exacerbations (Rate)",1,1,"","reported","reported",5,-0.317721522445199,0.0694120790539964,0.0185472466476099,2018.8,0,3079.4
"CD011600","CD011600_pub3_data","1|10|SGRQ, ≥ 4 decrease from baseline|","SGRQ, ≥ 4 decrease from baseline",1,10,"","or","binary",4,0.300492311844009,0.0367877767208325,0,2019,0.357607291148081,3517.5
"CD011600","CD011600_pub3_data","1|12|Pneumonia|","Pneumonia",1,12,"","or","binary",5,0.45605609162427,0.0889413576110419,0,2018.8,0.0286283194583485,3082.4
"CD011600","CD011600_pub3_data","1|13|Pneumonia (Time-to-first)|","Pneumonia (Time-to-first)",1,13,"","reported","reported",3,0.447371000879956,0.0931771539388595,0,2019.33333333333,0,4204.66666666667
"CD011600","CD011600_pub3_data","1|14|Serious adverse events, pneumonia|","Serious adverse events, pneumonia",1,14,"","or","binary",5,0.528912386023015,0.114617514300216,0,2018.8,0.0168289396382508,3082.4
"CD011600","CD011600_pub3_data","1|15|Serious adverse event, all-cause|","Serious adverse event, all-cause",1,15,"","or","binary",5,-0.0526818967892185,0.0426506103068443,0,2018.8,0.182461196618989,3082.4
"CD011600","CD011600_pub3_data","1|16|Change in E-RS|","Change in E-RS",1,16,"","or","binary",2,-0.00686137916647922,1.41472316994204,0,2018,0,1399
"CD011600","CD011600_pub3_data","1|18|TDI (Focal score), over 24 weeks|","TDI (Focal score), over 24 weeks",1,18,"","or","binary",3,-0.485060836925484,1.15499669693668,0,2019.33333333333,0,2438.66666666667
"CD011600","CD011600_pub3_data","1|19|Change in trough FEV1 (mL)|","Change in trough FEV1 (mL)",1,19,"","or","binary",5,-0.417561490349691,0.89474450443434,0,2018.8,0,2270.4
"CD011600","CD011600_pub3_data","1|2|Moderate-to-severe exacerbations (Time-to-first)|","Moderate-to-severe exacerbations (Time-to-first)",1,2,"","reported","reported",5,-0.164727234737631,0.0269954407435561,5.21785516166512e-06,2018.8,0,3079.4
"CD011600","CD011600_pub3_data","1|23|Death, all causes|","Death, all causes",1,23,"","or","binary",5,-0.362962042891963,0.12785343990882,6.12596907297446e-08,2018.8,0.01943908675994,3079.4
"CD011600","CD011600_pub3_data","1|24|Death, all causes (Time-to-event)|","Death, all causes (Time-to-event)",1,24,"","reported","reported",3,-0.467795231984735,0.144268577035742,0,2019.33333333333,0,4199.66666666667
"CD011600","CD011600_pub3_data","1|25|Death, cardiovascular causes|","Death, cardiovascular causes",1,25,"","or","binary",4,-0.674181430222248,0.20826878884411,5.71609805420688e-07,2019,0.00904994092734259,3466.25
"CD011600","CD011600_pub3_data","1|26|Death, respiratory causes|","Death, respiratory causes",1,26,"","or","binary",3,-0.031436980977969,0.28837334055814,0,2019.33333333333,0.00396499863275909,4199.66666666667
"CD011600","CD011600_pub3_data","1|3|Moderate-to-severe exacerbations (≥ 1 exacerbation)|","Moderate-to-severe exacerbations (≥ 1 exacerbation)",1,3,"","or","binary",3,-0.225224946224339,0.116552076338697,0.0269107125520216,2018,0.393502456237815,2036.33333333333
"CD011600","CD011600_pub3_data","1|4|Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)|High Eosinophils","Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)",1,4,"High Eosinophils","reported","reported",5,-0.385074721414298,0.0262662638652008,1.00204232926342e-06,2018.8,0,860.4
"CD011600","CD011600_pub3_data","1|4|Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)|Low Eosinophils","Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)",1,4,"Low Eosinophils","reported","reported",5,-0.141701643396973,0.0341655409165218,1.96440550101399e-07,2018.8,0,636.6
"CD011600","CD011600_pub3_data","1|5|Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)|Baseline ICS Use","Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)",1,5,"Baseline ICS Use","reported","reported",2,-0.281433235445152,0.045304339615966,0,2020,NA,0
"CD011600","CD011600_pub3_data","1|5|Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)|No Baseline ICS Use","Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)",1,5,"No Baseline ICS Use","reported","reported",2,-0.281210451960712,0.0966757378693781,0,2020,NA,0
"CD011600","CD011600_pub3_data","1|6|Severe exacerbations (Rate)|","Severe exacerbations (Rate)",1,6,"","reported","reported",4,-0.260550289088518,0.0802796842622279,0.0105451666476901,2019,0,3532.75
"CD011600","CD011600_pub3_data","1|7|Severe exacerbations (Time-to-first)|","Severe exacerbations (Time-to-first)",1,7,"","reported","reported",2,-0.264148467051457,0.0715117534330001,0,2018,0,3876.5
"CD011600","CD011600_pub3_data","1|9|Change in SGRQ|","Change in SGRQ",1,9,"","or","binary",5,-0.440672821625723,0.894656621062571,0,2018.8,0,2775.8
"CD011600","CD011600_pub3_data","2|1|Moderate-to-severe exacerbations (Rate)|","Moderate-to-severe exacerbations (Rate)",2,1,"","reported","reported",4,-0.358680700282213,0.0842143762273545,0.022897237586996,2019,0,3466.25
"CD011600","CD011600_pub3_data","2|10|SGRQ, ≥ 4 decrease from baseline|","SGRQ, ≥ 4 decrease from baseline",2,10,"","or","binary",3,0.316664387215012,0.0392746103556693,0,2019.33333333333,0.355715971530774,4179.33333333333
"CD011600","CD011600_pub3_data","2|12|Pneumonia|","Pneumonia",2,12,"","or","binary",4,0.50544066637626,0.0941018829578664,0,2019,0.0269963368229356,3470
"CD011600","CD011600_pub3_data","2|13|Pneumonia (Time-to-first)|","Pneumonia (Time-to-first)",2,13,"","reported","reported",3,0.447371000879956,0.0931771539388595,0,2019.33333333333,0,4204.66666666667
"CD011600","CD011600_pub3_data","2|14|Serious adverse events, pneumonia|","Serious adverse events, pneumonia",2,14,"","or","binary",4,0.589774944390086,0.121862713048841,0,2019,0.0155023203811468,3470
"CD011600","CD011600_pub3_data","2|15|Serious adverse event, all-cause|","Serious adverse event, all-cause",2,15,"","or","binary",4,-0.0457813783918019,0.0448200187466041,8.56121456082805e-07,2019,0.185758787440403,3470
"CD011600","CD011600_pub3_data","2|18|TDI (Focal score), over 24 weeks|","TDI (Focal score), over 24 weeks",2,18,"","or","binary",3,-0.485060836925484,1.15499669693668,0,2019.33333333333,0,2438.66666666667
"CD011600","CD011600_pub3_data","2|19|Change in trough FEV1 (mL)|","Change in trough FEV1 (mL)",2,19,"","or","binary",4,-0.523264068213201,1.00036193266385,0,2019,0,2455
"CD011600","CD011600_pub3_data","2|2|Moderate-to-severe exacerbations (Time-to-first)|","Moderate-to-severe exacerbations (Time-to-first)",2,2,"","reported","reported",4,-0.171528731008484,0.0284598805906111,3.00083696273174e-06,2019,0,3466.25
"CD011600","CD011600_pub3_data","2|23|Death, all causes|","Death, all causes",2,23,"","or","binary",4,-0.379917191197069,0.138588282743418,2.19651972428331e-06,2019,0.017462920949925,3466.25
"CD011600","CD011600_pub3_data","2|24|Death, all causes (Time-to-event)|","Death, all causes (Time-to-event)",2,24,"","reported","reported",3,-0.467795231984735,0.144268577035742,0,2019.33333333333,0,4199.66666666667
"CD011600","CD011600_pub3_data","2|25|Death, cardiovascular causes|","Death, cardiovascular causes",2,25,"","or","binary",4,-0.674181430222248,0.20826878884411,5.71609805420688e-07,2019,0.00904994092734259,3466.25
"CD011600","CD011600_pub3_data","2|26|Death, respiratory causes|","Death, respiratory causes",2,26,"","or","binary",3,-0.031436980977969,0.28837334055814,0,2019.33333333333,0.00396499863275909,4199.66666666667
"CD011600","CD011600_pub3_data","2|3|Moderate-to-severe exacerbations (≥ 1 exacerbation)|","Moderate-to-severe exacerbations (≥ 1 exacerbation)",2,3,"","or","binary",2,-0.301562102261349,0.182108555437847,0.0536044600153986,2018,0.394693430656934,2599.5
"CD011600","CD011600_pub3_data","2|4|Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)|High Eosinophils","Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)",2,4,"High Eosinophils","reported","reported",4,-0.394770187546993,0.0270710958915202,7.87008998148351e-06,2019,0,1075.5
"CD011600","CD011600_pub3_data","2|4|Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)|Low Eosinophils","Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)",2,4,"Low Eosinophils","reported","reported",4,-0.142137717246058,0.0357031381764557,5.25878114723348e-07,2019,0,795.75
"CD011600","CD011600_pub3_data","2|5|Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)|Baseline ICS Use","Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)",2,5,"Baseline ICS Use","reported","reported",2,-0.281433235445152,0.045304339615966,0,2020,NA,0
"CD011600","CD011600_pub3_data","2|5|Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)|No Baseline ICS Use","Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)",2,5,"No Baseline ICS Use","reported","reported",2,-0.281210451960712,0.0966757378693781,0,2020,NA,0
"CD011600","CD011600_pub3_data","2|6|Severe exacerbations (Rate)|","Severe exacerbations (Rate)",2,6,"","reported","reported",3,-0.259006265969858,0.0970466933994499,0.0159499984594168,2019.33333333333,0,4199.66666666667
"CD011600","CD011600_pub3_data","2|9|Change in SGRQ|","Change in SGRQ",2,9,"","or","binary",4,-0.552126273863272,1.00023911380268,0,2019,0,3086.75
"CD011624","CD011624_pub3_data","1|1|Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia)|NA","Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia)",1,1,NA,"reported","reported",2,0.149750602434944,0.190208882942713,0,2018.5,0,745.5
"CD011624","CD011624_pub3_data","1|12|Use of pharmacological therapy|NA","Use of pharmacological therapy",1,12,NA,"reported","reported",4,0.436234230610217,0.146926663874618,0.0430912729424042,2013.5,0,429.5
"CD011624","CD011624_pub3_data","1|2|Perinatal (foetal and neonatal) mortality|NA","Perinatal (foetal and neonatal) mortality",1,2,NA,"or","binary",2,-0.103007048806916,1.41542796172608,0,2018.5,0,749.5
"CD011624","CD011624_pub3_data","1|21|Stillbirth|NA","Stillbirth",1,21,NA,"or","binary",2,-1.36392807932007,1.20721275548025,0,2018.5,0.00297029702970297,749.5
"CD011624","CD011624_pub3_data","1|22|Neonatal death|NA","Neonatal death",1,22,NA,"or","binary",2,-0.103007048806916,1.41542796172608,0,2018.5,0,749.5
"CD011624","CD011624_pub3_data","1|23|Macrosomia|NA","Macrosomia",1,23,NA,"reported","reported",3,0.116727303703826,0.16721031533217,0,2011.66666666667,0,555.666666666667
"CD011624","CD011624_pub3_data","1|24|Small-for-gestational-age|NA","Small-for-gestational-age",1,24,NA,"reported","reported",3,-0.151334673901582,0.202726108817458,0,2011.66666666667,0,555.666666666667
"CD011624","CD011624_pub3_data","1|26|Gestational age at birth (weeks)|NA","Gestational age at birth (weeks)",1,26,NA,"reported","reported",4,-0.0849853469334245,0.101129314008977,0.0140182297867448,2013.5,0,431.75
"CD011624","CD011624_pub3_data","1|27|Birthweight|NA","Birthweight",1,27,NA,"reported","reported",4,2.41631084788892,25.7236200794007,0,2013.5,0,431.75
"CD011624","CD011624_pub3_data","1|3|Large-for-gestational-age|NA","Large-for-gestational-age",1,3,NA,"reported","reported",3,-0.0357362372609393,0.148101783320512,0,2018.66666666667,0,518.666666666667
"CD011624","CD011624_pub3_data","1|33|Infant hypoglycaemia|NA","Infant hypoglycaemia",1,33,NA,"reported","reported",3,-0.0834473762075002,0.126915587223846,0,2018.66666666667,0,518.666666666667
"CD011624","CD011624_pub3_data","1|34|Neonatal jaundice (hyperbilirubinaemia)|NA","Neonatal jaundice (hyperbilirubinaemia)",1,34,NA,"reported","reported",2,-0.347938935553644,0.228209296815623,0,2019,0,580.5
"CD011624","CD011624_pub3_data","1|4|Composite of mortality or serious morbidity (as defined by trial)|NA","Composite of mortality or serious morbidity (as defined by trial)",1,4,NA,"reported","reported",3,-0.244075723224887,0.316357347358656,0.0976867435137618,2018.66666666667,0,519.666666666667
"CD011624","CD011624_pub3_data","1|41|Admission to neonatal intensive care unit/nursery|NA","Admission to neonatal intensive care unit/nursery",1,41,NA,"reported","reported",2,-0.527646464524966,0.290382253262692,0,2019,0,580.5
"CD011624","CD011624_pub3_data","1|5|Caesarean section|NA","Caesarean section",1,5,NA,"reported","reported",3,-0.0209990022057961,0.10793874290536,0.00835405462038398,2011.66666666667,0,554
"CD011626","CD011626_pub3_data","1|1|Cardiac T2* value (ms)|At 12 months","Cardiac T2* value (ms)",1,1,"At 12 months","or","binary",4,0.137841995369556,1.01462921001206,0,2017,0,47.75
"CD011626","CD011626_pub3_data","1|1|Cardiac T2* value (ms)|At 6 months","Cardiac T2* value (ms)",1,1,"At 6 months","or","binary",4,0.0899234976834626,1.0207164589282,0,2017.25,0,30.5
"CD011626","CD011626_pub3_data","1|2|Myocardial iron concentration (mg/g)|At 12 months","Myocardial iron concentration (mg/g)",1,2,"At 12 months","or","binary",3,0.196974854504871,1.17369735270713,0,2017,0,46
"CD011626","CD011626_pub3_data","1|2|Myocardial iron concentration (mg/g)|At 6 months","Myocardial iron concentration (mg/g)",1,2,"At 6 months","or","binary",3,0.155804190907678,1.17605036731605,0,2016,0,35
"CD011626","CD011626_pub3_data","1|3|Left ventricular ejection fraction (%)|At 12 months","Left ventricular ejection fraction (%)",1,3,"At 12 months","or","binary",3,0.219984887891258,1.17380977678111,0,2017,0,45.3333333333333
"CD011626","CD011626_pub3_data","1|3|Left ventricular ejection fraction (%)|At 6 months","Left ventricular ejection fraction (%)",1,3,"At 6 months","or","binary",3,0.155804190907678,1.17605036731605,0,2016,0,35
"CD011626","CD011626_pub3_data","1|4|Serum ferritin (μg/mL)|At 12 months","Serum ferritin (μg/mL)",1,4,"At 12 months","reported","reported",4,0,0.310173928982566,0,2017,0,46.75
"CD011626","CD011626_pub3_data","1|4|Serum ferritin (μg/mL)|At 6 months","Serum ferritin (μg/mL)",1,4,"At 6 months","reported","reported",5,0,0.265042616429263,0,2017.2,0,36.6
"CD011626","CD011626_pub3_data","1|5|Liver T2* value (ms)|At 12 months","Liver T2* value (ms)",1,5,"At 12 months","or","binary",3,0.184643263269575,1.17431151337037,0,2015.33333333333,0,42.3333333333333
"CD011626","CD011626_pub3_data","1|5|Liver T2* value (ms)|At 6 months","Liver T2* value (ms)",1,5,"At 6 months","or","binary",3,0.155804190907678,1.17605036731605,0,2016,0,35
"CD011626","CD011626_pub3_data","1|6|Liver iron concentration (mg/g)|At 6 months","Liver iron concentration (mg/g)",1,6,"At 6 months","or","binary",2,-0.0787720004201709,1.42972333781319,0,2017.5,0,45
"CD011626","CD011626_pub3_data","1|7|Adverse events|Dizziness","Adverse events",1,7,"Dizziness","or","binary",2,1.80876205428751,1.12183298899572,0,2016.5,0,49.5
"CD011626","CD011626_pub3_data","1|7|Adverse events|Gastrointestinal symptoms","Adverse events",1,7,"Gastrointestinal symptoms","or","binary",2,0.507114169639934,1.06787211454001,1.89940667906748,2018,0.361538461538462,46.5
"CD011626","CD011626_pub3_data","1|7|Adverse events|Oedema","Adverse events",1,7,"Oedema","or","binary",4,1.83293395112523,0.800134033168344,0,2016.25,0,41.75
"CD011626","CD011626_pub3_data","2|1|Cardiac T2* (ms)|At 12 months","Cardiac T2* (ms)",2,1,"At 12 months","or","binary",4,0.137841995369556,1.01462921001206,0,2017,0,47.75
"CD011626","CD011626_pub3_data","2|1|Cardiac T2* (ms)|At 6 months","Cardiac T2* (ms)",2,1,"At 6 months","or","binary",3,0.155804190907678,1.17605036731605,0,2016,0,35
"CD011626","CD011626_pub3_data","2|2|Serum ferritin (μg/mL)|At 12 months","Serum ferritin (μg/mL)",2,2,"At 12 months","reported","reported",4,0,74.2131775682104,0,2017,0,46.75
"CD011626","CD011626_pub3_data","2|2|Serum ferritin (μg/mL)|At 6 months","Serum ferritin (μg/mL)",2,2,"At 6 months","reported","reported",4,0,0.189605855935013,0,2016.25,0,41.5
"CD011627","CD011627_pub3_data","1|1|Number of participants with incontinence-associated dermatitis|No-rinse skin cleansing product (A) versus soap and water (B)","Number of participants with incontinence-associated dermatitis",1,1,"No-rinse skin cleansing product (A) versus soap and water (B)","reported","reported",2,0,0.43577428234693,0,1998,0.21875,42.5
"CD011627","CD011627_pub3_data","3|1|Number of participants with incontinence-associated dermatitis|Skin cleansing and application of a skin protectant (A) versus skin cleansing alone (B)","Number of participants with incontinence-associated dermatitis",3,1,"Skin cleansing and application of a skin protectant (A) versus skin cleansing alone (B)","reported","reported",2,0,0.604613263503954,0,2018,0.177083333333333,105.5
"CD011670","CD011670_pub3_data","1|1|Overall morbidity|NA","Overall morbidity",1,1,NA,"or","binary",3,-0.148721670478964,1.19909222633663,3.46280213685898,2013.33333333333,0.314975845410628,48.6666666666667
"CD011670","CD011670_pub3_data","1|2|Wound infection|NA","Wound infection",1,2,NA,"or","binary",7,-0.030699740699048,0.366506099973519,0.349028590185227,2016.57142857143,0.0975431331953071,112.571428571429
"CD011670","CD011670_pub3_data","1|3|Abdominal abscess|NA","Abdominal abscess",1,3,NA,"or","binary",4,-1.3548058507538,0.613691644923019,0.282716652454681,2018.25,0.0953864734299517,156.5
"CD011670","CD011670_pub3_data","1|4|Bowel obstruction|NA","Bowel obstruction",1,4,NA,"or","binary",2,-1.9528503716832,1.11472899622841,0,2018,0.12536231884058,53
"CD011670","CD011670_pub3_data","1|5|Faecal fistula|NA","Faecal fistula",1,5,NA,"or","binary",5,0.485714579298128,0.764692131784906,0,2016.4,0.00222222222222222,77.6
"CD011670","CD011670_pub3_data","1|7|Total length of hospital stay (days)|NA","Total length of hospital stay (days)",1,7,NA,"or","binary",5,0,0.899710348388504,0,2015.4,0,136
"CD011671","CD011671_pub3_data","1|1|Delayed graft function|Continuous (from donor hospital to implanting centre)","Delayed graft function",1,1,"Continuous (from donor hospital to implanting centre)","reported","reported",8,0,0.0684161567232729,0,2004.4,0.449913378013225,195
"CD011671","CD011671_pub3_data","1|1|Delayed graft function|Mix of continuous and end-ischaemic","Delayed graft function",1,1,"Mix of continuous and end-ischaemic","reported","reported",2,0,0.14823412694686,0,2008,0.700854700854701,58
"CD011671","CD011671_pub3_data","1|1|Delayed graft function|Not specified","Delayed graft function",1,1,"Not specified","reported","reported",6,0,0.076969636497772,0,2004.5,0.441337702209608,233.666666666667
"CD011671","CD011671_pub3_data","1|10|Patient survival (12-month follow up, dichotomous)|Continuous (from donor hospital to implanting centre)","Patient survival (12-month follow up, dichotomous)",1,10,"Continuous (from donor hospital to implanting centre)","reported","reported",2,0,0.0129620418313223,0,2008,0.941735347985348,415
"CD011671","CD011671_pub3_data","1|11|Acute rejection in the first year|","Acute rejection in the first year",1,11,"","or","binary",3,-0.353756039989512,0.267858500253939,3.37377596548663e-09,2014,0.224903636668343,116.666666666667
"CD011671","CD011671_pub3_data","1|2|Delayed graft function: type of donor|DBD","Delayed graft function: type of donor",1,2,"DBD","or","binary",5,-0.421240600782753,0.108503819854852,0,2001.25,0.388787026476171,361.8
"CD011671","CD011671_pub3_data","1|2|Delayed graft function: type of donor|DCD","Delayed graft function: type of donor",1,2,"DCD","or","binary",8,-0.554941836725667,0.144242628906165,0,2011,0.573174180554023,109.25
"CD011671","CD011671_pub3_data","1|2|Delayed graft function: type of donor|Type of donor not specified","Delayed graft function: type of donor",1,2,"Type of donor not specified","or","binary",4,-0.357306525199959,0.522548772978383,0.870354005783718,1985,0.427122304860642,98.75
"CD011671","CD011671_pub3_data","1|3|Delayed graft function: era of study|Modern era","Delayed graft function: era of study",1,3,"Modern era","or","binary",7,-0.423764034230009,0.0930032361115156,0,2013.83333333333,0.443914562506091,327.857142857143
"CD011671","CD011671_pub3_data","1|3|Delayed graft function: era of study|Pre-2008","Delayed graft function: era of study",1,3,"Pre-2008","or","binary",9,-0.468552735643862,0.239273616656846,0.266035135665022,1991.25,0.504626744614469,87
"CD011671","CD011671_pub3_data","1|4|Delayed graft function: preservation times|Cold ischaemic time not reported","Delayed graft function: preservation times",1,4,"Cold ischaemic time not reported","or","binary",2,-0.257952114642416,0.695357208819789,0.669605359676283,2014,0.384259259259259,62.5
"CD011671","CD011671_pub3_data","1|4|Delayed graft function: preservation times|Long mean cold ischaemic time (≥ 24 hours)","Delayed graft function: preservation times",1,4,"Long mean cold ischaemic time (≥ 24 hours)","or","binary",6,-0.687289831854282,0.15378861486346,2.38572160193378e-06,1990.33333333333,0.551512696665851,120.833333333333
"CD011671","CD011671_pub3_data","1|4|Delayed graft function: preservation times|Short mean cold ischaemic time (< 24 hours)","Delayed graft function: preservation times",1,4,"Short mean cold ischaemic time (< 24 hours)","or","binary",8,-0.338812056531705,0.0945921771646811,2.37333745206819e-06,2010.5,0.446430992569903,278.5
"CD011671","CD011671_pub3_data","1|5|Graft survival (12 month follow-up)|Continuous (from donor hospital to implanting centre)","Graft survival (12 month follow-up)",1,5,"Continuous (from donor hospital to implanting centre)","reported","reported",3,-0.766324835820602,0.245541834068321,0,2014.33333333333,NA,0
"CD011671","CD011671_pub3_data","1|5|Graft survival (12 month follow-up)|Not specified","Graft survival (12 month follow-up)",1,5,"Not specified","reported","reported",2,-0.0904038654314494,0.414848166667474,0.0312359538735,2016,NA,0
"CD011671","CD011671_pub3_data","1|6|Graft survival (at maximum follow-up)|Continuous (from donor hospital to implanting centre)","Graft survival (at maximum follow-up)",1,6,"Continuous (from donor hospital to implanting centre)","reported","reported",4,-0.590406452016109,0.168762958421966,0,2014.33333333333,NA,0
"CD011671","CD011671_pub3_data","1|6|Graft survival (at maximum follow-up)|Not specified","Graft survival (at maximum follow-up)",1,6,"Not specified","reported","reported",2,-0.0904038654314494,0.414848166667474,0.0312359538735,2016,NA,0
"CD011671","CD011671_pub3_data","1|7|Primary non-function|Continuous (from donor hospital to implanting centre)","Primary non-function",1,7,"Continuous (from donor hospital to implanting centre)","reported","reported",3,0,0.38647267078106,0,2014,0.0354808590102708,311.333333333333
"CD011671","CD011671_pub3_data","1|7|Primary non-function|Mix of continuous and end-ischaemic","Primary non-function",1,7,"Mix of continuous and end-ischaemic","reported","reported",2,0,1.13413834139413,0,2008,0.0384615384615385,58
"CD011671","CD011671_pub3_data","1|7|Primary non-function|Not specified","Primary non-function",1,7,"Not specified","reported","reported",3,0,0.248205219717617,0,1993,0.124192277383767,146.333333333333
"CD011671","CD011671_pub3_data","1|8|Duration of delayed graft function|Not specified","Duration of delayed graft function",1,8,"Not specified","reported","reported",2,0,0.769364042382171,0,1985,0,58
"CD011671","CD011671_pub3_data","1|9|Patient survival (12 month follow up, time-to-event)|Continuous (from donor hospital to implanting centre)","Patient survival (12 month follow up, time-to-event)",1,9,"Continuous (from donor hospital to implanting centre)","reported","reported",2,-0.832587231753194,0.511240819088013,0,2020,NA,0
"CD011689","CD011689_pub4_data","1|1|Death|","Death",1,1,"","or","binary",2,0.432577878443674,1.41617997980045,0,2004.5,0,895
"CD011689","CD011689_pub4_data","1|11|Nausea|","Nausea",1,11,"","or","binary",3,-0.304109306042809,0.389369770102385,0.0914318744199271,2005.66666666667,0.0458553254838273,596
"CD011689","CD011689_pub4_data","1|12|Vomiting|","Vomiting",1,12,"","or","binary",3,0.184646052211357,0.52474206398627,0,2009,0.00314116777531412,716.666666666667
"CD011689","CD011689_pub4_data","1|13|Headache|","Headache",1,13,"","or","binary",2,0.504430764242637,0.652246364023996,0.37795066929298,2014.5,0.00856793145654835,852
"CD011689","CD011689_pub4_data","1|3|Blood transfusion|","Blood transfusion",1,3,"","or","binary",5,-0.260715444988349,0.216540225921868,0,2008.6,0.0148536643153775,1102.2
"CD011689","CD011689_pub4_data","1|6|PPH >= 500 mL|","PPH >= 500 mL",1,6,"","or","binary",7,-0.58475431198405,0.0786631371824507,0.00117983410866361,2005.71428571429,0.284257453734049,849.285714285714
"CD011689","CD011689_pub4_data","1|7|Additional uterotonics|","Additional uterotonics",1,7,"","or","binary",6,-1.33294632174654,0.462919737638083,0.937602038024162,2006,0.328760228831935,661.833333333333
"CD011689","CD011689_pub4_data","1|8|Blood loss|","Blood loss",1,8,"","or","binary",6,-0.130719938083962,0.82097893844921,0,2003.66666666667,0,407.5
"CD011689","CD011689_pub4_data","1|9|Change in haemoglobin|","Change in haemoglobin",1,9,"","or","binary",3,0.030452431803003,1.15893596937388,0,2008.33333333333,0,699.333333333333
"CD011689","CD011689_pub4_data","10|1|Death|","Death",10,1,"","or","binary",5,0.358272434816393,0.620003211203283,0,2010,2.70855904658722e-05,6880
"CD011689","CD011689_pub4_data","10|10|Breastfeeding|","Breastfeeding",10,10,"","or","binary",2,-0.682047245762579,0.607652197805308,0.151256522295132,2011,0.919923371647509,95
"CD011689","CD011689_pub4_data","10|11|Nausea|","Nausea",10,11,"","or","binary",11,0.019231936403095,0.194309379089644,0.172507173618973,2010.7,0.124980011563641,551.181818181818
"CD011689","CD011689_pub4_data","10|13|Headache|","Headache",10,13,"","or","binary",12,0.0916863949438933,0.146485867127455,0,2010.27272727273,0.0498275179997079,509.25
"CD011689","CD011689_pub4_data","10|14|Abdominal pain|","Abdominal pain",10,14,"","or","binary",8,-0.0473806969068885,0.127744936360945,0.0256844503834405,2008.71428571429,0.0661428538784244,4376.625
"CD011689","CD011689_pub4_data","10|15|Hypertension|","Hypertension",10,15,"","or","binary",2,-0.598947193430069,0.781133213809481,0.923940749785777,2018,0.0607371868448036,2040
"CD011689","CD011689_pub4_data","10|16|Shivering|","Shivering",10,16,"","or","binary",6,-0.282754011060803,0.198187129382955,0,2004.8,0.0555781424492116,253.333333333333
"CD011689","CD011689_pub4_data","10|17|Fever|","Fever",10,17,"","or","binary",2,-0.626961985772008,1.27953748601555,0,2004.5,0.0172413793103448,56
"CD011689","CD011689_pub4_data","10|2|PPH >= 1000 mL|","PPH >= 1000 mL",10,2,"","or","binary",10,-0.0366233524209658,0.0600247576659769,0,2014.66666666667,0.0798887648628306,3503.2
"CD011689","CD011689_pub4_data","10|3|Blood transfusion|","Blood transfusion",10,3,"","or","binary",10,0.0750102671801235,0.0956665166830149,0.00335124834291555,2010.5,0.0205542535268688,3568.5
"CD011689","CD011689_pub4_data","10|4|Severe maternal morbidity: intensive care admissions|","Severe maternal morbidity: intensive care admissions",10,4,"","or","binary",2,0.148923567685346,0.279427087226758,0,2014,0.000780560646168465,14923.5
"CD011689","CD011689_pub4_data","10|6|PPH >= 500 mL|","PPH >= 500 mL",10,6,"","or","binary",8,-0.00204713059806306,0.0335443054660311,3.15659635864074e-06,2011.57142857143,0.24241383335915,4324.75
"CD011689","CD011689_pub4_data","10|7|Additional uterotonics|","Additional uterotonics",10,7,"","or","binary",17,-0.283901273937104,0.148324267728651,0.154914685827739,2012.53333333333,0.149503793117961,2146.88235294118
"CD011689","CD011689_pub4_data","10|9|Change in haemoglobin|","Change in haemoglobin",10,9,"","or","binary",8,-0.0284829050519619,0.711473341214379,0,2010.25,0,179.5
"CD011689","CD011689_pub4_data","11|11|Nausea|","Nausea",11,11,"","or","binary",5,1.84519565591948,0.887440925553133,3.13277300091615,1996.6,0.0176401602292744,485.8
"CD011689","CD011689_pub4_data","11|12|Vomiting|","Vomiting",11,12,"","or","binary",4,1.14950490572655,0.840992405498454,1.98147843933607,2007.5,0.0225670120115578,560.75
"CD011689","CD011689_pub4_data","11|13|Headache|","Headache",11,13,"","or","binary",3,1.64058984747311,1.39235968528346,4.84042806745819,2009.33333333333,0.00991051910368836,731
"CD011689","CD011689_pub4_data","11|15|Hypertension|","Hypertension",11,15,"","or","binary",3,2.82151069299713,0.774459371238649,0.939903539325853,2009.66666666667,0.0377604166666667,470
"CD011689","CD011689_pub4_data","11|16|Shivering|","Shivering",11,16,"","or","binary",2,0.551491780699088,0.325065940854272,0,2004,0.0113452188006483,671.5
"CD011689","CD011689_pub4_data","11|2|PPH >= 1000 mL|","PPH >= 1000 mL",11,2,"","or","binary",5,0.228290655741033,0.446346937357613,0,2000.4,0.0252965964343598,508.2
"CD011689","CD011689_pub4_data","11|3|Blood transfusion|","Blood transfusion",11,3,"","or","binary",2,-0.79762588284575,1.06650287965038,1.5386347368304,2010,0.031422070046261,796.5
"CD011689","CD011689_pub4_data","11|6|PPH >= 500 mL|","PPH >= 500 mL",11,6,"","or","binary",7,0.207230179622489,0.214014774273717,0.0381214922235687,1998.85714285714,0.10805692522749,417.285714285714
"CD011689","CD011689_pub4_data","11|7|Additional uterotonics|","Additional uterotonics",11,7,"","or","binary",3,-0.166551767159972,0.548652546543823,0.813075602274731,2009.33333333333,0.117994156902783,731
"CD011689","CD011689_pub4_data","11|8|Blood loss|","Blood loss",11,8,"","or","binary",7,-0.0129586016359787,0.758656158954658,0,1998.85714285714,0,417.285714285714
"CD011689","CD011689_pub4_data","11|9|Change in haemoglobin|","Change in haemoglobin",11,9,"","or","binary",2,-0.0556262179341261,1.41507528829908,0,2007,0,946.5
"CD011689","CD011689_pub4_data","12|11|Nausea|","Nausea",12,11,"","or","binary",7,0.839974691665366,0.277681620939892,0.420315209092493,2009,0.177173799622581,1356.85714285714
"CD011689","CD011689_pub4_data","12|12|Vomiting|","Vomiting",12,12,"","or","binary",10,1.16136135882562,0.239572061108151,0.266355859384456,2006.3,0.0370904754220763,1311.7
"CD011689","CD011689_pub4_data","12|15|Hypertension|","Hypertension",12,15,"","or","binary",4,0.569934891338499,0.107679272745319,3.69390271995346e-06,2011.25,0.105775398312072,1228.75
"CD011689","CD011689_pub4_data","12|16|Shivering|","Shivering",12,16,"","or","binary",2,-0.0409769210693929,0.243988412778522,0,2002.5,0.044395602989353,795.5
"CD011689","CD011689_pub4_data","12|17|Fever|","Fever",12,17,"","or","binary",2,0.0703501043175079,0.403837956946321,0,2002.5,0.013881424037674,795.5
"CD011689","CD011689_pub4_data","12|18|Diarrhoea|","Diarrhoea",12,18,"","or","binary",3,0.209088888621586,0.287074514192774,0,2001.33333333333,0.017787674037674,676.666666666667
"CD011689","CD011689_pub4_data","12|2|PPH >= 1000 mL|","PPH >= 1000 mL",12,2,"","or","binary",8,-0.472257777371013,0.169817378396785,0.0558713410168624,2003.125,0.0943148563268725,1172.25
"CD011689","CD011689_pub4_data","12|6|PPH >= 500 mL|","PPH >= 500 mL",12,6,"","or","binary",8,-0.1190531977739,0.0489789013410505,7.00175450289179e-06,2002.125,0.120318326343955,1628.25
"CD011689","CD011689_pub4_data","12|7|Additional uterotonics|","Additional uterotonics",12,7,"","or","binary",11,-0.352606522507748,0.213523466362956,0.383685492589466,2008.09090909091,0.207965500071631,1062.18181818182
"CD011689","CD011689_pub4_data","12|9|Change in haemoglobin|","Change in haemoglobin",12,9,"","or","binary",5,-0.181997344525629,0.895540898381181,0,2005.6,0,634
"CD011689","CD011689_pub4_data","13|1|Death|","Death",13,1,"","or","binary",6,-0.0150206216225401,0.818349206312952,0,2010.16666666667,0,666
"CD011689","CD011689_pub4_data","13|11|Nausea|","Nausea",13,11,"","or","binary",5,0.919239833062846,0.403135891425457,0.409742319267408,2011,0.0481805941334445,681.2
"CD011689","CD011689_pub4_data","13|12|Vomiting|","Vomiting",13,12,"","or","binary",7,0.748781428199343,0.287823590147372,0.184449148413229,2008.28571428571,0.0216089199514887,815
"CD011689","CD011689_pub4_data","13|13|Headache|","Headache",13,13,"","or","binary",2,0.244575786268595,0.733007567241649,0.0280176621823818,2007.5,0.028,151.5
"CD011689","CD011689_pub4_data","13|16|Shivering|","Shivering",13,16,"","or","binary",12,1.4873906260153,0.235841119057933,0.397699504211539,2009.66666666667,0.0474504055806906,642.583333333333
"CD011689","CD011689_pub4_data","13|17|Fever|","Fever",13,17,"","or","binary",10,1.42066746857015,0.270431510610872,0.455929380480472,2010.6,0.0270078591988782,686
"CD011689","CD011689_pub4_data","13|18|Diarrhoea|","Diarrhoea",13,18,"","or","binary",6,0.746566805093293,0.433900130020472,0.448943483593872,2010.16666666667,0.00937139193765268,880.5
"CD011689","CD011689_pub4_data","13|2|PPH >= 1000 mL|","PPH >= 1000 mL",13,2,"","or","binary",12,-0.172436312470928,0.135815177383315,4.21294624979284e-06,2010.91666666667,0.0993244554089689,614.75
"CD011689","CD011689_pub4_data","13|3|Blood transfusion|","Blood transfusion",13,3,"","or","binary",12,-0.895424713678386,0.178235658116687,0.00843136685456899,2010.25,0.0626303791306378,578.5
"CD011689","CD011689_pub4_data","13|6|PPH >= 500 mL|","PPH >= 500 mL",13,6,"","or","binary",9,-0.529890061188895,0.150575617806009,0.109279456042373,2009.11111111111,0.223620878689363,797.888888888889
"CD011689","CD011689_pub4_data","13|7|Additional uterotonics|","Additional uterotonics",13,7,"","or","binary",12,-0.728715665010162,0.128519918985828,0.0644582702634992,2010.75,0.177573510986782,566
"CD011689","CD011689_pub4_data","13|8|Blood loss|","Blood loss",13,8,"","or","binary",11,-0.0110480021655287,0.60412598202428,0,2010.63636363636,0,655
"CD011689","CD011689_pub4_data","13|9|Change in haemoglobin|","Change in haemoglobin",13,9,"","or","binary",11,-0.00123735288887916,0.603902444991679,0,2010.63636363636,0,633.727272727273
"CD011689","CD011689_pub4_data","14|11|Nausea|","Nausea",14,11,"","or","binary",2,-1.38366309759874,0.679961356409058,0,2012.5,0.105454545454545,116.5
"CD011689","CD011689_pub4_data","14|12|Vomiting|","Vomiting",14,12,"","or","binary",2,0.433367065256183,2.43030967715957,10.3622339090668,2012.5,0.0606060606060606,116.5
"CD011689","CD011689_pub4_data","14|14|Abdominal pain|","Abdominal pain",14,14,"","or","binary",2,-0.00958709785789779,0.719509699495266,0,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","14|16|Shivering|","Shivering",14,16,"","or","binary",3,-3.49530476689641,0.845040457334265,0,2010.33333333333,0.240909090909091,117.666666666667
"CD011689","CD011689_pub4_data","14|17|Fever|","Fever",14,17,"","or","binary",2,-2.48688105519947,0.75667426088116,0,2012.5,0.158484848484848,116.5
"CD011689","CD011689_pub4_data","14|18|Diarrhoea|","Diarrhoea",14,18,"","or","binary",2,2.01195351180716,0.775741644634454,0,2012.5,0.00757575757575758,116.5
"CD011689","CD011689_pub4_data","14|3|Blood transfusion|","Blood transfusion",14,3,"","or","binary",3,-0.841077219825658,1.00568003989599,0,2010.33333333333,0.0106060606060606,117.666666666667
"CD011689","CD011689_pub4_data","14|6|PPH >= 500 mL|","PPH >= 500 mL",14,6,"","or","binary",2,0.296812876923238,0.400203686518096,0,2007.5,0.0939393939393939,126.5
"CD011689","CD011689_pub4_data","14|7|Additional uterotonics|","Additional uterotonics",14,7,"","or","binary",3,-0.223825197554772,0.722833657556914,1.04619768003177,2010.33333333333,0.107676767676768,117.666666666667
"CD011689","CD011689_pub4_data","14|8|Blood loss|","Blood loss",14,8,"","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","14|9|Change in haemoglobin|","Change in haemoglobin",14,9,"","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","16|1|Death|","Death",16,1,"","or","binary",6,0.315173149764195,0.817687483703423,0,2008.33333333333,0,825.666666666667
"CD011689","CD011689_pub4_data","16|11|Nausea|","Nausea",16,11,"","or","binary",9,0.339587195586082,0.184460560293809,0.0951042054542211,2006.77777777778,0.0887916605478144,500.444444444444
"CD011689","CD011689_pub4_data","16|12|Vomiting|","Vomiting",16,12,"","or","binary",10,0.038238008421656,0.259666260576112,0.277548744658102,2006.4,0.0512524294700984,543.8
"CD011689","CD011689_pub4_data","16|13|Headache|","Headache",16,13,"","or","binary",5,0.802670728989554,0.663823317248239,1.74344921269308,2004.8,0.0479994139155689,574.2
"CD011689","CD011689_pub4_data","16|14|Abdominal pain|","Abdominal pain",16,14,"","or","binary",2,0.403087148751497,1.82535484635188,5.13691390801422,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","16|16|Shivering|","Shivering",16,16,"","or","binary",11,-1.37313442895857,0.238786630568023,0.336892239962078,2006.36363636364,0.265846470010144,512.454545454545
"CD011689","CD011689_pub4_data","16|17|Fever|","Fever",16,17,"","or","binary",10,-1.57889894540882,0.241963260270769,0.201333786889099,2006.8,0.118395263353523,560.7
"CD011689","CD011689_pub4_data","16|18|Diarrhoea|","Diarrhoea",16,18,"","or","binary",6,0.103767767888544,0.435372283877737,0,2007.33333333333,0.0067290373362106,627.833333333333
"CD011689","CD011689_pub4_data","16|2|PPH >= 1000 mL|","PPH >= 1000 mL",16,2,"","or","binary",8,0.386811086947748,0.455863174446552,0.0988986507160187,2004.875,0.00770251683487587,651.625
"CD011689","CD011689_pub4_data","16|3|Blood transfusion|","Blood transfusion",16,3,"","or","binary",9,0.403100976071539,0.444953789222391,0,2006.22222222222,0.00438045986389113,526
"CD011689","CD011689_pub4_data","16|6|PPH >= 500 mL|","PPH >= 500 mL",16,6,"","or","binary",10,0.340291311632599,0.301627035668526,0.449567792148885,2005.4,0.060135660622029,554.6
"CD011689","CD011689_pub4_data","16|7|Additional uterotonics|","Additional uterotonics",16,7,"","or","binary",11,0.0657534718948757,0.221383800442773,0.246500064271054,2006.27272727273,0.060782575919027,526.545454545455
"CD011689","CD011689_pub4_data","16|8|Blood loss|","Blood loss",16,8,"","or","binary",9,0.210670545614084,0.668520384224582,0,2006.88888888889,0,591.555555555556
"CD011689","CD011689_pub4_data","16|9|Change in haemoglobin|","Change in haemoglobin",16,9,"","or","binary",7,0.270512910491573,0.757542046096554,0,2007.71428571429,0,582
"CD011689","CD011689_pub4_data","17|1|Death|","Death",17,1,"","or","binary",4,-0.000461151873995137,1.00309616204259,0,2003.5,0,814.5
"CD011689","CD011689_pub4_data","17|11|Nausea|","Nausea",17,11,"","or","binary",4,-0.477434001832304,0.121903599380507,5.55622070788913e-07,2004.25,0.148956097834229,849.75
"CD011689","CD011689_pub4_data","17|12|Vomiting|","Vomiting",17,12,"","or","binary",6,-0.356991002144182,0.209679801989526,0.0678910539425368,2003.66666666667,0.0594395354429536,830.5
"CD011689","CD011689_pub4_data","17|13|Headache|","Headache",17,13,"","or","binary",3,-0.0248857550620533,0.483627902443012,0.562344193813764,2002.66666666667,0.095413169109373,1086.33333333333
"CD011689","CD011689_pub4_data","17|15|Hypertension|","Hypertension",17,15,"","or","binary",3,-0.585014105199518,0.241156490328945,4.52147986335249e-06,2005.66666666667,0.0794789496405578,851
"CD011689","CD011689_pub4_data","17|16|Shivering|","Shivering",17,16,"","or","binary",6,1.35845177757768,0.0844249875170292,1.32168469635495e-06,2003.66666666667,0.107897765832515,830
"CD011689","CD011689_pub4_data","17|17|Fever|","Fever",17,17,"","or","binary",7,1.66266232825773,0.318454469530189,0.224761445233298,2003.71428571429,0.00642878505677183,720.714285714286
"CD011689","CD011689_pub4_data","17|18|Diarrhoea|","Diarrhoea",17,18,"","or","binary",6,0.0347121208140201,0.214577182932333,0,2003.33333333333,0.017083651322372,609.833333333333
"CD011689","CD011689_pub4_data","17|2|PPH >= 1000 mL|","PPH >= 1000 mL",17,2,"","or","binary",8,0.453971667722169,0.210445593148425,0.00155260766848458,2003.125,0.0120509844384291,741.375
"CD011689","CD011689_pub4_data","17|3|Blood transfusion|","Blood transfusion",17,3,"","or","binary",8,0.325091592355968,0.22106447228406,0.0569375732096975,2002.375,0.0118562348996652,791.875
"CD011689","CD011689_pub4_data","17|6|PPH >= 500 mL|","PPH >= 500 mL",17,6,"","or","binary",9,0.567834109927141,0.156559875805024,0.0836697201891875,2002.55555555556,0.0515242798764292,710.555555555556
"CD011689","CD011689_pub4_data","17|7|Additional uterotonics|","Additional uterotonics",17,7,"","or","binary",9,0.719501909840507,0.13189780613411,0.0522022149064935,2002.55555555556,0.0667398157491835,710.555555555556
"CD011689","CD011689_pub4_data","17|8|Blood loss|","Blood loss",17,8,"","or","binary",7,-0.0403925208508128,0.756801619128676,0,2002.42857142857,0,791
"CD011689","CD011689_pub4_data","17|9|Change in haemoglobin|","Change in haemoglobin",17,9,"","or","binary",8,-0.0241549842714229,0.708098329861307,0,2002.375,0,686.375
"CD011689","CD011689_pub4_data","18|12|Vomiting|","Vomiting",18,12,"","or","binary",3,0.301785016691832,0.472905739872256,0,2006.66666666667,0.0116356797774541,563
"CD011689","CD011689_pub4_data","18|16|Shivering|","Shivering",18,16,"","or","binary",3,-0.0669271093292833,0.152644316514094,7.93751748277777e-07,2006.66666666667,0.0836543130622289,563
"CD011689","CD011689_pub4_data","18|17|Fever|","Fever",18,17,"","or","binary",3,-0.030210103418337,0.236655320941448,0,2006.66666666667,0.042328502176901,563
"CD011689","CD011689_pub4_data","18|18|Diarrhoea|","Diarrhoea",18,18,"","or","binary",2,0.195264259345887,0.288436182394954,0,2002.5,0.0273110540480482,794.5
"CD011689","CD011689_pub4_data","18|2|PPH >= 1000 mL|","PPH >= 1000 mL",18,2,"","or","binary",2,0.613055506690648,0.300363024864704,0,2002.5,0.0211414532974494,794.5
"CD011689","CD011689_pub4_data","18|3|Blood transfusion|","Blood transfusion",18,3,"","or","binary",2,1.04351016526437,0.373700730072308,0,2002.5,0.011175649983951,794.5
"CD011689","CD011689_pub4_data","18|6|PPH >= 500 mL|","PPH >= 500 mL",18,6,"","or","binary",2,0.689689846357685,0.348103522173616,0.157384344023455,2002.5,0.0510018271153799,794.5
"CD011689","CD011689_pub4_data","18|7|Additional uterotonics|","Additional uterotonics",18,7,"","or","binary",3,0.675336310918043,0.217287398229383,0,2006.66666666667,0.0690488300700394,563
"CD011689","CD011689_pub4_data","18|9|Change in haemoglobin|","Change in haemoglobin",18,9,"","or","binary",3,0.0176804224789362,1.15707797850013,0,2006.66666666667,0,563
"CD011689","CD011689_pub4_data","20|1|Death|","Death",20,1,"","or","binary",2,0.026539281620473,1.42004325358767,0,2004.5,0,125
"CD011689","CD011689_pub4_data","20|11|Nausea|","Nausea",20,11,"","or","binary",3,0.0524162413081421,0.704252376775639,0,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","20|12|Vomiting|","Vomiting",20,12,"","or","binary",3,1.60899751706844,0.607662257712958,0.171186170255648,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","20|14|Abdominal pain|","Abdominal pain",20,14,"","or","binary",3,0.567338937873525,1.52458510831384,5.24019962131983,2006,0.06,128
"CD011689","CD011689_pub4_data","20|16|Shivering|","Shivering",20,16,"","or","binary",2,-1.44979707150952,1.20260080868559,0,2012.5,0.0298507462686567,117
"CD011689","CD011689_pub4_data","20|17|Fever|","Fever",20,17,"","or","binary",2,0.667780597833791,1.27164573085781,0,2012.5,0,117
"CD011689","CD011689_pub4_data","20|18|Diarrhoea|","Diarrhoea",20,18,"","or","binary",3,2.4828351392113,0.86595652063004,0,2006,0,128
"CD011689","CD011689_pub4_data","20|3|Blood transfusion|","Blood transfusion",20,3,"","or","binary",2,0,1.42031873718682,0,2012.5,0,117
"CD011689","CD011689_pub4_data","20|7|Additional uterotonics|","Additional uterotonics",20,7,"","or","binary",3,-0.268675473332355,0.417625714858312,0.0429352731865724,2011.66666666667,0.086318407960199,144.666666666667
"CD011689","CD011689_pub4_data","20|8|Blood loss|","Blood loss",20,8,"","or","binary",3,0.0176735900364008,1.15882906611243,0,2006.33333333333,0,150
"CD011689","CD011689_pub4_data","21|18|Diarrhoea|","Diarrhoea",21,18,"","or","binary",2,3.14594922783497,0.524015005972646,0,1998,0.012380088151413,320.5
"CD011689","CD011689_pub4_data","24|11|Nausea|","Nausea",24,11,"","or","binary",4,-1.30932940787626,0.0937025167088189,0,2010,0.167463766067323,1182.5
"CD011689","CD011689_pub4_data","24|12|Vomiting|","Vomiting",24,12,"","or","binary",4,-1.4612079102584,0.114831003821742,0,2010,0.126271014738588,1182.5
"CD011689","CD011689_pub4_data","24|13|Headache|","Headache",24,13,"","or","binary",4,-0.59462500439779,0.255687246694565,0.0665396303130693,2010,0.0403232782992197,1182.5
"CD011689","CD011689_pub4_data","24|14|Abdominal pain|","Abdominal pain",24,14,"","or","binary",3,-0.545945737329806,0.119299726761843,0,2011.33333333333,0.10046490004649,1476.66666666667
"CD011689","CD011689_pub4_data","24|15|Hypertension|","Hypertension",24,15,"","or","binary",3,-0.633359294172666,0.112493015825835,4.94685174960971e-07,2010.33333333333,0.065022640195054,1454.33333333333
"CD011689","CD011689_pub4_data","24|16|Shivering|","Shivering",24,16,"","or","binary",2,-0.935963896477536,0.331901930027089,0,2007.5,0.0902702702702703,335
"CD011689","CD011689_pub4_data","24|2|PPH >= 1000 mL|","PPH >= 1000 mL",24,2,"","or","binary",4,-0.0775897539004846,0.084137797220834,0,2010,0.0497270114942529,1183.25
"CD011689","CD011689_pub4_data","24|3|Blood transfusion|","Blood transfusion",24,3,"","or","binary",4,0.10389616902042,0.188409760241777,0,2010,0.0120850767085077,1182.25
"CD011689","CD011689_pub4_data","24|6|PPH >= 500 mL|","PPH >= 500 mL",24,6,"","or","binary",4,0.0941975065566456,0.0640472537351224,0,2010,0.133804576520094,1183.25
"CD011689","CD011689_pub4_data","24|7|Additional uterotonics|","Additional uterotonics",24,7,"","or","binary",4,0.0922170982346273,0.148115385988385,0.0315807493658765,2010,0.141272993705002,1182.25
"CD011689","CD011689_pub4_data","24|8|Blood loss|","Blood loss",24,8,"","or","binary",3,0,1.15665533030603,0,2008.66666666667,0,303.333333333333
"CD011689","CD011689_pub4_data","24|9|Change in haemoglobin|","Change in haemoglobin",24,9,"","or","binary",2,0,1.41685260205154,0,2008.5,0,270
"CD011689","CD011689_pub4_data","28|12|Vomiting|","Vomiting",28,12,"","or","binary",2,0.00865676622539346,0.637807086242733,0.165371667291148,2002.5,0.00752518812970324,802.5
"CD011689","CD011689_pub4_data","28|16|Shivering|","Shivering",28,16,"","or","binary",2,1.15344902872407,0.20291490988917,0,2002.5,0.0424760619015475,802.5
"CD011689","CD011689_pub4_data","28|17|Fever|","Fever",28,17,"","or","binary",2,1.04026797683743,0.327733512487069,0,2002.5,0.0150003750093752,802.5
"CD011689","CD011689_pub4_data","28|18|Diarrhoea|","Diarrhoea",28,18,"","or","binary",2,-0.211483396826395,0.286349944324649,0,2002.5,0.0337945948648716,802.5
"CD011689","CD011689_pub4_data","28|2|PPH >= 1000 mL|","PPH >= 1000 mL",28,2,"","or","binary",2,0.3264054678897,0.368305457973482,0,2002.5,0.0149878746968674,802.5
"CD011689","CD011689_pub4_data","28|3|Blood transfusion|","Blood transfusion",28,3,"","or","binary",2,-0.103994704628308,0.440231980603939,0,2002.5,0.0125128128203205,802.5
"CD011689","CD011689_pub4_data","28|6|PPH >= 500 mL|","PPH >= 500 mL",28,6,"","or","binary",2,0.336981326043,0.401589175917246,0.194966126654717,2002.5,0.0350008750218755,802.5
"CD011689","CD011689_pub4_data","28|7|Additional uterotonics|","Additional uterotonics",28,7,"","or","binary",2,0.388565465726023,0.303838179879924,0,2002.5,0.0225005625140628,802.5
"CD011689","CD011689_pub4_data","28|9|Change in haemoglobin|","Change in haemoglobin",28,9,"","or","binary",2,-0.00622833036225827,1.41509334764921,0,2002.5,0,802.5
"CD011689","CD011689_pub4_data","29|1|Death|Vaginal birth","Death",29,1,"Vaginal birth","or","binary",2,0.432577878443674,1.41617997980045,0,2004.5,0,895
"CD011689","CD011689_pub4_data","29|11|Nausea|Vaginal birth","Nausea",29,11,"Vaginal birth","or","binary",2,-0.148899581039255,0.29157669788737,0,2003.5,0.0354496548924076,857
"CD011689","CD011689_pub4_data","29|12|Vomiting|Vaginal birth","Vomiting",29,12,"Vaginal birth","or","binary",2,0.295322751494113,0.543392641637037,0,2008.5,0.00471175166297117,1038
"CD011689","CD011689_pub4_data","29|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",29,2,"Vaginal birth","or","binary",7,-0.571135637233517,0.103769415731733,0,2005.42857142857,0.0853883659454934,1075
"CD011689","CD011689_pub4_data","29|3|Blood transfusion|Vaginal birth","Blood transfusion",29,3,"Vaginal birth","or","binary",4,-0.248111906251391,0.217794945907817,0,2008.25,0.0185670803942218,1359.25
"CD011689","CD011689_pub4_data","29|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",29,6,"Vaginal birth","or","binary",6,-0.579709770294819,0.078604856484301,0.000910791022991699,2004.5,0.278300362689724,982.333333333333
"CD011689","CD011689_pub4_data","29|7|Additional uterotonics|Caesarean","Additional uterotonics",29,7,"Caesarean","or","binary",2,-2.56682053346364,0.961034910440093,1.32847648882495,2011.5,0.693333333333333,62.5
"CD011689","CD011689_pub4_data","29|7|Additional uterotonics|Vaginal birth","Additional uterotonics",29,7,"Vaginal birth","or","binary",4,-0.813322601986453,0.29377816114383,0.209631621528594,2003.25,0.146473676581236,961.5
"CD011689","CD011689_pub4_data","29|8|Blood loss|Caesarean","Blood loss",29,8,"Caesarean","or","binary",2,-0.691451218784789,1.42813445137709,0,2011.5,0,62.5
"CD011689","CD011689_pub4_data","29|8|Blood loss|Vaginal birth","Blood loss",29,8,"Vaginal birth","or","binary",4,0.146042738402618,1.00333385063869,0,1999.75,0,580
"CD011689","CD011689_pub4_data","29|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",29,9,"Vaginal birth","or","binary",2,0.0643123800777456,1.41527990832732,0,2006,0,1023.5
"CD011689","CD011689_pub4_data","3|1|Death|","Death",3,1,"","or","binary",4,0.0174749729686995,0.895815351059557,0,2009.5,0.000309405940594059,874.25
"CD011689","CD011689_pub4_data","3|11|Nausea|","Nausea",3,11,"","or","binary",4,0.173042777281852,0.211209241554146,1.66869486998116e-06,2005.75,0.0162577853792334,999.25
"CD011689","CD011689_pub4_data","3|12|Vomiting|","Vomiting",3,12,"","or","binary",6,0.398004579396395,0.247181623987134,0.0395688990993971,2003.66666666667,0.0105032447752556,824.833333333333
"CD011689","CD011689_pub4_data","3|14|Abdominal pain|","Abdominal pain",3,14,"","or","binary",3,0.0256400923682615,0.619008852717826,0.628230334975951,1999,0.0437777777777778,548.666666666667
"CD011689","CD011689_pub4_data","3|16|Shivering|","Shivering",3,16,"","or","binary",8,1.44972167287728,0.150702921344895,0.0755908712586876,2002.375,0.0938613580375343,629.75
"CD011689","CD011689_pub4_data","3|17|Fever|","Fever",3,17,"","or","binary",5,1.5238374267297,0.520514306008558,1.02539537859481,2004.8,0.0235205186239122,879.2
"CD011689","CD011689_pub4_data","3|18|Diarrhoea|","Diarrhoea",3,18,"","or","binary",5,0.897517312594216,0.394370840631436,0,2004.2,0.00357863460062018,908.6
"CD011689","CD011689_pub4_data","3|2|PPH >= 1000 mL|","PPH >= 1000 mL",3,2,"","or","binary",7,-0.326086700217547,0.124972803067474,4.46250563889346e-07,2002.85714285714,0.0762206462411439,771.428571428571
"CD011689","CD011689_pub4_data","3|3|Blood transfusion|","Blood transfusion",3,3,"","or","binary",4,-0.787466989520692,0.561580498205053,0,2005.25,0.00483250825082508,704.75
"CD011689","CD011689_pub4_data","3|6|PPH >= 500 mL|","PPH >= 500 mL",3,6,"","or","binary",6,-0.370584160994824,0.134686146139998,0.0456808085390294,2004.16666666667,0.231748302138907,663.333333333333
"CD011689","CD011689_pub4_data","3|7|Additional uterotonics|","Additional uterotonics",3,7,"","or","binary",6,-0.45736294279724,0.151665411680244,0,2003,0.141508568503909,571.833333333333
"CD011689","CD011689_pub4_data","3|8|Blood loss|","Blood loss",3,8,"","or","binary",7,0.0558070431259394,0.757913975878223,0,2005.85714285714,0,582.714285714286
"CD011689","CD011689_pub4_data","3|9|Change in haemoglobin|","Change in haemoglobin",3,9,"","or","binary",4,0.0627220757094974,1.00184123205264,0,2008.25,0,566.75
"CD011689","CD011689_pub4_data","31|1|Death|Vaginal birth","Death",31,1,"Vaginal birth","or","binary",4,0.0174749729686995,0.895815351059557,0,2009.5,0.000309405940594059,874.25
"CD011689","CD011689_pub4_data","31|11|Nausea|Vaginal birth","Nausea",31,11,"Vaginal birth","or","binary",4,0.173042777281852,0.211209241554146,1.66869486998116e-06,2005.75,0.0162577853792334,999.25
"CD011689","CD011689_pub4_data","31|12|Vomiting|Vaginal birth","Vomiting",31,12,"Vaginal birth","or","binary",6,0.398004579396395,0.247181623987134,0.0395688990993971,2003.66666666667,0.0105032447752556,824.833333333333
"CD011689","CD011689_pub4_data","31|14|Abdominal pain|Vaginal birth","Abdominal pain",31,14,"Vaginal birth","or","binary",3,0.0256400923682615,0.619008852717826,0.628230334975951,1999,0.0437777777777778,548.666666666667
"CD011689","CD011689_pub4_data","31|16|Shivering|Vaginal birth","Shivering",31,16,"Vaginal birth","or","binary",8,1.44972167287728,0.150702921344895,0.0755908712586876,2002.375,0.0938613580375343,629.75
"CD011689","CD011689_pub4_data","31|17|Fever|Vaginal birth","Fever",31,17,"Vaginal birth","or","binary",5,1.5238374267297,0.520514306008558,1.02539537859481,2004.8,0.0235205186239122,879.2
"CD011689","CD011689_pub4_data","31|18|Diarrhoea|Vaginal birth","Diarrhoea",31,18,"Vaginal birth","or","binary",5,0.897517312594216,0.394370840631436,0,2004.2,0.00357863460062018,908.6
"CD011689","CD011689_pub4_data","31|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",31,2,"Vaginal birth","or","binary",7,-0.326086700217547,0.124972803067474,4.46250563889346e-07,2002.85714285714,0.0762206462411439,771.428571428571
"CD011689","CD011689_pub4_data","31|3|Blood transfusion|Vaginal birth","Blood transfusion",31,3,"Vaginal birth","or","binary",4,-0.787466989520692,0.561580498205053,0,2005.25,0.00483250825082508,704.75
"CD011689","CD011689_pub4_data","31|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",31,6,"Vaginal birth","or","binary",6,-0.370584160994824,0.134686146139998,0.0456808085390294,2004.16666666667,0.231748302138907,663.333333333333
"CD011689","CD011689_pub4_data","31|7|Additional uterotonics|Vaginal birth","Additional uterotonics",31,7,"Vaginal birth","or","binary",6,-0.45736294279724,0.151665411680244,0,2003,0.141508568503909,571.833333333333
"CD011689","CD011689_pub4_data","31|8|Blood loss|Vaginal birth","Blood loss",31,8,"Vaginal birth","or","binary",7,0.0558070431259394,0.757913975878223,0,2005.85714285714,0,582.714285714286
"CD011689","CD011689_pub4_data","31|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",31,9,"Vaginal birth","or","binary",4,0.0627220757094974,1.00184123205264,0,2008.25,0,566.75
"CD011689","CD011689_pub4_data","32|7|Additional uterotonics|Vaginal birth","Additional uterotonics",32,7,"Vaginal birth","or","binary",2,-0.433800485020153,0.615888759240413,0,2003.5,0.0916666666666667,73
"CD011689","CD011689_pub4_data","32|8|Blood loss|Vaginal birth","Blood loss",32,8,"Vaginal birth","or","binary",2,0.0423396365605827,1.42518491500181,0,2003.5,0,73
"CD011689","CD011689_pub4_data","33|3|Blood transfusion|Vaginal birth","Blood transfusion",33,3,"Vaginal birth","or","binary",2,-0.665979359718477,0.878931091158685,0,2003,0.00207182320441989,764.5
"CD011689","CD011689_pub4_data","33|7|Additional uterotonics|Vaginal birth","Additional uterotonics",33,7,"Vaginal birth","or","binary",2,-1.64917486126375,0.493320771243391,0.253946090878428,2003,0.114226519337017,764.5
"CD011689","CD011689_pub4_data","33|8|Blood loss|Vaginal birth","Blood loss",33,8,"Vaginal birth","or","binary",2,0.0133483058069919,1.41794157251375,0,2003,0,764.5
"CD011689","CD011689_pub4_data","34|10|Breastfeeding|Vaginal birth","Breastfeeding",34,10,"Vaginal birth","or","binary",2,0.106801168208271,0.079759310865218,0,1993,0.719715680289099,1603.5
"CD011689","CD011689_pub4_data","34|12|Vomiting|Vaginal delivery","Vomiting",34,12,"Vaginal delivery","or","binary",2,0.804322837954812,0.180089320025217,0.0178926531163072,1993,0.0435167027423701,1603.5
"CD011689","CD011689_pub4_data","34|13|Headache|Vaginal birth","Headache",34,13,"Vaginal birth","or","binary",2,0.473265947570906,0.370661957505019,0,1993,0.00667477599146517,1603.5
"CD011689","CD011689_pub4_data","34|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",34,2,"Vaginal birth","or","binary",2,-0.81617593298649,0.437100870971701,0.234094666919307,1993,0.0284011371555079,1603.5
"CD011689","CD011689_pub4_data","34|3|Blood transfusion|Vaginal birth","Blood transfusion",34,3,"Vaginal birth","or","binary",3,-1.06545670349694,0.242598899806918,1.80161944233647e-06,1993,0.0275717043149008,1133.33333333333
"CD011689","CD011689_pub4_data","34|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",34,6,"Vaginal birth","or","binary",2,-1.11501759482402,0.125411569770453,0.00178350742152809,1993,0.171977811900665,1603.5
"CD011689","CD011689_pub4_data","34|7|Additional uterotonics|Vaginal birth","Additional uterotonics",34,7,"Vaginal birth","or","binary",3,-1.89873067607777,0.128235328261454,0,1993,0.195110183352279,1133.33333333333
"CD011689","CD011689_pub4_data","34|8|Blood loss|Vaginal birth","Blood loss",34,8,"Vaginal birth","or","binary",2,-0.0563605312423161,1.41627283068443,0,1995.5,0,852.5
"CD011689","CD011689_pub4_data","34|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",34,9,"Vaginal birth","or","binary",2,-0.0725230970783431,1.41631942714883,0,1990.5,0,727
"CD011689","CD011689_pub4_data","36|1|Death|Vaginal birth","Death",36,1,"Vaginal birth","or","binary",15,-0.15416567308949,0.453296864247824,0,2007.21428571429,0.000309430898985928,1782.86666666667
"CD011689","CD011689_pub4_data","36|11|Nausea|Caesarean","Nausea",36,11,"Caesarean","or","binary",2,-0.063414600374725,0.965267821433221,1.00809061901494,2013,0.09,100
"CD011689","CD011689_pub4_data","36|11|Nausea|Vaginal birth","Nausea",36,11,"Vaginal birth","or","binary",16,0.195919251385383,0.198148713350168,0.205548297408988,2006.8125,0.0257768548386665,1651.625
"CD011689","CD011689_pub4_data","36|12|Vomiting|Caesarean","Vomiting",36,12,"Caesarean","or","binary",6,-0.509069029959135,0.535378500218907,0.932111085648629,2009.83333333333,0.101985815602837,110
"CD011689","CD011689_pub4_data","36|12|Vomiting|Vaginal birth","Vomiting",36,12,"Vaginal birth","or","binary",21,0.576123128655799,0.135177652848897,0.0125821620582711,2006.33333333333,0.0196308344358102,1381
"CD011689","CD011689_pub4_data","36|13|Headache|Caesarean","Headache",36,13,"Caesarean","or","binary",3,-1.22024760501532,0.692810438895461,0.929134491097056,2011,0.206666666666667,103.333333333333
"CD011689","CD011689_pub4_data","36|13|Headache|Vaginal birth","Headache",36,13,"Vaginal birth","or","binary",3,0.189268711695957,0.342134723987233,0.0281135570655236,2007.33333333333,0.019634457687857,900.666666666667
"CD011689","CD011689_pub4_data","36|14|Abdominal pain|Vaginal birth","Abdominal pain",36,14,"Vaginal birth","or","binary",3,-0.258712238795469,0.12875954804064,0,2009.33333333333,0.13471557682084,669
"CD011689","CD011689_pub4_data","36|15|Hypertension|Vaginal birth","Hypertension",36,15,"Vaginal birth","or","binary",2,1.3931338008018,1.12606532784923,0,2006.5,0,414
"CD011689","CD011689_pub4_data","36|16|Shivering|Caesarean","Shivering",36,16,"Caesarean","or","binary",7,1.72542725055606,0.37542196284609,0.368392818034068,2008.57142857143,0.102472137791287,100
"CD011689","CD011689_pub4_data","36|16|Shivering|Vaginal birth","Shivering",36,16,"Vaginal birth","or","binary",24,1.82724409369966,0.266499253684606,1.39519243829841,2006.13043478261,0.0798740618317882,1248.70833333333
"CD011689","CD011689_pub4_data","36|17|Fever|Caesarean","Fever",36,17,"Caesarean","or","binary",5,0.0274102815760813,0.573061271864519,0.633929715239795,2009.6,0.0365106382978723,108
"CD011689","CD011689_pub4_data","36|17|Fever|Vaginal birth","Fever",36,17,"Vaginal birth","or","binary",21,1.52617635170605,0.200557648781506,0.38999883305845,2006.8,0.0179144508501796,1380.80952380952
"CD011689","CD011689_pub4_data","36|18|Diarrhoea|Vaginal birth","Diarrhoea",36,18,"Vaginal birth","or","binary",18,0.651847843638688,0.198890003809926,0.0917990188062777,2006.66666666667,0.0133177750721546,1580.66666666667
"CD011689","CD011689_pub4_data","36|2|PPH >= 1000 mL|Caesarean","PPH >= 1000 mL",36,2,"Caesarean","or","binary",5,-0.475510241731328,0.333902091030164,0,2005.8,0.109432624113475,98
"CD011689","CD011689_pub4_data","36|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",36,2,"Vaginal birth","or","binary",20,0.275816357545914,0.0796903252812986,0.00258422310532816,2004.42105263158,0.02181151116122,1477.5
"CD011689","CD011689_pub4_data","36|3|Blood transfusion|Caesarean","Blood transfusion",36,3,"Caesarean","or","binary",4,-0.0202895072247057,0.729700164782495,0,2005.75,0.0163120567375887,97.5
"CD011689","CD011689_pub4_data","36|3|Blood transfusion|Vaginal birth","Blood transfusion",36,3,"Vaginal birth","or","binary",19,-0.221718800700757,0.116868647834409,0,2004.61111111111,0.0104635420578051,1537.47368421053
"CD011689","CD011689_pub4_data","36|4|Severe maternal morbidity: intensive care admissions|Vaginal birth","Severe maternal morbidity: intensive care admissions",36,4,"Vaginal birth","or","binary",5,0.124105483481402,0.352996803327062,0,2008,0.00291534816892736,4161.6
"CD011689","CD011689_pub4_data","36|6|PPH >= 500 mL|Caesarean","PPH >= 500 mL",36,6,"Caesarean","or","binary",4,-0.00676566793659512,0.352675114265191,0.230656990512646,2007,0.71313829787234,107.5
"CD011689","CD011689_pub4_data","36|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",36,6,"Vaginal birth","or","binary",20,0.17009178444674,0.117038836190336,0.11890860680504,2004.95,0.0860126491183652,1456.3
"CD011689","CD011689_pub4_data","36|7|Additional uterotonics|Caesarean","Additional uterotonics",36,7,"Caesarean","or","binary",7,-0.0821926111645748,0.188800555545665,1.09544633668464e-07,2008.57142857143,0.214133738601824,100
"CD011689","CD011689_pub4_data","36|7|Additional uterotonics|Vaginal birth","Additional uterotonics",36,7,"Vaginal birth","or","binary",20,0.1902870866728,0.104345111414106,0.101775348788062,2005.15789473684,0.0916206711086693,1475
"CD011689","CD011689_pub4_data","36|8|Blood loss|Caesarean","Blood loss",36,8,"Caesarean","or","binary",6,-0.0337275878010047,0.821561806866165,0,2007.5,0,100
"CD011689","CD011689_pub4_data","36|9|Change in haemoglobin|Caesarean","Change in haemoglobin",36,9,"Caesarean","or","binary",5,-0.00422250789586345,0.900384555249975,0,2006.6,0,97.6
"CD011689","CD011689_pub4_data","36|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",36,9,"Vaginal birth","or","binary",15,-0.118319024061233,0.517052862684985,0,2006.13333333333,0,548.733333333333
"CD011689","CD011689_pub4_data","38|1|Death|Caesarean","Death",38,1,"Caesarean","or","binary",2,-0.0144538125718885,1.42119192321946,0,2004,0,217
"CD011689","CD011689_pub4_data","38|1|Death|Vaginal birth","Death",38,1,"Vaginal birth","or","binary",3,0.445883408758175,0.689028199457696,0,2016,4.51426507764536e-05,11322
"CD011689","CD011689_pub4_data","38|11|Nausea|Caesarean","Nausea",38,11,"Caesarean","or","binary",7,0.0794259459590094,0.290733476015256,0.349000621834105,2010.14285714286,0.169842109312401,230.857142857143
"CD011689","CD011689_pub4_data","38|12|Vomiting|Caesarean","Vomiting",38,12,"Caesarean","or","binary",5,0.249836003067574,0.39978090268153,0.377422010866888,2008.4,0.0645397139244555,300.4
"CD011689","CD011689_pub4_data","38|13|Headache|Caesarean","Headache",38,13,"Caesarean","or","binary",7,0.170454965338606,0.190341778219706,0,2009.42857142857,0.0598200212052316,229.857142857143
"CD011689","CD011689_pub4_data","38|14|Abdominal pain|Caesarean","Abdominal pain",38,14,"Caesarean","or","binary",3,0.0450326400484413,0.159062454065547,0,2002.33333333333,0.14679212006256,356.333333333333
"CD011689","CD011689_pub4_data","38|16|Shivering|Caesarean","Shivering",38,16,"Caesarean","or","binary",4,-0.350269702851025,0.215067812301575,0,2005,0.0606399409465447,306.25
"CD011689","CD011689_pub4_data","38|16|Shivering|Vaginal birth","Shivering",38,16,"Vaginal birth","or","binary",2,0.0973894710721707,0.510324984121207,0,2004,0.0454545454545455,147.5
"CD011689","CD011689_pub4_data","38|2|PPH >= 1000 mL|Caesarean","PPH >= 1000 mL",38,2,"Caesarean","or","binary",6,-0.0384510073726756,0.202035562624975,0,2013.66666666667,0.0935875678014043,154.5
"CD011689","CD011689_pub4_data","38|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",38,2,"Vaginal birth","or","binary",4,-0.0350661283437329,0.0692310686634496,0.00173856317179696,2016.66666666667,0.05934056045497,8526.25
"CD011689","CD011689_pub4_data","38|3|Blood transfusion|Caesarean","Blood transfusion",38,3,"Caesarean","or","binary",4,-0.122609629953158,0.464915711034951,0,2005.75,0.0129030647898572,295.25
"CD011689","CD011689_pub4_data","38|6|PPH >= 500 mL|Caesarean","PPH >= 500 mL",38,6,"Caesarean","or","binary",3,0.17658898214371,0.346694766777372,0,2009,0.283986453797775,73.3333333333333
"CD011689","CD011689_pub4_data","38|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",38,6,"Vaginal birth","or","binary",5,-0.00374323026391835,0.0336811118490906,5.36500183989846e-07,2013.5,0.217470261095976,6875.6
"CD011689","CD011689_pub4_data","38|7|Additional uterotonics|Caesarean","Additional uterotonics",38,7,"Caesarean","or","binary",10,-0.352671128018451,0.186870003479619,0.0711688422627596,2012.3,0.150838234498527,183.8
"CD011689","CD011689_pub4_data","38|8|Blood loss|Caesarean","Blood loss",38,8,"Caesarean","or","binary",5,-0.0261395396745003,0.90017623842066,0,2012,0,131.2
"CD011689","CD011689_pub4_data","38|8|Blood loss|Vaginal birth","Blood loss",38,8,"Vaginal birth","or","binary",3,0.00702028751147843,1.15700937183367,0,2011,0,368.333333333333
"CD011689","CD011689_pub4_data","38|9|Change in haemoglobin|Caesarean","Change in haemoglobin",38,9,"Caesarean","or","binary",6,-0.0363914430281685,0.821572616359587,0,2011.16666666667,0,204.333333333333
"CD011689","CD011689_pub4_data","39|11|Nausea|Vaginal birth","Nausea",39,11,"Vaginal birth","or","binary",5,1.84519565591948,0.887440925553133,3.13277300091615,1996.6,0.0176401602292744,485.8
"CD011689","CD011689_pub4_data","39|12|Vomiting|Vaginal birth","Vomiting",39,12,"Vaginal birth","or","binary",4,1.14950490572655,0.840992405498454,1.98147843933607,2007.5,0.0225670120115578,560.75
"CD011689","CD011689_pub4_data","39|13|Headache|Vaginal birth","Headache",39,13,"Vaginal birth","or","binary",3,1.64058984747311,1.39235968528346,4.84042806745819,2009.33333333333,0.00991051910368836,731
"CD011689","CD011689_pub4_data","39|15|Hypertension|Vaginal birth","Hypertension",39,15,"Vaginal birth","or","binary",3,2.82151069299713,0.774459371238649,0.939903539325853,2009.66666666667,0.0377604166666667,470
"CD011689","CD011689_pub4_data","39|16|Shivering|Vaginal birth","Shivering",39,16,"Vaginal birth","or","binary",2,0.551491780699088,0.325065940854272,0,2004,0.0113452188006483,671.5
"CD011689","CD011689_pub4_data","39|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",39,2,"Vaginal birth","or","binary",5,0.228290655741033,0.446346937357613,0,2000.4,0.0252965964343598,508.2
"CD011689","CD011689_pub4_data","39|3|Blood transfusion|Vaginal birth","Blood transfusion",39,3,"Vaginal birth","or","binary",2,-0.79762588284575,1.06650287965038,1.5386347368304,2010,0.031422070046261,796.5
"CD011689","CD011689_pub4_data","39|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",39,6,"Vaginal birth","or","binary",7,0.207230179622489,0.214014774273717,0.0381214922235687,1998.85714285714,0.10805692522749,417.285714285714
"CD011689","CD011689_pub4_data","39|7|Additional uterotonics|Vaginal birth","Additional uterotonics",39,7,"Vaginal birth","or","binary",3,-0.166551767159972,0.548652546543823,0.813075602274731,2009.33333333333,0.117994156902783,731
"CD011689","CD011689_pub4_data","39|8|Blood loss|Vaginal birth","Blood loss",39,8,"Vaginal birth","or","binary",7,-0.0129586016359787,0.758656158954658,0,1998.85714285714,0,417.285714285714
"CD011689","CD011689_pub4_data","39|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",39,9,"Vaginal birth","or","binary",2,-0.0556262179341261,1.41507528829908,0,2007,0,946.5
"CD011689","CD011689_pub4_data","4|7|Additional uterotonics|","Additional uterotonics",4,7,"","or","binary",2,-0.433800485020153,0.615888759240413,0,2003.5,0.0916666666666667,73
"CD011689","CD011689_pub4_data","4|8|Blood loss|","Blood loss",4,8,"","or","binary",2,0.0423396365605827,1.42518491500181,0,2003.5,0,73
"CD011689","CD011689_pub4_data","40|11|Nausea|Caesarean","Nausea",40,11,"Caesarean","or","binary",3,0.89238893724784,0.483060494459285,0.434326081538216,2015,0.225508084853879,177.333333333333
"CD011689","CD011689_pub4_data","40|12|Vomiting|Caesarean","Vomiting",40,12,"Caesarean","or","binary",3,0.7165538224044,0.35916924987302,4.84636011069854e-07,2015,0.088343717549325,177.333333333333
"CD011689","CD011689_pub4_data","40|13|Headache|Caesarean","Headache",40,13,"Caesarean","or","binary",2,0.530440776452578,0.855300857536673,0.841221505760729,2018.5,0.0467289719626168,242
"CD011689","CD011689_pub4_data","40|15|Hypertension|Caesarean","Hypertension",40,15,"Caesarean","or","binary",2,-0.45474587635929,0.535176889893375,0,2014.5,0.169047619047619,58
"CD011689","CD011689_pub4_data","40|15|Hypertension|Vaginal birth","Hypertension",40,15,"Vaginal birth","or","binary",2,0.61316267309462,0.10991247434657,0,2008,0.0425031775765253,2399.5
"CD011689","CD011689_pub4_data","40|16|Shivering|Vaginal birth","Shivering",40,16,"Vaginal birth","or","binary",2,-0.0409769210693929,0.243988412778522,0,2002.5,0.044395602989353,795.5
"CD011689","CD011689_pub4_data","40|17|Fever|Vaginal birth","Fever",40,17,"Vaginal birth","or","binary",2,0.0703501043175079,0.403837956946321,0,2002.5,0.013881424037674,795.5
"CD011689","CD011689_pub4_data","40|18|Diarrhoea|Vaginal birth","Diarrhoea",40,18,"Vaginal birth","or","binary",3,0.209088888621586,0.287074514192774,0,2001.33333333333,0.017787674037674,676.666666666667
"CD011689","CD011689_pub4_data","40|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",40,2,"Vaginal birth","or","binary",8,-0.189150407946421,0.116542732469187,0.0217669785212537,2002.125,0.0443066065908641,1628.25
"CD011689","CD011689_pub4_data","40|3|Blood transfusion|Caesarean","Blood transfusion",40,3,"Caesarean","or","binary",3,-1.17838709177754,0.339966581287564,0,2015.33333333333,0.104595015576324,208
"CD011689","CD011689_pub4_data","40|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",40,6,"Vaginal birth","or","binary",8,-0.1190531977739,0.0489789013410505,7.00175450289179e-06,2002.125,0.120318326343955,1628.25
"CD011689","CD011689_pub4_data","40|7|Additional uterotonics|Caesarean","Additional uterotonics",40,7,"Caesarean","or","binary",4,-0.681589184811553,0.480344418245689,0.71304874967295,2016.75,0.384465398308856,173
"CD011689","CD011689_pub4_data","40|8|Blood loss|Caesarean","Blood loss",40,8,"Caesarean","or","binary",3,0.0193280528822828,1.16023786926478,0,2015.33333333333,0,208
"CD011689","CD011689_pub4_data","40|8|Blood loss|Vaginal birth","Blood loss",40,8,"Vaginal birth","or","binary",5,-0.182642696750351,0.896734372673952,0,1998.8,0,589.6
"CD011689","CD011689_pub4_data","40|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",40,9,"Vaginal birth","or","binary",4,-0.227286648155773,1.00078286456296,0,2001.5,0,752.5
"CD011689","CD011689_pub4_data","41|1|Death|Caesarean","Death",41,1,"Caesarean","or","binary",2,-0.0551709912757403,1.42160725082736,0,2010.5,0,224.5
"CD011689","CD011689_pub4_data","41|1|Death|Vaginal birth","Death",41,1,"Vaginal birth","or","binary",4,0.00487805439512793,1.00079919279263,0,2010,0,886.75
"CD011689","CD011689_pub4_data","41|11|Nausea|Caesarean","Nausea",41,11,"Caesarean","or","binary",3,0.433039509182499,0.788913996264595,1.20871829596083,2010,0.076,134.333333333333
"CD011689","CD011689_pub4_data","41|11|Nausea|Vaginal birth","Nausea",41,11,"Vaginal birth","or","binary",2,1.18404144153146,0.349355263487417,0,2012.5,0.00645148533361136,1501.5
"CD011689","CD011689_pub4_data","41|12|Vomiting|Caesarean","Vomiting",41,12,"Caesarean","or","binary",2,0.300451694333693,0.391092126387727,0,2012,0.06,175
"CD011689","CD011689_pub4_data","41|12|Vomiting|Vaginal birth","Vomiting",41,12,"Vaginal birth","or","binary",5,0.969059705178562,0.339707441477715,0.176460444465129,2006.8,0.00625248793208414,1071
"CD011689","CD011689_pub4_data","41|13|Headache|Caesarean","Headache",41,13,"Caesarean","or","binary",2,0.244575786268595,0.733007567241649,0.0280176621823818,2007.5,0.028,151.5
"CD011689","CD011689_pub4_data","41|16|Shivering|Caesarean","Shivering",41,16,"Caesarean","or","binary",5,1.22001564347747,0.349256725375787,0.122497396317849,2011,0.0387111111111111,191.8
"CD011689","CD011689_pub4_data","41|16|Shivering|Vaginal birth","Shivering",41,16,"Vaginal birth","or","binary",7,1.61442750960997,0.301630242164372,0.488164738358777,2008.71428571429,0.0536927587732473,964.571428571429
"CD011689","CD011689_pub4_data","41|17|Fever|Caesarean","Fever",41,17,"Caesarean","or","binary",4,1.0146877579758,0.371436851335601,0,2012.25,0.0203005050505051,226.5
"CD011689","CD011689_pub4_data","41|17|Fever|Vaginal birth","Fever",41,17,"Vaginal birth","or","binary",6,1.58418302822399,0.34705499139239,0.569704186456564,2009.5,0.0314794286311269,992.333333333333
"CD011689","CD011689_pub4_data","41|18|Diarrhoea|Vaginal birth","Diarrhoea",41,18,"Vaginal birth","or","binary",5,0.642441989932328,0.437854716695666,0.409171629414729,2009.2,0.0112456703251832,977.4
"CD011689","CD011689_pub4_data","41|2|PPH >= 1000 mL|Caesarean","PPH >= 1000 mL",41,2,"Caesarean","or","binary",6,-0.118731464708105,0.191704409530754,0,2012.33333333333,0.175292922448989,231.833333333333
"CD011689","CD011689_pub4_data","41|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",41,2,"Vaginal birth","or","binary",6,-0.226549539428258,0.192436906404822,2.22132331635539e-06,2009.5,0.0233559883689487,997.666666666667
"CD011689","CD011689_pub4_data","41|3|Blood transfusion|Caesarean","Blood transfusion",41,3,"Caesarean","or","binary",6,-1.08355843043836,0.494458923651924,0.624210390363409,2012.16666666667,0.0927813158215913,216.5
"CD011689","CD011689_pub4_data","41|3|Blood transfusion|Vaginal birth","Blood transfusion",41,3,"Vaginal birth","or","binary",6,-0.856941952178628,0.221786141075119,0,2008.33333333333,0.0324794424396844,940.5
"CD011689","CD011689_pub4_data","41|6|PPH >= 500 mL|Caesarean","PPH >= 500 mL",41,6,"Caesarean","or","binary",2,-0.892782240255639,0.37857147955495,0.141465194396043,2010.5,0.728070175438597,219.5
"CD011689","CD011689_pub4_data","41|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",41,6,"Vaginal birth","or","binary",7,-0.421312271401338,0.142118588076474,0.0591806517326687,2008.71428571429,0.0794925081895818,963.142857142857
"CD011689","CD011689_pub4_data","41|7|Additional uterotonics|Caesarean","Additional uterotonics",41,7,"Caesarean","or","binary",6,-1.02528748001521,0.246039421674462,0.16106774314548,2013.16666666667,0.283913606639344,191.5
"CD011689","CD011689_pub4_data","41|7|Additional uterotonics|Vaginal birth","Additional uterotonics",41,7,"Vaginal birth","or","binary",6,-0.516187111275073,0.128737886271283,0,2008.33333333333,0.0712334153342197,940.5
"CD011689","CD011689_pub4_data","41|8|Blood loss|Caesarean","Blood loss",41,8,"Caesarean","or","binary",5,-0.0151556859208939,0.897289977834537,0,2011.6,0,256.2
"CD011689","CD011689_pub4_data","41|8|Blood loss|Vaginal birth","Blood loss",41,8,"Vaginal birth","or","binary",6,-0.00764203569586855,0.817061036875059,0,2009.83333333333,0,987.333333333333
"CD011689","CD011689_pub4_data","41|9|Change in haemoglobin|Caesarean","Change in haemoglobin",41,9,"Caesarean","or","binary",5,0.00681221794357483,0.896529395269429,0,2013.4,0,265.6
"CD011689","CD011689_pub4_data","41|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",41,9,"Vaginal birth","or","binary",6,-0.0079234966360974,0.817082718644199,0,2008.33333333333,0,940.5
"CD011689","CD011689_pub4_data","42|11|Nausea|Vaginal birth","Nausea",42,11,"Vaginal birth","or","binary",2,-1.38366309759874,0.679961356409058,0,2012.5,0.105454545454545,116.5
"CD011689","CD011689_pub4_data","42|12|Vomiting|Vaginal birth","Vomiting",42,12,"Vaginal birth","or","binary",2,0.433367065256183,2.43030967715957,10.3622339090668,2012.5,0.0606060606060606,116.5
"CD011689","CD011689_pub4_data","42|14|Abdominal pain|Vaginal birth","Abdominal pain",42,14,"Vaginal birth","or","binary",2,-0.00958709785789779,0.719509699495266,0,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","42|16|Shivering|Vaginal birth","Shivering",42,16,"Vaginal birth","or","binary",3,-3.49530476689641,0.845040457334265,0,2010.33333333333,0.240909090909091,117.666666666667
"CD011689","CD011689_pub4_data","42|17|Fever|Vaginal birth","Fever",42,17,"Vaginal birth","or","binary",2,-2.48688105519947,0.75667426088116,0,2012.5,0.158484848484848,116.5
"CD011689","CD011689_pub4_data","42|18|Diarrhoea|Vaginal birth","Diarrhoea",42,18,"Vaginal birth","or","binary",2,2.01195351180716,0.775741644634454,0,2012.5,0.00757575757575758,116.5
"CD011689","CD011689_pub4_data","42|3|Blood transfusion|Vaginal birth","Blood transfusion",42,3,"Vaginal birth","or","binary",3,-0.841077219825658,1.00568003989599,0,2010.33333333333,0.0106060606060606,117.666666666667
"CD011689","CD011689_pub4_data","42|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",42,6,"Vaginal birth","or","binary",2,0.296812876923238,0.400203686518096,0,2007.5,0.0939393939393939,126.5
"CD011689","CD011689_pub4_data","42|7|Additional uterotonics|Vaginal birth","Additional uterotonics",42,7,"Vaginal birth","or","binary",3,-0.223825197554772,0.722833657556914,1.04619768003177,2010.33333333333,0.107676767676768,117.666666666667
"CD011689","CD011689_pub4_data","42|8|Blood loss|Vaginal birth","Blood loss",42,8,"Vaginal birth","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","42|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",42,9,"Vaginal birth","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","44|1|Death|Vaginal birth","Death",44,1,"Vaginal birth","or","binary",6,0.315173149764195,0.817687483703423,0,2008.33333333333,0,825.666666666667
"CD011689","CD011689_pub4_data","44|11|Nausea|Vaginal birth","Nausea",44,11,"Vaginal birth","or","binary",9,0.339587195586082,0.184460560293809,0.0951042054542211,2006.77777777778,0.0887916605478144,500.444444444444
"CD011689","CD011689_pub4_data","44|12|Vomiting|Vaginal birth","Vomiting",44,12,"Vaginal birth","or","binary",10,0.038238008421656,0.259666260576112,0.277548744658102,2006.4,0.0512524294700984,543.8
"CD011689","CD011689_pub4_data","44|13|Headache|Vaginal birth","Headache",44,13,"Vaginal birth","or","binary",5,0.802670728989554,0.663823317248239,1.74344921269308,2004.8,0.0479994139155689,574.2
"CD011689","CD011689_pub4_data","44|14|Abdominal pain|Vaginal birth","Abdominal pain",44,14,"Vaginal birth","or","binary",2,0.403087148751497,1.82535484635188,5.13691390801422,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","44|16|Shivering|Vaginal birth","Shivering",44,16,"Vaginal birth","or","binary",11,-1.37313442895857,0.238786630568023,0.336892239962078,2006.36363636364,0.265846470010144,512.454545454545
"CD011689","CD011689_pub4_data","44|17|Fever|Vaginal birth","Fever",44,17,"Vaginal birth","or","binary",10,-1.57889894540882,0.241963260270769,0.201333786889099,2006.8,0.118395263353523,560.7
"CD011689","CD011689_pub4_data","44|18|Diarrhoea|Vaginal birth","Diarrhoea",44,18,"Vaginal birth","or","binary",6,0.103767767888544,0.435372283877737,0,2007.33333333333,0.0067290373362106,627.833333333333
"CD011689","CD011689_pub4_data","44|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",44,2,"Vaginal birth","or","binary",8,0.386811086947748,0.455863174446552,0.0988986507160187,2004.875,0.00770251683487587,651.625
"CD011689","CD011689_pub4_data","44|3|Blood transfusion|Vaginal birth","Blood transfusion",44,3,"Vaginal birth","or","binary",9,0.403100976071539,0.444953789222391,0,2006.22222222222,0.00438045986389113,526
"CD011689","CD011689_pub4_data","44|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",44,6,"Vaginal birth","or","binary",10,0.340291311632599,0.301627035668526,0.449567792148885,2005.4,0.060135660622029,554.6
"CD011689","CD011689_pub4_data","44|7|Additional uterotonics|Vaginal birth","Additional uterotonics",44,7,"Vaginal birth","or","binary",11,0.0657534718948757,0.221383800442773,0.246500064271054,2006.27272727273,0.060782575919027,526.545454545455
"CD011689","CD011689_pub4_data","44|8|Blood loss|Vaginal birth","Blood loss",44,8,"Vaginal birth","or","binary",9,0.210670545614084,0.668520384224582,0,2006.88888888889,0,591.555555555556
"CD011689","CD011689_pub4_data","44|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",44,9,"Vaginal birth","or","binary",7,0.270512910491573,0.757542046096554,0,2007.71428571429,0,582
"CD011689","CD011689_pub4_data","45|1|Death|Vaginal birth","Death",45,1,"Vaginal birth","or","binary",4,0.000461151873995137,1.00309616204259,0,2003.5,0,814.5
"CD011689","CD011689_pub4_data","45|11|Nausea|Vaginal birth","Nausea",45,11,"Vaginal birth","or","binary",4,-0.477434001832304,0.121903599380507,5.55622070788913e-07,2004.25,0.148956097834229,849.75
"CD011689","CD011689_pub4_data","45|12|Vomiting|Vaginal birth","Vomiting",45,12,"Vaginal birth","or","binary",6,-0.356991002144182,0.209679801989526,0.0678910539425368,2003.66666666667,0.0594395354429536,830.5
"CD011689","CD011689_pub4_data","45|13|Headache|Vaginal birth","Headache",45,13,"Vaginal birth","or","binary",3,-0.0248857550620533,0.483627902443012,0.562344193813764,2002.66666666667,0.095413169109373,1086.33333333333
"CD011689","CD011689_pub4_data","45|15|Hypertension|Vaginal birth","Hypertension",45,15,"Vaginal birth","or","binary",3,-0.585014105199518,0.241156490328945,4.52147986335249e-06,2005.66666666667,0.0794789496405578,851
"CD011689","CD011689_pub4_data","45|16|Shivering|Vaginal birth","Shivering",45,16,"Vaginal birth","or","binary",6,1.35845177757768,0.0844249875170292,1.32168469635495e-06,2003.66666666667,0.107897765832515,830
"CD011689","CD011689_pub4_data","45|17|Fever|Vaginal birth","Fever",45,17,"Vaginal birth","or","binary",7,1.66266232825773,0.318454469530189,0.224761445233298,2003.71428571429,0.00642878505677183,720.714285714286
"CD011689","CD011689_pub4_data","45|18|Diarrhoea|Vaginal birth","Diarrhoea",45,18,"Vaginal birth","or","binary",6,0.0347121208140201,0.214577182932333,0,2003.33333333333,0.017083651322372,609.833333333333
"CD011689","CD011689_pub4_data","45|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",45,2,"Vaginal birth","or","binary",8,0.453971667722169,0.210445593148425,0.00155260766848458,2003.125,0.0120509844384291,741.375
"CD011689","CD011689_pub4_data","45|3|Blood transfusion|Vaginal birth","Blood transfusion",45,3,"Vaginal birth","or","binary",8,0.325091592355968,0.22106447228406,0.0569375732096975,2002.375,0.0118562348996652,791.875
"CD011689","CD011689_pub4_data","45|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",45,6,"Vaginal birth","or","binary",9,0.567834109927141,0.156559875805024,0.0836697201891875,2002.55555555556,0.0515242798764292,710.555555555556
"CD011689","CD011689_pub4_data","45|7|Additional uterotonics|Vaginal birth","Additional uterotonics",45,7,"Vaginal birth","or","binary",9,0.719501909840507,0.13189780613411,0.0522022149064935,2002.55555555556,0.0667398157491835,710.555555555556
"CD011689","CD011689_pub4_data","45|8|Blood loss|Vaginal birth","Blood loss",45,8,"Vaginal birth","or","binary",7,-0.0403925208508128,0.756801619128676,0,2002.42857142857,0,791
"CD011689","CD011689_pub4_data","45|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",45,9,"Vaginal birth","or","binary",8,-0.0241549842714229,0.708098329861307,0,2002.375,0,686.375
"CD011689","CD011689_pub4_data","46|12|Vomiting|Vaginal birth","Vomiting",46,12,"Vaginal birth","or","binary",2,0.029937484736111,0.54257391806158,0,2002.5,0.00745351966618108,794.5
"CD011689","CD011689_pub4_data","46|16|Shivering|Vaginal birth","Shivering",46,16,"Vaginal birth","or","binary",2,-0.0879088901655197,0.153413167913943,0,2002.5,0.125481469593343,794.5
"CD011689","CD011689_pub4_data","46|17|Fever|Vaginal birth","Fever",46,17,"Vaginal birth","or","binary",2,-0.032364804930308,0.244949560436462,0,2002.5,0.0434927532653515,794.5
"CD011689","CD011689_pub4_data","46|18|Diarrhoea|Vaginal birth","Diarrhoea",46,18,"Vaginal birth","or","binary",2,0.195264259345887,0.288436182394954,0,2002.5,0.0273110540480482,794.5
"CD011689","CD011689_pub4_data","46|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",46,2,"Vaginal birth","or","binary",2,0.613055506690648,0.300363024864704,0,2002.5,0.0211414532974494,794.5
"CD011689","CD011689_pub4_data","46|3|Blood transfusion|Vaginal birth","Blood transfusion",46,3,"Vaginal birth","or","binary",2,1.04351016526437,0.373700730072308,0,2002.5,0.011175649983951,794.5
"CD011689","CD011689_pub4_data","46|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",46,6,"Vaginal birth","or","binary",2,0.689689846357685,0.348103522173616,0.157384344023455,2002.5,0.0510018271153799,794.5
"CD011689","CD011689_pub4_data","46|7|Additional uterotonics|Vaginal birth","Additional uterotonics",46,7,"Vaginal birth","or","binary",2,0.774734110337018,0.23689713959268,0,2002.5,0.0335732451050591,794.5
"CD011689","CD011689_pub4_data","46|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",46,9,"Vaginal birth","or","binary",2,0.0264449713770247,1.41510237425082,0,2002.5,0,794.5
"CD011689","CD011689_pub4_data","48|1|Death|Vaginal birth","Death",48,1,"Vaginal birth","or","binary",2,0.026539281620473,1.42004325358767,0,2004.5,0,125
"CD011689","CD011689_pub4_data","48|11|Nausea|Vaginal birth","Nausea",48,11,"Vaginal birth","or","binary",3,0.0524162413081421,0.704252376775639,0,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","48|12|Vomiting|Vaginal birth","Vomiting",48,12,"Vaginal birth","or","binary",3,1.60899751706844,0.607662257712958,0.171186170255648,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","48|14|Abdominal pain|Vaginal birth","Abdominal pain",48,14,"Vaginal birth","or","binary",3,0.567338937873525,1.52458510831384,5.24019962131983,2006,0.06,128
"CD011689","CD011689_pub4_data","48|16|Shivering|Vaginal birth","Shivering",48,16,"Vaginal birth","or","binary",2,-1.44979707150952,1.20260080868559,0,2012.5,0.0298507462686567,117
"CD011689","CD011689_pub4_data","48|17|Fever|Vaginal birth","Fever",48,17,"Vaginal birth","or","binary",2,0.667780597833791,1.27164573085781,0,2012.5,0,117
"CD011689","CD011689_pub4_data","48|18|Diarrhoea|Vaginal birth","Diarrhoea",48,18,"Vaginal birth","or","binary",3,2.4828351392113,0.86595652063004,0,2006,0,128
"CD011689","CD011689_pub4_data","48|3|Blood transfusion|Vaginal birth","Blood transfusion",48,3,"Vaginal birth","or","binary",2,0,1.42031873718682,0,2012.5,0,117
"CD011689","CD011689_pub4_data","48|7|Additional uterotonics|Vaginal birth","Additional uterotonics",48,7,"Vaginal birth","or","binary",3,-0.268675473332355,0.417625714858312,0.0429352731865724,2011.66666666667,0.086318407960199,144.666666666667
"CD011689","CD011689_pub4_data","48|8|Blood loss|Vaginal birth","Blood loss",48,8,"Vaginal birth","or","binary",3,0.0176735900364008,1.15882906611243,0,2006.33333333333,0,150
"CD011689","CD011689_pub4_data","5|3|Blood transfusion|","Blood transfusion",5,3,"","or","binary",2,-0.665979359718477,0.878931091158685,0,2003,0.00207182320441989,764.5
"CD011689","CD011689_pub4_data","5|7|Additional uterotonics|","Additional uterotonics",5,7,"","or","binary",2,-1.64917486126375,0.493320771243391,0.253946090878428,2003,0.114226519337017,764.5
"CD011689","CD011689_pub4_data","5|8|Blood loss|","Blood loss",5,8,"","or","binary",2,0.0133483058069919,1.41794157251375,0,2003,0,764.5
"CD011689","CD011689_pub4_data","52|15|Hypertension|Vaginal birth","Hypertension",52,15,"Vaginal birth","or","binary",3,-0.633359294172666,0.112493015825835,4.94685174960971e-07,2010.33333333333,0.065022640195054,1454.33333333333
"CD011689","CD011689_pub4_data","52|16|Shivering|Vaginal birth","Shivering",52,16,"Vaginal birth","or","binary",2,-0.935963896477536,0.331901930027089,0,2007.5,0.0902702702702703,335
"CD011689","CD011689_pub4_data","52|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",52,2,"Vaginal birth","or","binary",4,-0.0775897539004846,0.084137797220834,0,2010,0.0497270114942529,1183.25
"CD011689","CD011689_pub4_data","52|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",52,6,"Vaginal birth","or","binary",3,0.253128389852983,0.451646192793421,0,2008.66666666667,0.0181831831831832,303.333333333333
"CD011689","CD011689_pub4_data","52|8|Blood loss|Vaginal birth","Blood loss",52,8,"Vaginal birth","or","binary",3,0,1.15665533030603,0,2008.66666666667,0,303.333333333333
"CD011689","CD011689_pub4_data","52|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",52,9,"Vaginal birth","or","binary",2,0,1.41685260205154,0,2008.5,0,270
"CD011689","CD011689_pub4_data","56|12|Vomiting|Vaginal birth","Vomiting",56,12,"Vaginal birth","or","binary",2,0.00865676622539346,0.637807086242733,0.165371667291148,2002.5,0.00752518812970324,802.5
"CD011689","CD011689_pub4_data","56|16|Shivering|Vaginal birth","Shivering",56,16,"Vaginal birth","or","binary",2,1.15344902872407,0.20291490988917,0,2002.5,0.0424760619015475,802.5
"CD011689","CD011689_pub4_data","56|17|Fever|Vaginal birth","Fever",56,17,"Vaginal birth","or","binary",2,1.04026797683743,0.327733512487069,0,2002.5,0.0150003750093752,802.5
"CD011689","CD011689_pub4_data","56|18|Diarrhoea|Vaginal birth","Diarrhoea",56,18,"Vaginal birth","or","binary",2,-0.211483396826395,0.286349944324649,0,2002.5,0.0337945948648716,802.5
"CD011689","CD011689_pub4_data","56|2|PPH >= 1000 mL|Vaginal birth","PPH >= 1000 mL",56,2,"Vaginal birth","or","binary",2,0.3264054678897,0.368305457973482,0,2002.5,0.0149878746968674,802.5
"CD011689","CD011689_pub4_data","56|3|Blood transfusion|Vaginal birth","Blood transfusion",56,3,"Vaginal birth","or","binary",2,-0.103994704628308,0.440231980603939,0,2002.5,0.0125128128203205,802.5
"CD011689","CD011689_pub4_data","56|6|PPH >= 500 mL|Vaginal birth","PPH >= 500 mL",56,6,"Vaginal birth","or","binary",2,0.336981326043,0.401589175917246,0.194966126654717,2002.5,0.0350008750218755,802.5
"CD011689","CD011689_pub4_data","56|7|Additional uterotonics|Vaginal birth","Additional uterotonics",56,7,"Vaginal birth","or","binary",2,0.388565465726023,0.303838179879924,0,2002.5,0.0225005625140628,802.5
"CD011689","CD011689_pub4_data","56|9|Change in haemoglobin|Vaginal birth","Change in haemoglobin",56,9,"Vaginal birth","or","binary",2,-0.00622833036225827,1.41509334764921,0,2002.5,0,802.5
"CD011689","CD011689_pub4_data","57|11|Nausea|Hospital setting","Nausea",57,11,"Hospital setting","or","binary",2,-1.3596422610091,0.967226002121515,0,2000.5,0.0541666666666667,63
"CD011689","CD011689_pub4_data","57|12|Vomiting|Hospital setting","Vomiting",57,12,"Hospital setting","or","binary",2,-0.245918022834723,1.00523182885517,0,2005.5,0.00227272727272727,245
"CD011689","CD011689_pub4_data","57|2|PPH >= 1000 mL|Community setting","PPH >= 1000 mL",57,2,"Community setting","or","binary",2,-0.711785080816745,0.172727666099458,0,2014.5,0.0637910199893336,1627.5
"CD011689","CD011689_pub4_data","57|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",57,2,"Hospital setting","or","binary",5,-0.484023299638983,0.169212861757214,0.016692790954405,2005.2,0.071649681950335,820
"CD011689","CD011689_pub4_data","57|3|Blood transfusion|Hospital setting","Blood transfusion",57,3,"Hospital setting","or","binary",3,-0.339024760822114,0.264621602951993,0,2010.33333333333,0.0129726810376121,1201.33333333333
"CD011689","CD011689_pub4_data","57|6|PPH >= 500 mL|Community setting","PPH >= 500 mL",57,6,"Community setting","or","binary",2,-0.529389721993932,0.0949186469639352,0,2014.5,0.248579278871794,1627.5
"CD011689","CD011689_pub4_data","57|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",57,6,"Hospital setting","or","binary",4,-0.762412378758546,0.140055743516719,0,2003.75,0.277007058444843,617.25
"CD011689","CD011689_pub4_data","57|7|Additional uterotonics|Hospital setting","Additional uterotonics",57,7,"Hospital setting","or","binary",4,-1.89584404226919,0.614710171609944,0.957346100929017,2006,0.388950858034321,519.5
"CD011689","CD011689_pub4_data","57|8|Blood loss|Hospital setting","Blood loss",57,8,"Hospital setting","or","binary",5,-0.278578720904002,0.899882225046245,0,2005.2,0,444.8
"CD011689","CD011689_pub4_data","57|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",57,9,"Hospital setting","or","binary",3,0.030452431803003,1.15893596937388,0,2008.33333333333,0,699.333333333333
"CD011689","CD011689_pub4_data","59|1|Death|Community setting","Death",59,1,"Community setting","or","binary",3,0.0218070370593274,1.00071077249224,0,2007.33333333333,0.000412541254125413,1132.33333333333
"CD011689","CD011689_pub4_data","59|11|Nausea|Community setting","Nausea",59,11,"Community setting","or","binary",3,0.110324321628195,0.216940886173685,0,2007.33333333333,0.0205659360612,1132.33333333333
"CD011689","CD011689_pub4_data","59|12|Vomiting|Community setting","Vomiting",59,12,"Community setting","or","binary",3,0.239460010874898,0.236753249515549,0,2007.33333333333,0.0160569946010163,1132.33333333333
"CD011689","CD011689_pub4_data","59|12|Vomiting|Hospital setting","Vomiting",59,12,"Hospital setting","or","binary",3,0.893828235505693,0.52923887382259,0,2000,0.00494949494949495,517.333333333333
"CD011689","CD011689_pub4_data","59|14|Abdominal pain|Hospital setting","Abdominal pain",59,14,"Hospital setting","or","binary",3,0.0256400923682615,0.619008852717826,0.628230334975951,1999,0.0437777777777778,548.666666666667
"CD011689","CD011689_pub4_data","59|16|Shivering|Community setting","Shivering",59,16,"Community setting","or","binary",3,1.38719171958226,0.192930486233278,0.0793379739938927,2007.33333333333,0.149455996161094,1132.33333333333
"CD011689","CD011689_pub4_data","59|16|Shivering|Hospital setting","Shivering",59,16,"Hospital setting","or","binary",5,1.3788719431467,0.463492121025478,0.599042777320664,1999.4,0.0605045751633987,328.2
"CD011689","CD011689_pub4_data","59|17|Fever|Community setting","Fever",59,17,"Community setting","or","binary",3,1.08655679435155,0.73369405145398,1.42147502450274,2007.33333333333,0.0187927011078808,1132.33333333333
"CD011689","CD011689_pub4_data","59|17|Fever|Hospital setting","Fever",59,17,"Hospital setting","or","binary",2,2.2394023049705,0.263608813091599,0,2001,0.0306122448979592,499.5
"CD011689","CD011689_pub4_data","59|18|Diarrhoea|Community setting","Diarrhoea",59,18,"Community setting","or","binary",3,1.0613233055017,0.428987469483748,0,2007.33333333333,0.00485327988992253,1132.33333333333
"CD011689","CD011689_pub4_data","59|18|Diarrhoea|Hospital setting","Diarrhoea",59,18,"Hospital setting","or","binary",2,0.00366507019874961,1.00210350365531,0,1999.5,0.00166666666666667,573
"CD011689","CD011689_pub4_data","59|2|PPH >= 1000 mL|Community setting","PPH >= 1000 mL",59,2,"Community setting","or","binary",3,-0.561638273271059,0.188606802198945,6.28115018677782e-06,2007.33333333333,0.0718702356218145,1117.66666666667
"CD011689","CD011689_pub4_data","59|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",59,2,"Hospital setting","or","binary",4,-0.141696796248863,0.166868328816233,2.61427787659962e-06,1999.5,0.0794834542056409,511.75
"CD011689","CD011689_pub4_data","59|3|Blood transfusion|Hospital setting","Blood transfusion",59,3,"Hospital setting","or","binary",3,-0.247262409146274,0.720803351277767,0,2005,0.00355555555555556,399.666666666667
"CD011689","CD011689_pub4_data","59|6|PPH >= 500 mL|Community setting","PPH >= 500 mL",59,6,"Community setting","or","binary",3,-0.408879974554844,0.129398658908121,0.0235635368805329,2007.33333333333,0.284094221315059,1117.66666666667
"CD011689","CD011689_pub4_data","59|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",59,6,"Hospital setting","or","binary",3,-0.540643995435973,0.493717073914522,0.422013974094733,2001,0.179402382962754,209
"CD011689","CD011689_pub4_data","59|7|Additional uterotonics|Hospital setting","Additional uterotonics",59,7,"Hospital setting","or","binary",5,-0.448011280730997,0.155772498027748,0,2002.4,0.16832513368984,362.2
"CD011689","CD011689_pub4_data","59|8|Blood loss|Community setting","Blood loss",59,8,"Community setting","or","binary",3,0.0271268834964014,1.15528947597179,0,2007.33333333333,0,1117.33333333333
"CD011689","CD011689_pub4_data","59|8|Blood loss|Hospital setting","Blood loss",59,8,"Hospital setting","or","binary",4,0.077477055133825,1.00422172162017,0,2004.75,0,181.75
"CD011689","CD011689_pub4_data","59|9|Change in haemoglobin|Community setting","Change in haemoglobin",59,9,"Community setting","or","binary",2,0.0415070851034945,1.41506894365144,0,2008,0,880.5
"CD011689","CD011689_pub4_data","59|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",59,9,"Hospital setting","or","binary",2,0.0840422474504703,1.41857246942989,0,2008.5,0,253
"CD011689","CD011689_pub4_data","6|10|Breastfeeding|","Breastfeeding",6,10,"","reported","reported",2,0,0.0214806113814678,0,1993,0.719715680289099,1603.5
"CD011689","CD011689_pub4_data","6|12|Vomiting|","Vomiting",6,12,"","or","binary",2,0.804322837954812,0.180089320025217,0.0178926531163072,1993,0.0435167027423701,1603.5
"CD011689","CD011689_pub4_data","6|13|Headache|","Headache",6,13,"","or","binary",2,0.473265947570906,0.370661957505019,0,1993,0.00667477599146517,1603.5
"CD011689","CD011689_pub4_data","6|2|PPH >= 1000 mL|","PPH >= 1000 mL",6,2,"","or","binary",2,-0.81617593298649,0.437100870971701,0.234094666919307,1993,0.0284011371555079,1603.5
"CD011689","CD011689_pub4_data","6|3|Blood transfusion|","Blood transfusion",6,3,"","or","binary",3,-1.06545670349694,0.242598899806918,1.80161944233647e-06,1993,0.0275717043149008,1133.33333333333
"CD011689","CD011689_pub4_data","6|6|PPH >= 500 mL|","PPH >= 500 mL",6,6,"","or","binary",2,-1.11501759482402,0.125411569770453,0.00178350742152809,1993,0.171977811900665,1603.5
"CD011689","CD011689_pub4_data","6|7|Additional uterotonics|","Additional uterotonics",6,7,"","or","binary",3,-1.89873067607777,0.128235328261454,0,1993,0.195110183352279,1133.33333333333
"CD011689","CD011689_pub4_data","6|8|Blood loss|","Blood loss",6,8,"","or","binary",2,-0.0563605312423161,1.41627283068443,0,1995.5,0,852.5
"CD011689","CD011689_pub4_data","6|9|Change in haemoglobin|","Change in haemoglobin",6,9,"","or","binary",2,-0.0725230970783431,1.41631942714883,0,1990.5,0,727
"CD011689","CD011689_pub4_data","60|7|Additional uterotonics|Hospital setting","Additional uterotonics",60,7,"Hospital setting","or","binary",2,-0.433800485020153,0.615888759240413,0,2003.5,0.0916666666666667,73
"CD011689","CD011689_pub4_data","60|8|Blood loss|Hospital setting","Blood loss",60,8,"Hospital setting","or","binary",2,0.0423396365605827,1.42518491500181,0,2003.5,0,73
"CD011689","CD011689_pub4_data","61|3|Blood transfusion|Hospital setting","Blood transfusion",61,3,"Hospital setting","or","binary",2,-0.665979359718477,0.878931091158685,0,2003,0.00207182320441989,764.5
"CD011689","CD011689_pub4_data","61|7|Additional uterotonics|Hospital setting","Additional uterotonics",61,7,"Hospital setting","or","binary",2,-1.64917486126375,0.493320771243391,0.253946090878428,2003,0.114226519337017,764.5
"CD011689","CD011689_pub4_data","61|8|Blood loss|Hospital setting","Blood loss",61,8,"Hospital setting","or","binary",2,0.0133483058069919,1.41794157251375,0,2003,0,764.5
"CD011689","CD011689_pub4_data","62|10|Breastfeeding|Hospital setting","Breastfeeding",62,10,"Hospital setting","or","binary",2,0.106801168208271,0.079759310865218,0,1993,0.719715680289099,1603.5
"CD011689","CD011689_pub4_data","62|12|Vomiting|Hospital setting","Vomiting",62,12,"Hospital setting","or","binary",2,0.804322837954812,0.180089320025217,0.0178926531163072,1993,0.0435167027423701,1603.5
"CD011689","CD011689_pub4_data","62|13|Headache|Hospital setting","Headache",62,13,"Hospital setting","or","binary",2,0.473265947570906,0.370661957505019,0,1993,0.00667477599146517,1603.5
"CD011689","CD011689_pub4_data","62|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",62,2,"Hospital setting","or","binary",2,-0.81617593298649,0.437100870971701,0.234094666919307,1993,0.0284011371555079,1603.5
"CD011689","CD011689_pub4_data","62|3|Blood transfusion|Hospital setting","Blood transfusion",62,3,"Hospital setting","or","binary",3,-1.06545670349694,0.242598899806918,1.80161944233647e-06,1993,0.0275717043149008,1133.33333333333
"CD011689","CD011689_pub4_data","62|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",62,6,"Hospital setting","or","binary",2,-1.11501759482402,0.125411569770453,0.00178350742152809,1993,0.171977811900665,1603.5
"CD011689","CD011689_pub4_data","62|7|Additional uterotonics|Hospital setting","Additional uterotonics",62,7,"Hospital setting","or","binary",3,-1.89873067607777,0.128235328261454,0,1993,0.195110183352279,1133.33333333333
"CD011689","CD011689_pub4_data","62|8|Blood loss|Hospital setting","Blood loss",62,8,"Hospital setting","or","binary",2,-0.0563605312423161,1.41627283068443,0,1995.5,0,852.5
"CD011689","CD011689_pub4_data","62|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",62,9,"Hospital setting","or","binary",2,-0.0725230970783431,1.41631942714883,0,1990.5,0,727
"CD011689","CD011689_pub4_data","64|1|Death|Hospital setting","Death",64,1,"Hospital setting","or","binary",15,-0.125584888703377,0.453325503611509,0,2006.78571428571,0.000309430898985928,1769.33333333333
"CD011689","CD011689_pub4_data","64|11|Nausea|Hospital setting","Nausea",64,11,"Hospital setting","or","binary",17,0.221504801925786,0.188465546658103,0.186834656380821,2007,0.0340144282503261,1543.11764705882
"CD011689","CD011689_pub4_data","64|12|Vomiting|Hospital setting","Vomiting",64,12,"Hospital setting","or","binary",26,0.333648525289055,0.154752622313674,0.115706950095784,2006.76923076923,0.0393908621834244,1125.69230769231
"CD011689","CD011689_pub4_data","64|13|Headache|Hospital setting","Headache",64,13,"Hospital setting","or","binary",6,-0.473276442818617,0.46976205618553,0.872992924766963,2009.16666666667,0.113150562177262,502
"CD011689","CD011689_pub4_data","64|14|Abdominal pain|Hospital setting","Abdominal pain",64,14,"Hospital setting","or","binary",3,-0.258712238795469,0.12875954804064,0,2009.33333333333,0.13471557682084,669
"CD011689","CD011689_pub4_data","64|15|Hypertension|Hospital setting","Hypertension",64,15,"Hospital setting","or","binary",2,1.3931338008018,1.12606532784923,0,2006.5,0,414
"CD011689","CD011689_pub4_data","64|16|Shivering|Hospital setting","Shivering",64,16,"Hospital setting","or","binary",30,1.68887484898778,0.210385222137179,0.970858528970271,2006.37931034483,0.0861427482833975,1011.26666666667
"CD011689","CD011689_pub4_data","64|17|Fever|Hospital setting","Fever",64,17,"Hospital setting","or","binary",25,1.3645414182904,0.214481241481373,0.582537278261424,2007,0.0217828904872005,1165.76
"CD011689","CD011689_pub4_data","64|18|Diarrhoea|Hospital setting","Diarrhoea",64,18,"Hospital setting","or","binary",17,0.686880449564632,0.201931505731125,0.0927150273264932,2006.11764705882,0.0136839854539542,1650.52941176471
"CD011689","CD011689_pub4_data","64|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",64,2,"Hospital setting","or","binary",25,0.150737733720503,0.107977816466147,0.0239096267670953,2004.70833333333,0.039335733751671,1201.6
"CD011689","CD011689_pub4_data","64|3|Blood transfusion|Hospital setting","Blood transfusion",64,3,"Hospital setting","or","binary",23,-0.216681126231128,0.11539797284018,0,2004.81818181818,0.0114806750455936,1287.04347826087
"CD011689","CD011689_pub4_data","64|4|Severe maternal morbidity: intensive care admissions|Hospital setting","Severe maternal morbidity: intensive care admissions",64,4,"Hospital setting","or","binary",6,0.119745619416124,0.347651148358909,0,2008.33333333333,0.00242945680743946,3499.66666666667
"CD011689","CD011689_pub4_data","64|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",64,6,"Hospital setting","or","binary",24,0.139617327312419,0.113353498964306,0.135747947925815,2005.29166666667,0.190533590577361,1231.5
"CD011689","CD011689_pub4_data","64|7|Additional uterotonics|Hospital setting","Additional uterotonics",64,7,"Hospital setting","or","binary",27,0.149361750176702,0.0925415585467516,0.0917651635165643,2006.07692307692,0.123383318236524,1118.51851851852
"CD011689","CD011689_pub4_data","64|8|Blood loss|Hospital setting","Blood loss",64,8,"Hospital setting","or","binary",26,-0.0793510616162246,0.393338089021121,0,2006,0,1103.26923076923
"CD011689","CD011689_pub4_data","64|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",64,9,"Hospital setting","or","binary",19,-0.0693976770810598,0.460049428996151,0,2005.73684210526,0,442.894736842105
"CD011689","CD011689_pub4_data","66|1|Death|Hospital setting","Death",66,1,"Hospital setting","or","binary",5,0.358272434816393,0.620003211203283,0,2010,2.70855904658722e-05,6880
"CD011689","CD011689_pub4_data","66|10|Breastfeeding|Hospital setting","Breastfeeding",66,10,"Hospital setting","or","binary",2,-0.682047245762579,0.607652197805308,0.151256522295132,2011,0.919923371647509,95
"CD011689","CD011689_pub4_data","66|15|Hypertension|Hospital setting","Hypertension",66,15,"Hospital setting","or","binary",2,-0.598947193430069,0.781133213809481,0.923940749785777,2018,0.0607371868448036,2040
"CD011689","CD011689_pub4_data","66|16|Shivering|Hospital setting","Shivering",66,16,"Hospital setting","or","binary",6,-0.282754011060803,0.198187129382955,0,2004.8,0.0555781424492116,253.333333333333
"CD011689","CD011689_pub4_data","66|17|Fever|Hospital setting","Fever",66,17,"Hospital setting","or","binary",2,-0.626961985772008,1.27953748601555,0,2004.5,0.0172413793103448,56
"CD011689","CD011689_pub4_data","66|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",66,2,"Hospital setting","or","binary",10,-0.0366233524209658,0.0600247576659769,0,2014.66666666667,0.0798887648628306,3503.2
"CD011689","CD011689_pub4_data","66|4|Severe maternal morbidity: intensive care admissions|Hospital setting","Severe maternal morbidity: intensive care admissions",66,4,"Hospital setting","or","binary",2,0.148923567685346,0.279427087226758,0,2014,0.000780560646168465,14923.5
"CD011689","CD011689_pub4_data","66|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",66,6,"Hospital setting","or","binary",8,-0.00204713059806306,0.0335443054660311,3.15659635864074e-06,2011.57142857143,0.24241383335915,4324.75
"CD011689","CD011689_pub4_data","66|8|Blood loss|Hospital setting","Blood loss",66,8,"Hospital setting","or","binary",8,-0.0136359887097183,0.710472760625031,0,2011.71428571429,0,220.125
"CD011689","CD011689_pub4_data","66|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",66,9,"Hospital setting","or","binary",8,-0.0284829050519619,0.711473341214379,0,2010.25,0,179.5
"CD011689","CD011689_pub4_data","67|11|Nausea|Hospital setting","Nausea",67,11,"Hospital setting","or","binary",5,1.84519565591948,0.887440925553133,3.13277300091615,1996.6,0.0176401602292744,485.8
"CD011689","CD011689_pub4_data","67|12|Vomiting|Hospital setting","Vomiting",67,12,"Hospital setting","or","binary",4,1.14950490572655,0.840992405498454,1.98147843933607,2007.5,0.0225670120115578,560.75
"CD011689","CD011689_pub4_data","67|13|Headache|Hospital setting","Headache",67,13,"Hospital setting","or","binary",3,1.64058984747311,1.39235968528346,4.84042806745819,2009.33333333333,0.00991051910368836,731
"CD011689","CD011689_pub4_data","67|15|Hypertension|Hospital setting","Hypertension",67,15,"Hospital setting","or","binary",3,2.82151069299713,0.774459371238649,0.939903539325853,2009.66666666667,0.0377604166666667,470
"CD011689","CD011689_pub4_data","67|16|Shivering|Hospital setting","Shivering",67,16,"Hospital setting","or","binary",2,0.551491780699088,0.325065940854272,0,2004,0.0113452188006483,671.5
"CD011689","CD011689_pub4_data","67|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",67,2,"Hospital setting","or","binary",5,0.228290655741033,0.446346937357613,0,2000.4,0.0252965964343598,508.2
"CD011689","CD011689_pub4_data","67|3|Blood transfusion|Hospital setting","Blood transfusion",67,3,"Hospital setting","or","binary",2,-0.79762588284575,1.06650287965038,1.5386347368304,2010,0.031422070046261,796.5
"CD011689","CD011689_pub4_data","67|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",67,6,"Hospital setting","or","binary",7,0.207230179622489,0.214014774273717,0.0381214922235687,1998.85714285714,0.10805692522749,417.285714285714
"CD011689","CD011689_pub4_data","67|7|Additional uterotonics|Hospital setting","Additional uterotonics",67,7,"Hospital setting","or","binary",3,-0.166551767159972,0.548652546543823,0.813075602274731,2009.33333333333,0.117994156902783,731
"CD011689","CD011689_pub4_data","67|8|Blood loss|Hospital setting","Blood loss",67,8,"Hospital setting","or","binary",7,-0.0129586016359787,0.758656158954658,0,1998.85714285714,0,417.285714285714
"CD011689","CD011689_pub4_data","67|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",67,9,"Hospital setting","or","binary",2,-0.0556262179341261,1.41507528829908,0,2007,0,946.5
"CD011689","CD011689_pub4_data","68|15|Hypertension|Hospital setting","Hypertension",68,15,"Hospital setting","or","binary",4,0.569934891338499,0.107679272745319,3.69390271995346e-06,2011.25,0.105775398312072,1228.75
"CD011689","CD011689_pub4_data","68|16|Shivering|Hospital setting","Shivering",68,16,"Hospital setting","or","binary",2,-0.0409769210693929,0.243988412778522,0,2002.5,0.044395602989353,795.5
"CD011689","CD011689_pub4_data","68|17|Fever|Hospital setting","Fever",68,17,"Hospital setting","or","binary",2,0.0703501043175079,0.403837956946321,0,2002.5,0.013881424037674,795.5
"CD011689","CD011689_pub4_data","68|18|Diarrhoea|Hospital setting","Diarrhoea",68,18,"Hospital setting","or","binary",3,0.209088888621586,0.287074514192774,0,2001.33333333333,0.017787674037674,676.666666666667
"CD011689","CD011689_pub4_data","68|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",68,2,"Hospital setting","or","binary",9,-0.357277518734565,0.157306539221259,0.08377531780152,2004.33333333333,0.104661428080768,1465.11111111111
"CD011689","CD011689_pub4_data","68|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",68,6,"Hospital setting","or","binary",8,-0.1190531977739,0.0489789013410505,7.00175450289179e-06,2002.125,0.120318326343955,1628.25
"CD011689","CD011689_pub4_data","68|8|Blood loss|Hospital setting","Blood loss",68,8,"Hospital setting","or","binary",8,-0.107112572796187,0.709517148364801,0,2005,0,446.5
"CD011689","CD011689_pub4_data","68|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",68,9,"Hospital setting","or","binary",5,-0.181997344525629,0.895540898381181,0,2005.6,0,634
"CD011689","CD011689_pub4_data","69|1|Death|Hospital setting","Death",69,1,"Hospital setting","or","binary",6,-0.0150206216225401,0.818349206312952,0,2010.16666666667,0,666
"CD011689","CD011689_pub4_data","69|11|Nausea|Hospital setting","Nausea",69,11,"Hospital setting","or","binary",5,0.919239833062846,0.403135891425457,0.409742319267408,2011,0.0481805941334445,681.2
"CD011689","CD011689_pub4_data","69|12|Vomiting|Hospital setting","Vomiting",69,12,"Hospital setting","or","binary",7,0.748781428199343,0.287823590147372,0.184449148413229,2008.28571428571,0.0216089199514887,815
"CD011689","CD011689_pub4_data","69|13|Headache|Hospital setting","Headache",69,13,"Hospital setting","or","binary",2,0.244575786268595,0.733007567241649,0.0280176621823818,2007.5,0.028,151.5
"CD011689","CD011689_pub4_data","69|17|Fever|Hospital setting","Fever",69,17,"Hospital setting","or","binary",10,1.42066746857015,0.270431510610872,0.455929380480472,2010.6,0.0270078591988782,686
"CD011689","CD011689_pub4_data","69|18|Diarrhoea|Hospital setting","Diarrhoea",69,18,"Hospital setting","or","binary",6,0.746566805093293,0.433900130020472,0.448943483593872,2010.16666666667,0.00937139193765268,880.5
"CD011689","CD011689_pub4_data","69|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",69,2,"Hospital setting","or","binary",12,-0.172436312470928,0.135815177383315,4.21294624979284e-06,2010.91666666667,0.0993244554089689,614.75
"CD011689","CD011689_pub4_data","69|3|Blood transfusion|Hospital setting","Blood transfusion",69,3,"Hospital setting","or","binary",12,-0.895424713678386,0.178235658116687,0.00843136685456899,2010.25,0.0626303791306378,578.5
"CD011689","CD011689_pub4_data","69|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",69,6,"Hospital setting","or","binary",9,-0.529890061188895,0.150575617806009,0.109279456042373,2009.11111111111,0.223620878689363,797.888888888889
"CD011689","CD011689_pub4_data","69|7|Additional uterotonics|Hospital setting","Additional uterotonics",69,7,"Hospital setting","or","binary",12,-0.728715665010162,0.128519918985828,0.0644582702634992,2010.75,0.177573510986782,566
"CD011689","CD011689_pub4_data","69|8|Blood loss|Hospital setting","Blood loss",69,8,"Hospital setting","or","binary",11,-0.0110480021655287,0.60412598202428,0,2010.63636363636,0,655
"CD011689","CD011689_pub4_data","69|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",69,9,"Hospital setting","or","binary",11,-0.00123735288887916,0.603902444991679,0,2010.63636363636,0,633.727272727273
"CD011689","CD011689_pub4_data","70|11|Nausea|Hospital setting","Nausea",70,11,"Hospital setting","or","binary",2,-1.38366309759874,0.679961356409058,0,2012.5,0.105454545454545,116.5
"CD011689","CD011689_pub4_data","70|12|Vomiting|Hospital setting","Vomiting",70,12,"Hospital setting","or","binary",2,0.433367065256183,2.43030967715957,10.3622339090668,2012.5,0.0606060606060606,116.5
"CD011689","CD011689_pub4_data","70|14|Abdominal pain|Hospital setting","Abdominal pain",70,14,"Hospital setting","or","binary",2,-0.00958709785789779,0.719509699495266,0,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","70|16|Shivering|Hospital setting","Shivering",70,16,"Hospital setting","or","binary",3,-3.49530476689641,0.845040457334265,0,2010.33333333333,0.240909090909091,117.666666666667
"CD011689","CD011689_pub4_data","70|17|Fever|Hospital setting","Fever",70,17,"Hospital setting","or","binary",2,-2.48688105519947,0.75667426088116,0,2012.5,0.158484848484848,116.5
"CD011689","CD011689_pub4_data","70|18|Diarrhoea|Hospital setting","Diarrhoea",70,18,"Hospital setting","or","binary",2,2.01195351180716,0.775741644634454,0,2012.5,0.00757575757575758,116.5
"CD011689","CD011689_pub4_data","70|3|Blood transfusion|Hospital setting","Blood transfusion",70,3,"Hospital setting","or","binary",3,-0.841077219825658,1.00568003989599,0,2010.33333333333,0.0106060606060606,117.666666666667
"CD011689","CD011689_pub4_data","70|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",70,6,"Hospital setting","or","binary",2,0.296812876923238,0.400203686518096,0,2007.5,0.0939393939393939,126.5
"CD011689","CD011689_pub4_data","70|7|Additional uterotonics|Hospital setting","Additional uterotonics",70,7,"Hospital setting","or","binary",3,-0.223825197554772,0.722833657556914,1.04619768003177,2010.33333333333,0.107676767676768,117.666666666667
"CD011689","CD011689_pub4_data","70|8|Blood loss|Hospital setting","Blood loss",70,8,"Hospital setting","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","70|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",70,9,"Hospital setting","or","binary",2,0,1.42062103526994,0,2011,0,110
"CD011689","CD011689_pub4_data","72|1|Death|Hospital setting","Death",72,1,"Hospital setting","or","binary",5,0.378365547261432,0.895918565232409,0,2008.8,0,750.8
"CD011689","CD011689_pub4_data","72|11|Nausea|Hospital setting","Nausea",72,11,"Hospital setting","or","binary",8,0.234037307746374,0.173895595965863,3.02802151617122e-06,2006.875,0.0871822847829579,413
"CD011689","CD011689_pub4_data","72|12|Vomiting|Hospital setting","Vomiting",72,12,"Hospital setting","or","binary",9,0.0429711144178553,0.341473639869637,0.503533577068466,2006.44444444444,0.0513915883001093,470.888888888889
"CD011689","CD011689_pub4_data","72|13|Headache|Hospital setting","Headache",72,13,"Hospital setting","or","binary",5,0.802670728989554,0.663823317248239,1.74344921269308,2004.8,0.0479994139155689,574.2
"CD011689","CD011689_pub4_data","72|14|Abdominal pain|Hospital setting","Abdominal pain",72,14,"Hospital setting","or","binary",2,0.403087148751497,1.82535484635188,5.13691390801422,2012.5,0.0251515151515152,116.5
"CD011689","CD011689_pub4_data","72|16|Shivering|Hospital setting","Shivering",72,16,"Hospital setting","or","binary",10,-1.4060982188648,0.291928235379095,0.466000732586857,2006.4,0.243764450344491,443.7
"CD011689","CD011689_pub4_data","72|17|Fever|Hospital setting","Fever",72,17,"Hospital setting","or","binary",9,-1.70886773266259,0.221190354745024,0.0601835324014505,2006.88888888889,0.120809551874285,489.666666666667
"CD011689","CD011689_pub4_data","72|18|Diarrhoea|Hospital setting","Diarrhoea",72,18,"Hospital setting","or","binary",6,0.103767767888544,0.435372283877737,0,2007.33333333333,0.0067290373362106,627.833333333333
"CD011689","CD011689_pub4_data","72|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",72,2,"Hospital setting","or","binary",7,0.508570000038429,0.471755662495107,0.0871714098935261,2004.71428571429,0.00856478114462004,573.285714285714
"CD011689","CD011689_pub4_data","72|3|Blood transfusion|Hospital setting","Blood transfusion",72,3,"Hospital setting","or","binary",8,0.523506737370222,0.462428817543215,0,2006.25,0.00471968401354418,441.75
"CD011689","CD011689_pub4_data","72|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",72,6,"Hospital setting","or","binary",9,0.34327853025562,0.3391232902328,0.542842701715521,2005.33333333333,0.0660766599504026,482.888888888889
"CD011689","CD011689_pub4_data","72|7|Additional uterotonics|Hospital setting","Additional uterotonics",72,7,"Hospital setting","or","binary",10,0.083664073916206,0.234186579586183,0.266651725649982,2006.3,0.066194166844263,459.2
"CD011689","CD011689_pub4_data","72|8|Blood loss|Hospital setting","Blood loss",72,8,"Hospital setting","or","binary",8,0.237144643899263,0.709282760478223,0,2007,0,515.5
"CD011689","CD011689_pub4_data","72|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",72,9,"Hospital setting","or","binary",7,0.270512910491573,0.757542046096554,0,2007.71428571429,0,582
"CD011689","CD011689_pub4_data","73|1|Death|Hospital setting","Death",73,1,"Hospital setting","or","binary",4,0.000461151873995137,1.00309616204259,0,2003.5,0,814.5
"CD011689","CD011689_pub4_data","73|11|Nausea|Hospital setting","Nausea",73,11,"Hospital setting","or","binary",4,-0.477434001832304,0.121903599380507,5.55622070788913e-07,2004.25,0.148956097834229,849.75
"CD011689","CD011689_pub4_data","73|12|Vomiting|Hospital setting","Vomiting",73,12,"Hospital setting","or","binary",6,-0.356991002144182,0.209679801989526,0.0678910539425368,2003.66666666667,0.0594395354429536,830.5
"CD011689","CD011689_pub4_data","73|13|Headache|Hospital setting","Headache",73,13,"Hospital setting","or","binary",3,-0.0248857550620533,0.483627902443012,0.562344193813764,2002.66666666667,0.095413169109373,1086.33333333333
"CD011689","CD011689_pub4_data","73|15|Hypertension|Hospital setting","Hypertension",73,15,"Hospital setting","or","binary",3,-0.585014105199518,0.241156490328945,4.52147986335249e-06,2005.66666666667,0.0794789496405578,851
"CD011689","CD011689_pub4_data","73|16|Shivering|Hospital setting","Shivering",73,16,"Hospital setting","or","binary",6,1.35845177757768,0.0844249875170292,1.32168469635495e-06,2003.66666666667,0.107897765832515,830
"CD011689","CD011689_pub4_data","73|17|Fever|Hospital setting","Fever",73,17,"Hospital setting","or","binary",7,1.66266232825773,0.318454469530189,0.224761445233298,2003.71428571429,0.00642878505677183,720.714285714286
"CD011689","CD011689_pub4_data","73|18|Diarrhoea|Hospital setting","Diarrhoea",73,18,"Hospital setting","or","binary",6,0.0347121208140201,0.214577182932333,0,2003.33333333333,0.017083651322372,609.833333333333
"CD011689","CD011689_pub4_data","73|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",73,2,"Hospital setting","or","binary",8,0.453971667722169,0.210445593148425,0.00155260766848458,2003.125,0.0120509844384291,741.375
"CD011689","CD011689_pub4_data","73|3|Blood transfusion|Hospital setting","Blood transfusion",73,3,"Hospital setting","or","binary",8,0.325091592355968,0.22106447228406,0.0569375732096975,2002.375,0.0118562348996652,791.875
"CD011689","CD011689_pub4_data","73|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",73,6,"Hospital setting","or","binary",9,0.567834109927141,0.156559875805024,0.0836697201891875,2002.55555555556,0.0515242798764292,710.555555555556
"CD011689","CD011689_pub4_data","73|7|Additional uterotonics|Hospital setting","Additional uterotonics",73,7,"Hospital setting","or","binary",9,0.719501909840507,0.13189780613411,0.0522022149064935,2002.55555555556,0.0667398157491835,710.555555555556
"CD011689","CD011689_pub4_data","73|8|Blood loss|Hospital setting","Blood loss",73,8,"Hospital setting","or","binary",7,-0.0403925208508128,0.756801619128676,0,2002.42857142857,0,791
"CD011689","CD011689_pub4_data","73|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",73,9,"Hospital setting","or","binary",8,-0.0241549842714229,0.708098329861307,0,2002.375,0,686.375
"CD011689","CD011689_pub4_data","74|12|Vomiting|Hospital setting","Vomiting",74,12,"Hospital setting","or","binary",3,0.301785016691832,0.472905739872256,0,2006.66666666667,0.0116356797774541,563
"CD011689","CD011689_pub4_data","74|16|Shivering|Hospital setting","Shivering",74,16,"Hospital setting","or","binary",3,-0.0669271093292833,0.152644316514094,7.93751748277777e-07,2006.66666666667,0.0836543130622289,563
"CD011689","CD011689_pub4_data","74|17|Fever|Hospital setting","Fever",74,17,"Hospital setting","or","binary",3,-0.030210103418337,0.236655320941448,0,2006.66666666667,0.042328502176901,563
"CD011689","CD011689_pub4_data","74|18|Diarrhoea|Hospital setting","Diarrhoea",74,18,"Hospital setting","or","binary",2,0.195264259345887,0.288436182394954,0,2002.5,0.0273110540480482,794.5
"CD011689","CD011689_pub4_data","74|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",74,2,"Hospital setting","or","binary",2,0.613055506690648,0.300363024864704,0,2002.5,0.0211414532974494,794.5
"CD011689","CD011689_pub4_data","74|3|Blood transfusion|Hospital setting","Blood transfusion",74,3,"Hospital setting","or","binary",2,1.04351016526437,0.373700730072308,0,2002.5,0.011175649983951,794.5
"CD011689","CD011689_pub4_data","74|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",74,6,"Hospital setting","or","binary",2,0.689689846357685,0.348103522173616,0.157384344023455,2002.5,0.0510018271153799,794.5
"CD011689","CD011689_pub4_data","74|7|Additional uterotonics|Hospital setting","Additional uterotonics",74,7,"Hospital setting","or","binary",3,0.675336310918043,0.217287398229383,0,2006.66666666667,0.0690488300700394,563
"CD011689","CD011689_pub4_data","74|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",74,9,"Hospital setting","or","binary",3,0.0176804224789362,1.15707797850013,0,2006.66666666667,0,563
"CD011689","CD011689_pub4_data","76|1|Death|Hospital setting","Death",76,1,"Hospital setting","or","binary",2,0.026539281620473,1.42004325358767,0,2004.5,0,125
"CD011689","CD011689_pub4_data","76|11|Nausea|Hospital setting","Nausea",76,11,"Hospital setting","or","binary",3,0.0524162413081421,0.704252376775639,0,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","76|12|Vomiting|Hospital setting","Vomiting",76,12,"Hospital setting","or","binary",3,1.60899751706844,0.607662257712958,0.171186170255648,2006,0.0159707953737804,128
"CD011689","CD011689_pub4_data","76|14|Abdominal pain|Hospital setting","Abdominal pain",76,14,"Hospital setting","or","binary",3,0.567338937873525,1.52458510831384,5.24019962131983,2006,0.06,128
"CD011689","CD011689_pub4_data","76|16|Shivering|Hospital setting","Shivering",76,16,"Hospital setting","or","binary",2,-1.44979707150952,1.20260080868559,0,2012.5,0.0298507462686567,117
"CD011689","CD011689_pub4_data","76|17|Fever|Hospital setting","Fever",76,17,"Hospital setting","or","binary",2,0.667780597833791,1.27164573085781,0,2012.5,0,117
"CD011689","CD011689_pub4_data","76|18|Diarrhoea|Hospital setting","Diarrhoea",76,18,"Hospital setting","or","binary",3,2.4828351392113,0.86595652063004,0,2006,0,128
"CD011689","CD011689_pub4_data","76|3|Blood transfusion|Hospital setting","Blood transfusion",76,3,"Hospital setting","or","binary",2,0,1.42031873718682,0,2012.5,0,117
"CD011689","CD011689_pub4_data","76|7|Additional uterotonics|Hospital setting","Additional uterotonics",76,7,"Hospital setting","or","binary",3,-0.268675473332355,0.417625714858312,0.0429352731865724,2011.66666666667,0.086318407960199,144.666666666667
"CD011689","CD011689_pub4_data","76|8|Blood loss|Hospital setting","Blood loss",76,8,"Hospital setting","or","binary",3,0.0176735900364008,1.15882906611243,0,2006.33333333333,0,150
"CD011689","CD011689_pub4_data","77|18|Diarrhoea|Hospital setting","Diarrhoea",77,18,"Hospital setting","or","binary",2,3.14594922783497,0.524015005972646,0,1998,0.012380088151413,320.5
"CD011689","CD011689_pub4_data","8|1|Death|","Death",8,1,"","or","binary",16,-0.147688730155581,0.442140499328387,0,2007.4,0.000290091467799308,1683.3125
"CD011689","CD011689_pub4_data","8|11|Nausea|","Nausea",8,11,"","or","binary",18,0.206575845161655,0.183143843540637,0.179997690096563,2007.5,0.0329127598565925,1479.22222222222
"CD011689","CD011689_pub4_data","8|12|Vomiting|","Vomiting",8,12,"","or","binary",27,0.344029792858229,0.152727128194238,0.109470841931918,2007.11111111111,0.0379319413618161,1098.55555555556
"CD011689","CD011689_pub4_data","8|13|Headache|","Headache",8,13,"","or","binary",6,-0.473276442818617,0.46976205618553,0.872992924766963,2009.16666666667,0.113150562177262,502
"CD011689","CD011689_pub4_data","8|14|Abdominal pain|","Abdominal pain",8,14,"","or","binary",3,-0.258712238795469,0.12875954804064,0,2009.33333333333,0.13471557682084,669
"CD011689","CD011689_pub4_data","8|15|Hypertension|","Hypertension",8,15,"","or","binary",2,1.3931338008018,1.12606532784923,0,2006.5,0,414
"CD011689","CD011689_pub4_data","8|16|Shivering|","Shivering",8,16,"","or","binary",31,1.80040328966768,0.226173970182095,1.21404882307326,2006.7,0.0849768531774815,989.322580645161
"CD011689","CD011689_pub4_data","8|17|Fever|","Fever",8,17,"","or","binary",26,1.33617871885302,0.20675079986977,0.551659430989302,2007.36,0.0214906407439667,1136.03846153846
"CD011689","CD011689_pub4_data","8|18|Diarrhoea|","Diarrhoea",8,18,"","or","binary",18,0.651847843638688,0.198890003809926,0.0917990188062777,2006.66666666667,0.0133177750721546,1580.66666666667
"CD011689","CD011689_pub4_data","8|2|PPH >= 1000 mL|","PPH >= 1000 mL",8,2,"","or","binary",25,0.150737733720503,0.107977816466147,0.0239096267670953,2004.70833333333,0.039335733751671,1201.6
"CD011689","CD011689_pub4_data","8|3|Blood transfusion|","Blood transfusion",8,3,"","or","binary",23,-0.216681126231128,0.11539797284018,0,2004.81818181818,0.0114806750455936,1287.04347826087
"CD011689","CD011689_pub4_data","8|4|Severe maternal morbidity: intensive care admissions|","Severe maternal morbidity: intensive care admissions",8,4,"","or","binary",6,0.119745619416124,0.347651148358909,0,2008.33333333333,0.00242945680743946,3499.66666666667
"CD011689","CD011689_pub4_data","8|6|PPH >= 500 mL|","PPH >= 500 mL",8,6,"","or","binary",24,0.139617327312419,0.113353498964306,0.135747947925815,2005.29166666667,0.190533590577361,1231.5
"CD011689","CD011689_pub4_data","8|7|Additional uterotonics|","Additional uterotonics",8,7,"","or","binary",27,0.149361750176702,0.0925415585467516,0.0917651635165643,2006.07692307692,0.123383318236524,1118.51851851852
"CD011689","CD011689_pub4_data","8|8|Blood loss|","Blood loss",8,8,"","or","binary",26,-0.0793510616162246,0.393338089021121,0,2006,0,1103.26923076923
"CD011689","CD011689_pub4_data","8|9|Change in haemoglobin|","Change in haemoglobin",8,9,"","or","binary",20,-0.0900240689219,0.448380120818041,0,2006.25,0,435.95
"CD011689","CD011689_pub4_data","80|15|Hypertension|Hospital setting","Hypertension",80,15,"Hospital setting","or","binary",3,-0.633359294172666,0.112493015825835,4.94685174960971e-07,2010.33333333333,0.065022640195054,1454.33333333333
"CD011689","CD011689_pub4_data","80|16|Shivering|Hospital setting","Shivering",80,16,"Hospital setting","or","binary",2,-0.935963896477536,0.331901930027089,0,2007.5,0.0902702702702703,335
"CD011689","CD011689_pub4_data","80|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",80,2,"Hospital setting","or","binary",4,-0.0775897539004846,0.084137797220834,0,2010,0.0497270114942529,1183.25
"CD011689","CD011689_pub4_data","80|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",80,6,"Hospital setting","or","binary",3,0.253128389852983,0.451646192793421,0,2008.66666666667,0.0181831831831832,303.333333333333
"CD011689","CD011689_pub4_data","80|8|Blood loss|Hospital setting","Blood loss",80,8,"Hospital setting","or","binary",3,0,1.15665533030603,0,2008.66666666667,0,303.333333333333
"CD011689","CD011689_pub4_data","80|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",80,9,"Hospital setting","or","binary",2,0,1.41685260205154,0,2008.5,0,270
"CD011689","CD011689_pub4_data","84|12|Vomiting|Hospital setting","Vomiting",84,12,"Hospital setting","or","binary",2,0.00865676622539346,0.637807086242733,0.165371667291148,2002.5,0.00752518812970324,802.5
"CD011689","CD011689_pub4_data","84|16|Shivering|Hospital setting","Shivering",84,16,"Hospital setting","or","binary",2,1.15344902872407,0.20291490988917,0,2002.5,0.0424760619015475,802.5
"CD011689","CD011689_pub4_data","84|17|Fever|Hospital setting","Fever",84,17,"Hospital setting","or","binary",2,1.04026797683743,0.327733512487069,0,2002.5,0.0150003750093752,802.5
"CD011689","CD011689_pub4_data","84|18|Diarrhoea|Hospital setting","Diarrhoea",84,18,"Hospital setting","or","binary",2,-0.211483396826395,0.286349944324649,0,2002.5,0.0337945948648716,802.5
"CD011689","CD011689_pub4_data","84|2|PPH >= 1000 mL|Hospital setting","PPH >= 1000 mL",84,2,"Hospital setting","or","binary",2,0.3264054678897,0.368305457973482,0,2002.5,0.0149878746968674,802.5
"CD011689","CD011689_pub4_data","84|3|Blood transfusion|Hospital setting","Blood transfusion",84,3,"Hospital setting","or","binary",2,-0.103994704628308,0.440231980603939,0,2002.5,0.0125128128203205,802.5
"CD011689","CD011689_pub4_data","84|6|PPH >= 500 mL|Hospital setting","PPH >= 500 mL",84,6,"Hospital setting","or","binary",2,0.336981326043,0.401589175917246,0.194966126654717,2002.5,0.0350008750218755,802.5
"CD011689","CD011689_pub4_data","84|7|Additional uterotonics|Hospital setting","Additional uterotonics",84,7,"Hospital setting","or","binary",2,0.388565465726023,0.303838179879924,0,2002.5,0.0225005625140628,802.5
"CD011689","CD011689_pub4_data","84|9|Change in haemoglobin|Hospital setting","Change in haemoglobin",84,9,"Hospital setting","or","binary",2,-0.00622833036225827,1.41509334764921,0,2002.5,0,802.5
"CD011762","CD011762_pub2_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","reported","reported",15,0,0.259165013780288,0,2009.66666666667,0.00323824267110444,1709.46666666667
"CD011762","CD011762_pub2_data","1|10|Asymptomatic distal DVT|","Asymptomatic distal DVT",1,10,"","or","binary",14,-0.475955558407266,0.158439744631588,0.0539298023387509,2014.57142857143,0.0780338095932889,344.142857142857
"CD011762","CD011762_pub2_data","1|11|Fatal bleeding|","Fatal bleeding",1,11,"","or","binary",26,-0.573760210691773,0.378566982879422,0,2011.07692307692,2.51547014136942e-05,1203.57692307692
"CD011762","CD011762_pub2_data","1|12|Liver enzymes elevation|","Liver enzymes elevation",1,12,"","or","binary",21,-0.573129676286227,0.117755333441034,0.116609508182782,2010.42857142857,0.0537865741116004,1495.61904761905
"CD011762","CD011762_pub2_data","1|13|Minor adverse events|","Minor adverse events",1,13,"","or","binary",4,-0.293463518245618,0.158920775635944,1.75644510907542e-05,2017.25,0.550428326670474,252.75
"CD011762","CD011762_pub2_data","1|14|Volume of blood loss|","Volume of blood loss",1,14,"","reported","reported",12,0,2.45929565782237,0,2011.83333333333,0,543.25
"CD011762","CD011762_pub2_data","1|2|Major VTE|","Major VTE",1,2,"","reported","reported",23,0,0.10945299570098,0,2010.52173913043,0.0409972022293741,1037.52173913043
"CD011762","CD011762_pub2_data","1|3|Symptomatic VTE|","Symptomatic VTE",1,3,"","reported","reported",24,0,0.13453811109883,0,2011.20833333333,0.0160583150424683,1239.70833333333
"CD011762","CD011762_pub2_data","1|4|Major bleeding|","Major bleeding",1,4,"","reported","reported",28,0,0.103721311888566,0,2011.60714285714,0.0354052469157483,1324.85714285714
"CD011762","CD011762_pub2_data","1|5|Major bleeding: rivaroxaban versus LMWH|","Major bleeding: rivaroxaban versus LMWH",1,5,"","reported","reported",13,0,0.227444244182872,0,2012.07692307692,0.0133699816061415,1222.38461538462
"CD011762","CD011762_pub2_data","1|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",1,6,"","reported","reported",16,0,0.116246082332406,0,2011.9375,0.0510960720475696,1332.8125
"CD011762","CD011762_pub2_data","1|7|Serious hepatic adverse events|","Serious hepatic adverse events",1,7,"","or","binary",2,0.663865423566176,1.26666540186535,0,2015,0,1584.5
"CD011762","CD011762_pub2_data","1|8|Serious non-hepatic adverse events|","Serious non-hepatic adverse events",1,8,"","or","binary",15,-0.144651409755219,0.0635920981106475,0.0113170464823029,2011,0.060774268740188,1749.73333333333
"CD011762","CD011762_pub2_data","1|9|Fatal VTE|","Fatal VTE",1,9,"","or","binary",33,-0.314867384074141,0.313997436180004,0,2012.51515151515,0.000408171523806186,823.727272727273
"CD011762","CD011762_pub2_data","10|1|All-cause mortality|","All-cause mortality",10,1,"","or","binary",15,-0.107806135182942,0.24467779671019,0,2009.66666666667,0.00323824267110444,1709.46666666667
"CD011762","CD011762_pub2_data","10|10|Asymptomatic distal DVT|","Asymptomatic distal DVT",10,10,"","or","binary",12,-0.48262448754452,0.160920363637555,0.0570342962802645,2014,0.0910394445255037,383.5
"CD011762","CD011762_pub2_data","10|11|Fatal bleeding|","Fatal bleeding",10,11,"","or","binary",4,0.377077552749768,0.817264868815506,0,2010.25,0.000163505559189012,2698.5
"CD011762","CD011762_pub2_data","10|12|Liver enzymes elevation|","Liver enzymes elevation",10,12,"","or","binary",19,-0.600725854586031,0.13280711757902,0.150587809169545,2010.78947368421,0.0505917475022336,1594.52631578947
"CD011762","CD011762_pub2_data","10|13|Minor adverse events|","Minor adverse events",10,13,"","or","binary",4,-0.293463518245618,0.158920775635944,1.75644510907542e-05,2017.25,0.550428326670474,252.75
"CD011762","CD011762_pub2_data","10|14|Volume of blood loss|","Volume of blood loss",10,14,"","or","binary",11,-0.572128737866257,0.605291766988703,0,2012.27272727273,0,538.363636363636
"CD011762","CD011762_pub2_data","10|2|Major VTE|","Major VTE",10,2,"","reported","reported",21,0,0.114169336841622,0,2010.85714285714,0.0404787063409115,1096.14285714286
"CD011762","CD011762_pub2_data","10|3|Symptomatic VTE|","Symptomatic VTE",10,3,"","reported","reported",23,0,0.135092423893463,0,2011.39130434783,0.0167565026530104,1273.34782608696
"CD011762","CD011762_pub2_data","10|4|Major bleeding|","Major bleeding",10,4,"","reported","reported",24,0,0.107183443856234,0,2011.58333333333,0.0384449636444529,1433.95833333333
"CD011762","CD011762_pub2_data","10|5|Major bleeding: rivaroxaban versus LMWH|Rivaroxaban","Major bleeding: rivaroxaban versus LMWH",10,5,"Rivaroxaban","reported","reported",10,0,0.253157439520719,0,2010.7,0.012380976087984,1498.6
"CD011762","CD011762_pub2_data","10|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Other direct factor Xa inhibitors","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",10,6,"Other direct factor Xa inhibitors","reported","reported",14,0,0.118310661917807,0,2012.21428571429,0.0570620976133593,1387.78571428571
"CD011762","CD011762_pub2_data","10|8|Serious non-hepatic adverse events|","Serious non-hepatic adverse events",10,8,"","or","binary",15,-0.144651409755219,0.0635920981106475,0.0113170464823029,2011,0.060774268740188,1749.73333333333
"CD011762","CD011762_pub2_data","10|9|Fatal VTE|","Fatal VTE",10,9,"","or","binary",9,0.195146654007328,0.496904057787537,0,2009.77777777778,0.00149662892062268,1989.55555555556
"CD011762","CD011762_pub2_data","11|1|All-cause mortality|","All-cause mortality",11,1,"","reported","reported",14,0,0.274385416517234,0,2009.78571428571,0.00281197544121703,1707.78571428571
"CD011762","CD011762_pub2_data","11|10|Asymptomatic distal DVT|","Asymptomatic distal DVT",11,10,"","or","binary",11,-0.459124513002012,0.160358145204445,0.054008771615328,2014.09090909091,0.0907394283331396,408.727272727273
"CD011762","CD011762_pub2_data","11|11|Fatal bleeding|","Fatal bleeding",11,11,"","or","binary",4,0.377077552749768,0.817264868815506,0,2010.25,0.000163505559189012,2698.5
"CD011762","CD011762_pub2_data","11|12|Liver enzymes elevation|","Liver enzymes elevation",11,12,"","or","binary",20,-0.538766674102987,0.121179751671987,0.110491933602124,2010.55,0.0538126725766306,1453.85
"CD011762","CD011762_pub2_data","11|13|Minor adverse events|","Minor adverse events",11,13,"","or","binary",4,-0.293463518245618,0.158920775635944,1.75644510907542e-05,2017.25,0.550428326670474,252.75
"CD011762","CD011762_pub2_data","11|14|Volume of blood loss|","Volume of blood loss",11,14,"","reported","reported",10,0,2.79864946026659,0,2010.9,0,636.3
"CD011762","CD011762_pub2_data","11|2|Major VTE|","Major VTE",11,2,"","reported","reported",21,0,0.113533124125606,0,2010.19047619048,0.0291428619209549,1042.38095238095
"CD011762","CD011762_pub2_data","11|3|Symptomatic VTE|","Symptomatic VTE",11,3,"","reported","reported",21,0,0.144867371262937,0,2010.80952380952,0.0112625602400171,1279.52380952381
"CD011762","CD011762_pub2_data","11|4|Major bleeding|","Major bleeding",11,4,"","reported","reported",27,0,0.104001632809731,0,2011.74074074074,0.0366864164441049,1282.92592592593
"CD011762","CD011762_pub2_data","11|5|Major bleeding: rivaroxaban versus LMWH|Rivaroxaban versus LMWH","Major bleeding: rivaroxaban versus LMWH",11,5,"Rivaroxaban versus LMWH","reported","reported",12,0,0.230446529889025,0,2012.41666666667,0.0144163409358098,1119.5
"CD011762","CD011762_pub2_data","11|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Other direct factor Xa inhibitors versus LMWH","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",11,6,"Other direct factor Xa inhibitors versus LMWH","reported","reported",16,0,0.116246082332406,0,2011.9375,0.0510960720475696,1332.8125
"CD011762","CD011762_pub2_data","11|8|Serious non-hepatic adverse events|","Serious non-hepatic adverse events",11,8,"","or","binary",14,-0.102121097450984,0.0589012860207316,0.00371111734363063,2011.21428571429,0.0575016647812023,1699.21428571429
"CD011762","CD011762_pub2_data","11|9|Fatal VTE|","Fatal VTE",11,9,"","or","binary",9,0.354214250615561,0.499560570501715,0,2009.66666666667,0.00124090714591356,1848.77777777778
"CD011762","CD011762_pub2_data","12|1|Liver enzymes elevation|","Liver enzymes elevation",12,1,"","or","binary",14,-0.385537662797065,0.10058991858534,0.0371679817936246,2008.78571428571,0.0419642357084174,2040.57142857143
"CD011762","CD011762_pub2_data","2|1|All-cause mortality|Apixaban","All-cause mortality",2,1,"Apixaban","or","binary",5,0.150693779101589,0.407695014707776,0.0187768165266037,2011.4,0.00519755385142828,2500.4
"CD011762","CD011762_pub2_data","2|1|All-cause mortality|Darexaban","All-cause mortality",2,1,"Darexaban","or","binary",2,-0.00223401438474399,1.15753084096293,0,2012,0,489
"CD011762","CD011762_pub2_data","2|1|All-cause mortality|Rivaroxaban","All-cause mortality",2,1,"Rivaroxaban","or","binary",7,-0.278899944024595,0.326968272470595,0,2007.28571428571,0.00322655297277504,1573.14285714286
"CD011762","CD011762_pub2_data","2|10|Liver enzymes elevation|Apixaban","Liver enzymes elevation",2,10,"Apixaban","or","binary",4,-0.22125049863914,0.145178823649949,1.67775721016624e-06,2009,0.0195855858475165,3121
"CD011762","CD011762_pub2_data","2|10|Liver enzymes elevation|Darexaban","Liver enzymes elevation",2,10,"Darexaban","or","binary",2,-0.806640997811901,0.405160913139846,0,2014,0.0564524926366314,355
"CD011762","CD011762_pub2_data","2|10|Liver enzymes elevation|Edoxaban","Liver enzymes elevation",2,10,"Edoxaban","or","binary",5,-1.24460594271401,0.4922088302634,0.793949472571574,2013.4,0.0878102698215381,510.4
"CD011762","CD011762_pub2_data","2|10|Liver enzymes elevation|Rivaroxaban","Liver enzymes elevation",2,10,"Rivaroxaban","or","binary",7,-0.484833753268609,0.15090956685692,0.0528768547574462,2008.85714285714,0.0352438313987244,1986.14285714286
"CD011762","CD011762_pub2_data","2|11|Volume of blood loss|Rivaroxaban","Volume of blood loss",2,11,"Rivaroxaban","reported","reported",11,0,3.77819376525909,0,2012.36363636364,0,489.181818181818
"CD011762","CD011762_pub2_data","2|2|Major VTE|Apixaban","Major VTE",2,2,"Apixaban","reported","reported",5,0,0.215785743846593,0,2013.6,0.0278505672196092,1558
"CD011762","CD011762_pub2_data","2|2|Major VTE|Rivaroxaban","Major VTE",2,2,"Rivaroxaban","or","binary",11,-0.861326312133206,0.281465462756393,0.454169148440421,2009,0.0510113862027043,1084.45454545455
"CD011762","CD011762_pub2_data","2|3|Symptomatic VTE|Apixaban","Symptomatic VTE",2,3,"Apixaban","or","binary",5,-0.034711153392206,0.302568766071702,0.093657870109497,2014,0.0100839646180092,2382.8
"CD011762","CD011762_pub2_data","2|3|Symptomatic VTE|Darexaban","Symptomatic VTE",2,3,"Darexaban","or","binary",4,-0.388689020703801,0.682243987677983,0,2011.25,0.0078125,353.75
"CD011762","CD011762_pub2_data","2|3|Symptomatic VTE|Rivaroxaban","Symptomatic VTE",2,3,"Rivaroxaban","reported","reported",12,0,0.173657658386316,0,2010.08333333333,0.0198868883095247,1243.75
"CD011762","CD011762_pub2_data","2|4|Major bleeding|Apixaban","Major bleeding",2,4,"Apixaban","or","binary",5,-0.26754096265044,0.221342627397306,0.0605476065683515,2011.4,0.139314770556253,2537.4
"CD011762","CD011762_pub2_data","2|4|Major bleeding|Darexaban","Major bleeding",2,4,"Darexaban","or","binary",3,-0.396205719329033,0.370064498897444,0,2012.33333333333,0.00879344349407809,1050.66666666667
"CD011762","CD011762_pub2_data","2|4|Major bleeding|Edoxaban","Major bleeding",2,4,"Edoxaban","or","binary",5,-0.0402173142464063,0.540914773351659,0.267943796085106,2013.4,0.0114563285901719,510.4
"CD011762","CD011762_pub2_data","2|4|Major bleeding|Rivaroxaban","Major bleeding",2,4,"Rivaroxaban","reported","reported",12,0,0.229711260094446,0,2011.16666666667,0.0144841467399867,1314.25
"CD011762","CD011762_pub2_data","2|5|Major bleeding: rivaroxaban versus LMWH|","Major bleeding: rivaroxaban versus LMWH",2,5,"","reported","reported",13,0,0.227444244182872,0,2012.07692307692,0.0133699816061415,1222.38461538462
"CD011762","CD011762_pub2_data","2|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",2,6,"","reported","reported",16,0,0.116246082332406,0,2011.9375,0.0510960720475696,1332.8125
"CD011762","CD011762_pub2_data","2|7|Serious non-hepatic adverse events|Apixaban","Serious non-hepatic adverse events",2,7,"Apixaban","or","binary",4,-0.009772802698548,0.0709350171005091,0,2009,0.0717510541554515,3147.75
"CD011762","CD011762_pub2_data","2|7|Serious non-hepatic adverse events|Darexaban","Serious non-hepatic adverse events",2,7,"Darexaban","or","binary",2,-0.685940667413404,0.558323556532062,0.0129038847128053,2014,0.0256742179072276,358
"CD011762","CD011762_pub2_data","2|7|Serious non-hepatic adverse events|Edoxaban","Serious non-hepatic adverse events",2,7,"Edoxaban","or","binary",5,-0.0369222644288277,0.256599286464134,1.19088912617595e-07,2013.4,0.0394251210409417,510.4
"CD011762","CD011762_pub2_data","2|7|Serious non-hepatic adverse events|Rivaroxaban","Serious non-hepatic adverse events",2,7,"Rivaroxaban","or","binary",3,-0.271095672796521,0.0767469501559035,0,2008,0.0922522971580909,3116.33333333333
"CD011762","CD011762_pub2_data","2|8|Fatal VTE|Apixaban","Fatal VTE",2,8,"Apixaban","or","binary",3,0.716125604856588,0.926547038489432,0,2009,0,3070.33333333333
"CD011762","CD011762_pub2_data","2|8|Fatal VTE|Rivaroxaban","Fatal VTE",2,8,"Rivaroxaban","or","binary",6,-0.0643380756383628,0.588593048165735,0,2009,0.00224494338093402,1490.5
"CD011762","CD011762_pub2_data","2|9|Asymptomatic distal DVT|Darexaban","Asymptomatic distal DVT",2,9,"Darexaban","or","binary",2,-0.203830207273012,0.343551596363013,0,2014,0.10594512195122,280
"CD011762","CD011762_pub2_data","2|9|Asymptomatic distal DVT|Edoxaban","Asymptomatic distal DVT",2,9,"Edoxaban","or","binary",4,-0.778816032526639,0.228676344719345,0,2014.25,0.0694217317372047,348.5
"CD011762","CD011762_pub2_data","2|9|Asymptomatic distal DVT|Rivaroxaban","Asymptomatic distal DVT",2,9,"Rivaroxaban","or","binary",4,-0.938862455279885,0.583166281798271,0.595831456232431,2013.5,0.0724345671794862,578.5
"CD011762","CD011762_pub2_data","3|1|All-cause mortality|Extended prophylaxis (> 14 days)","All-cause mortality",3,1,"Extended prophylaxis (> 14 days)","or","binary",4,0.30889658831287,0.435008893106328,0,2012.25,0.00603543565478458,2341
"CD011762","CD011762_pub2_data","3|10|Volume of blood loss|Extended prophylaxis (> 14 days)","Volume of blood loss",3,10,"Extended prophylaxis (> 14 days)","reported","reported",3,0,2.95643055576329,0,2018.66666666667,0,153.666666666667
"CD011762","CD011762_pub2_data","3|10|Volume of blood loss|Short prophylaxis (≤ 14 days)","Volume of blood loss",3,10,"Short prophylaxis (≤ 14 days)","or","binary",7,-1.04703187384612,0.757148271405867,0,2008.28571428571,0,844.571428571429
"CD011762","CD011762_pub2_data","3|2|Major VTE|Extended prophylaxis (> 14 days)","Major VTE",3,2,"Extended prophylaxis (> 14 days)","reported","reported",7,0,0.19904478306311,0,2012.85714285714,0.0590446400221885,1724.42857142857
"CD011762","CD011762_pub2_data","3|3|Symptomatic VTE|Extended prophylaxis (> 14 days)","Symptomatic VTE",3,3,"Extended prophylaxis (> 14 days)","or","binary",5,-0.552152690638386,0.302196513968507,0,2013,0.0107788875235017,2175.6
"CD011762","CD011762_pub2_data","3|3|Symptomatic VTE|Short prophylaxis (≤ 14 days)","Symptomatic VTE",3,3,"Short prophylaxis (≤ 14 days)","reported","reported",16,0,0.155837700803608,0,2010.875,0.0198387885224673,995.5625
"CD011762","CD011762_pub2_data","3|4|Major bleeding|Extended prophylaxis (> 14 days)","Major bleeding",3,4,"Extended prophylaxis (> 14 days)","reported","reported",6,0,0.135860792817138,0,2013.83333333333,0.12419336406212,2139.33333333333
"CD011762","CD011762_pub2_data","3|4|Major bleeding|Short prophylaxis (≤ 14 days)","Major bleeding",3,4,"Short prophylaxis (≤ 14 days)","reported","reported",20,0,0.162442890681512,0,2010.95,0.0114353196475722,1084.15
"CD011762","CD011762_pub2_data","3|5|Major bleeding: rivaroxaban versus LMWH|Extended prophylaxis (> 14 days) rivaroxaban","Major bleeding: rivaroxaban versus LMWH",3,5,"Extended prophylaxis (> 14 days) rivaroxaban","reported","reported",2,0,0.720535206753539,0,2014.5,0.022671862509992,2263
"CD011762","CD011762_pub2_data","3|5|Major bleeding: rivaroxaban versus LMWH|Short prophylaxis (≤ 14 days) rivaroxaban","Major bleeding: rivaroxaban versus LMWH",3,5,"Short prophylaxis (≤ 14 days) rivaroxaban","reported","reported",8,0,0.248875438943237,0,2010.25,0.0138732124428834,1083.5
"CD011762","CD011762_pub2_data","3|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Extended prophylaxis (> 14 days) Other DFXa","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",3,6,"Extended prophylaxis (> 14 days) Other DFXa","reported","reported",10,0,0.0969335238802786,0,2013.7,0.144497664372546,2114.6
"CD011762","CD011762_pub2_data","3|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Short prophylaxis (≤ 14 days) Other DFXa","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",3,6,"Short prophylaxis (≤ 14 days) Other DFXa","reported","reported",12,0,0.214414947381339,0,2011.41666666667,0.00981005778403139,1084.58333333333
"CD011762","CD011762_pub2_data","3|7|Serious non-hepatic adverse events|Extended prophylaxis (> 14 days)","Serious non-hepatic adverse events",3,7,"Extended prophylaxis (> 14 days)","or","binary",2,-0.0765419284851107,0.145192199690915,0.0295061932715086,2009,0.0730354321281598,4882.5
"CD011762","CD011762_pub2_data","3|7|Serious non-hepatic adverse events|Short prophylaxis (≤ 14 days)","Serious non-hepatic adverse events",3,7,"Short prophylaxis (≤ 14 days)","or","binary",12,-0.121708961891657,0.0722293525836762,0,2011.58333333333,0.0549127035567093,1168.66666666667
"CD011762","CD011762_pub2_data","3|8|Asymptomatic distal DVT|Short prophylaxis (≤ 14 days)","Asymptomatic distal DVT",3,8,"Short prophylaxis (≤ 14 days)","or","binary",10,-0.439196998223147,0.160758409875598,0.0530104138571513,2013.8,0.0957317385133923,430.2
"CD011762","CD011762_pub2_data","3|9|Liver enzymes elevation|Extended prophylaxis (> 14 days)","Liver enzymes elevation",3,9,"Extended prophylaxis (> 14 days)","or","binary",2,-0.257051424824935,0.149706426059852,0,2009,0.0221786153927918,4751
"CD011762","CD011762_pub2_data","3|9|Liver enzymes elevation|Short prophylaxis (≤ 14 days)","Liver enzymes elevation",3,9,"Short prophylaxis (≤ 14 days)","or","binary",18,-0.628027032988458,0.14754882848344,0.164702245816654,2010.72222222222,0.0573275678192793,1087.5
"CD011762","CD011762_pub2_data","4|1|All-cause mortality|Start of comparator after surgery","All-cause mortality",4,1,"Start of comparator after surgery","or","binary",8,-0.106454991145865,0.347188997289533,0,2010.625,0.00357143895880284,1166.75
"CD011762","CD011762_pub2_data","4|1|All-cause mortality|Start of comparator before surgery","All-cause mortality",4,1,"Start of comparator before surgery","reported","reported",7,0,0.370749840590582,0,2008.57142857143,0.00285744691373484,2329.71428571429
"CD011762","CD011762_pub2_data","4|10|Liver enzymes elevation|Start of comparator after surgery","Liver enzymes elevation",4,10,"Start of comparator after surgery","or","binary",13,-0.863403233554323,0.192278714192385,0.186750462142143,2011.92307692308,0.058382818314739,951.307692307692
"CD011762","CD011762_pub2_data","4|10|Liver enzymes elevation|Start of comparator before surgery","Liver enzymes elevation",4,10,"Start of comparator before surgery","or","binary",8,-0.34945473179281,0.135682753325917,0.0616815166765402,2008,0.0463176772815,2380.125
"CD011762","CD011762_pub2_data","4|11|Volume of blood loss|Start of comparator after surgery","Volume of blood loss",4,11,"Start of comparator after surgery","reported","reported",8,0,2.58191596853026,0,2014.5,0,545.375
"CD011762","CD011762_pub2_data","4|11|Volume of blood loss|Start of comparator before surgery","Volume of blood loss",4,11,"Start of comparator before surgery","or","binary",5,-0.807027127964381,0.898129680527367,0,2009.8,0,455.2
"CD011762","CD011762_pub2_data","4|2|Major VTE|Start of comparator after surgery","Major VTE",4,2,"Start of comparator after surgery","reported","reported",8,0,0.186715125583038,0,2012.5,0.0719077655501613,608.5
"CD011762","CD011762_pub2_data","4|2|Major VTE|Start of comparator before surgery","Major VTE",4,2,"Start of comparator before surgery","or","binary",12,-0.711297401999632,0.23834854777798,0.38443701242239,2008.33333333333,0.027349986888649,1525.75
"CD011762","CD011762_pub2_data","4|3|Symptomatic VTE|Start of comparator after surgery","Symptomatic VTE",4,3,"Start of comparator after surgery","reported","reported",12,0,0.185999878615089,0,2012.75,0.0259618994446958,785.666666666667
"CD011762","CD011762_pub2_data","4|3|Symptomatic VTE|Start of comparator before surgery","Symptomatic VTE",4,3,"Start of comparator before surgery","or","binary",9,-0.677061256204454,0.195884535958794,4.12287632262236e-07,2008.22222222222,0.00674431921622757,2182.11111111111
"CD011762","CD011762_pub2_data","4|4|Major bleeding|Start of comparator after surgery","Major bleeding",4,4,"Start of comparator after surgery","reported","reported",17,0,0.129196342909408,0,2013.64705882353,0.0527639311512391,814.294117647059
"CD011762","CD011762_pub2_data","4|4|Major bleeding|Start of comparator before surgery","Major bleeding",4,4,"Start of comparator before surgery","or","binary",11,0.0401090877981961,0.168487959171018,9.00539178674122e-07,2008.45454545455,0.008578189460899,2113.90909090909
"CD011762","CD011762_pub2_data","4|5|Major bleeding: rivaroxaban versus LMWH|Start of comparator after surgery","Major bleeding: rivaroxaban versus LMWH",4,5,"Start of comparator after surgery","reported","reported",6,0,0.339177376238162,0,2015.16666666667,0.0221657333726299,708
"CD011762","CD011762_pub2_data","4|5|Major bleeding: rivaroxaban versus LMWH|Start of comparator before surgery","Major bleeding: rivaroxaban versus LMWH",4,5,"Start of comparator before surgery","or","binary",6,0.506491150435173,0.293609531824085,4.57527585362509e-07,2007.16666666667,0.0068025601073434,1920.5
"CD011762","CD011762_pub2_data","4|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Start of comparator after surgery","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",4,6,"Start of comparator after surgery","reported","reported",11,0,0.139730368145197,0,2012.81818181818,0.0694538572122986,872.272727272727
"CD011762","CD011762_pub2_data","4|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Start of comparator before surgery","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",4,6,"Start of comparator before surgery","or","binary",5,-0.206774156318747,0.218921424888096,0.0183051374842972,2010,0.0107089446851657,2346
"CD011762","CD011762_pub2_data","4|7|Serious non-hepatic adverse events|Start of comparator after surgery","Serious non-hepatic adverse events",4,7,"Start of comparator after surgery","or","binary",10,-0.0531888706363884,0.098994674859369,7.89340702392267e-07,2012.1,0.0501868780190654,855.6
"CD011762","CD011762_pub2_data","4|7|Serious non-hepatic adverse events|Start of comparator before surgery","Serious non-hepatic adverse events",4,7,"Start of comparator before surgery","or","binary",5,-0.180279126885817,0.0820459688519261,0.0161962752840535,2008.8,0.0819490501824332,3538
"CD011762","CD011762_pub2_data","4|8|Fatal VTE|Start of comparator after surgery","Fatal VTE",4,8,"Start of comparator after surgery","or","binary",5,-0.041911330286884,0.724331212879996,0,2010.4,0.00210526315789474,911.2
"CD011762","CD011762_pub2_data","4|8|Fatal VTE|Start of comparator before surgery","Fatal VTE",4,8,"Start of comparator before surgery","or","binary",5,0.330005821829051,0.630279230470493,0,2008.6,0.000588668899226089,2763.2
"CD011762","CD011762_pub2_data","4|9|Asymptomatic distal DVT|Start of comparator after surgery","Asymptomatic distal DVT",4,9,"Start of comparator after surgery","or","binary",10,-0.414616666169664,0.179633866853436,0.0683532328505368,2013.3,0.0740426550680314,434.8
"CD011762","CD011762_pub2_data","5|1|All-cause mortality|Once daily administration","All-cause mortality",5,1,"Once daily administration","reported","reported",9,0,0.328455799815544,0,2008.55555555556,0.00250954120104725,1351.44444444444
"CD011762","CD011762_pub2_data","5|1|All-cause mortality|Twice daily administration","All-cause mortality",5,1,"Twice daily administration","reported","reported",10,0,0.375143825590572,0,2009.6,0.00259877692571414,1416
"CD011762","CD011762_pub2_data","5|10|Liver enzymes elevation|Once daily administration","Liver enzymes elevation",5,10,"Once daily administration","or","binary",14,-0.681473074451413,0.161059874371999,0.166810957484158,2010.42857142857,0.0590289803315085,1245.21428571429
"CD011762","CD011762_pub2_data","5|10|Liver enzymes elevation|Twice daily administration","Liver enzymes elevation",5,10,"Twice daily administration","or","binary",9,-0.334739559861852,0.12728520827157,0.00168110245030924,2010,0.0408433663112857,1577.44444444444
"CD011762","CD011762_pub2_data","5|11|Volume of blood loss|Once daily administration","Volume of blood loss",5,11,"Once daily administration","reported","reported",8,0,3.84359663786615,0,2014.125,0,510.875
"CD011762","CD011762_pub2_data","5|11|Volume of blood loss|Twice daily administration","Volume of blood loss",5,11,"Twice daily administration","or","binary",3,-1.01652794621754,1.156571326248,0,2010,0,512.333333333333
"CD011762","CD011762_pub2_data","5|2|Major VTE|Once daily administration","Major VTE",5,2,"Once daily administration","reported","reported",14,0,0.140109466010046,0,2009.64285714286,0.0489836729745032,993.642857142857
"CD011762","CD011762_pub2_data","5|3|Symptomatic VTE|Once daily administration","Symptomatic VTE",5,3,"Once daily administration","reported","reported",14,0,0.170548775007618,0,2010.71428571429,0.0178684506684118,1134.14285714286
"CD011762","CD011762_pub2_data","5|3|Symptomatic VTE|Twice daily administration","Symptomatic VTE",5,3,"Twice daily administration","or","binary",11,-0.139014399609273,0.21775283474138,0.032635143836654,2011.72727272727,0.0156307726698088,1264.63636363636
"CD011762","CD011762_pub2_data","5|4|Major bleeding|Once daily administration","Major bleeding",5,4,"Once daily administration","reported","reported",21,0,0.188931615362406,0,2011.90476190476,0.0123995607846383,1035.09523809524
"CD011762","CD011762_pub2_data","5|4|Major bleeding|Twice daily administration","Major bleeding",5,4,"Twice daily administration","reported","reported",11,0,0.159564255147784,0,2010.18181818182,0.0699950828757194,1474.90909090909
"CD011762","CD011762_pub2_data","5|5|Major bleeding: rivaroxaban versus LMWH|Once daily administration","Major bleeding: rivaroxaban versus LMWH",5,5,"Once daily administration","reported","reported",10,0,0.255374407145178,0,2012.3,0.0139427476497556,1407.9
"CD011762","CD011762_pub2_data","5|5|Major bleeding: rivaroxaban versus LMWH|Twice daily administration","Major bleeding: rivaroxaban versus LMWH",5,5,"Twice daily administration","reported","reported",3,0,0.504165494142551,0,2006,0.0114607614607615,618
"CD011762","CD011762_pub2_data","5|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Once daily administration","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",5,6,"Once daily administration","reported","reported",11,0,0.280812847286714,0,2011.54545454545,0.0109966636345316,696.181818181818
"CD011762","CD011762_pub2_data","5|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Twice daily administration","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",5,6,"Twice daily administration","reported","reported",8,0,0.168211106894247,0,2011.75,0.0919454534063286,1796.25
"CD011762","CD011762_pub2_data","5|7|Serious non-hepatic adverse events|Once daily administration","Serious non-hepatic adverse events",5,7,"Once daily administration","or","binary",10,-0.228199474013641,0.0703885821121558,2.86874041891013e-06,2010.8,0.064037547262629,1299
"CD011762","CD011762_pub2_data","5|7|Serious non-hepatic adverse events|Twice daily administration","Serious non-hepatic adverse events",5,7,"Twice daily administration","or","binary",7,-0.0443670115827072,0.0687482062579792,0,2010.57142857143,0.0625330763462627,1938
"CD011762","CD011762_pub2_data","5|8|Fatal VTE|Once daily administration","Fatal VTE",5,8,"Once daily administration","reported","reported",4,0,0.724276829116193,0,2010.5,0.00336741507140103,2027.75
"CD011762","CD011762_pub2_data","5|8|Fatal VTE|Twice daily administration","Fatal VTE",5,8,"Twice daily administration","reported","reported",6,0,0.656044074566502,0,2008.83333333333,0,1646
"CD011762","CD011762_pub2_data","5|9|Asymptomatic distal DVT|Once daily administration","Asymptomatic distal DVT",5,9,"Once daily administration","or","binary",8,-0.623381172176471,0.220476850751039,0.0961304701480344,2013.875,0.0709281494583454,463.5
"CD011762","CD011762_pub2_data","5|9|Asymptomatic distal DVT|Twice daily administration","Asymptomatic distal DVT",5,9,"Twice daily administration","or","binary",4,-0.215582321810009,0.32652701499601,0.154683035901276,2014.25,0.13126203465982,223.5
"CD011762","CD011762_pub2_data","6|1|All-cause mortality|Total hip replacement surgery only","All-cause mortality",6,1,"Total hip replacement surgery only","reported","reported",6,0,0.391900510415874,0,2008.66666666667,0.00208573219588886,2074.16666666667
"CD011762","CD011762_pub2_data","6|1|All-cause mortality|Total knee replacement surgery only","All-cause mortality",6,1,"Total knee replacement surgery only","or","binary",8,-0.173793486935441,0.340350075452427,0,2009,0.00190323919473752,1637.625
"CD011762","CD011762_pub2_data","6|10|Liver enzymes elevation|Total hip replacement surgery only","Liver enzymes elevation",6,10,"Total hip replacement surgery only","or","binary",10,-0.547772732237979,0.156644613504472,0.10474928642024,2010.8,0.0532575933717701,1612.2
"CD011762","CD011762_pub2_data","6|10|Liver enzymes elevation|Total knee replacement surgery only","Liver enzymes elevation",6,10,"Total knee replacement surgery only","or","binary",9,-0.636462132160843,0.234138025647438,0.273269226646389,2010,0.0374209851023251,1632.33333333333
"CD011762","CD011762_pub2_data","6|11|Volume of blood loss|Total hip replacement surgery only","Volume of blood loss",6,11,"Total hip replacement surgery only","or","binary",6,-0.673585804747966,0.820524295749511,0,2011.16666666667,0,390.333333333333
"CD011762","CD011762_pub2_data","6|11|Volume of blood loss|Total knee replacement surgery only","Volume of blood loss",6,11,"Total knee replacement surgery only","reported","reported",5,0,2.84206192759097,0,2011.6,0,797.2
"CD011762","CD011762_pub2_data","6|2|Major VTE|Total hip or knee replacement surgery","Major VTE",6,2,"Total hip or knee replacement surgery","or","binary",2,0.214380030528332,0.520871224438015,0,2014,0.0334935897435897,237
"CD011762","CD011762_pub2_data","6|2|Major VTE|Total knee replacement surgery only","Major VTE",6,2,"Total knee replacement surgery only","reported","reported",8,0,0.174422976916189,0,2010.5,0.027830533702076,1022.125
"CD011762","CD011762_pub2_data","6|3|Symptomatic VTE|Total hip or knee replacement surgery","Symptomatic VTE",6,3,"Total hip or knee replacement surgery","or","binary",2,-0.0140877844683542,0.655356219417125,0,2018.5,0.0216948621553885,182
"CD011762","CD011762_pub2_data","6|3|Symptomatic VTE|Total hip replacement surgery only","Symptomatic VTE",6,3,"Total hip replacement surgery only","reported","reported",10,0,0.246245435762496,0,2009.9,0.0146179912700692,1502.4
"CD011762","CD011762_pub2_data","6|3|Symptomatic VTE|Total knee replacement surgery only","Symptomatic VTE",6,3,"Total knee replacement surgery only","or","binary",12,-0.277479473414148,0.187302887607221,0.0591619690561049,2011.08333333333,0.0163191603339809,1197.08333333333
"CD011762","CD011762_pub2_data","6|4|Major bleeding|Total hip or knee replacement surgery","Major bleeding",6,4,"Total hip or knee replacement surgery","reported","reported",3,0,0.165048108326339,0,2014.33333333333,0.231481481481481,241
"CD011762","CD011762_pub2_data","6|4|Major bleeding|Total hip replacement surgery only","Major bleeding",6,4,"Total hip replacement surgery only","reported","reported",12,0,0.1862952381295,0,2010.58333333333,0.011588007761275,1599.91666666667
"CD011762","CD011762_pub2_data","6|4|Major bleeding|Total knee replacement surgery only","Major bleeding",6,4,"Total knee replacement surgery only","reported","reported",11,0,0.194112928039275,0,2010.90909090909,0.0112148743127745,1532.54545454545
"CD011762","CD011762_pub2_data","6|5|Major bleeding: rivaroxaban versus LMWH|Total hip replacement surgery only","Major bleeding: rivaroxaban versus LMWH",6,5,"Total hip replacement surgery only","reported","reported",6,0,0.318337102433782,0,2009.16666666667,0.014328790938659,1537.33333333333
"CD011762","CD011762_pub2_data","6|5|Major bleeding: rivaroxaban versus LMWH|Total knee replacement surgery only","Major bleeding: rivaroxaban versus LMWH",6,5,"Total knee replacement surgery only","reported","reported",4,0,0.346560656044729,0,2010.75,0.0177925871453049,1549.75
"CD011762","CD011762_pub2_data","6|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Total hip or knee replacement surgery","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",6,6,"Total hip or knee replacement surgery","reported","reported",2,0,0.165908290719969,0,2014,0.338888888888889,301.5
"CD011762","CD011762_pub2_data","6|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Total hip replacement surgery only","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",6,6,"Total hip replacement surgery only","reported","reported",6,0,0.229744778251836,0,2012,0.00884722458389101,1662.5
"CD011762","CD011762_pub2_data","6|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Total knee replacement surgery only","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",6,6,"Total knee replacement surgery only","reported","reported",7,0,0.23431800645507,0,2011,0.00745618126561431,1522.71428571429
"CD011762","CD011762_pub2_data","6|7|Serious non-hepatic adverse events|Total hip replacement surgery only","Serious non-hepatic adverse events",6,7,"Total hip replacement surgery only","or","binary",7,-0.167529028296199,0.126237093432653,0.0405211026369046,2011.28571428571,0.0491352152450496,2061.28571428571
"CD011762","CD011762_pub2_data","6|7|Serious non-hepatic adverse events|Total knee replacement surgery only","Serious non-hepatic adverse events",6,7,"Total knee replacement surgery only","or","binary",7,-0.118031097505266,0.0745155642142392,0,2010.28571428571,0.0663170355036292,1675.57142857143
"CD011762","CD011762_pub2_data","6|8|Fatal VTE|Total hip replacement surgery only","Fatal VTE",6,8,"Total hip replacement surgery only","or","binary",4,0.07600267402409,0.689925151108265,0,2008.25,0.000735836124032611,2689.75
"CD011762","CD011762_pub2_data","6|8|Fatal VTE|Total knee replacement surgery only","Fatal VTE",6,8,"Total knee replacement surgery only","or","binary",5,0.516685178140709,0.716046245144492,0,2009,0,1484.4
"CD011762","CD011762_pub2_data","6|9|Asymptomatic distal DVT|Total hip replacement surgery only","Asymptomatic distal DVT",6,9,"Total hip replacement surgery only","or","binary",4,-0.683882537318863,0.33596242124439,5.69491414320079e-06,2014,0.0559466340291868,295.75
"CD011762","CD011762_pub2_data","6|9|Asymptomatic distal DVT|Total knee replacement surgery only","Asymptomatic distal DVT",6,9,"Total knee replacement surgery only","or","binary",7,-0.466479252720873,0.196591032039342,0.0815417755208436,2014,0.118807108736037,478
"CD011762","CD011762_pub2_data","7|1|All-cause mortality|Apixaban dose (2.5 to 20 mg/day)","All-cause mortality",7,1,"Apixaban dose (2.5 to 20 mg/day)","reported","reported",5,0,0.442157553565941,0,2011.4,0.00519755385142828,2500.4
"CD011762","CD011762_pub2_data","7|1|All-cause mortality|Rivaroxaban dose (5 to 30 mg/day)","All-cause mortality",7,1,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",7,0,0.341185194847084,0,2007.28571428571,0.00322655297277504,1521.85714285714
"CD011762","CD011762_pub2_data","7|2|Major VTE|Apixaban dose (2.5 to 20 mg/day)","Major VTE",7,2,"Apixaban dose (2.5 to 20 mg/day)","reported","reported",5,0,0.215576232846811,0,2013.6,0.0278505672196092,1558
"CD011762","CD011762_pub2_data","7|2|Major VTE|Darexaban low dose (≤ 40 mg/day)","Major VTE",7,2,"Darexaban low dose (≤ 40 mg/day)","reported","reported",5,0,0.336973228123517,0,2011.6,0.0115029663810152,381.6
"CD011762","CD011762_pub2_data","7|2|Major VTE|Rivaroxaban dose (5 to 30 mg/day)","Major VTE",7,2,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",11,0,0.165103636290882,0,2009,0.0510113862027043,1044.18181818182
"CD011762","CD011762_pub2_data","7|3|Symptomatic VTE|Apixaban dose (2.5 to 20 mg/day)","Symptomatic VTE",7,3,"Apixaban dose (2.5 to 20 mg/day)","reported","reported",5,0,0.255109828800825,0,2014,0.0100839646180092,2382.8
"CD011762","CD011762_pub2_data","7|3|Symptomatic VTE|Darexaban low dose (≤ 40 mg/day)","Symptomatic VTE",7,3,"Darexaban low dose (≤ 40 mg/day)","reported","reported",3,0,0.822236323141184,0,2010.33333333333,0.0104166666666667,246.666666666667
"CD011762","CD011762_pub2_data","7|3|Symptomatic VTE|Rivaroxaban dose (5 to 30 mg/day)","Symptomatic VTE",7,3,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",12,0,0.173315127902272,0,2010.08333333333,0.0198868883095247,1222.25
"CD011762","CD011762_pub2_data","7|4|Major bleeding|Apixaban dose (2.5 to 20 mg/day)","Major bleeding",7,4,"Apixaban dose (2.5 to 20 mg/day)","reported","reported",5,0,0.130144362028193,0,2011.4,0.139314770556253,2537.4
"CD011762","CD011762_pub2_data","7|4|Major bleeding|Darexaban low dose (≤ 40 mg/day)","Major bleeding",7,4,"Darexaban low dose (≤ 40 mg/day)","reported","reported",2,0,0.474634545230583,0,2011.5,0.0131901652411171,895.5
"CD011762","CD011762_pub2_data","7|4|Major bleeding|Edoxaban dose (30 to 60 mg/day)","Major bleeding",7,4,"Edoxaban dose (30 to 60 mg/day)","reported","reported",4,0,0.566658235234458,0,2013.25,0.00569972108254243,501.5
"CD011762","CD011762_pub2_data","7|4|Major bleeding|Rivaroxaban dose (5 to 30 mg/day)","Major bleeding",7,4,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",12,0,0.235447277440061,0,2011.16666666667,0.0144841467399867,1259
"CD011762","CD011762_pub2_data","7|5|Serious non-hepatic adverse events|Darexaban low dose (≤ 40 mg/day)","Serious non-hepatic adverse events",7,5,"Darexaban low dose (≤ 40 mg/day)","or","binary",2,-0.728511449287813,0.653217436242359,0,2014,0.0256742179072276,227
"CD011762","CD011762_pub2_data","7|5|Serious non-hepatic adverse events|Edoxaban dose (30 to 60 mg/day)","Serious non-hepatic adverse events",7,5,"Edoxaban dose (30 to 60 mg/day)","reported","reported",2,0,0.590594123324266,0,2012,0.0144680566693397,349.5
"CD011762","CD011762_pub2_data","7|5|Serious non-hepatic adverse events|Rivaroxaban dose (5 to 30 mg/day)","Serious non-hepatic adverse events",7,5,"Rivaroxaban dose (5 to 30 mg/day)","or","binary",3,-0.271095672796521,0.0767469501559035,0,2008,0.0922522971580909,3116.33333333333
"CD011762","CD011762_pub2_data","7|6|Fatal VTE|Apixaban dose (2.5 to 20 mg/day)","Fatal VTE",7,6,"Apixaban dose (2.5 to 20 mg/day)","or","binary",3,0.716125604856588,0.926547038489432,0,2009,0,3070.33333333333
"CD011762","CD011762_pub2_data","7|6|Fatal VTE|Rivaroxaban dose (5 to 30 mg/day)","Fatal VTE",7,6,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",2,0,1.12054470754392,0,2006,0,305.5
"CD011762","CD011762_pub2_data","7|7|Asymptomatic distal DVT|Darexaban low dose (≤ 40 mg/day)","Asymptomatic distal DVT",7,7,"Darexaban low dose (≤ 40 mg/day)","or","binary",2,-0.0805361682756332,0.381627554212081,0,2014,0.10594512195122,180
"CD011762","CD011762_pub2_data","7|7|Asymptomatic distal DVT|Edoxaban dose (30 to 60 mg/day)","Asymptomatic distal DVT",7,7,"Edoxaban dose (30 to 60 mg/day)","reported","reported",2,0,0.704580656294287,0,2014,0.0387887887887888,109.5
"CD011762","CD011762_pub2_data","7|7|Asymptomatic distal DVT|Rivaroxaban dose (5 to 30 mg/day)","Asymptomatic distal DVT",7,7,"Rivaroxaban dose (5 to 30 mg/day)","or","binary",4,-0.938862455279885,0.583166281798271,0.595831456232431,2013.5,0.0724345671794862,578.5
"CD011762","CD011762_pub2_data","7|8|Liver enzymes elevation|Darexaban low dose (≤ 40 mg/day)","Liver enzymes elevation",7,8,"Darexaban low dose (≤ 40 mg/day)","or","binary",2,-0.867122752740896,0.542698973495597,0.0344940333208624,2014,0.0564524926366314,225.5
"CD011762","CD011762_pub2_data","7|8|Liver enzymes elevation|Edoxaban dose (30 to 60 mg/day)","Liver enzymes elevation",7,8,"Edoxaban dose (30 to 60 mg/day)","reported","reported",2,0,0.377050624200919,0,2012,0.0720729751403368,349.5
"CD011762","CD011762_pub2_data","7|8|Liver enzymes elevation|Rivaroxaban dose (5 to 30 mg/day)","Liver enzymes elevation",7,8,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",2,0,0.286593614331753,0,2006.5,0.0587406015037594,556
"CD011762","CD011762_pub2_data","7|9|Volume of blood loss|Rivaroxaban dose (5 to 30 mg/day)","Volume of blood loss",7,9,"Rivaroxaban dose (5 to 30 mg/day)","reported","reported",11,0,3.80765576702238,0,2011.90909090909,0,485.636363636364
"CD011762","CD011762_pub2_data","8|1|Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH |Apixaban 5 mg/day","Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH ",8,1,"Apixaban 5 mg/day","reported","reported",5,0,0.130185858622403,0,2011.4,0.139314770556253,2415
"CD011762","CD011762_pub2_data","8|1|Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH |Other direct factor Xa inhibitors at low dose","Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH ",8,1,"Other direct factor Xa inhibitors at low dose","reported","reported",9,0,0.307631162685071,0,2011.77777777778,0.00960894903990647,576.444444444444
"CD011762","CD011762_pub2_data","8|1|Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH |Rivaroxaban 10 mg/day","Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH ",8,1,"Rivaroxaban 10 mg/day","reported","reported",13,0,0.255190706000176,0,2012.07692307692,0.0133699816061415,1086.07692307692
"CD011762","CD011762_pub2_data","9|1|All-cause mortality|","All-cause mortality",9,1,"","reported","reported",11,0,0.326507691211462,0,2009,0.00145358028219167,2214.72727272727
"CD011762","CD011762_pub2_data","9|10|Asymptomatic distal DVT|","Asymptomatic distal DVT",9,10,"","or","binary",11,-0.459124513002012,0.160358145204445,0.054008771615328,2014.09090909091,0.0907394283331396,408.727272727273
"CD011762","CD011762_pub2_data","9|11|Fatal bleeding|","Fatal bleeding",9,11,"","or","binary",2,1.09661909394122,1.15494091505544,0,2008.5,0,3733.5
"CD011762","CD011762_pub2_data","9|12|Liver enzymes elevation|","Liver enzymes elevation",9,12,"","or","binary",20,-0.590141547871922,0.134091433458191,0.179068190782895,2010.15,0.0554490824189708,1535.35
"CD011762","CD011762_pub2_data","9|13|Minor adverse events|","Minor adverse events",9,13,"","or","binary",4,-0.293463518245618,0.158920775635944,1.75644510907542e-05,2017.25,0.550428326670474,252.75
"CD011762","CD011762_pub2_data","9|14|Volume of blood loss|","Volume of blood loss",9,14,"","reported","reported",11,0,4.12793089536387,0,2011.45454545455,0,579
"CD011762","CD011762_pub2_data","9|2|Major VTE|","Major VTE",9,2,"","reported","reported",21,0,0.110313653744396,0,2009.57142857143,0.0305763008543938,1129.38095238095
"CD011762","CD011762_pub2_data","9|3|Symptomatic VTE|","Symptomatic VTE",9,3,"","reported","reported",21,0,0.14926380891231,0,2010.61904761905,0.0116379344899816,1395.90476190476
"CD011762","CD011762_pub2_data","9|4|Major bleeding|","Major bleeding",9,4,"","reported","reported",26,0,0.135902929638828,0,2010.92307692308,0.010137274456276,1416.92307692308
"CD011762","CD011762_pub2_data","9|5|Major bleeding: rivaroxaban versus LMWH|Rivaroxaban","Major bleeding: rivaroxaban versus LMWH",9,5,"Rivaroxaban","reported","reported",12,0,0.246379647553571,0,2011.41666666667,0.01031748007332,1310.91666666667
"CD011762","CD011762_pub2_data","9|6|Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH|Other direct factor Xa inhibitors","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH",9,6,"Other direct factor Xa inhibitors","reported","reported",15,0,0.162116922149843,0,2011.33333333333,0.00931729166555573,1415.26666666667
"CD011762","CD011762_pub2_data","9|8|Serious non-hepatic adverse events|","Serious non-hepatic adverse events",9,8,"","or","binary",15,-0.144959285761058,0.0648174296321505,0.0118903144057633,2011,0.0594814158447989,1749.73333333333
"CD011762","CD011762_pub2_data","9|9|Fatal VTE|","Fatal VTE",9,9,"","or","binary",8,0.161467955272774,0.530410764819982,0,2009.5,0.00153986403742664,2223.5
"CD011778","CD011778_pub2_data","1|1|PPD (change from baseline (mm)); 3 months|Multiple sessions","PPD (change from baseline (mm)); 3 months",1,1,"Multiple sessions","reported","reported",10,0.293003954864471,0.0946218388809158,0.0767342341652923,2017.75,0,30.2
"CD011778","CD011778_pub2_data","1|1|PPD (change from baseline (mm)); 3 months|Single session","PPD (change from baseline (mm)); 3 months",1,1,"Single session","reported","reported",28,0.503668493430629,0.105114787071571,0.269308509273039,2015.91666666667,0,41
"CD011778","CD011778_pub2_data","1|10|CAL at 6 months. Subgroup analysis according to type of control (placebo or negative control)|Negative control","CAL at 6 months. Subgroup analysis according to type of control (placebo or negative control)",1,10,"Negative control","reported","reported",14,0.408179396256215,0.130690982584211,0.195296596567931,2017.41666666667,0,44.4285714285714
"CD011778","CD011778_pub2_data","1|2|PPD (change from baseline (mm)); 6 months|Multiple sessions","PPD (change from baseline (mm)); 6 months",1,2,"Multiple sessions","reported","reported",2,0.464567901234568,0.404999769494572,0.3268,2022,0,26
"CD011778","CD011778_pub2_data","1|2|PPD (change from baseline (mm)); 6 months|Single session","PPD (change from baseline (mm)); 6 months",1,2,"Single session","reported","reported",15,0.535787221032775,0.128365246103455,0.204924296344143,2016.53846153846,0,42.7333333333333
"CD011778","CD011778_pub2_data","1|3|BOP (change from baseline (%)); 3 months|Multiple sessions","BOP (change from baseline (%)); 3 months",1,3,"Multiple sessions","reported","reported",4,1.94233814653027,1.00691551647402,3.49857406669138,2018,0,25.5
"CD011778","CD011778_pub2_data","1|3|BOP (change from baseline (%)); 3 months|Single session","BOP (change from baseline (%)); 3 months",1,3,"Single session","reported","reported",9,3.11125385333198,1.57417512101245,13.3006077851283,2015.33333333333,0,35.1111111111111
"CD011778","CD011778_pub2_data","1|4|BOP (change from baseline (%)); 6 months|Multiple sessions","BOP (change from baseline (%)); 6 months",1,4,"Multiple sessions","reported","reported",2,6.72711344922233,5.46490564661267,59.23705,2022,0,26
"CD011778","CD011778_pub2_data","1|4|BOP (change from baseline (%)); 6 months|Single session","BOP (change from baseline (%)); 6 months",1,4,"Single session","reported","reported",5,5.18501304742874,2.46915474508905,21.9744715127394,2017,0,34.8
"CD011778","CD011778_pub2_data","1|5|CAL (change from baseline (mm)); 3 months|Multiple sessions","CAL (change from baseline (mm)); 3 months",1,5,"Multiple sessions","reported","reported",10,0.255316004818036,0.124499485625669,0.127191451993738,2017.75,0,30.2
"CD011778","CD011778_pub2_data","1|5|CAL (change from baseline (mm)); 3 months|Single session","CAL (change from baseline (mm)); 3 months",1,5,"Single session","reported","reported",27,0.424737714204238,0.123880407798737,0.355977956170155,2015.73913043478,0,43.1851851851852
"CD011778","CD011778_pub2_data","1|6|CAL (change from baseline (mm)); 6 months|Multiple sessions","CAL (change from baseline (mm)); 6 months",1,6,"Multiple sessions","reported","reported",2,0.524098360655738,0.304998667286421,0.183,2022,0,26
"CD011778","CD011778_pub2_data","1|6|CAL (change from baseline (mm)); 6 months|Single session","CAL (change from baseline (mm)); 6 months",1,6,"Single session","reported","reported",13,0.429899252191337,0.146758752022622,0.227065203691297,2016.63636363636,0,47.3076923076923
"CD011778","CD011778_pub2_data","1|7|REC (change from baseline (mm)); 3 months|Multiple sessions","REC (change from baseline (mm)); 3 months",1,7,"Multiple sessions","reported","reported",2,-0.0595238095238095,0.207776807690509,0.061,2015,0,34
"CD011778","CD011778_pub2_data","1|7|REC (change from baseline (mm)); 3 months|Single session","REC (change from baseline (mm)); 3 months",1,7,"Single session","reported","reported",11,-0.0168786230985028,0.0132375806709438,8.99625759407431e-05,2013.8,0,39.4545454545455
"CD011778","CD011778_pub2_data","1|8|REC (change from baseline (mm)); 6 months|Single session","REC (change from baseline (mm)); 6 months",1,8,"Single session","reported","reported",4,0.00097100712030776,0.0805679543962148,0,2014.25,0,41.5
"CD011778","CD011778_pub2_data","1|9|PPD at 6 months. Subgroup analysis according to type of control (placebo or negative control)|Negative control","PPD at 6 months. Subgroup analysis according to type of control (placebo or negative control)",1,9,"Negative control","reported","reported",15,0.452987264185067,0.112446018370446,0.157176303297382,2017,0,39.8666666666667
"CD011778","CD011778_pub2_data","1|9|PPD at 6 months. Subgroup analysis according to type of control (placebo or negative control)|Placebo control ","PPD at 6 months. Subgroup analysis according to type of control (placebo or negative control)",1,9,"Placebo control ","reported","reported",2,1.11566265060241,0.414485289087662,0.2832,2019,0,47.5
"CD011778","CD011778_pub2_data","2|1|PPD (change from baseline (mm)); 3 months|Multiple sessions","PPD (change from baseline (mm)); 3 months",2,1,"Multiple sessions","reported","reported",3,0.622618570839642,0.641464826528778,1.20490481310773,2018.66666666667,0,51
"CD011778","CD011778_pub2_data","2|1|PPD (change from baseline (mm)); 3 months|Single session","PPD (change from baseline (mm)); 3 months",2,1,"Single session","reported","reported",3,0.214767830792426,0.351415066891819,0.302924277936653,2010.66666666667,0,34.6666666666667
"CD011778","CD011778_pub2_data","2|2|PPD (change from baseline (mm)); 6 months|Multiple sessions","PPD (change from baseline (mm)); 6 months",2,2,"Multiple sessions","reported","reported",2,0,0.0692574626333042,0,2020,0,50.5
"CD011778","CD011778_pub2_data","2|3|BOP (change from baseline (%)); 3 months|Multiple sessions","BOP (change from baseline (%)); 3 months",2,3,"Multiple sessions","reported","reported",3,-0.279303454380839,0.198543421237944,0,2018.66666666667,0,51
"CD011778","CD011778_pub2_data","2|3|BOP (change from baseline (%)); 3 months|Single session","BOP (change from baseline (%)); 3 months",2,3,"Single session","reported","reported",2,22.0639213548953,20.3959326891556,772.863116584782,2009.5,0,39
"CD011778","CD011778_pub2_data","2|4|BOP (change from baseline (%)); 6 months|Multiple sessions","BOP (change from baseline (%)); 6 months",2,4,"Multiple sessions","or","binary",2,-0.0156933831148112,1.42827918529427,0,2020,0,51.5
"CD011778","CD011778_pub2_data","2|5|CAL (change from baseline (mm)); 3 months|Multiple sessions","CAL (change from baseline (mm)); 3 months",2,5,"Multiple sessions","reported","reported",2,-0.137675675675676,0.15190466427015,0,2018.5,0,56.5
"CD011778","CD011778_pub2_data","2|5|CAL (change from baseline (mm)); 3 months|Single session","CAL (change from baseline (mm)); 3 months",2,5,"Single session","reported","reported",3,0.305931011839581,0.244345068867004,0.0856383569378414,2010.66666666667,0,34.6666666666667
"CD011778","CD011778_pub2_data","2|7|REC (change from baseline (mm)); 3 months|Single session","REC (change from baseline (mm)); 3 months",2,7,"Single session","reported","reported",2,-0.00763919821826281,0.132140169891242,0,2011,0,25
"CD011793","CD011793_pub3_data","1|1|Mortality|NA","Mortality",1,1,NA,"or","binary",10,-0.106163264362003,0.393165238213792,0,2012,0.0369569597069597,98.5
"CD011793","CD011793_pub3_data","1|10|Intensive care unit stay (days)|NA","Intensive care unit stay (days)",1,10,NA,"or","binary",9,-0.0151596882230326,0.670872966663486,0,2012,0,113.666666666667
"CD011793","CD011793_pub3_data","1|11|Postoperative pulmonary function tests (% FEV1)|NA","Postoperative pulmonary function tests (% FEV1)",1,11,NA,"or","binary",5,0.0051549065766945,0.902459033992982,0,2007.4,0,59.4
"CD011793","CD011793_pub3_data","1|12|Re-exploration|NA","Re-exploration",1,12,NA,"or","binary",13,-0.126867849435135,0.260930382914995,0,2013.07692307692,0.0555899157822235,104.230769230769
"CD011793","CD011793_pub3_data","1|13|Postoperative atrial fibrillation|NA","Postoperative atrial fibrillation",1,13,NA,"or","binary",9,0.166747022729935,0.162328965923825,0.0261338285341803,2012.77777777778,0.249789716456383,112.444444444444
"CD011793","CD011793_pub3_data","1|14|Postoperative ventilation time (hours)|NA","Postoperative ventilation time (hours)",1,14,NA,"or","binary",9,-0.0112391677695305,0.67101890591947,0,2010.77777777778,0,109.888888888889
"CD011793","CD011793_pub3_data","1|2|Cardiopulmonary bypass time (minutes)|NA","Cardiopulmonary bypass time (minutes)",1,2,NA,"or","binary",10,0.00376577635402996,0.636880045204743,0,2012.8,0,104.3
"CD011793","CD011793_pub3_data","1|3|Aortic cross-clamp time (minutes)|NA","Aortic cross-clamp time (minutes)",1,3,NA,"or","binary",12,0.0031363645864353,0.581224149175994,0,2012.5,0,102.916666666667
"CD011793","CD011793_pub3_data","1|4|Length of hospital stay (days)|NA","Length of hospital stay (days)",1,4,NA,"or","binary",11,-0.000418052065492234,0.607148945645196,0,2012.27272727273,0,103.727272727273
"CD011793","CD011793_pub3_data","1|5|Postoperative blood loss (mL)|NA","Postoperative blood loss (mL)",1,5,NA,"or","binary",8,0.00320961334618139,0.712104050263368,0,2009.875,0,95.875
"CD011793","CD011793_pub3_data","1|6|Deep sternal wound infection|NA","Deep sternal wound infection",1,6,NA,"or","binary",8,-0.216439888464646,0.436227062416938,0,2014.25,0.0285977564102564,108.5
"CD011793","CD011793_pub3_data","1|7|Pain scores|NA","Pain scores",1,7,NA,"or","binary",5,-0.0345918052312515,0.899644876486723,0,2010.2,0,129.8
"CD011793","CD011793_pub3_data","1|8|Quality of life|NA","Quality of life",1,8,NA,"or","binary",4,-0.0692900851007472,1.00365374709754,0,2018.25,0,156
"CD011793","CD011793_pub3_data","1|9|Index admission costs|NA","Index admission costs",1,9,NA,"or","binary",2,0.0628375259607609,1.41710682649625,0,2018.5,0,246
"CD011800","CD011800_pub2_data","2|2|Vitamin D status (change in 25OHD level from baseline)|NA","Vitamin D status (change in 25OHD level from baseline)",2,2,NA,"or","binary",2,0.39756175545872,1.43595869082585,0,2009,0,36.5
"CD011800","CD011800_pub2_data","2|7|Secondary hyperparathyroidism (change in parathyroid hormone level from baseline)|NA","Secondary hyperparathyroidism (change in parathyroid hormone level from baseline)",2,7,NA,"or","binary",2,0.421651254446326,1.43616011954955,0,2009,0,36
"CD011806","CD011806_pub2_data","1|10|Disease activity at end of follow-up (Crohn's disease) – sensitivity analysis (fixed-effect)|All-treatment-dose vitamin D (mixed measures at end of treatment)","Disease activity at end of follow-up (Crohn's disease) – sensitivity analysis (fixed-effect)",1,10,"All-treatment-dose vitamin D (mixed measures at end of treatment)","or","binary",2,0.0222625606621283,1.42792341804898,0,2019,0,50.5
"CD011806","CD011806_pub2_data","1|12|Disease activity at end of follow-up (ulcerative colitis)|All-treatment-dose vitamin D (mixed scores)","Disease activity at end of follow-up (ulcerative colitis)",1,12,"All-treatment-dose vitamin D (mixed scores)","or","binary",2,-0.0217197460892245,1.42875995374559,0,2019,0,47.5
"CD011806","CD011806_pub2_data","1|13|Disease activity at end of follow-up (ulcerative colitis) – sensitivity analysis (fixed-effect)|All -treatment-dose vitamin D (mixed scores)","Disease activity at end of follow-up (ulcerative colitis) – sensitivity analysis (fixed-effect)",1,13,"All -treatment-dose vitamin D (mixed scores)","or","binary",2,-0.0217197460892245,1.42875995374559,0,2019,0,47.5
"CD011806","CD011806_pub2_data","1|14|Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes)|All-treatment-dose vitamin D (mixed measures)","Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes)",1,14,"All-treatment-dose vitamin D (mixed measures)","or","binary",4,-0.018099012832773,1.00823058314322,0,2016.75,0,79.75
"CD011806","CD011806_pub2_data","1|15|Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes) – sensitivity analysis (fixed effect)|All-treatment-dose vitamin D (mixed measures)","Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes) – sensitivity analysis (fixed effect)",1,15,"All-treatment-dose vitamin D (mixed measures)","or","binary",4,-0.018099012832773,1.00823058314322,0,2016.75,0,79.75
"CD011806","CD011806_pub2_data","1|17|Total serious adverse events – mixed dose (mixed population)|All-treatment-dose vitamin D (mixed population)","Total serious adverse events – mixed dose (mixed population)",1,17,"All-treatment-dose vitamin D (mixed population)","or","binary",8,-0.00239762843232769,0.573203057157531,0,2017.875,0.0173855633802817,80.625
"CD011806","CD011806_pub2_data","1|17|Total serious adverse events – mixed dose (mixed population)|Low-treatment-dose vitamin D (mixed population)","Total serious adverse events – mixed dose (mixed population)",1,17,"Low-treatment-dose vitamin D (mixed population)","or","binary",2,0.0342246567715338,1.4225637913867,0,2002.5,0,84.5
"CD011806","CD011806_pub2_data","1|18|Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (fixed-effect)|All-treatment-dose vitamin D (mixed population)","Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (fixed-effect)",1,18,"All-treatment-dose vitamin D (mixed population)","or","binary",8,-0.00239762843232769,0.573203057157531,0,2017.875,0.0173855633802817,80.625
"CD011806","CD011806_pub2_data","1|18|Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (fixed-effect)|Low-treatment-dose vitamin D (mixed population)","Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (fixed-effect)",1,18,"Low-treatment-dose vitamin D (mixed population)","or","binary",2,0.0342246567715338,1.4225637913867,0,2002.5,0,84.5
"CD011806","CD011806_pub2_data","1|19|Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (removal of studies at risk of bias)|","Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (removal of studies at risk of bias)",1,19,"","or","binary",4,-0.332194516955448,0.847962917737539,0,2016,0.03125,92
"CD011806","CD011806_pub2_data","1|2|Clinical relapse (mixed IBD)|","Clinical relapse (mixed IBD)",1,2,"","or","binary",3,-0.693822032280054,0.3425835533927,0.11107915686709,2017,0.282828282828283,103.333333333333
"CD011806","CD011806_pub2_data","1|3|Clinical relapse (mixed IBD) – sensitivity analysis (fixed-effect)|","Clinical relapse (mixed IBD) – sensitivity analysis (fixed-effect)",1,3,"","or","binary",3,-0.693822032280054,0.3425835533927,0.11107915686709,2017,0.282828282828283,103.333333333333
"CD011806","CD011806_pub2_data","1|4|Quality of life (QoL) (end of follow-up/change in score)|Any-treatment-dose-vitamin D (mixed measures of quality of life – mixed population)","Quality of life (QoL) (end of follow-up/change in score)",1,4,"Any-treatment-dose-vitamin D (mixed measures of quality of life – mixed population)","or","binary",2,-0.00695473512901604,1.42015542683319,0,2020.5,0,121.5
"CD011806","CD011806_pub2_data","1|5|QoL (end of follow-up/change in score) – sensitivity analysis (fixed-effect)|Any-treatment-dose-vitamin D (mixed measures of QoL – mixed population)","QoL (end of follow-up/change in score) – sensitivity analysis (fixed-effect)",1,5,"Any-treatment-dose-vitamin D (mixed measures of QoL – mixed population)","or","binary",2,-0.00695473512901604,1.42015542683319,0,2020.5,0,121.5
"CD011806","CD011806_pub2_data","1|6|Withdrawals due to adverse events|Any-treatment-dose vitamin D (mixed population)","Withdrawals due to adverse events",1,6,"Any-treatment-dose vitamin D (mixed population)","or","binary",8,0.120940509614089,0.616642526732685,0,2017.875,0.00176056338028169,80.875
"CD011806","CD011806_pub2_data","1|6|Withdrawals due to adverse events|Low-treatment-dose vitamin D (Crohn's disease)","Withdrawals due to adverse events",1,6,"Low-treatment-dose vitamin D (Crohn's disease)","or","binary",2,0.0342246567715338,1.4225637913867,0,2002.5,0,84.5
"CD011806","CD011806_pub2_data","1|6|Withdrawals due to adverse events|Supplemental-dose vitamin D (mixed population)","Withdrawals due to adverse events",1,6,"Supplemental-dose vitamin D (mixed population)","or","binary",2,-0.00420342723531751,1.4174718844004,0,2019,0,217.5
"CD011806","CD011806_pub2_data","1|7|Withdrawals due to adverse events – sensitivity analysis (fixed-effect)|Any-treatment-dose vitamin D (mixed population)","Withdrawals due to adverse events – sensitivity analysis (fixed-effect)",1,7,"Any-treatment-dose vitamin D (mixed population)","or","binary",8,0.120940509614089,0.616642526732685,0,2017.875,0.00176056338028169,80.875
"CD011806","CD011806_pub2_data","1|7|Withdrawals due to adverse events – sensitivity analysis (fixed-effect)|Low-treatment-dose vitamin D (Crohn's disease)","Withdrawals due to adverse events – sensitivity analysis (fixed-effect)",1,7,"Low-treatment-dose vitamin D (Crohn's disease)","or","binary",2,0.0342246567715338,1.4225637913867,0,2002.5,0,84.5
"CD011806","CD011806_pub2_data","1|7|Withdrawals due to adverse events – sensitivity analysis (fixed-effect)|Supplemental-dose vitamin D (mixed population)","Withdrawals due to adverse events – sensitivity analysis (fixed-effect)",1,7,"Supplemental-dose vitamin D (mixed population)","or","binary",2,-0.00420342723531751,1.4174718844004,0,2019,0,217.5
"CD011806","CD011806_pub2_data","1|8|Withdrawals due to adverse events – sensitivity analysis (removal of studies at risk of bias)|","Withdrawals due to adverse events – sensitivity analysis (removal of studies at risk of bias)",1,8,"","or","binary",4,-0.136303028578117,1.01167543707005,0,2016,0,95.5
"CD011806","CD011806_pub2_data","1|9|Disease activity at end of follow-up (Crohn's disease)|All-treatment-dose vitamin D (mixed measures at end of treatment)","Disease activity at end of follow-up (Crohn's disease)",1,9,"All-treatment-dose vitamin D (mixed measures at end of treatment)","or","binary",2,0.0222625606621283,1.42792341804898,0,2019,0,50.5
"CD011806","CD011806_pub2_data","2|2|Withdrawals due to adverse events – high-dose vitamin D versus low-dose vitamin D (mixed population)|","Withdrawals due to adverse events – high-dose vitamin D versus low-dose vitamin D (mixed population)",2,2,"","or","binary",3,-0.0712225394925359,0.924059125946471,0,2019,0.0208333333333333,34.6666666666667
"CD011806","CD011806_pub2_data","2|3|Normalisation of vitamin D levels (vitamin D level at end of follow-up) – high-treatment-dose vitamin D versus low-treatment-dose vitamin D (mixed measures)|","Normalisation of vitamin D levels (vitamin D level at end of follow-up) – high-treatment-dose vitamin D versus low-treatment-dose vitamin D (mixed measures)",2,3,"","or","binary",2,-0.0577273912118517,1.44087162804297,0,2018.5,0,27
"CD011806","CD011806_pub2_data","3|1|Withdrawals due to adverse events|Any-treatment-dose vitamin D (mixed population)","Withdrawals due to adverse events",3,1,"Any-treatment-dose vitamin D (mixed population)","or","binary",4,0.381274145239457,0.954827344127417,0,2015,0,53.25
"CD011806","CD011806_pub2_data","3|3|Normalisation of vitamin D levels (vitamin D level at end of follow-up) – any-treatment-dose vitamin D versus supplemental-dose vitamin D (mixed measures)|","Normalisation of vitamin D levels (vitamin D level at end of follow-up) – any-treatment-dose vitamin D versus supplemental-dose vitamin D (mixed measures)",3,3,"","or","binary",2,-0.0363488000459601,1.43489380180273,0,2017,0,51.5
"CD011841","CD011841_pub3_data","1|1|Mean change in BCVA between baseline and 12 months (± 6)|","Mean change in BCVA between baseline and 12 months (± 6)",1,1,"","or","binary",2,0.0642104392370611,1.44146006424433,0,2014.5,0,46.5
"CD011841","CD011841_pub3_data","10|1|Mean change in BCVA between baseline and 12 months (± 6)|Non-pulsed","Mean change in BCVA between baseline and 12 months (± 6)",10,1,"Non-pulsed","reported","reported",2,0,0.0157796093029059,0,2019,0,44
"CD011841","CD011841_pub3_data","17|1|Mean change in best-corrected visual acuity between baseline and 12 months (± 6)|","Mean change in best-corrected visual acuity between baseline and 12 months (± 6)",17,1,"","or","binary",3,0.0114381180489264,1.16524800905128,0,2016,0,69.6666666666667
"CD011841","CD011841_pub3_data","17|2|Recurrence of central serous chorioretinopathy at 12 months (± 6)|","Recurrence of central serous chorioretinopathy at 12 months (± 6)",17,2,"","or","binary",3,1.62001244210818,0.38035460220749,6.00577412125566e-06,2016,0.143790849673203,61.6666666666667
"CD011841","CD011841_pub3_data","17|4|Mean change in central retinal thickness between baseline and 12 months (± 6)|","Mean change in central retinal thickness between baseline and 12 months (± 6)",17,4,"","or","binary",3,0.0114381180489264,1.16524800905128,0,2016,0,69.6666666666667
"CD011841","CD011841_pub3_data","2|1|Recurrence of central serous chorioretinopathy at 12 months (± 6)|","Recurrence of central serous chorioretinopathy at 12 months (± 6)",2,1,"","or","binary",2,-1.17029748395606,0.584418909659775,0.21163169260579,2014,0.210992907801418,82
"CD011841","CD011841_pub3_data","22|1|Mean change in best-corrected visual acuity between baseline and 12 months (± 6)|","Mean change in best-corrected visual acuity between baseline and 12 months (± 6)",22,1,"","or","binary",5,-0.265311492625193,0.9030325034165,0,2020.2,0,68.2
"CD011841","CD011841_pub3_data","22|2|Recurrence of central serous chorioretinopathy at 12 months (± 6)|","Recurrence of central serous chorioretinopathy at 12 months (± 6)",22,2,"","or","binary",4,0.206153500002868,0.38976202937726,0.0366950913225053,2019.5,0.297106481481481,74.75
"CD011841","CD011841_pub3_data","22|3|Persistent central serous chorioretinopathy at 12 months (± 6)|","Persistent central serous chorioretinopathy at 12 months (± 6)",22,3,"","or","binary",3,-1.23712441100703,0.345364775291595,0.0623225064223937,2021.66666666667,0.355721076309312,87.3333333333333
"CD011841","CD011841_pub3_data","22|4|Mean change in contrast sensitivity at 12 months (± 6)|","Mean change in contrast sensitivity at 12 months (± 6)",22,4,"","or","binary",2,-1.06223186157925,1.44406001240522,0,2019,0,77.5
"CD011841","CD011841_pub3_data","22|6|Quality of life at 12 months (± 6)|","Quality of life at 12 months (± 6)",22,6,"","or","binary",3,-0.387952662427316,1.16552705846135,0,2020.66666666667,0,79.3333333333333
"CD011841","CD011841_pub3_data","5|1|Mean change in BCVA between baseline and 12 months (± 6)|","Mean change in BCVA between baseline and 12 months (± 6)",5,1,"","or","binary",2,-0.307279713928759,1.43819237138492,0,2018.5,0,61
"CD011841","CD011841_pub3_data","6|1|Mean change in BCVA between baseline and 12 months (± 6)|","Mean change in BCVA between baseline and 12 months (± 6)",6,1,"","or","binary",2,0,1.43675753407464,0,2011.5,0,32
"CD011841","CD011841_pub3_data","6|2|Mean change in central retinal thickness between baseline and 12 months (± 6)|","Mean change in central retinal thickness between baseline and 12 months (± 6)",6,2,"","or","binary",2,0,1.43675753407464,0,2011.5,0,32
"CD011841","CD011841_pub3_data","9|1|Mean change in BCVA between baseline and 12 months (± 6)|","Mean change in BCVA between baseline and 12 months (± 6)",9,1,"","or","binary",2,-0.0289164553223829,1.43957072938409,0,2011.5,0,28
"CD011841","CD011841_pub3_data","9|2|Recurrence of central serous chorioretinopathy at 12 months (± 6)|","Recurrence of central serous chorioretinopathy at 12 months (± 6)",9,2,"","or","binary",2,1.92975063109104,1.54356640716398,3.25855816911154,2011.5,0.2,21.5
"CD011841","CD011841_pub3_data","9|4|Mean change in central retinal thickness between baseline and 12 months (± 6)|","Mean change in central retinal thickness between baseline and 12 months (± 6)",9,4,"","or","binary",2,0.0359494468383907,1.44030631035013,0,2011.5,0,27
"CD011851","CD011851_pub3_data","1|1|Fatal cardiovascular events|NA","Fatal cardiovascular events",1,1,NA,"or","binary",4,-0.1789778853845,0.277135828996131,0,2019,0.0442331769717983,413.5
"CD011851","CD011851_pub3_data","1|10|Diastolic blood pressure|NA","Diastolic blood pressure",1,10,NA,"or","binary",5,-0.0025979383211247,0.895987844328288,0,2017.4,0,627.4
"CD011851","CD011851_pub3_data","1|11|Diastolic blood pressure: sensitivity analysis using fixed-effect model|NA","Diastolic blood pressure: sensitivity analysis using fixed-effect model",1,11,NA,"or","binary",5,-0.0025979383211247,0.895987844328288,0,2017.4,0,627.4
"CD011851","CD011851_pub3_data","1|12|Diastolic blood pressure: sensitivity analysis excluding studies with high risk of bias|NA","Diastolic blood pressure: sensitivity analysis excluding studies with high risk of bias",1,12,NA,"or","binary",2,0.00307134084585647,1.41734377123179,0,2018,0,667.5
"CD011851","CD011851_pub3_data","1|13|Heart rate|NA","Heart rate",1,13,NA,"or","binary",4,-0.00739196939580177,1.0012590179055,0,2019.75,0,736.5
"CD011851","CD011851_pub3_data","1|14|Heart rate: sensitivity analysis using fixed-effect model|NA","Heart rate: sensitivity analysis using fixed-effect model",1,14,NA,"or","binary",4,-0.00739196939580177,1.0012590179055,0,2019.75,0,736.5
"CD011851","CD011851_pub3_data","1|2|Fatal cardiovascular events: sensitivity analysis using fixed-effect model|NA","Fatal cardiovascular events: sensitivity analysis using fixed-effect model",1,2,NA,"or","binary",4,-0.1789778853845,0.277135828996131,0,2019,0.0442331769717983,413.5
"CD011851","CD011851_pub3_data","1|3|Low-density lipoprotein cholesterol|NA","Low-density lipoprotein cholesterol",1,3,NA,"or","binary",8,-0.0135032422515686,0.708113928664711,0,2019,0,622.875
"CD011851","CD011851_pub3_data","1|4|Low-density lipoprotein cholesterol: sensitivity analysis using fixed-effect model|NA","Low-density lipoprotein cholesterol: sensitivity analysis using fixed-effect model",1,4,NA,"or","binary",8,-0.0135032422515686,0.708113928664711,0,2019,0,622.875
"CD011851","CD011851_pub3_data","1|5|Low-density lipoprotein cholesterol: sensitivity analysis excluding studies with high risk of bias|NA","Low-density lipoprotein cholesterol: sensitivity analysis excluding studies with high risk of bias",1,5,NA,"or","binary",3,-0.0325038333242604,1.15669777465882,0,2019,0,624
"CD011851","CD011851_pub3_data","1|6|Systolic blood pressure|NA","Systolic blood pressure",1,6,NA,"or","binary",8,-0.00984481638646774,0.708107129591248,0,2019,0,646.625
"CD011851","CD011851_pub3_data","1|7|Systolic blood pressure: sensitivity analysis using fixed-effect model|NA","Systolic blood pressure: sensitivity analysis using fixed-effect model",1,7,NA,"or","binary",8,-0.00984481638646774,0.708107129591248,0,2019,0,646.625
"CD011851","CD011851_pub3_data","1|8|Systolic blood pressure: sensitivity of analysis excluding studies with high risk of bias|NA","Systolic blood pressure: sensitivity of analysis excluding studies with high risk of bias",1,8,NA,"or","binary",3,-0.0227414201607329,1.15666814070582,0,2019,0,687.333333333333
"CD011851","CD011851_pub3_data","1|9| Systolic blood pressure: sensitivity analysis excluding outlier|NA"," Systolic blood pressure: sensitivity analysis excluding outlier",1,9,NA,"or","binary",7,-0.0136685759865027,0.757075310148032,0,2019.57142857143,0,637.571428571429
"CD011858","CD011858_pub2_data","11|3|Minor bleeding|","Minor bleeding",11,3,"","or","binary",2,-1.58787240023172,0.669708183842851,0,2000.5,0.331730769230769,41
"CD011858","CD011858_pub2_data","3|1|Extracorporeal circuit thrombosis|","Extracorporeal circuit thrombosis",3,1,"","or","binary",3,0.614337914637772,0.764691109391804,2.00680245902906e-06,1999,0.144444444444444,30.3333333333333
"CD011858","CD011858_pub2_data","3|2|Dialysis vascular access thrombosis|","Dialysis vascular access thrombosis",3,2,"","or","binary",2,-1.14742944852326,1.26648630797372,0,2002,0.1,22.5
"CD011858","CD011858_pub2_data","3|4|Death (any cause)|","Death (any cause)",3,4,"","or","binary",2,0.595015648988805,0.949878638393516,0,1997,0.0142857142857143,47.5
"CD011866","CD011866_pub3_data","1|1|Dropouts|CBT","Dropouts",1,1,"CBT","or","binary",8,-0.191096278643096,0.263088978348015,0.280495085675435,2009.625,0.32200969690889,106.375
"CD011866","CD011866_pub3_data","1|1|Dropouts|Contingency management","Dropouts",1,1,"Contingency management","or","binary",16,-0.369500647193038,0.107498219157028,0.0111075864781682,2009.5,0.364975623495369,142.9375
"CD011866","CD011866_pub3_data","1|1|Dropouts|Motivational interviewing","Dropouts",1,1,"Motivational interviewing","or","binary",3,-0.0835550615050995,0.214691783932317,0,2007.33333333333,0.238709287595426,204.666666666667
"CD011866","CD011866_pub3_data","1|2|Point abstinence, end of treatment|CBT","Point abstinence, end of treatment",1,2,"CBT","or","binary",4,0.107378643195412,0.214585637559906,0.0175746980265777,2007.25,0.378152978489652,113.5
"CD011866","CD011866_pub3_data","1|2|Point abstinence, end of treatment|Contingency management","Point abstinence, end of treatment",1,2,"Contingency management","or","binary",5,0.846078794499396,0.419143104060758,0.510778278483874,2013,0.311524331292298,101.4
"CD011866","CD011866_pub3_data","1|3|Point abstinence, longest follow-up|CBT","Point abstinence, longest follow-up",1,3,"CBT","or","binary",4,0.84655586827056,0.384490621431821,0.347637275810289,2001.75,0.286110419174935,121
"CD011866","CD011866_pub3_data","1|3|Point abstinence, longest follow-up|Contingency management","Point abstinence, longest follow-up",1,3,"Contingency management","or","binary",2,-0.15105101758696,1.21745079583852,2.55117756855579,2010,0.504728132387707,70.5
"CD011866","CD011866_pub3_data","1|4|Continuous abstinence, end of treatment|CBT","Continuous abstinence, end of treatment",1,4,"CBT","or","binary",2,0.340869007173479,0.633190432787204,0.632693664013783,2006.5,0.220430107526882,141
"CD011866","CD011866_pub3_data","1|4|Continuous abstinence, end of treatment|Contingency management","Continuous abstinence, end of treatment",1,4,"Contingency management","or","binary",9,1.20511967227995,0.303349620082466,0.401688497880833,2009.88888888889,0.170774723398708,144.777777777778
"CD011866","CD011866_pub3_data","1|5|Continuous abstinence, longest follow-up|Contingency management","Continuous abstinence, longest follow-up",1,5,"Contingency management","or","binary",2,0.651781022248292,0.842214965742756,1.00249087011114,2006,0.254508196721311,90.5
"CD011866","CD011866_pub3_data","1|6|Frequency of drug intake, end of treatment|CBT","Frequency of drug intake, end of treatment",1,6,"CBT","or","binary",3,0.185973596220307,1.16889163969717,0,2018.5,0,44.3333333333333
"CD011866","CD011866_pub3_data","1|6|Frequency of drug intake, end of treatment|Contingency management","Frequency of drug intake, end of treatment",1,6,"Contingency management","or","binary",5,-0.0699891147751297,0.898781475197706,0,2017,0,142.2
"CD011866","CD011866_pub3_data","1|7|Longest period of abstinence|CBT","Longest period of abstinence",1,7,"CBT","or","binary",5,0.138526564601833,0.902308411115173,0,2015.25,0,88
"CD011866","CD011866_pub3_data","1|7|Longest period of abstinence|Contingency management","Longest period of abstinence",1,7,"Contingency management","or","binary",12,-0.133713242121223,0.58111828389694,0,2012.54545454545,0,139.833333333333
"CD011866","CD011866_pub3_data","1|8|Craving|Contingency management","Craving",1,8,"Contingency management","or","binary",2,-0.190065314053989,1.42298131689709,0,2015,0,121
"CD011866","CD011866_pub3_data","1|9|Severity of dependence|Contingency management","Severity of dependence",1,9,"Contingency management","or","binary",4,-0.464058665086802,1.01113799330994,0,2005.75,0,55.75
"CD011866","CD011866_pub3_data","2|1|Dropouts|CBT","Dropouts",2,1,"CBT","or","binary",6,-0.50547461981618,0.201460862667576,0,2006.16666666667,0.490575798470535,90
"CD011866","CD011866_pub3_data","2|1|Dropouts|Motivational interviewing","Dropouts",2,1,"Motivational interviewing","or","binary",2,0.389164817152924,0.563718181044615,0.129947341123408,2016,0.171794871794872,56.5
"CD011866","CD011866_pub3_data","2|8|Severity of dependence (ASI)|CBT","Severity of dependence (ASI)",2,8,"CBT","or","binary",3,-0.132932573737839,1.1603823464261,0,2007.66666666667,0,104
"CD011866","CD011866_pub3_data","2|8|Severity of dependence (ASI)|Motivational interviewing","Severity of dependence (ASI)",2,8,"Motivational interviewing","or","binary",2,0.223519036695457,1.43178949540404,0,2016,0,39.5
"CD011866","CD011866_pub3_data","3|1|Dropouts|","Dropouts",3,1,"","or","binary",6,-0.22464427094364,0.338186615864221,0.487739254372844,2006.83333333333,0.401174655047204,117.333333333333
"CD011866","CD011866_pub3_data","3|2|Point abstinence, longest follow-up|","Point abstinence, longest follow-up",3,2,"","or","binary",2,0.548469112178119,0.285712166355404,0,2006.5,0.205882352941176,123
"CD011866","CD011866_pub3_data","3|3|Continuous abstinence, end of treatment|","Continuous abstinence, end of treatment",3,3,"","or","binary",2,2.30077948810505,0.807538627016346,0,1997,0.0277777777777778,48
"CD011866","CD011866_pub3_data","4|4|Continuous abstinence, end of treatment|12-step facilitation","Continuous abstinence, end of treatment",4,4,"12-step facilitation","or","binary",2,0.331131129346944,0.272040051081919,0,1998,0.359420289855072,112.5
"CD011885","CD011885_pub2_data","1|1|Clinically relevant response, as defined by study authors|NA","Clinically relevant response, as defined by study authors",1,1,NA,"or","binary",7,0.391719602125026,0.364767519739008,0.359472812230247,2008.28571428571,0.256214755074937,99
"CD011885","CD011885_pub2_data","1|10|Remission as defined by Andreasen (2005)|NA","Remission as defined by Andreasen (2005)",1,10,NA,"or","binary",4,0.40018455798358,0.388274491412188,0.205245727555988,2015.5,0.290014506769826,67.25
"CD011885","CD011885_pub2_data","1|13|Positive symptoms: clinically important change in PANSS positive subscore|NA","Positive symptoms: clinically important change in PANSS positive subscore",1,13,NA,"or","binary",2,0.264355483327459,0.749388111501994,0,2011,0.738636363636364,17
"CD011885","CD011885_pub2_data","1|14|Positive symptoms: average endpoint or change PANSS positive subscore (lower is better)|NA","Positive symptoms: average endpoint or change PANSS positive subscore (lower is better)",1,14,NA,"reported","reported",2,0,2.57574766609162,0,2011,0,17
"CD011885","CD011885_pub2_data","1|15|Negative symptoms: clinically important change in PANSS negative subscore|NA","Negative symptoms: clinically important change in PANSS negative subscore",1,15,NA,"or","binary",2,-0.445855591111245,0.663092147638892,0,2011,0.522727272727273,17
"CD011885","CD011885_pub2_data","1|16|Negative symptoms: average endpoint or change in PANSS negative subscore (lower is better)|NA","Negative symptoms: average endpoint or change in PANSS negative subscore (lower is better)",1,16,NA,"reported","reported",2,0,2.70095427710375,0,2011,0,17
"CD011885","CD011885_pub2_data","1|18|Depressive symptoms: clinically relevant response, as defined by study authors|NA","Depressive symptoms: clinically relevant response, as defined by study authors",1,18,NA,"or","binary",3,-0.020097391729659,0.42019364106776,0.197167306754272,2010.66666666667,0.565656565656566,137.333333333333
"CD011885","CD011885_pub2_data","1|19|Depressive symptoms: average endpoint PANSS G6 item (depression) score (lower is better)|NA","Depressive symptoms: average endpoint PANSS G6 item (depression) score (lower is better)",1,19,NA,"or","binary",2,0.229298032165168,1.45455924543588,0,2011,0,17
"CD011885","CD011885_pub2_data","1|2|Tolerability: leaving study early due to adverse effects|NA","Tolerability: leaving study early due to adverse effects",1,2,NA,"or","binary",6,-0.200841803440182,0.36500402408141,0,2010.83333333333,0.0322719661150512,112
"CD011885","CD011885_pub2_data","1|22|Aggressive behaviour: clinically important change in PANSS-Excited Component subscore|NA","Aggressive behaviour: clinically important change in PANSS-Excited Component subscore",1,22,NA,"or","binary",2,-0.898249776349494,0.833641745135316,0,2011,0.892045454545455,17
"CD011885","CD011885_pub2_data","1|23|Aggressive behaviour: average endpoint PANSS-Excited Component subscore (lower is better)|NA","Aggressive behaviour: average endpoint PANSS-Excited Component subscore (lower is better)",1,23,NA,"or","binary",2,0.229298032165168,1.45455924543588,0,2011,0,17
"CD011885","CD011885_pub2_data","1|24|Duration of hospitalisation in days (lower is better)|NA","Duration of hospitalisation in days (lower is better)",1,24,NA,"or","binary",2,0.229298032165168,1.45455924543588,0,2011,0,17
"CD011885","CD011885_pub2_data","1|25|Adverse effects: number of participants experiencing at least one adverse effect|NA","Adverse effects: number of participants experiencing at least one adverse effect",1,25,NA,"or","binary",3,0.579517604396308,0.477726536457181,0.297742820196784,2010.66666666667,0.387626262626263,137.333333333333
"CD011885","CD011885_pub2_data","1|26|Adverse effects: extrapyramidal – akathisia as a dichotomous outcome|NA","Adverse effects: extrapyramidal – akathisia as a dichotomous outcome",1,26,NA,"or","binary",3,0.497759121206392,0.743925526067196,0.863280306108137,2016.66666666667,0.0205870764381403,200.666666666667
"CD011885","CD011885_pub2_data","1|27|Adverse effects: extrapyramidal – akathisia measured by mean score change in BAS (lower is better)|NA","Adverse effects: extrapyramidal – akathisia measured by mean score change in BAS (lower is better)",1,27,NA,"or","binary",2,-0.0254632736854831,1.41828657637328,0,2016,0,228.5
"CD011885","CD011885_pub2_data","1|33|Adverse effects: extrapyramidal – extrapyramidal disorder as a dichotomous outcome|NA","Adverse effects: extrapyramidal – extrapyramidal disorder as a dichotomous outcome",1,33,NA,"or","binary",2,-0.116195876797674,0.564936761274919,0,2016,0.0245271867612293,254.5
"CD011885","CD011885_pub2_data","1|35|Adverse effects: extrapyramidal – parkinsonism measured by mean score change in SAS (lower is better)|NA","Adverse effects: extrapyramidal – parkinsonism measured by mean score change in SAS (lower is better)",1,35,NA,"or","binary",2,-0.0374078596212479,1.41831847498982,0,2016,0,227.5
"CD011885","CD011885_pub2_data","1|37|Adverse effects: agitation|NA","Adverse effects: agitation",1,37,NA,"or","binary",2,0.362454211330052,0.685417668595485,0,2016,0.00797872340425532,254.5
"CD011885","CD011885_pub2_data","1|38|Adverse effects: anxiety|NA","Adverse effects: anxiety",1,38,NA,"or","binary",2,0.0476543867336931,0.456985593003375,0,2016,0.0282210401891253,254.5
"CD011885","CD011885_pub2_data","1|39|Adverse effects: diarrhoea|NA","Adverse effects: diarrhoea",1,39,NA,"or","binary",2,0.0281431192776029,1.51581484669899,3.91584640889112,2014,0.0372340425531915,230
"CD011885","CD011885_pub2_data","1|4|Exacerbations of psychosis, as defined by study authors|NA","Exacerbations of psychosis, as defined by study authors",1,4,NA,"or","binary",4,-0.542103984028807,0.732738894020541,0,2015.5,0.0782358156028369,67.25
"CD011885","CD011885_pub2_data","1|40|Adverse effects: dry mouth|NA","Adverse effects: dry mouth",1,40,NA,"or","binary",2,-0.249676858853884,0.548689951506451,0,2016,0.0271867612293144,254.5
"CD011885","CD011885_pub2_data","1|41|Adverse effects: fatigue|NA","Adverse effects: fatigue",1,41,NA,"or","binary",2,0.394677137514371,0.383613155094314,0,2014,0.127659574468085,230
"CD011885","CD011885_pub2_data","1|42|Adverse effects: headache|NA","Adverse effects: headache",1,42,NA,"or","binary",3,0.398443614194286,0.399758382663129,0,2016.66666666667,0.0259062253743105,200.666666666667
"CD011885","CD011885_pub2_data","1|44|Adverse effects: insomnia|NA","Adverse effects: insomnia",1,44,NA,"or","binary",3,-0.0617209927810713,0.770492260414814,1.25779870989026,2016.66666666667,0.0589046493301812,200.666666666667
"CD011885","CD011885_pub2_data","1|45|Adverse effects: lethargy|NA","Adverse effects: lethargy",1,45,NA,"or","binary",2,0.475305877491652,0.461085499637913,0.105214747345567,2014,0.156914893617021,230
"CD011885","CD011885_pub2_data","1|46|Adverse effects: prolactin – high levels|NA","Adverse effects: prolactin – high levels",1,46,NA,"or","binary",2,-0.16895243684125,0.488925846737851,0,2016,0.0282210401891253,254.5
"CD011885","CD011885_pub2_data","1|48|Adverse effects: restlessness|NA","Adverse effects: restlessness",1,48,NA,"or","binary",2,-0.555460957145903,0.56719181499874,0,2016,0.0341312056737589,254.5
"CD011885","CD011885_pub2_data","1|49|Adverse effects: sedation|NA","Adverse effects: sedation",1,49,NA,"or","binary",3,0.542746919032862,0.337499954144841,0.0841770779402016,2016.66666666667,0.128053585500394,200.666666666667
"CD011885","CD011885_pub2_data","1|5|Acceptability: leaving study early for any reason|NA","Acceptability: leaving study early for any reason",1,5,NA,"or","binary",6,-0.256606725247373,0.242314692706784,0.079927861911112,2010.83333333333,0.241762879063411,112
"CD011885","CD011885_pub2_data","1|50|Adverse effects: somnolence|NA","Adverse effects: somnolence",1,50,NA,"or","binary",2,-0.754826796633087,0.503745780351532,0,2016,0.0361997635933806,254.5
"CD011885","CD011885_pub2_data","1|53|Adverse effects: weight – clinically important increase in weight (≥ 7%)|NA","Adverse effects: weight – clinically important increase in weight (≥ 7%)",1,53,NA,"or","binary",3,0.439442585833646,0.247524143153018,0,2016.66666666667,0.0968282111899133,200.666666666667
"CD011885","CD011885_pub2_data","1|54|Adverse effects: weight – average change in kg (lower is better)|NA","Adverse effects: weight – average change in kg (lower is better)",1,54,NA,"or","binary",3,-0.0154279946810666,1.15950314149845,0,2016.66666666667,0,185
"CD011885","CD011885_pub2_data","1|6|Efficacy: leaving study early due to inefficacy of treatment|NA","Efficacy: leaving study early due to inefficacy of treatment",1,6,NA,"or","binary",6,-0.171676586866311,0.38280365949736,0,2010.83333333333,0.0848640868587677,112
"CD011885","CD011885_pub2_data","1|7|General mental state: clinically important change in PANSS total score|NA","General mental state: clinically important change in PANSS total score",1,7,NA,"or","binary",3,-0.0693808280375823,0.323713653560604,0.0876568104788711,2010.66666666667,0.658209074875742,134
"CD011885","CD011885_pub2_data","1|8|General mental state: average endpoint or change PANSS total score (lower is better)|NA","General mental state: average endpoint or change PANSS total score (lower is better)",1,8,NA,"or","binary",6,0.0444664154852215,0.826160398759944,0,2013.66666666667,0,129.5
"CD011885","CD011885_pub2_data","1|9|General mental state: average endpoint BPRS total score (lower is better)|NA","General mental state: average endpoint BPRS total score (lower is better)",1,9,NA,"or","binary",2,0.196394027343415,1.43893371289519,0,1993,0,28
"CD011885","CD011885_pub2_data","2|1|Response: exclusion of studies with unclear randomisation and allocation concealment methods|NA","Response: exclusion of studies with unclear randomisation and allocation concealment methods",2,1,NA,"or","binary",5,0.680125641553101,0.311223325083495,0.112486546011714,2014.4,0.209128007532263,127.4
"CD011885","CD011885_pub2_data","2|2|Tolerability: exclusion of studies with unclear randomisation and allocation concealment methods|NA","Tolerability: exclusion of studies with unclear randomisation and allocation concealment methods",2,2,NA,"reported","reported",5,0,0.337106547423384,0,2014.4,0.0387263593380615,129.4
"CD011885","CD011885_pub2_data","2|3|Response: exclusion of studies with a high risk of bias regarding blinding of participants and personnel|NA","Response: exclusion of studies with a high risk of bias regarding blinding of participants and personnel",2,3,NA,"or","binary",5,0.513712687951909,0.402945000489352,0.409525566354885,2007.2,0.290518838923094,131.8
"CD011885","CD011885_pub2_data","2|4|Tolerability: exclusion of studies with a high risk of bias regarding blinding of participants and personnel|NA","Tolerability: exclusion of studies with a high risk of bias regarding blinding of participants and personnel",2,4,NA,"reported","reported",4,0,0.34417335796764,0,2010.75,0.0484079491725768,159.5
"CD011885","CD011885_pub2_data","2|5|Response: exclusion of studies with a high risk of bias in selective reporting|NA","Response: exclusion of studies with a high risk of bias in selective reporting",2,5,NA,"or","binary",2,1.09028184864931,0.30855158764721,0,2016,0.192791005291005,255
"CD011885","CD011885_pub2_data","2|6|Tolerability: exclusion of studies with a high risk of bias in selective reporting |NA","Tolerability: exclusion of studies with a high risk of bias in selective reporting ",2,6,NA,"or","binary",2,0.0290601897900793,0.421127990387512,0,2016,0.0329861111111111,260
"CD011885","CD011885_pub2_data","2|7|Response: fixed-effect model|NA","Response: fixed-effect model",2,7,NA,"or","binary",7,0.391719602125026,0.364767519739008,0.359472812230247,2008.28571428571,0.256214755074937,99
"CD011885","CD011885_pub2_data","2|8|Tolerability: fixed-effect model|NA","Tolerability: fixed-effect model",2,8,NA,"or","binary",6,-0.200841803440182,0.36500402408141,0,2010.83333333333,0.0322719661150512,112
"CD012067","CD012067_pub3_data","1|15|Serious adverse events|","Serious adverse events",1,15,"","or","binary",4,0.03027208488492,0.249466968137768,0.116850500199106,2016.25,0.111905754751695,769
"CD012067","CD012067_pub3_data","1|16|Adverse events|Diarrhoea","Adverse events",1,16,"Diarrhoea","or","binary",4,0.117436887611954,0.143040213286242,8.0597033567225e-07,2016.25,0.0884293091226291,769
"CD012067","CD012067_pub3_data","1|16|Adverse events|Dizziness","Adverse events",1,16,"Dizziness","or","binary",3,0.178920166129195,0.233190927266814,0.0284260261284056,2016,0.0756817051053654,570
"CD012067","CD012067_pub3_data","1|16|Adverse events|Dry mouth","Adverse events",1,16,"Dry mouth","or","binary",4,1.72252034858535,0.778150540532126,1.82015319679875,2012.75,0.0386804642517115,749
"CD012067","CD012067_pub3_data","1|16|Adverse events|Headache","Adverse events",1,16,"Headache","or","binary",4,0.0627167725098085,0.10534944987573,0,2012.75,0.0895970289099454,749
"CD012067","CD012067_pub3_data","1|16|Adverse events|Hypertension","Adverse events",1,16,"Hypertension","or","binary",2,-0.789354870941889,0.393239707855541,0.149748823537242,2017.5,0.0814737573861661,770.5
"CD012067","CD012067_pub3_data","1|16|Adverse events|Liver enzyme elevation","Adverse events",1,16,"Liver enzyme elevation","or","binary",3,0.76146235549109,0.200246183576688,0,2015.66666666667,0.01889851042501,967
"CD012067","CD012067_pub3_data","1|16|Adverse events|Nausea","Adverse events",1,16,"Nausea","or","binary",3,-0.460617593182201,0.321353512596407,0.129062619719363,2016,0.125347071757587,570
"CD012067","CD012067_pub3_data","1|16|Adverse events|Nocturia","Adverse events",1,16,"Nocturia","or","binary",2,2.32033824558765,1.51873294915692,4.34330439797136,2018,0.0436428450178238,728.5
"CD012067","CD012067_pub3_data","1|16|Adverse events|Polyuria","Adverse events",1,16,"Polyuria","or","binary",2,3.43458365213221,1.51953937593313,4.31720075538148,2018,0.0312850110337803,728.5
"CD012067","CD012067_pub3_data","1|16|Adverse events|Thirst","Adverse events",1,16,"Thirst","or","binary",4,2.12145920111892,0.812870919388774,2.43652349435415,2016.25,0.10332895426332,769
"CD012067","CD012067_pub3_data","1|16|Adverse events|Upper respiratory tract infection","Adverse events",1,16,"Upper respiratory tract infection","or","binary",2,-0.458835887351386,0.761341317496868,0.865040662134011,2018,0.065591580376846,728.5
"CD012067","CD012067_pub3_data","1|17|Withdrawal due to adverse events|","Withdrawal due to adverse events",1,17,"","or","binary",3,1.05671088278699,0.501003117629257,0.313891930022994,2018,0.0229877159939968,544
"CD012067","CD012067_pub3_data","1|3|Mean change in eGFR [mL/min/1.73 m2]|Studies ≤ 1 year","Mean change in eGFR [mL/min/1.73 m2]",1,3,"Studies ≤ 1 year","reported","reported",2,0,0.335805313107223,0,2018,0,726
"CD012067","CD012067_pub3_data","1|6|Pain|Back pain","Pain",1,6,"Back pain","or","binary",2,-0.595604902943867,0.248645532406469,0,2018,0.088066542182991,728.5
"CD012067","CD012067_pub3_data","1|6|Pain|Kidney pain","Pain",1,6,"Kidney pain","or","binary",4,-0.724345209313313,0.276343425544112,0.165643752346312,2016.25,0.164013999317484,769
"CD012067","CD012067_pub3_data","13|1|Serum creatinine [mg/dL]|","Serum creatinine [mg/dL]",13,1,"","or","binary",2,-0.0939525570021565,1.44710215983282,0,2005,0,21
"CD012067","CD012067_pub3_data","13|2|GFR [mL/min/1.73 m²]|","GFR [mL/min/1.73 m²]",13,2,"","or","binary",3,-0.0949376859040708,1.17561369295018,0,2004.33333333333,0,34.3333333333333
"CD012067","CD012067_pub3_data","13|4|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",13,4,"","or","binary",2,-0.0939525570021565,1.44710215983282,0,2005,0,21
"CD012067","CD012067_pub3_data","13|5|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",13,5,"","or","binary",2,-0.0939525570021565,1.44710215983282,0,2005,0,21
"CD012067","CD012067_pub3_data","13|7|Total kidney volume [mL]|","Total kidney volume [mL]",13,7,"","or","binary",2,-0.0939525570021565,1.44710215983282,0,2005,0,21
"CD012067","CD012067_pub3_data","13|8|Albuminuria|","Albuminuria",13,8,"","or","binary",3,-0.0949376859040708,1.17561369295018,0,2004.33333333333,0,34.3333333333333
"CD012067","CD012067_pub3_data","15|1|Serum creatinine [mg/dL]|","Serum creatinine [mg/dL]",15,1,"","or","binary",2,-0.18530218951499,1.4418150340923,0,2011,0,26
"CD012067","CD012067_pub3_data","16|2|Annual change in eGFR [mL/min/1.73 m2]|","Annual change in eGFR [mL/min/1.73 m2]",16,2,"","reported","reported",2,0,0.187398384339708,0,2011,0,521.5
"CD012067","CD012067_pub3_data","16|4|Back or flank pain|","Back or flank pain",16,4,"","or","binary",2,-0.847452369613194,0.862032094459535,0,2011,0.00764100333478324,522
"CD012067","CD012067_pub3_data","16|5|Quality of life scores|SF-36 physical component summary","Quality of life scores",16,5,"SF-36 physical component summary","or","binary",2,0.0194157329082546,1.41557314173166,0,2011,0,521.5
"CD012067","CD012067_pub3_data","16|6|Cardiovascular events|","Cardiovascular events",16,6,"","or","binary",2,-0.0679549338404606,0.424837039430815,0.166631048440728,2011,0.0477163984341018,522
"CD012067","CD012067_pub3_data","16|9|Albuminuria|","Albuminuria",16,9,"","or","binary",2,0.0176610771564799,1.41557422916988,0,2011,0,521
"CD012067","CD012067_pub3_data","17|10|Albuminuria|","Albuminuria",17,10,"","or","binary",2,0.148226940332685,1.43565177825781,0,2005.5,0,32.5
"CD012067","CD012067_pub3_data","17|2|GFR [mL/min/1.73 m²]|","GFR [mL/min/1.73 m²]",17,2,"","or","binary",2,0.148226940332685,1.43565177825781,0,2005.5,0,32.5
"CD012067","CD012067_pub3_data","21|1|Serum creatinine [mg/dL]|","Serum creatinine [mg/dL]",21,1,"","or","binary",2,0,1.47232534973893,0,2001,0,11
"CD012067","CD012067_pub3_data","21|2|GFR [mL/min/1.73 m²]|","GFR [mL/min/1.73 m²]",21,2,"","or","binary",2,0,1.47232534973893,0,2001,0,11
"CD012067","CD012067_pub3_data","21|3|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",21,3,"","or","binary",2,0,1.47232534973893,0,2001,0,11
"CD012067","CD012067_pub3_data","21|4|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",21,4,"","or","binary",2,0,1.47232534973893,0,2001,0,11
"CD012067","CD012067_pub3_data","21|5|Albuminuria [µg/min]|","Albuminuria [µg/min]",21,5,"","or","binary",2,0,1.47232534973893,0,2001,0,11
"CD012067","CD012067_pub3_data","22|1|Change in eGFR|","Change in eGFR",22,1,"","or","binary",2,-0.257710166216372,1.42532659084232,0,2003.5,0,70
"CD012067","CD012067_pub3_data","22|4|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",22,4,"","or","binary",2,-0.257710166216372,1.42532659084232,0,2010.5,0,70
"CD012067","CD012067_pub3_data","22|5|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",22,5,"","or","binary",2,-0.257710166216372,1.42532659084232,0,2010.5,0,70
"CD012067","CD012067_pub3_data","24|18|Adverse events|Cyst infection","Adverse events",24,18,"Cyst infection","or","binary",2,0.00315877159541178,1.16719456789148,0,2018,0.00543478260869565,113
"CD012067","CD012067_pub3_data","24|18|Adverse events|Hyponatraemia","Adverse events",24,18,"Hyponatraemia","or","binary",2,1.36615113779513,0.666609544120322,0,2018,0.0108695652173913,113
"CD012067","CD012067_pub3_data","24|18|Adverse events|Urinary tract infection","Adverse events",24,18,"Urinary tract infection","reported","reported",2,0,0.348591342077018,0,2018,0.112836438923395,113
"CD012067","CD012067_pub3_data","5|13|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",5,13,"","or","binary",2,-0.0128860710037481,1.44479714810392,0,2009,0,45.5
"CD012067","CD012067_pub3_data","5|14|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",5,14,"","or","binary",2,-0.0128860710037481,1.44479714810392,0,2009,0,45.5
"CD012067","CD012067_pub3_data","5|16|Total kidney volume [L]|","Total kidney volume [L]",5,16,"","or","binary",3,0.166210369955536,1.17779755752278,0,2009,0,38
"CD012067","CD012067_pub3_data","5|17|Total kidney volume (TKV), height-adjusted TKV and absolute change (pooled)|","Total kidney volume (TKV), height-adjusted TKV and absolute change (pooled)",5,17,"","or","binary",6,0.237636694806812,0.828287077904458,0,2012,0,83.3333333333333
"CD012067","CD012067_pub3_data","5|18|Cyst volume [L]|","Cyst volume [L]",5,18,"","or","binary",2,0,1.44537855629052,0,2009,0,41
"CD012067","CD012067_pub3_data","5|19|Parenchymal volume [mL]|","Parenchymal volume [mL]",5,19,"","or","binary",2,0,1.44537855629052,0,2009,0,41
"CD012067","CD012067_pub3_data","5|2|GFR [mL/min/1.73 m2]|Duration > 1 year","GFR [mL/min/1.73 m2]",5,2,"Duration > 1 year","reported","reported",2,0,4.10520759552214,0,2016,0,69.5
"CD012067","CD012067_pub3_data","5|2|GFR [mL/min/1.73 m2]|Duration ≤ 1 year","GFR [mL/min/1.73 m2]",5,2,"Duration ≤ 1 year","reported","reported",2,0,8.8500670162269,0,2007.5,0,20.5
"CD012067","CD012067_pub3_data","5|21|Albuminuria [g/24 hours]|","Albuminuria [g/24 hours]",5,21,"","or","binary",2,-0.0128860710037481,1.44479714810392,0,2009,0,45.5
"CD012067","CD012067_pub3_data","5|22|Serious adverse events|","Serious adverse events",5,22,"","or","binary",2,0.710498991559724,0.374485158789761,0.128351763165772,2017.5,0.144132653061224,202.5
"CD012067","CD012067_pub3_data","5|23|Adverse events|Anaemia","Adverse events",5,23,"Anaemia","or","binary",3,0.618424857497061,1.26424225928024,4.06164941556799,2016,0.207744636316065,161.333333333333
"CD012067","CD012067_pub3_data","5|23|Adverse events|Diarrhoea or abnormal faeces","Adverse events",5,23,"Diarrhoea or abnormal faeces","or","binary",4,2.55945794655471,0.95346641158125,2.9698234714705,2013.25,0.0675985981437109,124
"CD012067","CD012067_pub3_data","5|23|Adverse events|Dizziness","Adverse events",5,23,"Dizziness","or","binary",3,0.73618753728823,0.417110716395677,0.12029776148221,2016,0.0484682401975635,161.333333333333
"CD012067","CD012067_pub3_data","5|23|Adverse events|Fatigue","Adverse events",5,23,"Fatigue","or","binary",2,0.723661142207235,0.364402118017761,0.134215600113032,2017.5,0.186895810955961,202.5
"CD012067","CD012067_pub3_data","5|23|Adverse events|Infection","Adverse events",5,23,"Infection","or","binary",3,-0.211933447141046,0.261212681927113,0.0633158694259235,2016,0.28332966114921,161.333333333333
"CD012067","CD012067_pub3_data","5|3|Change in GFR [mL/min/1.73 m²]|Duration > 1 year","Change in GFR [mL/min/1.73 m²]",5,3,"Duration > 1 year","reported","reported",2,0,0.308545173453032,0,2017.5,0,187.5
"CD012067","CD012067_pub3_data","5|5|Kidney failure|","Kidney failure",5,5,"","or","binary",2,-0.444289597947212,0.683802416902929,0.378171465421803,2017.5,0.0882116004296455,202.5
"CD012067","CD012067_pub3_data","6|1|GFR [mL/min/1.73 m²]|Duration > 1 year","GFR [mL/min/1.73 m²]",6,1,"Duration > 1 year","reported","reported",2,0,1.92255109592398,0,2011.5,0,66.5
"CD012067","CD012067_pub3_data","6|1|GFR [mL/min/1.73 m²]|Duration ≤ 1 year","GFR [mL/min/1.73 m²]",6,1,"Duration ≤ 1 year","reported","reported",2,0,9.2067119777865,0,2012,0,16
"CD012067","CD012067_pub3_data","6|16|Proteinuria|","Proteinuria",6,16,"","or","binary",3,0.0648745267648675,1.17240981075048,0,2012,0,159.666666666667
"CD012067","CD012067_pub3_data","6|19|Albuminuria|","Albuminuria",6,19,"","or","binary",3,0.0602679580314356,1.17392240226795,0,2011,0,49.3333333333333
"CD012067","CD012067_pub3_data","6|20|Serious adverse events|","Serious adverse events",6,20,"","or","binary",2,0.0192433475352217,0.562213838313601,0,2015,0.2,35.5
"CD012067","CD012067_pub3_data","6|21|Adverse events|Angioedema","Adverse events",6,21,"Angioedema","or","binary",3,2.74477491791993,0.865443628491258,0,2009,0,186.666666666667
"CD012067","CD012067_pub3_data","6|21|Adverse events|Dermatitis","Adverse events",6,21,"Dermatitis","or","binary",2,0.941904393135326,0.864611351219032,0,2015,0.025,35.5
"CD012067","CD012067_pub3_data","6|21|Adverse events|Diarrhoea","Adverse events",6,21,"Diarrhoea","or","binary",4,0.94051020271975,0.374194192383818,0.206038863494548,2010.75,0.115322580645161,150.25
"CD012067","CD012067_pub3_data","6|21|Adverse events|Infection","Adverse events",6,21,"Infection","or","binary",5,0.65750288839696,0.325581600874475,0.171150348732271,2011.4,0.457032258064516,126.2
"CD012067","CD012067_pub3_data","6|21|Adverse events|Oral ulcers","Adverse events",6,21,"Oral ulcers","or","binary",4,2.74864381303712,0.340320608455601,0.0949808009454584,2010.25,0.0499769585253456,147.5
"CD012067","CD012067_pub3_data","6|21|Adverse events|Peripheral oedema","Adverse events",6,21,"Peripheral oedema","or","binary",2,0.191358421632478,1.40200462013724,3.07867657416164,2015,0.375,35.5
"CD012067","CD012067_pub3_data","6|3|Kidney failure|","Kidney failure",6,3,"","or","binary",2,1.39752480819019,1.13688543713409,0,2013,0,236
"CD012067","CD012067_pub3_data","6|6|Systolic blood pressure [mm Hg]|","Systolic blood pressure [mm Hg]",6,6,"","or","binary",2,0.0714584827662464,1.43931184634591,0,2008.5,0,56
"CD012067","CD012067_pub3_data","6|7|Diastolic blood pressure [mm Hg]|","Diastolic blood pressure [mm Hg]",6,7,"","or","binary",2,0.0714584827662464,1.43931184634591,0,2008.5,0,56
"CD012067","CD012067_pub3_data","6|9|Total kidney volume [L]|","Total kidney volume [L]",6,9,"","reported","reported",4,0,0.285554511926697,0,2011.75,0,37.75
"CD012067","CD012067_pub3_data","9|12|Serious adverse events|","Serious adverse events",9,12,"","or","binary",2,0.166038533418736,0.781446926727748,0.331116830904043,2020,0.0520833333333333,74
"CD012067","CD012067_pub3_data","9|13|Adverse events|Diarrhoea","Adverse events",9,13,"Diarrhoea","or","binary",2,0.918638136753871,0.346003658470072,0,2020,0.275416666666667,74
"CD012067","CD012067_pub3_data","9|13|Adverse events|Infection","Adverse events",9,13,"Infection","or","binary",2,-0.172235018997704,0.490583467608917,0,2020,0.240833333333333,74
"CD012067","CD012067_pub3_data","9|14|Dose completion|Completed full dose","Dose completion",9,14,"Completed full dose","reported","reported",2,0,0.168090116839609,0,2020,0.645833333333333,71
"CD012079","CD012079_pub2_data","1|1|Awareness of prolapse (0.5 to 7 years)|Anterior compartment mesh","Awareness of prolapse (0.5 to 7 years)",1,1,"Anterior compartment mesh","or","binary",11,-0.487039170404934,0.152490438207444,1.19910355996483e-06,2012.6,0.165988065381453,127.181818181818
"CD012079","CD012079_pub2_data","1|1|Awareness of prolapse (0.5 to 7 years)|Multi-compartment mesh","Awareness of prolapse (0.5 to 7 years)",1,1,"Multi-compartment mesh","or","binary",7,-0.189709629602947,0.171333648369027,0.0630219545668658,2014.33333333333,0.234474335476178,219
"CD012079","CD012079_pub2_data","1|10|Bladder function: de novo stress urinary incontinence (0.5 to 7 years)|Anterior compartment mesh","Bladder function: de novo stress urinary incontinence (0.5 to 7 years)",1,10,"Anterior compartment mesh","or","binary",8,0.413647229308123,0.230284954003061,1.30730416580108e-06,2011.14285714286,0.0778059313930857,133
"CD012079","CD012079_pub2_data","1|10|Bladder function: de novo stress urinary incontinence (0.5 to 7 years)|Multi-compartment mesh ","Bladder function: de novo stress urinary incontinence (0.5 to 7 years)",1,10,"Multi-compartment mesh ","or","binary",9,0.5113051987542,0.180359861695951,0,2014.33333333333,0.128675718654305,104.111111111111
"CD012079","CD012079_pub2_data","1|11|Bladder function: de novo urge incontinence or voiding dysfunction |De novo urgency, urge incontinence or bladder overactivity ","Bladder function: de novo urge incontinence or voiding dysfunction ",1,11,"De novo urgency, urge incontinence or bladder overactivity ","or","binary",6,0.0373282664378205,0.260785217066748,0,2014.16666666667,0.0880300127713921,99.5
"CD012079","CD012079_pub2_data","1|11|Bladder function: de novo urge incontinence or voiding dysfunction |De novo voiding dysfunction ","Bladder function: de novo urge incontinence or voiding dysfunction ",1,11,"De novo voiding dysfunction ","or","binary",4,-0.294444333157061,0.424608804455395,0,2013.25,0.0803791701710121,86
"CD012079","CD012079_pub2_data","1|12|Painful intercourse - de novo dyspareunia |Anterior compartment mesh","Painful intercourse - de novo dyspareunia ",1,12,"Anterior compartment mesh","or","binary",10,0.254029682242665,0.382221418649615,0.307279940668773,2011.7,0.0934787331887113,81.3
"CD012079","CD012079_pub2_data","1|12|Painful intercourse - de novo dyspareunia |Multi-compartment mesh ","Painful intercourse - de novo dyspareunia ",1,12,"Multi-compartment mesh ","or","binary",6,0.242361685897141,0.412200812112655,0.250480528498769,2014,0.134609411794656,82.5
"CD012079","CD012079_pub2_data","1|13|Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 12 (PISQ-12) (0-48)|","Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 12 (PISQ-12) (0-48)",1,13,"","or","binary",7,-0.00835340078013748,0.760754412945855,0,2010.85714285714,0,122.428571428571
"CD012079","CD012079_pub2_data","1|14|Quality of life|International Consultation on Incontinence Questionnaire Vaginal Symptoms (ICIQ-VS)","Quality of life",1,14,"International Consultation on Incontinence Questionnaire Vaginal Symptoms (ICIQ-VS)","or","binary",2,0.133073607925038,1.41941640510304,0,2015.5,0,350
"CD012079","CD012079_pub2_data","1|14|Quality of life|Pelvic Floor Impact Questionnaire-7 (PFIQ-7) 0-300","Quality of life",1,14,"Pelvic Floor Impact Questionnaire-7 (PFIQ-7) 0-300","or","binary",4,0.104563512903702,1.00716253078707,0,2011,0,83.5
"CD012079","CD012079_pub2_data","1|14|Quality of life|Prolapse Quality of Life Questionnaire (P-QoL) 0-100","Quality of life",1,14,"Prolapse Quality of Life Questionnaire (P-QoL) 0-100","or","binary",3,0.00387399228119817,1.16047194256357,0,2011.66666666667,0,110.333333333333
"CD012079","CD012079_pub2_data","1|15|Quality of life (combined) |","Quality of life (combined) ",1,15,"","reported","reported",9,0,0.0543450568394756,0,2012.22222222222,0,151.666666666667
"CD012079","CD012079_pub2_data","1|16|Patient Global Impression of Improvement (PGI-I) (better or very much better)|","Patient Global Impression of Improvement (PGI-I) (better or very much better)",1,16,"","or","binary",4,0.335510679913404,0.241320242468576,4.07905269558547e-07,2015.5,0.769785115303983,117.75
"CD012079","CD012079_pub2_data","1|17|Operating time (minutes)|Anterior compartment mesh ","Operating time (minutes)",1,17,"Anterior compartment mesh ","or","binary",11,0.0142865630152453,0.606767291980787,0,2012.72727272727,0,115
"CD012079","CD012079_pub2_data","1|17|Operating time (minutes)|Multi-compartment mesh ","Operating time (minutes)",1,17,"Multi-compartment mesh ","or","binary",5,0.140547646403459,0.899320197195056,0,2015.4,0,119
"CD012079","CD012079_pub2_data","1|18|Length of stay in hospital (days)|","Length of stay in hospital (days)",1,18,"","or","binary",8,0.117006181873749,0.711360693645094,0,2011.125,0,131.125
"CD012079","CD012079_pub2_data","1|19|Blood transfusion|","Blood transfusion",1,19,"","or","binary",10,0.361002078488855,0.308628913097995,0,2015.4,0.0325310492819009,199.1
"CD012079","CD012079_pub2_data","1|2|Repeat surgery (0.5 to 7 years)|Surgery for mesh exposure ","Repeat surgery (0.5 to 7 years)",1,2,"Surgery for mesh exposure ","or","binary",27,1.95919654653434,0.275431255952801,0,2013.23076923077,0.0012010718729065,142.703703703704
"CD012079","CD012079_pub2_data","1|2|Repeat surgery (0.5 to 7 years)|Surgery for recurrent prolapse ","Repeat surgery (0.5 to 7 years)",1,2,"Surgery for recurrent prolapse ","or","binary",17,-0.385586567711415,0.206838443011095,0.165486145181621,2013.25,0.0851814103545664,146.176470588235
"CD012079","CD012079_pub2_data","1|2|Repeat surgery (0.5 to 7 years)|Surgery for urinary incontinence","Repeat surgery (0.5 to 7 years)",1,2,"Surgery for urinary incontinence","or","binary",13,-0.0696407724789956,0.244226397963821,6.04876386124546e-06,2013.25,0.0434685158782466,169.692307692308
"CD012079","CD012079_pub2_data","1|20|Any repeat surgery (0.5 to 7 years)|","Any repeat surgery (0.5 to 7 years)",1,20,"","reported","reported",26,0,0.106291200097587,0,2013,0.0750235129319105,147.384615384615
"CD012079","CD012079_pub2_data","1|21|Awareness of prolapse (0.5 to 7 years) including trials at high risk of bias |Anterior compartment mesh","Awareness of prolapse (0.5 to 7 years) including trials at high risk of bias ",1,21,"Anterior compartment mesh","or","binary",11,-0.487039170404934,0.152490438207444,1.19910355996483e-06,2012.6,0.165988065381453,127.181818181818
"CD012079","CD012079_pub2_data","1|21|Awareness of prolapse (0.5 to 7 years) including trials at high risk of bias |Multi-compartment mesh","Awareness of prolapse (0.5 to 7 years) including trials at high risk of bias ",1,21,"Multi-compartment mesh","or","binary",8,-0.127291849427543,0.145063566538671,0.0376514191926103,2015.14285714286,0.240879329255941,209.25
"CD012079","CD012079_pub2_data","1|22|Repeat surgery (0.5 to 7 years) including trials at high risk of bias|Surgery for mesh exposure ","Repeat surgery (0.5 to 7 years) including trials at high risk of bias",1,22,"Surgery for mesh exposure ","or","binary",28,1.97555111339157,0.270767878439794,0,2013.48148148148,0.00115817644887412,142.607142857143
"CD012079","CD012079_pub2_data","1|22|Repeat surgery (0.5 to 7 years) including trials at high risk of bias|Surgery for recurrent prolapse ","Repeat surgery (0.5 to 7 years) including trials at high risk of bias",1,22,"Surgery for recurrent prolapse ","or","binary",18,-0.446030297425393,0.20042343230385,0.173900023287088,2013.64705882353,0.0892674519309882,145.833333333333
"CD012079","CD012079_pub2_data","1|22|Repeat surgery (0.5 to 7 years) including trials at high risk of bias|Surgery for urinary incontinence","Repeat surgery (0.5 to 7 years) including trials at high risk of bias",1,22,"Surgery for urinary incontinence","or","binary",13,-0.0696407724789956,0.244226397963821,6.04876386124546e-06,2013.25,0.0434685158782466,169.692307692308
"CD012079","CD012079_pub2_data","1|23|Recurrent prolapse on examination (any compartment) including trials at high risk of bias|Anterior compartment mesh","Recurrent prolapse on examination (any compartment) including trials at high risk of bias",1,23,"Anterior compartment mesh","or","binary",15,-1.603785760141,0.20037538646006,0.273900532665844,2012,0.371836622771675,122.4
"CD012079","CD012079_pub2_data","1|24|Any repeat surgery (0.5 to 7 years) including trials at high risk of bias|","Any repeat surgery (0.5 to 7 years) including trials at high risk of bias",1,24,"","reported","reported",26,0,0.106291200097587,0,2013,0.0750235129319105,147.384615384615
"CD012079","CD012079_pub2_data","1|3|Recurrent prolapse on examination (any compartment) |Anterior compartment mesh","Recurrent prolapse on examination (any compartment) ",1,3,"Anterior compartment mesh","or","binary",15,-1.603785760141,0.20037538646006,0.273900532665844,2012,0.371836622771675,122.4
"CD012079","CD012079_pub2_data","1|3|Recurrent prolapse on examination (any compartment) |Multi-compartment mesh ","Recurrent prolapse on examination (any compartment) ",1,3,"Multi-compartment mesh ","or","binary",10,-0.87825320865615,0.249329920579194,0.470324478078951,2014.1,0.54328406677677,184.4
"CD012079","CD012079_pub2_data","1|4|Recurrent prolapse on examination (anterior compartment) |Anterior compartment mesh ","Recurrent prolapse on examination (anterior compartment) ",1,4,"Anterior compartment mesh ","or","binary",9,-1.3826224078643,0.191992304796299,0.0359370157590267,2011.77777777778,0.307248511473897,110
"CD012079","CD012079_pub2_data","1|4|Recurrent prolapse on examination (anterior compartment) |Multi-compartment mesh ","Recurrent prolapse on examination (anterior compartment) ",1,4,"Multi-compartment mesh ","or","binary",4,-0.595879109079363,0.274445948626434,0.0490021882087864,2012.75,0.261574074074074,106.75
"CD012079","CD012079_pub2_data","1|5|Recurrent prolapse on examination (posterior compartment) |Anterior compartment mesh ","Recurrent prolapse on examination (posterior compartment) ",1,5,"Anterior compartment mesh ","or","binary",2,-0.261175830641982,0.470044526957479,0,2012.5,0.112007168458781,95
"CD012079","CD012079_pub2_data","1|6|Visceral injury |Bladder injury","Visceral injury ",1,6,"Bladder injury","or","binary",14,0.964128244158678,0.35750987419164,0,2013,0.00636287857738261,142.642857142857
"CD012079","CD012079_pub2_data","1|7|Mesh exposure|","Mesh exposure",1,7,"","or","binary",26,2.3445399865616,0.253478794499406,0,2012.84,0.00401647780221016,114.615384615385
"CD012079","CD012079_pub2_data","1|8|POP-Q assessment |Point Ba ","POP-Q assessment ",1,8,"Point Ba ","or","binary",13,0.0232780341011977,0.557487947808492,0,2014.25,0,150.230769230769
"CD012079","CD012079_pub2_data","1|8|POP-Q assessment |Point Bp","POP-Q assessment ",1,8,"Point Bp","or","binary",10,-0.00136916128939486,0.635489953734468,0,2014.44444444444,0,167.4
"CD012079","CD012079_pub2_data","1|8|POP-Q assessment |Point C","POP-Q assessment ",1,8,"Point C","or","binary",11,0.010417207775536,0.605934494399013,0,2014.4,0,159.818181818182
"CD012079","CD012079_pub2_data","1|9|POP-Q assessment Total Vaginal Length (TVL)|","POP-Q assessment Total Vaginal Length (TVL)",1,9,"","or","binary",7,-0.00191869397345314,0.759250551831818,0,2013.83333333333,0,199.571428571429
"CD012079","CD012079_pub2_data","3|1|Awareness of prolapse (1 to 3 years)|Anterior compartment repair","Awareness of prolapse (1 to 3 years)",3,1,"Anterior compartment repair","or","binary",4,-0.320960621659352,0.295093732366519,0,2009,0.161030107072167,107.25
"CD012079","CD012079_pub2_data","3|1|Awareness of prolapse (1 to 3 years)|Multi-compartment repair","Awareness of prolapse (1 to 3 years)",3,1,"Multi-compartment repair","or","binary",2,0.706686810016171,0.46753720156412,0.27100936791719,2014,0.169351230425056,361.5
"CD012079","CD012079_pub2_data","3|1|Awareness of prolapse (1 to 3 years)|Posterior compartment repair","Awareness of prolapse (1 to 3 years)",3,1,"Posterior compartment repair","or","binary",2,-0.142139932442794,0.6796068219983,0.487840549261267,2012,0.117857142857143,111
"CD012079","CD012079_pub2_data","3|10|Bladder function: de novo stress urinary incontinence|","Bladder function: de novo stress urinary incontinence",3,10,"","or","binary",2,1.81549771843344,1.06929738318313,0.629006898697963,2013,0.00847457627118644,71.5
"CD012079","CD012079_pub2_data","3|11|Bladder function: de novo urge incontinence or voiding dysfunction |De novo voiding dysfunction ","Bladder function: de novo urge incontinence or voiding dysfunction ",3,11,"De novo voiding dysfunction ","or","binary",2,-0.178523061695684,0.584115392672586,0,2007.5,0.15948275862069,46.5
"CD012079","CD012079_pub2_data","3|12|Painful intercourse - de novo dyspareunia |","Painful intercourse - de novo dyspareunia ",3,12,"","or","binary",2,0.309739602520357,0.574593153175535,0,2012.5,0.113659022931206,62.5
"CD012079","CD012079_pub2_data","3|14|Quality of life |","Quality of life ",3,14,"","reported","reported",3,0,2.35363259958368,0,2010,0,37.3333333333333
"CD012079","CD012079_pub2_data","3|16|Operating time (minutes)|","Operating time (minutes)",3,16,"","or","binary",5,0.153604980795553,0.901709896863771,0,2011.5,0,63.8
"CD012079","CD012079_pub2_data","3|18|Blood transfusion|","Blood transfusion",3,18,"","or","binary",2,0.126614626374409,0.95392687505537,0,2017,0.00871533899663408,417.5
"CD012079","CD012079_pub2_data","3|2|Repeat surgery (1 to 2 years)|Surgery for recurrent prolapse ","Repeat surgery (1 to 2 years)",3,2,"Surgery for recurrent prolapse ","or","binary",6,0.155510797008682,0.244077860424445,0,2011.2,0.0928797257834957,149.833333333333
"CD012079","CD012079_pub2_data","3|3|Recurrent prolapse on examination (any compartment) |Anterior compartment repair","Recurrent prolapse on examination (any compartment) ",3,3,"Anterior compartment repair","or","binary",5,-0.4731567717931,0.237126363012877,0,2009.8,0.366463166463166,73.8
"CD012079","CD012079_pub2_data","3|3|Recurrent prolapse on examination (any compartment) |Multi-compartment repair ","Recurrent prolapse on examination (any compartment) ",3,3,"Multi-compartment repair ","or","binary",2,0.0709151358711165,0.297140065179728,0.0869840666212809,2016.5,0.394609613781606,345.5
"CD012079","CD012079_pub2_data","3|3|Recurrent prolapse on examination (any compartment) |Posterior compartment repair","Recurrent prolapse on examination (any compartment) ",3,3,"Posterior compartment repair","or","binary",2,0.852848586648093,0.484092966869215,0.184453054439012,2012,0.133766233766234,109
"CD012079","CD012079_pub2_data","3|4|Recurrent prolapse on examination (anterior compartment) |","Recurrent prolapse on examination (anterior compartment) ",3,4,"","or","binary",7,-0.493998796717529,0.203836585085841,0.0378103439402765,2010.71428571429,0.332355798513912,97.7142857142857
"CD012079","CD012079_pub2_data","3|5|Recurrent prolapse on examination (posterior compartment)|","Recurrent prolapse on examination (posterior compartment)",3,5,"","or","binary",3,0.194404140753104,0.712900507677978,1.22305825310104,2011.5,0.222510822510823,94.3333333333333
"CD012079","CD012079_pub2_data","3|6|Visceral injury |Bladder injury","Visceral injury ",3,6,"Bladder injury","or","binary",2,-1.08399922629948,1.16154208569436,0,2014,0.0156174334140436,127
"CD012079","CD012079_pub2_data","3|8|POP-Q assessment |Point Ba ","POP-Q assessment ",3,8,"Point Ba ","or","binary",2,-0.0246281355679773,1.42095993249997,0,2013.5,0,324
"CD012079","CD012079_pub2_data","3|8|POP-Q assessment |Point Bp","POP-Q assessment ",3,8,"Point Bp","or","binary",2,-0.0194509286432135,1.42096307660109,0,2013.5,0,322.5
"CD012079","CD012079_pub2_data","3|8|POP-Q assessment |Point C","POP-Q assessment ",3,8,"Point C","or","binary",2,-0.0348264946012483,1.42096811340494,0,2013.5,0,320
"CD012079","CD012079_pub2_data","3|9|POP-Q assessment Total Vaginal Length (TVL)|","POP-Q assessment Total Vaginal Length (TVL)",3,9,"","or","binary",2,-0.0261082859652513,1.42097555894066,0,2013.5,0,316.5
"CD012079","CD012079_pub2_data","4|10|Bladder function: de novo stress urinary incontinence|","Bladder function: de novo stress urinary incontinence",4,10,"","or","binary",2,0.457997119488939,0.890920793782646,0.602751117206018,2020,0.0458041958041958,87.5
"CD012079","CD012079_pub2_data","4|16|Operating time (minutes)|","Operating time (minutes)",4,16,"","or","binary",3,-0.00506017844635812,1.16016477153963,0,2018.66666666667,0,107
"CD012079","CD012079_pub2_data","4|3|Recurrent prolapse on examination (any compartment) |","Recurrent prolapse on examination (any compartment) ",4,3,"","or","binary",2,0.285272783467731,0.730097081209717,0,2020,0.0275757575757576,116
"CD012079","CD012079_pub2_data","4|6|Visceral injury |Bladder injury","Visceral injury ",4,6,"Bladder injury","or","binary",2,0.673134266999171,1.27958096882935,0,2020,0,87.5
"CD012079","CD012079_pub2_data","4|7|Mesh exposure|","Mesh exposure",4,7,"","or","binary",4,-0.433225431139303,0.479595202688489,0,2019,0.0545260295260295,91.25
"CD012079","CD012079_pub2_data","5|2|Repeat surgery |Surgery for mesh exposure ","Repeat surgery ",5,2,"Surgery for mesh exposure ","or","binary",2,1.69675568061893,1.10971888952662,0,2017.5,0,145
"CD012079","CD012079_pub2_data","5|3|Recurrent prolapse on examination (any compartment) |","Recurrent prolapse on examination (any compartment) ",5,3,"","or","binary",2,-0.039945998765005,0.368606758681425,0,2017.5,0.137111801242236,145
"CD012079","CD012079_pub2_data","5|7|Mesh exposure|","Mesh exposure",5,7,"","or","binary",2,0.629547596680449,1.27570272192182,0,2017.5,0,144.5
"CD012152","CD012152_pub4_data","1|1|Hypoglycaemia|","Hypoglycaemia",1,1,"","or","binary",2,-0.247997471181728,0.093817027858441,0.00300011631050206,2015.5,0.471593930222095,1274
"CD012152","CD012152_pub4_data","1|14|Receipt of oral dextrose gel treatment for hypoglycaemia|","Receipt of oral dextrose gel treatment for hypoglycaemia",1,14,"","or","binary",2,-0.153001395325,0.0883147223863448,0,2015.5,0.294173585831731,1274
"CD012152","CD012152_pub4_data","1|15|Receipt of any medications for hypoglycaemia such as glucagon or corticosteroids|","Receipt of any medications for hypoglycaemia such as glucagon or corticosteroids",1,15,"","or","binary",2,-0.350371108870023,1.41533461229596,0,2015.5,0,1274
"CD012152","CD012152_pub4_data","1|17|Neonatal seizures|","Neonatal seizures",1,17,"","or","binary",2,-0.350689289170142,1.1560742281223,0,2015.5,0.000470366886171214,1274
"CD012152","CD012152_pub4_data","1|18|Duration of initial hospital stay (days)|","Duration of initial hospital stay (days)",1,18,"","or","binary",2,-0.355440640727562,1.41534678768549,0,2015.5,0,1268.5
"CD012152","CD012152_pub4_data","1|19|Breastfeeding (any) after discharge |Breastfeeding (full or exclusive) after discharge ","Breastfeeding (any) after discharge ",1,19,"Breastfeeding (full or exclusive) after discharge ","reported","reported",2,0,0.0182666509194636,0,2015.5,0.832557797805643,1161.5
"CD012152","CD012152_pub4_data","1|2|Major neurological disability at two years of age |Major neurological disability at two years of age","Major neurological disability at two years of age ",1,2,"Major neurological disability at two years of age","reported","reported",2,0,0.287760027281923,0,2015.5,0.0435199720914007,777
"CD012152","CD012152_pub4_data","1|20|Visual impairment at two years of age|","Visual impairment at two years of age",1,20,"","or","binary",2,-1.30372648549876,1.22600806994677,0,2015.5,0.00170357751277683,775.5
"CD012152","CD012152_pub4_data","1|21|Hearing impairment at two years of age|","Hearing impairment at two years of age",1,21,"","or","binary",2,-0.914242305618124,0.87444941558899,0,2015.5,0.00601392234036304,775.5
"CD012152","CD012152_pub4_data","1|22|Cerebral palsy at two years of age|","Cerebral palsy at two years of age",1,22,"","or","binary",2,-0.583871713803835,0.919117765577992,0,2015.5,0.00171526586620926,771.5
"CD012152","CD012152_pub4_data","1|23|Developmental delay/intellectual impairment at two years of age|Developmental delay/intellectual impairment at two years of age","Developmental delay/intellectual impairment at two years of age",1,23,"Developmental delay/intellectual impairment at two years of age","reported","reported",2,0,0.110231084347041,0,2015.5,0.192273743674238,773
"CD012152","CD012152_pub4_data","1|28|Executive dysfunction at two years of age|Executive dysfunction at two years of age","Executive dysfunction at two years of age",1,28,"Executive dysfunction at two years of age","reported","reported",2,0,0.198411134901297,0,2015.5,0.0863852203591037,772
"CD012152","CD012152_pub4_data","1|5|Receipt of treatment for hypoglycaemia during initial hospital stay|","Receipt of treatment for hypoglycaemia during initial hospital stay",1,5,"","reported","reported",2,0,0.0613383646528782,0,2015.5,0.310687553683177,1274
"CD012152","CD012152_pub4_data","1|6|Separation from mother for treatment of hypoglycaemia (admission to NICU for hypoglycaemia)|","Separation from mother for treatment of hypoglycaemia (admission to NICU for hypoglycaemia)",1,6,"","or","binary",2,-0.197273656369649,0.566085528619255,0.540302616629337,2015.5,0.0660558714057835,1274
"CD012152","CD012152_pub4_data","1|7|Receipt of intravenous treatment for hypoglycaemia|","Receipt of intravenous treatment for hypoglycaemia",1,7,"","or","binary",2,-0.081233941845079,0.31807043243293,0.104096162670516,2015.5,0.0553771797074182,1274
"CD012152","CD012152_pub4_data","1|8|Adverse effects (e.g. choking or vomiting at time of administration)|","Adverse effects (e.g. choking or vomiting at time of administration)",1,8,"","or","binary",2,0.175907835307708,0.348967853580276,0,2015.5,0.0403312629399586,1255
"CD012152","CD012152_pub4_data","1|9|Developmental disability at two years of age|Developmental disability at two years of age","Developmental disability at two years of age",1,9,"Developmental disability at two years of age","reported","reported",2,0,0.105867512336896,0,2015.5,0.205606380483228,776.5
"CD012170","CD012170_pub2_data","1|1|Amount of physical activity|NA","Amount of physical activity",1,1,NA,"reported","reported",4,0.38282953651,0.0967561417655076,0.0107241929362467,2020.25,0,303.25
"CD012170","CD012170_pub2_data","1|2|Minutes of sedentary behaviour|NA","Minutes of sedentary behaviour",1,2,NA,"reported","reported",2,-15.1768558056864,7.98361002856544,0,2019.5,0,523.5
"CD012170","CD012170_pub2_data","2|1|Fruit and vegetable consumption|NA","Fruit and vegetable consumption",2,1,NA,"reported","reported",5,0.500387781714802,0.0746631296078617,0,2018.4,0,280.4
"CD012170","CD012170_pub2_data","2|2|Sugary drink consumption|NA","Sugary drink consumption",2,2,NA,"reported","reported",2,-0.371004731121648,0.137684531691496,0,2018,0,112.5
"CD012170","CD012170_pub2_data","3|1|Alcohol consumption in the last week|NA","Alcohol consumption in the last week",3,1,NA,"reported","reported",7,-0.573192596196003,0.760476134238969,2.98208975055521,2016.85714285714,0,313.714285714286
"CD012170","CD012170_pub2_data","4|1|Weight|NA","Weight",4,1,NA,"reported","reported",8,-2.06367899384632,1.51170306708968,10.9146211886162,2018,0,275.5
"CD012170","CD012170_pub2_data","4|2|Body mass index|NA","Body mass index",4,2,NA,"reported","reported",6,-1.25704051257325,0.204341566407988,0.124538025578056,2018.66666666667,0,339.166666666667
"CD012170","CD012170_pub2_data","5|1|Systolic blood pressure|NA","Systolic blood pressure",5,1,NA,"reported","reported",8,-1.99327821165826,1.05643451623273,3.10450432242097,2018,0,258.5
"CD012170","CD012170_pub2_data","5|2|Diastolic blood pressure|NA","Diastolic blood pressure",5,2,NA,"reported","reported",8,-1.65988740883116,0.719083158883663,1.4649861014856,2018,0,258.5
"CD012170","CD012170_pub2_data","6|1|Total quality of life|NA","Total quality of life",6,1,NA,"reported","reported",2,0.309903056784971,0.340903219752334,0.2009352462385,2021,0,534.5
"CD012170","CD012170_pub2_data","6|2|Mental health quality of life|NA","Mental health quality of life",6,2,NA,"reported","reported",2,3.10003826409538,1.87083994212246,5.058273110003,2013.5,0,375
"CD012170","CD012170_pub2_data","6|3|Physical health quality of life|NA","Physical health quality of life",6,3,NA,"reported","reported",3,1.60659987889487,1.47120807243338,3.08249271658342,2015.33333333333,0,255.333333333333
"CD012170","CD012170_pub2_data","7|1|Mental health literacy|NA","Mental health literacy",7,1,NA,"reported","reported",2,0.900505550938231,1.1094515128376,2.3913145923825,2023.5,0,216
"CD012178","CD012178_pub2_data","1|1|Incidence of ROP at any stage|NA","Incidence of ROP at any stage",1,1,NA,"or","binary",4,-0.134088924675517,0.209548489106557,0,2012,0.247373908419167,133
"CD012178","CD012178_pub2_data","1|2|Incidence of ROP stage 3 and above|NA","Incidence of ROP stage 3 and above",1,2,NA,"or","binary",4,-0.761936589077916,0.283487179848204,0,2012,0.156543887147335,133
"CD012178","CD012178_pub2_data","1|3|Mortality assessed throughout NICU stay|NA","Mortality assessed throughout NICU stay",1,3,NA,"or","binary",4,-0.0590045341089832,0.409297647851269,0,2012.25,0.046060889541493,117.5
"CD012178","CD012178_pub2_data","1|4|Incidence of IVH (all grades of IVH and severe IVH grades III and IV)|NA","Incidence of IVH (all grades of IVH and severe IVH grades III and IV)",1,4,NA,"or","binary",4,-0.123845203254184,0.361191896266396,0,2012.25,0.0681622615889857,120.75
"CD012178","CD012178_pub2_data","1|5|Incidence of NEC|NA","Incidence of NEC",1,5,NA,"or","binary",5,-0.0968582791284681,0.358403805251968,0,2012.2,0.0434263294177087,133.2
"CD012178","CD012178_pub2_data","1|6|Any reported adverse effects|NA","Any reported adverse effects",1,6,NA,"or","binary",3,0.0135956121166326,1.15903485313713,0,2012.66666666667,0,163
"CD012186","CD012186_pub2_data","1|1|SAEs|Alemtuzumab versus interferon beta-1a (Rebif)","SAEs",1,1,"Alemtuzumab versus interferon beta-1a (Rebif)","or","binary",3,0.227569143869069,0.159161737150881,0.0019972157504305,2010.66666666667,0.142626082289372,561.333333333333
"CD012186","CD012186_pub2_data","1|1|SAEs|Cladribine versus placebo","SAEs",1,1,"Cladribine versus placebo","or","binary",2,0.0527612717666675,0.290397148784953,0.102190385119484,2012,0.0831547818323848,967.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Dimethyl fumarate versus placebo","SAEs",1,1,"Dimethyl fumarate versus placebo","or","binary",5,-0.301194960759869,0.105035076373102,0,2014.4,0.138047201660377,566.8
"CD012186","CD012186_pub2_data","1|1|SAEs|Fingolimod versus interferon beta-1b","SAEs",1,1,"Fingolimod versus interferon beta-1b","or","binary",2,1.18616651795063,0.795735650796591,0,2018.5,0.0106382978723404,82
"CD012186","CD012186_pub2_data","1|1|SAEs|Fingolimod versus placebo","SAEs",1,1,"Fingolimod versus placebo","or","binary",5,0.0251085838637467,0.0917520085064291,1.24117571922852e-06,2011.6,0.164485409013119,754.8
"CD012186","CD012186_pub2_data","1|1|SAEs|Glatiramer acetate versus placebo","SAEs",1,1,"Glatiramer acetate versus placebo","or","binary",8,-0.160130353251233,0.12513461918183,0,2008.5,0.0611518370524598,623
"CD012186","CD012186_pub2_data","1|1|SAEs|Immunoglobulins versus placebo","SAEs",1,1,"Immunoglobulins versus placebo","or","binary",3,0.0788204767533956,0.660480340603485,0.27553830303654,2005.66666666667,0.0272887946270767,135.666666666667
"CD012186","CD012186_pub2_data","1|1|SAEs|Interferon beta-1a (Avonex) versus placebo","SAEs",1,1,"Interferon beta-1a (Avonex) versus placebo","or","binary",5,-0.112094475938526,0.250589333171942,0.142180543094251,2005.6,0.0853269933893542,377
"CD012186","CD012186_pub2_data","1|1|SAEs|Interferon beta-1a (Rebif) versus placebo","SAEs",1,1,"Interferon beta-1a (Rebif) versus placebo","or","binary",7,-0.0699089813546884,0.146740289619918,8.4048513999305e-06,2005.85714285714,0.0888513995881104,340.571428571429
"CD012186","CD012186_pub2_data","1|1|SAEs|Interferon beta 1a (Rebif) versus interferon beta-1b","SAEs",1,1,"Interferon beta 1a (Rebif) versus interferon beta-1b","or","binary",2,-0.0742357056130808,0.558483027373891,0,2012.5,0.0457291666666667,172
"CD012186","CD012186_pub2_data","1|1|SAEs|Laquinimod versus placebo","SAEs",1,1,"Laquinimod versus placebo","or","binary",7,0.118842223662453,0.138264978437025,0.0232765789032131,2014,0.0552576792196255,622.857142857143
"CD012186","CD012186_pub2_data","1|1|SAEs|Natalizumab versus placebo","SAEs",1,1,"Natalizumab versus placebo","or","binary",4,-0.0195692875844734,0.127740468123878,0.00123155515091413,2011,0.112889913308826,533.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Ocrelizumab versus interferon beta 1a (Rebif)","SAEs",1,1,"Ocrelizumab versus interferon beta 1a (Rebif)","or","binary",2,-0.248041508110397,0.183404971397856,0,2017,0.0870814350964216,825.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Ocrelizumab versus placebo","SAEs",1,1,"Ocrelizumab versus placebo","or","binary",2,-0.111274899176111,0.186350534763323,0,2014,0.129397179606385,444.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Ofatumumab versus placebo","SAEs",1,1,"Ofatumumab versus placebo","or","binary",2,1.03813133150647,1.10475381680016,0,2019.5,0,147.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Ofatumumab versus teriflunomide","SAEs",1,1,"Ofatumumab versus teriflunomide","or","binary",2,0.150943845547873,0.164966523128668,0,2020,0.0791002246698449,941
"CD012186","CD012186_pub2_data","1|1|SAEs|Ozanimod versus interferon beta-1a (Avonex)","SAEs",1,1,"Ozanimod versus interferon beta-1a (Avonex)","or","binary",2,0.114150777299725,0.195935918884281,0,2019,0.0441777323799796,1329.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Rituximab versus placebo","SAEs",1,1,"Rituximab versus placebo","or","binary",2,0.121879073102101,0.256451095644337,0,2008.5,0.139455782312925,271.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Siponimod versus placebo","SAEs",1,1,"Siponimod versus placebo","or","binary",2,0.749519663562198,0.923914930632682,1.14132784762775,2015.5,0.076007326007326,970.5
"CD012186","CD012186_pub2_data","1|1|SAEs|Teriflunomide versus placebo","SAEs",1,1,"Teriflunomide versus placebo","or","binary",4,0.0646106483307451,0.11794153523837,0,2011.25,0.116725888773974,761
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Alemtuzumab versus interferon beta-1a (Rebif)","Withdrawals due to AEs",1,2,"Alemtuzumab versus interferon beta-1a (Rebif)","or","binary",3,-1.37055264848847,0.385806897988626,0.214387677972927,2010.66666666667,0.0848587607523809,561.333333333333
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Azathioprine versus interferons","Withdrawals due to AEs",1,2,"Azathioprine versus interferons","or","binary",2,0.699077054668163,0.499279065619847,0.121615922076449,2010.5,0.0708759325780602,120
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Azathioprine versus placebo","Withdrawals due to AEs",1,2,"Azathioprine versus placebo","or","binary",4,1.85240933650338,0.461851328755956,0,1990.25,0.0246825396825397,128.25
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Cladribine versus placebo","Withdrawals due to AEs",1,2,"Cladribine versus placebo","or","binary",2,0.567186962146106,0.497495028057893,0.285502074801818,2012,0.0201818993415913,967.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Dimethyl fumarate versus placebo","Withdrawals due to AEs",1,2,"Dimethyl fumarate versus placebo","or","binary",4,0.165017463837538,0.130772332846755,0,2016,0.0735558173105497,644.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Fingolimod versus interferon beta-1b","Withdrawals due to AEs",1,2,"Fingolimod versus interferon beta-1b","or","binary",2,-0.300895771757088,0.669194288295485,0,2018.5,0.0319148936170213,82
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Fingolimod versus placebo","Withdrawals due to AEs",1,2,"Fingolimod versus placebo","or","binary",5,0.667230692917218,0.143991800700118,0.0273781789652739,2011.6,0.0700689357848456,754.8
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Glatiramer acetate versus interferon beta-1b","Withdrawals due to AEs",1,2,"Glatiramer acetate versus interferon beta-1b","or","binary",2,-0.038465430638701,0.338527590320015,0,2009,0.0518075117370892,1147.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Glatiramer acetate versus placebo","Withdrawals due to AEs",1,2,"Glatiramer acetate versus placebo","or","binary",9,0.461849992865123,0.210900680456842,0.100623368085713,2006.11111111111,0.0263016966033633,559.111111111111
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Immunoglobulins versus placebo","Withdrawals due to AEs",1,2,"Immunoglobulins versus placebo","or","binary",7,0.634614211092654,0.299766681293186,0,2002.85714285714,0.0176294343689581,143.285714285714
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Interferon beta-1a (Avonex) versus placebo","Withdrawals due to AEs",1,2,"Interferon beta-1a (Avonex) versus placebo","or","binary",6,0.411169808552416,0.218462367259913,2.99350950383875e-06,2004.33333333333,0.022373378002004,361.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Interferon beta-1a (Rebif) versus placebo","Withdrawals due to AEs",1,2,"Interferon beta-1a (Rebif) versus placebo","or","binary",7,0.570206248360183,0.336746829373674,0.348660363174051,2005.85714285714,0.0251501404974259,384.714285714286
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Interferon beta-1b versus placebo","Withdrawals due to AEs",1,2,"Interferon beta-1b versus placebo","or","binary",6,1.15121301632014,0.203259401774212,2.13698249948854e-06,2000.5,0.0202832344685799,433.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Laquinimod versus placebo","Withdrawals due to AEs",1,2,"Laquinimod versus placebo","or","binary",7,0.369887912198412,0.152073512748356,2.32911742839525e-06,2014,0.0280831916458521,622.857142857143
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Mitoxantrone versus placebo","Withdrawals due to AEs",1,2,"Mitoxantrone versus placebo","or","binary",2,0.948476372722606,1.13059557931384,1.36609308518386,1999.5,0.015625,121
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Natalizumab versus placebo","Withdrawals due to AEs",1,2,"Natalizumab versus placebo","or","binary",4,0.224247623953443,0.194384494582235,0,2011,0.0427995385262951,533.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Ocrelizumab versus interferon beta-1a (Rebif)","Withdrawals due to AEs",1,2,"Ocrelizumab versus interferon beta-1a (Rebif)","or","binary",2,-0.574890832548115,0.235131654724242,0,2017,0.0617608602604469,825.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Ocrelizumab versus placebo","Withdrawals due to AEs",1,2,"Ocrelizumab versus placebo","or","binary",2,0.304764793964658,0.423318061237595,0.0219534188036059,2014,0.0167364016736402,444.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Ofatumumab versus placebo","Withdrawals due to AEs",1,2,"Ofatumumab versus placebo","or","binary",2,0.607640456734428,1.20254453241419,0,2019.5,0,147.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Ofatumumab versus teriflunomide","Withdrawals due to AEs",1,2,"Ofatumumab versus teriflunomide","or","binary",2,0.0897050233992169,0.201076201382024,0,2020,0.0523453339909036,941
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Ozanimod versus interferon beta-1a (Avonex)","Withdrawals due to AEs",1,2,"Ozanimod versus interferon beta-1a (Avonex)","or","binary",2,-0.39093482217255,0.226434868411442,0,2019,0.0384320735444331,1329.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Rituximab versus placebo","Withdrawals due to AEs",1,2,"Rituximab versus placebo","or","binary",2,0.40139190372585,0.767227432984767,0.421399903838336,2008.5,0.0319727891156463,271.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Siponimod versus placebo","Withdrawals due to AEs",1,2,"Siponimod versus placebo","or","binary",2,0.468287113516177,0.212138259737657,0,2015.5,0.0420344682639765,970.5
"CD012186","CD012186_pub2_data","1|2|Withdrawals due to AEs|Teriflunomide versus placebo","Withdrawals due to AEs",1,2,"Teriflunomide versus placebo","or","binary",4,0.41348540527401,0.213729792788255,0.0912439832691444,2011.25,0.076827373546511,761
"CD012214","CD012214_pub3_data","1|1|Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium|","Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium",1,1,"","or","binary",2,1.39601001589713,0.55820245199162,0,2015,0.60952380952381,41.5
"CD012214","CD012214_pub3_data","1|2|Progression of endometrial hyperplasia to endometrial cancer|","Progression of endometrial hyperplasia to endometrial cancer",1,2,"","or","binary",2,-0.0227489491616425,1.43077920432388,0,2015,0,41.5
"CD012214","CD012214_pub3_data","1|3|Hysterectomy rate|","Hysterectomy rate",1,3,"","or","binary",2,-0.0567361060221042,1.02859612147674,0,2015,0.0238095238095238,42.5
"CD012214","CD012214_pub3_data","2|1|Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory or atrophic endometrium|","Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory or atrophic endometrium",2,1,"","reported","reported",4,0,0.346868159932569,0,2018.25,0.515594293272865,64.5
"CD012214","CD012214_pub3_data","2|3|Progression of endometrial hyperplasia to endometrial cancer|","Progression of endometrial hyperplasia to endometrial cancer",2,3,"","or","binary",3,0.546494922131683,1.08568243287847,0,2017.66666666667,0,52
"CD012214","CD012214_pub3_data","2|4|Hysterectomy rate|","Hysterectomy rate",2,4,"","or","binary",2,0.742127267662495,1.30362877094675,0,2017.5,0,36
"CD012268","CD012268_pub2_data","1|1|Body weight|Final body weight [kg]","Body weight",1,1,"Final body weight [kg]","or","binary",2,0.0172630780473908,1.42718310378217,0,2014,0,53.5
"CD012268","CD012268_pub2_data","1|1|Body weight|Mean change in weight [kg]","Body weight",1,1,"Mean change in weight [kg]","or","binary",19,-0.0394937319784813,0.465703953107529,0,2010.26315789474,0,63.6842105263158
"CD012268","CD012268_pub2_data","1|10|Subgroup analysis: body weight by trial duration|Trial duration of 2 months to less than 6 months","Subgroup analysis: body weight by trial duration",1,10,"Trial duration of 2 months to less than 6 months","or","binary",17,-0.0549059301234627,0.492687096476961,0,2011.29411764706,0,49.8823529411765
"CD012268","CD012268_pub2_data","1|10|Subgroup analysis: body weight by trial duration|Trial duration of 6 months or more ","Subgroup analysis: body weight by trial duration",1,10,"Trial duration of 6 months or more ","or","binary",4,0.0535221407189934,1.00903580214527,0,2007.75,0,117.25
"CD012268","CD012268_pub2_data","1|11|Subgroup analysis: body weight by trial size|100 participants or more","Subgroup analysis: body weight by trial size",1,11,"100 participants or more","or","binary",3,-0.012955037368704,1.15774566126267,0,2016.33333333333,0,216.666666666667
"CD012268","CD012268_pub2_data","1|11|Subgroup analysis: body weight by trial size|Fewer than 100 participants ","Subgroup analysis: body weight by trial size",1,11,"Fewer than 100 participants ","or","binary",18,-0.0376420317060921,0.479147555308118,0,2009.66666666667,0,37.0555555555556
"CD012268","CD012268_pub2_data","1|12|Subgroup analysis: intention-to-treat|Intention-to-treat analysis ","Subgroup analysis: intention-to-treat",1,12,"Intention-to-treat analysis ","or","binary",6,0.0864456321253518,0.824047037661495,0,2012.16666666667,0,95.3333333333333
"CD012268","CD012268_pub2_data","1|12|Subgroup analysis: intention-to-treat|No intention-to-treat analysis ","Subgroup analysis: intention-to-treat",1,12,"No intention-to-treat analysis ","or","binary",15,-0.0829192783501676,0.524924846850184,0,2010,0,49.6666666666667
"CD012268","CD012268_pub2_data","1|2|BMI|Final BMI","BMI",1,2,"Final BMI","or","binary",4,-0.0216111052631668,1.01521992337708,0,2011.75,0,40.5
"CD012268","CD012268_pub2_data","1|2|BMI|Mean change in BMI","BMI",1,2,"Mean change in BMI","or","binary",5,-0.00250856401089747,0.90081474756128,0,2013.4,0,113.8
"CD012268","CD012268_pub2_data","1|3|Waist circumference|Change in waist circumference","Waist circumference",1,3,"Change in waist circumference","or","binary",2,0.0166861974263607,1.42672241576566,0,2015,0,55.5
"CD012268","CD012268_pub2_data","1|3|Waist circumference|Final waist circumference","Waist circumference",1,3,"Final waist circumference","or","binary",4,-0.0216111052631668,1.01521992337708,0,2011.75,0,40.5
"CD012268","CD012268_pub2_data","1|4|Fat mass|Final fat mass (kg)","Fat mass",1,4,"Final fat mass (kg)","or","binary",3,-0.0288738221781786,1.1734748372059,0,2012.33333333333,0,40.6666666666667
"CD012268","CD012268_pub2_data","1|4|Fat mass|Mean change in fat mass","Fat mass",1,4,"Mean change in fat mass","or","binary",11,0.0613965043169296,0.611909415551274,0,2008.45454545455,0,62.7272727272727
"CD012268","CD012268_pub2_data","1|5|Subgroup analysis: body weight by menopausal status|Postmenopausal","Subgroup analysis: body weight by menopausal status",1,5,"Postmenopausal","or","binary",4,0.0519400432821436,1.01752826642456,0,2008.25,0,30.75
"CD012268","CD012268_pub2_data","1|5|Subgroup analysis: body weight by menopausal status|Premenopausal","Subgroup analysis: body weight by menopausal status",1,5,"Premenopausal","or","binary",6,-0.176424766920869,0.832410652439551,0,2008.66666666667,0,30.1666666666667
"CD012268","CD012268_pub2_data","1|6|Subgroup analysis: body weight by sex|Women ","Subgroup analysis: body weight by sex",1,6,"Women ","or","binary",14,-0.0610412959196106,0.542692738970281,0,2010.71428571429,0,51.8571428571429
"CD012268","CD012268_pub2_data","1|6|Subgroup analysis: body weight by sex|Women and men","Subgroup analysis: body weight by sex",1,6,"Women and men","or","binary",7,0.0197119218862425,0.765528325872689,0,2010.42857142857,0,84.4285714285714
"CD012268","CD012268_pub2_data","1|7|Subgroup analysis: body weight by baseline BMI|Obese","Subgroup analysis: body weight by baseline BMI",1,7,"Obese","or","binary",4,-0.0148621800690806,1.01541382540364,0,2010.75,0,58
"CD012268","CD012268_pub2_data","1|7|Subgroup analysis: body weight by baseline BMI|Overweight","Subgroup analysis: body weight by baseline BMI",1,7,"Overweight","or","binary",3,0.0165729018499966,1.16582454065628,0,2010.66666666667,0,85
"CD012268","CD012268_pub2_data","1|7|Subgroup analysis: body weight by baseline BMI|Overweight or obese ","Subgroup analysis: body weight by baseline BMI",1,7,"Overweight or obese ","or","binary",14,-0.0504695699074631,0.542631985308012,0,2010.57142857143,0,59.2857142857143
"CD012268","CD012268_pub2_data","1|8|Subgroup analysis: body weight by dose|Dose of 0.5 g/day to less than 1 g/day ","Subgroup analysis: body weight by dose",1,8,"Dose of 0.5 g/day to less than 1 g/day ","or","binary",9,-0.137771242577862,0.677801757723458,0,2012.55555555556,0,59.1111111111111
"CD012268","CD012268_pub2_data","1|8|Subgroup analysis: body weight by dose|Dose of 1 g/day or more","Subgroup analysis: body weight by dose",1,8,"Dose of 1 g/day or more","or","binary",10,0.0602377827015202,0.639645470064078,0,2009.1,0,71.3
"CD012268","CD012268_pub2_data","1|8|Subgroup analysis: body weight by dose|Dose of less than 0.5 g/day","Subgroup analysis: body weight by dose",1,8,"Dose of less than 0.5 g/day","or","binary",2,-0.0435923660037473,1.44187251489831,0,2009.5,0,36
"CD012268","CD012268_pub2_data","1|9|Subgroup analysis: body weight by co-intervention|No co-intervention","Subgroup analysis: body weight by co-intervention",1,9,"No co-intervention","or","binary",8,-0.00983723792314056,0.713360392291748,0,2014.5,0,110.625
"CD012268","CD012268_pub2_data","1|9|Subgroup analysis: body weight by co-intervention|With co-intervention","Subgroup analysis: body weight by co-intervention",1,9,"With co-intervention","or","binary",13,-0.0491894586702325,0.564628815901263,0,2008.23076923077,0,33.2307692307692
"CD012335","CD012335_pub2_data","1|1|All‐cause mortality|","All‐cause mortality",1,1,"","reported","reported",2,1.01478429898039,0.624563951099413,0,2023.5,0.035,370
"CD012335","CD012335_pub2_data","1|12|Severe perioperative adverse events (grade 3 or higher)|","Severe perioperative adverse events (grade 3 or higher)",1,12,"","reported","reported",2,0.996405491022633,0.347323940620687,0,2023.5,0.0511627906976744,361
"CD012335","CD012335_pub2_data","1|13|Quality of life outcomes|Cognitive functioning at 6-month","Quality of life outcomes",1,13,"Cognitive functioning at 6-month","reported","reported",2,-2.78532360504748,2.00990132180626,0,2023.5,NA,206
"CD012335","CD012335_pub2_data","1|13|Quality of life outcomes|Emotional functioning at 6-month","Quality of life outcomes",1,13,"Emotional functioning at 6-month","reported","reported",2,-0.873498427693558,2.29382601051939,0,2023.5,NA,205.5
"CD012335","CD012335_pub2_data","1|13|Quality of life outcomes|Global Health Status at 6-month","Quality of life outcomes",1,13,"Global Health Status at 6-month","reported","reported",2,1.36077414014012,3.71926237817715,13.4103223291304,2023.5,NA,204.5
"CD012335","CD012335_pub2_data","1|13|Quality of life outcomes|Physical functioning at 6-month","Quality of life outcomes",1,13,"Physical functioning at 6-month","reported","reported",2,3.64689144822499,4.02835342201508,23.9350027701259,2023.5,NA,207
"CD012335","CD012335_pub2_data","1|13|Quality of life outcomes|Role functioning at 6-month","Quality of life outcomes",1,13,"Role functioning at 6-month","reported","reported",2,10.1092541592636,11.3739259125796,215.634576407547,2023.5,NA,206.5
"CD012335","CD012335_pub2_data","1|2|Overall survival|","Overall survival",1,2,"","reported","reported",2,0.230913202403816,0.488794579813636,0,2023.5,NA,NA
"CD012335","CD012335_pub2_data","1|3|Cancer-related mortality|","Cancer-related mortality",1,3,"","reported","reported",2,3.79569310815051,8.00066682573781,0,2023.5,0.00142857142857143,370
"CD012335","CD012335_pub2_data","1|4|Disease-free survival|","Disease-free survival",1,4,"","reported","reported",2,0.00677631578947371,0.377533724484673,0.15355,2023.5,NA,NA
"CD012335","CD012335_pub2_data","1|5|Rate of cancer recurrence: overall|","Rate of cancer recurrence: overall",1,5,"","reported","reported",2,1.50211886549203,0.665258973597077,0,2023.5,0.0142857142857143,370
"CD012335","CD012335_pub2_data","1|6|Rate of cancer recurrence: pelvic recurrence|","Rate of cancer recurrence: pelvic recurrence",1,6,"","reported","reported",2,1.10171175602116,0.531286534123145,0,2023.5,0.0142857142857143,370
"CD012335","CD012335_pub2_data","1|8|Overall perioperative adverse event|","Overall perioperative adverse event",1,8,"","reported","reported",2,0.823507606514271,0.0688112553750516,0,2023.5,0.373571428571429,370
"CD012397","CD012397_pub2_data","1|7|Specific behaviours: aggression, other episode of aggression (incidents per treatment days)|Corrected for design effect","Specific behaviours: aggression, other episode of aggression (incidents per treatment days)",1,7,"Corrected for design effect","or","binary",3,-0.0637400210124676,1.18262932649612,0,2010.66666666667,0,20
"CD012397","CD012397_pub2_data","1|7|Specific behaviours: aggression, other episode of aggression (incidents per treatment days)|Uncorrected","Specific behaviours: aggression, other episode of aggression (incidents per treatment days)",1,7,"Uncorrected","or","binary",3,0.024226760124872,0.648149559412752,1.20675724895187,2010.66666666667,0.0143496743605152,13120.3333333333
"CD012397","CD012397_pub2_data","1|8|Specific behaviours: aggression, other episode of aggression (participants)|Corrected for design effect","Specific behaviours: aggression, other episode of aggression (participants)",1,8,"Corrected for design effect","or","binary",2,-0.897241014946345,0.513466281961006,0,2013.5,0.186363636363636,110
"CD012397","CD012397_pub2_data","1|8|Specific behaviours: aggression, other episode of aggression (participants)|Uncorrected","Specific behaviours: aggression, other episode of aggression (participants)",1,8,"Uncorrected","or","binary",2,-0.724511134674848,0.227012603168408,0,2013.5,0.173505976095618,329
"CD012426","CD012426_pub2_data","1|1|Unfavourable functional outcome at 90 days|NA","Unfavourable functional outcome at 90 days",1,1,NA,"reported","reported",3,0.923779995783516,0.0406276337027736,3.80236546518006e-06,2010,0.593589842869737,469.333333333333
"CD012426","CD012426_pub2_data","1|2|All-cause mortality at 90 days|NA","All-cause mortality at 90 days",1,2,NA,"reported","reported",4,0.943451107884006,0.144466528356634,0,2011,0.083095614088847,355
"CD012426","CD012426_pub2_data","1|3|Improvement of stroke severity at 90 days|NA","Improvement of stroke severity at 90 days",1,3,NA,"reported","reported",3,0.234215971955212,0.263981081956658,0.153065689157306,2010,0.48780487804878,40
"CD012426","CD012426_pub2_data","1|4|Serious adverse events at 90 days|NA","Serious adverse events at 90 days",1,4,NA,"reported","reported",4,0.822566098078135,0.0679957702360655,0.00123801528930575,2011,0.373410027206599,355
"CD012426","CD012426_pub2_data","1|5|Adverse events at 90 days|NA","Adverse events at 90 days",1,5,NA,"reported","reported",3,1.00515681403976,0.0246086550828793,0.000425400782391289,2012.33333333333,0.861972101409956,433.333333333333
"CD012426","CD012426_pub2_data","2|1|Unfavourable functional outcome at 90 days: Sensitivity analysis to remove studies with results at high risk of bias|NA","Unfavourable functional outcome at 90 days: Sensitivity analysis to remove studies with results at high risk of bias",2,1,NA,"reported","reported",2,0.941326371940304,0.0423334349160506,0,2011.5,0.609896959426557,644
"CD012426","CD012426_pub2_data","2|2|Improvement of stroke severity at 90 days: Sensitivity analysis to remove studies with results at high risk of bias|NA","Improvement of stroke severity at 90 days: Sensitivity analysis to remove studies with results at high risk of bias",2,2,NA,"reported","reported",2,0.0513943334092788,0.218233452209096,0.0686711529085,2011.5,NA,0
"CD012426","CD012426_pub2_data","2|3|Serious adverse events at 90 days: Sensitivity analysis to remove studies with results at high risk of bias|NA","Serious adverse events at 90 days: Sensitivity analysis to remove studies with results at high risk of bias",2,3,NA,"reported","reported",3,0.836890346485704,0.075738564397078,0.00234438626170878,2012.33333333333,0.37592881676327,433.333333333333
"CD012426","CD012426_pub2_data","2|4|Serious adverse events at 90 days: Sensitivity analysis to remove Hacke 2014|NA","Serious adverse events at 90 days: Sensitivity analysis to remove Hacke 2014",2,4,NA,"reported","reported",3,0.870006699569505,0.079824889429974,0,2010,0.404461777252111,263.333333333333
"CD012429","CD012429_pub2_data","4|1|Total serious adverse events/effects|Lurasidone 80 mg/d","Total serious adverse events/effects",4,1,"Lurasidone 80 mg/d","or","binary",2,-0.484818237091991,0.768647247753714,0,2007.5,0.0416666666666667,58.5
"CD012429","CD012429_pub2_data","4|10|Akathisia|Lurasidone 80 mg/d","Akathisia",4,10,"Lurasidone 80 mg/d","or","binary",2,-1.15052789699673,1.29471682637841,2.25425203954617,2007.5,0.291666666666667,58.5
"CD012429","CD012429_pub2_data","4|21|Nausea|Lurasidone 80 mg/d","Nausea",4,21,"Lurasidone 80 mg/d","or","binary",2,-0.316818593120015,1.83198539083619,5.12224047012539,2007.5,0.145833333333333,58.5
"CD012429","CD012429_pub2_data","4|3|Sedation|Lurasidone 80 mg/d","Sedation",4,3,"Lurasidone 80 mg/d","or","binary",2,-0.419869578410345,0.486821141886635,0.0123399660405608,2007.5,0.354166666666667,58.5
"CD012429","CD012429_pub2_data","4|9|Insomnia|Lurasidone 80 mg/d","Insomnia",4,9,"Lurasidone 80 mg/d","or","binary",2,-0.00326419719283799,1.21033268949675,1.68684546892716,2007.5,0.0625,58.5
"CD012429","CD012429_pub2_data","5|3|Due to loss to follow-up|Lurasidone 80 mg/d","Due to loss to follow-up",5,3,"Lurasidone 80 mg/d","or","binary",2,-2.17654293420714,1.1517708790755,0,2007.5,0.120833333333333,59.5
"CD012445","CD012445_pub2_data","1|10|Parent mindfulness – latest follow-up|NA","Parent mindfulness – latest follow-up",1,10,NA,"reported","reported",2,0,0.214082803682423,0,2016.5,0,230.5
"CD012445","CD012445_pub2_data","1|2|Child emotional and behavioural adjustment – latest follow-up|NA","Child emotional and behavioural adjustment – latest follow-up",1,2,NA,"or","binary",2,-0.255324502942436,1.42491847543306,0,2018,0,142
"CD012445","CD012445_pub2_data","1|4|Parenting skills – latest follow-up|NA","Parenting skills – latest follow-up",1,4,NA,"or","binary",2,-0.359442988885562,1.41738499750047,0,2016.5,0,231
"CD012445","CD012445_pub2_data","1|7|Parenting stress – postintervention|NA","Parenting stress – postintervention",1,7,NA,"reported","reported",2,0,2.11696425436492,0,2019,0,56
"CD012445","CD012445_pub2_data","1|8|Parenting stress – latest follow-up|NA","Parenting stress – latest follow-up",1,8,NA,"or","binary",2,-0.0388442618234307,1.42813602593137,0,2019,0,56
"CD012445","CD012445_pub2_data","2|1|Child emotional and behavioural adjustment – postintervention|NA","Child emotional and behavioural adjustment – postintervention",2,1,NA,"reported","reported",2,0,0.239471311927436,0,2015,0,40
"CD012445","CD012445_pub2_data","2|10|Parent mindfulness – latest follow-up|NA","Parent mindfulness – latest follow-up",2,10,NA,"or","binary",2,0.0565516137268697,1.42717801164018,0,2017.5,0,142.5
"CD012445","CD012445_pub2_data","2|4|Parenting skills – latest follow-up|NA","Parenting skills – latest follow-up",2,4,NA,"or","binary",2,0.0240584687799827,1.4382825609572,0,2008,0,135
"CD012445","CD012445_pub2_data","2|8|Parenting stress – latest follow-up|NA","Parenting stress – latest follow-up",2,8,NA,"or","binary",2,-0.00466711346434721,1.43143705827026,0,2020,0,40
"CD012503","CD012503_pub3_data","2|1|Recurrence of ischemic stroke at the endpoint (for all studies)|","Recurrence of ischemic stroke at the endpoint (for all studies)",2,1,"","reported","reported",4,0,0.095637661773255,0,2019.75,0.161035971286907,980.25
"CD012503","CD012503_pub3_data","2|2|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)|unilateral limb","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,"unilateral limb","reported","reported",2,0,0.281715303028851,0,2021,0.137799420900237,444.5
"CD012503","CD012503_pub3_data","2|3|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)|RIC with reperfusion therapy","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",2,3,"RIC with reperfusion therapy","reported","reported",3,0,0.844979560373443,0,2019.33333333333,0.0810457516339869,37.3333333333333
"CD012503","CD012503_pub3_data","2|3|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)|RIC without reperfusion therapy","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",2,3,"RIC without reperfusion therapy","reported","reported",11,0,0.0901552852557894,0,2018.36363636364,0.148649612218521,480.090909090909
"CD012503","CD012503_pub3_data","2|4|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)|acute RIC","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",2,4,"acute RIC","reported","reported",2,0,0.282058359891623,0,2021,0.149681152574398,364.5
"CD012503","CD012503_pub3_data","2|4|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)|delayed RIC","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",2,4,"delayed RIC","or","binary",4,-0.0854200123424039,0.421763345632472,0,2020,0.0594386343026063,483.25
"CD012503","CD012503_pub3_data","2|5|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)|long-duration RIC","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",2,5,"long-duration RIC","reported","reported",4,0,0.0928359601507124,0,2015.25,0.217136260836789,806.75
"CD012503","CD012503_pub3_data","2|5|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)|medium-duration RIC","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",2,5,"medium-duration RIC","reported","reported",3,0,0.47627597735589,0,2021.33333333333,0.0653626235145862,637.666666666667
"CD012503","CD012503_pub3_data","2|5|Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)|short-duration RIC","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",2,5,"short-duration RIC","reported","reported",9,0,0.239716212809696,0,2020.44444444444,0.0925814304927229,128
"CD012503","CD012503_pub3_data","3|1|Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)|","Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",3,1,"","or","binary",10,0.281703301111066,0.0756235938388452,3.22237868891184e-07,2019.3,0.463179851099352,309.1
"CD012503","CD012503_pub3_data","3|2|Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)|bilateral limb","Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",3,2,"bilateral limb","reported","reported",4,0,0.0921787249707656,0,2017,0.494635585298236,533.5
"CD012503","CD012503_pub3_data","3|2|Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)|unilateral limb","Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",3,2,"unilateral limb","reported","reported",6,0,0.0674337894718684,0,2020.83333333333,0.442209361633429,159.5
"CD012503","CD012503_pub3_data","3|3|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)|RIC with reperfusion therapy","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,3,"RIC with reperfusion therapy","reported","reported",4,0,0.0684668835372867,0,2019.75,0.618364135864136,217.75
"CD012503","CD012503_pub3_data","3|3|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)|RIC without reperfusion therapy","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,3,"RIC without reperfusion therapy","reported","reported",3,0,0.0973308344272503,0,2017.33333333333,0.304852646166288,634.666666666667
"CD012503","CD012503_pub3_data","3|4|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)|acute RIC","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",3,4,"acute RIC","reported","reported",7,0,0.065647592481804,0,2020.14285714286,0.531034367499237,169.571428571429
"CD012503","CD012503_pub3_data","3|4|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)|delayed RIC","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",3,4,"delayed RIC","reported","reported",2,0,0.0984884077173469,0,2020,0.390612302582765,918
"CD012503","CD012503_pub3_data","3|5|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)|medium-duration RIC","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",3,5,"medium-duration RIC","reported","reported",3,0,0.096779341861624,0,2020,0.42707486838851,634
"CD012503","CD012503_pub3_data","3|5|Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)|short-duration RIC","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",3,5,"short-duration RIC","reported","reported",6,0,0.0661734574638529,0,2020.16666666667,0.536206762082443,186.833333333333
"CD012503","CD012503_pub3_data","4|1|Treatment-related adverse events|","Treatment-related adverse events",4,1,"","reported","reported",3,0,0.171736527296769,0,2019,0.0290324045688853,377
"CD012503","CD012503_pub3_data","5|1|Functional independence (mRS 0-2) at 90 days (for all studies)|","Functional independence (mRS 0-2) at 90 days (for all studies)",5,1,"","or","binary",11,0.160932863897341,0.0737194454466156,4.38051823357937e-06,2021.09090909091,0.646381171211451,361.727272727273
"CD012503","CD012503_pub3_data","5|2|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)|bilateral limb","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",5,2,"bilateral limb","reported","reported",4,0,0.105664763939775,0,2020,0.593002789202293,535.75
"CD012503","CD012503_pub3_data","5|2|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)|unilateral limb","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",5,2,"unilateral limb","reported","reported",7,0,0.0416920328301314,0,2021.71428571429,0.676883103788112,262.285714285714
"CD012503","CD012503_pub3_data","5|3|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)|RIC with reperfusion therapy","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",5,3,"RIC with reperfusion therapy","reported","reported",4,0,0.0440084650074347,0,2019.75,0.755702679673268,217.75
"CD012503","CD012503_pub3_data","5|3|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)|RIC without reperfusion therapy","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",5,3,"RIC without reperfusion therapy","reported","reported",2,0,0.11188036109649,0,2023,0.452327491785323,926.5
"CD012503","CD012503_pub3_data","5|4|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)|acute RIC","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",5,4,"acute RIC","reported","reported",9,0,0.0413152527722925,0,2020.88888888889,0.640514312094025,240.222222222222
"CD012503","CD012503_pub3_data","5|4|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)|delayed RIC","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",5,4,"delayed RIC","reported","reported",2,0,0.112491433328805,0,2022,0.672782037239869,908.5
"CD012503","CD012503_pub3_data","5|5|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)|medium-duration RIC","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,5,"medium-duration RIC","reported","reported",3,0,0.109795861350894,0,2022,0.497630092562764,639.666666666667
"CD012503","CD012503_pub3_data","5|5|Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)|short-duration RIC","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,5,"short-duration RIC","reported","reported",8,0,0.0414544551201249,0,2020.75,0.702162825704708,257.5
"CD012503","CD012503_pub3_data","7|1|&nbsp;Improvement in neurological impairment at the endpoint (for all studies)|","&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",7,1,"","reported","reported",3,0,0.197349232524508,0,2022,0,233.333333333333
"CD012503","CD012503_pub3_data","7|2|Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)|bilateral limb","Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",7,2,"bilateral limb","reported","reported",3,0,0.367914360239946,0,2019.33333333333,0,54.3333333333333
"CD012503","CD012503_pub3_data","7|2|Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)|unilateral limb","Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",7,2,"unilateral limb","reported","reported",9,0,0.0966183433055501,0,2020.44444444444,0,130.888888888889
"CD012503","CD012503_pub3_data","7|3|Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)|RIC with reperfusion theraphy","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",7,3,"RIC with reperfusion theraphy","reported","reported",4,0,0.185383286326625,0,2021.5,0,187.25
"CD012503","CD012503_pub3_data","7|3|Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)|RIC without reperfusion theraphy","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",7,3,"RIC without reperfusion theraphy","reported","reported",5,0,0.384203953859913,0,2018.8,0,53.4
"CD012503","CD012503_pub3_data","7|4|Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)|acute RIC","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",7,4,"acute RIC","reported","reported",9,0,0.0960033908238285,0,2021,0,130.555555555556
"CD012503","CD012503_pub3_data","7|4|Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)|delayed RIC","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",7,4,"delayed RIC","reported","reported",2,0,0.530551076045085,0,2019,0,54
"CD012503","CD012503_pub3_data","7|5|Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)|medium-duration RIC","Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",7,5,"medium-duration RIC","reported","reported",2,0,0.703306471197125,0,2021,0,67.5
"CD012503","CD012503_pub3_data","7|5|Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)|short-duration RIC","Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",7,5,"short-duration RIC","reported","reported",9,0,0.0953331725229076,0,2020.55555555556,0,127.555555555556
"CD012503","CD012503_pub3_data","8|2|Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)|bilateral limb","Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",8,2,"bilateral limb","or","binary",3,-0.280933593045107,0.18938215059242,0,2021.66666666667,0.167209029610085,1046.66666666667
"CD012503","CD012503_pub3_data","8|2|Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)|unilateral limb","Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",8,2,"unilateral limb","or","binary",5,-0.0636470824262754,0.19136879684209,0,2019.8,0.0524550503525026,243.4
"CD012503","CD012503_pub3_data","8|3|Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)|RIC without reperfusion therapy","Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",8,3,"RIC without reperfusion therapy","or","binary",4,-0.292045145097899,0.188167836540864,0,2020.75,0.138387541438333,796
"CD012503","CD012503_pub3_data","8|4|Cardiovascular events during follow-up (based on RIC intervention timing)|acute RIC","Cardiovascular events during follow-up (based on RIC intervention timing)",8,4,"acute RIC","or","binary",6,-0.199496324453093,0.235603616497993,0.0383137766038132,2020.33333333333,0.114545875293752,212.666666666667
"CD012503","CD012503_pub3_data","8|5|Cardiovascular events during follow-up( based on the duration of RIC intervention)|short-duration","Cardiovascular events during follow-up( based on the duration of RIC intervention)",8,5,"short-duration","or","binary",6,-0.0778692014871571,0.190129521805475,0,2019.66666666667,0.05482365307153,207.833333333333
"CD012570","CD012570_pub2_data","1|1|All-cause mortality|NA","All-cause mortality",1,1,NA,"or","binary",3,-0.89024637117242,0.818454666590921,0,2006.66666666667,0.00913548816774623,644
"CD012570","CD012570_pub2_data","1|2|Withdrawal due to adverse effects (WDAE)|NA","Withdrawal due to adverse effects (WDAE)",1,2,NA,"or","binary",9,-0.356856856091281,0.18562986940412,0,1929.22222222222,0.038350773770875,514.888888888889
"CD012570","CD012570_pub2_data","1|3|Serious adverse events|NA","Serious adverse events",1,3,NA,"or","binary",6,-0.286686539516911,0.271240663228685,0,1890,0.0258609496075666,547.166666666667
"CD012570","CD012570_pub2_data","1|4|Adverse events|NA","Adverse events",1,4,NA,"or","binary",10,-0.0325860831335,0.0672913172873473,0,1937.6,0.31860093297537,472.2
"CD012570","CD012570_pub2_data","1|5|Systolic blood pressure|NA","Systolic blood pressure",1,5,NA,"or","binary",10,-0.362469876258365,0.634223633236986,0,1937.6,0,422.2
"CD012570","CD012570_pub2_data","1|6|Diastolic blood pressure|NA","Diastolic blood pressure",1,6,NA,"or","binary",10,-0.362469876258365,0.634223633236986,0,1937.6,0,422.2
"CD012572","CD012572_pub3_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","or","binary",4,0.629474508679465,0.483567902894456,0,1989.25,0.0334470636889992,157.5
"CD012572","CD012572_pub3_data","1|10|Diastolic blood pressure subgrouped on duration|12 months or longer","Diastolic blood pressure subgrouped on duration",1,10,"12 months or longer","or","binary",2,0.065648897732873,1.42560060374539,0,1982.5,0,61
"CD012572","CD012572_pub3_data","1|10|Diastolic blood pressure subgrouped on duration|Less than 12 months","Diastolic blood pressure subgrouped on duration",1,10,"Less than 12 months","or","binary",3,0.0307175312855309,1.1583468368203,0,1996.33333333333,0,215.333333333333
"CD012572","CD012572_pub3_data","1|11|Diastolic blood pressure subgrouped on drug type|Diuretics","Diastolic blood pressure subgrouped on drug type",1,11,"Diuretics","or","binary",4,0.0615188060274394,1.0060400694417,0,1984.75,0,103
"CD012572","CD012572_pub3_data","1|13|Success rate – withdrawal/resumption due to hypertension or other clinical reason|","Success rate – withdrawal/resumption due to hypertension or other clinical reason",1,13,"","or","binary",3,1.02942326220501,0.7191819947722,1.11707366030672,1987.33333333333,0.0920347394540943,113.666666666667
"CD012572","CD012572_pub3_data","1|3|Myocardial infarction (fatal and non-fatal)|","Myocardial infarction (fatal and non-fatal)",1,3,"","or","binary",2,0.327519323319534,0.949021676037203,0,1999,0.00268817204301075,223.5
"CD012572","CD012572_pub3_data","1|5|Stroke (fatal + non-fatal + transient ischaemic attack)|","Stroke (fatal + non-fatal + transient ischaemic attack)",1,5,"","or","binary",3,0.255786959112352,0.775597033024659,0,1993.33333333333,0.0125448028673835,174.666666666667
"CD012572","CD012572_pub3_data","1|6|Systolic blood pressure|","Systolic blood pressure",1,6,"","or","binary",5,0.0632175776455115,0.899043415089451,0,1990.8,0,153.4
"CD012572","CD012572_pub3_data","1|7|Systolic blood pressure subgrouped on duration|12 months or longer","Systolic blood pressure subgrouped on duration",1,7,"12 months or longer","or","binary",2,0.10198477029458,1.42583256845038,0,1982.5,0,60
"CD012572","CD012572_pub3_data","1|7|Systolic blood pressure subgrouped on duration|Less than 12 months","Systolic blood pressure subgrouped on duration",1,7,"Less than 12 months","or","binary",3,0.0376323629315908,1.15832622024768,0,1996.33333333333,0,215.666666666667
"CD012572","CD012572_pub3_data","1|8|Systolic blood pressure subgrouped on drug type|Diuretics","Systolic blood pressure subgrouped on drug type",1,8,"Diuretics","or","binary",4,0.0848262194329756,1.00610807133948,0,1984.75,0,102.75
"CD012572","CD012572_pub3_data","1|9|Diastolic blood pressure|","Diastolic blood pressure",1,9,"","or","binary",5,0.0446085559637701,0.89899489316699,0,1990.8,0,153.6
"CD012586","CD012586_pub2_data","1|1|Live birth or ongoing pregnancy|High response","Live birth or ongoing pregnancy",1,1,"High response","or","binary",3,-0.0949997848319041,0.172618951811857,0,2009.33333333333,0.374984326018809,192
"CD012586","CD012586_pub2_data","1|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",1,1,"Low response","or","binary",5,-0.136671654622708,0.156508172695891,0,2014,0.112012393977134,300.4
"CD012586","CD012586_pub2_data","1|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",1,1,"Normal response","or","binary",8,-0.0770537100717853,0.0860811702696422,0,2007.42857142857,0.298818975595172,352.125
"CD012586","CD012586_pub2_data","1|10|Frozen embryo number|Normal response","Frozen embryo number",1,10,"Normal response","or","binary",5,-0.310921666058553,0.89614599207008,0,2007,0,406.4
"CD012586","CD012586_pub2_data","1|2|OHSS|High response","OHSS",1,2,"High response","or","binary",2,-0.102789486054845,0.499770256176445,0,2008,0.0544827586206897,178
"CD012586","CD012586_pub2_data","1|2|OHSS|Normal response","OHSS",1,2,"Normal response","or","binary",7,-0.227698864995585,0.112573349148907,0,2007.66666666667,0.102318047023205,378.571428571429
"CD012586","CD012586_pub2_data","1|3|Clinical pregnancy|Low response","Clinical pregnancy",1,3,"Low response","or","binary",3,-0.0767486371916876,0.165972348153595,0,2012,0.133209720617347,385
"CD012586","CD012586_pub2_data","1|3|Clinical pregnancy|Normal response","Clinical pregnancy",1,3,"Normal response","or","binary",10,-0.0123024830814372,0.219790039039232,0.378638942727944,2007.11111111111,0.350947547729088,224.3
"CD012586","CD012586_pub2_data","1|4|Multiple pregnancy|Normal response","Multiple pregnancy",1,4,"Normal response","or","binary",2,-0.0875894978990471,0.332167878997676,0,2005.5,0.091410723581468,250.5
"CD012586","CD012586_pub2_data","1|5|Miscarriage|High response","Miscarriage",1,5,"High response","or","binary",2,-0.126718090913635,0.372155308347881,0,2008,0.0811494252873563,178
"CD012586","CD012586_pub2_data","1|5|Miscarriage|Low response","Miscarriage",1,5,"Low response","or","binary",3,0.139851941300291,0.331159134636504,0,2012,0.0275854913306879,385
"CD012586","CD012586_pub2_data","1|5|Miscarriage|Normal response","Miscarriage",1,5,"Normal response","or","binary",9,-0.0479132880408509,0.140762603962669,0,2006.875,0.0630778146153534,315.222222222222
"CD012586","CD012586_pub2_data","1|6|Ectopic|Normal response","Ectopic",1,6,"Normal response","or","binary",3,-0.0543663012983012,0.86155649847727,0,2003,0.00366300366300366,158.333333333333
"CD012586","CD012586_pub2_data","1|7|Cancellation|High response","Cancellation",1,7,"High response","or","binary",3,0.281161059666818,0.390662477584446,0.0996763326075965,2009.33333333333,0.0603622431208638,192
"CD012586","CD012586_pub2_data","1|7|Cancellation|Low response","Cancellation",1,7,"Low response","or","binary",5,0.706056478066781,0.296911154518755,0.239511073076295,2014,0.134122054265774,300.4
"CD012586","CD012586_pub2_data","1|7|Cancellation|Normal response","Cancellation",1,7,"Normal response","or","binary",12,-0.366153124338558,0.288194764149996,0.545683443457849,2007.45454545455,0.0789002843022425,292.833333333333
"CD012586","CD012586_pub2_data","1|8|Oocyte number|High response","Oocyte number",1,8,"High response","or","binary",3,0.250584759484144,1.16141172916706,0,2007.66666666667,0,144.666666666667
"CD012586","CD012586_pub2_data","1|8|Oocyte number|Low response","Oocyte number",1,8,"Low response","or","binary",5,-0.0031368027274553,0.897615898251183,0,2014,0,300.4
"CD012586","CD012586_pub2_data","1|8|Oocyte number|Normal response","Oocyte number",1,8,"Normal response","or","binary",17,-0.186611376874976,0.487372577445904,0,2008.1875,0,238.941176470588
"CD012586","CD012586_pub2_data","10|1|Live birth or ongoing pregnancy|High response","Live birth or ongoing pregnancy",10,1,"High response","or","binary",2,0.0399978312709379,0.283220195777741,0,2011,0.344345238095238,122
"CD012586","CD012586_pub2_data","10|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",10,1,"Normal response","or","binary",6,-0.133464522287596,0.161880201842422,0.045855645510719,2000.16666666667,0.280850512954794,215.333333333333
"CD012586","CD012586_pub2_data","10|10|Frozen embryo number|High response","Frozen embryo number",10,10,"High response","or","binary",2,0,1.42054940165742,0,2011,0,122
"CD012586","CD012586_pub2_data","10|10|Frozen embryo number|Normal response","Frozen embryo number",10,10,"Normal response","or","binary",2,0.0320641610967262,1.41878567409105,0,2004.5,0,153.5
"CD012586","CD012586_pub2_data","10|2|OHSS|Normal response","OHSS",10,2,"Normal response","or","binary",3,-0.166451509068294,0.475375859698819,0,1996.66666666667,0.0458333333333333,125.666666666667
"CD012586","CD012586_pub2_data","10|3|Clinical pregnancy|High response","Clinical pregnancy",10,3,"High response","or","binary",2,0.0653049853743386,0.255717536203256,0,2011,0.468154761904762,122
"CD012586","CD012586_pub2_data","10|3|Clinical pregnancy|Normal response","Clinical pregnancy",10,3,"Normal response","or","binary",8,-0.0238986181958529,0.120899091891988,0.0149682639989502,2001.25,0.319447689077746,198.25
"CD012586","CD012586_pub2_data","10|4|Multiple pregnancy|High response","Multiple pregnancy",10,4,"High response","or","binary",2,-0.00248958563327692,0.39454754531547,0,2011,0.155952380952381,122
"CD012586","CD012586_pub2_data","10|4|Multiple pregnancy|Normal response","Multiple pregnancy",10,4,"Normal response","or","binary",3,0.174598970794095,0.234175189081354,1.05888566273613e-06,2000.66666666667,0.0906222933913429,306
"CD012586","CD012586_pub2_data","10|5|Miscarriage|Normal response","Miscarriage",10,5,"Normal response","or","binary",4,0.0253878310289137,0.334986639884977,1.20161506041177e-06,2002.75,0.0472971680061232,179
"CD012586","CD012586_pub2_data","10|7|Cancellation|Normal response","Cancellation",10,7,"Normal response","or","binary",4,-0.145156040970548,0.220320090652993,0,2004.75,0.0983426113360324,232
"CD012586","CD012586_pub2_data","10|8|Oocyte number|High response","Oocyte number",10,8,"High response","or","binary",2,0,1.42054940165742,0,2011,0,122
"CD012586","CD012586_pub2_data","10|8|Oocyte number|Normal response","Oocyte number",10,8,"Normal response","or","binary",6,0.0157387756955317,0.818853220751293,0,2002.66666666667,0,219.666666666667
"CD012586","CD012586_pub2_data","10|9|Cleavage embryo number|Normal response","Cleavage embryo number",10,9,"Normal response","or","binary",2,0.00791014160096235,1.41932544972547,0,1997.5,0,139
"CD012586","CD012586_pub2_data","11|1|Live birth or ongoing pregnancy|High response","Live birth or ongoing pregnancy",11,1,"High response","or","binary",2,0.0399978312709379,0.283220195777741,0,2011,0.344345238095238,122
"CD012586","CD012586_pub2_data","11|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",11,1,"Normal response","or","binary",16,-0.153042750161272,0.0842924621079317,0.00339951548791657,2001,0.309871978322326,185.5
"CD012586","CD012586_pub2_data","12|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",12,1,"Normal response","or","binary",4,0.158090025546706,0.101835158383663,0,2004.25,0.212923223002595,545.25
"CD012586","CD012586_pub2_data","12|2|OHSS|Normal response","OHSS",12,2,"Normal response","or","binary",4,0.101584469586629,0.191329556148196,2.31020890188418e-06,2006.5,0.0392115246659598,705
"CD012586","CD012586_pub2_data","12|3|Clinical pregnancy|Normal response","Clinical pregnancy",12,3,"Normal response","or","binary",2,0.229004867137371,0.121229220035079,0,2004,0.216652117594053,756
"CD012586","CD012586_pub2_data","12|4|Multiple pregnancy|Normal response","Multiple pregnancy",12,4,"Normal response","or","binary",2,0.15245977682247,0.319548114411198,0.031729334551452,2001.5,0.0349740932642487,410.5
"CD012586","CD012586_pub2_data","12|5|Miscarriage|Normal response","Miscarriage",12,5,"Normal response","or","binary",2,-0.0700419866624677,0.184021642038098,0,2004,0.0879632236990313,756
"CD012586","CD012586_pub2_data","12|6|Cancellation|Normal response","Cancellation",12,6,"Normal response","or","binary",2,-0.126278112624946,0.172530161188733,0,2008,0.118127984418196,705
"CD012586","CD012586_pub2_data","12|7|Oocyte number|Normal response","Oocyte number",12,7,"Normal response","or","binary",2,0.0259500400486125,1.41521634542959,0,2008,0,705
"CD012586","CD012586_pub2_data","13|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",13,1,"Normal response","or","binary",11,0.216598189101279,0.0846546127431157,0,2006.18181818182,0.232794602868322,280.454545454545
"CD012586","CD012586_pub2_data","15|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",15,1,"Normal response","or","binary",5,0.13402976244691,0.271460906071411,1.58869366984499e-06,2000.2,0.183617131062951,71.8
"CD012586","CD012586_pub2_data","17|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",17,1,"Low response","or","binary",3,0.0311054558326649,0.167963699776849,0.00126224197728278,2011.33333333333,0.144862639762404,437.666666666667
"CD012586","CD012586_pub2_data","17|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",17,1,"Normal response","or","binary",4,-0.0469937352951587,0.161647300133223,2.97507506970752e-06,2010,0.207155718265651,217.75
"CD012586","CD012586_pub2_data","17|2|OHSS|Normal response","OHSS",17,2,"Normal response","or","binary",2,-1.47772929246231,1.21332098350233,0,2008.5,0.0254237288135593,150.5
"CD012586","CD012586_pub2_data","17|3|Clinical pregnancy|Low response","Clinical pregnancy",17,3,"Low response","or","binary",2,-0.163913751156999,0.160655253139649,0,2014.5,0.161982442348008,591.5
"CD012586","CD012586_pub2_data","17|3|Clinical pregnancy|Normal response","Clinical pregnancy",17,3,"Normal response","or","binary",6,-0.0848340811691567,0.12263508550576,5.14110050369317e-08,2009.16666666667,0.293945437588014,214.833333333333
"CD012586","CD012586_pub2_data","17|4|Multiple pregnancy|Normal response","Multiple pregnancy",17,4,"Normal response","or","binary",4,0.117054817913906,0.30504178022894,0.0603521083819562,2011.25,0.0542251012381222,236
"CD012586","CD012586_pub2_data","17|5|Miscarriage|Low response","Miscarriage",17,5,"Low response","or","binary",3,-0.560223471116985,0.197693024518294,0,2011.33333333333,0.120218597134871,437.666666666667
"CD012586","CD012586_pub2_data","17|5|Miscarriage|Normal response","Miscarriage",17,5,"Normal response","or","binary",6,-0.125846031580907,0.239224430841954,0,2009.16666666667,0.0595218773153221,214.833333333333
"CD012586","CD012586_pub2_data","17|7|Cancellation|Low response","Cancellation",17,7,"Low response","or","binary",3,-0.011852142537756,0.202127655958226,0,2011.33333333333,0.0973219205235715,437.666666666667
"CD012586","CD012586_pub2_data","17|7|Cancellation|Normal response","Cancellation",17,7,"Normal response","or","binary",3,-0.539756079912175,0.657187765433409,0.481999534890855,2007.66666666667,0.0451624055037951,257
"CD012586","CD012586_pub2_data","17|8|Oocyte number|Low response","Oocyte number",17,8,"Low response","or","binary",2,0.0160109950720994,1.41727774373761,0,2011,0,534.5
"CD012586","CD012586_pub2_data","17|8|Oocyte number|Normal response","Oocyte number",17,8,"Normal response","or","binary",6,-0.0496957235354242,0.819114898406061,0,2009.16666666667,0,214.833333333333
"CD012586","CD012586_pub2_data","18|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",18,1,"Low response","or","binary",4,0.27188117814561,0.240506736422452,0.111883892568517,2009.5,0.159572905747729,355.25
"CD012586","CD012586_pub2_data","18|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",18,1,"Normal response","or","binary",5,-0.0419881490224176,0.146845972940746,2.28103063247583e-06,2009.6,0.230513307006887,203.4
"CD012586","CD012586_pub2_data","18|2|OHSS|Normal response","OHSS",18,2,"Normal response","or","binary",4,-1.30234115155899,0.683581717883073,0,2008.5,0.0157058763828276,355
"CD012586","CD012586_pub2_data","2|1|Live birth or ongoing pregnancy|High response","Live birth or ongoing pregnancy",2,1,"High response","or","binary",10,0.0347514797988094,0.108529791099618,0.0292284848260773,2009.88888888889,0.319749218457951,246.6
"CD012586","CD012586_pub2_data","2|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",2,1,"Low response","or","binary",8,-0.0823999398664338,0.141123525856973,6.50684858660193e-06,2013,0.10893631766428,229.125
"CD012586","CD012586_pub2_data","2|2|OHSS|Normal response","OHSS",2,2,"Normal response","or","binary",23,-0.247871457122656,0.093214342489812,0,2007.54545454545,0.0812395660024004,269.608695652174
"CD012586","CD012586_pub2_data","24|5|Cancellation|Normal response","Cancellation",24,5,"Normal response","or","binary",2,-0.0851840048473944,0.197942377633087,0,2014.5,0.0912347199848384,652.5
"CD012586","CD012586_pub2_data","24|6|Oocyte number|Normal response","Oocyte number",24,6,"Normal response","or","binary",2,-0.00431080158120671,1.41529977374934,0,2014.5,0,652.5
"CD012586","CD012586_pub2_data","25|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",25,1,"Normal response","or","binary",4,0.337324833529502,0.116594321348999,0,2011.5,0.304535159620362,343.5
"CD012586","CD012586_pub2_data","27|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",27,1,"Normal response","or","binary",2,0.106917903071516,0.1377859287634,0,2010,0.287809523809524,514.5
"CD012586","CD012586_pub2_data","27|2|OHSS|Normal response","OHSS",27,2,"Normal response","or","binary",2,0.228499467487767,0.344751132176978,0,2010,0.0311904761904762,514.5
"CD012586","CD012586_pub2_data","27|3|Clinical pregnancy|Normal response","Clinical pregnancy",27,3,"Normal response","or","binary",2,0.0999930803795437,0.133064389776999,0,2010,0.341761904761905,514.5
"CD012586","CD012586_pub2_data","27|5|Miscarriage|Normal response","Miscarriage",27,5,"Normal response","or","binary",2,0.0718210461521346,0.215516611502972,0,2010,0.0846190476190476,514.5
"CD012586","CD012586_pub2_data","27|6|Cancellation|Normal response","Cancellation",27,6,"Normal response","or","binary",2,0.124260279331838,0.288139040561149,0,2010,0.0633333333333333,514.5
"CD012586","CD012586_pub2_data","28|1|Live birth or ongoing pregnancy|High response","Live birth or ongoing pregnancy",28,1,"High response","or","binary",2,0.193880702685304,0.169773507336263,0,2020,0.167152103559871,339.5
"CD012586","CD012586_pub2_data","28|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",28,1,"Normal response","or","binary",4,0.0757218035456144,0.125871677943336,0,2010,0.287913978494624,308.25
"CD012586","CD012586_pub2_data","29|5|Miscarriage|Normal response","Miscarriage",29,5,"Normal response","or","binary",2,0.0586991154782422,0.397464216083689,0,2008.5,0.0504807692307692,235.5
"CD012586","CD012586_pub2_data","29|6|Ectopic|Normal response","Ectopic",29,6,"Normal response","or","binary",2,-0.224680020236528,0.614872784394198,0,2008.5,0.0222355769230769,235.5
"CD012586","CD012586_pub2_data","29|7|Cancellation|Normal response","Cancellation",29,7,"Normal response","or","binary",3,-0.214137999948528,0.357330666708242,0.144809785466194,2009.33333333333,0.0709001068376068,397
"CD012586","CD012586_pub2_data","29|8|Oocyte number|Normal response","Oocyte number",29,8,"Normal response","or","binary",3,-0.0225544764416123,1.15660318570902,0,2009.33333333333,0,397
"CD012586","CD012586_pub2_data","29|9|Frozen embryo number|Normal response","Frozen embryo number",29,9,"Normal response","or","binary",2,0.0117965496104926,1.41609366765996,0,2012,0,486.5
"CD012586","CD012586_pub2_data","3|2|Clinical pregnancy|Normal response","Clinical pregnancy",3,2,"Normal response","or","binary",2,-0.139015007178108,0.557541173504991,0.436067610886684,2000,0.314492753623188,165.5
"CD012586","CD012586_pub2_data","3|4|Cancellation|Normal response","Cancellation",3,4,"Normal response","or","binary",2,0.39866973847359,0.61983108172623,0,2000,0.0434782608695652,275.5
"CD012586","CD012586_pub2_data","30|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",30,1,"Normal response","or","binary",2,0.01844313915853,0.233007738575888,0,2009.5,0.198076923076923,229
"CD012586","CD012586_pub2_data","30|2|OHSS|Normal response","OHSS",30,2,"Normal response","or","binary",2,-0.184647254564481,0.609707905605595,0,2013,0.00694444444444444,480
"CD012586","CD012586_pub2_data","38|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",38,1,"Low response","or","binary",2,-0.337263687169206,0.488769812350655,0,2017.5,0.0994152046783626,101.5
"CD012586","CD012586_pub2_data","4|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",4,1,"Low response","or","binary",2,-0.153951413154031,0.557329101358959,0,2013,0.131449631449631,59
"CD012586","CD012586_pub2_data","40|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",40,1,"Low response","or","binary",2,0.397993189623344,0.442349548973709,0,2014.5,0.103703703703704,82.5
"CD012586","CD012586_pub2_data","41|3|Cancellation|Normal response","Cancellation",41,3,"Normal response","or","binary",2,-0.447365773084365,0.59442924844688,0,2021.5,0.103074141048825,92
"CD012586","CD012586_pub2_data","41|4|Oocyte number|Normal response","Oocyte number",41,4,"Normal response","or","binary",2,0.107695918829403,1.42993250345886,0,2021.5,0,92
"CD012586","CD012586_pub2_data","42|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",42,1,"Normal response","or","binary",4,0.265978487611575,0.396639427686611,0.252191428450946,2013.33333333333,0.20370705244123,74.75
"CD012586","CD012586_pub2_data","5|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",5,1,"Normal response","or","binary",2,-0.159647166399203,0.684972684705065,0.838150251931076,2005,0.327688172043011,357
"CD012586","CD012586_pub2_data","5|2|Clinical pregnancy|Normal response","Clinical pregnancy",5,2,"Normal response","or","binary",2,-0.452387660781638,0.442553147202988,0.316292675139514,2005,0.444473684210526,360
"CD012586","CD012586_pub2_data","5|3|Multiple pregnancy|Normal response","Multiple pregnancy",5,3,"Normal response","or","binary",2,-1.33586543236119,0.78774169277727,0.98518272615263,2005,0.153942652329749,357
"CD012586","CD012586_pub2_data","5|5|Cancellation|Normal response","Cancellation",5,5,"Normal response","or","binary",2,-0.368215039582854,0.848271682178435,1.23993901728517,2005,0.11084229390681,357
"CD012586","CD012586_pub2_data","5|6|Oocyte number|Normal response","Oocyte number",5,6,"Normal response","or","binary",2,0.332471689945513,1.41745976280562,0,2005,0,357
"CD012586","CD012586_pub2_data","6|1|Live birth or ongoing pregnancy|Normal response","Live birth or ongoing pregnancy",6,1,"Normal response","or","binary",6,-0.506463189925792,0.23514670634158,0.156189699562787,1994.83333333333,0.251013016411998,215
"CD012586","CD012586_pub2_data","8|1|Live birth or ongoing pregnancy|Low response","Live birth or ongoing pregnancy",8,1,"Low response","reported","reported",2,0,0.393642420229707,0,2009.5,0.16455938697318,164.5
"CD012586","CD012586_pub2_data","9|1|Cancellation|Normal response","Cancellation",9,1,"Normal response","or","binary",2,-0.149594847866067,0.526950523686455,0,2019,0.0301726968284195,256
"CD012594","CD012594_pub2_data","1|1|Number of unexpected (previously unknown) adverse drug reaction reports|NA","Number of unexpected (previously unknown) adverse drug reaction reports",1,1,NA,"or","binary",2,0.468799866206016,0.293500882309686,0,2010,0.182665424044734,134
"CD012609","CD012609_pub2_data","1|1|Clinical relapse|NA","Clinical relapse",1,1,NA,"or","binary",2,-0.970356578137885,0.233830307087895,0,NA,0.71489898989899,204
"CD012609","CD012609_pub2_data","1|4|Withdrawal due to adverse events |NA","Withdrawal due to adverse events ",1,4,NA,"or","binary",2,-0.546747798374307,0.363368162134555,0,2004,0.208333333333333,177.5
"CD012609","CD012609_pub2_data","1|6|Total adverse events |NA","Total adverse events ",1,6,NA,"or","binary",2,-0.313583156722247,0.374392522818451,0,2004,0.944444444444444,177.5
"CD012609","CD012609_pub2_data","2|4|Serious adverse events|NA","Serious adverse events",2,4,NA,"or","binary",2,0.176029172584953,0.435196006792015,0,NA,0.0741951710261569,128.5
"CD012623","CD012623_pub2_data","1|1|Macular hole closure|","Macular hole closure",1,1,"","or","binary",8,0.773159414108781,0.270418916914438,1.3859161195053e-06,2014.625,0.865592903828198,88.625
"CD012623","CD012623_pub2_data","1|2|Visual outcome gained following intervention in ETDRS letters|","Visual outcome gained following intervention in ETDRS letters",1,2,"","or","binary",3,-0.00951900610663699,1.16258797330402,0,2015.33333333333,0,72.3333333333333
"CD012623","CD012623_pub2_data","2|1|Macular hole closure|10 days positioning","Macular hole closure",2,1,"10 days positioning","or","binary",3,1.03211870321837,0.578566658589413,3.04205852161359e-06,2011.33333333333,0.814035087719298,44
"CD012623","CD012623_pub2_data","2|1|Macular hole closure|3 days positioning","Macular hole closure",2,1,"3 days positioning","or","binary",3,0.342774992975369,0.408689635396253,0,2018.33333333333,0.893300653594771,84
"CD012623","CD012623_pub2_data","2|1|Macular hole closure|5 days positioning","Macular hole closure",2,1,"5 days positioning","or","binary",2,1.2800626698345,0.45384526409392,0,2014,0.825213675213675,129
"CD012623","CD012623_pub2_data","2|2|Vision gained following intervention in ETDRS letters|3 days positioning","Vision gained following intervention in ETDRS letters",2,2,"3 days positioning","or","binary",2,0,1.42366996111883,0,2017.5,0,74
"CD012623","CD012623_pub2_data","3|1|Macular hole closure |Size 400 μm or larger","Macular hole closure ",3,1,"Size 400 μm or larger","or","binary",5,1.14760740779251,0.394554476934549,1.0065617709606e-08,2013.4,0.81008547008547,65.4
"CD012623","CD012623_pub2_data","3|1|Macular hole closure |Size less than 400 μm","Macular hole closure ",3,1,"Size less than 400 μm","or","binary",4,0.812533132748975,0.916977727825916,0,2011.75,0.973193473193473,32.25
"CD012635","CD012635_pub2_data","1|1|All-cause mortality at 24 hours|","All-cause mortality at 24 hours",1,1,"","or","binary",3,0.0863948095203724,0.363524037352863,1.92876422726675e-07,2021,0.215151515151515,93
"CD012635","CD012635_pub2_data","1|2|All-cause mortality at 30 days|","All-cause mortality at 30 days",1,2,"","or","binary",3,-0.0459857045536659,0.172949123567844,0,2020.66666666667,0.24249222999223,221.333333333333
"CD012635","CD012635_pub2_data","1|4|Total thromboembolic events in the first 30 days after injury|","Total thromboembolic events in the first 30 days after injury",1,4,"","or","binary",4,0.198181852869014,0.323332978642099,0,2021.25,0.083989903555121,146.5
"CD012635","CD012635_pub2_data","1|5|Arterial thromboembolic events in the first 30 days after injury|","Arterial thromboembolic events in the first 30 days after injury",1,5,"","or","binary",3,0.547583501390746,0.839725876204905,0,2020.66666666667,0.0045045045045045,188.666666666667
"CD012635","CD012635_pub2_data","1|6|Venous thromboembolic events in the first 30 days after injury|","Venous thromboembolic events in the first 30 days after injury",1,6,"","or","binary",3,0.0139730424360751,0.367287268016868,1.50319909710693e-06,2020.66666666667,0.0468759729629295,188.666666666667
"CD012635","CD012635_pub2_data","2|3|All-cause mortality at 30 days|Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","All-cause mortality at 30 days",2,3,"Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","or","binary",2,-0.28520656866241,0.453761605837092,0.251291393683291,2019,0.273207337409672,786
"CD012635","CD012635_pub2_data","2|6|Total thromboembolic events in the first 30 days after injury|Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","Total thromboembolic events in the first 30 days after injury",2,6,"Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","or","binary",2,-0.686624659295341,1.07694524515424,1.61663878072115,2019,0.148033126293996,822.5
"CD012635","CD012635_pub2_data","2|8|Arterial thromboembolic events in the first 30 days after injury|Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","Arterial thromboembolic events in the first 30 days after injury",2,8,"Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone ","or","binary",2,0.0151668531975429,0.273143416999578,0,2019,0.0399585921325052,822.5
"CD012635","CD012635_pub2_data","4|2|All-cause mortality at 30 days|","All-cause mortality at 30 days",4,2,"","or","binary",2,-0.398183196706743,0.307753961010021,0.0920760471424857,2018.5,0.323570759137769,253
"CD012635","CD012635_pub2_data","4|3|Mortality due to haemorrhage within 24 hours|","Mortality due to haemorrhage within 24 hours",4,3,"","or","binary",2,-0.474347942848659,0.339067992702619,0,2018.5,0.251785714285714,109
"CD012642","CD012642_pub2_data","1|1|Mortality (latest time reported up to hospital discharge)|","Mortality (latest time reported up to hospital discharge)",1,1,"","or","binary",3,0.0134960703497368,0.593879185486621,0,1993.5,0.156565656565657,27.6666666666667
"CD012642","CD012642_pub2_data","1|2|Hyponatraemia (< 130 mmol/L)|","Hyponatraemia (< 130 mmol/L)",1,2,"","or","binary",3,-0.723683186722863,0.526238484613518,0,1993.5,0.31952861952862,27.6666666666667
"CD012642","CD012642_pub2_data","1|3|Hypernatraemia (≥ 150 mmol/L)|","Hypernatraemia (≥ 150 mmol/L)",1,3,"","or","binary",4,0.834335039502418,0.457910318419143,0,1992,0.175,25.75
"CD012642","CD012642_pub2_data","1|5|Patent ductus arteriosus|","Patent ductus arteriosus",1,5,"","or","binary",3,0.682938261879914,0.470577181522753,0,1993.5,0.225757575757576,27.3333333333333
"CD012642","CD012642_pub2_data","1|7|Intraventricular haemorrhage (any)|","Intraventricular haemorrhage (any)",1,7,"","or","binary",3,0.333917569311274,0.542242295742667,0,1993.5,0.185606060606061,27
"CD012642","CD012642_pub2_data","10|2|Hyponatraemia (< 130 mmol/L)|Enteral","Hyponatraemia (< 130 mmol/L)",10,2,"Enteral","or","binary",2,-2.40431239395861,0.708328192496578,0,1995,0.542307692307692,34.5
"CD012642","CD012642_pub2_data","10|3|Hypernatraemia (≥ 150 mmol/L)|Enteral","Hypernatraemia (≥ 150 mmol/L)",10,3,"Enteral","or","binary",2,1.40644231369652,1.23074659028337,0,1995,0,34.5
"CD012642","CD012642_pub2_data","11|1|Mortality (latest time reported up to hospital discharge)|","Mortality (latest time reported up to hospital discharge)",11,1,"","or","binary",2,0.0147363597937172,0.620568240914848,0,2000,0.234848484848485,31.5
"CD012642","CD012642_pub2_data","11|2|Hyponatraemia (< 130 mmol/L)|","Hyponatraemia (< 130 mmol/L)",11,2,"","or","binary",2,-0.672898809021778,0.553654819986555,0,2000,0.429292929292929,31.5
"CD012642","CD012642_pub2_data","11|3|Hypernatraemia (≥ 150 mmol/L)|","Hypernatraemia (≥ 150 mmol/L)",11,3,"","or","binary",2,0.661163013847181,0.551683116903243,0,2000,0.25,31.5
"CD012642","CD012642_pub2_data","2|2|Hyponatraemia (< 130 mmol/L)|≥ 3 mmol/kg/day to < 5 mmol/kg/day","Hyponatraemia (< 130 mmol/L)",2,2,"≥ 3 mmol/kg/day to < 5 mmol/kg/day","or","binary",2,-2.40431239395861,0.708328192496578,0,1995,0.542307692307692,34.5
"CD012642","CD012642_pub2_data","2|3|Hypernatraemia (≥ 150 mmol/L)|≥ 3 mmol/kg/day to < 5 mmol/kg/day","Hypernatraemia (≥ 150 mmol/L)",2,3,"≥ 3 mmol/kg/day to < 5 mmol/kg/day","or","binary",2,1.40644231369652,1.23074659028337,0,1995,0,34.5
"CD012642","CD012642_pub2_data","4|3|Hypernatraemia (≥ 150 mmol/L)|< 32 weeks or 1500 g","Hypernatraemia (≥ 150 mmol/L)",4,3,"< 32 weeks or 1500 g","or","binary",2,0.695550882098753,0.497254789218342,0,1994.5,0.35,33
"CD012642","CD012642_pub2_data","6|1|Mortality (latest time reported up to hospital discharge)|Higher fluid intake","Mortality (latest time reported up to hospital discharge)",6,1,"Higher fluid intake","or","binary",2,0.0147363597937172,0.620568240914848,0,2000,0.234848484848485,31.5
"CD012642","CD012642_pub2_data","6|2|Hyponatraemia (< 130 mmol/L)|Higher fluid intake","Hyponatraemia (< 130 mmol/L)",6,2,"Higher fluid intake","or","binary",2,-0.672898809021778,0.553654819986555,0,2000,0.429292929292929,31.5
"CD012642","CD012642_pub2_data","6|3|Hypernatraemia (≥ 150 mmol/L)|Higher fluid intake","Hypernatraemia (≥ 150 mmol/L)",6,3,"Higher fluid intake","or","binary",2,0.661163013847181,0.551683116903243,0,2000,0.25,31.5
"CD012642","CD012642_pub2_data","6|3|Hypernatraemia (≥ 150 mmol/L)|Lower fluid intake","Hypernatraemia (≥ 150 mmol/L)",6,3,"Lower fluid intake","or","binary",2,1.21787904720052,0.821028864996796,0,1988,0.1,20
"CD012642","CD012642_pub2_data","8|1|Mortality (latest time reported up to hospital discharge)|Sick infants","Mortality (latest time reported up to hospital discharge)",8,1,"Sick infants","or","binary",3,0.0134960703497368,0.593879185486621,0,1993.5,0.156565656565657,27.6666666666667
"CD012642","CD012642_pub2_data","8|2|Hyponatraemia (< 130 mmol/L)|Sick infants","Hyponatraemia (< 130 mmol/L)",8,2,"Sick infants","or","binary",3,-0.723683186722863,0.526238484613518,0,1993.5,0.31952861952862,27.6666666666667
"CD012642","CD012642_pub2_data","8|3|Hypernatraemia (≥ 150 mmol/L)|Sick infants","Hypernatraemia (≥ 150 mmol/L)",8,3,"Sick infants","or","binary",3,0.712747196058592,0.524544552683021,0,1993.5,0.166666666666667,27.6666666666667
"CD012642","CD012642_pub2_data","9|1|Mortality (latest time reported up to hospital discharge)|Parenteral","Mortality (latest time reported up to hospital discharge)",9,1,"Parenteral","or","binary",3,0.0134960703497368,0.593879185486621,0,1993.5,0.156565656565657,27.6666666666667
"CD012642","CD012642_pub2_data","9|2|Hyponatraemia (< 130 mmol/L)|Parenteral","Hyponatraemia (< 130 mmol/L)",9,2,"Parenteral","or","binary",3,-0.723683186722863,0.526238484613518,0,1993.5,0.31952861952862,27.6666666666667
"CD012642","CD012642_pub2_data","9|3|Hypernatraemia (≥ 150 mmol/L)|Parenteral","Hypernatraemia (≥ 150 mmol/L)",9,3,"Parenteral","or","binary",3,0.712747196058592,0.524544552683021,0,1993.5,0.166666666666667,27.6666666666667
"CD012693","CD012693_pub3_data","1|1|Live birth or ongoing pregnancy|300/450 IU vs 150 IU","Live birth or ongoing pregnancy",1,1,"300/450 IU vs 150 IU","or","binary",3,0.0951809185912998,0.313222058177958,0.0997019039227549,2013.5,0.161644416189871,179.333333333333
"CD012693","CD012693_pub3_data","1|11|Cycle cancellations for poor response|300/450 IU vs 150 IU","Cycle cancellations for poor response",1,11,"300/450 IU vs 150 IU","or","binary",3,-0.882817873519472,0.783041862847129,1.32165778206301,2013.5,0.168404322949778,179.333333333333
"CD012693","CD012693_pub3_data","1|11|Cycle cancellations for poor response|400/450 IU vs 300 IU","Cycle cancellations for poor response",1,11,"400/450 IU vs 300 IU","or","binary",2,0.361348542919107,0.430582253888685,0,2008.5,0.212365591397849,55
"CD012693","CD012693_pub3_data","1|12|Cycle cancellations for hyper-response|300/450 IU vs 150 IU","Cycle cancellations for hyper-response",1,12,"300/450 IU vs 150 IU","or","binary",2,0.708807984962231,1.27207694196789,0,2005,0,143
"CD012693","CD012693_pub3_data","1|12|Cycle cancellations for hyper-response|400/450 IU vs 300 IU","Cycle cancellations for hyper-response",1,12,"400/450 IU vs 300 IU","or","binary",2,0,1.42697970503695,0,2008.5,0,55
"CD012693","CD012693_pub3_data","1|13|Cycle cancellations for poor or hyper-response|300/450 IU vs 150 IU","Cycle cancellations for poor or hyper-response",1,13,"300/450 IU vs 150 IU","or","binary",2,-0.922620719755776,1.08330128981122,2.03604301350089,2005,0.244914176732359,143
"CD012693","CD012693_pub3_data","1|13|Cycle cancellations for poor or hyper-response|400/450 IU vs 300 IU","Cycle cancellations for poor or hyper-response",1,13,"400/450 IU vs 300 IU","or","binary",2,0.361348542919107,0.430582253888685,0,2008.5,0.212365591397849,55
"CD012693","CD012693_pub3_data","1|14|Women with at least one transferable embryo|300/450 IU vs 150 IU","Women with at least one transferable embryo",1,14,"300/450 IU vs 150 IU","or","binary",3,0.27362145312923,0.360556553669611,0.23313727543438,2013.5,0.708031362576817,179.333333333333
"CD012693","CD012693_pub3_data","1|14|Women with at least one transferable embryo|400/450 IU vs 300 IU","Women with at least one transferable embryo",1,14,"400/450 IU vs 300 IU","or","binary",2,-0.327160799668786,0.406685215567657,0,2008.5,0.725134408602151,55
"CD012693","CD012693_pub3_data","1|15|Total dose of FSH|300/450 IU vs 150 IU","Total dose of FSH",1,15,"300/450 IU vs 150 IU","or","binary",2,0.0343016066693156,1.42233002800863,0,2005,0,143
"CD012693","CD012693_pub3_data","1|15|Total dose of FSH|400/450 IU vs 300 IU","Total dose of FSH",1,15,"400/450 IU vs 300 IU","or","binary",2,0,1.42697970503695,0,2008.5,0,55
"CD012693","CD012693_pub3_data","1|16|Duration of FSH administration|400/450 IU vs 300 IU","Duration of FSH administration",1,16,"400/450 IU vs 300 IU","or","binary",2,0,1.42697970503695,0,2008.5,0,55
"CD012693","CD012693_pub3_data","1|18|Cumulative live birth: 1 cycle (fresh + frozen)|300/450 IU vs 150 IU","Cumulative live birth: 1 cycle (fresh + frozen)",1,18,"300/450 IU vs 150 IU","or","binary",2,0.167889148840319,0.332998753172005,0.116493383542564,2022,0.223808010171647,243
"CD012693","CD012693_pub3_data","1|2|Severe OHSS|300/450 IU vs 150 IU","Severe OHSS",1,2,"300/450 IU vs 150 IU","or","binary",2,0.0343016066693156,1.42233002800863,0,2005,0,143
"CD012693","CD012693_pub3_data","1|20|Multiple pregnancy in women with clinical pregnancy|300/450 IU vs 150 IU","Multiple pregnancy in women with clinical pregnancy",1,20,"300/450 IU vs 150 IU","or","binary",2,0.226315306629619,0.979885902248232,0,2005,0.0416666666666667,20.5
"CD012693","CD012693_pub3_data","1|3|Clinical pregnancy|300/450 IU vs 150 IU","Clinical pregnancy",1,3,"300/450 IU vs 150 IU","or","binary",3,-0.26621906495985,0.33577934221232,0.155100804078129,2013.5,0.266115702479339,179.333333333333
"CD012693","CD012693_pub3_data","1|3|Clinical pregnancy|400/450 IU vs 300 IU","Clinical pregnancy",1,3,"400/450 IU vs 300 IU","or","binary",2,-0.154568455101581,0.557586690294297,0,2008.5,0.122311827956989,55
"CD012693","CD012693_pub3_data","1|5|Moderate or severe OHSS|300/450 IU vs 150 IU","Moderate or severe OHSS",1,5,"300/450 IU vs 150 IU","or","binary",2,0.0343016066693156,1.42233002800863,0,2005,0,143
"CD012693","CD012693_pub3_data","1|6|Multiple pregnancy in randomised women|300/450 IU vs 150 IU","Multiple pregnancy in randomised women",1,6,"300/450 IU vs 150 IU","or","binary",3,-0.0495825723202958,0.484989561239058,0,2013.5,0.0208942572578936,179.333333333333
"CD012693","CD012693_pub3_data","1|7|Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes|300/450 IU vs 150 IU","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes",1,7,"300/450 IU vs 150 IU","reported","reported",3,0.565975991803868,0.212409828156137,0.112238963447285,2013.5,0,17.3333333333333
"CD012693","CD012693_pub3_data","1|7|Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes|400/450 IU vs 300 IU","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes",1,7,"400/450 IU vs 300 IU","reported","reported",2,-0.0217142857142857,0.174199978912344,0.023,2008.5,0,31
"CD012693","CD012693_pub3_data","1|8|Poor response to stimulation|300/450 IU vs 150 IU","Poor response to stimulation",1,8,"300/450 IU vs 150 IU","or","binary",2,-0.640967086617603,0.240983294355388,0,2005,0.649237126509854,143
"CD012693","CD012693_pub3_data","2|1|Live birth or ongoing pregnancy|200 IU vs 100 IU","Live birth or ongoing pregnancy",2,1,"200 IU vs 100 IU","or","binary",2,-0.1255685276677,0.221544617933409,0,2003.5,0.216842704446272,261
"CD012693","CD012693_pub3_data","2|1|Live birth or ongoing pregnancy|225/200 IU vs 150 IU","Live birth or ongoing pregnancy",2,1,"225/200 IU vs 150 IU","or","binary",2,-0.0220890571146115,0.168189164159831,0,2022,0.291009852216749,343
"CD012693","CD012693_pub3_data","2|11|Cycle cancellations for poor response|200 IU vs 100 IU","Cycle cancellations for poor response",2,11,"200 IU vs 100 IU","or","binary",2,-0.625526137627032,0.868563162903268,1.0307456911876,2003.5,0.100246663715135,261
"CD012693","CD012693_pub3_data","2|11|Cycle cancellations for poor response|225/200 IU vs 150 IU","Cycle cancellations for poor response",2,11,"225/200 IU vs 150 IU","or","binary",6,-0.539934315372118,0.240629831767405,0.0143747079689294,2009,0.078950957718081,241
"CD012693","CD012693_pub3_data","2|12|Cycle cancellations for hyper-response|200 IU vs 100 IU","Cycle cancellations for hyper-response",2,12,"200 IU vs 100 IU","or","binary",2,0.305807143174401,1.34175862389852,1.05605908636162,2003.5,0.00515463917525773,261
"CD012693","CD012693_pub3_data","2|12|Cycle cancellations for hyper-response|225/200 IU vs 150 IU","Cycle cancellations for hyper-response",2,12,"225/200 IU vs 150 IU","or","binary",5,0.614537129399463,0.422861645842598,0,2002.5,0.0140909090909091,207.4
"CD012693","CD012693_pub3_data","2|13|Cycle cancellations for poor or hyper-response|200 IU vs 100 IU","Cycle cancellations for poor or hyper-response",2,13,"200 IU vs 100 IU","or","binary",2,-0.846119803189555,0.454520725327427,0.13760530074095,2003.5,0.105401302890393,261
"CD012693","CD012693_pub3_data","2|13|Cycle cancellations for poor or hyper-response|225/200 IU vs 150 IU","Cycle cancellations for poor or hyper-response",2,13,"225/200 IU vs 150 IU","or","binary",5,-0.265528731882163,0.201196816884806,1.75433708237621e-06,2002.5,0.108832058352606,207.4
"CD012693","CD012693_pub3_data","2|14|Women with at least one transferable embryo|200 IU vs 100 IU","Women with at least one transferable embryo",2,14,"200 IU vs 100 IU","or","binary",2,0.060650864205641,0.764567695176653,0.932868287507433,2003.5,0.864904180633736,261
"CD012693","CD012693_pub3_data","2|14|Women with at least one transferable embryo|225/200 IU vs 150 IU","Women with at least one transferable embryo",2,14,"225/200 IU vs 150 IU","or","binary",6,0.0251271379156287,0.258205446315229,0.201935252577012,2009,0.865282566197776,241
"CD012693","CD012693_pub3_data","2|15|Total dose of FSH|200 IU vs 100 IU","Total dose of FSH",2,15,"200 IU vs 100 IU","or","binary",2,0.0224500982788092,1.41711014708304,0,2003.5,0,261
"CD012693","CD012693_pub3_data","2|15|Total dose of FSH|225/200 IU vs 150 IU","Total dose of FSH",2,15,"225/200 IU vs 150 IU","or","binary",5,0.00859464748730148,0.897262432081654,0,2002.5,0,207.4
"CD012693","CD012693_pub3_data","2|16|Duration of FSH administration|225/200 IU vs 150 IU","Duration of FSH administration",2,16,"225/200 IU vs 150 IU","or","binary",4,-0.015058090635079,1.00234498672324,0,2002.5,0,240.25
"CD012693","CD012693_pub3_data","2|18|Cumulative live birth: 1 cycle (fresh + frozen)|225/200 IU vs 150 IU","Cumulative live birth: 1 cycle (fresh + frozen)",2,18,"225/200 IU vs 150 IU","or","binary",2,0.0802193647892785,0.161043587907382,0,2022,0.37487684729064,343
"CD012693","CD012693_pub3_data","2|2|Severe OHSS|200 IU vs 100 IU","Severe OHSS",2,2,"200 IU vs 100 IU","or","binary",2,-0.661367982996416,1.26863125030773,0,2003.5,0.00515463917525773,261
"CD012693","CD012693_pub3_data","2|2|Severe OHSS|225/200 IU vs 150 IU","Severe OHSS",2,2,"225/200 IU vs 150 IU","or","binary",4,0.0436683189027139,0.660228245458822,0,2004,0.00557359307359307,185
"CD012693","CD012693_pub3_data","2|20|Multiple pregnancy in women with clinical pregnancy|225/200 IU vs 150 IU","Multiple pregnancy in women with clinical pregnancy",2,20,"225/200 IU vs 150 IU","or","binary",2,0.345510612380552,0.830800952635863,0,NA,0.111111111111111,44.5
"CD012693","CD012693_pub3_data","2|3|Clinical pregnancy|225/200 IU vs 150 IU","Clinical pregnancy",2,3,"225/200 IU vs 150 IU","or","binary",6,0.00248540698575024,0.119045241489565,0,2009,0.295094374475574,241
"CD012693","CD012693_pub3_data","2|5|Moderate or severe OHSS|200 IU vs 100 IU","Moderate or severe OHSS",2,5,"200 IU vs 100 IU","or","binary",2,-0.418792772813458,0.536383690555748,0,2003.5,0.0328884953513377,261
"CD012693","CD012693_pub3_data","2|5|Moderate or severe OHSS|225/200 IU vs 150 IU","Moderate or severe OHSS",2,5,"225/200 IU vs 150 IU","or","binary",4,0.185760112388839,0.428853706227241,0,2004,0.0187229437229437,185
"CD012693","CD012693_pub3_data","2|6|Multiple pregnancy in randomised women|225/200 IU vs 150 IU","Multiple pregnancy in randomised women",2,6,"225/200 IU vs 150 IU","or","binary",3,0.031523764373975,0.357063696972387,0,2022,0.0324575807334428,269.666666666667
"CD012693","CD012693_pub3_data","2|7|Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes|200 IU vs 100 IU","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes",2,7,"200 IU vs 100 IU","reported","reported",2,0.514050632911392,0.394998859114974,0.3064,2003.5,0,165
"CD012693","CD012693_pub3_data","2|7|Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes|225/200 IU vs 150 IU","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes",2,7,"225/200 IU vs 150 IU","reported","reported",6,0.163601975214601,0.0472153743431474,0.00507618241534567,2009,0,77.1666666666667
"CD012693","CD012693_pub3_data","4|1|Live birth or ongoing pregnancy|Control group: standard dose 150 IU","Live birth or ongoing pregnancy",4,1,"Control group: standard dose 150 IU","or","binary",7,0.134766922821865,0.0914978705977832,0.0183428573920715,2016.14285714286,0.245849027301604,628.571428571429
"CD012693","CD012693_pub3_data","4|10|Hyper-response to stimulation|Control group: standard dose 150 IU","Hyper-response to stimulation",4,10,"Control group: standard dose 150 IU","or","binary",4,0.0127419327074219,0.376953909300839,0.440514954487562,2015,0.142962927106209,464.5
"CD012693","CD012693_pub3_data","4|11|Cycle cancellations for poor response|Control group: standard dose 150 IU","Cycle cancellations for poor response",4,11,"Control group: standard dose 150 IU","or","binary",6,0.170976397595044,0.147295365166557,0,2015.33333333333,0.0395277918628514,565.166666666667
"CD012693","CD012693_pub3_data","4|12|Cycle cancellations for hyper-response|Control group: standard dose 150 IU","Cycle cancellations for hyper-response",4,12,"Control group: standard dose 150 IU","or","binary",5,-1.01650313779889,0.272164604576242,0.0624695548034494,2014.6,0.0425465058867179,634
"CD012693","CD012693_pub3_data","4|13|Cycle cancellations for poor or hyper-response|Control group: standard dose 150 IU","Cycle cancellations for poor or hyper-response",4,13,"Control group: standard dose 150 IU","or","binary",4,-0.235081716513394,0.124173082939976,2.8278455646915e-06,2013,0.104765309794859,705.75
"CD012693","CD012693_pub3_data","4|14|Women with at least one transferable embryo|Control group: standard dose 150 IU","Women with at least one transferable embryo",4,14,"Control group: standard dose 150 IU","or","binary",7,-0.0162279901117309,0.0817684867926039,0,2016.14285714286,0.827294235920261,628.142857142857
"CD012693","CD012693_pub3_data","4|15|Total dose of FSH|Control group: standard dose 150 IU","Total dose of FSH",4,15,"Control group: standard dose 150 IU","or","binary",5,0.0368380225591399,0.895643357159206,0,2015.4,0,570
"CD012693","CD012693_pub3_data","4|16|Duration of FSH administration|Control group: standard dose 150 IU","Duration of FSH administration",4,16,"Control group: standard dose 150 IU","or","binary",7,-0.0774778352282052,0.756979455029594,0,2016.14285714286,0,628.571428571429
"CD012693","CD012693_pub3_data","4|18|Cumulative live birth: 1 cycle (fresh + frozen)|Control group: standard dose 150 IU","Cumulative live birth: 1 cycle (fresh + frozen)",4,18,"Control group: standard dose 150 IU","or","binary",2,-0.142378443561585,0.125818629390002,0,2018,0.321618701243938,626.5
"CD012693","CD012693_pub3_data","4|2|Severe OHSS|Control group: standard dose 150 IU","Severe OHSS",4,2,"Control group: standard dose 150 IU","or","binary",5,-0.291310520514294,0.275081536242172,0,2015,0.0132323748357904,544.8
"CD012693","CD012693_pub3_data","4|20|Multiple pregnancy in women with clinical pregnancy|Control group: standard dose 150 IU","Multiple pregnancy in women with clinical pregnancy",4,20,"Control group: standard dose 150 IU","or","binary",4,-0.32325570145278,0.299951250078413,0,2013,0.121013885994724,224.5
"CD012693","CD012693_pub3_data","4|3|Clinical pregnancy|Control group: standard dose 150 IU","Clinical pregnancy",4,3,"Control group: standard dose 150 IU","or","binary",7,0.0436681927993637,0.0771779745247215,0.00814780902242262,2016.14285714286,0.30575244594174,628.571428571429
"CD012693","CD012693_pub3_data","4|5|Moderate or severe OHSS|Control group: standard dose 150 IU","Moderate or severe OHSS",4,5,"Control group: standard dose 150 IU","or","binary",7,-0.495494612972568,0.176585773858664,0,2016.14285714286,0.0437098704281028,628.571428571429
"CD012693","CD012693_pub3_data","4|6|Multiple pregnancy in randomised women|Control group: standard dose 150 IU","Multiple pregnancy in randomised women",4,6,"Control group: standard dose 150 IU","or","binary",4,-0.242960519894388,0.286567045909072,0,2013,0.0399075184692861,705.75
"CD012693","CD012693_pub3_data","4|7|Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes|Control group: standard dose 150 IU","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes",4,7,"Control group: standard dose 150 IU","reported","reported",6,0.0596477475107826,0.153051993762495,0.137507543955164,2015.66666666667,0,295
"CD012693","CD012693_pub3_data","4|8|Poor response to stimulation|Control group: standard dose 150 IU","Poor response to stimulation",4,8,"Control group: standard dose 150 IU","or","binary",4,-0.162755114090952,0.397594913017757,0.456336331092221,2015,0.15825909800901,464.5
"CD012693","CD012693_pub3_data","4|9|Normal response to stimulation|Control group: standard dose 150 IU","Normal response to stimulation",4,9,"Control group: standard dose 150 IU","or","binary",6,0.148203490496094,0.0638161678667046,2.72260056499634e-06,2016.33333333333,0.577115027143547,699.333333333333
"CD012712","CD012712_pub2_data","1|3|Chronic lung disease at 36 weeks|","Chronic lung disease at 36 weeks",1,3,"","or","binary",2,-0.859835502637128,0.727403466203096,0,2019.5,0.07,90
"CD012712","CD012712_pub2_data","1|4|Pulmonary air leak syndromes|","Pulmonary air leak syndromes",1,4,"","or","binary",2,-1.15980843586929,0.687599681830147,0,2019.5,0.0925,90
"CD012712","CD012712_pub2_data","2|1|Mortality before hospital discharge|nHFV versus nCPAP","Mortality before hospital discharge",2,1,"nHFV versus nCPAP","or","binary",4,0.00578099340773114,0.446400707365636,0,2020.25,0.0355601092896175,132.75
"CD012712","CD012712_pub2_data","2|10|Pulmonary air leak syndromes|nHFV versus nCPAP","Pulmonary air leak syndromes",2,10,"nHFV versus nCPAP","or","binary",6,0.540929198768926,0.493909055391482,0,2018.83333333333,0.00930783242258652,107.5
"CD012712","CD012712_pub2_data","2|10|Pulmonary air leak syndromes|nHFV versus nIPPV","Pulmonary air leak syndromes",2,10,"nHFV versus nIPPV","or","binary",5,-0.346651048104606,0.492303742317477,0,2021.2,0.0742218072898432,53.4
"CD012712","CD012712_pub2_data","2|11|Proven sepsis|nHFV versus nCPAP","Proven sepsis",2,11,"nHFV versus nCPAP","or","binary",2,-0.167011690269255,0.629340357532888,0,2016,0.2,38.5
"CD012712","CD012712_pub2_data","2|12|Necrotising enterocolitis|nHFV versus nCPAP","Necrotising enterocolitis",2,12,"nHFV versus nCPAP","or","binary",3,0.134319432708067,0.48865702663908,0.0938567631719062,2020.33333333333,0.0449673202614379,135.666666666667
"CD012712","CD012712_pub2_data","2|15|Intraventricular haemorrhage, any|nHFV versus nCPAP","Intraventricular haemorrhage, any",2,15,"nHFV versus nCPAP","or","binary",3,-0.79771005279155,0.516090245516059,0,2020.33333333333,0.114551083591331,59.6666666666667
"CD012712","CD012712_pub2_data","2|15|Intraventricular haemorrhage, any|nHFV versus nIPPV","Intraventricular haemorrhage, any",2,15,"nHFV versus nIPPV","or","binary",5,-0.420984694976623,0.399868797553748,0,2021.8,0.117992709045341,57.6
"CD012712","CD012712_pub2_data","2|16|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP","Intraventricular haemorrhage, Papile grade 3/4",2,16,"nHFV versus nCPAP","or","binary",4,0.123257506459689,0.53808872144451,0,2020.25,0.0156284153005464,132.75
"CD012712","CD012712_pub2_data","2|2|Endotracheal intubation|nHFV versus nCPAP","Endotracheal intubation",2,2,"nHFV versus nCPAP","or","binary",5,-0.692164484119259,0.266150582551038,0,2018.4,0.167704275152684,114.2
"CD012712","CD012712_pub2_data","2|20|Length of hospital stay, days|nHFV versus nCPAP","Length of hospital stay, days",2,20,"nHFV versus nCPAP","or","binary",4,0.00195078850180929,1.00427863678362,0,2021,0,150.5
"CD012712","CD012712_pub2_data","2|20|Length of hospital stay, days|nHFV versus nIPPV","Length of hospital stay, days",2,20,"nHFV versus nIPPV","or","binary",2,-0.0226117567861278,1.42643998856686,0,2021.5,0,62.5
"CD012712","CD012712_pub2_data","2|3|Trauma to the nostrils and upper airway|nHFV versus nCPAP","Trauma to the nostrils and upper airway",2,3,"nHFV versus nCPAP","or","binary",2,0.58209575985325,1.12980268846699,2.22463563998386,2020.5,0.413114754098361,80.5
"CD012712","CD012712_pub2_data","2|3|Trauma to the nostrils and upper airway|nHFV versus nIPPV","Trauma to the nostrils and upper airway",2,3,"nHFV versus nIPPV","or","binary",2,-0.0782241290796973,0.638282654054605,0,2020.5,0.419127086007702,59
"CD012712","CD012712_pub2_data","2|4|Failure of respiratory support|nHFV versus nCPAP","Failure of respiratory support",2,4,"nHFV versus nCPAP","or","binary",3,-0.65167436484822,0.272820961899597,0,2020.66666666667,0.240291438979964,154.333333333333
"CD012712","CD012712_pub2_data","2|5|Duration of respiratory support, days|nHFV versus nIPPV","Duration of respiratory support, days",2,5,"nHFV versus nIPPV","or","binary",5,0.038773042231955,0.903206267671275,0,2021.6,0,53.8
"CD012712","CD012712_pub2_data","2|5|Duration of respiratory support, days|nHFV vs nCPAP","Duration of respiratory support, days",2,5,"nHFV vs nCPAP","or","binary",6,0.0273171729865956,0.821585222132923,0,2020.66666666667,0,117.833333333333
"CD012712","CD012712_pub2_data","2|6|Duration of oxygen therapy, days|nHFV versus nCPAP","Duration of oxygen therapy, days",2,6,"nHFV versus nCPAP","or","binary",3,-0.0151458114806449,1.16150318559315,0,2017.33333333333,0,155.333333333333
"CD012712","CD012712_pub2_data","2|6|Duration of oxygen therapy, days|nHFV versus nIPPV","Duration of oxygen therapy, days",2,6,"nHFV versus nIPPV","or","binary",3,0.0287344878833498,1.16451129394607,0,2021.33333333333,0,61.6666666666667
"CD012712","CD012712_pub2_data","2|7|Chronic lung disease at 36 weeks|nHFV versus nCPAP","Chronic lung disease at 36 weeks",2,7,"nHFV versus nCPAP","or","binary",4,0.314291428478314,0.295120334441739,0,2020.5,0.0903637770897833,120.25
"CD012712","CD012712_pub2_data","2|9|Patent ductus arteriosus|nHFV versus nCPAP","Patent ductus arteriosus",2,9,"nHFV versus nCPAP","or","binary",2,-0.41419746155019,0.505308615204591,0,2020,0.213235294117647,52.5
"CD012712","CD012712_pub2_data","2|9|Patent ductus arteriosus|nHFV versus nIPPV","Patent ductus arteriosus",2,9,"nHFV versus nIPPV","or","binary",2,-0.39359918779765,0.72612102249334,0,2022,0.131578947368421,42
"CD012712","CD012712_pub2_data","3|1|Mortality before hospital discharge|nHFV versus nCPAP - nHFV Hz ≥ 10","Mortality before hospital discharge",3,1,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,-0.588170996686392,1.28376470228418,0,2020,0.025,52.5
"CD012712","CD012712_pub2_data","3|1|Mortality before hospital discharge|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Mortality before hospital discharge",3,1,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",4,0.00578099340773114,0.446400707365636,0,2020.25,0.0355601092896175,132.75
"CD012712","CD012712_pub2_data","3|1|Mortality before hospital discharge|nHFV versus nCPAP - preterm infants","Mortality before hospital discharge",3,1,"nHFV versus nCPAP - preterm infants","or","binary",4,0.00578099340773114,0.446400707365636,0,2020.25,0.0355601092896175,132.75
"CD012712","CD012712_pub2_data","3|2|Endotracheal intubation|nHFV versus nCPAP - nHFV Hz < 10","Endotracheal intubation",3,2,"nHFV versus nCPAP - nHFV Hz < 10","or","binary",2,-0.801322518911647,0.577707325237352,0,2015.5,0.0737704918032787,82
"CD012712","CD012712_pub2_data","3|2|Endotracheal intubation|nHFV versus nCPAP - nHFV Hz ≥ 10","Endotracheal intubation",3,2,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,-0.893963320551803,0.808860092414899,0.405144873159645,2020,0.258823529411765,52.5
"CD012712","CD012712_pub2_data","3|2|Endotracheal intubation|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Endotracheal intubation",3,2,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",5,-0.692164484119259,0.266150582551038,0,2018.4,0.167704275152684,114.2
"CD012712","CD012712_pub2_data","3|2|Endotracheal intubation|nHFV versus nCPAP - preterm infants","Endotracheal intubation",3,2,"nHFV versus nCPAP - preterm infants","or","binary",4,-0.704340696074179,0.268481370793243,0,2020.25,0.209630343940855,132.75
"CD012712","CD012712_pub2_data","3|3|Failure of respiratory support|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Failure of respiratory support",3,3,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",3,-0.65167436484822,0.272820961899597,0,2020.66666666667,0.240291438979964,154.333333333333
"CD012712","CD012712_pub2_data","3|3|Failure of respiratory support|nHFV versus nCPAP - preterm infants","Failure of respiratory support",3,3,"nHFV versus nCPAP - preterm infants","or","binary",3,-0.65167436484822,0.272820961899597,0,2020.66666666667,0.240291438979964,154.333333333333
"CD012712","CD012712_pub2_data","3|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV Hz ≥ 10","Chronic lung disease at 36 weeks",3,4,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,0.966022083033202,0.553835918068019,0,2020,0.104411764705882,52.5
"CD012712","CD012712_pub2_data","3|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Chronic lung disease at 36 weeks",3,4,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",3,0.404840878825975,0.327333235404165,0.0248678206739284,2020.33333333333,0.102941176470588,135.666666666667
"CD012712","CD012712_pub2_data","3|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - preterm infants","Chronic lung disease at 36 weeks",3,4,"nHFV versus nCPAP - preterm infants","or","binary",4,0.314291428478314,0.295120334441739,0,2020.5,0.0903637770897833,120.25
"CD012712","CD012712_pub2_data","3|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP - nHFV Hz ≥ 10","Intraventricular haemorrhage, Papile grade 3/4",3,6,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,0.0786473218160305,1.4286018253401,0,2020,0,52.5
"CD012712","CD012712_pub2_data","3|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Intraventricular haemorrhage, Papile grade 3/4",3,6,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",4,0.123257506459689,0.53808872144451,0,2020.25,0.0156284153005464,132.75
"CD012712","CD012712_pub2_data","3|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP - preterm infants","Intraventricular haemorrhage, Papile grade 3/4",3,6,"nHFV versus nCPAP - preterm infants","or","binary",4,0.123257506459689,0.53808872144451,0,2020.25,0.0156284153005464,132.75
"CD012712","CD012712_pub2_data","4|1|Mortality before hospital discharge|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Mortality before hospital discharge",4,1,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",2,0.936752727904506,0.569036900481299,0,2022,0.145833333333333,42
"CD012712","CD012712_pub2_data","4|2|Endotracheal intubation|nHFV versus nIPPV- preterm infants","Endotracheal intubation",4,2,"nHFV versus nIPPV- preterm infants","or","binary",4,0.555073011037563,0.416480736096728,0.00171390101457055,2022,0.120065789473684,46.75
"CD012712","CD012712_pub2_data","4|2|Endotracheal intubation|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Endotracheal intubation",4,2,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",3,0.259288053900963,0.889300110201957,1.4736881231312,2022,0.194178628389155,41.6666666666667
"CD012712","CD012712_pub2_data","4|4|Chronic lung disease at 36 weeks|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Chronic lung disease at 36 weeks",4,4,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",2,-0.402621358710298,0.643047149251155,0.0440334371468029,2022,0.263157894736842,42
"CD012712","CD012712_pub2_data","5|1|Mortality before hospital discharge|nHFV versus nCPAP","Mortality before hospital discharge",5,1,"nHFV versus nCPAP","or","binary",2,0.335503615077323,0.596298396627786,0,2020,0.0133333333333333,185
"CD012712","CD012712_pub2_data","5|2|Endotracheal intubation|nHFV versus nCPAP","Endotracheal intubation",5,2,"nHFV versus nCPAP","or","binary",3,-0.699023251222352,0.329898267677751,0,2017,0.0969934640522876,136.666666666667
"CD012712","CD012712_pub2_data","5|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP","Chronic lung disease at 36 weeks",5,4,"nHFV versus nCPAP","or","binary",2,0.254476517622376,0.335631426696373,0,2020,0.0794117647058823,185
"CD012712","CD012712_pub2_data","5|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP","Intraventricular haemorrhage, Papile grade 3/4",5,6,"nHFV versus nCPAP","or","binary",2,0.508179248936035,0.741346718143062,0,2020,0.00666666666666667,185
"CD012712","CD012712_pub2_data","6|1|Mortality before hospital discharge|nHFV versus nCPAP","Mortality before hospital discharge",6,1,"nHFV versus nCPAP","or","binary",6,-0.0892338836531334,0.297094759754823,0,2018.33333333333,0.0551329924964802,237.833333333333
"CD012712","CD012712_pub2_data","6|1|Mortality before hospital discharge|nHFV versus nIPPV","Mortality before hospital discharge",6,1,"nHFV versus nIPPV","or","binary",2,0.586284610160678,0.497847847664484,0,2016.5,0.0875,492
"CD012712","CD012712_pub2_data","6|10|Pulmonary air leak syndromes|nHFV versus nCPAP","Pulmonary air leak syndromes",6,10,"nHFV versus nCPAP","or","binary",8,-0.303871638265939,0.368198257340198,0.106267076540951,2019.375,0.0519633256528418,209.125
"CD012712","CD012712_pub2_data","6|10|Pulmonary air leak syndromes|nHFV versus nIPPV","Pulmonary air leak syndromes",6,10,"nHFV versus nIPPV","or","binary",5,-0.0386458851790623,0.576954291973672,0.507239083271562,2019.2,0.0134011627906977,264.4
"CD012712","CD012712_pub2_data","6|11|Proven sepsis|nHFV versus nIPPV","Proven sepsis",6,11,"nHFV versus nIPPV","or","binary",2,-0.0053759974463507,0.371465650011845,0,2016.5,0.096875,492
"CD012712","CD012712_pub2_data","6|12|Necrotising enterocolitis|nHFV versus nCPAP","Necrotising enterocolitis",6,12,"nHFV versus nCPAP","or","binary",4,-0.320585798950108,0.455882633784528,0.340317148408011,2019.5,0.104241388242898,130.75
"CD012712","CD012712_pub2_data","6|12|Necrotising enterocolitis|nHFV versus nIPPV","Necrotising enterocolitis",6,12,"nHFV versus nIPPV","or","binary",4,0.0435088066371974,0.560645184997498,0,2018.75,0.0287930597771023,79.5
"CD012712","CD012712_pub2_data","6|13|Necrotising enterocolitis, Bell stage ≥ 2|nHFV versus nCPAP","Necrotising enterocolitis, Bell stage ≥ 2",6,13,"nHFV versus nCPAP","or","binary",3,0.281486590049992,0.249696745310234,0,2019.66666666667,0.0535158891142664,380.666666666667
"CD012712","CD012712_pub2_data","6|13|Necrotising enterocolitis, Bell stage ≥ 2|nHFV versus nIPPV","Necrotising enterocolitis, Bell stage ≥ 2",6,13,"nHFV versus nIPPV","or","binary",2,-0.0911408194042881,0.246636736015765,0,2016.5,0.0375,492
"CD012712","CD012712_pub2_data","6|14|Intraventricular haemorrhage, any|nHFV versus nCPAP","Intraventricular haemorrhage, any",6,14,"nHFV versus nCPAP","or","binary",7,0.0131479436002923,0.221151467971703,0.0728794848449577,2019.71428571429,0.0826967929450076,234.857142857143
"CD012712","CD012712_pub2_data","6|14|Intraventricular haemorrhage, any|nHFV versus nIPPV","Intraventricular haemorrhage, any",6,14,"nHFV versus nIPPV","or","binary",4,0.237204618187029,0.368521058373171,0.260258254702532,2018.75,0.148769946808511,309
"CD012712","CD012712_pub2_data","6|15|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP","Intraventricular haemorrhage, Papile grade 3/4",6,15,"nHFV versus nCPAP","or","binary",3,-0.248922460758896,0.195623630427283,0,2019,0.0615948867536033,372.333333333333
"CD012712","CD012712_pub2_data","6|15|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nIPPV","Intraventricular haemorrhage, Papile grade 3/4",6,15,"nHFV versus nIPPV","or","binary",4,-0.270850489165394,0.192857140209313,0,2018.75,0.120814520451921,290.5
"CD012712","CD012712_pub2_data","6|17|Retinopathy of prematurity, any|nHFV versus nCPAP","Retinopathy of prematurity, any",6,17,"nHFV versus nCPAP","or","binary",4,-0.391824367278849,0.24614428510824,0.0816216926753397,2020,0.168895674103147,354.5
"CD012712","CD012712_pub2_data","6|17|Retinopathy of prematurity, any|nHFV versus nIPPV","Retinopathy of prematurity, any",6,17,"nHFV versus nIPPV","or","binary",4,-0.188713240857654,0.167426575638529,0,2018.75,0.124468085106383,309
"CD012712","CD012712_pub2_data","6|18|Retinopathy of prematurity, stage ≥ 3|nHFV versus nCPAP","Retinopathy of prematurity, stage ≥ 3",6,18,"nHFV versus nCPAP","or","binary",2,-0.242984761364643,0.172767899490918,0,2020,0.226019503546099,526
"CD012712","CD012712_pub2_data","6|18|Retinopathy of prematurity, stage ≥ 3|nHFV versus nIPPV","Retinopathy of prematurity, stage ≥ 3",6,18,"nHFV versus nIPPV","or","binary",2,-0.174868876798744,0.17421236224716,0,2020,0.192021276595745,526
"CD012712","CD012712_pub2_data","6|19|Length of hospital stay, days|nHFV versus nCPAP","Length of hospital stay, days",6,19,"nHFV versus nCPAP","or","binary",5,0.01554761333965,0.898437121732092,0,2020.2,0,128
"CD012712","CD012712_pub2_data","6|19|Length of hospital stay, days|nHFV versus nIPPV","Length of hospital stay, days",6,19,"nHFV versus nIPPV","or","binary",3,0.0144528200868412,1.16548801435451,0,2018.66666666667,0,92
"CD012712","CD012712_pub2_data","6|2|Endotracheal reintubation|nHFV versus nCPAP","Endotracheal reintubation",6,2,"nHFV versus nCPAP","or","binary",11,-1.18841152855353,0.156917017284175,0.0510349963766198,2019.45454545455,0.417992567826054,172.454545454545
"CD012712","CD012712_pub2_data","6|2|Endotracheal reintubation|nHFV versus nIPPV","Endotracheal reintubation",6,2,"nHFV versus nIPPV","or","binary",6,-0.412039244518249,0.154280201161843,3.52675261590732e-07,2019.16666666667,0.240227610094013,227.333333333333
"CD012712","CD012712_pub2_data","6|3|Trauma to the nostrils and upper airway|nHFV versus nCPAP","Trauma to the nostrils and upper airway",6,3,"nHFV versus nCPAP","or","binary",4,-0.140252508151063,0.485848183742087,0.557929912081867,2020,0.118628102836879,354.5
"CD012712","CD012712_pub2_data","6|3|Trauma to the nostrils and upper airway|nHFV versus nIPPV","Trauma to the nostrils and upper airway",6,3,"nHFV versus nIPPV","or","binary",4,-0.0130281536334221,0.258419635369122,0.0325258203807901,2020,0.115841881965552,313.5
"CD012712","CD012712_pub2_data","6|5|Duration of respiratory support, days|nHFV versus nCPAP","Duration of respiratory support, days",6,5,"nHFV versus nCPAP","or","binary",7,-0.0869542132126788,0.766872513776132,0,2019.57142857143,0,195.857142857143
"CD012712","CD012712_pub2_data","6|5|Duration of respiratory support, days|nHFV versus nIPPV","Duration of respiratory support, days",6,5,"nHFV versus nIPPV","or","binary",2,0.0214048045397625,1.41836219357274,0,2020,0,526
"CD012712","CD012712_pub2_data","6|6|Duration of oxygen therapy, days|nHFV versus nCPAP","Duration of oxygen therapy, days",6,6,"nHFV versus nCPAP","or","binary",4,-0.12114320129286,1.01962162706112,0,2020,0,304.5
"CD012712","CD012712_pub2_data","6|6|Duration of oxygen therapy, days|nHFV versus nIPPV","Duration of oxygen therapy, days",6,6,"nHFV versus nIPPV","or","binary",3,0.01427145597935,1.15815224823082,0,2020.33333333333,0,404
"CD012712","CD012712_pub2_data","6|7|Chronic lung disease at 36 weeks|nHFV versus nCPAP","Chronic lung disease at 36 weeks",6,7,"nHFV versus nCPAP","or","binary",10,-0.569214227345312,0.208950148113272,0.111784059879728,2019.3,0.233661949091855,182.9
"CD012712","CD012712_pub2_data","6|7|Chronic lung disease at 36 weeks|nHFV versus nIPPV","Chronic lung disease at 36 weeks",6,7,"nHFV versus nIPPV","or","binary",4,-0.190328158760832,0.125464819754855,0,2018.75,0.301883865248227,309
"CD012712","CD012712_pub2_data","6|8|Death or chronic lung disease at 36 weeks|nHFV versus nCPAP","Death or chronic lung disease at 36 weeks",6,8,"nHFV versus nCPAP","or","binary",2,-0.165027916843563,0.132787126509355,0,2019,0.446875,483
"CD012712","CD012712_pub2_data","6|8|Death or chronic lung disease at 36 weeks|nHFV versus nIPPV","Death or chronic lung disease at 36 weeks",6,8,"nHFV versus nIPPV","or","binary",3,-0.128290892645599,0.126689117855454,0,2018,0.432138242894057,356.666666666667
"CD012712","CD012712_pub2_data","6|9|Patent ductus arteriosus|nHFV versus nCPAP","Patent ductus arteriosus",6,9,"nHFV versus nCPAP","or","binary",3,-0.0166964420070407,0.12085387024935,0,2019.66666666667,0.35217528517983,419.333333333333
"CD012712","CD012712_pub2_data","6|9|Patent ductus arteriosus|nHFV versus nIPPV","Patent ductus arteriosus",6,9,"nHFV versus nIPPV","or","binary",3,-0.18979810505171,0.130771539705428,0,2018,0.33778073286052,358.666666666667
"CD012712","CD012712_pub2_data","7|1|Mortality before hospital discharge|nHFV versus nCPAP - nHFV Hz < 10","Mortality before hospital discharge",7,1,"nHFV versus nCPAP - nHFV Hz < 10","or","binary",2,0.378182079231206,0.533818672280374,0,2019,0.00520833333333333,483
"CD012712","CD012712_pub2_data","7|1|Mortality before hospital discharge|nHFV versus nCPAP - nHFV Hz ≥ 10","Mortality before hospital discharge",7,1,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,-0.360387801501891,0.508205135763048,0,2018,0.0675877520537715,141
"CD012712","CD012712_pub2_data","7|1|Mortality before hospital discharge|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Mortality before hospital discharge",7,1,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",3,-0.452235579239754,0.638877431616845,0,2017.66666666667,0.0471464019851117,49
"CD012712","CD012712_pub2_data","7|1|Mortality before hospital discharge|nHFV versus nCPAP - preterm infants","Mortality before hospital discharge",7,1,"nHFV versus nCPAP - preterm infants","or","binary",6,-0.0892338836531334,0.297094759754823,0,2018.33333333333,0.0551329924964802,237.833333333333
"CD012712","CD012712_pub2_data","7|2|Endotracheal reintubation|nHFV versus nCPAP - nHFV Hz < 10","Endotracheal reintubation",7,2,"nHFV versus nCPAP - nHFV Hz < 10","or","binary",2,-0.834402735592758,0.169671011539235,0,2019,0.628125,483
"CD012712","CD012712_pub2_data","7|2|Endotracheal reintubation|nHFV versus nCPAP - nHFV Hz ≥ 10","Endotracheal reintubation",7,2,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,-1.12005424591371,0.279030165532821,0,2018,0.451954194672641,141
"CD012712","CD012712_pub2_data","7|2|Endotracheal reintubation|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Endotracheal reintubation",7,2,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",3,-1.34976646516005,0.369776383257362,0,2017.66666666667,0.650399779432038,49
"CD012712","CD012712_pub2_data","7|2|Endotracheal reintubation|nHFV versus nCPAP - nHFV MAP ≥ 10 cm H2O","Endotracheal reintubation",7,2,"nHFV versus nCPAP - nHFV MAP ≥ 10 cm H2O","or","binary",2,-1.59833617365645,0.663026839336343,0.669792775083652,2020,0.43586035942987,149
"CD012712","CD012712_pub2_data","7|2|Endotracheal reintubation|nHFV versus nCPAP - preterm infants","Endotracheal reintubation",7,2,"nHFV versus nCPAP - preterm infants","or","binary",10,-1.16966039556111,0.163266014133921,0.0524231469132168,2019.4,0.41979182460866,181.7
"CD012712","CD012712_pub2_data","7|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV Hz < 10","Chronic lung disease at 36 weeks",7,4,"nHFV versus nCPAP - nHFV Hz < 10","or","binary",2,-0.194425169147362,0.133854377770211,0,2019,0.441666666666667,483
"CD012712","CD012712_pub2_data","7|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV Hz ≥ 10","Chronic lung disease at 36 weeks",7,4,"nHFV versus nCPAP - nHFV Hz ≥ 10","or","binary",2,-0.557248664442546,0.495198118715884,0,2018,0.0932287776947971,141
"CD012712","CD012712_pub2_data","7|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV MAP < 10 cm H2O","Chronic lung disease at 36 weeks",7,4,"nHFV versus nCPAP - nHFV MAP < 10 cm H2O","or","binary",3,-0.424628864976198,0.571962567753379,0,2017.66666666667,0.220154397573752,49
"CD012712","CD012712_pub2_data","7|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV MAP ≥ 10 cm H2O","Chronic lung disease at 36 weeks",7,4,"nHFV versus nCPAP - nHFV MAP ≥ 10 cm H2O","or","binary",2,-1.13959259712409,0.368558500213047,0,2020,0.337636851890105,149
"CD012712","CD012712_pub2_data","7|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP - preterm infants","Chronic lung disease at 36 weeks",7,4,"nHFV versus nCPAP - preterm infants","or","binary",9,-0.576346393695906,0.216993191883199,0.121523961326609,2019.22222222222,0.254068832324283,194.333333333333
"CD012712","CD012712_pub2_data","7|5|Death or chronic lung disease at 36 weeks|nHFV versus nCPAP - nHFV Hz < 10","Death or chronic lung disease at 36 weeks",7,5,"nHFV versus nCPAP - nHFV Hz < 10","or","binary",2,-0.165027916843563,0.132787126509355,0,2019,0.446875,483
"CD012712","CD012712_pub2_data","7|5|Death or chronic lung disease at 36 weeks|nHFV versus nCPAP - preterm infants","Death or chronic lung disease at 36 weeks",7,5,"nHFV versus nCPAP - preterm infants","or","binary",2,-0.165027916843563,0.132787126509355,0,2019,0.446875,483
"CD012712","CD012712_pub2_data","7|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP - preterm infants","Intraventricular haemorrhage, Papile grade 3/4",7,6,"nHFV versus nCPAP - preterm infants","or","binary",3,-0.248922460758896,0.195623630427283,0,2019,0.0615948867536033,372.333333333333
"CD012712","CD012712_pub2_data","8|1|Mortality before hospital discharge|nHFV versus nIPPV - preterm infants","Mortality before hospital discharge",8,1,"nHFV versus nIPPV - preterm infants","or","binary",2,0.586284610160678,0.497847847664484,0,2016.5,0.0875,492
"CD012712","CD012712_pub2_data","8|2|Endotracheal reintubation|nHFV versus nIPPV - nHFV Hz ≥ 10","Endotracheal reintubation",8,2,"nHFV versus nIPPV - nHFV Hz ≥ 10","or","binary",2,-0.102898311277393,0.454138201980289,0,2017.5,0.301356589147287,55
"CD012712","CD012712_pub2_data","8|2|Endotracheal reintubation|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Endotracheal reintubation",8,2,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",2,-0.102898311277393,0.454138201980289,0,2017.5,0.301356589147287,55
"CD012712","CD012712_pub2_data","8|2|Endotracheal reintubation|nHFV versus nIPPV - nHFV MAP ≥ 10 cm H2O","Endotracheal reintubation",8,2,"nHFV versus nIPPV - nHFV MAP ≥ 10 cm H2O","or","binary",2,-1.39456201912205,0.5056829997555,0,2020,0.294326241134752,67
"CD012712","CD012712_pub2_data","8|2|Endotracheal reintubation|nHFV versus nIPPV - preterm infants","Endotracheal reintubation",8,2,"nHFV versus nIPPV - preterm infants","or","binary",6,-0.412039244518249,0.154280201161843,3.52675261590732e-07,2019.16666666667,0.240227610094013,227.333333333333
"CD012712","CD012712_pub2_data","8|3|Chronic lung disease at 36 weeks|nHFV versus nIPPV - preterm infants","Chronic lung disease at 36 weeks",8,3,"nHFV versus nIPPV - preterm infants","or","binary",4,-0.190328158760832,0.125464819754855,0,2018.75,0.301883865248227,309
"CD012712","CD012712_pub2_data","8|4|Death or chronic lung disease at 36 weeks|nHFV versus nIPPV - nHFV Hz ≥ 10","Death or chronic lung disease at 36 weeks",8,4,"nHFV versus nIPPV - nHFV Hz ≥ 10","or","binary",2,-0.0807913354829187,0.402054525485048,0,2017.5,0.454457364341085,55
"CD012712","CD012712_pub2_data","8|4|Death or chronic lung disease at 36 weeks|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Death or chronic lung disease at 36 weeks",8,4,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",2,-0.0807913354829187,0.402054525485048,0,2017.5,0.454457364341085,55
"CD012712","CD012712_pub2_data","8|4|Death or chronic lung disease at 36 weeks|nHFV versus nIPPV - preterm infants","Death or chronic lung disease at 36 weeks",8,4,"nHFV versus nIPPV - preterm infants","or","binary",3,-0.128290892645599,0.126689117855454,0,2018,0.432138242894057,356.666666666667
"CD012712","CD012712_pub2_data","8|5|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nIPPV - nHFV Hz ≥ 10","Intraventricular haemorrhage, Papile grade 3/4",8,5,"nHFV versus nIPPV - nHFV Hz ≥ 10","or","binary",2,-0.783115433658521,0.751413076020076,0,2017.5,0.148255813953488,55
"CD012712","CD012712_pub2_data","8|5|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nIPPV - nHFV MAP < 10 cm H2O","Intraventricular haemorrhage, Papile grade 3/4",8,5,"nHFV versus nIPPV - nHFV MAP < 10 cm H2O","or","binary",2,-0.783115433658521,0.751413076020076,0,2017.5,0.148255813953488,55
"CD012712","CD012712_pub2_data","8|5|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nIPPV - preterm infants","Intraventricular haemorrhage, Papile grade 3/4",8,5,"nHFV versus nIPPV - preterm infants","or","binary",4,-0.270850489165394,0.192857140209313,0,2018.75,0.120814520451921,290.5
"CD012712","CD012712_pub2_data","9|1|Mortality before hospital discharge|nHFV versus nCPAP","Mortality before hospital discharge",9,1,"nHFV versus nCPAP","or","binary",4,-0.0092463655355336,0.368077274728741,0,2018.5,0.0363980426935524,312
"CD012712","CD012712_pub2_data","9|2|Endotracheal reintubation|nHFV versus nCPAP","Endotracheal reintubation",9,2,"nHFV versus nCPAP","or","binary",5,-1.2432643391841,0.283034170492466,0.187176463322742,2019,0.538414656592461,268
"CD012712","CD012712_pub2_data","9|2|Endotracheal reintubation|nHFV versus nIPPV","Endotracheal reintubation",9,2,"nHFV versus nIPPV","or","binary",3,-0.385336697016105,0.164727282577082,3.47891578095536e-08,2020.33333333333,0.205455220188026,379.333333333333
"CD012712","CD012712_pub2_data","9|4|Chronic lung disease at 36 weeks|nHFV versus nCPAP","Chronic lung disease at 36 weeks",9,4,"nHFV versus nCPAP","or","binary",5,-0.596208415588143,0.306873224322317,0.194143351142952,2019,0.337362433063734,268
"CD012712","CD012712_pub2_data","9|4|Chronic lung disease at 36 weeks|nHFV versus nIPPV","Chronic lung disease at 36 weeks",9,4,"nHFV versus nIPPV","or","binary",2,-0.184513421009931,0.128674452424634,0,2020,0.370434397163121,526
"CD012712","CD012712_pub2_data","9|5|Death or chronic lung disease at 36 weeks|nHFV versus nCPAP","Death or chronic lung disease at 36 weeks",9,5,"nHFV versus nCPAP","or","binary",2,-0.165027916843563,0.132787126509355,0,2019,0.446875,483
"CD012712","CD012712_pub2_data","9|5|Death or chronic lung disease at 36 weeks|nHFV versus nIPPV","Death or chronic lung disease at 36 weeks",9,5,"nHFV versus nIPPV","or","binary",2,-0.139697929866258,0.128270384559619,0,2020,0.356540697674419,523
"CD012712","CD012712_pub2_data","9|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nCPAP","Intraventricular haemorrhage, Papile grade 3/4",9,6,"nHFV versus nCPAP","or","binary",2,-0.273322687707557,0.199022022793819,0,2020,0.0762632978723404,526
"CD012712","CD012712_pub2_data","9|6|Intraventricular haemorrhage, Papile grade 3/4|nHFV versus nIPPV","Intraventricular haemorrhage, Papile grade 3/4",9,6,"nHFV versus nIPPV","or","binary",3,-0.245072790865996,0.1960690880908,0,2020.33333333333,0.0777526939358953,379.333333333333
"CD012718","CD012718_pub2_data","2|1|Caries arrest (at end of study follow-up)|Primary dentition","Caries arrest (at end of study follow-up)",2,1,"Primary dentition","reported","reported",3,0,0.241654315394944,0,2016.33333333333,0,124
"CD012718","CD012718_pub2_data","3|3|Caries arrest (at end of study follow-up)|Primary dentition ","Caries arrest (at end of study follow-up)",3,3,"Primary dentition ","or","binary",2,-0.645279203108613,1.41924200638344,0,2018,0,154.5
"CD012718","CD012718_pub2_data","3|4|Caries arrest (at end of study follow-up)|","Caries arrest (at end of study follow-up)",3,4,"","reported","reported",3,0.408959040979512,0.232820302355874,0.137187695627736,2018.66666666667,NA,0
"CD012718","CD012718_pub2_data","3|5|Secondary prevention of caries (at end of study follow-up)|Primary dentition","Secondary prevention of caries (at end of study follow-up)",3,5,"Primary dentition","or","binary",2,-0.645279203108613,1.41924200638344,0,2018,0,154.5
"CD012718","CD012718_pub2_data","3|8|Adverse effects|","Adverse effects",3,8,"","reported","reported",2,0,0.346947967068235,0,2018,0.330188679245283,154.5
"CD012757","CD012757_pub2_data","1|10|Tumour response measures after treatment (progressive disease)|NA","Tumour response measures after treatment (progressive disease)",1,10,NA,"or","binary",3,-1.26221611365795,0.42019732647541,0,2014,0.25,78
"CD012757","CD012757_pub2_data","1|3|Mortality at 24 months' follow-up|NA","Mortality at 24 months' follow-up",1,3,NA,"or","binary",3,-0.917377458206822,0.289112200280638,0,2014,0.764285714285714,78
"CD012757","CD012757_pub2_data","1|4|Mortality at 36 months' follow-up|NA","Mortality at 36 months' follow-up",1,4,NA,"or","binary",2,-1.74938644781317,0.605700331716729,0,2012.5,0.957142857142857,77
"CD012757","CD012757_pub2_data","1|6|Tumour response measures after treatment (overall response rate = complete response + partial response)|NA","Tumour response measures after treatment (overall response rate = complete response + partial response)",1,6,NA,"or","binary",3,1.45725581288411,0.294727899852854,1.48643740084948e-06,2014,0.426190476190476,78
"CD012757","CD012757_pub2_data","1|7|Tumour response measures after treatment (complete response)|NA","Tumour response measures after treatment (complete response)",1,7,NA,"or","binary",2,0.552033048735529,0.376593375691519,0,2015,0.235714285714286,82
"CD012757","CD012757_pub2_data","1|8|Tumour response measures after treatment (partial response)|NA","Tumour response measures after treatment (partial response)",1,8,NA,"or","binary",2,0.68048616254958,0.328557645050376,0,2015,0.303571428571429,82
"CD012757","CD012757_pub2_data","1|9|Tumour response measures after treatment (stable disease)|NA","Tumour response measures after treatment (stable disease)",1,9,NA,"or","binary",3,-0.891706764206535,0.318618901117339,0,2014,0.323809523809524,78
"CD012850","CD012850_pub2_data","1|17|Frequency of joint noise|Long term","Frequency of joint noise",1,17,"Long term","or","binary",2,-0.641740080316838,0.624915940359226,0.189951934991578,2006,0.666666666666667,38
"CD012850","CD012850_pub2_data","1|17|Frequency of joint noise|Short term","Frequency of joint noise",1,17,"Short term","or","binary",3,0.0587820275516331,0.380223308206224,0,2004.66666666667,0.443874643874644,47
"CD012850","CD012850_pub2_data","3|13|Participant satisfaction or quality of life|Short term","Participant satisfaction or quality of life",3,13,"Short term","or","binary",2,-0.0656415898044089,1.43319124084227,0,2020,0,37.5
"CD012850","CD012850_pub2_data","3|19|Range of mandibular motion (maximum assisted (mandibular opening)|Short term","Range of mandibular motion (maximum assisted (mandibular opening)",3,19,"Short term","or","binary",2,-0.0450209434432283,1.43865305825935,0,2014.5,0,30.5
"CD012850","CD012850_pub2_data","3|23|Range of mandibular motion (unassisted (mandibular) opening without pain)|Short term","Range of mandibular motion (unassisted (mandibular) opening without pain)",3,23,"Short term","or","binary",2,-0.0450209434432283,1.43865305825935,0,2014.5,0,30.5
"CD012850","CD012850_pub2_data","4|2|Participant satisfaction or quality of life|Short term","Participant satisfaction or quality of life",4,2,"Short term","or","binary",2,-0.114642058246679,1.43361123638825,0,2020,0,36.5
"CD012850","CD012850_pub2_data","5|3|Range of mandibular motion (unassisted opening without pain)|Short term","Range of mandibular motion (unassisted opening without pain)",5,3,"Short term","or","binary",2,-0.0355322964379518,1.43530045438162,0,2018.5,0,33.5
"CD012886","CD012886_pub3_data","1|10|Outcome 10 Intensity of musculoskeletal symptoms (discomfort - left shoulder/upper arm)|NA","Outcome 10 Intensity of musculoskeletal symptoms (discomfort - left shoulder/upper arm)",1,10,NA,"reported","reported",2,-0.113903941277888,0.482439693868465,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","1|13|Outcome 13 Intensity of musculoskeletal symptoms (discomfort - forearms/wrists)|NA","Outcome 13 Intensity of musculoskeletal symptoms (discomfort - forearms/wrists)",1,13,NA,"reported","reported",2,-0.0337085160267824,0.327349093144387,0,2010.5,NA,19.5
"CD012886","CD012886_pub3_data","1|14|Outcome 14 Intensity of musculoskeletal symptoms (discomfort - right forearm/wrist/hand)|NA","Outcome 14 Intensity of musculoskeletal symptoms (discomfort - right forearm/wrist/hand)",1,14,NA,"reported","reported",2,-0.111143383671155,0.57215636949971,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","1|16|Outcome 16 Intensity of musculoskeletal symptoms (discomfort - buttocks)|NA","Outcome 16 Intensity of musculoskeletal symptoms (discomfort - buttocks)",1,16,NA,"reported","reported",2,-0.0941005614869564,0.382944945252857,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","1|17|Outcome 17 Intensity of musculoskeletal symptoms (discomfort - legs)|NA","Outcome 17 Intensity of musculoskeletal symptoms (discomfort - legs)",1,17,NA,"reported","reported",2,-0.0499129077340953,0.178210859112706,0,2013.5,NA,63
"CD012886","CD012886_pub3_data","1|18|Outcome 18 Productivity or work performance (productivity - keystrokes per hour)|NA","Outcome 18 Productivity or work performance (productivity - keystrokes per hour)",1,18,NA,"reported","reported",2,263.410276597129,2569.3772377949,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","1|19|Outcome 19 Productivity or work performance (productivity - entered documents per day)|NA","Outcome 19 Productivity or work performance (productivity - entered documents per day)",1,19,NA,"reported","reported",2,-7.48187354138439,182.241460200756,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","1|6|Outcome 6 Intensity of musculoskeletal symptoms (discomfort - neck)|NA","Outcome 6 Intensity of musculoskeletal symptoms (discomfort - neck)",1,6,NA,"reported","reported",5,-0.148063318238282,0.10692641751493,0,2009.8,NA,74.4
"CD012886","CD012886_pub3_data","1|7|Outcome 7 Intensity of musculoskeletal symptoms (discomfort - back)|NA","Outcome 7 Intensity of musculoskeletal symptoms (discomfort - back)",1,7,NA,"reported","reported",5,-0.035575724895704,0.106752575535018,0,2009.8,NA,74.4
"CD012886","CD012886_pub3_data","1|8|Outcome 8 Intensity of musculoskeletal symptoms (discomfort - shoulders)|NA","Outcome 8 Intensity of musculoskeletal symptoms (discomfort - shoulders)",1,8,NA,"reported","reported",2,-0.305704380570103,0.364025794751374,0.0408815842563596,2010.5,NA,19.5
"CD012886","CD012886_pub3_data","1|9|Outcome 9 Intensity of musculoskeletal symptoms (discomfort - right shoulder/upper arm)|NA","Outcome 9 Intensity of musculoskeletal symptoms (discomfort - right shoulder/upper arm)",1,9,NA,"reported","reported",2,-0.129158664502964,0.518374128822179,0,2003.5,NA,93
"CD012886","CD012886_pub3_data","3|1|Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)|NA","Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)",3,1,NA,"reported","reported",2,-0.226155686467838,0.166397030761196,0,2020,NA,73
"CD012886","CD012886_pub3_data","4|1|Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)|NA","Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)",4,1,NA,"reported","reported",2,-0.181972226605915,0.19972975538905,0.0190194500420682,2020,NA,70.5
"CD012886","CD012886_pub3_data","5|1|Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)|NA","Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)",5,1,NA,"reported","reported",2,-0.0323447189300988,0.171283613804124,0,2020,NA,68.5
"CD012891","CD012891_pub2_data","1|3|Standard controlled ovarian hyperstimulation with gonadotropins + letrozole versus standard controlled ovarian hyperstimulation with gonadotropins + tamoxifen: number of oocytes retrieved after ovarian stimulation|","Standard controlled ovarian hyperstimulation with gonadotropins + letrozole versus standard controlled ovarian hyperstimulation with gonadotropins + tamoxifen: number of oocytes retrieved after ovarian stimulation",1,3,"","reported","reported",2,0,1.3671054014779,0,NA,0,101.5
"CD012891","CD012891_pub2_data","3|1|Ovarian insufficiency grouped by strict or broad definition|Ovarian insufficiency, broad definition","Ovarian insufficiency grouped by strict or broad definition",3,1,"Ovarian insufficiency, broad definition","or","binary",8,-0.945460372818785,0.400913903735296,0.770645791714728,2012,0.522888761565232,89.125
"CD012891","CD012891_pub2_data","3|3|Live birth|","Live birth",3,3,"","or","binary",4,0.483625357871815,0.323043300368721,0,NA,0.0421877703107326,149.75
"CD012891","CD012891_pub2_data","3|7|Clinical pregnancy|","Clinical pregnancy",3,7,"","or","binary",7,0.521744333486542,0.253669830197563,0,2012,0.056346869095192,133.285714285714
"CD012891","CD012891_pub2_data","3|8|Clinical pregnancy grouped by receptor status|Clinical pregnancy in hormone-receptor-negative patients","Clinical pregnancy grouped by receptor status",3,8,"Clinical pregnancy in hormone-receptor-negative patients","reported","reported",5,0,0.283211110894936,0,NA,0.0711783319924913,85.8
"CD012891","CD012891_pub2_data","4|1|Ovarian insufficiency grouped by strict or broad definition|Ovarian insufficiency, any definition","Ovarian insufficiency grouped by strict or broad definition",4,1,"Ovarian insufficiency, any definition","or","binary",5,-1.77609559118713,1.02540881120869,3.78318945290617,NA,0.408461538461538,38.4
"CD012891","CD012891_pub2_data","4|4|Clinical pregnancy|","Clinical pregnancy",4,4,"","or","binary",3,-0.103951214853289,0.667612177149329,0.390847026400222,NA,0.220634920634921,38
"CD012905","CD012905_pub2_data","1|1|Development of AKI|All populations","Development of AKI",1,1,"All populations","reported","reported",8,0,0.0963399418533032,0,2005.25,0.291425719849367,143.375
"CD012905","CD012905_pub2_data","1|1|Development of AKI|Patients undergoing cardiac surgery","Development of AKI",1,1,"Patients undergoing cardiac surgery","or","binary",4,-0.830675751195784,0.263052127151151,6.67186101705849e-06,2007.5,0.352400278293135,98.5
"CD012905","CD012905_pub2_data","1|2|Need for kidney replacement therapy|All populations","Need for kidney replacement therapy",1,2,"All populations","reported","reported",6,0,0.43554985500401,0,2006.83333333333,0.0504776184369189,131.666666666667
"CD012905","CD012905_pub2_data","1|2|Need for kidney replacement therapy|Patients undergoing cardiac surgery","Need for kidney replacement therapy",1,2,"Patients undergoing cardiac surgery","or","binary",5,-0.531003081982242,0.673680713853484,0.618550868737475,2007.6,0.0523791621911923,86.8
"CD012905","CD012905_pub2_data","1|3|Death|All populations","Death",1,3,"All populations","reported","reported",5,0,0.13943640016895,0,2005.6,0.130566449568738,163.8
"CD012905","CD012905_pub2_data","1|4|Change in serum creatinine from baseline|","Change in serum creatinine from baseline",1,4,"","or","binary",9,0.00458744273444394,0.670820261658905,0,2004.77777777778,0,131.333333333333
"CD012905","CD012905_pub2_data","1|5|Change in urine output from baseline|","Change in urine output from baseline",1,5,"","or","binary",2,-0.0669799753415408,1.43771719692233,0,2001.5,0,29
"CD012905","CD012905_pub2_data","1|6|Duration of ICU stay [days]|","Duration of ICU stay [days]",1,6,"","or","binary",5,0.00622438352455728,0.899503389026332,0,2007,0,140.6
"CD012905","CD012905_pub2_data","1|8|Sensitivity analysis: development of AKI based on risk of attrition bias|Low risk of attrition bias","Sensitivity analysis: development of AKI based on risk of attrition bias",1,8,"Low risk of attrition bias","or","binary",7,-0.698413599369042,0.172781378604261,2.23965591430954e-06,2005.85714285714,0.290005127968748,123.428571428571
"CD012905","CD012905_pub2_data","2|1|Development of AKI|All studies","Development of AKI",2,1,"All studies","reported","reported",4,0,0.192493947680826,0,2005.75,0.313541666666667,99.5
"CD012905","CD012905_pub2_data","2|1|Development of AKI|Excluding Caimmi 2003","Development of AKI",2,1,"Excluding Caimmi 2003","or","binary",3,-0.124761906492851,0.300278837879507,0,2006.66666666667,0.313888888888889,79.3333333333333
"CD012905","CD012905_pub2_data","2|2|Need for kidney replacement therapy|","Need for kidney replacement therapy",2,2,"","or","binary",4,-0.290583801876356,0.469473567351587,0,2004.5,0.0545833333333333,108.5
"CD012905","CD012905_pub2_data","2|3|Death|","Death",2,3,"","or","binary",2,0.210113848722471,0.631709286322577,0,2004.5,0.0479166666666667,87
"CD012905","CD012905_pub2_data","2|4|Change in serum creatinine from baseline [mg/dL]|","Change in serum creatinine from baseline [mg/dL]",2,4,"","or","binary",6,-0.00986432803393115,0.821912256792306,0,2005.5,0,89.3333333333333
"CD012905","CD012905_pub2_data","2|5|Duration of ICU stay [days]|","Duration of ICU stay [days]",2,5,"","or","binary",2,0.021010641885824,1.42011721716647,0,2003.5,0,127
"CD012905","CD012905_pub2_data","3|1|Development of AKI|","Development of AKI",3,1,"","or","binary",3,0.579997988875627,0.398457520505519,0.142263574376183,2004,0.110883751605401,119.666666666667
"CD012905","CD012905_pub2_data","3|2|Need for kidney replacement therapy|","Need for kidney replacement therapy",3,2,"","or","binary",2,-0.0176330263523325,0.905144869935525,0,2006,0.05,68.5
"CD012905","CD012905_pub2_data","3|4|Change in serum creatinine from baseline [mg/dL]|","Change in serum creatinine from baseline [mg/dL]",3,4,"","or","binary",2,0.130617099824548,1.42259579987001,0,2004,0,83.5
"CD012905","CD012905_pub2_data","4|1|Need for kidney replacement therapy|","Need for kidney replacement therapy",4,1,"","or","binary",2,-0.116125040364244,0.33081237990666,0.136025600520696,2007.5,0.217852077001013,411
"CD012905","CD012905_pub2_data","4|2|Death|","Death",4,2,"","or","binary",2,-0.262315850964165,0.373628409844822,0.192847495909787,2007.5,0.239128672745694,411
"CD012905","CD012905_pub2_data","4|3|Adverse events|Hypotension","Adverse events",4,3,"Hypotension","or","binary",2,0.602596172106172,0.184864030981443,0,2007.5,0.12113475177305,411
"CD012925","CD012925_pub2_data","1|1|Provider adherence to recommended practice (dichotomous outcomes)|Counselled to initiate complementary food at six months","Provider adherence to recommended practice (dichotomous outcomes)",1,1,"Counselled to initiate complementary food at six months","reported","reported",2,0.116427963596662,0.0177139911269364,0,2019,0,2198.5
"CD012925","CD012925_pub2_data","1|1|Provider adherence to recommended practice (dichotomous outcomes)|Counselled to initiate complementary food at six months (non-randomised)","Provider adherence to recommended practice (dichotomous outcomes)",1,1,"Counselled to initiate complementary food at six months (non-randomised)","reported","reported",2,0.116991098868487,0.026878235859014,0,2022,0,880.5
"CD012925","CD012925_pub2_data","1|1|Provider adherence to recommended practice (dichotomous outcomes)|Home visit in the first week after delivery","Provider adherence to recommended practice (dichotomous outcomes)",1,1,"Home visit in the first week after delivery","reported","reported",2,0.104249545482602,0.0182820231950322,0,2019,0,2275.5
"CD012925","CD012925_pub2_data","1|1|Provider adherence to recommended practice (dichotomous outcomes)|Home visit within 24 hours of delivery","Provider adherence to recommended practice (dichotomous outcomes)",1,1,"Home visit within 24 hours of delivery","reported","reported",2,0.0726840807900238,0.0687722135884517,0.007838627472,2019,0,2286
"CD012925","CD012925_pub2_data","1|3|Client's health behaviour|At least 90 iron-folic acid tablets consumed during pregnancy (RCTs)","Client's health behaviour",1,3,"At least 90 iron-folic acid tablets consumed during pregnancy (RCTs)","reported","reported",2,0.0297960707667707,0.0192755184418458,0,2019,0,2288
"CD012925","CD012925_pub2_data","1|3|Client's health behaviour|Early initiation of breastfeeding","Client's health behaviour",1,3,"Early initiation of breastfeeding","reported","reported",2,0.0824044579276109,0.0173953130739482,0,2019,0,2288
"CD012925","CD012925_pub2_data","1|3|Client's health behaviour|Exclusive breastfeeding for 6 months","Client's health behaviour",1,3,"Exclusive breastfeeding for 6 months","reported","reported",2,0.093907474770966,0.0567416000898747,0.00429801976,2019,0,2170
"CD012925","CD012925_pub2_data","1|7|Client utilisation of primary healthcare and/or services (risk difference)|Full childhood immunisation (RCTs)","Client utilisation of primary healthcare and/or services (risk difference)",1,7,"Full childhood immunisation (RCTs)","reported","reported",3,0.0133885581385678,0.0179909292190399,0,2018,0,1534
"CD012925","CD012925_pub2_data","1|7|Client utilisation of primary healthcare and/or services (risk difference)|Women gave birth in a health facility","Client utilisation of primary healthcare and/or services (risk difference)",1,7,"Women gave birth in a health facility","reported","reported",2,-0.00944548389187704,0.0166947703477948,0,2019,0,2417
"CD012925","CD012925_pub2_data","1|8|Client utilisation of primary health care and/or services (odds ratio)|At least three antenatal care visits","Client utilisation of primary health care and/or services (odds ratio)",1,8,"At least three antenatal care visits","reported","reported",2,0.322723979018844,0.0223681717931193,0,2017.5,0,1267.5
"CD012925","CD012925_pub2_data","1|8|Client utilisation of primary health care and/or services (odds ratio)|Women giving birth in a health facility non randomised  (Prinja, Ilozumba)","Client utilisation of primary health care and/or services (odds ratio)",1,8,"Women giving birth in a health facility non randomised  (Prinja, Ilozumba)","reported","reported",2,0.0970706161137441,0.264879197519864,0.11084368,2017.5,0,1268
"CD012925","CD012925_pub2_data","3|5|Patient/client health status and well-being (continuous outcomes)|Mean change in body mass index (BMI)","Patient/client health status and well-being (continuous outcomes)",3,5,"Mean change in body mass index (BMI)","reported","reported",2,-0.363448946353105,0.43219315308193,0,2019,0,5983
"CD012925","CD012925_pub2_data","3|5|Patient/client health status and well-being (continuous outcomes)|Mean change in systolic blood pressure (SBP)","Patient/client health status and well-being (continuous outcomes)",3,5,"Mean change in systolic blood pressure (SBP)","reported","reported",2,0.289157689312081,1.45003958962355,0,2019,0,5983
"CD012942","CD012942_pub2_data","1|1|Comparison 1 All antidepressants versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|","Comparison 1 All antidepressants versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,1,"","reported","reported",4,0,0.0780329457601527,0,2009.75,0.414396756815882,245
"CD012942","CD012942_pub2_data","1|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,2,"Other","reported","reported",2,0,0.0599793093513046,0,2014.5,0.419160788450129,502.5
"CD012942","CD012942_pub2_data","1|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,2,"SNRIs","reported","reported",14,0,0.0322268732293384,0,2006.21428571429,0.409940776925002,332.785714285714
"CD012942","CD012942_pub2_data","1|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,2,"SSRIs","reported","reported",4,0,0.0525388837193302,0,2008,0.390667277233381,306.5
"CD012942","CD012942_pub2_data","1|4|Comparison 4 Duloxetine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|","Comparison 4 Duloxetine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,4,"","or","binary",6,0.629073751413903,0.135052484532128,0.0572985409936296,2009.33333333333,0.39623129308658,345
"CD012942","CD012942_pub2_data","1|6|Comparison 6 Sertraline versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A|","Comparison 6 Sertraline versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A",1,6,"","or","binary",2,0.781794420567037,0.338970117050734,0.181139892806496,2005,0.387017336485422,348
"CD012942","CD012942_pub2_data","10|1|Comparison 1 All antidepressants versus placebo, Outcome 10 Average score/change in quality of life/satisfaction|","Comparison 1 All antidepressants versus placebo, Outcome 10 Average score/change in quality of life/satisfaction",10,1,"","reported","reported",3,0,0.98195975002112,0,2007.33333333333,0,224.333333333333
"CD012942","CD012942_pub2_data","10|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 10 Average score/change in quality of life/satisfaction|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 10 Average score/change in quality of life/satisfaction",10,2,"SSRIs","reported","reported",3,0,0.841378679716877,0,2005.66666666667,0,253.333333333333
"CD012942","CD012942_pub2_data","11|1|Comparison 1 All antidepressants versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 1 All antidepressants versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,1,"","reported","reported",3,0,0.46489404696424,0,2006,0.0337509637481425,418.333333333333
"CD012942","CD012942_pub2_data","11|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,2,"Other","reported","reported",2,0,0.552751786903704,0,2014.5,0.0152641060284372,511.5
"CD012942","CD012942_pub2_data","11|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,2,"SNRIs","reported","reported",13,0,0.135126050618954,0,2006.38461538462,0.08700259506647,367.307692307692
"CD012942","CD012942_pub2_data","11|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,2,"SSRIs","reported","reported",14,0,0.176205776815789,0,2004.64285714286,0.0438655308754927,345.142857142857
"CD012942","CD012942_pub2_data","11|3|Comparison 3 Agomelatine versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 3 Agomelatine versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,3,"","or","binary",3,-0.851977975495653,0.403120015139037,0.25332500898278,2013,0.12016937988376,267.666666666667
"CD012942","CD012942_pub2_data","11|5|Comparison 5 Escitalopram versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 5 Escitalopram versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,5,"","or","binary",7,-0.745292275499815,0.269853159480598,0.0842597159436131,2005.57142857143,0.0568472129559476,310.571428571429
"CD012942","CD012942_pub2_data","11|6|Comparison 6 Paroxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 6 Paroxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,6,"","or","binary",6,-0.369665150027307,0.268203468160631,3.7797909696804e-07,2003.66666666667,0.0333549909819937,349.666666666667
"CD012942","CD012942_pub2_data","11|7|Comparison 7 Sertraline versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 7 Sertraline versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,7,"","or","binary",2,-0.504601738004247,0.526317291577538,0,2005,0.0260141093474427,349.5
"CD012942","CD012942_pub2_data","11|8|Comparison 8 Venlafaxine versus placebo, Outcome 11 Dropouts due to a lack of efficacy|","Comparison 8 Venlafaxine versus placebo, Outcome 11 Dropouts due to a lack of efficacy",11,8,"","or","binary",9,-1.03675928810739,0.173987242391623,0,2004.77777777778,0.0891834799782564,334.222222222222
"CD012942","CD012942_pub2_data","12|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects",12,2,"Other","reported","reported",2,0,0.328826470691937,0,2014.5,0.0304156211799524,511.5
"CD012942","CD012942_pub2_data","12|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects",12,2,"SNRIs","reported","reported",14,0,0.0997297124744476,0,2005.85714285714,0.0665197615681331,362.714285714286
"CD012942","CD012942_pub2_data","12|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects",12,2,"SSRIs","reported","reported",16,0,0.119080603627236,0,2004.6875,0.0429548776418454,332.1875
"CD012942","CD012942_pub2_data","12|3|Comparison 3 Agomelatine versus placebo, Outcome 12 Dropouts due to adverse effects|","Comparison 3 Agomelatine versus placebo, Outcome 12 Dropouts due to adverse effects",12,3,"","or","binary",3,0.0851750160722531,0.542842555712247,0,2013,0.0125255348887216,267.666666666667
"CD012942","CD012942_pub2_data","12|4|Comparison 4 Duloxetine versus placebo, Outcome 12 Dropouts due to adverse effects|","Comparison 4 Duloxetine versus placebo, Outcome 12 Dropouts due to adverse effects",12,4,"","or","binary",7,1.20947839041715,0.262695414776874,0.2752509518001,2009.28571428571,0.0497339230911898,346.428571428571
"CD012942","CD012942_pub2_data","12|6|Comparison 6 Paroxetine versus placebo, Outcome 12 Dropouts due to adverse effects|","Comparison 6 Paroxetine versus placebo, Outcome 12 Dropouts due to adverse effects",12,6,"","or","binary",7,0.895459758834784,0.194890932332031,0.0309226349027419,2003.85714285714,0.0404869077132892,334.857142857143
"CD012942","CD012942_pub2_data","12|7|Comparison 7 Sertraline versus placebo, Outcome 12 Dropouts due to adverse effects|","Comparison 7 Sertraline versus placebo, Outcome 12 Dropouts due to adverse effects",12,7,"","or","binary",2,0.289460737205629,0.613916473521142,0.512656253822541,2005,0.0595238095238095,349.5
"CD012942","CD012942_pub2_data","12|8|Comparison 8 Venlafaxine versus placebo, Outcome 12 Dropouts due to adverse effects|","Comparison 8 Venlafaxine versus placebo, Outcome 12 Dropouts due to adverse effects",12,8,"","or","binary",10,0.793582619796023,0.157815794911616,0.0844557227874288,2004.2,0.077176904109516,331.1
"CD012942","CD012942_pub2_data","2|1|Comparison 1 All antidepressants versus placebo, Outcome 2 Acceptability|","Comparison 1 All antidepressants versus placebo, Outcome 2 Acceptability",2,1,"","reported","reported",3,0,0.126932858588246,0,2003.66666666667,0.188103442646793,335
"CD012942","CD012942_pub2_data","2|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability",2,2,"Other","reported","reported",5,0,0.0975835458568627,0,2013.6,0.195142606715194,366
"CD012942","CD012942_pub2_data","2|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability",2,2,"SNRIs","reported","reported",15,0,0.0437555120552062,0,2005.33333333333,0.316373470337663,324.2
"CD012942","CD012942_pub2_data","2|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability",2,2,"SSRIs","reported","reported",16,0,0.0550071197117855,0,2005.125,0.235974808845804,314.4375
"CD012942","CD012942_pub2_data","2|3|Comparison 3 Agomelatine versus placebo, Outcome 2 Acceptability|","Comparison 3 Agomelatine versus placebo, Outcome 2 Acceptability",2,3,"","or","binary",3,-0.597666171410346,0.194941824840898,1.55284673222487e-06,2013,0.182469565131422,267.666666666667
"CD012942","CD012942_pub2_data","2|4|Comparison 4 Duloxetine versus placebo, Outcome 2 Acceptability|","Comparison 4 Duloxetine versus placebo, Outcome 2 Acceptability",2,4,"","or","binary",5,0.0976421277718156,0.199829756483362,0.141899476504128,2009.8,0.320673548697158,349.8
"CD012942","CD012942_pub2_data","2|6|Comparison 6 Paroxetine versus placebo, Outcome 2 Acceptability|","Comparison 6 Paroxetine versus placebo, Outcome 2 Acceptability",2,6,"","or","binary",7,0.282809738000361,0.108800632673865,0,2004.42857142857,0.197046841605241,316.428571428571
"CD012942","CD012942_pub2_data","2|7|Comparison 7 Sertraline versus placebo, Outcome 2 Acceptability|","Comparison 7 Sertraline versus placebo, Outcome 2 Acceptability",2,7,"","or","binary",3,-0.074064103949386,0.187156876334363,0.0188657210524956,2006,0.346336429308566,252.666666666667
"CD012942","CD012942_pub2_data","2|8|Comparison 8 Venlafaxine versus placebo, Outcome 2 Acceptability|","Comparison 8 Venlafaxine versus placebo, Outcome 2 Acceptability",2,8,"","or","binary",12,-0.0651089923397555,0.136242883541962,0.141438774643698,2003.91666666667,0.329302752903048,307.75
"CD012942","CD012942_pub2_data","3|1|Comparison 1 All antidepressants versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|","Comparison 1 All antidepressants versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,1,"","or","binary",19,0.68684667171813,0.0622018085573067,0.0178924973678713,2004.47368421053,0.458189301498892,348.052631578947
"CD012942","CD012942_pub2_data","3|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,2,"SNRIs","reported","reported",7,0,0.0386014359831216,0,2003.42857142857,0.458042643641374,309.142857142857
"CD012942","CD012942_pub2_data","3|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,2,"SSRIs","reported","reported",10,0,0.030679443076283,0,2004.5,0.450529015149813,366.1
"CD012942","CD012942_pub2_data","3|5|Comparison 5 Paroxetine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|","Comparison 5 Paroxetine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,5,"","or","binary",6,0.514215628398384,0.11433973146504,0.0235085253996455,2003.83333333333,0.45856593714058,333
"CD012942","CD012942_pub2_data","3|6|Comparison 6 Sertraline versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|","Comparison 6 Sertraline versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,6,"","or","binary",2,0.745737510420165,0.314738023271848,0.149501998965791,2005,0.457775151037562,348
"CD012942","CD012942_pub2_data","3|7|Comparison 7 Venlafaxine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)|","Comparison 7 Venlafaxine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)",3,7,"","or","binary",8,0.854861202152301,0.0875641300693816,0,2003.125,0.461364236263125,316.375
"CD012942","CD012942_pub2_data","4|1|Comparison 1 All antidepressants versus placebo, Outcome 4 Remission rate|","Comparison 1 All antidepressants versus placebo, Outcome 4 Remission rate",4,1,"","reported","reported",3,0,0.0887281955660851,0,2007.66666666667,0.32816029143898,258.333333333333
"CD012942","CD012942_pub2_data","4|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate",4,2,"Other","or","binary",4,0.763924806858383,0.219956187447357,0.100833507129595,2013.25,0.19335121606772,272
"CD012942","CD012942_pub2_data","4|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate",4,2,"SNRIs","reported","reported",8,0,0.0709564522454715,0,2006.875,0.205826518931632,329.875
"CD012942","CD012942_pub2_data","4|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate",4,2,"SSRIs","reported","reported",7,0,0.0602332784479693,0,2004.85714285714,0.257848224561793,403.857142857143
"CD012942","CD012942_pub2_data","4|5|Comparison 5 Escitalopram versus placebo, Outcome 4 Remission rate|","Comparison 5 Escitalopram versus placebo, Outcome 4 Remission rate",4,5,"","or","binary",3,0.569153888842616,0.14445961771089,0,2009.33333333333,0.244203922918382,356
"CD012942","CD012942_pub2_data","5|1|Comparison 1 All antidepressants versus placebo, Outcome 5 Change in symptom levels|","Comparison 1 All antidepressants versus placebo, Outcome 5 Change in symptom levels",5,1,"","reported","reported",28,0,0.184197328877295,0,2006.25,0,319.642857142857
"CD012942","CD012942_pub2_data","5|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels",5,2,"Other","reported","reported",2,0,0.48254646721444,0,2014.5,0,446
"CD012942","CD012942_pub2_data","5|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels",5,2,"SNRIs","reported","reported",16,0,0.232566553840463,0,2005.4375,0,327.75
"CD012942","CD012942_pub2_data","5|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels",5,2,"SSRIs","reported","reported",15,0,0.244453111124629,0,2005.06666666667,0,312.6
"CD012942","CD012942_pub2_data","5|4|Comparison 5 Duloxetine versus placebo, Outcome 4 Change in symptom levels|","Comparison 5 Duloxetine versus placebo, Outcome 4 Change in symptom levels",5,4,"","reported","reported",2,0,0.585192273093338,0,2008,0,360
"CD012942","CD012942_pub2_data","5|7|Comparison 8 Paroxetine versus placebo, Outcome 4 Change in symptom levels|","Comparison 8 Paroxetine versus placebo, Outcome 4 Change in symptom levels",5,7,"","or","binary",7,-0.0867881251751737,0.757460689811333,0,2004.42857142857,0,311.857142857143
"CD012942","CD012942_pub2_data","5|9|Comparison 10 Venlafaxine versus placebo, Outcome 4 Change in symptom levels|","Comparison 10 Venlafaxine versus placebo, Outcome 4 Change in symptom levels",5,9,"","or","binary",12,-0.32944436393862,0.578824451406864,0,2003.91666666667,0,291.5
"CD012942","CD012942_pub2_data","6|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 6 Total number of participants reporting adverse events|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 6 Total number of participants reporting adverse events",6,2,"SNRIs","reported","reported",5,0,0.0277254630919493,0,2006.2,0.641472329784394,262.6
"CD012942","CD012942_pub2_data","6|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 6 Total number of participants reporting adverse events|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 6 Total number of participants reporting adverse events",6,2,"SSRIs","reported","reported",13,0,0.020872339596619,0,2004.92307692308,0.596925657091112,312.923076923077
"CD012942","CD012942_pub2_data","6|3|Comparison 3 Agomelatine versus placebo, Outcome 6 Total number of participants reporting adverse events|","Comparison 3 Agomelatine versus placebo, Outcome 6 Total number of participants reporting adverse events",6,3,"","or","binary",3,0.212236059352922,0.153354938573227,0,2013,0.348239511650936,267
"CD012942","CD012942_pub2_data","6|4|Comparison 4 Duloxetine versus placebo, Outcome 6 Total number of participants reporting adverse events|","Comparison 4 Duloxetine versus placebo, Outcome 6 Total number of participants reporting adverse events",6,4,"","or","binary",4,0.654192881374937,0.136971151867569,0,2010,0.646941718548808,292.25
"CD012942","CD012942_pub2_data","6|8|Comparison 8 Venlafaxine versus placebo, Outcome 6 Total number of participants reporting adverse events|","Comparison 8 Venlafaxine versus placebo, Outcome 6 Total number of participants reporting adverse events",6,8,"","or","binary",4,0.635332662050015,0.180062606112518,0,2005,0.689303416300045,219.75
"CD012942","CD012942_pub2_data","7|1|Comparison 1 All antidepressants versus placebo, Outcome 7 Sleepiness/drowsiness|","Comparison 1 All antidepressants versus placebo, Outcome 7 Sleepiness/drowsiness",7,1,"","or","binary",26,0.882533283699485,0.0997373572376159,3.48551885622506e-06,2007.53846153846,0.0438911099147089,336.076923076923
"CD012942","CD012942_pub2_data","7|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness|Other","Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness",7,2,"Other","reported","reported",2,0,0.32742352841726,0,2014.5,0.0345063538611926,510
"CD012942","CD012942_pub2_data","7|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness|SNRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness",7,2,"SNRIs","reported","reported",9,0,0.161950654896073,0,2008,0.040010918777875,335.111111111111
"CD012942","CD012942_pub2_data","7|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness|SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness",7,2,"SSRIs","reported","reported",12,0,0.118360226013665,0,2004.75,0.0570929384994935,327.75
"CD012942","CD012942_pub2_data","7|3|Comparison 3 Agomelatine versus placebo, Outcome 7 Sleepiness/drowsiness|","Comparison 3 Agomelatine versus placebo, Outcome 7 Sleepiness/drowsiness",7,3,"","or","binary",2,0.560705848510724,0.552649130406921,0,2015.5,0.0150218102508179,340
"CD012942","CD012942_pub2_data","7|5|Comparison 5 Escitalopram versus placebo, Outcome 7 Sleepiness/drowsiness|","Comparison 5 Escitalopram versus placebo, Outcome 7 Sleepiness/drowsiness",7,5,"","or","binary",6,0.65894673731589,0.188749757296002,0,2005.5,0.0524220486590477,322.166666666667
"CD012942","CD012942_pub2_data","7|6|Comparison 6 Paroxetine versus placebo, Outcome 7 Sleepiness/drowsiness|","Comparison 6 Paroxetine versus placebo, Outcome 7 Sleepiness/drowsiness",7,6,"","or","binary",7,0.938538842065026,0.161799119207921,1.35157425278066e-07,2003.14285714286,0.0543910189177162,327.714285714286
"CD012942","CD012942_pub2_data","7|8|Comparison 8 Venlafaxine versus placebo, Outcome 7 Sleepiness/drowsiness|","Comparison 8 Venlafaxine versus placebo, Outcome 7 Sleepiness/drowsiness",7,8,"","or","binary",6,0.845884651809901,0.19446006078154,0,2006.5,0.050882560306132,294.333333333333
"CD012942","CD012942_pub2_data","8|1|Comparison 1 All antidepressants versus placebo, Outcome 8 Agitation/anxiety|","Comparison 1 All antidepressants versus placebo, Outcome 8 Agitation/anxiety",8,1,"","or","binary",6,0.0448517520448971,0.202875174692011,0,2003.5,0.0588275984559305,337.666666666667
"CD012942","CD012942_pub2_data","8|2|Comparison 2 Each class of antidepressant versus placebo, Outcome 8 Agitation/anxiety |SSRIs","Comparison 2 Each class of antidepressant versus placebo, Outcome 8 Agitation/anxiety ",8,2,"SSRIs","reported","reported",5,0,0.246351850755762,0,2004,0.0358823743454637,356.6
"CD012942","CD012942_pub2_data","8|3|Comparison 3 Escitalopram versus placebo, Outcome 8 Agitation/anxiety|","Comparison 3 Escitalopram versus placebo, Outcome 8 Agitation/anxiety",8,3,"","or","binary",2,-0.566532114246312,0.941858383574562,1.25864876848652,2005,0.0366814828392063,428.5
"CD012942","CD012942_pub2_data","8|4|Comparison 4 Paroxetine versus placebo, Outcome 8 Agitation/anxiety|","Comparison 4 Paroxetine versus placebo, Outcome 8 Agitation/anxiety",8,4,"","or","binary",2,0.546065517963809,0.485356664869876,0,2002,0.0197938946140385,325
"CD012942","CD012942_pub2_data","8|5|Comparison 5 Sertraline versus placebo, Outcome 8 Agitation/anxiety|","Comparison 5 Sertraline versus placebo, Outcome 8 Agitation/anxiety",8,5,"","or","binary",2,0.103278915724073,0.335342148887769,0,2006,0.0476190476190476,207.5
"CD012942","CD012942_pub2_data","9|1|Comparison 1 All antidepressants versus placebo, Outcome 9 Suicide wishes/gestures/attempts|","Comparison 1 All antidepressants versus placebo, Outcome 9 Suicide wishes/gestures/attempts",9,1,"","or","binary",3,-0.302361247824506,0.32146100789452,3.16575899098544e-06,2011.33333333333,0.0499485750306891,267.333333333333
"CD012967","CD012967_pub2_data","1|4|Change in impairment score at 24 months|NA","Change in impairment score at 24 months",1,4,NA,"or","binary",2,-0.412335574303129,1.42124725946632,0,2005,0,243
"CD012967","CD012967_pub2_data","1|5|Adverse events leading to cessation of treatment|NA","Adverse events leading to cessation of treatment",1,5,NA,"or","binary",3,0.288603367106669,0.530481200532108,0,2003,0.00956890331890332,363.333333333333
"CD013023","CD013023_pub2_data","1|1|Arterial catheter failure|NA","Arterial catheter failure",1,1,NA,"or","binary",2,-0.904443263994849,0.44823479797493,0,2014.5,0.206382978723404,82.5
"CD013023","CD013023_pub2_data","1|2|Dislodgement|NA","Dislodgement",1,2,NA,"or","binary",2,-0.642741343123811,1.52687029938549,2.14004110632693,2014.5,0.05,82.5
"CD013023","CD013023_pub2_data","1|3|Occlusion|NA","Occlusion",1,3,NA,"or","binary",2,0.165050057012747,0.584273382140724,0,2014.5,0.0712765957446809,82.5
"CD013023","CD013023_pub2_data","1|4|Adverse events|NA","Adverse events",1,4,NA,"or","binary",2,-0.121217891053177,1.16586352252619,0,2014.5,0.0166666666666667,82.5
"CD013023","CD013023_pub2_data","2|2|Incidence of catheter-related bloodstream infection|NA","Incidence of catheter-related bloodstream infection",2,2,NA,"or","binary",2,0.674460142474107,1.27013216775997,0,2015.5,0,286
"CD013023","CD013023_pub2_data","2|3|Dislodgement|NA","Dislodgement",2,3,NA,"or","binary",2,-0.232238922179609,0.695663784372737,0,2015.5,0.051937984496124,286
"CD013023","CD013023_pub2_data","2|4|Occlusion|NA","Occlusion",2,4,NA,"or","binary",2,-0.30392539401008,0.197058837366277,0,2015.5,0.195348837209302,286
"CD013023","CD013023_pub2_data","5|1|Arterial catheter failure|NA","Arterial catheter failure",5,1,NA,"or","binary",2,-0.286549804936975,0.401378955865748,0,2014.5,0.206382978723404,78.5
"CD013023","CD013023_pub2_data","5|2|Dislodgement|NA","Dislodgement",5,2,NA,"or","binary",2,-1.33068039351562,1.21961330728315,0,2014.5,0.05,78.5
"CD013023","CD013023_pub2_data","5|3|Occlusion|NA","Occlusion",5,3,NA,"or","binary",2,0.669323263980059,0.675121345503513,0.309992204454374,2014.5,0.0712765957446809,78.5
"CD013023","CD013023_pub2_data","8|1|Arterial catheter failure|NA","Arterial catheter failure",8,1,NA,"or","binary",2,0.615926579426586,0.46108892813718,0,2014.5,0.0848214285714286,84
"CD013023","CD013023_pub2_data","8|2|Dislodgement|NA","Dislodgement",8,2,NA,"or","binary",2,-0.578331362890223,1.27426881783017,0,2014.5,0.00892857142857143,84
"CD013023","CD013023_pub2_data","8|3|Occlusion|NA","Occlusion",8,3,NA,"or","binary",2,0.573978659298044,0.485493355513714,0,2014.5,0.0758928571428572,84
"CD013023","CD013023_pub2_data","8|4|Adverse events|NA","Adverse events",8,4,NA,"or","binary",2,0.0924828782400025,1.60974369939999,2.73097336865752,2014.5,0.0178571428571429,84
"CD013038","CD013038_pub3_data","1|10|Time to first discharge home (days) – by type of exposure|After receiving only smell of milk","Time to first discharge home (days) – by type of exposure",1,10,"After receiving only smell of milk","or","binary",3,0,1.16488839019297,0,2014.33333333333,0,68
"CD013038","CD013038_pub3_data","1|10|Time to first discharge home (days) – by type of exposure|After receiving smell and taste of milk","Time to first discharge home (days) – by type of exposure",1,10,"After receiving smell and taste of milk","or","binary",2,-0.0747563666077812,1.42166757847025,0,2020,0,291
"CD013038","CD013038_pub3_data","1|11|Time to first discharge home (postmenstrual age in weeks) – by type of exposure|After receiving smell and taste of milk","Time to first discharge home (postmenstrual age in weeks) – by type of exposure",1,11,"After receiving smell and taste of milk","or","binary",3,-0.0589309803980869,1.15932609090982,0,2020.33333333333,0,325.333333333333
"CD013038","CD013038_pub3_data","1|4|Time to reach full enteral feeds (days)|","Time to reach full enteral feeds (days)",1,4,"","reported","reported",3,0,0.34946923726293,0,2018,0,224.666666666667
"CD013038","CD013038_pub3_data","1|5|Time to reach full enteral feeds (days) – by type of exposure|After receiving only smell of milk","Time to reach full enteral feeds (days) – by type of exposure",1,5,"After receiving only smell of milk","or","binary",2,0.0316762183590404,1.42359709875469,0,2017,0,77
"CD013038","CD013038_pub3_data","1|5|Time to reach full enteral feeds (days) – by type of exposure|After receiving smell and taste of milk","Time to reach full enteral feeds (days) – by type of exposure",1,5,"After receiving smell and taste of milk","or","binary",2,-0.0747563666077812,1.42166757847025,0,2020,0,291
"CD013038","CD013038_pub3_data","1|7|Late infection during hospitalisation|","Late infection during hospitalisation",1,7,"","or","binary",2,0.143812439393083,0.259902596062531,0,2019,0.103790412486065,218
"CD013038","CD013038_pub3_data","1|8|Time to first discharge home (days)|","Time to first discharge home (days)",1,8,"","reported","reported",3,0,0.904988240773868,0,2014,0,74.3333333333333
"CD013038","CD013038_pub3_data","1|9|Time to first discharge home (postmenstrual age in weeks)|","Time to first discharge home (postmenstrual age in weeks)",1,9,"","reported","reported",2,0,0.256046671792084,0,2019,0,222.5
"CD013042","CD013042_pub2_data","10|1|Mean pain (0 to 10, 0 is no pain)|End of intervention (6 weeks to 3 months)","Mean pain (0 to 10, 0 is no pain)",10,1,"End of intervention (6 weeks to 3 months)","or","binary",3,0.141438435695958,1.17756049408899,0,2011.66666666667,0,29.6666666666667
"CD013042","CD013042_pub2_data","10|2|Mean elbow disability (0 to 100, 0 is no disability)|End of intervention (6 to 7 weeks)","Mean elbow disability (0 to 100, 0 is no disability)",10,2,"End of intervention (6 to 7 weeks)","or","binary",2,0.211387613132214,1.4395914956279,0,2013.5,0,34.5
"CD013042","CD013042_pub2_data","10|5|Proportion with any adverse event|","Proportion with any adverse event",10,5,"","or","binary",2,-0.729608626255953,1.29305407192909,0,2013.5,0.0416666666666667,37
"CD013042","CD013042_pub2_data","11|1|Subgroup analysis: pain end of intervention|Average symptom duration for more than 3 months up to 6 months","Subgroup analysis: pain end of intervention",11,1,"Average symptom duration for more than 3 months up to 6 months","or","binary",3,0.032895277883792,1.16258462969247,0,2010,0,94.6666666666667
"CD013042","CD013042_pub2_data","11|1|Subgroup analysis: pain end of intervention|Average symptom duration more than 6 months","Subgroup analysis: pain end of intervention",11,1,"Average symptom duration more than 6 months","or","binary",3,-0.0534003480159216,1.16895572771514,0,2011.33333333333,0,48
"CD013042","CD013042_pub2_data","11|2|Subgroup analysis: disability end of intervention|Average symptom duration for more than 3 months up to 6 months","Subgroup analysis: disability end of intervention",11,2,"Average symptom duration for more than 3 months up to 6 months","or","binary",3,0.032895277883792,1.16258462969247,0,2010,0,94.6666666666667
"CD013042","CD013042_pub2_data","11|2|Subgroup analysis: disability end of intervention|Symptom duration more than 6 months","Subgroup analysis: disability end of intervention",11,2,"Symptom duration more than 6 months","or","binary",2,-0.10630693874983,1.43115288492041,0,2011,0,53.5
"CD013042","CD013042_pub2_data","2|1|Mean pain (0 to 10, 0 is no pain)|End of intervention (4 weeks to 3 months)","Mean pain (0 to 10, 0 is no pain)",2,1,"End of intervention (4 weeks to 3 months)","reported","reported",2,0,0.449575735586087,0,2019,0,75
"CD013042","CD013042_pub2_data","2|1|Mean pain (0 to 10, 0 is no pain)|First time point (3 to 6 weeks)","Mean pain (0 to 10, 0 is no pain)",2,1,"First time point (3 to 6 weeks)","reported","reported",2,0,0.338716352718678,0,2009,0,79
"CD013042","CD013042_pub2_data","2|2|Mean disability (0 to 100, 0 is no disability)|End of intervention (4 weeks to 3 months)","Mean disability (0 to 100, 0 is no disability)",2,2,"End of intervention (4 weeks to 3 months)","or","binary",10,-0.0748857327389001,0.638936526784456,0,2012,0,73.2
"CD013042","CD013042_pub2_data","2|2|Mean disability (0 to 100, 0 is no disability)|First time point (3 to 6 weeks)","Mean disability (0 to 100, 0 is no disability)",2,2,"First time point (3 to 6 weeks)","or","binary",3,-0.264004842642775,1.16130766129834,0,2009.66666666667,0,100.666666666667
"CD013042","CD013042_pub2_data","2|4|Participant reported treatment success|End of intervention (6 weeks to 3 months)","Participant reported treatment success",2,4,"End of intervention (6 weeks to 3 months)","or","binary",6,0.501378404208764,0.268308273669004,0.261066605944875,2008.33333333333,0.352597889331392,128.333333333333
"CD013042","CD013042_pub2_data","2|4|Participant reported treatment success|First time point (3 weeks)","Participant reported treatment success",2,4,"First time point (3 weeks)","or","binary",2,0.664005158114895,0.350291461036031,0,2004,0.122050816696915,121.5
"CD013042","CD013042_pub2_data","2|4|Participant reported treatment success|Last time point (12 months)","Participant reported treatment success",2,4,"Last time point (12 months)","or","binary",5,0.161531290457477,0.215630960236778,0,2006,0.852359251473145,140.4
"CD013042","CD013042_pub2_data","2|7|Pain-free grip strength (SMD)|End of intervention (6 to 8 weeks)","Pain-free grip strength (SMD)",2,7,"End of intervention (6 to 8 weeks)","or","binary",8,0.0143072488498262,0.71465189966106,0,2009.625,0,75.75
"CD013042","CD013042_pub2_data","2|7|Pain-free grip strength (SMD)|First time point (3 weeks)","Pain-free grip strength (SMD)",2,7,"First time point (3 weeks)","or","binary",3,-0.0539195342833038,1.16284939409958,0,2006.66666666667,0,93.3333333333333
"CD013042","CD013042_pub2_data","2|7|Pain-free grip strength (SMD)|Last time point (12 months)","Pain-free grip strength (SMD)",2,7,"Last time point (12 months)","or","binary",4,0.00934483547135854,1.00423755479517,0,2006.75,0,117.5
"CD013042","CD013042_pub2_data","3|2|Mean disability (0 to 100, 0 is no disability)|End of intervention (6 weeks)","Mean disability (0 to 100, 0 is no disability)",3,2,"End of intervention (6 weeks)","or","binary",4,0.0166633749876919,1.00418232509667,0,2006.75,0,119
"CD013042","CD013042_pub2_data","3|2|Mean disability (0 to 100, 0 is no disability)|First time point (3 weeks)","Mean disability (0 to 100, 0 is no disability)",3,2,"First time point (3 weeks)","or","binary",2,-0.106259055021967,1.41999058644961,0,2004,0,121.5
"CD013042","CD013042_pub2_data","3|2|Mean disability (0 to 100, 0 is no disability)|Last time point (12 months)","Mean disability (0 to 100, 0 is no disability)",3,2,"Last time point (12 months)","or","binary",4,0.0140578653613278,1.00424861233836,0,2006.75,0,117.25
"CD013042","CD013042_pub2_data","3|4|Participant reported treatment success|End of intervention (6 weeks)","Participant reported treatment success",3,4,"End of intervention (6 weeks)","or","binary",4,0.750318352283047,0.306865799083179,0.219625390422619,2006.75,0.285421409899654,121.25
"CD013042","CD013042_pub2_data","3|4|Participant reported treatment success|First time point (3 weeks)","Participant reported treatment success",3,4,"First time point (3 weeks)","or","binary",2,0.664005158114895,0.350291461036031,0,2004,0.122050816696915,121.5
"CD013042","CD013042_pub2_data","3|4|Participant reported treatment success|Last time point (12 months)","Participant reported treatment success",3,4,"Last time point (12 months)","or","binary",4,0.189398291622331,0.276610672983942,0,2006.75,0.860707685031086,117.5
"CD013042","CD013042_pub2_data","3|5|Proportion of overall withdrawals|","Proportion of overall withdrawals",3,5,"","or","binary",4,-0.497952104727066,0.382601168484995,0,2006.75,0.0718769765970904,122.5
"CD013042","CD013042_pub2_data","3|7|Pain free grip strength (SMD)|End of intervention (6 weeks)","Pain free grip strength (SMD)",3,7,"End of intervention (6 weeks)","or","binary",4,0.029371693785773,1.0040959920866,0,2006.75,0,121.25
"CD013042","CD013042_pub2_data","3|7|Pain free grip strength (SMD)|First time point (3 weeks)","Pain free grip strength (SMD)",3,7,"First time point (3 weeks)","or","binary",2,-0.106259055021967,1.41999058644961,0,2004,0,121.5
"CD013042","CD013042_pub2_data","3|7|Pain free grip strength (SMD)|Last time point (12 months)","Pain free grip strength (SMD)",3,7,"Last time point (12 months)","or","binary",4,0.00934483547135854,1.00423755479517,0,2006.75,0,117.5
"CD013042","CD013042_pub2_data","4|1|Mean pain (0 to 10, 0 is no pain)|End of intervention (4 to 6 weeks)","Mean pain (0 to 10, 0 is no pain)",4,1,"End of intervention (4 to 6 weeks)","or","binary",2,-0.19596110056899,1.43727214214148,0,2017,0,30
"CD013042","CD013042_pub2_data","4|1|Mean pain (0 to 10, 0 is no pain)|Last time point (8 weeks to 3 months)","Mean pain (0 to 10, 0 is no pain)",4,1,"Last time point (8 weeks to 3 months)","or","binary",2,-0.19596110056899,1.43727214214148,0,2017,0,30
"CD013042","CD013042_pub2_data","4|2|Mean disability (0 to 100, 0 is no disability)|Last time point (8 weeks to 3 months)","Mean disability (0 to 100, 0 is no disability)",4,2,"Last time point (8 weeks to 3 months)","or","binary",2,-0.19596110056899,1.43727214214148,0,2017,0,30
"CD013042","CD013042_pub2_data","5|1|Mean pain (0 to 10, 0 is no pain)|End of intervention (6 weeks to 3 months)","Mean pain (0 to 10, 0 is no pain)",5,1,"End of intervention (6 weeks to 3 months)","or","binary",6,-0.0670707110996163,0.825814693076964,0,2012.33333333333,0,79.6666666666667
"CD013042","CD013042_pub2_data","5|1|Mean pain (0 to 10, 0 is no pain)|Last time point (12 months)","Mean pain (0 to 10, 0 is no pain)",5,1,"Last time point (12 months)","or","binary",2,-0.289310681446813,1.42208251880288,0,2012,0,145.5
"CD013042","CD013042_pub2_data","5|2|Mean disability (0 to 100, 0 is no disability)|End of intervention (7 weeks to 3 months)","Mean disability (0 to 100, 0 is no disability)",5,2,"End of intervention (7 weeks to 3 months)","or","binary",4,-0.107929862519937,1.01338021239972,0,2014.75,0,49
"CD013042","CD013042_pub2_data","5|4|Participant-reported treatment success|End of intervention (8 weeks to 3 months)","Participant-reported treatment success",5,4,"End of intervention (8 weeks to 3 months)","or","binary",2,-0.0876424602121599,0.25681415686015,0,2011.5,0.486950848194867,142.5
"CD013042","CD013042_pub2_data","5|5|Proportion of overall withdrawals|","Proportion of overall withdrawals",5,5,"","or","binary",6,-0.0345085333259436,0.317510821369922,0.148170981614579,2012.33333333333,0.159222544594885,94.8333333333333
"CD013042","CD013042_pub2_data","5|7|Pain-free grip strength (SMD)|End of intervention (6 to 8 weeks)","Pain-free grip strength (SMD)",5,7,"End of intervention (6 to 8 weeks)","or","binary",3,0.0700606985915993,1.17456101571511,0,2013,0,31.3333333333333
"CD013042","CD013042_pub2_data","6|1|Mean pain (0 to 10, 0 is no pain)|First time point (3 weeks)","Mean pain (0 to 10, 0 is no pain)",6,1,"First time point (3 weeks)","or","binary",3,-0.00891946183454944,1.17200750117916,0,2012,0,34.6666666666667
"CD013042","CD013042_pub2_data","6|1|Mean pain (0 to 10, 0 is no pain)|Last time point (3 to 12 months)","Mean pain (0 to 10, 0 is no pain)",6,1,"Last time point (3 to 12 months)","or","binary",2,0.016138875326518,1.43886121613853,0,2017,0,28.5
"CD013042","CD013042_pub2_data","6|2|Mean disability (0 to 100, 0 is no disability)|First time point (2 to 4 weeks)","Mean disability (0 to 100, 0 is no disability)",6,2,"First time point (2 to 4 weeks)","or","binary",3,-0.00892858707363924,1.17260687112231,0,2018,0,32.6666666666667
"CD013042","CD013042_pub2_data","6|2|Mean disability (0 to 100, 0 is no disability)|Last time point (3 to 12 months)","Mean disability (0 to 100, 0 is no disability)",6,2,"Last time point (3 to 12 months)","or","binary",3,0.0107216739172531,1.17277195124123,0,2018,0,32.3333333333333
"CD013042","CD013042_pub2_data","6|3|Participant-reported treatment success|End of treatment (4 to 6 weeks)","Participant-reported treatment success",6,3,"End of treatment (4 to 6 weeks)","or","binary",2,2.67380655521581,0.739656752761174,0,2015,0.513235294117647,37
"CD013042","CD013042_pub2_data","6|4|Proportion of overall withdrawals|","Proportion of overall withdrawals",6,4,"","or","binary",3,-0.132908004632428,0.635623462270154,0.187012441632315,2019,0.215151515151515,36
"CD013042","CD013042_pub2_data","6|5|Mean grip strength (kg)|First time point (2 to 3 weeks)","Mean grip strength (kg)",6,5,"First time point (2 to 3 weeks)","or","binary",3,0.0184634954642046,1.16874962479746,0,2014,0,40.3333333333333
"CD013042","CD013042_pub2_data","6|5|Mean grip strength (kg)|Last time point (3 months)","Mean grip strength (kg)",6,5,"Last time point (3 months)","or","binary",3,0.0379923177930407,1.16891308096798,0,2014,0,40
"CD013042","CD013042_pub2_data","8|1|Mean pain (0 to 10, 0 is no pain)|End of intervention (6 weeks to 6 months)","Mean pain (0 to 10, 0 is no pain)",8,1,"End of intervention (6 weeks to 6 months)","or","binary",4,0.12996291543583,1.01629997287319,0,2012,0,42.75
"CD013042","CD013042_pub2_data","8|1|Mean pain (0 to 10, 0 is no pain)|First time point (2 to 4 weeks)","Mean pain (0 to 10, 0 is no pain)",8,1,"First time point (2 to 4 weeks)","or","binary",2,-0.0148983658145494,1.42536484277065,0,2016.5,0,66
"CD013042","CD013042_pub2_data","8|1|Mean pain (0 to 10, 0 is no pain)|Last time point (12 months)","Mean pain (0 to 10, 0 is no pain)",8,1,"Last time point (12 months)","or","binary",2,0.00931986340052724,1.4253722812329,0,2016.5,0,66
"CD013042","CD013042_pub2_data","8|2|Mean elbow disability (0 to 100, 0 is no disability)|End of intervention (6 weeks to 6 months)","Mean elbow disability (0 to 100, 0 is no disability)",8,2,"End of intervention (6 weeks to 6 months)","or","binary",3,0.172474246961969,1.17077737201441,0,2013.33333333333,0,50.3333333333333
"CD013042","CD013042_pub2_data","8|2|Mean elbow disability (0 to 100, 0 is no disability)|First time point (2 to 4 weeks)","Mean elbow disability (0 to 100, 0 is no disability)",8,2,"First time point (2 to 4 weeks)","or","binary",2,-0.0148983658145494,1.42536484277065,0,2016.5,0,66
"CD013042","CD013042_pub2_data","8|2|Mean elbow disability (0 to 100, 0 is no disability)|Last time point (12 months)","Mean elbow disability (0 to 100, 0 is no disability)",8,2,"Last time point (12 months)","or","binary",2,0.00931986340052724,1.4253722812329,0,2016.5,0,66
"CD013042","CD013042_pub2_data","8|4|Participant-reported treatment success|End of intervention (3 to 6 months)","Participant-reported treatment success",8,4,"End of intervention (3 to 6 months)","or","binary",2,0.0879748307300687,0.39320023479104,0,2010.5,0.529069767441861,51
"CD013042","CD013042_pub2_data","8|5|Proportion of overall withdrawals|","Proportion of overall withdrawals",8,5,"","or","binary",2,1.21925057628038,1.3903661179658,2.39227638995623,2010,0.0232558139534884,53.5
"CD013042","CD013042_pub2_data","8|6|Proportion with any adverse event|","Proportion with any adverse event",8,6,"","or","binary",3,-0.285905878271117,0.502506553140813,0,2013.33333333333,0.0975452196382429,52.3333333333333
"CD013051","CD013051_pub3_data","2|1|Resolution of ear discharge|Measured at 2–4 weeks","Resolution of ear discharge",2,1,"Measured at 2–4 weeks","or","binary",2,1.44530290219323,0.482606277892543,0,NA,0.5,45
"CD013051","CD013051_pub3_data","2|2|Subgroup analysis: CSOM diagnosis|Chronic ear discharge","Subgroup analysis: CSOM diagnosis",2,2,"Chronic ear discharge","or","binary",2,1.50738426568078,0.411036706716442,0,2003,0.6,75
"CD013051","CD013051_pub3_data","3|1|Resolution of ear discharge (1 to up to 2 weeks)|Quinolones versus aminoglycosides","Resolution of ear discharge (1 to up to 2 weeks)",3,1,"Quinolones versus aminoglycosides","or","binary",7,1.61666005766023,0.336123457971459,0.497785603634397,2004.5,0.458268699646542,113.428571428571
"CD013051","CD013051_pub3_data","3|2|Resolution of ear discharge (2 to up to 4 weeks)|Quinolones versus aminoglycosides","Resolution of ear discharge (2 to up to 4 weeks)",3,2,"Quinolones versus aminoglycosides","or","binary",2,1.07117484066971,0.906490150214773,0.645834097087248,2012,0.8,70
"CD013052","CD013052_pub3_data","2|1|Resolution of ear discharge (1 to 2 weeks)|","Resolution of ear discharge (1 to 2 weeks)",2,1,"","or","binary",3,0.245276857972585,0.31524324999095,0,2018,0.72,100
"CD013052","CD013052_pub3_data","2|2|Resolution of ear discharge (2 to 4 weeks)|","Resolution of ear discharge (2 to 4 weeks)",2,2,"","or","binary",2,-0.302991325344566,0.558000940043397,0,NA,0.865,45
"CD013052","CD013052_pub3_data","2|3|Subgroup analysis: CSOM diagnosis|Chronic ear discharge","Subgroup analysis: CSOM diagnosis",2,3,"Chronic ear discharge","or","binary",2,0.212212744986733,0.463038217032502,0,NA,0.86,75
"CD013052","CD013052_pub3_data","2|3|Subgroup analysis: CSOM diagnosis|CSOM","Subgroup analysis: CSOM diagnosis",2,3,"CSOM","or","binary",3,0.0586782958173072,0.340796338986108,0,2018,0.723333333333333,80
"CD013052","CD013052_pub3_data","2|5|Ototoxicity|Dizziness/vertigo/balance","Ototoxicity",2,5,"Dizziness/vertigo/balance","or","binary",2,0.669814612391753,1.27307823870037,0,2018,0,100
"CD013052","CD013052_pub3_data","6|1|Resolution of ear discharge (1 to 2 weeks)|Other beta-lactam versus cephalosporin","Resolution of ear discharge (1 to 2 weeks)",6,1,"Other beta-lactam versus cephalosporin","or","binary",3,-0.0977591402840206,0.338914407895812,0.0790858078465514,1995.66666666667,0.754174443200199,84.6666666666667
"CD013053","CD013053_pub3_data","1|1|Resolution of ear discharge|At 1–2 weeks","Resolution of ear discharge",1,1,"At 1–2 weeks","or","binary",2,1.43465987762895,0.332855127307271,0,1999,0.55,105
"CD013053","CD013053_pub3_data","1|1|Resolution of ear discharge|At 2–4 weeks","Resolution of ear discharge",1,1,"At 2–4 weeks","or","binary",2,1.59964662014472,0.446592380208102,0,1993.5,0.5,57.5
"CD013053","CD013053_pub3_data","1|2|Subgroup analyses: diagnosis of chronic suppurative otitis media (CSOM)|Chronic ear discharge","Subgroup analyses: diagnosis of chronic suppurative otitis media (CSOM)",1,2,"Chronic ear discharge","or","binary",3,1.41746053638214,0.286420402451066,0,1998.33333333333,0.566666666666667,95
"CD013054","CD013054_pub3_data","1|1|Resolution of ear discharge 2 to 4 weeks|Aminoglycosides plus steroids","Resolution of ear discharge 2 to 4 weeks",1,1,"Aminoglycosides plus steroids","or","binary",2,1.14264695507346,0.345852576935204,0,1983,0.234261501210654,77
"CD013054","CD013054_pub3_data","11|1|Resolution of ear discharge 1 to 2 weeks|","Resolution of ear discharge 1 to 2 weeks",11,1,"","or","binary",2,1.61413686291365,0.449137649462602,0,2002,0.655,70
"CD013054","CD013054_pub3_data","2|1|Resolution of ear discharge 1 to 2 weeks|Quinolones","Resolution of ear discharge 1 to 2 weeks",2,1,"Quinolones","or","binary",3,0.208309502703984,0.302542053903186,0,2008.5,0.771282051282051,98.3333333333333
"CD013054","CD013054_pub3_data","2|2|Resolution of ear discharge 2 to 4 weeks|Quinolones","Resolution of ear discharge 2 to 4 weeks",2,2,"Quinolones","or","binary",2,0.321507748492812,0.458957787779286,0,2008.5,0.823076923076923,72.5
"CD013054","CD013054_pub3_data","3|1|Resolution of ear discharge 1 to 2 weeks|Framycetin-gramicidin-dexamethasone","Resolution of ear discharge 1 to 2 weeks",3,1,"Framycetin-gramicidin-dexamethasone","or","binary",2,-1.35117636274038,0.414145300140871,0,NA,0.85,65
"CD013054","CD013054_pub3_data","3|1|Resolution of ear discharge 1 to 2 weeks|Neomycin-polymixin B-steroids","Resolution of ear discharge 1 to 2 weeks",3,1,"Neomycin-polymixin B-steroids","or","binary",4,-1.11129161638143,0.221669651178066,0.0406456396285247,NA,0.862467854418655,171
"CD013054","CD013054_pub3_data","3|2|Sensitivity analysis: unpublished - resolution of ear discharge 1 to 2 weeks|All studies (published and unpublished)","Sensitivity analysis: unpublished - resolution of ear discharge 1 to 2 weeks",3,2,"All studies (published and unpublished)","or","binary",6,-1.14451327130009,0.184840055587503,0.0166252686710244,NA,0.85831190294577,135.666666666667
"CD013054","CD013054_pub3_data","3|2|Sensitivity analysis: unpublished - resolution of ear discharge 1 to 2 weeks|Published only","Sensitivity analysis: unpublished - resolution of ear discharge 1 to 2 weeks",3,2,"Published only","or","binary",2,-1.09552622851483,0.40661645138611,0.211467898636466,NA,0.864523809523809,236
"CD013054","CD013054_pub3_data","3|7|Subgroup analysis: resolution of ear discharge - CSOM diagnosis|CSOM","Subgroup analysis: resolution of ear discharge - CSOM diagnosis",3,7,"CSOM","or","binary",6,-0.911418695113129,0.177002196817196,0,NA,0.789052643686511,125.5
"CD013054","CD013054_pub3_data","3|7|Subgroup analysis: resolution of ear discharge - CSOM diagnosis|Ear discharge","Subgroup analysis: resolution of ear discharge - CSOM diagnosis",3,7,"Ear discharge","or","binary",2,-1.5416259022723,0.325294079358517,0,1999,0.86,112.5
"CD013056","CD013056_pub3_data","1|1|Resolution of ear discharge (1–2 weeks)|Aminoglycosides","Resolution of ear discharge (1–2 weeks)",1,1,"Aminoglycosides","or","binary",3,-0.902350774324912,0.305679453408837,0,2014.66666666667,0.88969696969697,110.666666666667
"CD013056","CD013056_pub3_data","1|3|Ear pain, discomfort, irritation|Aminoglycosides","Ear pain, discomfort, irritation",1,3,"Aminoglycosides","or","binary",2,-1.11997537430049,1.16391497276418,0,2015,0.0213636363636364,94
"CD013056","CD013056_pub3_data","2|2|Resolution of ear discharge (2–4 weeks)|Quinolones","Resolution of ear discharge (2–4 weeks)",2,2,"Quinolones","or","binary",2,0.636002534494908,0.187582496721675,0,2008.5,0.574005359719645,244
"CD013056","CD013056_pub3_data","2|3|Ear pain, discomfort, irritation|Quinolones","Ear pain, discomfort, irritation",2,3,"Quinolones","or","binary",2,-0.629685211173275,0.313548538160505,0,2008.5,0.0728155339805825,255
"CD013056","CD013056_pub3_data","5|1|Resolution of ear discharge (2–4 weeks)|Quinolones","Resolution of ear discharge (2–4 weeks)",5,1,"Quinolones","or","binary",2,-1.00086877139222,0.288919488043373,0,2021,0.62,100
"CD013056","CD013056_pub3_data","5|2|Resolution of ear discharge (after 4 weeks)|Quinolones","Resolution of ear discharge (after 4 weeks)",5,2,"Quinolones","or","binary",2,-1.54987344583271,0.344286048911348,0,2021,0.86,100
"CD013059","CD013059_pub2_data","1|1|Depressive symptomatology|End-of-intervention","Depressive symptomatology",1,1,"End-of-intervention","or","binary",18,-0.176990739322173,0.480589042097356,0,2005.11111111111,0,35.7777777777778
"CD013059","CD013059_pub2_data","1|1|Depressive symptomatology|Long-term","Depressive symptomatology",1,1,"Long-term","or","binary",2,-0.506876400697033,1.43069791891698,0,2003.5,0,46
"CD013059","CD013059_pub2_data","1|1|Depressive symptomatology|Medium-term","Depressive symptomatology",1,1,"Medium-term","or","binary",8,-0.278154712095421,0.720583855336171,0,2004.5,0,44.375
"CD013059","CD013059_pub2_data","1|1|Depressive symptomatology|Short-term","Depressive symptomatology",1,1,"Short-term","or","binary",16,-0.200647967162096,0.510229599383567,0,2004.5,0,32
"CD013059","CD013059_pub2_data","1|2|Treatment non-acceptability|End-of-intervention","Treatment non-acceptability",1,2,"End-of-intervention","or","binary",12,0.723303356672098,0.418781862696107,0,2006,0.0151881720430108,48.75
"CD013059","CD013059_pub2_data","1|3|Quality of life and psychological well-being|End-of-intervention","Quality of life and psychological well-being",1,3,"End-of-intervention","or","binary",6,-0.205849330142123,0.834186528766235,0,2011.66666666667,0,32.5
"CD013059","CD013059_pub2_data","1|3|Quality of life and psychological well-being|Medium-term","Quality of life and psychological well-being",1,3,"Medium-term","or","binary",2,-0.448108155284041,1.43706864830371,0,2000.5,0,34
"CD013059","CD013059_pub2_data","1|3|Quality of life and psychological well-being|Short-term","Quality of life and psychological well-being",1,3,"Short-term","or","binary",5,-0.231784483993715,0.914270702823583,0,2012.2,0,34
"CD013059","CD013059_pub2_data","1|4|Anxious symptomatology|End-of-intervention","Anxious symptomatology",1,4,"End-of-intervention","or","binary",2,0.0485543902422732,1.45447577090031,0,2013,0,57.5
"CD013059","CD013059_pub2_data","10|1|Depressive symptomatology|","Depressive symptomatology",10,1,"","or","binary",6,-0.102478643249044,0.830787299592342,0,2012.16666666667,0,47
"CD013059","CD013059_pub2_data","11|1|Depressive symptomatology|","Depressive symptomatology",11,1,"","or","binary",14,-0.140416569886603,0.544898005049387,0,2005,0,35.6428571428571
"CD013059","CD013059_pub2_data","12|1|Depressive symptomatology|End-of-intervention","Depressive symptomatology",12,1,"End-of-intervention","or","binary",17,-0.182904719906619,0.494803414497628,0,2004.23529411765,0,34.9411764705882
"CD013059","CD013059_pub2_data","12|1|Depressive symptomatology|Short-term","Depressive symptomatology",12,1,"Short-term","or","binary",15,-0.208978211464837,0.527337072684759,0,2003.46666666667,0,30.8
"CD013059","CD013059_pub2_data","12|2|Quality of life and psychological well-being|End-of-intervention","Quality of life and psychological well-being",12,2,"End-of-intervention","or","binary",5,-0.232052765845103,0.915978761421937,0,2010,0,29
"CD013059","CD013059_pub2_data","12|2|Quality of life and psychological well-being|Short-term","Quality of life and psychological well-being",12,2,"Short-term","or","binary",4,-0.271305366461313,1.02536153904978,0,2010.25,0,30
"CD013059","CD013059_pub2_data","13|1|Depressive symptomatology|End-of-intervention","Depressive symptomatology",13,1,"End-of-intervention","or","binary",17,-0.189543645901988,0.494862050588351,0,2004.94117647059,0,34.1764705882353
"CD013059","CD013059_pub2_data","13|1|Depressive symptomatology|Medium-term","Depressive symptomatology",13,1,"Medium-term","or","binary",7,-0.323496097983567,0.771577671470622,0,2004,0,41.7142857142857
"CD013059","CD013059_pub2_data","13|1|Depressive symptomatology|Short-term","Depressive symptomatology",13,1,"Short-term","or","binary",15,-0.216526128631814,0.527408053722182,0,2004.26666666667,0,29.9333333333333
"CD013059","CD013059_pub2_data","14|1|Depressive symptomatology|End-of-intervention","Depressive symptomatology",14,1,"End-of-intervention","or","binary",17,-0.182879804969039,0.494533637190613,0,2005.47058823529,0,36.4117647058824
"CD013059","CD013059_pub2_data","14|1|Depressive symptomatology|Short-term","Depressive symptomatology",14,1,"Short-term","or","binary",15,-0.208917636887445,0.527010541974174,0,2004.86666666667,0,32.4666666666667
"CD013059","CD013059_pub2_data","15|1|Depressive symptomatology|","Depressive symptomatology",15,1,"","or","binary",18,-0.176990739322173,0.480589042097356,0,2005.11111111111,0,35.7777777777778
"CD013059","CD013059_pub2_data","2|1|Depressive symptomatology (end-of-intervention)|< 54.8 points on a standardised 100-point scale","Depressive symptomatology (end-of-intervention)",2,1,"< 54.8 points on a standardised 100-point scale","or","binary",9,0.00201730232024689,0.678080796065226,0,2008.22222222222,0,41.2222222222222
"CD013059","CD013059_pub2_data","2|1|Depressive symptomatology (end-of-intervention)|> 54.8 points on a standardised 100-point scale","Depressive symptomatology (end-of-intervention)",2,1,"> 54.8 points on a standardised 100-point scale","or","binary",9,-0.357671371389669,0.681241309023526,0,2002,0,30.3333333333333
"CD013059","CD013059_pub2_data","3|1|Depressive symptomatology (end-of-intervention)|BT","Depressive symptomatology (end-of-intervention)",3,1,"BT","or","binary",8,-0.149777390330521,0.721701629629337,0,2004.375,0,37.875
"CD013059","CD013059_pub2_data","3|1|Depressive symptomatology (end-of-intervention)|CBT","Depressive symptomatology (end-of-intervention)",3,1,"CBT","or","binary",5,-0.183169990947427,0.91713926682398,0,1998.2,0,25
"CD013059","CD013059_pub2_data","3|1|Depressive symptomatology (end-of-intervention)|RT","Depressive symptomatology (end-of-intervention)",3,1,"RT","or","binary",6,-0.145595843450272,0.831445405520209,0,2007.5,0,33.8333333333333
"CD013059","CD013059_pub2_data","4|1|Depressive symptomatology (end-of-intervention)|Non-specific attentional control","Depressive symptomatology (end-of-intervention)",4,1,"Non-specific attentional control","or","binary",6,-0.423579589728325,0.831321540253254,0,2003.33333333333,0,34.6666666666667
"CD013059","CD013059_pub2_data","4|1|Depressive symptomatology (end-of-intervention)|Treatment as usual","Depressive symptomatology (end-of-intervention)",4,1,"Treatment as usual","or","binary",12,-0.10645400997257,0.589419948962351,0,2006,0,35.8333333333333
"CD013059","CD013059_pub2_data","5|1|Depressive symptomatology (end-of-intervention)|High cognitive impairment","Depressive symptomatology (end-of-intervention)",5,1,"High cognitive impairment","or","binary",5,-0.393649829472837,0.911752441474922,0,2010.8,0,35.2
"CD013059","CD013059_pub2_data","5|1|Depressive symptomatology (end-of-intervention)|Low cognitive impairment","Depressive symptomatology (end-of-intervention)",5,1,"Low cognitive impairment","or","binary",7,0.0145776387665513,0.772709271842187,0,2007,0,38.1428571428571
"CD013059","CD013059_pub2_data","6|1|Depressive symptomatology (end-of-intervention)|Professional therapist with LTC staff involvement","Depressive symptomatology (end-of-intervention)",6,1,"Professional therapist with LTC staff involvement","or","binary",9,-0.299984667828826,0.678790407594646,0,2008.22222222222,0,33.6666666666667
"CD013059","CD013059_pub2_data","6|1|Depressive symptomatology (end-of-intervention)|Professional therapist without LTC staff involvement","Depressive symptomatology (end-of-intervention)",6,1,"Professional therapist without LTC staff involvement","or","binary",5,-0.132870002054831,0.911451606852156,0,1996.6,0,33.4
"CD013059","CD013059_pub2_data","7|1|Depressive symptomatology, therapeutic contact (weeks)|< 8.5 weeks","Depressive symptomatology, therapeutic contact (weeks)",7,1,"< 8.5 weeks","or","binary",8,-0.129941040530483,0.722224923752535,0,2009.75,0,31.375
"CD013059","CD013059_pub2_data","7|1|Depressive symptomatology, therapeutic contact (weeks)|> 8.5 weeks","Depressive symptomatology, therapeutic contact (weeks)",7,1,"> 8.5 weeks","or","binary",9,-0.229611835614887,0.678567253776478,0,2000.55555555556,0,40.8888888888889
"CD013059","CD013059_pub2_data","7|2|Depressive symptomatology, therapeutic contact (number of sessions)|< 9.5 total sessions","Depressive symptomatology, therapeutic contact (number of sessions)",7,2,"< 9.5 total sessions","or","binary",9,-0.0626264340800769,0.681719647208491,0,2009.44444444444,0,34.4444444444444
"CD013059","CD013059_pub2_data","7|2|Depressive symptomatology, therapeutic contact (number of sessions)|> 9.5 total sessions","Depressive symptomatology, therapeutic contact (number of sessions)",7,2,"> 9.5 total sessions","or","binary",7,-0.362001071904304,0.768450368998604,0,2001,0,38.7142857142857
"CD013059","CD013059_pub2_data","7|3|Depressive symptomatology, therapeutic contact (total treatment dose)|< 6.5 total hours","Depressive symptomatology, therapeutic contact (total treatment dose)",7,3,"< 6.5 total hours","or","binary",6,-0.0922061352140285,0.833354565153697,0,2013.66666666667,0,32
"CD013059","CD013059_pub2_data","7|3|Depressive symptomatology, therapeutic contact (total treatment dose)|> 6.5 total hours","Depressive symptomatology, therapeutic contact (total treatment dose)",7,3,"> 6.5 total hours","or","binary",6,-0.276776980736057,0.838220471007024,0,1995.33333333333,0,22.3333333333333
"CD013059","CD013059_pub2_data","8|1|Depressive symptomatology (end-of-intervention)|","Depressive symptomatology (end-of-intervention)",8,1,"","or","binary",12,-0.216640097888837,0.587699331126664,0,2004.66666666667,0,39.0833333333333
"CD013059","CD013059_pub2_data","9|1|Depressive symptomatology (end-of-intervention)|","Depressive symptomatology (end-of-intervention)",9,1,"","or","binary",4,-0.240128054646806,1.01731421863376,0,2007.75,0,39.5
"CD013071","CD013071_pub2_data","1|1|Erectile function (AMS sexual)|","Erectile function (AMS sexual)",1,1,"","or","binary",3,-0.360980825219251,1.15770493841829,0,2011,0,264
"CD013071","CD013071_pub2_data","1|10|Erectile function (subgroup: age and testosterone level, conversion to IIEF-EF)|All ages over 18 years/testosterone ≤ 12 nmol/L","Erectile function (subgroup: age and testosterone level, conversion to IIEF-EF)",1,10,"All ages over 18 years/testosterone ≤ 12 nmol/L","or","binary",9,-0.0631573257906681,0.671297407784075,0,2011.55555555556,0,194.777777777778
"CD013071","CD013071_pub2_data","1|11|Cardiovascular mortality (subgroup: age and testosterone level)|All ages over 18 years/testosterone ≤ 12 nmol/L","Cardiovascular mortality (subgroup: age and testosterone level)",1,11,"All ages over 18 years/testosterone ≤ 12 nmol/L","or","binary",9,0.020831921225092,0.565140943835576,0,2014.11111111111,0.00341679707876891,304.111111111111
"CD013071","CD013071_pub2_data","1|12|Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)|MS: not reported","Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)",1,12,"MS: not reported","or","binary",6,0.0219640639889647,0.821093937254792,0,2012.83333333333,0,295.833333333333
"CD013071","CD013071_pub2_data","1|12|Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)|MS: participants with MS","Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)",1,12,"MS: participants with MS","or","binary",2,-0.21682877120785,1.4182863447944,0,2013.5,0,178
"CD013071","CD013071_pub2_data","1|12|Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)|MS: participants without MS","Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)",1,12,"MS: participants without MS","or","binary",2,-0.12868323743062,1.4312712256119,0,2008,0,46
"CD013071","CD013071_pub2_data","1|13|Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total)|MS: not reported","Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total)",1,13,"MS: not reported","or","binary",4,-0.234229684940419,1.00429922076411,0,2010.5,0,211
"CD013071","CD013071_pub2_data","1|14|Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF - overall satisfaction)|MS: not reported","Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF - overall satisfaction)",1,14,"MS: not reported","or","binary",2,-0.0101338662291936,1.42599506753569,0,2011.5,0,315
"CD013071","CD013071_pub2_data","1|15|Cardiovascular mortality (subgroup: metabolic syndrome (MS))|MS: not reported","Cardiovascular mortality (subgroup: metabolic syndrome (MS))",1,15,"MS: not reported","or","binary",7,0.0890108292404359,0.615556574648365,0,2013.71428571429,0.00274353396180807,441
"CD013071","CD013071_pub2_data","1|15|Cardiovascular mortality (subgroup: metabolic syndrome (MS))|MS: participants with MS","Cardiovascular mortality (subgroup: metabolic syndrome (MS))",1,15,"MS: participants with MS","or","binary",3,-0.671738598227269,1.07448514514051,0,2015.66666666667,0.00469483568075117,146
"CD013071","CD013071_pub2_data","1|16|Erectile function (conversion to IIEF-EF; sensitivity analysis)|","Erectile function (conversion to IIEF-EF; sensitivity analysis)",1,16,"","or","binary",6,-0.054297838142822,0.818938258796526,0,2014,0,336
"CD013071","CD013071_pub2_data","1|17|Sexual quality of life (AMS total; sensitivity analysis)|","Sexual quality of life (AMS total; sensitivity analysis)",1,17,"","or","binary",5,-0.178682359866689,0.897980779636081,0,2011.8,0,206
"CD013071","CD013071_pub2_data","1|18|Sexual quality of life (IIEF-overall satisfaction; sensitivity analysis)|","Sexual quality of life (IIEF-overall satisfaction; sensitivity analysis)",1,18,"","or","binary",2,0.0113523188037526,1.41668886187355,0,2016.5,0,393
"CD013071","CD013071_pub2_data","1|19|Treatment withdrawal due to adverse events (sensitivity analysis)|","Treatment withdrawal due to adverse events (sensitivity analysis)",1,19,"","or","binary",12,-0.229777580339772,0.198140205506693,0,2012.33333333333,0.0346246270312944,247.166666666667
"CD013071","CD013071_pub2_data","1|2|Erectile function (IIEF)|IIEF-5","Erectile function (IIEF)",1,2,"IIEF-5","or","binary",4,-0.114532534994716,1.00816379595858,0,2011.75,0,86.75
"CD013071","CD013071_pub2_data","1|2|Erectile function (IIEF)|IIEF-EF","Erectile function (IIEF)",1,2,"IIEF-EF","or","binary",7,-0.0146778104793223,0.760978414975605,0,2011.42857142857,0,272.285714285714
"CD013071","CD013071_pub2_data","1|20|Prostate-related events (sensitivity analysis)|","Prostate-related events (sensitivity analysis)",1,20,"","or","binary",10,0.468345724309919,0.22639931460815,0.0239424077703291,2013.5,0.0215148324762937,343.9
"CD013071","CD013071_pub2_data","1|21|Lower urinary tract symptoms (sensitivity analysis)|","Lower urinary tract symptoms (sensitivity analysis)",1,21,"","or","binary",6,-0.146288286578971,0.819390633806347,0,2011,0,248
"CD013071","CD013071_pub2_data","1|3|Erectile function (conversion to IIEF-EF)|","Erectile function (conversion to IIEF-EF)",1,3,"","or","binary",10,-0.0559163784786888,0.636473476505619,0,2012,0,222.3
"CD013071","CD013071_pub2_data","1|4|Sexual quality of life (AMS total)|","Sexual quality of life (AMS total)",1,4,"","or","binary",6,-0.149095481387103,0.820273048195148,0,2012.66666666667,0,182
"CD013071","CD013071_pub2_data","1|5|Sexual quality of life (IIEF-overall satisfaction)|","Sexual quality of life (IIEF-overall satisfaction)",1,5,"","or","binary",4,-0.0581788490811754,1.00886592347949,0,2009.75,0,211.5
"CD013071","CD013071_pub2_data","1|6|Cardiovascular mortality|","Cardiovascular mortality",1,6,"","or","binary",10,-0.0989702463885669,0.534117323147375,0,2014.3,0.003328924477491,352.5
"CD013071","CD013071_pub2_data","1|7|Treatment withdrawal due to adverse events|","Treatment withdrawal due to adverse events",1,7,"","or","binary",19,-0.31238421950244,0.180814331209598,0,2009.15789473684,0.0591411925725504,175.789473684211
"CD013071","CD013071_pub2_data","1|8|Prostate-related events|","Prostate-related events",1,8,"","or","binary",11,0.4621772859405,0.224164580612729,0.0218554292419643,2012.90909090909,0.0195589386148125,316.090909090909
"CD013071","CD013071_pub2_data","1|9|Lower urinary tract symptoms|","Lower urinary tract symptoms",1,9,"","or","binary",9,-0.126691646142483,0.670428837292579,0,2011.66666666667,0,182.666666666667
"CD013071","CD013071_pub2_data","2|2|Treatment withdrawal due to adverse events|","Treatment withdrawal due to adverse events",2,2,"","or","binary",2,-0.0432720574147894,0.457296399482769,0,2009,0.243548387096774,61
"CD013071","CD013071_pub2_data","4|1|Erectile function|IIEF-5","Erectile function",4,1,"IIEF-5","or","binary",2,0.00568180490841989,1.42372391110465,0,2011.5,0,74
"CD013071","CD013071_pub2_data","4|1|Erectile function|IIEF-EF","Erectile function",4,1,"IIEF-EF","or","binary",2,-0.00264914640684416,1.41935562382981,0,2011.5,0,141
"CD013071","CD013071_pub2_data","4|2|Erectile function (conversion to IIEF-EF)|","Erectile function (conversion to IIEF-EF)",4,2,"","or","binary",4,0.00150352908031794,1.00517684988403,0,2011.5,0,107.5
"CD013071","CD013071_pub2_data","4|3|Sexual quality of life (IIEF - overall satisfaction)|","Sexual quality of life (IIEF - overall satisfaction)",4,3,"","or","binary",2,-0.00264914640684416,1.41935562382981,0,2011.5,0,141
"CD013071","CD013071_pub2_data","4|5|Treatment withdrawal due to adverse events|","Treatment withdrawal due to adverse events",4,5,"","or","binary",3,0.230920556778561,0.683411229186288,0.505733350712905,2009,0.0318936877076412,129.333333333333
"CD013071","CD013071_pub2_data","4|6|Prostate-related events|","Prostate-related events",4,6,"","or","binary",3,1.53708959200573,0.952163702194987,0,2011,0,124.333333333333
"CD013071","CD013071_pub2_data","4|7|Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)|MS: not reported","Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)",4,7,"MS: not reported","or","binary",3,0.0180355372536546,1.16035827773736,0,2011,0,116
"CD013078","CD013078_pub2_data","1|1|Pain intensity at the end of the treatment (6 months)|NA","Pain intensity at the end of the treatment (6 months)",1,1,NA,"reported","reported",2,0,6.17766855643757,0,2022,0,18
"CD013078","CD013078_pub2_data","1|2|Function at the end of treatment|NA","Function at the end of treatment",1,2,NA,"reported","reported",3,0,3.97143032453096,0,2016.33333333333,0,22.3333333333333
"CD013078","CD013078_pub2_data","2|1|Pain intensity at the end of treatment|NA","Pain intensity at the end of treatment",2,1,NA,"or","binary",2,-0.730887508542792,1.45394639308336,0,2009,0,19
"CD013078","CD013078_pub2_data","2|2|Pain intensity at 6 months|NA","Pain intensity at 6 months",2,2,NA,"or","binary",2,-0.730887508542792,1.45394639308336,0,2009,0,19
"CD013078","CD013078_pub2_data","2|3|Function at the end of treatment|NA","Function at the end of treatment",2,3,NA,"or","binary",2,-0.730887508542792,1.45394639308336,0,2009,0,19
"CD013078","CD013078_pub2_data","2|4|Function at 6 months' follow-up|NA","Function at 6 months' follow-up",2,4,NA,"or","binary",2,-0.692433936569642,1.45445541627569,0,2009,0,18.5
"CD013105","CD013105_pub2_data","1|5|Adverse events |Bladder injury ","Adverse events ",1,5,"Bladder injury ","or","binary",2,0.0556116458463364,1.43375283972123,0,2013.5,0,38
"CD013105","CD013105_pub2_data","1|6|Patient-reported outcome measures |Colorectal Anal Distress Inventory (CRADI 0-100)","Patient-reported outcome measures ",1,6,"Colorectal Anal Distress Inventory (CRADI 0-100)","or","binary",3,0.0362979261677536,1.16182983494051,0,2018,0,97
"CD013105","CD013105_pub2_data","1|6|Patient-reported outcome measures |Pelvic Floor Distress Inventory-20 ( PFDI-20) higher the score greater dysfunction (range 0-300)","Patient-reported outcome measures ",1,6,"Pelvic Floor Distress Inventory-20 ( PFDI-20) higher the score greater dysfunction (range 0-300)","or","binary",3,0.0290786322071214,1.16105187603655,0,2015.66666666667,0,170.666666666667
"CD013105","CD013105_pub2_data","1|6|Patient-reported outcome measures |Pelvic Organ Prolapse - Distress inventory (POP-DI range 0-100)","Patient-reported outcome measures ",1,6,"Pelvic Organ Prolapse - Distress inventory (POP-DI range 0-100)","or","binary",2,0.0410633249411082,1.42495429923299,0,2016.5,0,71.5
"CD013105","CD013105_pub2_data","1|6|Patient-reported outcome measures |Urinary Distress Inventory (UDI) range 0-100","Patient-reported outcome measures ",1,6,"Urinary Distress Inventory (UDI) range 0-100","or","binary",3,0.0272992249869188,1.16184726236377,0,2018,0,96.3333333333333
"CD013105","CD013105_pub2_data","10|4|Patient-reported outcome measures |Pelvic Floor Distress Inventory -20 ( PFDI-20)","Patient-reported outcome measures ",10,4,"Pelvic Floor Distress Inventory -20 ( PFDI-20)","or","binary",2,0.096953775422545,1.42083731670334,0,2018,0,114.5
"CD013105","CD013105_pub2_data","11|1|Bladder function |Urinary tract infections ","Bladder function ",11,1,"Urinary tract infections ","or","binary",2,0.0873941857203017,0.307307618854535,0,2018.5,0.15,122
"CD013105","CD013105_pub2_data","12|2|Bladder function |Urinary tract infections ","Bladder function ",12,2,"Urinary tract infections ","or","binary",2,-0.380117423630076,0.314065335870294,0,2022,0.181348221670802,144.5
"CD013105","CD013105_pub2_data","13|1|Patient-reported outcome measures |Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ)","Patient-reported outcome measures ",13,1,"Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ)","reported","reported",2,0,0.287998272879105,0,2013,0,50
"CD013105","CD013105_pub2_data","2|1|Bladder function |Urinary tract infections ","Bladder function ",2,1,"Urinary tract infections ","or","binary",4,-0.968503994587584,0.604864371944967,0.741514180162265,2018,0.234935344827586,95.25
"CD013105","CD013105_pub2_data","2|3|Perioperative outcomes |Length of stay (days) ","Perioperative outcomes ",2,3,"Length of stay (days) ","or","binary",3,0.0126174324148271,1.16410796456011,0,2018.33333333333,0,60.3333333333333
"CD013105","CD013105_pub2_data","3|2|Bladder function |Urinary tract infections ","Bladder function ",3,2,"Urinary tract infections ","or","binary",2,2.15242874392646,0.464675899306436,0,2014.5,0.0255102040816327,137
"CD013105","CD013105_pub2_data","5|3|Bowel function |Surgeons satisfaction with surgical field ","Bowel function ",5,3,"Surgeons satisfaction with surgical field ","or","binary",4,0.293008959586592,0.571187716578551,1.03989921124018,2018.5,0.757758166491043,120
"CD013105","CD013105_pub2_data","7|1|Perioperative outcomes |Estimated blood loss (mL) ","Perioperative outcomes ",7,1,"Estimated blood loss (mL) ","or","binary",2,-0.052022105877933,1.42376476458239,0,2018.5,0,73
"CD013111","CD013111_pub2_data","1|1|Metformin plus progestin compared to progestin. Live birth rate. RCTs|NA","Metformin plus progestin compared to progestin. Live birth rate. RCTs",1,1,NA,"or","binary",2,0.82351858842547,0.510080930149367,0,2017,0.274774774774775,36
"CD013111","CD013111_pub2_data","1|2|Metformin plus progestin compared to progestin. Complete pathological response rate (12-16 weeks). RCTs|NA","Metformin plus progestin compared to progestin. Complete pathological response rate (12-16 weeks). RCTs",1,2,NA,"or","binary",2,0.912334682267686,0.48660944951472,0.126474585037893,2017,0.228448275862069,70.5
"CD013111","CD013111_pub2_data","1|3|Metformin plus progestin compared to progestin.  Pregnancy rate. RCTs|NA","Metformin plus progestin compared to progestin.  Pregnancy rate. RCTs",1,3,NA,"or","binary",2,0.0742939217685955,0.465896178494504,0,2017,0.408602150537634,36
"CD013111","CD013111_pub2_data","1|4|Metformin plus progestin compared to progestin. Surgery for persistent/progressive disease (hysterectomy). RCTs|NA","Metformin plus progestin compared to progestin. Surgery for persistent/progressive disease (hysterectomy). RCTs",1,4,NA,"or","binary",2,-0.0141937209161978,0.683436003483491,0,2017,0.138513513513514,83
"CD013158","CD013158_pub2_data","1|1|Mortality prior to hospital discharge|NA","Mortality prior to hospital discharge",1,1,NA,"or","binary",3,0.124268165044945,0.618383978876946,0.557821330581248,2011,0.058257345491388,187.333333333333
"CD013158","CD013158_pub2_data","1|2|Bronchopulmonary dysplasia|NA","Bronchopulmonary dysplasia",1,2,NA,"or","binary",3,-0.129323026186887,0.232664836553284,0,2011,0.164274456827648,187.333333333333
"CD013158","CD013158_pub2_data","1|3|Surfactant utilization (number of infants receiving surfactant)|NA","Surfactant utilization (number of infants receiving surfactant)",1,3,NA,"or","binary",3,-0.305352879579021,0.342231887895427,0.215213908346566,2011,0.651759915944313,187.333333333333
"CD013158","CD013158_pub2_data","1|4|Any pneumothorax|NA","Any pneumothorax",1,4,NA,"or","binary",2,-0.579057239148612,0.637381800947234,0,2006.5,0.0212343802769335,253
"CD013158","CD013158_pub2_data","1|5|Retinopathy of prematurity (all grades)|NA","Retinopathy of prematurity (all grades)",1,5,NA,"or","binary",2,-0.272418705594253,0.367732417172368,0,2006.5,0.14289935832489,253
"CD013166","CD013166_pub3_data","1|1|Erectile function |","Erectile function ",1,1,"","reported","reported",4,0,0.612757582171285,0,2015,0,59.5
"CD013166","CD013166_pub3_data","1|2|Discontinuation from treatment|","Discontinuation from treatment",1,2,"","reported","reported",3,0,0.841461090917023,0,2019.33333333333,0.0741496598639456,73.6666666666667
"CD013166","CD013166_pub3_data","1|4|Penile rigidity|","Penile rigidity",1,4,"","or","binary",4,0.00185430994583702,1.00800516029308,0,2021,0,63
"CD013166","CD013166_pub3_data","2|3|Subgroup analysis by PDE-5i response status: treatment-related adverse events|PDE-5i responders","Subgroup analysis by PDE-5i response status: treatment-related adverse events",2,3,"PDE-5i responders","or","binary",2,-0.0242977690907127,1.42282411223942,0,2017,0,91.5
"CD013166","CD013166_pub3_data","3|1|Erectile function |","Erectile function ",3,1,"","reported","reported",2,0,0.896520797922098,0,2016.5,0,50.5
"CD013166","CD013166_pub3_data","3|2|Discontinuation from treatment|","Discontinuation from treatment",3,2,"","reported","reported",3,0,0.841461090917023,0,2019.33333333333,0.0741496598639456,73.6666666666667
"CD013166","CD013166_pub3_data","3|3|Treatment-related adverse events|","Treatment-related adverse events",3,3,"","or","binary",14,-0.156636101926733,0.47739197850201,0,2018.64285714286,0.00264550264550265,69.3571428571429
"CD013166","CD013166_pub3_data","4|2|Treatment-related adverse events|","Treatment-related adverse events",4,2,"","or","binary",6,-0.132602492193853,0.823051802296437,0,2019.33333333333,0,68.5
"CD013166","CD013166_pub3_data","4|3|Penile rigidity|","Penile rigidity",4,3,"","or","binary",3,-0.0610588826112545,1.16478943233055,0,2019.33333333333,0,56.3333333333333
"CD013166","CD013166_pub3_data","5|1|Subgroup analysis by PDE-5i response status: treatment-related adverse events|PDE-5i responders","Subgroup analysis by PDE-5i response status: treatment-related adverse events",5,1,"PDE-5i responders","or","binary",2,-0.0242977690907127,1.42282411223942,0,2017,0,91.5
"CD013166","CD013166_pub3_data","6|1|Erectile function|","Erectile function",6,1,"","or","binary",3,-0.0610588826112545,1.16478943233055,0,2019.33333333333,0,56.3333333333333
"CD013166","CD013166_pub3_data","6|2|Treatment-related adverse events|","Treatment-related adverse events",6,2,"","or","binary",6,-0.132602492193853,0.823051802296437,0,2019.33333333333,0,68.5
"CD013197","CD013197_pub2_data","1|1|All-cause mortality short-term|","All-cause mortality short-term",1,1,"","reported","reported",2,7.21143036909244,65.5873115055376,0,2021,0,172
"CD013197","CD013197_pub2_data","1|10|Postoperative pain 24 hours after surgery|","Postoperative pain 24 hours after surgery",1,10,"","reported","reported",16,-0.593781376174919,0.245186255042883,0.791815220934087,2019.26666666667,NA,87.75
"CD013197","CD013197_pub2_data","1|12|Measures of early postoperative recovery: length of hospital stay|","Measures of early postoperative recovery: length of hospital stay",1,12,"","reported","reported",19,-0.27302644751639,0.194643517867203,0.364747623803162,2020.15789473684,NA,109.684210526316
"CD013197","CD013197_pub2_data","1|13|Operating time|","Operating time",1,13,"","reported","reported",34,-0.50989810881127,1.51246518762736,26.7666906081603,2019.05882352941,NA,92.4411764705882
"CD013197","CD013197_pub2_data","1|14|Postoperative pain one hour after surgery or at PACU: subgroup BMI|High BMI","Postoperative pain one hour after surgery or at PACU: subgroup BMI",1,14,"High BMI","reported","reported",9,-0.478713292477908,0.191507568875927,0.0878317214185062,2019,NA,85.6666666666667
"CD013197","CD013197_pub2_data","1|14|Postoperative pain one hour after surgery or at PACU: subgroup BMI|Normal BMI","Postoperative pain one hour after surgery or at PACU: subgroup BMI",1,14,"Normal BMI","reported","reported",12,-0.203711853885995,0.180122941933364,0.257928062108781,2018.91666666667,NA,82.0833333333333
"CD013197","CD013197_pub2_data","1|15|Postoperative pain 24 hours after surgery: subgroup BMI|High BMI","Postoperative pain 24 hours after surgery: subgroup BMI",1,15,"High BMI","reported","reported",6,-0.350519069858026,0.180215778140412,0.0674893923311273,2019.33333333333,NA,101.666666666667
"CD013197","CD013197_pub2_data","1|15|Postoperative pain 24 hours after surgery: subgroup BMI|Normal BMI","Postoperative pain 24 hours after surgery: subgroup BMI",1,15,"Normal BMI","reported","reported",10,-0.72163789857186,0.37326506487383,1.21377554439989,2019.22222222222,NA,79.4
"CD013197","CD013197_pub2_data","1|16|Postoperative pain one hour after surgery or at PACU: subgroup intra-abdominal pressure|Low-pressure pneumoperitoneum","Postoperative pain one hour after surgery or at PACU: subgroup intra-abdominal pressure",1,16,"Low-pressure pneumoperitoneum","reported","reported",8,-0.630572450378442,0.213180412517154,0.190143957277191,2018.5,NA,82.5
"CD013197","CD013197_pub2_data","1|16|Postoperative pain one hour after surgery or at PACU: subgroup intra-abdominal pressure|Standard-pressure pneumoperitoneum","Postoperative pain one hour after surgery or at PACU: subgroup intra-abdominal pressure",1,16,"Standard-pressure pneumoperitoneum","reported","reported",14,-0.101108541132891,0.130844685041738,0.0792632821327633,2019.42857142857,NA,83.0714285714286
"CD013197","CD013197_pub2_data","1|17|Postoperative pain 24 hours after surgery: subgroup intra-abdominal pressure|Low-pressure pneumoperitoneum","Postoperative pain 24 hours after surgery: subgroup intra-abdominal pressure",1,17,"Low-pressure pneumoperitoneum","reported","reported",8,-0.753803010581412,0.244698570480598,0.322070923827731,2018.85714285714,NA,79
"CD013197","CD013197_pub2_data","1|17|Postoperative pain 24 hours after surgery: subgroup intra-abdominal pressure|Standard-pressure pneumoperitoneum","Postoperative pain 24 hours after surgery: subgroup intra-abdominal pressure",1,17,"Standard-pressure pneumoperitoneum","reported","reported",8,-0.451246507733887,0.433818900734564,1.34732144501931,2019.625,NA,96.5
"CD013197","CD013197_pub2_data","1|18|Serious adverse events (sensitivity analysis)|Best-worst case short-term","Serious adverse events (sensitivity analysis)",1,18,"Best-worst case short-term","or","binary",16,-0.854278768935062,0.268463264545117,0.307476310787313,2019.625,0.112854572004194,119.8125
"CD013197","CD013197_pub2_data","1|18|Serious adverse events (sensitivity analysis)|Best-worst case start of surgery until 8 hours after surgery","Serious adverse events (sensitivity analysis)",1,18,"Best-worst case start of surgery until 8 hours after surgery","or","binary",20,-0.213973842098559,0.216035402232531,0,2019,0.0519276644631729,109.6
"CD013197","CD013197_pub2_data","1|18|Serious adverse events (sensitivity analysis)|Worst-best case short-term","Serious adverse events (sensitivity analysis)",1,18,"Worst-best case short-term","or","binary",16,0.598925647751968,0.309271441329579,0.596720259131729,2019.625,0.0623112046817213,119.8125
"CD013197","CD013197_pub2_data","1|18|Serious adverse events (sensitivity analysis)|Worst-best case start of surgery until 8 hours after surgery","Serious adverse events (sensitivity analysis)",1,18,"Worst-best case start of surgery until 8 hours after surgery","or","binary",20,0.196922949970465,0.217505703129545,0,2019,0.0414175408107342,109.6
"CD013197","CD013197_pub2_data","1|19|Non-serious adverse events (sensitivity analysis)|Best-worst case start of surgery until 8 hours after surgery","Non-serious adverse events (sensitivity analysis)",1,19,"Best-worst case start of surgery until 8 hours after surgery","or","binary",11,-0.721388338478421,0.383959490829804,0.623606489642763,2019.5,0.101316826768978,114.727272727273
"CD013197","CD013197_pub2_data","1|19|Non-serious adverse events (sensitivity analysis)|Best-worst short-term","Non-serious adverse events (sensitivity analysis)",1,19,"Best-worst short-term","or","binary",11,-0.558370581857023,0.202819035533893,0.082599998853243,2019.72727272727,0.18095315222487,124.272727272727
"CD013197","CD013197_pub2_data","1|19|Non-serious adverse events (sensitivity analysis)|Worst-best case start of surgery until 8 hours after surgery","Non-serious adverse events (sensitivity analysis)",1,19,"Worst-best case start of surgery until 8 hours after surgery","or","binary",11,0.201686683529897,0.266358337140631,0.130851737388736,2019.5,0.0676653148821718,114.727272727273
"CD013197","CD013197_pub2_data","1|19|Non-serious adverse events (sensitivity analysis)|Worst-best short-term","Non-serious adverse events (sensitivity analysis)",1,19,"Worst-best short-term","or","binary",11,0.52020956646401,0.266481430018782,0.316348643541918,2019.72727272727,0.115710109588843,124.272727272727
"CD013197","CD013197_pub2_data","1|2|Health-related quality of life short-term|","Health-related quality of life short-term",1,2,"","reported","reported",5,4.42189552479024,2.04398963571205,3.25270753100069,2020.4,NA,88
"CD013197","CD013197_pub2_data","1|4|Serious adverse events (SAEs) start of surgery until eight hours after surgery|","Serious adverse events (SAEs) start of surgery until eight hours after surgery",1,4,"","reported","reported",14,0.488732380803687,0.239964752483356,0.0526226786254061,2019.15384615385,0.0594405728939829,92.3571428571429
"CD013197","CD013197_pub2_data","1|5|Serious adverse events (SAEs) short-term|","Serious adverse events (SAEs) short-term",1,5,"","reported","reported",14,0.503455334198141,0.205665282714863,0,2019.92857142857,0.0725287681399958,96.5714285714286
"CD013197","CD013197_pub2_data","1|6|Non-serious adverse events (nSAEs) start of surgery until eight hours after surgery|","Non-serious adverse events (nSAEs) start of surgery until eight hours after surgery",1,6,"","reported","reported",8,0.377384304833462,0.146535068491539,0,2019.57142857143,0.0972320419671624,97.625
"CD013197","CD013197_pub2_data","1|7|Non-serious adverse events (nSAEs) short-term|","Non-serious adverse events (nSAEs) short-term",1,7,"","reported","reported",9,0.718448735865793,0.170220694584708,0,2020.11111111111,0.15043844059151,98.7777777777778
"CD013197","CD013197_pub2_data","1|8|Readmissions within three months after surgery|","Readmissions within three months after surgery",1,8,"","reported","reported",5,0.143430745242124,0.266167333321607,0,2019.8,0.0519088793412102,78.8
"CD013197","CD013197_pub2_data","1|9|Postoperative pain one hour after surgery or at postanaesthesia care unit (PACU)|","Postoperative pain one hour after surgery or at postanaesthesia care unit (PACU)",1,9,"","reported","reported",22,-0.312757643538705,0.131303041707375,0.200007815281526,2019.09090909091,NA,82.8636363636364
"CD013197","CD013197_pub2_data","2|1|Serious adverse events (SAEs) short-term|","Serious adverse events (SAEs) short-term",2,1,"","reported","reported",2,1.39930455156461,1.3375070493729,0,2015,0.0490118577075099,79
"CD013197","CD013197_pub2_data","2|2|Readmissions within three months after surgery|","Readmissions within three months after surgery",2,2,"","reported","reported",2,1.36773451825643,1.50760458703361,0,2015,0.0272727272727273,79
"CD013197","CD013197_pub2_data","2|3|Measures of early postoperative recovery: length of hospital stay|","Measures of early postoperative recovery: length of hospital stay",2,3,"","reported","reported",2,0.00837062855413367,0.178442085767577,0,2016,NA,99.5
"CD013197","CD013197_pub2_data","2|4|Operating time|","Operating time",2,4,"","reported","reported",3,-3.9552581577468,2.6447843517068,0,2015.33333333333,NA,82.3333333333333
"CD013232","CD013232_pub2_data","1|1|Irritability|Lurasidone vs placebo","Irritability",1,1,"Lurasidone vs placebo","or","binary",2,-0.692900470502411,1.42478656985334,0,2016,0,74
"CD013232","CD013232_pub2_data","1|1|Irritability|Risperidone vs placebo","Irritability",1,1,"Risperidone vs placebo","or","binary",6,0.0249859038273088,0.825650713684937,0,2004.4,0,55.5
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Aggression","Adverse effects: neurological",1,12,"Aggression","or","binary",4,-1.06651757544318,0.518642127451852,0,2011.25,0.0548055501270276,115.25
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Agitation/excitation","Adverse effects: neurological",1,12,"Agitation/excitation","or","binary",2,-0.737790616757739,0.669398938270892,0,2005.5,0.184821428571429,48.5
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Dizziness","Adverse effects: neurological",1,12,"Dizziness","or","binary",2,1.42877034676014,0.677490580320544,0,2002,0.0196078431372549,69.5
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Fatigue","Adverse effects: neurological",1,12,"Fatigue","or","binary",9,1.33805525059914,0.293874430398675,0,2011.11111111111,0.0422389810625105,97.8888888888889
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Headache","Adverse effects: neurological",1,12,"Headache","or","binary",6,0.144375574661772,0.325959901474318,0.0707578682905895,2007.4,0.0804050851109675,99.5
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Hyperactivity","Adverse effects: neurological",1,12,"Hyperactivity","or","binary",3,-0.739186444303032,0.615236364442621,0,2009.33333333333,0.0598972922502334,101.666666666667
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Hypersomnia","Adverse effects: neurological",1,12,"Hypersomnia","or","binary",2,0.868386797806197,0.864411755094955,0,2011,0.0142857142857143,141
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Insomnia","Adverse effects: neurological",1,12,"Insomnia","or","binary",7,-0.470126002352637,0.253987243778147,0,2008.5,0.136862239230815,97
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Restlessness (akathisia)","Adverse effects: neurological",1,12,"Restlessness (akathisia)","or","binary",5,0.021931669154613,0.504358774656247,0.222884899233313,2011.2,0.0292436974789916,106.2
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Sedation","Adverse effects: neurological",1,12,"Sedation","or","binary",6,1.28333906760015,0.526152852607086,0.347688909380062,2009.66666666667,0.0655555555555555,61
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Somnolence","Adverse effects: neurological",1,12,"Somnolence","or","binary",10,1.8159963168896,0.284820933498981,0.221099080382427,2009.33333333333,0.0584023917259211,86.9
"CD013232","CD013232_pub2_data","1|12|Adverse effects: neurological|Tremor","Adverse effects: neurological",1,12,"Tremor","or","binary",5,1.65724416231262,0.55300083590226,0,2007.6,0.00857273141814865,114.8
"CD013232","CD013232_pub2_data","1|13|Adverse effects: psychological|Anxiety","Adverse effects: psychological",1,13,"Anxiety","or","binary",2,0.381707959665699,0.455303151741274,0,2002,0.0980392156862745,69.5
"CD013232","CD013232_pub2_data","1|13|Adverse effects: psychological|Depression","Adverse effects: psychological",1,13,"Depression","or","binary",2,1.47938795344199,1.16061960063647,0,2010,0,39.5
"CD013232","CD013232_pub2_data","1|14|Adverse effects: respiratory|Nasal congestion","Adverse effects: respiratory",1,14,"Nasal congestion","or","binary",2,0.609326115224488,0.676326434508336,0,2009,0.0198039215686275,156.5
"CD013232","CD013232_pub2_data","1|14|Adverse effects: respiratory|Nasopharyngitis","Adverse effects: respiratory",1,14,"Nasopharyngitis","or","binary",7,0.284539861247902,0.306061318032472,0,2013.42857142857,0.0605798288307571,100.285714285714
"CD013232","CD013232_pub2_data","1|14|Adverse effects: respiratory|Upper respiratory tract infection","Adverse effects: respiratory",1,14,"Upper respiratory tract infection","or","binary",6,0.763012701222787,0.374751214906895,0.112382574250954,2008.5,0.0574815137742634,106.666666666667
"CD013232","CD013232_pub2_data","1|15|Adverse effects: skin|Rash","Adverse effects: skin",1,15,"Rash","or","binary",2,-0.344592874248721,0.837381539381139,0,2005,0.0931372549019608,114
"CD013232","CD013232_pub2_data","1|16|Adverse effects: urinary|Enuresis","Adverse effects: urinary",1,16,"Enuresis","or","binary",6,0.136659300925402,0.320700799717782,0,2005.33333333333,0.0933986928104575,92
"CD013232","CD013232_pub2_data","1|17|Quality of life|","Quality of life",1,17,"","or","binary",2,-0.578451930475315,1.42726854146565,0,2009,0,67.5
"CD013232","CD013232_pub2_data","1|18|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",1,18,"","or","binary",15,-0.868689547974328,0.182206817234458,0.0387038866218434,2008.69230769231,0.276061182454296,66.9333333333333
"CD013232","CD013232_pub2_data","1|19|Subgroup analysis: age - irritability|Children only","Subgroup analysis: age - irritability",1,19,"Children only","or","binary",13,-0.36791822945683,0.560395111899745,0,2010,0,69.8461538461538
"CD013232","CD013232_pub2_data","1|2|Relapse|","Relapse",1,2,"","or","binary",2,-1.93863682625988,0.601827106724773,0,2005,0.645833333333333,28
"CD013232","CD013232_pub2_data","1|21|Subgroup analysis: cognitive ability - irritability|Mixed IQ","Subgroup analysis: cognitive ability - irritability",1,21,"Mixed IQ","or","binary",13,-0.346640563832855,0.559613403260431,0,2009.30769230769,0,71.1538461538462
"CD013232","CD013232_pub2_data","1|3|Improvement|Ariprazole vs placebo","Improvement",1,3,"Ariprazole vs placebo","or","binary",4,0.738408918879167,0.278764381944901,0,2009,0.297652714932127,75.75
"CD013232","CD013232_pub2_data","1|3|Improvement|Risperidone vs placebo","Improvement",1,3,"Risperidone vs placebo","or","binary",2,2.40832065197917,0.398601872504477,0.0192337144882311,2007.5,0.257692307692308,83.5
"CD013232","CD013232_pub2_data","1|6|Adverse effects: cardiovascular|Tachycardia","Adverse effects: cardiovascular",1,6,"Tachycardia","or","binary",2,1.86326557862487,0.789163008957852,0,2003,0.00980392156862745,89.5
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Abdominal pain","Adverse effects: gastrointestinal",1,7,"Abdominal pain","or","binary",4,0.923214156509574,0.491209497906103,0,2008.66666666667,0.024132730015083,100
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",1,7,"Constipation","or","binary",8,0.876305242513814,0.327627317591175,0,2010,0.031482439129498,74.5
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",1,7,"Diarrhoea","or","binary",5,-0.0643830553971325,0.410777330948344,0,2006.75,0.0599626517273576,63.6
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Drooling","Adverse effects: gastrointestinal",1,7,"Drooling","or","binary",2,2.35432519812794,1.04266545443666,0,2009,0,156.5
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Dry mouth","Adverse effects: gastrointestinal",1,7,"Dry mouth","or","binary",2,0.742534712132893,0.545697352651605,0,2000,0.0490196078431373,65.5
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Hypersalivation","Adverse effects: gastrointestinal",1,7,"Hypersalivation","or","binary",5,1.36740322035315,0.424855991666188,0,2003.8,0.020814479638009,89.8
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Nausea","Adverse effects: gastrointestinal",1,7,"Nausea","or","binary",5,0.360219320008595,0.439111191404443,0,2011.2,0.0292436974789916,106.2
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Stomach ache","Adverse effects: gastrointestinal",1,7,"Stomach ache","or","binary",2,-0.756768617337778,0.540098031670822,0,2007.5,0.13109243697479,83
"CD013232","CD013232_pub2_data","1|7|Adverse effects: gastrointestinal|Vomiting/nausea","Adverse effects: gastrointestinal",1,7,"Vomiting/nausea","or","binary",10,0.71558121492234,0.241699200109716,0,2011.11111111111,0.065629148856919,92
"CD013232","CD013232_pub2_data","1|8|Adverse effects: immune system|Cough","Adverse effects: immune system",1,8,"Cough","or","binary",4,0.300512636458626,0.403144377068381,0,2011.25,0.0558616138763198,111
"CD013232","CD013232_pub2_data","1|8|Adverse effects: immune system|Pyrexia","Adverse effects: immune system",1,8,"Pyrexia","or","binary",5,0.868476812486612,0.502528668761051,0.205980900926403,2009.8,0.0398974358974359,108
"CD013232","CD013232_pub2_data","1|9|Adverse effects: metabolic (dichotomous)|Decreased appetite","Adverse effects: metabolic (dichotomous)",1,9,"Decreased appetite","or","binary",6,0.688190258651199,0.450178485091498,0,2009.6,0.031313893078599,71
"CD013232","CD013232_pub2_data","1|9|Adverse effects: metabolic (dichotomous)|Increased appetite","Adverse effects: metabolic (dichotomous)",1,9,"Increased appetite","or","binary",10,1.07406331107792,0.293933412836665,0.208729566055383,2008.33333333333,0.0967983293496289,70.2
"CD013232","CD013232_pub2_data","1|9|Adverse effects: metabolic (dichotomous)|Thirst","Adverse effects: metabolic (dichotomous)",1,9,"Thirst","or","binary",3,0.360569999686831,0.489108129082556,0,2008,0.0392156862745098,127.333333333333
"CD013232","CD013232_pub2_data","1|9|Adverse effects: metabolic (dichotomous)|Weight gain","Adverse effects: metabolic (dichotomous)",1,9,"Weight gain","or","binary",5,0.669100334023502,0.485310861287481,0,2013.5,0.0236834733893557,94
"CD013232","CD013232_pub2_data","11|1|Irritability (continuous)|","Irritability (continuous)",11,1,"","reported","reported",2,0,0.245487980233649,0,2011,0,25
"CD013232","CD013232_pub2_data","11|10|Adverse events: respiratory|Cough","Adverse events: respiratory",11,10,"Cough","or","binary",2,0.55716684406564,0.531727092051283,0,2018,0.0308401639344262,219
"CD013232","CD013232_pub2_data","11|10|Adverse events: respiratory|Nasopharyngitis","Adverse events: respiratory",11,10,"Nasopharyngitis","or","binary",2,-0.440643217740669,0.854831254115687,0.676529229986193,2018,0.047233606557377,219
"CD013232","CD013232_pub2_data","11|13|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",11,13,"","or","binary",5,-0.123590756721217,0.198351248173606,0,2016.8,0.299793222932924,110.6
"CD013232","CD013232_pub2_data","11|14|Subgroup analysis: age - irritability (continuous)|Children only","Subgroup analysis: age - irritability (continuous)",11,14,"Children only","reported","reported",2,0,0.245487980233649,0,2011,0,25
"CD013232","CD013232_pub2_data","11|3|Aggression|","Aggression",11,3,"","reported","reported",2,0,0.247402926592042,0,2011,0,25
"CD013232","CD013232_pub2_data","11|4|Adverse effects: gastrointestinal|Abdominal pain","Adverse effects: gastrointestinal",11,4,"Abdominal pain","or","binary",2,-0.0307410381343495,0.74381572356542,0,2013,0.0726190476190476,41.5
"CD013232","CD013232_pub2_data","11|4|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",11,4,"Constipation","or","binary",2,-1.17018936005696,1.1754374021076,0,2013.5,0.0488095238095238,41.5
"CD013232","CD013232_pub2_data","11|4|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",11,4,"Vomiting","or","binary",2,-0.622657440887875,0.59094764890219,0,2018,0.0585553278688525,219
"CD013232","CD013232_pub2_data","11|5|Adverse events: metabolic|Decreased appetite","Adverse events: metabolic",11,5,"Decreased appetite","or","binary",4,-0.00911210026336096,0.675250569877916,0,2012,0.05,40.75
"CD013232","CD013232_pub2_data","11|5|Adverse events: metabolic|Increased appetite","Adverse events: metabolic",11,5,"Increased appetite","or","binary",4,0.158322968579592,0.485375234675229,8.73414785375123e-07,2012,0.125,40.75
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Daytime drowsiness","Adverse effects: neurological",11,7,"Daytime drowsiness","or","binary",2,-0.152575820740935,0.54590446000909,0,2011,0.25,40
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Dizziness","Adverse effects: neurological",11,7,"Dizziness","or","binary",2,-0.0154465401447639,0.680680648606437,0,2013,0.0988095238095238,41.5
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Fatigue","Adverse effects: neurological",11,7,"Fatigue","or","binary",2,0.326728368137368,0.596733165717171,0,2010.5,0.122619047619048,41.5
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Headache","Adverse effects: neurological",11,7,"Headache","or","binary",2,-0.141126433246259,0.569613322335677,0,2018,0.0339651639344262,219
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Hyperactivity","Adverse effects: neurological",11,7,"Hyperactivity","or","binary",2,-0.840231582327613,0.705382157255819,0,2018,0.0390368852459016,219
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Insomnia","Adverse effects: neurological",11,7,"Insomnia","or","binary",4,-0.0374307558126493,0.486900262791734,1.35885973027507e-06,2016,0.139513696685828,56.75
"CD013232","CD013232_pub2_data","11|7|Adverse effects: neurological|Sedation","Adverse effects: neurological",11,7,"Sedation","or","binary",2,0.289332783086576,0.781963287888236,0.0450411216077792,2013,0.0738095238095238,41.5
"CD013232","CD013232_pub2_data","11|8|Adverse events: other|Pyrexia","Adverse events: other",11,8,"Pyrexia","or","binary",2,-0.326096642793256,0.602677222620953,0,2018,0.0390368852459016,219
"CD013232","CD013232_pub2_data","11|9|Adverse events: psychological|Agitation","Adverse events: psychological",11,9,"Agitation","or","binary",2,0.556566322408788,0.657426511906061,0,2018,0.0144467213114754,219
"CD013232","CD013232_pub2_data","11|9|Adverse events: psychological|Anxiety","Adverse events: psychological",11,9,"Anxiety","or","binary",3,-0.921502086914912,1.29086859167387,3.25342477996197,2016.66666666667,0.0489412568306011,159.333333333333
"CD013232","CD013232_pub2_data","11|9|Adverse events: psychological|Irritability","Adverse events: psychological",11,9,"Irritability","or","binary",3,-0.159168518616486,0.399655492632587,0,2019,0.154272230501739,153.666666666667
"CD013232","CD013232_pub2_data","12|4|Adverse effects: neurological|Insomnia","Adverse effects: neurological",12,4,"Insomnia","or","binary",2,0.845798600473681,0.764418889139285,0,2007,0.05,39.5
"CD013232","CD013232_pub2_data","13|10|Other adverse effects|Ear and labyrinth disorders","Other adverse effects",13,10,"Ear and labyrinth disorders","or","binary",2,0.91516046287619,0.932860557108611,0.324443528384638,2016,0.0172413793103448,83
"CD013232","CD013232_pub2_data","13|10|Other adverse effects|Ear infection","Other adverse effects",13,10,"Ear infection","or","binary",2,0.0598087596799135,0.448229185769197,0,2016,0.140394088669951,83
"CD013232","CD013232_pub2_data","13|10|Other adverse effects|Eye disorders","Other adverse effects",13,10,"Eye disorders","or","binary",2,0.899434757042426,0.663247929136585,0,2016,0.0350985221674877,83
"CD013232","CD013232_pub2_data","13|10|Other adverse effects|Renal and urinary disorders","Other adverse effects",13,10,"Renal and urinary disorders","or","binary",2,-0.0829215697462072,0.476201189597721,0,2016,0.122536945812808,83
"CD013232","CD013232_pub2_data","13|11|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",13,11,"","or","binary",3,-0.16273219529638,0.388402183468826,0,2015.66666666667,0.150328407224959,68.6666666666667
"CD013232","CD013232_pub2_data","13|3|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",13,3,"Constipation","or","binary",2,-0.0592828328735019,0.595735143956596,0.345003185921314,2016,0.175492610837438,83
"CD013232","CD013232_pub2_data","13|3|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",13,3,"Diarrhoea","or","binary",2,0.0550425345768117,0.335974789248093,0,2016,0.350985221674877,83
"CD013232","CD013232_pub2_data","13|3|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",13,3,"Vomiting","or","binary",2,0.0254702538248969,0.330224985526628,0,2016,0.386083743842365,83
"CD013232","CD013232_pub2_data","13|4|Adverse effects: immune System|Nasopharyngitis","Adverse effects: immune System",13,4,"Nasopharyngitis","or","binary",2,-0.203450118710478,0.514795241957255,0,2016,0.105295566502463,83
"CD013232","CD013232_pub2_data","13|4|Adverse effects: immune System|Pyrexia","Adverse effects: immune System",13,4,"Pyrexia","or","binary",2,-0.0109606796758087,0.323363832029839,0,2016,0.508620689655172,83
"CD013232","CD013232_pub2_data","13|4|Adverse effects: immune System|Upper respiratory tract infection","Adverse effects: immune System",13,4,"Upper respiratory tract infection","or","binary",2,-1.03934995126609,0.462039435644461,0,2016,0.210591133004926,83
"CD013232","CD013232_pub2_data","13|5|Adverse effects: metabolic|Decreased appetite","Adverse effects: metabolic",13,5,"Decreased appetite","or","binary",2,0.115813678708411,0.377246781105662,0,2016,0.227832512315271,83
"CD013232","CD013232_pub2_data","13|5|Adverse effects: metabolic|Increased appetite","Adverse effects: metabolic",13,5,"Increased appetite","or","binary",3,0.484872751071735,0.340919347724642,0,2015.66666666667,0.2396004378763,66.6666666666667
"CD013232","CD013232_pub2_data","13|6|Adverse effects: neurological|Hyperactivity","Adverse effects: neurological",13,6,"Hyperactivity","or","binary",2,-0.344350703528997,0.354677477618477,0,2016,0.315886699507389,83
"CD013232","CD013232_pub2_data","13|6|Adverse effects: neurological|Increased aggression","Adverse effects: neurological",13,6,"Increased aggression","or","binary",2,-0.171025001526594,0.3347780100401,0,2016,0.386083743842365,83
"CD013232","CD013232_pub2_data","13|6|Adverse effects: neurological|Insomnia","Adverse effects: neurological",13,6,"Insomnia","or","binary",2,0.566350226900185,0.503580737610937,0.286470905986726,2016,0.508620689655172,83
"CD013232","CD013232_pub2_data","13|6|Adverse effects: neurological|Irritability","Adverse effects: neurological",13,6,"Irritability","or","binary",2,-0.247540274488396,0.371430709341632,0,2016,0.262931034482759,83
"CD013232","CD013232_pub2_data","13|6|Adverse effects: neurological|Somnolence","Adverse effects: neurological",13,6,"Somnolence","or","binary",2,0.442496248044659,0.548237047669097,0,2016,0.0701970443349754,83
"CD013232","CD013232_pub2_data","13|7|Adverse effects: psychological|Anxiety","Adverse effects: psychological",13,7,"Anxiety","or","binary",2,0.800086149514677,0.833758700032043,0.00639200573244825,2016,0.0172413793103448,83
"CD013232","CD013232_pub2_data","13|8|Adverse effects: respiratory system|Cough","Adverse effects: respiratory system",13,8,"Cough","or","binary",2,-0.202197594346252,0.323189592499153,0,2016,0.491379310344828,83
"CD013232","CD013232_pub2_data","13|8|Adverse effects: respiratory system|Epistaxis","Adverse effects: respiratory system",13,8,"Epistaxis","or","binary",2,-0.702895033536124,0.532248411335295,0,2016,0.122536945812808,83
"CD013232","CD013232_pub2_data","13|8|Adverse effects: respiratory system|Nasal congestion","Adverse effects: respiratory system",13,8,"Nasal congestion","or","binary",2,-0.279804620809623,0.45086507806501,0,2016,0.157635467980296,83
"CD013232","CD013232_pub2_data","13|8|Adverse effects: respiratory system|Rhinorrhoea","Adverse effects: respiratory system",13,8,"Rhinorrhoea","or","binary",2,0.129082556322382,0.359159551693647,0,2016,0.262931034482759,83
"CD013232","CD013232_pub2_data","13|8|Adverse effects: respiratory system|Sinus congestion","Adverse effects: respiratory system",13,8,"Sinus congestion","or","binary",2,-0.163256674853339,0.350456660396217,0,2016,0.315886699507389,83
"CD013232","CD013232_pub2_data","13|9|Adverse effects: skin|Rash","Adverse effects: skin",13,9,"Rash","or","binary",2,0.140148702056228,0.463543051701271,0,2016,0.122536945812808,83
"CD013232","CD013232_pub2_data","14|1|Irritability|Bumetanide","Irritability",14,1,"Bumetanide","or","binary",2,0.019727785701977,1.43050026257558,0,2021,0,52
"CD013232","CD013232_pub2_data","14|1|Irritability|N-acetylcysteine","Irritability",14,1,"N-acetylcysteine","or","binary",4,-0.0494998563861963,1.01583793115743,0,2014,0,31.25
"CD013232","CD013232_pub2_data","14|1|Irritability|Riluzole","Irritability",14,1,"Riluzole","or","binary",2,0,1.44575315226837,0,2013,0,27
"CD013232","CD013232_pub2_data","14|10|Adverse effects: respiratory|Congestion/cold","Adverse effects: respiratory",14,10,"Congestion/cold","or","binary",4,0.0677194814282769,0.395011171050358,0,2013,0.334817772317772,64
"CD013232","CD013232_pub2_data","14|10|Adverse effects: respiratory|Cough","Adverse effects: respiratory",14,10,"Cough","or","binary",3,0.191704328456935,0.438700326438918,0,2016,0.0842205842205842,82.6666666666667
"CD013232","CD013232_pub2_data","14|11|Adverse effects: skin|Itches","Adverse effects: skin",14,11,"Itches","or","binary",2,-0.554279022551275,0.981139339380061,0,2014.5,0.0690476190476191,31
"CD013232","CD013232_pub2_data","14|11|Adverse effects: skin|Rash","Adverse effects: skin",14,11,"Rash","or","binary",7,-0.272723063745692,0.469128903373086,0,2015.8,0.0673235589205024,62.8571428571429
"CD013232","CD013232_pub2_data","14|11|Adverse effects: skin|Skin lesion","Adverse effects: skin",14,11,"Skin lesion","or","binary",2,0.609575353789943,0.498195395864416,0,2020,0.0813953488372093,49
"CD013232","CD013232_pub2_data","14|12|Adverse effects: urinary|Enuresis","Adverse effects: urinary",14,12,"Enuresis","or","binary",5,0.976524448148369,0.594362699978279,0,2018,0.017984496124031,41
"CD013232","CD013232_pub2_data","14|12|Adverse effects: urinary|Urinary retention","Adverse effects: urinary",14,12,"Urinary retention","or","binary",2,-0.322484713818873,1.42074722860785,1.41595053203035,2013,0.0416666666666667,44
"CD013232","CD013232_pub2_data","14|13|Adverse effects: other|Sweating","Adverse effects: other",14,13,"Sweating","or","binary",3,-0.221570032297608,0.75208784719767,0,2016.33333333333,0.0495894909688013,43
"CD013232","CD013232_pub2_data","14|14|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",14,14,"","or","binary",31,0.0883777560664642,0.121300665951168,0,2016,0.148498470593142,61.7096774193548
"CD013232","CD013232_pub2_data","14|15|Subgroup analyses: age - irritability (option 1)|Adults only","Subgroup analyses: age - irritability (option 1)",14,15,"Adults only","or","binary",3,0,1.17600792780045,0,2012,0,28
"CD013232","CD013232_pub2_data","14|15|Subgroup analyses: age - irritability (option 1)|Children and adults","Subgroup analyses: age - irritability (option 1)",14,15,"Children and adults","or","binary",2,0.0628840588883085,1.43967025399872,0,NA,0,72
"CD013232","CD013232_pub2_data","14|15|Subgroup analyses: age - irritability (option 1)|Children only","Subgroup analyses: age - irritability (option 1)",14,15,"Children only","or","binary",23,-0.0396861458675607,0.422372406945872,0,2015.1,0,44.0869565217391
"CD013232","CD013232_pub2_data","14|16|Subgroup analyses: age - irritability (option 2)|N-acetylcysteine: children only","Subgroup analyses: age - irritability (option 2)",14,16,"N-acetylcysteine: children only","or","binary",4,-0.0494998563861963,1.01583793115743,0,2014,0,31.25
"CD013232","CD013232_pub2_data","14|17|Subgroup analyses: age - self-injury (option 1)|Children only","Subgroup analyses: age - self-injury (option 1)",14,17,"Children only","or","binary",2,0.0534008450836442,1.42940920211851,0,2015.5,0,63.5
"CD013232","CD013232_pub2_data","14|18|Subgroup analyses: age - self-injury (option 2)|Bumetanide: children only","Subgroup analyses: age - self-injury (option 2)",14,18,"Bumetanide: children only","or","binary",2,0.0413725006398086,1.42877475913513,0,2021.5,0,74
"CD013232","CD013232_pub2_data","14|18|Subgroup analyses: age - self-injury (option 2)|N-acetylcysteine: children only","Subgroup analyses: age - self-injury (option 2)",14,18,"N-acetylcysteine: children only","or","binary",2,0.0534008450836442,1.42940920211851,0,2015.5,0,63.5
"CD013232","CD013232_pub2_data","14|2|Self-injury|Bumetanide","Self-injury",14,2,"Bumetanide","or","binary",2,0.0413725006398086,1.42877475913513,0,2021.5,0,74
"CD013232","CD013232_pub2_data","14|2|Self-injury|N-acetylcysteine","Self-injury",14,2,"N-acetylcysteine","or","binary",2,0.0534008450836442,1.42940920211851,0,2015.5,0,63.5
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Abdominal pain","Adverse effects: gastrointestinal",14,3,"Abdominal pain","or","binary",16,0.365207747177465,0.219775408225954,0,2016.81818181818,0.082924007435375,45.875
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Change in bowel habits","Adverse effects: gastrointestinal",14,3,"Change in bowel habits","or","binary",2,-1.10563675758305,1.18877916729202,0.730866643544367,2010,0.21195652173913,27
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",14,3,"Constipation","or","binary",13,0.272630211792185,0.274668510468266,0,2017.23076923077,0.100163294236813,51.1538461538462
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",14,3,"Diarrhoea","or","binary",20,-0.224601713720269,0.221003023526461,0,2014.69230769231,0.12969940008988,49.1
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Dry mouth","Adverse effects: gastrointestinal",14,3,"Dry mouth","or","binary",5,-0.155649769941249,0.466827574928705,0,2015.2,0.106428571428571,34.6
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Nausea","Adverse effects: gastrointestinal",14,3,"Nausea","or","binary",15,0.309233815560618,0.229806912342169,0,2013.92307692308,0.0913097141150556,51.2
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Thirst","Adverse effects: gastrointestinal",14,3,"Thirst","or","binary",6,1.30446466688587,0.567792156039135,0,2020,0.00387596899224806,37.3333333333333
"CD013232","CD013232_pub2_data","14|3|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",14,3,"Vomiting","or","binary",15,0.324977293210174,0.223030771461468,0,2014.63636363636,0.12231106115228,52.8666666666667
"CD013232","CD013232_pub2_data","14|4|Adverse effects: immune system|Fever","Adverse effects: immune system",14,4,"Fever","or","binary",2,0.949508186812576,0.882596902465995,0,2017.5,0.0135135135135135,51
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Decreased appetite","Adverse effects: metabolic (dichotomous)",14,5,"Decreased appetite","or","binary",17,0.47305577877926,0.272796980822777,0,2011.16666666667,0.084401131459955,47.4117647058824
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Hypoglycemia","Adverse effects: metabolic (dichotomous)",14,5,"Hypoglycemia","or","binary",2,-0.368137044944068,0.934640900419855,0.229208295658223,2018,0.0348837209302326,60
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Hypokalemia","Adverse effects: metabolic (dichotomous)",14,5,"Hypokalemia","or","binary",6,3.18505636328498,0.616143171579574,0,2021,0,55.1666666666667
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Increased appetite","Adverse effects: metabolic (dichotomous)",14,5,"Increased appetite","or","binary",14,0.469163225184895,0.219136661638021,0.0808847250453853,2016.45454545455,0.138468146854017,48.2857142857143
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Weight gain","Adverse effects: metabolic (dichotomous)",14,5,"Weight gain","or","binary",2,-1.28500661914661,1.21930973254302,0,2011.5,0.158333333333333,19.5
"CD013232","CD013232_pub2_data","14|5|Adverse effects: metabolic (dichotomous)|Weight loss","Adverse effects: metabolic (dichotomous)",14,5,"Weight loss","or","binary",5,0.37781514058917,0.542394894367675,0,2020.5,0.04995085995086,61.2
"CD013232","CD013232_pub2_data","14|7|Adverse effects: musculoskeletal|Myalgia","Adverse effects: musculoskeletal",14,7,"Myalgia","or","binary",2,0.517137302630136,0.412029696773903,0,2019,0.138477801268499,77.5
"CD013232","CD013232_pub2_data","14|7|Adverse effects: musculoskeletal|Stiffness","Adverse effects: musculoskeletal",14,7,"Stiffness","or","binary",2,0.807428557511787,0.953904077379831,0,2015.5,0.125,21.5
"CD013232","CD013232_pub2_data","14|7|Adverse effects: musculoskeletal|Weakness","Adverse effects: musculoskeletal",14,7,"Weakness","or","binary",3,-0.48720032115975,0.593393290898564,0,2016.33333333333,0.201149425287356,30
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Agitation/excitement","Adverse effects: neurological",14,8,"Agitation/excitement","or","binary",5,-0.401327331997231,0.433013940370189,0,2004,0.317477477477477,44
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Anxiety","Adverse effects: neurological",14,8,"Anxiety","or","binary",3,0.0330705064564654,0.479951495453027,6.68173098120584e-07,2019.5,0.128583128583129,83.3333333333333
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Daytime drowsiness","Adverse effects: neurological",14,8,"Daytime drowsiness","or","binary",6,0.503752872045032,0.436730459834076,0,2009.66666666667,0.148809523809524,28.6666666666667
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Difficulty sleeping","Adverse effects: neurological",14,8,"Difficulty sleeping","or","binary",6,-0.196881403895722,0.354708735259623,2.83030690813232e-07,2011.4,0.224883678144548,54.3333333333333
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Dizziness","Adverse effects: neurological",14,8,"Dizziness","or","binary",9,0.220341778458577,0.303238060655488,0,2017,0.104602450425663,49
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Drowsiness","Adverse effects: neurological",14,8,"Drowsiness","or","binary",5,1.28800375817934,0.541008204970558,0,2015,0.0627027027027027,59.6
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Fatigue","Adverse effects: neurological",14,8,"Fatigue","or","binary",8,0.302448384132528,0.337391318518275,0,2016.16666666667,0.137465078526125,42.25
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Headache","Adverse effects: neurological",14,8,"Headache","or","binary",18,-0.107130337150659,0.188392623595789,0,2017.21428571429,0.179298737132622,52.3888888888889
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Hypoactivity","Adverse effects: neurological",14,8,"Hypoactivity","or","binary",3,-1.12875075432371,1.32782713982491,2.17277350328406,1995.33333333333,0.316666666666667,9.33333333333333
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Increased aggression","Adverse effects: neurological",14,8,"Increased aggression","or","binary",4,-0.27964599407821,0.44782026580406,9.23663165392398e-07,2003,0.140656565656566,37.25
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Increased hyperactivity","Adverse effects: neurological",14,8,"Increased hyperactivity","or","binary",6,-0.314608242938097,0.388720077459283,5.43378793199113e-07,2004.2,0.115456860022077,53.5
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Increased irritability","Adverse effects: neurological",14,8,"Increased irritability","or","binary",5,0.170339442553534,0.342974148376904,0,2005.4,0.187913921826965,35.4
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Insomnia","Adverse effects: neurological",14,8,"Insomnia","or","binary",8,-0.0161795008523673,0.273005947147564,0,2011,0.153441953938036,61
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Nervousness","Adverse effects: neurological",14,8,"Nervousness","or","binary",4,0.590993209360594,0.701808009207896,0.946334192616155,2013.33333333333,0.108333333333333,39.75
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Restlessness","Adverse effects: neurological",14,8,"Restlessness","or","binary",5,0.212233287014458,0.454697772321975,1.29398302305428e-06,2013.4,0.206753246753247,31.6
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Sedation","Adverse effects: neurological",14,8,"Sedation","or","binary",13,-0.090267804463866,0.243426486522991,0,2011.90909090909,0.159780914474838,48
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Tremor","Adverse effects: neurological",14,8,"Tremor","or","binary",4,0.566217704731113,0.713204169408241,0,2013,0.0291666666666667,35
"CD013232","CD013232_pub2_data","14|8|Adverse effects: neurological|Twitching","Adverse effects: neurological",14,8,"Twitching","or","binary",2,1.36130730878775,1.14922010002638,0,2013,0,35.5
"CD013232","CD013232_pub2_data","14|9|Adverse effects: psychological|Depression","Adverse effects: psychological",14,9,"Depression","or","binary",3,0.6940595996813,0.621538796849471,0,2015.33333333333,0.0303030303030303,36
"CD013232","CD013232_pub2_data","14|9|Adverse effects: psychological|Increased self-injurious behaviour","Adverse effects: psychological",14,9,"Increased self-injurious behaviour","or","binary",3,-0.758966736830736,0.678322231614504,3.99647536189829e-06,2001.33333333333,0.125925925925926,35
"CD013232","CD013232_pub2_data","14|9|Adverse effects: psychological|Irritability","Adverse effects: psychological",14,9,"Irritability","or","binary",2,-0.105009264673765,0.5065558571972,0,2018,0.0540540540540541,81
"CD013232","CD013232_pub2_data","14|9|Adverse effects: psychological|Worsening of temper tantrums","Adverse effects: psychological",14,9,"Worsening of temper tantrums","or","binary",2,0.52608646601351,0.918837355323703,0,1990,0.0277777777777778,26
"CD013232","CD013232_pub2_data","15|5|Tolerability/acceptabiity: loss to follow-up|","Tolerability/acceptabiity: loss to follow-up",15,5,"","or","binary",2,-0.91726716754403,0.795600898682808,0,2001,0.25,20
"CD013232","CD013232_pub2_data","2|1|Irritability|Oxytocin","Irritability",2,1,"Oxytocin","or","binary",3,0.0112332841258767,1.16713527067213,0,2018,0,117.666666666667
"CD013232","CD013232_pub2_data","2|1|Irritability|Secretin","Irritability",2,1,"Secretin","or","binary",3,0.01307333724189,1.19912954352166,0,2002.66666666667,0,23
"CD013232","CD013232_pub2_data","2|10|Adverse effects: psychological|Anxiety","Adverse effects: psychological",2,10,"Anxiety","or","binary",2,0.99541037823943,0.86444698464675,0,2015,0.0166666666666667,48.5
"CD013232","CD013232_pub2_data","2|10|Adverse effects: psychological|Depression","Adverse effects: psychological",2,10,"Depression","or","binary",4,-0.11205168349985,0.559537004147048,0,2015.5,0.0364583333333333,106.75
"CD013232","CD013232_pub2_data","2|10|Adverse effects: psychological|Self-injury","Adverse effects: psychological",2,10,"Self-injury","or","binary",2,9.84202922210686e-05,1.16929504190303,0,2014.5,0.0166666666666667,59
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Cold symptoms","Adverse effects: respiratory",2,11,"Cold symptoms","or","binary",2,-0.56627891083163,0.622437635752115,0,2019.5,0.202777777777778,36.5
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Cough","Adverse effects: respiratory",2,11,"Cough","or","binary",5,0.322802984241323,0.292752747100669,0,2015.8,0.0824603174603175,86
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Epistaxis","Adverse effects: respiratory",2,11,"Epistaxis","or","binary",3,0.18519853602236,0.359750326963234,0,2016.66666666667,0.0914021164021164,126.333333333333
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Nasal congestion","Adverse effects: respiratory",2,11,"Nasal congestion","or","binary",5,-0.453275434821108,0.386781815739629,3.70210057950336e-06,2016.8,0.268045977011494,93.6
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Respiratory, thoracic and mediastinal disorders","Adverse effects: respiratory",2,11,"Respiratory, thoracic and mediastinal disorders","or","binary",2,-0.570587998138842,0.753792310596779,0,2021,0.0688679245283019,73.5
"CD013232","CD013232_pub2_data","2|11|Adverse effects: respiratory|Upper respiratory tract infection","Adverse effects: respiratory",2,11,"Upper respiratory tract infection","or","binary",4,-0.00716002212479405,0.543998573685777,0,2017.5,0.0449604743083004,68.25
"CD013232","CD013232_pub2_data","2|12|Adverse effects: skin |Skin rash","Adverse effects: skin ",2,12,"Skin rash","or","binary",4,0.124303660732065,0.316760189218737,4.34100093917004e-09,2017.25,0.0909722222222222,104
"CD013232","CD013232_pub2_data","2|15|Quality of life|Oxytocin","Quality of life",2,15,"Oxytocin","or","binary",2,-0.050101373771076,1.45008755081367,0,2013.5,0,18.5
"CD013232","CD013232_pub2_data","2|16|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",2,16,"","or","binary",16,0.139987330264422,0.163645638452979,0,2016.125,0.0827427746893406,82
"CD013232","CD013232_pub2_data","2|17|Subgroup analyses: gender - irritability|Male and female participants","Subgroup analyses: gender - irritability",2,17,"Male and female participants","or","binary",9,0.0286481175908632,0.678601115861631,0,2007.85714285714,0,62.5555555555556
"CD013232","CD013232_pub2_data","2|17|Subgroup analyses: gender - irritability|Male participants only","Subgroup analyses: gender - irritability",2,17,"Male participants only","or","binary",2,-0.0330609662265804,1.43146569170207,0,2009.5,0,45.5
"CD013232","CD013232_pub2_data","2|3|Adverse effects: cardiovascular|Cardiac disorders","Adverse effects: cardiovascular",2,3,"Cardiac disorders","or","binary",3,0.369584385179026,0.949719316450833,0,2018,0.00231481481481481,152
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",2,4,"Constipation","or","binary",3,-0.13376459743481,0.390019767165577,0,2020.66666666667,0.120833333333333,120.333333333333
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",2,4,"Diarrhoea","or","binary",5,-0.368663433870388,0.323765958925062,0,2018.2,0.120503663003663,90
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Dry mouth","Adverse effects: gastrointestinal",2,4,"Dry mouth","or","binary",2,-0.701733650666241,0.8800076851482,0,2017,0.0236111111111111,175
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Gastrointestinal disorders","Adverse effects: gastrointestinal",2,4,"Gastrointestinal disorders","or","binary",2,0.195040514493795,0.627613306178258,0,2016.5,0.0449685534591195,83
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Salivary hypersecretion","Adverse effects: gastrointestinal",2,4,"Salivary hypersecretion","or","binary",2,-1.17669659544878,1.17077742517891,0,2018.5,0.0391865079365079,159.5
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Stomatitis","Adverse effects: gastrointestinal",2,4,"Stomatitis","or","binary",2,-2.09786599339803,1.10285783313255,0,2018.5,0.0596868884540117,160.5
"CD013232","CD013232_pub2_data","2|4|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",2,4,"Vomiting","or","binary",4,-0.806794701017226,0.394871181709841,0,2017.25,0.146199633699634,102.25
"CD013232","CD013232_pub2_data","2|6|Adverse effects: metabolic (dichotomous)|Decreased appetite","Adverse effects: metabolic (dichotomous)",2,6,"Decreased appetite","or","binary",4,-0.418374626759186,0.336612194865132,0,2017.25,0.161580433455433,102.25
"CD013232","CD013232_pub2_data","2|6|Adverse effects: metabolic (dichotomous)|Increased appetite","Adverse effects: metabolic (dichotomous)",2,6,"Increased appetite","or","binary",2,0.616128723074317,0.335240823890978,0,2017,0.0652777777777778,175
"CD013232","CD013232_pub2_data","2|6|Adverse effects: metabolic (dichotomous)|Thirst","Adverse effects: metabolic (dichotomous)",2,6,"Thirst","or","binary",2,0.356207966113933,0.68448613368573,0.200819708435269,2018.5,0.0496031746031746,159.5
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Aggression","Adverse effects: neurological",2,9,"Aggression","or","binary",3,-0.140995175826423,0.328589885837018,0.056401168183349,2018.66666666667,0.315527065527066,118.666666666667
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Agitation","Adverse effects: neurological",2,9,"Agitation","or","binary",3,0.132265188960165,0.31288598119078,0,2016.66666666667,0.15974765974766,114.666666666667
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Decreased attention","Adverse effects: neurological",2,9,"Decreased attention","or","binary",3,0.400295194058214,0.966916768813384,0,2015.33333333333,0.0238095238095238,36
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Dizziness","Adverse effects: neurological",2,9,"Dizziness","or","binary",3,-0.392130325849109,1.06470203139844,1.5409048771954,2017,0.0490740740740741,123
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Fatigue","Adverse effects: neurological",2,9,"Fatigue","or","binary",3,-0.242971184276566,0.454662005561108,0,2015.66666666667,0.242592592592593,40
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Headache","Adverse effects: neurological",2,9,"Headache","or","binary",9,-0.603392293768182,0.241542206400237,0,2017.22222222222,0.114012345679012,76.5555555555556
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Insomnia","Adverse effects: neurological",2,9,"Insomnia","or","binary",6,-0.422204181773847,0.243757107264902,1.20440378542337e-07,2017,0.160861823361823,79.5
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Irritability","Adverse effects: neurological",2,9,"Irritability","or","binary",6,-0.202066007864369,0.25834799724713,3.70463634681384e-06,2016.5,0.244248575498576,109.166666666667
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Restlessness","Adverse effects: neurological",2,9,"Restlessness","or","binary",2,0.487641011929473,1.13364379397462,1.45345929231101,2018.5,0.0461309523809524,159.5
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Sedation","Adverse effects: neurological",2,9,"Sedation","or","binary",2,0.570654789827154,0.370139750028615,0,2017,0.0416666666666667,175
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Somnolence","Adverse effects: neurological",2,9,"Somnolence","or","binary",2,1.41632269969752,1.14777253230343,0,2014.5,0,44.5
"CD013232","CD013232_pub2_data","2|9|Adverse effects: neurological|Tics","Adverse effects: neurological",2,9,"Tics","or","binary",2,-0.43165874294811,0.664763412838344,0,2016.5,0.0694444444444444,154.5
"CD013232","CD013232_pub2_data","3|1|Irritability|Irritability: non-stimulant ADHD-related drugs","Irritability",3,1,"Irritability: non-stimulant ADHD-related drugs","or","binary",8,0.029776597211006,0.719216047517783,0,2006.125,0,42.75
"CD013232","CD013232_pub2_data","3|1|Irritability|Irritability: stimulant ADHD-related drugs","Irritability",3,1,"Irritability: stimulant ADHD-related drugs","or","binary",4,0,1.03279555898864,0,2008.5,0,14.5
"CD013232","CD013232_pub2_data","3|10|Adverse effects: respiratory|Cough","Adverse effects: respiratory",3,10,"Cough","or","binary",2,-0.236312359301621,0.586092071091539,0,2011,0.110887096774194,61
"CD013232","CD013232_pub2_data","3|11|Adverse effects: skin|Rash","Adverse effects: skin",3,11,"Rash","or","binary",5,1.26819542103196,0.927109120826949,1.96969402684776,2012,0.05,20.4
"CD013232","CD013232_pub2_data","3|12|Adverse effects: urinary|Enuresis","Adverse effects: urinary",3,12,"Enuresis","or","binary",2,-0.167893892182355,0.701380400307168,0,2011,0.063508064516129,61
"CD013232","CD013232_pub2_data","3|14|Tolerability/acceptability: loss to follow-up|ADHD-related drugs: loss to follow-up","Tolerability/acceptability: loss to follow-up",3,14,"ADHD-related drugs: loss to follow-up","or","binary",9,-0.0593518211601065,0.362118195416027,0.24807904197475,2010.33333333333,0.157884745893578,42.2222222222222
"CD013232","CD013232_pub2_data","3|15|Subgroup analyses: gender - irritability|Male and female participants","Subgroup analyses: gender - irritability",3,15,"Male and female participants","or","binary",9,-0.00638176717935706,0.688935693850356,0,2010.22222222222,0,30.4444444444444
"CD013232","CD013232_pub2_data","3|15|Subgroup analyses: gender - irritability|Male participants only","Subgroup analyses: gender - irritability",3,15,"Male participants only","or","binary",2,-0.10079350000382,1.48730463886435,0,1992,0,8.5
"CD013232","CD013232_pub2_data","3|16|Subgroup analyses: age - irritability|Children only","Subgroup analyses: age - irritability",3,16,"Children only","or","binary",10,-0.00274496084414777,0.654353486265343,0,2008.4,0,28.4
"CD013232","CD013232_pub2_data","3|3|Adverse effects: cardiovascular|Bradycardia","Adverse effects: cardiovascular",3,3,"Bradycardia","reported","reported",3,0,0.537328601428249,0,2005,0.363636363636364,22
"CD013232","CD013232_pub2_data","3|3|Adverse effects: cardiovascular|Tachycardia","Adverse effects: cardiovascular",3,3,"Tachycardia","reported","reported",2,0,1.05554404377385,0,2009.5,0,24
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",3,4,"Constipation","or","binary",5,1.29981457001289,0.437295255562285,0.180303643108373,2012.2,0.122423835125448,44
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",3,4,"Diarrhoea","or","binary",8,-0.215484533875964,0.304648027635698,0,2009,0.142871169728889,53.25
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Dry mouth","Adverse effects: gastrointestinal",3,4,"Dry mouth","or","binary",4,2.08047562022462,0.608792965919537,0,2011.75,0.0390625,25.5
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Nausea","Adverse effects: gastrointestinal",3,4,"Nausea","or","binary",7,1.14567469915775,0.416858176384494,4.21881237021428e-07,2013.14285714286,0.0741618075801749,34.1428571428571
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Stomach or abdominal discomfort","Adverse effects: gastrointestinal",3,4,"Stomach or abdominal discomfort","or","binary",8,1.04472188826636,0.282387092020481,0,2009.375,0.124417861444431,63
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Stomachache","Adverse effects: gastrointestinal",3,4,"Stomachache","or","binary",4,1.18015810226473,0.526981511678396,0,2013.5,0.09375,21.5
"CD013232","CD013232_pub2_data","3|4|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",3,4,"Vomiting","or","binary",4,0.334012184558232,0.296919839509347,0,2012.75,0.120268268597762,86.75
"CD013232","CD013232_pub2_data","3|5|Adverse effects: immune system|Fever","Adverse effects: immune system",3,5,"Fever","or","binary",3,-1.19230736566294,0.753198768920345,0,2014,0.0794359410430839,61
"CD013232","CD013232_pub2_data","3|5|Adverse effects: immune system|Myalgia","Adverse effects: immune system",3,5,"Myalgia","or","binary",2,1.66416032092765,1.13545186374371,0,2016,0,57.5
"CD013232","CD013232_pub2_data","3|6|Adverse effects: metabolic (dichotomous)|Decreased appetite","Adverse effects: metabolic (dichotomous)",3,6,"Decreased appetite","or","binary",13,1.15135259689271,0.226260169420689,0,2011.30769230769,0.127179154051274,39.3076923076923
"CD013232","CD013232_pub2_data","3|6|Adverse effects: metabolic (dichotomous)|Increased appetite","Adverse effects: metabolic (dichotomous)",3,6,"Increased appetite","or","binary",2,-0.368566875845394,0.801293377196897,0,2011,0.063508064516129,61
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Aggression","Adverse effects: neurological (dichotomous)",3,7,"Aggression","or","binary",5,-0.0552669651468352,0.273290190985463,0,2013.8,0.173983249213664,73
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Dizziness","Adverse effects: neurological (dichotomous)",3,7,"Dizziness","or","binary",3,0.717705900551811,0.611700284820894,0,2011.66666666667,0.0276360544217687,58.3333333333333
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Drowsiness","Adverse effects: neurological (dichotomous)",3,7,"Drowsiness","or","binary",6,1.71638570379206,0.722398142364566,1.60220381218629,2013.16666666667,0.0841733870967742,31
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Emotional / tearful","Adverse effects: neurological (dichotomous)",3,7,"Emotional / tearful","or","binary",4,2.51903624788915,0.653134386478671,0.330317310657069,2007.5,0.0234375,32
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Fatigue","Adverse effects: neurological (dichotomous)",3,7,"Fatigue","or","binary",4,1.65308894795362,0.47773009626054,0.274103701178998,2010.5,0.114410179394338,58.75
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Headache","Adverse effects: neurological (dichotomous)",3,7,"Headache","or","binary",12,0.607386107210403,0.265492842725502,0,2011,0.124143488040377,31.9166666666667
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Hyperactivity","Adverse effects: neurological (dichotomous)",3,7,"Hyperactivity","or","binary",2,-0.382158753326052,1.09957954767957,0.853951718201676,2016,0.0408163265306122,57.5
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Increased motor activity","Adverse effects: neurological (dichotomous)",3,7,"Increased motor activity","or","binary",3,0.581791023765942,0.673070912329788,0,2005,0.0909090909090909,22
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Insomnia","Adverse effects: neurological (dichotomous)",3,7,"Insomnia","or","binary",11,0.677826581087105,0.289393986220671,0.0817016976905358,2011.09090909091,0.190477654560447,37.3636363636364
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Irritability","Adverse effects: neurological (dichotomous)",3,7,"Irritability","or","binary",10,1.04574848340808,0.248102283799933,0,2010.8,0.271732954545455,33.6
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Motor tics","Adverse effects: neurological (dichotomous)",3,7,"Motor tics","or","binary",3,1.02184092725331,1.00937691004539,1.44817353929092,2013,0.0625,39.3333333333333
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Nightmares","Adverse effects: neurological (dichotomous)",3,7,"Nightmares","or","binary",2,0.418284838617928,0.714700462010861,0,2011,0.0483870967741935,61
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Repetitive behaviour","Adverse effects: neurological (dichotomous)",3,7,"Repetitive behaviour","or","binary",4,0.500968360064103,0.442743626172969,0,2007.5,0.159801136363636,32
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Restless","Adverse effects: neurological (dichotomous)",3,7,"Restless","or","binary",2,0.481730098029121,1.77718413308547,4.57777151147453,2006.5,0.1875,38
"CD013232","CD013232_pub2_data","3|7|Adverse effects: neurological (dichotomous)|Sleep disturbance","Adverse effects: neurological (dichotomous)",3,7,"Sleep disturbance","or","binary",4,0.165560819723169,0.48967745063049,0,2011.5,0.352822580645161,21
"CD013232","CD013232_pub2_data","3|9|Adverse effects: psychological (dichotomous)|Anxiety","Adverse effects: psychological (dichotomous)",3,9,"Anxiety","or","binary",9,0.447836285003592,0.424947532326065,0.419405986667273,2010.44444444444,0.19669477028348,28
"CD013232","CD013232_pub2_data","3|9|Adverse effects: psychological (dichotomous)|Depression","Adverse effects: psychological (dichotomous)",3,9,"Depression","or","binary",7,1.05185816742178,0.496645268047472,0,2009.85714285714,0.137581168831169,21.7142857142857
"CD013232","CD013232_pub2_data","3|9|Adverse effects: psychological (dichotomous)|Self-injury","Adverse effects: psychological (dichotomous)",3,9,"Self-injury","or","binary",5,0.555500980253448,0.432386574770665,0,2007.4,0.128445747800587,37.6
"CD013232","CD013232_pub2_data","3|9|Adverse effects: psychological (dichotomous)|Social withdrawal","Adverse effects: psychological (dichotomous)",3,9,"Social withdrawal","or","binary",4,0.984710426818818,0.98765786208375,1.89983787251662,2005.5,0.032258064516129,31.5
"CD013232","CD013232_pub2_data","4|1|Irritability|SSRIs","Irritability",4,1,"SSRIs","or","binary",2,0.0200292228311696,1.41986322423215,0,2011.5,0,127.5
"CD013232","CD013232_pub2_data","4|10|Adverse effects: skin|Rash or skin irritation","Adverse effects: skin",4,10,"Rash or skin irritation","or","binary",3,0.0165415037412366,0.622649939186306,0.810582620163131,2009.33333333333,0.265212080834999,110.666666666667
"CD013232","CD013232_pub2_data","4|13|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",4,13,"","or","binary",7,0.29256462669227,0.19321591075858,0,2008.57142857143,0.301900234062947,80.5714285714286
"CD013232","CD013232_pub2_data","4|14|Subgroup analyses: gender - irritability|Male and female participants","Subgroup analyses: gender - irritability",4,14,"Male and female participants","or","binary",2,0.0200292228311696,1.41986322423215,0,2011.5,0,127.5
"CD013232","CD013232_pub2_data","4|2|Adverse effects: cardiovascular|Tachycardia","Adverse effects: cardiovascular",4,2,"Tachycardia","or","binary",2,1.09027676237322,1.20828721853443,0,1997,0,17.5
"CD013232","CD013232_pub2_data","4|3|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",4,3,"Constipation","or","binary",2,-0.00109585358703246,1.21711849823108,1.75244914040583,2005.5,0.141025641025641,35
"CD013232","CD013232_pub2_data","4|3|Adverse effects: gastrointestinal|Diarrhoea","Adverse effects: gastrointestinal",4,3,"Diarrhoea","or","binary",4,-0.163843884889062,0.652404264676124,1.35752841916975,2013,0.269006486934118,102.25
"CD013232","CD013232_pub2_data","4|3|Adverse effects: gastrointestinal|Gastrointestinal disturbance","Adverse effects: gastrointestinal",4,3,"Gastrointestinal disturbance","or","binary",3,0.504330436339967,0.280586209833738,0,2013,0.300369198312236,113.666666666667
"CD013232","CD013232_pub2_data","4|3|Adverse effects: gastrointestinal|Nausea/abdominal pain","Adverse effects: gastrointestinal",4,3,"Nausea/abdominal pain","or","binary",5,0.564238888230891,0.378139030053913,0,2002.2,0.0703508771929825,50.2
"CD013232","CD013232_pub2_data","4|3|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",4,3,"Vomiting","or","binary",5,0.442446547936849,0.432821995005988,0.295381862411465,2008.2,0.0613663967611336,80
"CD013232","CD013232_pub2_data","4|4|Adverse effect: immune system|Infections","Adverse effect: immune system",4,4,"Infections","or","binary",3,0.209861581973452,0.23622234123348,0,2014.33333333333,0.218201754385965,157.333333333333
"CD013232","CD013232_pub2_data","4|5|Adverse effects: metabolic|Decreased appetite","Adverse effects: metabolic",4,5,"Decreased appetite","or","binary",4,0.33011991655243,0.386429354855117,0,2005.25,0.0841767881241565,60.5
"CD013232","CD013232_pub2_data","4|5|Adverse effects: metabolic|Weight gain","Adverse effects: metabolic",4,5,"Weight gain","or","binary",2,0.452601558444943,1.64716031284728,2.74188868364074,2005,0.0138888888888889,46.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Aggression or hostility","Adverse effects: neurological",4,7,"Aggression or hostility","or","binary",3,0.0638115914721452,0.443633221140673,0.247307662128997,2010.66666666667,0.318556005398111,75
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Agitation","Adverse effects: neurological",4,7,"Agitation","or","binary",2,0.141619609669356,0.833977817546585,0.839874449682144,2012.5,0.4625,98.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Anger/irritability","Adverse effects: neurological",4,7,"Anger/irritability","or","binary",2,0.363759175221058,0.368548082070297,0,2007,0.285526315789474,83.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Decreased attention","Adverse effects: neurological",4,7,"Decreased attention","or","binary",2,1.38874608657676,0.668530623720783,0,2013.5,0.0131578947368421,103.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Drowsiness/fatigue","Adverse effects: neurological",4,7,"Drowsiness/fatigue","or","binary",4,0.224738934542029,0.339675502437122,6.21431155723376e-07,2008.25,0.121356275303644,70.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Headache","Adverse effects: neurological",4,7,"Headache","or","binary",3,0.487591568235411,0.408478415343361,1.79915491373361e-07,2013,0.0566801619433198,81.3333333333333
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Hyperactivity","Adverse effects: neurological",4,7,"Hyperactivity","or","binary",2,0.708525982869018,0.675604788110697,0.516090185514247,2013.5,0.186234817813765,103.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Insomnia","Adverse effects: neurological",4,7,"Insomnia","or","binary",7,0.447491809755325,0.244150783996645,0,2006.42857142857,0.281954887218045,64.1428571428571
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Mood lability","Adverse effects: neurological",4,7,"Mood lability","or","binary",2,-0.533099602350185,0.69230679508667,0.307957090735758,2007,0.209210526315789,83.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Sedation","Adverse effects: neurological",4,7,"Sedation","or","binary",3,0.667211954036988,0.50453237606481,0,1998,0.114814814814815,39
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Sleep disturbance","Adverse effects: neurological",4,7,"Sleep disturbance","or","binary",2,0.24704528602535,0.805584159855938,0.982134109543212,2016,0.146299902629017,111.5
"CD013232","CD013232_pub2_data","4|7|Adverse effects: neurological|Tremor","Adverse effects: neurological",4,7,"Tremor","or","binary",3,1.0065288196528,0.834021710159786,0,2002,0.0555555555555556,28.3333333333333
"CD013232","CD013232_pub2_data","4|8|Adverse effects: psychological|Anxiety/nervousness","Adverse effects: psychological",4,8,"Anxiety/nervousness","or","binary",2,-0.515511834254737,0.510949243538086,0.196748706614446,2007,0.359210526315789,94
"CD013232","CD013232_pub2_data","4|9|Adverse effects: respiratory|Respiratory","Adverse effects: respiratory",4,9,"Respiratory","or","binary",2,0.7701271553236,0.483199139051222,0,2011.5,0.0392238507661559,157
"CD013232","CD013232_pub2_data","4|9|Adverse effects: respiratory|Upper respiratory infection (URI)","Adverse effects: respiratory",4,9,"Upper respiratory infection (URI)","or","binary",2,-0.0616671284971923,0.35135188391267,0,2019,0.440384615384615,108
"CD013232","CD013232_pub2_data","5|10|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",5,10,"","or","binary",2,1.09958542517134,1.26383747572992,0,2004.5,0,21
"CD013232","CD013232_pub2_data","5|5|Adverse effects: metabolic (continuous)|Weight gain (kg)","Adverse effects: metabolic (continuous)",5,5,"Weight gain (kg)","or","binary",2,0,1.45197634075685,0,2004.5,0,21
"CD013232","CD013232_pub2_data","5|9|Adverse effects: urinary|Enuresis","Adverse effects: urinary",5,9,"Enuresis","or","binary",2,0,0.714929218728928,0,2004.5,0.183333333333333,21
"CD013232","CD013232_pub2_data","6|1|Irritability|","Irritability",6,1,"","or","binary",2,-0.040992324445463,1.42687172066231,0,2016.5,0,55
"CD013232","CD013232_pub2_data","6|10|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",6,10,"","or","binary",2,-0.417634859652351,0.449578287749777,0,2016.5,0.25,60
"CD013232","CD013232_pub2_data","6|2|Adverse effects: cardiovascular|Tachycardia","Adverse effects: cardiovascular",6,2,"Tachycardia","or","binary",2,0.0682126723481257,0.896022365645734,0,2016.5,0.0333333333333333,60
"CD013232","CD013232_pub2_data","6|3|Adverse effects: gastrointestinal|Constipation","Adverse effects: gastrointestinal",6,3,"Constipation","or","binary",2,0.212998765298447,0.656941342595696,0,2016.5,0.0666666666666667,60
"CD013232","CD013232_pub2_data","6|3|Adverse effects: gastrointestinal|Drooling","Adverse effects: gastrointestinal",6,3,"Drooling","or","binary",2,-0.470372477283589,0.451189618794218,0,2016.5,0.266666666666667,60
"CD013232","CD013232_pub2_data","6|3|Adverse effects: gastrointestinal|Vomiting","Adverse effects: gastrointestinal",6,3,"Vomiting","or","binary",2,0.395406012953417,0.962649707650946,0,2016.5,0.0166666666666667,60
"CD013232","CD013232_pub2_data","6|4|Adverse effects: metabolic|Decreased appetite","Adverse effects: metabolic",6,4,"Decreased appetite","or","binary",2,0.575279671865798,0.625334139304597,0,2016.5,0.0666666666666667,60
"CD013232","CD013232_pub2_data","6|4|Adverse effects: metabolic|Increased appetite","Adverse effects: metabolic",6,4,"Increased appetite","or","binary",2,-0.595440978189499,0.740004942223937,0.402783990114829,2016.5,0.25,60
"CD013232","CD013232_pub2_data","6|6|Adverse effects: neurological|Dizziness","Adverse effects: neurological",6,6,"Dizziness","or","binary",2,-0.323263542426612,0.892131385927719,0.0853888516501504,2016.5,0.05,60
"CD013232","CD013232_pub2_data","6|6|Adverse effects: neurological|Restlessness","Adverse effects: neurological",6,6,"Restlessness","or","binary",2,-0.702804168272746,0.895998293980512,0,2016.5,0.05,60
"CD013232","CD013232_pub2_data","6|9|Adverse effects: urinary|Enuresis","Adverse effects: urinary",6,9,"Enuresis","or","binary",2,0.350933545620912,1.97221618319689,5.40010762931225,2016.5,0.0333333333333333,60
"CD013232","CD013232_pub2_data","9|1|Irritability|","Irritability",9,1,"","or","binary",3,0.0766564340356598,1.17257473690052,0,2008.33333333333,0,32.3333333333333
"CD013232","CD013232_pub2_data","9|11|Tolerability/acceptability: loss to follow-up|","Tolerability/acceptability: loss to follow-up",9,11,"","or","binary",6,0.648904133726068,0.454586457689567,0,2006.4,0.0741462241462241,27.8333333333333
"CD013232","CD013232_pub2_data","9|2|Aggression|","Aggression",9,2,"","or","binary",2,-0.244860618955331,1.43849705033797,0,2007.5,0,28.5
"CD013232","CD013232_pub2_data","9|3|Adverse effects: gastrointestinal|Nausea","Adverse effects: gastrointestinal",9,3,"Nausea","or","binary",2,0.915531885756526,0.602387014536237,0,2007.5,0.121428571428571,35
"CD013232","CD013232_pub2_data","9|5|Adverse effects: metabolic (dichotomous)|Decreased appetite","Adverse effects: metabolic (dichotomous)",9,5,"Decreased appetite","or","binary",2,1.78722081014142,0.836405432569611,0,2008,0.025,30
"CD013232","CD013232_pub2_data","9|5|Adverse effects: metabolic (dichotomous)|Increased appetite","Adverse effects: metabolic (dichotomous)",9,5,"Increased appetite","or","binary",2,0.194886044924573,1.68694936448013,4.85280668229934,2007.5,0.196428571428571,35
"CD013232","CD013232_pub2_data","9|5|Adverse effects: metabolic (dichotomous)|Weight gain","Adverse effects: metabolic (dichotomous)",9,5,"Weight gain","or","binary",3,0.445835295069205,0.595818203283602,0,2007,0.125541125541126,25.6666666666667
"CD013232","CD013232_pub2_data","9|7|Adverse Effects: neurological|Aggression","Adverse Effects: neurological",9,7,"Aggression","or","binary",2,0.794450649509203,0.940156430486866,0,2003.5,0.05,24
"CD013232","CD013232_pub2_data","9|7|Adverse Effects: neurological|Agitation","Adverse Effects: neurological",9,7,"Agitation","or","binary",2,0.104632255985365,0.827560382397065,0,2008,0.0954545454545455,23.5
"CD013232","CD013232_pub2_data","9|7|Adverse Effects: neurological|Insomnia","Adverse Effects: neurological",9,7,"Insomnia","or","binary",4,0.57101814709807,0.713615804934934,0.531107414439013,2006.75,0.0829545454545455,28.75
"CD013232","CD013232_pub2_data","9|9|Adverse effects: skin|Rash","Adverse effects: skin",9,9,"Rash","or","binary",2,1.62273340566595,0.844693465720955,0,2007.5,0.0357142857142857,28.5
"CD013255","CD013255_pub2_data","1|2|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",1,2,NA,"reported","reported",2,0,0.347622985589388,0,2005.5,0.495,90
"CD013255","CD013255_pub2_data","10|2|Acute procedural success (atrial flutter)|NA","Acute procedural success (atrial flutter)",10,2,NA,"or","binary",2,3.75291174476264,0.744338849015011,0,1997,0.0121951219512195,89
"CD013255","CD013255_pub2_data","11|1|Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)",11,1,NA,"reported","reported",2,0,0.610289519351334,0,2004.5,0.796256104177971,159.5
"CD013255","CD013255_pub2_data","11|2|Acute procedural success (persistent AF)|NA","Acute procedural success (persistent AF)",11,2,NA,"reported","reported",2,0,0.610289519351334,0,2004.5,0.796256104177971,159.5
"CD013255","CD013255_pub2_data","12|1|Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)",12,1,NA,"reported","reported",2,0,1.07923600790677,0,2005.5,0.00378787878787879,221.5
"CD013255","CD013255_pub2_data","12|2|30-day cardiovascular mortality|NA","30-day cardiovascular mortality",12,2,NA,"or","binary",2,-0.381348134491339,1.42043134392566,0,2005.5,0,221.5
"CD013255","CD013255_pub2_data","12|3|30-day all-cause mortality|NA","30-day all-cause mortality",12,3,NA,"or","binary",2,-1.00886489029106,1.2741198529605,0,2005.5,0.0161290322580645,221.5
"CD013255","CD013255_pub2_data","14|1|Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)",14,1,NA,"reported","reported",2,0,1.00943276804554,0,2005.5,0.218123861566485,282.5
"CD013255","CD013255_pub2_data","14|2|30-day cardiovascular mortality|NA","30-day cardiovascular mortality",14,2,NA,"or","binary",2,0.112551794685591,1.42050462578644,0,2005.5,0,282.5
"CD013255","CD013255_pub2_data","14|3|30-day all-cause mortality|NA","30-day all-cause mortality",14,3,NA,"or","binary",2,0.112551794685591,1.42050462578644,0,2005.5,0,282.5
"CD013255","CD013255_pub2_data","2|1|Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)",2,1,NA,"reported","reported",3,0,0.295150045311782,0,2004,0.830243902439024,160.666666666667
"CD013255","CD013255_pub2_data","2|2|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",2,2,NA,"reported","reported",3,0,0.239182614295184,0,2004,0.572560975609756,160.666666666667
"CD013255","CD013255_pub2_data","3|1|Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)",3,1,NA,"reported","reported",7,0,0.208229369769455,0,2003.71428571429,0.802359282932314,110.285714285714
"CD013255","CD013255_pub2_data","3|3|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",3,3,NA,"reported","reported",7,0,0.204475820211991,0,2003.71428571429,0.590091831148734,110.285714285714
"CD013255","CD013255_pub2_data","4|1|Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)",4,1,NA,"reported","reported",5,0,0.278733807354918,0,2003,0.512092970521542,106.8
"CD013255","CD013255_pub2_data","4|2|Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)",4,2,NA,"or","binary",6,2.87527221407994,0.586274938002991,0.65037580315075,2003,0.0048087255534064,150.833333333333
"CD013255","CD013255_pub2_data","4|3|30-day all-cause mortality|NA","30-day all-cause mortality",4,3,NA,"or","binary",7,-0.442206185968312,0.734860587940788,0,2002,0.00460829493087558,149.714285714286
"CD013255","CD013255_pub2_data","4|4|30-day cardiovascular mortality|NA","30-day cardiovascular mortality",4,4,NA,"or","binary",7,-0.243504252204237,0.759830182552145,0,2002,0,149.714285714286
"CD013255","CD013255_pub2_data","4|5|Stroke or systemic embolism at 30 days|NA","Stroke or systemic embolism at 30 days",4,5,NA,"reported","reported",3,0,0.811963985470295,0,1999.33333333333,0,114.666666666667
"CD013255","CD013255_pub2_data","4|6|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",4,6,NA,"reported","reported",6,0,0.258903587032471,0,2003,0.42584908037289,115.666666666667
"CD013255","CD013255_pub2_data","6|1|Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)",6,1,NA,"or","binary",9,1.84407704777049,0.287613679755898,0.543504541940508,1999.44444444444,0.338846579401617,131.333333333333
"CD013255","CD013255_pub2_data","6|2|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",6,2,NA,"reported","reported",9,0,0.214389269756083,0,1999.44444444444,0.306124978364508,131.333333333333
"CD013255","CD013255_pub2_data","7|2|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",7,2,NA,"reported","reported",2,0,1.01666859924913,0,2016.5,0.0698529411764706,154
"CD013255","CD013255_pub2_data","7|3|Stroke or systemic embolism at 30 days|NA","Stroke or systemic embolism at 30 days",7,3,NA,"or","binary",4,-0.939712546085492,0.947193511341466,0,2011.5,0.00367647058823529,213
"CD013255","CD013255_pub2_data","7|5|30-day cardiovascular mortality|NA","30-day cardiovascular mortality",7,5,NA,"or","binary",5,-0.0425239590295491,0.778162310938556,0,2012.6,0.00294117647058824,192.6
"CD013255","CD013255_pub2_data","8|1|Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)|NA","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)",8,1,NA,"or","binary",3,0.942339023940841,1.19409373860598,3.26535079266194,2001.33333333333,0.155797101449275,37.3333333333333
"CD013255","CD013255_pub2_data","8|2|Acute procedural success (paroxysmal AF)|NA","Acute procedural success (paroxysmal AF)",8,2,NA,"reported","reported",2,0,1.08180557396438,0,2005,0.233695652173913,47
"CD013278","CD013278_pub3_data","1|1|All-cause mortality during hospital stay|Intravenous/oral ibuprofen","All-cause mortality during hospital stay",1,1,"Intravenous/oral ibuprofen","or","binary",3,-0.432363095760513,0.452592140220708,0,2011.66666666667,0.0998217468805704,101.666666666667
"CD013278","CD013278_pub3_data","1|1|All-cause mortality during hospital stay|Intravenous/oral indomethacin","All-cause mortality during hospital stay",1,1,"Intravenous/oral indomethacin","or","binary",3,-0.0349092350272486,0.444733887151101,0,1991,0.201587301587302,65
"CD013278","CD013278_pub3_data","1|10|Intraventricular hemorrhage (IVH; grades I to IV)|Intravenous/oral indomethacin","Intraventricular hemorrhage (IVH; grades I to IV)",1,10,"Intravenous/oral indomethacin","or","binary",2,-0.249431816019336,1.57844817514183,3.47604688696973,1992,0.115079365079365,84
"CD013278","CD013278_pub3_data","1|11|Severe IVH (grades III and IV)|","Severe IVH (grades III and IV)",1,11,"","or","binary",2,-0.185300932434533,0.516760472478246,0,2011,0.0837789661319073,85.5
"CD013278","CD013278_pub3_data","1|12|Periventricular leukomalacia (PVL; any grade)|Intravenous/oral ibuprofen","Periventricular leukomalacia (PVL; any grade)",1,12,"Intravenous/oral ibuprofen","or","binary",2,-0.0285753011323753,0.503941359652365,0,2011,0.105169340463458,85.5
"CD013278","CD013278_pub3_data","1|13|Necrotizing enterocolitis (NEC; stage 2 or greater)|Intravenous/oral ibuprofen","Necrotizing enterocolitis (NEC; stage 2 or greater)",1,13,"Intravenous/oral ibuprofen","or","binary",3,0.947927398021461,0.598756988082719,1.86201244190996e-06,2011.66666666667,0.0231729055258467,101.666666666667
"CD013278","CD013278_pub3_data","1|13|Necrotizing enterocolitis (NEC; stage 2 or greater)|Intravenous/oral indomethacin","Necrotizing enterocolitis (NEC; stage 2 or greater)",1,13,"Intravenous/oral indomethacin","or","binary",2,0.213260021616132,1.18240890977821,1.31916837320352,1992,0.0615079365079365,84
"CD013278","CD013278_pub3_data","1|14|Spontaneous intestinal perforation|Intravenous/oral ibuprofen","Spontaneous intestinal perforation",1,14,"Intravenous/oral ibuprofen","or","binary",2,-0.591387800517104,0.75460156706227,0,2011,0.0392156862745098,85.5
"CD013278","CD013278_pub3_data","1|18|Definite sepsis|Intravenous/oral ibuprofen","Definite sepsis",1,18,"Intravenous/oral ibuprofen","or","binary",2,-0.124711413048633,0.330213933795507,0,2011,0.316399286987522,85.5
"CD013278","CD013278_pub3_data","1|18|Definite sepsis|Intravenous/oral indomethacin","Definite sepsis",1,18,"Intravenous/oral indomethacin","or","binary",2,0.183856064621256,0.42586696523418,0,1992,0.152777777777778,84
"CD013278","CD013278_pub3_data","1|2|Surgical PDA ligation or transcatheter occlusion|Intravenous/oral ibuprofen","Surgical PDA ligation or transcatheter occlusion",1,2,"Intravenous/oral ibuprofen","or","binary",3,-0.464043338223811,0.918879462923842,1.89994803182236,2011.66666666667,0.190943677335249,101.666666666667
"CD013278","CD013278_pub3_data","1|5|Chronic lung disease (CLD)|Intravenous/oral ibuprofen","Chronic lung disease (CLD)",1,5,"Intravenous/oral ibuprofen","or","binary",2,-0.0633947660099219,0.40288124779884,0,2011,0.172014260249554,85.5
"CD013278","CD013278_pub3_data","1|5|Chronic lung disease (CLD)|Intravenous/oral indomethacin","Chronic lung disease (CLD)",1,5,"Intravenous/oral indomethacin","or","binary",2,-0.283986921718294,0.35432459267883,0,1992,0.349206349206349,84
"CD013278","CD013278_pub3_data","2|1|All-cause mortality during hospital stay|Intravenous/oral ibuprofen","All-cause mortality during hospital stay",2,1,"Intravenous/oral ibuprofen","reported","reported",2,0,0.0227306324780032,0,2022.5,0.121417674621336,437
"CD013278","CD013278_pub3_data","2|1|All-cause mortality during hospital stay|Intravenous/oral indomethacin","All-cause mortality during hospital stay",2,1,"Intravenous/oral indomethacin","or","binary",4,-0.252435395619475,0.454646358326681,0.178954161410752,1997,0.231211496836497,47
"CD013278","CD013278_pub3_data","2|10|Pneumothorax|Intravenous/oral ibuprofen","Pneumothorax",2,10,"Intravenous/oral ibuprofen","or","binary",2,0.285469407018868,0.772207811722441,0,2023.5,0.00735294117647059,459.5
"CD013278","CD013278_pub3_data","2|11|Pulmonary hemorrhage|Intravenous/oral ibuprofen","Pulmonary hemorrhage",2,11,"Intravenous/oral ibuprofen","or","binary",5,-0.398670927864081,0.355375232196399,0.245388795605348,2020.2,0.102786161375305,254.2
"CD013278","CD013278_pub3_data","2|11|Pulmonary hemorrhage|Intravenous/oral indomethacin","Pulmonary hemorrhage",2,11,"Intravenous/oral indomethacin","or","binary",2,-0.21106021176581,0.964167143142931,1.21577165280792,2012,0.137310606060606,68
"CD013278","CD013278_pub3_data","2|12|Pulmonary hypertension|Intravenous/oral ibuprofen","Pulmonary hypertension",2,12,"Intravenous/oral ibuprofen","or","binary",2,-0.135128886076989,0.294769376347517,0,2022.5,0.0529857251825215,437
"CD013278","CD013278_pub3_data","2|13|IVH (grades I to IV)|Intravenous/oral ibuprofen","IVH (grades I to IV)",2,13,"Intravenous/oral ibuprofen","or","binary",3,0.00764780296149339,0.129507572422501,4.83679235577678e-06,2019.66666666667,0.459562629399586,327.666666666667
"CD013278","CD013278_pub3_data","2|13|IVH (grades I to IV)|Intravenous/oral indomethacin","IVH (grades I to IV)",2,13,"Intravenous/oral indomethacin","or","binary",2,-0.330686500443476,0.629715662736562,0.18604304989453,2012,0.130681818181818,68
"CD013278","CD013278_pub3_data","2|14|Severe IVH (grades III and IV)|Intravenous/oral ibuprofen","Severe IVH (grades III and IV)",2,14,"Intravenous/oral ibuprofen","or","binary",5,0.240902010294033,0.183016780111682,0,2020.2,0.0757593952912973,254.2
"CD013278","CD013278_pub3_data","2|15|PVL (any grade)|Intravenous/oral ibuprofen","PVL (any grade)",2,15,"Intravenous/oral ibuprofen","reported","reported",5,0,0.11322026016094,0,2020.2,0.198492514854912,254.2
"CD013278","CD013278_pub3_data","2|16|NEC (stage 2 or greater)|Intravenous/oral ibuprofen","NEC (stage 2 or greater)",2,16,"Intravenous/oral ibuprofen","or","binary",5,-0.0635943904428022,0.170207035091629,0,2020.2,0.129202938612516,254.2
"CD013278","CD013278_pub3_data","2|16|NEC (stage 2 or greater)|Intravenous/oral indomethacin","NEC (stage 2 or greater)",2,16,"Intravenous/oral indomethacin","or","binary",2,-0.183058203512897,0.699454816172948,0,2012,0.0662878787878788,68
"CD013278","CD013278_pub3_data","2|17|Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy|Intravenous/oral ibuprofen","Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy",2,17,"Intravenous/oral ibuprofen","or","binary",2,0.307070741231621,0.458596730865593,0.0916636854797835,2023.5,0.0213280964559737,459.5
"CD013278","CD013278_pub3_data","2|18|Spontaneous intestinal perforation|Intravenous/oral ibuprofen","Spontaneous intestinal perforation",2,18,"Intravenous/oral ibuprofen","or","binary",4,0.204621755119812,0.223751249153728,0,2020,0.0587981903287631,302.75
"CD013278","CD013278_pub3_data","2|18|Spontaneous intestinal perforation|Intravenous/oral indomethacin","Spontaneous intestinal perforation",2,18,"Intravenous/oral indomethacin","or","binary",2,0.0432796857967183,1.42580866738643,0,2012,0,68
"CD013278","CD013278_pub3_data","2|19|Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)|Intravenous/oral indomethacin","Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)",2,19,"Intravenous/oral indomethacin","or","binary",2,0.0432796857967183,1.42580866738643,0,2012,0,68
"CD013278","CD013278_pub3_data","2|2|Surgical PDA ligation or transcatheter occlusion|Intravenous/oral ibuprofen","Surgical PDA ligation or transcatheter occlusion",2,2,"Intravenous/oral ibuprofen","or","binary",4,-0.568958540954471,0.405257555759612,0.299487529643786,2022.25,0.106963059823472,301.75
"CD013278","CD013278_pub3_data","2|2|Surgical PDA ligation or transcatheter occlusion|Intravenous/oral indomethacin","Surgical PDA ligation or transcatheter occlusion",2,2,"Intravenous/oral indomethacin","or","binary",3,-0.443065394921619,0.8702985546764,0,2001.66666666667,0.0395299145299145,53.6666666666667
"CD013278","CD013278_pub3_data","2|20|Severe ROP|Intravenous/oral ibuprofen","Severe ROP",2,20,"Intravenous/oral ibuprofen","or","binary",4,-0.0891123325239621,0.18333851049223,0,2022.25,0.113304761263773,301.75
"CD013278","CD013278_pub3_data","2|20|Severe ROP|Intravenous/oral indomethacin","Severe ROP",2,20,"Intravenous/oral indomethacin","or","binary",2,-1.22537425994669,1.21831736593399,0,2012,0.03125,68
"CD013278","CD013278_pub3_data","2|21|Definite sepsis|Intravenous/oral ibuprofen","Definite sepsis",2,21,"Intravenous/oral ibuprofen","or","binary",5,0.0843737828650021,0.142716044718863,0,2020.2,0.285932229871354,254.2
"CD013278","CD013278_pub3_data","2|21|Definite sepsis|Intravenous/oral indomethacin","Definite sepsis",2,21,"Intravenous/oral indomethacin","or","binary",2,-0.16184210709793,0.353957088652815,0,2012,0.369318181818182,68
"CD013278","CD013278_pub3_data","2|23|Duration of hospitalization|Intravenous/oral ibuprofen","Duration of hospitalization",2,23,"Intravenous/oral ibuprofen","or","binary",4,-0.00339232577740928,1.00458891807606,0,2020,0,260.75
"CD013278","CD013278_pub3_data","2|3|Receipt of any pharmacotherapy for a hs-PDA|Intravenous/oral ibuprofen","Receipt of any pharmacotherapy for a hs-PDA",2,3,"Intravenous/oral ibuprofen","or","binary",4,5.11799377283224,1.17498496175008,4.69196648864673,2022.25,0.315407484504099,301.75
"CD013278","CD013278_pub3_data","2|3|Receipt of any pharmacotherapy for a hs-PDA|Intravenous/oral indomethacin","Receipt of any pharmacotherapy for a hs-PDA",2,3,"Intravenous/oral indomethacin","or","binary",3,4.13272523065283,1.21887925190732,1.89862062685325,1991.33333333333,0.366466866466866,32
"CD013278","CD013278_pub3_data","2|4|Receipt of repeat courses of pharmacotherapy for a persistent hs-PDA|Intravenous/oral ibuprofen","Receipt of repeat courses of pharmacotherapy for a persistent hs-PDA",2,4,"Intravenous/oral ibuprofen","or","binary",3,1.83456140837651,1.80416584930914,8.40268427541181,2019.66666666667,0.0993788819875776,327.666666666667
"CD013278","CD013278_pub3_data","2|4|Receipt of repeat courses of pharmacotherapy for a persistent hs-PDA|Intravenous/oral indomethacin","Receipt of repeat courses of pharmacotherapy for a persistent hs-PDA",2,4,"Intravenous/oral indomethacin","or","binary",2,0.288876214880519,0.840063028452118,0.261715047874461,1995.5,0.0839160839160839,34.5
"CD013278","CD013278_pub3_data","2|5|Receipt of rescue medical treatment for a hs-PDA|Intravenous/oral ibuprofen","Receipt of rescue medical treatment for a hs-PDA",2,5,"Intravenous/oral ibuprofen","or","binary",2,-1.38241345547149,0.648201994157195,0.7368895320837,2022.5,0.354881769641495,437
"CD013278","CD013278_pub3_data","2|6|Chronic lung disease (CLD)|Intravenous/oral indomethacin","Chronic lung disease (CLD)",2,6,"Intravenous/oral indomethacin","or","binary",4,0.285071413511827,0.590300221139209,0.712157902643784,1997,0.175028096903097,47
"CD013278","CD013278_pub3_data","2|7|Duration of ventilator support (days)|Intravenous/oral ibuprofen","Duration of ventilator support (days)",2,7,"Intravenous/oral ibuprofen","or","binary",5,-0.0157795512094969,0.899655825920887,0,2020.2,0,247.2
"CD013278","CD013278_pub3_data","2|7|Duration of ventilator support (days)|Intravenous/oral indomethacin","Duration of ventilator support (days)",2,7,"Intravenous/oral indomethacin","or","binary",3,0.053134024440276,1.174216909653,0,1991.33333333333,0,30.6666666666667
"CD013278","CD013278_pub3_data","2|8|Duration of need for supplementary oxygen (days)|Intravenous/oral ibuprofen","Duration of need for supplementary oxygen (days)",2,8,"Intravenous/oral ibuprofen","or","binary",4,-0.00338310422097933,1.00322257265287,0,2022.25,0,301.75
"CD013278","CD013278_pub3_data","2|8|Duration of need for supplementary oxygen (days)|Intravenous/oral indomethacin","Duration of need for supplementary oxygen (days)",2,8,"Intravenous/oral indomethacin","or","binary",2,0.0412965744113453,1.43658511753571,0,1996.5,0,33.5
"CD013278","CD013278_pub3_data","2|9|Postnatal corticosteroid use for CLD any time during hospital stay|Intravenous/oral ibuprofen","Postnatal corticosteroid use for CLD any time during hospital stay",2,9,"Intravenous/oral ibuprofen","or","binary",3,0.159838117338982,0.142450936458323,0,2022.66666666667,0.234559330978768,326.333333333333
"CD013284","CD013284_pub2_data","1|1|Rate of moderate or severe exacerbations|","Rate of moderate or severe exacerbations",1,1,"","reported","reported",5,-0.0250269108529844,0.0653642179464882,0,2017.4,0,196
"CD013284","CD013284_pub2_data","1|10|Inter-arm difference in mean change in FEV1 (% predicted)|","Inter-arm difference in mean change in FEV1 (% predicted)",1,10,"","reported","reported",7,2.72205394119401,3.15025583948484,55.5366162136502,2017.28571428571,0,151.857142857143
"CD013284","CD013284_pub2_data","1|11|Inter-arm difference in mean change in FVC (% predicted)|","Inter-arm difference in mean change in FVC (% predicted)",1,11,"","reported","reported",5,-1.30953637070756,1.59779201118269,0,2017.4,0,182.4
"CD013284","CD013284_pub2_data","1|12|Proportion of participants with one or more serious adverse event of any cause|","Proportion of participants with one or more serious adverse event of any cause",1,12,"","or","binary",5,0.165990289221933,0.185465974820688,0,2015.8,0.227080611374397,132.6
"CD013284","CD013284_pub2_data","1|13|Mortality (all-cause)|","Mortality (all-cause)",1,13,"","or","binary",6,0.0927863756647421,0.291937634716589,0,2016.66666666667,0.0306704699360067,169.833333333333
"CD013284","CD013284_pub2_data","1|14|Mortality (all-cause), risk difference|","Mortality (all-cause), risk difference",1,14,"","or","binary",6,0.0927863756647421,0.291937634716589,0,2016.66666666667,0.0306704699360067,169.833333333333
"CD013284","CD013284_pub2_data","1|15|Mortality (respiratory)|","Mortality (respiratory)",1,15,"","or","binary",5,0.14108940130222,0.548096020072991,0,2015.6,0.00879120879120879,172.8
"CD013284","CD013284_pub2_data","1|2|Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)|Baseline 25(OH)D < 25 nmol/L","Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)",1,2,"Baseline 25(OH)D < 25 nmol/L","reported","reported",4,-0.368016465048893,0.209779683828621,0.0239433598890953,2016.5,0,29.5
"CD013284","CD013284_pub2_data","1|2|Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)|Baseline 25(OH)D ≥ 75 nmol/L","Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)",1,2,"Baseline 25(OH)D ≥ 75 nmol/L","reported","reported",4,0.316743447985146,0.148345468997203,0,2017.5,0,48.5
"CD013284","CD013284_pub2_data","1|2|Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)|Baseline 25(OH)D 25 to 49.9 nmol/L","Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)",1,2,"Baseline 25(OH)D 25 to 49.9 nmol/L","reported","reported",5,-0.0241158103389861,0.0975938497046034,0,2017.4,0,76
"CD013284","CD013284_pub2_data","1|2|Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)|Baseline 25(OH)D 50 to 74.9 nmol/L","Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)",1,2,"Baseline 25(OH)D 50 to 74.9 nmol/L","reported","reported",5,-0.0366893196370471,0.138524427283808,0,2017.4,0,55.2
"CD013284","CD013284_pub2_data","1|3|Rate of moderate or severe exacerbations (stratified by baseline FEV1, % predicted)|Baseline FEV1 < 50% predicted","Rate of moderate or severe exacerbations (stratified by baseline FEV1, % predicted)",1,3,"Baseline FEV1 < 50% predicted","reported","reported",5,0.00274893868498156,0.0895281317152431,0,2017.4,0,63.8
"CD013284","CD013284_pub2_data","1|3|Rate of moderate or severe exacerbations (stratified by baseline FEV1, % predicted)|Baseline FEV1 ≥ 50% predicted","Rate of moderate or severe exacerbations (stratified by baseline FEV1, % predicted)",1,3,"Baseline FEV1 ≥ 50% predicted","reported","reported",5,-0.0190800446535194,0.0954561459006865,1.00315684308365e-06,2017.4,0,131.8
"CD013284","CD013284_pub2_data","1|4|Rate of moderate or severe exacerbations (stratified by baseline corticosteroid use)|Any baseline corticosteroid use","Rate of moderate or severe exacerbations (stratified by baseline corticosteroid use)",1,4,"Any baseline corticosteroid use","reported","reported",5,-0.084324802701131,0.0714652167825498,0,2017.4,0,104
"CD013284","CD013284_pub2_data","1|4|Rate of moderate or severe exacerbations (stratified by baseline corticosteroid use)|No baseline corticosteroid use","Rate of moderate or severe exacerbations (stratified by baseline corticosteroid use)",1,4,"No baseline corticosteroid use","reported","reported",5,-0.0324649132539298,0.147665044021028,0,2017.4,0,92
"CD013284","CD013284_pub2_data","1|5|Proportion of participants experiencing one or more exacerbations (moderate or severe)|","Proportion of participants experiencing one or more exacerbations (moderate or severe)",1,5,"","reported","reported",5,-0.0589830873104978,0.140277260102521,0,2017.4,0,196
"CD013284","CD013284_pub2_data","1|6|Time to first exacerbation|","Time to first exacerbation",1,6,"","reported","reported",4,-0.0127271226165412,0.102871007098699,0,2016.5,0,156
"CD013284","CD013284_pub2_data","1|7|Rate of severe exacerbation, requiring ED attendance or hospitalisation|","Rate of severe exacerbation, requiring ED attendance or hospitalisation",1,7,"","reported","reported",4,0.14627501903358,0.200206916495557,0,2016.5,0,155.5
"CD013284","CD013284_pub2_data","1|8|Rate of moderate exacerbation|","Rate of moderate exacerbation",1,8,"","reported","reported",3,-0.157575731783242,0.096369239442565,0,2014.66666666667,0,155.666666666667
"CD013284","CD013284_pub2_data","1|9|Incidence of study defined exacerbation|","Incidence of study defined exacerbation",1,9,"","reported","reported",5,-0.0364841868710421,0.0654647466754848,0,2017.4,0,195.8
"CD013284","CD013284_pub2_data","2|1|Inter-arm difference in mean change in FEV1 (% predicted), excluding studies at high risk of bias|","Inter-arm difference in mean change in FEV1 (% predicted), excluding studies at high risk of bias",2,1,"","reported","reported",6,0.421045726770424,0.382314499233547,0,2017.66666666667,0,162.5
"CD013294","CD013294_pub2_data","1|1|Time (%) in target oxygen saturation range|","Time (%) in target oxygen saturation range",1,1,"","or","binary",12,-0.0311323256667177,0.586722414288697,0,2015.58333333333,0,41.4166666666667
"CD013294","CD013294_pub2_data","1|11|Average oxygen saturation (%)|Invasive respiratory support","Average oxygen saturation (%)",1,11,"Invasive respiratory support","or","binary",2,-0.079785885974909,1.43892766340523,0,2014.5,0,28
"CD013294","CD013294_pub2_data","1|11|Average oxygen saturation (%)|Non-invasive respiratory support","Average oxygen saturation (%)",1,11,"Non-invasive respiratory support","or","binary",6,-0.0358710308888167,0.831337082874821,0,2016.66666666667,0,41.8333333333333
"CD013294","CD013294_pub2_data","1|12|Average fraction of inspired oxygen|","Average fraction of inspired oxygen",1,12,"","or","binary",8,-0.0468610794997231,0.719835136727299,0,2016.125,0,38.375
"CD013294","CD013294_pub2_data","1|13|Number of manual adjustments during study|","Number of manual adjustments during study",1,13,"","or","binary",4,-0.0931891728427497,1.01510186508571,0,2015.25,0,36.75
"CD013294","CD013294_pub2_data","1|4|Time (%) above alarm limit or desired oxygen saturation range, regardless of fraction of inspired oxygen received|Invasive respiratory support","Time (%) above alarm limit or desired oxygen saturation range, regardless of fraction of inspired oxygen received",1,4,"Invasive respiratory support","or","binary",2,-0.0792012612801449,1.43364615700997,0,2015.5,0,44
"CD013294","CD013294_pub2_data","1|4|Time (%) above alarm limit or desired oxygen saturation range, regardless of fraction of inspired oxygen received|Non-invasive respiratory support","Time (%) above alarm limit or desired oxygen saturation range, regardless of fraction of inspired oxygen received",1,4,"Non-invasive respiratory support","or","binary",6,-0.0355130995802349,0.827179025835391,0,2017.33333333333,0,46.5
"CD013294","CD013294_pub2_data","1|5|Time (%) above alarm limit or desired oxygen saturation range, excluding time in room air|Non-invasive respiratory support","Time (%) above alarm limit or desired oxygen saturation range, excluding time in room air",1,5,"Non-invasive respiratory support","or","binary",3,0,1.1643246944962,0,2016.33333333333,0,66
"CD013294","CD013294_pub2_data","1|6|Time (%) below alarm limit or desired oxygen saturation range|Invasive respiratory support","Time (%) below alarm limit or desired oxygen saturation range",1,6,"Invasive respiratory support","or","binary",3,-0.0528458471186518,1.17106596194338,0,2013.33333333333,0,40
"CD013294","CD013294_pub2_data","1|6|Time (%) below alarm limit or desired oxygen saturation range|Non-invasive respiratory support","Time (%) below alarm limit or desired oxygen saturation range",1,6,"Non-invasive respiratory support","or","binary",6,-0.0355130995802349,0.827179025835391,0,2017.33333333333,0,46.5
"CD013294","CD013294_pub2_data","1|7|Hypoxic episodes during study period|","Hypoxic episodes during study period",1,7,"","or","binary",2,-0.079785885974909,1.43892766340523,0,2014.5,0,28
"CD013294","CD013294_pub2_data","1|8|Time (%) with oxygen saturation below 80%|","Time (%) with oxygen saturation below 80%",1,8,"","or","binary",3,0,1.17922495895347,0,2015,0,37.3333333333333
"CD013294","CD013294_pub2_data","1|9|Time with oxygen saturation between 97% and 100%, excluding time in room air|","Time with oxygen saturation between 97% and 100%, excluding time in room air",1,9,"","or","binary",2,0,1.45584357658387,0,2012,0,21
"CD013294","CD013294_pub2_data","2|1|Time (%) in desired oxygen saturation range|","Time (%) in desired oxygen saturation range",2,1,"","or","binary",2,0,1.45735850267178,0,2008,0,19
"CD013294","CD013294_pub2_data","2|6|Average oxygen saturation (%)|","Average oxygen saturation (%)",2,6,"","or","binary",2,0,1.45735850267178,0,2008,0,19
"CD013294","CD013294_pub2_data","2|7|Average fraction of inspired oxygen|","Average fraction of inspired oxygen",2,7,"","or","binary",2,0,1.45735850267178,0,2008,0,19
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|Aprotinin vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"Aprotinin vs placebo","or","binary",5,-0.788440579560167,0.217702889386745,0,2002,0.430146227982719,146.2
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|EACA vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"EACA vs placebo","or","binary",3,-0.671674236951741,0.483159103079136,0.238320743722847,2004.33333333333,0.291666666666667,56
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA IV 1 g intraoperatively vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA IV 1 g intraoperatively vs placebo","or","binary",2,-1.9036078514412,0.583207554140398,0,2004.5,0.398809523809524,40
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA IV 1 g pre-incision vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA IV 1 g pre-incision vs placebo","or","binary",7,-0.701433834844423,0.267884471908512,0.130668658954816,2010.85714285714,0.348209835379647,68.7142857142857
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA IV total dose 2 g, intraoperatively and postoperatively vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA IV total dose 2 g, intraoperatively and postoperatively vs placebo","or","binary",4,-1.6977055453518,0.352150356329647,1.13591149444824e-06,2000.5,0.458394532843737,65
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA IV total dose 2 g, pre-incision and postoperatively vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA IV total dose 2 g, pre-incision and postoperatively vs placebo","or","binary",4,-0.9377180590234,0.332940867826717,0,2014.75,0.262451737451737,84
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA IV total dose 3 g, intraoperatively and postoperatively vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA IV total dose 3 g, intraoperatively and postoperatively vs placebo","or","binary",2,-2.27313261719692,0.542565002142254,0,2003,0.847368421052632,43.5
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA topical 1 g intraoperatively vs placebo","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA topical 1 g intraoperatively vs placebo","or","binary",2,-1.58425556932445,0.549102257714406,0,2018.5,0.181776133209991,88.5
"CD013295","CD013295_pub2_data","1|1|Need for allogeneic blood transfusion (only trials included in the NMA)|TXA_IV_1g_preI_intra vs TXA_oral_2g_preI","Need for allogeneic blood transfusion (only trials included in the NMA)",1,1,"TXA_IV_1g_preI_intra vs TXA_oral_2g_preI","or","binary",2,-0.60099406212279,0.76325798095821,0,2017,0.0522058823529412,77
"CD013295","CD013295_pub2_data","1|2|Units of red blood cells transfused (only trials included in the NMA)|Aprotinin vs placebo","Units of red blood cells transfused (only trials included in the NMA)",1,2,"Aprotinin vs placebo","or","binary",7,-0.0111337637878739,0.766967508453914,0,2000.14285714286,0,78.4285714285714
"CD013295","CD013295_pub2_data","1|2|Units of red blood cells transfused (only trials included in the NMA)|Desmopressin vs placebo","Units of red blood cells transfused (only trials included in the NMA)",1,2,"Desmopressin vs placebo","or","binary",2,0.012544363429745,1.42551217064737,0,1993.5,0,64.5
"CD013295","CD013295_pub2_data","1|2|Units of red blood cells transfused (only trials included in the NMA)|TXA_IV_1g_preI vs placebo","Units of red blood cells transfused (only trials included in the NMA)",1,2,"TXA_IV_1g_preI vs placebo","or","binary",2,0.0274836212472048,1.4259381647755,0,2010.5,0,61
"CD013295","CD013295_pub2_data","1|2|Units of red blood cells transfused (only trials included in the NMA)|TXA_IV_2g_intra_post vs placebo","Units of red blood cells transfused (only trials included in the NMA)",1,2,"TXA_IV_2g_intra_post vs placebo","or","binary",3,0.116483537705334,1.16228057209325,0,2002.66666666667,0,83.3333333333333
"CD013295","CD013295_pub2_data","1|3|Risk of experiencing DVT (only trials included in the NMA)|Aprotinin vs placebo","Risk of experiencing DVT (only trials included in the NMA)",1,3,"Aprotinin vs placebo","or","binary",2,-0.288738799764691,0.402029496189465,0,2003.5,0.0564197817506385,323
"CD013295","CD013295_pub2_data","1|3|Risk of experiencing DVT (only trials included in the NMA)|TXA_IV_1g_intra vs placebo","Risk of experiencing DVT (only trials included in the NMA)",1,3,"TXA_IV_1g_intra vs placebo","or","binary",2,-0.0525677165193859,0.48701527480886,0,2002,0.272435897435897,49.5
"CD013295","CD013295_pub2_data","1|3|Risk of experiencing DVT (only trials included in the NMA)|TXA_IV_1g_preI vs placebo","Risk of experiencing DVT (only trials included in the NMA)",1,3,"TXA_IV_1g_preI vs placebo","or","binary",2,-0.113609484501012,0.492923840891288,0,2009,0.257796257796258,61
"CD013295","CD013295_pub2_data","1|3|Risk of experiencing DVT (only trials included in the NMA)|TXA_IV_2g_intra_post vs placebo","Risk of experiencing DVT (only trials included in the NMA)",1,3,"TXA_IV_2g_intra_post vs placebo","or","binary",3,0.104032848541309,0.503810168156392,0,1998.66666666667,0.0925540595675235,55
"CD013295","CD013295_pub2_data","1|4|Length of hospital stay (only trials included in the NMA)|Desmopressin vs placebo","Length of hospital stay (only trials included in the NMA)",1,4,"Desmopressin vs placebo","or","binary",2,0.124472766976413,1.42992762052309,0,1994,0,46
"CD013295","CD013295_pub2_data","1|4|Length of hospital stay (only trials included in the NMA)|TXA_IV_1g_preI vs placebo","Length of hospital stay (only trials included in the NMA)",1,4,"TXA_IV_1g_preI vs placebo","or","binary",2,0.0273525505190034,1.42253391689279,0,2019.5,0,86
"CD013295","CD013295_pub2_data","1|4|Length of hospital stay (only trials included in the NMA)|TXA_IV_1g_preI_intra vs TXA_oral_2g_preI","Length of hospital stay (only trials included in the NMA)",1,4,"TXA_IV_1g_preI_intra vs TXA_oral_2g_preI","or","binary",2,-0.0774144215260958,1.42331691782594,0,2017,0,77
"CD013295","CD013295_pub2_data","1|4|Length of hospital stay (only trials included in the NMA)|TXA_IV_2g_preI_post vs placebo","Length of hospital stay (only trials included in the NMA)",1,4,"TXA_IV_2g_preI_post vs placebo","or","binary",3,0.00458101487312396,1.16092177099451,0,2018,0,101.333333333333
"CD013295","CD013295_pub2_data","12|1|Risk of allogeneic blood transfusion|TXA, IV 2 g","Risk of allogeneic blood transfusion",12,1,"TXA, IV 2 g","or","binary",3,-0.494097199481789,1.07384470017706,0,2017,0.00462962962962963,143.333333333333
"CD013295","CD013295_pub2_data","12|5|Risk of experiencing DVT|TXA, IV 2 g","Risk of experiencing DVT",12,5,"TXA, IV 2 g","or","binary",3,-0.500863306805455,1.07353088457622,0,2017,0.00347222222222222,143
"CD013295","CD013295_pub2_data","12|6|Risk of experiencing PE|TXA, IV 2 g","Risk of experiencing PE",12,6,"TXA, IV 2 g","or","binary",3,-0.0851271234296004,0.846598600612498,0.283907341824607,2017,0.0104166666666667,143
"CD013295","CD013295_pub2_data","12|7|Risk of experiencing MI|TXA, IV 2 g","Risk of experiencing MI",12,7,"TXA, IV 2 g","or","binary",2,0.641758335303731,1.27160026739879,0,NA,0,117.5
"CD013295","CD013295_pub2_data","12|8|Risk of experiencing CVA|TXA, IV 2 g","Risk of experiencing CVA",12,8,"TXA, IV 2 g","or","binary",3,-0.500863306805455,1.07353088457622,0,2017,0.00347222222222222,143
"CD013295","CD013295_pub2_data","17|1|Risk of allogeneic blood transfusion|","Risk of allogeneic blood transfusion",17,1,"","or","binary",9,-0.738403653358413,0.223125175818473,0,2000.77777777778,0.390821978508918,80.7777777777778
"CD013295","CD013295_pub2_data","17|10|Risk of suspected serious drug reactions|","Risk of suspected serious drug reactions",17,10,"","or","binary",3,0.0602901382980844,0.322450595715462,0,1996.66666666667,0.136986301369863,76
"CD013295","CD013295_pub2_data","17|2|All-cause mortality|","All-cause mortality",17,2,"","or","binary",2,-1.11597697393947,1.15884527234727,0,2003.5,0.0096741738255553,250
"CD013295","CD013295_pub2_data","17|3|Units of red blood cells transfused|","Units of red blood cells transfused",17,3,"","or","binary",8,-0.0331577396672085,0.716960137064815,0,1999.5,0,75.25
"CD013295","CD013295_pub2_data","17|6|Risk of experiencing DVT|","Risk of experiencing DVT",17,6,"","or","binary",9,-0.274806266721448,0.383572599136537,0,2000.44444444444,0.0403155070556974,82.7777777777778
"CD013295","CD013295_pub2_data","17|7|Risk of experiencing PE|","Risk of experiencing PE",17,7,"","or","binary",3,-0.33139268713296,0.841020324165976,0,2002,0.00376647834274953,140.666666666667
"CD013295","CD013295_pub2_data","17|8|Risk of experiencing MI|","Risk of experiencing MI",17,8,"","or","binary",2,-0.371718867287966,0.947078501924346,0,2003.5,0.0096741738255553,250
"CD013295","CD013295_pub2_data","17|9|Risk of experiencing CVA|","Risk of experiencing CVA",17,9,"","or","binary",2,-0.78288398363533,1.27635521417182,0,2001,0.0208333333333333,202.5
"CD013295","CD013295_pub2_data","18|1|Risk of allogeneic blood transfusion|","Risk of allogeneic blood transfusion",18,1,"","or","binary",3,-0.671674236951741,0.483159103079136,0.238320743722847,2004.33333333333,0.291666666666667,56
"CD013295","CD013295_pub2_data","18|4|Risk of experiencing DVT|","Risk of experiencing DVT",18,4,"","or","binary",3,0.237559928840134,1.16717955963871,0,2004.33333333333,0,56
"CD013295","CD013295_pub2_data","18|5|Risk of experiencing PE|","Risk of experiencing PE",18,5,"","or","binary",3,0.237559928840134,1.16717955963871,0,2004.33333333333,0,56
"CD013295","CD013295_pub2_data","2|1|Need for allogeneic blood transfusion|TXA, IV 1 g","Need for allogeneic blood transfusion",2,1,"TXA, IV 1 g","or","binary",20,-1.21056572330103,0.218980534056839,0.252453458825291,2007.83333333333,0.347695242399029,56.65
"CD013295","CD013295_pub2_data","2|1|Need for allogeneic blood transfusion|TXA, IV 2 g","Need for allogeneic blood transfusion",2,1,"TXA, IV 2 g","or","binary",10,-1.39060104722299,0.29237886586196,0.166546392268899,2008.4,0.434465820838819,70.7
"CD013295","CD013295_pub2_data","2|1|Need for allogeneic blood transfusion|TXA, IV more than 3 g","Need for allogeneic blood transfusion",2,1,"TXA, IV more than 3 g","or","binary",4,-1.63013067111319,0.569055308900423,0.223077430355048,2011.75,0.372619047619048,74
"CD013295","CD013295_pub2_data","2|10|Risk of having suspected serious drug reactions|TXA, IV 1 g","Risk of having suspected serious drug reactions",2,10,"TXA, IV 1 g","or","binary",2,0.0824366476372608,1.42689200375164,0,2004.5,0,66.5
"CD013295","CD013295_pub2_data","2|2|All-cause mortality|TXA, IV 1 g","All-cause mortality",2,2,"TXA, IV 1 g","or","binary",3,-0.0109448317312128,1.17428058861384,0,2018,0,35
"CD013295","CD013295_pub2_data","2|3|Units of red blood cells transfused|TXA, IV 1 g","Units of red blood cells transfused",2,3,"TXA, IV 1 g","or","binary",5,0.0764547445322343,0.902528246192793,0,2011.75,0,65.2
"CD013295","CD013295_pub2_data","2|3|Units of red blood cells transfused|TXA, IV 2 g","Units of red blood cells transfused",2,3,"TXA, IV 2 g","or","binary",3,0.000455552603876074,1.16161558097735,0,2007,0,84
"CD013295","CD013295_pub2_data","2|4|Reoperation|TXA, IV more than 3 g","Reoperation",2,4,"TXA, IV more than 3 g","or","binary",2,1.05687143552371,1.23121247951298,0,2019.5,0,126.5
"CD013295","CD013295_pub2_data","2|5|Length of hospital stay|TXA, IV 1 g","Length of hospital stay",2,5,"TXA, IV 1 g","or","binary",3,-0.00615704644998687,1.16157251666196,0,2019.66666666667,0,84.3333333333333
"CD013295","CD013295_pub2_data","2|5|Length of hospital stay|TXA, IV 2 g","Length of hospital stay",2,5,"TXA, IV 2 g","or","binary",3,0.00458101487312396,1.16092177099451,0,2018,0,101.333333333333
"CD013295","CD013295_pub2_data","2|6|Risk of experiencing DVT|TXA, IV 1 g","Risk of experiencing DVT",2,6,"TXA, IV 1 g","or","binary",21,0.11349733371061,0.289467489224685,0,2007.22222222222,0.0391685449824985,52.2380952380952
"CD013295","CD013295_pub2_data","2|6|Risk of experiencing DVT|TXA, IV 2 g","Risk of experiencing DVT",2,6,"TXA, IV 2 g","or","binary",10,-0.135132667172123,0.419381371408888,0,2008.4,0.0314580369843528,71.4
"CD013295","CD013295_pub2_data","2|6|Risk of experiencing DVT|TXA, IV 3 g","Risk of experiencing DVT",2,6,"TXA, IV 3 g","or","binary",2,-0.021556684801426,1.01009098252545,0,2018.5,0.0072463768115942,100
"CD013295","CD013295_pub2_data","2|6|Risk of experiencing DVT|TXA, IV more than 3 g","Risk of experiencing DVT",2,6,"TXA, IV more than 3 g","or","binary",4,-0.240366618797615,0.695681332923917,0,2011.75,0.0330687830687831,76.25
"CD013295","CD013295_pub2_data","2|7|Risk of experiencing PE|TXA, IV 1 g","Risk of experiencing PE",2,7,"TXA, IV 1 g","or","binary",16,0.100437712411656,0.426616429605206,0,2007.6,0.0184989429175476,58.875
"CD013295","CD013295_pub2_data","2|7|Risk of experiencing PE|TXA, IV 2 g","Risk of experiencing PE",2,7,"TXA, IV 2 g","or","binary",7,-0.161335883312198,0.714053570308827,0,2008.57142857143,0.0037593984962406,71.2857142857143
"CD013295","CD013295_pub2_data","2|7|Risk of experiencing PE|TXA, IV 3 g","Risk of experiencing PE",2,7,"TXA, IV 3 g","or","binary",2,-0.686418427214339,1.27309467492788,0,2018.5,0.0072463768115942,100
"CD013295","CD013295_pub2_data","2|7|Risk of experiencing PE|TXA, IV more than 3 g","Risk of experiencing PE",2,7,"TXA, IV more than 3 g","or","binary",3,0.0408460801361021,1.17437009793302,0,2016,0,87.6666666666667
"CD013295","CD013295_pub2_data","2|8|Risk of experiencing MI|More than 3 g","Risk of experiencing MI",2,8,"More than 3 g","or","binary",2,0.707013848239789,1.27113728753502,0,2019.5,0,126.5
"CD013295","CD013295_pub2_data","2|8|Risk of experiencing MI|TXA, IV 1 g","Risk of experiencing MI",2,8,"TXA, IV 1 g","or","binary",7,0.041990539371163,0.717632446721715,0,2013.6,0.00366300366300366,55.1428571428571
"CD013295","CD013295_pub2_data","2|8|Risk of experiencing MI|TXA, IV 2 g","Risk of experiencing MI",2,8,"TXA, IV 2 g","or","binary",3,-0.49576970829414,1.07817528649491,0,2005.33333333333,0.0087719298245614,89.3333333333333
"CD013295","CD013295_pub2_data","2|9|Risk of experiencing CVA|TXA, IV 1 g","Risk of experiencing CVA",2,9,"TXA, IV 1 g","or","binary",3,0.212350476151042,1.1636404498667,0,2009.66666666667,0,77.6666666666667
"CD013295","CD013295_pub2_data","20|1|All-cause mortality|","All-cause mortality",20,1,"","or","binary",2,0.124472766976413,1.42992762052309,0,1994,0,46
"CD013295","CD013295_pub2_data","20|2|Units of red blood cells transfused|","Units of red blood cells transfused",20,2,"","or","binary",2,0.012544363429745,1.42551217064737,0,1993.5,0,64.5
"CD013295","CD013295_pub2_data","20|3|Risk of experiencing DVT|","Risk of experiencing DVT",20,3,"","or","binary",2,0.124472766976413,1.42992762052309,0,1994,0,46
"CD013295","CD013295_pub2_data","20|5|Risk of experiencing MI|","Risk of experiencing MI",20,5,"","or","binary",3,0.0911013819110771,1.16564361758286,0,1994.5,0,57
"CD013295","CD013295_pub2_data","20|6|Risk of suspected serious drug reactions|","Risk of suspected serious drug reactions",20,6,"","or","binary",2,0.0539085655575001,1.43062454858324,0,1993,0,43
"CD013295","CD013295_pub2_data","20|7|Length of hospital stay|","Length of hospital stay",20,7,"","or","binary",2,0.124472766976413,1.42992762052309,0,1994,0,46
"CD013295","CD013295_pub2_data","23|1|Risk of allogeneic blood transfusion|TXA, IV 1 g","Risk of allogeneic blood transfusion",23,1,"TXA, IV 1 g","or","binary",2,-0.605044592736819,0.730008741800881,0.686702920062939,2019,0.248062015503876,74.5
"CD013295","CD013295_pub2_data","23|2|Length of hospital stay|TXA, IV 1 g","Length of hospital stay",23,2,"TXA, IV 1 g","or","binary",2,-0.0334323601842573,1.42390421563529,0,2019,0,74.5
"CD013295","CD013295_pub2_data","23|3|Risk of experiencing DVT|TXA, IV 1 g","Risk of experiencing DVT",23,3,"TXA, IV 1 g","or","binary",2,-0.0334323601842573,1.42390421563529,0,2019,0,74.5
"CD013295","CD013295_pub2_data","23|4|Risk of experiencing PE|TXA, IV 1 g","Risk of experiencing PE",23,4,"TXA, IV 1 g","or","binary",2,-0.0334323601842573,1.42390421563529,0,2019,0,74.5
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","or","binary",2,0.37536278168663,0.953023018181513,0,2018.5,0.00833333333333333,110
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,1.11694409249765,1.1626117965158,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","or","binary",2,1.11694409249765,1.1626117965158,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0.668479234452375,1.272137924735,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0.668479234452375,1.272137924735,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|1|Risk of allogeneic blood transfusion|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Risk of allogeneic blood transfusion",29,1,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Length of hospital stay",29,3,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","Length of hospital stay",29,3,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Length of hospital stay",29,3,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Length of hospital stay",29,3,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Length of hospital stay",29,3,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|3|Length of hospital stay|TXA, oral + TXA, tpical 4 g vs TXA, oral + TXA, topical 5 g","Length of hospital stay",29,3,"TXA, oral + TXA, tpical 4 g vs TXA, oral + TXA, topical 5 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,0.831510767629666,0,2018.5,0.0166666666666667,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,0.831510767629666,0,2018.5,0.0166666666666667,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 4 g vs TXA, oral, + TXA, topical 5 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 4 g vs TXA, oral, + TXA, topical 5 g","or","binary",2,0.414772692108985,0.930012785414503,0,2018.5,0.00833333333333333,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,-0.414772692108985,0.930012785414503,0,2018.5,0.0166666666666667,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,-0.414772692108985,0.930012785414503,0,2018.5,0.0166666666666667,110
"CD013295","CD013295_pub2_data","29|4|Risk of experiencing DVT|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing DVT",29,4,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,0.831510767629666,0,2018.5,0.0166666666666667,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|5|Risk of experiencing PE|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing PE",29,5,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|6|Risk of experiencing MI|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing MI",29,6,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","29|7|Risk of experiencing CVA|TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","Risk of experiencing CVA",29,7,"TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g","or","binary",2,0,1.42062103526994,0,2018.5,0,110
"CD013295","CD013295_pub2_data","3|1|Need for allogeneic blood transfusion|TXA, oral 2 g","Need for allogeneic blood transfusion",3,1,"TXA, oral 2 g","or","binary",2,-1.73750168038136,0.800803004148185,0,2018,0.11,90
"CD013295","CD013295_pub2_data","3|4|Risk of experiencing DVT|TXA, oral 2 g","Risk of experiencing DVT",3,4,"TXA, oral 2 g","or","binary",2,0,1.42205615702513,0,2018,0,90
"CD013295","CD013295_pub2_data","3|5|Risk of experiencing PE|TXA, oral 2 g","Risk of experiencing PE",3,5,"TXA, oral 2 g","or","binary",2,0,1.42205615702513,0,2018,0,90
"CD013295","CD013295_pub2_data","4|1|Risk of allogeneic blood transfusion|TXA, topical 2 g","Risk of allogeneic blood transfusion",4,1,"TXA, topical 2 g","or","binary",2,-1.7717660166493,0.868140673339797,0,2015,0.082693947144075,92
"CD013295","CD013295_pub2_data","4|1|Risk of allogeneic blood transfusion|TXA, topical 3 g","Risk of allogeneic blood transfusion",4,1,"TXA, topical 3 g","or","binary",2,-1.43570111881482,1.13771620890838,0,2019,0.0476190476190476,65.5
"CD013295","CD013295_pub2_data","4|2|All-cause mortality|TXA, topical 3 g","All-cause mortality",4,2,"TXA, topical 3 g","or","binary",2,0.648815902345824,1.27763043505113,0,2019,0,65.5
"CD013295","CD013295_pub2_data","4|5|Risk of experiencing DVT|TXA, Topical 2g","Risk of experiencing DVT",4,5,"TXA, Topical 2g","or","binary",2,-0.846281485134273,0.584128538742752,0,2015,0.0882352941176471,92
"CD013295","CD013295_pub2_data","4|5|Risk of experiencing DVT|TXA, Topical 3g","Risk of experiencing DVT",4,5,"TXA, Topical 3g","or","binary",2,-0.00181611152539009,1.42492813285384,0,2019,0,65
"CD013295","CD013295_pub2_data","4|6|Risk of experiencing PE|TXA, topical 2 g","Risk of experiencing PE",4,6,"TXA, topical 2 g","or","binary",2,-0.13580184941924,0.873755068721897,0,2015,0.0196078431372549,92
"CD013295","CD013295_pub2_data","4|6|Risk of experiencing PE|TXA, topical 3 g","Risk of experiencing PE",4,6,"TXA, topical 3 g","or","binary",2,-0.00181611152539009,1.42492813285384,0,2019,0,65
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 1 g vs TXA, IV 2 g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 1 g vs TXA, IV 2 g","or","binary",5,0.125038300877972,0.407053802689191,0.033173266384927,2015,0.0722222222222222,59.4
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 2g vs TXA, IV 3g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 2g vs TXA, IV 3g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 2g vs TXA, IV More than 3g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 2g vs TXA, IV More than 3g","or","binary",3,0.47692884403228,0.701288046185395,0,2017.5,0.00900900900900901,119.666666666667
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 3g vs TXA, IV More than 3g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 3g vs TXA, IV More than 3g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 4g vs TXA, IV 5g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 4g vs TXA, IV 5g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|1|Risk of allogeneic blood transfusion|TXA, IV 5g vs TXA, IV More than 5g","Risk of allogeneic blood transfusion",6,1,"TXA, IV 5g vs TXA, IV More than 5g","or","binary",2,-0.0122934706200815,1.41986966007311,0,2021.5,0,131
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 1 g vs TXA, IV 2 g","Length of hospital stay",6,5,"TXA, IV 1 g vs TXA, IV 2 g","or","binary",2,-0.0218879914348674,1.42330938860398,0,2018.5,0,77
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 2 g vs TXA, IV 3 g","Length of hospital stay",6,5,"TXA, IV 2 g vs TXA, IV 3 g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 2 g vs TXA, IV more than 3 g","Length of hospital stay",6,5,"TXA, IV 2 g vs TXA, IV more than 3 g","or","binary",3,0.0391669167924866,1.15955397022039,0,2017.5,0,121.666666666667
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 3 g vs TXA, IV more than 3 g","Length of hospital stay",6,5,"TXA, IV 3 g vs TXA, IV more than 3 g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 4 g vs TXA, IV 5 g","Length of hospital stay",6,5,"TXA, IV 4 g vs TXA, IV 5 g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|5|Length of hospital stay|TXA, IV 5 g vs TXA, IV more than 5 g","Length of hospital stay",6,5,"TXA, IV 5 g vs TXA, IV more than 5 g","or","binary",2,-0.0122934706200815,1.41986966007311,0,2021.5,0,131
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 1 g vs TXA, IV 2 g","Risk of experiencing DVT",6,6,"TXA, IV 1 g vs TXA, IV 2 g","or","binary",5,-0.201846978301109,0.741933369108765,0,2015,0.0155555555555556,59.4
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 1 g vs TXA, IV 3 g","Risk of experiencing DVT",6,6,"TXA, IV 1 g vs TXA, IV 3 g","or","binary",2,0.0102755806437267,1.42635777079457,0,2021,0,68.5
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 2 g vs TXA, IV 3 g","Risk of experiencing DVT",6,6,"TXA, IV 2 g vs TXA, IV 3 g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 2 g vs TXA, IV more than 3 g","Risk of experiencing DVT",6,6,"TXA, IV 2 g vs TXA, IV more than 3 g","or","binary",3,0.0391669167924866,1.15955397022039,0,2017.5,0,121.666666666667
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 3 g vs TXA, IV more than 3 g","Risk of experiencing DVT",6,6,"TXA, IV 3 g vs TXA, IV more than 3 g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 4 g vs TXA, IV 5 g","Risk of experiencing DVT",6,6,"TXA, IV 4 g vs TXA, IV 5 g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|6|Risk of experiencing DVT|TXA, IV 5 g vs TXA, IV more than 5 g","Risk of experiencing DVT",6,6,"TXA, IV 5 g vs TXA, IV more than 5 g","or","binary",2,-0.0185942897889741,1.00818570852157,0,2021.5,0.00625,131
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 1 g vs TXA, IV 2 g","Risk of experiencing PE",6,7,"TXA, IV 1 g vs TXA, IV 2 g","or","binary",4,0.403724859609289,0.954559458336531,0,2014.5,0,56.5
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 1 g vs TXA, IV 3 g","Risk of experiencing PE",6,7,"TXA, IV 1 g vs TXA, IV 3 g","or","binary",2,0.0102755806437267,1.42635777079457,0,2021,0,68.5
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 2 g vs TXA, IV 3 g","Risk of experiencing PE",6,7,"TXA, IV 2 g vs TXA, IV 3 g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 2 g vs TXA, IV more than 3 g","Risk of experiencing PE",6,7,"TXA, IV 2 g vs TXA, IV more than 3 g","or","binary",3,0.0391669167924866,1.15955397022039,0,2017.5,0,121.666666666667
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 3 g vs TXA, IV more than 3 g","Risk of experiencing PE",6,7,"TXA, IV 3 g vs TXA, IV more than 3 g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 4 g vs TXA, IV 5 g","Risk of experiencing PE",6,7,"TXA, IV 4 g vs TXA, IV 5 g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|7|Risk of experiencing PE|TXA, IV 5 g vs TXA, IV more than 5 g","Risk of experiencing PE",6,7,"TXA, IV 5 g vs TXA, IV more than 5 g","or","binary",2,-0.0122934706200815,1.41986966007311,0,2021.5,0,131
"CD013295","CD013295_pub2_data","6|8|Risk of experiencing MI|TXA, IV 2 g vs TXA, IV 3 g","Risk of experiencing MI",6,8,"TXA, IV 2 g vs TXA, IV 3 g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|8|Risk of experiencing MI|TXA, IV 2 g vs TXA, IV more than 3 g","Risk of experiencing MI",6,8,"TXA, IV 2 g vs TXA, IV more than 3 g","or","binary",3,-0.438968677401426,1.07413922968349,0,2017.5,0.00427350427350427,121.666666666667
"CD013295","CD013295_pub2_data","6|8|Risk of experiencing MI|TXA, IV 3 g vs TXA, IV more than 3 g","Risk of experiencing MI",6,8,"TXA, IV 3 g vs TXA, IV more than 3 g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|8|Risk of experiencing MI|TXA, IV 4 g vs TXA, IV 5 g","Risk of experiencing MI",6,8,"TXA, IV 4 g vs TXA, IV 5 g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|8|Risk of experiencing MI|TXA, IV 5 g vs TXA, IV more than 5 g","Risk of experiencing MI",6,8,"TXA, IV 5 g vs TXA, IV more than 5 g","or","binary",2,-0.0122934706200815,1.41986966007311,0,2021.5,0,131
"CD013295","CD013295_pub2_data","6|9|Risk of experiencing CVA|TXA, IV 2 g vs TXA, IV 3 g","Risk of experiencing CVA",6,9,"TXA, IV 2 g vs TXA, IV 3 g","or","binary",2,-0.0388579086830071,1.42113489040635,0,2016,0,101
"CD013295","CD013295_pub2_data","6|9|Risk of experiencing CVA|TXA, IV 2 g vs TXA, IV more than 3 g","Risk of experiencing CVA",6,9,"TXA, IV 2 g vs TXA, IV more than 3 g","or","binary",2,0.0458660775143531,1.42085371614861,0,2016,0,105.5
"CD013295","CD013295_pub2_data","6|9|Risk of experiencing CVA|TXA, IV 3 g vs TXA, IV more than 3 g","Risk of experiencing CVA",6,9,"TXA, IV 3 g vs TXA, IV more than 3 g","or","binary",2,0.0847234819896165,1.42098666892776,0,2016,0,103.5
"CD013295","CD013295_pub2_data","6|9|Risk of experiencing CVA|TXA, IV 4 g vs TXA, IV 5 g","Risk of experiencing CVA",6,9,"TXA, IV 4 g vs TXA, IV 5 g","or","binary",2,0,1.4211973755246,0,2019,0,100
"CD013295","CD013295_pub2_data","6|9|Risk of experiencing CVA|TXA, IV 5 g vs TXA, IV more than 5 g","Risk of experiencing CVA",6,9,"TXA, IV 5 g vs TXA, IV more than 5 g","or","binary",2,-0.0122934706200815,1.41986966007311,0,2021.5,0,131
"CD013295","CD013295_pub2_data","7|1|Risk of allogeneic blood transfusion|TXA, IV 1g","Risk of allogeneic blood transfusion",7,1,"TXA, IV 1g","or","binary",4,-0.267149069838965,0.389235518124219,0,2018.5,0.119581202046036,70.75
"CD013295","CD013295_pub2_data","7|1|Risk of allogeneic blood transfusion|TXA, IV 2 g","Risk of allogeneic blood transfusion",7,1,"TXA, IV 2 g","or","binary",2,0.245441347825504,0.481197190929749,0,2019,0.0994565217391304,83
"CD013295","CD013295_pub2_data","7|2|Units of red blood cells transfused|TXA, IV 1 g","Units of red blood cells transfused",7,2,"TXA, IV 1 g","or","binary",2,-0.0359482878339266,1.42696665777039,0,NA,0,61.5
"CD013295","CD013295_pub2_data","7|3|Length of hospital stay|TXA, IV 1 g","Length of hospital stay",7,3,"TXA, IV 1 g","or","binary",4,-0.0220568115760522,1.00762537932744,0,2018.5,0,70.75
"CD013295","CD013295_pub2_data","7|3|Length of hospital stay|TXA, IV 2 g","Length of hospital stay",7,3,"TXA, IV 2 g","or","binary",2,0.0691023534864698,1.42263647821468,0,2019,0,83
"CD013295","CD013295_pub2_data","7|4|Risk of experiencing DVT|TXA, IV 1 g","Risk of experiencing DVT",7,4,"TXA, IV 1 g","or","binary",4,-0.385722665668984,0.950677879666189,0,2018.5,0.00543478260869565,70.75
"CD013295","CD013295_pub2_data","7|4|Risk of experiencing DVT|TXA, IV 2 g","Risk of experiencing DVT",7,4,"TXA, IV 2 g","or","binary",2,-0.588123162620641,1.27463412419308,0,2019,0.0108695652173913,83
"CD013295","CD013295_pub2_data","7|5|Risk of experiencing PE|TXA, IV 1 g","Risk of experiencing PE",7,5,"TXA, IV 1 g","or","binary",4,-0.0220568115760522,1.00762537932744,0,2018.5,0,70.75
"CD013295","CD013295_pub2_data","7|5|Risk of experiencing PE|TXA, IV 2 g","Risk of experiencing PE",7,5,"TXA, IV 2 g","or","binary",2,0.0691023534864698,1.42263647821468,0,2019,0,83
"CD013295","CD013295_pub2_data","8|1|Risk of allogeneic blood transfusion|TXA, IV vs TXA, topical 2 g","Risk of allogeneic blood transfusion",8,1,"TXA, IV vs TXA, topical 2 g","or","binary",4,-0.45958612239821,0.43914088177193,0,2017,0.0476449275362319,88
"CD013295","CD013295_pub2_data","8|1|Risk of allogeneic blood transfusion|TXA, IV vs TXA, topical 3 g","Risk of allogeneic blood transfusion",8,1,"TXA, IV vs TXA, topical 3 g","or","binary",3,0.74753058672506,1.05083294710365,0,2018,0,117
"CD013295","CD013295_pub2_data","8|2|All-cause mortality|TXA, IV vs TXA, topical 3 g","All-cause mortality",8,2,"TXA, IV vs TXA, topical 3 g","or","binary",2,-0.644489164434383,1.2778240734835,0,2018,0.015625,63
"CD013295","CD013295_pub2_data","8|4|Length of hospital stay|TXA, IV vs TXA, topical 3 g","Length of hospital stay",8,4,"TXA, IV vs TXA, topical 3 g","or","binary",2,-0.0118486593849054,1.41921799516776,0,2018.5,0,144
"CD013295","CD013295_pub2_data","8|5|Risk of experiencing DVT|TXA, IV vs TXA, topical 2 g","Risk of experiencing DVT",8,5,"TXA, IV vs TXA, topical 2 g","or","binary",4,-0.324765299229018,0.951453192189987,0,2017,0.00641025641025641,88.25
"CD013295","CD013295_pub2_data","8|5|Risk of experiencing DVT|TXA, IV vs TXA, topical 3 g","Risk of experiencing DVT",8,5,"TXA, IV vs TXA, topical 3 g","or","binary",3,-0.0550350262066025,0.703194283316084,0,2018,0.0120481927710843,116.666666666667
"CD013295","CD013295_pub2_data","8|6|Risk of experiencing PE|TXA, IV vs TXA, topical 2 g","Risk of experiencing PE",8,6,"TXA, IV vs TXA, topical 2 g","or","binary",4,0.054666794355447,0.752762168860165,0,2017,0.00833333333333333,88.25
"CD013295","CD013295_pub2_data","8|6|Risk of experiencing PE|TXA, IV vs TXA, topical 3 g","Risk of experiencing PE",8,6,"TXA, IV vs TXA, topical 3 g","or","binary",2,0,1.42271180455056,0,2018.5,0,91
"CD013295","CD013295_pub2_data","8|7|Risk of experiencing MI|TXA, IV vs TXA, topical 2 g","Risk of experiencing MI",8,7,"TXA, IV vs TXA, topical 2 g","or","binary",2,-0.411235552083654,0.931192124172582,0,2018.5,0.0144927536231884,82
"CD013303","CD013303_pub2_data","1|9|Self-efficacy to manage one's disease (short-term: immediately post-intervention)|","Self-efficacy to manage one's disease (short-term: immediately post-intervention)",1,9,"","or","binary",2,0.00373038040701221,1.41990027425861,0,2008,0,166.5
"CD013303","CD013303_pub2_data","2|10|Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - all studies|","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - all studies",2,10,"","or","binary",6,-0.0649939484821406,0.821220075081911,0,2014,0,183.5
"CD013303","CD013303_pub2_data","2|11|Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - by subgroup length of programme|12 months","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - by subgroup length of programme",2,11,"12 months","or","binary",2,-0.00110763087908282,1.4171842083324,0,2017,0,241
"CD013303","CD013303_pub2_data","2|11|Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - by subgroup length of programme|Up to 6 months","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - by subgroup length of programme",2,11,"Up to 6 months","or","binary",4,-0.0972914047734318,1.00764263712838,0,2012.5,0,154.75
"CD013303","CD013303_pub2_data","2|12|Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - studies without high risk of bias|","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - studies without high risk of bias",2,12,"","or","binary",3,-0.0114828039788244,1.15937242202963,0,2016,0,142.666666666667
"CD013303","CD013303_pub2_data","2|13|Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - without Kaur 2019|","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - without Kaur 2019",2,13,"","or","binary",5,-0.0780626768482576,0.900004780441408,0,2013,0,192.2
"CD013303","CD013303_pub2_data","2|14|Any health-related knowledge, 0 to 100 (medium-term: up to 6 months post-intervention)|","Any health-related knowledge, 0 to 100 (medium-term: up to 6 months post-intervention)",2,14,"","or","binary",2,-0.187559977308884,1.42931586524933,0,2009.5,0,149
"CD013303","CD013303_pub2_data","2|15|Health outcome: any depression (short-term: immediately post-intervention)|","Health outcome: any depression (short-term: immediately post-intervention)",2,15,"","or","binary",4,-0.103714798945186,1.00753303742694,0,2012,0,138.75
"CD013303","CD013303_pub2_data","2|16|Health outcome: any depression (medium-term: up to 6 months post-intervention)|","Health outcome: any depression (medium-term: up to 6 months post-intervention)",2,16,"","or","binary",2,-0.191319575734098,1.42948450708381,0,2009.5,0,133.5
"CD013303","CD013303_pub2_data","2|23|Self-efficacy to manage one's disease (short-term: immediately post-intervention) - all studies|","Self-efficacy to manage one's disease (short-term: immediately post-intervention) - all studies",2,23,"","or","binary",4,-0.111073244908961,1.00754199139712,0,2012,0,138
"CD013303","CD013303_pub2_data","2|24|Self-efficacy to manage one's disease (short-term: immediately post-intervention) - studies without high risk of bias|","Self-efficacy to manage one's disease (short-term: immediately post-intervention) - studies without high risk of bias",2,24,"","or","binary",2,-0.031852676304656,1.42031880928734,0,2014.5,0,142.5
"CD013303","CD013303_pub2_data","2|3|Any disease-specific health literacy (short-term: immediately post-intervention) - all studies|","Any disease-specific health literacy (short-term: immediately post-intervention) - all studies",2,3,"","or","binary",4,0.0245789549375114,1.0022818286544,0,2017.5,0,238.75
"CD013303","CD013303_pub2_data","2|4|Any disease-specific health literacy (short-term: immediately post-intervention - by subgroup length of programme)|12 months","Any disease-specific health literacy (short-term: immediately post-intervention - by subgroup length of programme)",2,4,"12 months","or","binary",2,0.0398642148185142,1.41707643272575,0,2017,0,246
"CD013303","CD013303_pub2_data","2|4|Any disease-specific health literacy (short-term: immediately post-intervention - by subgroup length of programme)|Up to 6 months","Any disease-specific health literacy (short-term: immediately post-intervention - by subgroup length of programme)",2,4,"Up to 6 months","or","binary",2,0.00927797455717301,1.41780495891262,0,2018,0,231.5
"CD013303","CD013303_pub2_data","2|5|Any disease-specific health literacy (short-term: immediately post-intervention) - studies without high risk of bias|","Any disease-specific health literacy (short-term: immediately post-intervention) - studies without high risk of bias",2,5,"","or","binary",2,0.0399232178191761,1.41812475195797,0,2019.5,0,195
"CD013303","CD013303_pub2_data","2|6|Any disease-specific health literacy (short-term: immediately post-intervention) - without Kaur 2019|","Any disease-specific health literacy (short-term: immediately post-intervention) - without Kaur 2019",2,6,"","or","binary",3,0.0327445920201482,1.1568523732619,0,2017,0,271.666666666667
"CD013303","CD013303_pub2_data","2|9|Diabetes-related quality of life, DQOL (short-term: immediately post-intervention) - all studies|","Diabetes-related quality of life, DQOL (short-term: immediately post-intervention) - all studies",2,9,"","or","binary",2,-0.0172328995820262,1.420293726374,0,2014.5,0,144
"CD013303","CD013303_pub2_data","3|1|Any generic health literacy (short-term: up to 1 month post-intervention)|","Any generic health literacy (short-term: up to 1 month post-intervention)",3,1,"","or","binary",2,-0.622316174108975,1.42328912406746,0,2016.5,0,114.5
"CD013303","CD013303_pub2_data","3|3|Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - all studies|","Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - all studies",3,3,"","or","binary",2,-0.608737440749593,1.43029217729327,0,2017.5,0,55.5
"CD013303","CD013303_pub2_data","3|6|Health behaviour: any screening adherence, odds ratio short-/medium-term: up to 6 months post-intervention)|","Health behaviour: any screening adherence, odds ratio short-/medium-term: up to 6 months post-intervention)",3,6,"","or","binary",2,1.11342159538957,0.93234995128662,1.11751111083373,2014,0.215827338129496,220
"CD013303","CD013303_pub2_data","5|3|Any health-related knowledge, 0 to 100 (short-term: immediately up to 3 months post-intervention)|","Any health-related knowledge, 0 to 100 (short-term: immediately up to 3 months post-intervention)",5,3,"","or","binary",2,-0.0647641110884929,1.41903245938325,0,2016.5,0,146.5
"CD013303","CD013303_pub2_data","5|4|Health outcome: any depression (short-term: up to 1 week post-intervention)|","Health outcome: any depression (short-term: up to 1 week post-intervention)",5,4,"","or","binary",2,-0.15520398212679,1.41857235251433,0,2015.5,0,168.5
"CD013303","CD013303_pub2_data","6|11|Health behaviour: any cancer screening uptake (medium-term: up to 6-month follow-up)|","Health behaviour: any cancer screening uptake (medium-term: up to 6-month follow-up)",6,11,"","or","binary",2,0.13832279236784,0.14482448806907,0,2018.5,0.656492248062016,401.5
"CD013303","CD013303_pub2_data","6|14|Cancer-related self-efficacy (medium-term: at 3-month follow-up)|","Cancer-related self-efficacy (medium-term: at 3-month follow-up)",6,14,"","or","binary",2,-0.197785189396912,1.42184784856763,0,2019.5,0,128
"CD013303","CD013303_pub2_data","6|2|Health literacy - competencies: inhaler use technique, checklist 0 to 10 (medium-term: 3 months post-intervention)|","Health literacy - competencies: inhaler use technique, checklist 0 to 10 (medium-term: 3 months post-intervention)",6,2,"","or","binary",2,-1.35597687660778,1.42670980854326,0,2016,0,88
"CD013303","CD013303_pub2_data","6|6|Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - all studies|","Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - all studies",6,6,"","or","binary",3,-0.182111747483176,1.15727289543273,0,2016,0,329
"CD013303","CD013303_pub2_data","6|7|Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)|Visual format (print only)","Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)",6,7,"Visual format (print only)","or","binary",2,-0.319755670880085,1.41836089051883,0,2016.5,0,189.5
"CD013303","CD013303_pub2_data","6|8|Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - all studies|","Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - all studies",6,8,"","or","binary",3,-0.31629354027497,1.15927151131188,0,2019,0,326.333333333333
"CD013303","CD013303_pub2_data","6|9|Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)|Audiovisual format (multimedia)","Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)",6,9,"Audiovisual format (multimedia)","or","binary",2,-0.13692153311308,1.42057847290885,0,2018.5,0,393
"CD013303","CD013303_pub2_data","7|1|Health literacy - competencies: inhaler use technique, checklist 0 to 10 (medium-term: 3 months post-intervention)|","Health literacy - competencies: inhaler use technique, checklist 0 to 10 (medium-term: 3 months post-intervention)",7,1,"","or","binary",2,-0.0591957793956557,1.42943406135047,0,2016,0,45.5
"CD013331","CD013331_pub2_data","1|1|Pain relief: high-frequency TENS versus placebo or no treatment|No treatment","Pain relief: high-frequency TENS versus placebo or no treatment",1,1,"No treatment","or","binary",4,0.0306067791069351,1.01976380975255,0,2014.25,0,29.75
"CD013331","CD013331_pub2_data","1|1|Pain relief: high-frequency TENS versus placebo or no treatment|Sham TENS","Pain relief: high-frequency TENS versus placebo or no treatment",1,1,"Sham TENS","or","binary",6,0.0577289736010464,0.828543568979055,0,2011.16666666667,0,37.6666666666667
"CD013331","CD013331_pub2_data","1|2|Adverse effects: high-frequency TENS versus placebo or no treatment|Sham TENS","Adverse effects: high-frequency TENS versus placebo or no treatment",1,2,"Sham TENS","or","binary",2,1.49419928754054,1.21170253356583,0,2002.5,0,52
"CD013331","CD013331_pub2_data","1|3|Requirements for additional analgesics - number of tablets: high-frequency TENS versus placebo or no treatment|Sham TENS","Requirements for additional analgesics - number of tablets: high-frequency TENS versus placebo or no treatment",1,3,"Sham TENS","or","binary",2,0,1.43675753407464,0,2005,0,32
"CD013331","CD013331_pub2_data","2|1|Pain relief: low-frequency TENS versus placebo or no treatment|Placebo pill","Pain relief: low-frequency TENS versus placebo or no treatment",2,1,"Placebo pill","or","binary",2,0.0455308800910956,1.44677767953356,0,1988,0,20.5
"CD013331","CD013331_pub2_data","3|1|Pain relief: high-frequency TENS versus low-frequency TENS|","Pain relief: high-frequency TENS versus low-frequency TENS",3,1,"","or","binary",3,0,1.18829926057738,0,2002,0,18
"CD013331","CD013331_pub2_data","4|3|Pain relief: high-frequency TENS versus interferential current therapy|","Pain relief: high-frequency TENS versus interferential current therapy",4,3,"","or","binary",2,-0.0607346558734492,1.43620025197376,0,2013,0,31
"CD013331","CD013331_pub2_data","4|4|Adverse effects: high-frequency TENS versus NSAIDs|","Adverse effects: high-frequency TENS versus NSAIDs",4,4,"","or","binary",2,2.4190449686327,1.98522784253599,6.36073825411821,1992,0.03125,44
"CD013332","CD013332_pub2_data","1|1|SSI|","SSI",1,1,"","or","binary",3,-0.0194276962654182,0.184539883211333,0,2001,0.0676813097367804,521.333333333333
"CD013332","CD013332_pub2_data","1|2|All-cause mortality|","All-cause mortality",1,2,"","or","binary",3,-0.390003782033941,0.483407004504263,0.313462189361644,2001,0.0359062704226648,521.333333333333
"CD013332","CD013332_pub2_data","2|1|SSI|","SSI",2,1,"","or","binary",2,-0.683976152902985,1.14126392570081,0,2004,0.0454545454545455,57.5
"CD013332","CD013332_pub2_data","2|2|All-cause mortality|","All-cause mortality",2,2,"","or","binary",2,-0.640405949224389,0.967501940127225,0,2004,0.0435606060606061,57.5
"CD013332","CD013332_pub2_data","3|1|SSI|","SSI",3,1,"","or","binary",3,-0.912004500682536,0.414791035842799,0.204480561793962,2012,0.183519081391422,175.666666666667
"CD013332","CD013332_pub2_data","3|2|All-cause mortality|","All-cause mortality",3,2,"","or","binary",2,-0.0107404668458924,0.644714422602515,0.1608970707675,2012.5,0.0316326530612245,216.5
"CD013332","CD013332_pub2_data","4|1|SSI|","SSI",4,1,"","or","binary",2,-0.138805756786339,0.338297542825849,0,2011,0.0780555555555555,292
"CD013332","CD013332_pub2_data","4|2|All-cause mortality|","All-cause mortality",4,2,"","or","binary",2,-0.469944856927926,0.59799169749627,0,2011,0.0266666666666667,292
"CD013332","CD013332_pub2_data","5|1|SSI|Diabetic patients only","SSI",5,1,"Diabetic patients only","or","binary",5,-1.10989316081037,0.304950471020909,7.20047036763549e-07,2010.4,0.172063267139993,112.8
"CD013332","CD013332_pub2_data","5|2|All-cause mortality|Diabetic and non-diabetic patients","All-cause mortality",5,2,"Diabetic and non-diabetic patients","or","binary",3,-0.529115117440463,0.220729915983045,1.29406295772876e-06,2014,0.0604831279353701,931.333333333333
"CD013332","CD013332_pub2_data","5|2|All-cause mortality|Diabetic only patients","All-cause mortality",5,2,"Diabetic only patients","or","binary",3,-0.319566457519123,0.525579097152163,0,2012.66666666667,0.0482246952835188,101
"CD013332","CD013332_pub2_data","5|3|Hospital length of stay|","Hospital length of stay",5,3,"","or","binary",4,0.0183803797233928,1.00192795540868,0,2011.75,0,759.5
"CD013332","CD013332_pub2_data","5|4|Adverse effects: Hypoglycaemia|","Adverse effects: Hypoglycaemia",5,4,"","or","binary",4,0.722749098282182,0.632553390963219,1.01276429084637,2015.25,0.0207354691384268,698.25
"CD013332","CD013332_pub2_data","6|1|SSI|","SSI",6,1,"","or","binary",2,-1.66543287941792,0.806957534383105,0,2016,0.104741379310345,72
"CD013332","CD013332_pub2_data","7|1|SSI|Deep sternal wound infection","SSI",7,1,"Deep sternal wound infection","or","binary",2,-1.48504649408849,1.16959179167429,1.18020915806066,2018,0.0787878787878788,110
"CD013332","CD013332_pub2_data","7|1|SSI|Superficial sternal wound infection","SSI",7,1,"Superficial sternal wound infection","or","binary",2,-0.451859003787649,0.665588563290716,0,2018,0.0419831223628692,111
"CD013332","CD013332_pub2_data","8|1|SSI|","SSI",8,1,"","or","binary",2,-0.871242415694586,1.15654462955167,1.49560062599194,2017,0.0422619047619048,188
"CD013332","CD013332_pub2_data","8|2|All-cause mortality|","All-cause mortality",8,2,"","or","binary",2,0.273838840287429,0.530687650733367,0,2017,0.0339285714285714,188
"CD013332","CD013332_pub2_data","8|3|Hospital length of stay|","Hospital length of stay",8,3,"","or","binary",2,0.0169033387532995,1.41820615931154,0,2017,0,188
"CD013332","CD013332_pub2_data","9|1|SSI|Deep SSI","SSI",9,1,"Deep SSI","or","binary",5,-0.411610878222868,0.180335065308931,9.32859086449264e-07,2009.8,0.061386953234746,538.2
"CD013332","CD013332_pub2_data","9|1|SSI|Superficial SSI","SSI",9,1,"Superficial SSI","or","binary",5,-0.539746719214038,0.240356626285453,0.163341967301374,2009.8,0.110323057836875,538.2
"CD013332","CD013332_pub2_data","9|2|All-cause mortality|All-cause mortality","All-cause mortality",9,2,"All-cause mortality","or","binary",4,-0.0231969262100879,0.209885688715333,0.0112358263686174,2009.25,0.018844242151993,1165.5
"CD013342","CD013342_pub2_data","1|1|Mean overall pain (0 to 10, 0 is no pain)|> 3 months to 6 months","Mean overall pain (0 to 10, 0 is no pain)",1,1,"> 3 months to 6 months","reported","reported",6,0,0.230869997150142,0,2019.66666666667,0,70.8333333333333
"CD013342","CD013342_pub2_data","1|1|Mean overall pain (0 to 10, 0 is no pain)|> 6 months to 1 year","Mean overall pain (0 to 10, 0 is no pain)",1,1,"> 6 months to 1 year","reported","reported",2,0,0.670039298534679,0,2017.5,0,35
"CD013342","CD013342_pub2_data","1|1|Mean overall pain (0 to 10, 0 is no pain)|Up to 3 months","Mean overall pain (0 to 10, 0 is no pain)",1,1,"Up to 3 months","reported","reported",6,0,0.22142812175744,0,2019.66666666667,0,70.5
"CD013342","CD013342_pub2_data","1|10|Total adverse events|","Total adverse events",1,10,"","reported","reported",2,0,0.376538706696467,0,2018.5,0.431666666666667,35.5
"CD013342","CD013342_pub2_data","1|12|Mean overall pain (0 to 10 points, 0 is no pain)|","Mean overall pain (0 to 10 points, 0 is no pain)",1,12,"","or","binary",7,-0.143789244694587,0.768205514088482,0,2019.57142857143,0,63.5714285714286
"CD013342","CD013342_pub2_data","1|2|Mean overall pain by cell origin (0 to 10, 0 is no pain)|Allogeneic (> 3 months to 6 months)","Mean overall pain by cell origin (0 to 10, 0 is no pain)",1,2,"Allogeneic (> 3 months to 6 months)","reported","reported",2,0,0.579033326597731,0,2020.5,0,28
"CD013342","CD013342_pub2_data","1|2|Mean overall pain by cell origin (0 to 10, 0 is no pain)|Autologous (> 3 months to 6 months)","Mean overall pain by cell origin (0 to 10, 0 is no pain)",1,2,"Autologous (> 3 months to 6 months)","reported","reported",4,0,0.251746217548725,0,2019.25,0,92.25
"CD013342","CD013342_pub2_data","1|3|Mean function (0 to 100, 0 is best function)|> 3 months to 6 months","Mean function (0 to 100, 0 is best function)",1,3,"> 3 months to 6 months","reported","reported",7,0,1.92973028068651,0,2020,0,61.7142857142857
"CD013342","CD013342_pub2_data","1|3|Mean function (0 to 100, 0 is best function)|> 6 months to 1 year","Mean function (0 to 100, 0 is best function)",1,3,"> 6 months to 1 year","reported","reported",2,0,8.4769206469198,0,2019,0,23
"CD013342","CD013342_pub2_data","1|3|Mean function (0 to 100, 0 is best function)|Up to 3 months","Mean function (0 to 100, 0 is best function)",1,3,"Up to 3 months","reported","reported",6,0,1.7202872977682,0,2020.33333333333,0,65.1666666666667
"CD013342","CD013342_pub2_data","1|4|Mean function by cell origin (0 to 100, 0 is best function)|Allogeneic","Mean function by cell origin (0 to 100, 0 is best function)",1,4,"Allogeneic","reported","reported",3,0,3.609474480621,0,2020,0,25.3333333333333
"CD013342","CD013342_pub2_data","1|4|Mean function by cell origin (0 to 100, 0 is best function)|Autologous","Mean function by cell origin (0 to 100, 0 is best function)",1,4,"Autologous","reported","reported",4,0,2.28346995929168,0,2020,0,89
"CD013342","CD013342_pub2_data","1|5|Mean quality of life (SF-36 mental health)|> 3 months to 6 months","Mean quality of life (SF-36 mental health)",1,5,"> 3 months to 6 months","or","binary",2,0.00799511612943811,1.42503252393648,0,2023,0,144
"CD013342","CD013342_pub2_data","1|5|Mean quality of life (SF-36 mental health)|Up to 3 months","Mean quality of life (SF-36 mental health)",1,5,"Up to 3 months","or","binary",2,0.00799511612943811,1.42503252393648,0,2023,0,144
"CD013342","CD013342_pub2_data","1|8|Withdrawals due to adverse events|","Withdrawals due to adverse events",1,8,"","or","binary",5,-0.389205454594786,0.912526608032248,0,2018.6,0,30.6
"CD013342","CD013342_pub2_data","4|1|Mean overall pain (0 to 10, 0 is no pain)|> 3 months to 6 months","Mean overall pain (0 to 10, 0 is no pain)",4,1,"> 3 months to 6 months","reported","reported",4,0,0.256741175494107,0,2018.5,0,41.25
"CD013342","CD013342_pub2_data","4|1|Mean overall pain (0 to 10, 0 is no pain)|> 6 months to 1 year","Mean overall pain (0 to 10, 0 is no pain)",4,1,"> 6 months to 1 year","reported","reported",4,0,0.238930481687055,0,2018.5,0,41.25
"CD013342","CD013342_pub2_data","4|1|Mean overall pain (0 to 10, 0 is no pain)|Up to 3 months","Mean overall pain (0 to 10, 0 is no pain)",4,1,"Up to 3 months","reported","reported",3,0,0.441471005081057,0,2018,0,46.3333333333333
"CD013342","CD013342_pub2_data","4|2|Mean function (0 to 100, 0 is best function)|> 3 months to 6 months","Mean function (0 to 100, 0 is best function)",4,2,"> 3 months to 6 months","reported","reported",5,0,2.70546640830374,0,2019.2,0,37
"CD013342","CD013342_pub2_data","4|2|Mean function (0 to 100, 0 is best function)|> 6 months to 1 year","Mean function (0 to 100, 0 is best function)",4,2,"> 6 months to 1 year","reported","reported",6,0,2.34743970138468,0,2019.66666666667,0,50
"CD013342","CD013342_pub2_data","4|2|Mean function (0 to 100, 0 is best function)|Up to 3 months","Mean function (0 to 100, 0 is best function)",4,2,"Up to 3 months","reported","reported",3,0,3.60930544010787,0,2019.33333333333,0,34.3333333333333
"CD013342","CD013342_pub2_data","4|5|Withdrawals due to adverse events|","Withdrawals due to adverse events",4,5,"","reported","reported",2,0,1.01851445707553,0,2019,0.0192307692307692,40
"CD013342","CD013342_pub2_data","4|8|Treatment failure|","Treatment failure",4,8,"","or","binary",2,-0.201001812889949,0.63560656513131,0,2020.5,0.0428571428571429,89
"CD013342","CD013342_pub2_data","5|1|Mean overall pain (0 to 10, 0 is no pain)|Up to 3 months","Mean overall pain (0 to 10, 0 is no pain)",5,1,"Up to 3 months","reported","reported",2,0,0.370120875958335,0,2021,0,71
"CD013342","CD013342_pub2_data","5|2|Mean function (0 to 100, 0 is best function)|> 3 months to 6 months","Mean function (0 to 100, 0 is best function)",5,2,"> 3 months to 6 months","reported","reported",2,0,2.58158030717803,0,2021,0,71
"CD013342","CD013342_pub2_data","5|2|Mean function (0 to 100, 0 is best function)|Up to 3 months","Mean function (0 to 100, 0 is best function)",5,2,"Up to 3 months","reported","reported",2,0,2.53848553014619,0,2021,0,71
"CD013342","CD013342_pub2_data","5|4|Withdrawals due to adverse events|","Withdrawals due to adverse events",5,4,"","or","binary",2,-0.306134238244641,0.793398007766721,0,2021,0.0416666666666667,77.5
"CD013342","CD013342_pub2_data","8|1|Mean overall pain (0 to 10, 0 is no pain)|> 3 months to 6 months","Mean overall pain (0 to 10, 0 is no pain)",8,1,"> 3 months to 6 months","or","binary",3,-0.422628087665492,1.1688214046571,0,2017.33333333333,0,46.6666666666667
"CD013342","CD013342_pub2_data","8|1|Mean overall pain (0 to 10, 0 is no pain)|> 6 months to 1 year","Mean overall pain (0 to 10, 0 is no pain)",8,1,"> 6 months to 1 year","or","binary",3,-0.422628087665492,1.1688214046571,0,2017.33333333333,0,46.6666666666667
"CD013342","CD013342_pub2_data","8|1|Mean overall pain (0 to 10, 0 is no pain)|Up to 3 months","Mean overall pain (0 to 10, 0 is no pain)",8,1,"Up to 3 months","reported","reported",2,0,0.448319559449129,0,2018,0,40
"CD013342","CD013342_pub2_data","8|3|Radiographic joint progression|","Radiographic joint progression",8,3,"","reported","reported",2,0,0.48527911850712,0,2018,0,40
"CD013342","CD013342_pub2_data","8|6|MRI cartilage loss (Whole-Organ Magnetic Resonance Imaging (WORMS score))|","MRI cartilage loss (Whole-Organ Magnetic Resonance Imaging (WORMS score))",8,6,"","reported","reported",2,0,4.89576805945111,0,2016,0,45
"CD013344","CD013344_pub2_data","2|1|Graft loss|","Graft loss",2,1,"","or","binary",3,-0.984823114507279,0.709649537926337,0,2015.33333333333,0.0493114723279688,131
"CD013344","CD013344_pub2_data","2|10|BK virus-associated nephropathy (BKVAN)|","BK virus-associated nephropathy (BKVAN)",2,10,"","or","binary",3,0.433497632287876,0.741227745693817,0,2015.33333333333,0.0271973466003317,127.666666666667
"CD013344","CD013344_pub2_data","2|12|Death|","Death",2,12,"","or","binary",3,-0.320409051606951,0.771289173077521,0,2015.33333333333,0.0225189840272323,131
"CD013344","CD013344_pub2_data","2|14|Infection|Clostridium difficile","Infection",2,14,"Clostridium difficile","or","binary",2,0.26463401639449,1.26971595630343,0,2016,0,177
"CD013344","CD013344_pub2_data","2|14|Infection|Urinary tract infection","Infection",2,14,"Urinary tract infection","reported","reported",2,0,0.129218755240352,0,2016,0.400401836969001,177
"CD013344","CD013344_pub2_data","2|15|Therapy-related adverse events: tendonitis|","Therapy-related adverse events: tendonitis",2,15,"","or","binary",2,1.58655449446961,0.795821959741303,0,2013.5,0.00641025641025641,96.5
"CD013344","CD013344_pub2_data","2|2|Acute rejection|","Acute rejection",2,2,"","or","binary",3,0.11667526904914,0.364808625760906,0,2015.33333333333,0.0561933920142875,131
"CD013344","CD013344_pub2_data","2|3|Serum creatinine [µmol/L]|6 months","Serum creatinine [µmol/L]",2,3,"6 months","reported","reported",2,0,6.47732578067097,0,2013.5,0,96.5
"CD013344","CD013344_pub2_data","2|8|Viral load > 10,000 copies/mL|","Viral load > 10,000 copies/mL",2,8,"","reported","reported",2,0,0.39294392791212,0,2016.5,0.137313432835821,114.5
"CD013344","CD013344_pub2_data","3|1|Graft loss|","Graft loss",3,1,"","or","binary",2,-0.29475289358224,0.404636522725314,0,2009,0.101445895522388,131.5
"CD013344","CD013344_pub2_data","3|5|BK viraemia|","BK viraemia",3,5,"","or","binary",2,-0.562289877857826,0.536558137878294,0.282865000682999,2009,0.231576492537313,131.5
"CD013353","CD013353_pub2_data","1|1|PIPP during endotracheal suctioning|Facilitated tucking / four-handed care / gentle human touch versus standard care","PIPP during endotracheal suctioning",1,1,"Facilitated tucking / four-handed care / gentle human touch versus standard care","or","binary",4,0,1.01315180422847,0,2015.25,0,37
"CD013353","CD013353_pub2_data","1|3|Heart rate during endotracheal suctioning (bpm)|Facilitated tucking / four-handed care / gentle human touch versus standard care","Heart rate during endotracheal suctioning (bpm)",1,3,"Facilitated tucking / four-handed care / gentle human touch versus standard care","or","binary",2,0,1.43135617084109,0,2021.5,0,40
"CD013353","CD013353_pub2_data","1|4|Oxygen saturation during endotracheal suctioning (%)|Facilitated tucking / four-handed care / gentle human touch versus standard care","Oxygen saturation during endotracheal suctioning (%)",1,4,"Facilitated tucking / four-handed care / gentle human touch versus standard care","or","binary",2,0,1.43135617084109,0,2021.5,0,40
"CD013355","CD013355_pub2_data","1|1|PIPP during endotracheal suctioning|NA","PIPP during endotracheal suctioning",1,1,NA,"or","binary",4,-0.0508541841791486,1.00764128785081,0,2007,0,280.75
"CD013355","CD013355_pub2_data","1|2|Pulmonary outcome: chronic lung disease|NA","Pulmonary outcome: chronic lung disease",1,2,NA,"or","binary",2,0.0351008722915667,0.352364739553683,0,2010.5,0.188311688311688,90
"CD013355","CD013355_pub2_data","1|3|Haemodynamic outcome: arterial hypotension|NA","Haemodynamic outcome: arterial hypotension",1,3,NA,"or","binary",2,0.467277608901211,0.401378661233537,0.101007280842373,2008,0.228762328985046,464
"CD013355","CD013355_pub2_data","1|4|Neurological outcome: periventricular leukomalacia|NA","Neurological outcome: periventricular leukomalacia",1,4,NA,"or","binary",3,-0.21975586779987,0.250477417105568,0,2006.66666666667,0.0554120417880636,309.666666666667
"CD013355","CD013355_pub2_data","1|5|Neurological outcome: overall intraventricular haemorrhage|NA","Neurological outcome: overall intraventricular haemorrhage",1,5,NA,"or","binary",2,-0.726223014856089,0.325439798064651,0,2006,0.296536796536797,97.5
"CD013355","CD013355_pub2_data","1|6|Neurological outcome: severe intraventricular haemorrhage|NA","Neurological outcome: severe intraventricular haemorrhage",1,6,NA,"or","binary",4,-0.15981666085836,0.449256361148005,0.297905152901001,2007,0.0852480852480852,266.25
"CD013355","CD013355_pub2_data","1|7|28-day mortality|NA","28-day mortality",1,7,NA,"or","binary",4,-0.100352545775951,0.333112680249842,0.133124688830057,2007,0.126277490141633,280.75
"CD013358","CD013358_pub2_data","1|1|Systolic blood pressure (mmHg), change from baseline|","Systolic blood pressure (mmHg), change from baseline",1,1,"","or","binary",6,-0.0315786587045822,0.824835337482531,0,2019,0,64.6666666666667
"CD013358","CD013358_pub2_data","1|11|Fasting blood glucose (mmol/L), change from baseline|","Fasting blood glucose (mmol/L), change from baseline",1,11,"","or","binary",2,-0.269535290266788,1.42330628563948,0,2016.5,0,100
"CD013358","CD013358_pub2_data","1|12|HbA1c (%), change from baseline|","HbA1c (%), change from baseline",1,12,"","or","binary",4,-0.185311846012959,1.00698986591083,0,2016.5,0,82.75
"CD013358","CD013358_pub2_data","1|13|Weight (kg), change from baseline|","Weight (kg), change from baseline",1,13,"","or","binary",10,-0.0816341651991962,0.639489720528183,0,2014.4,0,55.2
"CD013358","CD013358_pub2_data","1|14|BMI (kg/m2), change from baseline|","BMI (kg/m2), change from baseline",1,14,"","or","binary",7,-0.133616159047682,0.765102761577917,0,2016.42857142857,0,46
"CD013358","CD013358_pub2_data","1|15|Smoking cessation|","Smoking cessation",1,15,"","or","binary",6,0.529645804221031,0.429370339444651,0.874838859895786,2017.6,0.145067787292149,181.166666666667
"CD013358","CD013358_pub2_data","1|16|Quality of life, change from baseline|","Quality of life, change from baseline",1,16,"","or","binary",2,-0.298492988555997,1.44074158869163,0,2017,0,26
"CD013358","CD013358_pub2_data","1|17|Self-efficacy, change from baseline|","Self-efficacy, change from baseline",1,17,"","or","binary",4,-0.13146833553559,1.00967656029437,0,2003,0,52
"CD013358","CD013358_pub2_data","1|2|Diastolic blood pressure (mmHg), change from baseline|","Diastolic blood pressure (mmHg), change from baseline",1,2,"","or","binary",6,-0.0315786587045822,0.824835337482531,0,2019,0,64.6666666666667
"CD013358","CD013358_pub2_data","1|3|Anxiety, change from baseline|","Anxiety, change from baseline",1,3,"","or","binary",9,-0.133650720654308,0.674558927620241,0,2016.77777777778,0,48.6666666666667
"CD013358","CD013358_pub2_data","1|4|Depression, change from baseline|","Depression, change from baseline",1,4,"","or","binary",11,-0.113222578111072,0.609624500685305,0,2014.27272727273,0,54.0909090909091
"CD013358","CD013358_pub2_data","1|5|Perceived stress, change from baseline|","Perceived stress, change from baseline",1,5,"","or","binary",6,-0.068560727539803,0.824169596593133,0,2019,0,59.5
"CD013358","CD013358_pub2_data","1|8|LDL cholesterol (mmol/L), change from baseline|","LDL cholesterol (mmol/L), change from baseline",1,8,"","or","binary",3,-0.0256093450965602,1.16385085707808,0,2018,0,82.3333333333333
"CD013358","CD013358_pub2_data","2|10|LDL cholesterol (mmol/L), change from baseline|","LDL cholesterol (mmol/L), change from baseline",2,10,"","or","binary",2,-0.299572853428208,1.42591418944261,0,2015.5,0,77.5
"CD013358","CD013358_pub2_data","2|11|HDL cholesterol (mmol/L), change from baseline|","HDL cholesterol (mmol/L), change from baseline",2,11,"","or","binary",2,-0.299572853428208,1.42591418944261,0,2015.5,0,77.5
"CD013358","CD013358_pub2_data","2|12|Triglycerides (mmol/L), change from baseline|","Triglycerides (mmol/L), change from baseline",2,12,"","or","binary",2,-0.299572853428208,1.42591418944261,0,2015.5,0,77.5
"CD013358","CD013358_pub2_data","2|13|Fasting blood glucose (mmol/L), change from baseline|","Fasting blood glucose (mmol/L), change from baseline",2,13,"","or","binary",5,0.0184240891964092,0.900526673082172,0,2019,0,91.8
"CD013358","CD013358_pub2_data","2|14|HbA1c (%), change from baseline|","HbA1c (%), change from baseline",2,14,"","or","binary",12,-0.0314653904087866,0.582235874223047,0,2017.91666666667,0,82.5
"CD013358","CD013358_pub2_data","2|15|Weight (kg), change from baseline|","Weight (kg), change from baseline",2,15,"","or","binary",4,-0.0435008233641306,1.01574316534854,0,2009.75,0,35
"CD013358","CD013358_pub2_data","2|16|BMI (kg/m2), change from baseline|","BMI (kg/m2), change from baseline",2,16,"","or","binary",8,-0.222265127790354,0.717664011190089,0,2016.5,0,48.75
"CD013358","CD013358_pub2_data","2|17|Smoking cessation|","Smoking cessation",2,17,"","or","binary",2,0.33964167987229,0.267796896966536,0,2015,0.129680998613037,226.5
"CD013358","CD013358_pub2_data","2|18|Quality of life, change from baseline|","Quality of life, change from baseline",2,18,"","or","binary",15,-0.0724994125082617,0.526248868306645,0,2017,0,42.9333333333333
"CD013358","CD013358_pub2_data","2|19|Self-efficacy, change from baseline|","Self-efficacy, change from baseline",2,19,"","or","binary",6,-0.146746548178904,0.826094832799447,0,2009,0,54.1666666666667
"CD013358","CD013358_pub2_data","2|2|Systolic blood pressure (mmHg), change from baseline|","Systolic blood pressure (mmHg), change from baseline",2,2,"","or","binary",9,-0.181472635050477,0.677000674130903,0,2018,0,42.1111111111111
"CD013358","CD013358_pub2_data","2|3|Diastolic blood pressure (mmHg), change from baseline|","Diastolic blood pressure (mmHg), change from baseline",2,3,"","or","binary",9,-0.181472635050477,0.677000674130903,0,2018,0,42.1111111111111
"CD013358","CD013358_pub2_data","2|4|Anxiety, change from baseline|","Anxiety, change from baseline",2,4,"","or","binary",9,-0.181702043259664,0.675274045417263,0,2016.44444444444,0,59.2222222222222
"CD013358","CD013358_pub2_data","2|5|Depression, change from baseline|","Depression, change from baseline",2,5,"","or","binary",15,-0.115168148189766,0.522806656948381,0,2014.6,0,60.8
"CD013358","CD013358_pub2_data","2|6|Perceived stress, change from baseline|","Perceived stress, change from baseline",2,6,"","or","binary",11,-0.142842982077896,0.610027863894214,0,2016.1,0,64.3636363636364
"CD013358","CD013358_pub2_data","2|7|Well-being|","Well-being",2,7,"","or","binary",2,0,1.42236983669989,0,2017,0,99
"CD013358","CD013358_pub2_data","2|9|Total cholesterol (mmol/L), change from baseline|","Total cholesterol (mmol/L), change from baseline",2,9,"","or","binary",3,-0.190483937109089,1.16366107016671,0,2016,0,76
"CD013358","CD013358_pub2_data","3|10|Triglycerides (mmol/L), change from baseline|","Triglycerides (mmol/L), change from baseline",3,10,"","or","binary",2,-0.0711853303805516,1.42736503390525,0,2013.5,0,61
"CD013358","CD013358_pub2_data","3|12|BMI (kg/m2), change from baseline|","BMI (kg/m2), change from baseline",3,12,"","or","binary",4,0.0274927562586474,1.00609837802796,0,2018.25,0,105.75
"CD013358","CD013358_pub2_data","3|2|Systolic blood pressure (mmHg), change from baseline|","Systolic blood pressure (mmHg), change from baseline",3,2,"","or","binary",9,0.124423659922563,0.671230790256796,0,2012.11111111111,0,86
"CD013358","CD013358_pub2_data","3|3|Diastolic blood pressure (mmHg), change from baseline|","Diastolic blood pressure (mmHg), change from baseline",3,3,"","or","binary",9,0.124423659922563,0.671230790256796,0,2012.11111111111,0,86
"CD013358","CD013358_pub2_data","3|4|Anxiety, change from baseline|","Anxiety, change from baseline",3,4,"","or","binary",3,-0.0550587939049563,1.16365946271942,0,2008.66666666667,0,66.6666666666667
"CD013358","CD013358_pub2_data","3|5|Depression, change from baseline|","Depression, change from baseline",3,5,"","or","binary",5,-0.0420662543390928,0.901111742887921,0,2011.8,0,84.2
"CD013358","CD013358_pub2_data","3|6|Perceived stress, change from baseline|","Perceived stress, change from baseline",3,6,"","or","binary",3,-0.0364118977331214,1.16432423359395,0,2017.66666666667,0,64.6666666666667
"CD013358","CD013358_pub2_data","3|7|Total cholesterol (mmol/L), change from baseline|","Total cholesterol (mmol/L), change from baseline",3,7,"","or","binary",3,-0.0746788807797924,1.16577320875586,0,2011.33333333333,0,56.6666666666667
"CD013358","CD013358_pub2_data","3|8|LDL cholesterol (mmol/L), change from baseline|","LDL cholesterol (mmol/L), change from baseline",3,8,"","or","binary",3,-0.05726455009192,1.165903607871,0,2011.33333333333,0,56.3333333333333
"CD013358","CD013358_pub2_data","3|9|HDL cholesterol (mmol/L), change from baseline|","HDL cholesterol (mmol/L), change from baseline",3,9,"","or","binary",3,-0.05726455009192,1.165903607871,0,2011.33333333333,0,56.3333333333333
"CD013358","CD013358_pub2_data","4|1|Systolic blood pressure (mmHg), change from baseline|","Systolic blood pressure (mmHg), change from baseline",4,1,"","or","binary",2,0.109151691176875,1.42983953767231,0,1994.5,0,69.5
"CD013358","CD013358_pub2_data","4|2|Diastolic blood pressure (mmHg), change from baseline|","Diastolic blood pressure (mmHg), change from baseline",4,2,"","or","binary",2,0.109151691176875,1.42983953767231,0,1994.5,0,69.5
"CD013358","CD013358_pub2_data","5|1|Systolic blood pressure (mmHg), change from baseline|Primary prevention","Systolic blood pressure (mmHg), change from baseline",5,1,"Primary prevention","or","binary",5,0.0458922879343629,0.905388524591539,0,2018.5,0,47.4
"CD013358","CD013358_pub2_data","5|1|Systolic blood pressure (mmHg), change from baseline|Secondary prevention","Systolic blood pressure (mmHg), change from baseline",5,1,"Secondary prevention","or","binary",4,-0.469819583464505,1.01960259803249,0,2017.5,0,35.5
"CD013358","CD013358_pub2_data","5|2|Diastolic blood pressure (mmHg), change from baseline|Primary prevention","Diastolic blood pressure (mmHg), change from baseline",5,2,"Primary prevention","or","binary",5,0.0458922879343629,0.905388524591539,0,2018.5,0,47.4
"CD013358","CD013358_pub2_data","5|2|Diastolic blood pressure (mmHg), change from baseline|Secondary prevention","Diastolic blood pressure (mmHg), change from baseline",5,2,"Secondary prevention","or","binary",4,-0.469819583464505,1.01960259803249,0,2017.5,0,35.5
"CD013358","CD013358_pub2_data","5|3|Anxiety, change from baseline|Primary prevention","Anxiety, change from baseline",5,3,"Primary prevention","or","binary",5,0.0610196518852531,0.90075426215417,0,2015.6,0,81.4
"CD013358","CD013358_pub2_data","5|3|Anxiety, change from baseline|Secondary prevention","Anxiety, change from baseline",5,3,"Secondary prevention","or","binary",4,-0.493157722557896,1.0203523164425,0,2017.5,0,31.5
"CD013358","CD013358_pub2_data","5|4|Depression, change from baseline|Primary prevention","Depression, change from baseline",5,4,"Primary prevention","or","binary",11,0.019392610965701,0.608792731124868,0,2013.54545454545,0,71.4545454545455
"CD013358","CD013358_pub2_data","5|4|Depression, change from baseline|Secondary prevention","Depression, change from baseline",5,4,"Secondary prevention","or","binary",4,-0.493157722557896,1.0203523164425,0,2017.5,0,31.5
"CD013358","CD013358_pub2_data","5|5|Perceived stress, change from baseline|Primary prevention","Perceived stress, change from baseline",5,5,"Primary prevention","or","binary",7,-0.0297906936342902,0.763775669184369,0,2016.16666666667,0,67.1428571428571
"CD013358","CD013358_pub2_data","5|5|Perceived stress, change from baseline|Secondary prevention","Perceived stress, change from baseline",5,5,"Secondary prevention","or","binary",3,-0.483506753503534,1.17426875688956,0,2017.33333333333,0,42.6666666666667
"CD013358","CD013358_pub2_data","6|1|Systolic blood pressure (mmHg), change from baseline|Primary prevention","Systolic blood pressure (mmHg), change from baseline",6,1,"Primary prevention","or","binary",6,0.197687318305746,0.822177842782965,0,2011.66666666667,0,77.3333333333333
"CD013358","CD013358_pub2_data","6|1|Systolic blood pressure (mmHg), change from baseline|Secondary prevention","Systolic blood pressure (mmHg), change from baseline",6,1,"Secondary prevention","or","binary",3,-0.022005997494268,1.1623475142973,0,2013,0,103.333333333333
"CD013358","CD013358_pub2_data","6|2|Diastolic blood pressure (mmHg), change from baseline|Primary prevention","Diastolic blood pressure (mmHg), change from baseline",6,2,"Primary prevention","or","binary",6,0.197687318305746,0.822177842782965,0,2011.66666666667,0,77.3333333333333
"CD013358","CD013358_pub2_data","6|2|Diastolic blood pressure (mmHg), change from baseline|Secondary prevention","Diastolic blood pressure (mmHg), change from baseline",6,2,"Secondary prevention","or","binary",3,-0.022005997494268,1.1623475142973,0,2013,0,103.333333333333
"CD013358","CD013358_pub2_data","6|3|Anxiety, change from baseline|Primary prevention","Anxiety, change from baseline",6,3,"Primary prevention","or","binary",2,-0.0116416389259566,1.4265096692908,0,2010,0,58
"CD013358","CD013358_pub2_data","6|4|Depression, change from baseline|Primary prevention","Depression, change from baseline",6,4,"Primary prevention","or","binary",2,-0.0116416389259566,1.4265096692908,0,2010,0,58
"CD013358","CD013358_pub2_data","6|4|Depression, change from baseline|Secondary prevention","Depression, change from baseline",6,4,"Secondary prevention","or","binary",3,-0.0622676650175211,1.16239309108845,0,2013,0,101.666666666667
"CD013358","CD013358_pub2_data","6|5|Perceived stress, change from baseline|Primary prevention","Perceived stress, change from baseline",6,5,"Primary prevention","or","binary",2,0.0638998522693941,1.42342648875326,0,2016,0,76.5
"CD013366","CD013366_pub2_data","1|1|Venous thromboembolism|","Venous thromboembolism",1,1,"","or","binary",3,-0.320474986621936,0.648231447009527,0,2017.33333333333,0.0225225225225225,145.666666666667
"CD013366","CD013366_pub2_data","1|10|Catheter failure (sensitivity analyses)|Not terminated early","Catheter failure (sensitivity analyses)",1,10,"Not terminated early","or","binary",3,-0.365107292010671,0.358903866267669,0.077289304630506,2016.66666666667,0.154603266367972,119.333333333333
"CD013366","CD013366_pub2_data","1|10|Catheter failure (sensitivity analyses)|Patient unit of randomisation","Catheter failure (sensitivity analyses)",1,10,"Patient unit of randomisation","or","binary",3,-0.365107292010671,0.358903866267669,0.077289304630506,2016.66666666667,0.154603266367972,119.333333333333
"CD013366","CD013366_pub2_data","1|11|Incidence of PICC-related BSI|","Incidence of PICC-related BSI",1,11,"","or","binary",2,-0.679232225583111,0.480973350462978,0,2006.5,0.032967032967033,271
"CD013366","CD013366_pub2_data","1|12|Catheter breakage|","Catheter breakage",1,12,"","or","binary",4,0.0782066808823667,0.626506269770637,0,2012.75,0.0128823878823879,199.75
"CD013366","CD013366_pub2_data","1|13|Catheter breakage (sensitivity analyses)|Not terminated early","Catheter breakage (sensitivity analyses)",1,13,"Not terminated early","or","binary",3,-0.213072543401101,0.744178318745553,0.162494599632532,2012.33333333333,0.0171765171765172,206.333333333333
"CD013366","CD013366_pub2_data","1|13|Catheter breakage (sensitivity analyses)|Patient unit of randomisation","Catheter breakage (sensitivity analyses)",1,13,"Patient unit of randomisation","or","binary",3,-0.270341661336705,1.07062274503025,0.710217374595128,2017.33333333333,0.0135135135135135,145.666666666667
"CD013366","CD013366_pub2_data","1|14|PICC dwell time|","PICC dwell time",1,14,"","or","binary",2,-0.328686289586467,1.4190389822586,0,2005.5,0,231.5
"CD013366","CD013366_pub2_data","1|2|Venous thromboembolism (subgroup analysis - age)|Adult patients","Venous thromboembolism (subgroup analysis - age)",1,2,"Adult patients","or","binary",2,0.745060632845272,1.16129805596955,0,2017,0,145.5
"CD013366","CD013366_pub2_data","1|3|Venous thromboembolism (sensitivity analysis)|","Venous thromboembolism (sensitivity analysis)",1,3,"","or","binary",2,-0.402281273060642,0.775274728327633,0.1510296853196,2019,0.0337837837837838,128.5
"CD013366","CD013366_pub2_data","1|4|PICC-associated BSI|","PICC-associated BSI",1,4,"","or","binary",2,-1.02651271092616,1.23207874581461,0,2019,0.0181818181818182,128.5
"CD013366","CD013366_pub2_data","1|5|Occlusion|","Occlusion",1,5,"","or","binary",5,-0.213207939024257,0.307456127420186,0,2012.6,0.103696829698824,180
"CD013366","CD013366_pub2_data","1|6|Occlusion (subgroup analyses - age)|Adult patients","Occlusion (subgroup analyses - age)",1,6,"Adult patients","or","binary",4,-0.0785489948073116,0.325501584442786,0,2011.25,0.112729145231638,188.5
"CD013366","CD013366_pub2_data","1|7|Occlusion (sensitivity analyses)|Not terminated early","Occlusion (sensitivity analyses)",1,7,"Not terminated early","or","binary",3,-0.303770455499068,0.581783699105152,0.175669542369297,2012.33333333333,0.0340776340776341,206.333333333333
"CD013366","CD013366_pub2_data","1|7|Occlusion (sensitivity analyses)|Patient unit of randomisation","Occlusion (sensitivity analyses)",1,7,"Patient unit of randomisation","or","binary",4,-0.194740282633446,0.330703819501868,2.68979738908862e-06,2016,0.125500158002651,134.5
"CD013366","CD013366_pub2_data","1|8|All-cause mortality|","All-cause mortality",1,8,"","or","binary",2,-0.1767848122082,0.354234295200478,0,2009.5,0.0621378621378621,236.5
"CD013366","CD013366_pub2_data","1|9|Catheter failure|","Catheter failure",1,9,"","or","binary",4,-0.324206151168673,0.181354832431851,0,2012.25,0.20661179043532,180
"CD013366","CD013366_pub2_data","2|2|Occlusion|","Occlusion",2,2,"","or","binary",3,-0.258603781302731,0.265765104300917,0,2007.66666666667,0.173914325180244,186.666666666667
"CD013366","CD013366_pub2_data","2|4|Catheter failure|","Catheter failure",2,4,"","or","binary",2,-0.936600720789606,0.194862694235894,0,2005.5,0.427190721649485,246
"CD013366","CD013366_pub2_data","2|6|Catheter breakage|","Catheter breakage",2,6,"","or","binary",2,-1.42850316660877,0.661001795269352,0,2005.5,0.0701245704467354,246
"CD013366","CD013366_pub2_data","5|1|Venous thromboembolism|","Venous thromboembolism",5,1,"","or","binary",2,-0.195692303215951,0.519314214023283,0,2014,0.0255431440869031,255.5
"CD013366","CD013366_pub2_data","5|2|Occlusion|","Occlusion",5,2,"","or","binary",3,0.113925285783988,0.299048491579783,0.0794743776045377,2013.33333333333,0.186667349866776,204.333333333333
"CD013366","CD013366_pub2_data","6|2|Occlusion|","Occlusion",6,2,"","or","binary",3,-0.189566547818128,0.25616554290698,1.66163996818568e-06,2011.33333333333,0.166969880735799,172.666666666667
"CD013366","CD013366_pub2_data","6|3|Occlusion - sensitivity analysis|","Occlusion - sensitivity analysis",6,3,"","or","binary",2,-0.0306370583612537,0.569296438059699,0.180436135495809,2012,0.191176470588235,63
"CD013366","CD013366_pub2_data","6|4|Catheter failure|","Catheter failure",6,4,"","or","binary",3,-0.909180727459891,0.207548670787472,0,2011.33333333333,0.230203796607678,172.666666666667
"CD013366","CD013366_pub2_data","6|5|Catheter failure - sensitivity analysis|","Catheter failure - sensitivity analysis",6,5,"","or","binary",2,-0.77838804504467,0.808944369630246,0,2012,0.105614973262032,63
"CD013366","CD013366_pub2_data","6|6|Catheter breakage|","Catheter breakage",6,6,"","or","binary",2,-1.03978086384564,0.693428323457484,0,2011,0.0180412371134021,208.5
"CD013366","CD013366_pub2_data","7|2|Occlusion|","Occlusion",7,2,"","or","binary",4,-0.153816135626417,0.248896498556654,0,2008.75,0.130435743885183,154.5
"CD013366","CD013366_pub2_data","7|3|Occlusion - sensitivity analysis|","Occlusion - sensitivity analysis",7,3,"","or","binary",2,-0.0306370583612537,0.569296438059699,0.180436135495809,2012,0.191176470588235,63
"CD013366","CD013366_pub2_data","7|5|Catheter failure|","Catheter failure",7,5,"","or","binary",3,-0.934401136556356,0.191959697728141,0,2007.66666666667,0.34539987503905,172.333333333333
"CD013366","CD013366_pub2_data","7|6|Catheter breakage|","Catheter breakage",7,6,"","or","binary",3,-1.31465938736258,0.62877522460344,0,2007.66666666667,0.0467497136311569,172.333333333333
"CD013366","CD013366_pub2_data","8|1|Venous thromboembolism|","Venous thromboembolism",8,1,"","or","binary",2,-0.402281273060642,0.775274728327633,0.1510296853196,2019,0.0337837837837838,128.5
"CD013366","CD013366_pub2_data","8|3|PICC-associated BSI|","PICC-associated BSI",8,3,"","or","binary",2,-1.02651271092616,1.23207874581461,0,2019,0.0181818181818182,128.5
"CD013366","CD013366_pub2_data","8|4|Occlusion|","Occlusion",8,4,"","or","binary",2,-0.35123356320924,1.187141330581,1.90109522360097,2019,0.0496314496314496,128.5
"CD013366","CD013366_pub2_data","8|6|Catheter failure|","Catheter failure",8,6,"","or","binary",2,-0.335541135148998,0.418897291589711,0.145581900772833,2019,0.217199017199017,128.5
"CD013366","CD013366_pub2_data","8|8|Catheter breakage|","Catheter breakage",8,8,"","or","binary",2,-1.25220433163456,1.21264764550299,0,2019,0.0202702702702703,128.5
"CD013366","CD013366_pub2_data","9|3|Occlusion|","Occlusion",9,3,"","or","binary",2,0.00323944071402898,0.2951299422934,0,2008,0.0605453087409784,512.5
"CD013366","CD013366_pub2_data","9|4|All-cause mortality|","All-cause mortality",9,4,"","or","binary",2,0.121058174366766,0.246738241206508,0,2008,0.0382830626450116,541
"CD013366","CD013366_pub2_data","9|6|PICC-related BSI|","PICC-related BSI",9,6,"","or","binary",2,0.0523086317650435,0.220373664778791,0,2008,0.0510440835266821,541
"CD013366","CD013366_pub2_data","9|8|PICC dwell time|","PICC dwell time",9,8,"","or","binary",2,0.0912866504690253,1.41791300235945,0,2006.5,0,194
"CD013377","CD013377_pub2_data","1|1|Overall survival|","Overall survival",1,1,"","reported","reported",2,-0.192303749443505,0.123362098988348,0,2012.5,0,185
"CD013377","CD013377_pub2_data","1|3|Adverse events grades 3 to 5 (Participants with at least one serious adverse event)|","Adverse events grades 3 to 5 (Participants with at least one serious adverse event)",1,3,"","reported","reported",2,0,0.16087736134543,0,2012.5,0.28751298026999,181
"CD013377","CD013377_pub2_data","2|2|Adverse events grades 3 to 5 (Participants with at least one serious adverse event)|","Adverse events grades 3 to 5 (Participants with at least one serious adverse event)",2,2,"","reported","reported",2,0,0.204373472214359,0,2012,0.0984848484848485,229
"CD013396","CD013396_pub2_data","1|3|Atopic dermatitis|","Atopic dermatitis",1,3,"","or","binary",2,-0.154719890863043,0.257237668216984,0,2017,0.195096622719884,300
"CD013396","CD013396_pub2_data","1|4|Adverse events|Infant death","Adverse events",1,4,"Infant death","or","binary",2,-1.32394023714124,1.13958537039992,1.70959586806908,2017,0.0449163449163449,739
"CD013396","CD013396_pub2_data","1|4|Adverse events|Infant hypercalcaemia","Adverse events",1,4,"Infant hypercalcaemia","or","binary",2,0.575717700183567,1.18535725314437,0,2018,0,589.5
"CD013396","CD013396_pub2_data","1|4|Adverse events|Intrauterine death","Adverse events",1,4,"Intrauterine death","or","binary",4,-0.804474649952821,0.40671787499136,0.0634721240629847,2017.5,0.0209614245989351,667.5
"CD013396","CD013396_pub2_data","1|4|Adverse events|Maternal hypercalcaemia","Adverse events",1,4,"Maternal hypercalcaemia","or","binary",4,0.127648493382688,0.709145157495066,0,2017.5,0.00111607142857143,678.5
"CD013396","CD013396_pub2_data","1|4|Adverse events|Maternal hypertension","Adverse events",1,4,"Maternal hypertension","or","binary",2,0.180277168217925,0.302050121091507,0.0481386298091353,2021,0.0305555367066791,1216
"CD013396","CD013396_pub2_data","1|4|Adverse events|Preterm delivery","Adverse events",1,4,"Preterm delivery","or","binary",2,0.48496534831957,0.386834471578812,0,2021,0.0102880658436214,1131.5
"CD013396","CD013396_pub2_data","1|7|Upper respiratory tract infection|","Upper respiratory tract infection",1,7,"","or","binary",2,0.260077407670087,0.232708235604949,0,2017,0.934444444444444,664
"CD013396","CD013396_pub2_data","2|2|Wheeze|","Wheeze",2,2,"","or","binary",2,-0.0816434737753196,0.413579898285805,0.249236427097452,2018,0.322879274513508,215.5
"CD013396","CD013396_pub2_data","2|3|Atopic dermatitis|","Atopic dermatitis",2,3,"","or","binary",2,0.0812741562829165,0.325139029053139,0.130680436050136,2018,0.361721611721612,224
"CD013396","CD013396_pub2_data","2|4|Adverse events|Infant elevated 25OHD","Adverse events",2,4,"Infant elevated 25OHD","or","binary",2,1.72929123574419,1.07177355728727,0,2013.5,0,1631.5
"CD013396","CD013396_pub2_data","2|4|Adverse events|Infant hypercalcaemia","Adverse events",2,4,"Infant hypercalcaemia","or","binary",2,1.72946138140511,2.16463394247886,6.42502780836493,2016.5,0,248.5
"CD013396","CD013396_pub2_data","2|4|Adverse events|Infant/child death","Adverse events",2,4,"Infant/child death","or","binary",2,0.444629761258898,0.36031871808821,0,2015,0.0717440502263104,1573
"CD013396","CD013396_pub2_data","2|5|Any airway infection|","Any airway infection",2,5,"","or","binary",2,-0.714179323417403,0.696085111131738,0.671990308135229,2016.5,0.792992424242424,250
"CD013396","CD013396_pub2_data","3|2|Asthma (6-year follow-up data)|","Asthma (6-year follow-up data)",3,2,"","or","binary",2,0.227556864434268,0.16562495671766,0,2016,0.118842205159175,624.5
"CD013396","CD013396_pub2_data","3|4|Atopic dermatitis|","Atopic dermatitis",3,4,"","or","binary",3,-0.118339668101782,0.128014801126219,6.07962086091718e-08,2016.33333333333,0.17873112963512,479.666666666667
"CD013396","CD013396_pub2_data","3|5|Adverse events|Congenital malformations","Adverse events",3,5,"Congenital malformations","or","binary",2,-0.173202489241275,0.245602401177953,0,2016,0.0561247322827095,730
"CD013396","CD013396_pub2_data","3|5|Adverse events|Infant elevated 25OHD","Adverse events",3,5,"Infant elevated 25OHD","or","binary",2,0.346533255998175,1.27105015161569,0,2016.5,0,464
"CD013396","CD013396_pub2_data","3|5|Adverse events|Intrauterine death","Adverse events",3,5,"Intrauterine death","or","binary",2,0.00357470605327384,0.375897089589862,0,2016,0.0174848087692124,749.5
"CD013396","CD013396_pub2_data","3|5|Adverse events|Maternal death","Adverse events",3,5,"Maternal death","or","binary",2,-0.0157779169838579,1.41518300356239,0,2016,0,749.5
"CD013396","CD013396_pub2_data","3|5|Adverse events|Maternal hospitalisation","Adverse events",3,5,"Maternal hospitalisation","or","binary",2,0.0161299176729667,0.177646166308316,0,2016,0.0894197545573692,749.5
"CD013396","CD013396_pub2_data","3|5|Adverse events|Maternal hypercalcaemia","Adverse events",3,5,"Maternal hypercalcaemia","or","binary",2,-0.349448365251002,1.41593480177567,0,2016.5,0,588
"CD013396","CD013396_pub2_data","3|5|Adverse events|Pre-eclampsia","Adverse events",3,5,"Pre-eclampsia","or","binary",2,0.0269985631032183,0.204443126057803,0,2016,0.0630585011318956,749.5
"CD013396","CD013396_pub2_data","3|5|Adverse events|Preterm delivery < 32 weeks","Adverse events",3,5,"Preterm delivery < 32 weeks","or","binary",2,-0.0447330918105322,1.07930106861836,1.40426275663348,2016,0.0126146788990826,730
"CD013396","CD013396_pub2_data","3|6|Any airway infection|","Any airway infection",3,6,"","or","binary",3,-0.0687851470867689,0.113247264527185,0,2014.66666666667,0.246889685524187,480.333333333333
"CD013396","CD013396_pub2_data","3|7|Lower respiratory tract infection|","Lower respiratory tract infection",3,7,"","or","binary",3,-0.0687851470867689,0.113247264527185,0,2014.66666666667,0.246889685524187,480.333333333333
"CD013396","CD013396_pub2_data","3|9|Allergic sensitisation – specific IgE against common allergens (dichotomous)|","Allergic sensitisation – specific IgE against common allergens (dichotomous)",3,9,"","or","binary",2,0.102812874824229,0.27920413284138,0.104649286195976,2016,0.317977436232832,555
"CD013396","CD013396_pub2_data","4|1|Asthma|","Asthma",4,1,"","or","binary",2,-0.480984408283777,0.74366979959432,0.349480903050451,2016.5,0.236141304347826,100.5
"CD013396","CD013396_pub2_data","4|2|Wheeze|","Wheeze",4,2,"","or","binary",2,-0.484772668922759,0.422300964226467,0.29549703137032,2018,0.235839598997494,547.5
"CD013396","CD013396_pub2_data","4|4|Adverse events|Infant hypercalcaemia","Adverse events",4,4,"Infant hypercalcaemia","or","binary",3,0.469709625519491,1.07285857695392,0,2019,0,591
"CD013396","CD013396_pub2_data","4|7|Upper respiratory tract infection|","Upper respiratory tract infection",4,7,"","or","binary",3,0.0247966259533866,0.126614978074258,0,2017.66666666667,0.759825742147317,599.333333333333
"CD013396","CD013396_pub2_data","5|1|Asthma – as defined by trial authors|","Asthma – as defined by trial authors",5,1,"","or","binary",6,-0.325135202659416,0.154408980238424,0.0207319825517214,2016.83333333333,0.168072818869829,451.333333333333
"CD013396","CD013396_pub2_data","5|2|Wheeze – as defined by trial authors|","Wheeze – as defined by trial authors",5,2,"","or","binary",8,-0.28297499340172,0.132360394511675,0.055061900151419,2016.75,0.219829992822757,390.375
"CD013408","CD013408_pub2_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","or","binary",5,-0.471042859910271,0.187313740934992,0.0688421891861758,2017.4,0.0870225816578394,932.8
"CD013408","CD013408_pub2_data","1|11|Thromboembolic complications|","Thromboembolic complications",1,11,"","or","binary",5,0.131751673809527,0.220388703563867,0,2017.4,0.0193923884457557,930.6
"CD013408","CD013408_pub2_data","1|12|Thromboembolic complications - sensitivity analysis|","Thromboembolic complications - sensitivity analysis",1,12,"","or","binary",3,0.129762094931012,0.283823437111496,0,2015.66666666667,0.0225142112176194,800.333333333333
"CD013408","CD013408_pub2_data","1|13|Major cerebrovascular bleeding events|","Major cerebrovascular bleeding events",1,13,"","or","binary",3,0.227285897063121,0.242676205381193,0,2017.33333333333,0.0224885044390211,988
"CD013408","CD013408_pub2_data","1|15|All bleeding events|","All bleeding events",1,15,"","or","binary",4,0.128525188886222,0.1724405804783,0,2016.75,0.0564156262900372,824.75
"CD013408","CD013408_pub2_data","1|16|All bleeding events - sensitivity analysis|","All bleeding events - sensitivity analysis",1,16,"","or","binary",2,0.0678981091591907,0.270718124047573,0,2013.5,0.0772892417412366,523.5
"CD013408","CD013408_pub2_data","1|2|All-cause mortality - sensitivity analysis|","All-cause mortality - sensitivity analysis",1,2,"","or","binary",3,-0.374679431038359,0.312615844013952,0.187110589683053,2015.66666666667,0.0953305276856424,800.333333333333
"CD013408","CD013408_pub2_data","1|3|All-cause hospitalisation|","All-cause hospitalisation",1,3,"","or","binary",2,-0.176699385060288,0.227756236916814,0.0581894537580098,2017.5,0.636818059382964,670
"CD013408","CD013408_pub2_data","1|6|Cardiovascular mortality - sensitivity analysis|","Cardiovascular mortality - sensitivity analysis",1,6,"","or","binary",3,-0.196480188530366,0.689644859706863,0.856294093067661,2018,0.0173738635237272,767
"CD013408","CD013408_pub2_data","1|7|Cardiovascular hospitalisation|","Cardiovascular hospitalisation",1,7,"","or","binary",5,-0.268238177043676,0.0938935759072997,0.0079324472063933,2017.8,0.307184093819609,728.2
"CD013408","CD013408_pub2_data","1|8|Cardiovascular hospitalisation - sensitivity analysis|","Cardiovascular hospitalisation - sensitivity analysis",1,8,"","or","binary",4,-0.330374774186093,0.0966266844716919,0.00229506942547129,2017.25,0.347647937343715,659
"CD013408","CD013408_pub2_data","1|9|AF-related emergency department visits|","AF-related emergency department visits",1,9,"","or","binary",2,-0.581670554073643,0.491878361229155,0.344258337348883,2020,0.0980286139195997,1306
"CD013414","CD013414_pub2_data","1|1|eGFR: change|","eGFR: change",1,1,"","or","binary",3,0.0136926993536796,1.16150765469715,0,2019,0,168.333333333333
"CD013414","CD013414_pub2_data","1|12|Vitamin B12 deficiency|","Vitamin B12 deficiency",1,12,"","or","binary",2,0.828521512318824,0.4042890345398,0.0430498042653547,2017.5,0.0442708333333333,241.5
"CD013414","CD013414_pub2_data","1|4|All-cause death|","All-cause death",1,4,"","or","binary",3,0.116697881417345,0.317116707026374,0.0764836053065318,2012.33333333333,0.115717127871224,288.333333333333
"CD013414","CD013414_pub2_data","1|6|Adverse events|B12 deficient","Adverse events",1,6,"B12 deficient","or","binary",2,0.828521512318824,0.4042890345398,0.0430498042653547,2017.5,0.0442708333333333,241.5
"CD013414","CD013414_pub2_data","1|6|Adverse events|Diarrhoea","Adverse events",1,6,"Diarrhoea","or","binary",2,0.918638136753871,0.346003658470072,0,2020,0.275416666666667,74
"CD013414","CD013414_pub2_data","1|6|Adverse events|Nausea","Adverse events",1,6,"Nausea","or","binary",2,0.874716401687129,0.373675028909063,0,2020,0.184166666666667,74
"CD013414","CD013414_pub2_data","1|6|Adverse events|Raised lactate","Adverse events",1,6,"Raised lactate","or","binary",2,0.738398133149724,0.740127407572903,0.519985601883215,2017.5,0.208333333333333,242
"CD013414","CD013414_pub2_data","1|6|Adverse events|Serious adverse events","Adverse events",1,6,"Serious adverse events","or","binary",3,0.161864885300912,0.240904268873542,0,2019,0.0841640085061138,192
"CD013414","CD013414_pub2_data","1|6|Adverse events|Vomiting","Adverse events",1,6,"Vomiting","or","binary",2,0.286586037711431,0.555963649154845,0.177055297704935,2020,0.1225,74
"CD013414","CD013414_pub2_data","1|8|Withdrawal due to intolerance|","Withdrawal due to intolerance",1,8,"","or","binary",4,0.916880444615938,0.240737920011688,0,2019.5,0.0415171451355662,161.5
"CD013414","CD013414_pub2_data","2|2|eGFR: final measure|","eGFR: final measure",2,2,"","or","binary",2,0.393683975126058,1.41941033052742,0,2006.5,0,1991
"CD013414","CD013414_pub2_data","2|3|All-cause death|","All-cause death",2,3,"","or","binary",3,-0.0433616428188088,0.21025378807209,0,2005.66666666667,0.00915404314172404,1869.33333333333
"CD013414","CD013414_pub2_data","2|4|Adverse events|Diarrhoea","Adverse events",2,4,"Diarrhoea","or","binary",2,1.12386473307078,0.0840566538347933,0,2003,0.062685421122411,2772.5
"CD013414","CD013414_pub2_data","2|4|Adverse events|Nausea","Adverse events",2,4,"Nausea","or","binary",2,0.528203313222874,0.103083342045003,0,2003,0.0481422762182793,2772.5
"CD013414","CD013414_pub2_data","2|4|Adverse events|Serious adverse events","Adverse events",2,4,"Serious adverse events","or","binary",2,0.16121942227136,0.203612977835187,0.0580404367591628,2003,0.137163495535438,2772.5
"CD013414","CD013414_pub2_data","2|5|Withdrawal due to adverse events|","Withdrawal due to adverse events",2,5,"","or","binary",3,-0.0879275849466239,0.0891305876320277,0,2000,0.0676342245111185,1864.33333333333
"CD013414","CD013414_pub2_data","2|7|UACR: % change|","UACR: % change",2,7,"","or","binary",2,0.35483718487739,1.41979166592017,0,2006.5,0,1918
"CD013414","CD013414_pub2_data","3|1|Death: ADPKD subgroup analysis|No ADPKD patients","Death: ADPKD subgroup analysis",3,1,"No ADPKD patients","or","binary",2,0.0619007467225299,0.295538141705885,0.0538628863207557,2009.5,0.173575691806837,384
"CD013414","CD013414_pub2_data","3|2|eGFR change: ADPKD subgroup analysis|ADPKD","eGFR change: ADPKD subgroup analysis",3,2,"ADPKD","or","binary",2,0.0123236905829044,1.42578640974544,0,2020,0,70
"CD013414","CD013414_pub2_data","3|3|Death: age subgroup analysis|Age ≤ 60 years","Death: age subgroup analysis",3,3,"Age ≤ 60 years","or","binary",2,0.861352859641492,0.697144049168136,0,2017.5,0.00515463917525773,242
"CD013414","CD013414_pub2_data","3|4|eGFR change: duration of study subgroup analysis|Duration ≤ 2 years","eGFR change: duration of study subgroup analysis",3,4,"Duration ≤ 2 years","or","binary",2,0.0123236905829044,1.42578640974544,0,2020,0,70
"CD013414","CD013414_pub2_data","3|5|Death: duration of study subgroup analysis|Duration > 2 years","Death: duration of study subgroup analysis",3,5,"Duration > 2 years","or","binary",2,0.0619007467225299,0.295538141705885,0.0538628863207557,2009.5,0.173575691806837,384
"CD013414","CD013414_pub2_data","4|1|Death: age subgroup analysis|Age ≤ 60 years","Death: age subgroup analysis",4,1,"Age ≤ 60 years","or","binary",2,-0.0632016440616025,0.211976913500853,0,2003,0.0137310647125861,2772.5
"CD013421","CD013421_pub2_data","1|1|Mean time to hemostasis|","Mean time to hemostasis",1,1,"","or","binary",7,-0.249451748039684,0.76315460110824,0,2007.14285714286,0,71.1428571428571
"CD013421","CD013421_pub2_data","1|2|Proportion achieving hemostasis at time points|Time to hemostasis - 10 minutes","Proportion achieving hemostasis at time points",1,2,"Time to hemostasis - 10 minutes","or","binary",4,1.79246262645703,0.668936652987774,1.09697145224447,2014.75,0.707642785305226,155.75
"CD013421","CD013421_pub2_data","1|2|Proportion achieving hemostasis at time points|Time to hemostasis - 4 minutes","Proportion achieving hemostasis at time points",1,2,"Time to hemostasis - 4 minutes","or","binary",3,1.47377465203542,0.36680884154261,0.282272228599765,2008.33333333333,0.369071669071669,162.666666666667
"CD013421","CD013421_pub2_data","1|2|Proportion achieving hemostasis at time points|Time to hemostasis - 5 minutes","Proportion achieving hemostasis at time points",1,2,"Time to hemostasis - 5 minutes","or","binary",2,1.22389415583996,0.283693720974591,0,2010.5,0.504873294346978,127
"CD013421","CD013421_pub2_data","2|1|Failure of hemostatic intervention|","Failure of hemostatic intervention",2,1,"","or","binary",17,-1.18690793055066,0.189757315470976,0.266227331638565,2007.64705882353,0.365053181186971,124.705882352941
"CD013421","CD013421_pub2_data","3|1|Intraoperative blood loss|","Intraoperative blood loss",3,1,"","or","binary",3,-0.0173334051237613,1.16858132144856,0,2003.66666666667,0,88.6666666666667
"CD013421","CD013421_pub2_data","5|1|Postoperative bleeding|","Postoperative bleeding",5,1,"","or","binary",9,-0.333664776953503,0.20193230422399,0,2006.44444444444,0.0876022699339779,135.111111111111
"CD013421","CD013421_pub2_data","6|1|Unplanned return to operating room for bleeding complications|","Unplanned return to operating room for bleeding complications",6,1,"","or","binary",8,-0.652152574248046,0.655318534917711,0,2004.875,0.0065392303848076,90.125
"CD013421","CD013421_pub2_data","7|1|Mean time to hemostasis - studies combining multiple surgery indications|","Mean time to hemostasis - studies combining multiple surgery indications",7,1,"","or","binary",4,-0.0500896907891191,1.01050573095281,0,2004.75,0,74.75
"CD013421","CD013421_pub2_data","7|2|Proportion achieving hemostasis at time points - studies combining multiple surgery indications|Time to hemostasis - 10 minutes","Proportion achieving hemostasis at time points - studies combining multiple surgery indications",7,2,"Time to hemostasis - 10 minutes","or","binary",2,1.31244689978664,0.803981094592815,1.17680824967079,2015.5,0.612216516902011,248.5
"CD013421","CD013421_pub2_data","7|2|Proportion achieving hemostasis at time points - studies combining multiple surgery indications|Time to hemostasis - 4 minutes","Proportion achieving hemostasis at time points - studies combining multiple surgery indications",7,2,"Time to hemostasis - 4 minutes","or","binary",3,1.47377465203542,0.36680884154261,0.282272228599765,2008.33333333333,0.369071669071669,162.666666666667
"CD013421","CD013421_pub2_data","7|2|Proportion achieving hemostasis at time points - studies combining multiple surgery indications|Time to hemostasis - 5 minutes","Proportion achieving hemostasis at time points - studies combining multiple surgery indications",7,2,"Time to hemostasis - 5 minutes","or","binary",2,1.22389415583996,0.283693720974591,0,2010.5,0.504873294346978,127
"CD013421","CD013421_pub2_data","7|3|Failure of hemostatic intervention - studies combining multiple surgery indications|","Failure of hemostatic intervention - studies combining multiple surgery indications",7,3,"","or","binary",13,-1.11618075469892,0.218883876521998,0.306270755016113,2007.38461538462,0.372376440631665,136.384615384615
"CD013421","CD013421_pub2_data","7|4|Intraoperative blood loss - studies combining multiple surgery indications|","Intraoperative blood loss - studies combining multiple surgery indications",7,4,"","or","binary",3,-0.0173334051237613,1.16858132144856,0,2003.66666666667,0,88.6666666666667
"CD013421","CD013421_pub2_data","7|6|Postoperative bleeding up to 30 days - studies combining multiple surgery indications|","Postoperative bleeding up to 30 days - studies combining multiple surgery indications",7,6,"","or","binary",8,-0.357044635049393,0.209179824559102,0,2006.875,0.0935525536757252,133.125
"CD013421","CD013421_pub2_data","7|7|Unplanned return to operating room for bleeding complications up to 30 days - studies combining multiple surgery indications|","Unplanned return to operating room for bleeding complications up to 30 days - studies combining multiple surgery indications",7,7,"","or","binary",7,-0.562430596438676,0.714779984675523,0,2005.14285714286,0.00556864424930392,81.4285714285714
"CD013425","CD013425_pub2_data","1|1|Global state: clinically important change|Short-term","Global state: clinically important change",1,1,"Short-term","or","binary",5,-0.369826617662529,0.184852785080731,0.0998468472645488,2000.8,0.533377884922795,601.4
"CD013425","CD013425_pub2_data","1|2|Global state: relapse|Long-term","Global state: relapse",1,2,"Long-term","or","binary",2,0.880544115359641,0.251061092617334,0,2001,0.132083196855552,214.5
"CD013425","CD013425_pub2_data","1|2|Global state: relapse|Medium-term","Global state: relapse",1,2,"Medium-term","or","binary",4,0.0997388409224339,0.240213658297069,0,2003.75,0.324477039902572,180
"CD013425","CD013425_pub2_data","1|3|Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score)|Short-term","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score)",1,3,"Short-term","or","binary",12,-0.452947071625634,0.144144160298028,0,2009.41666666667,0.333722390937303,84
"CD013425","CD013425_pub2_data","1|4|Mental state: overall - average endpoint score (PANSS, BPRS total scores, SMD, high = poor)|Medium-term (PANSS, BPRS total scores)","Mental state: overall - average endpoint score (PANSS, BPRS total scores, SMD, high = poor)",1,4,"Medium-term (PANSS, BPRS total scores)","or","binary",13,0.0321813995705183,0.558205114091825,0,2009.38461538462,0,97.7692307692308
"CD013425","CD013425_pub2_data","1|4|Mental state: overall - average endpoint score (PANSS, BPRS total scores, SMD, high = poor)|Short-term (PANSS, BPRS total scores)","Mental state: overall - average endpoint score (PANSS, BPRS total scores, SMD, high = poor)",1,4,"Short-term (PANSS, BPRS total scores)","or","binary",28,0.053992935697947,0.381589834345952,0,2005.17857142857,0,148
"CD013425","CD013425_pub2_data","1|5|Adverse effects/events: specific - extrapyramidal - any effect|Medium-term","Adverse effects/events: specific - extrapyramidal - any effect",1,5,"Medium-term","reported","reported",3,0,0.310915789016743,0,2006.33333333333,0.148806527873103,130
"CD013425","CD013425_pub2_data","1|5|Adverse effects/events: specific - extrapyramidal - any effect|Short-term","Adverse effects/events: specific - extrapyramidal - any effect",1,5,"Short-term","reported","reported",11,0,0.0611213131333516,0,2007.90909090909,0.108831954864781,320.909090909091
"CD013425","CD013425_pub2_data","1|6|Adverse effects/events: specific - metabolic - weight increase|Increase - long-term","Adverse effects/events: specific - metabolic - weight increase",1,6,"Increase - long-term","or","binary",2,-1.80129323907661,0.545867175379638,0,2003,0.132818753573471,183.5
"CD013425","CD013425_pub2_data","1|6|Adverse effects/events: specific - metabolic - weight increase|Increase - medium-term","Adverse effects/events: specific - metabolic - weight increase",1,6,"Increase - medium-term","or","binary",2,-1.16571952389181,0.368565920923175,0.145596843127868,2006,0.59935263441827,194
"CD013425","CD013425_pub2_data","1|6|Adverse effects/events: specific - metabolic - weight increase|Increase - short-term","Adverse effects/events: specific - metabolic - weight increase",1,6,"Increase - short-term","or","binary",14,-1.15641408350462,0.296357657458865,0.758877308493735,2008.28571428571,0.355178831677972,253.357142857143
"CD013425","CD013425_pub2_data","1|8|Quality of life: overall - average endpoint total score (various scales, SMD, high = good)|Medium-term - MANSA, QoL, S-QoL scales (high = good)","Quality of life: overall - average endpoint total score (various scales, SMD, high = good)",1,8,"Medium-term - MANSA, QoL, S-QoL scales (high = good)","or","binary",3,-0.0414676595345455,1.15933813099894,0,2006,0,155.666666666667
"CD013425","CD013425_pub2_data","1|8|Quality of life: overall - average endpoint total score (various scales, SMD, high = good)|Short-term - GQOLT, Q-LES-Q, QLS, SF-36 scales, high = good","Quality of life: overall - average endpoint total score (various scales, SMD, high = good)",1,8,"Short-term - GQOLT, Q-LES-Q, QLS, SF-36 scales, high = good","or","binary",8,0.101920037059919,0.71290774599696,0,2007,0,93.25
"CD013425","CD013425_pub2_data","1|9|Leaving the study early: adverse effects|Long-term","Leaving the study early: adverse effects",1,9,"Long-term","or","binary",3,0.804812460770864,0.284137372794668,0,2001.33333333333,0.105616815050777,137
"CD013425","CD013425_pub2_data","1|9|Leaving the study early: adverse effects|Medium-term","Leaving the study early: adverse effects",1,9,"Medium-term","or","binary",6,0.687108866975453,0.235289169416522,0,2007.16666666667,0.04790618518236,184.833333333333
"CD013425","CD013425_pub2_data","1|9|Leaving the study early: adverse effects|Short-term","Leaving the study early: adverse effects",1,9,"Short-term","or","binary",12,0.826490933131193,0.19045538866164,0.042897943838508,2003.25,0.0244439705140727,293.916666666667
"CD013425","CD013425_pub2_data","2|1|Global state: clinically important change; sensitivity analysis (inadequate randomised, high attrition rate data excluded)|Short-term","Global state: clinically important change; sensitivity analysis (inadequate randomised, high attrition rate data excluded)",2,1,"Short-term","or","binary",5,-0.369826617662529,0.184852785080731,0.0998468472645488,2000.8,0.533377884922795,601.4
"CD013425","CD013425_pub2_data","2|10|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (high attrition rate data excluded)|Increase - long-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (high attrition rate data excluded)",2,10,"Increase - long-term","or","binary",2,-1.80129323907661,0.545867175379638,0,2003,0.132818753573471,183.5
"CD013425","CD013425_pub2_data","2|10|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (high attrition rate data excluded)|Increase - short-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (high attrition rate data excluded)",2,10,"Increase - short-term","or","binary",12,-1.248115287129,0.358989968538837,1.01185180801997,2009.08333333333,0.309109921609426,275.833333333333
"CD013425","CD013425_pub2_data","2|11|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)|Increase - long-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)",2,11,"Increase - long-term","or","binary",2,-1.80129323907661,0.545867175379638,0,2003,0.132818753573471,183.5
"CD013425","CD013425_pub2_data","2|11|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)|Increase - medium-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)",2,11,"Increase - medium-term","or","binary",2,-1.16571952389181,0.368565920923175,0.145596843127868,2006,0.59935263441827,194
"CD013425","CD013425_pub2_data","2|11|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)|Increase - short-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)",2,11,"Increase - short-term","or","binary",14,-1.15641408350462,0.296357657458865,0.758877308493735,2008.28571428571,0.355178831677972,253.357142857143
"CD013425","CD013425_pub2_data","2|12|Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)|Long-term","Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)",2,12,"Long-term","or","binary",2,1.16887369484655,0.414380727062809,0,2002,0.111255411255411,77.5
"CD013425","CD013425_pub2_data","2|12|Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)|Medium-term","Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)",2,12,"Medium-term","or","binary",5,0.660878088982022,0.238117770703434,0,2007.4,0.057487422218832,207.6
"CD013425","CD013425_pub2_data","2|12|Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)|Short-term","Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)",2,12,"Short-term","or","binary",9,0.664954374335503,0.158439399710517,0,2002.66666666667,0.0317101264702627,345.333333333333
"CD013425","CD013425_pub2_data","2|13|Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)|Long-term","Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)",2,13,"Long-term","or","binary",3,0.804812460770864,0.284137372794668,0,2001.33333333333,0.105616815050777,137
"CD013425","CD013425_pub2_data","2|13|Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)|Medium-term","Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)",2,13,"Medium-term","or","binary",6,0.687108866975453,0.235289169416522,0,2007.16666666667,0.04790618518236,184.833333333333
"CD013425","CD013425_pub2_data","2|13|Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)|Short-term","Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)",2,13,"Short-term","or","binary",12,0.826490933131193,0.19045538866164,0.042897943838508,2003.25,0.0244439705140727,293.916666666667
"CD013425","CD013425_pub2_data","2|2|Global state: clinically important change; sensitivity analysis (fixed-effect model applied)|Short-term","Global state: clinically important change; sensitivity analysis (fixed-effect model applied)",2,2,"Short-term","or","binary",5,-0.369826617662529,0.184852785080731,0.0998468472645488,2000.8,0.533377884922795,601.4
"CD013425","CD013425_pub2_data","2|3|Global state: relapse: sensitivity analysis (inadequate randomised, high attrition rate data excluded)|Medium-term","Global state: relapse: sensitivity analysis (inadequate randomised, high attrition rate data excluded)",2,3,"Medium-term","or","binary",3,0.0827257110877984,0.255833197515909,0.0130046102491191,2003,0.432636053203429,216.333333333333
"CD013425","CD013425_pub2_data","2|4|Global state: relapse: sensitivity analysis (fixed-effect model applied)|Long-term","Global state: relapse: sensitivity analysis (fixed-effect model applied)",2,4,"Long-term","or","binary",2,0.880544115359641,0.251061092617334,0,2001,0.132083196855552,214.5
"CD013425","CD013425_pub2_data","2|4|Global state: relapse: sensitivity analysis (fixed-effect model applied)|Medium-term","Global state: relapse: sensitivity analysis (fixed-effect model applied)",2,4,"Medium-term","or","binary",4,0.0997388409224339,0.240213658297069,0,2003.75,0.324477039902572,180
"CD013425","CD013425_pub2_data","2|5|Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (inadequate randomised, high attrition rate data excluded)|Short-term","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (inadequate randomised, high attrition rate data excluded)",2,5,"Short-term","or","binary",8,-0.401054829889483,0.173813500552055,0,2009.125,0.368621031746032,82.375
"CD013425","CD013425_pub2_data","2|6|Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (fixed-effect model applied)|Short-term","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (fixed-effect model applied)",2,6,"Short-term","or","binary",12,-0.452947071625634,0.144144160298028,0,2009.41666666667,0.333722390937303,84
"CD013425","CD013425_pub2_data","2|7|Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (inadequate randomised, high attrition rate data excluded)|Short-term","Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (inadequate randomised, high attrition rate data excluded)",2,7,"Short-term","or","binary",7,1.29262101364203,0.0968496527441059,7.00775979072023e-07,2006.71428571429,0.0561917113861529,452.285714285714
"CD013425","CD013425_pub2_data","2|8|Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (fixed-effect model applied)|Medium-term","Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (fixed-effect model applied)",2,8,"Medium-term","reported","reported",3,0,0.310915789016743,0,2006.33333333333,0.148806527873103,130
"CD013425","CD013425_pub2_data","2|8|Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (fixed-effect model applied)|Short-term","Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (fixed-effect model applied)",2,8,"Short-term","reported","reported",11,0,0.0611213131333516,0,2007.90909090909,0.108831954864781,320.909090909091
"CD013425","CD013425_pub2_data","2|9|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (inadequate randomised trials excluded)|Increase - medium-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (inadequate randomised trials excluded)",2,9,"Increase - medium-term","or","binary",2,-1.16571952389181,0.368565920923175,0.145596843127868,2006,0.59935263441827,194
"CD013425","CD013425_pub2_data","2|9|Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (inadequate randomised trials excluded)|Increase - short-term","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (inadequate randomised trials excluded)",2,9,"Increase - short-term","or","binary",11,-1.25047354832796,0.272213218929335,0.433203015435561,2008.72727272727,0.346437848817278,305.818181818182
"CD013429","CD013429_pub2_data","1|1|Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: 0 to 3 months|Change from baseline","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: 0 to 3 months",1,1,"Change from baseline","or","binary",3,-0.285760865419551,1.16672843279725,0,2019,0,95.6666666666667
"CD013429","CD013429_pub2_data","1|2|Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: > 3 months|Sensitivity analysis","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: > 3 months",1,2,"Sensitivity analysis","or","binary",4,-0.230371436766405,1.01168509077312,0,2019.5,0,79.5
"CD013429","CD013429_pub2_data","1|3|Primary: Eustachian tube function measured by an objective or semi-objective test: improvement of tympanometry (by ear)|0 to 3 months","Primary: Eustachian tube function measured by an objective or semi-objective test: improvement of tympanometry (by ear)",1,3,"0 to 3 months","or","binary",3,1.56504886701864,0.242760959986902,0,2018.66666666667,0.171679197994987,123
"CD013429","CD013429_pub2_data","1|4|Primary: Eustachian tube function measured by an objective or semi-objective test: ability to perform positive Valsalva/Toynbee (by ear)|0 to 3 months","Primary: Eustachian tube function measured by an objective or semi-objective test: ability to perform positive Valsalva/Toynbee (by ear)",1,4,"0 to 3 months","or","binary",2,1.4041858690187,0.238923447433085,0,2019,0.31109022556391,183
"CD013429","CD013429_pub2_data","1|8|Secondary: Tympanic membrane abnormalities: normalisation of TM position|0 to 3 months","Secondary: Tympanic membrane abnormalities: normalisation of TM position",1,8,"0 to 3 months","or","binary",2,3.02284143200043,1.0990869195484,0,2020,0,25
"CD013429","CD013429_pub2_data","5|2|Secondary: Hearing: air-bone gap|> 3 to 12 months","Secondary: Hearing: air-bone gap",5,2,"> 3 to 12 months","reported","reported",2,0,0.956904632875348,0,2020.5,0,55
"CD013429","CD013429_pub2_data","5|2|Secondary: Hearing: air-bone gap|0 to 3 months","Secondary: Hearing: air-bone gap",5,2,"0 to 3 months","reported","reported",2,0,0.793376482328483,0,2020.5,0,55
"CD013429","CD013429_pub2_data","5|4|Secondary: Quality of life: COMOT-15|> 3 to 12 months","Secondary: Quality of life: COMOT-15",5,4,"> 3 to 12 months","reported","reported",2,0,0.900132816182749,0,2020.5,0,55
"CD013429","CD013429_pub2_data","5|4|Secondary: Quality of life: COMOT-15|0 to 3 months","Secondary: Quality of life: COMOT-15",5,4,"0 to 3 months","reported","reported",2,0,0.841917145072635,0,2020.5,0,55
"CD013445","CD013445_pub2_data","1|1|Stone-free rate|","Stone-free rate",1,1,"","or","binary",39,0.866824747632756,0.133208857304764,0.250784276357829,2017.46153846154,0.760700256711625,104.820512820513
"CD013445","CD013445_pub2_data","1|10|Ureteral stricture or injury|","Ureteral stricture or injury",1,10,"","or","binary",13,-0.0912147589923911,0.378756421666205,0,2016.38461538462,0.0186684153369839,121.076923076923
"CD013445","CD013445_pub2_data","1|11|Pain on postoperative day 0|","Pain on postoperative day 0",1,11,"","or","binary",7,0.0432546438984443,0.759810128556043,0,2017.42857142857,0,113.571428571429
"CD013445","CD013445_pub2_data","1|12|Pain on postoperative day 1|","Pain on postoperative day 1",1,12,"","or","binary",8,0.00592421065072595,0.712487601681437,0,2016.125,0,94.25
"CD013445","CD013445_pub2_data","1|13|Pain on postoperative days 2 to 7|","Pain on postoperative days 2 to 7",1,13,"","or","binary",2,0.0119650224749789,1.41813323662108,0,2018.5,0,184.5
"CD013445","CD013445_pub2_data","1|16|Subgroup analysis by access size: stone-free rate|Access size < 15 Fr","Subgroup analysis by access size: stone-free rate",1,16,"Access size < 15 Fr","or","binary",8,0.743247534487134,0.260039845919528,0,2017,0.868594285661299,90.625
"CD013445","CD013445_pub2_data","1|16|Subgroup analysis by access size: stone-free rate|Access size ≥ 24 Fr","Subgroup analysis by access size: stone-free rate",1,16,"Access size ≥ 24 Fr","or","binary",7,1.29017113108105,0.373358590821269,0.506277190711975,2016.14285714286,0.666326620239664,105.571428571429
"CD013445","CD013445_pub2_data","1|16|Subgroup analysis by access size: stone-free rate|Access size 15–23 Fr","Subgroup analysis by access size: stone-free rate",1,16,"Access size 15–23 Fr","or","binary",10,0.567604991897737,0.360276152776223,0.624761867384603,2016.9,0.875363943506624,101
"CD013445","CD013445_pub2_data","1|17|Subgroup analysis by stone burden: stone-free rate|Multiple stones","Subgroup analysis by stone burden: stone-free rate",1,17,"Multiple stones","or","binary",12,1.03622958928345,0.326098730215911,0.779166695929299,2016.5,0.693787626495793,96.25
"CD013445","CD013445_pub2_data","1|17|Subgroup analysis by stone burden: stone-free rate|Solitary stone","Subgroup analysis by stone burden: stone-free rate",1,17,"Solitary stone","or","binary",12,0.486406006469646,0.164354786414401,1.84195548343287e-06,2016.91666666667,0.856546737311778,125
"CD013445","CD013445_pub2_data","1|18|Subgroup analysis by stone location: stone-free rate|Lower pole stone","Subgroup analysis by stone location: stone-free rate",1,18,"Lower pole stone","or","binary",10,0.667833140758477,0.186685504249475,0.0274284548622587,2018.6,0.820136108181954,128.6
"CD013445","CD013445_pub2_data","1|19|Subgroup analysis by stone size: stone-free rate|> 20 mm","Subgroup analysis by stone size: stone-free rate",1,19,"> 20 mm","or","binary",8,1.23051706708556,0.352143890985772,0.594196511693336,2017.25,0.643864810942984,100.5
"CD013445","CD013445_pub2_data","1|19|Subgroup analysis by stone size: stone-free rate|≤ 20 mm","Subgroup analysis by stone size: stone-free rate",1,19,"≤ 20 mm","or","binary",22,0.663978502393218,0.175965518603411,0.194052933779725,2017.31818181818,0.797007278796047,96.0454545454545
"CD013445","CD013445_pub2_data","1|2|Major complications|","Major complications",1,2,"","or","binary",34,-0.154387067587552,0.191929651874143,0,2017.11764705882,0.0221133227212267,107.323529411765
"CD013445","CD013445_pub2_data","1|20|Subgroup analysis by access size: major complications|Access size < 15 Fr","Subgroup analysis by access size: major complications",1,20,"Access size < 15 Fr","or","binary",7,0.657981969868207,0.47651068820031,0,2016.85714285714,0.0148107839767824,84.7142857142857
"CD013445","CD013445_pub2_data","1|20|Subgroup analysis by access size: major complications|Access size ≥ 24 Fr","Subgroup analysis by access size: major complications",1,20,"Access size ≥ 24 Fr","or","binary",6,-0.336790549563629,0.347470461034819,0,2015.83333333333,0.0394927536231884,112.166666666667
"CD013445","CD013445_pub2_data","1|20|Subgroup analysis by access size: major complications|Access size 15–23 Fr","Subgroup analysis by access size: major complications",1,20,"Access size 15–23 Fr","or","binary",10,0.425475158293535,0.552156470170415,0,2016.9,0.00256410256410256,101
"CD013445","CD013445_pub2_data","1|21|Subgroup analysis by stone burden: major complications|Multi-stone","Subgroup analysis by stone burden: major complications",1,21,"Multi-stone","or","binary",11,0.273700327445734,0.385554354983888,0.0171809558492966,2016.54545454545,0.0227753304264203,103.727272727273
"CD013445","CD013445_pub2_data","1|21|Subgroup analysis by stone burden: major complications|Solitary stone","Subgroup analysis by stone burden: major complications",1,21,"Solitary stone","or","binary",9,-0.219648449040385,0.335904670495266,0,2015.88888888889,0.00966183574879227,134.333333333333
"CD013445","CD013445_pub2_data","1|22|Subgroup analysis by stone location: major complications|Lower pole stone","Subgroup analysis by stone location: major complications",1,22,"Lower pole stone","or","binary",8,-0.320641974240255,0.311047120164017,0,2018.375,0.0338580709645177,152.25
"CD013445","CD013445_pub2_data","1|23|Subgroup analysis by stone size: major complications|> 20 mm","Subgroup analysis by stone size: major complications",1,23,"> 20 mm","or","binary",8,0.031210913362238,0.690722457505545,0,2017.25,0,100.5
"CD013445","CD013445_pub2_data","1|23|Subgroup analysis by stone size: major complications|≤ 20 mm","Subgroup analysis by stone size: major complications",1,23,"≤ 20 mm","or","binary",17,-0.177337963378743,0.264391931633997,0,2016.88235294118,0.0245716302687817,101.882352941176
"CD013445","CD013445_pub2_data","1|24|Subgroup analysis by access size: secondary interventions|Access size < 15 Fr","Subgroup analysis by access size: secondary interventions",1,24,"Access size < 15 Fr","or","binary",5,-1.13736947393772,0.408298018738499,0.289062999297626,2017.6,0.211227795193312,114.4
"CD013445","CD013445_pub2_data","1|24|Subgroup analysis by access size: secondary interventions|Access size ≥ 24 Fr","Subgroup analysis by access size: secondary interventions",1,24,"Access size ≥ 24 Fr","or","binary",4,-1.64624572903414,0.943134964266126,2.47714110350767,2015.5,0.261585968379447,144.5
"CD013445","CD013445_pub2_data","1|24|Subgroup analysis by access size: secondary interventions|Access size 15–23 Fr","Subgroup analysis by access size: secondary interventions",1,24,"Access size 15–23 Fr","or","binary",6,-0.779412646054065,0.370177970214262,0,2016,0.115314551942459,66.5
"CD013445","CD013445_pub2_data","1|25|Subgroup analysis by stone burden: secondary interventions|Multi-stone","Subgroup analysis by stone burden: secondary interventions",1,25,"Multi-stone","or","binary",11,-1.3808545552308,0.473294895149352,0.853075129303366,2016.27272727273,0.167087014344068,77.8181818181818
"CD013445","CD013445_pub2_data","1|25|Subgroup analysis by stone burden: secondary interventions|Solitary stone","Subgroup analysis by stone burden: secondary interventions",1,25,"Solitary stone","or","binary",8,-0.490216512666116,0.402769591530679,0.528293173104074,2015.5,0.102230118423875,124.125
"CD013445","CD013445_pub2_data","1|26|Subgroup analysis by stone location: secondary intervention|Lower pole stone","Subgroup analysis by stone location: secondary intervention",1,26,"Lower pole stone","or","binary",6,-0.270577307157431,0.281306362003493,0,2017.83333333333,0.0656421789105447,147.833333333333
"CD013445","CD013445_pub2_data","1|27|Subgroup analysis by stone size: secondary intervention|> 20 mm","Subgroup analysis by stone size: secondary intervention",1,27,"> 20 mm","or","binary",3,-1.41455617438259,1.63463802833372,6.76884431206872,2014,0.28510101010101,64
"CD013445","CD013445_pub2_data","1|27|Subgroup analysis by stone size: secondary intervention|≤ 20 mm","Subgroup analysis by stone size: secondary intervention",1,27,"≤ 20 mm","or","binary",14,-1.71239000699444,0.61500762603762,3.85144232893752,2016.42857142857,0.335465473270398,98.3571428571429
"CD013445","CD013445_pub2_data","1|28|Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 4 mm by any imaging modality)|","Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 4 mm by any imaging modality)",1,28,"","or","binary",18,0.550398643171588,0.150979938043742,0.0804104051246059,2018.38888888889,0.800658832206062,121
"CD013445","CD013445_pub2_data","1|29|Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 2 mm by any imaging modality)|","Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 2 mm by any imaging modality)",1,29,"","or","binary",7,1.07621784143267,0.402455804604652,0.665768504974574,2018.42857142857,0.696769522038064,80.8571428571429
"CD013445","CD013445_pub2_data","1|3|Secondary interventions|","Secondary interventions",1,3,"","or","binary",21,-1.57883789823201,0.439889022533952,2.82206631741569,2016.42857142857,0.294056950142586,95.4761904761905
"CD013445","CD013445_pub2_data","1|30|Sensitivity analysis for stone-free rate by definition of stone freedom (totally stone-free by CT scan)|","Sensitivity analysis for stone-free rate by definition of stone freedom (totally stone-free by CT scan)",1,30,"","or","binary",5,1.30949596066206,0.319458084630672,0,2016.6,0.744279170441961,63.2
"CD013445","CD013445_pub2_data","1|32|Sensitivity analysis for major complications by definition of stone freedom (≤ 2 mm by any imaging modality)|","Sensitivity analysis for major complications by definition of stone freedom (≤ 2 mm by any imaging modality)",1,32,"","or","binary",7,0.320799365050971,0.713633635184017,0,2018.42857142857,0,81
"CD013445","CD013445_pub2_data","1|33|Sensitivity analysis for major complications by definition of stone freedom (totally stone-free by CT scan)|","Sensitivity analysis for major complications by definition of stone freedom (totally stone-free by CT scan)",1,33,"","or","binary",4,-0.768548570950103,0.749122984317704,0,2015.25,0.0303030303030303,79.75
"CD013445","CD013445_pub2_data","1|34|Sensitivity analysis for secondary interventions by definition of stone freedom (≤ 4 mm by any imaging modality)|","Sensitivity analysis for secondary interventions by definition of stone freedom (≤ 4 mm by any imaging modality)",1,34,"","or","binary",9,-0.864542550030491,0.287336968874684,0.208363972478589,2017.33333333333,0.201370148259204,130
"CD013445","CD013445_pub2_data","1|35|Sensitivity analysis for secondary interventions by definition of stone freedom (≤  2 mm by any imaging modality)|","Sensitivity analysis for secondary interventions by definition of stone freedom (≤  2 mm by any imaging modality)",1,35,"","or","binary",3,-2.16275160738589,1.86204078802151,8.93636701407776,2016.66666666667,0.542899584076055,55.6666666666667
"CD013445","CD013445_pub2_data","1|36|Sensitivity analysis for secondary interventions by definition of stone freedom (totally stone-free by CT scan)|","Sensitivity analysis for secondary interventions by definition of stone freedom (totally stone-free by CT scan)",1,36,"","or","binary",4,-2.25225894168584,0.588174897935089,0.419166686417098,2015.25,0.626849894291755,46
"CD013445","CD013445_pub2_data","1|4|Length of hospital stay|","Length of hospital stay",1,4,"","or","binary",26,-0.169755331858293,0.394951686035632,0,2016.53846153846,0,107.846153846154
"CD013445","CD013445_pub2_data","1|5|Minor complications|","Minor complications",1,5,"","or","binary",35,0.116152960750795,0.163582078929203,0.44789820082934,2017.17142857143,0.160429056925074,101.371428571429
"CD013445","CD013445_pub2_data","1|6|Blood transfusions|","Blood transfusions",1,6,"","or","binary",20,0.774377201103641,0.287861634288262,0,2016.35,0.00431453928090599,93.7
"CD013445","CD013445_pub2_data","1|7|Procedure time|","Procedure time",1,7,"","or","binary",29,-0.0976135245412335,0.373728758083891,0,2016.86206896552,0,108.896551724138
"CD013445","CD013445_pub2_data","1|8|Postprocedure drainage tube or stent|","Postprocedure drainage tube or stent",1,8,"","or","binary",18,-2.41973084539563,0.646532845035796,5.07977001792679,2017.11111111111,0.859784213232489,105.111111111111
"CD013456","CD013456_pub2_data","1|1|Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment|Behavioural Therapy","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment",1,1,"Behavioural Therapy","or","binary",7,-0.221366729775514,0.76926749562711,0,2015.57142857143,0,33.2857142857143
"CD013456","CD013456_pub2_data","1|1|Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment|Cognitive Behavioural Therapy","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment",1,1,"Cognitive Behavioural Therapy","or","binary",10,-0.903541896968901,0.641938533741613,0,2004.1,0,57.5
"CD013456","CD013456_pub2_data","1|1|Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment|Psychosocial (low-intensity) interventions","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment",1,1,"Psychosocial (low-intensity) interventions","or","binary",4,-0.0428139313599321,1.00731372409821,0,2017.75,0,80.5
"CD013456","CD013456_pub2_data","1|2|Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, 3 months|","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, 3 months",1,2,"","or","binary",8,-0.184346459649849,0.712651702901472,0,2015.75,0,96.25
"CD013456","CD013456_pub2_data","1|3|Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment|Behavioural Therapy","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment",1,3,"Behavioural Therapy","or","binary",4,-0.137926583125239,1.0176734757103,0,2009.5,0,30.75
"CD013456","CD013456_pub2_data","1|3|Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment|Cognitive Behavioural Therapy","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment",1,3,"Cognitive Behavioural Therapy","or","binary",11,-0.845691540512633,0.61249087796782,0,2004.18181818182,0,54.0909090909091
"CD013456","CD013456_pub2_data","1|3|Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment|Psychosocial (low-intensity) interventions","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment",1,3,"Psychosocial (low-intensity) interventions","or","binary",2,0.0654629592520269,1.42468370836961,0,2011,0,91.5
"CD013456","CD013456_pub2_data","1|4|Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, 3 months|","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, 3 months",1,4,"","or","binary",3,-0.0904551235667296,1.16525673131871,0,2012.66666666667,0,125.333333333333
"CD013456","CD013456_pub2_data","1|5|Psychosocial interventions versus inactive control; outcome 3: Dropout from treatment|","Psychosocial interventions versus inactive control; outcome 3: Dropout from treatment",1,5,"","or","binary",5,-0.265036765084189,0.38058198034586,0.247917710646333,2015.4,0.338536585365854,48.4
"CD013456","CD013456_pub2_data","1|6|Psychosocial interventions versus inactive control; outcome 4: Adverse events|","Psychosocial interventions versus inactive control; outcome 4: Adverse events",1,6,"","or","binary",6,0.444534205494762,0.628371692683975,0,2014.66666666667,0.0207317073170732,103.666666666667
"CD013456","CD013456_pub2_data","1|7|Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, post-treatment|","Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, post-treatment",1,7,"","or","binary",13,-0.455721995700042,0.565164530619429,0,2008.30769230769,0,33.5384615384615
"CD013456","CD013456_pub2_data","1|8|Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, 3 months|","Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, 3 months",1,8,"","or","binary",4,-0.0016246908355346,1.00861108354582,0,2013.25,0,112.25
"CD013456","CD013456_pub2_data","1|9|Psychosocial interventions versus inactive control; outcome 6: Global mental health/distress, post-treatment|","Psychosocial interventions versus inactive control; outcome 6: Global mental health/distress, post-treatment",1,9,"","or","binary",3,-0.105975238308381,1.17700770952066,0,2009,0,26.6666666666667
"CD013456","CD013456_pub2_data","2|1|Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, post-treatment|","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, post-treatment",2,1,"","or","binary",12,0.293466436844791,0.587231236661479,0,2008.58333333333,0,60.5833333333333
"CD013456","CD013456_pub2_data","2|10|Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 3 months|","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 3 months",2,10,"","or","binary",6,0.210045679159374,0.833623124513738,0,2002.83333333333,0,67.1666666666667
"CD013456","CD013456_pub2_data","2|11|Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 6 months|","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 6 months",2,11,"","or","binary",3,-0.089474955303636,1.16293365371658,0,2004.66666666667,0,133
"CD013456","CD013456_pub2_data","2|12|Trauma-focused versus non-trauma focused interventions; outcome 7: Trauma-related beliefs, post-treatment|","Trauma-focused versus non-trauma focused interventions; outcome 7: Trauma-related beliefs, post-treatment",2,12,"","or","binary",5,0.681188077579021,0.918077652645717,0,2003.6,0,30.4
"CD013456","CD013456_pub2_data","2|13|Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, post-treatment|","Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, post-treatment",2,13,"","or","binary",4,0.522755216989937,1.02166795221123,0,2010.75,0,85.5
"CD013456","CD013456_pub2_data","2|14|Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, 3 months|","Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, 3 months",2,14,"","or","binary",3,0.0584163324792848,1.16924144223746,0,2012,0,113.666666666667
"CD013456","CD013456_pub2_data","2|2|Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 3 months|","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 3 months",2,2,"","or","binary",9,0.0978863821059724,0.677618587104816,0,2007.44444444444,0,64.8888888888889
"CD013456","CD013456_pub2_data","2|3|Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 6 months|","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 6 months",2,3,"","or","binary",5,-0.163920128913162,0.901195073894588,0,2008.6,0,106.6
"CD013456","CD013456_pub2_data","2|4|Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, post-treatment|","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, post-treatment",2,4,"","or","binary",11,0.259806552050941,0.613740876860491,0,2007.45454545455,0,61.1818181818182
"CD013456","CD013456_pub2_data","2|5|Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 3 months|","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 3 months",2,5,"","or","binary",8,0.0920297413793799,0.719663822439964,0,2005.75,0,66.875
"CD013456","CD013456_pub2_data","2|6|Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 6 months|","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 6 months",2,6,"","or","binary",5,-0.159462055593364,0.901206095223661,0,2008.6,0,106.4
"CD013456","CD013456_pub2_data","2|7|Trauma-focused versus non trauma-focused interventions; outcome 3: Dropout from treatment|","Trauma-focused versus non trauma-focused interventions; outcome 3: Dropout from treatment",2,7,"","or","binary",12,0.44624528445673,0.214943271272471,0.153471555572244,2008.58333333333,0.215280409245926,71.5833333333333
"CD013456","CD013456_pub2_data","2|8|Trauma-focused versus non trauma-focused interventions; outcome 4: Adverse events|","Trauma-focused versus non trauma-focused interventions; outcome 4: Adverse events",2,8,"","or","binary",5,-0.415807453495875,0.426266354536214,0.120179482814811,2013,0.0590654959076012,118.2
"CD013456","CD013456_pub2_data","2|9|Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, post-treatment|","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, post-treatment",2,9,"","or","binary",9,0.379132998241401,0.679951327603099,0,2005.88888888889,0,60
"CD013462","CD013462_pub3_data","1|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)|","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)",1,1,"","reported","reported",9,0.758224453777202,0.219713287927786,0.155609957393176,2016.11111111111,0.159214759611403,147.222222222222
"CD013462","CD013462_pub3_data","1|2|Postoperative mortality|","Postoperative mortality",1,2,"","reported","reported",10,0.560661377461958,0.269833482084296,0,2012.6,0.0390899015578849,144.2
"CD013462","CD013462_pub3_data","1|3|Rate of surgical reintervention|","Rate of surgical reintervention",1,3,"","reported","reported",11,0.807663118371492,0.35665855429411,0,2011.45454545455,0.0483609321143014,141.090909090909
"CD013462","CD013462_pub3_data","1|4|Rate of postoperative bleeding|","Rate of postoperative bleeding",1,4,"","reported","reported",11,0.783731777340799,0.241328129745399,0,2012.72727272727,0.0645989769318763,134.363636363636
"CD013462","CD013462_pub3_data","1|5|Overall rate of surgical complications|","Overall rate of surgical complications",1,5,"","reported","reported",8,1.0435148114554,0.0666271455148956,2.43062044815454e-06,2011.625,0.445767072801911,133.875
"CD013462","CD013462_pub3_data","1|6|Length of hospital stay|","Length of hospital stay",1,6,"","reported","reported",4,-0.542714867428686,0.84410175607136,0.470969924804884,2009.5,NA,164.5
"CD013462","CD013462_pub3_data","2|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2016 ISGPS definition)|","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2016 ISGPS definition)",2,1,"","reported","reported",2,1.12656293879628,0.361267877234437,0,2020.5,0.0904321954274976,223
"CD013462","CD013462_pub3_data","2|4|Rate of surgical reintervention|","Rate of surgical reintervention",2,4,"","reported","reported",2,2.02499473939669,1.1294840135927,0,2020.5,0.0290479173191356,223
"CD013462","CD013462_pub3_data","2|5|Rate of postoperative bleeding|","Rate of postoperative bleeding",2,5,"","reported","reported",2,1.39927509545361,0.408253711042038,0,2020.5,0.0766129032258065,223
"CD013462","CD013462_pub3_data","3|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)|Grade B","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)",3,1,"Grade B","reported","reported",9,0.46537573731595,0.109808295567305,0.00391889971337102,2016.11111111111,0.142292143319569,147.222222222222
"CD013462","CD013462_pub3_data","3|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)|Grade C","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)",3,1,"Grade C","reported","reported",8,0.567708886344755,0.619213616490904,0,2017,0.0190379433283124,157.625
"CD013462","CD013462_pub3_data","4|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)|Firm pancreas","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)",4,1,"Firm pancreas","reported","reported",4,0.847270215812188,0.451373013375301,0,2014.5,0.102442701218418,79
"CD013462","CD013462_pub3_data","4|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)|Soft pancreas","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)",4,1,"Soft pancreas","reported","reported",5,1.30035791488589,0.489334365226098,0.630614160403605,2013.4,0.189297614150555,101
"CD013462","CD013462_pub3_data","4|2|Postoperative mortality|Soft pancreas","Postoperative mortality",4,2,"Soft pancreas","reported","reported",2,1.0850435196258,3.80401915905992,0,2006,0.015625,104
"CD013462","CD013462_pub3_data","5|1|Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)|No stents","Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)",5,1,"No stents","reported","reported",2,2.70613953115623,3.04889016943635,0,2015,0.0217443249701314,207.5
"CD013462","CD013462_pub3_data","5|1|Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)|Pancreatic duct stents","Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)",5,1,"Pancreatic duct stents","reported","reported",2,2.37669115182455,0.832309021310949,0,2013.5,0.0858474576271187,158.5
"CD013462","CD013462_pub3_data","5|2|Postoperative mortality|No stents","Postoperative mortality",5,2,"No stents","reported","reported",3,0.771768925240101,0.782711658207633,0,2013,0.0246913580246914,204
"CD013462","CD013462_pub3_data","5|2|Postoperative mortality|Pancreatic duct stents","Postoperative mortality",5,2,"Pancreatic duct stents","or","binary",2,-0.00776462231977343,1.42022505233945,0,2011.5,0,116.5
"CD013462","CD013462_pub3_data","6|1|Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)|No somatostatin","Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)",6,1,"No somatostatin","reported","reported",3,0.217028837535769,0.170679220044454,3.95255805056772e-08,2011.33333333333,0.123823529411765,131
"CD013462","CD013462_pub3_data","6|2|Postoperative mortality|No somatostatin","Postoperative mortality",6,2,"No somatostatin","reported","reported",3,0.530481580611598,1.89185236763162,0,2011.33333333333,0.0153186274509804,131
"CD013462","CD013462_pub3_data","6|2|Postoperative mortality|Prophylactic somatostatin","Postoperative mortality",6,2,"Prophylactic somatostatin","reported","reported",2,3.01905854125202,13.1848562499977,0,2009,0,226
"CD013462","CD013462_pub3_data","7|1|Rate of postoperative pancreatic fistula (grade B or C defined according to the 2016 ISGPS definition)|Grade B","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2016 ISGPS definition)",7,1,"Grade B","reported","reported",2,1.04867043430346,0.370367557185771,0,2020.5,0.0823676792984654,223
"CD013468","CD013468_pub2_data","1|1|Change in burn‐related pruritus|NA","Change in burn‐related pruritus",1,1,NA,"or","binary",2,0.473713381601769,1.44732287543733,0,2011,0,24.5
"CD013468","CD013468_pub2_data","11|1|Change in burn‐related pruritus|NA","Change in burn‐related pruritus",11,1,NA,"or","binary",2,-0.041650156531092,1.43304663422451,0,2007,0,83
"CD013468","CD013468_pub2_data","11|2|Pain|NA","Pain",11,2,NA,"or","binary",2,-0.041650156531092,1.43304663422451,0,2007,0,83
"CD013468","CD013468_pub2_data","13|1|Change in burn-related pruritus|NA","Change in burn-related pruritus",13,1,NA,"or","binary",2,0.0217375241355785,1.42934456843196,0,2018.5,0,45.5
"CD013468","CD013468_pub2_data","16|1|Change in burn-related pruritus|NA","Change in burn-related pruritus",16,1,NA,"or","binary",2,-0.201418121971842,1.42772815113898,0,2017.5,0,59
"CD013468","CD013468_pub2_data","16|2|Pain|NA","Pain",16,2,NA,"or","binary",2,-0.201418121971842,1.42772815113898,0,2017.5,0,59
"CD013474","CD013474_pub2_data","1|1|Overall survival (time to event)|","Overall survival (time to event)",1,1,"","reported","reported",3,-0.0660873272407155,0.126987430045419,0,2017.66666666667,0,384
"CD013474","CD013474_pub2_data","1|10|Treatment discontinuation|","Treatment discontinuation",1,10,"","or","binary",6,-0.123294394321663,0.23365292148207,0.18252558628979,2016.83333333333,0.383346034970268,220.166666666667
"CD013474","CD013474_pub2_data","1|11|Treatment discontinuation: type of drug|Ofatumumab","Treatment discontinuation: type of drug",1,11,"Ofatumumab","or","binary",2,-0.136766156591173,0.179732858470743,0,2017.5,0.287424194063198,258.5
"CD013474","CD013474_pub2_data","1|11|Treatment discontinuation: type of drug|Rituximab","Treatment discontinuation: type of drug",1,11,"Rituximab","or","binary",4,-0.195936842432965,0.349641598977516,0.350021921968801,2016.5,0.431306955423803,201
"CD013474","CD013474_pub2_data","1|12|All adverse events|","All adverse events",1,12,"","reported","reported",6,0.207022578192327,0.0921466606431103,0.0258233072683045,2016.83333333333,0,220.166666666667
"CD013474","CD013474_pub2_data","1|13|All adverse events: type of drug|Ofatumumab","All adverse events: type of drug",1,13,"Ofatumumab","reported","reported",2,0.147073008297011,0.0982313171768075,0,2017.5,0,258.5
"CD013474","CD013474_pub2_data","1|13|All adverse events: type of drug|Rituximab","All adverse events: type of drug",1,13,"Rituximab","reported","reported",4,0.233334640738191,0.130988264250794,0.0449409267195477,2016.5,0,201
"CD013474","CD013474_pub2_data","1|14|Complete response rate|","Complete response rate",1,14,"","or","binary",2,0.474535810595509,0.385739378992306,0,2016,0.230113636363636,66
"CD013474","CD013474_pub2_data","1|15|Overall response rate|","Overall response rate",1,15,"","or","binary",2,0.783756306933095,0.350817362654289,0,2016,0.368844696969697,66
"CD013474","CD013474_pub2_data","1|2|Overall survival (time to event): type of drug|Rituximab","Overall survival (time to event): type of drug",1,2,"Rituximab","reported","reported",2,-0.153908531983433,0.203520514981679,0,2017,0,336
"CD013474","CD013474_pub2_data","1|4|Grade 3 and 4 adverse events|","Grade 3 and 4 adverse events",1,4,"","reported","reported",5,0.291345417529662,0.130973985456398,0.0474851134325259,2017,0,256.8
"CD013474","CD013474_pub2_data","1|5|Grade 3 and 4 adverse events: type of drug|Rituximab","Grade 3 and 4 adverse events: type of drug",1,5,"Rituximab","reported","reported",4,0.259917867172648,0.180628601488285,0.0808995844230091,2016.5,0,201
"CD013474","CD013474_pub2_data","1|6|Progression-free survival (time to event)|","Progression-free survival (time to event)",1,6,"","reported","reported",5,-0.507902658869697,0.102531925008032,0.0204956830448582,2017.4,0,251
"CD013474","CD013474_pub2_data","1|7|Progression-free survival (time to event): type of drug|Ofatumumab","Progression-free survival (time to event): type of drug",1,7,"Ofatumumab","reported","reported",2,-0.42027181122449,0.137121916077111,0.026949295,2017.5,0,258.5
"CD013474","CD013474_pub2_data","1|7|Progression-free survival (time to event): type of drug|Rituximab","Progression-free survival (time to event): type of drug",1,7,"Rituximab","reported","reported",3,-0.688697555264611,0.155631584128029,0,2017.33333333333,0,246
"CD013474","CD013474_pub2_data","1|8|Treatment-related mortality|","Treatment-related mortality",1,8,"","or","binary",4,-0.208198075860302,0.38207869419452,0.258474734870286,2017.25,0.0660159222813146,297.25
"CD013474","CD013474_pub2_data","1|9|Treatment-related mortality: type of drug|Ofatumumab","Treatment-related mortality: type of drug",1,9,"Ofatumumab","or","binary",2,-0.67184998892477,0.381071819483675,0,2017.5,0.0778806255984679,258.5
"CD013474","CD013474_pub2_data","1|9|Treatment-related mortality: type of drug|Rituximab","Treatment-related mortality: type of drug",1,9,"Rituximab","or","binary",2,0.135116114942022,0.469175520321362,0.186396383674954,2017,0.0541512189641613,336
"CD013474","CD013474_pub2_data","2|1|Overall survival (time to event)|","Overall survival (time to event)",2,1,"","reported","reported",3,-0.0966777768994311,0.202712448511653,0,2017.33333333333,0,153.666666666667
"CD013474","CD013474_pub2_data","2|2|Grade 3 and 4 adverse events|","Grade 3 and 4 adverse events",2,2,"","reported","reported",2,0.596362386008713,0.138851028365703,0,2017,0,200
"CD013474","CD013474_pub2_data","2|3|Progression-free survival (time to event)|","Progression-free survival (time to event)",2,3,"","reported","reported",3,-0.991670762505771,0.382771027322281,0.322634996432213,2017.33333333333,0,153.666666666667
"CD013474","CD013474_pub2_data","2|4|Treatment-related mortality|","Treatment-related mortality",2,4,"","or","binary",3,0.0943627594111565,0.574338644851903,0,2017.33333333333,0.0281689362149132,152.666666666667
"CD013474","CD013474_pub2_data","2|5|Treatment discontinuation|","Treatment discontinuation",2,5,"","or","binary",2,-0.864479833186537,0.317030625096158,0.0817151443490134,2017,0.754926108374384,200
"CD013474","CD013474_pub2_data","2|6|All adverse events|","All adverse events",2,6,"","reported","reported",3,0.340290398608085,0.0480158665259646,2.29611042838525e-07,2017.33333333333,0,152.666666666667
"CD013476","CD013476_pub2_data","1|1|Disease-specific health-related quality of life scores at 6 months follow-up (SNOT-score)|Disease-specific health-related quality of life scores at 6 months follow-up (all studies)","Disease-specific health-related quality of life scores at 6 months follow-up (SNOT-score)",1,1,"Disease-specific health-related quality of life scores at 6 months follow-up (all studies)","or","binary",3,-0.0408007944388197,1.17717391640482,0,2016,0,28.3333333333333
"CD013476","CD013476_pub2_data","1|11|Change in medication score at 6 months follow-up (dosage of inhaled/intranasal corticosteroid) |","Change in medication score at 6 months follow-up (dosage of inhaled/intranasal corticosteroid) ",1,11,"","or","binary",2,0,1.43385267182682,0,2016,0,35
"CD013476","CD013476_pub2_data","1|13|Asthma exacerbations after 6 months follow-up|","Asthma exacerbations after 6 months follow-up",1,13,"","or","binary",2,-0.938841794498636,0.495298199270929,0,2016,0.486842105263158,35
"CD013476","CD013476_pub2_data","1|6|Significant adverse events during maintenance therapy up to 6 months follow-up|Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","Significant adverse events during maintenance therapy up to 6 months follow-up",1,6,"Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","or","binary",4,1.15108355855598,0.84286879422609,0,2016.33333333333,0,32.25
"CD013508","CD013508_pub3_data","1|1|Depression|NA","Depression",1,1,NA,"or","binary",21,0.0119531706208816,0.439660552372158,0,2014.7619047619,0,120.52380952381
"CD013508","CD013508_pub3_data","1|10|SF12/36 (PCS)|NA","SF12/36 (PCS)",1,10,NA,"reported","reported",7,0,0.31714272188127,0,2012.57142857143,0,88.7142857142857
"CD013508","CD013508_pub3_data","1|11|HRQoL (MCS)|NA","HRQoL (MCS)",1,11,NA,"reported","reported",10,0,0.220310003910022,0,2013.2,0,75
"CD013508","CD013508_pub3_data","1|12|SF12/36 (MCS)|NA","SF12/36 (MCS)",1,12,NA,"reported","reported",7,0,0.371805253303373,0,2012.57142857143,0,88.7142857142857
"CD013508","CD013508_pub3_data","1|13|Self-efficacy|NA","Self-efficacy",1,13,NA,"or","binary",3,0.113830413693211,1.16904094940704,0,2013.66666666667,0,58
"CD013508","CD013508_pub3_data","1|14|Mortality (all-cause)|NA","Mortality (all-cause)",1,14,NA,"or","binary",3,-0.189705972443425,0.379845942008555,0,2019.66666666667,0.0372437063997574,205
"CD013508","CD013508_pub3_data","1|15|MACE|NA","MACE",1,15,NA,"or","binary",4,0.21275028485207,0.364503068102118,0.175627959875973,2017.25,0.125748069498069,112.5
"CD013508","CD013508_pub3_data","1|2|HADS-D |NA","HADS-D ",1,2,NA,"or","binary",8,0.0511479020153035,0.710172170413084,0,2014.5,0,163.125
"CD013508","CD013508_pub3_data","1|3|BDI-II|NA","BDI-II",1,3,NA,"or","binary",3,0.0198240448160796,1.17308519024532,0,2014.66666666667,0,55.3333333333333
"CD013508","CD013508_pub3_data","1|4|PHQ-9|NA","PHQ-9",1,4,NA,"or","binary",4,-0.146430677807314,1.00512257148597,0,2017,0,152.5
"CD013508","CD013508_pub3_data","1|5|Anxiety|NA","Anxiety",1,5,NA,"or","binary",19,0.0208883791975424,0.462460428663122,0,2015.42105263158,0,117.631578947368
"CD013508","CD013508_pub3_data","1|6|HADS-A|NA","HADS-A",1,6,NA,"or","binary",9,0.0528381906918829,0.670446956285078,0,2014.44444444444,0,148.222222222222
"CD013508","CD013508_pub3_data","1|7|GAD-7|NA","GAD-7",1,7,NA,"or","binary",3,-0.196924439165943,1.16076599067472,0,2018,0,168
"CD013508","CD013508_pub3_data","1|8|BAI|NA","BAI",1,8,NA,"or","binary",3,-0.0712786236024893,1.17076630680398,0,2014.33333333333,0,51
"CD013508","CD013508_pub3_data","1|9|HRQoL (PCS)|NA","HRQoL (PCS)",1,9,NA,"reported","reported",10,0,0.213364491766784,0,2013.2,0,75
"CD013539","CD013539_pub2_data","1|1|Progression-free survival|Lung cancer","Progression-free survival",1,1,"Lung cancer","reported","reported",4,0.00229880454510394,0.046835935604351,0,2020.75,0,633.5
"CD013539","CD013539_pub2_data","1|3|Overall survival|Lung cancer","Overall survival",1,3,"Lung cancer","reported","reported",4,0.0574939610220306,0.062079485247916,0,2020.75,0,664.25
"CD013539","CD013539_pub2_data","1|5|Objective response rate|Colorectal cancer","Objective response rate",1,5,"Colorectal cancer","or","binary",7,-0.0841789247148231,0.119870744760908,0,2019.71428571429,0.452091371050579,171.428571428571
"CD013539","CD013539_pub2_data","1|6|Mortality|Colorectal cancer","Mortality",1,6,"Colorectal cancer","or","binary",6,-0.0727181553770349,0.149650600338846,0,2019.16666666667,0.168880904246219,210.333333333333
"CD013539","CD013539_pub2_data","1|7|Neutralising antibodies|","Neutralising antibodies",1,7,"","or","binary",14,-0.423819339375776,0.237987787525375,0,2020.64285714286,0.0632258053986905,484.142857142857
"CD013539","CD013539_pub2_data","1|8|Antidrug antibodies|Antidrug antibodies at baseline","Antidrug antibodies",1,8,"Antidrug antibodies at baseline","or","binary",12,-0.165182374909562,0.159439778573306,0,2020.33333333333,0.0250617962435103,528.416666666667
"CD013539","CD013539_pub2_data","2|2|Duration of response|","Duration of response",2,2,"","reported","reported",2,0.323523927682322,0.238830730488611,0,2018.5,0,261
"CD013539","CD013539_pub2_data","2|4|Serious adverse events|","Serious adverse events",2,4,"","or","binary",15,0.136085027767351,0.0817075424752881,0,2019.53333333333,0.211107569777316,279.8
"CD013539","CD013539_pub2_data","2|5|Objective response rate|","Objective response rate",2,5,"","or","binary",16,0.105206110997989,0.0852582212926987,0.00155820680702039,2019.3125,0.773734067735834,245.125
"CD013539","CD013539_pub2_data","2|6|Mortality|","Mortality",2,6,"","or","binary",8,-0.0321383974647296,0.177640071362611,0,2017.75,0.0503880290584876,319.625
"CD013539","CD013539_pub2_data","2|8|Antidrug antibodies |Antidrug antibodies at baseline","Antidrug antibodies ",2,8,"Antidrug antibodies at baseline","or","binary",8,-0.149167845583866,0.265637831001323,1.48471058195915e-07,2019.625,0.0366710905021766,243.125
"CD013539","CD013539_pub2_data","2|9|Neutralising antibodies|","Neutralising antibodies",2,9,"","or","binary",10,0.0890379403181568,0.463954187486227,0,2018.6,0.00386572453223201,256.1
"CD013539","CD013539_pub2_data","3|1|Progression-free survival|","Progression-free survival",3,1,"","reported","reported",4,-0.0593925759565866,0.0666395356117936,0.000560970497559676,2019,0,570.25
"CD013539","CD013539_pub2_data","3|10|Neutralising antibodies|","Neutralising antibodies",3,10,"","or","binary",10,-0.0613540366505123,0.379656858796724,0,2019.6,0.00439459991815488,510.4
"CD013539","CD013539_pub2_data","3|11|Any adverse events|","Any adverse events",3,11,"","or","binary",15,0.0363133134335553,0.0730442004079488,6.3265155999473e-07,2019.46666666667,0.801982266390468,465.133333333333
"CD013539","CD013539_pub2_data","3|4|Pathological complete response|","Pathological complete response",3,4,"","or","binary",7,0.0995532532623396,0.0984909285724603,0.0293253389949188,2019.71428571429,0.432880877026366,486.142857142857
"CD013539","CD013539_pub2_data","3|5|Serious adverse events|","Serious adverse events",3,5,"","or","binary",13,-0.00480662733588422,0.0794678132758126,0,2019.38461538462,0.125901052677565,475.615384615385
"CD013539","CD013539_pub2_data","3|6|Objective response rate|","Objective response rate",3,6,"","or","binary",13,0.121449171927684,0.0753074093643036,0.00856124924376272,2020.07692307692,0.728310035290052,423.769230769231
"CD013539","CD013539_pub2_data","3|7|Mortality|","Mortality",3,7,"","or","binary",12,-0.153054638357392,0.120792699773177,0,2019.5,0.0543438833382016,498.083333333333
"CD013539","CD013539_pub2_data","3|8|Event-free survival|","Event-free survival",3,8,"","reported","reported",2,-0.0215061740112822,0.170487057955919,0,2020,0,674.5
"CD013539","CD013539_pub2_data","3|9|Antidrug antibodies|","Antidrug antibodies",3,9,"","or","binary",10,-0.0134186801852713,0.257436993740901,0,2019.8,0.0119171075920928,498.9
"CD013541","CD013541_pub2_data","1|1|Relapse (≤ 1 month postintervention)|","Relapse (≤ 1 month postintervention)",1,1,"","reported","reported",4,0,0.148980806447955,0,2002,0.510856991978273,57.25
"CD013541","CD013541_pub2_data","1|2|Relapse (≤ 1 month postintervention, completer)|","Relapse (≤ 1 month postintervention, completer)",1,2,"","reported","reported",4,0,0.209403565640478,0,2002,0.427962255136168,49
"CD013541","CD013541_pub2_data","1|3|Relapse (> 6 months postintervention)|","Relapse (> 6 months postintervention)",1,3,"","reported","reported",5,0,0.0754398683784329,0,1998.4,0.583357302118172,61.8
"CD013541","CD013541_pub2_data","1|4|Relapse (> 6 months postintervention, completer)|","Relapse (> 6 months postintervention, completer)",1,4,"","reported","reported",5,0,0.10657078318796,0,1998.4,0.574268239694195,56.4
"CD013541","CD013541_pub2_data","12|1|Caregiving: competence (≤ 1 month postintervention)|","Caregiving: competence (≤ 1 month postintervention)",12,1,"","reported","reported",2,0,0.866285682953795,0,2007,0,84.5
"CD013541","CD013541_pub2_data","12|2|Caregiving: competence (1-6 months postintervention)|","Caregiving: competence (1-6 months postintervention)",12,2,"","reported","reported",2,0,0.999587499117963,0,2007,0,84.5
"CD013541","CD013541_pub2_data","12|3|Caregiving: competence (> 6 months postintervention)|","Caregiving: competence (> 6 months postintervention)",12,3,"","reported","reported",2,0,1.16316905682909,0,2007,0,84.5
"CD013541","CD013541_pub2_data","13|1|Social support (≤ 1 month postintervention)|","Social support (≤ 1 month postintervention)",13,1,"","reported","reported",6,0,0.0989791280483251,0,2010.33333333333,0,73.6666666666667
"CD013541","CD013541_pub2_data","13|2|Social support (1-6 months postintervention)|","Social support (1-6 months postintervention)",13,2,"","reported","reported",2,0,0.156848208387114,0,2007,0,84.5
"CD013541","CD013541_pub2_data","13|3|Social support (> 6 months postintervention)|","Social support (> 6 months postintervention)",13,3,"","reported","reported",4,0,0.0993366056569771,0,2008,0,84.25
"CD013541","CD013541_pub2_data","14|1|Family outcomes: family service usage (≤ 1 month postintervention, positive outcome)|","Family outcomes: family service usage (≤ 1 month postintervention, positive outcome)",14,1,"","reported","reported",5,0,0.124251924300932,0,2007.6,0,78.8
"CD013541","CD013541_pub2_data","14|2|Family outcomes: family service usage (1-6 months postintervention, positive outcome)|","Family outcomes: family service usage (1-6 months postintervention, positive outcome)",14,2,"","reported","reported",2,0,0.239015733583583,0,2004.5,0,72
"CD013541","CD013541_pub2_data","14|3|Family outcomes: family service usage (> 6 months postintervention, positive outcome)|","Family outcomes: family service usage (> 6 months postintervention, positive outcome)",14,3,"","reported","reported",4,0,0.135448893123799,0,2008.5,0,86.5
"CD013541","CD013541_pub2_data","14|5|Family outcomes: family functioning (> 6 months postintervention)|","Family outcomes: family functioning (> 6 months postintervention)",14,5,"","or","binary",4,-0.164861586180831,1.00605874442159,0,2009.75,0,85.5
"CD013541","CD013541_pub2_data","16|1|Family members' satisfaction with care|","Family members' satisfaction with care",16,1,"","or","binary",2,0.024857625485356,1.42756143576532,0,2000.5,0,57.5
"CD013541","CD013541_pub2_data","17|1|Leaving the study early (≤ 1 month postintervention)|","Leaving the study early (≤ 1 month postintervention)",17,1,"","reported","reported",5,0,0.193732599657799,0,2009.2,0.21881644066762,72
"CD013541","CD013541_pub2_data","17|2|Leaving the study early (1-6 months postintervention)|","Leaving the study early (1-6 months postintervention)",17,2,"","reported","reported",2,0,0.415579743137848,0,2009,0.165384615384615,69
"CD013541","CD013541_pub2_data","17|3|Leaving the study early (6-12 months postintervention)|","Leaving the study early (6-12 months postintervention)",17,3,"","reported","reported",8,0,0.235449103222494,0,2001.125,0.167522025776252,63.75
"CD013541","CD013541_pub2_data","17|4|Leaving the study early (> 12 months postintervention)|","Leaving the study early (> 12 months postintervention)",17,4,"","reported","reported",8,0,0.212556735727599,0,2005.125,0.119341859005369,85.75
"CD013541","CD013541_pub2_data","19|1|Family members' knowledge (≤ 1 month postintervention)|Postintervention mean ","Family members' knowledge (≤ 1 month postintervention)",19,1,"Postintervention mean ","reported","reported",2,0,0.883505153870938,0,1996.5,0,30
"CD013541","CD013541_pub2_data","2|1|Caregiver burden (≤ 1 month postintervention)|Postintervention mean","Caregiver burden (≤ 1 month postintervention)",2,1,"Postintervention mean","reported","reported",7,0,0.0950801111041629,0,2008.71428571429,0,73.7142857142857
"CD013541","CD013541_pub2_data","2|2|Caregiver burden (1-6 months postintervention)|","Caregiver burden (1-6 months postintervention)",2,2,"","reported","reported",3,0,1.22139244028196,0,2006.33333333333,0,66.3333333333333
"CD013541","CD013541_pub2_data","2|3|Caregiver burden (> 6 months postintervention)|","Caregiver burden (> 6 months postintervention)",2,3,"","reported","reported",3,0,0.625926672800153,0,2007,0,80
"CD013541","CD013541_pub2_data","3|2|Number of people shifting to low expressed emotion (completer, positive outcome)|","Number of people shifting to low expressed emotion (completer, positive outcome)",3,2,"","or","binary",2,1.8481905328951,0.779300367195499,0,1999,0.0909090909090909,30.5
"CD013541","CD013541_pub2_data","3|3|Expressed emotion (1-6 months, negative outcome)|","Expressed emotion (1-6 months, negative outcome)",3,3,"","reported","reported",2,0,0.233926228997271,0,2014.5,0,54.5
"CD013541","CD013541_pub2_data","4|1|Adverse effects|Suicide ","Adverse effects",4,1,"Suicide ","or","binary",5,-0.646360289452959,0.618196783489164,0,1995,0.0656400966183575,54.8
"CD013541","CD013541_pub2_data","5|1|Global state (≤ 1 month postintervention)|Post-intervention mean","Global state (≤ 1 month postintervention)",5,1,"Post-intervention mean","or","binary",2,-0.0330192354382805,1.43056198166605,0,2010,0,51.5
"CD013541","CD013541_pub2_data","6|1|Service use: hospital admission (≤ 1 month postintervention)|","Service use: hospital admission (≤ 1 month postintervention)",6,1,"","reported","reported",2,0,0.232235206933088,0,2004,0.33940620782726,76.5
"CD013541","CD013541_pub2_data","6|2|Service use: hospital admission (> 6 months postintervention)|","Service use: hospital admission (> 6 months postintervention)",6,2,"","reported","reported",5,0,0.0966492593089188,0,1997,0.508457264957265,63.6
"CD013541","CD013541_pub2_data","6|4|Service use: average number of hospital admissions (≤ 1 month postintervention)|","Service use: average number of hospital admissions (≤ 1 month postintervention)",6,4,"","reported","reported",4,0,0.109644541741181,0,2008.75,0,80.5
"CD013541","CD013541_pub2_data","6|5|Service use: average number of hospital admissions (1-6 months postintervention)|","Service use: average number of hospital admissions (1-6 months postintervention)",6,5,"","reported","reported",2,0,0.187784737323941,0,2004.5,0,72
"CD013541","CD013541_pub2_data","6|6|Service use: average number of hospital admissions (> 6 months postintervention)|","Service use: average number of hospital admissions (> 6 months postintervention)",6,6,"","reported","reported",4,0,0.140284516316653,0,2009,0,92.5
"CD013541","CD013541_pub2_data","6|7|Service use: days in hospital (≤ 1 month postintervention)|","Service use: days in hospital (≤ 1 month postintervention)",6,7,"","reported","reported",6,0,0.522093682161402,0,2008,0,81
"CD013541","CD013541_pub2_data","6|8|Service use: days in hospital (1-6 months postintervention)|","Service use: days in hospital (1-6 months postintervention)",6,8,"","reported","reported",2,0,1.16793111048466,0,2004.5,0,72
"CD013541","CD013541_pub2_data","6|9|Service use: days in hospital (> 6 months postintervention)|","Service use: days in hospital (> 6 months postintervention)",6,9,"","reported","reported",5,0,0.628088536664788,0,2008.8,0,87.6
"CD013541","CD013541_pub2_data","7|1|Mental state: overall (≤ 1 month postintervention, negative outcome)|","Mental state: overall (≤ 1 month postintervention, negative outcome)",7,1,"","reported","reported",7,0,0.380187426617008,0,2012.71428571429,0,73.1428571428571
"CD013541","CD013541_pub2_data","7|10|Mental state: insight (≤ 1 month postintervention, positive outcome)|Post-intervention mean","Mental state: insight (≤ 1 month postintervention, positive outcome)",7,10,"Post-intervention mean","or","binary",2,-0.0193768172568799,1.43062706842331,0,2015,0,51
"CD013541","CD013541_pub2_data","7|2|Mental state: overall (> 6 months postintervention, negative outcome)|","Mental state: overall (> 6 months postintervention, negative outcome)",7,2,"","reported","reported",2,0,0.736522462018848,0,2009,0,84
"CD013541","CD013541_pub2_data","7|4|Mental state: positive symptoms (≤ 1 month postintervention, negative outcome)|","Mental state: positive symptoms (≤ 1 month postintervention, negative outcome)",7,4,"","reported","reported",6,0,0.105452103254803,0,2013.5,0,63
"CD013541","CD013541_pub2_data","7|5|Mental state: positive symptoms (1-6 months postintervention, negative outcome)|","Mental state: positive symptoms (1-6 months postintervention, negative outcome)",7,5,"","reported","reported",2,0,1.0922162902007,0,2007.5,0,75.5
"CD013541","CD013541_pub2_data","7|6|Mental state: positive symptoms (> 6 months postintervention, negative outcome)|","Mental state: positive symptoms (> 6 months postintervention, negative outcome)",7,6,"","reported","reported",2,0,0.74077172391527,0,2009,0,101
"CD013541","CD013541_pub2_data","7|7|Mental state: negative symptoms (≤ 1 month postintervention, negative outcome)|","Mental state: negative symptoms (≤ 1 month postintervention, negative outcome)",7,7,"","reported","reported",4,0,0.289650029722743,0,2014,0,51.75
"CD013541","CD013541_pub2_data","7|8|Mental state: general psychopathology (≤ 1 month postintervention, negative outcome)|","Mental state: general psychopathology (≤ 1 month postintervention, negative outcome)",7,8,"","reported","reported",2,0,1.8198089998363,0,2015,0,52.5
"CD013541","CD013541_pub2_data","7|9|Mental state: mania-hostility symptoms (≤ 1 month postintervention, negative outcome)|","Mental state: mania-hostility symptoms (≤ 1 month postintervention, negative outcome)",7,9,"","or","binary",2,-0.175155942231026,1.42528511005038,0,2009,0,63.5
"CD013541","CD013541_pub2_data","8|1|Functioning: overall (≤ 1 month postintervention)|","Functioning: overall (≤ 1 month postintervention)",8,1,"","reported","reported",6,0,0.0960513993064453,0,2008.5,0,83.3333333333333
"CD013541","CD013541_pub2_data","8|2|Functioning: overall (> 6 months postintervention)|","Functioning: overall (> 6 months postintervention)",8,2,"","reported","reported",4,0,2.84172651614176,0,2009,0,90.5
"CD013541","CD013541_pub2_data","8|4|Functioning: social functioning (≤ 1 month postintervention)|","Functioning: social functioning (≤ 1 month postintervention)",8,4,"","reported","reported",2,0,2.50911952994986,0,2000,0,46
"CD013561","CD013561_pub2_data","2|2|Adverse events|NA","Adverse events",2,2,NA,"reported","reported",4,0,0.281942984150329,0,2011.5,0.199462870886895,61.75
"CD013561","CD013561_pub2_data","2|3|Biochemical remission according to IGF-1 normalisation and GH < 1 ug/L|NA","Biochemical remission according to IGF-1 normalisation and GH < 1 ug/L",2,3,NA,"reported","reported",5,0,0.237480852252467,0,2009.4,0.383343323747156,53.4
"CD013561","CD013561_pub2_data","2|4|Biochemical remission according to normalisation of IGF-1|NA","Biochemical remission according to normalisation of IGF-1",2,4,NA,"reported","reported",4,0,0.227183819283968,0,2011.5,0.476032029959692,61.75
"CD013561","CD013561_pub2_data","2|5|Biochemical remission according to normalisation of GH < 1 ug/L|NA","Biochemical remission according to normalisation of GH < 1 ug/L",2,5,NA,"reported","reported",2,0,0.364271261377329,0,2011,0.43969298245614,44
"CD013561","CD013561_pub2_data","2|7|Non-surgical therapy for recurrent or persistent disease|NA","Non-surgical therapy for recurrent or persistent disease",2,7,NA,"reported","reported",2,0,0.318736443404237,0,2012,0.250424448217317,50
"CD013571","CD013571_pub2_data","2|1|Participant-reported cure or improvement: immediately after treatment|NA","Participant-reported cure or improvement: immediately after treatment",2,1,NA,"or","binary",4,1.16954849598336,0.345633000375656,6.88008212175392e-07,1992.25,0.586546052631579,64.5
"CD013571","CD013571_pub2_data","2|11|Number of micturition episodes per 24 hours: immediately after treatment|NA","Number of micturition episodes per 24 hours: immediately after treatment",2,11,NA,"or","binary",3,0.0383781234725768,1.16572416413646,0,2009,0,58.3333333333333
"CD013571","CD013571_pub2_data","2|12|Number of micturition episodes per 24 hours: long-term effect (> 2 months after treatment)|NA","Number of micturition episodes per 24 hours: long-term effect (> 2 months after treatment)",2,12,NA,"or","binary",2,-0.0872358566767756,1.43015556245342,0,2010.5,0,56
"CD013571","CD013571_pub2_data","2|2|Participant-reported cure or improvement: long-term effect (> 2 months after treatment)|NA","Participant-reported cure or improvement: long-term effect (> 2 months after treatment)",2,2,NA,"or","binary",2,1.02294271938822,0.335212665079405,0,1991,0.421052631578947,75
"CD013571","CD013571_pub2_data","2|3|Symptom-related quality of life (QoL): immediately after treatment|NA","Symptom-related quality of life (QoL): immediately after treatment",2,3,NA,"or","binary",2,-0.0447322681856119,1.42843755375873,0,2010.5,0,58.5
"CD013571","CD013571_pub2_data","2|4|Symptom-related QoL: long-term effect (> 2 months after treatment)|NA","Symptom-related QoL: long-term effect (> 2 months after treatment)",2,4,NA,"or","binary",2,-0.0872358566767756,1.43015556245342,0,2010.5,0,56
"CD013571","CD013571_pub2_data","2|5|Adverse events: immediately after treatment|NA","Adverse events: immediately after treatment",2,5,NA,"or","binary",3,-4.06079992706465,0.848318412356468,0,1994,0.496686507936508,62.3333333333333
"CD013571","CD013571_pub2_data","2|7|Number of incontinence episodes per 24 hours: immediately after treatment|NA","Number of incontinence episodes per 24 hours: immediately after treatment",2,7,NA,"or","binary",2,-0.0447322681856119,1.42843755375873,0,2010.5,0,58.5
"CD013571","CD013571_pub2_data","2|8|Number of incontinence episodes per 24 hours: long-term effect (> 2 months after treatment)|NA","Number of incontinence episodes per 24 hours: long-term effect (> 2 months after treatment)",2,8,NA,"or","binary",2,-0.0872358566767756,1.43015556245342,0,2010.5,0,56
"CD013571","CD013571_pub2_data","2|9|Number of urgency episodes per 24 hours: immediately after treatment|NA","Number of urgency episodes per 24 hours: immediately after treatment",2,9,NA,"or","binary",2,0.0457407272719987,1.43028885796752,0,2007,0,46
"CD013571","CD013571_pub2_data","3|1|Symptom-related quality of life (QoL): immediately after treatment|NA","Symptom-related quality of life (QoL): immediately after treatment",3,1,NA,"or","binary",2,0.0184680752051827,1.42211414588409,0,2015.5,0,89
"CD013571","CD013571_pub2_data","4|1|Participant-reported cure or improvement: immediately after treatment|NA","Participant-reported cure or improvement: immediately after treatment",4,1,NA,"or","binary",2,0.268946819200575,0.188889416144476,0,2004.5,0.666585603112841,282
"CD013571","CD013571_pub2_data","4|10|Number of urgency episodes per 24 hours: immediately after treatment|NA","Number of urgency episodes per 24 hours: immediately after treatment",4,10,NA,"or","binary",4,0.0949748458957235,1.00669934434659,0,2006.75,0,294.25
"CD013571","CD013571_pub2_data","4|11|Number of urgency episodes per 24 hours: long-term effect (> 2 months after treatment)|NA","Number of urgency episodes per 24 hours: long-term effect (> 2 months after treatment)",4,11,NA,"or","binary",2,0.0512927791032932,1.42811457483219,0,2009,0,313.5
"CD013571","CD013571_pub2_data","4|12|Number of micturition episodes per 24 hours: immediately after treatment|NA","Number of micturition episodes per 24 hours: immediately after treatment",4,12,NA,"or","binary",4,0.0938142701598814,1.00669664248934,0,2006.75,0,295.5
"CD013571","CD013571_pub2_data","4|13|Number of micturition episodes per 24 hours: long-term effect (> 2 months after treatment)|NA","Number of micturition episodes per 24 hours: long-term effect (> 2 months after treatment)",4,13,NA,"or","binary",2,0.0512927791032932,1.42811457483219,0,2009,0,313.5
"CD013571","CD013571_pub2_data","4|2|Symptom-related quality of life (QoL): immediately after treatment|NA","Symptom-related quality of life (QoL): immediately after treatment",4,2,NA,"or","binary",2,0.150019160540176,1.42697562453853,0,2009,0,315
"CD013571","CD013571_pub2_data","4|3|Symptom-related QOL: long-term effect (> 2 months after treatment)|NA","Symptom-related QOL: long-term effect (> 2 months after treatment)",4,3,NA,"or","binary",2,0.0512927791032932,1.42811457483219,0,2009,0,313.5
"CD013571","CD013571_pub2_data","4|8|Number of incontinence episodes per 24 hours: immediately after treatment|NA","Number of incontinence episodes per 24 hours: immediately after treatment",4,8,NA,"or","binary",3,0.141932452733607,1.16226577868863,0,2007,0,310.333333333333
"CD013571","CD013571_pub2_data","4|9|Number of incontinence episodes per 24 hours: long-term effect (> 2 months after treatment)|NA","Number of incontinence episodes per 24 hours: long-term effect (> 2 months after treatment)",4,9,NA,"or","binary",2,0.0512927791032932,1.42811457483219,0,2009,0,313.5
"CD013590","CD013590_pub2_data","10|4|Haemoglobin status|Mean change from baseline in haemoglobin (g/L) (at up to 12 months)","Haemoglobin status",10,4,"Mean change from baseline in haemoglobin (g/L) (at up to 12 months)","or","binary",2,0,1.44729151697067,0,2007,0,75
"CD013590","CD013590_pub2_data","10|5|Laboratory markers of haemolysis and inflammation|Platelet count 103/μL (mean count at up to 12 months)","Laboratory markers of haemolysis and inflammation",10,5,"Platelet count 103/μL (mean count at up to 12 months)","or","binary",2,0,1.44729151697067,0,2007,0,75
"CD013590","CD013590_pub2_data","10|5|Laboratory markers of haemolysis and inflammation|Total white blood cells 103/μL (mean count at up to 12 months)","Laboratory markers of haemolysis and inflammation",10,5,"Total white blood cells 103/μL (mean count at up to 12 months)","or","binary",2,0,1.44729151697067,0,2007,0,75
"CD013590","CD013590_pub2_data","15|1|Frequency of SCD-related complications (improvement in leg ulcer size)|Mean reduction in leg ulcer areas (cm) (change from baseline at up to six months)","Frequency of SCD-related complications (improvement in leg ulcer size)",15,1,"Mean reduction in leg ulcer areas (cm) (change from baseline at up to six months)","reported","reported",2,-22.871739396163,7.67976879554612,0,2005.5,0,23
"CD013590","CD013590_pub2_data","15|2|Frequency of SCD-related complications (leg ulcer healing rate) |Number of completely-healed leg ulcers (at up to 6 months)","Frequency of SCD-related complications (leg ulcer healing rate) ",15,2,"Number of completely-healed leg ulcers (at up to 6 months)","reported","reported",2,0.325218635205408,0.392464271260161,0,2005.5,0,23
"CD013590","CD013590_pub2_data","9|2|Severity of pain|Dose of opioid use mg/kg (mean difference post intervention at up to 6 months)","Severity of pain",9,2,"Dose of opioid use mg/kg (mean difference post intervention at up to 6 months)","or","binary",2,-0.0118129308085464,1.42539389181447,0,2017,0,62.5
"CD013590","CD013590_pub2_data","9|2|Severity of pain|Mean change from baseline in pain scores using a 10-cm visual analogue scale, at up to 6 months (lower score is better )","Severity of pain",9,2,"Mean change from baseline in pain scores using a 10-cm visual analogue scale, at up to 6 months (lower score is better )","reported","reported",2,0,0.119558334425413,0,2017,0,62.5
"CD013590","CD013590_pub2_data","9|3| Frequency of hospitalization|Mean length of hospitalization in days (at up to 6 months)"," Frequency of hospitalization",9,3,"Mean length of hospitalization in days (at up to 6 months)","or","binary",2,-0.0118129308085464,1.42539389181447,0,2017,0,62.5
"CD013590","CD013590_pub2_data","9|4|Haemoglobin status (g/dL)|Mean change from baseline in g/dL (at up to 6 months)","Haemoglobin status (g/dL)",9,4,"Mean change from baseline in g/dL (at up to 6 months)","or","binary",2,0,1.42728750138775,0,2016,0,53
"CD013590","CD013590_pub2_data","9|5|Laboratory markers of haemolysis and inflammation|Platelets (x 109/L) (mean change from baseline at up to 6 months)","Laboratory markers of haemolysis and inflammation",9,5,"Platelets (x 109/L) (mean change from baseline at up to 6 months)","or","binary",2,0,1.42728750138775,0,2016,0,53
"CD013590","CD013590_pub2_data","9|5|Laboratory markers of haemolysis and inflammation|Reticulocytes % (mean change from baseline at up to 6 months)","Laboratory markers of haemolysis and inflammation",9,5,"Reticulocytes % (mean change from baseline at up to 6 months)","or","binary",2,0,1.42728750138775,0,2016,0,53
"CD013591","CD013591_pub2_data","1|1|Physical activity (moderate to vigorous physical activity)|Short-term: 3 to 4 months (MVPA in min/week)","Physical activity (moderate to vigorous physical activity)",1,1,"Short-term: 3 to 4 months (MVPA in min/week)","reported","reported",2,0,4.47835479647364,0,2020.5,0,89.5
"CD013591","CD013591_pub2_data","1|3|Anthropometric measures (BMI)|Medium-term: 6 to 8 months (BMI)","Anthropometric measures (BMI)",1,3,"Medium-term: 6 to 8 months (BMI)","or","binary",2,0,1.42403506259701,0,2016,0,73
"CD013591","CD013591_pub2_data","1|3|Anthropometric measures (BMI)|Short-term: 3 to 4 months (BMI)","Anthropometric measures (BMI)",1,3,"Short-term: 3 to 4 months (BMI)","reported","reported",4,0,0.0681762465468604,0,2019.75,0,76.5
"CD013591","CD013591_pub2_data","1|3|Anthropometric measures (BMI)|Short-term: 3 to 4 months (BMI) - only change data","Anthropometric measures (BMI)",1,3,"Short-term: 3 to 4 months (BMI) - only change data","reported","reported",3,0,0.0682239194727392,0,2020,0,82
"CD013591","CD013591_pub2_data","1|4|Anthropometric measures (body weight)|Long-term: 12 months","Anthropometric measures (body weight)",1,4,"Long-term: 12 months","reported","reported",2,0,0.787727775327534,0,2018.5,0,197
"CD013591","CD013591_pub2_data","1|4|Anthropometric measures (body weight)|Short-term: 3 to 4 months","Anthropometric measures (body weight)",1,4,"Short-term: 3 to 4 months","reported","reported",6,0,0.135380965733909,0,2020.5,0,185.166666666667
"CD013591","CD013591_pub2_data","1|6|Dietary behaviour (fruit/vegetable intake)|Short-term: 3 to 4 months","Dietary behaviour (fruit/vegetable intake)",1,6,"Short-term: 3 to 4 months","or","binary",2,0.519340468058988,1.43720393516892,0,2021,0,75
"CD013591","CD013591_pub2_data","1|7|Dietary behaviour (energy intake)|Short-term: 3 months","Dietary behaviour (energy intake)",1,7,"Short-term: 3 months","reported","reported",2,0,61.8983885748097,0,2020,0,96
"CD013595","CD013595_pub2_data","1|1|Overall survival|","Overall survival",1,1,"","reported","reported",2,-0.453305893552456,0.0888936286987292,0,NA,0,721.5
"CD013595","CD013595_pub2_data","2|1|Progression-free survival|","Progression-free survival",2,1,"","reported","reported",3,-0.744753785386419,0.110766040669479,0.0172571512273615,NA,0,554.333333333333
"CD013595","CD013595_pub2_data","3|2|EORTC 9 month|","EORTC 9 month",3,2,"","reported","reported",2,0,1.59325713013736,0,NA,0,318.5
"CD013595","CD013595_pub2_data","3|3|EORTC 12 month|","EORTC 12 month",3,3,"","reported","reported",2,0,1.67150997491214,0,NA,0,313.5
"CD013595","CD013595_pub2_data","3|4|EQ-5D 3 month|","EQ-5D 3 month",3,4,"","or","binary",2,-0.0846909321245474,1.41556181883158,0,NA,0,525.5
"CD013595","CD013595_pub2_data","3|5|EQ-5D 9 month|","EQ-5D 9 month",3,5,"","or","binary",2,-0.200944609351442,1.41584906395358,0,NA,0,437
"CD013595","CD013595_pub2_data","3|6|EQ-5D 12 month|","EQ-5D 12 month",3,6,"","or","binary",2,-0.184262240752357,1.41589836979308,0,NA,0,424
"CD013595","CD013595_pub2_data","4|1|On-study mortality|","On-study mortality",4,1,"","or","binary",3,-0.485031501590238,0.110340087460739,7.31753442177293e-08,NA,0.293973670986526,548
"CD013595","CD013595_pub2_data","6|10|Nausea|","Nausea",6,10,"","or","binary",2,0.276564413804525,0.309817389191805,0.161618937570211,NA,0.227892577973841,714.5
"CD013595","CD013595_pub2_data","8|1|Minimal residual disease negativity|","Minimal residual disease negativity",8,1,"","reported","reported",2,0,0.151141986471768,0,NA,0.0893393393393393,478.5
"CD013613","CD013613_pub2_data","1|10|Depression severity at study endpoint|NA","Depression severity at study endpoint",1,10,NA,"or","binary",2,0.322820406147476,1.44492687049886,0,2013.5,0,23.5
"CD013613","CD013613_pub2_data","1|15|Dropout for any reason at study endpoint|NA","Dropout for any reason at study endpoint",1,15,NA,"or","binary",3,-0.048971379450894,0.193917209118925,0,2015,0.379595512977974,143.333333333333
"CD013613","CD013613_pub2_data","1|2|PTSD severity at study endpoint|NA","PTSD severity at study endpoint",1,2,NA,"or","binary",3,0.136193888443678,1.16873980772948,0,2015,0,85
"CD013613","CD013613_pub2_data","1|7|PTSD rate at study endpoint|NA","PTSD rate at study endpoint",1,7,NA,"or","binary",2,0.267887449734396,0.69540501747951,0,2013.5,0.2,23.5
"CD013613","CD013613_pub2_data","1|8|Sensitivity analysis: PTSD rate at study endpoint (cases out of randomised)|NA","Sensitivity analysis: PTSD rate at study endpoint (cases out of randomised)",1,8,NA,"or","binary",2,0.0292206978118007,0.618743623003307,0,2013.5,0.130434782608696,38.5
"CD013613","CD013613_pub2_data","2|1|PTSD severity at three months|NA","PTSD severity at three months",2,1,NA,"or","binary",3,-0.0480971362942483,1.17208447316499,0,2015.33333333333,0,45.3333333333333
"CD013613","CD013613_pub2_data","2|10|Depression severity at study endpoint|NA","Depression severity at study endpoint",2,10,NA,"or","binary",3,-0.00165856070058857,1.17152237517041,0,2015.33333333333,0,52
"CD013613","CD013613_pub2_data","2|11|Anxiety severity at three months|NA","Anxiety severity at three months",2,11,NA,"or","binary",2,-0.187761752126638,1.43807635591548,0,2016.5,0,46.5
"CD013613","CD013613_pub2_data","2|12|Anxiety severity at study endpoint|NA","Anxiety severity at study endpoint",2,12,NA,"or","binary",2,-0.117686411228826,1.43703853287438,0,2016.5,0,56.5
"CD013613","CD013613_pub2_data","2|14|Dropout for any reason at three months|NA","Dropout for any reason at three months",2,14,NA,"or","binary",3,0.0649450334246528,0.47889089023535,0.367443973824834,2015.33333333333,0.301253918495298,69
"CD013613","CD013613_pub2_data","2|15|Dropout for any reason at study endpoint|NA","Dropout for any reason at study endpoint",2,15,NA,"or","binary",3,0.136412373555193,0.413104031514987,0.169296925982277,2015.33333333333,0.232288401253919,69
"CD013613","CD013613_pub2_data","2|2|PTSD severity at study endpoint|NA","PTSD severity at study endpoint",2,2,NA,"or","binary",3,-0.00165856070058857,1.17152237517041,0,2015.33333333333,0,52
"CD013613","CD013613_pub2_data","2|3|Dropouts due to adverse events at three months|NA","Dropouts due to adverse events at three months",2,3,NA,"or","binary",2,0.697636849816744,1.27586954603764,0,2017.5,0,91
"CD013613","CD013613_pub2_data","2|4|Dropouts due to adverse events at study endpoint|NA","Dropouts due to adverse events at study endpoint",2,4,NA,"or","binary",2,0.697636849816744,1.27586954603764,0,2017.5,0,91
"CD013613","CD013613_pub2_data","2|5|PTSD rate at three months|NA","PTSD rate at three months",2,5,NA,"or","binary",3,-0.928032635596611,0.936676366637328,1.1666590993903,2015.33333333333,0.196969696969697,45.3333333333333
"CD013613","CD013613_pub2_data","2|6|Sensitivity analysis: PTSD rate at three months (cases out of randomised)|NA","Sensitivity analysis: PTSD rate at three months (cases out of randomised)",2,6,NA,"or","binary",3,-1.01140609404759,1.07027144500323,1.9232068961239,2015.33333333333,0.147544409613375,69
"CD013613","CD013613_pub2_data","2|7|PTSD rate at study endpoint|NA","PTSD rate at study endpoint",2,7,NA,"or","binary",3,-0.981412517731652,0.804438184883313,0.622033835585895,2015.33333333333,0.196296296296296,52
"CD013613","CD013613_pub2_data","2|8|Sensitivity analysis: PTSD rate at study endpoint (cases out of randomised)|NA","Sensitivity analysis: PTSD rate at study endpoint (cases out of randomised)",2,8,NA,"or","binary",3,-1.10803942925452,0.90316615818238,1.05770585569889,2015.33333333333,0.153291536050157,69
"CD013613","CD013613_pub2_data","2|9|Depression severity at three months|NA","Depression severity at three months",2,9,NA,"or","binary",3,-0.0480971362942483,1.17208447316499,0,2015.33333333333,0,45.3333333333333
"CD013614","CD013614_pub2_data","1|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Adalimumab vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,"Adalimumab vs Placebo","or","binary",7,1.80442320272047,0.196665251020189,0.11091066783251,2015.42857142857,0.079440660243259,314.857142857143
"CD013614","CD013614_pub2_data","1|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Etanercept vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,"Etanercept vs Placebo","or","binary",2,2.55554752006588,0.426640155325734,0,2002,0.0407051282051282,132.5
"CD013614","CD013614_pub2_data","1|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Golimumab vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,"Golimumab vs Placebo","or","binary",2,2.65046485672247,0.437196292374975,0.160610580104718,2013,0.0358055318991373,442.5
"CD013614","CD013614_pub2_data","1|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Infliximab vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,"Infliximab vs Placebo","or","binary",2,3.12705613874613,0.712785534738927,0.305588421551484,2005,0.015,152
"CD013614","CD013614_pub2_data","1|10|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).|Golimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",1,10,"Golimumab vs Placebo","or","binary",2,-0.497265060001281,1.41606893612618,0,2013,0,430
"CD013614","CD013614_pub2_data","1|11|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). |Adalimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",1,11,"Adalimumab vs Placebo","or","binary",3,0.0221886758931094,1.15653541149407,0,2014.33333333333,0,419
"CD013614","CD013614_pub2_data","1|11|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). |Golimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",1,11,"Golimumab vs Placebo","or","binary",2,-0.495218556845054,1.41607399755528,0,2013,0,428.5
"CD013614","CD013614_pub2_data","1|12|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). |Adalimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",1,12,"Adalimumab vs Placebo","or","binary",3,0.0221886758931094,1.15653541149407,0,2014.33333333333,0,419
"CD013614","CD013614_pub2_data","1|12|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). |Golimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",1,12,"Golimumab vs Placebo","or","binary",2,-0.495218556845054,1.41607399755528,0,2013,0,428.5
"CD013614","CD013614_pub2_data","1|13|Radiographic progression (change from baseline) at 24 weeks|Adalimumab vs Placebo","Radiographic progression (change from baseline) at 24 weeks",1,13,"Adalimumab vs Placebo","or","binary",3,0.0233721407063185,1.1565264324612,0,2014.33333333333,0,419.666666666667
"CD013614","CD013614_pub2_data","1|13|Radiographic progression (change from baseline) at 24 weeks|Golimumab vs Placebo","Radiographic progression (change from baseline) at 24 weeks",1,13,"Golimumab vs Placebo","or","binary",2,-0.473106170354777,1.41603748365724,0,2013,0,439.5
"CD013614","CD013614_pub2_data","1|14|Number of patients with serious adverse events at any time |Adalimumab vs Placebo","Number of patients with serious adverse events at any time ",1,14,"Adalimumab vs Placebo","or","binary",7,0.111768440759576,0.25315649743331,0,2015.42857142857,0.0276989972343175,314.857142857143
"CD013614","CD013614_pub2_data","1|14|Number of patients with serious adverse events at any time |Etanercept vs Placebo","Number of patients with serious adverse events at any time ",1,14,"Etanercept vs Placebo","or","binary",2,-0.138563359328726,0.630190462482707,0,2002,0.0358974358974359,132.5
"CD013614","CD013614_pub2_data","1|14|Number of patients with serious adverse events at any time |Golimumab vs Placebo","Number of patients with serious adverse events at any time ",1,14,"Golimumab vs Placebo","or","binary",2,-0.548212598345407,0.426004700782985,0.0936638277902546,2013,0.0477098530010738,442
"CD013614","CD013614_pub2_data","1|15|(OR) Number of patients with serious adverse events at any time |Adalimumab vs Placebo","(OR) Number of patients with serious adverse events at any time ",1,15,"Adalimumab vs Placebo","or","binary",7,0.111768440759576,0.25315649743331,0,2015.42857142857,0.0276989972343175,314.857142857143
"CD013614","CD013614_pub2_data","1|15|(OR) Number of patients with serious adverse events at any time |Etanercept vs Placebo","(OR) Number of patients with serious adverse events at any time ",1,15,"Etanercept vs Placebo","or","binary",2,-0.138563359328726,0.630190462482707,0,2002,0.0358974358974359,132.5
"CD013614","CD013614_pub2_data","1|15|(OR) Number of patients with serious adverse events at any time |Golimumab vs Placebo","(OR) Number of patients with serious adverse events at any time ",1,15,"Golimumab vs Placebo","or","binary",2,-0.548212598345407,0.426004700782985,0.0936638277902546,2013,0.0477098530010738,442
"CD013614","CD013614_pub2_data","1|16|Withdrawal due to adverse events|Adalimumab vs Placebo","Withdrawal due to adverse events",1,16,"Adalimumab vs Placebo","or","binary",7,0.493443020266895,0.264335777467055,0,2015.42857142857,0.0164556109909312,314.857142857143
"CD013614","CD013614_pub2_data","1|16|Withdrawal due to adverse events|Etanercept vs Placebo","Withdrawal due to adverse events",1,16,"Etanercept vs Placebo","or","binary",2,0.0220695573876557,1.00753641849335,0,2002,0.00480769230769231,132.5
"CD013614","CD013614_pub2_data","1|16|Withdrawal due to adverse events|Golimumab vs Placebo","Withdrawal due to adverse events",1,16,"Golimumab vs Placebo","or","binary",2,-0.224498741176138,0.628039832151721,0.381808245773587,2013,0.0284000444329248,442
"CD013614","CD013614_pub2_data","1|16|Withdrawal due to adverse events|Infliximab vs Placebo","Withdrawal due to adverse events",1,16,"Infliximab vs Placebo","or","binary",2,0.983945059517688,0.697581485411983,0,2005,0.0146153846153846,152
"CD013614","CD013614_pub2_data","1|17|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Adalimumab vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",1,17,"Adalimumab vs Placebo","or","binary",7,1.38408859342369,0.209033275590013,0.210344615292195,2015.42857142857,0.256232633307282,314.857142857143
"CD013614","CD013614_pub2_data","1|17|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Etanercept vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",1,17,"Etanercept vs Placebo","or","binary",2,2.20182330151056,0.298064971897846,0,2002,0.143589743589744,132.5
"CD013614","CD013614_pub2_data","1|17|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Golimumab vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",1,17,"Golimumab vs Placebo","or","binary",2,2.32506153681144,0.18264677061899,0,2013,0.153034398489281,442.5
"CD013614","CD013614_pub2_data","1|17|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Infliximab vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",1,17,"Infliximab vs Placebo","or","binary",3,2.50334428899316,0.301471068250055,0,2006.66666666667,0.17982905982906,103.333333333333
"CD013614","CD013614_pub2_data","1|18|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.|Adalimumab vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",1,18,"Adalimumab vs Placebo","or","binary",3,1.31338237653378,0.327645746683036,0.265077236492515,2014.33333333333,0.300523861208994,458
"CD013614","CD013614_pub2_data","1|18|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.|Golimumab vs Placebo","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",1,18,"Golimumab vs Placebo","or","binary",2,2.27680528678033,0.175010825613952,0,2013,0.183285814788758,442.5
"CD013614","CD013614_pub2_data","1|19|Enthesitis: resolution as LEI=0 at 12 weeks|Adalimumab vs Placebo","Enthesitis: resolution as LEI=0 at 12 weeks",1,19,"Adalimumab vs Placebo","or","binary",4,0.607811758391457,0.143171808320688,4.31476204720166e-06,2019.5,0.309543228482953,216
"CD013614","CD013614_pub2_data","1|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks|Adalimumab vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",1,2,"Adalimumab vs Placebo","or","binary",3,1.50955021447429,0.303980491177497,0.196483757700642,2014.33333333333,0.133932362265473,458
"CD013614","CD013614_pub2_data","1|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks|Golimumab vs Placebo","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",1,2,"Golimumab vs Placebo","or","binary",2,2.7514466458419,0.252025241938728,0,2013,0.0490798681823231,442.5
"CD013614","CD013614_pub2_data","1|20|Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks|Adalimumab vs Placebo","Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks",1,20,"Adalimumab vs Placebo","or","binary",2,-0.0644088543579064,1.41989786709051,0,2017,0,124.5
"CD013614","CD013614_pub2_data","1|21|Enthesitis: resolution as LEI=0 at 24 weeks|Adalimumab vs Placebo","Enthesitis: resolution as LEI=0 at 24 weeks",1,21,"Adalimumab vs Placebo","or","binary",2,0.635481999214525,0.169689607411071,0,2019,0.258316954211254,308.5
"CD013614","CD013614_pub2_data","1|23|Resolution of dactylitis as no dactylitis at 12 weeks|Adalimumab vs Placebo","Resolution of dactylitis as no dactylitis at 12 weeks",1,23,"Adalimumab vs Placebo","or","binary",4,0.887155289644309,0.254054833360882,0.0706072130812393,2019.5,0.457347489675076,114.75
"CD013614","CD013614_pub2_data","1|24|Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.|Adalimumab vs Placebo","Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",1,24,"Adalimumab vs Placebo","or","binary",3,0.108699415514355,1.16268947361976,0,2013.66666666667,0,83.6666666666667
"CD013614","CD013614_pub2_data","1|25|Resolution of dactylitis as no dactylitis at 24 weeks|Adalimumab vs Placebo","Resolution of dactylitis as no dactylitis at 24 weeks",1,25,"Adalimumab vs Placebo","or","binary",2,1.57981737312509,0.286354614334364,0.0249347067302022,2019,0.323412698412698,149.5
"CD013614","CD013614_pub2_data","1|27|Improvement in pain as measured by VAS or NRS at week 12.|Adalimumab vs Placebo","Improvement in pain as measured by VAS or NRS at week 12.",1,27,"Adalimumab vs Placebo","or","binary",6,0.12068919486585,0.818301105063756,0,2015,0,341.166666666667
"CD013614","CD013614_pub2_data","1|27|Improvement in pain as measured by VAS or NRS at week 12.|Infliximab vs Placebo","Improvement in pain as measured by VAS or NRS at week 12.",1,27,"Infliximab vs Placebo","or","binary",2,0,1.41932683448582,0,2005,0,152
"CD013614","CD013614_pub2_data","1|28|Improvement in pain as measured by VAS or NRS at week 24.|Adalimumab vs Placebo","Improvement in pain as measured by VAS or NRS at week 24.",1,28,"Adalimumab vs Placebo","or","binary",3,0.0161810702265264,1.15649304688645,0,2014.33333333333,0,425.666666666667
"CD013614","CD013614_pub2_data","1|29|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.|Adalimumab vs Placebo","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",1,29,"Adalimumab vs Placebo","or","binary",6,1.8314866313486,0.277519622797541,0.263864181018313,2016.83333333333,0.146502572239106,184.333333333333
"CD013614","CD013614_pub2_data","1|29|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.|Golimumab vs Placebo","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",1,29,"Golimumab vs Placebo","or","binary",2,2.65070830466935,0.583610326206653,0.480510138471848,2013,0.0808400460299194,345
"CD013614","CD013614_pub2_data","1|29|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.|Infliximab vs Placebo","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",1,29,"Infliximab vs Placebo","or","binary",2,4.65019765549397,0.628272100465936,0,2005,0.0114942528735632,104.5
"CD013614","CD013614_pub2_data","1|3|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks|Adalimumab vs Placebo","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",1,3,"Adalimumab vs Placebo","or","binary",4,1.57301717686495,0.149777198952418,0,2019.75,0.107208929608036,395
"CD013614","CD013614_pub2_data","1|3|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks|Golimumab vs Placebo","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",1,3,"Golimumab vs Placebo","or","binary",2,2.32022573424677,0.423731146842177,0.110534581940362,2013,0.0253452808531122,442.5
"CD013614","CD013614_pub2_data","1|30|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.|Adalimumab vs Placebo","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",1,30,"Adalimumab vs Placebo","or","binary",3,2.43047161678695,0.77195456110882,1.50153019331569,2014.33333333333,0.128124403055128,231.666666666667
"CD013614","CD013614_pub2_data","1|30|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.|Golimumab vs Placebo","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",1,30,"Golimumab vs Placebo","or","binary",2,3.21648221680255,0.893443084124021,1.27481999039587,2013,0.0719856795806163,345
"CD013614","CD013614_pub2_data","1|31|Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.|Adalimumab vs Placebo","Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",1,31,"Adalimumab vs Placebo","or","binary",5,0.131882006773508,0.896450961111121,0,2014.6,0,362.2
"CD013614","CD013614_pub2_data","1|32|Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.|Adalimumab vs Placebo","Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",1,32,"Adalimumab vs Placebo","or","binary",2,-0.00456657556885372,1.41587747435748,0,2013,0,526
"CD013614","CD013614_pub2_data","1|33|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). |Adalimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",1,33,"Adalimumab vs Placebo","or","binary",3,0.0221886758931094,1.15653541149407,0,2014.33333333333,0,419
"CD013614","CD013614_pub2_data","1|33|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). |Golimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",1,33,"Golimumab vs Placebo","or","binary",2,-0.495218556845054,1.41607399755528,0,2013,0,428.5
"CD013614","CD013614_pub2_data","1|4|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks|Adalimumab vs Placebo","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",1,4,"Adalimumab vs Placebo","or","binary",2,1.19544568417249,0.15887423132543,0,2019,0.136937419153397,529.5
"CD013614","CD013614_pub2_data","1|4|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks|Golimumab vs Placebo","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",1,4,"Golimumab vs Placebo","or","binary",2,1.9522693231945,0.381103149492056,0.164451676705286,2013,0.0584107823897508,442.5
"CD013614","CD013614_pub2_data","1|5|Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks|Golimumab vs Placebo","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",1,5,"Golimumab vs Placebo","or","binary",2,-0.497265060001281,1.41606893612618,0,2013,0,430
"CD013614","CD013614_pub2_data","1|5|Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks|Infliximab vs Placebo","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",1,5,"Infliximab vs Placebo","or","binary",2,0,1.41932683448582,0,2005,0,152
"CD013614","CD013614_pub2_data","1|6|MCID in HAQ proportion of patients at 12 weeks|Adalimumab vs Placebo","MCID in HAQ proportion of patients at 12 weeks",1,6,"Adalimumab vs Placebo","or","binary",4,0.745362955222826,0.120440441873976,0.00756764748462634,2019.5,0.315060542215773,365
"CD013614","CD013614_pub2_data","1|7|Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks|Adalimumab vs Placebo","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",1,7,"Adalimumab vs Placebo","or","binary",3,0.018238667342928,1.1564912167526,0,2014.33333333333,0,426
"CD013614","CD013614_pub2_data","1|7|Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks|Golimumab vs Placebo","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",1,7,"Golimumab vs Placebo","or","binary",2,-0.495218556845054,1.41607399755528,0,2013,0,428.5
"CD013614","CD013614_pub2_data","1|8|MCID in HAQ proportion of patients at 24 weeks|Adalimumab vs Placebo","MCID in HAQ proportion of patients at 24 weeks",1,8,"Adalimumab vs Placebo","or","binary",2,0.704777876499469,0.184629177559118,0.024920247804803,2019,0.316736152471709,467
"CD013614","CD013614_pub2_data","1|9|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). |Adalimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",1,9,"Adalimumab vs Placebo","or","binary",5,0.00970323327206886,0.896656866272523,0,2013.4,0,318.8
"CD013614","CD013614_pub2_data","1|9|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). |Golimumab vs Placebo","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",1,9,"Golimumab vs Placebo","or","binary",2,-0.497265060001281,1.41606893612618,0,2013,0,430
"CD013614","CD013614_pub2_data","2|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Golimumab (+ Methotrexate) vs Methotrexate","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",2,1,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,1.81205937937031,0.518730888292774,0.109144886539348,2019.5,0.188695652173913,47.5
"CD013614","CD013614_pub2_data","2|14|Number of patients with serious adverse events at any time|Golimumab (+ Methotreate) vs Methotrexate ","Number of patients with serious adverse events at any time",2,14,"Golimumab (+ Methotreate) vs Methotrexate ","or","binary",2,-1.11525658849523,1.17290383469618,0,2019.5,0.0417391304347826,47.5
"CD013614","CD013614_pub2_data","2|15|(OR) Number of patients with serious adverse events at any time|Golimumab (+ Methotreate) vs Methotrexate ","(OR) Number of patients with serious adverse events at any time",2,15,"Golimumab (+ Methotreate) vs Methotrexate ","or","binary",2,-1.11525658849523,1.17290383469618,0,2019.5,0.0417391304347826,47.5
"CD013614","CD013614_pub2_data","2|16|Withdrawal due to adverse events at any time|Golimumab (+ Methotrexate) vs Methotrexate","Withdrawal due to adverse events at any time",2,16,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,-0.258635044703246,1.0326323358556,0.5398359571801,2019.5,0.06,47.5
"CD013614","CD013614_pub2_data","2|17|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Golimumab (+ Methotrexate) vs Methotrexate","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",2,17,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,1.97576480190113,0.470539377524538,0,2019.5,0.375652173913044,47.5
"CD013614","CD013614_pub2_data","2|18|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks|Golimumab (+Methotrexate) vs Methotrexate","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",2,18,"Golimumab (+Methotrexate) vs Methotrexate","or","binary",2,1.06799183503238,0.448939917392442,0,2019.5,0.540869565217391,47.5
"CD013614","CD013614_pub2_data","2|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks|Golimumab (+ Methotrexate) vs Methotrexate","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,2,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,1.56247196240093,0.511138904025561,0.131638361998928,2019.5,0.312173913043478,47.5
"CD013614","CD013614_pub2_data","2|20|Enthesitis: resolution as LEI=0 at 12 weeks|Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","Enthesitis: resolution as LEI=0 at 12 weeks",2,20,"Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","or","binary",2,-0.906056981077038,1.11498864153068,0.892291736612994,2019.5,0.702380952380952,17
"CD013614","CD013614_pub2_data","2|21|Enthesitis: resolution as LEI=0 at 24 weeks|Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","Enthesitis: resolution as LEI=0 at 24 weeks",2,21,"Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","or","binary",2,0.902766121092898,0.925241959733307,0,2019.5,0.589285714285714,17
"CD013614","CD013614_pub2_data","2|22|Resolution of dactylitis as no dactylitis at 12 weeks|Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","Resolution of dactylitis as no dactylitis at 12 weeks",2,22,"Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","or","binary",2,-0.206814137641739,0.629059228556488,0,2019.5,0.27445652173913,30.5
"CD013614","CD013614_pub2_data","2|23|Resolution of dactylitis as no dactylitis at 24 weeks|Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","Resolution of dactylitis as no dactylitis at 24 weeks",2,23,"Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)","or","binary",2,0.704110234782916,0.648575173621005,0,2019.5,0.52445652173913,30.5
"CD013614","CD013614_pub2_data","2|4|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks|Golimumab (+ Methotrexate) vs Methotrexate","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",2,4,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,1.64074775260897,0.468667622920568,0,2019.5,0.165217391304348,47.5
"CD013614","CD013614_pub2_data","2|5|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks|Golimumab (+ Methotrexate) vs Methotrexate","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",2,5,"Golimumab (+ Methotrexate) vs Methotrexate","or","binary",2,1.37308213635884,0.876008603895762,1.14928437185025,2019.5,0.335652173913043,47.5
"CD013614","CD013614_pub2_data","4|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks|Adalimumab vs Ixekizumab","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",4,1,"Adalimumab vs Ixekizumab","or","binary",2,0.0750146050729108,0.147311188063054,0,2018.5,0.373171295531852,387
"CD013614","CD013614_pub2_data","4|10|Proportion of patients achieving MCID in HAQ at 24 weeks|Adalimumab vs Ixekizumab","Proportion of patients achieving MCID in HAQ at 24 weeks",4,10,"Adalimumab vs Ixekizumab","or","binary",2,-0.0306534842897385,0.156597619050517,0,2018.5,0.576323987538941,351
"CD013614","CD013614_pub2_data","4|15|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). |Adalimumab vs Ixekizumab","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",4,15,"Adalimumab vs Ixekizumab","or","binary",2,0.0286727338543219,1.41652664773378,0,2018.5,0,387
"CD013614","CD013614_pub2_data","4|16|Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). |Adalimumab vs Ixekizumab","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",4,16,"Adalimumab vs Ixekizumab","or","binary",2,0.0286727338543219,1.41652664773378,0,2018.5,0,387
"CD013614","CD013614_pub2_data","4|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks|Adalimumab vs Ixekizumab","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",4,2,"Adalimumab vs Ixekizumab","or","binary",2,-0.131567433191543,0.14441529384584,0,2018.5,0.453584756117698,387
"CD013614","CD013614_pub2_data","4|21|Number of patients with serious adverse events at any time|Adalimumab vs Ixekizumab","Number of patients with serious adverse events at any time",4,21,"Adalimumab vs Ixekizumab","or","binary",2,0.496098772833286,0.49734147654914,0.266793473885367,2018.5,0.0457052277005383,387
"CD013614","CD013614_pub2_data","4|22|Withdrawal due to adverse events|Adalimumab vs Ixekizumab","Withdrawal due to adverse events",4,22,"Adalimumab vs Ixekizumab","or","binary",2,0.495296394941888,0.412483495335846,0,2018.5,0.0217132855586011,387
"CD013614","CD013614_pub2_data","4|23|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks|Adalimumab vs Ixekizumab","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",4,23,"Adalimumab vs Ixekizumab","or","binary",2,0.00301678923117533,0.151117499561637,0,2018.5,0.620735774908358,387
"CD013614","CD013614_pub2_data","4|24|Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks|Adalimumab vs Ixekizumab","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",4,24,"Adalimumab vs Ixekizumab","or","binary",2,0.0997558267381386,0.153711977473841,0,2018.5,0.634242594366104,387
"CD013614","CD013614_pub2_data","4|28|Enthesitis: resolution as LEI=0 at 24 weeks|Adalimumab vs Ixekizumab","Enthesitis: resolution as LEI=0 at 24 weeks",4,28,"Adalimumab vs Ixekizumab","or","binary",2,-0.243612476387571,0.19658212188458,0,2018.5,0.511977432482427,214
"CD013614","CD013614_pub2_data","4|34|Resolution of dactylitis as no dactylitis at 24 weeks|Adalimumab vs Ixekizumab","Resolution of dactylitis as no dactylitis at 24 weeks",4,34,"Adalimumab vs Ixekizumab","or","binary",2,0.213937497388214,0.471581326828315,0,2018.5,0.837912087912088,78.5
"CD013614","CD013614_pub2_data","4|39|Improvement in pain as measured by VAS or NRS at week 24.|Adalimumab vs Ixekizumab","Improvement in pain as measured by VAS or NRS at week 24.",4,39,"Adalimumab vs Ixekizumab","or","binary",2,0.0286727338543219,1.41652664773378,0,2018.5,0,387
"CD013614","CD013614_pub2_data","4|41|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.|Adalimumab vs Ixekizumab","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",4,41,"Adalimumab vs Ixekizumab","or","binary",2,-1.35352507314427,0.323999629114185,0.133045400187785,2018.5,0.788373106152282,353.5
"CD013614","CD013614_pub2_data","4|42|Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.|Adalimumab vs Ixekizumab","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",4,42,"Adalimumab vs Ixekizumab","or","binary",2,-0.628331698904372,0.171412567363937,0,2018.5,0.757224454233022,353.5
"CD013614","CD013614_pub2_data","4|5|Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks|Adalimumab vs Ixekizumab","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,5,"Adalimumab vs Ixekizumab","or","binary",2,-0.264099610124326,0.292332167300387,0.116629547689644,2018.5,0.388048611340444,387
"CD013614","CD013614_pub2_data","4|9|Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks|Adalimumab vs Ixekizumab","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",4,9,"Adalimumab vs Ixekizumab","or","binary",2,0.0286727338543219,1.41652664773378,0,2018.5,0,387
"CD013614","CD013614_pub2_data","9|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex|Golimumab vs Placebo in female patients","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",9,1,"Golimumab vs Placebo in female patients","or","binary",2,2.1597621247597,0.496428968746257,0.152569018856063,2013,0.0508474576271186,196
"CD013614","CD013614_pub2_data","9|1|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex|Golimumab vs Placebo in male patients","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",9,1,"Golimumab vs Placebo in male patients","or","binary",2,2.86466866472376,0.433176898723826,0,2013,0.0268894478380644,246.5
"CD013614","CD013614_pub2_data","9|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex|Golimumab vs Placebo in female patients","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",9,2,"Golimumab vs Placebo in female patients","or","binary",2,2.55893669891793,0.490261805145538,0.198851309414574,2013,0.0523882896764253,196
"CD013614","CD013614_pub2_data","9|2|Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex|Golimumab vs Placebo in male patients","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",9,2,"Golimumab vs Placebo in male patients","or","binary",2,2.71064335769435,0.34041545532225,0,2013,0.0475506048628578,246.5
"CD013614","CD013614_pub2_data","9|3|Number of patients with serious adverse events at any time stratified for sex|Golimumab vs Placebo in female patients","Number of patients with serious adverse events at any time stratified for sex",9,3,"Golimumab vs Placebo in female patients","or","binary",2,-1.09205929994488,1.10153767692881,1.13546118711777,2013,0.0354391371340524,196
"CD013614","CD013614_pub2_data","9|3|Number of patients with serious adverse events at any time stratified for sex|Golimumab vs Placebo in male patients","Number of patients with serious adverse events at any time stratified for sex",9,3,"Golimumab vs Placebo in male patients","or","binary",2,-0.372279846496652,0.422563674017306,0,2013,0.0568930410827644,246.5
"CD013631","CD013631_pub2_data","2|11|Patient-reported outcomes: HRQoL at 24 weeks|CKD stage G5D with diabetes and hypertension","Patient-reported outcomes: HRQoL at 24 weeks",2,11,"CKD stage G5D with diabetes and hypertension","or","binary",2,-0.85560634592889,1.43923551811526,0,2019,0,32.5
"CD013631","CD013631_pub2_data","2|12|Adverse events: any adverse event|CKD stage 5GD","Adverse events: any adverse event",2,12,"CKD stage 5GD","or","binary",2,0.120428875818176,0.434425993341157,0,2019,0.13,73.5
"CD013631","CD013631_pub2_data","2|12|Adverse events: any adverse event|CKD stage G3a (transplant)","Adverse events: any adverse event",2,12,"CKD stage G3a (transplant)","or","binary",2,1.82568413677275,1.9669829819813,4.65327760440136,2015.5,0,32
"CD013631","CD013631_pub2_data","2|13|Withdrawals due to adverse events|CKD stage 3Ga (transplant)","Withdrawals due to adverse events",2,13,"CKD stage 3Ga (transplant)","or","binary",2,-0.490028260780034,1.43687919783924,0,2015.5,0,32
"CD013631","CD013631_pub2_data","2|13|Withdrawals due to adverse events|CKD stage G5D","Withdrawals due to adverse events",2,13,"CKD stage G5D","or","binary",2,-0.287677079332724,0.458164048768947,0,2019,0.13,73.5
"CD013631","CD013631_pub2_data","3|2|Uraemic toxins: indoxyl sulfate at 6 weeks|CKD stage G5D with diabetes","Uraemic toxins: indoxyl sulfate at 6 weeks",3,2,"CKD stage G5D with diabetes","or","binary",2,0,1.43675753407464,0,2015.5,0,32
"CD013631","CD013631_pub2_data","3|26|Adverse events: number participants reporting an event|CKD stage G5D","Adverse events: number participants reporting an event",3,26,"CKD stage G5D","or","binary",2,1.298355569931,1.82152994490711,5.19063329726961,2006,0.075,39.5
"CD013631","CD013631_pub2_data","3|3|Uraemic toxins: p-cresol sulfate at 6 weeks|CKD stage G5D with diabetes","Uraemic toxins: p-cresol sulfate at 6 weeks",3,3,"CKD stage G5D with diabetes","or","binary",2,0,1.43675753407464,0,2015.5,0,32
"CD013631","CD013631_pub2_data","6|1|Kidney function: eGFR at 6 or 12 weeks|CKD stage G3b","Kidney function: eGFR at 6 or 12 weeks",6,1,"CKD stage G3b","or","binary",2,-0.137219486838815,1.43355303928797,0,2018.5,0,49
"CD013631","CD013631_pub2_data","6|2|Kidney function: SrCr at 6 or 12 weeks|CKD stage G3b","Kidney function: SrCr at 6 or 12 weeks",6,2,"CKD stage G3b","or","binary",2,-0.137219486838815,1.43355303928797,0,2018.5,0,49
"CD013631","CD013631_pub2_data","7|1|Kidney function: serum creatinine at 8 or 12 weeks|CKD stage G5D","Kidney function: serum creatinine at 8 or 12 weeks",7,1,"CKD stage G5D","or","binary",2,-0.0135460095963649,1.4330063441901,0,2018,0,37.5
"CD013631","CD013631_pub2_data","7|3|Uraemic toxins: indoxyl sulfate at 8 weeks|CKD stage G5D","Uraemic toxins: indoxyl sulfate at 8 weeks",7,3,"CKD stage G5D","or","binary",2,-0.0135460095963649,1.4330063441901,0,2018,0,37.5
"CD013631","CD013631_pub2_data","8|12|Adverse events: any adverse event (number of participants)|CKD stage G5D","Adverse events: any adverse event (number of participants)",8,12,"CKD stage G5D","or","binary",2,1.53630501910194,0.827319960859832,0,2018,0.0217391304347826,52.5
"CD013631","CD013631_pub2_data","8|13|Withdrawals due to adverse events|CKD stage G5D","Withdrawals due to adverse events",8,13,"CKD stage G5D","or","binary",2,1.53630501910194,0.827319960859832,0,2018,0.0217391304347826,52.5
"CD013631","CD013631_pub2_data","8|2|Kidney function: serum creatinine at 8, 12 or 24 weeks|CKD stage G5D with diabetes and hypertension","Kidney function: serum creatinine at 8, 12 or 24 weeks",8,2,"CKD stage G5D with diabetes and hypertension","or","binary",2,0,1.42688339079448,0,2019,0,55
"CD013631","CD013631_pub2_data","8|2|Kidney function: serum creatinine at 8, 12 or 24 weeks|Diabetic nephropathy all CKD stages","Kidney function: serum creatinine at 8, 12 or 24 weeks",8,2,"Diabetic nephropathy all CKD stages","or","binary",2,0,1.42575835443665,0,2018.5,0,60
"CD013631","CD013631_pub2_data","8|3|Kidney function: albuminuria at 12 or 24 weeks|CKD stage G5D with diabetes and hypertension","Kidney function: albuminuria at 12 or 24 weeks",8,3,"CKD stage G5D with diabetes and hypertension","or","binary",3,0,1.16535208964462,0,2019.33333333333,0,53.3333333333333
"CD013631","CD013631_pub2_data","8|5|Uraemic toxins: urea at 12 or 24 weeks|CKD stage G5D with diabetes and hypertension","Uraemic toxins: urea at 12 or 24 weeks",8,5,"CKD stage G5D with diabetes and hypertension","or","binary",2,0,1.42688339079448,0,2019,0,55
"CD013631","CD013631_pub2_data","8|5|Uraemic toxins: urea at 12 or 24 weeks|Diabetic nephropathy all CKD stages","Uraemic toxins: urea at 12 or 24 weeks",8,5,"Diabetic nephropathy all CKD stages","or","binary",2,0,1.42575835443665,0,2018.5,0,60
"CD013631","CD013631_pub2_data","8|7|Uraemic toxins: p-cresyl sulfate at 4, 12 or 24 weeks|CKD stage G5D","Uraemic toxins: p-cresyl sulfate at 4, 12 or 24 weeks",8,7,"CKD stage G5D","or","binary",2,0.0293316547928381,1.43271575299147,0,2018,0,37.5
"CD013643","CD013643_pub2_data","1|1|Number of continent women (objective measure as reported by the trialists), short term (< 1 year)|","Number of continent women (objective measure as reported by the trialists), short term (< 1 year)",1,1,"","or","binary",3,0.823398823745423,0.364695168387186,0.0578754098667349,2021.66666666667,0.434088693957115,65.3333333333333
"CD013643","CD013643_pub2_data","1|10|Improvement in clinical measures of urinary incontinence (mean number of voids on 3-day voiding diary), short term (< 1 year)|","Improvement in clinical measures of urinary incontinence (mean number of voids on 3-day voiding diary), short term (< 1 year)",1,10,"","or","binary",2,-0.305463620336961,1.424820600772,0,22019.5,0,69.5
"CD013643","CD013643_pub2_data","1|12|Improvement in patient-reported sexual function, short term (< 1 year)|CO2 Laser","Improvement in patient-reported sexual function, short term (< 1 year)",1,12,"CO2 Laser","or","binary",2,0.033844783160772,1.42476238523305,0,2022,0,67
"CD013643","CD013643_pub2_data","1|14|Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year) |CO2 Laser","Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year) ",1,14,"CO2 Laser","reported","reported",2,0,1.04697538519108,0,2020.5,0.0208333333333333,35.5
"CD013643","CD013643_pub2_data","1|14|Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year) |ER:YAG Laser","Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year) ",1,14,"ER:YAG Laser","reported","reported",3,0,0.21986909356705,0,15352.6666666667,0.12973137973138,79
"CD013643","CD013643_pub2_data","1|3|Improvement in patient-reported incontinence, short term (< 1 year)|Er:YAG Laser","Improvement in patient-reported incontinence, short term (< 1 year)",1,3,"Er:YAG Laser","reported","reported",2,0,0.314753851797286,0,22020,0,72
"CD013643","CD013643_pub2_data","1|5|Number of major adverse events (Clavien-Dindo III-V), short term (< 1 year)|","Number of major adverse events (Clavien-Dindo III-V), short term (< 1 year)",1,5,"","or","binary",9,-0.198854839699866,0.672458811768234,0,6465.44444444444,0,76.5555555555556
"CD013643","CD013643_pub2_data","1|6|Number of continent women by patient-reported measures, short term (< 1 year)|CO2 Laser","Number of continent women by patient-reported measures, short term (< 1 year)",1,6,"CO2 Laser","or","binary",2,0.672719048359403,1.41526419515921,2.39641515874552,2022,0.0208333333333333,86.5
"CD013672","CD013672_pub2_data","1|2|Treatment retention, subgroup analysis: buprenorphine versus methadone|Buprenorphine maintenance","Treatment retention, subgroup analysis: buprenorphine versus methadone",1,2,"Buprenorphine maintenance","or","binary",2,0.297373507715579,0.753547822069217,0.857674792692748,2004,0.580018501387604,69.5
"CD013672","CD013672_pub2_data","1|3|Treatment retention, subgroup analysis: single provider primary care setting versus availability of a primary care team|Single-provider treatment settings","Treatment retention, subgroup analysis: single provider primary care setting versus availability of a primary care team",1,3,"Single-provider treatment settings","or","binary",2,1.45996702760996,0.294278593415584,0,2010,0.643939393939394,143
"CD013672","CD013672_pub2_data","1|3|Treatment retention, subgroup analysis: single provider primary care setting versus availability of a primary care team|Team-based treatment settings","Treatment retention, subgroup analysis: single provider primary care setting versus availability of a primary care team",1,3,"Team-based treatment settings","or","binary",4,0.296581147903922,0.451766785042779,0.322880443271663,2003.75,0.710148139582691,51.75
"CD013672","CD013672_pub2_data","1|4|Treatment retention, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care|OAT initiation in primary care","Treatment retention, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care",1,4,"OAT initiation in primary care","or","binary",4,0.552969973177681,0.469788446841214,0.729371329655618,2011.5,0.589861902953134,454.75
"CD013672","CD013672_pub2_data","1|4|Treatment retention, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care|OAT maintenance in primary care","Treatment retention, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care",1,4,"OAT maintenance in primary care","or","binary",3,0.599536252376424,0.479407502737949,0,2004.33333333333,0.822811447811448,44.3333333333333
"CD013672","CD013672_pub2_data","1|5|Treatment retention, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used|No mention of DSM criteria","Treatment retention, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used",1,5,"No mention of DSM criteria","or","binary",4,1.10063036106791,0.404646095956618,0.225369217199392,2006.75,0.742108585858586,88.5
"CD013672","CD013672_pub2_data","2|1|Abstinence from non-prescribed opioids|","Abstinence from non-prescribed opioids",2,1,"","or","binary",5,0.851834876804692,0.342200705099398,0.282302266220113,2005.8,0.330283174015829,85.6
"CD013672","CD013672_pub2_data","2|2|Abstinence from non-prescribed opioids, subgroup analysis: buprenorphine versus methadone|Buprenorphine maintenance","Abstinence from non-prescribed opioids, subgroup analysis: buprenorphine versus methadone",2,2,"Buprenorphine maintenance","or","binary",2,1.063959855043,0.363322089147242,0,2004,0.235430157261795,69.5
"CD013672","CD013672_pub2_data","2|2|Abstinence from non-prescribed opioids, subgroup analysis: buprenorphine versus methadone|Methadone maintenance","Abstinence from non-prescribed opioids, subgroup analysis: buprenorphine versus methadone",2,2,"Methadone maintenance","or","binary",3,0.726796940760965,0.679811663769257,1.010825262846,2007,0.393518518518518,96.3333333333333
"CD013672","CD013672_pub2_data","2|3|Abstinence from non-prescribed opioids, subgroup analysis: single-provider primary care settings versus availability of a primary care team|Team-based treatment settings","Abstinence from non-prescribed opioids, subgroup analysis: single-provider primary care settings versus availability of a primary care team",2,3,"Team-based treatment settings","or","binary",4,0.899235266565785,0.537880045009677,0.728026150197496,2003.75,0.329520634186453,51.75
"CD013672","CD013672_pub2_data","2|4|Abstinence from non-prescribed opioids, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care|OAT initiation in primary care","Abstinence from non-prescribed opioids, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care",2,4,"OAT initiation in primary care","or","binary",3,0.952930204965934,0.233431900164888,0,2007.33333333333,0.268064549285641,120
"CD013672","CD013672_pub2_data","2|4|Abstinence from non-prescribed opioids, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care|OAT maintenance in primary care","Abstinence from non-prescribed opioids, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care",2,4,"OAT maintenance in primary care","or","binary",2,0.747652535131972,1.33918319618458,2.98038502419762,2003.5,0.423611111111111,34
"CD013672","CD013672_pub2_data","2|5|Abstinence from non-prescribed opioids, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used|No mention of DSM criteria","Abstinence from non-prescribed opioids, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used",2,5,"No mention of DSM criteria","or","binary",3,0.726796940760965,0.679811663769257,1.010825262846,2007,0.393518518518518,96.3333333333333
"CD013672","CD013672_pub2_data","2|5|Abstinence from non-prescribed opioids, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used|Using DSM criteria to identify patients","Abstinence from non-prescribed opioids, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used",2,5,"Using DSM criteria to identify patients","or","binary",2,1.063959855043,0.363322089147242,0,2004,0.235430157261795,69.5
"CD013707","CD013707_pub2_data","1|1|All-cause mortality within 30 days|NA","All-cause mortality within 30 days",1,1,NA,"or","binary",4,-0.30640027171287,0.714488193610903,0,2014,0.0680555555555555,42.25
"CD013707","CD013707_pub2_data","1|10|Reduced left ventricular ejection fraction (< 50%) or shortening fraction (< 28%)|NA","Reduced left ventricular ejection fraction (< 50%) or shortening fraction (< 28%)",1,10,NA,"or","binary",2,-0.524695713787023,0.695258930379054,0,2016.5,0.653153153153153,42
"CD013707","CD013707_pub2_data","1|11|Renal failure requiring replacement therapy|NA","Renal failure requiring replacement therapy",1,11,NA,"or","binary",2,0.177562788535668,0.895145909661352,0,2015.5,0.0409356725146199,53
"CD013707","CD013707_pub2_data","1|2|Low cardiac output syndrome|NA","Low cardiac output syndrome",1,2,NA,"or","binary",3,-0.378188761205759,0.54169398765294,0,2015.33333333333,0.211111111111111,33
"CD013707","CD013707_pub2_data","1|3|Length of intensive care stay|NA","Length of intensive care stay",1,3,NA,"or","binary",4,0.0551453708839728,1.01092800252219,0,2016,0,47.25
"CD013707","CD013707_pub2_data","1|4|Length of hospital stay|NA","Length of hospital stay",1,4,NA,"or","binary",4,0.0551453708839728,1.01092800252219,0,2016,0,47.25
"CD013707","CD013707_pub2_data","1|5|Duration of mechanical ventilation|NA","Duration of mechanical ventilation",1,5,NA,"or","binary",4,0.0551453708839728,1.01092800252219,0,2016,0,47.25
"CD013707","CD013707_pub2_data","1|6|Inotrope score|NA","Inotrope score",1,6,NA,"or","binary",3,0.0115041458501774,1.1712629617524,0,2015,0,43
"CD013707","CD013707_pub2_data","1|7|Number of patients requiring mechanical circulatory support|NA","Number of patients requiring mechanical circulatory support",1,7,NA,"or","binary",3,0.30194536156089,0.879868630294055,0,2014.66666666667,0.0166666666666667,43.3333333333333
"CD013707","CD013707_pub2_data","1|8|Arrhythmia|NA","Arrhythmia",1,8,NA,"or","binary",4,-0.371263505103029,0.587231494856933,0,2014,0.0460526315789474,42.25
"CD013707","CD013707_pub2_data","1|9|Hypokalaemia|NA","Hypokalaemia",1,9,NA,"or","binary",2,1.11141101398602,0.651548597019874,0,2016.5,0.0394736842105263,45
"CD013707","CD013707_pub2_data","2|1|All-cause mortality within 30 days|NA","All-cause mortality within 30 days",2,1,NA,"or","binary",2,-0.528046065419433,0.662182789014989,0,2019.5,0.0881720430107527,108.5
"CD013707","CD013707_pub2_data","2|2|Length of intensive care stay|NA","Length of intensive care stay",2,2,NA,"or","binary",2,-0.00538952411573591,1.42731258214107,0,2019.5,0,108.5
"CD013707","CD013707_pub2_data","2|3|Duration of mechanical ventilation|NA","Duration of mechanical ventilation",2,3,NA,"or","binary",2,-0.00538952411573591,1.42731258214107,0,2019.5,0,108.5
"CD013707","CD013707_pub2_data","2|4|Inotrope score|NA","Inotrope score",2,4,NA,"or","binary",2,-0.00538952411573591,1.42731258214107,0,2019.5,0,108.5
"CD013707","CD013707_pub2_data","3|1|Arrhythmia|NA","Arrhythmia",3,1,NA,"or","binary",2,0.992273276722192,0.401850121515633,0,2008.5,0.198059964726631,114.5
"CD013707","CD013707_pub2_data","3|2|Hypotension|NA","Hypotension",3,2,NA,"or","binary",2,1.31830462006668,1.54014563489139,3.74222371326027,2008.5,0.0617283950617284,114.5
"CD013707","CD013707_pub2_data","3|3|Thrombocytopaenia|NA","Thrombocytopaenia",3,3,NA,"or","binary",2,-0.32129824830337,0.421169659184828,0,2008.5,0.126984126984127,114.5
"CD013715","CD013715_pub2_data","1|1|PedACR70 at up to 16 weeks |Infliximab vs Placebo","PedACR70 at up to 16 weeks ",1,1,"Infliximab vs Placebo","or","binary",2,1.58875191669091,1.02565008945843,1.52003232841969,2014.5,0.0921658986175115,74
"CD013715","CD013715_pub2_data","1|14|Withdrawals due to adverse events at end of study|Adalimumab vs Placebo","Withdrawals due to adverse events at end of study",1,14,"Adalimumab vs Placebo","or","binary",2,-0.374251391191812,1.4252706206785,0,2011.5,0,89.5
"CD013715","CD013715_pub2_data","1|14|Withdrawals due to adverse events at end of study|Etanercept vs Placebo","Withdrawals due to adverse events at end of study",1,14,"Etanercept vs Placebo","or","binary",2,-0.031870665426473,1.43000910630946,0,2006.5,0,44.5
"CD013715","CD013715_pub2_data","1|18|Serious adverse events at the end of study|Adalimumab vs Placebo ","Serious adverse events at the end of study",1,18,"Adalimumab vs Placebo ","or","binary",2,0.543395446122902,0.726992860034538,0,2011.5,0.0153846153846154,89.5
"CD013715","CD013715_pub2_data","1|18|Serious adverse events at the end of study|Etanercept vs Placebo","Serious adverse events at the end of study",1,18,"Etanercept vs Placebo","or","binary",2,1.11184448623798,1.17442449617531,0,2006.5,0,44.5
"CD013715","CD013715_pub2_data","1|19|PedACR50 at up to 16 weeks |Infliximab vs Placebo","PedACR50 at up to 16 weeks ",1,19,"Infliximab vs Placebo","or","binary",2,1.26453632929311,0.782164223866894,0.83509305489417,2014.5,0.304147465437788,74
"CD013715","CD013715_pub2_data","1|22|Total adverse events|Adalimumab vs Placebo","Total adverse events",1,22,"Adalimumab vs Placebo","or","binary",2,0.442935990632722,0.313077238106024,0,2011.5,0.566666666666667,89.5
"CD013715","CD013715_pub2_data","1|22|Total adverse events|Etanercept vs Placebo","Total adverse events",1,22,"Etanercept vs Placebo","or","binary",2,0.948666755330472,0.543815554208054,0.181839300076303,2006.5,0.536324786324786,44.5
"CD013715","CD013715_pub2_data","1|23|Sensitivity analysis: pedACR70 at the latest time point|Adalimumab vs placebo","Sensitivity analysis: pedACR70 at the latest time point",1,23,"Adalimumab vs placebo","or","binary",2,1.23689406911262,0.324386150995171,0,2011.5,0.238461538461538,89.5
"CD013715","CD013715_pub2_data","1|23|Sensitivity analysis: pedACR70 at the latest time point|Etanercept vs placebo","Sensitivity analysis: pedACR70 at the latest time point",1,23,"Etanercept vs placebo","or","binary",2,0.87105963301415,0.447429142343082,0,2006.5,0.346153846153846,44.5
"CD013715","CD013715_pub2_data","1|23|Sensitivity analysis: pedACR70 at the latest time point|Infliximab vs placebo","Sensitivity analysis: pedACR70 at the latest time point",1,23,"Infliximab vs placebo","or","binary",2,1.58875191669091,1.02565008945843,1.52003232841969,2014.5,0.0921658986175115,74
"CD013715","CD013715_pub2_data","1|6|Mean CHAQ at up to 16 weeks |Infliximab vs Placebo","Mean CHAQ at up to 16 weeks ",1,6,"Infliximab vs Placebo","or","binary",2,0.0896468939506586,1.43002074739984,0,2014.5,0,74
"CD013715","CD013715_pub2_data","1|7|Participant global assessment of disease activity at up to 16 weeks |Infliximab vs Placebo","Participant global assessment of disease activity at up to 16 weeks ",1,7,"Infliximab vs Placebo","reported","reported",2,0,0.164651784754857,0,2014.5,0,74
"CD013719","CD013719_pub2_data","1|1|Short-term hair regrowth ≥ 75%|","Short-term hair regrowth ≥ 75%",1,1,"","or","binary",2,1.64251585100458,1.11913776581903,0,2012,0,39.5
"CD013719","CD013719_pub2_data","1|2|Incidence of serious adverse events|","Incidence of serious adverse events",1,2,"","or","binary",2,-0.0684274707076221,1.43173037530236,0,2012,0,39.5
"CD013719","CD013719_pub2_data","11|1|Short-term hair regrowth ≥ 75%|","Short-term hair regrowth ≥ 75%",11,1,"","or","binary",2,1.10444977677476,1.11981357821139,2.07849764171735,1988.5,0.316666666666667,101
"CD013719","CD013719_pub2_data","11|2|Incidence of serious adverse events|","Incidence of serious adverse events",11,2,"","or","binary",4,-0.13335905188307,1.00917806498258,0,1988.25,0,76
"CD013719","CD013719_pub2_data","13|1|Sensitivity analysis. Oral classical immunosuppressants vs placebo: short-term hair regrowth|","Sensitivity analysis. Oral classical immunosuppressants vs placebo: short-term hair regrowth",13,1,"","or","binary",2,-0.47578881158731,0.638013990112811,0,2012,0.155555555555556,39.5
"CD013719","CD013719_pub2_data","13|11|Sensitivity analysis. Topical hair growth stimulants vs placebo: short-term hair-regrowth|","Sensitivity analysis. Topical hair growth stimulants vs placebo: short-term hair-regrowth",13,11,"","or","binary",2,1.10444977677476,1.11981357821139,2.07849764171735,1988.5,0.316666666666667,101
"CD013719","CD013719_pub2_data","13|2|Sensitivity analysis. Betamethasone vs azathioprine or prednisolone: short-term hair regrowth|","Sensitivity analysis. Betamethasone vs azathioprine or prednisolone: short-term hair regrowth",13,2,"","or","binary",2,0.00139340842430602,0.508191647547669,0.00953555038995552,2009.5,0.5,40
"CD013719","CD013719_pub2_data","13|5|Sensitivity analysis. Oral small molecule inhibitors: baricitinib vs placebo|Long-term hair regrowth","Sensitivity analysis. Oral small molecule inhibitors: baricitinib vs placebo",13,5,"Long-term hair regrowth","or","binary",2,0.72299636810303,0.167927344184625,0,2022,0.1498778998779,600
"CD013719","CD013719_pub2_data","13|5|Sensitivity analysis. Oral small molecule inhibitors: baricitinib vs placebo|Short-term hair regrowth","Sensitivity analysis. Oral small molecule inhibitors: baricitinib vs placebo",13,5,"Short-term hair regrowth","or","binary",2,2.10525175850554,0.432436180671091,0.130251522008664,2022,0.0249287749287749,600
"CD013719","CD013719_pub2_data","2|1|Short-term hair regrowth ≥ 75%|","Short-term hair regrowth ≥ 75%",2,1,"","or","binary",2,1.23839547526883,1.48910188744946,3.19693523025931,2009.5,0.333333333333333,40
"CD013719","CD013719_pub2_data","2|2|Incidence of serious adverse events|","Incidence of serious adverse events",2,2,"","or","binary",4,0,1.01380221697585,0,2013.5,0,38.5
"CD013719","CD013719_pub2_data","3|2|Incidence of serious adverse events|","Incidence of serious adverse events",3,2,"","or","binary",4,-0.44746726816301,1.00734606247076,0,2017.75,0,135.75
"CD013719","CD013719_pub2_data","5|1|Short-term hair regrowth ≥ 75%|","Short-term hair regrowth ≥ 75%",5,1,"","or","binary",2,2.10525175850554,0.432436180671091,0.130251522008664,2022,0.0249287749287749,600
"CD013719","CD013719_pub2_data","5|2|Incidence of serious adverse events|","Incidence of serious adverse events",5,2,"","or","binary",3,0.245580206971301,0.427098607067044,0,2021,0.0117845117845118,408
"CD013719","CD013719_pub2_data","5|3|Long-term hair regrowth ≥ 75%|","Long-term hair regrowth ≥ 75%",5,3,"","or","binary",2,2.39931896210574,0.519620771463094,0.307862690068076,2022,0.0302197802197802,600
"CD013726","CD013726_pub2_data","3|1|Pain|Moderate to severe (intermetatarsal angle > 12 degrees)","Pain",3,1,"Moderate to severe (intermetatarsal angle > 12 degrees)","or","binary",5,-0.004971313325627,0.902037702237764,0,2014.2,0,63.6
"CD013726","CD013726_pub2_data","3|2|Function|Mild to severe (any preoperative intermetatarsal angle)","Function",3,2,"Mild to severe (any preoperative intermetatarsal angle)","or","binary",2,0.162040118936223,1.42682682370109,0,2017,0,78
"CD013726","CD013726_pub2_data","3|2|Function|Moderate to severe (intermetatarsal angle > 12 degrees)","Function",3,2,"Moderate to severe (intermetatarsal angle > 12 degrees)","or","binary",7,0.0342721428837889,0.763131908814475,0,2014.42857142857,0,57.1428571428571
"CD013726","CD013726_pub2_data","3|4|Participant global assessment of treatment success|","Participant global assessment of treatment success",3,4,"","or","binary",8,0.556715512294354,0.300833763949738,0,2012,0.0784977172369414,57.75
"CD013726","CD013726_pub2_data","3|5|Reoperation (treatment failure)|Mild to severe (any preoperative intermetatarsal angle)","Reoperation (treatment failure)",3,5,"Mild to severe (any preoperative intermetatarsal angle)","or","binary",2,0.048610468567471,0.748373185544652,0,2006.5,0.0849420849420849,58
"CD013726","CD013726_pub2_data","3|5|Reoperation (treatment failure)|Moderate to severe (hallux valgus angle > 20 degrees)","Reoperation (treatment failure)",3,5,"Moderate to severe (hallux valgus angle > 20 degrees)","or","binary",5,0.956774039425508,0.461685377608467,0,2009.4,0.024812030075188,69
"CD013726","CD013726_pub2_data","3|6|Adverse events|","Adverse events",3,6,"","or","binary",12,-0.286357167453948,0.405485050126595,1.40807290385596,2011.08333333333,0.264504347858477,65.5833333333333
"CD013726","CD013726_pub2_data","3|7|Serious adverse events|","Serious adverse events",3,7,"","or","binary",12,0.0310886562798741,0.582361854721303,0,2011.08333333333,0,65.5833333333333
"CD013729","CD013729_pub2_data","1|1|Change in systolic blood pressure (medium-term follow-up)|NA","Change in systolic blood pressure (medium-term follow-up)",1,1,NA,"or","binary",2,0.00929356330518698,1.42176686254969,0,2012.5,0,92.5
"CD013729","CD013729_pub2_data","2|2|Change in systolic blood pressure (medium-term follow-up)|NA","Change in systolic blood pressure (medium-term follow-up)",2,2,NA,"or","binary",2,-0.0018669521634539,1.4186515172352,0,2012,0,314.5
"CD013729","CD013729_pub2_data","2|4|Change in diastolic blood pressure (medium-term follow-up)|NA","Change in diastolic blood pressure (medium-term follow-up)",2,4,NA,"or","binary",2,-0.0018669521634539,1.4186515172352,0,2012,0,314.5
"CD013745","CD013745_pub2_data","1|4|NOACs versus antiplatelet therapy|NA","NOACs versus antiplatelet therapy",1,4,NA,"or","binary",3,0.538089628957438,0.168433757659932,0,2021.33333333333,0.0326069154241194,974
"CD013745","CD013745_pub2_data","1|7|NOACs versus VKA|NA","NOACs versus VKA",1,7,NA,"or","binary",2,-0.0753171076614709,0.141986562761591,0,2021.5,0.115655987795576,938.5
"CD013745","CD013745_pub2_data","2|4|NOACs versus antiplatelet therapy|NA","NOACs versus antiplatelet therapy",2,4,NA,"or","binary",3,0.291289321064612,0.209675044462472,5.5443469337572e-08,2021.33333333333,0.0192879771738809,974
"CD013745","CD013745_pub2_data","2|7|NOACs versus VKA|NA","NOACs versus VKA",2,7,NA,"or","binary",2,0.1516773584473,0.180614316712563,0,2021.5,0.0651528013582343,938.5
"CD013745","CD013745_pub2_data","3|3|NOACs versus antiplatelet therapy|NA","NOACs versus antiplatelet therapy",3,3,NA,"or","binary",2,0.165811306271852,0.261332409215095,0,2021,0.0237557498653185,936.5
"CD013745","CD013745_pub2_data","3|6|NOACs versus VKA|NA","NOACs versus VKA",3,6,NA,"or","binary",2,-0.136608487013454,0.236989367035163,0,2021.5,0.0333161093477031,938.5
"CD013745","CD013745_pub2_data","4|4|NOACs versus antiplatelet therapy|NA","NOACs versus antiplatelet therapy",4,4,NA,"or","binary",3,0.38007811258788,0.254729965383409,0.074246720596372,2021.33333333333,0.0388062936374562,974
"CD013745","CD013745_pub2_data","4|7|NOACs versus VKA|NA","NOACs versus VKA",4,7,NA,"or","binary",2,0.210072958175032,0.253565330612716,0.0766672619529059,2021.5,0.104703378361753,938.5
"CD013748","CD013748_pub2_data","1|1|Poor functional outcome|NA","Poor functional outcome",1,1,NA,"reported","reported",2,0,0.326575222799877,0,2010,0.8,22
"CD013748","CD013748_pub2_data","1|3|Haemorrhagic complications|NA","Haemorrhagic complications",1,3,NA,"or","binary",6,0.35032376748772,0.380717595121634,0,2008,0.0695011337868481,56.8333333333333
"CD013748","CD013748_pub2_data","1|4|Cerebral artery vasospasm|NA","Cerebral artery vasospasm",1,4,NA,"or","binary",5,-0.703411149515148,0.322593310640888,0.12569917549158,2007.6,0.486545158944081,60.4
"CD013748","CD013748_pub2_data","1|5|Delayed cerebral ischaemia|NA","Delayed cerebral ischaemia",1,5,NA,"or","binary",5,-0.721683448641539,0.389962278155446,0.374705537039966,2003,0.424927827326749,65
"CD013748","CD013748_pub2_data","1|6|Cerebral infarction|NA","Cerebral infarction",1,6,NA,"or","binary",3,-0.427922939778307,0.650440147495254,0.657221020124165,2012.33333333333,0.338888888888889,37.3333333333333
"CD013748","CD013748_pub2_data","1|7|Hydrocephalus|NA","Hydrocephalus",1,7,NA,"or","binary",6,-0.38593977621396,0.393826822800758,0.254899508225351,2008,0.315146750524109,56.8333333333333
"CD013748","CD013748_pub2_data","2|3|Haemorrhagic complications|NA","Haemorrhagic complications",2,3,NA,"or","binary",6,0.360026732843318,0.377434357948349,0,2008,0.0695011337868481,58.5
"CD013748","CD013748_pub2_data","2|4|Cerebral artery vasospasm|NA","Cerebral artery vasospasm",2,4,NA,"or","binary",5,-0.703411149515148,0.322593310640888,0.12569917549158,2007.6,0.486545158944081,60.4
"CD013748","CD013748_pub2_data","2|5|Delayed cerebral ischaemia|NA","Delayed cerebral ischaemia",2,5,NA,"or","binary",5,-0.594449028993006,0.324409468609891,0.219466715457082,2003,0.424927827326749,74
"CD013748","CD013748_pub2_data","2|6|Cerebral infarction|NA","Cerebral infarction",2,6,NA,"or","binary",3,-0.307148877049655,0.516943582781218,0.317657834518212,2012.33333333333,0.338888888888889,44
"CD013748","CD013748_pub2_data","2|7|Hydrocephalus|NA","Hydrocephalus",2,7,NA,"or","binary",6,-0.464207588314836,0.410643617343909,0.344122134958663,2008,0.315146750524109,60.1666666666667
"CD013757","CD013757_pub3_data","1|1|Hospitalisation due to RSV infection|Systemic (intramuscular/intravenous)","Hospitalisation due to RSV infection",1,1,"Systemic (intramuscular/intravenous)","reported","reported",5,0,0.136594507979757,0,2005,0.118496050203027,668.6
"CD013757","CD013757_pub3_data","1|10|Mechanical ventilation days|","Mechanical ventilation days",1,10,"","reported","reported",2,-0.333424780254162,1.85742049747562,6.4706773979755,2000.5,0,1394.5
"CD013757","CD013757_pub3_data","1|2|Mortality|","Mortality",1,2,"","or","binary",5,-0.365670184759034,0.258808861268654,0,2005,0.0203333333333333,668.6
"CD013757","CD013757_pub3_data","1|3|Adverse events|","Adverse events",1,3,"","or","binary",4,0.0838936435282244,0.133818329905119,0,2005.5,0.0854581260364842,774.75
"CD013757","CD013757_pub3_data","1|4|Hospitalisation due to respiratory‐related illness|","Hospitalisation due to respiratory‐related illness",1,4,"","or","binary",6,-0.297926519926223,0.0884173242660542,0.00224960597587269,2008,0.232107741582287,572.833333333333
"CD013757","CD013757_pub3_data","1|5|Subgroup analysis: hospitalisation due to respiratory‐related illness|High-income countries","Subgroup analysis: hospitalisation due to respiratory‐related illness",1,5,"High-income countries","or","binary",5,-0.282900963036016,0.0871543632214654,0.00131895799270107,2007,0.226148337517792,670.8
"CD013757","CD013757_pub3_data","1|6|Length of hospital stay|","Length of hospital stay",1,6,"","reported","reported",2,-0.715927161794942,0.134109038091717,0.00384791277549999,2000.5,0,1394.5
"CD013757","CD013757_pub3_data","1|7|RSV infection|Systemic (intramuscular/intravenous)","RSV infection",1,7,"Systemic (intramuscular/intravenous)","reported","reported",3,0,0.253774617493354,0,2008,0.271908453303802,184.666666666667
"CD013757","CD013757_pub3_data","1|8|Days of supplemental oxygen|","Days of supplemental oxygen",1,8,"","reported","reported",2,-0.914507516605991,0.399228944255282,0.2695762920995,2000.5,0,1394.5
"CD013757","CD013757_pub3_data","1|9|Intensive care unit length of stay|","Intensive care unit length of stay",1,9,"","reported","reported",2,-0.757299313759263,0.78107074988449,1.105923176513,2000.5,0,1394.5
"CD013758","CD013758_pub2_data","1|1|Underweight (weight-for-age z-score)|Sole feeding method","Underweight (weight-for-age z-score)",1,1,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|1|Underweight (weight-for-age z-score)|With complementary foods","Underweight (weight-for-age z-score)",1,1,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|11|Any adverse event|Sole feeding method","Any adverse event",1,11,"Sole feeding method","or","binary",3,-0.135939694080015,0.278856678315448,0,2011.66666666667,0.470323140911376,97
"CD013758","CD013758_pub2_data","1|14|Weight (kg)|Sole feeding method","Weight (kg)",1,14,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|14|Weight (kg)|With complementary foods","Weight (kg)",1,14,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|15|Weight (kg): subgroup analysis by duration of treatment|1 year","Weight (kg): subgroup analysis by duration of treatment",1,15,"1 year","or","binary",2,0.351636447069265,1.42194009069851,0,2007,0,114
"CD013758","CD013758_pub2_data","1|15|Weight (kg): subgroup analysis by duration of treatment|2 months","Weight (kg): subgroup analysis by duration of treatment",1,15,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|15|Weight (kg): subgroup analysis by duration of treatment|4 months","Weight (kg): subgroup analysis by duration of treatment",1,15,"4 months","or","binary",5,-0.0171668989056486,0.901939700650856,0,2007.8,0,93
"CD013758","CD013758_pub2_data","1|15|Weight (kg): subgroup analysis by duration of treatment|5 years","Weight (kg): subgroup analysis by duration of treatment",1,15,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|15|Weight (kg): subgroup analysis by duration of treatment|6 months","Weight (kg): subgroup analysis by duration of treatment",1,15,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|16|Height (cm)|Sole feeding method","Height (cm)",1,16,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|16|Height (cm)|With complementary foods","Height (cm)",1,16,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|17|Height (cm): subgroup analysis by duration of treatment|1 year","Height (cm): subgroup analysis by duration of treatment",1,17,"1 year","or","binary",2,0.351636447069265,1.42194009069851,0,2007,0,114
"CD013758","CD013758_pub2_data","1|17|Height (cm): subgroup analysis by duration of treatment|2 months","Height (cm): subgroup analysis by duration of treatment",1,17,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|17|Height (cm): subgroup analysis by duration of treatment|4 months","Height (cm): subgroup analysis by duration of treatment",1,17,"4 months","or","binary",5,-0.0171668989056486,0.901939700650856,0,2007.8,0,93
"CD013758","CD013758_pub2_data","1|17|Height (cm): subgroup analysis by duration of treatment|5 years","Height (cm): subgroup analysis by duration of treatment",1,17,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|17|Height (cm): subgroup analysis by duration of treatment|6 months","Height (cm): subgroup analysis by duration of treatment",1,17,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|18|BMI (z-score)|Sole feeding method","BMI (z-score)",1,18,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|18|BMI (z-score)|With complementary foods","BMI (z-score)",1,18,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|19|BMI (z-score): subgroup analysis by duration of treatment|1 year","BMI (z-score): subgroup analysis by duration of treatment",1,19,"1 year","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|19|BMI (z-score): subgroup analysis by duration of treatment|2 months","BMI (z-score): subgroup analysis by duration of treatment",1,19,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|19|BMI (z-score): subgroup analysis by duration of treatment|4 months","BMI (z-score): subgroup analysis by duration of treatment",1,19,"4 months","or","binary",6,-0.0173637085145545,0.822263171273249,0,2008,0,259.166666666667
"CD013758","CD013758_pub2_data","1|19|BMI (z-score): subgroup analysis by duration of treatment|5 years","BMI (z-score): subgroup analysis by duration of treatment",1,19,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|19|BMI (z-score): subgroup analysis by duration of treatment|6 months","BMI (z-score): subgroup analysis by duration of treatment",1,19,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|1 year","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",1,2,"1 year","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|2 months","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",1,2,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|4 months","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",1,2,"4 months","or","binary",6,-0.0173637085145545,0.822263171273249,0,2008,0,259.166666666667
"CD013758","CD013758_pub2_data","1|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|5 years","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",1,2,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|6 months","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",1,2,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|20|BMI (kg/m2)|Sole feeding method","BMI (kg/m2)",1,20,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|20|BMI (kg/m2)|With complementary foods","BMI (kg/m2)",1,20,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|21|BMI (kg/m2): subgroup analysis by duration of treatment|1 year","BMI (kg/m2): subgroup analysis by duration of treatment",1,21,"1 year","or","binary",2,0.351636447069265,1.42194009069851,0,2007,0,114
"CD013758","CD013758_pub2_data","1|21|BMI (kg/m2): subgroup analysis by duration of treatment|2 months","BMI (kg/m2): subgroup analysis by duration of treatment",1,21,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|21|BMI (kg/m2): subgroup analysis by duration of treatment|4 months","BMI (kg/m2): subgroup analysis by duration of treatment",1,21,"4 months","or","binary",5,-0.0171668989056486,0.901939700650856,0,2007.8,0,93
"CD013758","CD013758_pub2_data","1|21|BMI (kg/m2): subgroup analysis by duration of treatment|5 years","BMI (kg/m2): subgroup analysis by duration of treatment",1,21,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|21|BMI (kg/m2): subgroup analysis by duration of treatment|6 months","BMI (kg/m2): subgroup analysis by duration of treatment",1,21,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|22|Head circumference (z-score)|Sole feeding method","Head circumference (z-score)",1,22,"Sole feeding method","or","binary",2,-0.0135789649085347,1.42182718258955,0,2014.5,0,95
"CD013758","CD013758_pub2_data","1|23|Head circumference (z-score): subgroup analysis by duration of treatment|2 months","Head circumference (z-score): subgroup analysis by duration of treatment",1,23,"2 months","or","binary",2,-0.065065159505232,1.41959030718356,0,2017,0,133.5
"CD013758","CD013758_pub2_data","1|23|Head circumference (z-score): subgroup analysis by duration of treatment|4 months","Head circumference (z-score): subgroup analysis by duration of treatment",1,23,"4 months","or","binary",3,-0.0349330500656833,1.16008455672372,0,2015,0,114.666666666667
"CD013758","CD013758_pub2_data","1|24|Head circumference (cm)|Sole feeding method","Head circumference (cm)",1,24,"Sole feeding method","or","binary",2,-0.0135789649085347,1.42182718258955,0,2014.5,0,95
"CD013758","CD013758_pub2_data","1|25|Head circumference (cm): subgroup analysis by duration of treatment|2 months","Head circumference (cm): subgroup analysis by duration of treatment",1,25,"2 months","or","binary",2,-0.065065159505232,1.41959030718356,0,2017,0,133.5
"CD013758","CD013758_pub2_data","1|25|Head circumference (cm): subgroup analysis by duration of treatment|4 months","Head circumference (cm): subgroup analysis by duration of treatment",1,25,"4 months","or","binary",3,-0.0349330500656833,1.16008455672372,0,2015,0,114.666666666667
"CD013758","CD013758_pub2_data","1|3|Stunting (height-for-age z-score)|Sole feeding method","Stunting (height-for-age z-score)",1,3,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|3|Stunting (height-for-age z-score)|With complementary foods","Stunting (height-for-age z-score)",1,3,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|1 year","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",1,4,"1 year","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|2 months","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",1,4,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|4 months","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",1,4,"4 months","or","binary",6,-0.0173637085145545,0.822263171273249,0,2008,0,259.166666666667
"CD013758","CD013758_pub2_data","1|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|5 years","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",1,4,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|6 months","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",1,4,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","1|5|Wasting (weight-for-height z-score)|Sole feeding method","Wasting (weight-for-height z-score)",1,5,"Sole feeding method","or","binary",4,-0.0018987707518371,1.00970524578075,0,2005.75,0,77.75
"CD013758","CD013758_pub2_data","1|5|Wasting (weight-for-height z-score)|With complementary foods","Wasting (weight-for-height z-score)",1,5,"With complementary foods","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|1 year","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",1,6,"1 year","or","binary",3,0.227491576080048,1.15907307240473,0,2007.66666666667,0,439.333333333333
"CD013758","CD013758_pub2_data","1|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|2 months","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",1,6,"2 months","or","binary",4,-0.0322183534652889,1.00323398689912,0,2012.25,0,364.5
"CD013758","CD013758_pub2_data","1|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|4 months","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",1,6,"4 months","or","binary",6,-0.0173637085145545,0.822263171273249,0,2008,0,259.166666666667
"CD013758","CD013758_pub2_data","1|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|5 years","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",1,6,"5 years","or","binary",2,-0.0478135327394736,1.41681425991787,0,2012.5,0,622
"CD013758","CD013758_pub2_data","1|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|6 months","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",1,6,"6 months","or","binary",3,-0.0323276348059189,1.16499609180665,0,2004.33333333333,0,421.333333333333
"CD013758","CD013758_pub2_data","2|1|Underweight (weight-for-age z-score)|Sole feeding method","Underweight (weight-for-age z-score)",2,1,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|10|Weight (kg): subgroup analysis by duration of treatment|2 months","Weight (kg): subgroup analysis by duration of treatment",2,10,"2 months","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|10|Weight (kg): subgroup analysis by duration of treatment|4 months","Weight (kg): subgroup analysis by duration of treatment",2,10,"4 months","or","binary",2,0.079424093289251,1.42822299314058,0,2007.5,0,103
"CD013758","CD013758_pub2_data","2|11|Height (cm)|Sole feeding method","Height (cm)",2,11,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|12|Height (cm): subgroup analysis by duration of treatment|2 months","Height (cm): subgroup analysis by duration of treatment",2,12,"2 months","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|12|Height (cm): subgroup analysis by duration of treatment|4 months","Height (cm): subgroup analysis by duration of treatment",2,12,"4 months","or","binary",2,0.079424093289251,1.42822299314058,0,2007.5,0,103
"CD013758","CD013758_pub2_data","2|13|BMI (z-score)|Sole feeding method","BMI (z-score)",2,13,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|14|BMI (z-score): subgroup analysis by duration of treatment|2 months","BMI (z-score): subgroup analysis by duration of treatment",2,14,"2 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|14|BMI (z-score): subgroup analysis by duration of treatment|4 months","BMI (z-score): subgroup analysis by duration of treatment",2,14,"4 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|15|BMI (kg/m2)|Sole feeding method","BMI (kg/m2)",2,15,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|16|BMI (kg/m2): subgroup analysis by duration of treatment|2 months","BMI (kg/m2): subgroup analysis by duration of treatment",2,16,"2 months","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|16|BMI (kg/m2): subgroup analysis by duration of treatment|4 months","BMI (kg/m2): subgroup analysis by duration of treatment",2,16,"4 months","or","binary",2,0.079424093289251,1.42822299314058,0,2007.5,0,103
"CD013758","CD013758_pub2_data","2|17|Head circumference (z-score)|Sole feeding method","Head circumference (z-score)",2,17,"Sole feeding method","or","binary",2,-0.336389501304771,1.44345382784631,0,1987.5,0,25
"CD013758","CD013758_pub2_data","2|18|Head circumference (z-score): subgroup analysis by duration of treatment|2 months","Head circumference (z-score): subgroup analysis by duration of treatment",2,18,"2 months","or","binary",3,-0.213975397170037,1.17156839605029,0,1998.33333333333,0,76
"CD013758","CD013758_pub2_data","2|18|Head circumference (z-score): subgroup analysis by duration of treatment|4 months","Head circumference (z-score): subgroup analysis by duration of treatment",2,18,"4 months","or","binary",3,-0.213975397170037,1.17156839605029,0,1998.33333333333,0,76
"CD013758","CD013758_pub2_data","2|19|Head circumference (cm)|Sole feeding method","Head circumference (cm)",2,19,"Sole feeding method","or","binary",2,-0.336389501304771,1.44345382784631,0,1987.5,0,25
"CD013758","CD013758_pub2_data","2|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|2 months","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",2,2,"2 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|2|Underweight (weight-for-age z-score): subgroup analysis by duration of treatment|4 months","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment",2,2,"4 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|20|Head circumference (cm): subgroup analysis by duration of treatment|2 months","Head circumference (cm): subgroup analysis by duration of treatment",2,20,"2 months","or","binary",2,-0.336389501304771,1.44345382784631,0,1987.5,0,25
"CD013758","CD013758_pub2_data","2|3|Stunting (height-for-age z-score)|Sole feeding method","Stunting (height-for-age z-score)",2,3,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|2 months","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",2,4,"2 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|4|Stunting (height-for-age z-score): subgroup analysis by duration of treatment|4 months","Stunting (height-for-age z-score): subgroup analysis by duration of treatment",2,4,"4 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|5|Wasting (weight-for-height z-score)|Sole feeding method","Wasting (weight-for-height z-score)",2,5,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013758","CD013758_pub2_data","2|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|2 months","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",2,6,"2 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|6|Wasting (weight-for-height z-score): subgroup analysis by duration of treatment|4 months","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment",2,6,"4 months","or","binary",4,-0.126277368807394,1.01524823659769,0,1997.5,0,64
"CD013758","CD013758_pub2_data","2|7|Any adverse event|Sole feeding method","Any adverse event",2,7,"Sole feeding method","or","binary",2,0.410825344572535,0.397188282867445,0,2007.5,0.0666666666666667,103
"CD013758","CD013758_pub2_data","2|8|Adverse events: subgroup analysis by type|Milk hypersensitivity","Adverse events: subgroup analysis by type",2,8,"Milk hypersensitivity","or","binary",2,-0.309416867999571,0.695679966699581,0.307373020898549,2007.5,0.0611111111111111,103
"CD013758","CD013758_pub2_data","2|9|Weight (kg)|Sole feeding method","Weight (kg)",2,9,"Sole feeding method","or","binary",3,-0.177484321281995,1.17722343862273,0,1990,0,26
"CD013763","CD013763_pub3_data","1|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",1,1,"","or","binary",17,0.0335097948378093,0.489502473096289,0,2019.64705882353,0,56.3529411764706
"CD013763","CD013763_pub3_data","1|11|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",1,11,"","or","binary",23,0.0144036810400518,0.420835520368838,0,2019.5,0,58.304347826087
"CD013763","CD013763_pub3_data","1|12|Cumulative mean oral morphine requirement in mg - 48 hours|","Cumulative mean oral morphine requirement in mg - 48 hours",1,12,"","or","binary",4,0,1.00765989805182,0,2020,0,65
"CD013763","CD013763_pub3_data","1|13|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",1,13,"","or","binary",21,-1.16786964772864,0.187559603534288,0.176549588531321,2019.55,0.355094206143681,52.9047619047619
"CD013763","CD013763_pub3_data","1|14|Rates of opioid-related adverse events (pruritus)|","Rates of opioid-related adverse events (pruritus)",1,14,"","or","binary",7,-1.16953587366746,0.29817913777657,0.100152166190795,2019.83333333333,0.301190476190476,62.8571428571429
"CD013763","CD013763_pub3_data","1|2|Rates of block-related adverse events|","Rates of block-related adverse events",1,2,"","or","binary",18,-0.00179612652648361,0.475702901983028,0,2019.41176470588,0,58.0555555555556
"CD013763","CD013763_pub3_data","1|3|Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)",1,3,"","or","binary",9,0,0.672421041361758,0,2019.66666666667,0,57.5555555555556
"CD013763","CD013763_pub3_data","1|4|Mean difference in postoperative pain intensity at rest - 2 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)",1,4,"","or","binary",10,-0.00323016772557687,0.637940058859876,0,2019.6,0,61.1
"CD013763","CD013763_pub3_data","1|5|Mean difference in postoperative pain intensity at rest - 48 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 48 hours (VAS)",1,5,"","or","binary",6,0,0.823423310911883,0,2019.66666666667,0,60
"CD013763","CD013763_pub3_data","1|6|Mean difference in postoperative pain intensity during activity - 2 hours (VAS)|","Mean difference in postoperative pain intensity during activity - 2 hours (VAS)",1,6,"","or","binary",4,0,1.00816340075553,0,2019.5,0,60
"CD013763","CD013763_pub3_data","1|7|Mean difference in postoperative pain intensity during activity - 48 hours (VAS)|","Mean difference in postoperative pain intensity during activity - 48 hours (VAS)",1,7,"","or","binary",5,0,0.902433509600244,0,2019.6,0,56
"CD013763","CD013763_pub3_data","10|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery|Abdominal surgery","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery",10,1,"Abdominal surgery","or","binary",4,-0.00807827945794683,1.00885040770467,0,2020,0,56.25
"CD013763","CD013763_pub3_data","10|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery|Breast surgery","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery",10,1,"Breast surgery","or","binary",3,0,1.16636556057886,0,2020,0,49.3333333333333
"CD013763","CD013763_pub3_data","10|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery|Spine surgery","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery",10,1,"Spine surgery","or","binary",4,0,1.00864362952168,0,2019.5,0,60
"CD013763","CD013763_pub3_data","10|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery|Thoracic surgery","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery",10,1,"Thoracic surgery","or","binary",6,0.10014253601263,0.823173088909468,0,2019.6,0,64.1666666666667
"CD013763","CD013763_pub3_data","10|2|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of local anaesthetic|Bupivacaine 0.25% to 0.5%","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of local anaesthetic",10,2,"Bupivacaine 0.25% to 0.5%","or","binary",8,0.0751896186675941,0.713281257677028,0,2019.5,0,59.875
"CD013763","CD013763_pub3_data","10|2|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of local anaesthetic|Ropivacaine 0.3% to 0.5%","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of local anaesthetic",10,2,"Ropivacaine 0.3% to 0.5%","or","binary",10,-0.00323328554812729,0.638247860861194,0,2019.77777777778,0,55.9
"CD013763","CD013763_pub3_data","10|3|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Volume of local anaesthetic|20 mL to 24 mL","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Volume of local anaesthetic",10,3,"20 mL to 24 mL","or","binary",11,0.0517611938570071,0.608374704343931,0,2019.54545454545,0,58.7272727272727
"CD013763","CD013763_pub3_data","10|3|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Volume of local anaesthetic|25 mL to 30 mL","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Volume of local anaesthetic",10,3,"25 mL to 30 mL","or","binary",6,0,0.823677412192921,0,2019.8,0,58
"CD013763","CD013763_pub3_data","10|4|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia|No specified multimodal analgesia","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia",10,4,"No specified multimodal analgesia","or","binary",3,0,1.16564439080394,0,2018.66666666667,0,53.3333333333333
"CD013763","CD013763_pub3_data","10|4|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia|Non-opioid + PCA","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia",10,4,"Non-opioid + PCA","or","binary",8,-0.004033690859374,0.71288363124499,0,2019.85714285714,0,62.375
"CD013763","CD013763_pub3_data","10|4|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia|Non-opioid + rescue opioids","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia",10,4,"Non-opioid + rescue opioids","or","binary",7,0.086090216454877,0.763235867329216,0,2019.85714285714,0,54.1428571428571
"CD013763","CD013763_pub3_data","10|5|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia|Both paracetamol + NSAID","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia",10,5,"Both paracetamol + NSAID","or","binary",4,-0.00808082539175312,1.00900936878268,0,2019.75,0,57.75
"CD013763","CD013763_pub3_data","10|5|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia|Not specified","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia",10,5,"Not specified","or","binary",4,0.150072957862192,1.00770425556846,0,2019.5,0,66.25
"CD013763","CD013763_pub3_data","10|5|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia|NSAID","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia",10,5,"NSAID","or","binary",5,0,0.90277789073419,0,2019,0,56
"CD013763","CD013763_pub3_data","10|5|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia|Paracetamol","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia",10,5,"Paracetamol","or","binary",5,0,0.902998809028627,0,2020.2,0,52.4
"CD013763","CD013763_pub3_data","2|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",2,1,"","or","binary",8,0.00313566767892243,0.712707994683072,0,2019.625,0,62.375
"CD013763","CD013763_pub3_data","2|2|Rates of block-related adverse events|","Rates of block-related adverse events",2,2,"","or","binary",10,-0.0033274175496914,0.637862335722429,0,2019.7,0,59.2
"CD013763","CD013763_pub3_data","2|3|Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)",2,3,"","or","binary",3,0.0083550936292282,1.16338182903709,0,2020,0,66.3333333333333
"CD013763","CD013763_pub3_data","2|4|Mean difference in postoperative pain intensity at rest - 2 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)",2,4,"","or","binary",7,0.0035833743854424,0.761890762761683,0,2019.42857142857,0,62.7142857142857
"CD013763","CD013763_pub3_data","2|5|Mean difference in postoperative pain intensity at rest - 48 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 48 hours (VAS)",2,5,"","or","binary",2,0,1.42575835443665,0,2020.5,0,60
"CD013763","CD013763_pub3_data","2|6|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",2,6,"","or","binary",11,-0.000898636034035942,0.608026502293447,0,2019.63636363636,0,61.5454545454545
"CD013763","CD013763_pub3_data","2|7|Cumulative mean oral morphine requirement in mg - 48 hours|","Cumulative mean oral morphine requirement in mg - 48 hours",2,7,"","or","binary",3,0.00879107975862394,1.16350814099964,0,2020.33333333333,0,65
"CD013763","CD013763_pub3_data","2|8|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",2,8,"","or","binary",11,-1.14772986701725,0.221119777448247,0,2019.54545454545,0.257006197504139,63.1818181818182
"CD013763","CD013763_pub3_data","2|9|Rates of opioid-related adverse events (pruritus)|","Rates of opioid-related adverse events (pruritus)",2,9,"","or","binary",2,-0.915872252076247,0.581149809799306,0.303786129691262,2019.5,0.396666666666667,55
"CD013763","CD013763_pub3_data","3|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",3,1,"","or","binary",7,-0.000375841331770464,0.761675492336436,0,2019.42857142857,0,68.2857142857143
"CD013763","CD013763_pub3_data","3|10|Cumulative mean oral morphine requirement in mg - 48 hours|","Cumulative mean oral morphine requirement in mg - 48 hours",3,10,"","or","binary",5,0,0.901195728299864,0,2019.6,0,67.2
"CD013763","CD013763_pub3_data","3|11|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",3,11,"","or","binary",10,0.173169517409943,0.218936437362952,0.0258303428806029,2019.4,0.144976535541753,66.8
"CD013763","CD013763_pub3_data","3|2|Rates of block-related adverse events|","Rates of block-related adverse events",3,2,"","or","binary",7,-1.37159649854035,0.658328347255017,0,2019.57142857143,0.0547116237799468,74.5714285714286
"CD013763","CD013763_pub3_data","3|3|Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)",3,3,"","or","binary",6,-0.000438566406470739,0.822783159231657,0,2019.5,0,68
"CD013763","CD013763_pub3_data","3|4|Mean difference in postoperative pain intensity at rest - 2 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)",3,4,"","or","binary",3,-0.00814675119928741,1.16288265890014,0,2019.33333333333,0,70.3333333333333
"CD013763","CD013763_pub3_data","3|5|Mean difference in postoperative pain intensity at rest - 48 hours|","Mean difference in postoperative pain intensity at rest - 48 hours",3,5,"","or","binary",4,-0.000656640606205965,1.00677304793703,0,2019.5,0,74.5
"CD013763","CD013763_pub3_data","3|6|Mean difference in postoperative pain intensity during activity - 2 hours|","Mean difference in postoperative pain intensity during activity - 2 hours",3,6,"","or","binary",2,-0.012220955632055,1.42428287123035,0,2019.5,0,70.5
"CD013763","CD013763_pub3_data","3|7|Mean difference in postoperative pain intensity during activity - 48 hours (VAS)|","Mean difference in postoperative pain intensity during activity - 48 hours (VAS)",3,7,"","or","binary",4,-0.000656640606205965,1.00677304793703,0,2019.5,0,74.5
"CD013763","CD013763_pub3_data","3|9|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",3,9,"","or","binary",8,0,0.713002433434459,0,2019.5,0,62
"CD013763","CD013763_pub3_data","4|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",4,1,"","or","binary",3,0,1.16563592877185,0,2019.66666666667,0,53.3333333333333
"CD013763","CD013763_pub3_data","4|2|Rates of block-related adverse events|","Rates of block-related adverse events",4,2,"","or","binary",4,0,0.723903984301378,0,2019.75,0.018716577540107,50.5
"CD013763","CD013763_pub3_data","4|3|Mean difference in postoperative pain intensity at rest - 2 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)",4,3,"","or","binary",3,0,1.16563592877185,0,2019.66666666667,0,53.3333333333333
"CD013763","CD013763_pub3_data","4|4|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",4,4,"","or","binary",3,0,1.16583160029304,0,2019.66666666667,0,52.6666666666667
"CD013763","CD013763_pub3_data","4|5|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",4,5,"","or","binary",3,-0.526662302302559,0.352712003565838,0,2019.66666666667,0.347147950089127,53.3333333333333
"CD013763","CD013763_pub3_data","5|1|Rates of block-related adverse events|","Rates of block-related adverse events",5,1,"","or","binary",2,0,1.42688339079448,0,2020,0,55
"CD013763","CD013763_pub3_data","5|3|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",5,3,"","or","binary",2,0,1.42688339079448,0,2020,0,55
"CD013763","CD013763_pub3_data","5|4|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",5,4,"","or","binary",3,-0.354772668608255,0.490117431051455,0,2020,0.111111111111111,56.6666666666667
"CD013763","CD013763_pub3_data","5|5|Rates of opioid-related adverse events (pruritus)|","Rates of opioid-related adverse events (pruritus)",5,5,"","or","binary",2,-0.569877005704403,0.627410910149032,0,2020,0.116666666666667,60
"CD013763","CD013763_pub3_data","6|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",6,1,"","or","binary",2,-0.0510929449434677,1.42900650319643,0,2019,0,49
"CD013763","CD013763_pub3_data","6|3|Mean difference in postoperative pain intensity at rest - 2 hours (VAS)|","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)",6,3,"","or","binary",3,-0.0339989559238439,1.16569927831826,0,2019.33333333333,0,54
"CD013763","CD013763_pub3_data","6|4|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",6,4,"","or","binary",3,-0.0479524778000276,1.16674322467785,0,2019,0,48.3333333333333
"CD013763","CD013763_pub3_data","7|4|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",7,4,"","or","binary",2,0,1.42711761794411,0,2019,0,60
"CD013763","CD013763_pub3_data","7|5|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",7,5,"","or","binary",2,0,0.579400754597633,0,2019,0.075,60
"CD013763","CD013763_pub3_data","8|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",8,1,"","or","binary",2,0.0139068981159903,1.42487961884859,0,2020,0,65.5
"CD013763","CD013763_pub3_data","8|2|Rates of block-related adverse events|","Rates of block-related adverse events",8,2,"","or","binary",3,-1.22786869947188,1.03522381364081,0,2020,0.0666666666666667,60.3333333333333
"CD013763","CD013763_pub3_data","8|3|Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)",8,3,"","or","binary",2,0.0139068981159903,1.42487961884859,0,2020,0,65.5
"CD013763","CD013763_pub3_data","8|6|Cumulative mean oral morphine requirement in mg - 24 hours|","Cumulative mean oral morphine requirement in mg - 24 hours",8,6,"","or","binary",2,0.0139288269665419,1.42600257467382,0,2020,0,60.5
"CD013763","CD013763_pub3_data","8|7|Cumulative mean oral morphine requirement in mg - 48 hours|","Cumulative mean oral morphine requirement in mg - 48 hours",8,7,"","or","binary",2,0.0139288269665419,1.42600257467382,0,2020,0,60.5
"CD013763","CD013763_pub3_data","8|8|Rates of opioid-related adverse events (PONV)|","Rates of opioid-related adverse events (PONV)",8,8,"","or","binary",2,0.193760652435723,0.611706310602208,0,2020,0.0877777777777778,60.5
"CD013763","CD013763_pub3_data","9|1|Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)|","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)",9,1,"","or","binary",2,-0.0310822600721399,1.43206911667524,0,2019,0,40.5
"CD013764","CD013764_pub2_data","1|1|Successful abortion|NA","Successful abortion",1,1,NA,"or","binary",2,-0.353663230515123,0.462582362910299,0,2022.5,0.99,418.5
"CD013764","CD013764_pub2_data","1|7|Satisfaction|NA","Satisfaction",1,7,NA,"or","binary",2,1.20959365476521,0.666392762277386,0,2022.5,0.957636778115502,416
"CD013773","CD013773_pub2_data","1|1|Refractive error (D)|At 1 year","Refractive error (D)",1,1,"At 1 year","or","binary",4,0.122103664633179,1.00264366292679,0,2016.25,0,414
"CD013773","CD013773_pub2_data","1|1|Refractive error (D)|At 2 years","Refractive error (D)",1,1,"At 2 years","or","binary",4,-0.235387879835002,1.00243495857328,0,1586.25,0,613.5
"CD013773","CD013773_pub2_data","1|2|Incidence of myopia|At 1 year","Incidence of myopia",1,2,"At 1 year","or","binary",3,-0.214291047614961,0.210557894074242,0,2018,0.0952052128180405,421.666666666667
"CD013773","CD013773_pub2_data","1|2|Incidence of myopia|At 2 years","Incidence of myopia",1,2,"At 2 years","or","binary",3,-0.227371917730165,0.105681479276437,0,1444.66666666667,0.276805397535361,701.333333333333
"CD013773","CD013773_pub2_data","1|3|Axial length (mm)|At 1 year","Axial length (mm)",1,3,"At 1 year","or","binary",3,0.312306231778284,1.15585571348133,0,2018,0,555.333333333333
"CD013773","CD013773_pub2_data","1|3|Axial length (mm)|At 2 years","Axial length (mm)",1,3,"At 2 years","or","binary",3,-0.169985337992428,1.15553023996599,0,1444.66666666667,0,826.333333333333
"CD013774","CD013774_pub2_data","1|1|Time to death from any cause|","Time to death from any cause",1,1,"","reported","reported",3,-0.0332188299202623,0.0524423657074722,0,2020.33333333333,0,689.333333333333
"CD013774","CD013774_pub2_data","1|3|Adverse events grade 3 to 5|","Adverse events grade 3 to 5",1,3,"","or","binary",3,-1.83166786478877,0.431625033424865,0.521296817660901,2020.33333333333,0.775681578540163,682
"CD013774","CD013774_pub2_data","1|4|Time to disease progression|","Time to disease progression",1,4,"","reported","reported",2,0.281832633628425,0.0630646854773687,0,2020.5,0,674.5
"CD013774","CD013774_pub2_data","1|5|Discontinuation due to adverse events|","Discontinuation due to adverse events",1,5,"","or","binary",3,-0.905966572813274,0.555220031128342,0.874662109652317,2020.33333333333,0.238464317041751,682
"CD013774","CD013774_pub2_data","2|1|Time to death from any cause|","Time to death from any cause",2,1,"","reported","reported",2,-0.335103741995732,0.0660331637949667,0,2017,0,736.5
"CD013774","CD013774_pub2_data","2|2|Health-related quality of life|","Health-related quality of life",2,2,"","or","binary",2,-0.250358412104327,1.41631224026089,0,2017,0,363.5
"CD013774","CD013774_pub2_data","2|3|Adverse events grade 3 to 5|","Adverse events grade 3 to 5",2,3,"","or","binary",2,-0.287333034189716,0.108008897903858,8.43495876274917e-05,2017,0.620723232859735,711.5
"CD013774","CD013774_pub2_data","2|4|Time to disease progression|","Time to disease progression",2,4,"","reported","reported",2,-0.0109991725466374,0.0817962227252966,0,2017,NA,0
"CD013774","CD013774_pub2_data","2|5|Discontinuation due to adverse events|","Discontinuation due to adverse events",2,5,"","or","binary",2,-1.12201433672658,0.395406584118311,0.218657001548519,2017,0.12600805559244,711.5
"CD013774","CD013774_pub2_data","2|6|Time to death from any cause – subgroup analysis: positive versus negative PD-L1 status|PD-L1 positive (CPS > 10)","Time to death from any cause – subgroup analysis: positive versus negative PD-L1 status",2,6,"PD-L1 positive (CPS > 10)","reported","reported",2,-0.240959688101186,0.268196031431238,0.1159779828545,2019,NA,0
"CD013781","CD013781_pub2_data","10|1|All-cause mortality|With bolus","All-cause mortality",10,1,"With bolus","or","binary",7,-0.656207048305415,0.343167873714483,0.138259726220195,2012,0.0642752239509665,114.571428571429
"CD013781","CD013781_pub2_data","10|1|All-cause mortality|Without bolus","All-cause mortality",10,1,"Without bolus","or","binary",12,-0.45522961777939,0.255792766012605,0.0805262234984129,2014.41666666667,0.0841973947140218,151.916666666667
"CD013781","CD013781_pub2_data","10|2|Incidence of LCOS|With bolus","Incidence of LCOS",10,2,"With bolus","or","binary",4,-1.13796829494697,0.489028364228577,0.588972818383997,2012.5,0.241008353960396,150
"CD013781","CD013781_pub2_data","10|2|Incidence of LCOS|Without bolus","Incidence of LCOS",10,2,"Without bolus","or","binary",5,-0.583079633735547,0.219861315718428,0.0356899808228791,2016,0.202511232578771,266.4
"CD013781","CD013781_pub2_data","10|3|Adverse events: atrial fibrillation|With bolus","Adverse events: atrial fibrillation",10,3,"With bolus","or","binary",5,-0.292284778882019,0.301207704676764,0.240899517754877,2010.4,0.330113861386139,141.2
"CD013781","CD013781_pub2_data","10|3|Adverse events: atrial fibrillation|Without bolus","Adverse events: atrial fibrillation",10,3,"Without bolus","or","binary",11,-0.232311526628087,0.287011585281542,0.454245775855229,2014.63636363636,0.324008622019311,144.181818181818
"CD013781","CD013781_pub2_data","10|4|Adverse events: Perioperative myocardial infarction|With bolus","Adverse events: Perioperative myocardial infarction",10,4,"With bolus","or","binary",4,-0.497512270905955,0.352710021805084,0.101221807956494,2011.5,0.099279702970297,170.5
"CD013781","CD013781_pub2_data","10|4|Adverse events: Perioperative myocardial infarction|Without bolus","Adverse events: Perioperative myocardial infarction",10,4,"Without bolus","or","binary",6,0.0266166438232421,0.184037956460177,0,2014,0.0352819830390445,219
"CD013781","CD013781_pub2_data","10|5|Adverse events: non-embolic stroke or transient ischaemic attack|With bolus","Adverse events: non-embolic stroke or transient ischaemic attack",10,5,"With bolus","or","binary",3,-0.397266543666608,0.275578275970127,0,2012.33333333333,0.146805280528053,193.333333333333
"CD013781","CD013781_pub2_data","10|5|Adverse events: non-embolic stroke or transient ischaemic attack|Without bolus","Adverse events: non-embolic stroke or transient ischaemic attack",10,5,"Without bolus","or","binary",6,-0.208008034440723,0.415263837526045,0.207957319992759,2015.16666666667,0.0720662579057322,222.333333333333
"CD013781","CD013781_pub2_data","3|1|Primary outcome: all-cause mortality|","Primary outcome: all-cause mortality",3,1,"","or","binary",2,0,1.01712580754836,0,2011.5,0.0125,60
"CD013781","CD013781_pub2_data","3|11|Secondary outcome: proportion of weaning failure within 48 hours of extubation|","Secondary outcome: proportion of weaning failure within 48 hours of extubation",3,11,"","or","binary",2,0.146783903143275,0.582542194253677,0,2013,0.0745901639344262,82
"CD013781","CD013781_pub2_data","3|12|Secondary outcome: number of participants requiring mechanical circulatory support|","Secondary outcome: number of participants requiring mechanical circulatory support",3,12,"","or","binary",2,-0.915694149718872,0.635863074443393,0,2014.5,0.0956967213114754,102
"CD013781","CD013781_pub2_data","3|13|Secondary outcome: number of participants requiring additional inotropic drugs|","Secondary outcome: number of participants requiring additional inotropic drugs",3,13,"","or","binary",2,-0.111639693220372,0.295767375857206,0,2014.5,0.401844262295082,102
"CD013781","CD013781_pub2_data","3|18|Secondary outcome: proportion of renal failure|","Secondary outcome: proportion of renal failure",3,18,"","or","binary",2,-0.744295834688422,0.735434253491313,0,2011.5,0.0875,60
"CD013781","CD013781_pub2_data","3|7|Secondary outcome: cardiac index|Cardiac index 6 hours after surgery","Secondary outcome: cardiac index",3,7,"Cardiac index 6 hours after surgery","or","binary",2,0,1.43409142304122,0,2006,0,35
"CD013781","CD013781_pub2_data","3|8|Secondary outcome: mean arterial pressure|End of surgery mean arterial pressure","Secondary outcome: mean arterial pressure",3,8,"End of surgery mean arterial pressure","or","binary",2,-0.0161303925551513,1.4255736200605,0,2013,0,82
"CD013781","CD013781_pub2_data","4|1|Primary outcome: adverse events - atrial fibrillation|","Primary outcome: adverse events - atrial fibrillation",4,1,"","or","binary",2,-0.704641485784569,0.598294379564319,0.25766984043018,2015,0.216666666666667,70
"CD013781","CD013781_pub2_data","4|10|Secondary outcome: number of participants requiring additional inotropic drugs - epinephrine|","Secondary outcome: number of participants requiring additional inotropic drugs - epinephrine",4,10,"","or","binary",2,0.502862966384228,0.826256279841764,0.693698731982468,2015,0.0708333333333333,70
"CD013781","CD013781_pub2_data","4|11|Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine|","Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine",4,11,"","or","binary",2,1.5741856978082,0.60907116068488,0.339523680380298,2015,0.108333333333333,70
"CD013781","CD013781_pub2_data","4|3|Secondary outcome: length of ICU stay (days)|","Secondary outcome: length of ICU stay (days)",4,3,"","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","4|5|Secondary outcome: mean arterial pressure|Baseline mean arterial pressure","Secondary outcome: mean arterial pressure",4,5,"Baseline mean arterial pressure","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","4|5|Secondary outcome: mean arterial pressure|Mean arterial pressure after 12 hours","Secondary outcome: mean arterial pressure",4,5,"Mean arterial pressure after 12 hours","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","4|5|Secondary outcome: mean arterial pressure|Mean arterial pressure after 24 hours","Secondary outcome: mean arterial pressure",4,5,"Mean arterial pressure after 24 hours","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","4|5|Secondary outcome: mean arterial pressure|Mean arterial pressure after 6 hours","Secondary outcome: mean arterial pressure",4,5,"Mean arterial pressure after 6 hours","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","4|7|Secondary outcome: duration of mechanical ventilation (hours)|","Secondary outcome: duration of mechanical ventilation (hours)",4,7,"","or","binary",2,0,1.42433529953127,0,2015,0,70
"CD013781","CD013781_pub2_data","5|1|Primary outcome: all-cause mortality|","Primary outcome: all-cause mortality",5,1,"","or","binary",3,-0.970943659388742,0.535900124660824,0,2015,0.0743055555555556,69.3333333333333
"CD013781","CD013781_pub2_data","5|10|Secondary outcome: mean arterial pressure|Baseline mean arterial pressure","Secondary outcome: mean arterial pressure",5,10,"Baseline mean arterial pressure","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|10|Secondary outcome: mean arterial pressure|End of surgery mean arterial pressure","Secondary outcome: mean arterial pressure",5,10,"End of surgery mean arterial pressure","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|10|Secondary outcome: mean arterial pressure|Mean arterial pressure 24 hours after surgery","Secondary outcome: mean arterial pressure",5,10,"Mean arterial pressure 24 hours after surgery","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|10|Secondary outcome: mean arterial pressure|Mean arterial pressure 6 hours after surgery","Secondary outcome: mean arterial pressure",5,10,"Mean arterial pressure 6 hours after surgery","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|14|Secondary outcome: number of participants requiring mechanical circulatory support|","Secondary outcome: number of participants requiring mechanical circulatory support",5,14,"","or","binary",3,-0.186529838333005,0.365410847389395,0,2015,0.121875,69.3333333333333
"CD013781","CD013781_pub2_data","5|15|Secondary outcome: number of participants requiring additional inotropic drugs|","Secondary outcome: number of participants requiring additional inotropic drugs",5,15,"","or","binary",2,1.25907432471852,0.476272554609522,0,2015.5,0.333333333333333,40
"CD013781","CD013781_pub2_data","5|17|Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine|","Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine",5,17,"","or","binary",2,0.440809246594535,0.77676243341141,0.987631835093498,2016,0.405208333333333,94
"CD013781","CD013781_pub2_data","5|2|Primary outcome: incidence of LCOS|","Primary outcome: incidence of LCOS",5,2,"","or","binary",3,-0.703921097732169,0.578925831565959,0.357582364908094,2015,0.157291666666667,69.3333333333333
"CD013781","CD013781_pub2_data","5|22|Secondary outcome: proportion of renal failure|","Secondary outcome: proportion of renal failure",5,22,"","or","binary",3,-0.751079742362757,0.430731576351248,0,2015,0.129861111111111,69.3333333333333
"CD013781","CD013781_pub2_data","5|4|Primary outcome: adverse events - atrial fibrillation|","Primary outcome: adverse events - atrial fibrillation",5,4,"","or","binary",2,-1.0651583053738,0.713675236474317,0.642257402394306,2016,0.277083333333333,94
"CD013781","CD013781_pub2_data","5|7|Secondary outcome: length of hospital stay (days)|","Secondary outcome: length of hospital stay (days)",5,7,"","or","binary",2,0,1.43650272912082,0,2015.5,0,40
"CD013781","CD013781_pub2_data","5|8|Secondary outcome: length of ICU stay (days)|","Secondary outcome: length of ICU stay (days)",5,8,"","or","binary",2,0,1.43650272912082,0,2015.5,0,40
"CD013781","CD013781_pub2_data","5|9|Secondary outcome: cardiac index|Baseline cardiac index","Secondary outcome: cardiac index",5,9,"Baseline cardiac index","or","binary",3,0,1.16826812281767,0,2015,0,69.3333333333333
"CD013781","CD013781_pub2_data","5|9|Secondary outcome: cardiac index|Cardiac index 24 hours after surgery","Secondary outcome: cardiac index",5,9,"Cardiac index 24 hours after surgery","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|9|Secondary outcome: cardiac index|Cardiac index 6 hours after surgery","Secondary outcome: cardiac index",5,9,"Cardiac index 6 hours after surgery","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","5|9|Secondary outcome: cardiac index|End-of-surgery cardiac index","Secondary outcome: cardiac index",5,9,"End-of-surgery cardiac index","or","binary",2,0,1.42271166727376,0,2016,0,94
"CD013781","CD013781_pub2_data","6|1|Primary outcome: all-cause mortality|","Primary outcome: all-cause mortality",6,1,"","or","binary",2,-1.35649516870616,1.23510336472503,0,2011.5,0.1,35
"CD013781","CD013781_pub2_data","6|4|Secondary outcome: length of ICU stay (days)|","Secondary outcome: length of ICU stay (days)",6,4,"","or","binary",2,0,1.42854903699424,0,2017.5,0,50
"CD013781","CD013781_pub2_data","6|6|Secondary outcome: duration of mechanical ventilation (hours)|","Secondary outcome: duration of mechanical ventilation (hours)",6,6,"","or","binary",3,0,1.16864953137067,0,2014,0,43.3333333333333
"CD013781","CD013781_pub2_data","6|7|Secondary outcome: number of participants requiring mechanical circulatory support|","Secondary outcome: number of participants requiring mechanical circulatory support",6,7,"","or","binary",2,-0.601073551830936,0.933049448730261,0.613513200563794,2013,0.183333333333333,45
"CD013781","CD013781_pub2_data","7|1|Primary outcome: all-cause mortality|","Primary outcome: all-cause mortality",7,1,"","or","binary",14,-0.452631117747757,0.220831851046491,0.0963341623401277,2013.5,0.0740984741113115,167.642857142857
"CD013781","CD013781_pub2_data","7|10|Secondary outcome: mean arterial pressure|Baseline mean arterial pressure","Secondary outcome: mean arterial pressure",7,10,"Baseline mean arterial pressure","or","binary",4,0,1.01472553322108,0,2011.5,0,36.5
"CD013781","CD013781_pub2_data","7|10|Secondary outcome: mean arterial pressure|End of surgery mean arterial pressure","Secondary outcome: mean arterial pressure",7,10,"End of surgery mean arterial pressure","or","binary",3,0,1.16596693970462,0,2012.33333333333,0,134.666666666667
"CD013781","CD013781_pub2_data","7|10|Secondary outcome: mean arterial pressure|Mean arterial pressure 12 hours after surgery","Secondary outcome: mean arterial pressure",7,10,"Mean arterial pressure 12 hours after surgery","or","binary",3,0,1.168974582089,0,2013.66666666667,0,124.666666666667
"CD013781","CD013781_pub2_data","7|10|Secondary outcome: mean arterial pressure|Mean arterial pressure 24 hours after surgery","Secondary outcome: mean arterial pressure",7,10,"Mean arterial pressure 24 hours after surgery","or","binary",5,0,0.905205176682458,0,2013.2,0,93.2
"CD013781","CD013781_pub2_data","7|10|Secondary outcome: mean arterial pressure|Mean arterial pressure 6 hours after surgery","Secondary outcome: mean arterial pressure",7,10,"Mean arterial pressure 6 hours after surgery","or","binary",3,0,1.168974582089,0,2013.66666666667,0,124.666666666667
"CD013781","CD013781_pub2_data","7|11|Secondary outcome: PCWP|Baseline PCWP","Secondary outcome: PCWP",7,11,"Baseline PCWP","or","binary",5,0,0.906703940539388,0,2012,0,39.2
"CD013781","CD013781_pub2_data","7|11|Secondary outcome: PCWP|End of surgery PCWP","Secondary outcome: PCWP",7,11,"End of surgery PCWP","or","binary",3,0,1.16917515031661,0,2010.33333333333,0,44.6666666666667
"CD013781","CD013781_pub2_data","7|11|Secondary outcome: PCWP|PCWP 12 hours after surgery","Secondary outcome: PCWP",7,11,"PCWP 12 hours after surgery","or","binary",3,0,1.17220775278511,0,2011.66666666667,0,34.6666666666667
"CD013781","CD013781_pub2_data","7|11|Secondary outcome: PCWP|PCWP 24 hours after surgery","Secondary outcome: PCWP",7,11,"PCWP 24 hours after surgery","or","binary",5,0,0.906703940539388,0,2012,0,39.2
"CD013781","CD013781_pub2_data","7|11|Secondary outcome: PCWP|PCWP 6 hours after surgery","Secondary outcome: PCWP",7,11,"PCWP 6 hours after surgery","or","binary",2,0,1.43952392849938,0,2010.5,0,27
"CD013781","CD013781_pub2_data","7|12|Secondary outcome: duration of mechanical ventilation (hours)|","Secondary outcome: duration of mechanical ventilation (hours)",7,12,"","or","binary",7,-0.00563535073205237,0.765509592514684,0,2012.71428571429,0,81.7142857142857
"CD013781","CD013781_pub2_data","7|13|Secondary outcome: proportion of weaning failure within 48 hours after extubation|","Secondary outcome: proportion of weaning failure within 48 hours after extubation",7,13,"","or","binary",5,-1.24183539499528,0.354209532483572,0,2013.6,0.205033333333333,246.6
"CD013781","CD013781_pub2_data","7|14|Secondary outcome: number of participants requiring mechanical circulatory support|","Secondary outcome: number of participants requiring mechanical circulatory support",7,14,"","or","binary",10,-0.836442014452321,0.359722175790648,0.685102569707456,2013.7,0.187301305069428,188.1
"CD013781","CD013781_pub2_data","7|15|Secondary outcome: number of participants requiring additional inotropic drugs|","Secondary outcome: number of participants requiring additional inotropic drugs",7,15,"","or","binary",6,-1.01510268068392,0.504075219823931,1.24379498433396,2012.5,0.43232258794254,268.666666666667
"CD013781","CD013781_pub2_data","7|16|Secondary outcome: number of participants requiring additional inotropic drugs - epinephrine|","Secondary outcome: number of participants requiring additional inotropic drugs - epinephrine",7,16,"","or","binary",5,-0.804532744975287,0.749414709094917,1.866039840876,2012.8,0.341512258368694,131.6
"CD013781","CD013781_pub2_data","7|17|Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine|","Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine",7,17,"","or","binary",6,0.833799858701775,0.449429284394409,0.777063167261099,2013.16666666667,0.46477683482634,113
"CD013781","CD013781_pub2_data","7|19|Secondary outcome: number of participants requiring additional inotropic drugs - dobutamine|","Secondary outcome: number of participants requiring additional inotropic drugs - dobutamine",7,19,"","or","binary",4,-1.4139450899882,0.470851855713986,0.319360317951754,2011.5,0.366615099009901,69.25
"CD013781","CD013781_pub2_data","7|2|Primary outcome: incidence of LCOS|","Primary outcome: incidence of LCOS",7,2,"","or","binary",6,-1.06815725022748,0.33525247128892,0.362742165568347,2014.16666666667,0.250785763122573,287.333333333333
"CD013781","CD013781_pub2_data","7|21|Secondary outcome: number of participants requiring additional inotropic drugs - milrinone|","Secondary outcome: number of participants requiring additional inotropic drugs - milrinone",7,21,"","or","binary",2,-1.52618505062521,0.926186786791809,0.594205201744873,2010,0.122937293729373,130
"CD013781","CD013781_pub2_data","7|25|Secondary outcome: number of participants requiring cardiac transplantation|","Secondary outcome: number of participants requiring cardiac transplantation",7,25,"","or","binary",4,-1.57876399331671,0.823101832841652,0,2014,0.0563810240963855,162
"CD013781","CD013781_pub2_data","7|27|Secondary outcome: proportion of renal failure |","Secondary outcome: proportion of renal failure ",7,27,"","or","binary",9,-0.349724264581709,0.260893099583084,0.146189006904792,2014.22222222222,0.129251207128554,202.111111111111
"CD013781","CD013781_pub2_data","7|3|Primary outcome: adverse events - cardiogenic shock|","Primary outcome: adverse events - cardiogenic shock",7,3,"","or","binary",3,-0.44498433367298,0.264306372767699,0,2015.66666666667,0.0629262894809642,404
"CD013781","CD013781_pub2_data","7|4|Primary outcome: adverse events - atrial fibrillation|","Primary outcome: adverse events - atrial fibrillation",7,4,"","or","binary",11,-0.0319475600765741,0.226715674106812,0.271188624723008,2013.09090909091,0.341863407497859,175.818181818182
"CD013781","CD013781_pub2_data","7|5|Primary outcome: adverse events - perioperative myocardial infarction|","Primary outcome: adverse events - perioperative myocardial infarction",7,5,"","or","binary",8,-0.0732544467913352,0.163222009426109,0.00112571486745597,2013.625,0.0604763387644319,229.75
"CD013781","CD013781_pub2_data","7|6|Primary outcome: adverse events - non-embolic stroke or transient ischaemic attack |","Primary outcome: adverse events - non-embolic stroke or transient ischaemic attack ",7,6,"","or","binary",8,-0.112864209916348,0.234285167461765,0,2014.25,0.0778516736273189,223.25
"CD013781","CD013781_pub2_data","7|7|Secondary outcome: length of hospital stay (days)|","Secondary outcome: length of hospital stay (days)",7,7,"","or","binary",6,-0.00318748065666235,0.826524918120077,0,2011.16666666667,0,70.3333333333333
"CD013781","CD013781_pub2_data","7|8|Secondary outcome: length of ICU stay (days)|","Secondary outcome: length of ICU stay (days)",7,8,"","or","binary",7,-0.00563535073205237,0.765509592514684,0,2012.71428571429,0,81.7142857142857
"CD013781","CD013781_pub2_data","7|9|Secondary outcome: cardiac index|Baseline cardiac index","Secondary outcome: cardiac index",7,9,"Baseline cardiac index","or","binary",5,0,0.905492892067835,0,2014.2,0,91.2
"CD013781","CD013781_pub2_data","7|9|Secondary outcome: cardiac index|Cardiac index 12 hours after surgery","Secondary outcome: cardiac index",7,9,"Cardiac index 12 hours after surgery","or","binary",3,0,1.17220775278511,0,2011.66666666667,0,34.6666666666667
"CD013781","CD013781_pub2_data","7|9|Secondary outcome: cardiac index|Cardiac index 24 hours after surgery","Secondary outcome: cardiac index",7,9,"Cardiac index 24 hours after surgery","or","binary",5,0,0.905492892067835,0,2014.2,0,91.2
"CD013781","CD013781_pub2_data","7|9|Secondary outcome: cardiac index|Cardiac index 6 hours after surgery","Secondary outcome: cardiac index",7,9,"Cardiac index 6 hours after surgery","or","binary",2,0,1.43952392849938,0,2010.5,0,27
"CD013781","CD013781_pub2_data","7|9|Secondary outcome: cardiac index|End of surgery cardiac index","Secondary outcome: cardiac index",7,9,"End of surgery cardiac index","or","binary",2,0,1.43506304411829,0,2011,0,37
"CD013781","CD013781_pub2_data","8|1|Adverse event: atrial fibrillation|Levosimendan vs active controlled","Adverse event: atrial fibrillation",8,1,"Levosimendan vs active controlled","or","binary",3,-0.534796216819933,0.39528117779515,0,2012.33333333333,0.3,56.6666666666667
"CD013781","CD013781_pub2_data","8|1|Adverse event: atrial fibrillation|Levosimendan vs passive controlled","Adverse event: atrial fibrillation",8,1,"Levosimendan vs passive controlled","or","binary",13,-0.179134715951979,0.226758734313762,0.344634027753489,2013.53846153846,0.331897242241778,163.230769230769
"CD013781","CD013781_pub2_data","9|1|All-cause mortality|Perioperative/anaesthesia induction period","All-cause mortality",9,1,"Perioperative/anaesthesia induction period","or","binary",8,-0.0862511880030841,0.222451267004893,0,2012.25,0.0564848296947951,204.125
"CD013781","CD013781_pub2_data","9|1|All-cause mortality|Preoperative period","All-cause mortality",9,1,"Preoperative period","or","binary",5,-1.11860670786115,0.395573304679325,0,2014.2,0.1046,78.8
"CD013781","CD013781_pub2_data","9|2|Incidence of LCOS|Perioperative/anaesthesia induction period","Incidence of LCOS",9,2,"Perioperative/anaesthesia induction period","or","binary",3,-1.18621561711944,0.644413808663457,0.870340669941735,2015,0.282238192911813,460.666666666667
"CD013781","CD013781_pub2_data","9|2|Incidence of LCOS|Preoperative period","Incidence of LCOS",9,2,"Preoperative period","or","binary",3,-1.04338532428445,0.326595188583088,0,2013.33333333333,0.219333333333333,114
"CD013781","CD013781_pub2_data","9|3|Adverse events: atrial fibrillation|Perioperative/anaesthesia induction period","Adverse events: atrial fibrillation",9,3,"Perioperative/anaesthesia induction period","or","binary",6,0.251039660729368,0.10833066244765,0,2012.16666666667,0.312999580412741,256.666666666667
"CD013781","CD013781_pub2_data","9|3|Adverse events: atrial fibrillation|Preoperative period","Adverse events: atrial fibrillation",9,3,"Preoperative period","or","binary",5,-0.333489338236384,0.536089695560377,0.93321266776582,2014.2,0.3765,78.8
"CD013781","CD013781_pub2_data","9|4|Adverse events: perioperative myocardial infarction|Perioperative/anaesthesia induction period ","Adverse events: perioperative myocardial infarction",9,4,"Perioperative/anaesthesia induction period ","or","binary",5,-0.0126226015570671,0.166089521501779,0,2013.4,0.0739621420230911,302.8
"CD013781","CD013781_pub2_data","9|4|Adverse events: perioperative myocardial infarction|Preoperative period","Adverse events: perioperative myocardial infarction",9,4,"Preoperative period","or","binary",3,-0.974825548575333,0.744950184092481,0.228763187698578,2014,0.038,108
"CD013781","CD013781_pub2_data","9|5|Adverse events: non-embolic stroke or transient ischaemic attack|Perioperative/anaesthesia induction period","Adverse events: non-embolic stroke or transient ischaemic attack",9,5,"Perioperative/anaesthesia induction period","or","binary",4,-0.1201190438968,0.373768143482192,0.143946684779028,2014.5,0.0545783472546379,353
"CD013781","CD013781_pub2_data","9|5|Adverse events: non-embolic stroke or transient ischaemic attack|Preoperative period","Adverse events: non-embolic stroke or transient ischaemic attack",9,5,"Preoperative period","or","binary",4,-0.253592598987608,0.433078200823597,0,2014,0.101125,93.5
"CD013789","CD013789_pub2_data","1|1|Scar improvement (VSS) (PGT vs other scar management therapy)|PGT + scar management therapy (including silicone) vs scar management therapy (including silicone)","Scar improvement (VSS) (PGT vs other scar management therapy)",1,1,"PGT + scar management therapy (including silicone) vs scar management therapy (including silicone)","or","binary",5,-0.0571022970106168,0.9013310761149,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|1|Scar improvement (VSS) (PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar improvement (VSS) (PGT vs other scar management therapy)",1,1,"PGT + silicone vs no treatment/lanolin","or","binary",2,-1.16643488500687,1.43841058866039,0,2004,0,39
"CD013789","CD013789_pub2_data","1|1|Scar improvement (VSS) (PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar improvement (VSS) (PGT vs other scar management therapy)",1,1,"PGT + silicone vs silicone","or","binary",2,-0.260726262463253,1.42746980296174,0,2004,0,53
"CD013789","CD013789_pub2_data","1|1|Scar improvement (VSS) (PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar improvement (VSS) (PGT vs other scar management therapy)",1,1,"PGT vs no treatment/lanolin","or","binary",5,-1.16801789658951,0.909572675640094,0,2005.6,0,40.8
"CD013789","CD013789_pub2_data","1|1|Scar improvement (VSS) (PGT vs other scar management therapy)|PGT vs silicone","Scar improvement (VSS) (PGT vs other scar management therapy)",1,1,"PGT vs silicone","or","binary",2,-0.383958902887201,1.42680389310089,0,2004,0,57
"CD013789","CD013789_pub2_data","1|10|Scar pigmentation (POSAS observer, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar pigmentation (POSAS observer, PGT vs other scar management therapy)",1,10,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0636160229015272,0.901376133256133,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|10|Scar pigmentation (POSAS observer, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar pigmentation (POSAS observer, PGT vs other scar management therapy)",1,10,"PGT + silicone vs silicone","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|10|Scar pigmentation (POSAS observer, PGT vs other scar management therapy)|PGT vs silicone","Scar pigmentation (POSAS observer, PGT vs other scar management therapy)",1,10,"PGT vs silicone","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|11|Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)",1,11,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.122674063354337,0.906493546173025,0,2018,0,40.2
"CD013789","CD013789_pub2_data","1|11|Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)",1,11,"PGT + silicone vs silicone","or","binary",4,0.116113291868532,1.00633945567501,0,2020,0,81.75
"CD013789","CD013789_pub2_data","1|11|Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)",1,11,"PGT vs silicone","or","binary",4,0.0918708306502718,1.00618754292763,0,2020,0,82
"CD013789","CD013789_pub2_data","1|12|Scar colour – lightness (PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar colour – lightness (PGT vs other scar management therapy)",1,12,"PGT + silicone vs no treatment/lanolin","or","binary",7,-0.428336870312568,0.764181896319415,0,2008.28571428571,0,48.8571428571429
"CD013789","CD013789_pub2_data","1|12|Scar colour – lightness (PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar colour – lightness (PGT vs other scar management therapy)",1,12,"PGT + silicone vs silicone","or","binary",11,-0.0927644401406759,0.607806911917009,0,2012.54545454545,0,67.3636363636364
"CD013789","CD013789_pub2_data","1|12|Scar colour – lightness (PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar colour – lightness (PGT vs other scar management therapy)",1,12,"PGT vs no treatment/lanolin","or","binary",9,-0.776823625346784,0.675211207259523,0,2008.66666666667,0,47.8888888888889
"CD013789","CD013789_pub2_data","1|12|Scar colour – lightness (PGT vs other scar management therapy)|PGT vs silicone","Scar colour – lightness (PGT vs other scar management therapy)",1,12,"PGT vs silicone","or","binary",11,-0.113623527994848,0.607739845629748,0,2012.54545454545,0,67.6363636363636
"CD013789","CD013789_pub2_data","1|13|Scar colour – redness (PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar colour – redness (PGT vs other scar management therapy)",1,13,"PGT + silicone vs no treatment/lanolin","or","binary",7,-0.556796105299871,0.765012980926328,0,2008.28571428571,0,46.8571428571429
"CD013789","CD013789_pub2_data","1|13|Scar colour – redness (PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar colour – redness (PGT vs other scar management therapy)",1,13,"PGT + silicone vs silicone","or","binary",11,-0.0892466551689709,0.607743299473028,0,2012.54545454545,0,69.6363636363636
"CD013789","CD013789_pub2_data","1|13|Scar colour – redness (PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar colour – redness (PGT vs other scar management therapy)",1,13,"PGT vs no treatment/lanolin","or","binary",9,-0.776823625346784,0.675211207259523,0,2008.66666666667,0,47.8888888888889
"CD013789","CD013789_pub2_data","1|13|Scar colour – redness (PGT vs other scar management therapy)|PGT vs silicone","Scar colour – redness (PGT vs other scar management therapy)",1,13,"PGT vs silicone","or","binary",11,-0.104980757426514,0.607683678490272,0,2012.54545454545,0,69.6363636363636
"CD013789","CD013789_pub2_data","1|14|Scar colour – redness (high vs low pressure)|Burns, adults, measured with Minolta Chromameter","Scar colour – redness (high vs low pressure)",1,14,"Burns, adults, measured with Minolta Chromameter","or","binary",3,-0.184734103199339,1.16233699829102,0,2005,0,75
"CD013789","CD013789_pub2_data","1|14|Scar colour – redness (high vs low pressure)|Mixed population, adults, measured with Spectrocolorimeter","Scar colour – redness (high vs low pressure)",1,14,"Mixed population, adults, measured with Spectrocolorimeter","or","binary",5,0,0.902238930505273,0,2010,0,56
"CD013789","CD013789_pub2_data","1|15|Scar colour – yellowness (PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar colour – yellowness (PGT vs other scar management therapy)",1,15,"PGT + silicone vs no treatment/lanolin","or","binary",7,-0.556796105299871,0.765012980926328,0,2008.28571428571,0,46.8571428571429
"CD013789","CD013789_pub2_data","1|15|Scar colour – yellowness (PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar colour – yellowness (PGT vs other scar management therapy)",1,15,"PGT + silicone vs silicone","or","binary",7,-0.207145972556766,0.762972880123806,0,2008.28571428571,0,53
"CD013789","CD013789_pub2_data","1|15|Scar colour – yellowness (PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar colour – yellowness (PGT vs other scar management therapy)",1,15,"PGT vs no treatment/lanolin","or","binary",9,-0.776823625346784,0.675211207259523,0,2008.66666666667,0,47.8888888888889
"CD013789","CD013789_pub2_data","1|15|Scar colour – yellowness (PGT vs other scar management therapy)|PGT vs silicone","Scar colour – yellowness (PGT vs other scar management therapy)",1,15,"PGT vs silicone","or","binary",7,-0.266186438774253,0.762796840327903,0,2008.28571428571,0,54.8571428571429
"CD013789","CD013789_pub2_data","1|16|Scar pliability (VSS, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar pliability (VSS, PGT vs other scar management therapy)",1,16,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0571022970106168,0.9013310761149,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|16|Scar pliability (VSS, PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar pliability (VSS, PGT vs other scar management therapy)",1,16,"PGT + silicone vs no treatment/lanolin","or","binary",5,-0.316337328212157,0.903372562456014,0,2010,0,50
"CD013789","CD013789_pub2_data","1|16|Scar pliability (VSS, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar pliability (VSS, PGT vs other scar management therapy)",1,16,"PGT + silicone vs silicone","or","binary",5,-0.185717145795093,0.902741893523875,0,2010,0,53
"CD013789","CD013789_pub2_data","1|16|Scar pliability (VSS, PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar pliability (VSS, PGT vs other scar management therapy)",1,16,"PGT vs no treatment/lanolin","or","binary",6,-0.306093124361893,0.824358165556611,0,2008.33333333333,0,52
"CD013789","CD013789_pub2_data","1|16|Scar pliability (VSS, PGT vs other scar management therapy)|PGT vs silicone","Scar pliability (VSS, PGT vs other scar management therapy)",1,16,"PGT vs silicone","or","binary",5,-0.219053566062685,0.90261876911313,0,2010,0,54
"CD013789","CD013789_pub2_data","1|17|Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)",1,17,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.122674063354337,0.906493546173025,0,2018,0,40.2
"CD013789","CD013789_pub2_data","1|17|Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)",1,17,"PGT + silicone vs silicone","or","binary",4,0.130875164349852,1.00637550890011,0,2020,0,81
"CD013789","CD013789_pub2_data","1|17|Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)",1,17,"PGT vs silicone","or","binary",4,0.0835665692767818,1.0061532414552,0,2020,0,82.25
"CD013789","CD013789_pub2_data","1|18|Scar pliability (POSAS observer, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar pliability (POSAS observer, PGT vs other scar management therapy)",1,18,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0636160229015272,0.901376133256133,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|18|Scar pliability (POSAS observer, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar pliability (POSAS observer, PGT vs other scar management therapy)",1,18,"PGT + silicone vs silicone","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|18|Scar pliability (POSAS observer, PGT vs other scar management therapy)|PGT vs silicone","Scar pliability (POSAS observer, PGT vs other scar management therapy)",1,18,"PGT vs silicone","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|19|Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)",1,19,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.122674063354337,0.906493546173025,0,2018,0,40.2
"CD013789","CD013789_pub2_data","1|19|Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)",1,19,"PGT + silicone vs silicone","or","binary",4,0.125858057529145,1.00636301710264,0,2020,0,81.25
"CD013789","CD013789_pub2_data","1|19|Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)",1,19,"PGT vs silicone","or","binary",4,0.0777457418221426,1.00613640359638,0,2020,0,82.5
"CD013789","CD013789_pub2_data","1|2|Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)",1,2,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.122674063354337,0.906493546173025,0,2018,0,40.2
"CD013789","CD013789_pub2_data","1|2|Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)",1,2,"PGT + silicone vs silicone","or","binary",4,0.105373555337049,1.00639122038707,0,2020,0,80.75
"CD013789","CD013789_pub2_data","1|2|Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)",1,2,"PGT vs silicone","or","binary",4,0.08306206316951,1.00625041135842,0,2020,0,81
"CD013789","CD013789_pub2_data","1|20|Scar relief (POSAS observer, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar relief (POSAS observer, PGT vs other scar management therapy)",1,20,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0683974082086312,0.901388814078268,0,2018,0,67
"CD013789","CD013789_pub2_data","1|20|Scar relief (POSAS observer, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar relief (POSAS observer, PGT vs other scar management therapy)",1,20,"PGT + silicone vs silicone","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|20|Scar relief (POSAS observer, PGT vs other scar management therapy)|PGT vs silicone","Scar relief (POSAS observer, PGT vs other scar management therapy)",1,20,"PGT vs silicone","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|21|Scar height (VSS, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar height (VSS, PGT vs other scar management therapy)",1,21,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0571022970106168,0.9013310761149,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|22|Vascularity (POSAS observer, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Vascularity (POSAS observer, PGT vs other scar management therapy)",1,22,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0730570791630571,0.901326573298032,0,2018,0,67.4
"CD013789","CD013789_pub2_data","1|22|Vascularity (POSAS observer, PGT vs other scar management therapy)|PGT + silicone vs silicone","Vascularity (POSAS observer, PGT vs other scar management therapy)",1,22,"PGT + silicone vs silicone","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|22|Vascularity (POSAS observer, PGT vs other scar management therapy)|PGT vs silicone","Vascularity (POSAS observer, PGT vs other scar management therapy)",1,22,"PGT vs silicone","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|3|Scar improvement (POSAS) (observer, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Scar improvement (POSAS) (observer, PGT vs other scar management therapy)",1,3,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.0746034457249839,0.901409628758981,0,2018,0,66.8
"CD013789","CD013789_pub2_data","1|3|Scar improvement (POSAS) (observer, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar improvement (POSAS) (observer, PGT vs other scar management therapy)",1,3,"PGT + silicone vs silicone","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|3|Scar improvement (POSAS) (observer, PGT vs other scar management therapy)|PGT vs silicone","Scar improvement (POSAS) (observer, PGT vs other scar management therapy)",1,3,"PGT vs silicone","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|4|Pain (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Pain (POSAS participant/caregiver, PGT vs other scar management therapy)",1,4,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.113556611092466,0.906539292191637,0,2018,0,40
"CD013789","CD013789_pub2_data","1|4|Pain (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Pain (POSAS participant/caregiver, PGT vs other scar management therapy)",1,4,"PGT + silicone vs silicone","or","binary",4,0.116113291868532,1.00633945567501,0,2020,0,81.75
"CD013789","CD013789_pub2_data","1|4|Pain (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Pain (POSAS participant/caregiver, PGT vs other scar management therapy)",1,4,"PGT vs silicone","or","binary",4,0.0828607230323805,1.00614939911764,0,2020,0,82.25
"CD013789","CD013789_pub2_data","1|5|Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone","Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)",1,5,"PGT + scar management therapy including silicone vs scar management therapy including silicone","or","binary",5,-0.113556611092465,0.906539292191637,0,2018,0,40
"CD013789","CD013789_pub2_data","1|5|Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT + silicone vs silicone","Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)",1,5,"PGT + silicone vs silicone","or","binary",4,0.110671841557957,1.00635416537989,0,2020,0,81.5
"CD013789","CD013789_pub2_data","1|5|Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)|PGT vs silicone","Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)",1,5,"PGT vs silicone","or","binary",4,0.0774201550954204,1.00616411287137,0,2020,0,82
"CD013789","CD013789_pub2_data","1|6|Scar thickness (ultrasound, PGT vs other scar management therapy)|PGT + silicone vs no treatment/lanolin","Scar thickness (ultrasound, PGT vs other scar management therapy)",1,6,"PGT + silicone vs no treatment/lanolin","or","binary",7,-0.556796105299871,0.765012980926328,0,2008.28571428571,0,46.8571428571429
"CD013789","CD013789_pub2_data","1|6|Scar thickness (ultrasound, PGT vs other scar management therapy)|PGT + silicone vs silicone","Scar thickness (ultrasound, PGT vs other scar management therapy)",1,6,"PGT + silicone vs silicone","or","binary",11,-0.061775908241091,0.607819714932766,0,2012.54545454545,0,68.1818181818182
"CD013789","CD013789_pub2_data","1|6|Scar thickness (ultrasound, PGT vs other scar management therapy)|PGT vs no treatment/lanolin","Scar thickness (ultrasound, PGT vs other scar management therapy)",1,6,"PGT vs no treatment/lanolin","or","binary",9,-0.776823625346784,0.675211207259523,0,2008.66666666667,0,47.8888888888889
"CD013789","CD013789_pub2_data","1|6|Scar thickness (ultrasound, PGT vs other scar management therapy)|PGT vs silicone","Scar thickness (ultrasound, PGT vs other scar management therapy)",1,6,"PGT vs silicone","or","binary",11,-0.0952391625408534,0.607725659977037,0,2012.54545454545,0,68.9090909090909
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone, caregiver rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT + scar management therapy including silicone vs scar management therapy including silicone, caregiver rated","or","binary",5,-0.130153910695872,0.906524368320066,0,2018,0,40
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT + scar management therapy including silicone vs scar management therapy including silicone, observer rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT + scar management therapy including silicone vs scar management therapy including silicone, observer rated","or","binary",5,-0.0636160229015272,0.901376133256133,0,2018,0,67.2
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT + silicone vs silicone, caregiver rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT + silicone vs silicone, caregiver rated","or","binary",4,0.130875164349852,1.00637550890011,0,2020,0,81
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT + silicone vs silicone, observer rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT + silicone vs silicone, observer rated","or","binary",4,0.116031761840241,1.00524326916111,0,2020,0,98.75
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT vs silicone, caregiver rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT vs silicone, caregiver rated","or","binary",4,0.0777457418221426,1.00613640359638,0,2020,0,82.5
"CD013789","CD013789_pub2_data","1|7|Scar thickness (POSAS, PGT vs other scar management therapy)|PGT vs silicone, observer rated","Scar thickness (POSAS, PGT vs other scar management therapy)",1,7,"PGT vs silicone, observer rated","or","binary",4,0.156288376658153,1.00531329727105,0,2020,0,96.25
"CD013789","CD013789_pub2_data","1|8|Scar thickness (ultrasound, high vs low pressure)|","Scar thickness (ultrasound, high vs low pressure)",1,8,"","or","binary",10,-0.140721201126237,0.637635333786024,0,2008,0,61.8
"CD013789","CD013789_pub2_data","1|9|Scar pigmentation (VSS, PGT vs other scar management therapy)|PGT + standard care (including silicone) vs standard care (including silicone)","Scar pigmentation (VSS, PGT vs other scar management therapy)",1,9,"PGT + standard care (including silicone) vs standard care (including silicone)","or","binary",5,-0.0571022970106168,0.9013310761149,0,2018,0,67.2
"CD013800","CD013800_pub2_data","1|1|Residual kidney function at 6 months [mL/min/1.73 m2]|","Residual kidney function at 6 months [mL/min/1.73 m2]",1,1,"","or","binary",2,-0.360159294378096,1.42887599014449,0,2007,0,73
"CD013800","CD013800_pub2_data","1|10|Infection episodes (all types)|","Infection episodes (all types)",1,10,"","or","binary",3,0.348083230223666,0.26329805987777,1.57316399570515e-06,2012,0.463818860877684,92.3333333333333
"CD013800","CD013800_pub2_data","1|11|Bacteraemia/bloodstream infection episodes|","Bacteraemia/bloodstream infection episodes",1,11,"","or","binary",2,-1.17546362291716,0.0954632868651046,0,2009,0.3260702208792,1318.5
"CD013800","CD013800_pub2_data","1|12|Acute myocardial infarction|","Acute myocardial infarction",1,12,"","or","binary",4,-0.105758105353851,0.116465695817468,0.0285420409974079,2012,0.0834164133419392,27712.5
"CD013800","CD013800_pub2_data","1|13|Coronary artery disease|","Coronary artery disease",1,13,"","or","binary",3,-0.0688026031300949,0.400107632804225,0.315407550010916,2012,0.0887739629354132,1942
"CD013800","CD013800_pub2_data","1|14|Ischaemic heart disease|","Ischaemic heart disease",1,14,"","or","binary",2,-0.161537110006384,0.217561761736573,0.0895367251107511,2013.5,0.076460749045999,29187
"CD013800","CD013800_pub2_data","1|15|Congestive heart failure|","Congestive heart failure",1,15,"","or","binary",3,0.0799534054523422,0.340824534177783,0.297986622733858,2012,0.048437115714238,16503.6666666667
"CD013800","CD013800_pub2_data","1|16|Stroke|","Stroke",1,16,"","or","binary",4,-0.0675677785206936,0.0261636316381211,0,2018.5,0.0648875584412135,25635.5
"CD013800","CD013800_pub2_data","1|17|Hospitalisation|","Hospitalisation",1,17,"","or","binary",4,-0.029631933034662,0.309565821849873,0.288785792775411,2011.75,0.51979402901281,820.5
"CD013800","CD013800_pub2_data","1|18|All-cause hospitalisation events|","All-cause hospitalisation events",1,18,"","or","binary",4,-0.0200262969505052,0.240232776937576,0.185120247031533,2015.25,0.545143848579348,10645.5
"CD013800","CD013800_pub2_data","1|19|Employed patients 1 year after dialysis initiation|","Employed patients 1 year after dialysis initiation",1,19,"","or","binary",2,-0.589255515323446,1.3377579343476,3.39540930790291,2016,0.50797342192691,296.5
"CD013800","CD013800_pub2_data","1|3|Residual kidney function at 24 months [mL/min/1.73 m2]|","Residual kidney function at 24 months [mL/min/1.73 m2]",1,3,"","or","binary",3,-0.0916095054320566,1.16636772495567,0,2009.33333333333,0,111.333333333333
"CD013800","CD013800_pub2_data","1|4|Residual urine volume at 12 months [mL/day]|","Residual urine volume at 12 months [mL/day]",1,4,"","or","binary",3,-0.0830009774216562,1.16348212381182,0,2015.66666666667,0,84.3333333333333
"CD013800","CD013800_pub2_data","1|5|Loss of residual kidney function (number who became anuric) at approximately 12-month follow-up|","Loss of residual kidney function (number who became anuric) at approximately 12-month follow-up",1,5,"","or","binary",3,-1.18474864891139,0.210547404950265,0.0526903276635796,2005,0.359282936297797,944.666666666667
"CD013800","CD013800_pub2_data","1|7|Cardiovascular death|Adults","Cardiovascular death",1,7,"Adults","or","binary",21,-0.0325240589489642,0.123118196193203,0.178833309085688,2011.71428571429,0.102570826694243,3261.52380952381
"CD013800","CD013800_pub2_data","1|7|Cardiovascular death|Paediatric","Cardiovascular death",1,7,"Paediatric","or","binary",3,0.134002130267879,0.235180349594587,1.07501771233924e-06,2009.66666666667,0.0159733300609482,2357.66666666667
"CD013800","CD013800_pub2_data","1|8|Infection-related death|Adult","Infection-related death",1,8,"Adult","or","binary",17,-0.116988051792615,0.161276087162986,0.302641081789819,2011.41176470588,0.0690575451229813,6843.11764705882
"CD013800","CD013800_pub2_data","1|8|Infection-related death|Paediatric","Infection-related death",1,8,"Paediatric","or","binary",4,-0.0325033628556591,0.480337251332669,0.490239403882891,2010.75,0.0217790624435612,1862.75
"CD013800","CD013800_pub2_data","1|9|Bacteraemia/bloodstream infection |","Bacteraemia/bloodstream infection ",1,9,"","or","binary",2,-1.17537763981078,0.505219188800806,0.350874155912098,2007,0.291103865859339,1291
"CD013801","CD013801_pub2_data","1|2|Physician-evaluated change in severity of symptoms and signs (medium-term)|","Physician-evaluated change in severity of symptoms and signs (medium-term)",1,2,"","reported","reported",3,-1.13464210893389,0.917405622429415,0.736179259673665,2011.33333333333,NA,42.6666666666667
"CD013801","CD013801_pub2_data","1|21|Incidence of headache|Active MG","Incidence of headache",1,21,"Active MG","reported","reported",3,0.356126136160049,0.129516590607473,0.0322950681948366,2011.33333333333,0.103395061728395,42.6666666666667
"CD013801","CD013801_pub2_data","1|28|Incidence of all-cause mortality|Active MG","Incidence of all-cause mortality",1,28,"Active MG","reported","reported",3,0.0132801458088467,0.0277830891421041,0,2011.33333333333,0,42.6666666666667
"CD013801","CD013801_pub2_data","1|3|Physician-evaluated change in severity of symptoms and signs (medium-term) (sensitivity analysis)|","Physician-evaluated change in severity of symptoms and signs (medium-term) (sensitivity analysis)",1,3,"","reported","reported",2,-1.86079251953613,0.80381426440611,0,2016,NA,56.5
"CD013801","CD013801_pub2_data","1|6|Patient-reported change in functional capacity (medium-term)|","Patient-reported change in functional capacity (medium-term)",1,6,"","reported","reported",2,0.0803147303720974,0.797592371524989,1.09080751482096,2013.5,NA,38.5
"CD013801","CD013801_pub2_data","2|1|Physician-evaluated change in severity of symptoms and signs (short-term)|","Physician-evaluated change in severity of symptoms and signs (short-term)",2,1,"","reported","reported",4,0.702829357009357,0.473572110916704,0.753661314493769,2004.75,NA,55.75
"CD013801","CD013801_pub2_data","2|17|Incidence of hypotension requiring vascular expansion|","Incidence of hypotension requiring vascular expansion",2,17,"","reported","reported",2,-0.0627628468843795,0.0353711860306866,0,2003.5,0.084390243902439,63.5
"CD013801","CD013801_pub2_data","2|2|Physician-evaluated change in severity of symptoms and signs (short-term) (sensitivity analysis)|","Physician-evaluated change in severity of symptoms and signs (short-term) (sensitivity analysis)",2,2,"","reported","reported",2,2.91817880004623,1.27251979128726,2.66220139992178,2010.5,NA,62
"CD013801","CD013801_pub2_data","2|27|Incidence of all-cause mortality|Active MG","Incidence of all-cause mortality",2,27,"Active MG","reported","reported",4,0,0.015292641597945,0,2004.75,0,55.75
"CD013801","CD013801_pub2_data","2|3|Physician-evaluated change in severity of symptoms and signs (medium-term)|","Physician-evaluated change in severity of symptoms and signs (medium-term)",2,3,"","reported","reported",2,0.773958972527035,1.03251275148342,1.67868392223227,2006,NA,48
"CD013810","CD013810_pub2_data","1|16|Continuous positive airway pressure adherence|NA","Continuous positive airway pressure adherence",1,16,NA,"reported","reported",2,0,0.17638599882613,0,2017,0,180
"CD013810","CD013810_pub2_data","2|1|Sleepiness (Epworth Sleepiness Scale)|NA","Sleepiness (Epworth Sleepiness Scale)",2,1,NA,"or","binary",2,-0.0427976649401928,1.41668114248277,0,2017.5,0,286.5
"CD013810","CD013810_pub2_data","2|12|Continuous positive airway pressure adherence|NA","Continuous positive airway pressure adherence",2,12,NA,"or","binary",2,-0.0304991485608236,1.41890510442705,0,2017.5,0,164
"CD013810","CD013810_pub2_data","2|2|Quality of life (Assessment of Quality of Life – 8 Dimensions – Global Utility; EuroQol 5-Dimensions)|NA","Quality of life (Assessment of Quality of Life – 8 Dimensions – Global Utility; EuroQol 5-Dimensions)",2,2,NA,"or","binary",2,-0.0427976649401928,1.41668114248277,0,2017.5,0,286.5
"CD013816","CD013816_pub2_data","1|1|Thromboembolic events (composite)|NA","Thromboembolic events (composite)",1,1,NA,"or","binary",5,-0.144172534973285,0.750207428402603,0,2012,0.00349176215336633,253.2
"CD013816","CD013816_pub2_data","1|10|Hemothorax|NA","Hemothorax",1,10,NA,"or","binary",2,0.00267776653339136,1.41638067911112,0,2013,0,447
"CD013816","CD013816_pub2_data","1|11|Cardiac tamponade|NA","Cardiac tamponade",1,11,NA,"or","binary",2,0.666666832815201,1.2669266303215,0,2013,0,447
"CD013816","CD013816_pub2_data","1|12|Non-tamponade pericardial effusion|NA","Non-tamponade pericardial effusion",1,12,NA,"or","binary",2,0.66465780108732,1.27175137226106,0,2012,0,156.5
"CD013816","CD013816_pub2_data","1|13|All-cause mortality|NA","All-cause mortality",1,13,NA,"or","binary",3,-0.699032518269416,0.837556025811296,0,2012,0.0105539358600583,317.666666666667
"CD013816","CD013816_pub2_data","1|14|Adverse events|NA","Adverse events",1,14,NA,"or","binary",4,0.401554799254459,0.311452555633,0,2012.25,0.0373143110437932,291.5
"CD013816","CD013816_pub2_data","1|15|Adverse events - Bleeding (clinically significant bleeding that does not qualify as device-pocket hematoma, hemothorax, cardiac tamponade, or non-tamponade pericardial effusion)|NA","Adverse events - Bleeding (clinically significant bleeding that does not qualify as device-pocket hematoma, hemothorax, cardiac tamponade, or non-tamponade pericardial effusion)",1,15,NA,"or","binary",2,0.181334945869629,0.451926630159411,0,2013.5,0.0424528301886792,190
"CD013816","CD013816_pub2_data","1|16|Adverse events - Pneumothorax|NA","Adverse events - Pneumothorax",1,16,NA,"or","binary",3,0.22091040281328,0.734074244235758,0,2011.66666666667,0.00411647138639823,331.666666666667
"CD013816","CD013816_pub2_data","1|17|Adverse events - Infection|NA","Adverse events - Infection",1,17,NA,"or","binary",3,0.826790539386285,0.525606853347095,0,2011.66666666667,0.0095821185617104,331.666666666667
"CD013816","CD013816_pub2_data","1|19|Economic costs - Days of hospitalization|NA","Economic costs - Days of hospitalization",1,19,NA,"or","binary",3,-0.00471786109207861,1.15775818898148,0,2011.66666666667,0,331.666666666667
"CD013816","CD013816_pub2_data","1|3|Transient ischemic attack|NA","Transient ischemic attack",1,3,NA,"or","binary",4,-0.000466558835037155,0.898010886928601,0,2011.5,0.000728862973760933,273.75
"CD013816","CD013816_pub2_data","1|4|Ischemic stroke|NA","Ischemic stroke",1,4,NA,"or","binary",5,-0.254634891440097,0.787276102707619,0,2012,0.00290867177435758,253.2
"CD013816","CD013816_pub2_data","1|5|Deep vein thrombosis|NA","Deep vein thrombosis",1,5,NA,"or","binary",2,-0.0024016831215257,1.41818075290574,0,2011,0,391
"CD013816","CD013816_pub2_data","1|6|Pulmonary embolism|NA","Pulmonary embolism",1,6,NA,"or","binary",2,-0.0024016831215257,1.41818075290574,0,2011,0,391
"CD013816","CD013816_pub2_data","1|7|Peripheral embolism|NA","Peripheral embolism",1,7,NA,"or","binary",2,-0.0024016831215257,1.41818075290574,0,2011,0,391
"CD013816","CD013816_pub2_data","2|1|Thromboembolic events (composite)|NA","Thromboembolic events (composite)",2,1,NA,"or","binary",3,-0.0148324754860851,0.897615810280896,0,2017.66666666667,0.00101626016260163,281
"CD013816","CD013816_pub2_data","2|10|Non-tamponade pericardial effusion|NA","Non-tamponade pericardial effusion",2,10,NA,"or","binary",2,0.644242807018294,1.26823845798431,0,2018,0,381.5
"CD013816","CD013816_pub2_data","2|11|All-cause mortality|NA","All-cause mortality",2,11,NA,"or","binary",2,-0.424506514809451,0.92066224812438,0,2018,0.00304878048780488,381.5
"CD013816","CD013816_pub2_data","2|15|Adverse events - Infection|NA","Adverse events - Infection",2,15,NA,"or","binary",2,-1.12893365389499,1.15961051771056,0,2018,0.0115243902439024,381.5
"CD013816","CD013816_pub2_data","2|3|Transient ischemic attack|NA","Transient ischemic attack",2,3,NA,"or","binary",2,-0.0188511454630738,1.41819570625052,0,2018,0,381.5
"CD013816","CD013816_pub2_data","2|4|Ischemic stroke |NA","Ischemic stroke ",2,4,NA,"or","binary",2,-0.0185168023534036,1.00292087142425,0,2018,0.00152439024390244,381.5
"CD013816","CD013816_pub2_data","2|5|Deep vein thrombosis|NA","Deep vein thrombosis",2,5,NA,"or","binary",2,-0.0188511454630738,1.41819570625052,0,2018,0,381.5
"CD013816","CD013816_pub2_data","2|6|Pulmonary embolism|NA","Pulmonary embolism",2,6,NA,"or","binary",2,-0.0188511454630738,1.41819570625052,0,2018,0,381.5
"CD013816","CD013816_pub2_data","2|8|Hemothorax|NA","Hemothorax",2,8,NA,"or","binary",2,-0.0188511454630738,1.41819570625052,0,2018,0,381.5
"CD013816","CD013816_pub2_data","2|9|Cardiac tamponade|NA","Cardiac tamponade",2,9,NA,"or","binary",2,-0.681677139380025,1.26823850523845,0,2018,0.00152439024390244,381.5
"CD013821","CD013821_pub2_data","1|10|Duration of surgery (minutes)|NA","Duration of surgery (minutes)",1,10,NA,"or","binary",2,-0.285888501932496,1.41716395382524,0,2017,0,418
"CD013821","CD013821_pub2_data","1|11|Length of postoperative stay (days)|NA","Length of postoperative stay (days)",1,11,NA,"reported","reported",3,0,0.138186082300899,0,2008.33333333333,0,376.666666666667
"CD013821","CD013821_pub2_data","1|2|Postoperative physical well-being|NA","Postoperative physical well-being",1,2,NA,"or","binary",6,-0.746027512190641,0.818646036199571,0,2017.83333333333,0,555.833333333333
"CD013821","CD013821_pub2_data","1|3|Postoperative sexual well-being|NA","Postoperative sexual well-being",1,3,NA,"or","binary",6,-0.746027512190641,0.818646036199571,0,2017.83333333333,0,555.833333333333
"CD013821","CD013821_pub2_data","1|4|Satisfaction with breast|NA","Satisfaction with breast",1,4,NA,"or","binary",6,-0.746027512190641,0.818646036199571,0,2017.83333333333,0,555.833333333333
"CD013821","CD013821_pub2_data","1|5|Satisfaction with reconstruction|NA","Satisfaction with reconstruction",1,5,NA,"or","binary",4,-0.903954717130988,1.00287975596468,0,2018.25,0,299
"CD013821","CD013821_pub2_data","1|6|Short-term complications|NA","Short-term complications",1,6,NA,"or","binary",22,-0.247422721241301,0.130149336963873,0.242244394880602,2013.90909090909,0.259079886909923,1556.54545454545
"CD013821","CD013821_pub2_data","1|7|Long-term complications|NA","Long-term complications",1,7,NA,"reported","reported",16,0,0.0374323746677698,0,2014.5625,0.166882439400999,1667.25
"CD013821","CD013821_pub2_data","1|8|Locoregional recurrence|NA","Locoregional recurrence",1,8,NA,"or","binary",2,-0.223720804767845,0.27937562373194,0.0722230329357783,2020.5,0.134913638293009,516
"CD013821","CD013821_pub2_data","1|9|Reintervention|NA","Reintervention",1,9,NA,"reported","reported",14,0,0.0402160375688975,0,2015.21428571429,0.189829485786113,852.642857142857
"CD013822","CD013822_pub2_data","2|1|Confidence - decisional conflict - continuous|Decisional conflict scale (0 to 100) - higher scores/more conflict","Confidence - decisional conflict - continuous",2,1,"Decisional conflict scale (0 to 100) - higher scores/more conflict","or","binary",3,0.0306704674471837,1.15737500449703,0,2016,0,335.666666666667
"CD013822","CD013822_pub2_data","2|3|Confidence - regret/anticipated regret|Anticipated regret","Confidence - regret/anticipated regret",2,3,"Anticipated regret","reported","reported",2,0,0.250355965436255,0,2019,0,113
"CD013822","CD013822_pub2_data","2|4|Knowledge - continuous|Scale 0 to 10","Knowledge - continuous",2,4,"Scale 0 to 10","or","binary",2,0.26449493267516,1.41595558517498,0,2008.5,0,505
"CD013822","CD013822_pub2_data","2|5|Knowledge - informed choice (composite of knowledge, attitudes and intentions)|","Knowledge - informed choice (composite of knowledge, attitudes and intentions)",2,5,"","or","binary",4,0.393436587117201,0.281369256621415,0.277755125193411,2013.5,0.441826602226837,612.25
"CD013822","CD013822_pub2_data","2|6|Knowledge - dichotomous (correct answers)|","Knowledge - dichotomous (correct answers)",2,6,"","or","binary",13,0.242091084352593,0.132615129678426,0.172156651666162,2020,0.564926566816926,1001
"CD013822","CD013822_pub2_data","2|7|Anxiety - continuous|","Anxiety - continuous",2,7,"","or","binary",2,0.0342769578518299,1.41786209240608,0,2013,0,374.5
"CD013822","CD013822_pub2_data","3|1|Confidence|Anticipated regret - 2 weeks","Confidence",3,1,"Anticipated regret - 2 weeks","or","binary",2,0,1.41505610850823,0,2021,0,838
"CD013822","CD013822_pub2_data","3|1|Confidence|Decisional conflict - post intervention to 2 weeks","Confidence",3,1,"Decisional conflict - post intervention to 2 weeks","or","binary",3,-0.0152149478559625,1.15685272560755,0,2018.33333333333,0,443
"CD013822","CD013822_pub2_data","3|1|Confidence|Decisional conflict - post intervention to 2 weeks - sensitivity analysis","Confidence",3,1,"Decisional conflict - post intervention to 2 weeks - sensitivity analysis","or","binary",2,-0.00846787266556836,1.41563258856899,0,2018,0,595.5
"CD013822","CD013822_pub2_data","3|2|Confidence - long-term follow-up|24 months - Anticipated regret","Confidence - long-term follow-up",3,2,"24 months - Anticipated regret","reported","reported",2,0,0.0531249910026765,0,2021,0,712
"CD013822","CD013822_pub2_data","3|3|Knowledge - continuous|Analysis with all included studies","Knowledge - continuous",3,3,"Analysis with all included studies","reported","reported",5,0,0.0394389160768987,0,2018,0,529.6
"CD013822","CD013822_pub2_data","3|3|Knowledge - continuous|Sensitivity analysis (excluding studies at high risk of bias)","Knowledge - continuous",3,3,"Sensitivity analysis (excluding studies at high risk of bias)","reported","reported",4,0,0.0401891172292433,0,2017.75,0,627.5
"CD013822","CD013822_pub2_data","3|5|Knowledge - informed choice (composite of knowledge, attitudes and intentions)|All studies","Knowledge - informed choice (composite of knowledge, attitudes and intentions)",3,5,"All studies","reported","reported",3,0,0.0358892372375428,0,2020,0.296834724463763,672
"CD013822","CD013822_pub2_data","3|5|Knowledge - informed choice (composite of knowledge, attitudes and intentions)|Sensitivity analysis (excluding studies at high risk of bias)","Knowledge - informed choice (composite of knowledge, attitudes and intentions)",3,5,"Sensitivity analysis (excluding studies at high risk of bias)","reported","reported",2,0,0.0359118957590375,0,2020.5,0.440444394387952,902.5
"CD013822","CD013822_pub2_data","3|6|Knowledge - dichotomous (correct answers)|12 month follow-up","Knowledge - dichotomous (correct answers)",3,6,"12 month follow-up","or","binary",2,0.562722741033361,0.21985288109126,0,2002,0.0476190476190476,717
"CD013822","CD013822_pub2_data","3|6|Knowledge - dichotomous (correct answers)|24 month follow-up","Knowledge - dichotomous (correct answers)",3,6,"24 month follow-up","or","binary",2,0.693568864570409,0.240975303329995,0,2002,0.037037037037037,717
"CD013822","CD013822_pub2_data","3|6|Knowledge - dichotomous (correct answers)|Post intervention","Knowledge - dichotomous (correct answers)",3,6,"Post intervention","or","binary",10,0.897438495096651,0.311467374326682,0.907147109847265,2006,0.497177419354839,668
"CD013822","CD013822_pub2_data","3|7|Anxiety and depression|Anxiety ≤ 1 month","Anxiety and depression",3,7,"Anxiety ≤ 1 month","or","binary",3,-0.00768556291625126,1.15684963678034,0,2018.33333333333,0,443.666666666667
"CD013822","CD013822_pub2_data","3|7|Anxiety and depression|Anxiety ≤ 1 month - sensitivity analysis","Anxiety and depression",3,7,"Anxiety ≤ 1 month - sensitivity analysis","or","binary",2,0.00280672945049045,1.41562692865041,0,2018,0,596.5
"CD013822","CD013822_pub2_data","3|9|Cancer worry|All studies","Cancer worry",3,9,"All studies","reported","reported",2,0,0.0648585153706203,0,2018,0,479.5
"CD013823","CD013823_pub2_data","1|1|Maternal anaemia|NA","Maternal anaemia",1,1,NA,"or","binary",2,0.285790827285431,0.27258965954239,0,2015,0.546428571428571,142
"CD013823","CD013823_pub2_data","1|10|Infant homocysteine concentrations|NA","Infant homocysteine concentrations",1,10,NA,"or","binary",2,-0.0870151924853072,1.42390214432301,0,2015,0,72.5
"CD013823","CD013823_pub2_data","1|11|Infant haemoglobin concentrations|NA","Infant haemoglobin concentrations",1,11,NA,"or","binary",2,-0.0932918318595753,1.42415625462851,0,2015,0,70.5
"CD013823","CD013823_pub2_data","1|12|Infant anaemia|NA","Infant anaemia",1,12,NA,"or","binary",2,-0.289757954004993,0.344774797452181,0,2015,0.452678571428571,70.5
"CD013823","CD013823_pub2_data","1|2|Maternal vitamin B12 deficiency or insufficiency|NA","Maternal vitamin B12 deficiency or insufficiency",1,2,NA,"or","binary",2,-2.1457885293042,0.307704182579643,0,2015,0.549719887955182,136
"CD013823","CD013823_pub2_data","1|3|Low birthweight (< 2500 g)|NA","Low birthweight (< 2500 g)",1,3,NA,"or","binary",2,0.478359900990304,0.322924427841913,0.0161806256921306,2015,0.105035405192762,167
"CD013823","CD013823_pub2_data","1|4|Preterm birth (< 37 weeks)|NA","Preterm birth (< 37 weeks)",1,4,NA,"or","binary",2,-0.0351667385484054,0.332719928172191,0,2015,0.0952563856347225,170
"CD013823","CD013823_pub2_data","1|5|Maternal total vitamin B12 concentrations|NA","Maternal total vitamin B12 concentrations",1,5,NA,"or","binary",3,0.0953233049556426,1.15979264971407,0,1982.33333333333,0,137.333333333333
"CD013823","CD013823_pub2_data","1|6|Maternal total vitamin B12 concentrations|NA","Maternal total vitamin B12 concentrations",1,6,NA,"or","binary",2,0.0288554091239803,1.42103381209934,0,2015,0,136
"CD013823","CD013823_pub2_data","1|7|Maternal haemoglobin concentrations|NA","Maternal haemoglobin concentrations",1,7,NA,"or","binary",3,0.0953147401342068,1.15974054472205,0,1999.33333333333,0,141.333333333333
"CD013823","CD013823_pub2_data","1|8|Maternal hyperhomocysteinaemia|NA","Maternal hyperhomocysteinaemia",1,8,NA,"or","binary",2,-0.191538711748471,0.346855483963619,0,2015,0.176785714285714,137
"CD013823","CD013823_pub2_data","1|9|Infant total vitamin B12 concentrations|NA","Infant total vitamin B12 concentrations",1,9,NA,"or","binary",2,-0.101304366553231,1.42397370592246,0,2015,0,72
"CD013827","CD013827_pub2_data","1|10|Duration of stimulation (days)|Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) ","Duration of stimulation (days)",1,10,"Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) ","or","binary",2,-0.00681642999367037,1.41734936032443,0,2020,0,245.5
"CD013827","CD013827_pub2_data","1|11|Total dose of gonadotropins (IU)|Normoresponders - Donor oocytes - Early ophase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists","Total dose of gonadotropins (IU)",1,11,"Normoresponders - Donor oocytes - Early ophase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists","or","binary",2,-0.0125559410690696,1.41733773814024,0,2020,0,246
"CD013827","CD013827_pub2_data","1|12|Moderate or severe OHSS|Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)","Moderate or severe OHSS",1,12,"Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)","or","binary",2,-0.0125490422076792,1.41694830655375,0,2020,0,267
"CD013827","CD013827_pub2_data","1|14|Oocyte pick-up cancellation sensitivity analysis|Normoresponders (MPA 10 mg versus GnRH antagonists) - Donor oocytes  - Early phase stimulation protocol - Fresh embryo transfer","Oocyte pick-up cancellation sensitivity analysis",1,14,"Normoresponders (MPA 10 mg versus GnRH antagonists) - Donor oocytes  - Early phase stimulation protocol - Fresh embryo transfer","or","binary",2,-0.149257714115426,0.526366719744413,0,2020,0.0280726586459071,267
"CD013827","CD013827_pub2_data","1|2|Oocyte pick-up cancellation|Normoresponders (MPA 10 mg versus GnRH antagonists) - Donor oocytes  - Early phase stimulation protocol - Fresh embryo transfer","Oocyte pick-up cancellation",1,2,"Normoresponders (MPA 10 mg versus GnRH antagonists) - Donor oocytes  - Early phase stimulation protocol - Fresh embryo transfer","or","binary",2,-0.149257714115426,0.526366719744413,0,2020,0.0280726586459071,267
"CD013827","CD013827_pub2_data","1|8|Total oocytes|Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)","Total oocytes",1,8,"Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)","or","binary",2,-0.0125490422076792,1.41694830655375,0,2020,0,267
"CD013827","CD013827_pub2_data","1|9|MII oocytes|Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) ","MII oocytes",1,9,"Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) ","or","binary",2,-0.0125490422076792,1.41694830655375,0,2020,0,267
"CD013827","CD013827_pub2_data","3|10|Duration of stimulation|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Duration of stimulation",3,10,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013827","CD013827_pub2_data","3|11|Total dose of gonadotropins|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Total dose of gonadotropins",3,11,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013827","CD013827_pub2_data","3|12|Moderate or severe OHSS|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Moderate or severe OHSS",3,12,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013827","CD013827_pub2_data","3|2|Oocyte pick-up cancellation|Normo-responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol","Oocyte pick-up cancellation",3,2,"Normo-responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol","reported","reported",2,0,0.269738803509511,0,2018.5,0.163333333333333,275
"CD013827","CD013827_pub2_data","3|5|Miscarriage|Miscarriage per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Miscarriage",3,5,"Miscarriage per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,-0.488724635091735,0.487880548491619,0,2018.5,0.0949248120300752,117
"CD013827","CD013827_pub2_data","3|5|Miscarriage|Miscarriage per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Miscarriage",3,5,"Miscarriage per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,-0.716006380634564,0.47683875995816,0,2018.5,0.0493333333333333,275
"CD013827","CD013827_pub2_data","3|6|Multiple pregnancy|Multiple pregnancy per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Multiple pregnancy",3,6,"Multiple pregnancy per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0.437474131650178,0.288817936087945,0,2018.5,0.238721804511278,117
"CD013827","CD013827_pub2_data","3|6|Multiple pregnancy|Multiple pregnancy per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Multiple pregnancy",3,6,"Multiple pregnancy per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0.0678087614267169,0.260837033770022,0,2018.5,0.12,275
"CD013827","CD013827_pub2_data","3|7|Premature LH surge|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Premature LH surge",3,7,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013827","CD013827_pub2_data","3|8|Total oocytes|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","Total oocytes",3,8,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013827","CD013827_pub2_data","3|9|MII oocytes|Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","MII oocytes",3,9,"Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol","or","binary",2,0,1.41679430570767,0,2018.5,0,275
"CD013830","CD013830_pub2_data","1|11|Patent ductus arteriosus (PDA) requiring any treatment|Caffeine","Patent ductus arteriosus (PDA) requiring any treatment",1,11,"Caffeine","or","binary",2,-0.696197134259671,0.0908365351408727,0,2011,0.407346153846154,1029
"CD013830","CD013830_pub2_data","1|13|Any intraventricular hemorrhage (IVH)|Aminophylline","Any intraventricular hemorrhage (IVH)",1,13,"Aminophylline","or","binary",2,-1.46857410065049,0.763907104433205,0,2000,0.407692307692308,36.5
"CD013830","CD013830_pub2_data","1|13|Any intraventricular hemorrhage (IVH)|Caffeine","Any intraventricular hemorrhage (IVH)",1,13,"Caffeine","or","binary",2,0.102411309621248,0.713400651981126,0.404721097308411,2002,0.137692307692308,51
"CD013830","CD013830_pub2_data","1|13|Any intraventricular hemorrhage (IVH)|Theophylline","Any intraventricular hemorrhage (IVH)",1,13,"Theophylline","or","binary",2,-0.507553653434315,0.626384990640241,0,1986,0.211111111111111,35
"CD013830","CD013830_pub2_data","1|16|Necrotizing enterocolitis (NEC) (Bell's stage II or greater OR any grade; requiring surgery)|Caffeine","Necrotizing enterocolitis (NEC) (Bell's stage II or greater OR any grade; requiring surgery)",1,16,"Caffeine","or","binary",3,-0.0688410362863075,0.175485300997476,4.5729047087398e-08,2007.33333333333,0.065992376992377,713.333333333333
"CD013830","CD013830_pub2_data","1|19|Oxygen therapy at 28 to 30 days|Aminophylline","Oxygen therapy at 28 to 30 days",1,19,"Aminophylline","or","binary",2,-1.67836852598398,0.595167059312561,0,2003.5,0.461538461538462,36
"CD013830","CD013830_pub2_data","1|2|Death at hospital discharge|Aminophylline","Death at hospital discharge",1,2,"Aminophylline","or","binary",2,0.903687561240927,0.63764763763292,0,2000,0.155594405594406,38.5
"CD013830","CD013830_pub2_data","1|2|Death at hospital discharge|Caffeine","Death at hospital discharge",1,2,"Caffeine","or","binary",3,-0.0353068029025194,0.193207156200247,0,2007.33333333333,0.0273423423423423,713.333333333333
"CD013830","CD013830_pub2_data","1|2|Death at hospital discharge|Theophylline","Death at hospital discharge",1,2,"Theophylline","or","binary",2,-1.25685584478924,0.876036004222172,0,1983,0.152597402597403,36
"CD013830","CD013830_pub2_data","1|21|Tachycardia leading to cessation of treatment|Caffeine","Tachycardia leading to cessation of treatment",1,21,"Caffeine","or","binary",3,0.633859404831167,0.709969573054105,0,1997.33333333333,0.025679012345679,52
"CD013830","CD013830_pub2_data","1|21|Tachycardia leading to cessation of treatment|Theophylline","Tachycardia leading to cessation of treatment",1,21,"Theophylline","or","binary",2,1.14862270924277,1.17616521070673,0,1985,0,40
"CD013830","CD013830_pub2_data","1|6|Any apneic episodes|Aminophylline","Any apneic episodes",1,6,"Aminophylline","or","binary",2,-2.07328053737235,0.74939759680632,0.401972260334905,2003.5,0.557692307692308,36
"CD013830","CD013830_pub2_data","1|7|Failed apnea reduction|Theophylline","Failed apnea reduction",1,7,"Theophylline","or","binary",3,-1.53547995188123,0.646582856035481,0.60100325835376,1985.33333333333,0.664935064935065,30.6666666666667
"CD013830","CD013830_pub2_data","1|8|Positive-pressure ventilation after institution of treatment|Aminophylline","Positive-pressure ventilation after institution of treatment",1,8,"Aminophylline","or","binary",2,-0.352967943773433,1.05406107804496,0.587665165957645,2000,0.454545454545455,38.5
"CD013830","CD013830_pub2_data","1|8|Positive-pressure ventilation after institution of treatment|Caffeine","Positive-pressure ventilation after institution of treatment",1,8,"Caffeine","or","binary",4,-0.616836315223213,0.602673363628396,0,1989.25,0.102592592592593,51
"CD013830","CD013830_pub2_data","1|8|Positive-pressure ventilation after institution of treatment|Theophylline","Positive-pressure ventilation after institution of treatment",1,8,"Theophylline","or","binary",3,-1.03703530111111,0.633664710505592,0,1985.33333333333,0.154545454545455,30.6666666666667
"CD013830","CD013830_pub2_data","2|12|Any intraventricular hemorrhage (IVH)|Aminophylline","Any intraventricular hemorrhage (IVH)",2,12,"Aminophylline","or","binary",2,-1.46857410065049,0.763907104433205,0,2000,0.407692307692308,36.5
"CD013830","CD013830_pub2_data","2|12|Any intraventricular hemorrhage (IVH)|Caffeine","Any intraventricular hemorrhage (IVH)",2,12,"Caffeine","or","binary",2,0.102411309621248,0.713400651981126,0.404721097308411,2002,0.137692307692308,51
"CD013830","CD013830_pub2_data","2|17|Tachycardia leading to cessation of treatment|Caffeine","Tachycardia leading to cessation of treatment",2,17,"Caffeine","or","binary",3,0.633859404831167,0.709969573054105,0,1997.33333333333,0.025679012345679,52
"CD013830","CD013830_pub2_data","2|2|Death at hospital discharge|Aminophylline","Death at hospital discharge",2,2,"Aminophylline","or","binary",2,0.903687561240927,0.63764763763292,0,2000,0.155594405594406,38.5
"CD013830","CD013830_pub2_data","2|6|Positive-pressure ventilation after institution of treatment|Caffeine","Positive-pressure ventilation after institution of treatment",2,6,"Caffeine","or","binary",3,0.00911344573645717,0.665040496694668,0.123079462159062,1997.33333333333,0.062716049382716,52
"CD013830","CD013830_pub2_data","3|2|Death at hospital discharge|Theophylline","Death at hospital discharge",3,2,"Theophylline","or","binary",2,-1.25685584478924,0.876036004222172,0,1983,0.152597402597403,36
"CD013830","CD013830_pub2_data","3|6|Failed apnea reduction|Theophylline","Failed apnea reduction",3,6,"Theophylline","or","binary",3,-1.53547995188123,0.646582856035481,0.60100325835376,1985.33333333333,0.664935064935065,30.6666666666667
"CD013830","CD013830_pub2_data","3|7|Positive-pressure ventilation after institution of treatment|Caffeine","Positive-pressure ventilation after institution of treatment",3,7,"Caffeine","or","binary",2,-1.19381450301138,1.26391488710731,0,1990.5,0.111111111111111,50
"CD013830","CD013830_pub2_data","3|7|Positive-pressure ventilation after institution of treatment|Theophylline","Positive-pressure ventilation after institution of treatment",3,7,"Theophylline","or","binary",3,-1.03703530111111,0.633664710505592,0,1985.33333333333,0.154545454545455,30.6666666666667
"CD013830","CD013830_pub2_data","4|10|Any intraventricular hemorrhage (IVH)|Theophylline","Any intraventricular hemorrhage (IVH)",4,10,"Theophylline","or","binary",2,-0.507553653434315,0.626384990640241,0,1986,0.211111111111111,35
"CD013830","CD013830_pub2_data","4|4|Failed extubation|Theophylline","Failed extubation",4,4,"Theophylline","or","binary",3,-1.60709838950148,0.44095376802575,0,1985.66666666667,0.614935064935065,38
"CD013830","CD013830_pub2_data","5|1|Failed extubation|Methylxanthine to prevent re-intubation in preterm infants","Failed extubation",5,1,"Methylxanthine to prevent re-intubation in preterm infants","or","binary",2,-0.923520993516405,1.01752626343295,1.13722835105416,1990,0.561111111111111,20.5
"CD013834","CD013834_pub2_data","1|1|TUG|NA","TUG",1,1,NA,"or","binary",6,-0.166632144623119,0.826705174457037,0,2019,0,44
"CD013834","CD013834_pub2_data","1|2|MS Walking Scale - 12|NA","MS Walking Scale - 12",1,2,NA,"or","binary",4,-0.170128245499681,1.01127503900799,0,NA,0,48.5
"CD013834","CD013834_pub2_data","1|3|Walking endurance|NA","Walking endurance",1,3,NA,"or","binary",4,-0.186544825314555,1.01463744850726,0,2019,0,35.25
"CD013834","CD013834_pub2_data","1|4|Gait speed|NA","Gait speed",1,4,NA,"reported","reported",3,0,0.189246513130271,0,NA,0,39.3333333333333
"CD013834","CD013834_pub2_data","10|1|Fatigue|NA","Fatigue",10,1,NA,"or","binary",5,0.0235213067044186,0.908041453726804,0,2017.5,0,32.2
"CD013834","CD013834_pub2_data","11|1|PASAT|NA","PASAT",11,1,NA,"or","binary",2,-0.034710184935789,1.44514515080212,0,2021,0,26
"CD013834","CD013834_pub2_data","2|1|BBS|NA","BBS",2,1,NA,"or","binary",4,-0.269650734011587,1.01494016801006,0,2019,0,34.25
"CD013834","CD013834_pub2_data","3|1|9HPT|NA","9HPT",3,1,NA,"or","binary",2,-0.044519898271412,1.43061324067831,0,NA,0,42
"CD013834","CD013834_pub2_data","4|1|TUG - cognitive|NA","TUG - cognitive",4,1,NA,"or","binary",3,-0.163403472900431,1.16625017280307,0,NA,0,54.3333333333333
"CD013834","CD013834_pub2_data","4|2|Symbol Digit Modalities Test|NA","Symbol Digit Modalities Test",4,2,NA,"or","binary",3,-0.0297870043668391,1.17019590263662,0,NA,0,37.3333333333333
"CD013834","CD013834_pub2_data","5|1|ABC scale|NA","ABC scale",5,1,NA,"or","binary",3,-0.133909361234322,1.16665255888943,0,NA,0,53
"CD013834","CD013834_pub2_data","5|2|BDI|NA","BDI",5,2,NA,"or","binary",2,-0.0737474161393464,1.43581040389833,0,NA,0,33
"CD013834","CD013834_pub2_data","5|3|MS International QoL|NA","MS International QoL",5,3,NA,"or","binary",2,-0.286556943015089,1.43164585333934,0,2019,0,41
"CD013834","CD013834_pub2_data","6|1|TUG|NA","TUG",6,1,NA,"or","binary",4,-0.0857255973098198,1.02178610477737,0,2021,0,26.75
"CD013834","CD013834_pub2_data","6|2|MS Walking Scale - 12|NA","MS Walking Scale - 12",6,2,NA,"or","binary",4,-0.0446450919031663,1.01439571601532,0,2021.5,0,34.5
"CD013834","CD013834_pub2_data","6|3|Walking endurance|NA","Walking endurance",6,3,NA,"or","binary",4,-0.0207083963356506,1.01746819836097,0,2022,0,27.75
"CD013834","CD013834_pub2_data","6|4|Gait speed|NA","Gait speed",6,4,NA,"or","binary",8,-0.0773730371392027,0.719831771488915,0,2021.5,0,30.875
"CD013834","CD013834_pub2_data","7|1|BBS|NA","BBS",7,1,NA,"or","binary",7,-0.0487268455668631,0.770351408905188,0,2017,0,28.7142857142857
"CD013834","CD013834_pub2_data","7|2|Tinetti Test|NA","Tinetti Test",7,2,NA,"or","binary",2,-0.0815779195452456,1.45507570404302,0,NA,0,19.5
"CD013834","CD013834_pub2_data","7|3|FSST|NA","FSST",7,3,NA,"or","binary",2,-0.115524637505301,1.43917224673939,0,NA,0,27.5
"CD013834","CD013834_pub2_data","9|1|ABC scale|NA","ABC scale",9,1,NA,"or","binary",2,-0.0540324306553308,1.43230423602864,0,2021,0,38
"CD013834","CD013834_pub2_data","9|2|BDI|NA","BDI",9,2,NA,"or","binary",2,-0.0794191638334232,1.43559483368261,0,NA,0,32.5
"CD013834","CD013834_pub2_data","9|3|FES-1|NA","FES-1",9,3,NA,"or","binary",3,0.0167379175303868,1.17142826562891,0,2021,0,33.6666666666667
"CD013835","CD013835_pub2_data","1|1|All-cause mortality at 30 days|NA","All-cause mortality at 30 days",1,1,NA,"reported","reported",2,-0.206554269017591,0.0643949476514636,0,2012,NA,0
"CD013835","CD013835_pub2_data","1|2|PE-related mortality at 30 days|NA","PE-related mortality at 30 days",1,2,NA,"reported","reported",2,0.0791206751430848,0.342102354482008,0,2017.5,NA,0
"CD013844","CD013844_pub2_data","1|1|Acceptability (dropouts)|Psychoeducation","Acceptability (dropouts)",1,1,"Psychoeducation","or","binary",5,-0.860554701895986,0.831873204588746,2.70945631535457,2008.6,0.126232203871182,1303.2
"CD013844","CD013844_pub2_data","1|1|Acceptability (dropouts)|Psychological","Acceptability (dropouts)",1,1,"Psychological","or","binary",4,0.40934170914568,0.698735484008152,1.38569233794856,2007.5,0.121067680861696,503
"CD013844","CD013844_pub2_data","1|4|Self-harm at long-term (> 12 months) follow-up|Psychological","Self-harm at long-term (> 12 months) follow-up",1,4,"Psychological","or","binary",2,-0.143991118990048,0.20871514912293,0,2014,0.0965986394557823,583.5
"CD013844","CD013844_pub2_data","1|5|Suicidal ideation at postintervention follow-up|Psychoeducation","Suicidal ideation at postintervention follow-up",1,5,"Psychoeducation","or","binary",3,-0.594823735157503,1.15870191019462,0,2011,0,225
"CD013844","CD013844_pub2_data","1|6|Suicidal ideation postintervention: sensitivity analysis (ICC 0.01)|Psychoeducation","Suicidal ideation postintervention: sensitivity analysis (ICC 0.01)",1,6,"Psychoeducation","or","binary",3,-0.595175890665297,1.15901768475312,0,2011,0,172.666666666667
"CD013844","CD013844_pub2_data","1|7|Suicidal ideation postintervention: sensitivity analysis (ICC 0.05)|Psychoeducation","Suicidal ideation postintervention: sensitivity analysis (ICC 0.05)",1,7,"Psychoeducation","or","binary",3,-0.593947716047907,1.16027477988823,0,2011,0,123.333333333333
"CD013844","CD013844_pub2_data","1|8|Suicidal ideation postintervention: sensitivity analysis (ICC 0.1)|Psychoeducation","Suicidal ideation postintervention: sensitivity analysis (ICC 0.1)",1,8,"Psychoeducation","or","binary",3,-0.608450785713584,1.16177186508062,0,2011,0,110
"CD013844","CD013844_pub2_data","2|5|Acceptability (dropouts)|Gatekeeper training","Acceptability (dropouts)",2,5,"Gatekeeper training","or","binary",4,-0.0308475647399398,0.530522467312935,1.03529629334018,2015,0.166155860583887,1465.25
"CD013844","CD013844_pub2_data","2|5|Acceptability (dropouts)|Others","Acceptability (dropouts)",2,5,"Others","or","binary",2,-1.0674267658689,2.10127663925535,7.64082245922119,2013.5,0.248834498834499,58
"CD013844","CD013844_pub2_data","2|6|Self-harm at short-term (1-3 months) follow-up|Gatekeeper training","Self-harm at short-term (1-3 months) follow-up",2,6,"Gatekeeper training","or","binary",2,-0.42752450316703,0.152373599375443,0,2009.5,0.0268789147450456,4145.5
"CD013844","CD013844_pub2_data","2|8|Suicidal ideation at postintervention follow-up|","Suicidal ideation at postintervention follow-up",2,8,"","or","binary",2,0.386523911096702,1.42830577098268,0,2017.5,0,51
"CD013844","CD013844_pub2_data","3|1|Self-harm at postintervention follow-up|","Self-harm at postintervention follow-up",3,1,"","or","binary",2,-1.65409138337878,1.13375655056892,0,2014.5,0.100840336134454,38
"CD013844","CD013844_pub2_data","3|10|Hopelessness postintervention|CBT-type","Hopelessness postintervention",3,10,"CBT-type","or","binary",3,-0.191727363899191,1.16412576659746,0,2008,0,74.3333333333333
"CD013844","CD013844_pub2_data","3|10|Hopelessness postintervention|Others","Hopelessness postintervention",3,10,"Others","or","binary",2,-0.401584626742274,1.42785072366464,0,2020,0,55
"CD013844","CD013844_pub2_data","3|11|Hopelessness at short-term (1-3 months) follow-up|","Hopelessness at short-term (1-3 months) follow-up",3,11,"","or","binary",3,-0.1566489027535,1.16555563376451,0,2008,0,71.3333333333333
"CD013844","CD013844_pub2_data","3|2|Non-suicidal self-injury at postintervention follow-up|","Non-suicidal self-injury at postintervention follow-up",3,2,"","or","binary",2,-0.40527385038737,0.49510766041322,0,2016,0.254475703324808,44.5
"CD013844","CD013844_pub2_data","3|3|Acceptability (dropouts)|DBT-type","Acceptability (dropouts)",3,3,"DBT-type","or","binary",3,0.111406459416368,0.473516530774161,0.218727674880701,2016.33333333333,0.264583333333333,48.3333333333333
"CD013844","CD013844_pub2_data","3|3|Acceptability (dropouts)|Others","Acceptability (dropouts)",3,3,"Others","or","binary",7,0.411810157618564,0.369687688629536,0,2017.42857142857,0.0592572873069373,63.7142857142857
"CD013844","CD013844_pub2_data","3|4|Self-harm at medium-term (4-12 months) follow-up|DBT-type","Self-harm at medium-term (4-12 months) follow-up",3,4,"DBT-type","or","binary",2,0.470289516368555,1.28219842669674,0,2016,0,49
"CD013844","CD013844_pub2_data","3|6|Suicidal ideation at postintervention follow-up|CBT-type","Suicidal ideation at postintervention follow-up",3,6,"CBT-type","or","binary",4,-0.143621679803679,1.00755288841325,0,2010.75,0,77.25
"CD013844","CD013844_pub2_data","3|6|Suicidal ideation at postintervention follow-up|DBT-type","Suicidal ideation at postintervention follow-up",3,6,"DBT-type","or","binary",2,-0.322058624653054,1.42774195901941,0,2016,0,55.5
"CD013844","CD013844_pub2_data","3|6|Suicidal ideation at postintervention follow-up|Others","Suicidal ideation at postintervention follow-up",3,6,"Others","or","binary",4,-0.159037964497155,1.01223606352918,0,2019.5,0,48
"CD013844","CD013844_pub2_data","3|7|Suicidal ideation at short-term (1-3 months) follow-up|","Suicidal ideation at short-term (1-3 months) follow-up",3,7,"","or","binary",3,-0.1566489027535,1.16555563376451,0,2008,0,71.3333333333333
"CD013844","CD013844_pub2_data","3|9|Suicidal ideation at the longest follow-up|CBT-type","Suicidal ideation at the longest follow-up",3,9,"CBT-type","or","binary",3,-0.1566489027535,1.16555563376451,0,2008,0,71.3333333333333
"CD013853","CD013853_pub2_data","1|1|Exergaming vs control at the end of treatment: change in global physical functioning (composite)|NA","Exergaming vs control at the end of treatment: change in global physical functioning (composite)",1,1,NA,"reported","reported",2,-0.328260869565217,0.57475629749685,0.5844,2020,0,56.5
"CD013853","CD013853_pub2_data","1|2|Exergaming vs control at the end of treatment: change in global cognitive functioning (composite)|NA","Exergaming vs control at the end of treatment: change in global cognitive functioning (composite)",1,2,NA,"reported","reported",2,1.47,0.64,0.7231,2020,0,56.5
"CD013853","CD013853_pub2_data","2|1|Exergaming vs alternative treatment at the end of treatment: change in global physical functioning (composite)|NA","Exergaming vs alternative treatment at the end of treatment: change in global physical functioning (composite)",2,1,NA,"reported","reported",2,0.140654329147389,0.222690467427058,0,2021,0,42.5
"CD013853","CD013853_pub2_data","2|2|Exergaming vs alternative treatment at the end of treatment: change in functional status and physical performance|NA","Exergaming vs alternative treatment at the end of treatment: change in functional status and physical performance",2,2,NA,"or","binary",2,0.194560406649975,1.43839994054295,0,2021,0,42.5
"CD013853","CD013853_pub2_data","2|3|Exergaming vs alternative treatment at the end of treatment: change in global cognitive functioning (composite)|NA","Exergaming vs alternative treatment at the end of treatment: change in global cognitive functioning (composite)",2,3,NA,"reported","reported",2,0.160769230769231,0.291243000271424,0.055,2021,0,42.5
"CD013853","CD013853_pub2_data","2|4|Exergaming vs alternative treatment at the end of treatment: change in lower limb functioning|NA","Exergaming vs alternative treatment at the end of treatment: change in lower limb functioning",2,4,NA,"or","binary",2,0.194560406649975,1.43839994054295,0,2021,0,42.5
"CD013853","CD013853_pub2_data","3|2|Exergaming vs control at the end of treatment: change in global cognitive functioning (composite)|NA","Exergaming vs control at the end of treatment: change in global cognitive functioning (composite)",3,2,NA,"reported","reported",2,0.908526248941575,0.580729598509057,0.3667405,2018.5,0,17
"CD013853","CD013853_pub2_data","3|3|Exergaming vs control at the end of treatment: change in activities of daily living (ADL)|NA","Exergaming vs control at the end of treatment: change in activities of daily living (ADL)",3,3,NA,"reported","reported",2,0,0.264279180505616,0,2017.5,0,30
"CD013853","CD013853_pub2_data","3|6|Exergaming vs control at the end of treatment: change in attention, processing speed, working memory|NA","Exergaming vs control at the end of treatment: change in attention, processing speed, working memory",3,6,NA,"or","binary",2,-0.132847779876078,1.45440655645264,0,2018.5,0,17
"CD013853","CD013853_pub2_data","7|1|Exergaming vs control at follow-up: change in global cognitive functioning (composite)|NA","Exergaming vs control at follow-up: change in global cognitive functioning (composite)",7,1,NA,"reported","reported",2,0.0238173410404624,0.328747632357021,0,2017.5,0,19
"CD013853","CD013853_pub2_data","9|1|Number of dropouts at the end of treatment (exergaming vs control intervention) for people with dementia|NA","Number of dropouts at the end of treatment (exergaming vs control intervention) for people with dementia",9,1,NA,"or","binary",2,-0.121098133133317,0.477625266931769,0,2020,0.156695156695157,66
"CD013853","CD013853_pub2_data","9|2|Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with dementia|NA","Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with dementia",9,2,NA,"reported","reported",2,0,0.426750205984642,0,2021,0.172932330827068,49.5
"CD013853","CD013853_pub2_data","9|4|Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with mild cognitive impairment (MCI)|NA","Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with mild cognitive impairment (MCI)",9,4,NA,"or","binary",4,0.313660274458204,0.570141549503789,0,2020.5,0.0345982142857143,60.75
"CD013853","CD013853_pub2_data","9|5|Number of dropouts at follow-up (exergame vs control intervention) for people with dementia|NA","Number of dropouts at follow-up (exergame vs control intervention) for people with dementia",9,5,NA,"or","binary",2,0.00658987450625312,0.458363670440183,0,2020,0.166666666666667,72
"CD013853","CD013853_pub2_data","9|6|Number of dropouts at follow-up (exergame vs control intervention) for people with mild cognitive impairment (MCI)|NA","Number of dropouts at follow-up (exergame vs control intervention) for people with mild cognitive impairment (MCI)",9,6,NA,"or","binary",2,-1.57577587136093,1.14644745701472,0,2017.5,0.183333333333333,21.5
"CD013874","CD013874_pub3_data","5|1|Time to disability worsening over 24 months' follow-up|Rituximab vs natalizumab","Time to disability worsening over 24 months' follow-up",5,1,"Rituximab vs natalizumab","reported","reported",2,0.197391024172881,0.456084397116794,0.2383834739175,2020.5,0,823
"CD013874","CD013874_pub3_data","5|10|MRI gadolinium-enhancing lesions over 18 to 24 months' follow-up|Rituximab vs fingolimod","MRI gadolinium-enhancing lesions over 18 to 24 months' follow-up",5,10,"Rituximab vs fingolimod","reported","reported",2,-2.3835439311181,0.599119377692066,0,2017.5,0,144
"CD013874","CD013874_pub3_data","5|13|Cardiovascular events over 18 to 24 months' follow-up – by type of DMT|Rituximab vs fingolimod","Cardiovascular events over 18 to 24 months' follow-up – by type of DMT",5,13,"Rituximab vs fingolimod","or","binary",2,-0.962143304413381,0.80919452706268,0,2017.5,0.0232874519846351,196
"CD013874","CD013874_pub3_data","5|2|Time to relapse over 18 to 24 months' follow-up|Rituximab vs natalizumab","Time to relapse over 18 to 24 months' follow-up",5,2,"Rituximab vs natalizumab","reported","reported",3,-0.0457273174176187,0.0720355040333162,0,2020,0,640.666666666667
"CD013874","CD013874_pub3_data","5|3|Serious adverse events assessed with Grades 3/4 CTCAE over 18 to 24 months' follow-up|Rituximab vs fingolimod","Serious adverse events assessed with Grades 3/4 CTCAE over 18 to 24 months' follow-up",5,3,"Rituximab vs fingolimod","or","binary",2,-0.858470394221453,0.826453379169564,0,2017.5,0.0276088348271447,196
"CD013874","CD013874_pub3_data","5|4|Common infections over 18 to 72 months' follow-up|Rituximab vs fingolimod","Common infections over 18 to 72 months' follow-up",5,4,"Rituximab vs fingolimod","reported","reported",3,0.174538116506224,0.27315070346686,0.0604126505011536,2018.33333333333,0,1729
"CD013874","CD013874_pub3_data","5|4|Common infections over 18 to 72 months' follow-up|Rituximab vs natalizumab","Common infections over 18 to 72 months' follow-up",5,4,"Rituximab vs natalizumab","reported","reported",2,0.459099183635452,0.195531520427901,0,2019.5,0,2500.5
"CD013874","CD013874_pub3_data","5|5|Time to cancer over 24 to 36 months' follow-up|Rituximab versus natalizumab","Time to cancer over 24 to 36 months' follow-up",5,5,"Rituximab versus natalizumab","reported","reported",2,-0.239385358544732,0.11888355759857,0,2021,NA,0
"CD013875","CD013875_pub2_data","1|10|Clinical pregnancy – all studies|NA","Clinical pregnancy – all studies",1,10,NA,"or","binary",9,0.764665608364637,0.1959550395781,0.0883968958050141,2020.66666666667,0.200343531937735,91.5555555555556
"CD013875","CD013875_pub2_data","1|11|Clinical pregnancy – sensitivity analysis (risk ratio)|NA","Clinical pregnancy – sensitivity analysis (risk ratio)",1,11,NA,"or","binary",9,0.764665608364637,0.1959550395781,0.0883968958050141,2020.66666666667,0.200343531937735,91.5555555555556
"CD013875","CD013875_pub2_data","1|12|Clinical pregnancy – sensitivity analysis (full text only)|NA","Clinical pregnancy – sensitivity analysis (full text only)",1,12,NA,"or","binary",7,0.695210390772273,0.24420463326676,0.151349866233829,2021.42857142857,0.201235334713596,93.4285714285714
"CD013875","CD013875_pub2_data","1|13|Multiple pregnancy – all studies|NA","Multiple pregnancy – all studies",1,13,NA,"or","binary",2,0.84964988444603,0.560562279108045,0,2021.5,0.0333333333333333,120
"CD013875","CD013875_pub2_data","1|14|Multiple pregnancy – sensitivity analysis (risk ratio)|NA","Multiple pregnancy – sensitivity analysis (risk ratio)",1,14,NA,"or","binary",2,0.84964988444603,0.560562279108045,0,2021.5,0.0333333333333333,120
"CD013875","CD013875_pub2_data","1|2|Live birth (or ongoing pregnancy) – all studies|NA","Live birth (or ongoing pregnancy) – all studies",1,2,NA,"or","binary",6,0.834360478171393,0.355997527012616,0.382154371161125,2021.33333333333,0.146763285024155,94
"CD013875","CD013875_pub2_data","1|3|Live birth (or ongoing pregnancy) – sensitivity analysis (risk ratio)|NA","Live birth (or ongoing pregnancy) – sensitivity analysis (risk ratio)",1,3,NA,"or","binary",6,0.834360478171393,0.355997527012616,0.382154371161125,2021.33333333333,0.146763285024155,94
"CD013875","CD013875_pub2_data","1|4|Live birth (or ongoing pregnancy) – sensitivity analysis (live birth only)|NA","Live birth (or ongoing pregnancy) – sensitivity analysis (live birth only)",1,4,NA,"or","binary",3,0.142338680748185,0.388013459005969,4.7144906521921e-07,2020.66666666667,0.151304347826087,74.6666666666667
"CD013875","CD013875_pub2_data","1|6|Miscarriage – all studies|NA","Miscarriage – all studies",1,6,NA,"or","binary",5,0.36148648215413,0.428172531101412,0,2021.6,0.0314734299516908,100.8
"CD013875","CD013875_pub2_data","1|7|Miscarriage – sensitivity analysis (risk ratio)|NA","Miscarriage – sensitivity analysis (risk ratio)",1,7,NA,"or","binary",5,0.36148648215413,0.428172531101412,0,2021.6,0.0314734299516908,100.8
"CD013875","CD013875_pub2_data","1|8|Miscarriage – sensitivity analysis (per clinical pregnancy)|NA","Miscarriage – sensitivity analysis (per clinical pregnancy)",1,8,NA,"or","binary",5,-0.284684297490178,0.538013168901605,0.342808338377861,2021.6,0.216515151515152,29.8
"CD013875","CD013875_pub2_data","2|6|Clinical pregnancy|NA","Clinical pregnancy",2,6,NA,"or","binary",2,0.213355921545087,0.318754370567496,0,2019,0.298684210526316,86
"CD013875","CD013875_pub2_data","2|7|Clinical pregnancy – sensitivity analysis (risk ratio)|NA","Clinical pregnancy – sensitivity analysis (risk ratio)",2,7,NA,"or","binary",2,0.213355921545087,0.318754370567496,0,2019,0.298684210526316,86
"CD014040","CD014040_pub2_data","2|1|Fertilization rate |Previous low or no fertilization","Fertilization rate ",2,1,"Previous low or no fertilization","or","binary",3,0.886406594575394,0.27450586325452,0.139966890018967,2013.66666666667,0.550349150721509,363
"CD014040","CD014040_pub2_data","2|1|Fertilization rate |Unselected population","Fertilization rate ",2,1,"Unselected population","or","binary",6,0.0694848493996272,0.151125598418899,0.0601468021586306,2016.16666666667,0.687790706949511,344.333333333333
"CD014040","CD014040_pub2_data","2|2|Cleavage rate|Male factor","Cleavage rate",2,2,"Male factor","or","binary",2,-0.116375796230627,0.369548952442031,0,2019.5,0.907113567480834,156.5
"CD014040","CD014040_pub2_data","2|2|Cleavage rate|Unselected population","Cleavage rate",2,2,"Unselected population","or","binary",3,-0.157261749890343,0.25714379051148,2.3353250185119e-07,2013.33333333333,0.741886526961154,352.666666666667
"CD014040","CD014040_pub2_data","2|3|Blastocyst development rate|Unselected population","Blastocyst development rate",2,3,"Unselected population","or","binary",4,0.264253955795154,0.114406602398047,0,2015.5,0.455394921343937,315.25
"CD014089_data","CD014089_data","1|1|Frequency of attacks (average per week)|","Frequency of attacks (average per week)",1,1,"","reported","reported",9,-3.09473572266807,1.09588391720324,6.82506295212765,1673.33333333333,NA,0
"CD014089_data","CD014089_data","1|11|Adverse effects|Headache","Adverse effects",1,11,"Headache","or","binary",3,0.859007883499577,0.372531862769718,6.73930835487673e-07,2012.66666666667,0.192355175688509,50.3333333333333
"CD014089_data","CD014089_data","1|11|Adverse effects|Myalgia","Adverse effects",1,11,"Myalgia","or","binary",2,0.262417880722609,0.570840277762089,0.126921936436051,2010.5,0.151709401709402,55
"CD014089_data","CD014089_data","1|2|Duration of attacks (average attack duration, minutes)|","Duration of attacks (average attack duration, minutes)",1,2,"","reported","reported",9,-6.09642957960874,2.19058772071283,23.8036806197549,1673.33333333333,NA,0
"CD014089_data","CD014089_data","1|4|Pain (0 to 10 VAS)|","Pain (0 to 10 VAS)",1,4,"","reported","reported",5,-0.119608085048228,0.316695360221233,0.279144990734423,1404.4,NA,0
"CD014089_data","CD014089_data","1|6|Function|","Function",1,6,"","reported","reported",2,2.59181573033708,1.23447869177618,0,2010,NA,0
"CD014089_data","CD014089_data","1|7|Raynaud's Condition Score |Cross-over: change of changes","Raynaud's Condition Score ",1,7,"Cross-over: change of changes","reported","reported",3,-0.717433375593522,0.365228843105908,0.321282781099308,2007,NA,0
"CD014089_data","CD014089_data","1|7|Raynaud's Condition Score |Cross-over: endline changes","Raynaud's Condition Score ",1,7,"Cross-over: endline changes","reported","reported",2,-1.07814049586777,0.604765042905437,0.61555,2011,NA,0
"CD014089_data","CD014089_data","1|7|Raynaud's Condition Score |Parallel RCTs","Raynaud's Condition Score ",1,7,"Parallel RCTs","reported","reported",3,-0.555815902892516,0.383401979779979,0,2012.66666666667,NA,0
"CD014089_data","CD014089_data","1|9|Number of people with healed digital ulcers|","Number of people with healed digital ulcers",1,9,"","or","binary",2,1.75874004713956,0.726439504367308,0,2013.5,0.192307692307692,17.5
"CD014089_data","CD014089_data","2|1|Frequency of attacks (average per week)|Primary Raynaud's phenomenon","Frequency of attacks (average per week)",2,1,"Primary Raynaud's phenomenon","reported","reported",2,-1.68490238573877,1.73657109188308,0,1248.5,NA,0
"CD014089_data","CD014089_data","2|1|Frequency of attacks (average per week)|Secondary Raynaud's phenomenon","Frequency of attacks (average per week)",2,1,"Secondary Raynaud's phenomenon","reported","reported",9,-3.41245723009312,1.11540167280436,6.9272424677291,1841.44444444444,NA,0
"CD014089_data","CD014089_data","2|2|Duration of attacks (average attack duration, minutes)|Primary Raynaud's phenomenon","Duration of attacks (average attack duration, minutes)",2,2,"Primary Raynaud's phenomenon","reported","reported",2,-6.587517710988,4.27385850700942,0,1248.5,NA,0
"CD014089_data","CD014089_data","2|2|Duration of attacks (average attack duration, minutes)|Secondary Raynaud's phenomenon","Duration of attacks (average attack duration, minutes)",2,2,"Secondary Raynaud's phenomenon","reported","reported",9,-8.01668498544807,2.73411192559216,42.4470033110186,1841.44444444444,NA,0
"CD014089_data","CD014089_data","3|1|Frequency of attacks (average per week)|PF-00489791","Frequency of attacks (average per week)",3,1,"PF-00489791","reported","reported",2,-1.60060773480663,1.40482593640714,0,492,NA,0
"CD014089_data","CD014089_data","3|1|Frequency of attacks (average per week)|Sildenafil","Frequency of attacks (average per week)",3,1,"Sildenafil","reported","reported",3,-0.91627128134572,0.886169068574968,0.646175071235291,2011,NA,0
"CD014089_data","CD014089_data","3|1|Frequency of attacks (average per week)|Tadalafil","Frequency of attacks (average per week)",3,1,"Tadalafil","reported","reported",4,-5.30054950496657,2.13921933875529,13.5938854254015,2009,NA,0
"CD014089_data","CD014089_data","3|2|Duration of attacks (minutes)|PF-00489791","Duration of attacks (minutes)",3,2,"PF-00489791","reported","reported",2,-2.13733267716535,2.05512633756216,1.82355,492,NA,0
"CD014089_data","CD014089_data","3|2|Duration of attacks (minutes)|Sildenafil","Duration of attacks (minutes)",3,2,"Sildenafil","reported","reported",3,-7.78445017773413,4.96594918735002,56.6952114021057,2011,NA,0
"CD014089_data","CD014089_data","3|2|Duration of attacks (minutes)|Tadalafil","Duration of attacks (minutes)",3,2,"Tadalafil","reported","reported",4,-13.8677270040169,7.26366639304603,146.134708952061,2009,NA,0
"CD014089_data","CD014089_data","4|1|Frequency of attacks (average per week)|Sildenafil 100 mg/day","Frequency of attacks (average per week)",4,1,"Sildenafil 100 mg/day","reported","reported",2,-3.02176650782845,2.34118496467108,0,2011,NA,0
"CD014089_data","CD014089_data","4|2|Duration of attacks (average attack duration, minutes)|Sildenafil 100 mg/day","Duration of attacks (average attack duration, minutes)",4,2,"Sildenafil 100 mg/day","reported","reported",2,-13.112910645351,3.88453232623467,0,2011,NA,0
"CD014089_data","CD014089_data","5|1|Frequency of attacks (average per week)|Cross-over: change of changes","Frequency of attacks (average per week)",5,1,"Cross-over: change of changes","reported","reported",4,-2.73332101599506,1.72588831541642,8.99288168470506,1250,NA,0
"CD014089_data","CD014089_data","5|1|Frequency of attacks (average per week)|Cross-over: endline changes","Frequency of attacks (average per week)",5,1,"Cross-over: endline changes","reported","reported",2,-5.494,2.40719006312339,7.8385,2011,NA,0
"CD014089_data","CD014089_data","5|1|Frequency of attacks (average per week)|Parallel RCTs","Frequency of attacks (average per week)",5,1,"Parallel RCTs","reported","reported",3,-1.63077255864593,1.77024744520985,4.35768327594331,2012.66666666667,NA,0
"CD014089_data","CD014089_data","5|2|Duration of attacks (average attack duration, minutes)|Cross-over: change of changes","Duration of attacks (average attack duration, minutes)",5,2,"Cross-over: change of changes","reported","reported",4,-7.06783579391965,4.01679166807903,39.9312527611695,1250,NA,0
"CD014089_data","CD014089_data","5|2|Duration of attacks (average attack duration, minutes)|Cross-over: endline changes","Duration of attacks (average attack duration, minutes)",5,2,"Cross-over: endline changes","reported","reported",2,-6.0653264604811,4.22420916935726,24.8582,2011,NA,0
"CD014089_data","CD014089_data","5|2|Duration of attacks (average attack duration, minutes)|Parallel RCTs","Duration of attacks (average attack duration, minutes)",5,2,"Parallel RCTs","reported","reported",3,-13.8486039566527,11.2131029610061,302.021715763193,2012.66666666667,NA,0
"CD014089_data","CD014089_data","6|1|Frequency of attacks (average per week)|","Frequency of attacks (average per week)",6,1,"","reported","reported",9,-2.57357961534029,0.922131510598976,3.21091484795426,1673.33333333333,NA,0
"CD014089_data","CD014089_data","6|2|Duration of attacks (average attack duration, minutes)|","Duration of attacks (average attack duration, minutes)",6,2,"","reported","reported",9,-5.10842721600898,1.99327997782203,15.6588151669933,1673.33333333333,NA,0
"CD014089_data","CD014089_data","6|4|Pain (0 to 10 VAS)|","Pain (0 to 10 VAS)",6,4,"","reported","reported",5,-0.119608085048228,0.316695360221233,0.279144990734423,1404.4,NA,0
"CD014145","CD014145_pub2_data","1|1|Failed apnea reduction after 2 to 7 days|Doxapram compared to alternative treatment for the treatment of apnea","Failed apnea reduction after 2 to 7 days",1,1,"Doxapram compared to alternative treatment for the treatment of apnea","or","binary",4,0.287789135955412,0.536743601203193,0,1991.5,0.149206349206349,21
"CD014145","CD014145_pub2_data","1|2|Need for positive pressure ventilation after initiation of treatment|Doxapram compared to alternative treatment for the treatment of apnea","Need for positive pressure ventilation after initiation of treatment",1,2,"Doxapram compared to alternative treatment for the treatment of apnea","or","binary",2,0.536030296134665,1.31097426023507,0,1987.5,0,18.5
"CD014145","CD014145_pub2_data","1|3|Side effects causing cessation of therapy|Doxapram compared to alternative treatment for the treatment of apnea","Side effects causing cessation of therapy",1,3,"Doxapram compared to alternative treatment for the treatment of apnea","or","binary",2,-0.163193281650054,1.4508974233528,0,1987.5,0,18.5
"CD014145","CD014145_pub2_data","2|8|Death (at any time during initial hospitalization)|Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation in preterm infants","Death (at any time during initial hospitalization)",2,8,"Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation in preterm infants","or","binary",2,0.322343952652066,0.7092139176523,0,1998,0.067816091954023,42.5
"CD014145","CD014145_pub2_data","2|9|Side effects causing cessation of therapy|Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation in preterm infants","Side effects causing cessation of therapy",2,9,"Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation in preterm infants","or","binary",2,1.88963776779391,1.12401628327786,0,1998,0,42.5
"CD014160","CD014160_pub2_data","1|2|Adverse events (e.g. local irritation, vital sign instability)|NA","Adverse events (e.g. local irritation, vital sign instability)",1,2,NA,"or","binary",2,-0.0262525115828348,1.43082250720228,0,2013,0,52
"CD014300","CD014300_pub2_data","1|13|Acceptability at study endpoint: children|","Acceptability at study endpoint: children",1,13,"","or","binary",10,-0.0770286122609293,0.285911172969588,0.530460274310619,2015,0.103850561901375,643
"CD014300","CD014300_pub2_data","1|14|Acceptability at study endpoint: adults|","Acceptability at study endpoint: adults",1,14,"","or","binary",2,-0.285395237724818,0.165326108827599,0,2021.5,0.241666666666667,480
"CD014300","CD014300_pub2_data","1|3|Mental well-being at study endpoint: adults|Caregiver Support Intervention (CSI)","Mental well-being at study endpoint: adults",1,3,"Caregiver Support Intervention (CSI)","or","binary",2,-0.0417634607331953,1.41732281595165,0,2021.5,0,299.5
"CD014428","CD014428_pub2_data","1|1|Pain intensity|Short-term (≤ 3 months after randomisation)","Pain intensity",1,1,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,2.67672700591689,0,2015.5,0,85
"CD014428","CD014428_pub2_data","2|1|Pain intensity|Short-term (≤ 3 months after randomisation)","Pain intensity",2,1,"Short-term (≤ 3 months after randomisation)","reported","reported",3,0,0.479684071230044,0,2020.66666666667,0,48.6666666666667
"CD014428","CD014428_pub2_data","2|2|Function|Short-term (≤ 3 months after randomisation)","Function",2,2,"Short-term (≤ 3 months after randomisation)","reported","reported",3,0,0.530715699712987,0,2020.66666666667,0,48
"CD014428","CD014428_pub2_data","2|4|Health-related quality of life (Physical Component Summary)|Short-term (≤ 3 months after randomisation)","Health-related quality of life (Physical Component Summary)",2,4,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,1.11081137931654,0,2019,0,32
"CD014428","CD014428_pub2_data","2|5|Health-related quality of life (Mental Component Summary)|Short-term (≤ 3 months after randomisation)","Health-related quality of life (Mental Component Summary)",2,5,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,0.797691697562324,0,2019,0,32
"CD014428","CD014428_pub2_data","3|2|Function|Short-term (≤ 3 months after randomisation)","Function",3,2,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,2.8446098533905,0,2023,0,45.5
"CD014428","CD014428_pub2_data","4|1|Pain intensity|Short-term (≤ 3 months after randomisation)","Pain intensity",4,1,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,0.478324824939645,0,2023.5,0,57.5
"CD014428","CD014428_pub2_data","4|2|Function|Short-term (≤ 3 months after randomisation)","Function",4,2,"Short-term (≤ 3 months after randomisation)","reported","reported",2,0,0.556536969246241,0,2023.5,0,57.5
"CD014541","CD014541_pub2_data","1|1|Symptomatic VTE: short-term (45 days or fewer)|","Symptomatic VTE: short-term (45 days or fewer)",1,1,"","reported","reported",4,0,0.134532127291592,0,2016.5,0.0213425978353216,6193.25
"CD014541","CD014541_pub2_data","1|11|Major bleeding: short-term (45 days or fewer)|","Major bleeding: short-term (45 days or fewer)",1,11,"","reported","reported",5,0,0.158042924516993,0,2013.6,0.0032234258522922,7951.2
"CD014541","CD014541_pub2_data","1|12|Major bleeding: short-term (45 days or fewer); COVID-19 sensitivty analysis|","Major bleeding: short-term (45 days or fewer); COVID-19 sensitivty analysis",1,12,"","reported","reported",5,0,0.158042924516993,0,2013.6,0.0032234258522922,7951.2
"CD014541","CD014541_pub2_data","1|13|Major bleeding: short-term (45 days or fewer); same extended agent sensitivity analysis|","Major bleeding: short-term (45 days or fewer); same extended agent sensitivity analysis",1,13,"","reported","reported",2,0,0.241976260293685,0,2015.5,0.00262703972836222,9980
"CD014541","CD014541_pub2_data","1|14|Major bleeding: short-term (45 days or fewer); men versus women subgroup analysis|Women","Major bleeding: short-term (45 days or fewer); men versus women subgroup analysis",1,14,"Women","or","binary",3,0.931590489283613,0.301234657646097,0,2014.66666666667,0.00243811090408268,4256
"CD014541","CD014541_pub2_data","1|19|All-cause mortality: short-term (45 days or fewer)|","All-cause mortality: short-term (45 days or fewer)",1,19,"","reported","reported",5,0,0.0546415776632572,0,2013.6,0.036807679921966,7616
"CD014541","CD014541_pub2_data","1|2|Symptomatic VTE: short-term (45 days or fewer); random-effects sensitivity anaysis|","Symptomatic VTE: short-term (45 days or fewer); random-effects sensitivity anaysis",1,2,"","reported","reported",4,0,0.134532127291592,0,2016.5,0.0213425978353216,6193.25
"CD014541","CD014541_pub2_data","1|20|All-cause mortality: short-term (45 days or fewer); same extended agent sensitivity analysis|","All-cause mortality: short-term (45 days or fewer); same extended agent sensitivity analysis",1,20,"","reported","reported",2,0,0.0906784145099047,0,2015.5,0.0315419702301508,9142
"CD014541","CD014541_pub2_data","1|22|Total VTE: short-term (45 days or fewer)|","Total VTE: short-term (45 days or fewer)",1,22,"","reported","reported",4,0,0.077338378212268,0,2013,0.0346780832592948,6883.25
"CD014541","CD014541_pub2_data","1|26|Fatal bleeding: short-term (45 days or fewer)|","Fatal bleeding: short-term (45 days or fewer)",1,26,"","reported","reported",4,0,0.69270378607424,0,2013,0.000217908687267101,8081
"CD014541","CD014541_pub2_data","1|27|VTE-related mortality: short-term (45 days or fewer)|","VTE-related mortality: short-term (45 days or fewer)",1,27,"","reported","reported",6,0,0.151589784416692,0,2015,0.00716730757633315,6028.33333333333
"CD014541","CD014541_pub2_data","1|3|Symptomatic VTE: short-term (45 days or fewer); COVID-19 sensitivity analysis|","Symptomatic VTE: short-term (45 days or fewer); COVID-19 sensitivity analysis",1,3,"","reported","reported",3,0,0.135640071917563,0,2014.66666666667,0.0116853086441605,8151.66666666667
"CD014541","CD014541_pub2_data","1|4|Symptomatic VTE: short-term (45 days or fewer); same extended agent sensitivity analysis|","Symptomatic VTE: short-term (45 days or fewer); same extended agent sensitivity analysis",1,4,"","reported","reported",2,0,0.183744283578205,0,2020,0.0306462546604903,6168.5
"CD014544","CD014544_pub2_data","2|4|Adverse events|","Adverse events",2,4,"","reported","reported",6,0,0.143065085275713,0,2018,0.254385964912281,60
"CD014544","CD014544_pub2_data","3|1|Bleeding rates|Annualized joint bleeding rate (AjBR) - Concizumab","Bleeding rates",3,1,"Annualized joint bleeding rate (AjBR) - Concizumab","or","binary",2,-0.57567605589109,1.43550840630397,0,2019,0,39
"CD014544","CD014544_pub2_data","3|4|Adverse events|All adverse events","Adverse events",3,4,"All adverse events","or","binary",2,0.516250090990735,0.484548074387351,0,2019,0.599415204678363,39
"CD014544","CD014544_pub2_data","3|4|Adverse events|Injection site reaction","Adverse events",3,4,"Injection site reaction","or","binary",2,3.2212929842313,1.06748913101213,0,2019,0,39
"CD014544","CD014544_pub2_data","3|4|Adverse events|Upper respiratory tract infection","Adverse events",3,4,"Upper respiratory tract infection","or","binary",2,-0.299077797729017,0.808647505309564,0,2019,0.0818713450292398,39
"CD014544","CD014544_pub2_data","3|5|Bleeding rates (fixed effects model)|Annualized joint bleeding rate (AjBR) - Concizumab","Bleeding rates (fixed effects model)",3,5,"Annualized joint bleeding rate (AjBR) - Concizumab","or","binary",2,-0.57567605589109,1.43550840630397,0,2019,0,39
"CD014573_data","CD014573_data","1|2|Cases of cholera (2 doses ± booster dose; 5-month and 2-year follow-up; per-protocol analysis)|NA","Cases of cholera (2 doses ± booster dose; 5-month and 2-year follow-up; per-protocol analysis)",1,2,NA,"reported","reported",2,-1.44730769230769,0.519993030221838,0.5211,1997,0,8211.5
"CD014573_data","CD014573_data","2|1|Cases of cholera (2 doses; 1-year follow-up; per-protocol analysis)|NA","Cases of cholera (2 doses; 1-year follow-up; per-protocol analysis)",2,1,NA,"reported","reported",2,-0.458612593383138,0.148968706647735,0,2014,0,120815.5
"CD014573_data","CD014573_data","2|2|Cases of cholera (2 doses; 2-year follow-up; per-protocol analysis)|NA","Cases of cholera (2 doses; 2-year follow-up; per-protocol analysis)",2,2,NA,"reported","reported",2,-1.02126506024096,0.414952706968128,0.32715,2014,0,84270
"CD014574","CD014574_pub2_data","1|1|Improvement in symptom severity: long term (> 9 months)|","Improvement in symptom severity: long term (> 9 months)",1,1,"","reported","reported",2,-1.6211063873091,0.9744554783904,0,NA,NA,47
"CD014574","CD014574_pub2_data","1|2|Improvement in functional ability: long term  (> 9 months)|","Improvement in functional ability: long term  (> 9 months)",1,2,"","reported","reported",2,-1.16136891272177,0.673345986431505,0,NA,NA,47.5
"CD014574","CD014574_pub2_data","1|3|Steroid sparing effect: long term (> 9 months)|","Steroid sparing effect: long term (> 9 months)",1,3,"","reported","reported",2,1.00294716745967,0.0420417500596122,0,NA,0.903846153846154,47
"CD014574","CD014574_pub2_data","1|4|Relapse requiring rescue therapy: long term (> 9 months)|","Relapse requiring rescue therapy: long term (> 9 months)",1,4,"","reported","reported",2,0.448006925227079,0.138939799935805,0,NA,0.511784511784512,49
"CD014574","CD014574_pub2_data","1|5|Serious adverse events: long term |","Serious adverse events: long term ",1,5,"","reported","reported",2,0.733572564897555,0.233362181603608,0,NA,0.35016835016835,49.5
"CD014574","CD014574_pub2_data","2|1|Improvement in symptom severity: medium term (2-9 months)|","Improvement in symptom severity: medium term (2-9 months)",2,1,"","reported","reported",2,-2.131608756162,0.831423351109772,0,NA,NA,47.5
"CD014574","CD014574_pub2_data","2|17|Steroid sparing effect: medium term (2-9 months)|","Steroid sparing effect: medium term (2-9 months)",2,17,"","reported","reported",2,0.924169921369722,0.11667007990839,0.0160812246088846,NA,0.860805860805861,47.5
"CD014574","CD014574_pub2_data","2|20|Quality of life: long term (> 9 months)|","Quality of life: long term (> 9 months)",2,20,"","reported","reported",2,-0.836005621780446,2.12199921683934,0,NA,NA,47.5
"CD014574","CD014574_pub2_data","2|21|Quality of life: medium term (2-9 months)|","Quality of life: medium term (2-9 months)",2,21,"","reported","reported",2,-1.92179474019596,1.9408515782487,0,NA,NA,47
"CD014574","CD014574_pub2_data","2|23|Hospital admissions: long term (> 9 months)|","Hospital admissions: long term (> 9 months)",2,23,"","reported","reported",2,0.342929063700377,0.278375105579987,0,NA,0.216329966329966,49.5
"CD014574","CD014574_pub2_data","2|25|Antibody titre: medium term (2-9 months)|","Antibody titre: medium term (2-9 months)",2,25,"","reported","reported",2,-9.82688989071546,3.65942758728881,0,NA,NA,46.5
"CD014574","CD014574_pub2_data","2|26|Any adverse event: long term|","Any adverse event: long term",2,26,"","reported","reported",2,1.03498207009043,0.0508561829297466,0,NA,0.890572390572391,49.5
"CD014574","CD014574_pub2_data","2|3|Improvement in functional ability: medium term (2-9 months)|","Improvement in functional ability: medium term (2-9 months)",2,3,"","reported","reported",2,-1.32419084825368,0.686954835160679,0,NA,NA,47.5
"CD014574","CD014574_pub2_data","2|5|Clinically significant improvement in QMG: long term (> 9 months)|","Clinically significant improvement in QMG: long term (> 9 months)",2,5,"","reported","reported",2,1.16815731643489,0.246914913960488,0.0768182619871942,NA,0.713250517598344,44
"CD014574","CD014574_pub2_data","2|6|Clinically significant improvement in QMG: medium term  (2-9 months)|","Clinically significant improvement in QMG: medium term  (2-9 months)",2,6,"","reported","reported",2,1.24325207721065,0.211485992303116,0,NA,0.507246376811594,45.5
"CD014574","CD014574_pub2_data","2|8|Clinically significant improvement in MG-ADL: long term (> 9 months)|","Clinically significant improvement in MG-ADL: long term (> 9 months)",2,8,"","reported","reported",2,1.32571539804316,0.267441313655556,0,NA,0.468864468864469,47.5
"CD014574","CD014574_pub2_data","2|9|Clinially significant improvement in MG-ADL: medium term (2-9 months)|","Clinially significant improvement in MG-ADL: medium term (2-9 months)",2,9,"","reported","reported",2,1.44840835545668,0.335828125513152,0,NA,0.391941391941392,47.5
"CD014585","CD014585_pub2_data","1|1|Global symptoms of dyspepsia (dichotomous)|","Global symptoms of dyspepsia (dichotomous)",1,1,"","reported","reported",4,0,0.0452263899337784,0,2004.25,0.542864360057356,889
"CD014585","CD014585_pub2_data","1|3|Incident ulcer|","Incident ulcer",1,3,"","reported","reported",7,0,0.149700624722889,0,2008.14285714286,0.160699445485555,892.428571428571
"CD014585","CD014585_pub2_data","1|4|Adverse events|","Adverse events",1,4,"","reported","reported",3,0,0.0526033286946734,0,2005.33333333333,0.364310232101994,1033.33333333333
"CD014585","CD014585_pub2_data","1|6|Quality of life|","Quality of life",1,6,"","reported","reported",2,0,0.0814484137937024,0,2005,0,574.5
"CD014585","CD014585_pub2_data","4|1|Global symptoms of dyspepsia (continuous)|Non-selective NSAID","Global symptoms of dyspepsia (continuous)",4,1,"Non-selective NSAID","or","binary",2,-0.664844161058281,1.41635622512856,0,2005,0,369.5
"CD014585","CD014585_pub2_data","4|1|Global symptoms of dyspepsia (continuous)|Selective NSAID","Global symptoms of dyspepsia (continuous)",4,1,"Selective NSAID","reported","reported",2,0,0.134630229603621,0,2005,0,497
"CD014585","CD014585_pub2_data","4|2|Incident ulcer|Non-selective","Incident ulcer",4,2,"Non-selective","reported","reported",9,0,0.105666717316057,0,2005.88888888889,0.166264661136489,627.111111111111
"CD014585","CD014585_pub2_data","4|2|Incident ulcer|Selective","Incident ulcer",4,2,"Selective","reported","reported",2,0,0.194978313092585,0,2006,0.1356210142727,689
"CD014585","CD014585_pub2_data","4|3|Adverse events|Non-selective","Adverse events",4,3,"Non-selective","reported","reported",8,0,0.0228514129535011,0,2005.625,0.386625134087843,593.25
"CD014585","CD014585_pub2_data","4|3|Adverse events|Selective","Adverse events",4,3,"Selective","reported","reported",4,0,0.102404354866488,0,2006,0.198209983845771,696
"CD014585","CD014585_pub2_data","5|1|Global symptoms of dyspepsia (Dichotomous)|Esomeprazole","Global symptoms of dyspepsia (Dichotomous)",5,1,"Esomeprazole","reported","reported",3,0,0.0293069243367705,0,2005.66666666667,0.664995617331376,1150.66666666667
"CD014585","CD014585_pub2_data","5|1|Global symptoms of dyspepsia (Dichotomous)|Omeprazole","Global symptoms of dyspepsia (Dichotomous)",5,1,"Omeprazole","reported","reported",4,0,0.125100085607549,0,2005.5,0.256425078955601,347
"CD014585","CD014585_pub2_data","5|2|Incident ulcer|Esomeprazole","Incident ulcer",5,2,"Esomeprazole","reported","reported",4,0,0.143366785953516,0,2006.75,0.0999982643764905,1198.75
"CD014585","CD014585_pub2_data","5|2|Incident ulcer|Lansoprazole","Incident ulcer",5,2,"Lansoprazole","reported","reported",2,0,0.150276085783676,0,2008,0.306708217155978,383.5
"CD014585","CD014585_pub2_data","5|2|Incident ulcer|Omeprazole","Incident ulcer",5,2,"Omeprazole","reported","reported",4,0,0.220256117579617,0,2005.5,0.140934574119924,348
"CD014585","CD014585_pub2_data","5|3|Adverse events|Esomeprazole","Adverse events",5,3,"Esomeprazole","reported","reported",5,0,0.0507651741901145,0,2006.2,0.232605254157362,1042
"CD014585","CD014585_pub2_data","5|3|Adverse events|Lansoprazole","Adverse events",5,3,"Lansoprazole","reported","reported",2,0,0.064023878023335,0,2008,0.375163260263334,414
"CD014585","CD014585_pub2_data","5|3|Adverse events|Omeprazole","Adverse events",5,3,"Omeprazole","reported","reported",4,0,0.027157271842006,0,2005.5,0.478416171840145,347
"CD014594","CD014594_pub2_data","1|1|First-pass success|NA","First-pass success",1,1,NA,"or","binary",7,1.20170164613141,0.139224519605448,0.0846573772796896,2017.28571428571,0.592302247804474,610.571428571429
"CD014594","CD014594_pub2_data","1|2|Sensitivity analysis: first-pass success excluding rescue U/S|NA","Sensitivity analysis: first-pass success excluding rescue U/S",1,2,NA,"or","binary",3,1.13699070201568,0.183493010502492,0.0538556545866101,2018.66666666667,0.53258380275187,585
"CD014594","CD014594_pub2_data","10|1|Dissection|NA","Dissection",10,1,NA,"or","binary",4,-0.502164870064765,0.651248010120082,0,2011.25,0.00918931368033164,363.25
"CD014594","CD014594_pub2_data","10|2|Dissection: sensitivity analysis excluding rescue U/S|NA","Dissection: sensitivity analysis excluding rescue U/S",10,2,NA,"or","binary",2,-1.01409186270984,1.23173844470842,0,2011,0.0153846153846154,120.5
"CD014594","CD014594_pub2_data","11|2|AV fistula: sensitivity analysis excluding rescue U/S|NA","AV fistula: sensitivity analysis excluding rescue U/S",11,2,NA,"or","binary",4,-1.19389603545501,0.698324404730512,0,2015,0.00510204081632653,453.75
"CD014594","CD014594_pub2_data","12|1|Target vessel occlusion|NA","Target vessel occlusion",12,1,NA,"or","binary",3,-0.828284035174176,1.00168008021871,0,2016,0.00172018831535242,589.333333333333
"CD014594","CD014594_pub2_data","12|2|Target vessel occlusion: sensitivity analysis excluding rescue U/S|NA","Target vessel occlusion: sensitivity analysis excluding rescue U/S",12,2,NA,"or","binary",2,-0.662005857727669,1.26774615920757,0,2019,0.00158227848101266,382
"CD014594","CD014594_pub2_data","2|1|Time to successful CFA access|NA","Time to successful CFA access",2,1,NA,"or","binary",6,0.0132366482443471,0.817769066282921,0,2014.5,0,595
"CD014594","CD014594_pub2_data","2|2|Time to successful CFA access: sensitivity analysis from local anesthetic|NA","Time to successful CFA access: sensitivity analysis from local anesthetic",2,2,NA,"or","binary",3,-0.00135002049309012,1.15620947807314,0,2018.33333333333,0,505.666666666667
"CD014594","CD014594_pub2_data","2|3|Time to successful CFA access: sensitivity analysis from fluoroscopy table movement or US probe application|NA","Time to successful CFA access: sensitivity analysis from fluoroscopy table movement or US probe application",2,3,NA,"or","binary",2,0.0416491225867828,1.41494270841332,0,2014,0,970.5
"CD014594","CD014594_pub2_data","2|5|Time to successful CFA access: sensitivity analysis excluding rescue U/S|NA","Time to successful CFA access: sensitivity analysis excluding rescue U/S",2,5,NA,"or","binary",2,0.0438137332661075,1.41770422567412,0,2011,0,525.5
"CD014594","CD014594_pub2_data","3|1|Major bleeding|NA","Major bleeding",3,1,NA,"or","binary",6,-0.484063517100135,0.314946691890703,0.210910427459285,2018,0.0410966685227407,669.333333333333
"CD014594","CD014594_pub2_data","3|2|Minor bleeding|NA","Minor bleeding",3,2,NA,"or","binary",3,-0.173142485914826,0.719707946995347,0.42609644058027,2010.66666666667,0.0430952380952381,140
"CD014594","CD014594_pub2_data","3|3|Minor bleeding: sensitivity analysis excluding rescue U/S|NA","Minor bleeding: sensitivity analysis excluding rescue U/S",3,3,NA,"or","binary",2,0.216399795884552,0.587787379438019,0,2009.5,0.0446428571428571,106
"CD014594","CD014594_pub2_data","3|4|Major bleeding: sensitivity analysis excluding rescue U/S|NA","Major bleeding: sensitivity analysis excluding rescue U/S",3,4,NA,"or","binary",3,-0.955260853671379,0.468315128613794,0.157246627111832,2018.66666666667,0.0385744755545841,567.666666666667
"CD014594","CD014594_pub2_data","4|1|Overall cannulation success|NA","Overall cannulation success",4,1,NA,"or","binary",4,0.37490963800253,0.227807313032308,0.105975601500165,2016.25,0.886105653967208,630
"CD014594","CD014594_pub2_data","5|1|Venipuncture|NA","Venipuncture",5,1,NA,"or","binary",7,-1.29979486248101,0.187730994404165,0.0918185561832218,2016,0.137563823969857,596.857142857143
"CD014594","CD014594_pub2_data","5|2|Venipuncture: sensitivity analysis excluding rescue U/S|NA","Venipuncture: sensitivity analysis excluding rescue U/S",5,2,NA,"or","binary",4,-1.20078795939086,0.229744934781325,0,2015,0.139885377227814,466.75
"CD014594","CD014594_pub2_data","7|1|Number of attempts|NA","Number of attempts",7,1,NA,"or","binary",5,0.0311665968956172,0.895672068669948,0,2014.8,0,672.4
"CD014594","CD014594_pub2_data","7|2|Number of attempts: sensitivity analysis excluding rescue U/S|NA","Number of attempts: sensitivity analysis excluding rescue U/S",7,2,NA,"or","binary",2,0.0438137332661075,1.41770422567412,0,2011,0,525.5
"CD014594","CD014594_pub2_data","8|1|Retroperitoneal hematoma|NA","Retroperitoneal hematoma",8,1,NA,"or","binary",6,-0.348778247775475,0.68166375277789,0,2014,0.00762983299016243,446.666666666667
"CD014594","CD014594_pub2_data","8|2|Retroperitoneal hematoma: sensitivity analysis excluding rescue U/S|NA","Retroperitoneal hematoma: sensitivity analysis excluding rescue U/S",8,2,NA,"or","binary",3,-0.802680590408004,1.04993709420698,0,2013,0.0141843971631206,282.333333333333
"CD014594","CD014594_pub2_data","9|1|Pseudoaneurysm formation|NA","Pseudoaneurysm formation",9,1,NA,"or","binary",7,-0.189302076106935,0.455483685592658,0,2015,0.00523682449166404,521.142857142857
"CD014594","CD014594_pub2_data","9|2|Pseudoaneurysm formation: sensitivity analysis excluding rescue U/S|NA","Pseudoaneurysm formation: sensitivity analysis excluding rescue U/S",9,2,NA,"or","binary",4,-0.135679863084587,0.619424954708496,0,2015,0.00593863640879916,453.75
"CD014617","CD014617_pub3_data","2|1|Risk of ocular infection within one month of corneal abrasion|Conjunctivitis","Risk of ocular infection within one month of corneal abrasion",2,1,"Conjunctivitis","or","binary",2,0.173123565300457,0.187215223241432,0,1975,0.407294832826748,254
"CD014617","CD014617_pub3_data","2|2|Proportion of eyes healed within 48 hours|6% sulphacetamide sodium versus 1% chloramphenicol","Proportion of eyes healed within 48 hours",2,2,"6% sulphacetamide sodium versus 1% chloramphenicol","reported","reported",2,0,0.0192848567078136,0,1975,0.925126646403242,254
"CD014617","CD014617_pub3_data","2|3|Adverse events|","Adverse events",2,3,"","reported","reported",2,0,0.387532949738855,0,1975,0.0411525701718418,338.5
"CD014623","CD014623_pub2_data","1|5|Sural sensory nerve action potential (SNAP) amplitudes (μV)|NA","Sural sensory nerve action potential (SNAP) amplitudes (μV)",1,5,NA,"reported","reported",2,-0.0452407271522687,0.988519030710281,0,2016.5,NA,38.5
"CD014623","CD014623_pub2_data","1|6|Any adverse events|NA","Any adverse events",1,6,NA,"reported","reported",2,1.02334623275832,0.24640387062741,0,2016.5,0.473684210526316,39
"CD014623","CD014623_pub2_data","1|7|Serious adverse events|NA","Serious adverse events",1,7,NA,"reported","reported",2,0.480713788932226,0.559390731838862,0,2016.5,0.131578947368421,39
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|12 hours post-infusion","Depression response (early phase)",1,1,"12 hours post-infusion","or","binary",4,-0.177596996567082,0.270926633165082,0,2017.5,0.212998253759123,81.25
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|2 hours post-infusion","Depression response (early phase)",1,1,"2 hours post-infusion","or","binary",3,-0.0169373343677541,0.530243101163147,0,2017.66666666667,0.0381105743424584,89
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|24 hours post-infusion","Depression response (early phase)",1,1,"24 hours post-infusion","or","binary",4,0.224600348087004,0.238290334886781,1.48643019785649e-06,2017.5,0.32874945103206,81.25
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|30 days post-infusion","Depression response (early phase)",1,1,"30 days post-infusion","reported","reported",3,0,0.096089802469361,0,2017.66666666667,0.509588640023423,89
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|36 hours post-infusion","Depression response (early phase)",1,1,"36 hours post-infusion","or","binary",3,0.539297203229208,0.253860717661694,3.1177390546916e-06,2017.66666666667,0.418313570487484,89
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|4 hours post-infusion","Depression response (early phase)",1,1,"4 hours post-infusion","or","binary",3,0.148296582520048,0.35647480660776,0,2017.66666666667,0.126116234811887,89
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|60 hours post-infusion","Depression response (early phase)",1,1,"60 hours post-infusion","or","binary",4,0.574084107476439,0.231741155096935,0,2017.5,0.472005249179162,81.25
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|7 days post-infusion","Depression response (early phase)",1,1,"7 days post-infusion","or","binary",3,0.516928145642982,0.254948014846881,3.31376035092566e-06,2017.66666666667,0.379446640316206,89
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|72 hours post-infusion","Depression response (early phase)",1,1,"72 hours post-infusion","or","binary",4,0.595547700748078,0.233792977257051,7.47688779239246e-07,2017.5,0.485322949996863,81.25
"CD014624","CD014624_pub2_data","1|1|Depression response (early phase)|8 hours post-infusion","Depression response (early phase)",1,1,"8 hours post-infusion","or","binary",3,0.149811194608667,0.296629006985935,0,2017.66666666667,0.187039476894549,89
"CD014624","CD014624_pub2_data","1|2|Depression remission (early phase)|30 days post-infusion","Depression remission (early phase)",1,2,"30 days post-infusion","reported","reported",3,0,0.141583175343544,0,2017.66666666667,0.352339823354316,89
"CD014624","CD014624_pub2_data","1|2|Depression remission (early phase)|60 hours post-infusion","Depression remission (early phase)",1,2,"60 hours post-infusion","reported","reported",2,0,0.192217523240615,0,2017.5,0.230639730639731,64.5
"CD014624","CD014624_pub2_data","1|2|Depression remission (early phase)|72 hours post-infusion","Depression remission (early phase)",1,2,"72 hours post-infusion","reported","reported",2,0,0.29540838655093,0,2017.5,0.177865612648221,79.5
"CD014624","CD014624_pub2_data","1|2|Depression remission (early phase)|8 hours post-infusion","Depression remission (early phase)",1,2,"8 hours post-infusion","reported","reported",2,0,0.911833892786913,0,2017.5,0.0217391304347826,79.5
"CD014624","CD014624_pub2_data","1|3|Adverse events (mother)|Any adverse event","Adverse events (mother)",1,3,"Any adverse event","reported","reported",3,0,0.133616870011834,0,2017.66666666667,0.549992680427463,89
"CD014624","CD014624_pub2_data","1|3|Adverse events (mother)|Serious adverse event","Adverse events (mother)",1,3,"Serious adverse event","reported","reported",2,0,1.14707792512933,0,2018,0,123
"CD014624","CD014624_pub2_data","1|3|Adverse events (mother)|Severe adverse event","Adverse events (mother)",1,3,"Severe adverse event","reported","reported",3,0,0.826384876617251,0,2017.66666666667,0.0364758698092031,89
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|12 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"12 hours post-infusion","reported","reported",5,-0.45509247981045,0.615207265223618,1.83053288553044e-06,2017.6,0,11.6
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|2 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"2 hours post-infusion","reported","reported",4,-0.289725247802289,0.473279256917299,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|24 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"24 hours post-infusion","reported","reported",5,-2.79780015934362,0.98456906730875,1.79805937983159,2017.6,0,11.6
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|30 days post-infusion","Depression severity according to HAMD (early phase)",1,4,"30 days post-infusion","reported","reported",4,-4.26108689291378,2.22601641896279,14.7157610113466,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|36 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"36 hours post-infusion","reported","reported",4,-3.78171566950385,1.57982908233326,6.36841549855521,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|4 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"4 hours post-infusion","reported","reported",4,-1.11965205754433,0.603861777647706,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|48 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"48 hours post-infusion","reported","reported",5,-3.43965357345974,0.780946007999995,8.89469713137323e-07,2017.6,0,11.6
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|60 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"60 hours post-infusion","reported","reported",5,-3.6725892023089,1.08934384477467,2.65032103927306,2017.6,0,11.6
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|7 days post-infusion","Depression severity according to HAMD (early phase)",1,4,"7 days post-infusion","reported","reported",4,-3.55339997298717,0.915455306827258,2.71464257414053e-08,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|72 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"72 hours post-infusion","reported","reported",5,-3.51931192628305,0.757376753437682,9.10216065754213e-06,2017.6,0,11.6
"CD014624","CD014624_pub2_data","1|4|Depression severity according to HAMD (early phase)|8 hours post-infusion","Depression severity according to HAMD (early phase)",1,4,"8 hours post-infusion","reported","reported",4,-1.26723444115755,0.661181017553415,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","1|5|Treatment acceptability (measured by dropouts)|","Treatment acceptability (measured by dropouts)",1,5,"","or","binary",3,1.05714209947649,0.434372842694409,0,2017.66666666667,0.0413311862587225,89
"CD014624","CD014624_pub2_data","2|1|Depression response (early phase)|Day 15","Depression response (early phase)",2,1,"Day 15","reported","reported",2,0,0.108351546167619,0,2022,0.408834586466165,174.5
"CD014624","CD014624_pub2_data","2|1|Depression response (early phase)|Day 21","Depression response (early phase)",2,1,"Day 21","reported","reported",2,0,0.100842541728636,0,2022,0.448308270676692,174.5
"CD014624","CD014624_pub2_data","2|1|Depression response (early phase)|Day 3","Depression response (early phase)",2,1,"Day 3","reported","reported",2,0,0.190763907640938,0,2022,0.192803437164339,174.5
"CD014624","CD014624_pub2_data","2|1|Depression response (early phase)|Day 8","Depression response (early phase)",2,1,"Day 8","reported","reported",2,0,0.124040871662366,0,2022,0.339554242749731,174.5
"CD014624","CD014624_pub2_data","2|2|Depression response (acute phase)|","Depression response (acute phase)",2,2,"","reported","reported",2,0,0.0937340569276866,0,2022,0.491272824919441,174.5
"CD014624","CD014624_pub2_data","2|3|Depression remission (early phase)|Day 15","Depression remission (early phase)",2,3,"Day 15","reported","reported",2,0,0.189895253937636,0,2022,0.188372717508056,174.5
"CD014624","CD014624_pub2_data","2|3|Depression remission (early phase)|Day 21","Depression remission (early phase)",2,3,"Day 21","reported","reported",2,0,0.177165395477439,0,2022,0.224892588614393,174.5
"CD014624","CD014624_pub2_data","2|3|Depression remission (early phase)|Day 3","Depression remission (early phase)",2,3,"Day 3","reported","reported",2,0,0.387026565314539,0,2022,0.0518259935553169,174.5
"CD014624","CD014624_pub2_data","2|3|Depression remission (early phase)|Day 8","Depression remission (early phase)",2,3,"Day 8","reported","reported",2,0,0.227626589408234,0,2022,0.148227712137487,174.5
"CD014624","CD014624_pub2_data","2|4|Depression remission (acute phase)|","Depression remission (acute phase)",2,4,"","reported","reported",2,0,0.150692407338182,0,2022,0.265708915145005,174.5
"CD014624","CD014624_pub2_data","2|5|Adverse events (mother)|Deaths","Adverse events (mother)",2,5,"Deaths","or","binary",2,-0.00648902145115069,1.41829789655431,0,2022,0,174.5
"CD014624","CD014624_pub2_data","2|6|Depression severity (early phase)|Day 15","Depression severity (early phase)",2,6,"Day 15","reported","reported",2,-4.08434900486783,0.889704016053734,0,2022,NA,0
"CD014624","CD014624_pub2_data","2|6|Depression severity (early phase)|Day 21","Depression severity (early phase)",2,6,"Day 21","reported","reported",2,-2.7507130825379,0.930840702403469,0,2022,NA,0
"CD014624","CD014624_pub2_data","2|6|Depression severity (early phase)|Day 3","Depression severity (early phase)",2,6,"Day 3","reported","reported",2,-3.10352941176471,0.774441734412603,0,2022,NA,0
"CD014624","CD014624_pub2_data","2|6|Depression severity (early phase)|Day 8","Depression severity (early phase)",2,6,"Day 8","reported","reported",2,-3.57994757077945,0.828697720895844,0,2022,NA,0
"CD014624","CD014624_pub2_data","2|7|Depression severity (acute phase)|","Depression severity (acute phase)",2,7,"","reported","reported",2,-3.78626674432149,0.925581408362396,0,2022,NA,0
"CD014624","CD014624_pub2_data","2|8|Treatment acceptability|","Treatment acceptability",2,8,"","reported","reported",2,0,1.02956820427684,0,2022,0.107277121374866,174.5
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|12 hours post-infusion","Depression response (early phase)",3,1,"12 hours post-infusion","or","binary",3,-0.149349790243692,0.27463723574377,1.7424039169247e-06,2017.66666666667,0.272092909774069,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|2 hours post-infusion","Depression response (early phase)",3,1,"2 hours post-infusion","or","binary",3,-0.0169373343677541,0.530243101163147,0,2017.66666666667,0.0381105743424584,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|24 hours post-infusion","Depression response (early phase)",3,1,"24 hours post-infusion","or","binary",3,0.364624323424829,0.25534480028622,3.39732746442943e-06,2017.66666666667,0.354999268042746,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|30 days post-infusion","Depression response (early phase)",3,1,"30 days post-infusion","reported","reported",3,0,0.096089802469361,0,2017.66666666667,0.509588640023423,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|36 hours post-infusion","Depression response (early phase)",3,1,"36 hours post-infusion","or","binary",3,0.539297203229208,0.253860717661694,3.1177390546916e-06,2017.66666666667,0.418313570487484,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|4 hours post-infusion","Depression response (early phase)",3,1,"4 hours post-infusion","or","binary",3,0.148296582520048,0.35647480660776,0,2017.66666666667,0.126116234811887,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|48 hours post-infusion","Depression response (early phase)",3,1,"48 hours post-infusion","or","binary",3,0.45615418818752,0.309717408502865,0.0711889264376216,2017.66666666667,0.484604499097253,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|60 hours post-infusion","Depression response (early phase)",3,1,"60 hours post-infusion","or","binary",3,0.679685165606662,0.258895989229241,0,2017.66666666667,0.48648318938174,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|7 days post-infusion","Depression response (early phase)",3,1,"7 days post-infusion","or","binary",3,0.516928145642982,0.254948014846881,3.31376035092566e-06,2017.66666666667,0.379446640316206,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|72 hours post-infusion","Depression response (early phase)",3,1,"72 hours post-infusion","or","binary",3,0.646137585223174,0.260972259056646,5.6692015170758e-07,2017.66666666667,0.468525838091055,89
"CD014624","CD014624_pub2_data","3|1|Depression response (early phase)|8 hours post-infusion","Depression response (early phase)",3,1,"8 hours post-infusion","or","binary",3,0.149811194608667,0.296629006985935,0,2017.66666666667,0.187039476894549,89
"CD014624","CD014624_pub2_data","3|2|Depression remission (early phase)|30 days post-infusion","Depression remission (early phase)",3,2,"30 days post-infusion","reported","reported",3,0,0.141583175343544,0,2017.66666666667,0.352339823354316,89
"CD014624","CD014624_pub2_data","3|2|Depression remission (early phase)|60 hours post-infusion","Depression remission (early phase)",3,2,"60 hours post-infusion","reported","reported",2,0,0.192217523240615,0,2017.5,0.230639730639731,64.5
"CD014624","CD014624_pub2_data","3|2|Depression remission (early phase)|72 hours post-infusion","Depression remission (early phase)",3,2,"72 hours post-infusion","reported","reported",2,0,0.29540838655093,0,2017.5,0.177865612648221,79.5
"CD014624","CD014624_pub2_data","3|3|Adverse events (mother)|Any adverse event","Adverse events (mother)",3,3,"Any adverse event","reported","reported",3,0,0.133616870011834,0,2017.66666666667,0.549992680427463,89
"CD014624","CD014624_pub2_data","3|3|Adverse events (mother)|Serious adverse event","Adverse events (mother)",3,3,"Serious adverse event","reported","reported",2,0,1.14707792512933,0,2018,0,123
"CD014624","CD014624_pub2_data","3|3|Adverse events (mother)|Severe adverse event","Adverse events (mother)",3,3,"Severe adverse event","reported","reported",3,0,0.826384876617251,0,2017.66666666667,0.0364758698092031,89
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|12 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"12 hours post-infusion","reported","reported",4,-0.881031282232501,0.691143833558012,1.05951269032977e-06,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|2 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"2 hours post-infusion","reported","reported",4,-0.289725247802289,0.473279256917299,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|24 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"24 hours post-infusion","reported","reported",4,-3.56155390054686,1.34130493597001,3.99936740747086,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|30 days post-infusion","Depression severity according to HAMD (early phase)",3,4,"30 days post-infusion","reported","reported",4,-4.26108689291378,2.22601641896279,14.7157610113466,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|36 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"36 hours post-infusion","reported","reported",4,-3.78171566950385,1.57982908233326,6.36841549855521,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|4 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"4 hours post-infusion","reported","reported",4,-1.11965205754433,0.603861777647706,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|48 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"48 hours post-infusion","reported","reported",4,-3.74628563858812,0.965555810030591,0.731276291475891,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|60 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"60 hours post-infusion","reported","reported",4,-4.30697533056223,1.15805196107786,2.42202008398912,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|7 days post-infusion","Depression severity according to HAMD (early phase)",3,4,"7 days post-infusion","reported","reported",4,-3.55339997298717,0.915455306827257,2.71464184641065e-08,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|72 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"72 hours post-infusion","reported","reported",4,-3.92642118962509,0.797434961810923,3.25845259317497e-06,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|4|Depression severity according to HAMD (early phase)|8 hours post-infusion","Depression severity according to HAMD (early phase)",3,4,"8 hours post-infusion","reported","reported",4,-1.26723444115755,0.661181017553415,0,2017.75,NA,0
"CD014624","CD014624_pub2_data","3|5|Treatment acceptability (measured by dropouts)|","Treatment acceptability (measured by dropouts)",3,5,"","or","binary",3,1.05714209947649,0.434372842694409,0,2017.66666666667,0.0413311862587225,89
"CD014666","CD014666_pub2_data","1|2|Fear of falling: subgrouped according to mean age|≥ 75 years","Fear of falling: subgrouped according to mean age",1,2,"≥ 75 years","reported","reported",2,0,0.199351135512927,0,1992,0,45.5
"CD014666","CD014666_pub2_data","1|3|Fear of falling: subgrouped according to control|Placebo","Fear of falling: subgrouped according to control",1,3,"Placebo","reported","reported",2,0,0.199351135512927,0,1992,0,45.5
"CD014666","CD014666_pub2_data","1|3|Fear of falling: subgrouped according to control|Usual care","Fear of falling: subgrouped according to control",1,3,"Usual care","or","binary",9,-0.139445734439108,0.668765412460688,0,2012.55555555556,0,237.333333333333
"CD014666","CD014666_pub2_data","1|4|Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions|AMB-based interventions","Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions",1,4,"AMB-based interventions","or","binary",3,0.0689641622825033,1.15720334638586,0,2012.33333333333,0,304
"CD014666","CD014666_pub2_data","1|4|Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions|Non AMB-based interventions","Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions",1,4,"Non AMB-based interventions","reported","reported",2,0,0.199351135512927,0,1992,0,45.5
"CD014666","CD014666_pub2_data","1|5|Fear of falling: subgrouped according to group versus individual interventions|Group intervention","Fear of falling: subgrouped according to group versus individual interventions",1,5,"Group intervention","reported","reported",2,0,0.199351135512927,0,1992,0,45.5
"CD014666","CD014666_pub2_data","1|5|Fear of falling: subgrouped according to group versus individual interventions|Individual intervention","Fear of falling: subgrouped according to group versus individual interventions",1,5,"Individual intervention","or","binary",5,0.0769722840047943,0.898250232464746,0,2015,0,220.6
"CD014666","CD014666_pub2_data","2|1|Fear of falling: subgrouped according to intervention approach|CBT only","Fear of falling: subgrouped according to intervention approach",2,1,"CBT only","or","binary",2,-0.302616987802431,1.41967131159589,0,2013.5,0,202
"CD014666","CD014666_pub2_data","2|1|Fear of falling: subgrouped according to intervention approach|CBT with exercise interventions","Fear of falling: subgrouped according to intervention approach",2,1,"CBT with exercise interventions","or","binary",7,-0.0603895665951521,0.759406533016952,0,2013,0,197.142857142857
"CD014666","CD014666_pub2_data","2|2|Fear of falling: subgrouped according to control|Usual care","Fear of falling: subgrouped according to control",2,2,"Usual care","or","binary",8,-0.140317771326798,0.709570030252928,0,2012.5,0,218
"CD014666","CD014666_pub2_data","2|3|Fear of falling: subgrouped according to  AMB versus non-AMB based interventions|AMB-based interventions","Fear of falling: subgrouped according to  AMB versus non-AMB based interventions",2,3,"AMB-based interventions","or","binary",3,0.0342101218496051,1.1572012080888,0,2012.33333333333,0,289.333333333333
"CD014666","CD014666_pub2_data","2|3|Fear of falling: subgrouped according to  AMB versus non-AMB based interventions|Non AMB-based interventions","Fear of falling: subgrouped according to  AMB versus non-AMB based interventions",2,3,"Non AMB-based interventions","or","binary",6,-0.189030841448894,0.8210496268925,0,2013.5,0,152.666666666667
"CD014666","CD014666_pub2_data","2|4|Fear of falling: subgrouped according to group versus individual interventions|Group intervention","Fear of falling: subgrouped according to group versus individual interventions",2,4,"Group intervention","or","binary",4,-0.346700712352607,1.00432547996646,0,2010.75,0,183
"CD014666","CD014666_pub2_data","2|4|Fear of falling: subgrouped according to group versus individual interventions|Individual intervention","Fear of falling: subgrouped according to group versus individual interventions",2,4,"Individual intervention","or","binary",5,0.0717304777568329,0.898473268846936,0,2015,0,210.4
"CD014666","CD014666_pub2_data","3|1|Fear of falling: subgrouped according to intervention approach|Sustainability of effects, CBT with exercise","Fear of falling: subgrouped according to intervention approach",3,1,"Sustainability of effects, CBT with exercise","or","binary",4,0.0724766502680975,1.00394528009842,0,2014,0,217.75
"CD014666","CD014666_pub2_data","3|2|Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions|AMB-based interventions","Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions",3,2,"AMB-based interventions","or","binary",3,0.0812653750164628,1.15857022607687,0,2012.33333333333,0,261.666666666667
"CD014666","CD014666_pub2_data","3|2|Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions|Non AMB-based interventions","Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions",3,2,"Non AMB-based interventions","or","binary",2,0.0611686932202052,1.41938197088161,0,2017.5,0,200
"CD014666","CD014666_pub2_data","3|3|Fear of falling: subgrouped according to group versus individual interventions|Group intervention","Fear of falling: subgrouped according to group versus individual interventions",3,3,"Group intervention","or","binary",2,0.0254661922695949,1.42018833407754,0,2010.5,0,236.5
"CD014666","CD014666_pub2_data","3|3|Fear of falling: subgrouped according to group versus individual interventions|Individual intervention","Fear of falling: subgrouped according to group versus individual interventions",3,3,"Individual intervention","or","binary",3,0.104992503933895,1.15813231726416,0,2017,0,237.333333333333
"CD014666","CD014666_pub2_data","4|2|Occurrence of falls: immediate postintervention|CBT with exercise intervention","Occurrence of falls: immediate postintervention",4,2,"CBT with exercise intervention","or","binary",5,0.082482209270334,0.526069332869561,1.16117989558641,2014.6,0.393477935360781,205.8
"CD014666","CD014666_pub2_data","4|5|Quality of life: immediate postintervention|CBT only","Quality of life: immediate postintervention",4,5,"CBT only","reported","reported",2,0,0.10155241667913,0,2004,0,191
"CD014666","CD014666_pub2_data","4|5|Quality of life: immediate postintervention|CBT with exercise","Quality of life: immediate postintervention",4,5,"CBT with exercise","reported","reported",2,0,0.170247767091799,0,2000,0,71.5
"CD014678","CD014678_pub2_data","1|1|All-cause mortality (apixaban versus placebo)|","All-cause mortality (apixaban versus placebo)",1,1,"","or","binary",2,0.0933207504821817,0.112818962006699,0,2013,0.0292124272613513,4319
"CD014678","CD014678_pub2_data","1|2|All-cause mortality (rivaroxaban versus placebo)|","All-cause mortality (rivaroxaban versus placebo)",1,2,"","or","binary",3,-0.201197023065887,0.0938285330440018,0,2012.66666666667,0.01962278081366,7290
"CD014678","CD014678_pub2_data","2|1|Cardiovascular mortality (apixaban versus placebo)|","Cardiovascular mortality (apixaban versus placebo)",2,1,"","or","binary",2,-0.00927829231940554,0.130597301353211,0,2013,0.0237833019717617,4319
"CD014678","CD014678_pub2_data","2|2|Cardiovascular mortality (rivaroxaban versus placebo)|","Cardiovascular mortality (rivaroxaban versus placebo)",2,2,"","or","binary",3,-0.172237974885385,0.112047725715431,0.0043961480127098,2012.66666666667,0.0167912558101998,7290
"CD014678","CD014678_pub2_data","3|1|Major bleeding (apixaban versus placebo)|","Major bleeding (apixaban versus placebo)",3,1,"","or","binary",2,0.85784677339389,0.261800535168372,0,2013,0.00414061876878818,4272
"CD014678","CD014678_pub2_data","3|2|Major bleeding (rivaroxaban versus placebo)|","Major bleeding (rivaroxaban versus placebo)",3,2,"","or","binary",3,1.17058525102053,0.537336620421766,0.612238093757506,2012.66666666667,0.0032827263951605,7290
"CD014678","CD014678_pub2_data","4|1|All-cause mortality|Apixaban 10 mg versus placebo","All-cause mortality",4,1,"Apixaban 10 mg versus placebo","or","binary",2,0.0661156987201965,0.11518914784891,0,2013,0.0292124272613513,4160.5
"CD014678","CD014678_pub2_data","4|1|All-cause mortality|Apixaban total versus placebo","All-cause mortality",4,1,"Apixaban total versus placebo","or","binary",2,0.0933207504821817,0.112818962006699,0,2013,0.0292124272613513,4319
"CD014678","CD014678_pub2_data","4|2|Cardiovascular mortality|Apixaban 10 mg versus placebo","Cardiovascular mortality",4,2,"Apixaban 10 mg versus placebo","or","binary",2,-0.0576183951594578,0.134408119175102,0,2013,0.0237833019717617,4160.5
"CD014678","CD014678_pub2_data","4|2|Cardiovascular mortality|Apixaban total versus placebo","Cardiovascular mortality",4,2,"Apixaban total versus placebo","or","binary",2,-0.00927829231940554,0.130597301353211,0,2013,0.0237833019717617,4319
"CD014678","CD014678_pub2_data","4|3|Major bleeding|Apixaban 10 mg versus placebo","Major bleeding",4,3,"Apixaban 10 mg versus placebo","or","binary",2,0.927184521377986,0.261830830603994,0,2013,0.00414061876878818,4114.5
"CD014678","CD014678_pub2_data","4|3|Major bleeding|Apixaban total versus placebo","Major bleeding",4,3,"Apixaban total versus placebo","or","binary",2,0.85784677339389,0.261800535168372,0,2013,0.00414061876878818,4272
"CD014678","CD014678_pub2_data","4|4|Myocardial infarction|Apixaban 10 mg versus placebo","Myocardial infarction",4,4,"Apixaban 10 mg versus placebo","or","binary",2,-0.0946613892233355,0.103045025487788,0,2013,0.0426752641319059,4160.5
"CD014678","CD014678_pub2_data","4|4|Myocardial infarction|Apixaban total versus placebo","Myocardial infarction",4,4,"Apixaban total versus placebo","or","binary",2,-0.125586422844458,0.135324185582512,0.00996835960386972,2013,0.0426752641319059,4319
"CD014678","CD014678_pub2_data","4|5|Stroke|Apixaban 10 mg versus placebo","Stroke",4,5,"Apixaban 10 mg versus placebo","or","binary",2,-0.358254454368207,0.259884775611273,0,2013,0.00624745589515425,4160.5
"CD014678","CD014678_pub2_data","4|5|Stroke|Apixaban total versus placebo","Stroke",4,5,"Apixaban total versus placebo","or","binary",2,-0.401911679399853,0.259872729273136,0,2013,0.00624745589515425,4319
"CD014678","CD014678_pub2_data","4|7|Non-major bleeding|apixaban 10mg versus placebo","Non-major bleeding",4,7,"apixaban 10mg versus placebo","or","binary",2,0.982441002031746,0.315717887539608,0,2013,0.00401433287586211,4114.5
"CD014678","CD014678_pub2_data","4|7|Non-major bleeding|apixaban total versus placebo","Non-major bleeding",4,7,"apixaban total versus placebo","or","binary",2,0.959172184178341,0.305590728200178,0,2013,0.00401433287586211,4272
"CD014678","CD014678_pub2_data","5|1|All-cause mortality|Rivaroxaban 10 mg versus placebo","All-cause mortality",5,1,"Rivaroxaban 10 mg versus placebo","or","binary",2,-0.159756236557145,0.18555566936726,0.0273486399520013,2011,0.0218584136447325,6222
"CD014678","CD014678_pub2_data","5|1|All-cause mortality|Rivaroxaban 5 mg versus placebo ","All-cause mortality",5,1,"Rivaroxaban 5 mg versus placebo ","or","binary",3,0.0248567638974212,0.331302363428422,0.249184460036296,2012.66666666667,0.01962278081366,4910.66666666667
"CD014678","CD014678_pub2_data","5|1|All-cause mortality|Rivaroxaban total versus placebo","All-cause mortality",5,1,"Rivaroxaban total versus placebo","or","binary",3,-0.201197023065887,0.0938285330440018,0,2012.66666666667,0.01962278081366,7290
"CD014678","CD014678_pub2_data","5|2|Cardiovascular mortality|Rivaroxaban 10 mg versus placebo","Cardiovascular mortality",5,2,"Rivaroxaban 10 mg versus placebo","or","binary",2,-0.103119208648409,0.117686677389898,0,2011,0.0195874107245223,6222
"CD014678","CD014678_pub2_data","5|2|Cardiovascular mortality|Rivaroxaban 5 mg versus placebo","Cardiovascular mortality",5,2,"Rivaroxaban 5 mg versus placebo","or","binary",3,0.146351379731742,0.405185452204712,0.398164261701549,2012.66666666667,0.0167912558101998,4910.66666666667
"CD014678","CD014678_pub2_data","5|2|Cardiovascular mortality|Rivaroxaban total versus placebo","Cardiovascular mortality",5,2,"Rivaroxaban total versus placebo","or","binary",3,-0.172237974885385,0.112047725715431,0.0043961480127098,2012.66666666667,0.0167912558101998,7290
"CD014678","CD014678_pub2_data","5|3|Major bleeding|Rivaroxaban 10 mg versus placebo","Major bleeding",5,3,"Rivaroxaban 10 mg versus placebo","or","binary",2,1.66402574034801,0.420134155179596,0.15664494956341,2011,0.00228904347943376,6222
"CD014678","CD014678_pub2_data","5|3|Major bleeding|Rivaroxaban 5 mg versus placebo","Major bleeding",5,3,"Rivaroxaban 5 mg versus placebo","or","binary",3,0.867213309369725,0.405143443430084,0.240074058808891,2012.66666666667,0.0032827263951605,4910.66666666667
"CD014678","CD014678_pub2_data","5|3|Major bleeding|Rivaroxaban total versus placebo","Major bleeding",5,3,"Rivaroxaban total versus placebo","or","binary",3,1.17058525102053,0.537336620421766,0.612238093757506,2012.66666666667,0.0032827263951605,7290
"CD014678","CD014678_pub2_data","5|4|Myocardial infarction|Rivaroxaban 10 mg versus placebo","Myocardial infarction",5,4,"Rivaroxaban 10 mg versus placebo","or","binary",2,-0.267780239676339,0.0932327995237921,0,2011,0.0426525185969503,6222
"CD014678","CD014678_pub2_data","5|4|Myocardial infarction|Rivaroxaban 5 mg versus placebo","Myocardial infarction",5,4,"Rivaroxaban 5 mg versus placebo","or","binary",3,-0.0483480961399312,0.0925178882094472,0.00241417310033833,2012.66666666667,0.0391947840273037,4910.66666666667
"CD014678","CD014678_pub2_data","5|4|Myocardial infarction|Rivaroxaban total versus placebo","Myocardial infarction",5,4,"Rivaroxaban total versus placebo","or","binary",3,-0.146741852612811,0.07228523402768,3.66916421445627e-06,2012.66666666667,0.0391947840273037,7290
"CD014678","CD014678_pub2_data","5|5|Stroke|Rivaroxaban 10 mg versus placebo","Stroke",5,5,"Rivaroxaban 10 mg versus placebo","or","binary",2,0.218684926625104,0.196157133947386,0,2011,0.00659559473148229,6222
"CD014678","CD014678_pub2_data","5|5|Stroke|Rivaroxaban 5 mg versus placebo","Stroke",5,5,"Rivaroxaban 5 mg versus placebo","or","binary",3,-0.0404952469435592,0.231822782448364,0.0290106873055412,2012.66666666667,0.00703210926762851,4910.66666666667
"CD014678","CD014678_pub2_data","5|5|Stroke|Rivaroxaban total versus placebo","Stroke",5,5,"Rivaroxaban total versus placebo","or","binary",3,-0.181435556024979,0.309448808105592,0.147692219398707,2012.66666666667,0.00703210926762851,7290
"CD014678","CD014678_pub2_data","5|6|Stent thrombosis|Rivaroxaban 5 mg versus placebo","Stent thrombosis",5,6,"Rivaroxaban 5 mg versus placebo","or","binary",2,-0.270684806468339,0.227683110442863,0.041346493841534,2014.5,0.0123109684245408,6632
"CD014678","CD014678_pub2_data","5|6|Stent thrombosis|Rivaroxaban total versus placebo","Stent thrombosis",5,6,"Rivaroxaban total versus placebo","or","binary",2,-0.271618717840881,0.19901722920102,0.029731119632445,2014.5,0.0123109684245408,9189.5
"CD014678","CD014678_pub2_data","5|7|Non-major bleeding|Rivaroxaban 10 mg versus placebo","Non-major bleeding",5,7,"Rivaroxaban 10 mg versus placebo","or","binary",2,0.905344415933048,0.248346087870255,0,2011,0.00281786790938581,6222
"CD014678","CD014678_pub2_data","5|7|Non-major bleeding|Rivaroxaban 5 mg versus placebo","Non-major bleeding",5,7,"Rivaroxaban 5 mg versus placebo","or","binary",3,0.535882824249796,0.246301443219174,0,2012.66666666667,0.00275692731069287,4910.66666666667
"CD014678","CD014678_pub2_data","5|7|Non-major bleeding|Rivaroxaban total versus placebo","Non-major bleeding",5,7,"Rivaroxaban total versus placebo","or","binary",3,0.749874703803557,0.21562830926504,0,2012.66666666667,0.00275692731069287,7290
"CD014678","CD014678_pub2_data","8|1|All-cause mortality|","All-cause mortality",8,1,"","or","binary",2,0.456315210634061,0.843521099657565,1.30862892780071,2011,0.0176686217008798,5796.5
"CD014678","CD014678_pub2_data","8|2|Cardiovascular mortality|","Cardiovascular mortality",8,2,"","or","binary",2,0.448393822770888,0.852622044901103,1.33851202600412,2011,0.0166911045943304,5796.5
"CD014678","CD014678_pub2_data","8|3|Major bleeding|","Major bleeding",8,3,"","or","binary",2,-0.334086138606595,0.290897894822268,0.0668693815154473,2011,0.0155913978494624,5796.5
"CD014678","CD014678_pub2_data","8|4|Myocardial infarction|","Myocardial infarction",8,4,"","or","binary",2,0.16371167049832,0.0993574893578761,0,2011,0.0321755865102639,5796.5
"CD014678","CD014678_pub2_data","8|5|Stroke|","Stroke",8,5,"","or","binary",2,-0.14753980576737,0.196247791842975,0,2011,0.00717253176930596,5796.5
"CD014678","CD014678_pub2_data","8|7|Non-major bleeding|","Non-major bleeding",8,7,"","or","binary",2,-0.41297470997812,0.219894945926619,0,2011,0.00763074291300098,5796.5
"CD014687","CD014687_pub2_data","10|2|Satisfaction: meta-analysis intermediate term|NA","Satisfaction: meta-analysis intermediate term",10,2,NA,"or","binary",2,1.38074253322174,0.567512743805565,0.305020002950865,2019,0.459677419354839,57
"CD014687","CD014687_pub2_data","11|1|Adverse events: long term|NA","Adverse events: long term",11,1,NA,"or","binary",2,-0.922814514211701,0.652794830409753,0,2019,0.113636363636364,58
"CD014687","CD014687_pub2_data","3|1|Pain: VAS (0-100) meta-analysis (change from baseline and final values) short-term results|NA","Pain: VAS (0-100) meta-analysis (change from baseline and final values) short-term results",3,1,NA,"or","binary",2,0.115562104712607,1.42685581752398,0,2015,0,78.5
"CD014687","CD014687_pub2_data","3|2|Pain: VAS (0-100) meta-analysis (change from baseline and final values) intermediate-term results|NA","Pain: VAS (0-100) meta-analysis (change from baseline and final values) intermediate-term results",3,2,NA,"or","binary",2,0.115562104712607,1.42685581752398,0,2015,0,78.5
"CD014687","CD014687_pub2_data","4|1|Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) short term|NA","Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) short term",4,1,NA,"or","binary",2,0.115562104712607,1.42685581752398,0,2015,0,78.5
"CD014687","CD014687_pub2_data","4|2|Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) intermediate term|NA","Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) intermediate term",4,2,NA,"or","binary",2,0.115562104712607,1.42685581752398,0,2015,0,78.5
"CD014687","CD014687_pub2_data","7|1|Adverse events: intermediate term|NA","Adverse events: intermediate term",7,1,NA,"or","binary",2,2.43718485934525,1.07456433449887,0,2015,0,78.5
"CD014687","CD014687_pub2_data","8|2|Pain: VAS (0-100) meta-analysis (final values) intermediate term|NA","Pain: VAS (0-100) meta-analysis (final values) intermediate term",8,2,NA,"or","binary",2,-0.0914820011638952,1.42677109851788,0,2019,0,58
"CD014687","CD014687_pub2_data","8|3|Pain: VAS (0-100) meta-analysis (final values) long term|NA","Pain: VAS (0-100) meta-analysis (final values) long term",8,3,NA,"or","binary",2,-0.0914820011638952,1.42677109851788,0,2019,0,58
"CD014687","CD014687_pub2_data","9|2|Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) intermediate term|NA","Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) intermediate term",9,2,NA,"or","binary",2,-0.0914820011638952,1.42677109851788,0,2019,0,58
"CD014687","CD014687_pub2_data","9|3|Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) long term|NA","Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) long term",9,3,NA,"or","binary",2,-0.0914820011638952,1.42677109851788,0,2019,0,58
"CD014688","CD014688_pub2_data","1|2|Child/adolescent quality of life between baseline and 12 months (parent proxy-reported)|NA","Child/adolescent quality of life between baseline and 12 months (parent proxy-reported)",1,2,NA,"or","binary",2,-0.331237382163244,1.41903609215885,0,2017.5,0,154.5
"CD014688","CD014688_pub2_data","2|1|Parent quality of life between baseline and 24 months |NA","Parent quality of life between baseline and 24 months ",2,1,NA,"reported","reported",3,0,0.0883948534066069,0,2016.33333333333,0,252.333333333333
"CD014688","CD014688_pub2_data","3|1|Hospitalisation rates between baseline and 12 months|NA","Hospitalisation rates between baseline and 12 months",3,1,NA,"reported","reported",2,0,0.00919226754667989,0,2012,0,190.5
"CD014688","CD014688_pub2_data","4|1|Rates of emergency department attendance between baseline and 12 months|NA","Rates of emergency department attendance between baseline and 12 months",4,1,NA,"reported","reported",2,0,0.0139237978836139,0,2012,0,190.5
"CD014713","CD014713_pub2_data","1|1|Unplanned hospital presentation rates - unplanned hospital admissions within one month (30 days)|NA","Unplanned hospital presentation rates - unplanned hospital admissions within one month (30 days)",1,1,NA,"reported","reported",3,0,0.174673018620748,0,2009.33333333333,0.0910709609845509,507.666666666667
"CD014713","CD014713_pub2_data","1|2|Unplanned hospital presentation rates - unplanned hospital admissions within 12 months (365 days)|NA","Unplanned hospital presentation rates - unplanned hospital admissions within 12 months (365 days)",1,2,NA,"or","binary",3,-0.395585404931855,0.209631318874635,0.0618691736487197,2016.66666666667,0.622737127371274,265
"CD014713","CD014713_pub2_data","1|4|Unplanned hospital presentation rates - emergency department presentations within 12 months (365 days)|NA","Unplanned hospital presentation rates - emergency department presentations within 12 months (365 days)",1,4,NA,"or","binary",2,-0.0609268759715939,0.24390750157902,0.0722684960376082,2022.5,0.700794979079498,436.5
"CD014722","CD014722_pub2_data","1|3|Quality of life at 0-1 months|","Quality of life at 0-1 months",1,3,"","or","binary",4,-0.0309196809786048,1.00531162681954,0,2018.75,0,171
"CD014722","CD014722_pub2_data","1|5|Depressive symptoms at 0-1 months|","Depressive symptoms at 0-1 months",1,5,"","or","binary",3,0.0220716039946557,1.16202812473727,0,2017.66666666667,0,116.333333333333
"CD014722","CD014722_pub2_data","1|7|Depressive symptoms at 7-24 months|","Depressive symptoms at 7-24 months",1,7,"","or","binary",2,0.0377558471702285,1.41684137375746,0,2011.5,0,603.5
"CD014722","CD014722_pub2_data","1|9|Distress/PTSD symptoms at 0-1 months|","Distress/PTSD symptoms at 0-1 months",1,9,"","or","binary",4,-0.019006352057936,1.00673437469901,0,2016.25,0,180.5
"CD014722","CD014722_pub2_data","10|1|Depressive symptoms at 0-1 months—indicated prevention adults|Community setting","Depressive symptoms at 0-1 months—indicated prevention adults",10,1,"Community setting","or","binary",8,-0.129999543348106,0.713339648649813,0,2019.125,0,159.75
"CD014722","CD014722_pub2_data","10|1|Depressive symptoms at 0-1 months—indicated prevention adults|Other","Depressive symptoms at 0-1 months—indicated prevention adults",10,1,"Other","or","binary",9,0.144662374778789,0.671642726876764,0,2018.55555555556,0,109.666666666667
"CD014722","CD014722_pub2_data","10|2|Depressive symptoms at 1-6 months—indicated prevention adults|Community setting","Depressive symptoms at 1-6 months—indicated prevention adults",10,2,"Community setting","or","binary",4,0.0158273225363692,1.00275025165979,0,2019.5,0,364.5
"CD014722","CD014722_pub2_data","10|2|Depressive symptoms at 1-6 months—indicated prevention adults|Other","Depressive symptoms at 1-6 months—indicated prevention adults",10,2,"Other","or","binary",6,-0.0251257955373908,0.820202603953561,0,2017.16666666667,0,167.5
"CD014722","CD014722_pub2_data","10|3|Distress/PTSD symptoms at 0-1 months—indicated prevention adults|Community setting","Distress/PTSD symptoms at 0-1 months—indicated prevention adults",10,3,"Community setting","or","binary",6,-0.0776218940582156,0.82463934262227,0,2019.66666666667,0,172.166666666667
"CD014722","CD014722_pub2_data","10|3|Distress/PTSD symptoms at 0-1 months—indicated prevention adults|Other","Distress/PTSD symptoms at 0-1 months—indicated prevention adults",10,3,"Other","or","binary",11,0.0340226929668909,0.607358533457139,0,2017.72727272727,0,124.272727272727
"CD014722","CD014722_pub2_data","2|10|Social outcomes at 0-1 months|","Social outcomes at 0-1 months",2,10,"","or","binary",3,-0.062512988450917,1.17115991697771,0,2021,0,40.3333333333333
"CD014722","CD014722_pub2_data","2|11|Social outcomes at 1-6 months|","Social outcomes at 1-6 months",2,11,"","or","binary",2,-0.0315240918599223,1.4201725999369,0,2021,0,118
"CD014722","CD014722_pub2_data","2|2|Quality of life at 0-1 months|","Quality of life at 0-1 months",2,2,"","or","binary",3,-0.022260648426526,1.16699177374721,0,2018.66666666667,0,76.3333333333333
"CD014722","CD014722_pub2_data","2|3|Quality of life at 1-6 months |","Quality of life at 1-6 months ",2,3,"","or","binary",5,0.00857366830082595,0.898536087588995,0,2019.2,0,159.6
"CD014722","CD014722_pub2_data","2|4|Depressive symptoms at 0-1 months|","Depressive symptoms at 0-1 months",2,4,"","or","binary",4,0.208612274639452,1.01646769323684,0,2013,0,55.75
"CD014722","CD014722_pub2_data","2|5|Depressive symptoms at 1-6 months|","Depressive symptoms at 1-6 months",2,5,"","or","binary",3,0.0260275074752724,1.16737569479516,0,2019,0,62
"CD014722","CD014722_pub2_data","2|7|Distress/PTSD symptoms at 0-1 months|","Distress/PTSD symptoms at 0-1 months",2,7,"","or","binary",7,0.0553163990815028,0.762323582308733,0,2017.14285714286,0,76.4285714285714
"CD014722","CD014722_pub2_data","2|8|Distress/PTSD symptoms at 1-6 months|","Distress/PTSD symptoms at 1-6 months",2,8,"","or","binary",5,0.0297859518123192,0.901281900949849,0,2014.8,0,92.8
"CD014722","CD014722_pub2_data","3|1|Diagnosis of mental disorders at 0-1 months|","Diagnosis of mental disorders at 0-1 months",3,1,"","or","binary",3,-1.19831518636222,0.727945273592297,1.25421891831353,2018.66666666667,0.177003916990698,281
"CD014722","CD014722_pub2_data","3|10|Psychological functioning and impairment at 7-24 months|","Psychological functioning and impairment at 7-24 months",3,10,"","or","binary",2,0.0372114591692255,1.42049606570171,0,2018.5,0,120.5
"CD014722","CD014722_pub2_data","3|11|Depressive symptoms at 0-1 months|","Depressive symptoms at 0-1 months",3,11,"","or","binary",18,0.0147241014284499,0.475179711530478,0,2018.33333333333,0,130.055555555556
"CD014722","CD014722_pub2_data","3|12|Depressive symptoms at 1-6 months|","Depressive symptoms at 1-6 months",3,12,"","or","binary",11,-0.0103928978861433,0.605304258382202,0,2018.36363636364,0,237.181818181818
"CD014722","CD014722_pub2_data","3|13|Depressive symptoms at 7-24 months|","Depressive symptoms at 7-24 months",3,13,"","or","binary",8,-0.0689830666911582,0.709080695284761,0,2016.5,0,268.625
"CD014722","CD014722_pub2_data","3|14|Anxiety symptoms at 0-1 months|","Anxiety symptoms at 0-1 months",3,14,"","or","binary",5,0,0.903530078447546,0,2019.4,0,50
"CD014722","CD014722_pub2_data","3|15|Anxiety symptoms at 1-6 months |","Anxiety symptoms at 1-6 months ",3,15,"","or","binary",4,-0.0044804120280085,1.00510738053025,0,2020.5,0,192.75
"CD014722","CD014722_pub2_data","3|16|Anxiety symptoms at 7-24 months|","Anxiety symptoms at 7-24 months",3,16,"","or","binary",2,-0.0212707421022984,1.41947074392667,0,2020.5,0,274.5
"CD014722","CD014722_pub2_data","3|17|Distress/PTSD symptoms at 0-1 months|","Distress/PTSD symptoms at 0-1 months",3,17,"","or","binary",19,-0.00468821624016612,0.462538731280171,0,2017.89473684211,0,133.473684210526
"CD014722","CD014722_pub2_data","3|18|Distress/PTSD symptoms at 1-6 months |","Distress/PTSD symptoms at 1-6 months ",3,18,"","or","binary",9,0.0288594388640198,0.670420657475577,0,2018.44444444444,0,189.111111111111
"CD014722","CD014722_pub2_data","3|19|Distress/PTSD symptoms at 7-24 months|","Distress/PTSD symptoms at 7-24 months",3,19,"","or","binary",5,-0.0148138112111651,0.896955752453032,0,2018.4,0,216.2
"CD014722","CD014722_pub2_data","3|2|Diagnosis of mental disorders at 1-6 months |","Diagnosis of mental disorders at 1-6 months ",3,2,"","or","binary",6,-0.536447637260905,0.194683074255749,0.0791821249505422,2016.83333333333,0.236439932143257,225.333333333333
"CD014722","CD014722_pub2_data","3|20|Social outcomes at 0-1 months|","Social outcomes at 0-1 months",3,20,"","or","binary",5,0.000458048225964802,0.899041578184785,0,2015.2,0,186.4
"CD014722","CD014722_pub2_data","3|3|Diagnosis of mental disorders at 7-24 months|","Diagnosis of mental disorders at 7-24 months",3,3,"","or","binary",2,-0.397688753418937,0.305957421421661,0,2011.5,0.148776637726914,190
"CD014722","CD014722_pub2_data","3|4|Quality of life at 0-1 months|","Quality of life at 0-1 months",3,4,"","or","binary",8,-0.0623892035471884,0.712424200493995,0,2016.75,0,142
"CD014722","CD014722_pub2_data","3|5|Quality of life at 1-6 months |","Quality of life at 1-6 months ",3,5,"","or","binary",4,0.0292835411092492,1.00629378736839,0,2020.5,0,211.75
"CD014722","CD014722_pub2_data","3|8|Psychological functioning and impairment at 0-1 months|","Psychological functioning and impairment at 0-1 months",3,8,"","or","binary",4,0.123874937623707,1.01152023852852,0,2020,0,165.75
"CD014722","CD014722_pub2_data","3|9|Psychological functioning and impairment at 1-6 months |","Psychological functioning and impairment at 1-6 months ",3,9,"","or","binary",2,0.18281285164276,1.41960985003132,0,2020,0,297
"CD014722","CD014722_pub2_data","4|1|Quality of life at 0-1 months|","Quality of life at 0-1 months",4,1,"","or","binary",2,-0.0148339219634878,1.41792151687828,0,2016,0,401.5
"CD014722","CD014722_pub2_data","4|11|Distress/PTSD  symptoms at 0-1 months|","Distress/PTSD  symptoms at 0-1 months",4,11,"","or","binary",2,0.125288894784719,1.41806737832505,0,2018,0,400
"CD014722","CD014722_pub2_data","4|13|Social outcomes at 0-1 months|","Social outcomes at 0-1 months",4,13,"","or","binary",3,-0.141933554725958,1.16396613917458,0,2018.33333333333,0,107
"CD014722","CD014722_pub2_data","4|14|Social outcomes at 1-6 months |","Social outcomes at 1-6 months ",4,14,"","or","binary",2,-0.19782476485124,1.42095600086779,0,2016,0,107.5
"CD014722","CD014722_pub2_data","4|3|Psychological functioning and impairment at 0-1 months|","Psychological functioning and impairment at 0-1 months",4,3,"","or","binary",2,-0.204457219197593,1.42804779856403,0,2019,0,106
"CD014722","CD014722_pub2_data","4|7|Depressive symptoms at 1-6 months|","Depressive symptoms at 1-6 months",4,7,"","or","binary",3,-0.0925958785037037,1.15949701052558,0,2014.33333333333,0,128.333333333333
"CD014722","CD014722_pub2_data","5|10|Social outcomes at 0-1 months|","Social outcomes at 0-1 months",5,10,"","or","binary",2,0.00414945481290974,1.41715381699187,0,2015.5,0,319
"CD014722","CD014722_pub2_data","5|3|Depressive symptoms at 0-1 months|","Depressive symptoms at 0-1 months",5,3,"","or","binary",2,0.00414945481290974,1.41715381699187,0,2015.5,0,319
"CD014722","CD014722_pub2_data","5|4|Depressive symptoms at 1-6 months|","Depressive symptoms at 1-6 months",5,4,"","or","binary",3,-0.067979595740645,1.15737537189767,0,2018,0,263.666666666667
"CD014722","CD014722_pub2_data","6|10|Anxiety symptoms at 1-6 months |","Anxiety symptoms at 1-6 months ",6,10,"","or","binary",3,-0.285253027109773,1.15889313211586,0,2012.33333333333,0,454
"CD014722","CD014722_pub2_data","6|11|Distress/PTSD symptoms at 0-1 months|","Distress/PTSD symptoms at 0-1 months",6,11,"","or","binary",2,0.0620719703962801,1.4221180003483,0,2016.5,0,224
"CD014722","CD014722_pub2_data","6|12|Distress/PTSD symptoms at 1-6 months|","Distress/PTSD symptoms at 1-6 months",6,12,"","or","binary",2,0.00768309378732096,1.43314648536664,0,2011,0,208.5
"CD014722","CD014722_pub2_data","6|13|Social outcomes at 0-1 months|","Social outcomes at 0-1 months",6,13,"","or","binary",2,0.0334838220383236,1.42214865215234,0,2021,0,217.5
"CD014722","CD014722_pub2_data","6|14|Social outcomes at 1-6 months|","Social outcomes at 1-6 months",6,14,"","or","binary",2,-0.0352885619975126,1.42386071196479,0,2013.5,0,210.5
"CD014722","CD014722_pub2_data","6|3|Quality of life at 0-1 months|","Quality of life at 0-1 months",6,3,"","or","binary",2,0.0887656045641733,1.42465499740737,0,2020.5,0,76
"CD014722","CD014722_pub2_data","6|4|Psychological functioning and impairment at 0-1 months|","Psychological functioning and impairment at 0-1 months",6,4,"","or","binary",2,0.0620719703962801,1.4221180003483,0,2016.5,0,224
"CD014722","CD014722_pub2_data","6|5|Psychological functioning and impairment at 1-6 months |","Psychological functioning and impairment at 1-6 months ",6,5,"","or","binary",3,-0.00197984588973911,1.16139986851378,0,2013,0,271
"CD014722","CD014722_pub2_data","6|6|Depressive symptoms at 0-1 months|","Depressive symptoms at 0-1 months",6,6,"","or","binary",4,0.0726930198028282,1.00455854502309,0,2013.75,0,192.75
"CD014722","CD014722_pub2_data","6|7|Depressive symptoms at 1-6 months|","Depressive symptoms at 1-6 months",6,7,"","or","binary",6,-0.111639126390106,0.82000366124967,0,2012.33333333333,0,413.833333333333
"CD014722","CD014722_pub2_data","6|9|Anxiety symptoms at 0-1 months|","Anxiety symptoms at 0-1 months",6,9,"","or","binary",3,0.00354660636772194,1.15752147632961,0,2017.66666666667,0,296
"CD014722","CD014722_pub2_data","7|1|Diagnosis of mental disorders at 0-1 months—indicated prevention adults|","Diagnosis of mental disorders at 0-1 months—indicated prevention adults",7,1,"","or","binary",2,-2.08239379163754,0.454120331176904,0,2017,0.198090145148969,169.5
"CD014722","CD014722_pub2_data","7|2|Quality of life at 0-1 months—selective prevention adults|","Quality of life at 0-1 months—selective prevention adults",7,2,"","or","binary",2,-0.0330950637872885,1.4229200553283,0,2017.5,0,102.5
"CD014722","CD014722_pub2_data","7|3|Quality of life at 1-6 months—selective prevention adults|","Quality of life at 1-6 months—selective prevention adults",7,3,"","or","binary",3,0.0142485318967063,1.15834317718944,0,2020.33333333333,0,211.333333333333
"CD014722","CD014722_pub2_data","8|1|Psychological functioning and impairment at 0-1 months—indicated prevention adults|","Psychological functioning and impairment at 0-1 months—indicated prevention adults",8,1,"","or","binary",2,0.182109170739123,1.43676120365958,0,2019,0,63
"CD014722","CD014722_pub2_data","8|2|Depressive symptoms at 0-1 months—indicated prevention adults|","Depressive symptoms at 0-1 months—indicated prevention adults",8,2,"","or","binary",2,0.0928410230916226,1.44019163344621,0,2019,0,62
"CD014722","CD014722_pub2_data","8|3|Distress/PTSD symptoms at 0-1 months—indicated prevention adults|","Distress/PTSD symptoms at 0-1 months—indicated prevention adults",8,3,"","or","binary",2,0.123201319812625,1.4438914575403,0,2019,0,56
"CD014722","CD014722_pub2_data","9|1|Depressive symptoms at 0-1 months—indicated prevention adults|Community workers","Depressive symptoms at 0-1 months—indicated prevention adults",9,1,"Community workers","or","binary",12,0.0543501337374639,0.582301712492211,0,2018.5,0,147.916666666667
"CD014722","CD014722_pub2_data","9|1|Depressive symptoms at 0-1 months—indicated prevention adults|Primary healthcare workers","Depressive symptoms at 0-1 months—indicated prevention adults",9,1,"Primary healthcare workers","or","binary",6,-0.0642609571962599,0.822110594721081,0,2018,0,94.3333333333333
"CD014722","CD014722_pub2_data","9|2|Depressive symptoms at 1-6 months—indicated prevention adults|Community workers","Depressive symptoms at 1-6 months—indicated prevention adults",9,2,"Community workers","or","binary",5,-0.0142065449191592,0.896952269297162,0,2016.2,0,292.6
"CD014722","CD014722_pub2_data","9|2|Depressive symptoms at 1-6 months—indicated prevention adults|Primary healthcare workers","Depressive symptoms at 1-6 months—indicated prevention adults",9,2,"Primary healthcare workers","or","binary",6,-0.00720367527245866,0.820241054877069,0,2020.16666666667,0,191
"CD014722","CD014722_pub2_data","9|3|Distress/PTSD symptoms at 0-1 months—indicated prevention adults|Community workers","Distress/PTSD symptoms at 0-1 months—indicated prevention adults",9,3,"Community workers","or","binary",14,-0.0154873363563356,0.539060522433939,0,2017.28571428571,0,136.142857142857
"CD014722","CD014722_pub2_data","9|3|Distress/PTSD symptoms at 0-1 months—indicated prevention adults|Primary healthcare workers","Distress/PTSD symptoms at 0-1 months—indicated prevention adults",9,3,"Primary healthcare workers","or","binary",5,0.025456101720321,0.90062930276702,0,2019.6,0,126
"CD014736","CD014736_pub2_data","1|1|Maximum Walking Distance (metres)|Change in distance from baseline to end of follow-up","Maximum Walking Distance (metres)",1,1,"Change in distance from baseline to end of follow-up","or","binary",2,-0.104658096717356,1.42979555485083,0,2001,0,44.5
"CD014736","CD014736_pub2_data","1|1|Maximum Walking Distance (metres)|Final maximum walking distance at 6 months","Maximum Walking Distance (metres)",1,1,"Final maximum walking distance at 6 months","or","binary",2,-0.236512026616214,1.42749178183281,0,2012,0,53.5
"CD014736","CD014736_pub2_data","1|1|Maximum Walking Distance (metres)|Final maximum walking distance at end of follow-up","Maximum Walking Distance (metres)",1,1,"Final maximum walking distance at end of follow-up","or","binary",2,-0.217953059705359,1.42737107970268,0,2012,0,54
"CD014736","CD014736_pub2_data","1|3|Pain-free walking distance at end of follow-up (change from baseline, metres)|","Pain-free walking distance at end of follow-up (change from baseline, metres)",1,3,"","or","binary",2,-0.111866334406725,1.43008327212407,0,2001,0,43.5
"CD014736","CD014736_pub2_data","2|1|Ankle-brachial index (ABI) - Absolute values at end of follow-up|","Ankle-brachial index (ABI) - Absolute values at end of follow-up",2,1,"","or","binary",2,-0.0994358786830561,1.42721052987492,0,2012,0,55
"CD014736","CD014736_pub2_data","2|2|Mortality by end of follow-up|","Mortality by end of follow-up",2,2,"","reported","reported",3,0,0.412118740127497,0,2009.33333333333,0.104444444444444,70.6666666666667
"CD014736","CD014736_pub2_data","2|3|Health-related quality of life: SF-36 Physical component - Absolute values at end of follow-up|","Health-related quality of life: SF-36 Physical component - Absolute values at end of follow-up",2,3,"","or","binary",2,-0.135272747171206,1.42763066647037,0,2012,0,52.5
"CD014736","CD014736_pub2_data","2|4|Health-related quality of life: SF-36 Mental component - Absolute values at end of follow-up|","Health-related quality of life: SF-36 Mental component - Absolute values at end of follow-up",2,4,"","or","binary",2,-0.135272747171206,1.42763066647037,0,2012,0,52.5
"CD014736","CD014736_pub2_data","2|6|Reintervention by end of follow-up|","Reintervention by end of follow-up",2,6,"","reported","reported",2,0,0.447243439251846,0,2019.5,0.452214452214452,60
"CD014741","CD014741_pub2_data","1|4|Adverse events|Anakinra","Adverse events",1,4,"Anakinra","or","binary",2,-1.54887396682833,0.78505629406622,0,2011.5,0.866666666666667,20
"CD014741","CD014741_pub2_data","1|5|Adverse events (by patients)|Anakinra","Adverse events (by patients)",1,5,"Anakinra","reported","reported",3,0.165241150512986,0.53100074164966,0.622460119208663,2013.66666666667,0,36.6666666666667
"CD014741","CD014741_pub2_data","1|6|Adverse events (any infections)|Anakinra","Adverse events (any infections)",1,6,"Anakinra","reported","reported",3,0.380887509648521,0.550275115492408,0,2013.66666666667,0,36.6666666666667
"CD014741","CD014741_pub2_data","1|8|Heart failure|Anakinra","Heart failure",1,8,"Anakinra","or","binary",2,-1.52563355852056,0.875093668620816,0,2011.5,0.333333333333333,20
"CD014741","CD014741_pub2_data","2|1|All-cause mortality|","All-cause mortality",2,1,"","or","binary",3,-0.316684891940449,0.773346102717465,0.475598566079855,2017.33333333333,0.0502548853016143,109.666666666667
"CD014741","CD014741_pub2_data","2|2|Myocardial Infarction (fatal or non-fatal)|","Myocardial Infarction (fatal or non-fatal)",2,2,"","or","binary",3,-1.34430217973344,0.95540578480303,0,2017.33333333333,0.0440243557065987,109.666666666667
"CD014741","CD014741_pub2_data","2|3|Adverse events|","Adverse events",2,3,"","or","binary",5,0.632783280043393,0.258992832584706,0.126893559077791,2015.8,0.723128425541839,210.2
"CD014741","CD014741_pub2_data","2|4|Adverse events (incidence rate)|Tocilizumab","Adverse events (incidence rate)",2,4,"Tocilizumab","reported","reported",4,3.32821704801861,0.180580987042324,0,2017.75,0,155.25
"CD014741","CD014741_pub2_data","2|5|Adverse event: any infection (incidence rate)|Tocilizumab","Adverse event: any infection (incidence rate)",2,5,"Tocilizumab","reported","reported",5,0.0953317503980601,0.111106313376328,1.69447773741952e-06,2015.8,0,209.6
"CD014741","CD014741_pub2_data","2|8|Heart failure|","Heart failure",2,8,"","or","binary",2,0.0197392905412569,1.16168476225772,0,2018,0.0113636363636364,149.5
"CD014741","CD014741_pub2_data","3|1|All-cause mortality|","All-cause mortality",3,1,"","or","binary",3,0.419790096670369,0.920919986298745,1.13432339040735,2006,0.078962703962704,203
"CD014741","CD014741_pub2_data","3|3|Adverse events|Etanercept","Adverse events",3,3,"Etanercept","or","binary",10,0.197224701678841,0.112643739092485,4.95719424203477e-07,2009.7,0.46415844082827,151.6
"CD014741","CD014741_pub2_data","3|3|Adverse events|Infliximab","Adverse events",3,3,"Infliximab","or","binary",3,1.00802283140631,0.559615093647342,0.711007877516402,2007,0.588030218835172,379.333333333333
"CD014741","CD014741_pub2_data","3|4|Adverse events any infection (incidence rate)|Etanercept","Adverse events any infection (incidence rate)",3,4,"Etanercept","reported","reported",20,0.264345375699495,0.0734470173627328,0.0530458783154446,2007.2,0,205.75
"CD014741","CD014741_pub2_data","3|4|Adverse events any infection (incidence rate)|Infliximab","Adverse events any infection (incidence rate)",3,4,"Infliximab","reported","reported",2,0.336515151515152,0.157715628481775,0.02635,2008.5,0,441.5
"CD014741","CD014741_pub2_data","3|5|Adverse events (serious infections)|Etanercept","Adverse events (serious infections)",3,5,"Etanercept","reported","reported",19,0.073502790074001,0.0816350537317887,0.0044771232020068,2007.84210526316,0,205.315789473684
"CD014741","CD014741_pub2_data","3|5|Adverse events (serious infections)|Infliximab","Adverse events (serious infections)",3,5,"Infliximab","reported","reported",3,0.651358516033272,0.500937882364186,0.312498665326444,2007,0,379.333333333333
"CD014741","CD014741_pub2_data","3|6|Stroke (fatal or non-fatal)|","Stroke (fatal or non-fatal)",3,6,"","or","binary",3,-0.805223641452888,0.967192617727895,0,2009.33333333333,0.0727272727272727,188.666666666667
"CD014741","CD014741_pub2_data","4|1|All-cause mortality|Anakinra","All-cause mortality",4,1,"Anakinra","or","binary",5,0.043498896385051,0.383102806046955,0,2015,0.0916577351686084,91
"CD014741","CD014741_pub2_data","4|1|All-cause mortality|Canakinumab","All-cause mortality",4,1,"Canakinumab","or","binary",3,-0.0706103152316272,0.0675890879677295,0,2017.33333333333,0.0373803827751196,3429.33333333333
"CD014741","CD014741_pub2_data","4|2|Myocardial infarction (fatal or non-fatal)|Anakinra","Myocardial infarction (fatal or non-fatal)",4,2,"Anakinra","or","binary",3,0.768332678610714,0.566717015704629,0,2017.33333333333,0.0170144462279294,113.666666666667
"CD014741","CD014741_pub2_data","4|2|Myocardial infarction (fatal or non-fatal)|Canakinumab","Myocardial infarction (fatal or non-fatal)",4,2,"Canakinumab","or","binary",3,-0.16327996568502,0.0765059949736278,0,2017.33333333333,0.0326529573450066,3429.33333333333
"CD014741","CD014741_pub2_data","4|3|Unstable angina|Canakinumab","Unstable angina",4,3,"Canakinumab","or","binary",2,-0.142408814475088,0.158169577396356,0,2016.5,0.00941985645933014,5152
"CD014741","CD014741_pub2_data","4|4|Adverse events|Anakinra","Adverse events",4,4,"Anakinra","or","binary",2,-0.598432773711888,1.16495503117735,1.37993931127088,2016,0.4,25.5
"CD014741","CD014741_pub2_data","4|4|Adverse events|Canakinumab","Adverse events",4,4,"Canakinumab","or","binary",2,-0.203200882487187,0.353199580388439,0,2018,0.540916530278232,106.5
"CD014741","CD014741_pub2_data","4|5|Adverse events by incidence rate|Anakinra","Adverse events by incidence rate",4,5,"Anakinra","reported","reported",8,-0.0776416752771948,0.147196113358195,0.0579820687927991,2015.625,0,67.125
"CD014741","CD014741_pub2_data","4|5|Adverse events by incidence rate|Canakinumab","Adverse events by incidence rate",4,5,"Canakinumab","reported","reported",4,-0.00764154677599387,0.120726437352244,0.0378770397987661,2018,0,2578
"CD014741","CD014741_pub2_data","4|6|Adverse events: serious infections by incidence rate |Anakinra","Adverse events: serious infections by incidence rate ",4,6,"Anakinra","reported","reported",8,0.0243042540602483,0.279438196562082,0.0538085528650137,2015.625,0,67.125
"CD014741","CD014741_pub2_data","4|6|Adverse events: serious infections by incidence rate |Canakinumab","Adverse events: serious infections by incidence rate ",4,6,"Canakinumab","reported","reported",4,0.108007059191723,0.0296906192507103,0,2018,0,2578
"CD014741","CD014741_pub2_data","4|7|Peripheral vascular disease|","Peripheral vascular disease",4,7,"","or","binary",3,-0.182082795532765,0.756976657990803,0.673968120036512,2017.33333333333,0.0337320574162679,3429.33333333333
"CD014741","CD014741_pub2_data","4|8|Stroke (fatal or non-fatal)|Anakinra","Stroke (fatal or non-fatal)",4,8,"Anakinra","or","binary",5,0.00405777200847651,0.509741848001242,0,2015,0.0372350891576143,91
"CD014741","CD014741_pub2_data","4|8|Stroke (fatal or non-fatal)|Canakinumab","Stroke (fatal or non-fatal)",4,8,"Canakinumab","or","binary",2,-0.0746667519378471,0.130360258325425,0,2016.5,0.013755980861244,5125
"CD014741","CD014741_pub2_data","4|9|Heart failure|Anakinra","Heart failure",4,9,"Anakinra","or","binary",4,-0.554686935672208,0.449376550695665,4.37349764207049e-06,2017.75,0.191071428571429,55
"CD014741","CD014741_pub2_data","4|9|Heart failure|Canakinumab","Heart failure",4,9,"Canakinumab","or","binary",3,0.376575677165318,0.464785329504404,0,2017.33333333333,0.0206114900403814,3429.66666666667
"CD014741","CD014741_pub2_data","5|1|All-cause mortality|All-cause mortality","All-cause mortality",5,1,"All-cause mortality","or","binary",2,0.151710859988218,0.444822161280615,0,2018.5,0.170731707317073,99
"CD014741","CD014741_pub2_data","5|2|Myocardial Infarction (fatal or non-fatal)|Tocilizumab","Myocardial Infarction (fatal or non-fatal)",5,2,"Tocilizumab","or","binary",3,-0.696152035870097,0.868040666801425,0.915479246179225,2018.33333333333,0.0570376455667013,115
"CD014741","CD014741_pub2_data","5|4|Adverse events|","Adverse events",5,4,"","or","binary",2,-0.722667156892528,0.583510253939626,0,2019.5,0.527616279069767,56.5
"CD014741","CD014741_pub2_data","5|5|Adverse events (incidence rate)|Tocilizumab","Adverse events (incidence rate)",5,5,"Tocilizumab","reported","reported",3,-0.210947770232977,0.340942489164725,0.138327454440077,2018.33333333333,0,116
"CD014741","CD014741_pub2_data","5|6|Adverse events (any infection) incidence rate|Tocilizumab","Adverse events (any infection) incidence rate",5,6,"Tocilizumab","reported","reported",4,-0.418676025442666,0.369254962487853,0,2019,0,108.25
"CD014741","CD014741_pub2_data","6|1|All-cause mortality|Etanercept","All-cause mortality",6,1,"Etanercept","or","binary",4,0.151670835701779,0.313921214447253,0.180889808146267,2002.25,0.0586460359978458,657.5
"CD014741","CD014741_pub2_data","6|3|Adverse events by incidence rate|Etanercept","Adverse events by incidence rate",6,3,"Etanercept","reported","reported",5,0.162207070057576,0.0472767394319424,0,2004.2,0,426.6
"CD014741","CD014741_pub2_data","6|4|Adverse events: incidence rate for serious infection|Etanercept","Adverse events: incidence rate for serious infection",6,4,"Etanercept","reported","reported",6,0.215081346716832,0.0861411403279997,0,2004.66666666667,0,445.166666666667
"CD014741","CD014741_pub2_data","6|6|Heart failure|Etanercept","Heart failure",6,6,"Etanercept","or","binary",3,-0.0245202403833862,0.188836137538256,0.0347728767814524,2000.66666666667,0.10068802762522,698.333333333333
"CD014758","CD014758_pub3_data","1|1|Change in refractive error from baseline|At 1 year","Change in refractive error from baseline",1,1,"At 1 year","or","binary",2,-0.0406396250508238,1.42510354792087,0,2004,0,71
"CD014758","CD014758_pub3_data","1|1|Change in refractive error from baseline|At 2 years","Change in refractive error from baseline",1,1,"At 2 years","or","binary",2,0,1.4202609891501,0,2009,0,122
"CD014758","CD014758_pub3_data","1|2|Change in axial length from baseline|At 2 years","Change in axial length from baseline",1,2,"At 2 years","or","binary",2,0,1.4202609891501,0,2009,0,122
"CD014758","CD014758_pub3_data","10|1|Change in axial length|At 1 year","Change in axial length",10,1,"At 1 year","reported","reported",2,0,0.0274756500224207,0,2023,0,75.5
"CD014758","CD014758_pub3_data","10|1|Change in axial length|At 2 years","Change in axial length",10,1,"At 2 years","or","binary",3,-0.0336072599701829,1.1623495426493,0,2022,0,74.6666666666667
"CD014758","CD014758_pub3_data","11|1|Change in refractive error from baseline|At 1-year","Change in refractive error from baseline",11,1,"At 1-year","reported","reported",2,0,0.0543598282375905,0,2022.5,0,166
"CD014758","CD014758_pub3_data","11|2|Change in axial length from baseline|At 1-year","Change in axial length from baseline",11,2,"At 1-year","reported","reported",2,0,0.0237138008984102,0,2022.5,0,166
"CD014758","CD014758_pub3_data","2|1|Change in refractive error from baseline|At 1 year","Change in refractive error from baseline",2,1,"At 1 year","reported","reported",9,0.142864414866335,0.0345628173472155,0.00402817224277211,2001.55555555556,0,162.555555555556
"CD014758","CD014758_pub3_data","2|1|Change in refractive error from baseline|At 2 years","Change in refractive error from baseline",2,1,"At 2 years","reported","reported",9,0.192677961894896,0.0494453731855579,0.00998419258599626,2003.55555555556,0,165
"CD014758","CD014758_pub3_data","2|1|Change in refractive error from baseline|At 3 years","Change in refractive error from baseline",2,1,"At 3 years","reported","reported",4,0.265378557708353,0.198487973799546,0.139801572763835,2002,0,208.75
"CD014758","CD014758_pub3_data","2|2|Change in axial length from baseline |At 1 year","Change in axial length from baseline ",2,2,"At 1 year","reported","reported",4,-0.0629168446597262,0.0129455425366567,0,2005.5,0,224
"CD014758","CD014758_pub3_data","2|2|Change in axial length from baseline |At 2 years","Change in axial length from baseline ",2,2,"At 2 years","reported","reported",4,-0.0875123794093075,0.0388015573766027,0.00389317168211029,2008,0,195.75
"CD014758","CD014758_pub3_data","2|2|Change in axial length from baseline |At 3 years","Change in axial length from baseline ",2,2,"At 3 years","reported","reported",2,-0.156076178571429,0.0657848825206356,0.005649775,2004,0,279
"CD014758","CD014758_pub3_data","3|1|Change in refractive error from baseline |At 1 year","Change in refractive error from baseline ",3,1,"At 1 year","reported","reported",3,0,0.0480231551399943,0,2018.66666666667,0,153.666666666667
"CD014758","CD014758_pub3_data","3|1|Change in refractive error from baseline |At 2 years","Change in refractive error from baseline ",3,1,"At 2 years","reported","reported",3,0,0.0543866109931208,0,2018.66666666667,0,162
"CD014758","CD014758_pub3_data","3|2|Change in axial length from baseline|At 2 years","Change in axial length from baseline",3,2,"At 2 years","reported","reported",2,0,0.0376358051743605,0,2018,0,163.5
"CD014758","CD014758_pub3_data","4|1|Change in refractive error from baseline|At 1 year","Change in refractive error from baseline",4,1,"At 1 year","reported","reported",12,0.270077413793357,0.0453845024699673,0.0139062792530392,2018,0,111.5
"CD014758","CD014758_pub3_data","4|1|Change in refractive error from baseline|At 2 years","Change in refractive error from baseline",4,1,"At 2 years","reported","reported",5,0.298994285033276,0.0552193704052378,0.00752294567060653,2017.4,0,168.6
"CD014758","CD014758_pub3_data","4|1|Change in refractive error from baseline|At 3 years","Change in refractive error from baseline",4,1,"At 3 years","reported","reported",2,0.474806014084507,0.177333168303993,0.054444175,2019.5,0,197.5
"CD014758","CD014758_pub3_data","4|2|Change in axial length from baseline|At 1 year","Change in axial length from baseline",4,2,"At 1 year","reported","reported",12,-0.108097034595381,0.00879687997575995,0,2018,0,111.5
"CD014758","CD014758_pub3_data","4|2|Change in axial length from baseline|At 2 years","Change in axial length from baseline",4,2,"At 2 years","reported","reported",5,-0.15495883337749,0.0183033742893211,0,2017.4,0,168.6
"CD014758","CD014758_pub3_data","4|2|Change in axial length from baseline|At 3 years","Change in axial length from baseline",4,2,"At 3 years","reported","reported",2,-0.220502833333333,0.0599978929516603,0.0053419,2019.5,0,197
"CD014758","CD014758_pub3_data","5|1|Change in refractive error from baseline|At 1 year","Change in refractive error from baseline",5,1,"At 1 year","or","binary",2,0.201616771471164,1.41848496036692,0,2003.5,0,210
"CD014758","CD014758_pub3_data","5|1|Change in refractive error from baseline|At 2 years","Change in refractive error from baseline",5,1,"At 2 years","or","binary",2,0.321671525440896,1.41867935919246,0,2003.5,0,199
"CD014758","CD014758_pub3_data","5|2|Change in axial length from baseline|At 1 year","Change in axial length from baseline",5,2,"At 1 year","or","binary",2,0.20187086879965,1.41850513274153,0,2003.5,0,207.5
"CD014758","CD014758_pub3_data","5|2|Change in axial length from baseline|At 2 years","Change in axial length from baseline",5,2,"At 2 years","or","binary",2,0.310916546695054,1.41868954216811,0,2003.5,0,197
"CD014758","CD014758_pub3_data","6|1|Change in axial length from baseline|At 1 year","Change in axial length from baseline",6,1,"At 1 year","reported","reported",12,-0.177858253226488,0.0167198184341521,0.00107787541247441,2020.83333333333,0,112.25
"CD014758","CD014758_pub3_data","6|1|Change in axial length from baseline|At 2 years","Change in axial length from baseline",6,1,"At 2 years","reported","reported",4,-0.304938396182395,0.0364115280153821,0,2017.75,0,64.25
"CD014758","CD014758_pub3_data","7|1|Change in refractive error from baseline (1 year)|Atropine (high dose)","Change in refractive error from baseline (1 year)",7,1,"Atropine (high dose)","reported","reported",3,0.903240831075306,0.136660154341158,0.0524051623511869,2014,0,357.333333333333
"CD014758","CD014758_pub3_data","7|1|Change in refractive error from baseline (1 year)|Atropine eyedrops (low dose)","Change in refractive error from baseline (1 year)",7,1,"Atropine eyedrops (low dose)","reported","reported",16,0.25450987111422,0.055581951647018,0.0407665496990516,2022,0,180.125
"CD014758","CD014758_pub3_data","7|1|Change in refractive error from baseline (1 year)|Pirenzepine 2% gel","Change in refractive error from baseline (1 year)",7,1,"Pirenzepine 2% gel","reported","reported",2,0.322,0.0877268487978452,0.00399999999999999,2004,0,163
"CD014758","CD014758_pub3_data","7|10|Change in axial length following cessation of treatment |At 1 year after cessation of treatment (low dose)","Change in axial length following cessation of treatment ",7,10,"At 1 year after cessation of treatment (low dose)","or","binary",2,0.0433339984949874,1.42345168334999,0,2022,0,96.5
"CD014758","CD014758_pub3_data","7|2|Change in axial length from baseline (1 year)|Atropine eyedrops (high dose)","Change in axial length from baseline (1 year)",7,2,"Atropine eyedrops (high dose)","reported","reported",3,-0.326752175054759,0.0147865575438845,0.000336285590996166,2014,0,357.333333333333
"CD014758","CD014758_pub3_data","7|2|Change in axial length from baseline (1 year)|Atropine eyedrops (low dose)","Change in axial length from baseline (1 year)",7,2,"Atropine eyedrops (low dose)","reported","reported",17,-0.101093549187192,0.0178926523130113,0.00338407853947101,2022.05882352941,0,174.117647058824
"CD014758","CD014758_pub3_data","7|2|Change in axial length from baseline (1 year)|Pirenzepine 2% gel","Change in axial length from baseline (1 year)",7,2,"Pirenzepine 2% gel","reported","reported",2,-0.100830833333333,0.0421234461549886,0.002580335,2004,0,163
"CD014758","CD014758_pub3_data","7|3|Change in refractive error from baseline (2 years)|Atropine eyedrops (high dose)","Change in refractive error from baseline (2 years)",7,3,"Atropine eyedrops (high dose)","reported","reported",2,1.16943378571429,0.24495987741718,0.114478555,2013.5,0,458
"CD014758","CD014758_pub3_data","7|3|Change in refractive error from baseline (2 years)|Atropine eyedrops (low dose)","Change in refractive error from baseline (2 years)",7,3,"Atropine eyedrops (low dose)","reported","reported",9,0.35378369124207,0.125601563025344,0.135839787619488,2022.75,0,221.444444444444
"CD014758","CD014758_pub3_data","7|4|Change in axial length from baseline (2 years)|Atropine eyedrops (high dose)","Change in axial length from baseline (2 years)",7,4,"Atropine eyedrops (high dose)","reported","reported",2,-0.47448,0.0698564928979404,0.00889056,2013.5,0,458
"CD014758","CD014758_pub3_data","7|4|Change in axial length from baseline (2 years)|Atropine eyedrops (low dose)","Change in axial length from baseline (2 years)",7,4,"Atropine eyedrops (low dose)","reported","reported",10,-0.165972668927256,0.0439786314428991,0.0176251721384847,2022.77777777778,0,207.6
"CD014758","CD014758_pub3_data","7|9|Change in refractive error following cessation of treatment |At 1 year after cessation of treatment (high dose)","Change in refractive error following cessation of treatment ",7,9,"At 1 year after cessation of treatment (high dose)","reported","reported",2,0,0.0341773562091421,0,2013.5,0,451.5
"CD014758","CD014758_pub3_data","7|9|Change in refractive error following cessation of treatment |At 1 year after cessation of treatment (low dose)","Change in refractive error following cessation of treatment ",7,9,"At 1 year after cessation of treatment (low dose)","or","binary",2,0.0433339984949874,1.42345168334999,0,2022,0,96.5
"CD014758","CD014758_pub3_data","8|1|Change in refractive error from baseline (1 year)|Atropine (low dose). Non-Asian studies","Change in refractive error from baseline (1 year)",8,1,"Atropine (low dose). Non-Asian studies","reported","reported",5,0.106695352605439,0.0335294711154351,0.00076464692411609,2023,0,168.8
"CD014758","CD014758_pub3_data","8|1|Change in refractive error from baseline (1 year)|Low dose atropine (Asian studies)","Change in refractive error from baseline (1 year)",8,1,"Low dose atropine (Asian studies)","reported","reported",11,0.32039915861736,0.0731160161868151,0.048469629137241,2021.54545454545,0,185.272727272727
"CD014758","CD014758_pub3_data","8|2|Change in axial length from baseline (1 year)|Low dose atropine (Asian studies)","Change in axial length from baseline (1 year)",8,2,"Low dose atropine (Asian studies)","reported","reported",12,-0.130571788367662,0.0281062563762615,0.00636583120785516,2021.66666666667,0,176.333333333333
"CD014758","CD014758_pub3_data","8|2|Change in axial length from baseline (1 year)|Low dose atropine (non-Asian studies)","Change in axial length from baseline (1 year)",8,2,"Low dose atropine (non-Asian studies)","reported","reported",5,-0.0582908748324874,0.0135380259508986,0,2023,0,168.8
"CD014758","CD014758_pub3_data","8|3|Change in refractive error from baseline (2 years)|Low dose atropine  (Asian studies)","Change in refractive error from baseline (2 years)",8,3,"Low dose atropine  (Asian studies)","reported","reported",4,0.650026350450402,0.209028275689515,0.168114992396448,2022.5,0,216.5
"CD014758","CD014758_pub3_data","8|3|Change in refractive error from baseline (2 years)|Low dose atropine (non-Asian studies)","Change in refractive error from baseline (2 years)",8,3,"Low dose atropine (non-Asian studies)","reported","reported",5,0.141438111529784,0.0461141244079447,0.00562843785679,2023,0,225.4
"CD014758","CD014758_pub3_data","8|4|Change in axial length from baseline (2 years)|Atropine (low dose). Non-Asian studies","Change in axial length from baseline (2 years)",8,4,"Atropine (low dose). Non-Asian studies","reported","reported",5,-0.0767704292935165,0.0302451737799178,0.00339866856430959,2023,0,225.6
"CD014758","CD014758_pub3_data","8|4|Change in axial length from baseline (2 years)|Atropine eyedrops (low dose). Asian studies","Change in axial length from baseline (2 years)",8,4,"Atropine eyedrops (low dose). Asian studies","reported","reported",5,-0.264593806631866,0.0647732679213546,0.0187331031451873,2022.6,0,189.6
"CD014762","CD014762_pub2_data","1|1|Short-term resolution of symptoms (days 1 to 4 after randomisation)|NSAIDs versus antibiotics","Short-term resolution of symptoms (days 1 to 4 after randomisation)",1,1,"NSAIDs versus antibiotics","or","binary",4,-0.771182606188234,0.333932357053528,0.339858058816782,2014.25,0.495273003822633,286
"CD014762","CD014762_pub2_data","1|2|Medium-term resolution of symptoms (days 5 to 10 after randomisation)|NSAIDs versus antibiotics","Medium-term resolution of symptoms (days 5 to 10 after randomisation)",1,2,"NSAIDs versus antibiotics","or","binary",4,-0.612595439876537,0.459841236989378,0.736007063484065,2014.25,0.744305723047432,285
"CD014762","CD014762_pub2_data","1|3|Adverse events (to day 30 after randomisation)|NSAIDs vs antibiotics","Adverse events (to day 30 after randomisation)",1,3,"NSAIDs vs antibiotics","or","binary",4,0.211153952090708,0.260676131025163,0.16953242188872,2014.25,0.479994966308949,291.25
"CD014762","CD014762_pub2_data","2|1|Duration of symptoms [days]|NSAIDs versus antibiotics","Duration of symptoms [days]",2,1,"NSAIDs versus antibiotics","or","binary",2,-0.0384740928455796,1.41996460134021,0,2011,0,276.5
"CD014762","CD014762_pub2_data","2|3|Microbiological resolution (by day 10 after randomisation)|NSAIDs vs antibiotics","Microbiological resolution (by day 10 after randomisation)",2,3,"NSAIDs vs antibiotics","or","binary",2,-1.39278278584184,0.313736609922748,0,2013.5,0.815151515151515,161
"CD014762","CD014762_pub2_data","2|5|Emergence of antibiotic resistant bacteria|NSAIDs vs antibiotics","Emergence of antibiotic resistant bacteria",2,5,"NSAIDs vs antibiotics","or","binary",3,-0.0676444159848021,0.153879508724666,0,2015.66666666667,0.301563194312195,323.333333333333
"CD014763","CD014763_pub2_data","1|1|Surgical site infection|","Surgical site infection",1,1,"","or","binary",9,-1.66416059176147,0.264705404769931,0,2015.66666666667,0.274935535468629,84.1111111111111
"CD014763","CD014763_pub2_data","1|2|Participant satisfaction (very satisfied or satisfied)|Satisfied","Participant satisfaction (very satisfied or satisfied)",1,2,"Satisfied","or","binary",2,-0.903161020391069,0.404586575190627,0.0116143830265486,2011.5,0.428494623655914,61
"CD014763","CD014763_pub2_data","1|2|Participant satisfaction (very satisfied or satisfied)|Satisfied or very satisfied","Participant satisfaction (very satisfied or satisfied)",1,2,"Satisfied or very satisfied","or","binary",2,1.79047425520241,1.4854412881703,1.46436621188749,2011.5,0.883333333333333,61
"CD014763","CD014763_pub2_data","1|2|Participant satisfaction (very satisfied or satisfied)|Very satisfied","Participant satisfaction (very satisfied or satisfied)",1,2,"Very satisfied","or","binary",2,1.40143446557281,0.939574736294151,1.41600055229887,2011.5,0.454838709677419,61
"CD014763","CD014763_pub2_data","1|3|Participant satisfaction (unsatisfied or very unsatisfied)|Unsatisfied","Participant satisfaction (unsatisfied or very unsatisfied)",1,3,"Unsatisfied","or","binary",2,-1.71464645031524,1.38723587715695,0.911575620462349,2011.5,0.1,61
"CD014763","CD014763_pub2_data","1|3|Participant satisfaction (unsatisfied or very unsatisfied)|Unsatisfied or very unsatisfied","Participant satisfaction (unsatisfied or very unsatisfied)",1,3,"Unsatisfied or very unsatisfied","or","binary",2,-1.7904742552024,1.4854412881703,1.46436621188749,2011.5,0.116666666666667,61
"CD014763","CD014763_pub2_data","1|3|Participant satisfaction (unsatisfied or very unsatisfied)|Very unsatisfied","Participant satisfaction (unsatisfied or very unsatisfied)",1,3,"Very unsatisfied","or","binary",2,-0.683232022058359,1.27825276121427,0,2011.5,0.0166666666666667,61
"CD014763","CD014763_pub2_data","1|4|Incisional hernia|","Incisional hernia",1,4,"","or","binary",4,-0.679498526954954,0.967913401429279,1.81339093092673,2016.25,0.0549070847851336,74.25
"CD014763","CD014763_pub2_data","1|5|Anastomotic leak|","Anastomotic leak",1,5,"","or","binary",3,-0.610093603149086,0.814571489113316,0,2017.33333333333,0.0277777777777778,71
"CD014763","CD014763_pub2_data","1|6|Intestinal obstruction|","Intestinal obstruction",1,6,"","or","binary",2,0.0612643998188152,0.475735144141922,0,2013,0.11869918699187,72.5
"CD014763","CD014763_pub2_data","1|7|Operative time (minutes)|","Operative time (minutes)",1,7,"","or","binary",6,-0.059260895379844,0.822015968443925,0,2015.16666666667,0,76.6666666666667
"CD014763","CD014763_pub2_data","1|8|Length of hospital stay (days)|","Length of hospital stay (days)",1,8,"","or","binary",6,-0.059260895379844,0.822015968443925,0,2015.16666666667,0,76.6666666666667
"CD014763","CD014763_pub2_data","2|1|Surgical site infection|","Surgical site infection",2,1,"","or","binary",5,-1.75117258123234,0.363847015011853,0,2015.4,0.289738202431947,68.8
"CD014763","CD014763_pub2_data","2|4|Incisional hernia|","Incisional hernia",2,4,"","or","binary",2,0.444003094394499,1.21368409615389,1.39457646267562,2017,0.0264808362369338,78
"CD014763","CD014763_pub2_data","2|7|Operative time (minutes)|","Operative time (minutes)",2,7,"","or","binary",5,-0.0711839144303362,0.900921773068469,0,2015.4,0,68.8
"CD014763","CD014763_pub2_data","2|8|Length of hospital stay (days)|","Length of hospital stay (days)",2,8,"","or","binary",5,-0.0711839144303362,0.900921773068469,0,2015.4,0,68.8
"CD014769","CD014769_pub2_data","1|1|Any VTE|","Any VTE",1,1,"","reported","reported",6,0,0.191597329565676,0,2009.5,0.0167382127896203,2760.83333333333
"CD014769","CD014769_pub2_data","1|10|Sensitivity analysis for any VTE excluding unpublished data|","Sensitivity analysis for any VTE excluding unpublished data",1,10,"","reported","reported",2,0,0.575630681205906,0,2017,0.0341530054644809,391.5
"CD014769","CD014769_pub2_data","1|12|Sensitivity analysis for any VTE excluding data from  > 15% missing outcome data|","Sensitivity analysis for any VTE excluding data from  > 15% missing outcome data",1,12,"","reported","reported",3,0,0.255455562488597,0,2008,0.0308504141601653,2116.66666666667
"CD014769","CD014769_pub2_data","1|13|Subgroup analysis for DVT stratified by type of statin|Rosuvastatin","Subgroup analysis for DVT stratified by type of statin",1,13,"Rosuvastatin","reported","reported",4,0,0.208772155549322,0,2012.5,0.00351624970637206,8504.75
"CD014769","CD014769_pub2_data","1|15|PE|","PE",1,15,"","or","binary",5,-0.186342090637876,0.241957543033669,4.98164941002293e-07,2009,0.00314379505111716,5685.4
"CD014769","CD014769_pub2_data","1|17|Subgroup analysis for myopathy stratified by type of statin|Atorvastatin","Subgroup analysis for myopathy stratified by type of statin",1,17,"Atorvastatin","or","binary",2,-0.00188403587024834,0.472069937432163,0,2005,0.00183415154480285,3784
"CD014769","CD014769_pub2_data","1|17|Subgroup analysis for myopathy stratified by type of statin|Rosuvastatin","Subgroup analysis for myopathy stratified by type of statin",1,17,"Rosuvastatin","or","binary",5,0.0532279542278495,0.158927498694607,0,2010,0.0292308639248706,7266.2
"CD014769","CD014769_pub2_data","1|18|Subgroup analysis for rhabdomyolysis stratified by type of statin|Atorvastatin","Subgroup analysis for rhabdomyolysis stratified by type of statin",1,18,"Atorvastatin","or","binary",2,-0.233892405991279,0.67338467911235,0,2006,0.00117983293159645,3297.5
"CD014769","CD014769_pub2_data","1|19|Bleeding|","Bleeding",1,19,"","or","binary",2,-0.0463726231956539,0.0855624426797061,0,2016,0.0373332243908584,9194.5
"CD014769","CD014769_pub2_data","1|2|Subgroup analysis for any VTE stratified by provoked status|Provoked VTE","Subgroup analysis for any VTE stratified by provoked status",1,2,"Provoked VTE","reported","reported",4,0,0.215915857966544,0,2012.25,0.0234316325083349,2330
"CD014769","CD014769_pub2_data","1|2|Subgroup analysis for any VTE stratified by provoked status|Unprovoked VTE","Subgroup analysis for any VTE stratified by provoked status",1,2,"Unprovoked VTE","or","binary",5,-0.533543853466819,0.161029391525211,0,2007.2,0.0031029455667065,9185
"CD014769","CD014769_pub2_data","1|20|Subgroup analysis for muscular weakness, stiffness, or pain, stratified by type of statin|Rosuvastatin","Subgroup analysis for muscular weakness, stiffness, or pain, stratified by type of statin",1,20,"Rosuvastatin","or","binary",5,0.0825876038053407,0.0540451387797054,0.00486160922063215,2009.4,0.0920937725210206,8214.6
"CD014769","CD014769_pub2_data","1|21|Subgroup analysis for gastrointestinal disorders stratified by type of statin|Atorvastatin","Subgroup analysis for gastrointestinal disorders stratified by type of statin",1,21,"Atorvastatin","reported","reported",2,0,0.0851561006834275,0,2004.5,0.0680671010876836,7455.5
"CD014769","CD014769_pub2_data","1|21|Subgroup analysis for gastrointestinal disorders stratified by type of statin|Rosuvastatin","Subgroup analysis for gastrointestinal disorders stratified by type of statin",1,21,"Rosuvastatin","reported","reported",2,0,0.590550385470212,0,2011.5,0.0528503056126368,2878
"CD014769","CD014769_pub2_data","1|22|Sensitivity analysis for gastrointestinal disorders|","Sensitivity analysis for gastrointestinal disorders",1,22,"","reported","reported",4,0,0.0934122992564752,0,2011,0.0392370437006993,2432.25
"CD014769","CD014769_pub2_data","1|23|Subgroup analysis for hepatic disorders stratified by type of statin|Atorvastatin","Subgroup analysis for hepatic disorders stratified by type of statin",1,23,"Atorvastatin","reported","reported",6,0,0.251772697786555,0,2007.5,0.00893060392759313,3285.16666666667
"CD014769","CD014769_pub2_data","1|23|Subgroup analysis for hepatic disorders stratified by type of statin|Rosuvastatin","Subgroup analysis for hepatic disorders stratified by type of statin",1,23,"Rosuvastatin","reported","reported",4,0,0.205250874627892,0,2010.25,0.0130968457956452,2649.75
"CD014769","CD014769_pub2_data","1|24|Sensitivity analysis for hepatic disorders|","Sensitivity analysis for hepatic disorders",1,24,"","reported","reported",3,0,0.208096115254507,0,2007,0.00680358037890251,4120.33333333333
"CD014769","CD014769_pub2_data","1|25|Subgroup analysis for renal disorders stratified by types of statins|Rosuvastatin","Subgroup analysis for renal disorders stratified by types of statins",1,25,"Rosuvastatin","reported","reported",3,0,0.532692885989638,0,2010.33333333333,0.00485428881338836,3443.33333333333
"CD014769","CD014769_pub2_data","1|26|Subgroup analysis for mortality stratified by types of statins|Atorvastatin","Subgroup analysis for mortality stratified by types of statins",1,26,"Atorvastatin","reported","reported",2,0,0.170834883116255,0,2016.5,0.218582887700535,359.5
"CD014769","CD014769_pub2_data","1|26|Subgroup analysis for mortality stratified by types of statins|Pravastatin","Subgroup analysis for mortality stratified by types of statins",1,26,"Pravastatin","or","binary",3,-0.277657803012818,0.0598709009713122,2.66095357956868e-06,2002.66666666667,0.0566014108505527,5903.33333333333
"CD014769","CD014769_pub2_data","1|26|Subgroup analysis for mortality stratified by types of statins|Rosuvastatin","Subgroup analysis for mortality stratified by types of statins",1,26,"Rosuvastatin","or","binary",8,-0.0569254454637668,0.0340526276879902,0.000679518082080765,2010.25,0.178985398553507,5607.5
"CD014769","CD014769_pub2_data","1|27|Mortality after PE|","Mortality after PE",1,27,"","or","binary",3,-0.297867834566513,0.717343425715465,0.753783546118012,2006.66666666667,0.00145970293678821,8305
"CD014769","CD014769_pub2_data","1|28|Sensitivity analysis for mortality after PE|","Sensitivity analysis for mortality after PE",1,28,"","reported","reported",2,0,0.664525649466815,0,2008,0.00171426923407966,11406.5
"CD014769","CD014769_pub2_data","1|3|Subgroup analysis for any VTE stratified by age|Age 50 to 69 years","Subgroup analysis for any VTE stratified by age",1,3,"Age 50 to 69 years","or","binary",4,-0.440420114368122,0.237584852537122,0,2011.25,0.00907699193367761,5376.75
"CD014769","CD014769_pub2_data","1|3|Subgroup analysis for any VTE stratified by age|Age 70 to 97 years","Subgroup analysis for any VTE stratified by age",1,3,"Age 70 to 97 years","or","binary",2,-0.0783676280856744,0.432961054791722,0.280665911465207,2010,0.00792774608909631,5697
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Aortic valve stenosis","Subgroup analysis for any VTE stratified by disease",1,5,"Aortic valve stenosis","reported","reported",2,0,1.15909311711714,0,2007.5,0.0101139601139601,212
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Cerebrovascular disease","Subgroup analysis for any VTE stratified by disease",1,5,"Cerebrovascular disease","reported","reported",2,0,0.249163882218856,0,2008,0.00766222922900601,2685.5
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Chronic kidney disease","Subgroup analysis for any VTE stratified by disease",1,5,"Chronic kidney disease","reported","reported",3,0,0.27805593380067,0,2006,0.0137364571511207,1032.66666666667
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Diabetes mellitus","Subgroup analysis for any VTE stratified by disease",1,5,"Diabetes mellitus","reported","reported",3,0,0.236117768185447,0,2005,0.0165989994840231,1985.66666666667
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Heart failure","Subgroup analysis for any VTE stratified by disease",1,5,"Heart failure","reported","reported",3,0,0.255487409482189,0,2007,0.017394113717653,3231
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Hypercholesterolaemia","Subgroup analysis for any VTE stratified by disease",1,5,"Hypercholesterolaemia","reported","reported",3,0,0.39997274244222,0,2003.66666666667,0.00129580175305099,5139.33333333333
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Other","Subgroup analysis for any VTE stratified by disease",1,5,"Other","reported","reported",7,0,0.122849058050828,0,2011.14285714286,0.018855610782036,5119.42857142857
"CD014769","CD014769_pub2_data","1|5|Subgroup analysis for any VTE stratified by disease|Vascular disease","Subgroup analysis for any VTE stratified by disease",1,5,"Vascular disease","reported","reported",2,0,0.101774186914527,0,2006.5,0.0121589511185722,13117.5
"CD014769","CD014769_pub2_data","1|6|Subgroup analysis for any VTE stratified by type of statin|Pravastatin","Subgroup analysis for any VTE stratified by type of statin",1,6,"Pravastatin","or","binary",4,0.151028615143039,0.138508915140842,0,2004.75,0.00707761407216959,5852.25
"CD014769","CD014769_pub2_data","1|6|Subgroup analysis for any VTE stratified by type of statin|Rosuvastatin","Subgroup analysis for any VTE stratified by type of statin",1,6,"Rosuvastatin","reported","reported",2,0,0.575630681205906,0,2017,0.0341530054644809,391.5
"CD014769","CD014769_pub2_data","1|7|Subgroup analysis for any VTE statified by different doses of rosuvstatin|10-20 mg/day","Subgroup analysis for any VTE statified by different doses of rosuvstatin",1,7,"10-20 mg/day","reported","reported",6,0,0.143735633630433,0,2012.33333333333,0.0158464396032106,6812.5
"CD014769","CD014769_pub2_data","1|7|Subgroup analysis for any VTE statified by different doses of rosuvstatin|40 mg/day","Subgroup analysis for any VTE statified by different doses of rosuvstatin",1,7,"40 mg/day","reported","reported",2,0,1.1568455977628,0,2008.5,0.0037037037037037,625
"CD014769","CD014769_pub2_data","1|8|Subgroup analysis for any VTE stratified by different doses of atorvastatin|10 mg/day","Subgroup analysis for any VTE stratified by different doses of atorvastatin",1,8,"10 mg/day","reported","reported",4,0,0.224063808195076,0,2005.75,0.0119889880459556,3784.75
"CD014769","CD014769_pub2_data","1|8|Subgroup analysis for any VTE stratified by different doses of atorvastatin|20 mg/day","Subgroup analysis for any VTE stratified by different doses of atorvastatin",1,8,"20 mg/day","reported","reported",3,0,0.301190224139915,0,2011.33333333333,0.0292601063041315,650
"CD014769","CD014769_pub2_data","1|8|Subgroup analysis for any VTE stratified by different doses of atorvastatin|80 mg/day","Subgroup analysis for any VTE stratified by different doses of atorvastatin",1,8,"80 mg/day","reported","reported",4,0,0.217293481670135,0,2006.25,0.00907705914616182,1992
"CD014769","CD014769_pub2_data","1|9|Subgroup analysis for any VTE stratified by treatment duration|Long-term","Subgroup analysis for any VTE stratified by treatment duration",1,9,"Long-term","reported","reported",6,0,0.0818479480955244,0,2004,0.0107352114266162,9799
"CD014769","CD014769_pub2_data","1|9|Subgroup analysis for any VTE stratified by treatment duration|Medium-term","Subgroup analysis for any VTE stratified by treatment duration",1,9,"Medium-term","reported","reported",16,0,0.101668708451954,0,2006.8125,0.00910119634530237,3722.625
"CD014769","CD014769_pub2_data","1|9|Subgroup analysis for any VTE stratified by treatment duration|Short term","Subgroup analysis for any VTE stratified by treatment duration",1,9,"Short term","reported","reported",4,0,0.360935444194915,0,2015.75,0.0339115195672573,369.5
"CD014792","CD014792_pub2_data","1|1|Mortality (Grade V Clavien-Dindo)|","Mortality (Grade V Clavien-Dindo)",1,1,"","or","binary",4,-0.794283023042936,0.618166687842852,0,2008.75,0.0147058823529412,86.5
"CD014792","CD014792_pub2_data","1|2|Length of hospital stay|","Length of hospital stay",1,2,"","reported","reported",3,0,0.296181620039885,0,2008.33333333333,0,105.333333333333
"CD014792","CD014792_pub2_data","1|3|Major complications|Abdominal abscess","Major complications",1,3,"Abdominal abscess","or","binary",3,-0.489294996551213,0.440434428125847,0,2008,0.152287581699346,96
"CD014792","CD014792_pub2_data","1|3|Major complications|Anastomotic leak","Major complications",1,3,"Anastomotic leak","or","binary",2,-0.031273536141309,1.03523524255498,0.78382273365524,2005,0.0147058823529412,121
"CD014792","CD014792_pub2_data","1|3|Major complications|Biliary fistula","Major complications",1,3,"Biliary fistula","or","binary",3,-0.0748855106821701,0.628040057518715,0,2008.33333333333,0.0410130718954248,105.333333333333
"CD014792","CD014792_pub2_data","1|3|Major complications|Pneumonia","Major complications",1,3,"Pneumonia","or","binary",3,-0.758361221541546,0.562997190041866,0,2008.33333333333,0.0647058823529412,105.333333333333
"CD014792","CD014792_pub2_data","1|4|Minor complications|Wound infection","Minor complications",1,4,"Wound infection","or","binary",3,-0.138470222313561,0.476204204065297,0,2008,0.109150326797386,96
"CD014792","CD014792_pub2_data","1|5|Complications related to nutritional support|Discontinuation","Complications related to nutritional support",1,5,"Discontinuation","or","binary",3,0.820877846216208,1.19537423914722,1.93200020306883,2008.33333333333,0.0277777777777778,106
"CD014792","CD014792_pub2_data","1|6|Postoperative pancreatic fistula|","Postoperative pancreatic fistula",1,6,"","or","binary",4,-0.338124784380704,0.331205309008351,4.88585685164445e-07,2008.75,0.227328431372549,86.5
"CD014792","CD014792_pub2_data","1|7|Delayed gastric emptying|","Delayed gastric emptying",1,7,"","reported","reported",2,0,0.358766792262975,0,2005.5,0.173529411764706,135
"CD014792","CD014792_pub2_data","1|8|Post pancreatectomy haemorrhage|","Post pancreatectomy haemorrhage",1,8,"","reported","reported",2,0,0.484720089480669,0,2005.5,0.186764705882353,135
"CD014792","CD014792_pub2_data","2|10|Post pancreatectomy haemorrhage|","Post pancreatectomy haemorrhage",2,10,"","reported","reported",2,0,0.24615402753096,0,2014,0.143811881188119,121
"CD014792","CD014792_pub2_data","2|3|Mortality (Grade V Clavien-Dindo)|","Mortality (Grade V Clavien-Dindo)",2,3,"","or","binary",2,0.639221468126996,0.527181485890875,0,2014,0.0247524752475248,121
"CD014792","CD014792_pub2_data","2|4|Length of hospital stay|","Length of hospital stay",2,4,"","or","binary",2,0.0409440647274652,1.42491174095369,0,2014,0,121
"CD014792","CD014792_pub2_data","2|7|Mesenteric ischaemia|","Mesenteric ischaemia",2,7,"","or","binary",2,1.4699327620074,1.20408588168621,0,2014,0,121
"CD014792","CD014792_pub2_data","2|8|Postoperative pancreatic fistula|","Postoperative pancreatic fistula",2,8,"","or","binary",2,0.932751343911013,0.34819849379646,0,2014,0.0693069306930693,121
"CD014792","CD014792_pub2_data","2|9|Delayed gastric emptying|","Delayed gastric emptying",2,9,"","reported","reported",2,0,0.212877640196028,0,2014,0.158663366336634,121
"CD014792","CD014792_pub2_data","3|4|Length of hospital stay|","Length of hospital stay",3,4,"","reported","reported",2,-1.99269607843137,1.48274804021753,3.46475,2008.5,0,150.5
"CD014792","CD014792_pub2_data","3|5|Major complications|Bacteraemia","Major complications",3,5,"Bacteraemia","reported","reported",2,0,1.09266827934463,0,2008.5,0.104032258064516,153.5
"CD014792","CD014792_pub2_data","3|5|Major complications|Intra-abdominal abscess","Major complications",3,5,"Intra-abdominal abscess","reported","reported",2,0,0.851100342187235,0,2008.5,0.0666666666666667,153.5
"CD014792","CD014792_pub2_data","3|5|Major complications|Respiratory tract infection","Major complications",3,5,"Respiratory tract infection","reported","reported",2,0,0.624715577328064,0,2008.5,0.0913978494623656,153.5
"CD014792","CD014792_pub2_data","3|7|Delayed gastric emptying|","Delayed gastric emptying",3,7,"","or","binary",2,-0.078962043014239,0.523017837136646,0.243845590432977,2008.5,0.125537634408602,153.5
"CD014802","CD014802_pub2_data","1|10|Adverse events: cardiac events (7 days, or discharge, or up to 4 years + 11 months)|NA","Adverse events: cardiac events (7 days, or discharge, or up to 4 years + 11 months)",1,10,NA,"or","binary",2,-0.365612154007397,0.257806227625092,0,2019,0.186120186120186,300.5
"CD014802","CD014802_pub2_data","1|4|Death at more than 90 days (90 days, or up to 4 years + 11 months)|NA","Death at more than 90 days (90 days, or up to 4 years + 11 months)",1,4,NA,"or","binary",2,-0.321924234870162,0.521965172160758,0.415769299522495,2019,0.367814242814243,297.5
"CD014802","CD014802_pub2_data","1|8|Serious adverse events (up to 4 years + 11 months)|NA","Serious adverse events (up to 4 years + 11 months)",1,8,NA,"or","binary",2,0.287607208167833,0.250892830829278,0.0430806884471909,2019,0.700673200673201,300.5
"CD014803","CD014803_pub2_data","1|1|Self-reported depression symptoms (continuous measure)|NA","Self-reported depression symptoms (continuous measure)",1,1,NA,"reported","reported",3,0,0.168435397526115,0,2019.33333333333,0,46.3333333333333
"CD014803","CD014803_pub2_data","1|2|Depression remission (dichotomous measure)|NA","Depression remission (dichotomous measure)",1,2,NA,"reported","reported",2,0,0.436265023681023,0,2019,0.571428571428571,40.5
"CD014803","CD014803_pub2_data","2|1|Attrition (dropouts)|NA","Attrition (dropouts)",2,1,NA,"reported","reported",2,0,0.691683245627536,0,2019,0.127777777777778,54
"CD014811","CD014811_pub2_data","1|1|Net weight loss (kg)|NA","Net weight loss (kg)",1,1,NA,"or","binary",5,0.00724924342682806,0.903131637545965,0,2015.4,0,99.4
"CD014811","CD014811_pub2_data","1|2|All-cause mortality|NA","All-cause mortality",1,2,NA,"or","binary",5,0.45432848773678,0.371865380276571,0.0763309306507269,2015.2,0.05,106
"CD014811","CD014811_pub2_data","1|3|Length of hospital stay (days)|NA","Length of hospital stay (days)",1,3,NA,"or","binary",4,-0.0230675500418644,1.0106366657757,0,2015,0,52.75
"CD014811","CD014811_pub2_data","1|4|Readmission to hospital following discharge for the longest available follow-up stated in the trials |NA","Readmission to hospital following discharge for the longest available follow-up stated in the trials ",1,4,NA,"or","binary",3,-0.217333039852273,0.218395358486491,0,2015,0.313373554550025,133.333333333333
"CD014811","CD014811_pub2_data","1|5|Acute kidney injury (adverse event)|NA","Acute kidney injury (adverse event)",1,5,NA,"or","binary",3,0.029829107660375,0.234419125510562,0,2015.33333333333,0.185215903554392,163.666666666667
"CD014811","CD014811_pub2_data","2|1|Net weight loss (kg)|NA","Net weight loss (kg)",2,1,NA,"or","binary",3,0.00264855476477741,1.16618330181025,0,2012,0,126
"CD014811","CD014811_pub2_data","2|2|All-cause mortality|NA","All-cause mortality",2,2,NA,"or","binary",3,0.205567980527068,0.354555749665482,0,2011.66666666667,0.05,136.333333333333
"CD014811","CD014811_pub2_data","2|3|Length of hospital stay (days)|NA","Length of hospital stay (days)",2,3,NA,"or","binary",3,-0.00615301008946349,1.16874969031071,0,2013,0,43.3333333333333
"CD014811","CD014811_pub2_data","2|4|Readmission to hospital following discharge for the longest available follow-up stated in the trials |NA","Readmission to hospital following discharge for the longest available follow-up stated in the trials ",2,4,NA,"or","binary",2,-0.203051972015055,0.228529546314459,0,2012.5,0.293589743589744,184
"CD014811","CD014811_pub2_data","2|5|Acute kidney injury (adverse event)|NA","Acute kidney injury (adverse event)",2,5,NA,"or","binary",2,0.123743170193931,0.25941862499193,0,2012.5,0.162439239946973,205
"CD014820","CD014820_pub2_data","1|1|Acute kidney injury|","Acute kidney injury",1,1,"","or","binary",18,-0.0481133470890436,0.082546663592433,0,2012,0.265555177074836,295.222222222222
"CD014820","CD014820_pub2_data","1|10|Adverse events: hypertension|","Adverse events: hypertension",1,10,"","or","binary",7,-0.231864989743913,0.251139830142055,0,2010.28571428571,0.109689846832704,217.428571428571
"CD014820","CD014820_pub2_data","1|2|Death (any cause)|","Death (any cause)",1,2,"","or","binary",18,-0.107101399395539,0.0902655379953378,0,2012.44444444444,0.115760155072516,292.388888888889
"CD014820","CD014820_pub2_data","1|3|Dialysis|","Dialysis",1,3,"","or","binary",14,0.187824948219873,0.17693192060468,0,2013.57142857143,0.140548336453613,147.071428571429
"CD014820","CD014820_pub2_data","1|4|Change in serum creatinine [mg/dL]|","Change in serum creatinine [mg/dL]",1,4,"","reported","reported",3,0,2.49847798965195,0,2011.66666666667,0,46.6666666666667
"CD014820","CD014820_pub2_data","1|5|Change in serum cystatin C [mg/L]|","Change in serum cystatin C [mg/L]",1,5,"","or","binary",4,0.160768808688003,1.00541960689726,0,2015,0,287.75
"CD014820","CD014820_pub2_data","1|7|Adverse events: myocardial infarction|","Adverse events: myocardial infarction",1,7,"","or","binary",11,-0.132856618221952,0.306595992572416,0,2011.81818181818,0.0134462387091705,226.909090909091
"CD014820","CD014820_pub2_data","1|8|Adverse events: stroke|","Adverse events: stroke",1,8,"","or","binary",10,-0.229921577710304,0.399803649803536,0,2011.2,0.0169560729765556,193.1
"CD014820","CD014820_pub2_data","1|9|Adverse events: thrombosis|","Adverse events: thrombosis",1,9,"","or","binary",8,-0.0855966707371463,0.169152394236125,0,2011.375,0.0340364737589419,435.5
"CD014820","CD014820_pub2_data","2|1|AKI: KDIGO or AKIN or RIFLE|","AKI: KDIGO or AKIN or RIFLE",2,1,"","or","binary",11,-0.127108766806323,0.142802534443389,0.0843547868411867,2013.81818181818,0.387092231203081,224.181818181818
"CD014820","CD014820_pub2_data","2|2|AKI: KDIGO|","AKI: KDIGO",2,2,"","or","binary",4,-0.0808301264236745,0.105760392989675,2.1819326585243e-06,2017.25,0.326714917285155,460.75
"CD014820","CD014820_pub2_data","2|3|AKI: AKIN|","AKI: AKIN",2,3,"","or","binary",5,0.11459675989588,0.242057637033099,0.0815210392169363,2011.2,0.371399239857886,97.2
"CD014820","CD014820_pub2_data","2|4|AKI: RIFLE|","AKI: RIFLE",2,4,"","or","binary",3,-0.357283906664145,0.406459490133764,0.245039938130929,2013.66666666667,0.452438856513559,70.6666666666667
"CD014820","CD014820_pub2_data","2|5|AKI: severe AKI|","AKI: severe AKI",2,5,"","or","binary",9,0.147233528284818,0.190725817006521,0.114443689876022,2014.22222222222,0.190511553501882,254.444444444444
"CD014820","CD014820_pub2_data","3|1|Acute kidney injury|Intravenous","Acute kidney injury",3,1,"Intravenous","or","binary",10,-0.183871711440565,0.204014494371444,0.20281331924583,2012.8,0.381910432660154,107.5
"CD014820","CD014820_pub2_data","3|1|Acute kidney injury|Subcutaneous","Acute kidney injury",3,1,"Subcutaneous","or","binary",7,0.05898516225712,0.158293966073693,0,2009.57142857143,0.0824419359395787,473.714285714286
"CD014820","CD014820_pub2_data","3|10|Adverse events: hypertension|Intravenous","Adverse events: hypertension",3,10,"Intravenous","or","binary",3,-0.467160928933713,0.429176745036433,0,2011,0.134673134673135,105.333333333333
"CD014820","CD014820_pub2_data","3|10|Adverse events: hypertension|Subcutaneous","Adverse events: hypertension",3,10,"Subcutaneous","or","binary",4,-0.109340045885133,0.309700011677347,0,2009.75,0.090952380952381,301.5
"CD014820","CD014820_pub2_data","3|2|Death|Intravenous","Death",3,2,"Intravenous","or","binary",9,-0.206704785284621,0.185322049662103,0,2012.66666666667,0.175032864023783,111.111111111111
"CD014820","CD014820_pub2_data","3|2|Death|Subcutaneous","Death",3,2,"Subcutaneous","or","binary",8,-0.155536036515928,0.11703185517932,0,2011.125,0.052354347035658,417.5
"CD014820","CD014820_pub2_data","3|3|Dialysis|Intravenous","Dialysis",3,3,"Intravenous","or","binary",9,0.214172686865053,0.215994839009778,0,2013,0.0864633930567859,111.222222222222
"CD014820","CD014820_pub2_data","3|3|Dialysis|Subcutaneous","Dialysis",3,3,"Subcutaneous","or","binary",4,0.141669886524472,0.317071002760765,0,2016,0.0973765432098765,262
"CD014820","CD014820_pub2_data","3|4|Change in serum creatinine [mg/dL]|Intravenous","Change in serum creatinine [mg/dL]",3,4,"Intravenous","reported","reported",6,0,0.0568508491720232,0,2011.5,0,93.5
"CD014820","CD014820_pub2_data","3|4|Change in serum creatinine [mg/dL]|Subcutaneous","Change in serum creatinine [mg/dL]",3,4,"Subcutaneous","reported","reported",2,0,0.0543241049232995,0,2018.5,0,312
"CD014820","CD014820_pub2_data","3|6|Length of hospital stay [days]|intravenous","Length of hospital stay [days]",3,6,"intravenous","reported","reported",8,0,0.384848371535681,0,2012.25,0,95.375
"CD014820","CD014820_pub2_data","3|6|Length of hospital stay [days]|Subcutaneous","Length of hospital stay [days]",3,6,"Subcutaneous","reported","reported",3,0,0.936441651642197,0,2011.33333333333,0,72.3333333333333
"CD014820","CD014820_pub2_data","3|7|Adverse events: myocardial infarction|Intravenous","Adverse events: myocardial infarction",3,7,"Intravenous","or","binary",5,-0.11353840009168,0.769392159844071,0.211035066211467,2013,0.0116138763197587,96.4
"CD014820","CD014820_pub2_data","3|7|Adverse events: myocardial infarction|Subctaneous","Adverse events: myocardial infarction",3,7,"Subctaneous","or","binary",6,-0.136188736380133,0.336810090687217,0,2010.83333333333,0.0149732073670137,335.666666666667
"CD014820","CD014820_pub2_data","3|8|Adverse events: stroke|Intravenous","Adverse events: stroke",3,8,"Intravenous","or","binary",5,-0.449312765648679,0.586278274256773,0,2012.4,0.0209586668675567,103.4
"CD014820","CD014820_pub2_data","3|9|Adverse events: thrombosis|Intravenous","Adverse events: thrombosis",3,9,"Intravenous","or","binary",3,0.865465794996016,0.534895390987923,0,2012.66666666667,0.0119047619047619,151.333333333333
"CD014820","CD014820_pub2_data","3|9|Adverse events: thrombosis|Subcutaneous","Adverse events: thrombosis",3,9,"Subcutaneous","or","binary",5,-0.191275303357232,0.178302703110713,0,2010.6,0.0473155008714499,606
"CD014820","CD014820_pub2_data","4|1|Acute kidney injury|Cardiac surgeries","Acute kidney injury",4,1,"Cardiac surgeries","or","binary",12,-0.163773269093432,0.202334269178268,0.198448783797502,2011.25,0.311731988146851,160.916666666667
"CD014820","CD014820_pub2_data","4|1|Acute kidney injury|Miscellaneous","Acute kidney injury",4,1,"Miscellaneous","or","binary",5,0.0330457004920137,0.151336733182787,0,2012,0.131082804083278,492
"CD014820","CD014820_pub2_data","4|2|Death|Cardiac surgeries","Death",4,2,"Cardiac surgeries","or","binary",11,-0.112248362680667,0.206241893582803,1.77546399302875e-07,2011,0.109773160993004,168.727272727273
"CD014820","CD014820_pub2_data","4|2|Death|Children/neonates","Death",4,2,"Children/neonates","or","binary",2,0.202934277442336,0.219036377604913,0,2021.5,0.0447761194029851,473.5
"CD014820","CD014820_pub2_data","4|2|Death|Miscellaneous","Death",4,2,"Miscellaneous","or","binary",5,-0.188005974726362,0.112953989235122,0,2012,0.157325156315254,492
"CD014820","CD014820_pub2_data","4|3|Dialysis|Cardiac surgeries","Dialysis",4,3,"Cardiac surgeries","or","binary",10,0.0414434571125108,0.232714729001488,0,2012.7,0.0575414805588675,167.5
"CD014820","CD014820_pub2_data","4|3|Dialysis|Children/neonates","Dialysis",4,3,"Children/neonates","or","binary",2,0.466180820713497,0.688958430128272,0,2015.5,0.566666666666667,17
"CD014820","CD014820_pub2_data","4|3|Dialysis|Miscellaneous","Dialysis",4,3,"Miscellaneous","or","binary",2,0.373942225892254,0.296538878882472,0,2016,0.129464285714286,175
"CD014820","CD014820_pub2_data","4|4|Change in serum creatinine [mg/dL]|Cardiac surgeries","Change in serum creatinine [mg/dL]",4,4,"Cardiac surgeries","reported","reported",7,0,0.0392939907169729,0,2012,0,165.857142857143
"CD014820","CD014820_pub2_data","4|4|Change in serum creatinine [mg/dL]|Children/neonates","Change in serum creatinine [mg/dL]",4,4,"Children/neonates","reported","reported",3,0,0.0185014339807556,0,2017.33333333333,0,319
"CD014820","CD014820_pub2_data","4|5|Change in serum cystatin C [mg/L]|Cardiac surgeries","Change in serum cystatin C [mg/L]",4,5,"Cardiac surgeries","reported","reported",2,0,0.119009029936174,0,2013.5,0,84
"CD014820","CD014820_pub2_data","4|6|Length of hospital stay [days]|Cardiac surgeries","Length of hospital stay [days]",4,6,"Cardiac surgeries","reported","reported",9,0,0.506650558911234,0,2010.44444444444,0,90.8888888888889
"CD014820","CD014820_pub2_data","4|7|Adverse events: myocardial infarction|Cardiac surgeries","Adverse events: myocardial infarction",4,7,"Cardiac surgeries","or","binary",9,-0.00369506597439057,0.339504007116818,0,2011.55555555556,0.0138846663872355,187.555555555556
"CD014820","CD014820_pub2_data","4|7|Adverse events: myocardial infarction|Miscellaneous","Adverse events: myocardial infarction",4,7,"Miscellaneous","or","binary",2,-0.703894319425035,0.71385608832445,0,2013,0.0114733141578779,404
"CD014820","CD014820_pub2_data","4|8|Adverse events: stroke|Cardiac surgeries","Adverse events: stroke",4,8,"Cardiac surgeries","or","binary",8,-0.282681098911567,0.435706130772196,0,2010.75,0.0200046150302184,140.375
"CD014820","CD014820_pub2_data","4|8|Adverse events: stroke|Miscellaneous","Adverse events: stroke",4,8,"Miscellaneous","or","binary",2,0.0512156485697696,1.00577868121427,0,2013,0.00476190476190476,404
"CD014820","CD014820_pub2_data","4|9|Adverse events: thrombosis|Cardiac surgeries","Adverse events: thrombosis",4,9,"Cardiac surgeries","or","binary",4,-0.510852415522677,0.609615358946192,0,2011.75,0.00570987654320988,290.5
"CD014820","CD014820_pub2_data","4|9|Adverse events: thrombosis|Miscellaneous","Adverse events: thrombosis",4,9,"Miscellaneous","or","binary",4,-0.0501243886039962,0.176065948502008,0,2011,0.0623630709746739,580.5
"CD014820","CD014820_pub2_data","5|1|Acute kidney injury|Long-acting","Acute kidney injury",5,1,"Long-acting","or","binary",2,0.461018562795089,0.675056910348825,0,2012,0.0283018867924528,153
"CD014820","CD014820_pub2_data","5|1|Acute kidney injury|Short-acting","Acute kidney injury",5,1,"Short-acting","or","binary",16,-0.0558417807985023,0.0831708177870633,0,2012,0.295211838360133,313
"CD014820","CD014820_pub2_data","5|2|Death|Long-acting","Death",5,2,"Long-acting","or","binary",2,0.153738455772666,1.20104232291501,1.35495049934156,2012,0.0142857142857143,153
"CD014820","CD014820_pub2_data","5|2|Death|Short-acting","Death",5,2,"Short-acting","or","binary",16,-0.10740297515776,0.0907991470390918,0,2012.5,0.128444460170866,309.8125
"CD014820","CD014820_pub2_data","5|3|Dialysis|Short-acting","Dialysis",5,3,"Short-acting","or","binary",13,0.188994740861626,0.177621754706224,0,2013.30769230769,0.151359746950045,150.384615384615
"CD014820","CD014820_pub2_data","5|4|Adverse events: myocardial infarction|Long-acting","Adverse events: myocardial infarction",5,4,"Long-acting","or","binary",2,0.103393091880956,0.885108217299618,0,2012,0.0141958670260557,153
"CD014820","CD014820_pub2_data","5|4|Adverse events: myocardial infarction|Short-acting","Adverse events: myocardial infarction",5,4,"Short-acting","or","binary",9,-0.165069028220756,0.326830320383966,0,2011.77777777778,0.0132796546387516,243.333333333333
"CD014820","CD014820_pub2_data","5|5|Adverse events: stroke|Long-acting","Adverse events: stroke",5,5,"Long-acting","or","binary",2,0.568314440249151,0.756584221294759,0,2012,0.0141958670260557,153
"CD014820","CD014820_pub2_data","5|5|Adverse events: stroke|Short-acting","Adverse events: stroke",5,5,"Short-acting","or","binary",8,-0.539178980559428,0.470924919143853,0,2011,0.0176461244641806,203.125
"CD014820","CD014820_pub2_data","5|6|Adverse events: thrombosis|Short-acting","Adverse events: thrombosis",5,6,"Short-acting","or","binary",7,-0.0891658743813119,0.170969482172325,0,2012,0.0375382829353894,468.857142857143
"CD014820","CD014820_pub2_data","5|7|Adverse events: hypertension|Short-acting","Adverse events: hypertension",5,7,"Short-acting","or","binary",6,-0.236148473489346,0.25312438435476,0,2009.16666666667,0.127971487971488,236.333333333333
"CD014820","CD014820_pub2_data","6|1|Acute kidney injury|","Acute kidney injury",6,1,"","or","binary",17,-0.0553836757719754,0.0854138412201151,0,2012.58823529412,0.279461887238386,236
"CD014820","CD014820_pub2_data","6|3|Adverse events: thrombosis|","Adverse events: thrombosis",6,3,"","or","binary",7,-0.035943110410994,0.266933528130221,0.0712855554706634,2012.71428571429,0.0356122364431728,311.714285714286
"CD014820","CD014820_pub2_data","7|1|Acute kidney injury|","Acute kidney injury",7,1,"","or","binary",14,-0.0816223625988581,0.0862719821645283,1.67580614038929e-07,2012.35714285714,0.250502880982073,326.214285714286
"CD014820","CD014820_pub2_data","7|2|Death|","Death",7,2,"","or","binary",14,-0.100412420308944,0.0956596562968035,0,2012.92857142857,0.0884284974983067,322.571428571429
"CD014820","CD014820_pub2_data","7|3|Dialysis|","Dialysis",7,3,"","or","binary",10,0.1902406857645,0.191260080871137,0,2014.5,0.102626813883448,150.4
"CD014820","CD014820_pub2_data","7|4|Change in serum creatinine [mg/dL]|","Change in serum creatinine [mg/dL]",7,4,"","reported","reported",2,0,2.57496526489756,0,2013,0,65
"CD014820","CD014820_pub2_data","7|6|Adverse events: myocardial infarction|","Adverse events: myocardial infarction",7,6,"","or","binary",7,-0.0126973927957541,0.364025713535142,0,2012.42857142857,0.0107474171129766,249.857142857143
"CD014820","CD014820_pub2_data","7|7|Adverse events: stroke|","Adverse events: stroke",7,7,"","or","binary",7,0.0779461390649768,0.496342375886031,0,2012.14285714286,0.0147224090373843,178.142857142857
"CD014820","CD014820_pub2_data","7|8|Adverse events: thrombosis|","Adverse events: thrombosis",7,8,"","or","binary",5,-0.0906182823312179,0.172861531191209,0,2012.8,0.0513190282083105,560
"CD014820","CD014820_pub2_data","7|9|Adverse events: hypertension|","Adverse events: hypertension",7,9,"","or","binary",5,-0.2494748926158,0.263577758910778,0,2010.4,0.14843758043758,208
"CD014820","CD014820_pub2_data","8|1|Change in serum creatinine [mg/dL]|","Change in serum creatinine [mg/dL]",8,1,"","reported","reported",2,0,7.24720056954688,0,2011.5,0,40
"CD014820","CD014820_pub2_data","8|2|Change in serum cystatin C [mg/L]|","Change in serum cystatin C [mg/L]",8,2,"","or","binary",3,-0.0109025036536454,1.15953627454222,0,2016,0,363.666666666667
"CD014820","CD014820_pub2_data","9|1|Acute kidney injury|","Acute kidney injury",9,1,"","or","binary",18,-0.0481133470890436,0.082546663592433,0,2012,0.265555177074836,295.222222222222
"CD014820","CD014820_pub2_data","9|10|Adverse events: hypertension|","Adverse events: hypertension",9,10,"","or","binary",7,-0.231864989743913,0.251139830142055,0,2010.28571428571,0.109689846832704,217.428571428571
"CD014820","CD014820_pub2_data","9|2|Death|","Death",9,2,"","or","binary",18,-0.107101399395539,0.0902655379953378,0,2012.44444444444,0.115760155072516,292.388888888889
"CD014820","CD014820_pub2_data","9|3|Dialysis|","Dialysis",9,3,"","or","binary",14,0.187824948219873,0.17693192060468,0,2013.57142857143,0.140548336453613,147.071428571429
"CD014820","CD014820_pub2_data","9|4|Change in serum creatinine [mg/dL]|","Change in serum creatinine [mg/dL]",9,4,"","reported","reported",3,0,2.49841344109464,0,2011.66666666667,0,46.6666666666667
"CD014820","CD014820_pub2_data","9|5|Change in serum cystatin C [mg/L]|","Change in serum cystatin C [mg/L]",9,5,"","or","binary",4,0.160768808688003,1.00541960689726,0,2015,0,287.75
"CD014820","CD014820_pub2_data","9|7|Adverse events: myocardial infarction|","Adverse events: myocardial infarction",9,7,"","or","binary",11,-0.132856618221952,0.306595992572416,0,2011.81818181818,0.0134462387091705,226.909090909091
"CD014820","CD014820_pub2_data","9|8|Adverse events: stroke|","Adverse events: stroke",9,8,"","or","binary",10,-0.229921577710304,0.399803649803536,0,2011.2,0.0169560729765556,193.1
"CD014820","CD014820_pub2_data","9|9|Adverse events: thrombosis|","Adverse events: thrombosis",9,9,"","or","binary",8,-0.0855966707371463,0.169152394236125,0,2011.375,0.0340364737589419,435.5
"CD014833","CD014833_pub2_data","1|3|Incidence of depression medium-term 4 to 6 months post-intervention|NA","Incidence of depression medium-term 4 to 6 months post-intervention",1,3,NA,"or","binary",2,-0.354995188102341,0.858824667645102,1.21870221071062,2019.5,0.211630036630037,148.5
"CD014833","CD014833_pub2_data","1|5|Depressive symptoms short-term 1 to 3 months post-intervention|NA","Depressive symptoms short-term 1 to 3 months post-intervention",1,5,NA,"or","binary",2,0.0713861557063123,1.41982172452824,0,2018.5,0,138
"CD014833","CD014833_pub2_data","1|8|Breastfeeding exclusivity short-term 1 to 3 months post-intervention|NA","Breastfeeding exclusivity short-term 1 to 3 months post-intervention",1,8,NA,"or","binary",5,0.431216122129112,0.217642022261779,0.132179427801128,2009.6,0.367826870813169,212.4
"CD014833","CD014833_pub2_data","1|9|Breastfeeding exclusivity medium-term 4 to 6 months post-intervention|NA","Breastfeeding exclusivity medium-term 4 to 6 months post-intervention",1,9,NA,"or","binary",4,0.40968237371938,0.179273310474782,0.038811926241607,2014.25,0.429581133783149,226.25
"CD014844","CD014844_pub2_data","1|1|Uterine infection|","Uterine infection",1,1,"","or","binary",6,-0.260103922697189,0.260026406445351,0.148308779508948,2005.16666666667,0.0957458884987928,728.5
"CD014844","CD014844_pub2_data","1|10|Subgroup: uterine infection by antibiotic class|Uterine infection (tetracyclines)","Subgroup: uterine infection by antibiotic class",1,10,"Uterine infection (tetracyclines)","or","binary",5,-0.222054735208076,0.26419579379088,0.149900546684691,2003.8,0.104638655942141,858.4
"CD014844","CD014844_pub2_data","1|11|Subgroup: uterine infection by length of treatment course|Uterine infection (short-course treatment)","Subgroup: uterine infection by length of treatment course",1,11,"Uterine infection (short-course treatment)","or","binary",5,-0.492758578402091,0.196208999922121,0,2008.4,0.053561732865218,847.2
"CD014844","CD014844_pub2_data","1|12|Subgroup: uterine infection by administration route|Uterine infection (intravenous route)","Subgroup: uterine infection by administration route",1,12,"Uterine infection (intravenous route)","or","binary",2,-0.176691853855187,0.684889012016331,0.296930461019351,2003.5,0.0548076923076923,159.5
"CD014844","CD014844_pub2_data","1|12|Subgroup: uterine infection by administration route|Uterine infection (oral route)","Subgroup: uterine infection by administration route",1,12,"Uterine infection (oral route)","or","binary",4,-0.300784052789533,0.319390376154042,0.211077690515678,2006,0.116214986594343,1013
"CD014844","CD014844_pub2_data","1|6|Antibiotics to treat infection after uterine evacuation procedure for miscarriage|","Antibiotics to treat infection after uterine evacuation procedure for miscarriage",1,6,"","or","binary",3,-0.0537604297129196,0.344972164052929,0.182048512396968,2006.66666666667,0.137724790385123,1191.33333333333
"CD014844","CD014844_pub2_data","1|7|Hospitalisation for treatment of infection|","Hospitalisation for treatment of infection",1,7,"","or","binary",3,-0.256933820270228,0.323897581057406,0,2003,0.00415676959619952,1286.33333333333
"CD014844","CD014844_pub2_data","1|8|Sensitivity analysis: uterine infection – studies at low risk of bias|","Sensitivity analysis: uterine infection – studies at low risk of bias",1,8,"","or","binary",3,-0.576319979544239,0.217452746486501,0,2017.33333333333,0.0600927502335953,1245.66666666667
"CD014844","CD014844_pub2_data","1|9|Subgroup: uterine infection by gestation|Gestation < 12 weeks","Subgroup: uterine infection by gestation",1,9,"Gestation < 12 weeks","or","binary",2,-1.1140279314443,0.411910430202956,0,2015.5,0.038261217948718,872
"CD014845","CD014845_pub2_data","1|1|Food selection/purchasing (kcal)|","Food selection/purchasing (kcal)",1,1,"","reported","reported",19,-0.0547743165084867,0.0113373294465158,0,2016.10526315789,0,518.421052631579
"CD014845","CD014845_pub2_data","1|10|Subgroup analysis: food consumption by label type (kcal)|Calorie","Subgroup analysis: food consumption by label type (kcal)",1,10,"Calorie","or","binary",8,-0.490257396555054,0.710882990279011,0,2012.75,0,233.75
"CD014845","CD014845_pub2_data","1|11|Subgroup analysis: food consumption by socioeconomic status (kcal)|High","Subgroup analysis: food consumption by socioeconomic status (kcal)",1,11,"High","or","binary",9,-0.567198482340596,0.671178479868101,0,2013.44444444444,0,171.111111111111
"CD014845","CD014845_pub2_data","1|12|Sensitivity analysis: food consumption by low risk of bias (kcal)|Some concerns or high risk of bias ","Sensitivity analysis: food consumption by low risk of bias (kcal)",1,12,"Some concerns or high risk of bias ","or","binary",9,-0.515473619198811,0.670792247175343,0,2012.11111111111,0,227.444444444444
"CD014845","CD014845_pub2_data","1|2|Subgroup analysis: food selection/purchasing by setting (kcal)|Laboratory","Subgroup analysis: food selection/purchasing by setting (kcal)",1,2,"Laboratory","reported","reported",2,-0.29318059310642,0.101915821102995,0,2015,0,218.5
"CD014845","CD014845_pub2_data","1|2|Subgroup analysis: food selection/purchasing by setting (kcal)|Naturalistic","Subgroup analysis: food selection/purchasing by setting (kcal)",1,2,"Naturalistic","reported","reported",8,-0.0653058639030327,0.0483485318205777,0,2014,0,238.375
"CD014845","CD014845_pub2_data","1|2|Subgroup analysis: food selection/purchasing by setting (kcal)|Restaurant","Subgroup analysis: food selection/purchasing by setting (kcal)",1,2,"Restaurant","reported","reported",7,-0.0537711748021583,0.0159662902434133,3.13533232975472e-07,2017.42857142857,0,1066.57142857143
"CD014845","CD014845_pub2_data","1|2|Subgroup analysis: food selection/purchasing by setting (kcal)|Store","Subgroup analysis: food selection/purchasing by setting (kcal)",1,2,"Store","reported","reported",2,-0.0477155,0.0173241161390704,0,2021,0,20
"CD014845","CD014845_pub2_data","1|3|Subgroup analysis: food selection/purchasing by label type (kcal)|Calorie and nutrient","Subgroup analysis: food selection/purchasing by label type (kcal)",1,3,"Calorie and nutrient","reported","reported",4,-0.052916385139982,0.0171365352493918,5.14677533357277e-06,2017.75,0,120
"CD014845","CD014845_pub2_data","1|3|Subgroup analysis: food selection/purchasing by label type (kcal)|Calorie with PACE","Subgroup analysis: food selection/purchasing by label type (kcal)",1,3,"Calorie with PACE","reported","reported",2,-0.0456114052575707,0.0362342325562809,0,2018,0,24
"CD014845","CD014845_pub2_data","1|3|Subgroup analysis: food selection/purchasing by label type (kcal)|Simple calorie","Subgroup analysis: food selection/purchasing by label type (kcal)",1,3,"Simple calorie","reported","reported",14,-0.0664565681966904,0.0203785574316981,0.000644858993501088,2015.35714285714,0,680.642857142857
"CD014845","CD014845_pub2_data","1|4|Subgroup analysis: food selection/purchasing by socioeconomic status (kcal)|Both low and high","Subgroup analysis: food selection/purchasing by socioeconomic status (kcal)",1,4,"Both low and high","reported","reported",5,-0.0374363522176708,0.0143228495311848,0,2017.4,0,130.4
"CD014845","CD014845_pub2_data","1|4|Subgroup analysis: food selection/purchasing by socioeconomic status (kcal)|High","Subgroup analysis: food selection/purchasing by socioeconomic status (kcal)",1,4,"High","reported","reported",14,-0.0838640645282314,0.0185524110084058,0,2015.64285714286,0,657
"CD014845","CD014845_pub2_data","1|5|Additional exploratory subgroup analysis: food selection/purchasing by placement of labels|Both adjacent to and on product packaging","Additional exploratory subgroup analysis: food selection/purchasing by placement of labels",1,5,"Both adjacent to and on product packaging","reported","reported",3,-0.046692819840193,0.0156427977183851,0,2021.33333333333,0,20
"CD014845","CD014845_pub2_data","1|5|Additional exploratory subgroup analysis: food selection/purchasing by placement of labels|On menus","Additional exploratory subgroup analysis: food selection/purchasing by placement of labels",1,5,"On menus","reported","reported",14,-0.078662764504842,0.0235528862506877,0.00138037432121568,2014.78571428571,0,669.214285714286
"CD014845","CD014845_pub2_data","1|6|Sensitivity analysis: food selection/purchasing by low risk of bias (kcal)|Low risk of bias","Sensitivity analysis: food selection/purchasing by low risk of bias (kcal)",1,6,"Low risk of bias","reported","reported",8,-0.0465472476535885,0.0119960043467139,0,2020.5,0,747
"CD014845","CD014845_pub2_data","1|6|Sensitivity analysis: food selection/purchasing by low risk of bias (kcal)|Some concerns or high risk of bias","Sensitivity analysis: food selection/purchasing by low risk of bias (kcal)",1,6,"Some concerns or high risk of bias","reported","reported",11,-0.127789441718498,0.0391644337156932,0.00181455518573019,2012.90909090909,0,352.181818181818
"CD014845","CD014845_pub2_data","1|7|Sensitivity analysis: food selection/purchasing excluding Reynolds 2022, Vasiljevic 2018, Vasiljevic 2019|","Sensitivity analysis: food selection/purchasing excluding Reynolds 2022, Vasiljevic 2018, Vasiljevic 2019",1,7,"","reported","reported",16,-0.0655655646421005,0.0133243046513005,0,2015.4375,0,613.25
"CD014845","CD014845_pub2_data","1|8|Food consumption (kcal)|","Food consumption (kcal)",1,8,"","or","binary",10,-0.512590847685517,0.63635792007523,0,2012.9,0,213.4
"CD014845","CD014845_pub2_data","1|9|Subgroup analysis: food consumption by setting (kcal)|Laboratory","Subgroup analysis: food consumption by setting (kcal)",1,9,"Laboratory","or","binary",3,-0.397753224441316,1.16172563367715,0,2013.33333333333,0,143
"CD014845","CD014845_pub2_data","1|9|Subgroup analysis: food consumption by setting (kcal)|Naturalistic","Subgroup analysis: food consumption by setting (kcal)",1,9,"Naturalistic","or","binary",7,-0.56181903612046,0.760621157594218,0,2012.71428571429,0,243.571428571429
"CD014845","CD014845_pub2_data","2|1|Alcohol selection/purchasing of energy (kcal)|","Alcohol selection/purchasing of energy (kcal)",2,1,"","reported","reported",2,-0.0458631768933917,0.103301635045638,0.0147436144045,2021.5,0,2878
"CD014852","CD014852_pub2_data","1|10|Subgroup analysis – nutritional status at baseline: nutritional status (body weight ) |No inclusion criteria with malnutrition or malnutrition risk","Subgroup analysis – nutritional status at baseline: nutritional status (body weight ) ",1,10,"No inclusion criteria with malnutrition or malnutrition risk","or","binary",2,0.0237742434293314,1.4297641370862,0,2008,0,44.5
"CD014852","CD014852_pub2_data","1|12|All-cause mortality at follow-up|Acute phase","All-cause mortality at follow-up",1,12,"Acute phase","or","binary",2,-0.486208137956337,0.622033660661696,0.559026081803592,2001.5,0.229696063776781,2032.5
"CD014852","CD014852_pub2_data","1|8|Nutritional status change (body weight ) during intervention phase|Acute and subacute phase","Nutritional status change (body weight ) during intervention phase",1,8,"Acute and subacute phase","or","binary",2,0.0236350297658993,1.42557189136152,0,2008,0,78.5
"CD014852","CD014852_pub2_data","1|9|Subgroup analysis – type of stroke: nutritional status (body weight ) |Ischaemic stroke","Subgroup analysis – type of stroke: nutritional status (body weight ) ",1,9,"Ischaemic stroke","or","binary",2,0.0237742434293314,1.4297641370862,0,2008,0,44.5
"CD014852","CD014852_pub2_data","10|2|Neurological impairment (NIHSS score) at end of intervention phase|Acute phase","Neurological impairment (NIHSS score) at end of intervention phase",10,2,"Acute phase","or","binary",2,-0.109200204479565,1.42503628980208,0,2015.5,0,67
"CD014852","CD014852_pub2_data","13|2|Nutritional status (change in body weight) during follow-up or intervention phase|Acute phase","Nutritional status (change in body weight) during follow-up or intervention phase",13,2,"Acute phase","or","binary",2,0.0640786640335286,1.4197833643175,0,2015,0,126
"CD014852","CD014852_pub2_data","8|1|Disability: modified Rankin Scale (mRS 0 to 3, good status) at follow‐up|Acute phase","Disability: modified Rankin Scale (mRS 0 to 3, good status) at follow‐up",8,1,"Acute phase","or","binary",2,0.306981347019049,0.294482120621267,0.112250558618272,2010,0.274893547330495,502.5
"CD014852","CD014852_pub2_data","8|10|Nutritional status (arm muscular circumference) at end of intervention phase|Acute phase","Nutritional status (arm muscular circumference) at end of intervention phase",8,10,"Acute phase","or","binary",3,-0.172644195271059,1.16160593684246,0,2012.66666666667,0,95.3333333333333
"CD014852","CD014852_pub2_data","8|13|All-cause mortality at follow-up|Acute phase","All-cause mortality at follow-up",8,13,"Acute phase","or","binary",3,-0.591321204681134,0.331128242602215,0.173707437495028,2008,0.309733274246482,359
"CD014852","CD014852_pub2_data","8|14|Subgroup analysis – type of stroke: mortality |Mixed: ischaemic stroke and intracerebral haemorrhage","Subgroup analysis – type of stroke: mortality ",8,14,"Mixed: ischaemic stroke and intracerebral haemorrhage","or","binary",2,-0.500363185230939,0.397132673180839,0.211791693606489,2010,0.332246970193253,502.5
"CD014852","CD014852_pub2_data","8|16|Complication (pneumonia) during intervention phase|Acute phase","Complication (pneumonia) during intervention phase",8,16,"Acute phase","or","binary",4,-0.534149812516457,0.399039008099171,0.449721404383474,2011,0.323769933784192,288.75
"CD014852","CD014852_pub2_data","8|17|Subgroup analysis – type of stroke: pneumonia|Mixed: ischaemic stroke and intracerebral haemorrhage","Subgroup analysis – type of stroke: pneumonia",8,17,"Mixed: ischaemic stroke and intracerebral haemorrhage","or","binary",2,-0.0521494216661739,0.139523170758309,0,2010,0.260284965607599,502.5
"CD014852","CD014852_pub2_data","8|18|Complication (urinary tract infection) during intervention phase|Acute phase","Complication (urinary tract infection) during intervention phase",8,18,"Acute phase","or","binary",3,-0.0137847902521211,0.172749277249862,0,2013.33333333333,0.119558175928959,361
"CD014852","CD014852_pub2_data","8|19|Subgroup analysis – type of stroke: urinary tract infection|Mixed: ischaemic stroke and intracerebral haemorrhage","Subgroup analysis – type of stroke: urinary tract infection",8,19,"Mixed: ischaemic stroke and intracerebral haemorrhage","or","binary",2,-0.020946984989806,0.176670705385059,0,2010,0.146003930560105,502.5
"CD014852","CD014852_pub2_data","8|2|Activities of daily living (Barthel Index score) at end of intervention phase|Acute phase","Activities of daily living (Barthel Index score) at end of intervention phase",8,2,"Acute phase","or","binary",2,-0.258473103318252,1.42131556192236,0,2017.5,0,112
"CD014852","CD014852_pub2_data","8|20|Complication (intestinal infection) during intervention phase|Acute phase","Complication (intestinal infection) during intervention phase",8,20,"Acute phase","or","binary",2,-1.05807736858774,0.666334234333068,0.482176812100901,2009.5,0.210439105219553,109
"CD014852","CD014852_pub2_data","8|23|Complication (pressure sores) during intervention phase|Acute phase","Complication (pressure sores) during intervention phase",8,23,"Acute phase","or","binary",2,-0.451339403059318,1.00370267050837,1.22791019663529,2010,0.0327546675401245,502.5
"CD014852","CD014852_pub2_data","8|25|Complication (diarrhoea) during intervention phase|Acute phase","Complication (diarrhoea) during intervention phase",8,25,"Acute phase","or","binary",2,0.275265724596287,0.349669524792514,0,2012.5,0.0782945736434109,468.5
"CD014852","CD014852_pub2_data","8|26|Complication (gastrointestinal haemorrhage) during intervention phase|Acute phase","Complication (gastrointestinal haemorrhage) during intervention phase",8,26,"Acute phase","or","binary",3,-0.782411234061962,0.830218175732947,1.72071214148702,2004,0.246351293705779,331
"CD014852","CD014852_pub2_data","8|5|Neurological impairment (NIHSS score) at and of intervention phase|Acute phase","Neurological impairment (NIHSS score) at and of intervention phase",8,5,"Acute phase","or","binary",2,-0.258473103318252,1.42131556192236,0,2017.5,0,112
"CD014852","CD014852_pub2_data","8|8|Nutritional status (triceps skinfold thickness) at end of intervention phase|Acute phase","Nutritional status (triceps skinfold thickness) at end of intervention phase",8,8,"Acute phase","or","binary",3,-0.172644195271059,1.16160593684246,0,2012.66666666667,0,95.3333333333333
"CD014855","CD014855_pub2_data","1|1|Intraperitoneal abscess|","Intraperitoneal abscess",1,1,"","reported","reported",7,0,0.225659749040754,0,2000.28571428571,0.134097388863274,95.8571428571429
"CD014855","CD014855_pub2_data","1|2|Wound infection|","Wound infection",1,2,"","reported","reported",7,0,0.0987947517373213,0,2006.42857142857,0.209979962064302,99.4285714285714
"CD014855","CD014855_pub2_data","1|3|Morbidity|","Morbidity",1,3,"","reported","reported",2,0,0.423858043620528,0,2016.5,0.209803921568627,62
"CD014855","CD014855_pub2_data","1|4|Mortality|","Mortality",1,4,"","reported","reported",3,0,0.722361316005699,0,1981,0.0072463768115942,74.3333333333333
"CD014855","CD014855_pub2_data","1|5|Hospital stay|","Hospital stay",1,5,"","reported","reported",5,0,0.147537086448023,0,2015,0,103.2
"CD014855","CD014855_pub2_data","2|1|Intraperitoneal abscess|Laparoscopic appendectomy","Intraperitoneal abscess",2,1,"Laparoscopic appendectomy","or","binary",2,-0.194622924493225,0.463994085821363,0,2022.5,0.179316888045541,109
"CD014855","CD014855_pub2_data","2|1|Intraperitoneal abscess|Open appendectomy","Intraperitoneal abscess",2,1,"Open appendectomy","or","binary",5,0.296661139602598,0.541537355854392,0.868389720978123,1991.4,0.116009589190367,90.6
"CD014855","CD014855_pub2_data","2|2|Wound infection|Laparoscopic appendectomy","Wound infection",2,2,"Laparoscopic appendectomy","or","binary",2,0.192408133077009,0.549216252591124,0,2022.5,0.0562934851359899,109
"CD014855","CD014855_pub2_data","2|2|Wound infection|Open appendectomy","Wound infection",2,2,"Open appendectomy","reported","reported",5,0,0.0998588328960218,0,2000,0.271454552835627,95.6
"CD014855","CD014855_pub2_data","2|4|Mortality|Laparoscopic appendectomy ","Mortality",2,4,"Laparoscopic appendectomy ","or","binary",2,0.0109343633708882,1.42608331816621,0,2022.5,0,109
"CD014855","CD014855_pub2_data","2|4|Mortality|Open appendectomy","Mortality",2,4,"Open appendectomy","or","binary",4,1.13986187675439,0.692738364864255,0,1986.5,0.00543478260869565,90.75
"CD014855","CD014855_pub2_data","2|5|Hospital stay|Laparoscopic appendectomy","Hospital stay",2,5,"Laparoscopic appendectomy","or","binary",2,0.0109343633708882,1.42608331816621,0,2022.5,0,109
"CD014855","CD014855_pub2_data","2|5|Hospital stay|Open appendectomy","Hospital stay",2,5,"Open appendectomy","or","binary",3,0,1.16094728416414,0,2010,0,99.3333333333333
"CD014855","CD014855_pub2_data","3|1|Intraperitoneal abscess|Children","Intraperitoneal abscess",3,1,"Children","or","binary",4,-0.278392821418203,0.350753855410352,0,2005.25,0.14698927109044,100.25
"CD014855","CD014855_pub2_data","3|2|Wound infection|Children","Wound infection",3,2,"Children","reported","reported",2,0,0.471743866366098,0,2013,0.0411674347158218,162
"CD014855","CD014855_pub2_data","3|4|Mortality|Children","Mortality",3,4,"Children","or","binary",4,0.519811652236962,0.936324793465982,0,2005.25,0,100.25
"CD014855","CD014855_pub2_data","3|5|Hospital stay|Children","Hospital stay",3,5,"Children","or","binary",3,0.00726609193068639,1.16251507321226,0,2016,0,119.333333333333
"CD014861","CD014861_pub2_data","1|11|Proportion of participants completing treatment regimen as planned|NA","Proportion of participants completing treatment regimen as planned",1,11,NA,"reported","reported",3,0,0.181072693079757,0,2006.33333333333,0.777777777777778,51.3333333333333
"CD014861","CD014861_pub2_data","1|4|Hospital attendance within 48 hours of treatment administration (proportion of participants with a visit)|NA","Hospital attendance within 48 hours of treatment administration (proportion of participants with a visit)",1,4,NA,"or","binary",2,1.1105480466123,1.16645424548239,0,2015.5,0,74.5
"CD014861","CD014861_pub2_data","1|8|Health-related quality of life (EORTC QLQC30 all domains)|NA","Health-related quality of life (EORTC QLQC30 all domains)",1,8,NA,"reported","reported",5,0.132336210122057,0.33366687038767,0,2008.2,0,46.4
"CD014861","CD014861_pub2_data","1|9|Health-related quality of life (EORTC QOL-C30)|NA","Health-related quality of life (EORTC QOL-C30)",1,9,NA,"reported","reported",2,-0.00239308293045742,0.487762649636139,0,2007,0,48
"CD014861","CD014861_pub2_data","2|6|Health-related quality of life (EORTC QLQC30 all domain and unit scores)|NA","Health-related quality of life (EORTC QLQC30 all domain and unit scores)",2,6,NA,"reported","reported",2,5.9304006880734,7.45175241780951,91.1859854999999,2013,0,40
"CD014869","CD014869_pub2_data","1|1| All-cause mortality (between  1 and 5 years)|at 1 year"," All-cause mortality (between  1 and 5 years)",1,1,"at 1 year","reported","reported",3,0,0.0165822228284564,0,1997.33333333333,0.8125,78.3333333333333
"CD014869","CD014869_pub2_data","1|1| All-cause mortality (between  1 and 5 years)|between 2 and 3 years"," All-cause mortality (between  1 and 5 years)",1,1,"between 2 and 3 years","or","binary",3,0.17401856304092,0.15532333608277,0,1995,0.582661290322581,225.666666666667
"CD014869","CD014869_pub2_data","1|5|Adverse events considered non-serious (number of participants) (between 1 and 3 years)|","Adverse events considered non-serious (number of participants) (between 1 and 3 years)",1,5,"","or","binary",4,0.125606955124546,0.481334084242866,0,1995.33333333333,0.0201923076923077,115.5
"CD014869","CD014869_pub2_data","1|6|Sensitivity analysis: all-cause mortality between 1 and 5 years (best-worst case scenario)|at 1 year","Sensitivity analysis: all-cause mortality between 1 and 5 years (best-worst case scenario)",1,6,"at 1 year","reported","reported",3,0,0.0165822228284564,0,1997.33333333333,0.8125,78.3333333333333
"CD014869","CD014869_pub2_data","1|6|Sensitivity analysis: all-cause mortality between 1 and 5 years (best-worst case scenario)|between 2 and 3 years","Sensitivity analysis: all-cause mortality between 1 and 5 years (best-worst case scenario)",1,6,"between 2 and 3 years","reported","reported",2,0,0.0733600619884528,0,1995,0.556451612903226,308
"CD014869","CD014869_pub2_data","1|7|Sensitivity analysis: all-cause mortality between 1 and 5 years (worst-best case scenario)|at 1 year","Sensitivity analysis: all-cause mortality between 1 and 5 years (worst-best case scenario)",1,7,"at 1 year","reported","reported",3,0,0.0164840439532213,0,1997.33333333333,0.8375,78.3333333333333
"CD014869","CD014869_pub2_data","1|7|Sensitivity analysis: all-cause mortality between 1 and 5 years (worst-best case scenario)|between 2 and 3 years","Sensitivity analysis: all-cause mortality between 1 and 5 years (worst-best case scenario)",1,7,"between 2 and 3 years","reported","reported",2,0,0.0733600619884528,0,1995,0.530241935483871,308
"CD014871","CD014871_pub2_data","1|1|Walking energy cost|Carbon (custom-made)","Walking energy cost",1,1,"Carbon (custom-made)","or","binary",2,0.0621222906985529,1.43093084540781,0,2017,0,47
"CD014871","CD014871_pub2_data","1|11|Stride length|Carbon","Stride length",1,11,"Carbon","or","binary",2,0,1.44672846651124,0,2014,0,22
"CD014871","CD014871_pub2_data","1|21|Peak ankle dorsiflexion angle in terminal stance|Carbon","Peak ankle dorsiflexion angle in terminal stance",1,21,"Carbon","or","binary",2,0.0621886110653673,1.43169445652676,0,2017,0,46
"CD014871","CD014871_pub2_data","1|25|Peak knee flexion angle in midstance|Carbon","Peak knee flexion angle in midstance",1,25,"Carbon","or","binary",2,0.0621886110653673,1.43169445652676,0,2017,0,46
"CD014871","CD014871_pub2_data","1|3|Self-selected comfortable walking speed|Carbon","Self-selected comfortable walking speed",1,3,"Carbon","or","binary",4,0.0313452531406367,1.016437795246,0,2015,0,36.5
"CD014871","CD014871_pub2_data","1|3|Self-selected comfortable walking speed|Polypropylene","Self-selected comfortable walking speed",1,3,"Polypropylene","or","binary",2,0.237623426009433,1.43865740056226,0,2012,0,28.5
"CD014871","CD014871_pub2_data","1|45|Peak ankle power in terminal stance|Carbon","Peak ankle power in terminal stance",1,45,"Carbon","or","binary",2,0.0622645793751047,1.43256865367118,0,2017,0,45
"CD014872","CD014872_pub2_data","1|1|Progression-free survival|","Progression-free survival",1,1,"","reported","reported",14,-0.416129352581546,0.0570326215286033,0.0189539875130647,2020.11111111111,0,274.857142857143
"CD014872","CD014872_pub2_data","1|10|Overall response rate (solid cancer vs haematological cancer)|Haematological cancer","Overall response rate (solid cancer vs haematological cancer)",1,10,"Haematological cancer","or","binary",3,1.22362147268557,0.173877817280374,0,2019,0.163754645367311,308
"CD014872","CD014872_pub2_data","1|10|Overall response rate (solid cancer vs haematological cancer)|Solid cancer","Overall response rate (solid cancer vs haematological cancer)",1,10,"Solid cancer","reported","reported",2,0,0.0782533300262685,0,2021,0.0723880597014925,160
"CD014872","CD014872_pub2_data","1|11|Overall response rate (standard-of-care chemotherapy vs hormonal therapy)|Chemotherapy","Overall response rate (standard-of-care chemotherapy vs hormonal therapy)",1,11,"Chemotherapy","reported","reported",2,0,0.239076642013821,0,2020.5,0.146774193548387,243
"CD014872","CD014872_pub2_data","1|14|Severe adverse events (haematological vs non-haematological events)|Haematological","Severe adverse events (haematological vs non-haematological events)",1,14,"Haematological","reported","reported",2,0,0.296675721395636,0,2021,0.117105263157895,184.5
"CD014872","CD014872_pub2_data","1|14|Severe adverse events (haematological vs non-haematological events)|Non-haematological","Severe adverse events (haematological vs non-haematological events)",1,14,"Non-haematological","or","binary",3,-0.0994575290738519,0.771681815916225,1.62274595046194,2020.66666666667,0.215587044534413,251.666666666667
"CD014872","CD014872_pub2_data","1|2|Progression-free survival (solid cancer vs haematological cancer)|Haematological cancer","Progression-free survival (solid cancer vs haematological cancer)",1,2,"Haematological cancer","reported","reported",4,-0.335009011409652,0.11840510164919,0.033299623216414,2019,0,322.75
"CD014872","CD014872_pub2_data","1|2|Progression-free survival (solid cancer vs haematological cancer)|Solid cancer","Progression-free survival (solid cancer vs haematological cancer)",1,2,"Solid cancer","reported","reported",10,-0.456462871259348,0.0630137152364258,0.0119015580126728,2020.42857142857,0,255.7
"CD014872","CD014872_pub2_data","1|3|Progression-free survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care chemotherapy","Progression-free survival (standard-of-care chemotherapy vs hormonal therapy)",1,3,"Standard-of-care chemotherapy","reported","reported",13,-0.367044850169033,0.0505383910903464,0.00545994529490819,2020.125,0,255.384615384615
"CD014872","CD014872_pub2_data","1|3|Progression-free survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care hormonal therapy","Progression-free survival (standard-of-care chemotherapy vs hormonal therapy)",1,3,"Standard-of-care hormonal therapy","reported","reported",2,-0.757259009187882,0.117304306542238,0,2020,0,264
"CD014872","CD014872_pub2_data","1|4|Progression-free survival (FDA/EMA approved vs not approved)|FDA/EMA approved","Progression-free survival (FDA/EMA approved vs not approved)",1,4,"FDA/EMA approved","reported","reported",12,-0.463961910267759,0.0556262586674447,0.0100293845371014,2020,0,270.25
"CD014872","CD014872_pub2_data","1|4|Progression-free survival (FDA/EMA approved vs not approved)|FDA/EMA not approved","Progression-free survival (FDA/EMA approved vs not approved)",1,4,"FDA/EMA not approved","reported","reported",2,-0.165456680888095,0.101031036194658,0,2020.5,0,302.5
"CD014872","CD014872_pub2_data","1|5|Overall survival|","Overall survival",1,5,"","reported","reported",14,-0.163968453170628,0.0653860518999837,0.0272939879096268,2020.11111111111,0,274.857142857143
"CD014872","CD014872_pub2_data","1|6|Overall survival (solid cancer vs haematological cancer)|Haematological cancer","Overall survival (solid cancer vs haematological cancer)",1,6,"Haematological cancer","reported","reported",4,-0.335656983545299,0.0879199984952036,0.0105240421954758,2019,0,322.75
"CD014872","CD014872_pub2_data","1|6|Overall survival (solid cancer vs haematological cancer)|Solid cancer","Overall survival (solid cancer vs haematological cancer)",1,6,"Solid cancer","reported","reported",10,-0.0665162645206211,0.0719952569809744,0.0140601535179544,2020.42857142857,0,255.7
"CD014872","CD014872_pub2_data","1|7|Overall survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care chemotherapy","Overall survival (standard-of-care chemotherapy vs hormonal therapy)",1,7,"Standard-of-care chemotherapy","reported","reported",13,-0.151101933521927,0.0687230519624007,0.0293412011714268,2020.125,0,255.384615384615
"CD014872","CD014872_pub2_data","1|7|Overall survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care hormonal therapy","Overall survival (standard-of-care chemotherapy vs hormonal therapy)",1,7,"Standard-of-care hormonal therapy","reported","reported",2,-0.384501448713036,0.221541448329088,0,2020,0,264
"CD014872","CD014872_pub2_data","1|8|Overall survival (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Overall survival (FDA/EMA-approved vs not approved)",1,8,"FDA/EMA-approved","reported","reported",12,-0.160575596954088,0.0774866510365586,0.0372467856497477,2020,0,270.25
"CD014872","CD014872_pub2_data","1|8|Overall survival (FDA/EMA-approved vs not approved)|FDA/EMA-not approved","Overall survival (FDA/EMA-approved vs not approved)",1,8,"FDA/EMA-not approved","reported","reported",2,-0.185350666601087,0.117467998414622,0.00313014545,2020.5,0,302.5
"CD014872","CD014872_pub2_data","1|9|Overall response rate|","Overall response rate",1,9,"","reported","reported",6,0,0.189032941056502,0,2021.25,0.204718716081258,223.833333333333
"CD014872","CD014872_pub2_data","2|1|Progression-free survival|","Progression-free survival",2,1,"","reported","reported",14,-0.490613306096876,0.0752702858773983,0.0277865706604056,2019.5,0,188.357142857143
"CD014872","CD014872_pub2_data","2|10|Overall response rate (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care chemotherapy","Overall response rate (standard-of-care chemotherapy vs hormonal therapy)",2,10,"Standard-of-care chemotherapy","reported","reported",2,0,0.196296357445396,0,2018.5,0.05,18.5
"CD014872","CD014872_pub2_data","2|11|Overall response rate (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Overall response rate (FDA/EMA-approved vs not approved)",2,11,"FDA/EMA-approved","reported","reported",2,0,0.330404298195179,0,2021,0.140243902439024,96.5
"CD014872","CD014872_pub2_data","2|12|Severe adverse events|","Severe adverse events",2,12,"","or","binary",5,0.986890609481225,0.242043605514183,0.249314291902464,2018.33333333333,0.421552088797979,442.6
"CD014872","CD014872_pub2_data","2|14|Quality of life|","Quality of life",2,14,"","reported","reported",2,0,0.0735705867353715,0,NA,0,370
"CD014872","CD014872_pub2_data","2|2|Progression-free survival (standard-of-care-chemotherapy vs hormonal therapy)|Standard-of-care chemotherapy","Progression-free survival (standard-of-care-chemotherapy vs hormonal therapy)",2,2,"Standard-of-care chemotherapy","reported","reported",7,-0.299634467061121,0.0855362872833035,0,2018,0,123.142857142857
"CD014872","CD014872_pub2_data","2|2|Progression-free survival (standard-of-care-chemotherapy vs hormonal therapy)|Standard-of-care hormonal therapy","Progression-free survival (standard-of-care-chemotherapy vs hormonal therapy)",2,2,"Standard-of-care hormonal therapy","reported","reported",7,-0.602993717143681,0.0899073932154924,0.0232500545072658,2021.6,0,253.571428571429
"CD014872","CD014872_pub2_data","2|3|Progression-free survival (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Progression-free survival (FDA/EMA-approved vs not approved)",2,3,"FDA/EMA-approved","reported","reported",12,-0.519412384379656,0.0744645888202854,0.0236397634283685,2019.6,0,214.75
"CD014872","CD014872_pub2_data","2|3|Progression-free survival (FDA/EMA-approved vs not approved)|FDA/EMA-not approved","Progression-free survival (FDA/EMA-approved vs not approved)",2,3,"FDA/EMA-not approved","reported","reported",2,0.0237960225244434,0.289488486540606,0,2019,0,30
"CD014872","CD014872_pub2_data","2|4|Sensitivity analysis: Progression-free survival|","Sensitivity analysis: Progression-free survival",2,4,"","reported","reported",8,-0.520263316999437,0.129731825805695,0.0536854139532536,2020.57142857143,0,120.625
"CD014872","CD014872_pub2_data","2|5|Overall survival|","Overall survival",2,5,"","reported","reported",11,-0.232857261846927,0.0566076447428814,0,2019.33333333333,0,234.090909090909
"CD014872","CD014872_pub2_data","2|6|Overall survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care chemotherapy","Overall survival (standard-of-care chemotherapy vs hormonal therapy)",2,6,"Standard-of-care chemotherapy","reported","reported",5,-0.167528328836694,0.0807836425370375,0,2016.8,0,164.2
"CD014872","CD014872_pub2_data","2|6|Overall survival (standard-of-care chemotherapy vs hormonal therapy)|Standard-of-care hormonal therapy","Overall survival (standard-of-care chemotherapy vs hormonal therapy)",2,6,"Standard-of-care hormonal therapy","reported","reported",6,-0.301767044443303,0.0846751045065483,0.00470874238039636,2022.5,0,292.333333333333
"CD014872","CD014872_pub2_data","2|7|Overall survival (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Overall survival (FDA/EMA-approved vs not approved)",2,7,"FDA/EMA-approved","reported","reported",9,-0.223723785087031,0.0591678708757846,8.26174271027975e-07,2019.42857142857,0,279.222222222222
"CD014872","CD014872_pub2_data","2|7|Overall survival (FDA/EMA-approved vs not approved)|FDA/EMA-not approved","Overall survival (FDA/EMA-approved vs not approved)",2,7,"FDA/EMA-not approved","reported","reported",2,-0.331664364087669,0.194587026181405,0,2019,0,31
"CD014872","CD014872_pub2_data","2|8|Sensitivity analysis: Overall survival|","Sensitivity analysis: Overall survival",2,8,"","reported","reported",6,-0.317474028760521,0.130139216779206,0.0364366407972615,2020.6,0,153.666666666667
"CD014872","CD014872_pub2_data","2|9|Overall response rate|","Overall response rate",2,9,"","reported","reported",3,0,0.0527575666678476,0,2018.5,0.075968992248062,126
"CD014872","CD014872_pub2_data","3|1|Progression-free survival |","Progression-free survival ",3,1,"","reported","reported",3,-0.276725305352979,0.0906362128667083,0.00310326392758599,2018.33333333333,0,522.666666666667
"CD014872","CD014872_pub2_data","3|2|Progression-free survival (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Progression-free survival (FDA/EMA-approved vs not approved)",3,2,"FDA/EMA-approved","reported","reported",2,-0.341454835180393,0.0994095811696953,0,2020,0,676
"CD014872","CD014872_pub2_data","3|4|Overall response rate|","Overall response rate",3,4,"","reported","reported",3,0,0.151327998054624,0,2018.33333333333,0.0819901826731525,503
"CD014872","CD014872_pub2_data","3|5|Overall response rate (FDA/EMA-approved vs not approved)|FDA/EMA-approved","Overall response rate (FDA/EMA-approved vs not approved)",3,5,"FDA/EMA-approved","reported","reported",2,0,0.130095038246966,0,2020,0.106131341425459,661
"CD014872","CD014872_pub2_data","4|1|Progression-free survival|","Progression-free survival",4,1,"","reported","reported",4,-0.991084735838697,0.148999685293195,0.0407926196863389,2014.75,0,214.5
"CD014872","CD014872_pub2_data","4|2|Overall survival|","Overall survival",4,2,"","reported","reported",3,-0.128470804071725,0.0953771927080657,0,2015,0,261
"CD014872","CD014872_pub2_data","4|4|Severe adverse events|","Severe adverse events",4,4,"","or","binary",2,1.24533746511795,2.45380528803057,11.0301302983679,2014,0.364406779661017,211.5
"CD014889","CD014889_pub2_data","1|1|All-cause mortality|NA","All-cause mortality",1,1,NA,"or","binary",6,-0.886816606373102,0.299313134562325,0,2014.16666666667,0.169761904761905,65
"CD014889","CD014889_pub2_data","1|4|Sepsis or mediastinitis|NA","Sepsis or mediastinitis",1,4,NA,"or","binary",6,-1.29862070132122,0.283703402767209,0,2014.16666666667,0.309285714285714,65
"CD014889","CD014889_pub2_data","1|5|Esophageal stricture|NA","Esophageal stricture",1,5,NA,"or","binary",2,-0.360436647823942,0.639654962575835,0.325980433619225,2015,0.21375,57
"CD014891","CD014891_pub2_data","1|1|Uncorrected distance visual acuity worse than 6/6|","Uncorrected distance visual acuity worse than 6/6",1,1,"","or","binary",2,0.206119305543352,0.274844709036462,0,2020,0.563636363636364,127
"CD014891","CD014891_pub2_data","1|12|Contrast sensitivity under photopic and mesopic conditions|","Contrast sensitivity under photopic and mesopic conditions",1,12,"","or","binary",2,0.071458963982145,1.43927752558627,0,2020,0,27
"CD014891","CD014891_pub2_data","1|16|Any adverse outcome: posterior capsular opacification (PCO)|","Any adverse outcome: posterior capsular opacification (PCO)",1,16,"","or","binary",2,0.0697866754498299,1.04472649887185,0,2020,0.0357142857142857,33
"CD014891","CD014891_pub2_data","1|2|Corrected distance visual acuity worse than 6/6 |","Corrected distance visual acuity worse than 6/6 ",1,2,"","or","binary",2,0.0425603786974534,0.302933184162224,0,2020,0.322727272727273,127
"CD014891","CD014891_pub2_data","1|3|Uncorrected distance visual acuity (logMAR)|","Uncorrected distance visual acuity (logMAR)",1,3,"","or","binary",2,0.035321017740499,1.4310268698868,0,2018.5,0,53.5
"CD014891","CD014891_pub2_data","1|6|Uncorrected near visual acuity (logMAR)|","Uncorrected near visual acuity (logMAR)",1,6,"","or","binary",2,0.035321017740499,1.4310268698868,0,2018.5,0,53.5
"CD014891","CD014891_pub2_data","1|9|Uncorrected intermediate visual acuity (logMAR)|","Uncorrected intermediate visual acuity (logMAR)",1,9,"","or","binary",2,0.035321017740499,1.4310268698868,0,2018.5,0,53.5
"CD014914","CD014914_pub2_data","1|1|Proportion of participants developing colds/URTI: primary analysis|","Proportion of participants developing colds/URTI: primary analysis",1,1,"","reported","reported",9,0.907161412085808,0.0398563563115048,0.00222037546973553,2000.66666666667,0.677494543696415,161
"CD014914","CD014914_pub2_data","10|1|Risk of ongoing cold/URTIs at end of study (treatment): primary analysis|","Risk of ongoing cold/URTIs at end of study (treatment): primary analysis",10,1,"","reported","reported",5,0.306164039720294,0.109600870615393,0,1999.6,0.277696299572461,71.4
"CD014914","CD014914_pub2_data","11|1|Adverse events (treatment): primary analysis|","Adverse events (treatment): primary analysis",11,1,"","reported","reported",16,1.15322461926457,0.050265878455098,0.000394612618599259,2000.5,0.329795206952968,130.25
"CD014914","CD014914_pub2_data","11|2|Subgroup analysis (treatment): intranasal vs lozenge|Lozenge","Subgroup analysis (treatment): intranasal vs lozenge",11,2,"Lozenge","reported","reported",3,0,0.172216716429556,0,1998.66666666667,0.295359611149085,80.6666666666667
"CD014914","CD014914_pub2_data","11|3|Subgroup analysis (treatment): zinc acetate vs zinc gluconate|Zinc gluconate","Subgroup analysis (treatment): zinc acetate vs zinc gluconate",11,3,"Zinc gluconate","reported","reported",2,0,0.232996722530621,0,1988,0.288277511961722,77
"CD014914","CD014914_pub2_data","11|4|Subgroup analysis (treatment): daily dose of zinc|< 85 mg/d","Subgroup analysis (treatment): daily dose of zinc",11,4,"< 85 mg/d","reported","reported",9,1.11278599818036,0.0538696603164419,0,2002.66666666667,0.301740262052253,176
"CD014914","CD014914_pub2_data","11|4|Subgroup analysis (treatment): daily dose of zinc|> 85 mg/d","Subgroup analysis (treatment): daily dose of zinc",11,4,"> 85 mg/d","reported","reported",7,1.33111509884458,0.126457896521623,0.00804117688721543,1997.71428571429,0.365865850396743,71.4285714285714
"CD014914","CD014914_pub2_data","11|5|Subgroup analysis (treatment): age groupings|< 18 yo","Subgroup analysis (treatment): age groupings",11,5,"< 18 yo","reported","reported",2,1.10974030974179,0.0629762278543016,0,2005,0.413543859649123,181.5
"CD014914","CD014914_pub2_data","11|5|Subgroup analysis (treatment): age groupings|> 18 yo","Subgroup analysis (treatment): age groupings",11,5,"> 18 yo","reported","reported",13,1.21276941261937,0.0855992653853556,0.00736770717250561,2000.61538461538,0.325557252892416,122.384615384615
"CD014914","CD014914_pub2_data","12|1|Standardised mean global symptom severity (treatment)|","Standardised mean global symptom severity (treatment)",12,1,"","reported","reported",2,-0.0286445135381908,0.271297712243191,0.114926227015565,1999.5,NA,130.5
"CD014914","CD014914_pub2_data","14|1|Cough (continuous) (treatment)|","Cough (continuous) (treatment)",14,1,"","reported","reported",6,-1.6698889052451,0.627429325115028,1.45745235412725,2000.5,NA,89.5
"CD014914","CD014914_pub2_data","14|10|Sneezing (continuous) (treatment)|","Sneezing (continuous) (treatment)",14,10,"","reported","reported",6,-0.771153017370923,0.277197148402944,0,2000.5,NA,90.5
"CD014914","CD014914_pub2_data","14|11|Sore throat (continuous) (treatment)|","Sore throat (continuous) (treatment)",14,11,"","reported","reported",6,-0.875521993831451,0.35836795387342,0.433940404473825,2000.5,NA,85.6666666666667
"CD014914","CD014914_pub2_data","14|2|Fever (continuous) (treatment)|","Fever (continuous) (treatment)",14,2,"","reported","reported",5,-0.287806099269299,0.252923111671529,0.124071454435236,2001,NA,75.2
"CD014914","CD014914_pub2_data","14|3|Headache (continuous) (treatment)|","Headache (continuous) (treatment)",14,3,"","reported","reported",6,-0.49411473981001,0.241379580791929,0,2000.5,NA,81.3333333333333
"CD014914","CD014914_pub2_data","14|4|Hoarseness (continuous) (treatment)|","Hoarseness (continuous) (treatment)",14,4,"","reported","reported",6,-0.942017397911459,0.483956241587742,0.719118526537863,2000.5,NA,82.1666666666667
"CD014914","CD014914_pub2_data","14|6|Muscle aches (continuous) (treatment)|","Muscle aches (continuous) (treatment)",14,6,"","reported","reported",6,-0.665399516264946,0.271962463047985,0.0804091411614169,2000.5,NA,73.5
"CD014914","CD014914_pub2_data","14|7|Nasal congestion (continuous) (treatment)|","Nasal congestion (continuous) (treatment)",14,7,"","reported","reported",6,-1.40624138204652,0.394618021907733,0.259166453433317,2000.5,NA,98
"CD014914","CD014914_pub2_data","14|8|Nasal drainage (continuous) (treatment)|","Nasal drainage (continuous) (treatment)",14,8,"","reported","reported",6,-1.74887085753853,0.522402162115075,1.04685461131479,2000.5,NA,97
"CD014914","CD014914_pub2_data","15|1|Cough (dichotomous) (treatment)|","Cough (dichotomous) (treatment)",15,1,"","reported","reported",2,0.409581551829486,0.210209955559663,0,1988,0.356811145510836,53
"CD014914","CD014914_pub2_data","15|10|Sore throat (dichotomous) (treatment)|","Sore throat (dichotomous) (treatment)",15,10,"","reported","reported",2,0.119037993999503,0.239699947143136,0,1988,0.208881578947368,57
"CD014914","CD014914_pub2_data","15|3|Headache (dichotomous) (treatment)|","Headache (dichotomous) (treatment)",15,3,"","reported","reported",2,0.2457191008408,0.403269411227,0,1988,0.143962848297214,55.5
"CD014914","CD014914_pub2_data","15|4|Hoarseness (dichotomous) (treatment)|","Hoarseness (dichotomous) (treatment)",15,4,"","reported","reported",2,0.173403870442363,0.278052871577963,0,1988,0.178362573099415,57.5
"CD014914","CD014914_pub2_data","15|5|Muscle aches (dichotomous) (treatment)|","Muscle aches (dichotomous) (treatment)",15,5,"","reported","reported",2,0.162937583559161,0.312848413152861,0,1988,0.179824561403509,52
"CD014914","CD014914_pub2_data","15|6|Nasal congestion (dichotomous) (treatment)|","Nasal congestion (dichotomous) (treatment)",15,6,"","reported","reported",2,0.338597392940946,0.168697330001349,0,1988,0.345394736842105,59.5
"CD014914","CD014914_pub2_data","15|7|Nasal drainage (dichotomous) (treatment)|","Nasal drainage (dichotomous) (treatment)",15,7,"","reported","reported",2,0.358737612390369,0.142215389940162,0,1988,0.415570175438596,62
"CD014914","CD014914_pub2_data","15|8|Scratchy throat (dichotomous) (treatment)|","Scratchy throat (dichotomous) (treatment)",15,8,"","reported","reported",2,0.163106211128699,0.293146337727142,0,1988,0.169172932330827,58
"CD014914","CD014914_pub2_data","15|9|Sneezing (dichotomous) (treatment)|","Sneezing (dichotomous) (treatment)",15,9,"","reported","reported",2,0.408097678463568,0.4048723099117,0,1988,0.171052631578947,55
"CD014914","CD014914_pub2_data","2|1|Mean number of colds/URTIs developed: primary analysis|","Mean number of colds/URTIs developed: primary analysis",2,1,"","reported","reported",2,-0.904511033821349,0.524913840773559,0.530842754762468,2012,NA,642
"CD014914","CD014914_pub2_data","3|1|Mean duration of colds/URTIs (prevention): primary analysis |","Mean duration of colds/URTIs (prevention): primary analysis ",3,1,"","reported","reported",3,-0.684139625482869,0.454832065655775,0.505578545365512,2010.33333333333,NA,246.666666666667
"CD014914","CD014914_pub2_data","4|1|Adverse events (prevention): primary analysis|","Adverse events (prevention): primary analysis",4,1,"","reported","reported",6,1.0454015269745,0.160606998286274,0,2000.5,0.161428571428571,115.166666666667
"CD014914","CD014914_pub2_data","4|2|Serious adverse events (prevention): primary analysis|","Serious adverse events (prevention): primary analysis",4,2,"","reported","reported",2,1.62347089079928,0.714242503497471,0,2014.5,0.00827814569536424,736
"CD014914","CD014914_pub2_data","5|1|Standardised mean global symptom severity (prevention)|","Standardised mean global symptom severity (prevention)",5,1,"","reported","reported",2,0.0416092003541099,0.199687357124799,0,1994,NA,50.5
"CD014914","CD014914_pub2_data","7|1|Cough (continuous) (prevention)|","Cough (continuous) (prevention)",7,1,"","reported","reported",2,-1.8370694769024,1.82334157187123,5.61953079668146,2009.5,NA,147
"CD014914","CD014914_pub2_data","7|2|Nasal drainage (continuous) (prevention)|","Nasal drainage (continuous) (prevention)",7,2,"","reported","reported",2,-1.89862240607632,2.01966180002703,6.90775594042208,2009.5,NA,147
"CD014914","CD014914_pub2_data","7|3|Fever (continuous) (prevention)|","Fever (continuous) (prevention)",7,3,"","reported","reported",2,-0.0922557139455594,0.17253393209698,0,2009.5,NA,147
"CD014914","CD014914_pub2_data","8|2|Mean days missed from work or school (prevention)|","Mean days missed from work or school (prevention)",8,2,"","reported","reported",2,-0.648446220345364,0.194043716039063,0.0167011143397283,2007.5,NA,197
"CD014914","CD014914_pub2_data","9|1|Mean duration of colds/URTIs (treatment): primary analysis|","Mean duration of colds/URTIs (treatment): primary analysis",9,1,"","reported","reported",8,-2.38903416711606,0.780089719498291,4.5869334799835,2000,NA,121.5
"CD014914","CD014914_pub2_data","9|2|Subgroup analysis (treatment): all administration routes|Intranasal","Subgroup analysis (treatment): all administration routes",9,2,"Intranasal","reported","reported",3,-3.16078200890314,1.89548343407115,10.5457614163743,2001.33333333333,NA,150.333333333333
"CD014914","CD014914_pub2_data","9|2|Subgroup analysis (treatment): all administration routes|Lozenge","Subgroup analysis (treatment): all administration routes",9,2,"Lozenge","reported","reported",5,-1.9471112948676,0.642788063189872,1.7629465589247,1999.2,NA,104.2
"CD014914","CD014914_pub2_data","9|3|Subgroup analysis (treatment): daily dose of zinc|< 85 mg/d","Subgroup analysis (treatment): daily dose of zinc",9,3,"< 85 mg/d","reported","reported",4,-2.3973882960435,1.56468764103898,9.46034551627601,2000.5,NA,175
"CD014914","CD014914_pub2_data","9|3|Subgroup analysis (treatment): daily dose of zinc|> 85 mg/d","Subgroup analysis (treatment): daily dose of zinc",9,3,"> 85 mg/d","reported","reported",4,-2.36051996521903,0.600686556629108,1.21331424107698,1999.5,NA,68
"CD014920","CD014920_pub2_data","1|1|Acute myocardial infarction (short term < 30 days)|NA","Acute myocardial infarction (short term < 30 days)",1,1,NA,"or","binary",2,-1.2624981121746,1.33650594823144,2.74701439344071,2007,0.0931585292344786,444
"CD014920","CD014920_pub2_data","1|3|All-cause mortality (perioperative)|NA","All-cause mortality (perioperative)",1,3,NA,"or","binary",2,-0.229019637922291,0.484361765535348,0,2007,0.0216395418927064,444
"CD014920","CD014920_pub2_data","1|4|All-cause mortality (long term)|NA","All-cause mortality (long term)",1,4,NA,"or","binary",2,-0.309988239645083,0.492034334072,0.399328915849745,2007,0.198493068113321,444
"CD014923","CD014923_pub2_data","1|1|Gait speed - unpaired, parallel assessment < 12 months|NA","Gait speed - unpaired, parallel assessment < 12 months",1,1,NA,"or","binary",3,-0.119248867305966,1.18066599778051,0,2018,0,38.6666666666667
"CD014923","CD014923_pub2_data","1|2|Gait speed -  paired assessment < 12 months|NA","Gait speed -  paired assessment < 12 months",1,2,NA,"or","binary",3,0.0951889980188591,1.18332153993942,0,2018,0,34.3333333333333
"CD014923","CD014923_pub2_data","3|2|Patient disability - functionally independent (unpaired, parallel assessment < 12 months)|NA","Patient disability - functionally independent (unpaired, parallel assessment < 12 months)",3,2,NA,"or","binary",3,1.26489530487743,0.402103314023752,0,2018,0.152777777777778,39.3333333333333
"CD014923","CD014923_pub2_data","3|3|Patient disability - number of participants who improved  (paired assessment < 12 months)|NA","Patient disability - number of participants who improved  (paired assessment < 12 months)",3,3,NA,"or","binary",2,0.917529956047954,0.811515830560132,0,2019.5,0.166666666666667,15
"CD014923","CD014923_pub2_data","3|4|Patient disability - functionally independent (paired assessment < 12 months)|NA","Patient disability - functionally independent (paired assessment < 12 months)",3,4,NA,"or","binary",2,1.1590308799749,0.932443188369508,0,2019.5,0.0555555555555556,15
"CD014923","CD014923_pub2_data","5|1|General cognitive screening - unpaired, parallel assessment < 6 months|NA","General cognitive screening - unpaired, parallel assessment < 6 months",5,1,NA,"or","binary",2,-0.0460075006641899,1.43839817734078,0,2019,0,52
"CD014923","CD014923_pub2_data","5|2|General cognitive screening - paired assessment < 12 months|NA","General cognitive screening - paired assessment < 12 months",5,2,NA,"or","binary",2,0.139003138446441,1.44023316736112,0,2019,0,46.5
"CD014923","CD014923_pub2_data","5|3|Symbol Digit Tests - unpaired, parallel assessment < 6 months|NA","Symbol Digit Tests - unpaired, parallel assessment < 6 months",5,3,NA,"or","binary",2,-0.0425941292393847,1.43936218044701,0,2019,0,43.5
"CD014923","CD014923_pub2_data","5|4|Symbol Digit Tests - paired assessment < 12 months|NA","Symbol Digit Tests - paired assessment < 12 months",5,4,NA,"or","binary",2,0.124175921438476,1.44121877145178,0,2019,0,39.5
"CD014932","CD014932_pub2_data","2|1|Long-term reduction in disease severity, as measured by clinical signs (SCORAD) across all age groups|","Long-term reduction in disease severity, as measured by clinical signs (SCORAD) across all age groups",2,1,"","or","binary",5,-0.156983257818,0.897484427271417,0,2009.6,0,284.8
"CD014932","CD014932_pub2_data","2|2|Short-term reduction in disease severity, as measured by clinical signs (SCORAD)|Short Term Reduction in disease severity, as measured by clinical signs, unspecified age- SCORAD","Short-term reduction in disease severity, as measured by clinical signs (SCORAD)",2,2,"Short Term Reduction in disease severity, as measured by clinical signs, unspecified age- SCORAD","or","binary",3,-0.0865432990734698,1.15963023469247,0,2013,0,243.666666666667
"CD014932","CD014932_pub2_data","2|3|Reduction in disease severity, as measured by patient-reported symptoms|","Reduction in disease severity, as measured by patient-reported symptoms",2,3,"","or","binary",4,-0.123087301849032,1.00343363231361,0,2008.5,0,227
"CD014932","CD014932_pub2_data","2|5|Improvement in quality-of-life measures: family impact| Improvement in quality-of-life measures-Family-impact","Improvement in quality-of-life measures: family impact",2,5," Improvement in quality-of-life measures-Family-impact","or","binary",2,-0.0482235743728403,1.42263271251464,0,2011,0,94.5
"CD014932","CD014932_pub2_data","2|5|Improvement in quality-of-life measures: family impact|Improvement in Quality of Life Measures- Infants-IDLQI","Improvement in quality-of-life measures: family impact",2,5,"Improvement in Quality of Life Measures- Infants-IDLQI","or","binary",2,-0.0321634722122592,1.42425640565849,0,2011.5,0,183.5
"CD014932","CD014932_pub2_data","2|5|Improvement in quality-of-life measures: family impact|Improvement in Quality of Life Measures -Children-CDLQI","Improvement in quality-of-life measures: family impact",2,5,"Improvement in Quality of Life Measures -Children-CDLQI","or","binary",3,0.214398111172013,1.16796103572316,0,2012.66666666667,0,83.6666666666667
"CD014932","CD014932_pub2_data","3|2|Reduction in disease severity, as measured by patient-reported symptoms (POEM)|Reduction in disease severity as measured by patient-POEM-unspecified age","Reduction in disease severity, as measured by patient-reported symptoms (POEM)",3,2,"Reduction in disease severity as measured by patient-POEM-unspecified age","or","binary",2,0.0532164486476316,1.42139957947539,0,2017.5,0,97.5
"CD014932","CD014932_pub2_data","3|3|Improvement in quality-of-life measures|Improvement in quality of life measures- Health related quality of life-unspecified age","Improvement in quality-of-life measures",3,3,"Improvement in quality of life measures- Health related quality of life-unspecified age","or","binary",2,0.0560078020518918,1.41901288521033,0,2018,0,215
"CD014935","CD014935_pub2_data","1|10|Days of hospitalisation - Sensitivity analysis (fixed-effect model)|NA","Days of hospitalisation - Sensitivity analysis (fixed-effect model)",1,10,NA,"or","binary",3,0.0145761313439768,1.17045045170476,0,2003,0,41
"CD014935","CD014935_pub2_data","1|4|Serious adverse events|NA","Serious adverse events",1,4,NA,"reported","reported",2,0,0.627392238633462,0,1997.5,0.268774703557312,33.5
"CD014935","CD014935_pub2_data","1|5|Serious adverse events - Sensitivity Analysis (fixed-effect model)|NA","Serious adverse events - Sensitivity Analysis (fixed-effect model)",1,5,NA,"reported","reported",2,0,0.583663109643529,0,1997.5,0.268774703557312,33.5
"CD014935","CD014935_pub2_data","1|6|Serious adverse events - Sensitivity Analysis (best-case scenario)|NA","Serious adverse events - Sensitivity Analysis (best-case scenario)",1,6,NA,"reported","reported",2,0,0.601316169731346,0,1997.5,0.314229249011858,33.5
"CD014935","CD014935_pub2_data","1|7|Serious adverse events - Sensitivity Analysis (worst-case scenario)|NA","Serious adverse events - Sensitivity Analysis (worst-case scenario)",1,7,NA,"reported","reported",2,0,0.570903953329556,0,1997.5,0.268774703557312,33.5
"CD014935","CD014935_pub2_data","1|9|Days of hospitalisation|NA","Days of hospitalisation",1,9,NA,"reported","reported",2,0,0.78645073490831,0,1997.5,0,33.5
"CD014937","CD014937_pub2_data","1|1|Acute kidney injury|","Acute kidney injury",1,1,"","reported","reported",31,0,0.0838835845041732,0,2011.32258064516,0.312488768155967,160.387096774194
"CD014937","CD014937_pub2_data","1|10|Sensitivity analysis: acute kidney injury (placebo-controlled studies)|","Sensitivity analysis: acute kidney injury (placebo-controlled studies)",1,10,"","reported","reported",16,0,0.113526861181324,0,2010.0625,0.357473728731096,150.5625
"CD014937","CD014937_pub2_data","1|11|Sensitivity analysis: acute kidney injury (excluding kidney transplantation)|","Sensitivity analysis: acute kidney injury (excluding kidney transplantation)",1,11,"","reported","reported",29,0,0.0877609249332549,0,2013,0.30060189114269,162.413793103448
"CD014937","CD014937_pub2_data","1|12|Subgroup analysis: acute kidney injury by population|Cardiac-related procedures","Subgroup analysis: acute kidney injury by population",1,12,"Cardiac-related procedures","reported","reported",23,0,0.0658656261321878,0,2013.26086956522,0.301579254965612,145.826086956522
"CD014937","CD014937_pub2_data","1|12|Subgroup analysis: acute kidney injury by population|Critical care","Subgroup analysis: acute kidney injury by population",1,12,"Critical care","reported","reported",5,0,0.3172016650252,0,2017.6,0.369045972753838,78.2
"CD014937","CD014937_pub2_data","1|12|Subgroup analysis: acute kidney injury by population|Non-cardiac-related procedures","Subgroup analysis: acute kidney injury by population",1,12,"Non-cardiac-related procedures","reported","reported",7,0,0.0357828576518053,0,2008.85714285714,0.40213240478088,93.2857142857143
"CD014937","CD014937_pub2_data","1|12|Subgroup analysis: acute kidney injury by population|Procedures with contrast media","Subgroup analysis: acute kidney injury by population",1,12,"Procedures with contrast media","reported","reported",4,0,0.182426946335622,0,2011.25,0.162593388977488,335.25
"CD014937","CD014937_pub2_data","1|12|Subgroup analysis: acute kidney injury by population|Surgery","Subgroup analysis: acute kidney injury by population",1,12,"Surgery","reported","reported",18,0,0.109792850147247,0,2010.55555555556,0.356527917790172,141.833333333333
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Acetazolamide","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Acetazolamide","reported","reported",2,0,0.294967247788792,0,2014.5,0.298717948717949,160
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Furosemide","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Furosemide","reported","reported",11,0,0.144793220571611,0,2016.27272727273,0.263462623856338,190.818181818182
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Furosemide with RenalGuard","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Furosemide with RenalGuard","reported","reported",4,0,0.169099366842869,0,2019,0.164843557819728,301
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Furosemide without RenalGuard","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Furosemide without RenalGuard","reported","reported",8,0,0.208475710630531,0,2012.125,0.329839328892601,116.25
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Mannitol","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Mannitol","reported","reported",4,0,0.257074553701541,0,1997.25,0.352039627039627,87
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Natriuretic peptide","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Natriuretic peptide","reported","reported",12,0,0.142734835451888,0,2008.83333333333,0.37777520727007,134.833333333333
"CD014937","CD014937_pub2_data","1|13|Subgroup analysis: acute kidney injury by type of diuretic|Spironolactone","Subgroup analysis: acute kidney injury by type of diuretic",1,13,"Spironolactone","reported","reported",2,0,0.268071033518426,0,2014.5,0.171278680963911,263.5
"CD014937","CD014937_pub2_data","1|14|Subgroup analysis: acute kidney injury by definition|KDIGO","Subgroup analysis: acute kidney injury by definition",1,14,"KDIGO","reported","reported",9,0,0.159849750566774,0,2018,0.443103622177794,123.444444444444
"CD014937","CD014937_pub2_data","1|15|Subgroup analysis: acute kidney injury by age|Acute kidney injury (≥ 16 years)","Subgroup analysis: acute kidney injury by age",1,15,"Acute kidney injury (≥ 16 years)","reported","reported",32,0,0.0834784789793946,0,2011.5,0.314442244151093,156.875
"CD014937","CD014937_pub2_data","1|17|Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)|","Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)",1,17,"","reported","reported",5,0,0.453579939130269,0,2021.6,0.0122229628395267,243.4
"CD014937","CD014937_pub2_data","1|18|Sensitivity analysis: any use of KRT (placebo-controlled studies)|","Sensitivity analysis: any use of KRT (placebo-controlled studies)",1,18,"","reported","reported",2,0,1.12299896156577,0,2015.5,0,62
"CD014937","CD014937_pub2_data","1|19|Sensitivity analysis: any use of KRT (excluding kidney transplantation)|","Sensitivity analysis: any use of KRT (excluding kidney transplantation)",1,19,"","reported","reported",3,0,0.503194278948164,0,2017.66666666667,0.0203716047325446,295.333333333333
"CD014937","CD014937_pub2_data","1|2|Any use of kidney replacement therapy|","Any use of kidney replacement therapy",1,2,"","reported","reported",3,0,0.503194278948164,0,2017.66666666667,0.0203716047325446,295.333333333333
"CD014937","CD014937_pub2_data","1|20|Subgroup analysis: any use of KRT by population|Critical care","Subgroup analysis: any use of KRT by population",1,20,"Critical care","reported","reported",4,0,0.441799819917056,0,2017.5,0.0470265533467781,87
"CD014937","CD014937_pub2_data","1|20|Subgroup analysis: any use of KRT by population|Procedures with contrast media","Subgroup analysis: any use of KRT by population",1,20,"Procedures with contrast media","reported","reported",4,0,0.416275800070626,0,2015.75,0.0389928207660524,304.5
"CD014937","CD014937_pub2_data","1|20|Subgroup analysis: any use of KRT by population|Surgery","Subgroup analysis: any use of KRT by population",1,20,"Surgery","reported","reported",12,0,0.284113943080835,0,2011.58333333333,0.0831186806158459,152.166666666667
"CD014937","CD014937_pub2_data","1|21|Subgroup analysis: any use of KRT by type of diuretic|Furosemide","Subgroup analysis: any use of KRT by type of diuretic",1,21,"Furosemide","reported","reported",6,0,0.351524369791339,0,2016.5,0.0348146953390832,232.833333333333
"CD014937","CD014937_pub2_data","1|21|Subgroup analysis: any use of KRT by type of diuretic|Furosemide with RenalGuard","Subgroup analysis: any use of KRT by type of diuretic",1,21,"Furosemide with RenalGuard","reported","reported",3,0,0.537697908728492,0,2020.33333333333,0.0256626100235499,364
"CD014937","CD014937_pub2_data","1|21|Subgroup analysis: any use of KRT by type of diuretic|Furosemide without RenalGuard","Subgroup analysis: any use of KRT by type of diuretic",1,21,"Furosemide without RenalGuard","reported","reported",3,0,0.464546979999676,0,2012.66666666667,0.0439667806546165,101.666666666667
"CD014937","CD014937_pub2_data","1|21|Subgroup analysis: any use of KRT by type of diuretic|Mannitol","Subgroup analysis: any use of KRT by type of diuretic",1,21,"Mannitol","reported","reported",2,0,0.535290863704094,0,2015,0.101170568561873,71.5
"CD014937","CD014937_pub2_data","1|21|Subgroup analysis: any use of KRT by type of diuretic|Natriuretic peptide","Subgroup analysis: any use of KRT by type of diuretic",1,21,"Natriuretic peptide","reported","reported",10,0,0.315742216628571,0,2010.2,0.0947185993024359,149
"CD014937","CD014937_pub2_data","1|22|Subgroup analysis: any use of KRT by age|Age ≥ 16 years","Subgroup analysis: any use of KRT by age",1,22,"Age ≥ 16 years","reported","reported",20,0,0.210173078970591,0,2013.6,0.0670750831920736,169.6
"CD014937","CD014937_pub2_data","1|3|Death|","Death",1,3,"","or","binary",33,-0.37488623627253,0.130916811175442,0,2013.27272727273,0.0799555240765469,195.363636363636
"CD014937","CD014937_pub2_data","1|4|Permanent dialysis|","Permanent dialysis",1,4,"","or","binary",2,-0.593601792428003,0.925075267636884,0.431632143293895,2021,0.0121857997212105,478
"CD014937","CD014937_pub2_data","1|5|Adverse events|Arrhythmia","Adverse events",1,5,"Arrhythmia","reported","reported",11,0,0.0888899557262042,0,2013.90909090909,0.222222096945898,284.454545454545
"CD014937","CD014937_pub2_data","1|5|Adverse events|Hypokalaemia","Adverse events",1,5,"Hypokalaemia","reported","reported",6,0,0.0992641980464261,0,2017.83333333333,0.226414285504973,230.5
"CD014937","CD014937_pub2_data","1|5|Adverse events|Hypotension","Adverse events",1,5,"Hypotension","reported","reported",5,0,0.193836133555189,0,2010.6,0.133207586064729,112.6
"CD014937","CD014937_pub2_data","1|7|Urinary output|","Urinary output",1,7,"","or","binary",8,0.0589581282539525,0.711357355290893,0,2015,0,144.375
"CD014937","CD014937_pub2_data","1|9|Sensitivity analysis: acute kidney injury (overall risk of bias 'some concerns' or 'low')|","Sensitivity analysis: acute kidney injury (overall risk of bias 'some concerns' or 'low')",1,9,"","reported","reported",22,0,0.0321477405527635,0,2013.22727272727,0.325414048898597,171.5
"CD014937","CD014937_pub2_data","2|1|Any use of kidney replacement therapy|","Any use of kidney replacement therapy",2,1,"","reported","reported",3,0,0.295083118783289,0,1990.66666666667,0.366179031696273,110
"CD014937","CD014937_pub2_data","2|2|Death|","Death",2,2,"","or","binary",14,0.123375385895084,0.102022870840477,0,2002.35714285714,0.284288921787609,146.571428571429
"CD014937","CD014937_pub2_data","2|3|Adverse events|Arrhythmias","Adverse events",2,3,"Arrhythmias","reported","reported",5,0,0.186952007842932,0,2009,0.12880619009102,189
"CD014937","CD014937_pub2_data","2|3|Adverse events|Hypokalaemia","Adverse events",2,3,"Hypokalaemia","reported","reported",3,0,0.345373924434599,0,2011.66666666667,0.0897116628823946,159.333333333333
"CD014937","CD014937_pub2_data","2|3|Adverse events|Hypotension","Adverse events",2,3,"Hypotension","reported","reported",2,0,0.0709699541400943,0,1998.5,0.38844169246646,360
"CD014937","CD014937_pub2_data","2|4|Urinary output|","Urinary output",2,4,"","or","binary",3,0.00313378611790048,1.17157535996024,0,2010.66666666667,0,109.666666666667
"CD014937","CD014937_pub2_data","2|6|Sensitivity analysis: any use of KRT (placebo-controlled studies)|","Sensitivity analysis: any use of KRT (placebo-controlled studies)",2,6,"","reported","reported",2,0,0.324502172549457,0,1998,0.518965517241379,132
"CD014937","CD014937_pub2_data","2|7|Subgroup analysis: any use of KRT by population|Critical care","Subgroup analysis: any use of KRT by population",2,7,"Critical care","reported","reported",5,0,0.13942840541588,0,1996,0.396964693373362,190.2
"CD014937","CD014937_pub2_data","2|7|Subgroup analysis: any use of KRT by population|Surgery","Subgroup analysis: any use of KRT by population",2,7,"Surgery","reported","reported",3,0,0.323853751903726,0,2012.33333333333,0.255661696178938,108
"CD014937","CD014937_pub2_data","2|8|Subgroup analysis: any use of KRT by type of diuretic|Furosemide","Subgroup analysis: any use of KRT by type of diuretic",2,8,"Furosemide","reported","reported",4,0,0.31796025280746,0,2001,0.198109473109473,76.5
"CD014937","CD014937_pub2_data","2|8|Subgroup analysis: any use of KRT by type of diuretic|Natriuretic peptide","Subgroup analysis: any use of KRT by type of diuretic",2,8,"Natriuretic peptide","reported","reported",4,0,0.139914396971547,0,2003.25,0.489842665741433,242.25
"CD014941","CD014941_pub2_data","1|1|50% responder rate|","50% responder rate",1,1,"","or","binary",2,1.22361987158457,0.195577013581004,0,2020,0.235294117647059,302.5
"CD014941","CD014941_pub2_data","1|10|Cenobamate versus placebo - subgroup analysis, 50% responder rate|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, 50% responder rate",1,10,"Cenobamate 200 mg","or","binary",2,1.28944496980743,0.215657347006964,0,2020,0.235294117647059,204
"CD014941","CD014941_pub2_data","1|11|Cenobamate versus placebo - subgroup analysis, seizure freedom|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, seizure freedom",1,11,"Cenobamate 200 mg","or","binary",2,1.50844773836725,0.365873566727307,0,2020,0.0490196078431373,204
"CD014941","CD014941_pub2_data","1|12|Cenobamate versus placebo - subgroup analysis, any adverse event|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, any adverse event",1,12,"Cenobamate 200 mg","or","binary",2,0.460114075255156,0.212242747366164,0,2020,0.668365613319742,220
"CD014941","CD014941_pub2_data","1|13|Cenobamate versus placebo - subgroup analysis, ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline",1,13,"Cenobamate 200 mg","or","binary",2,1.06755803740797,0.244657230516433,0,2020,0.151960784313725,204
"CD014941","CD014941_pub2_data","1|14|Cenobamate versus placebo - subgroup analysis, ≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, ≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline",1,14,"Cenobamate 200 mg","or","binary",2,1.68280664587316,0.33175225117452,0,2020,0.0588235294117647,204
"CD014941","CD014941_pub2_data","1|16|Cenobamate versus placebo - subgroup analysis, withdrawal rate|Cenobatame 200 mg","Cenobamate versus placebo - subgroup analysis, withdrawal rate",1,16,"Cenobatame 200 mg","or","binary",2,0.25550473695654,0.287180678775778,0,2020,0.110686374447842,220
"CD014941","CD014941_pub2_data","1|17|Cenobamate versus placebo - subgroup analysis, any treatment-related adverse events|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, any treatment-related adverse events",1,17,"Cenobamate 200 mg","or","binary",2,1.37721474001384,0.458806480521108,0.334447877253275,2020,0.304706082229018,220
"CD014941","CD014941_pub2_data","1|18|Cenobamate versus placebo - subgroup analysis, any serious adverse event|Cenobamate 200 mg","Cenobamate versus placebo - subgroup analysis, any serious adverse event",1,18,"Cenobamate 200 mg","or","binary",2,-0.496463689456151,0.494399220216226,0,2020,0.0461264016309888,220
"CD014941","CD014941_pub2_data","1|19|Cenobamate versus placebo - sensitivity analysis, 50% responder rate (random-effects model)|","Cenobamate versus placebo - sensitivity analysis, 50% responder rate (random-effects model)",1,19,"","or","binary",2,1.22361987158457,0.195577013581004,0,2020,0.235294117647059,302.5
"CD014941","CD014941_pub2_data","1|2|Seizure freedom|Cenobamate (any dose)","Seizure freedom",1,2,"Cenobamate (any dose)","or","binary",2,1.52596172086603,0.362948431261101,0,2020,0.0490196078431373,302.5
"CD014941","CD014941_pub2_data","1|20|Cenobamate versus placebo - sensitivity analysis, seizure freedom (random-effects model)|Cenobamate (any dose)","Cenobamate versus placebo - sensitivity analysis, seizure freedom (random-effects model)",1,20,"Cenobamate (any dose)","or","binary",2,1.52596172086603,0.362948431261101,0,2020,0.0490196078431373,302.5
"CD014941","CD014941_pub2_data","1|21|Cenobamate versus placebo - sensitivity analysis, any adverse event (random-effects model) |Cenobamate (any dose)","Cenobamate versus placebo - sensitivity analysis, any adverse event (random-effects model) ",1,21,"Cenobamate (any dose)","or","binary",2,0.460858042600168,0.189378325255679,0,2020,0.668365613319742,329.5
"CD014941","CD014941_pub2_data","1|3|Any adverse event|Cenobamate (any dose)","Any adverse event",1,3,"Cenobamate (any dose)","or","binary",2,0.460858042600168,0.189378325255679,0,2020,0.668365613319742,329.5
"CD014941","CD014941_pub2_data","1|4| ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline|Cenobamate (any dose)"," ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline",1,4,"Cenobamate (any dose)","or","binary",2,1.09995641805956,0.246545689419853,0.0127095511068333,2020,0.151960784313725,302.5
"CD014941","CD014941_pub2_data","1|5|≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline|Cenobamate (any dose)","≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline",1,5,"Cenobamate (any dose)","or","binary",2,1.69709540265002,0.324673189656946,0,2020,0.0588235294117647,302.5
"CD014941","CD014941_pub2_data","1|6|Withdrawal from the study due to adverse events|Cenobamate (any dose)","Withdrawal from the study due to adverse events",1,6,"Cenobamate (any dose)","or","binary",2,0.947978933341994,0.386502516019382,0,2020,0.0369096160380564,329.5
"CD014941","CD014941_pub2_data","1|7|Withdrawal rate|Cenobamate (any dose)","Withdrawal rate",1,7,"Cenobamate (any dose)","or","binary",2,0.315471567227122,0.257798786067482,0,2020,0.110686374447842,329.5
"CD014941","CD014941_pub2_data","1|9|Any serious adverse event|Cenobamate (any dose)","Any serious adverse event",1,9,"Cenobamate (any dose)","or","binary",2,-0.0518868284158847,0.398615119127734,0,2020,0.0461264016309888,329.5
"CD014944","CD014944_pub2_data","1|1|Proportion of participants without treatment success at the longest follow-up (1–4 years)|","Proportion of participants without treatment success at the longest follow-up (1–4 years)",1,1,"","reported","reported",2,0,1.0009662348382,0,2007,0.600782778864971,146.5
"CD014944","CD014944_pub2_data","5|1|Best-worst case scenario analysis|","Best-worst case scenario analysis",5,1,"","reported","reported",3,0,0.0742567905118196,0,1404,0.564035659926071,113.333333333333
"CD014944","CD014944_pub2_data","5|2|Worst-best case scenario analysis|","Worst-best case scenario analysis",5,2,"","reported","reported",2,0,0.0903388508568268,0,1106,0.440068493150685,130.5
"CD014959","CD014959_pub2_data","1|11|Proportion of people with clinical diagnosis of leptospirosis confirmed by laboratory diagnosis (exclusive of asymptomatic cases)|NA","Proportion of people with clinical diagnosis of leptospirosis confirmed by laboratory diagnosis (exclusive of asymptomatic cases)",1,11,NA,"or","binary",4,-0.577303746367622,0.363015378331513,0.113725054905244,2006,0.059226714146069,413.25
"CD014959","CD014959_pub2_data","1|13|Sensitivity analysis: clinical diagnosis confirmed by laboratory diagnosis (worst-case scenario)|NA","Sensitivity analysis: clinical diagnosis confirmed by laboratory diagnosis (worst-case scenario)",1,13,NA,"or","binary",4,0.374726344758152,0.819181127347925,2.01828781611535,2006,0.0535615746620898,477.25
"CD014959","CD014959_pub2_data","1|14|Proportion of people with non-serious adverse events|NA","Proportion of people with non-serious adverse events",1,14,NA,"or","binary",3,2.17717198609669,0.66643145878029,0,2000.66666666667,0.000707714083510262,636.333333333333
"CD014959","CD014959_pub2_data","1|15|Sensitivity analysis: non-serious adverse events (best-case scenario)|NA","Sensitivity analysis: non-serious adverse events (best-case scenario)",1,15,NA,"or","binary",3,-0.872556082607048,1.7058331777428,8.32079585157528,2000.66666666667,0.13633783703433,721.666666666667
"CD014959","CD014959_pub2_data","1|16|Sensitivity analysis: non-serious adverse events (worst-case scenario)|NA","Sensitivity analysis: non-serious adverse events (worst-case scenario)",1,16,NA,"or","binary",3,3.39200018536423,1.11529440218663,2.22531728986753,2000.66666666667,0.000707714083510262,721.666666666667
"CD014959","CD014959_pub2_data","1|2|Proportion of people with laboratory-confirmed leptospirosis regardless of the presence of an identified clinical syndrome (inclusive of asymptomatic cases) |NA","Proportion of people with laboratory-confirmed leptospirosis regardless of the presence of an identified clinical syndrome (inclusive of asymptomatic cases) ",1,2,NA,"or","binary",5,-0.766954092868789,0.559472419184832,1.12896002215632,2001.6,0.161819106264144,518.6
"CD014959","CD014959_pub2_data","1|3|Sensitivity analysis: laboratory-confirmed leptospirosis (best-case scenario)|NA","Sensitivity analysis: laboratory-confirmed leptospirosis (best-case scenario)",1,3,NA,"or","binary",5,-1.2119604970574,0.505686751669982,0.883937316785532,2001.6,0.222984466319617,569.8
"CD014959","CD014959_pub2_data","1|4|Sensitivity analysis: laboratory-confirmed leptospirosis (worst-case scenario)|NA","Sensitivity analysis: laboratory-confirmed leptospirosis (worst-case scenario)",1,4,NA,"or","binary",5,-0.496736062990106,0.716544554153951,2.06911253410443,2001.6,0.141606392549125,569.8
"CD014959","CD014959_pub2_data","1|5|Sensitivity analysis: laboratory-confirmed leptospirosis (only pre-exposure prophylaxis)|NA","Sensitivity analysis: laboratory-confirmed leptospirosis (only pre-exposure prophylaxis)",1,5,NA,"or","binary",3,-1.02343902193673,0.781422169651329,1.56395830929041,2000.66666666667,0.17917111668704,636.333333333333
"CD014959","CD014959_pub2_data","1|6|Sensitivity analysis: laboratory-confirmed leptospirosis (only postexposure prophylaxis)|NA","Sensitivity analysis: laboratory-confirmed leptospirosis (only postexposure prophylaxis)",1,6,NA,"or","binary",2,-0.329256528059993,0.9898382617481,1.14176558019137,2003,0.1357910906298,342
"CD014959","CD014959_pub2_data","1|7|Sensitivity analysis: laboratory-confirmed leptospirosis (including only endemic community)|NA","Sensitivity analysis: laboratory-confirmed leptospirosis (including only endemic community)",1,7,NA,"or","binary",4,-0.28385653262989,0.414029576426917,0.416452722851163,2006,0.191658171577526,413.25
"CD014959","CD014959_pub2_data","1|8|Proportion of people with clinical diagnosis of leptospirosis regardless of the presence of laboratory confirmation |NA","Proportion of people with clinical diagnosis of leptospirosis regardless of the presence of laboratory confirmation ",1,8,NA,"or","binary",4,-0.313468149495309,0.202015026859005,1.89685254020257e-06,2006,0.103052646278453,413.25
"CD014960","CD014960_pub2_data","1|1|All-cause mortality|NA","All-cause mortality",1,1,NA,"reported","reported",2,0,0.912369664452265,0,1994,0.0365853658536585,57
"CD014960","CD014960_pub2_data","1|2|Proportion of people with adverse events considered non-serious|NA","Proportion of people with adverse events considered non-serious",1,2,NA,"or","binary",2,0.0293845660551361,0.611706643351942,0,1972,0.0645161290322581,81
"CD014960","CD014960_pub2_data","1|3|Days of hospitalisation |NA","Days of hospitalisation ",1,3,NA,"or","binary",2,0.0944903277847853,1.42535093680957,0,2001.5,0,144
"CD014960","CD014960_pub2_data","2|1|All-cause mortality (penicillin versus cefotaxime or ceftriaxone)|NA","All-cause mortality (penicillin versus cefotaxime or ceftriaxone)",2,1,NA,"or","binary",2,0.237435589126794,0.578329521703789,0,2003.5,0.028735632183908,174
"CD014964","CD014964_pub2_data","1|1|Number of attempts until success or procedure termination|","Number of attempts until success or procedure termination",1,1,"","reported","reported",47,-0.432009074056028,0.0655096717130102,0.156002267062003,2020,NA,111.085106382979
"CD014964","CD014964_pub2_data","1|2|Procedure time (needling time)|","Procedure time (needling time)",1,2,"","reported","reported",43,-38.8909006796601,9.23335718373553,2844.86402008479,2020,NA,97.1627906976744
"CD014964","CD014964_pub2_data","1|3|Participant satisfaction during the procedure|","Participant satisfaction during the procedure",1,3,"","reported","reported",24,0.158867549495706,0.100481355666175,0.190440547759087,NA,NA,110.708333333333
"CD014964","CD014964_pub2_data","1|4|First‐attempt success|","First‐attempt success",1,4,"","reported","reported",50,1.32031299642593,0.0513192044619849,0.0684851330875224,2020,0.52762826393725,104.1
"CD014964","CD014964_pub2_data","1|5|Technical failure of neuraxial anaesthesia|","Technical failure of neuraxial anaesthesia",1,5,"","reported","reported",31,0.42908118331633,0.147424023653056,0,2020,0.0500125286412565,132.645161290323
"CD014964","CD014964_pub2_data","1|6|Pain during the procedure|","Pain during the procedure",1,6,"","reported","reported",12,-0.209036120431513,0.184699643111911,0.258520042614075,NA,NA,112.666666666667
"CD014964","CD014964_pub2_data","1|7|Any adverse events|","Any adverse events",1,7,"","reported","reported",9,0.600734927606289,0.103656160541337,0,NA,0.134669612794613,120.666666666667
"CD014964","CD014964_pub2_data","2|1|Number of attempts (Difficulty of palpating landmarks)|Difficut","Number of attempts (Difficulty of palpating landmarks)",2,1,"Difficut","reported","reported",14,-0.752083825268563,0.166789359003757,0.29753368925966,NA,NA,97.9285714285714
"CD014964","CD014964_pub2_data","2|1|Number of attempts (Difficulty of palpating landmarks)|Not difficult","Number of attempts (Difficulty of palpating landmarks)",2,1,"Not difficult","reported","reported",18,-0.244562958674302,0.0749625874342787,0.0777602875390069,2020,NA,105
"CD014964","CD014964_pub2_data","2|2|Number of attempts (Experience of operators)|Experienced","Number of attempts (Experience of operators)",2,2,"Experienced","reported","reported",27,-0.484582158087614,0.0836172891151479,0.150251752789741,NA,NA,95.6666666666667
"CD014964","CD014964_pub2_data","2|2|Number of attempts (Experience of operators)|Inexperienced","Number of attempts (Experience of operators)",2,2,"Inexperienced","reported","reported",13,-0.21128961112888,0.117150694857744,0.120056906951908,2020,NA,124.538461538462
"CD014964","CD014964_pub2_data","2|3|Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)|","Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)",2,3,"","reported","reported",2,-0.0960651100969725,0.130511262969199,0.0175873324118857,NA,NA,90
"CD014964","CD014964_pub2_data","2|3|Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)",2,3,"Ultrasound preprocedure","reported","reported",44,-0.44442010822896,0.0705143415617414,0.170398131370941,2020,NA,111.159090909091
"CD014964","CD014964_pub2_data","2|3|Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound real-time","Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)",2,3,"Ultrasound real-time","reported","reported",4,-0.200519339816168,0.117452219798749,0.0411387432625781,NA,NA,92.5
"CD014964","CD014964_pub2_data","2|4|Number of attempts (Types of neuraxial anaesthesia)|Lumbar epidural","Number of attempts (Types of neuraxial anaesthesia)",2,4,"Lumbar epidural","reported","reported",21,-0.429507318996292,0.0912826464191321,0.142318709306662,NA,NA,123.952380952381
"CD014964","CD014964_pub2_data","2|4|Number of attempts (Types of neuraxial anaesthesia)|Spinal","Number of attempts (Types of neuraxial anaesthesia)",2,4,"Spinal","reported","reported",24,-0.442105115941553,0.106715822275095,0.211691054297206,2020,NA,100.291666666667
"CD014964","CD014964_pub2_data","2|5|Number of attempts (Definition of outcome: used 'number of insertions through the skin')|No","Number of attempts (Definition of outcome: used 'number of insertions through the skin')",2,5,"No","reported","reported",8,-0.626412428725524,0.0848136006778709,0.0084430803432301,NA,NA,118.5
"CD014964","CD014964_pub2_data","2|5|Number of attempts (Definition of outcome: used 'number of insertions through the skin')|Yes","Number of attempts (Definition of outcome: used 'number of insertions through the skin')",2,5,"Yes","reported","reported",39,-0.397689822251716,0.071700897873734,0.166761418694319,2020,NA,109.564102564103
"CD014964","CD014964_pub2_data","2|6|Number of attempts (Including only studies that were judged 'low risk of bias')|","Number of attempts (Including only studies that were judged 'low risk of bias')",2,6,"","reported","reported",15,-0.408816548521095,0.175295975060648,0.392264863966826,NA,NA,114.8
"CD014964","CD014964_pub2_data","2|7|Number of attempts (Including only studies that reported both the mean and standard deviation)|","Number of attempts (Including only studies that reported both the mean and standard deviation)",2,7,"","reported","reported",21,-0.371962940183519,0.106402360081411,0.198723405214125,NA,NA,107.428571428571
"CD014964","CD014964_pub2_data","3|1|Procedure time (Difficulty of palpating landmarks)|Difficut","Procedure time (Difficulty of palpating landmarks)",3,1,"Difficut","reported","reported",16,-47.554973159862,17.0271115309116,3465.82567481882,NA,NA,96.125
"CD014964","CD014964_pub2_data","3|1|Procedure time (Difficulty of palpating landmarks)|Not difficult","Procedure time (Difficulty of palpating landmarks)",3,1,"Not difficult","reported","reported",18,-22.9929787446905,5.62935259190033,399.599263167407,2020,NA,99.7777777777778
"CD014964","CD014964_pub2_data","3|2|Procedure time (Experience of operators)|Experienced","Procedure time (Experience of operators)",3,2,"Experienced","reported","reported",24,-27.5438069262193,7.54844244430587,856.925346582966,NA,NA,91.4166666666667
"CD014964","CD014964_pub2_data","3|2|Procedure time (Experience of operators)|Inexperienced","Procedure time (Experience of operators)",3,2,"Inexperienced","reported","reported",12,-23.8999446296443,11.6137074848016,1215.14417687329,2020,NA,112.916666666667
"CD014964","CD014964_pub2_data","3|3|Procedure time (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","Procedure time (Types of ultrasound guidance: preprocedural versus real‐time)",3,3,"Ultrasound preprocedure","reported","reported",40,-42.4438344127732,9.70562118335711,2949.83200843207,2020,NA,98.5
"CD014964","CD014964_pub2_data","3|3|Procedure time (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound real-time","Procedure time (Types of ultrasound guidance: preprocedural versus real‐time)",3,3,"Ultrasound real-time","reported","reported",4,1.82420424030865,15.1282824563274,487.053330307274,NA,NA,72
"CD014964","CD014964_pub2_data","3|4|Procedure time (Types of neuraxial anaesthesia)|Lumbar epidural","Procedure time (Types of neuraxial anaesthesia)",3,4,"Lumbar epidural","reported","reported",13,-43.3059532986509,12.6380875955053,1422.61077186827,NA,NA,97.1538461538462
"CD014964","CD014964_pub2_data","3|4|Procedure time (Types of neuraxial anaesthesia)|Spinal","Procedure time (Types of neuraxial anaesthesia)",3,4,"Spinal","reported","reported",27,-35.6617286820407,13.7493547594784,4206.68314833888,2020,NA,100.037037037037
"CD014964","CD014964_pub2_data","3|4|Procedure time (Types of neuraxial anaesthesia)|Thoracic epidural","Procedure time (Types of neuraxial anaesthesia)",3,4,"Thoracic epidural","reported","reported",3,-56.1202849925148,19.2733592790793,409.167400700154,NA,NA,71.3333333333333
"CD014964","CD014964_pub2_data","3|5|Procedure time (Including only studies that were judged 'low risk of bias')|","Procedure time (Including only studies that were judged 'low risk of bias')",3,5,"","reported","reported",18,-36.8993425511801,11.9048831667722,1944.88626527421,NA,NA,118.111111111111
"CD014964","CD014964_pub2_data","3|6|Procedure time (Including only studies that reported both the mean and standard deviation)|","Procedure time (Including only studies that reported both the mean and standard deviation)",3,6,"","reported","reported",21,-30.4589977177623,11.5546713543742,2240.45749804439,NA,NA,96.8571428571429
"CD014964","CD014964_pub2_data","4|1|Participant satisfaction (Difficulty of palpating landmarks)|Difficut","Participant satisfaction (Difficulty of palpating landmarks)",4,1,"Difficut","reported","reported",12,0.0155919192435653,0.148357631241287,0.197717236118079,NA,NA,97.1666666666667
"CD014964","CD014964_pub2_data","4|1|Participant satisfaction (Difficulty of palpating landmarks)|Not difficult","Participant satisfaction (Difficulty of palpating landmarks)",4,1,"Not difficult","reported","reported",8,0.329371951807501,0.184934507211,0.233259425176739,NA,NA,114
"CD014964","CD014964_pub2_data","4|2|Participant satisfaction (Experience of operators)|Experienced","Participant satisfaction (Experience of operators)",4,2,"Experienced","reported","reported",15,0.195017953136242,0.141508591735292,0.245801367308614,NA,NA,112.866666666667
"CD014964","CD014964_pub2_data","4|2|Participant satisfaction (Experience of operators)|Inexperienced","Participant satisfaction (Experience of operators)",4,2,"Inexperienced","reported","reported",6,0.0267541672946035,0.198478080013329,0.183350164142979,NA,NA,111.333333333333
"CD014964","CD014964_pub2_data","4|3|Participant satisfaction (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","Participant satisfaction (Types of ultrasound guidance: preprocedural versus real‐time)",4,3,"Ultrasound preprocedure","reported","reported",22,0.189703440105132,0.104879172997665,0.19039454637937,NA,NA,113.681818181818
"CD014964","CD014964_pub2_data","4|3|Participant satisfaction (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound real-time","Participant satisfaction (Types of ultrasound guidance: preprocedural versus real‐time)",4,3,"Ultrasound real-time","reported","reported",2,-0.187706820101693,0.374493135356211,0.225429903842,NA,NA,78
"CD014964","CD014964_pub2_data","4|4|Participant satisfaction (Types of neuraxial anaesthesia)|Lumbar epidural","Participant satisfaction (Types of neuraxial anaesthesia)",4,4,"Lumbar epidural","reported","reported",5,0.0716054293441972,0.252551295735218,0.253360192777308,NA,NA,122.4
"CD014964","CD014964_pub2_data","4|4|Participant satisfaction (Types of neuraxial anaesthesia)|Spinal","Participant satisfaction (Types of neuraxial anaesthesia)",4,4,"Spinal","reported","reported",18,0.182336847107833,0.118487279875376,0.202824610904392,NA,NA,108.277777777778
"CD014964","CD014964_pub2_data","4|5|Participant satisfaction (Including only studies that were judged 'low risk of bias')|","Participant satisfaction (Including only studies that were judged 'low risk of bias')",4,5,"","reported","reported",4,0.141015888484677,0.0851354465700605,0,NA,NA,138.5
"CD014964","CD014964_pub2_data","4|6|Participant satisfaction (Including only studies that reported both the mean and standard deviation)|","Participant satisfaction (Including only studies that reported both the mean and standard deviation)",4,6,"","reported","reported",9,0.41095931764628,0.164256337284641,0.170499314714597,NA,NA,95.1111111111111
"CD014964","CD014964_pub2_data","5|1|First-attempt success (Difficulty of palpating landmarks)|Difficut","First-attempt success (Difficulty of palpating landmarks)",5,1,"Difficut","reported","reported",16,1.37122148816008,0.105390704819264,0.101231439440892,NA,0.52500372765598,109.125
"CD014964","CD014964_pub2_data","5|1|First-attempt success (Difficulty of palpating landmarks)|Not difficult","First-attempt success (Difficulty of palpating landmarks)",5,1,"Not difficult","reported","reported",21,1.18984388436172,0.046123717422506,0.0140125354828763,2020,0.568446505473993,100.809523809524
"CD014964","CD014964_pub2_data","5|2|First-attempt success  (Experience of operators)|Experienced","First-attempt success  (Experience of operators)",5,2,"Experienced","reported","reported",28,1.31432175458008,0.0620238542800755,0.0497487822445731,NA,0.558007625388318,89.7857142857143
"CD014964","CD014964_pub2_data","5|2|First-attempt success  (Experience of operators)|Inexperienced","First-attempt success  (Experience of operators)",5,2,"Inexperienced","reported","reported",10,1.16812272990969,0.127403037126667,0.0937508124137489,2020,0.45650728109267,118.2
"CD014964","CD014964_pub2_data","5|3|First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)|","First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)",5,3,"","reported","reported",2,1.216331133803,0.395267254896587,0.201831155299919,NA,0.66,90
"CD014964","CD014964_pub2_data","5|3|First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)",5,3,"Ultrasound preprocedure","reported","reported",48,1.315598585521,0.0524867402836877,0.0691383252502103,2020,0.52765096937908,103.9375
"CD014964","CD014964_pub2_data","5|3|First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound real-time","First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)",5,3,"Ultrasound real-time","reported","reported",4,1.32477299833249,0.218648515522185,0.109499141551957,NA,0.593541666666667,69
"CD014964","CD014964_pub2_data","5|4|First-attempt success (Types of neuraxial anaesthesia)|Lumbar epidural","First-attempt success (Types of neuraxial anaesthesia)",5,4,"Lumbar epidural","reported","reported",20,1.29255462009263,0.063056238127694,0.0341237189027907,NA,0.561646563561886,102.8
"CD014964","CD014964_pub2_data","5|4|First-attempt success (Types of neuraxial anaesthesia)|Spinal","First-attempt success (Types of neuraxial anaesthesia)",5,4,"Spinal","reported","reported",26,1.35715638027785,0.0870555824717477,0.118303317848041,2020,0.51369753504354,108.384615384615
"CD014964","CD014964_pub2_data","5|4|First-attempt success (Types of neuraxial anaesthesia)|Thoracic epidural","First-attempt success (Types of neuraxial anaesthesia)",5,4,"Thoracic epidural","reported","reported",3,1.52232759647769,0.274293952560517,0.0609171587100435,NA,0.415157004830918,63.3333333333333
"CD014964","CD014964_pub2_data","5|5|First-attempt success (Definition of outcome: used 'first skin insertion')|No","First-attempt success (Definition of outcome: used 'first skin insertion')",5,5,"No","reported","reported",15,1.35045616130351,0.0829572706641769,0.0202744865002156,2020,0.384855070943923,96.5333333333333
"CD014964","CD014964_pub2_data","5|5|First-attempt success (Definition of outcome: used 'first skin insertion')|Yes","First-attempt success (Definition of outcome: used 'first skin insertion')",5,5,"Yes","reported","reported",35,1.30770729248857,0.0608982717149634,0.0804526821593325,NA,0.588816775220105,107.342857142857
"CD014964","CD014964_pub2_data","5|6|First-attempt success (Including only studies that were judged 'low risk of bias')|","First-attempt success (Including only studies that were judged 'low risk of bias')",5,6,"","reported","reported",6,1.32514726780206,0.160467333605842,0.110036259302334,NA,0.609190115440115,141.5
"CD014964","CD014964_pub2_data","6|1|Technical failure (Difficulty of palpating landmarks)|Difficut","Technical failure (Difficulty of palpating landmarks)",6,1,"Difficut","reported","reported",11,0.538314509796755,0.251107932351818,0,NA,0.0469203019203019,144.454545454545
"CD014964","CD014964_pub2_data","6|1|Technical failure (Difficulty of palpating landmarks)|Not difficult","Technical failure (Difficulty of palpating landmarks)",6,1,"Not difficult","reported","reported",9,0.26493896504589,0.28386588507343,0,2020,0.0554788371577587,98.7777777777778
"CD014964","CD014964_pub2_data","6|2|Technical failure (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","Technical failure (Types of ultrasound guidance: preprocedural versus real‐time)",6,2,"Ultrasound preprocedure","reported","reported",30,0.480201713676538,0.158174859415975,0,2020,0.0482073907070761,133.866666666667
"CD014964","CD014964_pub2_data","6|3|Technical failure (Types of neuraxial anaesthesia)|Lumbar epidural","Technical failure (Types of neuraxial anaesthesia)",6,3,"Lumbar epidural","reported","reported",12,0.321102116582975,0.191938813870484,0,NA,0.0448226912807369,160.916666666667
"CD014964","CD014964_pub2_data","6|3|Technical failure (Types of neuraxial anaesthesia)|Spinal","Technical failure (Types of neuraxial anaesthesia)",6,3,"Spinal","reported","reported",16,0.820064503917411,0.281727144526964,0,2020,0.0541060874260259,117.125
"CD014964","CD014964_pub2_data","6|3|Technical failure (Types of neuraxial anaesthesia)|Thoracic epidural","Technical failure (Types of neuraxial anaesthesia)",6,3,"Thoracic epidural","reported","reported",2,0.099811254603147,0.400344786826295,0,NA,0.0655968468468469,83
"CD014964","CD014964_pub2_data","6|4|Technical failure (Including only studies that were judged 'low risk of bias')|","Technical failure (Including only studies that were judged 'low risk of bias')",6,4,"","reported","reported",14,0.54989743456461,0.229410346896418,0,2020,0.0577311209896221,134.785714285714
"CD014964","CD014964_pub2_data","7|1|Pain (Difficulty of palpating landmarks)|Difficut","Pain (Difficulty of palpating landmarks)",7,1,"Difficut","reported","reported",6,-0.590228975781662,0.270575511154674,0.194275333617589,NA,NA,88.3333333333333
"CD014964","CD014964_pub2_data","7|1|Pain (Difficulty of palpating landmarks)|Not difficult","Pain (Difficulty of palpating landmarks)",7,1,"Not difficult","reported","reported",2,0.300272858407377,0.674546935704743,0.862025256076114,NA,NA,130
"CD014964","CD014964_pub2_data","7|2|Pain (Experience of operators)|Experienced","Pain (Experience of operators)",7,2,"Experienced","reported","reported",6,-0.54434075198522,0.304303692628968,0.324765460554973,NA,NA,94.8333333333333
"CD014964","CD014964_pub2_data","7|2|Pain (Experience of operators)|Inexperienced","Pain (Experience of operators)",7,2,"Inexperienced","reported","reported",3,0.213069610978087,0.430725546378402,0.46143700316806,NA,NA,106.666666666667
"CD014964","CD014964_pub2_data","7|3|Pain (Types of neuraxial anaesthesia)|Spinal","Pain (Types of neuraxial anaesthesia)",7,3,"Spinal","reported","reported",11,-0.238737108341043,0.205381844090548,0.303684864779477,NA,NA,103.363636363636
"CD014964","CD014964_pub2_data","7|4|Pain (Including only studies that were judged 'low risk of bias')|","Pain (Including only studies that were judged 'low risk of bias')",7,4,"","reported","reported",2,-0.637953745740163,0.665888400084979,0.755780546651135,NA,NA,142.5
"CD014964","CD014964_pub2_data","7|5|Pain (Including only studies that reported both the mean and standard deviation)|","Pain (Including only studies that reported both the mean and standard deviation)",7,5,"","reported","reported",3,-0.271611979748409,0.0985026764193987,0,NA,NA,99.3333333333333
"CD014964","CD014964_pub2_data","8|1|Adverse events (Difficulty of palpating landmarks)|Difficut","Adverse events (Difficulty of palpating landmarks)",8,1,"Difficut","reported","reported",4,0.664039851429813,0.31549072657354,0.098835691113125,NA,0.149621212121212,91
"CD014964","CD014964_pub2_data","8|1|Adverse events (Difficulty of palpating landmarks)|Not difficult","Adverse events (Difficulty of palpating landmarks)",8,1,"Not difficult","reported","reported",4,0.38122854793886,0.404222887881412,0,NA,0.0633854166666667,105.5
"CD014964","CD014964_pub2_data","8|2|Adverse events (Experience of operators)|Experienced","Adverse events (Experience of operators)",8,2,"Experienced","reported","reported",5,0.582381191481855,0.108677862419327,0,NA,0.165738636363636,136.4
"CD014964","CD014964_pub2_data","8|3|Adverse events (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound preprocedure","Adverse events (Types of ultrasound guidance: preprocedural versus real‐time)",8,3,"Ultrasound preprocedure","reported","reported",8,0.601532585803587,0.104107210762231,0,NA,0.151503314393939,117.5
"CD014964","CD014964_pub2_data","8|3|Adverse events (Types of ultrasound guidance: preprocedural versus real‐time)|Ultrasound real-time","Adverse events (Types of ultrasound guidance: preprocedural versus real‐time)",8,3,"Ultrasound real-time","reported","reported",2,0.513536636955059,1.34645030681615,0,NA,0.02,98
"CD014964","CD014964_pub2_data","8|4|Adverse events (Types of neuraxial anaesthesia)|Lumbar epidural","Adverse events (Types of neuraxial anaesthesia)",8,4,"Lumbar epidural","reported","reported",3,0.586601310583519,0.111426704313171,0,NA,0.202291666666667,162.666666666667
"CD014964","CD014964_pub2_data","8|4|Adverse events (Types of neuraxial anaesthesia)|Spinal","Adverse events (Types of neuraxial anaesthesia)",8,4,"Spinal","reported","reported",4,0.865345373873975,0.34484949828738,0.0191740125123251,NA,0.109621212121212,113.5
"CD014964","CD014964_pub2_data","8|4|Adverse events (Types of neuraxial anaesthesia)|Thoracic epidural","Adverse events (Types of neuraxial anaesthesia)",8,4,"Thoracic epidural","reported","reported",2,0.252236666729367,0.521842246444422,0,NA,0.0833333333333333,72
"CD014965","CD014965_pub2_data","1|1|Irritability|Risperidone","Irritability",1,1,"Risperidone","reported","reported",3,0,1.14573695935406,0,2009,0,67.6666666666667
"CD014965","CD014965_pub2_data","1|11|Metabolic side effects: total cholesterol levels above clinically relevant thresholds|Aripiprazole","Metabolic side effects: total cholesterol levels above clinically relevant thresholds",1,11,"Aripiprazole","reported","reported",2,0,1.05107495763325,0,2013,0.0444444444444444,98.5
"CD014965","CD014965_pub2_data","1|13|Other side effects: somnolence|Risperidone","Other side effects: somnolence",1,13,"Risperidone","or","binary",2,1.96685753491245,0.60797526941779,0,2012.5,0.0698412698412698,52.5
"CD014965","CD014965_pub2_data","1|14|Other side effects: sedation|Aripiprazole","Other side effects: sedation",1,14,"Aripiprazole","reported","reported",2,0,0.610297460530698,0,2013,0.0294117647058824,98.5
"CD014965","CD014965_pub2_data","1|14|Other side effects: sedation|Risperidone","Other side effects: sedation",1,14,"Risperidone","or","binary",2,2.04615642719647,0.478616465370864,0,2007.5,0.0588235294117647,83
"CD014965","CD014965_pub2_data","1|15|Other side effects: headache|Aripiprazole","Other side effects: headache",1,15,"Aripiprazole","reported","reported",4,0,0.432661260704947,0,2008,0.177928921568627,78.75
"CD014965","CD014965_pub2_data","1|16|Other side effects: constipation|Aripiprazole","Other side effects: constipation",1,16,"Aripiprazole","reported","reported",2,0,0.579161123437792,0,2007,0.05,56.5
"CD014965","CD014965_pub2_data","1|18|Other side effects: hypersalivation|Aripiprazole","Other side effects: hypersalivation",1,18,"Aripiprazole","reported","reported",2,0,1.03184768618823,0,2009,0.00980392156862745,101
"CD014965","CD014965_pub2_data","1|19|Other side effects: tremor|Aripiprazole","Other side effects: tremor",1,19,"Aripiprazole","reported","reported",2,0,1.02736067085852,0,2009,0,101
"CD014965","CD014965_pub2_data","1|20|Other side effects: akathisia|Aripiprazole","Other side effects: akathisia",1,20,"Aripiprazole","or","binary",2,-1.11613817499752,1.16326445930028,0,2009,0.0198039215686275,101
"CD014965","CD014965_pub2_data","1|23|Other side effects: insomnia|Aripiprazole","Other side effects: insomnia",1,23,"Aripiprazole","or","binary",2,-0.6617175233738,0.518094314463285,0,2007,0.19375,56.5
"CD014965","CD014965_pub2_data","1|24|Lethargy/withdrawal|Aripiprazole","Lethargy/withdrawal",1,24,"Aripiprazole","reported","reported",4,0,0.802040511680073,0,2008,0,76.5
"CD014965","CD014965_pub2_data","1|24|Lethargy/withdrawal|Risperidone","Lethargy/withdrawal",1,24,"Risperidone","or","binary",2,0.0070304158222531,1.42222476620457,0,2003,0,88.5
"CD014965","CD014965_pub2_data","1|25|Hyperactivity|Aripiprazole","Hyperactivity",1,25,"Aripiprazole","or","binary",5,-0.00767846932362781,0.900904342096941,0,2009.8,0,80.4
"CD014965","CD014965_pub2_data","1|25|Hyperactivity|Risperidone","Hyperactivity",1,25,"Risperidone","or","binary",2,0.0070304158222531,1.42222476620457,0,2003,0,88.5
"CD014965","CD014965_pub2_data","1|26|Stereotypy|Aripiprazole","Stereotypy",1,26,"Aripiprazole","or","binary",5,-0.0131470487518547,0.900909635340758,0,2009.8,0,80
"CD014965","CD014965_pub2_data","1|26|Stereotypy|Risperidone","Stereotypy",1,26,"Risperidone","or","binary",2,0.0070304158222531,1.42222476620457,0,2003,0,88.5
"CD014965","CD014965_pub2_data","1|3|Weight gain above clinically relevant thresholds|Aripiprazole","Weight gain above clinically relevant thresholds",1,3,"Aripiprazole","or","binary",3,0.591383082838872,0.465462142197341,0,2007.66666666667,0.0690359477124183,72.6666666666667
"CD014965","CD014965_pub2_data","1|5|Extrapyramidal side effects: any extrapyramidal symptom|Aripiprazole","Extrapyramidal side effects: any extrapyramidal symptom",1,5,"Aripiprazole","reported","reported",2,0,0.453387837131609,0,2013,0.0511111111111111,94.5
"CD014965","CD014965_pub2_data","1|6|Obsessive-compulsive behaviours|Aripiprazole","Obsessive-compulsive behaviours",1,6,"Aripiprazole","reported","reported",4,0,0.357343064364815,0,2010,0,89.25
"CD014965","CD014965_pub2_data","1|7|Inappropriate speech|Aripiprazole","Inappropriate speech",1,7,"Aripiprazole","reported","reported",4,0,0.2767940543656,0,2008,0,76.75
"CD014965","CD014965_pub2_data","1|7|Inappropriate speech|Risperidone","Inappropriate speech",1,7,"Risperidone","or","binary",2,0.0070304158222531,1.42222476620457,0,2003,0,88.5
"CD014965","CD014965_pub2_data","1|9|Metabolic side effects: triglyceride levels above clinically relevant thresholds|Aripiprazole","Metabolic side effects: triglyceride levels above clinically relevant thresholds",1,9,"Aripiprazole","reported","reported",2,0,0.7270187281103,0,2013,0.0196078431372549,98.5
"CD014965","CD014965_pub2_data","2|1|Weight gain as a continuous measure|Risperidone","Weight gain as a continuous measure",2,1,"Risperidone","or","binary",2,0.0665610004500604,1.43757415259648,0,2006,0,31
"CD014965","CD014965_pub2_data","4|1|Irritability|","Irritability",4,1,"","or","binary",2,0.040992324445463,1.42687172066231,0,2016.5,0,55
"CD014965","CD014965_pub2_data","6|1|Irritability: posology (fixed-dose scheme versus flexible-dose scheme)|Fixed-dose scheme","Irritability: posology (fixed-dose scheme versus flexible-dose scheme)",6,1,"Fixed-dose scheme","reported","reported",6,0,0.795087409594234,0,2010.16666666667,0,78
"CD014965","CD014965_pub2_data","6|1|Irritability: posology (fixed-dose scheme versus flexible-dose scheme)|Flexible-dose scheme","Irritability: posology (fixed-dose scheme versus flexible-dose scheme)",6,1,"Flexible-dose scheme","reported","reported",5,0,0.950846018198145,0,2008.4,0,64.4
"CD014965","CD014965_pub2_data","6|2|Weight gain above clinically relevant thresholds: posology (fixed-dose scheme versus flexible-dose scheme)|Fixed-dose scheme","Weight gain above clinically relevant thresholds: posology (fixed-dose scheme versus flexible-dose scheme)",6,2,"Fixed-dose scheme","reported","reported",6,0,0.340542688908515,0,2009.66666666667,0.0807764772575697,65.8333333333333
"CD014966","CD014966_pub2_data","1|1|Kidney graft loss|Up to 1 year","Kidney graft loss",1,1,"Up to 1 year","reported","reported",2,0,0.0679010029912566,0,2003,0.168985637342908,1922
"CD014966","CD014966_pub2_data","1|1|Kidney graft loss|Up to 10 years ","Kidney graft loss",1,1,"Up to 10 years ","or","binary",2,-0.281220009063628,0.102891442276815,0,2020.5,0.381595462417184,856
"CD014966","CD014966_pub2_data","1|1|Kidney graft loss|Up to 5 years ","Kidney graft loss",1,1,"Up to 5 years ","or","binary",5,-0.0758130028710499,0.254703705222849,0.217316727645233,2016.2,0.151835448963677,640.2
"CD014966","CD014966_pub2_data","1|2|Kidney graft loss: time-to-event analysis|","Kidney graft loss: time-to-event analysis",1,2,"","reported","reported",6,0.0658337780407588,0.0586020594422205,0.0078100349662618,2017.5,0,39822.8333333333
"CD014966","CD014966_pub2_data","1|3|Kidney graft loss: female donor|","Kidney graft loss: female donor",1,3,"","or","binary",10,-0.0247536136116997,0.0149327328191317,9.99336553437746e-06,2011.8,0.299835304205722,8597.1
"CD014966","CD014966_pub2_data","1|4|Kidney graft loss: male donor|","Kidney graft loss: male donor",1,4,"","reported","reported",3,0,0.079514185975379,0,2011.33333333333,0.237634315674243,483
"CD014966","CD014966_pub2_data","2|1|Pancreatic graft loss|","Pancreatic graft loss",2,1,"","or","binary",3,0.0495818934299561,0.164953091783594,7.3360082032099e-08,2015.66666666667,0.532963236097454,289.333333333333
"CD014966","CD014966_pub2_data","3|1|Death|Death up to 30 years","Death",3,1,"Death up to 30 years","or","binary",13,-0.0646392698951667,0.135899096303824,0.18361903607579,2017,0.20510252171941,4678.30769230769
"CD014966","CD014966_pub2_data","3|1|Death|Early death (≤ 5 years)","Death",3,1,"Early death (≤ 5 years)","or","binary",6,-0.0359147537768267,0.351776980376729,0.51892598490681,2018.66666666667,0.0976090483905328,4723.83333333333
"CD014966","CD014966_pub2_data","3|1|Death|Late death (> 5 years)","Death",3,1,"Late death (> 5 years)","reported","reported",6,0,0.0445941309929135,0,2014.66666666667,0.224785164583658,1039.83333333333
"CD014966","CD014966_pub2_data","4|1|Cancer incidence|","Cancer incidence",4,1,"","or","binary",7,-0.191425202997737,0.11321740046773,0.0494420875049357,2014.57142857143,0.103836923739477,3582.28571428571
"CD014966","CD014966_pub2_data","5|1|Rejection: acute and chronic|Acute and/or chronic rejection","Rejection: acute and chronic",5,1,"Acute and/or chronic rejection","or","binary",9,-0.132432039816669,0.101008738122586,0.0327708955163295,2011.33333333333,0.283909231628671,684.222222222222
"CD014966","CD014966_pub2_data","5|1|Rejection: acute and chronic|Chronic rejection ","Rejection: acute and chronic",5,1,"Chronic rejection ","or","binary",4,0.0571658371516031,0.171147300759042,0,2014,0.0893528470305967,519.25
"CD014967","CD014967_pub2_data","10|1|Seizure burden during hospitalisation|NA","Seizure burden during hospitalisation",10,1,NA,"or","binary",2,-0.287918297954315,1.43470714060428,0,2012.5,0,34
"CD014967","CD014967_pub2_data","10|2|Mortality before hospital discharge|NA","Mortality before hospital discharge",10,2,NA,"or","binary",2,-0.72999448834083,0.555405905754499,0,2012.5,0.35,34
"CD014967","CD014967_pub2_data","2|11|Duration of hospital stay|NA","Duration of hospital stay",2,11,NA,"or","binary",2,0,1.43126819728362,0,2017.5,0,45
"CD014967","CD014967_pub2_data","2|12|Recurrence of seizure before hospital discharge|NA","Recurrence of seizure before hospital discharge",2,12,NA,"or","binary",2,0.440530080694497,0.674075907628936,0,2018.5,0.03,65
"CD014967","CD014967_pub2_data","2|14|Proportion of infants discharged on gavage feeds|NA","Proportion of infants discharged on gavage feeds",2,14,NA,"or","binary",2,0,1.42895566574028,0,2018.5,0,65
"CD014967","CD014967_pub2_data","2|15|Proportion of infants with an abnormal neurological examination at discharge|NA","Proportion of infants with an abnormal neurological examination at discharge",2,15,NA,"reported","reported",2,0,0.826078574188397,0,2020.5,0.358333333333333,56
"CD014967","CD014967_pub2_data","2|2|Proportion of infants who achieve seizure control after the maximal loading dose of ASM|NA","Proportion of infants who achieve seizure control after the maximal loading dose of ASM",2,2,NA,"or","binary",3,-1.46637251550634,0.324661097162,0.0752617002189722,2019,0.784444444444444,86.6666666666667
"CD014967","CD014967_pub2_data","2|3|Mortality before hospital discharge|NA","Mortality before hospital discharge",2,3,NA,"or","binary",6,0.385345189903993,0.319777193088149,0,2018.83333333333,0.0791197691197691,75.3333333333333
"CD014967","CD014967_pub2_data","2|4|Requirement for mechanical ventilation|NA","Requirement for mechanical ventilation",2,4,NA,"or","binary",5,0.559733669992035,0.772579196092714,0,2018.8,0.00666666666666667,78.8
"CD014967","CD014967_pub2_data","2|6|Bradycardia|NA","Bradycardia",2,6,NA,"or","binary",4,1.15716856294378,0.867245807668215,0,2019.5,0,83.5
"CD014967","CD014967_pub2_data","2|8|Shock requiring volume or inotropes|NA","Shock requiring volume or inotropes",2,8,NA,"or","binary",3,-0.590135021968452,0.490759015647328,0,2017.66666666667,0.166666666666667,63.3333333333333
"CD014967","CD014967_pub2_data","4|1|Proportion of infants who achieve seizure control after the first loading dose of ASM|NA","Proportion of infants who achieve seizure control after the first loading dose of ASM",4,1,NA,"or","binary",2,1.20837206650915,1.45080909953,3.97230099522151,2014,0.415584415584416,89.5
"CD014967","CD014967_pub2_data","4|2|Mortality before hospital discharge|NA","Mortality before hospital discharge",4,2,NA,"or","binary",2,0.604565360417594,0.921053054458081,1.39463615815711,2014,0.188311688311688,89.5
"CD014967","CD014967_pub2_data","9|1|Proportion of infants with repeat seizure before hospital discharge|NA","Proportion of infants with repeat seizure before hospital discharge",9,1,NA,"or","binary",2,-0.436177043215515,0.234583403889572,0,2018.5,0.32327380952381,186.5
"CD014967","CD014967_pub2_data","9|10|Abnormal neurological examination at discharge|NA","Abnormal neurological examination at discharge",9,10,NA,"or","binary",2,-0.179620469603752,0.296167040848914,0.0596336760372663,2018.5,0.269404761904762,186.5
"CD014967","CD014967_pub2_data","9|2|Mortality before hospital discharge|NA","Mortality before hospital discharge",9,2,NA,"or","binary",2,-0.401174147626848,0.319765175701345,0,2018.5,0.144702380952381,186.5
"CD014967","CD014967_pub2_data","9|6|Shock requiring volume or inotropes|NA","Shock requiring volume or inotropes",9,6,NA,"or","binary",2,-0.292253572696826,0.209125921054551,0,2018.5,0.456666666666667,186.5
"CD014967","CD014967_pub2_data","9|8|Duration of hospital stay|NA","Duration of hospital stay",9,8,NA,"or","binary",2,0.000468556717418118,1.41811153980541,0,2018.5,0,186.5
"CD014999","CD014999_pub2_data","1|1|Rebleeding|NA","Rebleeding",1,1,NA,"reported","reported",2,0,0.371569880403839,0,2016.5,0.128339140534262,173
"CD014999","CD014999_pub2_data","1|2|Reintervention (events)|NA","Reintervention (events)",1,2,NA,"reported","reported",2,0,0.353240735680959,0,2016.5,0.131605691056911,173
"CD014999","CD014999_pub2_data","1|3|Reintervention (patients)|NA","Reintervention (patients)",1,3,NA,"reported","reported",2,0,0.354208136976541,0,2016.5,0.119410569105691,173
"CD014999","CD014999_pub2_data","1|5|30-day all-cause mortality|NA","30-day all-cause mortality",1,5,NA,"reported","reported",2,0,0.533448735032391,0,2016.5,0.0917537746806039,173
"CD014999","CD014999_pub2_data","1|6|Duration of hospitalization|NA","Duration of hospitalization",1,6,NA,"or","binary",2,0.189621127222613,1.41918234211317,0,2016.5,0,162
"CD014999","CD014999_pub2_data","2|1|Rebleeding: sensitivity analysis, Forrest Ia–IIa|NA","Rebleeding: sensitivity analysis, Forrest Ia–IIa",2,1,NA,"reported","reported",2,0,0.403236766907414,0,2016.5,0.135341941654711,169.5
"CD014999","CD014999_pub2_data","2|2|Reintervention (events): sensitivity analysis, Forrest Ia–IIa|NA","Reintervention (events): sensitivity analysis, Forrest Ia–IIa",2,2,NA,"reported","reported",2,0,0.347403783256856,0,2016.5,0.137733142037303,169.5
"CD014999","CD014999_pub2_data","2|3|Reintervention (patients): sensitivity analysis, Forrest Ia–IIa|NA","Reintervention (patients): sensitivity analysis, Forrest Ia–IIa",2,3,NA,"reported","reported",2,0,0.374089410251356,0,2016.5,0.125538020086083,169.5
"CD014999","CD014999_pub2_data","2|4|30-day all-cause mortality: sensitivity analysis, Forrest Ia–IIa|NA","30-day all-cause mortality: sensitivity analysis, Forrest Ia–IIa",2,4,NA,"reported","reported",2,0,0.550379369323948,0,2016.5,0.0889526542324247,169.5
"CD015003","CD015003_pub2_data","1|1|All-cause mortality|","All-cause mortality",1,1,"","reported","reported",2,0,0.461584976092364,0,1986.5,0.316666666666667,62
"CD015003","CD015003_pub2_data","1|4|Adverse events|Gastrointestinal (diarrhoea)","Adverse events",1,4,"Gastrointestinal (diarrhoea)","reported","reported",2,0,1.08368956628799,0,2003,0.0270453008789723,78.5
"CD015003","CD015003_pub2_data","1|4|Adverse events|Neurological (seizure, confusion)","Adverse events",1,4,"Neurological (seizure, confusion)","reported","reported",2,0,1.07664388749324,0,1998,0.119230769230769,77.5
"CD015003","CD015003_pub2_data","1|5|Cardiovascular mortality|","Cardiovascular mortality",1,5,"","reported","reported",2,0,1.09817589652569,0,1987,0.0217391304347826,80
"CD015003","CD015003_pub2_data","3|1|All-cause mortality|","All-cause mortality",3,1,"","or","binary",2,0.101655457050819,0.162447823173156,0,1997,0.275454545454545,364.5
"CD015014","CD015014_pub2_data","1|1|ED visits (proportion of residents with at least one ED visit)|","ED visits (proportion of residents with at least one ED visit)",1,1,"","or","binary",7,0.0344760646649202,0.164193650917942,0.0111299920928605,2014.42857142857,0.337386120270855,182.285714285714
"CD015014","CD015014_pub2_data","1|10|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by timing of effect|Long term > 12 months","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by timing of effect",1,10,"Long term > 12 months","or","binary",2,-0.122959333043341,0.206282546727469,0,2016.5,0.516692851531815,191
"CD015014","CD015014_pub2_data","1|10|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by timing of effect|Short term < 12 months","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by timing of effect",1,10,"Short term < 12 months","or","binary",6,-0.58160729667484,0.317349773388194,0.339018602671315,2014.5,0.326968265517451,146.833333333333
"CD015014","CD015014_pub2_data","1|11|Unplanned hospital admissions (mean number of unplanned hospital admissions per resident)|","Unplanned hospital admissions (mean number of unplanned hospital admissions per resident)",1,11,"","or","binary",3,0.0300156098856225,1.16095217352425,0,2012.66666666667,0,273.333333333333
"CD015014","CD015014_pub2_data","1|12|Unplanned hospital admissions (logarithm of rate ratio)|","Unplanned hospital admissions (logarithm of rate ratio)",1,12,"","reported","reported",4,-0.0687316993971931,0.0941092806797261,0.0226385774088785,2013.5,0,2492
"CD015014","CD015014_pub2_data","1|13|Adverse events/falls (proportion of residents with a fall)|","Adverse events/falls (proportion of residents with a fall)",1,13,"","or","binary",3,0.252483047439728,0.219835449847946,0.0551006532882827,2005,0.418973695659866,353.666666666667
"CD015014","CD015014_pub2_data","1|14|Adverse events/falls (proportion of residents with a fall): subgroup analysis by type of care provided|Primary care","Adverse events/falls (proportion of residents with a fall): subgroup analysis by type of care provided",1,14,"Primary care","or","binary",2,0.0480470074597864,0.217307784377814,0,1998,0.46730351869641,410.5
"CD015014","CD015014_pub2_data","1|15|Adverse events/falls (proportion of residents with a fall): sensitivity analysis by risk of bias|High or unclear risk of bias","Adverse events/falls (proportion of residents with a fall): sensitivity analysis by risk of bias",1,15,"High or unclear risk of bias","or","binary",2,0.270473210612188,0.40461583991931,0.214787364111722,2004.5,0.580910111213142,200
"CD015014","CD015014_pub2_data","1|16|Adverse events/falls (proportion of residents with a fall): sensitivity analysis by timing of effects|Short-term","Adverse events/falls (proportion of residents with a fall): sensitivity analysis by timing of effects",1,16,"Short-term","or","binary",2,0.376188552137107,0.237871789870884,0.044995197509671,2012.5,0.208707457070045,450.5
"CD015014","CD015014_pub2_data","1|17|Adverse events/falls (mean number of falls per resident)|","Adverse events/falls (mean number of falls per resident)",1,17,"","or","binary",2,-0.225828303846291,1.41976711437848,0,2005,0,135
"CD015014","CD015014_pub2_data","1|18|Adverse events/falls (logarithm of rate ratio)|","Adverse events/falls (logarithm of rate ratio)",1,18,"","reported","reported",4,0.0766963273290828,0.200818582303924,0.110471413365329,2009.5,0,257
"CD015014","CD015014_pub2_data","1|2|ED visits (proportion of residents with at least one ED visit): sensitivity analysis by risk of bias|High or unclear risk of bias","ED visits (proportion of residents with at least one ED visit): sensitivity analysis by risk of bias",1,2,"High or unclear risk of bias","or","binary",4,-0.0556466659457474,0.288575914885217,0.123206674192179,2015.75,0.277169051878354,207.25
"CD015014","CD015014_pub2_data","1|2|ED visits (proportion of residents with at least one ED visit): sensitivity analysis by risk of bias|Low risk of bias","ED visits (proportion of residents with at least one ED visit): sensitivity analysis by risk of bias",1,2,"Low risk of bias","or","binary",3,-0.0333942010941466,0.269292193707445,0,2012.66666666667,0.417675544794189,149
"CD015014","CD015014_pub2_data","1|22|Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy)|","Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy)",1,22,"","or","binary",2,2.16413368324552,0.671691118979055,0,2003,0.0454545454545455,43.5
"CD015014","CD015014_pub2_data","1|23|Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy, two intervention arms combined)|","Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy, two intervention arms combined)",1,23,"","or","binary",2,1.7824656882314,0.818373353475324,0,2003,0.0454545454545455,32.5
"CD015014","CD015014_pub2_data","1|24|Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy)|","Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy)",1,24,"","or","binary",2,1.97657465198053,1.1029483404066,0,2003,0,34
"CD015014","CD015014_pub2_data","1|25|Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy, two arms combined)|","Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy, two arms combined)",1,25,"","or","binary",2,1.313035113194,1.11581926842768,0,2003,0,26
"CD015014","CD015014_pub2_data","1|28|Quality of life (standardised mean difference)|EQ-5D","Quality of life (standardised mean difference)",1,28,"EQ-5D","reported","reported",6,-0.0592911807629761,0.0179991023212676,0,2017.33333333333,0,329
"CD015014","CD015014_pub2_data","1|28|Quality of life (standardised mean difference)|QUALIDEM","Quality of life (standardised mean difference)",1,28,"QUALIDEM","reported","reported",2,-0.0160392163134746,0.0840235758313213,0,2015,0,462
"CD015014","CD015014_pub2_data","1|29|Quality of life (standardised mean difference): sensitivity analysis by risk of bias|High or unclear risk of bias","Quality of life (standardised mean difference): sensitivity analysis by risk of bias",1,29,"High or unclear risk of bias","reported","reported",7,-0.0358164173953179,0.0216399136331872,2.41372935159386e-06,2018.14285714286,0,371.142857142857
"CD015014","CD015014_pub2_data","1|29|Quality of life (standardised mean difference): sensitivity analysis by risk of bias|Low risk of bias","Quality of life (standardised mean difference): sensitivity analysis by risk of bias",1,29,"Low risk of bias","reported","reported",5,-0.0618831394616646,0.0317773073626943,0.000406979223603964,2012.4,0,283.6
"CD015014","CD015014_pub2_data","1|3|ED visits (mean number of ED visits per resident)|","ED visits (mean number of ED visits per resident)",1,3,"","or","binary",2,0.027920557426222,1.42268436776886,0,2012,0,352
"CD015014","CD015014_pub2_data","1|30|Quality of life (standardised mean difference): sensitivity analysis by timing of effect|Longer-term","Quality of life (standardised mean difference): sensitivity analysis by timing of effect",1,30,"Longer-term","reported","reported",4,-0.0590119735856785,0.0187132326045214,0,2015.25,0,530
"CD015014","CD015014_pub2_data","1|30|Quality of life (standardised mean difference): sensitivity analysis by timing of effect|Short-term","Quality of life (standardised mean difference): sensitivity analysis by timing of effect",1,30,"Short-term","reported","reported",8,0.00382239739778509,0.0395127307405099,1.5126236588631e-07,2016,0,237
"CD015014","CD015014_pub2_data","1|33|Mortality (proportion of residents who died): sensitivity analyses by risk of bias|Low risk of bias","Mortality (proportion of residents who died): sensitivity analyses by risk of bias",1,33,"Low risk of bias","or","binary",10,0.0638988876964935,0.128112464175527,0,2012.8,0.159082589128811,184.5
"CD015014","CD015014_pub2_data","1|34|Mortality (proportion of residents who died): sensitivity analysis by timing of effect|Longer-term","Mortality (proportion of residents who died): sensitivity analysis by timing of effect",1,34,"Longer-term","or","binary",3,-0.109081712866912,0.180493100415653,0,2007.33333333333,0.318140894216214,213
"CD015014","CD015014_pub2_data","1|34|Mortality (proportion of residents who died): sensitivity analysis by timing of effect|Short-term","Mortality (proportion of residents who died): sensitivity analysis by timing of effect",1,34,"Short-term","or","binary",21,0.0988615155194336,0.0934551196020994,0,2013.66666666667,0.167034684510161,156.238095238095
"CD015014","CD015014_pub2_data","1|36|Any hospital admission (proportion of residents with at least one hospital admission): sensitivity analysis by risk of bias|Low risk of bias","Any hospital admission (proportion of residents with at least one hospital admission): sensitivity analysis by risk of bias",1,36,"Low risk of bias","or","binary",6,-0.157451778905748,0.169628413878946,0.0277477269199891,2012.66666666667,0.285773530789817,170.5
"CD015014","CD015014_pub2_data","1|37|Any hospital admission (proportion of residents with at least one hospital admission): sensitivity by timing of effect|Longer-term","Any hospital admission (proportion of residents with at least one hospital admission): sensitivity by timing of effect",1,37,"Longer-term","or","binary",2,-0.313894571614363,0.289111474539345,0.0929005291967002,2002.5,0.588492721577299,232.5
"CD015014","CD015014_pub2_data","1|38|Any hospital admission (mean number of hospital admissions per resident)|","Any hospital admission (mean number of hospital admissions per resident)",1,38,"","or","binary",4,0.0287187372969397,1.00483437175798,0,2007,0,245
"CD015014","CD015014_pub2_data","1|39|Any hospital admission (logarithm of rate ratio)|","Any hospital admission (logarithm of rate ratio)",1,39,"","reported","reported",6,-0.0903313306508831,0.0944882040168134,0.0263332187508484,2014.33333333333,NA,0
"CD015014","CD015014_pub2_data","1|4|ED visits: logarithm of rate ratio per person-time|","ED visits: logarithm of rate ratio per person-time",1,4,"","reported","reported",2,-0.31520442069028,0.551459911886947,0.46686816,2016,0,102
"CD015014","CD015014_pub2_data","1|40|Length of hospital stay (mean number of days per resident)|","Length of hospital stay (mean number of days per resident)",1,40,"","reported","reported",5,-2.00548501840494,1.05147074761381,3.69310590716608,2009.6,0,766.4
"CD015014","CD015014_pub2_data","1|41|Length of hospital stay (mean number of days per resident): subgroup analysis by type of care provided|Primary and secondary care","Length of hospital stay (mean number of days per resident): subgroup analysis by type of care provided",1,41,"Primary and secondary care","reported","reported",3,-1.2512661386803,1.15660902731816,2.19389945775034,2017.33333333333,0,1003.66666666667
"CD015014","CD015014_pub2_data","1|41|Length of hospital stay (mean number of days per resident): subgroup analysis by type of care provided|Primary care","Length of hospital stay (mean number of days per resident): subgroup analysis by type of care provided",1,41,"Primary care","reported","reported",2,-3.29589814814815,2.67667926328783,12.57175,1998,0,410.5
"CD015014","CD015014_pub2_data","1|42|Length of hospital stay (mean number of days per resident): sensitivity analysis by risk of bias|Low risk of bias","Length of hospital stay (mean number of days per resident): sensitivity analysis by risk of bias",1,42,"Low risk of bias","reported","reported",3,-0.543527048947218,0.351184888721936,0.20401678066441,2013.33333333333,0,1209.66666666667
"CD015014","CD015014_pub2_data","1|42|Length of hospital stay (mean number of days per resident): sensitivity analysis by risk of bias|Unclear or high risk of bias","Length of hospital stay (mean number of days per resident): sensitivity analysis by risk of bias",1,42,"Unclear or high risk of bias","reported","reported",2,-4.92800985491377,1.34785501644649,0,2004,0,101.5
"CD015014","CD015014_pub2_data","1|43|Length of hospital stay (mean number of days per resident): sensitivity analysis by timing of effect|Short term","Length of hospital stay (mean number of days per resident): sensitivity analysis by timing of effect",1,43,"Short term","reported","reported",4,-0.707480790431574,0.407021544366067,0.306753216635803,2014.5,0,918
"CD015014","CD015014_pub2_data","1|44|Length of hospital stay (mean number of days per resident): no meta-analysis, calculations for individual studies |","Length of hospital stay (mean number of days per resident): no meta-analysis, calculations for individual studies ",1,44,"","or","binary",6,0.0938111079332456,0.819791567487262,0,2013.33333333333,0,215.5
"CD015014","CD015014_pub2_data","1|45|Length of hospital stay (mean number of days per admission/admitted resident) |","Length of hospital stay (mean number of days per admission/admitted resident) ",1,45,"","or","binary",2,0.195614383266787,1.42087298814215,0,2019,0,112.5
"CD015014","CD015014_pub2_data","1|48|'Next of kin' satisfaction with the health care received|","'Next of kin' satisfaction with the health care received",1,48,"","or","binary",2,0.0670846435380079,1.41810977349064,0,2018.5,0,210.5
"CD015014","CD015014_pub2_data","1|5|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission)|","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission)",1,5,"","or","binary",8,-0.424971579671781,0.206943335689861,0.14670650700111,2015,0.374399412021041,157.875
"CD015014","CD015014_pub2_data","1|6|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by EPOC category|Co-ordination of care","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by EPOC category",1,6,"Co-ordination of care","or","binary",7,-0.458803730356018,0.253270207031562,0.239427970347687,2014.57142857143,0.360215869377431,169.428571428571
"CD015014","CD015014_pub2_data","1|7|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by type of care provided|Primary and secondary care","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by type of care provided",1,7,"Primary and secondary care","or","binary",4,-0.460351004190968,0.481151567160361,0.730370680155263,2016.5,0.465711297533504,176
"CD015014","CD015014_pub2_data","1|7|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by type of care provided|Primary care","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by type of care provided",1,7,"Primary care","or","binary",4,-0.633530158668191,0.229299525848242,0,2013.5,0.283087526508579,139.75
"CD015014","CD015014_pub2_data","1|8|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition|Mixed health residents","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition",1,8,"Mixed health residents","or","binary",2,-0.122959333043341,0.206282546727469,0,2016.5,0.516692851531815,191
"CD015014","CD015014_pub2_data","1|8|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition|Recently discharged","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition",1,8,"Recently discharged","or","binary",3,-0.692241762080522,0.743698611797215,1.39360159650236,2017,0.434381232532234,133
"CD015014","CD015014_pub2_data","1|8|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition|Residents with infections","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition",1,8,"Residents with infections","or","binary",2,-0.690528409141582,0.357767171876602,0.0178117720899238,2014,0.117794486215539,191
"CD015014","CD015014_pub2_data","1|9|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by risk of bias|High or unclear risk of bias","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by risk of bias",1,9,"High or unclear risk of bias","or","binary",4,-0.788303886867569,0.495881519031311,0.596811360326675,2016.75,0.355432645504416,127.75
"CD015014","CD015014_pub2_data","1|9|Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by risk of bias|Low risk of bias","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by risk of bias",1,9,"Low risk of bias","or","binary",4,-0.234825967575972,0.211905488782032,0.0627817891929846,2013.25,0.393366178537667,188
"CD015033","CD015033_pub2_data","1|1|All-cause mortality (range from18 months to 24 months)|","All-cause mortality (range from18 months to 24 months)",1,1,"","or","binary",3,1.26386385647817,0.933146573967865,0,2013.33333333333,0,117
"CD015033","CD015033_pub2_data","1|10|Health-related quality of life (psychosocial health, 24 months)|","Health-related quality of life (psychosocial health, 24 months)",1,10,"","or","binary",2,-0.0361777970305023,1.42004770323995,0,2010.5,0,125.5
"CD015033","CD015033_pub2_data","1|11|Non-serious adverse events (number of events, 24 months)|","Non-serious adverse events (number of events, 24 months)",1,11,"","reported","reported",2,0,0.110236455015161,0,2010.5,0.559825508932281,141.5
"CD015033","CD015033_pub2_data","1|12|Non-serious averse events. Best-worst case scenario sensitivity analysis|","Non-serious averse events. Best-worst case scenario sensitivity analysis",1,12,"","reported","reported",2,0,0.110236455015161,0,2010.5,0.708869962609057,141.5
"CD015033","CD015033_pub2_data","1|13|Non-serious averse events. Worst-best case scenario sensitivity analysis|","Non-serious averse events. Worst-best case scenario sensitivity analysis",1,13,"","reported","reported",2,0,0.110236455015161,0,2010.5,0.559825508932281,141.5
"CD015033","CD015033_pub2_data","1|14|Liver enzyme levels. Serum ALT levels (range from 2 months to 24 months)|","Liver enzyme levels. Serum ALT levels (range from 2 months to 24 months)",1,14,"","or","binary",11,-0.0055831645514966,0.609125353213426,0,2014,0,64.3636363636364
"CD015033","CD015033_pub2_data","1|16|Liver enzyme levels. Serum ALP levels (range from 2 months to 24 months)|","Liver enzyme levels. Serum ALP levels (range from 2 months to 24 months)",1,16,"","or","binary",5,0.0156384858797283,0.901354523648171,0,2014,0,83.2
"CD015033","CD015033_pub2_data","1|17|Liver enzyme levels. Serum GGT levels (range from 12 months to 24 months)|","Liver enzyme levels. Serum GGT levels (range from 12 months to 24 months)",1,17,"","or","binary",3,0.0167081063651259,1.16083201884678,0,2011.33333333333,0,105
"CD015033","CD015033_pub2_data","1|18|Imaging response. No-improvement in steatosis on ultrasound (range from 5 months to 12 months)|","Imaging response. No-improvement in steatosis on ultrasound (range from 5 months to 12 months)",1,18,"","or","binary",4,-0.818766710512635,0.301241460443649,0,2014.66666666667,0.736426767676768,59
"CD015033","CD015033_pub2_data","1|2|All-cause mortality. Best-worst case scenario sensitivity analysis|","All-cause mortality. Best-worst case scenario sensitivity analysis",1,2,"","reported","reported",3,0,0.918611033130631,0,2013.33333333333,0.19072843096524,117
"CD015033","CD015033_pub2_data","1|21|Imaging response. Proportion of participants without a normal ultrasound (range from 5 months to 12 months)|","Imaging response. Proportion of participants without a normal ultrasound (range from 5 months to 12 months)",1,21,"","or","binary",4,-0.653210624005489,0.413930288486066,0.258149520814208,2014.75,0.711886724386724,64
"CD015033","CD015033_pub2_data","1|22|Imaging response. Proportion of participants without a normal ultrasound. Best-worst case scenario sensitivity analysis|","Imaging response. Proportion of participants without a normal ultrasound. Best-worst case scenario sensitivity analysis",1,22,"","reported","reported",2,0,0.118843616709957,0,2008.5,0.694805194805195,57.5
"CD015033","CD015033_pub2_data","1|23|Imaging response. Proportion of participants without a normal ultrasound. Worst-best case scenario sensitivity analysis|","Imaging response. Proportion of participants without a normal ultrasound. Worst-best case scenario sensitivity analysis",1,23,"","reported","reported",2,0,0.120135853529035,0,2008.5,0.581168831168831,57.5
"CD015033","CD015033_pub2_data","1|3|All-cause mortality. Worst-best case scenario sensitivity analysis|","All-cause mortality. Worst-best case scenario sensitivity analysis",1,3,"","or","binary",3,2.77971193184169,0.852603059504398,0,2013.33333333333,0,117
"CD015033","CD015033_pub2_data","1|5|Serious adverse events (24 months)|","Serious adverse events (24 months)",1,5,"","or","binary",2,0.610851763587872,0.91122556053003,0.368073669153184,2010.5,0.0172413793103448,141.5
"CD015033","CD015033_pub2_data","1|6|Serious adverse events. Best-worst case scenario sensitivity analysis|","Serious adverse events. Best-worst case scenario sensitivity analysis",1,6,"","or","binary",2,-1.56718085373541,0.473810958140679,0,2010.5,0.178334025758205,141.5
"CD015033","CD015033_pub2_data","1|7|Serious adverse events. Worst-best case scenario sensitivity analysis|","Serious adverse events. Worst-best case scenario sensitivity analysis",1,7,"","or","binary",2,1.87964875663634,0.653218838167151,0,2010.5,0.0172413793103448,141.5
"CD015033","CD015033_pub2_data","1|9|Health-related quality of life (physical health, 24 months)|","Health-related quality of life (physical health, 24 months)",1,9,"","or","binary",2,-0.0361777970305023,1.42004770323995,0,2010.5,0,125.5
"CD015033","CD015033_pub2_data","2|7|Liver enzyme levels. Serum ALT levels (range from 6 months to 12 months)|","Liver enzyme levels. Serum ALT levels (range from 6 months to 12 months)",2,7,"","or","binary",2,-0.0442220392193467,1.42581090264819,0,2004.5,0,66.5
"CD015033","CD015033_pub2_data","3|1|Serum ALT levels (for treatment time)|＜ 1 year","Serum ALT levels (for treatment time)",3,1,"＜ 1 year","or","binary",6,-0.00507563726187871,0.825973794907663,0,2016.2,0,48.6666666666667
"CD015033","CD015033_pub2_data","3|1|Serum ALT levels (for treatment time)|≥ 1 year","Serum ALT levels (for treatment time)",3,1,"≥ 1 year","or","binary",5,-0.00618827484301936,0.901890555552343,0,2011.8,0,83.2
"CD015033","CD015033_pub2_data","3|2|Serum ALT levels (for daily dosage)|≥ 400 IU","Serum ALT levels (for daily dosage)",3,2,"≥ 400 IU","or","binary",10,-0.0185331477779939,0.639010241575466,0,2014.11111111111,0,64.4
"CD015033","CD015033_pub2_data","3|3|Serum ALT levels (for profit support)|for profit","Serum ALT levels (for profit support)",3,3,"for profit","or","binary",4,0.0703971931229437,1.00823178562855,0,2010,0,89.75
"CD015033","CD015033_pub2_data","3|3|Serum ALT levels (for profit support)|without for profit","Serum ALT levels (for profit support)",3,3,"without for profit","or","binary",6,-0.0573559270232899,0.824850959385989,0,2019.2,0,53.5
"CD015033","CD015033_pub2_data","3|4|Serum AST levels (for treatment time)|＜ 1 year","Serum AST levels (for treatment time)",3,4,"＜ 1 year","or","binary",6,-0.0050722446626421,0.825697704800028,0,2020,0,49.3333333333333
"CD015033","CD015033_pub2_data","3|4|Serum AST levels (for treatment time)|≥ 1 year","Serum AST levels (for treatment time)",3,4,"≥ 1 year","or","binary",5,-0.0102181362544249,0.902021476765712,0,2011.8,0,79.8
"CD015033","CD015033_pub2_data","3|5|Serum AST levels (for daily dosage)|≥ 400 IU","Serum AST levels (for daily dosage)",3,5,"≥ 400 IU","or","binary",10,-0.0205494368709845,0.638928906595446,0,2016.22222222222,0,63.1
"CD015033","CD015033_pub2_data","3|6|Serum AST levels (for profit support)|for profit","Serum AST levels (for profit support)",3,6,"for profit","or","binary",4,0.0653884165173524,1.00841470229418,0,2010,0,85.5
"CD015033","CD015033_pub2_data","3|6|Serum AST levels (for profit support)|without for profit","Serum AST levels (for profit support)",3,6,"without for profit","or","binary",7,-0.0492286682738645,0.764179487318227,0,2019.83333333333,0,50.4285714285714
"CD015038","CD015038_pub2_data","1|1|Mortality|","Mortality",1,1,"","or","binary",5,-0.235728437834122,0.722169651947663,0,2011,0.0016260162601626,475.4
"CD015038","CD015038_pub2_data","1|10|Complicated appendicitis at surgery|","Complicated appendicitis at surgery",1,10,"","or","binary",8,-0.204629628939617,0.286808257477422,0.250588014217993,2013.125,0.0836407039817682,328.25
"CD015038","CD015038_pub2_data","1|11|Pain score (acute)|","Pain score (acute)",1,11,"","or","binary",3,-0.00550552854928451,1.16596037874822,0,2009,0,199.666666666667
"CD015038","CD015038_pub2_data","1|13|Length of hospital stay|","Length of hospital stay",1,13,"","or","binary",11,0.0112535283346695,0.606432746858542,0,2015,0,290.181818181818
"CD015038","CD015038_pub2_data","1|14|Period of sick leave|","Period of sick leave",1,14,"","or","binary",9,-0.0444649052442799,0.670614379102753,0,2016.44444444444,0,267.777777777778
"CD015038","CD015038_pub2_data","1|15|Negative appendectomy rate (normal histology)|","Negative appendectomy rate (normal histology)",1,15,"","or","binary",5,1.3324274414745,0.341649957092223,4.56126425915214e-07,2012.2,0.0765944278237735,141.4
"CD015038","CD015038_pub2_data","1|16|Postoperative quality of life|","Postoperative quality of life",1,16,"","or","binary",3,0.000543711948825069,1.15635746205987,0,2018.66666666667,0,650
"CD015038","CD015038_pub2_data","1|2|Success of treatment|","Success of treatment",1,2,"","or","binary",7,-2.03247485107927,0.738871935409473,2.04188956385675,2016.85714285714,0.957552251669899,353
"CD015038","CD015038_pub2_data","1|3|Clostridium difficile diarrhoea|","Clostridium difficile diarrhoea",1,3,"","or","binary",3,-0.0267520688458714,0.605505898721949,0,2012,0.00203252032520325,517.333333333333
"CD015038","CD015038_pub2_data","1|4|Wound infection|","Wound infection",1,4,"","or","binary",9,-1.39183261514667,0.552955240304476,0.821082096274387,2015.44444444444,0.070956295935205,289.555555555556
"CD015038","CD015038_pub2_data","1|7|Intra-abdominal abscess or collection|","Intra-abdominal abscess or collection",1,7,"","or","binary",6,0.560694858849127,0.298408782782785,4.91927107294441e-06,2019.33333333333,0.0229523091779874,305.166666666667
"CD015038","CD015038_pub2_data","2|1|Success of treatment|At < 2 weeks","Success of treatment",2,1,"At < 2 weeks","or","binary",5,-2.53269224454469,0.697914309911532,0,2015.4,1,190.4
"CD015038","CD015038_pub2_data","2|1|Success of treatment|At > 4 weeks","Success of treatment",2,1,"At > 4 weeks","or","binary",2,-1.84926259091804,1.9969564419996,7.06464914397737,2020.5,0.851432880844646,759.5
"CD015040","CD015040_pub2_data","1|3|PTSD symptom severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)|","PTSD symptom severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)",1,3,"","reported","reported",5,0,0.155499968891637,0,2017,0,48.8
"CD015040","CD015040_pub2_data","2|1|Stimulation frequency: low versus high frequency|High frequency (10 Hz to 50 Hz)","Stimulation frequency: low versus high frequency",2,1,"High frequency (10 Hz to 50 Hz)","reported","reported",5,0,0.137200315355399,0,2018.4,0,43.2
"CD015040","CD015040_pub2_data","2|1|Stimulation frequency: low versus high frequency|Low frequency (1 Hz)","Stimulation frequency: low versus high frequency",2,1,"Low frequency (1 Hz)","reported","reported",2,0,0.358585335033938,0,2016,0,17.5
"CD015040","CD015040_pub2_data","2|2|Combination treatment status: rTMS alone versus rTMS paired with exposure/psychotherapy|rTMS combined with exposure/psychotherapy","Combination treatment status: rTMS alone versus rTMS paired with exposure/psychotherapy",2,2,"rTMS combined with exposure/psychotherapy","reported","reported",2,0,0.167732526407102,0,2017,0,72.5
"CD015040","CD015040_pub2_data","2|2|Combination treatment status: rTMS alone versus rTMS paired with exposure/psychotherapy|rTMS stand-alone treatment","Combination treatment status: rTMS alone versus rTMS paired with exposure/psychotherapy",2,2,"rTMS stand-alone treatment","reported","reported",3,0,0.221815040399523,0,2017,0,33
"CD015040","CD015040_pub2_data","6|1|Depression severity: immediately after treatment, SMD (ITT, endpoint)|","Depression severity: immediately after treatment, SMD (ITT, endpoint)",6,1,"","or","binary",3,-0.25553906622731,1.17479863160167,0,2017,0,33
"CD015040","CD015040_pub2_data","6|2|Depression severity: immediately after treatment, SMD (ITT, endpoint, with data imputation)|","Depression severity: immediately after treatment, SMD (ITT, endpoint, with data imputation)",6,2,"","or","binary",4,-0.170121371175848,1.01399521991269,0,2018,0,56
"CD015040","CD015040_pub2_data","6|3|Depression severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)|","Depression severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)",6,3,"","or","binary",4,-0.170121371175848,1.01399521991269,0,2018,0,56
"CD015040","CD015040_pub2_data","7|2|Anxiety severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)|","Anxiety severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)",7,2,"","reported","reported",2,0,0.306537929237733,0,2016,0,24.5
"CD015042","CD015042_pub2_data","1|1|Number of continuously abstinent women|NA","Number of continuously abstinent women",1,1,NA,"reported","reported",3,0,0.0806714529771478,0,2004.5,0.499518999519,126
"CD015042","CD015042_pub2_data","1|2|Number of drinks per day|NA","Number of drinks per day",1,2,NA,"reported","reported",2,0,0.135671953231206,0,2004.5,0,78.5
"CD015042","CD015042_pub2_data","1|3|Number of women who completed treatment|NA","Number of women who completed treatment",1,3,NA,"reported","reported",7,0,0.0214892940532575,0,2006.66666666667,0.818211635033265,183.285714285714
"CD015060","CD015060_pub2_data","1|3|Haematuria resolution|","Haematuria resolution",1,3,"","or","binary",2,2.39205425408766,1.00237515914029,0.97767871587335,2005.5,0.0833333333333333,30
"CD015060","CD015060_pub2_data","2|1|Proteinuria: ≥ 50% increase from baseline or ≥ 1 g/d|","Proteinuria: ≥ 50% increase from baseline or ≥ 1 g/d",2,1,"","or","binary",2,-1.11755814811026,0.729927194606654,0,1997,0.135746606334842,51.5
"CD015060","CD015060_pub2_data","3|1|Final proteinuria |","Final proteinuria ",3,1,"","or","binary",2,-0.0413007664344453,1.42584649865337,0,1997.5,0,62
"CD015064","CD015064_pub2_data","2|1|Pimecrolimus 1% versus vehicle|NA","Pimecrolimus 1% versus vehicle",2,1,NA,"or","binary",2,-0.360905277865577,1.42055924418923,0,2003.5,0,137.5
"CD015064","CD015064_pub2_data","3|1|Pimecrolimus 1% versus vehicle|NA","Pimecrolimus 1% versus vehicle",3,1,NA,"or","binary",2,0.795370193813012,0.407920513172768,0.230911930009654,2002,0.492300724637681,221
"CD015064","CD015064_pub2_data","4|1|Pimecrolimus 1% versus vehicle|NA","Pimecrolimus 1% versus vehicle",4,1,NA,"or","binary",3,0.0466656222784864,0.412073281603653,0.222806454833521,2004,0.0454722492697176,459.333333333333
"CD015064","CD015064_pub2_data","5|1|Topical corticosteroids versus topical calcineurin inhibitors|NA","Topical corticosteroids versus topical calcineurin inhibitors",5,1,NA,"reported","reported",3,0,0.902748887967556,0,2008,0,1356.33333333333
"CD015066","CD015066_pub2_data","1|1|Personal attenuation rating (PAR; dB) (immediate, short-term, long-term)|Simple instructions versus no instructions, earplugs, short-term follow-up (1 and 4 months)","Personal attenuation rating (PAR; dB) (immediate, short-term, long-term)",1,1,"Simple instructions versus no instructions, earplugs, short-term follow-up (1 and 4 months)","or","binary",2,-0.00258971441350588,1.41768529189848,0,2007,0,203
"CD015066","CD015066_pub2_data","2|1|Personal attenuation rating (PAR; dB) (immediate)|Earplugs","Personal attenuation rating (PAR; dB) (immediate)",2,1,"Earplugs","or","binary",2,-0.633398769951783,1.41903791936718,0,2021,0,160.5
"CD015066","CD015066_pub2_data","2|2|Earplugs, PAR pass rate (%) (immediate)|","Earplugs, PAR pass rate (%) (immediate)",2,2,"","or","binary",2,1.97366323373416,0.389709308255302,0.137766896568846,2021,0.504545454545455,160.5
"CD015083","CD015083_pub2_data","1|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",1,1,"","reported","reported",18,-0.0734127711435662,0.0436900546856377,0.00711988931142881,2016.66666666667,0,897.611111111111
"CD015083","CD015083_pub2_data","1|10|Referral or use of any injection to the lumbar spine at last follow-up within 12 months|","Referral or use of any injection to the lumbar spine at last follow-up within 12 months",1,10,"","reported","reported",8,-0.0685881090057621,0.151978588461246,0,2018,0,696.625
"CD015083","CD015083_pub2_data","1|11|Health-related quality of life at last follow-up within 12 months|","Health-related quality of life at last follow-up within 12 months",1,11,"","reported","reported",24,0.128536458387192,0.0261829728644841,1.19394263998483e-06,2017.70833333333,0,375.291666666667
"CD015083","CD015083_pub2_data","1|12|Participant satisfaction with care at last follow-up within 12 months|","Participant satisfaction with care at last follow-up within 12 months",1,12,"","reported","reported",12,0.552385688817366,0.313319892551663,1.0199473927075,2016.41666666667,0,394.083333333333
"CD015083","CD015083_pub2_data","1|2|Prescription or use of opioid medication at last follow-up within 12 months|","Prescription or use of opioid medication at last follow-up within 12 months",1,2,"","reported","reported",15,-0.05829411431647,0.0472370399760073,0.00399434523573013,2019.33333333333,0,879
"CD015083","CD015083_pub2_data","1|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",1,3,"","reported","reported",10,0.0415879408952341,0.140421085955034,0,2016.7,0,418.9
"CD015083","CD015083_pub2_data","1|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|","Admission to hospital for non-specific LBP at last follow-up within 12 months",1,4,"","reported","reported",12,-0.171686043729067,0.111265453341915,0,2015.58333333333,0,873.75
"CD015083","CD015083_pub2_data","1|5|Pain at last follow-up within 12 months|","Pain at last follow-up within 12 months",1,5,"","reported","reported",39,-0.241730379621222,0.10089903313176,0.224211760610408,2014.66666666667,0,241.102564102564
"CD015083","CD015083_pub2_data","1|6|Back-related function at last follow-up within 12 months|","Back-related function at last follow-up within 12 months",1,6,"","reported","reported",48,-0.122356891015561,0.0421898581403962,0.0484502339958557,2014.5,0,285.166666666667
"CD015083","CD015083_pub2_data","1|7|Adverse events at last follow-up within 12 months|","Adverse events at last follow-up within 12 months",1,7,"","reported","reported",10,-0.208491130693249,0.344627542640901,0.41377123851016,2017.8,0,288
"CD015083","CD015083_pub2_data","1|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",1,8,"","reported","reported",9,-0.0604202222278383,0.10841894152482,0,2015.55555555556,0,956.666666666667
"CD015083","CD015083_pub2_data","1|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",1,9,"","reported","reported",7,-0.0526135459995421,0.0803266823508214,0,2020.14285714286,0,583.142857142857
"CD015083","CD015083_pub2_data","2|1|Referral for or receipt of any lumbar spine imaging|Up to 6 months","Referral for or receipt of any lumbar spine imaging",2,1,"Up to 6 months","reported","reported",10,-0.0208636228169408,0.0583535983299338,0,2016.4,0,1143.7
"CD015083","CD015083_pub2_data","2|10|Referral or use of any injection to the lumbar spine|> 6 months up to 12 months","Referral or use of any injection to the lumbar spine",2,10,"> 6 months up to 12 months","reported","reported",6,-0.0892415666743474,0.169187376928436,0.00888928302327316,2017.66666666667,0,737.833333333333
"CD015083","CD015083_pub2_data","2|10|Referral or use of any injection to the lumbar spine|Up to 6 months","Referral or use of any injection to the lumbar spine",2,10,"Up to 6 months","reported","reported",3,-0.138517483272923,0.502341548394357,0,2020.33333333333,0,478.666666666667
"CD015083","CD015083_pub2_data","2|11|Health-related quality of life|> 6 months up to 12 months","Health-related quality of life",2,11,"> 6 months up to 12 months","reported","reported",15,0.122544422026423,0.0299581671674856,0,2016.6,0,455.066666666667
"CD015083","CD015083_pub2_data","2|11|Health-related quality of life|Up to 6 months","Health-related quality of life",2,11,"Up to 6 months","reported","reported",19,0.169426648746289,0.0365922599025423,0.00461179588521164,2017.42105263158,0,290.947368421053
"CD015083","CD015083_pub2_data","2|12|Participant satisfaction with care|> 6 months up to 12 months","Participant satisfaction with care",2,12,"> 6 months up to 12 months","reported","reported",3,-0.132626912104179,0.169626198911976,0,2015.66666666667,0,317.666666666667
"CD015083","CD015083_pub2_data","2|12|Participant satisfaction with care|Up to 6 months","Participant satisfaction with care",2,12,"Up to 6 months","reported","reported",11,0.603192323369916,0.330457898819157,1.0804451918984,2016.36363636364,0,404.636363636364
"CD015083","CD015083_pub2_data","2|2|Prescription or use of opioid medication|> 6 months up to 12 months","Prescription or use of opioid medication",2,2,"> 6 months up to 12 months","reported","reported",9,-0.0347030008043162,0.0653670619225819,0.00731201347739218,2018,0,765.222222222222
"CD015083","CD015083_pub2_data","2|2|Prescription or use of opioid medication|Up to 6 months","Prescription or use of opioid medication",2,2,"Up to 6 months","reported","reported",10,-0.0787316570166171,0.0397786555051464,0,2020.6,0,986
"CD015083","CD015083_pub2_data","2|3|Referral to surgeon or lumbar spine surgery|> 6 months up to 12 months","Referral to surgeon or lumbar spine surgery",2,3,"> 6 months up to 12 months","reported","reported",7,0.0138745792423375,0.15273096999165,0,2015.14285714286,0,408
"CD015083","CD015083_pub2_data","2|3|Referral to surgeon or lumbar spine surgery|Up to 6 months","Referral to surgeon or lumbar spine surgery",2,3,"Up to 6 months","reported","reported",4,0.204415523717366,0.349873678908535,0,2018.25,0,372.25
"CD015083","CD015083_pub2_data","2|4|Admission to hospital for non-specific LBP|> 6 months up to 12 months","Admission to hospital for non-specific LBP",2,4,"> 6 months up to 12 months","reported","reported",7,-0.178822123514576,0.124493640519253,0,2013.85714285714,0,618
"CD015083","CD015083_pub2_data","2|4|Admission to hospital for non-specific LBP|Up to 6 months","Admission to hospital for non-specific LBP",2,4,"Up to 6 months","reported","reported",5,-0.146781835216899,0.312765684828635,0.0711017605814841,2018,0,1213.6
"CD015083","CD015083_pub2_data","2|5|Pain|> 6 months up to 12 months","Pain",2,5,"> 6 months up to 12 months","reported","reported",16,-0.365439232771124,0.0817735363388391,0.0226882697067312,2014.125,0,319.125
"CD015083","CD015083_pub2_data","2|5|Pain|Up to 6 months","Pain",2,5,"Up to 6 months","reported","reported",39,-0.25796106454136,0.103388201667091,0.247542966809904,2014.66666666667,0,240.666666666667
"CD015083","CD015083_pub2_data","2|6|Back-related function|> 6 months up to 12 months","Back-related function",2,6,"> 6 months up to 12 months","reported","reported",20,-0.155702287397223,0.0412368621101783,0.0145063500831388,2014.5,0,381.85
"CD015083","CD015083_pub2_data","2|6|Back-related function|Up to 6 months","Back-related function",2,6,"Up to 6 months","reported","reported",46,-0.122330105594962,0.0432064659190156,0.048525640022205,2014.26086956522,0,283.652173913043
"CD015083","CD015083_pub2_data","2|7|Adverse events|> 6 months up to 12 months","Adverse events",2,7,"> 6 months up to 12 months","reported","reported",8,-0.138690958459964,0.37442583656496,0.460865970989058,2017.75,0,334.875
"CD015083","CD015083_pub2_data","2|7|Adverse events|Up to 6 months","Adverse events",2,7,"Up to 6 months","reported","reported",3,-0.741802174428578,0.937248396301608,0,2018.66666666667,0,112.333333333333
"CD015083","CD015083_pub2_data","2|8|Referral for or receipt of advanced lumbar spine imaging|> 6 months up to 12 months","Referral for or receipt of advanced lumbar spine imaging",2,8,"> 6 months up to 12 months","reported","reported",6,-0.0859104077581291,0.117685784608633,8.38169585460111e-07,2016,0,618.166666666667
"CD015083","CD015083_pub2_data","2|8|Referral for or receipt of advanced lumbar spine imaging|Up to 6 months","Referral for or receipt of advanced lumbar spine imaging",2,8,"Up to 6 months","reported","reported",6,-0.129921577776155,0.263828537909066,0.153563876470413,2016.66666666667,0,1274.5
"CD015083","CD015083_pub2_data","2|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants|> 6 months up to 12 months","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants",2,9,"> 6 months up to 12 months","reported","reported",5,-0.0962791495136949,0.0859515278324037,0,2019.8,0,715
"CD015083","CD015083_pub2_data","2|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants|Up to 6 months","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants",2,9,"Up to 6 months","reported","reported",6,-0.0155731846065273,0.138436380802185,0.056392158072788,2020,0,678.166666666667
"CD015083","CD015083_pub2_data","3|1|Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months|Co-ordination of care and management of care processes","Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months",3,1,"Co-ordination of care and management of care processes","reported","reported",10,-0.0686735558941507,0.0637828181736856,0,2016.6,0,634.2
"CD015083","CD015083_pub2_data","3|1|Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months|Coordination of care and management of care processes/Information and communication technology","Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months",3,1,"Coordination of care and management of care processes/Information and communication technology","reported","reported",2,-0.063834693924107,0.133317689900265,0,2018.5,0,216
"CD015083","CD015083_pub2_data","3|1|Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months|How and when care is delivered/Co-ordination of care and management of care processes","Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months",3,1,"How and when care is delivered/Co-ordination of care and management of care processes","reported","reported",2,0.0867930133686819,0.102893205655807,0,2006,0,1144.5
"CD015083","CD015083_pub2_data","3|1|Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months|Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months",3,1,"Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,-0.133098002515478,0.118037986730485,0.023744757544,2022,0,1209.5
"CD015083","CD015083_pub2_data","3|10|Referral or use of any injection to the lumbar spine at last follow-up within 12 months|Co-ordination of care and management of care processes","Referral or use of any injection to the lumbar spine at last follow-up within 12 months",3,10,"Co-ordination of care and management of care processes","reported","reported",6,-0.297404158955761,0.244612351681934,0,2017,0,820.833333333333
"CD015083","CD015083_pub2_data","3|11|Health-related quality of life at last follow-up within 12 months|Co-ordination of care and management of care processes","Health-related quality of life at last follow-up within 12 months",3,11,"Co-ordination of care and management of care processes","reported","reported",8,0.0800804584140667,0.0438203139641592,0,2016.625,0,371.875
"CD015083","CD015083_pub2_data","3|11|Health-related quality of life at last follow-up within 12 months|Co-ordination of care and management of care processes/Information and communication technology","Health-related quality of life at last follow-up within 12 months",3,11,"Co-ordination of care and management of care processes/Information and communication technology","reported","reported",4,0.152963084302613,0.0543946707946879,4.33171686190222e-08,2019,0,437.25
"CD015083","CD015083_pub2_data","3|11|Health-related quality of life at last follow-up within 12 months|Information and communication technology","Health-related quality of life at last follow-up within 12 months",3,11,"Information and communication technology","reported","reported",3,0.423044847575684,0.186900697572989,0.0492419865195372,2021,0,77.6666666666667
"CD015083","CD015083_pub2_data","3|11|Health-related quality of life at last follow-up within 12 months|Who provides care and how the healthcare workforce is managed","Health-related quality of life at last follow-up within 12 months",3,11,"Who provides care and how the healthcare workforce is managed","reported","reported",2,0.0363400535548637,0.163257902759773,0.008663323808,2010.5,0,90
"CD015083","CD015083_pub2_data","3|11|Health-related quality of life at last follow-up within 12 months|Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","Health-related quality of life at last follow-up within 12 months",3,11,"Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,0.180055708220206,0.0795258908866357,0.00528995386,2022,0,1319.5
"CD015083","CD015083_pub2_data","3|12|Participant satisfaction with care at last follow-up within 12 months|Co-ordination of care and management of care processes","Participant satisfaction with care at last follow-up within 12 months",3,12,"Co-ordination of care and management of care processes","reported","reported",7,0.0924840152750562,0.162857146308881,0.0946717347773403,2015.71428571429,0,449
"CD015083","CD015083_pub2_data","3|12|Participant satisfaction with care at last follow-up within 12 months|Information and communication technology","Participant satisfaction with care at last follow-up within 12 months",3,12,"Information and communication technology","reported","reported",2,2.85437054260945,0.253180995204587,0,2012,0,136.5
"CD015083","CD015083_pub2_data","3|2|Prescription or use of opioid medication at last follow-up within 12 months|Co-ordination of care and management of care processes","Prescription or use of opioid medication at last follow-up within 12 months",3,2,"Co-ordination of care and management of care processes","reported","reported",10,0.00734836676745333,0.0687586652717639,0,2017.8,0,588.4
"CD015083","CD015083_pub2_data","3|2|Prescription or use of opioid medication at last follow-up within 12 months|Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","Prescription or use of opioid medication at last follow-up within 12 months",3,2,"Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,-0.0894803708386115,0.109123488924478,0.0183961477695,2022,0,1303
"CD015083","CD015083_pub2_data","3|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|Co-ordination of care and management of care processes","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",3,3,"Co-ordination of care and management of care processes","reported","reported",6,0.0703710971527456,0.204299483095028,0,2014.66666666667,0,517.333333333333
"CD015083","CD015083_pub2_data","3|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|Co-ordination of care and management of care processes/Information and communication technology","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",3,3,"Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,0.0433280936740946,0.228308182966225,0,2018.5,0,218.5
"CD015083","CD015083_pub2_data","3|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Co-ordination of care and management of care processes","Admission to hospital for non-specific LBP at last follow-up within 12 months",3,4,"Co-ordination of care and management of care processes","reported","reported",5,-0.220493204855642,0.159535776386321,0,2014.2,0,895.4
"CD015083","CD015083_pub2_data","3|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Co-ordination of care and management of care processes/Information and communication technology","Admission to hospital for non-specific LBP at last follow-up within 12 months",3,4,"Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,0.701385412814354,0.54461811739139,0,2018.5,0,216
"CD015083","CD015083_pub2_data","3|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|How and when care is delivered","Admission to hospital for non-specific LBP at last follow-up within 12 months",3,4,"How and when care is delivered","reported","reported",3,0.633207481096991,0.897713530166371,1.38561040225605,2012.66666666667,0,300.333333333333
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|Co-ordination of care and management of care processes","Pain at last follow-up within 12 months",3,5,"Co-ordination of care and management of care processes","reported","reported",19,-0.254351700008939,0.079505600686857,0.00753683224918848,2011.73684210526,0,245.157894736842
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|Co-ordination of care and management of care processes/Information and communication technology","Pain at last follow-up within 12 months",3,5,"Co-ordination of care and management of care processes/Information and communication technology","reported","reported",4,-0.616658078574787,0.166267106473386,0.0377262698216985,2019,0,437.25
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|How and when care is delivered","Pain at last follow-up within 12 months",3,5,"How and when care is delivered","reported","reported",2,-0.4571126272725,0.498157277634817,0.2736965778315,2007,0,78.5
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|How and when care is delivered/Co-ordination of care and management of care processes","Pain at last follow-up within 12 months",3,5,"How and when care is delivered/Co-ordination of care and management of care processes","reported","reported",2,-0.516092848940972,0.329985957086168,0.0461357156814999,2013.5,0,307.5
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|How and when care is delivered/Who provides care and how the healthcare workforce is managed","Pain at last follow-up within 12 months",3,5,"How and when care is delivered/Who provides care and how the healthcare workforce is managed","reported","reported",2,-0.505723107233656,0.260108787682254,0,2009,0,153
"CD015083","CD015083_pub2_data","3|5|Pain at last follow-up within 12 months|Information and communication technology","Pain at last follow-up within 12 months",3,5,"Information and communication technology","reported","reported",4,-0.334760066280119,0.251191816318912,0.00993336146307212,2021.5,0,78
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |Co-ordination of care and management of care processes","Back-related function at last follow-up within 12 months ",3,6,"Co-ordination of care and management of care processes","reported","reported",22,-0.127177163525486,0.0492823420567001,0.0204062169273194,2012.90909090909,0,291.863636363636
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |Coordination of care and management of care processes/Information and communication technology","Back-related function at last follow-up within 12 months ",3,6,"Coordination of care and management of care processes/Information and communication technology","reported","reported",4,-0.122282184512825,0.0549565672260177,0,2019,0,437.25
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |How and when care is delivered","Back-related function at last follow-up within 12 months ",3,6,"How and when care is delivered","reported","reported",2,-0.0846095219700539,0.159832997782075,0,2007,0,78.5
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |How and when care is delivered/Co-ordination of care and management of care processes","Back-related function at last follow-up within 12 months ",3,6,"How and when care is delivered/Co-ordination of care and management of care processes","reported","reported",2,-0.142171846658716,0.0968634964950426,0,2013.5,0,307.5
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |How and when care is delivered/Who provides care and how the healthcare workforce is managed","Back-related function at last follow-up within 12 months ",3,6,"How and when care is delivered/Who provides care and how the healthcare workforce is managed","reported","reported",2,-0.00143361116652188,0.227511993206298,0.0602320021915,2009,0,153
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |Information and communication technology","Back-related function at last follow-up within 12 months ",3,6,"Information and communication technology","reported","reported",8,-0.264142705915681,0.131625094405458,0.0858255463965919,2015.625,0,115
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |Who provides care and how the healthcare workforce is managed","Back-related function at last follow-up within 12 months ",3,6,"Who provides care and how the healthcare workforce is managed","reported","reported",2,-0.113926537163528,0.14936345935017,0,2010.5,0,90
"CD015083","CD015083_pub2_data","3|6|Back-related function at last follow-up within 12 months |Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","Back-related function at last follow-up within 12 months ",3,6,"Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology","reported","reported",2,-0.387830448127084,0.0690886088440439,0.001178996992,2022,0,1335.5
"CD015083","CD015083_pub2_data","3|7|Adverse events at last follow-up within 12 months|Co-ordination of care and management of care processes","Adverse events at last follow-up within 12 months",3,7,"Co-ordination of care and management of care processes","reported","reported",4,-0.550854618317688,0.526632014722636,0,2018.25,0,324
"CD015083","CD015083_pub2_data","3|7|Adverse events at last follow-up within 12 months|Information and communication technology","Adverse events at last follow-up within 12 months",3,7,"Information and communication technology","reported","reported",2,-0.481511003887352,0.389010901335653,0,2020.5,0,102.5
"CD015083","CD015083_pub2_data","3|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|Co-ordination of care and management of care processes","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",3,8,"Co-ordination of care and management of care processes","reported","reported",6,-0.101577749771783,0.114665079932286,0,2014.66666666667,0,616
"CD015083","CD015083_pub2_data","3|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Co-ordination of care and management of care processes","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",3,9,"Co-ordination of care and management of care processes","reported","reported",6,-0.0661164842128393,0.0960525568672786,0,2019.83333333333,0,581.833333333333
"CD015083","CD015083_pub2_data","4|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|General practice","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",4,1,"General practice","reported","reported",8,-0.0836957911474298,0.0656320517938758,0.0125429005595462,2017.125,0,1197.625
"CD015083","CD015083_pub2_data","4|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|Military/veterans affairs healthcare system","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",4,1,"Military/veterans affairs healthcare system","reported","reported",2,-0.058977453801677,0.112577560112279,0,2018.5,0,267.5
"CD015083","CD015083_pub2_data","4|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|Physiotherapy practices","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",4,1,"Physiotherapy practices","reported","reported",5,-0.270663015202257,0.185332834004425,0,2016.8,0,198.8
"CD015083","CD015083_pub2_data","4|10|Referral or use of any injection to the lumbar spine at last follow-up within 12 months|General practice","Referral or use of any injection to the lumbar spine at last follow-up within 12 months",4,10,"General practice","reported","reported",5,-0.0267127704493988,0.159449767024524,0,2017.8,0,1015.4
"CD015083","CD015083_pub2_data","4|10|Referral or use of any injection to the lumbar spine at last follow-up within 12 months|Physiotherapy practices","Referral or use of any injection to the lumbar spine at last follow-up within 12 months",4,10,"Physiotherapy practices","reported","reported",2,-1.33901111322573,1.19873131231307,0,2016,0,103
"CD015083","CD015083_pub2_data","4|11|Health-related quality of life at last follow-up within 12 months|Emergency department","Health-related quality of life at last follow-up within 12 months",4,11,"Emergency department","reported","reported",2,0.0654031878073537,0.141566450533749,0,2014.5,0,257.5
"CD015083","CD015083_pub2_data","4|11|Health-related quality of life at last follow-up within 12 months|General practice","Health-related quality of life at last follow-up within 12 months",4,11,"General practice","reported","reported",8,0.169558068892733,0.0344994507722537,0,2019,0,750.375
"CD015083","CD015083_pub2_data","4|11|Health-related quality of life at last follow-up within 12 months|Physiotherapy practices","Health-related quality of life at last follow-up within 12 months",4,11,"Physiotherapy practices","reported","reported",5,0.0937191375527577,0.0745813005786755,1.43778306727875e-06,2019.6,0,185.4
"CD015083","CD015083_pub2_data","4|11|Health-related quality of life at last follow-up within 12 months|Primary care and physiotherapy","Health-related quality of life at last follow-up within 12 months",4,11,"Primary care and physiotherapy","reported","reported",2,-0.0914805370251545,0.0976655250280353,0,2020,0,210
"CD015083","CD015083_pub2_data","4|11|Health-related quality of life at last follow-up within 12 months|Veterans affairs healthcare system","Health-related quality of life at last follow-up within 12 months",4,11,"Veterans affairs healthcare system","reported","reported",3,0.10286714596534,0.102005292172242,0,2017,0,128.666666666667
"CD015083","CD015083_pub2_data","4|12|Participant satisfaction with care at last follow-up within 12 months|General practice","Participant satisfaction with care at last follow-up within 12 months",4,12,"General practice","reported","reported",6,0.660907739249278,0.471524622340996,1.2015539123556,2015.33333333333,0,570.5
"CD015083","CD015083_pub2_data","4|12|Participant satisfaction with care at last follow-up within 12 months|Physiotherapy practices","Participant satisfaction with care at last follow-up within 12 months",4,12,"Physiotherapy practices","reported","reported",3,0.974996083834644,0.988793733087098,2.56926739261146,2021,0,123.666666666667
"CD015083","CD015083_pub2_data","4|2|Prescription or use of opioid medication at last follow-up within 12 months|General practice","Prescription or use of opioid medication at last follow-up within 12 months",4,2,"General practice","reported","reported",6,-0.0497328369451096,0.0564088010892079,0.00482999486997503,2019.33333333333,0,1164.5
"CD015083","CD015083_pub2_data","4|2|Prescription or use of opioid medication at last follow-up within 12 months|Military/veterans affairs healthcare system","Prescription or use of opioid medication at last follow-up within 12 months",4,2,"Military/veterans affairs healthcare system","reported","reported",2,-0.139326562798646,0.335631394203399,0.117241593751,2021.5,0,170
"CD015083","CD015083_pub2_data","4|2|Prescription or use of opioid medication at last follow-up within 12 months|Physiotherapy practices","Prescription or use of opioid medication at last follow-up within 12 months",4,2,"Physiotherapy practices","reported","reported",2,-0.608237348447516,0.468367327258746,0,2017.5,0,171.5
"CD015083","CD015083_pub2_data","4|2|Prescription or use of opioid medication at last follow-up within 12 months|Primary care and physiotherapy","Prescription or use of opioid medication at last follow-up within 12 months",4,2,"Primary care and physiotherapy","reported","reported",2,0.199640775090461,0.229739243320133,0,2021,0,305
"CD015083","CD015083_pub2_data","4|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|General practices","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",4,3,"General practices","reported","reported",4,-0.0779670884987265,0.216846776771279,0,2017,0,704
"CD015083","CD015083_pub2_data","4|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|Physiotherapy practices","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",4,3,"Physiotherapy practices","reported","reported",3,1.05265874162358,0.925234400438726,0,2018.33333333333,0,131
"CD015083","CD015083_pub2_data","4|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Emergency department","Admission to hospital for non-specific LBP at last follow-up within 12 months",4,4,"Emergency department","reported","reported",2,0.432831301483081,0.861971945552567,0.880874153789499,2014.5,0,2367.5
"CD015083","CD015083_pub2_data","4|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|General practice","Admission to hospital for non-specific LBP at last follow-up within 12 months",4,4,"General practice","reported","reported",4,-0.321183277892004,0.133474656181083,0,2018,0,1153.25
"CD015083","CD015083_pub2_data","4|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Physiotherapy practices","Admission to hospital for non-specific LBP at last follow-up within 12 months",4,4,"Physiotherapy practices","reported","reported",4,1.37153522383892,0.762981693836169,0,2015.75,0,123.75
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Emergency department","Pain at last follow-up within 12 months",4,5,"Emergency department","reported","reported",2,-0.0428312445529631,0.343438352842425,0,2014.5,0,257.5
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|General practice","Pain at last follow-up within 12 months",4,5,"General practice","reported","reported",13,-0.278860604149673,0.0907974729453953,0.0219163075305806,2012.38461538462,0,433.846153846154
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Occupational health clinic","Pain at last follow-up within 12 months",4,5,"Occupational health clinic","reported","reported",2,-1.06691050134158,0.430662513326778,0,2004.5,0,85
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Outpatient spine clinic","Pain at last follow-up within 12 months",4,5,"Outpatient spine clinic","reported","reported",3,0.881442235868378,0.462565220603028,0.53703365705251,2021.33333333333,0,60.3333333333333
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Physiotherapy practices","Pain at last follow-up within 12 months",4,5,"Physiotherapy practices","reported","reported",9,-0.444761709478958,0.192261175818324,0.111929993832458,2016.33333333333,0,138.222222222222
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Primary care and physiotherapy","Pain at last follow-up within 12 months",4,5,"Primary care and physiotherapy","reported","reported",3,-0.433919319095771,0.270986748274674,0.00642219315950989,2015.33333333333,0,159.333333333333
"CD015083","CD015083_pub2_data","4|5|Pain at last follow-up within 12 months|Veterans affairs healthcare system","Pain at last follow-up within 12 months",4,5,"Veterans affairs healthcare system","reported","reported",3,-0.710747216310468,0.333077035082497,0.169699793010008,2017,0,131.333333333333
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Emergency department","Back-related function at last follow-up within 12 months",4,6,"Emergency department","reported","reported",2,-0.023415213993884,0.141490248872326,0,2014.5,0,257.5
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|General practice","Back-related function at last follow-up within 12 months",4,6,"General practice","reported","reported",16,-0.143883610139305,0.0452063030499207,0.0122722285736001,2013.8125,0,559.0625
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Military/veterans affairs healthcare system","Back-related function at last follow-up within 12 months",4,6,"Military/veterans affairs healthcare system","reported","reported",4,-0.125875984015332,0.0833788404065441,0.00272473613775661,2018.5,0,166
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Occupational health clinic","Back-related function at last follow-up within 12 months",4,6,"Occupational health clinic","reported","reported",3,-0.373971246254357,0.125211834690397,0,2003.66666666667,0,89
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Outpatient spine clinic","Back-related function at last follow-up within 12 months",4,6,"Outpatient spine clinic","reported","reported",3,0.96223503917992,0.805294941418618,1.84399548213636,2021.33333333333,0,60.3333333333333
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Physiotherapy practices","Back-related function at last follow-up within 12 months",4,6,"Physiotherapy practices","reported","reported",13,-0.185507916222127,0.0959120759263767,0.0712709953752635,2014.30769230769,0,142.846153846154
"CD015083","CD015083_pub2_data","4|6|Back-related function at last follow-up within 12 months|Primary care and physiotherapy","Back-related function at last follow-up within 12 months",4,6,"Primary care and physiotherapy","reported","reported",3,0.0258897915262064,0.0915446539425811,0,2015.33333333333,0,159.333333333333
"CD015083","CD015083_pub2_data","4|7|Adverse events at last follow-up within 12 months|General practice","Adverse events at last follow-up within 12 months",4,7,"General practice","reported","reported",2,-0.641163476379755,0.171152499545119,0,2019.5,0,702.5
"CD015083","CD015083_pub2_data","4|7|Adverse events at last follow-up within 12 months|Military/veterans affairs healthcare system","Adverse events at last follow-up within 12 months",4,7,"Military/veterans affairs healthcare system","reported","reported",3,0.340107954233055,0.657119613416328,0.77121799381481,2018,0,221.666666666667
"CD015083","CD015083_pub2_data","4|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|General practice","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",4,8,"General practice","reported","reported",2,-0.111107060703883,0.147277908760672,0,2016,0,1414
"CD015083","CD015083_pub2_data","4|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|Physiotherapy practices","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",4,8,"Physiotherapy practices","reported","reported",3,0.42575321780016,0.49226742500462,0,2014.33333333333,0,148.333333333333
"CD015083","CD015083_pub2_data","4|9|Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months|General practices","Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months",4,9,"General practices","reported","reported",3,-0.155848839372627,0.111948275200831,0,2021.66666666667,0,1103
"CD015083","CD015083_pub2_data","4|9|Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Military/veterans affairs healthcare system","Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months",4,9,"Military/veterans affairs healthcare system","reported","reported",2,-0.333524875786049,0.446608243843977,0.2963217562375,2021.5,0,170
"CD015083","CD015083_pub2_data","4|9|Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Physiotherapy practices","Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months",4,9,"Physiotherapy practices","reported","reported",2,0.158838931256095,0.746678228433581,0,2016.5,0,216.5
"CD015083","CD015083_pub2_data","5|1|Referral or receipt of any lumbar spine imaging at last follow-up within 12 months|Acute and chronic symptoms","Referral or receipt of any lumbar spine imaging at last follow-up within 12 months",5,1,"Acute and chronic symptoms","reported","reported",12,-0.0632935732423011,0.0631094807408574,0,2018.08333333333,0,549.333333333333
"CD015083","CD015083_pub2_data","5|1|Referral or receipt of any lumbar spine imaging at last follow-up within 12 months|Acute symptoms","Referral or receipt of any lumbar spine imaging at last follow-up within 12 months",5,1,"Acute symptoms","reported","reported",2,-0.0879574359493338,0.170975859686488,0.0514973087125,2013,0,2004
"CD015083","CD015083_pub2_data","5|1|Referral or receipt of any lumbar spine imaging at last follow-up within 12 months|Not stated","Referral or receipt of any lumbar spine imaging at last follow-up within 12 months",5,1,"Not stated","reported","reported",3,-0.0176934686826719,0.0554036476616215,0,2014.33333333333,0,1770.66666666667
"CD015083","CD015083_pub2_data","5|10|Referral for or use of any injection to the lumbar spine at last follow-up within 12 months|Acute and chronic symptoms","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months",5,10,"Acute and chronic symptoms","reported","reported",7,-0.310109525932891,0.242562328035432,0,2017.42857142857,0,710.714285714286
"CD015083","CD015083_pub2_data","5|11|Health-related quality of life at last follow-up within 12 months|Acute and chronic symptoms","Health-related quality of life at last follow-up within 12 months",5,11,"Acute and chronic symptoms","reported","reported",11,0.0966988826001587,0.0425329913743883,9.35323149712574e-07,2017.09090909091,0,273.363636363636
"CD015083","CD015083_pub2_data","5|11|Health-related quality of life at last follow-up within 12 months|Acute symptoms","Health-related quality of life at last follow-up within 12 months",5,11,"Acute symptoms","reported","reported",6,0.19787940448264,0.0478468024453634,1.04998174673283e-06,2017.83333333333,0,633.833333333333
"CD015083","CD015083_pub2_data","5|11|Health-related quality of life at last follow-up within 12 months|Chronic symptoms","Health-related quality of life at last follow-up within 12 months",5,11,"Chronic symptoms","reported","reported",5,0.0950762627517827,0.0686739009687862,0,2017.4,0,192.6
"CD015083","CD015083_pub2_data","5|11|Health-related quality of life at last follow-up within 12 months|Not stated","Health-related quality of life at last follow-up within 12 months",5,11,"Not stated","reported","reported",2,0.104925495745265,0.066029885739671,0,2021.5,0,617
"CD015083","CD015083_pub2_data","5|12|Participant satisfaction with care at last follow-up within 12 months|Acute and chronic symptoms","Participant satisfaction with care at last follow-up within 12 months",5,12,"Acute and chronic symptoms","reported","reported",3,-0.0382225025495568,0.209445197532247,0,2019,0,579
"CD015083","CD015083_pub2_data","5|12|Participant satisfaction with care at last follow-up within 12 months|Not stated","Participant satisfaction with care at last follow-up within 12 months",5,12,"Not stated","reported","reported",7,0.991684169651757,0.484323600100045,1.48082486326021,2017,0,353.285714285714
"CD015083","CD015083_pub2_data","5|2|Prescription or use of opioid medication at last follow-up within 12 months|Acute and chronic symptoms","Prescription or use of opioid medication at last follow-up within 12 months",5,2,"Acute and chronic symptoms","reported","reported",9,0.0133125418890198,0.0719605107535232,0,2019.11111111111,0,624.888888888889
"CD015083","CD015083_pub2_data","5|2|Prescription or use of opioid medication at last follow-up within 12 months|Chronic symptoms","Prescription or use of opioid medication at last follow-up within 12 months",5,2,"Chronic symptoms","reported","reported",3,-0.168911432438675,0.264660514042965,0.0482785730891145,2017.66666666667,0,182
"CD015083","CD015083_pub2_data","5|2|Prescription or use of opioid medication at last follow-up within 12 months|Not stated","Prescription or use of opioid medication at last follow-up within 12 months",5,2,"Not stated","reported","reported",2,-0.0703949555633927,0.10811302608249,0.0147918528,2021.5,0,2597
"CD015083","CD015083_pub2_data","5|3|Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months|Acute and chronic symptoms","Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months",5,3,"Acute and chronic symptoms","reported","reported",7,-0.0278003122925216,0.254595042058204,0,2017.42857142857,0,420.571428571429
"CD015083","CD015083_pub2_data","5|3|Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months|Chronic symptoms","Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months",5,3,"Chronic symptoms","reported","reported",2,0.106107237276147,0.189296841022336,0,2011.5,0,323.5
"CD015083","CD015083_pub2_data","5|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Acute and chronic symptoms","Admission to hospital for non-specific LBP at last follow-up within 12 months",5,4,"Acute and chronic symptoms","reported","reported",7,-0.202623995764729,0.175563212405731,0,2016.14285714286,0,631.285714285714
"CD015083","CD015083_pub2_data","5|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Chronic symptoms","Admission to hospital for non-specific LBP at last follow-up within 12 months",5,4,"Chronic symptoms","reported","reported",2,0.203537687149692,0.418663040088252,0.1514182439375,2011.5,0,321
"CD015083","CD015083_pub2_data","5|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Not stated","Admission to hospital for non-specific LBP at last follow-up within 12 months",5,4,"Not stated","reported","reported",2,-0.258873953185818,0.164466345193186,0,2021.5,0,2657
"CD015083","CD015083_pub2_data","5|5|Pain at last follow-up within 12 months|Acute and chronic symptoms","Pain at last follow-up within 12 months",5,5,"Acute and chronic symptoms","reported","reported",15,-0.230042384419314,0.10738045180747,0.0261533013256359,2016.93333333333,0,271.6
"CD015083","CD015083_pub2_data","5|5|Pain at last follow-up within 12 months|Acute symptoms","Pain at last follow-up within 12 months",5,5,"Acute symptoms","reported","reported",7,-0.426280900313473,0.102847534270136,2.23158766647532e-06,2014.57142857143,0,290
"CD015083","CD015083_pub2_data","5|5|Pain at last follow-up within 12 months|Chronic symptoms","Pain at last follow-up within 12 months",5,5,"Chronic symptoms","reported","reported",11,0.0932411316378857,0.281239109284401,0.628750805645733,2013,0,139.727272727273
"CD015083","CD015083_pub2_data","5|5|Pain at last follow-up within 12 months|Not stated","Pain at last follow-up within 12 months",5,5,"Not stated","reported","reported",6,-0.47006939235442,0.109066060401768,0,2012.16666666667,0,293.666666666667
"CD015083","CD015083_pub2_data","5|6|Back-related function at last follow-up within 12 months|Acute and chronic symptoms","Back-related function at last follow-up within 12 months",5,6,"Acute and chronic symptoms","reported","reported",19,-0.133442851993766,0.0552626191618677,0.0252298180930803,2016.68421052632,0,311.894736842105
"CD015083","CD015083_pub2_data","5|6|Back-related function at last follow-up within 12 months|Acute symptoms","Back-related function at last follow-up within 12 months",5,6,"Acute symptoms","reported","reported",10,-0.164202061641763,0.0590452979208553,0.0118151165470798,2015.4,0,423.1
"CD015083","CD015083_pub2_data","5|6|Back-related function at last follow-up within 12 months|Chronic symptoms","Back-related function at last follow-up within 12 months",5,6,"Chronic symptoms","reported","reported",11,0.198947466675285,0.2272464595587,0.497580930287244,2013.09090909091,0,111.818181818182
"CD015083","CD015083_pub2_data","5|6|Back-related function at last follow-up within 12 months|Not stated","Back-related function at last follow-up within 12 months",5,6,"Not stated","reported","reported",8,-0.200127099621854,0.0718706700230733,0.0174701396138028,2010.125,0,287.625
"CD015083","CD015083_pub2_data","5|7|Adverse events at last follow-up within 12 months|Acute and chronic symptoms","Adverse events at last follow-up within 12 months",5,7,"Acute and chronic symptoms","reported","reported",5,-0.454794799753357,0.323229761738365,0,2017.2,0,283.4
"CD015083","CD015083_pub2_data","5|7|Adverse events at last follow-up within 12 months|Chronic symptoms","Adverse events at last follow-up within 12 months",5,7,"Chronic symptoms","reported","reported",3,0.284297503457429,0.884366048779205,1.19362724524654,2019.33333333333,0,165
"CD015083","CD015083_pub2_data","5|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|Acute and chronic symptoms","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",5,8,"Acute and chronic symptoms","reported","reported",7,-0.0847920887094048,0.115609361464756,0,2017,0,556.571428571429
"CD015083","CD015083_pub2_data","5|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|Not stated","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",5,8,"Not stated","reported","reported",2,0.117424905653978,0.312298280772107,0,2010.5,0,2357
"CD015083","CD015083_pub2_data","5|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Acute and chronic symptoms","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",5,9,"Acute and chronic symptoms","reported","reported",2,-0.00112257584578025,0.108960620539316,0,2022.5,0,373.5
"CD015083","CD015083_pub2_data","5|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Not stated","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",5,9,"Not stated","reported","reported",4,-0.180163376744937,0.122244105176069,0,2019,0,821.25
"CD015083","CD015083_pub2_data","6|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|Low risk of bias","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",6,1,"Low risk of bias","reported","reported",8,-0.0322126730597936,0.041285314778844,1.2256151040321e-06,2018.125,0,1139.25
"CD015083","CD015083_pub2_data","6|10|Referral for or use of any injection to the lumbar spine at last follow-up within 12 months|High or unclear risk of bias","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months",6,10,"High or unclear risk of bias","reported","reported",4,0.0733619122698672,0.183007492454173,0,2019.25,0,574.75
"CD015083","CD015083_pub2_data","6|10|Referral for or use of any injection to the lumbar spine at last follow-up within 12 months|Low risk of bias","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months",6,10,"Low risk of bias","reported","reported",4,-0.384021073478451,0.272806477642089,0,2016.75,0,818.5
"CD015083","CD015083_pub2_data","6|11|Health-related quality of life at last follow-up within 12 months|High or unclear risk of bias","Health-related quality of life at last follow-up within 12 months",6,11,"High or unclear risk of bias","reported","reported",22,0.127227913715641,0.0289760586195854,5.29119483873179e-06,2017.81818181818,0,352.954545454545
"CD015083","CD015083_pub2_data","6|11|Health-related quality of life at last follow-up within 12 months|Low risk of bias","Health-related quality of life at last follow-up within 12 months",6,11,"Low risk of bias","reported","reported",2,0.135801596897261,0.0646222000337395,0,2016.5,0,621
"CD015083","CD015083_pub2_data","6|12|Participant satisfaction with care at last follow-up within 12 months|High or unclear risk of bias","Participant satisfaction with care at last follow-up within 12 months",6,12,"High or unclear risk of bias","reported","reported",9,0.685593907689858,0.418781419461851,1.37935997042323,2016.22222222222,0,295.222222222222
"CD015083","CD015083_pub2_data","6|12|Participant satisfaction with care at last follow-up within 12 months|Low risk of bias","Participant satisfaction with care at last follow-up within 12 months",6,12,"Low risk of bias","reported","reported",3,0.244965672754736,0.280791123830395,0.169946152357595,2017,0,690.666666666667
"CD015083","CD015083_pub2_data","6|2|Prescription or use of opioid medication at last follow-up within 12 months|High or unclear risk of bias","Prescription or use of opioid medication at last follow-up within 12 months",6,2,"High or unclear risk of bias","reported","reported",9,-0.0621694692935066,0.0584603050850913,0.00564023792466115,2020.11111111111,0,574.333333333333
"CD015083","CD015083_pub2_data","6|2|Prescription or use of opioid medication at last follow-up within 12 months|Low risk of bias","Prescription or use of opioid medication at last follow-up within 12 months",6,2,"Low risk of bias","reported","reported",6,-0.0555796452989877,0.0988372122680476,0.00566387806824662,2018.16666666667,0,1336
"CD015083","CD015083_pub2_data","6|3|Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months|High or unclear risk of bias","Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months",6,3,"High or unclear risk of bias","reported","reported",6,0.0753995644156581,0.199208034730165,0,2018.16666666667,0,480.5
"CD015083","CD015083_pub2_data","6|3|Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months|Low risk of bias","Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months",6,3,"Low risk of bias","reported","reported",4,0.00819488949340079,0.197974483112475,3.90248841336742e-06,2014.5,0,326.5
"CD015083","CD015083_pub2_data","6|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|High or unclear risk of bias","Admission to hospital for non-specific LBP at last follow-up within 12 months",6,4,"High or unclear risk of bias","reported","reported",7,-0.289686499438395,0.161575406811332,0,2015.42857142857,0,375.857142857143
"CD015083","CD015083_pub2_data","6|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Low risk of bias","Admission to hospital for non-specific LBP at last follow-up within 12 months",6,4,"Low risk of bias","reported","reported",5,-0.0312265782723447,0.176844926053747,0.017363685331186,2015.8,0,1570.8
"CD015083","CD015083_pub2_data","6|5|Pain at last follow-up within 12 months|High or unclear risk of bias","Pain at last follow-up within 12 months",6,5,"High or unclear risk of bias","reported","reported",35,-0.267124026033798,0.111547648982768,0.255804861205335,2014.22857142857,0,200.628571428571
"CD015083","CD015083_pub2_data","6|5|Pain at last follow-up within 12 months|Low risk of bias","Pain at last follow-up within 12 months",6,5,"Low risk of bias","reported","reported",4,-0.0591611752554751,0.128637172133994,0,2018.5,0,595.25
"CD015083","CD015083_pub2_data","6|6|Back-related function at last follow-up within 12 months|High or unclear risk of bias","Back-related function at last follow-up within 12 months",6,6,"High or unclear risk of bias","reported","reported",44,-0.119652222572167,0.0475422109308143,0.0606924939546095,2014.13636363636,0,260.454545454545
"CD015083","CD015083_pub2_data","6|6|Back-related function at last follow-up within 12 months|Low risk of bias","Back-related function at last follow-up within 12 months",6,6,"Low risk of bias","reported","reported",4,-0.119422014138737,0.0691250316336628,0.00192195443107698,2018.5,0,557
"CD015083","CD015083_pub2_data","6|7|Adverse events at last follow-up within 12 months|High or unclear risk of bias","Adverse events at last follow-up within 12 months",6,7,"High or unclear risk of bias","reported","reported",8,-0.63664901552838,0.160410243155843,0,2018.375,0,313.125
"CD015083","CD015083_pub2_data","6|7|Adverse events at last follow-up within 12 months|Low risk of bias","Adverse events at last follow-up within 12 months",6,7,"Low risk of bias","reported","reported",2,0.375648302126016,0.774823058756691,1.0226175719275,2015.5,0,187.5
"CD015083","CD015083_pub2_data","6|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|High or unclear risk of bias","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",6,8,"High or unclear risk of bias","reported","reported",3,0.383559531217402,0.502929759416521,0,2010.33333333333,0,126
"CD015083","CD015083_pub2_data","6|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|Low risk of bias","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",6,8,"Low risk of bias","reported","reported",6,-0.0820586439893036,0.111029540485815,0,2018.16666666667,0,1372
"CD015083","CD015083_pub2_data","6|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|High or unclear risk of bias","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",6,9,"High or unclear risk of bias","reported","reported",4,-0.185193429537078,0.123721012137678,0,2021.25,0,343.75
"CD015083","CD015083_pub2_data","6|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Low risk of bias","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",6,9,"Low risk of bias","reported","reported",3,-0.0404259233812301,0.105613869749701,0,2018.66666666667,0,902.333333333333
"CD015083","CD015083_pub2_data","7|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|Missing/imputed data","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",7,1,"Missing/imputed data","reported","reported",7,-0.0311543742443317,0.0599201439183045,0,2020.42857142857,0,749
"CD015083","CD015083_pub2_data","7|1|Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months|No missing/imputed data","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months",7,1,"No missing/imputed data","reported","reported",11,-0.0842436227309356,0.0554631847427292,0.0102580935683334,2014.27272727273,0,992.181818181818
"CD015083","CD015083_pub2_data","7|10|Referral for or use of any injection to the lumbar spine at last follow-up within 12 months|Missing/imputed data","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months",7,10,"Missing/imputed data","reported","reported",4,-0.0687944763321852,0.211239789590632,0.0273103786692772,2020,0,866
"CD015083","CD015083_pub2_data","7|10|Referral for or use of any injection to the lumbar spine at last follow-up within 12 months|No missing/imputed data","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months",7,10,"No missing/imputed data","reported","reported",4,-0.217213826053614,0.339611020174035,0,2016,0,527.25
"CD015083","CD015083_pub2_data","7|11|Health-related quality of life at last follow-up within 12 months|Missing/imputed data","Health-related quality of life at last follow-up within 12 months",7,11,"Missing/imputed data","reported","reported",8,0.137731792734953,0.0422661213395043,0,2019.25,0,564
"CD015083","CD015083_pub2_data","7|11|Health-related quality of life at last follow-up within 12 months|No missing/imputed data","Health-related quality of life at last follow-up within 12 months",7,11,"No missing/imputed data","reported","reported",16,0.122769866569486,0.0340272372135366,9.17370058890063e-05,2016.9375,0,280.9375
"CD015083","CD015083_pub2_data","7|12|Participant satisfaction with care at last follow-up within 12 months|Missing/imputed data","Participant satisfaction with care at last follow-up within 12 months",7,12,"Missing/imputed data","reported","reported",9,0.712048203753678,0.412728295449171,1.33526706321079,2016.33333333333,0,305.111111111111
"CD015083","CD015083_pub2_data","7|12|Participant satisfaction with care at last follow-up within 12 months|No missing/imputed data","Participant satisfaction with care at last follow-up within 12 months",7,12,"No missing/imputed data","reported","reported",3,0.165879950048353,0.307511265195741,0.215532740051212,2016.66666666667,0,661
"CD015083","CD015083_pub2_data","7|2|Prescription or use of opioid medication at last follow-up within 12 months|Missing/imputed data","Prescription or use of opioid medication at last follow-up within 12 months",7,2,"Missing/imputed data","reported","reported",7,0.00283906542278765,0.0458022087656551,0,2019.42857142857,0,780
"CD015083","CD015083_pub2_data","7|2|Prescription or use of opioid medication at last follow-up within 12 months|No missing/imputed data","Prescription or use of opioid medication at last follow-up within 12 months",7,2,"No missing/imputed data","reported","reported",8,-0.155524275562375,0.065863583862494,0,2019.25,0,965.625
"CD015083","CD015083_pub2_data","7|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|Missing/imputed data","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",7,3,"Missing/imputed data","reported","reported",5,0.0641523798924426,0.234724536493973,0,2018.2,0,357.4
"CD015083","CD015083_pub2_data","7|3|Referral to surgeon or lumbar spine surgery at last follow-up within 12 months|No missing/imputed data","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months",7,3,"No missing/imputed data","reported","reported",5,0.02901132442583,0.175239327848494,1.53222964878508e-06,2015.2,0,480.4
"CD015083","CD015083_pub2_data","7|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|Missing/imputed data","Admission to hospital for non-specific LBP at last follow-up within 12 months",7,4,"Missing/imputed data","reported","reported",4,-0.297501785703309,0.171967131630471,0,2018.75,0,883.5
"CD015083","CD015083_pub2_data","7|4|Admission to hospital for non-specific LBP at last follow-up within 12 months|No missing/imputed data","Admission to hospital for non-specific LBP at last follow-up within 12 months",7,4,"No missing/imputed data","reported","reported",8,0.0287070826950838,0.218968604583441,0.0876535530963493,2014,0,868.875
"CD015083","CD015083_pub2_data","7|5|Pain at last follow-up within 12 months|Missing/imputed data","Pain at last follow-up within 12 months",7,5,"Missing/imputed data","reported","reported",10,-0.419361579786068,0.105766036343006,0,2011.8,0,228.5
"CD015083","CD015083_pub2_data","7|5|Pain at last follow-up within 12 months|No missing/imputed data","Pain at last follow-up within 12 months",7,5,"No missing/imputed data","reported","reported",29,-0.242434345606952,0.122040965799596,0.279267909501837,2015.65517241379,0,245.448275862069
"CD015083","CD015083_pub2_data","7|6|Back-related function at last follow-up within 12 months|Missing/imputed data","Back-related function at last follow-up within 12 months",7,6,"Missing/imputed data","reported","reported",20,-0.145869327737421,0.0479808787128664,0.0186788248207686,2015.15,0,439.05
"CD015083","CD015083_pub2_data","7|6|Back-related function at last follow-up within 12 months|No missing/imputed data","Back-related function at last follow-up within 12 months",7,6,"No missing/imputed data","reported","reported",28,-0.102081659519779,0.080501436709318,0.135693799980123,2014.03571428571,0,175.25
"CD015083","CD015083_pub2_data","7|7|Adverse events at last follow-up within 12 months|Missing/imputed data","Adverse events at last follow-up within 12 months",7,7,"Missing/imputed data","reported","reported",2,-0.641163476379755,0.171152499545119,0,2019.5,0,702.5
"CD015083","CD015083_pub2_data","7|7|Adverse events at last follow-up within 12 months|No missing/imputed data","Adverse events at last follow-up within 12 months",7,7,"No missing/imputed data","reported","reported",8,-0.0598442917670927,0.419818653225564,0.478256991201672,2017.375,0,184.375
"CD015083","CD015083_pub2_data","7|8|Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months|No missing/imputed data","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months",7,8,"No missing/imputed data","reported","reported",8,-0.0662274127359475,0.108792806205411,0,2014.625,0,1052.875
"CD015083","CD015083_pub2_data","7|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|Missing/imputed data","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",7,9,"Missing/imputed data","reported","reported",4,-0.153835418199624,0.111784858049117,0,2021.5,0,896.5
"CD015083","CD015083_pub2_data","7|9|Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months|No missing/imputed data","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months",7,9,"No missing/imputed data","reported","reported",3,-0.211291103860871,0.308349058689364,0.134855237923327,2018.33333333333,0,165.333333333333
"CD015083","CD015083_pub2_data","8|10|Health-related quality of life at last follow-up within 12 months|","Health-related quality of life at last follow-up within 12 months",8,10,"","reported","reported",7,0.100932964804253,0.0435244445338393,3.72886429777296e-06,2014.57142857143,0,304.571428571429
"CD015083","CD015083_pub2_data","8|11|Patient satisfaction with care at last follow-up within 12 months|","Patient satisfaction with care at last follow-up within 12 months",8,11,"","reported","reported",2,-0.387152577166611,0.439253736436301,0.23127496298,2014.5,0,102
"CD015083","CD015083_pub2_data","8|5|Pain at last follow-up within 12 months|","Pain at last follow-up within 12 months",8,5,"","reported","reported",9,-0.483268763310201,0.211258427053657,0.183495604323263,2014.44444444444,0,162
"CD015083","CD015083_pub2_data","8|6|Back-related function at last follow-up within 12 months|","Back-related function at last follow-up within 12 months",8,6,"","reported","reported",10,-0.17675266928139,0.0710769966630418,0.0194186706643592,2013.4,0,220.7
"CD015083","CD015083_pub2_data","8|7|Adverse events at last follow-up within 12 months|","Adverse events at last follow-up within 12 months",8,7,"","reported","reported",4,-0.0109224594845082,0.396401565844968,0,2018,0,252.75
"CD015084","CD015084_pub2_data","1|6|Withdrawals due to adverse events|","Withdrawals due to adverse events",1,6,"","or","binary",2,1.05388161550991,0.91622616118811,0,2007,0.0555555555555556,15.5
"CD015087","CD015087_pub2_data","1|1|Adverse events|NA","Adverse events",1,1,NA,"reported","reported",2,0.413870457793619,0.49171021590247,0,NA,0.141666666666667,50
"CD015087","CD015087_pub2_data","1|7|Nausea and/or vomiting|NA","Nausea and/or vomiting",1,7,NA,"reported","reported",2,0.647359128314374,0.374332832357811,0.0338658282013679,NA,0.233333333333333,50
"CD015087","CD015087_pub2_data","2|1|Adverse events|NA","Adverse events",2,1,NA,"reported","reported",3,0.12476348398107,0.340998813857251,0,NA,0.156746031746032,46.6666666666667
"CD015087","CD015087_pub2_data","2|3|Requiring rescue medication (2 to 24 hours)|NA","Requiring rescue medication (2 to 24 hours)",2,3,NA,"reported","reported",5,0.633846727448196,0.119097096151177,0,NA,0.379571428571429,48
"CD015087","CD015087_pub2_data","2|5|Nausea and/or vomiting|NA","Nausea and/or vomiting",2,5,NA,"reported","reported",7,0.627894295588483,0.185800604061193,0.105488161139536,NA,0.356305826678497,66.1428571428571
"CD015087","CD015087_pub2_data","2|6|Nausea and/or vomiting - risk difference analysis|NA","Nausea and/or vomiting - risk difference analysis",2,6,NA,"reported","reported",7,-0.129069603353907,0.077745670735217,0.0322674757625835,NA,0.356305826678497,66.1428571428571
"CD015087","CD015087_pub2_data","2|7|Any bleeding|NA","Any bleeding",2,7,NA,"reported","reported",2,2.8416862607553,1.44987661040124,0,NA,0.032967032967033,111
"CD015087","CD015087_pub2_data","2|8|Any bleeding - risk difference analysis|NA","Any bleeding - risk difference analysis",2,8,NA,"reported","reported",2,0.127665993049306,0.0424180270465899,0,NA,0.032967032967033,111
"CD015087","CD015087_pub2_data","3|1|Pain intensity reported by the child (0 to 2 hours)|NA","Pain intensity reported by the child (0 to 2 hours)",3,1,NA,"reported","reported",2,-0.440745748972042,0.163701437541484,0.00721004902334891,NA,NA,90
"CD015087","CD015087_pub2_data","3|11|Opioid consumption (2 to 24 hours)|NA","Opioid consumption (2 to 24 hours)",3,11,NA,"reported","reported",2,-1.37402874239796,0.499325038205144,0.445696467324813,NA,NA,66
"CD015087","CD015087_pub2_data","3|13|Time to rescue medication reported by a third party|NA","Time to rescue medication reported by a third party",3,13,NA,"reported","reported",3,3.02894880977541,1.33930181296455,5.10361428664627,NA,NA,59
"CD015087","CD015087_pub2_data","3|15|Nausea and/or vomiting|NA","Nausea and/or vomiting",3,15,NA,"reported","reported",3,0.227769743996811,0.111625088268791,1.47998035960216e-07,NA,0.325,76
"CD015087","CD015087_pub2_data","3|16|Any bleeding|NA","Any bleeding",3,16,NA,"reported","reported",2,0.60432070825972,0.85854083332492,0,NA,0.0458333333333333,84
"CD015087","CD015087_pub2_data","3|2|Pain intensity reported by the child (2 to 24 hours)|NA","Pain intensity reported by the child (2 to 24 hours)",3,2,NA,"reported","reported",3,-2.62180205178406,2.21751552138583,14.5585459931445,NA,NA,100
"CD015087","CD015087_pub2_data","3|3|Adverse events|NA","Adverse events",3,3,NA,"reported","reported",3,0.529271367377138,0.195833166121869,0,NA,0.157936507936508,79
"CD015087","CD015087_pub2_data","3|6|Pain intensity as reported by a third party (2 to 24 hours)|NA","Pain intensity as reported by a third party (2 to 24 hours)",3,6,NA,"reported","reported",2,-0.597355111710851,0.311182740713468,0.121036376973072,NA,NA,58.5
"CD015087","CD015087_pub2_data","3|7|Pain intensity as reported by a third party (1 to 7 days)|NA","Pain intensity as reported by a third party (1 to 7 days)",3,7,NA,"reported","reported",2,-0.324276717971958,0.186209007916514,0,NA,NA,58.5
"CD015087","CD015087_pub2_data","3|9|Requiring rescue medication (2 to 24 hours)|NA","Requiring rescue medication (2 to 24 hours)",3,9,NA,"reported","reported",3,0.75360447749555,0.222692735784421,0.0961228610507323,NA,0.474242424242424,80
"CD015087","CD015087_pub2_data","4|1|Adverse events|NA","Adverse events",4,1,NA,"reported","reported",2,0.51308028829337,1.28206338576388,0,NA,0.05,39
"CD015087","CD015087_pub2_data","4|3|Pain intensity reported by a third party (0 to 2 hours)|NA","Pain intensity reported by a third party (0 to 2 hours)",4,3,NA,"reported","reported",2,0.386661599700976,0.216182018381254,0,NA,NA,44
"CD015087","CD015087_pub2_data","4|4|Pain intensity reported by a third party (2 to 24 hours)|NA","Pain intensity reported by a third party (2 to 24 hours)",4,4,NA,"reported","reported",2,0.385580026526242,0.215538692931139,0,NA,NA,44
"CD015087","CD015087_pub2_data","4|6|Requiring rescue medication (2 to 24 hours)|NA","Requiring rescue medication (2 to 24 hours)",4,6,NA,"reported","reported",4,1.08488353570637,0.11884748109873,0.0266961008920286,NA,0.611184210526316,61.25
"CD015087","CD015087_pub2_data","4|8|Time to rescue medication reported by a third party|NA","Time to rescue medication reported by a third party",4,8,NA,"reported","reported",2,0.547379808260621,3.62489477433598,25.807521571139,NA,NA,83.5
"CD015087","CD015087_pub2_data","4|9|Nausea and/or vomiting|NA","Nausea and/or vomiting",4,9,NA,"reported","reported",4,0.882607849928725,0.278636068111257,0,NA,0.235555555555556,42
"CD015101_data","CD015101_data","1|1|All symptoms|Baseline to > 3 months' follow-up","All symptoms",1,1,"Baseline to > 3 months' follow-up","or","binary",4,-0.110386047617197,1.01188442447697,0,2008.25,0,58.75
"CD015101_data","CD015101_data","1|1|All symptoms|Baseline to ≤ 3 months' follow-up","All symptoms",1,1,"Baseline to ≤ 3 months' follow-up","or","binary",5,-0.154561756024362,0.904341738179847,0,2009.2,0,61
"CD015101_data","CD015101_data","1|2|GSS|Baseline to ≤ 3 months' follow-up","GSS",1,2,"Baseline to ≤ 3 months' follow-up","or","binary",2,0,1.42968069775034,0,2009,0,45
"CD015101_data","CD015101_data","1|4|BCTQ (SSS)|Baseline to > 3 months' follow-up","BCTQ (SSS)",1,4,"Baseline to > 3 months' follow-up","or","binary",2,-0.148400063996731,1.43819186521856,0,2011.5,0,31
"CD015101_data","CD015101_data","1|4|BCTQ (SSS)|Baseline to ≤ 3 months' follow-up","BCTQ (SSS)",1,4,"Baseline to ≤ 3 months' follow-up","or","binary",2,-0.29937485245003,1.43563079171071,0,2011.5,0,34
"CD015101_data","CD015101_data","2|1|All function|Baseline to > 3 months' follow-up","All function",2,1,"Baseline to > 3 months' follow-up","or","binary",3,-0.147388699513906,1.16924605326867,0,2009.33333333333,0,61.6666666666667
"CD015101_data","CD015101_data","2|1|All function|Baseline to ≤ 3 months' follow-up","All function",2,1,"Baseline to ≤ 3 months' follow-up","or","binary",3,-0.25765318461218,1.16761404687136,0,2009.33333333333,0,71.6666666666667
"CD015101_data","CD015101_data","2|3|BCTQ (FSS)|Baseline to > 3 months' follow-up","BCTQ (FSS)",2,3,"Baseline to > 3 months' follow-up","or","binary",2,-0.148400063996731,1.43819186521856,0,2011.5,0,31
"CD015101_data","CD015101_data","2|3|BCTQ (FSS)|Baseline to ≤ 3 months' follow-up","BCTQ (FSS)",2,3,"Baseline to ≤ 3 months' follow-up","or","binary",2,-0.29937485245003,1.43563079171071,0,2011.5,0,34
"CD015101_data","CD015101_data","3|1|Median DML|Baseline to > 3 months' follow-up","Median DML",3,1,"Baseline to > 3 months' follow-up","or","binary",3,-0.338652062975362,1.16709560097369,0,2005.33333333333,0,54
"CD015101_data","CD015101_data","3|2|Median SCV|Baseline to > 3 months' follow-up","Median SCV",3,2,"Baseline to > 3 months' follow-up","or","binary",2,-0.355103034805852,1.43244748797744,0,2005.5,0,42
"CD015101_data","CD015101_data","5|1|Adverse events|End of study","Adverse events",5,1,"End of study","or","binary",3,-0.759534365332128,0.866245629606502,0,2012,0.0772727272727273,37.3333333333333
"CD015120","CD015120_pub2_data","11|1|Smoking cessation|","Smoking cessation",11,1,"","reported","reported",2,1.44378932565897,0.691330694183323,0,2010,0,349
"CD015120","CD015120_pub2_data","12|1|Smoking cessation|","Smoking cessation",12,1,"","reported","reported",2,-1.2609436696834,0.712796946726113,0,2010,0,357.5
"CD015120","CD015120_pub2_data","16|1|Smoking cessation|","Smoking cessation",16,1,"","reported","reported",3,-0.146830568868174,0.219887908332618,0.0635628443200914,2012.66666666667,0,1480
"CD015120","CD015120_pub2_data","17|1|Smoking cessation|","Smoking cessation",17,1,"","reported","reported",2,0.256391752577319,0.233336401550765,0,2008.5,0,770
"CD015120","CD015120_pub2_data","18|1|Smoking cessation|","Smoking cessation",18,1,"","reported","reported",3,-0.0362658161653202,0.145029074046433,0.00200258619604323,2017,0,2509.33333333333
"CD015120","CD015120_pub2_data","2|1|Smoking cessation|","Smoking cessation",2,1,"","reported","reported",2,0.296847133757962,0.765959243445219,0.692249999999999,2015,0,534.5
"CD015120","CD015120_pub2_data","22|1|Smoking cessation|","Smoking cessation",22,1,"","reported","reported",2,0.197850454607138,0.118821736087101,0,2010,0,68
"CD015120","CD015120_pub2_data","23|1|Smoking cessation|","Smoking cessation",23,1,"","reported","reported",2,0.341374783067984,0.215945433832528,0,2019.5,0,1247
"CD015120","CD015120_pub2_data","24|1|Smoking cessation|High-income country economic classification","Smoking cessation",24,1,"High-income country economic classification","reported","reported",2,-0.3288,0.255806176625976,0,2012.5,0,2127
"CD015120","CD015120_pub2_data","28|1|Smoking cessation|","Smoking cessation",28,1,"","reported","reported",2,0.542541114058356,0.211439928824539,0,2011,0,1371
"CD015120","CD015120_pub2_data","29|1|Smoking cessation|Education","Smoking cessation",29,1,"Education","reported","reported",2,-0.0782863842426137,0.597617446594891,0,2012.5,0,677
"CD015120","CD015120_pub2_data","29|1|Smoking cessation|Level of deprivation","Smoking cessation",29,1,"Level of deprivation","reported","reported",2,0.852390878361828,0.874764211605082,0,2018.5,0,345.5
"CD015120","CD015120_pub2_data","3|1|Smoking cessation|","Smoking cessation",3,1,"","reported","reported",4,0.114598971150284,0.339146187963073,0.177875299989429,2013,0,1064
"CD015120","CD015120_pub2_data","30|1|Smoking cessation|","Smoking cessation",30,1,"","reported","reported",3,-0.714249432354021,0.305886702196356,0,2015,0,999
"CD015120","CD015120_pub2_data","32|1|Smoking cessation|","Smoking cessation",32,1,"","reported","reported",4,0.10775270723806,0.421808330047781,0,2013.5,0,784.5
"CD015120","CD015120_pub2_data","33|1|Smoking cessation|","Smoking cessation",33,1,"","reported","reported",3,0.031393990955209,0.427245757651868,0,2006.66666666667,0,75.3333333333333
"CD015120","CD015120_pub2_data","4|1|Smoking cessation|","Smoking cessation",4,1,"","reported","reported",2,-0.174753287332379,0.239613019610319,0,2009.5,0,628.5
"CD015120","CD015120_pub2_data","7|1|Smoking cessation (lozenge comparator)|","Smoking cessation (lozenge comparator)",7,1,"","reported","reported",2,0.05696,0.528,0,2010,0,343.5
"CD015120","CD015120_pub2_data","7|2|Smoking cessation (patch comparator)|","Smoking cessation (patch comparator)",7,2,"","reported","reported",2,-0.0226181484127793,0.562586116710974,0,2010,0,354.5
"CD015122","CD015122_pub2_data","1|1|Blood transfusion|NA","Blood transfusion",1,1,NA,"or","binary",9,-0.8118380264344,0.24752511731227,0.104668044044275,2017.88888888889,0.111804905422792,150.333333333333
"CD015122","CD015122_pub2_data","1|18|Blood transfusion (Sensitivity analysis & definition of stone freedom)|NA","Blood transfusion (Sensitivity analysis & definition of stone freedom)",1,18,NA,"or","binary",3,-1.55143364928815,0.414632854495295,0,2016.66666666667,0.112039295392954,184.333333333333
"CD015122","CD015122_pub2_data","1|19|Stone-free rate (Sensitivity analysis & definition of stone freedom)|NA","Stone-free rate (Sensitivity analysis & definition of stone freedom)",1,19,NA,"or","binary",3,0.591983799829687,0.216128505377038,0,2016.66666666667,0.553651761517615,184.333333333333
"CD015122","CD015122_pub2_data","1|2|Stone-free rate|NA","Stone-free rate",1,2,NA,"or","binary",4,0.586791655438546,0.201710411909546,0,2017,0.683884654471545,150.75
"CD015122","CD015122_pub2_data","1|20|Thromboembolic events (Sensitivity analysis & definition of stone freedom)|NA","Thromboembolic events (Sensitivity analysis & definition of stone freedom)",1,20,NA,"or","binary",3,0.754373840567749,1.04813565750642,0,2016.66666666667,0,184.333333333333
"CD015122","CD015122_pub2_data","1|21|Adverse Eeents (Sensitivity analysis & definition of stone freedom)|NA","Adverse Eeents (Sensitivity analysis & definition of stone freedom)",1,21,NA,"or","binary",2,0.826974259901029,1.86737846099547,4.55104288751905,2014.5,0.00609756097560976,182
"CD015122","CD015122_pub2_data","1|23|Major surgical complications (Sensitivity analysis & definition of stone freedom)|NA","Major surgical complications (Sensitivity analysis & definition of stone freedom)",1,23,NA,"or","binary",3,-1.1320503185323,0.312990336481642,0,2016.66666666667,0.149613821138211,184.333333333333
"CD015122","CD015122_pub2_data","1|24|Minor surgical complications (Sensitivity analysis & definition of stone freedom)|NA","Minor surgical complications (Sensitivity analysis & definition of stone freedom)",1,24,NA,"or","binary",3,-0.718653602086879,0.205579735860279,0,2016.66666666667,0.311026422764228,184.333333333333
"CD015122","CD015122_pub2_data","1|26|Hospital length of stay (days) (Sensitivity analysis & definition of Stone freedom)|NA","Hospital length of stay (days) (Sensitivity analysis & definition of Stone freedom)",1,26,NA,"or","binary",3,0.0105289575341557,1.15783314330849,0,2016.66666666667,0,184.333333333333
"CD015122","CD015122_pub2_data","1|3|Thromboembolic events|NA","Thromboembolic events",1,3,NA,"or","binary",6,0.420431521133535,0.77819615306241,0,2018,0,140.166666666667
"CD015122","CD015122_pub2_data","1|4|Adverse events|NA","Adverse events",1,4,NA,"or","binary",4,1.98064249430621,1.30737505760061,5.16952617634692,2017.25,0.0257760532150776,150.5
"CD015122","CD015122_pub2_data","1|5|Secondary interventions|NA","Secondary interventions",1,5,NA,"or","binary",2,0.194422919561711,0.265681653365442,0,2020,0.248579545454545,159.5
"CD015122","CD015122_pub2_data","1|6|Major Surgical complications|NA","Major Surgical complications",1,6,NA,"or","binary",5,-1.03462792245688,0.282564158817808,0,2017.4,0.127828898743533,146.6
"CD015122","CD015122_pub2_data","1|7|Minor surgical complications|NA","Minor surgical complications",1,7,NA,"or","binary",5,-0.60079440523971,0.181851581894235,0,2017.4,0.396312823355506,146.6
"CD015122","CD015122_pub2_data","1|9|Hospital length of stay (days)|NA","Hospital length of stay (days)",1,9,NA,"or","binary",7,0.00887467542924412,0.758381883223812,0,2018,0,164.428571428571
"CD015124","CD015124_pub2_data","1|1|Assessment of prognostic factors around breast cancer diagnosis|Adjusted results","Assessment of prognostic factors around breast cancer diagnosis",1,1,"Adjusted results","reported","reported",4,-0.0395661928596519,0.0117414270253495,0,2011.25,NA,0.25
"CD015124","CD015124_pub2_data","2|1|Assessment of prognostic factors around breast cancer diagnosis|Adjusted results","Assessment of prognostic factors around breast cancer diagnosis",2,1,"Adjusted results","reported","reported",4,-0.427184219618213,0.229031045116254,0,2011.5,NA,0
"CD015124","CD015124_pub2_data","2|1|Assessment of prognostic factors around breast cancer diagnosis|Unadjusted results","Assessment of prognostic factors around breast cancer diagnosis",2,1,"Unadjusted results","reported","reported",4,-0.918499037462144,0.164448028635508,0,2011,NA,0
"CD015124","CD015124_pub2_data","3|1|Assessment of prognostic factors around breast cancer diagnosis|Unadjusted","Assessment of prognostic factors around breast cancer diagnosis",3,1,"Unadjusted","reported","reported",4,-0.0965689873693801,0.153011488405093,0,2011,NA,0
"CD015124","CD015124_pub2_data","4|1|Assessment of prognostic factors around breast cancer diagnosis|Unadjusted results","Assessment of prognostic factors around breast cancer diagnosis",4,1,"Unadjusted results","reported","reported",5,-0.732678257942356,0.21558233682479,0.0706677613719377,2010.6,NA,0
"CD015124","CD015124_pub2_data","5|1|Assessment of prognostic factors around breast cancer diagnosis|Unadjusted results","Assessment of prognostic factors around breast cancer diagnosis",5,1,"Unadjusted results","reported","reported",4,0.0382506104474926,0.249400340880946,0.123000166636395,2011,NA,0
"CD015134","CD015134_pub2_data","1|1|Infant hospitalisation with laboratory-confirmed RSV disease|NA","Infant hospitalisation with laboratory-confirmed RSV disease",1,1,NA,"or","binary",4,-0.63853148044,0.166663124664853,0.0143670608814201,2022,0.0193275056668389,3054
"CD015134","CD015134_pub2_data","1|2|Intrauterine growth restriction|NA","Intrauterine growth restriction",1,2,NA,"reported","reported",2,0,0.298015312013162,0,2023,0.00136054421768707,3785
"CD015134","CD015134_pub2_data","1|5|Preterm birth|NA","Preterm birth",1,5,NA,"reported","reported",3,0,0.0777768875051769,0,2023,0.0474689497329517,4189
"CD015134","CD015134_pub2_data","1|6|Congenital abnormalities|NA","Congenital abnormalities",1,6,NA,"reported","reported",2,0,0.227557468925223,0,2022.5,0.141025641025641,304.5
"CD015134","CD015134_pub2_data","1|7|Infant death|NA","Infant death",1,7,NA,"reported","reported",2,0,0.402592020002081,0,2021.5,0.00553003058315409,5847.5
"CD015140","CD015140_pub2_data","1|1|Overall survival (OS) - fixed-effect model|","Overall survival (OS) - fixed-effect model",1,1,"","reported","reported",3,-0.613864858879101,0.151431466319235,1.26672746580836e-06,2019.66666666667,0,288
"CD015140","CD015140_pub2_data","1|10|Risk of relapse in drug-off time - fixed-effect model|","Risk of relapse in drug-off time - fixed-effect model",1,10,"","or","binary",5,-0.135714931473045,0.312563882816628,0.251033664055919,2017.4,0.369367760617761,112
"CD015140","CD015140_pub2_data","1|12|Risk of relapse in drug-on time - fixed-effect model|","Risk of relapse in drug-on time - fixed-effect model",1,12,"","or","binary",5,-1.0621161813158,0.351810313985228,0.301023072847546,2017.4,0.287872252272114,233.8
"CD015140","CD015140_pub2_data","1|13|Risk of relapse in drug-on time - random-effects model|","Risk of relapse in drug-on time - random-effects model",1,13,"","or","binary",5,-1.0621161813158,0.351810313985228,0.301023072847546,2017.4,0.287872252272114,233.8
"CD015140","CD015140_pub2_data","1|14|Risk of brain relapse|","Risk of brain relapse",1,14,"","or","binary",3,-0.296789809178664,0.9913548799847,2.23396780599975,2016.66666666667,0.10955234118098,164
"CD015140","CD015140_pub2_data","1|2|Overall survival (OS) - random-effects model|","Overall survival (OS) - random-effects model",1,2,"","reported","reported",3,-0.613864858879101,0.151431466319235,1.26672746580836e-06,2019.66666666667,0,288
"CD015140","CD015140_pub2_data","1|3|Disease-free survival (DFS) - fixed-effect model|","Disease-free survival (DFS) - fixed-effect model",1,3,"","reported","reported",5,-0.860362023615892,0.245438973180693,0.185232564039518,2017.4,0,230.6
"CD015140","CD015140_pub2_data","1|4|Disease-free survival (DFS) - random-effects model|","Disease-free survival (DFS) - random-effects model",1,4,"","reported","reported",5,-0.860362023615892,0.245438973180693,0.185232564039518,2017.4,0,230.6
"CD015140","CD015140_pub2_data","1|5|Disease-free survival (DFS) in stage IB|","Disease-free survival (DFS) in stage IB",1,5,"","reported","reported",2,-0.991002330500527,0.255030613157729,0,2018,0,165
"CD015140","CD015140_pub2_data","1|6|Adverse events ≥ grade 3|","Adverse events ≥ grade 3",1,6,"","reported","reported",2,0,0.0486810765349755,0,2018,0.213593912141128,419.5
"CD015140","CD015140_pub2_data","1|7|Adverse events grades 1 and 2|","Adverse events grades 1 and 2",1,7,"","reported","reported",2,0,0.0439418544796678,0,2018,0.483273212432673,419.5
"CD015140","CD015140_pub2_data","2|1|Overall survival (OS)|","Overall survival (OS)",2,1,"","reported","reported",4,-0.243022390586806,0.215373567213788,0.10413720641479,2021.5,0,219.5
"CD015140","CD015140_pub2_data","2|10|Disease-free survival (DFS) by smoking status|Non-smokers","Disease-free survival (DFS) by smoking status",2,10,"Non-smokers","reported","reported",4,-0.553710573111722,0.201300609549851,0.0959379182557029,2021.5,0,127
"CD015140","CD015140_pub2_data","2|10|Disease-free survival (DFS) by smoking status|Smokers","Disease-free survival (DFS) by smoking status",2,10,"Smokers","reported","reported",4,-0.657177477075402,0.325421189917646,0.256146886210827,2021.5,0,58.25
"CD015140","CD015140_pub2_data","2|11|Disease-free survival (DFS) by gender|Female","Disease-free survival (DFS) by gender",2,11,"Female","reported","reported",4,-0.530259852733957,0.140096523505258,0.0086619196265392,2021.5,0,109.25
"CD015140","CD015140_pub2_data","2|11|Disease-free survival (DFS) by gender|Male","Disease-free survival (DFS) by gender",2,11,"Male","reported","reported",4,-0.699627039350248,0.420413028126859,0.561791077879991,2021.5,0,76
"CD015140","CD015140_pub2_data","2|12|Adverse events ≥ grade 3|","Adverse events ≥ grade 3",2,12,"","reported","reported",2,0,0.117088639551056,0,2022,0.588776541961577,161.5
"CD015140","CD015140_pub2_data","2|13|Adverse events grades 1 and 2|","Adverse events grades 1 and 2",2,13,"","or","binary",4,1.31822143715869,0.546070523758117,1.07411187156769,2021.5,0.290588815513608,202.75
"CD015140","CD015140_pub2_data","2|14|Health-related quality of life (HRQoL) - FACT-L|FACT- L ","Health-related quality of life (HRQoL) - FACT-L",2,14,"FACT- L ","reported","reported",2,0,0.102152656817511,0,2021,0,199.5
"CD015140","CD015140_pub2_data","2|15|Health-related quality of life (HRQoL) - LCSS|","Health-related quality of life (HRQoL) - LCSS",2,15,"","reported","reported",2,0,0.101967575703091,0,2021,0,200
"CD015140","CD015140_pub2_data","2|16|Risk of relapse in drug-off time|","Risk of relapse in drug-off time",2,16,"","or","binary",4,0.440332244320967,0.245128773358215,0.00332914207473031,2021.5,0.382097763347763,93
"CD015140","CD015140_pub2_data","2|18|Risk of brain relapse|","Risk of brain relapse",2,18,"","or","binary",3,0.0789214662596406,0.36653437381803,0.201479032483531,2021.66666666667,0.177384706796472,165.666666666667
"CD015140","CD015140_pub2_data","2|2|Overall survival (OS) by EGFR type mutation|EGFR Del 19","Overall survival (OS) by EGFR type mutation",2,2,"EGFR Del 19","reported","reported",3,-0.542241336435292,0.392163815246872,0.311429844889734,2021.66666666667,0,98.6666666666667
"CD015140","CD015140_pub2_data","2|2|Overall survival (OS) by EGFR type mutation|EGFR L858R","Overall survival (OS) by EGFR type mutation",2,2,"EGFR L858R","reported","reported",3,0.0810622304321271,0.195367891497132,0,2021.66666666667,0,85.6666666666667
"CD015140","CD015140_pub2_data","2|3|Overall survival (OS) by age|Age < 65","Overall survival (OS) by age",2,3,"Age < 65","reported","reported",3,-0.332262999746038,0.53912081499399,0.746175637765358,2021.66666666667,0,65.3333333333333
"CD015140","CD015140_pub2_data","2|3|Overall survival (OS) by age|Age ≥ 65","Overall survival (OS) by age",2,3,"Age ≥ 65","reported","reported",3,-0.201913413271961,0.206201031414936,0,2021.66666666667,0,46
"CD015140","CD015140_pub2_data","2|4|Overall survival (OS) by smoking status|Non-smokers","Overall survival (OS) by smoking status",2,4,"Non-smokers","reported","reported",2,-0.294548464067985,0.484157979029251,0.3551642724655,2021.5,0,109.5
"CD015140","CD015140_pub2_data","2|4|Overall survival (OS) by smoking status|Smokers","Overall survival (OS) by smoking status",2,4,"Smokers","reported","reported",2,-0.883216359579188,0.979239615553564,1.3500591463425,2021.5,0,57.5
"CD015140","CD015140_pub2_data","2|5|Overall survival (OS) by gender|Female","Overall survival (OS) by gender",2,5,"Female","reported","reported",3,-0.368912254581575,0.377719812715994,0.314222156311279,2021.66666666667,0,112.666666666667
"CD015140","CD015140_pub2_data","2|5|Overall survival (OS) by gender|Male","Overall survival (OS) by gender",2,5,"Male","reported","reported",3,-0.153377252850109,0.224022672688631,1.08637774042118e-06,2021.66666666667,0,72.6666666666667
"CD015140","CD015140_pub2_data","2|6|Disease-free survival (DFS)|","Disease-free survival (DFS)",2,6,"","reported","reported",4,-0.621852277838478,0.219811321184866,0.146221823321751,2021.5,0,219.5
"CD015140","CD015140_pub2_data","2|7|Disease-free survival (DFS) by EGFR type mutation|EGFR Del 19","Disease-free survival (DFS) by EGFR type mutation",2,7,"EGFR Del 19","reported","reported",4,-0.758827917340009,0.252569767258508,0.168370434781569,2021.5,0,98.5
"CD015140","CD015140_pub2_data","2|7|Disease-free survival (DFS) by EGFR type mutation|EGFR L858R","Disease-free survival (DFS) by EGFR type mutation",2,7,"EGFR L858R","reported","reported",4,-0.393203039641391,0.243412163967554,0.147431536685363,2021.5,0,86.25
"CD015140","CD015140_pub2_data","2|8|Disease-free survival (DFS) by stage|Stage II","Disease-free survival (DFS) by stage",2,8,"Stage II","reported","reported",2,-0.576188008513639,0.583657093728818,0.5389562685315,2021.5,0,92.5
"CD015140","CD015140_pub2_data","2|8|Disease-free survival (DFS) by stage|Stage IIIA","Disease-free survival (DFS) by stage",2,8,"Stage IIIA","reported","reported",2,-0.490639428599142,0.466379483163928,0.388356701544,2021.5,0,165
"CD015140","CD015140_pub2_data","2|9|Disease-free survival (DFS) by age|<65","Disease-free survival (DFS) by age",2,9,"<65","reported","reported",3,-0.54482128557797,0.333713675058404,0.259503243795617,2021.66666666667,0,139.666666666667
"CD015140","CD015140_pub2_data","2|9|Disease-free survival (DFS) by age|≥ 65","Disease-free survival (DFS) by age",2,9,"≥ 65","reported","reported",3,-0.805499747313708,0.437007175477906,0.37078375885921,2021.66666666667,0,66
"CD015145","CD015145_pub2_data","1|1|Postoperative pain (VAS) 24 hours|","Postoperative pain (VAS) 24 hours",1,1,"","reported","reported",6,-11.6218173648608,4.7909822557619,116.789527895796,2019.83333333333,NA,65.5
"CD015145","CD015145_pub2_data","1|10|Postoperative pain score (VAS) 24 hours (surgery covariate)|Other","Postoperative pain score (VAS) 24 hours (surgery covariate)",1,10,"Other","reported","reported",5,-10.4406472690833,5.69871751126931,139.921335653705,2020,NA,66.2
"CD015145","CD015145_pub2_data","1|11|Postoperative pain score (VAS) 24 hours (technique covariate)|Laparoscopic","Postoperative pain score (VAS) 24 hours (technique covariate)",1,11,"Laparoscopic","reported","reported",2,-21.0068980505606,12.489717945828,270.90361107741,2021,NA,32
"CD015145","CD015145_pub2_data","1|11|Postoperative pain score (VAS) 24 hours (technique covariate)|Ultrasound","Postoperative pain score (VAS) 24 hours (technique covariate)",1,11,"Ultrasound","reported","reported",4,-7.29308212151066,3.74718232108669,43.967075765263,2019.25,NA,82.25
"CD015145","CD015145_pub2_data","1|12|Postoperative pain score (VAS) 24 hours (approach)|Laparoscopic","Postoperative pain score (VAS) 24 hours (approach)",1,12,"Laparoscopic","reported","reported",2,-21.0068980505606,12.489717945828,270.90361107741,2021,NA,32
"CD015145","CD015145_pub2_data","1|12|Postoperative pain score (VAS) 24 hours (approach)|Lateral","Postoperative pain score (VAS) 24 hours (approach)",1,12,"Lateral","reported","reported",2,-4.2934319796784,3.38854293262469,15.7170914271458,2022,NA,77
"CD015145","CD015145_pub2_data","1|13|Postoperative pain score (VAS) 24 hours (timing covariate)|After","Postoperative pain score (VAS) 24 hours (timing covariate)",1,13,"After","reported","reported",2,-2.11121991798572,1.00297689859859,0,2022.5,NA,52
"CD015145","CD015145_pub2_data","1|13|Postoperative pain score (VAS) 24 hours (timing covariate)|Before","Postoperative pain score (VAS) 24 hours (timing covariate)",1,13,"Before","reported","reported",4,-15.2026481306765,6.51618410171906,149.757766469031,2018.5,NA,72.25
"CD015145","CD015145_pub2_data","1|14|Postoperative pain score (VAS) 24 hours (formulation)|Bupivacaine","Postoperative pain score (VAS) 24 hours (formulation)",1,14,"Bupivacaine","reported","reported",2,-2.11121991798572,1.00297689859859,0,2022.5,NA,52
"CD015145","CD015145_pub2_data","1|14|Postoperative pain score (VAS) 24 hours (formulation)|Ropivacaine","Postoperative pain score (VAS) 24 hours (formulation)",1,14,"Ropivacaine","reported","reported",2,-17.29499041211,15.4986441687289,457.931359566014,2016.5,NA,76.5
"CD015145","CD015145_pub2_data","1|15|Postoperative pain score (VAS) 24 hours (adjuvant)|Without adjuvant","Postoperative pain score (VAS) 24 hours (adjuvant)",1,15,"Without adjuvant","reported","reported",5,-10.4406472690833,5.69871751126931,139.921335653705,2020,NA,66.2
"CD015145","CD015145_pub2_data","1|16|Postoperative pain score (VAS) 24 hours (control pain score)|Control group mean pain score > or = to 30","Postoperative pain score (VAS) 24 hours (control pain score)",1,16,"Control group mean pain score > or = to 30","reported","reported",5,-12.1836030357552,5.85954218560738,150.322684148004,2019.4,NA,63.8
"CD015145","CD015145_pub2_data","1|3|Opioid use (MME) 0 to 24 hours after surgery|","Opioid use (MME) 0 to 24 hours after surgery",1,3,"","reported","reported",2,-8.20958478517682,5.85946472223706,56.5041340440533,2016.5,NA,88.5
"CD015145","CD015145_pub2_data","1|6|Postoperative pain score (VAS) 6 hours|","Postoperative pain score (VAS) 6 hours",1,6,"","reported","reported",4,-9.09425880969335,4.08014671307075,55.6139759048468,2019.75,NA,81
"CD015145","CD015145_pub2_data","1|7|Postoperative pain score (VAS) 12 hours|","Postoperative pain score (VAS) 12 hours",1,7,"","reported","reported",3,-13.9107485761048,10.2794790018989,315.126307237509,2020.66666666667,NA,58.6666666666667
"CD015145","CD015145_pub2_data","1|8|Postoperative pain score (VAS) 48 hours|","Postoperative pain score (VAS) 48 hours",1,8,"","reported","reported",2,-5.65222680790313,2.43405785128022,0,2020.5,NA,51
"CD015145","CD015145_pub2_data","2|1|Postoperative pain (VAS) 24 hours|","Postoperative pain (VAS) 24 hours",2,1,"","reported","reported",4,-14.2683284503316,6.13035589215842,145.367644566402,2015.75,NA,92.75
"CD015145","CD015145_pub2_data","2|10|Postoperative pain score (VAS) 24 hours (technique)|Laparoscopic","Postoperative pain score (VAS) 24 hours (technique)",2,10,"Laparoscopic","reported","reported",2,-15.8271053599628,11.7486651876489,269.371052182148,2016.5,NA,122.5
"CD015145","CD015145_pub2_data","2|10|Postoperative pain score (VAS) 24 hours (technique)|Ultrasound","Postoperative pain score (VAS) 24 hours (technique)",2,10,"Ultrasound","reported","reported",2,-12.6068631242034,9.04989719333576,160.489315042967,2015,NA,63
"CD015145","CD015145_pub2_data","2|11|Postoperative pain score (VAS) 24 hours (approach)|Laparoscopic","Postoperative pain score (VAS) 24 hours (approach)",2,11,"Laparoscopic","reported","reported",2,-15.8271053599628,11.7486651876489,269.371052182148,2016.5,NA,122.5
"CD015145","CD015145_pub2_data","2|12|Postoperative pain score (VAS) 24 hours (timing)|Before","Postoperative pain score (VAS) 24 hours (timing)",2,12,"Before","reported","reported",3,-17.5516428038017,7.19465194464833,152.21795811425,2016.33333333333,NA,58.3333333333333
"CD015145","CD015145_pub2_data","2|13|Postoperative pain score (VAS) 24 hours (formulation)|Bupivacaine","Postoperative pain score (VAS) 24 hours (formulation)",2,13,"Bupivacaine","reported","reported",2,-15.8271053599628,11.7486651876489,269.371052182148,2016.5,NA,122.5
"CD015145","CD015145_pub2_data","2|13|Postoperative pain score (VAS) 24 hours (formulation)|Ropivacaine","Postoperative pain score (VAS) 24 hours (formulation)",2,13,"Ropivacaine","reported","reported",2,-12.6068631242034,9.04989719333576,160.489315042967,2015,NA,63
"CD015145","CD015145_pub2_data","2|14|Postoperative pain score (VAS) 24 hours (adjuvant)|Without adjuvant","Postoperative pain score (VAS) 24 hours (adjuvant)",2,14,"Without adjuvant","reported","reported",4,-14.2683284503316,6.13035589215842,145.367644566402,2015.75,NA,92.75
"CD015145","CD015145_pub2_data","2|15|Postoperative pain score (VAS) 24 hours (control pain score)|Control group mean pain score > or = to 30","Postoperative pain score (VAS) 24 hours (control pain score)",2,15,"Control group mean pain score > or = to 30","reported","reported",4,-14.2683284503316,6.13035589215842,145.367644566402,2015.75,NA,92.75
"CD015145","CD015145_pub2_data","2|3|Nausea and vomiting|","Nausea and vomiting",2,3,"","reported","reported",3,0.640085264427368,0.148505283596235,0,2016.33333333333,0.350009112447603,81.3333333333333
"CD015145","CD015145_pub2_data","2|4|Opioid use (MME) 0 to 24 hours after surgery|","Opioid use (MME) 0 to 24 hours after surgery",2,4,"","reported","reported",4,-13.0992944217117,8.60082087869696,284.9931185216,2014,NA,65.25
"CD015145","CD015145_pub2_data","2|8|Time to discharge (hours)|","Time to discharge (hours)",2,8,"","reported","reported",2,-3.69056819747886,4.29630281699307,29.2834668746537,2011,NA,68
"CD015145","CD015145_pub2_data","2|9|Postoperative pain score (VAS) 24 hours (surgery)|Hysterectomy","Postoperative pain score (VAS) 24 hours (surgery)",2,9,"Hysterectomy","reported","reported",3,-9.82038243551535,6.03551642715655,103.5519323099,2014.66666666667,NA,107.333333333333
"CD015145","CD015145_pub2_data","3|1|Postoperative pain (VAS) 24 hours|","Postoperative pain (VAS) 24 hours",3,1,"","reported","reported",4,-4.74826826623985,2.84662542628205,24.6603653770002,2016.25,NA,60.5
"CD015145","CD015145_pub2_data","3|10|Postoperative pain score (VAS) during movement 2 hours|","Postoperative pain score (VAS) during movement 2 hours",3,10,"","reported","reported",2,-4.01557756243542,5.54837188806583,56.047151032506,2018,NA,73
"CD015145","CD015145_pub2_data","3|11|Postoperative pain score (VAS) during movement 6 hours|","Postoperative pain score (VAS) during movement 6 hours",3,11,"","reported","reported",2,3.10659156714526,7.0969937244149,97.2718765393642,2018,NA,73
"CD015145","CD015145_pub2_data","3|13|Postoperative pain score (VAS) 24 hours (surgery)|Hysterectomy","Postoperative pain score (VAS) 24 hours (surgery)",3,13,"Hysterectomy","reported","reported",3,-5.77907678623725,3.71339174327758,31.689127733299,2015,NA,46.6666666666667
"CD015145","CD015145_pub2_data","3|14|Postoperative pain score (VAS) 24 hours (approach)|Lateral","Postoperative pain score (VAS) 24 hours (approach)",3,14,"Lateral","reported","reported",2,-6.56105581237139,5.04877872425981,48.060903794424,2016.5,NA,42
"CD015145","CD015145_pub2_data","3|14|Postoperative pain score (VAS) 24 hours (approach)|Unspecified","Postoperative pain score (VAS) 24 hours (approach)",3,14,"Unspecified","reported","reported",2,-1.87549927005723,1.97827425915956,0,2016,NA,79
"CD015145","CD015145_pub2_data","3|15|Postoperative pain score (VAS) 24 hours (timing)|After","Postoperative pain score (VAS) 24 hours (timing)",3,15,"After","reported","reported",2,-1.87549927005723,1.97827425915956,0,2016,NA,79
"CD015145","CD015145_pub2_data","3|15|Postoperative pain score (VAS) 24 hours (timing)|Before","Postoperative pain score (VAS) 24 hours (timing)",3,15,"Before","reported","reported",2,-6.56105581237139,5.04877872425981,48.060903794424,2016.5,NA,42
"CD015145","CD015145_pub2_data","3|16|Postoperative pain score (VAS) 24 hours (formulation)|Ropivacaine","Postoperative pain score (VAS) 24 hours (formulation)",3,16,"Ropivacaine","reported","reported",2,-8.9145924675233,4.07238697612384,21.4462352916653,2014.5,NA,48
"CD015145","CD015145_pub2_data","3|17|Postoperative pain score (VAS) 24 hours (adjuvant)|Without adjuvant","Postoperative pain score (VAS) 24 hours (adjuvant)",3,17,"Without adjuvant","reported","reported",3,-5.05729750672404,3.37864939335314,30.8596657016043,2017.66666666667,NA,62
"CD015145","CD015145_pub2_data","3|18|Postoperative pain score (VAS) 24 hours (control pain score)|Control group mean pain score < 30","Postoperative pain score (VAS) 24 hours (control pain score)",3,18,"Control group mean pain score < 30","reported","reported",2,-6.56105581237139,5.04877872425981,48.060903794424,2016.5,NA,42
"CD015145","CD015145_pub2_data","3|18|Postoperative pain score (VAS) 24 hours (control pain score)|Control group mean pain score > or = to 30","Postoperative pain score (VAS) 24 hours (control pain score)",3,18,"Control group mean pain score > or = to 30","reported","reported",2,-1.87549927005723,1.97827425915956,0,2016,NA,79
"CD015145","CD015145_pub2_data","3|2|Postoperative pain score (VAS) at rest 24 hours|","Postoperative pain score (VAS) at rest 24 hours",3,2,"","reported","reported",2,-0.158920701257821,0.73443840936817,0,2018,NA,73
"CD015145","CD015145_pub2_data","3|3|Postoperative pain score (VAS) during movement 24 hours|","Postoperative pain score (VAS) during movement 24 hours",3,3,"","reported","reported",2,-1.59240595989528,1.45260759147311,0,2018,NA,73
"CD015145","CD015145_pub2_data","3|4|Nausea and vomiting|","Nausea and vomiting",3,4,"","reported","reported",2,0.558631501339946,0.357413598003641,0,2016.5,0.205555555555556,55.5
"CD015145","CD015145_pub2_data","3|6|Opioid use (MME) 0 to 24 hours after surgery|","Opioid use (MME) 0 to 24 hours after surgery",3,6,"","reported","reported",3,3.08292943686636,3.44159147384596,21.0985082907489,2015,NA,46.6666666666667
"CD015145","CD015145_pub2_data","3|8|Postoperative pain score (VAS) at rest 2 hours|","Postoperative pain score (VAS) at rest 2 hours",3,8,"","reported","reported",2,-6.57615799924505,1.55076750988122,0,2018,NA,73
"CD015145","CD015145_pub2_data","3|9|Postoperative pain score (VAS) at rest 6 hours|","Postoperative pain score (VAS) at rest 6 hours",3,9,"","reported","reported",2,-6.49537757224867,1.29916771832545,1.56980631885608,2018,NA,73
"CD015160","CD015160_pub2_data","1|1|Surgical site infections (as defined by the included studies) within 30 days of repair|","Surgical site infections (as defined by the included studies) within 30 days of repair",1,1,"","or","binary",2,0.559380509790785,0.388290035508221,0.135371389087575,2017,0.109980928162746,227
"CD015160","CD015160_pub2_data","1|2|Mortality (defined as all‐cause mortality) within 30 days of repair|","Mortality (defined as all‐cause mortality) within 30 days of repair",1,2,"","or","binary",4,0.281908812136476,0.439850744490804,0,2013.5,0.0192307692307692,135.25
"CD015160","CD015160_pub2_data","1|4|Clinical recurrence or reoperation for recurrence within 30 days of repair|","Clinical recurrence or reoperation for recurrence within 30 days of repair",1,4,"","or","binary",3,0,1.16439419727539,0,2015,0,66.6666666666667
"CD015160","CD015160_pub2_data","1|5|Clinical recurrence or reoperation for recurrence within one year of repair|","Clinical recurrence or reoperation for recurrence within one year of repair",1,5,"","or","binary",3,-1.42404803736491,0.777327897966284,0,2012,0.123214285714286,48
"CD015160","CD015160_pub2_data","1|6|Mesh removal within 30 days of repair|","Mesh removal within 30 days of repair",1,6,"","or","binary",5,0.8797260569144,0.832064666503677,0,2012.6,0,80.4
"CD015160","CD015160_pub2_data","1|7|Mesh removal within 90 days of repair|","Mesh removal within 90 days of repair",1,7,"","or","binary",4,-0.0196335086256787,1.0101728067898,0,2011.25,0,48.5
"CD015160","CD015160_pub2_data","2|1|Clinical recurrence or reoperation for recurrence within 30 days of repair|Inguinal hernia","Clinical recurrence or reoperation for recurrence within 30 days of repair",2,1,"Inguinal hernia","or","binary",3,0,1.16486635834793,0,2015,0,60
"CD015160","CD015160_pub2_data","3|2|Mortality (defined as all‐cause mortality) within 30 days of repair|Clean to clean-contaminated surgical field","Mortality (defined as all‐cause mortality) within 30 days of repair",3,2,"Clean to clean-contaminated surgical field","or","binary",3,-0.0303164443725077,1.16454093280687,0,2012,0,111
"CD015160","CD015160_pub2_data","3|3|Mesh removal within 30 days of repair|Clean to clean-contaminated surgical field","Mesh removal within 30 days of repair",3,3,"Clean to clean-contaminated surgical field","or","binary",4,-0.0196335086256787,1.0101728067898,0,2011.25,0,48.5
"CD015160","CD015160_pub2_data","4|1|Clinical recurrence or reoperation for recurrence within 30 days of repair|Male sex","Clinical recurrence or reoperation for recurrence within 30 days of repair",4,1,"Male sex","or","binary",2,-0.0151619119407842,1.42532371127203,0,2016.5,0,62.5
"CD015160","CD015160_pub2_data","5|2|Mesh removal within 30 days of repair|No bowel resection","Mesh removal within 30 days of repair",5,2,"No bowel resection","or","binary",2,0,1.42917920202099,0,2010,0,47
"CD015160","CD015160_pub2_data","6|1|Clinical recurrence or reoperation for recurrence within one year of repair|Best-case scenario","Clinical recurrence or reoperation for recurrence within one year of repair",6,1,"Best-case scenario","or","binary",3,-1.41617155865947,0.777176921788529,0,2012,0.121710526315789,49.6666666666667
"CD015160","CD015160_pub2_data","6|1|Clinical recurrence or reoperation for recurrence within one year of repair|Worst-case scenario","Clinical recurrence or reoperation for recurrence within one year of repair",6,1,"Worst-case scenario","or","binary",3,-0.688999481547616,0.682798903030018,0.127398930969036,2012,0.121710526315789,49.6666666666667
"CD015192","CD015192_pub2_data","1|2|All-cause mortality|","All-cause mortality",1,2,"","reported","reported",2,0,1.1182291257474,0,1986.5,0.0208333333333333,160
"CD015192","CD015192_pub2_data","2|2|Surgical site infection rate|Cefazolin","Surgical site infection rate",2,2,"Cefazolin","reported","reported",2,0,0.311741455654461,0,1982.5,0.163621262458472,181.5
"CD015192","CD015192_pub2_data","2|3|All-cause mortality|","All-cause mortality",2,3,"","reported","reported",2,0,1.1182291257474,0,1986.5,0.0266472868217054,160
"CD015192","CD015192_pub2_data","4|2|Surgical site infection rate|Glycopeptide versus cephalosporin","Surgical site infection rate",4,2,"Glycopeptide versus cephalosporin","reported","reported",2,0,0.660974031220322,0,1999,0.0215612560813799,156
"CD015192","CD015192_pub2_data","5|2|Surgical site infection rate|Glycopeptide versus cephalosporin","Surgical site infection rate",5,2,"Glycopeptide versus cephalosporin","reported","reported",2,0,0.703018137326111,0,1999,0.034719150818222,156
"CD015192","CD015192_pub2_data","5|2|Surgical site infection rate|Second or third generation cephalosporin versus first generation cephalosporin","Surgical site infection rate",5,2,"Second or third generation cephalosporin versus first generation cephalosporin","reported","reported",3,0,0.697432252938704,0,1994,0.0149558498896247,208.333333333333
"CD015213","CD015213_pub2_data","1|1|Time to wound healing|Limberg flap","Time to wound healing",1,1,"Limberg flap","or","binary",2,0,1.42205615702513,0,2017,0,90
"CD015213","CD015213_pub2_data","1|10|Length of hospital stay|Limberg flap","Length of hospital stay",1,10,"Limberg flap","or","binary",5,0,0.897920689228448,0,2010.4,0,152.4
"CD015213","CD015213_pub2_data","1|10|Length of hospital stay|Modified Limberg flap","Length of hospital stay",1,10,"Modified Limberg flap","or","binary",2,0,1.42289327346289,0,2013,0,90
"CD015213","CD015213_pub2_data","1|10|Length of hospital stay|Rotational flap","Length of hospital stay",1,10,"Rotational flap","or","binary",2,0.020642196140266,1.42220156818276,0,2017,0,88
"CD015213","CD015213_pub2_data","1|3|Recurrence rate|Rotational flap","Recurrence rate",1,3,"Rotational flap","or","binary",2,-1.10066067866022,1.16458141883984,0,2017,0.0227040816326531,88
"CD015213","CD015213_pub2_data","1|4|Recurrence rate (Subgroup analysis according to follow-up duration)|Follow-up ≥ 12 months","Recurrence rate (Subgroup analysis according to follow-up duration)",1,4,"Follow-up ≥ 12 months","reported","reported",2,0,0.736765687888093,0,2009.5,0.126666666666667,80
"CD015213","CD015213_pub2_data","1|4|Recurrence rate (Subgroup analysis according to follow-up duration)|Follow-up＜12 months","Recurrence rate (Subgroup analysis according to follow-up duration)",1,4,"Follow-up＜12 months","or","binary",3,-0.824009205432717,1.00764873157978,0,2018,0.0151360544217687,92
"CD015213","CD015213_pub2_data","1|5|Wound infection|Limberg flap","Wound infection",1,5,"Limberg flap","reported","reported",8,0,0.242555277699598,0,2011.125,0.143813314417823,131.375
"CD015213","CD015213_pub2_data","1|5|Wound infection|Modified Limberg flap","Wound infection",1,5,"Modified Limberg flap","reported","reported",2,0,0.544735345591413,0,2013,0.183333333333333,90
"CD015213","CD015213_pub2_data","1|5|Wound infection|Rotational flap","Wound infection",1,5,"Rotational flap","reported","reported",2,0,0.746645412692502,0,2017,0.0533163265306122,88
"CD015213","CD015213_pub2_data","1|6|Wound infection (Sensitivity analysis according to risk of bias)|Limberg flap","Wound infection (Sensitivity analysis according to risk of bias)",1,6,"Limberg flap","or","binary",7,-1.1510978580785,0.272066389073417,0,2011.28571428571,0.148973458235753,113
"CD015213","CD015213_pub2_data","1|6|Wound infection (Sensitivity analysis according to risk of bias)|Modified Limberg flap","Wound infection (Sensitivity analysis according to risk of bias)",1,6,"Modified Limberg flap","or","binary",2,-1.24180830386843,0.544613519675186,0,2013,0.183333333333333,90
"CD015213","CD015213_pub2_data","1|6|Wound infection (Sensitivity analysis according to risk of bias)|Rotational flap","Wound infection (Sensitivity analysis according to risk of bias)",1,6,"Rotational flap","or","binary",2,-0.69330596451622,0.731429520860225,0,2017,0.0533163265306122,88
"CD015213","CD015213_pub2_data","1|8|Time to return to work|Modified Limberg flap","Time to return to work",1,8,"Modified Limberg flap","or","binary",2,0,1.42289327346289,0,2013,0,90
"CD015213","CD015213_pub2_data","2|10|Wound dehiscence|Limberg flap","Wound dehiscence",2,10,"Limberg flap","or","binary",2,-0.304490201044758,0.796318820204801,0,2016.5,0.0583333333333333,50
"CD015213","CD015213_pub2_data","2|12|Operative time|Limberg Flap","Operative time",2,12,"Limberg Flap","or","binary",2,0,1.42347238478543,0,2015,0,80
"CD015213","CD015213_pub2_data","2|14|Postoperative or post-procedural pain|","Postoperative or post-procedural pain",2,14,"","or","binary",2,0,1.42347238478543,0,2015,0,80
"CD015213","CD015213_pub2_data","2|3|Recurrence rate|Limberg flap","Recurrence rate",2,3,"Limberg flap","or","binary",4,-0.890802945701419,0.582065764382711,0,2014,0.0813636363636364,73.25
"CD015213","CD015213_pub2_data","2|4|Recurrence rate (Subgroup analysis according to follow-up duration)|Follow-up ≥ 12months","Recurrence rate (Subgroup analysis according to follow-up duration)",2,4,"Follow-up ≥ 12months","or","binary",5,-0.196148493364196,0.406210089492044,0,2016.6,0.076698752228164,90.2
"CD015213","CD015213_pub2_data","2|5|Recurrence rate (Sensitivity analysis according to risk of bias)|Limberg flap","Recurrence rate (Sensitivity analysis according to risk of bias)",2,5,"Limberg flap","or","binary",3,-0.551185967933915,0.632121222458084,0,2012.33333333333,0.0418181818181818,77.6666666666667
"CD015213","CD015213_pub2_data","2|7|Wound infection|Limberg flap","Wound infection",2,7,"Limberg flap","reported","reported",4,0,0.606380959618209,0,2014,0.0831818181818182,73.25
"CD015213","CD015213_pub2_data","2|8|Wound infection (Sensitivity analysis according to risk of bias)|Limberg flap","Wound infection (Sensitivity analysis according to risk of bias)",2,8,"Limberg flap","reported","reported",3,0,0.74318468138739,0,2012.33333333333,0.0442424242424242,77.6666666666667
"CD015213","CD015213_pub2_data","3|1|Time to wound healing|","Time to wound healing",3,1,"","or","binary",6,-0.0288048237565229,0.822817738140369,0,2017.33333333333,0,87.6666666666667
"CD015213","CD015213_pub2_data","3|10|Time to return to work|","Time to return to work",3,10,"","or","binary",6,-0.0335515363981021,0.822555357587168,0,2017.33333333333,0,90.1666666666667
"CD015213","CD015213_pub2_data","3|11|Time to return to work (Sensitivity analysis according to risk of bias)|","Time to return to work (Sensitivity analysis according to risk of bias)",3,11,"","or","binary",5,-0.0511012977629876,0.901923502856765,0,2018,0,70.8
"CD015213","CD015213_pub2_data","3|13|Length of hospital stay|","Length of hospital stay",3,13,"","or","binary",5,-0.0402054338312036,0.900432797924098,0,2018,0,89
"CD015213","CD015213_pub2_data","3|2|Time to wound healing (Sensitivity analysis according to risk of bias)|","Time to wound healing (Sensitivity analysis according to risk of bias)",3,2,"","or","binary",5,-0.045407102059197,0.902269432191846,0,2018,0,67.8
"CD015213","CD015213_pub2_data","3|4|Recurrence rate|Follow-up ＜12 months","Recurrence rate",3,4,"Follow-up ＜12 months","or","binary",4,-0.00967805967435681,0.466627754035042,0.2213383025405,2018.25,0.0450367647058824,131
"CD015213","CD015213_pub2_data","3|4|Recurrence rate|Follow-up ≥12 months","Recurrence rate",3,4,"Follow-up ≥12 months","or","binary",5,0.391544140603418,0.554612377287185,0,2017.4,0.0253333333333333,73.2
"CD015213","CD015213_pub2_data","3|5|Recurrence rate (Sensitivity analysis according to risk of bias)|Follow-up ＜12 months","Recurrence rate (Sensitivity analysis according to risk of bias)",3,5,"Follow-up ＜12 months","or","binary",2,-0.446108028804718,0.5261227854177,0,2019,0.0441176470588235,134
"CD015213","CD015213_pub2_data","3|5|Recurrence rate (Sensitivity analysis according to risk of bias)|Follow-up ≥12 months","Recurrence rate (Sensitivity analysis according to risk of bias)",3,5,"Follow-up ≥12 months","or","binary",6,0.235712668646578,0.525718513165703,0,2018,0.0260130718954248,74
"CD015213","CD015213_pub2_data","3|6|Wound infection|","Wound infection",3,6,"","or","binary",8,0.472972443363159,0.301985030672029,0.0938282998095308,2018,0.0508426257139492,108.625
"CD015213","CD015213_pub2_data","3|7|Wound infection (Sensitivity analysis according to risk of bias)|","Wound infection (Sensitivity analysis according to risk of bias)",3,7,"","or","binary",7,0.384365104878813,0.328852826423573,0.108068237885085,2018.57142857143,0.0551296674826087,97.4285714285714
"CD015213","CD015213_pub2_data","3|8|Wound dehiscence|","Wound dehiscence",3,8,"","or","binary",7,0.161203860536831,0.52047040082494,0.919611865084686,2016.85714285714,0.0711789310318722,110.857142857143
"CD015213","CD015213_pub2_data","3|9|Wound dehiscence (Sensitivity analysis according to risk of bias)|","Wound dehiscence (Sensitivity analysis according to risk of bias)",3,9,"","or","binary",6,-0.475961435702199,0.373543949321285,0.0449394020330332,2017.33333333333,0.0795698639816287,98.1666666666667
"CD015213","CD015213_pub2_data","6|1|Time to wound healing|","Time to wound healing",6,1,"","or","binary",2,-0.165091181861682,1.41856496875181,0,2012,0,168
"CD015213","CD015213_pub2_data","6|2|Recurrence rate|","Recurrence rate",6,2,"","or","binary",2,-0.808179700792774,0.900465536720322,1.09397553663767,2012,0.0787545787545788,168
"CD015213","CD015213_pub2_data","6|3|Wound infection|","Wound infection",6,3,"","or","binary",2,-0.160716122947006,0.4630519589409,0,2012,0.0550258564964447,172
"CD015213","CD015213_pub2_data","6|4|Wound dehiscence|","Wound dehiscence",6,4,"","or","binary",2,-0.905733626461937,0.661539178055553,0.441220654882391,2012,0.0989819004524887,172
"CD015213","CD015213_pub2_data","6|5|Time to return to work|","Time to return to work",6,5,"","or","binary",2,-0.165091181861682,1.41856496875181,0,2012,0,168
"CD015213","CD015213_pub2_data","6|6|Operative time|","Operative time",6,6,"","or","binary",2,-0.146949161758086,1.41841818528382,0,2012,0,172
"CD015213","CD015213_pub2_data","6|7|Length of hospital stay|","Length of hospital stay",6,7,"","or","binary",2,-0.146949161758086,1.41841818528382,0,2012,0,172
"CD015215","CD015215_pub2_data","1|1|Return to normal hearing, randomised by ear (medium-term)|Randomised by ear: normal defined as < 15 dB; CC = 0.5 (medium-term)","Return to normal hearing, randomised by ear (medium-term)",1,1,"Randomised by ear: normal defined as < 15 dB; CC = 0.5 (medium-term)","reported","reported",2,0.120353321036396,0.452543364990063,0.2973683918445,1993,NA,0
"CD015215","CD015215_pub2_data","1|10|Adverse event: tympanosclerosis, randomised by ear (medium-term)|","Adverse event: tympanosclerosis, randomised by ear (medium-term)",1,10,"","or","binary",2,2.90149297348204,0.810533840396246,0.106363322448228,1993,0.0142857142857143,72
"CD015215","CD015215_pub2_data","1|2|Mean final hearing threshold, randomised by ear (medium-term)|Correlation coefficient = 0.5","Mean final hearing threshold, randomised by ear (medium-term)",1,2,"Correlation coefficient = 0.5","reported","reported",3,-3.46702286034262,3.24578762833838,29.0216138048548,1989.66666666667,NA,0
"CD015215","CD015215_pub2_data","1|3|Change in hearing threshold from baseline, randomised by ear (medium-term)|","Change in hearing threshold from baseline, randomised by ear (medium-term)",1,3,"","reported","reported",2,-0.157421875,1.59363467528524,1.77375,1993,NA,0
"CD015215","CD015215_pub2_data","1|4|Adverse event: perforation/retraction, randomised by ear (medium-term)|Correlation coefficient 0.5","Adverse event: perforation/retraction, randomised by ear (medium-term)",1,4,"Correlation coefficient 0.5","reported","reported",2,-0.165808364894492,0.415670058698001,0,1993,NA,0
"CD015215","CD015215_pub2_data","1|7|Persistence of OME: randomised by ear (medium-term)|Correlation coefficient = 0.5","Persistence of OME: randomised by ear (medium-term)",1,7,"Correlation coefficient = 0.5","reported","reported",2,-0.412123351304388,0.522944090994331,0.4313255744805,1993,NA,0
"CD015215","CD015215_pub2_data","2|14|Presence/persistence of OME, randomised by child (long-term)|","Presence/persistence of OME, randomised by child (long-term)",2,14,"","or","binary",3,0.264322683633193,0.255365820355897,0,1999,0.147959183673469,194.666666666667
"CD015215","CD015215_pub2_data","2|3|Mean final hearing threshold (air conduction), randomised by child (medium-term)|","Mean final hearing threshold (air conduction), randomised by child (medium-term)",2,3,"","or","binary",2,-0.196285077916732,1.41843108361888,0,1999,0,175.5
"CD015215","CD015215_pub2_data","2|5|Mean final hearing threshold, randomised by child (long-term)|Assumed correlation coefficient for Paradise 2007 (left and right ear data combined) of 0.5","Mean final hearing threshold, randomised by child (long-term)",2,5,"Assumed correlation coefficient for Paradise 2007 (left and right ear data combined) of 0.5","or","binary",3,-0.087035425451223,1.15764236161749,0,2003,0,211
"CD015215","CD015215_pub2_data","4|1|Hearing returned to normal: VT versus laser myringotomy (medium-term)|Adjusted for non-independence of within-individual measurements; assumed ICC of 0.5","Hearing returned to normal: VT versus laser myringotomy (medium-term)",4,1,"Adjusted for non-independence of within-individual measurements; assumed ICC of 0.5","or","binary",2,1.20161634547569,0.433112654904883,0,2016,0.764705882352941,66
"CD015215","CD015215_pub2_data","4|12|Persistence of OME: mean days to first recurrence|","Persistence of OME: mean days to first recurrence",4,12,"","or","binary",2,-0.237380751354898,1.41790345213088,0,1989,0,194.5
"CD015215","CD015215_pub2_data","4|13|Persistence of OME (long-term)|","Persistence of OME (long-term)",4,13,"","or","binary",2,-0.152642594168484,0.24923968496733,0,1989,0.856290438533429,245.5
"CD015215","CD015215_pub2_data","4|14|Adverse events: otorrhoea (long-term)|","Adverse events: otorrhoea (long-term)",4,14,"","or","binary",2,0.57110991597845,0.270795951733441,0.0444674740888822,1989,0.169841840402588,245.5
"CD015215","CD015215_pub2_data","4|6|Adverse event: persistent perforation cold-steel myringotomy (medium-term)|","Adverse event: persistent perforation cold-steel myringotomy (medium-term)",4,6,"","or","binary",2,1.98582561249462,1.10082293959358,0,1984,0,104
"CD015215","CD015215_pub2_data","5|1|Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.3|Sensitivity analysis: normal defined as < 15 dB; CC = 0.3","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.3",5,1,"Sensitivity analysis: normal defined as < 15 dB; CC = 0.3","reported","reported",2,0.119690423311572,0.452537457849522,0.2535683918445,1993,NA,0
"CD015215","CD015215_pub2_data","5|12|Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.3|Sensitivity analysis: correlation coefficient = 0.3","Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.3",5,12,"Sensitivity analysis: correlation coefficient = 0.3","reported","reported",2,-0.4186245,0.5229845,0.3870255744805,1993,NA,0
"CD015215","CD015215_pub2_data","5|13|Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.7|Sensitivity analysis: correlation coefficient = 0.7","Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.7",5,13,"Sensitivity analysis: correlation coefficient = 0.7","reported","reported",2,-0.4186245,0.5229845,0.4794255744805,1993,NA,0
"CD015215","CD015215_pub2_data","5|2|Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.7|Sensitivity analysis: normal defined as < 15 dB; CC = 0.7","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.7",5,2,"Sensitivity analysis: normal defined as < 15 dB; CC = 0.7","reported","reported",2,0.1240545,0.4525585,0.3420183918445,1993,NA,0
"CD015215","CD015215_pub2_data","5|3|Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term). Normal defined as < 25 dB; CC = 0.5|Sensitivity analysis: normal defined as < 25 dB; CC = 0.5 (medium-term)","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term). Normal defined as < 25 dB; CC = 0.5",5,3,"Sensitivity analysis: normal defined as < 25 dB; CC = 0.5 (medium-term)","reported","reported",2,-0.000462897626112749,0.288880423548901,0,1993,NA,0
"CD015215","CD015215_pub2_data","5|4|Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.3|Sensitivity analysis: correlation coefficient = 0.3","Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.3",5,4,"Sensitivity analysis: correlation coefficient = 0.3","reported","reported",3,-3.47529041929434,3.25508887092197,28.2378646739411,1989.66666666667,NA,0
"CD015215","CD015215_pub2_data","5|5|Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.7|Sensitivity analysis: correlation coefficient = 0.7","Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.7",5,5,"Sensitivity analysis: correlation coefficient = 0.7","reported","reported",3,-3.49708164745229,3.26721675543824,30.013523176463,1989.66666666667,NA,0
"CD015215","CD015215_pub2_data","5|6|Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.3|","Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.3",5,6,"","reported","reported",2,-0.103796875,1.58792453653826,0.41175,1993,NA,0
"CD015215","CD015215_pub2_data","5|7|Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.7|","Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.7",5,7,"","reported","reported",2,-0.21125,1.5975366779827,3.0936,1993,NA,0
"CD015215","CD015215_pub2_data","5|8|Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.3|Sensitivity analysis: correlation coefficient = 0.3","Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.3",5,8,"Sensitivity analysis: correlation coefficient = 0.3","reported","reported",2,-0.164197308081309,0.487731527213057,0,1993,NA,0
"CD015215","CD015215_pub2_data","5|9|Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.7|Sensitivity analysis: correlation coefficient = 0.7","Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.7",5,9,"Sensitivity analysis: correlation coefficient = 0.7","reported","reported",2,-0.0932577235028976,0.362917348623271,0,1993,NA,0
"CD015215","CD015215_pub2_data","6|3|Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.3|Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.3","Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.3",6,3,"Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.3","or","binary",3,-0.087035425451223,1.15764236161749,0,2003,0,211
"CD015215","CD015215_pub2_data","6|4|Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.7|Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.7","Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.7",6,4,"Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.7","or","binary",3,-0.087035425451223,1.15764236161749,0,2003,0,211
"CD015215","CD015215_pub2_data","7|1|Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = 1.0|Sensitivity analysis: ICC of 1.0 (complete correlation between ears)","Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = 1.0",7,1,"Sensitivity analysis: ICC of 1.0 (complete correlation between ears)","or","binary",2,1.16004495648148,0.479263991891822,0,2016,0.768292682926829,56
"CD015215","CD015215_pub2_data","7|2|Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = zero|Sensitivity analysis: ICC of zero (no correlation between ears)","Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = zero",7,2,"Sensitivity analysis: ICC of zero (no correlation between ears)","or","binary",2,1.16686696796093,0.37487235292142,0,2016,0.764705882352941,83
"CD015219","CD015219_pub2_data","1|1|All-cause mortality – at 28 to 30 days, or in‐hospital|","All-cause mortality – at 28 to 30 days, or in‐hospital",1,1,"","reported","reported",11,0,0.143814584068109,0,2021.27272727273,0.1000251870801,314.454545454545
"CD015219","CD015219_pub2_data","1|10|All adverse events|","All adverse events",1,10,"","reported","reported",18,0,0.0501925377744519,0,2021.33333333333,0.263709402985601,261.055555555556
"CD015219","CD015219_pub2_data","1|11|Serious adverse events attributable to the drug|","Serious adverse events attributable to the drug",1,11,"","or","binary",12,0.0432739316432205,0.172924366537747,0,2021.33333333333,0.0659689364097423,276.416666666667
"CD015219","CD015219_pub2_data","1|12|Hyperuricaemia|","Hyperuricaemia",1,12,"","reported","reported",10,0,0.143408225407728,0,2021,0.0490346243388648,247.2
"CD015219","CD015219_pub2_data","1|13|Need for admission to hospital (if ambulatory) – fixed-effect model|","Need for admission to hospital (if ambulatory) – fixed-effect model",1,13,"","or","binary",4,0.00374899018779204,0.470975381452923,0.425118175196056,2021.75,0.140111874169251,167.5
"CD015219","CD015219_pub2_data","1|14|Time to negative PCR for SARS‐CoV‐2 – fixed-effect model|","Time to negative PCR for SARS‐CoV‐2 – fixed-effect model",1,14,"","reported","reported",4,0.318931779725304,0.238078917351544,0.147795697076805,2020.75,NA,0
"CD015219","CD015219_pub2_data","1|15|All adverse events – fixed-effect model|","All adverse events – fixed-effect model",1,15,"","reported","reported",18,0,0.0501925377744519,0,2021.33333333333,0.263709402985601,261.055555555556
"CD015219","CD015219_pub2_data","1|2|Progression to invasive mechanical ventilation|","Progression to invasive mechanical ventilation",1,2,"","reported","reported",8,0,0.1207266947432,0,2021,0.142459072290342,172.875
"CD015219","CD015219_pub2_data","1|3|Need for admission to hospital (if ambulatory)|","Need for admission to hospital (if ambulatory)",1,3,"","or","binary",4,0.00374899018779204,0.470975381452923,0.425118175196056,2021.75,0.140111874169251,167.5
"CD015219","CD015219_pub2_data","1|4|Time to clinical improvement (defined as time to a 2-point reduction in participants’ admission status on WHO’s ordinal scale)|","Time to clinical improvement (defined as time to a 2-point reduction in participants’ admission status on WHO’s ordinal scale)",1,4,"","reported","reported",4,0.115891710827174,0.256593750859957,0.19690551521299,2020.75,NA,0
"CD015219","CD015219_pub2_data","1|5|Progression to oxygen therapy|","Progression to oxygen therapy",1,5,"","or","binary",2,0.225029517789238,0.228611240219142,0,2020.5,0.194689655172414,271.5
"CD015219","CD015219_pub2_data","1|6|Need for critical or intensive care (any reason)|","Need for critical or intensive care (any reason)",1,6,"","reported","reported",5,0,0.188284746658321,0,2021.2,0.109211781660962,243
"CD015219","CD015219_pub2_data","1|8|Duration of hospitalization|","Duration of hospitalization",1,8,"","or","binary",3,-0.0204214323298559,1.16077826390167,0,2021.33333333333,0,215.666666666667
"CD015219","CD015219_pub2_data","1|9|Time to negative PCR for SARS‐CoV‐2|","Time to negative PCR for SARS‐CoV‐2",1,9,"","reported","reported",4,0.318931779725304,0.238078917351544,0.147795697076805,2020.75,NA,0
"CD015219","CD015219_pub2_data","2|1|All-cause mortality – at 28 to 30 days, or in-hospital|Ambulatory, mild","All-cause mortality – at 28 to 30 days, or in-hospital",2,1,"Ambulatory, mild","reported","reported",3,0,0.239304057784073,0,2022.33333333333,0.0462535559014546,605.333333333333
"CD015219","CD015219_pub2_data","2|1|All-cause mortality – at 28 to 30 days, or in-hospital|Moderate, severe or critical","All-cause mortality – at 28 to 30 days, or in-hospital",2,1,"Moderate, severe or critical","reported","reported",3,0,0.210301674367839,0,2021.33333333333,0.295461768011472,177.333333333333
"CD015219","CD015219_pub2_data","2|2|All adverse events|Ambulatory, mild","All adverse events",2,2,"Ambulatory, mild","reported","reported",2,0,0.0892076997630589,0,2022.5,0.286209677419355,349
"CD015219","CD015219_pub2_data","2|2|All adverse events|Moderate, severe, or critical","All adverse events",2,2,"Moderate, severe, or critical","or","binary",2,0.137443178328429,0.300772584035872,0.0885210196363824,2020.5,0.253921568627451,221
"CD015219","CD015219_pub2_data","2|3|Serious adverse events attributable to the drug|Ambulatory, mild","Serious adverse events attributable to the drug",2,3,"Ambulatory, mild","reported","reported",8,0,0.170320075905567,0,2021.75,0.0322867379479468,362.25
"CD015219","CD015219_pub2_data","2|4|Hyperuricaemia|Ambulatory, mild","Hyperuricaemia",2,4,"Ambulatory, mild","or","binary",4,2.10524576947691,0.249034430381262,0,2021.5,0.0284884044933086,379.75
"CD015219","CD015219_pub2_data","3|1|All-cause mortality – at 28 to 30 days, or in-hospital|Dose < 1600 mg/day","All-cause mortality – at 28 to 30 days, or in-hospital",3,1,"Dose < 1600 mg/day","or","binary",3,-0.922558486024578,0.937688419637666,1.78636672028145,2021.66666666667,0.257210401891253,88.3333333333333
"CD015219","CD015219_pub2_data","3|1|All-cause mortality – at 28 to 30 days, or in-hospital|Dose ≥ 1600 mg/day","All-cause mortality – at 28 to 30 days, or in-hospital",3,1,"Dose ≥ 1600 mg/day","or","binary",8,0.0365100385308743,0.196465027431673,0.0218527343291208,2021.125,0.0410807315259177,399.25
"CD015219","CD015219_pub2_data","3|2|All adverse events|Dose < 1600 mg/day","All adverse events",3,2,"Dose < 1600 mg/day","or","binary",3,0.0955792862747751,0.239182800862233,0.0426014239014197,2020.66666666667,0.292088063295494,165.666666666667
"CD015219","CD015219_pub2_data","3|2|All adverse events|Dose ≥ 1600 mg/day","All adverse events",3,2,"Dose ≥ 1600 mg/day","reported","reported",2,0,0.0892076997630589,0,2022.5,0.286209677419355,349
"CD015219","CD015219_pub2_data","3|3|Serious adverse events attributable to the drug|Dose ≥ 1600 mg/day","Serious adverse events attributable to the drug",3,3,"Dose ≥ 1600 mg/day","reported","reported",11,0,0.159087947146042,0,2021.45454545455,0.0719661124469916,283.363636363636
"CD015219","CD015219_pub2_data","3|4|Hyperuricaemia|Dose < 1600 mg/day","Hyperuricaemia",3,4,"Dose < 1600 mg/day","or","binary",2,1.58039034778764,0.543109423393744,0,2021,0.0388157894736842,131
"CD015219","CD015219_pub2_data","3|4|Hyperuricaemia|Dose ≥ 1600 mg/day","Hyperuricaemia",3,4,"Dose ≥ 1600 mg/day","or","binary",8,2.14819233248318,0.204135815994316,0,2021,0.05158933305516,276.25
"CD015219","CD015219_pub2_data","4|1|All-cause mortality – at 28 to 30 days, or in-hospital|Favipiravir versus SOC/placebo","All-cause mortality – at 28 to 30 days, or in-hospital",4,1,"Favipiravir versus SOC/placebo","or","binary",7,-0.00398699868785938,0.272468465703964,0.0628465754539421,2021.28571428571,0.0305559648352408,411
"CD015219","CD015219_pub2_data","4|10|Hyperuricaemia|Favipiravir versus SOC/placebo","Hyperuricaemia",4,10,"Favipiravir versus SOC/placebo","or","binary",7,2.17108301458377,0.204431847191627,0,2021.14285714286,0.0593351776269497,308.142857142857
"CD015219","CD015219_pub2_data","4|2|Progression to invasive mechanical ventilation|Favipiravir versus standard care/placebo","Progression to invasive mechanical ventilation",4,2,"Favipiravir versus standard care/placebo","or","binary",4,-0.303898989666271,0.424959772583171,0.0249101713279591,2021,0.222307692307692,208.5
"CD015219","CD015219_pub2_data","4|3|Time to clinical improvement (defined as time to a 2-point reduction in participants’ admission status on WHO’s ordinal scale)|","Time to clinical improvement (defined as time to a 2-point reduction in participants’ admission status on WHO’s ordinal scale)",4,3,"","reported","reported",3,0.251184006778412,0.287957529923175,0.190277576959319,2020.66666666667,NA,0
"CD015219","CD015219_pub2_data","4|5|Need for critical or intensive care (any reason)|Favipiravir versus standard care/placebo","Need for critical or intensive care (any reason)",4,5,"Favipiravir versus standard care/placebo","or","binary",3,-0.0749440251789261,0.348093064684237,0,2021.33333333333,0.0475934065934066,258
"CD015219","CD015219_pub2_data","4|7|Time to negative PCR for SARS‐CoV‐2|","Time to negative PCR for SARS‐CoV‐2",4,7,"","reported","reported",3,0.227756192936017,0.27846547531868,0.170006209956806,2020.66666666667,NA,0
"CD015219","CD015219_pub2_data","4|8|All adverse events|Favipiravir versus standard care/placebo","All adverse events",4,8,"Favipiravir versus standard care/placebo","reported","reported",2,0,0.0892076997630589,0,2022.5,0.286209677419355,349
"CD015219","CD015219_pub2_data","4|9|Serious adverse events attributable to the drug|","Serious adverse events attributable to the drug",4,9,"","or","binary",8,0.0595627234379341,0.185817366813345,0,2021.375,0.0311124955237044,355.375
"CD015219","CD015219_pub2_data","5|1|All-cause mortality – at 28 to 30 days, or in‐hospital|Favipiravir versus standard care/placebo","All-cause mortality – at 28 to 30 days, or in‐hospital",5,1,"Favipiravir versus standard care/placebo","or","binary",9,-0.172988522889841,0.51704680013487,1.22853502029712,2021.33333333333,0.0946877362430124,336
"CD015219","CD015219_pub2_data","5|2|Progression to invasive mechanical ventilation|Favipiravir versus standard care/placebo","Progression to invasive mechanical ventilation",5,2,"Favipiravir versus standard care/placebo","or","binary",7,-0.258559496460123,0.354753970021921,0,2021,0.143294365209259,144.285714285714
"CD015219","CD015219_pub2_data","5|3|Need for critical or intensive care (any reason)|Favipiravir versus standard care/placebo","Need for critical or intensive care (any reason)",5,3,"Favipiravir versus standard care/placebo","or","binary",3,-0.0749440251789261,0.348093064684237,0,2021.33333333333,0.0475934065934066,258
"CD015219","CD015219_pub2_data","5|4|All adverse events|Favipiravir versus standard care/placebo","All adverse events",5,4,"Favipiravir versus standard care/placebo","reported","reported",2,0,0.0892076997630589,0,2022.5,0.286209677419355,349
"CD015219","CD015219_pub2_data","5|5|Hyperuricaemia|Favipiravir versus standard care/placebo","Hyperuricaemia",5,5,"Favipiravir versus standard care/placebo","or","binary",9,2.11917527631941,0.201430862974024,0,2021,0.0517051381542942,248.444444444444
"CD015229","CD015229_pub2_data","1|1|Quality of life at 14 days|NA","Quality of life at 14 days",1,1,NA,"reported","reported",4,-0.726504011214184,0.538348168170469,1.02229250899351,2007,NA,37.5
"CD015229","CD015229_pub2_data","1|2|Pain score at 14 days|NA","Pain score at 14 days",1,2,NA,"reported","reported",5,-0.436877754767084,0.27594140480409,0.216512258412226,2004.2,NA,42.8
"CD015229","CD015229_pub2_data","1|3|Pain score at 1 month|NA","Pain score at 1 month",1,3,NA,"reported","reported",7,-0.835829571626617,0.282977012187723,0.421672282527085,2007.85714285714,NA,51.2857142857143
"CD015229","CD015229_pub2_data","1|4|Pain score at 3 months|NA","Pain score at 3 months",1,4,NA,"reported","reported",8,-1.10017672015844,0.582253633646749,2.38953817923156,2009.625,NA,49.25
"CD015229","CD015229_pub2_data","1|5|Opiate consumption at 14 days|NA","Opiate consumption at 14 days",1,5,NA,"reported","reported",4,-41.7242562032269,16.2971486643524,901.326000969388,2004.25,NA,32.5
"CD015229","CD015229_pub2_data","1|6|Opiate consumption at 1 month|NA","Opiate consumption at 1 month",1,6,NA,"reported","reported",8,-47.3546089072321,13.3326285346776,1143.30774762204,2007.5,NA,47.75
"CD015229","CD015229_pub2_data","1|7|Opiate consumption at 3 months|NA","Opiate consumption at 3 months",1,7,NA,"reported","reported",9,-64.7359876049096,8.11934812981082,220.565947948701,2009.44444444444,NA,50.1111111111111
"CD015229","CD015229_pub2_data","2|3|Pain score at 1 month|NA","Pain score at 1 month",2,3,NA,"reported","reported",2,-1.84517060860188,0.249953349604929,0.0865525484676957,2016.5,NA,41
"CD015229","CD015229_pub2_data","2|4|Pain score at 3 months|NA","Pain score at 3 months",2,4,NA,"reported","reported",2,-1.93055552000041,0.364972939541459,0.240331899404284,2016.5,NA,41
"CD015229","CD015229_pub2_data","2|7|Opiate consumption at 3 months|NA","Opiate consumption at 3 months",2,7,NA,"reported","reported",2,-16.0832167262778,3.99789703605982,0,2016.5,NA,41
"CD015252","CD015252_pub2_data","1|3|Presence or persistence of OME|Over 12 months","Presence or persistence of OME",1,3,"Over 12 months","or","binary",3,-0.544347425848024,0.270365574042526,0,1989,0.581752202169943,118
"CD015252","CD015252_pub2_data","1|3|Presence or persistence of OME|Up to 12 months","Presence or persistence of OME",1,3,"Up to 12 months","or","binary",2,-0.594568779014915,0.405436394386851,0,NA,0.358297413793103,58.5
"CD015252","CD015252_pub2_data","1|3|Presence or persistence of OME|Up to 3 months","Presence or persistence of OME",1,3,"Up to 3 months","or","binary",2,-0.692276648543999,0.414355826413436,0,NA,0.785560344827586,58.5
"CD015252","CD015252_pub2_data","1|4|Sensitivity analysis: presence or persistence of OME (complete correlation between ears)|Over 12 months","Sensitivity analysis: presence or persistence of OME (complete correlation between ears)",1,4,"Over 12 months","or","binary",3,-0.548096484822803,0.286986214608048,0,1989,0.588206834702162,108.333333333333
"CD015252","CD015252_pub2_data","1|4|Sensitivity analysis: presence or persistence of OME (complete correlation between ears)|Up to 12 months","Sensitivity analysis: presence or persistence of OME (complete correlation between ears)",1,4,"Up to 12 months","or","binary",2,-0.593169083122623,0.460223128478687,0,NA,0.367424242424242,44
"CD015252","CD015252_pub2_data","1|4|Sensitivity analysis: presence or persistence of OME (complete correlation between ears)|Up to 3 months","Sensitivity analysis: presence or persistence of OME (complete correlation between ears)",1,4,"Up to 3 months","or","binary",2,-0.556726186414101,0.474708264334314,0,NA,0.78219696969697,44
"CD015252","CD015252_pub2_data","1|5|Sensitivity analysis: presence or persistence of OME (no correlation between ears)|Over 12 months","Sensitivity analysis: presence or persistence of OME (no correlation between ears)",1,5,"Over 12 months","or","binary",3,-0.521359111832386,0.242069890610641,0,1989,0.580631077126404,137.666666666667
"CD015252","CD015252_pub2_data","1|5|Sensitivity analysis: presence or persistence of OME (no correlation between ears)|Up to 12 months","Sensitivity analysis: presence or persistence of OME (no correlation between ears)",1,5,"Up to 12 months","or","binary",2,-0.520791164440631,0.332655764396266,0,NA,0.345643939393939,88
"CD015252","CD015252_pub2_data","1|5|Sensitivity analysis: presence or persistence of OME (no correlation between ears)|Up to 3 months","Sensitivity analysis: presence or persistence of OME (no correlation between ears)",1,5,"Up to 3 months","or","binary",2,-0.685534177402263,0.338991558248592,0,NA,0.78125,88
"CD015252","CD015252_pub2_data","2|2|Final hearing threshold|Up to 12 months","Final hearing threshold",2,2,"Up to 12 months","or","binary",2,-0.0694328220728866,1.4177208526104,0,NA,0,202.5
"CD015252","CD015252_pub2_data","2|2|Final hearing threshold|Up to 3 months","Final hearing threshold",2,2,"Up to 3 months","or","binary",2,-0.095922539191073,1.41769417558139,0,NA,0,204.5
"CD015252","CD015252_pub2_data","2|3|Serious adverse event: haemorrhage|","Serious adverse event: haemorrhage",2,3,"","or","binary",2,0.996903823461297,1.15699867521285,0,1989,0,395.5
"CD015252","CD015252_pub2_data","2|4|Presence/persistence of OME|Up to 12 months","Presence/persistence of OME",2,4,"Up to 12 months","or","binary",2,-0.419926241181541,0.266681331715448,0.0483614086825804,NA,0.554515252189671,172
"CD015252","CD015252_pub2_data","2|8|Sensitivity analysis: presence/persistence of OME ICC 0|Up to 12 months","Sensitivity analysis: presence/persistence of OME ICC 0",2,8,"Up to 12 months","or","binary",2,-0.423710504051813,0.246040794472574,0.0397045294693504,NA,0.551930458342741,198.5
"CD015252","CD015252_pub2_data","2|9|Sensitivity analysis: presence/persistence of OME ICC 1|Up to 12 months","Sensitivity analysis: presence/persistence of OME ICC 1",2,9,"Up to 12 months","or","binary",2,-0.387975442796976,0.256602655453817,0.0279679696752619,NA,0.554201050262566,156
"CD015252","CD015252_pub2_data","3|2|Hearing threshold|Up to 12 months","Hearing threshold",3,2,"Up to 12 months","or","binary",2,0.118314235520221,1.42338096071703,0,1993,0,77
"CD015252","CD015252_pub2_data","3|3|Presence or persistence of OME|SENSITIVITY ANALYSIS: Up to 12 months. Dempster data from otoscopy","Presence or persistence of OME",3,3,"SENSITIVITY ANALYSIS: Up to 12 months. Dempster data from otoscopy","or","binary",2,-1.26922498674821,0.577314440848331,0.469060560216902,1993,0.710837438423645,94.5
"CD015252","CD015252_pub2_data","3|3|Presence or persistence of OME|Up to 12 months. Dempster data from tympanometry","Presence or persistence of OME",3,3,"Up to 12 months. Dempster data from tympanometry","or","binary",2,-1.34654179520853,0.506915610642809,0.312838115895827,1993,0.739408866995074,94.5
"CD015254","CD015254_pub2_data","1|14|Episodes of acute otitis media|","Episodes of acute otitis media",1,14,"","or","binary",2,-0.440641097872081,0.272705382863263,0,1989,0.133333333333333,307.5
"CD015254","CD015254_pub2_data","1|2|Hearing threshold: speech reception threshold (short-term). Correction of variance assuming correlation coefficient of 0.5|","Hearing threshold: speech reception threshold (short-term). Correction of variance assuming correlation coefficient of 0.5",1,2,"","or","binary",2,-0.605885470147142,1.41761868642523,0,1989,0,249.5
"CD015254","CD015254_pub2_data","1|3|Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3|","Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3",1,3,"","or","binary",2,-0.605885470147142,1.41761868642523,0,1989,0,249.5
"CD015254","CD015254_pub2_data","1|4|Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7|","Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7",1,4,"","or","binary",2,-0.605885470147142,1.41761868642523,0,1989,0,249.5
"CD015254","CD015254_pub2_data","1|6|Persistence of OME (short-term)|Persistence defined as effusion in one ear or both","Persistence of OME (short-term)",1,6,"Persistence defined as effusion in one ear or both","or","binary",7,-0.259105978753516,0.235454732968768,0.216668958691095,1990.71428571429,0.705727569990243,172.571428571429
"CD015254","CD015254_pub2_data","1|7|Sensitivity analysis: persistence (short-term) including cases of acute otitis (Mandel 1987)|Persistence defined as effusion in one ear or both","Sensitivity analysis: persistence (short-term) including cases of acute otitis (Mandel 1987)",1,7,"Persistence defined as effusion in one ear or both","or","binary",8,-0.408418631189946,0.245780712273564,0.260583534734801,1991.5,0.752928290408129,161.125
"CD015254","CD015254_pub2_data","1|8|Sensitivity analysis: persistence (short-term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985)|Persistence defined as effusion in one ear or both","Sensitivity analysis: persistence (short-term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985)",1,8,"Persistence defined as effusion in one ear or both","or","binary",8,-0.317903060401999,0.212379690347764,0.161575775734059,1991.5,0.736906785031785,159.75
"CD015254","CD015254_pub2_data","1|9|Sensitivity analysis: persistence (short-term) assuming ICC of zero (no correlation between ears) (Puhakka 1985)|Persistence defined as effusion in one ear or both","Sensitivity analysis: persistence (short-term) assuming ICC of zero (no correlation between ears) (Puhakka 1985)",1,9,"Persistence defined as effusion in one ear or both","or","binary",8,-0.302950730503576,0.224623756833341,0.207320651657245,1991.5,0.738781785031785,163.25
"CD015254","CD015254_pub2_data","2|3|Persistence of OME (short-term)|Analysis by child: persistence in any affected ear","Persistence of OME (short-term)",2,3,"Analysis by child: persistence in any affected ear","or","binary",2,-1.91077200532957,1.01733407958786,1.87179412561014,1991,0.87452159650082,150
"CD015254","CD015254_pub2_data","2|3|Persistence of OME (short-term)|Analysis by child: persistence in any ear","Persistence of OME (short-term)",2,3,"Analysis by child: persistence in any ear","or","binary",2,-1.92085395411991,0.421835745014475,0,1996.5,0.894444444444444,75.5
"CD015254","CD015254_pub2_data","2|3|Persistence of OME (short-term)|Analysis by ear. Adjusted for non-independence, assuming ICC of 0.5","Persistence of OME (short-term)",2,3,"Analysis by ear. Adjusted for non-independence, assuming ICC of 0.5","or","binary",2,-0.984933653857295,0.547816792677138,0,1994.5,0.71547619047619,45.5
"CD015254","CD015254_pub2_data","2|4|Sensitivity analysis 1: persistence of OME (short-term). ICC = zero|Analysis by child: persistence in any affected ear","Sensitivity analysis 1: persistence of OME (short-term). ICC = zero",2,4,"Analysis by child: persistence in any affected ear","or","binary",2,-1.91077200532957,1.01733407958786,1.87179412561014,1991,0.87452159650082,150
"CD015254","CD015254_pub2_data","2|4|Sensitivity analysis 1: persistence of OME (short-term). ICC = zero|Analysis by child: persistence in any ear","Sensitivity analysis 1: persistence of OME (short-term). ICC = zero",2,4,"Analysis by child: persistence in any ear","or","binary",2,-1.92085395411991,0.421835745014475,0,1996.5,0.894444444444444,75.5
"CD015254","CD015254_pub2_data","2|4|Sensitivity analysis 1: persistence of OME (short-term). ICC = zero|Analysis by ear. Adjusted for non-independence, assuming ICC of 0","Sensitivity analysis 1: persistence of OME (short-term). ICC = zero",2,4,"Analysis by ear. Adjusted for non-independence, assuming ICC of 0","or","binary",2,-1.09069279491911,0.457451257263258,0,1994.5,0.713095238095238,64.5
"CD015254","CD015254_pub2_data","2|5|Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0|Analysis by child: persistence in any affected ear","Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0",2,5,"Analysis by child: persistence in any affected ear","or","binary",2,-1.91077200532957,1.01733407958786,1.87179412561014,1991,0.87452159650082,150
"CD015254","CD015254_pub2_data","2|5|Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0|Analysis by child: persistence in any ear","Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0",2,5,"Analysis by child: persistence in any ear","or","binary",2,-1.92085395411991,0.421835745014475,0,1996.5,0.894444444444444,75.5
"CD015254","CD015254_pub2_data","2|5|Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0|Analysis by ear. Adjusted for non-independence, assuming ICC of 1","Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0",2,5,"Analysis by ear. Adjusted for non-independence, assuming ICC of 1","or","binary",2,-1.16752515410403,0.595855677148809,0,1994.5,0.727272727272727,36
"CD015255","CD015255_pub2_data","1|10|Sensitivity analysis: persistence of OME (very short-term); persistence in all affected ears (Berman 1990)|Persistence defined as effusion in all affected ears","Sensitivity analysis: persistence of OME (very short-term); persistence in all affected ears (Berman 1990)",1,10,"Persistence defined as effusion in all affected ears","or","binary",3,-0.729212633522462,0.731019913051738,1.32746487075456,2018,0.737242154046968,177.666666666667
"CD015255","CD015255_pub2_data","1|10|Sensitivity analysis: persistence of OME (very short-term); persistence in all affected ears (Berman 1990)|Persistence defined as effusion in either or both ears","Sensitivity analysis: persistence of OME (very short-term); persistence in all affected ears (Berman 1990)",1,10,"Persistence defined as effusion in either or both ears","or","binary",2,-0.768195746288065,0.355192294700083,0,1984,0.821367521367521,76
"CD015255","CD015255_pub2_data","1|11|Sensitivity analysis: persistence of OME (very short-term); effusion in both ears (Niederman 1984)|Persistence defined as effusion in all affected ears","Sensitivity analysis: persistence of OME (very short-term); effusion in both ears (Niederman 1984)",1,11,"Persistence defined as effusion in all affected ears","or","binary",2,-0.262054173923056,0.894033601909599,1.40553640636369,2018,0.865122490329711,240
"CD015255","CD015255_pub2_data","1|11|Sensitivity analysis: persistence of OME (very short-term); effusion in both ears (Niederman 1984)|Persistence in one or both affected ears","Sensitivity analysis: persistence of OME (very short-term); effusion in both ears (Niederman 1984)",1,11,"Persistence in one or both affected ears","or","binary",2,-0.607557619446958,0.876259581323906,1.23138713335882,NA,0.546296296296296,56.5
"CD015255","CD015255_pub2_data","1|12|Persistence of OME (short-term - up to 3 months); ICC = 0.5|Persistence in any ear","Persistence of OME (short-term - up to 3 months); ICC = 0.5",1,12,"Persistence in any ear","or","binary",2,-0.429926817062273,1.05620127441972,1.80837997324013,1985,0.669082125603865,56
"CD015255","CD015255_pub2_data","1|13|Sensitivity analysis: persistence of OME (short-term); ICC = 1.0|Persistence in any ear","Sensitivity analysis: persistence of OME (short-term); ICC = 1.0",1,13,"Persistence in any ear","or","binary",2,-0.428920426188599,1.07445164216927,1.84500957192832,1985,0.66403162055336,50
"CD015255","CD015255_pub2_data","1|14|Sensitivity analysis: persistence of OME (short-term); ICC = zero|Persistence in any ear","Sensitivity analysis: persistence of OME (short-term); ICC = zero",1,14,"Persistence in any ear","or","binary",2,-0.451903759572822,1.06279525417647,1.87211410974815,1985,0.662732919254658,65.5
"CD015255","CD015255_pub2_data","1|17|Acute otitis media (very short-term - up to 6 weeks)|","Acute otitis media (very short-term - up to 6 weeks)",1,17,"","or","binary",3,0.104270621579087,0.657168214319897,0.133445453054452,1984,0.0524216524216524,69
"CD015255","CD015255_pub2_data","1|9|Persistence of OME (very short-term - up to 6 weeks)|Persistence defined as effusion in all affected ears","Persistence of OME (very short-term - up to 6 weeks)",1,9,"Persistence defined as effusion in all affected ears","or","binary",2,-0.262054173923056,0.894033601909599,1.40553640636369,2018,0.865122490329711,240
"CD015255","CD015255_pub2_data","1|9|Persistence of OME (very short-term - up to 6 weeks)|Persistence defined as effusion in either or both ears","Persistence of OME (very short-term - up to 6 weeks)",1,9,"Persistence defined as effusion in either or both ears","or","binary",2,-0.768195746288065,0.355192294700083,0,1984,0.821367521367521,76
"CD015255","CD015255_pub2_data","1|9|Persistence of OME (very short-term - up to 6 weeks)|Persistence in one or both affected ears","Persistence of OME (very short-term - up to 6 weeks)",1,9,"Persistence in one or both affected ears","or","binary",2,-0.607557619446958,0.876259581323906,1.23138713335882,NA,0.546296296296296,56.5
"CD015255","CD015255_pub2_data","3|10|Persistence of OME (short-term - up to 3 months)|Analysis per child","Persistence of OME (short-term - up to 3 months)",3,10,"Analysis per child","or","binary",2,-1.18029674160389,1.0694264227919,1.94844839963979,2022,0.688372093023256,106
"CD015255","CD015255_pub2_data","3|11|Sensitivity analysis: persistence of OME (short-term); ICC = 1.0|Analysis per child","Sensitivity analysis: persistence of OME (short-term); ICC = 1.0",3,11,"Analysis per child","or","binary",2,-1.18029674160389,1.0694264227919,1.94844839963979,2022,0.688372093023256,106
"CD015255","CD015255_pub2_data","3|12|Sensitivity analysis: persistence of OME (short-term); ICC = zero|Analysis per child","Sensitivity analysis: persistence of OME (short-term); ICC = zero",3,12,"Analysis per child","or","binary",2,-1.18029674160389,1.0694264227919,1.94844839963979,2022,0.688372093023256,106
"CD015255","CD015255_pub2_data","4|2|Persistence of OME (very short-term - up to 6 weeks); ICC = 0.5|Persistence in any affected ear","Persistence of OME (very short-term - up to 6 weeks); ICC = 0.5",4,2,"Persistence in any affected ear","or","binary",2,-1.53796560979987,0.870422811771652,1.26460468089783,2022,0.850274725274725,138
"CD015255","CD015255_pub2_data","4|2|Persistence of OME (very short-term - up to 6 weeks); ICC = 0.5|Persistence undefined","Persistence of OME (very short-term - up to 6 weeks); ICC = 0.5",4,2,"Persistence undefined","or","binary",2,-1.4272605013597,0.77939568244003,0.94360665947044,NA,0.560227272727273,82
"CD015255","CD015255_pub2_data","4|3|Sensitivity analysis: persistence of OME (very short-term); ICC = 1.0|Persistence in any affected ear","Sensitivity analysis: persistence of OME (very short-term); ICC = 1.0",4,3,"Persistence in any affected ear","or","binary",2,-1.52829982726153,0.871476939526743,1.20309593260156,2022,0.851190476190476,104.5
"CD015255","CD015255_pub2_data","4|3|Sensitivity analysis: persistence of OME (very short-term); ICC = 1.0|Persistence undefined","Sensitivity analysis: persistence of OME (very short-term); ICC = 1.0",4,3,"Persistence undefined","or","binary",2,-1.4272605013597,0.77939568244003,0.94360665947044,NA,0.560227272727273,82
"CD015255","CD015255_pub2_data","4|4|Sensitivity analysis: persistence of OME (very short-term); ICC = zero|Persistence in any affected ear","Sensitivity analysis: persistence of OME (very short-term); ICC = zero",4,4,"Persistence in any affected ear","or","binary",2,-1.53032627949644,0.861658124968338,1.30363161866755,2022,0.851833976833977,204.5
"CD015255","CD015255_pub2_data","4|4|Sensitivity analysis: persistence of OME (very short-term); ICC = zero|Persistence undefined","Sensitivity analysis: persistence of OME (very short-term); ICC = zero",4,4,"Persistence undefined","or","binary",2,-1.4272605013597,0.77939568244003,0.94360665947044,NA,0.560227272727273,82
"CD015255","CD015255_pub2_data","4|5|Persistence of OME (short-term - up to 3 months); ICC = 0.5|Persistence in affected ears","Persistence of OME (short-term - up to 3 months); ICC = 0.5",4,5,"Persistence in affected ears","or","binary",2,-1.06130507273264,0.394530398032941,0,NA,0.805668016194332,67
"CD015255","CD015255_pub2_data","4|6|Sensitivity analysis: persistence of OME (short-term); ICC = 1.0|Persistence in affected ears. ICC 1.0","Sensitivity analysis: persistence of OME (short-term); ICC = 1.0",4,6,"Persistence in affected ears. ICC 1.0","or","binary",2,-1.13943594378841,0.450687411416823,0,NA,0.811986863711002,52
"CD015255","CD015255_pub2_data","4|7|Sensitivity analysis: persistence of OME (short-term); ICC = zero|Persistence in affected ears. ICC zero","Sensitivity analysis: persistence of OME (short-term); ICC = zero",4,7,"Persistence in affected ears. ICC zero","or","binary",2,-1.06950603971104,0.374031894857564,0.0544526241836927,NA,0.805651105651106,96
"CD015284","CD015284_pub2_data","1|1|Seizure frequency per month|Short term (3-6 months)","Seizure frequency per month",1,1,"Short term (3-6 months)","reported","reported",2,0,0.861412976163121,0,2008.5,0,32
"CD015284","CD015284_pub2_data","1|3|World Health Organization Quality of Life instrument, short version (WHOQOL- BREF) scale|Post-intervention","World Health Organization Quality of Life instrument, short version (WHOQOL- BREF) scale",1,3,"Post-intervention","reported","reported",2,0,2.26513946274486,0,2007,0,22.5
"CD015284","CD015284_pub2_data","1|3|World Health Organization Quality of Life instrument, short version (WHOQOL- BREF) scale|Short term (6 months)","World Health Organization Quality of Life instrument, short version (WHOQOL- BREF) scale",1,3,"Short term (6 months)","reported","reported",2,0,1.7581373396631,0,2007,0,22.5
"CD015284","CD015284_pub2_data","1|4|Satisfaction With Life Scale (SWLS) scale|Long term (1 year)","Satisfaction With Life Scale (SWLS) scale",1,4,"Long term (1 year)","reported","reported",2,0,1.87714251387163,0,2007,0,22.5
"CD015284","CD015284_pub2_data","1|4|Satisfaction With Life Scale (SWLS) scale|Post-intervention","Satisfaction With Life Scale (SWLS) scale",1,4,"Post-intervention","reported","reported",2,0,1.88199391025237,0,2007,0,22.5
"CD015284","CD015284_pub2_data","1|4|Satisfaction With Life Scale (SWLS) scale|Short term (6 months)","Satisfaction With Life Scale (SWLS) scale",1,4,"Short term (6 months)","reported","reported",2,0,2.06085937085906,0,2007,0,22.5
"CD015284","CD015284_pub2_data","2|1|Change in seizure frequency per month from baseline|Short term (6 - 8 weeks)","Change in seizure frequency per month from baseline",2,1,"Short term (6 - 8 weeks)","reported","reported",2,0,1.57614783867723,0,2003.5,0,42
"CD015284","CD015284_pub2_data","2|2|Seizure frequency per month|Short term (6 - 8 weeks)","Seizure frequency per month",2,2,"Short term (6 - 8 weeks)","reported","reported",2,0,2.10747129667891,0,2003.5,0,42
"CD015284","CD015284_pub2_data","3|1|Seizure frequency|Short term (20 weeks - 6 months)","Seizure frequency",3,1,"Short term (20 weeks - 6 months)","or","binary",3,-0.00272552511895234,1.1635946057827,0,2019,0,74
"CD015284","CD015284_pub2_data","3|12|SF-36 Health Survey mental health score|Short term (6 months)","SF-36 Health Survey mental health score",3,12,"Short term (6 months)","or","binary",2,0.0396888009418516,1.42036401142588,0,2010,0,158
"CD015284","CD015284_pub2_data","3|2|Seizure freedom|Short term (20 weeks - 6 months)","Seizure freedom",3,2,"Short term (20 weeks - 6 months)","reported","reported",3,0,0.818914663224225,0,2019.66666666667,0.22943945228926,166.666666666667
"CD015284","CD015284_pub2_data","3|4|Seizure frequency per month|Long term (12 months to 72 weeks)","Seizure frequency per month",3,4,"Long term (12 months to 72 weeks)","or","binary",2,-0.0118270702252361,1.42192864368389,0,2019,0,90.5
"CD015284","CD015284_pub2_data","3|8|Seizure severity|Short term (24 weeks)","Seizure severity",3,8,"Short term (24 weeks)","reported","reported",2,0,1.5818522049418,0,2017,0,62
"CD015284","CD015284_pub2_data","3|9|Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-31-P)|Long term (12 months)","Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-31-P)",3,9,"Long term (12 months)","or","binary",2,0.0365452759973628,1.4190632854126,0,2019,0,211.5
"CD015284","CD015284_pub2_data","3|9|Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-31-P)|Short term (6 months)","Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-31-P)",3,9,"Short term (6 months)","or","binary",2,0.0469821513611333,1.41968229368084,0,2020.5,0,196.5
"CD015284","CD015284_pub2_data","4|1|Seizure freedom|Short term (12 weeks)","Seizure freedom",4,1,"Short term (12 weeks)","reported","reported",2,0,0.226455406828919,0,2011,0.55,22
"CD015284","CD015284_pub2_data","4|2|Percentage change in seizure frequency from baseline|Short term (3-6 months)","Percentage change in seizure frequency from baseline",4,2,"Short term (3-6 months)","reported","reported",2,0,35.6655446996789,0,2021,0,20.5
"CD015284","CD015284_pub2_data","6|1|Seizure freedom|Long term ( 9 months - 12 months)","Seizure freedom",6,1,"Long term ( 9 months - 12 months)","reported","reported",3,0,0.0391308052808031,0,2010.66666666667,0.484027175205517,581.666666666667
"CD015314","CD015314_pub2_data","1|1|Tobacco cessation at longest follow-up|Duration ≤ 1 hour","Tobacco cessation at longest follow-up",1,1,"Duration ≤ 1 hour","reported","reported",2,0,0.238264198077368,0,2011.5,0.100152671755725,175
"CD015314","CD015314_pub2_data","1|1|Tobacco cessation at longest follow-up|Duration 1 to 3 hours","Tobacco cessation at longest follow-up",1,1,"Duration 1 to 3 hours","reported","reported",2,0,0.261889613863569,0,2011.5,0.130501618122977,170
"CD015314","CD015314_pub2_data","1|2|Subgrouped by modality of support|Face-to-face group","Subgrouped by modality of support",1,2,"Face-to-face group","reported","reported",5,0,0.159774724323781,0,2004.4,0.145372487532037,230
"CD015314","CD015314_pub2_data","1|2|Subgrouped by modality of support|Face-to-face individual","Subgrouped by modality of support",1,2,"Face-to-face individual","reported","reported",6,0,0.161142388277777,0,2009.83333333333,0.0849715255058767,158.833333333333
"CD015314","CD015314_pub2_data","1|2|Subgrouped by modality of support|Telephone support","Subgrouped by modality of support",1,2,"Telephone support","reported","reported",8,0,0.0526177872245074,0,2009.375,0.188455324853572,618.25
"CD015314","CD015314_pub2_data","2|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",2,1,"","reported","reported",2,0,0.136381324647344,0,2010,0.196883998354587,285.5
"CD015314","CD015314_pub2_data","3|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",3,1,"","reported","reported",2,0,1.03968239541096,0,2024,0.0757575757575758,132
"CD015314","CD015314_pub2_data","4|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",4,1,"","or","binary",2,-0.143940045610478,0.300173215296254,0,2004.5,0.165966386554622,146.5
"CD015314","CD015314_pub2_data","5|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",5,1,"","or","binary",2,0.487454379466916,0.182673044376869,0,2010.5,0.325325929502656,254
"CD015314","CD015314_pub2_data","6|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",6,1,"","reported","reported",2,0,1.01291507797578,0,2019.5,0.211222393425783,421
"CD015314","CD015314_pub2_data","7|1|Tobacco cessation at longest follow up|","Tobacco cessation at longest follow up",7,1,"","reported","reported",2,0,1.01951985332507,0,2006.5,0.165975609756098,141
"CD015326","CD015326_pub2_data","1|2|zBMI (Short-term)|Main Analysis","zBMI (Short-term)",1,2,"Main Analysis","reported","reported",2,0.0260799926019281,0.0815673584111447,0,2018,0,72.5
"CD015326","CD015326_pub2_data","2|1|BMI (Short-term)|","BMI (Short-term)",2,1,"","reported","reported",6,-0.0824394549938366,0.10600085413216,0.00933578749330703,2011.33333333333,0,137.666666666667
"CD015326","CD015326_pub2_data","2|10|zBMI (Medium-term) - Subgroup analysis: Socioeconomic status|Assumed Mixed","zBMI (Medium-term) - Subgroup analysis: Socioeconomic status",2,10,"Assumed Mixed","reported","reported",3,0.00195551315657221,0.0619983549296642,0,2011,0,325.333333333333
"CD015326","CD015326_pub2_data","2|11|BMI (Short-term) - Sensitivity Analysis: ICC=0.04 |","BMI (Short-term) - Sensitivity Analysis: ICC=0.04 ",2,11,"","reported","reported",7,-0.0555224131424839,0.109607969082586,0.00556970140722655,2012.14285714286,0,125.285714285714
"CD015326","CD015326_pub2_data","2|13|zBMI (Short Term) -  Sensitivity Analysis ICC=0.04 |","zBMI (Short Term) -  Sensitivity Analysis ICC=0.04 ",2,13,"","reported","reported",3,-0.064910680554806,0.0749331830381784,0,2008.66666666667,0,211.666666666667
"CD015326","CD015326_pub2_data","2|14|zBMI (Medium Term) - Sensitivity Analysis ICC=0.04 |","zBMI (Medium Term) - Sensitivity Analysis ICC=0.04 ",2,14,"","reported","reported",4,-0.00103519768569521,0.0641076546680217,0,2012.25,0,270.75
"CD015326","CD015326_pub2_data","2|3|zBMI (Short-term)|","zBMI (Short-term)",2,3,"","reported","reported",3,-0.058077597047584,0.0688107646069969,0.000936835249003196,2008.66666666667,0,211.666666666667
"CD015326","CD015326_pub2_data","2|4|zBMI (Medium-term)|","zBMI (Medium-term)",2,4,"","reported","reported",4,-0.00495090168705941,0.0598616673507985,0,2012.25,0,270.75
"CD015326","CD015326_pub2_data","2|7|BMI (Short-term) - Subgroup analysis: Setting of intervention|Childcare","BMI (Short-term) - Subgroup analysis: Setting of intervention",2,7,"Childcare","reported","reported",5,-0.130748256177812,0.09841606705835,0,2009.8,0,148.4
"CD015326","CD015326_pub2_data","2|8|zBMI (Short-term) - Subgroup analysis: Setting of intervention|Childcare","zBMI (Short-term) - Subgroup analysis: Setting of intervention",2,8,"Childcare","reported","reported",2,-0.124846153846154,0.0868287439113959,0,2010,0,77
"CD015326","CD015326_pub2_data","3|1|BMI (Short-term)|Main Analysis","BMI (Short-term)",3,1,"Main Analysis","reported","reported",13,-0.0867943868151258,0.064285809662231,0.0321297265545498,2014.69230769231,0,297.461538461538
"CD015326","CD015326_pub2_data","3|10|BMI (Short Term) - Subgroup Analysis - Setting of Intervention|Main Setting of Intervention Delivery - Childcare & Home","BMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,10,"Main Setting of Intervention Delivery - Childcare & Home","reported","reported",4,0.0223002261016461,0.0801553368476681,0.0176330510767571,2008,0,593.25
"CD015326","CD015326_pub2_data","3|10|BMI (Short Term) - Subgroup Analysis - Setting of Intervention|Main Setting of Intervention Delivery - Home","BMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,10,"Main Setting of Intervention Delivery - Home","reported","reported",4,-0.338137999059197,0.0922482170543426,2.860006874612e-07,2016.75,0,91.75
"CD015326","CD015326_pub2_data","3|10|BMI (Short Term) - Subgroup Analysis - Setting of Intervention|Main Setting of Intervention Delivery - Other ","BMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,10,"Main Setting of Intervention Delivery - Other ","reported","reported",4,-0.14585979292702,0.160650779745028,0.068602926954744,2017.75,0,68.5
"CD015326","CD015326_pub2_data","3|11|BMI (Short Term) - Subgroup Analysis- Socioeconomic Status|Socioeconomic Status- Assumed Mixed","BMI (Short Term) - Subgroup Analysis- Socioeconomic Status",3,11,"Socioeconomic Status- Assumed Mixed","reported","reported",7,-0.135759812681546,0.115189079938036,0.0662575935973778,2016.85714285714,0,219.571428571429
"CD015326","CD015326_pub2_data","3|11|BMI (Short Term) - Subgroup Analysis- Socioeconomic Status|Socioeconomic Status- Low","BMI (Short Term) - Subgroup Analysis- Socioeconomic Status",3,11,"Socioeconomic Status- Low","reported","reported",6,-0.0379714800852801,0.0484555282510748,0.00328498431181498,2012.16666666667,0,393.166666666667
"CD015326","CD015326_pub2_data","3|12|BMI (Medium Term) - Subgroup Analysis- Setting of Intervention|Childcare + Home","BMI (Medium Term) - Subgroup Analysis- Setting of Intervention",3,12,"Childcare + Home","reported","reported",3,-0.170590148891123,0.198738111581466,0.0792192766418073,2009.33333333333,0,328.666666666667
"CD015326","CD015326_pub2_data","3|12|BMI (Medium Term) - Subgroup Analysis- Setting of Intervention|Home","BMI (Medium Term) - Subgroup Analysis- Setting of Intervention",3,12,"Home","reported","reported",3,0.0304547653604257,0.171083233151876,0,2016.33333333333,0,215.666666666667
"CD015326","CD015326_pub2_data","3|12|BMI (Medium Term) - Subgroup Analysis- Setting of Intervention|Other","BMI (Medium Term) - Subgroup Analysis- Setting of Intervention",3,12,"Other","reported","reported",3,-0.0956744761629253,0.0764040004579384,0.00704968733891449,2020.33333333333,0,1697.33333333333
"CD015326","CD015326_pub2_data","3|13|BMI (Medium Term) - Subgroup Analysis - Socioeconomic Status|Assumed Mixed","BMI (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,13,"Assumed Mixed","reported","reported",5,-0.0534878387787008,0.0477742152584879,0.00161946651671613,2018.6,0,1100.2
"CD015326","CD015326_pub2_data","3|13|BMI (Medium Term) - Subgroup Analysis - Socioeconomic Status|Low","BMI (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,13,"Low","reported","reported",5,-0.0897429764877443,0.157731428233143,0.0733324548750861,2013,0,303
"CD015326","CD015326_pub2_data","3|14|BMI (Medium Term) - Subgroup Analysis - Duration of Intervention|Medium","BMI (Medium Term) - Subgroup Analysis - Duration of Intervention",3,14,"Medium","reported","reported",3,-0.0161068147876389,0.110187733663456,0.0285520488314215,2020.66666666667,0,1759
"CD015326","CD015326_pub2_data","3|14|BMI (Medium Term) - Subgroup Analysis - Duration of Intervention|Short","BMI (Medium Term) - Subgroup Analysis - Duration of Intervention",3,14,"Short","reported","reported",7,-0.109398069078274,0.12557287998467,0.0379740280735486,2013.71428571429,0,248.428571428571
"CD015326","CD015326_pub2_data","3|15|BMI (Long Term) - Subgroup Analysis - Setting of Intervention|Childcare+Home","BMI (Long Term) - Subgroup Analysis - Setting of Intervention",3,15,"Childcare+Home","reported","reported",3,-0.333253752441706,0.137728223624928,0,2009.33333333333,0,323.666666666667
"CD015326","CD015326_pub2_data","3|15|BMI (Long Term) - Subgroup Analysis - Setting of Intervention|Home","BMI (Long Term) - Subgroup Analysis - Setting of Intervention",3,15,"Home","reported","reported",2,-0.0731998128664286,0.13655288049796,0,2018,0,551.5
"CD015326","CD015326_pub2_data","3|16|BMI (Long Term) - Subgroup Analysis - Socioeconomic Status|Low","BMI (Long Term) - Subgroup Analysis - Socioeconomic Status",3,16,"Low","reported","reported",4,-0.21414001775897,0.130015095058433,0.0184380624166304,2011.75,0,433.5
"CD015326","CD015326_pub2_data","3|17|BMI (Long Term) - Subgroup Analysis - Duration of Intervention|Short","BMI (Long Term) - Subgroup Analysis - Duration of Intervention",3,17,"Short","reported","reported",4,-0.292917886184494,0.116738839468244,0,2011.5,0,366
"CD015326","CD015326_pub2_data","3|18|zBMI (Short Term) - Subgroup Analysis - Setting of Intervention|Childcare","zBMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,18,"Childcare","reported","reported",4,-0.0239731526704502,0.0366270471150332,0.00277318044153987,2017.5,0,831.5
"CD015326","CD015326_pub2_data","3|18|zBMI (Short Term) - Subgroup Analysis - Setting of Intervention|Childcare+Home","zBMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,18,"Childcare+Home","reported","reported",4,-0.0362266297782344,0.0294148005918189,0,2010.25,0,342.5
"CD015326","CD015326_pub2_data","3|18|zBMI (Short Term) - Subgroup Analysis - Setting of Intervention|Home","zBMI (Short Term) - Subgroup Analysis - Setting of Intervention",3,18,"Home","reported","reported",5,-0.0887592634782851,0.0654078669514664,0.0105731374443411,2015.2,0,153.4
"CD015326","CD015326_pub2_data","3|19|zBMI (Short Term) - Subgroup Analysis - Socioeconomic Status|Assumed Mixed","zBMI (Short Term) - Subgroup Analysis - Socioeconomic Status",3,19,"Assumed Mixed","reported","reported",5,-0.0368816871172344,0.072700924598929,0.0145782207934889,2015.6,0,142.2
"CD015326","CD015326_pub2_data","3|19|zBMI (Short Term) - Subgroup Analysis - Socioeconomic Status|Low","zBMI (Short Term) - Subgroup Analysis - Socioeconomic Status",3,19,"Low","reported","reported",9,-0.0251704075079261,0.0204293401169934,0.000829924693117804,2013.77777777778,0,534.111111111111
"CD015326","CD015326_pub2_data","3|2|BMI (Medium Term)|","BMI (Medium Term)",3,2,"","reported","reported",10,-0.0563603841435577,0.0776442082674479,0.0251449389893739,2015.8,0,701.6
"CD015326","CD015326_pub2_data","3|20|zBMI (Short Term) - Subgroup Analysis - Duration of Intervention|Short","zBMI (Short Term) - Subgroup Analysis - Duration of Intervention",3,20,"Short","reported","reported",13,-0.0450847536713165,0.025068254752067,0.00209038171875171,2014.30769230769,0,284.769230769231
"CD015326","CD015326_pub2_data","3|21|zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention|Childcare","zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention",3,21,"Childcare","reported","reported",3,-0.0841417092768444,0.0227027027027027,0,2015,0,1066.33333333333
"CD015326","CD015326_pub2_data","3|21|zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention|Childcare+Home","zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention",3,21,"Childcare+Home","reported","reported",3,-0.113189925211869,0.0840075447011125,0.0120666400077555,2009.33333333333,0,328.666666666667
"CD015326","CD015326_pub2_data","3|21|zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention|Home","zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention",3,21,"Home","reported","reported",8,-0.0427072413356324,0.0393152300415208,0.00185284032455867,2017.625,0,234
"CD015326","CD015326_pub2_data","3|21|zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention|Other","zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention",3,21,"Other","reported","reported",2,-0.053125,0.03626616019101,0.000950000000000002,2021,0,2493
"CD015326","CD015326_pub2_data","3|22|zBMI (Medium Term) - Subgroup Analysis - Socioeconomic Status|Assumed Mixed","zBMI (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,22,"Assumed Mixed","reported","reported",9,-0.0559310853919979,0.0198684104410276,0.000359376190979225,2018.22222222222,0,825.777777777778
"CD015326","CD015326_pub2_data","3|22|zBMI (Medium Term) - Subgroup Analysis - Socioeconomic Status|Low","zBMI (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,22,"Low","reported","reported",7,-0.110437711688823,0.0388396180143446,0.00313811868408639,2013.14285714286,0,515.857142857143
"CD015326","CD015326_pub2_data","3|23|zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention|Long","zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention",3,23,"Long","reported","reported",2,-0.067,0.0379473319220206,0,2018.5,0,1037.5
"CD015326","CD015326_pub2_data","3|23|zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention|Medium","zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention",3,23,"Medium","reported","reported",4,-0.0792129903213104,0.030415166139422,0.00148473289099394,2018.25,0,1468.5
"CD015326","CD015326_pub2_data","3|23|zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention|Short","zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention",3,23,"Short","reported","reported",10,-0.0779669540851735,0.0361454029446864,0.0050308589402609,2014.6,0,309.4
"CD015326","CD015326_pub2_data","3|24|zBMI (Long Term) - Subgroup Analysis - Setting of Intervention|Childcare+Home","zBMI (Long Term) - Subgroup Analysis - Setting of Intervention",3,24,"Childcare+Home","reported","reported",5,-0.141178147832213,0.0634213272013074,0.010879326098571,2011.6,0,318.8
"CD015326","CD015326_pub2_data","3|24|zBMI (Long Term) - Subgroup Analysis - Setting of Intervention|Home","zBMI (Long Term) - Subgroup Analysis - Setting of Intervention",3,24,"Home","reported","reported",3,-0.0503619590149472,0.0548245552461545,0,2019,0,306.333333333333
"CD015326","CD015326_pub2_data","3|25|zBMI (Long Term) - Subgroup Analysis - Socioeconomic Status|Assumed Mixed","zBMI (Long Term) - Subgroup Analysis - Socioeconomic Status",3,25,"Assumed Mixed","reported","reported",3,-0.035161632561205,0.0688003540942676,0,2018.66666666667,0,255.333333333333
"CD015326","CD015326_pub2_data","3|25|zBMI (Long Term) - Subgroup Analysis - Socioeconomic Status|Low","zBMI (Long Term) - Subgroup Analysis - Socioeconomic Status",3,25,"Low","reported","reported",7,-0.0839681092633907,0.0376231583095196,0.00481480931836334,2013.57142857143,0,561
"CD015326","CD015326_pub2_data","3|26|zBMI (Long Term) - Subgroup Analysis - Duration of Intervention|Long","zBMI (Long Term) - Subgroup Analysis - Duration of Intervention",3,26,"Long","reported","reported",3,-0.0202179094313926,0.0191902824120297,0,2019,0,809
"CD015326","CD015326_pub2_data","3|26|zBMI (Long Term) - Subgroup Analysis - Duration of Intervention|Short","zBMI (Long Term) - Subgroup Analysis - Duration of Intervention",3,26,"Short","reported","reported",7,-0.107052430488865,0.0410443964495332,0.00390411315689173,2013.42857142857,0,323.714285714286
"CD015326","CD015326_pub2_data","3|28|BMI percentile (Medium Term) - Subgroup Analysis - Setting of Intervention|Childcare","BMI percentile (Medium Term) - Subgroup Analysis - Setting of Intervention",3,28,"Childcare","reported","reported",3,-0.860809855009828,1.38406384667537,3.09224428293339,2018.66666666667,0,598
"CD015326","CD015326_pub2_data","3|28|BMI percentile (Medium Term) - Subgroup Analysis - Setting of Intervention|Home","BMI percentile (Medium Term) - Subgroup Analysis - Setting of Intervention",3,28,"Home","reported","reported",3,-2.67602807682502,1.1975548759458,9.56568556343936e-08,2016,0,254.333333333333
"CD015326","CD015326_pub2_data","3|29|BMI percentile (Medium Term) - Subgroup Analysis - Socioeconomic Status|Assumed Mixed","BMI percentile (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,29,"Assumed Mixed","reported","reported",3,-1.77355193091604,1.00521359803783,0.755953880727007,2018,0,560.666666666667
"CD015326","CD015326_pub2_data","3|29|BMI percentile (Medium Term) - Subgroup Analysis - Socioeconomic Status|Low","BMI percentile (Medium Term) - Subgroup Analysis - Socioeconomic Status",3,29,"Low","reported","reported",3,-1.96078260700158,1.77339831876502,5.19203567571156,2016.66666666667,0,291.666666666667
"CD015326","CD015326_pub2_data","3|3|BMI (Long Term)|","BMI (Long Term)",3,3,"","reported","reported",5,-0.205079638770249,0.101816983037151,0.00436316175848304,2012.8,0,414.8
"CD015326","CD015326_pub2_data","3|30|BMI percentile (Medium Term)- Subgroup Analysis - Duration of Intervention|Medium","BMI percentile (Medium Term)- Subgroup Analysis - Duration of Intervention",3,30,"Medium","reported","reported",2,0.910484397263704,1.51349898517496,0,2019.5,0,424.5
"CD015326","CD015326_pub2_data","3|30|BMI percentile (Medium Term)- Subgroup Analysis - Duration of Intervention|Short","BMI percentile (Medium Term)- Subgroup Analysis - Duration of Intervention",3,30,"Short","reported","reported",4,-2.62555335451465,0.694276357712023,0,2016.25,0,427
"CD015326","CD015326_pub2_data","3|32|BMI (Short Term) - Sensitivity Analysis ICC=0.04|Main Setting of Intervention","BMI (Short Term) - Sensitivity Analysis ICC=0.04",3,32,"Main Setting of Intervention","reported","reported",13,-0.0926081855647746,0.0671746259175792,0.0333848972536117,2014.69230769231,0,297.461538461538
"CD015326","CD015326_pub2_data","3|33|BMI (Medium Term) - Sensitivity Analysis ICC=0.04 |","BMI (Medium Term) - Sensitivity Analysis ICC=0.04 ",3,33,"","reported","reported",10,-0.0370774037640808,0.0777542548242639,0.0180921150112766,2015.8,0,701.6
"CD015326","CD015326_pub2_data","3|34|BMI (Long Term) - Sensitivity Analysis ICC=0.04 |","BMI (Long Term) - Sensitivity Analysis ICC=0.04 ",3,34,"","reported","reported",5,-0.163335608752119,0.110140903716334,0,2012.8,0,414.8
"CD015326","CD015326_pub2_data","3|35|BMI-z (Short Term) - Sensitivity Analysis ICC=0.04 |","BMI-z (Short Term) - Sensitivity Analysis ICC=0.04 ",3,35,"","reported","reported",14,-0.0375550882568547,0.0277152812215179,0.00270434226550981,2014.42857142857,0,394.142857142857
"CD015326","CD015326_pub2_data","3|36|zBMI (Medium Term) - Sensitivity Analysis ICC=0.04 |","zBMI (Medium Term) - Sensitivity Analysis ICC=0.04 ",3,36,"","reported","reported",16,-0.0741172061396292,0.0209379130462956,0,2016,0,690.1875
"CD015326","CD015326_pub2_data","3|37|zBMI (Long Term) - Sensitivity Analysis ICC=0.04 |","zBMI (Long Term) - Sensitivity Analysis ICC=0.04 ",3,37,"","reported","reported",10,-0.0530459187896103,0.0247218112544245,8.14495443569077e-08,2015.1,0,469.3
"CD015326","CD015326_pub2_data","3|38|BMI percentile (Medium Term) - Sensitivity Analysis ICC=0.04 |","BMI percentile (Medium Term) - Sensitivity Analysis ICC=0.04 ",3,38,"","reported","reported",6,-1.86779857624397,0.749002943501101,2.57954224522555e-06,2017.33333333333,0,426.166666666667
"CD015326","CD015326_pub2_data","3|4|zBMI (Short Term)|","zBMI (Short Term)",3,4,"","reported","reported",14,-0.0335765883408747,0.0220182136013848,0.00194278051485479,2014.42857142857,0,394.142857142857
"CD015326","CD015326_pub2_data","3|5|zBMI (Medium Term)|","zBMI (Medium Term)",3,5,"","reported","reported",16,-0.071731331616745,0.0180416406220688,0.000778766018272801,2016,0,690.1875
"CD015326","CD015326_pub2_data","3|6|zBMI (Long Term)|","zBMI (Long Term)",3,6,"","reported","reported",10,-0.0687758299295658,0.0288319392338794,0.00246023598957841,2015.1,0,469.3
"CD015326","CD015326_pub2_data","3|7|BMI percentile (Short Term)|","BMI percentile (Short Term)",3,7,"","reported","reported",2,3.60502583366637,4.02517851855176,7.95708707541501,2016.5,0,56
"CD015326","CD015326_pub2_data","3|8|BMI percentile (Medium Term)|","BMI percentile (Medium Term)",3,8,"","reported","reported",6,-1.87666085603911,0.734559138354242,0.463338651814108,2017.33333333333,0,426.166666666667
"CD015326","CD015326_pub2_data","3|9|BMI percentile (Long Term)|","BMI percentile (Long Term)",3,9,"","reported","reported",2,-0.611973002966312,1.4959811300973,0,2018,0,336
"CD015326","CD015326_pub2_data","5|4|BMI percentile (Medium-Term)|","BMI percentile (Medium-Term)",5,4,"","reported","reported",2,0.00254240623974925,0.318803463300304,0,2018.5,0,177
"CD015326","CD015326_pub2_data","5|5|BMI percentile (Medium-Term) - Subgroup analysis - socioeconomic status|Assumed Mixed","BMI percentile (Medium-Term) - Subgroup analysis - socioeconomic status",5,5,"Assumed Mixed","reported","reported",2,0.039216,0.0672,0,2021,0,160.5
"CD015328","CD015328_pub2_data","1|1|BMI short-term|NA","BMI short-term",1,1,NA,"reported","reported",5,0.00360763325577008,0.0544979481329582,0.000686993081481126,2013.4,NA,NA
"CD015328","CD015328_pub2_data","1|2|BMI medium-term|NA","BMI medium-term",1,2,NA,"reported","reported",9,0.00118887336957745,0.0545725351907666,0.00581158183175867,2013.55555555556,NA,NA
"CD015328","CD015328_pub2_data","1|3|BMI long-term|NA","BMI long-term",1,3,NA,"reported","reported",2,-0.172950381697286,0.154143525787912,0.0054760403885482,2009,NA,NA
"CD015328","CD015328_pub2_data","1|4|zBMI short-term|NA","zBMI short-term",1,4,NA,"reported","reported",8,-0.0577840528031887,0.0320971532733055,0.00427731386995797,2014.125,NA,NA
"CD015328","CD015328_pub2_data","1|5|zBMI medium-term|NA","zBMI medium-term",1,5,NA,"reported","reported",9,-0.0442710560910258,0.0252218174987714,0.00321801883017656,2014.11111111111,NA,NA
"CD015328","CD015328_pub2_data","1|6|zBMI long-term|NA","zBMI long-term",1,6,NA,"reported","reported",7,-0.0454969117960886,0.0288237517803321,0.00363090969390714,2011.57142857143,NA,NA
"CD015328","CD015328_pub2_data","1|7|Percentile short-term|NA","Percentile short-term",1,7,NA,"reported","reported",3,1.95224999644617,2.87760912778405,12.5188916161851,2017.33333333333,NA,NA
"CD015328","CD015328_pub2_data","1|8|Percentile medium-term|NA","Percentile medium-term",1,8,NA,"reported","reported",3,-0.918608772765568,0.947020542857729,0.916694737147632,2018.33333333333,NA,NA
"CD015328","CD015328_pub2_data","1|9|Percentile long-term|NA","Percentile long-term",1,9,NA,"reported","reported",2,-1.48991875044305,1.6899999980469,4.38052533449453,2016.5,NA,NA
"CD015328","CD015328_pub2_data","2|1|BMI short-term|NA","BMI short-term",2,1,NA,"reported","reported",14,-0.0142831515054174,0.0852192636413866,0.0691336402136697,2016.35714285714,NA,NA
"CD015328","CD015328_pub2_data","2|2|BMI medium-term|NA","BMI medium-term",2,2,NA,"reported","reported",16,-0.117837330748039,0.0352755894191607,0.00453372289012427,2014,NA,NA
"CD015328","CD015328_pub2_data","2|3|BMI long-term|NA","BMI long-term",2,3,NA,"reported","reported",8,-0.0685745651816886,0.0914304865819359,0.0422038770035506,2011.875,NA,NA
"CD015328","CD015328_pub2_data","2|4|zBMI short-term|NA","zBMI short-term",2,4,NA,"reported","reported",6,-0.0193235546915728,0.0178633214989617,0.000355647267704448,2016.16666666667,NA,NA
"CD015328","CD015328_pub2_data","2|5|zBMI medium-term|NA","zBMI medium-term",2,5,NA,"reported","reported",13,-0.0520324663200548,0.0180898151293675,0.00188967016036863,2016.76923076923,NA,NA
"CD015328","CD015328_pub2_data","2|6|zBMI long-term|NA","zBMI long-term",2,6,NA,"reported","reported",6,-0.0234648485030195,0.0329730373041948,0.00340182475171453,2014.16666666667,NA,NA
"CD015328","CD015328_pub2_data","2|9|Percentile long-term|NA","Percentile long-term",2,9,NA,"reported","reported",3,-0.776752536798197,0.86163801219614,4.25592492639305e-06,2017,NA,NA
"CD015328","CD015328_pub2_data","3|1|BMI short-term|NA","BMI short-term",3,1,NA,"reported","reported",27,-0.0996218067843929,0.0632653922653785,0.0645081270378595,2012.25925925926,NA,NA
"CD015328","CD015328_pub2_data","3|2|BMI medium-term|NA","BMI medium-term",3,2,NA,"reported","reported",21,-0.105874734297162,0.0585219529644444,0.0440646658854648,2014.14285714286,NA,NA
"CD015328","CD015328_pub2_data","3|3|BMI long-term|NA","BMI long-term",3,3,NA,"reported","reported",16,0.0291386411660369,0.0842080007107631,0.0756442653102154,2013.1875,NA,NA
"CD015328","CD015328_pub2_data","3|4|zBMI short-term|NA","zBMI short-term",3,4,NA,"reported","reported",26,-0.0300842904639633,0.0170181013976539,0.00319951100671843,2014.84615384615,NA,NA
"CD015328","CD015328_pub2_data","3|5|zBMI medium-term|NA","zBMI medium-term",3,5,NA,"reported","reported",24,-0.0465312271551595,0.0169690946160005,0.00473677773087342,2015.375,NA,NA
"CD015328","CD015328_pub2_data","3|6|zBMI long-term|NA","zBMI long-term",3,6,NA,"reported","reported",22,-0.0231837782144153,0.0248849003771266,0.0106623767196155,2015.09090909091,NA,NA
"CD015328","CD015328_pub2_data","3|7|Percentile short-term|NA","Percentile short-term",3,7,NA,"reported","reported",5,0.734769516474775,0.629178477991751,0,2011.2,NA,NA
"CD015328","CD015328_pub2_data","3|8|Percentile medium-term|NA","Percentile medium-term",3,8,NA,"reported","reported",8,-0.723563559333252,0.683291789152331,2.35514722735895,2015,NA,NA
"CD015328","CD015328_pub2_data","3|9|Percentile long-term|NA","Percentile long-term",3,9,NA,"reported","reported",5,-0.767947439368274,1.49329287830935,9.17617635332882,2015,NA,NA
"CD015328","CD015328_pub2_data","4|1|BMI medium-term|NA","BMI medium-term",4,1,NA,"reported","reported",2,-0.247608797322694,0.155811606452882,0,2017,NA,NA
"CD015328","CD015328_pub2_data","4|2|zBMI medium-term|NA","zBMI medium-term",4,2,NA,"reported","reported",2,-0.109809697240825,0.0540080625442155,0,2017,NA,NA
"CD015328","CD015328_pub2_data","5|1|BMI medium-term|NA","BMI medium-term",5,1,NA,"reported","reported",2,-0.160807404744991,0.13219252077396,0,2018,NA,NA
"CD015328","CD015328_pub2_data","5|2|zBMI medium-term|NA","zBMI medium-term",5,2,NA,"reported","reported",2,-0.0257294866398666,0.0354578034121761,0,2018,NA,NA
"CD015328","CD015328_pub2_data","6|1|BMI short-term|NA","BMI short-term",6,1,NA,"reported","reported",2,0.340881017938512,0.302105378344187,0,2009,NA,NA
"CD015328","CD015328_pub2_data","6|2|BMI medium-term|NA","BMI medium-term",6,2,NA,"reported","reported",2,0.187106822050165,0.156955783229452,0,2018,NA,NA
"CD015328","CD015328_pub2_data","6|5|zBMI medium-term|NA","zBMI medium-term",6,5,NA,"reported","reported",2,-0.0697389211799619,0.177998947646661,0.0573057269976559,2018,NA,NA
"CD015330","CD015330_pub2_data","1|1|BMI short term|NA","BMI short term",1,1,NA,"reported","reported",3,-0.176996728911025,0.119286158507186,0,2011.66666666667,NA,NA
"CD015330","CD015330_pub2_data","1|2|BMI medium term|NA","BMI medium term",1,2,NA,"reported","reported",3,-0.641743869021783,0.307528633153071,0.249747295809031,2015.33333333333,NA,NA
"CD015330","CD015330_pub2_data","1|4|zBMI short term|NA","zBMI short term",1,4,NA,"reported","reported",5,-0.0625000819358996,0.0299395850039112,0.00293433909835275,2014.2,NA,NA
"CD015330","CD015330_pub2_data","1|6|zBMI long term|NA","zBMI long term",1,6,NA,"reported","reported",2,-0.142332327246144,0.121975177340759,0.023583081760461,2017,NA,NA
"CD015330","CD015330_pub2_data","1|7|Percentile short term|NA","Percentile short term",1,7,NA,"reported","reported",2,-0.0526372537271811,0.601846181331635,0,2019,NA,NA
"CD015330","CD015330_pub2_data","1|8|Percentile medium term|NA","Percentile medium term",1,8,NA,"reported","reported",2,-1.88797112070955,1.05321286622908,0,2016,NA,NA
"CD015330","CD015330_pub2_data","2|1|BMI short term|NA","BMI short term",2,1,NA,"reported","reported",6,-0.635875201752155,0.689615715077482,2.78631912074174,2012.83333333333,NA,NA
"CD015330","CD015330_pub2_data","2|2|BMI medium term|NA","BMI medium term",2,2,NA,"reported","reported",3,-0.323367450842397,0.103711781297134,0.00942125839735077,2015.66666666667,NA,NA
"CD015330","CD015330_pub2_data","2|4|zBMI short term|NA","zBMI short term",2,4,NA,"reported","reported",7,0.0193733838191481,0.0132140023240424,0,2017.71428571429,NA,NA
"CD015330","CD015330_pub2_data","2|5|zBMI medium term|NA","zBMI medium term",2,5,NA,"reported","reported",6,0.00447608049393033,0.0229919991596678,0.0015341364420898,2015.5,NA,NA
"CD015330","CD015330_pub2_data","3|1|BMI short term|NA","BMI short term",3,1,NA,"reported","reported",11,0.0301385304393969,0.0530503547771829,4.92795947025556e-07,2011.63636363636,NA,NA
"CD015330","CD015330_pub2_data","3|2|BMI medium term|NA","BMI medium term",3,2,NA,"reported","reported",8,0.0130429211412208,0.0505394460182542,0,2013.5,NA,NA
"CD015330","CD015330_pub2_data","3|3|BMI long term|NA","BMI long term",3,3,NA,"reported","reported",6,0.0610843180380293,0.0492275519171033,0.00671929167164069,2011.16666666667,NA,NA
"CD015330","CD015330_pub2_data","3|4|zBMI short term|NA","zBMI short term",3,4,NA,"reported","reported",3,-0.0924371306868809,0.0592142899776295,0.00830605306894195,2017,NA,NA
"CD015330","CD015330_pub2_data","3|5|zBMI medium term|NA","zBMI medium term",3,5,NA,"reported","reported",6,-0.0468780061271614,0.0277454705698895,0.0024424518218393,2012.83333333333,NA,NA
"CD015330","CD015330_pub2_data","3|6|zBMI long term|NA","zBMI long term",3,6,NA,"reported","reported",7,-0.0166749919094554,0.0112591519563638,1.02199048534083e-07,2013.71428571429,NA,NA
"CD015331","CD015331_pub2_data","1|1|Mental state - general: mean endpoint PANSS total (high = poor)|< 12 months","Mental state - general: mean endpoint PANSS total (high = poor)",1,1,"< 12 months","or","binary",10,-0.193287243958808,0.639059524406798,0,2017.75,0,80.8
"CD015331","CD015331_pub2_data","1|1|Mental state - general: mean endpoint PANSS total (high = poor)|< 6 months","Mental state - general: mean endpoint PANSS total (high = poor)",1,1,"< 6 months","or","binary",13,-0.044785961964487,0.561209218429438,0,2013.53846153846,0,65.9230769230769
"CD015331","CD015331_pub2_data","1|1|Mental state - general: mean endpoint PANSS total (high = poor)|> 1 year","Mental state - general: mean endpoint PANSS total (high = poor)",1,1,"> 1 year","or","binary",7,-0.0235584421013814,0.763050629490031,0,2012.66666666667,0,79.2857142857143
"CD015331","CD015331_pub2_data","1|10|Mental state - specific: number of participants with clinically important change in positive symptoms (separated time points)|> 6 months","Mental state - specific: number of participants with clinically important change in positive symptoms (separated time points)",1,10,"> 6 months","or","binary",2,1.00229463581405,0.408762239967647,0,2013.5,0.329166666666667,49.5
"CD015331","CD015331_pub2_data","1|11|Mental state - specific: mean endpoint PANSS positive (high = poor)|< 12 months","Mental state - specific: mean endpoint PANSS positive (high = poor)",1,11,"< 12 months","or","binary",9,-0.198015803587777,0.67410706937112,0,2017.75,0,76
"CD015331","CD015331_pub2_data","1|11|Mental state - specific: mean endpoint PANSS positive (high = poor)|< 6 months","Mental state - specific: mean endpoint PANSS positive (high = poor)",1,11,"< 6 months","or","binary",14,-0.0516661658815014,0.540686867341081,0,2014,0,65.2142857142857
"CD015331","CD015331_pub2_data","1|11|Mental state - specific: mean endpoint PANSS positive (high = poor)|> 1 year","Mental state - specific: mean endpoint PANSS positive (high = poor)",1,11,"> 1 year","or","binary",7,-0.0408285640932759,0.763648924616095,0,2013.71428571429,0,71.7142857142857
"CD015331","CD015331_pub2_data","1|13|Mental state - specific: mean endpoint BPRS positive (high = poor)|< 12 months","Mental state - specific: mean endpoint BPRS positive (high = poor)",1,13,"< 12 months","or","binary",3,-0.0851969474471252,1.1718995781111,0,2007.33333333333,0,32.6666666666667
"CD015331","CD015331_pub2_data","1|13|Mental state - specific: mean endpoint BPRS positive (high = poor)|< 6 months","Mental state - specific: mean endpoint BPRS positive (high = poor)",1,13,"< 6 months","or","binary",5,0.131522786598352,0.903273666273627,0,2008.2,0,50.6
"CD015331","CD015331_pub2_data","1|13|Mental state - specific: mean endpoint BPRS positive (high = poor)|> 1 year","Mental state - specific: mean endpoint BPRS positive (high = poor)",1,13,"> 1 year","or","binary",2,-0.012217832538372,1.42410087019897,0,2008.5,0,71.5
"CD015331","CD015331_pub2_data","1|14|Mental state - specific: mean endpoint SAPS (high = poor)|< 12 months","Mental state - specific: mean endpoint SAPS (high = poor)",1,14,"< 12 months","or","binary",2,-0.496173561841287,1.43150433213281,0,2017,0,43
"CD015331","CD015331_pub2_data","1|14|Mental state - specific: mean endpoint SAPS (high = poor)|< 6 months","Mental state - specific: mean endpoint SAPS (high = poor)",1,14,"< 6 months","or","binary",2,-0.536044646847734,1.42895691167617,0,2017,0,52.5
"CD015331","CD015331_pub2_data","1|15|Mental state - specific: mean endpoint positive symptoms scales (high = poor) (combined time points)|","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (combined time points)",1,15,"","or","binary",24,-0.114015789416391,0.413157758420926,0,2013.04347826087,0,65.2083333333333
"CD015331","CD015331_pub2_data","1|16|Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)|< 12 months","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)",1,16,"< 12 months","or","binary",14,-0.216556982633353,0.540995408355748,0,2015.23076923077,0,62
"CD015331","CD015331_pub2_data","1|16|Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)|< 6 months","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)",1,16,"< 6 months","or","binary",21,-0.0541378370756815,0.441252008328168,0,2012.90476190476,0,60.5238095238095
"CD015331","CD015331_pub2_data","1|16|Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)|> 1 year","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)",1,16,"> 1 year","or","binary",9,-0.0344389814108003,0.672996053868429,0,2012.55555555556,0,71.6666666666667
"CD015331","CD015331_pub2_data","1|17|Mental state - specific: mean endpoint PANSS negative (high = poor)|< 12 months","Mental state - specific: mean endpoint PANSS negative (high = poor)",1,17,"< 12 months","or","binary",9,-0.200100902863882,0.674108683615171,0,2017.75,0,75.7777777777778
"CD015331","CD015331_pub2_data","1|17|Mental state - specific: mean endpoint PANSS negative (high = poor)|< 6 months","Mental state - specific: mean endpoint PANSS negative (high = poor)",1,17,"< 6 months","or","binary",12,-0.147480244467488,0.584607918821965,0,2016,0,58.8333333333333
"CD015331","CD015331_pub2_data","1|17|Mental state - specific: mean endpoint PANSS negative (high = poor)|> 1 year","Mental state - specific: mean endpoint PANSS negative (high = poor)",1,17,"> 1 year","or","binary",7,-0.0379489919742377,0.763654311216914,0,2013.71428571429,0,71.5714285714286
"CD015331","CD015331_pub2_data","1|19|Mental state - specific: mean endpoint BPRS negative (high = poor)|< 12 months","Mental state - specific: mean endpoint BPRS negative (high = poor)",1,19,"< 12 months","or","binary",2,-0.157275947776613,1.43547819517481,0,2008,0,32.5
"CD015331","CD015331_pub2_data","1|19|Mental state - specific: mean endpoint BPRS negative (high = poor)|< 6 months","Mental state - specific: mean endpoint BPRS negative (high = poor)",1,19,"< 6 months","or","binary",2,0.26649576662973,1.42875885239349,0,2008,0,49
"CD015331","CD015331_pub2_data","1|20|Mental state - specific: mean endpoint SANS (high = poor)|< 12 months","Mental state - specific: mean endpoint SANS (high = poor)",1,20,"< 12 months","or","binary",4,-0.113047583284306,1.00955007602674,0,2012.33333333333,0,68
"CD015331","CD015331_pub2_data","1|20|Mental state - specific: mean endpoint SANS (high = poor)|< 6 months","Mental state - specific: mean endpoint SANS (high = poor)",1,20,"< 6 months","or","binary",4,-0.077096265635971,1.01031905137939,0,2011.75,0,49
"CD015331","CD015331_pub2_data","1|20|Mental state - specific: mean endpoint SANS (high = poor)|> 1 year","Mental state - specific: mean endpoint SANS (high = poor)",1,20,"> 1 year","or","binary",2,-0.0958229537149584,1.4231881955722,0,2008,0,83
"CD015331","CD015331_pub2_data","1|22|Mental state - specific: mean endpoint negative symptoms scale (high = poor) (combined time points)|","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (combined time points)",1,22,"","or","binary",24,-0.0789368422076968,0.41303631053032,0,2013.09090909091,0,68.7916666666667
"CD015331","CD015331_pub2_data","1|23|Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)|< 12 months","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)",1,23,"< 12 months","or","binary",15,-0.171141231291093,0.522204867397365,0,2015,0,67.9333333333333
"CD015331","CD015331_pub2_data","1|23|Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)|< 6 months","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)",1,23,"< 6 months","or","binary",18,-0.0856563007271073,0.476973991544936,0,2014.16666666667,0,55.5555555555556
"CD015331","CD015331_pub2_data","1|23|Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)|> 1 year","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)",1,23,"> 1 year","or","binary",9,-0.0508868958497933,0.672903344013875,0,2013,0,74.1111111111111
"CD015331","CD015331_pub2_data","1|24|Mental state - specific: mean endpoint BDI short form (high = poor)|< 6 months","Mental state - specific: mean endpoint BDI short form (high = poor)",1,24,"< 6 months","or","binary",2,0.0625937949588045,1.4290524104117,0,2008.5,0,46.5
"CD015331","CD015331_pub2_data","1|25|Mental state - specific: mean endpoint BDI-II (high = poor)|> 1 year","Mental state - specific: mean endpoint BDI-II (high = poor)",1,25,"> 1 year","or","binary",2,-0.286324178056326,1.42518846296072,0,2020,0,73
"CD015331","CD015331_pub2_data","1|26|Mental state - specific: mean endpoint HADS Depression (high = poor)|< 12 months","Mental state - specific: mean endpoint HADS Depression (high = poor)",1,26,"< 12 months","or","binary",2,0.12813603627069,1.44611526778777,0,2019,0,26.5
"CD015331","CD015331_pub2_data","1|26|Mental state - specific: mean endpoint HADS Depression (high = poor)|< 6 months","Mental state - specific: mean endpoint HADS Depression (high = poor)",1,26,"< 6 months","or","binary",2,-0.0316053806678928,1.44108983157703,0,2019,0,29.5
"CD015331","CD015331_pub2_data","1|27|Mental state - specific: mean endpoint CDS (high = poor)|< 12 months","Mental state - specific: mean endpoint CDS (high = poor)",1,27,"< 12 months","or","binary",5,-0.440406248247072,0.906824949290602,0,2015.4,0,43
"CD015331","CD015331_pub2_data","1|27|Mental state - specific: mean endpoint CDS (high = poor)|< 6 months","Mental state - specific: mean endpoint CDS (high = poor)",1,27,"< 6 months","or","binary",8,-0.33728170016649,0.717973147008549,0,2013.25,0,42.125
"CD015331","CD015331_pub2_data","1|27|Mental state - specific: mean endpoint CDS (high = poor)|> 1 year","Mental state - specific: mean endpoint CDS (high = poor)",1,27,"> 1 year","or","binary",3,-0.469949697295132,1.17307251568027,0,2018,0,44.6666666666667
"CD015331","CD015331_pub2_data","1|32|Mental state - specific: mean endpoint depressive symptoms (high = poor) (combined time points)|","Mental state - specific: mean endpoint depressive symptoms (high = poor) (combined time points)",1,32,"","or","binary",18,-0.188359978346703,0.477846911189198,0,2013.6875,0,65.6666666666667
"CD015331","CD015331_pub2_data","1|33|Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)|< 12 months","Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)",1,33,"< 12 months","or","binary",11,-0.227692366032638,0.610725808385789,0,2014.44444444444,0,71.7272727272727
"CD015331","CD015331_pub2_data","1|33|Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)|< 6 months","Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)",1,33,"< 6 months","or","binary",14,-0.195313758802155,0.541953078315486,0,2013.57142857143,0,51
"CD015331","CD015331_pub2_data","1|33|Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)|> 1 year","Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)",1,33,"> 1 year","or","binary",5,-0.333966336145679,0.904933856195396,0,2015.75,0,62.6
"CD015331","CD015331_pub2_data","1|34|Global state - number of participants with relapse/exacerbations of psychosis (combined time points)|","Global state - number of participants with relapse/exacerbations of psychosis (combined time points)",1,34,"","or","binary",8,-0.350645760963955,0.29427755461647,0.277786901564295,2010.375,0.312082489513816,86.625
"CD015331","CD015331_pub2_data","1|35|Global state - number of participants with relapse/exacerbations of psychosis (separated time points)|< 12 months","Global state - number of participants with relapse/exacerbations of psychosis (separated time points)",1,35,"< 12 months","or","binary",5,-0.633435465843065,0.430653420718622,0.277792129222268,2016,0.150714285714286,72.6
"CD015331","CD015331_pub2_data","1|35|Global state - number of participants with relapse/exacerbations of psychosis (separated time points)|< 6 months","Global state - number of participants with relapse/exacerbations of psychosis (separated time points)",1,35,"< 6 months","or","binary",3,-0.848300844614443,0.738241561223926,0,2019,0.0555555555555556,57.3333333333333
"CD015331","CD015331_pub2_data","1|35|Global state - number of participants with relapse/exacerbations of psychosis (separated time points)|> 1 year","Global state - number of participants with relapse/exacerbations of psychosis (separated time points)",1,35,"> 1 year","or","binary",6,-0.270850426949231,0.269297891181708,0.185047460905216,2007.5,0.408768716177151,100.166666666667
"CD015331","CD015331_pub2_data","1|36|Global state - number of participants with remission (combined time points)|","Global state - number of participants with remission (combined time points)",1,36,"","or","binary",2,0.24520953539231,0.461180368122095,0,2015.5,0.428333333333333,36.5
"CD015331","CD015331_pub2_data","1|4|Mental state - general: mean endpoint BPRS total (high = poor)|< 12 months","Mental state - general: mean endpoint BPRS total (high = poor)",1,4,"< 12 months","or","binary",4,-0.0697957962825374,1.01266939492362,0,2007.75,0,44.75
"CD015331","CD015331_pub2_data","1|4|Mental state - general: mean endpoint BPRS total (high = poor)|< 6 months","Mental state - general: mean endpoint BPRS total (high = poor)",1,4,"< 6 months","or","binary",5,0.134756661087238,0.90633951621447,0,2005.8,0,42.8
"CD015331","CD015331_pub2_data","1|40|Global state - mean endpoint/change CGI-S (high = poor) (separated time points)|< 6 months","Global state - mean endpoint/change CGI-S (high = poor) (separated time points)",1,40,"< 6 months","or","binary",3,0.0610992664294093,1.16402232662068,0,2016.66666666667,0,89.3333333333333
"CD015331","CD015331_pub2_data","1|41|Global state - mean endpoint CGI-I (high = poor) (separated time points)|< 6 months","Global state - mean endpoint CGI-I (high = poor) (separated time points)",1,41,"< 6 months","or","binary",2,0.0508737487096203,1.42415483397662,0,2019.5,0,110
"CD015331","CD015331_pub2_data","1|42|Global state - mean endpoint/change global state scales (high = poor) (combined time points)|","Global state - mean endpoint/change global state scales (high = poor) (combined time points)",1,42,"","or","binary",4,-0.00619965349860155,1.00813266097194,0,2017.25,0,82.25
"CD015331","CD015331_pub2_data","1|43|Global state - mean endpoint/change global state scales (high = poor) (separated time points)|< 12 months","Global state - mean endpoint/change global state scales (high = poor) (separated time points)",1,43,"< 12 months","or","binary",2,-0.0817408919698512,1.42808058831147,0,2018.5,0,52
"CD015331","CD015331_pub2_data","1|43|Global state - mean endpoint/change global state scales (high = poor) (separated time points)|< 6 months","Global state - mean endpoint/change global state scales (high = poor) (separated time points)",1,43,"< 6 months","or","binary",4,-0.0180167670780538,1.0080632552205,0,2017.25,0,82.5
"CD015331","CD015331_pub2_data","1|44|Service use - admission to hospital (combined time points)|","Service use - admission to hospital (combined time points)",1,44,"","or","binary",11,0.0116732061545759,0.156745477292497,2.71089559741281e-06,2012.8,0.213759789313833,101.909090909091
"CD015331","CD015331_pub2_data","1|45|Service use - admission to hospital (separated time points)|< 12 months","Service use - admission to hospital (separated time points)",1,45,"< 12 months","or","binary",5,-0.0665138841927713,0.228390821819825,2.76767006515228e-06,2017.75,0.173174603174603,118
"CD015331","CD015331_pub2_data","1|45|Service use - admission to hospital (separated time points)|< 6 months","Service use - admission to hospital (separated time points)",1,45,"< 6 months","or","binary",4,0.338010802040451,0.670886003253262,0,2016,0.0618055555555556,60
"CD015331","CD015331_pub2_data","1|45|Service use - admission to hospital (separated time points)|> 1 year","Service use - admission to hospital (separated time points)",1,45,"> 1 year","or","binary",6,-0.115241054839323,0.19887198721498,6.86224064492084e-06,2010.83333333333,0.320464375646789,97.6666666666667
"CD015331","CD015331_pub2_data","1|46|Service use - number of days in hospital (combined time points)|","Service use - number of days in hospital (combined time points)",1,46,"","or","binary",7,-0.0949594886842781,0.765642191842486,0,2009.33333333333,0,81.5714285714286
"CD015331","CD015331_pub2_data","1|47|Service use - number of days in hospital (separated time points)|< 12 months","Service use - number of days in hospital (separated time points)",1,47,"< 12 months","or","binary",4,-0.170607725309232,1.00705558020802,0,2015.33333333333,0,122
"CD015331","CD015331_pub2_data","1|47|Service use - number of days in hospital (separated time points)|< 6 months","Service use - number of days in hospital (separated time points)",1,47,"< 6 months","or","binary",3,-0.0239348893572307,1.17795601434163,0,2007,0,32.6666666666667
"CD015331","CD015331_pub2_data","1|47|Service use - number of days in hospital (separated time points)|> 1 year","Service use - number of days in hospital (separated time points)",1,47,"> 1 year","or","binary",4,-0.0437316550858204,1.01207154543672,0,2008.75,0,49.75
"CD015331","CD015331_pub2_data","1|48|Leaving the study early - for any reason - overall acceptability (combined time points)|","Leaving the study early - for any reason - overall acceptability (combined time points)",1,48,"","or","binary",27,-0.179807150129252,0.137071651966213,0.102581160037008,2012.68,0.220423454794524,83.037037037037
"CD015331","CD015331_pub2_data","1|49|Leaving the study early - for any reason - overall acceptability (separated time points)|< 12 months","Leaving the study early - for any reason - overall acceptability (separated time points)",1,49,"< 12 months","or","binary",16,-0.225912199497006,0.199608701434657,0.233897259372544,2013.85714285714,0.241130641323652,87.25
"CD015331","CD015331_pub2_data","1|49|Leaving the study early - for any reason - overall acceptability (separated time points)|< 6 months","Leaving the study early - for any reason - overall acceptability (separated time points)",1,49,"< 6 months","or","binary",23,-0.154573852002588,0.138352378849731,0,2012.52173913043,0.1805768392245,71.9565217391304
"CD015331","CD015331_pub2_data","1|49|Leaving the study early - for any reason - overall acceptability (separated time points)|> 1 year","Leaving the study early - for any reason - overall acceptability (separated time points)",1,49,"> 1 year","or","binary",12,-0.407217583412836,0.156882635910101,0,2011.72727272727,0.344194598518822,89.6666666666667
"CD015331","CD015331_pub2_data","1|5|Mental state - general: mean endpoint overall symptom scales (high = poor) (combined time points)|","Mental state - general: mean endpoint overall symptom scales (high = poor) (combined time points)",1,5,"","or","binary",22,-0.0826270505978464,0.431761507697951,0,2011.7,0,68.5454545454545
"CD015331","CD015331_pub2_data","1|50|Functioning - mean endpoint GAF (high = good)|< 12 months","Functioning - mean endpoint GAF (high = good)",1,50,"< 12 months","or","binary",7,-0.337570976232889,0.763559017472877,0,2016.16666666667,0,84.5714285714286
"CD015331","CD015331_pub2_data","1|50|Functioning - mean endpoint GAF (high = good)|< 6 months","Functioning - mean endpoint GAF (high = good)",1,50,"< 6 months","or","binary",8,-0.310894356637874,0.713733623884885,0,2017,0,71.25
"CD015331","CD015331_pub2_data","1|50|Functioning - mean endpoint GAF (high = good)|> 1 year","Functioning - mean endpoint GAF (high = good)",1,50,"> 1 year","or","binary",4,-0.415670153928039,1.01392422870981,0,2018.25,0,49
"CD015331","CD015331_pub2_data","1|52|Functioning - mean endpoint SOFAS (high = good)|< 12 months","Functioning - mean endpoint SOFAS (high = good)",1,52,"< 12 months","or","binary",3,-0.112427792926218,1.16784726604957,0,2012.33333333333,0,50.3333333333333
"CD015331","CD015331_pub2_data","1|52|Functioning - mean endpoint SOFAS (high = good)|< 6 months","Functioning - mean endpoint SOFAS (high = good)",1,52,"< 6 months","or","binary",4,-0.077096265635971,1.01031905137939,0,2011.75,0,49
"CD015331","CD015331_pub2_data","1|52|Functioning - mean endpoint SOFAS (high = good)|> 1 year","Functioning - mean endpoint SOFAS (high = good)",1,52,"> 1 year","or","binary",2,-0.012217832538372,1.42410087019897,0,2008.5,0,71.5
"CD015331","CD015331_pub2_data","1|53|Functioning - mean endpoint PSP (high = good)|< 12 months","Functioning - mean endpoint PSP (high = good)",1,53,"< 12 months","or","binary",2,0.0462945983000906,1.42674205699514,0,2018.5,0,61
"CD015331","CD015331_pub2_data","1|53|Functioning - mean endpoint PSP (high = good)|< 6 months","Functioning - mean endpoint PSP (high = good)",1,53,"< 6 months","or","binary",3,-0.25348165835228,1.16860895748562,0,2018.33333333333,0,51
"CD015331","CD015331_pub2_data","1|56|Functioning - mean endpoint functioning scale (high = good) (combined time points)|","Functioning - mean endpoint functioning scale (high = good) (combined time points)",1,56,"","or","binary",18,-0.21073801367102,0.478733753414716,0,2015.82352941176,0,68.9444444444444
"CD015331","CD015331_pub2_data","1|57|Functioning - mean endpoint functioning scale (high = good) (separated time points)|< 12 months","Functioning - mean endpoint functioning scale (high = good) (separated time points)",1,57,"< 12 months","or","binary",13,-0.235736331798554,0.564599275128763,0,2015.91666666667,0,66.7692307692308
"CD015331","CD015331_pub2_data","1|57|Functioning - mean endpoint functioning scale (high = good) (separated time points)|< 6 months","Functioning - mean endpoint functioning scale (high = good) (separated time points)",1,57,"< 6 months","or","binary",15,-0.146276082082828,0.522754739570415,0,2016,0,59.8666666666667
"CD015331","CD015331_pub2_data","1|57|Functioning - mean endpoint functioning scale (high = good) (separated time points)|> 1 year","Functioning - mean endpoint functioning scale (high = good) (separated time points)",1,57,"> 1 year","or","binary",7,-0.239588332801086,0.764103819190511,0,2015.57142857143,0,59.8571428571429
"CD015331","CD015331_pub2_data","1|58|Quality of life - mean endpoint WHO QoL-bref (high = good)|< 12 months","Quality of life - mean endpoint WHO QoL-bref (high = good)",1,58,"< 12 months","or","binary",3,-0.172728992672274,1.16691401244155,0,2013,0,55.3333333333333
"CD015331","CD015331_pub2_data","1|58|Quality of life - mean endpoint WHO QoL-bref (high = good)|< 6 months","Quality of life - mean endpoint WHO QoL-bref (high = good)",1,58,"< 6 months","or","binary",2,-0.349246552639898,1.43146127707465,0,2015,0,43.5
"CD015331","CD015331_pub2_data","1|59|Quality of life - mean endpoint EQ5d (WHO) (high = good)|< 12 months","Quality of life - mean endpoint EQ5d (WHO) (high = good)",1,59,"< 12 months","or","binary",2,-0.232253218824579,1.45062135091172,0,2019.5,0,42
"CD015331","CD015331_pub2_data","1|59|Quality of life - mean endpoint EQ5d (WHO) (high = good)|< 6 months","Quality of life - mean endpoint EQ5d (WHO) (high = good)",1,59,"< 6 months","or","binary",3,-0.203299950260082,1.17549390616269,0,2019,0,41.6666666666667
"CD015331","CD015331_pub2_data","1|6|Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)|< 12 months","Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)",1,6,"< 12 months","or","binary",14,-0.158114865506209,0.540443269529755,0,2014.41666666667,0,70.5
"CD015331","CD015331_pub2_data","1|6|Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)|< 6 months","Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)",1,6,"< 6 months","or","binary",18,0.0049743641040646,0.477143202819181,0,2011.38888888889,0,59.5
"CD015331","CD015331_pub2_data","1|6|Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)|> 1 year","Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)",1,6,"> 1 year","or","binary",8,-0.0236631741233193,0.713471902550393,0,2012.14285714286,0,79.5
"CD015331","CD015331_pub2_data","1|60|Quality of life - mean endpoint QLS (high = good)|< 6 months","Quality of life - mean endpoint QLS (high = good)",1,60,"< 6 months","or","binary",2,-0.00789987209472078,1.4387988059322,0,2009.5,0,33.5
"CD015331","CD015331_pub2_data","1|64|Quality of life - mean endpoint quality of life scale (high = good) (combined time points)|","Quality of life - mean endpoint quality of life scale (high = good) (combined time points)",1,64,"","or","binary",9,-0.20918937784447,0.677537196719737,0,2015.55555555556,0,42.8888888888889
"CD015331","CD015331_pub2_data","1|65|Quality of life - mean endpoint quality of life scale (high = good) (separated time points)|< 12 months","Quality of life - mean endpoint quality of life scale (high = good) (separated time points)",1,65,"< 12 months","or","binary",7,-0.164829623465958,0.768656153299246,0,2015.85714285714,0,44
"CD015331","CD015331_pub2_data","1|65|Quality of life - mean endpoint quality of life scale (high = good) (separated time points)|< 6 months","Quality of life - mean endpoint quality of life scale (high = good) (separated time points)",1,65,"< 6 months","or","binary",7,-0.175020248780834,0.766933963748962,0,2015.85714285714,0,42.2857142857143
"CD015331","CD015331_pub2_data","1|66|Behaviour - occurence of violent incidents|< 12 months","Behaviour - occurence of violent incidents",1,66,"< 12 months","or","binary",2,-0.0319146477190546,0.90432033509537,0,2019,0.0454545454545455,46
"CD015331","CD015331_pub2_data","1|67|Behaviour - participants with self-injury|< 12 months","Behaviour - participants with self-injury",1,67,"< 12 months","or","binary",2,1.08734647026317,0.576115131931711,0,2019,0.159090909090909,46
"CD015331","CD015331_pub2_data","1|68|Behaviour - participants with suicide attempts|< 12 months","Behaviour - participants with suicide attempts",1,68,"< 12 months","or","binary",2,-0.0197919364724161,1.22525072760913,0.209067029223801,2020,0.0416666666666667,34
"CD015331","CD015331_pub2_data","1|7|Mental state - general: number of participants with clinically important change in general mental state (combined time points)|","Mental state - general: number of participants with clinically important change in general mental state (combined time points)",1,7,"","or","binary",5,0.655284944144963,0.270540271835271,4.19523606406023e-06,2014.6,0.246212121212121,60.2
"CD015331","CD015331_pub2_data","1|70|Adverse events - specific: Non Compliance|< 6 months","Adverse events - specific: Non Compliance",1,70,"< 6 months","or","binary",2,0.0175763152597362,0.465500524568213,0,2016.5,0.110714285714286,95
"CD015331","CD015331_pub2_data","1|71|Adverse events - specific: Deterioration of symptoms|< 12 months","Adverse events - specific: Deterioration of symptoms",1,71,"< 12 months","or","binary",3,-0.521168493221912,0.79804150359448,8.62447662681657e-07,2019.33333333333,0.0833333333333333,39
"CD015331","CD015331_pub2_data","1|71|Adverse events - specific: Deterioration of symptoms|< 6 months","Adverse events - specific: Deterioration of symptoms",1,71,"< 6 months","or","binary",2,0.0761387668120024,0.904390483280565,0,2019,0.0435606060606061,46
"CD015331","CD015331_pub2_data","1|71|Adverse events - specific: Deterioration of symptoms|> 1 year","Adverse events - specific: Deterioration of symptoms",1,71,"> 1 year","or","binary",2,-0.903995590690615,0.482172945820072,0,2019.5,0.324074074074074,43.5
"CD015331","CD015331_pub2_data","1|72|Mortality - overall mortality (combined time points)|","Mortality - overall mortality (combined time points)",1,72,"","or","binary",5,0.18774513434325,0.514436273454356,1.37275400019321e-07,2006,0.0145492662473795,180
"CD015331","CD015331_pub2_data","1|73|Mortality - overall mortality (separated time points)|< 12 months","Mortality - overall mortality (separated time points)",1,73,"< 12 months","or","binary",2,-0.0915058246929538,0.790245995036608,0,NA,0.00793650793650794,240.5
"CD015331","CD015331_pub2_data","1|73|Mortality - overall mortality (separated time points)|> 1 year","Mortality - overall mortality (separated time points)",1,73,"> 1 year","or","binary",3,0.368511596062424,0.918672257443971,0.920805752675912,2006,0.0189577717879605,139.666666666667
"CD015331","CD015331_pub2_data","1|74|Mortality - due to natural causes|> 1 year","Mortality - due to natural causes",1,74,"> 1 year","or","binary",2,1.83564299595231,1.16108603282082,0,2002,0,154.5
"CD015331","CD015331_pub2_data","1|76|Sensitivity analysis - Blinding of outcome assessor|","Sensitivity analysis - Blinding of outcome assessor",1,76,"","or","binary",21,-0.0650892865716233,0.442148062546043,0,2011.7,0,58.5238095238095
"CD015331","CD015331_pub2_data","1|77|Sensitivity analysis - Assumptions for missing data|","Sensitivity analysis - Assumptions for missing data",1,77,"","or","binary",17,-0.0752461490977073,0.490480308281744,0,2012.33333333333,0,71.4705882352941
"CD015331","CD015331_pub2_data","1|78|Sensitivity analysis - Risk of Bias|","Sensitivity analysis - Risk of Bias",1,78,"","or","binary",16,-0.0523081170932659,0.505840763010043,0,2012.1875,0,62.875
"CD015331","CD015331_pub2_data","1|79|Sensitivity analysis - Imputed values|","Sensitivity analysis - Imputed values",1,79,"","or","binary",20,-0.0742604157974912,0.452679525129749,0,2012.15789473684,0,60.7
"CD015331","CD015331_pub2_data","1|8|Mental state - general: number of participants with clinically important change in general mental state (separated time points)|< 12 months","Mental state - general: number of participants with clinically important change in general mental state (separated time points)",1,8,"< 12 months","or","binary",4,0.504983638428288,0.329073454508128,1.10789934354843e-06,2013.5,0.245265151515151,55.25
"CD015331","CD015331_pub2_data","1|8|Mental state - general: number of participants with clinically important change in general mental state (separated time points)|< 6 months","Mental state - general: number of participants with clinically important change in general mental state (separated time points)",1,8,"< 6 months","or","binary",4,0.940392317970586,0.342128374354941,0.0734124959442407,2013.5,0.223484848484848,55.25
"CD015331","CD015331_pub2_data","1|80|Sensitivity analysis - Fixed-effect|","Sensitivity analysis - Fixed-effect",1,80,"","or","binary",22,-0.0826270505978464,0.431761507697951,0,2011.7,0,68.5454545454545
"CD015331","CD015331_pub2_data","1|81|Sensitivity analysis excluding outliers|","Sensitivity analysis excluding outliers",1,81,"","or","binary",21,-0.0743245497972577,0.442016933971685,0,2011.31578947368,0,68.8571428571429
"CD015331","CD015331_pub2_data","1|82|Subgroup analysis - Different types of CBT|CBT","Subgroup analysis - Different types of CBT",1,82,"CBT","or","binary",13,0.0478684884391203,0.562283488352086,0,2011.30769230769,0,59.6153846153846
"CD015331","CD015331_pub2_data","1|82|Subgroup analysis - Different types of CBT|CBT and Motivational Interviewing for cannabis use cessation","Subgroup analysis - Different types of CBT",1,82,"CBT and Motivational Interviewing for cannabis use cessation","or","binary",3,-0.216955125702642,1.16852490776792,0,2011,0,46.3333333333333
"CD015331","CD015331_pub2_data","1|82|Subgroup analysis - Different types of CBT|CBT integrated with other psychosocial interventions","Subgroup analysis - Different types of CBT",1,82,"CBT integrated with other psychosocial interventions","or","binary",4,-0.412522093032332,1.00812432289855,0,2018.5,0,123.5
"CD015331","CD015331_pub2_data","1|82|Subgroup analysis - Different types of CBT|Special types of CBT","Subgroup analysis - Different types of CBT",1,82,"Special types of CBT","or","binary",2,-0.0615414261709299,1.43583589053356,0,2008.5,0,50
"CD015331","CD015331_pub2_data","1|83|Subgroup analysis - Modality of treatment|Group CBT","Subgroup analysis - Modality of treatment",1,83,"Group CBT","or","binary",4,-0.141560150053952,1.01015931732557,0,2011.66666666667,0,65.5
"CD015331","CD015331_pub2_data","1|83|Subgroup analysis - Modality of treatment|Individual CBT","Subgroup analysis - Modality of treatment",1,83,"Individual CBT","or","binary",18,-0.0694542210621312,0.477583999999026,0,2011.70588235294,0,69.2222222222222
"CD015331","CD015331_pub2_data","1|84|Subgroup analysis - Method of delivery|Face to face","Subgroup analysis - Method of delivery",1,84,"Face to face","or","binary",21,-0.048114189571262,0.441793864696535,0,2011.36842105263,0,70.3809523809524
"CD015331","CD015331_pub2_data","1|85|Subgroup analysis - Control group|CBT compared to other psychosocial interventions","Subgroup analysis - Control group",1,85,"CBT compared to other psychosocial interventions","or","binary",7,-0.0215304265459688,0.768047883591869,0,2007,0,42.4285714285714
"CD015331","CD015331_pub2_data","1|85|Subgroup analysis - Control group|CBT compared to TAU","Subgroup analysis - Control group",1,85,"CBT compared to TAU","or","binary",15,-0.110855272767784,0.522061243415764,0,2014.23076923077,0,80.7333333333333
"CD015331","CD015331_pub2_data","1|9|Mental state - specific: number of participants with clinically important change in positive symptoms (combined time points)|","Mental state - specific: number of participants with clinically important change in positive symptoms (combined time points)",1,9,"","or","binary",2,0.780398850654146,0.410876055862168,0,2013.5,0.429166666666667,49.5
"CD015332","CD015332_pub2_data","2|1|Mental state – general: mean endpoint PANSS total (high = poor)|< 12 months","Mental state – general: mean endpoint PANSS total (high = poor)",2,1,"< 12 months","or","binary",2,-0.0713506919806492,1.43891780364446,0,2019,0,31.5
"CD015332","CD015332_pub2_data","2|1|Mental state – general: mean endpoint PANSS total (high = poor)|< 6 months","Mental state – general: mean endpoint PANSS total (high = poor)",2,1,"< 6 months","or","binary",2,0.0570254670877409,1.43208484769104,0,2019,0,39
"CD015332","CD015332_pub2_data","2|12|Leaving the study early – for any reason – overall acceptability (separated time points)|< 12 months","Leaving the study early – for any reason – overall acceptability (separated time points)",2,12,"< 12 months","or","binary",2,0.402590330895644,0.967685979897994,0,2019,0.0208333333333333,45
"CD015332","CD015332_pub2_data","2|12|Leaving the study early – for any reason – overall acceptability (separated time points)|< 6 months","Leaving the study early – for any reason – overall acceptability (separated time points)",2,12,"< 6 months","or","binary",2,0.402590330895644,0.967685979897994,0,2019,0.0208333333333333,45
"CD015332","CD015332_pub2_data","2|15|Functioning – mean endpoint functioning scales (high = good)|< 12 months","Functioning – mean endpoint functioning scales (high = good)",2,15,"< 12 months","or","binary",2,-0.203046417736064,1.50446538754887,0,2019,0,23
"CD015332","CD015332_pub2_data","2|15|Functioning – mean endpoint functioning scales (high = good)|< 6 months","Functioning – mean endpoint functioning scales (high = good)",2,15,"< 6 months","or","binary",2,0.296792821714403,1.45894058019467,0,2019,0,26.5
"CD015332","CD015332_pub2_data","2|18|Quality of life – mean endpoint quality of life scales (high = good)|< 12 months","Quality of life – mean endpoint quality of life scales (high = good)",2,18,"< 12 months","or","binary",2,0.0236725851937585,1.45951713015725,0,2019,0,25.5
"CD015332","CD015332_pub2_data","2|18|Quality of life – mean endpoint quality of life scales (high = good)|< 6 months","Quality of life – mean endpoint quality of life scales (high = good)",2,18,"< 6 months","or","binary",2,0.161743220091398,1.44492121062176,0,2019,0,28
"CD015332","CD015332_pub2_data","2|19|Behaviour – violent incidents (separated time points)|< 12 months","Behaviour – violent incidents (separated time points)",2,19,"< 12 months","or","binary",2,0.163183215272841,0.862316546007198,0,2019,0.0454545454545455,45
"CD015332","CD015332_pub2_data","2|2|Number of participants with clinically important change in general mental state (separated time points)|< 12 months","Number of participants with clinically important change in general mental state (separated time points)",2,2,"< 12 months","or","binary",2,-0.102372317693811,0.537909946388351,0,2019,0.172348484848485,45
"CD015332","CD015332_pub2_data","2|2|Number of participants with clinically important change in general mental state (separated time points)|< 6 months","Number of participants with clinically important change in general mental state (separated time points)",2,2,"< 6 months","or","binary",2,0.115020499549858,0.56141741870274,0,2019,0.153409090909091,45
"CD015332","CD015332_pub2_data","2|20|Behaviour – self-injury (separated time points)|< 12 months","Behaviour – self-injury (separated time points)",2,20,"< 12 months","or","binary",2,0.0576072286450687,0.624800875186312,0,2019,0.159090909090909,45
"CD015332","CD015332_pub2_data","2|23|Adverse events – participants with serious adverse events |< 12 months","Adverse events – participants with serious adverse events ",2,23,"< 12 months","or","binary",2,1.02377849044771,0.648732918674991,0,2019,0.0662878787878788,45
"CD015332","CD015332_pub2_data","2|24|Adverse events – deterioration of symptoms |< 12 months","Adverse events – deterioration of symptoms ",2,24,"< 12 months","or","binary",2,-0.453706998939393,0.947745977365142,0,2019,0.0416666666666667,45
"CD015332","CD015332_pub2_data","2|24|Adverse events – deterioration of symptoms |< 6 months","Adverse events – deterioration of symptoms ",2,24,"< 6 months","or","binary",2,0.620770110322525,0.762164327195593,0,2019,0.0435606060606061,45
"CD015332","CD015332_pub2_data","2|25|Adverse events – mean endpoint ANNSERS (high = poor)|< 12 months","Adverse events – mean endpoint ANNSERS (high = poor)",2,25,"< 12 months","or","binary",2,-0.207248534145183,1.46642658283297,0,2019,0,21
"CD015332","CD015332_pub2_data","2|25|Adverse events – mean endpoint ANNSERS (high = poor)|< 6 months","Adverse events – mean endpoint ANNSERS (high = poor)",2,25,"< 6 months","or","binary",2,-1.12431893629084e-05,1.45218242594988,0,2019,0,24
"CD015332","CD015332_pub2_data","2|3|Mental state – specific: mean endpoint PANSS positive (high = poor)|< 12 m","Mental state – specific: mean endpoint PANSS positive (high = poor)",2,3,"< 12 m","or","binary",2,-0.0713506919806492,1.43891780364446,0,2019,0,31.5
"CD015332","CD015332_pub2_data","2|3|Mental state – specific: mean endpoint PANSS positive (high = poor)|< 6 m","Mental state – specific: mean endpoint PANSS positive (high = poor)",2,3,"< 6 m","or","binary",2,0.0342430717151776,1.43226636068167,0,2019,0,38.5
"CD015332","CD015332_pub2_data","2|4|Mental state – specific: mean endpoint PANSS negative (high = poor)|< 12 m","Mental state – specific: mean endpoint PANSS negative (high = poor)",2,4,"< 12 m","or","binary",2,-0.0713506919806492,1.43891780364446,0,2019,0,31.5
"CD015332","CD015332_pub2_data","2|4|Mental state – specific: mean endpoint PANSS negative (high = poor)|< 6 m","Mental state – specific: mean endpoint PANSS negative (high = poor)",2,4,"< 6 m","or","binary",2,0.0570254670877409,1.43208484769104,0,2019,0,39
"CD015332","CD015332_pub2_data","2|5|Mental state – specific: mean endpoint HADS Depression (high = poor)|< 12 m","Mental state – specific: mean endpoint HADS Depression (high = poor)",2,5,"< 12 m","or","binary",2,0.270854902499419,1.45243094993465,0,2019,0,27
"CD015332","CD015332_pub2_data","2|5|Mental state – specific: mean endpoint HADS Depression (high = poor)|< 6 m","Mental state – specific: mean endpoint HADS Depression (high = poor)",2,5,"< 6 m","or","binary",2,0.0613652525329359,1.44366884302379,0,2019,0,29.5
"CD015332","CD015332_pub2_data","2|6|Mental state – specific: mean endpoint HADS Anxiety (high = poor)|< 12 months","Mental state – specific: mean endpoint HADS Anxiety (high = poor)",2,6,"< 12 months","or","binary",2,0.270854902499419,1.45243094993465,0,2019,0,27
"CD015332","CD015332_pub2_data","2|6|Mental state – specific: mean endpoint HADS Anxiety (high = poor)|< 6 months","Mental state – specific: mean endpoint HADS Anxiety (high = poor)",2,6,"< 6 months","or","binary",2,0.116069546083223,1.4426359561139,0,2019,0,30
"CD015332","CD015332_pub2_data","2|7|Global state – number of participants with relapse/exacerbations of psychosis (separated time points)|< 12 months","Global state – number of participants with relapse/exacerbations of psychosis (separated time points)",2,7,"< 12 months","or","binary",2,0.712375444624372,1.28240416011642,0,2019,0,45
"CD015332","CD015332_pub2_data","2|7|Global state – number of participants with relapse/exacerbations of psychosis (separated time points)|< 6 months","Global state – number of participants with relapse/exacerbations of psychosis (separated time points)",2,7,"< 6 months","or","binary",2,0.727664086316867,0.901385197415519,0,2019,0.0208333333333333,45
"CD015332","CD015332_pub2_data","3|1|Mental state – general: mean endpoint PANSS total (high = poor)|< 12 months","Mental state – general: mean endpoint PANSS total (high = poor)",3,1,"< 12 months","or","binary",2,-0.0240404405362632,1.43774629688628,0,2019,0,31.5
"CD015332","CD015332_pub2_data","3|1|Mental state – general: mean endpoint PANSS total (high = poor)|< 6 months","Mental state – general: mean endpoint PANSS total (high = poor)",3,1,"< 6 months","or","binary",2,0.0293167887299521,1.43235263774923,0,2019,0,38.5
"CD015332","CD015332_pub2_data","3|10|Mental state – specific: mean endpoint negative symptoms scales (high = poor)|< 12 m","Mental state – specific: mean endpoint negative symptoms scales (high = poor)",3,10,"< 12 m","or","binary",3,-0.127426099972998,1.17071269817291,0,2019.33333333333,0,41
"CD015332","CD015332_pub2_data","3|10|Mental state – specific: mean endpoint negative symptoms scales (high = poor)|< 6 m","Mental state – specific: mean endpoint negative symptoms scales (high = poor)",3,10,"< 6 m","or","binary",3,-0.0130494678999432,1.16734037078467,0,2019.33333333333,0,47.6666666666667
"CD015332","CD015332_pub2_data","3|11|Mental state – specific: mean endpoint HADS Depression (high = poor)|< 12 m","Mental state – specific: mean endpoint HADS Depression (high = poor)",3,11,"< 12 m","or","binary",2,0.141816055869967,1.45359114348843,0,2019,0,24.5
"CD015332","CD015332_pub2_data","3|11|Mental state – specific: mean endpoint HADS Depression (high = poor)|< 6 m","Mental state – specific: mean endpoint HADS Depression (high = poor)",3,11,"< 6 m","or","binary",2,0.0928590161971684,1.44240925992881,0,2019,0,29
"CD015332","CD015332_pub2_data","3|13|Mental state – specific: mean endpoint depression scales (high = poor)|< 12 m","Mental state – specific: mean endpoint depression scales (high = poor)",3,13,"< 12 m","or","binary",3,0.0131991385209784,1.17922962580293,0,2019.33333333333,0,36
"CD015332","CD015332_pub2_data","3|13|Mental state – specific: mean endpoint depression scales (high = poor)|< 6 m","Mental state – specific: mean endpoint depression scales (high = poor)",3,13,"< 6 m","or","binary",3,0.0099743067421168,1.17291191246558,0,2019.33333333333,0,41
"CD015332","CD015332_pub2_data","3|14|Mental state – specific: mean endpoint HADS Anxiety (high = poor)|< 12 months","Mental state – specific: mean endpoint HADS Anxiety (high = poor)",3,14,"< 12 months","or","binary",2,0.170304031533898,1.45330934013008,0,2019,0,25
"CD015332","CD015332_pub2_data","3|14|Mental state – specific: mean endpoint HADS Anxiety (high = poor)|< 6 months","Mental state – specific: mean endpoint HADS Anxiety (high = poor)",3,14,"< 6 months","or","binary",2,0.118197682573437,1.4421854139108,0,2019,0,29.5
"CD015332","CD015332_pub2_data","3|16|Mental state – specific: mean endpoint anxiety scales (high = poor)|< 12 months","Mental state – specific: mean endpoint anxiety scales (high = poor)",3,16,"< 12 months","or","binary",3,0.0319832601091747,1.17907915311476,0,2019.33333333333,0,36.3333333333333
"CD015332","CD015332_pub2_data","3|16|Mental state – specific: mean endpoint anxiety scales (high = poor)|< 6 months","Mental state – specific: mean endpoint anxiety scales (high = poor)",3,16,"< 6 months","or","binary",3,0.0376608713718995,1.1727406282284,0,2019.33333333333,0,41.6666666666667
"CD015332","CD015332_pub2_data","3|17|Global state – number of participants with relapse/exacerbations of psychosis (separated time points)|< 12 months","Global state – number of participants with relapse/exacerbations of psychosis (separated time points)",3,17,"< 12 months","or","binary",2,0.718333740876128,1.28231001858697,0,2019,0,45
"CD015332","CD015332_pub2_data","3|17|Global state – number of participants with relapse/exacerbations of psychosis (separated time points)|< 6 months","Global state – number of participants with relapse/exacerbations of psychosis (separated time points)",3,17,"< 6 months","or","binary",2,0.705835427019709,0.954320257758503,0,2019,0.0238095238095238,45
"CD015332","CD015332_pub2_data","3|22|Leaving the study early – for any reason – overall acceptability (separated time points)|< 12 months","Leaving the study early – for any reason – overall acceptability (separated time points)",3,22,"< 12 months","or","binary",2,-0.25932557380193,0.799219605901808,0,2019,0.0638095238095238,45
"CD015332","CD015332_pub2_data","3|22|Leaving the study early – for any reason – overall acceptability (separated time points)|< 6 months","Leaving the study early – for any reason – overall acceptability (separated time points)",3,22,"< 6 months","or","binary",3,-0.425126909164181,0.378068404459465,0,2019.33333333333,0.262236652236652,60
"CD015332","CD015332_pub2_data","3|27|Functioning – mean endpoint functioning scales (high = good)|< 12 months","Functioning – mean endpoint functioning scales (high = good)",3,27,"< 12 months","or","binary",3,-0.0916747116259005,1.19630319673804,0,2019.33333333333,0,36.6666666666667
"CD015332","CD015332_pub2_data","3|27|Functioning – mean endpoint functioning scales (high = good)|< 6 months","Functioning – mean endpoint functioning scales (high = good)",3,27,"< 6 months","or","binary",3,-0.0548378514122991,1.18702534676648,0,2019.33333333333,0,39.6666666666667
"CD015332","CD015332_pub2_data","3|3|Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)|< 12 months","Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)",3,3,"< 12 months","or","binary",3,-0.102018915334392,1.17057431756367,0,2019.33333333333,0,41.6666666666667
"CD015332","CD015332_pub2_data","3|3|Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)|< 6 months","Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)",3,3,"< 6 months","or","binary",3,-0.0206558485910035,1.16743516736734,0,2019.33333333333,0,47.6666666666667
"CD015332","CD015332_pub2_data","3|31|Quality of life – mean endpoint quality of life scales (high = good)|< 12 months","Quality of life – mean endpoint quality of life scales (high = good)",3,31,"< 12 months","or","binary",3,-0.0842104534332804,1.1804293096338,0,2019.33333333333,0,35.3333333333333
"CD015332","CD015332_pub2_data","3|31|Quality of life – mean endpoint quality of life scales (high = good)|< 6 months","Quality of life – mean endpoint quality of life scales (high = good)",3,31,"< 6 months","or","binary",3,-0.046466240990491,1.17580327797513,0,2019.33333333333,0,38.6666666666667
"CD015332","CD015332_pub2_data","3|32|Behaviour – violent incidents (separated time points)|< 12 months","Behaviour – violent incidents (separated time points)",3,32,"< 12 months","or","binary",2,0.156557458501226,0.907378500785404,0,2019,0.0438095238095238,45
"CD015332","CD015332_pub2_data","3|33|Behaviour – self-injury (separated time points)|< 12 months","Behaviour – self-injury (separated time points)",3,33,"< 12 months","or","binary",2,-1.04417986040985,0.598771138011894,0,2019,0.325714285714286,45
"CD015332","CD015332_pub2_data","3|35|Adverse events – participants with at least 1 adverse event (pooled time points)|","Adverse events – participants with at least 1 adverse event (pooled time points)",3,35,"","or","binary",2,-0.846030572279017,1.07724527107014,1.98584476164803,2020,0.699134199134199,64.5
"CD015332","CD015332_pub2_data","3|37|Adverse events – participants with serious adverse events (separated time points)|< 12 months","Adverse events – participants with serious adverse events (separated time points)",3,37,"< 12 months","or","binary",2,-0.393517008377941,0.50388579026591,0,2019,0.27047619047619,45
"CD015332","CD015332_pub2_data","3|38|Adverse events – deterioration of symptoms (separated time points)|< 12 months","Adverse events – deterioration of symptoms (separated time points)",3,38,"< 12 months","or","binary",2,0.0559615168482822,1.17414769716086,0,2019,0.0238095238095238,45
"CD015332","CD015332_pub2_data","3|38|Adverse events – deterioration of symptoms (separated time points)|< 6 months","Adverse events – deterioration of symptoms (separated time points)",3,38,"< 6 months","or","binary",3,0.0810258217114327,0.55051113169407,0,2019.33333333333,0.062049062049062,60
"CD015332","CD015332_pub2_data","3|4|Mental state – general: number of participants with clinically important change in general mental state (separated time points)|< 12 months","Mental state – general: number of participants with clinically important change in general mental state (separated time points)",3,4,"< 12 months","or","binary",2,-0.231533412913229,0.529341893573386,0,2019,0.191428571428571,45
"CD015332","CD015332_pub2_data","3|4|Mental state – general: number of participants with clinically important change in general mental state (separated time points)|< 6 months","Mental state – general: number of participants with clinically important change in general mental state (separated time points)",3,4,"< 6 months","or","binary",2,-0.548323261901862,0.789023032094194,0.685232795026423,2019,0.259047619047619,45
"CD015332","CD015332_pub2_data","3|40|Adverse events – mean endpoint ANNSERS (high = poor)|< 12 months","Adverse events – mean endpoint ANNSERS (high = poor)",3,40,"< 12 months","or","binary",2,0.247773140064345,1.45349169345312,0,2019,0,24.5
"CD015332","CD015332_pub2_data","3|40|Adverse events – mean endpoint ANNSERS (high = poor)|< 6 months","Adverse events – mean endpoint ANNSERS (high = poor)",3,40,"< 6 months","or","binary",2,0.18689303646448,1.44868854564748,0,2019,0,26
"CD015332","CD015332_pub2_data","3|41|Adverse events – mean endpoint UKU (high = poor)|< 12 months","Adverse events – mean endpoint UKU (high = poor)",3,41,"< 12 months","or","binary",2,0.247773140064345,1.45349169345312,0,2019,0,24.5
"CD015332","CD015332_pub2_data","3|41|Adverse events – mean endpoint UKU (high = poor)|< 6 months","Adverse events – mean endpoint UKU (high = poor)",3,41,"< 6 months","or","binary",3,0.084710451969173,1.17606155322031,0,2019.33333333333,0,40.6666666666667
"CD015332","CD015332_pub2_data","3|5|Mental state – specific: mean endpoint PANSS positive (high = poor)|< 12 m","Mental state – specific: mean endpoint PANSS positive (high = poor)",3,5,"< 12 m","or","binary",2,-0.0240404405362632,1.43774629688628,0,2019,0,31.5
"CD015332","CD015332_pub2_data","3|5|Mental state – specific: mean endpoint PANSS positive (high = poor)|< 6 m","Mental state – specific: mean endpoint PANSS positive (high = poor)",3,5,"< 6 m","or","binary",2,0.0293167887299521,1.43235263774923,0,2019,0,38.5
"CD015332","CD015332_pub2_data","3|7|Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)|< 12 m","Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)",3,7,"< 12 m","or","binary",3,-0.089991279885773,1.17051236346186,0,2019.33333333333,0,42
"CD015332","CD015332_pub2_data","3|7|Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)|< 6 m","Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)",3,7,"< 6 m","or","binary",3,-0.00933340190949272,1.16730637878547,0,2019.33333333333,0,48.6666666666667
"CD015332","CD015332_pub2_data","3|8|Mental state – specific: mean endpoint PANSS negative (high = poor)|< 12 m","Mental state – specific: mean endpoint PANSS negative (high = poor)",3,8,"< 12 m","or","binary",2,-0.0240404405362632,1.43774629688628,0,2019,0,31.5
"CD015332","CD015332_pub2_data","3|8|Mental state – specific: mean endpoint PANSS negative (high = poor)|< 6 m","Mental state – specific: mean endpoint PANSS negative (high = poor)",3,8,"< 6 m","or","binary",2,0.0570254670877409,1.43208484769104,0,2019,0,39
"CD015350","CD015350_pub2_data","1|1|Days to healing|2nd/3rd Generation Fluoroquinolones","Days to healing",1,1,"2nd/3rd Generation Fluoroquinolones","reported","reported",3,0,0.251285710041605,0,2005,0,43
"CD015350","CD015350_pub2_data","1|1|Days to healing|4th Generation Fluoroquinolones","Days to healing",1,1,"4th Generation Fluoroquinolones","reported","reported",2,0,2.63807444500117,0,2008.5,0,86.5
"CD015350","CD015350_pub2_data","1|3|Distance visual acuity|Corrected","Distance visual acuity",1,3,"Corrected","reported","reported",2,0,0.0525502506876697,0,2014.5,0,204.5
"CD015350","CD015350_pub2_data","1|5|Proportion cured or with complete corneal healing|2nd/3rd Generation Fluoroquinolones","Proportion cured or with complete corneal healing",1,5,"2nd/3rd Generation Fluoroquinolones","reported","reported",4,0,0.268079887059698,0,1996.75,0.670994156184848,100.5
"CD015350","CD015350_pub2_data","1|5|Proportion cured or with complete corneal healing|4th Generation Fluoroquinolones","Proportion cured or with complete corneal healing",1,5,"4th Generation Fluoroquinolones","reported","reported",3,0,0.18978457590599,0,2012,0.767582471465967,192.333333333333
"CD015350","CD015350_pub2_data","1|6|Proportion with non-serious or non-severe harms/adverse events|2nd/3rd Generation Fluoroquinolones","Proportion with non-serious or non-severe harms/adverse events",1,6,"2nd/3rd Generation Fluoroquinolones","reported","reported",4,0,0.21693376251514,0,1996.75,0.191817647223545,138.25
"CD015350","CD015350_pub2_data","1|6|Proportion with non-serious or non-severe harms/adverse events|4th Generation Fluoroquinolones","Proportion with non-serious or non-severe harms/adverse events",1,6,"4th Generation Fluoroquinolones","reported","reported",4,0,0.443939764852779,0,2011.5,0.0452070179011927,159.5
"CD015350","CD015350_pub2_data","1|7|Proportion with serious/severe harms/adverse events|","Proportion with serious/severe harms/adverse events",1,7,"","or","binary",5,-0.100734642667041,0.507270440409072,0,2005.8,0.0132414848832759,137
"CD015350","CD015350_pub2_data","2|1|Days to healing|Ciprofloxacin control","Days to healing",2,1,"Ciprofloxacin control","reported","reported",3,0,0.102104159891905,0,2003.66666666667,0,108
"CD015350","CD015350_pub2_data","2|1|Days to healing|Moxifloxacin control","Days to healing",2,1,"Moxifloxacin control","reported","reported",2,0,2.87256243897273,0,2008.5,0,77.5
"CD015350","CD015350_pub2_data","2|4|Proportion cured or with complete ulcer healing|Ciprofloxacin control","Proportion cured or with complete ulcer healing",2,4,"Ciprofloxacin control","reported","reported",3,0,0.289129199601877,0,2004.33333333333,0.781032368154429,126.666666666667
"CD015350","CD015350_pub2_data","2|5|Proportion with non-serious or non-severe harms/adverse events|Moxifloxacin control","Proportion with non-serious or non-severe harms/adverse events",2,5,"Moxifloxacin control","reported","reported",2,0,0.902801451003674,0,2008.5,0.012987012987013,96
"CD015373","CD015373_pub2_data","1|1|Pain intensity (continuous), immediate-term follow-up|","Pain intensity (continuous), immediate-term follow-up",1,1,"","reported","reported",3,-15.7997932613558,8.10992593804674,132.357826431013,2013,NA,57.6666666666667
"CD015373","CD015373_pub2_data","1|10|Adverse events (total): clinical condition subgroup analysis|Peripheral neuropathic pain","Adverse events (total): clinical condition subgroup analysis",1,10,"Peripheral neuropathic pain","reported","reported",2,1.13501629868671,1.14574213510131,0,2016.5,0.166666666666667,10.5
"CD015373","CD015373_pub2_data","1|11|Adverse events (total): duration of administration subgroup analysis|≤1 day","Adverse events (total): duration of administration subgroup analysis",1,11,"≤1 day","reported","reported",3,1.16360556355967,1.14443241058644,0,2017.33333333333,0.121527777777778,40.3333333333333
"CD015373","CD015373_pub2_data","1|12|Psychotomimetic effects|","Psychotomimetic effects",1,12,"","reported","reported",2,5.4672005146962,2.50630004320391,0,2014,0.0833333333333333,80
"CD015373","CD015373_pub2_data","1|15|Nausea|","Nausea",1,15,"","reported","reported",3,3.77962404991629,1.81706522003275,0,2016,0.0555555555555556,58
"CD015373","CD015373_pub2_data","1|18|Headache|","Headache",1,18,"","reported","reported",2,1.10139291812227,0.41907029460943,0,2014.5,0.166666666666667,37
"CD015373","CD015373_pub2_data","1|2|Pain intensity (continuous), immediate-term follow-up: duration of administration subgroup analysis|≤1 day","Pain intensity (continuous), immediate-term follow-up: duration of administration subgroup analysis",1,2,"≤1 day","reported","reported",2,-8.74138042350362,8.31930040037091,64.9361028269816,2015,NA,56.5
"CD015373","CD015373_pub2_data","1|23|Tolerability|","Tolerability",1,23,"","reported","reported",2,3.8167963494605,13.5510056093179,0,2014,0,80
"CD015373","CD015373_pub2_data","1|4|Pain intensity (continuous), short-term follow-up|","Pain intensity (continuous), short-term follow-up",1,4,"","reported","reported",4,-5.31821533119745,5.19977443108423,0,2012.25,NA,28.5
"CD015373","CD015373_pub2_data","1|5|Pain intensity (continuous), short-term follow-up: clinical condition subgroup analysis|Complex regional pain syndrome","Pain intensity (continuous), short-term follow-up: clinical condition subgroup analysis",1,5,"Complex regional pain syndrome","reported","reported",2,-7.68333335733956,5.70165822467611,0,2009,NA,39.5
"CD015373","CD015373_pub2_data","1|6|Pain intensity (continuous), short-term follow-up: duration of administration subgroup analysis|≤1 day","Pain intensity (continuous), short-term follow-up: duration of administration subgroup analysis",1,6,"≤1 day","reported","reported",2,6.36964674728297,12.6748348927092,0,2015.5,NA,17.5
"CD015373","CD015373_pub2_data","1|9|Adverse events (total)|","Adverse events (total)",1,9,"","reported","reported",4,1.38037488237793,1.02055742538531,0,2015.25,0.141145833333333,35
"CD015373","CD015373_pub2_data","10|2|Pain intensity (continuous), short-term follow-up|","Pain intensity (continuous), short-term follow-up",10,2,"","reported","reported",2,-3.47217363068017,6.00942684868097,0,2011.5,NA,41
"CD015373","CD015373_pub2_data","11|1|Pain intensity (continuous), short-term follow up|","Pain intensity (continuous), short-term follow up",11,1,"","reported","reported",2,-0.5505124085044,3.9619359015616,6.2595566859733,2010.5,NA,59
"CD015373","CD015373_pub2_data","2|1|Ketamine versus ketorolac: pain intensity (continuous), immediate-term follow up|","Ketamine versus ketorolac: pain intensity (continuous), immediate-term follow up",2,1,"","or","binary",2,-0.0499819422662112,1.44835816238891,0,2020,0,19.5
"CD015373","CD015373_pub2_data","2|2|Ketamine versus ketorolac: serious adverse events|","Ketamine versus ketorolac: serious adverse events",2,2,"","or","binary",2,-0.0499819422662112,1.44835816238891,0,2020,0,19.5
"CD015373","CD015373_pub2_data","3|1|Pain intensity (continuous), immediate-term follow-up|","Pain intensity (continuous), immediate-term follow-up",3,1,"","reported","reported",2,-2.63959353992113,5.50166798961465,11.3132860123923,2008.5,NA,23
"CD015373","CD015373_pub2_data","3|2|Pain intensity (continuous), short-term follow-up|","Pain intensity (continuous), short-term follow-up",3,2,"","reported","reported",2,-9.80206386288259,7.01626265276379,33.4336605493272,2008.5,NA,20
"CD015373","CD015373_pub2_data","5|2|Pain intensity (continuous), short-term follow-up|","Pain intensity (continuous), short-term follow-up",5,2,"","reported","reported",2,2.81644163526764,8.83044281950045,0,2012,NA,32
"CD015373","CD015373_pub2_data","7|10|Adverse events (total)|","Adverse events (total)",7,10,"","reported","reported",3,1.02274844450853,0.204371762820603,0,2006.66666666667,0.490740740740741,33.3333333333333
"CD015373","CD015373_pub2_data","7|11|Adverse events (total): duration of administration subgroup analysis|>1 month","Adverse events (total): duration of administration subgroup analysis",7,11,">1 month","reported","reported",2,1.24224104534991,0.287967234038884,0,2008.5,0.458333333333333,32
"CD015373","CD015373_pub2_data","7|12|Adverse events (total): medicine dose subgroup analysis|Standard dose","Adverse events (total): medicine dose subgroup analysis",7,12,"Standard dose","reported","reported",2,1.24224104534991,0.287967234038884,0,2008.5,0.458333333333333,32
"CD015373","CD015373_pub2_data","7|13|Sedation|","Sedation",7,13,"","reported","reported",3,0.705351557704396,0.217423784323245,0,2005,0.25,40.3333333333333
"CD015373","CD015373_pub2_data","7|14|Nausea|","Nausea",7,14,"","reported","reported",3,0.394160146360534,0.415848625237713,0,2005,0.125,40.3333333333333
"CD015373","CD015373_pub2_data","7|15|Dizziness|","Dizziness",7,15,"","reported","reported",3,1.31479066500917,0.510477977877703,0,2005,0.194444444444444,40.3333333333333
"CD015373","CD015373_pub2_data","7|16|Headache|","Headache",7,16,"","reported","reported",3,0.960733878484613,0.447027754615849,0,2005,0.184027777777778,40.3333333333333
"CD015373","CD015373_pub2_data","7|18|Disability (Pain Disability Index), short-term follow up|","Disability (Pain Disability Index), short-term follow up",7,18,"","reported","reported",2,-5.06689136510478,10.5430416756204,203.799578794315,2006.5,NA,28
"CD015373","CD015373_pub2_data","7|19|Depressive symptoms, short-term follow up|","Depressive symptoms, short-term follow up",7,19,"","reported","reported",3,-0.817136831826937,0.193064975137939,5.67318462802309e-06,2009,NA,39.6666666666667
"CD015373","CD015373_pub2_data","7|2|Pain intensity (continuous), short-term follow-up|","Pain intensity (continuous), short-term follow-up",7,2,"","reported","reported",6,-8.73182895067315,5.36293632546151,93.7271579747643,2008.33333333333,NA,36.1666666666667
"CD015373","CD015373_pub2_data","7|21|Health-related quality of life, short-term follow up|","Health-related quality of life, short-term follow up",7,21,"","reported","reported",2,0.797583514134441,0.205434940316214,0,2016.5,NA,51.5
"CD015373","CD015373_pub2_data","7|23|Tolerability|","Tolerability",7,23,"","reported","reported",5,0.255032240787478,0.562552706966133,0,2006.8,0.109583333333333,35.6
"CD015373","CD015373_pub2_data","7|3|Pain intensity (continuous), short-term follow-up: clinical condition subgroup analysis|Peripheral neuropathic pain","Pain intensity (continuous), short-term follow-up: clinical condition subgroup analysis",7,3,"Peripheral neuropathic pain","reported","reported",4,0.154091825504739,4.78558958524799,0,2006.5,NA,33.5
"CD015373","CD015373_pub2_data","7|4|Pain intensity (continuous), short-term follow-up: duration of administration subgroup analysis|>1 month","Pain intensity (continuous), short-term follow-up: duration of administration subgroup analysis",7,4,">1 month","reported","reported",5,-10.761058519197,5.93751689735728,98.1327759599131,2009.4,NA,36.2
"CD015373","CD015373_pub2_data","7|5|Pain intensity (continuous), short-term follow-up: medicine dose subgroup analysis|Above standard dose","Pain intensity (continuous), short-term follow-up: medicine dose subgroup analysis",7,5,"Above standard dose","reported","reported",4,-13.0909847300436,6.86598988564943,112.242185325936,2008.25,NA,39.25
"CD015373","CD015373_pub2_data","7|5|Pain intensity (continuous), short-term follow-up: medicine dose subgroup analysis|Standard dose","Pain intensity (continuous), short-term follow-up: medicine dose subgroup analysis",7,5,"Standard dose","reported","reported",2,0.259259270422408,6.4273361964504,0,2008.5,NA,30
"CD015373","CD015373_pub2_data","7|7|Pain intensity (≥ 50% reduction), short-term follow-up|","Pain intensity (≥ 50% reduction), short-term follow-up",7,7,"","reported","reported",2,1.36811003192764,0.435010138284706,0,2006.5,0.416666666666667,28
"CD015373","CD015373_pub2_data","7|8|Pain intensity (continuous), medium-term follow-up|","Pain intensity (continuous), medium-term follow-up",7,8,"","reported","reported",2,-1.74360404739932,21.1437292487596,819.334136580456,2010,NA,50.5
"CD015373","CD015373_pub2_data","8|4|Tolerability|","Tolerability",8,4,"","reported","reported",3,1.03149834864455,1.47264630333229,0,2007.66666666667,0.0666666666666667,24.6666666666667
"CD015383","CD015383_pub2_data","1|1|Anxiety on STAI-T (scale 20 to 80)|LSD versus placebo","Anxiety on STAI-T (scale 20 to 80)",1,1,"LSD versus placebo","reported","reported",2,-11.3351035192622,4.38689655213313,0,2018,0,15.5
"CD015383","CD015383_pub2_data","1|1|Anxiety on STAI-T (scale 20 to 80)|Psilocybin versus placebo","Anxiety on STAI-T (scale 20 to 80)",1,1,"Psilocybin versus placebo","reported","reported",3,-7.29381022501842,2.70772784479428,0,2014.33333333333,0,30.3333333333333
"CD015383","CD015383_pub2_data","1|2|Anxiety on STAI-S (scale 20 to 80)|LSD versus placebo","Anxiety on STAI-S (scale 20 to 80)",1,2,"LSD versus placebo","reported","reported",2,-11.8898393274235,4.86901741388232,4.58137695510148,2018,0,15.5
"CD015383","CD015383_pub2_data","1|2|Anxiety on STAI-S (scale 20 to 80)|Psilocybin versus placebo","Anxiety on STAI-S (scale 20 to 80)",1,2,"Psilocybin versus placebo","reported","reported",3,-7.84755837262263,2.91418705200409,0,2014.33333333333,0,30.3333333333333
"CD015383","CD015383_pub2_data","1|3|Depression on BDI (scale 0 to 63)|Psilocybin versus placebo","Depression on BDI (scale 0 to 63)",1,3,"Psilocybin versus placebo","reported","reported",3,-4.83456520003875,2.16199693767626,0,2014.33333333333,0,30.3333333333333
"CD015383","CD015383_pub2_data","1|4|Depression on different scales (BDI, HADS-D), SMD|LSD versus placebo","Depression on different scales (BDI, HADS-D), SMD",1,4,"LSD versus placebo","reported","reported",2,-0.341878271686709,0.37653084278703,0,2018,0,15.5
"CD015383","CD015383_pub2_data","1|4|Depression on different scales (BDI, HADS-D), SMD|Psilocybin versus placebo","Depression on different scales (BDI, HADS-D), SMD",1,4,"Psilocybin versus placebo","reported","reported",3,-0.455635515095114,0.212809386390274,0,2014.33333333333,0,30.3333333333333
"CD015387","CD015387_pub2_data","1|1|Good functional outcome at the end of scheduled follow-up|","Good functional outcome at the end of scheduled follow-up",1,1,"","reported","reported",17,1.22264581492755,0.0774037346360274,0.030678403221473,2005.41176470588,0.291139357306938,237.294117647059
"CD015387","CD015387_pub2_data","1|2|Good functional outcome at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only|","Good functional outcome at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only",1,2,"","reported","reported",4,1.09299493870991,0.0512964527194038,0,2015.25,0.42536971346497,576.5
"CD015387","CD015387_pub2_data","1|3|All-cause mortality at the end of scheduled follow-up|","All-cause mortality at the end of scheduled follow-up",1,3,"","reported","reported",21,0.733904540295168,0.0512407201305547,0.0136217017568936,2007.33333333333,0.382191069644851,200.761904761905
"CD015387","CD015387_pub2_data","1|4|All-cause mortality at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only|","All-cause mortality at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only",1,4,"","reported","reported",5,0.863250107274701,0.0648777425516561,0.00318526867136896,2015.4,0.279083080978353,489.4
"CD015387","CD015387_pub2_data","1|5|Thirty-day case fatality|","Thirty-day case fatality",1,5,"","reported","reported",10,0.691017719105315,0.0829994062325069,0.0176168433776733,2009.1,0.198209167972993,311.7
"CD015387","CD015387_pub2_data","1|6|Health-related quality of life at the end of scheduled follow-up|","Health-related quality of life at the end of scheduled follow-up",1,6,"","reported","reported",2,0.0306206527054343,0.0394854045664418,0,2008,NA,236
"CD015387","CD015387_pub2_data","2|1|Good functional outcome at the end of scheduled follow-up|","Good functional outcome at the end of scheduled follow-up",2,1,"","reported","reported",6,0.947294493463076,0.33423610505047,0.192733440525767,2002.16666666667,0.201213752123377,142.166666666667
"CD015387","CD015387_pub2_data","2|3|All-cause mortality at the end of scheduled follow-up|","All-cause mortality at the end of scheduled follow-up",2,3,"","reported","reported",5,0.780350592255555,0.0731383992831957,0,2004.6,0.46114817060845,169
"CD015387","CD015387_pub2_data","2|5|Thirty-day case fatality|","Thirty-day case fatality",2,5,"","reported","reported",3,0.636293091435076,0.130447650686409,0,2000,0.26348928269284,225.333333333333
"CD015387","CD015387_pub2_data","3|1|Good functional outcome at the end of scheduled follow-up|","Good functional outcome at the end of scheduled follow-up",3,1,"","reported","reported",9,1.32918913319555,0.100691987612103,0.0353173751243366,2008.33333333333,0.335310495570712,245.444444444444
"CD015387","CD015387_pub2_data","3|2|Good functional outcome at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only|","Good functional outcome at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only",3,2,"","reported","reported",2,1.11399626259613,0.0918690383027971,0,2021.5,0.413369304556355,387.5
"CD015387","CD015387_pub2_data","3|3|Good functional outcome at the end of scheduled follow-up: stratified by surgical approach|Non-visualised minimally invasive surgery","Good functional outcome at the end of scheduled follow-up: stratified by surgical approach",3,3,"Non-visualised minimally invasive surgery","reported","reported",6,1.34768639075899,0.127733824663355,0.0517087685628534,2007.66666666667,0.378480068737868,286.5
"CD015387","CD015387_pub2_data","3|4|All-cause mortality at the end of scheduled follow-up|","All-cause mortality at the end of scheduled follow-up",3,4,"","reported","reported",13,0.640110740465512,0.0592036485083022,0.00332090526280175,2008.46153846154,0.328714377771521,179.923076923077
"CD015387","CD015387_pub2_data","3|5|All-cause mortality at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only|","All-cause mortality at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only",3,5,"","reported","reported",3,0.793866460543634,0.102659067278477,0,2019.66666666667,0.261348192362445,292
"CD015387","CD015387_pub2_data","3|6|All-cause mortality at the end of scheduled follow-up: stratified by surgical approach|Endoscopic evacuation","All-cause mortality at the end of scheduled follow-up: stratified by surgical approach",3,6,"Endoscopic evacuation","reported","reported",3,0.590829356892374,0.113488391336267,0,2004.33333333333,0.511111111111111,42.6666666666667
"CD015387","CD015387_pub2_data","3|6|All-cause mortality at the end of scheduled follow-up: stratified by surgical approach|Non-visualised minimally invasive surgery","All-cause mortality at the end of scheduled follow-up: stratified by surgical approach",3,6,"Non-visualised minimally invasive surgery","reported","reported",9,0.638802183098635,0.0870646354039857,0.0172541994807,2008.11111111111,0.27646166850504,213.888888888889
"CD015387","CD015387_pub2_data","3|7|Thirty-day case fatality|","Thirty-day case fatality",3,7,"","reported","reported",6,0.582488304676848,0.0861142562247478,0,2014.33333333333,0.15635974751946,243.166666666667
"CD015387","CD015387_pub2_data","3|8|Thirty-day case fatality: stratified by surgical approach|Non-visualised minimally invasive surgery","Thirty-day case fatality: stratified by surgical approach",3,8,"Non-visualised minimally invasive surgery","reported","reported",4,0.580592959196534,0.0976837918783643,0,2011.5,0.189237607856371,285
"CD015432","CD015432_pub2_data","1|1|Pain intensity – as reported by the child, less than 2 hours postintervention|NA","Pain intensity – as reported by the child, less than 2 hours postintervention",1,1,NA,"or","binary",3,-0.00819180180820223,1.16372725387317,0,2016.33333333333,0,86.3333333333333
"CD015432","CD015432_pub2_data","1|10|Opioid consumption, 2 hours to less than 24 hours postintervention|NA","Opioid consumption, 2 hours to less than 24 hours postintervention",1,10,NA,"or","binary",3,0.106246483472399,1.16523128354187,0,1992.66666666667,0,69.6666666666667
"CD015432","CD015432_pub2_data","1|11|Opioid consumption, from 24 hours up to 7 days postintervention|NA","Opioid consumption, from 24 hours up to 7 days postintervention",1,11,NA,"or","binary",2,0.147546678913838,1.42927524331074,0,1992,0,64
"CD015432","CD015432_pub2_data","1|12|Time to rescue medication, as reported by a third party, e.g. parents and caregivers|NA","Time to rescue medication, as reported by a third party, e.g. parents and caregivers",1,12,NA,"or","binary",4,-0.0281283531723174,1.00715036039302,0,2015,0,87
"CD015432","CD015432_pub2_data","1|13|Nausea or vomiting |NA","Nausea or vomiting ",1,13,NA,"or","binary",10,-0.105079447056831,0.213237403029736,0,2008.7,0.142266579768786,77.5
"CD015432","CD015432_pub2_data","1|14|Any bleeding, including gastrointestinal bleeding and oral bleeding|NA","Any bleeding, including gastrointestinal bleeding and oral bleeding",1,14,NA,"or","binary",9,-0.0877017657790196,0.290240037368886,0,2010.33333333333,0.0671282711077015,88.5555555555556
"CD015432","CD015432_pub2_data","1|2|Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention|NA","Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention",1,2,NA,"or","binary",5,-0.00446926187445839,0.902968994649709,0,2016,0,69
"CD015432","CD015432_pub2_data","1|3|Pain intensity – as reported by the child, from 24 hours up to 7 days postintervention|NA","Pain intensity – as reported by the child, from 24 hours up to 7 days postintervention",1,3,NA,"or","binary",4,0.00380584441573078,1.01118649235459,0,2016.5,0,46
"CD015432","CD015432_pub2_data","1|5|Pain intensity – as reported by a third party, e.g. parents and caregivers, less than 2 hours postintervention|NA","Pain intensity – as reported by a third party, e.g. parents and caregivers, less than 2 hours postintervention",1,5,NA,"or","binary",3,0.0169080816702385,1.16802276059291,0,2013.33333333333,0,56
"CD015432","CD015432_pub2_data","1|6|Number of children who required rescue medication less than 2 hours postintervention|NA","Number of children who required rescue medication less than 2 hours postintervention",1,6,NA,"or","binary",10,-0.497559769870375,0.197258209427697,0,2008.4,0.382039097330237,71.8
"CD015432","CD015432_pub2_data","1|7|Number of children who required rescue medication 2 hours to less than 24 hours postintervention|NA","Number of children who required rescue medication 2 hours to less than 24 hours postintervention",1,7,NA,"or","binary",12,-0.245417751345148,0.415030207102992,1.098173789627,2004.75,0.335147666562555,57.3333333333333
"CD015432","CD015432_pub2_data","1|8|Number of children who required rescue medication, from 24 hours up to 7 days|NA","Number of children who required rescue medication, from 24 hours up to 7 days",1,8,NA,"or","binary",6,-0.639768087394192,0.316957916604276,0,2000,0.241477272727273,54.3333333333333
"CD015432","CD015432_pub2_data","1|9|Opioid consumption, less than 2 hours postintervention|NA","Opioid consumption, less than 2 hours postintervention",1,9,NA,"or","binary",7,0.0264961840393992,0.761718180793418,0,2005.42857142857,0,84.2857142857143
"CD015432","CD015432_pub2_data","2|1|Pain intensity – as reported by the child, less than 2 hours postintervention|NA","Pain intensity – as reported by the child, less than 2 hours postintervention",2,1,NA,"or","binary",2,0.0237380303715085,1.42868616512755,0,2017.5,0,50
"CD015432","CD015432_pub2_data","2|10|Number of children who required rescue medication, from 24 hours up to 7 days|NA","Number of children who required rescue medication, from 24 hours up to 7 days",2,10,NA,"or","binary",4,-0.0334179956732096,0.483662629938159,0,2012,0.0408163265306122,58
"CD015432","CD015432_pub2_data","2|13|Nausea or vomiting|NA","Nausea or vomiting",2,13,NA,"or","binary",3,-0.623854588599848,0.505110802826184,0,2006.66666666667,0.175,47.3333333333333
"CD015432","CD015432_pub2_data","2|14|Any bleeding, including gastrointestinal bleeding and oral bleeding|NA","Any bleeding, including gastrointestinal bleeding and oral bleeding",2,14,NA,"or","binary",5,0.295753073733438,0.213065242258338,0,2012.2,0.105018761726079,200
"CD015432","CD015432_pub2_data","2|2|Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention|NA","Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention",2,2,NA,"or","binary",6,0.0377674260242229,0.824241552593783,0,2013.66666666667,0,70.3333333333333
"CD015432","CD015432_pub2_data","2|3|Pain intensity – as reported by the child, from 24 hours up to 7 days|NA","Pain intensity – as reported by the child, from 24 hours up to 7 days",2,3,NA,"or","binary",6,0.0429345214051171,0.824306297335101,0,2013.66666666667,0,65.6666666666667
"CD015432","CD015432_pub2_data","2|5|Pain intensity – as reported by a third party, e.g. parents and caregivers, less than 2 hours postintervention|NA","Pain intensity – as reported by a third party, e.g. parents and caregivers, less than 2 hours postintervention",2,5,NA,"or","binary",3,0.06875879840272,1.16776924372963,0,2005.66666666667,0,56.6666666666667
"CD015432","CD015432_pub2_data","2|6|Pain intensity – as reported by a third party, e.g. parents and caregivers, 2 hours to less than 24 hours|NA","Pain intensity – as reported by a third party, e.g. parents and caregivers, 2 hours to less than 24 hours",2,6,NA,"or","binary",2,-0.07491047762946,1.42968181436841,0,2017.5,0,45.5
"CD015432","CD015432_pub2_data","2|8|Number of children who required rescue medication less than 2 hours postintervention|NA","Number of children who required rescue medication less than 2 hours postintervention",2,8,NA,"or","binary",4,-0.118135029683376,0.491864813752779,0,2004.25,0.0988520408163265,65.75
"CD015432","CD015432_pub2_data","2|9|Number of children who required rescue medication 2 hours to less than 24 hours postintervention|NA","Number of children who required rescue medication 2 hours to less than 24 hours postintervention",2,9,NA,"or","binary",10,-0.0856614720603026,0.243131944255212,0.0734163519954217,2008.6,0.218986237144586,67.8
"CD015432","CD015432_pub2_data","7|2|Number of children who required rescue medication 2 hours to less than 24 hours postintervention|NA","Number of children who required rescue medication 2 hours to less than 24 hours postintervention",7,2,NA,"or","binary",2,0,1.42895456483594,0,1999.5,0,48
"CD015432","CD015432_pub2_data","7|3|Number of children who required rescue medication from 24 hours to 7 days postintervention|NA","Number of children who required rescue medication from 24 hours to 7 days postintervention",7,3,NA,"or","binary",2,0,1.42895456483594,0,1999.5,0,48
"CD015443","CD015443_pub2_data","1|2|Relapse (24 months)|Immunoglobulins versus placebo/no treatment","Relapse (24 months)",1,2,"Immunoglobulins versus placebo/no treatment","or","binary",2,-0.0662871055888519,0.175420607607835,0,2005.5,0.413180202351654,274.5
"CD015443","CD015443_pub2_data","1|3|Relapse (36 months)|Interferon beta 1b (Betaferon) versus placebo/no treatment","Relapse (36 months)",1,3,"Interferon beta 1b (Betaferon) versus placebo/no treatment","or","binary",2,-0.33503658051799,0.104371050254005,0,2001,0.453674816803308,828.5
"CD015443","CD015443_pub2_data","1|4|Disability worsening (24 months)|Glatiramer acetate versus placebo/no treatment","Disability worsening (24 months)",1,4,"Glatiramer acetate versus placebo/no treatment","or","binary",2,-0.250698177787489,0.133539570594095,0,1999,0.353538550057537,524.5
"CD015443","CD015443_pub2_data","1|4|Disability worsening (24 months)|Immunoglobulins versus placebo/no treatment","Disability worsening (24 months)",1,4,"Immunoglobulins versus placebo/no treatment","or","binary",2,-0.187906752646892,0.377420030315844,0.22456882248814,2005.5,0.533169264424392,274.5
"CD015443","CD015443_pub2_data","1|5|Disability worsening (36 months)|Interferon Beta 1b (Betaferon) versus placebo/no treatment","Disability worsening (36 months)",1,5,"Interferon Beta 1b (Betaferon) versus placebo/no treatment","or","binary",2,-0.191336948450602,0.246706731885839,0.0996779601271623,2001,0.419057897409853,828.5
"CD015443","CD015443_pub2_data","2|1|Serious adverse events|Immunoglobulins versus placebo/no treatment","Serious adverse events",2,1,"Immunoglobulins versus placebo/no treatment","or","binary",2,1.6950308346654,0.779333076743855,0,2005.5,0.00314465408805031,274.5
"CD015443","CD015443_pub2_data","2|1|Serious adverse events|Rituximab versus placebo/no treatment","Serious adverse events",2,1,"Rituximab versus placebo/no treatment","or","binary",2,-0.119431486476208,0.529188572767298,0.307259823210327,2012.5,0.290249433106576,233
"CD015443","CD015443_pub2_data","2|2|Discontinuations due to adverse events|Immunoglobulins versus placebo / no treatements","Discontinuations due to adverse events",2,2,"Immunoglobulins versus placebo / no treatements","or","binary",2,0.637118464543428,0.336241501185341,0,2005.5,0.0548537052228603,274.5
"CD015443","CD015443_pub2_data","2|2|Discontinuations due to adverse events|Interferon Beta 1b versus placebo / no treatment","Discontinuations due to adverse events",2,2,"Interferon Beta 1b versus placebo / no treatment","or","binary",2,1.06384364618233,0.219844160981107,0,2001,0.0404302401509105,828.5
"CD015443","CD015443_pub2_data","2|2|Discontinuations due to adverse events|Rituximab versus placebo / no treatment ","Discontinuations due to adverse events",2,2,"Rituximab versus placebo / no treatment ","reported","reported",2,0,1.10176569150572,0,2012.5,0,235
"CD015443","CD015443_pub2_data","3|10|Mortality|Interferon beta-1a versus placebo/no treatment","Mortality",3,10,"Interferon beta-1a versus placebo/no treatment","or","binary",3,0.296980549419446,0.609676557987691,0,2002.33333333333,0.00526900350970723,475
"CD015443","CD015443_pub2_data","3|10|Mortality|Interferon beta-1b versus placebo/no treatment ","Mortality",3,10,"Interferon beta-1b versus placebo/no treatment ","or","binary",3,0.665134602419419,0.607429429879594,3.47202765946561e-06,2003.66666666667,0.0110223587877219,577
"CD015448","CD015448_pub2_data","1|1|Mean change from baseline in symptom scores at 4 weeks|SPEED; eye-level","Mean change from baseline in symptom scores at 4 weeks",1,1,"SPEED; eye-level","reported","reported",2,-0.120268380615969,0.0459909215244866,0,2020.5,0,78
"CD015448","CD015448_pub2_data","1|1|Mean change from baseline in symptom scores at 4 weeks|SPEED; participant-level","Mean change from baseline in symptom scores at 4 weeks",1,1,"SPEED; participant-level","reported","reported",2,-2.11739745762712,1.00852274395686,1.132942,2017.5,0,38
"CD015448","CD015448_pub2_data","1|3|Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD|Eye-level","Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD",1,3,"Eye-level","reported","reported",3,0,0.128057530388941,0,2019.66666666667,0,82
"CD015448","CD015448_pub2_data","1|3|Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD|Participant-level","Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD",1,3,"Participant-level","reported","reported",2,0,0.253674716018315,0,2017.5,0,38
"CD015448","CD015448_pub2_data","1|6|Mean change from baseline in tear film breakup time at 4 weeks—SMD|Eye-level","Mean change from baseline in tear film breakup time at 4 weeks—SMD",1,6,"Eye-level","reported","reported",2,0,0.28076847635605,0,2020,0,95
"CD015448","CD015448_pub2_data","2|1|Mean change from baseline in symptom scores at 4 weeks|OSDI","Mean change from baseline in symptom scores at 4 weeks",2,1,"OSDI","reported","reported",4,0,0.168163643595329,0,2021.5,0,138.25
"CD015448","CD015448_pub2_data","2|1|Mean change from baseline in symptom scores at 4 weeks|SANDE","Mean change from baseline in symptom scores at 4 weeks",2,1,"SANDE","reported","reported",2,0,2.26731144481686,0,2022,0,185
"CD015448","CD015448_pub2_data","2|3|Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD|","Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD",2,3,"","reported","reported",3,0,0.069854711359401,0,2021.33333333333,0,273.333333333333
"CD015448","CD015448_pub2_data","2|4|Mean change from baseline in meibum quality scores at 4 weeks—SMD|","Mean change from baseline in meibum quality scores at 4 weeks—SMD",2,4,"","reported","reported",2,0,0.631828393103628,0,2022,0,177
"CD015448","CD015448_pub2_data","2|6|Mean change from baseline in tear film breakup time at 4 weeks—SMD|","Mean change from baseline in tear film breakup time at 4 weeks—SMD",2,6,"","reported","reported",2,0,0.150474497033304,0,2021,0,276
"CD015448","CD015448_pub2_data","2|7|Mean change from baseline in non-invasive tear film breakup time at 4 weeks—SMD|","Mean change from baseline in non-invasive tear film breakup time at 4 weeks—SMD",2,7,"","reported","reported",2,0,0.639933080700591,0,2022,0,269
"CD015462","CD015462_pub2_data","1|1|All-cause mortality prior to hospital discharge|NA","All-cause mortality prior to hospital discharge",1,1,NA,"or","binary",2,0.129534689145839,0.294340067886672,0,2017,0.137820512820513,198
"CD015462","CD015462_pub2_data","1|10|Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week|NA","Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week",1,10,NA,"or","binary",5,0.0229259520133316,0.908018059409554,0,2003.2,0,49.2
"CD015462","CD015462_pub2_data","1|13|Number of days of supplemental oxygen|NA","Number of days of supplemental oxygen",1,13,NA,"or","binary",2,-0.040024581284446,1.42555472116196,0,2016,0,82.5
"CD015462","CD015462_pub2_data","1|16|Necrotizing enterocolitis (proven = Bell stage 2 or greater)|NA","Necrotizing enterocolitis (proven = Bell stage 2 or greater)",1,16,NA,"or","binary",2,-1.28044372991501,0.594551036375704,0,2002,0.164102564102564,88
"CD015462","CD015462_pub2_data","1|17|Patent ductus arteriosus (PDA) requiring treatment (cyclo-oxygenase inhibitors or surgical ligation)|NA","Patent ductus arteriosus (PDA) requiring treatment (cyclo-oxygenase inhibitors or surgical ligation)",1,17,NA,"or","binary",2,-0.274648761055776,0.333164233805465,0,2017,0.144871794871795,198
"CD015462","CD015462_pub2_data","1|18|Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater])|NA","Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater])",1,18,NA,"or","binary",2,-0.071886453134465,0.985740908009549,0.97786434730541,2019,0.0356410256410256,178
"CD015462","CD015462_pub2_data","1|5|Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age|NA","Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age",1,5,NA,"or","binary",3,0.541789252131299,0.34512252635519,4.97971088548113e-06,2018,0.123333333333333,160.333333333333
"CD015462","CD015462_pub2_data","1|7|Failure to extubate within one week of commencing treatment|NA","Failure to extubate within one week of commencing treatment",1,7,NA,"or","binary",2,-0.275837095478887,0.955650454603419,0,1992,0.166666666666667,29.5
"CD015462","CD015462_pub2_data","1|8|Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea|NA","Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea",1,8,NA,"or","binary",4,0.568598212397867,0.698811733346414,0,1988.25,0.0357142857142857,21
"CD015462","CD015462_pub2_data","1|9|Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24-hour period|NA","Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24-hour period",1,9,NA,"or","binary",4,0.0287010828843169,1.01596778701176,0,2000,0,51.5
"CD015476","CD015476_pub2_data","2|1|Polyp detection rate|","Polyp detection rate",2,1,"","or","binary",12,0.32999949661924,0.0515119399237379,0.00631832230136189,2021,0.50932139521713,936.916666666667
"CD015476","CD015476_pub2_data","2|2|Sessile serrated lesion detection rate|","Sessile serrated lesion detection rate",2,2,"","reported","reported",2,0,0.259333133042541,0,2022.5,0.0642290933907292,608
"CD015476","CD015476_pub2_data","2|4|Number of polyps per participant|","Number of polyps per participant",2,4,"","or","binary",7,0.0473164500545785,0.756550678290084,0,2021.42857142857,0,1027.85714285714
"CD015476","CD015476_pub2_data","2|5|Number of flat polyps per participant|","Number of flat polyps per participant",2,5,"","or","binary",4,0.0135370663472317,1.00112092123639,0,2021.5,0,541.75
"CD015476","CD015476_pub2_data","3|1|Adenoma detection rate between LASEREO and ELUXEO|ELUXEO","Adenoma detection rate between LASEREO and ELUXEO",3,1,"ELUXEO","reported","reported",3,0,0.0403886375873211,0,2020.33333333333,0.393709183020751,809
"CD015476","CD015476_pub2_data","3|1|Adenoma detection rate between LASEREO and ELUXEO|LASEREO","Adenoma detection rate between LASEREO and ELUXEO",3,1,"LASEREO","reported","reported",6,0,0.0332729480937917,0,2021.16666666667,0.479919874353927,497.5
"CD015476","CD015476_pub2_data","3|11|Polyp detection rate excluding studies that included patients with Lynch syndrome|","Polyp detection rate excluding studies that included patients with Lynch syndrome",3,11,"","or","binary",11,0.328779206121928,0.054583340838776,0.0079166731952877,2020.90909090909,0.522853784211499,991.909090909091
"CD015476","CD015476_pub2_data","3|13|Number of adenomas per participant excluding studies that included patients with Lynch syndrome|","Number of adenomas per participant excluding studies that included patients with Lynch syndrome",3,13,"","or","binary",10,0.359103258076104,0.633137259848089,0,2021.4,0,1050.1
"CD015476","CD015476_pub2_data","3|14|Number of polyps per participant excluding studies that included patients with Lynch syndrome|","Number of polyps per participant excluding studies that included patients with Lynch syndrome",3,14,"","or","binary",6,0.0431918491887246,0.81707572240328,0,2021.33333333333,0,1143.83333333333
"CD015476","CD015476_pub2_data","3|15|Number of flat polyps per participant excluding studies that included patients with Lynch syndrome|","Number of flat polyps per participant excluding studies that included patients with Lynch syndrome",3,15,"","or","binary",3,-0.00596519262537414,1.15584817598369,0,2021.33333333333,0,611.666666666667
"CD015476","CD015476_pub2_data","3|2|Adenoma detection rate between pre-2020 and post-2020|Post-2020","Adenoma detection rate between pre-2020 and post-2020",3,2,"Post-2020","reported","reported",10,0,0.0224098155209176,0,2022,0.419404921124477,969.1
"CD015476","CD015476_pub2_data","3|2|Adenoma detection rate between pre-2020 and post-2020|Pre-2020","Adenoma detection rate between pre-2020 and post-2020",3,2,"Pre-2020","reported","reported",5,0,0.0379611844336185,0,2019.2,0.328593651405371,637.2
"CD015476","CD015476_pub2_data","3|3|Adenoma detection rate between lesions <10 mm and ≥10 mm|lesions <10 mm","Adenoma detection rate between lesions <10 mm and ≥10 mm",3,3,"lesions <10 mm","reported","reported",3,0,0.0688651950608728,0,2021.33333333333,0.334851211072664,581
"CD015476","CD015476_pub2_data","3|3|Adenoma detection rate between lesions <10 mm and ≥10 mm|lesions ≥10 mm","Adenoma detection rate between lesions <10 mm and ≥10 mm",3,3,"lesions ≥10 mm","reported","reported",3,0,0.107340098362556,0,2021.33333333333,0.133688095671705,581
"CD015476","CD015476_pub2_data","3|4|Adenoma detection rate between Western countries and Asia|Asia","Adenoma detection rate between Western countries and Asia",3,4,"Asia","reported","reported",10,0,0.0221033612564402,0,2021.3,0.391550453714957,1022.4
"CD015476","CD015476_pub2_data","3|4|Adenoma detection rate between Western countries and Asia|Western countries","Adenoma detection rate between Western countries and Asia",3,4,"Western countries","reported","reported",3,0,0.0437044342152315,0,2020.66666666667,0.320313834183541,753
"CD015476","CD015476_pub2_data","3|5|Adenoma detection rate between experienced colonoscopists and trainees|Experienced colonoscopists","Adenoma detection rate between experienced colonoscopists and trainees",3,5,"Experienced colonoscopists","reported","reported",6,0,0.0352794386942871,0,2021,0.401049156019219,576.833333333333
"CD015476","CD015476_pub2_data","3|6|Adenoma detection rate excluding studies with a high overall risk of bias|","Adenoma detection rate excluding studies with a high overall risk of bias",3,6,"","or","binary",12,0.421169315284649,0.078257970960823,0.0367596339429882,2021.33333333333,0.342719041010482,911.333333333333
"CD015476","CD015476_pub2_data","3|7|Polyp detection rate excluding studies with a high overall risk of bias|","Polyp detection rate excluding studies with a high overall risk of bias",3,7,"","or","binary",9,0.391364350719161,0.0471848662102513,0,2021.33333333333,0.466467348471887,1053.77777777778
"CD015476","CD015476_pub2_data","3|9|Number of polyps per participant excluding studies with a high overall risk of bias|","Number of polyps per participant excluding studies with a high overall risk of bias",3,9,"","or","binary",6,0.0542532702287175,0.817183026475829,0,2021.5,0,1082.5
"CD015495_data","CD015495_data","1|1|Overall survival (hazard ratio) in people aged 65 years and older, at any time point|NA","Overall survival (hazard ratio) in people aged 65 years and older, at any time point",1,1,NA,"reported","reported",8,-0.244848443016785,0.058030237523377,0,2020,0,261.625
"CD015495_data","CD015495_data","1|2|Overall survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point|NA","Overall survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point",1,2,NA,"reported","reported",6,-0.283171858895753,0.0720348448019582,0,2019.66666666667,0,234.333333333333
"CD015495_data","CD015495_data","1|3|Overall survival (hazard ratio) in people aged 75 years and older, at any time point|NA","Overall survival (hazard ratio) in people aged 75 years and older, at any time point",1,3,NA,"reported","reported",4,-0.106235138404226,0.128790407321487,0,2019,0,74.25
"CD015495_data","CD015495_data","3|1|Progression-free survival (hazard ratio) in people aged 65 years and older, at any time point|NA","Progression-free survival (hazard ratio) in people aged 65 years and older, at any time point",3,1,NA,"reported","reported",7,-0.494856519985502,0.0590799133895092,0,2019.85714285714,0,269.285714285714
"CD015495_data","CD015495_data","3|2|Progression-free survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point|NA","Progression-free survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point",3,2,NA,"reported","reported",8,-0.445575153180418,0.0641097687112597,0.000229586471695586,2020.375,0,183.25
"CD015495_data","CD015495_data","3|3|Progression-free survival (hazard ratio) in people aged 75 years and older, at any time point|NA","Progression-free survival (hazard ratio) in people aged 75 years and older, at any time point",3,3,NA,"reported","reported",3,-0.184409760974737,0.250022100351711,0.113908635654588,2019.66666666667,0,75.3333333333333
"CD015514","CD015514_pub2_data","1|2|Proportion of eyes with retinal displacement within 3 months|","Proportion of eyes with retinal displacement within 3 months",1,2,"","reported","reported",2,0,0.142971209376659,0,2019.5,0.383333333333333,144.5
"CD015517_data","CD015517_data","1|1|CRF at 12 weeks or less after the intervention|","CRF at 12 weeks or less after the intervention",1,1,"","reported","reported",5,0,0.142008602560104,0,2012.6,0,92.6
"CD015517_data","CD015517_data","1|3|CRF at 6 months or greater after the intervention|","CRF at 6 months or greater after the intervention",1,3,"","reported","reported",2,0,0.215694328579462,0,2013,0,115
"CD015517_data","CD015517_data","1|4|QoL at 12 weeks or less after the intervention|","QoL at 12 weeks or less after the intervention",1,4,"","reported","reported",6,0,0.241950648487265,0,2012.5,0,102
"CD015517_data","CD015517_data","1|6|QoL at 6 months or greater after the intervention|","QoL at 6 months or greater after the intervention",1,6,"","reported","reported",2,0,0.478124583033405,0,2013,0,115
"CD015517_data","CD015517_data","10|1|CRF ≤ 12 weeks after the intervention|Breast","CRF ≤ 12 weeks after the intervention",10,1,"Breast","reported","reported",2,0,0.126281465398702,0,2009,0,126.5
"CD015517_data","CD015517_data","10|1|CRF ≤ 12 weeks after the intervention|Testicular","CRF ≤ 12 weeks after the intervention",10,1,"Testicular","reported","reported",2,0,0.200717944053945,0,2015.5,0,56.5
"CD015517_data","CD015517_data","10|2|QoL ≤ 12 weeks after the intervention |Breast","QoL ≤ 12 weeks after the intervention ",10,2,"Breast","reported","reported",4,0,0.10598544678734,0,2010.75,0,93
"CD015517_data","CD015517_data","10|2|QoL ≤ 12 weeks after the intervention |Mixed","QoL ≤ 12 weeks after the intervention ",10,2,"Mixed","reported","reported",2,0,0.193479607710549,0,2008.5,0,53.5
"CD015517_data","CD015517_data","10|3|Anxiety ≤ 12 weeks after the intervention|Breast","Anxiety ≤ 12 weeks after the intervention",10,3,"Breast","reported","reported",2,0,0.125018463807061,0,2013,0,129.5
"CD015517_data","CD015517_data","10|4|Depression ≤ 12 weeks after the intervention|Breast","Depression ≤ 12 weeks after the intervention",10,4,"Breast","reported","reported",2,0,0.125106887544565,0,2013,0,129.5
"CD015517_data","CD015517_data","11|1|CRF ≤ 12 weeks after the intervention|Individual training","CRF ≤ 12 weeks after the intervention",11,1,"Individual training","reported","reported",4,0,0.102031095141861,0,2009.75,0,99.5
"CD015517_data","CD015517_data","11|3|QoL ≤ 12 weeks after the intervention |Group training","QoL ≤ 12 weeks after the intervention ",11,3,"Group training","reported","reported",2,0,0.193628886632728,0,2012.5,0,59.5
"CD015517_data","CD015517_data","11|3|QoL ≤ 12 weeks after the intervention |Individual training","QoL ≤ 12 weeks after the intervention ",11,3,"Individual training","reported","reported",5,0,0.0940626533685025,0,2008.6,0,93.4
"CD015517_data","CD015517_data","11|4|Anxiety ≤ 12 weeks after the intervention|Individual training","Anxiety ≤ 12 weeks after the intervention",11,4,"Individual training","reported","reported",3,0,0.109492115876462,0,2012,0,115.333333333333
"CD015517_data","CD015517_data","11|5|Depression ≤ 12 weeks after the intervention|Individual training","Depression ≤ 12 weeks after the intervention",11,5,"Individual training","reported","reported",3,0,0.10956631426212,0,2012,0,115.333333333333
"CD015517_data","CD015517_data","12|1|CRF ≤ 12 weeks after the intervention|Mixed","CRF ≤ 12 weeks after the intervention",12,1,"Mixed","reported","reported",2,0,0.130093952252535,0,2014,0,119.5
"CD015517_data","CD015517_data","12|1|CRF ≤ 12 weeks after the intervention|Supervised","CRF ≤ 12 weeks after the intervention",12,1,"Supervised","reported","reported",3,0,0.162783596130882,0,2011.33333333333,0,55
"CD015517_data","CD015517_data","12|3|QoL ≤ 12 weeks after the intervention |Mixed","QoL ≤ 12 weeks after the intervention ",12,3,"Mixed","reported","reported",2,0,0.130242087331244,0,2014,0,119.5
"CD015517_data","CD015517_data","12|3|QoL ≤ 12 weeks after the intervention |Supervised","QoL ≤ 12 weeks after the intervention ",12,3,"Supervised","reported","reported",5,0,0.119875469121466,0,2010,0,58.4
"CD015517_data","CD015517_data","12|4|Anxiety ≤ 12 weeks after the intervention|Supervised","Anxiety ≤ 12 weeks after the intervention",12,4,"Supervised","reported","reported",2,0,0.193434153864676,0,2014.5,0,55
"CD015517_data","CD015517_data","12|5|Depression ≤ 12 weeks after the intervention|Supervised","Depression ≤ 12 weeks after the intervention",12,5,"Supervised","reported","reported",2,0,0.193341463334917,0,2014.5,0,55
"CD015517_data","CD015517_data","2|1|CRF ≤ 12 weeks after the intervention |Moderate to high","CRF ≤ 12 weeks after the intervention ",2,1,"Moderate to high","reported","reported",3,0,0.142372413060566,0,2008.33333333333,0,114
"CD015517_data","CD015517_data","3|1|CRF ≤ 12 weeks after the intervention |Prostate","CRF ≤ 12 weeks after the intervention ",3,1,"Prostate","reported","reported",2,0,0.217011012324325,0,2015,0,63
"CD015517_data","CD015517_data","4|1|QoL ≤ 12 weeks after the intervention|Individual training","QoL ≤ 12 weeks after the intervention",4,1,"Individual training","reported","reported",4,0,0.114579194636416,0,2010.5,0,104.5
"CD015517_data","CD015517_data","5|1|CRF ≤ 12 weeks after the intervention |Supervised","CRF ≤ 12 weeks after the intervention ",5,1,"Supervised","reported","reported",5,0,0.0882409100327315,0,2013,0,104
"CD015517_data","CD015517_data","5|2|QoL ≤ 12 weeks after the intervention|Supervised","QoL ≤ 12 weeks after the intervention",5,2,"Supervised","reported","reported",4,0,0.0920303830397068,0,2011,0,118.75
"CD015517_data","CD015517_data","6|1|CRF ≤ 12 weeks after the intervention |Not reported","CRF ≤ 12 weeks after the intervention ",6,1,"Not reported","reported","reported",2,0,0.151711344280903,0,2020,0,89
"CD015517_data","CD015517_data","6|1|CRF ≤ 12 weeks after the intervention |Younger than 65 years","CRF ≤ 12 weeks after the intervention ",6,1,"Younger than 65 years","reported","reported",3,0,0.109507295275656,0,2011,0,112.333333333333
"CD015517_data","CD015517_data","6|2|QoL ≤ 12 weeks after the intervention|Younger than 65 years","QoL ≤ 12 weeks after the intervention",6,2,"Younger than 65 years","reported","reported",4,0,0.10014044705934,0,2011.75,0,100.25
"CD015517_data","CD015517_data","7|1|CRF ≤ 12 weeks after the intervention |Mixed","CRF ≤ 12 weeks after the intervention ",7,1,"Mixed","reported","reported",5,0,0.0935829903318219,0,2012.6,0,92.6
"CD015517_data","CD015517_data","7|3|QoL ≤ 12 weeks after the intervention|Chemotherapy","QoL ≤ 12 weeks after the intervention",7,3,"Chemotherapy","reported","reported",2,0,0.144211969231823,0,2016.5,0,97
"CD015517_data","CD015517_data","7|3|QoL ≤ 12 weeks after the intervention|Mixed","QoL ≤ 12 weeks after the intervention",7,3,"Mixed","reported","reported",4,0,0.0980827177480221,0,2010.5,0,104.5
"CD015517_data","CD015517_data","8|1|CRF at 12 weeks or less after the intervention|","CRF at 12 weeks or less after the intervention",8,1,"","reported","reported",5,0,0.114776790270473,0,2010.4,0,87.2
"CD015517_data","CD015517_data","8|3|QoL at 12 weeks or less after the intervention|","QoL at 12 weeks or less after the intervention",8,3,"","reported","reported",7,0,0.131399179354419,0,2010,0,81
"CD015517_data","CD015517_data","9|1|CRF ≤ 12 weeks after the intervention|High","CRF ≤ 12 weeks after the intervention",9,1,"High","reported","reported",2,0,0.197612843426554,0,2010.5,0,52
"CD015517_data","CD015517_data","9|1|CRF ≤ 12 weeks after the intervention|Moderate to high","CRF ≤ 12 weeks after the intervention",9,1,"Moderate to high","reported","reported",3,0,0.111981561705475,0,2010.33333333333,0,110.666666666667
"CD015517_data","CD015517_data","9|3|QoL ≤ 12 weeks after the intervention |High","QoL ≤ 12 weeks after the intervention ",9,3,"High","reported","reported",4,0,0.133888246216004,0,2009.75,0,58.75
"CD015517_data","CD015517_data","9|3|QoL ≤ 12 weeks after the intervention |Moderate to high","QoL ≤ 12 weeks after the intervention ",9,3,"Moderate to high","reported","reported",3,0,0.112102855948338,0,2010.33333333333,0,110.666666666667
"CD015517_data","CD015517_data","9|4|Anxiety ≤ 12 weeks after the intervention|Moderate to high","Anxiety ≤ 12 weeks after the intervention",9,4,"Moderate to high","reported","reported",2,0,0.118985160322417,0,2009,0,147
"CD015517_data","CD015517_data","9|5|Depression ≤ 12 weeks after the intervention|Moderate to high","Depression ≤ 12 weeks after the intervention",9,5,"Moderate to high","reported","reported",2,0,0.11906461598069,0,2009,0,147
"CD015518_data","CD015518_data","1|1|Cancer-related fatigue ≤ 12 weeks|","Cancer-related fatigue ≤ 12 weeks",1,1,"","reported","reported",9,0,0.0803274559317014,0,2015.33333333333,0,88.8888888888889
"CD015518_data","CD015518_data","1|4|Quality of life ≤ 12 weeks|","Quality of life ≤ 12 weeks",1,4,"","reported","reported",9,0,0.19069026537427,0,2015.22222222222,0,87.6666666666667
"CD015518_data","CD015518_data","1|7|Depression ≤ 12 weeks|","Depression ≤ 12 weeks",1,7,"","or","binary",4,-0.0985231054992046,1.0058527832815,0,2013.75,0,106
"CD015518_data","CD015518_data","10|1|Cancer-related fatigue ≤ 12 weeks|Individual training","Cancer-related fatigue ≤ 12 weeks",10,1,"Individual training","reported","reported",2,0,0.194071293119771,0,2019.5,0,53.5
"CD015518_data","CD015518_data","10|2|Quality of life ≤ 12 weeks|Individual training","Quality of life ≤ 12 weeks",10,2,"Individual training","reported","reported",2,0,0.193775353841903,0,2019.5,0,53.5
"CD015518_data","CD015518_data","10|2|Quality of life ≤ 12 weeks|Individual training and group training","Quality of life ≤ 12 weeks",10,2,"Individual training and group training","reported","reported",2,0,0.172408048633477,0,2010.5,0,68
"CD015518_data","CD015518_data","11|1|Cancer-related fatigue ≤ 12 weeks|Supervised training and self-administered training","Cancer-related fatigue ≤ 12 weeks",11,1,"Supervised training and self-administered training","reported","reported",2,0,0.173749709260017,0,2014.5,0,67
"CD015518_data","CD015518_data","11|2|Quality of life ≤ 12 weeks|Supervised training and self-administered training","Quality of life ≤ 12 weeks",11,2,"Supervised training and self-administered training","reported","reported",3,0,0.140898025658944,0,2012.66666666667,0,67.6666666666667
"CD015518_data","CD015518_data","2|1|Cancer-related fatigue ≤ 12 weeks|Moderate intensity","Cancer-related fatigue ≤ 12 weeks",2,1,"Moderate intensity","reported","reported",4,0,0.113139671386064,0,2012.75,0,79.5
"CD015518_data","CD015518_data","2|1|Cancer-related fatigue ≤ 12 weeks|Moderate to vigorous intensity","Cancer-related fatigue ≤ 12 weeks",2,1,"Moderate to vigorous intensity","reported","reported",4,0,0.110011967392733,0,2016.75,0,87.5
"CD015518_data","CD015518_data","2|2|Quality of life ≤ 12 weeks|Moderate intensity","Quality of life ≤ 12 weeks",2,2,"Moderate intensity","reported","reported",4,0,0.111338964810998,0,2012.75,0,81.25
"CD015518_data","CD015518_data","2|2|Quality of life ≤ 12 weeks|Moderate to vigorous intensity","Quality of life ≤ 12 weeks",2,2,"Moderate to vigorous intensity","reported","reported",4,0,0.114532887033739,0,2016.75,0,81.25
"CD015518_data","CD015518_data","2|3|Depression ≤ 12 weeks|Moderate intensity","Depression ≤ 12 weeks",2,3,"Moderate intensity","reported","reported",2,0,0.142805506208705,0,2013.5,0,98.5
"CD015518_data","CD015518_data","2|3|Depression ≤ 12 weeks|Moderate to vigorous intensity","Depression ≤ 12 weeks",2,3,"Moderate to vigorous intensity","reported","reported",2,0,0.133515118651491,0,2014,0,113.5
"CD015518_data","CD015518_data","3|1|Cancer-related fatigue ≤ 12 weeks|Breast cancer","Cancer-related fatigue ≤ 12 weeks",3,1,"Breast cancer","reported","reported",5,0,0.0844608247262169,0,2013.8,0,113.6
"CD015518_data","CD015518_data","3|1|Cancer-related fatigue ≤ 12 weeks|Prostate cancer","Cancer-related fatigue ≤ 12 weeks",3,1,"Prostate cancer","reported","reported",2,0,0.183266677543381,0,2014.5,0,61
"CD015518_data","CD015518_data","3|2|Quality of life ≤ 12 weeks|Breast cancer","Quality of life ≤ 12 weeks",3,2,"Breast cancer","reported","reported",6,0,0.0823377565916674,0,2014.66666666667,0,100.166666666667
"CD015518_data","CD015518_data","3|2|Quality of life ≤ 12 weeks|Prostate cancer","Quality of life ≤ 12 weeks",3,2,"Prostate cancer","reported","reported",2,0,0.17726391012364,0,2014.5,0,64.5
"CD015518_data","CD015518_data","3|3|Depression ≤ 12 weeks|Breast cancer","Depression ≤ 12 weeks",3,3,"Breast cancer","reported","reported",3,0,0.103511841486627,0,2011.66666666667,0,125.333333333333
"CD015518_data","CD015518_data","4|1|Cancer-related fatigue ≤ 12 weeks|Group training","Cancer-related fatigue ≤ 12 weeks",4,1,"Group training","reported","reported",3,0,0.107773712837533,0,2016,0,127.333333333333
"CD015518_data","CD015518_data","4|1|Cancer-related fatigue ≤ 12 weeks|Individual training","Cancer-related fatigue ≤ 12 weeks",4,1,"Individual training","reported","reported",5,0,0.105917402032518,0,2015,0,74.2
"CD015518_data","CD015518_data","4|2|Quality of life ≤ 12 weeks|Group training","Quality of life ≤ 12 weeks",4,2,"Group training","reported","reported",4,0,0.100758015283696,0,2016.75,0,103
"CD015518_data","CD015518_data","4|2|Quality of life ≤ 12 weeks|Individual training","Quality of life ≤ 12 weeks",4,2,"Individual training","reported","reported",5,0,0.104733879005592,0,2015,0,75.6
"CD015518_data","CD015518_data","4|3|Depression ≤ 12 weeks|Group training","Depression ≤ 12 weeks",4,3,"Group training","reported","reported",2,0,0.133515118651491,0,2014,0,113.5
"CD015518_data","CD015518_data","4|3|Depression ≤ 12 weeks|Individual training","Depression ≤ 12 weeks",4,3,"Individual training","reported","reported",2,0,0.142805506208705,0,2013.5,0,98.5
"CD015518_data","CD015518_data","5|1|Cancer-related fatigue ≤ 12 weeks|Supervised training","Cancer-related fatigue ≤ 12 weeks",5,1,"Supervised training","reported","reported",8,0,0.0758284042981961,0,2014.875,0,92.625
"CD015518_data","CD015518_data","5|2|Quality of life ≤ 12 weeks|Supervised training","Quality of life ≤ 12 weeks",5,2,"Supervised training","reported","reported",9,0,0.072777081482056,0,2015.33333333333,0,86.4444444444444
"CD015518_data","CD015518_data","6|1|Cancer-related fatigue ≤ 12 weeks|Androgen deprivation therapy","Cancer-related fatigue ≤ 12 weeks",6,1,"Androgen deprivation therapy","or","binary",2,-0.263953448283503,1.42478213135985,0,2009,0,99
"CD015518_data","CD015518_data","6|1|Cancer-related fatigue ≤ 12 weeks|Radiotherapy with or without androgen deprivation therapy","Cancer-related fatigue ≤ 12 weeks",6,1,"Radiotherapy with or without androgen deprivation therapy","reported","reported",2,0,0.183266677543381,0,2014.5,0,61
"CD015518_data","CD015518_data","6|1|Cancer-related fatigue ≤ 12 weeks|Surgery with or without additional therapy","Cancer-related fatigue ≤ 12 weeks",6,1,"Surgery with or without additional therapy","reported","reported",5,0,0.0844608247262169,0,2013.8,0,113.6
"CD015518_data","CD015518_data","6|2|Quality of life ≤ 12 weeks|Radiotherapy with or without androgen deprivation therapy","Quality of life ≤ 12 weeks",6,2,"Radiotherapy with or without androgen deprivation therapy","reported","reported",2,0,0.17726391012364,0,2014.5,0,64.5
"CD015518_data","CD015518_data","6|2|Quality of life ≤ 12 weeks|Surgery with or without additional therapy","Quality of life ≤ 12 weeks",6,2,"Surgery with or without additional therapy","reported","reported",6,0,0.0823377565916674,0,2014.66666666667,0,100.166666666667
"CD015518_data","CD015518_data","6|3|Depression ≤ 12 weeks|Surgery with or without additional therapy","Depression ≤ 12 weeks",6,3,"Surgery with or without additional therapy","reported","reported",3,0,0.103511841486627,0,2011.66666666667,0,125.333333333333
"CD015518_data","CD015518_data","7|1|Cancer-related fatigue ≤ 12 weeks|","Cancer-related fatigue ≤ 12 weeks",7,1,"","or","binary",3,-0.0394250872088966,1.16501300398133,0,2017,0,58
"CD015518_data","CD015518_data","7|2|Quality of life ≤ 12 weeks|","Quality of life ≤ 12 weeks",7,2,"","reported","reported",3,0,0.263280242953039,0,2018,0,54.6666666666667
"CD015519","CD015519_pub2_data","1|5|Depression ≤ 12 weeks|","Depression ≤ 12 weeks",1,5,"","or","binary",2,0.0133358835823294,1.42370576411686,0,2013.5,0,99
"CD015519","CD015519_pub2_data","1|9|Adverse events  ≥ 6 months|","Adverse events  ≥ 6 months",1,9,"","or","binary",2,0.421122744623069,0.936795929072217,0,2014.5,0.0125,64
"CD015519","CD015519_pub2_data","2|1|Cancer-related fatigue (CRF) ≤ 12 weeks|People with breast cancer","Cancer-related fatigue (CRF) ≤ 12 weeks",2,1,"People with breast cancer","reported","reported",2,0,0.159602202976559,0,2011,0,95.5
"CD015519","CD015519_pub2_data","2|1|Cancer-related fatigue (CRF) ≤ 12 weeks|People with prostate cancer","Cancer-related fatigue (CRF) ≤ 12 weeks",2,1,"People with prostate cancer","reported","reported",2,0,0.182936196269095,0,2014.5,0,60
"CD015519","CD015519_pub2_data","2|2|Quality of life (QoL) ≤ 12 weeks|People with breast cancer","Quality of life (QoL) ≤ 12 weeks",2,2,"People with breast cancer","reported","reported",2,0,0.145116698606682,0,2011,0,95.5
"CD015519","CD015519_pub2_data","3|1|Cancer-related fatigue (CRF) ≤ 12 weeks|Treated with chemotherapy","Cancer-related fatigue (CRF) ≤ 12 weeks",3,1,"Treated with chemotherapy","reported","reported",2,0,0.159602202976559,0,2011,0,95.5
"CD015519","CD015519_pub2_data","3|1|Cancer-related fatigue (CRF) ≤ 12 weeks|Treated with radiotherapy","Cancer-related fatigue (CRF) ≤ 12 weeks",3,1,"Treated with radiotherapy","reported","reported",2,0,0.182936196269095,0,2014.5,0,60
"CD015519","CD015519_pub2_data","3|2|Quality of life (QoL) ≤ 12 weeks|Treated with chemotherapy","Quality of life (QoL) ≤ 12 weeks",3,2,"Treated with chemotherapy","reported","reported",2,0,0.145116698606682,0,2011,0,95.5
"CD015520_data","CD015520_data","1|1|CRF ≤ 12 weeks |","CRF ≤ 12 weeks ",1,1,"","or","binary",3,-0.268581874483651,1.16293869762668,0,2018.33333333333,0,84.3333333333333
"CD015520_data","CD015520_data","1|3|CRF ≥ 6 months|","CRF ≥ 6 months",1,3,"","or","binary",2,-0.260860325819829,1.42579380532098,0,2018.5,0,77.5
"CD015520_data","CD015520_data","1|4|QoL ≤ 12 weeks|","QoL ≤ 12 weeks",1,4,"","reported","reported",4,0,0.22702784228967,0,2018,0,93.5
"CD015520_data","CD015520_data","1|5|QoL > 12 weeks to < 6 months |","QoL > 12 weeks to < 6 months ",1,5,"","reported","reported",2,0,3.15327035645138,0,2019,0,75.5
"CD015520_data","CD015520_data","1|6|Depression ≤ 12 weeks|","Depression ≤ 12 weeks",1,6,"","or","binary",3,-0.194353954634488,1.16319590910851,0,2019.33333333333,0,78.3333333333333
"CD015520_data","CD015520_data","1|9|Anxiety ≤ 12 weeks|","Anxiety ≤ 12 weeks",1,9,"","or","binary",2,-0.469590265607477,1.42667058212529,0,2018.5,0,60.5
"CD015520_data","CD015520_data","2|1|CRF ≤ 12 weeks |Group yoga course","CRF ≤ 12 weeks ",2,1,"Group yoga course","reported","reported",2,0,0.187756008032182,0,2018.5,0,60
"CD015520_data","CD015520_data","2|2|QoL ≤ 12 weeks|Group yoga course","QoL ≤ 12 weeks",2,2,"Group yoga course","reported","reported",3,0,0.120422024664993,0,2017.33333333333,0,93.6666666666667
"CD015520_data","CD015520_data","3|1|QoL ≤ 12 weeks|Mixed yoga style","QoL ≤ 12 weeks",3,1,"Mixed yoga style","reported","reported",3,0,0.115878857094073,0,2018,0,101
"CD015520_data","CD015520_data","4|1|QoL ≤ 12 weeks|Supervised yoga","QoL ≤ 12 weeks",4,1,"Supervised yoga","reported","reported",2,0,0.138932007563418,0,2017,0,105
"CD015520_data","CD015520_data","4|1|QoL ≤ 12 weeks|Supervised yoga and self-administered yoga","QoL ≤ 12 weeks",4,1,"Supervised yoga and self-administered yoga","reported","reported",2,0,0.15848147832266,0,2019,0,82
"CD015520_data","CD015520_data","4|2|Depression ≤ 12 weeks|Supervised yoga and self-administered yoga","Depression ≤ 12 weeks",4,2,"Supervised yoga and self-administered yoga","reported","reported",2,0,0.595610471525033,0,2018.5,0,60.5
"CD015520_data","CD015520_data","5|1|CRF ≤ 12 weeks|","CRF ≤ 12 weeks",5,1,"","reported","reported",4,0,0.122907922492465,0,2014,0,68.5
"CD015520_data","CD015520_data","5|3|QoL ≤ 12 weeks|","QoL ≤ 12 weeks",5,3,"","reported","reported",4,0,0.404573341387633,0,2011.66666666667,0,68.75
"CD015520_data","CD015520_data","5|5|Depression ≤ 12 weeks|","Depression ≤ 12 weeks",5,5,"","reported","reported",2,0,0.272948042441842,0,2021,0,35.5
"CD015520_data","CD015520_data","5|7|Anxiety ≤ 12 weeks|","Anxiety ≤ 12 weeks",5,7,"","or","binary",2,0.0831273914113362,1.43042196677931,0,2018.5,0,44.5
"CD015520_data","CD015520_data","6|1|CRF ≤ 12 weeks|Hatha yoga","CRF ≤ 12 weeks",6,1,"Hatha yoga","reported","reported",2,0,0.191089679486424,0,2014,0,55.5
"CD015520_data","CD015520_data","6|1|CRF ≤ 12 weeks|Mixed yoga styles","CRF ≤ 12 weeks",6,1,"Mixed yoga styles","reported","reported",3,0,0.0919202122776604,0,2015.66666666667,0,163.666666666667
"CD015520_data","CD015520_data","6|2|QoL ≤ 12 weeks|Hatha yoga","QoL ≤ 12 weeks",6,2,"Hatha yoga","reported","reported",3,0,0.167392414778942,0,2014,0,49
"CD015520_data","CD015520_data","6|3|Depression ≤ 12 weeks|Hatha yoga","Depression ≤ 12 weeks",6,3,"Hatha yoga","reported","reported",2,0,0.214271941839579,0,2016,0,45
"CD015520_data","CD015520_data","7|1|CRF ≤ 12 weeks|Group yoga course","CRF ≤ 12 weeks",7,1,"Group yoga course","reported","reported",4,0,0.0871610535082895,0,2015.75,0,136.25
"CD015520_data","CD015520_data","7|2|QoL ≤ 12 weeks|Group yoga course","QoL ≤ 12 weeks",7,2,"Group yoga course","reported","reported",3,0,0.141172114865628,0,2011.5,0,72.6666666666667
"CD015520_data","CD015520_data","8|1|CRF ≤ 12 weeks|Breast cancer","CRF ≤ 12 weeks",8,1,"Breast cancer","reported","reported",3,0,0.139171531989518,0,2013.33333333333,0,73.3333333333333
"CD015520_data","CD015520_data","8|2|QoL ≤ 12 weeks|Breast cancer","QoL ≤ 12 weeks",8,2,"Breast cancer","reported","reported",3,0,0.139812998908436,0,2009.5,0,73.6666666666667
"CD015520_data","CD015520_data","8|3|Depression ≤ 12 weeks|Breast cancer","Depression ≤ 12 weeks",8,3,"Breast cancer","reported","reported",2,0,0.241927097207337,0,2021,0,35.5
"CD015520_data","CD015520_data","9|1|CRF ≤ 12 weeks|Younger than 65 years","CRF ≤ 12 weeks",9,1,"Younger than 65 years","reported","reported",4,0,0.0868872235671372,0,2014.75,0,137
"CD015520_data","CD015520_data","9|2|QoL ≤ 12 weeks|Younger than 65 years","QoL ≤ 12 weeks",9,2,"Younger than 65 years","reported","reported",2,0,0.152920707842315,0,2009.5,0,92.5
"CD015524","CD015524_pub2_data","1|1|Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events|NA","Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events",1,1,NA,"or","binary",4,0.324578470113378,0.688181954285383,0,2018.5,0.01,76
"CD015524","CD015524_pub2_data","1|10|Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model|NA","Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",1,10,NA,"reported","reported",2,0,0.320408748856349,0,2020.5,0.297435897435897,42.5
"CD015524","CD015524_pub2_data","1|13|Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis|NA","Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis",1,13,NA,"reported","reported",2,0,0.111504338864785,0,2019,0.881410256410256,39
"CD015524","CD015524_pub2_data","1|14|Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model|NA","Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",1,14,NA,"reported","reported",2,0,0.129181393485961,0,2019,0.881410256410256,39
"CD015524","CD015524_pub2_data","1|17|Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning|NA","Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning",1,17,NA,"reported","reported",2,0,0.0877595690503171,0,2019,0.83974358974359,39
"CD015524","CD015524_pub2_data","1|18|Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model|NA","Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model",1,18,NA,"reported","reported",2,0,0.0877595690503171,0,2019,0.83974358974359,39
"CD015524","CD015524_pub2_data","1|2|Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘best-worst’ case scenario|NA","Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘best-worst’ case scenario",1,2,NA,"reported","reported",2,0,0.764270058732515,0,2019.5,0.103333333333333,79.5
"CD015524","CD015524_pub2_data","1|21|Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis|NA","Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis",1,21,NA,"reported","reported",2,0,0.139074960312341,0,2019,0.721153846153846,39
"CD015524","CD015524_pub2_data","1|3|Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘worst-best’ case scenario|NA","Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘worst-best’ case scenario",1,3,NA,"reported","reported",2,0,0.764113498918972,0,2019.5,0.02,79.5
"CD015524","CD015524_pub2_data","1|35|Analysis 1.35. Outcome 19: BMI (kg/m2)|NA","Analysis 1.35. Outcome 19: BMI (kg/m2)",1,35,NA,"reported","reported",2,0,0.829423031607031,0,2022,0,60
"CD015524","CD015524_pub2_data","1|36|Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model|NA","Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model",1,36,NA,"reported","reported",2,0,0.829423031607031,0,2022,0,60
"CD015524","CD015524_pub2_data","1|4|Analysis 1.4. Outcome 2: ALT (U/L)|NA","Analysis 1.4. Outcome 2: ALT (U/L)",1,4,NA,"reported","reported",3,0,2.89449128817218,0,2019.33333333333,0,66.6666666666667
"CD015524","CD015524_pub2_data","1|5|Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model|NA","Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",1,5,NA,"reported","reported",3,0,2.89449128817218,0,2019.33333333333,0,66.6666666666667
"CD015524","CD015524_pub2_data","1|6|Analysis 1.6. Outcome 3: AST (U/L)|NA","Analysis 1.6. Outcome 3: AST (U/L)",1,6,NA,"or","binary",6,0.101609098089498,0.822910853088142,0,2018,0,68.1666666666667
"CD015524","CD015524_pub2_data","2|10|Analysis 2.10. Outcome 7: TG (mmol/L) |NA","Analysis 2.10. Outcome 7: TG (mmol/L) ",2,10,NA,"reported","reported",2,0,0.134374894169438,0,2012,0,33
"CD015524","CD015524_pub2_data","2|11|Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",2,11,NA,"reported","reported",2,0,0.134374894169438,0,2012,0,33
"CD015524","CD015524_pub2_data","2|14|Analysis 2.14. Outcome 10: FBS (mmol/L) |NA","Analysis 2.14. Outcome 10: FBS (mmol/L) ",2,14,NA,"reported","reported",2,0,0.0717748444364523,0,2012,0,33
"CD015524","CD015524_pub2_data","2|15|Analysis 2.15. Outcome 11: HOMA-IR|NA","Analysis 2.15. Outcome 11: HOMA-IR",2,15,NA,"reported","reported",2,0,0.183877057802041,0,2012,0,33
"CD015524","CD015524_pub2_data","2|16|Analysis 2.16. Outcome 12: Insulin (mmol/l)|NA","Analysis 2.16. Outcome 12: Insulin (mmol/l)",2,16,NA,"reported","reported",2,0,0.829602030321197,0,2012,0,33
"CD015524","CD015524_pub2_data","2|17|Analysis 2.17. Outcome 13: Weight (kg)|NA","Analysis 2.17. Outcome 13: Weight (kg)",2,17,NA,"reported","reported",2,0,2.49008202658516,0,2012,0,33
"CD015524","CD015524_pub2_data","2|2|Analysis 2.2. Outcome 2: ALT (U/L)|NA","Analysis 2.2. Outcome 2: ALT (U/L)",2,2,NA,"reported","reported",2,0,3.31220453171318,0,2012,0,33
"CD015524","CD015524_pub2_data","2|3|Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model|NA","Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",2,3,NA,"reported","reported",2,0,3.31220453171318,0,2012,0,33
"CD015524","CD015524_pub2_data","2|4|Analysis 2.4. Outcome 3: AST (U/L)|NA","Analysis 2.4. Outcome 3: AST (U/L)",2,4,NA,"reported","reported",2,0,2.08103117959706,0,2012,0,33
"CD015524","CD015524_pub2_data","2|5|Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model|NA","Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",2,5,NA,"reported","reported",2,0,2.08103117959706,0,2012,0,33
"CD015524","CD015524_pub2_data","3|1|Analysis 3.1. Outcome 1: Proportion of participants with serious adverse events|NA","Analysis 3.1. Outcome 1: Proportion of participants with serious adverse events",3,1,NA,"or","binary",2,-0.0210420463820587,1.42610527650872,0,2013.5,0,89.5
"CD015524","CD015524_pub2_data","3|16|Analysis 3.16. Outcome 10: TG (mmol/L)|NA","Analysis 3.16. Outcome 10: TG (mmol/L)",3,16,NA,"reported","reported",2,0,0.128904482716139,0,2019.5,0,78.5
"CD015524","CD015524_pub2_data","3|17|Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model",3,17,NA,"reported","reported",2,0,0.128904482716139,0,2019.5,0,78.5
"CD015524","CD015524_pub2_data","3|18|Analysis 3.18. Outcome 11: HDL cholesterol (mmol/L)|NA","Analysis 3.18. Outcome 11: HDL cholesterol (mmol/L)",3,18,NA,"or","binary",2,0.00823008849877751,1.42286947189127,0,2022.5,0,90.5
"CD015524","CD015524_pub2_data","3|20|Analysis 3.20. Outcome 12: LDL cholesterol (mmol/L)|NA","Analysis 3.20. Outcome 12: LDL cholesterol (mmol/L)",3,20,NA,"or","binary",2,0.00823008849877751,1.42286947189127,0,2022.5,0,90.5
"CD015524","CD015524_pub2_data","3|22|Analysis 3.22. Outcome 13: FBS (mmol/L)|NA","Analysis 3.22. Outcome 13: FBS (mmol/L)",3,22,NA,"or","binary",5,-0.278990266644271,0.903285850518335,0,2020.4,0,61.8
"CD015524","CD015524_pub2_data","3|23|Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",3,23,NA,"reported","reported",3,0,0.0996529263582768,0,2022,0,71
"CD015524","CD015524_pub2_data","3|24|Analysis 3.24. Outcome 14: HOMA-IR|NA","Analysis 3.24. Outcome 14: HOMA-IR",3,24,NA,"reported","reported",2,0,0.545064907929156,0,2021,0,46
"CD015524","CD015524_pub2_data","3|25|Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model|NA","Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model",3,25,NA,"reported","reported",3,0,0.281756841298745,0,2020,0,73
"CD015524","CD015524_pub2_data","3|26|Analysis 3.26. Outcome 15: Insulin (pmol/L)|NA","Analysis 3.26. Outcome 15: Insulin (pmol/L)",3,26,NA,"or","binary",3,-0.464445572484953,1.1654619383255,0,2022,0,71
"CD015524","CD015524_pub2_data","3|27|Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model|NA","Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model",3,27,NA,"or","binary",3,-0.464445572484953,1.1654619383255,0,2022,0,71
"CD015524","CD015524_pub2_data","3|28|Analysis 3.28. Outcome 16: Weight (kg)|NA","Analysis 3.28. Outcome 16: Weight (kg)",3,28,NA,"or","binary",2,0.00827274208702741,1.42655181731577,0,2019.5,0,78.5
"CD015524","CD015524_pub2_data","3|30|Analysis 3.30. Outcome 17: BMI (kg/m2)|NA","Analysis 3.30. Outcome 17: BMI (kg/m2)",3,30,NA,"reported","reported",2,0,0.673585486502934,0,2021,0,46
"CD015524","CD015524_pub2_data","3|32|Analysis 3.32. Outcome 18: WC (cm)|NA","Analysis 3.32. Outcome 18: WC (cm)",3,32,NA,"or","binary",2,0.00827274208702741,1.42655181731577,0,2019.5,0,78.5
"CD015524","CD015524_pub2_data","3|34|Analysis 3.34. Outcome 19: LSM (Kpa)|NA","Analysis 3.34. Outcome 19: LSM (Kpa)",3,34,NA,"reported","reported",2,0,0.372936635160947,0,2021,0,46
"CD015524","CD015524_pub2_data","3|35|Analysis 3.35. Outcome 20: CAP (dB/m)|NA","Analysis 3.35. Outcome 20: CAP (dB/m)",3,35,NA,"reported","reported",2,0,6.71240355324061,0,2021,0,46
"CD015524","CD015524_pub2_data","3|4|Analysis 3.4. Outcome 2: ALT (U/L)|NA","Analysis 3.4. Outcome 2: ALT (U/L)",3,4,NA,"reported","reported",3,0,5.23645524960396,0,2019,0,42.6666666666667
"CD015524","CD015524_pub2_data","3|5|Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model|NA","Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",3,5,NA,"reported","reported",4,0,2.05863775880486,0,2020.25,0,62.25
"CD015524","CD015524_pub2_data","3|6|Analysis 3.6. Outcome 3: AST (U/L)|NA","Analysis 3.6. Outcome 3: AST (U/L)",3,6,NA,"reported","reported",2,0,3.96509449606845,0,2021,0,46
"CD015524","CD015524_pub2_data","3|7|Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model|NA","Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",3,7,NA,"reported","reported",3,0,1.00897245149641,0,2022,0,71
"CD015524","CD015524_pub2_data","3|8|Analysis 3.8. Outcome 4: GGT (U/L)|NA","Analysis 3.8. Outcome 4: GGT (U/L)",3,8,NA,"or","binary",4,-0.349039451582427,1.01034091380645,0,2020.25,0,62.25
"CD015524","CD015524_pub2_data","3|9|Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model|NA","Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model",3,9,NA,"reported","reported",2,0,12.7329018732058,0,2021,0,46
"CD015524","CD015524_pub2_data","4|1|Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events|NA","Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events",4,1,NA,"or","binary",3,0.0104633434765245,1.15723802074988,0,2016.33333333333,0,306.666666666667
"CD015524","CD015524_pub2_data","4|10|Analysis 4.10. Outcome 8: HDL cholesterol (mmol/L)|NA","Analysis 4.10. Outcome 8: HDL cholesterol (mmol/L)",4,10,NA,"reported","reported",2,0,0.0526081490651883,0,2017,0,213
"CD015524","CD015524_pub2_data","4|11|Analysis 4.11. Outcome 9: LDL cholesterol (mmol/L)|NA","Analysis 4.11. Outcome 9: LDL cholesterol (mmol/L)",4,11,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|12|Analysis 4.12. Outcome 9: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 4.12. Outcome 9: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",4,12,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|2|Analysis 4.2. Outcome 2: ALT (U/L)|NA","Analysis 4.2. Outcome 2: ALT (U/L)",4,2,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|3|Analysis 4.3. Outcome 3: AST (U/L)|NA","Analysis 4.3. Outcome 3: AST (U/L)",4,3,NA,"reported","reported",2,0,0.906425615329533,0,2017,0,213
"CD015524","CD015524_pub2_data","4|6|Analysis 4.6. Outcome 6: TC (mmol/L)|NA","Analysis 4.6. Outcome 6: TC (mmol/L)",4,6,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|7|Analysis 4.7. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 4.7. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",4,7,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|8|Analysis 4.8. Outcome 7: TG (mmol/L)|NA","Analysis 4.8. Outcome 7: TG (mmol/L)",4,8,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015524","CD015524_pub2_data","4|9|Analysis 4.9. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model|NA","Analysis 4.9. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",4,9,NA,"or","binary",2,0.0157136742424419,1.41816357227257,0,2017,0,213
"CD015530","CD015530_pub2_data","1|1|Incidence of herpes zoster (up to 21 months after final dose)|NA","Incidence of herpes zoster (up to 21 months after final dose)",1,1,NA,"reported","reported",2,0,0.168806665113648,0,2019,0.0547947303921569,1533.5
"CD015530","CD015530_pub2_data","1|3|Adverse events of any grade (up to 30 days after final dose)|NA","Adverse events of any grade (up to 30 days after final dose)",1,3,NA,"or","binary",2,0.310384440992506,0.229187250792632,0.0872522156769195,2019,0.58692600282462,1555
"CD015532_data","CD015532_data","2|1|Overall mortality|","Overall mortality",2,1,"","or","binary",2,0.619012630991623,0.978183551963796,1.559785299323,2021,0.260572460030944,359.5
"CD015532_data","CD015532_data","2|4|Mortality (time to event)|","Mortality (time to event)",2,4,"","reported","reported",2,-0.060213932613721,0.209592588870424,0,2021,0,422
"CD015532_data","CD015532_data","3|1|In-hospital mortality|","In-hospital mortality",3,1,"","or","binary",6,0.0998279124289415,0.209611843205999,0,2021.16666666667,0.291040002326397,102.5
"CD015532_data","CD015532_data","3|11|Postoperative bleeding|","Postoperative bleeding",3,11,"","or","binary",2,0.267036051858885,0.751519027024239,0.661237160804098,2021,0.143103448275862,76
"CD015532_data","CD015532_data","3|12|Need for ECMO|","Need for ECMO",3,12,"","or","binary",2,-0.38568537720243,1.6963452486727,4.81920848624837,2021,0.198620689655172,76
"CD015532_data","CD015532_data","3|2|28-day (± 2) mortality|","28-day (± 2) mortality",3,2,"","or","binary",2,0.0737002695099728,0.381738079525418,0.093369300419979,2021.5,0.51858486341245,112.5
"CD015532_data","CD015532_data","3|3|60-day mortality|","60-day mortality",3,3,"","or","binary",3,0.684891970633778,0.445236905744233,0.275646324374382,2021,0.523415435139573,101.666666666667
"CD015532_data","CD015532_data","3|4|90-day mortality|","90-day mortality",3,4,"","or","binary",2,0.0287592964795211,0.503723501087802,0,2021.5,0.644312583967756,112.5
"CD015532_data","CD015532_data","3|5|Mortality (time to event)|","Mortality (time to event)",3,5,"","reported","reported",2,-0.428582450630879,0.64287037766678,0.705722530136001,2020.5,0,106.5
"CD015532_data","CD015532_data","3|6|Duration to liberation from invasive mechanical ventilation|","Duration to liberation from invasive mechanical ventilation",3,6,"","or","binary",2,0.786919230730363,1.43296682233095,0,2020,0,54.5
"CD015532_data","CD015532_data","3|7|Liberation from mechanical ventilation|","Liberation from mechanical ventilation",3,7,"","or","binary",4,0.0939310605783974,0.232318059978346,0,2021,0.633015557485826,112.25
"CD015532_data","CD015532_data","3|8|Duration to decannulation|","Duration to decannulation",3,8,"","or","binary",2,0.786919230730363,1.43296682233095,0,2020,0,54.5
"CD015532_data","CD015532_data","3|9|Ventilator-associated pneumonia|","Ventilator-associated pneumonia",3,9,"","or","binary",3,-0.434459109228977,0.138725944351083,0,2021.33333333333,0.516649191786806,317.666666666667
"CD015532_data","CD015532_data","4|1|Overall mortality and in-hospital mortality|Early ≤ 10 days vs late > 10 days","Overall mortality and in-hospital mortality",4,1,"Early ≤ 10 days vs late > 10 days","or","binary",2,0.456335590592551,1.18236715088702,2.41444281464033,2021,0.260572460030944,359.5
"CD015532_data","CD015532_data","4|1|Overall mortality and in-hospital mortality|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Overall mortality and in-hospital mortality",4,1,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",6,0.0998279124289415,0.209611843205999,0,2021.16666666667,0.291040002326397,102.5
"CD015532_data","CD015532_data","4|10|Ventilator-associated pneumonia|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Ventilator-associated pneumonia",4,10,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",3,-0.434459109228977,0.138725944351083,0,2021.33333333333,0.516649191786806,317.666666666667
"CD015532_data","CD015532_data","4|12|Postoperative bleeding|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Postoperative bleeding",4,12,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",3,0.579172407084495,0.435164705954849,0.303923965654558,2021.33333333333,0.118735632183908,278
"CD015532_data","CD015532_data","4|15|Need for ECMO |Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Need for ECMO ",4,15,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",2,-0.38568537720243,1.6963452486727,4.81920848624837,2021,0.198620689655172,76
"CD015532_data","CD015532_data","4|17|ICU length of stay|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","ICU length of stay",4,17,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",3,0.990256394610736,1.16902453192404,0,2020.66666666667,0,60.3333333333333
"CD015532_data","CD015532_data","4|2|28-day (± 2) mortality|Early ≤ 10 days vs late > 10 days","28-day (± 2) mortality",4,2,"Early ≤ 10 days vs late > 10 days","or","binary",2,0.00756971316816879,0.373906643636398,0.142433049065027,2021,0.412217366520996,373.5
"CD015532_data","CD015532_data","4|2|28-day (± 2) mortality|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","28-day (± 2) mortality",4,2,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",2,0.0737002695099728,0.381738079525418,0.093369300419979,2021.5,0.51858486341245,112.5
"CD015532_data","CD015532_data","4|2|28-day (± 2) mortality|Early ≤ 7 days vs late > 7 days","28-day (± 2) mortality",4,2,"Early ≤ 7 days vs late > 7 days","or","binary",2,0.344958959357095,0.387293842156721,0,2022,0.236680327868852,91
"CD015532_data","CD015532_data","4|3|60-day (± 3) mortality|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","60-day (± 3) mortality",4,3,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",2,1.07448745442417,0.365595541401509,0,2020.5,0.638571428571429,116.5
"CD015532_data","CD015532_data","4|4|90-day (± 1) mortality|Early ≤ 10 days vs late > 10 days","90-day (± 1) mortality",4,4,"Early ≤ 10 days vs late > 10 days","or","binary",2,-0.288874884152838,0.409750761717717,0.294581147286364,2021,0.481373560254427,573
"CD015532_data","CD015532_data","4|4|90-day (± 1) mortality|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","90-day (± 1) mortality",4,4,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",2,0.253962007275829,0.346608979019596,0,2021,0.641536429672023,136.5
"CD015532_data","CD015532_data","4|5|Mortality (time to event)|Early ≤ 10 days vs late > 10 days","Mortality (time to event)",4,5,"Early ≤ 10 days vs late > 10 days","reported","reported",2,-0.060213932613721,0.209592588870424,0,2021,0,422
"CD015532_data","CD015532_data","4|5|Mortality (time to event)|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Mortality (time to event)",4,5,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","reported","reported",2,-0.428582450630879,0.64287037766678,0.705722530136001,2020.5,0,106.5
"CD015532_data","CD015532_data","4|6|Duration to liberation from invasive mechanical ventilation|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Duration to liberation from invasive mechanical ventilation",4,6,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",2,0.786919230730363,1.43296682233095,0,2020,0,54.5
"CD015532_data","CD015532_data","4|7|Liberation from invasive mechanical ventilation|Early ≤ 14 (± 1) days vs late > 14 (± 1) days","Liberation from invasive mechanical ventilation",4,7,"Early ≤ 14 (± 1) days vs late > 14 (± 1) days","or","binary",4,0.0939310605783974,0.232318059978346,0,2021,0.633015557485826,112.25
"CD015532_data","CD015532_data","4|8|Duration to decannulation|Early ≤ 14 (±1) days vs late > 14 (±1) days","Duration to decannulation",4,8,"Early ≤ 14 (±1) days vs late > 14 (±1) days","or","binary",2,0.786919230730363,1.43296682233095,0,2020,0,54.5
"CD015536","CD015536_pub2_data","1|10|Proportion of people without normalisation of transaminases|","Proportion of people without normalisation of transaminases",1,10,"","reported","reported",9,0,0.0592843244657421,0,2013.77777777778,0.586545577352675,105.444444444444
"CD015536","CD015536_pub2_data","1|2|Proportion of people with serious adverse events|","Proportion of people with serious adverse events",1,2,"","reported","reported",10,0,0.238878277874196,0,2013.5,0.0778096393510894,128
"CD015536","CD015536_pub2_data","1|4|Proportion of people with non-serious adverse events|","Proportion of people with non-serious adverse events",1,4,"","reported","reported",10,0,0.0380775927593217,0,2013.9,0.566718905484269,137.9
"CD015536","CD015536_pub2_data","1|6|Proportion of people with detectable HBsAg|","Proportion of people with detectable HBsAg",1,6,"","reported","reported",8,0,0.00939282564685119,0,2016,0.958938069908815,170.625
"CD015536","CD015536_pub2_data","1|7|Proportion of people with detectable HBV-DNA|","Proportion of people with detectable HBV-DNA",1,7,"","reported","reported",14,0,0.0232418390115563,0,2013.78571428571,0.672105283974055,115.571428571429
"CD015536","CD015536_pub2_data","1|8|Proportion of people with detectable HBeAg|","Proportion of people with detectable HBeAg",1,8,"","reported","reported",7,0,0.0408629505634628,0,2013.14285714286,0.823143286973074,95.7142857142857
"CD015536","CD015536_pub2_data","1|9|Proportion of people without HBeAg seroconversion|","Proportion of people without HBeAg seroconversion",1,9,"","reported","reported",9,0,0.0237002643231418,0,2014.55555555556,0.887377604807454,103
"CD015536","CD015536_pub2_data","2|1|Proportion of people with serious adverse events (risk of bias)|High risk of bias","Proportion of people with serious adverse events (risk of bias)",2,1,"High risk of bias","reported","reported",7,0,0.266886986531949,0,2014.85714285714,0.0895638526033625,126.714285714286
"CD015536","CD015536_pub2_data","2|1|Proportion of people with serious adverse events (risk of bias)|Some concerns","Proportion of people with serious adverse events (risk of bias)",2,1,"Some concerns","reported","reported",2,0,1.14197844774541,0,2007.5,0.0172413793103448,106.5
"CD015536","CD015536_pub2_data","2|2|Proportion of people with serious adverse events (age of participants)|Adults","Proportion of people with serious adverse events (age of participants)",2,2,"Adults","reported","reported",9,0,0.259884109588394,0,2013.22222222222,0.0734921918715808,122.222222222222
"CD015536","CD015536_pub2_data","2|3|Proportion of people with serious adverse events (history of treatment with other antivirals)|Participants with previous treatment","Proportion of people with serious adverse events (history of treatment with other antivirals)",2,3,"Participants with previous treatment","reported","reported",3,0,0.463337050232254,0,2013,0.0766794380587484,112.333333333333
"CD015536","CD015536_pub2_data","2|3|Proportion of people with serious adverse events (history of treatment with other antivirals)|Participants with treatment-naïve","Proportion of people with serious adverse events (history of treatment with other antivirals)",2,3,"Participants with treatment-naïve","reported","reported",2,0,0.757595347271945,0,2016,0.0501543209876543,190
"CD015536","CD015536_pub2_data","2|4|Proportion of people with serious adverse events (co-interventions)|With co-interventions","Proportion of people with serious adverse events (co-interventions)",2,4,"With co-interventions","reported","reported",7,0,0.267879717613575,0,2015.85714285714,0.0895638526033625,130.428571428571
"CD015536","CD015536_pub2_data","2|4|Proportion of people with serious adverse events (co-interventions)|Without co-interventions","Proportion of people with serious adverse events (co-interventions)",2,4,"Without co-interventions","reported","reported",3,0,0.527844994945142,0,2008,0.0503831417624521,122.333333333333
"CD015536","CD015536_pub2_data","3|10|Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)|","Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)",3,10,"","reported","reported",11,0,0.169126943439377,0,2013.90909090909,0.0706632419466341,124.454545454545
"CD015536","CD015536_pub2_data","3|4|Proportion of people with serious adverse events (restricting the analysis to treatment-naïve participants)|","Proportion of people with serious adverse events (restricting the analysis to treatment-naïve participants)",3,4,"","reported","reported",2,0,0.757595347271945,0,2016,0.0501543209876543,190
"CD015536","CD015536_pub2_data","3|5|Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)|","Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)",3,5,"","or","binary",2,0.0601990306343318,1.42984383213359,0,2015.5,0,44.5
"CD015536","CD015536_pub2_data","3|6|Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)|","Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)",3,6,"","reported","reported",10,0,0.238878277874196,0,2013.5,0.0778096393510894,128
"CD015536","CD015536_pub2_data","3|7|Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)|","Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)",3,7,"","reported","reported",10,0,0.238878277874196,0,2013.5,0.0778096393510894,128
"CD015536","CD015536_pub2_data","3|8|Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))|","Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))",3,8,"","reported","reported",10,0,0.238878277874196,0,2013.5,0.0778096393510894,128
"CD015536","CD015536_pub2_data","3|9|Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)|","Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)",3,9,"","reported","reported",11,0,0.232563236322345,0,2013.90909090909,0.108820442579657,124.454545454545
"CD015551","CD015551_pub2_data","1|2|All-cause mortality (up to 28 days after final dose)|NA","All-cause mortality (up to 28 days after final dose)",1,2,NA,"reported","reported",2,0,0.126024964394572,0,2016,0.0397473997028232,1372
"CD015551","CD015551_pub2_data","1|3|Any-grade adverse events (up to 30 days after final dose)|NA","Any-grade adverse events (up to 30 days after final dose)",1,3,NA,"reported","reported",2,0,0.0934245175995259,0,2016,0.742179557362947,1372
"CD015551","CD015551_pub2_data","1|4|Serious adverse events (up to 30 days after final dose)|NA","Serious adverse events (up to 30 days after final dose)",1,4,NA,"reported","reported",3,0,0.0510333873934933,0,2017,0.145751629542232,992
"CD015551","CD015551_pub2_data","1|5|Localised events at the injection site (up to 30 days after final dose)|NA","Localised events at the injection site (up to 30 days after final dose)",1,5,NA,"reported","reported",3,0,0.0399138671679592,0,2017,0.067483073481353,988.666666666667
"CD015551","CD015551_pub2_data","1|6|Systemic events (up to 30 days after final dose)|NA","Systemic events (up to 30 days after final dose)",1,6,NA,"reported","reported",3,0,0.0669789987720612,0,2017,0.243005088027376,988.666666666667
"CD015573_data","CD015573_data","2|2|Complications of treatment|Major complications","Complications of treatment",2,2,"Major complications","reported","reported",2,0,0.829526604664547,0,2021,0.0865853658536585,71
"CD015573_data","CD015573_data","2|3|Duration of hospital stay (days)|","Duration of hospital stay (days)",2,3,"","or","binary",2,0,1.42423043331004,0,2021,0,71
"CD015584","CD015584_pub2_data","1|1|Pain: during tenaculum placement|","Pain: during tenaculum placement",1,1,"","reported","reported",3,0,0.234347102847211,0,2017.66666666667,0,87
"CD015584","CD015584_pub2_data","1|10|Adverse events occurring before clinic discharge: vasovagal reaction|","Adverse events occurring before clinic discharge: vasovagal reaction",1,10,"","reported","reported",3,0,0.475761979774219,0,2011.66666666667,0.0495063176175668,138
"CD015584","CD015584_pub2_data","1|2|Pain: during intrauterine device placement|","Pain: during intrauterine device placement",1,2,"","reported","reported",7,0,0.0947600171573453,0,2015.14285714286,0,109.428571428571
"CD015584","CD015584_pub2_data","1|3|Pain: after intrauterine device placement before clinic discharge|","Pain: after intrauterine device placement before clinic discharge",1,3,"","reported","reported",5,0,0.140538469473435,0,2015.8,0,89.6
"CD015584","CD015584_pub2_data","1|4|Providers' ease of placement|","Providers' ease of placement",1,4,"","reported","reported",8,0,0.074028700884081,0,2015,0,106
"CD015584","CD015584_pub2_data","1|5|Need for adjunctive placement measures: cervical dilation|No recent failed IUD placement attempt","Need for adjunctive placement measures: cervical dilation",1,5,"No recent failed IUD placement attempt","reported","reported",5,0,0.404194035948865,0,2011.8,0.0847551082143937,72.6
"CD015584","CD015584_pub2_data","1|6|Placement success|No recent failed IUD placement attempt","Placement success",1,6,"No recent failed IUD placement attempt","reported","reported",8,0,0.226244919762799,0,2012.75,0.93750471239377,151.25
"CD015584","CD015584_pub2_data","1|7|Patient satisfaction with procedure|","Patient satisfaction with procedure",1,7,"","reported","reported",2,0,0.0530714222782682,0,2018.5,0,113
"CD015584","CD015584_pub2_data","1|8|Misoprostol side effects occurring before clinic discharge: preplacement abdominal pain or cramping|","Misoprostol side effects occurring before clinic discharge: preplacement abdominal pain or cramping",1,8,"","reported","reported",7,0,0.180361691215618,0,2013.57142857143,0.170466227797784,111.571428571429
"CD015584","CD015584_pub2_data","1|9|Misoprostol side effects occurring before clinic discharge: diarrhea|","Misoprostol side effects occurring before clinic discharge: diarrhea",1,9,"","reported","reported",7,0,0.323363485100259,0,2013.57142857143,0.0498610289218267,116.857142857143
"CD015584","CD015584_pub2_data","2|1|Need for adjunctive placement measures: ultrasound guidance|","Need for adjunctive placement measures: ultrasound guidance",2,1,"","reported","reported",2,0,0.955304003823416,0,2012.5,0.0294117647058824,89
"CD015584","CD015584_pub2_data","2|2|Need for adjunctive placement measures: local anesthesia|","Need for adjunctive placement measures: local anesthesia",2,2,"","reported","reported",4,0,0.570738465371552,0,2011.5,0.158212560386473,75.5
"CD015584","CD015584_pub2_data","2|4|Misoprostol side effects occurring before clinic discharge: nausea|","Misoprostol side effects occurring before clinic discharge: nausea",2,4,"","reported","reported",8,0,0.247744225902995,0,2012.375,0.135334403895596,100.375
"CD015584","CD015584_pub2_data","2|5|Misoprostol side effects occurring before clinic discharge: vomiting|","Misoprostol side effects occurring before clinic discharge: vomiting",2,5,"","reported","reported",5,0,0.53572554980689,0,2013.4,0.0189522380595149,97.4
"CD015584","CD015584_pub2_data","2|6|Adverse events occurring before clinic discharge: uterine perforation|","Adverse events occurring before clinic discharge: uterine perforation",2,6,"","or","binary",7,0.0180666580652759,0.759344879866933,0,2015.14285714286,0,127.714285714286
"CD015584","CD015584_pub2_data","3|1|Pain: during intrauterine device placement (dichotomous; % moderate/severe pain)|","Pain: during intrauterine device placement (dichotomous; % moderate/severe pain)",3,1,"","or","binary",3,-0.44088497351433,0.390224637960052,0.355846661442132,2013.66666666667,0.611280193236715,222.666666666667
"CD015584","CD015584_pub2_data","3|2|Providers' ease of placement (dichotomous; % easy placement)|","Providers' ease of placement (dichotomous; % easy placement)",3,2,"","reported","reported",3,0,0.253518791047538,0,2010,0.638218793828892,115.666666666667
"CD015584","CD015584_pub2_data","4|1|Placement success (restricted to studies with low overall risk of bias)|No recent failed IUD placement attempt","Placement success (restricted to studies with low overall risk of bias)",4,1,"No recent failed IUD placement attempt","reported","reported",7,0,0.43092332126942,0,2012,0.96000538559288,115.714285714286
"CD015588","CD015588_pub2_data","1|1|All-cause death|All CKD stages","All-cause death",1,1,"All CKD stages","or","binary",6,-0.156416771045624,0.0634466441362418,0.00130467139643597,2018.66666666667,0.054627388818107,2734.33333333333
"CD015588","CD015588_pub2_data","1|1|All-cause death|CKD stages 1-2","All-cause death",1,1,"CKD stages 1-2","or","binary",6,-0.346311443846478,0.213945479583472,0.081612773738924,2016,0.0248958742154438,2048.66666666667
"CD015588","CD015588_pub2_data","1|1|All-cause death|CKD stages 3-5","All-cause death",1,1,"CKD stages 3-5","or","binary",12,-0.0626913421493393,0.0735765707139709,0,2016.83333333333,0.029438364017049,1308.25
"CD015588","CD015588_pub2_data","1|11|Fatal or nonfatal myocardial infarction (Hazard Ratio)|CKD stages 1-2","Fatal or nonfatal myocardial infarction (Hazard Ratio)",1,11,"CKD stages 1-2","reported","reported",2,-0.067514855505135,0.209069419437122,0.0641017600000001,2015,NA,0
"CD015588","CD015588_pub2_data","1|11|Fatal or nonfatal myocardial infarction (Hazard Ratio)|CKD stages 3-5","Fatal or nonfatal myocardial infarction (Hazard Ratio)",1,11,"CKD stages 3-5","reported","reported",3,-0.302659538605064,0.124345124807484,0.0159652097965197,2016.66666666667,NA,0
"CD015588","CD015588_pub2_data","1|13|Stroke (Hazard Ratio)|All CKD stages","Stroke (Hazard Ratio)",1,13,"All CKD stages","reported","reported",3,-0.608115603866123,0.24829138114921,0,2015,0,913
"CD015588","CD015588_pub2_data","1|13|Stroke (Hazard Ratio)|CKD stages 3-5","Stroke (Hazard Ratio)",1,13,"CKD stages 3-5","reported","reported",4,0.0413377868417902,0.179978965796302,0,2015,0,874.5
"CD015588","CD015588_pub2_data","1|15|Nonfatal stroke (Hazard Ratio)|All CKD stages","Nonfatal stroke (Hazard Ratio)",1,15,"All CKD stages","reported","reported",2,-0.0603323501065974,0.0915461714011236,0,2018.5,NA,0
"CD015588","CD015588_pub2_data","1|17|Fatal or nonfatal stroke (Hazard Ratio)|CKD stages 1-2","Fatal or nonfatal stroke (Hazard Ratio)",1,17,"CKD stages 1-2","reported","reported",2,0.00845110970196576,0.15426211519439,0.01371349,2015,NA,0
"CD015588","CD015588_pub2_data","1|17|Fatal or nonfatal stroke (Hazard Ratio)|CKD stages 3-5","Fatal or nonfatal stroke (Hazard Ratio)",1,17,"CKD stages 3-5","reported","reported",3,-0.387696955966133,0.143898117158278,0.0172476502352975,2016.66666666667,NA,0
"CD015588","CD015588_pub2_data","1|18|Kidney failure|All CKD stages","Kidney failure",1,18,"All CKD stages","or","binary",4,-0.398432106434995,0.0708014687938662,0,2018.5,0.0834191591278075,2649.75
"CD015588","CD015588_pub2_data","1|18|Kidney failure|CKD stages 3-5","Kidney failure",1,18,"CKD stages 3-5","or","binary",2,-0.405268763565774,0.922212973714587,0,2018.5,0.0062111801242236,316.5
"CD015588","CD015588_pub2_data","1|19|Kidney failure (Hazard Ratio)|All CKD stages","Kidney failure (Hazard Ratio)",1,19,"All CKD stages","reported","reported",4,-0.380042223099382,0.0931004847997596,0,2016.25,0,175
"CD015588","CD015588_pub2_data","1|2|All-cause death (Hazard Ratio)|All CKD stages","All-cause death (Hazard Ratio)",1,2,"All CKD stages","reported","reported",7,-0.142086617933173,0.0463353375517426,0,2018.42857142857,0,1096.57142857143
"CD015588","CD015588_pub2_data","1|2|All-cause death (Hazard Ratio)|CKD stages 1-2","All-cause death (Hazard Ratio)",1,2,"CKD stages 1-2","reported","reported",3,-0.339018281035373,0.221993716591218,0.0882680250864346,2015,0,2674
"CD015588","CD015588_pub2_data","1|2|All-cause death (Hazard Ratio)|CKD stages 3-5","All-cause death (Hazard Ratio)",1,2,"CKD stages 3-5","reported","reported",9,-0.0875522564834907,0.0614270835831441,0,2016.66666666667,0,1660.66666666667
"CD015588","CD015588_pub2_data","1|20|3P-MACE|All CKD stages","3P-MACE",1,20,"All CKD stages","or","binary",2,0.244062982003255,0.621873103255124,0.61410208062073,2019.5,0.070904425270046,2354.5
"CD015588","CD015588_pub2_data","1|20|3P-MACE|CKD stages 1-2","3P-MACE",1,20,"CKD stages 1-2","or","binary",3,-0.0997983097748458,0.062191077247324,0.00360501676588675,2017,0.108228798046084,5942
"CD015588","CD015588_pub2_data","1|20|3P-MACE|CKD stages 3-5","3P-MACE",1,20,"CKD stages 3-5","or","binary",5,-0.130317875318665,0.0859872276742866,0.014448801427034,2018,0.109552442002173,3157
"CD015588","CD015588_pub2_data","1|21|3P-MACE (Hazard Ratio)|All CKD stages","3P-MACE (Hazard Ratio)",1,21,"All CKD stages","reported","reported",4,-0.109688558127258,0.0953290522800537,0.0128891737062793,2018.25,0,2666
"CD015588","CD015588_pub2_data","1|21|3P-MACE (Hazard Ratio)|CKD stages 1-2","3P-MACE (Hazard Ratio)",1,21,"CKD stages 1-2","reported","reported",3,-0.101744469755583,0.0599072765395381,0.00328365364557755,2016,0,4452
"CD015588","CD015588_pub2_data","1|21|3P-MACE (Hazard Ratio)|CKD stages 3-5","3P-MACE (Hazard Ratio)",1,21,"CKD stages 3-5","reported","reported",7,-0.229505296506111,0.0565202481011747,3.35401543341929e-07,2016.28571428571,0,713.857142857143
"CD015588","CD015588_pub2_data","1|22|4P-MACE|All CKD stages","4P-MACE",1,22,"All CKD stages","or","binary",3,-0.165924292551721,0.120231180440326,0.0248458716104854,2019.66666666667,0.123143592608483,4318.33333333333
"CD015588","CD015588_pub2_data","1|23|4P-MACE (Hazard Ratio)|All CKD stages","4P-MACE (Hazard Ratio)",1,23,"All CKD stages","reported","reported",3,-0.161925702355892,0.105002937686151,0.0180465558799395,2019.66666666667,NA,0
"CD015588","CD015588_pub2_data","1|25|Heart failure (Hazard Ratio)|All CKD stages","Heart failure (Hazard Ratio)",1,25,"All CKD stages","reported","reported",3,-0.560854650531481,0.200282154729499,1.27696040998979e-06,2015,0,913
"CD015588","CD015588_pub2_data","1|25|Heart failure (Hazard Ratio)|CKD stages 3-5","Heart failure (Hazard Ratio)",1,25,"CKD stages 3-5","reported","reported",2,-0.453950434399648,0.156617453895521,0,2015.5,0,1542
"CD015588","CD015588_pub2_data","1|26|Hospital admission for heart failure|CKD stages 1-2","Hospital admission for heart failure",1,26,"CKD stages 1-2","or","binary",3,-0.324283194906189,0.0929345792636799,0,2017,0.0324659286198754,5943.66666666667
"CD015588","CD015588_pub2_data","1|26|Hospital admission for heart failure|CKD stages 3-5","Hospital admission for heart failure",1,26,"CKD stages 3-5","or","binary",5,-0.4325494612529,0.136136711038526,0.0342758802866993,2018.4,0.0912398105762751,1221.4
"CD015588","CD015588_pub2_data","1|27|Hospital admission for heart failure (Hazard Ratio)|All CKD stages","Hospital admission for heart failure (Hazard Ratio)",1,27,"All CKD stages","reported","reported",3,-0.428918052816522,0.0935642908976174,0,2019.66666666667,NA,0
"CD015588","CD015588_pub2_data","1|27|Hospital admission for heart failure (Hazard Ratio)|CKD stages 1-2","Hospital admission for heart failure (Hazard Ratio)",1,27,"CKD stages 1-2","reported","reported",3,-0.373876565476617,0.0931342289328842,0,2016,NA,0
"CD015588","CD015588_pub2_data","1|27|Hospital admission for heart failure (Hazard Ratio)|CKD stages 3-5","Hospital admission for heart failure (Hazard Ratio)",1,27,"CKD stages 3-5","reported","reported",4,-0.360990260529331,0.119552030251893,0.0186446601512167,2017,NA,0
"CD015588","CD015588_pub2_data","1|29|Change eGFR|All CKD stages","Change eGFR",1,29,"All CKD stages","or","binary",2,-0.379660530038422,1.41737052447308,0,2018.5,0,1586
"CD015588","CD015588_pub2_data","1|3|Cardiovascular death|All CKD stages","Cardiovascular death",1,3,"All CKD stages","or","binary",4,-0.220570008306464,0.105074971330873,0,2018.25,0.0378397416076304,1966.75
"CD015588","CD015588_pub2_data","1|3|Cardiovascular death|CKD stages 1-2","Cardiovascular death",1,3,"CKD stages 1-2","or","binary",7,-0.263182393768023,0.203321657434293,0.10945740488584,2016.57142857143,0.0206410935864255,2675.71428571429
"CD015588","CD015588_pub2_data","1|3|Cardiovascular death|CKD stages 3-5","Cardiovascular death",1,3,"CKD stages 3-5","or","binary",9,-0.161149942301724,0.0731123301438788,0,2018.11111111111,0.0518489224958072,1910.44444444444
"CD015588","CD015588_pub2_data","1|31|Doubling of serum creatinine|All CKD stages","Doubling of serum creatinine",1,31,"All CKD stages","or","binary",2,-0.369122419447421,0.133054472825978,0.0200681095511396,2018.5,0.0618584613286014,6323.5
"CD015588","CD015588_pub2_data","1|32|Doubling of serum creatinine (Hazard Ratio)|All CKD stages","Doubling of serum creatinine (Hazard Ratio)",1,32,"All CKD stages","reported","reported",3,-0.400602747158754,0.182495359381067,0.0302477089041023,2015,0,233.333333333333
"CD015588","CD015588_pub2_data","1|33|Kidney composite outcome|All CKD stages","Kidney composite outcome",1,33,"All CKD stages","or","binary",4,-0.390230595603305,0.0955636673363655,0.0132381771016878,2019.75,0.069972184728131,3965.25
"CD015588","CD015588_pub2_data","1|33|Kidney composite outcome|CKD stages 3-5","Kidney composite outcome",1,33,"CKD stages 3-5","or","binary",3,-0.307519202815356,0.15685641545622,6.03403293627259e-08,2019.33333333333,0.0294408706550119,4262.33333333333
"CD015588","CD015588_pub2_data","1|34|Kidney composite outcome (Hazard Ratio)|All CKD stages","Kidney composite outcome (Hazard Ratio)",1,34,"All CKD stages","reported","reported",4,-0.414965977098048,0.0961112103453855,0.0140315650273597,2019.75,0,1781.75
"CD015588","CD015588_pub2_data","1|34|Kidney composite outcome (Hazard Ratio)|CKD stages 1-2","Kidney composite outcome (Hazard Ratio)",1,34,"CKD stages 1-2","reported","reported",2,-0.583588285333515,0.115793077775456,0,2017.5,0,6678
"CD015588","CD015588_pub2_data","1|34|Kidney composite outcome (Hazard Ratio)|CKD stages 3-5","Kidney composite outcome (Hazard Ratio)",1,34,"CKD stages 3-5","reported","reported",7,-0.548688287562673,0.140730682106566,0.0682670382046541,2017.57142857143,0,804.857142857143
"CD015588","CD015588_pub2_data","1|4|Cardiovascular death (Hazard Ratio)|All CKD stages","Cardiovascular death (Hazard Ratio)",1,4,"All CKD stages","reported","reported",5,-0.139607806945467,0.0680239812915297,0,2018.6,0,1511.8
"CD015588","CD015588_pub2_data","1|4|Cardiovascular death (Hazard Ratio)|CKD stage 1-2","Cardiovascular death (Hazard Ratio)",1,4,"CKD stage 1-2","reported","reported",3,-0.261895393734582,0.211995372764355,0.114293534163398,2016,0,4452
"CD015588","CD015588_pub2_data","1|4|Cardiovascular death (Hazard Ratio)|CKD stages 3-5","Cardiovascular death (Hazard Ratio)",1,4,"CKD stages 3-5","reported","reported",8,-0.134487525403063,0.0713948591942873,1.96975680871146e-06,2017,0,3187.25
"CD015588","CD015588_pub2_data","1|42|Hypoglycaemia|All CKD stages","Hypoglycaemia",1,42,"All CKD stages","or","binary",5,-0.0813621534160845,0.0444912146768488,0,2017.6,0.23763228127861,2672
"CD015588","CD015588_pub2_data","1|42|Hypoglycaemia|CKD stages 1-2","Hypoglycaemia",1,42,"CKD stages 1-2","or","binary",2,-0.0288330994296937,0.279623129427621,0,2014,0.131578947368421,235
"CD015588","CD015588_pub2_data","1|43|Hypoglycaemia (Hazard Ratio)|All CKD stages","Hypoglycaemia (Hazard Ratio)",1,43,"All CKD stages","reported","reported",4,0.0170934565536161,0.0723993979101746,0.00461097858074287,2015.75,0,310.25
"CD015588","CD015588_pub2_data","1|43|Hypoglycaemia (Hazard Ratio)|CKD stages 3-5","Hypoglycaemia (Hazard Ratio)",1,43,"CKD stages 3-5","reported","reported",6,-0.161427456257304,0.0793795156082013,0.00337646652603771,2016.16666666667,0,555.5
"CD015588","CD015588_pub2_data","1|44|Hypoglycaemia requiring third-party assistance|All CKD stages","Hypoglycaemia requiring third-party assistance",1,44,"All CKD stages","or","binary",4,-0.465312076538009,0.204742994812801,0.0528213267463482,2018.25,0.0331723085862402,2922.25
"CD015588","CD015588_pub2_data","1|44|Hypoglycaemia requiring third-party assistance|CKD stages 1-2","Hypoglycaemia requiring third-party assistance",1,44,"CKD stages 1-2","or","binary",4,-0.485417307178142,0.372350620297657,0,2014.5,0.0373563218390805,262.25
"CD015588","CD015588_pub2_data","1|44|Hypoglycaemia requiring third-party assistance|CKD stages 3-5","Hypoglycaemia requiring third-party assistance",1,44,"CKD stages 3-5","or","binary",9,-0.158279550927217,0.155593641245079,0,2016.77777777778,0.00742717705677742,1526.66666666667
"CD015588","CD015588_pub2_data","1|45|HbA1c [%]|All CKD stages","HbA1c [%]",1,45,"All CKD stages","reported","reported",3,-0.300778942804397,0.0290727584088123,0,2016.66666666667,0,1514.66666666667
"CD015588","CD015588_pub2_data","1|45|HbA1c [%]|CKD stages 3-5","HbA1c [%]",1,45,"CKD stages 3-5","reported","reported",11,-0.289083597020302,0.0413766229375434,0.00915473281157245,2015.63636363636,0,547.272727272727
"CD015588","CD015588_pub2_data","1|46|Change HbA1c [%]|CKD stages 3-5","Change HbA1c [%]",1,46,"CKD stages 3-5","or","binary",2,-0.698232742193534,1.42578667984227,0,2014,0,69.5
"CD015588","CD015588_pub2_data","1|47|Withdrawn due to adverse events|All CKD stages","Withdrawn due to adverse events",1,47,"All CKD stages","or","binary",6,-0.037161882868692,0.176378128754957,0.0924462850826029,2018.33333333333,0.0982027848931275,2027
"CD015588","CD015588_pub2_data","1|49|Amputation|All CKD stages","Amputation",1,49,"All CKD stages","or","binary",5,0.172710225073842,0.111647259155769,0,2019.6,0.0128731891389547,3228.4
"CD015588","CD015588_pub2_data","1|49|Amputation|CKD stages 3-5","Amputation",1,49,"CKD stages 3-5","or","binary",3,0.0261202441134826,0.241114785671308,0,2020,0.00208096859629209,3722
"CD015588","CD015588_pub2_data","1|50|Amputation (Hazard Ratio)|All CKD stages","Amputation (Hazard Ratio)",1,50,"All CKD stages","reported","reported",2,0.0414360425390774,0.141456100384934,0,2018.5,0,3653.5
"CD015588","CD015588_pub2_data","1|50|Amputation (Hazard Ratio)|Stage 3-5 CKD","Amputation (Hazard Ratio)",1,50,"Stage 3-5 CKD","reported","reported",5,0.164336304715675,0.170023626952519,0.0259467395700664,2018,0,3004.6
"CD015588","CD015588_pub2_data","1|51|Fracture|All CKD stages","Fracture",1,51,"All CKD stages","or","binary",6,0.0490421880413503,0.0881357444799956,6.80011274052341e-07,2018.66666666667,0.0289593029829041,2732.33333333333
"CD015588","CD015588_pub2_data","1|51|Fracture|CKD stages 1-2","Fracture",1,51,"CKD stages 1-2","or","binary",3,0.0143211106589727,0.100183542190341,4.78965438789517e-06,2016.33333333333,0.0318384532083392,2755.66666666667
"CD015588","CD015588_pub2_data","1|51|Fracture|CKD stages 3-5","Fracture",1,51,"CKD stages 3-5","or","binary",7,-0.0803657709065685,0.100377591464423,0,2017.42857142857,0.0304361263596045,2167.28571428571
"CD015588","CD015588_pub2_data","1|52|Fracture (Hazard Ratio)|All-stage CKD","Fracture (Hazard Ratio)",1,52,"All-stage CKD","reported","reported",3,0.131761390459233,0.142824844471173,0.0087752078192533,2017,0,84
"CD015588","CD015588_pub2_data","1|52|Fracture (Hazard Ratio)|CKD stages 1-2","Fracture (Hazard Ratio)",1,52,"CKD stages 1-2","reported","reported",3,0.116583743398061,0.134281346751176,0.0232824726362437,2016.33333333333,0,4599.33333333333
"CD015588","CD015588_pub2_data","1|52|Fracture (Hazard Ratio)|CKD stages 3-5","Fracture (Hazard Ratio)",1,52,"CKD stages 3-5","reported","reported",7,0.0211418732768844,0.117178773567341,0,2016,0,945
"CD015588","CD015588_pub2_data","1|53|Genital infection|All CKD stages","Genital infection",1,53,"All CKD stages","or","binary",6,1.25949692593193,0.139692669488422,0,2017.83333333333,0.0105709164031989,2275.5
"CD015588","CD015588_pub2_data","1|53|Genital infection|CKD stages 1-2","Genital infection",1,53,"CKD stages 1-2","or","binary",2,0.107818459083761,0.394176125747239,0,2015.5,0.0488203266787659,270.5
"CD015588","CD015588_pub2_data","1|53|Genital infection|CKD stages 3-5","Genital infection",1,53,"CKD stages 3-5","or","binary",8,0.97190766741909,0.141823954680933,0,2016.375,0.0115823494907167,1794.75
"CD015588","CD015588_pub2_data","1|54|Genital infection (Hazard Ratio)|All CKD stages","Genital infection (Hazard Ratio)",1,54,"All CKD stages","reported","reported",5,1.00589631783443,0.222067162155075,0,2015.6,0,506.4
"CD015588","CD015588_pub2_data","1|54|Genital infection (Hazard Ratio)|CKD stages 3-5","Genital infection (Hazard Ratio)",1,54,"CKD stages 3-5","reported","reported",8,0.977362814620741,0.144550383327271,0,2017.25,0,1767.625
"CD015588","CD015588_pub2_data","1|55|Diabetic ketoacidosis|All CKD stages","Diabetic ketoacidosis",1,55,"All CKD stages","or","binary",5,1.13597802819766,0.402736023551537,0.00377513868255714,2019.6,0.00413285661321358,3228.4
"CD015588","CD015588_pub2_data","1|55|Diabetic ketoacidosis|CKD stages 1-2","Diabetic ketoacidosis",1,55,"CKD stages 1-2","or","binary",2,0.344081656330728,0.423770702519032,0,2017.5,0.0122654610997843,3988.5
"CD015588","CD015588_pub2_data","1|56|Diabetic ketoacidosis (Hazard Ratio)|All CKD stages","Diabetic ketoacidosis (Hazard Ratio)",1,56,"All CKD stages","reported","reported",3,0.814608388571689,0.91106321961585,1.47077960972734,2018,0,3120.33333333333
"CD015588","CD015588_pub2_data","1|56|Diabetic ketoacidosis (Hazard Ratio)|CKD stages 3-5","Diabetic ketoacidosis (Hazard Ratio)",1,56,"CKD stages 3-5","reported","reported",3,0.715423724055958,0.303773488762364,0,2017,0,7113.33333333333
"CD015588","CD015588_pub2_data","1|6|Myocardial infarction (Hazard Ratio)|All CKD stages","Myocardial infarction (Hazard Ratio)",1,6,"All CKD stages","reported","reported",3,-0.727371683777068,0.402269360577385,0.17348370378279,2015,0,913
"CD015588","CD015588_pub2_data","1|6|Myocardial infarction (Hazard Ratio)|CKD stages 3-5","Myocardial infarction (Hazard Ratio)",1,6,"CKD stages 3-5","reported","reported",3,-0.0920190738545446,0.139360044870952,0,2014.66666666667,0,1117.66666666667
"CD015588","CD015588_pub2_data","1|7|Nonfatal myocardial infarction|CKD stages 3-5","Nonfatal myocardial infarction",1,7,"CKD stages 3-5","or","binary",2,-0.508706990121436,0.806516672380197,0.393364696650846,2021.5,0.0268817204301075,150
"CD015588","CD015588_pub2_data","1|8|Nonfatal myocardial infarction (Hazard Ratio)|All CKD stages","Nonfatal myocardial infarction (Hazard Ratio)",1,8,"All CKD stages","reported","reported",2,-0.05691038671294,0.100738565434937,0.009976465,2018.5,NA,0
"CD015592","CD015592_pub3_data","1|2|Episodes of bradycardia|NA","Episodes of bradycardia",1,2,NA,"or","binary",3,0.556683054299599,0.2494015515808,0,2013.33333333333,0.0158730158730159,426.333333333333
"CD015592","CD015592_pub3_data","1|4|Episodes of desaturation (decrease of SpO2 to less than 80%)|NA","Episodes of desaturation (decrease of SpO2 to less than 80%)",1,4,NA,"or","binary",2,0.801670254436697,0.213420956051714,0,2019,0.032051282051282,624.5
"CD015592","CD015592_pub3_data","1|5|Apnea: number of episodes (interruption of breathing for more than 20 seconds) during the procedure|NA","Apnea: number of episodes (interruption of breathing for more than 20 seconds) during the procedure",1,5,NA,"or","binary",2,0.0180895179644998,1.42754085243234,0,2009,0,98.5
"CD015594","CD015594_pub2_data","1|1|Neonatal Facial Coding System pain score during the procedure|NA","Neonatal Facial Coding System pain score during the procedure",1,1,NA,"or","binary",2,0.0755195405142658,1.42666260103782,0,2005,0,56
"CD015594","CD015594_pub2_data","1|3|Adverse events|NA","Adverse events",1,3,NA,"or","binary",2,-0.8609480820497,0.617184039342097,0,2005,0.178571428571429,56
"CD015673","CD015673_pub2_data","1|1|Number of participants with continuous abstinence|NA","Number of participants with continuous abstinence",1,1,NA,"or","binary",6,0.346781987124829,0.136325985326236,0,2003.33333333333,0.256289226232294,197.333333333333
"CD015673","CD015673_pub2_data","1|10|Craving|NA","Craving",1,10,NA,"or","binary",3,0.0340664323133403,1.16350116557962,0,1998,0,78
"CD015673","CD015673_pub2_data","1|2|Number of heavy-drinking participants|NA","Number of heavy-drinking participants",1,2,NA,"or","binary",8,-0.538475579081957,0.157395130987511,0.0484581467770589,2004,0.733021842083736,201.125
"CD015673","CD015673_pub2_data","1|3|% Abstinent days|NA","% Abstinent days",1,3,NA,"reported","reported",2,0,1.8432702702059,0,2007.5,0,431
"CD015673","CD015673_pub2_data","1|5|Number of drinks per drinking day|NA","Number of drinks per drinking day",1,5,NA,"or","binary",7,-0.210586441091841,0.762713634365572,0,2004.14285714286,0,115
"CD015673","CD015673_pub2_data","1|6|Adverse events|NA","Adverse events",1,6,NA,"or","binary",4,0.602275612463108,0.26875330649129,0.0696987700465918,2004.5,0.478795180722892,127
"CD015673","CD015673_pub2_data","1|7|Serious adverse events|NA","Serious adverse events",1,7,NA,"or","binary",4,-1.22354181446613,0.697832330016676,0,2004.5,0.0179617834394904,131
"CD015673","CD015673_pub2_data","1|8|Dropouts|NA","Dropouts",1,8,NA,"or","binary",15,-0.176418326897858,0.0926929273177116,0,2005.6,0.26202900732622,201.4
"CD015673","CD015673_pub2_data","1|9|Dropouts due to adverse events|NA","Dropouts due to adverse events",1,9,NA,"or","binary",8,0.592337720570417,0.30138340095161,0,2003.625,0.0149509978251762,196.5
"CD015673","CD015673_pub2_data","2|5|Dropouts|NA","Dropouts",2,5,NA,"or","binary",3,0.0086193049934109,0.319136575839398,0.212717603264671,2005.33333333333,0.326891623711222,415.333333333333
"CD015673","CD015673_pub2_data","2|6|Dropouts due to adverse events|NA","Dropouts due to adverse events",2,6,NA,"or","binary",2,-0.478832992551546,0.730857443941471,0.748364901404437,2004,0.043262171015475,582.5
"CD015698","CD015698_pub2_data","1|1|Overall survival (Subgroup analysis: IPC Types)|HIPEC","Overall survival (Subgroup analysis: IPC Types)",1,1,"HIPEC","reported","reported",5,-0.340335603737444,0.203293199593883,0,2011.2,NA,NA
"CD015698","CD015698_pub2_data","1|2|Overall survival (Subgroup analysis: Chemotherapy drugs)|CDDP","Overall survival (Subgroup analysis: Chemotherapy drugs)",1,2,"CDDP","reported","reported",2,-0.184011215764355,0.419770142659411,0,2017.5,NA,NA
"CD015698","CD015698_pub2_data","1|2|Overall survival (Subgroup analysis: Chemotherapy drugs)|CDDP + 5-Fu","Overall survival (Subgroup analysis: Chemotherapy drugs)",1,2,"CDDP + 5-Fu","reported","reported",2,-0.35050489031178,0.358698424190121,0,2011,NA,NA
"CD015698","CD015698_pub2_data","1|3|Overall survival (Sensitivity analysis: Excluding studies with overall high risk of bias)|","Overall survival (Sensitivity analysis: Excluding studies with overall high risk of bias)",1,3,"","reported","reported",3,-0.418461022743847,0.212043495366382,0,2013,NA,NA
"CD015698","CD015698_pub2_data","1|5|Anastomotic leakage (Subgroup analysis: IPC Types)|HIPEC","Anastomotic leakage (Subgroup analysis: IPC Types)",1,5,"HIPEC","reported","reported",2,1.9884688861779,3.25909386080475,0,2016.5,0.0441176470588235,60
"CD015698","CD015698_pub2_data","2|1|Overall survival|","Overall survival",2,1,"","reported","reported",2,-0.652094879033185,0.313414757233918,0.1010374803095,2017.5,NA,NA
"CD015698","CD015698_pub2_data","2|5|Anastomotic leakage|","Anastomotic leakage",2,5,"","reported","reported",2,0.638073680032966,1.71981195599792,0,2017.5,0.0410216718266254,63
"CD015721","CD015721_pub2_data","1|1|Functional independence: mRS score < 3 within 90 days|NA","Functional independence: mRS score < 3 within 90 days",1,1,NA,"reported","reported",2,0,1.00026011508077,0,2020.5,0.427378431965588,597.5
"CD015721","CD015721_pub2_data","1|2|Excellent functional outcome: mRS score < 2 within 90 days|NA","Excellent functional outcome: mRS score < 2 within 90 days",1,2,NA,"reported","reported",2,0,0.0362325555317845,0,2021,0.550883110289051,371.5
"CD015721","CD015721_pub2_data","1|3|Mortality within 90 days|NA","Mortality within 90 days",1,3,NA,"or","binary",6,-0.0714141750004854,0.114671971079548,0,2021.16666666667,0.148703555761972,389.333333333333
"CD015721","CD015721_pub2_data","1|6|Successful revascularisation: TICI grades 2b to 3|NA","Successful revascularisation: TICI grades 2b to 3",1,6,NA,"or","binary",6,0.276586622533495,0.112905436989781,5.00071153049336e-06,2021.16666666667,0.837657724250308,387.666666666667
"CD015721","CD015721_pub2_data","1|7|Complete revascularisation: TICI grade 3|NA","Complete revascularisation: TICI grade 3",1,7,NA,"or","binary",5,0.211548311568678,0.0924354330315232,0,2021,0.354503121653571,407.4
"CD015746","CD015746_pub2_data","1|4|Serious adverse events|Vi-TT versus Meningococcal A vaccine","Serious adverse events",1,4,"Vi-TT versus Meningococcal A vaccine","reported","reported",2,0,0.125127575815848,0,2022.5,0.00591922535248178,24074.5
"CD015746","CD015746_pub2_data","2|3|Serious adverse events|Vi-TT versus ViPS","Serious adverse events",2,3,"Vi-TT versus ViPS","or","binary",2,-1.0551116091891,0.854944752897341,0,2016,0.0421328972284386,366
"CD015746","CD015746_pub2_data","4|4|Serious adverse events sensitivity analysis for risk of bias and trial phase|Vi-TT versus Meningococcal A vaccine","Serious adverse events sensitivity analysis for risk of bias and trial phase",4,4,"Vi-TT versus Meningococcal A vaccine","reported","reported",2,0,0.125127575815848,0,2022.5,0.00591922535248178,24074.5
"CD015746","CD015746_pub2_data","5|1|Acute typhoid fever sensitivity analysis for cRCTs (Mitra 2016)|","Acute typhoid fever sensitivity analysis for cRCTs (Mitra 2016)",5,1,"","reported","reported",7,-2.77386435732339,0.552776428552554,0,2016,0,1191.71428571429
"CD015746","CD015746_pub2_data","5|2|Acute typhoid fever sensitivity analysis for cRCTs (Qadri 2021)|","Acute typhoid fever sensitivity analysis for cRCTs (Qadri 2021)",5,2,"","reported","reported",7,-1.88541176012372,0.105195192396864,0,2021,0,31180.8571428571
"CD015746","CD015746_pub2_data","5|3|All-cause mortality sensitivity analysis for cRCTs (Qadri 2021)|","All-cause mortality sensitivity analysis for cRCTs (Qadri 2021)",5,3,"","reported","reported",7,0.67424487610764,0.182999606366596,0,2021,0,31180.8571428571
"CD015746","CD015746_pub2_data","5|4|Serious adverse events sensitivity analysis for cRCTs (Qadri 2021)|","Serious adverse events sensitivity analysis for cRCTs (Qadri 2021)",5,4,"","reported","reported",7,-0.169228850283404,0.0405229786539198,0,2021,0,31180.8571428571
"CD015749","CD015749_pub2_data","2|3|Body composition and weight|Body composition (post intervention/follow-up closest to 6 months)","Body composition and weight",2,3,"Body composition (post intervention/follow-up closest to 6 months)","or","binary",2,-0.110094735423683,1.42922314857854,0,2012.5,0,47.5
"CD015749","CD015749_pub2_data","2|5|Appetite |Appetite (post intervention/follow-up closest to 6 months)","Appetite ",2,5,"Appetite (post intervention/follow-up closest to 6 months)","reported","reported",2,0,0.679564303404496,0,2012.5,0,47.5
"CD015749","CD015749_pub2_data","2|7|Biochemical markers |Biochemical markers (post intervention/follow-up closest to 6 months)","Biochemical markers ",2,7,"Biochemical markers (post intervention/follow-up closest to 6 months)","reported","reported",2,0,4.1671206720251,0,2012.5,0,47.5
"CD015749","CD015749_pub2_data","3|2|Occurrence of adverse events|","Occurrence of adverse events",3,2,"","reported","reported",3,0,0.300883032273062,0,2012,0.348360655737705,131.666666666667
"CD015749","CD015749_pub2_data","3|3|Body composition and weight|Body composition (post intervention/follow-up closest to 6 months)","Body composition and weight",3,3,"Body composition (post intervention/follow-up closest to 6 months)","reported","reported",5,0,0.275989087274833,0,2010,0,145.2
"CD015749","CD015749_pub2_data","3|3|Body composition and weight|Weight (post intervention/follow-up closest to 6 months)","Body composition and weight",3,3,"Weight (post intervention/follow-up closest to 6 months)","reported","reported",3,0,0.438642056864552,0,2010,0,129.666666666667
"CD015749","CD015749_pub2_data","3|4|Quality of life|Quality of life (post intervention/follow-up closest to 6 months)","Quality of life",3,4,"Quality of life (post intervention/follow-up closest to 6 months)","reported","reported",4,0,0.124779099686714,0,2013,0,102.75
"CD015749","CD015749_pub2_data","3|5|Appetite |Appetite (post intervention/follow-up closest to 6 months)","Appetite ",3,5,"Appetite (post intervention/follow-up closest to 6 months)","reported","reported",3,0,0.242907995910182,0,2012,0,131.666666666667
"CD015749","CD015749_pub2_data","3|7|Biochemical markers |Biochemical markers (post intervention/follow-up closest to 6 months)","Biochemical markers ",3,7,"Biochemical markers (post intervention/follow-up closest to 6 months)","reported","reported",4,0,1.73115110716176,0,2013,0,102.75
"CD015751","CD015751_pub2_data","1|1|Contact lens discomfort|Postintervention value","Contact lens discomfort",1,1,"Postintervention value","or","binary",3,-0.432114528137555,1.17023719877628,0,2018.66666666667,0,39.6666666666667
"CD015751","CD015751_pub2_data","1|2|Corneal fluorescein staining|Depth","Corneal fluorescein staining",1,2,"Depth","reported","reported",2,0,0.420571255388526,0,2019,0,36.5
"CD015751","CD015751_pub2_data","1|2|Corneal fluorescein staining|Extent","Corneal fluorescein staining",1,2,"Extent","or","binary",3,-0.432114528137555,1.17023719877628,0,2018.66666666667,0,39.6666666666667
"CD015751","CD015751_pub2_data","1|2|Corneal fluorescein staining|Type","Corneal fluorescein staining",1,2,"Type","reported","reported",2,0,0.420571255388526,0,2019,0,36.5
"CD015751","CD015751_pub2_data","1|3|Conjunctival redness|Nasal region","Conjunctival redness",1,3,"Nasal region","reported","reported",2,0,0.19922688472021,0,2019,0,36.5
"CD015751","CD015751_pub2_data","1|3|Conjunctival redness|Temporal region","Conjunctival redness",1,3,"Temporal region","reported","reported",2,0,0.19922688472021,0,2019,0,36.5
"CD015751","CD015751_pub2_data","1|4|Participant discontinuation|","Participant discontinuation",1,4,"","reported","reported",2,0,1.05512704456007,0,2009.5,0.0111111111111111,69
"CD015751","CD015751_pub2_data","1|5|Comfortable lens wear time (hours)|","Comfortable lens wear time (hours)",1,5,"","reported","reported",3,0,0.799603395061,0,2018.66666666667,0,39.6666666666667
"CD015751","CD015751_pub2_data","1|6|Other dry eye symptoms|SPEED","Other dry eye symptoms",1,6,"SPEED","or","binary",3,-0.432114528137555,1.17023719877628,0,2018.66666666667,0,39.6666666666667
"CD015751","CD015751_pub2_data","2|2|Participant discontinuation|","Participant discontinuation",2,2,"","reported","reported",3,0,0.607759234017188,0,2007.66666666667,0.0463848463848464,89.6666666666667
"CD015751","CD015751_pub2_data","2|3|Comfortable lens wear time (hours)|","Comfortable lens wear time (hours)",2,3,"","reported","reported",2,0,0.450661799038463,0,2010,0,109
"CD015779_data","CD015779_data","2|2|Recurrence of rheumatic fever (rate, rate ratio)|","Recurrence of rheumatic fever (rate, rate ratio)",2,2,"","reported","reported",2,-2.14530926424905,0.523840393440056,0,1963.5,NA,0
"CD015779_data","CD015779_data","2|5|Poor treatment adherence|","Poor treatment adherence",2,5,"","or","binary",2,-2.63720983188739,0.34342624319646,0,1960.5,0.313333333333333,288.5
"CD015786","CD015786_pub2_data","1|1|Overall survival|Adjusted data for age, etc.","Overall survival",1,1,"Adjusted data for age, etc.","reported","reported",2,-0.0687878209075918,0.146421405200685,0,2008.5,0,925.5
"CD015786","CD015786_pub2_data","1|1|Overall survival|Unadjusted data","Overall survival",1,1,"Unadjusted data","reported","reported",2,-0.156862313005858,0.128459747252185,0,2008.5,0,961
"CD015786","CD015786_pub2_data","1|2|Progression (disease)-free survival|Adjusted data for age, etc.","Progression (disease)-free survival",1,2,"Adjusted data for age, etc.","reported","reported",2,-0.213255919219582,0.124161101657681,0,2008.5,0,925.5
"CD015786","CD015786_pub2_data","1|2|Progression (disease)-free survival|Unadjusted data","Progression (disease)-free survival",1,2,"Unadjusted data","reported","reported",2,-0.253287746068639,0.108356943168665,0,2008.5,0,961
"CD015786","CD015786_pub2_data","1|3|Early adverse effects|Blood transfusion","Early adverse effects",1,3,"Blood transfusion","or","binary",2,-0.274859457258908,0.193819248338292,0,2008.5,0.0770598279514114,958.5
"CD015786","CD015786_pub2_data","1|3|Early adverse effects|Direct surgical morbidity","Early adverse effects",1,3,"Direct surgical morbidity","reported","reported",2,0,0.334755703349532,0,2010,0.0675905169485769,720.5
"CD015786","CD015786_pub2_data","1|3|Early adverse effects|Surgically-related systemic morbidity","Early adverse effects",1,3,"Surgically-related systemic morbidity","reported","reported",2,0,0.89533142373335,0,2010,0.0280891243801372,720.5
"CD015786","CD015786_pub2_data","1|4|Late adverse effects|Lymphoedema","Late adverse effects",1,4,"Lymphoedema","reported","reported",2,0,0.86038576895997,0,2010,0.0409279260919774,720.5
"CD015786","CD015786_pub2_data","1|5|Surgically related mortality |","Surgically related mortality ",1,5,"","or","binary",2,-0.469698524867724,0.57358811849697,0,2008.5,0.00499286733238231,958.5
"CD015790","CD015790_pub2_data","1|1|Overall health-related quality of life – change score|Self-management intervention versus active comparator: change score","Overall health-related quality of life – change score",1,1,"Self-management intervention versus active comparator: change score","or","binary",2,0.0436236830395406,1.4179890514126,0,2010.5,0,226
"CD015790","CD015790_pub2_data","1|11|QOL subscore: self-efficacy-final value|Self-management intervention versus active comparator: final value","QOL subscore: self-efficacy-final value",1,11,"Self-management intervention versus active comparator: final value","or","binary",3,-0.0873893210767094,1.16060238771989,0,2018.66666666667,0,113.666666666667
"CD015790","CD015790_pub2_data","1|12|QOL subscore: adaptation to vision loss-final value|Self-management intervention versus active comparator: final value","QOL subscore: adaptation to vision loss-final value",1,12,"Self-management intervention versus active comparator: final value","or","binary",2,-0.206033504878213,1.41794262570899,0,2015,0,209
"CD015790","CD015790_pub2_data","1|2|Overall health-related quality of life – final value|Self-management intervention versus active comparator: final values","Overall health-related quality of life – final value",1,2,"Self-management intervention versus active comparator: final values","or","binary",2,0.0503048805749258,1.41830042766912,0,2017,0,196
"CD015790","CD015790_pub2_data","1|3|Overall vision-related quality of life – change score|Self-management intervention versus active comparator: change score","Overall vision-related quality of life – change score",1,3,"Self-management intervention versus active comparator: change score","reported","reported",3,0,0.097119151236605,0,2013,0,136.666666666667
"CD015790","CD015790_pub2_data","1|4|Overall vision-related quality of life – final value|Self-management intervention versus active comparator: final value","Overall vision-related quality of life – final value",1,4,"Self-management intervention versus active comparator: final value","or","binary",5,-0.0420789194576583,0.898031947029508,0,2016.8,0,159.4
"CD015790","CD015790_pub2_data","1|6|QOL subscore: psychological well-being, emotional distress, depression and anxiety-change score|Self-management intervention versus waiting list or no care: change score","QOL subscore: psychological well-being, emotional distress, depression and anxiety-change score",1,6,"Self-management intervention versus waiting list or no care: change score","reported","reported",3,0,0.102743781448338,0,2009,0,138.666666666667
"CD015790","CD015790_pub2_data","1|9|QOL subscore: physical functioning-final value|Self-management intervention versus active comparator: final value","QOL subscore: physical functioning-final value",1,9,"Self-management intervention versus active comparator: final value","reported","reported",3,0,0.105372679597976,0,2018,0,134.333333333333
"CD015790","CD015790_pub2_data","1|9|QOL subscore: physical functioning-final value|Self-management intervention versus waiting list or no care: final value","QOL subscore: physical functioning-final value",1,9,"Self-management intervention versus waiting list or no care: final value","or","binary",2,-0.0445242228123797,1.43067907438081,0,2010,0,48.5
"CD015802","CD015802_pub2_data","2|1|Apnea: number of infants with at least 1 episode (interruption of breathing for more than 20 seconds, or as defined by the authors) in the 7 days after treatment discontinued|NA","Apnea: number of infants with at least 1 episode (interruption of breathing for more than 20 seconds, or as defined by the authors) in the 7 days after treatment discontinued",2,1,NA,"or","binary",2,-0.537458922400147,0.445831974425215,0.103041405174248,2022,0.138218390804598,147
"CD015804","CD015804_pub2_data","1|1|Change from baseline in best-corrected visual acuity (BCVA) at 8 to 12 weeks|Aflibercept biosimilar versus reference aflibercept","Change from baseline in best-corrected visual acuity (BCVA) at 8 to 12 weeks",1,1,"Aflibercept biosimilar versus reference aflibercept","reported","reported",2,-0.132178053664162,0.504263229249358,0,2021.5,0,510.5
"CD015804","CD015804_pub2_data","1|1|Change from baseline in best-corrected visual acuity (BCVA) at 8 to 12 weeks|Ranibizumab biosimilar versus reference ranibizumab","Change from baseline in best-corrected visual acuity (BCVA) at 8 to 12 weeks",1,1,"Ranibizumab biosimilar versus reference ranibizumab","reported","reported",6,-0.725627586628815,0.382664131191994,0.175360822686146,2021.16666666667,0,430.333333333333
"CD015804","CD015804_pub2_data","1|10|The cumulative incidence of antidrug antibodies (ADAs) during the study period|Ranibizumab biosimilar versus reference ranibizumab","The cumulative incidence of antidrug antibodies (ADAs) during the study period",1,10,"Ranibizumab biosimilar versus reference ranibizumab","or","binary",7,-0.221755669349362,0.173791226434684,0,2021.14285714286,0.0467196111398256,384.571428571429
"CD015804","CD015804_pub2_data","1|2|Proportion of participants who lost fewer than 15 letters in BCVA from baseline at 24 to 48 weeks|Ranibizumab biosimilar versus reference ranibizumab","Proportion of participants who lost fewer than 15 letters in BCVA from baseline at 24 to 48 weeks",1,2,"Ranibizumab biosimilar versus reference ranibizumab","reported","reported",2,0,0.0256539640599407,0,2022,0.968359879466207,237
"CD015804","CD015804_pub2_data","1|3|Proportion of participants who experienced at least one serious ocular adverse event (AE) during the study period|Aflibercept biosimilar versus reference aflibercept","Proportion of participants who experienced at least one serious ocular adverse event (AE) during the study period",1,3,"Aflibercept biosimilar versus reference aflibercept","reported","reported",2,0,0.636603569492357,0,2021.5,0.00922514985014985,510.5
"CD015804","CD015804_pub2_data","1|3|Proportion of participants who experienced at least one serious ocular adverse event (AE) during the study period|Ranibizumab biosimilar versus reference ranibizumab","Proportion of participants who experienced at least one serious ocular adverse event (AE) during the study period",1,3,"Ranibizumab biosimilar versus reference ranibizumab","reported","reported",3,0,0.598417953138616,0,2020.33333333333,0.00461361014994233,363.333333333333
"CD015804","CD015804_pub2_data","1|4|Change from baseline in central subfield thickness (CST) at 4 to 12 weeks|Ranibizumab biosimilar versus reference ranibizumab","Change from baseline in central subfield thickness (CST) at 4 to 12 weeks",1,4,"Ranibizumab biosimilar versus reference ranibizumab","reported","reported",2,-5.42743117391304,5.03471707985424,2.3974975,2019,NA,0
"CD015804","CD015804_pub2_data","1|7|Proportion of participants who experienced at least one serious non-ocular AE during the study period|Ranibizumab biosimilar versus reference ranibizumab","Proportion of participants who experienced at least one serious non-ocular AE during the study period",1,7,"Ranibizumab biosimilar versus reference ranibizumab","or","binary",5,-0.164685097796358,0.153826087392046,0,2020.8,0.0699796190024371,454.4
"CD015804","CD015804_pub2_data","1|9|Proportion of participants who experienced TEAEs leading to investigational product discontinuation or death|Aflibercept biosimiar versus reference aflibercept","Proportion of participants who experienced TEAEs leading to investigational product discontinuation or death",1,9,"Aflibercept biosimiar versus reference aflibercept","or","binary",2,-0.512395399066905,0.489625056498764,0,2021.5,0.0200892857142857,512
"CD015804","CD015804_pub2_data","1|9|Proportion of participants who experienced TEAEs leading to investigational product discontinuation or death|Ranibizumab biosimilar versus reference ranibizumab","Proportion of participants who experienced TEAEs leading to investigational product discontinuation or death",1,9,"Ranibizumab biosimilar versus reference ranibizumab","reported","reported",3,0,0.294427751500422,0,2022,0.0297715026223324,587.333333333333
"CD015820","CD015820_pub2_data","1|1|Objective adherence (1 week to 3 months)|NA","Objective adherence (1 week to 3 months)",1,1,NA,"reported","reported",4,0,6.02998541846749,0,2014.75,0,26
"CD015820","CD015820_pub2_data","3|3|Visual acuity (1 week to 3 months)|NA","Visual acuity (1 week to 3 months)",3,3,NA,"reported","reported",4,0,0.0206534253781154,0,2018.25,0,47.25
"CD015820","CD015820_pub2_data","3|6|Adverse events|NA","Adverse events",3,6,NA,"reported","reported",4,0,0.349653357536934,0,2017.25,0.161574074074074,63.25
"CD015824","CD015824_pub2_data","1|1|Clinical worsening|Combination therapy versus ambrisentan","Clinical worsening",1,1,"Combination therapy versus ambrisentan","reported","reported",2,0,0.170528749592064,0,2014.5,0.280009920634921,251.5
"CD015824","CD015824_pub2_data","1|1|Clinical worsening|Combination therapy versus bosentan","Clinical worsening",1,1,"Combination therapy versus bosentan","reported","reported",2,0,0.553828238030095,0,2014,0.0744234800838574,117.5
"CD015824","CD015824_pub2_data","1|2|Mortality|Combination therapy versus ambrisentan","Mortality",1,2,"Combination therapy versus ambrisentan","reported","reported",2,0,0.698710999795137,0,2014.5,0.0157490079365079,251.5
"CD015824","CD015824_pub2_data","1|3|Hospitalisation|Combination therapy versus ambrisentan","Hospitalisation",1,3,"Combination therapy versus ambrisentan","reported","reported",2,0,0.368034686206439,0,2014.5,0.0870535714285714,251.5
"CD015824","CD015824_pub2_data","1|4|Change from baseline in 6-minute walk distance (6MWD) (subgroups with different formulations)|Combination therapy versus ambrisentan","Change from baseline in 6-minute walk distance (6MWD) (subgroups with different formulations)",1,4,"Combination therapy versus ambrisentan","reported","reported",2,0,5.65939023052648,0,2014.5,0,248
"CD015824","CD015824_pub2_data","1|4|Change from baseline in 6-minute walk distance (6MWD) (subgroups with different formulations)|Combination therapy versus bosentan","Change from baseline in 6-minute walk distance (6MWD) (subgroups with different formulations)",1,4,"Combination therapy versus bosentan","reported","reported",2,0,8.6431913045562,0,2014,0,93
"CD015824","CD015824_pub2_data","1|5|Change from baseline in 6MWD (subgroups with different study durations)|Change from baseline in 6MWD at 3 months","Change from baseline in 6MWD (subgroups with different study durations)",1,5,"Change from baseline in 6MWD at 3 months","reported","reported",4,0,6.80922539679616,0,2016.5,0,103.75
"CD015824","CD015824_pub2_data","1|6|Worsening in World Health Organization functional class |Combination therapy versus ambrisentan","Worsening in World Health Organization functional class ",1,6,"Combination therapy versus ambrisentan","reported","reported",2,0,0.325033438496879,0,2014.5,0.130040322580645,250
"CD015824","CD015824_pub2_data","1|6|Worsening in World Health Organization functional class |Combination therapy versus bosentan","Worsening in World Health Organization functional class ",1,6,"Combination therapy versus bosentan","reported","reported",2,0,0.491720596129666,0,2014,0.0649895178197065,117.5
"CD015824","CD015824_pub2_data","1|9|Withdrawal from the trial|Combination therapy versus ambrisentan","Withdrawal from the trial",1,9,"Combination therapy versus ambrisentan","reported","reported",2,0,0.163269342804562,0,2014.5,0.183799342105263,289
"CD015824","CD015824_pub2_data","2|1|Clinical worsening|Combination therapy versus tadalafil","Clinical worsening",2,1,"Combination therapy versus tadalafil","reported","reported",2,0,0.188750713688479,0,2013,0.201306678579406,267.5
"CD015824","CD015824_pub2_data","2|2|Mortality|Combination therapy versus PDE5is","Mortality",2,2,"Combination therapy versus PDE5is","reported","reported",3,0,0.466875379805734,0,2016.66666666667,0.0210334301243392,228.666666666667
"CD015824","CD015824_pub2_data","2|4|Change from baseline in 6-minute walk distance (6MWT) (subgroups with different formulations)|Combination therapy versus tadalafil","Change from baseline in 6-minute walk distance (6MWT) (subgroups with different formulations)",2,4,"Combination therapy versus tadalafil","reported","reported",3,0,5.86758631515122,0,2016.66666666667,0,191.333333333333
"CD015824","CD015824_pub2_data","2|5|Change from baseline in 6MWD (subgroups with different study durations)|Change from baseline in 6MWD at 3 months","Change from baseline in 6MWD (subgroups with different study durations)",2,5,"Change from baseline in 6MWD at 3 months","reported","reported",3,0,8.85068561757141,0,2018.66666666667,0,77.6666666666667
"CD015824","CD015824_pub2_data","2|5|Change from baseline in 6MWD (subgroups with different study durations)|Change from baseline in 6MWD at 6 months","Change from baseline in 6MWD (subgroups with different study durations)",2,5,"Change from baseline in 6MWD at 6 months","reported","reported",2,0,6.04301088092317,0,2014,0,334
"CD015824","CD015824_pub2_data","2|6|Worsening in World Health Organization functional class |Combination therapy versus tadalafil","Worsening in World Health Organization functional class ",2,6,"Combination therapy versus tadalafil","reported","reported",3,0,0.308461609002681,0,2016.66666666667,0.0898148148148148,184
"CD015824","CD015824_pub2_data","2|8|Serious adverse events|Combination therapy versus tadalafil","Serious adverse events",2,8,"Combination therapy versus tadalafil","reported","reported",2,0,0.12972201393617,0,2019.5,0.250093984962406,191
"CD015824","CD015824_pub2_data","2|9|Withdrawal from the trial|Combination therapy versus tadalafil","Withdrawal from the trial",2,9,"Combination therapy versus tadalafil","reported","reported",2,0,0.165013697107848,0,2019.5,0.163681517158338,302.5
"CD015824","CD015824_pub2_data","3|1|Clinical worsening|","Clinical worsening",3,1,"","reported","reported",3,0,0.133098983098943,0,2013,0.249278499278499,214.666666666667
"CD015824","CD015824_pub2_data","3|2|Mortality|","Mortality",3,2,"","reported","reported",2,0,0.719126473790202,0,2010,0.00793650793650794,136.5
"CD015824","CD015824_pub2_data","3|3|Hospitalisation|","Hospitalisation",3,3,"","reported","reported",2,0,0.333347284637438,0,2010,0.196428571428571,136.5
"CD015824","CD015824_pub2_data","3|4|Change from baseline in 6-minute walk distance (6MWD)|","Change from baseline in 6-minute walk distance (6MWD)",3,4,"","reported","reported",3,0,6.2925613060757,0,2010.33333333333,0,117
"CD015824","CD015824_pub2_data","3|5|Change from baseline in 6MWD (subgroups with different study durations)|Change from baseline in 6MWD at 3 months","Change from baseline in 6MWD (subgroups with different study durations)",3,5,"Change from baseline in 6MWD at 3 months","reported","reported",2,0,10.7563854284854,0,2008,0,53.5
"CD015824","CD015824_pub2_data","3|6|Worsening in World Health Organization functional class|","Worsening in World Health Organization functional class",3,6,"","reported","reported",3,0,0.331997616660388,0,2016.66666666667,0.0797491039426523,133.666666666667
"CD015824","CD015824_pub2_data","3|8|Serious adverse events|","Serious adverse events",3,8,"","reported","reported",2,0,0.12972201393617,0,2019.5,0.250093984962406,191
"CD015824","CD015824_pub2_data","3|9|Withdrawal from the trial|","Withdrawal from the trial",3,9,"","reported","reported",3,0,0.174705562775175,0,2014.66666666667,0.0964912280701754,136
"CD015830","CD015830_pub2_data","1|1|Duration of delirium|NA","Duration of delirium",1,1,NA,"reported","reported",4,-1.07430337028713,0.307126914129797,0.0590875006749429,2020.75,NA,30.25
"CD015830","CD015830_pub2_data","1|2|Mortality in the ICU|NA","Mortality in the ICU",1,2,NA,"reported","reported",2,0.334552031654639,1.17206998893453,0,2022.5,0.175,15
"CD015830","CD015830_pub2_data","1|3|ICUs length of stay|NA","ICUs length of stay",1,3,NA,"reported","reported",3,-2.24181756978447,0.708561739812221,0,2022.33333333333,NA,35.6666666666667
"CD015830","CD015830_pub2_data","1|4|Hospital length of stay|NA","Hospital length of stay",1,4,NA,"reported","reported",2,-7.97617419699995,13.9287857238961,232.094998185718,2022.5,NA,14
"CD015849","CD015849_pub2_data","1|1|All-cause death|All CKD stages","All-cause death",1,1,"All CKD stages","or","binary",3,-0.178718323183882,0.855091189990074,0,2024,0.0111111111111111,102.333333333333
"CD015849","CD015849_pub2_data","1|12|Composite kidney outcome (Hazard ratio)|CKD stages 3-5","Composite kidney outcome (Hazard ratio)",1,12,"CKD stages 3-5","reported","reported",2,-0.142502983892358,0.077090143321246,0,2018,0,1099.5
"CD015849","CD015849_pub2_data","1|16|Nonfatal myocardial infarction (Hazard ratio)|CKD stages 1-2","Nonfatal myocardial infarction (Hazard ratio)",1,16,"CKD stages 1-2","reported","reported",2,-0.533276477370596,0.595536503212258,0.56684580901,2020,NA,0
"CD015849","CD015849_pub2_data","1|16|Nonfatal myocardial infarction (Hazard ratio)|CKD stages 3-5","Nonfatal myocardial infarction (Hazard ratio)",1,16,"CKD stages 3-5","reported","reported",2,-0.217883451773334,0.120349857925041,0,2020,NA,0
"CD015849","CD015849_pub2_data","1|2|All-cause death (Hazard ratio) |CKD stages 3-5","All-cause death (Hazard ratio) ",1,2,"CKD stages 3-5","reported","reported",3,-0.289442417271175,0.106081515201507,3.05737453060729e-06,2017.33333333333,0,921
"CD015849","CD015849_pub2_data","1|22|Nonfatal stroke (Hazard ratio)|CKD stages 1-2 ","Nonfatal stroke (Hazard ratio)",1,22,"CKD stages 1-2 ","reported","reported",2,0.137131168554738,0.156243455526571,0,2020,NA,0
"CD015849","CD015849_pub2_data","1|22|Nonfatal stroke (Hazard ratio)|CKD stages 3-5","Nonfatal stroke (Hazard ratio)",1,22,"CKD stages 3-5","reported","reported",2,-0.193898047216823,0.46794607406342,0.3907285616625,2020,NA,0
"CD015849","CD015849_pub2_data","1|28|Hospitalisation due to heart failure|CKD stages 3-5","Hospitalisation due to heart failure",1,28,"CKD stages 3-5","or","binary",3,-0.133748253884953,0.213175713222178,0.0687713302343114,2017.66666666667,0.0531268454335392,1886.33333333333
"CD015849","CD015849_pub2_data","1|3|Cardiovascular death|All CKD stages","Cardiovascular death",1,3,"All CKD stages","or","binary",2,-0.683130036860337,1.2761380887759,0,2024,0,123.5
"CD015849","CD015849_pub2_data","1|3|Cardiovascular death|CKD stages 1-2","Cardiovascular death",1,3,"CKD stages 1-2","or","binary",2,-0.256108263344278,0.0961351458881031,0,2020.5,0.0221932114882507,5797
"CD015849","CD015849_pub2_data","1|3|Cardiovascular death|CKD stages 3-5","Cardiovascular death",1,3,"CKD stages 3-5","or","binary",4,-0.118441097727457,0.233089106510538,0.0951848412414872,2017.25,0.0471488709534274,1484
"CD015849","CD015849_pub2_data","1|34|Change in body weight [kg]|CKD stages 3-5","Change in body weight [kg]",1,34,"CKD stages 3-5","reported","reported",2,-0.889860964705882,0.42496892864802,0.14528182,2016.5,0,230
"CD015849","CD015849_pub2_data","1|38|Serious adverse events|CKD stages 3-5","Serious adverse events",1,38,"CKD stages 3-5","reported","reported",2,0,0.723612787263515,0,2017.5,0.110645146665458,300.5
"CD015849","CD015849_pub2_data","1|39|Withdrawal due to adverse events|All CKD stages","Withdrawal due to adverse events",1,39,"All CKD stages","reported","reported",3,0,0.462297072174515,0,2023.66666666667,0.105040246471584,1259.66666666667
"CD015849","CD015849_pub2_data","1|39|Withdrawal due to adverse events|CKD stages 3-5","Withdrawal due to adverse events",1,39,"CKD stages 3-5","reported","reported",2,0,1.00501586177732,0,2018,0.0742689047579309,1241
"CD015849","CD015849_pub2_data","1|4|Cardiovascular death (Hazard ratio) |CKD stages 3-5","Cardiovascular death (Hazard ratio) ",1,4,"CKD stages 3-5","reported","reported",2,0.0671242508021575,0.123042178239529,0,2018,0,1243
"CD015849","CD015849_pub2_data","1|40|Withdrawal due to adverse events (Hazard ratio)|CKD stages 3-5","Withdrawal due to adverse events (Hazard ratio)",1,40,"CKD stages 3-5","reported","reported",2,0.485150152484285,0.981075029558239,1.7784246156465,2016.5,0,138.5
"CD015849","CD015849_pub2_data","1|41|Hypoglycaemia|CKD stages 3-5","Hypoglycaemia",1,41,"CKD stages 3-5","reported","reported",2,0,1.01380980460218,0,2017.5,0.140703631500204,300.5
"CD015849","CD015849_pub2_data","1|43|Acute kidney injury|All CKD stages","Acute kidney injury",1,43,"All CKD stages","or","binary",2,-1.70001545831546,1.27615024013708,0,2024,0.0161290322580645,123.5
"CD015849","CD015849_pub2_data","1|44|Acute kidney injury (Hazard ratio)|CKD stages 3-5","Acute kidney injury (Hazard ratio)",1,44,"CKD stages 3-5","reported","reported",2,-0.186359613661232,0.149276203629506,0,2018,0,1241
"CD015849","CD015849_pub2_data","1|47|Change in HbA1c [%]|CKD stages 3-5","Change in HbA1c [%]",1,47,"CKD stages 3-5","reported","reported",2,0,0.0879457001691447,0,2017.5,0,293.5
"CD015849","CD015849_pub2_data","1|48|Change in HbA1c [%]|CKD stages 3-5","Change in HbA1c [%]",1,48,"CKD stages 3-5","reported","reported",4,-0.740693177007902,0.064393399050347,0,2016.75,0,214
"CD015849","CD015849_pub2_data","1|5|3-point MACE|CKD stages 3-5","3-point MACE",1,5,"CKD stages 3-5","reported","reported",3,0,0.0562270894672541,0,2016.66666666667,0.166950515945221,2091.33333333333
"CD015849","CD015849_pub2_data","1|6|3-point MACE (Hazard ratio)|All CKD stages","3-point MACE (Hazard ratio)",1,6,"All CKD stages","reported","reported",2,-0.265824082178086,0.0952550874170243,0.00492064452000002,2022,0,1018.5
"CD015849","CD015849_pub2_data","1|6|3-point MACE (Hazard ratio)|CKD stages 1-2","3-point MACE (Hazard ratio)",1,6,"CKD stages 1-2","reported","reported",3,-0.270596938678318,0.0891212243882775,0.0162046582416476,2017.33333333333,0,5310.33333333333
"CD015849","CD015849_pub2_data","1|6|3-point MACE (Hazard ratio)|CKD stages 3-5","3-point MACE (Hazard ratio)",1,6,"CKD stages 3-5","reported","reported",5,-0.154626456200284,0.0891523663518815,0.0193787241938953,2017.4,0,1441.6
"CD015849","CD015849_pub2_data","1|8|4-point MACE (Hazard ratio)|CKD stages 3-5","4-point MACE (Hazard ratio)",1,8,"CKD stages 3-5","reported","reported",2,-0.154670812767358,0.151497277361913,0.03533956,2017.5,NA,0
"CD015849","CD015849_pub2_data","1|9|Kidney failure|CKD stages 3-5","Kidney failure",1,9,"CKD stages 3-5","or","binary",2,-0.242490134758539,0.492071166458262,0,2017.5,0.0323026703540826,300.5
"CD015849","CD015849_pub2_data","10|1|All-cause death|All CKD stages","All-cause death",10,1,"All CKD stages","or","binary",3,-0.178718323183882,0.855091189990074,0,2024,0.0111111111111111,102.333333333333
"CD015849","CD015849_pub2_data","10|12|Withdrawal due to adverse events|All CKD stages","Withdrawal due to adverse events",10,12,"All CKD stages","reported","reported",2,0,0.489125270303519,0,2024,0.0983870967741935,123.5
"CD015849","CD015849_pub2_data","10|2|All-cause death (Hazard ratio) |CKD stages 3-5","All-cause death (Hazard ratio) ",10,2,"CKD stages 3-5","reported","reported",2,0.352480366429122,1.03803895665539,0.857352415,2017.5,0,300.5
"CD015849","CD015849_pub2_data","10|3|Cardiovascular death|All CKD stages","Cardiovascular death",10,3,"All CKD stages","or","binary",2,-0.683130036860337,1.2761380887759,0,2024,0,123.5
"CD015849","CD015849_pub2_data","10|3|Cardiovascular death|CKD stages 3-5","Cardiovascular death",10,3,"CKD stages 3-5","or","binary",2,0.354071937715206,0.946569959968319,0,2017.5,0.0031055900621118,300.5
"CD015849","CD015849_pub2_data","10|7|Kidney failure|CKD stages 3-5","Kidney failure",10,7,"CKD stages 3-5","or","binary",2,-0.242490134758539,0.492071166458262,0,2017.5,0.0323026703540826,300.5
"CD015849","CD015849_pub2_data","2|1|All-cause death|All CKD stages","All-cause death",2,1,"All CKD stages","or","binary",2,-0.701624690745801,1.29546151004863,0,2019,0.05,52
"CD015849","CD015849_pub2_data","2|2|Cardiovascular death|All CKD stages","Cardiovascular death",2,2,"All CKD stages","or","binary",2,-0.701624690745801,1.29546151004863,0,2019,0.05,52
"CD015849","CD015849_pub2_data","2|5|Urinary albumin excretion rate [µg/min]|All CKD stages","Urinary albumin excretion rate [µg/min]",2,5,"All CKD stages","or","binary",2,-0.115462115391676,1.43885610648785,0,2019,0,50
"CD015849","CD015849_pub2_data","4|25|Change in HbA1c [%]|CKD stages 3-5","Change in HbA1c [%]",4,25,"CKD stages 3-5","reported","reported",4,-0.850262261097397,0.332864663294315,0.368806325000212,2015.25,0,168.25
"CD015849","CD015849_pub2_data","8|1|All-cause death|All CKD stages","All-cause death",8,1,"All CKD stages","or","binary",3,-0.178718323183882,0.855091189990074,0,2024,0.0111111111111111,102.333333333333
"CD015849","CD015849_pub2_data","8|2|Cardiovascular death|All CKD stages","Cardiovascular death",8,2,"All CKD stages","or","binary",2,-0.683130036860337,1.2761380887759,0,2024,0,123.5
"CD015849","CD015849_pub2_data","8|2|Cardiovascular death|CKD stages 1-2","Cardiovascular death",8,2,"CKD stages 1-2","or","binary",2,-0.256108263344278,0.0961351458881031,0,2020.5,0.0221932114882507,5797
"CD015849","CD015849_pub2_data","8|2|Cardiovascular death|CKD stages 3-5","Cardiovascular death",8,2,"CKD stages 3-5","or","binary",4,-0.118441097727457,0.233089106510538,0.0951848412414872,2017.25,0.0471488709534274,1484
"CD015849","CD015849_pub2_data","8|3|Change in body weight [kg]|CKD stages 3-5","Change in body weight [kg]",8,3,"CKD stages 3-5","reported","reported",2,-0.889860964705882,0.42496892864802,0.14528182,2016.5,0,230
"CD015849","CD015849_pub2_data","8|5|Change in HbA1c [%]|CKD stages 3-5","Change in HbA1c [%]",8,5,"CKD stages 3-5","reported","reported",3,-0.764020637599758,0.0703416182314615,0,2017.33333333333,0,253
"CD015849","CD015849_pub2_data","9|1|All-cause death|All CKD stages","All-cause death",9,1,"All CKD stages","or","binary",3,-0.178718323183882,0.855091189990074,0,2024,0.0111111111111111,102.333333333333
"CD015849","CD015849_pub2_data","9|14|Withdrawal due to adverse events|All CKD stages","Withdrawal due to adverse events",9,14,"All CKD stages","reported","reported",2,0,0.489125270303519,0,2024,0.0983870967741935,123.5
"CD015849","CD015849_pub2_data","9|2|All-cause death (Hazard ratio) |CKD stages 3-5","All-cause death (Hazard ratio) ",9,2,"CKD stages 3-5","reported","reported",2,0.352480366429122,1.03803895665539,0.857352415,2017.5,0,300.5
"CD015849","CD015849_pub2_data","9|3|Cardiovascular death|All CKD stages","Cardiovascular death",9,3,"All CKD stages","or","binary",2,-0.683130036860337,1.2761380887759,0,2024,0,123.5
"CD015849","CD015849_pub2_data","9|3|Cardiovascular death|CKD stages 3-5","Cardiovascular death",9,3,"CKD stages 3-5","or","binary",2,0.354071937715206,0.946569959968319,0,2017.5,0.0031055900621118,300.5
"CD015849","CD015849_pub2_data","9|6|3-point MACE (Hazard ratio)|CKD stages 3-5","3-point MACE (Hazard ratio)",9,6,"CKD stages 3-5","reported","reported",3,-0.12455712623118,0.100957974421265,0,2017.66666666667,0,1339
"CD015849","CD015849_pub2_data","9|8|Kidney failure|CKD stages 3-5","Kidney failure",9,8,"CKD stages 3-5","or","binary",2,-0.242490134758539,0.492071166458262,0,2017.5,0.0323026703540826,300.5
"CD015854_data","CD015854_data","2|1|Improvement in function or disability (assessed with change in Health Assessment Questionnaire) |Abatacept immediate vs placebo (at 3 or 6 months)","Improvement in function or disability (assessed with change in Health Assessment Questionnaire) ",2,1,"Abatacept immediate vs placebo (at 3 or 6 months)","or","binary",2,-0.080667774714746,1.43422889376313,0,2014,0,73.5
"CD015854_data","CD015854_data","2|3|Improvement in muscle strength (assessed with change in MMT8) (GIV analysis)|Abatacept immediate vs placebo (at 3 or 6 months)","Improvement in muscle strength (assessed with change in MMT8) (GIV analysis)",2,3,"Abatacept immediate vs placebo (at 3 or 6 months)","reported","reported",2,4.06242087275402,2.74790987515047,7.2803292835815,2014,0,9.5
"CD015854_data","CD015854_data","2|6|Serious adverse event|","Serious adverse event",2,6,"","or","binary",2,-0.035626170953793,0.651906372064353,0,2014,0.0273972602739726,83.5
"CD015854_data","CD015854_data","2|7|Withdrawals for either lack of benefit or adverse events|","Withdrawals for either lack of benefit or adverse events",2,7,"","or","binary",2,-0.425651558383391,0.616463568252698,0,2014,0.138508371385084,83.5
"CD015854_data","CD015854_data","6|4|Change in skin disease activity (assessed with change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI))|Lenabasum 20 mg ","Change in skin disease activity (assessed with change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI))",6,4,"Lenabasum 20 mg ","reported","reported",2,0,1.36445411093789,0,2018.5,0,76.5
"CD015854_data","CD015854_data","8|3|Improvement of muscle strength (assessed with change in MMT24, measured at 12 weeks)|Siponimod 2 mg ","Improvement of muscle strength (assessed with change in MMT24, measured at 12 weeks)",8,3,"Siponimod 2 mg ","reported","reported",2,0,4.91375059756267,0,2013,0,10
"CD015854_data","CD015854_data","8|6|Serious adverse event|Siponimod dosage 10 mg ","Serious adverse event",8,6,"Siponimod dosage 10 mg ","reported","reported",2,0,0.859046352949544,0,2011.5,0.15,12.5
"CD015854_data","CD015854_data","8|6|Serious adverse event|Siponimod dosage 2 mg ","Serious adverse event",8,6,"Siponimod dosage 2 mg ","or","binary",2,-0.481499646503616,1.39605295293212,0.943365333943357,2013,0.2,10.5
"CD015855_data","CD015855_data","1|4|Improvement of muscle strength (assessed with change in MMT or other validated muscle score)|MMT (potential score 0 to 90)","Improvement of muscle strength (assessed with change in MMT or other validated muscle score)",1,4,"MMT (potential score 0 to 90)","reported","reported",2,0,0.58036419025041,0,1999.5,0,20.5
"CD015855_data","CD015855_data","1|7|Serious adverse event|","Serious adverse event",1,7,"","or","binary",2,0.548529765416561,0.655552249520325,0,2011.5,0.0435606060606061,72
"CD015855_data","CD015855_data","3|5|Serious adverse event|","Serious adverse event",3,5,"","reported","reported",2,0,0.512771137917313,0,2017.5,0.13563829787234,62
"CD015855_data","CD015855_data","3|6|Withdrawals for either lack of benefit or adverse events |","Withdrawals for either lack of benefit or adverse events ",3,6,"","reported","reported",3,0,0.263385779516405,0,2012.33333333333,0.293232860520095,50.3333333333333
"CD015855_data","CD015855_data","5|6|Withdrawals for either lack of benefit or adverse events  |","Withdrawals for either lack of benefit or adverse events  ",5,6,"","reported","reported",2,0,0.255789287278719,0,2009,0.346099290780142,62
"CD015875_data","CD015875_data","1|1|Body Mass Index (kg/m2) (10 to 19 years)|NA","Body Mass Index (kg/m2) (10 to 19 years)",1,1,NA,"reported","reported",2,0.121532103949391,0.88298625256655,0.950486556441846,2019.5,NA,13.5
"CD015875_data","CD015875_data","1|2|Weight (kg) (10 to 19 years)|NA","Weight (kg) (10 to 19 years)",1,2,NA,"reported","reported",2,-3.56006517719381,3.31753444217534,0,2016.5,NA,29
"CD015875_data","CD015875_data","1|21|Fasting insulin (uIU/mL) (10 to 19 years)|NA","Fasting insulin (uIU/mL) (10 to 19 years)",1,21,NA,"reported","reported",3,1.88980214977045,1.59384619497261,0,2017,NA,25.6666666666667
"CD015875_data","CD015875_data","1|22|HOMA-IR (10 to 19 years)|NA","HOMA-IR (10 to 19 years)",1,22,NA,"reported","reported",2,0.146899881551684,0.720668612291342,0,2016.5,NA,29
"CD015875_data","CD015875_data","1|23|Fasting glucose (mg/dL) (10 to 19 years)|NA","Fasting glucose (mg/dL) (10 to 19 years)",1,23,NA,"reported","reported",3,-1.56912929815622,3.10428685228242,21.2647098812452,2017,NA,25.6666666666667
"CD015875_data","CD015875_data","1|3|Waist circumference (cm) (10 to 19 years)|NA","Waist circumference (cm) (10 to 19 years)",1,3,NA,"reported","reported",2,2.84064819981491,1.93360926399212,0,2015,NA,34.5
"CD015875_data","CD015875_data","1|4|Total Body Fat Percentage (%TBF) (10 to 19 years)|NA","Total Body Fat Percentage (%TBF) (10 to 19 years)",1,4,NA,"reported","reported",2,1.94925654150759,1.38639076197642,2.41616342462906,2015,NA,34.5
"CD015875_data","CD015875_data","1|8|BMI Z-scores (10 to 19 years)|NA","BMI Z-scores (10 to 19 years)",1,8,NA,"reported","reported",2,-0.0368034019466999,0.0554126744214639,0,2016.5,NA,29
"CD015875_data","CD015875_data","4|16|BMI Z-scores (0 to 19 years)|NA","BMI Z-scores (0 to 19 years)",4,16,NA,"reported","reported",2,-0.0353749052475009,0.199170782971351,0,2019.5,NA,72
"CD015875_data","CD015875_data","4|26|Fasting insulin (uIU/mL) (0 to 19 years)|NA","Fasting insulin (uIU/mL) (0 to 19 years)",4,26,NA,"reported","reported",2,12.743881394646,8.10079639371722,0,2018,NA,57
"CD015875_data","CD015875_data","4|28|Fasting glucose (mg/dL) (0 to 19 years)|NA","Fasting glucose (mg/dL) (0 to 19 years)",4,28,NA,"reported","reported",3,2.87891214967916,0.234421478779876,2.15080126905376e-06,2020,NA,71
"CD015875_data","CD015875_data","4|30|Total cholesterol (mg/dL) (0 to 19 years)|NA","Total cholesterol (mg/dL) (0 to 19 years)",4,30,NA,"reported","reported",3,1.2517273473693,0.148622628917043,0,2020,NA,71
"CD015875_data","CD015875_data","4|31|LDL cholesterol (mg/dL) (0 to 19 years)|NA","LDL cholesterol (mg/dL) (0 to 19 years)",4,31,NA,"reported","reported",3,3.49183727542162,0.161194382221861,0,2020,NA,71
"CD015875_data","CD015875_data","4|32|HDL cholesterol (mg/dL) (0 to 19 years)|NA","HDL cholesterol (mg/dL) (0 to 19 years)",4,32,NA,"reported","reported",3,0.904613843120508,0.721901973885919,0.573986154769329,2020,NA,71
"CD015875_data","CD015875_data","4|33|Triglycerides (mg/dL) (0 to 19 years)|NA","Triglycerides (mg/dL) (0 to 19 years)",4,33,NA,"reported","reported",3,-16.827067057141,0.245930341735681,0,2020,NA,71
"CD015875_data","CD015875_data","5|1|Body Mass Index (kg/m2) (0 to 19 years)|NA","Body Mass Index (kg/m2) (0 to 19 years)",5,1,NA,"reported","reported",2,-0.20356404603715,1.37576314911368,0,2020,NA,62
"CD015875_data","CD015875_data","5|16|Fasting insulin (uIU/mL) (0 to 19 years)|NA","Fasting insulin (uIU/mL) (0 to 19 years)",5,16,NA,"reported","reported",3,-0.764586811712882,1.78725527761394,0.530577638316503,2019.33333333333,NA,45.3333333333333
"CD015875_data","CD015875_data","5|17|HOMA-IR (0 to 19 years)|NA","HOMA-IR (0 to 19 years)",5,17,NA,"reported","reported",3,-0.154434687540059,0.412003130341822,2.8413599179562e-06,2019.33333333333,NA,45.3333333333333
"CD015875_data","CD015875_data","5|18|Fasting glucose (mg/dL) (0 to 19 years)|NA","Fasting glucose (mg/dL) (0 to 19 years)",5,18,NA,"reported","reported",3,-0.505082285263712,1.6066430426492,0.279322420653463,2019.33333333333,NA,45.3333333333333
"CD015875_data","CD015875_data","5|2|Weight (kg) (0 to 19 years)|NA","Weight (kg) (0 to 19 years)",5,2,NA,"reported","reported",2,0.729887937789614,0.954916028531498,0,2019,NA,50.5
"CD015875_data","CD015875_data","5|20|Total cholesterol (mg/dL) (0 to 19 years)|NA","Total cholesterol (mg/dL) (0 to 19 years)",5,20,NA,"reported","reported",2,0.0509458031272345,4.51420734020909,0,2019.5,NA,41.5
"CD015875_data","CD015875_data","5|21|LDL cholesterol (mg/dL) (0 to 19 years)|NA","LDL cholesterol (mg/dL) (0 to 19 years)",5,21,NA,"reported","reported",2,-1.21217447839681,3.90992506000131,0,2019.5,NA,41.5
"CD015875_data","CD015875_data","5|22|HDL cholesterol (mg/dL) (0 to 19 years)|NA","HDL cholesterol (mg/dL) (0 to 19 years)",5,22,NA,"reported","reported",2,3.09637880518831,1.29757185855299,0,2019.5,NA,41.5
"CD015875_data","CD015875_data","5|23|Triglycerides (mg/dL) (0 to 19 years)|NA","Triglycerides (mg/dL) (0 to 19 years)",5,23,NA,"reported","reported",2,-5.5838417503264,6.64351753028664,0,2019.5,NA,41.5
"CD015875_data","CD015875_data","5|3|Waist circumference (cm) (0 to 19 years)|NA","Waist circumference (cm) (0 to 19 years)",5,3,NA,"reported","reported",2,-0.950924365757047,0.486667915619883,0,2019,NA,50.5
"CD015875_data","CD015875_data","5|4|Total Body Fat Percentage (%TBF) (0 to 19 years)|NA","Total Body Fat Percentage (%TBF) (0 to 19 years)",5,4,NA,"reported","reported",2,-0.0900588949449523,0.478687856419809,0,2019.5,NA,41.5
"CD015875_data","CD015875_data","5|5|Systolic blood pressure (0 to 19 years)|NA","Systolic blood pressure (0 to 19 years)",5,5,NA,"reported","reported",2,4.7191333615749,2.70638777425993,0,2019.5,NA,44
"CD015875_data","CD015875_data","5|6|Diastolic blood pressure (mmHg) (0 to 19 years)|NA","Diastolic blood pressure (mmHg) (0 to 19 years)",5,6,NA,"reported","reported",2,0.0701458671388483,2.52733574972363,0,2019.5,NA,44
"CD015875_data","CD015875_data","5|7|Adverse events (0 to 19 years)|NA","Adverse events (0 to 19 years)",5,7,NA,"or","binary",3,-0.0130808872292849,1.16482864205633,0,2019.66666666667,0,57.3333333333333
"CD015875_data","CD015875_data","6|12|Total cholesterol (mg/dL) (0 to 19 years)|NA","Total cholesterol (mg/dL) (0 to 19 years)",6,12,NA,"reported","reported",2,-4.24896064117112,0.114005825503078,0,2018.5,NA,55
"CD015875_data","CD015875_data","6|13|LDL cholesterol (mg/dL) (0 to 19 years)|NA","LDL cholesterol (mg/dL) (0 to 19 years)",6,13,NA,"reported","reported",2,-1.54995635807145,0.0360547809140419,0,2018.5,NA,55
"CD015875_data","CD015875_data","6|14|HDL cholesterol (mg/dL) (0 to 19 years)|NA","HDL cholesterol (mg/dL) (0 to 19 years)",6,14,NA,"reported","reported",2,0.389802551262919,0.041224949293784,0,2018.5,NA,55
"CD015875_data","CD015875_data","6|15|Triglycerides (mg/dL) (0 to 19 years)|NA","Triglycerides (mg/dL) (0 to 19 years)",6,15,NA,"reported","reported",2,-1.7702147207093,0.156194167422357,0,2018.5,NA,55
"CD015875_data","CD015875_data","6|2|Weight (kg) (0 to 19 years)|NA","Weight (kg) (0 to 19 years)",6,2,NA,"reported","reported",2,-2.34738977600883,1.22471240357119,0,2018.5,NA,55
"CD015875_data","CD015875_data","6|6|Adverse events (0 to 19 years)|NA","Adverse events (0 to 19 years)",6,6,NA,"or","binary",2,-0.0714814045907618,1.42680453321176,0,2018.5,0,55
"CD015894","CD015894_pub2_data","1|1|Pain assessed with a validated scale for procedural pain in newborns during the procedure|NIPPS","Pain assessed with a validated scale for procedural pain in newborns during the procedure",1,1,"NIPPS","reported","reported",2,0,0.171576747430713,0,2020,0,77.5
"CD015894","CD015894_pub2_data","1|1|Pain assessed with a validated scale for procedural pain in newborns during the procedure|PIPP","Pain assessed with a validated scale for procedural pain in newborns during the procedure",1,1,"PIPP","reported","reported",4,0,0.128620326654198,0,2017,0,61.5
"CD015894","CD015894_pub2_data","1|2|Pain assessed with a validated scale for procedural pain in newborns up to 10 minutes after the procedure|NIPS","Pain assessed with a validated scale for procedural pain in newborns up to 10 minutes after the procedure",1,2,"NIPS","reported","reported",2,0,0.17700147394107,0,2020,0,77.5
"CD015894","CD015894_pub2_data","2|1|Pain assessed with a validated scale for procedural pain in newborns during the procedure|PIPP","Pain assessed with a validated scale for procedural pain in newborns during the procedure",2,1,"PIPP","reported","reported",2,0,0.49642272756687,0,2016,0,57
"CD015894","CD015894_pub2_data","2|2|Pain assessed with a validated scale for procedural pain in newborns up to 10 minutes after the procedure|PIPP","Pain assessed with a validated scale for procedural pain in newborns up to 10 minutes after the procedure",2,2,"PIPP","reported","reported",2,0,0.200340233596841,0,2016,0,57
"CD015894","CD015894_pub2_data","2|3|Any harms|","Any harms",2,3,"","or","binary",3,0.264944304604752,1.16312234612695,0,2017.33333333333,0,82.3333333333333
"CD015932","CD015932_pub2_data","2|11|Rate of pulmonary complications (pneumonia)|","Rate of pulmonary complications (pneumonia)",2,11,"","or","binary",2,-0.523276219405766,0.494225995277443,0.396513258267132,2018,0.412441314553991,4893
"CD015932","CD015932_pub2_data","2|4|In-hospital mortality|","In-hospital mortality",2,4,"","reported","reported",2,1.20409793448718,0.0766191480923124,0,2019,0.0436619718309859,4842
"CD015932","CD015932_pub2_data","2|7|ICU length of stay (days)|","ICU length of stay (days)",2,7,"","reported","reported",2,-24.0264202536184,15.1990088516208,439.854005448031,2022,0,73
"CD015932","CD015932_pub2_data","2|9|Hospital length of stay (days)|","Hospital length of stay (days)",2,9,"","reported","reported",3,-17.801428893464,12.3927007707202,417.623310516476,2016.33333333333,NA,86.3333333333333
"CD015932","CD015932_pub2_data","3|2|ICU length of stay|NRSI","ICU length of stay",3,2,"NRSI","reported","reported",2,-24.0264202536184,15.1990088516208,439.854005448031,2022,NA,73
"CD015932","CD015932_pub2_data","3|3|Rate of pulmonary complications (pneumonia)|NRSI","Rate of pulmonary complications (pneumonia)",3,3,"NRSI","reported","reported",2,0.691895718954079,0.269537377047798,0.130662968156999,2018,0.412441314553991,4893
"CD015932","CD015932_pub2_data","4|1|All-cause mortality|≤ 7 days","All-cause mortality",4,1,"≤ 7 days","reported","reported",4,1.1191177078539,0.268351698647805,0.0594752032138526,2012.25,0.118990835838662,237.75
"CD015932","CD015932_pub2_data","4|12|Rate of pulmonary complications – pneumonia|≤ 10 days","Rate of pulmonary complications – pneumonia",4,12,"≤ 10 days","reported","reported",2,0.691895718954079,0.269537377047798,0.130662968156999,2018,0.412441314553991,4893
"CD015932","CD015932_pub2_data","4|12|Rate of pulmonary complications – pneumonia|≤ 4 days","Rate of pulmonary complications – pneumonia",4,12,"≤ 4 days","reported","reported",3,0.666569167884968,0.181198332186929,0.0916809204986392,2011.66666666667,0.633779582062163,9295.33333333333
"CD015932","CD015932_pub2_data","4|12|Rate of pulmonary complications – pneumonia|≤ 7 days","Rate of pulmonary complications – pneumonia",4,12,"≤ 7 days","reported","reported",3,0.631469817605532,0.114608424755686,0.0289472502439569,2001.33333333333,0.677056277056277,122
"CD015932","CD015932_pub2_data","4|13|Rate of pulmonary complications – pneumonia (with RCT)|≤ 4 days","Rate of pulmonary complications – pneumonia (with RCT)",4,13,"≤ 4 days","or","binary",3,-1.06470310397026,0.580873085530596,0.755095942417453,2011.66666666667,0.667350367291017,9292
"CD015932","CD015932_pub2_data","4|15|Rate of pulmonary complications – ventilator-associated pneumonia|≤ 7 days","Rate of pulmonary complications – ventilator-associated pneumonia",4,15,"≤ 7 days","reported","reported",2,0.698525628990196,0.0840701661729467,0,2019.5,0.346277107146672,360.5
"CD015932","CD015932_pub2_data","4|2|All-cause mortality (with RCT)|≤ 7 days","All-cause mortality (with RCT)",4,2,"≤ 7 days","or","binary",4,0.354001177279466,0.285448649949988,0.128087236975398,2012.25,0.118990835838662,237.75
"CD015932","CD015932_pub2_data","4|3|All-cause mortality (time-to-event)|≤ 7 days","All-cause mortality (time-to-event)",4,3,"≤ 7 days","reported","reported",2,0.0354402801268126,0.190424435730717,0,2021.5,NA,0
"CD015932","CD015932_pub2_data","4|4|ICU length of stay|≤ 10 days","ICU length of stay",4,4,"≤ 10 days","reported","reported",2,-24.0264265116799,15.1990089230894,439.85482381424,2022,NA,73
"CD015932","CD015932_pub2_data","4|4|ICU length of stay|≤ 7 days","ICU length of stay",4,4,"≤ 7 days","reported","reported",4,-7.47165062561722,1.57796462584094,0,2008.5,NA,199.75
"CD015932","CD015932_pub2_data","4|5|ICU length of stay (with RCT)|≤ 10 days","ICU length of stay (with RCT)",4,5,"≤ 10 days","or","binary",2,-0.188060132862048,1.43568445946248,0,2022,0,73
"CD015932","CD015932_pub2_data","4|5|ICU length of stay (with RCT)|≤ 7 days","ICU length of stay (with RCT)",4,5,"≤ 7 days","or","binary",4,0.610038419263827,1.00394462723283,0,2008.5,0,199.75
"CD015932","CD015932_pub2_data","5|1|All-cause mortality|percutaneous and open surgical","All-cause mortality",5,1,"percutaneous and open surgical","or","binary",2,0.784118346722776,0.529935336873795,0.235791568544684,2019.5,0.0526061776061776,206
"CD015932","CD015932_pub2_data","5|2|All-cause mortality (with RCT)|Open surgical","All-cause mortality (with RCT)",5,2,"Open surgical","or","binary",2,-0.233023217812565,0.425539319945242,0,2002,0.138539898132428,108.5
"CD015932","CD015932_pub2_data","5|2|All-cause mortality (with RCT)|Percutaneous and open surgical","All-cause mortality (with RCT)",5,2,"Percutaneous and open surgical","or","binary",2,0.784118346722776,0.529935336873795,0.235791568544684,2019.5,0.0526061776061776,206
"CD015968_data","CD015968_data","1|2|BMI (z-score) - End of study|NA","BMI (z-score) - End of study",1,2,NA,"reported","reported",2,0.0542584574960975,0.0562124194214567,0,2017,NA,85
"CD015968_data","CD015968_data","1|3|BMI (kg/m2) - End of study|NA","BMI (kg/m2) - End of study",1,3,NA,"reported","reported",2,-0.214578558293693,0.920367722589685,0.707632226018327,2015.5,NA,69
"CD015968_data","CD015968_data","1|4|Waist circumference (cm) - End of study|NA","Waist circumference (cm) - End of study",1,4,NA,"reported","reported",3,-1.10725062257248,1.2870278200467,5.95385932342508e-06,2013,NA,67.6666666666667
"CD015968_data","CD015968_data","1|5|Fat mass (%) - End of study|NA","Fat mass (%) - End of study",1,5,NA,"reported","reported",3,-2.60686833751675,1.01934100663021,0.333628023137323,2013,NA,67.6666666666667
"CD015968_data","CD015968_data","1|6|Blood pressure - systolic - End of study|NA","Blood pressure - systolic - End of study",1,6,NA,"reported","reported",2,0.918854055994431,1.94252772761986,0,2015.5,NA,69
"CD015968_data","CD015968_data","1|7|Blood pressure - diastolic - End of study|NA","Blood pressure - diastolic - End of study",1,7,NA,"reported","reported",2,0.0874911499041293,1.58453610396016,0,2015.5,NA,69
"CD015968_data","CD015968_data","2|1|BMI (z-score) Change|NA","BMI (z-score) Change",2,1,NA,"reported","reported",3,0.00680012329935696,0.0378727550261089,0.00139798447519936,2020.33333333333,NA,71.6666666666667
"CD015968_data","CD015968_data","2|2|BMI (z-score) - End of study|NA","BMI (z-score) - End of study",2,2,NA,"reported","reported",3,0.00847053873630961,0.0493624205672676,0,2017.33333333333,NA,61.6666666666667
"CD015968_data","CD015968_data","2|4|BMI (percentile) - End of study|NA","BMI (percentile) - End of study",2,4,NA,"reported","reported",2,-0.34934192988397,0.803097791611909,0,2016.5,NA,67
"CD016001_data","CD016001_data","1|1|Death|&lt; 12 Weeks","Death",1,1,"&lt; 12 Weeks","reported","reported",17,0,0.0135267445440873,0,2012.14285714286,0,32.2941176470588
"CD016001_data","CD016001_data","1|1|Death|≥ 12 Weeks","Death",1,1,"≥ 12 Weeks","reported","reported",7,0.000324746872032946,0.0145686158182552,0,2013.57142857143,0.00297619047619048,47.2857142857143
"CD016001_data","CD016001_data","1|10|Musculoskeletal fitness (strength, UL affected)|&lt; 12 Weeks","Musculoskeletal fitness (strength, UL affected)",1,10,"&lt; 12 Weeks","reported","reported",4,0.660199732581062,0.51989633279891,0.871101770344746,2014.75,NA,22.5
"CD016001_data","CD016001_data","1|11|Musculoskeletal fitness (strength, UL unaffected)|&lt; 12 Weeks","Musculoskeletal fitness (strength, UL unaffected)",1,11,"&lt; 12 Weeks","reported","reported",2,0.702854659461697,0.300316666870882,0,2019,NA,24
"CD016001_data","CD016001_data","1|13|Walking speed (comfortable)|&lt; 12 Weeks","Walking speed (comfortable)",1,13,"&lt; 12 Weeks","reported","reported",2,-0.0567367611930382,0.0434306658643573,0,2004.5,NA,19
"CD016001_data","CD016001_data","1|13|Walking speed (comfortable)|≥ 12 Weeks","Walking speed (comfortable)",1,13,"≥ 12 Weeks","reported","reported",4,0.0411866826268478,0.0618398667484716,0.00764749994826108,2013.25,NA,43.5
"CD016001_data","CD016001_data","1|14|Walking speed (maximal)|&lt; 12 Weeks","Walking speed (maximal)",1,14,"&lt; 12 Weeks","reported","reported",6,0.146549567005386,0.0958661692367059,0.0341832637172934,2012,NA,18.6666666666667
"CD016001_data","CD016001_data","1|14|Walking speed (maximal)|≥ 12 Weeks","Walking speed (maximal)",1,14,"≥ 12 Weeks","reported","reported",3,0.0297877682541156,0.0453098698115413,0.000798427050418884,2016.33333333333,NA,43
"CD016001_data","CD016001_data","1|15|Walking endurance (6-MWT)|&lt; 12 Weeks","Walking endurance (6-MWT)",1,15,"&lt; 12 Weeks","reported","reported",2,29.4279717238504,8.46788276979303,0,2011.5,NA,12
"CD016001_data","CD016001_data","1|15|Walking endurance (6-MWT)|≥ 12 Weeks","Walking endurance (6-MWT)",1,15,"≥ 12 Weeks","reported","reported",3,17.871705707925,10.6540592101632,0,2013,NA,54.6666666666667
"CD016001_data","CD016001_data","1|16|Balance|&lt; 12 Weeks","Balance",1,16,"&lt; 12 Weeks","reported","reported",3,0.571471364231369,0.380387287951465,0.240844857827655,2017,NA,22.6666666666667
"CD016001_data","CD016001_data","1|16|Balance|≥ 12 Weeks","Balance",1,16,"≥ 12 Weeks","reported","reported",2,0.36354998551013,0.182834491899771,0,2017,NA,61
"CD016001_data","CD016001_data","1|17|Functional mobility (Timed Up and Go)|&lt; 12 Weeks","Functional mobility (Timed Up and Go)",1,17,"&lt; 12 Weeks","reported","reported",6,-3.60359413305248,1.17773989818858,5.41872069643499,2016,NA,21
"CD016001_data","CD016001_data","1|17|Functional mobility (Timed Up and Go)|≥ 12 Weeks","Functional mobility (Timed Up and Go)",1,17,"≥ 12 Weeks","reported","reported",2,-2.25943789943466,0.943079735142007,0,2017,NA,61
"CD016001_data","CD016001_data","1|23|Mood (depression)|≥ 12 Weeks","Mood (depression)",1,23,"≥ 12 Weeks","reported","reported",2,-0.238058198842241,0.188203416535328,0,2013,NA,57
"CD016001_data","CD016001_data","1|25|Fatigue severity (overall)|≥ 12 Weeks","Fatigue severity (overall)",1,25,"≥ 12 Weeks","reported","reported",2,0.638881286376626,0.568148911395035,0.466904726483533,2014,NA,25.5
"CD016001_data","CD016001_data","1|8|Musculoskeletal fitness (strength, LL affected)|&lt; 12 Weeks","Musculoskeletal fitness (strength, LL affected)",1,8,"&lt; 12 Weeks","reported","reported",3,0.758755392022846,0.362412262476787,0.229392221430958,2010.33333333333,NA,31
"CD016001_data","CD016001_data","1|8|Musculoskeletal fitness (strength, LL affected)|≥ 12 Weeks","Musculoskeletal fitness (strength, LL affected)",1,8,"≥ 12 Weeks","reported","reported",4,0.719885919973369,0.274067959964691,0.0911322571678863,2012.75,NA,22.75
"CD016001_data","CD016001_data","1|9|Musculoskeletal fitness (strength, LL unaffected)|&lt; 12 Weeks","Musculoskeletal fitness (strength, LL unaffected)",1,9,"&lt; 12 Weeks","reported","reported",2,1.03170065489429,0.249981444151095,0,2011.5,NA,37.5
"CD016001_data","CD016001_data","1|9|Musculoskeletal fitness (strength, LL unaffected)|≥ 12 Weeks","Musculoskeletal fitness (strength, LL unaffected)",1,9,"≥ 12 Weeks","reported","reported",2,0.957039632367248,0.5702812361623,0.515567022310363,2010,NA,35
"CD016001_data","CD016001_data","2|1|Death|&lt; 12 Weeks","Death",2,1,"&lt; 12 Weeks","reported","reported",4,0,0.0321476246004503,0,2011,0,27.25
"CD016002_data","CD016002_data","1|1|Death|&lt; 12 Weeks","Death",1,1,"&lt; 12 Weeks","reported","reported",15,0,0.0131903265077852,0,2012.66666666667,0,34.2
"CD016002_data","CD016002_data","1|1|Death|≥ 12 Weeks","Death",1,1,"≥ 12 Weeks","reported","reported",11,-0.00678629102106844,0.00862160263334251,0,2013.09090909091,0.0169965786901271,76.2727272727273
"CD016002_data","CD016002_data","1|10|Musculoskeletal fitness (strength UL, affected side)|&lt; 12 Weeks","Musculoskeletal fitness (strength UL, affected side)",1,10,"&lt; 12 Weeks","reported","reported",2,0.150548545477681,0.576589909897246,0.4985992238995,2022,NA,26.5
"CD016002_data","CD016002_data","1|11|Musculoskeletal fitness (strength UL, unaffected side)|&lt; 12 Weeks","Musculoskeletal fitness (strength UL, unaffected side)",1,11,"&lt; 12 Weeks","reported","reported",2,0.539711327613966,0.356254346935204,0.0867189529473457,2022,NA,26.5
"CD016002_data","CD016002_data","1|13|Walking speed (comfortable)|&lt; 12 Weeks","Walking speed (comfortable)",1,13,"&lt; 12 Weeks","reported","reported",8,0.101424064916199,0.0206525174326425,0,2006,NA,42.5
"CD016002_data","CD016002_data","1|13|Walking speed (comfortable)|≥ 12 Weeks","Walking speed (comfortable)",1,13,"≥ 12 Weeks","reported","reported",5,0.0709710598591495,0.0499494491302542,0.00852620342349897,2016,NA,87.2
"CD016002_data","CD016002_data","1|14|Walking speed (maximal)|&lt; 12 Weeks","Walking speed (maximal)",1,14,"&lt; 12 Weeks","reported","reported",2,0.0496045085434733,0.0524995208231512,0.0034167566255,2019.5,NA,34
"CD016002_data","CD016002_data","1|14|Walking speed (maximal)|≥ 12 Weeks","Walking speed (maximal)",1,14,"≥ 12 Weeks","reported","reported",3,0.121374195921383,0.0473124193240198,0.00365271440491192,2012,NA,66.3333333333333
"CD016002_data","CD016002_data","1|15|Walking endurance (6-MWT)|&lt; 12 Weeks","Walking endurance (6-MWT)",1,15,"&lt; 12 Weeks","reported","reported",8,25.7464729976644,7.14780115407884,1.50304395951742e-07,2016.25,NA,30.125
"CD016002_data","CD016002_data","1|15|Walking endurance (6-MWT)|≥ 12 Weeks","Walking endurance (6-MWT)",1,15,"≥ 12 Weeks","reported","reported",7,41.1650202386164,8.68152960572661,167.212344256641,2012.71428571429,NA,70
"CD016002_data","CD016002_data","1|16|Balance|&lt; 12 Weeks","Balance",1,16,"&lt; 12 Weeks","reported","reported",9,0.115926240926285,0.120157850283302,0.00726589333501085,2012.22222222222,NA,34.8888888888889
"CD016002_data","CD016002_data","1|16|Balance|≥ 12 Weeks","Balance",1,16,"≥ 12 Weeks","reported","reported",7,0.324330826305649,0.0881382850668494,0,2013.57142857143,NA,75
"CD016002_data","CD016002_data","1|17|Functional mobility (timed up and go)|&lt; 12 Weeks","Functional mobility (timed up and go)",1,17,"&lt; 12 Weeks","reported","reported",4,-3.11542413424796,1.54695846644093,1.14448474678229,2012.25,NA,34.75
"CD016002_data","CD016002_data","1|17|Functional mobility (timed up and go)|≥ 12 Weeks","Functional mobility (timed up and go)",1,17,"≥ 12 Weeks","reported","reported",6,-1.7295677479944,0.295151247197292,0.0688726486916084,2015.5,NA,80.8333333333333
"CD016002_data","CD016002_data","1|18|Health status (overall)|&lt; 12 Weeks","Health status (overall)",1,18,"&lt; 12 Weeks","reported","reported",3,1.05952680955401,0.450828481609759,0.44161555676386,2009.66666666667,NA,51
"CD016002_data","CD016002_data","1|18|Health status (overall)|≥ 12 Weeks","Health status (overall)",1,18,"≥ 12 Weeks","reported","reported",2,0.340120470921178,0.190245649983362,0,2012.5,NA,57
"CD016002_data","CD016002_data","1|19|Health status (physical health)|≥ 12 Weeks","Health status (physical health)",1,19,"≥ 12 Weeks","reported","reported",2,0.14823337139885,0.445643072270413,0.287501175094049,2012.5,NA,57
"CD016002_data","CD016002_data","1|2|Disability|Chronic (&gt;6mth)","Disability",1,2,"Chronic (&gt;6mth)","reported","reported",4,-0.0532824418249341,0.16487012018893,0,2021,NA,37.25
"CD016002_data","CD016002_data","1|2|Disability|Early sub-acute (7d to 3mth)","Disability",1,2,"Early sub-acute (7d to 3mth)","reported","reported",8,0.306060661743691,0.099566766985629,0.012823368561946,2008.375,NA,71.75
"CD016002_data","CD016002_data","1|21|Health status (social health)|≥ 12 Weeks","Health status (social health)",1,21,"≥ 12 Weeks","reported","reported",2,0.307740214029644,0.203397643083052,0.00631055188702998,2012.5,NA,55.5
"CD016002_data","CD016002_data","1|22|Mood (anxiety)|≥ 12 Weeks","Mood (anxiety)",1,22,"≥ 12 Weeks","reported","reported",2,-0.0699041802675654,0.112558908920426,0,2009.5,NA,158
"CD016002_data","CD016002_data","1|23|Mood (depression)|≥ 12 Weeks","Mood (depression)",1,23,"≥ 12 Weeks","reported","reported",3,-0.0982864192668644,0.25641837671345,0.158294456948655,2007.33333333333,NA,136.333333333333
"CD016002_data","CD016002_data","1|24|Cognitive function|&lt; 12 Weeks","Cognitive function",1,24,"&lt; 12 Weeks","reported","reported",2,-0.13889351619981,0.17306895480672,0,2021,NA,71
"CD016002_data","CD016002_data","1|24|Cognitive function|≥ 12 Weeks","Cognitive function",1,24,"≥ 12 Weeks","reported","reported",3,0.105763091198467,0.162748979432646,0,2013.33333333333,NA,50.6666666666667
"CD016002_data","CD016002_data","1|25|Fatigue severity (overall)|≥ 12 Weeks","Fatigue severity (overall)",1,25,"≥ 12 Weeks","reported","reported",4,0.000539699957877832,0.104459363192927,0,2014.75,NA,91.75
"CD016002_data","CD016002_data","1|3|Secondary events|&lt; 12 Weeks","Secondary events",1,3,"&lt; 12 Weeks","reported","reported",2,-0.0280715914400215,0.0405965217016953,0,2021,0.0208333333333333,52
"CD016002_data","CD016002_data","1|3|Secondary events|≥ 12 Weeks","Secondary events",1,3,"≥ 12 Weeks","reported","reported",6,-0.00190866672643287,0.0109561596050769,4.63762268940422e-05,2012.66666666667,0.00268817204301075,96.6666666666667
"CD016002_data","CD016002_data","1|4|Falls|≥ 12 Weeks","Falls",1,4,"≥ 12 Weeks","reported","reported",3,0.0740608464685648,0.0400404486489209,0,2012,0.0475490196078431,58
"CD016002_data","CD016002_data","1|5|Blood pressure (systolic)|&lt; 12 Weeks","Blood pressure (systolic)",1,5,"&lt; 12 Weeks","reported","reported",3,-3.35128386507597,6.34477803400032,100.229384954553,2017,NA,23.3333333333333
"CD016002_data","CD016002_data","1|5|Blood pressure (systolic)|≥ 12 Weeks","Blood pressure (systolic)",1,5,"≥ 12 Weeks","reported","reported",2,0.521029001984556,5.52976455565302,36.4983067063879,2019,NA,35
"CD016002_data","CD016002_data","1|6|Blood pressure (diastolic)|&lt; 12 Weeks","Blood pressure (diastolic)",1,6,"&lt; 12 Weeks","reported","reported",3,-0.710871262740297,0.964260184249767,0,2017,NA,23.3333333333333
"CD016002_data","CD016002_data","1|6|Blood pressure (diastolic)|≥ 12 Weeks","Blood pressure (diastolic)",1,6,"≥ 12 Weeks","reported","reported",2,-3.07957594840168,3.54723818534158,16.9030301649879,2019,NA,35
"CD016002_data","CD016002_data","1|7|Cardiorespiratory fitness (peak VO<sub>2</sub>)|&lt; 12 Weeks","Cardiorespiratory fitness (peak VO<sub>2</sub>)",1,7,"&lt; 12 Weeks","reported","reported",3,3.07783675111061,2.33396359576788,11.2613962664622,2014.33333333333,NA,25
"CD016002_data","CD016002_data","1|7|Cardiorespiratory fitness (peak VO<sub>2</sub>)|≥ 12 Weeks","Cardiorespiratory fitness (peak VO<sub>2</sub>)",1,7,"≥ 12 Weeks","reported","reported",2,1.76808532423985,1.16085201125923,1.84719797208442,2009,NA,70
"CD016002_data","CD016002_data","1|8|Musculoskeletal fitness (strength LL, affected side)|&lt; 12 Weeks","Musculoskeletal fitness (strength LL, affected side)",1,8,"&lt; 12 Weeks","reported","reported",3,0.371009393957032,0.274445669637902,0.13092418901602,2017.33333333333,NA,50.3333333333333
"CD016002_data","CD016002_data","2|1|Death|&lt; 12 Weeks","Death",2,1,"&lt; 12 Weeks","reported","reported",3,-0.027475968290721,0.0258656719767661,0.000191979523412223,2013.66666666667,0.0508771929824561,62.6666666666667
"CD016002_data","CD016002_data","2|1|Death|≥ 12 Weeks","Death",2,1,"≥ 12 Weeks","reported","reported",5,-0.00241662093181221,0.0170697730922865,0,2013.6,0.0163333333333333,68.6
"CD016002_data","CD016002_data","2|13|Walking speed (comfortable)|&lt; 12 Weeks","Walking speed (comfortable)",2,13,"&lt; 12 Weeks","reported","reported",3,-0.0226655161460272,0.0650022084137731,0,2011.33333333333,NA,57.3333333333333
"CD016002_data","CD016002_data","2|13|Walking speed (comfortable)|≥ 12 Weeks","Walking speed (comfortable)",2,13,"≥ 12 Weeks","reported","reported",4,0.0507426869606407,0.0657403632451404,0.0111198177412956,2014.75,NA,108.25
"CD016002_data","CD016002_data","2|15|Walking endurance (6-MWT)|&lt; 12 Weeks","Walking endurance (6-MWT)",2,15,"&lt; 12 Weeks","reported","reported",3,38.4614408443864,31.0609283146116,1682.14350367375,2017.66666666667,NA,55
"CD016002_data","CD016002_data","2|15|Walking endurance (6-MWT)|≥ 12 Weeks","Walking endurance (6-MWT)",2,15,"≥ 12 Weeks","reported","reported",3,42.7128671091452,14.4477528995629,0,2017.33333333333,NA,121.666666666667
"CD016002_data","CD016002_data","2|16|Balance|&lt; 12 Weeks","Balance",2,16,"&lt; 12 Weeks","reported","reported",2,0.0958068209321778,0.421083588030319,0.271002450713184,2007.5,NA,51
"CD016002_data","CD016002_data","2|16|Balance|≥ 12 Weeks","Balance",2,16,"≥ 12 Weeks","reported","reported",4,0.325989840518539,0.097020496071458,1.20054341361145e-06,2014.75,NA,108.25
"CD016002_data","CD016002_data","2|17|Functional mobility (timed up and go)|≥ 12 Weeks","Functional mobility (timed up and go)",2,17,"≥ 12 Weeks","reported","reported",4,-1.60322736992611,1.34216110166262,3.50249308378484,2013.75,NA,114
"CD016002_data","CD016002_data","2|18|Health status (overall)|Chronic (&gt;6mth)","Health status (overall)",2,18,"Chronic (&gt;6mth)","reported","reported",2,-0.299856420481001,0.267859924180989,0,2020,NA,28.5
"CD016002_data","CD016002_data","2|18|Health status (overall)|Early sub-acute (7d to 3mth)","Health status (overall)",2,18,"Early sub-acute (7d to 3mth)","reported","reported",3,0.28919227977339,0.149614028576046,0,2011,NA,62.6666666666667
"CD016002_data","CD016002_data","2|19|Health status (physical)|≥ 12 Weeks","Health status (physical)",2,19,"≥ 12 Weeks","reported","reported",3,0.0964048332564419,0.173115556290989,0,2014.33333333333,NA,45
"CD016002_data","CD016002_data","2|2|Disability|&lt; 12 Weeks","Disability",2,2,"&lt; 12 Weeks","reported","reported",3,0.135003568729319,0.159618778410476,2.17887291782796e-06,2014.33333333333,NA,53
"CD016002_data","CD016002_data","2|2|Disability|≥ 12 Weeks","Disability",2,2,"≥ 12 Weeks","reported","reported",5,0.0408851510965194,0.133979241420492,0.0311700811345691,2012.4,NA,91
"CD016002_data","CD016002_data","2|20|Health status (mental)|≥ 12 Weeks","Health status (mental)",2,20,"≥ 12 Weeks","reported","reported",2,0.2541042627272,0.184934893625315,0,2010.5,NA,59
"CD016002_data","CD016002_data","2|21|Health status (social)|≥ 12 Weeks","Health status (social)",2,21,"≥ 12 Weeks","reported","reported",2,0.222663342688309,0.20435534221613,0,2012.5,NA,48.5
"CD016002_data","CD016002_data","2|22|Mood (anxiety)|≥ 12 Weeks","Mood (anxiety)",2,22,"≥ 12 Weeks","reported","reported",2,-0.0185216865606081,0.112529923463054,0,2009.5,NA,158
"CD016002_data","CD016002_data","2|23|Mood (depression)|≥ 12 Weeks","Mood (depression)",2,23,"≥ 12 Weeks","reported","reported",2,0.0626804626460381,0.112548684664057,0,2009.5,NA,158
"CD016002_data","CD016002_data","2|24|Cognitive function|&lt; 12 Weeks","Cognitive function",2,24,"&lt; 12 Weeks","reported","reported",2,0.0988577429635488,0.185675296070736,0,2021,NA,61.5
"CD016002_data","CD016002_data","2|24|Cognitive function|≥ 12 Weeks","Cognitive function",2,24,"≥ 12 Weeks","reported","reported",2,0.22654927705581,0.203740519025288,0,2012.5,NA,49
"CD016002_data","CD016002_data","2|25|Fatigue severity (overall)|≥ 12 Weeks","Fatigue severity (overall)",2,25,"≥ 12 Weeks","reported","reported",4,-0.0664955331795747,0.1048554038454,0,2014.75,NA,91.25
"CD016002_data","CD016002_data","2|3|Secondary events|≥ 12 Weeks","Secondary events",2,3,"≥ 12 Weeks","reported","reported",3,0.0352404950800565,0.0410392199697504,0.00279598201513256,2009.33333333333,0.00980392156862745,70.3333333333333
"CD016002_data","CD016002_data","2|4|Falls|≥ 12 Weeks","Falls",2,4,"≥ 12 Weeks","reported","reported",2,0.060268037160639,0.0638704540122301,0.000363546134375832,2014.5,0.0882352941176471,49.5
"CD016031_data","CD016031_data","1|10|Comparison 1: Anterior vs posterior, Outcome 10: Mortality, intermediate (4-24 months, categorical data)|","Comparison 1: Anterior vs posterior, Outcome 10: Mortality, intermediate (4-24 months, categorical data)",1,10,"","reported","reported",3,0.987426337005013,0.341171306729564,0,2017.33333333333,0.148333333333333,80.6666666666667
"CD016031_data","CD016031_data","1|12|Comparison 1: Anterior vs posterior, Outcome 12: Pain, early (≤ 4 months, continuous data)|","Comparison 1: Anterior vs posterior, Outcome 12: Pain, early (≤ 4 months, continuous data)",1,12,"","reported","reported",2,-0.119024202716909,0.153378212395602,0,2016,NA,85.5
"CD016031_data","CD016031_data","1|14|Comparison 1: Anterior vs posterior, Outcome 14: Pain, intermediate (4-24 months, continuous data)|","Comparison 1: Anterior vs posterior, Outcome 14: Pain, intermediate (4-24 months, continuous data)",1,14,"","reported","reported",3,-0.437001548969926,0.704568285127954,1.42733905192289,2016.66666666667,NA,77.6666666666667
"CD016031_data","CD016031_data","1|17|Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)|Deep wound infection","Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)",1,17,"Deep wound infection","or","binary",4,-0.130736520566013,0.952569619313151,0,2015.75,0.00568181818181818,61.25
"CD016031_data","CD016031_data","1|17|Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)|Dislocation of the prosthesis (categorical data)","Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)",1,17,"Dislocation of the prosthesis (categorical data)","or","binary",5,-1.24978510339859,0.636046256113492,0,2016,0.0559090909090909,70.2
"CD016031_data","CD016031_data","1|17|Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)|Post-operative periprosthetic fracture (categorical data)","Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)",1,17,"Post-operative periprosthetic fracture (categorical data)","or","binary",3,-0.714811210056123,1.0135513787617,0,2019.66666666667,0.0274193548387097,55
"CD016031_data","CD016031_data","1|17|Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)|Superficial wound infection","Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)",1,17,"Superficial wound infection","or","binary",4,-0.208459633865284,0.89269693332125,0,2016.75,0.025,53.25
"CD016031_data","CD016031_data","1|18|Comparison 1: Anterior vs posterior, Outcome 18: Adverse events, not implant related (categorical data)|Deep vein thrombosis (DVT)","Comparison 1: Anterior vs posterior, Outcome 18: Adverse events, not implant related (categorical data)",1,18,"Deep vein thrombosis (DVT)","or","binary",5,0.333194859094589,0.64557645828928,0,2016.4,0.035,59
"CD016031_data","CD016031_data","1|18|Comparison 1: Anterior vs posterior, Outcome 18: Adverse events, not implant related (categorical data)|Pulmonary embolism (PE)","Comparison 1: Anterior vs posterior, Outcome 18: Adverse events, not implant related (categorical data)",1,18,"Pulmonary embolism (PE)","or","binary",2,-0.0456912285984381,1.42812169066703,0,2019.5,0,52.5
"CD016031_data","CD016031_data","1|19|Comparison 1: Anterior vs posterior, Outcome 19: Operative details (Continuous data)|Operative blood loss (milliliters)","Comparison 1: Anterior vs posterior, Outcome 19: Operative details (Continuous data)",1,19,"Operative blood loss (milliliters)","reported","reported",2,0,4.02131586705042,0,2018,0,34.5
"CD016031_data","CD016031_data","1|20|Comparison 1: Anterior vs posterior, Outcome 20: Operative details (Categorical data)|Blood transfusion (categorical data)","Comparison 1: Anterior vs posterior, Outcome 20: Operative details (Categorical data)",1,20,"Blood transfusion (categorical data)","or","binary",2,-1.16711951616466,1.31364696760615,2.52803858366875,2017.5,0.354545454545455,71
"CD016031_data","CD016031_data","1|21|Comparison 1: Anterior vs posterior, Outcome 21: Post-operative care outcomes (Continuous data)|Length of hospital stay (days)","Comparison 1: Anterior vs posterior, Outcome 21: Post-operative care outcomes (Continuous data)",1,21,"Length of hospital stay (days)","or","binary",3,0.00972530508687168,1.16233305787364,0,2015.33333333333,0,75.3333333333333
"CD016031_data","CD016031_data","1|5|Comparison 1: Anterior vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)|","Comparison 1: Anterior vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)",1,5,"","reported","reported",3,0.0605304558030195,0.159590817132993,0,2017.66666666667,NA,52.6666666666667
"CD016031_data","CD016031_data","1|6|Comparison 1: Anterior vs posterior, Outcome 6: Functional status, early (≤ 4 months, categorical data)|","Comparison 1: Anterior vs posterior, Outcome 6: Functional status, early (≤ 4 months, categorical data)",1,6,"","reported","reported",2,1.56879992934322,0.300139491045387,0,2014,0.348484848484849,80.5
"CD016031_data","CD016031_data","1|7|Comparison 1: Anterior vs posterior, Outcome 7: Functional status, intermediate (4-24 months, categorical data)|","Comparison 1: Anterior vs posterior, Outcome 7: Functional status, intermediate (4-24 months, categorical data)",1,7,"","reported","reported",2,0.956272160536355,0.123049976495164,0,2014,0.617424242424242,80.5
"CD016031_data","CD016031_data","1|8|Comparison 1: Anterior vs posterior, Outcome 8: Functional status, intermediate (4-24 months, continuous data)|","Comparison 1: Anterior vs posterior, Outcome 8: Functional status, intermediate (4-24 months, continuous data)",1,8,"","reported","reported",4,0.276400617158035,0.130167306413944,0,2019,NA,61.5
"CD016031_data","CD016031_data","1|9|Comparison 1: Anterior vs posterior, Outcome 9: Mortality, early (≤ 4 months, categorical data)|","Comparison 1: Anterior vs posterior, Outcome 9: Mortality, early (≤ 4 months, categorical data)",1,9,"","reported","reported",3,0.888967796473652,0.589453309072955,0,2017.33333333333,0.0734848484848485,80.6666666666667
"CD016031_data","CD016031_data","2|1|Comparison 2: Anterior vs lateral, Outcome 1: ADL, early (≤ 4 months, continuous data)|","Comparison 2: Anterior vs lateral, Outcome 1: ADL, early (≤ 4 months, continuous data)",2,1,"","reported","reported",2,3.07615858539437,9.1972765001987,161.04898715469,2017,NA,70
"CD016031_data","CD016031_data","2|11|Comparison 2: Anterior vs lateral, Outcome 11: Re-operation rate, early (≤ 4 months, categorical data)|","Comparison 2: Anterior vs lateral, Outcome 11: Re-operation rate, early (≤ 4 months, categorical data)",2,11,"","reported","reported",2,1.04246251021001,0.650482597620482,0,2015,0.0542328042328042,120
"CD016031_data","CD016031_data","2|13|Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)|Deep wound infection","Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)",2,13,"Deep wound infection","reported","reported",2,0,0.493280969145967,0,2014.5,0.046343537414966,115.5
"CD016031_data","CD016031_data","2|13|Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)|Dislocation of the prosthesis (categorical data)","Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)",2,13,"Dislocation of the prosthesis (categorical data)","reported","reported",2,0,1.08507183614416,0,2017,0.0125,111.5
"CD016031_data","CD016031_data","2|13|Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)|Intra-operative fracture (categorical data)","Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)",2,13,"Intra-operative fracture (categorical data)","reported","reported",3,0,0.913765971312082,0,2018,0.0277777777777778,102.666666666667
"CD016031_data","CD016031_data","2|14|Comparison 2 Anterior vs lateral, Outcome 14: Adverse events, not implant related (categorical data)|Deep vein thrombosis (DVT)","Comparison 2 Anterior vs lateral, Outcome 14: Adverse events, not implant related (categorical data)",2,14,"Deep vein thrombosis (DVT)","reported","reported",2,0,0.904830029483962,0,2011.5,0.0578703703703704,52.5
"CD016031_data","CD016031_data","2|15|Comparison 2: Anterior vs lateral, Outcome 15: Operative details (Continuous data)|Length of surgery (minutes)","Comparison 2: Anterior vs lateral, Outcome 15: Operative details (Continuous data)",2,15,"Length of surgery (minutes)","reported","reported",3,0,1.59562162895005,0,2021.66666666667,0,114.333333333333
"CD016031_data","CD016031_data","2|15|Comparison 2: Anterior vs lateral, Outcome 15: Operative details (Continuous data)|Operative blood loss (milliliters)","Comparison 2: Anterior vs lateral, Outcome 15: Operative details (Continuous data)",2,15,"Operative blood loss (milliliters)","reported","reported",2,0,3.80166853565891,0,2016.5,0,75.5
"CD016031_data","CD016031_data","2|16|Comparison 2: Anterior vs lateral, Outcome 16: Operative details (Categorical data)|Blood transfusion (participants transfused)","Comparison 2: Anterior vs lateral, Outcome 16: Operative details (Categorical data)",2,16,"Blood transfusion (participants transfused)","or","binary",2,-0.186232833956926,0.389563993306583,0,2021.5,0.169912790697674,130
"CD016031_data","CD016031_data","2|17|Comparison 2: Anterior vs lateral, Outcome 17: Post-operative care outcomes (Continuous data)|Length of hospital stay (days)","Comparison 2: Anterior vs lateral, Outcome 17: Post-operative care outcomes (Continuous data)",2,17,"Length of hospital stay (days)","reported","reported",3,0,0.09104921693735,0,2021.66666666667,0,114.333333333333
"CD016031_data","CD016031_data","2|3|Comparison 2: Anterior vs lateral, Outcome 3: Functional status, early (≤ 4 months, continuous data)|","Comparison 2: Anterior vs lateral, Outcome 3: Functional status, early (≤ 4 months, continuous data)",2,3,"","reported","reported",2,1.16751264042685,0.57964077360761,0,2016,NA,71
"CD016031_data","CD016031_data","2|5|Comparison 2: Anterior vs lateral, Outcome 5: Functional status, intermediate (4-24 months, continuous data)|","Comparison 2: Anterior vs lateral, Outcome 5: Functional status, intermediate (4-24 months, continuous data)",2,5,"","reported","reported",2,3.89477904885737,2.12278018777304,0,2016.5,NA,101
"CD016031_data","CD016031_data","2|8|Comparison 2: Anterior vs lateral, Outcome 8: Mortality, intermediate (4-24 months, categorical data)|","Comparison 2: Anterior vs lateral, Outcome 8: Mortality, intermediate (4-24 months, categorical data)",2,8,"","reported","reported",2,1.43428249768239,0.38198105780934,0,2014.5,0.161010101010101,115.5
"CD016031_data","CD016031_data","2|9|Comparison 2: Anterior vs lateral, Outcome 9: Pain, early (≤ 4 months, continuous data)|","Comparison 2: Anterior vs lateral, Outcome 9: Pain, early (≤ 4 months, continuous data)",2,9,"","reported","reported",4,-0.2596997923649,0.37281324942563,0.455317292312761,2016.5,NA,70.5
"CD016031_data","CD016031_data","3|10|Comparison 3: Lateral vs posterior, Outcome 10: Mortality, late (≥ 24 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 10: Mortality, late (≥ 24 months, categorical data)",3,10,"","reported","reported",2,0.885686773818833,0.226876044202467,0,2019.5,0.325396825396825,51
"CD016031_data","CD016031_data","3|11|Comparison 3: Lateral vs posterior, Outcome 11: Pain, early (≤ 4 months, continuous data)|","Comparison 3: Lateral vs posterior, Outcome 11: Pain, early (≤ 4 months, continuous data)",3,11,"","reported","reported",6,-0.0958219093562459,0.238924080859231,0.286123009778002,2021.2,NA,125.333333333333
"CD016031_data","CD016031_data","3|12|Comparison 3: Lateral vs posterior, Outcome 12: Pain, intermediate (4-24 months, continuous data)|","Comparison 3: Lateral vs posterior, Outcome 12: Pain, intermediate (4-24 months, continuous data)",3,12,"","reported","reported",4,-0.0169584709370259,0.117102853281316,0.0227577406833239,2020.33333333333,NA,154.5
"CD016031_data","CD016031_data","3|13|Comparison 3: Lateral vs posterior, Outcome 13: Re-operation rate, early (≤ 4 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 13: Re-operation rate, early (≤ 4 months, categorical data)",3,13,"","reported","reported",4,0.726461574863371,0.601775587240255,0,2006,0.0536423379901641,98.5
"CD016031_data","CD016031_data","3|14|Comparison 3: Lateral vs posterior, Outcome 14: Re-operation rate, intermediate (4-24 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 14: Re-operation rate, intermediate (4-24 months, categorical data)",3,14,"","reported","reported",4,0.605081825956494,0.148198800083282,0,2010.5,0.0532288142943881,328
"CD016031_data","CD016031_data","3|15|Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)|Deep wound infection","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)",3,15,"Deep wound infection","reported","reported",2,0,0.687082514587026,0,2021,0.0258714596949891,307
"CD016031_data","CD016031_data","3|15|Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)|Dislocation of the prosthesis (categorical data)","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)",3,15,"Dislocation of the prosthesis (categorical data)","reported","reported",5,0,0.459067280146462,0,2010.5,0.0286607838432132,263
"CD016031_data","CD016031_data","3|15|Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)|Intra-operative fracture (categorical data)","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)",3,15,"Intra-operative fracture (categorical data)","reported","reported",4,0,0.573532019794822,0,2018,0.0165343915343915,92
"CD016031_data","CD016031_data","3|15|Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)|Post-operative periprosthetic fracture (categorical data)","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)",3,15,"Post-operative periprosthetic fracture (categorical data)","reported","reported",3,0,0.909122514835539,0,2021.33333333333,0.0123456790123457,115.333333333333
"CD016031_data","CD016031_data","3|15|Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)|Superficial wound infection","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)",3,15,"Superficial wound infection","reported","reported",4,0,0.478717243513304,0,2009,0.0384134248665141,190.5
"CD016031_data","CD016031_data","3|16|Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)|Damage to nerve, vessel, or tendon","Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)",3,16,"Damage to nerve, vessel, or tendon","reported","reported",4,0,0.724774770955487,0,2023.25,0.0156131595150137,235.75
"CD016031_data","CD016031_data","3|16|Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)|Deep vein thrombosis (DVT)","Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)",3,16,"Deep vein thrombosis (DVT)","reported","reported",2,0,0.565806201594887,0,2016.5,0.0601851851851852,137.5
"CD016031_data","CD016031_data","3|16|Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)|Pulmonary embolism (PE)","Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)",3,16,"Pulmonary embolism (PE)","reported","reported",2,0,0.761829380196804,0,2019.5,0.00367647058823529,385.5
"CD016031_data","CD016031_data","3|17|Comparison 3: Lateral vs posterior, Outcome 17: Operative details (Continuous data)|Length of surgery (minutes)","Comparison 3: Lateral vs posterior, Outcome 17: Operative details (Continuous data)",3,17,"Length of surgery (minutes)","reported","reported",8,0,0.0770143784265281,0,2021.28571428571,0,141.875
"CD016031_data","CD016031_data","3|17|Comparison 3: Lateral vs posterior, Outcome 17: Operative details (Continuous data)|Operative blood loss (milliliters)","Comparison 3: Lateral vs posterior, Outcome 17: Operative details (Continuous data)",3,17,"Operative blood loss (milliliters)","reported","reported",6,0,0.0812274739035467,0,2022.4,0,139.166666666667
"CD016031_data","CD016031_data","3|19|Comparison 3: Lateral vs posterior, Outcome 19: Post-operative care outcomes (Continuous data)|Days to mobilization","Comparison 3: Lateral vs posterior, Outcome 19: Post-operative care outcomes (Continuous data)",3,19,"Days to mobilization","reported","reported",2,0,0.405733562915831,0,2022.5,0,72
"CD016031_data","CD016031_data","3|19|Comparison 3: Lateral vs posterior, Outcome 19: Post-operative care outcomes (Continuous data)|Length of hospital stay (days)","Comparison 3: Lateral vs posterior, Outcome 19: Post-operative care outcomes (Continuous data)",3,19,"Length of hospital stay (days)","reported","reported",5,0,0.202179188234739,0,2020.75,0,189.6
"CD016031_data","CD016031_data","3|3|Comparison 3: Lateral vs posterior, Outcome 3: HRQoL, early (≤ 4 months, continuous data)|","Comparison 3: Lateral vs posterior, Outcome 3: HRQoL, early (≤ 4 months, continuous data)",3,3,"","reported","reported",2,-0.03,0.0283141919137541,0,2024,NA,264.5
"CD016031_data","CD016031_data","3|5|Comparison 3: Lateral vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)|","Comparison 3: Lateral vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)",3,5,"","reported","reported",5,0.089273978951171,0.308428596285863,0.409310975907457,2020.5,NA,98.8
"CD016031_data","CD016031_data","3|6|Comparison 3: Lateral vs posterior, Outcome 6: Functional status, intermediate (4-24 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 6: Functional status, intermediate (4-24 months, categorical data)",3,6,"","reported","reported",2,1.02345254563405,0.386641332416191,0.217032320094199,2002.5,0.495436105476673,163
"CD016031_data","CD016031_data","3|7|Comparison 3: Lateral vs posterior, Outcome 7: Functional status, intermediate (4-24 months, continuous data)|","Comparison 3: Lateral vs posterior, Outcome 7: Functional status, intermediate (4-24 months, continuous data)",3,7,"","reported","reported",5,0.0575430542239977,0.120095268776596,0.0154650203589195,2020,NA,77.8
"CD016031_data","CD016031_data","3|8|Comparison 3: Lateral vs posterior, Outcome 8: Mortality, early (≤ 4 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 8: Mortality, early (≤ 4 months, categorical data)",3,8,"","reported","reported",4,0.812357330388081,0.215703612148344,0.0850288081472429,2011,0.147676673186355,354.25
"CD016031_data","CD016031_data","3|9|Comparison 3: Lateral vs posterior, Outcome 9: Mortality, intermediate (4-24 months, categorical data)|","Comparison 3: Lateral vs posterior, Outcome 9: Mortality, intermediate (4-24 months, categorical data)",3,9,"","reported","reported",5,0.824764481255777,0.145858670747923,0.029538499991579,2010.75,0.221474166515946,254.8
"CD016058","CD016058_pub2_data","1|3|Vaping cessation at between 3 & 6 months|","Vaping cessation at between 3 & 6 months",1,3,"","reported","reported",2,0.933641024585516,0.324987950139005,0.163024450927966,2022.5,0.563888888888889,262
"CD016058","CD016058_pub2_data","3|3|Vaping cessation at between 3 & 6 months|","Vaping cessation at between 3 & 6 months",3,3,"","reported","reported",3,1.50310818338904,0.405622247530415,1.02772203238258e-07,2022.33333333333,0.5,60.6666666666667
"CD016058","CD016058_pub2_data","3|4|Number of participants reporting AEs|","Number of participants reporting AEs",3,4,"","reported","reported",3,1.09356483661605,0.147578472157861,0,2022.33333333333,0.664141414141414,43.3333333333333
"CD016064_data","CD016064_data","1|1|Rate of falls|","Rate of falls",1,1,"","reported","reported",12,-0.137017172684446,0.12861172135504,0.153793822075456,2007.58333333333,0,403.583333333333
"CD016064_data","CD016064_data","1|2|Risk of falling|","Risk of falling",1,2,"","reported","reported",11,-0.0959877989160588,0.0485810597006633,0.0046394024656958,2006.27272727273,0,414.272727272727
"CD016064_data","CD016064_data","1|3|Risk of fracture|","Risk of fracture",1,3,"","reported","reported",6,-0.0361705384683728,0.274480265560284,0.0753663051517205,2010.33333333333,0,636.166666666667
"CD016064_data","CD016064_data","1|4|Rate of falls sensitivity analyses: excluding trials at high risk of bias|","Rate of falls sensitivity analyses: excluding trials at high risk of bias",1,4,"","reported","reported",4,-0.197916938646881,0.163454461580904,0.090843136440251,2001.25,0,200.5
"CD016064_data","CD016064_data","1|5|Risk of falling sensitivity analyses: excluding trials at high risk of bias|","Risk of falling sensitivity analyses: excluding trials at high risk of bias",1,5,"","reported","reported",5,-0.106353905206637,0.0499931299034462,0,2001.6,0,215.2
"CD016064_data","CD016064_data","1|6|Risk of fracture sensitivity analyses: excluding trials at high risk of bias|","Risk of fracture sensitivity analyses: excluding trials at high risk of bias",1,6,"","reported","reported",3,-0.627097302910685,0.39130996193629,4.53297169495377e-06,2002.66666666667,0,546.333333333333
"CD016064_data","CD016064_data","10|1|Rate of falls|Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Rate of falls",10,1,"Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",10,-0.651296999565086,0.154697433108228,0.172983419416966,2017.4,0,129.2
"CD016064_data","CD016064_data","10|1|Rate of falls|NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Rate of falls",10,1,"NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",4,0.217899219618544,0.20646707928343,0.115494762064352,2004.75,0,230.75
"CD016064_data","CD016064_data","10|2|Risk of falling|Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Risk of falling",10,2,"Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",9,-0.264892612370776,0.116044253233263,0.0467396527600463,2016,0,146.444444444444
"CD016064_data","CD016064_data","10|2|Risk of falling|NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Risk of falling",10,2,"NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",4,-0.0184702447547217,0.0849022081081726,0,2006.75,0,272.5
"CD016064_data","CD016064_data","10|3|Risk of fracture|Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Risk of fracture",10,3,"Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",2,0.0168350623217981,0.315822033746439,0,2021,0,370.5
"CD016064_data","CD016064_data","10|4|Rate of falls sensitivity analysis: excluding trials at high risk of bias|Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Rate of falls sensitivity analysis: excluding trials at high risk of bias",10,4,"Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",5,-0.573132913116169,0.258272987995547,0.285376302293029,2018.4,0,195.6
"CD016064_data","CD016064_data","10|5|Risk of falling sensitivity analysis: excluding trials at high risk of bias|Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Risk of falling sensitivity analysis: excluding trials at high risk of bias",10,5,"Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",6,-0.274352595140386,0.153826710852003,0.0734530198821271,2017.83333333333,0,185.833333333333
"CD016064_data","CD016064_data","10|5|Risk of falling sensitivity analysis: excluding trials at high risk of bias|NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","Risk of falling sensitivity analysis: excluding trials at high risk of bias",10,5,"NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents","reported","reported",2,-0.0531143232588699,0.123974903144645,0,2013.5,0,184.5
"CD016064_data","CD016064_data","11|1|Rate of falls|Additional gait, balance, functional training","Rate of falls",11,1,"Additional gait, balance, functional training","reported","reported",2,-0.474107268877911,0.22071809729982,0,2008.5,0,28
"CD016064_data","CD016064_data","11|2|Risk of falling|Additional gait, balance, and functional training","Risk of falling",11,2,"Additional gait, balance, and functional training","reported","reported",2,-0.233680412371134,0.310163907449813,0,2008.5,0,28
"CD016064_data","CD016064_data","12|1|Rate of falls|Interventions including medication review/deprescribing vs usual care","Rate of falls",12,1,"Interventions including medication review/deprescribing vs usual care","reported","reported",12,-0.0558973682771648,0.105061234536483,0.0936766586398841,2016.83333333333,0,343.75
"CD016064_data","CD016064_data","12|3|Risk of falling|Interventions including medication review/deprescribing vs usual care","Risk of falling",12,3,"Interventions including medication review/deprescribing vs usual care","reported","reported",9,-0.105043720691245,0.0574493187429354,0,2015.77777777778,0,214.888888888889
"CD016064_data","CD016064_data","12|4|Risk of fracture|Interventions including medication review/deprescribing vs usual care","Risk of fracture",12,4,"Interventions including medication review/deprescribing vs usual care","reported","reported",4,-0.425710373039142,0.306026161961354,0,2020.25,0,175.75
"CD016064_data","CD016064_data","12|6|Medication review/deprescribing: Rate of falls sensitivity analysis excluding trials at high risk of bias|","Medication review/deprescribing: Rate of falls sensitivity analysis excluding trials at high risk of bias",12,6,"","reported","reported",5,-0.0855996727617028,0.213475344024054,0.168640471558345,2017.6,0,181.6
"CD016064_data","CD016064_data","12|7|Medication review/deprescribing: Risk of falling sensitivity analysis excluding trials at high risk of bias|","Medication review/deprescribing: Risk of falling sensitivity analysis excluding trials at high risk of bias",12,7,"","reported","reported",4,-0.120204629099774,0.114873055226791,0,2018.5,0,160.75
"CD016064_data","CD016064_data","12|8|Medication review/deprescribing: Risk of fracture sensitivity analysis excluding trials at high risk of bias|","Medication review/deprescribing: Risk of fracture sensitivity analysis excluding trials at high risk of bias",12,8,"","reported","reported",2,-0.411823453608247,0.965983900831904,0.918637499999999,2018,0,96
"CD016064_data","CD016064_data","13|1|Rate of falls|Interventions including deprescribing vs usual care","Rate of falls",13,1,"Interventions including deprescribing vs usual care","reported","reported",6,0.136744543191593,0.14949390359225,0.0801098624780114,2016.66666666667,0,149.333333333333
"CD016064_data","CD016064_data","13|1|Rate of falls|Interventions including medication review vs usual care","Rate of falls",13,1,"Interventions including medication review vs usual care","reported","reported",6,-0.210086369184442,0.109159356652388,0.0492100372835613,2017,0,538.166666666667
"CD016064_data","CD016064_data","13|2|Risk of falling|Interventions including deprescribing vs usual care","Risk of falling",13,2,"Interventions including deprescribing vs usual care","reported","reported",5,-0.103284799277723,0.0861997185020255,0,2018.6,0,112.4
"CD016064_data","CD016064_data","13|2|Risk of falling|Interventions including medication review vs usual care","Risk of falling",13,2,"Interventions including medication review vs usual care","reported","reported",4,-0.104179648446541,0.0797966818215004,0.00134060314958579,2012.25,0,332.75
"CD016064_data","CD016064_data","13|3|Risk of fracture|Interventions including deprescribing vs usual care","Risk of fracture",13,3,"Interventions including deprescribing vs usual care","reported","reported",3,-0.445444907891081,0.325322601730204,7.11637288709677e-07,2019.66666666667,0,165
"CD016064_data","CD016064_data","14|1|Rate of falls (grouped by professional)|Multidisciplinary","Rate of falls (grouped by professional)",14,1,"Multidisciplinary","reported","reported",6,0.167351104979894,0.122951236391324,0.0520270521284944,2017.33333333333,0,423.166666666667
"CD016064_data","CD016064_data","14|1|Rate of falls (grouped by professional)|Not multidisciplinary - medical doctor led","Rate of falls (grouped by professional)",14,1,"Not multidisciplinary - medical doctor led","reported","reported",2,-0.381655711494049,0.251910447758366,0,2016.5,0,54
"CD016064_data","CD016064_data","14|1|Rate of falls (grouped by professional)|Not multidisciplinary - pharmacist led","Rate of falls (grouped by professional)",14,1,"Not multidisciplinary - pharmacist led","reported","reported",4,-0.221690292377248,0.150742133605605,0.0817093317402214,2016.25,0,369.5
"CD016064_data","CD016064_data","14|2|Risk of falling (grouped by professional)|Multidisciplinary","Risk of falling (grouped by professional)",14,2,"Multidisciplinary","reported","reported",4,-0.0175033173175163,0.0975253808555158,0,2014.5,0,317
"CD016064_data","CD016064_data","14|2|Risk of falling (grouped by professional)|Not multidisciplinary - medical doctor led","Risk of falling (grouped by professional)",14,2,"Not multidisciplinary - medical doctor led","reported","reported",2,-0.186437158876419,0.303433507941126,0,2016.5,0,54
"CD016064_data","CD016064_data","14|2|Risk of falling (grouped by professional)|Not multidisciplinary - pharmacist led","Risk of falling (grouped by professional)",14,2,"Not multidisciplinary - pharmacist led","reported","reported",4,-0.0960435914784204,0.0665225840258955,5.0659841061573e-06,2013.75,0,320.5
"CD016064_data","CD016064_data","15|1|Rate of falls|Vitamin D supplementation","Rate of falls",15,1,"Vitamin D supplementation","reported","reported",5,-0.515748670060883,0.196567911103123,0.121551943898693,2006.75,0,920.6
"CD016064_data","CD016064_data","15|2|Risk of falling|Vitamin D supplementation","Risk of falling",15,2,"Vitamin D supplementation","reported","reported",6,-0.000951803640711017,0.0376970330383191,0,2005.8,0,864.333333333333
"CD016064_data","CD016064_data","15|3|Risk of fracture|","Risk of fracture",15,3,"","reported","reported",4,-0.0828465274544602,0.264653393805938,0.160435736186353,2004.33333333333,0,1261.75
"CD016064_data","CD016064_data","15|5|Adverse events|Gastrointestinal disorders","Adverse events",15,5,"Gastrointestinal disorders","or","binary",2,0.0568227536671024,0.668777437584425,0.424819241015391,2002,0.0421052631578947,352.5
"CD016064_data","CD016064_data","15|6|Risk of falling sensitivity analysis: including trial that excludes falls during intervention period|Vitamin D supplementation","Risk of falling sensitivity analysis: including trial that excludes falls during intervention period",15,6,"Vitamin D supplementation","reported","reported",7,-0.00356602942159678,0.0376055121596561,0,2007.33333333333,0,745.714285714286
"CD016064_data","CD016064_data","15|7|Rate of falls sensitivity analysis: excluding trials at high risk of bias|","Rate of falls sensitivity analysis: excluding trials at high risk of bias",15,7,"","reported","reported",3,-0.580869545475227,0.262223898077404,0.105695343428691,2006,0,265
"CD016064_data","CD016064_data","15|8|Risk of falling sensitivity analysis: excluding trials at high risk of bias|","Risk of falling sensitivity analysis: excluding trials at high risk of bias",15,8,"","reported","reported",3,-0.187694892041685,0.104314338629519,0,2006,0,265
"CD016064_data","CD016064_data","15|9|Risk of fracture sensitivity analysis: excluding trials at high risk of bias|","Risk of fracture sensitivity analysis: excluding trials at high risk of bias",15,9,"","reported","reported",2,-0.299059347569763,0.244828938696205,0,2005,0,373.5
"CD016064_data","CD016064_data","18|1|Rate of falls|Falls risk assessment tools vs usual care","Rate of falls",18,1,"Falls risk assessment tools vs usual care","reported","reported",2,-0.27,0.24454038521275,0.1078,2012.5,0,637.5
"CD016064_data","CD016064_data","2|1|Rate of falls|Outcomes after period of post-intervention follow-up","Rate of falls",2,1,"Outcomes after period of post-intervention follow-up","reported","reported",3,-0.438344861267077,0.133394554798484,0.0203896982716695,2002,0,223.333333333333
"CD016064_data","CD016064_data","2|1|Rate of falls|Outcomes at end of intervention period","Rate of falls",2,1,"Outcomes at end of intervention period","reported","reported",9,-0.0438692834015543,0.159427020971354,0.17954944803263,2009.44444444444,0,463.666666666667
"CD016064_data","CD016064_data","2|2|Risk of falling|Outcomes after period of post-intervention follow-up","Risk of falling",2,2,"Outcomes after period of post-intervention follow-up","reported","reported",3,-0.222740512802399,0.136238337095872,0.0208197791379509,2002,0,223.333333333333
"CD016064_data","CD016064_data","2|2|Risk of falling|Outcomes at end of intervention period","Risk of falling",2,2,"Outcomes at end of intervention period","reported","reported",8,-0.0717295155901021,0.0441444295891579,4.26157018992203e-07,2007.875,0,485.875
"CD016064_data","CD016064_data","2|3|Risk of fracture|Outcomes at end of intervention period","Risk of fracture",2,3,"Outcomes at end of intervention period","reported","reported",5,0.072960935712085,0.238046196213415,0.0177086612364153,2012,0,686.6
"CD016064_data","CD016064_data","3|1|Rate of falls|Trial length ≥12 months ","Rate of falls",3,1,"Trial length ≥12 months ","reported","reported",8,-0.152257879650748,0.169095800645974,0.196942579780192,2005.875,0,520.5
"CD016064_data","CD016064_data","3|1|Rate of falls|Trial length 6-11 months","Rate of falls",3,1,"Trial length 6-11 months","reported","reported",4,-0.0698527142797533,0.175222434538732,0.062479607892904,2011,0,169.75
"CD016064_data","CD016064_data","3|2|Risk of falling|Trial length ≥12 months","Risk of falling",3,2,"Trial length ≥12 months","reported","reported",8,-0.0719913740512755,0.0430875995524852,1.36001884395768e-06,2005.125,0,490
"CD016064_data","CD016064_data","3|2|Risk of falling|Trial length 5-11 months","Risk of falling",3,2,"Trial length 5-11 months","reported","reported",3,-0.276630486394528,0.118518140466763,0,2009.33333333333,0,212.333333333333
"CD016064_data","CD016064_data","3|3|Risk of fracture|Trial length ≥12 months","Risk of fracture",3,3,"Trial length ≥12 months","reported","reported",4,0.0346138766344919,0.253990447554194,0.031810817718236,2010.75,0,810.5
"CD016064_data","CD016064_data","3|3|Risk of fracture|Trial length 5-11 months","Risk of fracture",3,3,"Trial length 5-11 months","reported","reported",2,-0.343773291925466,1.59947721996122,3.40435,2009.5,0,287.5
"CD016064_data","CD016064_data","4|1|Rate of falls|Participants with cognitive impairment","Rate of falls",4,1,"Participants with cognitive impairment","reported","reported",4,-0.190007646653994,0.262002824168622,0.201623504106287,2007.75,0,299.75
"CD016064_data","CD016064_data","4|1|Rate of falls|Participants with no cognitive impairment or mixed sample","Rate of falls",4,1,"Participants with no cognitive impairment or mixed sample","reported","reported",10,-0.174499508437457,0.128862841268102,0.136242334466353,2006.5,0,320.9
"CD016064_data","CD016064_data","4|2|Risk of falling|Participants with cognitive impairment","Risk of falling",4,2,"Participants with cognitive impairment","reported","reported",4,-0.22958884641049,0.17401865083976,0.0848716704819293,2006.25,0,238.75
"CD016064_data","CD016064_data","4|2|Risk of falling|Participants with no cognitive impairment or mixed sample","Risk of falling",4,2,"Participants with no cognitive impairment or mixed sample","reported","reported",10,-0.0685826535250558,0.0526517536649073,2.13251013187425e-06,2006.5,0,320.9
"CD016064_data","CD016064_data","5|1|Rate of falls|Facility engagement and tailored intervention delivery","Rate of falls",5,1,"Facility engagement and tailored intervention delivery","reported","reported",7,-0.48616662744336,0.0618603873131943,0,2007.85714285714,0,507.571428571429
"CD016064_data","CD016064_data","5|1|Rate of falls|Without facility engagement and tailored intervention delivery","Rate of falls",5,1,"Without facility engagement and tailored intervention delivery","reported","reported",4,0.114358597611581,0.0818868952252702,0.0124244384073379,2005,0,240
"CD016064_data","CD016064_data","5|2|Risk of falling|Facility engagement and tailored intervention delivery","Risk of falling",5,2,"Facility engagement and tailored intervention delivery","reported","reported",5,-0.208481060133889,0.0658809802197041,0,2006,0,598.6
"CD016064_data","CD016064_data","5|2|Risk of falling|Without facility engagement and tailored intervention delivery","Risk of falling",5,2,"Without facility engagement and tailored intervention delivery","reported","reported",5,-0.0446500803729277,0.0527886312879366,0,2004.6,0,246.8
"CD016064_data","CD016064_data","5|3|Risk of fracture|Facility engagement and tailored intervention delivery","Risk of fracture",5,3,"Facility engagement and tailored intervention delivery","reported","reported",3,-0.0969522553023648,0.390159635846093,0.145797845783581,2008.66666666667,0,1007.33333333333
"CD016064_data","CD016064_data","5|3|Risk of fracture|Without facility engagement and tailored intervention delivery","Risk of fracture",5,3,"Without facility engagement and tailored intervention delivery","reported","reported",2,-0.0948780487804879,0.883375239859139,0.795399999999999,2010,0,232.5
"CD016064_data","CD016064_data","5|4|Multifactorial interventions (grouped by alignment with QCA theory): Rate of falls sensitivity analyses: excluding trials at high risk of bias|Facility engagement and tailored intervention delivery","Multifactorial interventions (grouped by alignment with QCA theory): Rate of falls sensitivity analyses: excluding trials at high risk of bias",5,4,"Facility engagement and tailored intervention delivery","reported","reported",2,-0.49,0.161245154965971,0.026,2003,0,290
"CD016064_data","CD016064_data","5|4|Multifactorial interventions (grouped by alignment with QCA theory): Rate of falls sensitivity analyses: excluding trials at high risk of bias|Without facility engagement and tailored intervention delivery","Multifactorial interventions (grouped by alignment with QCA theory): Rate of falls sensitivity analyses: excluding trials at high risk of bias",5,4,"Without facility engagement and tailored intervention delivery","reported","reported",2,0.0463333333333333,0.0719019393958806,0.00445,1999.5,0,111
"CD016064_data","CD016064_data","5|5|Multifactorial interventions (grouped by alignment with QCA theory): Risk of falling sensitivity analyses: excluding trials at high risk of bias|Facility engagement and tailored intervention delivery","Multifactorial interventions (grouped by alignment with QCA theory): Risk of falling sensitivity analyses: excluding trials at high risk of bias",5,5,"Facility engagement and tailored intervention delivery","reported","reported",2,-0.178285714285714,0.174494956362407,0.037,2003,0,290
"CD016064_data","CD016064_data","5|5|Multifactorial interventions (grouped by alignment with QCA theory): Risk of falling sensitivity analyses: excluding trials at high risk of bias|Without facility engagement and tailored intervention delivery","Multifactorial interventions (grouped by alignment with QCA theory): Risk of falling sensitivity analyses: excluding trials at high risk of bias",5,5,"Without facility engagement and tailored intervention delivery","reported","reported",3,-0.0812507343556915,0.0563895116664227,0,2000.66666666667,0,165.333333333333
"CD016064_data","CD016064_data","6|1|Rate of falls|Active exercise","Rate of falls",6,1,"Active exercise","reported","reported",14,-0.387018494011456,0.164297285031171,0.310711051722668,2013.78571428571,0,158.214285714286
"CD016064_data","CD016064_data","6|3|Risk of falling|Active exercise","Risk of falling",6,3,"Active exercise","reported","reported",13,-0.145120197395509,0.0753431822766403,0.0241295056968826,2013.15384615385,0,185.230769230769
"CD016064_data","CD016064_data","6|4|Risk of fracture|Active exercise: All fractures","Risk of fracture",6,4,"Active exercise: All fractures","reported","reported",3,0.0139120116691028,0.287097908231074,0,2020.33333333333,0,309
"CD016064_data","CD016064_data","6|6|Rate of falls sensitivity analysis: active exercise including Cadore 2014|","Rate of falls sensitivity analysis: active exercise including Cadore 2014",6,6,"","reported","reported",15,-0.469974533029652,0.183720973826147,0.418528374977808,2013.8,0,149.266666666667
"CD016064_data","CD016064_data","6|7|Rate of falls sensitivity analysis: active exercise excluding trials with <40 participants|","Rate of falls sensitivity analysis: active exercise excluding trials with <40 participants",6,7,"","reported","reported",12,-0.46830634273707,0.16450340341853,0.268169956942037,2014.58333333333,0,180
"CD016064_data","CD016064_data","6|8|Rate of falls sensitivity analysis: active exercise excluding trials at high risk of bias|","Rate of falls sensitivity analysis: active exercise excluding trials at high risk of bias",6,8,"","reported","reported",6,-0.437637438433937,0.251499852141669,0.32965119724941,2018.5,0,194
"CD016064_data","CD016064_data","6|9|Risk of falling sensitivity analysis: active exercise excluding trials at high risk of bias|","Risk of falling sensitivity analysis: active exercise excluding trials at high risk of bias",6,9,"","reported","reported",8,-0.185740313596967,0.105789467116726,0.0397052162367512,2016.75,0,185.5
"CD016064_data","CD016064_data","7|1|Rate of falls|Active exercise","Rate of falls",7,1,"Active exercise","reported","reported",7,0.00697233124741278,0.162222634072111,0.120569236395357,2010,0,193.428571428571
"CD016064_data","CD016064_data","7|1|Rate of falls|Whole body vibration","Rate of falls",7,1,"Whole body vibration","reported","reported",2,0.238333333333333,0.218587638158144,0.0576499999999999,2011.5,0,116.5
"CD016064_data","CD016064_data","7|2|Risk of falling|Active Exercise","Risk of falling",7,2,"Active Exercise","reported","reported",7,0.063575349358006,0.0650985335825684,1.73766763748718e-06,2012.5,0,206.142857142857
"CD016064_data","CD016064_data","7|2|Risk of falling|Whole body vibration","Risk of falling",7,2,"Whole body vibration","reported","reported",2,0.128444444444444,0.222500492439461,0.0538,2011.5,0,116.5
"CD016064_data","CD016064_data","7|3|Risk of fracture|All fractures: active exercise","Risk of fracture",7,3,"All fractures: active exercise","reported","reported",2,-0.640900207147868,0.395813470648524,0,2013.5,0,179.5
"CD016064_data","CD016064_data","7|3|Risk of fracture|Hip fractures: active exercise","Risk of fracture",7,3,"Hip fractures: active exercise","reported","reported",2,-0.45943918918919,0.810617396722778,0.4039375,2013.5,0,179.5
"CD016064_data","CD016064_data","7|4|Rate of falls sensitivity analyses: excluding trials at high risk of bias|","Rate of falls sensitivity analyses: excluding trials at high risk of bias",7,4,"","reported","reported",4,-0.138771820134223,0.188506612460371,0.0725913994061219,2011,0,154.5
"CD016064_data","CD016064_data","7|5|Risk of falling sensitivity analysis: excluding trials at high risk of bias|","Risk of falling sensitivity analysis: excluding trials at high risk of bias",7,5,"","reported","reported",5,0.0239838974693478,0.0820782110839335,2.83197850186473e-07,2012,0,144.6
"CD016064_data","CD016064_data","8|1|Rate of falls|Combination of exercise categories","Rate of falls",8,1,"Combination of exercise categories","reported","reported",8,-0.388336013019533,0.213088178280496,0.316365057495513,2015.5,0,180
"CD016064_data","CD016064_data","8|1|Rate of falls|Gait, balance, functional training","Rate of falls",8,1,"Gait, balance, functional training","reported","reported",3,-0.447320805220659,0.245653518927998,0.118313604343508,2013.33333333333,0,220
"CD016064_data","CD016064_data","8|1|Rate of falls|General physical activity","Rate of falls",8,1,"General physical activity","reported","reported",2,0.283068965517241,0.723786424539177,0.900450000000001,2009,0,27.5
"CD016064_data","CD016064_data","8|2|Risk of falling|Combination of exercise categories","Risk of falling",8,2,"Combination of exercise categories","reported","reported",9,-0.123612677504177,0.0885319245272674,0.0312323612408591,2014.66666666667,0,183.888888888889
"CD016064_data","CD016064_data","8|2|Risk of falling|Gait, balance and functional training","Risk of falling",8,2,"Gait, balance and functional training","reported","reported",2,-0.171002465078061,0.142179305128778,0,2009.5,0,294.5
"CD016064_data","CD016064_data","9|1|Rate of falls|Cognitive impairment","Rate of falls",9,1,"Cognitive impairment","reported","reported",4,-0.54777255177453,0.381578668572881,0.497071436614579,2017.75,0,112.75
"CD016064_data","CD016064_data","9|1|Rate of falls|Mixed cognition","Rate of falls",9,1,"Mixed cognition","reported","reported",6,-0.191676982068791,0.156700189970135,0.102221195065506,2012,0,192.166666666667
"CD016064_data","CD016064_data","9|1|Rate of falls|No cognitive impairment","Rate of falls",9,1,"No cognitive impairment","reported","reported",4,-0.431738248151029,0.484848265182885,0.822384637575593,2012.5,0,46.5
"CD016064_data","CD016064_data","9|2|Risk of falling|Cognitive impairment","Risk of falling",9,2,"Cognitive impairment","reported","reported",4,-0.329751593381089,0.118381037499821,0.0141094518082907,2017.75,0,112.75
"CD016064_data","CD016064_data","9|2|Risk of falling|Mixed cognition","Risk of falling",9,2,"Mixed cognition","reported","reported",8,-0.0372271796099573,0.0774515542093931,0,2010.625,0,173.125
"CD016064_data","CD016064_data","9|3|Risk of fracture|All fractures - mixed cognition","Risk of fracture",9,3,"All fractures - mixed cognition","reported","reported",2,-0.506744569249295,0.508186712257275,0,2021,0,178.5
"CD016064_data","CD016064_data","9|4|Rate of falls (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias|Cognitive impairment","Rate of falls (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias",9,4,"Cognitive impairment","reported","reported",3,-0.632551328774329,0.507118017621131,0.703404133125743,2019.33333333333,0,129.666666666667
"CD016064_data","CD016064_data","9|4|Rate of falls (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias|Mixed cognition","Rate of falls (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias",9,4,"Mixed cognition","reported","reported",5,-0.297548166861889,0.144031858323111,0.0566819099260842,2015.6,0,191.8
"CD016064_data","CD016064_data","9|5|Risk of falling (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias|Cognitive impairment","Risk of falling (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias",9,5,"Cognitive impairment","reported","reported",3,-0.330963653978614,0.151239393196299,0.0322071886970504,2019.33333333333,0,129.666666666667
"CD016064_data","CD016064_data","9|5|Risk of falling (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias|Mixed cognition","Risk of falling (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias",9,5,"Mixed cognition","reported","reported",4,-0.0434887490480036,0.115806904907001,0,2015.25,0,130.75
"CD016119_data","CD016119_data","1|1|Requirement for blood transfusion|Country income status – high","Requirement for blood transfusion",1,1,"Country income status – high","reported","reported",5,0,0.183676652115079,0,2013.8,0.0752470867513028,410
"CD016119_data","CD016119_data","1|1|Requirement for blood transfusion|Country income status – upper middle","Requirement for blood transfusion",1,1,"Country income status – upper middle","reported","reported",7,0,0.212029432175991,0,2016.28571428571,0.0944291888154332,530.428571428571
"CD016119_data","CD016119_data","1|10|Estimated blood loss|Country income status – high","Estimated blood loss",1,10,"Country income status – high","reported","reported",3,0,11.3974808228993,0,2016.33333333333,0,175.333333333333
"CD016119_data","CD016119_data","1|10|Estimated blood loss|Country income status – upper middle","Estimated blood loss",1,10,"Country income status – upper middle","reported","reported",3,0,3.24942128252024,0,2021.33333333333,0,966.666666666667
"CD016119_data","CD016119_data","1|11|Additional uterotonics or tranexamic acid|","Additional uterotonics or tranexamic acid",1,11,"","or","binary",3,-0.177527812798066,0.35090558048527,0,2018.5,0.083903010995332,200.666666666667
"CD016119_data","CD016119_data","1|12|Postpartum haemoglobin concentration|Country income status – high","Postpartum haemoglobin concentration",1,12,"Country income status – high","reported","reported",5,0,0.0739878785952686,0,2015.2,0,289
"CD016119_data","CD016119_data","1|12|Postpartum haemoglobin concentration|Country income status – upper middle","Postpartum haemoglobin concentration",1,12,"Country income status – upper middle","reported","reported",10,0,0.0538849043704613,0,2016.44444444444,0,204.9
"CD016119_data","CD016119_data","1|14|Fatigue|","Fatigue",1,14,"","or","binary",2,-0.385820884270809,1.42116768537629,0,2016.5,0,131
"CD016119_data","CD016119_data","1|19|Ileus|","Ileus",1,19,"","or","binary",2,0.687593481689436,0.508192902260853,0,2021,0.0211175337186898,215.5
"CD016119_data","CD016119_data","1|2|Incidence of haemorrhage|","Incidence of haemorrhage",1,2,"","reported","reported",9,0,0.147014394448292,0,2012.77777777778,0.0959936614808886,192.111111111111
"CD016119_data","CD016119_data","1|3|Size of fibroid on incidence of haemorrhage|Fibroid size < 3 cm","Size of fibroid on incidence of haemorrhage",1,3,"Fibroid size < 3 cm","or","binary",2,0.147757077667874,0.594458780439969,0,2004,0.0770735524256651,65.5
"CD016119_data","CD016119_data","1|3|Size of fibroid on incidence of haemorrhage|Fibroid size > 6 cm","Size of fibroid on incidence of haemorrhage",1,3,"Fibroid size > 6 cm","or","binary",2,0.45731442274048,0.493678806753175,0,2004,0.120720720720721,64
"CD016119_data","CD016119_data","1|3|Size of fibroid on incidence of haemorrhage|Fibroid size 3–6 cm","Size of fibroid on incidence of haemorrhage",1,3,"Fibroid size 3–6 cm","or","binary",2,-0.207982411175472,0.455409287202375,0,2004,0.152164948453608,91
"CD016119_data","CD016119_data","1|4|Change in haemoglobin|Country income status – high","Change in haemoglobin",1,4,"Country income status – high","reported","reported",5,0,0.0488618807010825,0,2014,0,165.6
"CD016119_data","CD016119_data","1|4|Change in haemoglobin|Country income status – upper middle","Change in haemoglobin",1,4,"Country income status – upper middle","reported","reported",10,0,0.0337596804542845,0,2017.44444444444,0,209.4
"CD016119_data","CD016119_data","1|5|Length of hospitalisation|Country income status – high","Length of hospitalisation",1,5,"Country income status – high","reported","reported",4,0,0.0771105482815617,0,2012.5,0,261
"CD016119_data","CD016119_data","1|5|Length of hospitalisation|Country income status – upper middle","Length of hospitalisation",1,5,"Country income status – upper middle","reported","reported",10,0,0.0276167116791008,0,2017,0,173.3
"CD016119_data","CD016119_data","1|6|Length of hospitalisation – sensitivity analysis|Country income status – high","Length of hospitalisation – sensitivity analysis",1,6,"Country income status – high","reported","reported",4,0,0.0771105482815617,0,2012.5,0,261
"CD016119_data","CD016119_data","1|6|Length of hospitalisation – sensitivity analysis|Country income status – upper middle","Length of hospitalisation – sensitivity analysis",1,6,"Country income status – upper middle","reported","reported",8,0,0.0408788802334289,0,2016.375,0,192.25
"CD016119_data","CD016119_data","1|7|Length of operation|Country income status – high","Length of operation",1,7,"Country income status – high","reported","reported",7,0,0.589581542813796,0,2014,0,293.857142857143
"CD016119_data","CD016119_data","1|7|Length of operation|Country income status – upper middle ","Length of operation",1,7,"Country income status – upper middle ","reported","reported",11,0,0.393331634614016,0,2017.1,0,192.454545454545
"CD016119_data","CD016119_data","1|8|Major surgery at time of procedure|","Major surgery at time of procedure",1,8,"","reported","reported",3,0,0.715372414209293,0,2022.5,0.0146515735388568,265.666666666667
"CD016119_data","CD016119_data","1|9|Postpartum fever|Country income status – high ","Postpartum fever",1,9,"Country income status – high ","reported","reported",5,0,0.185059053428904,0,2010.8,0.110422661026432,287.8
"CD016119_data","CD016119_data","1|9|Postpartum fever|Country income status – upper middle","Postpartum fever",1,9,"Country income status – upper middle","reported","reported",7,0,0.244529171766781,0,2017.14285714286,0.0906462585034014,133.714285714286
"CD016120_data","CD016120_data","1|11|Amniotic fluid embolism|NA","Amniotic fluid embolism",1,11,NA,"or","binary",3,-0.00134424179053292,1.15786672343697,0,2020,0,1078.66666666667
"CD016120_data","CD016120_data","1|12|Side effects|NA","Side effects",1,12,NA,"reported","reported",4,0,0.117291012635067,0,2014.5,0.190784219383334,815.25
"CD016120_data","CD016120_data","1|13|Clotting abnormalities: Prothrombin time (PT) at day 1 postpartum|NA","Clotting abnormalities: Prothrombin time (PT) at day 1 postpartum",1,13,NA,"or","binary",3,-0.00347127995241766,1.16010976887097,0,2021.33333333333,0,107.666666666667
"CD016120_data","CD016120_data","1|14|Clotting abnormalities: Activated partial thromboplastin time (APTT) at day 1 postpartum|NA","Clotting abnormalities: Activated partial thromboplastin time (APTT) at day 1 postpartum",1,14,NA,"or","binary",3,-0.00347127995241766,1.16010976887097,0,2021.33333333333,0,107.666666666667
"CD016120_data","CD016120_data","1|17|Clotting abnormalities: Platelets amount at day 1 postpartum|NA","Clotting abnormalities: Platelets amount at day 1 postpartum",1,17,NA,"or","binary",3,-0.00347127995241766,1.16010976887097,0,2021.33333333333,0,107.666666666667
"CD016120_data","CD016120_data","1|4|Length of hospitalisation|NA","Length of hospitalisation",1,4,NA,"or","binary",3,-0.00134727171683464,1.15917090702431,0,2012,0,1058
"CD016120_data","CD016120_data","1|5|Length of operation|NA","Length of operation",1,5,NA,"or","binary",2,0,1.41992259736665,0,2021,0,123
"CD016131_data","CD016131_data","1|1|RSV-associated lower respiratory tract illness|Authorised vaccines","RSV-associated lower respiratory tract illness",1,1,"Authorised vaccines","reported","reported",2,0,0.173993544184355,0,2023,0.00652755445616744,29625.5
"CD016131_data","CD016131_data","1|3|Mortality from illness caused by RSV|","Mortality from illness caused by RSV",1,3,"","or","binary",2,0.347535256366038,1.41425006207153,0,2023,0,25218.5
"CD016131_data","CD016131_data","3|1|Medically attended RSV-associated lower respiratory tract illness in infants|Authorised vaccines (RSV prefusion F protein-based vaccine )","Medically attended RSV-associated lower respiratory tract illness in infants",3,1,"Authorised vaccines (RSV prefusion F protein-based vaccine )","or","binary",2,-1.14604656345905,0.460243145566475,0.240846819633061,2022.5,0.0323178216716884,3741.5
"CD016131_data","CD016131_data","3|2|Medically attended RSV-associated severe lower respiratory tract illness in infants|Authorised vaccines (RSV prefusion F protein-based vaccine)","Medically attended RSV-associated severe lower respiratory tract illness in infants",3,2,"Authorised vaccines (RSV prefusion F protein-based vaccine)","or","binary",2,-1.74613823529652,0.393347456754223,0,2022.5,0.0193044861064613,3741.5
"CD016131_data","CD016131_data","3|6|Serious adverse events (SAEs) related to vaccination|Authorised vaccines (RSV prefusion F protein-based vaccine)","Serious adverse events (SAEs) related to vaccination",3,6,"Authorised vaccines (RSV prefusion F protein-based vaccine)","or","binary",2,0.462838845397301,1.09192535111083,0.70569371051275,2022.5,0.000136054421768707,3881.5
"CD016131_data","CD016131_data","4|1|All-cause medically attended acute respiratory illnesses (MAARI)|","All-cause medically attended acute respiratory illnesses (MAARI)",4,1,"","or","binary",5,-0.53288914985115,0.331353665728709,0,2019.6,0.538005050505051,34.2
"CD016131_data","CD016131_data","4|2|RSV-associated medically attended acute respiratory illnesses (MAARI)|","RSV-associated medically attended acute respiratory illnesses (MAARI)",4,2,"","or","binary",5,-0.687187923099753,0.42619873425759,0,2019.6,0.200757575757576,38.4
"CD016131_data","CD016131_data","4|3|Acute otitis Media|","Acute otitis Media",4,3,"","or","binary",5,-0.0913314398947577,0.641510965874965,0,2019.6,0.0444444444444444,40.8
"CD016131_data","CD016131_data","4|4|Serious adverse events (SAEs) related to vaccination&nbsp;|","Serious adverse events (SAEs) related to vaccination&nbsp;",4,4,"","or","binary",5,-0.822192706064419,0.908007508702993,0,2019.6,0,40.8
"CD016131_data","CD016131_data","4|5|Any solicited systemic reaction (fever)|","Any solicited systemic reaction (fever)",4,5,"","or","binary",5,0.211807068855618,0.406601175636402,0,2019.6,0.17260101010101,40.8
"CD016136_data","CD016136_data","1|1|Implementation outcome|","Implementation outcome",1,1,"","reported","reported",30,0.962089628353083,0.139831340256174,0.422162945333892,2014.6,0,163.733333333333
"CD016136_data","CD016136_data","2|1|Excluding overall high risk of bias|","Excluding overall high risk of bias",2,1,"","reported","reported",12,1.10493125800158,0.222377181903071,0.370639534716815,2015.25,0,32.0833333333333
"CD016136_data","CD016136_data","2|2|ICC 0.07|","ICC 0.07",2,2,"","reported","reported",30,0.962466225512311,0.13975879403564,0.426634686590352,2014.6,0,163.733333333333
"CD016136_data","CD016136_data","2|3|ICC 0.351|","ICC 0.351",2,3,"","reported","reported",30,0.963729127342818,0.138715720690193,0.408954583948174,2014.6,0,163.733333333333
"CD016136_data","CD016136_data","2|4|Adjusting for clustering where the unit of analysis was unclear |","Adjusting for clustering where the unit of analysis was unclear ",2,4,"","reported","reported",30,0.930109571859963,0.142266580772728,0.448021892106735,2014.6,0,163.733333333333
"CD016136_data","CD016136_data","2|5|Including trials that explicitly described a trial aim or objective to test the effectiveness of an implementation strategy on an implementation outcome|","Including trials that explicitly described a trial aim or objective to test the effectiveness of an implementation strategy on an implementation outcome",2,5,"","reported","reported",13,1.0135078504946,0.22326653450268,0.537901203174795,2015.46153846154,0,141.076923076923
"CD016136_data","CD016136_data","3|1|School type|Elementary","School type",3,1,"Elementary","reported","reported",19,0.93752035734765,0.154117404451602,0.295374340465223,2013.89473684211,0,70.5263157894737
"CD016136_data","CD016136_data","3|1|School type|High","School type",3,1,"High","reported","reported",8,0.787415430553661,0.321606443608558,0.689048221089129,2017.375,0,430
"CD016136_data","CD016136_data","3|1|School type|Middle","School type",3,1,"Middle","reported","reported",3,1.74514217968122,0.705421631939074,1.19099237354542,2011.66666666667,0,37.3333333333333
"CD016136_data","CD016136_data","3|2|Targeted health behaviour or risk factor|Diet","Targeted health behaviour or risk factor",3,2,"Diet","reported","reported",11,0.863115394586441,0.13785389178574,0.0221766504892739,2012.27272727273,0,28.9090909090909
"CD016136_data","CD016136_data","3|2|Targeted health behaviour or risk factor|Diet and physical activity","Targeted health behaviour or risk factor",3,2,"Diet and physical activity","reported","reported",5,1.23680171172618,0.498721252098999,1.01200553146172,2011.8,0,51.4
"CD016136_data","CD016136_data","3|2|Targeted health behaviour or risk factor|Physical activity","Targeted health behaviour or risk factor",3,2,"Physical activity","reported","reported",12,0.990544218792426,0.267341455593513,0.73862127152079,2017.58333333333,0,302
"CD016136_data","CD016136_data","3|2|Targeted health behaviour or risk factor|Tobacco and/or alcohol use","Targeted health behaviour or risk factor",3,2,"Tobacco and/or alcohol use","reported","reported",2,1.11645097506717,0.115346756604398,0,2016.5,0,356.5
"CD016147_data","CD016147_data","1|1|Manual removal of the placenta (end of treatment)|NA","Manual removal of the placenta (end of treatment)",1,1,NA,"reported","reported",2,0,0.161766671827794,0,2013,0.441176470588235,97
"CD016147_data","CD016147_data","1|12|Blood loss (mL)|NA","Blood loss (mL)",1,12,NA,"reported","reported",3,0,75.8007900733882,0,2010.66666666667,0,81.3333333333333
"CD016147_data","CD016147_data","1|2|PPH ≥ 1000 mL (end of treatment)|NA","PPH ≥ 1000 mL (end of treatment)",1,2,NA,"reported","reported",2,0,0.208277940185837,0,2013,0.418627450980392,97
"CD016147_data","CD016147_data","1|4|Adverse effects (nausea)|NA","Adverse effects (nausea)",1,4,NA,"or","binary",2,0.695888053207615,1.38613317814368,2.25291923858629,2009.5,0.0290346907993967,71.5
"CD016147_data","CD016147_data","1|6|Adverse effects (abdominal pain)|NA","Adverse effects (abdominal pain)",1,6,NA,"or","binary",2,-0.113244935389595,0.467716422921131,0,2009.5,0.163461538461538,62
"CD016147_data","CD016147_data","1|8|Adverse effects (dizziness)|NA","Adverse effects (dizziness)",1,8,NA,"or","binary",2,0.176607886791469,0.620143539598878,0,2009.5,0.0661057692307692,62
"CD016148_data","CD016148_data","1|1|2nd degree tears|NA","2nd degree tears",1,1,NA,"or","binary",2,-0.421814710845972,0.547884932579671,0.482582823714256,2010,0.383449285975833,2770.5
"CD016148_data","CD016148_data","1|2|3rd or 4th degree tears|NA","3rd or 4th degree tears",1,2,NA,"or","binary",2,0.235642079915429,0.231543272629522,0,2010,0.0342470052832557,2770.5
"CD016148_data","CD016148_data","11|3|3rd or 4th degree tears|NA","3rd or 4th degree tears",11,3,NA,"or","binary",2,-0.345792468501932,0.739993671669425,0.56877870240589,2019,0.0478223898254954,595
"CD016148_data","CD016148_data","3|1|2nd degree tears|NA","2nd degree tears",3,1,NA,"or","binary",2,-0.0820130558596447,0.162631513329603,0,2009.5,0.212796279627963,503
"CD016148_data","CD016148_data","3|2|3rd or 4th degree tears|NA","3rd or 4th degree tears",3,2,NA,"or","binary",3,-0.792409109422306,0.283466988992348,0,2008.66666666667,0.0439964164483675,574.333333333333
"CD016148_data","CD016148_data","3|4|4th degree tears|NA","4th degree tears",3,4,NA,"or","binary",2,-1.66628068445645,1.19728939017801,0,2009.5,0.00495049504950495,503
"CD016148_data","CD016148_data","4|2|3rd degree tears|NA","3rd degree tears",4,2,NA,"or","binary",4,-0.525534571196147,0.501708927265737,0.31253722205464,2006.75,0.0250416073811402,600.25
"CD016148_data","CD016148_data","4|3|4th degree tears|NA","4th degree tears",4,3,NA,"or","binary",4,-0.84931144581338,0.70906839311922,0,2006.75,0.00287081714500564,600.25
"CD016168_data","CD016168_data","2|1|Maternal death|NA","Maternal death",2,1,NA,"or","binary",2,-0.0313826662634858,1.41647513048772,0,2018,0,337
"CD016168_data","CD016168_data","2|2|Severe maternal morbidity – ICU admission|NA","Severe maternal morbidity – ICU admission",2,2,NA,"or","binary",2,0.115981316871902,0.21131023124921,0,2019,0.165608465608466,242.5
"CD016168_data","CD016168_data","2|6|Adverse effects – thromboembolic events|NA","Adverse effects – thromboembolic events",2,6,NA,"or","binary",2,-1.04707006608907,1.22716791897637,0,2018,0.00476190476190476,337
"CD016211_data","CD016211_data","1|1|Maternal sepsis|","Maternal sepsis",1,1,"","reported","reported",4,0.651978330740795,0.0548275455685977,0,2021,0.0143504280008937,10607.5
"CD016211_data","CD016211_data","1|11|Adverse effects of antibiotics: vomiting|","Adverse effects of antibiotics: vomiting",1,11,"","reported","reported",3,1.31333149745864,0.240597056786739,0.117870805187914,2022.33333333333,0.0308255759875903,13885.6666666667
"CD016211_data","CD016211_data","1|12|Adverse effects of antibiotics: diarrhea|","Adverse effects of antibiotics: diarrhea",1,12,"","reported","reported",2,1.15939937754575,0.198056898172863,0,2022,0.00224688500034044,15016
"CD016211_data","CD016211_data","1|13|Adverse effects of antibiotics: pyloric stenosis|","Adverse effects of antibiotics: pyloric stenosis",1,13,"","reported","reported",2,0.886109593897697,0.641171635326772,0,2023,NA,0
"CD016211_data","CD016211_data","1|15|Other maternal infections: chorioamnionitis|","Other maternal infections: chorioamnionitis",1,15,"","reported","reported",2,0.306553265360835,0.172851079881984,0,2022,0.0162723311546841,15017
"CD016211_data","CD016211_data","1|16|Other maternal infections: endometritis|","Other maternal infections: endometritis",1,16,"","reported","reported",2,0.655672448016717,0.059094419948683,0,2022,0.0360279691657003,14986.5
"CD016211_data","CD016211_data","1|17|Other maternal infections: mastitis or breast abscess|","Other maternal infections: mastitis or breast abscess",1,17,"","reported","reported",4,0.497777456302579,0.119643406235153,0.0187043531916529,2021,0.0149109626688092,10605.75
"CD016211_data","CD016211_data","1|18|Other maternal infections: pyelonephritis|","Other maternal infections: pyelonephritis",1,18,"","reported","reported",2,0.264403298326223,0.0926409416053801,0,2022,0.00746707608324804,14984.5
"CD016211_data","CD016211_data","1|19|Other neonatal infections|","Other neonatal infections",1,19,"","reported","reported",2,0.82923089607508,0.136247710776593,0.0338475512497029,2023,0.0492788160182417,20506.5
"CD016211_data","CD016211_data","1|2|Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)|Monopharmacy","Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)",1,2,"Monopharmacy","reported","reported",2,0,0.402508339438702,0,2022,0.00911626309462476,6001.5
"CD016211_data","CD016211_data","1|20|Intrapartum stillbirth|","Intrapartum stillbirth",1,20,"","reported","reported",4,0.100427051749139,0.133319968914669,0,2021,NA,0
"CD016211_data","CD016211_data","1|3|Maternal mortality|","Maternal mortality",1,3,"","reported","reported",3,1.22127290811869,0.492278016713477,0,2022.33333333333,0.00188178694327438,13847.3333333333
"CD016211_data","CD016211_data","1|4|Maternal mortality: subgroup analysis (polypharmacy vs monopharmacy)|Monopharmacy","Maternal mortality: subgroup analysis (polypharmacy vs monopharmacy)",1,4,"Monopharmacy","reported","reported",3,0,0.337817374687706,0,2022.33333333333,0.000548453609941046,13721.3333333333
"CD016211_data","CD016211_data","1|5|Neonatal sepsis|","Neonatal sepsis",1,5,"","reported","reported",4,0.0285785916815882,0.0346236232537155,0,2021,NA,0
"CD016211_data","CD016211_data","1|6|Neonatal sepsis: subgroup analysis (polypharmacy vs monopharmacy)|Monopharmacy","Neonatal sepsis: subgroup analysis (polypharmacy vs monopharmacy)",1,6,"Monopharmacy","reported","reported",4,0.0248836136091759,0.0344808935268309,0,2021,NA,0
"CD016211_data","CD016211_data","1|7|Neonatal mortality|","Neonatal mortality",1,7,"","reported","reported",4,0.0269459524518784,0.0824039595904126,0,2021,NA,0
"CD016211_data","CD016211_data","1|8|Neonatal mortality: subgroup analysis (polypharmacy vs monopharmacy)|Monopharmacy","Neonatal mortality: subgroup analysis (polypharmacy vs monopharmacy)",1,8,"Monopharmacy","reported","reported",4,0.0218610784052583,0.084612006512519,0,2021,NA,0
"CD016278_data","CD016278_data","1|1|Estimated blood loss ≥ 1000ml|Gravimetrically estimated blood loss","Estimated blood loss ≥ 1000ml",1,1,"Gravimetrically estimated blood loss","reported","reported",2,0,0.050645053562882,0,2022,0.236146539867637,1859
"CD016278_data","CD016278_data","1|1|Estimated blood loss ≥ 1000ml|Provider estimated blood loss","Estimated blood loss ≥ 1000ml",1,1,"Provider estimated blood loss","or","binary",2,-0.418503679983492,0.457058399686561,0.301201895629044,2022.5,0.140236168816969,4662
"CD016278_data","CD016278_data","1|12|Clinical diagnosis of PPH|","Clinical diagnosis of PPH",1,12,"","or","binary",3,-0.106178802552253,0.0853185540769085,0,2022.33333333333,0.139404256205231,1518.66666666667
"CD016278_data","CD016278_data","1|13|Estimated mean blood loss (mL)|","Estimated mean blood loss (mL)",1,13,"","reported","reported",2,0,28.4939186674435,0,2022,0,1822
"CD016278_data","CD016278_data","1|14|Calculated mean blood loss (mL)|","Calculated mean blood loss (mL)",1,14,"","reported","reported",3,0,20.6040164654334,0,2022,0,1565
"CD016278_data","CD016278_data","1|17|Seizures|","Seizures",1,17,"","reported","reported",2,0,1.04428768536157,0,2022,0.000243427458617332,7083
"CD016278_data","CD016278_data","1|18|Organ failure/dysfunction|","Organ failure/dysfunction",1,18,"","or","binary",2,-0.00308608868566752,1.44025006830087,0,2022,0,2189.5
"CD016278_data","CD016278_data","1|19|ICU admission|","ICU admission",1,19,"","reported","reported",2,0,0.210247973240677,0,2022,0.00668098988017938,7247.5
"CD016278_data","CD016278_data","1|2|Calculated blood loss ≥ 1000ml|","Calculated blood loss ≥ 1000ml",1,2,"","reported","reported",2,0,0.0482939024327283,0,2022,0.283682435666947,2163.5
"CD016278_data","CD016278_data","1|20|Nausea|","Nausea",1,20,"","reported","reported",3,0,0.0331220163852772,0,2022.33333333333,0.157071248611754,5146
"CD016278_data","CD016278_data","1|21|Vomiting|","Vomiting",1,21,"","reported","reported",2,0,0.0838848982702528,0,2023,0.0250137438152831,5543
"CD016278_data","CD016278_data","1|5|Blood transfusion|","Blood transfusion",1,5,"","reported","reported",3,0,0.0865345362901598,0,2022,0.0321466141825215,5178
"CD016278_data","CD016278_data","1|6|Receipt of surgical interventions to control PPH|","Receipt of surgical interventions to control PPH",1,6,"","reported","reported",2,0,0.0892012888836302,0,2022,0.0226996010172777,7712.5
"CD016278_data","CD016278_data","1|7|Thromboembolic events|","Thromboembolic events",1,7,"","reported","reported",2,0,0.356733300195468,0,2022,0.00178742215562333,7085
"CD016278_data","CD016278_data","1|8|Receipt of additional uterotonics|","Receipt of additional uterotonics",1,8,"","or","binary",4,-0.153008428788204,0.0511191662735223,4.13556848581412e-06,2022.5,0.209989379412254,3932
"CD016278_data","CD016278_data","1|9|Hysterectomy|","Hysterectomy",1,9,"","reported","reported",2,0,0.718487736983356,0,2022,0.0347091053839309,2273
